{
    "NCT01352598_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT00894712_inc": {
        "Annotations": [
            "Procedure 10 24--*--pathologically",
            "Value 25 34--*--confirmed",
            "Condition 35 58--*--invasive adenocarcinoma",
            "Condition 62 86--*--ductal carcinoma in situ",
            "Procedure 132 152--*--segmental mastectomy",
            "Procedure 160 170--*--lumpectomy",
            "Procedure 212 229--*--radiation therapy",
            "Negation 188 191--*--not",
            "Qualifier 87 100--*--of the breast",
            "Condition 276 298--*--local-regional disease",
            "Undefined_semantics 276 298--*--local-regional disease",
            "Temporal 269 275--*--active",
            "Negation 260 263--*--not",
            "Pregnancy_considerations 323 677--*--Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy.",
            "Post-eligibility 679 804--*--Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.",
            "Post-eligibility 806 970--*--All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines."
        ],
        "Text": "Must have pathologically confirmed invasive adenocarcinoma or ductal carcinoma in situ of the breast. . Patients must have undergone segmental mastectomy (i.e., lumpectomy). . Patients must not have received prior radiation therapy to the breast. . Patients must not have active local-regional disease prior to registration. . Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy. . Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. . All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines. . "
    },
    "NCT00344318_inc": {
        "Text": "Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination. . Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol . Written informed consent obtained from the parent or guardian of the subject. . Free of obvious health problems as established by medical history and clinical examination before entering into the study. . Born after a gestation period between 36 and 42 weeks. . ",
        "Annotations": [
            "Value 15 22;39 49--*--between 6-12 weeks",
            "Value 15 22;51 64--*--between 42 to 90 days",
            "Person 66 72--*--of age",
            "Temporal 73 109--*--at the time of the first vaccination",
            "Condition 339 354--*--health problems",
            "Qualifier 331 338--*--obvious",
            "Negation 323 327--*--Free",
            "Value 477 500--*--between 36 and 42 weeks",
            "Measurement 460 476--*--gestation period",
            "Condition 447 451--*--Born",
            "Non-query-able 112 242--*--Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol",
            "Observation 244 268--*--Written informed consent",
            "Qualifier 287 293--*--parent",
            "Qualifier 297 305--*--guardian",
            "Scope 287 305--*--parent or guardian"
        ]
    },
    "NCT01051414_exc": {
        "Annotations": [
            "Condition 26 41--*--liver cirrhosis",
            "Mood 14 22--*--evidence",
            "Condition 55 58--*--HCC",
            "Mood 43 51--*--Evidence",
            "Condition 78 95--*--hepatitis B virus",
            "Condition 97 100--*--HIV"
        ],
        "Text": "Subjects with evidence of liver cirrhosis . Evidence of HCC . Co-infection with hepatitis B virus, HIV       .     . "
    },
    "NCT02056288_exc": {
        "Text": "Pulseless extremity. Compromised neurologic status on exam (specifically assessment of radial, ulnar, and median nerve). Known allergy to local anesthetics (7) Not scheduled for closed reduction with percutaneous pinning under general anesthesia. Bleeding diathesis. American Society of Anesthesiologist (ASA) status 4 or higher.. Sleep apnea by polysomnography. ",
        "Annotations": [
            "Condition 0 19--*--Pulseless extremity",
            "Condition 21 50--*--Compromised neurologic status",
            "Qualifier 113 118;87 93--*--nerve radial",
            "Qualifier 113 118;95 100--*--nerve ulnar",
            "Qualifier 106 118--*--median nerve",
            "Scope 87 118--*--radial, ulnar, and median nerve",
            "Condition 127 134--*--allergy",
            "Drug 138 155--*--local anesthetics",
            "Negation 160 163--*--Not",
            "Mood 164 177--*--scheduled for",
            "Procedure 178 220--*--closed reduction with percutaneous pinning",
            "Procedure 227 245--*--general anesthesia",
            "Condition 247 265--*--Bleeding diathesis",
            "Measurement 267 316--*--American Society of Anesthesiologist (ASA) status",
            "Value 317 328--*--4 or higher",
            "Condition 331 342--*--Sleep apnea",
            "Procedure 346 361--*--polysomnography"
        ]
    },
    "NCT03233880_inc": {
        "Annotations": [
            "Condition 0 12--*--primigravida",
            "Condition 14 33--*--singleton pregnancy",
            "Person 35 47--*--maternal age",
            "Value 48 59--*--18-35 years",
            "Measurement 65 83--*--pregnancy duration",
            "Value 84 95--*--16-20 weeks",
            "Temporal 96 126--*--at the time of study inclusion"
        ],
        "Text": "primigravida, singleton pregnancy, maternal age 18-35 years, and pregnancy duration 16-20 weeks at the time of study inclusion.. "
    },
    "NCT03463564_inc": {
        "Annotations": [
            "Condition 0 4--*--T1DM",
            "Temporal 5 27--*--for at least 12 months",
            "Measurement 40 52--*--HbA1c levels",
            "Multiplier 29 39--*--persistent",
            "Value 53 59--*--= 7.5%",
            "Value 61 72--*--58 mmol/mol",
            "Procedure 82 109--*--optimized education therapy",
            "Multiplier 112 121--*--recurrent",
            "Qualifier 122 128--*--severe",
            "Condition 129 150--*--hypoglycemic episodes",
            "Condition 154 178--*--high glucose variability",
            "Scope 129 178--*--hypoglycemic episodes or high glucose variability",
            "Mood 180 191--*--willingness",
            "Procedure 195 216--*--wear the insulin pump",
            "Device 204 216--*--insulin pump"
        ],
        "Text": "T1DM for at least 12 months. persistent HbA1c levels = 7.5% (58 mmol/mol) despite optimized education therapy,. recurrent severe hypoglycemic episodes or high glucose variability. willingness to wear the insulin pump. "
    },
    "NCT02678377_exc": {
        "Annotations": [
            "Condition 11 24--*--recurrent UTI",
            "Multiplier 37 42--*--three",
            "Measurement 43 50--*--culture",
            "Temporal 63 84--*--within last 12 months",
            "Condition 96 117--*--neuromuscular disease",
            "Procedure 182 198--*--prolapse surgery",
            "Procedure 209 229--*--incontinence surgery",
            "Drug 246 272--*--anticholinergic medication",
            "Temporal 280 292--*--last 2 month",
            "Qualifier 304 321--*--bladder injection",
            "Drug 327 345--*--onabotulinumtoxinA",
            "Person 347 355--*--Prisoner",
            "Condition 364 373--*--Pregnancy"
        ],
        "Text": "History of recurrent UTI (defined as three culture proven UTIs within last 12 months). Systemic neuromuscular disease known to affect the lower urinary tract. Undergoing concomitant prolapse surgery. Previous incontinence surgery. Treatment with anticholinergic medication in the last 2 months. Previous bladder injection with onabotulinumtoxinA. Prisoner Status. Pregnancy. "
    },
    "NCT02242188_inc": {
        "Text": "Term singleton infants (>37 weeks gestational age). Birth weight > 2500g. Healthy at inclusion. Breastfed exclusively or predominantly (>50% meals) at inclusion. No previous iron supplementation. No previous blood transfusion. Informed consent given. ",
        "Annotations": [
            "Condition 5 22--*--singleton infants",
            "Condition 0 4;15 22--*--Term infants",
            "Value 24 33--*-->37 weeks",
            "Measurement 34 49--*--gestational age",
            "Scope 0 22--*--Term singleton infants",
            "Scope 24 49--*-->37 weeks gestational age",
            "Measurement 52 64--*--Birth weight",
            "Value 65 72--*--> 2500g",
            "Condition 74 81--*--Healthy",
            "Temporal 82 94--*--at inclusion",
            "Condition 96 105--*--Breastfed",
            "Qualifier 106 117--*--exclusively",
            "Qualifier 121 134--*--predominantly",
            "Multiplier 136 146--*-->50% meals",
            "Temporal 148 160--*--at inclusion",
            "Scope 106 134--*--exclusively or predominantly",
            "Negation 162 164--*--No",
            "Temporal 165 173--*--previous",
            "Procedure 174 194--*--iron supplementation",
            "Negation 196 198--*--No",
            "Temporal 199 207--*--previous",
            "Procedure 208 225--*--blood transfusion",
            "Informed_consent 227 249--*--Informed consent given"
        ]
    },
    "NCT02167022_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 240 242--*--2.",
            "Parsing_Error 356 358--*--3.",
            "Parsing_Error 544 546--*--4.",
            "Person 3 6--*--Age",
            "Value 8 30--*--12 to 36 months of age",
            "Not_a_criteria 31 237--*--(The diagnosis of CP is often uncertain under the age of 12 months. The cutoff at 36 months is to have a population of young children when the brain is most \"plastic\" and most susceptible to reorganization)",
            "Condition 267 277--*--spastic CP",
            "Non-query-able 359 542--*--Etiology: The insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age.",
            "Temporal 490 510--*--one year after birth",
            "Measurement 571 621--*--Gross Motor Function Classification System (GMFCS)",
            "Value 622 642--*--levels I, II and III"
        ],
        "Text": "1. Age: 12 to 36 months of age (The diagnosis of CP is often uncertain under the age of 12 months. The cutoff at 36 months is to have a population of young children when the brain is most \"plastic\" and most susceptible to reorganization). . 2. Diagnosis: Diagnosis of spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist. . 3. Etiology: The insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age. . 4. Disease severity level: Gross Motor Function Classification System (GMFCS) levels I, II and III. . "
    },
    "NCT02364648_inc": {
        "Annotations": [
            "Condition 12 34--*--Chronic Kidney Disease",
            "Measurement 0 5--*--Stage",
            "Value 6 11--*--3 - 5"
        ],
        "Text": "Stage 3 - 5 Chronic Kidney Disease. "
    },
    "NCT02833116_inc": {
        "Text": "Unilateral leg pain secondary to lateral stenosis, disc protrusion or herniated disc.. Age between 18 and 80 years.. Moderate to severe pain (NVS>4).. Right proficient oral and written language.. ",
        "Annotations": [
            "Condition 0 19--*--Unilateral leg pain",
            "Condition 33 49--*--lateral stenosis",
            "Condition 51 66--*--disc protrusion",
            "Condition 70 84--*--herniated disc",
            "Scope 33 84--*--lateral stenosis, disc protrusion or herniated disc",
            "Person 87 90--*--Age",
            "Value 91 114--*--between 18 and 80 years",
            "Condition 136 140--*--pain",
            "Measurement 142 145--*--NVS",
            "Value 145 148--*-->4)",
            "Qualifier 129 135--*--severe",
            "Qualifier 117 125--*--Moderate",
            "Scope 117 135--*--Moderate to severe",
            "Post-eligibility 151 193--*--Right proficient oral and written language"
        ]
    },
    "NCT02222272_inc": {
        "Text": "All adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and 30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of their response to these drugs. . ",
        "Annotations": [
            "Condition 24 49--*--chronic myeloid leukaemia",
            "Procedure 109 145--*--allogeneic stem cell transplantation",
            "Temporal 146 179--*--between 01/01/2010 and 30/09/2013",
            "Drug 218 227--*--Nilotinib",
            "Drug 231 240--*--Dasatinib",
            "Temporal 194 204--*--previously",
            "Scope 218 240--*--Nilotinib or Dasatinib",
            "Qualifier 64 71--*--chronic",
            "Qualifier 73 84--*--accelerated",
            "Qualifier 88 95--*--blastic",
            "Qualifier 53 62--*--any phase",
            "Scope 64 95--*--chronic, accelerated or blastic",
            "Person 4 9--*--adult"
        ]
    },
    "NCT01352598_inc": {
        "Text": "Patient age >= 18 years. Zubrod performance status of 0-3. T1-3 N0 M0 adenocarcinoma of the prostate. Prostate volume = 100 cc. Signed study-specific consent form. Extension of local tumor to involve adjacent organs other than seminal vesicles (T4). Prostate volume > 100 cc. Nodal involvement. Metastatic disease. Prior pelvic radiotherapy except as part of combination therapy for prostate cancer. History of scleroderma. Patients with psychiatric or addictive disorder that would preclude obtaining informed consent. ",
        "Annotations": [
            "Person 0 11--*--Patient age",
            "Value 12 23--*-->= 18 years",
            "Measurement 25 50--*--Zubrod performance status",
            "Value 54 57--*--0-3",
            "Measurement 59 60--*--T",
            "Value 60 63--*--1-3",
            "Measurement 64 65--*--N",
            "Measurement 67 68--*--M",
            "Value 65 66--*--0",
            "Value 68 69--*--0",
            "Scope 59 69--*--T1-3 N0 M0",
            "Condition 70 84--*--adenocarcinoma",
            "Qualifier 92 100--*--prostate",
            "Measurement 102 117--*--Prostate volume",
            "Value 118 126--*--= 100 cc",
            "Informed_consent 128 162--*--Signed study-specific consent form",
            "Condition 164 188--*--Extension of local tumor",
            "Qualifier 200 215--*--adjacent organs",
            "Negation 216 226--*--other than",
            "Qualifier 227 243--*--seminal vesicles",
            "Scope 200 243--*--adjacent organs other than seminal vesicles",
            "Measurement 250 265--*--Prostate volume",
            "Value 266 274--*--> 100 cc",
            "Condition 276 293--*--Nodal involvement",
            "Condition 295 313--*--Metastatic disease",
            "Temporal 315 320--*--Prior",
            "Qualifier 321 327--*--pelvic",
            "Procedure 328 340--*--radiotherapy",
            "Negation 341 347--*--except",
            "Procedure 359 378--*--combination therapy",
            "Condition 383 399--*--prostate cancer",
            "Condition 383 398--*--prostate cancer",
            "Observation 400 407--*--History",
            "Condition 411 422--*--scleroderma",
            "Condition 438 449;463 471--*--psychiatric disorder",
            "Condition 453 471--*--addictive disorder"
        ]
    },
    "NCT00344318_exc": {
        "Text": "Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period . Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. . Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3. . Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations . History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases. . History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. . History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease. . Acute disease at the time of enrolment . Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical . A family history of congenital or hereditary immunodeficiency. . Major congenital defects or serious chronic illness. . Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study.       .     . ",
        "Annotations": [
            "Drug 45 52;7 26;71 102--*--product any investigational other than the study vaccine(s)",
            "Drug 30 52;7 10;71 102--*--non-registered product any other than the study vaccine(s)",
            "Drug 54 58--*--drug",
            "Drug 62 69--*--vaccine",
            "Scope 54 69--*--drug or vaccine",
            "Scope 7 52;71 102--*--any investigational or non-registered product other than the study vaccine(s)",
            "Temporal 103 117--*--within 30 days",
            "Observation 164 175--*--planned use",
            "Temporal 176 199--*--during the study period",
            "Drug 258 276--*--immunosuppressants",
            "Drug 280 308--*--other immune-modifying drugs",
            "Temporal 309 326--*--within six months",
            "Temporal 201 208--*--Chronic",
            "Temporal 236 253--*--more than 14 days",
            "Scope 258 308--*--immunosuppressants or other immune-modifying drugs",
            "Observation 361 368--*--Planned",
            "Drug 405 412--*--vaccine",
            "Qualifier 413 447--*--not foreseen by the study protocol",
            "Temporal 459 515--*--period starting one month before each dose of vaccine(s)",
            "Temporal 561 581--*--1 month after dose 3",
            "Temporal 520 557--*--ending 7 days after dose 1 and dose 2",
            "Drug 540 546--*--dose 1",
            "Drug 551 557--*--dose 2",
            "Drug 575 581--*--dose 3",
            "Scope 540 557--*--dose 1 and dose 2",
            "Scope 459 581--*--period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3",
            "Drug 593 604--*--vaccination",
            "Condition 613 623--*--diphtheria",
            "Condition 625 632--*--tetanus",
            "Condition 634 643--*--pertussis",
            "Condition 645 650--*--polio",
            "Condition 652 663--*--hepatitis B",
            "Condition 665 694--*--Haemophilus influenzae type b",
            "Condition 703 716--*--S. pneumoniae",
            "Temporal 782 816--*--within the first two weeks of life",
            "Qualifier 758 781--*--first dose can be given",
            "Scope 613 716--*--diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae",
            "Scope 593 716--*--vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae",
            "Drug 739 747--*--vaccines",
            "Observation 860 867--*--History",
            "Condition 887 897--*--diphtheria",
            "Condition 899 906--*--tetanus",
            "Condition 908 917--*--pertussis",
            "Condition 919 930--*--hepatitis B",
            "Condition 932 937--*--polio",
            "Condition 943 972--*--Haemophilus influenzae type b",
            "Scope 887 972--*--diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b",
            "Condition 995 1011--*--allergic disease",
            "Observation 984 991--*--History",
            "Condition 1015 1024;995 1003--*--reactions allergic",
            "Scope 995 1024--*--allergic disease or reactions",
            "Qualifier 1038 1049--*--exacerbated",
            "Condition 1096 1104--*--seizures",
            "Observation 1085 1092--*--History",
            "Condition 1185 1203--*--febrile convulsion",
            "Qualifier 1171 1184--*--uncomplicated",
            "Multiplier 1163 1169--*--single",
            "Condition 1220 1240--*--neurological disease",
            "Condition 1243 1256--*--Acute disease",
            "Temporal 1257 1281--*--at the time of enrolment",
            "Condition 1310 1327;1347 1356--*--immunosuppressive condition",
            "Condition 1331 1356--*--immunodeficient condition",
            "Observation 1398 1412--*--family history",
            "Condition 1416 1426;1441 1457--*--congenital immunodeficiency",
            "Condition 1430 1457--*--hereditary immunodeficiency",
            "Scope 1416 1457--*--congenital or hereditary immunodeficiency",
            "Condition 1460 1484--*--Major congenital defects",
            "Condition 1488 1511--*--serious chronic illness",
            "Drug 1532 1547--*--immunoglobulins",
            "Drug 1555 1573--*--any blood products",
            "Temporal 1574 1585--*--since birth",
            "Scope 1532 1573--*--immunoglobulins and/or any blood products",
            "Observation 1589 1596--*--planned",
            "Temporal 1612 1648--*--during the active phase of the study",
            "Scope 1574 1648--*--since birth or planned administration during the active phase of the study",
            "Negation 717 738--*--with the exception of",
            "Reference_point 789 816--*--the first two weeks of life",
            "Negation 1121 1135--*--does not apply",
            "Scope 1096 1240--*--seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease",
            "Reference_point 1272 1281--*--enrolment",
            "Reference_point 1623 1648--*--active phase of the study",
            "Reference_point 1580 1585--*--birth",
            "Reference_point 492 515--*--each dose of vaccine(s)",
            "Reference_point 540 557--*--dose 1 and dose 2",
            "Reference_point 575 581--*--dose 3"
        ]
    },
    "NCT00894712_exc": {
        "Annotations": [
            "Condition 8 22--*--skin pathology",
            "Condition 34 42--*--freckles",
            "Qualifier 24 33--*--excessive",
            "Condition 47 61--*--skin blemishes",
            "Condition 92 104--*--skin disease",
            "Condition 108 124--*--hypersensitivity",
            "Condition 138 155--*--contact allergies",
            "Condition 158 165--*--Sarcoma",
            "Condition 169 182--*--squamous cell",
            "Procedure 183 192--*--histology",
            "Scope 158 182--*--Sarcoma or squamous cell",
            "Condition 195 213--*--Metastatic disease",
            "Qualifier 214 227--*--to the breast",
            "Observation 238 249--*--tobacco use",
            "Temporal 230 237--*--Current"
        ],
        "Text": "Visible skin pathology, excessive freckles, or skin blemishes in the test area. . History of skin disease or hypersensitivity and repeated contact allergies. . Sarcoma or squamous cell histology. . Metastatic disease to the breast. . Current tobacco use.       .     . "
    },
    "NCT02678377_inc": {
        "Annotations": [
            "Procedure 11 37--*--mid-urethral sling surgery",
            "Condition 72 100--*--urgency urinary incontinence",
            "Condition 61 67;80 100--*--stress urinary incontinence",
            "Post-eligibility 102 199--*--Able to consent, fill out study documents, and complete all study procedures and follow-up visits",
            "Person 222 225--*--age",
            "Value 201 218--*--At least 18 years",
            "Non-query-able 227 243--*--English speaking",
            "Non-query-able 245 323--*--Be able and willing to learn clean intermittent self catheterization technique"
        ],
        "Text": "Undergoing mid-urethral sling surgery. Have symptoms of both stress and urgency urinary incontinence. Able to consent, fill out study documents, and complete all study procedures and follow-up visits. At least 18 years of age. English speaking. Be able and willing to learn clean intermittent self catheterization technique. "
    },
    "NCT03463564_exc": {
        "Annotations": [
            "Device 16 28--*--insulin pump",
            "Condition 30 39--*--pregnancy",
            "Mood 43 61--*--planning to become",
            "Condition 62 70--*--pregnant",
            "Temporal 71 90--*--in the next 2 years",
            "Negation 93 100--*--lack of",
            "Observation 101 133--*--ability to use the study devices",
            "Device 120 133--*--study devices",
            "Qualifier 146 152--*--severe",
            "Condition 153 169--*--chronic diseases",
            "Observation 135 142--*--history",
            "Temporal 171 177--*--recent",
            "Temporal 181 192--*--concomitant",
            "Drug 200 215--*--corticosteroids",
            "Scope 171 192--*--recent or concomitant",
            "Drug 217 221;233 238--*--drug abuse",
            "Drug 225 238--*--alcohol abuse",
            "Condition 240 262--*--psychiatric complaints",
            "Observation 287 313--*--correct use of the devices",
            "Mood 268 282--*--interfere with"
        ],
        "Text": "previous use of insulin pump. pregnancy or planning to become pregnant in the next 2 years,. lack of ability to use the study devices. history of severe chronic diseases. recent or concomitant use of corticosteroids. drug or alcohol abuse. psychiatric complaints that interfere with the correct use of the devices. "
    },
    "NCT02167022_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 64 66--*--2.",
            "Parsing_Error 364 366--*--3.",
            "Condition 27 61--*--CP secondary to neuronal migration",
            "Undefined_semantics 67 361--*--Co-morbidities: Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis)",
            "Post-eligibility 367 508--*--Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study.",
            "Undefined_semantics 367 508--*--Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study."
        ],
        "Text": "1. Diagnosis: Diagnosis of CP secondary to neuronal migration. . 2. Co-morbidities: Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis). . 3. Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study.       .     . "
    },
    "NCT02242188_exc": {
        "Text": "preterm delivery (<37 weeks of gestation). birth weight < 2500 g. multiple pregnancy. major illness or congenital anomaly. being <50% breastfed at the time of inclusion. food allergy. anaemia (Hb <105 g/L [10.5 g/dL]) at inclusion, lack of informed consent. ",
        "Annotations": [
            "Condition 0 16--*--preterm delivery",
            "Value 18 27--*--<37 weeks",
            "Measurement 31 40--*--gestation",
            "Scope 18 40--*--<37 weeks of gestation",
            "Measurement 43 55--*--birth weight",
            "Value 56 64--*--< 2500 g",
            "Condition 66 84--*--multiple pregnancy",
            "Condition 86 99--*--major illness",
            "Condition 103 121--*--congenital anomaly",
            "Multiplier 129 133--*--<50%",
            "Observation 134 143--*--breastfed",
            "Temporal 144 168--*--at the time of inclusion",
            "Condition 170 182--*--food allergy",
            "Condition 184 191--*--anaemia",
            "Measurement 193 195--*--Hb",
            "Value 196 204--*--<105 g/L",
            "Value 206 215--*--10.5 g/dL",
            "Scope 193 216--*--Hb <105 g/L [10.5 g/dL]",
            "Temporal 218 230--*--at inclusion",
            "Informed_consent 232 256--*--lack of informed consent"
        ]
    },
    "NCT01051414_inc": {
        "Annotations": [
            "Condition 35 38--*--HCV",
            "Qualifier 39 49--*--Genotype 1",
            "Temporal 9 20--*--chronically",
            "Multiplier 9 20--*--chronically",
            "Measurement 51 69--*--HCV RNA viral load",
            "Value 73 86--*--\u2265 10*5* IU/mL",
            "Value 88 101--*--100,000 IU/mL",
            "Temporal 103 115--*--at screening",
            "Reference_point 106 115--*--screening"
        ],
        "Text": "Subjects chronically infected with HCV Genotype 1 . HCV RNA viral load of \u2265 10*5* IU/mL (100,000 IU/mL) at screening . "
    },
    "NCT03233880_exc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 11 32--*--multi-fetal pregnancy",
            "Condition 34 51--*--diabetes mellitus",
            "Condition 53 73--*--chronic hypertension",
            "Condition 78 99--*--chronic renal disease"
        ],
        "Text": "Women with multi-fetal pregnancy, diabetes mellitus, chronic hypertension, or chronic renal disease. "
    },
    "NCT02056288_inc": {
        "Text": "Supracondylar fracture. Age 2-17 years. American Society of Anesthesiologists Status 1 -3. Scheduled for closed reduction with percutaneous pinning under general anesthesia. ",
        "Annotations": [
            "Condition 0 22--*--Supracondylar fracture",
            "Person 24 27--*--Age",
            "Value 28 38--*--2-17 years",
            "Measurement 40 84--*--American Society of Anesthesiologists Status",
            "Value 85 89--*--1 -3",
            "Procedure 105 147--*--closed reduction with percutaneous pinning",
            "Procedure 154 172--*--general anesthesia",
            "Mood 91 104--*--Scheduled for"
        ]
    },
    "NCT02364648_exc": {
        "Annotations": [
            "Condition 11 33--*--cardiovascular disease",
            "Observation 0 7--*--History",
            "Temporal 36 43--*--Current",
            "Condition 44 53--*--pregnancy",
            "Condition 69 81--*--hypertension",
            "Qualifier 56 68--*--Uncontrolled",
            "Qualifier 84 96--*--Uncontrolled",
            "Condition 97 111--*--hyperlipidemia",
            "Procedure 122 149--*--hormone replacement therapy",
            "Temporal 114 121--*--Current",
            "Observation 160 183--*--use of tobacco products",
            "Temporal 152 159--*--Current",
            "Condition 186 208--*--Elevated liver enzymes",
            "Condition 219 237--*--autoimmune disease",
            "Temporal 211 218--*--Current",
            "Multiplier 240 249--*--Daily use",
            "Drug 256 268--*--antioxidants",
            "Multiplier 269 275--*-->300mg"
        ],
        "Text": "History of cardiovascular disease;. Current pregnancy;. Uncontrolled hypertension;. Uncontrolled hyperlipidemia;. Current hormone replacement therapy;. Current use of tobacco products;. Elevated liver enzymes;. Current autoimmune disease;. Daily use of of antioxidants >300mg. "
    },
    "NCT02222272_exc": {
        "Text": "    . ",
        "Annotations": []
    },
    "NCT02833116_exc": {
        "Text": "Patients with high intracranial pressure.. Patients with Multiple Sclerosis.. Patients with Guillain-Barr\u00e9 syndrome radiculopathy of vascular origin.. Patients with previous lumbar surgery.. Patients pregnant or lactating.. Patients with allergy or intolerance to any of the drugs used.. Patients with severe cognitive impairment.. Patients with intrathecal injectio radiculalgia.. Patients with poorly controlled major psychiatric pathology.. Patients with type I diabetes or poorly controlled type II diabetes (Hb1Ac>8.5).. Patients with glaucoma.. Patients with caudal equine syndrome.. Patients with pre-treatment with steroid injections/or local anesthetics.. Patients with central canal stenosis.. patients with chronic treatment with oral corticosteroids without stabilized pattern.. ",
        "Annotations": [
            "Measurement 19 40--*--intracranial pressure",
            "Value 14 18--*--high",
            "Condition 57 75--*--Multiple Sclerosis",
            "Condition 92 129--*--Guillain-Barr\u00e9 syndrome radiculopathy",
            "Qualifier 133 141--*--vascular",
            "Procedure 174 189--*--lumbar surgery.",
            "Pregnancy_considerations 191 221--*--Patients pregnant or lactating",
            "Condition 238 245--*--allergy",
            "Condition 249 260--*--intolerance",
            "Drug 275 280--*--drugs",
            "Scope 238 260--*--allergy or intolerance",
            "Condition 309 329--*--cognitive impairment",
            "Qualifier 302 308--*--severe",
            "Procedure 346 379--*--intrathecal injectio radiculalgia",
            "Condition 420 441--*--psychiatric pathology",
            "Qualifier 414 419--*--major",
            "Qualifier 396 413--*--poorly controlled",
            "Condition 458 473--*--type I diabetes",
            "Condition 495 511--*--type II diabetes",
            "Qualifier 477 494--*--poorly controlled",
            "Measurement 513 518--*--Hb1Ac",
            "Value 518 522--*-->8.5",
            "Condition 540 548--*--glaucoma",
            "Condition 565 587--*--caudal equine syndrome",
            "Procedure 623 641--*--steroid injections",
            "Procedure 645 662--*--local anesthetics",
            "Condition 679 701--*--central canal stenosis",
            "Drug 741 761--*--oral corticosteroids"
        ]
    },
    "NCT02992938_inc": {
        "Annotations": [
            "Mood 9 22--*--scheduled for",
            "Procedure 23 36--*--thyroidectomy",
            "Procedure 42 60--*--general anesthesia",
            "Visit 68 104--*--University of Chile Clinical Hospita"
        ],
        "Text": "Patients scheduled for thyroidectomy with general anesthesia in the University of Chile Clinical Hospital. "
    },
    "NCT03278548_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT03026465_inc": {
        "Annotations": [
            "Person 23 28--*--years",
            "Value 9 22--*--older than 18",
            "Condition 30 47--*--Ischemic symptoms",
            "Mood 51 59--*--evidence",
            "Condition 63 82--*--myocardial ischemia",
            "Qualifier 84 93--*--inducible",
            "Qualifier 97 108--*--spontaneous",
            "Scope 84 108--*--inducible or spontaneous",
            "Value 129 133--*-->50%",
            "Qualifier 134 141--*--de novo",
            "Measurement 142 150--*--stenosis",
            "Condition 142 150--*--stenosis",
            "Qualifier 162 185--*--native coronary vessels"
        ],
        "Text": "Patients older than 18 years. Ischemic symptoms or evidence of myocardial ischemia (inducible or spontaneous) in the presence of >50% de novo stenosis located in native coronary vessels. "
    },
    "NCT01809041_inc": {
        "Annotations": [
            "Qualifier 6 14--*--elective",
            "Procedure 15 31;68 75--*--gastrointestinal surgery",
            "Procedure 60 75--*--bladder surgery",
            "Procedure 48 56;68 75--*--prostate surgery",
            "Procedure 33 46;68 75--*--gynecological surgery",
            "Scope 15 75--*--gastrointestinal, gynecological, prostate or bladder surgery",
            "Value 93 107--*--= 60 years old",
            "Person 104 107--*--old",
            "Procedure 125 145--*--laparoscopic surgery",
            "Measurement 165 169--*--last",
            "Value 174 182--*--= 2 hour",
            "Mood 153 161--*--expected",
            "Qualifier 184 208--*--under general anesthesia",
            "Mood 225 229--*--will",
            "Procedure 230 246--*--stay in hospital",
            "Value 251 280--*--at least 7 days after surgery",
            "Negation 283 290--*--lack of",
            "Condition 311 328--*--vision impairment",
            "Condition 299 306;318 328--*--hearing impairment",
            "Scope 299 328--*--hearing and vision impairment",
            "Condition 336 348--*--able to read",
            "Procedure 357 378--*--neurobehavioral tests",
            "Mood 379 395--*--can be performed"
        ],
        "Text": "major elective gastrointestinal, gynecological, prostate or bladder surgery patients who are = 60 years old.. the surgery is laparoscopic surgery and is expected to last for = 2 hours under general anesthesia and the patient will stay in hospital for at least 7 days after surgery.. lack of serious hearing and vision impairment and be able to read so that neurobehavioral tests can be performed.. "
    },
    "NCT03089086_inc": {
        "Annotations": [
            "Observation 17 42--*--secondary school students",
            "Qualifier 46 54--*--years 10",
            "Qualifier 46 51;56 58--*--years 11",
            "Qualifier 46 51;64 66--*--years 12",
            "Temporal 67 74--*--in 2017",
            "Scope 46 66--*--years 10, 11, and 12",
            "Visit 0 16--*--South Australian",
            "Informed_consent 76 130--*--Written parental consent for those under the age of 18",
            "Informed_consent 132 246--*--Written student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)",
            "Multiplier 285 290--*--first",
            "Procedure 291 306--*--pharyngeal swab",
            "Mood 311 321--*--willing to",
            "Observation 322 350--*--comply with study procedures"
        ],
        "Text": "South Australian secondary school students in years 10, 11, and 12 in 2017. Written parental consent for those under the age of 18. Written student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves). Available at school for at least the first pharyngeal swab and willing to comply with study procedures. "
    },
    "NCT02802644_inc": {
        "Text": "Non-ST segement elevation acute coronary syndrome. ",
        "Annotations": [
            "Condition 0 25--*--Non-ST segement elevation",
            "Condition 26 49--*--acute coronary syndrome"
        ]
    },
    "NCT01501201_inc": {
        "Annotations": [
            "Condition 0 24--*--Type 2 diabetes mellitus",
            "Measurement 30 35--*--HbA1c",
            "Value 36 43--*--> 7.5 %",
            "Measurement 45 60--*--Body mass index",
            "Value 61 80--*--> 35 and < 50 kg/m2",
            "Procedure 96 111--*--Gastric By-Pass",
            "Mood 82 91--*--Candidate",
            "Drug 128 165--*--GLP1 (glucagon-like peptide) analogue",
            "Drug 169 176--*--insulin",
            "Procedure 113 122--*--Treatment",
            "Scope 128 176--*--GLP1 (glucagon-like peptide) analogue or insulin"
        ],
        "Text": "Type 2 diabetes mellitus with HbA1c > 7.5 %. Body mass index > 35 and < 50 kg/m2. Candidate for Gastric By-Pass. Treatment with GLP1 (glucagon-like peptide) analogue or insulin. "
    },
    "NCT02957305_inc": {
        "Annotations": [
            "Visit 29 97--*--Gynecological emergency Unit at Hospital de Cl\u00ednicas de Porto Alegre",
            "Procedure 112 130--*--uterine evacuation",
            "Condition 149 158--*--gestation",
            "Multiplier 136 145--*--<12 weeks"
        ],
        "Text": "All patients admitted at the Gynecological emergency Unit at Hospital de Cl\u00ednicas de Porto Alegre scheduled for uterine evacuation with <12 weeks of gestation.. "
    },
    "NCT01531257_exc": {
        "Annotations": [
            "Procedure 12 42--*--combined organ transplantation",
            "Qualifier 51 68--*--extra-renal organ",
            "Procedure 76 97--*--islet cell transplant",
            "Scope 51 97--*--extra-renal organ and/or islet cell transplant",
            "Procedure 126 147;166 181--*--non-renal solid organ transplantation",
            "Procedure 155 181--*--islet cell transplantation",
            "Temporal 117 125--*--previous",
            "Scope 126 181--*--non-renal solid organ and/or islet cell transplantation",
            "Condition 187 205--*--Infection with HIV",
            "Non-query-able 211 298--*--Inability or unwillingness of a participant and/or guardian to provide informed consent",
            "Post-eligibility 211 298--*--Inability or unwillingness of a participant and/or guardian to provide informed consent"
        ],
        "Text": "1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. . 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. . 3. Infection with HIV. . 4. Inability or unwillingness of a participant and/or guardian to provide informed consent       .     . "
    },
    "NCT03364036_exc": {
        "Text": "Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.. Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).. Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.. Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.. History of tuberculosis , presence of active tuberculosis, or latent tuberculosis. Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).. Active malignancy or history of malignancy.. Other protocol defined exclusion criteria could apply.. ",
        "Annotations": [
            "Temporal 0 8--*--Previous",
            "Drug 21 26--*--drugs",
            "Drug 35 45--*--fingolimod",
            "Drug 47 58--*--natalizumab",
            "Drug 60 71--*--alemtuzumab",
            "Drug 73 85--*--mitoxantrone",
            "Drug 90 101--*--ocrelizumab",
            "Scope 35 101--*--fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab",
            "Value 104 112--*--Positive",
            "Measurement 113 124;140 160--*--hepatitis C surface antigen test",
            "Measurement 128 160--*--hepatitis B surface antigen test",
            "Measurement 168 197--*--hepatits B core antibody test",
            "Qualifier 202 224--*--immunoglobulin G (IgG)",
            "Qualifier 232 254--*--immunoglobulin M (IgM)",
            "Scope 202 254--*--immunoglobulin G (IgG) and/or immunoglobulin M (IgM)",
            "Scope 113 254--*--hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM)",
            "Temporal 257 264--*--Current",
            "Temporal 268 284--*--previous history",
            "Condition 288 315--*--immune deficiency disorders",
            "Measurement 337 371--*--human immunodeficiency virus (HIV)",
            "Value 328 336--*--positive",
            "Scope 257 284--*--Current or previous history",
            "Procedure 401 418;439 446--*--immunosuppressive therapy",
            "Procedure 422 446--*--myelosuppressive therapy",
            "Temporal 381 390--*--Currently",
            "Drug 466 487--*--monoclonal antibodies",
            "Drug 489 501--*--methotrexate",
            "Drug 503 519--*--cyclophosphamide",
            "Drug 521 533--*--cyclosporine",
            "Drug 537 549--*--azathioprine",
            "Drug 569 584--*--corticosteroids",
            "Multiplier 554 565--*--chronic use",
            "Scope 466 584--*--monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids",
            "Scope 401 446--*--immunosuppressive or myelosuppressive therapy",
            "Procedure 598 610--*--tuberculosis",
            "Procedure 632 644--*--tuberculosis",
            "Procedure 656 668--*--tuberculosis",
            "Qualifier 649 655--*--latent",
            "Qualifier 625 631--*--active",
            "Observation 587 594--*--History",
            "Condition 693 741--*--Progressive Multifocal Leukoencephalopathy (PML)",
            "Procedure 745 777--*--Magnetic Resonance Imaging (MRI)",
            "Mood 670 678--*--Evidence",
            "Mood 682 689--*--suspect",
            "Scope 670 689--*--Evidence or suspect",
            "Observation 801 808--*--history",
            "Condition 812 822--*--malignancy",
            "Condition 787 797--*--malignancy",
            "Qualifier 780 786--*--Active",
            "Non-representable 825 879--*--Other protocol defined exclusion criteria could apply."
        ]
    },
    "NCT03299517_inc": {
        "Text": "Adult men and women> 18 years old. Presence of sustained ventricular tachycardia with HR> 120 bpm. Systolic blood pressure> 90 mmHg. No signs of poor peripheral perfusion. Absence of dyspnea. Absence of severe angina. Signed consent form. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 6 9--*--men",
            "Person 14 19--*--women",
            "Value 19 33--*--> 18 years old",
            "Person 30 33--*--old",
            "Qualifier 47 56--*--sustained",
            "Condition 57 80--*--ventricular tachycardia",
            "Measurement 86 88--*--HR",
            "Value 88 97--*--> 120 bpm",
            "Measurement 99 122--*--Systolic blood pressure",
            "Value 122 131--*--> 90 mmHg",
            "Negation 133 135--*--No",
            "Mood 136 144--*--signs of",
            "Condition 145 170--*--poor peripheral perfusion",
            "Condition 183 190--*--dyspnea",
            "Negation 172 182--*--Absence of",
            "Negation 192 202--*--Absence of",
            "Condition 210 216--*--angina",
            "Qualifier 203 209--*--severe",
            "Informed_consent 218 237--*--Signed consent form"
        ]
    },
    "NCT03278548_inc": {
        "Annotations": [
            "Qualifier 20 28--*--elective",
            "Procedure 29 46--*--abdominal surgery",
            "Measurement 55 74--*--expected blood loss",
            "Value 78 86--*--= 500 ml",
            "Measurement 88 107--*--ASA Physical Status",
            "Value 108 116--*--II - III",
            "Informed_consent 118 154--*--Signed written informed consent form",
            "Measurement 156 167--*--Body weight",
            "Value 168 176--*--= 140 kg",
            "Condition 178 184--*--Sepsis",
            "Condition 186 191--*--Burns",
            "Condition 193 209--*--Renal impairment",
            "Measurement 211 221--*--AKIN stage",
            "Value 222 225--*--= 1",
            "Qualifier 230 235--*--acute",
            "Qualifier 243 250--*--chronic",
            "Procedure 251 276--*--renal replacement therapy",
            "Scope 230 250--*--acute and/or chronic",
            "Condition 294 314--*--cerebral haemorrhage",
            "Condition 278 290;303 314--*--Intracranial haemorrhage",
            "Condition 316 330--*--Critically ill",
            "Visit 367 386--*--intensive care unit",
            "Mood 341 350--*--typically",
            "Procedure 351 359--*--admitted",
            "Condition 389 403--*--Hyperhydration",
            "Condition 405 421--*--Pulmonary oedema",
            "Condition 423 434--*--Dehydration",
            "Condition 436 449--*--Hyperkalaemia",
            "Condition 458 472--*--hypernatraemia",
            "Qualifier 451 457--*--Severe",
            "Condition 481 496--*--hyperchloraemia",
            "Qualifier 474 480--*--Severe",
            "Condition 507 532--*--impaired hepatic function",
            "Qualifier 498 506--*--Severely",
            "Condition 534 558--*--Congestive heart failure",
            "Condition 567 579--*--coagulopathy",
            "Qualifier 560 566--*--Severe",
            "Procedure 581 597--*--Organ transplant",
            "Condition 608 627--*--Metabolic alkalosis",
            "Competing_trial 629 731--*--Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)"
        ],
        "Text": "Patients undergoing elective abdominal surgery with an expected blood loss of = 500 ml. ASA Physical Status II - III. Signed written informed consent form. Body weight = 140 kg. Sepsis. Burns. Renal impairment (AKIN stage = 1) or acute and/or chronic renal replacement therapy. Intracranial or cerebral haemorrhage. Critically ill patients (typically admitted to the intensive care unit). Hyperhydration. Pulmonary oedema. Dehydration. Hyperkalaemia. Severe hypernatraemia. Severe hyperchloraemia. Severely impaired hepatic function. Congestive heart failure. Severe coagulopathy. Organ transplant patients. Metabolic alkalosis. Simultaneous participation in another interventional clinical trial (drugs or medical devices studies). "
    },
    "NCT03026465_exc": {
        "Annotations": [
            "Condition 0 13--*--Target lesion",
            "Qualifier 29 43--*--left main stem",
            "Condition 45 50--*--STEMI",
            "Condition 52 62--*--Restenosis",
            "Condition 64 81--*--Cardiogenic shock",
            "Condition 83 95--*--Malignancies",
            "Condition 105 124--*--comorbid conditions",
            "Qualifier 99 104--*--other",
            "Observation 130 145--*--life expectancy",
            "Value 146 165--*--less than 12 months",
            "Observation 188 210--*--protocol noncompliance",
            "Mood 174 177--*--may",
            "Scope 130 210--*--life expectancy less than 12 months or that may result in protocol noncompliance",
            "Scope 83 124--*--Malignancies or other comorbid conditions",
            "Condition 218 225--*--allergy",
            "Drug 233 250--*--study medications",
            "Drug 252 260--*--probucol",
            "Drug 262 271--*--sirolimus",
            "Drug 273 284--*--zotarolimus",
            "Scope 252 284--*--probucol, sirolimus, zotarolimus",
            "Condition 287 296--*--Pregnancy",
            "Temporal 298 305--*--present",
            "Mood 307 316--*--suspected",
            "Mood 321 328--*--planned",
            "Scope 298 328--*--present, suspected, or planned"
        ],
        "Text": "Target lesion located in the left main stem. STEMI. Restenosis. Cardiogenic shock. Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol noncompliance. Known allergy to the study medications (probucol, sirolimus, zotarolimus). Pregnancy (present, suspected, or planned). "
    },
    "NCT02992938_exc": {
        "Annotations": [
            "Measurement 9 12--*--ASA",
            "Value 13 21--*--III y IV",
            "Condition 23 35--*--Chronic pain",
            "Condition 45 49;62 67--*--Drug abuse",
            "Condition 54 67--*--alcohol abuse",
            "Drug 84 90--*--opioid",
            "Drug 95 104--*--sedatives",
            "Multiplier 69 80--*--Chronic use",
            "Scope 84 104--*--opioid and sedatives",
            "Condition 106 130--*--Neuropsychiatric illness",
            "Drug 132 137--*--NSAID",
            "Qualifier 142 147--*--other",
            "Drug 148 158--*--analgesics",
            "Temporal 168 200--*--48 hours previous to the surgery",
            "Reference_point 189 200--*--the surgery",
            "Scope 132 158--*--NSAID and other analgesics",
            "Measurement 202 205--*--CMI",
            "Value 206 209--*--> 3"
        ],
        "Text": "Patients ASA III y IV. Chronic pain history. Drug and alcohol abuse. Chronic use of opioid and sedatives. Neuropsychiatric illness. NSAID and other analgesics used the 48 hours previous to the surgery. CMI > 30. "
    },
    "NCT03089086_exc": {
        "Annotations": [
            "Condition 9 20--*--anaphylaxis",
            "Temporal 0 8--*--Previous",
            "Drug 48 63--*--Bexsero vaccine",
            "Temporal 65 73--*--Previous",
            "Drug 85 108--*--meningococcal B vaccine",
            "Drug 110 117--*--Bexsero",
            "Condition 126 135--*--pregnancy"
        ],
        "Text": "Previous anaphylaxis following any component of Bexsero vaccine. Previous receipt of meningococcal B vaccine (Bexsero). Known pregnancy. "
    },
    "NCT02802644_exc": {
        "Text": "Left main disease. Known hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin. Congestive heart failure (patients with LVEF <30% or cardiogenic shock). Uncontrolled myocardial ischemia (repeated chest pain or dyspnea after revascularization). Uncontrolled ventricular arrhythmia. History of malignancy with chemotherapy. Serious hematologic disease (e.g. CML, MDS). Current infectious disease needs antibiotics therapy. Creatinine level >1.5 mg/dL or dependence on dialysis. Other severe concurrent illness (e.g. active infection, malignancy).. Life expectancy of less than one year. Pregnancy or women with potential childbearing. Type I DM. Treatment with insulin. History of pancreatitis. Who cannot read the informed consent form (e.g. illiteracy, foreigner). ",
        "Annotations": [
            "Condition 0 17--*--Left main disease",
            "Condition 25 41--*--hypersensitivity",
            "Condition 45 61--*--contraindication",
            "Drug 99 106--*--Heparin",
            "Drug 108 115--*--aspirin",
            "Drug 117 128--*--clopidogrel",
            "Drug 130 139--*--sirolimus",
            "Drug 141 153--*--siptagliptin",
            "Drug 158 164--*--statin",
            "Scope 99 164--*--Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin",
            "Scope 25 61--*--hypersensitivity or contraindication",
            "Condition 166 190--*--Congestive heart failure",
            "Measurement 206 210--*--LVEF",
            "Value 211 215--*--<30%",
            "Condition 219 236--*--cardiogenic shock",
            "Scope 207 236--*--VEF <30% or cardiogenic shock",
            "Condition 252 271--*--myocardial ischemia",
            "Qualifier 239 251--*--Uncontrolled",
            "Condition 282 292--*--chest pain",
            "Qualifier 273 281--*--repeated",
            "Condition 296 303--*--dyspnea",
            "Temporal 304 327--*--after revascularization",
            "Reference_point 310 327--*--revascularization",
            "Procedure 310 327--*--revascularization",
            "Scope 282 303--*--chest pain or dyspnea",
            "Condition 343 365--*--ventricular arrhythmia",
            "Qualifier 330 342--*--Uncontrolled",
            "Condition 378 388--*--malignancy",
            "Procedure 394 406--*--chemotherapy",
            "Condition 416 435--*--hematologic disease",
            "Qualifier 408 415--*--Serious",
            "Condition 442 445--*--CML",
            "Condition 447 450--*--MDS",
            "Scope 442 450--*--CML, MDS",
            "Condition 461 479--*--infectious disease",
            "Drug 486 497--*--antibiotics",
            "Measurement 507 523--*--Creatinine level",
            "Value 524 534--*-->1.5 mg/dL",
            "Procedure 552 560--*--dialysis",
            "Condition 600 616--*--active infection",
            "Condition 618 628--*--malignancy",
            "Condition 586 593--*--illness",
            "Qualifier 575 585--*--concurrent",
            "Qualifier 568 574--*--severe",
            "Scope 600 628--*--active infection, malignancy",
            "Observation 633 647--*--ife expectancy",
            "Value 651 669--*--less than one year",
            "Pregnancy_considerations 671 717--*--Pregnancy or women with potential childbearing",
            "Condition 719 728--*--Type I DM",
            "Drug 745 752--*--insulin",
            "Condition 765 777--*--pancreatitis",
            "Informed_consent 779 849--*--Who cannot read the informed consent form (e.g. illiteracy, foreigner)"
        ]
    },
    "NCT01809041_exc": {
        "Annotations": [
            "Observation 17 37--*--expected to be alive",
            "Negation 13 16--*--not",
            "Value 42 62--*--longer than 3 months",
            "Measurement 65 101--*--Mini-mental State Examination (MMSE)",
            "Value 113 117--*--= 23",
            "Condition 131 139--*--dementia",
            "Condition 141 160--*--psychiatric illness",
            "Condition 168 202--*--diseases of central nervous system",
            "Drug 220 229--*--sedatives",
            "Temporal 205 212--*--current",
            "Drug 233 247--*--antidepressant",
            "Scope 220 247--*--sedatives or antidepressant",
            "Condition 250 260--*--alcoholism",
            "Condition 265 280--*--drug dependence",
            "Non-query-able 283 405--*--patients previously included in this study (for patients who have second intra-abdominal surgery during the study period).",
            "Non-query-able 407 463--*--difficult to follow up or patients with poor compliance.",
            "Condition 465 490--*--uncontrolled hypertension",
            "Value 492 506--*--> 180/100 mmHg"
        ],
        "Text": "Patients are not expected to be alive for longer than 3 months.. Mini-mental State Examination (MMSE) [18] score = 23.. history of dementia, psychiatric illness or any diseases of central nervous system.. current use of sedatives or antidepressant.. alcoholism and drug dependence.. patients previously included in this study (for patients who have second intra-abdominal surgery during the study period).. difficult to follow up or patients with poor compliance.. uncontrolled hypertension (> 180/100 mmHg). "
    },
    "NCT01501201_exc": {
        "Annotations": [
            "Procedure 20 37--*--bariatric surgery",
            "Condition 0 16--*--Contraindication",
            "Condition 39 48--*--Pregnancy",
            "Observation 50 86--*--Affiliation of health care assurance",
            "Condition 88 109--*--Psychiatric disorders"
        ],
        "Text": "Contraindication to bariatric surgery. Pregnancy. Affiliation of health care assurance. Psychiatric disorders. "
    },
    "NCT03299517_exc": {
        "Text": "Pregnancy. Hemodynamic instability. Body mass index greater than 40 kg / m2. Use of intravenous amiodarone or lidocaine in the last 24 hours. Acute coronary syndrome. Presence of tachycardia with irregular or supraventricular RR. Contraindications to study drugs. ",
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 11 34--*--Hemodynamic instability",
            "Measurement 36 51--*--Body mass index",
            "Value 52 75--*--greater than 40 kg / m2",
            "Qualifier 84 95--*--intravenous",
            "Drug 96 106--*--amiodarone",
            "Drug 110 119--*--lidocaine",
            "Temporal 120 140--*--in the last 24 hours",
            "Scope 96 119--*--amiodarone or lidocaine",
            "Condition 142 165--*--Acute coronary syndrome",
            "Condition 179 190--*--tachycardia",
            "Condition 196 205;226 228--*--irregular RR",
            "Condition 209 228--*--supraventricular RR",
            "Condition 230 247--*--Contraindications",
            "Drug 251 262--*--study drugs"
        ]
    },
    "NCT03364036_inc": {
        "Text": "Highly active RMS as defined by:. One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs). Two or more relapses in the previous year, whether on DMD treatment or not.. Expanded Disability Status Scale (EDSS) score less than equals to (<=) 5.0.. Other protocol defined inclusion criteria could apply.. ",
        "Annotations": [
            "Qualifier 0 13--*--Highly active",
            "Condition 14 17--*--RMS",
            "Non-representable 18 32--*--as defined by:",
            "Multiplier 34 37--*--One",
            "Condition 38 45--*--relapse",
            "Temporal 46 66--*--in the previous year",
            "Multiplier 71 81--*--at least 1",
            "Condition 102 108--*--lesion",
            "Qualifier 82 101--*--T1 Gadolinium (Gd)+",
            "Multiplier 112 121--*--9 or more",
            "Condition 122 132--*--T2 lesions",
            "Temporal 134 150--*--while on therapy",
            "Reference_point 143 150--*--therapy",
            "Procedure 143 150--*--therapy",
            "Drug 162 192--*--disease modifying drugs (DMDs)",
            "Qualifier 156 161--*--other",
            "Scope 34 132--*--One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions",
            "Multiplier 194 205--*--Two or more",
            "Condition 206 214--*--relapses",
            "Temporal 215 235--*--in the previous year",
            "Measurement 271 316--*--Expanded Disability Status Scale (EDSS) score",
            "Value 317 345--*--less than equals to (<=) 5.0",
            "Post-eligibility 348 402--*--Other protocol defined inclusion criteria could apply."
        ]
    },
    "NCT01531257_inc": {
        "Annotations": [
            "Person 3 7--*--Male",
            "Person 12 18--*--female",
            "Value 44 53--*--\u226518 years",
            "Person 57 60--*--age",
            "Multiplier 86 93--*--primary",
            "Multiplier 97 107--*--subsequent",
            "Procedure 126 161--*--living donor kidney transplantation",
            "Procedure 108 122;139 161--*--deceased-donor kidney transplantation",
            "Scope 108 161--*--deceased-donor or living donor kidney transplantation",
            "Scope 86 107--*--primary or subsequent",
            "Non-query-able 167 232--*--Subject and/or guardian must be able to provide informed consent.",
            "Post-eligibility 167 232--*--Subject and/or guardian must be able to provide informed consent.",
            "Non-query-able 237 308--*--Subject and/or guardian must be able to comply with the study protocol.",
            "Post-eligibility 237 308--*--Subject and/or guardian must be able to comply with the study protocol."
        ],
        "Text": "1. Male and female recipients of all races, \u226518 years of age. . 2. Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation. . 3. Subject and/or guardian must be able to provide informed consent. . 4. Subject and/or guardian must be able to comply with the study protocol. . "
    },
    "NCT02957305_exc": {
        "Annotations": [
            "Post-eligibility 0 54--*--patients who do not wish to participate in the project",
            "Condition 71 88--*--ectopic pregnancy",
            "Condition 105 118--*--comorbidities",
            "Condition 120 144--*--heart failure congestive",
            "Condition 146 183--*--chronic obstructive pulmonary disease",
            "Scope 120 183--*--heart failure congestive, chronic obstructive pulmonary disease",
            "Condition 201 218--*--hypovolemic shock",
            "Condition 235 256--*--cervical incompetence",
            "Qualifier 273 281--*--infected",
            "Condition 294 302--*--abortion",
            "Condition 282 293--*--miscarriage",
            "Scope 282 302--*--miscarriage/abortion",
            "Condition 316 321--*--fever",
            "Condition 323 342--*--pus from the cervix",
            "Measurement 344 356--*--leukocytosis",
            "Temporal 358 365--*--> 14000",
            "Scope 316 366--*--fever, pus from the cervix, leukocytosis [> 14000]",
            "Qualifier 384 388--*--twin",
            "Condition 389 398--*--pregnancy",
            "Condition 415 430--*--Marfan syndrome",
            "Condition 442 450--*--allergic",
            "Drug 454 465--*--misoprostol",
            "Condition 482 494--*--coagulopathy",
            "Observation 511 542--*--opening of cervical internal os",
            "Value 544 562--*--4 mm of dilatation",
            "Procedure 617 624--*--surgery",
            "Qualifier 632 638--*--cervix",
            "Procedure 640 650--*--conization",
            "Drug 687 691--*--IUDs"
        ],
        "Text": "patients who do not wish to participate in the project;. patients with ectopic pregnancy;. patients with comorbidities (heart failure congestive, chronic obstructive pulmonary disease);. patients with hypovolemic shock;. patients with cervical incompetence;. patients with infected miscarriage/abortion (presence of fever, pus from the cervix, leukocytosis [> 14000]);. patients with twin pregnancy;. patients with Marfan syndrome;. patients allergic to misoprostol;. patients with coagulopathy;. patients with opening of cervical internal os (4 mm of dilatation at the time of consultation);. patients with previous surgery of the cervix (conization);. patients with concomitant use of IUDs.. "
    },
    "NCT02746900_exc": {
        "Text": "Multiple pregnancy. Prior spontaneous preterm birth or second trimester losses between 16(0) and 36(6) weeks. Cerclage in situ. Painful regular uterine contraction and/or preterm labor. Ruptured membranes. Major fetal defects. Active vaginal bleeding. Placenda previa and/or accreta. Cervical dilation >1.5 cm and/or visible membranes by pelvic exam. Suspicion of chorioamnionitis. ",
        "Annotations": [
            "Condition 0 18--*--Multiple pregnancy",
            "Temporal 20 25--*--Prior",
            "Condition 26 51--*--spontaneous preterm birth",
            "Condition 72 78--*--losses",
            "Qualifier 79 108--*--between 16(0) and 36(6) weeks",
            "Qualifier 55 71--*--second trimester",
            "Scope 26 108--*--spontaneous preterm birth or second trimester losses between 16(0) and 36(6) weeks",
            "Condition 110 126--*--Cerclage in situ",
            "Condition 128 163--*--Painful regular uterine contraction",
            "Condition 171 184--*--preterm labor",
            "Condition 186 204--*--Ruptured membranes",
            "Condition 206 225--*--Major fetal defects",
            "Condition 227 250--*--Active vaginal bleeding",
            "Condition 252 267--*--Placenda previa",
            "Condition 275 282--*--accreta",
            "Measurement 284 301--*--Cervical dilation",
            "Value 302 309--*-->1.5 cm",
            "Condition 317 334--*--visible membranes",
            "Procedure 338 349--*--pelvic exam",
            "Mood 351 363--*--Suspicion of",
            "Condition 364 380--*--chorioamnionitis"
        ]
    },
    "NCT02704754_inc": {
        "Text": "Physically healthy adults age 18-55 who meet DSM-5 criteria for insomnia and Criterion A (exposure to a traumatic event) for PTSD. The index trauma must have occurred within the past 5 years and at least 3 months before enrolling, and insomnia symptoms must have started or worsened after the exposure to the index trauma. ",
        "Annotations": [
            "Qualifier 11 18--*--healthy",
            "Person 19 25--*--adults",
            "Person 26 29--*--age",
            "Value 30 35--*--18-55",
            "Condition 64 72--*--insomnia",
            "Qualifier 45 50--*--DSM-5",
            "Condition 125 129--*--PTSD",
            "Qualifier 77 88--*--Criterion A",
            "Condition 141 147--*--trauma",
            "Qualifier 135 140--*--index",
            "Temporal 174 212--*--the past 5 years and at least 3 months",
            "Non-query-able 231 321--*--and insomnia symptoms must have started or worsened after the exposure to the index trauma"
        ]
    },
    "NCT02965027_inc": {
        "Text": "Male and female Active-duty SMs or Veterans aged 18 or older who are in good general health.. History of blast and/or impact head trauma mTBI meeting Defense and Veterans Brain Injury Center (DVBIC) mTBI criteria, which define mTBI as an injury to the head causing at least one of the following: alteration in consciousness (for up to 24 hours after the injury), loss of consciousness 0-30 minutes, and/or post-traumatic amnesia up to 1 day post-injury. If available, the Glasgow Coma Scale score must be 13-15, and head imaging findings (if imaging was performed) must be negative.. Frequent HAs that started within 3months after a head injury. The HAs either 1) must last 4 or more hours a day and reach a moderate to severe intensity at any point during the headache, or 2) may be of any severity or duration if the participant takes a triptan or ergotamine. HAs meeting these criteria must have been present on average at least 8 days per 4-week period, starting within 30 days after head injury and occurring by self-report for at least 3 months prior to the Initial Screening Visit. The 4-week HA frequency/severity criteria must be confirmed during the Preliminary Screening Period.. Women of childbearing potential must agree to abstain from sexual relations that could result in pregnancy or use an effective method of birth control acceptable to both participant and the clinician prescriber during the study. Men are not required to use contraception during the study.. Participants must have English fluency sufficient to complete study measures.. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 16 31--*--Active-duty SMs",
            "Person 35 43--*--Veterans",
            "Value 49 60--*--18 or older",
            "Person 44 48--*--aged",
            "Condition 72 91--*--good general health",
            "Observation 105 110--*--blast",
            "Observation 94 104--*--History of",
            "Condition 118 136--*--impact head trauma",
            "Measurement 150 212--*--Defense and Veterans Brain Injury Center (DVBIC) mTBI criteria",
            "Value 142 149--*--meeting",
            "Condition 296 323--*--alteration in consciousness",
            "Temporal 325 360--*--for up to 24 hours after the injury",
            "Reference_point 350 360--*--the injury",
            "Condition 363 384--*--loss of consciousness",
            "Temporal 385 397--*--0-30 minutes",
            "Condition 406 428--*--post-traumatic amnesia",
            "Temporal 429 452--*--up to 1 day post-injury",
            "Measurement 472 490--*--Glasgow Coma Scale",
            "Value 505 510--*--13-15",
            "Procedure 516 528--*--head imaging",
            "Condition 529 537--*--findings",
            "Negation 573 581--*--negative",
            "Scope 296 452--*--alteration in consciousness (for up to 24 hours after the injury), loss of consciousness 0-30 minutes, and/or post-traumatic amnesia up to 1 day post-injury",
            "Condition 593 596--*--HAs",
            "Qualifier 584 592--*--Frequent",
            "Temporal 610 644--*--within 3months after a head injury",
            "Reference_point 631 644--*--a head injury",
            "Condition 650 653--*--HAs",
            "Multiplier 669 695--*--last 4 or more hours a day",
            "Qualifier 708 736--*--moderate to severe intensity",
            "Drug 839 846--*--triptan",
            "Drug 850 860--*--ergotamine",
            "Multiplier 923 956--*--at least 8 days per 4-week period",
            "Temporal 967 999--*--within 30 days after head injury",
            "Temporal 1033 1087--*--at least 3 months prior to the Initial Screening Visit",
            "Reference_point 1060 1087--*--the Initial Screening Visit",
            "Scope 669 736--*--last 4 or more hours a day and reach a moderate to severe intensity",
            "Scope 839 860--*--triptan or ergotamine",
            "Scope 669 860--*--last 4 or more hours a day and reach a moderate to severe intensity at any point during the headache, or 2) may be of any severity or duration if the participant takes a triptan or ergotamine",
            "Pregnancy_considerations 1191 1479--*--Women of childbearing potential must agree to abstain from sexual relations that could result in pregnancy or use an effective method of birth control acceptable to both participant and the clinician prescriber during the study. Men are not required to use contraception during the study.",
            "Non-query-able 1482 1557--*--articipants must have English fluency sufficient to complete study measures"
        ]
    },
    "NCT03318874_exc": {
        "Text": "Glaucoma,. Ocular allergy. Autoimmune disease. Contact lens-wear during study. Current punctal plugging. Pregnant/lactating. Candidate for topical anti-inflammatory. Cicatricial meibomian gland dysfunction. ",
        "Annotations": [
            "Condition 0 8--*--Glaucoma",
            "Condition 11 25--*--Ocular allergy",
            "Condition 27 45--*--Autoimmune disease",
            "Observation 47 64--*--Contact lens-wear",
            "Temporal 65 77--*--during study",
            "Temporal 79 86--*--Current",
            "Condition 87 103--*--punctal plugging",
            "Condition 105 113--*--Pregnant",
            "Condition 114 123--*--lactating",
            "Mood 125 138--*--Candidate for",
            "Drug 139 164--*--topical anti-inflammatory",
            "Qualifier 166 177--*--Cicatricial",
            "Condition 178 205--*--meibomian gland dysfunction"
        ]
    },
    "NCT02550769_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 17--*--over 18 years",
            "Condition 33 46--*--rectal cancer",
            "Qualifier 47 52--*--stage",
            "Measurement 54 56--*--cT",
            "Measurement 63 65--*--cN",
            "Measurement 70 72--*--cM",
            "Value 56 61--*--1-2-3",
            "Value 65 68--*--0-1",
            "Value 72 73--*--0",
            "Scope 54 73--*--cT1-2-3, cN0-1, cM0",
            "Qualifier 82 122--*--equal or below 10 cm from the anal verge",
            "Mood 124 134--*--candidates",
            "Procedure 144 166--*--low anterior resection",
            "Procedure 144 156;171 182--*--low anterior anastomosis",
            "Scope 144 182--*--low anterior resection and anastomosis",
            "Temporal 200 212--*--preoperative",
            "Procedure 213 231--*--chemo-radiotherapy",
            "Condition 76 81--*--Tumor",
            "Condition 234 248--*--Adenocarcinoma",
            "Qualifier 252 283--*--low or moderate differentiation",
            "Measurement 285 288--*--ASA",
            "Value 289 299--*--I, II, III"
        ],
        "Text": "Age over 18 years. Patients with rectal cancer stage: cT1-2-3, cN0-1, cM0.. Tumor equal or below 10 cm from the anal verge, candidates to (ETM) low anterior resection and anastomosis, with or without preoperative chemo-radiotherapy.. Adenocarcinoma of low or moderate differentiation. ASA I, II, III.. "
    },
    "NCT02637076_exc": {
        "Text": "use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine at start of baseline period. significant unstable or uncontrolled medical/psychiatric disease. significant history of head trauma/surgery or seizure disorder. radiation exposure exceeding 20mSv in last 12 months. pregnancy. substance abuse/dependence (including alcohol). have sleep apnea, or are shift workers. on a sodium-restricted diet. has ever taken Xyrem / sodium oxybate / GHB at any time. claustrophobia. metal implants / objects in the body that may interfere with MRI. succinic semialdehyde dehydrogenase deficiency. ",
        "Annotations": [
            "Drug 11 29--*--sedative hypnotics",
            "Drug 31 44--*--tranquilizers",
            "Drug 46 61--*--anticonvulsants",
            "Drug 63 77--*--antihistamines",
            "Qualifier 86 98--*--non-sedating",
            "Negation 79 85--*--except",
            "Drug 101 116--*--benzodiazepines",
            "Drug 118 127--*--clonidine",
            "Drug 135 170--*--medication known to affect dopamine",
            "Temporal 171 198--*--at start of baseline period",
            "Scope 11 170--*--sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine",
            "Qualifier 200 211--*--significant",
            "Qualifier 224 236--*--uncontrolled",
            "Qualifier 212 220--*--unstable",
            "Scope 212 236--*--unstable or uncontrolled",
            "Condition 245 264--*--psychiatric disease",
            "Condition 237 244;257 264--*--medical disease",
            "Scope 237 264--*--medical/psychiatric disease",
            "Condition 289 300--*--head trauma",
            "Procedure 289 293;301 308--*--head surgery",
            "Condition 312 328--*--seizure disorder",
            "Observation 278 285--*--history",
            "Scope 289 328--*--head trauma/surgery or seizure disorder",
            "Qualifier 266 277--*--significant",
            "Condition 330 348--*--radiation exposure",
            "Value 349 364--*--exceeding 20mSv",
            "Temporal 365 382--*--in last 12 months",
            "Condition 384 393--*--pregnancy",
            "Condition 395 410--*--substance abuse",
            "Condition 395 404;411 421--*--substance dependence",
            "Drug 433 440--*--alcohol",
            "Scope 395 421--*--substance abuse/dependence",
            "Condition 448 459--*--sleep apnea",
            "Person 468 481--*--shift workers",
            "Procedure 488 510--*--sodium-restricted diet",
            "Drug 527 532--*--Xyrem",
            "Drug 535 549--*--sodium oxybate",
            "Drug 552 555--*--GHB",
            "Temporal 516 520--*--ever",
            "Scope 527 555--*--Xyrem / sodium oxybate / GHB",
            "Condition 569 583--*--claustrophobia",
            "Device 585 599--*--metal implants",
            "Device 585 590;602 609--*--metal objects",
            "Mood 627 645--*--may interfere with",
            "Procedure 646 649--*--MRI",
            "Scope 585 609--*--metal implants / objects",
            "Condition 651 697--*--succinic semialdehyde dehydrogenase deficiency"
        ]
    },
    "NCT01866800_inc": {
        "Annotations": [
            "Value 11 19--*--65 years",
            "Person 20 23--*--old",
            "Informed_consent 31 75--*--able and willing to give an informed consent",
            "Procedure 106 124--*--trans-femoral TAVI",
            "Temporal 87 97--*--undergoing",
            "Qualifier 98 105--*--planned",
            "Measurement 127 142--*--Calculated eGFR",
            "Value 143 164--*--below 60ml/min/1.73m2"
        ],
        "Text": "Subject is 65 years old who is able and willing to give an informed consent.. Patients undergoing planned trans-femoral TAVI.. Calculated eGFR below 60ml/min/1.73m2 (MDRD). "
    },
    "NCT02704754_exc": {
        "Text": "Psychiatric disorders other than insomnia, PTSD and specific phobias; including bipolar and psychotic disorders and meeting criteria for DSM-5 moderate alcohol or drug use disorders within the past year.. Diagnosis of a sleep disorder other than insomnia including PSG findings of apnea/hypopnea or periodic limb movement indices > 10/hour;. Medical conditions that require consistent use of medication or compromise sleep;. History of moderate to severe traumatic brain injury or mild traumatic brain injury with ongoing post-concussive symptoms;. Suicidal ideation with intent to act or with specific plan and intent in the past 6 months (Type 4 - 5 ideation on the Columbia Suicide Severity Rating Scale) or a concerning history of prior suicidal behavior.. Caffeine use exceeding 5 cups of coffee per day or its equivalent;. Habitual bedtimes after 3 AM, habitual rise times after 10 AM, or habitual napping > 1hour/day;. Pregnancy or breastfeeding, or expecting to conceive while in study;. Positive urine toxicology.. ",
        "Annotations": [
            "Condition 0 21--*--Psychiatric disorders",
            "Negation 22 27--*--other",
            "Condition 33 41--*--insomnia",
            "Condition 43 47--*--PTSD",
            "Condition 61 68--*--phobias",
            "Condition 80 87--*--bipolar",
            "Condition 92 111--*--psychotic disorders",
            "Temporal 193 202--*--past year",
            "Qualifier 137 142--*--DSM-5",
            "Qualifier 143 151--*--moderate",
            "Condition 163 181--*--drug use disorders",
            "Condition 152 159;168 181--*--alcohol use disorders",
            "Scope 80 111--*--bipolar and psychotic disorders",
            "Scope 33 68--*--insomnia, PTSD and specific phobias",
            "Scope 152 181--*--alcohol or drug use disorders",
            "Condition 220 234--*--sleep disorder",
            "Negation 235 240--*--other",
            "Condition 246 254--*--insomnia",
            "Condition 281 286--*--apnea",
            "Condition 287 295--*--hypopnea",
            "Measurement 299 329--*--periodic limb movement indices",
            "Value 330 339--*--> 10/hour",
            "Measurement 265 268--*--PSG",
            "Scope 281 295--*--apnea/hypopnea",
            "Scope 265 339--*--PSG findings of apnea/hypopnea or periodic limb movement indices > 10/hour",
            "Non-query-able 342 422--*--Medical conditions that require consistent use of medication or compromise sleep",
            "Condition 455 477--*--traumatic brain injury",
            "Qualifier 436 444--*--moderate",
            "Qualifier 448 454--*--severe",
            "Condition 486 508--*--traumatic brain injury",
            "Qualifier 481 485--*--mild",
            "Condition 522 546--*--post-concussive symptoms",
            "Scope 436 454--*--moderate to severe",
            "Condition 549 566--*--Suicidal ideation",
            "Temporal 626 639--*--past 6 months",
            "Measurement 668 706--*--Columbia Suicide Severity Rating Scale",
            "Value 641 645;650 660--*--Type 5 ideation",
            "Value 641 647;652 660--*--Type 4 ideation",
            "Scope 641 660--*--Type 4 - 5 ideation",
            "Condition 741 759--*--suicidal behavior.",
            "Drug 761 769--*--Caffeine",
            "Non-query-able 761 826--*--Caffeine use exceeding 5 cups of coffee per day or its equivalent",
            "Non-query-able 829 923--*--Habitual bedtimes after 3 AM, habitual rise times after 10 AM, or habitual napping > 1hour/day",
            "Pregnancy_considerations 926 993--*--Pregnancy or breastfeeding, or expecting to conceive while in study",
            "Measurement 1005 1021--*--urine toxicology",
            "Value 996 1004--*--Positive"
        ]
    },
    "NCT02746900_inc": {
        "Text": "18-50 ages. Singleton pregnancy. Cervical length <=25mm between 18(0) and 23(6) weeks. ",
        "Annotations": [
            "Person 6 10--*--ages",
            "Value 0 5--*--18-50",
            "Measurement 33 48--*--Cervical length",
            "Value 49 55--*--<=25mm",
            "Qualifier 56 85--*--between 18(0) and 23(6) weeks",
            "Condition 12 31--*--Singleton pregnancy"
        ]
    },
    "NCT02550769_exc": {
        "Annotations": [
            "Condition 49 64--*--Liver cirrhosis",
            "Observation 0 28--*--Do not sign informed consent",
            "Condition 30 38--*--Pregnant",
            "Condition 83 97--*--adenocarcinoma",
            "Qualifier 66 82--*--Undifferentiated",
            "Condition 100 103--*--cT4",
            "Condition 105 128--*--Metastatic disease (M1)",
            "Condition 130 151--*--chronic renal failure",
            "Procedure 155 163--*--dialysis",
            "Measurement 165 168--*--ASA",
            "Value 169 171--*--IV",
            "Measurement 173 176--*--BMI",
            "Value 177 196--*--<18 and> 35 kg / m2"
        ],
        "Text": "Do not sign informed consent. Pregnant patients. Liver cirrhosis. Undifferentiated adenocarcinoma.. cT4. Metastatic disease (M1). chronic renal failure on dialysis. ASA IV. BMI <18 and> 35 kg / m2. "
    },
    "NCT03318874_inc": {
        "Text": "Meibomian Gland Dysfunction. Eligible for heat treatment. Ocular Surface Disease Index (OSDI) >12. Quality or expressibility score =20 years old: >1 or >20 years old: =1. Non-invasive tear film break-up time (NITBUT) <10 s in at least one eye. Schirmer-1 test >5 mm after 5 min. ",
        "Annotations": [
            "Condition 0 27--*--Meibomian Gland Dysfunction",
            "Mood 29 41--*--Eligible for",
            "Procedure 42 56--*--heat treatment",
            "Measurement 58 86--*--Ocular Surface Disease Index",
            "Measurement 88 92--*--OSDI",
            "Value 94 97--*-->12",
            "Measurement 125 130;99 106--*--score Quality",
            "Measurement 110 130--*--expressibility score",
            "Non-representable 99 169--*--Quality or expressibility score =20 years old: >1 or >20 years old: =1",
            "Measurement 171 216--*--Non-invasive tear film break-up time (NITBUT)",
            "Value 217 222--*--<10 s",
            "Multiplier 226 238--*--at least one",
            "Qualifier 239 242--*--eye",
            "Measurement 244 259--*--Schirmer-1 test",
            "Value 260 265--*-->5 mm",
            "Temporal 266 277--*--after 5 min"
        ]
    },
    "NCT02965027_exc": {
        "Text": "Participation in other interventional research.. History of penetrating head injury. History of TBI more severe than mild by DVBIC criteria. Diagnosis of a primary or secondary HA disorder other than PTHA. Lifetime history of 5 or more migraine or probable migraine headaches pre-dating mTBI. HAs of any kind of moderate or severe intensity on an average of more than 2 days per month preceding the concussive trauma. Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours between attacks). Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness], chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, or diagnosed but untreated sleep apnea). The eligibility of potential participants having acute serious and/or chronic medical illnesses other than those listed will be evaluated on a case-by-case basis by a study physician, PA-C, or ARNP.. Use of prazosin or other alpha-1 antagonist (including but not limited to alfuzosin, doxazosin, silodosin, tamsulosin, terazosin) for any purpose in the 2 weeks prior to initial screen (P1) visit and prohibited throughout the study. Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist. Active psychosis or psychotic disorder, severe depression (as determined per clinician prescriber judgment), severe psychiatric instability or severe situational life crisis (including evidence of being actively suicidal or homicidal).. Meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for any Substance Use Disorder except caffeine-related disorders, or tobacco-related disorders.. History of delirium within the prior 3 months, epilepsy, stroke, dementia, psychotic disorder, or bipolar disorder. Structural brain abnormalities on any prior imaging with associated clinically evident manifestations. Current participation in transcranial magnetic stimulation studies. Women of childbearing potential must not be pregnant, planning to become pregnant during the study period, or nursing.. Participation in a HA support group or other activity such as meditation or yoga intended to mitigate HA or other chronic pain must be stable at least 4 weeks prior to beginning the initial screen (P1) visit and may not be started during the study. Failure to record HA data for at least 80% of days during the Screening Period. Not suitable for study per clinician judgement.. The use of HA rescue or symptom-relieving medications will be allowed during the study. This includes triptans, ergotamines, opioids, simple analgesics (e.g. acetaminophen, aspirin, or non-steroidal anti-inflammatories [NSAIDS], and combination analgesics. Their use will be recorded on the concurrent medication CRF during the Preliminary Screening Period (P1) and throughout the remainder of the study. Randomization of participants will be stratified based on whether their use of HA medications meets ICHD-3 beta criteria for overuse of these medications, as described in section 5.5 below.. Opioid Medications: Use of opioids for treatment of HA or non-HA-related pain or for any other purpose is allowed during the study. Any opioid use would ideally be excluded due to potential confounding effects on interpretation of response to treatment. However, in this population, particularly in Veterans with chronic pain or undergoing minor orthopedic or dental procedures, opioid use is common. Use of opioids, including frequency and dose, will be recorded on the concurrent medication CRF.. Other Medications: Participants who are taking other medications on a routine basis must be on a stable dose for at least 4 weeks prior to the Preliminary Screening Period (P1), and must intend to continue the medication at the same regimen for the duration of the trial unless lack of efficacy, safety, or tolerability dictates otherwise. The following medications are not excluded:. Psychoactive drugs (for example, anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics),. Antihypertensive medications (including beta-blockers, calcium channel blockers, angiotensin converting enzyme [ACE] inhibitors, and angiotensin receptor blockers),. The use of magnesium in any dose that is prescribed for the purpose of HA prevention or treatment must be stable for at least 4 weeks. The incidental use of magnesium in multi-vitamins, laxatives, etc. is permissible but must be documented.. Hormones (for example, testosterone, estrogen, or progesterone) in any form.. The \"as-needed\" (prn) use of psychoactive and other drugs such as antibiotics is not excluded; however, such use must be discussed with a clinician prescriber and documented.. The use of butalbital in any form within 4 weeks of beginning the Preliminary Screening Period (P1) through the end of the participant's study involvement is exclusionary.. Participants who have been taking trazodone will undergo a 2-week washout period before the Preliminary Screening Period (P1 visit). Combining prazosin and trazodone may increase the risk of priapism. We have decided to begin the washout period before the Preliminary Screening Period in order to remove any confounding variables while on the headache log and actigraphy.. Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) will not be permitted during the study drug dose Titration Period, because of increased risk of hypotension in combination with alpha-1 blockers, but will be allowed at half the usual starting dose following the study drug dose Titration Period, per VA prescribing guidelines.. Use of supplements containing nitrates and supplements containing stimulants (such as ephedra) are exclusionary in the two weeks prior to initial screen (P1) visit and prohibited throughout the study. Participants who take these supplements will be asked to discontinue them for a minimum of two weeks before the Preliminary Screening Period (P1 visit)... Use of prescribed stimulants (such as amphetamine or dextroamphetamine containing medications) is exclusionary in the 2 weeks prior to the initial screen (P1) visit and prohibited throughout the study. Participants who take these medications will be asked to discontinue them for a minimum of 2 weeks before the Preliminary Screening Period.. ",
        "Annotations": [
            "Non-query-able 0 47--*--Participation in other interventional research.",
            "Condition 60 83--*--penetrating head injury",
            "Condition 96 99--*--TBI",
            "Value 100 121--*--more severe than mild",
            "Measurement 125 139--*--DVBIC criteria",
            "Qualifier 156 163--*--primary",
            "Qualifier 167 176--*--secondary",
            "Condition 177 188--*--HA disorder",
            "Condition 200 204--*--PTHA",
            "Negation 189 199--*--other than",
            "Scope 156 176--*--primary or secondary",
            "Observation 206 222--*--Lifetime history",
            "Multiplier 226 235--*--5 or more",
            "Condition 236 244--*--migraine",
            "Qualifier 248 256--*--probable",
            "Condition 257 265--*--migraine",
            "Temporal 276 291--*--pre-dating mTBI",
            "Procedure 287 291--*--mTBI",
            "Reference_point 287 291--*--mTBI",
            "Scope 236 265--*--migraine or probable migraine",
            "Condition 293 296--*--HAs",
            "Qualifier 312 340--*--moderate or severe intensity",
            "Multiplier 347 384--*--average of more than 2 days per month",
            "Temporal 385 416--*--preceding the concussive trauma",
            "Condition 429 432--*--HAs",
            "Qualifier 418 428--*--Continuous",
            "Qualifier 452 462--*--persistent",
            "Multiplier 463 468--*--daily",
            "Measurement 481 495;514 529--*--HA-free period between attacks",
            "Value 496 513--*--less than 8 hours",
            "Negation 478 480--*--no",
            "Condition 469 472--*--HAs",
            "Qualifier 532 537--*--Acute",
            "Qualifier 541 548--*--serious",
            "Condition 549 564--*--medical illness",
            "Qualifier 568 576--*--unstable",
            "Condition 577 600--*--chronic medical illness",
            "Condition 608 623--*--unstable angina",
            "Condition 625 646--*--myocardial infarction",
            "Temporal 647 662--*--within 6 months",
            "Condition 664 688--*--congestive heart failure",
            "Qualifier 690 712--*--clinically significant",
            "Qualifier 716 726--*--concerning",
            "Condition 727 746--*--cardiac arrhythmias",
            "Temporal 748 759--*--preexisting",
            "Condition 760 771--*--hypotension",
            "Measurement 773 796--*--systolic blood pressure",
            "Value 796 800--*--<110",
            "Condition 805 828--*--orthostatic hypotension",
            "Measurement 830 843--*--systolic drop",
            "Value 844 853--*-->20 mm Hg",
            "Temporal 854 874--*--after 2 min standing",
            "Condition 890 905--*--lightheadedness",
            "Condition 908 921;933 940--*--chronic renal failure",
            "Condition 925 940--*--hepatic failure",
            "Condition 942 960--*--acute pancreatitis",
            "Condition 962 979--*--Meniere's disease",
            "Condition 1008 1019--*--sleep apnea",
            "Qualifier 998 1007--*--untreated",
            "Non-representable 1022 1220--*--The eligibility of potential participants having acute serious and/or chronic medical illnesses other than those listed will be evaluated on a case-by-case basis by a study physician, PA-C, or ARNP.",
            "Scope 532 548--*--Acute or serious",
            "Scope 690 726--*--clinically significant or concerning",
            "Scope 830 905--*--systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness",
            "Scope 608 1019--*--unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness], chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, or diagnosed but untreated sleep apnea",
            "Scope 532 600--*--Acute or serious medical illness or unstable chronic medical illness",
            "Drug 1229 1237--*--prazosin",
            "Qualifier 1241 1246--*--other",
            "Drug 1247 1265--*--alpha-1 antagonist",
            "Drug 1296 1305--*--alfuzosin",
            "Drug 1307 1316--*--doxazosin",
            "Drug 1318 1327--*--silodosin",
            "Drug 1329 1339--*--tamsulosin",
            "Drug 1341 1350--*--terazosin",
            "Temporal 1368 1417--*--in the 2 weeks prior to initial screen (P1) visit",
            "Reference_point 1392 1417--*--initial screen (P1) visit",
            "Scope 1229 1265--*--prazosin or other alpha-1 antagonist",
            "Scope 1296 1350--*--alfuzosin, doxazosin, silodosin, tamsulosin, terazosin",
            "Condition 1455 1462--*--Allergy",
            "Condition 1475 1491--*--adverse reaction",
            "Temporal 1466 1474--*--previous",
            "Drug 1495 1503--*--prazosin",
            "Drug 1513 1531--*--alpha-1 antagonist",
            "Qualifier 1507 1512--*--other",
            "Scope 1495 1531--*--prazosin or other alpha-1 antagonist",
            "Scope 1455 1491--*--Allergy or previous adverse reaction",
            "Condition 1553 1571--*--psychotic disorder",
            "Condition 1540 1549--*--psychosis",
            "Qualifier 1533 1539--*--Active",
            "Condition 1573 1590--*--severe depression",
            "Condition 1649 1672--*--psychiatric instability",
            "Qualifier 1642 1648--*--severe",
            "Condition 1683 1706--*--situational life crisis",
            "Qualifier 1676 1682--*--severe",
            "Condition 1745 1753--*--suicidal",
            "Condition 1757 1766--*--homicidal",
            "Scope 1745 1766--*--suicidal or homicidal",
            "Condition 1868 1890--*--Substance Use Disorder",
            "Condition 1898 1924--*--caffeine-related disorders",
            "Negation 1891 1897--*--except",
            "Condition 1929 1954--*--tobacco-related disorders",
            "Scope 1898 1954--*--caffeine-related disorders, or tobacco-related disorders",
            "Measurement 1776 1859--*--Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria",
            "Value 1770 1775--*--Meets",
            "Condition 1968 1976--*--delirium",
            "Temporal 1977 2002--*--within the prior 3 months",
            "Condition 2004 2012--*--epilepsy",
            "Condition 2014 2020--*--stroke",
            "Condition 2022 2030--*--dementia",
            "Condition 2032 2050--*--psychotic disorder",
            "Condition 2055 2071--*--bipolar disorder",
            "Condition 2073 2103--*--Structural brain abnormalities",
            "Procedure 2117 2124--*--imaging",
            "Temporal 2111 2116--*--prior",
            "Qualifier 2107 2110--*--any",
            "Qualifier 2141 2159--*--clinically evident",
            "Condition 2160 2174--*--manifestations",
            "Procedure 2201 2242--*--transcranial magnetic stimulation studies",
            "Temporal 2176 2183--*--Current",
            "Condition 2253 2275--*--childbearing potential",
            "Person 2244 2249--*--Women",
            "Negation 2281 2287--*--not be",
            "Condition 2288 2296--*--pregnant",
            "Mood 2298 2316--*--planning to become",
            "Condition 2317 2325--*--pregnant",
            "Temporal 2326 2349--*--during the study period",
            "Condition 2354 2361--*--nursing",
            "Scope 2288 2361--*--pregnant, planning to become pregnant during the study period, or nursing",
            "Scope 2244 2275--*--Women of childbearing potential",
            "Procedure 2364 2399--*--Participation in a HA support group",
            "Procedure 2426 2436--*--meditation",
            "Procedure 2440 2444--*--yoga",
            "Non-representable 2364 2611--*--Participation in a HA support group or other activity such as meditation or yoga intended to mitigate HA or other chronic pain must be stable at least 4 weeks prior to beginning the initial screen (P1) visit and may not be started during the study",
            "Observation 2613 2638--*--Failure to record HA data",
            "Multiplier 2639 2663--*--for at least 80% of days",
            "Temporal 2664 2691--*--during the Screening Period",
            "Non-query-able 2693 2740--*--Not suitable for study per clinician judgement.",
            "Non-representable 2742 3336--*--The use of HA rescue or symptom-relieving medications will be allowed during the study. This includes triptans, ergotamines, opioids, simple analgesics (e.g. acetaminophen, aspirin, or non-steroidal anti-inflammatories [NSAIDS], and combination analgesics. Their use will be recorded on the concurrent medication CRF during the Preliminary Screening Period (P1) and throughout the remainder of the study. Randomization of participants will be stratified based on whether their use of HA medications meets ICHD-3 beta criteria for overuse of these medications, as described in section 5.5 below.",
            "Non-representable 3338 3835--*--Opioid Medications: Use of opioids for treatment of HA or non-HA-related pain or for any other purpose is allowed during the study. Any opioid use would ideally be excluded due to potential confounding effects on interpretation of response to treatment. However, in this population, particularly in Veterans with chronic pain or undergoing minor orthopedic or dental procedures, opioid use is common. Use of opioids, including frequency and dose, will be recorded on the concurrent medication CRF.",
            "Drug 3890 3901--*--medications",
            "Multiplier 3902 3920--*--on a routine basis",
            "Qualifier 3934 3945--*--stable dose",
            "Temporal 3946 4013--*--for at least 4 weeks prior to the Preliminary Screening Period (P1)",
            "Qualifier 3884 3889--*--other",
            "Scope 3884 3920--*--other medications on a routine basis",
            "Non-representable 4177 4220--*--The following medications are not excluded:",
            "Non-representable 4222 4326--*--Psychoactive drugs (for example, anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics),",
            "Non-representable 4328 4492--*--Antihypertensive medications (including beta-blockers, calcium channel blockers, angiotensin converting enzyme [ACE] inhibitors, and angiotensin receptor blockers),",
            "Non-representable 4494 4734--*--The use of magnesium in any dose that is prescribed for the purpose of HA prevention or treatment must be stable for at least 4 weeks. The incidental use of magnesium in multi-vitamins, laxatives, etc. is permissible but must be documented.",
            "Non-representable 4736 4812--*--Hormones (for example, testosterone, estrogen, or progesterone) in any form.",
            "Non-representable 4814 4988--*--The \"as-needed\" (prn) use of psychoactive and other drugs such as antibiotics is not excluded; however, such use must be discussed with a clinician prescriber and documented.",
            "Drug 5001 5011--*--butalbital",
            "Temporal 5024 5089--*--within 4 weeks of beginning the Preliminary Screening Period (P1)",
            "Non-representable 5163 5534--*--Participants who have been taking trazodone will undergo a 2-week washout period before the Preliminary Screening Period (P1 visit). Combining prazosin and trazodone may increase the risk of priapism. We have decided to begin the washout period before the Preliminary Screening Period in order to remove any confounding variables while on the headache log and actigraphy.",
            "Drug 5536 5546--*--Sildenafil",
            "Drug 5548 5554--*--Viagra",
            "Drug 5557 5566--*--tadalafil",
            "Drug 5568 5574--*--Cialis",
            "Drug 5577 5587--*--vardenafil",
            "Drug 5589 5596--*--Levitra",
            "Drug 5603 5611--*--avanafil",
            "Drug 5613 5620--*--Stendra",
            "Temporal 5644 5687--*--during the study drug dose Titration Period",
            "Scope 5536 5621--*--Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra)",
            "Drug 5930 5938--*--nitrates",
            "Drug 5966 5976--*--stimulants",
            "Drug 5986 5993--*--ephedra",
            "Temporal 6012 6063--*--in the two weeks prior to initial screen (P1) visit",
            "Scope 5930 5994--*--nitrates and supplements containing stimulants (such as ephedra)",
            "Drug 6263 6284--*--prescribed stimulants",
            "Drug 6294 6305--*--amphetamine",
            "Drug 6309 6326--*--dextroamphetamine",
            "Scope 6294 6326--*--amphetamine or dextroamphetamine",
            "Temporal 6367 6420--*--in the 2 weeks prior to the initial screen (P1) visit"
        ]
    },
    "NCT01866800_exc": {
        "Annotations": [
            "Condition 11 34--*--acute coronary syndrome",
            "Temporal 35 54--*--in the past 30 days",
            "Condition 68 92--*--congesting heart failure",
            "Measurement 98 132--*--left ventricular ejection fraction",
            "Value 133 137--*--<30%",
            "Condition 141 153--*--exacerbation",
            "Temporal 154 173--*--in the past 30 days",
            "Scope 98 173--*--left ventricular ejection fraction <30% or exacerbation in the past 30 days",
            "Procedure 184 202--*--dialysis treatment",
            "Temporal 176 183--*--Current",
            "Drug 211 221--*--furosemide",
            "Condition 222 238--*--hypersensitivity",
            "Condition 241 258--*--Contraindications",
            "Procedure 262 291--*--placement of a Foley catheter",
            "Qualifier 299 306--*--bladder"
        ],
        "Text": "History of acute coronary syndrome in the past 30 days.. History of congesting heart failure with left ventricular ejection fraction <30% or exacerbation in the past 30 days.. Current dialysis treatment.. Known furosemide hypersensitivity.. Contraindications to placement of a Foley catheter in the bladder.. "
    },
    "NCT02637076_inc": {
        "Text": "current diagnosis of narcolepsy with cataplexy OR healthy control. ",
        "Annotations": [
            "Condition 21 31--*--narcolepsy",
            "Condition 37 46--*--cataplexy",
            "Condition 50 57--*--healthy"
        ]
    },
    "NCT02920177_exc": {
        "Annotations": [
            "Condition 12 26--*--Osteoarthritis",
            "Measurement 28 45--*--Kellgren-Lawrence",
            "Value 46 49--*--> 3",
            "Measurement 52 71--*--Minimum joint space",
            "Value 72 78--*--> 2 mm",
            "Procedure 94 107--*--AP radiograph",
            "Condition 109 122--*--Hip dysplasia",
            "Measurement 124 141--*--center edge angle",
            "Value 142 147--*--< 20\u00b0",
            "Procedure 151 164--*--AP radiograph",
            "Condition 204 218;246 253--*--cardiovascular disease",
            "Condition 220 225;246 253--*--renal disease",
            "Condition 227 234;246 253--*--hepatic disease",
            "Condition 236 253--*--endocrine disease",
            "Condition 255 261--*--cancer",
            "Condition 265 273--*--diabetes",
            "Qualifier 192 203--*--significant",
            "Scope 204 273--*--cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes",
            "Condition 297 306--*--infection",
            "Qualifier 289 296--*--ongoing",
            "Condition 317 320--*--HIV",
            "Condition 325 334--*--Hepatitis",
            "Parsing_Error 321 324--*--and",
            "Scope 317 334--*--HIV and Hepatitis",
            "Condition 374 390--*--septic arthritis",
            "Condition 360 373--*--osteomyelitis",
            "Parsing_Error 373 374--*--/",
            "Procedure 392 415--*--Anticoagulation therapy",
            "Pregnancy_considerations 417 460--*--Patients who are pregnant or breast feeding",
            "Condition 535 552--*--chondrocalcinosis",
            "Condition 554 569--*--hemochromatosis",
            "Condition 571 593--*--inflammatory arthritis",
            "Condition 595 618--*--arthropathy of the knee",
            "Condition 651 666--*--Paget's disease",
            "Condition 690 712--*--hemophilic arthropathy",
            "Condition 714 734--*--infectious arthritis",
            "Condition 736 756--*--Charcot's knee joint",
            "Condition 758 780--*--villonodular synovitis",
            "Condition 786 809--*--synovial chondromatosis",
            "Parsing_Error 782 785--*--and",
            "Qualifier 674 679--*--femur",
            "Qualifier 683 688--*--tibia",
            "Qualifier 635 650--*--juxta-articular",
            "Qualifier 527 531--*--knee",
            "Condition 499 519--*--inflammatory disease",
            "Condition 486 495;512 519--*--rheumatic disease",
            "Condition 476 484;512 519--*--systemic disease",
            "Scope 476 519--*--systemic, rheumatic or inflammatory disease",
            "Scope 674 688--*--femur or tibia",
            "Scope 595 688--*--arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia",
            "Procedure 827 855--*--immunosuppressant medication",
            "Measurement 894 913--*--serum chemistry lab",
            "Measurement 880 890;910 913--*--hematology lab",
            "Value 871 879--*--abnormal",
            "Scope 880 913--*--hematology or serum chemistry lab",
            "Procedure 942 951--*--injection",
            "Qualifier 965 969--*--knee",
            "Temporal 970 1005--*--within 2 months of study enrollment",
            "Reference_point 989 1005--*--study enrollment",
            "Measurement 1007 1010--*--BMI",
            "Value 1011 1026--*--greater than 35",
            "Value 1030 1042--*--less than 20",
            "Scope 1011 1042--*--greater than 35 or less than 20"
        ],
        "Text": "Established Osteoarthritis (Kellgren-Lawrence > 3). Minimum joint space > 2 mm as measured on AP radiograph. Hip dysplasia (center edge angle < 20\u00b0 on AP radiograph). Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes. Patients with ongoing infection including HIV and Hepatitis. Patient with history of osteomyelitis/septic arthritis. Anticoagulation therapy. Patients who are pregnant or breast feeding. Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis. Patients taking immunosuppressant medication. Patients with abnormal hematology or serum chemistry lab results. Patients receiving injection to treatment knee within 2 months of study enrollment. BMI greater than 35 or less than 20. "
    },
    "NCT02489045_exc": {
        "Annotations": [
            "Person 0 7--*--Females",
            "Condition 16 24--*--pregnant",
            "Condition 28 35--*--nursing",
            "Negation 47 50--*--not",
            "Mood 51 60--*--scheduled",
            "Procedure 65 91--*--trans-jugular liver biopsy",
            "Non-query-able 93 237--*--Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h afterwards,.",
            "Condition 306 344--*--transient right-to-left cardiac shunts",
            "Condition 287 301;330 344--*--bi-directional cardiac shunts",
            "Condition 272 285;330 344--*--right-to-left cardiac shunts",
            "Mood 262 271--*--suspected",
            "Mood 253 258--*--known",
            "Scope 253 271--*--known or suspected",
            "Scope 272 344--*--right-to-left, bi-directional, or transient right-to-left cardiac shunts",
            "Condition 360 382--*--pulmonary hypertension",
            "Condition 386 421--*--unstable cardiopulmonary conditions",
            "Procedure 445 457--*--chemotherapy",
            "Temporal 432 441--*--currently",
            "Procedure 510 541--*--hepatic loco-regional treatment",
            "Procedure 498 506;518 541--*--systemic loco-regional treatment",
            "Condition 472 487--*--primary cancers",
            "Qualifier 466 471--*--other",
            "Scope 498 541--*--systemic or hepatic loco-regional treatment",
            "Scope 445 541--*--chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment",
            "Condition 561 579--*--medically unstable",
            "Condition 598 607;622 625--*--seriously ill",
            "Condition 611 625--*--terminally ill",
            "Condition 646 678--*--clinical course is unpredictable",
            "Procedure 706 718--*--life support",
            "Visit 727 745--*--critical care unit",
            "Condition 762 788--*--unstable occlusive disease",
            "Scope 796 812--*--crescendo angina",
            "Qualifier 829 848--*--clinically unstable",
            "Condition 849 868--*--cardiac arrhythmias",
            "Condition 888 911--*--ventricular tachycardia",
            "Multiplier 878 887--*--recurrent",
            "Scope 829 868--*--clinically unstable cardiac arrhythmias",
            "Qualifier 928 940--*--uncontrolled",
            "Condition 941 965--*--congestive heart failure",
            "Measurement 967 971--*--NYHA",
            "Value 972 980--*--Class IV",
            "Scope 928 965--*--uncontrolled congestive heart failure",
            "Temporal 997 1003--*--recent",
            "Condition 1004 1023--*--cerebral hemorrhage",
            "Procedure 1054 1061--*--surgery",
            "Temporal 1062 1120--*--within 24 hours prior to the study sonographic examination",
            "Reference_point 1087 1120--*--the study sonographic examination",
            "Procedure 1097 1120--*--sonographic examination",
            "Condition 1150 1170--*--anaphylactic allergy",
            "Drug 1174 1178--*--eggs",
            "Drug 1182 1194--*--egg products",
            "Scope 1174 1194--*--eggs or egg products",
            "Condition 1249 1270--*--generalized urticaria",
            "Condition 1272 1295--*--difficulty in breathing",
            "Condition 1297 1318--*--swelling of the mouth",
            "Condition 1297 1312;1323 1329--*--swelling of the throat",
            "Condition 1331 1342--*--hypotension",
            "Condition 1347 1352--*--shock",
            "Scope 1249 1352--*--generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock",
            "Scope 1150 1194--*--anaphylactic allergy to eggs or egg products",
            "Condition 1545 1569--*--congenital heart defects",
            "Qualifier 1586 1592--*--severe",
            "Condition 1593 1602--*--emphysema",
            "Condition 1604 1624--*--pulmonary vasculitis",
            "Condition 1642 1658--*--pulmonary emboli",
            "Condition 1675 1704--*--respiratory distress syndrome",
            "Condition 1720 1730--*--thrombosis",
            "Qualifier 1762 1778--*--mesenteric veins",
            "Qualifier 1751 1757;1773 1778--*--portal veins",
            "Qualifier 1742 1749;1773 1778--*--hepatic veins",
            "Scope 1742 1778--*--hepatic, portal, or mesenteric veins"
        ],
        "Text": "Females who are pregnant or nursing.. Patients not scheduled for trans-jugular liver biopsy. Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h afterwards,.. Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts. Patients with pulmonary hypertension or unstable cardiopulmonary conditions. Patients currently on chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment.. Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:. Patients on life support or in a critical care unit.. Patients with unstable occlusive disease (e.g., crescendo angina). Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.. Patients with uncontrolled congestive heart failure (NYHA Class IV). Patients with recent cerebral hemorrhage.. Patients who have undergone surgery within 24 hours prior to the study sonographic examination.. Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 h following the administration of SONAZOID).. Patients with congenital heart defects.. Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli.. Patients with respiratory distress syndrome. Patients with thrombosis within the hepatic, portal, or mesenteric veins.. "
    },
    "NCT03297021_exc": {
        "Text": "Patients with allergies or contraindications to study medications. ",
        "Annotations": [
            "Condition 14 23--*--allergies",
            "Condition 27 44--*--contraindications",
            "Drug 48 65--*--study medications",
            "Scope 14 44--*--allergies or contraindications"
        ]
    },
    "NCT02243553_inc": {
        "Text": "1. Signed informed consent . 2. Healthy subjects aged between 18 years and 45 years inclusive . 3. Weighing at least 50 kg . 4. Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20) . 5. Volunteers must be willing to complete all study-related activities . 6. Each volunteer must have a valid social security number . 7. Each volunteer must have acceptable medical history, physical examination and laboratory test . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 28 30--*--2.",
            "Parsing_Error 94 96--*--3.",
            "Parsing_Error 122 124--*--4.",
            "Parsing_Error 268 270--*--5.",
            "Parsing_Error 340 342--*--6.",
            "Parsing_Error 400 402--*--7.",
            "Post-eligibility 3 26--*--Signed informed consent",
            "Non-query-able 3 26--*--Signed informed consent",
            "Person 48 52--*--aged",
            "Value 53 92--*--between 18 years and 45 years inclusive",
            "Condition 31 38--*--Healthy",
            "Measurement 97 105--*--Weighing",
            "Value 106 120--*--at least 50 kg",
            "Not_a_criteria 125 266--*--Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20)",
            "Post-eligibility 125 266--*--Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20)",
            "Post-eligibility 271 338--*--Volunteers must be willing to complete all study-related activities",
            "Post-eligibility 343 398--*--Each volunteer must have a valid social security number",
            "Non-query-able 343 398--*--Each volunteer must have a valid social security number",
            "Non-query-able 271 338--*--Volunteers must be willing to complete all study-related activities",
            "Observation 439 454--*--medical history",
            "Procedure 456 476--*--physical examination",
            "Measurement 481 496--*--laboratory test",
            "Undefined_semantics 439 496--*--medical history, physical examination and laboratory test",
            "Post-eligibility 403 496--*--Each volunteer must have acceptable medical history, physical examination and laboratory test"
        ]
    },
    "NCT02164734_exc": {
        "Text": "Weight < 800 g;. Airway anomalies;. Pulmonary air leaks;. Craniofacial or cardiothoracic malformations. ",
        "Annotations": [
            "Measurement 0 6--*--Weight",
            "Value 7 14--*--< 800 g",
            "Condition 17 33--*--Airway anomalies",
            "Condition 36 55--*--Pulmonary air leaks",
            "Condition 74 102--*--cardiothoracic malformations",
            "Condition 58 70;89 102--*--Craniofacial malformations"
        ]
    },
    "NCT02437045_exc": {
        "Text": "Patient not expected to survive more than 4 days. Patient allergic to a penicillin or a carbapenem. Patient with significant polymicrobial bacteraemia (that is, a Gram positive skin contaminant in one set of blood cultures is not regarded as significant polymicrobial bacteraemia).. Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion).. Pregnancy or breast-feeding.. Use of concomitant antimicrobials in the first 4 days after enrolment with known activity against Gram-negative bacilli (except trimethoprim/sulphamethoxazole may be continued as Pneumocystis prophylaxis).. Severe acute illness as defined by Pitt bacteraemia score of >4. Likely source to be from (proven or suspected at the time of randomisation) the central nervous system, e.g. brain abscess, post-surgical meningitis, shunt infection (due to concerns over CNS penetration of piperacillin/tazobactam). ",
        "Annotations": [
            "Observation 24 31--*--survive",
            "Negation 8 11--*--not",
            "Value 32 48--*--more than 4 days",
            "Condition 58 66--*--allergic",
            "Drug 72 82--*--penicillin",
            "Drug 88 98--*--carbapenem",
            "Scope 72 98--*--penicillin or a carbapenem",
            "Condition 139 150--*--bacteraemia",
            "Qualifier 125 138--*--polymicrobial",
            "Non-query-able 283 380--*--Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion)",
            "Pregnancy_considerations 383 410--*--Pregnancy or breast-feeding",
            "Drug 432 446--*--antimicrobials",
            "Qualifier 420 431--*--concomitant",
            "Temporal 454 482--*--first 4 days after enrolment",
            "Reference_point 473 482--*--enrolment",
            "Observation 511 532--*--Gram-negative bacilli",
            "Negation 534 540--*--except",
            "Drug 542 571--*--rimethoprim/sulphamethoxazole",
            "Measurement 655 677--*--Pitt bacteraemia score",
            "Value 681 683--*-->4",
            "Condition 794 807--*--brain abscess",
            "Condition 823 833--*--meningitis",
            "Qualifier 809 822--*--post-surgical",
            "Condition 835 850--*--shunt infection"
        ]
    },
    "NCT02332291_exc": {
        "Text": "Current or past diagnoses of other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring during a depressive episode. History of alcohol or drug dependence or abuse in the last three years. History of developmental disorder or IQ score < 70. Presence of acute suicidality. Acute grief (< 1 month). Current or past psychosis. Primary neurological disorder, including but not limited to dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases. MRI contraindications. Any physical or intellectual disability adversely affecting ability to complete assessments. Electroconvulsive therapy in last 6 months. Use of antidepressant medications or other psychotropic medications in the last 4 weeks (or the last 6 weeks for fluoxetine). Occasional use of benzodiazepines or non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during this period is allowable.. A failed therapeutic trial of escitalopram in the current depressive episode (defined as at least 6 weeks of treatment at a daily dose of 10mg or higher). Known allergy or hypersensitivity to escitalopram or bupropion. Current or planned psychotherapy. ",
        "Annotations": [
            "Qualifier 29 34--*--other",
            "Condition 35 63--*--Axis I psychiatric disorders",
            "Negation 65 75--*--except for",
            "Condition 76 110--*--generalized anxiety disorder (GAD)",
            "Temporal 130 157--*--during a depressive episode",
            "Reference_point 139 157--*--depressive episode",
            "Condition 139 157--*--depressive episode",
            "Condition 181 196--*--drug dependence",
            "Condition 170 177;186 196--*--alcohol dependence",
            "Condition 181 185;200 205--*--drug abuse",
            "Condition 170 177;200 205--*--alcohol abuse",
            "Temporal 206 229--*--in the last three years",
            "Scope 170 205--*--alcohol or drug dependence or abuse",
            "Condition 242 264--*--developmental disorder",
            "Measurement 268 276--*--IQ score",
            "Value 277 281--*--< 70",
            "Condition 295 312--*--acute suicidality",
            "Condition 314 325--*--Acute grief",
            "Temporal 327 336--*--< 1 month",
            "Condition 355 364--*--psychosis",
            "Temporal 350 354--*--past",
            "Temporal 339 346--*--Current",
            "Scope 339 354--*--Current or past",
            "Condition 366 395--*--Primary neurological disorder",
            "Condition 426 434--*--dementia",
            "Condition 436 442--*--stroke",
            "Condition 444 456--*--brain tumors",
            "Condition 458 466--*--epilepsy",
            "Condition 468 487--*--Parkinson's disease",
            "Condition 492 514--*--demyelinating diseases",
            "Scope 426 514--*--dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases",
            "Procedure 516 519--*--MRI",
            "Condition 520 537--*--contraindications",
            "Condition 555 578--*--intellectual disability",
            "Condition 543 551;568 578--*--physical disability",
            "Procedure 632 657--*--Electroconvulsive therapy",
            "Temporal 658 674--*--in last 6 months",
            "Drug 683 709--*--antidepressant medications",
            "Qualifier 713 718--*--other",
            "Drug 719 743--*--psychotropic medications",
            "Temporal 744 763--*--in the last 4 weeks",
            "Temporal 744 746;768 784--*--in the last 6 weeks",
            "Drug 789 799--*--fluoxetine",
            "Scope 744 800--*--in the last 4 weeks (or the last 6 weeks for fluoxetine)",
            "Scope 683 743--*--antidepressant medications or other psychotropic medications",
            "Multiplier 802 816--*--Occasional use",
            "Drug 820 835;858 867--*--benzodiazepines sedatives",
            "Drug 839 867--*--non-benzodiazepine sedatives",
            "Drug 877 885--*--zolpidem",
            "Drug 887 898--*--eszopiclone",
            "Drug 903 911--*--zaleplon",
            "Scope 877 911--*--zolpidem, eszopiclone, or zaleplon",
            "Negation 932 944--*--is allowable",
            "Scope 820 867--*--benzodiazepines or non-benzodiazepine sedatives",
            "Drug 977 989--*--escitalopram",
            "Procedure 956 973--*--therapeutic trial",
            "Qualifier 949 955--*--failed",
            "Temporal 990 1023--*--in the current depressive episode",
            "Reference_point 1005 1023--*--depressive episode",
            "Condition 1005 1023--*--depressive episode",
            "Temporal 1036 1065--*--at least 6 weeks of treatment",
            "Multiplier 1071 1099--*--daily dose of 10mg or higher",
            "Scope 1036 1099--*--at least 6 weeks of treatment at a daily dose of 10mg or higher",
            "Condition 1108 1115--*--allergy",
            "Condition 1119 1135--*--hypersensitivity",
            "Drug 1139 1151--*--escitalopram",
            "Drug 1155 1164--*--bupropion",
            "Scope 1108 1135--*--allergy or hypersensitivity",
            "Scope 1139 1164--*--escitalopram or bupropion",
            "Mood 1177 1184--*--planned",
            "Temporal 1166 1173--*--Current",
            "Procedure 1185 1198--*--psychotherapy",
            "Scope 1166 1184--*--Current or planned"
        ]
    },
    "NCT02678663_inc": {
        "Text": "Subjects over the age of 18 years who agree informed consent and who have at least one polyp of eligible size (6-10mm) . ",
        "Annotations": [
            "Person 18 21--*--age",
            "Value 25 33;9 13--*--18 years over",
            "Non-query-able 38 60--*--agree informed consent",
            "Post-eligibility 38 60--*--agree informed consent",
            "Multiplier 74 86--*--at least one",
            "Condition 87 92--*--polyp",
            "Qualifier 96 109--*--eligible size",
            "Context_Error 96 109--*--eligible size",
            "Value 111 117--*--6-10mm"
        ]
    },
    "NCT00312429_exc": {
        "Text": "Undergoing Interleukin-2 (IL-2) therapy within 8 weeks of study entry . Diagnosed with a medical or psychiatric illness that may interfere with study participation . Pregnant       .     . ",
        "Annotations": [
            "Procedure 11 39--*--Interleukin-2 (IL-2) therapy",
            "Temporal 40 69--*--within 8 weeks of study entry",
            "Condition 111 162;88 95--*--illness that may interfere with study participation medical",
            "Condition 99 162--*--psychiatric illness that may interfere with study participation",
            "Condition 164 172--*--Pregnant"
        ]
    },
    "NCT01997112_exc": {
        "Annotations": [
            "Condition 11 34--*--ischaemic heart disease",
            "Condition 36 51--*--cardiac failure",
            "Condition 53 76--*--cerebrovascular disease",
            "Condition 78 94--*--liver impairment",
            "Measurement 96 99--*--ALT",
            "Measurement 100 103--*--AST",
            "Value 103 110--*-->50IU/L",
            "Measurement 115 120--*--stage",
            "Value 121 124--*--3-5",
            "Condition 125 147--*--chronic kidney disease",
            "Scope 96 110--*--ALT/AST>50IU/L",
            "Condition 161 169--*--overdose",
            "Condition 173 190--*--suicidal ideation",
            "Measurement 201 209--*--weighing",
            "Value 210 216--*--<55kgs",
            "Condition 233 245--*--chronic pain",
            "Qualifier 246 265--*--requiring treatment",
            "Condition 274 287--*--known allergy",
            "Drug 291 302--*--paracetamol",
            "Drug 326 359--*--non-steroidal anti-inflammatories",
            "Temporal 307 318--*--concomitant",
            "Drug 362 381--*--oral anticoagulants",
            "Drug 385 400--*--corticosteroids",
            "Scope 326 400--*--non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids"
        ],
        "Text": "History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.. History of overdose or suicidal ideation. Patients weighing <55kgs.. Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.. "
    },
    "NCT01909934_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Person 24 27--*--age",
            "Value 28 45--*--18 years or older",
            "Condition 75 80--*--sALCL",
            "Qualifier 64 74--*--refractory",
            "Qualifier 52 60--*--relapsed",
            "Multiplier 110 120--*--at least 1",
            "Procedure 132 144--*--chemotherapy",
            "Scope 52 74--*--relapsed or refractory",
            "Non-query-able 146 178--*--Bidimensional measurable disease",
            "Measurement 183 217;225 243--*--Eastern Cooperative Oncology Group performance status",
            "Measurement 219 223--*--ECOG",
            "Value 247 253--*--0 or 1",
            "Pregnancy_considerations 255 577--*--Female patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence",
            "Pregnancy_considerations 579 775--*--Male patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence",
            "Non-query-able 777 838--*--Clinical laboratory values as specified in the study protocol"
        ],
        "Text": "Male or female patients age 18 years or older, with relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy. Bidimensional measurable disease. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Female patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence. Male patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence. Clinical laboratory values as specified in the study protocol. "
    },
    "NCT02920177_inc": {
        "Annotations": [
            "Condition 26 29--*--FAI",
            "Qualifier 14 25--*--symptomatic",
            "Condition 69 72--*--FAI",
            "Qualifier 44 65--*--radiographic evidence",
            "Qualifier 31 39;57 65--*--Clinical evidence",
            "Scope 31 65--*--Clinical and radiographic evidence",
            "Post-eligibility 74 129--*--Patients able to provide consent to study participation",
            "Procedure 156 180--*--physical therapy program",
            "Temporal 145 152--*--6 weeks"
        ],
        "Text": "Patients with symptomatic FAI. Clinical and radiographic evidence of FAI. Patients able to provide consent to study participation. Completion of 6 weeks of physical therapy program. "
    },
    "NCT02164734_inc": {
        "Text": "Mild-to-moderate RDS;. Postnatal age 2 to 48 hours;. Gestational age 27 0/7 to 36 6/7 weeks;. Treated with nasal CPAP modalities = 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 90-95%;. Informed consent. ",
        "Annotations": [
            "Value 0 16--*--Mild-to-moderate",
            "Measurement 17 20--*--RDS",
            "Measurement 23 36--*--Postnatal age",
            "Value 37 50--*--2 to 48 hours",
            "Measurement 53 68--*--Gestational age",
            "Value 69 91--*--27 0/7 to 36 6/7 weeks",
            "Measurement 107 117--*--nasal CPAP",
            "Value 129 139--*--= 5 cm H2O",
            "Measurement 144 148--*--FiO2",
            "Value 149 170--*--between 0.30 and 0.60",
            "Temporal 171 191--*--for at least 2 hours",
            "Measurement 204 208--*--SpO2",
            "Value 209 215--*--90-95%",
            "Informed_consent 218 234--*--Informed consent"
        ]
    },
    "NCT02243553_exc": {
        "Text": "1. History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation . 2. Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance . 3. History or diagnosis of any significant medical conditions: Including but not limited to gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, psychiatric, neurological, oncological or hormonal disorders . 4. Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed) . 5. Clinically relevant laboratory abnormalities (e.g. Hgb<11g/dL, Hct<30g/dL, total cholesterol >240mg/dL, triglycerides >500mg/dL, fasting glucose >130mg/dL, liver function tests >2.5x upper limit of normal, baseline international normalized ratio >1.2) . 6. History of evidence of clinically significant hepatic, cardiac, pulmonary, endocrine, immunological, gastrointestinal, hematological, vascular or collagen disease . 7. History of alcohol abuse or use of any illicit drugs . 8. Unable to abstain from more than one beer or alcohol equivalent per day for the duration of the study . 9. Use of tobacco products and/or history of smoking within the past 2 months . 10. Pregnant or breast feeding . 11. Sexually active women of childbearing age who do not use an acceptable barrier method of birth control . 12. Hypersensitivity to caffeine, warfarin, vitamin K, omeprazole, dextromethorphan, midazolam, tipranavir, ritonavir or their excipients . 13. Concomitant treatment with other experimental compounds . 14. Concomitant administration of any prescription or over the counter medications known to alter P450 enzyme or P-gp activity . 15. Concomitant administration of any prescription or over the counter medications known to be highly dependent on P450 or P-gp for clearance for which elevated plasma concentrations are known to be associated with serious toxicity . 16. Concomitant administration of any food product known to alter P450 enzyme or P-gp activity such as grapefruit juice, Seville oranges . 17. Concomitant administration of any drug that could affect bleeding (e.g., aspirin, clopidogrel, ticlopidine, warfarin, heparin, low-molecular weight heparin) . 18. Concomitant administration of oral contraceptives (may be included with 7-day washout period) . 19. Concomitant administration of any herbal medications . 20. Inadequate venous access . 21. Renal or hepatic insufficiency . 22. Clinically unacceptable result at the screening physical examination . 23. Use of investigational medications within 30 days before study entry . 24. HIV-positive . 25. Body Mass Index (BMI) > 30 kg/m\u00b2       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 224 226--*--2.",
            "Parsing_Error 2789 2792--*--25.",
            "Parsing_Error 2771 2774--*--24.",
            "Parsing_Error 2697 2700--*--23.",
            "Parsing_Error 2623 2626--*--22.",
            "Parsing_Error 2587 2590--*--21.",
            "Parsing_Error 2557 2560--*--20.",
            "Parsing_Error 2499 2502--*--19.",
            "Parsing_Error 2400 2403--*--18.",
            "Parsing_Error 2238 2241--*--17.",
            "Parsing_Error 2100 2103--*--16.",
            "Parsing_Error 1867 1870--*--15.",
            "Parsing_Error 1739 1742--*--14.",
            "Parsing_Error 1678 1681--*--13.",
            "Parsing_Error 1539 1542--*--12.",
            "Parsing_Error 1431 1434--*--11.",
            "Parsing_Error 1399 1402--*--10.",
            "Parsing_Error 1320 1322--*--9.",
            "Parsing_Error 1214 1216--*--8.",
            "Parsing_Error 1157 1159--*--7.",
            "Parsing_Error 990 992--*--6.",
            "Parsing_Error 734 736--*--5.",
            "Parsing_Error 632 634--*--4.",
            "Parsing_Error 376 378--*--3.",
            "Measurement 2793 2814--*--Body Mass Index (BMI)",
            "Value 2815 2825--*--> 30 kg/m\u00b2",
            "Measurement 2775 2778--*--HIV",
            "Value 2779 2787--*--positive",
            "Drug 2708 2735--*--investigational medications",
            "Undefined_semantics 2708 2735--*--investigational medications",
            "Temporal 2736 2769--*--within 30 days before study entry",
            "Reference_point 2758 2769--*--study entry",
            "Condition 2627 2657--*--Clinically unacceptable result",
            "Temporal 2658 2695--*--at the screening physical examination",
            "Reference_point 2661 2695--*--the screening physical examination",
            "Procedure 2675 2695--*--physical examination",
            "Qualifier 2627 2650--*--Clinically unacceptable",
            "Subjective_judgement 2627 2650--*--Clinically unacceptable",
            "Undefined_semantics 2627 2657--*--Clinically unacceptable result",
            "Condition 2600 2621--*--hepatic insufficiency",
            "Condition 2591 2596;2608 2621--*--Renal insufficiency",
            "Device 2572 2585--*--venous access",
            "Qualifier 2561 2571--*--Inadequate",
            "Drug 2537 2555--*--herbal medications",
            "Temporal 2503 2514--*--Concomitant",
            "Drug 2434 2453--*--oral contraceptives",
            "Temporal 2404 2415--*--Concomitant",
            "Not_a_criteria 2454 2497--*--(may be included with 7-day washout period)",
            "Drug 2276 2307--*--drug that could affect bleeding",
            "Undefined_semantics 2276 2307--*--drug that could affect bleeding",
            "Drug 2315 2322--*--aspirin",
            "Drug 2324 2335--*--clopidogrel",
            "Drug 2337 2348--*--ticlopidine",
            "Drug 2350 2358--*--warfarin",
            "Drug 2360 2367--*--heparin",
            "Drug 2369 2397--*--low-molecular weight heparin",
            "Scope 2315 2397--*--aspirin, clopidogrel, ticlopidine, warfarin, heparin, low-molecular weight heparin",
            "Temporal 2104 2115--*--Concomitant",
            "Drug 2138 2177;2186 2194--*--food product known to alter P450 enzyme activity",
            "Drug 2138 2165;2181 2194--*--food product known to alter P-gp activity",
            "Drug 2203 2219--*--grapefruit juice",
            "Drug 2221 2236--*--Seville oranges",
            "Scope 2203 2236--*--grapefruit juice, Seville oranges",
            "Scope 2138 2194--*--food product known to alter P450 enzyme or P-gp activity",
            "Temporal 1871 1882--*--Concomitant",
            "Drug 1938 1986;1995 2008--*--medications known to be highly dependent on P450 for clearance",
            "Drug 1938 1981;1990 2008--*--medications known to be highly dependent on P-gp for clearance",
            "Measurement 2028 2049--*--plasma concentrations",
            "Value 2019 2027--*--elevated",
            "Condition 2090 2098--*--toxicity",
            "Scope 1938 2008--*--medications known to be highly dependent on P450 or P-gp for clearance",
            "Qualifier 2082 2089--*--serious",
            "Scope 2019 2049--*--elevated plasma concentrations",
            "Drug 1810 1848;1857 1865--*--medications known to alter P450 enzyme activity",
            "Drug 1810 1836;1852 1865--*--medications known to alter P-gp activity",
            "Undefined_semantics 1938 2008--*--medications known to be highly dependent on P450 or P-gp for clearance",
            "Undefined_semantics 2138 2194--*--food product known to alter P450 enzyme or P-gp activity",
            "Temporal 1743 1754--*--Concomitant",
            "Scope 1810 1865--*--medications known to alter P450 enzyme or P-gp activity",
            "Temporal 1682 1693--*--Concomitant",
            "Drug 1715 1737--*--experimental compounds",
            "Drug 1563 1571--*--caffeine",
            "Drug 1573 1581--*--warfarin",
            "Drug 1583 1592--*--vitamin K",
            "Drug 1594 1604--*--omeprazole",
            "Drug 1606 1622--*--dextromethorphan",
            "Drug 1624 1633--*--midazolam",
            "Drug 1635 1645--*--tipranavir",
            "Drug 1647 1656--*--ritonavir",
            "Condition 1543 1559--*--Hypersensitivity",
            "Scope 1563 1656--*--caffeine, warfarin, vitamin K, omeprazole, dextromethorphan, midazolam, tipranavir, ritonavir",
            "Person 1451 1456--*--women",
            "Condition 1435 1450--*--Sexually active",
            "Value 1460 1472--*--childbearing",
            "Person 1473 1476--*--age",
            "Device 1506 1537--*--barrier method of birth control",
            "Qualifier 1495 1505--*--acceptable",
            "Negation 1484 1487--*--not",
            "Condition 1403 1411--*--Pregnant",
            "Observation 1415 1429--*--breast feeding",
            "Drug 1330 1346--*--tobacco products",
            "Observation 1365 1372--*--smoking",
            "Temporal 1373 1397--*--within the past 2 months",
            "Observation 1354 1361--*--history",
            "Non-query-able 1217 1318--*--Unable to abstain from more than one beer or alcohol equivalent per day for the duration of the study",
            "Condition 1171 1184--*--alcohol abuse",
            "Condition 1188 1194;1199 1212--*--use of illicit drugs",
            "Condition 1139 1155--*--collagen disease",
            "Condition 1127 1135;1148 1155--*--vascular disease",
            "Condition 1112 1125;1148 1155--*--hematological disease",
            "Condition 1094 1110;1148 1155--*--gastrointestinal disease",
            "Condition 1079 1092;1148 1155--*--immunological disease",
            "Condition 1068 1077;1148 1155--*--endocrine disease",
            "Condition 1057 1066;1148 1155--*--pulmonary disease",
            "Condition 1048 1055;1148 1155--*--cardiac disease",
            "Condition 1039 1046;1148 1155--*--hepatic disease",
            "Subjective_judgement 1016 1038--*--clinically significant",
            "Scope 1039 1155--*--hepatic, cardiac, pulmonary, endocrine, immunological, gastrointestinal, hematological, vascular or collagen disease",
            "Qualifier 1016 1038--*--clinically significant",
            "Observation 993 1000--*--History",
            "Qualifier 737 756--*--Clinically relevant",
            "Undefined_semantics 737 756--*--Clinically relevant",
            "Condition 757 781--*--laboratory abnormalities",
            "Measurement 788 791--*--Hgb",
            "Value 791 798--*--<11g/dL",
            "Measurement 800 803--*--Hct",
            "Measurement 812 829--*--total cholesterol",
            "Measurement 841 854--*--triglycerides",
            "Measurement 866 881--*--fasting glucose",
            "Measurement 893 913--*--liver function tests",
            "Value 914 941--*-->2.5x upper limit of normal",
            "Measurement 952 982--*--international normalized ratio",
            "Value 983 987--*-->1.2",
            "Temporal 943 951--*--baseline",
            "Value 882 891--*-->130mg/dL",
            "Value 855 864--*-->500mg/dL",
            "Value 830 839--*-->240mg/dL",
            "Value 803 810--*--<30g/dL",
            "Scope 788 987--*--Hgb<11g/dL, Hct<30g/dL, total cholesterol >240mg/dL, triglycerides >500mg/dL, fasting glucose >130mg/dL, liver function tests >2.5x upper limit of normal, baseline international normalized ratio >1.2",
            "Scope 737 781--*--Clinically relevant laboratory abnormalities",
            "Measurement 650 663--*--liver enzymes",
            "Value 641 649--*--elevated",
            "Context_Error 635 732--*--Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed)",
            "Non-query-able 635 732--*--Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed)",
            "Condition 419 437--*--medical conditions",
            "Undefined_semantics 757 781--*--laboratory abnormalities",
            "Subjective_judgement 737 756--*--Clinically relevant",
            "Condition 612 630--*--hormonal disorders",
            "Condition 597 608;621 630--*--oncological disorders",
            "Condition 583 595;621 630--*--neurological disorders",
            "Condition 570 581;621 630--*--psychiatric disorders",
            "Condition 555 568;621 630--*--hematological disorders",
            "Condition 542 553;621 630--*--immunologic disorders",
            "Condition 531 540;621 630--*--metabolic disorders",
            "Condition 515 529;621 630--*--cardiovascular disorders",
            "Condition 502 513;621 630--*--respiratory disorders",
            "Condition 495 500;621 630--*--renal disorders",
            "Condition 486 493;621 630--*--hepatic disorders",
            "Condition 468 484;621 630--*--gastrointestinal disorders",
            "Scope 468 630--*--gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, psychiatric, neurological, oncological or hormonal disorders",
            "Qualifier 407 418--*--significant",
            "Subjective_judgement 407 418--*--significant",
            "Subjective_judgement 227 374--*--Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance",
            "Post-eligibility 227 374--*--Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance",
            "Condition 26 33--*--allergy",
            "Drug 41 52--*--study drugs",
            "Context_Error 41 52--*--study drugs",
            "Subjective_judgement 3 222--*--History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation",
            "Non-query-able 3 222--*--History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation"
        ]
    },
    "NCT03297021_inc": {
        "Text": "ASA I, II, III presenting for ambulatory surgery to be performed under general anesthesia. ",
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 5--*--I",
            "Value 7 9--*--II",
            "Value 11 14--*--III",
            "Scope 4 14--*--I, II, III",
            "Procedure 30 48--*--ambulatory surgery",
            "Procedure 71 89--*--general anesthesia",
            "Qualifier 65 89--*--under general anesthesia"
        ]
    },
    "NCT02489045_inc": {
        "Annotations": [
            "Procedure 17 43--*--trans-jugular liver biopsy",
            "Temporal 44 79--*--the day of the ultrasound procedure",
            "Reference_point 59 79--*--ultrasound procedure",
            "Procedure 59 79--*--ultrasound procedure",
            "Value 85 102--*--at least 21 years",
            "Person 106 109--*--age",
            "Condition 115 131--*--medically stable",
            "Person 139 145--*--female",
            "Condition 149 172--*--child-bearing potential",
            "Condition 186 194--*--negative",
            "Measurement 195 209--*--pregnancy test",
            "Scope 139 172--*--female of child-bearing potential",
            "Non-query-able 212 266--*--Be conscious and able to comply with study procedures.",
            "Post-eligibility 268 359--*--Have read and signed the IRB-approved Informed Consent form for participating in the study."
        ],
        "Text": "Be scheduled for trans-jugular liver biopsy the day of the ultrasound procedure.. Be at least 21 years of age.. Be medically stable.. If a female of child-bearing potential, must have a negative pregnancy test.. Be conscious and able to comply with study procedures.. Have read and signed the IRB-approved Informed Consent form for participating in the study.. "
    },
    "NCT02678663_exc": {
        "Text": "Anticoagulant therapy during the past 1 week of the procedure . Known coagulopathy . History of liver cirrhosis, chronic kidney disease, malignancy, inflammatory bowel disease, significant infectious disease, polyposis syndrome       .     . ",
        "Annotations": [
            "Drug 0 13--*--Anticoagulant",
            "Temporal 22 44--*--during the past 1 week",
            "Procedure 52 61--*--procedure",
            "Reference_point 52 61--*--procedure",
            "Condition 69 81--*--coagulopathy",
            "Condition 94 109--*--liver cirrhosis",
            "Condition 111 133--*--chronic kidney disease",
            "Condition 135 145--*--malignancy",
            "Condition 147 173--*--inflammatory bowel disease",
            "Condition 175 205--*--significant infectious disease",
            "Condition 207 225--*--polyposis syndrome",
            "Observation 83 90--*--History",
            "Scope 94 225--*--liver cirrhosis, chronic kidney disease, malignancy, inflammatory bowel disease, significant infectious disease, polyposis syndrome"
        ]
    },
    "NCT00312429_inc": {
        "Text": "Diagnosis reviewed at transplant center and confirmed to fit the criterion for high risk blood disease or cancer, as defined for the study . Estimated life expectancy of at least 6 weeks following study entry . Cancer and Leukemia Group B (CALGB) performance status less than or equal to 2 . White blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results reviewed by transplant center . Multiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT) performed and reviewed by transplant center (for individuals with an ejection fraction and diffusing capacity [DLCO] of 40-50%, the appropriate cardiology or pulmonary consultations should be considered if the individual has severe heart or lung disease at the initiation of therapy) . Sufficient number of umbilical cord blood units available for transplantation . If female, willing to use contraception throughout the study . ",
        "Annotations": [
            "Condition 79 102--*--high risk blood disease",
            "Condition 106 112--*--cancer",
            "Measurement 140 165--*--Estimated life expectancy",
            "Value 169 207--*--at least 6 weeks following study entry",
            "Measurement 209 263--*--Cancer and Leukemia Group B (CALGB) performance status",
            "Value 264 287--*--less than or equal to 2",
            "Measurement 289 311--*--White blood cell count",
            "Measurement 313 321--*--platelet",
            "Measurement 323 333--*--hematocrit",
            "Measurement 335 347--*--tuberculosis",
            "Measurement 349 381--*--aspartate aminotransferase (AST)",
            "Measurement 383 413--*--alanine aminotransferase (ALT)",
            "Measurement 415 435--*--alkaline phosphatase",
            "Measurement 437 447--*--creatinine",
            "Measurement 453 469--*--HIV test results",
            "Qualifier 470 499--*--reviewed by transplant center",
            "Scope 289 469--*--White blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results",
            "Procedure 501 534--*--Multiple gated acquisition (MUGA)",
            "Procedure 536 550--*--echocardiogram",
            "Procedure 552 563--*--cardiac MRI",
            "Procedure 572 602--*--pulmonary function tests (PFT)",
            "Qualifier 617 646--*--reviewed by transplant center",
            "Scope 501 602--*--Multiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT)",
            "Person 970 976--*--female",
            "Procedure 993 1006--*--contraception",
            "Temporal 1007 1027--*--throughout the study",
            "Measurement 909 945--*--umbilical cord blood units available",
            "Value 888 905--*--Sufficient number",
            "Qualifier 946 965--*--for transplantation",
            "Procedure 950 965--*--transplantation"
        ]
    },
    "NCT02332291_inc": {
        "Text": "Age 60 years or older.. Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam.. Minimum MADRS score = 15.. Mini-Mental State Exam = 24.. Fluent in English.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--60 years or older",
            "Condition 45 70--*--major depressive disorder",
            "Procedure 72 81--*--DSM-IV-TR",
            "Multiplier 84 98--*--single episode",
            "Multiplier 100 109--*--recurrent",
            "Multiplier 113 120--*--chronic",
            "Scope 84 120--*--single episode, recurrent or chronic",
            "Negation 122 129--*--without",
            "Condition 130 148--*--psychotic features",
            "Procedure 165 169--*--MINI",
            "Procedure 174 187--*--clinical exam",
            "Scope 165 187--*--MINI and clinical exam",
            "Measurement 198 209--*--MADRS score",
            "Value 190 197;210 214--*--Minimum = 15",
            "Measurement 217 239--*--Mini-Mental State Exam",
            "Value 240 244--*--= 24",
            "Non-query-able 247 265--*--Fluent in English."
        ]
    },
    "NCT02437045_inc": {
        "Text": "Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw. This will be determined in accordance with laboratory methods and susceptibility breakpoints defined by protocols used in the recruiting site laboratories... No more than 72 hours has elapsed since the first positive blood culture collection.. Patient is aged 18 years and over (>=21y in Singapore).. ",
        "Annotations": [
            "Condition 0 21--*--Bloodstream infection",
            "Qualifier 27 44--*--Enterobacter spp.",
            "Qualifier 46 65--*--Serratia marcescens",
            "Qualifier 67 83--*--Providencia spp.",
            "Qualifier 85 104--*--Morganella morganii",
            "Qualifier 108 128--*--Citrobacter freundii",
            "Scope 28 128--*--nterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii",
            "Drug 180 211--*--3rd generation cephalosporins (",
            "Drug 216 227--*--ceftriaxone",
            "Drug 229 239--*--cefotaxime",
            "Drug 243 254--*--ceftazidime",
            "Scope 216 254--*--ceftriaxone, cefotaxime or ceftazidime",
            "Drug 257 266--*--meropenem",
            "Drug 271 294--*--piperacillin-tazobactam",
            "Multiplier 300 312--*--at least one",
            "Measurement 313 326--*--blood culture",
            "Person 588 592--*--aged",
            "Value 593 610--*--18 years and over",
            "Temporal 491 512;525 574--*--No more than 72 hours since the first positive blood culture collection",
            "Reference_point 531 574--*--the first positive blood culture collection",
            "Value 541 549--*--positive",
            "Measurement 550 574--*--blood culture collection",
            "Value 612 617--*-->=21y",
            "Person 621 630--*--Singapore",
            "Scope 593 631--*--18 years and over (>=21y in Singapore)"
        ]
    },
    "NCT01909934_exc": {
        "Annotations": [
            "Drug 24 35--*--brentuximab",
            "Procedure 69 90--*--allogeneic transplant",
            "Condition 128 150--*--primary cutaneous ALCL",
            "Condition 191 196--*--sALCL",
            "Condition 228 245--*--meningeal disease",
            "Condition 219 227;238 245--*--cerebral disease",
            "Condition 277 319--*--progressive multifocal leukoencephalopathy",
            "Condition 321 324--*--PML",
            "Scope 219 245--*--cerebral/meningeal disease",
            "Pregnancy_considerations 327 390--*--Female patients who are lactating and breastfeeding or pregnant",
            "Measurement 398 426--*--human immunodeficiency virus",
            "Measurement 428 431--*--HIV",
            "Value 433 441--*--positive",
            "Measurement 449 476--*--hepatitis B surface antigen",
            "Value 477 485--*--positive",
            "Condition 516 537--*--hepatitis C infection",
            "Qualifier 509 515--*--active"
        ],
        "Text": "Previous treatment with brentuximab vedotin.. Previously received an allogeneic transplant.. Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has transformed to sALCL are eligible).. Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML). Female patients who are lactating and breastfeeding or pregnant. Known human immunodeficiency virus (HIV) positive. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection. "
    },
    "NCT01997112_inc": {
        "Annotations": [
            "Value 0 3--*--=18",
            "Person 4 13--*--years old",
            "Person 15 18--*--men",
            "Condition 22 37--*--post-menopausal",
            "Person 38 43--*--women",
            "Condition 56 66--*--no periods",
            "Temporal 67 88--*--for 12 months or more",
            "Procedure 114 122--*--surgical",
            "Condition 123 132--*--menopause",
            "Scope 56 132--*--no periods for 12 months or more, or those who have had a surgical menopause",
            "Condition 143 155--*--hypertensive",
            "Qualifier 135 142--*--Treated",
            "Measurement 173 233--*--average daytime ambulatory blood pressure measurement (ABPM)",
            "Value 234 245--*--<150/95mmHg",
            "Qualifier 249 261--*--stable doses",
            "Drug 277 304--*--antihypertensive medication",
            "Multiplier 265 276--*--one or more",
            "Drug 342 355--*--ACE inhibitor",
            "Drug 357 385--*--angiotensin receptor blocker",
            "Drug 389 397--*--diuretic",
            "Multiplier 306 318--*--at least one",
            "Scope 342 397--*--ACE inhibitor, angiotensin receptor blocker or diuretic",
            "Temporal 399 411--*--for 3 months",
            "Qualifier 416 425--*--untreated",
            "Condition 426 447--*--hypertensive patients",
            "Measurement 456 476--*--average daytime ABPM",
            "Value 477 496--*--=135/85 but <150/95",
            "Scope 135 155--*--Treated hypertensive",
            "Scope 416 447--*--untreated hypertensive patients",
            "Scope 173 411--*--average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months"
        ],
        "Text": "=18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause). Treated hypertensive patients with an average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime ABPM =135/85 but <150/95.. "
    },
    "NCT02205931_inc": {
        "Text": "Age between 1 month and 24 months of age (not beyond second birthday at baseline).. Diagnosis of epilepsy confirmed.. At least an average of 4 seizures/week in baseline period.. Failed response to previous trial of two anti-epileptic drugs. In the case of infantile spasms this could include a trial of corticosteroids.. Children with written informed consent from parent/guardian.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 40--*--between 1 month and 24 months of age",
            "Condition 97 105--*--epilepsy",
            "Condition 143 151--*--seizures",
            "Multiplier 118 142;151 156--*--At least an average of 4 /week",
            "Drug 219 239--*--anti-epileptic drugs",
            "Multiplier 215 218--*--two",
            "Condition 185 193--*--response",
            "Qualifier 178 184--*--Failed",
            "Drug 303 318--*--corticosteroids",
            "Informed_consent 321 380--*--Children with written informed consent from parent/guardian"
        ]
    },
    "NCT02112734_exc": {
        "Annotations": [
            "Person 0 7--*--Infants",
            "Procedure 34 69--*--postnatal vitamin D supplementation",
            "Drug 44 53--*--vitamin D",
            "Condition 71 82--*--prematurity",
            "Condition 95 110--*--low birthweight",
            "Measurement 99 110--*--birthweight",
            "Value 111 118--*--<2500 g",
            "Condition 120 131--*--poor health",
            "Temporal 141 148--*--current",
            "Temporal 152 156--*--past",
            "Condition 157 182--*--significant disease state",
            "Condition 186 208--*--congenital abnormality",
            "Scope 141 156--*--current or past"
        ],
        "Text": "Infants who have already received postnatal vitamin D supplementation. prematurity (<37 weeks)/low birthweight <2500 g. poor health due to a current or past significant disease state or congenital abnormality.. "
    },
    "NCT02715466_exc": {
        "Text": "Administration of HES, dextrane solutions or > 500 ml of Gelatin solutions within the 24 h prior to randomization. Death expected within the next 48 h (moribund patients as defined by ASA = class V). Patients whose medical condition does preclude the PLR manoeuvre. Patients for whom the need of pressure infusions are expected. Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration). Patients receiving therapeutic heparin medication due to chronic coagulation disease / anticoagulation medication (i.e. partial thromboplastin time > 60 sec). Acutely burned patients. Contraindications according to summary of product characteristics of investigational test and reference product. Simultaneous participation in another interventional clinical trial (drugs or medical devices studies). ",
        "Annotations": [
            "Drug 18 21--*--HES",
            "Drug 23 41--*--dextrane solutions",
            "Multiplier 45 53--*--> 500 ml",
            "Drug 57 74--*--Gelatin solutions",
            "Temporal 75 113--*--within the 24 h prior to randomization",
            "Scope 18 74--*--HES, dextrane solutions or > 500 ml of Gelatin solutions",
            "Observation 115 129--*--Death expected",
            "Temporal 130 150--*--within the next 48 h",
            "Condition 152 160--*--moribund",
            "Measurement 184 187--*--ASA",
            "Value 188 197--*--= class V",
            "Non-query-able 200 264--*--Patients whose medical condition does preclude the PLR manoeuvre",
            "Non-representable 266 327--*--Patients for whom the need of pressure infusions are expected",
            "Condition 345 358--*--renal support",
            "Mood 329 344--*--Requirement for",
            "Drug 517 524--*--heparin",
            "Condition 543 570--*--chronic coagulation disease",
            "Drug 573 599--*--anticoagulation medication",
            "Measurement 606 633--*--partial thromboplastin time",
            "Value 634 642--*--> 60 sec",
            "Scope 543 599--*--chronic coagulation disease / anticoagulation medication",
            "Condition 645 659--*--Acutely burned",
            "Non-representable 670 781--*--Contraindications according to summary of product characteristics of investigational test and reference product",
            "Non-query-able 783 885--*--Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)"
        ]
    },
    "NCT02205931_exc": {
        "Text": "Age <1m or > 24 months of age. No secure diagnosis of epilepsy. < 4 seizures/week on average in baseline period. Trial of < 2 AEDs. Continues on corticosteroids in previous 3 months prior to randomisation. Metabolic disease contraindicating use of the ketogenic diet e.g. pyruvate carboxylase deficiency, MCAD from previous medical investigation and screening at baseline.. Progressive neurological disease. Severe gastroesophageal reflux. Previous treatment with the ketogenic diet. Concurrent participation in another clinical trial of an investigational medicinal product.. Patients who are prescribed AEDs not listed in the trial IMPs. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 29--*--<1m or > 24 months of age",
            "Negation 31 33--*--No",
            "Condition 54 62--*--epilepsy",
            "Condition 68 76--*--seizures",
            "Multiplier 64 67;76 81--*--< 4 /week",
            "Drug 126 130--*--AEDs",
            "Multiplier 122 125--*--< 2",
            "Drug 145 160--*--corticosteroids",
            "Temporal 164 204--*--previous 3 months prior to randomisation",
            "Reference_point 191 204--*--randomisation",
            "Condition 206 223--*--Metabolic disease",
            "Condition 224 240--*--contraindicating",
            "Procedure 252 266--*--ketogenic diet",
            "Condition 272 304--*--pyruvate carboxylase deficiency,",
            "Condition 305 309--*--MCAD",
            "Scope 272 309--*--pyruvate carboxylase deficiency, MCAD",
            "Condition 386 406--*--neurological disease",
            "Qualifier 374 385--*--Progressive",
            "Condition 415 438--*--gastroesophageal reflux",
            "Qualifier 408 414--*--Severe",
            "Procedure 468 482--*--ketogenic diet",
            "Qualifier 440 448--*--Previous",
            "Competing_trial 484 574--*--Concurrent participation in another clinical trial of an investigational medicinal product",
            "Non-query-able 577 638--*--Patients who are prescribed AEDs not listed in the trial IMPs"
        ]
    },
    "NCT02112734_inc": {
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Condition 9 13--*--term",
            "Observation 15 28--*--breastfeeding",
            "Person 29 36--*--infants",
            "Observation 49 72--*--predominately breastfed",
            "Multiplier 73 94--*--for at least 6-months",
            "Non-representable 96 228--*--This will be determined by answering yes/no to question 'do you intend to breastfeed until your infant is at least 6 months of age.'"
        ],
        "Text": "Healthy, term, breastfeeding infants who will be predominately breastfed for at least 6-months. This will be determined by answering yes/no to question 'do you intend to breastfeed until your infant is at least 6 months of age.'. "
    },
    "NCT02715466_inc": {
        "Text": "Male or female patients = 18 and = 85 years of age. Women of child bearing potential must test negative on standard pregnancy test (urine or serum). Patients with body weight = 55 kg and = 140 kg and body mass index (BMI) = 18 kg/m2. Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis. Patients where antibiotic therapy has already been started (prior to randomization). Patient who are fluid responsive. Fluid responsiveness is defined as increase of > 10% in mean arterial pressure (MAP) after passive leg raising (PLR). Signed informed consent by patient, legal representative or authorized person or deferred consent. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 24 43--*--= 18 and = 85 years",
            "Person 47 50--*--age",
            "Person 52 57--*--Women",
            "Condition 61 84--*--child bearing potential",
            "Measurement 107 130--*--standard pregnancy test",
            "Value 95 103--*--negative",
            "Measurement 132 137--*--urine",
            "Measurement 141 146--*--serum",
            "Scope 132 146--*--urine or serum",
            "Scope 52 84--*--Women of child bearing potential",
            "Measurement 163 174--*--body weight",
            "Value 175 195--*--= 55 kg and = 140 kg",
            "Measurement 200 221--*--body mass index (BMI)",
            "Value 222 232--*--= 18 kg/m2",
            "Condition 253 266--*--severe sepsis",
            "Condition 269 281--*--septic shock",
            "Temporal 282 317--*--at admission on Intensive Care Unit",
            "Reference_point 285 317--*--admission on Intensive Care Unit",
            "Non-representable 326 367--*--be enrolled within 90 min after admission",
            "Drug 517 535--*--antibiotic therapy",
            "Temporal 562 584--*--prior to randomization",
            "Reference_point 571 584--*--randomization",
            "Condition 603 619--*--fluid responsive",
            "Measurement 677 705--*--mean arterial pressure (MAP)",
            "Qualifier 706 737--*--after passive leg raising (PLR)",
            "Value 668 673--*--> 10%",
            "Post-eligibility 739 836--*--Signed informed consent by patient, legal representative or authorized person or deferred consent"
        ]
    },
    "NCT03004209_inc": {
        "Text": "Clinically diagnosed autoimmune encephalitis. Ineffective 1st line treatment (e.g. steroid IV, IVIg) and 2nd line treatment (e.g. Rituximab or cyclophosphamide). ",
        "Annotations": [
            "Qualifier 0 20--*--Clinically diagnosed",
            "Condition 21 44--*--autoimmune encephalitis",
            "Qualifier 46 57--*--Ineffective",
            "Procedure 58 76--*--1st line treatment",
            "Drug 83 93--*--steroid IV",
            "Drug 95 99--*--IVIg",
            "Procedure 105 123--*--2nd line treatment",
            "Drug 130 139--*--Rituximab",
            "Drug 143 159--*--cyclophosphamide",
            "Scope 130 159--*--Rituximab or cyclophosphamide",
            "Scope 83 99--*--steroid IV, IVIg"
        ]
    },
    "NCT02301039_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--\u2265 18 years",
            "Person 16 19--*--Age",
            "Value 20 30--*--\u2265 12 years",
            "Condition 49 62--*--bone sarcomas",
            "Procedure 66 80--*--Histologically",
            "Value 81 90--*--confirmed",
            "Condition 158 169;178 185--*--soft-tissue sarcoma",
            "Qualifier 147 157--*--high grade",
            "Qualifier 136 146--*--metastatic",
            "Temporal 118 127--*--recurrent",
            "Qualifier 104 116--*--unresectable",
            "Condition 173 185--*--bone sarcoma",
            "Scope 158 185--*--soft-tissue or bone sarcoma",
            "Scope 104 157--*--unresectable, recurrent, and/or metastatic high grade",
            "Condition 220 240--*--soft tissue sarcomas",
            "Condition 242 256--*--leiomyosarcoma",
            "Condition 298 309--*--liposarcoma",
            "Qualifier 258 279--*--poorly differentiated",
            "Qualifier 280 297--*--de-differentiated",
            "Scope 258 297--*--poorly differentiated/de-differentiated",
            "Condition 351 358--*--sarcoma",
            "Qualifier 334 350--*--undifferentiated",
            "Qualifier 322 333--*--pleomorphic",
            "Qualifier 311 321--*--high grade",
            "Condition 359 362--*--MFH",
            "Condition 367 383--*--synovial sarcoma",
            "Scope 351 383--*--sarcoma/MFH and synovial sarcoma",
            "Scope 311 350--*--high grade pleomorphic undifferentiated",
            "Condition 390 403--*--bone sarcomas",
            "Condition 405 418--*--Ewing sarcoma",
            "Condition 420 432--*--osteosarcoma",
            "Condition 438 452--*--chondrosarcoma",
            "Qualifier 454 471--*--de-differentiated",
            "Qualifier 475 486--*--mesenchymal",
            "Scope 454 486--*--de-differentiated or mesenchymal",
            "Scope 404 488--*--(Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])",
            "Scope 242 383--*--leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma",
            "Grammar_Error 386 389--*--and",
            "Scope 220 488--*--soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])",
            "Measurement 491 514--*--ECOG Performance Status",
            "Value 518 524--*--0 or 1",
            "Condition 548 566--*--measurable disease",
            "Procedure 570 572;577 582--*--CT scans",
            "Procedure 573 582--*--MRI scans",
            "Scope 570 582--*--CT/MRI scans",
            "Procedure 618 625--*--imaging",
            "Temporal 609 617--*--Baseline",
            "Temporal 644 668--*--within 30 days of dosing",
            "Reference_point 662 668--*--dosing",
            "Non-query-able 671 811--*--At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.",
            "Multiplier 840 843--*--1-3",
            "Temporal 844 849--*--prior",
            "Procedure 850 868--*--systemic therapies",
            "Qualifier 876 894--*--metastatic setting",
            "Condition 897 920--*--Adequate organ function",
            "Temporal 921 945--*--within 14 days of dosing",
            "Reference_point 939 945--*--dosing",
            "Non-query-able 947 1027--*--Must be willing to provide and have available archival tissue for PD-L1 testing.",
            "Post-eligibility 1029 1065--*--Written, voluntary informed consent.",
            "Non-query-able 1029 1065--*--Written, voluntary informed consent.",
            "Person 1083 1088--*--women",
            "Person 1075 1078--*--men",
            "Condition 1092 1114--*--childbearing potential",
            "Procedure 1156 1169--*--birth control",
            "Temporal 1170 1199--*--from providing signed consent",
            "Reference_point 1175 1199--*--providing signed consent",
            "Temporal 1204 1253--*--for 120 days after last study drug administration",
            "Reference_point 1223 1253--*--last study drug administration",
            "Scope 1075 1114--*--men and women of childbearing potential",
            "Non-query-able 1067 1254--*--Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration.",
            "Non-query-able 1255 1377--*--Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause.",
            "Person 1255 1260--*--Women",
            "Condition 1264 1286--*--childbearing potential",
            "Condition 1295 1309--*--pre-menopausal",
            "Person 1310 1315--*--women",
            "Person 1320 1325--*--women",
            "Temporal 1326 1376--*--within the first 2 years of the onset of menopause",
            "Reference_point 1354 1376--*--the onset of menopause",
            "Condition 1387 1409--*--childbearing potential",
            "Person 1378 1383--*--Women",
            "Measurement 1431 1445--*--pregnancy test",
            "Value 1422 1430--*--negative",
            "Temporal 1446 1471--*--\u2264 72 hours prior to Day 1",
            "Reference_point 1466 1471--*--Day 1",
            "Scope 1378 1409--*--Women of childbearing potential",
            "Procedure 1504 1517--*--birth control",
            "Condition 1527 1545--*--surgically sterile",
            "Device 1547 1561--*--barrier device",
            "Device 1563 1569--*--condom",
            "Device 1571 1580--*--diaphragm",
            "Scope 1563 1580--*--condom, diaphragm",
            "Device 1583 1601--*--contraceptive coil",
            "Device 1603 1628--*--intrauterine device (IUD)",
            "Procedure 1634 1644--*--abstinence",
            "Grammar_Error 1630 1633--*--and",
            "Scope 1527 1644--*--surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence",
            "Observation 1647 1662--*--Life expectancy",
            "Value 1666 1675--*-->12 weeks",
            "Condition 1692 1722--*--central nervous system disease",
            "Procedure 1779 1791--*--radiotherapy",
            "Procedure 1795 1802--*--surgery",
            "Condition 1815 1837--*--CNS metastatic disease",
            "Condition 1866 1886--*--clinical progression",
            "Negation 1846 1853--*--without",
            "Temporal 1887 1926--*--for at least 4 weeks prior to screening",
            "Reference_point 1917 1926--*--screening",
            "Condition 1965 1981--*--brain metastases",
            "Qualifier 1955 1964--*--enlarging",
            "Qualifier 1948 1951--*--new",
            "Scope 1948 1964--*--new or enlarging",
            "Negation 1933 1935--*--no",
            "Drug 1995 2003--*--steroids",
            "Negation 1991 1994--*--off",
            "Temporal 2004 2058--*--for at least 7 days before first dose of pembrolizumab",
            "Reference_point 2031 2058--*--first dose of pembrolizumab",
            "Drug 2045 2058--*--pembrolizumab",
            "Scope 1779 2058--*--radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab"
        ],
        "Text": "Age \u2265 18 years (Age \u2265 12 years for patients with bone sarcomas). . Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). . ECOG Performance Status of 0 or 1. . At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. . At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. . Patients may have received 1-3 prior systemic therapies in the metastatic setting. . Adequate organ function within 14 days of dosing . Must be willing to provide and have available archival tissue for PD-L1 testing. . Written, voluntary informed consent. . Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test \u2264 72 hours prior to Day 1 of study. . Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. . Life expectancy of >12 weeks. . Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab. . "
    },
    "NCT02973035_inc": {
        "Text": "Controlled hypertension: systolic BP < 150 and diastolic BP < 90 mmHg in persons aged 60 years or older, systolic BP < 140 and diastolic BP < 90 mmHg in persons 40 through 59 years according to the JNC 8th guideline. Evidence of diastolic dysfunction showing E/E' > 10. The patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. ",
        "Annotations": [
            "Condition 11 23--*--hypertension",
            "Qualifier 0 10--*--Controlled",
            "Measurement 25 36--*--systolic BP",
            "Value 37 42--*--< 150",
            "Measurement 47 59--*--diastolic BP",
            "Value 60 69--*--< 90 mmHg",
            "Person 81 85--*--aged",
            "Value 86 103--*--60 years or older",
            "Measurement 105 116--*--systolic BP",
            "Value 117 122--*--< 140",
            "Measurement 127 139--*--diastolic BP",
            "Value 140 149--*--< 90 mmHg",
            "Person 175 180--*--years",
            "Value 161 174--*--40 through 59",
            "Qualifier 198 215--*--JNC 8th guideline",
            "Scope 25 180--*--systolic BP < 150 and diastolic BP < 90 mmHg in persons aged 60 years or older, systolic BP < 140 and diastolic BP < 90 mmHg in persons 40 through 59 years",
            "Scope 25 69--*--systolic BP < 150 and diastolic BP < 90 mmHg",
            "Scope 105 149--*--systolic BP < 140 and diastolic BP < 90 mmHg",
            "Condition 229 250--*--diastolic dysfunction",
            "Measurement 259 263--*--E/E'",
            "Value 264 268--*--> 10",
            "Post-eligibility 270 520--*--The patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site"
        ]
    },
    "NCT01630954_exc": {
        "Annotations": [
            "Condition 0 12--*--Partial mole",
            "Condition 39 54--*--molar pregnancy",
            "Procedure 25 34--*--treatment",
            "Procedure 66 76--*--evacuation",
            "Procedure 80 92--*--chemotherapy",
            "Scope 66 92--*--evacuation or chemotherapy",
            "Person 94 99--*--Women",
            "Procedure 110 122--*--hysterectomy",
            "Condition 140 146--*--H Mole"
        ],
        "Text": "Partial mole. History of treatment for molar pregnancy like prior evacuation or chemotherapy. Women requiring hysterectomy for treatment of H Mole. "
    },
    "NCT03297944_exc": {
        "Annotations": [
            "Multiplier 6 11--*--daily",
            "Drug 12 22--*--medication",
            "Condition 27 44--*--chronic condition",
            "Qualifier 46 51--*--acute",
            "Condition 52 73--*--narrow angle glaucoma",
            "Temporal 75 83--*--previous",
            "Condition 84 102--*--adverse experience",
            "Drug 108 119--*--study drugs",
            "Condition 133 148--*--motion sickness",
            "Measurement 183 186--*--BMI",
            "Value 187 191--*--> 30",
            "Person 193 198--*--women",
            "Condition 207 215--*--pregnant",
            "Condition 217 226--*--lactating",
            "Mood 231 251--*--planning on becoming",
            "Condition 252 260--*--pregnant",
            "Multiplier 262 269--*--regular",
            "Observation 270 293--*--use of tobacco products",
            "Temporal 295 302--*--current",
            "Condition 303 325--*--substance use disorder",
            "Qualifier 327 349--*--clinically significant",
            "Procedure 350 353--*--ECG",
            "Temporal 355 362--*--current",
            "Temporal 363 370--*--ongoing",
            "Condition 371 391--*--psychiatric disorder"
        ],
        "Text": "using daily medication for chronic condition. acute narrow angle glaucoma. previous adverse experience with study drugs. experiences motion sickness in response to driving simulator. BMI > 30. women who are pregnant, lactating, or planning on becoming pregnant. regular use of tobacco products. current substance use disorder. clinically significant ECG. current ongoing psychiatric disorder. "
    },
    "NCT02596555_exc": {
        "Text": "Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation. Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. Participation in another clinical trial during the present clinical trial or within the last three months. Medical or psychological condition that would not permit completion of the trial or signing of informed consent. Use of a fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE. Treatment with any therapeutically dosed anticoagulant for more than 48 hours prior to enrolment. Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;. Active bleeding or known significant bleeding risk (e.g., gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities). Artificial heart valves requiring treatment with an anticoagulant. Renal insufficiency with estimated creatinine clearance <30 ml/min/1.73m2. Chronic liver disease with aminotransferase levels two times or more above the local upper limit of normal range. Concomitant administration of strong inhibitors of P-glycoprotein like ketoconazole, cyclosporin, itraconazole or dronedarone. Unwillingness or inability to adhere to treatment or to the follow-up visits. Life expectancy less than 6 months. ",
        "Annotations": [
            "Pregnancy_considerations 0 145--*--Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation",
            "Pregnancy_considerations 147 288--*--Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond",
            "Non-query-able 290 501--*--History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product",
            "Competing_trial 503 608--*--Participation in another clinical trial during the present clinical trial or within the last three months",
            "Informed_consent 610 721--*--Medical or psychological condition that would not permit completion of the trial or signing of informed consent",
            "Drug 732 750--*--fibrinolytic agent",
            "Procedure 752 774--*--surgical thrombectomy,",
            "Procedure 810 829--*--thrombus aspiration",
            "Procedure 810 818;833 838--*--thrombus lysis",
            "Procedure 852 863--*--cava filter",
            "Condition 894 896--*--PE",
            "Scope 732 863--*--fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter",
            "Drug 939 952--*--anticoagulant",
            "Qualifier 917 932--*--therapeutically",
            "Temporal 957 994--*--more than 48 hours prior to enrolment",
            "Reference_point 985 994--*--enrolment",
            "Qualifier 1005 1014--*--long-term",
            "Drug 1032 1060--*--low molecular weight heparin",
            "Drug 1062 1083--*--vitamin K antagonists",
            "Drug 1087 1091--*--NOAC",
            "Condition 1132 1142--*--PE episode",
            "Drug 1151 1170--*--antiplatelet agents",
            "Negation 1171 1177--*--except",
            "Negation 1111 1116--*--other",
            "Qualifier 1126 1131--*--index",
            "Scope 1033 1091--*--ow molecular weight heparin, vitamin K antagonists or NOAC",
            "Drug 1178 1198--*--acetylsalicylic acid",
            "Multiplier 1211 1223--*--=100 mg/day;",
            "Scope 1151 1222--*--antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day",
            "Scope 1032 1223--*--low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;",
            "Condition 1225 1240--*--Active bleeding",
            "Observation 1262 1275--*--bleeding risk",
            "Qualifier 1250 1261--*--significant",
            "Condition 1283 1305--*--gastrointestinal ulcer",
            "Condition 1307 1326--*--malignant neoplasms",
            "Condition 1328 1336--*--injuries",
            "Procedure 1347 1356--*--surgeries",
            "Qualifier 1364 1369--*--brain",
            "Qualifier 1371 1382--*--spinal cord",
            "Qualifier 1386 1390--*--eyes",
            "Scope 1364 1390--*--brain, spinal cord or eyes",
            "Condition 1399 1421--*--intracranial bleedings",
            "Condition 1442 1459--*--esophagus varices",
            "Condition 1461 1470--*--aneurysms",
            "Condition 1502 1525--*--vascular abnormalities)",
            "Qualifier 1489 1501--*--intracranial",
            "Qualifier 1474 1485--*--intraspinal",
            "Scope 1474 1501--*--intraspinal or intracranial",
            "Scope 1283 1524--*--gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities",
            "Device 1527 1550--*--Artificial heart valves",
            "Drug 1579 1592--*--anticoagulant",
            "Condition 1594 1613--*--Renal insufficiency",
            "Measurement 1619 1649--*--estimated creatinine clearance",
            "Value 1650 1667--*--<30 ml/min/1.73m2",
            "Condition 1669 1690--*--Chronic liver disease",
            "Measurement 1696 1712--*--aminotransferase",
            "Value 1720 1781--*--two times or more above the local upper limit of normal range",
            "Drug 1820 1848--*--inhibitors of P-glycoprotein",
            "Drug 1854 1866--*--ketoconazole",
            "Drug 1868 1879--*--cyclosporin",
            "Drug 1881 1893--*--itraconazole",
            "Drug 1897 1908--*--dronedarone",
            "Scope 1854 1908--*--ketoconazole, cyclosporin, itraconazole or dronedarone",
            "Post-eligibility 1910 1986--*--Unwillingness or inability to adhere to treatment or to the follow-up visits",
            "Observation 1988 2003--*--Life expectancy",
            "Value 2004 2022--*--less than 6 months"
        ]
    },
    "NCT02564471_inc": {
        "Annotations": [
            "Non-query-able 0 47--*--Provide signed and dated informed consent form.",
            "Post-eligibility 49 140--*--Willing to comply with all study procedures and be available for the duration of the study.",
            "Person 142 146--*--Male",
            "Person 150 156--*--female",
            "Person 158 162--*--aged",
            "Value 163 181--*--= 18 to = 60 years",
            "Temporal 182 201--*--on day of inclusion",
            "Condition 207 226--*--good general health",
            "Observation 236 251--*--medical history",
            "Procedure 256 269--*--physical exam"
        ],
        "Text": "Provide signed and dated informed consent form.. Willing to comply with all study procedures and be available for the duration of the study.. Male or female, aged = 18 to = 60 years on day of inclusion.. In good general health based on medical history and physical exam. "
    },
    "NCT02831166_exc": {
        "Annotations": [
            "Value 0 18--*--Less than 18 years",
            "Person 22 25--*--age",
            "Condition 28 37--*--Pregnancy",
            "Drug 55 76--*--vitamin K antagonists",
            "Multiplier 40 47--*--Chronic",
            "Drug 80 106--*--direct thrombin inhibitors",
            "Drug 111 137--*--oral Xa-factor antagonists",
            "Scope 55 137--*--vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists",
            "Condition 140 156--*--Hypersensitivity",
            "Drug 160 172;194 199--*--antiplatelet drugs",
            "Drug 180 199--*--anticoagulant drugs",
            "Scope 160 199--*--antiplatelet and/or anticoagulant drugs",
            "Condition 221 239--*--high bleeding risk",
            "Condition 209 217--*--bleeding",
            "Qualifier 202 208--*--Active",
            "Condition 248 261--*--liver failure",
            "Qualifier 241 247--*--severe",
            "Qualifier 263 269--*--active",
            "Condition 270 282--*--peptic ulcer",
            "Measurement 284 304--*--creatinine clearance",
            "Value 305 316--*--< 30 mL/min",
            "Measurement 318 333--*--platelets count",
            "Value 334 347--*--< 100.000 mm3",
            "Qualifier 351 363--*--Uncontrolled",
            "Condition 364 385--*--systemic hypertension",
            "Condition 388 405--*--Cardiogenic shock",
            "Procedure 417 453--*--myocardial revascularization surgery",
            "Temporal 408 416--*--Previous",
            "Device 463 479;497 502--*--internal mammary graft",
            "Device 483 502--*--radial artery graft",
            "Multiplier 459 462--*--= 1",
            "Scope 463 502--*--internal mammary or radial artery graft",
            "Qualifier 516 523--*--chronic",
            "Condition 524 551--*--peripheral arterial disease",
            "Procedure 578 595--*--femoral technique",
            "Negation 552 562--*--preventing",
            "Qualifier 598 604--*--Severe",
            "Temporal 605 616--*--concomitant",
            "Condition 617 624--*--disease",
            "Observation 630 645--*--life expectancy",
            "Value 646 661--*--below 12 months",
            "Non-query-able 664 747--*--Participation in drug or devices investigative clinical trials in the last 30 days;",
            "Post-eligibility 749 893--*--Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term."
        ],
        "Text": "Less than 18 years of age;. Pregnancy;. Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists;. Hypersensitivity to antiplatelet and/or anticoagulant drugs;. Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3);. Uncontrolled systemic hypertension;. Cardiogenic shock;. Previous myocardial revascularization surgery with = 1 internal mammary or radial artery graft;. Documented chronic peripheral arterial disease preventing the use of the femoral technique;. Severe concomitant disease with life expectancy below 12 months;. Participation in drug or devices investigative clinical trials in the last 30 days;. Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.. "
    },
    "NCT02301039_exc": {
        "Annotations": [
            "Procedure 6 49--*--systemic therapy targeting PD-1: PD-L1 axis",
            "Procedure 80 121--*--conventional multidisciplinary management",
            "Qualifier 69 76--*--curable",
            "Context_Error 69 76--*--curable",
            "Condition 176 191--*--medical disease",
            "Undefined_semantics 176 191--*--medical disease",
            "Temporal 165 175--*--concurrent",
            "Qualifier 152 164--*--uncontrolled",
            "Qualifier 138 144--*--severe",
            "Scope 138 164--*--severe and/or uncontrolled",
            "Subjective_judgement 197 231--*--in the opinion of the investigator",
            "Non-query-able 124 313--*--Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.",
            "Procedure 342 365--*--wide field radiotherapy",
            "Temporal 366 375--*--\u2264 4 weeks",
            "Procedure 379 417--*--limited field radiation for palliation",
            "Temporal 418 446--*--< 2 weeks prior to screening",
            "Reference_point 437 446--*--screening",
            "Condition 463 472--*--recovered",
            "Qualifier 473 483--*--adequately",
            "Negation 459 462--*--not",
            "Condition 489 517--*--side effects of such therapy",
            "Undefined_semantics 489 517--*--side effects of such therapy",
            "Procedure 505 517--*--such therapy",
            "Condition 545 555--*--infections",
            "Procedure 566 573--*--therapy",
            "Qualifier 556 573--*--requiring therapy",
            "Measurement 619 653--*--Human Immunodeficiency Virus (HIV)",
            "Value 606 614--*--positive",
            "Qualifier 655 673--*--HIV 1/2 antibodies",
            "Condition 676 694--*--active Hepatitis B",
            "Measurement 696 701--*--HBsAg",
            "Value 702 710--*--reactive",
            "Condition 716 727--*--Hepatitis C",
            "Measurement 729 750--*--HCV RNA [qualitative]",
            "Value 754 762--*--detected",
            "Measurement 788 808--*--Hepatitis C antibody",
            "Value 779 787--*--negative",
            "Non-query-able 765 841--*--patients with negative Hepatitis C antibody testing may not need RNA testing",
            "Not_a_criteria 765 841--*--patients with negative Hepatitis C antibody testing may not need RNA testing",
            "Condition 871 882;902 910--*--psychiatric disorder",
            "Condition 886 910--*--substance abuse disorder",
            "Subjective_judgement 844 984--*--Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.",
            "Procedure 1008 1038--*--systemic anti-cancer treatment",
            "Temporal 1039 1076--*--prior to the first dose of study drug",
            "Reference_point 1048 1076--*--the first dose of study drug",
            "Parsing_Error 986 1110--*--Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames:",
            "Condition 1133 1151--*--autoimmune disease",
            "Temporal 1126 1132--*--active",
            "Condition 1179 1197--*--autoimmune disease",
            "Observation 1168 1175--*--history",
            "Condition 1201 1241--*--syndrome that requires systemic steroids",
            "Drug 1224 1241--*--systemic steroids",
            "Undefined_semantics 1201 1241--*--syndrome that requires systemic steroids",
            "Drug 1245 1269--*--immunosuppressive agents",
            "Condition 1201 1223;1245 1269--*--syndrome that requires immunosuppressive agents",
            "Condition 1306 1322--*--childhood asthma",
            "Qualifier 1297 1305--*--resolved",
            "Condition 1285 1293--*--vitiligo",
            "Condition 1323 1328--*--atopy",
            "Not_a_criteria 1271 1361--*--Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule.",
            "Not_a_criteria 1362 1466--*--Patients that require inhaled steroids or local steroid injections would not be excluded from the study.",
            "Condition 1481 1495--*--hypothyroidism",
            "Condition 1505 1523--*--autoimmune disease",
            "Negation 1496 1499--*--not",
            "Qualifier 1532 1561--*--stable on hormone replacement",
            "Procedure 1542 1561--*--hormone replacement",
            "Grammar_Error 1562 1597--*--will not be excluded from the study",
            "Not_a_criteria 1467 1598--*--Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study.",
            "Person 1600 1605--*--Women",
            "Condition 1614 1622--*--pregnant",
            "Condition 1626 1633--*--nursing",
            "Observation 1634 1647--*--breastfeeding",
            "Condition 1656 1689--*--hypersensitivity to pembrolizumab",
            "Drug 1676 1689--*--pembrolizumab",
            "Condition 1656 1675;1701 1704--*--hypersensitivity to mAb",
            "Drug 1701 1704--*--mAb",
            "Drug 1767 1775--*--steroids",
            "Condition 1787 1798--*--pneumonitis",
            "Temporal 1779 1786--*--current",
            "Condition 1741 1752--*--pneumonitis",
            "Observation 1713 1720--*--history",
            "Qualifier 1758 1775--*--required steroids",
            "Condition 1825 1855--*--central nervous system disease",
            "Undefined_semantics 1825 1855--*--central nervous system disease",
            "Qualifier 1815 1824--*--untreated",
            "Condition 1890 1901--*--CNS lesions",
            "Procedure 1921 1928--*--surgery",
            "Procedure 1932 1957--*--stereotactic radiosurgery",
            "Temporal 1969 1980--*--for 4 weeks",
            "Qualifier 1962 1968--*--stable",
            "Scope 1921 1957--*--surgery or stereotactic radiosurgery",
            "Qualifier 1871 1881--*--controlled",
            "Qualifier 1882 1889--*--treated",
            "Condition 1996 2050--*--Inability to comply with protocol required procedures.",
            "Undefined_semantics 1996 2050--*--Inability to comply with protocol required procedures.",
            "Non-query-able 1996 2050--*--Inability to comply with protocol required procedures.",
            "Post-eligibility 1996 2050--*--Inability to comply with protocol required procedures.",
            "Condition 2066 2084--*--medical conditions",
            "Procedure 2106 2137--*--systemic corticosteroid therapy",
            "Temporal 2098 2105--*--chronic",
            "Drug 2167 2195--*--immunosuppressive medication",
            "Undefined_semantics 2167 2195--*--immunosuppressive medication",
            "Qualifier 2090 2137--*--require chronic systemic corticosteroid therapy",
            "Qualifier 2141 2148;2167 2195--*--require immunosuppressive medication",
            "Scope 2090 2195--*--require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication",
            "Multiplier 2221 2250--*--physiologic replacement doses",
            "Drug 2254 2268--*--hydrocortisone",
            "Drug 2345 2359--*--hydrocortisone",
            "Multiplier 2333 2344--*--up to 20 mg",
            "Drug 2372 2382--*--prednisone",
            "Multiplier 2364 2368--*--5 mg",
            "Drug 2409 2423--*--hydrocortisone",
            "Multiplier 2403 2408--*--10 mg",
            "Drug 2435 2445--*--prednisone",
            "Multiplier 2428 2434--*--2.5 mg",
            "Multiplier 2384 2398--*--in the morning",
            "Multiplier 2447 2461--*--in the evening",
            "Scope 2333 2461--*--up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening",
            "Scope 2221 2268--*--physiologic replacement doses of hydrocortisone",
            "Condition 2499 2516--*--bowel obstruction",
            "Condition 2520 2537--*--bowel perforation",
            "Condition 2482 2516--*--risk factors for bowel obstruction",
            "Condition 2482 2498;2520 2537--*--risk factors for bowel perforation",
            "Observation 2577 2584--*--history",
            "Condition 2588 2608--*--acute diverticulitis",
            "Condition 2610 2633--*--intra-abdominal abscess",
            "Condition 2635 2659--*--abdominal carcinomatosis",
            "Scope 2588 2659--*--acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis",
            "Scope 2482 2537--*--risk factors for bowel obstruction or bowel perforation",
            "Drug 2692 2704--*--live vaccine",
            "Temporal 2705 2762--*--within 30 days prior to the first dose of trial treatment",
            "Reference_point 2729 2762--*--the first dose of trial treatment"
        ],
        "Text": "Prior systemic therapy targeting PD-1: PD-L1 axis. . Patients who are curable by conventional multidisciplinary management. . Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. . Patients who have received wide field radiotherapy \u2264 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy. . Patients who have active infections requiring therapy. . Patients that are known to be positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive), or Hepatitis C (HCV RNA [qualitative] is detected); patients with negative Hepatitis C antibody testing may not need RNA testing. . Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial. . Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames: . Patients with active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule. Patients that require inhaled steroids or local steroid injections would not be excluded from the study. Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study. . Women who are pregnant or nursing/breastfeeding. . Known hypersensitivity to pembrolizumab or another mAb. . Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. . Patients with untreated central nervous system disease. Patients with controlled treated CNS lesions who have undergone surgery or stereotactic radiosurgery and stable for 4 weeks are eligible. . Inability to comply with protocol required procedures. . Patients with medical conditions that require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication. However, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study: up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening. . Patients with the risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis). . Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment.       .     . "
    },
    "NCT03004209_exc": {
        "Text": "Hemoglobin > 12g/dL. Hematochrit >36%. Thrombocytosis > 750K. AST or ALT > 120. HIV (+). Allergic reaction upon erythropoietin. Uncontrolled hypertension. mRS before the autoimmune encephalitis > 3. Breast feeding or pregnancy. History of ischemic stroke or pulmonary thrombosis. Refuse to be enrolled. ",
        "Annotations": [
            "Measurement 0 10--*--Hemoglobin",
            "Value 11 19--*--> 12g/dL",
            "Measurement 21 32--*--Hematochrit",
            "Value 33 37--*-->36%",
            "Measurement 39 53--*--Thrombocytosis",
            "Value 54 60--*--> 750K",
            "Measurement 62 65--*--AST",
            "Measurement 69 72--*--ALT",
            "Value 73 78--*--> 120",
            "Scope 62 72--*--AST or ALT",
            "Condition 80 87--*--HIV (+)",
            "Condition 89 97--*--Allergic",
            "Drug 112 126--*--erythropoietin",
            "Condition 128 153--*--Uncontrolled hypertension",
            "Condition 170 193--*--autoimmune encephalitis",
            "Temporal 159 193--*--before the autoimmune encephalitis",
            "Reference_point 166 193--*--the autoimmune encephalitis",
            "Measurement 155 158--*--mRS",
            "Value 194 197--*--> 3",
            "Condition 217 226--*--pregnancy",
            "Observation 199 213--*--Breast feeding",
            "Condition 239 254--*--ischemic stroke",
            "Condition 258 278--*--pulmonary thrombosis",
            "Observation 228 235--*--History",
            "Scope 239 278--*--ischemic stroke or pulmonary thrombosis",
            "Observation 280 301--*--Refuse to be enrolled"
        ]
    },
    "NCT01630954_inc": {
        "Annotations": [
            "Procedure 0 10--*--Ultrasound",
            "Condition 21 34--*--complete mole"
        ],
        "Text": "Ultrasound confirmed complete mole. "
    },
    "NCT03297944_inc": {
        "Annotations": [
            "Observation 0 22--*--valid driver's license",
            "Observation 24 40--*--english-speaking",
            "Observation 45 53--*--literate"
        ],
        "Text": "valid driver's license. english-speaking and literate. "
    },
    "visual": {},
    "NCT02973035_exc": {
        "Text": "Unwillingness or inability to comply with the procedures described in this protocol. Planned cardiac surgery or planned major non-cardiac surgery within the study period.. Stroke or coronary revascularization in the past 6 months.. Clinically significant pulmonary disease.. Untreated hyperthyroidism, or hypothyroidism.. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.. Female of child-bearing potential who do not use adequate contraception and women who are pregnant or breast-feeding. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.. LV ejection fraction < 50%.. Significant renal disease manifested by serum creatinine > 2.5 mg/dL. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).. History of intolerance to ARB or amlodipine.. Hypertrophic or restrictive cardiomyopathy.. Moderate or severe valvular disease.. Constrictive pericarditis. Atrial fibrillation with a heart rate > 120/min.. Sitting systolic BP < 100 mmHg. ",
        "Annotations": [
            "Post-eligibility 0 83--*--Unwillingness or inability to comply with the procedures described in this protocol",
            "Temporal 146 169--*--within the study period",
            "Procedure 138 145--*--surgery",
            "Qualifier 130 137--*--cardiac",
            "Negation 126 129--*--non",
            "Qualifier 120 125--*--major",
            "Mood 112 119--*--planned",
            "Procedure 93 108--*--cardiac surgery",
            "Mood 85 92--*--Planned",
            "Scope 85 145--*--Planned cardiac surgery or planned major non-cardiac surgery",
            "Reference_point 157 169--*--study period",
            "Procedure 182 208--*--coronary revascularization",
            "Procedure 172 178;191 208--*--Stroke revascularization",
            "Temporal 209 229--*--in the past 6 months",
            "Scope 172 208--*--Stroke or coronary revascularization",
            "Condition 255 272--*--pulmonary disease",
            "Qualifier 232 242;243 254--*--Clinically significant",
            "Condition 285 300--*--hyperthyroidism",
            "Condition 305 319--*--hypothyroidism",
            "Qualifier 275 284--*--Untreated",
            "Scope 285 319--*--hyperthyroidism, or hypothyroidism",
            "Condition 337 343--*--cancer",
            "Negation 345 355--*--other than",
            "Condition 356 376;391 402--*--superficial squamous skin cancer",
            "Condition 380 402--*--basal cell skin cancer",
            "Scope 356 402--*--superficial squamous or basal cell skin cancer",
            "Temporal 404 423--*--in the past 3 years",
            "Procedure 435 444--*--treatment",
            "Condition 460 466--*--cancer",
            "Qualifier 453 459--*--active",
            "Scope 337 403--*--cancer (other than superficial squamous or basal cell skin cancer)",
            "Pregnancy_considerations 469 585--*--Female of child-bearing potential who do not use adequate contraception and women who are pregnant or breast-feeding",
            "Subjective_judgement 587 809--*--Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study",
            "Measurement 812 832--*--LV ejection fraction",
            "Value 833 838--*--< 50%",
            "Condition 853 866--*--renal disease",
            "Qualifier 841 852--*--Significant",
            "Measurement 881 897--*--serum creatinine",
            "Value 898 909--*--> 2.5 mg/dL",
            "Condition 911 926--*--Hepatic disease",
            "Condition 930 955--*--biliary tract obstruction",
            "Condition 972 996--*--hepatic enzyme elevation",
            "Qualifier 960 971--*--significant",
            "Measurement 998 1001--*--ALT",
            "Measurement 1005 1008--*--AST",
            "Value 1009 1040--*--> 3 times upper limit of normal",
            "Scope 998 1008--*--ALT or AST",
            "Condition 1055 1066--*--intolerance",
            "Drug 1070 1073--*--ARB",
            "Drug 1077 1087--*--amlodipine",
            "Scope 1070 1087--*--ARB or amlodipine",
            "Condition 1106 1132--*--restrictive cardiomyopathy",
            "Condition 1090 1102;1118 1132--*--Hypertrophic cardiomyopathy",
            "Condition 1154 1170--*--valvular disease",
            "Qualifier 1147 1153--*--severe",
            "Qualifier 1135 1143--*--Moderate",
            "Scope 1135 1153--*--Moderate or severe",
            "Condition 1173 1198--*--Constrictive pericarditis",
            "Condition 1200 1219--*--Atrial fibrillation",
            "Measurement 1227 1237--*--heart rate",
            "Value 1238 1247--*--> 120/min",
            "Condition 1258 1269--*--systolic BP",
            "Qualifier 1250 1257--*--Sitting",
            "Value 1270 1280--*--< 100 mmHg"
        ]
    },
    "NCT02596555_inc": {
        "Text": "Age =18 years. Objectively confirmed diagnosis of acute PE by multidetector CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography, according to established diagnostic criteria, with or without symptomatic deep vein thrombosis. Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation. At least one sign of RV pressure overload/dysfunction on CT angiography or echocardiography. Signs of myocardial injury as indicated by elevated troponin levels. Signs of (RV) failure as indicated by NT-proBNP levels >600 pg/ml at baseline.. Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 13--*--=18 years",
            "Qualifier 50 55--*--acute",
            "Condition 56 58--*--PE",
            "Procedure 76 90--*--CT angiography",
            "Procedure 92 123--*--ventilation/perfusion lung scan",
            "Procedure 138 169--*--invasive pulmonary angiography,",
            "Condition 244 264--*--deep vein thrombosis",
            "Scope 76 168--*--CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography",
            "Condition 277 297--*--hemodynamic collapse",
            "Negation 266 273--*--Absence",
            "Condition 277 288;302 316--*--hemodynamic decompensation",
            "Scope 277 316--*--hemodynamic collapse, or decompensation",
            "Multiplier 375 387--*--At least one",
            "Condition 388 416--*--sign of RV pressure overload",
            "Condition 388 407;417 428--*--sign of RV pressure dysfunction",
            "Procedure 432 446--*--CT angiography",
            "Procedure 450 466--*--echocardiography",
            "Scope 432 466--*--CT angiography or echocardiography",
            "Scope 388 428--*--sign of RV pressure overload/dysfunction",
            "Measurement 520 535--*--troponin levels",
            "Value 511 519--*--elevated",
            "Condition 477 494--*--myocardial injury",
            "Condition 547 558--*--RV) failure",
            "Measurement 575 591--*--NT-proBNP levels",
            "Value 592 602--*-->600 pg/ml",
            "Post-eligibility 617 827--*--Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures"
        ]
    },
    "NCT02831166_inc": {
        "Annotations": [
            "Qualifier 0 20--*--ST-segment elevation",
            "Condition 21 48--*--acute myocardial infarction",
            "Temporal 58 100--*--during the first 12 hours of sympton onset",
            "Condition 132 166--*--percutaneous coronary intervention",
            "Mood 103 123--*--Intention to perform",
            "Qualifier 124 131--*--primary",
            "Non-query-able 169 193--*--Signed informed consent;",
            "Qualifier 216 227--*--transradial",
            "Qualifier 232 244--*--transfemoral",
            "Qualifier 245 252--*--primary",
            "Procedure 253 287--*--percutaneous coronary intervention",
            "Scope 216 244--*--transradial and transfemoral",
            "Mood 203 215--*--eligible for",
            "Non-representable 289 508--*--being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process."
        ],
        "Text": "ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;. Intention to perform primary percutaneous coronary intervention;. Signed informed consent;. Patient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process.. "
    },
    "NCT02564471_exc": {
        "Annotations": [
            "Pregnancy_considerations 0 354--*--Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination.",
            "Non-query-able 356 576--*--Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.",
            "Drug 612 626--*--rabies vaccine",
            "Drug 659 681--*--rabies immune globulin",
            "Observation 578 594--*--Previous history",
            "Observation 629 645--*--Previous history",
            "Condition 688 714--*--major psychiatric disorder",
            "Qualifier 724 730--*--severe",
            "Condition 731 741--*--depression",
            "Qualifier 743 749--*--severe",
            "Condition 750 766--*--anxiety disorder",
            "Condition 768 777--*--psychosis",
            "Condition 779 792--*--schizophrenia",
            "Condition 800 827--*--major psychiatric disorders",
            "Qualifier 794 799--*--other",
            "Condition 832 840--*--seizures",
            "Qualifier 853 857--*--mild",
            "Condition 858 868--*--depression",
            "Condition 872 888--*--anxiety disorder",
            "Negation 918 921--*--not",
            "Qualifier 898 913--*--well controlled",
            "Scope 858 888--*--depression or anxiety disorder",
            "Scope 724 840--*--severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures",
            "Drug 954 976--*--immunosuppressive drug",
            "Temporal 977 1001--*--at the time of the study",
            "Temporal 1005 1023--*--30 days previously",
            "Scope 977 1023--*--at the time of the study or 30 days previously",
            "Drug 1025 1041--*--Topical steroids",
            "Negation 1047 1050--*--not",
            "Condition 1156 1182--*--immunosuppressive disorder",
            "Condition 1192 1205--*--HIV infection",
            "Condition 1207 1239--*--common variable immunodeficiency",
            "Temporal 1241 1247--*--active",
            "Condition 1248 1255--*--cancers",
            "Procedure 1259 1271--*--chemotherapy",
            "Scope 1248 1271--*--cancers or chemotherapy",
            "Scope 1192 1271--*--HIV infection, common variable immunodeficiency, active cancers or chemotherapy",
            "Condition 1285 1304--*--renal insufficiency",
            "Observation 1274 1281--*--History",
            "Procedure 1318 1326--*--dialysis",
            "Mood 1308 1317--*--requiring",
            "Scope 1285 1326--*--renal insufficiency or requiring dialysis",
            "Post-eligibility 1329 1523--*--Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",
            "Post-eligibility 1525 1843--*--Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator.",
            "Condition 1854 1870--*--adverse reaction",
            "Temporal 1845 1853--*--Previous",
            "Drug 1885 1903--*--antimalarial drugs",
            "Qualifier 1904 1922--*--used in this study"
        ],
        "Text": "Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination.. Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.. Previous history of receiving the rabies vaccine.. Previous history of receiving rabies immune globulin.. Any major psychiatric disorder, such as severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. History of mild depression or anxiety disorder that are well controlled are not exclusion criteria.. Use of any immunosuppressive drug at the time of the study or 30 days previously. Topical steroids will not be considered an immunosuppressive drug and their use will not be considered an exclusion criteria.. Any immunosuppressive disorder, such as HIV infection, common variable immunodeficiency, active cancers or chemotherapy.. History of renal insufficiency or requiring dialysis.. Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.. Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator.. Previous adverse reaction to any of the antimalarial drugs used in this study.. "
    },
    "NCT03345589_exc": {
        "Annotations": [
            "Condition 0 20--*--Autoimmune hepatitis",
            "Condition 22 52--*--Primary sclerosing cholangitis"
        ],
        "Text": "Autoimmune hepatitis. Primary sclerosing cholangitis. "
    },
    "NCT01228279_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 7 10--*--age",
            "Value 11 29--*--18 years and older",
            "Condition 46 69--*--end-stage renal disease",
            "Condition 70 74--*--ESRD",
            "Condition 76 98--*--chronic kidney disease",
            "Condition 99 102--*--CKD",
            "Qualifier 103 110--*--stage 5"
        ],
        "Text": "Adult (age 18 years and older). Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5. "
    },
    "NCT02528604_exc": {
        "Text": "Paroxysmal atrial fibrillation.. Long-standing persistent or permanent atrial fibrillation.. Previous pacemaker implantation.. Previous atrial ablation.. Patient is unable to take warfarin or other oral anti-coagulant medication.. Patient is suffering with unstable angina in last one week.. Patient has had a myocardial infarction within last two months.. Patient is expecting or has had major cardiac surgery within last two months.. Patient is participating in a conflicting study.. Patient is unable to perform exercise testing.. Patient is mentally incapacitated and cannot consent or comply with follow-up.. Patient has New York Heart Association (NYHA) class III/IV heart failure.. Patient has left ventricular ejection fraction (LVEF) less than 35% not secondary to tachycardia.. Pregnancy.. Patient suffers with other cardiac rhythm disorders.. Recent coronary artery intervention or other factors suggesting clinical instability (ECG, clinical or laboratory findings).. ",
        "Annotations": [
            "Condition 0 30--*--Paroxysmal atrial fibrillation",
            "Condition 71 90--*--atrial fibrillation",
            "Qualifier 47 57--*--persistent",
            "Qualifier 61 70--*--permanent",
            "Scope 47 70--*--persistent or permanent",
            "Device 102 124--*--pacemaker implantation",
            "Procedure 136 151--*--atrial ablation",
            "Mood 165 179--*--unable to take",
            "Drug 180 188--*--warfarin",
            "Drug 198 228--*--oral anti-coagulant medication",
            "Scope 180 228--*--warfarin or other oral anti-coagulant medication",
            "Condition 257 272--*--unstable angina",
            "Temporal 276 289--*--last one week",
            "Condition 310 331--*--myocardial infarction",
            "Temporal 339 354--*--last two months",
            "Procedure 389 410--*--major cardiac surgery",
            "Temporal 418 433--*--last two months",
            "Competing_trial 436 483--*--Patient is participating in a conflicting study",
            "Post-eligibility 486 531--*--Patient is unable to perform exercise testing",
            "Post-eligibility 534 611--*--Patient is mentally incapacitated and cannot consent or comply with follow-up",
            "Measurement 626 652--*--New York Heart Association",
            "Measurement 654 658--*--NYHA",
            "Value 660 672--*--class III/IV",
            "Condition 673 686--*--heart failure",
            "Measurement 701 735--*--left ventricular ejection fraction",
            "Measurement 737 741--*--LVEF",
            "Value 743 756--*--less than 35%",
            "Mood 757 773--*--not secondary to",
            "Condition 774 785--*--tachycardia",
            "Condition 788 797--*--Pregnancy",
            "Condition 827 851--*--cardiac rhythm disorders",
            "Qualifier 821 826--*--other",
            "Procedure 861 889--*--coronary artery intervention"
        ]
    },
    "NCT03639519_exc": {
        "Annotations": [
            "Drug 11 24--*--ascorbic acid",
            "Condition 0 7--*--Allergy",
            "Condition 26 32--*--Asthma",
            "Condition 34 38--*--COPD",
            "Condition 40 47--*--Allergy",
            "Drug 51 58--*--opioids",
            "Condition 80 99--*--chemical dependence",
            "Observation 69 76--*--history",
            "Temporal 60 68--*--Previous",
            "Procedure 107 122--*--cardiac surgery",
            "Temporal 101 106--*--Prior",
            "Condition 130 143--*--hyperoxaluria",
            "Condition 156 169--*--renal calculi",
            "Observation 145 152--*--History",
            "Condition 182 190--*--allergic",
            "Condition 194 210--*--hypersensitivity",
            "Drug 223 236--*--ascorbic acid",
            "Scope 182 210--*--allergic or hypersensitivity",
            "Multiplier 264 275--*--1 g or more",
            "Drug 279 292--*--ascorbic acid"
        ],
        "Text": "Allergy to ascorbic acid. Asthma. COPD. Allergy to opioids. Previous history of chemical dependence. Prior cardiac surgery. Known hyperoxaluria. History of renal calculi. History of allergic or hypersensitivity reaction to ascorbic acid products. Currently taking 1 g or more of ascorbic acid supplementation daily. "
    },
    "NCT01735955_exc": {
        "Text": "Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason. Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval or inducing Torsade de Pointes and the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcG laboratory test.. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib.",
        "Annotations": [
            "Negation 29 41--*--discontinued",
            "Multiplier 17 28--*--permanently",
            "Drug 47 56--*--nilotinib",
            "Procedure 57 66--*--treatment",
            "Condition 94 115--*--unacceptable toxicity",
            "Observation 117 131--*--non-compliance",
            "Procedure 135 151--*--study procedures",
            "Negation 153 163--*--withdrawal",
            "Observation 167 174--*--consent",
            "Observation 178 194--*--any other reason",
            "Scope 94 194--*--unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",
            "Qualifier 225 243--*--Novartis sponsored",
            "Observation 207 224;244 261--*--participated in a combination trial",
            "Non-representable 195 387--*--Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy",
            "Procedure 425 434--*--treatment",
            "Temporal 405 414--*--currently",
            "Drug 440 455--*--any medications",
            "Qualifier 461 506--*--have the potential to prolong the QT interval",
            "Qualifier 510 537--*--inducing Torsade de Pointes",
            "Scope 461 537--*--have the potential to prolong the QT interval or inducing Torsade de Pointes",
            "Non-representable 542 749--*--the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study",
            "Observation 750 758--*--Pregnant",
            "Observation 762 769--*--nursing",
            "Person 782 787--*--women",
            "Observation 771 780--*--lactating",
            "Observation 922 941--*--hcG laboratory test",
            "Value 913 921--*--positive",
            "Person 943 948--*--Women",
            "Observation 952 975--*--child-bearing potential",
            "Observation 998 1042--*--physiologically capable of becoming pregnant",
            "Person 992 997--*--women",
            "Negation 1044 1050--*--unless",
            "Qualifier 1066 1090--*--highly effective methods",
            "Observation 1094 1107--*--contraception",
            "Temporal 1108 1124--*--during the study",
            "Temporal 1129 1174--*--for 30 days after the final dose of nilotinib",
            "Reference_point 1147 1174--*--the final dose of nilotinib",
            "Scope 1108 1174--*--during the study and for 30 days after the final dose of nilotinib",
            "Scope 992 1174--*--women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib",
            "Scope 943 975--*--Women of child-bearing potential"
        ]
    },
    "NCT00917891_inc": {
        "Annotations": [
            "Person 3 8--*--Women",
            "Value 9 23--*--18 to 40 years",
            "Person 27 30--*--age",
            "Observation 45 78--*--can give written informed consent",
            "Post-eligibility 45 78--*--can give written informed consent",
            "Post-eligibility 83 168--*--Available for all visits and consent to follow all procedures scheduled for the study",
            "Post-eligibility 173 267--*--Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method",
            "Drug 203 206--*--gel",
            "Multiplier 182 187--*--daily",
            "Procedure 211 221--*--monitoring",
            "Condition 272 279--*--Healthy",
            "Condition 298 313--*--sexually active",
            "Observation 284 297--*--self-reported",
            "Qualifier 284 297--*--self-reported",
            "Condition 318 330--*--HIV-negative",
            "Measurement 318 321--*--HIV",
            "Value 322 330--*--negative",
            "Measurement 350 364--*--HIV rapid test",
            "Temporal 365 386--*--at time of enrollment",
            "Reference_point 368 386--*--time of enrollment",
            "Pregnancy_considerations 391 568--*--On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment",
            "Drug 602 619--*--exogenous hormone",
            "Negation 580 587--*--absence",
            "Scope 580 619--*--absence of the use of exogenous hormone",
            "Value 645 652--*--regular",
            "Measurement 653 668--*--menstrual cycle",
            "Condition 645 668--*--regular menstrual cycle",
            "Value 689 707--*--minimum of 21 days",
            "Value 714 732--*--maximum of 36 days",
            "Scope 689 732--*--minimum of 21 days and a maximum of 36 days",
            "Procedure 764 784--*--speculum examination",
            "Procedure 757 763;773 784--*--pelvic examination",
            "Procedure 789 799--*--colposcopy",
            "Temporal 800 825--*--at the time of enrollment",
            "Scope 757 799--*--pelvic/speculum examination and colposcopy",
            "Observation 842 848--*--vagina",
            "Observation 831 837--*--cervix",
            "Value 856 862--*--normal",
            "Qualifier 856 862--*--normal",
            "Subjective_judgement 863 896--*--as determined by the investigator",
            "Scope 831 862--*--cervix and vagina appear normal",
            "Condition 918 936--*--genital infections",
            "Mood 901 913--*--Asymptomatic",
            "Temporal 937 962--*--at the time of enrollment",
            "Mood 968 975--*--Willing",
            "Drug 999 1015--*--vaginal products",
            "Drug 1019 1026;999 1006--*--objects vaginal",
            "Temporal 1027 1061--*--within 14 days prior to enrollment",
            "Temporal 1066 1095--*--for the duration of the study",
            "Reference_point 1051 1061--*--enrollment",
            "Reference_point 1086 1095--*--the study",
            "Scope 999 1026--*--vaginal products or objects",
            "Observation 1137 1161--*--adherence questionnaires",
            "Observation 1119 1132;1147 1161--*--acceptability questionnaires",
            "Temporal 1162 1182--*--throughout the study",
            "Negation 979 986--*--refrain",
            "Mood 1101 1108--*--Willing",
            "Scope 1119 1161--*--acceptability and adherence questionnaires",
            "Post-eligibility 1188 1284--*--Willing to refrain from participation in any other research study for the duration of this study",
            "Post-eligibility 1101 1182--*--Willing to answer acceptability and adherence questionnaires throughout the study",
            "Post-eligibility 1290 1413--*--Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures",
            "Non-query-able 1290 1413--*--Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures",
            "Non-query-able 1188 1284--*--Willing to refrain from participation in any other research study for the duration of this study",
            "Non-query-able 1101 1182--*--Willing to answer acceptability and adherence questionnaires throughout the study"
        ],
        "Text": "1. Women 18 to 40 years of age inclusive who can give written informed consent . 2. Available for all visits and consent to follow all procedures scheduled for the study . 3. Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method . 4. Healthy and self-reported sexually active . 5. HIV-negative as determined by a HIV rapid test at time of enrollment . 6. On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment . 7. In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses . 8. Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator . 9. Asymptomatic for genital infections at the time of enrollment . 10. Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study . 11. Willing to answer acceptability and adherence questionnaires throughout the study . 12. Willing to refrain from participation in any other research study for the duration of this study . 13. Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures . "
    },
    "NCT03639519_inc": {
        "Annotations": [
            "Device 0 24--*--Elective Cardiac surgery",
            "Measurement 26 79--*--American Society of Anesthesiologists physical status",
            "Value 80 91--*--class I-III"
        ],
        "Text": "Elective Cardiac surgery. American Society of Anesthesiologists physical status class I-III. "
    },
    "NCT00917891_exc": {
        "Annotations": [
            "Condition 13 21--*--pregnant",
            "Condition 30 47--*--pregnancy outcome",
            "Temporal 48 82--*--within 3 months prior to enrolment",
            "Reference_point 73 82--*--enrolment",
            "Qualifier 25 29--*--last",
            "Temporal 25 29--*--last",
            "Condition 97 111--*--breast-feeding",
            "Temporal 87 96--*--Currently",
            "Temporal 3 12--*--Currently",
            "Context_Error 116 190--*--Participated in any other research study within 60 days prior to screening",
            "Context_Error 195 243--*--Previously participated in any HIV vaccine study",
            "Condition 258 279--*--urogenital infections",
            "Qualifier 248 257--*--Untreated",
            "Condition 288 299--*--symptomatic",
            "Condition 303 315--*--asymptomatic",
            "Scope 288 315--*--symptomatic or asymptomatic",
            "Temporal 317 351--*--within 2 weeks prior to enrollment",
            "Reference_point 341 351--*--enrollment",
            "Condition 368 406--*--abnormal physical finding on the vulva",
            "Condition 368 400;408 421--*--abnormal physical finding on the vaginal walls",
            "Condition 368 400;425 431--*--abnormal physical finding on the cervix",
            "Procedure 446 466--*--speculum examination",
            "Procedure 439 445;455 466--*--pelvic examination",
            "Procedure 474 484--*--colposcopy",
            "Scope 439 484--*--pelvic/speculum examination and/or colposcopy",
            "Scope 368 431--*--abnormal physical finding on the vulva, vaginal walls or cervix",
            "Condition 512 522;534 542--*--urogenital prolapse",
            "Condition 526 542--*--uterine prolapse",
            "Condition 556 572--*--vaginal bleeding",
            "Qualifier 544 555--*--undiagnosed",
            "Condition 574 594--*--urethral obstruction",
            "Qualifier 500 511--*--significant",
            "Observation 489 496--*--History",
            "Scope 512 542--*--urogenital or uterine prolapse",
            "Subjective_judgement 500 511--*--significant",
            "Measurement 599 608--*--Pap smear",
            "Temporal 616 628--*--at screening",
            "Value 634 654--*--requires cryotherapy",
            "Value 634 642;656 662--*--requires biopsy",
            "Value 634 642;664 673--*--requires treatment",
            "Procedure 643 654--*--cryotherapy",
            "Procedure 656 662--*--biopsy",
            "Procedure 664 673--*--treatment",
            "Value 634 642;705 723--*--requires further evaluation",
            "Procedure 705 723--*--further evaluation",
            "Scope 634 673;702 723--*--requires cryotherapy, biopsy, treatment or further evaluation",
            "Condition 794 816--*--laboratory abnormality",
            "Condition 783 793;805 816--*--urinalysis abnormality",
            "Condition 770 779;805 816--*--chemistry abnormality",
            "Condition 757 768;805 816--*--haematology abnormality",
            "Value 732 747--*--Grade 2, 3 or 4",
            "Temporal 748 756--*--baseline",
            "Measurement 834 877--*--DAIDS Table for Grading Adverse Experiences",
            "Procedure 757 768--*--haematology",
            "Procedure 770 779--*--chemistry",
            "Procedure 783 793--*--urinalysis",
            "Procedure 794 804--*--laboratory",
            "Condition 917 936--*--bleeding per vagina",
            "Qualifier 896 907--*--undiagnosed",
            "Qualifier 883 894--*--Unexplained",
            "Qualifier 908 916--*--abnormal",
            "Condition 938 957--*--bleeding per vagina",
            "Temporal 958 964;978 997--*--during vaginal intercourse",
            "Temporal 968 997--*--following vaginal intercourse",
            "Procedure 1002 1022--*--gynaecologic surgery",
            "Temporal 1023 1057--*--within 90 days prior to enrollment",
            "Reference_point 1047 1057--*--enrollment",
            "Scope 958 997--*--during or following vaginal intercourse",
            "Scope 917 957--*--bleeding per vagina, bleeding per vagina",
            "Scope 883 916--*--Unexplained, undiagnosed abnormal",
            "Condition 1078 1089--*--anaphylaxis",
            "Observation 1067 1074--*--history",
            "Condition 1100 1107--*--allergy",
            "Qualifier 1093 1099--*--severe",
            "Condition 1121 1131--*--angioedema",
            "Observation 1138 1145--*--history",
            "Condition 1149 1160;1169 1177--*--sensitivity to latex",
            "Condition 1161 1177--*--allergy to latex",
            "Scope 1149 1177--*--sensitivity/allergy to latex",
            "Scope 1078 1107--*--anaphylaxis or severe allergy",
            "Condition 1225 1232--*--disease",
            "Qualifier 1213 1224--*--progressive",
            "Multiplier 1202 1209--*--chronic",
            "Temporal 1195 1200--*--acute",
            "Qualifier 1187 1194--*--serious",
            "Scope 1187 1224--*--serious acute, chronic or progressive",
            "Post-eligibility 1238 1387--*--Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives",
            "Subjective_judgement 1183 1232--*--Any serious acute, chronic or progressive disease",
            "Post-eligibility 1183 1232--*--Any serious acute, chronic or progressive disease"
        ],
        "Text": "1. Currently pregnant or last pregnancy outcome within 3 months prior to enrolment . 2. Currently breast-feeding . 3. Participated in any other research study within 60 days prior to screening . 4. Previously participated in any HIV vaccine study . 5. Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks prior to enrollment . 6. Presence of abnormal physical finding on the vulva, vaginal walls or cervix during pelvic/speculum examination and/or colposcopy . 7. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction . 8. Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation . 9. Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory abnormality according to the DAIDS Table for Grading Adverse Experiences . 10. Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment . 11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex . 12. Any serious acute, chronic or progressive disease . 13. Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives       .     . "
    },
    "NCT01735955_inc": {
        "Text": "Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study. Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. Written informed consent obtained prior to enrolling in roll-over study",
        "Annotations": [
            "Temporal 11 20--*--currently",
            "Qualifier 35 53--*--Novartis-sponsored",
            "Observation 21 34;55 108--*--enrolled in a Oncology Clinical Development & Medical Affairs study",
            "Drug 119 128--*--nilotinib",
            "Non-representable 133 189--*--has fulfilled all their requirements in the parent study",
            "Procedure 232 241--*--treatment",
            "Drug 247 256--*--nilotinib",
            "Non-representable 258 291--*--as determined by the investigator",
            "Temporal 202 211--*--currently",
            "Observation 318 328;363 406--*--compliance with the parent study protocol requirements",
            "Non-representable 330 361--*--as assessed by the investigator",
            "Observation 408 419;432 463--*--Willingness to comply with scheduled visits",
            "Observation 424 463--*--ability to comply with scheduled visits",
            "Observation 408 419;432 446;465 480--*--Willingness to comply with treatment plans",
            "Observation 513 537--*--Written informed consent",
            "Temporal 547 584--*--prior to enrolling in roll-over study",
            "Reference_point 556 584--*--enrolling in roll-over study"
        ]
    },
    "NCT03345589_inc": {
        "Annotations": [
            "Condition 24 51--*--primary biliary cholangitis",
            "Drug 66 86--*--Ursodeoxycholic Acid",
            "Visit 90 109--*--West China Hospital",
            "Temporal 110 130--*--for at least 6 month",
            "Condition 135 154--*--suboptimal response",
            "Drug 158 178--*--Ursodeoxycholic Acid"
        ],
        "Text": "Patients diagnosed with primary biliary cholangitis. Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid. "
    },
    "NCT02528604_inc": {
        "Text": "Patients with symptomatic persistent atrial fibrillation of less than 1-year duration.. Patients must be over 65 years old.. Patients give informed consent prior to participating in this study.. ",
        "Annotations": [
            "Condition 37 56--*--atrial fibrillation",
            "Qualifier 26 36--*--persistent",
            "Qualifier 14 25--*--symptomatic",
            "Temporal 60 76--*--less than 1-year",
            "Person 119 122--*--old",
            "Value 105 118--*--over 65 years",
            "Informed_consent 125 192--*--Patients give informed consent prior to participating in this study"
        ]
    },
    "NCT01228279_exc": {
        "Annotations": [
            "Condition 0 17--*--Diabetes Mellitus",
            "Condition 19 42--*--Acute coronary syndrome",
            "Temporal 43 63--*--in the past 6 months",
            "Condition 65 83--*--Cardiac arrhythmia",
            "Condition 94 116--*--3rd degree heart block",
            "Condition 86 89;98 116--*--2nd degree heart block",
            "Condition 120 151--*--premature ventricular complexes",
            "Qualifier 155 169--*--Lown classes 4",
            "Qualifier 155 167;173 174--*--Lown classes 5",
            "Scope 155 174--*--Lown classes 4 or 5",
            "Scope 85 175--*--(2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)",
            "Condition 200 211;223 234--*--obstructive sleep apnea",
            "Condition 215 234--*--central sleep apnea",
            "Measurement 260 284--*--Epworth sleepiness scale",
            "Value 243 256--*--score of > 10",
            "Scope 200 234--*--obstructive or central sleep apnea",
            "Drug 303 312--*--Clonidine",
            "Measurement 314 329--*--Body mass index",
            "Measurement 331 334--*--BMI",
            "Value 336 340--*--> 34",
            "Informed_consent 342 373--*--Patients unable to give consent",
            "Pregnancy_considerations 375 389--*--Pregnant women",
            "Condition 405 415--*--leg injury",
            "Condition 426 438--*--nerve damage",
            "Drug 456 469--*--anticoagulant",
            "Condition 508 525--*--bleeding disorder",
            "Condition 529 543--*--liver disorder",
            "Qualifier 496 507--*--significant",
            "Measurement 545 555--*--Hemoglobin",
            "Value 556 566--*--<1.05 g/dl",
            "Temporal 567 603--*--at the time of initiation of therapy",
            "Reference_point 582 603--*--initiation of therapy",
            "Procedure 643 654--*--nephrectomy",
            "Qualifier 633 642--*--bilateral",
            "Qualifier 619 629--*--unilateral",
            "Scope 619 642--*--unilateral or bilateral",
            "Condition 664 681--*--kidney transplant",
            "Qualifier 656 663--*--Planned",
            "Temporal 682 702--*--in the next 4 months",
            "Observation 704 719--*--Life expectancy",
            "Value 720 734--*--under 6 months",
            "Condition 736 744--*--Oliguria",
            "Measurement 746 758--*--urine output",
            "Value 759 783--*--less than 400 ml per day"
        ],
        "Text": "Diabetes Mellitus. Acute coronary syndrome in the past 6 months. Cardiac arrhythmias (2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5). Symptoms suggestive of obstructive or central sleep apnea (with a score of > 10 on Epworth sleepiness scale). Patients taking Clonidine. Body mass index (BMI) > 34. Patients unable to give consent. Pregnant women. Patients with leg injury involving nerve damage. Patients taking anticoagulant medication. Patients with significant bleeding disorder or liver disorder. Hemoglobin <1.05 g/dl at the time of initiation of therapy. patients with unilateral or bilateral nephrectomy. Planned kidney transplant in the next 4 months. Life expectancy under 6 months. Oliguria (urine output less than 400 ml per day). "
    },
    "NCT02777580_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 34--*--equal or greater than 70 years",
            "Observation 36 53--*--Onset of symptoms",
            "Temporal 54 86--*--< 3 hours prior to randomisation",
            "Reference_point 73 86--*--randomisation",
            "Non-query-able 228 345--*--= 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of = 4 mm ST-elevation",
            "Non-query-able 88 223--*--= 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of = 4 mm ST-elevation",
            "Informed_consent 347 372--*--Informed consent received"
        ],
        "Text": "Age equal or greater than 70 years. Onset of symptoms < 3 hours prior to randomisation. = 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of = 4 mm ST-elevation or. = 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of = 4 mm ST-elevation. Informed consent received. "
    },
    "NCT03131050_inc": {
        "Annotations": [
            "Informed_consent 0 35--*--Has given written informed consent.",
            "Person 37 41--*--Male",
            "Person 45 51--*--female",
            "Visit 52 63--*--outpatients",
            "Value 69 113--*--at least 18 years and not more than 45 years",
            "Person 64 68--*--aged",
            "Condition 135 160--*--major depressive disorder",
            "Qualifier 164 251--*--Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria",
            "Measurement 262 269--*--HAMD-17",
            "Temporal 254 261--*--Current",
            "Value 270 280--*--score = 20",
            "Condition 305 318--*--index episode",
            "Temporal 322 357--*--greater than or equal to four weeks"
        ],
        "Text": "Has given written informed consent.. Male or female outpatients aged at least 18 years and not more than 45 years.. Has a diagnosis of major depressive disorder by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.. Current HAMD-17 score = 20 and the duration of the index episode is greater than or equal to four weeks.. "
    },
    "NCT03296488_inc": {
        "Text": "Male or female who is among 20 to 80 years of age at screening.. Scheduled to electively undergo open-laparotomy.. American Society of Anesthesiology Physical Class 1-3.. Ability and willingness to provide informed consent. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 28 42--*--20 to 80 years",
            "Person 46 49--*--age",
            "Temporal 50 62--*--at screening",
            "Mood 65 74--*--Scheduled",
            "Procedure 97 112--*--open-laparotomy",
            "Mood 78 88--*--electively",
            "Measurement 115 164--*--American Society of Anesthesiology Physical Class",
            "Value 165 168--*--1-3",
            "Informed_consent 171 222--*--Ability and willingness to provide informed consent"
        ]
    },
    "NCT03228498_inc": {
        "Annotations": [
            "Condition 3 23--*--Cognitive impairment",
            "Qualifier 29 45--*--mild to moderate",
            "Measurement 66 107--*--Clinical Deterioration Rating (CDR) score",
            "Value 108 133--*--range between 0.5 and 2.0",
            "Procedure 151 160--*--brain MRI",
            "Observation 164 193--*--white matter hyperintensities",
            "Condition 195 208--*--leukoaraiosis",
            "Value 212 237--*--moderate or severe degree",
            "Measurement 255 284--*--modified Fazekas visual scale",
            "Condition 304 320--*--lacunar infarcts",
            "Scope 195 320--*--leukoaraiosis of moderate or severe degree according to the modified Fazekas visual scale and/or presence of lacunar infarcts",
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 136 138--*--2.",
            "Parsing_Error 324 326--*--3.",
            "Non-query-able 327 365--*--Consent to participation in the study."
        ],
        "Text": "1. Cognitive impairment from mild to moderate degree defined by a Clinical Deterioration Rating (CDR) score range between 0.5 and 2.0. . 2. Evidence on brain MRI of white matter hyperintensities (leukoaraiosis of moderate or severe degree according to the modified Fazekas visual scale and/or presence of lacunar infarcts). . 3. Consent to participation in the study. . "
    },
    "NCT02566226_exc": {
        "Text": "planned surgical duration more than 3 hours. contraindication to spinal anaesthesia. severe respiratory disease. patient known and treated for sleep apnea syndrome. ",
        "Annotations": [
            "Measurement 0 25--*--planned surgical duration",
            "Value 26 43--*--more than 3 hours",
            "Condition 45 61--*--contraindication",
            "Procedure 65 83--*--spinal anaesthesia",
            "Qualifier 85 91--*--severe",
            "Condition 92 111--*--respiratory disease",
            "Condition 143 163--*--sleep apnea syndrome",
            "Procedure 131 138--*--treated"
        ]
    },
    "NCT00396734_inc": {
        "Annotations": [
            "Drug 0 9--*--Methadone",
            "Condition 21 38--*--cocaine-dependent",
            "Multiplier 60 74--*--1g to 2g a day",
            "Multiplier 76 95--*--1 to 3 times a week",
            "Qualifier 0 20--*--Methadone-maintained",
            "Scope 60 95--*--1g to 2g a day; 1 to 3 times a week"
        ],
        "Text": "Methadone-maintained cocaine-dependent patients use between 1g to 2g a day; 1 to 3 times a week . "
    },
    "NCT02863120_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 21 27--*--female",
            "Qualifier 12 20--*--pregnant",
            "Negation 8 11--*--non",
            "Person 40 44--*--ages",
            "Value 48 53--*--18-65",
            "Informed_consent 55 109--*--Patients willing and able to sign the informed consent",
            "Post-eligibility 112 189--*--atients able to comply with follow-up requirements including self-evaluations",
            "Procedure 212 242--*--primary total knee replacement",
            "Condition 273 287--*--osteoarthritis",
            "Condition 289 308--*--traumatic arthritis",
            "Condition 313 331--*--avascular necrosis"
        ],
        "Text": "Male or non-pregnant female between the ages of 18-65. Patients willing and able to sign the informed consent. Patients able to comply with follow-up requirements including self-evaluations. Patients requiring a primary total knee replacement. Patients with a diagnosis of osteoarthritis, traumatic arthritis, or avascular necrosis. "
    },
    "NCT02944292_inc": {
        "Text": "Age 18 years or older. Mechanical ventilation. IAP between 12 and 20 mmHg in at least two consecutive measurements within 1-12 h. Spontaneous breathing activity of at least 6 breaths/minute. RASS score between 0 and -4. Physician-led sedation (if sedated; as opposed to nurse-led protocol). ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--18 years or older",
            "Procedure 23 45--*--Mechanical ventilation",
            "Measurement 47 50--*--IAP",
            "Value 51 73--*--between 12 and 20 mmHg",
            "Multiplier 77 114--*--at least two consecutive measurements",
            "Temporal 115 128--*--within 1-12 h",
            "Measurement 130 160--*--Spontaneous breathing activity",
            "Procedure 234 242--*--sedation",
            "Qualifier 220 233--*--Physician-led",
            "Measurement 191 201--*--RASS score",
            "Value 202 218--*--between 0 and -4",
            "Value 164 189--*--at least 6 breaths/minute",
            "Negation 256 269--*--as opposed to",
            "Qualifier 270 288--*--nurse-led protocol"
        ]
    },
    "NCT02664558_exc": {
        "Text": "Exclusions Related to Cardiovascular Disease . 1. History of uncontrolled hypertension . 2. Persistent hypotension at Screening. . 3. Evidence or history of left-sided heart disease and/or clinically significant cardiac disease in which pulmonary hypertension is more likely WHO Group 2. . 4. Acute decompensated heart failure within 1 month of Screening. . 5. Recent initiation (<8 weeks from Screening) or planned initiation of cardiopulmonary rehabilitation exercise program. . Exclusions Related to Pulmonary Disease . 6. Newly diagnosed with PAH and not on PAH-specific therapy. . 7. Pulmonary hypertension due to: . 1. Uncorrected congenital systemic-to-pulmonary shunt. . 2. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis . 3. Persistent pulmonary hypertension of the newborn . 4. WHO clinical classification Groups 2-5 . 8. Evidence of significant airway and/or parenchymal lung disease. . 9. Chronic infection related to tuberculosis or fungal or mycobacterial disease. . Exclusions Based on Other Medical Conditions . 10. Chronic infections including, but not limited to tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV). . 11. History of portal hypertension or chronic liver disease, including positive serology for infection with HCV and/or HBV. . 12. Evidence of active infection requiring intravenous or oral antibiotics within 4 weeks of Screening. . 13. Body mass index \u226535.0 at Screening. . 14. History of obstructive sleep apnea. . 15. History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent. . 16. Neuropsychiatric disorders/symptoms or psychological conditions. . 17. Pregnancy or breast-feeding . 18. Prior treatment with B cell or lymphocyte-depleting agents (eg, rituximab, Campath) . Exclusions Based on Concomitant Medication Use . 19. Concurrent regular use of another leukotriene pathway inhibitor, including over-the-counter medications or herbal remedies. . Exclusions Based on Laboratory Values . 20. Significant/chronic renal insufficiency. . 21. Transaminases (alanine transaminase, aspartate transaminase) levels >3 \u00d7 upper limit of normal (ULN) and/or bilirubin level >2 \u00d7 ULN. . 22. Absolute neutrophil count <1500 mm3. . 23. Hemoglobin concentration <9 g/dL at Screening. . 24. Hepatic dysfunction as defined by Child-Pugh Class B or C       .     . ",
        "Annotations": [
            "Parsing_Error 46 48--*--1.",
            "Parsing_Error 87 89--*--2.",
            "Parsing_Error 128 130--*--3.",
            "Parsing_Error 286 288--*--4.",
            "Parsing_Error 353 355--*--5.",
            "Parsing_Error 516 518--*--6.",
            "Parsing_Error 578 580--*--7.",
            "Parsing_Error 613 615--*--1.",
            "Parsing_Error 669 671--*--2.",
            "Parsing_Error 749 751--*--3.",
            "Parsing_Error 802 804--*--4.",
            "Parsing_Error 845 847--*--8.",
            "Parsing_Error 913 915--*--9.",
            "Parsing_Error 1041 1044--*--10.",
            "Parsing_Error 1166 1169--*--11.",
            "Parsing_Error 1291 1294--*--12.",
            "Parsing_Error 1396 1399--*--13.",
            "Parsing_Error 1437 1440--*--14.",
            "Parsing_Error 1478 1481--*--15.",
            "Parsing_Error 1622 1625--*--16.",
            "Parsing_Error 1692 1695--*--17.",
            "Parsing_Error 1725 1728--*--18.",
            "Parsing_Error 1862 1865--*--19.",
            "Parsing_Error 2030 2033--*--20.",
            "Parsing_Error 2076 2079--*--21.",
            "Parsing_Error 2215 2218--*--22.",
            "Parsing_Error 2257 2260--*--23.",
            "Parsing_Error 2309 2312--*--24.",
            "Parsing_Error 0 44--*--Exclusions Related to Cardiovascular Disease",
            "Parsing_Error 475 514--*--Exclusions Related to Pulmonary Disease",
            "Parsing_Error 995 1039--*--Exclusions Based on Other Medical Conditions",
            "Parsing_Error 1814 1860--*--Exclusions Based on Concomitant Medication Use",
            "Parsing_Error 1991 2028--*--Exclusions Based on Laboratory Values",
            "Condition 73 85--*--hypertension",
            "Qualifier 60 72--*--uncontrolled",
            "Observation 49 56--*--History",
            "Condition 90 112--*--Persistent hypotension",
            "Temporal 113 125--*--at Screening",
            "Reference_point 116 125--*--Screening",
            "Observation 143 150--*--history",
            "Condition 154 178--*--left-sided heart disease",
            "Condition 209 224--*--cardiac disease",
            "Qualifier 186 208--*--clinically significant",
            "Undefined_semantics 186 208--*--clinically significant",
            "Subjective_judgement 186 208--*--clinically significant",
            "Condition 234 256--*--pulmonary hypertension",
            "Measurement 272 281--*--WHO Group",
            "Value 282 283--*--2",
            "Scope 154 283--*--left-sided heart disease and/or clinically significant cardiac disease in which pulmonary hypertension is more likely WHO Group 2",
            "Condition 309 322--*--heart failure",
            "Qualifier 295 308--*--decompensated",
            "Qualifier 289 294--*--Acute",
            "Temporal 323 350--*--within 1 month of Screening",
            "Reference_point 341 350--*--Screening",
            "Temporal 375 398--*--<8 weeks from Screening",
            "Temporal 356 362--*--Recent",
            "Reference_point 389 398--*--Screening",
            "Qualifier 403 410--*--planned",
            "Non-query-able 403 410--*--planned",
            "Procedure 425 472--*--cardiopulmonary rehabilitation exercise program",
            "Scope 356 410--*--Recent initiation (<8 weeks from Screening) or planned",
            "Condition 540 543--*--PAH",
            "Procedure 555 575--*--PAH-specific therapy",
            "Negation 548 551--*--not",
            "Temporal 519 534--*--Newly diagnosed",
            "Parsing_Error 581 611--*--Pulmonary hypertension due to:",
            "Condition 628 666--*--congenital systemic-to-pulmonary shunt",
            "Qualifier 616 627--*--Uncorrected",
            "Condition 672 704--*--Pulmonary veno-occlusive disease",
            "Undefined_semantics 672 704--*--Pulmonary veno-occlusive disease",
            "Condition 712 747--*--pulmonary capillary hemangiomatosis",
            "Condition 763 800--*--pulmonary hypertension of the newborn",
            "Qualifier 752 762--*--Persistent",
            "Measurement 805 832--*--WHO clinical classification",
            "Value 833 843--*--Groups 2-5",
            "Condition 872 878;903 910--*--airway disease",
            "Condition 886 910--*--parenchymal lung disease",
            "Qualifier 860 871--*--significant",
            "Scope 872 910--*--airway and/or parenchymal lung disease",
            "Subjective_judgement 860 871--*--significant",
            "Undefined_semantics 860 871--*--significant",
            "Condition 945 957--*--tuberculosis",
            "Condition 961 967;985 992--*--fungal disease",
            "Condition 971 992--*--mycobacterial disease",
            "Multiplier 916 923--*--Chronic",
            "Condition 924 933--*--infection",
            "Scope 945 992--*--tuberculosis or fungal or mycobacterial disease",
            "Observation 934 944--*--related to",
            "Condition 1094 1111--*--tuberculosis (TB)",
            "Condition 1113 1136--*--hepatitis B virus (HBV)",
            "Condition 1140 1163--*--hepatitis C virus (HCV)",
            "Condition 1053 1063--*--infections",
            "Multiplier 1045 1052--*--Chronic",
            "Scope 1094 1163--*--tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV)",
            "Condition 1181 1200--*--portal hypertension",
            "Condition 1204 1225--*--chronic liver disease",
            "Measurement 1246 1277--*--serology for infection with HCV",
            "Measurement 1246 1268;1285 1288--*--serology for infection HBV",
            "Value 1237 1245--*--positive",
            "Scope 1237 1288--*--positive serology for infection with HCV and/or HBV",
            "Condition 1314 1333;1354 1365--*--infection requiring antibiotics",
            "Undefined_semantics 1314 1333;1354 1365--*--infection requiring antibiotics",
            "Subjective_judgement 1314 1333;1354 1365--*--infection requiring antibiotics",
            "Temporal 1366 1393--*--within 4 weeks of Screening",
            "Reference_point 1384 1393--*--Screening",
            "Measurement 1400 1415--*--Body mass index",
            "Value 1416 1421--*--\u226535.0",
            "Temporal 1422 1434--*--at Screening",
            "Reference_point 1425 1434--*--Screening",
            "Condition 1452 1475--*--obstructive sleep apnea",
            "Observation 1441 1448--*--History",
            "Condition 1493 1503--*--malignancy",
            "Undefined_semantics 1493 1503--*--malignancy",
            "Temporal 1504 1527--*--within the last 5 years",
            "Observation 1482 1489--*--History",
            "Condition 1536 1559--*--nonmelanoma skin cancer",
            "Negation 1529 1535--*--except",
            "Condition 1564 1590--*--cervical carcinoma in situ",
            "Procedure 1591 1598--*--treated",
            "Qualifier 1604 1619--*--curative intent",
            "Condition 1626 1652--*--Neuropsychiatric disorders",
            "Undefined_semantics 1626 1652--*--Neuropsychiatric disorders",
            "Condition 1665 1689--*--psychological conditions",
            "Condition 1626 1642;1653 1661--*--Neuropsychiatric symptoms",
            "Undefined_semantics 1626 1642;1653 1661--*--Neuropsychiatric symptoms",
            "Undefined_semantics 1665 1689--*--psychological conditions",
            "Condition 1696 1705--*--Pregnancy",
            "Condition 1709 1723--*--breast-feeding",
            "Drug 1750 1756;1770 1787--*--B cell -depleting agents",
            "Drug 1760 1787--*--lymphocyte-depleting agents",
            "Drug 1793 1802--*--rituximab",
            "Drug 1804 1811--*--Campath",
            "Scope 1793 1811--*--rituximab, Campath",
            "Scope 1750 1787--*--B cell or lymphocyte-depleting agents",
            "Temporal 1729 1734--*--Prior",
            "Drug 1900 1929--*--leukotriene pathway inhibitor",
            "Qualifier 1892 1899--*--another",
            "Context_Error 1892 1899--*--another",
            "Multiplier 1877 1888--*--regular use",
            "Undefined_semantics 1941 1988--*--over-the-counter medications or herbal remedies",
            "Temporal 1866 1876--*--Concurrent",
            "Condition 2046 2073--*--chronic renal insufficiency",
            "Qualifier 2034 2045--*--Significant",
            "Subjective_judgement 2034 2045--*--Significant",
            "Measurement 2095 2115--*--alanine transaminase",
            "Measurement 2117 2139--*--aspartate transaminase",
            "Value 2148 2180--*-->3 \u00d7 upper limit of normal (ULN)",
            "Measurement 2080 2093;2141 2147--*--Transaminases levels",
            "Scope 2095 2139--*--alanine transaminase, aspartate transaminase",
            "Measurement 2188 2203--*--bilirubin level",
            "Value 2204 2212--*-->2 \u00d7 ULN",
            "Measurement 2219 2244--*--Absolute neutrophil count",
            "Value 2245 2254--*--<1500 mm3",
            "Measurement 2261 2285--*--Hemoglobin concentration",
            "Value 2286 2293--*--<9 g/dL",
            "Temporal 2294 2306--*--at Screening",
            "Reference_point 2297 2306--*--Screening",
            "Condition 2313 2332--*--Hepatic dysfunction",
            "Measurement 2347 2357--*--Child-Pugh",
            "Value 2358 2370--*--Class B or C"
        ]
    },
    "NCT00050349_exc": {
        "Text": "Patients with symptomatic CNS metastases or leptomeningeal involvement . Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression. . Patients with bone metastases as the only site(s) of measurable disease . Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease) . Patients who have been previously treated with radioactive directed therapies . Patients who have been previously treated with epothilone . Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 . Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports . Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ . Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae . Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits . HIV+ patients . Pregnant or lactating females.       .     . ",
        "Annotations": [
            "Condition 26 40--*--CNS metastases",
            "Condition 44 70--*--leptomeningeal involvement",
            "Procedure 144 151--*--treated",
            "Qualifier 164 179--*--been stable for",
            "Temporal 180 220--*--at least six months prior to study start",
            "Condition 92 108--*--brain metastases",
            "Observation 238 248--*--history of",
            "Condition 249 265--*--brain metastases",
            "Procedure 278 299--*--head CT with contrast",
            "Scope 238 265--*--history of brain metastases",
            "Condition 359 374 bone metastases",
            "Procedure 432 464 hepatic artery chemoembolization",
            "Temporal 465 489 within the last 6 months",
            "Temporal 491 500 one month",
            "Observation 514 547--*--other sites of measurable disease",
            "Scope 465 547 within the last 6 months (one month if there are other sites of measurable disease",
            "Procedure 597 627--*--radioactive directed therapies",
            "Drug 676 686--*--epothilone",
            "Condition 706 727--*--peripheral neuropathy",
            "Condition 731 750--*--unresolved diarrhea",
            "Measurement 764 769--*--Grade",
            "Value 751 763;770 771--*--greater than 1",
            "Condition 787 815--*--severe cardiac insufficiency",
            "Drug 832 840--*--Coumadin",
            "Drug 850 876--*--warfarin-containing agents",
            "Qualifier 899 907--*--low dose",
            "Drug 908 916--*--warfarin",
            "Multiplier 918 930--*--1 mg or less",
            "Device 955 972--*--in-dwelling lines",
            "Device 955 966;976 981--*--in-dwelling ports",
            "Scope 787 931--*--severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less)",
            "Condition 1037 1055--*--another malignancy",
            "Temporal 1056 1091--*--within 5 years prior to study entry",
            "Scope 832 876--*--Coumadin or other warfarin-containing agents",
            "Condition 1118 1142--*--non-melanoma skin cancer",
            "Qualifier 1099 1117--*--curatively treated",
            "Condition 1144 1159--*--prostate cancer",
            "Condition 1164 1187--*--cervical cancer in situ",
            "Scope 1118 1187--*--non-melanoma skin cancer, prostate cancer, or cervical cancer in situ",
            "Observation 1026 1036--*--history of",
            "Condition 1240 1262--*--uncontrolled infection",
            "Condition 1273 1281--*--abcesses",
            "Condition 1285 1293--*--fistulae",
            "Scope 1273 1293--*--abcesses or fistulae",
            "Qualifier 1203 1209--*--active",
            "Qualifier 1213 1222--*--suspected",
            "Qualifier 1223 1228--*--acute",
            "Qualifier 1232 1239--*--chronic",
            "Scope 1203 1239--*--active or suspected acute or chronic",
            "Condition 1322 1341--*--psychiatric illness",
            "Condition 1311 1318;1334 1341--*--medical illness",
            "Observation 1353 1367--*--preclude study",
            "Observation 1371 1387--*--informed consent",
            "Observation 1406 1439--*--noncompliance to medical regimens",
            "Observation 1443 1452;1470 1504--*--inability to return for all scheduled visits",
            "Observation 1456 1503--*--unwillingness to return for all scheduled visit",
            "Scope 1347 1504--*--would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits",
            "Condition 1506 1510--*--HIV+",
            "Measurement 1506 1509--*--HIV",
            "Value 1509 1510--*--+",
            "Condition 1521 1529--*--Pregnant",
            "Condition 1533 1542--*--lactating",
            "Qualifier 14 25--*--symptomatic",
            "Negation 877 898--*--with the exception of",
            "Negation 1092 1098--*--except",
            "Non-representable 983 1025--*--Patients taking any experimental therapies",
            "Temporal 652 662--*--previously",
            "Temporal 573 583--*--previously",
            "Multiplier 382 416--*--only site(s) of measurable disease",
            "Negation 110 116--*--unless"
        ]
    },
    "NCT02607748_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--< 18 years",
            "Measurement 16 26--*--Creatinine",
            "Value 27 38--*--> 1.5 mg/dL",
            "Condition 58 65--*--allergy",
            "Procedure 69 91--*--Iodine contrast agents",
            "Condition 93 102--*--Pregnancy",
            "Condition 111 130--*--atrial fibrillation",
            "Condition 132 162;173 185--*--Multiple premature ventricular contractions",
            "Condition 132 150;166 185--*--Multiple premature atrial contractions",
            "Measurement 187 204--*--Ejection fraction",
            "Value 205 209--*--<35%",
            "Condition 221 245--*--congestive heart failure",
            "Qualifier 211 220--*--Class III"
        ],
        "Text": "Age < 18 years. Creatinine > 1.5 mg/dL. History of severe allergy to Iodine contrast agents. Pregnancy. Active atrial fibrillation. Multiple premature ventricular or atrial contractions. Ejection fraction <35%. Class III congestive heart failure. "
    },
    "NCT03444142_exc": {
        "Annotations": [
            "Person 45 50--*--Women",
            "Person 0 5--*--Women",
            "Condition 34 43--*--pregnancy",
            "Qualifier 11 20--*--confirmed",
            "Qualifier 24 33--*--suspected",
            "Scope 11 33--*--confirmed or suspected",
            "Condition 57 66--*--lactation",
            "Condition 74 84--*--puerperium",
            "Condition 86 102--*--Hypersensibility",
            "Drug 106 133--*--ingredients of intervention",
            "Non-representable 135 176--*--Physical impossibility for apply the drug",
            "Condition 221 236--*--thyroid disease",
            "Condition 212 217;229 236--*--heart disease",
            "Condition 203 210;229 236--*--hepatic disease",
            "Condition 196 201;229 236--*--renal disease",
            "Condition 184 194;229 236--*--pancreatic disease",
            "Condition 239 251--*--Hypertension",
            "Procedure 272 293--*--treatment for glucose",
            "Temporal 263 271--*--Previous",
            "Measurement 295 310--*--Body Mass Index",
            "Value 311 322--*--=39.9 kg/m2",
            "Measurement 324 337--*--Triglycerides",
            "Value 338 348--*--=500 mg/dL",
            "Measurement 350 367--*--Total cholesterol",
            "Value 368 378--*--=300 mg/dL",
            "Person 389 411--*--rotating shift workers",
            "Person 380 385;398 411--*--Night shift workers",
            "Measurement 413 427--*--Blood Pressure",
            "Value 428 440--*--=140/90 mmHg"
        ],
        "Text": "Women with confirmed or suspected pregnancy. Women under lactation and/or puerperium. Hypersensibility to ingredients of intervention. Physical impossibility for apply the drug. Known pancreatic, renal, hepatic, heart or thyroid diseased. Hypertension diagnosis. Previous treatment for glucose. Body Mass Index =39.9 kg/m2. Triglycerides =500 mg/dL. Total cholesterol =300 mg/dL. Night or rotating shift workers. Blood Pressure =140/90 mmHg. "
    },
    "NCT03296488_exc": {
        "Text": "Body mass index less than 18 kg/m2 or greater than 30 kg/m2.. History of previous open-laparotomy.. Surgery with major complication, or need blood transfusion.. History of hypersensitivity or adverse reaction to local anesthetics, opioid, or any ingredient of the medications administered in this study.. Severe comorbidity.. Chronic preoperative opioid consumption.. Pregnant or breastfeeding.. Inability to use the PCA device.. ",
        "Annotations": [
            "Measurement 0 15--*--Body mass index",
            "Value 16 34--*--less than 18 kg/m2",
            "Value 38 59--*--greater than 30 kg/m2",
            "Scope 16 59--*--less than 18 kg/m2 or greater than 30 kg/m2",
            "Procedure 82 97--*--open-laparotomy",
            "Temporal 73 81--*--previous",
            "Observation 62 69--*--History",
            "Condition 113 131--*--major complication",
            "Procedure 100 107--*--Surgery",
            "Mood 136 140--*--need",
            "Condition 141 158--*--blood transfusion",
            "Scope 113 158--*--major complication, or need blood transfusion",
            "Condition 172 188--*--hypersensitivity",
            "Condition 192 208--*--adverse reaction",
            "Drug 212 229--*--local anesthetics",
            "Drug 231 237--*--opioid",
            "Drug 246 302--*--ingredient of the medications administered in this study",
            "Scope 212 302--*--local anesthetics, opioid, or any ingredient of the medications administered in this study",
            "Scope 172 208--*--hypersensitivity or adverse reaction",
            "Condition 312 323--*--comorbidity",
            "Qualifier 305 311--*--Severe",
            "Qualifier 326 333--*--Chronic",
            "Temporal 334 346--*--preoperative",
            "Drug 347 353--*--opioid",
            "Condition 368 376--*--Pregnant",
            "Observation 380 393--*--breastfeeding",
            "Condition 396 405--*--Inability",
            "Procedure 409 420--*--use the PCA"
        ]
    },
    "NCT03131050_exc": {
        "Annotations": [
            "Competing_trial 0 140--*--Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.",
            "Condition 165 186--*--psychiatric diagnosis",
            "Qualifier 157 164--*--primary",
            "Qualifier 150 156--*--Axis I",
            "Negation 187 197--*--other than",
            "Condition 198 223--*--major depressive disorder",
            "Condition 226 248--*--Organic mental disease",
            "Condition 260 278--*--mental retardation",
            "Qualifier 292 314--*--clinically significant",
            "Condition 315 322--*--disease",
            "Condition 338 352;426 433--*--cardiovascular disease",
            "Condition 396 410;426 433--*--endocrinologic disease",
            "Condition 383 394;426 433--*--hematologic disease",
            "Condition 370 381;426 433--*--respiratory disease",
            "Condition 363 368;426 433--*--renal disease",
            "Condition 354 361;426 433--*--hepatic disease",
            "Condition 415 433--*--neurologic disease",
            "Qualifier 438 460--*--clinically significant",
            "Condition 461 483--*--laboratory abnormality",
            "Negation 492 495--*--not",
            "Qualifier 496 506--*--stabilized",
            "Mood 513 535--*--anticipated to require",
            "Procedure 536 545--*--treatment",
            "Temporal 546 562--*--during the study",
            "Scope 492 562--*--not stabilized or is anticipated to require treatment during the study",
            "Competing_trial 565 730--*--Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.",
            "Pregnancy_considerations 732 845--*--Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.",
            "Drug 854 868--*--antipsychotics",
            "Drug 872 888--*--mood stabilizers",
            "Temporal 889 921--*--within 5 days prior to screening",
            "Scope 854 888--*--antipsychotics or mood stabilizers",
            "Drug 937 967--*--depot antipsychotic medication",
            "Temporal 968 1003--*--within one cycle prior to screening",
            "Condition 1012 1019--*--allergy",
            "Condition 1023 1039--*--lack of response",
            "Drug 1043 1054--*--mirtazapine",
            "Scope 1012 1039--*--allergy or lack of response",
            "Temporal 1082 1116--*--within 3 months prior to screening",
            "Reference_point 994 1003--*--screening",
            "Reference_point 912 921--*--screening",
            "Reference_point 1107 1116--*--screening",
            "Procedure 1070 1073--*--ECT",
            "Procedure 1077 1081--*--MECT",
            "Scope 1070 1081--*--ECT or MECT",
            "Drug 1130 1150--*--anticholinergic drug",
            "Condition 1151 1158--*--allergy",
            "Condition 1177 1194--*--allergic reaction",
            "Condition 1196 1205--*--skin rash",
            "Condition 1207 1216--*--urticaria",
            "Condition 1227 1245--*--allergic reactions",
            "Drug 1262 1267--*--drugs",
            "Qualifier 1221 1226--*--other",
            "Scope 1177 1245--*--allergic reaction, skin rash, urticaria and other allergic reactions",
            "Scope 1177 1267--*--allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs",
            "Scope 1130 1158--*--anticholinergic drug allergy",
            "Observation 1271 1278--*--Smokers",
            "Mood 1293 1300--*--risk of",
            "Observation 1301 1309;1327 1336--*--suicidal behaviors",
            "Observation 1317 1336--*--self-harm behaviors",
            "Scope 1301 1336--*--suicidal and/or self-harm behaviors"
        ],
        "Text": "Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.. Current Axis I primary psychiatric diagnosis other than major depressive disorder.. Organic mental disease, including mental retardation.. History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.. Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.. Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.. Use of antipsychotics or mood stabilizers within 5 days prior to screening.. Has received depot antipsychotic medication within one cycle prior to screening.. Known allergy or lack of response to mirtazapine.. Has received ECT or MECT within 3 months prior to screening.. History of anticholinergic drug allergy or complications (allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs).. Smokers.. Significant risk of suicidal and/or self-harm behaviors. "
    },
    "NCT02777580_exc": {
        "Annotations": [
            "Device 27 30--*--PCI",
            "Temporal 31 58--*--< 60 minutes from diagnosis",
            "Reference_point 49 58--*--diagnosis",
            "Non-query-able 79 147--*--inability to arrive at the catheterisation laboratory within 3 hours",
            "Procedure 158 162--*--CABG",
            "Condition 164 188--*--Left bundle branch block",
            "Condition 192 210--*--ventricular pacing",
            "Condition 226 243--*--cardiogenic shock",
            "Measurement 246 258--*--Killip Class",
            "Value 259 260--*--4",
            "Measurement 278 289--*--body weight",
            "Value 290 297--*--< 55 kg",
            "Condition 333 345--*--hypertension",
            "Qualifier 320 332--*--Uncontrolled",
            "Measurement 368 382--*--blood pressure",
            "Value 383 398--*--= 180/110 mm Hg",
            "Measurement 400 411--*--systolic BP",
            "Value 412 423--*--= 180 mm Hg",
            "Measurement 431 443--*--diastolic BP",
            "Value 444 455--*--= 110 mm Hg",
            "Scope 400 455--*--systolic BP = 180 mm Hg and/or diastolic BP = 110 mm Hg",
            "Condition 493 499--*--stroke",
            "Condition 503 506--*--TIA",
            "Drug 550 565--*--anticoagulation",
            "Temporal 566 581--*--within 12 hours",
            "Drug 593 615--*--unfractionated heparin",
            "Drug 617 627--*--enoxaparin",
            "Drug 636 647--*--bivalirudin",
            "Drug 666 686--*--oral anticoagulation",
            "Drug 693 701--*--warfarin",
            "Drug 707 712--*--NOACs",
            "Scope 593 713--*--unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs)",
            "Scope 693 712--*--warfarin or a NOACs",
            "Condition 715 730--*--Active bleeding",
            "Condition 740 757--*--bleeding disorder",
            "Condition 758 767--*--diathesis",
            "Condition 786 815--*--central nervous system damage",
            "Condition 822 830--*--neoplasm",
            "Condition 832 840--*--aneurysm",
            "Procedure 842 854;865 872--*--intracranial surgery",
            "Procedure 858 872--*--spinal surgery",
            "Scope 822 872--*--neoplasm, aneurysm, intracranial or spinal surgery",
            "Condition 884 890--*--trauma",
            "Qualifier 898 902--*--head",
            "Qualifier 906 913--*--cranium",
            "Temporal 920 930--*--< 3 months",
            "Scope 898 913--*--head or cranium",
            "Procedure 933 946--*--Major surgery",
            "Procedure 948 954--*--biopsy",
            "Qualifier 960 977--*--parenchymal organ",
            "Condition 994 1000--*--trauma",
            "Qualifier 982 993--*--significant",
            "Temporal 1012 1025--*--past 2 months",
            "Scope 933 1000--*--Major surgery, biopsy of a parenchymal organ, or significant trauma",
            "Condition 1080 1101--*--myocardial infarction",
            "Observation 1149 1165--*--risk of bleeding",
            "Qualifier 1139 1148--*--increased",
            "Condition 1189 1206--*--peptic ulceration",
            "Qualifier 1182 1188--*--active",
            "Condition 1214 1222--*--neoplasm",
            "Scope 1182 1222--*--active peptic ulceration and/or neoplasm",
            "Condition 1263 1292--*--cardiopulmonary resuscitation",
            "Qualifier 1253 1262--*--Prolonged",
            "Temporal 1318 1330--*--past 2 weeks",
            "Condition 1338 1356--*--acute pericarditis",
            "Condition 1364 1395--*--subacute bacterial endocarditis",
            "Condition 1403 1421--*--acute pancreatitis",
            "Condition 1438 1457--*--hepatic dysfunction",
            "Qualifier 1431 1437--*--severe",
            "Condition 1469 1484--*--hepatic failure",
            "Condition 1486 1495--*--cirrhosis",
            "Condition 1497 1516--*--portal hypertension",
            "Condition 1543 1559--*--active hepatitis",
            "Condition 1518 1537--*--oesophageal varices",
            "Scope 1469 1559--*--hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis",
            "Condition 1561 1569--*--Dementia",
            "Condition 1584 1603--*--renal insufficiency",
            "Qualifier 1577 1583--*--severe",
            "Competing_trial 1605 1737--*--Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days",
            "Condition 1745 1763--*--allergic reactions",
            "Drug 1767 1779--*--tenecteplase",
            "Drug 1781 1792--*--clopidogrel",
            "Drug 1794 1804--*--enoxaparin",
            "Drug 1809 1816--*--aspirin",
            "Scope 1767 1816--*--tenecteplase, clopidogrel, enoxaparin and aspirin",
            "Post-eligibility 1818 2023--*--Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated"
        ],
        "Text": "1. Expected performance of PCI < 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the catheterisation laboratory within 3 hours. Previous CABG. Left bundle branch block or ventricular pacing. Patients with cardiogenic shock - Killip Class 4. Patients with a body weight < 55 kg (known or estimated). Uncontrolled hypertension, defined as sustained blood pressure = 180/110 mm Hg (systolic BP = 180 mm Hg and/or diastolic BP = 110 mm Hg) prior to randomisation. Known prior stroke or TIA. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, including unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs). Active bleeding or known bleeding disorder/diathesis. Known history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. < 3 months). Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction). Clinical diagnosis associated with increased risk of bleeding including known active peptic ulceration and/or neoplasm with increased bleeding risk. Prolonged cardiopulmonary resuscitation (> 2 minutes) within the past 2 weeks. Known acute pericarditis and/or subacute bacterial endocarditis. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis. Dementia. Known severe renal insufficiency. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days. Known allergic reactions to tenecteplase, clopidogrel, enoxaparin and aspirin. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.. "
    },
    "NCT02566226_inc": {
        "Text": "physical status I - III. patients scheduled to undergo hip arthroplasty. ",
        "Annotations": [
            "Measurement 0 15--*--physical status",
            "Value 16 23--*--I - III",
            "Procedure 55 71--*--hip arthroplasty",
            "Mood 34 54--*--scheduled to undergo"
        ]
    },
    "NCT03228498_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 119 121--*--2.",
            "Parsing_Error 226 228--*--3.",
            "Parsing_Error 280 282--*--4.",
            "Parsing_Error 389 391--*--5.",
            "Parsing_Error 882 884--*--6.",
            "Parsing_Error 1120 1122--*--7.",
            "Parsing_Error 1267 1269--*--8.",
            "Parsing_Error 1327 1329--*--9.",
            "Parsing_Error 1446 1449--*--10.",
            "Parsing_Error 1499 1502--*--11.",
            "Parsing_Error 1556 1559--*--12.",
            "Parsing_Error 1635 1638--*--13.",
            "Parsing_Error 1687 1690--*--14.",
            "Parsing_Error 1729 1732--*--15.",
            "Parsing_Error 1784 1787--*--16.",
            "Parsing_Error 1819 1822--*--17.",
            "Parsing_Error 1857 1860--*--18.",
            "Parsing_Error 1870 1873--*--19.",
            "Parsing_Error 1909 1912--*--20.",
            "Subjective_judgement 14 27--*--objectionable",
            "Condition 28 48--*--cognitive impairment",
            "Qualifier 14 27--*--objectionable",
            "Negation 3 10--*--Absence",
            "Condition 64 72--*--dementia",
            "Qualifier 76 89--*--severe degree",
            "Measurement 101 110--*--CDR score",
            "Value 111 116--*--> 2.0",
            "Scope 14 116--*--objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0",
            "Procedure 140 149--*--brain MRI",
            "Negation 122 136--*--Unavailability",
            "Observation 122 136--*--Unavailability",
            "Non-query-able 122 136--*--Unavailability",
            "Procedure 201 211--*--cranial CT",
            "Condition 162 188--*--absolute contraindications",
            "Undefined_semantics 162 188--*--absolute contraindications",
            "Non-query-able 229 278--*--Expected poor compliance with the study protocol.",
            "Condition 301 317--*--major depression",
            "Condition 319 332--*--schizophrenia",
            "Condition 334 356--*--major anxiety syndrome",
            "Condition 361 386--*--manic- depressive illness",
            "Observation 283 297--*--Past diagnosis",
            "Scope 301 386--*--major depression, schizophrenia, major anxiety syndrome, or manic- depressive illness",
            "Condition 405 438--*--degenerative cognitive impairment",
            "Undefined_semantics 405 438--*--degenerative cognitive impairment",
            "Condition 448 490--*--clinical and/or neuroradiological findings",
            "Undefined_semantics 448 490--*--clinical and/or neuroradiological findings",
            "Condition 523 540--*--memory impairment",
            "Condition 550 573--*--medial temporal atrophy",
            "Procedure 577 586--*--brain MRI",
            "Negation 590 597--*--absence",
            "Condition 609 631--*--vascular abnormalities",
            "Subjective_judgement 601 608--*--evident",
            "Condition 639 656--*--Alzheimer disease",
            "Measurement 678 814--*--National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria",
            "Condition 816 833--*--Parkinson disease",
            "Condition 835 853--*--Huntington disease",
            "Condition 855 878--*--frontotemporal dementia",
            "Scope 523 586--*--memory impairment, or with medial temporal atrophy on brain MRI",
            "Scope 523 631--*--memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities",
            "Scope 639 878--*--Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia",
            "Scope 523 878--*--memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia",
            "Condition 898 918--*--cognitive impairment",
            "Qualifier 924 936--*--other causes",
            "Condition 944 956;972 982--*--vitamine B12 deficiency",
            "Condition 961 982--*--folic acid deficiency",
            "Condition 984 1001--*--thyroid disorders",
            "Condition 1003 1021--*--metabolic diseases",
            "Condition 1023 1034--*--head trauma",
            "Condition 1036 1041;1056 1085--*--tumor of the central nervous system",
            "Condition 1045 1085--*--infections of the central nervous system",
            "Condition 1087 1116--*--normal pressure hydrocephalus",
            "Scope 944 1116--*--vitamine B12 and folic acid deficiency, thyroid disorders, metabolic diseases, head trauma, tumor or infections of the central nervous system, normal pressure hydrocephalus",
            "Undefined_semantics 924 936--*--other causes",
            "Undefined_semantics 1123 1265--*--Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status.",
            "Subjective_judgement 1123 1265--*--Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status.",
            "Non-query-able 1123 1265--*--Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status.",
            "Condition 1290 1297;1311 1324--*--cardiac insufficiency",
            "Condition 1301 1324--*--pulmonary insufficiency",
            "Qualifier 1270 1289--*--Clinically relevant",
            "Scope 1290 1324--*--cardiac or pulmonary insufficiency",
            "Condition 1358 1371--*--abnormalities",
            "Procedure 1339 1357--*--electrocardiograph",
            "Condition 1373 1384--*--bradycardia",
            "Measurement 1386 1392--*--50 bpm",
            "Condition 1397 1408--*--tachycardia",
            "Measurement 1410 1417--*--120 bpm",
            "Qualifier 1419 1443--*--under resting conditions",
            "Scope 1373 1418--*--bradycardia (50 bpm) or tachycardia (120 bpm)",
            "Scope 1373 1443--*--bradycardia (50 bpm) or tachycardia (120 bpm) under resting conditions",
            "Qualifier 1330 1338--*--Relevant",
            "Undefined_semantics 1330 1338--*--Relevant",
            "Condition 1450 1471--*--Myocardial infarction",
            "Temporal 1472 1496--*--within the past 6 months",
            "Procedure 1526 1553--*--neurological rehabilitation",
            "Condition 1503 1509--*--Stroke",
            "Non-query-able 1516 1525--*--requiring",
            "Subjective_judgement 1516 1525--*--requiring",
            "Qualifier 1516 1525--*--requiring",
            "Context_Error 1577 1591--*--blood pressure",
            "Measurement 1593 1601--*--systolic",
            "Measurement 1613 1622--*--diastolic",
            "Value 1602 1611--*--180 mm Hg",
            "Value 1623 1631--*--95 mm Hg",
            "Scope 1593 1631--*--systolic 180 mm Hg, diastolic 95 mm Hg",
            "Measurement 1577 1591--*--blood pressure",
            "Qualifier 1560 1566--*--Severe",
            "Qualifier 1567 1576--*--untreated",
            "Scope 1560 1576--*--Severe/untreated",
            "Condition 1659 1684--*--liver function impairment",
            "Subjective_judgement 1639 1658--*--Clinically relevant",
            "Undefined_semantics 1639 1658--*--Clinically relevant",
            "Qualifier 1639 1658--*--Clinically relevant",
            "Condition 1691 1726--*--Insulin-dependent diabetes mellitus",
            "Condition 1733 1752--*--Idiopathic epilepsy",
            "Condition 1757 1781--*--anti-epileptic treatment",
            "Condition 1795 1801--*--anemia",
            "Qualifier 1788 1794--*--Severe",
            "Measurement 1803 1805--*--Hb",
            "Value 1806 1815--*--<10 mg/dL",
            "Condition 1830 1854--*--gastrointestinal disease",
            "Qualifier 1823 1829--*--Severe",
            "Undefined_semantics 1823 1829--*--Severe",
            "Subjective_judgement 1823 1829--*--Severe",
            "Condition 1861 1867--*--Cancer",
            "Condition 1880 1891--*--intolerance",
            "Drug 1895 1906--*--study drugs",
            "Context_Error 1880 1906--*--intolerance to study drugs",
            "Undefined_semantics 1913 1998--*--Coexistent serious illnesses that would imply a drop-out before the end of the trial."
        ],
        "Text": "1. Absence of objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0. . 2. Unavailability of brain MRI (in case of absolute contraindications, the use of cranial CT is allowed). . 3. Expected poor compliance with the study protocol. . 4. Past diagnosis of major depression, schizophrenia, major anxiety syndrome, or manic- depressive illness. . 5. Diagnosis of degenerative cognitive impairment based on clinical and/or neuroradiological findings (i.e., patients with prevailing memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia). . 6. Diagnosis of cognitive impairment from other causes (i.e., vitamine B12 and folic acid deficiency, thyroid disorders, metabolic diseases, head trauma, tumor or infections of the central nervous system, normal pressure hydrocephalus). . 7. Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status. . 8. Clinically relevant cardiac or pulmonary insufficiency. . 9. Relevant electrocardiograph abnormalities; bradycardia (50 bpm) or tachycardia (120 bpm) under resting conditions. . 10. Myocardial infarction within the past 6 months. . 11. Stroke still requiring neurological rehabilitation. . 12. Severe/untreated blood pressure (systolic 180 mm Hg, diastolic 95 mm Hg). . 13. Clinically relevant liver function impairment. . 14. Insulin-dependent diabetes mellitus. . 15. Idiopathic epilepsy and anti-epileptic treatment. . 16. Severe anemia (Hb <10 mg/dL). . 17. Severe gastrointestinal disease. . 18. Cancer. . 19. Known intolerance to study drugs. . 20. Coexistent serious illnesses that would imply a drop-out before the end of the trial.       .     . "
    },
    "NCT00396734_exc": {
        "Annotations": [
            "Multiplier 4 22--*--more than 2g a day",
            "Multiplier 24 50--*--5 times a week to everyday",
            "Condition 97 114--*--psychotic illness",
            "Measurement 128 134--*--DSM-IV",
            "Qualifier 136 142--*--Axis 1",
            "Observation 157 164--*--history",
            "Condition 168 179--*--CNS disease",
            "Observation 183 190--*--history",
            "Condition 194 203--*--infection",
            "Qualifier 215 225--*--affect CNS",
            "Condition 227 230--*--HIV",
            "Condition 232 240--*--syphilis",
            "Condition 242 257--*--cytomegalovirus",
            "Condition 259 265--*--herpes",
            "Scope 227 265--*--HIV, syphilis, cytomegalovirus, herpes",
            "Observation 273 280--*--history",
            "Condition 284 295--*--head injury",
            "Condition 301 322--*--loss of consciousness",
            "Condition 323 331--*--pregnant"
        ],
        "Text": "use more than 2g a day; 5 times a week to everyday . Subjects who are diagnosed as suffering from psychotic illness according to DSM-IV (Axis 1)22, or with a history of CNS disease, a history of infection that might affect CNS (HIV, syphilis, cytomegalovirus, herpes), or a history of head injury with loss of consciousness,pregnant women.       .     . "
    },
    "NCT02607748_inc": {
        "Annotations": [
            "Condition 0 23--*--Acute Coronary Syndrome",
            "Non-query-able 0 299--*--Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries. Only patients undergoing PCI will be included in the study",
            "Non-query-able 302 562--*--Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary angiography within 21 days prior to the imaging visit, with history of typical angina prior to the angiogram, but no prior myocardial infarction or coronary revascularization",
            "Negation 570 572--*--no",
            "Condition 579 582--*--CAD",
            "Condition 610 631--*--myocardial infarction",
            "Condition 633 656--*--acute coronary syndrome",
            "Procedure 658 676--*--coronary angiogram",
            "Procedure 681 684--*--PCI",
            "Scope 610 684--*--myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI",
            "Measurement 693 696--*--CAC",
            "Value 697 716--*--between 10 to <1000",
            "Non-query-able 723 864--*--match to patients in the ACS group by gender, age by decile, and CAC category (using CAC categories of 10 to <100, 100 to <400, 400 to <1000)"
        ],
        "Text": "Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries. Only patients undergoing PCI will be included in the study.. Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary angiography within 21 days prior to the imaging visit, with history of typical angina prior to the angiogram, but no prior myocardial infarction or coronary revascularization.. have no prior CAD associated event (no prior myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI),. have CAC between 10 to <1000, and. match to patients in the ACS group by gender, age by decile, and CAC category (using CAC categories of 10 to <100, 100 to <400, 400 to <1000).. "
    },
    "NCT03444142_inc": {
        "Annotations": [
            "Person 9 19--*--both sexes",
            "Person 21 24--*--Age",
            "Measurement 25 48--*--between 31 and 60 years",
            "Condition 63 71--*--diabetes",
            "Qualifier 82 94--*--ADA criteria"
        ],
        "Text": "Patients both sexes. Age between 31 and 60 years. Diagnosis of diabetes according ADA criteria:. "
    },
    "NCT02944292_exc": {
        "Text": "Contraindication for propofol administration. Contraindication for IAP measurement in supine position with head-of-bed at 0\u00b0. Other intervention for reduction of IAP planned. Previous propofol infusion rate >4 mg/kg/h. ",
        "Annotations": [
            "Condition 0 16--*--Contraindication",
            "Drug 21 29--*--propofol",
            "Condition 46 62--*--Contraindication",
            "Procedure 67 82--*--IAP measurement",
            "Qualifier 86 101--*--supine position",
            "Qualifier 107 124--*--head-of-bed at 0\u00b0",
            "Qualifier 126 131--*--Other",
            "Procedure 132 165--*--intervention for reduction of IAP",
            "Mood 166 173--*--planned",
            "Temporal 175 183--*--Previous",
            "Measurement 184 206--*--propofol infusion rate",
            "Value 207 217--*-->4 mg/kg/h"
        ]
    },
    "NCT02863120_exc": {
        "Annotations": [
            "Procedure 0 32--*--Revision total knee arthroplasty",
            "Procedure 34 67--*--Bilateral total knee arthroplasty",
            "Condition 83 105--*--inflammatory arthritis",
            "Measurement 123 138--*--body mass index",
            "Measurement 140 143--*--BMI",
            "Value 145 149--*--> 40",
            "Condition 151 158--*--Allergy",
            "Drug 162 173--*--ropivacaine",
            "Drug 175 186--*--bupivacaine",
            "Drug 197 220--*--local anesthetic agents",
            "Scope 162 220--*--ropivacaine, bupivacaine, or other local anesthetic agents",
            "Drug 237 243--*--opioid",
            "Qualifier 326 340--*--affected joint",
            "Procedure 304 318--*--reconstruction",
            "Qualifier 287 303--*--unicompartmental",
            "Qualifier 278 283--*--total",
            "Scope 278 303--*--total or unicompartmental",
            "Procedure 367 388--*--high tibial osteotomy",
            "Procedure 392 409--*--femoral osteotomy",
            "Condition 425 438;455 465--*--neuromuscular deficiency",
            "Condition 442 465--*--neurosensory deficiency",
            "Condition 548 566--*--metabolic disorder",
            "Condition 536 544;558 566--*--systemic disorder",
            "Condition 590 608--*--bone deterioration",
            "Qualifier 578 589--*--progressive",
            "Scope 536 566--*--systemic or metabolic disorder",
            "Condition 628 655--*--immunologically compromised",
            "Drug 678 686--*--steroids",
            "Qualifier 670 677--*--chronic",
            "Temporal 688 696--*-->30 days",
            "Negation 699 708--*--excluding",
            "Drug 709 717--*--inhalers",
            "Non-query-able 719 851--*--Patients' bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis",
            "Procedure 867 878--*--knee fusion",
            "Condition 946 955--*--infection",
            "Qualifier 972 982--*--knee joint",
            "Person 1002 1011--*--prisoners"
        ],
        "Text": "Revision total knee arthroplasty. Bilateral total knee arthroplasty. Patients with inflammatory arthritis. Patients with a body mass index (BMI) > 40. Allergy to ropivacaine, bupivacaine, or other local anesthetic agents. Current use of opioid drugs. Patients with a history of total or unicompartmental reconstruction of the affected joint. Patients that have had a high tibial osteotomy or femoral osteotomy. Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess pain levels. Patients with a systemic or metabolic disorder leading to progressive bone deterioration. Patients that are immunologically compromised, or receiving chronic steroids (>30 days), excluding inhalers. Patients' bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis. Patients with knee fusion to the affected joint. Patients with an active or suspected latent infection in or about the knee joint. Patients that are prisoners. "
    },
    "NCT00050349_inc": {
        "Text": "Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy . The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) . Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry . Must have a life expectancy of greater than three (3) months . Karnofsky Performance Status > 60 . Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.) . ",
        "Annotations": [
            "Condition 28 55--*--metastatic carcinoid tumors",
            "Value 21 27--*--proven",
            "Procedure 14 20--*--biopsy",
            "Condition 59 86--*--other neuroendocrine tumors",
            "Condition 88 98--*--Islet cell",
            "Condition 100 111--*--Gastrinomas",
            "Condition 116 123--*--VIPomas",
            "Scope 88 123--*--Islet cell, Gastrinomas and VIPomas",
            "Condition 143 160--*--measurable lesion",
            "Qualifier 173 177--*--bone",
            "Scope 14 124--*--biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)",
            "Procedure 215 225--*--irradiated",
            "Procedure 243 253--*--irradiated",
            "Observation 271 282--*--progression",
            "Procedure 293 310--*--radiation therapy",
            "Temporal 283 310--*--since the radiation therapy",
            "Negation 195 203--*--not been",
            "Scope 195 310--*--not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy",
            "Condition 331 356;368 376--*--major impairment of renal function",
            "Condition 331 350;360 376--*--major impairment of hepatic function",
            "Negation 328 330--*--no",
            "Scope 331 376--*--major impairment of renal or hepatic function",
            "Measurement 429 444--*--total bilirubin",
            "Value 445 455--*--<1.5 X ULN",
            "Measurement 457 460--*--AST",
            "Measurement 462 465--*--ALT",
            "Value 465 474--*--<2.5X ULN",
            "Condition 488 504--*--liver metastases",
            "Value 476 484--*--<5 X ULN",
            "Scope 457 517--*--AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)",
            "Scope 429 517--*--total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)",
            "Drug 531 546--*--Sandostatin Lar",
            "Drug 548 581--*--long acting somatostatin analogue",
            "Qualifier 596 607--*--stable dose",
            "Temporal 608 640--*--for 30 days prior to study entry",
            "Drug 645 680--*--short acting somatostatin analogues",
            "Qualifier 707 729--*--clinically stable dose",
            "Temporal 750 770--*--prior to study entry",
            "Observation 784 799--*--life expectancy",
            "Value 803 832--*--greater than three (3) months",
            "Measurement 834 862--*--Karnofsky Performance Status",
            "Value 863 867--*--> 60",
            "Person 869 875--*--Female",
            "Measurement 906 926--*--serum pregnancy test",
            "Value 897 905--*--negative",
            "Temporal 927 939--*--at screening",
            "Procedure 974 996--*--bilateral oophorectomy",
            "Procedure 1004 1016--*--hysterectomy",
            "Condition 1046 1060--*--postmenopausal",
            "Scope 974 1060--*--bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal",
            "Scope 974 1060--*--bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal",
            "Scope 897 939--*--negative serum pregnancy test at screening",
            "Reference_point 293 310--*--radiation therapy",
            "Negation 162 172--*--other than"
        ]
    },
    "NCT02664558_inc": {
        "Text": "1. Male or female, 18-75 years old. . 2. Has a diagnosis of WHO Group 1 PAH. . 3. Right heart catheterization performed at Screening with results that are: . 1. Mean pulmonary arterial pressure \u226525 mmHg (at rest) and . 2. Pulmonary venous hypertension (measured as pulmonary capillary wedge pressure (PCWP) \u226415 mmHg. If PCWP is not available, then mean left atrial pressure or left ventricular end-diastolic pressure \u226415 mmHg in the absence of left atrial obstruction. and . 3. Pulmonary vascular resistance (PVR) \u2265300 dyn\u2022s/cm5 (3.75 Wood units) . 4. Has WHO/NYHA-FC of II or III. . 5. Be on stable dose of at least one of the following PAH-specific therapies: endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog. . 6. Has a 6-minute walk distance that is \u2265150 and \u2264500 meters. . 7. Have a ventilation-perfusion scan that rules out thromboembolic disease. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 37 39--*--2.",
            "Parsing_Error 77 79--*--3.",
            "Parsing_Error 155 157--*--1.",
            "Parsing_Error 215 217--*--2.",
            "Parsing_Error 470 472--*--3.",
            "Parsing_Error 543 545--*--4.",
            "Parsing_Error 577 579--*--5.",
            "Parsing_Error 856 858--*--6.",
            "Parsing_Error 919 921--*--7.",
            "Person 3 7--*--Male",
            "Person 11 17--*--female",
            "Value 19 30--*--18-75 years",
            "Person 25 34--*--years old",
            "Measurement 59 68--*--WHO Group",
            "Value 69 70--*--1",
            "Condition 71 74--*--PAH",
            "Procedure 80 107--*--Right heart catheterization",
            "Parsing_Error 80 153--*--Right heart catheterization performed at Screening with results that are:",
            "Temporal 108 130--*--performed at Screening",
            "Reference_point 121 130--*--Screening",
            "Measurement 158 190--*--Mean pulmonary arterial pressure",
            "Value 191 199--*--\u226525 mmHg",
            "Qualifier 201 208--*--at rest",
            "Condition 218 247--*--Pulmonary venous hypertension",
            "Measurement 261 302--*--pulmonary capillary wedge pressure (PCWP)",
            "Value 303 311--*--\u226415 mmHg",
            "Condition 344 369--*--mean left atrial pressure",
            "Condition 373 412--*--left ventricular end-diastolic pressure",
            "Value 413 421--*--\u226415 mmHg",
            "Negation 429 436--*--absence",
            "Condition 440 463--*--left atrial obstruction",
            "Condition 473 508--*--Pulmonary vascular resistance (PVR)",
            "Value 509 523--*--\u2265300 dyn\u2022s/cm5",
            "Value 525 540--*--3.75 Wood units",
            "Measurement 550 561--*--WHO/NYHA-FC",
            "Value 565 567--*--II",
            "Value 571 574--*--III",
            "Scope 565 574--*--II or III",
            "Qualifier 586 597--*--stable dose",
            "Multiplier 601 613--*--at least one",
            "Procedure 631 653--*--PAH-specific therapies",
            "Drug 655 685--*--endothelin receptor antagonist",
            "Drug 690 730--*--agent acting on the nitric oxide pathway",
            "Drug 732 766--*--phosphodiesterase type 5 inhibitor",
            "Drug 770 806--*--soluble guanylate cyclase stimulator",
            "Scope 732 806--*--phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator",
            "Drug 818 830;847 853--*--prostacyclin analog",
            "Drug 834 853--*--prostacyclin analog",
            "Scope 655 853--*--endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog",
            "Measurement 865 887--*--6-minute walk distance",
            "Value 896 916--*--\u2265150 and \u2264500 meters",
            "Procedure 929 955--*--ventilation-perfusion scan",
            "Condition 971 993--*--thromboembolic disease",
            "Negation 961 970--*--rules out"
        ]
    },
    "NCT02965443_inc": {
        "Text": "Type 2 diabetes. Age 18 - 75 years. Anti-GAD antibodies negative (Glutamic Acid Decarboxylase). C-peptide levels = 1.5 ng/mL. Fasting blood glucose > 126 mg/dl. HbA1c 8.0 - 10.5 %. BMI 25.0 - 45.0 kg/m2. Previous therapy with BBIT (basal insulin and at least once daily bolus insulin). ",
        "Annotations": [
            "Condition 0 15--*--Type 2 diabetes",
            "Person 17 20--*--Age",
            "Value 21 34--*--18 - 75 years",
            "Measurement 36 55;65 94--*--Anti-GAD antibodies (Glutamic Acid Decarboxylase)",
            "Value 56 64--*--negative",
            "Measurement 96 112--*--C-peptide levels",
            "Value 113 124--*--= 1.5 ng/mL",
            "Measurement 126 147--*--Fasting blood glucose",
            "Value 148 159--*--> 126 mg/dl",
            "Measurement 161 166--*--HbA1c",
            "Value 167 179--*--8.0 - 10.5 %",
            "Measurement 181 184--*--BMI",
            "Temporal 204 212--*--Previous",
            "Procedure 213 220--*--therapy",
            "Drug 226 230--*--BBIT",
            "Drug 232 283--*--basal insulin and at least once daily bolus insulin",
            "Value 185 202--*--25.0 - 45.0 kg/m2"
        ]
    },
    "NCT02312960_inc": {
        "Text": "Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial. ",
        "Annotations": [
            "Competing_trial 0 166--*--Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial"
        ]
    },
    "NCT02965443_exc": {
        "Text": "Use of any oral antidiabetic treatment except for metformin (i.e., sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide) within the last three months prior to Screening. Repeated episodes of severe hypoglycaemia within the last six months prior to Screening. History of diabetic ketoacidosis, precoma diabetica, or diabetic coma. Treatment with any other investigational drug within the last three months before Screening. Acute infections within the last four weeks prior to Screening. Recurrent urogenital infections. History of pancreatitis. Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures. History of severe or multiple allergies. Concomitant participation in other clinical trials. Type 1 diabetes. Cardiovascular disease Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke.. Malignancy including leukemia and lymphoma within the last 5y.. Liver disease such as cirrhosis or chronic active hepatitis.. Significant renal dysfunction (see also exclusion criteria laboratory abnormalities).. State after kidney transplantation. Endocrine disease:. Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg at Screening. History of active substance abuse (including alcohol > 40g/day) within the past 2 years.. Pregnancy or childbearing potential without adequate contraception. Present therapy with systemic steroids. Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's (selective serotonin reuptake inhibitor). Potentially unreliable subjects, and those judged by the investigator to be unsuitable for the study.. Contraindications for Magnetic resonance (MR) scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia. ",
        "Annotations": [
            "Procedure 11 38--*--oral antidiabetic treatment",
            "Drug 11 28--*--oral antidiabetic",
            "Negation 39 49--*--except for",
            "Drug 50 59--*--metformin",
            "Drug 67 81--*--sulphonylureas",
            "Drug 83 100--*--DPP-IV inhibitors",
            "Drug 102 120--*--thiazolidinediones",
            "Drug 122 139--*--SGLT-2 inhibitors",
            "Drug 182 197--*--GLP-1 analogues",
            "Temporal 223 270--*--within the last three months prior to Screening",
            "Reference_point 261 270--*--Screening",
            "Scope 67 222--*--sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide)",
            "Scope 11 59--*--oral antidiabetic treatment except for metformin",
            "Multiplier 272 280--*--Repeated",
            "Condition 293 313--*--severe hypoglycaemia",
            "Temporal 314 359--*--within the last six months prior to Screening",
            "Reference_point 350 359--*--Screening",
            "Condition 372 393--*--diabetic ketoacidosis",
            "Observation 361 368--*--History",
            "Condition 395 412--*--precoma diabetica",
            "Condition 417 430--*--diabetic coma",
            "Scope 372 430--*--diabetic ketoacidosis, precoma diabetica, or diabetic coma",
            "Drug 457 477--*--investigational drug",
            "Procedure 432 441--*--Treatment",
            "Temporal 478 523--*--within the last three months before Screening",
            "Reference_point 514 523--*--Screening",
            "Condition 525 541--*--Acute infections",
            "Temporal 542 587--*--within the last four weeks prior to Screening",
            "Reference_point 578 587--*--Screening",
            "Multiplier 589 598--*--Recurrent",
            "Condition 599 620--*--urogenital infections",
            "Observation 622 629--*--History",
            "Condition 633 645--*--pancreatitis",
            "Observation 647 665--*--Anamnestic history",
            "Condition 669 685--*--hypersensitivity",
            "Drug 693 704--*--study drugs",
            "Drug 711 749--*--drugs with similar chemical structures",
            "Scope 693 749--*--study drugs or to drugs with similar chemical structures",
            "Condition 781 790--*--allergies",
            "Qualifier 762 768--*--severe",
            "Qualifier 772 780--*--multiple",
            "Scope 762 780--*--severe or multiple",
            "Observation 751 758--*--History",
            "Temporal 792 803--*--Concomitant",
            "Observation 804 842--*--participation in other clinical trials",
            "Condition 844 859--*--Type 1 diabetes",
            "Condition 861 883--*--Cardiovascular disease",
            "Qualifier 884 903--*--Clinically relevant",
            "Condition 904 927--*--ventricular tachycardia",
            "Condition 931 955--*--ventricular fibrillation",
            "Condition 957 976--*--3rd degree AV block",
            "Condition 980 999--*--Torsades de Pointes",
            "Procedure 1003 1012--*--treatment",
            "Drug 1018 1038--*--antiarrhythmic drugs",
            "Procedure 1040 1074--*--Percutaneous coronary intervention",
            "Temporal 1075 1099--*--within the past 6 months",
            "Scope 904 1038--*--ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs",
            "Temporal 1122 1146--*--within the past 6 months",
            "Condition 1148 1174--*--myocardial infarction (MI)",
            "Procedure 1176 1206--*--coronary artery bypass surgery",
            "Condition 1208 1223--*--unstable angina",
            "Condition 1228 1234--*--stroke",
            "Scope 1148 1234--*--myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke",
            "Scope 884 1234--*--Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke",
            "Condition 1237 1247--*--Malignancy",
            "Condition 1258 1266--*--leukemia",
            "Condition 1271 1279--*--lymphoma",
            "Temporal 1280 1298--*--within the last 5y",
            "Scope 1258 1279--*--leukemia and lymphoma",
            "Condition 1301 1314--*--Liver disease",
            "Condition 1323 1332--*--cirrhosis",
            "Condition 1336 1360--*--chronic active hepatitis",
            "Scope 1323 1360--*--cirrhosis or chronic active hepatitis",
            "Qualifier 1363 1374--*--Significant",
            "Condition 1375 1392--*--renal dysfunction",
            "Non-representable 1393 1447--*--(see also exclusion criteria laboratory abnormalities)",
            "Condition 1450 1484--*--State after kidney transplantation",
            "Procedure 1462 1484--*--kidney transplantation",
            "Condition 1486 1503--*--Endocrine disease",
            "Measurement 1506 1529--*--Systolic blood pressure",
            "Value 1530 1563--*--outside the range of 100-160 mmHg",
            "Measurement 1567 1591--*--diastolic blood pressure",
            "Value 1592 1605--*--above 95 mmHg",
            "Temporal 1606 1618--*--at Screening",
            "Scope 1506 1605--*--Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg",
            "Non-representable 1486 1504--*--Endocrine disease:",
            "Observation 1620 1627--*--History",
            "Qualifier 1631 1637--*--active",
            "Condition 1638 1653--*--substance abuse",
            "Measurement 1665 1672--*--alcohol",
            "Value 1673 1682--*--> 40g/day",
            "Scope 1665 1682--*--alcohol > 40g/day",
            "Temporal 1684 1707--*--within the past 2 years",
            "Condition 1710 1719--*--Pregnancy",
            "Observation 1723 1745--*--childbearing potential",
            "Negation 1746 1753--*--without",
            "Qualifier 1754 1762--*--adequate",
            "Procedure 1763 1776--*--contraception",
            "Procedure 1786 1793--*--therapy",
            "Temporal 1778 1785--*--Present",
            "Drug 1799 1816--*--systemic steroids",
            "Condition 1830 1850--*--psychiatric disorder",
            "Drug 1864 1879;1898 1904--*--anti-depressive agents",
            "Drug 1883 1904--*--anti-psychotic agents",
            "Negation 1905 1926--*--with the exception of",
            "Drug 1927 1942--*--benzodiazepines",
            "Drug 1947 1952--*--SSRIs",
            "Drug 1953 1959--*--SNRI's",
            "Scope 1927 1959--*--benzodiazepines and SSRIs/SNRI's",
            "Scope 1864 1904--*--anti-depressive or anti-psychotic agents",
            "Scope 1864 1959--*--anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's",
            "Observation 2014 2033--*--unreliable subjects",
            "Non-representable 2002 2013--*--Potentially",
            "Observation 2078 2102--*--unsuitable for the study",
            "Non-representable 2045 2071--*--judged by the investigator",
            "Condition 2105 2122--*--Contraindications",
            "Procedure 2127 2159--*--Magnetic resonance (MR) scanning",
            "Device 2181 2198--*--cardiac pacemaker",
            "Device 2203 2224--*--implants out of metal",
            "Condition 2228 2242--*--claustrophobia",
            "Scope 2105 2159--*--Contraindications for Magnetic resonance (MR) scanning",
            "Scope 2181 2242--*--cardiac pacemaker and implants out of metal or claustrophobia"
        ]
    },
    "NCT02312960_exc": {
        "Text": "Not applicable to this follow up study. ",
        "Annotations": [
            "Non-representable 0 38--*--Not applicable to this follow up study"
        ]
    },
    "NCT02456129_exc": {
        "Annotations": [
            "Condition 19 40--*--pre-existing diseases",
            "Qualifier 0 18--*--Incompletely cured",
            "Subjective_judgement 54 68--*--can be assumed",
            "Non-query-able 0 176--*--Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal",
            "Condition 197 211--*--liver diseases",
            "Qualifier 187 196--*--suspected",
            "Qualifier 178 183--*--Known",
            "Scope 178 196--*--Known or suspected",
            "Subjective_judgement 187 196--*--suspected",
            "Undefined_semantics 187 196--*--suspected",
            "Measurement 247 261--*--blood pressure",
            "Procedure 263 285--*--electrocardiogram(ECG)",
            "Procedure 300 325--*--gynecological examination",
            "Procedure 287 295;314 325--*--physical examination",
            "Procedure 327 349--*--laboratory examination",
            "Scope 247 349--*--blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination",
            "Qualifier 213 232--*--Clinically relevant",
            "Condition 233 241--*--findings",
            "Subjective_judgement 213 232--*--Clinically relevant",
            "Undefined_semantics 213 232--*--Clinically relevant"
        ],
        "Text": "Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal . Known or suspected liver diseases . Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)       .     . "
    },
    "NCT01907230_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 11 23--*--20 to 90 y/o",
            "Measurement 26 31--*--HBsAg",
            "Value 32 40--*--positive",
            "Temporal 45 63--*--more than 6 months",
            "Measurement 68 75--*--HBV DNA",
            "Value 76 88--*--< 2000 IU/ml",
            "Measurement 104 109--*--HBsAg",
            "Value 110 118--*--negative",
            "Measurement 123 131--*--anti-HBc",
            "Value 132 140--*--positive",
            "Measurement 146 153--*--HBV DNA",
            "Value 154 166--*--< 2000 IU/ml",
            "Scope 26 88--*--HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml",
            "Scope 0 25;26 166--*--Age : from 20 to 90 y/o.",
            "Scope 104 166--*--HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml",
            "Condition 182 204--*--Inflammatory arthritis",
            "Procedure 237 254--*--biological agents",
            "Drug 266 272--*--Humira",
            "Drug 276 282--*--Enbrel",
            "Drug 286 293--*--Simponi",
            "Drug 297 304--*--Orencia",
            "Drug 308 316--*--Mabthera",
            "Drug 320 327--*--Actemra",
            "Scope 266 327--*--Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra"
        ],
        "Text": "Age : from 20 to 90 y/o.. HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml (Subgroup 2).. Inflammatory arthritis patients who plan to treat with biological agents, including Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra; as first line biologic treatment is indicated.. "
    },
    "NCT02871206_exc": {
        "Text": "Anaphylactic reaction to a previous dose of influenza vaccine or to any of its components. Known Immunoglobulin E (IgE)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock. Guillain- Barr\u00e9 syndrome within eight weeks of a previous influenza vaccine. Use of aspirin or salicylate- containing products within 30 days before enrollment. Household members of children in Group A. ",
        "Annotations": [
            "Condition 0 21--*--Anaphylactic reaction",
            "Temporal 27 35--*--previous",
            "Drug 44 61--*--influenza vaccine",
            "Drug 75 89--*--its components",
            "Scope 44 89--*--influenza vaccine or to any of its components",
            "Condition 97 145--*--Immunoglobulin E (IgE)-mediated hypersensitivity",
            "Drug 149 153--*--eggs",
            "Condition 168 173--*--hives",
            "Condition 175 196--*--swelling of the mouth",
            "Condition 175 190;201 207--*--swelling of the throat",
            "Condition 209 232--*--difficulty in breathing",
            "Condition 234 245--*--hypotension",
            "Condition 250 255--*--shock",
            "Scope 168 255--*--hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock",
            "Condition 257 281--*--Guillain- Barr\u00e9 syndrome",
            "Temporal 282 332--*--within eight weeks of a previous influenza vaccine",
            "Reference_point 304 332--*--a previous influenza vaccine",
            "Temporal 306 314--*--previous",
            "Drug 315 332--*--influenza vaccine",
            "Drug 341 348--*--aspirin",
            "Drug 352 383--*--salicylate- containing products",
            "Temporal 384 416--*--within 30 days before enrollment",
            "Scope 341 383--*--aspirin or salicylate- containing products",
            "Person 418 435--*--Household members",
            "Person 439 447--*--children",
            "Person 451 458--*--Group A",
            "Scope 439 458--*--children in Group A"
        ]
    },
    "NCT03115151_exc": {
        "Text": "Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.. Immunocompromised subject. Coagulopathy. Severe liver and renal dysfunction. Preoperative neurological deficits. The dura damage during surgery. Inability to follow directions or comprehend the English language.. Females who are pregnant as determined by positive pregnancy test on or before the day of surgery.. Prisoners.. Patient refusal to provide informed consent.. Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl).. ",
        "Annotations": [
            "Post-eligibility 0 135--*--Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.",
            "Condition 137 154--*--Immunocompromised",
            "Condition 164 176--*--Coagulopathy",
            "Condition 185 190;201 212--*--liver dysfunction",
            "Condition 195 212--*--renal dysfunction",
            "Qualifier 178 184--*--Severe",
            "Scope 185 212--*--liver and renal dysfunction",
            "Condition 227 248--*--neurological deficits",
            "Qualifier 214 226--*--Preoperative",
            "Observation 254 265--*--dura damage",
            "Procedure 273 280--*--surgery",
            "Post-eligibility 282 347--*--Inability to follow directions or comprehend the English language",
            "Pregnancy_considerations 350 447--*--Females who are pregnant as determined by positive pregnancy test on or before the day of surgery",
            "Person 450 459--*--Prisoners",
            "Post-eligibility 462 505--*--Patient refusal to provide informed consent",
            "Condition 508 515--*--Allergy",
            "Drug 519 542--*--amide local anesthetics",
            "Drug 544 553--*--lidocaine",
            "Drug 555 566--*--bupivacaine",
            "Drug 568 579--*--ropivacaine",
            "Drug 584 590--*--opioid",
            "Drug 592 600--*--fentanyl",
            "Scope 544 579--*--lidocaine, bupivacaine, ropivacaine",
            "Scope 519 602--*--amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl)."
        ]
    },
    "NCT03036462_inc": {
        "Text": "Patients aged at least 18 years. Patients with chronic heart failure present for at least 12 months. Confirmed presence of iron deficiency. Serum haemoglobin of 9.5 to 14.0 g/dL. ",
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 31--*--at least 18 years",
            "Condition 47 68--*--chronic heart failure",
            "Temporal 77 99--*--for at least 12 months",
            "Drug 123 127--*--iron",
            "Condition 123 138--*--iron deficiency",
            "Measurement 140 157--*--Serum haemoglobin",
            "Value 161 177--*--9.5 to 14.0 g/dL"
        ]
    },
    "NCT02667730_exc": {
        "Annotations": [
            "Condition 13 27--*--ankle fracture",
            "Condition 31 47--*--ligament rupture",
            "Observation 61 99--*--release from the Canadian Armed Forces",
            "Temporal 100 115--*--within one year",
            "Observation 129 160--*--restrictions on military duties",
            "Drug 218 231--*--acetaminophen",
            "Drug 235 243--*--naproxen",
            "Drug 247 256--*--celecoxib",
            "Condition 198 214--*--adverse reaction",
            "Scope 218 256--*--acetaminophen or naproxen or celecoxib",
            "Condition 172 183--*--intolerance",
            "Scope 172 214--*--intolerance or documented adverse reaction",
            "Condition 289 304--*--kidney problems",
            "Condition 280 285;296 304--*--liver problems",
            "Observation 269 276--*--history",
            "Scope 280 304--*--liver or kidney problems",
            "Condition 306 314--*--pregnant",
            "Observation 318 331--*--breastfeeding"
        ],
        "Text": "Diagnosis of ankle fracture or ligament rupture. Has planned release from the Canadian Armed Forces within one year;. Documented restrictions on military duties. Has known intolerance or documented adverse reaction to acetaminophen or naproxen or celecoxib. Documented history of liver or kidney problems. pregnant or breastfeeding. "
    },
    "NCT02542956_inc": {
        "Text": "Undergoing abdominoplasty or TRAM flap breast reconstruction. ",
        "Annotations": [
            "Procedure 11 25--*--abdominoplasty",
            "Procedure 29 60--*--TRAM flap breast reconstruction"
        ]
    },
    "NCT02833623_inc": {
        "Annotations": [
            "Visit 0 11--*--outpatients",
            "Person 12 16--*--aged",
            "Value 17 28--*--18-70 years",
            "Condition 53 72--*--H. pylori infection",
            "Measurement 115 135--*--13C-urea breath test",
            "Measurement 137 146--*--histology",
            "Measurement 148 165--*--rapid urease test",
            "Measurement 169 186--*--bacterial culture",
            "Scope 115 186--*--13C-urea breath test, histology, rapid urease test or bacterial culture",
            "Informed_consent 188 267--*--an intention of H. pylori eradication treatment and have written inform consent",
            "Post-eligibility 269 319--*--ability to read short messages on the mobile phone"
        ],
        "Text": "outpatients aged 18-70 years. confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture. an intention of H. pylori eradication treatment and have written inform consent. ability to read short messages on the mobile phone. "
    },
    "NCT03194074_inc": {
        "Text": "Patients scheduled for laser laryngeal surgery under general anesthesia with either Propofol or desflurane based technique.. ",
        "Annotations": [
            "Mood 9 18--*--scheduled",
            "Procedure 23 46--*--laser laryngeal surgery",
            "Procedure 53 71--*--general anesthesia",
            "Drug 84 92--*--Propofol",
            "Drug 96 106--*--desflurane",
            "Scope 84 106--*--Propofol or desflurane"
        ]
    },
    "NCT02118467_inc": {
        "Text": "Age greater than or equal to 18 years old. Requirement for vasoactive drugs via a central venous catheter for the treatment of shock. Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg coupled with signs of tissue hypoperfusion (e.g. altered mental state, mottled skin, urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2 mmol per liter).. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 41--*--greater than or equal to 18 years old",
            "Drug 59 75--*--vasoactive drugs",
            "Device 82 105--*--central venous catheter",
            "Condition 127 132--*--shock",
            "Measurement 159 181--*--mean arterial pressure",
            "Value 182 199--*--less than 70 mmHg",
            "Measurement 203 226--*--systolic blood pressure",
            "Value 227 245--*--less than 100 mmHg",
            "Non-query-able 134 642--*--Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg coupled with signs of tissue hypoperfusion (e.g. altered mental state, mottled skin, urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2 mmol per liter)."
        ]
    },
    "NCT01978028_inc": {
        "Annotations": [
            "Condition 14 35--*--chronic heart failure",
            "Measurement 39 65--*--New York Heart Association",
            "Value 66 81--*--Class II or III",
            "Measurement 85 119--*--left ventricular ejection fraction",
            "Value 123 128--*--= 40%",
            "Measurement 145 149--*--NYHA",
            "Value 150 158--*--class II",
            "Measurement 184 188--*--NYHA",
            "Value 189 198--*--class III",
            "Value 162 167--*--= 45%",
            "Scope 184 198--*--NYHA class III",
            "Scope 145 158--*--NYHA class II",
            "Scope 123 198--*--= 40% for patients in NYHA class II or = 45% for patients in NYHA class III",
            "Measurement 202 218--*--hemoglobin level",
            "Temporal 219 241--*--at the screening visit",
            "Reference_point 222 241--*--the screening visit",
            "Value 242 263--*--between 9.5-13.5 g/dl",
            "Condition 269 284--*--iron deficiency",
            "Measurement 306 326--*--serum ferritin level",
            "Value 327 336--*--< 100\u00b5g/l",
            "Value 340 364--*--between 100 and 299 \u00b5g/l",
            "Scope 327 364--*--< 100\u00b5g/l or between 100 and 299 \u00b5g/l",
            "Measurement 371 394--*--transferring saturation",
            "Value 398 403--*--< 20%",
            "Scope 306 403--*--serum ferritin level < 100\u00b5g/l or between 100 and 299 \u00b5g/l, when transferring saturation is < 20%",
            "Person 406 409--*--Age",
            "Value 410 419--*--=18 years",
            "Post-eligibility 421 446--*--Obtained informed consent",
            "Procedure 455 478--*--pharmacological therapy",
            "Qualifier 448 454--*--Stable",
            "Temporal 479 502--*--during the last 4 weeks",
            "Reference_point 490 502--*--last 4 weeks",
            "Drug 526 535--*--diuretics",
            "Negation 504 525--*--with the exception of"
        ],
        "Text": "Patients with chronic heart failure of New York Heart Association Class II or III, a left ventricular ejection fraction of = 40% for patients in NYHA class II or = 45% for patients in NYHA class III, a hemoglobin level at the screening visit between 9.5-13.5 g/dl, and iron deficiency, which is defined as serum ferritin level < 100\u00b5g/l or between 100 and 299 \u00b5g/l, when transferring saturation is < 20%.. Age =18 years. Obtained informed consent. Stable pharmacological therapy during the last 4 weeks (with the exception of diuretics). "
    },
    "NCT02668016_inc": {
        "Text": "Aged 18 years or older. Previously taken one or more statins. Withdrawn from statins because of perceived side effects. Developed side effects within 2 weeks of initiation. Clinical indication for statins for primary or secondary prevention of cardiovascular disease or dyslipidaemia, on either no medication or non-statin lipid lowering therapy (e.g, ezetimibe). ",
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 22--*--18 years or older",
            "Multiplier 41 52--*--one or more",
            "Drug 53 60--*--statins",
            "Non-query-able 62 118--*--Withdrawn from statins because of perceived side effects",
            "Condition 130 142--*--side effects",
            "Temporal 143 171--*--within 2 weeks of initiation",
            "Reference_point 161 171--*--initiation",
            "Condition 182 192--*--indication",
            "Drug 197 204--*--statins",
            "Observation 230 266--*--prevention of cardiovascular disease",
            "Qualifier 220 229--*--secondary",
            "Qualifier 209 216--*--primary",
            "Condition 270 283--*--dyslipidaemia",
            "Scope 209 229--*--primary or secondary",
            "Scope 209 283--*--primary or secondary prevention of cardiovascular disease or dyslipidaemia"
        ]
    },
    "NCT01907230_exc": {
        "Annotations": [
            "Condition 0 3;17 28--*--HCV coinfection",
            "Condition 17 28;5 8--*--coinfection HIV",
            "Condition 13 16;17 28--*--HDV coinfection",
            "Condition 31 34--*--HCC",
            "Condition 44 54--*--malignancy",
            "Temporal 55 69--*--within 3 years",
            "Scope 31 54--*--HCC or other malignancy",
            "Condition 72 101--*--Decompensated liver cirrhosis",
            "Measurement 103 112--*--CTP score",
            "Value 113 116--*--= 7",
            "Condition 120 126--*--Uremia",
            "Procedure 142 154--*--hemodialysis",
            "Condition 158 199--*--continuous ambulatory peritoneal dialysis",
            "Measurement 217 220--*--Ccr",
            "Value 221 232--*--< 50 mL/min",
            "Scope 142 199--*--hemodialysis or continuous ambulatory peritoneal dialysis",
            "Scope 142 232--*--hemodialysis or continuous ambulatory peritoneal dialysis or patients with Ccr < 50 mL/min",
            "Pregnancy_considerations 234 265--*--Pregnant or breastfeeding women",
            "Pregnancy_considerations 268 477--*--Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug"
        ],
        "Text": "HCV, HIV, or HDV coinfection.. HCC or other malignancy within 3 years.. Decompensated liver cirrhosis (CTP score = 7).. Uremia patients under hemodialysis or continuous ambulatory peritoneal dialysis or patients with Ccr < 50 mL/min. Pregnant or breastfeeding women.. Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug.. "
    },
    "NCT02871206_inc": {
        "Text": "Healthy children aged 6 months to 72 months. ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 8 16--*--children",
            "Person 17 21--*--aged",
            "Value 22 43--*--6 months to 72 months"
        ]
    },
    "NCT02456129_inc": {
        "Annotations": [
            "Measurement 0 21--*--Body mass index (BMI)",
            "Value 23 42--*--18 \u2264 BMI \u2264 32 kg/m\u00b2",
            "Condition 44 64--*--Postmenopausal state",
            "Parsing_Error 44 77--*--Postmenopausal state revealed by:",
            "Condition 111 128--*--natural menopause",
            "Temporal 129 188--*--at least 12 months prior to first study drug administration",
            "Reference_point 157 188--*--first study drug administration",
            "Condition 193 211--*--surgical menopause",
            "Procedure 215 236--*--bilateral ovariectomy",
            "Temporal 237 295--*--at least 3 months prior to first study drug administration",
            "Reference_point 264 295--*--first study drug administration",
            "Value 320 330--*--< 65 years",
            "Person 325 334--*--years old",
            "Measurement 336 370--*--follicle stimulating hormone (FSH)",
            "Value 371 380--*--> 40 IU/L",
            "Person 314 319--*--women",
            "Scope 314 334--*--women < 65 years old"
        ],
        "Text": "Body mass index (BMI): 18 \u2264 BMI \u2264 32 kg/m\u00b2 . Postmenopausal state revealed by: . Medical history, if applicable (natural menopause at least 12 months prior to first study drug administration; or surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration), in addition: in women < 65 years old, follicle stimulating hormone (FSH) > 40 IU/L . "
    },
    "NCT03036462_exc": {
        "Text": "Hypersensitivity to the active substance, to FCM or any of its excipients. Known serious hypersensitivity to other parenteral iron products. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia. Evidence of iron overload or disturbances in the utilisation of iron. ",
        "Annotations": [
            "Condition 0 16--*--Hypersensitivity",
            "Drug 24 40--*--active substance",
            "Drug 45 48--*--FCM",
            "Drug 63 73--*--excipients",
            "Scope 24 73--*--active substance, to FCM or any of its excipients",
            "Condition 89 105--*--hypersensitivity",
            "Drug 115 139--*--parenteral iron products",
            "Qualifier 81 88--*--serious",
            "Condition 141 148--*--Anaemia",
            "Negation 149 152--*--not",
            "Drug 167 182--*--iron deficiency",
            "Mood 153 166--*--attributed to",
            "Qualifier 189 194--*--other",
            "Condition 195 213--*--microcytic anaemia",
            "Scope 141 182--*--Anaemia not attributed to iron deficiency",
            "Scope 189 213--*--other microcytic anaemia",
            "Condition 227 240--*--iron overload",
            "Condition 244 283--*--disturbances in the utilisation of iron",
            "Drug 227 231--*--iron",
            "Drug 279 283--*--iron"
        ]
    },
    "NCT03115151_inc": {
        "Text": "Adult subjects aged 18 years or older. Scheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 15 19--*--aged",
            "Value 20 37--*--18 years or older",
            "Procedure 62 100--*--posterior lumbar spinal fusion surgery",
            "Qualifier 53 61--*--elective",
            "Mood 39 52--*--Scheduled for",
            "Qualifier 101 123--*--between 1 and 3 levels"
        ]
    },
    "NCT02833623_exc": {
        "Annotations": [
            "Non-query-able 1 113--*--dvanced chronic disease that would not allow the patient to complete the treatment or follow-up or attend visits",
            "Non-representable 115 161--*--allergy to any of the drugs used in this study",
            "Procedure 172 213--*--Helicobacter Pylori eradication treatment",
            "Pregnancy_considerations 215 375--*--pregnancy or breastfeeding (female participants with childbearing potential were required to use medically accepted contraception for the duration of the study)",
            "Drug 384 395--*--antibiotics",
            "Drug 399 403--*--PPIs",
            "Drug 407 420--*--bismuth salts",
            "Temporal 421 438--*--within four weeks",
            "Scope 384 420--*--antibiotics or PPIs or bismuth salts",
            "Procedure 449 473--*--gastrointestinal surgery"
        ],
        "Text": "advanced chronic disease that would not allow the patient to complete the treatment or follow-up or attend visits. allergy to any of the drugs used in this study. previous Helicobacter Pylori eradication treatment. pregnancy or breastfeeding (female participants with childbearing potential were required to use medically accepted contraception for the duration of the study). taking antibiotics or PPIs or bismuth salts within four weeks. previous gastrointestinal surgery. "
    },
    "NCT03194074_exc": {
        "Text": "Patients with cardiac, pulmonary, hepatic, or renal dysfunction, epilepsy, or uncontrolled hypertension, or those taking medications that influence the central nervous system, are excluded from the study. Patients who show obvious alteration of mental status, or refuse to participate, are also excluded from the study.. ",
        "Annotations": [
            "Condition 46 63--*--renal dysfunction",
            "Condition 34 41;52 63--*--hepatic dysfunction",
            "Condition 23 32;52 63--*--pulmonary dysfunction",
            "Condition 14 21;52 63--*--cardiac dysfunction",
            "Condition 65 73--*--epilepsy",
            "Qualifier 78 90--*--uncontrolled",
            "Condition 91 103--*--hypertension",
            "Drug 121 174--*--medications that influence the central nervous system",
            "Condition 231 258--*--alteration of mental status",
            "Observation 263 284--*--refuse to participate",
            "Informed_consent 263 284--*--refuse to participate"
        ]
    },
    "NCT02542956_exc": {
        "Text": "A medical condition that could interfere with study participation. Body weight less than 50 kg. Participating in another study involving an investigational medication. ",
        "Annotations": [
            "Non-query-able 0 65--*--A medical condition that could interfere with study participation",
            "Measurement 67 78--*--Body weight",
            "Value 79 94--*--less than 50 kg",
            "Competing_trial 96 166--*--Participating in another study involving an investigational medication"
        ]
    },
    "NCT02667730_inc": {
        "Annotations": [
            "Condition 9 27--*--acute ankle injury",
            "Qualifier 0 8--*--Acquired",
            "Temporal 37 59--*--less than 48 hours ago",
            "Qualifier 87 94--*--Grade I",
            "Qualifier 87 92;98 100--*--Grade II",
            "Condition 101 113--*--ankle sprain",
            "Scope 87 100--*--Grade I or II",
            "Non-query-able 115 187--*--Is eligible to receive comprehensive medical care from Garrison Petawawa"
        ],
        "Text": "Acquired acute ankle injury (injured less than 48 hours ago);. Clinical diagnosis of a Grade I or II ankle sprain. Is eligible to receive comprehensive medical care from Garrison Petawawa. "
    },
    "NCT02668016_exc": {
        "Text": "History of neuropathy. Regularly taking prescribed analgesia. History of a chronic pain condition. History of severe mental illness (as their experience of symptoms may already be altered). Current use of fibrates (because of the risk of interaction with statins but will not exclude participants taking ezetimibe).. Severe previous reaction or reaction considered immunological, such as anaphylaxis, facial swelling, severe rash, muscle ache with rise in serum creatine kinase, inflammatory myopathy, rhabdomyolysis or liver function abnormalities (aspartate transaminase (AST) or alanine transaminase (ALT) greater than 3 times upper limit or normal).. Side-effects taking longer than 2 weeks to develop (because in such participants much longer blocks of treatment would be required, if the present study is positive such studies will be planned for the future)*.. History of statin intolerance with drug interaction to antiretroviral drugs.. History of statin intolerance to any other drug.. Pregnant or breast feeding.. Side effects taking longer than 2 weeks to present.. In clinical judgement of study doctor, participant should not participate.. ",
        "Annotations": [
            "Condition 11 21--*--neuropathy",
            "Drug 51 60--*--analgesia",
            "Qualifier 23 32--*--Regularly",
            "Condition 75 87--*--chronic pain",
            "Condition 117 131--*--mental illness",
            "Qualifier 110 116--*--severe",
            "Drug 205 213--*--fibrates",
            "Condition 388 399--*--anaphylaxis",
            "Condition 401 417--*--facial swelling,",
            "Condition 418 429--*--severe rash",
            "Condition 431 442--*--muscle ache",
            "Measurement 456 477--*--serum creatine kinase",
            "Value 448 452--*--rise",
            "Condition 479 500--*--inflammatory myopathy",
            "Condition 502 516--*--rhabdomyolysis",
            "Condition 520 548--*--liver function abnormalities",
            "Measurement 550 572--*--aspartate transaminase",
            "Measurement 574 577--*--AST",
            "Measurement 582 602--*--alanine transaminase",
            "Measurement 604 607--*--ALT",
            "Value 609 651--*--greater than 3 times upper limit or normal",
            "Scope 550 608--*--aspartate transaminase (AST) or alanine transaminase (ALT)",
            "Non-query-able 655 865--*--Side-effects taking longer than 2 weeks to develop (because in such participants much longer blocks of treatment would be required, if the present study is positive such studies will be planned for the future)*",
            "Condition 886 897--*--intolerance",
            "Drug 879 885--*--statin",
            "Drug 923 943--*--antiretroviral drugs",
            "Condition 964 975--*--intolerance",
            "Drug 957 963--*--statin",
            "Pregnancy_considerations 996 1022--*--Pregnant or breast feeding",
            "Non-query-able 1078 1151--*--In clinical judgement of study doctor, participant should not participate",
            "Non-query-able 1025 1075--*--Side effects taking longer than 2 weeks to present"
        ]
    },
    "NCT01978028_exc": {
        "Annotations": [
            "Condition 0 15--*--Hemochromatosis",
            "Condition 17 30--*--iron overload",
            "Measurement 43 47--*--TSAT",
            "Value 48 53--*--> 45%",
            "Condition 61 77--*--hypersensitivity",
            "Drug 81 91--*--Ferinject\u00ae",
            "Measurement 118 121--*--CRP",
            "Value 121 129--*-->20 mg/L",
            "Condition 100 116--*--active infection",
            "Qualifier 131 153--*--clinically significant",
            "Condition 154 162--*--bleeding",
            "Qualifier 164 170--*--active",
            "Condition 171 181--*--malignancy",
            "Condition 184 205--*--Chronic liver disease",
            "Measurement 223 249--*--alanine transaminase (ALT)",
            "Measurement 253 281--*--aspartate transaminase (AST)",
            "Value 282 335--*--above three times the upper limit of the normal range",
            "Scope 223 281--*--alanine transaminase (ALT) or aspartate transaminase (AST)",
            "Procedure 338 363--*--Immunosuppressive therapy",
            "Condition 367 381--*--renal dialysis",
            "Mood 383 390--*--current",
            "Mood 394 401--*--planned",
            "Temporal 402 426--*--within the next 6 months",
            "Reference_point 409 426--*--the next 6 months",
            "Scope 383 401--*--current or planned",
            "Scope 338 381--*--Immunosuppressive therapy or renal dialysis",
            "Drug 441 455--*--erythropoietin",
            "Procedure 466 483--*--oral iron therapy",
            "Procedure 489 506--*--blood transfusion",
            "Temporal 507 527--*--in previous 12 weeks",
            "Mood 548 555--*--planned",
            "Temporal 556 580--*--within the next 6 months",
            "Reference_point 563 580--*--the next 6 months",
            "Procedure 457 462;471 483--*--i. v. iron therapy",
            "Scope 441 506--*--erythropoietin, i. v. or oral iron therapy, and blood transfusion",
            "Scope 507 580--*--in previous 12 weeks and/or such therapy planned within the next 6 months",
            "Condition 583 607--*--Unstable angina pectoris",
            "Qualifier 639 661--*--clinically significant",
            "Condition 674 690--*--valvular disease",
            "Condition 694 730--*--left ventricular outflow obstruction",
            "Condition 732 758--*--obstructive cardiomyopathy",
            "Qualifier 760 777--*--poorly controlled",
            "Condition 778 802--*--fast atrial fibrillation",
            "Condition 778 789;806 813--*--fast atrial flutter",
            "Qualifier 815 832--*--poorly controlled",
            "Qualifier 833 844--*--symptomatic",
            "Condition 855 871--*--tachyarrhythmias",
            "Condition 845 851--*--brady-",
            "Scope 845 871--*--brady- or tachyarrhythmias",
            "Scope 778 813--*--fast atrial fibrillation or flutter",
            "Condition 874 901--*--Acute myocardial infarction",
            "Condition 905 928--*--acute coronary syndrome",
            "Condition 930 955--*--transient ischemic attack",
            "Condition 959 965--*--stroke",
            "Temporal 966 990--*--within the last 3 months",
            "Reference_point 973 990--*--the last 3 months",
            "Scope 874 965--*--Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke",
            "Procedure 993 1021--*--Coronary-artery bypass graft",
            "Procedure 1023 1048--*--percutaneous intervention",
            "Procedure 1126 1139--*--major surgery",
            "Procedure 1164 1179--*--cardiac surgery",
            "Procedure 1151 1159;1172 1179--*--thoracic surgery",
            "Temporal 1181 1205--*--within the last 3 months",
            "Reference_point 1188 1205--*--the last 3 months",
            "Scope 1151 1179--*--thoracic and cardiac surgery",
            "Non-query-able 1208 1248--*--Participation in a CHF training program.",
            "Condition 1250 1259--*--Known HIV",
            "Condition 1260 1264--*--AIDS",
            "Post-eligibility 1267 1358--*--Inability to fully comprehend and/or perform study procedures in the investigator's opinion",
            "Condition 1361 1372;1393 1403--*--Vitamin B12 deficiency",
            "Condition 1380 1403--*--serum folate deficiency",
            "Condition 1501 1510--*--lactation",
            "Condition 1488 1497--*--Pregnancy",
            "Procedure 1647 1662--*--Anticoagulation",
            "Post-eligibility 1513 1645--*--Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study."
        ],
        "Text": "Hemochromatosis, iron overload, defined as TSAT > 45%. Known hypersensitivity to Ferinject\u00ae.. Known active infection, CRP>20 mg/L, clinically significant bleeding, active malignancy.. Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range.. Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).. History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.. Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.. Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke within the last 3 months.. Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.. Participation in a CHF training program.. Known HIV/AIDS.. Inability to fully comprehend and/or perform study procedures in the investigator's opinion.. Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening is possible after substitution therapy).. Pregnancy or lactation.. Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.. Anticoagulation. "
    },
    "NCT02118467_exc": {
        "Text": "Cardiopulmonary arrest. Pregnancy. Severe right heart failure. ",
        "Annotations": [
            "Condition 0 22--*--Cardiopulmonary arrest",
            "Condition 24 33--*--Pregnancy",
            "Condition 42 61--*--right heart failure",
            "Qualifier 35 41--*--Severe"
        ]
    },
    "NCT02590315_inc": {
        "Annotations": [
            "Qualifier 0 12--*--Asymptomatic",
            "Person 13 18--*--women",
            "Value 19 30--*--45-68 years",
            "Visit 49 64--*--Piedmont Region",
            "Procedure 80 120--*--regional breast cancer screening program"
        ],
        "Text": "Asymptomatic women 45-68 years, residents in the Piedmont Region, attending the regional breast cancer screening program. "
    },
    "NCT02565277_exc": {
        "Text": "Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination. Participant has received a community available influenza vaccine within <6 months. History of Guillain-Barr\u00e9 syndrome. Immunosuppressive disorders or medications (including oral prednisone >10 mg daily, recent chemotherapy treatment). Emergency cases as determined by the investigator or physician. ",
        "Annotations": [
            "Negation 5 8--*--not",
            "Procedure 18 39--*--influenza vaccination",
            "Procedure 241 258--*--influenza vaccine",
            "Temporal 259 275--*--within <6 months",
            "Condition 288 311--*--Guillain-Barr\u00e9 syndrome",
            "Condition 313 340--*--Immunosuppressive disorders",
            "Drug 313 330;344 355--*--Immunosuppressive medications",
            "Drug 367 382--*--oral prednisone",
            "Multiplier 383 395--*-->10 mg daily",
            "Procedure 404 416--*--chemotherapy",
            "Scope 367 426--*--oral prednisone >10 mg daily, recent chemotherapy treatment",
            "Non-query-able 429 491--*--Emergency cases as determined by the investigator or physician"
        ]
    },
    "NCT03012984_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 27--*-->= 65 years, < 90 years",
            "Mood 30 39--*--Scheduled",
            "Procedure 51 58--*--surgery",
            "Qualifier 63 70--*--primary",
            "Condition 71 89--*--solid organ cancer",
            "Procedure 96 114--*--general anesthesia",
            "Non-representable 116 163--*--with an expected duration of surgery >=2 hours;",
            "Qualifier 180 198--*--patient-controlled",
            "Procedure 199 220--*--intravenous analgesia",
            "Temporal 221 234--*--after surgery",
            "Procedure 227 234--*--surgery",
            "Reference_point 227 234--*--surgery",
            "Post-eligibility 237 269--*--Provide written informed consent"
        ],
        "Text": "Age >= 65 years, < 90 years;. Scheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery >=2 hours;. Planned to use patient-controlled intravenous analgesia after surgery;. Provide written informed consent.. "
    },
    "NCT02590315_exc": {
        "Annotations": [
            "Condition 20 33--*--breast cancer",
            "Observation 0 16--*--Personal history",
            "Condition 37 53--*--terminal illness",
            "Observation 72 103--*--unable to give informed consent",
            "Device 105 120--*--Breast implants"
        ],
        "Text": "Personal history of breast cancer. A terminal illness. Patients who are unable to give informed consent. Breast implants. "
    },
    "NCT02565277_inc": {
        "Text": "Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, and able to converse with study personnel). Age 18 years or older. Undergoing major cardiac surgery using cardiopulmonary bypass. ",
        "Annotations": [
            "Post-eligibility 0 173--*--Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, and able to converse with study personnel",
            "Person 176 179--*--Age",
            "Value 180 197--*--18 years or older",
            "Procedure 210 231--*--major cardiac surgery",
            "Procedure 238 260--*--cardiopulmonary bypass"
        ]
    },
    "NCT03012984_exc": {
        "Annotations": [
            "Condition 24 37--*--schizophrenia",
            "Condition 39 47--*--epilepsy",
            "Condition 49 61--*--parkinsonism",
            "Condition 65 82--*--myasthenia gravis",
            "Observation 13 20--*--history",
            "Temporal 0 12--*--Preoperative",
            "Scope 24 82--*--schizophrenia, epilepsy, parkinsonism or myasthenia gravis",
            "Procedure 108 120--*--chemotherapy",
            "Procedure 113 120;98 103--*--therapy radio",
            "Temporal 85 97--*--Preoperative",
            "Scope 98 120--*--radio- or chemotherapy",
            "Condition 186 190--*--coma",
            "Condition 201 209--*--dementia",
            "Qualifier 192 200--*--profound",
            "Observation 213 229--*--language barrier",
            "Temporal 155 174--*--preoperative period",
            "Condition 123 147--*--Inability to communicate",
            "Scope 186 229--*--coma, profound dementia or language barrier",
            "Condition 245 268--*--obstructive sleep apnea",
            "Temporal 232 244--*--Preoperative",
            "Condition 294 317--*--obstructive sleep apnea",
            "Measurement 324 339--*--STOP-Bang score",
            "Value 340 344--*-->= 3",
            "Scope 294 344--*--obstructive sleep apnea, or a STOP-Bang score >= 3",
            "Scope 232 268--*--Preoperative obstructive sleep apnea",
            "Condition 348 360--*--Brain trauma",
            "Procedure 364 376--*--neurosurgery",
            "Measurement 392 426--*--left ventricular ejection fraction",
            "Value 427 432--*--< 30%",
            "Temporal 379 391--*--Preoperative",
            "Condition 434 453--*--sick sinus syndrome",
            "Qualifier 455 461--*--severe",
            "Condition 462 479--*--sinus bradycardia",
            "Value 481 502--*--< 50 beats per minute",
            "Condition 531 553--*--atrioventricular block",
            "Negation 554 561--*--without",
            "Device 562 571--*--pacemaker",
            "Qualifier 508 530--*--second-degree or above",
            "Qualifier 574 580--*--Severe",
            "Condition 581 600--*--hepatic dysfunction",
            "Measurement 602 612--*--Child-Pugh",
            "Value 613 620--*--class C",
            "Scope 574 600--*--Severe hepatic dysfunction",
            "Scope 602 620--*--Child-Pugh class C",
            "Qualifier 625 631--*--severe",
            "Condition 632 649--*--renal dysfunction",
            "Procedure 666 691--*--renal replacement therapy",
            "Temporal 692 706--*--before surgery",
            "Reference_point 699 706--*--surgery",
            "Procedure 699 706--*--surgery",
            "Scope 625 649--*--severe renal dysfunction",
            "Scope 666 706--*--renal replacement therapy before surgery",
            "Measurement 710 728--*--ASA classification",
            "Value 729 734--*-->= IV"
        ],
        "Text": "Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis;. Preoperative radio- or chemotherapy;. Inability to communicate in the preoperative period because of coma, profound dementia or language barrier;. Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or a STOP-Bang score >= 3);. Brain trauma or neurosurgery;. Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker;. Severe hepatic dysfunction (Child-Pugh class C) or severe renal dysfunction (requirement of renal replacement therapy before surgery);. ASA classification >= IV.. "
    },
    "NCT03537924_exc": {
        "Annotations": [
            "Qualifier 42 47--*--other",
            "Condition 48 55--*--disease",
            "Condition 24 38;48 55--*--cardiovascular disease",
            "Condition 11 22;48 55--*--respiratory disease",
            "Qualifier 4 10--*--active",
            "Mood 56 65--*--requiring",
            "Procedure 74 83--*--treatment",
            "Mood 103 111;87 92--*--relevant being",
            "Condition 116 125--*--tolerance",
            "Condition 129 136--*--hypoxia",
            "Condition 140 157--*--altitude exposure",
            "Scope 129 157--*--hypoxia or altitude exposure",
            "Scope 11 55--*--respiratory, cardiovascular or other disease",
            "Condition 236 249--*--heavy smoking",
            "Measurement 255 273--*--cigarettes per day",
            "Measurement 281 291--*--pack-years",
            "Condition 297 311--*--active smoking",
            "Temporal 312 336--*--during the last 10 years",
            "Value 251 254--*-->20",
            "Value 277 280--*-->20",
            "Scope 251 336--*-->20 cigarettes per day or >20 pack-years with active smoking during the last 10 years",
            "Condition 339 361--*--regular use of alcohol",
            "Condition 364 371--*--Allergy",
            "Drug 375 388--*--acetazolamide",
            "Drug 399 411--*--sulfonamides",
            "Qualifier 393 398--*--other",
            "Scope 375 411--*--acetazolamide and other sulfonamides"
        ],
        "Text": "Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol.. Allergy to acetazolamide and other sulfonamides.. "
    },
    "NCT02940912_exc": {
        "Text": "Atypical Parkinsonian Syndromes. Parkinson's disease with hallucinations. Parkinson's disease with impulse Control disorder (ICD). Parkinson's disease already treated with APOMORPHINE pump or justifying the use of the pump continuously day and night. Another obvious severe disease explaining insomnia. Exclusion for monitoring difficulties (mutation, insufficient motivation, priority associated pathology in care). Patient unwilling to accept a pump. Patient not accepting polysomnography and multiple sleep latency test. Patient with health problems or a skin disease precluding continuous subcutaneous infusion. Female parturient or nursing. Cardiac dysrhythmia precluding treatment with domperidone or apomorphine (increased QTc = 440 ms in men, QTc = 450 ms in women). antiemetic neuroleptics. Tetrabenazine. Excessive alcohol consumption. Hypersensitivity to apomorphine or one of the excipients. Respiratory Depression. Hepatic impairment. Intellectual Disability. Dementia. ",
        "Annotations": [
            "Qualifier 0 8--*--Atypical",
            "Condition 9 31--*--Parkinsonian Syndromes",
            "Condition 33 52--*--Parkinson's disease",
            "Condition 58 72--*--hallucinations",
            "Condition 74 93--*--Parkinson's disease",
            "Condition 99 129--*--impulse Control disorder (ICD)",
            "Condition 131 150--*--Parkinson's disease",
            "Drug 172 183--*--APOMORPHINE",
            "Non-representable 192 249--*--justifying the use of the pump continuously day and night",
            "Condition 267 281--*--severe disease",
            "Condition 293 301--*--insomnia",
            "Non-representable 303 415--*--Exclusion for monitoring difficulties (mutation, insufficient motivation, priority associated pathology in care)",
            "Mood 425 444--*--unwilling to accept",
            "Negation 425 434--*--unwilling",
            "Device 447 451--*--pump",
            "Procedure 475 490--*--polysomnography",
            "Mood 461 474--*--not accepting",
            "Negation 461 464--*--not",
            "Procedure 495 522--*--multiple sleep latency test",
            "Condition 537 552--*--health problems",
            "Condition 558 570--*--skin disease",
            "Negation 571 581--*--precluding",
            "Procedure 582 614--*--continuous subcutaneous infusion",
            "Scope 537 570--*--health problems or a skin disease",
            "Person 616 622--*--Female",
            "Condition 623 633--*--parturient",
            "Condition 637 644--*--nursing",
            "Condition 646 665--*--Cardiac dysrhythmia",
            "Drug 692 703--*--domperidone",
            "Drug 707 718--*--apomorphine",
            "Negation 666 676--*--precluding",
            "Scope 692 718--*--domperidone or apomorphine",
            "Scope 666 718--*--precluding treatment with domperidone or apomorphine",
            "Measurement 730 733--*--QTc",
            "Value 734 742--*--= 440 ms",
            "Measurement 751 754--*--QTc",
            "Value 755 763--*--= 450 ms",
            "Person 767 772--*--women",
            "Person 746 749--*--men",
            "Scope 730 772--*--QTc = 440 ms in men, QTc = 450 ms in women",
            "Drug 775 798--*--antiemetic neuroleptics",
            "Drug 800 813--*--Tetrabenazine",
            "Condition 815 844--*--Excessive alcohol consumption",
            "Condition 846 862--*--Hypersensitivity",
            "Drug 866 877--*--apomorphine",
            "Drug 892 902--*--excipients",
            "Scope 866 902--*--apomorphine or one of the excipients",
            "Condition 904 926--*--Respiratory Depression",
            "Condition 928 946--*--Hepatic impairment",
            "Condition 948 971--*--Intellectual Disability",
            "Condition 973 981--*--Dementia"
        ]
    },
    "NCT03445949_exc": {
        "Text": "indications to dual antiplatelet therapy other than atrial fibrillation or left atrial appendage occlusion at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease). indications to anticoagulation at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. pulmonary embolism). known allergy to clopidogrel or acetylsalicylic acid precluding its administration as specified by the protocol. any known inborn or acquired coagulation disorders. poor tolerance of or technical difficulties with performing transesophageal echocardiography. peridevice leak >5mm on transesophageal echocardiography study preceding enrollment. left atrial thrombus on transesophageal echocardiography study performed after successful left atrial appendage closure but before enrollment. life expectancy of less than 18months. participation in other clinical studies with experimental therapies at the time of enrollment and preceding 3 months. chronic kidney disease stage IV and V. women who are pregnant or breast feeding; women of childbearing potential who do not consent to apply at least to methods of contraception. This criterion does not apply to postmenopausal women. ",
        "Annotations": [
            "Procedure 15 40--*--dual antiplatelet therapy",
            "Negation 41 51--*--other than",
            "Condition 52 71--*--atrial fibrillation",
            "Condition 0 11--*--indications",
            "Condition 75 106--*--left atrial appendage occlusion",
            "Temporal 107 132--*--at the time of enrollment",
            "Mood 136 156--*--predicted appearance",
            "Temporal 177 209--*--within the duration of the trial",
            "Condition 215 238--*--coronary artery disease",
            "Scope 136 209--*--predicted appearance of such indications within the duration of the trial",
            "Scope 52 106--*--atrial fibrillation or left atrial appendage occlusion",
            "Scope 107 239--*--at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease)",
            "Condition 241 252--*--indications",
            "Procedure 256 271--*--anticoagulation",
            "Temporal 272 297--*--at the time of enrollment",
            "Mood 301 321--*--predicted appearance",
            "Temporal 342 374--*--within the duration of the trial",
            "Scope 301 374--*--predicted appearance of such indications within the duration of the trial",
            "Condition 380 398--*--pulmonary embolism",
            "Scope 272 399--*--at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. pulmonary embolism)",
            "Drug 418 429--*--clopidogrel",
            "Drug 433 453--*--acetylsalicylic acid",
            "Condition 407 414--*--allergy",
            "Non-representable 454 483--*--precluding its administration",
            "Scope 418 453--*--clopidogrel or acetylsalicylic acid",
            "Condition 543 564--*--coagulation disorders",
            "Condition 566 580--*--poor tolerance",
            "Observation 587 609--*--technical difficulties",
            "Procedure 626 658--*--transesophageal echocardiography",
            "Scope 566 609--*--poor tolerance of or technical difficulties",
            "Measurement 660 675--*--peridevice leak",
            "Value 676 680--*-->5mm",
            "Procedure 684 722--*--transesophageal echocardiography study",
            "Condition 745 765--*--left atrial thrombus",
            "Procedure 769 801--*--transesophageal echocardiography",
            "Procedure 835 864--*--left atrial appendage closure",
            "Temporal 818 864--*--after successful left atrial appendage closure",
            "Reference_point 824 864--*--successful left atrial appendage closure",
            "Qualifier 824 834--*--successful",
            "Temporal 869 886--*--before enrollment",
            "Reference_point 876 886--*--enrollment",
            "Scope 818 886--*--after successful left atrial appendage closure but before enrollment",
            "Observation 888 903--*--life expectancy",
            "Value 907 925--*--less than 18months",
            "Competing_trial 927 1043--*--participation in other clinical studies with experimental therapies at the time of enrollment and preceding 3 months",
            "Condition 1045 1067--*--chronic kidney disease",
            "Qualifier 1068 1076--*--stage IV",
            "Qualifier 1068 1073;1081 1082--*--stage V",
            "Scope 1068 1082--*--stage IV and V",
            "Person 1084 1089--*--women",
            "Condition 1098 1106--*--pregnant",
            "Observation 1110 1124--*--breast feeding",
            "Pregnancy_considerations 1084 1277--*--women who are pregnant or breast feeding; women of childbearing potential who do not consent to apply at least to methods of contraception. This criterion does not apply to postmenopausal women"
        ]
    },
    "NCT02959801_inc": {
        "Annotations": [
            "Qualifier 7 12--*--acute",
            "Condition 13 35--*--deep venous thrombosis",
            "Qualifier 0 6--*--proven",
            "Multiplier 37 54--*--less than 21 days",
            "Visit 84 119--*--interventional radiology department",
            "Mood 68 79--*--referred to"
        ],
        "Text": "proven acute deep venous thrombosis, less than 21 days and who were referred to the interventional radiology department.. "
    },
    "NCT02257580_inc": {
        "Text": "Scheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous procedures. ",
        "Annotations": [
            "Qualifier 14 23--*--bilateral",
            "Mood 0 13--*--Scheduled for",
            "Procedure 24 50--*--varus rotational osteotomy",
            "Procedure 52 55--*--VRO",
            "Procedure 100 118--*--osseous procedures",
            "Procedure 108 118;84 95--*--procedures soft tissue",
            "Scope 84 118--*--soft tissue and osseous procedures"
        ]
    },
    "NCT02634541_exc": {
        "Annotations": [
            "Condition 0 9--*--Psoriasis",
            "Condition 13 34--*--psoriasis arthropathy",
            "Condition 36 62--*--Inflammatory bowel disease",
            "Informed_consent 64 139--*--Unwillingness to participate in the study with additional imaging protocols",
            "Observation 141 159--*--Expected life-span",
            "Value 160 177--*--less than <1 year",
            "Condition 179 187--*--Diabetes",
            "Procedure 204 223--*--PET imaging quality",
            "Qualifier 226 234--*--Probable",
            "Condition 235 248--*--noncompliance",
            "Condition 250 259--*--Pregnancy",
            "Person 261 264--*--Age",
            "Value 265 274--*--<18 years",
            "Value 278 287--*-->75 years",
            "Scope 265 287--*--<18 years or >75 years",
            "Condition 289 305--*--Contraindication",
            "Drug 310 320--*--adalimumab",
            "Drug 322 334--*--Methotrexate",
            "Temporal 340 368--*--within the previous 6 months",
            "Drug 372 389--*--biologic medicine",
            "Temporal 395 423--*--within the previous 6 months"
        ],
        "Text": "Psoriasis or psoriasis arthropathy. Inflammatory bowel disease. Unwillingness to participate in the study with additional imaging protocols. Expected life-span less than <1 year. Diabetes (to improve the PET imaging quality). Probable noncompliance. Pregnancy. Age <18 years or >75 years. Contraindication for adalimumab. Methotrexate used within the previous 6 months. A biologic medicine used within the previous 6 months. "
    },
    "NCT02260700_exc": {
        "Annotations": [
            "Undefined_semantics 18 40--*--clinically significant",
            "Qualifier 18 40--*--clinically significant",
            "Condition 41 70--*--abnormal physical examination",
            "Undefined_semantics 41 70--*--abnormal physical examination",
            "Condition 41 49;72 83--*--abnormal vital signs",
            "Condition 41 49;87 98--*--abnormal 12 lead ECG",
            "Measurement 110 113--*--QTc",
            "Value 114 138--*--greater than (>) 450msec",
            "Condition 140 164--*--Left Bundle Branch Block",
            "Device 166 185--*--permanent pacemaker",
            "Condition 189 227--*--implantable cardioverter defibrillator",
            "Scope 110 227--*--QTc greater than (>) 450msec, Left Bundle Branch Block, permanent pacemaker or implantable cardioverter defibrillator",
            "Temporal 229 254--*--at Screening or admission",
            "Reference_point 232 241--*--Screening",
            "Reference_point 245 254--*--admission",
            "Scope 232 254--*--Screening or admission",
            "Scope 41 98--*--abnormal physical examination, vital signs or 12 lead ECG",
            "Condition 305 324--*--renal insufficiency",
            "Condition 296 301;311 324--*--liver insufficiency",
            "Observation 274 281--*--history",
            "Condition 453 475--*--metabolic disturbances",
            "Condition 437 448;463 475--*--psychiatric disturbances",
            "Condition 422 435;463 475--*--rheumatologic disturbances",
            "Condition 409 420;463 475--*--hematologic disturbances",
            "Condition 397 407;463 475--*--neurologic disturbances",
            "Condition 386 395;463 475--*--endocrine disturbances",
            "Condition 368 384;463 475--*--gastrointestinal disturbances",
            "Condition 357 366;463 475--*--pulmonary disturbances",
            "Condition 347 355;463 475--*--vascular disturbances",
            "Condition 338 345;463 475--*--cardiac disturbances",
            "Scope 338 475--*--cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances",
            "Qualifier 326 337--*--significant",
            "Subjective_judgement 326 337--*--significant",
            "Undefined_semantics 326 337--*--significant",
            "Scope 296 475--*--liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances",
            "Drug 484 500--*--any prescription",
            "Undefined_semantics 484 500--*--any prescription",
            "Drug 504 531--*--over-the-counter medication",
            "Undefined_semantics 504 531--*--over-the-counter medication",
            "Drug 533 550--*--herbal medication",
            "Drug 552 560--*--vitamins",
            "Drug 565 584--*--mineral supplements",
            "Temporal 585 634--*--within 14 days prior to study drug administration",
            "Reference_point 609 634--*--study drug administration",
            "Drug 650 661--*--paracetamol",
            "Negation 636 639--*--not",
            "Scope 484 584--*--any prescription or over-the-counter medication, herbal medication, vitamins, or mineral supplements",
            "Drug 664 674--*--Medication",
            "Condition 694 713--*--age related disease",
            "Undefined_semantics 694 713--*--age related disease",
            "Multiplier 679 690--*--chronic use",
            "Undefined_semantics 664 674--*--Medication",
            "Grammar_Error 714 729--*--will be allowed",
            "Subjective_judgement 736 788--*--approval by both the investigator and to the sponsor",
            "Not_a_criteria 790 913--*--No change in dose or regimen will be permitted during the study that is, from the Screening visit until the follow-up visit",
            "Condition 977 985--*--bleeding",
            "Qualifier 989 1003--*--unclear origin",
            "Qualifier 970 976--*--severe",
            "Qualifier 957 966--*--prolonged",
            "Qualifier 944 955--*--spontaneous",
            "Observation 933 940--*--history",
            "Scope 944 976--*--spontaneous, prolonged or severe",
            "Undefined_semantics 977 985--*--bleeding",
            "Condition 1034 1042--*--epilepsy",
            "Condition 1046 1050--*--fits",
            "Condition 1066 1076--*--black-outs",
            "Qualifier 1054 1065--*--unexplained",
            "Condition 1088 1106--*--vasovagal collapse",
            "Negation 1077 1087--*--other than",
            "Observation 1023 1030--*--history",
            "Scope 1034 1106--*--epilepsy or fits or unexplained black-outs other than vasovagal collapse"
        ],
        "Text": "Participant has a clinically significant abnormal physical examination, vital signs or 12 lead ECG (including QTc greater than (>) 450msec, Left Bundle Branch Block, permanent pacemaker or implantable cardioverter defibrillator) at Screening or admission . Participant has a history of or current liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances . Use of any prescription or over-the-counter medication, herbal medication, vitamins, or mineral supplements within 14 days prior to study drug administration (not including paracetamol). Medication for chronic use in age related disease will be allowed after approval by both the investigator and to the sponsor. No change in dose or regimen will be permitted during the study that is, from the Screening visit until the follow-up visit . Participant has a history of spontaneous, prolonged or severe bleeding of unclear origin . Participant has a history of epilepsy or fits or unexplained black-outs other than vasovagal collapse       .     . "
    },
    "NCT02563535_inc": {
        "Text": "age>18 years. critical limb ischemia (Rutherford class 4-6). angiographic stenosis>50% or occlusion of at least one tibial vessel of at least 40mm for which an interventional treatment is scheduled. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 3 12--*-->18 years",
            "Condition 23 36--*--limb ischemia",
            "Measurement 38 54--*--Rutherford class",
            "Value 55 58--*--4-6",
            "Qualifier 14 22--*--critical",
            "Scope 38 58--*--Rutherford class 4-6",
            "Measurement 61 82--*--angiographic stenosis",
            "Value 82 86--*-->50%",
            "Condition 90 99--*--occlusion",
            "Multiplier 103 115--*--at least one",
            "Qualifier 116 129--*--tibial vessel",
            "Qualifier 133 146--*--at least 40mm",
            "Procedure 160 184--*--interventional treatment",
            "Mood 188 197--*--scheduled"
        ]
    },
    "NCT02877485_inc": {
        "Text": "Age greater than 18. NOSE score greater than 55. Nasal septal deviation on exam. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 19--*--greater than 18",
            "Measurement 21 31--*--NOSE score",
            "Value 32 47--*--greater than 55",
            "Condition 49 71--*--Nasal septal deviation"
        ]
    },
    "NCT02912182_exc": {
        "Annotations": [
            "Condition 0 8--*--tinnitus",
            "Condition 12 24--*--hearing loss",
            "Condition 44 51--*--vertigo",
            "Condition 73 85--*--peptic ulcer",
            "Condition 64 72--*--bleeding",
            "Condition 87 95--*--glaucoma",
            "Pregnancy_considerations 97 182--*--pregnancy or non-acceptance to use anticonception measures during 13 days after debut",
            "Measurement 189 203;209 217--*--blood pressure systolic",
            "Measurement 189 203;224 233--*--blood pressure diastolic",
            "Value 204 208--*-->180",
            "Value 219 222--*--105",
            "Condition 235 247--*--ketoacidosis",
            "Measurement 255 266--*--Base Excess",
            "Value 267 270--*-->=2",
            "Condition 272 288--*--psychic disorder",
            "Negation 290 293--*--not",
            "Condition 304 319--*--mild depression",
            "Condition 330 339--*--infection",
            "Qualifier 322 329--*--serious",
            "Condition 341 352--*--neutropenia",
            "Condition 354 366--*--tuberculosis",
            "Scope 341 367--*--neutropenia, tuberculosis)",
            "Condition 369 383--*--chronic otitis",
            "Condition 396 415--*--vertiginous disease",
            "Condition 417 424--*--M\u00e9ni\u00e8re",
            "Condition 426 446--*--Vertiginous migraine",
            "Condition 448 461--*--atypical BPPV"
        ],
        "Text": "tinnitus or hearing loss with same debut as vertigo. history of bleeding peptic ulcer. glaucoma. pregnancy or non-acceptance to use anticonception measures during 13 days after debut. high blood pressure >180 systolic, 105, diastolic. ketoacidosis with a Base Excess >=2. psychic disorder (not including mild depression). serious infection (neutropenia, tuberculosis). chronic otitis. history of vertiginous disease; M\u00e9ni\u00e8re, Vertiginous migraine, atypical BPPV. "
    },
    "NCT02959801_exc": {
        "Annotations": [
            "Qualifier 12 20--*--subacute",
            "Qualifier 24 31--*--chronic",
            "Condition 32 35--*--DVT",
            "Scope 12 31--*--subacute or chronic",
            "Multiplier 36 65--*--more than 21 days in duration",
            "Condition 67 105--*--inability to lie in the prone position",
            "Non-representable 106 131--*--required for intervention",
            "Condition 133 158--*--terminal systemic disease",
            "Procedure 169 189--*--palliative treatment",
            "Mood 159 168--*--requiring",
            "Qualifier 191 197--*--active",
            "Condition 198 206--*--bleeding",
            "Condition 223 237--*--duodenal ulcer",
            "Condition 215 222;232 237--*--gastric ulcer",
            "Qualifier 245 267--*--cerebrovascular system",
            "Scope 215 267--*--gastric/duodenal ulcer or the cerebrovascular system",
            "Condition 272 291--*--haemorrhagic stroke",
            "Temporal 292 316--*--within the previous year",
            "Condition 321 355--*--impaired bleeding-clotting profile",
            "Condition 365 385--*--haemophilic disorder",
            "Condition 390 399--*--pregnancy"
        ],
        "Text": "presence of subacute or chronic DVT more than 21 days in duration, inability to lie in the prone position required for intervention, terminal systemic disease requiring palliative treatment, active bleeding (from a gastric/duodenal ulcer or the cerebrovascular system), a haemorrhagic stroke within the previous year, an impaired bleeding-clotting profile, and any haemophilic disorder, or pregnancy.. "
    },
    "NCT02257580_exc": {
        "Text": "Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.). History of hypersensitivity to EACA. History of thromboembolic event (e.g., PE or DVT). History of renal insufficiency or failure. Congenital or acquired coagulopathy as evidence by INR >1.4 or PTT > 1.4 times normal, or Platelets <150,000/mm3 on preoperative laboratory testing. Use of hormone replacement therapy or hormonal contraceptive agents within days prior to surgery. Use of acetylsalicylic acid (ASA), antiplatelet agents within 7 days prior to surgery. Pregnant. Breastfeeding. Not received neuraxial anesthesia. ",
        "Annotations": [
            "Temporal 0 12--*--Preoperative",
            "Drug 23 36--*--anticoagulant",
            "Drug 38 44--*--Plavix",
            "Drug 46 54--*--warfarin",
            "Drug 56 63--*--lovenox",
            "Scope 38 63--*--Plavix, warfarin, lovenox",
            "Condition 83 99--*--hypersensitivity",
            "Drug 103 107--*--EACA",
            "Condition 120 140--*--thromboembolic event",
            "Condition 171 190--*--renal insufficiency",
            "Condition 148 150--*--PE",
            "Condition 154 157--*--DVT",
            "Scope 148 157--*--PE or DVT",
            "Condition 171 176;194 201--*--renal failure",
            "Qualifier 203 213--*--Congenital",
            "Qualifier 217 225--*--acquired",
            "Condition 226 238--*--coagulopathy",
            "Scope 203 225--*--Congenital or acquired",
            "Measurement 254 257--*--INR",
            "Value 258 262;276 288--*-->1.4 times normal",
            "Measurement 266 269--*--PTT",
            "Value 270 288--*--> 1.4 times normal",
            "Scope 254 288--*--INR >1.4 or PTT > 1.4 times normal",
            "Measurement 293 302--*--Platelets",
            "Value 303 315--*--<150,000/mm3",
            "Procedure 319 350--*--preoperative laboratory testing",
            "Procedure 359 386--*--hormone replacement therapy",
            "Drug 390 419--*--hormonal contraceptive agents",
            "Temporal 420 448--*--within days prior to surgery",
            "Reference_point 441 448--*--surgery",
            "Scope 359 419--*--hormone replacement therapy or hormonal contraceptive agents",
            "Drug 457 477--*--acetylsalicylic acid",
            "Drug 479 482--*--ASA",
            "Drug 485 504--*--antiplatelet agents",
            "Temporal 505 535--*--within 7 days prior to surgery",
            "Reference_point 528 535--*--surgery",
            "Scope 457 504--*--acetylsalicylic acid (ASA), antiplatelet agents",
            "Condition 537 545--*--Pregnant",
            "Observation 547 560--*--Breastfeeding",
            "Procedure 575 595--*--neuraxial anesthesia",
            "Negation 562 574--*--Not received"
        ]
    },
    "NCT02940912_inc": {
        "Text": "Idiopathic Parkinson's disease ( Hughes AJ et al. 2001). Patients with motor fluctuations. Chronic Insomnia disorder criteria according to the criteria of DMS- V ( American Psychiatric Association, 2013) and insomnia severity index > 15. Able to use independently the device required for treatment by apomorphine. Collection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) .. Affiliate to social security or beneficiary of such a regime. ",
        "Annotations": [
            "Condition 11 30--*--Parkinson's disease",
            "Qualifier 0 10--*--Idiopathic",
            "Condition 71 89--*--motor fluctuations",
            "Condition 91 116--*--Chronic Insomnia disorder",
            "Qualifier 143 161--*--criteria of DMS- V",
            "Measurement 208 231--*--insomnia severity index",
            "Value 232 236--*--> 15",
            "Drug 301 312--*--apomorphine",
            "Device 268 274--*--device",
            "Non-query-able 314 448--*--Collection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) .",
            "Person 450 478--*--Affiliate to social security",
            "Person 463 478;482 493--*--social security beneficiary"
        ]
    },
    "NCT03537924_inc": {
        "Annotations": [
            "Observation 0 7--*--Healthy",
            "Person 8 11--*--men",
            "Person 16 21--*--women",
            "Person 23 26--*--age",
            "Value 27 36--*--40-75 yrs",
            "Negation 38 45--*--without",
            "Condition 46 57--*--any disease",
            "Mood 62 69--*--need of",
            "Drug 70 80--*--medication",
            "Scope 46 80--*--any disease and need of medication",
            "Observation 110 132--*--living at low altitude",
            "Observation 110 119;134 139--*--living at <800m",
            "Informed_consent 143 168--*--Written informed consent.",
            "Person 170 186--*--Kyrgyz ethnicity"
        ],
        "Text": "Healthy men and women, age 40-75 yrs, without any disease and need of medication.. Born, raised and currently living at low altitude (<800m).. Written informed consent.. Kyrgyz ethnicity. "
    },
    "NCT03445949_inc": {
        "Text": "successful left atrial appendage occlusion with Amulet device within 37 days prior to randomization.. treatment with dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) between left atrial appendage closure and randomization. participant's age 18 years or older at the time of signing the informed consent form. participant is willing to follow all study procedures; especially randomized antiplatelet treatment regimen and follow-up visits with transesophageal echocardiography when applicable. participant is willing to sign the study informed consent form. ",
        "Annotations": [
            "Procedure 11 42--*--left atrial appendage occlusion",
            "Qualifier 0 10--*--successful",
            "Device 48 61--*--Amulet device",
            "Temporal 62 99--*--within 37 days prior to randomization",
            "Procedure 117 142--*--dual antiplatelet therapy",
            "Drug 144 155--*--clopidogrel",
            "Drug 160 180--*--acetylsalicylic acid",
            "Scope 144 180--*--clopidogrel and acetylsalicylic acid",
            "Procedure 190 219--*--left atrial appendage closure",
            "Temporal 182 237--*--between left atrial appendage closure and randomization",
            "Reference_point 224 237--*--randomization",
            "Reference_point 190 219--*--left atrial appendage closure",
            "Scope 190 237--*--left atrial appendage closure and randomization",
            "Person 253 256--*--age",
            "Value 257 274--*--18 years or older",
            "Temporal 275 323--*--at the time of signing the informed consent form",
            "Reference_point 290 323--*--signing the informed consent form",
            "Post-eligibility 325 507--*--participant is willing to follow all study procedures; especially randomized antiplatelet treatment regimen and follow-up visits with transesophageal echocardiography when applicable",
            "Informed_consent 509 571--*--participant is willing to sign the study informed consent form"
        ]
    },
    "NCT02634541_inc": {
        "Annotations": [
            "Condition 0 23--*--Axial spondyloarthritis",
            "Qualifier 25 38--*--ASAS criteria",
            "Procedure 44 54--*--radiologic",
            "Condition 55 67--*--sacroiliitis",
            "Procedure 90 93--*--MRI",
            "Procedure 97 102--*--X-ray",
            "Scope 90 102--*--MRI or X-ray"
        ],
        "Text": "Axial spondyloarthritis (ASAS criteria) and radiologic sacroiliitis as detected either by MRI or X-ray.. "
    },
    "NCT02877485_exc": {
        "Text": "Intranasal steroid use within the last three months. Current systemic steroid use. Prior septal surgery. Individuals who are pregnant or actively breastfeeding. ",
        "Annotations": [
            "Procedure 0 22--*--Intranasal steroid use",
            "Temporal 23 51--*--within the last three months",
            "Temporal 53 60--*--Current",
            "Procedure 61 81--*--systemic steroid use",
            "Qualifier 61 69--*--systemic",
            "Drug 70 77--*--steroid",
            "Qualifier 0 10--*--Intranasal",
            "Drug 11 18--*--steroid",
            "Temporal 83 88--*--Prior",
            "Procedure 89 103--*--septal surgery",
            "Condition 125 133--*--pregnant",
            "Temporal 137 145--*--actively",
            "Observation 146 159--*--breastfeeding"
        ]
    },
    "NCT02563535_exc": {
        "Text": "need for major amputation known before intervention. allergy to Paclitaxel. contraindication for combined antiplatelet treatment. life expectancy <1 year. hypersensitivity or contraindication to one of the study drugs. lack of consent. ",
        "Annotations": [
            "Condition 9 25--*--major amputation",
            "Non-representable 26 51--*--known before intervention",
            "Drug 64 74--*--Paclitaxel",
            "Condition 53 60--*--allergy",
            "Condition 76 92--*--contraindication",
            "Procedure 97 128--*--combined antiplatelet treatment",
            "Observation 130 145--*--life expectancy",
            "Value 146 153--*--<1 year",
            "Condition 155 171--*--hypersensitivity",
            "Condition 175 191--*--contraindication",
            "Multiplier 195 201--*--one of",
            "Drug 206 217--*--study drugs",
            "Scope 155 191--*--hypersensitivity or contraindication",
            "Informed_consent 219 234--*--lack of consent"
        ]
    },
    "NCT02260700_inc": {
        "Annotations": [
            "Measurement 0 15--*--Body mass index",
            "Value 75 99--*--between 18 and 30 kg/m^2",
            "Measurement 17 20--*--BMI",
            "Measurement 22 73--*--weight [kilogram(kg)]/height^2 [meter square (m^2)]",
            "Not_a_criteria 17 73--*--BMI; weight [kilogram(kg)]/height^2 [meter square (m^2)]",
            "Procedure 188 208--*--physical examination",
            "Observation 210 225--*--medical history",
            "Measurement 227 238--*--vital signs",
            "Scope 244 275--*--12-lead electrocardiogram (ECG)",
            "Temporal 276 311--*--performed at Screening or admission",
            "Reference_point 289 298--*--Screening",
            "Reference_point 302 311--*--admission",
            "Scope 289 311--*--Screening or admission",
            "Scope 188 275--*--physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG)",
            "Condition 319 336--*--deviations in ECG",
            "Procedure 333 336--*--ECG",
            "Subjective_judgement 338 413--*--which are not considered to be of clinical significance to the investigator",
            "Grammar_Error 415 429--*--are acceptable",
            "Qualifier 338 413--*--which are not considered to be of clinical significance to the investigator",
            "Procedure 458 483--*--clinical laboratory tests",
            "Temporal 484 506--*--performed at Screening",
            "Reference_point 494 506--*--at Screening",
            "Undefined_semantics 458 483--*--clinical laboratory tests",
            "Condition 434 441--*--healthy",
            "Measurement 530 551--*--serum chemistry panel",
            "Measurement 563 576--*--liver enzymes",
            "Measurement 579 589--*--hematology",
            "Procedure 594 604--*--urinalysis",
            "Value 609 643--*--outside the normal reference range",
            "Scope 530 604--*--serum chemistry panel [including liver enzymes], hematology, or urinalysis",
            "Subjective_judgement 686 709--*--the investigator judges",
            "Subjective_judgement 760 786--*--not clinically significant",
            "Not_a_criteria 788 895--*--This determination must be recorded in the participants' source documents and initialed by the investigator",
            "Non-query-able 897 1353--*--Men who are sexually active with a woman of childbearing potential and have not had a vasectomy must agree to use a barrier method of birth control for example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug.",
            "Parsing_Error 1354 1474--*--In addition, their female partners should also use an appropriate method of birth control for at least the same duration",
            "Non-query-able 1354 1474--*--In addition, their female partners should also use an appropriate method of birth control for at least the same duration",
            "Post-eligibility 1476 1664--*--Participants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study",
            "Non-query-able 1476 1664--*--Participants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study"
        ],
        "Text": "Body mass index (BMI; weight [kilogram(kg)]/height^2 [meter square (m^2)]) between 18 and 30 kg/m^2, (inclusive) . Be healthy for their age group with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at Screening or admission. Minor deviations in ECG, which are not considered to be of clinical significance to the investigator, are acceptable . Be healthy on the basis of clinical laboratory tests performed at Screening. If the results of the serum chemistry panel [including liver enzymes], hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participants' source documents and initialed by the investigator . Men who are sexually active with a woman of childbearing potential and have not had a vasectomy must agree to use a barrier method of birth control for example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partners should also use an appropriate method of birth control for at least the same duration . Participants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study . "
    },
    "NCT02912182_inc": {
        "Annotations": [
            "Condition 20 34--*--vestibulopathy",
            "Qualifier 9 19--*--unilateral",
            "Negation 36 38--*--no",
            "Condition 52 57--*--HINTS",
            "Qualifier 39 51--*--pathological",
            "Condition 83 108--*--acute vestibular syndrome",
            "Post-eligibility 111 148--*--capable of making their own decisions"
        ],
        "Text": "definite unilateral vestibulopathy. no pathological HINTS (examination criteria in acute vestibular syndrome). capable of making their own decisions. "
    },
    "NCT03097068_exc": {
        "Annotations": [
            "Drug 11 50--*--anti-vascular endothelial growth factor",
            "Temporal 61 82--*--in the past 12 months",
            "Condition 88 110--*--diabetic macular edema",
            "Procedure 111 120--*--treatment",
            "Temporal 121 141--*--in the past 4 months",
            "Condition 143 155--*--Heart attack",
            "Condition 157 163--*--stroke",
            "Condition 165 190--*--transient ischemic attack",
            "Condition 194 224--*--acute congestive heart failure",
            "Temporal 225 240--*--within 4 months"
        ],
        "Text": "History of anti-vascular endothelial growth factor treatment in the past 12 months. Any diabetic macular edema treatment in the past 4 months. Heart attack, stroke, transient ischemic attack or acute congestive heart failure within 4 months. "
    },
    "NCT03624517_exc": {
        "Text": "Known upper gastrointestinal malignancy. Bleeding from gastric varices, with or without esophageal varices. Use of any other endoscopic method to stop GI bleeding beyond endoscopic band ligation. Variceal bleeding in the last 90 days. History of transjugular, intrahepatic, portosystemic shunt (TIPS) or vascular decompression surgery. Pregnant females. Incarcerated individuals. Myocardial infarct, cerebrovascular accident, sepsis, respiratory failure, or severe intercurrent illness within the previous 6 weeks. Non-cirrhotic portal hypertension causing esophageal varices. Known or suspected allergy to octreotide. ",
        "Annotations": [
            "Condition 6 39--*--upper gastrointestinal malignancy",
            "Condition 41 49--*--Bleeding",
            "Condition 55 70--*--gastric varices",
            "Condition 88 106--*--esophageal varices",
            "Negation 115 124--*--any other",
            "Procedure 125 142--*--endoscopic method",
            "Condition 151 162--*--GI bleeding",
            "Procedure 170 194--*--endoscopic band ligation",
            "Condition 196 213--*--Variceal bleeding",
            "Temporal 214 233--*--in the last 90 days",
            "Procedure 246 300--*--transjugular, intrahepatic, portosystemic shunt (TIPS)",
            "Procedure 304 334--*--vascular decompression surgery",
            "Observation 235 242--*--History",
            "Scope 246 334--*--transjugular, intrahepatic, portosystemic shunt (TIPS) or vascular decompression surgery",
            "Person 345 352--*--females",
            "Condition 336 344--*--Pregnant",
            "Person 354 378--*--Incarcerated individuals",
            "Condition 380 398--*--Myocardial infarct",
            "Condition 400 424--*--cerebrovascular accident",
            "Condition 426 432--*--sepsis",
            "Condition 434 453--*--respiratory failure",
            "Qualifier 458 464--*--severe",
            "Condition 465 485--*--intercurrent illness",
            "Temporal 486 513--*--within the previous 6 weeks",
            "Scope 380 485--*--Myocardial infarct, cerebrovascular accident, sepsis, respiratory failure, or severe intercurrent illness",
            "Condition 515 548--*--Non-cirrhotic portal hypertension",
            "Condition 557 575--*--esophageal varices",
            "Condition 596 603--*--allergy",
            "Mood 586 595--*--suspected",
            "Mood 577 582--*--Known",
            "Scope 577 595--*--Known or suspected",
            "Drug 607 617--*--octreotide"
        ]
    },
    "NCT02406495_exc": {
        "Text": "Is not a habitual wearer of Avaira sphere lenses . Has a CL prescription outside the range of the available parameters of the study lenses. . Has a spectacle cylinder \u22651.00D of cylinder in either eye. . Has a history of not achieving comfortable CL wear (5 days per week; > 8 hours/day) . Has contact lens best corrected distance vision worse than 20/25 (0.10 logMAR) in either eye. . Presence of clinically significant (grade 2-4) anterior segment abnormalities . Presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. . Slit lamp findings that would contraindicate contact lens wear such as: . Pathological dry eye or associated findings . Pterygium, pinguecula, or corneal scars within the visual axis . Neovascularization > 0.75 mm in from of the limbus . Giant papillary conjunctivitis (GCP) worse than grade 1 . Anterior uveitis or iritis (past or present) . Seborrheic eczema, Seborrheic conjunctivitis . History of corneal ulcers or fungal infections . Poor personal hygiene . Has a known history of corneal hypoesthesia (reduced corneal sensitivity) . Has aphakia, keratoconus or a highly irregular cornea. . Has Presbyopia or has dependence on spectacles for near work over the contact lenses. . Has undergone corneal refractive surgery. . Is participating in any other type of eye related clinical or research study       .     . ",
        "Annotations": [
            "Device 28 48--*--Avaira sphere lenses",
            "Device 56 71--*--CL prescription",
            "Context_Error 72 137--*--outside the range of the available parameters of the study lenses",
            "Non-query-able 72 137--*--outside the range of the available parameters of the study lenses",
            "Qualifier 72 137--*--outside the range of the available parameters of the study lenses",
            "Device 146 164--*--spectacle cylinder",
            "Value 165 171--*--\u22651.00D",
            "Observation 206 213--*--history",
            "Condition 231 250--*--comfortable CL wear",
            "Negation 217 220--*--not",
            "Temporal 252 267--*--5 days per week",
            "Temporal 269 282--*--> 8 hours/day",
            "Measurement 289 332--*--contact lens best corrected distance vision",
            "Value 333 349;364 377--*--worse than 20/25 in either eye",
            "Value 333 343;351 362;364 377--*--worse than 0.10 logMAR in either eye",
            "Scope 333 377--*--worse than 20/25 (0.10 logMAR) in either eye",
            "Qualifier 392 414--*--clinically significant",
            "Subjective_judgement 392 414--*--clinically significant",
            "Qualifier 416 425--*--grade 2-4",
            "Value 422 425--*--2-4",
            "Condition 427 457--*--anterior segment abnormalities",
            "Context_Error 427 457--*--anterior segment abnormalities",
            "Condition 481 497--*--systemic disease",
            "Condition 471 477;490 497--*--ocular disease",
            "Condition 501 520--*--need of medications",
            "Undefined_semantics 501 520--*--need of medications",
            "Subjective_judgement 501 520--*--need of medications",
            "Undefined_semantics 471 497--*--ocular or systemic disease",
            "Qualifier 527 565--*--might interfere with contact lens wear",
            "Subjective_judgement 527 565--*--might interfere with contact lens wear",
            "Scope 471 520--*--ocular or systemic disease or need of medications",
            "Procedure 568 577--*--Slit lamp",
            "Value 578 586--*--findings",
            "Undefined_semantics 578 586--*--findings",
            "Condition 598 625--*--contraindicate contact lens",
            "Undefined_semantics 598 625--*--contraindicate contact lens",
            "Parsing_Error 568 639--*--Slit lamp findings that would contraindicate contact lens wear such as:",
            "Condition 641 661--*--Pathological dry eye",
            "Condition 665 684--*--associated findings",
            "Condition 686 695--*--Pterygium",
            "Condition 697 707--*--pinguecula",
            "Condition 712 725--*--corneal scars",
            "Qualifier 726 748--*--within the visual axis",
            "Condition 750 768--*--Neovascularization",
            "Value 769 800--*--> 0.75 mm in from of the limbus",
            "Condition 802 838--*--Giant papillary conjunctivitis (GCP)",
            "Qualifier 839 857--*--worse than grade 1",
            "Condition 859 875--*--Anterior uveitis",
            "Condition 879 885--*--iritis",
            "Temporal 887 891--*--past",
            "Temporal 895 902--*--present",
            "Scope 887 902--*--past or present",
            "Scope 859 885--*--Anterior uveitis or iritis",
            "Condition 905 922--*--Seborrheic eczema",
            "Condition 924 949--*--Seborrheic conjunctivitis",
            "Condition 962 976--*--corneal ulcers",
            "Condition 980 997--*--fungal infections",
            "Observation 951 958--*--History",
            "Condition 999 1020--*--Poor personal hygiene",
            "Condition 1045 1065--*--corneal hypoesthesia",
            "Condition 1067 1094--*--reduced corneal sensitivity",
            "Observation 1034 1041--*--history",
            "Condition 1101 1108--*--aphakia",
            "Condition 1110 1121--*--keratoconus",
            "Condition 1127 1150--*--highly irregular cornea",
            "Condition 1157 1167--*--Presbyopia",
            "Condition 1175 1213--*--dependence on spectacles for near work",
            "Procedure 1254 1280--*--corneal refractive surgery",
            "Non-query-able 1283 1359--*--Is participating in any other type of eye related clinical or research study"
        ]
    },
    "NCT03029078_exc": {
        "Text": "Pregnant woman or breastfeeding. immunosuppression including AIDS, corticosteroids over 60mg/day. ongoing antibiotic treatment at the day of inclusion. impossibility to obtain a signed consent form.. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--woman",
            "Observation 18 31--*--breastfeeding",
            "Condition 33 50--*--immunosuppression",
            "Condition 61 65--*--AIDS",
            "Drug 67 82--*--corticosteroids",
            "Multiplier 83 96--*--over 60mg/day",
            "Scope 61 96--*--AIDS, corticosteroids over 60mg/day",
            "Procedure 117 126--*--treatment",
            "Drug 106 116--*--antibiotic",
            "Temporal 127 150--*--at the day of inclusion",
            "Observation 178 197--*--signed consent form",
            "Condition 152 175--*--impossibility to obtain",
            "Reference_point 134 150--*--day of inclusion"
        ]
    },
    "NCT03648021_inc": {
        "Text": "18-year or older patients. Patient hospitalized in neuro-critical care for:. Arachnoid hemorrhage. Intra parenchymatous hematoma. stroke. Acute brain Severe injury. Post-operative complication of an act of neurosurgery or programmed neuroradiology. Sedation and mechanical ventilation planned > 2 days. Monitoring of intracranial temperature and pressure by intraparenchymal sensor (Sophysa\u00ae). Brain temperature > 38.5\u00b0C for more than 30 minutes. ",
        "Annotations": [
            "Value 0 16--*--18-year or older",
            "Person 11 14--*--old",
            "Visit 35 47--*--hospitalized",
            "Visit 51 70--*--neuro-critical care",
            "Condition 77 97--*--Arachnoid hemorrhage",
            "Qualifier 99 119--*--Intra parenchymatous",
            "Condition 120 128--*--hematoma",
            "Condition 130 136--*--stroke",
            "Condition 138 163--*--Acute brain Severe injury",
            "Condition 165 192--*--Post-operative complication",
            "Procedure 206 218--*--neurosurgery",
            "Qualifier 193 218--*--of an act of neurosurgery",
            "Procedure 233 247--*--neuroradiology",
            "Qualifier 193 205;222 247--*--of an act of programmed neuroradiology",
            "Scope 193 247--*--of an act of neurosurgery or programmed neuroradiology",
            "Procedure 262 284--*--mechanical ventilation",
            "Procedure 249 257--*--Sedation",
            "Temporal 293 301--*--> 2 days",
            "Mood 285 292--*--planned",
            "Scope 249 284--*--Sedation and mechanical ventilation",
            "Measurement 317 341--*--intracranial temperature",
            "Measurement 317 329;346 354--*--intracranial pressure",
            "Device 358 381--*--intraparenchymal sensor",
            "Device 383 391--*--Sophysa\u00ae",
            "Scope 358 392--*--intraparenchymal sensor (Sophysa\u00ae)",
            "Scope 317 354--*--intracranial temperature and pressure",
            "Measurement 394 411--*--Brain temperature",
            "Value 412 420--*--> 38.5\u00b0C",
            "Temporal 421 445--*--for more than 30 minutes"
        ]
    },
    "NCT02543710_inc": {
        "Text": "All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.. Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.. Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.. ",
        "Annotations": [
            "Visit 27 56--*--participating research centre",
            "Mood 62 74--*--suspicion of",
            "Qualifier 78 87--*--confirmed",
            "Condition 88 106--*--endometrial cancer",
            "Scope 62 87--*--suspicion of or confirmed",
            "Condition 138 163--*--epithelial ovarian cancer",
            "Condition 123 134;149 163--*--endometrial ovarian cancer",
            "Multiplier 218 224--*--weekly",
            "Drug 225 231--*--taxane",
            "Drug 233 243--*--paclitaxel",
            "Procedure 245 254--*--treatment",
            "Non-representable 256 345--*--This will often be a third or fourth line treatment, i.e. patients with advanced disease.",
            "Procedure 385 398--*--tissue biopsy",
            "Mood 347 378--*--Technical possibility to obtain",
            "Condition 434 451--*--tumour recurrence"
        ]
    },
    "NCT01175044_exc": {
        "Annotations": [
            "Post-eligibility 0 132--*--Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).",
            "Person 134 137--*--Age",
            "Value 138 142--*--= 17",
            "Condition 145 152--*--Allergy",
            "Drug 156 171--*--povidone iodine",
            "Procedure 198 209--*--antibiotics",
            "Temporal 210 247--*--14 days prior to arriving for surgery",
            "Reference_point 227 247--*--arriving for surgery",
            "Procedure 240 247--*--surgery",
            "Condition 272 289--*--immunosuppression",
            "Qualifier 264 271--*--chronic",
            "Condition 299 307--*--HIV/AIDS",
            "Post-eligibility 311 364--*--Unable to adhere to follow up schedule and treatment.",
            "Procedure 396 428--*--revision total knee arthroplasty",
            "Condition 433 451--*--infectious reasons"
        ],
        "Text": "Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).. Age = 17.. Allergy to povidone iodine.. Any condition requiring antibiotics 14 days prior to arriving for surgery.. Patients with chronic immunosuppression (such as HIV/AIDS).. Unable to adhere to follow up schedule and treatment.. Patients scheduled to undergo revision total knee arthroplasty for infectious reasons.. "
    },
    "NCT02701881_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--19 years of older",
            "Qualifier 23 31--*--Moderate",
            "Qualifier 35 41--*--severe",
            "Condition 42 54--*--claudication",
            "Measurement 56 75--*--Rutherford category",
            "Value 76 82--*--2 or 3",
            "Scope 23 41--*--Moderate or severe",
            "Qualifier 85 93--*--Critical",
            "Condition 94 107--*--limb ischemia",
            "Measurement 109 128--*--Rutherford category",
            "Value 129 135--*--4 or 5",
            "Non-query-able 138 175--*--Patients with signed informed consent",
            "Condition 177 190--*--Target lesion",
            "Measurement 191 197--*--length",
            "Value 198 205--*--=150 mm",
            "Procedure 209 221--*--angiographic",
            "Condition 234 242--*--Stenosis",
            "Value 246 259--*--more than 50%",
            "Qualifier 263 285--*--femoropopliteal artery",
            "Multiplier 287 299--*--At least one",
            "Condition 300 306;339 366--*--patent tibioperoneal runoff vessel"
        ],
        "Text": "Age 19 years of older. Moderate or severe claudication (Rutherford category 2 or 3). Critical limb ischemia (Rutherford category 4 or 5). Patients with signed informed consent. Target lesion length =150 mm by angiographic estimation. Stenosis of more than 50% in femoropopliteal artery. At least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.. "
    },
    "NCT03097068_inc": {
        "Annotations": [
            "Condition 13 30--*--diabetes mellitus",
            "Measurement 32 60--*--Best corrected visual acuity",
            "Value 61 75--*--20/32 - 20/320",
            "Condition 77 99--*--Diabetic macular edema",
            "Qualifier 114 134--*--center of the macula",
            "Measurement 136 191--*--Optical coherence tomography central subfield thickness",
            "Value 195 215--*--at least 250 microns"
        ],
        "Text": "Diagnosis of diabetes mellitus. Best corrected visual acuity 20/32 - 20/320. Diabetic macular edema involving the center of the macula. Optical coherence tomography central subfield thickness of at least 250 microns. "
    },
    "NCT02406495_inc": {
        "Text": "Is between 18 and 40 years of age (inclusive) . Has had a self-reported visual exam in the last two years . Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) . Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) . Has a spectacle cylinder up to 0.75D in each eye. . Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. . Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. . Has clear corneas and no active ocular disease . Has read, understood and signed the information consent letter. . Patient contact lens refraction should fit within the available parameters of the study lenses. . Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). . Is willing to comply with the visit schedule . ",
        "Annotations": [
            "Value 3 26;34 45--*--between 18 and 40 years (inclusive)",
            "Person 30 33--*--age",
            "Procedure 57 82--*--self-reported visual exam",
            "Temporal 83 104--*--in the last two years",
            "Device 120 146--*--Avaira sphere contact lens",
            "Temporal 155 187--*--at least 1 week in Avaira sphere",
            "Reference_point 174 187--*--Avaira sphere",
            "Device 174 187--*--Avaira sphere",
            "Device 196 208--*--contact lens",
            "Value 240 268--*--+ 2.25 to - 8.00 (inclusive)",
            "Qualifier 209 218--*--spherical",
            "Device 276 294--*--spectacle cylinder",
            "Value 295 306--*--up to 0.75D",
            "Measurement 333 380--*--best corrected spectacle distance visual acuity",
            "Value 384 389;404 413--*--20/25 or better",
            "Value 391 402;404 413--*--0.10 logMAR or better",
            "Measurement 442 464--*--distance visual acuity",
            "Value 468 473;488 497--*--20/30 or better",
            "Value 475 486;488 497--*--0.18 logMAR or better",
            "Device 519 539--*--study contact lenses",
            "Condition 546 559--*--clear corneas",
            "Condition 574 588--*--ocular disease",
            "Negation 564 566--*--no",
            "Temporal 567 573--*--active",
            "Post-eligibility 590 653--*--Has read, understood and signed the information consent letter.",
            "Non-query-able 590 653--*--Has read, understood and signed the information consent letter.",
            "Non-query-able 655 750--*--Patient contact lens refraction should fit within the available parameters of the study lenses.",
            "Context_Error 655 750--*--Patient contact lens refraction should fit within the available parameters of the study lenses.",
            "Non-query-able 752 891--*--Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so).",
            "Non-query-able 893 937--*--Is willing to comply with the visit schedule",
            "Post-eligibility 893 937--*--Is willing to comply with the visit schedule",
            "Post-eligibility 752 891--*--Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so)."
        ]
    },
    "NCT03624517_inc": {
        "Text": "Adult males and females who are 18 years of age or older.. Evidence or suspicion of upper gastrointestinal bleed (GIB). Patient with known or suspected cirrhosis. Upper GIB secondary to bleeding esophageal varices as show by esophageal endoscopy, requiring endoscopic band ligation (EBL) at presentation. Willing and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do so. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 6 11--*--males",
            "Person 16 23--*--females",
            "Value 32 56--*--18 years of age or older",
            "Mood 71 80--*--suspicion",
            "Mood 59 67--*--Evidence",
            "Condition 84 118--*--upper gastrointestinal bleed (GIB)",
            "Scope 59 80--*--Evidence or suspicion",
            "Mood 142 151--*--suspected",
            "Mood 133 138--*--known",
            "Condition 152 161--*--cirrhosis",
            "Scope 133 151--*--known or suspected",
            "Condition 163 172--*--Upper GIB",
            "Qualifier 173 182--*--secondary",
            "Qualifier 186 194--*--bleeding",
            "Condition 195 213--*--esophageal varices",
            "Procedure 225 245--*--esophageal endoscopy",
            "Mood 247 256--*--requiring",
            "Procedure 257 287--*--endoscopic band ligation (EBL)",
            "Temporal 288 303--*--at presentation",
            "Informed_consent 305 460--*--Willing and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do so"
        ]
    },
    "NCT03648021_exc": {
        "Text": "Known hypersensitivity to paracetamol or mannitol (excipient with known effect). Severe hepatocellular insufficiency (ASAT or ALAT > 5N, or bilirubin > 2N). Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique) that may influence temperature in the last 6 hours.. Pregnant or breastfeeding women. Previous participation in this study. ",
        "Annotations": [
            "Condition 6 22--*--hypersensitivity",
            "Drug 26 37--*--paracetamol",
            "Drug 41 49--*--mannitol",
            "Non-representable 50 79--*--(excipient with known effect)",
            "Scope 26 49--*--paracetamol or mannitol",
            "Condition 88 116--*--hepatocellular insufficiency",
            "Measurement 118 122--*--ASAT",
            "Measurement 126 130--*--ALAT",
            "Value 131 135--*--> 5N",
            "Measurement 140 149--*--bilirubin",
            "Value 150 154--*--> 2N",
            "Scope 118 154--*--ASAT or ALAT > 5N, or bilirubin > 2N",
            "Procedure 157 185--*--Pharmacological intervention",
            "Drug 157 172--*--Pharmacological",
            "Drug 205 220--*--corticosteroids",
            "Drug 222 228--*--NSAIDs",
            "Drug 232 243--*--paracetamol",
            "Scope 205 243--*--corticosteroids, NSAIDs or paracetamol",
            "Procedure 248 269--*--physical intervention",
            "Procedure 271 297--*--external cooling technique",
            "Qualifier 299 329--*--that may influence temperature",
            "Temporal 330 349--*--in the last 6 hours",
            "Scope 157 298--*--Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique)",
            "Measurement 318 329--*--temperature",
            "Condition 352 360--*--Pregnant",
            "Observation 364 377--*--breastfeeding",
            "Person 378 383--*--women",
            "Competing_trial 385 421--*--Previous participation in this study"
        ]
    },
    "NCT02543710_exc": {
        "Text": "Patients who will not get surgical treatment for their endometrial cancer. Patients not suffering from endometrial or epithelial ovarian cancer. Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre. Patients who cannot or do not want to give informed consent (including language barriers). ",
        "Annotations": [
            "Negation 18 21--*--not",
            "Procedure 26 44--*--surgical treatment",
            "Condition 55 73--*--endometrial cancer",
            "Condition 118 143--*--epithelial ovarian cancer",
            "Condition 103 114;129 143--*--endometrial ovarian cancer",
            "Negation 84 87--*--not",
            "Scope 103 143--*--endometrial or epithelial ovarian cancer",
            "Negation 161 164--*--not",
            "Observation 165 196--*--agree to the proposed treatment",
            "Visit 242 266--*--non-participating centre",
            "Procedure 227 236--*--treatment",
            "Observation 306 327--*--give informed consent",
            "Negation 281 287--*--cannot",
            "Negation 291 305--*--do not want to",
            "Scope 281 305--*--cannot or do not want to",
            "Observation 339 356--*--language barriers"
        ]
    },
    "NCT03029078_inc": {
        "Text": "Patient harboring a GRE or CRE bacteria. Colonization confirmed by our microbiology department, including at least 3 positives swabs in the last month. ",
        "Annotations": [
            "Condition 27 39--*--CRE bacteria",
            "Condition 20 23;31 39--*--GRE bacteria",
            "Multiplier 106 116--*--at least 3",
            "Value 117 126--*--positives",
            "Procedure 127 132--*--swabs",
            "Temporal 133 149--*--in the last mont",
            "Condition 41 53--*--Colonization",
            "Qualifier 54 94--*--confirmed by our microbiology department"
        ]
    },
    "NCT02701881_exc": {
        "Annotations": [
            "Temporal 0 5--*--Acute",
            "Qualifier 6 14--*--critical",
            "Condition 15 28--*--limb ischemia",
            "Qualifier 30 36--*--Severe",
            "Qualifier 37 45--*--critical",
            "Condition 46 59--*--limb ischemia",
            "Measurement 61 80--*--Rutherford category",
            "Value 81 82--*--6",
            "Scope 30 45--*--Severe critical",
            "Condition 85 107--*--Major bleeding history",
            "Temporal 108 129--*--within prior 2 months",
            "Condition 137 153--*--hypersensitivity",
            "Condition 157 173--*--contraindication",
            "Drug 211 218--*--heparin",
            "Drug 220 227--*--aspirin",
            "Drug 229 240--*--clopidogrel",
            "Drug 244 259--*--contrast agents",
            "Scope 211 259--*--heparin, aspirin, clopidogrel or contrast agents",
            "Scope 137 173--*--hypersensitivity or contraindication",
            "Person 261 264--*--Age",
            "Value 265 275--*--> 85 years",
            "Qualifier 277 283--*--Severe",
            "Condition 284 303--*--hepatic dysfunction",
            "Non-representable 304 339--*--(> 3 times normal reference values)",
            "Qualifier 341 352--*--Significant",
            "Condition 353 370--*--renal dysfunction",
            "Measurement 372 388--*--Serum creatinine",
            "Value 389 400--*--> 2.0 mg/dl",
            "Condition 414 424--*--leucopenia",
            "Condition 426 437--*--neutropenia",
            "Condition 439 455--*--thrombocytopenia",
            "Condition 457 463--*--anemia",
            "Condition 474 492--*--bleeding diathesis",
            "Qualifier 402 413--*--Significant",
            "Scope 414 492--*--leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis",
            "Measurement 494 498--*--LVEF",
            "Value 499 503--*--<40%",
            "Qualifier 507 523--*--clinically overt",
            "Condition 524 548--*--congestive heart failure",
            "Condition 550 558--*--Pregnant",
            "Person 568 573--*--women",
            "Person 559 564--*--women",
            "Condition 579 601--*--potential childbearing",
            "Observation 603 618--*--Life expectancy",
            "Value 619 626--*--<1 year",
            "Condition 634 645--*--comorbidity",
            "Procedure 656 670--*--bypass surgery",
            "Temporal 647 655--*--Previous",
            "Device 674 716--*--stenting of the superficial femoral artery",
            "Qualifier 718 727--*--Untreated",
            "Condition 728 742--*--inflow disease",
            "Qualifier 750 777--*--ipsilateral pelvic arteries",
            "Value 779 792--*--more than 50%",
            "Condition 792 800--*--stenosis",
            "Value 807 816--*--occlusion",
            "Scope 779 792;804 816--*--more than 50% or occlusion",
            "Condition 818 843--*--Popliteal artery stenosis",
            "Value 844 848--*-->50%",
            "Qualifier 852 868--*--P2 or P3 segment"
        ],
        "Text": "Acute critical limb ischemia. Severe critical limb ischemia (Rutherford category 6). Major bleeding history within prior 2 months. Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel or contrast agents. Age > 85 years. Severe hepatic dysfunction (> 3 times normal reference values). Significant renal dysfunction (Serum creatinine > 2.0 mg/dl. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis. LVEF <40% or clinically overt congestive heart failure. Pregnant women or women with potential childbearing. Life expectancy <1 year due to comorbidity. Previous bypass surgery or stenting of the superficial femoral artery. Untreated inflow disease of the ipsilateral pelvic arteries (more than 50%stenosis or or occlusion. Popliteal artery stenosis >50% at P2 or P3 segment. "
    },
    "NCT01175044_inc": {
        "Annotations": [
            "Procedure 21 53--*--revision total knee arthroplasty"
        ],
        "Text": "Scheduled to undergo revision total knee arthroplasty. "
    },
    "NCT01711801_inc": {
        "Text": "Healthy male volunteers, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis . Body mass index (BMI) 18 to 30 kg/m2 inclusive . Male subjects (whether surgically sterilized or not) with female partners of child-bearing potential must use two forms of contraception, one of which must be a barrier method, for the duration of the study and for 77 days after the last dose . ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 8 12--*--male",
            "Value 25 39;46 57--*--18 to 45 years , inclusive",
            "Person 43 46--*--age",
            "Negation 88 95--*--absence",
            "Observation 99 140--*--evidence of any active or chronic disease",
            "Observation 162 169;183 190--*--medical history",
            "Observation 174 190--*--surgical history",
            "Procedure 203 223--*--physical examination",
            "Procedure 234 245--*--vital signs",
            "Procedure 247 258--*--12-lead ECG",
            "Procedure 260 270--*--hematology",
            "Procedure 272 287--*--blood chemistry",
            "Procedure 289 297--*--serology",
            "Procedure 302 312--*--urinalysis",
            "Scope 88 312--*--absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis",
            "Measurement 314 335--*--Body mass index (BMI)",
            "Value 336 360--*--18 to 30 kg/m2 inclusive",
            "Person 362 366--*--Male",
            "Condition 385 406--*--surgically sterilized",
            "Condition 385 406--*--surgically sterilized",
            "Negation 410 413--*--not",
            "Person 420 426--*--female",
            "Condition 439 462--*--child-bearing potential",
            "Multiplier 472 475--*--two",
            "Device 476 498--*--forms of contraception",
            "Undefined_semantics 476 498--*--forms of contraception",
            "Device 523 537--*--barrier method",
            "Temporal 539 568--*--for the duration of the study",
            "Temporal 573 604--*--for 77 days after the last dose",
            "Reference_point 591 604--*--the last dose",
            "Reference_point 559 568--*--the study"
        ]
    },
    "NCT02247128_exc": {
        "Annotations": [
            "Mood 0 8--*--Need for",
            "Procedure 9 39--*--long-term oral anticoagulation",
            "Device 42 60--*--Drug-eluting stent",
            "Procedure 61 73--*--implantation",
            "Temporal 74 113--*--within 3 months prior to TAVI procedure",
            "Reference_point 99 113--*--TAVI procedure",
            "Procedure 99 113--*--TAVI procedure",
            "Device 116 132--*--Bare-metal stent",
            "Procedure 133 145--*--implantation",
            "Temporal 146 184--*--within 1 month prior to TAVI procedure",
            "Procedure 170 184--*--TAVI procedure",
            "Reference_point 170 184--*--TAVI procedure",
            "Condition 187 194--*--Allergy",
            "Condition 198 209--*--intolerance",
            "Drug 213 220--*--aspirin",
            "Drug 224 235--*--clopidogrel",
            "Scope 187 209--*--Allergy or intolerance",
            "Scope 213 235--*--aspirin or clopidogrel",
            "Device 238 256--*--Drug-eluting stent",
            "Procedure 257 269--*--implantation",
            "Temporal 270 309--*--within 3 months prior to TAVI procedure",
            "Reference_point 295 309--*--TAVI procedure",
            "Procedure 295 309--*--TAVI procedure",
            "Device 312 328--*--Bare-metal stent",
            "Procedure 329 341--*--implantation",
            "Temporal 342 380--*--within 1 month prior to TAVI procedure",
            "Reference_point 366 380--*--TAVI procedure",
            "Procedure 366 380--*--TAVI procedure",
            "Condition 383 390--*--Allergy",
            "Condition 394 405--*--intolerance",
            "Drug 409 415--*--(N)OAC",
            "Drug 419 430--*--clopidogrel",
            "Scope 383 405--*--Allergy or intolerance",
            "Scope 409 430--*--(N)OAC or clopidogrel"
        ],
        "Text": "Need for long-term oral anticoagulation;. Drug-eluting stent implantation within 3 months prior to TAVI procedure;. Bare-metal stent implantation within 1 month prior to TAVI procedure;. Allergy or intolerance to aspirin or clopidogrel.. Drug-eluting stent implantation within 3 months prior to TAVI procedure;. Bare-metal stent implantation within 1 month prior to TAVI procedure;. Allergy or intolerance to (N)OAC or clopidogrel.. "
    },
    "NCT02624908_inc": {
        "Text": "use of basal-bolus insulin. onset of diabetes after age 30. BMI less than 35. eGFR at least 60 ml/mn. Hb A1c 7.0-10.0%. willingness to perform home glucose monitoring. willingness to transmit glucose and medication information weekly. ",
        "Annotations": [
            "Drug 7 26--*--basal-bolus insulin",
            "Measurement 28 45--*--onset of diabetes",
            "Value 46 58--*--after age 30",
            "Measurement 60 63--*--BMI",
            "Value 64 76--*--less than 35",
            "Measurement 78 82--*--eGFR",
            "Value 83 100--*--at least 60 ml/mn",
            "Measurement 102 108--*--Hb A1c",
            "Value 109 118--*--7.0-10.0%",
            "Non-query-able 120 166--*--willingness to perform home glucose monitoring",
            "Non-query-able 168 233--*--willingness to transmit glucose and medication information weekly"
        ]
    },
    "NCT02156999_inc": {
        "Annotations": [
            "Condition 0 12--*--Osteoporosis"
        ],
        "Text": "Osteoporosis. "
    },
    "NCT01446094_exc": {
        "Annotations": [
            "Informed_consent 0 34--*--Inability to give informed consent",
            "Condition 45 54--*--pregnancy",
            "Mood 36 44--*--Possible",
            "Procedure 69 79--*--urine test",
            "Value 56 65--*--confirmed",
            "Person 82 87--*--Women",
            "Observation 96 109--*--breastfeeding",
            "Qualifier 111 117--*--Severe",
            "Condition 118 132--*--claustrophobia",
            "Condition 134 155--*--Inability to lie flat",
            "Qualifier 160 173--*--20-30 minutes",
            "Qualifier 191 235--*--amount of time to complete the MRI procedure",
            "Device 255 272--*--cochlear implants",
            "Device 310 324--*--aneurysm clips",
            "Qualifier 295 309--*--MRI compatible",
            "Negation 291 294--*--non",
            "Non-representable 326 380--*--Potential contraindications to regadenoson use due to:",
            "Drug 420 464--*--Gadolinium (Gd) based contrast agents (GBCA)",
            "Condition 382 398--*--Contraindication"
        ],
        "Text": "Inability to give informed consent. Possible pregnancy (confirmed by urine test). Women who are breastfeeding. Severe claustrophobia. Inability to lie flat for 20-30 minutes (the anticipated amount of time to complete the MRI procedure). Individuals with cochlear implants. Individuals with non-MRI compatible aneurysm clips. Potential contraindications to regadenoson use due to:. Contraindication to administration of Gadolinium (Gd) based contrast agents (GBCA):. "
    },
    "NCT02526823_exc": {
        "Text": "Patients with severe complications or severe infection;. Invasion of central nervous system;. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;. Patients participate in other clinical studies;. Other patients who are not suitable for the study.. ",
        "Annotations": [
            "Condition 21 34--*--complications",
            "Qualifier 14 20--*--severe",
            "Qualifier 38 44--*--severe",
            "Condition 45 54--*--infection",
            "Condition 57 65--*--Invasion",
            "Qualifier 69 91--*--central nervous system",
            "Condition 115 128--*--heart disease",
            "Qualifier 108 114--*--severe",
            "Condition 148 171--*--ventricular tachycardia",
            "Condition 173 175--*--VT",
            "Condition 178 197--*--atrial fibrillation",
            "Condition 199 201--*--AF",
            "Condition 204 215--*--heart block",
            "Condition 217 238--*--myocardial infarction",
            "Condition 240 242--*--MI",
            "Condition 245 269--*--congestive heart failure",
            "Condition 271 274--*--CHF",
            "Condition 277 299--*--coronary heart disease",
            "Scope 148 299--*--ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease",
            "Condition 347 355--*--allergic",
            "Qualifier 340 346--*--severe",
            "Condition 387 395--*--allergic",
            "Condition 402 412--*--intolerant",
            "Procedure 436 457--*--chemotherapy regimens",
            "Scope 387 412--*--allergic to or intolerant",
            "Qualifier 464 469--*--other",
            "Condition 470 486--*--malignant tumors",
            "Temporal 494 506--*--past 5 years",
            "Drug 527 538--*--doxorubicin",
            "Drug 573 583--*--adriamycin",
            "Multiplier 588 607--*--more than 300 mg/m2",
            "Qualifier 548 569--*--total cumulative dose",
            "Drug 0 8--*--Patients",
            "Drug 634 644--*--epirubicin",
            "Qualifier 609 630--*--total cumulative dose",
            "Multiplier 649 668--*--more than 450 mg/m2",
            "Competing_trial 671 717--*--Patients participate in other clinical studies",
            "Non-query-able 720 769--*--Other patients who are not suitable for the study"
        ]
    },
    "NCT02849483_inc": {
        "Annotations": [
            "Person 13 16--*--age",
            "Value 0 9--*--20-70 yrs",
            "Measurement 18 21;61 82--*--ASA physical status class",
            "Measurement 22 59--*--American Society of Anesthesiologists",
            "Value 83 90--*--I or II",
            "Qualifier 106 119--*--gynecological",
            "Procedure 120 140--*--laparoscopic surgery",
            "Mood 92 101--*--Scheduled"
        ],
        "Text": "20-70 yrs of age. ASA(American Society of Anesthesiologists) physical status class I or II. Scheduled for gynecological laparoscopic surgery. "
    },
    "NCT02247128_inc": {
        "Annotations": [
            "Mood 0 8--*--Need for",
            "Procedure 9 39--*--long-term oral anticoagulation",
            "Informed_consent 42 87--*--Patient has provided written informed consent"
        ],
        "Text": "Need for long-term oral anticoagulation;. Patient has provided written informed consent.. "
    },
    "NCT02624908_exc": {
        "Text": "Type 1 diabetes. Known peripheral artery disease. Liver enzymes equal or more than 1.5 times the upper limit of normal. Chronic heart failure NYHA class III or IV. Current haemodialysis or peritoneal dialysis. End stage liver disease, defined as acute or chronic liver disease and recent history of one of the following: ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant. Known or suspected hypersensitivity to trial products or related products. Female of child-bearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods as required by law or local practice.. Expected simultaneous participation in any other clinical trial of an investigational medicinal product.. Receipt of any investigational medicinal product within 30 days before randomization. Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma). Any condition that in the investigator's opinion would make the subject unable to adhere to the trial visit schedule and procedures. Known history of non-compliance to treatment.. ",
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Condition 23 48--*--peripheral artery disease",
            "Measurement 50 63--*--Liver enzymes",
            "Value 64 118--*--equal or more than 1.5 times the upper limit of normal",
            "Measurement 142 146--*--NYHA",
            "Value 147 162--*--class III or IV",
            "Condition 120 141--*--Chronic heart failure",
            "Procedure 172 185--*--haemodialysis",
            "Procedure 189 208--*--peritoneal dialysis",
            "Temporal 164 171--*--Current",
            "Scope 172 208--*--haemodialysis or peritoneal dialysis",
            "Condition 210 233--*--End stage liver disease",
            "Condition 255 276--*--chronic liver disease",
            "Condition 246 251;263 276--*--acute liver disease",
            "Temporal 281 287--*--recent",
            "Condition 321 328--*--ascites",
            "Condition 330 344--*--encephalopathy",
            "Condition 346 363--*--variceal bleeding",
            "Measurement 365 374--*--bilirubin",
            "Value 375 406--*--equal or greater than 2.0 mg/dL",
            "Measurement 408 415--*--albumin",
            "Value 416 444--*--equal or less than 3.5 g/ dL",
            "Measurement 446 462--*--prothrombin time",
            "Value 463 492--*--greater or equal to 4 seconds",
            "Measurement 494 497--*--INR",
            "Value 498 526--*--greater than or equal to 1.7",
            "Temporal 530 535--*--prior",
            "Procedure 536 552--*--liver transplant",
            "Scope 321 552--*--ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant",
            "Scope 246 552--*--acute or chronic liver disease and recent history of one of the following: ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant",
            "Condition 573 589--*--hypersensitivity",
            "Drug 593 607--*--trial products",
            "Drug 611 627--*--related products",
            "Scope 593 627--*--trial products or related products",
            "Mood 563 572--*--suspected",
            "Mood 554 559--*--Known",
            "Scope 554 572--*--Known or suspected",
            "Pregnancy_considerations 629 809--*--Female of child-bearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods as required by law or local practice.",
            "Non-query-able 811 915--*--Expected simultaneous participation in any other clinical trial of an investigational medicinal product.",
            "Non-query-able 917 1001--*--Receipt of any investigational medicinal product within 30 days before randomization",
            "Condition 1045 1064--*--malignant neoplasms",
            "Temporal 1003 1010--*--Current",
            "Temporal 1014 1018--*--past",
            "Temporal 1020 1043--*--within the last 5 years",
            "Scope 1003 1044--*--Current or past (within the last 5 years)",
            "Condition 1073 1083;1107 1116--*--basal cell carcinoma",
            "Condition 1088 1116--*--squamous cell skin carcinoma",
            "Negation 1066 1072--*--except",
            "Scope 1073 1116--*--basal cell and squamous cell skin carcinoma",
            "Post-eligibility 1119 1250--*--Any condition that in the investigator's opinion would make the subject unable to adhere to the trial visit schedule and procedures",
            "Non-query-able 1252 1296--*--Known history of non-compliance to treatment"
        ]
    },
    "NCT01711801_exc": {
        "Text": "History or presence of any clinically significant disease or disorder . Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator . History of clinically significant hypersensitivity or allergic drug reactions . Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse . Regular smoker (> 5 cigarettes, > 1 pipeful or > 1 cigar per day) . Positive for hepatitis B, hepatitis C or HIV infection . Dietary restrictions that would prohibit the consumption of standardized meals . Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the follow-up from the previous study       .     . ",
        "Annotations": [
            "Qualifier 27 49--*--clinically significant",
            "Condition 27 57--*--clinically significant disease",
            "Condition 27 49;61 69--*--clinically significant disorder",
            "Undefined_semantics 27 69--*--clinically significant disease or disorder",
            "Subjective_judgement 27 69--*--clinically significant disease or disorder",
            "Observation 0 7--*--History",
            "Subjective_judgement 71 285--*--Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator",
            "Post-eligibility 71 285--*--Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator",
            "Qualifier 298 320--*--clinically significant",
            "Subjective_judgement 298 320--*--clinically significant",
            "Condition 321 337--*--hypersensitivity",
            "Condition 341 364--*--allergic drug reactions",
            "Condition 394 407--*--alcohol abuse",
            "Observation 370 379--*--suspicion",
            "Observation 383 390--*--history",
            "Scope 370 390--*--suspicion or history",
            "Condition 415 450--*--consumption of other drugs of abuse",
            "Scope 394 450--*--alcohol abuse and/or consumption of other drugs of abuse",
            "Condition 452 466--*--Regular smoker",
            "Multiplier 468 471--*--> 5",
            "Observation 472 482--*--cigarettes",
            "Multiplier 499 502;509 516--*--> 1 per day",
            "Observation 503 508--*--cigar",
            "Multiplier 484 487--*--> 1",
            "Observation 488 495--*--pipeful",
            "Scope 468 516--*--> 5 cigarettes, > 1 pipeful or > 1 cigar per day",
            "Measurement 532 543--*--hepatitis B",
            "Value 519 527--*--Positive",
            "Measurement 545 556--*--hepatitis C",
            "Condition 560 573--*--HIV infection",
            "Condition 575 595--*--Dietary restrictions",
            "Qualifier 601 653--*--would prohibit the consumption of standardized meals",
            "Undefined_semantics 601 653--*--would prohibit the consumption of standardized meals",
            "Subjective_judgement 601 653--*--would prohibit the consumption of standardized meals",
            "Context_Error 655 803--*--Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the follow-up from the previous study"
        ]
    },
    "NCT02156999_exc": {
        "Annotations": [
            "Qualifier 0 6--*--Kidney",
            "Qualifier 8 19--*--parathyroid",
            "Qualifier 21 31--*--congenital",
            "Qualifier 32 36--*--bone",
            "Qualifier 37 46--*--metabolic",
            "Condition 47 54--*--disease",
            "Scope 0 46--*--Kidney, parathyroid, congenital bone metabolic"
        ],
        "Text": "Kidney, parathyroid, congenital bone metabolic disease. "
    },
    "NCT01446094_inc": {
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 22--*--18 years or older",
            "Procedure 38 67--*--invasive coronary angiography",
            "Mood 24 33--*--Scheduled"
        ],
        "Text": "Aged 18 years or older. Scheduled for invasive coronary angiography. "
    },
    "NCT02526823_inc": {
        "Text": "Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;. Ages =18 years old, < 80 years old;. ECOG (Eastern Cooperative Oncology Group)score: 0-2. At least one measurable lesion;. Expected survival time=3 months;. Liver function: transaminase=2.5\u00d7 upper limit of normal value,bilirubin=1.5\u00d7upper limit of normal value;. Renal function: serum creatinine is 44-133 mmol/L;. Routine blood test:WBC=3.0\u00d7109/L,Neutrophils=1.5\u00d7109/L,Hb=100g/L,Platelet=80\u00d7109/L; LVEF=50%;. New York Heart Association (NYHA) heart function classification is I-II grade. signed informed consent.. ",
        "Annotations": [
            "Condition 0 13--*--Primary B-NHL",
            "Condition 15 19--*--PTCL",
            "Condition 21 101--*--ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma",
            "Negation 107 115--*--excluded",
            "Condition 120 122--*--HL",
            "Person 162 166--*--Ages",
            "Value 167 196--*--=18 years old, < 80 years old",
            "Multiplier 252 264--*--At least one",
            "Condition 276 282--*--lesion",
            "Observation 285 308--*--Expected survival time=",
            "Value 308 316--*--3 months",
            "Measurement 335 347--*--transaminase",
            "Value 347 380--*--=2.5\u00d7 upper limit of normal value",
            "Measurement 381 390--*--bilirubin",
            "Value 390 422--*--=1.5\u00d7upper limit of normal value",
            "Measurement 441 457--*--serum creatinine",
            "Value 461 474--*--44-133 mmol/L",
            "Measurement 491 499--*--test:WBC",
            "Value 499 509--*--=3.0\u00d7109/L",
            "Measurement 510 521--*--Neutrophils",
            "Value 521 531--*--=1.5\u00d7109/L",
            "Measurement 532 534--*--Hb",
            "Value 534 541--*--=100g/L",
            "Measurement 542 550--*--Platelet",
            "Value 550 559--*--=80\u00d7109/L",
            "Measurement 561 565--*--LVEF",
            "Value 565 569--*--=50%",
            "Measurement 572 598;606 635--*--New York Heart Association heart function classification",
            "Value 639 649--*--I-II grade",
            "Measurement 600 604--*--NYHA",
            "Informed_consent 651 674--*--signed informed consent",
            "Measurement 199 245--*--ECOG (Eastern Cooperative Oncology Group)score",
            "Value 247 250--*--0-2"
        ]
    },
    "NCT02849483_exc": {
        "Annotations": [
            "Condition 0 8--*--Allergic",
            "Drug 12 23--*--study drugs",
            "Drug 25 36--*--Antiemetics",
            "Drug 40 52--*--steroids use",
            "Temporal 53 83--*--within 24 hrs prior to surgery",
            "Reference_point 76 83--*--surgery",
            "Procedure 76 83--*--surgery",
            "Scope 25 52--*--Antiemetics or steroids use",
            "Condition 85 108--*--Dependence upon opioids",
            "Qualifier 110 127--*--Insulin dependent",
            "Drug 110 117--*--Insulin",
            "Condition 128 145--*--Diabetes Mellitus",
            "Condition 147 161;175 182--*--Cardiovascular disease",
            "Condition 165 182--*--pulmonary disease",
            "Condition 184 189;201 214--*--Renal insufficiency",
            "Condition 193 214--*--hepatic insufficiency",
            "Measurement 216 219--*--BMI",
            "Value 219 228--*-->=35kg/m2",
            "Observation 230 237--*--History",
            "Condition 241 256--*--motion sickness",
            "Condition 260 264--*--PONV",
            "Scope 241 264--*--motion sickness or PONV",
            "Observation 266 282--*--Cigarette smoker",
            "Observation 284 294--*--Conversion",
            "Procedure 298 313--*--open laparotomy",
            "Procedure 319 339--*--laparoscopic surgery",
            "Condition 341 350--*--Pregnants"
        ],
        "Text": "Allergic to study drugs. Antiemetics or steroids use within 24 hrs prior to surgery. Dependence upon opioids. Insulin dependent Diabetes Mellitus. Cardiovascular or pulmonary disease. Renal or hepatic insufficiency. BMI>=35kg/m2. History of motion sickness or PONV. Cigarette smoker. Conversion to open laparotomy from laparoscopic surgery. Pregnants. "
    },
    "NCT02942303_inc": {
        "Text": "Consecutive 30 female patients presenting to our clinic for brow lifting with botulinum toxin will be randomized to receive one of the two injection techniques. ",
        "Annotations": [
            "Procedure 60 72--*--brow lifting",
            "Drug 78 93--*--botulinum toxin",
            "Person 15 21--*--female",
            "Multiplier 12 14--*--30"
        ]
    },
    "NCT02256956_inc": {
        "Annotations": [
            "Value 0 7--*--Healthy",
            "Person 9 13--*--Male",
            "Value 15 17--*-->7",
            "Measurement 18 39--*--Metabolic Equivalents",
            "Condition 90 100--*--Drug abuse",
            "Condition 102 115--*--Alcohol abuse",
            "Condition 67 88--*--Chronic pain syndrome",
            "Informed_consent 41 65--*--Written informed consent",
            "Mood 117 126--*--Suspicion",
            "Condition 130 152--*--neurologic dysfunction",
            "Qualifier 156 168--*--tested sites",
            "Temporal 170 177--*--Ongoing",
            "Procedure 178 187--*--treatment",
            "Drug 193 208--*--antidepressants",
            "Temporal 210 217--*--Ongoing",
            "Procedure 218 227--*--treatment",
            "Drug 233 243--*--analgesics",
            "Procedure 245 257--*--Pretreatment",
            "Drug 267 281--*--CYP3A inducers",
            "Drug 267 272;285 295--*--CYP3A inhibitors",
            "Scope 267 295--*--CYP3A inducers or inhibitors",
            "Condition 303 310--*--allergy",
            "Condition 351 371--*--Obstructive uropathy",
            "Drug 314 326--*--tested drugs",
            "Condition 328 349--*--Elevated eye pressure",
            "Condition 373 386--*--Heart disease",
            "Condition 388 405--*--Pulmonary disease",
            "Condition 407 427--*--Neurological disease",
            "Condition 429 448--*--Psychiatric illness"
        ],
        "Text": "Healthy. Male. >7 Metabolic Equivalents. Written informed consent. Chronic pain syndrome. Drug abuse. Alcohol abuse. Suspicion of neurologic dysfunction at tested sites. Ongoing treatment with antidepressants. Ongoing treatment with analgesics. Pretreatment with any CYP3A inducers or inhibitors. Known allergy to tested drugs. Elevated eye pressure. Obstructive uropathy. Heart disease. Pulmonary disease. Neurological disease. Psychiatric illness. "
    },
    "NCT02314559_inc": {
        "Annotations": [
            "Procedure 26 39--*--deep sedation",
            "Visit 43 51--*--ambulant",
            "Procedure 67 78--*--colonoscopy",
            "Measurement 80 83--*--ASA",
            "Value 84 87--*--1-3"
        ],
        "Text": "All patients subjected to deep sedation in ambulant care, having a colonoscopy. ASA 1-3. "
    },
    "NCT03506009_exc": {
        "Annotations": [
            "Measurement 0 3--*--mRS",
            "Value 3 5--*--=2",
            "Condition 19 25--*--stroke",
            "Value 26 41--*--within 3 months",
            "Condition 55 78--*--intracranial hemorrhage",
            "Condition 91 114--*--subarachnoid hemorrhage",
            "Condition 117 136--*--Intracranial tumour",
            "Condition 138 159--*--vascular malformation",
            "Condition 163 180--*--arterial aneurysm",
            "Procedure 183 196--*--Major surgery",
            "Value 197 211--*--within 1 month",
            "Measurement 214 231--*--Systolic pressure",
            "Value 232 241--*--=180 mmHg",
            "Measurement 245 263--*--diastolic pressure",
            "Value 264 273--*--=110 mmHg",
            "Measurement 276 290--*--Platelet count",
            "Value 291 300--*--< 105/mm3",
            "Drug 303 310--*--Heparin",
            "Procedure 311 318--*--therapy",
            "Procedure 322 350--*--oral anticoagulation therapy",
            "Temporal 351 366--*--within 48 hours",
            "Scope 303 350--*--Heparin therapy or oral anticoagulation therapy",
            "Value 369 377--*--Abnormal",
            "Measurement 378 382--*--APTT",
            "Drug 385 393--*--Thrombin",
            "Drug 397 416--*--Xa factor inhibitor",
            "Observation 441 456--*--life expectancy",
            "Value 460 478--*--less than 3 months",
            "Condition 426 433--*--disease",
            "Qualifier 419 425--*--Severe",
            "Measurement 481 494--*--Blood glucose",
            "Value 495 505--*--< 50 mg/dL",
            "Value 507 516--*--2.7mmol/L",
            "Competing_trial 520 604--*--Patients who have received any other investigational drug or device within 3 months;",
            "Condition 606 615--*--Pregnancy",
            "Non-query-able 618 693--*--Researchers consider patients inappropriate to participate in the registry."
        ],
        "Text": "mRS=2;. History of stroke within 3 months;. History of intracranial hemorrhage;. Suspected subarachnoid hemorrhage;. Intracranial tumour, vascular malformation or arterial aneurysm;. Major surgery within 1 month;. Systolic pressure =180 mmHg or diastolic pressure =110 mmHg;. Platelet count < 105/mm3;. Heparin therapy or oral anticoagulation therapy within 48 hours;. Abnormal APTT;. Thrombin or Xa factor inhibitor;. Severe disease with a life expectancy of less than 3 months;. Blood glucose < 50 mg/dL (2.7mmol/L);. Patients who have received any other investigational drug or device within 3 months;. Pregnancy;. Researchers consider patients inappropriate to participate in the registry.. "
    },
    "NCT02782702_inc": {
        "Text": "Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases. . Moderate to very severe lesions located in large folds . Patient aged 18 ans or more . Patient with health coverage . Patient who have signed the consent form . Patient proficient into filling out the questionnaires. . ",
        "Annotations": [
            "Condition 60 73;84 91--*--Hailey Hailey disease",
            "Condition 77 91--*--Darier disease",
            "Procedure 34 46--*--histological",
            "Scope 60 92--*--Hailey Hailey or Darier diseases",
            "Condition 119 126--*--lesions",
            "Context_Error 119 126--*--lesions",
            "Qualifier 107 118--*--very severe",
            "Subjective_judgement 107 118--*--very severe",
            "Undefined_semantics 107 118--*--very severe",
            "Person 159 163--*--aged",
            "Value 164 178--*--18 ans or more",
            "Observation 193 208--*--health coverage",
            "Context_Error 193 208--*--health coverage",
            "Post-eligibility 210 250--*--Patient who have signed the consent form",
            "Context_Error 210 250--*--Patient who have signed the consent form",
            "Post-eligibility 252 307--*--Patient proficient into filling out the questionnaires.",
            "Non-query-able 252 307--*--Patient proficient into filling out the questionnaires.",
            "Non-query-able 210 250--*--Patient who have signed the consent form"
        ]
    },
    "NCT02630628_exc": {
        "Text": "Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial disease, renovascular disease), or transplanted kidney.. Estimated glomerular filtration rate (eGFR by MDRD) =20 mL/min per 1.73 m2 or serum creatinine >300 micromol/L (3.39 mg/dL) at screening.. Renal biopsy showing cellular or fibrocellular crescent in more than 25% of glomeruli.. CNS or other severe organ manifestation of lupus that necessitate aggressive immunosuppressive therapy on its own.. Co-morbidities that require corticosteroid therapy (e.g. asthma, inflammatory bowel disease).. Treatment with prednisolone (or prednisone, or equivalent) at >20 mg/D for over 4 weeks within the past 3 months.. Treatment with MMF at >1.5 g/D for over 4 weeks within the past 3 months.. Known hypersensitivity or intolerability to prednisolone (or prednisone, or equivalent), TAC, or MMF at a dose of 1.25 g or below per day.. Subjects who are already on treatment with TAC, cyclosporine or any other calcineurin inhibitor for over 4 weeks within the past 12 months.. Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).. Uncontrolled hypertension with systolic BP >160 mmHg or diastolic BP >95 mmHg.. Women who are pregnant or breastfeeding.. Women with childbearing potential or their male partners, who refuse to use an effective birth control method. ",
        "Annotations": [
            "Condition 0 13--*--Renal disease",
            "Negation 14 23--*--unrelated",
            "Condition 27 30--*--SLE",
            "Condition 37 54--*--diabetes mellitus",
            "Condition 76 102--*--tubulointerstitial disease",
            "Condition 62 72;95 102--*--glomerular disease",
            "Condition 104 124--*--renovascular disease",
            "Scope 37 124--*--diabetes mellitus, other glomerular or tubulointerstitial disease, renovascular disease",
            "Procedure 130 149--*--transplanted kidney",
            "Measurement 152 188--*--Estimated glomerular filtration rate",
            "Measurement 190 194--*--eGFR",
            "Value 204 226--*--=20 mL/min per 1.73 m2",
            "Measurement 230 246--*--serum creatinine",
            "Value 247 262--*-->300 micromol/L",
            "Value 264 274--*--3.39 mg/dL",
            "Procedure 291 303--*--Renal biopsy",
            "Condition 324 346--*--fibrocellular crescent",
            "Condition 312 320;338 346--*--cellular crescent",
            "Multiplier 350 376--*--more than 25% of glomeruli",
            "Scope 313 346--*--ellular or fibrocellular crescent",
            "Qualifier 379 382--*--CNS",
            "Condition 422 427--*--lupus",
            "Qualifier 399 418--*--organ manifestation",
            "Procedure 456 481--*--immunosuppressive therapy",
            "Scope 379 418--*--CNS or other severe organ manifestation",
            "Drug 523 545--*--corticosteroid therapy",
            "Condition 552 558--*--asthma",
            "Condition 560 586--*--inflammatory bowel disease",
            "Condition 495 509--*--Co-morbidities",
            "Scope 552 586--*--asthma, inflammatory bowel disease",
            "Drug 605 617--*--prednisolone",
            "Drug 622 632--*--prednisone",
            "Drug 622 632;637 647--*--prednisone equivalent",
            "Multiplier 652 677--*-->20 mg/D for over 4 weeks",
            "Temporal 689 702--*--past 3 months",
            "Scope 605 648--*--prednisolone (or prednisone, or equivalent)",
            "Drug 720 723--*--MMF",
            "Multiplier 727 752--*-->1.5 g/D for over 4 weeks",
            "Temporal 764 777--*--past 3 months",
            "Condition 786 802--*--hypersensitivity",
            "Condition 806 820--*--intolerability",
            "Drug 824 836--*--prednisolone",
            "Drug 841 851--*--prednisone",
            "Drug 841 851;856 866--*--prednisone equivalent",
            "Drug 869 872--*--TAC",
            "Drug 877 880--*--MMF",
            "Multiplier 894 917--*--1.25 g or below per day",
            "Scope 786 820--*--hypersensitivity or intolerability",
            "Scope 824 917--*--prednisolone (or prednisone, or equivalent), TAC, or MMF at a dose of 1.25 g or below per day",
            "Drug 963 966--*--TAC",
            "Drug 968 980--*--cyclosporine",
            "Drug 994 1015--*--calcineurin inhibitor",
            "Multiplier 1020 1032--*--over 4 weeks",
            "Temporal 1044 1059--*--past 12 months.",
            "Scope 963 1015--*--TAC, cyclosporine or any other calcineurin inhibitor",
            "Drug 1076 1092--*--cyclophosphamide",
            "Drug 1094 1105--*--leflunomide",
            "Drug 1110 1122--*--methotrexate",
            "Multiplier 1132 1139--*--2 weeks",
            "Procedure 1151 1167--*--biological agent",
            "Temporal 1206 1219--*--past 6 months",
            "Scope 1076 1122--*--cyclophosphamide, leflunomide, or methotrexate",
            "Scope 1076 1170--*--cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s)",
            "Negation 1316 1323--*--allowed",
            "Drug 1240 1252--*--azathioprine",
            "Drug 1254 1264--*--mizoribine",
            "Drug 1278 1293--*--immunoglobulins",
            "Drug 1298 1312--*--anti-malarials",
            "Scope 1240 1312--*--azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials",
            "Condition 1340 1352--*--hypertension",
            "Qualifier 1327 1339--*--Uncontrolled",
            "Measurement 1358 1369--*--systolic BP",
            "Measurement 1383 1395--*--diastolic BP",
            "Value 1370 1379--*-->160 mmHg",
            "Value 1396 1404--*-->95 mmHg",
            "Scope 1358 1404--*--systolic BP >160 mmHg or diastolic BP >95 mmHg",
            "Pregnancy_considerations 1407 1446--*--Women who are pregnant or breastfeeding",
            "Pregnancy_considerations 1449 1558--*--Women with childbearing potential or their male partners, who refuse to use an effective birth control method"
        ]
    },
    "NCT01602081_exc": {
        "Annotations": [
            "Procedure 20 31--*--fistulotomy",
            "Procedure 33 45--*--fistulectomy",
            "Procedure 47 51--*--LIFT",
            "Procedure 53 66--*--cutting seton",
            "Procedure 70 96--*--advancement flap procedure",
            "Condition 98 105--*--Fistula",
            "Qualifier 111 126--*--multiple tracts",
            "Condition 128 149--*--Recto-vaginal fistula",
            "Condition 175 187--*--anal fistula",
            "Condition 158 187--*--infection in the anal fistula",
            "Non-query-able 189 250--*--Physical allergies or cultural objections to porcine products",
            "Subjective_judgement 252 346--*--Patient is not medically fit to undergo the LIFT procedure as judged by the treating physician",
            "Post-eligibility 252 346--*--Patient is not medically fit to undergo the LIFT procedure as judged by the treating physician",
            "Condition 370 387--*--collagen disorder",
            "Condition 400 415--*--Crohn's Disease",
            "Condition 417 441--*--Irritable Bowel Syndrome",
            "Procedure 443 460--*--radiation therapy",
            "Qualifier 468 484--*--rectoanal region",
            "Observation 389 396--*--History",
            "Scope 400 484--*--Crohn's Disease, Irritable Bowel Syndrome, radiation therapy in the rectoanal region"
        ],
        "Text": "Patients with prior fistulotomy, fistulectomy, LIFT, cutting seton or advancement flap procedure . Fistula with multiple tracts . Recto-vaginal fistula . Active infection in the anal fistula . Physical allergies or cultural objections to porcine products . Patient is not medically fit to undergo the LIFT procedure as judged by the treating physician . Previous diagnosis of collagen disorder . History of Crohn's Disease, Irritable Bowel Syndrome, radiation therapy in the rectoanal region       .     . "
    },
    "NCT02270970_inc": {
        "Annotations": [
            "Measurement 18 35;44 67--*--1987 ACR criteria with 1996 modifications",
            "Condition 40 43--*--SLE",
            "Measurement 69 75--*--SLEDAI",
            "Value 76 81--*-->/= 6",
            "Temporal 82 100--*--at screening visit",
            "Reference_point 85 100--*--screening visit",
            "Measurement 111 114--*--ANA",
            "Value 102 110--*--Positive",
            "Measurement 118 128--*--anti-dsDNA",
            "Temporal 129 157--*--within one year of screening",
            "Reference_point 148 157--*--screening",
            "Subjective_judgement 159 329--*--In the opinion of the investigator there is intent to treat with a biologic (e.g. patient failed standard of care treatment) however there is no organ threatening disease"
        ],
        "Text": "Patients who meet 1987 ACR criteria for SLE with 1996 modifications. SLEDAI >/= 6 at screening visit. Positive ANA OR anti-dsDNA within one year of screening. In the opinion of the investigator there is intent to treat with a biologic (e.g. patient failed standard of care treatment) however there is no organ threatening disease. "
    },
    "NCT00954850_exc": {
        "Text": "Malignancy and other significant medical conditions that will impact follow up within this program. . Those less than 18 years of age. . Concomitant interstitial lung disease, sarcoidosis, other significant lung disease. . Those who have had a transplant. . Significant travel with work. . Unable to make appointments (every three to six months over 2 years). . Those residing in another country or planned absence for more than one month.       .     . ",
        "Annotations": [
            "Condition 0 10--*--Malignancy",
            "Condition 33 51--*--medical conditions",
            "Qualifier 21 32--*--significant",
            "Value 107 125--*--less than 18 years",
            "Person 129 132--*--age",
            "Condition 147 172--*--interstitial lung disease",
            "Condition 174 185--*--sarcoidosis",
            "Condition 205 217--*--lung disease",
            "Temporal 135 146--*--Concomitant",
            "Scope 147 217--*--interstitial lung disease, sarcoidosis, other significant lung disease",
            "Procedure 241 251--*--transplant",
            "Non-representable 254 283--*--Significant travel with work.",
            "Post-eligibility 285 354--*--Unable to make appointments (every three to six months over 2 years).",
            "Non-representable 356 433--*--Those residing in another country or planned absence for more than one month."
        ]
    },
    "NCT03518034_inc": {
        "Text": "Men between 45 and 80 years age. Participants with low serum testosterone concentrations (< 300 ng/dL) who exhibit at least one sign or symptom of hypogonadism and have evidence of cardiovascular (CV) disease or are at an increased risk for CV disease.. ",
        "Annotations": [
            "Person 0 3--*--Men",
            "Value 4 27--*--between 45 and 80 years",
            "Person 28 31--*--age",
            "Measurement 55 88--*--serum testosterone concentrations",
            "Value 51 54--*--low",
            "Value 90 101--*--< 300 ng/dL",
            "Multiplier 115 127--*--at least one",
            "Condition 128 132--*--sign",
            "Condition 136 143--*--symptom",
            "Condition 147 159--*--hypogonadism",
            "Scope 128 143--*--sign or symptom",
            "Mood 169 180--*--evidence of",
            "Condition 181 208--*--cardiovascular (CV) disease",
            "Mood 222 236--*--increased risk",
            "Condition 241 251--*--CV disease"
        ]
    },
    "NCT02256956_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT02942303_exc": {
        "Text": "Patients with previous periorbital/forehead surgery. Patients who plucked the upper eyebrow margin. Patients with eyebrow tatoos. Patients with upper face botulinum toxin injection in the past 12 months. Patients with resorbable upper face fillers injection in the past 12 months. Patients with previous permanent upper face fillers injection. Pregnant patients. Lactating patients. Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert syndrome). Patients using medication that could potentiate the effect of botulinum (ex: aminoglycoside antibiotics). Patients with sensitivity to botulinum toxin or human albumin. ",
        "Annotations": [
            "Procedure 35 51--*--forehead surgery",
            "Procedure 23 34;44 51--*--periorbital surgery",
            "Condition 66 98--*--plucked the upper eyebrow margin",
            "Observation 114 128--*--eyebrow tatoos",
            "Procedure 155 180--*--botulinum toxin injection",
            "Qualifier 144 154--*--upper face",
            "Temporal 181 202--*--in the past 12 months",
            "Temporal 258 279--*--in the past 12 months",
            "Procedure 218 228;240 257--*--resorbable fillers injection",
            "Qualifier 229 239--*--upper face",
            "Procedure 304 313;325 342--*--permanent fillers injection",
            "Qualifier 314 324--*--upper face",
            "Condition 344 352--*--Pregnant",
            "Condition 363 372--*--Lactating",
            "Condition 409 433--*--neuromuscular conditions",
            "Condition 435 452--*--myasthenia gravis",
            "Condition 454 476--*--Eaton Lambert syndrome",
            "Scope 435 476--*--myasthenia gravis, Eaton Lambert syndrome",
            "Drug 541 550--*--botulinum",
            "Condition 516 537--*--potentiate the effect",
            "Drug 494 504--*--medication",
            "Drug 556 582--*--aminoglycoside antibiotics",
            "Scope 494 550--*--medication that could potentiate the effect of botulinum",
            "Drug 614 629--*--botulinum toxin",
            "Drug 633 646--*--human albumin",
            "Condition 599 610--*--sensitivity",
            "Scope 614 646--*--botulinum toxin or human albumin"
        ]
    },
    "NCT02630628_inc": {
        "Text": "Biopsy-proven LN Class III/IV\u00b1V (ISN/RPS 2003), with biopsy performed within 12 weeks of randomization.. Positive anti-dsDNA.. Active LN with proteinuria (urine protein/creatinine ratio >1.0 or 24-hr urine protein >1.0 g at baseline), with or without hematuria.. Both 'incident' (i.e. new) patients and 'flare' patients can be included.. ",
        "Annotations": [
            "Condition 14 16--*--LN",
            "Qualifier 17 31--*--Class III/IV\u00b1V",
            "Procedure 53 59--*--biopsy",
            "Temporal 70 85--*--within 12 weeks",
            "Measurement 114 124--*--anti-dsDNA",
            "Value 105 113--*--Positive",
            "Condition 134 136--*--LN",
            "Condition 142 153--*--proteinuria",
            "Measurement 155 185--*--urine protein/creatinine ratio",
            "Value 186 190--*-->1.0",
            "Measurement 194 213--*--24-hr urine protein",
            "Value 214 220--*-->1.0 g",
            "Scope 155 220--*--urine protein/creatinine ratio >1.0 or 24-hr urine protein >1.0 g",
            "Qualifier 127 133--*--Active",
            "Condition 251 260--*--hematuria",
            "Non-query-able 263 335--*--Both 'incident' (i.e. new) patients and 'flare' patients can be included"
        ]
    },
    "NCT02782702_exc": {
        "Text": "Hypersensibility to toxin or excipients . Myastheny . Deglutition's problems . Past medical history of dysphagia or aspiration pneumonia . Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding . Mental , physical incapacity to fill in the questionnaires . Guardianship patients . Skin infections at the inclusion visit . Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months. . Systemic treatment with aminosides in the last 15 days . Inclusion in another study in the last 2 months.       .     . ",
        "Annotations": [
            "Condition 0 16--*--Hypersensibility",
            "Drug 20 25--*--toxin",
            "Drug 29 39--*--excipients",
            "Scope 20 39--*--toxin or excipients",
            "Condition 41 50--*--Myastheny",
            "Condition 52 74--*--Deglutition's problems",
            "Condition 100 109--*--dysphagia",
            "Observation 76 96--*--Past medical history",
            "Condition 113 133--*--aspiration pneumonia",
            "Scope 100 133--*--dysphagia or aspiration pneumonia",
            "Condition 135 144--*--Pregnancy",
            "Measurement 155 165--*--B-HCG test",
            "Value 146 154--*--positive",
            "Observation 200 213--*--breastfeeding",
            "Temporal 176 195--*--a maxima 72h before",
            "Non-query-able 275 296--*--Guardianship patients",
            "Condition 298 313--*--Skin infections",
            "Temporal 314 336--*--at the inclusion visit",
            "Visit 321 336--*--inclusion visit",
            "Temporal 350 368--*--in the last 7 days",
            "Procedure 338 349;394 413--*--Application of local treatments",
            "Drug 421 431--*--emollients",
            "Drug 435 446--*--antiseptics",
            "Negation 415 420--*--apart",
            "Scope 421 446--*--emollients or antiseptics",
            "Drug 465 479--*--botulism toxin",
            "Procedure 451 461--*--injections",
            "Procedure 483 503--*--dynamic phototherapy",
            "Procedure 507 512--*--laser",
            "Temporal 513 533--*--in the last 6 months",
            "Scope 451 512--*--injections of botulism toxin or dynamic phototherapy or laser",
            "Procedure 536 554--*--Systemic treatment",
            "Drug 560 570--*--aminosides",
            "Temporal 571 590--*--in the last 15 days",
            "Context_Error 592 618--*--Inclusion in another study",
            "Non-query-able 592 618--*--Inclusion in another study",
            "Post-eligibility 592 618--*--Inclusion in another study",
            "Temporal 619 639--*--in the last 2 months",
            "Procedure 592 618--*--Inclusion in another study",
            "Condition 224 243--*--physical incapacity",
            "Condition 215 221;233 243--*--Mental incapacity",
            "Procedure 247 273--*--fill in the questionnaires",
            "Scope 215 243--*--Mental , physical incapacity"
        ]
    },
    "NCT03506009_inc": {
        "Annotations": [
            "Person 12 15--*--old",
            "Value 0 15--*--18-80 years old",
            "Condition 31 68--*--posterior circulation ischemic stroke",
            "Observation 71 99--*--Time from onset to treatment",
            "Value 100 108--*--=6 hours",
            "Measurement 111 116--*--NIHSS",
            "Value 118 122--*--4-25",
            "Informed_consent 125 203--*--Signed informed consent by patient self or legally authorized representatives."
        ],
        "Text": "18-80 years old;. Diagnosis of posterior circulation ischemic stroke;. Time from onset to treatment =6 hours;. NIHSS: 4-25;. Signed informed consent by patient self or legally authorized representatives.. "
    },
    "NCT02314559_exc": {
        "Annotations": [
            "Condition 0 8--*--Dementia",
            "Procedure 11 22--*--Gastroscopy",
            "Mood 23 30--*--planned",
            "Temporal 31 47--*--at the same time",
            "Condition 50 59--*--Allergies",
            "Drug 63 71--*--propofol",
            "Non-representable 73 135--*--All cases were a 'full stomach' is suspected (gastric banding)",
            "Condition 137 146--*--Pregnancy"
        ],
        "Text": "Dementia.. Gastroscopy planned at the same time.. Allergies to propofol. All cases were a 'full stomach' is suspected (gastric banding). Pregnancy. "
    },
    "NCT00954850_inc": {
        "Text": "Adults (18 and older) with physiologically confirmed SA or mild-moderate asthma and followed by an asthma specialist for at least 6 months. . Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma). . Must have good compliance with medications Patients with asthma and COPD. . ",
        "Annotations": [
            "Value 8 20--*--18 and older",
            "Person 0 6--*--Adults",
            "Person 8 20--*--18 and older",
            "Condition 53 55--*--SA",
            "Condition 73 79--*--asthma",
            "Qualifier 59 63--*--mild",
            "Qualifier 64 72--*--moderate",
            "Scope 59 72--*--mild-moderate",
            "Observation 84 116--*--followed by an asthma specialist",
            "Temporal 117 138--*--for at least 6 months",
            "Post-eligibility 141 242--*--Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma).",
            "Condition 254 269--*--good compliance",
            "Drug 275 286--*--medications",
            "Condition 301 307--*--asthma",
            "Condition 312 316--*--COPD"
        ]
    },
    "NCT03518034_exc": {
        "Text": "Participants with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate. Participants with prostate specific antigen (PSA) > 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors). Participants who have been treated with testosterone in the past 6 months and for whom testosterone therapy is contraindicated. Confirmed testosterone < 100 ng/dL. Body Mass Index (BMI) > 50. Hemoglobin A1c (HbA1C) > 11%. Hematocrit (Hct) > 50%. Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min. History of deep vein thrombosis or pulmonary embolism or prostate cancer or heart failure (Class III and IV).. ",
        "Annotations": [
            "Condition 32 53--*--acquired hypogonadism",
            "Condition 18 28;41 53--*--congenital hypogonadism",
            "Non-representable 54 128--*--for whom long-term therapy with placebo would not be medically appropriate",
            "Measurement 148 179--*--prostate specific antigen (PSA)",
            "Value 180 191--*--> 3.0 ng/mL",
            "Drug 206 234--*--5-alpha reductase inhibitors",
            "Value 196 199--*--1.5",
            "Scope 180 235--*--> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)",
            "Drug 277 289--*--testosterone",
            "Temporal 290 310--*--in the past 6 months",
            "Condition 348 363--*--contraindicated",
            "Procedure 324 344--*--testosterone therapy",
            "Drug 324 336--*--testosterone",
            "Measurement 365 387--*--Confirmed testosterone",
            "Value 388 399--*--< 100 ng/dL",
            "Measurement 401 422--*--Body Mass Index (BMI)",
            "Value 423 427--*--> 50",
            "Measurement 429 451--*--Hemoglobin A1c (HbA1C)",
            "Value 452 457--*--> 11%",
            "Measurement 459 475--*--Hematocrit (Hct)",
            "Value 476 481--*--> 50%",
            "Measurement 483 526--*--Estimated Glomerular Filtration Rate (eGFR)",
            "Value 527 538--*--< 30 ml/min",
            "Condition 551 571--*--deep vein thrombosis",
            "Condition 575 593--*--pulmonary embolism",
            "Condition 597 612--*--prostate cancer",
            "Condition 616 629--*--heart failure",
            "Qualifier 631 640--*--Class III",
            "Qualifier 631 636;645 647--*--Class IV",
            "Scope 631 647--*--Class III and IV"
        ]
    },
    "NCT02270970_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT01602081_inc": {
        "Annotations": [
            "Condition 32 62--*--trans-sphincteric anal fistula",
            "Multiplier 22 31--*--recurrent",
            "Multiplier 11 18--*--primary",
            "Scope 11 31--*--primary or recurrent"
        ],
        "Text": "Persistent primary or recurrent trans-sphincteric anal fistula . "
    },
    "NCT02283905_exc": {
        "Text": "The patient's data will be excluded if they die within 3 days of hospital admission.. ",
        "Annotations": [
            "Observation 44 47--*--die",
            "Temporal 48 83--*--within 3 days of hospital admission",
            "Reference_point 65 83--*--hospital admission"
        ]
    },
    "NCT03027115_inc": {
        "Text": "Male. 18 years of age. Presenting with hernia requiring surgical intervention. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Value 6 14--*--18 years",
            "Person 18 21--*--age",
            "Condition 39 45--*--hernia",
            "Mood 46 55--*--requiring",
            "Procedure 56 77--*--surgical intervention"
        ]
    },
    "NCT02046395_inc": {
        "Annotations": [
            "Condition 0 15--*--Type 2 Diabetes",
            "Condition 17 29--*--Hypertension",
            "Measurement 31 74--*--Estimated glomerular filtration rate (eGFR)",
            "Value 75 86--*--> 30 ml/min",
            "Drug 95 102--*--Ace Inh",
            "Drug 107 110--*--ARB",
            "Procedure 115 140--*--control of blood pressure",
            "Scope 95 110--*--Ace Inh and ARB",
            "Informed_consent 149 239--*--willing to be placed on alternate drug(s) in the washout period for blood pressure control"
        ],
        "Text": "Type 2 Diabetes. Hypertension. Estimated glomerular filtration rate (eGFR) > 30 ml/min. Use of Ace Inh and ARB for control of blood pressure who are willing to be placed on alternate drug(s) in the washout period for blood pressure control. "
    },
    "NCT02766530_exc": {
        "Annotations": [
            "Measurement 0 13--*--Estimated GFR",
            "Measurement 15 19--*--eGFR",
            "Value 21 40--*--< 60 mL/min/1.73 m2",
            "Measurement 45 58--*--blood glucose",
            "Value 59 70--*--> 135 mg/dl",
            "Condition 99 118--*--acute renal failure",
            "Procedure 120 134--*--renal dialysis",
            "Condition 136 153--*--diabetes mellitus",
            "Person 156 161--*--Women",
            "Procedure 175 192--*--metallic fixation",
            "Device 194 215--*--coronary artery stent",
            "Temporal 219 234--*--recent 3 months",
            "Person 239 244--*--women",
            "Device 258 286--*--mechanical valve replacement",
            "Person 329 334--*--women",
            "Device 340 356--*--aneurysmal clips",
            "Device 358 368--*--pacemakers",
            "Scope 340 368--*--aneurysmal clips, pacemakers",
            "Scope 175 215--*--metallic fixation, coronary artery stent",
            "Condition 387 401--*--claustrophobia",
            "Pregnancy_considerations 404 552--*--Women who are pregnant or who are planning to be pregnant, or who are lactating (though the possibility in our target population should be very low)",
            "Condition 570 583--*--breast cancer",
            "Temporal 591 650--*--recent 5 years before the currently diagnosed breast cancer",
            "Reference_point 617 651--*--currently diagnosed breast cancer.",
            "Procedure 672 684--*--chemotherapy",
            "Temporal 713 726--*--recent 1 year",
            "Post-eligibility 729 777--*--Women who cannot cooperate with the examinations"
        ],
        "Text": "Estimated GFR (eGFR) < 60 mL/min/1.73 m2 and blood glucose > 135 mg/dl; Past or present history of acute renal failure, renal dialysis, diabetes mellitus.. Women who received metallic fixation, coronary artery stent in recent 3 months; or women who received mechanical valve replacement that is not compatible with MR magnet; or women with aneurysmal clips, pacemakers.. Past history of claustrophobia.. Women who are pregnant or who are planning to be pregnant, or who are lactating (though the possibility in our target population should be very low). Past history of breast cancer within recent 5 years before the currently diagnosed breast cancer.. Women who received chemotherapy for other disease entity in recent 1 year.. Women who cannot cooperate with the examinations.. "
    },
    "NCT02687724_exc": {
        "Text": "Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study. Patients aged <18 years of age. Patients who cannot give informed consent,. Pregnant patients or those who are breastfeeding will be deemed ineligible.. Prior treatment with any anti-TNF agent. Contra-indication to use of GLM (Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV). Have symptoms or signs suggestive of current active or latent TB upon medical history, physical examination and/or chest radiograph, or positive Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA). Patients with a history of, or at imminent risk for, colectomy; who required gastrointestinal surgery within 2 months before screening;. History of colonic mucosal dysplasia or adenomatous colonic polyps that were not removed. Screening stool study positive for enteric pathogens or Clostridium difficile toxin.. Oral corticosteroids at a dose >40 mg prednisone or its equivalent per day; receipt of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks before the first study agent injection; or use of an investigational agent within 5 half-lives of that agent before the first study agent injection.. Patients in recent receipt of live vaccinations within 4 weeks prior to enrolment. ",
        "Annotations": [
            "Pregnancy_considerations 0 100--*--Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study",
            "Person 111 115--*--aged",
            "Value 116 132--*--<18 years of age",
            "Non-query-able 134 176--*--Patients who cannot give informed consent,",
            "Pregnancy_considerations 178 252--*--Pregnant patients or those who are breastfeeding will be deemed ineligible",
            "Drug 280 294--*--anti-TNF agent",
            "Procedure 261 270--*--treatment",
            "Temporal 255 260--*--Prior",
            "Condition 296 313--*--Contra-indication",
            "Drug 324 327--*--GLM",
            "Condition 329 345--*--Hypersensitivity",
            "Drug 353 369--*--active substance",
            "Drug 387 397--*--excipients",
            "Scope 353 397--*--active substance or to any of the excipients",
            "Condition 406 423--*--tuberculosis (TB)",
            "Temporal 399 405--*--Active",
            "Qualifier 425 430--*--acute",
            "Qualifier 434 441--*--chronic",
            "Condition 442 463--*--Hepatitis B infection",
            "Scope 425 441--*--acute or chronic",
            "Condition 473 490--*--severe infections",
            "Condition 499 505--*--sepsis",
            "Condition 513 537--*--opportunistic infections",
            "Condition 548 561--*--HIV infection",
            "Qualifier 563 571--*--Moderate",
            "Qualifier 575 581--*--severe",
            "Condition 582 595--*--heart failure",
            "Measurement 597 601--*--NYHA",
            "Value 602 614--*--class III/IV",
            "Scope 563 581--*--Moderate or severe",
            "Scope 329 614--*--Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV",
            "Scope 296 327--*--Contra-indication to use of GLM",
            "Qualifier 672 678--*--latent",
            "Qualifier 662 668--*--active",
            "Temporal 654 661--*--current",
            "Condition 679 681--*--TB",
            "Scope 654 677--*--current active or laten",
            "Observation 687 702--*--medical history",
            "Procedure 704 724--*--physical examination",
            "Procedure 732 748--*--chest radiograph",
            "Measurement 762 843--*--Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)",
            "Value 753 761--*--positive",
            "Scope 687 748--*--medical history, physical examination and/or chest radiograph",
            "Procedure 922 946--*--gastrointestinal surgery",
            "Temporal 947 979--*--within 2 months before screening",
            "Procedure 898 907--*--colectomy",
            "Mood 879 896--*--imminent risk for",
            "Observation 861 871--*--history of",
            "Scope 861 896--*--history of, or at imminent risk for",
            "Condition 993 1018--*--colonic mucosal dysplasia",
            "Condition 1022 1048--*--adenomatous colonic polyps",
            "Procedure 1063 1070--*--removed",
            "Negation 1059 1062--*--not",
            "Procedure 1082 1093--*--stool study",
            "Value 1094 1102--*--positive",
            "Qualifier 1107 1124--*--enteric pathogens",
            "Qualifier 1128 1155--*--Clostridium difficile toxin",
            "Scope 1107 1155--*--enteric pathogens or Clostridium difficile toxin",
            "Drug 1158 1178--*--Oral corticosteroids",
            "Multiplier 1189 1206;1225 1232--*-->40 mg prednisone per day",
            "Drug 1245 1257--*--cyclosporine",
            "Drug 1259 1269--*--tacrolimus",
            "Drug 1271 1280--*--sirolimus",
            "Drug 1285 1306--*--mycophenolate mofetil",
            "Temporal 1307 1360--*--within 8 weeks before the first study agent injection",
            "Scope 1245 1306--*--cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil",
            "Drug 1375 1396--*--investigational agent",
            "Temporal 1397 1416--*--within 5 half-lives",
            "Temporal 1431 1469--*--before the first study agent injection",
            "Drug 1502 1519--*--live vaccinations",
            "Temporal 1520 1553--*--within 4 weeks prior to enrolment"
        ]
    },
    "NCT03027115_exc": {
        "Text": "Intolerability of tamsulosin or related drugs. Investigator discretion. Unwillingness or inability to comply with protocol procedures and assessments. ",
        "Annotations": [
            "Condition 0 14--*--Intolerability",
            "Drug 18 28--*--tamsulosin",
            "Drug 32 45--*--related drugs",
            "Scope 18 45--*--tamsulosin or related drugs",
            "Non-query-able 47 70--*--Investigator discretion",
            "Informed_consent 72 149--*--Unwillingness or inability to comply with protocol procedures and assessments"
        ]
    },
    "NCT02283905_inc": {
        "Text": "All adult patients 18 years of age or older admitted to the intensive care units of St. Boniface General Hospital with a diagnosis of acute pulmonary blastomycosis requiring mechanical ventilation.. ",
        "Annotations": [
            "Person 4 9--*--adult",
            "Value 19 27;35 43--*--18 years or older",
            "Person 31 34--*--age",
            "Visit 60 80--*--intensive care units",
            "Visit 84 113--*--St. Boniface General Hospital",
            "Procedure 44 52--*--admitted",
            "Scope 60 113--*--intensive care units of St. Boniface General Hospital",
            "Condition 134 163--*--acute pulmonary blastomycosis",
            "Procedure 174 196--*--mechanical ventilation"
        ]
    },
    "NCT02046395_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 25 47--*--chronic kidney disease",
            "Measurement 59 63--*--eGFR",
            "Value 64 75--*--< 30 ml/min",
            "Condition 77 80--*--CKD",
            "Qualifier 81 89--*--stage IV",
            "Qualifier 81 86;94 95--*--stage V",
            "Scope 81 95--*--stage IV and V",
            "Qualifier 98 113--*--Nephrotic range",
            "Condition 114 125--*--proteinuria",
            "Measurement 127 142--*--urinary protein",
            "Value 143 155--*--> 3.5 gm/day",
            "Measurement 169 190--*--renal transplantation",
            "Condition 203 219--*--multiple myeloma",
            "Observation 158 165--*--History",
            "Observation 192 199--*--History",
            "Condition 238 263--*--hypersensitivity reaction",
            "Condition 267 281--*--intolerability",
            "Drug 285 292--*--Ace Inh",
            "Drug 296 299--*--ARB",
            "Scope 285 299--*--Ace Inh or ARB",
            "Scope 238 281--*--hypersensitivity reaction or intolerability",
            "Observation 227 234--*--history"
        ],
        "Text": "Pregnancy. Patients with chronic kidney disease stage with eGFR < 30 ml/min (CKD stage IV and V). Nephrotic range proteinuria (urinary protein > 3.5 gm/day). History or renal transplantation. History of multiple myeloma. Known history of hypersensitivity reaction or intolerability to Ace Inh or ARB.. "
    },
    "NCT02687724_inc": {
        "Text": "Patients = 18 years of age. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol. Established diagnosis of UC and moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore =2.. Patients had an inadequate response to, or had failed to tolerate, 1 or more of the following conventional therapies: oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP); or corticosteroid dependent (ie, an inability to taper corticosteroids without recurrence of UC symptoms).. Patients concurrently treated with oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline. Patients were required to maintain stable doses of their concomitant UC medications during the study.. Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR. Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR. Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.. Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.. Subjects have following investigations within 1 month prior to enrolment.. Routine bloods including U&E, FBC, LFTs, inflammatory markers (CRP) and albumin will be measured.. Medical history, concomitant medications. Intradermal reaction to Tuberculin (PPD skin test) or Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA). TB screening: chest X-Ray unless performed in the last 6 months. Stool examination for enteric pathogens including Clostridium difficile. Inclusion/exclusion criteria. Informed consent. Mayo score (including sigmoidoscopy unless performed in previous 3 months). Patient's weight and height and abdominal circumference. ",
        "Annotations": [
            "Value 9 19--*--= 18 years",
            "Person 23 26--*--age",
            "Non-query-able 28 153--*--Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol",
            "Condition 180 182--*--UC",
            "Qualifier 187 205--*--moderate-to-severe",
            "Measurement 237 247--*--Mayo score",
            "Value 251 255--*--6-12",
            "Measurement 265 284--*--endoscopic subscore",
            "Value 285 287--*--=2",
            "Condition 306 325--*--inadequate response",
            "Condition 337 355--*--failed to tolerate",
            "Multiplier 357 366--*--1 or more",
            "Drug 408 431--*--oral 5-aminosalicylates",
            "Drug 433 453--*--oral corticosteroids",
            "Drug 455 473--*--azathioprine (AZA)",
            "Drug 482 504--*--6-mercaptopurine (6MP)",
            "Drug 509 523--*--corticosteroid",
            "Condition 524 533--*--dependent",
            "Non-representable 534 611--*--(ie, an inability to taper corticosteroids without recurrence of UC symptoms)",
            "Scope 408 504--*--oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP)",
            "Scope 306 355--*--inadequate response to, or had failed to tolerate",
            "Drug 649 672--*--oral 5-aminosalicylates",
            "Drug 676 691--*--corticosteroids",
            "Qualifier 710 721--*--stable dose",
            "Temporal 722 758--*--for at least 2 weeks before baseline",
            "Scope 649 691--*--oral 5-aminosalicylates or corticosteroids",
            "Drug 783 786--*--AZA",
            "Drug 794 797--*--6MP",
            "Qualifier 816 827--*--stable dose",
            "Temporal 828 864--*--for at least 4 weeks before baseline",
            "Scope 783 797--*--AZA and/or 6MP",
            "Procedure 636 643--*--treated",
            "Scope 649 864--*--oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline",
            "Non-representable 866 967--*--Patients were required to maintain stable doses of their concomitant UC medications during the study.",
            "Pregnancy_considerations 969 1140--*--Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR",
            "Pregnancy_considerations 1142 1272--*--Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR",
            "Pregnancy_considerations 1274 1385--*--Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.",
            "Pregnancy_considerations 1387 1532--*--Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.",
            "Non-representable 1534 1607--*--Subjects have following investigations within 1 month prior to enrolment.",
            "Procedure 1609 1623--*--Routine bloods",
            "Procedure 1634 1637--*--U&E",
            "Procedure 1639 1642--*--FBC",
            "Procedure 1644 1648--*--LFTs",
            "Procedure 1650 1676--*--inflammatory markers (CRP)",
            "Procedure 1681 1688--*--albumin",
            "Scope 1634 1688--*--U&E, FBC, LFTs, inflammatory markers (CRP) and albumin",
            "Non-representable 1708 1748--*--Medical history, concomitant medications",
            "Procedure 1750 1800--*--Intradermal reaction to Tuberculin (PPD skin test)",
            "Procedure 1804 1884--*--Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)",
            "Temporal 1573 1606--*--within 1 month prior to enrolment",
            "Procedure 1900 1911--*--chest X-Ray",
            "Procedure 1886 1898--*--TB screening",
            "Procedure 1951 1968--*--Stool examination",
            "Qualifier 1969 2022--*--for enteric pathogens including Clostridium difficile",
            "Non-query-able 2054 2070--*--Informed consent",
            "Non-representable 2024 2052--*--Inclusion/exclusion criteria",
            "Procedure 2072 2082--*--Mayo score",
            "Procedure 2094 2107--*--sigmoidoscopy",
            "Procedure 2180 2203--*--abdominal circumference",
            "Procedure 2169 2175--*--height",
            "Procedure 2158 2164--*--weight"
        ]
    },
    "NCT02766530_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 6 10--*--aged",
            "Value 11 26--*--25-75 years old",
            "Person 29 34--*--Women",
            "Condition 59 72--*--breast cancer",
            "Procedure 94 97--*--NAC",
            "Qualifier 101 120--*--reduce tumor burden",
            "Temporal 121 135--*--before surgery",
            "Reference_point 128 135--*--surgery"
        ],
        "Text": "Women aged 25-75 years old.. Women with recently diagnosed breast cancer and who will receive NAC to reduce tumor burden before surgery. (including locally advanced breast cancer (LABC) according to clinical assessment; or tumor size > 2cm, that is, at least T2 in TNM staging).. "
    },
    "NCT02731794_inc": {
        "Annotations": [
            "Qualifier 14 20--*--severe",
            "Condition 21 47--*--left ventricle dysfunction",
            "Measurement 56 78--*--ejection fraction (EF)",
            "Value 78 82--*--=40%",
            "Observation 84 103--*--being scheduled for",
            "Procedure 104 121--*--revascularization"
        ],
        "Text": "patients with severe left ventricle dysfunction with an ejection fraction (EF)=40%, being scheduled for revascularization.. "
    },
    "NCT00061308_exc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 9 32--*--child-bearing potential",
            "Negation 38 44--*--do not",
            "Procedure 54 76--*--adequate contraception",
            "Condition 79 87--*--Pregnant",
            "Condition 91 100--*--lactating",
            "Drug 126 154--*--primary chemotherapy regimen",
            "Multiplier 112 125--*--more than one",
            "Condition 181 193--*--malignancies",
            "Qualifier 172 180--*--previous",
            "Qualifier 157 168--*--Concomitant",
            "Scope 157 180--*--Concomitant or previous",
            "Condition 235 245;263 274--*--basal cell skin cancer",
            "Condition 249 274--*--squamous cell skin cancer",
            "Condition 276 299--*--in situ cervical cancer",
            "Condition 301 321--*--incidental carcinoid",
            "Condition 326 338--*--other cancer",
            "Negation 199 215--*--the exception of",
            "Qualifier 216 234--*--adequately treated",
            "Scope 235 338--*--basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer",
            "Temporal 384 395--*--for 5 years",
            "Qualifier 362 383--*--has been disease free",
            "Condition 418 427--*--infection",
            "Qualifier 398 417--*--Active uncontrolled",
            "Drug 438 449--*--antibiotics",
            "Procedure 575 584--*--radiation",
            "Value 588 601--*--more than 10%",
            "Qualifier 605 609--*--bone",
            "Drug 633 642--*--topotecan",
            "Drug 646 657--*--gemcitabine",
            "Observation 618 627--*--treatment",
            "Scope 633 657--*--topotecan or gemcitabine",
            "Condition 660 676--*--Hypersensitivity",
            "Drug 680 692--*--camptothecin",
            "Drug 696 716--*--nucleoside analogues",
            "Scope 680 716--*--camptothecin or nucleoside analogues",
            "Drug 729 750--*--investigational agent",
            "Temporal 751 765--*--within 30 days",
            "Temporal 612 617--*--Prior",
            "Temporal 452 462--*--Concurrent",
            "Qualifier 463 469--*--severe",
            "Condition 470 486--*--medical problems",
            "Qualifier 527 563--*--limit full compliance with the study",
            "Qualifier 487 514--*--unrelated to the malignancy",
            "Condition 504 514--*--malignancy"
        ],
        "Text": "Women of child-bearing potential that do not practice adequate contraception. . Pregnant or lactating. . Received more than one primary chemotherapy regimen. . Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years. . Active uncontrolled infection requiring antibiotics. . Concurrent severe medical problems unrelated to the malignancy which would limit full compliance with the study. . Received radiation to more than 10% of bone. . Prior treatment with topotecan or gemcitabine. . Hypersensitivity to camptothecin or nucleoside analogues. . Use of an investigational agent within 30 days.       .     . "
    },
    "NCT03156855_inc": {
        "Text": "children and teenagers aged less than 20 years,. history of gastrectomy,. gastric malignancy, including adenocarcinoma and lymphoma,. previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),. contraindication to treatment drugs,. pregnant or lactating women,. severe concurrent disease,. concomitant use of clopidogrel, or (9) Unwilling to accept random assignment of subjects. ",
        "Annotations": [
            "Person 0 8--*--children",
            "Person 13 22--*--teenagers",
            "Person 23 27--*--aged",
            "Value 28 46--*--less than 20 years",
            "Observation 49 56--*--history",
            "Procedure 60 71--*--gastrectomy",
            "Condition 74 92--*--gastric malignancy",
            "Condition 104 118--*--adenocarcinoma",
            "Condition 123 131--*--lymphoma",
            "Scope 104 131--*--adenocarcinoma and lymphoma",
            "Drug 177 184--*--bismuth",
            "Drug 186 197--*--amoxicillin",
            "Drug 199 212--*--metronidazole",
            "Drug 214 228--*--clarithromycin",
            "Drug 230 242--*--tetracycline",
            "Drug 248 251--*--PPI",
            "Drug 253 265--*--esomeprazole",
            "Drug 164 175--*--antibiotics",
            "Scope 177 242--*--bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline",
            "Temporal 134 142--*--previous",
            "Condition 143 160--*--allergic reaction",
            "Scope 164 266--*--antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole)",
            "Condition 269 285--*--contraindication",
            "Drug 289 304--*--treatment drugs",
            "Condition 307 315--*--pregnant",
            "Condition 319 328--*--lactating",
            "Person 329 334--*--women",
            "Qualifier 337 343--*--severe",
            "Temporal 344 354--*--concurrent",
            "Condition 355 362--*--disease",
            "Temporal 365 376--*--concomitant",
            "Drug 384 395--*--clopidogrel",
            "Informed_consent 404 453--*--Unwilling to accept random assignment of subjects"
        ]
    },
    "NCT02339844_inc": {
        "Annotations": [
            "Observation 19 27--*--Patients",
            "Observation 387 395--*--controls",
            "Condition 67 80--*--schizophrenia",
            "Condition 84 108--*--schizoaffective disorder",
            "Qualifier 122 182--*--ICD-10 (International Classification of Diseases version 10)",
            "Qualifier 186 243--*--DSM-IV/V (Diagnostic and Statistical Manual version 4 /5)",
            "Scope 122 243--*--ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5)",
            "Scope 67 108--*--schizophrenia or schizoaffective disorder",
            "Person 245 248--*--Age",
            "Value 249 260--*--18-45 years",
            "Negation 262 267--*--Never",
            "Drug 281 304--*--antipsychotic compounds",
            "Drug 308 347--*--central nervous system (CNS) stimulants",
            "Observation 349 366--*--Legally competent",
            "Scope 67 366--*--schizophrenia or schizoaffective disorder according to ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent",
            "Non-representable 397 474--*--Matching patients on age (+/- 2 years), sex and parental socioeconomic status",
            "Person 476 479--*--Age",
            "Value 480 491--*--18-45 years",
            "Negation 493 495--*--No",
            "Condition 496 507;520 527--*--psychiatric disease",
            "Condition 511 527--*--physical disease",
            "Scope 397 527--*--Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease"
        ],
        "Text": "Inclusion Criteria Patients: Fulfilling the diagnostic criteria of schizophrenia or schizoaffective disorder according to ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent. Inclusion criteria controls: Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease.. "
    },
    "NCT02348918_exc": {
        "Text": "Active proliferative diabetic retinopathy (PDR) in the study eye such as NVE, NVD, vitreous hemorrhage, or neovascular glaucoma.. Uncontrolled hypertension defined as systolic >180 mmHg or > 160 mmHg on 2 consecutive measurements or diastolic > 100 mmHg on optimal medical regimen. Screening HgA1c blood test > 10.0. Focal laser photocoagulation or intravitreal/periocular steroids of any type in the study eye within the last 90 days prior to study enrollment.. A history of intravitreal anti-VEGF injection of any type in the study eye within the last 45 days prior to study enrollment.. History of rhegmatogenous retinal detachment, retinal tear(s), or traction retinal detachments in the study eye.. Epiretinal membrane and/or vitreomacular traction in the study eye as determined by the central reading center.. Previous pars plana vitrectomy in the study eye. Any intraocular surgery in the study eye within the last 90 days prior to study enrollment.. YAG laser treatment in the study eye in last 30 days prior to study enrollment.. High myopia in the study eye, with a spherical equivalent of >8.00D at screening. Other ocular pathologies that in the investigator's opinion would interfere with the subject's vision in the study eye.. Chronic or recurrent uveitis.. Ongoing ocular infection or inflammation in either eye.. A history of cataract surgery complications/vitreous loss in the study eye.. Congenital eye malformations in the study eye.. A history of penetrating ocular trauma in the study eye.. Mentally handicapped.. Pregnant female, as determined for women less than 60 years old by a positive urine pregnancy test during the screening window.. Nursing female.. Currently participating in any other clinical research study.. Contraindication to the study medication.. ",
        "Annotations": [
            "Condition 0 47--*--Active proliferative diabetic retinopathy (PDR)",
            "Qualifier 48 64--*--in the study eye",
            "Condition 73 76--*--NVE",
            "Condition 78 81--*--NVD",
            "Condition 83 102--*--vitreous hemorrhage",
            "Condition 107 127--*--neovascular glaucoma",
            "Scope 73 127--*--NVE, NVD, vitreous hemorrhage, or neovascular glaucoma",
            "Condition 129 154--*--Uncontrolled hypertension",
            "Measurement 166 174--*--systolic",
            "Value 175 184--*-->180 mmHg",
            "Value 188 198--*--> 160 mmHg",
            "Multiplier 199 228--*--on 2 consecutive measurements",
            "Scope 175 228--*-->180 mmHg or > 160 mmHg on 2 consecutive measurements",
            "Measurement 232 241--*--diastolic",
            "Value 242 252--*--> 100 mmHg",
            "Procedure 256 279--*--optimal medical regimen",
            "Qualifier 253 279--*--on optimal medical regimen",
            "Scope 166 279--*--systolic >180 mmHg or > 160 mmHg on 2 consecutive measurements or diastolic > 100 mmHg on optimal medical regimen",
            "Temporal 280 289--*--Screening",
            "Measurement 290 306--*--HgA1c blood test",
            "Value 307 313--*--> 10.0",
            "Procedure 314 342--*--Focal laser photocoagulation",
            "Drug 346 378--*--intravitreal/periocular steroids",
            "Qualifier 391 407--*--in the study eye",
            "Temporal 408 457--*--within the last 90 days prior to study enrollment",
            "Reference_point 441 457--*--study enrollment",
            "Scope 314 378--*--Focal laser photocoagulation or intravitreal/periocular steroids",
            "Observation 461 471--*--history of",
            "Qualifier 472 484--*--intravitreal",
            "Procedure 485 504--*--anti-VEGF injection",
            "Qualifier 517 533--*--in the study eye",
            "Temporal 534 583--*--within the last 45 days prior to study enrollment",
            "Reference_point 567 583--*--study enrollment",
            "Condition 596 629--*--rhegmatogenous retinal detachment",
            "Observation 585 595--*--History of",
            "Condition 631 646--*--retinal tear(s)",
            "Condition 651 679--*--traction retinal detachments",
            "Qualifier 680 696--*--in the study eye",
            "Scope 596 679--*--rhegmatogenous retinal detachment, retinal tear(s), or traction retinal detachments",
            "Condition 698 717;739 747--*--Epiretinal membrane traction",
            "Condition 725 747--*--vitreomacular traction",
            "Qualifier 748 764--*--in the study eye",
            "Non-representable 765 808--*--as determined by the central reading center",
            "Scope 698 747--*--Epiretinal membrane and/or vitreomacular traction",
            "Temporal 810 818--*--Previous",
            "Procedure 819 840--*--pars plana vitrectomy",
            "Qualifier 841 857--*--in the study eye",
            "Procedure 862 881--*--intraocular surgery",
            "Qualifier 882 898--*--in the study eye",
            "Temporal 899 948--*--within the last 90 days prior to study enrollment",
            "Reference_point 932 948--*--study enrollment",
            "Procedure 950 969--*--YAG laser treatment",
            "Qualifier 970 986--*--in the study eye",
            "Temporal 987 1028--*--in last 30 days prior to study enrollment",
            "Reference_point 1012 1028--*--study enrollment",
            "Condition 1030 1041--*--High myopia",
            "Qualifier 1042 1058--*--in the study eye",
            "Measurement 1067 1087--*--spherical equivalent",
            "Value 1091 1097--*-->8.00D",
            "Temporal 1098 1110--*--at screening",
            "Qualifier 1111 1116--*--Other",
            "Condition 1117 1135--*--ocular pathologies",
            "Observation 1171 1229--*--would interfere with the subject's vision in the study eye",
            "Non-query-able 1141 1170--*--in the investigator's opinion",
            "Multiplier 1231 1238--*--Chronic",
            "Multiplier 1242 1251--*--recurrent",
            "Condition 1252 1259--*--uveitis",
            "Scope 1231 1251--*--Chronic or recurrent",
            "Temporal 1261 1268--*--Ongoing",
            "Condition 1269 1285--*--ocular infection",
            "Condition 1269 1275;1289 1301--*--ocular inflammation",
            "Qualifier 1302 1315--*--in either eye",
            "Scope 1269 1301--*--ocular infection or inflammation",
            "Observation 1319 1329--*--history of",
            "Procedure 1330 1346--*--cataract surgery",
            "Condition 1330 1360--*--cataract surgery complications",
            "Condition 1361 1374--*--vitreous loss",
            "Qualifier 1375 1391--*--in the study eye",
            "Scope 1330 1374--*--cataract surgery complications/vitreous loss",
            "Condition 1393 1421--*--Congenital eye malformations",
            "Qualifier 1422 1438--*--in the study eye",
            "Observation 1442 1452--*--history of",
            "Condition 1453 1478--*--penetrating ocular trauma",
            "Qualifier 1479 1495--*--in the study eye",
            "Condition 1497 1517--*--Mentally handicapped",
            "Condition 1519 1527--*--Pregnant",
            "Person 1528 1534--*--female",
            "Person 1554 1559--*--women",
            "Value 1560 1578--*--less than 60 years",
            "Person 1579 1582--*--old",
            "Value 1588 1596--*--positive",
            "Measurement 1597 1617--*--urine pregnancy test",
            "Temporal 1618 1645--*--during the screening window",
            "Observation 1647 1654--*--Nursing",
            "Person 1655 1661--*--female",
            "Competing_trial 1663 1724--*--Currently participating in any other clinical research study.",
            "Condition 1725 1741--*--Contraindication",
            "Drug 1749 1765--*--study medication"
        ]
    },
    "NCT02186782_exc": {
        "Text": "Age < 20 or > 35 years.. Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.. Presence of any infertility factor other than anovulation/oligoovulation.. Previous history of ovarian surgery or surgical removal of one ovary.. Previous exposure to cytotoxic drugs or pelvic irradiation.. Metabolic or hormonal abnormalities.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 8--*--< 20",
            "Value 12 22--*--> 35 years",
            "Scope 4 22--*--< 20 or > 35 years",
            "Measurement 25 40--*--Body mass index",
            "Measurement 42 45--*--BMI",
            "Value 47 59--*--< 18.5 kg/m2",
            "Value 63 73--*--> 25 kg/m2",
            "Scope 47 73--*--< 18.5 kg/m2 or > 25 kg/m2",
            "Condition 92 110--*--infertility factor",
            "Negation 111 121--*--other than",
            "Condition 122 133--*--anovulation",
            "Condition 134 148--*--oligoovulation",
            "Scope 122 148--*--anovulation/oligoovulation",
            "Procedure 171 186--*--ovarian surgery",
            "Procedure 190 206--*--surgical removal",
            "Qualifier 214 219--*--ovary",
            "Multiplier 210 213--*--one",
            "Drug 243 258--*--cytotoxic drugs",
            "Procedure 262 280--*--pelvic irradiation",
            "Condition 296 318--*--hormonal abnormalities",
            "Condition 283 292;305 318--*--Metabolic abnormalities"
        ]
    },
    "NCT02632318_inc": {
        "Text": "History of falls or dizziness at exit from bed in the morning (at least two incidents in the past year). At least 20/200 corrected visual acuity. Stable health. Normal hearing. ",
        "Annotations": [
            "Condition 11 16--*--falls",
            "Condition 20 29--*--dizziness",
            "Temporal 30 61--*--at exit from bed in the morning",
            "Multiplier 63 75--*--at least two",
            "Condition 76 85--*--incidents",
            "Temporal 86 102--*--in the past year",
            "Scope 11 29--*--falls or dizziness",
            "Value 105 120--*--At least 20/200",
            "Measurement 121 144--*--corrected visual acuity",
            "Condition 146 159--*--Stable health",
            "Condition 161 175--*--Normal hearing"
        ]
    },
    "NCT00061308_inc": {
        "Annotations": [
            "Drug 19 54--*--platinum-based chemotherapy regimen",
            "Condition 76 91--*--primary disease",
            "Temporal 13 18--*--prior",
            "Temporal 94 150--*--At least 4 weeks since last surgery or radiation therapy",
            "Reference_point 117 129--*--last surgery",
            "Reference_point 133 150--*--radiation therapy",
            "Condition 167 192--*--a treatment-free interval",
            "Temporal 196 248--*--greater than 6 months following response to platinum",
            "Reference_point 228 248--*--response to platinum",
            "Drug 240 248--*--platinum",
            "Measurement 251 274--*--ECOG performance status",
            "Value 278 279--*--0",
            "Value 278 281--*--0,1",
            "Value 287 288--*--.",
            "Scope 278 287--*--0,1, or 2"
        ],
        "Text": "Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease. . At least 4 weeks since last surgery or radiation therapy. . Must have had a treatment-free interval of greater than 6 months following response to platinum. . ECOG performance status of 0,1, or 2. . "
    },
    "NCT02339844_exc": {
        "Annotations": [
            "Observation 19 27--*--patients",
            "Condition 29 44--*--Substance abuse",
            "Multiplier 50 61--*--daily basis",
            "Multiplier 62 85--*--during the last 3 month",
            "Qualifier 156 171--*--ICD-10/DSM-IV/V",
            "Condition 133 148--*--substance abuse",
            "Temporal 125 132--*--ongoing",
            "Drug 188 202--*--antidepressant",
            "Temporal 203 226--*--during the last 30 days",
            "Condition 228 239--*--Head injury",
            "Multiplier 245 264--*--more than 5 minutes",
            "Condition 268 283--*--unconsciousness",
            "Observation 294 316--*--involuntarily admitted",
            "Observation 294 307;320 327--*--involuntarily treated",
            "Device 329 348--*--Components of metal",
            "Device 373 382--*--Pacemaker",
            "Condition 384 393--*--Pregnancy",
            "Condition 395 418--*--Severe physical illness",
            "Scope 29 418--*--Substance abuse on a daily basis during the last 3 month or patients fulfilling the criteria of ongoing substance abuse due to ICD-10/DSM-IV/V, Treatment with antidepressant during the last 30 days, Head injury with more than 5 minutes of unconsciousness, Patients involuntarily admitted or treated, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness",
            "Observation 439 447--*--controls",
            "Observation 449 471--*--First degree relatives",
            "Condition 477 496--*--psychiatric disease",
            "Condition 498 513--*--Substance abuse",
            "Temporal 514 537--*--during the last 3 month",
            "Value 541 549--*--positive",
            "Procedure 550 568--*--screening of drugs",
            "Qualifier 572 584--*--urine-sample",
            "Condition 586 597--*--Head injury",
            "Multiplier 603 622--*--more than 5 minutes",
            "Condition 626 641--*--unconsciousness",
            "Device 643 662--*--Components of metal",
            "Device 687 696--*--Pacemaker",
            "Condition 698 707--*--Pregnancy",
            "Condition 709 732--*--Severe physical illness",
            "Scope 449 732--*--First degree relatives with psychiatric disease, Substance abuse during the last 3 month or positive screening of drugs in urine-sample, Head injury with more than 5 minutes of unconsciousness, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness"
        ],
        "Text": "Exclusion Criteria patients: Substance abuse on a daily basis during the last 3 month or patients fulfilling the criteria of ongoing substance abuse due to ICD-10/DSM-IV/V, Treatment with antidepressant during the last 30 days, Head injury with more than 5 minutes of unconsciousness, Patients involuntarily admitted or treated, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness. Exclusion criteria controls: First degree relatives with psychiatric disease, Substance abuse during the last 3 month or positive screening of drugs in urine-sample, Head injury with more than 5 minutes of unconsciousness, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness. "
    },
    "NCT03156855_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT02731794_exc": {
        "Annotations": [
            "Condition 0 21--*--myocardial infarction",
            "Temporal 22 50--*--within the preceding 4 weeks",
            "Reference_point 29 50--*--the preceding 4 weeks",
            "Qualifier 52 58--*--severe",
            "Condition 59 72--*--valve disease",
            "Qualifier 73 100--*--requiring valve replacement",
            "Procedure 83 100--*--valve replacement",
            "Procedure 102 122--*--cardiac reoperations"
        ],
        "Text": "myocardial infarction within the preceding 4 weeks. severe valve disease requiring valve replacement. cardiac reoperations. "
    },
    "NCT02348918_inc": {
        "Text": "Male or female, 18 years of age or older.. Study eye with clinically significant diabetic macular edema (DME) with central subfield thickness \u2265 350\u00b5m on spectral domain OCT. Best corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to 23 letters) in the study eye, with BCVA decrement primarily attributable to DME.. Treatment na\u00efve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.. In the investigator's opinion, the subject still has significant intraretinal fluid with room for improvement in both macular edema and BCVA.. Intra-Ocular Pressure (IOP) is under control (i.e., IOP \u2264 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.. Willing and able to return for all study visits.. Able to meet the extensive post-op evaluation regimen.. Understands and signs the informed consent form.. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 16 24;32 40--*--18 years or older",
            "Person 28 31--*--age",
            "Condition 80 108--*--diabetic macular edema (DME)",
            "Qualifier 57 79--*--clinically significant",
            "Measurement 114 140--*--central subfield thickness",
            "Value 141 148--*--\u2265 350\u00b5m",
            "Procedure 152 171--*--spectral domain OCT",
            "Measurement 172 207--*--Best corrected visual acuity (BCVA)",
            "Value 211 243--*--20/50 to 20/320 ETDRS equivalent",
            "Value 245 269--*--65 letters to 23 letters",
            "Qualifier 271 287--*--in the study eye",
            "Non-representable 289 338--*--with BCVA decrement primarily attributable to DME",
            "Observation 340 355--*--Treatment na\u00efve",
            "Negation 363 365--*--no",
            "Temporal 366 374--*--previous",
            "Procedure 375 394--*--anti-VEGF treatment",
            "Qualifier 395 411--*--in the study eye",
            "Negation 415 417--*--no",
            "Procedure 418 437--*--anti-VEGF treatment",
            "Temporal 438 478--*--in the 45 days prior to study enrollment",
            "Reference_point 462 478--*--study enrollment",
            "Scope 363 478--*--no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment",
            "Non-query-able 480 509--*--In the investigator's opinion",
            "Qualifier 533 544--*--significant",
            "Condition 545 563--*--intraretinal fluid",
            "Qualifier 564 589--*--with room for improvement",
            "Non-representable 564 589--*--with room for improvement",
            "Condition 598 611--*--macular edema",
            "Condition 616 620--*--BCVA",
            "Scope 598 620--*--macular edema and BCVA",
            "Measurement 622 649--*--Intra-Ocular Pressure (IOP)",
            "Value 653 666--*--under control",
            "Measurement 674 677--*--IOP",
            "Value 678 685--*--\u2264 25 mm",
            "Qualifier 686 702--*--in the study eye",
            "Drug 739 757--*--IOP lowering drops",
            "Negation 721 724--*--not",
            "Qualifier 708 717--*--study eye",
            "Scope 674 702--*--IOP \u2264 25 mm in the study eye",
            "Scope 622 666--*--Intra-Ocular Pressure (IOP) is under control",
            "Post-eligibility 759 807--*--Willing and able to return for all study visits.",
            "Post-eligibility 808 862--*--Able to meet the extensive post-op evaluation regimen.",
            "Informed_consent 863 911--*--Understands and signs the informed consent form."
        ]
    },
    "NCT02186782_inc": {
        "Text": "Infertile women with eugonadotrophic anovulation/oligoovulation.. Unexplained infertility.. ",
        "Annotations": [
            "Person 10 15--*--women",
            "Condition 0 9--*--Infertile",
            "Condition 37 48--*--anovulation",
            "Condition 49 63--*--oligoovulation",
            "Qualifier 21 36--*--eugonadotrophic",
            "Scope 37 63--*--anovulation/oligoovulation",
            "Qualifier 66 77--*--Unexplained",
            "Condition 78 89--*--infertility"
        ]
    },
    "NCT02632318_exc": {
        "Text": "Regular cigarette smoker. Alcohol abuse. Drug abuse. ",
        "Annotations": [
            "Observation 0 24--*--Regular cigarette smoker",
            "Observation 26 39--*--Alcohol abuse",
            "Observation 41 51--*--Drug abuse"
        ]
    },
    "NCT03046108_inc": {
        "Annotations": [
            "Condition 22 36--*--Morton neuroma",
            "Procedure 50 65--*--ultrasound scan",
            "Mood 0 18--*--Clinical suspicion",
            "Temporal 84 104--*--more than six months",
            "Condition 67 75--*--Symptoms",
            "Measurement 110 132;155 168--*--thickness of the nerve in short axis",
            "Value 141 154--*--at least 2 mm",
            "Value 173 186--*--at least 5 mm",
            "Measurement 110 132;187 211--*--thickness of the nerve in the longitudinal axis"
        ],
        "Text": "Clinical suspicion of Morton neuroma confirmed in ultrasound scan. Symptoms present more than six months. The thickness of the nerve must be at least 2 mm in short axis and at least 5 mm in the longitudinal axis.. "
    },
    "NCT02509091_inc": {
        "Text": "Age=18 years and =80 years;. Patients with non-cystic fibrosis bronchiectasis diagnosed by high-resolution CT;. Are sensitive to amikacin;. Acute exacerbation of bronchiectasis;. Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc;. Willing to join in and sign the informed consent form.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 3 26--*--=18 years and =80 years",
            "Condition 43 77--*--non-cystic fibrosis bronchiectasis",
            "Procedure 91 109--*--high-resolution CT",
            "Condition 116 125--*--sensitive",
            "Drug 129 137--*--amikacin",
            "Condition 140 176--*--Acute exacerbation of bronchiectasis",
            "Post-eligibility 179 269--*--Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc",
            "Informed_consent 272 325--*--Willing to join in and sign the informed consent form"
        ]
    },
    "NCT02627521_exc": {
        "Text": "Anticoagulation therapy. Prior CABG.. Active bleeding or at high risk of bleeding. Severe liver or renal disease.. Hypersensitivity to ticagrelor. History of intracranial hemorrhage. ",
        "Annotations": [
            "Procedure 0 23--*--Anticoagulation therapy",
            "Temporal 25 30--*--Prior",
            "Procedure 31 35--*--CABG",
            "Qualifier 38 44--*--Active",
            "Condition 45 53--*--bleeding",
            "Qualifier 57 69--*--at high risk",
            "Condition 73 81--*--bleeding",
            "Condition 99 112--*--renal disease",
            "Condition 105 112;90 95--*--disease liver",
            "Qualifier 83 89--*--Severe",
            "Scope 90 112--*--liver or renal disease",
            "Condition 115 131--*--Hypersensitivity",
            "Drug 135 145--*--ticagrelor",
            "Observation 147 154--*--History",
            "Condition 158 181--*--intracranial hemorrhage"
        ]
    },
    "NCT01684501_exc": {
        "Text": "score level D on the SIGAM mobility grade . have experienced 1 or more falls in the last month before the study . have a residual limb length which does not allow for seven inches clearance of bracket attachment for the PowerFoot . the residual limb must be stable in volume (no change in socket or socket padding in last 6 months) and without pain that limits function . the sound-side (contralateral) lower extremity must be free of impediments that affect gait, range of motion, or limb muscle activity . Any diagnosed cardiovascular, pulmonary, neurological, and/ or orthopedic conditions that would interfere with subject participation       .     . ",
        "Annotations": [
            "Measurement 21 41--*--SIGAM mobility grade",
            "Value 6 13--*--level D",
            "Multiplier 60 69--*--1 or more",
            "Observation 70 75--*--falls",
            "Temporal 76 110--*--in the last month before the study",
            "Reference_point 83 110--*--last month before the study",
            "Measurement 119 139--*--residual limb length",
            "Value 146 209--*--does not allow for seven inches clearance of bracket attachment",
            "Negation 146 154--*--does not",
            "Non-query-able 229 366--*--the residual limb must be stable in volume (no change in socket or socket padding in last 6 months) and without pain that limits function",
            "Condition 431 459--*--impediments that affect gait",
            "Condition 431 454;461 476--*--impediments that affect range of motion",
            "Condition 431 454;481 501--*--impediments that affect limb muscle activity",
            "Observation 399 414--*--lower extremity",
            "Scope 431 501--*--impediments that affect gait, range of motion, or limb muscle activity",
            "Negation 423 427--*--free",
            "Condition 517 531;577 587--*--cardiovascular conditions",
            "Condition 533 542;577 587--*--pulmonary conditions",
            "Condition 544 556;577 587--*--neurological conditions",
            "Condition 566 587--*--orthopedic conditions",
            "Scope 517 587--*--cardiovascular, pulmonary, neurological, and/ or orthopedic conditions",
            "Qualifier 599 635--*--interfere with subject participation",
            "Undefined_semantics 599 635--*--interfere with subject participation",
            "Subjective_judgement 599 635--*--interfere with subject participation"
        ]
    },
    "NCT01177891_exc": {
        "Text": "Blood donation of more than 450ml in the previous three months. . Subject with an abnormal karyotype in favor of Turner syndrome or having a premutation of the FMR1 gene or a syndromic form . Subject exclusion period in another study without direct individual benefit . Subject refusing to sign the consent form       .     . ",
        "Annotations": [
            "Procedure 0 14--*--Blood donation",
            "Qualifier 15 33--*--of more than 450ml",
            "Value 18 33--*--more than 450ml",
            "Temporal 34 62--*--in the previous three months",
            "Condition 81 99--*--abnormal karyotype",
            "Condition 112 127--*--Turner syndrome",
            "Condition 140 168--*--premutation of the FMR1 gene",
            "Condition 174 188--*--syndromic form",
            "Undefined_semantics 174 188--*--syndromic form",
            "Post-eligibility 190 265--*--Subject exclusion period in another study without direct individual benefit",
            "Context_Error 190 265--*--Subject exclusion period in another study without direct individual benefit",
            "Post-eligibility 267 308--*--Subject refusing to sign the consent form",
            "Non-query-able 190 265--*--Subject exclusion period in another study without direct individual benefit",
            "Non-query-able 267 308--*--Subject refusing to sign the consent form"
        ]
    },
    "NCT01214096_exc": {
        "Text": "1. Atrial fibrillation; . 2. Subject underwent cardiac pacemaker treatment; . 3. Subject underwent metal graft treatment; . 4. Claustrophobia; . 5. Acute myocardial infarction, cardiac ischemia indicated by 6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension; . 6. Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months; . 7. Subject underwent cardiac surgery or cerebrovascular events within the previous six months; . 8. Subjects who plan to have cardiac transplantation; . 9. Severe hepatic and renal insufficiency (serum creatinine>2.0 mg /dl, AST or ALT is five times higher than the upper limit of normal range); . 10. Subject needs mechanical ventilation; . 11. Systolic blood pressure < 90mmHg, or > 160mmHg; . 12. Chronic heart failure complicated with acute hemodynamic disturbance or acute decompensation within last 1 month; . 13. Mobitz Type II or III\u00b0 atrial ventricular block\uff0csevere ventricular arrhythmia (polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia); . 14. Serum potassium<3.2mmol/L, or>5.5mmol/L; . 15. Female subject is pregnant or plan to become pregnant . 16. Childbearing-aged female subject who is unmarried or dose not bear child; . 17. Subject with life expectancy less than 6 months as assessed by investigators; . 18. Subject participated in any other clinical trial within the previous three months; . 19. Subject with previous history of tumor, or current tumor patient, or subject with pre-cancerous disease manifested by pathological examination (such as ductal carcinoma in situ or cervical epithelial dysplasia) . 20. Examinations (physical examination, X-ray examination, type-B ultrasonic detection or other methods) reveal that the subject has malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement); . 21. The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason).       .     . ",
        "Annotations": [
            "Condition 3 22--*--Atrial fibrillation",
            "Procedure 46 73--*--cardiac pacemaker treatment",
            "Device 46 63--*--cardiac pacemaker",
            "Procedure 97 118--*--metal graft treatment",
            "Device 97 108--*--metal graft",
            "Condition 124 138--*--Claustrophobia",
            "Condition 144 171--*--Acute myocardial infarction",
            "Condition 173 189--*--cardiac ischemia",
            "Procedure 203 221--*--6-minute walk test",
            "Condition 223 250--*--hypertrophic cardiomyopathy",
            "Condition 252 277--*--constrictive pericarditis",
            "Condition 291 304--*--valve disease",
            "Qualifier 279 290--*--significant",
            "Condition 308 332--*--congenital heart disease",
            "Condition 334 363--*--severe pulmonary hypertension",
            "Qualifier 334 340--*--severe",
            "Qualifier 308 318--*--congenital",
            "Scope 203 363--*--6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension",
            "Scope 144 189--*--Acute myocardial infarction, cardiac ischemia",
            "Condition 369 391--*--Ischemic heart failure",
            "Procedure 404 421--*--revascularization",
            "Negation 392 399--*--without",
            "Procedure 439 456--*--revascularization",
            "Temporal 457 477--*--within last 6 months",
            "Scope 392 477--*--without the revascularization or undergone the revascularization within last 6 months",
            "Procedure 501 516--*--cardiac surgery",
            "Condition 520 542--*--cerebrovascular events",
            "Temporal 543 573--*--within the previous six months",
            "Scope 501 542--*--cardiac surgery or cerebrovascular events",
            "Procedure 605 628--*--cardiac transplantation",
            "Observation 592 596--*--plan",
            "Condition 653 672--*--renal insufficiency",
            "Condition 641 648;659 672--*--hepatic insufficiency",
            "Measurement 674 690--*--serum creatinine",
            "Value 690 701--*-->2.0 mg /dl",
            "Measurement 703 706--*--AST",
            "Measurement 710 713--*--ALT",
            "Value 717 771--*--five times higher than the upper limit of normal range",
            "Scope 703 713--*--AST or ALT",
            "Scope 641 672--*--hepatic and renal insufficiency",
            "Procedure 793 815--*--mechanical ventilation",
            "Measurement 831 845--*--blood pressure",
            "Value 846 854--*--< 90mmHg",
            "Value 859 868--*--> 160mmHg",
            "Scope 846 868--*--< 90mmHg, or > 160mmHg",
            "Condition 875 896--*--Chronic heart failure",
            "Condition 914 943--*--acute hemodynamic disturbance",
            "Condition 947 967--*--acute decompensation",
            "Temporal 968 987--*--within last 1 month",
            "Scope 914 967--*--acute hemodynamic disturbance or acute decompensation",
            "Measurement 994 1000--*--Mobitz",
            "Value 1001 1015--*--Type II or III",
            "Condition 1017 1041--*--atrial ventricular block",
            "Qualifier 1042 1048--*--severe",
            "Condition 1049 1071--*--ventricular arrhythmia",
            "Observation 1098 1125--*--premature ventricular beats",
            "Condition 1150 1173--*--ventricular tachycardia",
            "Qualifier 1136 1149--*--non-sustained",
            "Multiplier 1127 1135--*--frequent",
            "Measurement 1181 1196--*--Serum potassium",
            "Value 1196 1206--*--<3.2mmol/L",
            "Value 1210 1220--*-->5.5mmol/L",
            "Scope 1196 1220--*--<3.2mmol/L, or>5.5mmol/L",
            "Multiplier 1089 1097--*--frequent",
            "Qualifier 1073 1084--*--polymorphic",
            "Scope 1073 1173--*--polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia",
            "Person 1227 1233--*--Female",
            "Condition 1245 1253--*--pregnant",
            "Observation 1257 1261--*--plan",
            "Condition 1272 1280--*--pregnant",
            "Person 1304 1310--*--female",
            "Observation 1326 1335--*--unmarried",
            "Observation 1348 1358--*--bear child",
            "Negation 1344 1347--*--not",
            "Value 1394 1412--*--less than 6 months",
            "Observation 1378 1393--*--life expectancy",
            "Context_Error 1448 1530--*--Subject participated in any other clinical trial within the previous three months;",
            "Condition 1569 1574--*--tumor",
            "Observation 1549 1565--*--previous history",
            "Condition 1587 1592--*--tumor",
            "Temporal 1579 1586--*--current",
            "Condition 1618 1639--*--pre-cancerous disease",
            "Procedure 1654 1678--*--pathological examination",
            "Condition 1688 1712--*--ductal carcinoma in situ",
            "Condition 1716 1745--*--cervical epithelial dysplasia",
            "Scope 1688 1745--*--ductal carcinoma in situ or cervical epithelial dysplasia",
            "Procedure 1766 1786--*--physical examination",
            "Procedure 1788 1805--*--X-ray examination",
            "Procedure 1807 1834--*--type-B ultrasonic detection",
            "Procedure 1838 1851--*--other methods",
            "Scope 1766 1851--*--physical examination, X-ray examination, type-B ultrasonic detection or other methods",
            "Procedure 1752 1764--*--Examinations",
            "Undefined_semantics 1752 1764--*--Examinations",
            "Condition 1881 1895--*--malignant mass",
            "Condition 1897 1914--*--gland hyperplasia",
            "Condition 1918 1925--*--adenoma",
            "Condition 1931 1949--*--endocrine activity",
            "Qualifier 1926 1949--*--with endocrine activity",
            "Condition 2002 2018--*--pheochromocytoma",
            "Condition 2020 2039--*--thyroid enlargement",
            "Condition 1954 1963;1974 1992--*--impact on endocrine function",
            "Condition 1954 1969--*--impact on heart",
            "Scope 1954 1992--*--impact on heart, or endocrine function",
            "Scope 2002 2039--*--pheochromocytoma, thyroid enlargement",
            "Scope 1881 2040--*--malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement)",
            "Post-eligibility 2047 2224--*--The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason)."
        ]
    },
    "NCT01991743_exc": {
        "Annotations": [
            "Non-query-able 0 7--*--Refusal",
            "Condition 9 25--*--Contraindication",
            "Procedure 29 38--*--neuraxial",
            "Condition 40 52--*--coagulopathy",
            "Drug 54 67--*--anticoagulant",
            "Condition 73 88--*--local infection",
            "Condition 90 96--*--sepsis",
            "Condition 103 123--*--Rupture of membranes",
            "Scope 41 96--*--oagulopathy, anticoagulant use, local infection, sepsis",
            "Scope 9 38--*--Contraindication to neuraxial",
            "Non-query-able 126 307--*--Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion."
        ],
        "Text": "Refusal. Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes.. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.. "
    },
    "NCT03034837_exc": {
        "Annotations": [
            "Observation 8 36--*--cooperate with the treatment",
            "Negation 4 7--*--not",
            "Negation 42 45--*--not",
            "Observation 57 81--*--child's parental consent",
            "Informed_consent 38 81--*--Can not obtain the child's parental consent"
        ],
        "Text": "Can not cooperate with the treatment. Can not obtain the child's parental consent. "
    },
    "NCT02509091_exc": {
        "Text": "Active bleeding without control;. Receiving nasal or facial surgery recently;. With severe cardio-pulmonary dysfunction, such as left heart failure, unstable arrhythmia, etc.. With other respiratory diseases: such as active pulmonary tuberculosis, non-tuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis, etc.. Be allergic to amikacin. ",
        "Annotations": [
            "Condition 7 15--*--bleeding",
            "Qualifier 0 6--*--Active",
            "Procedure 53 67--*--facial surgery",
            "Procedure 44 49;60 67--*--nasal surgery",
            "Condition 91 119--*--cardio-pulmonary dysfunction",
            "Qualifier 84 90--*--severe",
            "Condition 129 147--*--left heart failure",
            "Condition 158 168--*--arrhythmia",
            "Qualifier 149 157--*--unstable",
            "Scope 129 168--*--left heart failure, unstable arrhythmia",
            "Condition 187 207--*--respiratory diseases",
            "Condition 224 246--*--pulmonary tuberculosis",
            "Qualifier 217 223--*--active",
            "Condition 248 277;284 301--*--non-tuberculosis mycobacteria pulmonary disease",
            "Condition 279 282--*--NTM",
            "Condition 303 326--*--pulmonary aspergillosis",
            "Scope 217 326--*--active pulmonary tuberculosis, non-tuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis",
            "Condition 337 345--*--allergic",
            "Drug 349 357--*--amikacin"
        ]
    },
    "NCT03046108_exc": {
        "Annotations": [
            "Drug 32 47--*--corticosteroids",
            "Drug 51 68--*--local anesthetics",
            "Condition 0 16--*--Contraindication",
            "Scope 32 68--*--corticosteroids or local anesthetics",
            "Condition 82 106--*--inflammatory arthropathy",
            "Condition 110 120;82 94--*--neuropathy inflammatory",
            "Condition 122 134--*--Skin lesions",
            "Condition 148 165--*--diabetes mellitus",
            "Procedure 183 199--*--previous surgery",
            "Condition 167 179--*--Infiltration",
            "Post-eligibility 213 247--*--Refusal to participate in the stud"
        ],
        "Text": "Contraindication for the use of corticosteroids or local anesthetics. Presence of inflammatory arthropathy or neuropathy. Skin lesions in the area. diabetes mellitus. Infiltration or previous surgery in the area. Refusal to participate in the study. "
    },
    "NCT01684501_inc": {
        "Text": "weigh more than 200 lbs . are high level ambulators corresponding to levels E to F of the Special Interest Group of Amputee Medicine (SIGAM) mobility grade . have the ability to follow multi-step commands. . ",
        "Annotations": [
            "Measurement 0 5--*--weigh",
            "Value 6 23--*--more than 200 lbs",
            "Condition 29 50--*--high level ambulators",
            "Measurement 89 154--*--Special Interest Group of Amputee Medicine (SIGAM) mobility grade",
            "Value 68 81--*--levels E to F",
            "Condition 165 202--*--ability to follow multi-step commands"
        ]
    },
    "NCT02627521_inc": {
        "Text": "Accepted for CABG surgery. Treatment with Ticagrelor within 48 hours. ",
        "Annotations": [
            "Procedure 13 25--*--CABG surgery",
            "Mood 0 12--*--Accepted for",
            "Drug 42 52--*--Ticagrelor",
            "Temporal 53 68--*--within 48 hours",
            "Procedure 27 36--*--Treatment"
        ]
    },
    "NCT01177891_inc": {
        "Text": "Patients of familial cases of POF : . Female subjects between 16 and 40 years or women older than 40 years with a cessation of ovarian function before the age of 40 years with increased levels of FSH . Primary or secondary amenorrhea for more than three months with LH and FSH> 30mUI/ml . No cases of fragile X syndrome in the family or blepharophimosis syndrome . At least two cases in the family . Origin Caucasian . Patient signing the consent form for at least the blood sample . Patient with Social Security . Population Index related topics : . The presence of cycles until the age of 40 years with proven fertility, at least one child . Amenorrhea and FSH> 30mUI/ml according to the criteria of the index subject . Men of the family of index case . Population control : . Women of Caucasian origin . Women who had regular cycles until at least age 40 and at least one child . Lack of land autoimmune (no history of thyroid disease or diabetes type 1) . Woman signing the consent form for at least the blood sample . ",
        "Annotations": [
            "Parsing_Error 0 35--*--Patients of familial cases of POF :",
            "Person 37 43--*--Female",
            "Value 53 76--*--between 16 and 40 years",
            "Value 86 105--*--older than 40 years",
            "Person 71 76--*--years",
            "Person 80 85--*--women",
            "Reference_point 86 91--*--older",
            "Condition 113 142--*--cessation of ovarian function",
            "Value 143 169--*--before the age of 40 years",
            "Person 154 157--*--age",
            "Value 175 184--*--increased",
            "Measurement 185 198--*--levels of FSH",
            "Condition 221 231--*--amenorrhea",
            "Qualifier 211 220--*--secondary",
            "Qualifier 200 207--*--Primary",
            "Scope 200 220--*--Primary or secondary",
            "Temporal 232 258--*--for more than three months",
            "Measurement 264 266--*--LH",
            "Measurement 271 274--*--FSH",
            "Value 274 284--*--> 30mUI/ml",
            "Scope 264 274--*--LH and FSH",
            "Condition 298 316--*--fragile X syndrome",
            "Observation 317 330--*--in the family",
            "Condition 334 359--*--blepharophimosis syndrome",
            "Negation 286 288--*--No",
            "Scope 298 359--*--fragile X syndrome in the family or blepharophimosis syndrome",
            "Multiplier 361 373--*--At least two",
            "Undefined_semantics 374 393--*--cases in the family",
            "Parsing_Error 374 393--*--cases in the family",
            "Condition 402 411--*--Caucasian",
            "Post-eligibility 413 475--*--Patient signing the consent form for at least the blood sample",
            "Non-query-able 477 505--*--Patient with Social Security",
            "Parsing_Error 507 540--*--Population Index related topics :",
            "Condition 546 564--*--presence of cycles",
            "Value 565 590--*--until the age of 40 years",
            "Person 575 578--*--age",
            "Pregnancy_considerations 542 632--*--The presence of cycles until the age of 40 years with proven fertility, at least one child",
            "Condition 634 644--*--Amenorrhea",
            "Measurement 649 652--*--FSH",
            "Value 652 662--*--> 30mUI/ml",
            "Not_a_criteria 711 742--*--Men of the family of index case",
            "Condition 775 791--*--Caucasian origin",
            "Person 766 771--*--Women",
            "Person 793 798--*--Women",
            "Condition 807 821--*--regular cycles",
            "Not_a_criteria 744 764--*--Population control :",
            "Parsing_Error 744 764--*--Population control :",
            "Value 822 843--*--until at least age 40",
            "Person 837 840--*--age",
            "Condition 799 843--*--who had regular cycles until at least age 40",
            "Condition 881 891--*--autoimmune",
            "Condition 907 922--*--thyroid disease",
            "Condition 926 941--*--diabetes type 1",
            "Negation 893 895--*--no",
            "Observation 896 903--*--history",
            "Scope 907 941--*--thyroid disease or diabetes type 1",
            "Grammar_Error 868 880--*--Lack of land",
            "Post-eligibility 944 1004--*--Woman signing the consent form for at least the blood sample"
        ]
    },
    "NCT03034837_inc": {
        "Annotations": [
            "Condition 0 17--*--generally healthy",
            "Observation 18 34--*--grade 1-2 school",
            "Person 35 43--*--children",
            "Informed_consent 45 74--*--with written parental consent",
            "Multiplier 81 91--*--at least 1",
            "Qualifier 92 97--*--sound",
            "Qualifier 102 115--*--fully erupted",
            "Condition 116 137--*--permanent first molar"
        ],
        "Text": "generally healthy grade 1-2 school children. with written parental consent. with at least 1 sound and fully erupted permanent first molar. "
    },
    "NCT01214096_inc": {
        "Text": "1. Age: 18-75 years old, no limitation in gender; . 2. Left ventricular ejection fraction (LVEF) \u2264 40% (ECHO); . 3. Patients with chronic heart failure (NYHA class II or III); . 4. In the past one month, the clinical condition (including history, clinical symptoms and signs) was relatively stable; . 5. Patients on standard treatment of chronic heart failure at the target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month; . 6. Understand and sign the informed consent form; . ",
        "Annotations": [
            "Value 8 19--*--18-75 years",
            "Person 3 6--*--Age",
            "Measurement 54 95--*--Left ventricular ejection fraction (LVEF)",
            "Value 96 101--*--\u2264 40%",
            "Procedure 103 107--*--ECHO",
            "Condition 128 149--*--chronic heart failure",
            "Measurement 151 155--*--NYHA",
            "Value 156 171--*--class II or III",
            "Temporal 178 199--*--In the past one month",
            "Observation 235 242--*--history",
            "Condition 244 261--*--clinical symptoms",
            "Condition 244 252;266 271--*--clinical signs",
            "Qualifier 277 294--*--relatively stable",
            "Scope 235 271--*--history, clinical symptoms and signs",
            "Condition 334 355--*--chronic heart failure",
            "Procedure 321 355--*--treatment of chronic heart failure",
            "Observation 378 400--*--maximum tolerance dose",
            "Observation 363 374--*--target dose",
            "Temporal 401 417--*--for over 1 month",
            "Temporal 437 452--*--in last 1 month",
            "Observation 422 436--*--unchanged dose",
            "Scope 363 400--*--target dose or maximum tolerance dose",
            "Scope 363 452--*--target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month",
            "Post-eligibility 458 504--*--Understand and sign the informed consent form;",
            "Non-query-able 458 504--*--Understand and sign the informed consent form;"
        ]
    },
    "NCT01991743_inc": {
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 17 20--*--age",
            "Value 21 33--*--18 and older",
            "Observation 35 54--*--Breech presentation",
            "Condition 56 75--*--Singleton gestation",
            "Procedure 91 94--*--ECV",
            "Procedure 104 107--*--CSE",
            "Mood 95 103--*--desiring",
            "Mood 77 90--*--scheduled for"
        ],
        "Text": "Healthy patients age 18 and older. Breech presentation. Singleton gestation .scheduled for ECV desiring CSE.. "
    },
    "NCT00749112_inc": {
        "Text": "Age: > or = 16 years . Weight: more than 40 Kg . Autoimmune Hemolytic anemia with clinical and biochemical evidence of hemolysis refractory to treatment, in relapse or steroids dependant . Idiopathic thrombocytopenic purpura with platelet counts < 50,000, refractory to treatment, in relapse or steroids dependant . ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 5 20--*--> or = 16 years",
            "Measurement 22 28--*--Weight",
            "Value 30 45--*--more than 40 Kg",
            "Condition 47 74--*--Autoimmune Hemolytic anemia",
            "Mood 93 113--*--biochemical evidence",
            "Mood 105 113;80 88--*--evidence clinical",
            "Condition 117 126--*--hemolysis",
            "Qualifier 127 150--*--refractory to treatment",
            "Procedure 141 150--*--treatment",
            "Qualifier 166 184--*--steroids dependant",
            "Qualifier 152 162--*--in relapse",
            "Drug 166 174--*--steroids",
            "Scope 152 184--*--in relapse or steroids dependant",
            "Condition 186 221--*--Idiopathic thrombocytopenic purpura",
            "Measurement 227 242--*--platelet counts",
            "Value 243 251--*--< 50,000",
            "Qualifier 253 276--*--refractory to treatment",
            "Drug 267 276--*--treatment",
            "Qualifier 278 288--*--in relapse",
            "Qualifier 292 310--*--steroids dependant",
            "Drug 292 300--*--steroids",
            "Scope 253 310--*--refractory to treatment, in relapse or steroids dependant"
        ]
    },
    "NCT02015923_inc": {
        "Annotations": [
            "Condition 0 17--*--colorectal cancer",
            "Qualifier 18 52--*--above to 12 cm from the anal verge",
            "Qualifier 54 66--*--unresectable",
            "Qualifier 67 78--*--synchronous",
            "Condition 79 89--*--metastases",
            "Procedure 116 128--*--chemotherapy",
            "Condition 94 111--*--contraindications",
            "Negation 91 93--*--no",
            "Condition 141 166--*--peritoneal carcinomatosis",
            "Negation 130 137--*--absence",
            "Condition 168 190;198 208--*--central nervous system metastasis",
            "Condition 193 208--*--bone metastasis",
            "Scope 141 208--*--peritoneal carcinomatosis, central nervous system o bone metastasis",
            "Measurement 230 234--*--ECOG",
            "Value 235 238--*--= 2",
            "Measurement 211 229--*--performance status",
            "Measurement 240 274--*--Eastern Cooperative Oncology Group",
            "Scope 211 234;240 274--*--performance status ECOG Eastern Cooperative Oncology Group",
            "Qualifier 277 289--*--uncontrolled",
            "Temporal 290 301--*--concomitant",
            "Condition 302 356--*--medical conditions that may compromise to chemotherapy",
            "Qualifier 370 381--*--symptomatic",
            "Condition 382 397--*--cardiac disease",
            "Qualifier 358 369--*--significant",
            "Condition 403 412--*--pregnancy",
            "Observation 416 429--*--breastfeeding",
            "Negation 399 402--*--not",
            "Scope 403 429--*--pregnancy or breastfeeding"
        ],
        "Text": "colorectal cancer above to 12 cm from the anal verge. unresectable synchronous metastases. no contraindications for chemotherapy. absence of peritoneal carcinomatosis, central nervous system o bone metastasis.. performance status ECOG = 2 (Eastern Cooperative Oncology Group). uncontrolled concomitant medical conditions that may compromise to chemotherapy. significant symptomatic cardiac disease. not pregnancy or breastfeeding. "
    },
    "NCT02957877_exc": {
        "Text": "History of intolerance to LMWHs during HD. Receiving warfarin or other oral anticoagulant. Pregnant patients. ",
        "Annotations": [
            "Condition 11 22--*--intolerance",
            "Drug 26 31--*--LMWHs",
            "Procedure 39 41--*--HD",
            "Temporal 32 41--*--during HD",
            "Drug 53 61--*--warfarin",
            "Condition 71 89--*--oral anticoagulant",
            "Qualifier 65 70--*--other",
            "Condition 91 99--*--Pregnant"
        ]
    },
    "NCT02890719_inc": {
        "Text": "Age between 18 and 78 year-old. . Previous liver transplantation(more than 6 month). . Genotype 1 and 4 infection. . Hepatitis C recurrence defined by the presence of abnormal liver function test, positive HCV-RNA, histological signs of hepatitis C recurrence. . Viral load \u226510000UI/mL. . Immunosuppression with tacrolimus and/or mycophenolate (Prednisone use is allowed at low dose, \u226410 mg/d). . Treatment na\u00efve or treatment experienced (Peg-RBV or triple therapy). . ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 30--*--between 18 and 78 year-old",
            "Procedure 42 63--*--liver transplantation",
            "Temporal 33 41--*--Previous",
            "Temporal 64 81--*--more than 6 month",
            "Measurement 85 93--*--Genotype",
            "Value 94 101--*--1 and 4",
            "Condition 102 111--*--infection",
            "Condition 114 125--*--Hepatitis C",
            "Multiplier 126 136--*--recurrence",
            "Measurement 173 192--*--liver function test",
            "Value 164 172--*--abnormal",
            "Measurement 203 210--*--HCV-RNA",
            "Value 194 202--*--positive",
            "Procedure 212 224--*--histological",
            "Condition 234 245--*--hepatitis C",
            "Multiplier 246 256--*--recurrence",
            "Condition 212 256--*--histological signs of hepatitis C recurrence",
            "Scope 164 256--*--abnormal liver function test, positive HCV-RNA, histological signs of hepatitis C recurrence",
            "Scope 114 136--*--Hepatitis C recurrence",
            "Measurement 259 269--*--Viral load",
            "Value 270 281--*--\u226510000UI/mL",
            "Procedure 284 301--*--Immunosuppression",
            "Drug 307 317--*--tacrolimus",
            "Drug 325 338--*--mycophenolate",
            "Drug 340 350--*--Prednisone",
            "Multiplier 369 377--*--low dose",
            "Value 379 387--*--\u226410 mg/d",
            "Scope 307 388--*--tacrolimus and/or mycophenolate (Prednisone use is allowed at low dose, \u226410 mg/d)",
            "Condition 391 406--*--Treatment na\u00efve",
            "Condition 410 431--*--treatment experienced",
            "Procedure 433 440--*--Peg-RBV",
            "Procedure 444 458--*--triple therapy",
            "Scope 433 458--*--Peg-RBV or triple therapy",
            "Scope 391 431--*--Treatment na\u00efve or treatment experienced"
        ]
    },
    "NCT02974686_exc": {
        "Text": "Dual organ or kidney after another solid organ transplant. Presence of a preexisting significant GI condition that does not have a presumed causal relationship with MPA. Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA. eGFR<40 ml/min at time of possible conversion. Proteinuria >1 gram/day at time of possible conversion. Hemoglobin <10 g/dL. WBC <3 K/cumm. Platelets <100 K/cumm. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound infection, incisional hernia, lymphocele, seroma). Elevated total cholesterol (>350 mg/dL) and/or triglycerides (>500 ng/dL) at time of possible conversion. Hypersensitivity to everolimus, sirolimus, or other rapamycin deriviatives. ",
        "Annotations": [
            "Procedure 35 57--*--solid organ transplant",
            "Condition 0 10--*--Dual organ",
            "Condition 0 4;14 20--*--Dual kidney",
            "Scope 0 20--*--Dual organ or kidney",
            "Condition 97 109--*--GI condition",
            "Temporal 73 84--*--preexisting",
            "Qualifier 85 96--*--significant",
            "Condition 186 197--*--GI disorder",
            "Qualifier 198 221--*--induced by an infection",
            "Condition 212 221--*--infection",
            "Condition 223 251--*--underlying medical condition",
            "Drug 268 278--*--medication",
            "Drug 290 293--*--MPA",
            "Negation 279 289--*--other than",
            "Measurement 295 299--*--eGFR",
            "Value 299 309--*--<40 ml/min",
            "Temporal 310 340--*--at time of possible conversion",
            "Measurement 342 353--*--Proteinuria",
            "Value 354 365--*-->1 gram/day",
            "Temporal 366 396--*--at time of possible conversion",
            "Measurement 398 408--*--Hemoglobin",
            "Value 409 417--*--<10 g/dL",
            "Measurement 419 422--*--WBC",
            "Value 423 432--*--<3 K/cumm",
            "Measurement 434 443--*--Platelets",
            "Value 444 455--*--<100 K/cumm",
            "Condition 457 477--*--Wound healing issues",
            "Temporal 478 508--*--at time of possible conversion",
            "Condition 514 530--*--wound dehiscence",
            "Condition 532 547--*--wound infection",
            "Condition 549 566--*--incisional hernia",
            "Condition 568 578--*--lymphocele",
            "Condition 580 586--*--seroma",
            "Scope 514 586--*--wound dehiscence, wound infection, incisional hernia, lymphocele, seroma",
            "Measurement 598 615--*--total cholesterol",
            "Value 589 597--*--Elevated",
            "Value 617 627--*-->350 mg/dL",
            "Measurement 636 649--*--triglycerides",
            "Value 651 661--*-->500 ng/dL",
            "Temporal 663 693--*--at time of possible conversion",
            "Condition 695 711--*--Hypersensitivity",
            "Drug 715 725--*--everolimus",
            "Drug 727 736--*--sirolimus",
            "Drug 747 756--*--rapamycin"
        ]
    },
    "NCT03355469_exc": {
        "Text": "Morbidly obese patients (BMI >47 kg/m2) and overweight/lean patients (BMI <27 kg/m2). Evidence of type 1 diabetes and diabetics requiring insulin therapy.. Subjects who have not been weight stable (>2 kg weight change in past 3 months). Subjects who have been recently active (>30 min of moderate/high intensity exercise, 2 times/week).. Subjects who are smokers or who have quit smoking <5 years ago. Subjects prescribed metformin or have taken metformin within 1 year.. Subjects with abnormal estimated glomerular filtration rate (eGFR).. Hypertriglyceridemic (>400 mg/dl) and hypercholesterolemic (>260 mg/dl) subjects. Hypertensive (>160/100 mmHg). Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).. Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.. Pregnant (as evidenced by positive pregnancy test) or nursing women. Subjects with contraindications to participation in an exercise training program. Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine). Known hypersensitivity to perflutren (contained in Definity). ",
        "Annotations": [
            "Condition 0 14--*--Morbidly obese",
            "Measurement 25 28--*--BMI",
            "Value 29 38--*-->47 kg/m2",
            "Condition 44 54--*--overweight",
            "Condition 55 59--*--lean",
            "Measurement 70 73--*--BMI",
            "Value 74 83--*--<27 kg/m2",
            "Scope 25 38--*--BMI >47 kg/m2",
            "Scope 70 83--*--BMI <27 kg/m2",
            "Scope 44 59--*--overweight/lean",
            "Scope 44 84--*--overweight/lean patients (BMI <27 kg/m2)",
            "Condition 98 113--*--type 1 diabetes",
            "Condition 118 127--*--diabetics",
            "Qualifier 128 153--*--requiring insulin therapy",
            "Procedure 138 153--*--insulin therapy",
            "Drug 138 145--*--insulin",
            "Negation 174 177--*--not",
            "Observation 183 196--*--weight stable",
            "Value 198 203--*-->2 kg",
            "Measurement 204 217--*--weight change",
            "Temporal 218 234--*--in past 3 months",
            "Scope 198 234--*-->2 kg weight change in past 3 months",
            "Scope 174 196--*--not been weight stable",
            "Temporal 260 268--*--recently",
            "Condition 269 275--*--active",
            "Value 277 284--*-->30 min",
            "Measurement 288 320--*--moderate/high intensity exercise",
            "Multiplier 322 334--*--2 times/week",
            "Scope 277 334--*-->30 min of moderate/high intensity exercise, 2 times/week",
            "Scope 269 335--*--active (>30 min of moderate/high intensity exercise, 2 times/week)",
            "Observation 355 362--*--smokers",
            "Observation 375 387--*--quit smoking",
            "Temporal 388 400--*--<5 years ago",
            "Drug 422 431--*--metformin",
            "Drug 446 455--*--metformin",
            "Temporal 456 469--*--within 1 year",
            "Value 486 494--*--abnormal",
            "Measurement 495 538--*--estimated glomerular filtration rate (eGFR)",
            "Condition 541 561--*--Hypertriglyceridemic",
            "Value 563 573--*-->400 mg/dl",
            "Measurement 541 561--*--Hypertriglyceridemic",
            "Condition 579 599--*--hypercholesterolemic",
            "Measurement 584 595--*--cholesterol",
            "Value 601 611--*-->260 mg/dl",
            "Condition 623 635--*--Hypertensive",
            "Value 637 650--*-->160/100 mmHg",
            "Measurement 623 635--*--Hypertensive",
            "Drug 679 690--*--medications",
            "Qualifier 691 713--*--that affect heart rate",
            "Qualifier 691 708;718 724--*--that affect heart rhythm",
            "Drug 731 752--*--Ca++ channel blockers",
            "Drug 754 762--*--nitrates",
            "Drug 764 770;779 787--*--alpha- blockers",
            "Drug 774 787--*--beta-blockers",
            "Scope 731 787--*--Ca++ channel blockers, nitrates, alpha- or beta-blockers",
            "Scope 679 724--*--medications that affect heart rate and rhythm",
            "Observation 807 814--*--history",
            "Qualifier 818 829--*--significant",
            "Qualifier 830 839--*--metabolic",
            "Qualifier 841 848--*--cardiac",
            "Condition 850 874--*--congestive heart failure",
            "Qualifier 876 891--*--cerebrovascular",
            "Qualifier 893 906--*--hematological",
            "Qualifier 908 917--*--pulmonary",
            "Qualifier 919 935--*--gastrointestinal",
            "Qualifier 937 942--*--liver",
            "Qualifier 944 949--*--renal",
            "Qualifier 954 963--*--endocrine",
            "Condition 964 971--*--disease",
            "Scope 830 963--*--metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine",
            "Condition 975 981--*--cancer",
            "Non-query-able 982 1094--*--that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.",
            "Scope 850 874;964 981--*--congestive heart failure disease or cancer",
            "Condition 1096 1104--*--Pregnant",
            "Measurement 1131 1145--*--pregnancy test",
            "Value 1122 1130--*--positive",
            "Observation 1150 1157--*--nursing",
            "Person 1158 1163--*--women",
            "Condition 1179 1196--*--contraindications",
            "Observation 1200 1245--*--participation in an exercise training program",
            "Drug 1264 1300--*--active weight suppression medication",
            "Drug 1307 1318--*--phentermine",
            "Drug 1319 1327--*--orlistat",
            "Drug 1329 1339--*--lorcaserin",
            "Drug 1341 1376--*--naltrexone-bupropion in combination",
            "Drug 1378 1389--*--liraglutide",
            "Drug 1391 1405--*--benzephetamine",
            "Drug 1407 1421--*--diethylpropion",
            "Drug 1423 1438--*--phendimetrazine",
            "Scope 1307 1438--*--phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine",
            "Condition 1447 1463--*--hypersensitivity",
            "Drug 1467 1477--*--perflutren",
            "Drug 1492 1500--*--Definity"
        ]
    },
    "NCT01604187_inc": {
        "Text": "ASA I-III. Colonoscopy. Written informed consent from participating subject. ",
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 9--*--I-III",
            "Procedure 11 22--*--Colonoscopy",
            "Informed_consent 24 75--*--Written informed consent from participating subject"
        ]
    },
    "NCT02957877_inc": {
        "Text": "Prevalent NHHD patients who have received >1 year dialysis with unfractionated heparin as anticoagulant. Age >= 18. Informed consent available. ",
        "Annotations": [
            "Condition 10 14--*--NHHD",
            "Temporal 42 49--*-->1 year",
            "Procedure 50 58--*--dialysis",
            "Drug 64 86--*--unfractionated heparin",
            "Drug 90 103--*--anticoagulant",
            "Person 105 108--*--Age",
            "Value 109 114--*-->= 18",
            "Non-query-able 116 142--*--Informed consent available"
        ]
    },
    "NCT02015923_exc": {
        "Annotations": [
            "Condition 9 23--*--rectal tumours",
            "Qualifier 24 50--*--below 12cm from anal verge",
            "Condition 55 79--*--locally advanced tumours",
            "Condition 80 102--*--invading blood vessels",
            "Condition 104 110;80 88--*--nerves invading",
            "Condition 114 118;80 88--*--bone invading",
            "Scope 80 118--*--invading blood vessels, nerves or bone",
            "Condition 121 145--*--Multiple bone metastasis",
            "Condition 149 182--*--central nervous system metastasis",
            "Condition 190 208--*--neoplastic disease",
            "Qualifier 184 189--*--Other",
            "Temporal 209 232--*--in the 5 previous years",
            "Condition 253 278--*--basal cell skin carcinoma",
            "Condition 241 249;259 278--*--squamous cell skin carcinoma",
            "Condition 282 310--*--cervical \"in situ\" carcinoma",
            "Negation 234 240--*--except",
            "Scope 241 310--*--squamous or basal cell skin carcinoma or cervical \"in situ\" carcinoma",
            "Condition 324 337--*--heart disease",
            "Qualifier 312 323--*--Significant",
            "Condition 339 371--*--chronic congestive heart failure",
            "Condition 373 401--*--symptomatic coronary disease",
            "Scope 339 401--*--chronic congestive heart failure, symptomatic coronary disease",
            "Scope 312 337--*--Significant heart disease",
            "Condition 406 427--*--myocardial infarction",
            "Temporal 428 452--*--in the previous 6 months",
            "Condition 454 475--*--Peripheral neuropathy",
            "Non-query-able 477 518--*--Patients who do not give informed consent"
        ],
        "Text": "Cases of rectal tumours below 12cm from anal verge, or locally advanced tumours invading blood vessels, nerves or bone.. Multiple bone metastasis or central nervous system metastasis. Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical \"in situ\" carcinoma. Significant heart disease (chronic congestive heart failure, symptomatic coronary disease) or myocardial infarction in the previous 6 months. Peripheral neuropathy. Patients who do not give informed consent. "
    },
    "NCT00749112_exc": {
        "Text": "Current viral or bacterial infection. . Positive serology for HIV, HCV, HBV.       .     . ",
        "Annotations": [
            "Condition 17 36--*--bacterial infection",
            "Condition 27 36;8 13--*--infection viral",
            "Temporal 0 7--*--Current",
            "Scope 8 36--*--viral or bacterial infection",
            "Measurement 48 64--*--serology for HIV",
            "Measurement 48 60;66 69--*--serology for HCV",
            "Measurement 48 60;71 74--*--serology for HBV",
            "Value 39 47--*--Positive",
            "Scope 48 74--*--serology for HIV, HCV, HBV"
        ]
    },
    "NCT02890719_exc": {
        "Text": "Genotype 2, 3, 5 or 6 infection. . Decompensated cirrhosis defined by the presence of actual or previous history of clinical decompensation including ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C. . Hepatocellular carcinoma after liver transplantation. . Total bilirubin > 3 mg/dL. . Immunosuppression with cyclosporine or an mTOR inhibitor (everolimus or sirolimus). . Severe extrahepatic diseases: cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes. . Platelets < 75 x 109 cells/L. . Neutrophil count < 0.5 x 109 cells/L. . Hemoglobin < 9 g/dL. . Albumin < 3g/dL. . HIV infection. . Hepatitis B infection. . Active intake of toxic amounts of alcohol or recreational drugs. . Females who are pregnant, become to be pregnant or breastfeeding or males whose partners are pregnant, become to be pregnant or breastfeeding. . Intake of disallowed medications including(but not limited to): . 1. Antibiotics: clarithromycin, erythromycin, telithromycin, nafcillin, rifampin . 2. Antifungals: itraconazole, ketoconazole, voriconazole . 3. Antihypertensives: nifedipine . 4. Anticonvulsants: carbamazepine, phenytoin, phenobarbital . 5. Bosentan . 6. Modafinil . 7. St.Jonh's Wort . 8. Immunosuppressants: cyclosporin, everolimus, sirolimus . 9. Diabetes agents: glibenclamide, glyburide . 10. Lipid lowering agents: gemfibrozil . 11. Eltrombopag . 12. Lapatinib . 13. HIV medications: efavirenz, etravirine, all ritonavir boosted and unboosted HIV protease inhibitors . 14. Statins: simvastatin, fluvastatin, rosuvastatin at doses greater than 10 mg/d, atorvastatin at doses greater than 10 mg/d.       .     . ",
        "Annotations": [
            "Measurement 0 8--*--Genotype",
            "Value 9 21--*--2, 3, 5 or 6",
            "Condition 22 31--*--infection",
            "Parsing_Error 964 966--*--1.",
            "Parsing_Error 1046 1048--*--2.",
            "Parsing_Error 1104 1106--*--3.",
            "Parsing_Error 1138 1140--*--4.",
            "Parsing_Error 1199 1201--*--5.",
            "Parsing_Error 1212 1214--*--6.",
            "Parsing_Error 1226 1228--*--7.",
            "Parsing_Error 1245 1247--*--8.",
            "Parsing_Error 1304 1306--*--9.",
            "Parsing_Error 1350 1353--*--10.",
            "Parsing_Error 1390 1393--*--11.",
            "Parsing_Error 1407 1410--*--12.",
            "Parsing_Error 1422 1425--*--13.",
            "Parsing_Error 1527 1530--*--14.",
            "Condition 48 57--*--cirrhosis",
            "Qualifier 34 47--*--Decompensated",
            "Condition 115 138--*--clinical decompensation",
            "Undefined_semantics 115 138--*--clinical decompensation",
            "Condition 149 156--*--ascites",
            "Condition 158 180--*--hepatic encephalopathy",
            "Condition 182 199--*--variceal bleeding",
            "Condition 203 236--*--spontaneous bacterial peritonitis",
            "Measurement 243 253--*--Child-Pugh",
            "Value 254 260--*--B or C",
            "Scope 149 260--*--ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C",
            "Temporal 85 91--*--actual",
            "Temporal 95 103--*--previous",
            "Scope 85 103--*--actual or previous",
            "Condition 263 287--*--Hepatocellular carcinoma",
            "Procedure 294 315--*--liver transplantation",
            "Reference_point 294 315--*--liver transplantation",
            "Temporal 288 315--*--after liver transplantation",
            "Measurement 318 333--*--Total bilirubin",
            "Value 334 343--*--> 3 mg/dL",
            "Procedure 346 363--*--Immunosuppression",
            "Drug 369 381--*--cyclosporine",
            "Drug 388 402--*--mTOR inhibitor",
            "Drug 404 414--*--everolimus",
            "Drug 418 427--*--sirolimus",
            "Scope 404 427--*--everolimus or sirolimus",
            "Scope 369 428--*--cyclosporine or an mTOR inhibitor (everolimus or sirolimus)",
            "Condition 438 459--*--extrahepatic diseases",
            "Undefined_semantics 438 459--*--extrahepatic diseases",
            "Qualifier 431 437--*--Severe",
            "Undefined_semantics 431 437--*--Severe",
            "Subjective_judgement 431 437--*--Severe",
            "Condition 461 475--*--cardiovascular",
            "Condition 477 488--*--respiratory",
            "Condition 490 505--*--cerebrovascular",
            "Condition 528 536--*--diabetes",
            "Qualifier 510 527--*--poorly controlled",
            "Grammar_Error 506 509--*--and",
            "Scope 461 536--*--cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes",
            "Measurement 539 548--*--Platelets",
            "Value 549 567--*--< 75 x 109 cells/L",
            "Measurement 570 586--*--Neutrophil count",
            "Value 587 606--*--< 0.5 x 109 cells/L",
            "Measurement 609 619--*--Hemoglobin",
            "Value 620 628--*--< 9 g/dL",
            "Measurement 631 638--*--Albumin",
            "Value 639 646--*--< 3g/dL",
            "Condition 649 662--*--HIV infection",
            "Condition 665 686--*--Hepatitis B infection",
            "Condition 723 730--*--alcohol",
            "Multiplier 706 719--*--toxic amounts",
            "Undefined_semantics 706 719--*--toxic amounts",
            "Condition 734 752--*--recreational drugs",
            "Temporal 689 702--*--Active intake",
            "Condition 771 779--*--pregnant",
            "Person 755 762--*--Females",
            "Observation 781 787--*--become",
            "Condition 794 802--*--pregnant",
            "Observation 806 819--*--breastfeeding",
            "Non-query-able 835 896--*--partners are pregnant, become to be pregnant or breastfeeding",
            "Person 823 828--*--males",
            "Scope 823 896--*--males whose partners are pregnant, become to be pregnant or breastfeeding",
            "Scope 755 819--*--Females who are pregnant, become to be pregnant or breastfeeding",
            "Drug 909 931--*--disallowed medications",
            "Parsing_Error 899 962--*--Intake of disallowed medications including(but not limited to):",
            "Drug 980 994--*--clarithromycin",
            "Drug 996 1008--*--erythromycin",
            "Drug 1010 1023--*--telithromycin",
            "Drug 1025 1034--*--nafcillin",
            "Drug 1036 1044--*--rifampin",
            "Drug 1062 1074--*--itraconazole",
            "Drug 1076 1088--*--ketoconazole",
            "Drug 1090 1102--*--voriconazole",
            "Drug 1126 1136--*--nifedipine",
            "Drug 1158 1171--*--carbamazepine",
            "Drug 1173 1182--*--phenytoin",
            "Drug 1184 1197--*--phenobarbital",
            "Drug 1202 1210--*--Bosentan",
            "Drug 1215 1224--*--Modafinil",
            "Drug 1229 1243--*--St.Jonh's Wort",
            "Drug 1268 1279--*--cyclosporin",
            "Drug 1281 1291--*--everolimus",
            "Drug 1293 1302--*--sirolimus",
            "Drug 1324 1337--*--glibenclamide",
            "Drug 1339 1348--*--glyburide",
            "Drug 1377 1388--*--gemfibrozil",
            "Drug 1394 1405--*--Eltrombopag",
            "Drug 1411 1420--*--Lapatinib",
            "Multiplier 1626 1652--*--doses greater than 10 mg/d",
            "Drug 1502 1525--*--HIV protease inhibitors",
            "Drug 1470 1479--*--ritonavir",
            "Drug 1454 1464--*--etravirine",
            "Qualifier 1470 1479;1492 1501--*--ritonavir unboosted",
            "Qualifier 1470 1487--*--ritonavir boosted",
            "Grammar_Error 1488 1491--*--and",
            "Scope 1470 1501--*--ritonavir boosted and unboosted",
            "Drug 1443 1452--*--efavirenz",
            "Drug 1540 1551--*--simvastatin",
            "Drug 1553 1564--*--fluvastatin",
            "Drug 1566 1578--*--rosuvastatin",
            "Drug 1610 1622--*--atorvastatin",
            "Multiplier 1582 1608--*--doses greater than 10 mg/d"
        ]
    },
    "NCT02974686_inc": {
        "Text": "Kidney transplant recipients at Washington University/Barnes-Jewish Hospital. Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant. On standard immunosuppression with tacrolimus and prednisone. ",
        "Annotations": [
            "Procedure 0 17--*--Kidney transplant",
            "Visit 32 76--*--Washington University/Barnes-Jewish Hospital",
            "Procedure 91 102--*--GI toxicity",
            "Drug 108 111--*--MPA",
            "Procedure 195 221--*--standard immunosuppression",
            "Drug 227 237--*--tacrolimus",
            "Drug 242 251--*--prednison",
            "Scope 227 251--*--tacrolimus and prednison"
        ]
    },
    "NCT01604187_exc": {
        "Text": "A previous history of intolerance to the study drug or related compounds and additives. History of alcoholism, drug abuse, psychiatric, psychological or other emotional problems that are likely to invalidate informed consent. Sleep apnoea. Chronic obstructive pulmonary disease. BMI = 35 or weight < 50 kg. SpO2 < 90 %. Concomitant drug therapy known to cause significant enzyme induction or inhibition of CYP 3A4.. Pregnancy or nursing.. ",
        "Annotations": [
            "Observation 2 18--*--previous history",
            "Condition 22 33--*--intolerance",
            "Drug 41 51--*--study drug",
            "Drug 55 72--*--related compounds",
            "Scope 41 72--*--study drug or related compounds",
            "Condition 99 109--*--alcoholism",
            "Condition 111 121--*--drug abuse",
            "Condition 123 134;169 177--*--psychiatric problems",
            "Condition 136 149;169 177--*--psychological problems",
            "Condition 159 177--*--emotional problems",
            "Condition 226 238--*--Sleep apnoea",
            "Condition 240 277--*--Chronic obstructive pulmonary disease",
            "Measurement 279 282--*--BMI",
            "Value 283 287--*--= 35",
            "Measurement 291 297--*--weight",
            "Value 298 305--*--< 50 kg",
            "Measurement 307 311--*--SpO2",
            "Value 312 318--*--< 90 %",
            "Measurement 332 344--*--drug therapy",
            "Temporal 320 331--*--Concomitant",
            "Observation 372 388;403 413--*--enzyme induction of CYP 3A4",
            "Observation 372 378;392 413--*--enzyme inhibition of CYP 3A4",
            "Scope 372 413--*--enzyme induction or inhibition of CYP 3A4",
            "Condition 416 425--*--Pregnancy",
            "Condition 429 436--*--nursing"
        ]
    },
    "NCT03355469_inc": {
        "Text": "Male or female >40 and <70 years old.. Has a body mass index >27 and <47 kg/m2.. Not diagnosed with Type 2 diabetes.. Not currently engaged in > 60 min/wk of exercise. Meet at least 3 of 5 National Cholesterol Education Adult Treatment Panel III. Increased waist circumference (=102 cm in men; =88 cm in women). Elevated triglycerides (=150 mg/dl), or on medication for treating the condition. Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition. High blood pressure (=130 mmHg systolic or =85mmHg diastolic), or on medication for treating the condition. Elevated fasting glucose (=100 mg/dl), or on medication for treating the condition. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 15 32--*-->40 and <70 years",
            "Person 33 36--*--old",
            "Measurement 45 60--*--body mass index",
            "Value 61 78--*-->27 and <47 kg/m2",
            "Negation 81 84--*--Not",
            "Condition 100 115--*--Type 2 diabetes",
            "Negation 118 121--*--Not",
            "Observation 132 142;158 166--*--engaged in exercise",
            "Temporal 122 131--*--currently",
            "Value 143 154--*--> 60 min/wk",
            "Value 173 188--*--at least 3 of 5",
            "Measurement 189 245--*--National Cholesterol Education Adult Treatment Panel III",
            "Measurement 257 276--*--waist circumference",
            "Value 247 256--*--Increased",
            "Value 278 285--*--=102 cm",
            "Value 294 300--*--=88 cm",
            "Person 304 309--*--women",
            "Person 289 292--*--men",
            "Scope 278 309--*--=102 cm in men; =88 cm in women",
            "Measurement 321 334--*--triglycerides",
            "Value 312 320--*--Elevated",
            "Value 336 346--*--=150 mg/dl",
            "Drug 355 378--*--medication for treating",
            "Qualifier 321 334--*--triglycerides",
            "Value 394 401--*--Reduced",
            "Measurement 402 417--*--HDL-cholesterol",
            "Value 419 427--*--<40mg/dl",
            "Value 436 445--*--<50 mg/dl",
            "Person 449 454--*--women",
            "Person 431 434--*--men",
            "Scope 419 454--*--<40mg/dl in men, <50 mg/dl in women",
            "Drug 463 486--*--medication for treating",
            "Qualifier 402 417--*--HDL-cholesterol",
            "Value 502 506--*--High",
            "Measurement 507 521--*--blood pressure",
            "Condition 502 521--*--High blood pressure",
            "Value 523 541--*--=130 mmHg systolic",
            "Value 545 562--*--=85mmHg diastolic",
            "Scope 523 562--*--=130 mmHg systolic or =85mmHg diastolic",
            "Drug 571 594--*--medication for treating",
            "Value 610 618--*--Elevated",
            "Measurement 619 634--*--fasting glucose",
            "Value 636 646--*--=100 mg/dl",
            "Condition 610 634--*--Elevated fasting glucose",
            "Drug 655 678--*--medication for treating"
        ]
    },
    "NCT02686021_exc": {
        "Annotations": [
            "Temporal 0 12--*--simultaneous",
            "Qualifier 13 23--*--both sided",
            "Procedure 55 71--*--molar extraction",
            "Qualifier 38 54--*--only upper third",
            "Scope 13 54--*--both sided extraction or only upper third",
            "Procedure 73 91--*--general anesthesia",
            "Condition 111 138--*--abnormal coagulation status",
            "Qualifier 102 110--*--presumed",
            "Qualifier 93 98--*--known",
            "Scope 93 110--*--known or presumed",
            "Qualifier 140 145--*--known",
            "Qualifier 149 157--*--presumed",
            "Scope 140 157--*--known or presumed",
            "Condition 167 184--*--renal dysfunction",
            "Condition 158 163;173 184--*--liver dysfunction",
            "Scope 158 184--*--liver or renal dysfunction",
            "Condition 186 202--*--contraindication",
            "Drug 211 221--*--metamizole",
            "Qualifier 222 227--*--known",
            "Qualifier 231 240--*--suspected",
            "Scope 222 240--*--known or suspected",
            "Qualifier 242 247--*--known",
            "Qualifier 251 260--*--suspected",
            "Condition 261 268--*--allergy",
            "Drug 277 285--*--novalgin",
            "Drug 295 306--*--pyrazolones",
            "Qualifier 289 294--*--other",
            "Condition 308 329--*--anaphylactic reaction",
            "Drug 338 344--*--NSAIDS",
            "Measurement 356 376--*--bone marrow function",
            "Value 346 355--*--decreased",
            "Measurement 380 392--*--hematopoesis",
            "Scope 356 392--*--bone marrow function or hematopoesis",
            "Condition 394 411--*--hepatic porphyria",
            "Condition 413 457--*--glucose-6-phosphate dehydrogenase deficiency",
            "Condition 463 472--*--pregnancy",
            "Observation 473 486--*--breastfeeding",
            "Scope 277 306--*--novalgin or other pyrazolones",
            "Scope 242 260--*--known or suspected",
            "Scope 242 486--*--known or suspected allergy against novalgin or other pyrazolones, anaphylactic reaction against NSAIDS, decreased bone marrow function or hematopoesis, hepatic porphyria, glucose-6-phosphate dehydrogenase deficiency, and pregnancy/breastfeeding",
            "Scope 186 240--*--contraindication against metamizole known or suspected",
            "Condition 489 505--*--contraindication",
            "Drug 514 523--*--ibuprofen",
            "Qualifier 525 530--*--known",
            "Qualifier 534 543--*--suspected",
            "Condition 544 551--*--allergy",
            "Drug 560 569--*--ibuprofen",
            "Scope 525 543--*--known or suspected",
            "Condition 571 592--*--anaphylactic reaction",
            "Drug 601 645--*--Nonsteroidal anti-inflammatory drugs (NSAID)",
            "Temporal 647 653--*--active",
            "Qualifier 657 666--*--recurrent",
            "Qualifier 667 674--*--stomach",
            "Condition 697 705--*--bleeding",
            "Qualifier 678 686--*--duodenal",
            "Condition 687 693--*--ulcera",
            "Scope 687 705--*--ulcera or bleeding",
            "Scope 667 686--*--stomach or duodenal",
            "Scope 647 666--*--active or recurrent",
            "Condition 707 719;729 742--*--severe liver insufficiency",
            "Condition 707 713;723 742--*--severe renal insufficiency",
            "Condition 744 771--*--inflammatory bowel syndrome",
            "Condition 777 786--*--pregnancy",
            "Observation 787 800--*--breastfeeding",
            "Scope 525 800--*--known or suspected allergy against ibuprofen, anaphylactic reaction against Nonsteroidal anti-inflammatory drugs (NSAID), active or recurrent stomach or duodenal ulcera or bleeding, severe liver or renal insufficiency, inflammatory bowel syndrome, and pregnancy/breastfeeding",
            "Scope 489 523--*--contraindication against ibuprofen",
            "Condition 803 812--*--pregnancy",
            "Observation 817 831--*--breast feeding"
        ],
        "Text": "simultaneous both sided extraction or only upper third molar extraction. general anesthesia. known or presumed abnormal coagulation status. known or presumed liver or renal dysfunction. contraindication against metamizole known or suspected (known or suspected allergy against novalgin or other pyrazolones, anaphylactic reaction against NSAIDS, decreased bone marrow function or hematopoesis, hepatic porphyria, glucose-6-phosphate dehydrogenase deficiency, and pregnancy/breastfeeding). contraindication against ibuprofen (known or suspected allergy against ibuprofen, anaphylactic reaction against Nonsteroidal anti-inflammatory drugs (NSAID), active or recurrent stomach or duodenal ulcera or bleeding, severe liver or renal insufficiency, inflammatory bowel syndrome, and pregnancy/breastfeeding). pregnancy and breast feeding mothers. "
    },
    "NCT00250640_exc": {
        "Text": "Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis Summary of Product Characteristics and patient package insert)       .     . ",
        "Annotations": [
            "Condition 66 75--*--pregnancy",
            "Condition 86 103--*--contraindications",
            "Procedure 108 126--*--Ventavis treatment",
            "Qualifier 153 223--*--Ventavis Summary of Product Characteristics and patient package insert"
        ]
    },
    "NCT02613039_inc": {
        "Annotations": [
            "Person 0 6--*--Female",
            "Person 16 20--*--aged",
            "Value 21 33--*--=/> 18 years",
            "Condition 41 57--*--reproductive age",
            "Non-query-able 60 201--*--Capacity to give consent for study participation, after being adequately informed of the aims, benefits, risks, time and motion of the study."
        ],
        "Text": "Female subjects aged =/> 18 years and of reproductive age.. Capacity to give consent for study participation, after being adequately informed of the aims, benefits, risks, time and motion of the study.. "
    },
    "NCT01483118_inc": {
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 35--*--greater than 18 years",
            "Person 39 42--*--age",
            "Non-query-able 44 115--*--Ability to understand and willingness to comply with the study protocol",
            "Post-eligibility 44 115--*--Ability to understand and willingness to comply with the study protocol",
            "Post-eligibility 117 141--*--Written informed consent",
            "Non-query-able 117 141--*--Written informed consent",
            "Measurement 164 226--*--Rotterdam PCOS workshop criteria for polycystic ovary syndrome",
            "Value 152 159--*--meeting",
            "Condition 239 253--*--oligomenorrhea",
            "Condition 257 267--*--amenorrhea",
            "Multiplier 272 284--*--at least one",
            "Condition 349 365--*--hyperandrogenism",
            "Condition 391 401;412 419--*--polycystic ovaries",
            "Procedure 369 379--*--ultrasound"
        ],
        "Text": "Patients aged greater than 18 years of age . Ability to understand and willingness to comply with the study protocol . Written informed consent . Patients meeting the Rotterdam PCOS workshop criteria for polycystic ovary syndrome, defined by oligomenorrhea or amenorrhea and at least one of the following two signs: clinical or biochemical evidence of hyperandrogenism or ultrasound finding of polycystic appearing ovaries. . "
    },
    "NCT02467686_inc": {
        "Annotations": [
            "Condition 0 10--*--Menopausal",
            "Person 11 16--*--women",
            "Condition 22 35--*--breast cancer",
            "Procedure 36 43--*--treated",
            "Drug 54 63--*--tamoxifen",
            "Drug 67 86--*--aromatase inhibitor",
            "Scope 54 86--*--tamoxifen or aromatase inhibitor",
            "Condition 94 105--*--hot flashes",
            "Observation 118 144--*--without active sexual life",
            "Observation 110 114;126 144--*--with active sexual life"
        ],
        "Text": "Menopausal women with breast cancer treated and using tamoxifen or aromatase inhibitor.. With hot flashes and with or without active sexual life.. "
    },
    "NCT02022709_exc": {
        "Text": "Having significant medical illnesses that would interfere with the conduct of the study. Clinically significant abnormal laboratory finding. Having comorbid psychiatric conditions according to the criteria set forth in the DSM-IV(administered by the Mini-International Neuropsychiatric Interview (MINI)). The current OCD symptoms are too severe that the patient cannot finish the evaluation or receive the ERP. Being currently at risk for suicide. Being pregnant or having the intention to be pregnant before the end of the study. A history of having inadequate response to adequate SSRIs or CBT treatment. Subjects who are unable to undergo the MRI. ",
        "Annotations": [
            "Non-query-able 0 87--*--Having significant medical illnesses that would interfere with the conduct of the study",
            "Non-query-able 89 139--*--Clinically significant abnormal laboratory finding",
            "Condition 157 179--*--psychiatric conditions",
            "Qualifier 148 156--*--comorbid",
            "Qualifier 223 229--*--DSM-IV",
            "Condition 317 329--*--OCD symptoms",
            "Qualifier 338 344--*--severe",
            "Observation 430 446--*--risk for suicide",
            "Pregnancy_considerations 448 529--*--Being pregnant or having the intention to be pregnant before the end of the study",
            "Drug 583 588--*--SSRIs",
            "Drug 592 595--*--CBT",
            "Condition 562 570--*--response",
            "Scope 583 595--*--SSRIs or CBT",
            "Qualifier 551 561--*--inadequate",
            "Mood 624 633--*--unable to",
            "Procedure 646 649--*--MRI"
        ]
    },
    "NCT02056626_exc": {
        "Annotations": [
            "Condition 0 23--*--abnormal renal function",
            "Temporal 25 34--*--currently",
            "Condition 35 43--*--pregnant",
            "Mood 48 64--*--trying to become",
            "Condition 65 73--*--pregnant",
            "Drug 96 108--*--beta-blocker",
            "Procedure 81 88--*--treated",
            "Drug 117 130--*--illicit drugs"
        ],
        "Text": "abnormal renal function. currently pregnant, or trying to become pregnant. being treated with a beta-blocker. use of illicit drugs. "
    },
    "NCT00250640_inc": {
        "Text": "The treating physician has chosen Ventavis as a suitable long-term treatment for the patient . Patient with primary pulmonary hypertension (i.e. Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association) . No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma) . ",
        "Annotations": [
            "Drug 34 42--*--Ventavis",
            "Condition 107 137--*--primary pulmonary hypertension",
            "Condition 144 186--*--Idiopathic Pulmonary Arterial Hypertension",
            "Condition 190 230--*--Familial Pulmonary Arterial Hypertension",
            "Scope 144 230--*--Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension",
            "Measurement 250 271--*--NYHA functional class",
            "Value 272 275--*--III",
            "Procedure 322 345--*--treatment with Ventavis",
            "Condition 377 407--*--primary pulmonary hypertension",
            "Procedure 362 372--*--treatments",
            "Qualifier 373 407--*--for primary pulmonary hypertension",
            "Temporal 408 449--*--within 6 weeks of date of study inclusion",
            "Negation 313 315--*--No",
            "Scope 322 407--*--treatment with Ventavis or other active treatments for primary pulmonary hypertension",
            "Multiplier 57 66--*--long-term"
        ]
    },
    "NCT02686021_inc": {
        "Annotations": [
            "Mood 0 7--*--planned",
            "Qualifier 8 18--*--sequential",
            "Qualifier 19 29--*--both-sided",
            "Procedure 30 58--*--lower third molar extraction",
            "Qualifier 60 71--*--split-mouth",
            "Procedure 78 87--*--osteotomy",
            "Procedure 105 127--*--upper molar extraction",
            "Procedure 131 147--*--local anesthesia",
            "Scope 105 147--*--upper molar extraction in local anesthesia",
            "Observation 150 178--*--able to understand the study",
            "Non-representable 179 196--*--and the NRS scale"
        ],
        "Text": "planned sequential both-sided lower third molar extraction (split-mouth) with osteotomy (with or without upper molar extraction in local anesthesia). able to understand the study and the NRS scale. "
    },
    "NCT02613039_exc": {
        "Annotations": [
            "Non-query-able 0 40--*--Participation in another clinical trial.",
            "Mood 51 60--*--suspected",
            "Mood 42 47--*--Known",
            "Condition 77 87--*--malignancy",
            "Condition 91 106--*--chronic illness",
            "Scope 77 106--*--malignancy or chronic illness",
            "Observation 65 75--*--history of",
            "Scope 42 76--*--Known or suspected (or history of)",
            "Condition 128 142--*--mental disease",
            "Condition 117 124;135 142--*--organic disease",
            "Qualifier 143 170--*--diagnosed by a psychiatrist",
            "Scope 117 142--*--organic or mental disease",
            "Condition 178 194--*--major depression",
            "Procedure 205 212--*--treated",
            "Temporal 195 204--*--currently",
            "Drug 218 243--*--antidepressant medication",
            "Scope 117 170--*--organic or mental disease diagnosed by a psychiatrist",
            "Mood 245 254--*--suspected",
            "Observation 275 290--*--medical history",
            "Procedure 298 318--*--clinical examination",
            "Scope 275 318--*--medical history and/or clinical examination",
            "Post-eligibility 321 376--*--Conditions that may affect the compliance to the study.",
            "Post-eligibility 378 518--*--Contraindications to therapy with the study drug or hypersensitivity to the study drug (active ingredient or excipients of the formulation)."
        ],
        "Text": "Participation in another clinical trial.. Known or suspected (or history of) malignancy or chronic illness.. Serious organic or mental disease diagnosed by a psychiatrist (e.g., major depression currently treated with antidepressant medication) suspected on the basis of the medical history and/or clinical examination.. Conditions that may affect the compliance to the study.. Contraindications to therapy with the study drug or hypersensitivity to the study drug (active ingredient or excipients of the formulation).. "
    },
    "NCT02022709_inc": {
        "Text": "Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of = 16. Never receiving adequate treatment or stop receiving treatment for at least 8 weeks. Having an education degree of high school or above. Accepting to participate in the study. ",
        "Annotations": [
            "Condition 27 38--*--primary OCD",
            "Measurement 112 118--*--DSM-IV",
            "Measurement 57 110--*--Diagnostic and Statistical Manual of Mental Disorders",
            "Measurement 176 213--*--Yale-Brown Obsessive-Compulsive Scale",
            "Measurement 215 221--*--Y-BOCS",
            "Value 223 236--*--score of = 16",
            "Negation 238 243--*--Never",
            "Procedure 263 272--*--treatment",
            "Qualifier 254 262--*--adequate",
            "Negation 276 280--*--stop",
            "Procedure 291 300--*--treatment",
            "Temporal 301 321--*--for at least 8 weeks",
            "Person 343 364--*--degree of high school",
            "Post-eligibility 376 412--*--ccepting to participate in the study"
        ]
    },
    "NCT01483118_exc": {
        "Annotations": [
            "Condition 8 17--*--pregnancy",
            "Condition 21 30--*--lactation",
            "Condition 32 45--*--Liver disease",
            "Condition 49 71--*--elevated liver enzymes",
            "Condition 98 115--*--diabetes mellitus",
            "Value 117 125--*--Abnormal",
            "Measurement 58 71--*--liver enzymes",
            "Value 49 57--*--elevated",
            "Measurement 126 146--*--serum glucose levels",
            "Condition 117 146--*--Abnormal serum glucose levels",
            "Temporal 154 164--*--at fasting",
            "Temporal 168 210--*--after the 2-hr oral glucose tolerance test",
            "Reference_point 174 210--*--the 2-hr oral glucose tolerance test",
            "Procedure 178 210--*--2-hr oral glucose tolerance test",
            "Scope 154 210--*--at fasting or after the 2-hr oral glucose tolerance test",
            "Reference_point 157 164--*--fasting",
            "Measurement 219 313--*--criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association",
            "Value 211 218--*--meeting",
            "Qualifier 211 313--*--meeting criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association",
            "Condition 249 266--*--diabetes mellitus",
            "Procedure 316 345--*--Insulin sensitizing treatment",
            "Temporal 346 370;385 408--*--within 3 months prior to eight week study period",
            "Temporal 374 408--*--during the eight week study period",
            "Scope 346 408--*--within 3 months prior to or during the eight week study period",
            "Drug 440 448--*--estrogen",
            "Drug 452 464--*--progesterone",
            "Temporal 465 482;493 509--*--3 months prior to the study period",
            "Temporal 486 509--*--during the study period",
            "Drug 533 560--*--medroxyprogesterone acetate",
            "Condition 565 584--*--withdrawal bleeding",
            "Negation 520 529--*--exception",
            "Drug 599 622--*--inhaled corticosteroids",
            "Drug 587 595;607 622--*--Systemic corticosteroids",
            "Qualifier 587 595--*--Systemic",
            "Qualifier 599 606--*--inhaled",
            "Condition 631 666--*--hypersensitive reaction to cinnamon",
            "Observation 658 666--*--cinnamon",
            "Condition 683 700--*--seizure disorders",
            "Condition 708 730--*--cardiovascular disease",
            "Condition 735 758--*--cerebrovascular disease",
            "Measurement 761 782--*--Body mass index (BMI)",
            "Value 782 793--*--range 20-50",
            "Parsing_Error 794 844--*--(excluding all women with BMI under 20 or over 50)"
        ],
        "Text": "Current pregnancy or lactation . Liver disease or elevated liver enzymes . Established diagnosis of diabetes mellitus . Abnormal serum glucose levels either at fasting or after the 2-hr oral glucose tolerance test meeting criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association. . Insulin sensitizing treatment within 3 months prior to or during the eight week study period. . Hormonal treatment involving estrogen or progesterone 3 months prior to or during the study period, with the exception of medroxyprogesterone acetate for withdrawal bleeding. . Systemic or inhaled corticosteroids. . Known hypersensitive reaction to cinnamon. . Patients with seizure disorders, known cardiovascular disease, or cerebrovascular disease. . Body mass index (BMI)range 20-50 (excluding all women with BMI under 20 or over 50).       .     . "
    },
    "NCT02467686_exc": {
        "Annotations": [
            "Negation 10 13--*--not",
            "Condition 19 32--*--breast cancer",
            "Drug 45 54--*--tamoxifen",
            "Drug 58 77--*--aromatase inhibitor",
            "Negation 37 40--*--not",
            "Scope 45 77--*--tamoxifen or aromatase inhibitor",
            "Negation 79 82--*--not",
            "Condition 86 95--*--menopause",
            "Negation 100 103--*--not",
            "Condition 109 120--*--hot flashes"
        ],
        "Text": "Women did not have breast cancer. do not use tamoxifen or aromatase inhibitor. not in menopause and not have hot flashes. "
    },
    "NCT02056626_inc": {
        "Annotations": [
            "Measurement 0 23--*--systolic blood pressure",
            "Value 24 44--*--between 140-160 mmHG",
            "Value 46 65--*--between 18-80 years",
            "Person 66 69--*--old"
        ],
        "Text": "systolic blood pressure between 140-160 mmHG. between 18-80 years old. "
    },
    "NCT03446885_exc": {
        "Annotations": [
            "Condition 4 21--*--medical condition",
            "Condition 33 47--*--contraindicate",
            "Drug 55 75--*--stimulant medication",
            "Temporal 81 86--*--prior",
            "Condition 87 103--*--adverse response",
            "Drug 107 134--*--lisdexamfetamine dimesylate",
            "Qualifier 138 143--*--other",
            "Drug 144 164--*--stimulant medication",
            "Scope 107 164--*--lisdexamfetamine dimesylate or other stimulant medication",
            "Temporal 173 183--*--concurrent",
            "Drug 184 221--*--non-stimulant psychoactive medication",
            "Condition 236 249--*--schizophrenia",
            "Condition 265 281--*--thought disorder",
            "Mood 282 290--*--symptoms",
            "Condition 292 316--*--autism spectrum disorder"
        ],
        "Text": "any medical condition that would contraindicate use of stimulant medication. any prior adverse response to lisdexamfetamine dimesylate or other stimulant medication. use of concurrent,non-stimulant psychoactive medication. diagnosis of schizophrenia or presence of thought disorder symptoms. autism spectrum disorder. "
    },
    "NCT01401335_inc": {
        "Annotations": [
            "Not_a_criteria 0 134--*--100 orphans/vulnerable youth aged 15 to 25 will be recruited through their participation at the day care center, on a voluntary basis."
        ],
        "Text": "100 orphans/vulnerable youth aged 15 to 25 will be recruited through their participation at the day care center, on a voluntary basis. . "
    },
    "NCT03082573_inc": {
        "Annotations": [
            "Non-query-able 0 50--*--Fluent in reading and writing in English language.",
            "Person 66 69--*--age",
            "Value 52 62--*--= 21 years",
            "Temporal 70 98--*--at the time of participation",
            "Reference_point 85 98--*--participation"
        ],
        "Text": "Fluent in reading and writing in English language.. = 21 years of age at the time of participation.. "
    },
    "NCT01082549_inc": {
        "Text": "Eligible patients must meet the following criteria to be enrolled in the study: . 1. Newly diagnosed, stage IV squamous cell lung cancer. This includes patients who present with disseminated metastases, and those with a malignant pleural or pericardial effusion (i.e., formerly stage IIIB in the 6th TNM staging system). . 2. Patients who have received prior adjuvant therapy for early-stage lung cancer are eligible if at least 12 months have elapsed from that treatment. . 3. Histologically confirmed squamous cell bronchogenic carcinoma. Patients whose tumors contain mixed non-small cell histologies are eligible, as long as squamous carcinoma is the predominant histology. Mixed tumors with small cell anaplastic elements are not eligible. Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable. . 4. Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the recurrence is outside the original radiation therapy port. Radiation therapy must have been completed >4 weeks prior to the initiation of study treatment. Patients who have received chemo/radiation for locally advanced NSCLC are not eligible. Patients who have received palliative radiation therapy for symptomatic metastases must have completed treatment >14 days prior the initiation of the study treatment. . 5. Presence of evaluable (measureable or non-measurable) disease. . 6. ECOG Performance Status of 0 or 1. . 7. Laboratory values as follows: . Absolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL (\u226472 hours prior to initial treatment). . Hemoglobin >9 g/dL (Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level). . Bilirubin < ULN. . Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 times the upper limit of normal if no liver involvement or \u22645 times the upper limit of normal with liver involvement. . Creatinine <2.0 mg/dL, or creatinine clearance >40 mL/min (as calculated by the Cockcroft-Gault method. . 8. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately. . 9. >18 years of age. . 10. Ability to understand the nature of this study, give written informed consent, and comply with study requirements. . 11. Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes. If tissue is not available, a patient will still be eligible for enrollment into the study. . ",
        "Annotations": [
            "Parsing_Error 0 79--*--Eligible patients must meet the following criteria to be enrolled in the study:",
            "Mood 84 99--*--Newly diagnosed",
            "Temporal 84 89--*--Newly",
            "Qualifier 101 109--*--stage IV",
            "Measurement 101 106--*--stage",
            "Value 107 109--*--IV",
            "Condition 110 135--*--squamous cell lung cancer",
            "Condition 190 200--*--metastases",
            "Qualifier 177 189--*--disseminated",
            "Condition 240 260--*--pericardial effusion",
            "Condition 229 236;252 260--*--pleural effusion",
            "Qualifier 219 228--*--malignant",
            "Scope 229 260--*--pleural or pericardial effusion",
            "Measurement 295 317--*--6th TNM staging system",
            "Value 277 287--*--stage IIIB",
            "Scope 277 317--*--stage IIIB in the 6th TNM staging system",
            "Procedure 357 373--*--adjuvant therapy",
            "Condition 378 401--*--early-stage lung cancer",
            "Temporal 418 469--*--at least 12 months have elapsed from that treatment",
            "Reference_point 455 469--*--that treatment",
            "Procedure 460 469--*--treatment",
            "Scope 357 401--*--adjuvant therapy for early-stage lung cancer",
            "Condition 500 536--*--squamous cell bronchogenic carcinoma",
            "Procedure 475 489--*--Histologically",
            "Value 490 499--*--confirmed",
            "Condition 568 600--*--mixed non-small cell histologies",
            "Condition 626 644--*--squamous carcinoma",
            "Qualifier 652 673--*--predominant histology",
            "Observation 693 723--*--small cell anaplastic elements",
            "Negation 728 731--*--not",
            "Condition 675 687--*--Mixed tumors",
            "Qualifier 693 723--*--small cell anaplastic elements",
            "Procedure 881 893--*--radiotherapy",
            "Temporal 872 880--*--previous",
            "Qualifier 920 936--*--locally advanced",
            "Condition 937 963--*--non-small cell lung cancer",
            "Non-representable 989 1050--*--the recurrence is outside the original radiation therapy port",
            "Procedure 1052 1069--*--Radiation therapy",
            "Temporal 1095 1146--*-->4 weeks prior to the initiation of study treatment",
            "Reference_point 1113 1146--*--the initiation of study treatment",
            "Qualifier 1195 1211--*--locally advanced",
            "Condition 1212 1217--*--NSCLC",
            "Procedure 1175 1180--*--chemo",
            "Procedure 1181 1190--*--radiation",
            "Scope 1175 1190--*--chemo/radiation",
            "Negation 1222 1225--*--not",
            "Procedure 1263 1291--*--palliative radiation therapy",
            "Condition 1296 1318--*--symptomatic metastases",
            "Qualifier 1296 1307--*--symptomatic",
            "Temporal 1349 1401--*-->14 days prior the initiation of the study treatment",
            "Reference_point 1364 1401--*--the initiation of the study treatment",
            "Non-representable 1407 1469--*--Presence of evaluable (measureable or non-measurable) disease.",
            "Measurement 1474 1497--*--ECOG Performance Status",
            "Value 1501 1507--*--0 or 1",
            "Measurement 1544 1575--*--Absolute neutrophil count (ANC)",
            "Value 1576 1589--*-->1,500/microL",
            "Measurement 1594 1603--*--platelets",
            "Value 1604 1619--*-->100,000/microL",
            "Temporal 1621 1657--*--\u226472 hours prior to initial treatment",
            "Reference_point 1640 1657--*--initial treatment",
            "Scope 1544 1619--*--Absolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL",
            "Measurement 1661 1671--*--Hemoglobin",
            "Value 1672 1679--*-->9 g/dL",
            "Non-representable 1680 1773--*--(Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level)",
            "Measurement 1776 1785--*--Bilirubin",
            "Value 1786 1791--*--< ULN",
            "Measurement 1794 1824--*--Alanine aminotransferase (ALT)",
            "Measurement 1829 1861--*--aspartate aminotransferase (AST)",
            "Value 1862 1898--*--\u22642.5 times the upper limit of normal",
            "Condition 1905 1922--*--liver involvement",
            "Negation 1902 1904--*--no",
            "Context_Error 1905 1922--*--liver involvement",
            "Scope 1902 1922--*--no liver involvement",
            "Value 1926 1960--*--\u22645 times the upper limit of normal",
            "Condition 1966 1984--*--liver involvement.",
            "Scope 1862 1983--*--\u22642.5 times the upper limit of normal if no liver involvement or \u22645 times the upper limit of normal with liver involvement",
            "Measurement 1986 1996--*--Creatinine",
            "Value 1997 2007--*--<2.0 mg/dL",
            "Measurement 2012 2032--*--creatinine clearance",
            "Value 2033 2043--*-->40 mL/min",
            "Qualifier 2066 2088--*--Cockcroft-Gault method",
            "Pregnancy_considerations 2091 2842--*--8. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately.",
            "Value 2847 2856--*-->18 years",
            "Person 2860 2863--*--age",
            "Post-eligibility 2870 2984--*--Ability to understand the nature of this study, give written informed consent, and comply with study requirements.",
            "Post-eligibility 2990 3480--*--Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes. If tissue is not available, a patient will still be eligible for enrollment into the study"
        ]
    },
    "NCT02312076_inc": {
        "Text": "Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRHa.. ",
        "Annotations": [
            "Procedure 19 23--*--ICSI",
            "Person 0 5--*--Women",
            "Procedure 32 73--*--controlled ovarian hyperstimulation (COH)",
            "Procedure 79 112--*--pituitary downregulation by GnRHa",
            "Scope 32 112--*--controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRHa"
        ]
    },
    "NCT03344887_exc": {
        "Text": "Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time of first transfusion. Patients that require emergent release of a RBC transfusion and in whom emergency randomization could not be completed. Patients with complex antibody profile in which it is impossible to match RBC units. ",
        "Annotations": [
            "Observation 21 77--*--have a valid Ontario Health Insurance Plan (OHIP) number",
            "Negation 17 20--*--not",
            "Temporal 78 106--*--at time of first transfusion",
            "Reference_point 89 106--*--first transfusion",
            "Procedure 95 106--*--transfusion",
            "Multiplier 89 94--*--first",
            "Procedure 152 167--*--RBC transfusion",
            "Procedure 180 203--*--emergency randomization",
            "Qualifier 130 146--*--emergent release",
            "Mood 122 129--*--require",
            "Negation 204 226--*--could not be completed",
            "Condition 242 266--*--complex antibody profile",
            "Observation 282 311--*--impossible to match RBC units"
        ]
    },
    "NCT02923700_inc": {
        "Text": "patients affected by mono-lateral symptomatic knee articular degenerative pathology with history of chronic (for at least 4 months) pain or swelling;. imaging findings of degenerative changes of the joint (osteoarthritis or chondropathy with Kellgren Lawrence Score from 0 to 3 at X-ray evaluation).. ",
        "Annotations": [
            "Qualifier 21 33--*--mono-lateral",
            "Qualifier 34 45--*--symptomatic",
            "Condition 46 83--*--knee articular degenerative pathology",
            "Condition 132 136--*--pain",
            "Condition 140 148--*--swelling",
            "Temporal 100 107--*--chronic",
            "Temporal 109 130--*--for at least 4 months",
            "Scope 132 148--*--pain or swelling",
            "Procedure 151 158--*--imaging",
            "Condition 171 191--*--degenerative changes",
            "Condition 206 220--*--osteoarthritis",
            "Condition 224 236--*--chondropathy",
            "Measurement 242 265--*--Kellgren Lawrence Score",
            "Value 266 277--*--from 0 to 3",
            "Procedure 281 286--*--X-ray",
            "Scope 206 236--*--osteoarthritis or chondropathy",
            "Scope 206 286--*--osteoarthritis or chondropathy with Kellgren Lawrence Score from 0 to 3 at X-ray"
        ]
    },
    "NCT02527512_exc": {
        "Annotations": [
            "Condition 11 24--*--renal failure",
            "Condition 37 44--*--allergy",
            "Drug 48 54--*--iodine",
            "Drug 58 67--*--shellfish",
            "Scope 48 67--*--iodine or shellfish",
            "Procedure 78 98--*--spine fusion surgery",
            "Temporal 69 77--*--previous",
            "Qualifier 111 119--*--elective",
            "Qualifier 120 135--*--posterior spine",
            "Procedure 136 172--*--single-level instrumentation surgery",
            "Qualifier 185 199--*--anterior spine",
            "Procedure 200 235--*--multi-level instrumentation surgery",
            "Temporal 100 110--*--undergoing",
            "Temporal 174 184--*--undergoing",
            "Drug 245 259--*--antibiotic use",
            "Temporal 237 244--*--current"
        ],
        "Text": "Documented renal failure. documented allergy to iodine or shellfish. previous spine fusion surgery. undergoing elective posterior spine single-level instrumentation surgery. undergoing anterior spine multi-level instrumentation surgery. current antibiotic use.. "
    },
    "NCT02604459_inc": {
        "Annotations": [
            "Informed_consent 0 119--*--Subject or legal representative has voluntarily signed the informed consent approved by the Institutional Review Board,",
            "Procedure 121 141--*--Hip fracture surgery",
            "Procedure 158 176--*--general anesthesia",
            "Value 189 206--*--65 years or older",
            "Temporal 207 228--*--on the day of surgery",
            "Reference_point 210 228--*--the day of surgery",
            "Procedure 221 228--*--surgery",
            "Person 201 206--*--older"
        ],
        "Text": "Subject or legal representative has voluntarily signed the informed consent approved by the Institutional Review Board,. Hip fracture surgery scheduled under general anesthesia. Subject is 65 years or older on the day of surgery. "
    },
    "NCT01082549_exc": {
        "Text": "1. Prior treatment with gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib. . 2. Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences. . 3. A history of cardiac disease, as defined by: . Malignant hypertension . Unstable angina . Congestive heart failure . Myocardial infarction within the previous 6 months . Symptomatic, unstable or uncontrolled, cardiac arrhythmias. Patients who have stable, rate-controlled atrial fibrillation are eligible for study enrollment. . 4. Active brain metastases. Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids. . 5. Women who are pregnant or lactating. . 6. Any serious, active infection (> Grade 2) at the time of treatment. . 7. A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. . 8. A major surgical procedure, or significant traumatic injury \u226428 days of beginning treatment, or anticipation of the need for major surgery during the course of the study. . 9. Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results. . 10. History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results. . 11. Known or suspected allergy/hypersensitivity to any agent given in the course of this trial. . The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.       .     . ",
        "Annotations": [
            "Drug 24 35--*--gemcitabine",
            "Drug 37 48--*--carboplatin",
            "Drug 86 94--*--Iniparib",
            "Temporal 3 8--*--Prior",
            "Scope 24 94--*--gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib",
            "Condition 127 135--*--neoplasm",
            "Condition 198 222--*--non-melanoma skin cancer",
            "Procedure 190 197--*--treated",
            "Qualifier 190 197--*--treated",
            "Condition 226 243--*--carcinoma in-situ",
            "Condition 277 284--*--cancers",
            "Qualifier 268 276--*--invasive",
            "Qualifier 285 305--*--treated definitively",
            "Procedure 285 292--*--treated",
            "Negation 168 189--*--with the exception of",
            "Temporal 329 348--*-->5 years previously",
            "Observation 356 379--*--evidence of recurrences",
            "Negation 353 355--*--no",
            "Observation 116 123--*--history",
            "Temporal 108 115--*--current",
            "Temporal 100 104--*--Past",
            "Scope 100 115--*--Past or current",
            "Qualifier 136 166--*--other than the entry diagnosis",
            "Condition 151 166--*--entry diagnosis",
            "Scope 190 379--*--treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences",
            "Condition 398 413--*--cardiac disease",
            "Observation 387 394--*--history",
            "Parsing_Error 415 428--*--as defined by",
            "Condition 431 453--*--Malignant hypertension",
            "Condition 455 470--*--Unstable angina",
            "Condition 472 496--*--Congestive heart failure",
            "Condition 498 519--*--Myocardial infarction",
            "Temporal 520 548--*--within the previous 6 months",
            "Condition 589 608--*--cardiac arrhythmias",
            "Qualifier 575 587--*--uncontrolled",
            "Qualifier 563 571--*--unstable",
            "Qualifier 550 561--*--Symptomatic",
            "Scope 550 587--*--Symptomatic, unstable or uncontrolled",
            "Condition 652 671--*--atrial fibrillation",
            "Grammar_Error 672 684--*--are eligible",
            "Negation 672 684--*--are eligible",
            "Qualifier 636 651--*--rate-controlled",
            "Qualifier 628 634--*--stable",
            "Condition 718 734--*--brain metastases",
            "Temporal 711 717--*--Active",
            "Condition 758 774--*--brain metastases",
            "Procedure 750 757--*--treated",
            "Qualifier 750 757--*--treated",
            "Negation 775 787--*--are eligible",
            "Grammar_Error 775 787--*--are eligible",
            "Procedure 796 813--*--radiation therapy",
            "Temporal 828 865--*--at least 2 weeks prior to study entry",
            "Reference_point 854 865--*--study entry",
            "Condition 895 914--*--disease progression",
            "Procedure 871 885--*--follow-up scan",
            "Negation 892 894--*--no",
            "Drug 949 957--*--steroids",
            "Negation 937 940--*--not",
            "Mood 941 948--*--require",
            "Scope 796 957--*--radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids",
            "Scope 750 774--*--treated brain metastases",
            "Scope 750 957--*--treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids",
            "Condition 977 985--*--pregnant",
            "Person 963 968--*--Women",
            "Condition 989 998--*--lactating",
            "Pregnancy_considerations 963 998--*--Women who are pregnant or lactating",
            "Condition 1024 1033--*--infection",
            "Value 1035 1044--*--> Grade 2",
            "Qualifier 1035 1044--*--> Grade 2",
            "Qualifier 1008 1015--*--serious",
            "Temporal 1017 1023--*--active",
            "Condition 1097 1114--*--medical condition",
            "Qualifier 1078 1085--*--serious",
            "Subjective_judgement 1008 1015--*--serious",
            "Subjective_judgement 1078 1085--*--serious",
            "Post-eligibility 1076 1190--*--A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.",
            "Condition 1126 1189--*--impair the ability of the patient to receive protocol treatment",
            "Mood 1120 1125--*--would",
            "Procedure 1203 1221--*--surgical procedure",
            "Qualifier 1197 1202--*--major",
            "Subjective_judgement 1197 1202--*--major",
            "Qualifier 1226 1237--*--significant",
            "Subjective_judgement 1226 1237--*--significant",
            "Condition 1238 1254--*--traumatic injury",
            "Temporal 1255 1286--*--\u226428 days of beginning treatment",
            "Reference_point 1267 1286--*--beginning treatment",
            "Procedure 1320 1333--*--major surgery",
            "Mood 1311 1319--*--need for",
            "Temporal 1334 1364--*--during the course of the study",
            "Reference_point 1341 1364--*--the course of the study",
            "Qualifier 1370 1382--*--Uncontrolled",
            "Temporal 1386 1398--*--intercurrent",
            "Condition 1399 1406--*--illness",
            "Qualifier 1423 1480--*--in the opinion of the investigator may increase the risks",
            "Subjective_judgement 1423 1480--*--in the opinion of the investigator may increase the risks",
            "Scope 1370 1398--*--Uncontrolled or intercurrent",
            "Post-eligibility 1367 1629--*--9. Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results.",
            "Condition 1661 1682--*--psychiatric condition",
            "Condition 1686 1708--*--laboratory abnormality",
            "Procedure 1686 1696--*--laboratory",
            "Post-eligibility 1635 1926--*--History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.",
            "Condition 1959 1975--*--hypersensitivity",
            "Condition 1951 1958--*--allergy",
            "Mood 1932 1937--*--Known",
            "Mood 1941 1950--*--suspected",
            "Scope 1932 1950--*--Known or suspected",
            "Drug 1983 2022--*--agent given in the course of this trial",
            "Scope 1951 1975--*--allergy/hypersensitivity",
            "Post-eligibility 1932 2022--*--Known or suspected allergy/hypersensitivity to any agent given in the course of this trial",
            "Not_a_criteria 2025 2161--*--The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."
        ]
    },
    "NCT03082573_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02312076_exc": {
        "Text": "Moderate or severe endometriosis.. Hydrosalpinx.. Uterine abnormalities.. Myoma.. Previous uterine surgery.. ",
        "Annotations": [
            "Qualifier 0 8--*--Moderate",
            "Qualifier 12 18--*--severe",
            "Condition 19 32--*--endometriosis",
            "Scope 0 18--*--Moderate or severe",
            "Condition 35 47--*--Hydrosalpinx",
            "Condition 50 71--*--Uterine abnormalities",
            "Condition 74 79--*--Myoma",
            "Temporal 82 90--*--Previous",
            "Procedure 91 106--*--uterine surgery"
        ]
    },
    "NCT01401335_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 16--*--less than 15",
            "Value 20 35--*--greater than 25",
            "Scope 4 35--*--less than 15 or greater than 25",
            "Observation 44 80--*--participating in the day care center",
            "Negation 40 43--*--not"
        ],
        "Text": "Age less than 15 or greater than 25 and not participating in the day care center       .     . "
    },
    "NCT03446885_inc": {
        "Annotations": [
            "Condition 13 17--*--ADHD",
            "Informed_consent 19 80--*--parental permission and/or teen consent/assent as appropriate",
            "Value 90 101--*--16-25 years",
            "Person 105 108--*--age",
            "Measurement 110 112--*--IQ",
            "Value 113 140--*--greater than or equal to 70",
            "Observation 152 168--*--license to drive",
            "Observation 142 148;160 168--*--permit to drive",
            "Observation 170 185;201 208--*--ability to read English",
            "Observation 170 180;190 208--*--ability to understand English"
        ],
        "Text": "diagnosis of ADHD. parental permission and/or teen consent/assent as appropriate. between 16-25 years of age. IQ greater than or equal to 70. permit or license to drive. ability to read and understand English. "
    },
    "NCT02923700_exc": {
        "Text": "age > 80 years;. Kellgren-Lawrence score at X-ray evaluation > 3;. major axial deviation (varus >5\u00b0 , valgus > 5\u00b0),. systemic disorders such as diabetes, rheumatoid arthritis, haematological diseases (coagulopathy), severe cardiovascular diseases, infections, immunodepression;. patients in therapy with anticoagulants or antiaggregants;. use of NSAIDs in the 5 days before blood donation;. patients with Hb values < 11 g/dl and platelet values < 150,000/mmc.. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 14--*--> 80 years",
            "Measurement 17 40--*--Kellgren-Lawrence score",
            "Procedure 44 60--*--X-ray evaluation",
            "Value 61 64--*--> 3",
            "Condition 67 88--*--major axial deviation",
            "Measurement 90 95--*--varus",
            "Measurement 102 108--*--valgus",
            "Value 96 99--*-->5\u00b0",
            "Value 109 113--*--> 5\u00b0",
            "Scope 90 113--*--varus >5\u00b0 , valgus > 5\u00b0",
            "Condition 117 135--*--systemic disorders",
            "Condition 144 152--*--diabetes",
            "Condition 154 174--*--rheumatoid arthritis",
            "Condition 176 199--*--haematological diseases",
            "Condition 201 213--*--coagulopathy",
            "Qualifier 216 222--*--severe",
            "Condition 223 246--*--cardiovascular diseases",
            "Condition 248 258--*--infections",
            "Condition 260 276--*--immunodepression",
            "Scope 144 276--*--diabetes, rheumatoid arthritis, haematological diseases (coagulopathy), severe cardiovascular diseases, infections, immunodepression",
            "Drug 304 318--*--anticoagulants",
            "Drug 322 336--*--antiaggregants",
            "Procedure 291 298--*--therapy",
            "Scope 304 336--*--anticoagulants or antiaggregants",
            "Drug 346 352--*--NSAIDs",
            "Temporal 353 388--*--in the 5 days before blood donation",
            "Measurement 405 407--*--Hb",
            "Value 415 424--*--< 11 g/dl",
            "Measurement 429 437--*--platelet",
            "Value 445 458--*--< 150,000/mmc"
        ]
    },
    "NCT03344887_inc": {
        "Text": "All patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included.. ",
        "Annotations": [
            "Person 24 32--*--neonates",
            "Negation 14 23--*--excluding",
            "Multiplier 44 55--*--one or more",
            "Procedure 67 83--*--RBC transfusions",
            "Qualifier 56 66--*--allogeneic",
            "Condition 105 111--*--anemia",
            "Procedure 92 101--*--treatment",
            "Mood 34 43--*--requiring"
        ]
    },
    "NCT02604459_exc": {
        "Annotations": [
            "Observation 0 30--*--Inability to follow directions",
            "Observation 0 12;34 65--*--Inability to comprehend the English language",
            "Qualifier 67 73--*--Severe",
            "Qualifier 74 85--*--uncorrected",
            "Condition 96 114--*--auditory handicaps",
            "Condition 105 114;86 92--*--handicaps visual",
            "Scope 86 114--*--visual or auditory handicaps",
            "Temporal 125 137--*--at screening",
            "Temporal 125 127;141 149--*--at baseline",
            "Condition 116 124--*--Delirium",
            "Scope 125 149--*--at screening or baseline",
            "Procedure 151 168--*--Emergency surgery"
        ],
        "Text": "Inability to follow directions or comprehend the English language. Severe uncorrected visual or auditory handicaps. Delirium at screening or baseline. Emergency surgery. "
    },
    "NCT02527512_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 17--*--3 to 18 years",
            "Temporal 18 35--*--on day of surgery",
            "Condition 50 66--*--spinal deformity",
            "Temporal 68 78--*--undergoing",
            "Qualifier 79 87--*--elective",
            "Qualifier 88 103--*--posterior spine",
            "Procedure 104 139--*--multi-level instrumentation surgery"
        ],
        "Text": "Age 3 to 18 years on day of surgery. diagnosis of spinal deformity. undergoing elective posterior spine multi-level instrumentation surgery. "
    },
    "NCT02301962_exc": {
        "Annotations": [
            "Condition 29 62--*--central nervous system metastases",
            "Qualifier 76 83--*--another",
            "Condition 84 94--*--malignancy",
            "Condition 103 113--*--Malignancy",
            "Procedure 114 142--*--treated with curative intent",
            "Negation 152 154--*--no",
            "Condition 161 175--*--active disease",
            "Temporal 184 216--*--for >=5 years prior to enrolment",
            "Reference_point 207 216--*--enrolment",
            "Mood 221 243--*--felt to be at low risk",
            "Condition 248 258--*--recurrence",
            "Qualifier 286 296--*--Adequately",
            "Condition 305 333--*--non-melanomatous skin cancer",
            "Procedure 297 304--*--treated",
            "Condition 337 352--*--lentigo maligna",
            "Condition 361 380--*--evidence of disease",
            "Negation 353 360--*--without",
            "Qualifier 382 392--*--Adequately",
            "Procedure 393 400--*--treated",
            "Condition 401 427--*--cervical carcinoma in situ",
            "Negation 428 435--*--without",
            "Condition 448 455--*--disease",
            "Scope 305 352--*--non-melanomatous skin cancer or lentigo maligna",
            "Condition 457 492--*--Prostatic intraepithelial neoplasia",
            "Condition 513 528--*--prostate cancer",
            "Negation 493 500--*--without",
            "Mood 436 447--*--evidence of",
            "Mood 501 512--*--evidence of",
            "Negation 95 101--*--except",
            "Scope 103 528--*--Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer",
            "Condition 550 583--*--delayed hypersensitivity reaction",
            "Condition 537 546;558 583--*--immediate hypersensitivity reaction",
            "Condition 587 599--*--idiosyncrasy",
            "Drug 603 642--*--drugs chemically related to panitumumab",
            "Drug 603 642;646 656--*--drugs chemically related to panitumumab excipients",
            "Scope 603 656--*--drugs chemically related to panitumumab or excipients",
            "Procedure 706 743;751 767--*--anti-epidermal growth factor receptor antibody therapy",
            "Drug 775 786--*--panitumumab",
            "Drug 790 799--*--cetuximab",
            "Scope 775 799--*--panitumumab or cetuximab",
            "Procedure 745 749--*--EGFr",
            "Procedure 804 849--*--treatment with small molecule EGFr inhibitors",
            "Drug 857 866--*--gefitinib",
            "Drug 868 877--*--erlotinib",
            "Drug 879 888--*--lapatinib",
            "Scope 857 888--*--gefitinib, erlotinib, lapatinib",
            "Procedure 892 909--*--Antitumor therapy",
            "Procedure 917 929--*--chemotherapy",
            "Procedure 931 947--*--hormonal therapy",
            "Procedure 949 962--*--immunotherapy",
            "Procedure 964 980--*--antibody therapy",
            "Procedure 982 994--*--radiotherapy",
            "Scope 917 994--*--chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy",
            "Drug 1000 1021--*--investigational agent",
            "Procedure 1025 1032--*--therapy",
            "Temporal 1033 1079--*--<=30 days before first dose of study treatment",
            "Condition 1083 1120--*--not recovered from any acute toxicity",
            "Reference_point 1050 1079--*--first dose of study treatment",
            "Scope 892 1032--*--Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy",
            "Temporal 1155 1183--*--<=30 days before study entry",
            "Qualifier 1123 1128--*--Other",
            "Procedure 1129 1154--*--investigational procedure",
            "Condition 1197 1222--*--interstitial lung disease",
            "Condition 1224 1227--*--ILD",
            "Condition 1235 1259--*--interstitial pneumonitis",
            "Condition 1261 1279--*--pulmonary fibrosis",
            "Mood 1283 1294--*--evidence of",
            "Condition 1295 1298--*--ILD",
            "Temporal 1302 1310--*--baseline",
            "Procedure 1311 1336--*--chest computer tomography",
            "Scope 1235 1336--*--interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography",
            "Scope 1197 1228--*--interstitial lung disease (ILD)",
            "Non-query-able 1339 1381--*--Subject previously enrolled to this study.",
            "Condition 1394 1403--*--keratitis",
            "Condition 1405 1425--*--ulcerative keratitis",
            "Qualifier 1429 1435--*--severe",
            "Condition 1436 1443--*--dry eye",
            "Procedure 1446 1459--*--Major surgery",
            "Procedure 1477 1495--*--general anesthesia",
            "Temporal 1497 1543--*--<=30 days before first dose of study treatment",
            "Reference_point 1514 1543--*--first dose of study treatment",
            "Non-query-able 1545 1610--*--Subjects must have recovered from any surgery related toxicities.",
            "Procedure 1612 1636--*--Minor surgical procedure",
            "Procedure 1644 1655--*--open biopsy",
            "Temporal 1657 1702--*--<=7 days before first dose of study treatment",
            "Reference_point 1673 1702--*--first dose of study treatment",
            "Negation 1707 1714--*--not yet",
            "Condition 1715 1724--*--recovered",
            "Temporal 1730 1735--*--prior",
            "Procedure 1736 1749--*--minor surgery",
            "Qualifier 1927 1949--*--Clinically significant",
            "Condition 1950 1972--*--cardiovascular disease",
            "Condition 1984 2005--*--myocardial infarction",
            "Condition 2007 2022--*--unstable angina",
            "Condition 2036 2060--*--congestive heart failure",
            "Qualifier 2024 2035--*--symptomatic",
            "Qualifier 2062 2069--*--serious",
            "Qualifier 2070 2082--*--uncontrolled",
            "Condition 2083 2101--*--cardiac arrhythmia",
            "Temporal 2103 2132--*--<=6 months prior to enrolment",
            "Reference_point 2123 2132--*--enrolment",
            "Scope 1984 2101--*--myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia",
            "Scope 1927 1972--*--Clinically significant cardiovascular disease",
            "Post-eligibility 2135 2447--*--History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.",
            "Qualifier 2449 2457--*--Unstable",
            "Condition 2458 2476--*--pulmonary embolism",
            "Condition 2478 2498--*--deep vein thrombosis",
            "Qualifier 2503 2508--*--other",
            "Qualifier 2509 2520--*--significant",
            "Condition 2521 2529;2537 2557--*--arterial thromboembolic event",
            "Condition 2530 2557--*--venous thromboembolic event",
            "Temporal 2558 2604--*--<=30 days before first dose of study treatment",
            "Reference_point 2575 2604--*--first dose of study treatment",
            "Scope 2521 2557--*--arterial/venous thromboembolic event",
            "Scope 2449 2557--*--Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event",
            "Procedure 2612 2627--*--anticoagulation",
            "Qualifier 2648 2654--*--stable",
            "Multiplier 2655 2671--*--therapeutic dose",
            "Temporal 2672 2710--*--prior to first dose of study treatment",
            "Reference_point 2681 2710--*--first dose of study treatment",
            "Condition 2728 2736--*--pregnant",
            "Observation 2740 2754--*--breast feeding",
            "Observation 2771 2786--*--become pregnant",
            "Temporal 2787 2803--*--during treatment",
            "Temporal 2808 2868--*--within 2 months after the discontinuation of study treatment",
            "Reference_point 2830 2868--*--the discontinuation of study treatment",
            "Reference_point 2794 2803--*--treatment",
            "Scope 2787 2868--*--during treatment and within 2 months after the discontinuation of study treatment",
            "Scope 2728 2786--*--pregnant or breast feeding, or planning to become pregnant",
            "Measurement 2886 2936--*--test(s) for human immunodeficiency virus infection",
            "Value 2877 2885--*--positive",
            "Condition 3009 3018--*--infection",
            "Temporal 3002 3008--*--Active",
            "Procedure 3029 3047--*--systemic treatment",
            "Condition 3055 3077--*--uncontrolled infection",
            "Temporal 3078 3126--*--<=14 days prior to first dose of study treatment",
            "Reference_point 3097 3126--*--first dose of study treatment",
            "Qualifier 3051 3054--*--any",
            "Scope 3002 3077--*--Active infection requiring systemic treatment or any uncontrolled infection",
            "Condition 3164 3187--*--urinary tract infection",
            "Qualifier 3150 3163--*--uncomplicated",
            "Negation 3128 3149--*--with the exception of",
            "Condition 3191 3224--*--upper respiratory tract infection",
            "Scope 3150 3224--*--uncomplicated urinary tract infection or upper respiratory tract infection",
            "Post-eligibility 3228 3437--*--Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.",
            "Mood 2759 2770--*--planning to"
        ],
        "Text": "History or known presence of central nervous system metastases.. History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to panitumumab or excipients that contraindicates their participation.. Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g., panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib).. Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy <=30 days before first dose of study treatment or not recovered from any acute toxicity.. Other investigational procedure <=30 days before study entry.. History of interstitial lung disease (ILD) e.g., interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography.. Subject previously enrolled to this study.. History of keratitis, ulcerative keratitis or severe dry eye.. Major surgery (e.g., requiring general anesthesia) <=30 days before first dose of study treatment. Subjects must have recovered from any surgery related toxicities.. Minor surgical procedure (e.g., open biopsy) <=7 days before first dose of study treatment, or not yet recovered from prior minor surgery Note: uncomplicated placement of vascular access device, fine needle aspiration, thoracocentesis or paracentesis >=3 days prior to first dose of study treatment is acceptable.. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <=6 months prior to enrolment.. History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.. Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event <=30 days before first dose of study treatment. If on anticoagulation, subject must be on stable therapeutic dose prior to first dose of study treatment.. Subject who is pregnant or breast feeding, or planning to become pregnant during treatment and within 2 months after the discontinuation of study treatment.. Known positive test(s) for human immunodeficiency virus infection (testing is not required in the absence of clinical suspicion).. Active infection requiring systemic treatment or any uncontrolled infection <=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).. Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.. "
    },
    "NCT03624881_inc": {
        "Text": "Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment. Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry strip. Failed at least one antiarrhythmic drug (AAD) (Class I or III antiarrhythmic drugs) as evidenced by recurrent symptomatic AF, or intolerable to the AAD. Age 18 years or older. Signed Patient Informed Consent Form (ICF). Able and willing to comply with all pre-, post-, and follow-up testing and requirements. ",
        "Annotations": [
            "Qualifier 0 11--*--Symptomatic",
            "Condition 12 25--*--paroxysmal AF",
            "Multiplier 34 46--*--at least one",
            "Condition 47 57--*--AF episode",
            "Procedure 58 82--*--electrocardiographically",
            "Qualifier 58 93--*--electrocardiographically documented",
            "Temporal 94 133--*--within one (1) year prior to enrollment",
            "Reference_point 123 133--*--enrollment",
            "Procedure 161 184--*--electrocardiogram (ECG)",
            "Procedure 186 218--*--Transtelephonic monitoring (TTM)",
            "Procedure 220 234--*--Holter monitor",
            "Procedure 238 253--*--telemetry strip",
            "Multiplier 262 274--*--at least one",
            "Drug 275 300--*--antiarrhythmic drug (AAD)",
            "Drug 313 337--*--III antiarrhythmic drugs",
            "Drug 302 309;317 337--*--Class I antiarrhythmic drugs",
            "Scope 302 337--*--Class I or III antiarrhythmic drugs",
            "Condition 355 379--*--recurrent symptomatic AF",
            "Condition 384 395--*--intolerable",
            "Condition 403 406--*--AAD",
            "Person 408 411--*--Age",
            "Value 412 429--*--18 years or older",
            "Informed_consent 431 473--*--Signed Patient Informed Consent Form (ICF)",
            "Non-query-able 475 562--*--Able and willing to comply with all pre-, post-, and follow-up testing and requirements"
        ]
    },
    "NCT03352869_exc": {
        "Annotations": [
            "Condition 11 32--*--serious complications",
            "Condition 34 55--*--cardiovascular events",
            "Condition 101 108;79 84--*--disease liver",
            "Condition 101 108;86 92--*--disease kidney",
            "Condition 96 108--*--lung disease",
            "Temporal 109 124--*--within 3 months",
            "Qualifier 67 78--*--significant",
            "Scope 79 108--*--liver, kidney or lung disease",
            "Scope 34 108--*--cardiovascular events and recent significant liver, kidney or lung disease",
            "Scope 34 124--*--cardiovascular events and recent significant liver, kidney or lung disease within 3 months",
            "Condition 127 146--*--high blood pressure",
            "Value 148 160--*-->160/100mmHg",
            "Measurement 132 146--*--blood pressure",
            "Condition 163 179--*--active infection",
            "Qualifier 181 190--*--secondary",
            "Condition 191 199--*--diabetes",
            "Condition 201 210--*--pregnancy",
            "Condition 212 225--*--alcohol abuse",
            "Condition 227 235--*--allergic",
            "Drug 239 261--*--GLP-1 receptor agonist"
        ],
        "Text": "Except for serious complications (cardiovascular events and recent significant liver, kidney or lung disease within 3 months). high blood pressure (>160/100mmHg). active infection. secondary diabetes. pregnancy. alcohol abuse. allergic to GLP-1 receptor agonist. "
    },
    "NCT02698969_inc": {
        "Annotations": [
            "Measurement 0 19--*--ASA physical status",
            "Value 20 24--*--I-II",
            "Person 26 29--*--age",
            "Value 30 49--*--between 18-80 years",
            "Drug 55 75--*--dNMB with rocuronium",
            "Procedure 83 116--*--ear nose and throat (ENT) surgery"
        ],
        "Text": "ASA physical status I-II. age between 18-80 years old. dNMB with rocuronium during ear nose and throat (ENT) surgery. "
    },
    "NCT01996436_inc": {
        "Text": "Adult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral vasospasm post operatively within 3-21 days.. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 15 18--*--age",
            "Value 19 34--*--18-80 years old",
            "Condition 41 58--*--ruptured aneurysm",
            "Condition 77 95--*--cerebral vasospasm",
            "Temporal 96 129--*--post operatively within 3-21 days",
            "Reference_point 96 112--*--post operatively"
        ]
    },
    "NCT03355326_exc": {
        "Text": "Neurological Congenital malformations and/or those known to impair intestinal motility. Additional congenital gastrointestinal abnormalities requiring surgical intervention. Congenital Cyanotic heart disease. Surgical Closure of abdominal wall defect with prosthetic material (e.g. prosthetic or bio-prosthetic mesh). ",
        "Annotations": [
            "Condition 0 37--*--Neurological Congenital malformations",
            "Condition 60 86--*--impair intestinal motility",
            "Condition 110 140--*--gastrointestinal abnormalities",
            "Qualifier 88 98--*--Additional",
            "Procedure 151 172--*--surgical intervention",
            "Mood 141 150--*--requiring",
            "Qualifier 174 184--*--Congenital",
            "Condition 185 207--*--Cyanotic heart disease",
            "Qualifier 99 109--*--congenital",
            "Procedure 209 225--*--Surgical Closure",
            "Condition 229 250--*--abdominal wall defect",
            "Device 256 275--*--prosthetic material",
            "Device 282 292;311 315--*--prosthetic mesh",
            "Device 296 315--*--bio-prosthetic mesh",
            "Scope 282 315--*--prosthetic or bio-prosthetic mesh"
        ]
    },
    "NCT02558504_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 17--*--over 18 years",
            "Measurement 20 41--*--General Condition WHO",
            "Value 42 43--*--0",
            "Value 45 46--*--1",
            "Value 50 51--*--2",
            "Scope 42 51--*--0, 1 or 2",
            "Measurement 54 63--*--ASA Class",
            "Value 64 65--*--I",
            "Value 70 72--*--II",
            "Scope 64 72--*--I and II",
            "Mood 74 86--*--eligible for",
            "Procedure 110 119;87 97--*--treatment endoscopic",
            "Procedure 101 119--*--surgical treatment",
            "Qualifier 120 140--*--with curative intent",
            "Scope 87 119--*--endoscopic or surgical treatment",
            "Procedure 143 165--*--Histological diagnosis",
            "Condition 180 210--*--glandular epithelial neoplasia",
            "Measurement 212 218--*--Vienna",
            "Value 219 230--*--4-1 to 4-46",
            "Qualifier 169 179--*--high grade",
            "Qualifier 242 252--*--multifocal",
            "Measurement 256 261--*--stage",
            "Value 262 263--*--0",
            "Measurement 265 266--*--T",
            "Measurement 270 271--*--N",
            "Measurement 274 275--*--M",
            "Value 275 276--*--0",
            "Value 271 272--*--0",
            "Value 266 268--*--is",
            "Scope 265 276--*--Tis, N0, M0",
            "Scope 256 263--*--stage 0",
            "Qualifier 295 317--*--histological confirmed",
            "Qualifier 280 290;308 317--*--Endoscopic confirmed",
            "Condition 331 352--*--intestinal metaplasia",
            "Procedure 295 307--*--histological",
            "Procedure 280 290--*--Endoscopic",
            "Scope 280 317--*--Endoscopic and histological confirmed",
            "Qualifier 355 367--*--Histological",
            "Procedure 355 367--*--Histological",
            "Multiplier 391 394--*--two",
            "Procedure 395 406--*--endoscopies",
            "Procedure 412 420--*--biopsies",
            "Multiplier 425 428--*--two",
            "Procedure 429 450--*--pathological readings",
            "Condition 368 377--*--diagnosis",
            "Non-representable 452 599--*--biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining.",
            "Non-representable 600 671--*--Operators describe Barrett's esophagus using he SFED planimetric model.",
            "Non-representable 672 808--*--The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,",
            "Non-representable 810 823--*--Minimum 1 cm,",
            "Non-representable 825 839--*--Maximum 12 cm.",
            "Condition 845 860--*--resected lesion",
            "Qualifier 876 895--*--well differentiated",
            "Qualifier 900 922--*--confined to the mucosa",
            "Qualifier 924 934--*--m2 maximum",
            "Procedure 939 960--*--histological analysis",
            "Condition 963 972--*--resection",
            "Temporal 983 1003--*--more than two months",
            "Condition 1006 1015--*--resection",
            "Qualifier 1031 1065--*--macroscopically complete laterally",
            "Condition 1068 1077--*--resection",
            "Procedure 1093 1107--*--histologically",
            "Qualifier 1108 1125--*--complete in depth",
            "Condition 1128 1137--*--resection",
            "Procedure 1153 1167--*--histologically",
            "Qualifier 1168 1186--*--complete laterally",
            "Non-representable 1228 1367--*--that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),",
            "Condition 1206 1226--*--microinvasive cancer",
            "Non-representable 1369 1551--*--At least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment.",
            "Non-representable 1553 1641--*--Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole",
            "Qualifier 1683 1693--*--metastatic",
            "Qualifier 1662 1668--*--celiac",
            "Qualifier 1647 1658--*--mediastinal",
            "Scope 1647 1693--*--mediastinal or celiac, or suspected metastatic",
            "Condition 1694 1705--*--lymph nodes",
            "Procedure 1709 1712--*--EUS",
            "Negation 1644 1646--*--No",
            "Observation 1715 1754--*--Affiliation to a social security system",
            "Negation 1768 1775--*--Lack of",
            "Observation 1776 1792;1801 1815--*--participation in clinical study",
            "Qualifier 1793 1800--*--another",
            "Observation 1818 1841--*--Informed consent signed"
        ],
        "Text": "Age over 18 years,. General Condition WHO 0, 1 or 2,. ASA Class I and II, eligible for endoscopic or surgical treatment with curative intent,. Histological diagnosis of high grade glandular epithelial neoplasia (Vienna 4-1 to 4-46), possibly multifocal or stage 0 (Tis, N0, M0),. Endoscopic and histological confirmed diagnosis of intestinal metaplasia,. Histological diagnosis confirmed by two endoscopies with biopsies and two pathological readings; biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining. Operators describe Barrett's esophagus using he SFED planimetric model. The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,. Minimum 1 cm,. Maximum 12 cm.. the resected lesion must have been well differentiated and confined to the mucosa (m2 maximum) on histological analysis,. resection should be more than two months,. resection must have been macroscopically complete laterally,. resection must have been histologically complete in depth,. resection must have been histologically complete laterally with regard to the microinvasive cancer, that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),. At least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment.. Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole,. No mediastinal or celiac, or suspected metastatic lymph nodes by EUS,. Affiliation to a social security system or similar,. Lack of participation in another clinical study,. Informed consent signed.. "
    },
    "NCT03228238_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT02301962_inc": {
        "Annotations": [
            "Post-eligibility 0 85--*--Subject or subject's legally acceptable representative has provided informed consent.",
            "Person 87 91--*--Male",
            "Person 95 101--*--female",
            "Value 102 112--*-->=18 years",
            "Person 116 119--*--age",
            "Procedure 122 136--*--Histologically",
            "Procedure 140 153--*--cytologically",
            "Value 154 163--*--confirmed",
            "Condition 177 191--*--adenocarcinoma",
            "Qualifier 199 204--*--colon",
            "Qualifier 208 214--*--rectum",
            "Scope 199 214--*--colon or rectum",
            "Scope 122 153--*--Histologically or cytologically",
            "Non-query-able 217 480--*--Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status.",
            "Measurement 482 542--*--Eastern Cooperative Oncology Group (ECOG) performance status",
            "Value 546 555--*--0, 1 or 2",
            "Condition 572 594--*--non-measurable disease",
            "Condition 558 568;587 594--*--Measurable disease",
            "Procedure 599 617--*--RECIST Version 1.1",
            "Scope 558 594--*--Measurable or non-measurable disease",
            "Qualifier 630 636--*--failed",
            "Procedure 643 660;691 714--*--fluoropyrimidine- containing chemotherapy",
            "Procedure 662 674;691 714--*--oxaliplatin- containing chemotherapy",
            "Procedure 680 714--*--irinotecan-containing chemotherapy",
            "Condition 728 746--*--metastatic disease",
            "Scope 643 714--*--fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy",
            "Condition 777 796--*--disease progression",
            "Condition 827 838--*--intolerance",
            "Procedure 842 853--*--the regimen",
            "Condition 855 873--*--Metastatic relapse",
            "Temporal 874 928--*--within 6 months after completing adjuvant chemotherapy",
            "Reference_point 890 928--*--after completing adjuvant chemotherapy",
            "Procedure 945 955;971 989--*--irinotecan containing regimen",
            "Procedure 959 989--*--oxaliplatin containing regimen",
            "Scope 945 989--*--irinotecan or oxaliplatin containing regimen",
            "Condition 1091 1123--*--Adequate baseline organ function",
            "Temporal 1136 1183--*--<=7 days prior to first dose of study treatment",
            "Reference_point 1154 1183--*--first dose of study treatment",
            "Scope 748 1078--*--Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen. Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease.",
            "Measurement 1221 1252--*--Absolute neutrophil count (ANC)",
            "Value 1253 1275--*-->=1.5 x 10^9/Liter (L)",
            "Measurement 1277 1291--*--Platelet count",
            "Value 1292 1305--*-->=75 x 10^9/L",
            "Measurement 1307 1317--*--Hemoglobin",
            "Value 1318 1345--*-->=8.0 gram/deciliter (g/dL)",
            "Measurement 1376 1386--*--Creatinine",
            "Value 1387 1422--*--<=1.5 x upper limit of normal (ULN)",
            "Measurement 1456 1487--*--spartate aminotransferase (AST)",
            "Value 1488 1497--*--<=3 x ULN",
            "Measurement 1499 1529--*--Alanine aminotransferase (ALT)",
            "Value 1530 1539--*--<=3 x ULN",
            "Measurement 1541 1556--*--Total Bilirubin",
            "Value 1557 1568--*--<=1.5 x ULN",
            "Measurement 1603 1618--*--Serum Magnesium",
            "Value 1619 1639--*--within normal limits",
            "Measurement 1641 1654--*--Serum Calcium",
            "Value 1655 1675--*--within normal limits",
            "Measurement 1677 1692--*--Serum Potassium",
            "Value 1693 1713--*--within normal limits",
            "Pregnancy_considerations 1861 2324--*--Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.",
            "Non-query-able 1716 1859--*--All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 <=Grade 1 at the time of enrollment."
        ],
        "Text": "Subject or subject's legally acceptable representative has provided informed consent.. Male or female >=18 years of age.. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum.. Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status.. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.. Measurable or non-measurable disease per RECIST Version 1.1.. Must have failed after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens for metastatic disease. Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen. Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease. Laboratory: Adequate baseline organ function defined by (<=7 days prior to first dose of study treatment).. Hematologic function, as follows: Absolute neutrophil count (ANC) >=1.5 x 10^9/Liter (L), Platelet count >=75 x 10^9/L, Hemoglobin >=8.0 gram/deciliter (g/dL).. Renal function, as follows: Creatinine <=1.5 x upper limit of normal (ULN).. Hepatic function, as follows: Aspartate aminotransferase (AST) <=3 x ULN, Alanine aminotransferase (ALT) <=3 x ULN, Total Bilirubin <=1.5 x ULN.. Metabolic function, as follows: Serum Magnesium within normal limits. Serum Calcium within normal limits. Serum Potassium within normal limits.. All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 <=Grade 1 at the time of enrollment.. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.. "
    },
    "NCT02698969_exc": {
        "Annotations": [
            "Condition 33 46--*--renal disease",
            "Condition 22 29;39 46--*--hepatic disease",
            "Qualifier 0 18--*--Clinical diagnosis",
            "Qualifier 48 66--*--Clinical diagnosis",
            "Qualifier 81 86--*--acute",
            "Qualifier 70 77--*--chronic",
            "Condition 87 97--*--alcoholism",
            "Scope 70 86--*--chronic or acute",
            "Condition 110 117--*--allergy",
            "Condition 121 137--*--hypersensitivity",
            "Drug 141 151--*--Sugammadex",
            "Drug 159 167--*--atropine",
            "Drug 171 182--*--Neostigmine",
            "Scope 141 182--*--Sugammadex and/or atropine or Neostigmine",
            "Scope 110 137--*--allergy or hypersensitivity",
            "Condition 209 220--*--CNS effects",
            "Drug 192 203--*--medications",
            "Condition 233 251--*--neurologic disease",
            "Observation 222 229--*--History",
            "Condition 253 272--*--Diaphragmatic palsy",
            "Condition 274 283--*--Pregnancy",
            "Condition 287 294--*--nursing",
            "Observation 296 303--*--History",
            "Condition 307 328--*--malignant arrhythmias",
            "Scope 22 46--*--hepatic or renal disease",
            "Observation 99 106--*--History"
        ],
        "Text": "Clinical diagnosis of hepatic or renal disease. Clinical diagnosis of chronic or acute alcoholism. History of allergy or hypersensitivity to Sugammadex and/or atropine or Neostigmine. Current medications with CNS effects. History of neurologic disease. Diaphragmatic palsy. Pregnancy or nursing. History of malignant arrhythmias. "
    },
    "NCT01996436_exc": {
        "Text": "Inability to obtain consent from patient or patients kin. Pregnant women. less than 18 years of age of more than 80 years of age. Hunt Hess Grade 5 SAH. ",
        "Annotations": [
            "Informed_consent 0 56--*--Inability to obtain consent from patient or patients kin",
            "Pregnancy_considerations 58 72--*--Pregnant women",
            "Person 96 99--*--age",
            "Value 74 92--*--less than 18 years",
            "Person 125 128--*--age",
            "Value 103 121--*--more than 80 years",
            "Measurement 130 145--*--Hunt Hess Grade",
            "Value 146 147--*--5",
            "Condition 148 151--*--SAH"
        ]
    },
    "NCT03624881_exc": {
        "Text": "Previous surgical or catheter ablation for atrial fibrillation. Previous cardiac surgery (including CABG) within the past 6 months (180 days). Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve). Any carotid stenting or endarterectomy. Documented LA thrombus on imaging. LA size > 50 mm (parasternal long axis view). LVEF < 40%. Contraindication to anticoagulation (heparin or warfarin). History of blood clotting or bleeding abnormalities. PCI/MI within the past 2 months (60 days). Documented thromboembolic event (including TIA) within the past 12 months (365 days). Rheumatic Heart Disease. Uncontrolled heart failure or NYHA function class III or IV. Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2). Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days). Unstable angina. Acute illness or active systemic infection or sepsis. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.. Presence of implanted ICD/CRT-D.. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication). Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal). Concurrent enrollment in an investigational study evaluating another device, biologic, or drug.. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter.. Life expectancy less than 12 months. ",
        "Annotations": [
            "Procedure 21 38--*--catheter ablation",
            "Procedure 30 38;9 17--*--ablation surgical",
            "Condition 43 62--*--atrial fibrillation",
            "Scope 9 38--*--surgical or catheter ablation",
            "Procedure 73 88--*--cardiac surgery",
            "Temporal 0 8--*--Previous",
            "Temporal 64 72--*--Previous",
            "Procedure 100 104--*--CABG",
            "Temporal 106 141--*--within the past 6 months (180 days)",
            "Procedure 143 159;169 191--*--Valvular cardiac percutaneous procedure",
            "Procedure 143 168;182 191--*--Valvular cardiac surgical procedure",
            "Procedure 199 213--*--ventriculotomy",
            "Procedure 215 224--*--atriotomy",
            "Procedure 230 242--*--valve repair",
            "Procedure 230 235;246 257--*--valve replacement",
            "Device 276 292--*--prosthetic valve",
            "Scope 199 292--*--ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve",
            "Scope 143 191--*--Valvular cardiac surgical/percutaneous procedure",
            "Device 299 315--*--carotid stenting",
            "Procedure 319 333--*--endarterectomy",
            "Condition 346 357--*--LA thrombus",
            "Procedure 361 368--*--imaging",
            "Measurement 370 377--*--LA size",
            "Value 378 385--*--> 50 mm",
            "Qualifier 387 413--*--parasternal long axis view",
            "Measurement 416 420--*--LVEF",
            "Value 421 426--*--< 40%",
            "Condition 428 444--*--Contraindication",
            "Drug 448 463--*--anticoagulation",
            "Drug 465 472--*--heparin",
            "Drug 476 484--*--warfarin",
            "Scope 465 484--*--heparin or warfarin",
            "Scope 428 463--*--Contraindication to anticoagulation",
            "Observation 487 494--*--History",
            "Condition 498 512--*--blood clotting",
            "Condition 516 538--*--bleeding abnormalities",
            "Scope 498 538--*--blood clotting or bleeding abnormalities",
            "Condition 544 546--*--MI",
            "Procedure 540 543--*--PCI",
            "Temporal 547 571--*--within the past 2 months",
            "Temporal 547 562;573 580--*--within the past 60 days",
            "Scope 547 581--*--within the past 2 months (60 days)",
            "Scope 540 546--*--PCI/MI",
            "Condition 594 614--*--thromboembolic event",
            "Condition 626 629--*--TIA",
            "Temporal 631 656--*--within the past 12 months",
            "Temporal 631 646;658 666--*--within the past 365 days",
            "Scope 631 667--*--within the past 12 months (365 days)",
            "Scope 594 630--*--thromboembolic event (including TIA)",
            "Condition 669 692--*--Rheumatic Heart Disease",
            "Qualifier 694 706--*--Uncontrolled",
            "Condition 707 720--*--heart failure",
            "Measurement 724 743--*--NYHA function class",
            "Value 744 747--*--III",
            "Value 751 753--*--IV",
            "Scope 744 753--*--III or IV",
            "Scope 724 753--*--NYHA function class III or IV",
            "Condition 762 782--*--mitral regurgitation",
            "Qualifier 755 761--*--Severe",
            "Measurement 784 802--*--Regurgitant volume",
            "Value 803 815--*--= 60 mL/beat",
            "Measurement 817 837--*--Regurgitant fraction",
            "Value 838 843--*--= 50%",
            "Measurement 852 886--*--Effective regurgitant orifice area",
            "Value 887 896--*--= 0.40cm2",
            "Scope 784 896--*--Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2",
            "Scope 755 782--*--Severe mitral regurgitation",
            "Procedure 908 931--*--cardiac transplantation",
            "Procedure 941 956--*--cardiac surgery",
            "Temporal 957 982--*--within the next 12 months",
            "Temporal 957 972;984 992--*--within the next 365 days",
            "Scope 908 956--*--cardiac transplantation or other cardiac surgery",
            "Condition 995 1010--*--Unstable angina",
            "Condition 1012 1025--*--Acute illness",
            "Condition 1036 1054--*--systemic infection",
            "Qualifier 1029 1035--*--active",
            "Condition 1058 1064--*--sepsis",
            "Condition 1066 1068--*--AF",
            "Condition 1082 1103--*--electrolyte imbalance",
            "Qualifier 1069 1078--*--secondary",
            "Condition 1105 1120--*--thyroid disease",
            "Condition 1139 1156--*--non-cardiac cause",
            "Qualifier 1125 1135--*--reversible",
            "Device 1171 1190--*--implanted ICD/CRT-D",
            "Condition 1205 1222--*--pulmonary disease",
            "Qualifier 1193 1204--*--Significant",
            "Condition 1231 1260--*--restrictive pulmonary disease",
            "Condition 1278 1315--*--chronic obstructive pulmonary disease",
            "Condition 1262 1274;1298 1315--*--constrictive pulmonary disease",
            "Scope 1231 1315--*--restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease",
            "Scope 1193 1222--*--Significant pulmonary disease",
            "Qualifier 1320 1329--*--any other",
            "Condition 1330 1337;1353 1365--*--disease of the lungs",
            "Condition 1341 1365--*--malfunction of the lungs",
            "Scope 1330 1387--*--disease or malfunction of the lungs or respiratory system",
            "Condition 1330 1337;1353 1359;1369 1387--*--disease of the respiratory system",
            "Condition 1402 1418--*--chronic symptoms",
            "Condition 1421 1452--*--Gastroesophageal Reflux Disease",
            "Condition 1454 1458--*--GERD",
            "Procedure 1477 1501--*--significant intervention",
            "Drug 1516 1530--*--OTC medication",
            "Negation 1502 1505--*--not",
            "Condition 1545 1563--*--congenital anomaly",
            "Qualifier 1533 1544--*--Significant",
            "Condition 1567 1582--*--medical problem",
            "Non-representable 1533 1662--*--Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study",
            "Person 1665 1670--*--Women",
            "Condition 1679 1687--*--pregnant",
            "Procedure 1705 1719--*--pregnancy test",
            "Condition 1723 1737--*--pre-menopausal",
            "Competing_trial 1740 1835--*--Concurrent enrollment in an investigational study evaluating another device, biologic, or drug.",
            "Condition 1849 1870--*--intracardiac thrombus",
            "Condition 1872 1878--*--myxoma",
            "Condition 1880 1885--*--tumor",
            "Condition 1887 1905--*--interatrial baffle",
            "Device 1909 1914--*--patch",
            "Qualifier 1918 1923--*--other",
            "Condition 1924 1935--*--abnormality",
            "Procedure 1951 1966--*--vascular access",
            "Procedure 1971 1999--*--manipulation of the catheter",
            "Condition 1941 1950--*--precludes",
            "Scope 1951 1999--*--vascular access, or manipulation of the catheter",
            "Observation 2002 2017--*--Life expectancy",
            "Value 2018 2037--*--less than 12 months"
        ]
    },
    "NCT03352869_inc": {
        "Annotations": [
            "Condition 0 10--*--Overweight",
            "Condition 15 20--*--obese",
            "Condition 21 25--*--PCOS",
            "Temporal 40 55--*--newly diagnosed",
            "Condition 56 59--*--IGR",
            "Condition 62 66--*--PCOS",
            "Qualifier 86 109--*--2003 Rotterdam criteria",
            "Condition 111 121--*--Overweight",
            "Condition 124 131--*--obesity",
            "Qualifier 165 172--*--WHO-WPR",
            "Scope 111 131--*--Overweight / obesity",
            "Condition 174 201--*--Impaired glucose regulation",
            "Qualifier 235 263--*--1998 WHO diagnostic criteria"
        ],
        "Text": "Overweight and obese PCOS patients with newly diagnosed IGR;. PCOS diagnosis based on 2003 Rotterdam criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. Impaired glucose regulation diagnostic criteria according to 1998 WHO diagnostic criteria.. "
    },
    "NCT03355326_inc": {
        "Text": "Diagnosis of uncomplicated gastroschisis. Gestational age >33 weeks at time of delivery. Weight >1900g at time of delivery. Transfer of patient to Riley Hospital for Children prior to any abdominal surgery. ",
        "Annotations": [
            "Qualifier 13 26--*--uncomplicated",
            "Condition 27 40--*--gastroschisis",
            "Measurement 42 57--*--Gestational age",
            "Value 58 67--*-->33 weeks",
            "Temporal 68 87--*--at time of delivery",
            "Measurement 89 95--*--Weight",
            "Value 96 102--*-->1900g",
            "Temporal 103 122--*--at time of delivery",
            "Visit 147 174--*--Riley Hospital for Children",
            "Temporal 175 205--*--prior to any abdominal surgery",
            "Procedure 188 205--*--abdominal surgery",
            "Reference_point 184 205--*--any abdominal surgery",
            "Procedure 124 132--*--Transfer"
        ]
    },
    "NCT03228238_inc": {
        "Text": "Subject must be at least 30 years of age.. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.. Subject must have symptoms that are consistent with vasospastic angina with planned Coronary angiography and Provocation test.. ",
        "Annotations": [
            "Person 37 40--*--age",
            "Value 16 33--*--at least 30 years",
            "Post-eligibility 43 314--*--Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure",
            "Condition 335 343--*--symptoms",
            "Condition 369 387--*--vasospastic angina",
            "Mood 393 400--*--planned",
            "Procedure 401 421--*--Coronary angiography",
            "Procedure 426 442--*--Provocation test",
            "Scope 401 442--*--Coronary angiography and Provocation test"
        ]
    },
    "NCT02558504_exc": {
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 13--*--under 18",
            "Negation 16 23--*--Lack of",
            "Observation 24 47--*--informed consent signed",
            "Procedure 50 74--*--Radiofrequency treatment",
            "Observation 75 82--*--history",
            "Temporal 85 93--*--on going",
            "Condition 94 104--*--neoplastic",
            "Observation 105 112--*--history",
            "Value 120 125--*--short",
            "Measurement 126 135--*--prognosis",
            "Observation 150 189--*--participation in another clinical study",
            "Temporal 138 149--*--Concomitant",
            "Condition 191 207--*--Contraindication",
            "Procedure 211 229--*--general anesthesia",
            "Qualifier 248 267--*--esophageal location",
            "Condition 271 282--*--scleroderma",
            "Device 298 315--*--cardiac pacemaker",
            "Device 298 305;319 329--*--cardiac stimulator",
            "Observation 331 339--*--Pregnant",
            "Person 340 345--*--women",
            "Mood 349 361--*--likely to be",
            "Observation 331 339--*--Pregnant",
            "Qualifier 362 403--*--in the absence of effective contraception",
            "Condition 406 425--*--Esophageal stenosis",
            "Mood 426 440--*--preventing the",
            "Device 455 464--*--endoscope",
            "Procedure 441 464--*--passage of an endoscope",
            "Procedure 467 476--*--Histology",
            "Condition 488 507--*--glandular neoplasia",
            "Qualifier 477 487--*--other than",
            "Observation 510 517--*--History",
            "Temporal 524 531--*--current",
            "Condition 543 560--*--esophageal cancer",
            "Qualifier 561 607--*--invading the submucosal layer of the esophagus",
            "Scope 510 531--*--History of or current",
            "Procedure 618 636--*--Surgical treatment",
            "Observation 637 644--*--history",
            "Procedure 653 674--*--anti-reflux treatment",
            "Negation 646 652--*--except",
            "Procedure 679 702--*--esophageal radiotherapy",
            "Temporal 705 713--*--previous",
            "Procedure 714 734--*--esophageal treatment",
            "Qualifier 738 752--*--another method",
            "Procedure 753 761--*--ablation",
            "Procedure 763 783--*--photodynamic therapy",
            "Procedure 785 809--*--argon plasma coagulation",
            "Procedure 811 816--*--laser",
            "Scope 763 816--*--photodynamic therapy, argon plasma coagulation, laser",
            "Scope 738 761--*--another method ablation",
            "Condition 824 842--*--Esophageal varices",
            "Procedure 855 864--*--endoscopy",
            "Condition 867 879--*--Coagulopathy",
            "Drug 890 904--*--anticoagulants",
            "Measurement 920 923--*--INR",
            "Value 923 928--*--> 1.3",
            "Measurement 934 948--*--platelet count",
            "Value 949 967--*--<75,000 per microL",
            "Non-representable 905 919--*--responsible an",
            "Measurement 970 985--*--Life expectancy",
            "Value 989 1006--*--less than 3 years",
            "Condition 1015 1035--*--intercurrent disease",
            "Condition 1048 1058--*--neoplastic",
            "Scope 1015 1058--*--intercurrent disease, especially neoplastic",
            "Non-representable 1008 1014--*--due to",
            "Condition 1061 1076--*--Liver cirrhosis",
            "Measurement 1078 1088--*--Child-Pugh",
            "Value 1089 1099--*--all stages",
            "Condition 1102 1121--*--Respiratory failure",
            "Condition 1124 1137--*--Renal failure",
            "Measurement 1139 1144--*--Cl Cr",
            "Value 1145 1164--*--< 60 mL /min /1,73m",
            "Condition 1168 1180--*--Heart attack",
            "Temporal 1181 1207--*--within the last six months",
            "Condition 1211 1246--*--progressive coronary artery disease",
            "Reference_point 1188 1207--*--the last six months",
            "Qualifier 1249 1255--*--Severe",
            "Condition 1256 1276--*--distal arteriopathie",
            "Measurement 1279 1284;1288 1311--*--stage of Leriche and Fontaine",
            "Value 1277 1278;1285 1287--*--> II"
        ],
        "Text": "Aged under 18,. Lack of informed consent signed,. Radiofrequency treatment history,. on going neoplastic history with a short prognosis,. Concomitant participation in another clinical study. Contraindication to general anesthesia,. Patient with an esophageal location of scleroderma. Presence of a cardiac pacemaker or stimulator. Pregnant women or likely to be in the absence of effective contraception,. Esophageal stenosis preventing the passage of an endoscope,. Histology other than glandular neoplasia,. History of or current history of esophageal cancer invading the submucosal layer of the esophagus or more,. Surgical treatment history (except anti-reflux treatment) or esophageal radiotherapy,. previous esophageal treatment by another method ablation: photodynamic therapy, argon plasma coagulation, laser, ..... Esophageal varices observed in endoscopy,. Coagulopathy or taking anticoagulants responsible an INR> 1.3 or a platelet count <75,000 per microL,. Life expectancy of less than 3 years, due to intercurrent disease, especially neoplastic,. Liver cirrhosis (Child-Pugh all stages). Respiratory failure:. Renal failure (Cl Cr < 60 mL /min /1,73m),. Heart attack within the last six months or progressive coronary artery disease,. Severe distal arteriopathie > stage II of Leriche and Fontaine"
    },
    "NCT02531971_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 20 25--*--women",
            "Qualifier 7 19--*--non-pregnant",
            "Person 63 66--*--age",
            "Value 70 89--*--18 and 45 years old",
            "Person 108 119--*--non-smokers",
            "Informed_consent 369 443--*--Provide written informed consent before initiation of any study procedures",
            "Post-eligibility 445 506--*--Available for follow-up for the planned duration of the study",
            "Non-query-able 508 555--*--Able to communicate well with the investigators",
            "Post-eligibility 557 647--*--Able to adhere to the study protocol schedule, study restrictions and examination schedule",
            "Measurement 698 701--*--BMI",
            "Value 702 727--*--between >17 and =28 kg/m2",
            "Non-query-able 730 895--*--Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication histor",
            "Condition 971 975--*--pain",
            "Qualifier 949 954--*--acute",
            "Qualifier 958 970--*--intermittent",
            "Scope 949 970--*--acute or intermittent",
            "Condition 991 995--*--pain",
            "Qualifier 977 990--*--postoperative",
            "Condition 997 1019--*--respiratory compromise",
            "Condition 1037 1043--*--asthma",
            "Qualifier 1021 1026--*--acute",
            "Qualifier 1030 1036--*--severe",
            "Negation 912 914--*--no",
            "Scope 1021 1036--*--acute or severe",
            "Condition 1048 1060--*--constipation",
            "Scope 949 1060--*--acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation",
            "Measurement 1113 1138--*--urine drug screening test",
            "Value 1104 1112--*--Negative",
            "Value 1170 1176--*--normal",
            "Measurement 1204 1221--*--white blood cells",
            "Measurement 1223 1226--*--WBC",
            "Measurement 1229 1239--*--hemoglobin",
            "Measurement 1241 1244--*--Hgb",
            "Measurement 1247 1256--*--platelets",
            "Measurement 1258 1264--*--sodium",
            "Measurement 1266 1275--*--potassium",
            "Measurement 1277 1285--*--chloride",
            "Measurement 1287 1298--*--bicarbonate",
            "Measurement 1300 1319--*--blood urea nitrogen",
            "Measurement 1321 1324--*--BUN",
            "Measurement 1327 1337--*--creatinine",
            "Measurement 1339 1342--*--ALT",
            "Measurement 1361 1364--*--AST",
            "Measurement 1386 1395--*--bilirubin",
            "Scope 1204 1395--*--white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",
            "Value 1402 1408--*--normal",
            "Measurement 1436 1449--*--urine protein",
            "Measurement 1454 1467--*--urine glucose",
            "Scope 1436 1467--*--urine protein and urine glucose",
            "Pregnancy_considerations 1469 2016--*--Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parte",
            "Competing_trial 2019 2199--*--Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session",
            "Non-query-able 2202 2328--*--grees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day",
            "Measurement 2344 2347--*--ECG",
            "Value 2337 2343--*--normal",
            "Negation 2354 2357--*--not",
            "Observation 2395 2426--*--pathologic Q wave abnormalities",
            "Observation 2440 2457--*--ST-T wave changes",
            "Condition 2459 2487--*--left ventricular hypertrophy",
            "Condition 2489 2514--*--right bundle branch block",
            "Condition 2516 2540--*--left bundle branch block",
            "Scope 2395 2541--*--pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",
            "Measurement 2593 2604--*--Temperature",
            "Value 2605 2614--*--35-37.9\u00b0C",
            "Value 2616 2626--*--95-100.3\u00b0F",
            "Measurement 2629 2652--*--Systolic blood pressure",
            "Value 2653 2664--*--90-140 mmHg",
            "Measurement 2666 2690--*--Diastolic blood pressure",
            "Value 2691 2701--*--60-90 mmHg",
            "Measurement 2703 2713--*--Heart rate",
            "Value 2714 2737--*--55-100 beats per minute",
            "Measurement 2739 2755--*--Respiration rate",
            "Value 2756 2780--*--12-18 breaths per minute"
        ],
        "Text": "Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old. Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products. Provide written informed consent before initiation of any study procedures. Available for follow-up for the planned duration of the study. Able to communicate well with the investigators. Able to adhere to the study protocol schedule, study restrictions and examination schedule. Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2). Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history. Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days). Negative urine drug screening test at the time of screening. Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin. Have normal screening laboratories for urine protein and urine glucose. Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter. Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session. Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute). Temperature 35-37.9\u00b0C (95-100.3\u00b0F). Systolic blood pressure 90-140 mmHg. Diastolic blood pressure 60-90 mmHg. Heart rate 55-100 beats per minute. Respiration rate 12-18 breaths per minute. "
    },
    "NCT01770340_inc": {
        "Annotations": [
            "Qualifier 31 40--*--high-risk",
            "Qualifier 57 60--*--cT3",
            "Qualifier 10 27--*--intermediate-risk",
            "Condition 41 56--*--prostate cancer",
            "Scope 10 40--*--intermediate-risk or high-risk",
            "Measurement 62 75--*--Gleason score",
            "Value 76 79--*--= 7",
            "Value 81 84--*--3+4",
            "Value 92 95--*--4+3",
            "Scope 81 95--*--3+4 and/or 4+3",
            "Measurement 105 108--*--PSA",
            "Value 109 119--*--= 20 ng/ml",
            "Condition 121 127;141 158--*--intact erectile function",
            "Temporal 128 140--*--preoperative",
            "Measurement 167 171--*--IIEF",
            "Value 172 176--*--= 21",
            "Observation 178 184--*--IIEF-6",
            "Scope 167 176--*--IIEF = 21"
        ],
        "Text": "Localized intermediate-risk or high-risk prostate cancer cT3. Gleason score = 7 (3+4 and/or 4+3) and/or. PSA = 20 ng/ml. intact preoperative erectile function with an IIEF = 21 (IIEF-6).. "
    },
    "NCT02282319_inc": {
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 44 55--*--class 1 & 2",
            "Procedure 78 94--*--knee arthroscopy"
        ],
        "Text": "ASA (American Society of Anesthesiologists) class 1 & 2,. undergoing day-case knee arthroscopy. "
    },
    "NCT03555526_inc": {
        "Text": "H pylori infection failed after at least two eradication therapies. aged 20 years or greater. willingness to receive rescue therapy. ",
        "Annotations": [
            "Condition 0 18--*--H pylori infection",
            "Procedure 45 66--*--eradication therapies",
            "Multiplier 32 44--*--at least two",
            "Qualifier 19 25--*--failed",
            "Person 68 72--*--aged",
            "Value 73 92--*--20 years or greater",
            "Mood 94 105--*--willingness",
            "Procedure 117 131--*--rescue therapy"
        ]
    },
    "NCT02420015_inc": {
        "Text": "Currently smoke at least ten cigarettes a day. Have been smoking for at least one year. Meet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview. Can speak and write fluent conversational English. Are between 18 and 70 years of age. Are willing to make a smoking cessation attempt. Score 26 or higher on the Montreal Cognitive Assessment. ",
        "Annotations": [
            "Observation 10 15--*--smoke",
            "Multiplier 16 45--*--at least ten cigarettes a day",
            "Observation 57 64--*--smoking",
            "Temporal 69 86--*--at least one year",
            "Condition 106 119--*--schizophrenia",
            "Condition 121 145--*--schizoaffective disorder",
            "Condition 158 176--*--psychotic disorder",
            "Non-query-able 217 266--*--Can speak and write fluent conversational English",
            "Person 299 302--*--age",
            "Value 272 295--*--between 18 and 70 years",
            "Post-eligibility 304 351--*--Are willing to make a smoking cessation attempt",
            "Measurement 379 408--*--Montreal Cognitive Assessment",
            "Value 359 371--*--26 or higher"
        ]
    },
    "NCT02375295_exc": {
        "Annotations": [
            "Condition 14 35--*--medical comorbidities",
            "Procedure 57 84--*--definitive surgical therapy",
            "Mood 36 56--*--preventing them from",
            "Qualifier 101 111--*--persistent",
            "Observation 112 124--*--stone burden",
            "Temporal 125 162--*--following definitive surgical therapy",
            "Reference_point 135 162--*--definitive surgical therapy",
            "Procedure 135 162--*--definitive surgical therapy"
        ],
        "Text": "Patients with medical comorbidities preventing them from definitive surgical therapy.. Patients with persistent stone burden following definitive surgical therapy.. "
    },
    "NCT03305666_exc": {
        "Text": "Allergy or hypersensitivity to bupivacaine. Pregnancy. Incarceration. Age < 18 years. Indwelling continuous thoracic epidural analgesia. ",
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Condition 11 27--*--hypersensitivity",
            "Drug 31 42--*--bupivacaine",
            "Scope 0 27--*--Allergy or hypersensitivity",
            "Condition 44 53--*--Pregnancy",
            "Person 55 68--*--Incarceration",
            "Person 70 73--*--Age",
            "Value 74 84--*--< 18 years",
            "Procedure 108 135--*--thoracic epidural analgesia",
            "Qualifier 97 107--*--continuous",
            "Qualifier 86 96--*--Indwelling"
        ]
    },
    "NCT02315287_exc": {
        "Text": "Contraindication to sitagliptin or metformin or thiazolidinedione. Pregnant or breast feeding women. Type 1 diabetes, gestational diabetes, or secondary forms of diabetes. Not appropriate for oral antidiabetic agent. Medication which affect glycemic control. Disease which affect efficacy and safety of drugs. Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc). ",
        "Annotations": [
            "Drug 20 31--*--sitagliptin",
            "Drug 35 44--*--metformin",
            "Drug 48 65--*--thiazolidinedione",
            "Condition 0 16--*--Contraindication",
            "Scope 20 65--*--sitagliptin or metformin or thiazolidinedione",
            "Condition 67 75--*--Pregnant",
            "Condition 79 85--*--breast",
            "Condition 101 116--*--Type 1 diabetes",
            "Condition 118 138--*--gestational diabetes",
            "Condition 143 170--*--secondary forms of diabetes",
            "Negation 172 175--*--Not",
            "Observation 176 187--*--appropriate",
            "Drug 192 215--*--oral antidiabetic agent",
            "Drug 217 227--*--Medication",
            "Observation 234 257--*--affect glycemic control",
            "Drug 259 266--*--Disease",
            "Qualifier 273 288--*--affect efficacy",
            "Qualifier 293 308--*--safety of drugs",
            "Scope 273 308--*--affect efficacy and safety of drugs",
            "Condition 314 327--*--major illness",
            "Condition 329 342--*--Liver disease",
            "Condition 344 357--*--Renal failure",
            "Condition 359 372--*--Heart disease",
            "Condition 374 380--*--Cancer",
            "Scope 329 380--*--Liver disease, Renal failure, Heart disease, Cancer"
        ]
    },
    "NCT03228654_inc": {
        "Annotations": [
            "Measurement 0 12--*--uterine size",
            "Value 13 22--*--<12 weeks",
            "Condition 37 49--*--benign cause",
            "Procedure 58 70--*--hysterectomy",
            "Condition 76 90--*--fibroid uterus",
            "Condition 92 114--*--perimenopausal beeding",
            "Negation 115 118--*--not",
            "Qualifier 119 150--*--responding to medical treatment",
            "Procedure 133 150--*--medical treatment",
            "Condition 154 185--*--complex endometrial hyperplasia",
            "Negation 186 193--*--without",
            "Condition 194 200--*--atypia",
            "Scope 37 70--*--benign cause for the hysterectomy",
            "Scope 76 200--*--fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia",
            "Negation 203 210--*--Absence",
            "Condition 214 234--*--significant scarring",
            "Qualifier 242 248--*--pelvis",
            "Qualifier 249 272--*--from previous surgeries",
            "Temporal 254 262--*--previous",
            "Procedure 263 272--*--surgeries"
        ],
        "Text": "uterine size <12 weeks.. presence of benign cause for the hysterectomy e.g. fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.. Absence of significant scarring in the pelvis from previous surgeries.. "
    },
    "NCT02282319_exc": {
        "Annotations": [
            "Condition 0 11--*--micturition",
            "Observation 23 43--*--neurological history",
            "Procedure 57 80--*--lower abdominal surgery",
            "Condition 98 109--*--micturition",
            "Qualifier 89 97--*--abnormal"
        ],
        "Text": "micturition problems,. neurological history or. previous lower abdominal surgery with an abnormal micturition. "
    },
    "NCT02531971_exc": {
        "Annotations": [
            "Pregnancy_considerations 0 191--*--Women who are pregnant, lactating or breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of any study session",
            "Person 193 200--*--Smokers",
            "Competing_trial 391 481--*--Participation in any ongoing investigational drug trial/study or clinical drug trial/study",
            "Condition 494 531--*--chronic obstructive pulmonary disease",
            "Condition 535 549--*--cor pulmonale,",
            "Condition 567 596--*--decreased respiratory reserve",
            "Condition 598 605--*--hypoxia",
            "Condition 607 618--*--hypercapnia",
            "Condition 635 657--*--respiratory depression",
            "Measurement 694 708--*--HIV serologies",
            "Measurement 675 686;698 708--*--Hepatitis B serologies",
            "Measurement 675 684;688 689;698 708--*--Hepatitis C serologies",
            "Scope 675 708--*--Hepatitis B, C and HIV serologies",
            "Value 666 674--*--positive",
            "Measurement 719 744--*--urine drug screening test",
            "Value 710 718--*--Positive",
            "Non-query-able 746 1020--*--Use of any prescription medication during the session 0 to 30 days or over-the counter medication e.g. antihistamines or topical corticosteroids (vitamin, herbal supplements and birth control medications not included) during the session 0 to 3 days before entry to the study",
            "Non-query-able 1022 1536--*--Use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator with 72 hours prior to dosing (e.g. antihistamines, systemic or topical corticosteroids (within 3 weeks prior to dosing), cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy",
            "Drug 1546 1574--*--monoamine oxidase inhibitors",
            "Temporal 1575 1597--*--21 days prior to study",
            "Reference_point 1592 1597--*--study",
            "Drug 1648 1659--*--pentazocine",
            "Drug 1661 1671--*--nalbuphine",
            "Drug 1675 1686--*--butorphanol",
            "Drug 1709 1722--*--buprenorphine",
            "Drug 1751 1767--*--anticholinergics",
            "Non-query-able 1820 1983--*--Consumption of beverages containing alcohol, grapefruit juice, Seville oranges, or quinine (e.g. tonic water) or foods containing poppy seeds in the last 72 hours.",
            "Non-query-able 1985 2072--*--Donation or loss of greater than one pint of blood within 60 days of entry to the study",
            "Condition 2112 2128--*--hypersensitivity",
            "Drug 2132 2140--*--fentanyl",
            "Drug 2142 2150--*--morphine",
            "Drug 2152 2159--*--codeine",
            "Drug 2161 2172--*--hydrocodone",
            "Drug 2174 2187--*--hydromorphone",
            "Drug 2189 2198--*--oxycodone",
            "Drug 2200 2211--*--oxymorphone",
            "Drug 2213 2223--*--naltrexone",
            "Drug 2227 2235--*--naloxone",
            "Device 2278 2282--*--TDDS",
            "Device 2284 2313--*--polyester/ethyl vinyl acetate",
            "Device 2315 2336--*--polyacrylate adhesive",
            "Device 2338 2355--*--silicone adhesive",
            "Device 2357 2371--*--dimethicone NF",
            "Device 2376 2386--*--polyolefin",
            "Scope 2132 2386--*--fentanyl, morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, naltrexone or naloxone or any of the inactive ingredients in the TDDS (polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin",
            "Scope 2284 2386--*--polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin",
            "Condition 2409 2422--*--schizophrenia",
            "Condition 2432 2459--*--major psychiatric diagnosis",
            "Condition 2463 2477--*--mental illness",
            "Condition 2484 2500--*--major depression",
            "Condition 2547 2556--*--addiction",
            "Condition 2560 2565--*--abuse",
            "Qualifier 2539 2546--*--alcohol",
            "Qualifier 2531 2535--*--drug",
            "Scope 2531 2546--*--drug or alcohol",
            "Scope 2547 2565--*--addiction or abuse",
            "Non-query-able 2567 2741--*--Any condition that would, in the opinion of the MAI, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol",
            "Post-eligibility 2743 2803--*--Inability to communicate or cooperate with the investigators",
            "Non-query-able 2805 3125--*--Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application site (upper arm), sunburn, raised moles and scars, open sore, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug",
            "Non-query-able 3127 3461--*--Failure to pass opioid dependence challenge test on the first day study day of any study session (i.e., before taking the first dose of naltrexone hydrochloride). Each subject will be injected subcutaneously with naloxone hydrochloride (0.8 mg injection) and will be observed for 45 minutes for signs and symptoms of opioid withdrawal",
            "Non-query-able 3464 3755--*--Within 4 weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator"
        ],
        "Text": "Women who are pregnant, lactating or breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of any study session. Smokers (current use or use over the previous 2 months of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes). Participation in any ongoing investigational drug trial/study or clinical drug trial/study. History of chronic obstructive pulmonary disease or cor pulmonale, or substantially decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression. Active positive Hepatitis B, C and HIV serologies. Positive urine drug screening test. Use of any prescription medication during the session 0 to 30 days or over-the counter medication e.g. antihistamines or topical corticosteroids (vitamin, herbal supplements and birth control medications not included) during the session 0 to 3 days before entry to the study. Use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator with 72 hours prior to dosing (e.g. antihistamines, systemic or topical corticosteroids (within 3 weeks prior to dosing), cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy). Use of monoamine oxidase inhibitors 21 days prior to study. Current use of mixed agonist/antagonist (such as pentazocine, nalbuphine or butorphanol) and partial agonist (buprenorphine) analgesics. Current use of anticholinergics or other medications with anticholinergic activity. Consumption of beverages containing alcohol, grapefruit juice, Seville oranges, or quinine (e.g. tonic water) or foods containing poppy seeds in the last 72 hours.. Donation or loss of greater than one pint of blood within 60 days of entry to the study. Any prior serious adverse reaction or hypersensitivity to fentanyl, morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, naltrexone or naloxone or any of the inactive ingredients in the TDDS (polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin). Have a diagnosis of schizophrenia or other major psychiatric diagnosis or mental illness (e.g. major depression). Medical history of personal drug or alcohol addiction or abuse. Any condition that would, in the opinion of the MAI, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. Inability to communicate or cooperate with the investigators. Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application site (upper arm), sunburn, raised moles and scars, open sore, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug. Failure to pass opioid dependence challenge test on the first day study day of any study session (i.e., before taking the first dose of naltrexone hydrochloride). Each subject will be injected subcutaneously with naloxone hydrochloride (0.8 mg injection) and will be observed for 45 minutes for signs and symptoms of opioid withdrawal.. Within 4 weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator. "
    },
    "NCT01770340_exc": {
        "Annotations": [
            "Measurement 0 4--*--IIEF",
            "Value 5 9--*--< 21",
            "Temporal 22 42--*--in the past 6 months",
            "Procedure 11 21--*--Operations",
            "Condition 55 82--*--limit the erectile function",
            "Condition 84 104--*--Erectile dysfunction",
            "Observation 112 119--*--history",
            "Drug 131 141--*--medication",
            "Temporal 123 130--*--current",
            "Condition 146 166--*--erectile dysfunction",
            "Competing_trial 168 216--*--Current involvement in another comparable study."
        ],
        "Text": "IIEF < 21. Operations in the past 6 months which could limit the erectile function. Erectile dysfunction in the history or current medication for erectile dysfunction. Current involvement in another comparable study.. "
    },
    "NCT02375295_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--Female",
            "Qualifier 56 73--*--infection related",
            "Condition 74 79--*--stone",
            "Mood 82 99--*--Medically fit for",
            "Procedure 100 130--*--definitive surgical management",
            "Condition 134 139--*--stone",
            "Observation 142 157--*--Life expectancy",
            "Value 158 179--*--greater than one year",
            "Condition 182 187--*--Stone",
            "Negation 188 192--*--free",
            "Temporal 193 226--*--after definitive surgical therapy",
            "Reference_point 199 226--*--definitive surgical therapy",
            "Procedure 199 226--*--definitive surgical therapy",
            "Scope 182 192--*--Stone free",
            "Qualifier 238 261--*--fragments less than 3mm"
        ],
        "Text": "Male or Female.. No age restriction.. Diagnosed with an infection related stone.. Medically fit for definitive surgical management of stone.. Life expectancy greater than one year.. Stone free after definitive surgical therapy defined as fragments less than 3mm.. "
    },
    "NCT03555526_exc": {
        "Text": "aged less than 20 years. history of gastric resection surgery. history of allergy to study drugs. pregnancy or lactating women. severe underlying illness, such as end stage renal disease, decompensated liver cirrhosis, or non-curative malignancy. ",
        "Annotations": [
            "Person 0 4--*--aged",
            "Value 5 23--*--less than 20 years",
            "Procedure 36 61--*--gastric resection surgery",
            "Condition 74 81--*--allergy",
            "Drug 85 96--*--study drugs",
            "Condition 98 107--*--pregnancy",
            "Condition 111 120--*--lactating",
            "Person 121 126--*--women",
            "Condition 128 153--*--severe underlying illness",
            "Condition 163 186--*--end stage renal disease",
            "Condition 202 217--*--liver cirrhosis",
            "Qualifier 188 201--*--decompensated",
            "Condition 235 245--*--malignancy",
            "Qualifier 222 234--*--non-curative",
            "Scope 163 245--*--end stage renal disease, decompensated liver cirrhosis, or non-curative malignancy"
        ]
    },
    "NCT02420015_exc": {
        "Text": "Have a history of myocardial infarction in the past 6 months. Have a contraindication to NRT with no medical clearance from the primary care provider or study physician. Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco. Are pregnant. Meet criteria for a current manic episode based on structured clinical interview. Are currently enrolled in another smoking cessation trial. Are currently imprisoned or in psychiatric hospitalization. ",
        "Annotations": [
            "Condition 18 41--*--myocardial infarction i",
            "Temporal 47 60--*--past 6 months",
            "Condition 69 85--*--contraindication",
            "Procedure 89 92--*--NRT",
            "Post-eligibility 170 272--*--Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco",
            "Condition 278 286--*--pregnant",
            "Condition 316 329--*--manic episode",
            "Competing_trial 370 427--*--Are currently enrolled in another smoking cessation trial",
            "Person 443 453--*--imprisoned",
            "Observation 460 487--*--psychiatric hospitalization"
        ]
    },
    "NCT03228654_exc": {
        "Annotations": [
            "Condition 19 43--*--gynecological malignancy",
            "Mood 0 9--*--Suspected",
            "Mood 13 18--*--known",
            "Scope 0 18--*--Suspected or known",
            "Measurement 46 58--*--uterine size",
            "Value 59 68--*-->12 weeks",
            "Condition 71 84--*--Endometriosis",
            "Condition 98 110--*--adnexal mass",
            "Condition 113 143--*--cervix flushed with the vagina",
            "Condition 158 178--*--significant scarring",
            "Qualifier 186 197--*--pelvic area",
            "Procedure 212 219--*--surgery",
            "Qualifier 198 219--*--from previous surgery",
            "Temporal 203 211--*--previous"
        ],
        "Text": "Suspected or known gynecological malignancy.. uterine size >12 weeks.. Endometriosis. Presence of adnexal mass.. cervix flushed with the vagina.. presence of significant scarring in the pelvic area from previous surgery.. "
    },
    "NCT02315287_inc": {
        "Text": "HbA1c > 13.0 %. No treatment with insulin or oral agents for 6 months. 20 = Age < 80 years. ",
        "Annotations": [
            "Measurement 0 5--*--HbA1c",
            "Value 6 14--*--> 13.0 %",
            "Negation 16 18--*--No",
            "Procedure 19 28--*--treatment",
            "Drug 34 41--*--insulin",
            "Drug 45 56--*--oral agents",
            "Temporal 57 69--*--for 6 months",
            "Scope 34 56--*--insulin or oral agents",
            "Value 71 75--*--20 =",
            "Person 76 79--*--Age",
            "Value 80 90--*--< 80 years"
        ]
    },
    "NCT03305666_inc": {
        "Text": "Patients undergoing SSRF at Denver Health Medical Center. ",
        "Annotations": [
            "Procedure 20 24--*--SSRF",
            "Visit 28 56--*--Denver Health Medical Center"
        ]
    },
    "NCT01959425_inc": {
        "Annotations": [
            "Procedure 11 27--*--cardiac ablation",
            "Condition 32 34--*--AF",
            "Qualifier 0 10--*--Successful",
            "Negation 47 54--*--freedom",
            "Condition 60 73--*--AF recurrence",
            "Condition 103 125--*--arrhythmic recurrences",
            "Value 134 156--*--longer than 30 seconds",
            "Temporal 158 200--*--3 months after successful cardiac ablation",
            "Reference_point 184 200--*--cardiac ablation",
            "Non-query-able 202 258--*--AF recurrence during 3-month blanking period is excluded",
            "Drug 312 335--*--anticoagulation therapy",
            "Temporal 340 386--*--at least two (2) months prior to randomization",
            "Reference_point 373 386--*--randomization",
            "Measurement 406 418--*--CHADS2 score",
            "Value 419 422--*--= 2",
            "Measurement 426 444--*--CHA2DS2-VASc score",
            "Value 446 448--*--=3",
            "Measurement 451 485--*--Left ventricular ejection fraction",
            "Value 486 491--*--> 25%",
            "Measurement 493 500--*--LA size",
            "Value 501 505--*--< 65",
            "Observation 512 542--*--risk for thromboembolic events",
            "Value 507 511--*--High",
            "Measurement 550 562--*--CHADS2 score",
            "Value 563 566--*--= 2",
            "Measurement 570 588--*--CHA2DS2-VASc score",
            "Value 589 592--*--= 3",
            "Drug 606 609--*--OAT",
            "Temporal 610 644--*--before undergoing cardiac ablation",
            "Reference_point 628 644--*--cardiac ablation",
            "Scope 550 592--*--CHADS2 score = 2 or CHA2DS2-VASc score = 3",
            "Post-eligibility 647 725--*--ble and willing to comply with all pre- and follow-up testing and requirements",
            "Informed_consent 727 755--*--Signed informed consent form",
            "Person 757 760--*--Age",
            "Value 761 778--*--18 years or older"
        ],
        "Text": "Successful cardiac ablation for AF. Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation (AF recurrence during 3-month blanking period is excluded).. Patient must have been on a commercially approved anticoagulation therapy for at least two (2) months prior to randomization in the OAT Study.. CHADS2 score = 2 or CHA2DS2-VASc score (=3). Left ventricular ejection fraction > 25%. LA size < 65. High risk for thromboembolic events (i.e., CHADS2 score = 2 or CHA2DS2-VASc score = 3) and require OAT before undergoing cardiac ablation. Able and willing to comply with all pre- and follow-up testing and requirements. Signed informed consent form. Age 18 years or older. "
    },
    "NCT02827526_exc": {
        "Annotations": [
            "Temporal 0 12--*--Preoperative",
            "Condition 13 26--*--renal failure",
            "Measurement 41 57--*--serum creatinine",
            "Value 58 69--*--> 2.0 mg/dL",
            "Scope 41 69--*--serum creatinine > 2.0 mg/dL",
            "Measurement 73 126--*--American Society of Anesthesiologists Physical Status",
            "Value 127 134--*--IV or V",
            "Condition 136 153--*--Pulmonary disease",
            "Procedure 168 187--*--home oxygen therapy",
            "Drug 200 209--*--methadone",
            "Drug 211 224--*--hydromorphone",
            "Drug 229 237--*--ketamine",
            "Temporal 239 251--*--Preoperative",
            "Temporal 252 258--*--recent",
            "Observation 259 266--*--history",
            "Condition 280 293--*--alcohol abuse",
            "Condition 270 276;288 293--*--opioid abuse",
            "Scope 270 293--*--opioid or alcohol abuse",
            "Qualifier 295 306--*--Significant",
            "Condition 307 320--*--liver disease",
            "Device 341 351--*--PCA device",
            "Observation 322 338--*--Inability to use",
            "Observation 322 334;355 381--*--Inability to speak the English language"
        ],
        "Text": "Preoperative renal failure (defined as a serum creatinine > 2.0 mg/dL.). American Society of Anesthesiologists Physical Status IV or V. Pulmonary disease necessitating home oxygen therapy. Allergy to methadone, hydromorphone, or ketamine. Preoperative recent history of opioid or alcohol abuse. Significant liver disease. Inability to use a PCA device or speak the English language. "
    },
    "NCT00625742_inc": {
        "Annotations": [
            "Visit 23 38--*--Cachexia Clinic",
            "Condition 44 67--*--involuntary weight loss",
            "Value 71 100--*-->5% of their premorbid weight",
            "Temporal 101 129--*--within the previous 6 months",
            "Person 148 154--*--of age",
            "Value 139 147;155 163--*--18 years or older",
            "Measurement 175 202--*--Karnofsky performance score",
            "Value 206 218--*--60 or higher",
            "Non-query-able 224 270--*--Can maintain oral food intake during the study",
            "Non-query-able 275 348--*--Can understand the study procedures and can sign an informed consent form",
            "Drug 379 388--*--melatonin",
            "Temporal 362 371--*--currently",
            "Negation 358 361--*--not",
            "Drug 405 422--*--megestrol acetate",
            "Observation 439 450--*--lose weight",
            "Temporal 427 435--*--continue",
            "Temporal 459 475--*--at least 2 weeks",
            "Procedure 479 486--*--therapy",
            "Temporal 394 404--*--Are taking",
            "Measurement 499 530--*--calculated creatinine clearance",
            "Value 534 547--*-->/= 60 cc/min"
        ],
        "Text": "1. Are referred to the Cachexia Clinic with involuntary weight loss of >5% of their premorbid weight within the previous 6 months. . 2. Are 18 years of age or older . 3. Have a Karnofsky performance score of 60 or higher. . 4. Can maintain oral food intake during the study . 5. Can understand the study procedures and can sign an informed consent form. . 6. Are not currently taking melatonin. . 7. Are taking megestrol acetate and continue to lose weight despite at least 2 weeks of therapy. . 8. Have a calculated creatinine clearance of >/= 60 cc/min. . "
    },
    "NCT02872935_inc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Measurement 10 67--*--American Society of Anesthesiologists risk classification",
            "Value 68 76--*--I and II",
            "Person 78 81--*--Age",
            "Value 82 92--*--> 18 years",
            "Value 94 106--*--Non-laboring",
            "Qualifier 122 130--*--elective",
            "Procedure 131 148--*--cesarean sections"
        ],
        "Text": "Pregnant. American Society of Anesthesiologists risk classification I and II. Age > 18 years. Non-laboring. Patients with elective cesarean sections. "
    },
    "NCT03402945_inc": {
        "Text": "\u226518 years of age undergoing open-heart surgery (sternotomy, including minimally-invasive sternotomies). ",
        "Annotations": [
            "Value 0 9--*--\u226518 years",
            "Person 13 16--*--age",
            "Procedure 28 46--*--open-heart surgery",
            "Temporal 17 27--*--undergoing",
            "Procedure 48 58--*--sternotomy",
            "Procedure 70 101--*--minimally-invasive sternotomies",
            "Scope 48 101--*--sternotomy, including minimally-invasive sternotomies"
        ]
    },
    "NCT00931983_inc": {
        "Text": "Children between the ages of 4-18 with incomplete ASIA C or D spinal cord injuries at least 12 months before study enrolment . Non-ambulatory or 'exercise only' ambulators with or without assistive devices . Normal motor and cognitive development up to time of injury . Medical Stability . ",
        "Annotations": [
            "Person 21 25--*--ages",
            "Value 29 33--*--4-18",
            "Person 0 8--*--Children",
            "Condition 62 82--*--spinal cord injuries",
            "Measurement 50 54--*--ASIA",
            "Value 55 61--*--C or D",
            "Qualifier 39 49--*--incomplete",
            "Temporal 83 124--*--at least 12 months before study enrolment",
            "Reference_point 109 124--*--study enrolment",
            "Observation 126 140--*--Non-ambulatory",
            "Observation 144 170--*--'exercise only' ambulators",
            "Device 187 204--*--assistive devices",
            "Measurement 223 244--*--cognitive development",
            "Value 206 212--*--Normal",
            "Measurement 213 218;233 244--*--motor development",
            "Temporal 245 265--*--up to time of injury",
            "Reference_point 251 265--*--time of injury",
            "Scope 213 244--*--motor and cognitive development",
            "Condition 267 284--*--Medical Stability"
        ]
    },
    "NCT01440296_inc": {
        "Text": "male and female patients over the age of 18 years. . written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific procedures. . patient with mild to severe carotid artery disease . ",
        "Annotations": [
            "Person 0 4--*--male",
            "Person 9 15--*--female",
            "Value 25 29;41 49--*--over 18 years",
            "Person 34 37--*--age",
            "Non-query-able 52 76--*--written informed consent",
            "Condition 241 263--*--carotid artery disease",
            "Qualifier 234 240--*--severe",
            "Qualifier 226 230--*--mild",
            "Scope 226 240--*--mild to severe"
        ]
    },
    "NCT03639545_exc": {
        "Text": "diagnosed advanced heart, kidney or liver failure. benign prostatic hyperplasia. prostatic carcinoma. frequent urinary tract infections. non-type 1 diabetes mellitus. ",
        "Annotations": [
            "Condition 10 24;42 49--*--advanced heart failure",
            "Condition 26 32;42 49--*--kidney failure",
            "Condition 36 41;42 49--*--liver failure",
            "Condition 51 79--*--benign prostatic hyperplasia",
            "Condition 81 100--*--prostatic carcinoma",
            "Multiplier 102 110--*--frequent",
            "Condition 111 135--*--urinary tract infections",
            "Condition 137 165--*--non-type 1 diabetes mellitus"
        ]
    },
    "NCT00500500_inc": {
        "Annotations": [
            "Value 18 32--*--50 to 85 years",
            "Person 33 36--*--old",
            "Measurement 56 84--*--Mini Mental Status (MMS) tes",
            "Value 86 112--*--between 16 to 26 inclusive",
            "Measurement 114 149--*--Clinical Dementia Rating (CDR) test",
            "Value 150 172--*--inferior or equal to 1",
            "Measurement 174 323--*--National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test",
            "Value 324 332--*--positive",
            "Measurement 361 441--*--Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test",
            "Value 442 450--*--positive"
        ],
        "Text": "female or male of 50 to 85 years old with a care giver . Mini Mental Status (MMS) test between 16 to 26 inclusive . Clinical Dementia Rating (CDR) test inferior or equal to 1 . National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease . Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia . "
    },
    "NCT01959425_exc": {
        "Annotations": [
            "Drug 0 3--*--OAT",
            "Negation 25 28--*--not",
            "Qualifier 40 42--*--AF",
            "Device 50 66--*--prosthetic valve",
            "Condition 68 79--*--PV stenosis",
            "Condition 90 108--*--pulmonary embolism",
            "Measurement 157 170--*--standard echo",
            "Temporal 184 202--*--3-months follow-up",
            "Reference_point 193 202--*--follow-up",
            "Value 122 147--*--spontaneous echo contrast",
            "Value 149 152--*--SEC",
            "Scope 50 202--*--prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up",
            "Procedure 210 225--*--cardiac surgery",
            "Temporal 226 249--*--within the past 60 days",
            "Temporal 251 259--*--2 months",
            "Procedure 264 289--*--valvular cardiac surgical",
            "Procedure 319 333--*--ventriculotomy",
            "Procedure 335 344--*--atriotomy",
            "Procedure 350 362--*--valve repair",
            "Procedure 350 355;366 377--*--valve replacement",
            "Device 396 413--*--prosthetic valve)",
            "Scope 319 412--*--ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve",
            "Condition 424 445--*--myocardial infarction",
            "Condition 447 449--*--MI",
            "Procedure 456 490--*--percutaneous coronary intervention",
            "Procedure 491 494--*--PCI",
            "Temporal 495 519--*--within the past 3 months",
            "Scope 424 494--*--myocardial infarction (MI) or a percutaneous coronary intervention PCI",
            "Procedure 530 553--*--cardiac transplantation",
            "Mood 521 529--*--Awaiting",
            "Procedure 563 578--*--cardiac surgery",
            "Temporal 579 603--*--within the next 365 days",
            "Temporal 579 585;605 614--*--within 12 months",
            "Scope 530 578--*--cardiac transplantation or other cardiac surgery",
            "Condition 628 648--*--left atrial thrombus",
            "Condition 662 679--*--pulmonary disease",
            "Qualifier 650 661--*--Significant",
            "Condition 688 717--*--restrictive pulmonary disease",
            "Condition 735 739--*--COPD",
            "Non-query-able 744 842--*--any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms",
            "Scope 688 740--*--restrictive pulmonary disease, constrictive or COPD)",
            "Non-query-able 845 951--*--ignificant medical problem that in the opinion of the investigator would preclude enrollment in this study",
            "Pregnancy_considerations 953 1026--*--Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)",
            "Condition 1052 1070--*--systemic infection",
            "Condition 1074 1080--*--sepsis",
            "Non-query-able 1028 1041--*--Acute illness",
            "Condition 1082 1097--*--Unstable angina",
            "Condition 1099 1115--*--Contraindication",
            "Drug 1119 1134--*--anticoagulation",
            "Drug 1142 1149--*--heparin",
            "Drug 1151 1159--*--warfarin",
            "Non-query-able 1164 1220--*--nother commercially available anticoagulation medication",
            "Scope 1142 1159--*--heparin, warfarin",
            "Condition 1252 1274--*--bleeding abnormalities",
            "Condition 1234 1248;1261 1274--*--blood clotting abnormalities",
            "Observation 1276 1291--*--Life expectancy",
            "Value 1292 1310--*--less than 360 days",
            "Value 1292 1301;1312 1321--*--less than 12 months",
            "Condition 1337 1350--*--Heart Failure",
            "Qualifier 1324 1336--*--Uncontrolled",
            "Condition 1375 1388--*--heart failure",
            "Qualifier 1354 1368--*--NYHA Class III",
            "Qualifier 1354 1364;1372 1374--*--NYHA Class IV",
            "Scope 1354 1374--*--NYHA Class III or IV",
            "Competing_trial 1390 1480--*--Enrollment in a clinical study evaluating another device or drug, within the past 6 months",
            "Post-eligibility 1482 1538--*--Unable or unwilling to comply with protocol requirements"
        ],
        "Text": "OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up).. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve). Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within the past 3 months. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12 months). Documented left atrial thrombus. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or COPD) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Significant medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal). Acute illness or active systemic infection or sepsis. Unstable angina. Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially available anticoagulation medication). History of blood clotting or bleeding abnormalities. Life expectancy less than 360 days (12 months). Uncontrolled Heart Failure or NYHA Class III or IV heart failure. Enrollment in a clinical study evaluating another device or drug, within the past 6 months. Unable or unwilling to comply with protocol requirements. "
    },
    "NCT03402945_exc": {
        "Text": "On systemic antibiotics or with an active bacterial infection at the time of surgery. Patients previously enrolled in this trial. Patients known to be colonized with Methicillin-resistant S. aureus (MRSA)(unethical not to administer glycopeptides), beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively, or to silver precluding the use of Prevena. Participation in other studies that may interfere with this trial. ",
        "Annotations": [
            "Drug 3 23--*--systemic antibiotics",
            "Condition 42 61--*--bacterial infection",
            "Qualifier 35 41--*--active",
            "Temporal 62 84--*--at the time of surgery",
            "Reference_point 65 84--*--the time of surgery",
            "Procedure 77 84--*--surgery",
            "Observation 95 128--*--previously enrolled in this trial",
            "Qualifier 166 204--*--Methicillin-resistant S. aureus (MRSA)",
            "Condition 151 160--*--colonized",
            "Non-representable 204 247--*--(unethical not to administer glycopeptides)",
            "Drug 249 260--*--beta-lactam",
            "Drug 264 274--*--vancomycin",
            "Condition 275 282--*--allergy",
            "Scope 249 274;305 356--*--beta-lactam or vancomycin cefazolin or vancomycin, respectively, or to silver",
            "Drug 305 314--*--cefazolin",
            "Drug 318 328--*--vancomycin",
            "Drug 350 356--*--silver",
            "Competing_trial 388 453--*--Participation in other studies that may interfere with this trial"
        ]
    },
    "NCT00625742_exc": {
        "Annotations": [
            "Condition 8 16--*--dementia",
            "Condition 20 28--*--delirium",
            "Temporal 79 93--*--at study entry",
            "Scope 8 28--*--dementia or delirium",
            "Condition 103 111--*--pregnant",
            "Drug 133 148--*--corticosteroids",
            "Temporal 153 173--*--longer than 48 hours",
            "Condition 184 199--*--pulmonary edema",
            "Condition 201 208--*--ascites",
            "Condition 212 225--*--pitting edema",
            "Condition 259 273--*--unable to walk",
            "Observation 286 293--*--history",
            "Condition 305 336--*--adverse gastrointestinal events",
            "Qualifier 297 304--*--serious",
            "Condition 344 352--*--bleeding",
            "Condition 356 367--*--perforation",
            "Scope 344 367--*--bleeding or perforation",
            "Condition 382 394--*--coagulopathy",
            "Observation 369 376--*--history",
            "Drug 406 420--*--anti-coagulant",
            "Temporal 398 405--*--current",
            "Measurement 438 445--*--ALT/AST",
            "Value 445 470--*-->3x upper limit of normal",
            "Drug 488 500--*--methotrexate",
            "Drug 522 549--*--melatonin receptor agonists",
            "Drug 559 566--*--Rozerem",
            "Drug 569 578--*--ramelteon"
        ],
        "Text": "1. Have dementia or delirium (as determined by the palliative care specialist) at study entry. . 2. Are pregnant . 3. Have been taking corticosteroids for longer than 48 hours. . 4. Have pulmonary edema, ascites or pitting edema on clinical examination. . 5. Are unable to walk. . 6. Have a history of serious adverse gastrointestinal events (i.e., bleeding or perforation),history of a coagulopathy or current anti-coagulant use. . 7. Have an ALT/AST>3x upper limit of normal. . 8. Patients on methotrexate. . 9. Patients taking melatonin receptor agonists (such as Rozerem\u00ae [ramelteon]).       .     . "
    },
    "NCT02827526_inc": {
        "Annotations": [
            "Procedure 33 64--*--posterior spinal fusion surgery",
            "Qualifier 24 32--*--elective",
            "Qualifier 66 80--*--lower thoracic",
            "Qualifier 82 88--*--lumbar",
            "Qualifier 90 96--*--sacral",
            "Scope 66 96--*--lower thoracic, lumbar, sacral",
            "Person 99 103--*--Ages",
            "Value 104 109--*--18-80"
        ],
        "Text": "Patients presenting for elective posterior spinal fusion surgery (lower thoracic, lumbar, sacral). Ages 18-80. "
    },
    "NCT02872935_exc": {
        "Annotations": [
            "Observation 0 21--*--Non- English speakers",
            "Measurement 23 29--*--Height",
            "Value 30 38--*--< 4' 11\"",
            "Observation 40 43--*--BMI",
            "Value 44 54--*-->40 Kg/ mm",
            "Drug 56 71--*--Antiemetic drug",
            "Temporal 76 118--*--in the 24 hours prior to cesarean delivery",
            "Reference_point 101 118--*--cesarean delivery",
            "Procedure 101 118--*--cesarean delivery",
            "Condition 121 155--*--Hypertensive diseases of pregnancy",
            "Condition 157 177--*--Chronic hypertension",
            "Procedure 188 214--*--antihypertensive treatment",
            "Post-eligibility 216 330--*--Any other physical or psychiatric condition that may impair their ability to cooperate with study data collection."
        ],
        "Text": "Non- English speakers. Height < 4' 11\". BMI >40 Kg/ mm. Antiemetic drug use in the 24 hours prior to cesarean delivery,. Hypertensive diseases of pregnancy. Chronic hypertension receiving antihypertensive treatment. Any other physical or psychiatric condition that may impair their ability to cooperate with study data collection.. "
    },
    "NCT00931983_exc": {
        "Text": "Other neuromuscular disease . Contraindication to weight bearing on lower extremities . Pressure sores where harness would be applied . Uncontrollable hypotension when upright . Lower limb contractures impeding range of motion necessary for ambulation . Prior enrolment in a BWATT program . Unable to commit to intervention for duration of protocol       .     . ",
        "Annotations": [
            "Condition 6 27--*--neuromuscular disease",
            "Observation 49 84--*--weight bearing on lower extremities",
            "Condition 29 45--*--Contraindication",
            "Condition 86 100--*--Pressure sores",
            "Device 107 114--*--harness",
            "Condition 148 159--*--hypotension",
            "Qualifier 133 147--*--Uncontrollable",
            "Qualifier 160 172--*--when upright",
            "Condition 174 197--*--Lower limb contractures",
            "Mood 198 206--*--impeding",
            "Observation 207 247--*--range of motion necessary for ambulation",
            "Non-representable 249 283--*--Prior enrolment in a BWATT program",
            "Post-eligibility 285 342--*--Unable to commit to intervention for duration of protocol"
        ]
    },
    "NCT01440296_exc": {
        "Text": "any condition that would contra-indicate Magnetic Resonance Imaging or administration of contrast agent       .     . ",
        "Annotations": [
            "Undefined_semantics 0 103--*--any condition that would contra-indicate Magnetic Resonance Imaging or administration of contrast agent"
        ]
    },
    "NCT00500500_exc": {
        "Annotations": [
            "Context_Error 0 73--*--patient already treated by medicines which could interfere with the study",
            "Measurement 79 99--*--level of vitamin B12",
            "Value 75 78--*--low",
            "Measurement 104 110;79 87--*--folate level of",
            "Condition 193 210--*--pulmonary illness",
            "Condition 212 234--*--cardiovascular illness",
            "Condition 236 252--*--evolutive cancer",
            "Condition 254 274--*--neurological illness",
            "Condition 276 289--*--blood illness",
            "Context_Error 156 292--*--clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness\u2026.)"
        ],
        "Text": "patient already treated by medicines which could interfere with the study . low level of vitamin B12 and folate which are considered as clinically relevant . clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness\u2026.)       .     . "
    },
    "NCT03639545_inc": {
        "Text": "diabetes mellitus type 1. ",
        "Annotations": [
            "Condition 0 24--*--diabetes mellitus type 1"
        ]
    },
    "NCT02394158_inc": {
        "Text": "Singleton pregnancy;. 8-22 weeks gestation. Previous pregnancy complicated by gestational diabetes. ",
        "Annotations": [
            "Condition 0 19--*--Singleton pregnancy",
            "Condition 33 42--*--gestation",
            "Multiplier 22 32--*--8-22 weeks",
            "Condition 78 98--*--gestational diabetes",
            "Condition 53 62--*--pregnancy"
        ]
    },
    "NCT03099408_exc": {
        "Text": "Presence of another vaginal infection or STD. Allergy to metronidazole. Pregnant or nursing. Use of oral or intravaginal antibiotics within the past 2 weeks. HIV or other chronic disease. Inability to keep return appointments. Contraindications for Lactobacillus Vaginal Suppositories(those without sexual history). ",
        "Annotations": [
            "Condition 20 37--*--vaginal infection",
            "Qualifier 12 19--*--another",
            "Condition 41 44--*--STD",
            "Scope 20 44--*--vaginal infection or STD",
            "Condition 46 53--*--Allergy",
            "Drug 57 70--*--metronidazole",
            "Condition 72 80--*--Pregnant",
            "Condition 84 91--*--nursing",
            "Drug 108 132--*--intravaginal antibiotics",
            "Drug 100 104;121 132--*--oral antibiotics",
            "Temporal 133 156--*--within the past 2 weeks",
            "Scope 100 132--*--oral or intravaginal antibiotics",
            "Condition 158 161--*--HIV",
            "Qualifier 165 170--*--other",
            "Condition 171 186--*--chronic disease",
            "Observation 188 225--*--Inability to keep return appointments",
            "Condition 227 244--*--Contraindications",
            "Drug 249 284--*--Lactobacillus Vaginal Suppositories",
            "Negation 291 298--*--without",
            "Observation 299 313--*--sexual history",
            "Scope 291 313--*--without sexual history",
            "Scope 227 284--*--Contraindications for Lactobacillus Vaginal Suppositories"
        ]
    },
    "NCT03424733_inc": {
        "Text": "diagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) score. ",
        "Annotations": [
            "Condition 22 24--*--MS",
            "Qualifier 26 45--*--relapsing remitting",
            "Qualifier 47 66--*--primary progressive",
            "Qualifier 68 89--*--secondary progressive",
            "Qualifier 10 18--*--any form",
            "Scope 26 89--*--relapsing remitting, primary progressive, secondary progressive",
            "Value 92 95--*--any",
            "Measurement 135 140;96 100--*--score EDSS",
            "Measurement 102 133--*--expanded stability status scale"
        ]
    },
    "NCT03190304_inc": {
        "Annotations": [
            "Condition 26 39--*--heart failure",
            "Person 41 44--*--men",
            "Person 49 54--*--women",
            "Person 56 60--*--aged",
            "Value 61 70--*-->18 years",
            "Condition 0 11--*--Symptomatic",
            "Measurement 111 144--*--New York Heart Association (NYHA)",
            "Value 73 103--*--Functional class II, III or IV",
            "Measurement 146 180--*--Left ventricular ejection fraction",
            "Value 181 185--*--<35%",
            "Condition 187 195;212 220--*--Ischemic etiology",
            "Condition 200 220--*--nonischemic etiology",
            "Measurement 222 254--*--Type B natriuretic peptide (BNP)",
            "Value 255 265--*-->150 pg/ml",
            "Measurement 270 297--*--pro-BNP [N-terminal-proBNP]",
            "Value 298 311--*--= 600 pg / ml",
            "Procedure 335 347--*--hospitalized",
            "Condition 352 374--*--cardiac decompensation",
            "Temporal 375 405--*--within the preceding 12 months",
            "Scope 335 405--*--hospitalized for cardiac decompensation within the preceding 12 months",
            "Measurement 407 410--*--BNP",
            "Value 411 421--*-->100 pg/ml",
            "Measurement 426 443--*--N-terminal-proBNP",
            "Value 444 457--*--= 400 pg / ml",
            "Scope 407 458--*--BNP >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)",
            "Scope 222 312--*--Type B natriuretic peptide (BNP) >150 pg/ml (or pro-BNP [N-terminal-proBNP] = 600 pg / ml)"
        ],
        "Text": "Symptomatic patients with heart failure (men and women) aged >18 years,. Functional class II, III or IV by the New York Heart Association (NYHA). Left ventricular ejection fraction <35%. Ischemic and nonischemic etiology. Type B natriuretic peptide (BNP) >150 pg/ml (or pro-BNP [N-terminal-proBNP] = 600 pg / ml) or if the patient was hospitalized for cardiac decompensation within the preceding 12 months, BNP >100 pg/ml (or N-terminal-proBNP = 400 pg / ml). "
    },
    "NCT02560389_inc": {
        "Annotations": [
            "Person 15 18--*--age",
            "Value 0 11--*--25-50 years",
            "Observation 36 44;55 62--*--physical assault",
            "Observation 48 62--*--sexual assault",
            "Condition 20 24--*--PTSD",
            "Scope 36 62--*--physical or sexual assault",
            "Observation 64 81--*--Medically healthy",
            "Observation 83 99--*--English speaking"
        ],
        "Text": "25-50 years of age. PTSD related to physical or sexual assault. Medically healthy. English speaking. "
    },
    "NCT02939209_exc": {
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Condition 9 20--*--sensitivity",
            "Condition 34 51--*--contraindications",
            "Drug 66 77--*--medications",
            "Qualifier 94 99--*--study",
            "Scope 0 51--*--Allergy, sensitivity, or absolute contraindications",
            "Condition 113 127--*--CNS depression",
            "Drug 149 159--*--medication",
            "Condition 171 185--*--CNS depression",
            "Condition 199 217--*--cognitive deficits",
            "Condition 219 227--*--dementia",
            "Condition 232 240--*--delirium",
            "Condition 249 274--*--respiratory comorbidities",
            "Qualifier 242 248--*--severe",
            "Condition 281 318--*--chronic obstructive pulmonary disease",
            "Condition 320 329--*--pneumonia",
            "Condition 331 350--*--respiratory failure",
            "Scope 281 350--*--chronic obstructive pulmonary disease, pneumonia, respiratory failure",
            "Condition 353 379--*--sleep disordered breathing",
            "Condition 391 394--*--OSA",
            "Condition 396 428--*--obesity hypoventilation syndrome",
            "Scope 391 428--*--OSA, obesity hypoventilation syndrome",
            "Pregnancy_considerations 431 459--*--pregnancy and breast feeding",
            "Condition 472 484--*--chronic pain",
            "Drug 518 524--*--opioid",
            "Multiplier 497 516--*--at least once daily",
            "Qualifier 529 543--*--preoperatively",
            "Condition 545 561--*--renal impairment",
            "Measurement 564 568--*--CrCl",
            "Value 569 582--*--=60 mL/minute",
            "Post-eligibility 584 691--*--not fluent in English to be able to participate in the study process, including consent and phone interview",
            "Measurement 693 708--*--Body Mass Index",
            "Value 709 712--*-->35",
            "Mood 714 723--*--inability",
            "Drug 732 747--*--oral medication"
        ],
        "Text": "Allergy, sensitivity, or absolute contraindications to any of the medications involved in the study. preexisting CNS depression, or taking regularly medication that cause CNS depression. preexisting cognitive deficits, dementia, or delirium. severe respiratory comorbidities (e.g. chronic obstructive pulmonary disease, pneumonia, respiratory failure). sleep disordered breathing (diagnosed OSA, obesity hypoventilation syndrome). pregnancy and breast feeding. history of chronic pain or regular (at least once daily) opioid use preoperatively. renal impairment - CrCl =60 mL/minute. not fluent in English to be able to participate in the study process, including consent and phone interview. Body Mass Index >35. inability to take oral medication.. "
    },
    "NCT02384850_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 158 160--*--2.",
            "Parsing_Error 266 268--*--3.",
            "Parsing_Error 298 300--*--4.",
            "Parsing_Error 329 331--*--5.",
            "Parsing_Error 347 349--*--6.",
            "Parsing_Error 487 489--*--7.",
            "Parsing_Error 727 729--*--8.",
            "Parsing_Error 816 818--*--9.",
            "Parsing_Error 852 855--*--10.",
            "Condition 55 72--*--colorectal cancer",
            "Qualifier 89 101--*--unresectable",
            "Condition 118 125--*--disease",
            "Undefined_semantics 118 125--*--disease",
            "Qualifier 102 117--*--stage IV (UICC)",
            "Value 108 110--*--IV",
            "Procedure 17 31--*--histologically",
            "Value 32 41--*--confirmed",
            "Drug 206 212--*--FOLFOX",
            "Non-query-able 178 186--*--feasible",
            "Procedure 232 252--*--palliative treatment",
            "Procedure 220 228;243 252--*--adjuvant treatment",
            "Non-query-able 253 263--*--is allowed",
            "Measurement 269 292--*--ECOG Performance status",
            "Value 293 296--*--\u2264 1",
            "Observation 301 316--*--Life expectancy",
            "Value 317 327--*--> 3 months",
            "Person 332 335--*--Age",
            "Value 336 345--*--\u226518 years",
            "Parsing_Error 350 406--*--Haematologic function as follows (5% deviation allowed):",
            "Measurement 408 411--*--ANC",
            "Value 412 425--*--\u2265 1.5 x 109/L",
            "Measurement 427 436--*--platelets",
            "Value 437 449--*--\u2265 100 x109/L",
            "Measurement 451 461--*--hemoglobin",
            "Value 462 470--*--\u2265 9 g/dl",
            "Value 462 463;474 485--*--\u2265 5.59 mmol/l",
            "Scope 462 485--*--\u2265 9 g/dl or 5.59 mmol/l",
            "Measurement 499 513--*--liver function",
            "Value 490 498--*--Adequate",
            "Parsing_Error 490 548--*--Adequate liver function as follows (10% deviation allowed)",
            "Measurement 550 582--*--serum alanine transaminase (ALT)",
            "Value 583 594--*--\u2264 2.5 x ULN",
            "Condition 607 623--*--liver metastases",
            "Value 624 633--*--< 5 x ULN",
            "Measurement 636 651--*--total bilirubin",
            "Value 652 663--*--\u2264 1.5 x ULN",
            "Condition 679 697--*--Gilbert's syndrome",
            "Measurement 698 713--*--total bilirubin",
            "Value 714 724--*--\u22642.5 x ULN",
            "Measurement 739 753--*--renal function",
            "Value 730 738--*--Adequate",
            "Parsing_Error 730 788--*--Adequate renal function as follows (10% deviation allowed)",
            "Measurement 792 802--*--creatinine",
            "Value 803 814--*--\u2264 1.5 x ULN",
            "Post-eligibility 819 850--*--Signed written informed consent",
            "Condition 865 888--*--child-bearing potential",
            "Person 856 861--*--Women",
            "Measurement 910 924--*--pregnancy test",
            "Value 901 909--*--negative",
            "Scope 856 888--*--Women of child-bearing potential"
        ],
        "Text": "1. Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present) . 2. Patients who are feasible for treatment with FOLFOX (prior adjuvant or palliative treatment is allowed) . 3. ECOG Performance status \u2264 1 . 4. Life expectancy > 3 months . 5. Age \u226518 years . 6. Haematologic function as follows (5% deviation allowed): . ANC \u2265 1.5 x 109/L . platelets \u2265 100 x109/L . hemoglobin \u2265 9 g/dl or 5.59 mmol/l . 7. Adequate liver function as follows (10% deviation allowed) . serum alanine transaminase (ALT) \u2264 2.5 x ULN (in case of liver metastases < 5 x ULN) . total bilirubin \u2264 1.5 x ULN (patients with Gilbert's syndrome total bilirubin \u22642.5 x ULN) . 8. Adequate renal function as follows (10% deviation allowed) . \u00b7 creatinine \u2264 1.5 x ULN . 9. Signed written informed consent . 10. Women of child-bearing potential must have a negative pregnancy test . "
    },
    "NCT02394158_exc": {
        "Text": "Established pre-existing diabetes (including unrecognised diabetes defined as a fasting plasma glucose = 7.0mmol/L and/ or HbA1c = 48mmol/mol); Contraindications to metformin therapy (creatinine = 130\u00b5mol/L/ alanine transaminase = 2.0 x upper limit normal/ previous intolerance to metformin). Planned continued antenatal care/ delivery at centre not included in trial. Planned fast for cultural/ religious reasons e.g. Ramadan. ",
        "Annotations": [
            "Condition 25 33--*--diabetes",
            "Measurement 80 102--*--fasting plasma glucose",
            "Value 103 114--*--= 7.0mmol/L",
            "Measurement 123 128--*--HbA1c",
            "Value 129 142--*--= 48mmol/mol)",
            "Condition 144 161--*--Contraindications",
            "Drug 165 174--*--metformin",
            "Measurement 184 194--*--creatinine",
            "Value 195 207--*--= 130\u00b5mol/L/",
            "Measurement 208 228--*--alanine transaminase",
            "Value 229 255--*--= 2.0 x upper limit normal",
            "Condition 266 277--*--intolerance",
            "Drug 281 290--*--metformin",
            "Scope 80 141--*--fasting plasma glucose = 7.0mmol/L and/ or HbA1c = 48mmol/mol",
            "Scope 184 290--*--creatinine = 130\u00b5mol/L/ alanine transaminase = 2.0 x upper limit normal/ previous intolerance to metformin",
            "Competing_trial 293 367--*--Planned continued antenatal care/ delivery at centre not included in trial",
            "Non-query-able 369 426--*--Planned fast for cultural/ religious reasons e.g. Ramadan"
        ]
    },
    "NCT03099408_inc": {
        "Text": "Women be at least 18 years of age. Have symptoms of vaginal odor and or/discharge. Meet the clinical (Amsel) criteria for BV. Willing to participate in research. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Value 9 26--*--at least 18 years",
            "Person 30 33--*--age",
            "Mood 40 51--*--symptoms of",
            "Condition 52 64--*--vaginal odor",
            "Condition 52 59;72 81--*--vaginal discharge",
            "Scope 52 81--*--vaginal odor and or/discharge",
            "Condition 122 124--*--BV",
            "Qualifier 109 117;92 100--*--criteria clinical",
            "Qualifier 102 107;109 117--*--Amsel criteria",
            "Scope 92 117--*--clinical (Amsel) criteria",
            "Observation 137 160--*--participate in research",
            "Mood 126 136--*--Willing to"
        ]
    },
    "NCT03190304_exc": {
        "Annotations": [
            "Condition 11 27--*--hypersensitivity",
            "Condition 31 38--*--allergy",
            "Drug 53 64--*--study drugs",
            "Non-representable 67 99--*--rugs of similar chemical classes",
            "Drug 101 123--*--ACE inhibitors (ACEIs)",
            "Drug 125 164--*--angiotensin II receptor blockers (ARBs)",
            "Drug 169 190--*--neprilysin inhibitors",
            "Condition 222 239--*--contraindications",
            "Mood 203 208--*--known",
            "Mood 212 221--*--suspected",
            "Scope 203 221--*--known or suspected",
            "Drug 247 258--*--study drugs",
            "Scope 53 190--*--study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors",
            "Scope 11 38--*--hypersensitivity or allergy",
            "Drug 324 329--*--ACEIs",
            "Drug 333 337--*--ARBs",
            "Condition 281 292--*--intolerance",
            "Observation 270 277--*--history",
            "Temporal 261 269--*--Previous",
            "Scope 324 337--*--ACEIs or ARBs",
            "Condition 357 367--*--angioedema",
            "Drug 406 411--*--ACEIs",
            "Drug 416 420--*--ARBs",
            "Procedure 386 395--*--treatment",
            "Mood 370 385--*--Requirement for",
            "Scope 406 420--*--ACEIs and ARBs",
            "Observation 346 353--*--history",
            "Qualifier 431 436--*--acute",
            "Qualifier 437 450--*--decompensated",
            "Condition 451 464--*--heart failure",
            "Condition 466 478--*--exacerbation",
            "Condition 482 503--*--chronic heart failure",
            "Procedure 554 573--*--intravenous therapy",
            "Condition 518 523--*--signs",
            "Condition 528 536--*--symptoms",
            "Scope 518 536--*--signs and symptoms",
            "Scope 466 503--*--exacerbation of chronic heart failure",
            "Qualifier 577 588--*--Symptomatic",
            "Condition 589 600--*--hypotension",
            "Measurement 603 646--*--Estimated glomerular filtration rate (eGFR)",
            "Value 647 651--*--<30%",
            "Measurement 654 669--*--Serum potassium",
            "Value 670 681--*-->5.4 mmol/L",
            "Condition 684 707--*--Acute coronary syndrome",
            "Condition 709 715--*--stroke",
            "Condition 717 743--*--transient ischaemic attack",
            "Condition 745 752--*--cardiac",
            "Condition 754 761--*--carotid",
            "Procedure 772 800--*--major cardiovascular surgery",
            "Procedure 802 836--*--percutaneous coronary intervention",
            "Procedure 841 860--*--carotid angioplasty",
            "Temporal 861 880--*--within the 3 months",
            "Scope 772 860--*--major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty",
            "Condition 895 917--*--carotid artery disease",
            "Condition 883 891;903 917--*--Coronary artery disease",
            "Procedure 936 944;961 973--*--surgical intervention",
            "Mood 918 924--*--likely",
            "Procedure 948 973--*--percutaneous intervention",
            "Temporal 974 993--*--within the 6 months",
            "Scope 936 973--*--surgical or percutaneous intervention",
            "Scope 883 917--*--Coronary or carotid artery disease",
            "Device 1014 1060--*--cardiac resynchronization therapy (CRT) device",
            "Procedure 996 1008--*--Implantation",
            "Temporal 1061 1076--*--within 3 months",
            "Mood 1080 1086--*--intent",
            "Procedure 1090 1097--*--implant",
            "Device 1100 1103--*--CRT",
            "Procedure 1117 1133--*--heart transplant",
            "Observation 1106 1113--*--History",
            "Observation 1137 1157--*--on a transplant list",
            "Device 1166 1205--*--left ventricular (LV) assistance device",
            "Observation 1208 1215--*--History",
            "Condition 1219 1243--*--severe pulmonary disease",
            "Condition 1295 1309--*--cardiomyopathy",
            "Procedure 1274 1286--*--chemotherapy",
            "Qualifier 1274 1294--*--chemotherapy-induced",
            "Condition 1259 1269--*--peripartum",
            "Qualifier 1259 1270;1287 1294--*--peripartum- induced",
            "Scope 1259 1294--*--peripartum- or chemotherapy-induced",
            "Temporal 1310 1330--*--within the 12 months",
            "Condition 1354 1376--*--ventricular arrhythmia",
            "Qualifier 1344 1353--*--untreated",
            "Condition 1382 1399--*--syncopal episodes",
            "Temporal 1400 1419--*--within the 3 months",
            "Condition 1434 1445--*--bradycardia",
            "Condition 1473 1495--*--atrioventricular block",
            "Qualifier 1460 1472--*--third-degree",
            "Qualifier 1449 1456;1466 1472--*--second- degree",
            "Negation 1496 1503--*--without",
            "Device 1506 1515--*--pacemaker",
            "Scope 1449 1472--*--second- or third-degree",
            "Qualifier 1530 1558--*--haemodynamically significant",
            "Condition 1573 1593--*--aortic valve disease",
            "Condition 1559 1565;1580 1593--*--mitral valve disease",
            "Scope 1559 1593--*--mitral and/or aortic valve disease",
            "Condition 1602 1622--*--mitral regurgitation",
            "Qualifier 1623 1649--*--secondary to LV dilatation",
            "Condition 1636 1649--*--LV dilatation",
            "Negation 1595 1601--*--except",
            "Qualifier 1670 1698--*--haemodynamically significant",
            "Condition 1699 1718--*--obstructive lesions",
            "Qualifier 1726 1742--*--LV outflow tract",
            "Condition 1765 1783--*--subaortic stenosis",
            "Condition 1754 1760;1775 1783--*--aortic stenosis",
            "Scope 1670 1742--*--haemodynamically significant obstructive lesions of the LV outflow tract",
            "Scope 1754 1783--*--aortic and subaortic stenosis",
            "Condition 1790 1798;1810 1819--*--surgical condition",
            "Condition 1802 1819--*--medical condition",
            "Condition 1846 1906--*--alter the absorption, distribution, metabolism, or excretion",
            "Drug 1910 1921--*--study drugs",
            "Condition 1994 2020--*--inflammatory bowel disease",
            "Scope 1790 1819--*--surgical or medical condition",
            "Scope 1790 1921--*--surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs",
            "Temporal 2021 2041--*--during the 12 months",
            "Qualifier 1987 1993--*--active",
            "Qualifier 2043 2049--*--Active",
            "Condition 2050 2058;2070 2076--*--duodenal ulcers",
            "Condition 2062 2076--*--gastric ulcers",
            "Scope 2050 2076--*--duodenal or gastric ulcers",
            "Temporal 2077 2096--*--during the 3 months",
            "Condition 2110 2125--*--hepatic disease",
            "Measurement 2169 2195--*--aspartate aminotransferase",
            "Measurement 2199 2223--*--alanine aminotransferase",
            "Value 2231 2265--*--exceeding 2x upper limit of normal",
            "Scope 2169 2223--*--aspartate aminotransferase or alanine aminotransferase",
            "Condition 2278 2300--*--hepatic encephalopathy",
            "Observation 2267 2274--*--history",
            "Condition 2313 2332--*--oesophageal varices",
            "Observation 2302 2309--*--history",
            "Observation 2337 2344--*--history",
            "Condition 2348 2365--*--porto-caval shunt",
            "Procedure 2375 2384--*--treatment",
            "Temporal 2367 2374--*--Current",
            "Drug 2390 2404;2419 2425--*--cholestyramine resins",
            "Drug 2408 2425--*--colestipol resins",
            "Scope 2390 2425--*--cholestyramine or colestipol resins",
            "Mood 2098 2106--*--Evidence",
            "Scope 2098 2125--*--Evidence of hepatic disease",
            "Scope 2169 2425--*--aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins",
            "Scope 1987 2425--*--active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins",
            "Observation 2465 2480--*--life expectancy",
            "Value 2484 2492--*--<5 years",
            "Condition 2450 2457--*--disease",
            "Qualifier 2440 2449--*--any other"
        ],
        "Text": "History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors, as well as known or suspected contraindications to the study drugs.. Previous history of intolerance to recommended target doses of ACEIs or ARBs.. Known history of angioedema.. Requirement for treatment with both ACEIs and ARBs.. Current acute decompensated heart failure (exacerbation of chronic heart failure manifested by signs and symptoms that may require intravenous therapy).. Symptomatic hypotension.. Estimated glomerular filtration rate (eGFR) <30%.. Serum potassium >5.4 mmol/L.. Acute coronary syndrome, stroke, transient ischaemic attack, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within the 3 months.. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months.. Implantation of a cardiac resynchronization therapy (CRT) device within 3 months or intent to implant a CRT.. History of heart transplant or on a transplant list or with left ventricular (LV) assistance device.. History of severe pulmonary disease.. Diagnosis of peripartum- or chemotherapy-induced cardiomyopathy within the 12 months.. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months.. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker.. Presence of haemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation.. Presence of other haemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis.. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including, but not limited to, any of the following: History of active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins.. Presence of any other disease with a life expectancy of <5 years.. "
    },
    "NCT03424733_exc": {
        "Text": "prior allergic reaction to interferon products, congestive heart failure, elevated liver enzymes. ",
        "Annotations": [
            "Temporal 0 5--*--prior",
            "Condition 6 23--*--allergic reaction",
            "Drug 27 46--*--interferon products",
            "Condition 48 72--*--congestive heart failure",
            "Condition 74 96--*--elevated liver enzymes"
        ]
    },
    "NCT02560389_exc": {
        "Annotations": [
            "Condition 0 14--*--Claustrophobia",
            "Observation 23 65--*--inability to lie still in a confined space",
            "Condition 73 90--*--medical disorders",
            "Qualifier 67 72--*--Major",
            "Condition 98 101--*--HIV",
            "Condition 103 109--*--cancer",
            "Scope 98 109--*--HIV, cancer",
            "Device 112 138--*--Magnetic metallic implants",
            "Device 148 154--*--screws",
            "Device 156 160--*--pins",
            "Device 162 179--*--shrapnel remnants",
            "Device 181 195--*--aneurysm clips",
            "Device 197 220--*--artificial heart valves",
            "Device 222 231;243 251--*--inner ear implants",
            "Device 233 241;243 251--*--cochlear implants",
            "Device 253 270--*--artificial joints",
            "Device 276 291--*--vascular stents",
            "Scope 148 291--*--screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents",
            "Device 308 325--*--magnetic implants",
            "Device 294 304;317 325--*--Electronic implants",
            "Device 335 345--*--pacemakers",
            "Scope 294 325--*--Electronic or magnetic implants",
            "Observation 347 363--*--Permanent makeup",
            "Observation 367 374--*--tattoos",
            "Device 380 393--*--metallic dyes",
            "Condition 405 413--*--pregnant",
            "Observation 431 463--*--history of loss of consciousness",
            "Value 465 488--*--greater than 10 minutes",
            "Qualifier 417 430--*--self-reported",
            "Subjective_judgement 491 543--*--Physical disabilities that prohibit task performance",
            "Condition 553 562--*--blindness",
            "Condition 566 574--*--deafness",
            "Condition 577 596--*--Psychotic disorders",
            "Condition 604 617--*--schizophrenia",
            "Post-eligibility 620 704--*--Any other condition that the investigator believes might put the participant at risk"
        ],
        "Text": "Claustrophobia, or the inability to lie still in a confined space. Major medical disorders (e.g., HIV, cancer). Magnetic metallic implants (such as screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents). Electronic or magnetic implants, such as pacemakers. Permanent makeup or tattoos with metallic dyes. Currently pregnant. A self-reported history of loss of consciousness (greater than 10 minutes). Physical disabilities that prohibit task performance (such as blindness or deafness). Psychotic disorders (e.g., schizophrenia). Any other condition that the investigator believes might put the participant at risk. "
    },
    "NCT02384850_exc": {
        "Annotations": [
            "Subjective_judgement 0 117--*--adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2.",
            "Non-query-able 0 117--*--adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2.",
            "Procedure 137 164--*--systemic anticancer therapy",
            "Temporal 165 191--*--\u2264 3 weeks prior to cycle 1",
            "Reference_point 184 191--*--cycle 1",
            "Condition 232 243;250 259--*--Hepatitis B infection",
            "Condition 232 241;248 259--*--Hepatitis C infection",
            "Negation 264 267--*--NOT",
            "Condition 221 230--*--infection",
            "Temporal 214 220--*--active",
            "Qualifier 201 213--*--Uncontrolled",
            "Scope 232 286--*--Hepatitis B and C infection are NOT exclusion criteria",
            "Condition 301 314--*--HIV infection",
            "Condition 319 332--*--Renal failure",
            "Procedure 343 356--*--haemodialysis",
            "Procedure 360 379--*--peritoneal dialysis",
            "Scope 343 379--*--haemodialysis or peritoneal dialysis",
            "Condition 401 409--*--pregnant",
            "Condition 413 427--*--breast-feeding",
            "Parsing_Error 429 431--*--6.",
            "Parsing_Error 381 383--*--5.",
            "Condition 472 505--*--obstructed gastrointestinal tract",
            "Condition 460 468;483 505--*--diseased gastrointestinal tract",
            "Undefined_semantics 460 468;483 505--*--diseased gastrointestinal tract",
            "Qualifier 446 459--*--significantly",
            "Subjective_judgement 446 459--*--significantly",
            "Non-query-able 446 459--*--significantly",
            "Condition 507 520--*--malabsorption",
            "Condition 535 543--*--vomiting",
            "Qualifier 522 534--*--uncontrolled",
            "Condition 547 555--*--diarrhea",
            "Condition 569 606--*--inability to swallow oral medications",
            "Parsing_Error 608 610--*--7.",
            "Condition 635 649--*--CNS metastasis",
            "Parsing_Error 650 652--*--8.",
            "Qualifier 623 634--*--symptomatic",
            "Procedure 687 706--*--anti-cancer therapy",
            "Temporal 678 686--*--previous",
            "Procedure 735 742--*--surgery",
            "Condition 710 729--*--incomplete recovery",
            "Drug 758 769--*--oxaliplatin",
            "Qualifier 758 777--*--oxaliplatin-induced",
            "Condition 778 799--*--peripheral neuropathy",
            "Condition 653 672--*--Unresolved toxicity",
            "Parsing_Error 812 814--*--9.",
            "Temporal 836 891--*--within the 12 months prior to study drug administration",
            "Reference_point 866 891--*--study drug administration",
            "Condition 893 914--*--myocardial infarction",
            "Condition 923 938--*--unstable angina",
            "Condition 916 922;932 938--*--severe angina",
            "Condition 940 948;960 979--*--coronary artery bypass graft",
            "Condition 949 979--*--peripheral artery bypass graft",
            "Condition 981 1017--*--symptomatic congestive heart failure",
            "Condition 1019 1043--*--cerebrovascular accident",
            "Condition 1047 1072--*--transient ischemic attack",
            "Condition 1074 1092--*--pulmonary embolism",
            "Condition 1094 1114--*--deep vein thrombosis",
            "Condition 1119 1145--*--other thromboembolic event",
            "Scope 893 1145--*--myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event"
        ],
        "Text": "adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2. Treatment with any systemic anticancer therapy \u2264 3 weeks prior to cycle 1 day 1 3. Uncontrolled active infection (Hepatitis B and C infection are NOT exclusion criteria) and/or known HIV infection; 4. Renal failure requiring haemodialysis or peritoneal dialysis; 5. Patients who are pregnant or breast-feeding; 6. Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea resulting in inability to swallow oral medications; 7. Presence of symptomatic CNS metastasis 8. Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery, in particular oxaliplatin-induced peripheral neuropathy > grade 1. . 9. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.       .     . "
    },
    "NCT02939209_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 9--*--18-65",
            "Procedure 88 107--*--rotator cuff repair",
            "Procedure 112 125--*--acromioplasty",
            "Qualifier 64 75--*--day surgery",
            "Procedure 32 35--*--ISB",
            "Procedure 40 58--*--general anesthesia",
            "Scope 0 10;11 58--*--Age 18-65",
            "Scope 88 125--*--rotator cuff repair and acromioplasty",
            "Scope 32 58--*--ISB and general anesthesia"
        ],
        "Text": "Age 18-65. scheduled to receive ISB and general anesthesia as a day surgery patient for rotator cuff repair and acromioplasty, as a part of planned routine care. "
    },
    "NCT02748330_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02552459_inc": {
        "Text": "patients undergoing venous malformation embolization operation through general anesthesia.. aged 18-65 years old.. operating time varies 1-4h,and extubation after the operation.. ",
        "Annotations": [
            "Procedure 20 62--*--venous malformation embolization operation",
            "Procedure 71 89--*--general anesthesia",
            "Person 92 96--*--aged",
            "Value 97 112--*--18-65 years old",
            "Measurement 115 129--*--operating time",
            "Value 137 141--*--1-4h",
            "Procedure 146 156--*--extubation",
            "Temporal 157 176--*--after the operation",
            "Reference_point 163 176--*--the operation",
            "Procedure 167 176--*--operation"
        ]
    },
    "NCT02618057_exc": {
        "Text": "Immunosuppresant host. Chronic cardiovascular/pulmonary disease. Hospital acquired infection. ",
        "Annotations": [
            "Condition 0 21--*--Immunosuppresant host",
            "Condition 46 63--*--pulmonary disease",
            "Condition 31 45;56 63--*--cardiovascular disease",
            "Temporal 23 30--*--Chronic",
            "Scope 31 63--*--cardiovascular/pulmonary disease",
            "Condition 65 92--*--Hospital acquired infection"
        ]
    },
    "NCT01614041_inc": {
        "Annotations": [
            "Person 6 15--*--years old",
            "Value 0 5--*--18-65",
            "Person 17 21--*--Male",
            "Person 25 31--*--female",
            "Condition 48 51--*--GAD",
            "Measurement 65 71--*--DSM-IV",
            "Measurement 73 83--*--HAMA score",
            "Value 83 86--*--=17",
            "Post-eligibility 88 125--*--Provide with written informed consent",
            "Procedure 177 181--*--SSRI",
            "Procedure 183 187--*--SNRI",
            "Procedure 191 195--*--NASA",
            "Temporal 150 163--*--for two weeks",
            "Procedure 139 149--*--washed-out"
        ],
        "Text": "18-65 years old. Male or female. Diagnosed with GAD according to DSM-IV. HAMA score=17. Provide with written informed consent. Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.. "
    },
    "NCT02748330_inc": {
        "Annotations": [
            "Post-eligibility 0 144--*--Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures",
            "Person 147 151--*--Aged",
            "Value 152 169--*--18 years or older",
            "Person 171 175--*--male",
            "Person 179 185--*--female",
            "Condition 199 221--*--stable angina pectoris",
            "Qualifier 227 248--*--angiographic evidence",
            "Condition 252 255--*--CAD",
            "Observation 257 274--*--diameter stenosis",
            "Multiplier 275 280--*--= 50%",
            "Qualifier 356 379--*--right coronary arteries",
            "Qualifier 335 350;362 379--*--left circumflex coronary arteries",
            "Qualifier 309 333;362 379--*--left anterior descending coronary arteries",
            "Qualifier 298 307;362 379--*--left main coronary arteries",
            "Non-query-able 352 355--*--and",
            "Scope 298 379--*--left main, left anterior descending, left circumflex, and right coronary arteries",
            "Qualifier 285 290;362 379--*--major coronary arteries",
            "Condition 402 423--*--myocardial infarction",
            "Condition 425 427--*--MI",
            "Procedure 441 467--*--coronary revascularization",
            "Procedure 475 509--*--percutaneous coronary intervention",
            "Procedure 511 514--*--PCI",
            "Procedure 519 547--*--coronary artery bypass graft",
            "Procedure 549 553--*--CABG",
            "Negation 556 559--*--not",
            "Procedure 583 586--*--PCI",
            "Qualifier 574 582--*--elective",
            "Temporal 587 619--*--during the index hospitalization",
            "Reference_point 598 619--*--index hospitalization",
            "Scope 475 585--*--percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PC",
            "Condition 643 667--*--type 2 diabetes mellitus",
            "Observation 670 712--*--Post-procedural residual diameter stenosis",
            "Condition 728 735--*--lesions",
            "Qualifier 720 727--*--treated",
            "Value 736 741--*--< 20%",
            "Procedure 759 777--*--stent implantation",
            "Procedure 801 820--*--balloon angioplasty",
            "Value 781 786--*--< 50%",
            "Condition 728 735--*--lesions",
            "Observation 670 712--*--Post-procedural residual diameter stenosis",
            "Condition 822 850--*--Post-procedural thrombolysis",
            "Condition 854 875--*--myocardial infarction",
            "Measurement 854 875;883 888--*--myocardial infarction grade",
            "Value 889 890--*--3",
            "Qualifier 899 914--*--treated vessels",
            "Measurement 925 946--*--cardiac troponin test",
            "Value 916 924--*--Negative",
            "Temporal 947 977--*--before the index elective PCI.",
            "Reference_point 958 976--*--index elective PCI",
            "Procedure 973 976--*--PCI",
            "Measurement 877 881--*--TIMI",
            "Drug 986 997--*--Clopidogrel",
            "Multiplier 998 1003--*--75 mg",
            "Multiplier 1004 1009--*--daily",
            "Temporal 1015 1034--*--for at least 7 days",
            "Drug 1045 1056--*--Clopidogrel",
            "Multiplier 1057 1062--*--75 mg",
            "Multiplier 1063 1068--*--daily",
            "Temporal 1074 1094--*--for less than 7 days",
            "Drug 1118 1129--*--Clopidogrel",
            "Multiplier 1104 1117--*--300 to 600 mg",
            "Temporal 1143 1153--*--before PCI",
            "Reference_point 1150 1153--*--PCI",
            "Procedure 1150 1153--*--PCI",
            "Scope 1045 1154--*--Clopidogrel 75 mg daily dose for less than 7 days but with 300 to 600 mg Clopidogrel loading dose before PCI.",
            "Drug 1163 1183--*--acetylsalicylic acid",
            "Drug 1185 1188--*--ASA",
            "Multiplier 1190 1196--*--100 mg",
            "Multiplier 1197 1202--*--daily",
            "Temporal 1213 1232--*--for at least 7 days",
            "Drug 1243 1246--*--ASA",
            "Multiplier 1247 1253--*--100 mg",
            "Multiplier 1254 1259--*--daily",
            "Temporal 1265 1285--*--for less than 7 days",
            "Drug 1302 1305--*--ASA",
            "Multiplier 1295 1301--*--300 mg",
            "Temporal 1319 1329--*--before PCI",
            "Reference_point 1326 1329--*--PCI",
            "Procedure 1326 1329--*--PCI",
            "Scope 1243 1329--*--ASA 100 mg daily dose for less than 7 days but with 300 mg ASA loading dose before PCI",
            "Pregnancy_considerations 1332 1418--*--have a negative urine or blood pregnancy test at enrolment and prior to randomization;",
            "Pregnancy_considerations 1420 1663--*--currently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion"
        ],
        "Text": "Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures.. Aged 18 years or older, male or female.. History of stable angina pectoris with angiographic evidence of CAD (diameter stenosis = 50%) in major, i.e., left main, left anterior descending, left circumflex, and right coronary arteries.. History of previous myocardial infarction (MI). History of coronary revascularization, i.e., percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PCI during the index hospitalization. Documented history of type 2 diabetes mellitus.. Post-procedural residual diameter stenosis of the treated lesions < 20% in patients with stent implantation or < 50% in those with balloon angioplasty. Post-procedural thrombolysis in myocardial infarction (TIMI) grade 3 flow in treated vessels. Negative cardiac troponin test before the index elective PCI.. Taking Clopidogrel 75 mg daily dose for at least 7 days or taking Clopidogrel 75 mg daily dose for less than 7 days but with 300 to 600 mg Clopidogrel loading dose before PCI.. Taking acetylsalicylic acid (ASA) 100 mg daily treatment for at least 7 days or taking ASA 100 mg daily dose for less than 7 days but with 300 mg ASA loading dose before PCI.. have a negative urine or blood pregnancy test at enrolment and prior to randomization;. currently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion.. "
    },
    "NCT02552459_exc": {
        "Text": "long-term use of analgesics,sedatives or non steroidal anti-inflammatory drugs history.. known for dexmedetomidine or other drugs allergy in this study.. cannot communicate.. preoperative systolic blood pressure <90 mmHg, or the heart rate <50/min.. ",
        "Annotations": [
            "Multiplier 0 13--*--long-term use",
            "Drug 17 27--*--analgesics",
            "Drug 28 37--*--sedatives",
            "Drug 41 78--*--non steroidal anti-inflammatory drugs",
            "Observation 79 86--*--history",
            "Scope 17 37--*--analgesics,sedatives",
            "Drug 99 114--*--dexmedetomidine",
            "Qualifier 118 123--*--other",
            "Drug 124 129--*--drugs",
            "Condition 130 137--*--allergy",
            "Scope 99 129--*--dexmedetomidine or other drugs",
            "Observation 154 172--*--cannot communicate",
            "Measurement 175 211--*--preoperative systolic blood pressure",
            "Value 212 220--*--<90 mmHg",
            "Measurement 229 239--*--heart rate",
            "Value 240 247--*--<50/min"
        ]
    },
    "NCT01614041_exc": {
        "Annotations": [
            "Condition 8 25--*--suicidal tendency",
            "Measurement 31 62--*--score of the sixth item of HAMA",
            "Value 63 65--*--=3",
            "Measurement 71 84--*--score of HAMD",
            "Value 85 88--*--=21",
            "Condition 90 98--*--Pregnant",
            "Condition 102 111--*--lactating",
            "Person 112 117--*--women",
            "Condition 142 158--*--hypersensitivity",
            "Drug 162 174--*--tandospirone",
            "Condition 130 138--*--allergic",
            "Qualifier 162 174--*--tandospirone",
            "Scope 130 158--*--allergic or hypersensitivity",
            "Condition 196 203;265 272--*--cardiac disease",
            "Condition 205 210;265 272--*--renal disease",
            "Condition 212 222;265 272--*--neurologic disease",
            "Condition 224 239;265 272--*--cerebrovascular disease",
            "Condition 241 250;265 272--*--metabolic disease",
            "Condition 255 272--*--pulmonary disease",
            "Scope 196 272--*--cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease",
            "Qualifier 187 195--*--unstable",
            "Qualifier 176 183--*--Serious",
            "Scope 176 195--*--Serious or unstable",
            "Condition 274 301--*--Secondary anxiety disorders",
            "Condition 311 329--*--alcohol dependence",
            "Condition 303 307;319 329--*--Drug dependence",
            "Scope 303 329--*--Drug or alcohol dependence",
            "Temporal 330 343--*--within 1 year",
            "Procedure 371 391--*--benzodiazepine drugs",
            "Temporal 354 363--*--currently",
            "Person 393 400--*--Drivers",
            "Person 405 432--*--dangerous machine operators",
            "Grammar_Error 401 404--*--and",
            "Observation 434 472--*--Participated in other clinical studies",
            "Temporal 476 492--*--the last 30 days",
            "Condition 538 562--*--laboratory abnormalities",
            "Condition 531 534;549 562--*--ECG abnormalities",
            "Procedure 538 548--*--laboratory",
            "Procedure 531 534--*--ECG",
            "Scope 531 562--*--ECG or laboratory abnormalities",
            "Qualifier 508 530--*--clinically significant",
            "Condition 591 599--*--epilepsy",
            "Measurement 624 627--*--TSH",
            "Value 615 623--*--abnormal"
        ],
        "Text": "Serious suicidal tendency. The score of the sixth item of HAMA =3. The score of HAMD =21. Pregnant or lactating women. History of allergic or hypersensitivity to tandospirone. Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease. Secondary anxiety disorders. Drug or alcohol dependence within 1 year. Patients currently taking benzodiazepine drugs. Drivers and dangerous machine operators. Participated in other clinical studies in the last 30 days. Patients with clinically significant ECG or laboratory abnormalities. Patients with a history of epilepsy. Patients with abnormal TSH concentration. "
    },
    "NCT02618057_inc": {
        "Text": "Evidence of Mycoplasma pneumoniae infection. Lobar pneumonia or pneumoniae with pleural effusion. ",
        "Annotations": [
            "Condition 12 43--*--Mycoplasma pneumoniae infection",
            "Condition 45 60--*--Lobar pneumonia",
            "Condition 64 74--*--pneumoniae",
            "Condition 80 96--*--pleural effusion"
        ]
    },
    "NCT02571881_inc": {
        "Annotations": [
            "Condition 24 33--*--pregnancy",
            "Multiplier 17 23--*--single",
            "Qualifier 0 6--*--normal",
            "Qualifier 7 16--*--full term",
            "Person 35 38--*--age",
            "Value 39 55--*--18 years or more",
            "Measurement 57 60--*--BMI",
            "Value 61 74--*--20 - 35 kg/m2",
            "Post-eligibility 76 109--*--written informed consent obtained"
        ],
        "Text": "normal full term single pregnancy. age 18 years or more. BMI 20 - 35 kg/m2. written informed consent obtained. "
    },
    "NCT02905890_exc": {
        "Annotations": [
            "Pregnancy_considerations 0 128--*--Currently pregnant or using a reliable contraception (e.g. injectables, intrauterine devices, implant, oral contraceptive pills)",
            "Pregnancy_considerations 130 165--*--Desiring pregnancy in the next year",
            "Procedure 178 192--*--tubal ligation",
            "Procedure 196 208--*--hysterectomy",
            "Non-query-able 210 226--*--Contraindication",
            "Post-eligibility 261 354--*--Unable to comprehend consent material because of language barrier or psychological difficulty",
            "Procedure 245 259--*--contraceptives",
            "Drug 230 239--*--progestin",
            "Qualifier 240 244--*--only"
        ],
        "Text": "Currently pregnant or using a reliable contraception (e.g. injectables, intrauterine devices, implant, oral contraceptive pills). Desiring pregnancy in the next year. History of tubal ligation or hysterectomy. Contraindication to progestin-only contraceptives. Unable to comprehend consent material because of language barrier or psychological difficulty. "
    },
    "NCT03338296_exc": {
        "Text": "Clinically significant new illness within 1 month before randomization that may affect the participant's ability to fulfill the study requirements or significantly confound the assessments. Participants who cannot swallow investigational products. Participants with T2DM who have hypoglycemia unawareness. Aortic regurgitation mild or greater. Mitral regurgitation moderate or greater. Mitral or aortic valve stenosis greater than mild (ie, aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2). Systolic pulmonary artery pressure (SPAP) >40 mmHg (and/or tricuspid regurgitation [TR] jet velocity >2.9 m/s) In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility. Participants with a RVOTAT =100 milliseconds (msec) will be excluded, suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size.. Left ventricular ejection fraction <45%. Intracardiac mass, tumor, or thrombus. Evidence of congenital heart disease. Clinically significant pericardial effusion (eg, moderate or larger or with hemodynamic compromise). Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5\u00d7 upper limit of normal (ULN), serum transaminases greater than 3\u00d7 ULN, or total bilirubin greater than 1.5\u00d7 ULN in absence of Gilbert's syndrome. Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of Screening, as indicated by answering \"Yes\" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS). Any suicidal behavior in the past based on the C-SSRS. Any history of anorexia or bulimia within 2 years before Screening, Attention Deficit Hyperactivity Disorder, any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition depressive disorder, bipolar disorder, or schizophrenia. Known secondary causes (genetic, endocrine, or metabolic) for obesity (eg, Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed). Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations within 1 month before Screening. selective serotonin reuptake inhibitors. serotonin norepinephrine reuptake inhibitors. tricyclic antidepressants. bupropion. triptans. St. John's Wort. tryptophan. linezolid. dextromethorphan in any form (eg, OTC cold medicines). lithium. tramadol. antipsychotics or other dopamine antagonists\t. antiseizure medications including valproic acid, zonisamide, topiramate, and lamotrigine. oral steroids (topical and inhaled steroids are acceptable). stimulant medications (eg, Ritalin, Concerta, Biphetamine, and Dexedrine). benzodiazepines. Use of drugs known to increase the risk for cardiac valvulopathy within 6 months before Screening, including but not limited to pergolide, ergotamine, methysergide, and cabergoline. History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease. Use of Belviq XR within 6 months before Screening or hypersensitivity to Belviq XR or any of the excipients. Significant change in diet or level of physical activity within 1 month before dosing or change in weight of more than 5 kg within 3 months before Screening. Any use of a very-low-calorie (<1000 calories/day) weight loss diet within 6 months before Screening. History of alcohol or drug dependence or abuse. Recreational drug use within 2 years before Screening. Known to be human immunodeficiency virus positive. Known to have active viral hepatitis (B or C). Malignancy within 5 years before Screening. Unable to attend scheduled visits (eg, lack of transportation) or lack of a caregiver or guardian to supervise study participation. Special needs participants who are unable to comprehend study-related instructions (eg, mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism). Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of screening or any time between screening and randomization. Participants with a blood pressure in the 95th percentile or greater for age, sex, and height on 2 separate readings recorded on 2 separate days. Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time.. Currently enrolled in another clinical study or has used any investigational drug or device within 30 days before providing informed consent. Planned bariatric surgery during the study or prior bariatric surgical procedures. Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol. Female participants who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation. Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation. Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).. ",
        "Annotations": [
            "Qualifier 0 22--*--Clinically significant",
            "Qualifier 23 26--*--new",
            "Condition 27 34--*--illness",
            "Temporal 35 70--*--within 1 month before randomization",
            "Reference_point 57 70--*--randomization",
            "Observation 76 146--*--may affect the participant's ability to fulfill the study requirements",
            "Observation 150 188;76 79--*--significantly confound the assessments may",
            "Scope 76 188--*--may affect the participant's ability to fulfill the study requirements or significantly confound the assessments",
            "Observation 207 221--*--cannot swallow",
            "Drug 222 246--*--investigational products",
            "Condition 266 270--*--T2DM",
            "Condition 280 304--*--hypoglycemia unawareness",
            "Condition 306 326--*--Aortic regurgitation",
            "Qualifier 327 342--*--mild or greater",
            "Condition 344 364--*--Mitral regurgitation",
            "Qualifier 365 384--*--moderate or greater",
            "Condition 386 392;403 417--*--Mitral valve stenosis",
            "Condition 396 417--*--aortic valve stenosis",
            "Qualifier 418 435--*--greater than mild",
            "Scope 386 417--*--Mitral or aortic valve stenosis",
            "Condition 441 456--*--aortic stenosis",
            "Measurement 458 461--*--jet",
            "Value 462 490--*-->3.0 meters per second [m/s]",
            "Measurement 492 505--*--mean gradient",
            "Value 506 539--*-->25 millimeters of mercury [mmHg]",
            "Measurement 545 562--*--aortic valve area",
            "Value 563 594--*--<1.5 centimeters squared [cm^2]",
            "Condition 596 611--*--mitral stenosis",
            "Measurement 613 626--*--mean gradient",
            "Value 627 634--*-->5 mmHg",
            "Measurement 639 656--*--mitral valve area",
            "Value 657 666--*--<1.5 cm^2",
            "Scope 458 594--*--jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]",
            "Scope 613 666--*--mean gradient >5 mmHg and mitral valve area <1.5 cm^2",
            "Scope 441 666--*--aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2",
            "Scope 386 435--*--Mitral or aortic valve stenosis greater than mild",
            "Measurement 669 710--*--Systolic pulmonary artery pressure (SPAP)",
            "Value 711 719--*-->40 mmHg",
            "Measurement 728 769--*--tricuspid regurgitation [TR] jet velocity",
            "Value 770 778--*-->2.9 m/s",
            "Measurement 1016 1022--*--RVOTAT",
            "Value 1023 1047--*--=100 milliseconds (msec)",
            "Non-representable 780 995--*--In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility.",
            "Measurement 1283 1317--*--Left ventricular ejection fraction",
            "Value 1318 1322--*--<45%",
            "Condition 1324 1341--*--Intracardiac mass",
            "Condition 1343 1348--*--tumor",
            "Condition 1353 1361--*--thrombus",
            "Non-representable 1066 1281--*--suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size.",
            "Condition 1375 1399--*--congenital heart disease",
            "Mood 1363 1374--*--Evidence of",
            "Qualifier 1401 1423--*--Clinically significant",
            "Condition 1424 1444--*--pericardial effusion",
            "Qualifier 1450 1468--*--moderate or larger",
            "Condition 1477 1499--*--hemodynamic compromise",
            "Scope 1450 1499--*--moderate or larger or with hemodynamic compromise",
            "Qualifier 1502 1513--*--Significant",
            "Condition 1523 1538--*--hepatic disease",
            "Condition 1514 1519;1531 1538--*--renal disease",
            "Scope 1514 1538--*--renal or hepatic disease",
            "Measurement 1557 1573--*--serum creatinine",
            "Value 1574 1619--*--greater than 1.5\u00d7 upper limit of normal (ULN)",
            "Measurement 1621 1640--*--serum transaminases",
            "Value 1641 1660--*--greater than 3\u00d7 ULN",
            "Measurement 1665 1680--*--total bilirubin",
            "Value 1681 1702--*--greater than 1.5\u00d7 ULN",
            "Negation 1706 1716--*--absence of",
            "Condition 1717 1735--*--Gilbert's syndrome",
            "Scope 1557 1735--*--serum creatinine greater than 1.5\u00d7 upper limit of normal (ULN), serum transaminases greater than 3\u00d7 ULN, or total bilirubin greater than 1.5\u00d7 ULN in absence of Gilbert's syndrome",
            "Condition 1741 1758--*--suicidal ideation",
            "Qualifier 1759 1770--*--with intent",
            "Qualifier 1779 1793--*--without a plan",
            "Qualifier 1771 1775;1787 1793--*--with a plan",
            "Scope 1771 1793--*--with or without a plan",
            "Temporal 1795 1809;1832 1841--*--at the time of Screening",
            "Temporal 1813 1841--*--within 6 months of Screening",
            "Scope 1795 1841--*--at the time of or within 6 months of Screening",
            "Procedure 1902 1982--*--Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS)",
            "Measurement 1878 1889--*--questions 4",
            "Measurement 1878 1887;1893 1894--*--questions 5",
            "Value 1870 1873--*--Yes",
            "Scope 1878 1894--*--questions 4 or 5",
            "Condition 1988 2005--*--suicidal behavior",
            "Temporal 2006 2017--*--in the past",
            "Procedure 2031 2037--*--C-SSRS",
            "Observation 2043 2050--*--history",
            "Condition 2054 2062--*--anorexia",
            "Condition 2066 2073--*--bulimia",
            "Temporal 2074 2105--*--within 2 years before Screening",
            "Reference_point 2096 2105--*--Screening",
            "Scope 2054 2073--*--anorexia or bulimia",
            "Condition 2107 2147--*--Attention Deficit Hyperactivity Disorder",
            "Qualifier 2153 2219--*--Diagnostic and Statistical Manual of Mental Disorders, 5th Edition",
            "Condition 2220 2239--*--depressive disorder",
            "Condition 2241 2257--*--bipolar disorder",
            "Condition 2262 2275--*--schizophrenia",
            "Scope 2220 2275--*--depressive disorder, bipolar disorder, or schizophrenia",
            "Condition 2283 2299;2335 2346--*--secondary causes for obesity",
            "Qualifier 2301 2308--*--genetic",
            "Qualifier 2310 2319--*--endocrine",
            "Qualifier 2324 2333--*--metabolic",
            "Scope 2301 2333--*--genetic, endocrine, or metabolic",
            "Condition 2352 2373--*--Prader-Willi syndrome",
            "Condition 2375 2396--*--Bardet Biedl syndrome",
            "Condition 2398 2413--*--Down's Syndrome",
            "Condition 2415 2439--*--untreated hypothyroidism",
            "Condition 2441 2459--*--Cushing's syndrome",
            "Multiplier 2461 2466--*--daily",
            "Drug 2467 2490--*--systemic corticosteroid",
            "Temporal 2500 2523--*--for longer than 30 days",
            "Observation 2525 2532--*--history",
            "Qualifier 2536 2556--*--significant exposure",
            "Drug 2560 2575--*--corticosteroids",
            "Condition 2580 2595--*--chronic illness",
            "Temporal 2596 2616--*--during the past year",
            "Non-representable 2618 2650--*--inhaled steroids will be allowed",
            "Scope 2352 2650--*--Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed",
            "Scope 2283 2346--*--secondary causes (genetic, endocrine, or metabolic) for obesity",
            "Drug 2666 2699--*--products intended for weight loss",
            "Qualifier 2710 2722--*--prescription",
            "Qualifier 2730 2752--*--over-the-counter (OTC)",
            "Qualifier 2764 2770--*--herbal",
            "Temporal 2784 2815--*--within 1 month before Screening",
            "Reference_point 2806 2815--*--Screening",
            "Scope 2710 2770--*--prescription drugs, over-the-counter (OTC) drugs, and herbal",
            "Drug 2817 2856--*--selective serotonin reuptake inhibitors",
            "Drug 2858 2902--*--serotonin norepinephrine reuptake inhibitors",
            "Drug 2904 2929--*--tricyclic antidepressants",
            "Drug 2931 2940--*--bupropion",
            "Drug 2942 2950--*--triptans",
            "Drug 2952 2967--*--St. John's Wort",
            "Drug 2969 2979--*--tryptophan",
            "Drug 2981 2990--*--linezolid",
            "Drug 2992 3008--*--dextromethorphan",
            "Qualifier 3012 3020--*--any form",
            "Drug 3047 3054--*--lithium",
            "Drug 3056 3064--*--tramadol",
            "Drug 3066 3080--*--antipsychotics",
            "Drug 3090 3110--*--dopamine antagonists",
            "Drug 3113 3136--*--antiseizure medications",
            "Drug 3147 3160--*--valproic acid",
            "Drug 3162 3172--*--zonisamide",
            "Drug 3174 3184--*--topiramate",
            "Drug 3190 3201--*--lamotrigine",
            "Scope 3147 3201--*--valproic acid, zonisamide, topiramate, and lamotrigine",
            "Drug 3203 3216--*--oral steroids",
            "Drug 3230 3246--*--inhaled steroids",
            "Drug 3218 3225;3238 3246--*--topical steroids",
            "Negation 3251 3261--*--acceptable",
            "Scope 3218 3246--*--topical and inhaled steroids",
            "Drug 3264 3285--*--stimulant medications",
            "Drug 3291 3298--*--Ritalin",
            "Drug 3300 3308--*--Concerta",
            "Drug 3310 3321--*--Biphetamine",
            "Drug 3327 3336--*--Dexedrine",
            "Scope 3291 3336--*--Ritalin, Concerta, Biphetamine, and Dexedrine",
            "Drug 3339 3354--*--benzodiazepines",
            "Drug 3363 3368--*--drugs",
            "Condition 3400 3420--*--cardiac valvulopathy",
            "Temporal 3421 3453--*--within 6 months before Screening",
            "Drug 3484 3493--*--pergolide",
            "Drug 3495 3505--*--ergotamine",
            "Drug 3507 3519--*--methysergide",
            "Drug 3525 3536--*--cabergoline",
            "Scope 3484 3536--*--pergolide, ergotamine, methysergide, and cabergoline",
            "Qualifier 3369 3420--*--known to increase the risk for cardiac valvulopathy",
            "Scope 3363 3420--*--drugs known to increase the risk for cardiac valvulopathy",
            "Observation 3538 3545--*--History",
            "Qualifier 3561 3583--*--clinically significant",
            "Condition 3584 3591--*--disease",
            "Condition 3597 3607--*--malignancy",
            "Qualifier 3609 3616--*--cardiac",
            "Qualifier 3618 3629--*--respiratory",
            "Qualifier 3631 3647--*--gastrointestinal",
            "Qualifier 3649 3654--*--renal",
            "Qualifier 3659 3670--*--psychiatric",
            "Condition 3671 3678--*--disease",
            "Scope 3609 3670--*--cardiac, respiratory, gastrointestinal, renal, or psychiatric",
            "Scope 3609 3678--*--cardiac, respiratory, gastrointestinal, renal, or psychiatric disease",
            "Scope 3538 3583--*--History or evidence of clinically significant",
            "Scope 3538 3591--*--History or evidence of clinically significant disease",
            "Scope 3597 3678--*--malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease",
            "Negation 3680 3690--*--other than",
            "Condition 3691 3702--*--prediabetes",
            "Value 3704 3712--*--impaired",
            "Measurement 3713 3728--*--fasting glucose",
            "Condition 3732 3758--*--impaired glucose tolerance",
            "Condition 3704 3728--*--impaired fasting glucose",
            "Condition 3761 3776--*--type 2 diabetes",
            "Drug 3790 3815--*--oral anti-diabetic agents",
            "Drug 3827 3839--*--sulfonylurea",
            "Negation 3817 3826--*--excluding",
            "Scope 3817 3839--*--excluding sulfonylurea",
            "Qualifier 3844 3855--*--non-insulin",
            "Qualifier 3856 3866--*--injectable",
            "Drug 3867 3886--*--antidiabetic agents",
            "Condition 3888 3911--*--obstructive sleep apnea",
            "Condition 3913 3925--*--dyslipidemia",
            "Condition 3931 3963--*--nonalcoholic fatty liver disease",
            "Scope 3790 3886--*--oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents",
            "Scope 3704 3759--*--impaired fasting glucose or impaired glucose tolerance)",
            "Drug 3972 3981--*--Belviq XR",
            "Temporal 3982 4014--*--within 6 months before Screening",
            "Reference_point 4005 4014--*--Screening",
            "Condition 4018 4034--*--hypersensitivity",
            "Drug 4038 4047--*--Belviq XR",
            "Qualifier 4048 4072--*--or any of the excipients",
            "Observation 4086 4100--*--change in diet",
            "Qualifier 4074 4085--*--Significant",
            "Observation 4086 4095;4104 4130--*--change in level of physical activity",
            "Temporal 4131 4159--*--within 1 month before dosing",
            "Reference_point 4153 4159--*--dosing",
            "Scope 4086 4130--*--change in diet or level of physical activity",
            "Observation 4163 4179--*--change in weight",
            "Value 4183 4197--*--more than 5 kg",
            "Temporal 4198 4230--*--within 3 months before Screening",
            "Reference_point 4221 4230--*--Screening",
            "Observation 4245 4261;4283 4299--*--very-low-calorie weight loss diet",
            "Value 4263 4281--*--<1000 calories/day",
            "Temporal 4300 4332--*--within 6 months before Screening",
            "Reference_point 4323 4332--*--Screening",
            "Observation 4334 4341--*--History",
            "Condition 4345 4352;4375 4380--*--alcohol abuse",
            "Condition 4356 4371--*--drug dependence",
            "Condition 4356 4360;4375 4380--*--drug abuse",
            "Condition 4345 4352;4361 4371--*--alcohol dependence",
            "Scope 4345 4380--*--alcohol or drug dependence or abuse",
            "Observation 4382 4403--*--Recreational drug use",
            "Temporal 4404 4435--*--within 2 years before Screening",
            "Reference_point 4426 4435--*--Screening",
            "Condition 4449 4486--*--human immunodeficiency virus positive",
            "Measurement 4449 4477--*--human immunodeficiency virus",
            "Value 4478 4486--*--positive",
            "Condition 4509 4524--*--viral hepatitis",
            "Qualifier 4502 4508--*--active",
            "Qualifier 4526 4527--*--B",
            "Qualifier 4531 4532--*--C",
            "Scope 4526 4532--*--B or C",
            "Condition 4535 4545--*--Malignancy",
            "Temporal 4546 4577--*--within 5 years before Screening",
            "Reference_point 4568 4577--*--Screening",
            "Observation 4579 4612--*--Unable to attend scheduled visits",
            "Observation 4618 4640--*--lack of transportation",
            "Observation 4645 4664--*--lack of a caregiver",
            "Observation 4645 4652;4668 4676--*--lack of guardian",
            "Observation 4711 4724--*--Special needs",
            "Observation 4746 4766;4781 4793--*--unable to comprehend instructions",
            "Qualifier 4767 4780--*--study-related",
            "Qualifier 4799 4815--*--mild to profound",
            "Condition 4816 4834--*--mental retardation",
            "Measurement 4836 4857--*--intelligence quotient",
            "Value 4858 4861--*--<70",
            "Qualifier 4864 4882--*--moderate to severe",
            "Condition 4883 4912--*--cognitive developmental delay",
            "Condition 4914 4945--*--pervasive development disorders",
            "Condition 4947 4953--*--autism",
            "Scope 4836 4861--*--intelligence quotient <70",
            "Scope 4799 4834--*--mild to profound mental retardation",
            "Scope 4799 4953--*--mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism",
            "Scope 4746 4793--*--unable to comprehend study-related instructions",
            "Temporal 4956 4963--*--Ongoing",
            "Condition 4964 4972--*--epilepsy",
            "Qualifier 4956 4963--*--Ongoing",
            "Condition 4982 4998--*--seizure disorder",
            "Qualifier 4976 4981--*--other",
            "Drug 5010 5021--*--medications",
            "Condition 5028 5044--*--seizure disorder",
            "Temporal 5045 5073--*--within 6 months of screening",
            "Reference_point 5064 5073--*--screening",
            "Temporal 5077 5121--*--any time between screening and randomization",
            "Reference_point 5094 5103--*--screening",
            "Reference_point 5108 5121--*--randomization",
            "Scope 5045 5121--*--within 6 months of screening or any time between screening and randomization",
            "Measurement 5143 5157--*--blood pressure",
            "Value 5165 5191--*--95th percentile or greater",
            "Qualifier 5192 5199--*--for age",
            "Qualifier 5192 5195;5201 5204--*--for sex",
            "Qualifier 5192 5195;5210 5216--*--for height",
            "Multiplier 5220 5239--*--2 separate readings",
            "Qualifier 5252 5267--*--2 separate days",
            "Non-representable 5269 5437--*--Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time.",
            "Observation 5449 5460;5469 5483--*--enrolled in clinical study",
            "Qualifier 5461 5468--*--another",
            "Temporal 5439 5448--*--Currently",
            "Drug 5500 5520--*--investigational drug",
            "Temporal 5531 5579--*--within 30 days before providing informed consent",
            "Device 5524 5530--*--device",
            "Scope 5500 5530--*--investigational drug or device",
            "Mood 5581 5588--*--Planned",
            "Procedure 5589 5606--*--bariatric surgery",
            "Temporal 5607 5623--*--during the study",
            "Reference_point 5614 5623--*--the study",
            "Temporal 5627 5632--*--prior",
            "Procedure 5633 5662--*--bariatric surgical procedures",
            "Non-query-able 5664 5862--*--Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol",
            "Person 5864 5870--*--Female",
            "Observation 5892 5905--*--breastfeeding",
            "Condition 5909 5917--*--pregnant",
            "Temporal 5918 5930--*--at Screening",
            "Temporal 5918 5920;5934 5942--*--at Baseline",
            "Scope 5892 5917--*--breastfeeding or pregnant",
            "Scope 5918 5942--*--at Screening or Baseline",
            "Measurement 5972 6010--*--beta-human chorionic gonadotropin test",
            "Value 5963 5971--*--positive",
            "Value 6061 6069--*--negative",
            "Measurement 6070 6094--*--screening pregnancy test",
            "Qualifier 6015 6023--*--separate",
            "Procedure 6024 6043--*--Baseline assessment",
            "Temporal 6108 6162--*--more than 72 hours before the first dose of study drug",
            "Reference_point 6134 6162--*--the first dose of study drug",
            "Scope 6061 6162--*--negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug",
            "Scope 5963 6010--*--positive beta-human chorionic gonadotropin test",
            "Scope 6015 6162--*--separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug",
            "Condition 6169 6199--*--unprotected sexual intercourse",
            "Temporal 6200 6233--*--within 30 days before study entry",
            "Reference_point 6222 6233--*--study entry",
            "Observation 6242 6254--*--do not agree",
            "Qualifier 6264 6280--*--highly effective",
            "Observation 6281 6304--*--method of contraception",
            "Measurement 6316 6326--*--abstinence",
            "Value 6310 6315--*--total",
            "Device 6331 6350--*--intrauterine device",
            "Observation 6354 6375--*--double-barrier method",
            "Device 6385 6391--*--condom",
            "Device 6397 6422--*--diaphragm with spermicide",
            "Scope 6385 6422--*--condom plus diaphragm with spermicide",
            "Device 6427 6448--*--contraceptive implant",
            "Drug 6453 6471--*--oral contraceptive",
            "Procedure 6483 6495--*--vasectomized",
            "Person 6496 6503--*--partner",
            "Condition 6519 6530--*--azoospermia",
            "Scope 6385 6530--*--condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia",
            "Temporal 6532 6566--*--throughout the entire study period",
            "Temporal 6571 6615--*--for 28 days after study drug discontinuation",
            "Reference_point 6543 6566--*--the entire study period",
            "Reference_point 6589 6615--*--study drug discontinuation",
            "Drug 6589 6599--*--study drug",
            "Scope 6310 6530--*--total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia",
            "Scope 6264 6304--*--highly effective method of contraception",
            "Condition 6631 6640--*--abstinent",
            "Temporal 6621 6630--*--currently",
            "Observation 6667 6688--*--double-barrier method",
            "Observation 6645 6657--*--do not agree",
            "Observation 6726 6741--*--sexual activity",
            "Negation 6713 6720--*--refrain",
            "Temporal 6742 6765--*--during the study period",
            "Temporal 6770 6814--*--for 28 days after study drug discontinuation",
            "Reference_point 6749 6765--*--the study period",
            "Reference_point 6788 6814--*--study drug discontinuation",
            "Drug 6788 6798--*--study drug",
            "Scope 6742 6814--*--during the study period and for 28 days after study drug discontinuation",
            "Scope 6667 6741--*--double-barrier method (as described above) or refrain from sexual activity",
            "Drug 6826 6849--*--hormonal contraceptives",
            "Negation 6859 6862--*--not",
            "Qualifier 6868 6879--*--stable dose",
            "Drug 6892 6914--*--hormonal contraceptive",
            "Temporal 6923 6957--*--for at least 4 weeks before dosing",
            "Drug 6995 7008--*--contraceptive",
            "Temporal 7009 7025--*--during the study",
            "Temporal 7030 7074--*--for 28 days after study drug discontinuation",
            "Reference_point 7048 7074--*--study drug discontinuation",
            "Observation 6966 6978--*--do not agree",
            "Qualifier 6986 6994--*--the same",
            "Qualifier 6883 6891--*--the same",
            "Non-representable 7075 7328--*--(Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing])"
        ]
    },
    "NCT03249311_exc": {
        "Text": "Lifetime personal history of diagnosis of major depressive disorder according to the DSM-V (American Psychiatric Association, 2013) using the Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition (SCID-5-RV for DSM-V; First et al., 2015). A history of suicidal ideation and behaviour, including self-harm and/or harm to others.. A history of substance abuse and/or dependence.. A positive drug screen for illicit drugs. Substantial alcohol use. Current use of Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue). Current use of serotonin-precursors (such as L-tryptophan, oxitriptan). Current use of serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort). Concomitant use of NSAIDS, ASA, and other anticoagulants.. Current use of Thioridazine. Current use of CYP1A2 Inhibitors. Current use of Triptans (5HT1 Agonists). Blood pressure greater than 140/90 and/or a pulse rate greater than 90 bpm. Recent history of myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease.. Evidence of significant physical illness contraindicating the use of levomilnacipran and duloxetine found on the physical exam or in the laboratory data obtained during the first week of the study. Current use of medication that may affect voiding (ie- anticholinergics). History of obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.. History of Stevens-Johnson Syndrome and Erythema multiforme.. Diabetes Type I and II. Fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency.. Hepatic Impairment. Uncontrolled narrow-angle glaucoma. Severe renal impairment. History of seizure disorder. Anatomically narrow ocular angles.. Osteoporosis or major risk for bone fractures.. ",
        "Annotations": [
            "Condition 42 67--*--major depressive disorder",
            "Qualifier 85 90--*--DSM-V",
            "Procedure 142 237--*--Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition",
            "Condition 294 311--*--suicidal ideation",
            "Condition 294 302;316 325--*--suicidal behaviour",
            "Condition 337 346--*--self-harm",
            "Condition 354 368--*--harm to others",
            "Condition 384 399--*--substance abuse",
            "Condition 384 393;407 417--*--substance dependence",
            "Procedure 431 460--*--drug screen for illicit drugs",
            "Value 422 430--*--positive",
            "Condition 462 485--*--Substantial alcohol use",
            "Drug 502 538--*--Monoamine Oxidase Inhibitors (MAOIs)",
            "Drug 554 574--*--antibiotic linezolid",
            "Drug 583 595--*--thiazine dye",
            "Drug 596 621--*--methylthioninium chloride",
            "Drug 623 637--*--methylene blue",
            "Scope 554 638--*--antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue)",
            "Drug 655 675--*--serotonin-precursors",
            "Drug 685 697--*--L-tryptophan",
            "Drug 699 709--*--oxitriptan",
            "Scope 685 709--*--L-tryptophan, oxitriptan",
            "Drug 727 745--*--serotonergic drugs",
            "Drug 747 755--*--triptans",
            "Drug 765 789--*--tricyclic antidepressant",
            "Drug 792 799--*--lithium",
            "Drug 801 809--*--tramadol",
            "Drug 811 826--*--St. John's Wort",
            "Scope 747 826--*--triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort",
            "Drug 848 854--*--NSAIDS",
            "Drug 856 859--*--ASA",
            "Drug 871 885--*--anticoagulants",
            "Qualifier 865 870--*--other",
            "Drug 903 915--*--Thioridazine",
            "Temporal 829 840--*--Concomitant",
            "Scope 848 885--*--NSAIDS, ASA, and other anticoagulants",
            "Drug 932 949--*--CYP1A2 Inhibitors",
            "Drug 966 974--*--Triptans",
            "Drug 976 989--*--5HT1 Agonists",
            "Measurement 992 1006--*--Blood pressure",
            "Value 1007 1026--*--greater than 140/90",
            "Measurement 1036 1046--*--pulse rate",
            "Value 1047 1066--*--greater than 90 bpm",
            "Temporal 1068 1074--*--Recent",
            "Observation 1075 1082--*--history",
            "Condition 1086 1107--*--myocardial infarction",
            "Condition 1109 1133--*--cerebrovascular accident",
            "Condition 1135 1154--*--cardiac arrhythmias",
            "Condition 1159 1181--*--unstable heart disease",
            "Scope 1086 1181--*--myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease",
            "Condition 1208 1224--*--physical illness",
            "Condition 1225 1241--*--contraindicating",
            "Drug 1253 1268--*--levomilnacipran",
            "Drug 1273 1283--*--duloxetine",
            "Procedure 1297 1310--*--physical exam",
            "Procedure 1321 1331--*--laboratory",
            "Temporal 1346 1380--*--during the first week of the study",
            "Scope 1297 1331--*--physical exam or in the laboratory",
            "Scope 1253 1283--*--levomilnacipran and duloxetine",
            "Drug 1397 1407--*--medication",
            "Drug 1437 1453--*--anticholinergics",
            "Temporal 1382 1389--*--Current",
            "Condition 1417 1431--*--affect voiding",
            "Condition 1467 1496--*--obstructive urinary disorders",
            "Condition 1501 1508--*--dysuria",
            "Condition 1510 1531--*--prostatic hypertrophy",
            "Condition 1533 1544--*--prostatitis",
            "Condition 1556 1597--*--lower urinary tract obstructive disorders",
            "Qualifier 1550 1555--*--other",
            "Observation 1456 1463--*--History",
            "Scope 1467 1597--*--obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders",
            "Condition 1611 1635--*--Stevens-Johnson Syndrome",
            "Condition 1640 1659--*--Erythema multiforme",
            "Condition 1662 1677--*--Diabetes Type I",
            "Condition 1662 1675;1682 1684--*--Diabetes Type II",
            "Condition 1686 1706--*--Fructose intolerance",
            "Condition 1708 1739--*--glucose-galactose malabsorption",
            "Condition 1743 1775--*--sucrose-isomaltase insufficiency",
            "Condition 1778 1796--*--Hepatic Impairment",
            "Condition 1811 1832--*--narrow-angle glaucoma",
            "Qualifier 1798 1810--*--Uncontrolled",
            "Condition 1841 1857--*--renal impairment",
            "Qualifier 1834 1840--*--Severe",
            "Condition 1870 1886--*--seizure disorder",
            "Observation 1859 1866--*--History",
            "Condition 1888 1921--*--Anatomically narrow ocular angles",
            "Condition 1924 1936--*--Osteoporosis",
            "Mood 1940 1950--*--major risk",
            "Condition 1955 1969--*--bone fractures"
        ]
    },
    "NCT02455921_inc": {
        "Text": "Children undergoing ENT surgery under general anaesthesia.. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Procedure 20 31--*--ENT surgery",
            "Temporal 9 19--*--undergoing",
            "Procedure 38 57--*--general anaesthesia"
        ]
    },
    "NCT02350439_exc": {
        "Text": "1. Left main disease (angiographically> 50%) . 2. Cardiogenic shock / hemodynamic instability . 3. Previous CABG . 4. Increased risk of bradycardia on investigator clinical judgment . 5. Severe chronic obstructive pulmonary disease . 6. Coronary vessels with tortuosity or extremely calcified . 7. Severe left ventricular hypertrophy or severe valvular disease . 8. STEMI or non-STEMI within the past five days . 9. Previous myocardial infarction in the distribution of the target vessel for the FFR . 10. Acute decompensated heart failure.       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 46 48--*--2.",
            "Parsing_Error 94 96--*--3.",
            "Parsing_Error 112 114--*--4.",
            "Parsing_Error 180 182--*--5.",
            "Parsing_Error 229 231--*--6.",
            "Parsing_Error 289 291--*--7.",
            "Parsing_Error 356 358--*--8.",
            "Parsing_Error 405 407--*--9.",
            "Parsing_Error 493 496--*--10.",
            "Condition 3 20--*--Left main disease",
            "Value 38 43--*--> 50%",
            "Context_Error 21 44--*--(angiographically> 50%)",
            "Condition 49 66--*--Cardiogenic shock",
            "Condition 69 92--*--hemodynamic instability",
            "Condition 106 110--*--CABG",
            "Temporal 97 105--*--Previous",
            "Condition 133 144--*--bradycardia",
            "Subjective_judgement 148 178--*--investigator clinical judgment",
            "Non-query-able 115 129--*--Increased risk",
            "Subjective_judgement 115 129--*--Increased risk",
            "Qualifier 115 129--*--Increased risk",
            "Condition 190 227--*--chronic obstructive pulmonary disease",
            "Qualifier 183 189--*--Severe",
            "Condition 232 247;254 264--*--Coronary vessel tortuosity",
            "Condition 232 247;268 287--*--Coronary vessel extremely calcified",
            "Condition 299 327--*--left ventricular hypertrophy",
            "Qualifier 292 298--*--Severe",
            "Condition 338 354--*--valvular disease",
            "Qualifier 331 337--*--severe",
            "Condition 359 364--*--STEMI",
            "Condition 368 377--*--non-STEMI",
            "Temporal 378 403--*--within the past five days",
            "Condition 417 438--*--myocardial infarction",
            "Temporal 408 416--*--Previous",
            "Qualifier 439 479--*--in the distribution of the target vessel",
            "Condition 497 530--*--Acute decompensated heart failure"
        ]
    },
    "NCT03213834_exc": {
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 13--*--<18 years",
            "Condition 16 25--*--Pregnancy",
            "Informed_consent 27 70--*--inability to give informed written consent;",
            "Procedure 81 97--*--thoracic surgery",
            "Procedure 101 121--*--thrombolytic therapy",
            "Condition 126 143--*--pleural infection",
            "Scope 81 121--*--thoracic surgery or thrombolytic therapy",
            "Temporal 72 80--*--previous",
            "Procedure 146 166--*--medical thoracoscopy",
            "Mood 167 186--*--cannot be performed",
            "Temporal 187 202--*--within 48 hours",
            "Negation 167 173--*--cannot",
            "Condition 205 226--*--inability to tolerate",
            "Procedure 227 236--*--procedure",
            "Condition 244 267--*--hemodynamic instability",
            "Condition 278 287--*--hypoxemia",
            "Qualifier 271 277--*--severe",
            "Scope 244 287--*--hemodynamic instability or severe hypoxemia",
            "Scope 205 236--*--inability to tolerate procedure",
            "Condition 311 323--*--coagulopathy",
            "Procedure 303 310--*--correct",
            "Mood 290 302--*--inability to",
            "Condition 340 372--*--homogeneously echogenic effusion",
            "Procedure 376 386--*--pleural US"
        ],
        "Text": "age <18 years;. Pregnancy. inability to give informed written consent;. previous thoracic surgery or thrombolytic therapy for pleural infection;. medical thoracoscopy cannot be performed within 48 hours;. inability to tolerate procedure due to hemodynamic instability or severe hypoxemia;. inability to correct coagulopathy;. presence of a homogeneously echogenic effusion on pleural US27 -. "
    },
    "NCT01116973_inc": {
        "Text": "Subject's ability to lay in a supine position with their hands at their sides during CVP measurements . A consent form signed by the patient or patient's representative . Subjects that are age 18-90 . Subjects that have an indwelling CICC and are transitioning to a PICC for long-term IV access . CICC placed in the internal jugular vein or subclavian vein position . ",
        "Annotations": [
            "Observation 10 77--*--ability to lay in a supine position with their hands at their sides",
            "Temporal 78 101--*--during CVP measurements",
            "Procedure 85 101--*--CVP measurements",
            "Reference_point 85 101--*--CVP measurements",
            "Post-eligibility 103 167--*--A consent form signed by the patient or patient's representative",
            "Person 187 190--*--age",
            "Value 191 196--*--18-90",
            "Device 220 235--*--indwelling CICC",
            "Observation 244 267--*--transitioning to a PICC",
            "Device 263 267--*--PICC",
            "Device 293 304--*--CICC placed",
            "Qualifier 305 333;353 361--*--in the internal jugular vein position",
            "Qualifier 305 311;337 361--*--in the subclavian vein position",
            "Scope 305 361--*--in the internal jugular vein or subclavian vein position"
        ]
    },
    "NCT02321839_exc": {
        "Text": "Total lesion area of >12 DA or >30.5 mm2. The existence of subretinal hemorrhage area constituting =50% of total lesion area. The existence of scar or fibrosis area constituting =50% of total lesion area. The existence of RPE tear. Prior treatment for wet AMD. History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD. The pregnant or lactating woman. ",
        "Annotations": [
            "Measurement 0 17--*--Total lesion area",
            "Value 21 27--*-->12 DA",
            "Value 31 40--*-->30.5 mm2",
            "Scope 21 40--*-->12 DA or >30.5 mm2",
            "Measurement 59 85--*--subretinal hemorrhage area",
            "Value 99 124--*--=50% of total lesion area",
            "Measurement 143 147;160 164--*--scar area",
            "Measurement 151 164--*--fibrosis area",
            "Scope 143 164--*--scar or fibrosis area",
            "Value 178 203--*--=50% of total lesion area",
            "Condition 222 230--*--RPE tear",
            "Temporal 232 237--*--Prior",
            "Procedure 238 247--*--treatment",
            "Procedure 272 290--*--vitrectomy surgery",
            "Procedure 292 310--*--submacular surgery",
            "Procedure 321 342--*--surgical intervention",
            "Qualifier 315 320--*--other",
            "Condition 347 350--*--AMD",
            "Scope 272 342--*--vitrectomy surgery, submacular surgery, or other surgical intervention",
            "Condition 356 364--*--pregnant",
            "Condition 368 377--*--lactating",
            "Person 378 383--*--woman"
        ]
    },
    "NCT01728194_inc": {
        "Text": "Age: 60-85 years, right-handed;. Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria);. Age of onset of first episode = 50 years with up to three depressive episodes;. Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 5 16--*--60-85 years",
            "Observation 18 30--*--right-handed",
            "Condition 44 60--*--Major depression",
            "Qualifier 62 70--*--unipolar",
            "Measurement 148 150;75 142--*--IV Structured Clinical Interview for Diagnostic and Statistical Manual",
            "Measurement 164 180--*--DSM-IV criteria)",
            "Measurement 144 147--*--DSM",
            "Measurement 152 156--*--SCID",
            "Scope 75 179--*--Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria",
            "Condition 190 212--*--onset of first episode",
            "Person 183 186--*--Age",
            "Value 213 223--*--= 50 years",
            "Multiplier 235 240--*--three",
            "Condition 241 260--*--depressive episodes",
            "Condition 275 285--*--depression",
            "Measurement 289 329--*--24-Item Hamilton Depression Rating Scale",
            "Measurement 331 335--*--HDRS",
            "Value 337 341--*--= 20"
        ]
    },
    "NCT03338296_inc": {
        "Text": "Healthy male or female adolescents, age 12 to 17 years (inclusive) at Screening, with a body mass index (BMI) that is greater than or equal to the United States-weighted mean of the 95th percentile based on age and sex with a body weight greater than 60 kilograms (kg). Participants with Type 2 diabetes mellitus (T2DM) may have a pre-existing or new diagnosis of T2DM.. HbA1c =6.5%. fasting plasma glucose (FPG) =126 mg/dL (7.0 mmol/L). Participants and their families not planning to move away from the area for the duration of the study. Participants able and willing to comply with all aspects of the study, including a standardized, reduced calorie diet and an age appropriate, increased physical activity program. Participants considered in stable health in the opinion of the investigator. Able and willing to support and supervise study participation in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol. Able and willing to personally comply with and execute all aspects of the study requirements for the caregivers or guardians. ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 8 12--*--male",
            "Person 16 22--*--female",
            "Person 23 34--*--adolescents",
            "Person 36 39--*--age",
            "Value 40 54--*--12 to 17 years",
            "Temporal 67 79--*--at Screening",
            "Measurement 88 109--*--body mass index (BMI)",
            "Value 118 197--*--greater than or equal to the United States-weighted mean of the 95th percentile",
            "Qualifier 198 210--*--based on age",
            "Qualifier 198 206;215 218--*--based on sex",
            "Measurement 226 237--*--body weight",
            "Value 238 268--*--greater than 60 kilograms (kg)",
            "Value 118 142;178 197--*--greater than or equal to the 95th percentile",
            "Scope 198 218--*--based on age and sex",
            "Non-representable 270 369--*--Participants with Type 2 diabetes mellitus (T2DM) may have a pre-existing or new diagnosis of T2DM.",
            "Measurement 371 376--*--HbA1c",
            "Value 377 382--*--=6.5%",
            "Measurement 384 412--*--fasting plasma glucose (FPG)",
            "Value 413 423--*--=126 mg/dL",
            "Value 425 435--*--7.0 mmol/L",
            "Negation 470 473--*--not",
            "Observation 474 495--*--planning to move away",
            "Temporal 510 539--*--for the duration of the study",
            "Reference_point 530 539--*--the study",
            "Observation 563 580--*--willing to comply",
            "Observation 554 558;571 580--*--able to comply",
            "Observation 638 658--*--reduced calorie diet",
            "Qualifier 624 636--*--standardized",
            "Observation 683 718--*--increased physical activity program",
            "Scope 624 718--*--standardized, reduced calorie diet and an age appropriate, increased physical activity program",
            "Qualifier 666 681--*--age appropriate",
            "Scope 554 580--*--able and willing to comply",
            "Observation 747 760--*--stable health",
            "Non-query-able 761 795--*--in the opinion of the investigator",
            "Non-representable 797 1016--*--Able and willing to support and supervise study participation in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol",
            "Observation 1027 1055--*--willing to personally comply",
            "Observation 1018 1022;1035 1055--*--Able to personally comply",
            "Person 1119 1129--*--caregivers",
            "Person 1133 1142--*--guardians",
            "Scope 1119 1142--*--caregivers or guardians",
            "Scope 1018 1055--*--Able and willing to personally comply"
        ]
    },
    "NCT02905890_inc": {
        "Annotations": [
            "Post-eligibility 43 88--*--Capable of providing written informed consent",
            "Measurement 29 32--*--HIV",
            "Value 33 41--*--negative",
            "Measurement 0 2--*--BV",
            "Value 3 11--*--positive",
            "Measurement 15 27--*--Nugent score"
        ],
        "Text": "BV positive by Nugent score. HIV negative. Capable of providing written informed consent. "
    },
    "NCT02571881_exc": {
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 22--*--less than 18 years",
            "Condition 24 31--*--allergy",
            "Drug 35 46--*--study drugs",
            "Condition 48 64--*--substance misuse",
            "Condition 71 87--*--contraindication",
            "Drug 96 107--*--study drugs"
        ],
        "Text": "age less than 18 years. allergy to study drugs. substance misuse other contraindication to used study drugs no informed consent. "
    },
    "NCT02350439_inc": {
        "Text": "1. Age 18-80 years . 2. Patients with at least 1 \u226550% stenosis in a coronary vessel, subjected to FFR assessment, who exhibit variation in Pd / Pa ratio \u2265 0.05 (e.g. difference of max Pd/Pa minus min Pd/Pa) during steady state hyperaemia (determined by visual assessment). . 3. Written informed consent . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 20 22--*--2.",
            "Parsing_Error 273 275--*--3.",
            "Person 3 6--*--Age",
            "Value 7 18--*--18-80 years",
            "Multiplier 37 47--*--at least 1",
            "Value 48 52--*--\u226550%",
            "Measurement 53 82--*--stenosis in a coronary vessel",
            "Procedure 97 111--*--FFR assessment",
            "Measurement 138 151--*--Pd / Pa ratio",
            "Value 152 158--*--\u2265 0.05",
            "Measurement 179 188--*--max Pd/Pa",
            "Measurement 195 204--*--min Pd/Pa",
            "Condition 226 236--*--hyperaemia",
            "Qualifier 213 225--*--steady state",
            "Procedure 252 269--*--visual assessment",
            "Scope 159 205--*--(e.g. difference of max Pd/Pa minus min Pd/Pa)",
            "Condition 125 151--*--variation in Pd / Pa ratio"
        ]
    },
    "NCT02455921_exc": {
        "Text": "Parents refusal. Cognitive impairment. Difficulty in communication due to language issues. Psychiatric disorder. Severe systematic disorder. Known allergy to any drug used. ",
        "Annotations": [
            "Observation 0 15--*--Parents refusal",
            "Condition 17 37--*--Cognitive impairment",
            "Condition 39 66--*--Difficulty in communication",
            "Condition 74 89--*--language issues",
            "Condition 91 111--*--Psychiatric disorder",
            "Condition 113 139--*--Severe systematic disorder",
            "Condition 141 154--*--Known allergy",
            "Drug 158 171--*--any drug used"
        ]
    },
    "NCT03249311_inc": {
        "Text": "Male participants between 18 and 40 years-old. Written informed consent signed by the participant. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Value 18 41--*--between 18 and 40 years",
            "Person 42 45--*--old",
            "Informed_consent 47 97--*--Written informed consent signed by the participant"
        ]
    },
    "NCT01116973_exc": {
        "Text": "Inability to obtain consent . Subjects under 18 years of age . Non-English speaking subjects . Subjects that are unable to lay flat due to pulmonary complications, increased intracranial pressure (ICP), or unstable spinal cord injuries . Subjects with known cardiac abnormalities (atrial septal defects or ventricular septal defects, severe tricuspid valve disease, severe pulmonary hypertension, Ejection fraction < 15%) . Prisoners . Subjects with known upper extremity deep vein thromboses (subclavian or distal) . Subjects with non-functional CICC or PICC distal ports . Subjects with femoral CICCs . Pregnant women       .     . ",
        "Annotations": [
            "Post-eligibility 0 27--*--Inability to obtain consent",
            "Value 38 52--*--under 18 years",
            "Person 56 59--*--age",
            "Non-query-able 61 90--*--Non-English speaking subjects",
            "Condition 110 128--*--unable to lay flat",
            "Condition 136 159--*--pulmonary complications",
            "Qualifier 129 159--*--due to pulmonary complications",
            "Condition 161 198--*--increased intracranial pressure (ICP)",
            "Condition 212 232--*--spinal cord injuries",
            "Qualifier 203 211--*--unstable",
            "Condition 254 275--*--cardiac abnormalities",
            "Condition 277 298--*--atrial septal defects",
            "Condition 302 328--*--ventricular septal defects",
            "Condition 337 360--*--tricuspid valve disease",
            "Qualifier 330 336--*--severe",
            "Condition 369 391--*--pulmonary hypertension",
            "Qualifier 362 368--*--severe",
            "Measurement 393 410--*--Ejection fraction",
            "Value 411 416--*--< 15%",
            "Scope 277 416--*--atrial septal defects or ventricular septal defects, severe tricuspid valve disease, severe pulmonary hypertension, Ejection fraction < 15%",
            "Person 419 428--*--Prisoners",
            "Non-query-able 419 428--*--Prisoners",
            "Condition 450 486--*--upper extremity deep vein thromboses",
            "Qualifier 488 498--*--subclavian",
            "Qualifier 502 508--*--distal",
            "Scope 488 508--*--subclavian or distal",
            "Device 540 544;553 565--*--CICC distal ports",
            "Device 548 565--*--PICC distal ports",
            "Qualifier 525 539--*--non-functional",
            "Scope 540 565--*--CICC or PICC distal ports",
            "Device 581 594--*--femoral CICCs",
            "Person 605 610--*--women",
            "Condition 596 604--*--Pregnant"
        ]
    },
    "NCT03213834_inc": {
        "Annotations": [
            "Condition 28 53--*--septated pleural effusion",
            "Procedure 57 80--*--pleural ultrasonography",
            "Procedure 88 101--*--chest CT scan",
            "Condition 0 4--*--CPPE",
            "Scope 0 53--*--CPPE along with evidence of septated pleural effusion",
            "Mood 16 27--*--evidence of",
            "Scope 57 101--*--pleural ultrasonography and/or chest CT scan",
            "Condition 103 110--*--empyema"
        ],
        "Text": "CPPE along with evidence of septated pleural effusion on pleural ultrasonography and/or chest CT scan. empyema.. "
    },
    "NCT01728194_exc": {
        "Text": "Psychotic depression by DSM-IV, i.e., presence of delusions with a SCID-R score higher than 2;. High suicide risk, i.e. intent or plan to attempt suicide in near future;. Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse;. History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);. Dementia: Diagnosis of dementia by DSM-IV;. Mild Cognitive Impairment (MCI);. Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or use of drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal;. Neurological brain disease and/or history of electroconvulsive therapy;. History of any use of citalopram or escitalopram during the current episode or need for drugs that may interact with these agents, i.e. drug metabolized by the 2D6 P450 isoenzyme system;. Current involvement in psychotherapy;. Contraindications to MRI scanning including cardiac pacemaker, metallic objects and metallic implants contraindicating MRI, cardiac stent, claustrophobia;. Inability to speak English;. Corrected visual acuity < 20/70; Color blindness.. ",
        "Annotations": [
            "Condition 0 20--*--Psychotic depression",
            "Qualifier 24 30--*--DSM-IV",
            "Condition 50 59--*--delusions",
            "Measurement 67 79--*--SCID-R score",
            "Value 80 93--*--higher than 2",
            "Observation 101 113--*--suicide risk",
            "Qualifier 96 100--*--High",
            "Mood 120 126--*--intent",
            "Mood 130 137--*--plan to",
            "Observation 138 153--*--attempt suicide",
            "Temporal 154 168--*--in near future",
            "Scope 120 137--*--intent or plan to",
            "Condition 194 214--*--psychiatric disorder",
            "Qualifier 187 193--*--Axis I",
            "Negation 216 226--*--other than",
            "Condition 227 252--*--unipolar major depression",
            "Condition 257 272--*--substance abuse",
            "Scope 187 252--*--Axis I psychiatric disorder (other than unipolar major depression",
            "Condition 286 307--*--psychiatric disorders",
            "Negation 308 318--*--other than",
            "Condition 319 344--*--unipolar major depression",
            "Condition 348 376--*--generalized anxiety disorder",
            "Condition 378 394--*--bipolar disorder",
            "Condition 396 405--*--hypomania",
            "Condition 411 420--*--dysthymia",
            "Scope 319 376--*--unipolar major depression or generalized anxiety disorder",
            "Scope 378 420--*--bipolar disorder, hypomania, and dysthymia",
            "Condition 447 455--*--Dementia",
            "Qualifier 482 488--*--DSM-IV",
            "Condition 491 516--*--Mild Cognitive Impairment",
            "Condition 518 521--*--MCI",
            "Condition 541 556--*--medical illness",
            "Qualifier 525 530--*--Acute",
            "Qualifier 534 540--*--severe",
            "Condition 564 572--*--delirium",
            "Condition 574 591--*--metastatic cancer",
            "Qualifier 593 606--*--decompensated",
            "Condition 607 614;632 639--*--cardiac failure",
            "Condition 616 621;632 639--*--liver failure",
            "Condition 625 639--*--kidney failure",
            "Procedure 641 654--*--major surgery",
            "Condition 656 662--*--stroke",
            "Condition 666 687--*--myocardial infarction",
            "Temporal 699 726--*--three months prior to entry",
            "Reference_point 721 726--*--entry",
            "Drug 738 743--*--drugs",
            "Condition 759 769--*--depression",
            "Drug 777 786--*--reserpine",
            "Drug 788 805--*--alpha-methyl-dopa",
            "Drug 807 815--*--steroids",
            "Condition 817 844--*--sympathomimetics withdrawal",
            "Scope 525 540--*--Acute or severe",
            "Scope 564 687--*--delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction",
            "Scope 607 639--*--cardiac, liver or kidney failure",
            "Scope 777 844--*--reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal",
            "Condition 860 873--*--brain disease",
            "Qualifier 847 859--*--Neurological",
            "Procedure 892 917--*--electroconvulsive therapy",
            "Drug 942 952--*--citalopram",
            "Drug 956 968--*--escitalopram",
            "Qualifier 980 987--*--current",
            "Condition 988 995--*--episode",
            "Scope 942 968--*--citalopram or escitalopram",
            "Drug 1008 1013--*--drugs",
            "Drug 1043 1049--*--agents",
            "Non-query-able 999 1105--*--need for drugs that may interact with these agents, i.e. drug metabolized by the 2D6 P450 isoenzyme system",
            "Procedure 1131 1144--*--psychotherapy",
            "Condition 1147 1164--*--Contraindications",
            "Procedure 1168 1171--*--MRI",
            "Device 1191 1208--*--cardiac pacemaker",
            "Device 1210 1226--*--metallic objects",
            "Device 1231 1248--*--metallic implants",
            "Device 1271 1284--*--cardiac stent",
            "Condition 1286 1300--*--claustrophobia",
            "Scope 1191 1300--*--cardiac pacemaker, metallic objects and metallic implants contraindicating MRI, cardiac stent, claustrophobia",
            "Post-eligibility 1303 1329--*--Inability to speak English",
            "Measurement 1342 1355--*--visual acuity",
            "Qualifier 1332 1341--*--Corrected",
            "Value 1356 1364--*--< 20/70;",
            "Condition 1365 1380--*--Color blindness"
        ]
    },
    "NCT02321839_inc": {
        "Text": "Signed informed consent form. Male or female of aged 50 years or older. Typical AMD and PCV patients. BCVA of 24 letters or over. ",
        "Annotations": [
            "Informed_consent 0 28--*--Signed informed consent form",
            "Person 30 34--*--Male",
            "Person 38 44--*--female",
            "Person 48 52--*--aged",
            "Value 53 70--*--50 years or older",
            "Condition 88 100--*--PCV patients",
            "Condition 80 83--*--AMD",
            "Condition 102 106--*--BCVA",
            "Qualifier 110 128--*--24 letters or over"
        ]
    },
    "NCT02687178_inc": {
        "Text": "Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage. . ",
        "Annotations": [
            "Person 0 9--*--Caucasian",
            "Condition 46 68--*--essential hypertension",
            "Qualifier 31 44--*--uncomplicated",
            "Drug 123 128--*--ACE-I",
            "Drug 132 136--*--ARBs",
            "Drug 141 150--*--diuretics",
            "Multiplier 158 172--*--maximum dosage",
            "Qualifier 70 89--*--not well controlled",
            "Scope 123 172--*--ACE-I or ARBs and diuretics at the maximum dosage"
        ]
    },
    "NCT02721017_exc": {
        "Text": "age less than 13 years at time of procedure. use of pain medication prior to procedure. pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum. previous repair of pectus excavatum by any technique. previous thoracic surgery. congenital heart disease. bleeding dyscrasia. major anesthetic risk factors or history of previous problem with anesthesia. pregnancy. inability to communicate in English. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 22--*--less than 13 years",
            "Temporal 23 43--*--at time of procedure",
            "Drug 52 67--*--pain medication",
            "Temporal 68 86--*--prior to procedure",
            "Condition 88 104--*--pectus carinatum",
            "Condition 106 123--*--Poland's syndrome",
            "Condition 132 150--*--chest wall anomaly",
            "Negation 151 161--*--other than",
            "Condition 162 178--*--pectus excavatum",
            "Procedure 189 215--*--repair of pectus excavatum",
            "Temporal 180 188--*--previous",
            "Temporal 234 242--*--previous",
            "Procedure 243 259--*--thoracic surgery",
            "Condition 261 285--*--congenital heart disease",
            "Condition 287 305--*--bleeding dyscrasia",
            "Condition 313 336--*--anesthetic risk factors",
            "Qualifier 307 312--*--major",
            "Condition 360 383--*--problem with anesthesia",
            "Temporal 351 359--*--previous",
            "Condition 385 394--*--pregnancy",
            "Condition 396 431--*--inability to communicate in English"
        ]
    },
    "NCT02894268_inc": {
        "Annotations": [
            "Measurement 11 32--*--13 C-urea breath test",
            "Value 2 10--*--positive",
            "Procedure 41 59--*--H.pylori treatment",
            "Multiplier 60 79--*--more than two times",
            "Person 81 84--*--Age",
            "Value 85 94--*-->18 years"
        ],
        "Text": "A positive 13 C-urea breath test. Formal H.pylori treatment more than two times. Age >18 years. "
    },
    "NCT02687178_exc": {
        "Text": "diabetes mellitus . secondary hypertension . pregnancy       .     . ",
        "Annotations": [
            "Condition 0 17--*--diabetes mellitus",
            "Condition 19 41--*--secondary hypertension",
            "Condition 43 52--*--pregnancy"
        ]
    },
    "NCT02721017_inc": {
        "Text": "scheduled for Nuss procedure for pectus excavatum correction. at least 13 years old at the time of the procedure. ",
        "Annotations": [
            "Procedure 14 28--*--Nuss procedure",
            "Mood 0 9--*--scheduled",
            "Condition 33 49--*--pectus excavatum",
            "Value 62 79--*--at least 13 years",
            "Person 80 83--*--old",
            "Temporal 84 112--*--at the time of the procedure"
        ]
    },
    "NCT02894268_exc": {
        "Annotations": [
            "Drug 0 17--*--Bismuth compounds",
            "Drug 19 33--*--acid inhibitor",
            "Drug 38 49--*--antibiotics",
            "Temporal 50 95--*--during 4 weeks before the patient is enrolled",
            "Reference_point 72 95--*--the patient is enrolled",
            "Scope 0 49--*--Bismuth compounds, acid inhibitor, or antibiotics",
            "Condition 97 105--*--Allergic",
            "Drug 113 124--*--medications",
            "Procedure 126 156--*--Upper gastrointestinal surgery",
            "Observation 157 164--*--history",
            "Qualifier 166 173--*--Serious",
            "Condition 174 193--*--heart insufficiency",
            "Condition 195 214--*--liver insufficiency",
            "Condition 216 235--*--renal insufficiency",
            "Qualifier 240 245--*--other",
            "Condition 246 270--*--serious medical problems",
            "Condition 284 299--*--blood dyscrasia",
            "Mood 272 280--*--Evidence",
            "Condition 301 309--*--Pregnant",
            "Condition 314 323--*--lactating",
            "Person 324 329--*--women",
            "Non-query-able 331 407--*--Can't express his complain correctly and can't cooperate with the researcher"
        ],
        "Text": "Bismuth compounds, acid inhibitor, or antibiotics during 4 weeks before the patient is enrolled. Allergic to the medications. Upper gastrointestinal surgery history. Serious heart insufficiency, liver insufficiency, renal insufficiency and other serious medical problems. Evidence of blood dyscrasia. Pregnant and lactating women. Can't express his complain correctly and can't cooperate with the researcher. "
    },
    "NCT03146390_exc": {
        "Text": "Smoker or former smoker.. Presence of dental prostheses.. Presence of orthodontic devices.. Antibiotic treatment or routine use of oral antiseptics in the previous 3 months.. Presence of any systemic disease that could alter the production or composition of saliva.. ",
        "Annotations": [
            "Condition 0 6--*--Smoker",
            "Condition 10 23--*--former smoker",
            "Device 38 55--*--dental prostheses",
            "Device 70 89--*--orthodontic devices",
            "Drug 92 102--*--Antibiotic",
            "Multiplier 116 127--*--routine use",
            "Drug 131 147--*--oral antiseptics",
            "Temporal 148 172--*--in the previous 3 months",
            "Condition 191 207--*--systemic disease",
            "Qualifier 213 264--*--could alter the production or composition of saliva"
        ]
    },
    "NCT03373318_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Value 16 26--*--> 18 years",
            "Person 21 26--*--years",
            "Scope 16 26--*--> 18 years",
            "Procedure 42 72--*--cardiopulmonary bypass surgery",
            "Measurement 78 110--*--Glomerular Filtration Rate (GFR)",
            "Value 111 138--*--greater than or equal to 60",
            "Measurement 143 177--*--left ventricular ejection fraction",
            "Value 178 206--*--greater than or equal to 40%",
            "Mood 28 41--*--scheduled for"
        ],
        "Text": "Adult patients (> 18 years) scheduled for cardiopulmonary bypass surgery with Glomerular Filtration Rate (GFR) greater than or equal to 60 and left ventricular ejection fraction greater than or equal to 40%. "
    },
    "NCT03062358_exc": {
        "Annotations": [
            "Non-query-able 0 175--*--Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication",
            "Drug 190 199--*--sorafenib",
            "Drug 203 214--*--oxaliplatin",
            "Procedure 221 233--*--chemotherapy",
            "Qualifier 190 220--*--sorafenib or oxaliplatin-based",
            "Temporal 234 248--*--within 14 days",
            "Reference_point 252 282--*--first dose of study medication",
            "Condition 292 302;314 331--*--esophageal variceal bleeding",
            "Condition 306 331--*--gastric variceal bleeding",
            "Temporal 332 356--*--within the last 6 months",
            "Scope 292 331--*--esophageal or gastric variceal bleeding",
            "Condition 382 389--*--ascites",
            "Condition 419 439--*--portal vein invasion",
            "Qualifier 447 471--*--main portal branch (Vp4)",
            "Qualifier 473 491--*--inferior vena cava",
            "Condition 496 515--*--cardiac involvement",
            "Condition 519 522--*--HCC",
            "Procedure 532 539--*--imaging",
            "Scope 447 491--*--main portal branch (Vp4), inferior vena cava",
            "Scope 419 515--*--portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement",
            "Condition 570 592--*--hepatic encephalopathy",
            "Temporal 593 613--*--in the last 6 months",
            "Procedure 640 662--*--hematologic transplant",
            "Procedure 625 636;652 662--*--solid organ transplant",
            "Procedure 678 694--*--systemic therapy",
            "Condition 699 702--*--HCC",
            "Drug 750 759--*--sorafenib",
            "Drug 763 774--*--oxaliplatin",
            "Procedure 781 793--*--chemotherapy",
            "Qualifier 750 780--*--sorafenib or oxaliplatin-based",
            "Temporal 795 800--*--prior",
            "Reference_point 804 829--*--start of study medication",
            "Scope 678 793--*--systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy",
            "Temporal 838 844--*--active",
            "Condition 845 863--*--autoimmune disease",
            "Procedure 882 900--*--systemic treatment",
            "Temporal 901 920--*--in the past 2 years",
            "Not_a_criteria 922 989--*--Replacement therapy is not considered a form of systemic treatment.",
            "Condition 1010 1026--*--immunodeficiency",
            "Procedure 1043 1067--*--systemic steroid therapy",
            "Procedure 1089 1114--*--immunosuppressive therapy",
            "Temporal 1115 1134--*--within 7 days prior",
            "Reference_point 1138 1172--*--the first dose of study medication",
            "Scope 1043 1114--*--systemic steroid therapy or any other form of immunosuppressive therapy",
            "Procedure 1187 1207--*--locoregional therapy",
            "Procedure 1218 1256--*--transcatheter chemoembolization [TACE]",
            "Procedure 1258 1290--*--transcatheter embolization [TAE]",
            "Procedure 1292 1323--*--hepatic arterial infusion [HAI]",
            "Procedure 1325 1334--*--radiation",
            "Procedure 1336 1353--*--radioembolization",
            "Procedure 1358 1366--*--ablation",
            "Temporal 1382 1402--*--within 4 weeks prior",
            "Reference_point 1410 1440--*--first dose of study medication",
            "Qualifier 1211 1216--*--liver",
            "Qualifier 1371 1381--*--other site",
            "Scope 1218 1366--*--transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation",
            "Procedure 1450 1463--*--major surgery",
            "Qualifier 1467 1472--*--liver",
            "Qualifier 1476 1486--*--other site",
            "Temporal 1487 1507--*--within 4 weeks prior",
            "Reference_point 1515 1545--*--first dose of study medication",
            "Procedure 1557 1570--*--minor surgery",
            "Temporal 1571 1584--*--\u22647 days prior",
            "Reference_point 1592 1622--*--first dose of study medication",
            "Undefined_semantics 1624 1763--*--Has not recovered adequately (i.e., Grade \u22641 or baseline) from the toxicity and/or complications from any intervention prior to study start",
            "Context_Error 1624 1763--*--Has not recovered adequately (i.e., Grade \u22641 or baseline) from the toxicity and/or complications from any intervention prior to study start",
            "Subjective_judgement 1632 1652--*--recovered adequately",
            "Condition 1792 1802--*--malignancy",
            "Qualifier 1781 1791--*--additional",
            "Temporal 1803 1857--*--within 3 years prior to first dose of study medication",
            "Reference_point 1827 1857--*--first dose of study medication",
            "Procedure 1891 1898--*--treated",
            "Qualifier 1880 1890--*--curatively",
            "Undefined_semantics 1880 1898--*--curatively treated",
            "Condition 1899 1931--*--basal cell carcinoma of the skin",
            "Condition 1933 1968--*--squamous cell carcinoma of the skin",
            "Condition 1996 2011--*--in situ cancers",
            "Procedure 1987 1995--*--resected",
            "Qualifier 1976 1986--*--curatively",
            "Qualifier 1880 1898--*--curatively treated",
            "Qualifier 1976 1995--*--curatively resected",
            "Scope 1880 2011--*--curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",
            "Observation 2025 2032--*--history",
            "Observation 2044 2052--*--evidence",
            "Condition 2057 2096--*--central nervous system (CNS) metastases",
            "Condition 2104 2128--*--carcinomatous meningitis",
            "Scope 2057 2128--*--central nervous system (CNS) metastases and/or carcinomatous meningitis",
            "Drug 2190 2198--*--steroids",
            "Drug 2210 2221--*--pneumonitis",
            "Temporal 2202 2209--*--current",
            "Observation 2136 2143--*--history",
            "Condition 2148 2175--*--non-infectious) pneumonitis",
            "Procedure 2257 2273--*--systemic therapy",
            "Temporal 2230 2236--*--active",
            "Condition 2237 2246--*--infection",
            "Qualifier 2247 2273--*--requiring systemic therapy",
            "Procedure 2502 2515--*--immunotherapy",
            "Drug 2524 2568--*--anti-Programmed Cell Death Receptor 1 (PD-1)",
            "Drug 2570 2622--*--Programmed Cell Death Receptor Ligand 1 (anti-PD-L1)",
            "Drug 2627 2680--*--anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)",
            "Non-query-able 2699 2750--*--participated in clinical studies with pembrolizumab",
            "Drug 2737 2750--*--pembrolizumab",
            "Scope 2524 2680--*--anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)",
            "Observation 2699 2750--*--participated in clinical studies with pembrolizumab",
            "Condition 2775 2809--*--human immunodeficiency virus (HIV)",
            "Observation 2764 2771--*--history",
            "Condition 2832 2843--*--Hepatitis B",
            "Qualifier 2815 2824--*--untreated",
            "Qualifier 2825 2831--*--active",
            "Condition 2849 2860--*--hepatitis C",
            "Procedure 2892 2907--*--therapy for HCV",
            "Temporal 2908 2922--*--<4 weeks prior",
            "Drug 2936 2949--*--pembrolizumab",
            "Reference_point 2926 2949--*--receiving pembrolizumab",
            "Condition 2966 2978--*--live vaccine",
            "Temporal 2986 2999--*--30 days prior",
            "Reference_point 3007 3034--*--first dose of study therapy",
            "Negation 1858 1879--*--with the exception of",
            "Condition 2278 2286--*--pregnant",
            "Observation 2290 2304--*--breast feeding",
            "Observation 2308 2329--*--expecting to conceive",
            "Observation 2308 2320;2333 2339--*--expecting to father",
            "Temporal 2340 2388--*--starting from the first dose of study medication",
            "Reference_point 2354 2388--*--the first dose of study medication",
            "Temporal 2390 2417--*--throughout the study period",
            "Reference_point 2401 2417--*--the study period",
            "Temporal 2423 2481--*--for up to 120 days after the last dose of study medication",
            "Reference_point 2448 2481--*--the last dose of study medication",
            "Scope 2340 2481--*--starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication",
            "Negation 739 749--*--other than"
        ],
        "Text": "Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication . Has received sorafenib or oxaliplatin-based chemotherapy within 14 days of first dose of study medication . Has had esophageal or gastric variceal bleeding within the last 6 months . Has clinically apparent ascites on physical examination . Has portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging . Has had clinically diagnosed hepatic encephalopathy in the last 6 months . Has had a solid organ or hematologic transplant . Has had prior systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy, prior to start of study medication . Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment. . Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication . Has received locoregional therapy to liver (transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation) or other site within 4 weeks prior to the first dose of study medication . Has had major surgery to liver or other site within 4 weeks prior to the first dose of study medication . Has had a minor surgery \u22647 days prior to the first dose of study medication . Has not recovered adequately (i.e., Grade \u22641 or baseline) from the toxicity and/or complications from any intervention prior to study start . Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers . Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis . Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis . Has an active infection requiring systemic therapy . Is pregnant or breast feeding or expecting to conceive or father starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication . Has received prior immunotherapy with an anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2) or has previously participated in clinical studies with pembrolizumab . Has a known history of human immunodeficiency virus (HIV) . Has untreated active Hepatitis B . Has hepatitis C in which participants received therapy for HCV <4 weeks prior to receiving pembrolizumab . Has received a live vaccine within 30 days prior to the first dose of study therapy       .     . "
    },
    "NCT03083197_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Procedure 20 35--*--Hospitalization",
            "Condition 41 69--*--acute undifferentiated fever",
            "Measurement 71 82--*--temperature",
            "Value 83 91--*--> 37.5 C",
            "Condition 93 101--*--tympanic",
            "Scope 71 101--*--temperature > 37.5 C, tympanic",
            "Multiplier 103 111--*--=14 days",
            "Observation 152 159--*--history",
            "Condition 163 168--*--fever",
            "Multiplier 169 178--*--= 14 days",
            "Condition 204 209--*--fever",
            "Temporal 210 238--*--within 24 hours of admission",
            "Procedure 124 144--*--admitted to hospital",
            "Reference_point 229 238--*--admission",
            "Value 4 18--*--= 15 years old",
            "Scope 152 238--*--history of fever = 14 days who subsequently develop fever within 24 hours of admission",
            "Condition 261 273--*--scrub typhus",
            "Condition 286 314--*--acute undifferentiated fever",
            "Condition 329 347--*--focus of infection",
            "Negation 320 328--*--no clear",
            "Value 352 360--*--negative",
            "Measurement 361 380--*--malaria blood smear",
            "Value 388 396--*--negative",
            "Measurement 397 408--*--malaria RDT",
            "Multiplier 428 431--*--one",
            "Multiplier 433 437--*--none",
            "Multiplier 442 458--*--a combination of",
            "Scope 428 458--*--one, none, or a combination of",
            "Condition 491 497--*--eschar",
            "Condition 499 503--*--rash",
            "Condition 505 520--*--lymphadenopathy",
            "Condition 522 530--*--headache",
            "Condition 532 539--*--myalgia",
            "Condition 541 546--*--cough",
            "Condition 548 554--*--nausea",
            "Condition 559 579--*--abdominal discomfort",
            "Scope 491 579--*--eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort",
            "Scope 428 579--*--one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort",
            "Scope 286 408--*--acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT",
            "Measurement 593 609--*--scrub typhus RDT",
            "Value 584 592--*--positive",
            "Procedure 611 631--*--Scrub Typhus IgM RDT",
            "Value 680 688--*--positive",
            "Procedure 689 692--*--PCR",
            "Qualifier 712 732--*--O. tsutsugamushi DNA",
            "Qualifier 742 764--*--admission blood sample",
            "Observation 766 790--*--Written informed consent",
            "Observation 799 822--*--written informed assent",
            "Observation 836 864--*--Able to take oral medication",
            "Drug 849 864--*--oral medication"
        ],
        "Text": "Age = 15 years old. Hospitalization with acute undifferentiated fever (temperature > 37.5 C, tympanic) =14 days or patients admitted to hospital with a history of fever = 14 days who subsequently develop fever within 24 hours of admission. Clinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT. Patients may have one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort.. A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA, USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission blood sample. Written informed consent and/or, written informed assent as required. Able to take oral medication. "
    },
    "NCT02894372_exc": {
        "Annotations": [
            "Condition 0 18--*--Purulent infection",
            "Non-query-able 20 42--*--Refusal to participate",
            "Post-eligibility 20 42--*--Refusal to participate",
            "Condition 44 51--*--Allergy",
            "Drug 55 70--*--tested material",
            "Reference_point 55 70--*--tested material",
            "Context_Error 55 70--*--tested material"
        ],
        "Text": "Purulent infection . Refusal to participate . Allergy to tested material       .     . "
    },
    "NCT03199560_exc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 16 19--*--age",
            "Value 23 25;6 11--*--18 under",
            "Condition 48 62--*--axillary nodes",
            "Qualifier 39 47--*--positive",
            "Procedure 64 83--*--Neoadjuvant therapy",
            "Condition 96 109--*--breast cancer",
            "Person 121 126--*--Women",
            "Procedure 141 146--*--SLNBx",
            "Procedure 150 174--*--axillary node dissection",
            "Qualifier 132 140--*--previous",
            "Scope 141 174--*--SLNBx or axillary node dissection",
            "Pregnancy_considerations 176 190--*--Pregnant women",
            "Procedure 212 221--*--radiation",
            "Qualifier 222 241--*--above the diaphragm",
            "Qualifier 247 261--*--below the neck",
            "Qualifier 203 211--*--previous",
            "Person 192 197--*--Women"
        ],
        "Text": "Women under the age of 18,. Clinically positive axillary nodes. Neoadjuvant therapy for current breast cancer diagnosis. Women with previous SLNBx or axillary node dissection. Pregnant women. Women with previous radiation above the diaphragm, and below the neck. "
    },
    "NCT02441179_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 106 108--*--2.",
            "Parsing_Error 177 179--*--3.",
            "Parsing_Error 234 236--*--4.",
            "Parsing_Error 255 257--*--5.",
            "Parsing_Error 313 315--*--6.",
            "Parsing_Error 361 363--*--7.",
            "Value 12 22--*--\u2265 18 years",
            "Person 17 26--*--years-old",
            "Visit 33 59--*--Instituto Telet\u00f3n Santiago",
            "Visit 66 102--*--Hospital Cl\u00ednico Mutual de seguridad",
            "Grammar_Error 61 64--*--and",
            "Condition 119 137--*--spinal cord injury",
            "Qualifier 109 118--*--C5 to T12",
            "Measurement 153 160--*--ISNCSCI",
            "Value 161 175--*--grades C and D",
            "Qualifier 194 207--*--non-traumatic",
            "Condition 225 232--*--lesions",
            "Qualifier 180 189--*--Traumatic",
            "Qualifier 209 224--*--non-progressive",
            "Temporal 237 253--*--Onset > 6 months",
            "Condition 258 282;294 311--*--Ability to ambulate with assistive devices",
            "Condition 258 277;286 311--*--Ability to ambulate without assistive devices",
            "Condition 316 340;351 359--*--Ability to follow verbal commands",
            "Condition 316 333;344 359--*--Ability to follow visual commands",
            "Post-eligibility 364 387--*--Signed informed consent",
            "Non-query-able 364 387--*--Signed informed consent"
        ],
        "Text": "1. Patients \u2265 18 years-old from \"Instituto Telet\u00f3n Santiago\" and \"Hospital Cl\u00ednico Mutual de seguridad\". . 2. C5 to T12 spinal cord injury, classified as ISNCSCI grades C and D . 3. Traumatic and non-traumatic, non-progressive lesions . 4. Onset > 6 months . 5. Ability to ambulate with or without assistive devices . 6. Ability to follow verbal or visual commands . 7. Signed informed consent . "
    },
    "NCT02964715_exc": {
        "Text": "eGFR <45 ml/min. structural and functional urogenital abnormalities, that predispose for urogenital infections. Investigational product use in the last 6 months. SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA use within the past 6 months. DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome) within the last 6 months. Pregnancy. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).. Liver cirrhosis. Type 1 diabetes. Severe uncorrected insulin insufficiency. Significant alcohol intake. HIV infection. Use of Traditional Chinese Medication or alternative therapies. Coexisting causes of chronic liver disease - chronic viral hepatitis(B & C), autoimmune liver disease, hemochromatosis, Wilson's etc.. Use of medications associated with steatosis eg. Methotrexate, anticonvulsants, antiretroviral therapy etc.. h/o stroke. Steroid therapy. Endogenous Cushing's. Familial hypertriglyceridemia. ",
        "Annotations": [
            "Measurement 0 4--*--eGFR",
            "Value 5 15--*--<45 ml/min",
            "Condition 43 67--*--urogenital abnormalities",
            "Qualifier 17 27--*--structural",
            "Qualifier 32 42--*--functional",
            "Parsing_Error 28 31--*--and",
            "Scope 17 42--*--structural and functional",
            "Observation 74 110--*--predispose for urogenital infections",
            "Condition 89 110--*--urogenital infections",
            "Procedure 112 139--*--Investigational product use",
            "Temporal 140 160--*--in the last 6 months",
            "Drug 162 177--*--SGLT2 inhibitor",
            "Drug 179 182--*--TZD",
            "Drug 184 198--*--DPP4 inhibitor",
            "Drug 203 210--*--GLP1 RA",
            "Temporal 215 239--*--within the past 6 months",
            "Scope 162 210--*--SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA",
            "Condition 241 244--*--DKA",
            "Condition 245 266--*--Diabetic Ketoacidosis",
            "Condition 271 274--*--HHS",
            "Condition 275 312--*--Hyperosmoloar Hyperglycaemic Syndrome",
            "Temporal 314 338--*--within the last 6 months",
            "Scope 241 313--*--DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome)",
            "Pregnancy_considerations 340 349--*--Pregnancy",
            "Procedure 390 416--*--magnetic resonance imaging",
            "Observation 363 386--*--major contraindications",
            "Device 418 436--*--cardiac pacemakers",
            "Condition 438 452--*--claustrophobia",
            "Observation 454 468--*--foreign bodies",
            "Device 473 498--*--implanted medical devices",
            "Qualifier 504 528--*--ferromagnetic properties",
            "Condition 532 547--*--Liver cirrhosis",
            "Condition 549 564--*--Type 1 diabetes",
            "Condition 585 606--*--insulin insufficiency",
            "Qualifier 573 584--*--uncorrected",
            "Qualifier 566 572--*--Severe",
            "Scope 566 584--*--Severe uncorrected",
            "Observation 620 634--*--alcohol intake",
            "Qualifier 608 619--*--Significant",
            "Condition 636 649--*--HIV infection",
            "Procedure 658 688--*--Traditional Chinese Medication",
            "Procedure 692 713--*--alternative therapies",
            "Condition 736 757--*--chronic liver disease",
            "Condition 760 783;784 785--*--chronic viral hepatitis B",
            "Condition 760 783;788 789--*--chronic viral hepatitis C",
            "Parsing_Error 786 787--*--&",
            "Condition 792 816--*--autoimmune liver disease",
            "Condition 818 833--*--hemochromatosis",
            "Condition 835 843--*--Wilson's",
            "Scope 760 843--*--chronic viral hepatitis(B & C), autoimmune liver disease, hemochromatosis, Wilson's",
            "Drug 857 868--*--medications",
            "Condition 885 894--*--steatosis",
            "Drug 899 911--*--Methotrexate",
            "Drug 913 928--*--anticonvulsants",
            "Drug 930 952--*--antiretroviral therapy",
            "Scope 899 952--*--Methotrexate, anticonvulsants, antiretroviral therapy",
            "Condition 963 969--*--stroke",
            "Drug 971 986--*--Steroid therapy",
            "Condition 999 1008--*--Cushing's",
            "Qualifier 988 998--*--Endogenous",
            "Condition 1010 1038--*--Familial hypertriglyceridemi"
        ]
    },
    "NCT03479502_exc": {
        "Annotations": [
            "Drug 11 22--*--Doxycycline",
            "Drug 26 44--*--Methylprednisolone",
            "Condition 0 7--*--allergy",
            "Scope 11 44--*--Doxycycline or Methylprednisolone",
            "Condition 47 56--*--pregnancy",
            "Condition 59 68--*--diagnosis",
            "Condition 71 93--*--Inflammatory arthritis",
            "Condition 97 105--*--diabetes",
            "Qualifier 108 117--*--secondary",
            "Condition 118 137--*--adhesive capsulitis",
            "Observation 139 146--*--history",
            "Qualifier 150 161--*--significant",
            "Condition 162 168--*--trauma",
            "Condition 170 194--*--rotator cuff tear injury",
            "Condition 196 202--*--stroke",
            "Scope 150 202--*--significant trauma, rotator cuff tear injury, stroke",
            "Scope 139 202--*--history of significant trauma, rotator cuff tear injury, stroke",
            "Mood 205 216--*--evidence of",
            "Condition 217 226--*--arthritis",
            "Procedure 230 235--*--x-ray",
            "Temporal 238 245--*--current",
            "Condition 246 264--*--infectious disease",
            "Qualifier 271 274--*--any",
            "Temporal 275 283--*--previous",
            "Procedure 284 293--*--treatment",
            "Condition 306 325--*--adhesive capsulitis",
            "Qualifier 333 350--*--affected shoulder"
        ],
        "Text": "allergy to Doxycycline or Methylprednisolone,. pregnancy,. diagnosis,. Inflammatory arthritis or diabetes,. secondary adhesive capsulitis (history of significant trauma, rotator cuff tear injury, stroke). evidence of arthritis on x-ray,. current infectious disease, and. any previous treatment for the for adhesive capsulitis of the affected shoulder.. "
    },
    "NCT02590822_exc": {
        "Annotations": [
            "Condition 2 10--*--Diabetes",
            "Temporal 20 29--*-->12 years",
            "Multiplier 48 63--*--more than three",
            "Procedure 64 90--*--glucose lowering therapies",
            "Observation 92 103--*--Weight-loss",
            "Value 107 111--*-->5kg",
            "Temporal 119 137--*--preceding 6 months",
            "Condition 152 174--*--chronic kidney disease",
            "Qualifier 139 151--*--Stage 4 or 5",
            "Measurement 176 180--*--eGFR",
            "Value 180 197--*--< 30ml/min/1.73m2",
            "Drug 222 229--*--Insulin",
            "Drug 231 249--*--thiazolidinediones",
            "Drug 251 259--*--steroids",
            "Drug 263 296--*--atypical antipsychotic medication",
            "Condition 308 323--*--thyroid disease",
            "Qualifier 298 307--*--Untreated",
            "Condition 331 352--*--macrovascular disease",
            "Condition 363 386--*--coronary artery disease",
            "Condition 388 394--*--stroke",
            "Condition 395 398--*--TIA",
            "Condition 402 429--*--peripheral vascular disease",
            "Scope 363 429--*--coronary artery disease, stroke/TIA or peripheral vascular disease",
            "Condition 443 453--*--arrhythmia",
            "Condition 465 484--*--atrial fibrillation",
            "Condition 486 500--*--atrial flutter",
            "Condition 512 545--*--3rd degree atrioventricular block",
            "Condition 505 508;516 545--*--2nd degree atrioventricular block",
            "Scope 465 545--*--atrial fibrillation, atrial flutter, or 2nd or 3rd degree atrioventricular block",
            "Condition 554 567--*--heart failure",
            "Condition 595 608--*--heart disease",
            "Observation 623 631--*--exercise",
            "Procedure 647 650--*--MRP",
            "Negation 610 619--*--Inability",
            "Scope 623 650--*--exercise or undertake a MRP",
            "Condition 661 677--*--contraindication",
            "Procedure 681 684--*--CMR",
            "Condition 686 709--*--Cardiovascular symptoms",
            "Condition 711 717--*--angina",
            "Condition 728 736--*--dyspnoea",
            "Scope 711 736--*--angina, limiting dyspnoea",
            "Condition 771 783--*--Inflammatory",
            "Condition 799 826--*--Connective tissue disorder,",
            "Condition 827 847--*--Rheumatoid arthritis",
            "Scope 799 847--*--Connective tissue disorder, Rheumatoid arthritis"
        ],
        "Text": "\u2022 Diabetes duration >12 years. Currently taking more than three glucose lowering therapies. Weight-loss of >5kg in the preceding 6 months. Stage 4 or 5 chronic kidney disease (eGFR< 30ml/min/1.73m2),. Current therapy with Insulin, thiazolidinediones, steroids or atypical antipsychotic medication. Untreated thyroid disease. Known macrovascular disease including coronary artery disease, stroke/TIA or peripheral vascular disease. Presence of arrhythmia (including atrial fibrillation, atrial flutter, or 2nd or 3rd degree atrioventricular block). Known heart failure. Other clinically relevant heart disease. Inability to exercise or undertake a MRP. Absolute contraindication to CMR. Cardiovascular symptoms (angina, limiting dyspnoea during normal physical activity). Inflammatory condition e.g. Connective tissue disorder, Rheumatoid arthritis. "
    },
    "NCT02298504_exc": {
        "Text": "Teeth with clinical symptoms of irriversible pulpitis or pulp necrosis or acute dental infection. Children with systemic illness that contraindicated vital pulp treatment such a sickle cell disease. Teeth that are not restorable. ",
        "Annotations": [
            "Condition 32 53--*--irriversible pulpitis",
            "Condition 57 70--*--pulp necrosis",
            "Condition 74 96--*--acute dental infection",
            "Qualifier 0 5--*--Teeth",
            "Condition 112 128--*--systemic illness",
            "Condition 134 149--*--contraindicated",
            "Procedure 150 170--*--vital pulp treatment",
            "Condition 178 197--*--sickle cell disease",
            "Scope 112 170--*--systemic illness that contraindicated vital pulp treatment",
            "Observation 199 228--*--Teeth that are not restorable"
        ]
    },
    "NCT03146390_inc": {
        "Text": "Systemically healthy adults.. Minimum of 24 permanent teeth.. No gingivitis (Community Periodontal Index score = 0).. No periodontitis (Community Periodontal Index score = 0).. Absence of untreated caries.. ",
        "Annotations": [
            "Qualifier 0 12--*--Systemically",
            "Condition 13 20--*--healthy",
            "Person 21 27--*--adults",
            "Multiplier 30 43--*--Minimum of 24",
            "Observation 44 59--*--permanent teeth",
            "Negation 62 64--*--No",
            "Condition 65 75--*--gingivitis",
            "Measurement 77 110--*--Community Periodontal Index score",
            "Value 111 114--*--= 0",
            "Scope 62 75--*--No gingivitis",
            "Scope 77 114--*--Community Periodontal Index score = 0",
            "Negation 118 120--*--No",
            "Condition 121 134--*--periodontitis",
            "Measurement 136 169--*--Community Periodontal Index score",
            "Value 170 173--*--= 0",
            "Scope 136 173--*--Community Periodontal Index score = 0",
            "Scope 118 134--*--No periodontitis",
            "Qualifier 188 197--*--untreated",
            "Condition 198 204--*--caries",
            "Negation 177 184--*--Absence"
        ]
    },
    "NCT03373318_exc": {
        "Annotations": [
            "Negation 16 19--*--not",
            "Observation 20 47--*--meet the inclusion criteria",
            "Observation 69 76--*--history",
            "Condition 80 88--*--allergic",
            "Drug 102 115--*--human albumin",
            "Drug 152 170--*--iodinated contrast",
            "Temporal 171 205--*--during the 7 days prior to surgery",
            "Reference_point 198 205--*--surgery",
            "Procedure 198 205--*--surgery",
            "Condition 210 218--*--pregnant",
            "Person 219 224--*--women"
        ],
        "Text": "Patients who do not meet the inclusion criteria and those who have a history of allergic reactions to human albumin, as well as those who have received iodinated contrast during the 7 days prior to surgery and pregnant women, will be excluded from the study.. "
    },
    "NCT03083197_exc": {
        "Annotations": [
            "Condition 6 22--*--hypersensitivity",
            "Drug 26 38--*--tetracycline",
            "Drug 40 51--*--doxycycline",
            "Drug 55 67--*--azithromycin",
            "Scope 26 67--*--tetracycline, doxycycline or azithromycin",
            "Drug 87 98--*--doxycycline",
            "Drug 100 112--*--azithromycin",
            "Drug 114 129--*--chloramphenicol",
            "Drug 131 141--*--rifampicin",
            "Drug 146 158--*--tetracycline",
            "Temporal 159 186--*--during the preceding 7 days",
            "Scope 87 158--*--doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline",
            "Condition 188 197--*--Pregnancy",
            "Observation 201 215--*--breast-feeding",
            "Condition 231 248--*--myasthenia gravis",
            "Condition 252 280--*--systemic lupus erythematosus",
            "Condition 311 320--*--infection",
            "Procedure 322 337--*--diagnostic test",
            "Condition 353 366--*--acute malaria",
            "Condition 368 374--*--dengue",
            "Condition 376 389--*--leptospirosis",
            "Condition 391 398--*--typhoid",
            "Condition 400 421--*--Japanese encephalitis",
            "Scope 353 421--*--acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis",
            "Condition 436 438--*--TB",
            "Procedure 442 454--*--TB treatment",
            "Temporal 455 468--*--in = 6 months",
            "Procedure 529 534--*--HAART",
            "Condition 543 546--*--HIV",
            "Multiplier 548 561--*--long term use",
            "Drug 565 583--*--immunosuppressants",
            "Drug 590 598--*--steroids",
            "Drug 600 612--*--chemotherapy",
            "Drug 614 628--*--TNF-inhibitors",
            "Scope 590 628--*--steroids, chemotherapy, TNF-inhibitors",
            "Non-representable 650 900--*--Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)"
        ],
        "Text": "Known hypersensitivity to tetracycline, doxycycline or azithromycin. Administration of doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline during the preceding 7 days. Pregnancy or breast-feeding. Patients with myasthenia gravis or systemic lupus erythematosus. Patients with an established infection (diagnostic test required) e.g. acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis etc.. Current TB or TB treatment in = 6 months (contain active antibiotics against Orientia spp.). Current HAART use for HIV, long term use of immunosuppressants (e.g. steroids, chemotherapy, TNF-inhibitors and related agents). Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin). "
    },
    "NCT03062358_inc": {
        "Annotations": [
            "Condition 6 9--*--HCC",
            "Procedure 33 42--*--radiology",
            "Procedure 44 53--*--histology",
            "Procedure 58 66--*--cytology",
            "Scope 33 66--*--radiology, histology, or cytology",
            "Condition 127 134;68 81--*--subtype fibrolamellar",
            "Condition 87 134--*--mixed hepatocellular/cholangiocarcinoma subtype",
            "Negation 140 152--*--not eligible",
            "Scope 68 152--*--fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible",
            "Measurement 159 195--*--Barcelona Clinic Liver Cancer (BCLC)",
            "Value 196 203--*--Stage C",
            "Condition 204 211--*--disease",
            "Context_Error 204 211--*--disease",
            "Measurement 215 219--*--BCLC",
            "Value 220 227--*--Stage B",
            "Qualifier 240 272--*--amenable to locoregional therapy",
            "Qualifier 276 310--*--refractory to locoregional therapy",
            "Qualifier 319 360--*--amenable to a curative treatment approach",
            "Negation 236 239--*--not",
            "Negation 315 318--*--not",
            "Scope 240 310--*--amenable to locoregional therapy or refractory to locoregional therapy",
            "Condition 228 235--*--disease",
            "Context_Error 228 235--*--disease",
            "Measurement 368 378;381 392--*--Child-Pugh liver score",
            "Value 379 380--*--A",
            "Temporal 393 412--*--within 7 days prior",
            "Reference_point 416 446--*--first dose of study medication",
            "Observation 454 469--*--life expectancy",
            "Value 473 482--*-->3 months",
            "Multiplier 488 500--*--at least one",
            "Condition 512 518--*--lesion",
            "Measurement 528 546--*--RECIST version 1.1",
            "Value 501 511--*--measurable",
            "Measurement 582 642--*--Eastern Cooperative Oncology Group (ECOG) performance status",
            "Value 646 652--*--0 or 1",
            "Temporal 663 682--*--within 7 days prior",
            "Reference_point 686 730--*--receiving the first dose of study medication",
            "Procedure 757 769--*--radiographic",
            "Observation 747 756;770 781--*--objective progression",
            "Temporal 782 797--*--during or after",
            "Reference_point 798 856--*--treatment with sorafenib or oxaliplatin-based chemotherapy",
            "Drug 813 822--*--sorafenib",
            "Drug 826 837--*--oxaliplatin",
            "Qualifier 813 843--*--sorafenib or oxaliplatin-based",
            "Procedure 844 856--*--chemotherapy",
            "Condition 866 877--*--intolerance",
            "Drug 881 890--*--sorafenib",
            "Drug 894 905--*--oxaliplatin",
            "Qualifier 881 911--*--sorafenib or oxaliplatin-based",
            "Procedure 912 924--*--chemotherapy",
            "Person 926 932--*--Female",
            "Condition 949 971--*--childbearing potential",
            "Scope 926 971--*--Female participants of childbearing potential",
            "Measurement 1008 1022;993 998--*--pregnancy test urine",
            "Measurement 1002 1022--*--serum pregnancy test",
            "Temporal 1023 1044--*--within 72 hours prior",
            "Scope 993 1022--*--urine or serum pregnancy test",
            "Value 984 992--*--negative",
            "Reference_point 1048 1089--*--receiving the first dose of study therapy",
            "Procedure 1164 1186--*--adequate contraception",
            "Person 1102 1106--*--male",
            "Person 1091 1097--*--Female",
            "Grammar_Error 1098 1101--*--and",
            "Condition 1123 1145--*--reproductive potential",
            "Scope 1091 1145--*--Female and male participants of reproductive potential",
            "Non-query-able 1091 1328--*--Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication",
            "Post-eligibility 926 1089--*--Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy",
            "Post-eligibility 1091 1328--*--Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication"
        ],
        "Text": "Has a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) . Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach . Has a Child-Pugh A liver score within 7 days prior to first dose of study medication . Has a life expectancy of >3 months . Has at least one measurable lesion based on RECIST version 1.1 as determined by investigator . Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 7 days prior to receiving the first dose of study medication . Has documented objective radiographic progression during or after treatment with sorafenib or oxaliplatin-based chemotherapy, or else intolerance to sorafenib or oxaliplatin-based chemotherapy . Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy . Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication . "
    },
    "NCT03199560_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Value 6 20--*--above 18 years",
            "Person 24 27--*--age",
            "Condition 72 85--*--breast cancer",
            "Qualifier 59 66--*--stage 1",
            "Qualifier 59 64;70 71--*--stage 2",
            "Procedure 33 39--*--biopsy",
            "Scope 59 71--*--stage 1 or 2",
            "Procedure 109 127--*--partial mastectomy",
            "Procedure 133 138--*--SLNBx",
            "Visit 139 157--*--at Memorial Health",
            "Mood 90 108--*--will be undergoing"
        ],
        "Text": "Women above 18 years of age with biopsy proven, clinically stage 1 or 2 breast cancer who will be undergoing partial mastectomy with SLNBx at Memorial Health. "
    },
    "NCT02894372_inc": {
        "Annotations": [
            "Procedure 15 31--*--throat surgeries",
            "Procedure 33 46--*--tonsillectomy",
            "Procedure 48 66--*--adenotonsillectomy",
            "Procedure 68 85--*--uvulopalatoplasty",
            "Procedure 87 112--*--uvulopalatopharyngoplasty",
            "Scope 33 112--*--tonsillectomy, adenotonsillectomy, uvulopalatoplasty, uvulopalatopharyngoplasty",
            "Condition 128 149--*--acute throat diseases",
            "Undefined_semantics 128 149--*--acute throat diseases",
            "Condition 151 162--*--pharyngitis",
            "Condition 164 175--*--tonsillitis",
            "Condition 177 196--*--pharyngotonsillitis",
            "Scope 151 196--*--pharyngitis, tonsillitis, pharyngotonsillitis"
        ],
        "Text": "Patients after throat surgeries: tonsillectomy, adenotonsillectomy, uvulopalatoplasty, uvulopalatopharyngoplasty . Patients with acute throat diseases: pharyngitis, tonsillitis, pharyngotonsillitis . "
    },
    "NCT02590822_inc": {
        "Annotations": [
            "Informed_consent 0 72--*--Capacity to provide informed consent before any trial-related activities",
            "Condition 86 90--*--T2DM",
            "Temporal 92 100--*--=3months",
            "Measurement 103 108--*--HbA1c",
            "Measurement 0 110--*--Capacity to provide informed consent before any trial-related activities",
            "Value 109 113--*--= 9%",
            "Value 138 143--*--= 10%",
            "Scope 109 143--*--= 9% if on triple therapy or = 10%",
            "Procedure 203 227--*--glucose lowering therapy",
            "Drug 278 287--*--metformin",
            "Drug 289 302--*--sulphonylurea",
            "Drug 304 321--*--DPP-IV inhibitor,",
            "Drug 322 335--*--GLP-1 therapy",
            "Drug 342 347--*--SGLT2",
            "Observation 352 356--*--diet",
            "Observation 361 369--*--exercise",
            "Scope 278 369--*--metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise",
            "Condition 402 410--*--diabetes",
            "Measurement 417 422--*--HbA1c",
            "Value 423 429--*--> 6.5%",
            "Negation 432 435--*--not",
            "Procedure 457 481--*--glucose lowering therapy",
            "Measurement 513 528--*--Body mass index",
            "Value 529 538--*--> 30Kg/m2",
            "Value 542 554--*--> 27.5 Kg/m2",
            "Scope 529 554--*--> 30Kg/m2 or > 27.5 Kg/m2",
            "Condition 584 588--*--T2DM",
            "Person 600 603--*--age",
            "Value 589 595;607 622--*--before 60 years of age",
            "Person 624 627--*--Age",
            "Value 628 646--*--=18 and = 65 years"
        ],
        "Text": "Capacity to provide informed consent before any trial-related activities. Established T2DM (=3months). HbA1c = 9% if on triple therapy or = 10% on diet & exercise or monotherapy or dual therapy. Current glucose lowering therapy either mono, dual or triple of any combination of metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise. Poorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range). Body mass index > 30Kg/m2 or > 27.5 Kg/m2 (South Asian),. Diagnosis of T2DM before the age of 60 years of age. Age =18 and = 65 years. "
    },
    "NCT03479502_inc": {
        "Annotations": [
            "Value 0 8;16 25--*--18 years and older",
            "Person 12 15--*--age",
            "Qualifier 41 49--*--stage II",
            "Condition 50 69--*--adhesive capsulitis",
            "Qualifier 70 107--*--as determined by clinical examination",
            "Procedure 87 107--*--clinical examination",
            "Negation 140 150--*--absence of",
            "Condition 151 168--*--abnormal findings",
            "Procedure 172 177--*--X-ray"
        ],
        "Text": "18 years of age and older,. diagnosis of stage II adhesive capsulitis as determined by clinical examination of the treating physician, and. absence of abnormal findings on X-ray.. "
    },
    "NCT02964715_inc": {
        "Text": "biopsy proven NASH. Type 2 DM. HbA1c :>6.5%. BMI < 45kg/m2. Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists). ",
        "Annotations": [
            "Condition 14 18--*--NASH",
            "Procedure 0 6--*--biopsy",
            "Condition 20 29--*--Type 2 DM",
            "Measurement 31 36--*--HbA1c",
            "Value 38 43--*-->6.5%",
            "Measurement 45 48--*--BMI",
            "Value 49 58--*--< 45kg/m2",
            "Drug 64 83--*--anti-diabetic agent",
            "Negation 84 90--*--except",
            "Drug 91 107--*--SGLT2 inhibitors",
            "Drug 109 113--*--TZDs",
            "Drug 114 132--*--thiazolidinediones",
            "Drug 135 139;163 173--*--DPP4 inhibitors",
            "Drug 140 161;163 173--*--Dipeptidyl peptidase4 inhibitors",
            "Drug 178 186--*--GLP1 RAs",
            "Drug 187 228--*--Glucagon-like Peptide 1-Receptor Agonists",
            "Scope 91 228--*--SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists"
        ]
    },
    "NCT02298504_inc": {
        "Text": "Pediatric patients with deep dental decay in primary molars. Teeth with signs and symptoms of reversible pulpitis. ",
        "Annotations": [
            "Person 0 9--*--Pediatric",
            "Condition 24 41--*--deep dental decay",
            "Qualifier 45 59--*--primary molars",
            "Qualifier 61 66--*--Teeth",
            "Condition 94 113--*--reversible pulpitis"
        ]
    },
    "NCT02441179_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 42 44--*--2.",
            "Parsing_Error 99 101--*--3.",
            "Parsing_Error 144 146--*--4.",
            "Parsing_Error 167 169--*--5.",
            "Parsing_Error 196 198--*--6.",
            "Condition 3 22--*--Orthopedic injuries",
            "Qualifier 32 40--*--unstable",
            "Condition 45 57--*--Osteoporosis",
            "Qualifier 63 97--*--high risk of pathological fracture",
            "Subjective_judgement 63 97--*--high risk of pathological fracture",
            "Undefined_semantics 63 97--*--high risk of pathological fracture",
            "Non-query-able 63 97--*--high risk of pathological fracture",
            "Condition 102 119--*--Cutaneous lesions",
            "Condition 127 142--*--pressure ulcers",
            "Condition 147 165--*--Joint contractures",
            "Condition 170 194--*--Cardiopulmonary diseases",
            "Measurement 199 210--*--Body weight",
            "Value 211 227--*--exceeding 150 Kg"
        ],
        "Text": "1. Orthopedic injuries that are unstable . 2. Osteoporosis with high risk of pathological fracture . 3. Cutaneous lesions and/or pressure ulcers . 4. Joint contractures . 5. Cardiopulmonary diseases . 6. Body weight exceeding 150 Kg       .     . "
    },
    "NCT02425774_inc": {
        "Text": "patients undergoing partial or full resection of the pancreas due to a benign or malignant tumor. ",
        "Annotations": [
            "Procedure 31 61--*--full resection of the pancreas",
            "Procedure 20 27;36 61--*--partial resection of the pancreas",
            "Condition 81 96--*--malignant tumor",
            "Condition 71 77;91 96--*--benign tumor",
            "Scope 71 96--*--benign or malignant tumor",
            "Scope 20 61--*--partial or full resection of the pancreas"
        ]
    },
    "NCT03120728_inc": {
        "Text": "Healthy, women ages 18 to 39yo with BMI <30. Regular menstrual cycles with duration between 24-35 days. Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater). Not seeking pregnancy during the study period. Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence. Must speak English or Spanish. ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 9 14--*--women",
            "Person 15 19--*--ages",
            "Value 20 30--*--18 to 39yo",
            "Measurement 36 39--*--BMI",
            "Value 40 43--*--<30",
            "Condition 45 69--*--Regular menstrual cycles",
            "Value 84 102--*--between 24-35 days",
            "Measurement 75 83--*--duration",
            "Measurement 187 205--*--progesterone level",
            "Value 215 232--*--5ng/mL or greater",
            "Pregnancy_considerations 235 280--*--Not seeking pregnancy during the study period",
            "Procedure 291 325--*--non-hormonal form of contraception",
            "Procedure 336 349--*--sterilization",
            "Procedure 351 365--*--tubal ligation",
            "Procedure 367 373--*--Essure",
            "Scope 351 373--*--tubal ligation, Essure",
            "Procedure 376 386--*--copper IUD",
            "Procedure 388 407--*--intrauterine device",
            "Procedure 410 425--*--barrier methods",
            "Observation 429 439--*--abstinence",
            "Scope 336 439--*--sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence",
            "Non-query-able 441 470--*--Must speak English or Spanish"
        ]
    },
    "NCT03124329_exc": {
        "Text": "Molar teeth . Milller Class 4 recession defects . Pregnancy (Self-reported) . Smoking . Uncontrolled local or systemic diseases that affects wound healing (diabetes, autoimmune or inflammatory disorders) . Past history of systemic steroid use over 2 weeks within the last 2 years . Poor oral hygiene on a non-compliant individual . Ibuprofen Allergy/interlerance . Anticoagulant therapy (e.g. Warfarin, Plavix, etc.), will not be automatic exclusion but patients will be required to have INR test performed and have values between 2.0 to 3. Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery. . Objection to blood draw or application of blood products . Students and staff from USC Ostrow school of Dentistry will not be recruited for this study       .     . ",
        "Annotations": [
            "Condition 0 11--*--Molar teeth",
            "Measurement 13 20--*--Milller",
            "Value 21 28--*--Class 4",
            "Condition 29 46--*--recession defects",
            "Condition 48 57--*--Pregnancy",
            "Non-query-able 59 72--*--Self-reported",
            "Condition 75 82--*--Smoking",
            "Condition 115 123;97 102--*--diseases local",
            "Condition 106 123--*--systemic diseases",
            "Qualifier 84 96--*--Uncontrolled",
            "Scope 97 123--*--local or systemic diseases",
            "Qualifier 124 150--*--that affects wound healing",
            "Condition 152 160--*--diabetes",
            "Condition 162 172;189 198--*--autoimmune disorders",
            "Condition 176 198--*--inflammatory disorders",
            "Scope 152 198--*--diabetes, autoimmune or inflammatory disorders",
            "Scope 84 150--*--Uncontrolled local or systemic diseases that affects wound healing",
            "Observation 201 213--*--Past history",
            "Drug 217 233--*--systemic steroid",
            "Temporal 238 250--*--over 2 weeks",
            "Temporal 251 274--*--within the last 2 years",
            "Condition 276 293--*--Poor oral hygiene",
            "Observation 299 312--*--non-compliant",
            "Non-query-able 299 312--*--non-compliant",
            "Drug 325 334--*--Ibuprofen",
            "Condition 335 342--*--Allergy",
            "Condition 343 355--*--interlerance",
            "Procedure 357 378--*--Anticoagulant therapy",
            "Drug 385 393--*--Warfarin",
            "Drug 395 401--*--Plavix",
            "Scope 385 401--*--Warfarin, Plavix",
            "Grammar_Error 410 441--*--will not be automatic exclusion",
            "Measurement 480 488--*--INR test",
            "Value 515 531--*--between 2.0 to 3",
            "Procedure 595 616--*--anticoagulant therapy",
            "Not_a_criteria 533 665--*--Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery.",
            "Non-query-able 533 665--*--Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery.",
            "Non-query-able 667 723--*--Objection to blood draw or application of blood products",
            "Non-query-able 725 816--*--Students and staff from USC Ostrow school of Dentistry will not be recruited for this study"
        ]
    },
    "NCT02425774_exc": {
        "Text": "adjuvant radiotherapy. evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory results, including an abscess or cholecystitis). chronic pancreatitis. pancreatic polypeptide producing endocrine tumor. American Society of Anesthesiologists physical-health status classification (ASA-PS)>3. Poorly regulated diabetes (>200 mg/dl (=11 mmol/l)). ",
        "Annotations": [
            "Procedure 0 21--*--adjuvant radiotherapy",
            "Condition 31 59--*--intra-abdominal inflammation",
            "Procedure 74 81--*--imaging",
            "Procedure 89 99--*--laboratory",
            "Condition 122 129--*--abscess",
            "Condition 133 146--*--cholecystitis",
            "Scope 74 99--*--imaging and/or laboratory",
            "Scope 31 59;61 99--*--intra-abdominal inflammation diagnosed by imaging and/or laboratory",
            "Scope 122 146--*--abscess or cholecystitis",
            "Condition 149 170--*--chronic pancreatitis",
            "Multiplier 149 156--*--chronic",
            "Condition 157 169--*--pancreatitis",
            "Condition 171 219--*--pancreatic polypeptide producing endocrine tumor",
            "Measurement 221 305--*--American Society of Anesthesiologists physical-health status classification (ASA-PS)",
            "Value 305 307--*-->3",
            "Qualifier 309 325--*--Poorly regulated",
            "Condition 326 334--*--diabetes",
            "Qualifier 336 359--*-->200 mg/dl (=11 mmol/l)"
        ]
    },
    "NCT03120728_exc": {
        "Text": "Currently pregnant or breastfeeding. Severe pelvic organ prolapse or prolapse to any degree that may prevent retention of the vaginal ring after insertion. Use of oral contraceptive pills, patches, implants or hormonal intrauterine contraception in the month prior to screening. Use of depo medroxyprogesterone within 6 months of screening. Use of medications that interact with contraceptive steroid hormones: anti-epileptic medications, rifampin, rifabutin, fosamprenavir, etc. Medical condition with safety deemed to be category 3 or 4 when using a combined hormonal contraceptive, as determined by the Center for Disease Control Medical Eligibility Criteria: current or past history of breast cancer, severe decompensated cirrhosis, history of deep vein thrombosis or pulmonary embolus, diabetes with nephropathy/retinopathy/neuropathy or other vascular disease diagnosed more than 20 years ago, current symptomatic gallbladder disease, hypertension, ischemic heart disease, known thrombogenic mutations, hepatocellular adenoma, malignant hepatoma, multiple risk factors for atherosclerotic cardiovascular disease, multiple sclerosis with prolonged immobility, history of peripartum cardiomyopathy, cigarette smoking and =35yo, history of complicated solid organ transplant, history of stroke, history of superficial venous thrombosis not associated with catheter, systemic lupus erythematosus with positive antiphospholipid antibodies, valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis, and acute viral hepatitis. ",
        "Annotations": [
            "Condition 10 18--*--pregnant",
            "Temporal 0 9--*--Currently",
            "Observation 22 35--*--breastfeeding",
            "Qualifier 37 43--*--Severe",
            "Condition 44 65--*--pelvic organ prolapse",
            "Condition 69 77--*--prolapse",
            "Qualifier 97 154--*--may prevent retention of the vaginal ring after insertion",
            "Scope 44 77--*--pelvic organ prolapse or prolapse",
            "Drug 163 187--*--oral contraceptive pills",
            "Device 189 196--*--patches",
            "Device 198 206--*--implants",
            "Procedure 210 245--*--hormonal intrauterine contraception",
            "Temporal 246 277--*--in the month prior to screening",
            "Reference_point 268 277--*--screening",
            "Scope 163 245--*--oral contraceptive pills, patches, implants or hormonal intrauterine contraception",
            "Drug 286 310--*--depo medroxyprogesterone",
            "Temporal 311 339--*--within 6 months of screening",
            "Drug 348 359--*--medications",
            "Observation 365 378--*--interact with",
            "Drug 379 409--*--contraceptive steroid hormones",
            "Drug 411 437--*--anti-epileptic medications",
            "Drug 439 447--*--rifampin",
            "Drug 449 458--*--rifabutin",
            "Drug 460 473--*--fosamprenavir",
            "Scope 411 473--*--anti-epileptic medications, rifampin, rifabutin, fosamprenavir",
            "Scope 348 409--*--medications that interact with contraceptive steroid hormones",
            "Temporal 663 670--*--current",
            "Temporal 674 678--*--past",
            "Observation 679 686--*--history",
            "Condition 690 703--*--breast cancer",
            "Scope 663 678--*--current or past",
            "Qualifier 705 711--*--severe",
            "Qualifier 712 725--*--decompensated",
            "Condition 726 735--*--cirrhosis",
            "Observation 737 744--*--history",
            "Condition 748 768--*--deep vein thrombosis",
            "Condition 772 789--*--pulmonary embolus",
            "Condition 791 799--*--diabetes",
            "Condition 805 816--*--nephropathy",
            "Condition 817 828--*--retinopathy",
            "Condition 829 839--*--neuropathy",
            "Qualifier 843 848--*--other",
            "Condition 849 865--*--vascular disease",
            "Temporal 876 898--*--more than 20 years ago",
            "Scope 805 865--*--nephropathy/retinopathy/neuropathy or other vascular disease",
            "Temporal 900 907--*--current",
            "Qualifier 908 919--*--symptomatic",
            "Condition 920 939--*--gallbladder disease",
            "Condition 941 953--*--hypertension",
            "Condition 955 977--*--ischemic heart disease",
            "Condition 985 1007--*--thrombogenic mutations",
            "Condition 1009 1031--*--hepatocellular adenoma",
            "Condition 1033 1051--*--malignant hepatoma",
            "Drug 552 583--*--combined hormonal contraceptive",
            "Multiplier 1053 1061--*--multiple",
            "Mood 1062 1074--*--risk factors",
            "Condition 1079 1117--*--atherosclerotic cardiovascular disease",
            "Condition 1119 1137--*--multiple sclerosis",
            "Condition 1143 1163--*--prolonged immobility",
            "Observation 1165 1172--*--history",
            "Condition 1176 1201--*--peripartum cardiomyopathy",
            "Observation 1203 1220--*--cigarette smoking",
            "Value 1225 1230--*--=35yo",
            "Person 1228 1230--*--yo",
            "Scope 1203 1230--*--cigarette smoking and =35yo",
            "Procedure 1243 1277--*--complicated solid organ transplant",
            "Observation 1232 1239--*--history",
            "Observation 1279 1286--*--history",
            "Condition 1290 1296--*--stroke",
            "Observation 1298 1305--*--history",
            "Condition 1309 1338--*--superficial venous thrombosis",
            "Qualifier 1339 1353--*--not associated",
            "Device 1359 1367--*--catheter",
            "Condition 1369 1397--*--systemic lupus erythematosus",
            "Value 1403 1411--*--positive",
            "Measurement 1412 1439--*--antiphospholipid antibodies",
            "Condition 1441 1463--*--valvular heart disease",
            "Condition 1479 1501--*--pulmonary hypertension",
            "Condition 1505 1524--*--atrial fibrillation",
            "Condition 1528 1550--*--bacterial endocarditis",
            "Condition 1556 1577--*--acute viral hepatitis",
            "Scope 1441 1550--*--valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis",
            "Scope 920 977--*--gallbladder disease, hypertension, ischemic heart disease",
            "Condition 480 497--*--Medical condition",
            "Value 532 538--*--3 or 4",
            "Measurement 606 661--*--Center for Disease Control Medical Eligibility Criteria",
            "Measurement 503 509;523 531--*--safety category",
            "Scope 663 1577--*--current or past history of breast cancer, severe decompensated cirrhosis, history of deep vein thrombosis or pulmonary embolus, diabetes with nephropathy/retinopathy/neuropathy or other vascular disease diagnosed more than 20 years ago, current symptomatic gallbladder disease, hypertension, ischemic heart disease, known thrombogenic mutations, hepatocellular adenoma, malignant hepatoma, multiple risk factors for atherosclerotic cardiovascular disease, multiple sclerosis with prolonged immobility, history of peripartum cardiomyopathy, cigarette smoking and =35yo, history of complicated solid organ transplant, history of stroke, history of superficial venous thrombosis not associated with catheter, systemic lupus erythematosus with positive antiphospholipid antibodies, valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis, and acute viral hepatitis",
            "Scope 480 661--*--Medical condition with safety deemed to be category 3 or 4 when using a combined hormonal contraceptive, as determined by the Center for Disease Control Medical Eligibility Criteria",
            "Scope 10 35--*--pregnant or breastfeeding"
        ]
    },
    "NCT03124329_inc": {
        "Text": "Male and female individuals between ages of 18 to 70 years old . Multiple contiguous gingival recession defects on a minimum of two adjacent teeth, exhibiting 3mm or more recession on at least one of those teeth . No prior surgical treatment in the sites planned for therapy . Minimum of 2 mm of keratinized gingiva . Absence of cervical restorations extending to the CEJ . Miller class 1, 2 and 3 recession defects will be included . Availability to undergo treatment and return for follow up visits at specified post-operative intervals . ",
        "Annotations": [
            "Person 36 40--*--ages",
            "Value 28 35;44 62--*--between 18 to 70 years old",
            "Condition 84 110--*--gingival recession defects",
            "Multiplier 64 72--*--Multiple",
            "Multiplier 116 130--*--minimum of two",
            "Value 158 169--*--3mm or more",
            "Measurement 170 179--*--recession",
            "Multiplier 183 195--*--at least one",
            "Procedure 221 239--*--surgical treatment",
            "Negation 212 214--*--No",
            "Non-query-able 212 272--*--No prior surgical treatment in the sites planned for therapy",
            "Value 274 289--*--Minimum of 2 mm",
            "Measurement 293 312--*--keratinized gingiva",
            "Observation 325 367--*--cervical restorations extending to the CEJ",
            "Negation 314 321--*--Absence",
            "Measurement 369 375--*--Miller",
            "Condition 393 410--*--recession defects",
            "Value 376 392--*--class 1, 2 and 3",
            "Non-query-able 429 532--*--Availability to undergo treatment and return for follow up visits at specified post-operative intervals"
        ]
    },
    "NCT03620526_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT02901106_inc": {
        "Text": "patient 18 years old and more. with multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP). for which treatment with dimethyl-fumarate has been prescribed. followed at the Rothschild Foundation in the Neurology Department. having given written consent to participation in the study. ",
        "Annotations": [
            "Person 17 20--*--old",
            "Value 21 29;8 16--*--and more 18 years",
            "Condition 36 54--*--multiple sclerosis",
            "Measurement 72 99--*--criteria of Mac Donald 2010",
            "Qualifier 102 121--*--relapsing-remitting",
            "Qualifier 123 125--*--RR",
            "Qualifier 128 149--*--secondary-progressive",
            "Qualifier 151 153--*--SP",
            "Qualifier 158 177--*--primary-progressive",
            "Qualifier 179 181--*--PP",
            "Scope 102 182--*--relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)",
            "Drug 209 226--*--dimethyl-fumarate",
            "Visit 264 313--*--Rothschild Foundation in the Neurology Department",
            "Informed_consent 315 373--*--having given written consent to participation in the study"
        ]
    },
    "NCT03631355_exc": {
        "Text": "Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.). Younger than 18 years of age. Any patient considered a vulnerable subject. Have bleeding or clotting disorder. Preoperative anticoagulation therapy. Abnormal coagulation profile. Renal disorder or insufficiency. Sickle cell disease. ",
        "Annotations": [
            "Observation 0 19--*--Legally incompetent",
            "Condition 23 40--*--mentally impaired",
            "Person 48 54--*--minors",
            "Condition 56 67--*--Alzheimer's",
            "Condition 78 86--*--dementia",
            "Scope 48 86--*--minors, Alzheimer's subjects, dementia",
            "Scope 0 40--*--Legally incompetent or mentally impaired",
            "Value 95 116--*--Younger than 18 years",
            "Person 120 123--*--age",
            "Observation 150 168--*--vulnerable subject",
            "Condition 175 183;196 204--*--bleeding disorder",
            "Condition 187 204--*--clotting disorder",
            "Temporal 206 218--*--Preoperative",
            "Procedure 219 242--*--anticoagulation therapy",
            "Drug 219 234--*--anticoagulation",
            "Value 244 252--*--Abnormal",
            "Measurement 253 272--*--coagulation profile",
            "Condition 244 272--*--Abnormal coagulation profile",
            "Condition 274 288--*--Renal disorder",
            "Condition 274 279;292 305--*--Renal insufficiency",
            "Condition 307 326--*--Sickle cell disease"
        ]
    },
    "NCT01700790_exc": {
        "Text": "Non-compliance with DOTPlus. Alternatively DOT can be done by telephoning patient on a daily basis 5 times a week and having patient annotate taking drug in a log which would be reviewed by clinic staff. History of being treated for tuberculosis in the prior 2 years unless there is DST, including PCR testing, showing sensitivity to rifamycin.. Known hypersensitivity to rifampin or rifabutin.. Liver enzymes greater than 2 times ULN.. Bilirubin greater than 2 times ULN.. Serum creatinine greater than 3 times ULN.. Hemoglobin less than 7.0 gms even if receiving erythropoietin.. Absolute neutrophil count less than 750 cells/mm3 even if receiving G-CSF.. Fasting triglycerides greater than 400 mg/dL.. Fasting cholesterol > 1.6 upper limits of normal.. GI intolerance of tuberculosis medications requiring discontinuation of tuberculosis medications.. Fasting glucose greater 150 mg/dL.. Pregnant women.. Use of one of the prohibited medications. Any condition that the investigators feel could compromise the use of the current medication.. Have a CD4 cell count of 50 cells/mm3or less. Hepatitis B or C infection. Alcohol or illicit drug use, which in the investigators opinion may affect participation in study.. ",
        "Annotations": [
            "Condition 0 14--*--Non-compliance",
            "Procedure 20 27--*--DOTPlus",
            "Non-query-able 29 202--*--Alternatively DOT can be done by telephoning patient on a daily basis 5 times a week and having patient annotate taking drug in a log which would be reviewed by clinic staff",
            "Procedure 221 228--*--treated",
            "Condition 233 245--*--tuberculosis",
            "Temporal 246 266--*--in the prior 2 years",
            "Procedure 298 309--*--PCR testing",
            "Condition 319 330--*--sensitivity",
            "Drug 334 343--*--rifamycin",
            "Condition 283 286--*--DST",
            "Condition 352 368--*--hypersensitivity",
            "Drug 372 380--*--rifampin",
            "Drug 384 393--*--rifabutin",
            "Scope 372 393--*--rifampin or rifabutin",
            "Measurement 396 409--*--Liver enzymes",
            "Value 410 434--*--greater than 2 times ULN",
            "Measurement 437 446--*--Bilirubin",
            "Value 447 471--*--greater than 2 times ULN",
            "Measurement 474 490--*--Serum creatinine",
            "Value 491 515--*--greater than 3 times ULN",
            "Measurement 518 528--*--Hemoglobin",
            "Value 529 546--*--less than 7.0 gms",
            "Qualifier 547 579--*--even if receiving erythropoietin",
            "Measurement 582 607--*--Absolute neutrophil count",
            "Value 608 631--*--less than 750 cells/mm3",
            "Qualifier 632 655--*--even if receiving G-CSF",
            "Measurement 658 679--*--Fasting triglycerides",
            "Value 680 702--*--greater than 400 mg/dL",
            "Measurement 705 724--*--Fasting cholesterol",
            "Value 725 753--*--> 1.6 upper limits of normal",
            "Condition 756 770--*--GI intolerance",
            "Drug 774 798--*--tuberculosis medications",
            "Drug 828 852--*--tuberculosis medications",
            "Procedure 809 824--*--discontinuation",
            "Measurement 855 870--*--Fasting glucose",
            "Value 871 888--*--greater 150 mg/dL",
            "Condition 891 899--*--Pregnant",
            "Person 900 905--*--women",
            "Post-eligibility 908 948--*--Use of one of the prohibited medications",
            "Post-eligibility 950 1043--*--Any condition that the investigators feel could compromise the use of the current medication.",
            "Measurement 1052 1066--*--CD4 cell count",
            "Value 1070 1089--*--50 cells/mm3or less",
            "Condition 1091 1102--*--Hepatitis B",
            "Condition 1091 1100;1106 1107--*--Hepatitis C",
            "Observation 1119 1126;1143 1146--*--Alcohol use",
            "Observation 1130 1146--*--illicit drug use"
        ]
    },
    "NCT03335436_inc": {
        "Annotations": [
            "Qualifier 0 9--*--singleton",
            "Qualifier 11 15--*--term",
            "Condition 16 25--*--pregnancy",
            "Drug 40 53--*--buprenorphine",
            "Procedure 40 73--*--buprenorphine maintenance therapy",
            "Temporal 27 36--*--currently",
            "Mood 75 88--*--scheduled for",
            "Qualifier 89 97--*--elective",
            "Procedure 98 100--*--CD",
            "Procedure 107 124--*--spinal anesthesia"
        ],
        "Text": "singleton, term pregnancy. currently on buprenorphine maintenance therapy. scheduled for elective CD under spinal anesthesia. "
    },
    "NCT03536520_inc": {
        "Text": "Healthy men and women, age 40-75 yrs, without any disease and need of medication.. Born, raised and currently living at low altitude (<800m).. Written informed consent.. Kyrgyz ethnicity. ",
        "Annotations": [
            "Person 8 11--*--men",
            "Person 16 21--*--women",
            "Person 23 26--*--age",
            "Value 27 35--*--40-75 yr",
            "Qualifier 0 7--*--Healthy",
            "Negation 38 45--*--without",
            "Condition 50 57--*--disease",
            "Qualifier 46 49--*--any",
            "Procedure 70 80--*--medication",
            "Scope 8 22--*--men and women,",
            "Non-query-able 83 140--*--Born, raised and currently living at low altitude (<800m)",
            "Post-eligibility 143 167--*--Written informed consent",
            "Non-query-able 170 186--*--Kyrgyz ethnicity"
        ]
    },
    "NCT00094861_inc": {
        "Text": "Patients with a histologically or cytologically proven diagnosis of NSCLC . Unresectable (locally advanced) stage IIIa or IIIb disease . Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus . Life expectancy greater than or equal to 6 months . Estimated weight loss less than or equal to 10% in the 3 months before study randomization . Measurable disease . 18 years of age or older . Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 . Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization . Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization . Platelet count greater than or equal to 100 x 10^9/L . Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) . Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) . Females of childbearing potential: negative serum or urine pregnancy test . Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product. . Patients with reproductive capability must agree to practice adequate contraception methods. . ",
        "Annotations": [
            "Condition 68 73--*--NSCLC",
            "Qualifier 34 54--*--cytologically proven",
            "Qualifier 16 30;48 54--*--histologically proven",
            "Scope 16 54--*--histologically or cytologically proven",
            "Condition 107 112;121 133--*--stage IIIb disease",
            "Condition 107 117;126 133--*--stage IIIa disease",
            "Qualifier 75 87--*--Unresectable",
            "Qualifier 89 105--*--locally advanced",
            "Scope 107 133--*--stage IIIa or IIIb disease",
            "Qualifier 224 233--*--esophagus",
            "Multiplier 188 200;213 215--*--greater than 30",
            "Multiplier 204 216--*--equal to 30%",
            "Scope 188 216--*--greater than or equal to 30%",
            "Measurement 143 155--*--radiotherapy",
            "Qualifier 135 142--*--Initial",
            "Observation 235 250--*--Life expectancy",
            "Value 267 284--*--equal to 6 months",
            "Value 251 263;276 284--*--greater than 6 months",
            "Scope 251 284--*--greater than or equal to 6 months",
            "Condition 378 396--*--Measurable disease",
            "Temporal 341 376--*--3 months before study randomization",
            "Reference_point 357 376--*--study randomization",
            "Measurement 286 307--*--Estimated weight loss",
            "Value 321 333--*--equal to 10%",
            "Value 308 317;330 333--*--less than 10%",
            "Scope 308 333--*--less than or equal to 10%",
            "Measurement 424 458;466 484--*--Eastern Cooperative Oncology Group performance status",
            "Measurement 460 464--*--ECOG",
            "Value 488 493--*--0 - 2",
            "Measurement 495 505--*--Hemoglobin",
            "Measurement 507 510--*--hgb",
            "Value 528 544--*--equal to 10 g/dL",
            "Value 512 524;537 544--*--greater than 10 g/dL",
            "Scope 512 544--*--greater than or equal to 10 g/dL",
            "Temporal 596 637--*--in the 4 weeks before study randomization",
            "Reference_point 618 637--*--study randomization",
            "Negation 545 552--*--without",
            "Observation 553 574--*--transfusional support",
            "Observation 578 595--*--growth factor use",
            "Scope 553 595--*--transfusional support or growth factor use",
            "Measurement 639 664--*--Absolute neutrophil count",
            "Measurement 666 669--*--ANC",
            "Value 687 708--*--equal to 1.5 x 10^9/L",
            "Value 671 683;696 708--*--greater than 1.5 x 10^9/L",
            "Scope 671 708--*--greater than or equal to 1.5 x 10^9/L",
            "Negation 709 716--*--without",
            "Observation 717 734--*--growth factor use",
            "Temporal 735 776--*--in the 2 weeks before study randomization",
            "Reference_point 757 776--*--study randomization",
            "Measurement 778 792--*--Platelet count",
            "Value 793 805;818 830--*--greater than 100 x 10^9/L",
            "Value 809 830--*--equal to 100 x 10^9/L",
            "Scope 793 830--*--greater than or equal to 100 x 10^9/L",
            "Measurement 832 847--*--Serum bilirubin",
            "Value 861 917--*--equal to 1.5 x institutional upper limit of normal (ULN)",
            "Value 848 857;870 917--*--less than 1.5 x institutional upper limit of normal (ULN)",
            "Scope 848 917--*--less than or equal to 1.5 x institutional upper limit of normal (ULN)",
            "Measurement 919 935--*--Serum creatinine",
            "Value 949 967--*--equal to 2.0 mg/dL",
            "Value 936 945--*--less than",
            "Value 958 967--*--2.0 mg/dL",
            "Scope 937 967--*--ess than or equal to 2.0 mg/dL",
            "Measurement 991 1007--*--serum creatinine",
            "Value 1024 1036;1067 1072--*--equal to 1.4 mg/dL",
            "Value 1008 1020;1033 1036;1067 1072--*--greater than 1.4 mg/dL",
            "Value 1041 1050;1063 1072--*--less than 2.0 mg/dL",
            "Value 1054 1072--*--equal to 2.0 mg/dL",
            "Scope 1008 1072--*--greater than or equal to 1.4 and less than or equal to 2.0 mg/dL",
            "Measurement 1092 1128--*--24-hour urinary creatinine clearance",
            "Value 1145 1163--*--equal to 50 mL/min",
            "Value 1129 1141;1154 1163--*--greater than 50 mL/min",
            "Scope 1129 1163--*--greater than or equal to 50 mL/min",
            "Scope 919 967--*--Serum creatinine less than or equal to 2.0 mg/dL",
            "Scope 991 1163--*--serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min",
            "Person 1166 1173--*--Females",
            "Condition 1177 1199--*--childbearing potential",
            "Measurement 1219 1239--*--urine pregnancy test",
            "Measurement 1210 1215;1225 1239--*--serum pregnancy test",
            "Scope 1210 1239--*--serum or urine pregnancy test",
            "Value 1201 1209--*--negative",
            "Observation 1267 1283--*--informed consent",
            "Temporal 1284 1389--*--before participating in any study-specific procedure, randomization, or receiving investigational product",
            "Reference_point 1291 1389--*--participating in any study-specific procedure, randomization, or receiving investigational product",
            "Qualifier 1312 1326--*--study-specific",
            "Procedure 1327 1336--*--procedure",
            "Procedure 1338 1351--*--randomization",
            "Drug 1366 1389--*--investigational product",
            "Scope 1312 1389--*--study-specific procedure, randomization, or receiving investigational product",
            "Qualifier 1453 1461--*--adequate",
            "Procedure 1462 1483--*--contraception methods",
            "Condition 1406 1429--*--reproductive capability",
            "Value 398 406;414 422--*--18 years or older",
            "Person 410 413--*--age"
        ]
    },
    "NCT02580630_exc": {
        "Annotations": [
            "Non-query-able 0 77--*--Earlier operations in the foot and leg, that is judged to complicate training",
            "Condition 85 94--*--arthritis",
            "Condition 103 111--*--diabetes",
            "Condition 113 128--*--Leg ulcerations",
            "Condition 132 154--*--infections in the foot",
            "Post-eligibility 157 208--*--Judged unable to comply with the training protocol.",
            "Drug 223 235--*--pain killers",
            "Multiplier 210 215--*--Daily",
            "Drug 237 256--*--Glucocorticosteroid",
            "Procedure 257 266--*--injection",
            "Condition 274 298--*--diseased achilles tendon",
            "Temporal 299 323--*--within the last 6 months",
            "Condition 334 352--*--allergic reactions",
            "Drug 356 375--*--glucocorticosteroid",
            "Drug 379 395--*--local anesthetic",
            "Scope 356 395--*--glucocorticosteroid or local anesthetic",
            "Temporal 326 333--*--Earlier",
            "Condition 398 407--*--Pregnancy",
            "Mood 411 429--*--planning to become",
            "Condition 430 438--*--pregnant",
            "Measurement 440 443--*--BMI",
            "Value 444 452--*--above 30"
        ],
        "Text": "Earlier operations in the foot and leg, that is judged to complicate training. known arthritis.. known diabetes. Leg ulcerations or infections in the foot.. Judged unable to comply with the training protocol.. Daily use of pain killers. Glucocorticosteroid injection to the diseased achilles tendon within the last 6 months.. Earlier allergic reactions to glucocorticosteroid or local anesthetic.. Pregnancy or planning to become pregnant. BMI above 30.. "
    },
    "NCT02901106_exc": {
        "Text": "pregnant or breastfeeding woman. patient with a measure of legal protection. subject unaffiliated insurance. ",
        "Annotations": [
            "Pregnancy_considerations 0 31--*--pregnant or breastfeeding woman",
            "Post-eligibility 33 75--*--patient with a measure of legal protection",
            "Non-query-able 77 107--*--subject unaffiliated insurance"
        ]
    },
    "NCT03620526_inc": {
        "Text": "presence of typical HF symptoms and signs. LV ejection fraction = 50. elevated levels of NT-proBNP (at least >125 pg/ml). echocardiographic structural (a left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females) or functional alterations (E/e'=13 and a mean e' septal and lateral wall < 9 cm/s).. ",
        "Annotations": [
            "Condition 20 31--*--HF symptoms",
            "Condition 20 22;36 41--*--HF signs",
            "Qualifier 12 19--*--typical",
            "Scope 20 41--*--HF symptoms and signs",
            "Measurement 43 63--*--LV ejection fraction",
            "Value 64 68--*--= 50",
            "Measurement 89 98--*--NT-proBNP",
            "Qualifier 70 78--*--elevated",
            "Value 100 119--*--at least >125 pg/ml",
            "Measurement 122 150--*--echocardiographic structural",
            "Measurement 154 177--*--left atrial volume inde",
            "Value 179 189--*--> 34 mL/m2",
            "Measurement 195 222--*--left ventricular mass index",
            "Value 223 232--*--=115 g/m2",
            "Person 237 242--*--males",
            "Person 260 267--*--females",
            "Measurement 195 222--*--left ventricular mass index",
            "Value 247 255--*--=95 g/m2",
            "Measurement 272 294--*--functional alterations",
            "Measurement 296 300--*--E/e'",
            "Value 300 303--*--=13",
            "Measurement 310 341--*--mean e' septal and lateral wall",
            "Value 342 350--*--< 9 cm/s",
            "Scope 296 351--*--E/e'=13 and a mean e' septal and lateral wall < 9 cm/s)",
            "Scope 154 267--*--left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females"
        ]
    },
    "NCT01700790_inc": {
        "Text": "Antiretroviral naive. Taking Kaletra containing regimen with suppressed viral load.. Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2 weeks. Taking an NNRTI or integrase containing regimen with prior exposure to PI greater than 2 weeks. It must be clearly stated in the source document that PI was switched to another agent for convenience.. Taking another PI containing regimens with suppressed viral load. It must be clearly stated in source document that if another PI was used for greater than 2 weeks the regimen was switched to another agent for convenience. Subjects with prior history of PI use may be enrolled, if there is a genotype showing no resistance to Kaletra Other Inclusion criteria. Be at least 18 years of age and able to give informed consent.. Diagnosed with TB by criteria per Brazilian Ministry of Health. Have a good clinical response to TB.. Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,. Subjects taking protease inhibitors will be screened and initiate visit 1 within 3 days of starting TB medication. HIV positive with documentation present in source document.. Have a CD4 cell count greater than 50 cells/mm3if not taking ART. Persons with cd4 < 50 may be enrolled, if it is felt that in the best interest of the patient, that enrollment in the study will allow for quicker initiation of antiretroviral therapy than referral to another treatment center.. ",
        "Annotations": [
            "Condition 15 20--*--naive",
            "Drug 0 14--*--Antiretroviral",
            "Drug 29 36--*--Kaletra",
            "Measurement 72 82--*--viral load",
            "Value 61 71--*--suppressed",
            "Drug 95 100--*--NNRTI",
            "Drug 104 113--*--integrase",
            "Negation 133 140--*--without",
            "Temporal 141 146--*--prior",
            "Drug 165 167--*--PI",
            "Value 168 189--*--for more than 2 weeks",
            "Procedure 48 55--*--regimen",
            "Procedure 125 132--*--regimen",
            "Scope 95 113--*--NNRTI or integrase",
            "Drug 201 206--*--NNRTI",
            "Drug 210 219--*--integrase",
            "Procedure 231 238--*--regimen",
            "Scope 201 219--*--NNRTI or integrase",
            "Drug 262 264--*--PI",
            "Temporal 244 249--*--prior",
            "Temporal 265 285--*--greater than 2 weeks",
            "Drug 407 409--*--PI",
            "Procedure 421 429--*--regimens",
            "Measurement 446 456--*--viral load",
            "Value 435 445--*--suppressed",
            "Value 755 772--*--at least 18 years",
            "Person 776 779--*--age",
            "Non-query-able 784 813--*--able to give informed consent",
            "Post-eligibility 784 813--*--able to give informed consent",
            "Condition 831 833--*--TB",
            "Qualifier 837 878--*--criteria per Brazilian Ministry of Health",
            "Condition 887 909--*--good clinical response",
            "Condition 913 915--*--TB",
            "Condition 929 941--*--tuberculosis",
            "Procedure 929 949--*--tuberculosis therapy",
            "Drug 961 969--*--rifampin",
            "Temporal 970 1004--*--for the 2 weeks prior to screening",
            "Reference_point 995 1004--*--screening",
            "Drug 1031 1050--*--protease inhibitors",
            "Negation 1005 1011--*--except",
            "Temporal 1051 1077--*--at time of diagnosis of TB",
            "Reference_point 1054 1077--*--time of diagnosis of TB",
            "Measurement 1196 1199--*--HIV",
            "Value 1200 1208--*--positive",
            "Condition 1196 1208--*--HIV positive",
            "Measurement 1264 1278--*--CD4 cell count",
            "Value 1279 1304--*--greater than 50 cells/mm3",
            "Procedure 1318 1321--*--ART",
            "Negation 1307 1310--*--not",
            "Scope 1307 1321--*--not taking ART"
        ]
    },
    "NCT03631355_inc": {
        "Text": "Patients undergoing a high tibial osteotomy (HTO). Patients undergoing tibial tubercle osteotomy (TTO) with or without medial patello-femoral ligament (MPFL) reconstruction. ",
        "Annotations": [
            "Procedure 22 49--*--high tibial osteotomy (HTO)",
            "Temporal 9 19--*--undergoing",
            "Temporal 60 70--*--undergoing",
            "Procedure 71 102--*--tibial tubercle osteotomy (TTO)",
            "Procedure 119 172--*--medial patello-femoral ligament (MPFL) reconstruction"
        ]
    },
    "NCT03536520_exc": {
        "Text": "Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.. Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol.. Allergy to acetazolamide and other sulfonamides.. ",
        "Annotations": [
            "Condition 11 22;48 55--*--respiratory disease",
            "Condition 24 38;48 55--*--cardiovascular disease",
            "Condition 48 55--*--disease",
            "Qualifier 42 47--*--other",
            "Qualifier 4 10--*--active",
            "Scope 11 55--*--respiratory, cardiovascular or other disease",
            "Procedure 74 83--*--treatment",
            "Qualifier 66 73--*--regular",
            "Condition 116 125--*--tolerance",
            "Condition 129 136--*--hypoxia",
            "Mood 103 115--*--relevant for",
            "Observation 140 157--*--altitude exposure",
            "Scope 129 157--*--hypoxia or altitude exposure",
            "Non-query-able 160 361--*--Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol",
            "Condition 364 371--*--Allergy",
            "Drug 375 388--*--acetazolamide",
            "Drug 399 411--*--sulfonamides",
            "Scope 375 411--*--acetazolamide and other sulfonamides"
        ]
    },
    "NCT03335436_exc": {
        "Annotations": [
            "Drug 4 17--*--illicit drugs",
            "Condition 21 28--*--relapse",
            "Temporal 29 67--*--during the last trimester of pregnancy",
            "Reference_point 36 67--*--the last trimester of pregnancy",
            "Condition 58 67--*--pregnancy",
            "Qualifier 40 54--*--last trimester",
            "Scope 4 28--*--illicit drugs or relapse",
            "Measurement 78 89--*--drug screen",
            "Value 69 77--*--positive",
            "Temporal 90 113--*--at the time of delivery",
            "Reference_point 93 113--*--the time of delivery",
            "Procedure 105 113--*--delivery",
            "Condition 115 124--*--allergies",
            "Drug 132 161--*--medications used in the study",
            "Drug 181 191--*--gabapentin",
            "Qualifier 170 180--*--prescribed",
            "Temporal 192 223--*--at the time of admission for CD",
            "Reference_point 207 223--*--admission for CD",
            "Procedure 207 216--*--admission",
            "Procedure 221 223--*--CD",
            "Condition 225 242--*--contraindications",
            "Procedure 246 266--*--neuraxial anesthesia",
            "Mood 270 277--*--require",
            "Procedure 278 296--*--general anesthesia",
            "Procedure 301 303--*--CD",
            "Measurement 316 335--*--ASA physical status",
            "Value 336 346--*--4 or above"
        ],
        "Text": "use illicit drugs or relapse during the last trimester of pregnancy. positive drug screen at the time of delivery. allergies to any medications used in the study. taking prescribed gabapentin at the time of admission for CD. contraindications to neuraxial anesthesia or require general anesthesia for CD. designated ASA physical status 4 or above. "
    },
    "NCT00094861_exc": {
        "Text": "Metastatic disease (M1)/stage 4 NSCLC . Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized. . Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course . Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding) . Prior chemotherapy, radiotherapy, or surgery for NSCLC . Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized. . Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease [GERD], dyspepsia, etc) . History of pancreatitis . Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment . Previous treatment on this study or with a fibroblast growth factor . Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) . Pregnant or breastfeeding women . Known sensitivity to E. coli derived products . Compromised ability of the patient to give written informed consent and/or to comply with study procedures . Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable . Unwilling or unable to complete the patient reported outcome (PRO) questionnaires . Psychological, social, familial, or geographical reasons that would prevent regular follow-up       .     . ",
        "Annotations": [
            "Condition 0 18;32 37--*--Metastatic disease NSCLC",
            "Condition 19 31--*--(M1)/stage 4",
            "Condition 39 46;62 70--*--Pleural effusion",
            "Condition 50 70--*--pericardial effusion",
            "Value 71 100--*--greater than 100 ml in volume",
            "Measurement 139 167--*--positron emission tomography",
            "Measurement 175 194;200 204--*--computed tomography scan",
            "Measurement 169 172--*--PET",
            "Measurement 196 198--*--CT",
            "Measurement 208 218--*--ultrasound",
            "Scope 139 218--*--positron emission tomography [PET], computed tomography [CT] scan or ultrasound",
            "Non-query-able 39 744--*--Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.",
            "Temporal 782 838--*--before completing the protocol chemo/radiotherapy course",
            "Observation 746 781--*--Plan to remove the tumor surgically",
            "Qualifier 869 878--*--esophagus",
            "Multiplier 853 864--*--any part of",
            "Procedure 886 898--*--radiotherapy",
            "Procedure 840 849--*--Shielding",
            "Procedure 910 941--*--posterior spinal cord shielding",
            "Drug 950 962--*--chemotherapy",
            "Procedure 964 976--*--radiotherapy",
            "Procedure 981 988--*--surgery",
            "Condition 993 998--*--NSCLC",
            "Temporal 944 949--*--Prior",
            "Scope 950 988--*--chemotherapy, radiotherapy, or surgery",
            "Condition 1015 1025--*--malignancy",
            "Qualifier 1006 1014--*--invasive",
            "Temporal 1026 1049--*--during the past 3 years",
            "Negation 1050 1060--*--other than",
            "Condition 1061 1089--*--non-melanomatous skin cancer",
            "Negation 1232 1239--*--are not",
            "Condition 1117 1146--*--surgically-cured malignancies",
            "Non-query-able 1259 1321--*--sponsor approval must be obtained before patient is randomized",
            "Condition 1347 1356--*--dysphagia",
            "Condition 1360 1396--*--conditions predisposing to dysphagia",
            "Condition 1415 1446--*--gastroesophageal reflux disease",
            "Qualifier 1402 1414--*--uncontrolled",
            "Condition 1448 1452--*--GERD",
            "Condition 1455 1464--*--dyspepsia",
            "Scope 1402 1464--*--uncontrolled gastroesophageal reflux disease [GERD], dyspepsia",
            "Scope 1347 1396--*--dysphagia or conditions predisposing to dysphagia",
            "Condition 1483 1495--*--pancreatitis",
            "Observation 1472 1482--*--History of",
            "Temporal 1497 1545--*--Four weeks or less since completion of treatment",
            "Reference_point 1522 1545--*--completion of treatment",
            "Procedure 1536 1545--*--treatment",
            "Drug 1555 1578--*--investigational product",
            "Device 1555 1570;1579 1585--*--investigational device",
            "Qualifier 1631 1641--*--unresolved",
            "Condition 1642 1650--*--toxicity",
            "Competing_trial 1589 1611--*--another clinical study",
            "Temporal 1656 1664--*--previous",
            "Procedure 1665 1674--*--treatment",
            "Scope 1555 1585--*--investigational product/device",
            "Observation 1336 1346--*--history of",
            "Temporal 1000 1005--*--Prior",
            "Temporal 1676 1684--*--Previous",
            "Procedure 1685 1694--*--treatment",
            "Drug 1719 1743--*--fibroblast growth factor",
            "Value 1757 1770--*--sero-positive",
            "Measurement 1775 1809--*--human immunodeficiency virus (HIV)",
            "Condition 1757 1809--*--sero-positive for human immunodeficiency virus (HIV)",
            "Condition 1757 1774;1811 1834--*--sero-positive for hepatitis C virus (HCV)",
            "Condition 1757 1774;1839 1862--*--sero-positive for hepatitis B virus (HBV)",
            "Measurement 1811 1834--*--hepatitis C virus (HCV)",
            "Measurement 1839 1862--*--hepatitis B virus (HBV)",
            "Condition 1864 1872--*--Pregnant",
            "Condition 1876 1889--*--breastfeeding",
            "Person 1890 1895--*--women",
            "Condition 1903 1914--*--sensitivity",
            "Qualifier 1918 1933--*--E. coli derived",
            "Drug 1934 1942--*--products",
            "Condition 1944 1963--*--Compromised ability",
            "Informed_consent 1982 2011--*--give written informed consent",
            "Non-representable 2022 2050--*--comply with study procedures",
            "Scope 1982 2050--*--give written informed consent and/or to comply with study procedures",
            "Informed_consent 2063 2092--*--sign an informed consent form",
            "Observation 2052 2062--*--Refusal to",
            "Non-representable 2186 2267--*--Unwilling or unable to complete the patient reported outcome (PRO) questionnaires",
            "Non-query-able 2269 2362--*--Psychological, social, familial, or geographical reasons that would prevent regular follow-up",
            "Informed_consent 2127 2169--*--sign the hospital information release form"
        ]
    },
    "NCT02580630_inc": {
        "Annotations": [
            "Condition 0 17--*--Midsubstance pain",
            "Qualifier 25 40--*--achilles tendon",
            "Condition 42 50--*--Symptoms",
            "Temporal 51 72--*--for at least 3 months",
            "Procedure 74 93--*--Ultrasound scanning",
            "Temporal 94 112--*--at the first visit",
            "Condition 119 151--*--thickness of the achilles tendon",
            "Qualifier 152 162--*--above 7 mm",
            "Qualifier 166 200--*--20% thicker than the contralateral",
            "Scope 152 200--*--above 7 mm or 20% thicker than the contralateral",
            "Non-query-able 203 241--*--Patient can read and understand danish"
        ],
        "Text": "Midsubstance pain in the achilles tendon. Symptoms for at least 3 months. Ultrasound scanning at the first visit shows thickness of the achilles tendon above 7 mm or 20% thicker than the contralateral.. Patient can read and understand danish. "
    },
    "NCT02573168_exc": {
        "Text": "Patients posing a serious suicidal risk and/or violence as judged by the investigator;. Delirium. Dementia. Amnestic and other cognitive disorder;. Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months;. Patients who meet DSM-IV-TR criteria for any significant current substance abuse;. hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;. malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;. significant unstable medical condition or life threatening disease with anticipated survival of less than 6 months;. need for therapies that may obscure the results of treatment and/or of the study. Participation in another clinical trial within 30 days of the screening visit;. Anticipated inability to attend scheduled study visits;. Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;. Patients with a history of prior pharmacogenomic testing;. Any change in psychotropic medication (including change in dosage) between screening and baseline;. Patients who are known to be pregnant or lactating;. Patients with a history of gastric bypass surgery.. ",
        "Annotations": [
            "Observation 26 39--*--suicidal risk",
            "Observation 47 55--*--violence",
            "Condition 88 96--*--Delirium",
            "Condition 98 106--*--Dementia",
            "Condition 127 145--*--cognitive disorder",
            "Condition 108 116;137 145--*--Amnestic disorder",
            "Condition 175 189--*--hypothyroidism",
            "Negation 190 196--*--unless",
            "Drug 221 239--*--thyroid medication",
            "Condition 350 365--*--substance abuse",
            "Measurement 303 312--*--DSM-IV-TR",
            "Condition 368 389--*--hepatic insufficiency",
            "Measurement 439 465--*--aspartate aminotransferase",
            "Measurement 467 470--*--AST",
            "Measurement 479 503--*--alanine aminotransferase",
            "Measurement 505 508--*--ALT",
            "Value 391 428--*--three times the upper limit of normal",
            "Scope 439 509--*--aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)",
            "Procedure 512 528--*--liver transplant",
            "Condition 540 562--*--cirrhosis of the liver",
            "Condition 565 575--*--malignancy",
            "Negation 577 583--*--except",
            "Condition 584 604--*--basal cell carcinoma",
            "Procedure 613 625--*--chemotherapy",
            "Temporal 626 658--*--within 1 year prior to screening",
            "Reference_point 649 658--*--screening",
            "Condition 660 670--*--malignancy",
            "Temporal 671 687--*--more than 1 year",
            "Qualifier 722 727--*--local",
            "Negation 732 739--*--without",
            "Condition 740 750--*--metastasis",
            "Condition 758 768--*--recurrence",
            "Scope 740 768--*--metastasis and/or recurrence",
            "Condition 864 881--*--medical condition",
            "Qualifier 855 863--*--unstable",
            "Condition 885 909--*--life threatening disease",
            "Observation 915 935--*--anticipated survival",
            "Value 939 957--*--less than 6 months",
            "Scope 855 909--*--unstable medical condition or life threatening disease",
            "Non-query-able 960 1040--*--need for therapies that may obscure the results of treatment and/or of the study",
            "Competing_trial 1042 1119--*--Participation in another clinical trial within 30 days of the screening visit",
            "Post-eligibility 1122 1176--*--Anticipated inability to attend scheduled study visits",
            "Non-query-able 1179 1318--*--Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol",
            "Competing_trial 1321 1377--*--Patients with a history of prior pharmacogenomic testing",
            "Procedure 1394 1417--*--psychotropic medication",
            "Pregnancy_considerations 1480 1530--*--Patients who are known to be pregnant or lactating",
            "Procedure 1560 1582--*--gastric bypass surgery"
        ]
    },
    "NCT02946892_inc": {
        "Annotations": [
            "Observation 0 26--*--Informed consent of parent",
            "Observation 0 19;33 47--*--Informed consent of legal guardian",
            "Observation 49 65;76 86--*--informed consent of subject",
            "Observation 49 57;69 86--*--informed assent of subject",
            "Person 103 107--*--Male",
            "Person 111 117--*--female",
            "Person 118 126--*--children",
            "Value 127 134;147 162--*--between 10 and 35 years",
            "Person 139 143--*--ages",
            "Condition 168 192--*--congenital heart disease",
            "Procedure 224 242--*--Fontan circulation",
            "Observation 245 263--*--Ability of perform",
            "Procedure 266 287--*--maximal exercise test",
            "Measurement 304 336--*--respiratory exchange ratio (RER)",
            "Value 337 353--*--greater than 1.0",
            "Qualifier 354 385--*--at the time of maximal exercise",
            "Scope 245 287--*--Ability of perform a maximal exercise test",
            "Scope 304 385--*--respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exercise"
        ],
        "Text": "Informed consent of parent(s) or legal guardian; informed consent or assent of subject as applicable.. Male or female children between the ages of 10 and 35 years with congenital heart disease that has been palliated with a Fontan circulation.. Ability of perform a maximal exercise test as defined by a respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exercise. "
    },
    "NCT02034019_inc": {
        "Text": "Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens . Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes . ",
        "Annotations": [
            "Condition 6 14--*--cataract",
            "Procedure 42 72--*--clear corneal cataract surgery",
            "Qualifier 73 97--*--with phacoemulsification",
            "Qualifier 102 154--*--implantation of a posterior chamber intraocular lens",
            "Measurement 187 215--*--pinhole corrected Snellen VA",
            "Value 219 244--*--at least 20/200 or better",
            "Qualifier 248 257--*--both eyes"
        ]
    },
    "NCT03350659_inc": {
        "Text": "Age >=19 patients who complained of dizziness. Orthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=10. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 8--*-->=19",
            "Condition 36 45--*--dizziness",
            "Condition 47 70--*--Orthostatic hypotension",
            "Qualifier 71 94--*--after 3-minute standing",
            "Measurement 96 124--*--systolic blood pressure drop",
            "Measurement 133 162--*--diastolic blood pressure drop",
            "Value 163 167--*-->=10",
            "Value 125 129--*-->=20",
            "Scope 96 167--*--systolic blood pressure drop >=20 or diastolic blood pressure drop >=10"
        ]
    },
    "NCT02573168_inc": {
        "Text": "18 years of age or older;. Suffer from schizophrenia/schizoaffective disorder meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;. Have a total baseline score on the Brief Psychiatric Rating Scale (BPRS) = 45;. Be capable and willing to provide written informed consent to participate in this study;. Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests. ",
        "Annotations": [
            "Person 12 15--*--age",
            "Value 0 8;16 24--*--18 years or older",
            "Condition 39 52--*--schizophrenia",
            "Condition 53 77--*--schizoaffective disorder",
            "Measurement 86 170--*--Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision",
            "Measurement 172 181--*--DSM-IV-TR",
            "Measurement 229 259--*--Brief Psychiatric Rating Scale",
            "Measurement 261 265--*--BPRS",
            "Value 267 271--*--= 45",
            "Informed_consent 274 361--*--Be capable and willing to provide written informed consent to participate in this study",
            "Post-eligibility 364 502--*--Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests"
        ]
    },
    "NCT02946892_exc": {
        "Annotations": [
            "Drug 11 24--*--beta blockers",
            "Temporal 25 57--*--within 2 months of randomization",
            "Reference_point 44 57--*--randomization",
            "Observation 77 103--*--listed for transplantation",
            "Procedure 88 103--*--transplantation",
            "Temporal 104 135--*--at time of entry into the study",
            "Reference_point 115 135--*--entry into the study",
            "Mood 139 161--*--anticipated to undergo",
            "Procedure 162 183--*--heart transplantation",
            "Procedure 185 215--*--interventional catheterization",
            "Procedure 220 246--*--corrective cardiac surgery",
            "Temporal 247 297--*--during the 7 months following entry into the study",
            "Reference_point 277 297--*--entry into the study",
            "Scope 162 246--*--heart transplantation, interventional catheterization, or corrective cardiac surgery",
            "Qualifier 312 323--*--symptomatic",
            "Qualifier 299 308--*--Sustained",
            "Condition 324 348--*--ventricular dysrhythmias",
            "Qualifier 349 377--*--uncontrolled by drug therapy",
            "Procedure 365 377--*--drug therapy",
            "Drug 365 369--*--drug",
            "Scope 299 323--*--Sustained or symptomatic",
            "Device 395 420--*--implantable defibrillator",
            "Qualifier 349 364;381 420--*--uncontrolled by the use of an implantable defibrillator",
            "Scope 349 420--*--uncontrolled by drug therapy or the use of an implantable defibrillator",
            "Qualifier 429 440--*--significant",
            "Condition 441 467--*--cardiac conduction defects",
            "Condition 475 485;500 508--*--2nd degree AV block",
            "Condition 489 508--*--3rd degree AV block",
            "Condition 513 532--*--sick sinus syndrome",
            "Scope 429 467--*--significant cardiac conduction defects",
            "Scope 475 532--*--2nd degree or 3rd degree AV block, or sick sinus syndrome",
            "Negation 534 540--*--unless",
            "Qualifier 543 554--*--functioning",
            "Device 555 564--*--pacemaker",
            "Qualifier 578 589--*--Uncorrected",
            "Condition 590 601;624 637--*--obstructive valve disease",
            "Qualifier 605 611--*--severe",
            "Condition 612 637--*--regurgitant valve disease",
            "Condition 639 664--*--nondilated cardiomyopathy",
            "Qualifier 669 680--*--significant",
            "Condition 681 721--*--systemic ventricular outflow obstruction",
            "Condition 729 754--*--renovascular hypertension",
            "Condition 770 792--*--pulmonary hypertension",
            "Mood 758 769--*--evidence of",
            "Measurement 794 823--*--pulmonary vascular resistance",
            "Value 824 838--*--> 6 Wood units",
            "Scope 794 838--*--pulmonary vascular resistance > 6 Wood units",
            "Scope 758 792--*--evidence of pulmonary hypertension",
            "Qualifier 840 874--*--unresponsive to vasodilator agents",
            "Drug 856 874--*--vasodilator agents",
            "Drug 883 889--*--oxygen",
            "Drug 891 904--*--nitroprusside",
            "Drug 909 921--*--nitric oxide",
            "Scope 883 921--*--oxygen, nitroprusside, or nitric oxide",
            "Scope 729 839--*--renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units)",
            "Observation 923 930--*--History",
            "Temporal 934 941--*--current",
            "Mood 942 962--*--clinical evidence of",
            "Qualifier 963 981--*--moderate-to-severe",
            "Qualifier 982 987--*--fixed",
            "Condition 988 1017--*--obstructive pulmonary disease",
            "Qualifier 1021 1027--*--severe",
            "Condition 1028 1052--*--reactive airway diseases",
            "Condition 1060 1066--*--asthma",
            "Scope 1028 1067--*--reactive airway diseases (e.g., asthma)",
            "Scope 963 1067--*--moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma)",
            "Scope 923 941--*--History or current",
            "Procedure 1078 1093--*--hospitalization",
            "Mood 1068 1077--*--requiring",
            "Temporal 1094 1117--*--within the past 2 years",
            "Temporal 1129 1138--*--currently",
            "Drug 1145 1178--*--long-term inhaled bronchodilators",
            "Reference_point 1101 1117--*--the past 2 years",
            "Scope 1068 1178--*--requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators",
            "Qualifier 1180 1185--*--Renal",
            "Qualifier 1187 1194--*--hepatic",
            "Qualifier 1196 1212--*--gastrointestinal",
            "Qualifier 1217 1224--*--biliary",
            "Condition 1225 1233--*--disorder",
            "Scope 1180 1224--*--Renal, hepatic, gastrointestinal, or biliary",
            "Condition 1245 1262--*--impair absorption",
            "Condition 1245 1251;1264 1274--*--impair metabolism",
            "Condition 1245 1251;1278 1287--*--impair excretion",
            "Drug 1291 1321--*--orally administered medication",
            "Scope 1245 1287--*--impair absorption, metabolism or excretion",
            "Temporal 1323 1333--*--Concurrent",
            "Condition 1334 1350--*--terminal illness",
            "Condition 1360 1374--*--severe disease",
            "Qualifier 1354 1359--*--other",
            "Qualifier 1382 1388--*--active",
            "Condition 1389 1397--*--neoplasm",
            "Scope 1382 1397--*--active neoplasm",
            "Procedure 1420 1430--*--laboratory",
            "Condition 1408 1439--*--significant laboratory value(s)",
            "Non-representable 1440 1523--*--which, in the opinion of the investigator, could preclude participation or survival",
            "Measurement 1420 1430--*--laboratory",
            "Scope 1334 1439--*--terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s)",
            "Condition 1525 1544--*--Endocrine disorders",
            "Condition 1553 1574--*--primary aldosteronism",
            "Condition 1576 1592--*--pheochromocytoma",
            "Condition 1604 1618--*--hypothyroidism",
            "Condition 1594 1599;1608 1618--*--hyper thyroidism",
            "Qualifier 1620 1637--*--insulin-dependent",
            "Condition 1638 1655--*--diabetes mellitus",
            "Scope 1553 1655--*--primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus",
            "Observation 1657 1670;1684 1696--*--Unwillingness to cooperate",
            "Observation 1674 1696--*--inability to cooperate",
            "Observation 1657 1670;1701 1716;1730 1745--*--Unwillingness for the parents to give consent",
            "Observation 1674 1683;1701 1716;1730 1745--*--inability for the parents to give consent",
            "Observation 1657 1670;1701 1708;1720 1745--*--Unwillingness for the guardians to give consent",
            "Observation 1674 1683;1701 1708;1720 1745--*--inability for the guardians to give consent",
            "Condition 1856 1865--*--Pregnancy",
            "Mood 1869 1877--*--possible",
            "Condition 1878 1887--*--pregnancy",
            "Temporal 1888 1912--*--at time of randomization",
            "Reference_point 1891 1912--*--time of randomization",
            "Person 1917 1923--*--female",
            "Observation 1927 1950--*--child bearing potential",
            "Observation 1959 1968--*--lactating",
            "Scope 1917 1968--*--female of child bearing potential who are lactating",
            "Observation 1973 1988--*--sexually active",
            "Negation 1993 1996--*--not",
            "Qualifier 2004 2012--*--adequate",
            "Observation 2013 2038--*--contraceptive precautions",
            "Device 2046 2065--*--intrauterine device",
            "Drug 2069 2088--*--oral contraceptives",
            "Temporal 2089 2131--*--for 3 months prior to entry into the study",
            "Reference_point 2111 2131--*--entry into the study",
            "Scope 2046 2131--*--intrauterine device or oral contraceptives for 3 months prior to entry into the study",
            "Scope 1993 2038--*--not taking adequate contraceptive precautions",
            "Scope 1973 2132--*--sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)",
            "Drug 2144 2164--*--investigational drug",
            "Temporal 2165 2196--*--within 30 days of randomization",
            "Reference_point 2183 2196--*--randomization",
            "Temporal 2201 2248--*--within 5 half-lives of the investigational drug",
            "Drug 2228 2248--*--investigational drug",
            "Scope 2165 2248--*--within 30 days of randomization, or within 5 half-lives of the investigational drug",
            "Observation 2281 2288--*--History",
            "Condition 2292 2308--*--drug sensitivity",
            "Condition 2312 2329--*--allergic reaction",
            "Drug 2333 2347--*--alpha-blockers",
            "Drug 2351 2364--*--beta-blockers",
            "Scope 2333 2364--*--alpha-blockers or beta-blockers",
            "Scope 2292 2329--*--drug sensitivity or allergic reaction",
            "Temporal 2406 2439--*--within two weeks of randomization",
            "Drug 2441 2455--*--MAO inhibitors",
            "Drug 2457 2481--*--Calcium channel blockers",
            "Drug 2483 2497--*--alpha blockers",
            "Drug 2499 2512--*--beta blockers",
            "Drug 2514 2526--*--disopyramide",
            "Drug 2528 2538--*--flecainide",
            "Drug 2540 2549--*--encainide",
            "Drug 2551 2561--*--moricizine",
            "Drug 2563 2574--*--propafenone",
            "Drug 2576 2583--*--sotalol",
            "Drug 2588 2612--*--beta adrenergic agonists",
            "Scope 2441 2612--*--MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists",
            "Procedure 2614 2632--*--Hospital admission",
            "Condition 2637 2663--*--protein losing enteropathy",
            "Condition 2667 2685--*--plastic bronchitis",
            "Temporal 2686 2718--*--within 3 months of randomization",
            "Scope 2637 2685--*--protein losing enteropathy or plastic bronchitis",
            "Reference_point 2705 2718--*--randomization",
            "Qualifier 2720 2726--*--Active",
            "Qualifier 2734 2741--*--chronic",
            "Condition 2742 2768--*--protein losing enteropathy",
            "Condition 2772 2790--*--plastic bronchitis",
            "Drug 2795 2813--*--inhaled medication",
            "Scope 2742 2848--*--protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis)",
            "Scope 2720 2741--*--Active and/or chronic",
            "Condition 2851 2866--*--Hypoalbuminemia",
            "Measurement 2878 2891--*--serum albumin",
            "Value 2892 2900--*--<2.0g/dL",
            "Condition 2902 2919--*--Renal dysfunction",
            "Measurement 2931 2947--*--serum creatinine",
            "Value 2948 2957--*-->2.0mg/dL",
            "Condition 2959 2978--*--Hepatic dysfunction",
            "Measurement 2990 2999--*--serum AST",
            "Measurement 2990 2995;3007 3010--*--serum ALT",
            "Value 3010 3041--*--> 3 times upper limit of normal",
            "Scope 2990 3010--*--serum AST and/or ALT",
            "Value 3043 3065--*--approximately 120 IU/L",
            "Non-representable 3075 3101--*--will vary depending on age",
            "Scope 2990 3102--*--serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age)",
            "Qualifier 3105 3116--*--Significant",
            "Condition 3117 3123--*--anemia",
            "Condition 3127 3139--*--polycythemia",
            "Measurement 3151 3161--*--hemoglobin",
            "Value 3162 3170--*-->18gm/dL",
            "Measurement 3174 3184--*--hemoglobin",
            "Value 3185 3192--*--<7gm/dL",
            "Scope 3151 3192--*--hemoglobin >18gm/dL or hemoglobin <7gm/dL",
            "Scope 3105 3139--*--Significant anemia or polycythemia",
            "Scope 3117 3139--*--anemia or polycythemia",
            "Value 3194 3211--*--Severely elevated",
            "Measurement 3212 3221--*--serum BNP",
            "Measurement 3233 3236--*--BNP",
            "Value 3236 3245--*-->300pg/ml",
            "Scope 3194 3221--*--Severely elevated serum BNP",
            "Scope 3233 3245--*--BNP>300pg/ml"
        ],
        "Text": "The use of beta blockers within 2 months of randomization. Patients actively listed for transplantation at time of entry into the study or anticipated to undergo heart transplantation, interventional catheterization, or corrective cardiac surgery during the 7 months following entry into the study. Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator, and/or significant cardiac conduction defects, e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning pacemaker is in place. Uncorrected obstructive or severe regurgitant valve disease, nondilated cardiomyopathy, or significant systemic ventricular outflow obstruction. Known renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units) unresponsive to vasodilator agents such as oxygen, nitroprusside, or nitric oxide. History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma) requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators. Renal, hepatic, gastrointestinal, or biliary disorder that could impair absorption, metabolism or excretion of orally administered medication. Concurrent terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s) which, in the opinion of the investigator, could preclude participation or survival. Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus. Unwillingness or inability to cooperate, or for the parents or guardians to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation in the study. Pregnancy or possible pregnancy at time of randomization, or female of child bearing potential who are lactating, or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study). Use of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug (the longer period will apply). History of drug sensitivity or allergic reaction to alpha-blockers or beta-blockers. Use of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists. Hospital admission for protein losing enteropathy or plastic bronchitis within 3 months of randomization. Active and/or chronic protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis).. Hypoalbuminemia defined as serum albumin <2.0g/dL. Renal dysfunction defined as serum creatinine >2.0mg/dL. Hepatic dysfunction defined as serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age),. Significant anemia or polycythemia defined as hemoglobin >18gm/dL or hemoglobin <7gm/dL. Severely elevated serum BNP defined as BNP>300pg/ml. "
    },
    "NCT03350659_exc": {
        "Text": "Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month. Heart failure or Chronic renal failure. Severe supine hypertension (Systolic Blood Pressure >180 or Diastolic Blood Pressure>110mmHg). Pregnant women, breast-feeding. Unable to perform questionnaire. ",
        "Annotations": [
            "Qualifier 0 12--*--Drug-induced",
            "Condition 13 24--*--hypotension",
            "Non-representable 26 109--*--if necessary, evaluate patient after discontinuing the causative drug for one month",
            "Condition 111 124--*--Heart failure",
            "Condition 128 149--*--Chronic renal failure",
            "Condition 158 177--*--supine hypertension",
            "Qualifier 151 157--*--Severe",
            "Measurement 179 202--*--Systolic Blood Pressure",
            "Measurement 211 235--*--Diastolic Blood Pressure",
            "Value 203 207--*-->180",
            "Value 235 243--*-->110mmHg",
            "Scope 179 243--*--Systolic Blood Pressure >180 or Diastolic Blood Pressure>110mmHg",
            "Scope 151 177--*--Severe supine hypertension",
            "Condition 246 254--*--Pregnant",
            "Person 255 260--*--women",
            "Condition 262 276--*--breast-feeding",
            "Observation 278 309--*--Unable to perform questionnaire"
        ]
    },
    "NCT02034019_exc": {
        "Text": "Any intraocular inflammation in the study eye present during the screening slit lamp examination . Score greater than \"0\" on the Ocular Pain Assessment in the study eye at Screening . Any intraocular inflammation in the study eye present during the screening slit lamp examination       .     . ",
        "Annotations": [
            "Value 4 28--*--intraocular inflammation",
            "Temporal 54 96--*--during the screening slit lamp examination",
            "Reference_point 61 96--*--the screening slit lamp examination",
            "Procedure 75 96--*--slit lamp examination",
            "Condition 4 28--*--intraocular inflammation",
            "Measurement 128 150--*--Ocular Pain Assessment",
            "Value 104 120--*--greater than \"0\"",
            "Temporal 168 180--*--at Screening",
            "Condition 186 210--*--intraocular inflammation",
            "Temporal 236 278--*--during the screening slit lamp examination",
            "Reference_point 243 278--*--the screening slit lamp examination",
            "Procedure 257 278--*--slit lamp examination",
            "Value 186 210--*--intraocular inflammation"
        ]
    },
    "tools": {},
    "NCT02958566_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 9 16--*--females",
            "Value 17 36--*--above the age of 18",
            "Person 27 30--*--age",
            "Qualifier 58 70--*--laparoscopic",
            "Qualifier 74 81--*--robotic",
            "Procedure 82 103--*--colorectal resections",
            "Scope 58 81--*--laparoscopic or robotic"
        ],
        "Text": "Males or females above the age of 18. Patients undergoing laparoscopic or robotic colorectal resections. "
    },
    "NCT02885909_inc": {
        "Text": "Type 2 diabetic inpatient. Fasting glucose >140 mg/dl or random glucose >180 mg/dl. ",
        "Annotations": [
            "Condition 0 15--*--Type 2 diabetic",
            "Visit 16 25--*--inpatient",
            "Measurement 27 42--*--Fasting glucose",
            "Value 43 53--*-->140 mg/dl",
            "Measurement 57 71--*--random glucose",
            "Value 72 82--*-->180 mg/dl"
        ]
    },
    "NCT03615508_inc": {
        "Annotations": [
            "Condition 0 17--*--Horner's Syndrome",
            "Drug 40 53--*--alpha blocker",
            "Drug 55 65--*--tamsulosin",
            "Drug 67 76--*--terazosin",
            "Drug 77 86--*--doxazosin",
            "Drug 87 96--*--alfuzosin",
            "Drug 97 106--*--silodosin",
            "Scope 55 106--*--tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin"
        ],
        "Text": "Horner's Syndrome. History of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medication. "
    },
    "NCT02867618_inc": {
        "Text": "Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria). Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are eligible. In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies. Patients with DLBCL and HL will be eligible if there is no available standard therapy. . Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO criteria). Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies. Patients with DLBCL will be eligible if there is no available standard therapy. . Must have received front line chemotherapy. No upper limit for the number of prior therapies . Evaluable Disease in the Phase I, and measurable disease in the Phase II . Age > 18 years . ECOG performance status < 2 . Patients must have adequate organ and marrow function . Adequate Contraception . Ability to understand and the willingness to sign a written informed consent document . ",
        "Annotations": [
            "Procedure 28 42--*--histologically",
            "Value 43 52--*--confirmed",
            "Condition 57 60--*--NHL",
            "Condition 64 66--*--HL",
            "Scope 57 66--*--NHL or HL",
            "Qualifier 53 56--*--R/R",
            "Measurement 79 91--*--WHO criteria",
            "Scope 53 66--*--R/R NHL or HL",
            "Procedure 108 142--*--chronic lymphocytic leukemia (CLL)",
            "Procedure 147 179--*--small lymphocytic lymphoma (SLL)",
            "Grammar_Error 143 146--*--and",
            "Condition 221 224--*--NHL",
            "Condition 236 274--*--diffuse large B cell lymphomas (DLBCL)",
            "Multiplier 294 304--*--at least 2",
            "Negation 225 235--*--other than",
            "Scope 221 274--*--NHL other than diffuse large B cell lymphomas (DLBCL)",
            "Procedure 311 320--*--therapies",
            "Temporal 305 310--*--prior",
            "Context_Error 311 320--*--therapies",
            "Condition 336 341--*--DLBCL",
            "Condition 346 348--*--HL",
            "Grammar_Error 342 345--*--and",
            "Procedure 391 407--*--standard therapy",
            "Undefined_semantics 391 407--*--standard therapy",
            "Negation 378 380--*--no",
            "Scope 336 348--*--DLBCL and HL",
            "Measurement 439 453--*--histologically",
            "Qualifier 464 467--*--R/R",
            "Condition 468 471--*--NHL",
            "Measurement 487 499--*--WHO criteria",
            "Value 454 463--*--confirmed",
            "Condition 516 519--*--NHL",
            "Condition 531 569--*--diffuse large B cell lymphomas (DLBCL)",
            "Negation 520 530--*--other than",
            "Multiplier 589 599--*--at least 2",
            "Temporal 600 605--*--prior",
            "Procedure 606 615--*--therapies",
            "Undefined_semantics 606 615--*--therapies",
            "Context_Error 311 320--*--therapies",
            "Context_Error 606 615--*--therapies",
            "Scope 516 569--*--NHL other than diffuse large B cell lymphomas (DLBCL)",
            "Condition 631 636--*--DLBCL",
            "Procedure 679 695--*--standard therapy",
            "Undefined_semantics 679 695--*--standard therapy",
            "Negation 666 668--*--no",
            "Procedure 728 740--*--chemotherapy",
            "Qualifier 717 727--*--front line",
            "Not_a_criteria 742 790--*--No upper limit for the number of prior therapies",
            "Condition 802 809--*--Disease",
            "Qualifier 792 801--*--Evaluable",
            "Temporal 810 824--*--in the Phase I",
            "Temporal 849 864--*--in the Phase II",
            "Qualifier 830 840--*--measurable",
            "Person 866 869--*--Age",
            "Value 870 880--*--> 18 years",
            "Measurement 882 905--*--ECOG performance status",
            "Value 906 909--*--< 2",
            "Measurement 939 944;956 964--*--organ function",
            "Measurement 949 964--*--marrow function",
            "Value 930 938--*--adequate",
            "Subjective_judgement 930 938--*--adequate",
            "Undefined_semantics 930 938--*--adequate",
            "Procedure 975 988--*--Contraception",
            "Qualifier 966 974--*--Adequate",
            "Undefined_semantics 966 974--*--Adequate",
            "Subjective_judgement 966 974--*--Adequate",
            "Post-eligibility 990 1075--*--Ability to understand and the willingness to sign a written informed consent document",
            "Non-query-able 990 1075--*--Ability to understand and the willingness to sign a written informed consent document"
        ]
    },
    "NCT02344888_inc": {
        "Text": "Infertile lean women with PCOS as defined by the Rotterdam criteria.. CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).. ",
        "Annotations": [
            "Condition 0 9--*--Infertile",
            "Person 15 20--*--women",
            "Condition 26 30--*--PCOS",
            "Qualifier 49 67--*--Rotterdam criteria",
            "Condition 73 83--*--resistance",
            "Drug 70 72--*--CC",
            "Non-query-able 85 217--*--defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles"
        ]
    },
    "NCT00965900_exc": {
        "Text": "Patients with systolic blood pressure <100 mmHg or basal heart rate <60/min. Portal vein thrombosis. Uncontrolled ascites or hepatic encephalopathy. Severe coagulation disorder: prothrombin time <40% (or INR >1.7) or platelet count <30,000/mm3. Medium or large sized gastric or duodenal varices. Coexisting malignancy. Severe cardiovascular disorder, renal failure, peritonitis, sepsis. Severe erosive esophagitis, severe esophageal stricture, active gastric or duodenal ulcer. Contraindication to beta-blocker. Pregnancy. Refusal to give consent to participate in the trial. ",
        "Annotations": [
            "Measurement 14 37--*--systolic blood pressure",
            "Value 38 47--*--<100 mmHg",
            "Measurement 57 67--*--heart rate",
            "Qualifier 51 56--*--basal",
            "Value 68 75--*--<60/min",
            "Condition 77 99--*--Portal vein thrombosis",
            "Condition 114 121--*--ascites",
            "Condition 125 147--*--hepatic encephalopathy",
            "Qualifier 101 113--*--Uncontrolled",
            "Condition 156 176--*--coagulation disorder",
            "Qualifier 149 155--*--Severe",
            "Measurement 178 194--*--prothrombin time",
            "Value 195 199--*--<40%",
            "Measurement 204 207--*--INR",
            "Value 208 212--*-->1.7",
            "Measurement 217 231--*--platelet count",
            "Value 232 243--*--<30,000/mm3",
            "Scope 178 243--*--prothrombin time <40% (or INR >1.7) or platelet count <30,000/mm3",
            "Condition 278 294--*--duodenal varices",
            "Condition 267 274;291 292--*--gastric c",
            "Qualifier 255 260--*--large",
            "Qualifier 245 251--*--Medium",
            "Scope 267 294--*--gastric or duodenal varices",
            "Scope 245 260--*--Medium or large",
            "Condition 307 317--*--malignancy",
            "Qualifier 296 306--*--Coexisting",
            "Condition 326 349--*--cardiovascular disorder",
            "Qualifier 319 325--*--Severe",
            "Condition 351 364--*--renal failure",
            "Condition 366 377--*--peritonitis",
            "Condition 379 385--*--sepsis",
            "Condition 394 413--*--erosive esophagitis",
            "Condition 422 442--*--esophageal stricture",
            "Condition 462 476--*--duodenal ulcer",
            "Condition 451 458;471 476--*--gastric ulcer",
            "Qualifier 444 450--*--active",
            "Qualifier 415 421--*--severe",
            "Qualifier 387 393--*--Severe",
            "Scope 451 476--*--gastric or duodenal ulcer",
            "Condition 478 494--*--Contraindication",
            "Drug 498 510--*--beta-blocker",
            "Condition 512 521--*--Pregnancy",
            "Informed_consent 523 574--*--Refusal to give consent to participate in the trial"
        ]
    },
    "NCT03615508_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02885909_exc": {
        "Text": "incooperative for glucose monitor. refusal of insulin. pregnancy. ",
        "Annotations": [
            "Procedure 18 33--*--glucose monitor",
            "Condition 0 13--*--incooperative",
            "Drug 46 53--*--insulin",
            "Condition 35 42--*--refusal",
            "Condition 55 64--*--pregnancy"
        ]
    },
    "NCT02958566_exc": {
        "Annotations": [
            "Condition 11 23--*--constipation",
            "Drug 45 54--*--narcotics",
            "Drug 58 65--*--opioids",
            "Temporal 25 37--*--Pre-existing",
            "Scope 45 65--*--narcotics or opioids",
            "Condition 89 104--*--hepatic failure",
            "Temporal 67 79--*--Pre-existing",
            "Condition 80 85;97 104--*--renal failure",
            "Scope 80 104--*--renal or hepatic failure",
            "Condition 106 120--*--Mental illness",
            "Condition 122 140--*--mental retardation",
            "Condition 145 189--*--inability to participate in informed consent",
            "Condition 197 210--*--mental status",
            "Condition 225 233--*--dementia",
            "Temporal 212 224--*--Pre-existing",
            "Condition 235 242--*--Allergy",
            "Procedure 281 290--*--operation",
            "Qualifier 271 280--*--Emergency",
            "Non-representable 292 343--*--Subjects who are incarcerated or wards of the state",
            "Person 345 351--*--Minors",
            "Condition 367 393--*--inflammatory bowel disease",
            "Condition 402 409--*--colitis",
            "Temporal 395 401--*--active",
            "Condition 427 455--*--intra-abdominal inflammation",
            "Temporal 414 426--*--pre-existing",
            "Condition 457 471--*--Diverticulitis",
            "Temporal 480 486--*--active",
            "Condition 487 496--*--infection",
            "Condition 497 509--*--inflammation",
            "Negation 515 530--*--not be excluded",
            "Scope 487 509--*--infection/inflammation",
            "Negation 472 479--*--without"
        ],
        "Text": "History of constipation. Pre-existing use of narcotics or opioids. Pre-existing renal or hepatic failure. Mental illness, mental retardation, or inability to participate in informed consent due to mental status. Pre-existing dementia. Allergy to any protocol medication. Emergency operation. Subjects who are incarcerated or wards of the state. Minors. Subjects with inflammatory bowel disease, active colitis, or pre-existing intra-abdominal inflammation. Diverticulitis without active infection/inflammation will not be excluded.. "
    },
    "NCT00965900_inc": {
        "Text": "Liver cirrhosis. Age between 18 and 70 years. Esophageal varices with high bleeding risk: more than F2 and red color sign. No previous history of upper gastrointestinal bleeding. No previous history of endoscopic, radiologic, or surgical therapy for varices or ascites. Do not take beta-blocker, ACE inhibitor, or nitrate. Child-Pugh score <12. ",
        "Annotations": [
            "Condition 0 15--*--Liver cirrhosis",
            "Person 17 20--*--Age",
            "Value 21 44--*--between 18 and 70 years",
            "Condition 46 64--*--Esophageal varices",
            "Observation 70 88--*--high bleeding risk",
            "Measurement 100 102--*--F2",
            "Multiplier 90 99--*--more than",
            "Condition 107 121--*--red color sign",
            "Scope 90 121--*--more than F2 and red color sign",
            "Negation 123 125--*--No",
            "Condition 146 177--*--upper gastrointestinal bleeding",
            "Negation 179 181--*--No",
            "Condition 250 257--*--varices",
            "Condition 261 268--*--ascites",
            "Procedure 229 245--*--surgical therapy",
            "Procedure 214 224;238 245--*--radiologic therapy",
            "Procedure 202 212;238 245--*--endoscopic therapy",
            "Scope 202 245--*--endoscopic, radiologic, or surgical therapy",
            "Negation 270 276--*--Do not",
            "Drug 282 294--*--beta-blocker",
            "Drug 296 309--*--ACE inhibitor",
            "Drug 314 321--*--nitrate",
            "Scope 282 321--*--beta-blocker, ACE inhibitor, or nitrate",
            "Measurement 323 339--*--Child-Pugh score",
            "Value 340 343--*--<12",
            "Scope 250 268--*--varices or ascites"
        ]
    },
    "NCT02867618_exc": {
        "Text": "1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (\u2265 5 days) to the equivalent of \u226410 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. . 2. History of allergic reactions to TGR-1202 or carfilzomib . 3. Uncontrolled inter-current illness . 4. Pregnant women . 5. Nursing women . 6. Current malignancy or history of a prior malignancy . 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive . 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 394 396--*--2.",
            "Parsing_Error 455 457--*--3.",
            "Parsing_Error 494 496--*--4.",
            "Parsing_Error 513 515--*--5.",
            "Parsing_Error 531 533--*--6.",
            "Parsing_Error 587 589--*--7.",
            "Parsing_Error 655 657--*--8.",
            "Temporal 3 8--*--Prior",
            "Procedure 29 41--*--chemotherapy",
            "Procedure 45 57--*--radiotherapy",
            "Temporal 58 78--*--within 2 weeks prior",
            "Reference_point 82 100--*--entering the study",
            "Scope 29 57--*--chemotherapy or radiotherapy",
            "Condition 123 132--*--recovered",
            "Negation 119 122--*--not",
            "Condition 138 152--*--adverse events",
            "c-Requires_causality 153 159--*--due to",
            "Drug 160 166--*--agents",
            "Temporal 180 205--*--more than 2 weeks earlier",
            "Drug 207 224--*--Systemic steroids",
            "Qualifier 244 254--*--stabilized",
            "Negation 235 238--*--not",
            "Temporal 256 264--*--\u2265 5 days",
            "Multiplier 287 297--*--\u226410 mg/day",
            "Drug 298 308--*--prednisone",
            "Temporal 309 317--*--prior to",
            "Reference_point 322 346--*--start of the study drugs",
            "Drug 351 379--*--other investigational agents",
            "Grammar_Error 348 391--*--No other investigational agents are allowed",
            "Context_Error 351 379--*--other investigational agents",
            "Condition 408 426--*--allergic reactions",
            "Drug 430 438--*--TGR-1202",
            "Drug 442 453--*--carfilzomib",
            "Scope 430 453--*--TGR-1202 or carfilzomib",
            "Observation 397 404--*--History",
            "Condition 471 492--*--inter-current illness",
            "Qualifier 458 470--*--Uncontrolled",
            "Undefined_semantics 458 492--*--Uncontrolled inter-current illness",
            "Temporal 471 484--*--inter-current",
            "Person 506 511--*--women",
            "Condition 497 505--*--Pregnant",
            "Person 524 529--*--women",
            "Condition 516 523--*--Nursing",
            "Condition 542 552--*--malignancy",
            "Temporal 534 541--*--Current",
            "Condition 575 585--*--malignancy",
            "Observation 556 574--*--history of a prior",
            "Measurement 610 644--*--Human Immunodeficiency Virus (HIV)",
            "Value 645 653--*--positive",
            "Condition 665 676--*--Hepatitis A",
            "Condition 678 689--*--Hepatitis B",
            "Condition 694 705--*--Hepatitis C"
        ]
    },
    "NCT02344888_exc": {
        "Text": "Age < 20 or > 35 years.. Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.. Presence of any infertility factor other than anovulatory PCOS.. Previous history of ovarian surgery or surgical removal of one ovary.. Previous exposure to cytotoxic drugs or pelvic irradiation.. Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.. Metabolic or hormonal abnormalities. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--< 20 or > 35 years",
            "Measurement 25 40--*--Body mass index",
            "Measurement 42 45--*--BMI",
            "Value 47 73--*--< 18.5 kg/m2 or > 25 kg/m2",
            "Condition 92 110--*--infertility factor",
            "Negation 111 121--*--other than",
            "Condition 122 138--*--anovulatory PCOS",
            "Procedure 161 176--*--ovarian surgery",
            "Procedure 180 196--*--surgical removal",
            "Qualifier 204 209--*--ovary",
            "Multiplier 200 203--*--one",
            "Condition 221 229--*--exposure",
            "Drug 233 248--*--cytotoxic drugs",
            "Procedure 252 270--*--pelvic irradiation",
            "Scope 233 270--*--cytotoxic drugs or pelvic irradiation",
            "Procedure 294 310--*--hormonal therapy",
            "Procedure 278 290;303 310--*--hypoglycemic therapy",
            "Qualifier 273 277--*--Oral",
            "Scope 278 310--*--hypoglycemic or hormonal therapy",
            "Temporal 338 356--*--preceding 3 months",
            "Condition 372 394--*--hormonal abnormalities",
            "Condition 359 368;381 394--*--Metabolic abnormalities"
        ]
    },
    "NCT02334631_inc": {
        "Annotations": [
            "Procedure 20 55--*--small bowel video capsule endoscopy"
        ],
        "Text": "Patients undergoing small bowel video capsule endoscopy. "
    },
    "NCT03372265_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 18 years",
            "Observation 16 68--*--American Society of Anesthesiologists Classification",
            "Value 69 74--*--I-III",
            "Value 76 82--*--Normal",
            "Measurement 83 101--*--cognitive function",
            "Observation 179 210--*--Agreement to the trial protocol",
            "Observation 179 191;222 243--*--Agreement to the randomized manner"
        ],
        "Text": "Age = 18 years. American Society of Anesthesiologists Classification I-III. Normal cognitive function in order to sign written, informed consent and to understand trial protocol. Agreement to the trial protocol, including the randomized manner. "
    },
    "NCT03070847_exc": {
        "Text": "pregnancy. known allergies for tranexamic acid or any other substance in Exacyl. deep vein thrombosis. Hormone Replacement Therapy or oral contraceptive usage. anticoagulants usage. obesity - BMI (body mass index) >30 kg/m2. renal disease, as glomerular filtration rate (GFR) <60 ml/min/1,73 m*m. seizures or epilepsy in the past. ",
        "Annotations": [
            "Condition 0 9--*--pregnancy",
            "Condition 17 26--*--allergies",
            "Drug 31 46--*--tranexamic acid",
            "Drug 73 79--*--Exacyl",
            "Scope 31 79--*--tranexamic acid or any other substance in Exacyl",
            "Condition 81 101--*--deep vein thrombosis",
            "Procedure 103 130--*--Hormone Replacement Therapy",
            "Drug 134 152--*--oral contraceptive",
            "Drug 160 174--*--anticoagulants",
            "Condition 182 189--*--obesity",
            "Measurement 192 195--*--BMI",
            "Measurement 197 212--*--body mass index",
            "Value 214 223--*-->30 kg/m2",
            "Scope 192 223--*--BMI (body mass index) >30 kg/m2",
            "Condition 225 238--*--renal disease",
            "Measurement 243 269--*--glomerular filtration rate",
            "Measurement 271 274--*--GFR",
            "Value 276 295--*--<60 ml/min/1,73 m*m",
            "Value 297 305--*--seizures",
            "Value 309 317--*--epilepsy",
            "Temporal 318 329--*--in the past",
            "Scope 297 317--*--seizures or epilepsy"
        ]
    },
    "NCT01757717_inc": {
        "Annotations": [
            "Condition 41 51--*--malignancy",
            "Qualifier 52 82--*--suitable for radiation therapy",
            "Procedure 65 82--*--radiation therapy",
            "Procedure 19 29--*--histologic",
            "Value 30 35--*--proof",
            "Subjective_judgement 52 82--*--suitable for radiation therapy",
            "Procedure 119 150--*--external beam radiation therapy",
            "Temporal 113 118--*--prior",
            "Procedure 178 195--*--HDR brachytherapy",
            "Not_a_criteria 207 373--*--evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration.",
            "Qualifier 151 205--*--to the region proposed for HDR brachytherapy treatment",
            "Procedure 378 396--*--repeat irradiation",
            "Value 403 438--*--exceed any normal tissue constraint",
            "Measurement 446 506--*--MSKCC Radiation Oncology Department dose constraint criteria",
            "Context_Error 551 964--*--If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/\u03b1/\u03b2), where n = number of fractions and d = dose per fraction; \u03b1/\u03b2 is the constant for spinal cord late effect and equals 2. [Rades 2005, Nieder 2005, Sahgal 2012]",
            "Measurement 966 969--*--KPS",
            "Value 970 974--*--\u2265 60",
            "Person 976 979--*--Age",
            "Value 980 994--*--\u2265 18 years old"
        ],
        "Text": "Patients must have histologic proof of a malignancy suitable for radiation therapy. . Patients must have received prior external beam radiation therapy to the region proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration. . If repeat irradiation would exceed any normal tissue constraint set by MSKCC Radiation Oncology Department dose constraint criteria, the patient will potentially be eligible. . If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/\u03b1/\u03b2), where n = number of fractions and d = dose per fraction; \u03b1/\u03b2 is the constant for spinal cord late effect and equals 2. [Rades 2005, Nieder 2005, Sahgal 2012] . KPS \u2265 60 . Age \u2265 18 years old . "
    },
    "NCT03344042_inc": {
        "Annotations": [
            "Procedure 14 20--*--labour",
            "Person 0 10--*--parturient",
            "Negation 21 28--*--without",
            "Procedure 29 46--*--cervical dilation",
            "Condition 51 79--*--regular uterine contractions",
            "Scope 29 79--*--cervical dilation and regular uterine contractions"
        ],
        "Text": "parturient in labour without cervical dilation and regular uterine contractions. "
    },
    "NCT00461136_inc": {
        "Text": "Male and/or female patients from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria). . Incipient and established diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day). . Glomerular filtration rate (GFR) \u2265 40 ml/min (estimated using Modification of Diet in Renal Disease (MDRD) formula) in the last 4 months. . Female patients must be postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening. . To be eligible patients must fulfill the following criteria: Patients on ongoing hypertensive therapy must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day -1).; Newly diagnosed hypertensive patients must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1). . Patients must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 ( Day -1). . Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study. . Oral body temperature within the range 35.0-37.5 \u00b0C . Able to provide written informed consent prior to study participation. . . Able to communicate well with the investigator and comply with the requirements of the study. . ",
        "Annotations": [
            "Value 33 44--*--30-80 years",
            "Condition 72 87--*--Type 2 diabetes",
            "Condition 131 151--*--diabetic nephropathy",
            "Value 196 209--*--\u2264 2000 mg/day",
            "Person 45 51--*--of age",
            "Value 179 191--*--\u2265 100 mg/day",
            "Measurement 153 178--*--urinary albumin excretion",
            "Scope 153 209--*--urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day",
            "Measurement 213 245--*--Glomerular filtration rate (GFR)",
            "Value 246 257--*--\u2265 40 ml/min",
            "Qualifier 275 327--*--Modification of Diet in Renal Disease (MDRD) formula",
            "Temporal 329 349--*--in the last 4 months",
            "Person 352 358--*--Female",
            "Condition 376 390--*--postmenopausal",
            "Procedure 410 432--*--bilateral oophorectomy",
            "Procedure 451 472--*--surgically sterilized",
            "Procedure 476 491--*--hysterectomized",
            "Temporal 492 528--*--at least 6 months prior to screening",
            "Scope 451 491--*--surgically sterilized or hysterectomized",
            "Scope 376 528--*--postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening",
            "Procedure 612 632--*--hypertensive therapy",
            "Measurement 645 659--*--blood pressure",
            "Value 660 674--*--\u2265 135/85 mm Hg",
            "Value 679 703--*--lower than 170/105 mm Hg",
            "Scope 660 703--*--\u2265 135/85 mm Hg but lower than 170/105 mm Hg",
            "Drug 756 784--*--antihypertensive medications",
            "Qualifier 749 755--*--stable",
            "Temporal 789 823--*--at least 8 weeks prior to baseline",
            "Qualifier 835 850--*--Newly diagnosed",
            "Condition 851 872--*--hypertensive patients",
            "Measurement 885 899--*--blood pressure",
            "Value 900 914--*--\u2265 135/85 mm Hg",
            "Value 919 943--*--lower than 170/105 mm Hg",
            "Scope 900 943--*--\u2265 135/85 mm Hg but lower than 170/105 mm Hg",
            "Drug 994 1018--*--hypoglycemic medications",
            "Temporal 1023 1056--*--at least 8 weeks prior to Visit 2",
            "Qualifier 987 993--*--stable",
            "Non-query-able 1069 1321--*--Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.",
            "Measurement 1323 1344--*--Oral body temperature",
            "Value 1362 1374--*--35.0-37.5 \u00b0C",
            "Scope 835 872--*--Newly diagnosed hypertensive patients",
            "Temporal 944 964--*--at baseline (Day -1)",
            "Reference_point 947 964--*--baseline (Day -1)",
            "Reference_point 815 823--*--baseline",
            "Reference_point 1049 1056--*--Visit 2",
            "Observation 1392 1416--*--written informed consent",
            "Temporal 1417 1445--*--prior to study participation",
            "Reference_point 1426 1445--*--study participation",
            "Observation 1450 1474--*--Able to communicate well",
            "Observation 1501 1542--*--comply with the requirements of the study"
        ]
    },
    "NCT03004261_exc": {
        "Text": "Patients receiving prednisone = 1mg/kg/d for the treatment of acute GVHD or mild, severe chronic GVHD.. Recipient < 14years of age. Donor is sero-positive in HBV/HCV/HIV or RPR.. ",
        "Annotations": [
            "Drug 19 29--*--prednisone",
            "Value 30 40--*--= 1mg/kg/d",
            "Condition 62 72--*--acute GVHD",
            "Qualifier 76 80--*--mild",
            "Qualifier 82 88--*--severe",
            "Qualifier 89 96--*--chronic",
            "Condition 97 101--*--GVHD",
            "Scope 76 88--*--mild, severe",
            "Scope 62 101--*--acute GVHD or mild, severe chronic GVHD",
            "Value 114 123--*--< 14years",
            "Person 127 130--*--age",
            "Condition 141 157;158 161--*--sero-positive in HBV",
            "Condition 141 157;162 165--*--sero-positive in HCV",
            "Condition 141 157;166 169--*--sero-positive in HIV",
            "Condition 141 157;173 176--*--sero-positive in RPR"
        ]
    },
    "NCT03372265_exc": {
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Drug 11 13--*--LA",
            "Qualifier 31 50--*--near insertion site",
            "Qualifier 25 27;36 50--*--in insertion site",
            "Device 58 83--*--peripheral nerve catheter",
            "Scope 25 50--*--in or near insertion site",
            "Condition 85 109--*--Anatomical abnormalities",
            "Qualifier 121 131--*--successful",
            "Mood 110 120--*--preventing",
            "Device 132 151--*--peripheral catheter",
            "Procedure 152 161--*--insertion",
            "Negation 110 120--*--preventing",
            "Drug 179 186--*--opioids",
            "Multiplier 163 175--*--Habitual use",
            "Condition 188 197--*--Pregnancy",
            "Observation 201 214--*--breastfeeding",
            "Value 231 239--*--negative",
            "Procedure 240 254--*--pregnancy test",
            "Temporal 255 277--*--before trial inclusion",
            "Reference_point 262 277--*--trial inclusion",
            "Negation 216 228--*--disproved by"
        ],
        "Text": "Allergy to LA. Infection in or near insertion site of the peripheral nerve catheter. Anatomical abnormalities preventing successful peripheral catheter insertion. Habitual use of opioids. Pregnancy or breastfeeding (disproved by a negative pregnancy test before trial inclusion). "
    },
    "NCT02334631_exc": {
        "Annotations": [
            "Condition 16 32--*--contraindication",
            "Procedure 36 39--*--VCE",
            "Condition 41 63--*--small bowel strictures",
            "Condition 65 88--*--oropharyngeal dysphagia",
            "Condition 90 99--*--pregnancy",
            "Negation 118 121--*--not",
            "Observation 122 141--*--surgical candidates",
            "Scope 41 141--*--small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates",
            "Procedure 144 164--*--Endoscopic insertion",
            "Device 168 191--*--video capsule endoscope",
            "Procedure 193 213--*--Inpatient procedures",
            "Condition 225 236--*--GI bleeding",
            "Qualifier 218 224--*--active",
            "Observation 252 269--*--fluid restriction",
            "Observation 281 296--*--unable to drink",
            "Temporal 337 353--*--prior to the VCE",
            "Procedure 350 353--*--VCE",
            "Reference_point 346 353--*--the VCE",
            "Scope 252 296--*--fluid restriction or who are unable to drink"
        ],
        "Text": "Patients with a contraindication to VCE (small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates). Endoscopic insertion of video capsule endoscope. Inpatient procedures for active GI bleeding. Patients with fluid restriction or who are unable to drink up to 900 ml of fluid within 10 minutes prior to the VCE. "
    },
    "NCT03070847_inc": {
        "Text": "age > 18 y.o.. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2. signed informed consent form after reading the information about the study and talking with one of the investigators. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 12--*--> 18 y.o",
            "Measurement 15 83--*--American Society of Anesthesiologists Physical Status Classification",
            "Measurement 85 88--*--ASA",
            "Value 90 93--*--1-2",
            "Informed_consent 95 211--*--signed informed consent form after reading the information about the study and talking with one of the investigators"
        ]
    },
    "NCT00461136_exc": {
        "Text": "Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg) . Acetylsalicyclic acid (ASA) treatment >1g/day or regular use of Non steroidal anti-inflammatory drug (NSAIDs) . Kidney disease not caused by diabetes or hypertension . Serum potassium < 3.5 or > 5.1 mEq/L . GFR < 40 ml/min/1.73m2 as measured by the MDRD formula . Serum albumin < 2.0mg/dL . History of hypertensive encephalopathy or cerebrovascular accident at any time prior to Visit1. . Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV) . History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1 . Second or third degree heart block without a pacemaker . Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia . Clinically significant valvular heart disease . Type 1 diabetes mellitus . Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) >11 %) . History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years . Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. . Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing. . Significant illness within the two weeks prior to dosing. . Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following: . History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection . -Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1 Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1. . Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt . Current treatment with cholestyramine or cholestipol resins . History of immunocompromise, including a positive HIV test result. . History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. . History of drug or alcohol abuse within the 12 months prior to dosing. . Persons directly involved in the execution of this protocol. . Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety . History of noncompliance to medical regimens or unwillingness to comply with the study protocol . Known or suspected contraindications to the study medications, including history of allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics or other sulfonamide derived drug . Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study . Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol. . Patients who previously participated in any Aliskiren study. . Pregnant or nursing woman. . Other protocol-defined inclusion/exclusion criteria may apply       .     . ",
        "Annotations": [
            "Condition 0 19--*--Severe Hypertension",
            "Measurement 20 25;28 46--*--Grade WHO classification",
            "Value 26 27--*--3",
            "Measurement 48 93--*--Mean Sitting Diastolic Blood Pressure (MSDBP)",
            "Value 94 102--*--110 mmHg",
            "Measurement 110 152--*--Mean Sitting Systolic Blood Pressure MSSBP",
            "Value 153 161--*--180 mmHg",
            "Scope 48 161--*--Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg",
            "Procedure 164 201--*--Acetylsalicyclic acid (ASA) treatment",
            "Value 202 209--*-->1g/day",
            "Drug 228 273--*--Non steroidal anti-inflammatory drug (NSAIDs)",
            "Condition 275 289--*--Kidney disease",
            "Condition 304 312--*--diabetes",
            "Condition 316 328--*--hypertension",
            "Measurement 330 345--*--Serum potassium",
            "Value 346 351--*--< 3.5",
            "Value 355 366--*--> 5.1 mEq/L",
            "Measurement 368 371--*--GFR",
            "Value 372 390--*--< 40 ml/min/1.73m2",
            "Qualifier 410 422--*--MDRD formula",
            "Measurement 424 437--*--Serum albumin",
            "Value 438 448--*--< 2.0mg/dL",
            "Condition 461 488--*--hypertensive encephalopathy",
            "Condition 492 516--*--cerebrovascular accident",
            "Observation 450 457--*--History",
            "Temporal 520 534--*--any time prior",
            "Scope 461 516--*--hypertensive encephalopathy or cerebrovascular accident",
            "Condition 568 581--*--heart failure",
            "Measurement 583 622--*--New York Heart Association (NYHA) Class",
            "Value 623 628--*--II-IV",
            "Scope 583 628--*--New York Heart Association (NYHA) Class II-IV",
            "Condition 642 663--*--myocardial infarction",
            "Condition 665 689--*--unstable angina pectoris",
            "Condition 691 714--*--coronary bypass surgery",
            "Condition 723 763--*--percutaneous coronary intervention (PCI)",
            "Temporal 764 789--*--during the 6 months prior",
            "Observation 631 638--*--History",
            "Scope 642 763--*--myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI)",
            "Condition 812 836--*--third degree heart block",
            "Condition 802 808;818 836--*--Second degree heart block",
            "Device 847 856--*--pacemaker",
            "Negation 837 844--*--without",
            "Scope 802 836--*--Second or third degree heart block",
            "Condition 898 908--*--arrhythmia",
            "Qualifier 869 897--*--potentially life threatening",
            "Condition 924 934--*--arrhythmia",
            "Qualifier 912 923--*--symptomatic",
            "Condition 959 981--*--valvular heart disease",
            "Condition 983 1007--*--Type 1 diabetes mellitus",
            "Condition 1022 1047--*--Type II diabetes mellitus",
            "Measurement 1049 1079--*--Hemaglobin subtype A1C (HbA1C)",
            "Value 1080 1085--*-->11 %",
            "Qualifier 1009 1021--*--Uncontrolled",
            "Condition 1099 1109--*--malignancy",
            "Condition 1120 1128--*--leukemia",
            "Condition 1133 1141--*--lymphoma",
            "Condition 1151 1176--*--basal cell skin carcinoma",
            "Scope 1120 1141--*--leukemia and lymphoma",
            "Temporal 1178 1204--*--within the past five years",
            "Temporal 1250 1280--*--within 4 weeks prior to dosing",
            "Value 1345 1359--*--400 mL or more",
            "Temporal 1369 1389--*--within 8 weeks prior",
            "Procedure 1325 1333;1360 1368--*--Donation of blood",
            "Condition 1337 1341;1360 1368--*--loss of blood",
            "Condition 1402 1421--*--Significant illness",
            "Temporal 1422 1448--*--within the two weeks prior",
            "Condition 1465 1473;1485 1494--*--surgical condition",
            "Condition 1477 1494--*--medical condition",
            "Scope 1465 1494--*--surgical or medical condition",
            "Qualifier 1521 1596--*--alter the absorption, distribution, metabolism, or excretion of study drugs",
            "Observation 1651 1658--*--History",
            "Condition 1662 1698--*--major gastrointestinal tract surgery",
            "Procedure 1707 1718--*--gastrectomy",
            "Procedure 1720 1737--*--gastroenterostomy",
            "Procedure 1742 1757--*--bowel resection",
            "Scope 1707 1757--*--gastrectomy, gastroenterostomy, or bowel resection",
            "Condition 1798 1824--*--inflammatory bowel disease",
            "Temporal 1825 1851--*--during the 12 months prior",
            "Temporal 1863 1879--*--Currently active",
            "Temporal 1760 1776--*--Currently active",
            "Temporal 1780 1797--*--previously active",
            "Condition 1880 1889--*--gastritis",
            "Condition 1891 1899--*--duodenal",
            "Condition 1903 1917--*--gastric ulcers",
            "Condition 1922 1938;1946 1954--*--gastrointestinal bleeding",
            "Condition 1939 1954--*--rectal bleeding",
            "Temporal 1955 1980--*--during the 3 months prior",
            "Scope 1880 1954--*--gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding",
            "Condition 2009 2026--*--pancreatic injury",
            "Observation 1998 2005--*--history",
            "Condition 2028 2040--*--pancreatitis",
            "Measurement 2065 2084--*--pancreatic function",
            "Value 2056 2064--*--impaired",
            "Condition 2065 2075;2085 2091--*--pancreatic injury",
            "Measurement 2117 2123--*--lipase",
            "Value 2108 2116--*--abnormal",
            "Measurement 2127 2134--*--amylase",
            "Scope 2108 2134--*--abnormal lipase or amylase",
            "Condition 2147 2162--*--hepatic disease",
            "Observation 2166 2173--*--history",
            "Condition 2177 2199--*--hepatic encephalopathy",
            "Condition 2214 2232--*--esophageal varices",
            "Condition 2250 2266--*--portocaval shunt",
            "Observation 2239 2246--*--history",
            "Observation 2203 2210--*--history",
            "Scope 2009 2134--*--pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase",
            "Drug 2291 2305--*--cholestyramine",
            "Drug 2309 2327--*--cholestipol resins",
            "Temporal 2268 2275--*--Current",
            "Condition 2340 2356--*--immunocompromise",
            "Observation 2329 2336--*--History",
            "Measurement 2379 2387--*--HIV test",
            "Value 2370 2378--*--positive",
            "Observation 2397 2404--*--History",
            "Measurement 2419 2454;2470 2474--*--Hepatitis B surface antigen (HBsAg) test",
            "Measurement 2458 2474--*--Hepatitis C test",
            "Value 2410 2418--*--positive",
            "Scope 2410 2474--*--positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test",
            "Observation 2484 2491--*--History",
            "Condition 2495 2499;2511 2516--*--drug abuse",
            "Condition 2503 2516--*--alcohol abuse",
            "Temporal 2517 2543--*--within the 12 months prior",
            "Scope 2495 2516--*--drug or alcohol abuse",
            "Condition 2940 2947--*--allergy",
            "Drug 2951 2997--*--Angiotensin converting enzyme (ACE) inhibitors",
            "Drug 3008 3026--*--thiazide diuretics",
            "Drug 3036 3060--*--sulfonamide derived drug",
            "Condition 2875 2892--*--contraindications",
            "Drug 2900 2917--*--study medications",
            "Drug 3476 3485--*--Aliskiren",
            "Condition 3494 3502--*--Pregnant",
            "Condition 3506 3513--*--nursing",
            "Person 3514 3519--*--woman",
            "Competing_trial 1223 1249--*--any clinical investigation",
            "Reference_point 1274 1280--*--dosing",
            "Non-query-able 2556 2616--*--Persons directly involved in the execution of this protocol.",
            "Condition 2622 2631--*--condition",
            "Non-representable 2637 2671--*--in the opinion of the investigator",
            "Non-representable 2637 2654;2675 2703--*--in the opinion of the Novartis medical monitor",
            "Qualifier 2632 2636;2704 2747--*--that would jeopardize the evaluation of efficacy",
            "Qualifier 2632 2636;2704 2720;2751 2757--*--that would jeopardize safety",
            "Scope 2632 2636;2704 2747;2751 2757--*--that would jeopardize the evaluation of efficacy safety",
            "Scope 2637 2703--*--in the opinion of the investigator or the Novartis medical monitor",
            "Observation 2759 2769--*--History of",
            "Observation 2770 2803--*--noncompliance to medical regimens",
            "Mood 2807 2823--*--unwillingness to",
            "Informed_consent 2824 2854--*--comply with the study protocol",
            "Observation 2929 2939--*--history of",
            "Qualifier 3030 3035--*--other",
            "Condition 3078 3095--*--medical condition",
            "Condition 3066 3074;3086 3095--*--surgical condition",
            "Non-query-able 3103 3137--*--in the opinion of the investigator",
            "Scope 3066 3095--*--surgical or medical condition",
            "Drug 3339 3356--*--prescription drug",
            "Drug 3360 3393--*--over-the-counter (OTC) medication",
            "Qualifier 3403 3429--*--prohibited by the protocol",
            "Scope 3339 3393--*--prescription drug or over-the-counter (OTC) medication",
            "Qualifier 3143 3215--*--place the patient at higher risk from his/her participation in the study",
            "Mood 3223 3257--*--likely to prevent the patient from",
            "Informed_consent 3258 3302--*--complying with the requirements of the study",
            "Negation 3233 3240--*--prevent",
            "Temporal 3445 3455--*--previously",
            "Competing_trial 3476 3491--*--Aliskiren study",
            "Qualifier 3522 3527--*--Other",
            "Qualifier 3528 3544--*--protocol-defined",
            "Non-representable 3522 3583--*--Other protocol-defined inclusion/exclusion criteria may apply"
        ]
    },
    "NCT03344042_exc": {
        "Annotations": [
            "Informed_consent 0 10--*--no consent",
            "Condition 18 25--*--allergy",
            "Drug 42 48--*--opioid",
            "Condition 50 67--*--contraindications",
            "Procedure 71 89--*--epidural analgesia",
            "Condition 91 105--*--coagulopathies",
            "Measurement 116 130--*--platelet count",
            "Value 134 151--*--less than 100,000",
            "Scope 116 151--*--platelet count of less than 100,000",
            "Procedure 153 166--*--spine surgery",
            "Temporal 167 174--*--in past"
        ],
        "Text": "no consent. known allergy to administered opioid. contraindications to epidural analgesia. coagulopathies including platelet count of less than 100,000. spine surgery in past. "
    },
    "NCT01757717_exc": {
        "Annotations": [
            "Measurement 129 189--*--MSKCC Radiation Oncology Department dose constraint criteria",
            "Condition 13 112--*--may receive therapeutically effective doses via an external beam approach to the lesion of interest",
            "Qualifier 25 50--*--therapeutically effective",
            "Procedure 51 56--*--doses",
            "Procedure 64 77--*--external beam",
            "Context_Error 0 189--*--Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria",
            "Device 206 224--*--kyphoplasty cement",
            "Device 206 217;228 236--*--kyphoplasty hardware",
            "Qualifier 248 285--*--preclude effective catheter placement",
            "Scope 206 236--*--kyphoplasty cement or hardware",
            "Condition 302 333--*--paraspinal extension of disease",
            "Condition 339 359--*--visceral involvement",
            "Measurement 371 391--*--complete blood count",
            "Value 362 370--*--Abnormal",
            "Condition 362 391--*--Abnormal complete blood count",
            "Undefined_semantics 362 391--*--Abnormal complete blood count",
            "Parsing_Error 393 414--*--Any of the following:",
            "Measurement 416 430--*--Platelet count",
            "Value 431 442--*--< 75,000/ml",
            "Measurement 444 452--*--Hb level",
            "Value 453 461--*--< 9gm/dl",
            "Measurement 463 466--*--WBC",
            "Value 467 475--*--< 3.5/ml",
            "Measurement 486 505--*--coagulation profile",
            "Value 477 485--*--Abnormal",
            "Condition 477 505--*--Abnormal coagulation profile",
            "Measurement 507 510--*--INR",
            "Value 511 516--*--> 2.5",
            "Measurement 524 527--*--PTT",
            "Value 528 532--*--> 80",
            "Scope 507 532--*--INR > 2.5 and/or PTT > 80",
            "Drug 554 580--*--anticoagulation medication",
            "Undefined_semantics 554 580--*--anticoagulation medication",
            "Qualifier 586 626--*--may not be safely held for the procedure",
            "Subjective_judgement 586 626--*--may not be safely held for the procedure",
            "Multiplier 628 636--*--\u2265 5 days",
            "Drug 641 660--*--antiplatelet agents",
            "Drug 665 673--*--warfarin",
            "Multiplier 675 685--*--\u2265 24 hours",
            "Drug 690 718--*--low-molecular weight heparin",
            "Scope 628 673--*--\u2265 5 days for antiplatelet agents and warfarin",
            "Scope 675 718--*--\u2265 24 hours for low-molecular weight heparin",
            "Scope 628 718--*--\u2265 5 days for antiplatelet agents and warfarin; \u2265 24 hours for low-molecular weight heparin",
            "Scope 554 626--*--anticoagulation medication that may not be safely held for the procedure",
            "Condition 752 791--*--Contraindications to general anesthesia",
            "Procedure 773 791--*--general anesthesia"
        ],
        "Text": "Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria. . Patients with kyphoplasty cement or hardware that would preclude effective catheter placement. . Patients with paraspinal extension of disease with visceral involvement. . Abnormal complete blood count. Any of the following: . Platelet count < 75,000/ml . Hb level < 9gm/dl . WBC < 3.5/ml . Abnormal coagulation profile: INR > 2.5 and/or PTT > 80 . Patients who are on anticoagulation medication that may not be safely held for the procedure (\u2265 5 days for antiplatelet agents and warfarin; \u2265 24 hours for low-molecular weight heparin formulations) will be excluded. . Contraindications to general anesthesia       .     . "
    },
    "NCT03004261_inc": {
        "Text": "Any allogeneic stem cell transplant recipient = 14 years of age and = 60 years of age. Bilirubin/ SGOT/SGPT < 5 \u00d7 upper normal limits.. Creatinine < 2 \u00d7 upper normal limits.. Ejection fraction = 50%, no severe arrhythmia.. Estimated life expectancy = 6 months.. Patients' CMV-DNA = 1000cp/ml in treatment group and being negative in prophylactic group.. ",
        "Annotations": [
            "Procedure 4 35--*--allogeneic stem cell transplant",
            "Value 46 56--*--= 14 years",
            "Person 60 63--*--age",
            "Value 68 78--*--= 60 years",
            "Person 82 85--*--age",
            "Measurement 87 96--*--Bilirubin",
            "Measurement 98 102--*--SGOT",
            "Measurement 103 107--*--SGPT",
            "Value 108 133--*--< 5 \u00d7 upper normal limits",
            "Measurement 136 146--*--Creatinine",
            "Value 147 172--*--< 2 \u00d7 upper normal limits",
            "Measurement 175 192--*--Ejection fraction",
            "Value 193 198--*--= 50%",
            "Negation 200 202--*--no",
            "Qualifier 203 209--*--severe",
            "Condition 210 220--*--arrhythmia",
            "Observation 223 248--*--Estimated life expectancy",
            "Value 249 259--*--= 6 months",
            "Measurement 272 279--*--CMV-DNA",
            "Value 280 291--*--= 1000cp/ml",
            "Person 295 310--*--treatment group",
            "Person 333 351--*--prophylactic group",
            "Value 321 329--*--negative",
            "Scope 280 351--*--= 1000cp/ml in treatment group and being negative in prophylactic group"
        ]
    },
    "NCT03034733_exc": {
        "Annotations": [
            "Qualifier 0 6--*--severe",
            "Condition 7 30--*--coronary artery disease",
            "Condition 32 45--*--heart failure",
            "Condition 47 61--*--kidney failure",
            "Scope 7 61--*--coronary artery disease, heart failure, kidney failure",
            "Condition 63 83--*--insulin-dependent DM",
            "Condition 85 102--*--diabetes mellitus",
            "Qualifier 105 122--*--poorly controlled",
            "Condition 123 133--*--type II DM",
            "Condition 135 142;152 157--*--gastric ulcer",
            "Condition 143 157--*--duodenal ulcer",
            "Condition 159 166--*--allergy",
            "Condition 167 184--*--contra-indication",
            "Drug 193 215--*--drug used in the study",
            "Scope 159 184--*--allergy/contra-indication",
            "Drug 217 231--*--corticosteroid",
            "Temporal 236 256--*--during last 3 months",
            "Temporal 258 270--*--preoperative",
            "Drug 278 290--*--opioid drugs",
            "Negation 292 297--*--excl.",
            "Drug 298 305--*--codeine",
            "Drug 307 315--*--tramadol",
            "Scope 298 315--*--codeine, tramadol",
            "Condition 318 328--*--neuropathy",
            "Condition 329 347--*--sensory impairment",
            "Qualifier 351 362--*--lower limbs",
            "Scope 318 347--*--neuropathy/sensory impairment",
            "Observation 364 384--*--lack of co-operation",
            "Condition 391 407--*--inability to use",
            "Device 410 413;444 451--*--PCA -device"
        ],
        "Text": "severe coronary artery disease, heart failure, kidney failure. insulin-dependent DM (diabetes mellitus), poorly controlled type II DM. gastric/duodenal ulcer. allergy/contra-indication for any drug used in the study. corticosteroid use during last 3 months. preoperative use of opioid drugs (excl. codeine, tramadol). neuropathy/sensory impairment of lower limbs. lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device. "
    },
    "NCT02277041_exc": {
        "Annotations": [
            "Person 0 5--*--women",
            "Procedure 17 34--*--caesarean section",
            "Temporal 6 16--*--undergoing",
            "Value 38 56--*--less than 37 weeks",
            "Measurement 60 69--*--gestation",
            "Condition 72 84--*--Hypertension",
            "Condition 90 99--*--pregnancy",
            "Condition 114 131--*--coronary diseases",
            "Condition 102 109;123 131--*--Cardiac diseases",
            "Condition 137 146--*--pregnancy"
        ],
        "Text": "women undergoing caesarean section at less than 37 weeks of gestation.. Hypertension with pregnancy.. Cardiac and coronary diseases with pregnancy. "
    },
    "NCT02318446_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 14 23--*--lactation",
            "Grammar_Error 10 13--*--and",
            "Condition 39 47--*--diabetes",
            "Condition 49 77--*--Ischemic heart disease (IHD)",
            "Condition 79 85--*--stroke",
            "Condition 87 97--*--malignancy",
            "Condition 102 122--*--psychiatric diseases",
            "Grammar_Error 98 101--*--and",
            "Drug 172 191--*--vitamin supplements",
            "Condition 203 241--*--clinical evidence for an acute illness",
            "Condition 228 241--*--acute illness",
            "Undefined_semantics 203 241--*--clinical evidence for an acute illness",
            "Condition 243 260--*--renal dysfunction",
            "Condition 262 281--*--thyroid dysfunction",
            "Condition 283 312--*--chronic inflammatory diseases",
            "Condition 314 343;365 375--*--inborn errors of homocysteine metabolism",
            "Condition 314 330;358 375--*--inborn errors of folate metabolism",
            "Condition 314 330;345 354;365 375--*--inborn errors of cobalamin metabolism",
            "Condition 390 447--*--condition known to interfere with homocysteine metabolism",
            "Undefined_semantics 390 447--*--condition known to interfere with homocysteine metabolism",
            "Non-query-able 466 519--*--Patients who are already involved in any other trial.",
            "Post-eligibility 521 600--*--Patients not willing to fill consent/ assent form are also excluded from study.",
            "Non-query-able 521 600--*--Patients not willing to fill consent/ assent form are also excluded from study."
        ],
        "Text": "Pregnancy and lactation . Patients with diabetes, Ischemic heart disease (IHD), stroke, malignancy and psychiatric diseases are excluded from study. . The patients receiving vitamin supplements or who had clinical evidence for an acute illness, renal dysfunction, thyroid dysfunction, chronic inflammatory diseases, inborn errors of homocysteine, cobalamin or folate metabolism, or any other condition known to interfere with homocysteine metabolism will be excluded . Patients who are already involved in any other trial. . Patients not willing to fill consent/ assent form are also excluded from study.       .     . "
    },
    "NCT02260206_exc": {
        "Annotations": [
            "Condition 0 16--*--Hypersensitivity",
            "Drug 20 30--*--Colchicine",
            "Condition 49 71--*--intra-cardiac thrombus",
            "Procedure 75 108--*--trans-esophageal echocardiography",
            "Condition 110 119--*--Pregnancy"
        ],
        "Text": "Hypersensitivity on Colchicine. The existence of intra-cardiac thrombus on trans-esophageal echocardiography. Pregnancy. "
    },
    "NCT03532620_inc": {
        "Text": "Age 18-80 years old;. IFG: 5.6mmol/L (100mg/dl)=FPG<7.0mmol/L (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)=OGTT 2-h PG<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4% (39-47mmol/mol);. 2.6mmol/L (100mg/dl)=LDL-C=5.2mmol/L (200mg/dl), and TG<5.7mmol/L (500mg/dl);. 130mmHg=SBP<180mmHg, or 80mmHg=DBP<110mmHg or ongoing anti-hypertensive therapy;. Patients volunteered for the study and signed informed consent.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 19--*--18-80 years old",
            "Condition 22 25--*--IFG",
            "Value 27 36--*--5.6mmol/L",
            "Measurement 48 51--*--FPG",
            "Value 38 46--*--100mg/dl",
            "Value 51 61--*--<7.0mmol/L",
            "Value 63 71--*--126mg/dl",
            "Condition 77 80--*--IGT",
            "Value 82 91--*--7.8mmol/L",
            "Value 93 101--*--140mg/dl",
            "Measurement 103 114--*--OGTT 2-h PG",
            "Measurement 141 146--*--HbA1C",
            "Value 147 155--*--5.7-6.4%",
            "Value 157 170--*--39-47mmol/mol",
            "Value 114 125--*--<11.1mmol/L",
            "Value 127 135--*--200mg/dl",
            "Value 174 183--*--2.6mmol/L",
            "Value 185 193--*--100mg/dl",
            "Measurement 195 200--*--LDL-C",
            "Value 201 210--*--5.2mmol/L",
            "Value 212 220--*--200mg/dl",
            "Measurement 227 229--*--TG",
            "Value 229 239--*--<5.7mmol/L",
            "Value 241 249--*--500mg/dl",
            "Value 253 260--*--130mmHg",
            "Measurement 261 264--*--SBP",
            "Value 264 272--*--<180mmHg",
            "Value 277 284--*--80mmHg=",
            "Measurement 284 287--*--DBP",
            "Value 287 295--*--<110mmHg",
            "Temporal 299 306--*--ongoing",
            "Procedure 307 332--*--anti-hypertensive therapy",
            "Informed_consent 335 398--*--Patients volunteered for the study and signed informed consent."
        ]
    },
    "NCT02968342_exc": {
        "Text": "Medical history of chronic psychiatric disease. Medical conditions associated with female sexual dysfunction; cardiovascular disease, uncontrolled chronic HT (hypertension) ,DM (diabetes mellitus), History of gynecologic surgery, female gynecological cancer ( breast, ovarian, uterine, cervical). Medications associated with female sexual dysfunction; Antidepressants opiates, beta blockers, Antiepileptics ( gabapentin, topiramate,phenytoin) benzodiazepines. ",
        "Annotations": [
            "Observation 8 15--*--history",
            "Condition 19 46--*--chronic psychiatric disease",
            "Condition 83 108--*--female sexual dysfunction",
            "Condition 48 66--*--Medical conditions",
            "Qualifier 67 108--*--associated with female sexual dysfunction",
            "Condition 110 132--*--cardiovascular disease",
            "Qualifier 134 146--*--uncontrolled",
            "Qualifier 147 154--*--chronic",
            "Condition 155 157--*--HT",
            "Condition 159 171--*--hypertension",
            "Condition 174 176--*--DM",
            "Condition 178 195--*--diabetes mellitus",
            "Procedure 209 228--*--gynecologic surgery",
            "Condition 230 257--*--female gynecological cancer",
            "Condition 260 266--*--breast",
            "Condition 268 275--*--ovarian",
            "Condition 277 284--*--uterine",
            "Condition 286 294--*--cervical",
            "Scope 260 294--*--breast, ovarian, uterine, cervical",
            "Observation 198 205--*--History",
            "Condition 325 350--*--female sexual dysfunction",
            "Drug 297 308--*--Medications",
            "Qualifier 309 350--*--associated with female sexual dysfunction",
            "Scope 110 295--*--cardiovascular disease, uncontrolled chronic HT (hypertension) ,DM (diabetes mellitus), History of gynecologic surgery, female gynecological cancer ( breast, ovarian, uterine, cervical)",
            "Scope 48 108--*--Medical conditions associated with female sexual dysfunction",
            "Drug 352 367--*--Antidepressants",
            "Drug 368 375--*--opiates",
            "Drug 377 390--*--beta blockers",
            "Drug 392 406--*--Antiepileptics",
            "Drug 409 419--*--gabapentin",
            "Drug 421 431--*--topiramate",
            "Drug 432 441--*--phenytoin",
            "Drug 443 458--*--benzodiazepines",
            "Scope 409 441--*--gabapentin, topiramate,phenytoin",
            "Scope 352 458--*--Antidepressants opiates, beta blockers, Antiepileptics ( gabapentin, topiramate,phenytoin) benzodiazepines",
            "Scope 297 350--*--Medications associated with female sexual dysfunction"
        ]
    },
    "NCT01373684_inc": {
        "Text": "Chronic hepatitis B (HBsAg positive > 6 months). HBeAg negative within six months prior to initiation of peginterferon alfa-2a. HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a. Compensated liver disease. Age > 18 years. Written informed consent. ",
        "Annotations": [
            "Condition 0 19--*--Chronic hepatitis B",
            "Measurement 21 26--*--HBsAg",
            "Value 27 35--*--positive",
            "Temporal 36 46--*--> 6 months",
            "Measurement 49 54--*--HBeAg",
            "Value 55 63--*--negative",
            "Temporal 64 126--*--within six months prior to initiation of peginterferon alfa-2a",
            "Reference_point 91 126--*--initiation of peginterferon alfa-2a",
            "Drug 105 126--*--peginterferon alfa-2a",
            "Measurement 128 135--*--HBV DNA",
            "Value 136 147--*--< 200 IU/ml",
            "Temporal 209 270--*--within one month prior to initiation of peginterferon alfa-2a",
            "Reference_point 235 270--*--initiation of peginterferon alfa-2a",
            "Drug 249 270--*--peginterferon alfa-2a",
            "Drug 155 177--*--nucleos(t)ide analogue",
            "Drug 186 197--*--Telbivudine",
            "Negation 179 185--*--except",
            "Temporal 148 208--*--during nucleos(t)ide analogue (except Telbivudine) treatment",
            "Reference_point 155 208--*--nucleos(t)ide analogue (except Telbivudine) treatment",
            "Condition 284 297--*--liver disease",
            "Qualifier 272 283--*--Compensated",
            "Person 299 302--*--Age",
            "Value 303 313--*--> 18 years",
            "Informed_consent 315 339--*--Written informed consent"
        ]
    },
    "NCT03034733_inc": {
        "Annotations": [
            "Procedure 8 38--*--total knee replacement surgery",
            "Qualifier 0 7--*--primary",
            "Measurement 40 43;84 89--*--ASA class",
            "Value 90 93--*--1-3",
            "Measurement 45 82--*--american society of anesthesiologists"
        ],
        "Text": "primary total knee replacement surgery. ASA (american society of anesthesiologists) class 1-3. "
    },
    "NCT03532620_exc": {
        "Text": "Past history of hypersensitivity to the study drug;. Diagnosed diabetes;. Severe liver disease (including ALT or AST=2.5-fold the normal upper limit), biliary obstruction;. Ongoing treatment with cyclosporine within 2 weeks;. Renal dysfunction, including endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml\u2022min-1\u20221.73m-2;. Diagnosed or past history of ASCVD (including ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD, etc.. SBP=180mmHg, or DBP=110mmHg;. Ongoing treatment with Beta blockers, Diuretic;. Secondary hypertension, including SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension;. Ongoing treatment with statins, fibrates, and/or cation exchange resins within 2 weeks;. Pancreatic disease;. History of gastrectomy, short bowel syndrome;. Ongoing hormone replacement therapy;. Diagnosed or suspected malignant tumor;. Familial hypercholesterolemia;. Any diseases may limit the efficacy or safety of the study;. Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation;. IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis. ",
        "Annotations": [
            "Condition 16 32--*--hypersensitivity",
            "Drug 40 50--*--study drug",
            "Condition 63 71--*--diabetes",
            "Condition 81 94--*--liver disease",
            "Qualifier 74 80--*--Severe",
            "Measurement 113 116--*--AST",
            "Measurement 106 109--*--ALT",
            "Value 116 148--*--=2.5-fold the normal upper limit",
            "Condition 151 170--*--biliary obstruction",
            "Scope 106 116--*--ALT or AST",
            "Scope 74 94--*--Severe liver disease",
            "Drug 196 208--*--cyclosporine",
            "Procedure 181 190--*--treatment",
            "Temporal 173 180--*--Ongoing",
            "Temporal 209 223--*--within 2 weeks",
            "Condition 226 243--*--Renal dysfunction",
            "Measurement 255 286--*--endogenous creatinine clearance",
            "Person 287 291--*--male",
            "Person 303 309--*--female",
            "Value 309 319--*--<105ml/min",
            "Value 291 301--*--<120ml/min",
            "Measurement 321 337--*--serum creatinine",
            "Value 337 344--*--=2mg/dl",
            "Value 346 355--*--186umol/L",
            "Measurement 358 372--*--Renal function",
            "Value 373 392--*--progressive decline",
            "Measurement 394 397--*--GFR",
            "Value 397 416--*--<30ml\u2022min-1\u20221.73m-2",
            "Scope 287 319--*--male<120ml/min, female<105ml/min",
            "Scope 255 416--*--endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml\u2022min-1\u20221.73m-2",
            "Condition 448 453--*--ASCVD",
            "Condition 465 468--*--ACS",
            "Condition 470 474--*--SCAD",
            "Procedure 476 493--*--revascularization",
            "Condition 495 498--*--ICM",
            "Condition 500 515--*--ischemic stroke",
            "Condition 517 520--*--TIA",
            "Condition 522 526--*--PASD",
            "Scope 465 526--*--ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD",
            "Measurement 534 537--*--SBP",
            "Measurement 550 553--*--DBP",
            "Value 537 545--*--=180mmHg",
            "Value 553 561--*--=110mmHg",
            "Drug 587 600--*--Beta blockers",
            "Temporal 564 571--*--Ongoing",
            "Procedure 572 581--*--treatment",
            "Drug 602 610--*--Diuretic",
            "Scope 587 610--*--Beta blockers, Diuretic",
            "Condition 613 635--*--Secondary hypertension",
            "Condition 647 650--*--SAS",
            "Condition 652 654--*--PA",
            "Condition 656 659--*--RAS",
            "Condition 661 677--*--pheochromocytoma",
            "Condition 679 697--*--Cushing's syndrome",
            "Condition 699 713--*--aorta diseases",
            "Condition 728 740--*--hypertension",
            "Qualifier 715 727--*--drug induced",
            "Scope 647 740--*--SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension",
            "Drug 766 773--*--statins",
            "Drug 775 783--*--fibrates",
            "Temporal 743 750--*--Ongoing",
            "Procedure 751 760--*--treatment",
            "Drug 792 814--*--cation exchange resins",
            "Temporal 815 829--*--within 2 weeks",
            "Scope 766 814--*--statins, fibrates, and/or cation exchange resins",
            "Condition 832 850--*--Pancreatic disease",
            "Procedure 864 875--*--gastrectomy",
            "Condition 877 897--*--short bowel syndrome",
            "Observation 853 860--*--History",
            "Scope 864 897--*--gastrectomy, short bowel syndrome",
            "Temporal 900 907--*--Ongoing",
            "Procedure 908 935--*--hormone replacement therapy",
            "Condition 961 976--*--malignant tumor",
            "Mood 951 960--*--suspected",
            "Mood 938 947--*--Diagnosed",
            "Scope 938 960--*--Diagnosed or suspected",
            "Condition 979 1008--*--Familial hypercholesterolemia",
            "Non-query-able 1011 1069--*--Any diseases may limit the efficacy or safety of the study",
            "Pregnancy_considerations 1072 1198--*--Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation",
            "Non-representable 1201 1870--*--IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis"
        ]
    },
    "NCT02277041_inc": {
        "Annotations": [
            "Condition 13 32--*--singleton pregnancy",
            "Procedure 44 60--*--cesarean section",
            "Value 61 75--*--after 37 weeks",
            "Measurement 79 88--*--gestation"
        ],
        "Text": "Women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.. "
    },
    "NCT02260206_inc": {
        "Annotations": [
            "Procedure 19 37--*--pericardiocentesis",
            "Temporal 38 49--*--during RFCA",
            "Reference_point 45 49--*--RFCA",
            "Procedure 45 49--*--RFCA",
            "Qualifier 54 64--*--paroxysmal",
            "Qualifier 68 78--*--persistent",
            "Condition 79 98--*--atrial fibrillation",
            "Scope 54 78--*--paroxysmal or persistent"
        ],
        "Text": "Patients needed to pericardiocentesis during RFCA for paroxysmal or persistent atrial fibrillation.. "
    },
    "NCT02318446_inc": {
        "Annotations": [
            "Condition 10 19--*--epileptic",
            "Person 48 51--*--age",
            "Value 52 69--*--between 10-19 yrs",
            "Value 71 77--*--<19yrs",
            "Visit 103 114;127 138--*--Out Patient Departments",
            "Visit 116 138--*--In Patient Departments",
            "Procedure 154 165--*--AED therapy",
            "Temporal 166 188--*--for more than 6 months",
            "Measurement 212 231--*--homocysteine levels",
            "Value 207 211--*--high",
            "Value 237 250--*--> 10.9 \u00b5mol/L",
            "Not_a_criteria 251 528--*--(Normal homocysteine levels are 4.3-9.9 \u00b5mol/L for male and 3.3-7.2 \u00b5mol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 \u00b5mol/L for male and at least 10.4 \u00b5mol/L for female. Gender mean of high homocysteine concentration is 10.9 \u00b5mol/L)",
            "Parsing_Error 529 532--*--[5]"
        ],
        "Text": "Diagnosed epileptic patients of either sex with age between 10-19 yrs (<19yrs), coming to the medicine Out Patient /In Patient Departments and undergoing AED therapy for more than 6 months. . Epileptics with high homocysteine levels i.e. > 10.9 \u00b5mol/L (Normal homocysteine levels are 4.3-9.9 \u00b5mol/L for male and 3.3-7.2 \u00b5mol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 \u00b5mol/L for male and at least 10.4 \u00b5mol/L for female. Gender mean of high homocysteine concentration is 10.9 \u00b5mol/L) [5] . "
    },
    "NCT01373684_exc": {
        "Text": "Treatment with any investigational drug within 30 days of entry to this protocol. Current treatment with Telbivudine. Severe hepatitis activity as documented by ALT>10 x ULN. History of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy). Pre-existent neutropenia (neutrophils <1,500/mm3) or thrombocytopenia (platelets < 90,000/mm3). Co-infection with hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV). Other acquired or inherited causes of liver disease: alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency. Alpha fetoprotein > 50 ng/ml. Hyper- or hypothyroidism (subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met). Immune suppressive treatment within the previous 6 months. Contra-indications for alfa-interferon therapy like suspected hypersensitivity to interferon or Peginterferon or any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study.. Pregnancy, breast-feeding. Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant). Any medical condition requiring, or likely to require chronic systemic administration of steroids, during the course of the study. Substance abuse, such as alcohol (>80 g/day), I.V. drugs and inhaled drugs in the past 2 years.. Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study. ",
        "Annotations": [
            "Competing_trial 0 80--*--Treatment with any investigational drug within 30 days of entry to this protocol",
            "Drug 105 116--*--Telbivudine",
            "Condition 125 134--*--hepatitis",
            "Qualifier 118 124--*--Severe",
            "Measurement 161 164--*--ALT",
            "Value 164 173--*-->10 x ULN",
            "Condition 200 209--*--cirrhosis",
            "Qualifier 186 199--*--decompensated",
            "Condition 222 230--*--jaundice",
            "Condition 250 259--*--cirrhosis",
            "Condition 261 268--*--ascites",
            "Condition 270 286--*--bleeding gastric",
            "Condition 290 308--*--esophageal varices",
            "Condition 312 326--*--encephalopathy",
            "Scope 211 326--*--defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy",
            "Condition 342 353--*--neutropenia",
            "Qualifier 329 341--*--Pre-existent",
            "Measurement 355 366--*--neutrophils",
            "Value 367 377--*--<1,500/mm3",
            "Condition 382 398--*--thrombocytopenia",
            "Measurement 400 409--*--platelets",
            "Value 410 422--*--< 90,000/mm3",
            "Qualifier 443 460--*--hepatitis C virus",
            "Qualifier 462 479--*--hepatitis D virus",
            "Qualifier 483 511--*--human immunodeficiency virus",
            "Qualifier 513 516--*--HIV",
            "Condition 425 437--*--Co-infection",
            "Scope 443 516--*--hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV",
            "Condition 557 570--*--liver disease",
            "Qualifier 537 546--*--inherited",
            "Qualifier 525 533--*--acquired",
            "Scope 525 546--*--acquired or inherited",
            "Condition 572 595--*--alcoholic liver disease",
            "Condition 597 626--*--obesity induced liver disease",
            "Condition 628 654--*--drug related liver disease",
            "Condition 656 677--*--auto-immune hepatitis",
            "Condition 679 694--*--hemochromatosis",
            "Condition 696 712--*--Wilson's disease",
            "Condition 716 746--*--alpha-1 antitrypsin deficiency",
            "Scope 572 745--*--alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficienc",
            "Measurement 748 765--*--Alpha fetoprotein",
            "Value 766 776--*--> 50 ng/ml",
            "Condition 788 802--*--hypothyroidism",
            "Condition 778 783;792 802--*--Hyper thyroidism",
            "Drug 823 833--*--medication",
            "Non-query-able 804 939--*--subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met",
            "Procedure 942 970--*--Immune suppressive treatment",
            "Temporal 971 999--*--within the previous 6 months",
            "Condition 1001 1019--*--Contra-indications",
            "Drug 1024 1047--*--alfa-interferon therapy",
            "Condition 1063 1079--*--hypersensitivity",
            "Drug 1083 1093--*--interferon",
            "Drug 1097 1110--*--Peginterferon",
            "Non-query-able 1114 1239--*--any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study",
            "Scope 1083 1110--*--interferon or Peginterferon",
            "Pregnancy_considerations 1242 1267--*--Pregnancy, breast-feeding",
            "Qualifier 1275 1286--*--significant",
            "Condition 1287 1302--*--medical illness",
            "Qualifier 1341 1352--*--significant",
            "Condition 1353 1374--*--pulmonary dysfunction",
            "Temporal 1375 1399--*--in the previous 6 months",
            "Condition 1401 1411--*--malignancy",
            "Negation 1412 1422--*--other than",
            "Condition 1423 1450--*--skin basocellular carcinoma",
            "Temporal 1451 1470--*--in previous 5 years",
            "Condition 1472 1498--*--immunodeficiency syndromes",
            "Condition 1505 1519--*--HIV positivity",
            "Condition 1521 1541--*--auto-immune diseases",
            "Procedure 1543 1560--*--organ transplants",
            "Negation 1561 1571--*--other than",
            "Procedure 1572 1578;1588 1598--*--cornea transplant",
            "Procedure 1583 1598--*--hair transplant",
            "Scope 1572 1598--*--cornea and hair transplant",
            "Scope 1543 1598--*--organ transplants other than cornea and hair transplant",
            "Scope 1505 1598--*--HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant",
            "Scope 1401 1470--*--malignancy other than skin basocellular carcinoma in previous 5 years",
            "Scope 1341 1598--*--significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant",
            "Drug 1663 1671;1690 1698--*--systemic steroids",
            "Qualifier 1655 1662--*--chronic",
            "Temporal 1700 1730--*--during the course of the study",
            "Reference_point 1711 1730--*--course of the study",
            "Condition 1732 1747--*--Substance abuse",
            "Qualifier 1757 1764--*--alcohol",
            "Qualifier 1778 1788--*--I.V. drugs",
            "Qualifier 1793 1806--*--inhaled drugs",
            "Temporal 1807 1827--*--in the past 2 years.",
            "Multiplier 1766 1775--*-->80 g/day",
            "Scope 1757 1806--*--alcohol (>80 g/day), I.V. drugs and inhaled drugs",
            "Non-query-able 1829 2017--*--Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study"
        ]
    },
    "NCT02968342_inc": {
        "Text": "Menopausal status. Sexually active. ",
        "Annotations": [
            "Condition 0 10--*--Menopausal",
            "Observation 19 34--*--Sexually active"
        ]
    },
    "NCT02958072_exc": {
        "Text": "Hemoglobin concentration under 6.5 mmol/l screening . HBA1c more than 108 mmol/l . Non-compliant with blood-letting . Clinically infected ulcer . Patient planned for or has had a revascularization procedure in the affected leg within the last 8 weeks . The ulcer have been treated with growth factors in the last 8 weeks . History of deep venous insufficiency, chronic venous leg ulcer or stasis dermatitis . Breast-feeding women or fertile women not agreeing to use an effective method of contraception . Participation in another clinical ulcer-healing study within the last 4 weeks . Patient has previously been randomized in this study . Judgement by the investigator that the patient is not able to participate in the study       .     . ",
        "Annotations": [
            "Measurement 0 24--*--Hemoglobin concentration",
            "Value 25 41--*--under 6.5 mmol/l",
            "Measurement 53 58--*--HBA1c",
            "Value 59 79--*--more than 108 mmol/l",
            "Condition 81 94--*--Non-compliant",
            "Procedure 100 113--*--blood-letting",
            "Non-query-able 81 94--*--Non-compliant",
            "Condition 126 140--*--infected ulcer",
            "Procedure 175 202--*--revascularization procedure",
            "Reference_point 210 222--*--affected leg",
            "Temporal 223 246--*--within the last 8 weeks",
            "Observation 150 157--*--planned",
            "Observation 165 172--*--has had",
            "Scope 150 172--*--planned for or has had",
            "Condition 252 257--*--ulcer",
            "Procedure 268 275--*--treated",
            "Drug 281 295--*--growth factors",
            "Temporal 296 315--*--in the last 8 weeks",
            "Condition 328 353--*--deep venous insufficiency",
            "Condition 355 379--*--chronic venous leg ulcer",
            "Condition 383 400--*--stasis dermatitis",
            "Scope 328 400--*--deep venous insufficiency, chronic venous leg ulcer or stasis dermatitis",
            "Observation 317 324--*--History",
            "Condition 402 416--*--Breast-feeding",
            "Person 417 422--*--women",
            "Condition 426 433--*--fertile",
            "Person 434 439--*--women",
            "Observation 444 496--*--agreeing to use an effective method of contraception",
            "Negation 440 443--*--not",
            "Non-query-able 498 575--*--Participation in another clinical ulcer-healing study within the last 4 weeks",
            "Non-query-able 577 629--*--Patient has previously been randomized in this study",
            "Subjective_judgement 631 717--*--Judgement by the investigator that the patient is not able to participate in the study",
            "Non-query-able 631 717--*--Judgement by the investigator that the patient is not able to participate in the study"
        ]
    },
    "NCT02934269_exc": {
        "Text": "Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer). . Donation blood or serum within 8 weeks before the first dose administration to a blood bank or blood donation center. . History of alcohol or drug abuse (as defined by the current version of the DSM) within 2 years before the first dose administration, or positive alcohol or drug screen. . Vaccination within 30 days prior to the first dose administration or has plans to receive a vaccination during the course of the study (including the follow phone call on Day 105).       .     . ",
        "Annotations": [
            "Context_Error 0 240--*--Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer).",
            "Non-query-able 0 240--*--Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer).",
            "Procedure 242 256--*--Donation blood",
            "Grammar_Error 242 256--*--Donation blood",
            "Procedure 242 250;260 265--*--Donation serum",
            "Grammar_Error 242 250;260 265--*--Donation serum",
            "Temporal 266 287--*--within 8 weeks before",
            "Reference_point 292 317--*--first dose administration",
            "Condition 372 379;388 393--*--alcohol abuse",
            "Condition 383 393--*--drug abuse",
            "Observation 361 368--*--History",
            "Procedure 413 439--*--current version of the DSM",
            "Temporal 441 462--*--within 2 years before",
            "Reference_point 463 492--*--the first dose administration",
            "Measurement 506 513;522 528--*--alcohol screen",
            "Measurement 517 528--*--drug screen",
            "Value 497 505--*--positive",
            "Scope 372 393--*--alcohol or drug abuse",
            "Procedure 531 542--*--Vaccination",
            "Temporal 543 563--*--within 30 days prior",
            "Reference_point 567 596--*--the first dose administration",
            "Observation 604 609--*--plans",
            "Non-query-able 604 609--*--plans",
            "Procedure 623 634--*--vaccination",
            "Temporal 635 652--*--during the course",
            "Reference_point 660 665--*--study"
        ]
    },
    "NCT03260790_inc": {
        "Annotations": [
            "Condition 13 19--*--asthma"
        ],
        "Text": "Diagnosis of asthma. "
    },
    "NCT02219880_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT02934269_inc": {
        "Text": "Healthy male and/or female subjects between the ages of 18 and 55 years, and a body mass index (BMI) of \u2265 18 and \u2264 33 kg/m2 with body weight \u2265 50 and \u2264 90 kg at screening. . Females must have been surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening). . ",
        "Annotations": [
            "Person 8 12--*--male",
            "Condition 0 7--*--Healthy",
            "Person 20 26--*--female",
            "Person 48 52--*--ages",
            "Value 36 43;56 71--*--between 18 and 55 years",
            "Measurement 79 100--*--body mass index (BMI)",
            "Value 104 123--*--\u2265 18 and \u2264 33 kg/m2",
            "Measurement 129 140--*--body weight",
            "Value 141 157--*--\u2265 50 and \u2264 90 kg",
            "Temporal 158 170--*--at screening",
            "Reference_point 161 170--*--screening",
            "Scope 79 157--*--body mass index (BMI) of \u2265 18 and \u2264 33 kg/m2 with body weight \u2265 50 and \u2264 90 kg",
            "Person 173 180--*--Females",
            "Condition 196 217--*--surgically sterilized",
            "Procedure 219 231--*--hysterectomy",
            "Procedure 233 255--*--bilateral oophorectomy",
            "Procedure 260 291--*--bilateral salpingo-oophorectomy",
            "Temporal 324 348--*--at least 6 months before",
            "Reference_point 349 358--*--screening",
            "Scope 219 291--*--hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy",
            "Condition 366 380--*--postmenopausal",
            "Temporal 393 414--*--24 consecutive months",
            "Condition 423 429--*--menses",
            "Negation 415 422--*--without",
            "Temporal 430 446--*--before screening",
            "Reference_point 437 446--*--screening",
            "Measurement 455 489--*--follicle-stimulating hormone [FSH]",
            "Value 499 508--*--> 40 IU/L",
            "Temporal 509 521--*--at screening",
            "Reference_point 512 521--*--screening",
            "Scope 393 521--*--24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening",
            "Scope 196 522--*--surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening)"
        ]
    },
    "NCT02958072_inc": {
        "Text": "Diabetes mellitus . Foot ulcer at the malleoli area between 0,25 cm\u00b2 and 5,0 cm\u00b2 . Foot ulcer duration more than 6 weeks . Ankle-brachial index above 0,40 or presence of palpable pulses in arteria dorsalis pedes and/or arteria tibialis posterior . informed consent . ",
        "Annotations": [
            "Condition 0 17--*--Diabetes mellitus",
            "Condition 19 29--*--Foot ulcer",
            "Qualifier 37 50--*--malleoli area",
            "Value 51 79--*--between 0,25 cm\u00b2 and 5,0 cm\u00b2",
            "Condition 81 91--*--Foot ulcer",
            "Temporal 101 118--*--more than 6 weeks",
            "Measurement 120 140--*--Ankle-brachial index",
            "Value 141 151--*--above 0,40",
            "Condition 167 182--*--palpable pulses",
            "Reference_point 186 208--*--arteria dorsalis pedes",
            "Reference_point 216 242--*--arteria tibialis posterior",
            "Scope 186 242--*--arteria dorsalis pedes and/or arteria tibialis posterior",
            "Non-query-able 244 260--*--informed consent",
            "Post-eligibility 244 260--*--informed consent"
        ]
    },
    "NCT02219880_inc": {
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 24--*--between 18-70 years",
            "Measurement 36 108--*--Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria",
            "Scope 26 31--*--Meets",
            "Condition 113 141--*--generalised anxiety disorder",
            "Condition 143 146--*--GAD",
            "Procedure 157 177--*--structured interview",
            "Procedure 179 245--*--Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6]",
            "Condition 362 369--*--anxiety",
            "Measurement 371 400--*--Hamilton Anxiety Rating Scale",
            "Value 401 405--*--= 18",
            "Temporal 407 433--*--at the time of study entry",
            "Reference_point 414 433--*--time of study entry",
            "Non-query-able 435 471--*--Fluent in written and spoken English",
            "Non-query-able 473 515--*--Provides a signed copy of the consent form",
            "Condition 546 549--*--GAD",
            "Condition 517 534--*--Primary diagnosis",
            "Negation 535 545--*--other than",
            "Qualifier 567 585--*--moderate to severe",
            "Condition 586 605--*--depressive symptoms",
            "Scope 567 605--*--moderate to severe depressive symptoms",
            "Measurement 607 637--*--Montgomery-Asberg Rating Scale",
            "Measurement 639 644--*--MADRS",
            "Value 645 649--*--= 18",
            "Temporal 650 672--*--at time of study entry",
            "Value 676 680--*--= 24",
            "Temporal 681 705--*--at any time during study",
            "Scope 645 705--*--= 18 at time of study entry or = 24 at any time during study",
            "Scope 607 644--*--Montgomery-Asberg Rating Scale: MADRS",
            "Scope 607 705--*--Montgomery-Asberg Rating Scale: MADRS = 18 at time of study entry or = 24 at any time during study",
            "Condition 724 741--*--suicidal ideation",
            "Value 743 746--*--= 3",
            "Measurement 750 780--*--MADRS suicidal thoughts domain",
            "Temporal 781 803--*--at time of study entry",
            "Temporal 807 831--*--at any time during study",
            "Scope 781 831--*--at time of study entry or at any time during study",
            "Scope 743 831--*--= 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study",
            "Condition 855 871--*--bipolar disorder",
            "Condition 875 888--*--schizophrenia",
            "Measurement 892 912--*--structured interview",
            "Measurement 914 923--*--MINI Plus",
            "Scope 855 888--*--bipolar disorder or schizophrenia",
            "Condition 944 964--*--alcohol use disorder",
            "Condition 934 943;952 964--*--substance use disorder",
            "Measurement 968 988--*--structured interview",
            "Measurement 990 999--*--MINI Plus",
            "Scope 934 964--*--substance/alcohol use disorder",
            "Drug 1061 1075--*--antidepressant",
            "Condition 1051 1057--*--taking",
            "Temporal 1041 1050--*--Currently",
            "Drug 1077 1092--*--mood stabiliser",
            "Drug 1094 1107--*--antipsychotic",
            "Drug 1109 1123--*--anticonvulsant",
            "Drug 1125 1133--*--warfarin",
            "Drug 1137 1145--*--thyroxin",
            "Drug 1203 1217--*--benzodiazepine",
            "Drug 1221 1243--*--opioid-based analgesic",
            "Multiplier 1171 1196--*--more than 2 days per week",
            "Multiplier 1158 1165--*--regular",
            "Temporal 1150 1157--*--current",
            "Scope 1203 1243--*--benzodiazepine or opioid-based analgesic",
            "Scope 1061 1145--*--antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin",
            "Procedure 1166 1169--*--use",
            "Drug 1262 1288--*--psychotropic nutraceutical",
            "Condition 1295 1309--*--St John's wort",
            "Temporal 1245 1252--*--Current",
            "Procedure 1253 1256--*--use",
            "Condition 1321 1332--*--intolerance",
            "Drug 1336 1340--*--kava",
            "Temporal 1312 1320--*--Previous",
            "Multiplier 1342 1355--*--Three or more",
            "Procedure 1363 1388--*--trials of pharmacotherapy",
            "Qualifier 1356 1362--*--failed",
            "Condition 1405 1416--*--GAD episode",
            "Temporal 1397 1404--*--current",
            "Procedure 1437 1450--*--psychotherapy",
            "Temporal 1452 1484--*--within four weeks of study entry",
            "Temporal 1418 1426--*--Recently",
            "Qualifier 1506 1525--*--clinically unstable",
            "Qualifier 1526 1534--*--systemic",
            "Condition 1535 1551--*--medical disorder",
            "Mood 1496 1505--*--suspected",
            "Mood 1487 1492--*--Known",
            "Scope 1487 1505--*--Known or suspected",
            "Condition 1563 1585--*--hepato-biliary disease",
            "Condition 1563 1577;1586 1598--*--hepato-biliary inflammation",
            "Value 1600 1608--*--Elevated",
            "Measurement 1609 1622--*--liver enzymes",
            "Temporal 1626 1634--*--baseline",
            "Procedure 1635 1645--*--blood test",
            "Condition 1647 1656--*--Pregnancy",
            "Observation 1660 1673--*--breastfeeding",
            "Condition 1678 1696--*--trying to conceive",
            "Negation 1698 1701--*--Not",
            "Qualifier 1708 1726--*--medically approved",
            "Procedure 1727 1740--*--contraception",
            "Procedure 1752 1762--*--abstinence",
            "Person 1767 1773--*--female",
            "Person 1781 1797--*--childbearing age",
            "Observation 1794 1797--*--age",
            "Value 1781 1793--*--childbearing",
            "Scope 1781 1797--*--childbearing age",
            "Scope 1767 1797--*--female and of childbearing age",
            "Scope 1698 1763--*--Not using medically approved contraception (including abstinence)",
            "Observation 1799 1820--*--Unable to participate",
            "Visit 1828 1844--*--scheduled visits",
            "Observation 1846 1860--*--treatment plan",
            "Procedure 1871 1887--*--trial procedures",
            "Negation 1915 1925--*--except for",
            "Observation 1939 1956--*--genetic component",
            "Scope 1828 1887--*--scheduled visits, treatment plan, or other trial procedures"
        ],
        "Text": "Aged between 18-70 years. Meets the Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria for generalised anxiety disorder (GAD) based on structured interview (Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6]. Note that while the MINI-Plus 6 uses the DSM-IV criteria, the same criteria are used in the DSM-V).. Presents with anxiety (Hamilton Anxiety Rating Scale = 18) at the time of study entry. Fluent in written and spoken English. Provides a signed copy of the consent form. Primary diagnosis other than GAD. Presentation of moderate to severe depressive symptoms (Montgomery-Asberg Rating Scale: MADRS = 18 at time of study entry or = 24 at any time during study). Presentation of suicidal ideation (= 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study). Current diagnosis of bipolar disorder or schizophrenia on structured interview (MINI Plus). Current substance/alcohol use disorder on structured interview (MINI Plus) Page 21 of 39 Commercial-in-Confidence. Currently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin, or current regular use (more than 2 days per week) of a benzodiazepine or opioid-based analgesic. Current use of a psychotropic nutraceutical (e.g. St John's wort). Previous intolerance to kava. Three or more failed trials of pharmacotherapy for the current GAD episode. Recently commenced psychotherapy (within four weeks of study entry). Known or suspected clinically unstable systemic medical disorder. Diagnosed hepato-biliary disease/inflammation. Elevated liver enzymes at baseline blood test. Pregnancy or breastfeeding, or trying to conceive. Not using medically approved contraception (including abstinence) if female and of childbearing age. Unable to participate in all scheduled visits, treatment plan, or other trial procedures according to the protocol (except for the optional genetic component). "
    },
    "NCT03260790_exc": {
        "Annotations": [
            "Observation 0 28--*--Research exemption requested",
            "Observation 30 37--*--History",
            "Procedure 41 59--*--PCV-13 vaccination",
            "Observation 61 68--*--History",
            "Device 72 88--*--cochlear implant",
            "Condition 90 120--*--Cerebrospinal Fluid (CSF) leak",
            "Condition 122 152--*--Congestive Heart Failure (CHF)",
            "Condition 154 176--*--Diabetes Mellitus (DM)",
            "Condition 178 206--*--Chronic Kidney Disease (CKD)",
            "Condition 208 242--*--Human Immunodeficiency Virus (HIV)",
            "Condition 244 284--*--Common Variable Immune Deficiency (CVID)",
            "Drug 317 331--*--PPSV23 vaccine",
            "Temporal 332 351--*--in the last 5 years",
            "Person 353 358--*--Women",
            "Condition 367 375--*--pregnant",
            "Procedure 429 464--*--point of care urine pregnancy tests",
            "Multiplier 427 428--*--2",
            "Temporal 467 488--*--prior to vaccinations",
            "Procedure 476 488--*--vaccinations",
            "Reference_point 476 488--*--vaccinations"
        ],
        "Text": "Research exemption requested. History of PCV-13 vaccination. History of cochlear implant. Cerebrospinal Fluid (CSF) leak. Congestive Heart Failure (CHF). Diabetes Mellitus (DM). Chronic Kidney Disease (CKD). Human Immunodeficiency Virus (HIV). Common Variable Immune Deficiency (CVID). Patients who have received the PPSV23 vaccine in the last 5 years. Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations). "
    },
    "NCT03380429_inc": {
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 31--*--18 years or older",
            "Temporal 33 76--*--at the time of signing the informed consent",
            "Reference_point 48 76--*--signing the informed consent",
            "Condition 127 133--*--asthma",
            "Qualifier 143 170--*--primary respiratory disease",
            "Measurement 173 182--*--ACT score",
            "Value 183 186--*--<20",
            "Temporal 187 205--*--at screening visit",
            "Observation 208 219--*--Non-smokers",
            "Observation 221 233--*--never smoked",
            "Observation 237 248--*--not smoking",
            "Temporal 249 262--*--for >6 months",
            "Value 268 271--*--<10",
            "Measurement 272 282--*--pack years",
            "Non-representable 292 372--*--Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked",
            "Scope 221 372--*--never smoked or not smoking for >6 months with <10 pack years history (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked",
            "Person 376 380--*--Male",
            "Person 384 390--*--female",
            "Pregnancy_considerations 418 763--*--A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (i) Not a woman of childbearing potential (WOCBP). (ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days] after the last dose of study treatment.",
            "Informed_consent 765 912--*--Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and protocol.",
            "Non-query-able 914 1016--*--Subject understands and is willing, able, and likely to comply with study procedures and restrictions.",
            "Non-query-able 1018 1110--*--Subject must be able to read in a language supported by the smart phone app in their region.",
            "Procedure 1138 1157--*--maintenance therapy",
            "Multiplier 1159 1169--*--Fixed dose",
            "Drug 1170 1190--*--combination ICS/LABA",
            "Temporal 1192 1204--*--for 3 months",
            "Negation 1206 1212--*--cannot",
            "Multiplier 1218 1230--*--changed dose",
            "Temporal 1231 1262--*--in the month prior to screening",
            "Reference_point 1234 1262--*--the month prior to screening",
            "Non-representable 1263 1517--*--and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study. Other background asthma medication such as anti-leukotrienes and oral corticosteroids are permitted provided the dose has been stable for 1 month prior to screening",
            "Mood 1536 1543--*--able to",
            "Procedure 1544 1550--*--change",
            "Drug 1554 1564--*--Salbutamol",
            "Drug 1565 1574--*--Albuterol",
            "Procedure 1575 1585--*--MDI rescue",
            "Temporal 1586 1615--*--for the duration of the study",
            "Reference_point 1590 1615--*--the duration of the study",
            "Condition 1627 1649--*--capable of withholding",
            "Drug 1650 1659--*--albuterol",
            "Drug 1660 1670--*--salbutamol",
            "Multiplier 1671 1691--*--for at least 6 hours",
            "Temporal 1692 1713--*--prior to study visits",
            "Scope 1650 1670--*--albuterol/salbutamol",
            "Non-query-able 1716 2047--*--Subject must have their own Android or iPhone operating system (IOS) smart phone and a data package suitable for the installation and running of the app and sending and receiving data. Data used by the CIS is approximately 1 megabyte (MB) per month as a maximum; this is less data than a 1 minute video streamed from YouTube (2MB).",
            "Non-query-able 2049 2418--*--Subjects must be willing and able to download the app on their personal smart phone and keep it turned on for the duration of the study. This will also require Bluetooth to be turned on for duration of the study. Subjects will also have to turn on mobile data for the app for the duration of study; unless travelling and when extra data roaming costs could be incurred.",
            "Measurement 2420 2429--*--ACT score",
            "Value 2430 2433--*--<20",
            "Temporal 2434 2456--*--at randomization visit"
        ],
        "Text": "Subjects aged 18 years or older, at the time of signing the informed consent.. Subjects with documented physician diagnosis of asthma as their primary respiratory disease.. ACT score <20 at screening visit.. Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked).. Male or female subjects will be included. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (i) Not a woman of childbearing potential (WOCBP). (ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days] after the last dose of study treatment.. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and protocol.. Subject understands and is willing, able, and likely to comply with study procedures and restrictions.. Subject must be able to read in a language supported by the smart phone app in their region.. Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3 months, cannot have changed dose in the month prior to screening and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study. Other background asthma medication such as anti-leukotrienes and oral corticosteroids are permitted provided the dose has been stable for 1 month prior to screening.. Subject must be able to change to Salbutamol/Albuterol MDI rescue for the duration of the study and judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.. Subject must have their own Android or iPhone operating system (IOS) smart phone and a data package suitable for the installation and running of the app and sending and receiving data. Data used by the CIS is approximately 1 megabyte (MB) per month as a maximum; this is less data than a 1 minute video streamed from YouTube (2MB).. Subjects must be willing and able to download the app on their personal smart phone and keep it turned on for the duration of the study. This will also require Bluetooth to be turned on for duration of the study. Subjects will also have to turn on mobile data for the app for the duration of study; unless travelling and when extra data roaming costs could be incurred.. ACT score <20 at randomization visit (visit 2).. "
    },
    "NCT03249272_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 7 12--*--women",
            "Person 13 17--*--aged",
            "Value 18 35--*--18 years or older",
            "Condition 96 123--*--hypertrophic cardiomyopathy",
            "Measurement 133 164--*--left ventricular wall thickness",
            "Value 168 183--*--at least =15 mm",
            "Negation 191 198--*--absence",
            "Condition 223 252--*--systemic cause of hypertrophy",
            "Condition 212 219;232 252--*--cardiac cause of hypertrophy",
            "Scope 212 252--*--cardiac or systemic cause of hypertrophy",
            "Condition 313 346--*--idiopathic dilated cardiomyopathy",
            "Measurement 358 392--*--left ventricular ejection fraction",
            "Value 393 397--*--=40%",
            "Measurement 399 424--*--LV end-diastolic diameter",
            "Value 425 431--*--=55 mm",
            "Measurement 435 473--*--left ventricular end-systolic diameter",
            "Value 474 480--*--=45 mm",
            "Negation 490 497--*--absence",
            "Condition 501 518--*--coronary stenoses",
            "Procedure 522 533--*--angiography",
            "Scope 358 480--*--left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm",
            "Condition 578 588--*--chest pain",
            "Negation 593 600--*--without",
            "Condition 613 648--*--obstructive coronary artery disease",
            "Procedure 659 679--*--coronary angiography",
            "Procedure 683 697--*--stress testing",
            "Scope 659 697--*--coronary angiography or stress testing"
        ],
        "Text": "Men or women aged 18 years or older. Patients presenting for CMR with the clinical diagnosis of hypertrophic cardiomyopathy based on left ventricular wall thickness of at least =15 mm in the absence of any other cardiac or systemic cause of hypertrophy. Patients presenting for CMR with the clinical diagnosis of idiopathic dilated cardiomyopathy based upon left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm, and the absence of coronary stenoses on angiography.. Patients presenting for CMR evaluation of chest pain but without evidence of obstructive coronary artery disease either by coronary angiography or stress testing.. "
    },
    "NCT02175186_inc": {
        "Text": "Age between 20 and 80 years. Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks. Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy. mild gastrointestinal symptom. Creatinen in blood = 3mg/dl. BUN = 50mg/dl. Birilubin = 3mg/dl. AST and ALT = 80U/L. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 27--*--between 20 and 80 years",
            "Procedure 49 83--*--percutaneous coronary intervention",
            "Procedure 101 126--*--dual antiplatelet therapy",
            "Qualifier 127 139--*--continuously",
            "Temporal 140 156--*--at least 12weeks",
            "Measurement 158 184--*--Modified Lanza Score grade",
            "Value 185 188--*--0-1",
            "Procedure 201 233--*--upper gastrointestinal endoscopy",
            "Condition 240 264--*--gastrointestinal symptom",
            "Qualifier 235 239--*--mild",
            "Measurement 266 275--*--Creatinen",
            "Value 285 293--*--= 3mg/dl",
            "Measurement 295 298--*--BUN",
            "Value 299 308--*--= 50mg/dl",
            "Measurement 310 319--*--Birilubin",
            "Value 320 328--*--= 3mg/dl",
            "Measurement 330 333--*--AST",
            "Measurement 338 341--*--ALT",
            "Scope 330 341--*--AST and ALT",
            "Value 342 349--*--= 80U/L"
        ]
    },
    "NCT03404804_inc": {
        "Annotations": [
            "Person 0 8--*--Children",
            "Person 9 13--*--aged",
            "Value 14 18--*--3-16",
            "Condition 88 95--*--allergy",
            "Drug 101 122--*--penicillin antibiotic",
            "Temporal 172 222--*--at least six months prior to the current PED visit",
            "Condition 145 162--*--allergic reaction",
            "Condition 239 275--*--well enough to be discharged to home",
            "Temporal 276 310--*--at the conclusion of the PED visit",
            "Reference_point 279 310--*--the conclusion of the PED visit",
            "Visit 301 304--*--PED"
        ],
        "Text": "Children aged 3-16 with a parent/guardian (hereafter termed parent) reported history of allergy to a penicillin antibiotic in which the reported allergic reaction occurred at least six months prior to the current PED visit.. Only children well enough to be discharged to home at the conclusion of the PED visit are eligible.. "
    },
    "NCT01314898_exc": {
        "Text": "Subjects with a supine BP >140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic based on the average of the triplicate . Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary. . Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.       .     . ",
        "Annotations": [
            "Measurement 16 25--*--supine BP",
            "Value 26 45--*-->140 mm Hg systolic",
            "Value 49 68--*-->90 mm Hg diastolic",
            "Value 72 91--*--<100 mm Hg systolic",
            "Value 95 114--*--<60 mm Hg diastolic",
            "Scope 26 114--*-->140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic",
            "Measurement 155 170--*--Serum potassium",
            "Value 171 183--*-->=5.1 mmol/L",
            "Value 187 198--*--<3.5 mmol/L",
            "Temporal 199 211--*--at screening",
            "Scope 171 198--*-->=5.1 mmol/L or <3.5 mmol/L",
            "Measurement 264 277--*--Estimated GFR",
            "Value 278 296--*--<60 mL/min/1.73 m2",
            "Observation 307 330--*--Cockcroft-Gault formula"
        ]
    },
    "NCT03560310_exc": {
        "Annotations": [
            "Observation 11 33--*--enrolled in this study",
            "Temporal 0 10--*--Previously",
            "Procedure 86 104--*--surgical procedure",
            "Temporal 74 85--*--Concomitant",
            "Procedure 116 120--*--CABG",
            "Qualifier 105 115--*--other than",
            "Procedure 122 145--*--Anticoagulant treatment",
            "Temporal 146 165--*--after the operation",
            "Reference_point 152 165--*--the operation",
            "Procedure 156 165--*--operation",
            "Drug 172 180--*--warfarin",
            "Drug 182 208--*--direct thrombin inhibitors",
            "Drug 210 220--*--dabigatran",
            "Drug 223 237--*--FXa inhibitors",
            "Drug 239 250--*--rivaroxaban",
            "Drug 252 260--*--apixaban",
            "Drug 262 269--*--heparin",
            "Drug 271 299--*--low-molecular weight heparin",
            "Drug 301 313--*--fondaparinux",
            "Scope 239 313--*--rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux",
            "Scope 172 313--*--warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux",
            "Observation 316 325--*--Discharge",
            "Visit 335 353--*--operating hospital",
            "Visit 360 363--*--ICU",
            "Qualifier 367 374--*--another",
            "Visit 375 383--*--hospital",
            "Scope 360 383--*--ICU at another hospital",
            "Condition 385 394--*--Pregnancy",
            "Condition 398 407--*--lactation",
            "Condition 430 446--*--contraindication",
            "Condition 415 426--*--intolerance",
            "Drug 450 460--*--ticagrelor",
            "Drug 464 467--*--ASA",
            "Scope 415 446--*--intolerance or contraindication",
            "Scope 450 467--*--ticagrelor or ASA",
            "Condition 473 481--*--disorder",
            "Qualifier 487 521--*--may interfere with drug absorption",
            "Condition 548 571--*--coronary artery disease",
            "Negation 537 547--*--other than",
            "Condition 527 536--*--condition",
            "Observation 579 594--*--life expectancy",
            "Value 595 605--*--<12 months",
            "Condition 613 634--*--chronic liver disease",
            "Condition 636 649--*--renal disease",
            "Procedure 660 668--*--dialysis",
            "Condition 672 689--*--bleeding disorder",
            "Mood 650 659--*--requiring",
            "Condition 691 716--*--Atrioventricular block II",
            "Condition 691 713;721 724--*--Atrioventricular block III",
            "Negation 737 744--*--without",
            "Device 745 754--*--pacemaker",
            "Condition 781 806--*--dual antiplatelet therapy",
            "Procedure 820 838--*--stent implantation",
            "Temporal 813 819--*--recent",
            "Condition 766 776--*--indication",
            "Scope 766 806--*--indication for dual antiplatelet therapy",
            "Scope 813 838--*--recent stent implantation",
            "Temporal 860 891--*--within 90 days before inclusion",
            "Condition 853 859--*--stroke",
            "Condition 840 852--*--Debilitating",
            "Temporal 893 901--*--Previous",
            "Procedure 902 923--*--intracranial bleeding",
            "Drug 940 958--*--immunosuppressants",
            "Drug 965 977--*--cyclosporine",
            "Drug 982 992--*--tacrolimus",
            "Scope 965 992--*--cyclosporine and tacrolimus",
            "Drug 1010 1034--*--strong CYP3A4-inhibitors",
            "Drug 1041 1053--*--ketoconazole",
            "Drug 1055 1069--*--clarithromycin",
            "Drug 1071 1081--*--nefazodone",
            "Drug 1083 1092--*--ritonavir",
            "Drug 1096 1106--*--atazanavir",
            "Scope 1041 1106--*--ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir",
            "Non-query-able 1109 1209--*--Any condition that in the opinion of the investigator may interfere with adherence to trial protocol"
        ],
        "Text": "Previously enrolled in this study (i.e. patient now at repeat encounter). Concomitant surgical procedure other than CABG. Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux). Discharge from the operating hospital to an ICU at another hospital. Pregnancy or lactation. Known intolerance or contraindication to ticagrelor or ASA. Any disorder that may interfere with drug absorption. Any condition other than coronary artery disease with a life expectancy <12 months. Known chronic liver disease, renal disease requiring dialysis or bleeding disorder. Atrioventricular block II and III in patients without pacemaker. Any other indication for dual antiplatelet therapy, i.e. recent stent implantation. Debilitating stroke within 90 days before inclusion. Previous intracranial bleeding. Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus). Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir). Any condition that in the opinion of the investigator may interfere with adherence to trial protocol. "
    },
    "NCT02606565_inc": {
        "Annotations": [
            "Person 0 8--*--Newborns",
            "Measurement 9 17--*--weighing",
            "Value 18 31--*--1.5kg or more",
            "Temporal 32 40--*--at birth"
        ],
        "Text": "Newborns weighing 1.5kg or more at birth. "
    },
    "NCT01912677_inc": {
        "Text": "Pregnant gestational age >= 28 weeks. Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart. Able to swallow pills. >= 18 years. ",
        "Annotations": [
            "Measurement 9 24--*--gestational age",
            "Value 25 36--*-->= 28 weeks",
            "Measurement 38 61--*--Systolic blood pressure",
            "Value 62 73--*-->=160 mm Hg",
            "Measurement 79 103--*--diastolic blood pressure",
            "Value 107 118--*-->=110 mm Hg",
            "Non-query-able 119 160--*--measured twice more than 15 minutes apart",
            "Post-eligibility 162 183--*--Able to swallow pills",
            "Person 191 196--*--years",
            "Value 185 190--*-->= 18"
        ]
    },
    "NCT02427295_inc": {
        "Text": "Age 18 or older.. Patients diagnosed with acromegaly with GH-secreting pituitary adenoma on sellar MRI, meeting the biochemical criteria outlined above (refer to 1. Diagnosis of acromegaly) and with typical acromegalic features.. No prior use of somatostatin analogues.. Adequate hepatic and renal function. Provision of a signed written informed consent. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--18 or older",
            "Condition 42 52--*--acromegaly",
            "Condition 58 88--*--GH-secreting pituitary adenoma",
            "Procedure 92 102--*--sellar MRI",
            "Qualifier 116 151--*--biochemical criteria outlined above",
            "Condition 207 227--*--acromegalic features",
            "Qualifier 199 206--*--typical",
            "Drug 246 268--*--somatostatin analogues",
            "Negation 230 232--*--No",
            "Temporal 233 238--*--prior",
            "Condition 271 279;292 306--*--Adequate renal function",
            "Condition 271 287;298 306--*--Adequate hepatic function",
            "Informed_consent 308 354--*--Provision of a signed written informed consent"
        ]
    },
    "NCT03431831_inc": {
        "Annotations": [
            "Condition 0 10--*--Overweight",
            "Condition 11 16--*--Obese",
            "Person 17 22--*--Adult",
            "Person 33 36--*--age",
            "Value 37 49--*--19 years -65",
            "Procedure 70 89--*--WALI screening tool",
            "Value 52 60--*--eligible"
        ],
        "Text": "Overweight/Obese Adult patients (age 19 years -65). eligible based on WALI screening tool. "
    },
    "NCT03388840_exc": {
        "Annotations": [
            "Condition 14 50--*--Non-androgenetic causes of hair loss",
            "Person 53 59--*--Female",
            "Condition 74 95--*--androgenetic alopecia",
            "Procedure 120 144--*--anti-hair loss treatment",
            "Temporal 145 171--*--within the past six months",
            "Condition 199 217--*--bleeding disorders",
            "Procedure 224 245--*--anticoagulant therapy",
            "Condition 273 294--*--chronic liver disease",
            "Condition 296 302--*--cancer",
            "Condition 306 333--*--connective tissue disorders",
            "Temporal 350 357--*--current",
            "Condition 358 373--*--scalp infection",
            "Observation 188 195--*--history",
            "Observation 262 269--*--history",
            "Scope 199 245--*--bleeding disorders or on anticoagulant therapy",
            "Scope 273 333--*--chronic liver disease, cancer or connective tissue disorders"
        ],
        "Text": "Patients with Non-androgenetic causes of hair loss.. Female patients with androgenetic alopecia.. Patients who received anti-hair loss treatment within the past six months.. Patients with history of bleeding disorders or on anticoagulant therapy.. Patients with history of chronic liver disease, cancer or connective tissue disorders.. Patients with current scalp infection.. "
    },
    "NCT02995291_inc": {
        "Annotations": [
            "Person 12 15--*--age",
            "Value 0 11;16 24--*--18 years of or older",
            "Informed_consent 26 63--*--capable of providing informed consent"
        ],
        "Text": "18 years of age or older. capable of providing informed consent. "
    },
    "NCT02788045_exc": {
        "Text": "Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection . Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) . Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation . Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination . Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis       .     . ",
        "Annotations": [
            "Condition 4 23--*--chronic hepatitis B",
            "Measurement 37 69--*--hepatitis B surface antigen test",
            "Condition 74 92--*--active hepatitis C",
            "Measurement 106 137--*--hepatitis C virus [HCV] Ab test",
            "Value 142 150--*--positive",
            "Measurement 152 187--*--HCV ribonucleic acid [RNA] PCR test",
            "Qualifier 247 253--*--active",
            "Condition 254 272--*--syphilis infection",
            "Condition 274 283--*--chlamydia",
            "Condition 285 294--*--gonorrhea",
            "Condition 299 310--*--trichomonas",
            "Qualifier 313 319--*--Active",
            "Condition 320 328--*--syphilis",
            "Measurement 343 351--*--serology",
            "Measurement 368 376--*--serology",
            "Value 359 367--*--positive",
            "Condition 392 409--*--treated infection",
            "Negation 352 358--*--unless",
            "Procedure 421 434--*--thyroidectomy",
            "Condition 445 460--*--thyroid disease",
            "Qualifier 438 444--*--active",
            "Drug 471 481--*--medication",
            "Temporal 482 507--*--during the last 12 months",
            "Drug 532 555--*--thyroid supplementation",
            "Qualifier 525 531--*--stable",
            "Condition 572 591--*--psychiatric illness",
            "Qualifier 566 571--*--major",
            "Undefined_semantics 566 571--*--major",
            "Condition 599 614--*--substance abuse",
            "Temporal 624 649--*--during the past 12 months",
            "Procedure 661 676--*--hospitalization",
            "Condition 691 706--*--work disability",
            "Scope 661 706--*--hospitalization or periods of work disability",
            "Scope 566 614--*--major psychiatric illness and/or substance abuse",
            "Subjective_judgement 713 747--*--in the opinion of the investigator",
            "Context_Error 754 776--*--preclude participation",
            "Drug 805 821--*--licensed vaccine",
            "Temporal 822 842--*--within 14 days prior",
            "Reference_point 846 885--*--the first dose of study vaccine/placebo",
            "Temporal 904 924--*--within 14 days after",
            "Reference_point 929 952--*--first study vaccination",
            "Drug 864 877--*--study vaccine",
            "Drug 878 885--*--placebo",
            "Procedure 935 952--*--study vaccination",
            "Non-query-able 957 965--*--plans to",
            "Temporal 974 1004--*--within 14 days before or after",
            "Reference_point 1009 1044--*--second, third or fourth vaccination",
            "Drug 1033 1044--*--vaccination",
            "Non-query-able 887 895--*--plans to",
            "Scope 822 1044--*--within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination",
            "Drug 1094 1115--*--HIV vaccine candidate",
            "Temporal 1116 1127--*--at any time",
            "Drug 1147 1176--*--other experimental vaccine(s)",
            "Context_Error 1147 1176--*--other experimental vaccine(s)",
            "Temporal 1177 1202--*--within the last 12 months",
            "Qualifier 1082 1093--*--therapeutic",
            "Qualifier 1066 1078--*--prophylactic",
            "Scope 1066 1093--*--prophylactic or therapeutic",
            "Drug 1237 1257--*--experimental vaccine",
            "Drug 1266 1277--*--HIV vaccine",
            "Negation 1259 1265--*--except",
            "Temporal 1279 1302--*--more than 12 months ago",
            "Context_Error 1237 1257--*--experimental vaccine",
            "Undefined_semantics 1237 1257--*--experimental vaccine",
            "Subjective_judgement 1431 1449--*--case-by-case basis",
            "Negation 509 521--*--not excluded"
        ]
    },
    "NCT02437084_inc": {
        "Text": "Healthy adults 30- 65 years old,. BMI 25-35 kg/m2,. nondiabetic as defined by fasting plasma glucose <126 mg/dL. Lipids: one group with an LDL =/>130 and Triglycerides < 150 mg/dL The 2nd group will have and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL but less than 400 mg/dL.. ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 8 14--*--adults",
            "Value 15 31--*--30- 65 years old",
            "Person 28 31--*--old",
            "Measurement 34 37--*--BMI",
            "Value 38 49--*--25-35 kg/m2",
            "Condition 52 63--*--nondiabetic",
            "Measurement 78 100--*--fasting plasma glucose",
            "Value 101 111--*--<126 mg/dL",
            "Measurement 139 142--*--LDL",
            "Value 143 149--*--=/>130",
            "Measurement 154 167--*--Triglycerides",
            "Value 168 179--*--< 150 mg/dL",
            "Non-representable 180 279--*--The 2nd group will have and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL but less than 400 mg/dL.",
            "Non-representable 121 135--*--one group with"
        ]
    },
    "NCT03380429_exc": {
        "Annotations": [
            "Intoxication_considerations 0 179--*--Subjects with a known or suspected alcohol or drug abuse which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.",
            "Qualifier 192 208--*--life threatening",
            "Condition 209 215--*--asthma",
            "Condition 231 245--*--asthma episode",
            "Qualifier 251 270--*--required intubation",
            "Procedure 260 270--*--intubation",
            "Condition 298 309--*--hypercapnea",
            "Condition 311 329--*--respiratory arrest",
            "Condition 333 349--*--hypoxic seizures",
            "Temporal 350 374--*--within the last 6 months",
            "Scope 298 349--*--hypercapnea, respiratory arrest or hypoxic seizures",
            "Scope 231 374--*--asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months",
            "Condition 379 412--*--lower respiratory tract infection",
            "Temporal 413 449--*--within 7 days of the screening visit",
            "Reference_point 434 449--*--screening visit",
            "Condition 476 520--*--chronic obstructive pulmonary disease (COPD)",
            "Qualifier 524 529--*--other",
            "Condition 530 551--*--respiratory disorders",
            "Qualifier 562 568--*--active",
            "Condition 569 581--*--tuberculosis",
            "Condition 583 594--*--lung cancer",
            "Condition 596 610--*--bronchiectasis",
            "Condition 612 623--*--sarcoidosis",
            "Condition 625 638--*--lung fibrosis",
            "Condition 640 662--*--pulmonary hypertension",
            "Condition 664 690--*--interstitial lung diseases",
            "Qualifier 694 699--*--other",
            "Qualifier 700 706--*--active",
            "Condition 707 725--*--pulmonary diseases",
            "Scope 476 551--*--chronic obstructive pulmonary disease (COPD) or other respiratory disorders",
            "Scope 562 725--*--active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases",
            "Condition 739 755--*--hypersensitivity",
            "Condition 756 767--*--intolerance",
            "Drug 818 825--*--lactose",
            "Drug 827 845--*--magnesium stearate",
            "Drug 775 807--*--components of the study inhalers",
            "Scope 818 845--*--lactose, magnesium stearate",
            "Scope 739 767--*--hypersensitivity/intolerance",
            "Observation 877 884--*--history",
            "Qualifier 888 894--*--severe",
            "Drug 895 907--*--milk protein",
            "Condition 908 915--*--allergy",
            "Non-query-able 922 959--*--in the opinion of the study physician",
            "Condition 961 990--*--contraindicates participation",
            "Condition 1264 1291--*--hematological abnormalities",
            "Qualifier 1049 1071--*--clinically significant",
            "Qualifier 1075 1094--*--rapidly progressing",
            "Condition 1107 1121;1278 1291--*--cardiovascular abnormalities",
            "Qualifier 1098 1106--*--unstable",
            "Scope 1049 1106--*--clinically significant or rapidly progressing or unstable",
            "Condition 1123 1135;1278 1291--*--neurological abnormalities",
            "Condition 1137 1151;1278 1291--*--cardiovascular abnormalities",
            "Condition 1153 1165;1278 1291--*--neurological abnormalities",
            "Condition 1167 1172;1278 1291--*--renal abnormalities",
            "Condition 1174 1181;1278 1291--*--hepatic abnormalities",
            "Condition 1183 1196;1278 1291--*--immunological abnormalities",
            "Condition 1198 1207;1278 1291--*--endocrine abnormalities",
            "Qualifier 1219 1231--*--uncontrolled",
            "Condition 1232 1240--*--diabetes",
            "Condition 1244 1259--*--thyroid disease",
            "Scope 1232 1259--*--diabetes or thyroid disease",
            "Qualifier 1301 1313--*--uncontrolled",
            "Scope 1107 1291--*--cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities",
            "Observation 1015 1025--*--Historical",
            "Temporal 1029 1036--*--current",
            "Scope 1015 1036--*--Historical or current",
            "Non-representable 1315 1551--*--Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study.",
            "Procedure 1585 1594--*--treatment",
            "Drug 1634 1644--*--omalizumab",
            "Drug 1646 1657--*--mepolizumab",
            "Drug 1663 1669--*--asthma",
            "Scope 1634 1669--*--omalizumab, mepolizumab, for asthma",
            "Competing_trial 1672 1878--*--Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer.",
            "Non-query-able 1880 2134--*--A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Propeller Health employee."
        ],
        "Text": "Subjects with a known or suspected alcohol or drug abuse which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.. History of life threatening asthma: Defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months.. A lower respiratory tract infection within 7 days of the screening visit.. Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other respiratory disorders including active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.. History of hypersensitivity/intolerance to any components of the study inhalers (example, lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates participation will also be excluded.. Historical or current evidence of clinically significant or rapidly progressing or unstable cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study.. Subjects who have ever received treatment with biological based therapy example, omalizumab, mepolizumab, for asthma.. Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer.. A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Propeller Health employee.. "
    },
    "NCT03560310_inc": {
        "Annotations": [
            "Informed_consent 0 24--*--Written informed consent",
            "Person 26 29--*--Age",
            "Value 30 39--*--=18 years",
            "Procedure 66 79--*--isolated CABG",
            "Condition 101 124--*--acute coronary syndrome",
            "Condition 126 131--*--STEMI",
            "Condition 133 139--*--NSTEMI",
            "Condition 141 156--*--unstable angina",
            "Temporal 158 187--*--within 6 weeks before surgery",
            "Reference_point 180 187--*--surgery",
            "Scope 126 156--*--STEMI, NSTEMI, unstable angina",
            "Multiplier 55 65--*--first time"
        ],
        "Text": "Written informed consent. Age =18 years. Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery. "
    },
    "NCT01314898_inc": {
        "Text": "Male and/or female healthy volunteers, age 18 to 55 years. Females must be of non-childbearing potential. . Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs). . Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, diet restrictions and other trial procedures. . ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 12 18--*--female",
            "Condition 19 26--*--healthy",
            "Person 39 42--*--age",
            "Value 43 57--*--18 to 55 years",
            "Person 59 66--*--Females",
            "Condition 82 104--*--childbearing potential",
            "Negation 78 81--*--non",
            "Measurement 107 128--*--Body Mass Index (BMI)",
            "Value 132 150--*--17.5 to 30.5 kg/m2",
            "Measurement 158 175--*--total body weight",
            "Value 176 192--*-->50 kg (110 lbs)",
            "Post-eligibility 195 341--*--Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, diet restrictions and other trial procedures."
        ]
    },
    "NCT02175186_exc": {
        "Text": "Pregnant or breast feeding. History of Stomach or esophagus surgery. Peptic ulcer or reflux esophagitis. Zollinger-Ellison syndrome or primary esophageal motility disorders. Malignant tumor. Bleeding tendency or coagulopathy. Contraindication of ALBIS. Long term use of aspirin or P2Y12 receptor antagonist within 1month. Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed). Terminal patient. ",
        "Annotations": [
            "Pregnancy_considerations 0 26--*--Pregnant or breast feeding",
            "Procedure 50 67--*--esophagus surgery",
            "Procedure 39 46;60 67--*--Stomach surgery",
            "Condition 85 103--*--reflux esophagitis",
            "Condition 69 81--*--Peptic ulcer",
            "Condition 105 131--*--Zollinger-Ellison syndrome",
            "Condition 135 172--*--primary esophageal motility disorders",
            "Condition 174 189--*--Malignant tumor",
            "Condition 191 208--*--Bleeding tendency",
            "Condition 212 224--*--coagulopathy",
            "Condition 226 242--*--Contraindication",
            "Drug 246 251--*--ALBIS",
            "Qualifier 253 262--*--Long term",
            "Drug 270 277--*--aspirin",
            "Drug 281 306--*--P2Y12 receptor antagonist",
            "Temporal 307 320--*--within 1month",
            "Scope 270 306--*--aspirin or P2Y12 receptor antagonist",
            "Drug 357 360--*--PPI",
            "Drug 362 365--*--APA",
            "Drug 366 375--*--H2blocker",
            "Drug 377 406--*--Muscarine receptor antagonist",
            "Drug 408 425--*--anti-gastic agent",
            "Drug 427 434--*--antacid",
            "Drug 436 449--*--anticaogulant",
            "Drug 451 472--*--Bisphosphonate agents",
            "Drug 474 488--*--Cytotoxic drug",
            "Drug 490 495--*--NSAID",
            "Drug 497 526--*--adrenal cortex hormone agents",
            "Procedure 528 545--*--topical treatment",
            "Negation 549 556--*--allowed",
            "Person 568 575--*--patient",
            "Qualifier 559 567--*--Terminal"
        ]
    },
    "NCT03404804_exc": {
        "Annotations": [
            "Person 0 8--*--Children",
            "Condition 52 71--*--developmental delay",
            "Condition 75 111--*--inability to communicate the effects",
            "Condition 118 135--*--allergic reaction",
            "Qualifier 137 147--*--non-verbal",
            "Condition 155 171--*--contraindication",
            "Procedure 175 190--*--allergy testing",
            "Condition 241 265--*--severe allergic reaction",
            "Procedure 269 279--*--skin tests",
            "Observation 228 235--*--history",
            "Condition 283 294--*--anaphylaxis",
            "Temporal 295 316--*--in the past six weeks",
            "Condition 319 328--*--pregnancy",
            "Drug 346 359--*--antihistamine",
            "Temporal 360 382--*--in the past three days",
            "Drug 394 409--*--diphenhydramine",
            "Drug 411 419--*--Benadryl",
            "Drug 423 433--*--cetirizine",
            "Drug 435 441--*--Zyrtec",
            "Drug 445 455--*--loratadine",
            "Drug 457 465--*--Claritin",
            "Drug 469 481--*--fexofenadine",
            "Drug 483 490--*--Allegra",
            "Drug 494 508--*--levocetirizine",
            "Drug 510 515--*--Xyzal",
            "Drug 523 536--*--desloratadine",
            "Drug 538 546--*--Clarinex",
            "Scope 394 548--*--diphenhydramine (Benadryl\u00ae), cetirizine (Zyrtec\u00ae), loratadine (Claritin\u00ae), fexofenadine (Allegra\u00ae), levocetirizine (Xyzal\u00ae), and desloratadine (Clarinex\u00ae)",
            "Drug 605 626--*--beta blocker medicine",
            "Condition 631 649--*--cardiac conditions",
            "Condition 651 670--*--high blood pressure",
            "Condition 672 690--*--migraine headaches",
            "Condition 709 717--*--glaucoma",
            "Drug 695 704--*--eye drops",
            "Drug 724 735--*--propranolol",
            "Drug 737 747--*--metoprolol",
            "Drug 749 757--*--atenolol",
            "Drug 762 770--*--Timoptic",
            "Drug 776 784--*--Betoptic",
            "Drug 786 795--*--eye drops",
            "Scope 631 690--*--cardiac conditions, high blood pressure, migraine headaches",
            "Scope 724 795--*--propranolol, metoprolol, atenolol and Timoptic\u00ae, or Betoptic\u00ae eye drops",
            "Person 799 807--*--Children",
            "Visit 827 830--*--PED",
            "Condition 838 842--*--rash",
            "Condition 844 852--*--vomiting",
            "Condition 864 879--*--asthma symptoms",
            "Condition 890 898--*--coughing",
            "Condition 900 908--*--wheezing",
            "Condition 912 930--*--breathing problems",
            "Scope 890 930--*--coughing, wheezing or breathing problems",
            "Temporal 856 863--*--current",
            "Non-query-able 1014 1211--*--Patients being admitted to the hospital or those who are deemed too acutely ill for participation (triage level 1 or 2 or as determined by the ED patient care team) will be excluded from the study.",
            "Observation 1254 1274--*--non-English speaking",
            "Non-representable 1285 1368--*--However, in subsequent studies we will include the non-English speaking population.",
            "Observation 1387 1405--*--wards of the state",
            "Observation 1410 1421--*--foster care",
            "Observation 1425 1439--*--police custody",
            "Observation 1443 1452--*--detention",
            "Condition 1490 1505--*--basal condition",
            "Condition 1507 1513--*--trauma",
            "Condition 1515 1524--*--infection",
            "Condition 1526 1541--*--minor accidents",
            "Scope 1507 1541--*--trauma, infection, minor accidents"
        ],
        "Text": "Children will be excluded if they have a history of developmental delay or inability to communicate the effects of an allergic reaction (non-verbal).. Any contraindication to allergy testing will also result in exclusion. (i.e. history of a severe allergic reaction to skin tests,,. anaphylaxis in the past six weeks,. pregnancy,. child took any antihistamine in the past three days [including diphenhydramine (Benadryl\u00ae), cetirizine (Zyrtec\u00ae), loratadine (Claritin\u00ae), fexofenadine (Allegra\u00ae), levocetirizine (Xyzal\u00ae), and desloratadine (Clarinex\u00ae)] or. child has a history of a condition that requires a beta blocker medicine for cardiac conditions, high blood pressure, migraine headaches, or eye drops for glaucoma (e.g. propranolol, metoprolol, atenolol and Timoptic\u00ae, or Betoptic\u00ae eye drops).. Children who present to the PED with a rash, vomiting or current asthma symptoms including coughing, wheezing or breathing problems will also be excluded to ensure these do not mask reactions to an oral challenge.. Patients being admitted to the hospital or those who are deemed too acutely ill for participation (triage level 1 or 2 or as determined by the ED patient care team) will be excluded from the study.. During this pilot study, we will exclude non-English speaking families. However, in subsequent studies we will include the non-English speaking population.. Children who are wards of the state, in foster care or police custody or detention will be excluded.. Children with any basal condition (trauma, infection, minor accidents, etc..) will be able to participate in the study provided they and their family are willing and do not meet the above-mentioned exclusion criteria.. "
    },
    "NCT01912677_exc": {
        "Text": "Indication for emergent cesarean or known fetal anomaly. Anti-hypertensive therapy received in the past 12 hours. History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in this pregnancy. Actively wheezing at time of enrollment or history of asthma complications. Known coronary artery disease or type I DM with microvascular complications or signs of heart failure or clinical dissection of the aorta. ",
        "Annotations": [
            "Condition 0 10--*--Indication",
            "Procedure 15 32--*--emergent cesarean",
            "Condition 42 55--*--fetal anomaly",
            "Procedure 57 82--*--Anti-hypertensive therapy",
            "Temporal 99 112--*--past 12 hours",
            "Condition 125 134--*--eclampsia",
            "Condition 152 168--*--CNS complication",
            "Condition 176 182--*--stroke",
            "Condition 186 190--*--PRES",
            "Scope 176 190--*--stroke or PRES",
            "Temporal 192 209--*--in this pregnancy",
            "Scope 125 190--*--eclampsia or other adverse CNS complication (e.g., stroke or PRES",
            "Temporal 229 250--*--at time of enrollment",
            "Reference_point 240 250--*--enrollment",
            "Condition 265 285--*--asthma complications",
            "Condition 220 228--*--wheezing",
            "Condition 293 316--*--coronary artery disease",
            "Condition 320 329--*--type I DM",
            "Condition 335 362--*--microvascular complications",
            "Condition 375 388--*--heart failure",
            "Condition 401 424--*--dissection of the aorta"
        ]
    },
    "NCT02427295_exc": {
        "Text": "Severe co-morbid illness such as untreatable other malignancy and/or active infections.. Pregnant or lactating women. Hypersensitivity to Sandostatin or any component of the formulation.. ",
        "Annotations": [
            "Condition 7 24--*--co-morbid illness",
            "Qualifier 0 6--*--Severe",
            "Qualifier 33 44--*--untreatable",
            "Qualifier 45 50--*--other",
            "Condition 51 61--*--malignancy",
            "Qualifier 69 75--*--active",
            "Condition 76 86--*--infections",
            "Scope 33 86--*--untreatable other malignancy and/or active infections",
            "Scope 0 24--*--Severe co-morbid illness",
            "Condition 89 97--*--Pregnant",
            "Condition 101 110--*--lactating",
            "Person 111 116--*--women",
            "Condition 118 134--*--Hypersensitivity",
            "Drug 138 149--*--Sandostatin",
            "Drug 157 185--*--component of the formulation",
            "Scope 138 185--*--Sandostatin or any component of the formulation"
        ]
    },
    "NCT02606565_exc": {
        "Annotations": [
            "Person 0 8--*--Newborns",
            "Condition 14 41--*--severe congenital anomalies",
            "Person 43 51--*--Newborns",
            "Condition 57 88--*--infection of the umbilical cord",
            "Temporal 89 97--*--at birth"
        ],
        "Text": "Newborns with severe congenital anomalies. Newborns with infection of the umbilical cord at birth. "
    },
    "NCT03249272_exc": {
        "Annotations": [
            "Qualifier 0 13--*--Decompensated",
            "Condition 14 27--*--heart failure",
            "Condition 31 54--*--hemodynamic instability",
            "Temporal 56 61--*--Prior",
            "Condition 62 88--*--coronary revascularization",
            "Procedure 90 93--*--PCI",
            "Procedure 97 101--*--CABG",
            "Condition 106 127--*--myocardial infarction",
            "Measurement 165 171;184 190--*--CPK-MB levels",
            "Measurement 175 190--*--troponin levels",
            "Scope 165 190--*--CPK-MB or troponin levels",
            "Value 156 164--*--elevated",
            "Temporal 145 155--*--previously",
            "Scope 145 190--*--previously elevated CPK-MB or troponin levels",
            "Scope 90 101--*--PCI or CABG",
            "Condition 193 212--*--Accelerating angina",
            "Condition 216 231--*--unstable angina",
            "Condition 233 265--*--Inability to physically tolerate",
            "Procedure 266 269--*--MRI",
            "Device 273 290--*--implanted objects",
            "Qualifier 300 316--*--MRI incompatible",
            "Scope 266 316--*--MRI or implanted objects that are MRI incompatible",
            "Informed_consent 318 401--*--Inability to provide written informed consent obtained at time of study enrollment.",
            "Qualifier 403 409--*--Severe",
            "Condition 410 424--*--claustrophobia",
            "Condition 450 472--*--sinus node dysfunction",
            "Condition 435 446--*--heart block",
            "Qualifier 426 434--*--Advanced",
            "Scope 435 472--*--heart block or sinus node dysfunction",
            "Condition 474 490--*--Hypersensitivity",
            "Condition 494 502--*--allergic",
            "Drug 515 526--*--regadenoson",
            "Drug 530 539--*--adenosine",
            "Scope 515 539--*--regadenoson or adenosine",
            "Scope 474 502--*--Hypersensitivity or allergic",
            "Condition 541 552--*--Hypotension",
            "Qualifier 554 560--*--Active",
            "Condition 561 573--*--bronchospasm",
            "Observation 577 584--*--history",
            "Procedure 588 603--*--hospitalization",
            "Condition 611 623--*--bronchospasm",
            "Observation 625 632--*--History",
            "Condition 636 644--*--seizures",
            "Temporal 646 652--*--Recent",
            "Condition 653 677--*--cerebrovascular accident",
            "Drug 686 698--*--dipyridamole",
            "Temporal 699 721--*--within the last 5 days",
            "Condition 723 739--*--Contraindication",
            "Drug 743 756--*--aminophylline",
            "Qualifier 758 764--*--Severe",
            "Condition 765 784--*--renal insufficiency",
            "Measurement 790 826--*--estimated glomerular filtration rate",
            "Value 827 846--*--<30 ml/min/ 1.73 m2",
            "Condition 848 856--*--Pregnant",
            "Condition 860 867--*--nursing"
        ],
        "Text": "Decompensated heart failure or hemodynamic instability. Prior coronary revascularization (PCI or CABG) or myocardial infarction (as evidenced by previously elevated CPK-MB or troponin levels). Accelerating angina or unstable angina. Inability to physically tolerate MRI or implanted objects that are MRI incompatible. Inability to provide written informed consent obtained at time of study enrollment.. Severe claustrophobia. Advanced heart block or sinus node dysfunction. Hypersensitivity or allergic reaction to regadenoson or adenosine. Hypotension. Active bronchospasm or history of hospitalization due to bronchospasm. History of seizures. Recent cerebrovascular accident. Use of dipyridamole within the last 5 days. Contraindication to aminophylline. Severe renal insufficiency with estimated glomerular filtration rate <30 ml/min/ 1.73 m2. Pregnant or nursing. "
    },
    "NCT02995291_exc": {
        "Annotations": [
            "Condition 0 18--*--contra-indications",
            "Procedure 23 47--*--regular dental treatment",
            "Observation 49 64--*--medical history",
            "Condition 70 85--*--contraindicates",
            "Drug 97 108--*--epinephrine",
            "Drug 131 137--*--opioid",
            "Drug 144 165--*--opioid like analgesic",
            "Temporal 166 181--*--within 24 hours",
            "Scope 131 165--*--opioid or an opioid like analgesic",
            "Condition 183 191--*--pregnant"
        ],
        "Text": "contra-indications for regular dental treatment. medical history that contraindicates the use of epinephrine. participant taken an opioid or an opioid like analgesic within 24 hours. pregnant. "
    },
    "NCT03388840_inc": {
        "Annotations": [
            "Person 0 4--*--male",
            "Condition 19 40--*--androgenetic alopecia",
            "Value 41 70--*--between 18 years and 60 years",
            "Person 65 70--*--years"
        ],
        "Text": "male patients with androgenetic alopecia between 18 years and 60 years. "
    },
    "NCT03431831_exc": {
        "Annotations": [
            "Observation 0 40--*--Inability to understand and read English",
            "Person 43 48--*--Women",
            "Condition 49 57--*--pregnant",
            "Condition 61 70--*--lactating",
            "Condition 86 102--*--terminal illness"
        ],
        "Text": "Inability to understand and read English.. Women pregnant or lactating.. persons with terminal illness. "
    },
    "NCT02437084_exc": {
        "Text": "Less than 30 yrs of age or > 65 yrs of age. Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.. ",
        "Annotations": [
            "Value 0 16--*--Less than 30 yrs",
            "Person 20 23--*--age",
            "Value 27 35--*--> 65 yrs",
            "Person 39 42--*--age",
            "Qualifier 48 59--*--significant",
            "Condition 60 74--*--co-morbidities",
            "Qualifier 84 90--*--active",
            "Condition 115 123;91 96--*--diseases heart",
            "Condition 115 123;98 104--*--diseases kidney",
            "Condition 109 123--*--liver diseases",
            "Scope 91 123--*--heart, kidney, or liver diseases",
            "Qualifier 140 149--*--malignant",
            "Qualifier 125 136--*--accelerated",
            "Condition 150 162--*--hypertension",
            "Scope 125 149--*--accelerated or malignant",
            "Condition 164 177--*--heart failure",
            "Condition 179 192--*--severe anemia",
            "Scope 84 192--*--active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia",
            "Scope 48 74--*--significant co-morbidities"
        ]
    },
    "NCT02788045_inc": {
        "Text": "Are negative for human immunodeficiency virus (HIV) infection at screening . Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening . Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures . Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1 . Are assessed by the clinic staff as being at low risk for HIV infection . ",
        "Annotations": [
            "Condition 17 51--*--human immunodeficiency virus (HIV)",
            "Negation 4 12--*--negative",
            "Temporal 62 74--*--at screening",
            "Condition 79 86--*--healthy",
            "Procedure 142 165--*--electrocardiogram (ECG)",
            "Observation 125 140--*--medical history",
            "Procedure 103 123--*--physical examination",
            "Procedure 171 194--*--vital signs measurement",
            "Temporal 205 217--*--at screening",
            "Scope 103 194--*--physical examination, medical history, electrocardiogram (ECG), and vital signs measurement",
            "Post-eligibility 219 329--*--Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures",
            "Non-query-able 219 329--*--Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures",
            "Person 331 337--*--Female",
            "Condition 354 376--*--childbearing potential",
            "Measurement 398 418--*--serum pregnancy test",
            "Value 389 397--*--negative",
            "Measurement 420 464--*--beta human chorionic gonadotropin [beta hCG]",
            "Scope 398 465--*--serum pregnancy test (beta human chorionic gonadotropin [beta hCG])",
            "Temporal 466 488--*--at the Screening visit",
            "Reference_point 473 488--*--Screening visit",
            "Measurement 505 525--*--urine pregnancy test",
            "Value 496 504--*--negative",
            "Temporal 526 543--*--pre-dose on Day 1",
            "Reference_point 538 543--*--Day 1",
            "Grammar_Error 526 534--*--pre-dose",
            "Condition 590 598--*--low risk",
            "Condition 603 616--*--HIV infection",
            "Subjective_judgement 590 598--*--low risk",
            "Undefined_semantics 590 598--*--low risk"
        ]
    },
    "NCT02106624_inc": {
        "Text": "need mechanical ventilation for more than 2 days. mean blood pressure more than 60mmHg. predicted ICU stay more than 7 days. tolerance of parenteral or enteral nutrition. ",
        "Annotations": [
            "Procedure 5 27--*--mechanical ventilation",
            "Mood 0 4--*--need",
            "Multiplier 28 48--*--for more than 2 days",
            "Measurement 50 69--*--mean blood pressure",
            "Value 70 86--*--more than 60mmHg",
            "Observation 88 106--*--predicted ICU stay",
            "Value 107 123--*--more than 7 days",
            "Visit 98 101--*--ICU",
            "Condition 125 134--*--tolerance",
            "Procedure 138 148;160 169--*--parenteral nutrition",
            "Procedure 152 169--*--enteral nutrition",
            "Scope 138 169--*--parenteral or enteral nutrition"
        ]
    },
    "NCT02312089_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Procedure 19 23--*--ICSI",
            "Procedure 43 67--*--ovarian hyperstimulation",
            "Procedure 69 72--*--COH",
            "Procedure 79 103--*--pituitary downregulation",
            "Procedure 107 122--*--GnRH antagonist",
            "Scope 43 103--*--ovarian hyperstimulation (COH) with pituitary downregulation"
        ],
        "Text": "Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist.. "
    },
    "NCT03484091_exc": {
        "Annotations": [
            "Qualifier 0 6--*--Severe",
            "Condition 7 16--*--deformity",
            "Condition 18 23--*--varus",
            "Measurement 27 54--*--values from mechanical axis",
            "Value 55 74--*--more than 5 degrees",
            "Scope 18 74--*--varus or values from mechanical axis more than 5 degrees",
            "Condition 76 83--*--Allergy",
            "Drug 87 102--*--hyaluronic acid",
            "Condition 104 108--*--Pain",
            "Qualifier 112 115--*--hip",
            "Qualifier 119 124--*--ankle",
            "Scope 112 124--*--hip or ankle",
            "Temporal 126 140;157 175--*--Post-traumatic of lower extremity",
            "Temporal 144 175--*--post surgery of lower extremity",
            "Condition 182 199--*--infection of knee",
            "Temporal 177 181--*--Post",
            "Drug 210 225--*--hyaluronic acid",
            "Procedure 210 235--*--hyaluronic acid injection",
            "Temporal 236 251--*--within 6 months",
            "Temporal 201 209--*--Previous",
            "Condition 253 262--*--Pregnancy",
            "Condition 266 275--*--lactation",
            "Condition 288 308--*--Rheumatoid arthritis",
            "Condition 310 316--*--stroke",
            "Condition 318 328--*--malignancy",
            "Condition 330 346--*--venous occlusion",
            "Scope 288 346--*--Rheumatoid arthritis, stroke, malignancy, venous occlusion",
            "Qualifier 277 287--*--Underlying"
        ],
        "Text": "Severe deformity (varus or values from mechanical axis more than 5 degrees. Allergy to hyaluronic acid. Pain on hip or ankle. Post-traumatic or post surgery of lower extremity. Post infection of knee. Previous hyaluronic acid injection within 6 months. Pregnancy or lactation. Underlying Rheumatoid arthritis, stroke, malignancy, venous occlusion. "
    },
    "NCT02638935_inc": {
        "Annotations": [
            "Person 0 6--*--Female",
            "Value 12 21--*--\u226518 years",
            "Person 8 11--*--Age",
            "Condition 39 45--*--lesion",
            "Value 46 54--*--> 0.5 cm",
            "Measurement 58 79--*--largest diameter size",
            "Measurement 98 106--*--BI-RADS\u00ae",
            "Value 107 122--*--3, 4a, 4b or 4c",
            "Procedure 126 143--*--B-mode ultrasound",
            "Procedure 168 192--*--histological examination",
            "Procedure 194 215--*--core cut biopsy (CCB)",
            "Procedure 217 245--*--vacuum-assisted biopsy (VAB)",
            "Procedure 247 275--*--fine needle aspiration (FNA)",
            "Procedure 279 286--*--surgery",
            "Scope 194 286--*--core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery",
            "Post-eligibility 145 161--*--Informed consent",
            "Post-eligibility 346 392--*--Signed informed consent of study participation"
        ],
        "Text": "Female . Age \u226518 years . Patients with a lesion > 0.5 cm in largest diameter size, initially scored BI-RADS\u00ae 3, 4a, 4b or 4c in B-mode ultrasound . Informed consent about histological examination (core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery) has already been given in the course of clinical routine . Signed informed consent of study participation . "
    },
    "NCT02607319_exc": {
        "Annotations": [
            "Condition 12 31--*--low ovarian reserve",
            "Measurement 66 69--*--AMH",
            "Value 70 81--*--= 1,5 ng/mL",
            "Measurement 89 103--*--basal CD 3 FSH",
            "Value 104 115--*--= 10 mIU/mL",
            "Measurement 123 143--*--basal CD 3 Estradiol",
            "Value 144 154--*--= 60 ng/mL",
            "Measurement 171 191--*--egg collection yield",
            "Value 192 203--*--= 3 oocytes",
            "Scope 66 203--*--AMH = 1,5 ng/mL and/or basal CD 3 FSH = 10 mIU/mL and/or basal CD 3 Estradiol = 60 ng/mL and/or previous egg collection yield = 3 oocytes",
            "Condition 237 252--*--thyroid disease",
            "Condition 254 271--*--diabetes mellitus",
            "Condition 273 285--*--hypertension",
            "Condition 287 307--*--pulmonary conditions",
            "Condition 309 326--*--cardiac condition",
            "Condition 338 361--*--male factor infertility",
            "Qualifier 331 337--*--Severe",
            "Measurement 363 387--*--Total motile sperm count",
            "Value 388 402--*--< 5 million/ml",
            "Measurement 410 431--*--normal WHO morphology",
            "Value 432 436--*--<20%",
            "Scope 363 436--*--Total motile sperm count < 5 million/ml and/or normal WHO morphology <20%",
            "Condition 440 456--*--Hypersensitivity",
            "Drug 460 467--*--Heparin",
            "Condition 498 511--*--thrombophilia",
            "Qualifier 489 497--*--Acquired",
            "Condition 514 531--*--Active hemorrhage",
            "Observation 545 561--*--risk of bleeding",
            "Qualifier 535 544--*--increased",
            "Condition 569 594--*--impairment of homeostasis",
            "Condition 604 623--*--impairment of liver",
            "Condition 604 617;627 646--*--impairment of pancreatic function",
            "Scope 604 646--*--impairment of liver or pancreatic function",
            "Qualifier 597 603--*--Severe",
            "Qualifier 649 655--*--Severe",
            "Condition 656 675--*--renal insufficiency",
            "Measurement 677 697--*--Creatinine Clearance",
            "Value 698 709--*--< 30 ml/min",
            "Procedure 728 738--*--operations",
            "Condition 713 721--*--Injuries",
            "Qualifier 746 768--*--central nervous system",
            "Qualifier 770 774--*--eyes",
            "Qualifier 779 783--*--ears",
            "Temporal 795 808--*--last 2 months",
            "Scope 746 783--*--central nervous system, eyes and ears",
            "Scope 713 738--*--Injuries to or operations",
            "Condition 811 849--*--Disseminated Intravascular Coagulation",
            "Condition 851 854--*--DIC",
            "Condition 872 904--*--heparin-induced thrombocytopenia",
            "Condition 940 958--*--endocarditis lenta",
            "Condition 907 935--*--Acute bacterial endocarditis",
            "Condition 965 979--*--organic lesion",
            "Observation 990 1006--*--risk of bleeding",
            "Qualifier 985 989--*--high",
            "Condition 1014 1033--*--active peptic ulcer",
            "Condition 1035 1053--*--hemorrhagic stroke",
            "Condition 1055 1072--*--cerebral aneurysm",
            "Condition 1076 1094--*--cerebral neoplasms",
            "Scope 1014 1094--*--active peptic ulcer, hemorrhagic stroke, cerebral aneurysm or cerebral neoplasms"
        ],
        "Text": "Evidence of low ovarian reserve by at least one of the following: AMH = 1,5 ng/mL and/or basal CD 3 FSH = 10 mIU/mL and/or basal CD 3 Estradiol = 60 ng/mL and/or previous egg collection yield = 3 oocytes.. Preexisting medical condition (thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition\u2026).. Severe male factor infertility (Total motile sperm count < 5 million/ml and/or normal WHO morphology <20%).. Hypersensitivity to Heparin or its derivatives.. Acquired thrombophilia.. Active hemorrhage or increased risk of bleeding due to impairment of homeostasis.. Severe impairment of liver or pancreatic function.. Severe renal insufficiency (Creatinine Clearance < 30 ml/min).. Injuries to or operations on the central nervous system, eyes and ears within the last 2 months.. Disseminated Intravascular Coagulation (DIC) attributable to heparin-induced thrombocytopenia.. Acute bacterial endocarditis and endocarditis lenta.. Any organic lesion with high risk of bleeding (e.g.: active peptic ulcer, hemorrhagic stroke, cerebral aneurysm or cerebral neoplasms).. "
    },
    "NCT02462590_inc": {
        "Annotations": [
            "Person 21 24--*--age",
            "Value 7 17--*--= 18 years",
            "Person 0 6--*--Adults",
            "Visit 42 45--*--ICU",
            "Procedure 69 91--*--mechanical ventilation",
            "Qualifier 60 68--*--invasive",
            "Temporal 120 129--*--=72 hours",
            "Procedure 105 116--*--ventilation",
            "Mood 93 104--*--Anticipated"
        ],
        "Text": "Adults = 18 years of age. Admitted to any ICU and receiving invasive mechanical ventilation. Anticipated ventilation of =72 hours at the time of screening, as per the ICU physician.. "
    },
    "NCT02145026_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Measurement 51 54--*--MDS",
            "Value 31 50--*--intermediate-1 risk",
            "Value 24 27;46 50--*--low risk",
            "Scope 24 50--*--low or intermediate-1 risk",
            "Drug 83 111--*--hematopoietic growth factors",
            "Temporal 112 146--*--within 3 months prior to screening",
            "Reference_point 137 146--*--screening",
            "Condition 160 166--*--anemia",
            "Qualifier 148 159--*--Symptomatic",
            "Measurement 168 178--*--hemoglobin",
            "Value 179 187--*--<10 g/dL",
            "Measurement 220 240--*--Serum erythropoietin",
            "Value 241 267--*--<500 milliunits/milliliter",
            "Temporal 276 333--*--within 14 days prior to the first dose of study treatment",
            "Procedure 346 372--*--red blood cell transfusion",
            "Negation 343 345--*--no",
            "Multiplier 389 397--*--<4 units",
            "Temporal 398 431--*--within 8 weeks prior to screening",
            "Condition 444 450--*--stable",
            "Temporal 451 501--*--for at least 1 month prior to entry into the study",
            "Reference_point 481 501--*--entry into the study",
            "Pregnancy_considerations 503 707--*--For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception"
        ],
        "Text": "Adult participants with low or intermediate-1 risk MDS. No previous treatment with hematopoietic growth factors within 3 months prior to screening. Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator. Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment. Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening. Clinically stable for at least 1 month prior to entry into the study. For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception. "
    },
    "NCT03177811_exc": {
        "Annotations": [
            "Condition 0 17--*--COPD exacerbation",
            "Condition 31 35--*--COPD",
            "Qualifier 19 30--*--very severe",
            "Condition 41 50--*--hypoxemia",
            "Qualifier 54 66--*--low altitude",
            "Measurement 68 76--*--FEV1/FVC",
            "Value 77 81--*--<0.7",
            "Measurement 83 87--*--FEV1",
            "Value 88 102--*--<40% predicted",
            "Measurement 104 121--*--oxygen saturation",
            "Qualifier 125 133--*--room air",
            "Value 134 147--*--<92% at 750 m",
            "Scope 68 147--*--FEV1/FVC <0.7, FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m",
            "Condition 151 164--*--Comorbidities",
            "Condition 186 208--*--cardiovascular disease",
            "Qualifier 173 185--*--uncontrolled",
            "Condition 225 255--*--systemic arterial hypertension",
            "Qualifier 216 224--*--unstable",
            "Condition 257 280--*--coronary artery disease",
            "Condition 291 297--*--stroke",
            "Qualifier 282 290--*--previous",
            "Condition 299 302--*--OSA",
            "Condition 304 316--*--pneumothorax",
            "Temporal 317 337--*--in the last 2 months",
            "Scope 216 280--*--unstable systemic arterial hypertension, coronary artery disease",
            "Scope 173 337--*--uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months",
            "Condition 379 398--*--psychiatric disease",
            "Condition 362 375;391 398--*--rheumatologic disease",
            "Condition 350 360;391 398--*--neurologic disease",
            "Condition 340 348;391 398--*--Internal disease",
            "Observation 417 430--*--heavy smoking",
            "Multiplier 432 454--*-->20 cigarettes per day",
            "Condition 463 476--*--renal failure",
            "Condition 480 487--*--allergy",
            "Drug 491 504--*--acetazolamide",
            "Drug 515 527--*--sulfonamides",
            "Scope 491 527--*--acetazolamide and other sulfonamides"
        ],
        "Text": "COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7, FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).. Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.. Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (>20 cigarettes per day). Known renal failure or allergy to acetazolamide and other sulfonamides. "
    },
    "NCT03484091_inc": {
        "Annotations": [
            "Qualifier 0 11--*--Symptomatic",
            "Qualifier 12 19--*--primary",
            "Qualifier 20 24--*--knee",
            "Condition 25 39--*--osteoarthritis",
            "Procedure 52 74--*--conservative treatment",
            "Qualifier 45 51--*--failed",
            "Temporal 75 92--*--at least 3 months",
            "Measurement 94 117--*--Kellgren-Lawrence grade",
            "Value 118 123--*--I-III",
            "Informed_consent 125 146--*--Gave informed consent",
            "Observation 148 169--*--Can do questionnaires"
        ],
        "Text": "Symptomatic primary knee osteoarthritis with failed conservative treatment at least 3 months. Kellgren-Lawrence grade I-III. Gave informed consent. Can do questionnaires. "
    },
    "NCT02638935_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Condition 12 21--*--lactating",
            "Person 22 27--*--women",
            "Person 29 34--*--Women",
            "Device 40 55--*--breast implants",
            "Qualifier 63 86--*--same side as the lesion",
            "Reference_point 76 86--*--the lesion",
            "Procedure 109 124--*--local radiation",
            "Procedure 128 140--*--chemotherapy",
            "Temporal 141 166--*--within the last 12 months",
            "Person 88 93--*--Women",
            "Person 168 173--*--Women",
            "Condition 190 203--*--breast cancer",
            "Condition 207 221--*--breast surgery",
            "Qualifier 229 242--*--same quadrant",
            "Condition 244 251--*--Lesions",
            "Qualifier 252 278--*--in or close to scar tissue",
            "Value 280 285--*--< 1cm",
            "Condition 288 300--*--Skin lesions",
            "Condition 304 311--*--lesions",
            "Procedure 327 335--*--biopsied",
            "Temporal 336 346--*--previously",
            "Condition 348 354--*--Lesion",
            "Value 355 371--*--larger than 4 cm",
            "Measurement 379 396--*--longest dimension",
            "Condition 401 407--*--lesion",
            "Multiplier 432 459--*--more than 50% of the lesion",
            "Value 463 485--*--further down than 4 cm",
            "Measurement 486 508--*--beneath the skin level"
        ],
        "Text": "Pregnant or lactating women . Women with breast implants on the same side as the lesion . Women that underwent local radiation or chemotherapy within the last 12 months . Women with history of breast cancer or breast surgery in the same quadrant . Lesions in or close to scar tissue (< 1cm) . Skin lesions or lesions that have been biopsied previously . Lesion larger than 4 cm in the longest dimension . No lesion should be included when more than 50% of the lesion is further down than 4 cm beneath the skin level.       .     . "
    },
    "NCT02106624_exc": {
        "Text": "irreversible status of primary disease. any history of malnutrition before enrollment. history of steroid cortisol administration. severe liver dysfunction (Child-Pugh Score C). pregnancy. refuse to enrollment. re-admission to ICU and has been enrolled during former admission to ICU. ",
        "Annotations": [
            "Qualifier 0 19--*--irreversible status",
            "Condition 23 38--*--primary disease",
            "Condition 55 67--*--malnutrition",
            "Temporal 68 85--*--before enrollment",
            "Drug 98 114--*--steroid cortisol",
            "Qualifier 131 137--*--severe",
            "Condition 138 155--*--liver dysfunction",
            "Measurement 157 173--*--Child-Pugh Score",
            "Value 174 175--*--C",
            "Scope 157 175--*--Child-Pugh Score C",
            "Condition 178 187--*--pregnancy",
            "Informed_consent 189 209--*--refuse to enrollment",
            "Procedure 211 223--*--re-admission",
            "Visit 227 230--*--ICU",
            "Non-representable 235 283--*--has been enrolled during former admission to ICU"
        ]
    },
    "NCT02312089_exc": {
        "Annotations": [
            "Condition 19 32--*--endometriosis",
            "Qualifier 12 18--*--severe",
            "Qualifier 0 8--*--Moderate",
            "Scope 0 18--*--Moderate or severe",
            "Condition 35 47--*--Hydrosalpinx",
            "Condition 50 71--*--Uterine abnormalities",
            "Condition 74 79--*--Myoma",
            "Procedure 91 106--*--uterine surgery"
        ],
        "Text": "Moderate or severe endometriosis.. Hydrosalpinx.. Uterine abnormalities.. Myoma.. Previous uterine surgery.. "
    },
    "NCT03177811_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 26 29--*--age",
            "Value 30 39--*--18-75 yrs",
            "Condition 42 46--*--COPD",
            "Measurement 70 74--*--GOLD",
            "Measurement 76 80--*--FEV1",
            "Value 81 97--*--40-80% predicted",
            "Measurement 99 103--*--SpO2",
            "Value 104 117--*--=92% at 750 m",
            "Scope 76 117--*--FEV1 40-80% predicted, SpO2 =92% at 750 m",
            "Non-query-able 120 177--*--Born, raised and currently living at low altitude (<800m)",
            "Post-eligibility 180 204--*--Written informed consent"
        ],
        "Text": "Male and female patients, age 18-75 yrs.. COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.. Born, raised and currently living at low altitude (<800m).. Written informed consent.. "
    },
    "NCT02145026_exc": {
        "Annotations": [
            "Condition 0 17--*--Contraindications",
            "Condition 31 47--*--hypersensitivity",
            "Procedure 104 126--*--epoetin beta treatment",
            "Scope 0 47--*--Contraindications and/or known hypersensitivity",
            "Condition 146 158--*--hypertension",
            "Qualifier 128 145--*--Poorly controlled",
            "Condition 203 225--*--Acute Myeloid Leukemia",
            "Condition 227 230--*--AML",
            "Observation 240 252--*--risk for AML",
            "Qualifier 235 239--*--high",
            "Competing_trial 254 367--*--Administration of another investigational drug within 1 month before screening or planned during the study period",
            "Condition 403 424--*--Pure Red Cell Aplasia",
            "Condition 426 430--*--PRCA"
        ],
        "Text": "Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment. Poorly controlled hypertension as assessed by the investigator. History of Acute Myeloid Leukemia (AML) or high risk for AML. Administration of another investigational drug within 1 month before screening or planned during the study period. Previously documented evidence of Pure Red Cell Aplasia (PRCA). "
    },
    "NCT02462590_exc": {
        "Annotations": [
            "Procedure 11 34--*--mechanically ventilated",
            "Temporal 35 44--*-->72 hours",
            "Observation 104 142--*--risk of iatrogenic probiotic infection",
            "Condition 205 222--*--immunocompromised",
            "Condition 236 239--*--HIV",
            "Measurement 245 248--*--CD4",
            "Value 240 244;249 257--*--<200 cells/\u00b5L",
            "Procedure 283 312--*--immunosuppressive medications",
            "Qualifier 275 282--*--chronic",
            "Drug 320 332--*--azathioprine",
            "Drug 334 346--*--cyclosporine",
            "Drug 348 364--*--cyclophosphamide",
            "Drug 366 376--*--tacrolimus",
            "Drug 378 390--*--methotrexate",
            "Drug 392 404--*--mycofenolate",
            "Drug 406 414--*--Anti-IL2",
            "Scope 320 414--*--azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2",
            "Procedure 426 441--*--transplantation",
            "Procedure 498 510--*--chemotherapy",
            "Temporal 518 531--*--last 3 months",
            "Condition 533 544--*--neutropenia",
            "Measurement 546 571--*--absolute neutrophil count",
            "Value 572 578--*--< 500]",
            "Scope 205 579--*--immunocompromised populations (HIV <200 CD4 cells/\u00b5L, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500])",
            "Observation 720 751--*--risk for endovascular infection",
            "Condition 775 798--*--rheumatic heart disease",
            "Condition 800 824--*--congenital valve disease",
            "Condition 846 870--*--congenital heart disease",
            "Qualifier 826 845--*--surgically repaired",
            "Condition 883 916--*--cyanotic congenital heart disease",
            "Qualifier 872 882--*--unrepaired",
            "Procedure 922 941--*--intracardiac repair",
            "Device 947 966--*--prosthetic material",
            "Device 982 1012--*--bio-prosthetic cardiac valves]",
            "Device 968 978;997 1011--*--mechanical cardiac valves",
            "Scope 968 1011--*--mechanical or bio-prosthetic cardiac valves",
            "Condition 1034 1046--*--endocarditis",
            "Device 1058 1078--*--endovascular devices",
            "Qualifier 1048 1057--*--permanent",
            "Device 1086 1105--*--endovascular grafts",
            "Procedure 1113 1135--*--aortic aneurysm repair",
            "Device 1137 1143--*--stents",
            "Qualifier 1154 1168--*--large arteries",
            "Device 1208 1234--*--inferior vena cava filters",
            "Device 1236 1260--*--dialysis vascular grafts",
            "Device 1290 1312--*--hemodialysis catheters",
            "Device 1314 1324--*--pacemakers",
            "Device 1368 1392--*--central venous catheters",
            "Device 1394 1427--*--central venous dialysis catheters",
            "Device 1431 1470--*--peripherally inserted central catheters",
            "Negation 1483 1486--*--not",
            "Negation 1602 1605--*--not",
            "Device 1514 1536--*--coronary artery stents",
            "Device 1538 1567--*--coronary artery bypass grafts",
            "Device 1578 1597--*--neurovascular coils",
            "Negation 1681 1684--*--not",
            "Condition 1630 1651--*--mitral valve prolapse",
            "Condition 1655 1676--*--bicuspid aortic valve",
            "Scope 1630 1676--*--mitral valve prolapse or bicuspid aortic valve",
            "Scope 1514 1597--*--coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils",
            "Device 1472 1477--*--PICCs",
            "Scope 1368 1478--*--central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs)",
            "Scope 1086 1260--*--endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts",
            "Scope 753 1741--*--previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria",
            "Condition 1788 1806--*--acute pancreatitis",
            "Qualifier 1781 1787--*--severe",
            "Negation 1808 1815--*--without",
            "Measurement 1831 1843--*--Ranson score",
            "Negation 1917 1920--*--not",
            "Condition 1900 1912--*--pancreatitis",
            "Qualifier 1883 1887--*--mild",
            "Qualifier 1891 1899--*--moderate",
            "Scope 1883 1899--*--mild or moderate",
            "Device 1970 1991--*--jejunal feeding tubes",
            "Device 1959 1966;1978 1991--*--gastric feeding tubes",
            "Condition 2047 2063--*--contraindication",
            "Procedure 2088 2107--*--enteral medications",
            "Non-query-able 2110 2175--*--Intent to withdraw advanced life support as per the ICU physician",
            "Competing_trial 2178 2259--*--Previous enrolment in this or current enrolment in a potentially confounding tria"
        ],
        "Text": "Invasively mechanically ventilated >72 hours at the time of screening;. Patients at potential increased risk of iatrogenic probiotic infection (see Section 2.6 for detailed explanation) including specific immunocompromised populations (HIV <200 CD4 cells/\u00b5L, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500]). However, patients receiving corticosteroids previously or presently or projected to receive corticosteroids are not excluded;. Patients at risk for endovascular infection (previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;. Patients with a primary diagnosis of severe acute pancreatitis, without reference to a Ranson score [Ranson 1974]). However, patients with mild or moderate pancreatitis are not excluded;. Patients with percutaneous gastric or jejunal feeding tubes already in situ as per Health Canada guidance;. Strict contraindication or inability to receive enteral medications;. Intent to withdraw advanced life support as per the ICU physician;. Previous enrolment in this or current enrolment in a potentially confounding tria. "
    },
    "NCT02607319_inc": {
        "Annotations": [
            "Multiplier 11 24--*--three or more",
            "Qualifier 25 38;39 45--*--consecutively failed",
            "Procedure 46 68--*--In Vitro Fertilization",
            "Procedure 70 73--*--IVF",
            "Temporal 82 103--*--after embryo transfer",
            "Reference_point 88 103--*--embryo transfer",
            "Observation 113 127--*--uterine cavity",
            "Value 106 112--*--Normal",
            "Procedure 144 156--*--hysteroscopy",
            "Procedure 160 163--*--HSG",
            "Scope 144 163--*--hysteroscopy or HSG",
            "Procedure 174 197--*--hormonal investigation:",
            "Value 167 173--*--Normal",
            "Measurement 198 201--*--TSH",
            "Measurement 203 206--*--PRL",
            "Measurement 208 211--*--FBS",
            "Scope 198 211--*--TSH, PRL, FBS",
            "Measurement 240 261--*--thrombophilia profile",
            "Value 214 220--*--Normal",
            "Measurement 263 266--*--LAC",
            "Measurement 268 275--*--ACA IgG",
            "Measurement 281 287--*--Prot S",
            "Measurement 289 305--*--Antithrombin III",
            "Measurement 268 271;276 279--*--ACA IgM",
            "Measurement 307 326--*--beta-2 glycoprotein",
            "Measurement 328 337--*--Factors V",
            "Measurement 328 335;339 341--*--Factors II",
            "Measurement 343 348--*--MTHFR",
            "Scope 263 348--*--LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR",
            "Measurement 358 372--*--semen analysis",
            "Condition 391 402--*--male factor",
            "Qualifier 382 390--*--moderate",
            "Qualifier 377 381--*--mild",
            "Scope 377 390--*--mild/moderate",
            "Measurement 404 428--*--Total motile sperm count",
            "Value 429 443--*--> 5 million/ml",
            "Measurement 451 472--*--normal WHO morphology",
            "Value 473 477--*-->20%",
            "Scope 404 477--*--Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%",
            "Informed_consent 480 521--*--Patient provides written informed consent"
        ],
        "Text": "History of three or more consecutively failed In Vitro Fertilization (IVF) cycles after embryo transfer.. Normal uterine cavity (as assessed by hysteroscopy or HSG).. Normal hormonal investigation: TSH, PRL, FBS.. Normal acquired/inherited thrombophilia profile: LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR.. Normal semen analysis and mild/moderate male factor (Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%.. Patient provides written informed consent.. "
    },
    "NCT02299947_exc": {
        "Annotations": [
            "Condition 6 15--*--trombosis",
            "Temporal 0 5--*--Prior",
            "Condition 19 40--*--myocardial infarction",
            "Condition 42 73--*--congenital coagulation disorder",
            "Drug 82 97--*--anti-coagulants",
            "Temporal 98 114--*--prior to surgery",
            "Temporal 116 121--*--prior",
            "Procedure 122 138--*--thoracic surgery",
            "Condition 140 149--*--pregnancy",
            "Temporal 151 164--*--pre-operative",
            "Measurement 165 189--*--fibrinogen concentration",
            "Value 190 195--*--<1g/L"
        ],
        "Text": "Prior trombosis or myocardial infarction, congenital coagulation disorder, use of anti-coagulants prior to surgery, prior thoracic surgery, pregnancy, pre-operative fibrinogen concentration <1g/L. "
    },
    "NCT03073603_exc": {
        "Annotations": [
            "Condition 4 6--*--MS",
            "Condition 7 14--*--relapse",
            "Temporal 15 37--*--in the last five years",
            "Condition 116 131--*--T2/FLAIR lesion",
            "Drug 139 149--*--gadolinium",
            "Qualifier 139 159--*--gadolinium-enhancing",
            "Condition 160 166--*--lesion",
            "Temporal 167 194--*--within the past three years",
            "Multiplier 196 208--*--at least two",
            "Procedure 209 214--*--scans",
            "Temporal 215 248--*--separated by at least three years",
            "Procedure 279 293--*--spine MRI scan",
            "Procedure 270 275;285 293--*--brain MRI scan",
            "Qualifier 311 324--*--3mm or larger",
            "Condition 295 302--*--Lesions",
            "Scope 116 166--*--T2/FLAIR lesion or new gadolinium-enhancing lesion",
            "Qualifier 346 357--*--Significant",
            "Condition 381 392--*--intolerance",
            "Temporal 396 410--*--presently-used",
            "Drug 411 414--*--DMT",
            "Drug 423 430;442 450--*--inhaled steroids",
            "Drug 434 450--*--topical steroids",
            "Negation 455 458--*--not",
            "Scope 423 450--*--inhaled or topical steroids",
            "Non-representable 416 481--*--Use of inhaled or topical steroids are not an exclusion criteria.",
            "Drug 490 503--*--oral steroids",
            "Temporal 508 531--*--no greater than 14 days",
            "Condition 544 560--*--non-MS condition",
            "Negation 564 567--*--not",
            "Non-representable 483 581--*--Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.",
            "Drug 583 594--*--alemtuzumab",
            "Drug 597 609--*--mitoxantrone",
            "Drug 612 628--*--cyclophosphamide",
            "Drug 631 643--*--methotrexate",
            "Drug 646 658--*--cyclosporine",
            "Drug 664 673--*--rituximab",
            "Non-query-able 675 754--*--Prior use of any experimental agent used as a DMT for MS in the last five years",
            "Condition 769 781--*--hypertension",
            "Condition 797 805--*--diabetes",
            "Condition 821 827--*--asthma",
            "Condition 846 856--*--depression",
            "Qualifier 756 768--*--uncontrolled",
            "Qualifier 784 796--*--uncontrolled",
            "Qualifier 808 820--*--uncontrolled",
            "Qualifier 833 845--*--uncontrolled",
            "Condition 858 865--*--Cancers",
            "Negation 866 876--*--other than",
            "Condition 877 900--*--basal cell skin cancers",
            "Temporal 901 924--*--within the last 5 years",
            "Non-query-able 926 980--*--Unable to give informed consent or follow the protocol",
            "Procedure 1000 1009--*--brain MRI",
            "Mood 982 999--*--Unable to undergo",
            "Post-eligibility 1011 1055--*--Unwilling to be randomized per this protocol",
            "Condition 1074 1104--*--chronic neurological illnesses",
            "Observation 1057 1067--*--History of",
            "Qualifier 1116 1124--*--mimic MS",
            "Condition 1169 1172--*--ALS",
            "Condition 1174 1191--*--myasthenia gravis",
            "Condition 1193 1211--*--chronic neuropathy",
            "Scope 1169 1211--*--ALS, myasthenia gravis, chronic neuropathy",
            "Scope 1074 1124--*--chronic neurological illnesses that might mimic MS"
        ],
        "Text": "Any MS relapse in the last five years, as determined at the screen visit by the PI. Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan. Lesions must be 3mm or larger to be exclusionary.. Significant (as defined by the PI) intolerance of presently-used DMT. Use of inhaled or topical steroids are not an exclusion criteria.. Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.. alemtuzumab,. mitoxantrone,. cyclophosphamide,. methotrexate,. cyclosporine, or. rituximab. Prior use of any experimental agent used as a DMT for MS in the last five years. uncontrolled hypertension,. uncontrolled diabetes,. uncontrolled asthma, or. uncontrolled depression. Cancers other than basal cell skin cancers within the last 5 years. Unable to give informed consent or follow the protocol. Unable to undergo brain MRI. Unwilling to be randomized per this protocol. History of other chronic neurological illnesses that might mimic MS with chronic or intermittent symptoms (i.e. ALS, myasthenia gravis, chronic neuropathy, etc.). "
    },
    "NCT03231982_exc": {
        "Text": "The difference in blood pressure between the selected arm versus non-selected arm is = 20 mmHg for siSBP and = 10 mmHg for siDBP at Visit 1 (screening).. Blood pressure taken at screening and randomization is = 180 mmHg for siSBP or = 110 mmHg for siDBP.. Diagnosed with secondary hypertension or suspected of secondary hypertension [e.g., renovascular disease, adrenal medullary and cortical hyperfunction, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc.]. Patients with symptomatic orthostatic hypertension (the difference in the blood pressures between measured at supine position and measured at standing position is = 20 mmHg for siSBP and = 10 mmHg for siDBP). Diagnosis of type 1 diabetes mellitus (DM) or uncontrolled DM (patients on insulin therapy or with HbA1c > 9%). Patients with severe cardiac conditions: heart failure (NYHA Class 3 or 4), history of ischemic cardiac disease (unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months.. Patients with clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically significant arrhythmia at the discretion of the investigator. Patients with hypertrophic occlusive myocardiopathy, severe occlusive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve stenosis. History of cardiogenic shock. Presence of severe cerebrovascular disorders (diagnosis of stroke, cerebral infarction or cerebral hemorrhage within recent 6 months). History or current evidence of wasting, autoimmune (such as rheumatoid arthritis and systemic lupus erythematosus) or connective tissue diseases. Known diagnosis of moderate or malignant retinopathy (including retinal hemorrhage, visual disturbance and retinal microaneurysm within 6 months). Patients with surgical or medical intestinal diseases or having received surgeries that could interfere with drug absorption distribution, metabolism and elimination. History of malignancy including leukemia and lymphoma within recent 5 years except for localized basal cell carcinoma of the skin). Patients with any inflammatory diseases requiring chronic anti-inflammatory therapy. Renal failure on dialysis. AST or ALT >2 x upper limit of normal (ULN). Serum creatinine > 1.5 x ULN. Serum potassium < 3.5 mmol/L or >5.5 mmol/L. Needs for co-administration of non-study antihypertensive agents or contraindicated medications during the study. History of hypersensitivity to ARBs or dihydropyridines. History of angioedema to treatment with ACE inhibitors or ARBs. Pregnant or lactating women and female volunteers of childbearing potential (except for women who are surgically sterile) who are not willing to use an adequate method of contraception (oral contraceptives, intrauterine device, condom, etc.) during the study. Women of childbearing potential who are not surgically sterile will be allowed to participate in the study only if they have negative pregnancy test at Visit 1 (screening) and should continue to use medically acceptable method of contraception (basic body temperature method and rhythm method will not be allowed). Women with no menses for = 12 months will be considered as postmenopausal state and method of contraception using hormonal contraception such as oral contraceptive should be initiated from or prior to the screening.. History of drug or alcohol abuse within recent 1 year. Patients having received any other investigational product within recent 12 weeks. Conditions which render a subject ineligible for the study at the discretion of the investigator. ",
        "Annotations": [
            "Measurement 4 32--*--difference in blood pressure",
            "Qualifier 45 81--*--selected arm versus non-selected arm",
            "Value 85 94--*--= 20 mmHg",
            "Value 109 118--*--= 10 mmHg",
            "Measurement 123 128--*--siDBP",
            "Measurement 99 104--*--siSBP",
            "Temporal 129 139--*--at Visit 1",
            "Measurement 154 168--*--Blood pressure",
            "Temporal 175 187--*--at screening",
            "Temporal 175 177;192 205--*--at randomization",
            "Value 209 219--*--= 180 mmHg",
            "Value 233 243--*--= 110 mmHg",
            "Measurement 248 253--*--siDBP",
            "Measurement 224 229--*--siSBP",
            "Scope 209 253--*--= 180 mmHg for siSBP or = 110 mmHg for siDBP",
            "Condition 281 293--*--hypertension",
            "Qualifier 271 280--*--secondary",
            "Mood 297 306--*--suspected",
            "Qualifier 310 319--*--secondary",
            "Condition 320 332--*--hypertension",
            "Condition 340 360--*--renovascular disease",
            "Condition 362 379;393 406--*--adrenal medullary hyperfunction",
            "Condition 384 406--*--cortical hyperfunction",
            "Condition 408 432--*--coarctation of the aorta",
            "Condition 434 452--*--hyperaldosteronism",
            "Qualifier 454 464--*--unilateral",
            "Qualifier 468 477--*--bilateral",
            "Condition 478 499--*--renal artery stenosis",
            "Scope 454 477--*--unilateral or bilateral",
            "Condition 501 519--*--Cushing's syndrome",
            "Condition 521 537--*--pheochromocytoma",
            "Condition 539 564--*--polycystic kidney disease",
            "Scope 340 564--*--renovascular disease, adrenal medullary and cortical hyperfunction, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease",
            "Scope 271 332--*--secondary hypertension or suspected of secondary hypertension",
            "Condition 599 623--*--orthostatic hypertension",
            "Qualifier 587 598--*--symptomatic",
            "Measurement 629 662--*--difference in the blood pressures",
            "Qualifier 671 732--*--measured at supine position and measured at standing position",
            "Value 736 745--*--= 20 mmHg",
            "Value 760 769--*--= 10 mmHg",
            "Measurement 774 779--*--siDBP",
            "Measurement 750 755--*--siSBP",
            "Scope 629 779--*--difference in the blood pressures between measured at supine position and measured at standing position is = 20 mmHg for siSBP and = 10 mmHg for siDBP",
            "Scope 587 623--*--symptomatic orthostatic hypertension",
            "Condition 795 824--*--type 1 diabetes mellitus (DM)",
            "Qualifier 828 840--*--uncontrolled",
            "Condition 841 843--*--DM",
            "Procedure 857 872--*--insulin therapy",
            "Measurement 881 886--*--HbA1c",
            "Value 887 891--*--> 9%",
            "Scope 857 891--*--insulin therapy or with HbA1c > 9%",
            "Scope 795 843--*--type 1 diabetes mellitus (DM) or uncontrolled DM",
            "Qualifier 908 914--*--severe",
            "Condition 915 933--*--cardiac conditions",
            "Condition 935 948--*--heart failure",
            "Measurement 950 954--*--NYHA",
            "Value 955 967--*--Class 3 or 4",
            "Observation 970 977--*--history",
            "Condition 981 1005--*--ischemic cardiac disease",
            "Condition 1007 1022--*--unstable angina",
            "Condition 1024 1045--*--myocardial infarction",
            "Condition 1048 1076--*--peripheral vascular diseases",
            "Procedure 1078 1115--*--percutaneous transluminal angioplasty",
            "Procedure 1119 1147--*--coronary artery bypass graft",
            "Temporal 1148 1170--*--within recent 6 months",
            "Scope 1078 1147--*--percutaneous transluminal angioplasty or coronary artery bypass graft",
            "Scope 1007 1170--*--unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months",
            "Scope 935 1170--*--heart failure (NYHA Class 3 or 4), history of ischemic cardiac disease (unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months",
            "Qualifier 1187 1209--*--clinically significant",
            "Condition 1210 1233--*--ventricular tachycardia",
            "Condition 1235 1254--*--atrial fibrillation",
            "Condition 1256 1270--*--atrial flutter",
            "Qualifier 1280 1302--*--clinically significant",
            "Condition 1303 1313--*--arrhythmia",
            "Scope 1210 1270--*--ventricular tachycardia, atrial fibrillation, atrial flutter",
            "Condition 1367 1404--*--hypertrophic occlusive myocardiopathy",
            "Qualifier 1406 1412--*--severe",
            "Condition 1413 1446--*--occlusive coronary artery disease",
            "Condition 1448 1463--*--aortic stenosis",
            "Qualifier 1465 1492--*--hemodynamically significant",
            "Condition 1509 1530--*--mitral valve stenosis",
            "Condition 1543 1560--*--cardiogenic shock",
            "Observation 1532 1539--*--History",
            "Qualifier 1574 1580--*--severe",
            "Condition 1493 1505;1522 1530--*--aortic valve stenosis",
            "Scope 1493 1530--*--aortic valve or mitral valve stenosis",
            "Condition 1581 1606--*--cerebrovascular disorders",
            "Condition 1621 1627--*--stroke",
            "Condition 1629 1648--*--cerebral infarction",
            "Condition 1652 1671--*--cerebral hemorrhage",
            "Temporal 1672 1694--*--within recent 6 months",
            "Scope 1621 1671--*--stroke, cerebral infarction or cerebral hemorrhage",
            "Scope 1574 1606--*--severe cerebrovascular disorders",
            "Observation 1697 1704--*--History",
            "Temporal 1708 1715--*--current",
            "Observation 1728 1735--*--wasting",
            "Condition 1737 1747;1833 1841--*--autoimmune diseases",
            "Condition 1757 1777--*--rheumatoid arthritis",
            "Condition 1782 1810--*--systemic lupus erythematosus",
            "Condition 1815 1841--*--connective tissue diseases",
            "Scope 1757 1810--*--rheumatoid arthritis and systemic lupus erythematosus",
            "Scope 1697 1715--*--History or current",
            "Scope 1728 1841--*--wasting, autoimmune (such as rheumatoid arthritis and systemic lupus erythematosus) or connective tissue diseases",
            "Qualifier 1874 1883--*--malignant",
            "Qualifier 1862 1870--*--moderate",
            "Condition 1884 1895--*--retinopathy",
            "Condition 1907 1925--*--retinal hemorrhage",
            "Condition 1927 1945--*--visual disturbance",
            "Condition 1950 1971--*--retinal microaneurysm",
            "Temporal 1972 1987--*--within 6 months",
            "Scope 1862 1883--*--moderate or malignant",
            "Scope 1907 1971--*--retinal hemorrhage, visual disturbance and retinal microaneurysm",
            "Condition 2024 2043--*--intestinal diseases",
            "Qualifier 2004 2012--*--surgical",
            "Qualifier 2016 2023--*--medical",
            "Scope 2004 2023--*--surgical or medical",
            "Procedure 2063 2072--*--surgeries",
            "Qualifier 2078 2127--*--could interfere with drug absorption distribution",
            "Qualifier 2078 2103;2129 2139--*--could interfere with drug metabolism",
            "Qualifier 2078 2103;2144 2155--*--could interfere with drug elimination",
            "Scope 2078 2155--*--could interfere with drug absorption distribution, metabolism and elimination",
            "Scope 2004 2072--*--surgical or medical intestinal diseases or having received surgeries",
            "Condition 2168 2178--*--malignancy",
            "Observation 2157 2167--*--History of",
            "Condition 2189 2197--*--leukemia",
            "Condition 2202 2210--*--lymphoma",
            "Temporal 2211 2232--*--within recent 5 years",
            "Condition 2244 2286--*--localized basal cell carcinoma of the skin",
            "Negation 2233 2243--*--except for",
            "Scope 2189 2210--*--leukemia and lymphoma",
            "Condition 2307 2328--*--inflammatory diseases",
            "Qualifier 2339 2346--*--chronic",
            "Procedure 2347 2372--*--anti-inflammatory therapy",
            "Drug 2347 2372--*--anti-inflammatory therapy",
            "Condition 2374 2387--*--Renal failure",
            "Procedure 2391 2399--*--dialysis",
            "Measurement 2401 2404--*--AST",
            "Measurement 2408 2411--*--ALT",
            "Value 2412 2444--*-->2 x upper limit of normal (ULN)",
            "Scope 2401 2411--*--AST or ALT",
            "Measurement 2446 2462--*--Serum creatinine",
            "Value 2463 2474--*--> 1.5 x ULN",
            "Measurement 2476 2491--*--Serum potassium",
            "Value 2492 2504--*--< 3.5 mmol/L",
            "Value 2508 2519--*-->5.5 mmol/L",
            "Scope 2492 2519--*--< 3.5 mmol/L or >5.5 mmol/L",
            "Temporal 2531 2548;2617 2633--*--co-administration during the study",
            "Qualifier 2552 2561--*--non-study",
            "Drug 2562 2585--*--antihypertensive agents",
            "Drug 2589 2616--*--contraindicated medications",
            "Condition 2646 2662--*--hypersensitivity",
            "Drug 2666 2670--*--ARBs",
            "Drug 2674 2690--*--dihydropyridines",
            "Scope 2666 2690--*--ARBs or dihydropyridines",
            "Condition 2703 2713--*--angioedema",
            "Procedure 2717 2726--*--treatment",
            "Drug 2732 2746--*--ACE inhibitors",
            "Drug 2750 2754--*--ARBs",
            "Scope 2732 2754--*--ACE inhibitors or ARBs",
            "Observation 2692 2702--*--History of",
            "Observation 2635 2645--*--History of",
            "Condition 2756 2764--*--Pregnant",
            "Condition 2768 2777--*--lactating",
            "Person 2778 2783--*--women",
            "Person 2788 2794--*--female",
            "Observation 2809 2831--*--childbearing potential",
            "Scope 2756 2831--*--Pregnant or lactating women and female volunteers of childbearing potential",
            "Negation 2886 2889--*--not",
            "Mood 2890 2900--*--willing to",
            "Procedure 2908 2940--*--adequate method of contraception",
            "Pregnancy_considerations 2941 3546--*--(oral contraceptives, intrauterine device, condom, etc.) during the study. Women of childbearing potential who are not surgically sterile will be allowed to participate in the study only if they have negative pregnancy test at Visit 1 (screening) and should continue to use medically acceptable method of contraception (basic body temperature method and rhythm method will not be allowed). Women with no menses for = 12 months will be considered as postmenopausal state and method of contraception using hormonal contraception such as oral contraceptive should be initiated from or prior to the screening.",
            "Observation 3548 3555--*--History",
            "Condition 3559 3563;3575 3580--*--drug abuse",
            "Condition 3567 3580--*--alcohol abuse",
            "Temporal 3581 3601--*--within recent 1 year",
            "Scope 3559 3580--*--drug or alcohol abuse",
            "Drug 3632 3661--*--other investigational product",
            "Temporal 3662 3684--*--within recent 12 weeks",
            "Non-representable 3686 3782--*--Conditions which render a subject ineligible for the study at the discretion of the investigator"
        ]
    },
    "NCT01967420_inc": {
        "Text": "Non-affective psychosis . Premorbid IQ of over 70 . A service user of the early intervention service . Aged 18 or over (up to the age of 35 which is the limit for the early intervention service) . Psychiatrically stable enough to attend to completion (no hospitalisations or medication changes in last 4 weeks) . ",
        "Annotations": [
            "Condition 0 23--*--Non-affective psychosis",
            "Measurement 25 37--*--Premorbid IQ",
            "Value 41 48--*--over 70",
            "Non-query-able 50 98--*--A service user of the early intervention service",
            "Value 105 115--*--18 or over",
            "Person 100 104--*--Aged",
            "Value 117 136--*--up to the age of 35",
            "Condition 193 215--*--Psychiatrically stable",
            "Procedure 251 267--*--hospitalisations",
            "Negation 248 250--*--no",
            "Observation 271 289--*--medication changes",
            "Temporal 290 305--*--in last 4 weeks",
            "Scope 251 289--*--hospitalisations or medication changes"
        ]
    },
    "NCT00970866_inc": {
        "Text": "At least 18 years of age . No more than 20 wk of gestation . Given Ante-natal Cards of the Ghana Health Service . Completed the initial routine ante-natal examination at the clinics . HIV negative or status unknown (as from the Ante-natal card) . Free from chronic disease e.g. malignancy requiring frequent medical attention (as from the Ante-natal card) . Residing in the Manya Krobo or Yilo Krobo district . Prepared to sign an informed consent . Living in the area throughout the duration of the study . Acceptance of home visitors . ",
        "Annotations": [
            "Value 0 17--*--At least 18 years",
            "Person 21 24--*--age",
            "Value 26 44--*--No more than 20 wk",
            "Measurement 48 57--*--gestation",
            "Condition 48 57--*--gestation",
            "Non-representable 59 109--*--Given Ante-natal Cards of the Ghana Health Service",
            "Condition 133 163--*--routine ante-natal examination",
            "Visit 171 178--*--clinics",
            "Condition 180 183--*--HIV",
            "Negation 184 192--*--negative",
            "Qualifier 196 210--*--status unknown",
            "Scope 184 210--*--negative or status unknown",
            "Condition 252 267--*--chronic disease",
            "Condition 273 283--*--malignancy",
            "Visit 368 379;394 402--*--Manya Krobo district",
            "Visit 383 402--*--Yilo Krobo district",
            "Observation 352 360--*--Residing",
            "Scope 368 402--*--Manya Krobo or Yilo Krobo district",
            "Post-eligibility 404 440--*--Prepared to sign an informed consent",
            "Observation 442 460--*--Living in the area",
            "Temporal 461 497--*--throughout the duration of the study",
            "Reference_point 488 497--*--the study",
            "Post-eligibility 499 526--*--Acceptance of home visitors"
        ]
    },
    "NCT03176316_inc": {
        "Annotations": [
            "Visit 48 58--*--in-patient",
            "Procedure 59 82--*--spinal fusion procedure",
            "Value 88 105--*--18 years or older",
            "Person 91 96--*--years",
            "Temporal 116 130--*--post-operative",
            "Procedure 131 148--*--pain control plan",
            "Drug 158 164--*--opioid"
        ],
        "Text": "Patients will be included if they are having an in-patient spinal fusion procedure, are 18 years or older, post and post-operative pain control plan includes opioid medications.. "
    },
    "NCT02537899_inc": {
        "Text": "Male or female. Age 18 to 65 years. Diagnosed with spinal cord injury between 3 days and 4 weeks. American Spinal Injury Association Impairment Scale A or B. Informed consent for inclusion into the database is obtained. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Person 16 19--*--Age",
            "Value 20 34--*--18 to 65 years",
            "Condition 51 69--*--spinal cord injury",
            "Temporal 70 96--*--between 3 days and 4 weeks",
            "Measurement 98 149--*--American Spinal Injury Association Impairment Scale",
            "Value 150 156--*--A or B",
            "Informed_consent 158 218--*--Informed consent for inclusion into the database is obtained"
        ]
    },
    "NCT00994786_exc": {
        "Annotations": [
            "Qualifier 14 23--*--any other",
            "Negation 61 75--*--in addition to",
            "Condition 76 105--*--Obsessive Compulsive Disorder",
            "Condition 39 60--*--psychiatric diagnosis",
            "Qualifier 24 31--*--primary",
            "Qualifier 32 38--*--DSM-IV",
            "Scope 14 38--*--any other primary DSM-IV",
            "Condition 158 173--*--eating disorder",
            "Condition 175 199--*--body dysmorphic disorder",
            "Condition 220 235--*--substance abuse",
            "Condition 209 216;230 235--*--alcohol abuse",
            "Condition 271 287--*--bipolar disorder",
            "Condition 316 329--*--Schizophrenia",
            "Condition 340 359--*--psychotic disorders",
            "Qualifier 334 339--*--other",
            "Condition 361 369--*--Delirium",
            "Condition 371 379--*--Dementia",
            "Condition 385 393--*--Amnestic",
            "Condition 404 423--*--cognitive disorders",
            "Qualifier 398 403--*--other",
            "Qualifier 151 157--*--DSM-IV",
            "Scope 158 235--*--eating disorder, body dysmorphic disorder, current alcohol or substance abuse",
            "Condition 471 491--*--Personality Disorder",
            "Qualifier 453 470--*--Axis II Cluster A",
            "Condition 507 538--*--Antisocial Personality Disorder",
            "Condition 493 503;518 538--*--Borderline Personality Disorder",
            "Procedure 574 599--*--mental status examination",
            "Observation 619 645--*--risk of committing suicide",
            "Qualifier 607 618--*--significant",
            "Non-query-able 647 676--*--in the investigator's opinion",
            "Competing_trial 679 750--*--Subjects with a history of more than three adequate trials with an SSRI",
            "Competing_trial 753 806--*--Subjects who have had an adequate trial of pregabalin",
            "Procedure 837 850--*--psychotherapy",
            "Temporal 851 896--*--in the last 4 months prior to the first visit",
            "Reference_point 885 896--*--first visit",
            "Non-query-able 899 1017--*--Subjects who, during the course of the study, would be likely to require treatment with prohibited concomitant therapy",
            "Condition 1045 1052--*--allergy",
            "Condition 1056 1072--*--hypersensitivity",
            "Drug 1076 1086--*--pregabalin",
            "Scope 1045 1072--*--allergy or hypersensitivity",
            "Competing_trial 1089 1293--*--Subjects who have participated in any clinical trial within 30 days prior to entering the study, or in a clinical trial involving a psychotropic medication within the 6 months prior to entering the study.",
            "Non-query-able 1295 1848--*--Any subject who has been taking benzodiazepines before entering the study who: 1) cannot tolerate being free of benzodiazepines for 4 weeks, or 2) has signs or symptoms of benzodiazepine withdrawal or rebound at the end of those 4 weeks. Should a patient entering the study, who is currently on benzodiazepines develop discontinuation symptoms with discontinuation of their benzodiazepine, we will treat these symptoms with a more gradual benzodiazepine taper. Study will be delayed until the patient is able to tolerate the discontinuation for 4 weeks.",
            "Condition 1874 1890--*--seizure disorder",
            "Condition 1892 1914--*--organic brain disorder",
            "Condition 1920 1948--*--history of seizure disorders",
            "Negation 1950 1956--*--except",
            "Condition 1961 1977--*--febrile seizures",
            "Qualifier 1981 1990--*--childhood",
            "Condition 2008 2025--*--thyroid pathology",
            "Temporal 2078 2099--*--at least three months",
            "Negation 2054 2057--*--not",
            "Qualifier 2063 2073--*--stabilized",
            "Procedure 2031 2040--*--treatment",
            "Drug 2114 2131--*--neuroleptic drugs",
            "Temporal 2132 2170--*--in the two months prior to study entry",
            "Reference_point 2159 2170--*--study entry",
            "Procedure 2174 2203--*--cognitive behavioural therapy",
            "Condition 2216 2219--*--OCD",
            "Temporal 2220 2252--*--within four weeks of study entry",
            "Reference_point 2241 2252--*--study entry",
            "Pregnancy_considerations 2254 2381--*--Pregnant or lactating females, or if sexually active and of childbearing potential, not using adequate methods of birth control",
            "Non-query-able 2384 2587--*--Patients with a history or evidence of a medical condition that would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the trial",
            "Drug 2609 2622--*--psychotropics",
            "Drug 2646 2658--*--betablockers",
            "Drug 2669 2684--*--anticonvulsants",
            "Scope 2646 2684--*--betablockers and other anticonvulsants",
            "Drug 2686 2702--*--Sleep medication",
            "Negation 2749 2759--*--acceptable",
            "Drug 2735 2744--*--zopiclone",
            "Drug 2716 2731--*--chloral-hydrate",
            "Qualifier 2711 2715--*--oral",
            "Scope 2711 2744--*--oral chloral-hydrate or zopiclone",
            "Procedure 2781 2811--*--herbal psychoactive treatments",
            "Drug 2818 2832--*--St John's Wort",
            "Drug 2834 2842--*--Valerian",
            "Drug 2844 2853--*--Kava Kava",
            "Drug 2855 2867--*--L-tryptophan",
            "Scope 2818 2867--*--St John's Wort, Valerian, Kava Kava, L-tryptophan",
            "Non-query-able 2870 3032--*--Patients with any condition or on any therapy that, in the investigator's opinion, or as indicated in the pregabalin product label, may pose a risk to the subject",
            "Non-query-able 3035 3183--*--Patients who have had a major life event in the past three months, which in the judgement of the investigator is influencing their current condition",
            "Measurement 3234 3244;3253 3261--*--laboratory findings",
            "Measurement 3249 3261--*--ECG findings",
            "Value 3213 3233--*--significant abnormal",
            "Scope 3234 3261--*--laboratory, or ECG findings",
            "Non-query-able 3262 3298--*--not resolved by further examinations"
        ],
        "Text": "Patients with any other primary DSM-IV psychiatric diagnosis in addition to Obsessive Compulsive Disorder.. Patients who currently fulfil criteria for DSM-IV eating disorder, body dysmorphic disorder, current alcohol or substance abuse, or who have a lifetime history of bipolar disorder. Patients with a history of Schizophrenia and other psychotic disorders, Delirium, Dementia, and Amnestic and other cognitive disorders.. Subjects with a concurrent Axis II Cluster A Personality Disorder. Borderline or Antisocial Personality Disorder.. Subjects who based on history or mental status examination have a significant risk of committing suicide, in the investigator's opinion.. Subjects with a history of more than three adequate trials with an SSRI.. Subjects who have had an adequate trial of pregabalin.. Subjects who have initiated psychotherapy in the last 4 months prior to the first visit.. Subjects who, during the course of the study, would be likely to require treatment with prohibited concomitant therapy .. Prior use of or a known allergy or hypersensitivity to pregabalin.. Subjects who have participated in any clinical trial within 30 days prior to entering the study, or in a clinical trial involving a psychotropic medication within the 6 months prior to entering the study.. Any subject who has been taking benzodiazepines before entering the study who: 1) cannot tolerate being free of benzodiazepines for 4 weeks, or 2) has signs or symptoms of benzodiazepine withdrawal or rebound at the end of those 4 weeks. Should a patient entering the study, who is currently on benzodiazepines develop discontinuation symptoms with discontinuation of their benzodiazepine, we will treat these symptoms with a more gradual benzodiazepine taper. Study will be delayed until the patient is able to tolerate the discontinuation for 4 weeks.. Patients with a current seizure disorder, organic brain disorder or a history of seizure disorders (except for febrile seizures in childhood).. Patients with thyroid pathology, the treatment of which has not been stabilized for at least three months.. Patients on neuroleptic drugs in the two months prior to study entry or cognitive behavioural therapy specific to OCD within four weeks of study entry. Pregnant or lactating females, or if sexually active and of childbearing potential, not using adequate methods of birth control.. Patients with a history or evidence of a medical condition that would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the trial.. Patients receiving psychotropics of any kind, including betablockers and other anticonvulsants. Sleep medication such as oral chloral-hydrate or zopiclone are acceptable.. Patients using any herbal psychoactive treatments, e.g. St John's Wort, Valerian, Kava Kava, L-tryptophan.. Patients with any condition or on any therapy that, in the investigator's opinion, or as indicated in the pregabalin product label, may pose a risk to the subject.. Patients who have had a major life event in the past three months, which in the judgement of the investigator is influencing their current condition.. Patients having clinically significant abnormal laboratory, or ECG findings not resolved by further examinations.. "
    },
    "NCT02490839_inc": {
        "Annotations": [
            "Qualifier 20 37--*--H. pylori related",
            "Condition 38 55--*--chronic gastritis",
            "Condition 69 82--*--peptic ulcers",
            "Person 91 95--*--aged",
            "Value 96 121--*--greater than 20 years old",
            "Mood 130 149--*--willing to received",
            "Procedure 150 169--*--eradication therapy"
        ],
        "Text": "Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.. "
    },
    "NCT02299947_inc": {
        "Annotations": [
            "Procedure 0 16--*--Elective surgery",
            "Condition 21 38--*--thoracic aneurysm"
        ],
        "Text": "Elective surgery for thoracic aneurysm. "
    },
    "NCT01967420_exc": {
        "Text": "Active substance dependency . History of severe head injury       .     . ",
        "Annotations": [
            "Condition 7 27--*--substance dependency",
            "Condition 40 58--*--severe head injury",
            "Observation 29 36--*--History"
        ]
    },
    "NCT03231982_inc": {
        "Text": "Adult male and female aged 19 to 75 years. Voluntarily consented to participate in the study and signed the informed consent form after receiving the explanation of the objectives, methods and effects of the study.. ",
        "Annotations": [
            "Person 6 10--*--male",
            "Person 15 21--*--female",
            "Person 22 26--*--aged",
            "Value 27 41--*--19 to 75 years",
            "Informed_consent 43 214--*--Voluntarily consented to participate in the study and signed the informed consent form after receiving the explanation of the objectives, methods and effects of the study."
        ]
    },
    "NCT03073603_inc": {
        "Annotations": [
            "Condition 21 50--*--Relapsing-remitting MS (RRMS)",
            "Condition 52 83--*--Secondary progressive MS (SPMS)",
            "Condition 88 117--*--Primary progressive MS (PPMS)",
            "Non-representable 146 216--*--Patients defined by subtype based on 2013 updated phenotypic criteria.",
            "Condition 240 251--*--EDSS change",
            "Value 255 274--*--at least 1.0 points",
            "Temporal 275 298--*--over the last two years",
            "Qualifier 330 341--*--significant",
            "Condition 342 366--*--change in motor function",
            "Temporal 367 389--*--over at least one year",
            "Qualifier 391 411--*--unrelated to relapse",
            "Value 414 422;430 438--*--55 years or older",
            "Person 426 429--*--age",
            "Temporal 439 463--*--at time of randomization",
            "Condition 492 512--*--inflammatory disease",
            "Measurement 539 554--*--Lublin criteria",
            "Value 523 531--*--inactive",
            "Qualifier 488 491--*--new",
            "Negation 466 468--*--No",
            "Condition 570 577--*--relapse",
            "Qualifier 566 569--*--new",
            "Negation 563 565--*--no",
            "Temporal 578 601--*--for at least five years",
            "Condition 617 623--*--lesion",
            "Procedure 613 616--*--MRI",
            "Temporal 624 648--*--for at least three years",
            "Negation 606 608--*--no",
            "Qualifier 609 612--*--new",
            "Drug 650 665--*--interferon \u00df-1a",
            "Drug 668 683--*--interferon \u00df-1b",
            "Drug 686 704--*--glatiramer acetate",
            "Drug 707 718--*--natalizumab",
            "Drug 721 731--*--fingolimod",
            "Drug 734 751--*--dimethyl fumarate",
            "Drug 757 770--*--teriflunomide",
            "Temporal 785 809--*--for no less than 5 years",
            "Multiplier 772 784--*--continuously",
            "Drug 831 834--*--DMT",
            "Multiplier 835 847--*--continuously",
            "Temporal 849 875--*--for no less than two years",
            "Post-eligibility 878 1058--*--Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.",
            "Post-eligibility 1060 1090--*--Willing to follow the protocol",
            "Non-representable 1092 1300--*--Continuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e. one missed dose)."
        ],
        "Text": "Patients with either Relapsing-remitting MS (RRMS), Secondary progressive MS (SPMS), or Primary progressive MS (PPMS) by McDonald 2010 criteria.. Patients defined by subtype based on 2013 updated phenotypic criteria.. prospectively with an EDSS change of at least 1.0 points over the last two years, or. retrospectively, with any significant change in motor function over at least one year, unrelated to relapse.. 55 years of age or older at time of randomization;. No evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years. interferon \u00df-1a,. interferon \u00df-1b,. glatiramer acetate,. natalizumab,. fingolimod,. dimethyl fumarate, or. teriflunomide; continuously for no less than 5 years.. Taking most recent DMT continuously* for no less than two years.. Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.. Willing to follow the protocol. Continuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e. one missed dose).. "
    },
    "NCT00970866_exc": {
        "Text": "Known asthmatic or history of allergy towards peanut or milk products . Concurrent participation in another clinical trial . Severe illness warranting hospital referral       .     . ",
        "Annotations": [
            "Condition 6 15--*--asthmatic",
            "Observation 19 26--*--history",
            "Condition 30 37--*--allergy",
            "Drug 46 52--*--peanut",
            "Drug 56 69--*--milk products",
            "Scope 46 69--*--peanut or milk products",
            "Condition 130 137--*--illness",
            "Qualifier 123 129--*--Severe",
            "Procedure 149 166--*--hospital referral",
            "Mood 138 148--*--warranting",
            "Observation 82 121--*--participation in another clinical trial"
        ]
    },
    "NCT02490839_exc": {
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Condition 12 19--*--nursing",
            "Person 20 25--*--woman",
            "Qualifier 27 34--*--serious",
            "Temporal 35 46--*--concomitant",
            "Condition 47 54--*--illness",
            "Condition 59 74--*--malignant tumor",
            "Qualifier 78 86--*--any kind",
            "Observation 88 95--*--history",
            "Condition 99 115--*--hypersensitivity",
            "Drug 119 129--*--test drugs",
            "Qualifier 131 138--*--serious",
            "Condition 139 147--*--bleeding",
            "Temporal 148 178--*--during the course of the ulcer",
            "Reference_point 169 178--*--the ulcer",
            "Condition 173 178--*--ulcer",
            "Temporal 180 188--*--previous",
            "Procedure 189 204--*--gastric surgery",
            "Drug 216 229--*--bismuth salts",
            "Drug 231 235--*--PPIs",
            "Drug 240 251--*--antibiotics",
            "Temporal 252 273--*--in the previous month",
            "Scope 216 251--*--bismuth salts, PPIs, or antibiotics"
        ],
        "Text": "pregnant or nursing woman. serious concomitant illness and malignant tumor of any kind. history of hypersensitivity to test drugs. serious bleeding during the course of the ulcer. previous gastric surgery. receiving bismuth salts, PPIs, or antibiotics in the previous month.. "
    },
    "NCT02537899_exc": {
        "Text": "Non survivable injury. Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury. Other conditions that would limit clinical assessment of outcomes (e.g. dementia, demyelinating disease, autoimmune disease, etc). Refusal of treatment or contraindication to NeuroAiD. ",
        "Annotations": [
            "Condition 15 21--*--injury",
            "Qualifier 0 14--*--Non survivable",
            "Condition 44 50--*--trauma",
            "Qualifier 23 31--*--Multiple",
            "Qualifier 32 43--*--significant",
            "Condition 86 107--*--extracranial injuries",
            "Condition 69 81;99 107--*--intracranial injuries",
            "Condition 118 132--*--limb fractures",
            "Scope 69 132--*--intracranial and extracranial injuries including limb fractures",
            "Condition 272 280--*--dementia",
            "Condition 282 303--*--demyelinating disease",
            "Condition 305 323--*--autoimmune disease",
            "Condition 355 371--*--contraindication",
            "Procedure 375 383--*--NeuroAiD"
        ]
    },
    "NCT03176316_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Person 11 14--*--age",
            "Value 15 19--*--< 18",
            "Condition 21 28--*--nursing",
            "Condition 44 51--*--allergy",
            "Drug 55 63--*--naloxone"
        ],
        "Text": "Pregnancy, age < 18, nursing, or documented allergy to naloxone. "
    },
    "NCT00994786_inc": {
        "Annotations": [
            "Condition 44 73--*--Obsessive-Compulsive Disorder",
            "Qualifier 29 36--*--primary",
            "Qualifier 37 43--*--DSM-IV",
            "Scope 29 43--*--primary DSM-IV",
            "Visit 11 21--*--outpatient",
            "Measurement 128 165--*--Yale-Brown Obsessive Compulsive Scale",
            "Value 96 120--*--score of greater than 20",
            "Measurement 167 173--*--Y-BOCS",
            "Condition 229 253--*--major depressive episode",
            "Qualifier 222 228--*--DSM-IV",
            "Qualifier 213 221--*--comorbid",
            "Scope 213 228--*--comorbid DSM-IV",
            "Condition 327 330--*--OCD",
            "Measurement 353 387--*--Montgomery Depression Rating Scale",
            "Qualifier 344 352--*--baseline",
            "Measurement 389 394--*--MADRS",
            "Value 396 429--*--score of less than or equal to 19",
            "Condition 439 451--*--onset of OCD",
            "Temporal 452 529--*--predates the onset of the current episode of depression by five or more years",
            "Reference_point 465 507--*--onset of the current episode of depression",
            "Post-eligibility 532 595--*--The ability to comprehend and comply with protocol requirements",
            "Informed_consent 598 652--*--Written consent must be provided prior to study entry.",
            "Pregnancy_considerations 765 999--*--All female subjects of childbearing potential (WOCBP), including those who are practicing a medically acceptable method of birth control, must have a negative serum pregnancy test within 72 hours prior to the start of study medication",
            "Person 658 663--*--women",
            "Condition 667 689--*--childbearing potential",
            "Condition 691 696--*--WOCBP",
            "Scope 658 689--*--women of childbearing potential",
            "Qualifier 719 739--*--medically acceptable",
            "Procedure 750 763--*--birth control"
        ],
        "Text": "Must be an outpatient with a primary DSM-IV Obsessive-Compulsive Disorder. Patients must have a score of greater than 20 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman et al., 1989b).. Diagnosis of comorbid DSM-IV major depressive episode will be allowed in the study provided that the diagnosis is secondary to OCD, they have a baseline Montgomery Depression Rating Scale (MADRS) score of less than or equal to 19, and the onset of OCD predates the onset of the current episode of depression by five or more years.. The ability to comprehend and comply with protocol requirements.. Written consent must be provided prior to study entry.. All women of childbearing potential (WOCBP) must be practicing a medically acceptable method of birth control. All female subjects of childbearing potential (WOCBP), including those who are practicing a medically acceptable method of birth control, must have a negative serum pregnancy test within 72 hours prior to the start of study medication.. "
    },
    "NCT03134378_exc": {
        "Text": "Patients refuse to follow the research. Patient has had previous eradication therapy of Helicobacter pylori infection.. The patient is pregnant or breastfeeding. Patients have a history of allergy to one component of triple therapy regimen (proton pump inhibitor, penicillin, and / or macrolide) before.. Patients are known to have impaired liver function, evidenced by ALT values within normal limits, and no previous liver disease.. Patients were found to have arrhythmias or obtained QT wave elongation on electrocardiographic. ",
        "Annotations": [
            "Observation 9 38--*--refuse to follow the research",
            "Temporal 56 64--*--previous",
            "Procedure 65 84--*--eradication therapy",
            "Condition 88 117--*--Helicobacter pylori infection",
            "Condition 135 143--*--pregnant",
            "Observation 147 160--*--breastfeeding",
            "Observation 178 185--*--history",
            "Condition 189 196--*--allergy",
            "Drug 204 239--*--component of triple therapy regimen",
            "Drug 241 262--*--proton pump inhibitor",
            "Drug 264 274--*--penicillin",
            "Drug 285 294--*--macrolide",
            "Scope 241 295--*--proton pump inhibitor, penicillin, and / or macrolide)",
            "Value 332 340--*--impaired",
            "Measurement 341 355--*--liver function",
            "Measurement 370 380--*--ALT values",
            "Value 381 401--*--within normal limits",
            "Negation 407 409--*--no",
            "Temporal 410 418--*--previous",
            "Condition 419 432--*--liver disease",
            "Condition 463 474--*--arrhythmias",
            "Condition 487 505--*--QT wave elongation",
            "Procedure 509 529--*--electrocardiographic"
        ]
    },
    "NCT03338855_inc": {
        "Text": "Patients are able to provide signed and dated written informed consent prior to any study specific procedures.. Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged = 45 and = 70 years. Males are aged = 40 years and = 70 years. Patients should have suitable veins for cannulation or repeated venipuncture.. Patients are diagnosed with T2DM for at least the last 6 months.. Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5. HbA1c levels =6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol).. Have a body mass index (BMI) = 35 kg/m2.. ",
        "Annotations": [
            "Informed_consent 0 110--*--Patients are able to provide signed and dated written informed consent prior to any study specific procedures.",
            "Person 112 117--*--Women",
            "Condition 122 137--*--post-menopausal",
            "Condition 371 375--*--T2DM",
            "Temporal 147 190--*--as at least 1 year post cessation of menses",
            "Reference_point 171 190--*--cessation of menses",
            "Person 196 200--*--aged",
            "Value 201 220--*--= 45 and = 70 years",
            "Person 222 227--*--Males",
            "Person 232 236--*--aged",
            "Value 237 262--*--= 40 years and = 70 years",
            "Non-representable 264 341--*--Patients should have suitable veins for cannulation or repeated venipuncture.",
            "Scope 122 220--*--post-menopausal (defined as at least 1 year post cessation of menses) and aged = 45 and = 70 years",
            "Scope 232 262--*--aged = 40 years and = 70 years",
            "Temporal 376 406--*--for at least the last 6 months",
            "Procedure 434 462--*--anti-diabetic drug treatment",
            "Negation 425 427--*--no",
            "Qualifier 428 433--*--other",
            "Qualifier 470 476--*--stable",
            "Multiplier 477 503--*--maximum 3000 mg daily dose",
            "Drug 504 513--*--metformin",
            "Qualifier 534 545--*--stable dose",
            "Drug 551 566--*--DPPIV inhibitor",
            "Temporal 577 607--*--for at least the last 3 months",
            "Measurement 610 622--*--HbA1c levels",
            "Value 623 628--*--=6.0%",
            "Value 630 642--*--=42 mmol/mol",
            "Value 648 653--*--=9.0%",
            "Value 655 666--*--75 mmol/mol",
            "Scope 623 667--*--=6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol)",
            "Measurement 677 698--*--body mass index (BMI)",
            "Value 699 709--*--= 35 kg/m2"
        ]
    },
    "NCT01980680_exc": {
        "Text": "Patients with >14 follicles on day of trigger. Previous hyperresponse with OHSS development. Previous low response (less than 3 oocytes on a high dose of FSH stimulation). Endocrine disorders. ",
        "Annotations": [
            "Value 14 17--*-->14",
            "Measurement 18 27--*--follicles",
            "Temporal 28 45--*--on day of trigger",
            "Reference_point 31 45--*--day of trigger",
            "Condition 56 69--*--hyperresponse",
            "Observation 75 92--*--OHSS development",
            "Condition 102 114--*--low response",
            "Temporal 47 55--*--Previous",
            "Temporal 93 101--*--Previous",
            "Measurement 128 135--*--oocytes",
            "Value 116 127--*--less than 3",
            "Procedure 141 169--*--high dose of FSH stimulation",
            "Scope 116 169--*--less than 3 oocytes on a high dose of FSH stimulation",
            "Condition 172 191--*--Endocrine disorders"
        ]
    },
    "NCT03506477_exc": {
        "Annotations": [
            "Condition 18 27--*--psoriasis",
            "Negation 28 38--*--other than",
            "Condition 39 63--*--chronic plaque psoriasis",
            "Qualifier 70 77--*--guttate",
            "Qualifier 79 92--*--erythrodermic",
            "Qualifier 94 102--*--pustular",
            "Scope 28 63--*--other than chronic plaque psoriasis",
            "Scope 70 102--*--guttate, erythrodermic, pustular",
            "Qualifier 124 130--*--active",
            "Temporal 132 139--*--ongoing",
            "Condition 140 153--*--skin diseases",
            "Condition 157 172--*--skin infections",
            "Non-representable 182 229--*--interfere with examination of psoriasis lesions",
            "Scope 140 172--*--skin diseases or skin infections",
            "Procedure 262 271--*--treatment",
            "Condition 252 261--*--psoriasis",
            "Drug 301 308;321 336--*--topical corticosteroids",
            "Drug 312 336--*--systemic corticosteroids",
            "Drug 344 363--*--topical medications",
            "Drug 370 378--*--coal tar",
            "Drug 381 385;398 409--*--oral medications",
            "Drug 389 409--*--biologic medications",
            "Procedure 446 456--*--UV therapy",
            "Non-representable 458 642--*--The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies",
            "Temporal 231 238--*--Ongoing",
            "Scope 301 456--*--topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy",
            "Procedure 651 672--*--oral estrogen therapy",
            "Drug 684 708--*--oral contraceptive pills",
            "Negation 674 683--*--excluding",
            "Pregnancy_considerations 710 837--*--Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.",
            "Mood 848 857--*--unwilling",
            "Procedure 861 887--*--limit exposure to UV light",
            "Non-query-able 889 1012--*--Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk",
            "Condition 1028 1059--*--disorders of calcium metabolism",
            "Condition 1067 1080--*--hypercalcemia",
            "Competing_trial 1082 1233--*--Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)",
            "Condition 1246 1253--*--allergy",
            "Drug 1257 1280--*--any component of the IP"
        ],
        "Text": "Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular). Diagnosis of other active, ongoing skin diseases or skin infections that may interfere with examination of psoriasis lesions. Ongoing use of other psoriasis treatment including but not limited to topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy. The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies. Use of oral estrogen therapy, excluding oral contraceptive pills. Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.. Patients unwilling to limit exposure to UV light. Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk. Patients with disorders of calcium metabolism and/or hypercalcemia. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer). History of allergy to any component of the IP. "
    },
    "NCT03338855_exc": {
        "Text": "Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).. Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus.. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula).. Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion.. Contraindications to dapagliflozin according to the local label.. Use of antidiabetic drugs other than metformin within 3 months prior to screening.. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.. History of drug abuse or alcohol abuse in the past 12 months.. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study.. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men.. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors.. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity.. Use of loop diuretics.. Regular smoking and other regular nicotine use.. Central nervous system aneurysm clip. Implanted neural stimulator. Implanted cardiac pacemaker of defibrillator. Cochlear implant. Metal containing corpora aliena in the eye or brain.. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.. ",
        "Annotations": [
            "Non-query-able 0 153--*--Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).",
            "Competing_trial 155 328--*--Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.",
            "Qualifier 360 382--*--clinically significant",
            "Condition 383 390--*--disease",
            "Condition 394 402--*--disorder",
            "Temporal 415 421--*--recent",
            "Temporal 423 433--*--< 3 months",
            "Condition 435 455--*--cardiovascular event",
            "Post-eligibility 330 649--*--History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study",
            "Condition 674 689--*--Type 1 diabetes",
            "Condition 691 727--*--maturity onset diabetes of the young",
            "Condition 729 747--*--secondary diabetes",
            "Condition 751 769--*--diabetes insipidus",
            "Qualifier 781 800--*--rapidly progressing",
            "Qualifier 772 780--*--Unstable",
            "Condition 801 814--*--renal disease",
            "Measurement 818 854--*--estimated Glomerular Filtration Rate",
            "Value 855 866--*--< 60 mL/min",
            "Qualifier 868 891--*--Cockcroft-Gault formula",
            "Scope 772 800--*--Unstable/rapidly progressing",
            "Qualifier 895 917--*--Clinically significant",
            "Value 918 937--*--out of range values",
            "Measurement 964 994--*--alanine aminotransferase (ALT)",
            "Measurement 996 1028--*--aspartate aminotransferase (AST)",
            "Measurement 1032 1058--*--alkaline phosphatase (ALP)",
            "Scope 964 1058--*--alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)",
            "Drug 1112 1125--*--dapagliflozin",
            "Condition 1091 1108--*--Contraindications",
            "Drug 1164 1182--*--antidiabetic drugs",
            "Drug 1194 1203--*--metformin",
            "Negation 1183 1193--*--other than",
            "Temporal 1204 1238--*--within 3 months prior to screening",
            "Measurement 1241 1252--*--Weight gain",
            "Measurement 1241 1247;1256 1260--*--Weight loss",
            "Value 1261 1267--*--> 5 kg",
            "Temporal 1268 1288--*--in the last 3 months",
            "Observation 1298 1314--*--weight-loss diet",
            "Temporal 1290 1297--*--ongoing",
            "Observation 1316 1332--*--hypocaloric diet",
            "Drug 1344 1362--*--weight loss agents",
            "Scope 1241 1260--*--Weight gain or loss",
            "Observation 1390 1403--*--alcohol abuse",
            "Observation 1376 1386--*--drug abuse",
            "Temporal 1404 1425--*--in the past 12 months",
            "Scope 1376 1403--*--drug abuse or alcohol abuse",
            "Observation 1365 1372--*--History",
            "Post-eligibility 1428 1763--*--Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.",
            "Procedure 1765 1780--*--Plasma donation",
            "Temporal 1781 1810--*--within one month of screening",
            "Reference_point 1801 1810--*--screening",
            "Procedure 1818 1832--*--blood donation",
            "Measurement 1833 1843--*--blood loss",
            "Value 1844 1852--*--> 500 mL",
            "Scope 1818 1852--*--blood donation/blood loss > 500 mL",
            "Temporal 1853 1887--*--within 3 months prior to screening",
            "Temporal 1891 1907--*--during the study",
            "Scope 1853 1907--*--within 3 months prior to screening or during the study",
            "Condition 1910 1916--*--Anemia",
            "Measurement 1928 1943--*--Hemoglobin (Hb)",
            "Value 1944 1953--*--< 115 g/L",
            "Value 1955 1961--*--7.1 mM",
            "Person 1966 1971--*--women",
            "Value 1976 1985--*--< 120 g/L",
            "Value 1987 1993--*--7.5 mM",
            "Person 1998 2001--*--men",
            "Scope 1944 2001--*--< 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men",
            "Scope 1928 2001--*--Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men",
            "Procedure 2011 2035--*--anti-coagulant treatment",
            "Drug 2044 2051--*--heparin",
            "Drug 2053 2061--*--warfarin",
            "Drug 2063 2082--*--platelet inhibitors",
            "Drug 2084 2092--*--thrombin",
            "Drug 2097 2116--*--factor X inhibitors",
            "Scope 2044 2115--*--heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitor",
            "Drug 2145 2165--*--oral glucocorticoids",
            "Drug 2167 2181--*--anti-estrogens",
            "Drug 2191 2202--*--medications",
            "Qualifier 2185 2190--*--other",
            "Qualifier 2221 2259--*--markedly influence insulin sensitivity",
            "Scope 2145 2202--*--oral glucocorticoids, anti-estrogens or other medications",
            "Drug 2269 2283--*--loop diuretics",
            "Observation 2294 2301--*--smoking",
            "Multiplier 2286 2293--*--Regular",
            "Drug 2320 2328--*--nicotine",
            "Multiplier 2312 2319--*--regular",
            "Device 2335 2371--*--Central nervous system aneurysm clip",
            "Device 2373 2400--*--Implanted neural stimulator",
            "Device 2412 2429--*--cardiac pacemaker",
            "Device 2433 2446--*--defibrillator",
            "Device 2448 2464--*--Cochlear implant",
            "Device 2483 2508--*--corpora aliena in the eye",
            "Device 2483 2504;2512 2517--*--corpora aliena in the brain",
            "Qualifier 2466 2482--*--Metal containing",
            "Non-query-able 2520 2705--*--Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study."
        ]
    },
    "NCT03134378_inc": {
        "Text": "18 years or older patients who are proven to be infected by Helicobacter pylori based on positive in Urea Breath Test or positive in histopathologic examination of biopsy in antrum and corpus of gaster through esophagoduodenoscopy.. ",
        "Annotations": [
            "Value 0 17--*--18 years or older",
            "Condition 48 79--*--infected by Helicobacter pylori",
            "Value 89 97--*--positive",
            "Measurement 101 117--*--Urea Breath Test",
            "Value 121 129--*--positive",
            "Procedure 133 170--*--histopathologic examination of biopsy",
            "Qualifier 174 180;192 201--*--antrum of gaster",
            "Qualifier 185 201--*--corpus of gaster",
            "Procedure 210 230--*--esophagoduodenoscopy",
            "Person 12 15--*--old"
        ]
    },
    "NCT01980680_inc": {
        "Text": "Age between 20 and 40. Normal menstrual cycles: 25-34 days. Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam criteria 2004). BMI >18 and <35 kg/m2. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--between 20 and 40",
            "Condition 23 46--*--Normal menstrual cycles",
            "Value 48 58--*--25-34 days",
            "Condition 75 85--*--amenorrhea",
            "Condition 60 74--*--Oligomenorrhea",
            "Condition 89 108--*--polycystic syndrome",
            "Qualifier 135 158--*--Rotterdam criteria 2004",
            "Measurement 161 164--*--BMI",
            "Value 165 182--*-->18 and <35 kg/m2"
        ]
    },
    "NCT03506477_inc": {
        "Annotations": [
            "Informed_consent 0 100--*--Provide written, signed and dated informed consent prior to initiating any study-related activities.",
            "Person 102 106--*--Male",
            "Person 110 116--*--female",
            "Value 117 133--*-->18 years of age",
            "Person 130 133--*--age",
            "Temporal 134 158--*--at the time of screening",
            "Reference_point 137 158--*--the time of screening",
            "Measurement 160 186--*--Fitzpatrick Skin phototype",
            "Value 187 192--*--IV-VI",
            "Person 194 218--*--non-white race/ethnicity",
            "Person 253 270--*--African Americans",
            "Person 272 278--*--Asians",
            "Person 280 297--*--Pacific Islanders",
            "Person 302 311--*--Hispanics",
            "Scope 253 311--*--African Americans, Asians, Pacific Islanders and Hispanics",
            "Qualifier 344 355--*--plaque-type",
            "Qualifier 336 343--*--chronic",
            "Condition 356 377--*--psoriasis of the body",
            "Condition 379 395--*--Plaque psoriasis",
            "Value 401 428--*--=2% Body Surface Area (BSA)",
            "Measurement 429 440--*--involvement",
            "Measurement 474 484--*--PASI Score",
            "Value 485 488--*--= 2",
            "Measurement 490 508--*--IGA mod 2011 score",
            "Value 512 524--*--2 or greater",
            "Qualifier 535 547--*--scale of 0-4",
            "Scope 401 548--*--=2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score = 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)",
            "Pregnancy_considerations 550 878--*--Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d",
            "Non-query-able 880 991--*--Must be in general good health as judged by the Investigator, based on medical history and physical examination"
        ],
        "Text": "Provide written, signed and dated informed consent prior to initiating any study-related activities.. Male or female >18 years of age at the time of screening. Fitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.. Clinical diagnosis of chronic plaque-type psoriasis of the body. Plaque psoriasis with =2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score = 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4). Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d. Must be in general good health as judged by the Investigator, based on medical history and physical examination.. "
    },
    "NCT02937779_inc": {
        "Text": ">= 18 years old the day of inclusion. Pregnancy. Positive HBs Ag. Informed consent obtained with information sheet given and explained and the consent form signed by the participant of the project investigator at the latest the day of the inclusion. ",
        "Annotations": [
            "Person 12 15--*--old",
            "Value 0 11--*-->= 18 years",
            "Condition 38 47--*--Pregnancy",
            "Measurement 58 64--*--HBs Ag",
            "Value 49 57--*--Positive",
            "Informed_consent 66 247--*--Informed consent obtained with information sheet given and explained and the consent form signed by the participant of the project investigator at the latest the day of the inclusio"
        ]
    },
    "NCT02393287_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 32 34--*--2.",
            "Condition 21 30--*--neoplasia",
            "Person 35 38--*--Man",
            "Qualifier 15 20--*--other"
        ],
        "Text": "1. Presence of other neoplasia . 2. Man       .     . "
    },
    "NCT02844907_inc": {
        "Text": "Body Mass Index (BMI) = 35 kg/m2. HbA1c = 5.7%. Ability to speak and understand English. ",
        "Annotations": [
            "Measurement 0 21--*--Body Mass Index (BMI)",
            "Value 22 32--*--= 35 kg/m2",
            "Measurement 34 39--*--HbA1c",
            "Value 40 46--*--= 5.7%",
            "Observation 48 64;80 87--*--Ability to speak English",
            "Observation 48 58;69 87--*--Ability to understand English"
        ]
    },
    "NCT00236340_inc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--women",
            "Condition 20 38--*--abdomen discumfort",
            "Procedure 43 53--*--ultrasound",
            "Condition 67 81--*--polyhydramnios",
            "Measurement 83 86--*--AFI",
            "Value 86 91--*-->25cm",
            "Value 54 63--*--diagnosis",
            "Condition 109 120--*--pregnancies",
            "Value 94 100--*--Single",
            "Value 104 108--*--twin",
            "Scope 94 108--*--Single or twin"
        ],
        "Text": "Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm) . Single or twin pregnancies . "
    },
    "NCT01650792_inc": {
        "Annotations": [
            "Condition 13 26--*--heart failure",
            "Qualifier 40 59--*--Framingham criteria",
            "Informed_consent 61 77--*--Informed consent",
            "Person 79 82--*--Age",
            "Value 83 100--*--18 years or above"
        ],
        "Text": "Diagnosis of heart failure according to Framingham criteria. Informed consent. Age 18 years or above. "
    },
    "NCT01391780_inc": {
        "Annotations": [
            "Condition 30 50--*--urgency incontinence",
            "Condition 12 26;38 50--*--stress urinary incontinence"
        ],
        "Text": "presence of stress urinary or urgency incontinence . "
    },
    "NCT02953873_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ]
    },
    "NCT01822262_inc": {
        "Text": "Clinical diagnosis of calculous cholecystitis.. ",
        "Annotations": [
            "Condition 22 45--*--calculous cholecystitis",
            "Qualifier 0 18--*--Clinical diagnosis"
        ]
    },
    "NCT02937779_exc": {
        "Text": "Women refusing HBs Ag test. HIV co-infection. HCV co-infection. HBV treatment ongoing at the day of inclusion. Creatinine clearance < 30 mL/min. Severe gravidic disease present at inclusion involving life threatening to the mother and/or the child. Evidence of pre-existing fetal anomalies incompatible with the child's life. Imminent child's birth defined as cervix dilatation up to 7 centimeters. Intention to deliver in a maternity not linked to the study. Any concomitant medical condition that, according to the clinical site investigator would contraindicate participation in the study.. Concurrent participation in any other clinical trial without written agreement of the two study teams. ",
        "Annotations": [
            "Measurement 15 26--*--HBs Ag test",
            "Negation 6 14--*--refusing",
            "Condition 32 44--*--co-infection",
            "Condition 50 62--*--co-infection",
            "Qualifier 28 31--*--HIV",
            "Qualifier 46 49--*--HCV",
            "Procedure 64 77--*--HBV treatment",
            "Measurement 111 131--*--Creatinine clearance",
            "Value 132 143--*--< 30 mL/min",
            "Condition 152 168--*--gravidic disease",
            "Qualifier 145 151--*--Severe",
            "Qualifier 200 216--*--life threatening",
            "Condition 274 289--*--fetal anomalies",
            "Condition 326 348--*--Imminent child's birth",
            "Measurement 360 377--*--cervix dilatation",
            "Value 384 397--*--7 centimeters",
            "Post-eligibility 399 458--*--Intention to deliver in a maternity not linked to the study",
            "Post-eligibility 460 591--*--Any concomitant medical condition that, according to the clinical site investigator would contraindicate participation in the study",
            "Competing_trial 594 695--*--Concurrent participation in any other clinical trial without written agreement of the two study teams"
        ]
    },
    "NCT02844907_exc": {
        "Text": "Rheumatoid arthritis. Diabetes or immediate family history of diabetes. Coronary artery disease. Congestive heart failure. Pulmonary disorders, including COPD and asthma. Malabsorptive GI disease, such as celiac disease, or gastric bypass. Significant hepatic disease. Renal insufficiency (eGFR < 60 mL/kg/min). Anemia (hematocrit < 34%) as measured at screening visit. Pregnant females. Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide). Consumption or injection of insulin. Apparent sensitivity to any of the study peptides as determined by the skin test. Diagnosis or h/o PTSD, depression, substance use, mental health problems, sleep disorders, HPA disruption and/or TBI. ",
        "Annotations": [
            "Condition 0 20--*--Rheumatoid arthritis",
            "Condition 22 30--*--Diabetes",
            "Observation 34 58--*--immediate family history",
            "Condition 62 70--*--diabetes",
            "Condition 72 95--*--Coronary artery disease",
            "Condition 97 121--*--Congestive heart failure",
            "Condition 123 142--*--Pulmonary disorders",
            "Condition 154 158--*--COPD",
            "Condition 163 169--*--asthma",
            "Scope 154 169--*--COPD and asthma",
            "Condition 171 195--*--Malabsorptive GI disease",
            "Condition 205 219--*--celiac disease",
            "Procedure 224 238--*--gastric bypass",
            "Scope 205 238--*--celiac disease, or gastric bypass",
            "Qualifier 240 251--*--Significant",
            "Condition 252 267--*--hepatic disease",
            "Condition 269 288--*--Renal insufficiency",
            "Measurement 290 294--*--eGFR",
            "Value 295 309--*--< 60 mL/kg/min",
            "Scope 290 309--*--eGFR < 60 mL/kg/min",
            "Condition 312 318--*--Anemia",
            "Measurement 320 330--*--hematocrit",
            "Value 331 336--*--< 34%",
            "Visit 353 368--*--screening visit",
            "Scope 320 336--*--hematocrit < 34%",
            "Condition 370 378--*--Pregnant",
            "Person 379 386--*--females",
            "Multiplier 403 408--*--daily",
            "Drug 409 420--*--medications",
            "Qualifier 421 465--*--that alter glucose metabolism of GI function",
            "Drug 467 482--*--glucocorticoids",
            "Drug 484 497--*--psychotropics",
            "Drug 510 524--*--metoclopramide",
            "Drug 499 508--*--narcotics",
            "Scope 467 524--*--glucocorticoids, psychotropics, narcotics, metoclopramide",
            "Drug 555 562--*--insulin",
            "Procedure 542 551--*--injection",
            "Drug 555 562--*--insulin",
            "Condition 573 584--*--sensitivity",
            "Drug 599 613--*--study peptides",
            "Procedure 635 644--*--skin test",
            "Condition 663 667--*--PTSD",
            "Condition 669 679--*--depression",
            "Condition 681 694--*--substance use",
            "Condition 696 718--*--mental health problems",
            "Condition 720 735--*--sleep disorders",
            "Condition 737 751--*--HPA disruption",
            "Condition 759 762--*--TBI"
        ]
    },
    "NCT02393287_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 19 21--*--2.",
            "Parsing_Error 105 107--*--3.",
            "Parsing_Error 271 273--*--4.",
            "Person 3 6--*--Age",
            "Value 7 17--*--\u2265 18 years",
            "Condition 35 48--*--breast cancer",
            "Procedure 50 64--*--histologically",
            "Value 65 71--*--proven",
            "Qualifier 73 83--*--metastatic",
            "Qualifier 87 103--*--locally advanced",
            "Scope 50 103--*--histologically proven, metastatic or locally advanced",
            "Drug 127 135--*--Eribulin",
            "Temporal 136 168--*--between January and October 2014",
            "Temporal 201 241--*--between November 2014 and September 2015",
            "Scope 136 268--*--between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part)",
            "Drug 329 337--*--Eribulin",
            "Procedure 299 325--*--assessment of the response",
            "Non-query-able 274 337--*--Patient with at least an assessment of the response to Eribulin"
        ],
        "Text": "1. Age \u2265 18 years . 2. Patient with breast cancer, histologically proven, metastatic or locally advanced . 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). . 4. Patient with at least an assessment of the response to Eribulin . "
    },
    "NCT01650792_exc": {
        "Annotations": [
            "Qualifier 30 39--*--untreated",
            "Condition 40 50--*--malignancy",
            "Condition 59 77--*--local skin cancers",
            "Negation 52 58--*--except",
            "Condition 80 95--*--Ischemic stroke",
            "Qualifier 118 172--*--Questionnaire for Verifying Stroke-Free Status (QVSFS)",
            "Procedure 186 200--*--renal dialysis",
            "Condition 209 238--*--end-stage hepatic dysfunction",
            "Qualifier 240 245--*--Acute",
            "Condition 246 255--*--infection",
            "Condition 256 268--*--inflammation",
            "Scope 246 268--*--infection/inflammation",
            "Measurement 270 281--*--Temperature",
            "Measurement 300 303--*--WBC",
            "Value 282 291--*--> 101.5 F",
            "Value 303 312--*--> 15, 000",
            "Informed_consent 315 379--*--Inability to obtain informed consent from patient or next of kin",
            "Drug 381 394--*--Anticoagulant",
            "Drug 400 408--*--warfarin",
            "Drug 412 419--*--heparin",
            "Scope 400 419--*--warfarin or heparin"
        ],
        "Text": "Patients with a history of an untreated malignancy (except local skin cancers). Ischemic stroke (determined using the Questionnaire for Verifying Stroke-Free Status (QVSFS). Patients on renal dialysis or with end-stage hepatic dysfunction. Acute infection/inflammation (Temperature > 101.5 F, and/or WBC> 15, 000). Inability to obtain informed consent from patient or next of kin. Anticoagulant use (warfarin or heparin). "
    },
    "NCT00236340_exc": {
        "Annotations": [
            "Condition 0 18--*--Multiple pregnancy",
            "Value 20 31--*--more than 3",
            "Measurement 32 39--*--fetuses",
            "Condition 62 80--*--placental abruptio",
            "Observation 42 61--*--Maternal history of",
            "Condition 93 97--*--IUGR",
            "Condition 82 87--*--Fetus",
            "Condition 99 108--*--Pregnancy",
            "Condition 126 139--*--pre-eclampsia",
            "Observation 154 175--*--give informed consent",
            "Negation 141 153--*--Unability to",
            "Scope 20 39--*--more than 3 fetuses"
        ],
        "Text": "Multiple pregnancy (more than 3 fetuses) . Maternal history of placental abruptio . Fetus with IUGR . Pregnancy complicated with pre-eclampsia . Unability to give informed consent       .     . "
    },
    "NCT01822262_exc": {
        "Text": "Gallbladder's wall >3mm, atrophied gallbladder,gallstone obstruct the Hartmann's pouch.. Abdominal ultrasound display the contractibility of gallbladder is poor.. The aged patients with bad heart and lung function.. Patients who has acute cholecystitis,pancreatitis,pancreaticobiliary diseases, especially choledocholithiasis.. Pregnant or lactational women.. ",
        "Annotations": [
            "Measurement 0 18--*--Gallbladder's wall",
            "Value 19 23--*-->3mm",
            "Condition 25 46--*--atrophied gallbladder",
            "Condition 47 65--*--gallstone obstruct",
            "Qualifier 70 86--*--Hartmann's pouch",
            "Procedure 89 109--*--Abdominal ultrasound",
            "Measurement 122 152--*--contractibility of gallbladder",
            "Value 156 160--*--poor",
            "Person 167 171--*--aged",
            "Condition 186 195;205 213--*--bad heart function",
            "Condition 186 189;200 213--*--bad lung function",
            "Scope 186 213--*--bad heart and lung function",
            "Condition 233 252--*--acute cholecystitis",
            "Condition 253 265--*--pancreatitis",
            "Condition 266 293--*--pancreaticobiliary diseases",
            "Condition 306 325--*--choledocholithiasis",
            "Condition 328 336--*--Pregnant",
            "Condition 340 351--*--lactational",
            "Person 352 357--*--women"
        ]
    },
    "NCT02953873_inc": {
        "Text": "At least 18 years of age. Signed informed consent. African American race. History of a solitary renal transplant. Stable tacrolimus dose for at least 2 weeks prior to randomization. ",
        "Annotations": [
            "Person 21 24--*--age",
            "Value 0 17--*--At least 18 years",
            "Post-eligibility 26 49--*--Signed informed consent",
            "Person 68 72--*--race",
            "Value 51 67--*--African American",
            "Procedure 96 112--*--renal transplant",
            "Qualifier 87 95--*--solitary",
            "Drug 121 131--*--tacrolimus",
            "Temporal 137 180--*--for at least 2 weeks prior to randomization",
            "Reference_point 167 180--*--randomization",
            "Qualifier 114 120;132 136--*--Stable dose"
        ]
    },
    "NCT01391780_exc": {
        "Annotations": [
            "Condition 0 21--*--neurological diseases",
            "Procedure 32 48--*--pelvic surgeries",
            "Temporal 23 31--*--previous",
            "Condition 50 58--*--diabetes",
            "Condition 60 82--*--cognitive difficulties",
            "Condition 96 113--*--urinary infection",
            "Grammar_Error 92 95--*--and",
            "Condition 104 113;84 91--*--infection vaginal"
        ],
        "Text": "neurological diseases . previous pelvic surgeries . diabetes . cognitive difficulties . vaginal and urinary infection       .     . "
    },
    "NCT01518946_exc": {
        "Annotations": [
            "Condition 20 28--*--pregnant",
            "Condition 32 41--*--lactating",
            "Person 42 48--*--female",
            "Condition 93 112--*--supine hypertension",
            "Value 113 142--*--greater than 180mmHg systolic",
            "Value 147 164--*--110mmHg diastolic",
            "Measurement 165 167--*--BP",
            "Temporal 194 216--*--at the Screening Visit",
            "Reference_point 201 216--*--Screening Visit",
            "Temporal 70 82--*--pre-existing",
            "Temporal 83 92--*--sustained",
            "Scope 168 170;194 216;83 92--*--or at the Screening Visit sustained",
            "Temporal 242 254--*--persistently",
            "Value 255 262--*--greater",
            "Multiplier 266 276;290 314--*--2 separate at least 5 minutes apart",
            "Measurement 277 289--*--measurements",
            "Drug 402 425--*--medications of interest",
            "Temporal 390 401--*--concomitant",
            "Subjective_judgement 775 902--*--The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant",
            "Post-eligibility 907 1068--*--The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).",
            "Undefined_semantics 1073 1383--*--Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.",
            "Subjective_judgement 1073 1383--*--Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.",
            "Condition 1417 1424;1434 1441--*--chronic illness",
            "Condition 1428 1441--*--acute illness",
            "Condition 1443 1453--*--disability",
            "Condition 1458 1473--*--other condition",
            "Undefined_semantics 1388 1702--*--The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.",
            "Procedure 1522 1545--*--electrocardiogram [ECG]",
            "Condition 1508 1518;1546 1554--*--laboratory findings",
            "Condition 1522 1554--*--electrocardiogram [ECG] findings",
            "Undefined_semantics 1707 1853--*--Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.",
            "Condition 1864 1882--*--enrollment failure",
            "Non-query-able 1858 1914--*--Prior enrollment failure or randomization in this study.",
            "Condition 1931 1944--*--alcohol abuse",
            "Condition 1954 1969--*--substance abuse",
            "Temporal 1970 1990--*--within the last year",
            "Scope 1931 1969--*--alcohol abuse or other substance abuse"
        ],
        "Text": "1. The subject is a pregnant or lactating female. . 2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes. . 3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study. . 4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant . 5. The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406). . 6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures. . 7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject. . 8. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients. . 9. Prior enrollment failure or randomization in this study. . 10. History of alcohol abuse or other substance abuse within the last year.       .     . "
    },
    "NCT02916342_inc": {
        "Text": "ASA physical status I-III;. 18-85 years of age, inclusive;. surgery less than 3 hours.. ",
        "Annotations": [
            "Measurement 0 19--*--ASA physical status",
            "Value 20 25--*--I-III",
            "Value 28 39;46 57--*--18-85 years , inclusive",
            "Person 43 46--*--age",
            "Measurement 60 67--*--surgery",
            "Temporal 68 85--*--less than 3 hours"
        ]
    },
    "NCT02019628_inc": {
        "Annotations": [
            "Person 3 8--*--Women",
            "Person 13 16--*--men",
            "Person 17 21--*--ages",
            "Value 22 39--*--18 years and over",
            "Grammar_Error 9 12--*--and",
            "Post-eligibility 118 156--*--Willingness to follow recommendations.",
            "Post-eligibility 45 113--*--Interest in participating in a novel nutritional supplement program."
        ],
        "Text": "1. Women and men ages 18 years and over. . 2. Interest in participating in a novel nutritional supplement program. . 3. Willingness to follow recommendations. . "
    },
    "NCT00679341_exc": {
        "Text": "History of any chemotherapy for MBC. . An interval of < 6 months from the completion of cytotoxic chemotherapy in the neo-adjuvant or adjuvant setting until the time of metastatic diagnosis. . Trastuzumab \u2264 21 days prior to randomization. . Hormone therapy < 7 days prior to randomization. . Current peripheral neuropathy of Grade \u2265 3. . History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned. . Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization. . Brain metastases that are untreated, symptomatic, or require therapy to control symptoms or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to randomization. . History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; mitoxantrone > 120mg/m^2 and idarubicin > 90 mg/m^2. . Current unstable angina. . History of symptomatic congestive heart failure, or ventricular arrhythmia requiring treatment. . History of myocardial infarction within 6 months prior to randomization. . Left ventricular ejection fraction (LVEF) below 50% within approximately 28 days prior to randomization. . History of decreased LVEF or symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment. . Cardiac troponin I \u2265 0.2 ng/mL within 28 days of randomization. . Severe dyspnea at rest because of complications of advanced malignancy or requiring current continuous oxygen therapy. . Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures). . Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment. . Current pregnancy or lactation. . History of receiving any investigational treatment within approximately 28 days prior to randomization. . Current known infection with human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C virus. . History of intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel. . Known hypersensitivity to any of the study drugs, including the excipients, or any drugs formulated in polysorbate 80. . Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.       .     . ",
        "Annotations": [
            "Procedure 15 27--*--chemotherapy",
            "Condition 32 35--*--MBC",
            "Observation 0 7--*--History",
            "Value 53 63--*--< 6 months",
            "Procedure 87 109--*--cytotoxic chemotherapy",
            "Qualifier 117 129;142 149--*--neo-adjuvant setting",
            "Qualifier 133 149--*--adjuvant setting",
            "Condition 168 188--*--metastatic diagnosis",
            "Drug 191 202--*--Trastuzumab",
            "Temporal 203 235--*--\u2264 21 days prior to randomization",
            "Reference_point 222 235--*--randomization",
            "Procedure 238 253--*--Hormone therapy",
            "Temporal 254 285--*--< 7 days prior to randomization",
            "Reference_point 272 285--*--randomization",
            "Condition 296 317--*--peripheral neuropathy",
            "Qualifier 321 330--*--Grade \u2265 3",
            "Measurement 321 326--*--Grade",
            "Value 327 330--*--\u2265 3",
            "Temporal 288 295--*--Current",
            "Temporal 361 384--*--within the last 5 years",
            "Condition 419 450--*--carcinoma in situ of the cervix",
            "Qualifier 397 418--*--appropriately treated",
            "Procedure 411 418--*--treated",
            "Condition 452 479--*--non-melanoma skin carcinoma",
            "Condition 489 503--*--uterine cancer",
            "Measurement 481 486--*--Stage",
            "Value 487 488--*--I",
            "Condition 350 360--*--malignancy",
            "Qualifier 344 349--*--other",
            "Negation 386 396--*--except for",
            "Non-representable 505 574--*--or other cancers with a similar outcome as those previously mentioned",
            "Scope 397 503--*--appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer",
            "Procedure 586 598--*--radiotherapy",
            "Temporal 577 585--*--Previous",
            "Condition 665 678--*--breast cancer",
            "Qualifier 654 664--*--metastatic",
            "Qualifier 634 650--*--locally advanced",
            "Qualifier 620 632--*--unresectable",
            "Scope 620 664--*--unresectable, locally advanced or metastatic",
            "Value 697 710--*--more than 25%",
            "Measurement 714 733;743 753--*--marrow-bearing bone irradiated",
            "Non-representable 577 865--*--Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization.",
            "Condition 867 883--*--Brain metastases",
            "Qualifier 893 902--*--untreated",
            "Qualifier 904 915--*--symptomatic",
            "Qualifier 920 935--*--require therapy",
            "Procedure 963 972--*--radiation",
            "Procedure 974 981--*--surgery",
            "Procedure 986 1019--*--other therapy to control symptoms",
            "Condition 1025 1041--*--brain metastases",
            "Temporal 1042 1080--*--within 2 months prior to randomization",
            "Reference_point 1067 1080--*--randomization",
            "Scope 963 1019--*--radiation, surgery, or other therapy to control symptoms",
            "Scope 893 935--*--untreated, symptomatic, or require therapy",
            "Drug 1140 1154--*--anthracyclines",
            "Drug 1156 1167--*--Doxorubicin",
            "Drug 1171 1192--*--liposomal doxorubicin",
            "Multiplier 1193 1205--*--> 500 mg/m^2",
            "Drug 1207 1217--*--epirubicin",
            "Multiplier 1218 1230--*--> 900 mg/m^2",
            "Drug 1232 1244--*--mitoxantrone",
            "Multiplier 1245 1256--*--> 120mg/m^2",
            "Drug 1261 1271--*--idarubicin",
            "Multiplier 1272 1283--*--> 90 mg/m^2",
            "Scope 1156 1192--*--Doxorubicin or liposomal doxorubicin",
            "Scope 1156 1283--*--Doxorubicin or liposomal doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; mitoxantrone > 120mg/m^2 and idarubicin > 90 mg/m^2",
            "Scope 1094 1154--*--exposure to the following cumulative doses of anthracyclines",
            "Condition 1294 1309--*--unstable angina",
            "Temporal 1286 1293--*--Current",
            "Condition 1335 1359--*--congestive heart failure",
            "Qualifier 1323 1334--*--symptomatic",
            "Condition 1364 1386--*--ventricular arrhythmia",
            "Qualifier 1387 1406--*--requiring treatment",
            "Procedure 1397 1406--*--treatment",
            "Condition 1420 1441--*--myocardial infarction",
            "Temporal 1442 1480--*--within 6 months prior to randomization",
            "Reference_point 1467 1480--*--randomization",
            "Measurement 1483 1524--*--Left ventricular ejection fraction (LVEF)",
            "Value 1525 1534--*--below 50%",
            "Temporal 1535 1586--*--within approximately 28 days prior to randomization",
            "Reference_point 1573 1586--*--randomization",
            "Condition 1630 1660--*--congestive heart failure (CHF)",
            "Qualifier 1618 1629--*--symptomatic",
            "Measurement 1610 1614--*--LVEF",
            "Value 1600 1609--*--decreased",
            "Drug 1684 1695--*--trastuzumab",
            "Qualifier 1675 1683--*--adjuvant",
            "Temporal 1666 1674--*--previous",
            "Scope 1618 1705--*--symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment",
            "Observation 1589 1596--*--History",
            "Measurement 1708 1726--*--Cardiac troponin I",
            "Value 1727 1738--*--\u2265 0.2 ng/mL",
            "Temporal 1739 1770--*--within 28 days of randomization",
            "Reference_point 1757 1770--*--randomization",
            "Condition 1780 1787--*--dyspnea",
            "Qualifier 1773 1779--*--Severe",
            "Condition 1824 1843--*--advanced malignancy",
            "Procedure 1865 1890--*--continuous oxygen therapy",
            "Temporal 1857 1864--*--current",
            "Condition 1807 1820--*--complications",
            "Qualifier 1847 1890--*--requiring current continuous oxygen therapy",
            "Scope 1807 1890--*--complications of advanced malignancy or requiring current continuous oxygen therapy",
            "Condition 2285 2294--*--lactation",
            "Condition 2272 2281--*--pregnancy",
            "Temporal 2264 2271--*--Current",
            "Scope 2272 2294--*--pregnancy or lactation",
            "Condition 2431 2465--*--human immunodeficiency virus (HIV)",
            "Temporal 2402 2409--*--Current",
            "Condition 2474 2485;2505 2510--*--hepatitis B virus",
            "Condition 2493 2510--*--hepatitis C virus",
            "Condition 2524 2535--*--intolerance",
            "Condition 2557 2574--*--infusion reaction",
            "Measurement 2547 2552--*--Grade",
            "Value 2553 2556--*--3-4",
            "Condition 2579 2595--*--hypersensitivity",
            "Drug 2599 2610--*--trastuzumab",
            "Drug 2612 2627--*--murine proteins",
            "Drug 2632 2641--*--docetaxel",
            "Scope 2599 2641--*--trastuzumab, murine proteins, or docetaxel",
            "Qualifier 1901 1907--*--severe",
            "Qualifier 1909 1921--*--uncontrolled",
            "Condition 1922 1938--*--systemic disease",
            "Qualifier 1944 1966--*--clinically significant",
            "Condition 1983 1992;2007 2014--*--pulmonary disease",
            "Condition 1997 2014--*--metabolic disease",
            "Condition 1967 1981;2007 2014--*--cardiovascular disease",
            "Condition 2016 2039--*--wound healing disorders",
            "Condition 2041 2047--*--ulcers",
            "Condition 2052 2066--*--bone fractures",
            "Scope 1967 2014--*--cardiovascular, pulmonary, or metabolic disease",
            "Scope 1944 2066--*--clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures",
            "Procedure 2322 2347--*--investigational treatment",
            "Temporal 2348 2399--*--within approximately 28 days prior to randomization",
            "Reference_point 2386 2399--*--randomization",
            "Condition 2650 2666--*--hypersensitivity",
            "Drug 2681 2692--*--study drugs",
            "Drug 2727 2761--*--drugs formulated in polysorbate 80",
            "Scope 2681 2761--*--study drugs, including the excipients, or any drugs formulated in polysorbate 80",
            "Observation 2809 2866--*--unwilling to comply with the requirements of the protocol",
            "Observation 2799 2805;2819 2866--*--unable to comply with the requirements of the protocol",
            "Qualifier 2070 2075--*--Major",
            "Procedure 2076 2094--*--surgical procedure",
            "Qualifier 2098 2109--*--significant",
            "Condition 2110 2126--*--traumatic injury",
            "Temporal 2127 2178--*--within approximately 28 days prior to randomization",
            "Reference_point 2165 2178--*--randomization",
            "Scope 2070 2126--*--Major surgical procedure or significant traumatic injury",
            "Mood 2182 2206--*--anticipation of the need",
            "Procedure 2211 2224--*--major surgery",
            "Temporal 2225 2261--*--during the course of study treatment",
            "Reference_point 2246 2261--*--study treatment",
            "Procedure 2252 2261--*--treatment",
            "Observation 2297 2307--*--History of",
            "Observation 2513 2523--*--History of",
            "Scope 2547 2574--*--Grade 3-4 infusion reaction",
            "Scope 2524 2641--*--intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel"
        ]
    },
    "NCT03212352_exc": {
        "Annotations": [
            "Post-eligibility 0 72--*--Patient does not meet inclusion criteria, discovered after randomization",
            "Post-eligibility 74 108--*--Inability to give informed consent",
            "Condition 116 133--*--clotting disorder",
            "Drug 144 158--*--anticoagulants",
            "Condition 202 224--*--cardiovascular disease",
            "Observation 166 178;202 224--*--risk factors cardiovascular disease",
            "Non-query-able 226 242--*--Language barrier"
        ],
        "Text": "Patient does not meet inclusion criteria, discovered after randomization. Inability to give informed consent. Known clotting disorder or use of anticoagulants. Known risk factors for, or presence of, a cardiovascular disease. Language barrier. "
    },
    "NCT02842424_exc": {
        "Annotations": [
            "Condition 0 9--*--Rest pain",
            "Condition 13 24--*--tissue loss",
            "Condition 32 35--*--PAD",
            "Measurement 37 51--*--Fontaine stage",
            "Value 52 55--*--III",
            "Value 60 62--*--IV",
            "Scope 52 62--*--III and IV",
            "Scope 0 24--*--Rest pain or tissue loss",
            "Qualifier 66 71--*--acute",
            "Qualifier 72 87--*--lower extremity",
            "Condition 88 102--*--ischemic event",
            "Qualifier 103 138--*--secondary to thromboembolic disease",
            "Qualifier 103 115;142 154--*--secondary to acute trauma",
            "Condition 116 138--*--thromboembolic disease",
            "Condition 142 154--*--acute trauma",
            "Scope 103 154--*--secondary to thromboembolic disease or acute trauma",
            "Measurement 157 173--*--Walking capacity",
            "Value 174 195--*--significantly limited",
            "Condition 221 233--*--claudication",
            "Negation 210 220--*--other than",
            "Condition 244 247;319 328--*--leg pathology",
            "Condition 288 296;319 328--*--systemic pathology",
            "Qualifier 249 254--*--joint",
            "Qualifier 255 270--*--musculoskeletal",
            "Qualifier 272 282--*--neurologic",
            "Scope 249 282--*--joint/musculoskeletal, neurologic",
            "Condition 298 303;310 317--*--heart disease",
            "Condition 305 317--*--lung disease",
            "Scope 298 317--*--heart, lung disease",
            "Scope 244 328--*--leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology",
            "Condition 199 233--*--conditions other than claudication",
            "Qualifier 210 233--*--other than claudication",
            "Drug 353 367--*--ACE inhibitors",
            "Temporal 331 342--*--Current use",
            "Drug 371 403--*--angiotensin II receptor blockers",
            "Scope 353 403--*--ACE inhibitors or angiotensin II receptor blockers",
            "Condition 406 428--*--Chronic kidney disease",
            "Measurement 434 470--*--estimated Glomerular Filtration Rate",
            "Value 471 490--*--< 30 ml/min/1.73 m2",
            "Observation 493 500--*--History",
            "Qualifier 504 513--*--bilateral",
            "Qualifier 514 520--*--severe",
            "Condition 521 542--*--renal artery stenosis",
            "Observation 550 557--*--History",
            "Condition 561 571--*--angioedema",
            "Temporal 583 591--*--previous",
            "Procedure 592 615--*--ACE-inhibitor treatment",
            "Drug 592 605--*--ACE-inhibitor",
            "Qualifier 619 624--*--known",
            "Condition 625 641--*--hypersensitivity",
            "Drug 645 653--*--ramipril",
            "Drug 663 677--*--ACE inhibitors",
            "Scope 645 677--*--ramipril or other ACE inhibitors",
            "Scope 583 677--*--previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors"
        ],
        "Text": "Rest pain or tissue loss due to PAD (Fontaine stage III and IV),. acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma,. Walking capacity significantly limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology,. Current use of either ACE inhibitors or angiotensin II receptor blockers,. Chronic kidney disease with estimated Glomerular Filtration Rate < 30 ml/min/1.73 m2,. History of bilateral severe renal artery stenosis and 7) History of angioedema related to previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors.. "
    },
    "NCT00886158_exc": {
        "Annotations": [
            "Post-eligibility 0 15--*--Lack of consent"
        ],
        "Text": "Lack of consent       .     . "
    },
    "NCT01846507_inc": {
        "Annotations": [
            "Condition 3 15--*--Menstruating",
            "Person 16 23--*--females",
            "Value 24 35--*--10-19 years",
            "Person 39 42--*--age",
            "Condition 47 57--*--Non-smoker",
            "Drug 108 115--*--Lysteda",
            "Non-query-able 62 115--*--Physician and patient have agreed to initiate Lysteda",
            "Condition 133 136--*--HMB",
            "Non-query-able 137 204--*--based on the medical judgment of the principal or site investigator",
            "Subjective_judgement 137 204--*--based on the medical judgment of the principal or site investigator",
            "Condition 230 247--*--menstrual periods",
            "Temporal 258 304--*--within 21-60 days from the start of one period",
            "Reference_point 281 304--*--the start of one period",
            "Measurement 360 374--*--pregnancy test",
            "Value 351 359--*--Negative",
            "Post-eligibility 379 415--*--Informed consent obtained and signed",
            "Non-query-able 379 415--*--Informed consent obtained and signed",
            "Post-eligibility 420 455--*--Informed assent obtained and signed",
            "Non-query-able 420 455--*--Informed assent obtained and signed",
            "Non-query-able 460 493--*--Understanding of study procedures",
            "Post-eligibility 460 493--*--Understanding of study procedures",
            "Non-query-able 499 573--*--Ability to comply with study procedures for the entire length of the study",
            "Post-eligibility 499 573--*--Ability to comply with study procedures for the entire length of the study",
            "Condition 605 622--*--sexually inactive",
            "Condition 605 613;624 633--*--sexually abstinent",
            "Device 653 683--*--barrier method with spermicide",
            "Observation 638 650--*--agree to use"
        ],
        "Text": "1. Menstruating females 10-19 years of age . 2. Non-smoker . 3. Physician and patient have agreed to initiate Lysteda . 4. Diagnosis of HMB based on the medical judgment of the principal or site investigator . 5. Subjects must report menstrual periods occurring within 21-60 days from the start of one period to the start of the next menstrual period . 6. Negative pregnancy test . 7. Informed consent obtained and signed . 8. Informed assent obtained and signed . 9. Understanding of study procedures . 10. Ability to comply with study procedures for the entire length of the study . 11. Subjects should be either sexually inactive (abstinent) or agree to use a barrier method with spermicide in the event of sexual activity throughout the study period . "
    },
    "NCT03495557_inc": {
        "Text": "Age = 18 years. Laparoscopic cholecystectomy. Emergent/elective. =2 risk factors: diabetes mellitus, age =70 years, BMI =30, fascial enlargement. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 18 years",
            "Procedure 29 44--*--cholecystectomy",
            "Qualifier 16 28--*--Laparoscopic",
            "Qualifier 46 54--*--Emergent",
            "Qualifier 55 63--*--elective",
            "Multiplier 65 67--*--=2",
            "Condition 68 80--*--risk factors",
            "Condition 82 99--*--diabetes mellitus",
            "Person 101 104--*--age",
            "Value 105 114--*--=70 years",
            "Measurement 116 119--*--BMI",
            "Value 120 123--*--=30",
            "Condition 125 144--*--fascial enlargement",
            "Scope 82 144--*--diabetes mellitus, age =70 years, BMI =30, fascial enlargement"
        ]
    },
    "NCT00679341_inc": {
        "Text": "Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy. . Human epidermal growth factor receptor 2 (HER2)-positive. . No prior chemotherapy for their metastatic breast cancer (MBC). . Measurable disease. . Age \u2265 18 years. . For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner. Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the study. . ",
        "Annotations": [
            "Qualifier 18 41--*--cytologically confirmed",
            "Qualifier 0 14;32 41--*--Histologically confirmed",
            "Condition 42 70--*--adenocarcinoma of the breast",
            "Condition 96 114--*--metastatic disease",
            "Condition 107 114;76 92--*--disease locally advanced",
            "Condition 122 148--*--candidate for chemotherapy",
            "Procedure 136 148--*--chemotherapy",
            "Scope 0 41--*--Histologically or cytologically confirmed",
            "Scope 42 114--*--adenocarcinoma of the breast with locally advanced or metastatic disease",
            "Measurement 151 198--*--Human epidermal growth factor receptor 2 (HER2)",
            "Value 199 207--*--positive",
            "Procedure 219 231--*--chemotherapy",
            "Temporal 213 218--*--prior",
            "Negation 210 212--*--No",
            "Person 296 299--*--Age",
            "Value 300 310--*--\u2265 18 years",
            "Condition 275 293--*--Measurable disease",
            "Condition 242 272--*--metastatic breast cancer (MBC)",
            "Person 317 322--*--women",
            "Condition 326 348--*--childbearing potential",
            "Person 353 356--*--men",
            "Observation 357 396--*--with partners of childbearing potential",
            "Scope 317 348--*--women of childbearing potential",
            "Scope 353 396--*--men with partners of childbearing potential",
            "Scope 317 396--*--women of childbearing potential and men with partners of childbearing potential",
            "Qualifier 417 433--*--highly effective",
            "Qualifier 435 447--*--non-hormonal",
            "Procedure 456 469--*--contraception",
            "Multiplier 473 474--*--2",
            "Procedure 494 520--*--non-hormonal contraception",
            "Procedure 552 565--*--Contraception",
            "Temporal 575 619--*--continue for the duration of study treatment",
            "Reference_point 604 619--*--study treatment",
            "Temporal 624 684--*--for at least 6 months after the last dose of study treatment",
            "Reference_point 652 684--*--the last dose of study treatment",
            "Person 686 690--*--Male",
            "Observation 706 727--*--partners are pregnant",
            "Device 739 746--*--condoms",
            "Temporal 747 776--*--for the duration of the study",
            "Scope 686 727--*--Male patients whose partners are pregnant"
        ]
    },
    "NCT02916342_exc": {
        "Text": "indication for catheter insertion;. contraindications to brachial plexus block (e.g., allergy to local anaesthetics, malignancy or infection in the area);. existing neurological deficit in the area to be blocked;. pregnancy;. history of neck surgery or radiotherapy;. severe respiratory disease;. chest deformity;. inability to understand the informed consent and demands of the study;. patient refusal.. ",
        "Annotations": [
            "Procedure 15 33--*--catheter insertion",
            "Mood 0 10--*--indication",
            "Condition 36 53--*--contraindications",
            "Procedure 57 78--*--brachial plexus block",
            "Condition 86 93--*--allergy",
            "Drug 97 115--*--local anaesthetics",
            "Condition 117 127--*--malignancy",
            "Condition 131 140--*--infection",
            "Qualifier 141 152--*--in the area",
            "Scope 86 152--*--allergy to local anaesthetics, malignancy or infection in the area",
            "Scope 36 78--*--contraindications to brachial plexus block",
            "Condition 165 185--*--neurological deficit",
            "Temporal 156 164--*--existing",
            "Qualifier 193 211--*--area to be blocked",
            "Condition 214 223--*--pregnancy",
            "Temporal 226 233--*--history",
            "Procedure 237 249--*--neck surgery",
            "Procedure 253 265--*--radiotherapy",
            "Scope 237 265--*--neck surgery or radiotherapy",
            "Qualifier 268 274--*--severe",
            "Condition 275 294--*--respiratory disease",
            "Condition 297 312--*--chest deformity",
            "Informed_consent 315 385--*--inability to understand the informed consent and demands of the study;",
            "Informed_consent 387 402--*--patient refusal"
        ]
    },
    "NCT01518946_inc": {
        "Annotations": [
            "Person 3 7--*--Male",
            "Person 12 18--*--female",
            "Value 36 44;52 60--*--18 years or older",
            "Person 48 51--*--age",
            "Visit 65 75--*--ambulatory",
            "Person 81 88--*--Females",
            "Condition 92 115--*--child-bearing potential",
            "Measurement 144 204--*--serum beta human chorionic gonadotropin (HCG) pregnancy test",
            "Value 135 143--*--negative",
            "Scope 81 115--*--Females of child-bearing potential",
            "Condition 241 282--*--Symptomatic Orthostatic Hypotension (SOH)",
            "Qualifier 234 240--*--severe",
            "Drug 360 373--*--midodrine HCl",
            "Qualifier 394 405--*--stable dose",
            "Temporal 406 427--*--for at least 3 months",
            "Multiplier 460 470--*--at least 1",
            "Condition 610 619--*--dizziness",
            "Condition 621 636--*--lightheadedness",
            "Condition 638 651--*--feeling faint",
            "Condition 656 689--*--feeling like they might black out",
            "Condition 580 608--*--orthostatic hypotension (OH)",
            "Procedure 568 575--*--treated",
            "Negation 564 567--*--not",
            "Multiplier 540 541--*--1",
            "Scope 610 689--*--dizziness, lightheadedness, feeling faint, or feeling like they might black out"
        ],
        "Text": "1. Male and female subjects must be 18 years of age or older and ambulatory. . 2. Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test. . 3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months. . 4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out. . "
    },
    "NCT02019628_exc": {
        "Annotations": [
            "Subjective_judgement 3 152--*--Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.",
            "Post-eligibility 3 152--*--Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.",
            "Post-eligibility 157 188--*--Unable to consent to the study.",
            "Non-query-able 157 188--*--Unable to consent to the study.",
            "Person 193 198--*--Women",
            "Condition 207 215--*--pregnant",
            "Condition 299 319--*--spontaneous abortion",
            "Temporal 289 298--*--recurrent",
            "Condition 423 435--*--heart attack",
            "Temporal 416 422--*--recent",
            "Condition 439 445--*--stroke",
            "Condition 449 471--*--chronic kidney disease",
            "Drug 494 521--*--immunomodulatory medication",
            "Undefined_semantics 494 521--*--immunomodulatory medication",
            "Drug 528 538--*--interferon",
            "Drug 641 664--*--chemotherapeutic agents",
            "Undefined_semantics 641 664--*--chemotherapeutic agents",
            "Condition 676 691--*--allergy to rice",
            "Drug 687 691--*--rice",
            "Condition 676 686;693 702--*--allergy to rice bran",
            "Drug 693 702--*--rice bran",
            "Undefined_semantics 707 728--*--related food products",
            "Condition 740 760--*--allergy to mushrooms",
            "Condition 802 814--*--malignancies",
            "Observation 791 798--*--History",
            "Qualifier 815 842--*--related to the NK cell line",
            "Condition 855 872--*--NK cell leukemias",
            "Condition 877 919--*--T-cell large granular lymphocyte leukemias",
            "Grammar_Error 873 876--*--and",
            "Condition 921 980--*--NK-cell lymphoproliferative disease of granular lymphocytes",
            "Condition 986 1003--*--NK cell lymphomas",
            "Condition 1021 1051--*--nasal-like NK/T-cell lymphomas",
            "Condition 1011 1016;1032 1051--*--nasal NK/T-cell lymphomas",
            "Grammar_Error 1017 1020--*--and",
            "Grammar_Error 982 985--*--and",
            "Scope 855 1051--*--NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas",
            "Scope 802 842--*--malignancies related to the NK cell line",
            "Qualifier 325 330--*--Other",
            "Condition 331 352--*--medical complications",
            "Negation 364 372--*--preclude",
            "Informed_consent 382 408--*--participating in the study",
            "Scope 325 408--*--Other medical complications that might preclude one from participating in the study",
            "Scope 416 471--*--recent heart attack or stroke or chronic kidney disease",
            "Temporal 544 553--*--Currently",
            "Qualifier 561 566--*--other",
            "Drug 567 578--*--medications",
            "Qualifier 598 633--*--impact on immune system functioning",
            "Scope 561 633--*--other medications thought to have an impact on immune system functioning",
            "Condition 740 750;772 785--*--allergy to food products",
            "Temporal 1058 1065--*--Current",
            "Observation 1066 1072--*--smoker"
        ],
        "Text": "1. Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning. . 2. Unable to consent to the study. . 3. Women who are pregnant or are attempting conception, especially in the presence of a history of recurrent spontaneous abortion. . 4. Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease. . 5. Currently taking immunomodulatory medication, i.e. interferon. . 6. Currently taking other medications thought to have an impact on immune system functioning, i.e., chemotherapeutic agents. . 7. Known allergy to rice, rice bran, or related food products. . 8. Known allergy to mushrooms or related food products. . 9. History of malignancies related to the NK cell line, including: NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas. . 10. Current smoker.       .     . "
    },
    "NCT03212352_inc": {
        "Annotations": [
            "Measurement 2 19--*--crown-rump length",
            "Value 20 25--*--= 6mm",
            "Negation 30 32--*--no",
            "Observation 33 49--*--cardiac activity",
            "Measurement 56 73--*--crown-rump length",
            "Value 74 78--*--<6mm",
            "Negation 83 85--*--no",
            "Observation 86 98--*--fetal growth",
            "Temporal 99 122--*--at least one week later",
            "Scope 56 98--*--crown-rump length <6mm and no fetal growth",
            "Temporal 127 160--*--At least one week after diagnosis",
            "Reference_point 151 160--*--diagnosis",
            "Condition 166 177--*--discrepancy",
            "Temporal 181 253--*--at least one week between crown-rump length and calendar gestational age",
            "Reference_point 207 224--*--crown-rump length",
            "Reference_point 229 253--*--calendar gestational age",
            "Scope 99 126;127 160--*--at least one week later OR",
            "Condition 255 278--*--Intra-uterine pregnancy",
            "Person 280 285--*--Women",
            "Person 286 290--*--aged",
            "Value 291 305--*--above 16 years",
            "Condition 307 325--*--Hemodynamic stable",
            "Negation 335 337--*--No",
            "Negation 358 360--*--No",
            "Negation 391 393--*--No",
            "Condition 338 356--*--signs of infection",
            "Condition 361 389--*--signs of incomplete abortion",
            "Drug 416 428--*--mifepristone",
            "Drug 432 443--*--misoprostol",
            "Mood 394 415--*--contraindications for",
            "Scope 416 443--*--mifepristone or misoprostol"
        ],
        "Text": "a crown-rump length = 6mm and no cardiac activity OR. a crown-rump length <6mm and no fetal growth at least one week later OR. At least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age. Intra-uterine pregnancy. Women aged above 16 years. Hemodynamic stable patient. No signs of infection. No signs of incomplete abortion. No contraindications for mifepristone or misoprostol. "
    },
    "NCT02842424_inc": {
        "Annotations": [
            "Observation 2 18--*--positive history",
            "Condition 22 42--*--chronic claudication",
            "Condition 45 75--*--Exercise-limiting claudication",
            "Observation 91 98--*--history",
            "Procedure 103 121--*--direct observation",
            "Procedure 131 153--*--screening walking test",
            "Scope 91 153--*--history and direct observation during a screening walking test",
            "Condition 204 230--*--Arterial occlusive disease",
            "Procedure 235 268--*--ankle Brachial index measurements",
            "Procedure 282 300--*--imaging modalities",
            "Scope 235 300--*--ankle Brachial index measurements and/or other imaging modalities",
            "Qualifier 303 309--*--Stable",
            "Procedure 310 332--*--blood pressure regimen",
            "Qualifier 334 340--*--stable",
            "Procedure 341 354--*--lipid regimen",
            "Qualifier 356 362--*--stable",
            "Procedure 363 379--*--diabetes regimen",
            "Procedure 384 403--*--risk factor control",
            "Multiplier 404 415--*--for 6 weeks",
            "Scope 303 403--*--Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control"
        ],
        "Text": "A positive history of chronic claudication,. Exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon,. Arterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities,. Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.. "
    },
    "NCT03495557_exc": {
        "Text": "Conversion to laparotomy. Emergent re intervention. Immunosuppression. Umbilical hernia. ",
        "Annotations": [
            "Observation 0 13--*--Conversion to",
            "Procedure 14 24--*--laparotomy",
            "Procedure 35 50--*--re intervention",
            "Qualifier 26 34--*--Emergent",
            "Condition 52 69--*--Immunosuppression",
            "Condition 71 87--*--Umbilical hernia"
        ]
    },
    "NCT00886158_inc": {
        "Annotations": [
            "Value 4 26--*--from birth to 21 years",
            "Person 0 3--*--Age",
            "Visit 90 117--*--Seattle Children's Hospital",
            "Procedure 32 54--*--solid organ transplant",
            "Post-eligibility 119 174--*--Signed consent, and when age appropriate, signed assent"
        ],
        "Text": "Age from birth to 21 years . All solid organ transplant recipients receiving their care at Seattle Children's Hospital . Signed consent, and when age appropriate, signed assent . "
    },
    "NCT01846507_exc": {
        "Annotations": [
            "Condition 10 32--*--thromboembolic disease",
            "Condition 45 67--*--thromboembolic disease",
            "Observation 34 41--*--history",
            "Temporal 3 9--*--Active",
            "Condition 79 91--*--retinal vein",
            "Condition 95 111--*--artery occlusion",
            "Scope 79 111--*--retinal vein or artery occlusion",
            "Condition 120 143--*--inherited thrombophilia",
            "Observation 148 162--*--family history",
            "Condition 166 176--*--thrombosis",
            "Observation 177 203--*--in a first degree relative",
            "Condition 240 259--*--psychiatric illness",
            "Condition 229 236;252 259--*--medical illness",
            "Qualifier 222 228--*--severe",
            "Scope 229 259--*--medical or psychiatric illness",
            "Undefined_semantics 222 228--*--severe",
            "Qualifier 266 343--*--in the opinion of the Investigator, would affect subject safety or compliance",
            "Non-query-able 266 343--*--in the opinion of the Investigator, would affect subject safety or compliance",
            "Condition 376 393--*--bleeding disorder",
            "Condition 414 432--*--bleeding disorders",
            "Condition 441 470--*--type 1 von Willebrand disease",
            "Condition 472 502--*--mild platelet function defects",
            "Condition 511 532;544 551--*--platelet storage pool defects",
            "Condition 511 519;536 551--*--platelet release defects",
            "Scope 511 551--*--platelet storage pool or release defects",
            "Condition 587 609--*--Ehlers Danlos syndrome",
            "Grammar_Error 610 626--*--WILL be eligible",
            "Condition 571 579--*--bleeding",
            "Qualifier 369 375--*--severe",
            "Undefined_semantics 369 375--*--severe",
            "Qualifier 409 413--*--mild",
            "Undefined_semantics 409 413--*--mild",
            "Scope 441 551--*--type 1 von Willebrand disease, mild platelet function defects such as platelet storage pool or release defects",
            "Scope 409 432--*--mild bleeding disorders",
            "Condition 660 669--*--Pregnancy",
            "Temporal 670 694--*--within the past 6 months",
            "Condition 702 716--*--breast-feeding",
            "Procedure 728 750--*--hormonal contraception",
            "Drug 752 760--*--estrogen",
            "Drug 765 774--*--progestin",
            "Scope 752 774--*--estrogen and progestin",
            "Temporal 776 806--*--within 3 months of study entry",
            "Reference_point 795 806--*--study entry",
            "Observation 811 827--*--anticipated need",
            "Procedure 840 882--*--estrogen-containing hormonal contraception",
            "Drug 840 848--*--estrogen",
            "Qualifier 840 859--*--estrogen-containing",
            "Temporal 883 906--*--during the study period",
            "Reference_point 890 906--*--the study period",
            "Drug 918 935--*--systemic steroids",
            "Temporal 936 965--*--within 1 month of study entry",
            "Reference_point 954 965--*--study entry",
            "Condition 981 1004--*--subarachnoid hemorrhage",
            "Observation 970 977--*--History",
            "Condition 1020 1031--*--Hepatitis B",
            "Condition 1020 1029;1033 1034--*--Hepatitis C",
            "Condition 1039 1042--*--HIV",
            "Observation 1009 1016--*--History",
            "Scope 1020 1042--*--Hepatitis B, C, or HIV",
            "Measurement 1056 1066--*--creatinine",
            "Temporal 1047 1055--*--Baseline",
            "Value 1067 1111--*-->20% above the upper limit of normal for age",
            "Person 1108 1111--*--age",
            "Condition 1124 1130--*--anemia",
            "Qualifier 1117 1123--*--Severe",
            "Measurement 1132 1142--*--hemoglobin",
            "Value 1143 1150--*--<8 g/dL",
            "Measurement 1157 1180--*--Systolic blood pressure",
            "Value 1181 1184--*--<85",
            "Measurement 1188 1212--*--diastolic blood pressure",
            "Value 1213 1216--*--<55",
            "Measurement 1222 1232--*--Heart rate",
            "Value 1233 1236--*--<50",
            "Temporal 1237 1257--*--at time of screening",
            "Reference_point 1240 1257--*--time of screening",
            "Device 1270 1286--*--intranasal DDAVP",
            "Temporal 1287 1300--*--during menses",
            "Reference_point 1294 1300--*--menses",
            "Grammar_Error 1301 1318--*--will be permitted",
            "Grammar_Error 1263 1726--*--Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for \u22653 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period.",
            "Not_a_criteria 1263 1725--*--Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for \u22653 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period"
        ],
        "Text": "1. Active thromboembolic disease, history of thromboembolic disease (including retinal vein or artery occlusion), known inherited thrombophilia, or family history of thrombosis in a first degree relative . 2. Subject has a severe medical or psychiatric illness that, in the opinion of the Investigator, would affect subject safety or compliance . 3. Clinical evidence of severe bleeding disorder. Patients with mild bleeding disorders such as type 1 von Willebrand disease, mild platelet function defects such as platelet storage pool or release defects, and patients with bleeding due to Ehlers Danlos syndrome WILL be eligible to participate in the study. . 4. Pregnancy within the past 6 months and/or breast-feeding . 5. Use of hormonal contraception (estrogen and progestin) within 3 months of study entry, or anticipated need to initiate estrogen-containing hormonal contraception during the study period . 6. Use of systemic steroids within 1 month of study entry . 7. History of subarachnoid hemorrhage . 8. History of Hepatitis B, C, or HIV . 9. Baseline creatinine >20% above the upper limit of normal for age . 10. Severe anemia (hemoglobin <8 g/dL) . 11. Systolic blood pressure <85 or diastolic blood pressure <55 . 12. Heart rate <50 at time of screening . 13. Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for \u22653 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period.       .     . "
    },
    "NCT02593409_exc": {
        "Text": "HIV infection at screening. participation in previous or concurrent HIV vaccine trials. lactating, pregnant or planning pregnancy. renal function impairment (serum creatinine >1.5 mg/dl), Fanconi syndrome. abnormal liver function tests (AST/ALT > 43 U/L), liver disease, viral hepatitis, hepatitis B virus (HBV) infection. serum phosphorus <2.2mg/dl, osteoporosis. known sensitivity to components of the Truvada\u00ae formulation. any immunosuppressive treatment, such as systemic corticosteroids. assumption of medication that interacts with Truvada\u00ae. high likelihood of poor adherence to PREP and clinic attendance. any condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial. ",
        "Annotations": [
            "Condition 0 13--*--HIV infection",
            "Competing_trial 28 86--*--participation in previous or concurrent HIV vaccine trials",
            "Pregnancy_considerations 89 129--*--actating, pregnant or planning pregnancy",
            "Condition 131 156--*--renal function impairment",
            "Measurement 158 174--*--serum creatinine",
            "Value 175 185--*-->1.5 mg/dl",
            "Condition 188 204--*--Fanconi syndrome",
            "Measurement 215 235--*--liver function tests",
            "Value 206 214--*--abnormal",
            "Measurement 237 240--*--AST",
            "Measurement 241 244--*--ALT",
            "Value 245 253--*--> 43 U/L",
            "Scope 237 244--*--AST/ALT",
            "Condition 256 269--*--liver disease",
            "Condition 271 286--*--viral hepatitis",
            "Condition 288 321--*--hepatitis B virus (HBV) infection",
            "Measurement 323 339--*--serum phosphorus",
            "Value 340 349--*--<2.2mg/dl",
            "Condition 351 363--*--osteoporosis",
            "Condition 371 382--*--sensitivity",
            "Drug 404 411--*--Truvada",
            "Procedure 430 457--*--immunosuppressive treatment",
            "Drug 467 491--*--systemic corticosteroids",
            "Non-query-able 493 545--*--assumption of medication that interacts with Truvada",
            "Post-eligibility 548 610--*--high likelihood of poor adherence to PREP and clinic attendanc",
            "Non-query-able 613 771--*--any condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial"
        ]
    },
    "NCT02209545_exc": {
        "Text": "Patients who have had a prior abdominal myomectomy. Post-menopausal women. Patients with known bleeding/clotting disorders. Patients with a history of gynecologic malignancy. History of allergic reactions attributed to compounds of similar chemical or biologic composition to misoprostol. Any cases converted to abdominal hysterectomy or other additional elective surgical procedures performed at time of abdominal myomectomy will be excluded from data analysis. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. ",
        "Annotations": [
            "Temporal 24 29--*--prior",
            "Procedure 30 50--*--abdominal myomectomy",
            "Observation 52 67--*--Post-menopausal",
            "Person 68 73--*--women",
            "Condition 104 122--*--clotting disorders",
            "Condition 113 122;95 103--*--disorders bleeding",
            "Condition 151 173--*--gynecologic malignancy",
            "Observation 140 147--*--history",
            "Observation 175 182--*--History",
            "Condition 186 204--*--allergic reactions",
            "Drug 219 287--*--compounds of similar chemical or biologic composition to misoprostol",
            "Drug 276 287--*--misoprostol",
            "Procedure 312 334--*--abdominal hysterectomy",
            "Mood 299 311--*--converted to",
            "Qualifier 355 363--*--elective",
            "Procedure 364 383--*--surgical procedures",
            "Temporal 394 425--*--at time of abdominal myomectomy",
            "Reference_point 405 425--*--abdominal myomectomy",
            "Procedure 405 425--*--abdominal myomectomy",
            "Qualifier 344 354--*--additional",
            "Qualifier 338 343--*--other",
            "Qualifier 463 475--*--Uncontrolled",
            "Condition 476 496--*--intercurrent illness",
            "Qualifier 539 545--*--active",
            "Temporal 528 535--*--ongoing",
            "Condition 546 555--*--infection",
            "Scope 528 545--*--ongoing or active",
            "Qualifier 557 568--*--symptomatic",
            "Condition 569 593--*--congestive heart failure",
            "Condition 595 619--*--unstable angina pectoris",
            "Condition 621 639--*--cardiac arrhythmia",
            "Condition 644 663--*--psychiatric illness",
            "Observation 664 733--*--social situations that would limit compliance with study requirements",
            "Scope 528 733--*--ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
            "Scope 463 496--*--Uncontrolled intercurrent illness"
        ]
    },
    "NCT02571179_exc": {
        "Annotations": [
            "Condition 2 9--*--disease",
            "Qualifier 21 35;45 53--*--affect hepatic function",
            "Qualifier 21 27;39 53--*--affect renal function",
            "Condition 55 72--*--contraindications",
            "Drug 76 93--*--opioid analgesics",
            "Condition 95 119--*--fetal growth retardation",
            "Condition 130 144--*--fetal asphyxia",
            "Mood 121 129--*--signs of",
            "Procedure 148 164--*--cardiotocography",
            "Condition 166 197--*--meconium stained amniotic fluid",
            "Condition 201 224--*--placental insufficiency",
            "Scope 21 53--*--affect hepatic or renal function",
            "Drug 264 272--*--fentanyl",
            "Negation 246 249--*--not",
            "Temporal 273 300--*--during the previous 14 days"
        ],
        "Text": "a disease that might affect hepatic or renal function, contraindications to opioid analgesics, fetal growth retardation, signs of fetal asphyxia by cardiotocography, meconium stained amniotic fluid or placental insufficiency. The subjects should not have received fentanyl during the previous 14 days.. "
    },
    "NCT02649114_inc": {
        "Text": "satisfying DSM-V criteria for ED and for half of the patients in addition . have a history of childhood trauma. . ",
        "Annotations": [
            "Measurement 11 25--*--DSM-V criteria",
            "Value 0 10--*--satisfying",
            "Condition 30 32--*--ED",
            "Parsing_Error 33 73--*--and for half of the patients in addition",
            "Condition 93 109--*--childhood trauma",
            "Observation 82 89--*--history"
        ]
    },
    "NCT03138577_inc": {
        "Annotations": [
            "Temporal 0 10--*--Undergoing",
            "Procedure 11 40--*--right upper extremity surgery",
            "Procedure 46 67--*--supraclavicular block",
            "Qualifier 75 93--*--primary anesthetic",
            "Person 95 98--*--Age",
            "Value 99 132--*--greater than or equal to 18 years",
            "Measurement 141 200--*--American Society of Anesthesiologists (ASA) physical status",
            "Value 201 207--*--1 to 3",
            "Observation 209 238--*--Able to give informed consent"
        ],
        "Text": "Undergoing right upper extremity surgery with supraclavicular block as the primary anesthetic. Age greater than or equal to 18 years of age. American Society of Anesthesiologists (ASA) physical status 1 to 3. Able to give informed consent. "
    },
    "NCT03471117_exc": {
        "Text": "Allergy to Glitazones. Myocardial infarction. Heart failure. Angina. History of kidney stones. Liver disease (abnormal liver enzymes). Anemia (hemoglobin <8 g/dl). Cancer with current treatment. Previous organ transplantation. Immunosuppressant therapy. Human immunodeficiency virus infection. Pregnancy or lactating. Current tobacco use. Dilantin and oral contraceptive usage due to potential drug interaction with glitazones. Self-identified history of hypoglycemia. ",
        "Annotations": [
            "Drug 11 21--*--Glitazones",
            "Condition 0 7--*--Allergy",
            "Condition 23 44--*--Myocardial infarction",
            "Condition 46 59--*--Heart failure",
            "Condition 61 67--*--Angina",
            "Condition 80 93--*--kidney stones",
            "Observation 69 76--*--History",
            "Condition 95 108--*--Liver disease",
            "Measurement 119 132--*--liver enzymes",
            "Value 110 118--*--abnormal",
            "Scope 110 132--*--abnormal liver enzymes",
            "Condition 135 141--*--Anemia",
            "Measurement 143 153--*--hemoglobin",
            "Value 154 161--*--<8 g/dl",
            "Scope 143 161--*--hemoglobin <8 g/dl",
            "Condition 164 170--*--Cancer",
            "Procedure 184 193--*--treatment",
            "Temporal 176 183--*--current",
            "Temporal 195 203--*--Previous",
            "Procedure 204 225--*--organ transplantation",
            "Procedure 227 252--*--Immunosuppressant therapy",
            "Condition 254 292--*--Human immunodeficiency virus infection",
            "Condition 294 303--*--Pregnancy",
            "Condition 307 316--*--lactating",
            "Observation 326 337--*--tobacco use",
            "Temporal 318 325--*--Current",
            "Drug 339 347--*--Dilantin",
            "Drug 352 370--*--oral contraceptive",
            "Condition 394 410--*--drug interaction",
            "Drug 416 426--*--glitazones",
            "Mood 384 393--*--potential",
            "Scope 339 370--*--Dilantin and oral contraceptive",
            "Condition 455 467--*--hypoglycemia",
            "Observation 444 451--*--history",
            "Qualifier 428 443--*--Self-identified"
        ]
    },
    "NCT02810704_exc": {
        "Annotations": [
            "Procedure 37 53--*--knee replacement",
            "Procedure 30 33;42 53--*--hip replacement",
            "Scope 30 53--*--hip or knee replacement",
            "Qualifier 20 29--*--bilateral",
            "Procedure 76 81;89 105--*--total knee replacement",
            "Procedure 76 85;94 105--*--total hip replacement",
            "Competing_trial 57 179--*--atients undergoing total hip or knee replacement who have been enrolled in this study for a prior hip or knee replacement;",
            "Competing_trial 181 367--*--Patients who are concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban",
            "Condition 390 406--*--contraindication",
            "Non-representable 370 461--*--Patients who have a contraindication to two or more of the three study prophylaxis regimens",
            "Pregnancy_considerations 464 617--*--Women who are pregnant or breastfeeding, as well as those of reproductive potential unless there is a negative urine pregnancy test on the day of surgery",
            "Drug 673 688--*--anticoagulation",
            "Negation 689 699--*--other than",
            "Drug 705 717--*--antiplatelet",
            "Temporal 641 671--*--longer than the prior 6 months",
            "Condition 757 773;794 804--*--gastrointestinal hemorrhage",
            "Condition 775 783;794 804--*--cerebral hemorrhage",
            "Condition 794 804--*--hemorrhage",
            "Temporal 805 837--*--within 3 months of the operation",
            "Reference_point 828 837--*--operation",
            "Scope 757 804--*--gastrointestinal, cerebral, or other hemorrhage",
            "Condition 885 895--*--hemostasis",
            "Qualifier 875 884--*--defective",
            "Condition 925 933--*--bleeding",
            "Procedure 944 955--*--transfusion",
            "Procedure 960 969--*--treatment",
            "Scope 944 969--*--transfusion and treatment",
            "Procedure 997 1016--*--operative procedure",
            "Qualifier 1031 1034--*--eye",
            "Qualifier 1036 1039--*--ear",
            "Qualifier 1044 1066--*--central nervous system",
            "Temporal 1067 1083--*--within one month",
            "Scope 1031 1066--*--eye, ear, or central nervous system",
            "Condition 1120 1132--*--hypertension",
            "Qualifier 1107 1119--*--uncontrolled",
            "Qualifier 1100 1106--*--severe",
            "Measurement 1138 1149--*--systolic BP",
            "Value 1150 1159--*--> 220mmHg",
            "Measurement 1163 1175--*--diastolic BP",
            "Value 1176 1185--*--> 120mmHg",
            "Scope 1138 1185--*--systolic BP > 220mmHg or diastolic BP > 120mmHg",
            "Measurement 1214 1225--*--body weight",
            "Value 1229 1251--*--less than 41 kilograms",
            "Value 1253 1261--*--90.4 lbs",
            "Person 1324 1333--*--prisoners",
            "Visit 1338 1355--*--institutionalized"
        ],
        "Text": "Patients undergoing bilateral hip or knee replacement;. Patients undergoing total hip or knee replacement who have been enrolled in this study for a prior hip or knee replacement;. Patients who are concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban;. Patients who have a contraindication to two or more of the three study prophylaxis regimens;. Women who are pregnant or breastfeeding, as well as those of reproductive potential unless there is a negative urine pregnancy test on the day of surgery;. Patients on chronic (longer than the prior 6 months) anticoagulation other than with antiplatelet medications;. Patients with documented gastrointestinal, cerebral, or other hemorrhage within 3 months of the operation;. Patients with a known diagnosis of defective hemostasis and past history of clinical bleeding requiring transfusion and treatment;. Patients who have had an operative procedure involving the eye, ear, or central nervous system within one month;. Patients with severe uncontrolled hypertension with systolic BP > 220mmHg or diastolic BP > 120mmHg;. Patients with an absolute body weight of less than 41 kilograms (90.4 lbs) at baseline visit;. Vulnerable patient populations including prisoners and institutionalized individuals.. "
    },
    "NCT03473132_inc": {
        "Text": "LVAD on warfarin requiring temporary interruption of anticoagulation for procedures. ",
        "Annotations": [
            "Condition 0 4--*--LVAD",
            "Drug 8 16--*--warfarin",
            "Non-representable 17 83--*--requiring temporary interruption of anticoagulation for procedures",
            "Qualifier 17 83--*--requiring temporary interruption of anticoagulation for procedures"
        ]
    },
    "NCT03185130_exc": {
        "Text": "Pregnant. Meningeal signs are present. Acute angle closure glaucoma is suspected. Head trauma within the previous two weeks. Lumbar puncture within the previous two weeks. Thunderclap onset of the headache. Known allergy to one of the study drugs. History of intracranial hypertension. Is a prisoner. Patient declined informed consent. Non-English speaking patient or parent/guardian for pediatric patients. Attending provider excludes patient. Severe Dehydration. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Condition 10 25--*--Meningeal signs",
            "Condition 39 67--*--Acute angle closure glaucoma",
            "Mood 71 80--*--suspected",
            "Condition 82 93--*--Head trauma",
            "Temporal 94 123--*--within the previous two weeks",
            "Procedure 125 140--*--Lumbar puncture",
            "Temporal 141 170--*--within the previous two weeks",
            "Condition 172 189--*--Thunderclap onset",
            "Condition 197 205--*--headache",
            "Condition 213 220--*--allergy",
            "Drug 235 246--*--study drugs",
            "Observation 248 255--*--History",
            "Condition 259 284--*--intracranial hypertension",
            "Person 291 299--*--prisoner",
            "Qualifier 445 451--*--Severe",
            "Condition 452 463--*--Dehydration",
            "Non-query-able 336 406--*--Non-English speaking patient or parent/guardian for pediatric patients",
            "Negation 309 317--*--declined",
            "Competing_trial 318 334--*--informed consent",
            "Non-representable 408 443--*--Attending provider excludes patient"
        ]
    },
    "NCT02593409_inc": {
        "Text": "age =18 at screening. not intending to move away from the clinic's catchment area for the next 2 years. HIV-1 antibody negative. reports commercial sex work. contact information is provided. written informed consent. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 7--*--=18",
            "Non-query-able 22 102--*--not intending to move away from the clinic's catchment area for the next 2 years",
            "Measurement 104 118--*--HIV-1 antibody",
            "Value 119 127--*--negative",
            "Observation 137 156--*--commercial sex work",
            "Post-eligibility 158 189--*--contact information is provided",
            "Informed_consent 191 215--*--written informed consent"
        ]
    },
    "NCT02649114_exc": {
        "Text": "current suicidal risk . current psychosis . ongoing trauma (e.g. current involvement in an abusive relationship).       .     . ",
        "Annotations": [
            "Condition 8 21--*--suicidal risk",
            "Temporal 0 7--*--current",
            "Condition 31 40--*--psychosis",
            "Temporal 23 30--*--current",
            "Condition 50 56--*--trauma",
            "Temporal 42 49--*--ongoing",
            "Condition 71 109--*--involvement in an abusive relationship",
            "Temporal 63 70--*--current"
        ]
    },
    "NCT03471117_inc": {
        "Text": "CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.. Men and women 35 to 70 years of age. ",
        "Annotations": [
            "Condition 0 3--*--CKD",
            "Value 27 34--*--Stage 3",
            "Value 27 32;39 40--*--Stage 4",
            "Scope 27 40--*--Stage 3 and 4",
            "Measurement 44 85--*--National Kidney Foundation Classification",
            "Measurement 91 133--*--estimated glomerular filtration rate (GFR)",
            "Value 134 166--*--between 15 and 59 mL/min/1.73 m2",
            "Qualifier 184 236--*--Modification of Diet in Renal Disease (MDRD) formula",
            "Person 288 291--*--Men",
            "Person 296 301--*--women",
            "Value 302 316--*--35 to 70 years",
            "Person 320 323--*--age"
        ]
    },
    "NCT03138577_exc": {
        "Annotations": [
            "Observation 0 15--*--Patient refusal",
            "Procedure 20 41--*--supraclavicular block",
            "Observation 43 77--*--Inability to give informed consent",
            "Condition 79 86--*--Allergy",
            "Drug 90 107--*--local anesthetics",
            "Condition 109 138--*--Hemidiaphragmatic dysfunction",
            "Condition 159 162--*--PNP",
            "Qualifier 153 158--*--known",
            "Qualifier 140 149--*--suspected",
            "Scope 140 158--*--suspected or known",
            "Condition 164 185--*--Neuromuscular disease",
            "Condition 202 231--*--restrictive pulmonary disease",
            "Condition 187 198;214 231--*--Obstructive pulmonary disease",
            "Qualifier 244 252--*--anatomic",
            "Qualifier 233 240--*--Medical",
            "Condition 253 269--*--contraindication",
            "Procedure 273 297--*--supraclavicular blockade",
            "Scope 233 252--*--Medical or anatomic",
            "Non-representable 298 320--*--as judged by clinician",
            "Condition 322 331--*--Pregnancy"
        ],
        "Text": "Patient refusal for supraclavicular block. Inability to give informed consent. Allergy to local anesthetics. Hemidiaphragmatic dysfunction, suspected or known PNP. Neuromuscular disease. Obstructive or restrictive pulmonary disease. Medical or anatomic contraindication to supraclavicular blockade as judged by clinician. Pregnancy. "
    },
    "NCT02571179_inc": {
        "Annotations": [
            "Condition 0 7--*--healthy",
            "Person 8 19--*--parturients",
            "Qualifier 25 38--*--uncomplicated",
            "Qualifier 40 56--*--single gestation",
            "Condition 57 68--*--pregnancies",
            "Qualifier 70 79--*--full term",
            "Condition 107 116--*--pregnancy",
            "Value 81 86--*--38-42",
            "Measurement 87 105--*--weeks of gestation",
            "Scope 81 105--*--38-42 weeks of gestation",
            "Informed_consent 118 139--*--agreed to participate"
        ],
        "Text": "healthy parturients with uncomplicated, single gestation pregnancies, full term (38-42 weeks of gestation) pregnancy, agreed to participate. "
    },
    "NCT02209545_inc": {
        "Text": "Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months. Age = 18 years and = 50 years. Pre-operative hemoglobin >8 g/dl. Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.. Ability to understand and the willingness to sign a written informed consent.. Admissible medical/surgical history. Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills. Intraoperative use of vasopressin and uterine tourniquet is permissible. Can have had prior Cesarean delivery. ",
        "Annotations": [
            "Procedure 24 44--*--abdominal myomectomy",
            "Condition 61 77--*--uterine fibroids",
            "Procedure 81 95--*--pelvic imaging",
            "Procedure 97 114--*--pelvic ultrasound",
            "Procedure 118 121;97 103--*--MRI pelvic",
            "Scope 97 121--*--pelvic ultrasound or MRI",
            "Scope 81 122--*--pelvic imaging (pelvic ultrasound or MRI)",
            "Temporal 123 147--*--within in last 12 months",
            "Person 149 152--*--Age",
            "Value 153 178--*--= 18 years and = 50 years",
            "Temporal 180 193--*--Pre-operative",
            "Reference_point 184 193--*--operative",
            "Procedure 184 193--*--operative",
            "Measurement 194 204--*--hemoglobin",
            "Value 205 212--*-->8 g/dl",
            "Procedure 230 251--*--buccal administration",
            "Drug 255 266--*--misoprostol",
            "Qualifier 230 251--*--buccal administration",
            "Drug 272 279--*--placebo",
            "Temporal 280 311--*--at least one hour pre-procedure",
            "Mood 214 229--*--Willing to have",
            "Scope 255 279--*--misoprostol or a placebo",
            "Observation 314 335;364 390--*--Ability to understand a written informed consent",
            "Observation 344 390--*--willingness to sign a written informed consent",
            "Observation 412 428--*--surgical history",
            "Observation 404 411;421 428--*--medical history",
            "Qualifier 393 403--*--Admissible",
            "Drug 461 472--*--Depo-Lupron",
            "Drug 474 486--*--Depo-Provera",
            "Drug 491 515--*--Oral Contraceptive pills",
            "Procedure 448 455--*--treated",
            "Temporal 437 447--*--previously",
            "Scope 461 515--*--Depo-Lupron, Depo-Provera, or Oral Contraceptive pills",
            "Non-representable 517 588--*--Intraoperative use of vasopressin and uterine tourniquet is permissible",
            "Non-representable 590 626--*--Can have had prior Cesarean delivery"
        ]
    },
    "NCT02810704_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Person 30 33--*--age",
            "Value 18 26;34 42--*--21 years or older",
            "Procedure 142 163--*--total hip replacement",
            "Qualifier 56 64--*--elective",
            "Qualifier 65 72--*--primary",
            "Qualifier 100 108--*--revision",
            "Qualifier 113 141--*--second stage re-implantation",
            "Qualifier 74 98--*--resurfacing arthroplasty",
            "Scope 65 141--*--primary, resurfacing arthroplasty, revision, or second stage re-implantation",
            "Procedure 264 280--*--knee replacement",
            "Qualifier 246 263--*--uni compartmental",
            "Qualifier 208 242--*--second stage re-implantation total",
            "Qualifier 195 203--*--revision",
            "Qualifier 186 193--*--primary",
            "Qualifier 177 185--*--elective",
            "Scope 186 263--*--primary, revision, or second stage re-implantation total or uni compartmental",
            "Post-eligibility 283 390--*--Patient has necessary mental capacity to participate and is able to comply with study protocol requirements",
            "Informed_consent 393 445--*--Patient is willing and able to give informed consent",
            "Post-eligibility 452 503--*--Patient is willing to be randomized and participate"
        ],
        "Text": "Males and females 21 years of age or older;. Undergoing elective primary, resurfacing arthroplasty, revision, or second stage re-implantation total hip replacement;. Undergoing elective primary, revision, or second stage re-implantation total or uni compartmental knee replacement;. Patient has necessary mental capacity to participate and is able to comply with study protocol requirements;. Patient is willing and able to give informed consent; and. Patient is willing to be randomized and participate.. "
    },
    "NCT03185130_inc": {
        "Text": "Age 10 to 65 years. Temperature less than 100.4 F. Normal neurologic exam and normal mental status. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 18--*--10 to 65 years",
            "Measurement 20 31--*--Temperature",
            "Value 32 49--*--less than 100.4 F",
            "Procedure 58 73--*--neurologic exam",
            "Value 51 57--*--Normal",
            "Value 78 84--*--normal",
            "Measurement 85 98--*--mental status"
        ]
    },
    "NCT03473132_exc": {
        "Text": "recent thrombotic event. ",
        "Annotations": [
            "Temporal 0 6--*--recent",
            "Condition 7 23--*--thrombotic event"
        ]
    },
    "NCT02872090_inc": {
        "Annotations": [
            "Measurement 14 24--*--FEV1 / FVC",
            "Value 25 29--*--<70%"
        ],
        "Text": "patients with FEV1 / FVC <70%. "
    },
    "NCT02379156_inc": {
        "Annotations": [
            "Condition 12 15--*--SCI",
            "Temporal 16 23--*--=1 year",
            "Measurement 26 38--*--Level of SCI",
            "Value 39 44--*--C3-T1",
            "Measurement 46 49--*--AIS",
            "Value 50 55--*--A & B",
            "Person 58 61--*--Age",
            "Value 62 85--*--between 18 and 65 years"
        ],
        "Text": "Duration of SCI =1 year;. Level of SCI C3-T1, AIS A & B;. Age between 18 and 65 years.. "
    },
    "NCT02498483_exc": {
        "Text": "Newborns of substance abusing mothers.. Newborns with any contraindications to routine circumcision, anatomical or hematologic.. ",
        "Annotations": [
            "Person 0 8--*--Newborns",
            "Person 30 37--*--mothers",
            "Condition 12 29--*--substance abusing",
            "Person 40 48--*--Newborns",
            "Condition 58 75--*--contraindications",
            "Procedure 87 99--*--circumcision"
        ]
    },
    "NCT02478346_inc": {
        "Text": "Adult patients (age = 18). Diagnosed by preoperative imaging modalities to have a brain tumor (including metastatic brain tumors) or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention.. The patient is determined by a board certified neurosurgeon to have a tumor or vascular lesion that would take up fluorescein. Patient or legally authorized representative provides written informed consent to enroll in this study. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 16 19--*--age",
            "Value 20 24--*--= 18",
            "Scope 16 24--*--age = 18",
            "Temporal 40 52--*--preoperative",
            "Procedure 53 71--*--imaging modalities",
            "Condition 82 93--*--brain tumor",
            "Condition 105 128--*--metastatic brain tumors",
            "Condition 133 149--*--vascular lesions",
            "Condition 151 159--*--aneurysm",
            "Condition 161 187--*--arteriovenous malformation",
            "Condition 191 212--*--arteriovenous fistula",
            "Procedure 224 245--*--surgical intervention",
            "Condition 318 323--*--tumor",
            "Condition 327 342--*--vascular lesion",
            "Qualifier 348 373--*--would take up fluorescein",
            "Drug 362 373--*--fluorescein",
            "Scope 318 342--*--tumor or vascular lesion",
            "Informed_consent 375 477--*--Patient or legally authorized representative provides written informed consent to enroll in this study"
        ]
    },
    "NCT02589353_inc": {
        "Annotations": [
            "Condition 14 21--*--healthy",
            "Person 22 28--*--adults",
            "Person 41 45--*--ages",
            "Value 29 36;49 54--*--between 18-60",
            "Observation 63 80--*--fluent in English",
            "Qualifier 0 13--*--self-reported"
        ],
        "Text": "self-reported healthy adults between the ages of 18-60 who are fluent in English.. "
    },
    "NCT03168178_exc": {
        "Text": "Known fetal anomaly. Other indication for intrapartum antibiotics (endocarditis prophylaxis, other known maternal infection). ",
        "Annotations": [
            "Condition 6 19--*--fetal anomaly",
            "Condition 27 37--*--indication",
            "Drug 42 65--*--intrapartum antibiotics",
            "Condition 67 91--*--endocarditis prophylaxis",
            "Condition 105 123--*--maternal infection",
            "Scope 27 65--*--indication for intrapartum antibiotics",
            "Scope 67 123--*--endocarditis prophylaxis, other known maternal infection"
        ]
    },
    "NCT03017053_inc": {
        "Text": "Ability to understand and the willingness to sign a written informed consent document. Age= 18 and= 75 years. Clinical/ Histological/ cytological/ Imaging examination proven Oral/Oropharynx Squamous-cell carcinoma (Tongue, buccal mucosa, mouth floor, hard palate, Molar area), the depth of invasion > 4mm in preoperative assessment. In line with clinical stage I / II stage (T1-2 N0 M0; AJCC 2010) and receiving surgical resection. KPS= 70. Normal bone marrow reserve function and normal liver, kidney function. Expected survival period= 6 months. ",
        "Annotations": [
            "Post-eligibility 0 85--*--Ability to understand and the willingness to sign a written informed consent document",
            "Person 87 90--*--Age",
            "Value 90 108--*--= 18 and= 75 years",
            "Condition 190 213--*--Squamous-cell carcinoma",
            "Qualifier 179 189--*--Oropharynx",
            "Qualifier 174 178--*--Oral",
            "Scope 174 189--*--Oral/Oropharynx",
            "Qualifier 215 221--*--Tongue",
            "Qualifier 223 236--*--buccal mucosa",
            "Qualifier 238 249--*--mouth floor",
            "Qualifier 251 262--*--hard palate",
            "Qualifier 264 274--*--Molar area",
            "Scope 215 274--*--Tongue, buccal mucosa, mouth floor, hard palate, Molar area",
            "Measurement 281 298--*--depth of invasion",
            "Value 299 304--*--> 4mm",
            "Procedure 308 331--*--preoperative assessment",
            "Procedure 110 118;155 166--*--Clinical examination",
            "Procedure 120 132;155 166--*--Histological examination",
            "Procedure 134 145;155 166--*--cytological examination",
            "Procedure 147 166--*--Imaging examination",
            "Scope 110 166--*--Clinical/ Histological/ cytological/ Imaging examination",
            "Procedure 412 430--*--surgical resection",
            "Condition 346 362--*--clinical stage I",
            "Condition 346 360;365 367--*--clinical stage II",
            "Measurement 375 376--*--T",
            "Value 376 379--*--1-2",
            "Measurement 380 381--*--N",
            "Value 381 382--*--0",
            "Measurement 383 384--*--M",
            "Value 384 385--*--0",
            "Scope 375 385--*--T1-2 N0 M0",
            "Scope 346 367--*--clinical stage I / II",
            "Measurement 432 435--*--KPS",
            "Value 435 439--*--= 70",
            "Measurement 448 476--*--bone marrow reserve function",
            "Value 441 447--*--Normal",
            "Measurement 495 510--*--kidney function",
            "Measurement 488 493;502 510--*--liver function",
            "Value 481 487--*--normal",
            "Observation 512 536--*--Expected survival period",
            "Value 536 545--*--= 6 month"
        ]
    },
    "NCT00426751_exc": {
        "Annotations": [
            "Condition 44 68--*--Left Bundle Branch Block",
            "Procedure 70 90--*--Thrombolytic therapy",
            "Temporal 91 127--*--within 24 hours before randomization",
            "Procedure 129 149--*--Oral anticoagulation",
            "Measurement 155 191--*--International Normalized Ratio (INR)",
            "Value 192 195--*--> 2",
            "Measurement 203 212--*--platelets",
            "Value 213 225--*--< 100.000/\u00b5l",
            "Condition 235 256--*--hemorrhagic diathesis",
            "Condition 268 299--*--Transient Ischemic Attack (TIA)",
            "Condition 258 264--*--Stroke",
            "Scope 258 299--*--Stroke or Transient Ischemic Attack (TIA)",
            "Temporal 300 324--*--within the past 6 months",
            "Condition 342 370--*--residual neurological defect",
            "Condition 394 410;425 433--*--gastrointestinal bleeding",
            "Condition 414 433--*--urogenital bleeding",
            "Temporal 387 393--*--active",
            "Scope 394 433--*--gastrointestinal or urogenital bleeding",
            "Temporal 449 463--*--within 6 weeks",
            "Procedure 435 448--*--Major surgery",
            "Condition 476 493--*--allergic reaction",
            "Observation 465 472--*--History",
            "Drug 497 506--*--abciximab",
            "Drug 510 522--*--eptifibatide",
            "Drug 530 557--*--component used in the study",
            "Drug 569 583--*--contrast media",
            "Scope 497 584--*--abciximab or eptifibatide or any component used in the study (including contrast media)",
            "Measurement 606 626--*--creatinine clearance",
            "Value 627 636--*--<30ml/min",
            "Condition 641 662--*--hepatic insufficiency",
            "Measurement 674 700--*--Alanine transaminase (ALT)",
            "Measurement 701 729--*--aspartate transaminase (AST)",
            "Value 730 740--*--elevations",
            "Value 743 769--*--3xUpper limit normal (ULN)",
            "Condition 599 604;649 662--*--renal insufficiency",
            "Scope 606 636--*--creatinine clearance <30ml/min",
            "Scope 674 769--*--Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN)",
            "Condition 860 866;879 886--*--Severe disease",
            "Measurement 892 908--*--life expectation",
            "Value 909 917--*--< 1 year",
            "Qualifier 592 598--*--severe",
            "Temporal 867 878--*--concomitant",
            "Observation 931 956--*--participated in any study",
            "Drug 966 986--*--investigational drug",
            "Device 990 996--*--device",
            "Scope 966 996--*--investigational drug or device",
            "Temporal 1035 1062;997 1011--*--of the investigational drug within 30 days",
            "Temporal 1015 1062--*--within 5 half-lives of the investigational drug",
            "Reference_point 1035 1062--*--of the investigational drug",
            "Scope 997 1062--*--within 30 days or within 5 half-lives of the investigational drug",
            "Observation 1133 1145--*--inaccessible",
            "Temporal 1182 1211--*--during treatment or follow-up",
            "Reference_point 1189 1198--*--treatment",
            "Reference_point 1202 1211--*--follow-up",
            "Non-representable 1213 1309--*--In France, a subject is neither affiliated with nor a beneficiary of a social security category.",
            "Negation 9 12--*--not",
            "Informed_consent 21 42--*--give informed consent",
            "Mood 13 20--*--able to",
            "Reference_point 114 127--*--randomization"
        ],
        "Text": "Subjects not able to give informed consent . Left Bundle Branch Block . Thrombolytic therapy within 24 hours before randomization . Oral anticoagulation with International Normalized Ratio (INR) > 2 . Known platelets < 100.000/\u00b5l or known hemorrhagic diathesis . Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect . Evidence of an active gastrointestinal or urogenital bleeding . Major surgery within 6 weeks . History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media) . Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN); isolated AST-elevation is not considered an exclusion criteria from study participation . Severe concomitant disease with life expectation < 1 year . Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study. . Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up . In France, a subject is neither affiliated with nor a beneficiary of a social security category.       .     . "
    },
    "NCT02379156_exc": {
        "Annotations": [
            "Observation 12 33--*--sympathetic integrity",
            "Qualifier 34 56--*--below the lesion level",
            "Measurement 104 108;64 95--*--test skin axon-reflex vasodilatation",
            "Measurement 97 102--*--SkARV",
            "Condition 117 126--*--allergies",
            "Drug 130 153--*--midodrine hydrochloride",
            "Condition 242 259--*--diabetes mellitus",
            "Condition 212 237--*--cerebral vascular disease",
            "Condition 188 208;230 237--*--peripheral vascular, disease",
            "Condition 180 186;230 237--*--kidney disease",
            "Condition 173 178;230 237--*--heart disease",
            "Condition 262 274--*--Hypertension",
            "Measurement 276 278--*--BP",
            "Value 278 290--*-->140/90 mmHg",
            "Condition 304 319--*--thyroid disease",
            "Qualifier 294 303--*--Untreated",
            "Condition 339 348--*--infection",
            "Condition 328 335--*--illness",
            "Qualifier 322 327--*--Acute",
            "Scope 328 348--*--illness or infection",
            "Person 359 365--*--smoker",
            "Condition 368 377--*--Pregnancy"
        ],
        "Text": "Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;. Known allergies to midodrine hydrochloride;. PMH of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;. Hypertension (BP>140/90 mmHg);. Untreated thyroid disease;. Acute illness or infection;. Current smoker;. Pregnancy.. "
    },
    "NCT02872090_exc": {
        "Annotations": [
            "Drug 0 12--*--beta blocker",
            "Condition 14 46--*--supraventricular rhythm disorder",
            "Temporal 48 64--*--previous history",
            "Condition 68 87--*--respiratory disease",
            "Negation 88 98--*--other than",
            "Condition 99 103--*--COPD",
            "Condition 105 113--*--diabetes",
            "Condition 115 136--*--autonomic dysfunction",
            "Condition 138 150--*--dysautonomia",
            "Condition 152 165--*--renal failure",
            "Procedure 167 191--*--long-term oxygen therapy",
            "Observation 193 200--*--history",
            "Condition 204 223--*--psychiatric illness"
        ],
        "Text": "beta blocker. supraventricular rhythm disorder. previous history of respiratory disease other than COPD. diabetes. autonomic dysfunction. dysautonomia. renal failure. long-term oxygen therapy. history of psychiatric illness. "
    },
    "NCT02498483_inc": {
        "Text": "Apgar score at 5 minutes >7. birthweight greater than 2.4 kg. Age of at least 10 hours. At least one void.. ",
        "Annotations": [
            "Measurement 0 11--*--Apgar score",
            "Value 25 27--*-->7",
            "Temporal 12 24--*--at 5 minutes",
            "Measurement 29 40--*--birthweight",
            "Value 41 60--*--greater than 2.4 kg",
            "Person 62 65--*--Age",
            "Value 69 86--*--at least 10 hours",
            "Multiplier 88 100--*--At least one",
            "Observation 101 105--*--void"
        ]
    },
    "NCT03168178_inc": {
        "Text": "Pregnant women between 34-42 weeks gestation. Singleton fetus. Admitted for labor management & develops a fever of 100.4 F or greater. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--women",
            "Value 15 34--*--between 34-42 weeks",
            "Measurement 35 44--*--gestation",
            "Condition 46 61--*--Singleton fetus",
            "Procedure 76 92--*--labor management",
            "Mood 63 75--*--Admitted for",
            "Measurement 106 111--*--fever",
            "Value 115 133--*--100.4 F or greater"
        ]
    },
    "NCT02589353_exc": {
        "Annotations": [
            "Person 0 6--*--adults",
            "Value 20 29;7 15--*--and above 61 years",
            "Person 16 19--*--old",
            "Observation 31 38--*--smokers",
            "Person 49 54--*--women",
            "Condition 40 48--*--pregnant",
            "Drug 67 79;86 104--*--prescription insulin medication",
            "Drug 67 84;94 104--*--prescription pain medication",
            "Observation 112 119--*--history",
            "Condition 132 142--*--smell loss",
            "Condition 123 128;138 142--*--taste loss",
            "Qualifier 146 151--*--other",
            "Condition 152 166--*--oral disorders",
            "Condition 174 196--*--burning mouth syndrome",
            "Scope 146 166--*--other oral disorders",
            "Scope 123 197--*--taste or smell loss or other oral disorders (e.g., burning mouth syndrome)",
            "Temporal 203 210--*--current",
            "Condition 211 223--*--oral lesions",
            "Condition 225 237--*--canker sores",
            "Device 242 251--*--piercings",
            "Scope 211 251--*--oral lesions, canker sores, or piercings",
            "Observation 259 266--*--history",
            "Condition 270 282--*--food allergy"
        ],
        "Text": "adults 61 years old and above. smokers. pregnant women. taking any prescription pain/ insulin medication. has a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome). has current oral lesions, canker sores, or piercings. has a history of food allergy. "
    },
    "NCT02478346_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT00426751_inc": {
        "Annotations": [
            "Condition 14 28--*--postmenopausal",
            "Person 0 5--*--Women",
            "Temporal 34 43--*--12 months",
            "Condition 52 68--*--menstrual period",
            "Negation 44 51--*--without",
            "Scope 34 68--*--12 months without menstrual period",
            "Condition 74 92--*--surgically sterile",
            "Person 99 104--*--women",
            "Condition 108 131--*--child bearing potential",
            "Scope 99 131--*--women of child bearing potential",
            "Negation 136 139--*--not",
            "Condition 199 213--*--pregnancy test",
            "Qualifier 191 196--*--doubt",
            "Condition 320 347--*--Acute myocardial infarction",
            "Temporal 348 354--*--< 12 h",
            "Condition 371 377--*--Angina",
            "Condition 371 377;392 400--*--Angina symptoms",
            "Temporal 401 409--*--> 20 min",
            "Scope 371 400--*--Angina or equivalent symptoms",
            "Condition 418 430--*--ST elevation",
            "Measurement 465 480--*--precordial lead",
            "Measurement 489 498--*--limb lead",
            "Value 484 488--*--1 mm",
            "Value 460 464--*--2 mm",
            "Scope 460 498--*--2 mm precordial lead, = 1 mm limb lead",
            "Measurement 436 456--*--contiguous ECG leads",
            "Value 434 435--*--2",
            "Scope 434 456--*--2 contiguous ECG leads",
            "Observation 557 564--*--Planned",
            "Procedure 565 607--*--primary percutaneous coronary intervention",
            "Observation 625 647;655 662--*--given written informed consent"
        ],
        "Text": "Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study. In cases of doubt a pregnancy test should be performed. (NB -post menopausal women currently receiving hormone replacement are permissible) . Acute myocardial infarction < 12 h defined as: . 1. Angina or equivalent symptoms > 20 min and . 2. ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead). This ECG recording serves as baseline ECG, i.e. ECG I. . Planned primary percutaneous coronary intervention . The subject has given written informed, dated consent to participate in the study . "
    },
    "NCT03017053_exc": {
        "Text": "Inability to provide an informed consent. Evidence of oral distant metastasis or other malignancies. The patient has received prior surgery for primary tumor or lymph node ( except for biopsy ). Prior radiotherapy for primary tumor. The patient has previously received anti-tumor biological targeted therapy. The patient has received chemotherapy or immunotherapy for primary tumors. Prior malignancy within the previous 5 years (except for cured skin basal cell carcinoma or cervical carcinoma in situ). With 3-4 grad Allergy to any drug in the treatment. Peripheral neuropathy> 1 grade. Any unstable systematic disease (including active infection, uncontrolled high blood pressure, unstable angina, onset of angina within the last 3 months, congestive heart failure, myocardial infarction within the previous 12 months, severe arrhythmia needing drug treatment, liver, kidney or metabolic disease). HIV positive. Chronic diseases requiring immune agents or hormone therapy. Pregnant or lactating women. Drug/alcohol abuse, psychological or spiritual illness that may interfere compliance to the study. Patients with epilepsy requiring medications (such as steroids or antiepileptic drugs). The patient has participated in other experimental therapy studies within 30 days. Researchers believe that the situation is unsuitable for participation in the group. ",
        "Annotations": [
            "Non-query-able 0 40--*--Inability to provide an informed consent",
            "Qualifier 59 66--*--distant",
            "Qualifier 54 58--*--oral",
            "Condition 67 77--*--metastasis",
            "Qualifier 81 86--*--other",
            "Condition 87 99--*--malignancies",
            "Temporal 126 131--*--prior",
            "Procedure 132 139--*--surgery",
            "Qualifier 144 151--*--primary",
            "Condition 152 157--*--tumor",
            "Condition 161 171--*--lymph node",
            "Scope 152 171--*--tumor or lymph node",
            "Procedure 185 191--*--biopsy",
            "Negation 174 184--*--except for",
            "Scope 174 191--*--except for biopsy",
            "Procedure 201 213--*--radiotherapy",
            "Temporal 195 200--*--Prior",
            "Qualifier 218 225--*--primary",
            "Condition 226 231--*--tumor",
            "Procedure 269 307--*--anti-tumor biological targeted therapy",
            "Temporal 249 259--*--previously",
            "Procedure 334 346--*--chemotherapy",
            "Procedure 350 363--*--immunotherapy",
            "Condition 368 382--*--primary tumors",
            "Scope 334 363--*--chemotherapy or immunotherapy",
            "Condition 390 400--*--malignancy",
            "Temporal 384 389--*--Prior",
            "Temporal 401 428--*--within the previous 5 years",
            "Condition 441 472--*--cured skin basal cell carcinoma",
            "Condition 476 502--*--cervical carcinoma in situ",
            "Negation 430 440--*--except for",
            "Scope 441 502--*--cured skin basal cell carcinoma or cervical carcinoma in situ",
            "Qualifier 510 518--*--3-4 grad",
            "Condition 519 526--*--Allergy",
            "Drug 534 538--*--drug",
            "Qualifier 530 533--*--any",
            "Condition 557 578--*--Peripheral neuropathy",
            "Qualifier 578 587--*--> 1 grade",
            "Condition 602 620--*--systematic disease",
            "Qualifier 593 601--*--unstable",
            "Condition 639 648--*--infection",
            "Condition 663 682--*--high blood pressure",
            "Qualifier 650 662--*--uncontrolled",
            "Condition 684 699--*--unstable angina",
            "Temporal 717 741--*--within the last 3 months",
            "Measurement 701 706--*--onset",
            "Condition 710 716--*--angina",
            "Condition 743 767--*--congestive heart failure",
            "Condition 769 790--*--myocardial infarction",
            "Temporal 791 820--*--within the previous 12 months",
            "Qualifier 822 828--*--severe",
            "Condition 829 839--*--arrhythmia",
            "Drug 848 852--*--drug",
            "Procedure 853 862--*--treatment",
            "Condition 881 898--*--metabolic disease",
            "Condition 871 877;891 898--*--kidney disease",
            "Condition 864 869;891 898--*--liver disease",
            "Scope 639 898--*--infection, uncontrolled high blood pressure, unstable angina, onset of angina within the last 3 months, congestive heart failure, myocardial infarction within the previous 12 months, severe arrhythmia needing drug treatment, liver, kidney or metabolic disease",
            "Scope 593 620--*--unstable systematic disease",
            "Condition 901 913--*--HIV positive",
            "Condition 915 931--*--Chronic diseases",
            "Drug 942 955--*--immune agents",
            "Procedure 959 974--*--hormone therapy",
            "Scope 942 974--*--immune agents or hormone therapy",
            "Condition 976 984--*--Pregnant",
            "Condition 988 997--*--lactating",
            "Person 998 1003--*--women",
            "Intoxication_considerations 1005 1102--*--Drug/alcohol abuse, psychological or spiritual illness that may interfere compliance to the study",
            "Condition 1118 1126--*--epilepsy",
            "Drug 1137 1148--*--medications",
            "Drug 1158 1166--*--steroids",
            "Drug 1170 1189--*--antiepileptic drugs",
            "Scope 1158 1189--*--steroids or antiepileptic drugs",
            "Non-query-able 1192 1273--*--The patient has participated in other experimental therapy studies within 30 days",
            "Non-query-able 1275 1357--*--Researchers believe that the situation is unsuitable for participation in the grou"
        ]
    },
    "NCT02003339_inc": {
        "Annotations": [
            "Condition 46 70--*--Hepatocellular Carcinoma",
            "Negation 31 34--*--non",
            "Qualifier 35 45--*--metastatic",
            "Qualifier 21 29--*--advanced",
            "Qualifier 7 19--*--intermediate",
            "Qualifier 0 5--*--Early",
            "Scope 0 29--*--Early, intermediate, advanced",
            "Procedure 87 104--*--radioembolization",
            "Observation 72 82--*--Indication",
            "Subjective_judgement 72 82--*--Indication",
            "Non-query-able 105 156--*--validated after pluridisciplinary committee meeting",
            "Context_Error 159 238--*--Isolated target on initial imagery (invasive hepatocellular carcinoma excluded)",
            "Measurement 240 290--*--WHO (World Health organization) Performance status",
            "Value 292 301--*--0, 1 or 2",
            "Condition 306 315--*--cirrhosis",
            "Measurement 317 322;325 330--*--Child score",
            "Value 323 324--*--A",
            "Measurement 336 351--*--total bilirubin",
            "Value 352 385--*--less than 30 micromoles per liter",
            "Scope 317 385--*--Child A score with total bilirubin less than 30 micromoles per liter",
            "Measurement 387 407--*--Creatinine clearance",
            "Value 408 434--*--more or equal to 30 mL/min",
            "Post-eligibility 436 483--*--Patient informed and consent signature obtained"
        ],
        "Text": "Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication for radioembolization validated after pluridisciplinary committee meeting. . Isolated target on initial imagery (invasive hepatocellular carcinoma excluded) . WHO (World Health organization) Performance status: 0, 1 or 2 . If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter . Creatinine clearance more or equal to 30 mL/min . Patient informed and consent signature obtained . "
    },
    "NCT02426034_exc": {
        "Text": "Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; II-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class II cardiac dysfunction;. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 3 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result;. Abnormal Coagulation (INR>1.5<U+3001>APTT>1.5 UNL), with tendency of bleed;. Associated with CNS (central nervous system) metastases;. Pregnant or lactating women;. Other conditions regimented at investigators' discretion.. ",
        "Annotations": [
            "Condition 30 51--*--arterial hypertension",
            "Qualifier 14 29--*--poor-controlled",
            "Measurement 53 76--*--systolic blood pressure",
            "Value 76 86--*--> 140 mmHg",
            "Measurement 91 115--*--diastolic blood pressure",
            "Value 116 126--*--> 90 mm Hg",
            "Scope 53 126--*--systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg",
            "Condition 165 187--*--Coronary heart disease",
            "Qualifier 188 208--*--greater than ClassII",
            "Condition 219 229--*--arrhythmia",
            "Qualifier 210 218--*--II-level",
            "Qualifier 0 8--*--Subjects",
            "Condition 241 265--*--QT interval prolongation",
            "Condition 328 347--*--cardiac dysfunction",
            "Qualifier 319 327--*--Class II",
            "Scope 210 347--*--II-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class II cardiac dysfunction",
            "Condition 412 432--*--inability to swallow",
            "Condition 434 450--*--chronic diarrhea",
            "Condition 455 477--*--intestinal obstruction",
            "Observation 500 530--*--gastrointestinal bleeding risk",
            "Qualifier 495 499--*--high",
            "Condition 581 594--*--ulcer lesions",
            "Qualifier 574 580--*--active",
            "Measurement 609 632--*--fecal occult blood test",
            "Value 600 608--*--positive",
            "Value 634 636--*--++",
            "Condition 650 661--*--black stool",
            "Condition 666 680--*--vomiting blood",
            "Temporal 688 701--*--past 3 months",
            "Scope 650 680--*--black stool, or vomiting blood",
            "Condition 713 727--*--primary lesion",
            "Qualifier 731 738--*--stomach",
            "Measurement 753 776--*--fecal occult blood test",
            "Value 744 752--*--positive",
            "Value 778 779--*--+",
            "Condition 782 809--*--ulcerated gastric carcinoma",
            "Qualifier 823 839--*--alimentary tract",
            "Qualifier 815 822--*--massive",
            "Observation 840 853--*--bleeding risk",
            "Scope 568 901--*--local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 3 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result",
            "Condition 904 924--*--Abnormal Coagulation",
            "Measurement 926 929--*--INR",
            "Value 929 933--*-->1.5",
            "Measurement 941 945--*--APTT",
            "Value 945 953--*-->1.5 UNL",
            "Condition 961 978--*--tendency of bleed",
            "Scope 926 953--*--INR>1.5<U+3001>APTT>1.5 UNL",
            "Condition 1026 1036;997 1000--*--metastases CNS",
            "Pregnancy_considerations 1039 1066--*--Pregnant or lactating women",
            "Non-query-able 1069 1125--*--Other conditions regimented at investigators' discretion"
        ]
    },
    "NCT02845427_exc": {
        "Text": "Revision cases. Uncontrolled bleeding tendency (prothrombin conc. Less than 70%). History of deep venous thrombosis. Sever liver impairment (liver failure). Sever renal impairment (S. creatinine more than 3). ",
        "Annotations": [
            "Observation 0 14--*--Revision cases",
            "Qualifier 16 28--*--Uncontrolled",
            "Condition 29 46--*--bleeding tendency",
            "Measurement 48 59--*--prothrombin",
            "Value 66 79--*--Less than 70%",
            "Condition 93 115--*--deep venous thrombosis",
            "Observation 82 89--*--History",
            "Qualifier 117 122--*--Sever",
            "Condition 123 139--*--liver impairment",
            "Condition 141 154--*--liver failure",
            "Qualifier 157 162--*--Sever",
            "Condition 163 179--*--renal impairment",
            "Measurement 184 194--*--creatinine",
            "Value 195 206--*--more than 3",
            "Scope 184 206--*--creatinine more than 3",
            "Scope 157 179--*--Sever renal impairment"
        ]
    },
    "NCT03187379_inc": {
        "Text": "bariatric surgery patients. laparoscopic roux-en-y gastric bypass. use of EEA stapler anastomosis. ",
        "Annotations": [
            "Procedure 0 17--*--bariatric surgery",
            "Procedure 41 65--*--roux-en-y gastric bypass",
            "Qualifier 28 40--*--laparoscopic",
            "Device 74 97--*--EEA stapler anastomosis"
        ]
    },
    "NCT01997580_exc": {
        "Text": "DSM-IV-TR substance-related disorders (except nicotine). significant medical or neurological conditions. mental retardation or organic brain damage. ",
        "Annotations": [
            "Qualifier 0 9--*--DSM-IV-TR",
            "Condition 10 37--*--substance-related disorders",
            "Drug 46 54--*--nicotine",
            "Negation 39 45--*--except",
            "Post-eligibility 57 103--*--significant medical or neurological conditions",
            "Condition 105 123--*--mental retardation",
            "Condition 127 147--*--organic brain damage"
        ]
    },
    "NCT03320057_inc": {
        "Text": "Women seeking medication abortion through 70 days gestation. Eligible for Mifeprex(r) at a study clinical site. English or Spanish speaking. Willing and able to participate in the study, including willing to go to the study pharmacy to obtain mifepristone. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Procedure 14 33--*--medication abortion",
            "Temporal 34 59--*--through 70 days gestation",
            "Drug 74 85--*--Mifeprex(r)",
            "Mood 61 73--*--Eligible for",
            "Visit 91 110--*--study clinical site",
            "Observation 112 119;131 139--*--English speaking",
            "Observation 123 139--*--Spanish speaking",
            "Observation 141 185--*--Willing and able to participate in the study",
            "Observation 197 232--*--willing to go to the study pharmacy",
            "Drug 243 255--*--mifepristone",
            "Mood 233 242--*--to obtain"
        ]
    },
    "NCT02426034_inc": {
        "Text": "Age: 18 to75 years old;. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1);. Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;. ECOG PS of 0-2;. HB = 90g / L. ANC = 1.5 \u00d7 109 / L. PLT = 80 \u00d7 109 / L. Bilirubin <1.25 times the upper limit of normal (ULN). ALT and AST <2.5 \u00d7 ULN; liver metastases, if any, the ALT and AST<5 \u00d7 ULN. Serum Cr = 1 \u00d7 ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula). An expected survival of = 3 months;. Patient received apatinib treatment regimen at investigators' discretion;. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 5 22--*--18 to75 years old",
            "Condition 55 78--*--advanced gastric cancer",
            "Condition 90 104--*--adenocarcinoma",
            "Qualifier 112 137--*--gastroesophageal junction",
            "Condition 155 165--*--metastases",
            "Negation 166 173--*--outside",
            "Qualifier 178 185--*--stomach",
            "Multiplier 347 359--*--at least two",
            "Procedure 366 378--*--chemotherapy",
            "Qualifier 264 271--*--Failure",
            "Measurement 390 397--*--ECOG PS",
            "Value 401 404--*--0-2",
            "Measurement 407 409--*--HB",
            "Value 410 419--*--= 90g / L",
            "Measurement 421 424--*--ANC",
            "Value 425 440--*--= 1.5 \u00d7 109 / L",
            "Measurement 442 445--*--PLT",
            "Value 446 460--*--= 80 \u00d7 109 / L",
            "Measurement 462 471--*--Bilirubin",
            "Value 472 509--*--<1.25 times the upper limit of normal",
            "Measurement 517 520--*--ALT",
            "Measurement 525 528--*--AST",
            "Value 529 539--*--<2.5 \u00d7 ULN",
            "Condition 541 557--*--liver metastases",
            "Measurement 571 574--*--ALT",
            "Measurement 579 582--*--AST",
            "Value 582 590--*--<5 \u00d7 ULN",
            "Scope 571 582--*--ALT and AST",
            "Measurement 592 600--*--Serum Cr",
            "Value 601 610--*--= 1 \u00d7 ULN",
            "Measurement 611 642--*--endogenous creatinine clearance",
            "Value 642 651--*-->50ml/min",
            "Observation 682 699--*--expected survival",
            "Value 703 713--*--= 3 months",
            "Drug 733 741--*--apatinib",
            "Informed_consent 791 882--*--Patient has to voluntarily join the study and sign the Informed Consent Form for the study;",
            "Pregnancy_considerations 884 1357--*--Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug"
        ]
    },
    "NCT02003339_exc": {
        "Annotations": [
            "Condition 9 33--*--hepatocellular carcinoma",
            "Qualifier 0 8--*--Invasive",
            "Condition 46 60--*--isolated tumor",
            "Negation 34 41--*--without",
            "Context_Error 62 105--*--Disease needing 2 injections of Therasphere",
            "Condition 107 117--*--Thrombosis",
            "Qualifier 118 142--*--extending into the porta",
            "Condition 143 153--*--thrombosis",
            "Qualifier 164 168;178 184--*--left branch",
            "Qualifier 172 184--*--right branch",
            "Scope 164 184--*--left or right branch",
            "Grammar_Error 185 195--*--authorized",
            "Negation 185 195--*--authorized",
            "Condition 198 222--*--extra hepatic metastasis",
            "Procedure 246 263--*--chemoembolization",
            "Procedure 265 279--*--radiofrequency",
            "Temporal 280 323--*--less than 3 months before radioembolization",
            "Reference_point 306 323--*--radioembolization",
            "Scope 246 279--*--chemoembolization, radiofrequency",
            "Temporal 366 380;399 416--*--15 days before radioembolization",
            "Temporal 385 416--*--15 days after radioembolization",
            "Negation 325 327--*--No",
            "Procedure 328 342;355 364--*--antiangiogenic treatment",
            "Drug 428 437--*--Sorafenib",
            "Condition 439 457--*--Associated disease",
            "Qualifier 464 510--*--could prevent patient from receiving treatment",
            "Undefined_semantics 439 510--*--Associated disease which could prevent patient from receiving treatment",
            "Procedure 512 515--*--RMI",
            "Condition 512 533--*--RMI contre-indication",
            "Undefined_semantics 512 533--*--RMI contre-indication",
            "Context_Error 640 725--*--Patient already participating in an other therapeutic trial with an experimental drug",
            "Condition 727 735--*--Pregnant",
            "Condition 739 761--*--childbearing potential",
            "Person 762 767--*--women",
            "Observation 771 784--*--breastfeeding",
            "Person 785 790--*--women",
            "Non-query-able 792 997--*--minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons",
            "Person 792 798--*--minors",
            "Post-eligibility 999 1033--*--Unable to sign an informed consent"
        ],
        "Text": "Invasive hepatocellular carcinoma without any isolated tumor . Disease needing 2 injections of Therasphere . Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis . Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization . No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib . Associated disease which could prevent patient from receiving treatment . RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy) . Patient already participating in an other therapeutic trial with an experimental drug . Pregnant or childbearing potential women or breastfeeding women . minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons . Unable to sign an informed consent       .     . "
    },
    "NCT03187379_exc": {
        "Text": "age <18 years. previous history of roux-en-y gastric bypass. patients undergoing other bariatric procedures. pre-operative opioid analgesics. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 13--*--<18 years",
            "Observation 24 31--*--history",
            "Procedure 35 59--*--roux-en-y gastric bypass",
            "Temporal 15 23--*--previous",
            "Procedure 87 107--*--bariatric procedures",
            "Qualifier 81 86--*--other",
            "Temporal 70 80--*--undergoing",
            "Temporal 109 122--*--pre-operative",
            "Drug 123 140--*--opioid analgesics"
        ]
    },
    "NCT02845427_inc": {
        "Text": "Primary total hip arthroplasty (THA). ",
        "Annotations": [
            "Qualifier 0 7--*--Primary",
            "Condition 8 30--*--total hip arthroplasty",
            "Condition 32 35--*--THA"
        ]
    },
    "NCT03320057_exc": {
        "Text": "Not pregnant. Not seeking medication abortion. Under the age of 15. Contraindications for medication abortion. ",
        "Annotations": [
            "Condition 4 12--*--pregnant",
            "Procedure 26 45--*--medication abortion",
            "Person 57 60--*--age",
            "Value 47 52;64 66--*--Under 15",
            "Condition 68 85--*--Contraindications",
            "Procedure 90 109--*--medication abortion"
        ]
    },
    "NCT01997580_inc": {
        "Text": "DSM-IV-TR major depressive disorder. aged between 20 and 80. durg-naive or drug-free. ",
        "Annotations": [
            "Qualifier 0 9--*--DSM-IV-TR",
            "Condition 10 35--*--major depressive disorder",
            "Person 37 41--*--aged",
            "Value 42 59--*--between 20 and 80",
            "Drug 61 65--*--durg",
            "Negation 66 71--*--naive",
            "Drug 75 79--*--drug",
            "Negation 80 84--*--free"
        ]
    },
    "NCT02805504_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Condition 16 23--*--nursing",
            "Condition 34 41--*--Allergy",
            "Drug 45 56--*--bupivacaine",
            "Condition 70 88--*--drug/alcohol abuse",
            "Observation 59 66--*--History",
            "Condition 129 136;98 112--*--disease cardiovascular",
            "Condition 114 121;129 136--*--hepatic disease",
            "Condition 123 136--*--renal disease",
            "Condition 140 163--*--neurological impairment"
        ],
        "Text": "Pregnant and/or nursing mothers.. Allergy to bupivacaine.. History of drug/alcohol abuse.. Severe cardiovascular, hepatic, renal disease or neurological impairment.. "
    },
    "NCT03464552_inc": {
        "Text": "Females 18-65 years old who undergoing colposcopic directed biopsy. ",
        "Annotations": [
            "Person 0 7--*--Females",
            "Value 8 19--*--18-65 years",
            "Person 20 23--*--old",
            "Procedure 39 66--*--colposcopic directed biopsy",
            "Temporal 28 38--*--undergoing"
        ]
    },
    "NCT03223909_inc": {
        "Annotations": [
            "Person 18 21--*--old",
            "Value 0 17--*-->18 to < 90 years",
            "Person 23 33--*--Both sexes",
            "Qualifier 43 51--*--moderate",
            "Qualifier 35 39--*--Mild",
            "Condition 52 73--*--tear film dysfunction",
            "Scope 35 51--*--Mild to moderate",
            "Measurement 93 97--*--TBUT",
            "Value 98 119--*--> 5 sec. and < 10 sec",
            "Measurement 122 130--*--Schirmer",
            "Value 132 150--*--> 4 mm and < 14 mm",
            "Measurement 152 156--*--OSDI",
            "Value 157 168--*--< 30 points",
            "Condition 170 186--*--Corneal staining",
            "Qualifier 187 198--*--< grade III",
            "Qualifier 206 219--*--Oxford scale",
            "Qualifier 206 218--*--Oxford scale",
            "Post-eligibility 220 271--*--Availability to go to each revision when indicated."
        ],
        "Text": ">18 to < 90 years old. Both sexes. Mild to moderate tear film dysfunction clinical diagnose. TBUT > 5 sec. and < 10 sec.. Schirmer: > 4 mm and < 14 mm. OSDI < 30 points. Corneal staining < grade III on the Oxford scale. Availability to go to each revision when indicated.. "
    },
    "NCT02592980_inc": {
        "Text": "Only patients with atrial fibrillation, above 18 years, and with TTR <50% based on the last three values of INR will be included in this study.. ",
        "Annotations": [
            "Condition 19 38--*--atrial fibrillation",
            "Value 40 54--*--above 18 years",
            "Person 49 54--*--years",
            "Measurement 65 68--*--TTR",
            "Value 69 73--*--<50%",
            "Qualifier 74 111--*--based on the last three values of INR"
        ]
    },
    "NCT03315975_exc": {
        "Annotations": [
            "Drug 16 37--*--influenza vaccination",
            "Condition 4 12--*--allergic",
            "Drug 53 74--*--influenza vaccination",
            "Temporal 75 99--*--within the past 6 months",
            "Drug 109 119--*--prednisone",
            "Drug 121 133--*--methotrexate",
            "Drug 144 173--*--immunosuppressing medications",
            "Qualifier 138 143--*--other",
            "Condition 180 193--*--HIV infection",
            "Procedure 228 250--*--bone marrow transplant",
            "Procedure 213 224;240 250--*--solid organ transplant",
            "Qualifier 202 209--*--history",
            "Scope 213 251--*--solid organ or bone marrow transplant",
            "Procedure 260 285--*--combination immunotherapy",
            "Mood 252 259--*--require",
            "Competing_trial 287 409--*--are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study"
        ],
        "Text": "are allergic to influenza vaccination. have received influenza vaccination within the past 6 months. require prednisone, methotrexate, or other immunosuppressing medications. have HIV infection. have a history of solid organ or bone marrow transplant. require combination immunotherapy. are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study. "
    },
    "NCT03467750_inc": {
        "Text": "Diagnosis of sleep disordered breathing or obstructive sleep apnea. Children undergoing elective tonsillectomy or adenotonsillectomy at Children's Healthcare of Atlanta Egleston location. Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent. ",
        "Annotations": [
            "Condition 13 39--*--sleep disordered breathing",
            "Condition 43 66--*--obstructive sleep apnea",
            "Person 68 76--*--Children",
            "Qualifier 88 96--*--elective",
            "Procedure 97 110--*--tonsillectomy",
            "Procedure 114 132--*--adenotonsillectomy",
            "Scope 97 132--*--tonsillectomy or adenotonsillectomy",
            "Visit 136 177--*--Children's Healthcare of Atlanta Egleston",
            "Informed_consent 188 298--*--Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent"
        ]
    },
    "NCT03182114_inc": {
        "Text": "full term. singleton pregnant women. scheduled for elective cesarean delivery. ",
        "Annotations": [
            "Condition 0 9--*--full term",
            "Qualifier 11 20--*--singleton",
            "Condition 21 29--*--pregnant",
            "Person 30 35--*--women",
            "Qualifier 51 59--*--elective",
            "Procedure 60 77--*--cesarean delivery",
            "Mood 37 50--*--scheduled for"
        ]
    },
    "NCT02504203_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT02245256_inc": {
        "Text": "Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Value 16 36--*--18years old or older",
            "Person 18 23--*--years",
            "Scope 16 36--*--18years old or older",
            "Procedure 49 61;80 101--*--living-donor liver transplantation",
            "Procedure 65 101--*--deceased-donor liver transplantation"
        ]
    },
    "NCT02805504_inc": {
        "Annotations": [
            "Procedure 20 36--*--urologic surgery"
        ],
        "Text": "Patients undergoing urologic surgery.. "
    },
    "NCT03223909_exc": {
        "Annotations": [
            "Drug 29 48--*--systemic medication",
            "Drug 14 21;38 48--*--topical medication",
            "Device 52 70--*--mechanical devices",
            "Drug 136 160--*--topical immunomodulators",
            "Device 162 175--*--punctal plugs",
            "Drug 177 192--*--corticosteroids",
            "Drug 194 223--*--preservative artificial tears",
            "Device 225 239--*--contact lenses",
            "Scope 136 239--*--topical immunomodulators, punctal plugs, corticosteroids, preservative artificial tears, contact lenses",
            "Scope 14 70--*--topical and/or systemic medication or mechanical devices",
            "Person 253 260--*--females",
            "Observation 267 285--*--active sexual life",
            "Negation 294 297--*--not",
            "Procedure 304 324--*--contraceptive method",
            "Person 327 333--*--Female",
            "Condition 351 359--*--pregnant",
            "Condition 363 372--*--lactating",
            "Person 374 380--*--Female",
            "Value 397 405--*--positive",
            "Measurement 406 426--*--urine pregnancy test",
            "Condition 428 452--*--Positive drug addictions",
            "Procedure 455 475--*--verbal interrogatory",
            "Competing_trial 478 566--*--Subjects who have participated on any other research clinical trials on the last 40 days",
            "Condition 586 603--*--mentally disabled",
            "Condition 577 582;595 603--*--legal disabled",
            "Informed_consent 568 663--*--Subjects legal or mentally disabled to give an informed consent for participating on this study",
            "Non-query-able 665 748--*--Subjects who can't comply with the appointments or with every protocol requirement.",
            "Condition 750 788--*--Serious tear film dysfunction syndrome",
            "Measurement 789 793--*--TBUT",
            "Line 750 788--*--Serious tear film dysfunction syndrome",
            "Value 794 799--*--< 5 s",
            "Measurement 800 808--*--Schirmer",
            "Value 810 816--*--< 4 mm",
            "Measurement 817 821--*--OSDI",
            "Value 822 832--*--> 30 pints",
            "Measurement 833 849--*--Corneal staining",
            "Value 850 861--*--> grade III",
            "Qualifier 869 881--*--Oxford scale",
            "Line 789 799--*--TBUT < 5 s",
            "Line 800 816--*--Schirmer: < 4 mm",
            "Line 817 832--*--OSDI > 30 pints",
            "Line 833 881--*--Corneal staining > grade III on the Oxford scale",
            "Qualifier 883 897--*--Non perforated",
            "Condition 898 911--*--corneal ulcer",
            "Condition 924 937--*--corneal ulcer",
            "Qualifier 913 923--*--Perforated",
            "Condition 950 963--*--corneal ulcer",
            "Qualifier 939 949--*--Autoimmune",
            "Condition 965 997--*--Ocular surface scarring diseases",
            "Condition 1037 1044;999 1013--*--lesions Ocular surface",
            "Condition 1017 1044;999 1005--*--annexes metaplastic lesions Ocular",
            "Condition 1046 1082--*--Fibro vascular proliferation lesions",
            "Qualifier 1110 1125--*--corneal surface",
            "Qualifier 1090 1102--*--conjunctival",
            "Qualifier 1133 1142--*--pterygium",
            "Scope 1090 1125--*--conjunctival and/or corneal surface",
            "Temporal 1145 1156--*--Concomitant",
            "Condition 1157 1186--*--chronic inflammatory diseases",
            "Qualifier 1194 1210--*--ocular structure",
            "Condition 1232 1252--*--inflammatory disease",
            "Qualifier 1212 1217--*--Acute",
            "Qualifier 1221 1231--*--infectious",
            "Scope 1212 1231--*--Acute or infectious",
            "Condition 1254 1269--*--Corneal disease",
            "Procedure 1294 1303--*--treatment",
            "Mood 1270 1291--*--potentially requiring",
            "Temporal 1304 1333--*--during the following 3 months",
            "Non-representable 1335 1399--*--Use of topical or systemic drug products classified as forbidden",
            "Procedure 1401 1427--*--Ocular surgical procedures",
            "Temporal 1428 1467--*--3 months before the protocol inclusion",
            "Reference_point 1448 1466--*--protocol inclusion",
            "Temporal 1428 1466--*--3 months before the protocol inclusion",
            "Procedure 1468 1478--*--Treatments",
            "Procedure 1482 1492--*--procedures",
            "Procedure 1510 1541--*--tear film dysfunction treatment",
            "Device 1546 1568--*--punctal silicone plugs",
            "Scope 1468 1492--*--Treatments or procedures",
            "Condition 1571 1597--*--Posterior segment diseases",
            "Procedure 1610 1619--*--treatment",
            "Condition 1623 1655--*--threatening the visual prognosis",
            "Mood 1598 1607--*--requiring",
            "Scope 1598 1655--*--requiring a treatment or threatening the visual prognosis",
            "Device 1783 1802--*--hard contact lenses",
            "Procedure 1748 1772--*--penetrating keratoplasty",
            "Temporal 1706 1735--*--during the following 3 months",
            "Procedure 1696 1705--*--treatment",
            "Mood 1686 1695--*--requiring",
            "Condition 1657 1673--*--Retinal diseases",
            "Observation 1737 1744--*--History",
            "Device 1775 1779;1788 1802--*--Soft contact lenses",
            "Temporal 1807 1847--*--during the last month from inclusion day",
            "Reference_point 1834 1847--*--inclusion day",
            "Scope 1775 1802--*--Soft or hard contact lenses"
        ],
        "Text": "Subjects with topical and/or systemic medication or mechanical devices that interfere determinedly on the results of the study (such as topical immunomodulators, punctal plugs, corticosteroids, preservative artificial tears, contact lenses).. Subjects (females) with active sexual life that do not use a contraceptive method.. Female subjects who are pregnant or lactating. Female subjects with a positive urine pregnancy test. Positive drug addictions* (verbal interrogatory). Subjects who have participated on any other research clinical trials on the last 40 days. Subjects legal or mentally disabled to give an informed consent for participating on this study. Subjects who can't comply with the appointments or with every protocol requirement.. Serious tear film dysfunction syndrome TBUT < 5 s Schirmer: < 4 mm OSDI > 30 pints Corneal staining > grade III on the Oxford scale. Non perforated corneal ulcer. Perforated corneal ulcer. Autoimmune corneal ulcer. Ocular surface scarring diseases. Ocular surface or annexes metaplastic lesions. Fibro vascular proliferation lesions on the conjunctival and/or corneal surface (i.e.: pterygium). Concomitant chronic inflammatory diseases on any ocular structure. Acute or infectious inflammatory disease. Corneal disease potentially requiring a treatment during the following 3 months. Use of topical or systemic drug products classified as forbidden. Ocular surgical procedures 3 months before the protocol inclusion. Treatments or procedures indicated on the tear film dysfunction treatment, as punctal silicone plugs.. Posterior segment diseases requiring a treatment or threatening the visual prognosis. Retinal diseases potentially requiring treatment during the following 3 months. History of penetrating keratoplasty.. Soft or hard contact lenses use during the last month from inclusion day. "
    },
    "NCT02592980_exc": {
        "Text": "Patients will not be included if they have reached a stable dose of warfarin, liver dysfunction, alcoholism, use of another anticoagulant, use of chemotherapy, or if they do not meet the inclusion criteria. ",
        "Annotations": [
            "Multiplier 53 64--*--stable dose",
            "Drug 68 76--*--warfarin",
            "Condition 78 95--*--liver dysfunction",
            "Condition 97 107--*--alcoholism",
            "Qualifier 116 123--*--another",
            "Drug 124 137--*--anticoagulant",
            "Procedure 146 158--*--chemotherapy",
            "Post-eligibility 163 205--*--if they do not meet the inclusion criteria"
        ]
    },
    "NCT03464552_exc": {
        "Text": "A known allergy to Celecoxib, aspirin or another NSAID.. Active peptic ulceration or gastrointestinal bleeding.. Inflammatory bowel disease.. Congestive heart failure (NYHA II-IV).. Established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.. History of neurologic deficit.. Known hepatic or renal impairment.. Pregnancy.. Breast-feeding.. Post-hysterectomy.. Bleeding disorders.. Drug abuse.. Cervical and vaginal infection.. ",
        "Annotations": [
            "Condition 8 15--*--allergy",
            "Drug 19 28--*--Celecoxib",
            "Drug 30 37--*--aspirin",
            "Drug 49 54--*--NSAID",
            "Qualifier 41 48--*--another",
            "Scope 19 54--*--Celecoxib, aspirin or another NSAID",
            "Temporal 57 63--*--Active",
            "Condition 64 81--*--peptic ulceration",
            "Condition 85 110--*--gastrointestinal bleeding",
            "Scope 64 110--*--peptic ulceration or gastrointestinal bleeding",
            "Condition 113 139--*--Inflammatory bowel disease",
            "Condition 142 166--*--Congestive heart failure",
            "Measurement 168 172--*--NYHA",
            "Value 173 178--*--II-IV",
            "Scope 168 178--*--NYHA II-IV",
            "Condition 194 216--*--ischemic heart disease",
            "Condition 218 245--*--peripheral arterial disease",
            "Condition 253 276--*--cerebrovascular disease",
            "Condition 290 308--*--neurologic deficit",
            "Observation 279 286--*--History",
            "Condition 328 344--*--renal impairment",
            "Condition 317 324;334 344--*--hepatic impairment",
            "Condition 347 356--*--Pregnancy",
            "Observation 359 373--*--Breast-feeding",
            "Procedure 381 393--*--hysterectomy",
            "Temporal 376 380--*--Post",
            "Condition 396 414--*--Bleeding disorders",
            "Condition 417 427--*--Drug abuse",
            "Condition 430 438;451 460--*--Cervical infection",
            "Condition 443 460--*--vaginal infection"
        ]
    },
    "NCT03315975_inc": {
        "Annotations": [
            "Person 0 6--*--adults",
            "Informed_consent 7 35--*--capable of providing consent",
            "Condition 88 96--*--melanoma",
            "Qualifier 77 87--*--metastatic",
            "Qualifier 57 73--*--locally advanced",
            "Scope 57 87--*--locally advanced or metastatic"
        ],
        "Text": "adults capable of providing consent. have a diagnosis of locally advanced or metastatic melanoma. "
    },
    "NCT03467750_exc": {
        "Text": "Known coagulation defect. Patients on longstanding NSAID therapy. Known renal impairment. Patients may also be excluded at the discretion of the investigator. ",
        "Annotations": [
            "Condition 6 24--*--coagulation defect",
            "Procedure 51 64--*--NSAID therapy",
            "Temporal 38 50--*--longstanding",
            "Condition 72 88--*--renal impairment",
            "Non-query-able 90 157--*--Patients may also be excluded at the discretion of the investigator"
        ]
    },
    "NCT02504203_inc": {
        "Text": "Children born outside the cluster, and returning more than 72 hours after the delivery. Children that the nurse evaluates to die within the next 24 hours.. ",
        "Annotations": [
            "Non-query-able 0 86--*--Children born outside the cluster, and returning more than 72 hours after the delivery",
            "Non-query-able 88 154--*--Children that the nurse evaluates to die within the next 24 hours."
        ]
    },
    "NCT02245256_exc": {
        "Text": "Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine. ",
        "Annotations": [
            "Person 0 9--*--Pediatric",
            "Value 20 34--*--under 18 years",
            "Person 29 34--*--years",
            "Scope 20 34--*--under 18 years",
            "Line 46 169--*--Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine",
            "Line 0 35--*--Pediatric patients (under 18 years)",
            "Condition 36 45--*--Pregnancy",
            "Line 36 45--*--Pregnancy",
            "Observation 63 75--*--unresponsive",
            "Temporal 76 87--*--at baseline",
            "Condition 98 117--*--neurologic deficits",
            "Temporal 118 129--*--at baseline",
            "Condition 142 150--*--allergic",
            "Drug 154 169--*--dexmedetomidine"
        ]
    },
    "NCT03182114_exc": {
        "Text": "Cardiac morbidities. hypertensive disorders of pregnancy. peripartum bleeding. baseline systolic blood pressure (SBP) < 100 mmHg. body mass index > 35. ",
        "Annotations": [
            "Condition 0 19--*--Cardiac morbidities",
            "Condition 21 56--*--hypertensive disorders of pregnancy",
            "Condition 58 77--*--peripartum bleeding",
            "Temporal 79 87--*--baseline",
            "Measurement 88 111--*--systolic blood pressure",
            "Measurement 113 116--*--SBP",
            "Value 118 128--*--< 100 mmHg",
            "Measurement 130 145--*--body mass index",
            "Value 146 150--*--> 35"
        ]
    },
    "NCT02997215_inc": {
        "Text": "American Society of Anesthesiologist (ASA) status I-II adult patients undergoing elective laparoscopic cholecystectomy.. ",
        "Annotations": [
            "Measurement 0 42--*--American Society of Anesthesiologist (ASA)",
            "Value 43 54--*--status I-II",
            "Person 55 60--*--adult",
            "Qualifier 81 89--*--elective",
            "Procedure 90 118--*--laparoscopic cholecystectomy"
        ]
    },
    "NCT02415257_exc": {
        "Annotations": [
            "Condition 0 24--*--impaired decision making",
            "Condition 26 43--*--neurofibromatosis",
            "Mood 45 50--*--signs",
            "Condition 55 74--*--central dysfunction",
            "Condition 76 105--*--remaining vestibular function",
            "Non-representable 107 171--*--Patients are advised not to participate in the gentamicin arm if",
            "Measurement 173 180--*--hearing",
            "Value 184 211--*--better than 30 deciBel (dB)",
            "Qualifier 215 232--*--pure tone average",
            "Qualifier 234 260--*--500, 1000, 2000, 3-4000 Hz",
            "Measurement 266 287--*--speech discrimination",
            "Value 288 303--*--better than 70%",
            "Non-representable 305 416--*--the neurosurgeon aim at hearing preservation surgery and do not want to risk gentamicin associated hearing loss"
        ],
        "Text": "impaired decision making. neurofibromatosis. signs for central dysfunction. remaining vestibular function. Patients are advised not to participate in the gentamicin arm if. hearing is better than 30 deciBel (dB) in pure tone average (500, 1000, 2000, 3-4000 Hz) and speech discrimination better than 70%. the neurosurgeon aim at hearing preservation surgery and do not want to risk gentamicin associated hearing loss. "
    },
    "NCT02055053_exc": {
        "Annotations": [
            "Non-representable 0 44--*--Conversion from laparoscopic to open surgery",
            "Observation 46 53--*--History",
            "Condition 57 69--*--Chronic pain",
            "Condition 95 107--*--chronic pain",
            "Temporal 73 80--*--ongoing",
            "Procedure 81 90--*--treatment",
            "Person 109 112--*--Age",
            "Value 113 129--*--less than 18 yrs",
            "Condition 131 138--*--Allergy",
            "Drug 142 159--*--local anesthetics"
        ],
        "Text": "Conversion from laparoscopic to open surgery. History of Chronic pain or ongoing treatment for chronic pain. Age less than 18 yrs. Allergy to local anesthetics. "
    },
    "NCT02601157_inc": {
        "Annotations": [
            "Qualifier 14 21--*--de novo",
            "Condition 22 38--*--stenotic lesions",
            "Mood 47 55--*--suitable",
            "Procedure 60 77--*--coronary stenting",
            "Device 83 101--*--drug-eluting stent"
        ],
        "Text": "Patients with de novo stenotic lesions who are suitable for coronary stenting with drug-eluting stent. "
    },
    "NCT03366779_inc": {
        "Text": "Age 18 to 75 years old (male or female).. Patients with posterior or posterolateral disc herniations at one level between L1 and S1 with radiographic confirmation of neural compression using CT and/or MRI.. At least six (6) weeks of failed, conservative treatment prior to surgery, or requires immediate surgery to prevent permanent disability.. Minimum posterior disc height of 5mm at the index level(s).. Lower back pain and/or sciatica with or without spinal claudication.. Oswestry Questionnaire score of at least 40/100 at baseline.. VAS leg pain of at least 40/100 at baseline.. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--18 to 75 years old",
            "Person 24 28--*--male",
            "Person 32 38--*--female",
            "Scope 24 38--*--male or female",
            "Qualifier 69 83--*--posterolateral",
            "Qualifier 56 65--*--posterior",
            "Condition 84 100--*--disc herniations",
            "Qualifier 104 131--*--one level between L1 and S1",
            "Procedure 137 149--*--radiographic",
            "Qualifier 137 162--*--radiographic confirmation",
            "Condition 166 184--*--neural compression",
            "Procedure 191 193--*--CT",
            "Procedure 201 204--*--MRI",
            "Scope 191 204--*--CT and/or MRI",
            "Scope 56 83--*--posterior or posterolateral",
            "Multiplier 207 229--*--At least six (6) weeks",
            "Qualifier 233 239--*--failed",
            "Qualifier 241 253--*--conservative",
            "Procedure 254 263--*--treatment",
            "Temporal 264 280--*--prior to surgery",
            "Procedure 304 311--*--surgery",
            "Condition 323 343--*--permanent disability",
            "Mood 315 322--*--prevent",
            "Qualifier 294 303--*--immediate",
            "Measurement 354 375--*--posterior disc height",
            "Value 346 353;376 382--*--Minimum of 5mm",
            "Qualifier 390 404--*--index level(s)",
            "Condition 407 422--*--Lower back pain",
            "Condition 430 438--*--sciatica",
            "Condition 455 474--*--spinal claudication",
            "Scope 407 438--*--Lower back pain and/or sciatica",
            "Measurement 477 505--*--Oswestry Questionnaire score",
            "Value 509 524--*--at least 40/100",
            "Temporal 525 536--*--at baseline",
            "Measurement 539 551--*--VAS leg pain",
            "Value 555 570--*--at least 40/100",
            "Temporal 571 582--*--at baseline",
            "Post-eligibility 585 734--*--Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements."
        ]
    },
    "NCT02742233_inc": {
        "Text": "Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl). Ulcer located on the legs or feet, stage III or IV (Wagner Classification System). The subject agrees to comply with study protocol requirements and all follow up visit requirements.. ",
        "Annotations": [
            "Condition 13 30--*--diabetes mellitus",
            "Qualifier 44 78--*--World Health Organization criteria",
            "Drug 96 103--*--insulin",
            "Procedure 81 90--*--treatment",
            "Drug 110 133--*--oral hypoglycemic agent",
            "Multiplier 135 140--*--twice",
            "Measurement 141 168--*--random glucose measurements",
            "Value 169 189--*--major than 200 mg/dl",
            "Measurement 196 211--*--fasting glucose",
            "Value 212 232--*--major than 140 mg/dl",
            "Scope 96 133--*--insulin or an oral hypoglycemic agent",
            "Scope 81 232--*--treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl",
            "Scope 13 78--*--diabetes mellitus according to World Health Organization criteria",
            "Condition 235 240--*--Ulcer",
            "Qualifier 256 260--*--legs",
            "Qualifier 264 268--*--feet",
            "Measurement 270 275--*--stage",
            "Value 276 285--*--III or IV",
            "Qualifier 287 315--*--Wagner Classification System",
            "Scope 256 268--*--legs or feet",
            "Informed_consent 318 416--*--The subject agrees to comply with study protocol requirements and all follow up visit requirements"
        ]
    },
    "NCT03318393_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 31--*--1 day to less than 18 years",
            "Visit 50 79--*--pediatric intensive care unit",
            "Visit 83 120--*--pediatric cardiac intensive care unit",
            "Procedure 146 163--*--venoarterial ECMO",
            "Procedure 132 142;159 163--*--venovenous ECMO"
        ],
        "Text": "Age 1 day to less than 18 years. Cared for in the pediatric intensive care unit or pediatric cardiac intensive care unit. receiving venovenous or venoarterial ECMO. "
    },
    "NCT02589977_inc": {
        "Annotations": [
            "Measurement 0 43--*--estimated glomerular filtration rate (eGFR)",
            "Value 44 55--*--> 60 ml/min",
            "Measurement 67 101--*--left ventricular ejection fraction",
            "Value 57 66--*--preserved",
            "Value 103 109--*-->= 50%",
            "Procedure 114 130--*--echocardiography",
            "Condition 132 139--*--HEALTHY",
            "Value 141 165--*--normal cardiac structure",
            "Value 141 155;170 178--*--normal cardiac function",
            "Procedure 182 198--*--echocardiography",
            "Scope 141 178--*--normal cardiac structure and function",
            "Measurement 200 202--*--BP",
            "Value 203 211--*--< 140/90",
            "Scope 141 211--*--normal cardiac structure and function on echocardiography, BP < 140/90",
            "Condition 213 225--*--HYPERTENSIVE",
            "Condition 353 358--*--HFpEF",
            "Measurement 238 240--*--BP",
            "Value 241 248--*-->140/90",
            "Observation 227 234--*--history",
            "Multiplier 250 259--*--1 or more",
            "Drug 260 288--*--antihypertensive medications",
            "Measurement 290 317--*--LV ejection fraction (LVEF)",
            "Value 318 330--*--at least 50%",
            "Temporal 332 339--*--current",
            "Measurement 340 342--*--BP",
            "Value 343 351--*--< 160/90",
            "Scope 227 351--*--history of BP >140/90, 1 or more antihypertensive medications, LV ejection fraction (LVEF) at least 50%, current BP < 160/90",
            "Qualifier 360 379--*--physician-confirmed",
            "Condition 393 395--*--HF",
            "Qualifier 397 408--*--symptomatic",
            "Condition 409 411--*--HF",
            "Measurement 413 417--*--LVEF",
            "Value 418 430--*--at least 50%",
            "Value 432 440--*--elevated",
            "Measurement 441 460--*--LV filling pressure",
            "Procedure 464 479--*--catheterization",
            "Non-representable 481 507--*--echocardiographic criteria",
            "Measurement 511 537--*--B-type-natriuretic peptide",
            "Value 538 543--*--> 100",
            "Measurement 545 555--*--current BP",
            "Value 556 564--*--< 160/90",
            "Scope 360 564--*--physician-confirmed diagnosis of HF, symptomatic HF, LVEF at least 50%, elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide > 100, current BP < 160/90"
        ],
        "Text": "estimated glomerular filtration rate (eGFR) > 60 ml/min. preserved left ventricular ejection fraction (>= 50%) on echocardiography. HEALTHY: normal cardiac structure and function on echocardiography, BP < 140/90. HYPERTENSIVE: history of BP >140/90, 1 or more antihypertensive medications, LV ejection fraction (LVEF) at least 50%, current BP < 160/90. HFpEF: physician-confirmed diagnosis of HF, symptomatic HF, LVEF at least 50%, elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide > 100, current BP < 160/90. "
    },
    "NCT03025620_exc": {
        "Annotations": [
            "Non-query-able 0 72--*--Patients unable to understand the objectives of the dietary intervention",
            "Context_Error 74 100--*--Patients in paliative care",
            "Undefined_semantics 102 137--*--Patients receiving supplement diets"
        ],
        "Text": "Patients unable to understand the objectives of the dietary intervention . Patients in paliative care . Patients receiving supplement diets       .     . "
    },
    "NCT02601157_exc": {
        "Annotations": [
            "Line 0 368--*--1. High risk profiles for ischemic adverse events such as A. ST-segment elevation myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous sites of balloon angioplasty",
            "Line 369 506--*--2. Patients who cannot follow allocated DAPT schedule due to the planned surgery or elective procedure within 3 months after the stenting",
            "Line 507 622--*--3. Recent history of major surgery or evident events of gastrointestinal bleeding within 1 month from the procedure",
            "Line 623 699--*--4. Patients on anticoagulation therapy with warfarin or other anticoagulants",
            "Line 700 793--*--5. Life expectancy less than 1 year (such as malignancies or other chronic systemic diseases)",
            "Line 794 811--*--6. Pregnant women",
            "Line 812 964--*--7. Past history of allergy or other contraindications for the following medications/materials: aspirin, clopidogrel, heparin, cobalt chromium, sirolimus",
            "Condition 26 49--*--ischemic adverse events",
            "Condition 3 21--*--High risk profiles",
            "Condition 61 111--*--ST-segment elevation myocardial infarction (STEMI)",
            "Condition 129 146--*--cardiogenic shock",
            "Condition 183 196--*--heart failure",
            "Qualifier 162 168--*--severe",
            "Qualifier 169 182--*--decompensated",
            "Scope 58 368--*--A. ST-segment elevation myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous sites of balloon angioplasty",
            "Scope 3 49--*--High risk profiles for ischemic adverse events",
            "Condition 200 221--*--Myocardial infarction",
            "Condition 225 241--*--stent thrombosis",
            "Drug 273 293--*--antiplatelet therapy",
            "Scope 200 241--*--Myocardial infarction or stent thrombosis",
            "Scope 197 293--*--C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy",
            "Condition 297 307--*--Restenosis",
            "Mood 434 441--*--planned",
            "Procedure 442 449--*--surgery",
            "Qualifier 453 461--*--elective",
            "Procedure 462 471--*--procedure",
            "Scope 442 471--*--surgery or elective procedure",
            "Temporal 472 506--*--within 3 months after the stenting",
            "Condition 385 422--*--cannot follow allocated DAPT schedule",
            "Procedure 528 541--*--major surgery",
            "Condition 553 588--*--events of gastrointestinal bleeding",
            "Temporal 589 622--*--within 1 month from the procedure",
            "Scope 528 588--*--major surgery or evident events of gastrointestinal bleeding",
            "Procedure 638 661--*--anticoagulation therapy",
            "Drug 667 675--*--warfarin",
            "Qualifier 679 684--*--other",
            "Drug 685 699--*--anticoagulants",
            "Scope 667 699--*--warfarin or other anticoagulants",
            "Observation 703 718--*--Life expectancy",
            "Value 719 735--*--less than 1 year",
            "Condition 745 757--*--malignancies",
            "Condition 767 792--*--chronic systemic diseases",
            "Qualifier 761 766--*--other",
            "Scope 745 792--*--malignancies or other chronic systemic diseases",
            "Scope 703 735--*--Life expectancy less than 1 year",
            "Condition 797 805--*--Pregnant",
            "Person 806 811--*--women",
            "Condition 831 838--*--allergy",
            "Condition 848 865--*--contraindications",
            "Qualifier 842 847--*--other",
            "Drug 907 914--*--aspirin",
            "Drug 916 927--*--clopidogrel",
            "Drug 929 936--*--heparin",
            "Drug 938 953--*--cobalt chromium",
            "Drug 955 964--*--sirolimus",
            "Scope 907 964--*--aspirin, clopidogrel, heparin, cobalt chromium, sirolimus",
            "Scope 831 865--*--allergy or other contraindications"
        ],
        "Text": "1. High risk profiles for ischemic adverse events such as A. ST-segment elevation myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous sites of balloon angioplasty 2. Patients who cannot follow allocated DAPT schedule due to the planned surgery or elective procedure within 3 months after the stenting 3. Recent history of major surgery or evident events of gastrointestinal bleeding within 1 month from the procedure 4. Patients on anticoagulation therapy with warfarin or other anticoagulants 5. Life expectancy less than 1 year (such as malignancies or other chronic systemic diseases) 6. Pregnant women 7. Past history of allergy or other contraindications for the following medications/materials: aspirin, clopidogrel, heparin, cobalt chromium, sirolimus. "
    },
    "NCT02415257_inc": {
        "Annotations": [
            "Condition 0 21--*--Vestibular schwannoma",
            "Mood 22 29--*--advised",
            "Procedure 33 51--*--surgical treatment",
            "Negation 53 55--*--No",
            "Measurement 67 96--*--remaining vestibular function"
        ],
        "Text": "Vestibular schwannoma advised to surgical treatment. No measurable remaining vestibular function. "
    },
    "NCT02997215_exc": {
        "Text": "Open surgery;. Patients allergic to lidocaine or other local anesthetics;. Drug abuser.. ",
        "Annotations": [
            "Procedure 0 12--*--Open surgery",
            "Condition 24 32--*--allergic",
            "Drug 36 45--*--lidocaine",
            "Drug 55 72--*--local anesthetics",
            "Qualifier 49 54--*--other",
            "Scope 36 72--*--lidocaine or other local anesthetics",
            "Condition 75 86--*--Drug abuser"
        ]
    },
    "NCT02055053_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--18 or older",
            "Qualifier 21 31--*--unilateral",
            "Qualifier 35 44--*--bilateral",
            "Condition 45 59--*--inguinal herna",
            "Scope 21 44--*--unilateral or bilateral",
            "Measurement 85 131--*--American Society of Anesthesiology (ASA) Class",
            "Value 132 140--*--I and II",
            "Qualifier 60 83--*--for laparoscopic repair",
            "Procedure 64 83--*--laparoscopic repair"
        ],
        "Text": "Age 18 or older with unilateral or bilateral inguinal herna for laparoscopic repair. American Society of Anesthesiology (ASA) Class I and II. "
    },
    "NCT02742233_exc": {
        "Text": "Uncontrolled diabetes. Ulcer infection. Non-diabetic ulcers Orthopedic or neuromuscular pathologic conditions. ",
        "Annotations": [
            "Qualifier 0 12--*--Uncontrolled",
            "Condition 13 21--*--diabetes",
            "Condition 23 38--*--Ulcer infection",
            "Qualifier 40 52--*--Non-diabetic",
            "Condition 53 59--*--ulcers",
            "Condition 60 70;88 109--*--Orthopedic pathologic conditions",
            "Condition 74 109--*--neuromuscular pathologic conditions",
            "Line 60 109--*--Orthopedic or neuromuscular pathologic conditions",
            "Line 40 59--*--Non-diabetic ulcers"
        ]
    },
    "NCT03366779_exc": {
        "Text": "Spondylolisthesis Grade II or higher.. Subject requires uni or bilateral facetectomy to treat leg/back pain.. Subject has back or non-radicular leg pain of unknown etiology.. Prior surgery at the index lumbar level.. Subject requiring a spine DEXA (i.e., patients with SCORE of = 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.. Subject has clinically compromised vertebral bodies at the index level(s) due to any traumatic, neoplastic, metabolic, or infectious pathology.. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip.. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).. Any metabolic disease bone disease that has not been stabilized for at least three months (e.g., Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder, etc.).. Subject has an active infection either systemic or local.. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.. Subject has severe arterial insufficiency of the legs (Screening on physical examination= patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded) or other peripheral vascular disease).. Subject has significant peripheral neuropathy, patient defined as a patient with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.. Subject has insulin-dependent diabetes mellitus.. Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight).. Subject has been diagnosed with active hepatitis, AIDS, or HIV.. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.. Subject has a known allergy to titanium, polyethylene or polyester materials.. Subject is pregnant or interested in becoming pregnant in the next two (2) years.. Subject has active tuberculosis or has had tuberculosis in the past three (3) years.. Subject has a history of active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.. Subject is immunologically suppressed, received steroids >1 month over the past year.. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.. Subject has a life expectancy of less than three (3) years.. Subject is currently involved in another investigational study.. Subject is incarcerated.. ",
        "Annotations": [
            "Condition 0 17--*--Spondylolisthesis",
            "Measurement 18 23--*--Grade",
            "Value 24 36--*--II or higher",
            "Qualifier 63 72--*--bilateral",
            "Procedure 73 84--*--facetectomy",
            "Qualifier 56 59--*--uni",
            "Condition 98 107--*--back pain",
            "Condition 103 107;94 97--*--pain leg",
            "Scope 56 72--*--uni or bilateral",
            "Scope 94 107--*--leg/back pain",
            "Condition 130 152--*--non-radicular leg pain",
            "Condition 122 126;148 152--*--back pain",
            "Qualifier 156 172--*--unknown etiology",
            "Scope 122 152--*--back or non-radicular leg pain",
            "Procedure 181 188--*--surgery",
            "Qualifier 196 214--*--index lumbar level",
            "Temporal 175 180--*--Prior",
            "Procedure 237 247--*--spine DEXA",
            "Measurement 269 274--*--SCORE",
            "Value 278 281--*--= 6",
            "Measurement 290 297--*--T Score",
            "Value 298 312--*--less than -2.0",
            "Qualifier 320 331--*--index level",
            "Mood 225 234--*--requiring",
            "Condition 353 363--*--herniation",
            "Qualifier 367 372--*--L5/S1",
            "Measurement 378 393--*--average T score",
            "Qualifier 397 402--*--L1-L4",
            "Non-representable 403 416--*--shall be used",
            "Scope 353 372--*--herniation at L5/S1",
            "Condition 431 470--*--clinically compromised vertebral bodies",
            "Qualifier 478 492--*--index level(s)",
            "Condition 541 561--*--infectious pathology",
            "Condition 527 536;552 561--*--metabolic pathology",
            "Condition 515 525;552 561--*--neoplastic pathology",
            "Condition 504 513;552 561--*--traumatic pathology",
            "Scope 504 561--*--traumatic, neoplastic, metabolic, or infectious pathology",
            "Condition 597 622--*--fractures of the vertebra",
            "Multiplier 626 634--*--multiple",
            "Condition 635 660--*--fractures of the vertebra",
            "Condition 635 651;664 667--*--fractures of the hip",
            "Scope 635 667--*--fractures of the vertebra or hip",
            "Qualifier 586 596--*--pathologic",
            "Condition 682 691--*--scoliosis",
            "Qualifier 695 724--*--greater than ten (10) degrees",
            "Qualifier 731 738--*--angular",
            "Qualifier 743 753--*--rotational",
            "Scope 731 753--*--angular and rotational",
            "Condition 761 778--*--metabolic disease",
            "Observation 805 820--*--been stabilized",
            "Temporal 821 846--*--for at least three months",
            "Condition 854 869--*--Paget's disease",
            "Condition 871 883--*--osteomalacia",
            "Condition 885 908--*--osteogenesis imperfecta",
            "Condition 910 917--*--thyroid",
            "Condition 925 951--*--parathyroid gland disorder",
            "Scope 854 951--*--Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder",
            "Negation 801 804--*--not",
            "Condition 779 791--*--bone disease",
            "Scope 761 791--*--metabolic disease bone disease",
            "Condition 983 992--*--infection",
            "Qualifier 976 982--*--active",
            "Qualifier 1000 1008--*--systemic",
            "Qualifier 1012 1017--*--local",
            "Scope 1000 1017--*--systemic or local",
            "Condition 1032 1053--*--cauda equina syndrome",
            "Condition 1057 1073;1082 1093--*--neurogenic bowel dysfunction",
            "Condition 1057 1067;1074 1093--*--neurogenic bladder dysfunction",
            "Qualifier 1108 1114--*--severe",
            "Condition 1115 1137--*--arterial insufficiency",
            "Qualifier 1145 1149--*--legs",
            "Condition 1200 1239--*--diminution or absence of dorsalis pedis",
            "Condition 1200 1224;1243 1268--*--diminution or absence of posterior tibialis pulses",
            "Procedure 1316 1335--*--arterial ultrasound",
            "Procedure 1353 1377--*--vascular plethysmography",
            "Measurement 1386 1412--*--absolute arterial pressure",
            "Value 1416 1432--*--below 50mm of Hg",
            "Qualifier 1440 1444;1454 1459--*--calf level",
            "Qualifier 1448 1459--*--ankle level",
            "Scope 1440 1459--*--calf or ankle level",
            "Procedure 1297 1306--*--palpation",
            "Observation 1273 1283--*--diminished",
            "Observation 1287 1293--*--absent",
            "Scope 1273 1293--*--diminished or absent",
            "Condition 1506 1533--*--peripheral vascular disease",
            "Scope 1273 1306--*--diminished or absent by palpation",
            "Procedure 1151 1184--*--Screening on physical examination",
            "Scope 1200 1268--*--diminution or absence of dorsalis pedis or posterior tibialis pulses",
            "Negation 1487 1495--*--excluded",
            "Scope 1386 1459--*--absolute arterial pressure is below 50mm of Hg at the calf or ankle level",
            "Qualifier 1549 1560--*--significant",
            "Condition 1561 1582--*--peripheral neuropathy",
            "Qualifier 1628 1635--*--Type II",
            "Qualifier 1618 1624--*--Type I",
            "Condition 1636 1644--*--diabetes",
            "Scope 1618 1635--*--Type I or Type II",
            "Condition 1656 1684--*--systemic metabolic condition",
            "Qualifier 1648 1655--*--similar",
            "Condition 1693 1712--*--decreased sensation",
            "Qualifier 1718 1731;1768 1780--*--stocking-like distribution",
            "Qualifier 1735 1748;1768 1780--*--non-radicular distribution",
            "Qualifier 1753 1780--*--non-dermatomal distribution",
            "Qualifier 1788 1805--*--lower extremities",
            "Scope 1718 1780--*--stocking-like or non-radicular and non-dermatomal distribution",
            "Qualifier 1820 1837--*--insulin-dependent",
            "Condition 1838 1855--*--diabetes mellitus",
            "Condition 1869 1883--*--morbidly obese",
            "Measurement 1898 1913--*--body mass index",
            "Value 1914 1917--*-->40",
            "Measurement 1922 1928--*--weighs",
            "Value 1929 1969--*--more than 100 lbs over ideal body weight",
            "Scope 1898 1969--*--body mass index >40, or weighs more than 100 lbs over ideal body weight",
            "Condition 2012 2021--*--hepatitis",
            "Condition 2023 2027--*--AIDS",
            "Condition 2032 2035--*--HIV",
            "Scope 2012 2035--*--hepatitis, AIDS, or HIV",
            "Qualifier 2005 2011--*--active",
            "Condition 2070 2090--*--rheumatoid arthritis",
            "Qualifier 2094 2099--*--other",
            "Condition 2100 2118--*--autoimmune disease",
            "Drug 2152 2160--*--titanium",
            "Drug 2162 2174--*--polyethylene",
            "Drug 2178 2187--*--polyester",
            "Condition 2141 2148--*--allergy",
            "Scope 2152 2187--*--titanium, polyethylene or polyester",
            "Condition 2211 2219--*--pregnant",
            "Mood 2223 2245--*--interested in becoming",
            "Condition 2246 2254--*--pregnant",
            "Temporal 2255 2280--*--in the next two (2) years",
            "Scope 2211 2254--*--pregnant or interested in becoming pregnant",
            "Condition 2302 2314--*--tuberculosis",
            "Condition 2326 2338--*--tuberculosis",
            "Temporal 2339 2366--*--in the past three (3) years",
            "Condition 2454 2464--*--malignancy",
            "Condition 2473 2497--*--non-melanoma skin cancer",
            "Qualifier 2445 2453--*--invasive",
            "Condition 2523 2551--*--treated with curative intent",
            "Negation 2572 2574--*--no",
            "Condition 2575 2610--*--signs or symptoms of the malignancy",
            "Temporal 2611 2637--*--for at least two (2) years",
            "Scope 2523 2637--*--treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years",
            "Negation 2466 2472--*--except",
            "Condition 2394 2411--*--active malignancy",
            "Observation 2383 2390--*--history",
            "Scope 2445 2637--*--invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years",
            "Scope 2383 2411--*--history of active malignancy",
            "Condition 2651 2677--*--immunologically suppressed",
            "Drug 2688 2696--*--steroids",
            "Multiplier 2697 2705--*-->1 month",
            "Temporal 2706 2724--*--over the past year",
            "Drug 2744 2758--*--anticoagulants",
            "Drug 2771 2778--*--aspirin",
            "Negation 2760 2770--*--other than",
            "Non-representable 2780 2845--*--unless the patient can be taken off the anticoagulant for surgery",
            "Condition 2879 2897--*--alcohol dependency",
            "Condition 2870 2878;2887 2897--*--chemical dependency",
            "Condition 2913 2937--*--psychosocial disturbance",
            "Qualifier 2901 2912--*--significant",
            "Observation 2954 2969--*--life expectancy",
            "Value 2973 2998--*--less than three (3) years",
            "Competing_trial 3001 3065--*--Subject is currently involved in another investigational study.",
            "Competing_trial 3001 3064--*--Subject is currently involved in another investigational study.",
            "Observation 3077 3089--*--incarcerated"
        ]
    },
    "NCT03025620_inc": {
        "Annotations": [
            "Person 31 34--*--old",
            "Value 17 30--*--over 65 years",
            "Person 0 7--*--Elderly",
            "Undefined_semantics 46 88--*--clinical indices of cardiovascular disease",
            "Person 90 94--*--Male",
            "Person 98 104--*--female",
            "Visit 144 193--*--Geriatric Unit of the Emile Roux Hospital (AP-HP)",
            "Measurement 195 231--*--MMSE (Mini Mental State Examination)",
            "Value 231 246--*--score > or = 15",
            "Non-query-able 248 290--*--Supervision available for study medication",
            "Condition 292 316--*--Able to ingest oral diet",
            "Non-query-able 292 316--*--Able to ingest oral diet"
        ],
        "Text": "Elderly patients over 65 years old exhibiting clinical indices of cardiovascular disease . Male or female . Subjects who were hospitalized in the Geriatric Unit of the Emile Roux Hospital (AP-HP) . MMSE (Mini Mental State Examination)score > or = 15 . Supervision available for study medication . Able to ingest oral diet . "
    },
    "NCT03318393_exc": {
        "Annotations": [
            "Drug 33 40--*--heparin",
            "Condition 49 65--*--thrombocytopenia",
            "Temporal 66 82--*--prior to consent",
            "Reference_point 75 82--*--consent",
            "Qualifier 33 48--*--heparin induced",
            "Mood 23 32--*--suspected",
            "Mood 14 19--*--known",
            "Scope 14 32--*--known or suspected",
            "Condition 98 113--*--hepatic failure",
            "Condition 125 137--*--coagulopathy",
            "Measurement 152 165--*--transaminases",
            "Value 143 151;166 201--*--elevated more than three times normal values",
            "Temporal 247 262--*--within 48 hours",
            "Procedure 225 246--*--decannulate from ECMO",
            "Condition 283 291--*--pregnant",
            "Person 292 297--*--women",
            "Mood 273 282--*--suspected",
            "Mood 264 269--*--Known",
            "Scope 264 282--*--Known or suspected",
            "Competing_trial 299 332--*--Previous enrollment in this study",
            "Non-query-able 334 388--*--Primary language spoken that is not English or Spanish"
        ],
        "Text": "Patients with known or suspected heparin induced thrombocytopenia prior to consent. Patients with hepatic failure defined as coagulopathy with elevated transaminases more than three times normal values. Patients with plan to decannulate from ECMO within 48 hours. Known or suspected pregnant women. Previous enrollment in this study. Primary language spoken that is not English or Spanish. "
    },
    "NCT02589977_exc": {
        "Annotations": [
            "Condition 20 43--*--coronary artery disease",
            "Condition 45 62--*--diabetes mellitus",
            "Condition 64 81--*--contraindications",
            "Procedure 85 125--*--cardiac magnetic resonance imaging (CMR)",
            "Measurement 127 133--*--weight",
            "Value 134 142--*-->350 lbs",
            "Observation 144 177--*--inability to lie flat for imaging",
            "Condition 179 185--*--anemia",
            "Condition 187 204--*--contraindications",
            "Drug 208 219--*--regadenoson",
            "Drug 223 236--*--aminophylline",
            "Scope 208 236--*--regadenoson or aminophylline",
            "Condition 238 245--*--HEALTHY",
            "Condition 253 275--*--cardiovascular disease",
            "Condition 277 297--*--cardiac risk factors",
            "Drug 308 327--*--cardiac medications",
            "Scope 253 327--*--cardiovascular disease, cardiac risk factors or use of cardiac medications",
            "Condition 329 341--*--HYPERTENSIVE",
            "Condition 349 371--*--cardiovascular disease",
            "Condition 349 363;375 387--*--cardiovascular risk factors",
            "Condition 349 363;375 387;394 411--*--cardiovascular risk factors from hypertension",
            "Negation 388 398--*--aside from",
            "Drug 422 441--*--cardiac medications",
            "Scope 349 411--*--cardiovascular disease or risk factors aside from hypertension",
            "Scope 349 441--*--cardiovascular disease or risk factors aside from hypertension or use of cardiac medications",
            "Condition 443 448--*--HFpEF",
            "Observation 450 466--*--prior history of",
            "Measurement 467 471--*--LVEF",
            "Value 472 481--*--below 50%",
            "Qualifier 483 488--*--acute",
            "Condition 489 505--*--decompensated HF",
            "Qualifier 507 515--*--moderate",
            "Qualifier 519 526--*--greater",
            "Condition 527 543--*--valvular disease",
            "Scope 507 526--*--moderate or greater",
            "Qualifier 545 556--*--significant",
            "Condition 557 576--*--cardiac arrhythmias",
            "Condition 578 597--*--pericardial disease",
            "Condition 599 623--*--congenital heart disease",
            "Condition 625 655--*--primary pulmonary hypertension",
            "Scope 450 655--*--prior history of LVEF below 50%, acute decompensated HF, moderate or greater valvular disease, significant cardiac arrhythmias, pericardial disease, congenital heart disease, primary pulmonary hypertension"
        ],
        "Text": "Exclusion Criteria: coronary artery disease, diabetes mellitus, contraindications to cardiac magnetic resonance imaging (CMR), weight >350 lbs, inability to lie flat for imaging, anemia, contraindications to regadenoson or aminophylline. HEALTHY: known cardiovascular disease, cardiac risk factors or use of cardiac medications. HYPERTENSIVE: known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications. HFpEF: prior history of LVEF below 50%, acute decompensated HF, moderate or greater valvular disease, significant cardiac arrhythmias, pericardial disease, congenital heart disease, primary pulmonary hypertension. "
    },
    "NCT02926989_exc": {
        "Text": "An initial plasma sodium concentration of lower than 130 mmol/L. An initial plasma sodium concentration of higher than 150 mmol/L. An initial plasma potassium concentration of lower than 3.0 mmol/L. Need for 10% glucose solution. Diabetes. Diabetes insipidus. Diabetic ketoacidosis. Renal disease that needs dialysis. Protocol-determined chemotherapy hydration. Severe liver disease. Inborn errors of metabolism that need protocol-determined fluid therapy. ",
        "Annotations": [
            "Multiplier 3 10--*--initial",
            "Multiplier 68 75--*--initial",
            "Multiplier 134 141--*--initial",
            "Measurement 11 38--*--plasma sodium concentration",
            "Measurement 76 103--*--plasma sodium concentration",
            "Measurement 142 172--*--plasma potassium concentration",
            "Value 42 63--*--lower than 130 mmol/L",
            "Value 107 129--*--higher than 150 mmol/L",
            "Value 176 197--*--lower than 3.0 mmol/L",
            "Mood 199 207--*--Need for",
            "Drug 208 228--*--10% glucose solution",
            "Condition 230 238--*--Diabetes",
            "Condition 240 258--*--Diabetes insipidus",
            "Condition 260 281--*--Diabetic ketoacidosis",
            "Condition 283 296--*--Renal disease",
            "Mood 302 307--*--needs",
            "Procedure 308 316--*--dialysis",
            "Qualifier 318 337--*--Protocol-determined",
            "Procedure 338 360--*--chemotherapy hydration",
            "Qualifier 362 368--*--Severe",
            "Condition 369 382--*--liver disease",
            "Condition 384 411--*--Inborn errors of metabolism",
            "Mood 417 421--*--need",
            "Qualifier 422 441--*--protocol-determined",
            "Procedure 442 455--*--fluid therapy"
        ]
    },
    "NCT01891513_exc": {
        "Text": "Failure to provide informed consent . Inability to complete 400 m walk within 15 minutes without sitting or interpersonal assistance, as an indicator of disablement and likely inability to fully engage in the exercise intervention . Primary indication for ACE inhibitor use, i.e. Congestive Heart Failure, CAD, diabetes . Known hypersensitivity to ACE inhibitors . Resistant hypertension, defined as BP > 140/90, despite the use of three or more anti-hypertensive drugs . Office or average home SBP > 180 mm Hg or DBP > 110 mm Hg (Average home BP in any seven day period during trial) . Primary renal disease . Serum creatinine >2.5 mg/dL in men, or >2.0 mg/dL in women . Serum potassium >5.0 molar equivalent/L . Urinary protein > 1 on dipstick . Abnormal liver enzymes (Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal) . Severe cardiac disease, including New York Heart Association Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina . Acute myocardial infarction identified by ECG . Lives in a nursing home (persons living in assisted or independent housing will not be excluded) . Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24 . Unable to communicate because of severe hearing loss or speech disorder . Severe visual impairment, which would preclude completion of the assessments and/or intervention . Other significant co-morbid disease that would prevent participation in exercise . Planning to move out of the area during the study time frame . Simultaneous participation in another intervention trial       .     . ",
        "Annotations": [
            "Non-query-able 0 35--*--Failure to provide informed consent",
            "Condition 37 103--*--Inability to complete 400 m walk within 15 minutes without sitting",
            "Condition 107 131;37 95--*--interpersonal assistance Inability to complete 400 m walk within 15 minutes without",
            "Drug 254 267--*--ACE inhibitor",
            "Condition 231 271--*--Primary indication for ACE inhibitor use",
            "Condition 278 302--*--Congestive Heart Failure",
            "Condition 304 307--*--CAD",
            "Condition 309 317--*--diabetes",
            "Scope 278 317--*--Congestive Heart Failure, CAD, diabetes",
            "Condition 325 359--*--hypersensitivity to ACE inhibitors",
            "Drug 345 359--*--ACE inhibitors",
            "Condition 371 383--*--hypertension",
            "Qualifier 361 370--*--Resistant",
            "Measurement 396 398--*--BP",
            "Value 399 407--*--> 140/90",
            "Qualifier 409 465--*--despite the use of three or more anti-hypertensive drugs",
            "Drug 442 465--*--anti-hypertensive drugs",
            "Multiplier 428 441--*--three or more",
            "Measurement 490 493--*--SBP",
            "Value 494 505--*--> 180 mm Hg",
            "Measurement 509 512--*--DBP",
            "Value 513 524--*--> 110 mm Hg",
            "Condition 581 602--*--Primary renal disease",
            "Measurement 604 620--*--Serum creatinine",
            "Value 621 631--*-->2.5 mg/dL",
            "Person 635 638--*--men",
            "Value 643 653--*-->2.0 mg/dL",
            "Person 657 662--*--women",
            "Scope 621 662--*-->2.5 mg/dL in men, or >2.0 mg/dL in women",
            "Measurement 664 679--*--Serum potassium",
            "Value 680 703--*-->5.0 molar equivalent/L",
            "Measurement 705 720;725 736--*--Urinary protein on dipstick",
            "Value 721 724--*--> 1",
            "Measurement 747 760--*--liver enzymes",
            "Measurement 762 790--*--Aspartate transaminase (AST)",
            "Measurement 792 818--*--Alanine transaminase (ALT)",
            "Measurement 823 843--*--alkaline phosphatase",
            "Value 844 881--*--> 2.5 times the upper limit of normal",
            "Scope 762 843--*--Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase",
            "Value 738 746--*--Abnormal",
            "Scope 738 760--*--Abnormal liver enzymes",
            "Condition 891 906--*--cardiac disease",
            "Qualifier 884 890--*--Severe",
            "Measurement 918 944--*--New York Heart Association",
            "Value 945 960--*--Class III or IV",
            "Condition 961 985--*--congestive heart failure",
            "Qualifier 987 1009--*--clinically significant",
            "Condition 1010 1025--*--aortic stenosis",
            "Observation 1027 1034--*--history",
            "Condition 1038 1052--*--cardiac arrest",
            "Device 1063 1084--*--cardiac defibrillator",
            "Condition 1089 1108--*--uncontrolled angina",
            "Qualifier 918 960--*--New York Heart Association Class III or IV",
            "Condition 1110 1137--*--Acute myocardial infarction",
            "Procedure 1152 1155--*--ECG",
            "Observation 1157 1180--*--Lives in a nursing home",
            "Condition 1267 1287--*--cognitive impairment",
            "Qualifier 1255 1266--*--Significant",
            "Condition 1321 1329--*--dementia",
            "Measurement 1335 1364--*--Mini-Mental State Examination",
            "Value 1370 1380--*--score < 24",
            "Condition 1382 1403--*--Unable to communicate",
            "Condition 1415 1434--*--severe hearing loss",
            "Condition 1438 1453--*--speech disorder",
            "Scope 1415 1453--*--severe hearing loss or speech disorder",
            "Condition 1462 1479--*--visual impairment",
            "Qualifier 1455 1461--*--Severe",
            "Condition 1571 1588--*--co-morbid disease",
            "Qualifier 1559 1570--*--significant",
            "Qualifier 1589 1633--*--that would prevent participation in exercise",
            "Undefined_semantics 1589 1633--*--that would prevent participation in exercise",
            "Subjective_judgement 1589 1633--*--that would prevent participation in exercise",
            "Non-query-able 1635 1695--*--Planning to move out of the area during the study time frame",
            "Context_Error 1635 1695--*--Planning to move out of the area during the study time frame",
            "Context_Error 1697 1753--*--Simultaneous participation in another intervention trial",
            "Non-query-able 1697 1753--*--Simultaneous participation in another intervention trial"
        ]
    },
    "NCT03216447_inc": {
        "Annotations": [
            "Post-eligibility 0 175--*--Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure",
            "Condition 190 214--*--primary liver transplant",
            "Person 215 224--*--recipient",
            "Person 255 258--*--age",
            "Value 237 251--*--20 to 70 years",
            "Post-eligibility 260 346--*--Patient should be clearly conscious, fully understand and able to answer questionnaire"
        ],
        "Text": "Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure. Patient is a primary liver transplant recipient. Patient is 20 to 70 years of age. Patient should be clearly conscious, fully understand and able to answer questionnaire. "
    },
    "NCT02553226_exc": {
        "Text": "Unable to read and understand the Danish language or to give informed consent. Cervical dilatation > 4 cm. Non-cephalic presentation. Multiple gestation. Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon\u00ae initiation. Fetal weight estimation > 4500 g (clinical or ultrasonic). Subject declines participation. Gestational age less than 37 completed weeks. ",
        "Annotations": [
            "Observation 0 14--*--Unable to read",
            "Observation 0 9;19 49--*--Unable to understand the Danish language",
            "Observation 0 9;56 77--*--Unable to give informed consent",
            "Measurement 79 98--*--Cervical dilatation",
            "Value 99 105--*--> 4 cm",
            "Condition 107 132--*--Non-cephalic presentation",
            "Condition 134 152--*--Multiple gestation",
            "Condition 154 191--*--Pathological fetal heart rate pattern",
            "Procedure 193 207--*--cardiotocogram",
            "Procedure 209 212--*--CTG",
            "Temporal 214 243--*--before Syntocinon\u00ae initiation",
            "Drug 221 232--*--Syntocinon\u00ae",
            "Reference_point 221 243--*--Syntocinon\u00ae initiation",
            "Scope 193 212--*--cardiotocogram, CTG",
            "Measurement 245 268--*--Fetal weight estimation",
            "Value 269 277--*--> 4500 g",
            "Qualifier 279 287--*--clinical",
            "Procedure 291 301--*--ultrasonic",
            "Scope 279 301--*--clinical or ultrasonic",
            "Informed_consent 304 334--*--Subject declines participation",
            "Measurement 336 351--*--Gestational age",
            "Value 352 380--*--less than 37 completed weeks"
        ]
    },
    "NCT03241368_inc": {
        "Text": "Subject has provided informed consent. . Subject is \u2265 18 years of age . Subject is willing and able to comply with all aspects of treatment and evaluation schedule. . Subject has known CD and a recent history (within last 2 years) of mucosal disease (diagnosis based on radiologic, endoscopic, or histological evidence). . ",
        "Annotations": [
            "Person 65 68--*--age",
            "Value 51 61--*--\u2265 18 years",
            "Non-query-able 0 38--*--Subject has provided informed consent.",
            "Non-query-able 70 162--*--Subject is willing and able to comply with all aspects of treatment and evaluation schedule.",
            "Condition 231 246--*--mucosal disease",
            "Observation 267 277;307 315--*--radiologic evidence",
            "Observation 279 289;307 315--*--endoscopic evidence",
            "Observation 294 315--*--histological evidence",
            "Scope 248 315--*--diagnosis based on radiologic, endoscopic, or histological evidence",
            "Temporal 207 226--*--within last 2 years",
            "Temporal 191 205--*--recent history",
            "Undefined_semantics 182 184--*--CD"
        ]
    },
    "NCT03465397_exc": {
        "Text": "Patients with a calculated PRA higher than 0% per solid phase and / or anti-HLA class I and / or class II antibodies detectable by single antigen test (Luminex\u00ae).. Positive result of Cross Match.. Patients who receive a graft from a cadaver donor.. Identical HLA patients. Patients who have undergone a previous solid organ transplant (including kidney transplant) or who are going to receive another solid organ transplant concomitantly.. Glomerular primary focal and segmental sclerosis. Atypical hemolytic uremic syndrome (aHUS) / thrombotic thrombocytopenic purpura syndrome.. Patients with chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus (positive PCR result) at the time of transplant.. Patients with infection with the known Human Immunodeficiency Virus (HIV).. Patients with active systemic infection that requires the continued administration of antibiotics.. Patients with any neoplasm except localized skin cancer and who is receiving adequate treatment.. Patients with severe anemia (hemoglobin <6g / dl), leukopenia (WBC <2500 / mm3) and / or thrombocytopenia (platelets <80,000 / mm3).. Patients who are hemodynamically unstable even if they have hemoglobin levels> 6g / dL.. Patients with intestinal pathology or severe diarrhea that may decrease absorption according to medical criteria.. Patients with known hypersensitivity to any of the drugs used in this study.. Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.. Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study.. Patients who are legally detained in an official institution.. ",
        "Annotations": [
            "Measurement 16 30--*--calculated PRA",
            "Value 31 61--*--higher than 0% per solid phase",
            "Procedure 131 150--*--single antigen test",
            "Value 71 87--*--anti-HLA class I",
            "Value 71 79;97 105--*--anti-HLA class II",
            "Scope 71 104--*--anti-HLA class I and / or class I",
            "Procedure 152 159--*--Luminex",
            "Procedure 220 246--*--graft from a cadaver donor",
            "Condition 249 262--*--Identical HLA",
            "Procedure 183 194--*--Cross Match",
            "Value 164 172--*--Positive",
            "Procedure 312 334--*--solid organ transplant",
            "Temporal 303 311--*--previous",
            "Procedure 346 363--*--kidney transplant",
            "Qualifier 393 400--*--another",
            "Procedure 401 423--*--solid organ transplant",
            "Temporal 424 437--*--concomitantly",
            "Condition 440 464;479 488--*--Glomerular primary focal sclerosis",
            "Condition 440 450;469 488--*--Glomerular segmental sclerosis",
            "Condition 490 531--*--Atypical hemolytic uremic syndrome (aHUS)",
            "Condition 534 578--*--thrombotic thrombocytopenic purpura syndrome",
            "Condition 618 641--*--Hepatitis B virus (HBV)",
            "Condition 673 690--*--Hepatitis C virus",
            "Procedure 701 711--*--PCR result",
            "Value 692 700--*--positive",
            "Qualifier 595 602--*--chronic",
            "Qualifier 651 657--*--active",
            "Scope 692 711--*--positive PCR result",
            "Scope 595 690--*--chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus",
            "Temporal 713 738--*--at the time of transplant",
            "Condition 780 814--*--Human Immunodeficiency Virus (HIV)",
            "Condition 838 856--*--systemic infection",
            "Qualifier 831 837--*--active",
            "Drug 903 914--*--antibiotics",
            "Multiplier 875 899--*--continued administration",
            "Condition 935 943--*--neoplasm",
            "Negation 944 950--*--except",
            "Condition 951 972--*--localized skin cancer",
            "Qualifier 1029 1035--*--severe",
            "Condition 1036 1042--*--anemia",
            "Measurement 1044 1054--*--hemoglobin",
            "Value 1055 1063--*--<6g / dl",
            "Condition 1066 1076--*--leukopenia",
            "Measurement 1078 1081--*--WBC",
            "Value 1082 1093--*--<2500 / mm3",
            "Scope 1044 1063--*--hemoglobin <6g / dl",
            "Scope 1078 1093--*--WBC <2500 / mm3",
            "Scope 1029 1042--*--severe anemia",
            "Condition 1104 1120--*--thrombocytopenia",
            "Measurement 1122 1131--*--platelets",
            "Value 1132 1145--*--<80,000 / mm3",
            "Scope 1122 1145--*--platelets <80,000 / mm3",
            "Condition 1166 1190--*--hemodynamically unstable",
            "Measurement 1209 1226--*--hemoglobin levels",
            "Value 1226 1235--*--> 6g / dL",
            "Condition 1252 1272--*--intestinal pathology",
            "Condition 1276 1291--*--severe diarrhea",
            "Observation 1297 1320--*--may decrease absorption",
            "Scope 1252 1291--*--intestinal pathology or severe diarrhea",
            "Condition 1373 1389--*--hypersensitivity",
            "Drug 1404 1428--*--drugs used in this study",
            "Competing_trial 1431 1537--*--Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.",
            "Pregnancy_considerations 1539 1756--*--Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study.",
            "Observation 1775 1791--*--legally detained",
            "Visit 1798 1818--*--official institution"
        ]
    },
    "NCT01320579_exc": {
        "Text": "History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator . Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin . Current use of any active systemic medication for chronic atopic dermatitis within one month . Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks . History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study . Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic\u00ae ointment . History of any skin-related cancer . Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression . Earlier participation in a clinical study performed with cis-UCA . Any clinically significant laboratory test result . Suspected current drug or alcohol abuse . Clinically significant illness during the 4 weeks prior to the first dose administration . Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient . Unwillingness or doubtful capacity to comply with the protocol . Doubtful availability to complete the study       .     . ",
        "Annotations": [
            "Condition 29 41--*--skin disease",
            "Qualifier 17 28--*--significant",
            "Observation 0 7--*--History",
            "Condition 69 85--*--allergic illness",
            "Condition 95 117--*--dermatologic condition",
            "Condition 46 65--*--skin manifestations",
            "Scope 69 117--*--allergic illness or other dermatologic condition",
            "Condition 153 170--*--atopic dermatitis",
            "Qualifier 146 152--*--severe",
            "Qualifier 126 142--*--chronic moderate",
            "Scope 126 152--*--chronic moderate or severe",
            "Subjective_judgement 177 299--*--would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator",
            "Negation 119 125--*--except",
            "Condition 327 340--*--skin diseases",
            "Condition 349 374--*--chronic atopic dermatitis",
            "Negation 342 348--*--except",
            "Qualifier 381 442--*--could disturb the study assessment and evaluation of the skin",
            "Undefined_semantics 381 442--*--could disturb the study assessment and evaluation of the skin",
            "Condition 494 519--*--chronic atopic dermatitis",
            "Temporal 520 536--*--within one month",
            "Drug 470 489--*--systemic medication",
            "Temporal 463 469--*--active",
            "Condition 619 644--*--chronic atopic dermatitis",
            "Temporal 645 661--*--within two weeks",
            "Drug 560 578--*--topical medication",
            "Temporal 553 559--*--active",
            "Observation 676 689--*--sunny holiday",
            "Procedure 691 707--*--UV-light therapy",
            "Observation 711 723--*--solarium use",
            "Temporal 724 777--*--within one month before beginning of study treatments",
            "Reference_point 748 777--*--beginning of study treatments",
            "Observation 782 790--*--planning",
            "Temporal 796 812--*--during the study",
            "Temporal 816 845--*--within 7 days after the study",
            "Scope 796 845--*--during the study or within 7 days after the study",
            "Scope 676 723--*--sunny holiday, UV-light therapy or solarium use",
            "Condition 847 854--*--Allergy",
            "Drug 940 958--*--Protopic\u00ae ointment",
            "Drug 858 865--*--cis-UCA",
            "Drug 894 916--*--placebo emulsion cream",
            "Scope 858 958--*--cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic\u00ae ointment",
            "Condition 975 994--*--skin-related cancer",
            "Observation 960 967--*--History",
            "Condition 1010 1035--*--acquired immunodeficiency",
            "Condition 1019 1035;996 1006--*--immunodeficiency Congenital",
            "Procedure 1047 1083--*--therapy that cause immunosuppression",
            "Qualifier 1055 1083--*--that cause immunosuppression",
            "Condition 1066 1083--*--immunosuppression",
            "Temporal 1039 1046--*--ongoing",
            "Non-query-able 1085 1149--*--Earlier participation in a clinical study performed with cis-UCA",
            "Qualifier 1155 1177--*--clinically significant",
            "Procedure 1178 1193--*--laboratory test",
            "Undefined_semantics 1151 1200--*--Any clinically significant laboratory test result",
            "Subjective_judgement 1151 1200--*--Any clinically significant laboratory test result",
            "Condition 1228 1241--*--alcohol abuse",
            "Condition 1220 1224;1236 1241--*--drug abuse",
            "Observation 1202 1211--*--Suspected",
            "Temporal 1212 1219--*--current",
            "Scope 1220 1241--*--drug or alcohol abuse",
            "Temporal 1274 1331--*--during the 4 weeks prior to the first dose administration",
            "Reference_point 1302 1331--*--the first dose administration",
            "Condition 1266 1273--*--illness",
            "Qualifier 1243 1265--*--Clinically significant",
            "Subjective_judgement 1243 1331--*--Clinically significant illness during the 4 weeks prior to the first dose administration",
            "Post-eligibility 1333 1495--*--Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient",
            "Post-eligibility 1497 1559--*--Unwillingness or doubtful capacity to comply with the protocol",
            "Post-eligibility 1561 1604--*--Doubtful availability to complete the study"
        ]
    },
    "NCT02926989_inc": {
        "Text": "Acutely ill hospitalised children. Need for intravenous fluid therapy. ",
        "Annotations": [
            "Condition 0 11--*--Acutely ill",
            "Observation 12 24--*--hospitalised",
            "Person 25 33--*--children",
            "Mood 35 43--*--Need for",
            "Procedure 44 69--*--intravenous fluid therapy"
        ]
    },
    "NCT02553226_inc": {
        "Text": "Women stimulated with Syntocinon\u00ae infusion for induction of labour (with or without cervical priming by prostaglandin). ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Drug 22 33--*--Syntocinon\u00ae",
            "Procedure 22 42--*--Syntocinon\u00ae infusion",
            "Procedure 47 66--*--induction of labour",
            "Procedure 84 100--*--cervical priming",
            "Drug 104 117--*--prostaglandin"
        ]
    },
    "NCT01891513_inc": {
        "Text": "Age 65 years and older . Hypertension - untreated (Systolic Blood Pressure (SBP) \u2265 140 mm Hg or Diastolic Blood Pressure (DBP) \u2265 90 mm Hg) or treated . Physical limitations evidenced by either: . Score \u2264 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test . Sedentary lifestyle, defined as <150 min/wk of moderate physical activity as assessed by CHAMPS questionnaire . Willingness to participate in all study procedures . ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--65 years and older",
            "Condition 24 36--*--Hypertension",
            "Qualifier 39 48--*--untreated",
            "Measurement 50 79--*--Systolic Blood Pressure (SBP)",
            "Value 80 91--*--\u2265 140 mm Hg",
            "Measurement 95 125--*--Diastolic Blood Pressure (DBP)",
            "Value 126 136--*--\u2265 90 mm Hg",
            "Scope 50 136--*--Systolic Blood Pressure (SBP) \u2265 140 mm Hg or Diastolic Blood Pressure (DBP) \u2265 90 mm Hg",
            "Qualifier 141 148--*--treated",
            "Parsing_Error 150 191--*--Physical limitations evidenced by either:",
            "Measurement 211 245--*--Short Physical Performance Battery",
            "Value 193 203--*--Score \u2264 10",
            "Measurement 249 262--*--Walking speed",
            "Value 263 274--*--< 1.2 m/sec",
            "Procedure 282 304--*--400 m usual-paced test",
            "Condition 306 325--*--Sedentary lifestyle",
            "Value 338 349--*--<150 min/wk",
            "Measurement 353 379--*--moderate physical activity",
            "Procedure 395 415--*--CHAMPS questionnaire",
            "Non-query-able 417 467--*--Willingness to participate in all study procedures"
        ]
    },
    "NCT03216447_exc": {
        "Annotations": [
            "Procedure 51 67--*--organ transplant",
            "Negation 68 78--*--other than",
            "Qualifier 81 86--*--liver",
            "Procedure 116 124--*--dialysis",
            "Measurement 177 205--*--human immunodeficiency virus",
            "Value 160 172--*--seropositive",
            "Measurement 207 210--*--HIV",
            "Person 126 135--*--Recipient",
            "Person 139 144--*--donor",
            "Scope 126 144--*--Recipient or donor",
            "Procedure 236 252--*--liver transplant",
            "Person 278 283--*--donor",
            "Qualifier 264 277--*--heart beating",
            "Negation 260 263--*--non",
            "Measurement 300 303--*--HCV",
            "Value 304 312--*--negative",
            "Qualifier 381 386--*--liver",
            "Measurement 329 332--*--HCV",
            "Value 333 341--*--positive",
            "Person 375 380--*--donor",
            "Measurement 343 350--*--HCV RNA",
            "Measurement 361 373--*--HCV antibody",
            "Measurement 354 357--*--PCR",
            "Scope 343 373--*--HCV RNA by PCR or HCV antibody",
            "Measurement 403 408--*--HbsAg",
            "Value 409 417--*--negative",
            "Measurement 434 439--*--HbsAg",
            "Value 440 448--*--positive",
            "Measurement 461 464--*--PCR",
            "Measurement 450 457--*--HBV DNA",
            "Measurement 468 480--*--HBV antibody",
            "Scope 450 480--*--HBV DNA by PCR or HBV antibody",
            "Person 482 487--*--donor",
            "Qualifier 488 493--*--liver",
            "Procedure 518 534--*--liver transplant",
            "Person 551 556--*--donor",
            "Value 557 567--*--> 70 years",
            "Person 571 574--*--age",
            "Condition 598 608--*--malignancy",
            "Condition 614 635--*--history of malignancy",
            "Temporal 637 660--*--within the past 5 years",
            "Condition 670 694--*--hepatocellular carcinoma",
            "Negation 663 669--*--except",
            "Measurement 702 715--*--UCSF Criteria",
            "Condition 720 725;753 775--*--basal cell carcinoma of skin",
            "Condition 744 775--*--squamous cell carcinoma of skin",
            "Qualifier 729 743--*--non-metastatic",
            "Mood 790 810--*--treated successfully",
            "Scope 670 775--*--hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin",
            "Condition 824 848--*--hemodynamically unstable",
            "Measurement 852 858--*--POD 15"
        ],
        "Text": "Patient has previously received or is receiving an organ transplant other than a liver.. Patient currently requires dialysis. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV). Patient has received a liver transplant from a non-heart beating donor. Patient who is HCV negative has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver. Patient who is HbsAg negative has received an HbsAg positive (HBV DNA by PCR or HBV antibody) donor liver. Patient has received a liver transplant from a decrease donor > 70 years of age. Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.. Patient is hemodynamically unstable on POD 15. "
    },
    "NCT03241368_exc": {
        "Text": "Subject has indeterminate, ulcerative, antibiotic-associated colitis. . Subject has stool positive for ova and parasite and for Clostridium difficule toxins within 3 months prior to enrollment. . Subject with other known infectious cause of abdominal symptoms. . Subject with clinical evidence of renal disease with the past 6 months, defined as estimated glomerular filtration rate (GFR) outside the normal reference range. . Subject with known history of intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting, based on investigator judgment. . Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility. . Subjects with a history of small bowel or colonic resection. . Subject with any current condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction, stricture, or fistula. . Subject has used non-steroidal anti-inflammatory drugs including aspirin, two times per week, during the 4 weeks preceding enrollment. Low dose aspirin regimens (< 100 mg daily) are acceptable and not exclusionary. . Subject suffers from any condition, such as swallowing problems, that precludes compliance with study and/or device instructions. . Subject with cardiac pacemaker or other implanted electromedical device. . Subject has an allergy or other known contraindication to the medications used in the study. . Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding. . Subject is considered to be a part of a vulnerable population (eg. prisoners or those without sufficient mental capacity). . Subject has a known contraindication to MRE or IC. . Subject has participated in a drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in the study. . Subject has any medical condition that would make it unsafe for them to participate, per Investigator's descretion       .     . ",
        "Annotations": [
            "Condition 61 68--*--colitis",
            "Observation 39 60--*--antibiotic-associated",
            "Observation 27 37--*--ulcerative",
            "Observation 12 25--*--indeterminate",
            "Measurement 83 88--*--stool",
            "Value 89 105--*--positive for ova",
            "Value 110 118;89 101--*--parasite positive for",
            "Value 127 155;89 101--*--Clostridium difficule toxins positive for",
            "Temporal 156 177--*--within 3 months prior",
            "Reference_point 181 191--*--enrollment",
            "Context_Error 207 257--*--other known infectious cause of abdominal symptoms",
            "Condition 294 307--*--renal disease",
            "Temporal 308 330--*--with the past 6 months",
            "Measurement 343 385--*--estimated glomerular filtration rate (GFR)",
            "Value 386 393--*--outside",
            "Reference_point 398 420--*--normal reference range",
            "Condition 453 475--*--intestinal obstruction",
            "Observation 442 449--*--history",
            "Condition 487 507--*--obstructive symptoms",
            "Temporal 479 486--*--current",
            "Condition 517 538--*--severe abdominal pain",
            "Condition 557 563--*--nausea",
            "Condition 567 575--*--vomiting",
            "Condition 638 651--*--gastroparesis",
            "Condition 655 666--*--small bowel",
            "Condition 670 693--*--large bowel dysmotility",
            "Condition 723 734;746 755--*--small bowel resection",
            "Condition 738 755--*--colonic resection",
            "Observation 712 719--*--history",
            "Undefined_semantics 783 848--*--condition believed to have an increased risk of capsule retention",
            "Drug 936 973--*--non-steroidal anti-inflammatory drugs",
            "Drug 984 991--*--aspirin",
            "Multiplier 993 1011--*--two times per week",
            "Temporal 1013 1041--*--during the 4 weeks preceding",
            "Reference_point 1042 1052--*--enrollment",
            "Drug 1063 1070--*--aspirin",
            "Multiplier 1081 1095--*--< 100 mg daily",
            "Qualifier 1054 1062--*--Low dose",
            "Grammar_Error 1116 1132--*--not exclusionary",
            "Condition 1160 1169--*--condition",
            "Condition 1179 1198--*--swallowing problems",
            "Negation 1205 1214--*--precludes",
            "Informed_consent 1215 1236--*--compliance with study",
            "Informed_consent 1215 1230;1244 1263--*--compliance with device instructions",
            "Scope 1215 1263--*--compliance with study and/or device instructions",
            "Scope 1160 1198--*--condition, such as swallowing problems",
            "Device 1279 1296--*--cardiac pacemaker",
            "Device 1306 1337--*--implanted electromedical device",
            "Condition 1355 1362--*--allergy",
            "Condition 1378 1394--*--contraindication",
            "Drug 1402 1431--*--medications used in the study",
            "Scope 1355 1394--*--allergy or other known contraindication",
            "Condition 1445 1453--*--pregnant",
            "Value 1471 1479--*--positive",
            "Measurement 1480 1494--*--pregnancy test",
            "Qualifier 1502 1510--*--actively",
            "Temporal 1502 1510--*--actively",
            "Observation 1511 1525--*--breast-feeding",
            "Person 1558 1589--*--part of a vulnerable population",
            "Person 1595 1604--*--prisoners",
            "Condition 1614 1648--*--without sufficient mental capacity",
            "Scope 1595 1648--*--prisoners or those without sufficient mental capacity",
            "Condition 1672 1688--*--contraindication",
            "Procedure 1692 1695--*--MRE",
            "Procedure 1699 1701--*--IC",
            "Scope 1692 1701--*--MRE or IC",
            "Competing_trial 1704 1877--*--Subject has participated in a drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in the study.",
            "Non-representable 1879 1993--*--Subject has any medical condition that would make it unsafe for them to participate, per Investigator's descretion"
        ]
    },
    "NCT01320579_inc": {
        "Text": "Informed consent obtained prior to any screening procedure . Caucasian male or female patient . At least 18 years of age . Weight at least 45 kg . Patient with moderate or severe chronic atopic dermatitis . Good general health ascertained by medical history, physical examination and laboratory determinations, showing no signs of clinically significant findings, except chronic atopic dermatitis . Negative pregnancy test (premenopausal female patient) at screening and use of adequate contraceptive measures (both male and female patients) throughout the study and 30 days after the last cis-UCA dose . ",
        "Annotations": [
            "Post-eligibility 0 58--*--Informed consent obtained prior to any screening procedure",
            "Person 60 69--*--Caucasian",
            "Person 70 74--*--male",
            "Person 78 84--*--female",
            "Value 94 111--*--At least 18 years",
            "Person 115 118--*--age",
            "Measurement 120 126--*--Weight",
            "Value 127 141--*--at least 45 kg",
            "Condition 175 200--*--chronic atopic dermatitis",
            "Qualifier 168 174--*--severe",
            "Qualifier 156 164--*--moderate",
            "Scope 156 174--*--moderate or severe",
            "Condition 202 221--*--Good general health",
            "Observation 237 252--*--medical history",
            "Procedure 254 274--*--physical examination",
            "Procedure 279 304--*--laboratory determinations",
            "Negation 314 316--*--no",
            "Observation 317 357--*--signs of clinically significant findings",
            "Qualifier 326 348--*--clinically significant",
            "Subjective_judgement 326 348--*--clinically significant",
            "Condition 366 391--*--chronic atopic dermatitis",
            "Negation 359 365--*--except",
            "Qualifier 222 304--*--ascertained by medical history, physical examination and laboratory determinations",
            "Measurement 402 416--*--pregnancy test",
            "Value 393 401--*--Negative",
            "Condition 418 431--*--premenopausal",
            "Person 432 438--*--female",
            "Scope 418 438--*--premenopausal female",
            "Post-eligibility 393 596--*--Negative pregnancy test (premenopausal female patient) at screening and use of adequate contraceptive measures (both male and female patients) throughout the study and 30 days after the last cis-UCA dose"
        ]
    },
    "NCT03465397_inc": {
        "Text": "Adult men and women (=18 years).. Receptors of a first kidney transplant from an incompatible HLA living donor (at least 1 mismatch HLA at any antigenic level).. AB0 compatible transplant.. Patients with a calculated PRA of 0% by solid phase technique and absence of anti-HLA class I and class II antibodies by single antigen test (Luminex\u00ae).. Patients who agree to participate in the Trial by signing the Specific Informed Consent of this study.. Potentially fertile women should use high reliability contraceptive methods (Pearl-Index <1) in order to avoid pregnancy during the entire duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF). Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who is not post-menopausal (defined as amenorrhea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml). Potentially fertile women must have a pregnancy test with a negative result in the 72 hours prior to the start of the trial.. Sexually active males (including vasectomized males) who are being treated with MMF must accept the use of barrier contraceptive methods during MMF treatment and for 90 days thereafter. Potentially fertile partners of these patients should use a reliable contraceptive method during the same period, in order to minimize the risk of pregnancy.. Patients must agree not to donate blood during treatment with MMF and during the 6 subsequent weeks. Males should not make a sperm donation during MMF treatment and up to 90 days after completion.. ",
        "Annotations": [
            "Person 6 9--*--men",
            "Person 0 5--*--Adult",
            "Person 14 19--*--women",
            "Value 21 30--*--=18 years",
            "Person 25 30--*--years",
            "Procedure 49 72--*--first kidney transplant",
            "Qualifier 81 97--*--incompatible HLA",
            "Qualifier 98 110--*--living donor",
            "Multiplier 112 122--*--at least 1",
            "Observation 123 135--*--mismatch HLA",
            "Qualifier 162 176--*--AB0 compatible",
            "Procedure 177 187--*--transplant",
            "Measurement 206 220--*--calculated PRA",
            "Value 224 226--*--0%",
            "Qualifier 230 251--*--solid phase technique",
            "Procedure 311 341--*--single antigen test (Luminex\u00ae)",
            "Observation 256 283--*--absence of anti-HLA class I",
            "Observation 256 266;288 296--*--absence of class II",
            "Scope 256 296--*--absence of anti-HLA class I and class II",
            "Informed_consent 344 446--*--Patients who agree to participate in the Trial by signing the Specific Informed Consent of this study.",
            "Pregnancy_considerations 448 1228--*--Potentially fertile women should use high reliability contraceptive methods (Pearl-Index <1) in order to avoid pregnancy during the entire duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF). Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who is not post-menopausal (defined as amenorrhea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml). Potentially fertile women must have a pregnancy test with a negative result in the 72 hours prior to the start of the trial.",
            "Pregnancy_considerations 1230 1573--*--Sexually active males (including vasectomized males) who are being treated with MMF must accept the use of barrier contraceptive methods during MMF treatment and for 90 days thereafter. Potentially fertile partners of these patients should use a reliable contraceptive method during the same period, in order to minimize the risk of pregnancy.",
            "Non-query-able 1575 1771--*--Patients must agree not to donate blood during treatment with MMF and during the 6 subsequent weeks. Males should not make a sperm donation during MMF treatment and up to 90 days after completion."
        ]
    },
    "NCT03126214_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 65 years",
            "Multiplier 20 34--*--one additional",
            "Condition 42 53--*--risk factor",
            "Condition 35 41--*--stroke",
            "Condition 55 67--*--hypertension",
            "Condition 69 77--*--diabetes",
            "Condition 79 92--*--heart failure",
            "Measurement 107 141--*--left ventricular ejection fraction",
            "Value 142 147--*--<0.40",
            "Observation 93 100--*--history",
            "Temporal 150 158--*--previous",
            "Condition 159 165--*--stroke",
            "Condition 169 194--*--transient ischemic attack",
            "Scope 159 194--*--stroke or transient ischemic attack",
            "Scope 55 194--*--hypertension, diabetes, heart failure history of or left ventricular ejection fraction <0.40), previous stroke or transient ischemic attack",
            "Scope 35 53--*--stroke risk factor",
            "Condition 198 217--*--Atrial fibrillation",
            "Measurement 222 225--*--not",
            "Procedure 229 263--*--oral anticoagulation (OAC) therapy",
            "Non-representable 264 276--*--but eligible",
            "Condition 278 297--*--Atrial fibrillation",
            "Procedure 313 316--*--OAC",
            "Qualifier 301 312--*--sub-optimal"
        ],
        "Text": "Age = 65 years with one additional stroke risk factor (hypertension, diabetes, heart failure history of or left ventricular ejection fraction <0.40), previous stroke or transient ischemic attack).. Atrial fibrillation and not on oral anticoagulation (OAC) therapy but eligible. Atrial fibrillation on sub-optimal OAC. "
    },
    "NCT02862314_exc": {
        "Annotations": [
            "Condition 0 9--*--pregnancy",
            "Person 27 40--*--legal custody",
            "Negation 52 59--*--without",
            "Person 60 76--*--health insurance",
            "Competing_trial 79 211--*--patients included in another interventional clinical study involving infections or antibiotics and having the same primary parameter",
            "Condition 214 222--*--moribund",
            "Measurement 257 284--*--procalcitonin concentration",
            "Qualifier 294 303--*--increased",
            "Condition 350 366--*--poly-traumatised",
            "Procedure 378 400--*--surgical interventions",
            "Temporal 412 423--*--last 4 days",
            "Condition 426 450--*--cardiorespiratory arrest",
            "Drug 471 494--*--anti-thymocyte globulin",
            "Condition 497 512--*--immunodepressed",
            "Procedure 523 545--*--bone marrow transplant",
            "Condition 570 588--*--severe neutropenia",
            "Scope 523 588--*--bone marrow transplant patients, patients with severe neutropenia",
            "Visit 680 683--*--ICU",
            "Drug 651 662--*--antibiotics",
            "Condition 695 705--*--meningitis",
            "Condition 707 716--*--pneumonia",
            "Condition 618 628--*--indication",
            "Scope 695 716--*--meningitis, pneumonia",
            "Condition 723 740--*--chronic infection",
            "Qualifier 751 760--*--long-term",
            "Procedure 761 781--*--antibiotic treatment",
            "Condition 796 808--*--endocarditis",
            "Condition 810 836--*--osteo-articular infections",
            "Condition 838 851--*--mediastinitis",
            "Condition 853 867--*--deep abscesses",
            "Condition 869 891--*--pneumocystis infection",
            "Condition 893 906--*--toxoplasmosis",
            "Condition 908 920--*--tuberculosis",
            "Scope 795 920--*--(endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis",
            "Condition 965 971--*--septic",
            "Condition 937 961--*--haemodynamic instability",
            "Condition 985 1009--*--espiratory insufficiency",
            "Measurement 1030 1039--*--Pa02/Fi02",
            "Value 1040 1050--*--= 200 mmHg",
            "Measurement 1055 1058--*--PEP",
            "Value 1059 1068--*--= 5 cmH2O",
            "Scope 1030 1068--*--Pa02/Fi02 = 200 mmHg and PEP = 5 cmH2O"
        ],
        "Text": "pregnancy,. patients under legal custody,. patients without health insurance,. patients included in another interventional clinical study involving infections or antibiotics and having the same primary parameter,. moribund patients,. situation in which the procalcitonin concentration could be increased without correlation to an infectious process (poly-traumatised patients,. surgical interventions within the last 4 days,. cardiorespiratory arrest,. administration of anti-thymocyte globulin,. immunodepressed patients (bone marrow transplant patients, patients with severe neutropenia),. patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis). patients with haemodynamic instability of septic origin or a respiratory insufficiency (defined by a ratio Pa02/Fi02 = 200 mmHg and PEP = 5 cmH2O). "
    },
    "NCT02918409_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Person 29 32--*--age",
            "Temporal 33 44--*--at Visit 1.",
            "Reference_point 36 43--*--Visit 1",
            "Value 15 25--*--= 18 years",
            "Measurement 46 60--*--Sweat chloride",
            "Value 61 91--*--equal or greater than 60 mEq/L",
            "Measurement 95 138--*--quantitative pilocarpine iontophoresis test",
            "Multiplier 141 144--*--Two",
            "Condition 164 173--*--mutations",
            "Condition 181 232;240 244--*--cystic fibrosis transmembrane conductance regulator gene",
            "Condition 234 238--*--CFTR",
            "Measurement 255 281--*--nasal potential difference",
            "Measurement 283 286--*--NPD",
            "Value 246 254--*--Abnormal",
            "Value 379 394--*--less than -5 mV",
            "Non-query-able 288 378--*--as measured by a change in NPD in response to a low chloride solution and isoproterenol of",
            "Condition 433 461--*--acute pulmonary exacerbation",
            "Measurement 472 496--*--CF Foundation guidelines",
            "Non-query-able 498 561--*--as diagnosed by a faculty member of the Denver Adult CF Program",
            "Measurement 564 586--*--Respiratory culture(s)",
            "Value 613 635--*--Pseudomonas aeruginosa",
            "Value 639 660--*--Achromobacter species",
            "Scope 613 660--*--Pseudomonas aeruginosa or Achromobacter species",
            "Condition 661 677--*--airway infection",
            "Post-eligibility 680 763--*--Subject is able to produce sputum, undergo phlebotomy, and provide written consent.",
            "Post-eligibility 765 1290--*--The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment. Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms. If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin"
        ],
        "Text": "Male or female = 18 years of age at Visit 1.. Sweat chloride equal or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test.. Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Abnormal nasal potential difference (NPD) as measured by a change in NPD in response to a low chloride solution and isoproterenol of less than -5 mV.. Documentation of the presence of an acute pulmonary exacerbation, based on CF Foundation guidelines, as diagnosed by a faculty member of the Denver Adult CF Program.. Respiratory culture(s) demonstrating evidence of Pseudomonas aeruginosa or Achromobacter species airway infection.. Subject is able to produce sputum, undergo phlebotomy, and provide written consent.. The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment. Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms. If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin.. "
    },
    "NCT03045562_inc": {
        "Text": "Informed consent must be obtained prior to any study procedure.. Age>18 years.. Subjects of STEMI who underwent primary PCI within the first 12 hours.. ",
        "Annotations": [
            "Post-eligibility 0 62--*--Informed consent must be obtained prior to any study procedure",
            "Person 65 68--*--Age",
            "Value 68 78--*-->18 years.",
            "Condition 92 97--*--STEMI",
            "Procedure 112 123--*--primary PCI",
            "Temporal 124 150--*--within the first 12 hours."
        ]
    },
    "NCT03263481_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03481894_exc": {
        "Text": "Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients. Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration >1,000 g/dL).. Inborn errors of amino acid metabolism. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support). Hemophagocytic syndrome.. PN in the last 7 days prior to study enrollment.. Need for chronic PN before study start. Liver enzymes (either AST, ALT, GGPT), or direct bilirubin exceeding 2 x upper limit of normal range. Pathologically altered level of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate) unless corrected prior to the start of study treatment. Pathologically altered blood pH, or oxygen saturation, or carbon dioxide unless corrected prior to the start of study treatment. Pregnancy or lactation. Participation in another clinical study. ",
        "Annotations": [
            "Condition 6 22--*--hypersensitivity",
            "Drug 26 29--*--egg",
            "Drug 31 47--*--soybean proteins",
            "Drug 49 64--*--peanut proteins",
            "Drug 66 70--*--corn",
            "Drug 74 87--*--corn products",
            "Drug 106 123--*--active substances",
            "Drug 127 137--*--excipients",
            "Scope 26 137--*--egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients",
            "Condition 146 160--*--hyperlipidemia",
            "Qualifier 139 145--*--Severe",
            "Qualifier 164 170--*--severe",
            "Condition 171 200--*--disorders of lipid metabolism",
            "Condition 218 238--*--hypertriglyceridemia",
            "Measurement 240 272--*--serum triglyceride concentration",
            "Value 273 284--*-->1,000 g/dL",
            "Condition 288 326--*--Inborn errors of amino acid metabolism",
            "Condition 328 355--*--Cardiopulmonary instability",
            "Condition 367 382--*--pulmonary edema",
            "Condition 384 405--*--cardiac insufficiency",
            "Condition 407 428--*--myocardial infarction",
            "Condition 430 438--*--acidosis",
            "Condition 443 466--*--hemodynamic instability",
            "Qualifier 489 508--*--vasopressor support",
            "Qualifier 477 488--*--significant",
            "Drug 489 500--*--vasopressor",
            "Scope 367 508--*--pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support",
            "Condition 511 534--*--Hemophagocytic syndrome",
            "Procedure 537 539--*--PN",
            "Temporal 540 584--*--in the last 7 days prior to study enrollment",
            "Reference_point 568 584--*--study enrollment",
            "Procedure 596 606--*--chronic PN",
            "Temporal 607 625--*--before study start",
            "Reference_point 614 625--*--study start",
            "Measurement 627 640--*--Liver enzymes",
            "Measurement 649 652--*--AST",
            "Measurement 654 657--*--ALT",
            "Measurement 659 663--*--GGPT",
            "Measurement 669 685--*--direct bilirubin",
            "Value 686 727--*--exceeding 2 x upper limit of normal range",
            "Scope 649 663--*--AST, ALT, GGPT",
            "Scope 627 685--*--Liver enzymes (either AST, ALT, GGPT), or direct bilirubin",
            "Value 729 751--*--Pathologically altered",
            "Measurement 752 782--*--level of any serum electrolyte",
            "Measurement 784 790--*--sodium",
            "Measurement 792 801--*--potassium",
            "Measurement 803 812--*--magnesium",
            "Measurement 814 821--*--calcium",
            "Measurement 823 831--*--chloride",
            "Measurement 833 842--*--phosphate",
            "Scope 784 842--*--sodium, potassium, magnesium, calcium, chloride, phosphate",
            "Non-representable 844 898--*--unless corrected prior to the start of study treatment",
            "Value 900 922--*--Pathologically altered",
            "Measurement 923 931--*--blood pH",
            "Measurement 936 953--*--oxygen saturation",
            "Measurement 958 972--*--carbon dioxide",
            "Scope 923 972--*--blood pH, or oxygen saturation, or carbon dioxide",
            "Condition 1042 1051--*--lactation",
            "Condition 1029 1038--*--Pregnancy",
            "Competing_trial 1053 1092--*--Participation in another clinical study"
        ]
    },
    "NCT02862314_inc": {
        "Annotations": [
            "Person 0 4--*--aged",
            "Value 5 16--*--18 or older",
            "Procedure 34 57--*--oro-tracheal intubation",
            "Condition 64 68--*--coma",
            "Measurement 70 88--*--Glasgow Coma Score",
            "Value 89 109--*--below or equal to 8)",
            "Procedure 117 139--*--mechanical ventilation",
            "Temporal 157 200--*--first 48 hours following hospital admission",
            "Reference_point 182 200--*--hospital admission"
        ],
        "Text": "aged 18 or older,. have undergone oro-tracheal intubation for a coma (Glasgow Coma Score below or equal to 8),. with mechanical ventilation initiated in the first 48 hours following hospital admission. "
    },
    "NCT03126214_exc": {
        "Annotations": [
            "Condition 13 25--*--hypertension",
            "Qualifier 0 12--*--Uncontrolled",
            "Measurement 38 49--*--average SBP",
            "Value 50 60--*--= 160 mmHg",
            "Multiplier 62 72--*--2 readings",
            "Temporal 79 99--*--at time of screening",
            "Reference_point 90 99--*--screening",
            "Scope 38 100--*--average SBP = 160 mmHg [2 readings taken at time of screening]",
            "Scope 0 25--*--Uncontrolled hypertension",
            "Condition 104 127--*--End stage renal disease",
            "Measurement 129 133--*--CrCl",
            "Value 134 145--*--< 15 ml/min",
            "Scope 129 145--*--CrCl < 15 ml/min",
            "Condition 148 170--*--Valvular Heart Disease",
            "Device 192 208--*--prosthetic valve",
            "Condition 210 225--*--mitral stenosis",
            "Qualifier 227 235--*--moderate",
            "Qualifier 239 245--*--severe",
            "Procedure 250 262--*--valve repair",
            "Scope 227 245--*--moderate to severe",
            "Measurement 272 286--*--alcohol intake",
            "Person 288 293--*--males",
            "Value 295 310--*--= 28 units/week",
            "Value 265 271--*--Excess",
            "Person 312 319--*--females",
            "Value 321 336--*--= 21 units/week",
            "Non-representable 338 400--*--One unit of alcohol = 8 oz beer, 1 oz hard liquor or 4 oz wine",
            "Scope 288 336--*--males: = 28 units/week, females: = 21 units/week",
            "Condition 404 422--*--Intracranial bleed",
            "Temporal 423 435--*--at any point",
            "Condition 450 464--*--Major Bleeding",
            "Temporal 466 478--*--at any point",
            "Observation 438 445--*--History",
            "Condition 491 505--*--overt bleeding",
            "Qualifier 511 524--*--critical site",
            "Qualifier 535 547--*--intracranial",
            "Qualifier 549 560--*--intraspinal",
            "Qualifier 562 573--*--intraocular",
            "Qualifier 575 586--*--pericardial",
            "Qualifier 591 606--*--retroperitoneal",
            "Condition 611 616--*--bleed",
            "Procedure 627 642--*--hospitalization",
            "Scope 535 606--*--intracranial, intraspinal, intraocular, pericardial, or retroperitoneal",
            "Scope 491 642--*--overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization",
            "Observation 660 675--*--life-expectancy",
            "Value 646 659--*--Foreshortened",
            "Condition 679 699--*--severe comorbidities",
            "Non-query-able 735 768--*--Unable to read/understand English",
            "Qualifier 770 776--*--Severe",
            "Condition 777 797--*--cognitive impairment",
            "Measurement 827 869--*--Short Portable Mental Status Questionnaire",
            "Value 816 819--*--= 5",
            "Scope 770 797--*--Severe cognitive impairment",
            "Scope 816 869--*--= 5 on the Short Portable Mental Status Questionnaire"
        ],
        "Text": "Uncontrolled hypertension (defined as average SBP = 160 mmHg [2 readings taken at time of screening]).. End stage renal disease (CrCl < 15 ml/min). Valvular Heart Disease including those with prosthetic valve, mitral stenosis (moderate to severe) or valve repair.. Excess alcohol intake (males: = 28 units/week, females: = 21 units/week. One unit of alcohol = 8 oz beer, 1 oz hard liquor or 4 oz wine).. Intracranial bleed at any point.. History of \"Major Bleeding\" at any point (defined as overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization).. Foreshortened life-expectancy or severe comorbidities precluding study follow-up period. Unable to read/understand English. Severe cognitive impairment (defined as score = 5 on the Short Portable Mental Status Questionnaire). "
    },
    "NCT02918409_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03481894_inc": {
        "Text": "Male or female patients 2 to 16 years of age. Patients who require at least 80% of their caloric intake as PN at study start, and in whom an indication for PN is expected for at least 5 days. Patients who require a central venous line to receive PN or already have a central venous line in place for other reasons. Written informed consent from legal representative(s). ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 24 37--*--2 to 16 years",
            "Person 41 44--*--age",
            "Value 67 82;89 103--*--at least 80% of caloric intake",
            "Procedure 107 109--*--PN",
            "Temporal 110 124--*--at study start",
            "Condition 141 151--*--indication",
            "Procedure 156 158--*--PN",
            "Multiplier 171 190--*--for at least 5 days",
            "Mood 162 170--*--expected",
            "Device 215 234--*--central venous line",
            "Procedure 246 248--*--PN",
            "Device 267 286--*--central venous line",
            "Observation 300 313--*--other reasons",
            "Informed_consent 315 368--*--Written informed consent from legal representative(s)"
        ]
    },
    "NCT03263481_inc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03045562_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT02579928_inc": {
        "Text": "MDD Cohort: Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.. Anxiety Cohort: Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating \u22654 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy. Stable psychiatric medications and doses for the month prior to enrollment. Subjects may continue to engage in any ongoing psychotherapy.. Medically and neurologically healthy on the basis of physical examination and medical history.. Parents able to provide written informed consent and adolescents must additionally provide assent.. ",
        "Annotations": [
            "Observation 0 10--*--MDD Cohort",
            "Qualifier 17 31--*--DSM-5 criteria",
            "Condition 36 61--*--Major Depressive Disorder",
            "Procedure 65 85--*--structured interview",
            "Procedure 87 95--*--MINI-KID",
            "Measurement 98 110--*--CDRS-R score",
            "Value 111 114--*-->40",
            "Negation 116 123--*--Failure",
            "Condition 135 144--*--remission",
            "Multiplier 150 160--*--at least 1",
            "Qualifier 161 169--*--adequate",
            "Procedure 176 196--*--antidepressant trial",
            "Drug 203 207--*--SSRI",
            "Temporal 170 175--*--prior",
            "Drug 209 213--*--SNRI",
            "Drug 218 221--*--TCA",
            "Scope 203 221--*--SSRI, SNRI, or TCA",
            "Multiplier 232 248--*--at least 8 weeks",
            "Procedure 252 270--*--therapeutic dosing",
            "Multiplier 282 298--*--at least 4 weeks",
            "Procedure 302 315--*--stable dosing",
            "Scope 232 315--*--at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing",
            "Scope 150 222--*--at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA)",
            "Observation 318 332--*--Anxiety Cohort",
            "Qualifier 339 353--*--DSM-5 criteria",
            "Condition 379 396--*--anxiety disorders",
            "Condition 398 422--*--Social Anxiety Disorders",
            "Condition 424 452--*--Generalized Anxiety Disorder",
            "Condition 454 481--*--Separation Anxiety Disorder",
            "Condition 489 503--*--Panic Disorder",
            "Procedure 507 527--*--structured interview",
            "Procedure 529 537--*--MINI-KID",
            "Scope 398 503--*--Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder",
            "Measurement 540 569--*--ADIS Clinical Severity Rating",
            "Value 570 572--*--\u22654",
            "Qualifier 574 591--*--moderately severe",
            "Scope 540 572--*--ADIS Clinical Severity Rating \u22654",
            "Condition 619 636--*--anxiety disorders",
            "Condition 657 666--*--remission",
            "Negation 638 645--*--Failure",
            "Multiplier 672 682--*--at least 1",
            "Qualifier 683 691--*--adequate",
            "Temporal 692 697--*--prior",
            "Procedure 698 725--*--anxiolytic medication trial",
            "Drug 698 719--*--anxiolytic medication",
            "Drug 176 190--*--antidepressant",
            "Drug 732 736--*--SSRI",
            "Drug 738 742--*--SNRI",
            "Drug 747 750--*--TCA",
            "Scope 732 750--*--SSRI, SNRI, or TCA",
            "Multiplier 761 777--*--at least 8 weeks",
            "Procedure 781 799--*--therapeutic dosing",
            "Multiplier 811 827--*--at least 4 weeks",
            "Procedure 831 844--*--stable dosing",
            "Temporal 880 888--*--previous",
            "Procedure 889 892;925 932--*--CBT therapy",
            "Observation 896 912--*--subject declines",
            "Temporal 913 920--*--current",
            "Procedure 921 932--*--CBT therapy",
            "Condition 865 874--*--remission",
            "Negation 846 853--*--Failure",
            "Scope 880 932--*--previous CBT or subject declines current CBT therapy",
            "Scope 761 844--*--at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing",
            "Scope 672 751--*--at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA)",
            "Scope 339 932--*--DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating \u22654 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy",
            "Scope 12 315--*--Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing",
            "Qualifier 934 940--*--Stable",
            "Drug 941 964--*--psychiatric medications",
            "Multiplier 934 940;969 974--*--Stable doses",
            "Temporal 975 1008--*--for the month prior to enrollment",
            "Reference_point 998 1008--*--enrollment",
            "Non-representable 1010 1071--*--Subjects may continue to engage in any ongoing psychotherapy.",
            "Condition 1087 1109--*--neurologically healthy",
            "Condition 1073 1082;1102 1109--*--Medically healthy",
            "Procedure 1126 1146--*--physical examination",
            "Observation 1151 1166--*--medical history",
            "Scope 1126 1166--*--physical examination and medical history",
            "Scope 1073 1109--*--Medically and neurologically healthy",
            "Person 1169 1176--*--Parents",
            "Observation 1185 1217--*--provide written informed consent",
            "Person 1222 1233--*--adolescents",
            "Observation 1252 1266--*--provide assent"
        ]
    },
    "NCT02668978_exc": {
        "Text": "Traumatic pulmonary contusion or laceration. Lung reduction surgery. Planned removal of more than 10 lung lesions. Pneumonectomy. Known hypersensitivity to bovine protein. Known hypersensitivity to Brilliant Blue FCF (E133). Presence of active infection. ",
        "Annotations": [
            "Condition 10 29--*--pulmonary contusion",
            "Condition 33 43--*--laceration",
            "Qualifier 0 9--*--Traumatic",
            "Scope 10 43--*--pulmonary contusion or laceration",
            "Procedure 45 67--*--Lung reduction surgery",
            "Multiplier 88 100--*--more than 10",
            "Condition 101 113--*--lung lesions",
            "Mood 69 76--*--Planned",
            "Procedure 77 84--*--removal",
            "Procedure 115 128--*--Pneumonectomy",
            "Condition 136 152--*--hypersensitivity",
            "Drug 156 170--*--bovine protein",
            "Condition 178 194--*--hypersensitivity",
            "Drug 198 224--*--Brilliant Blue FCF (E133)",
            "Drug 198 223--*--Brilliant Blue FCF (E133)",
            "Condition 237 253--*--active infection"
        ]
    },
    "NCT03211741_exc": {
        "Annotations": [
            "Condition 14 22--*--pregnant",
            "Observation 26 39--*--breastfeeding",
            "Person 0 5--*--Women",
            "Measurement 161 189--*--human chorionic gonadotropin",
            "Procedure 161 205--*--human chorionic gonadotropin laboratory test",
            "Value 152 160--*--positive",
            "Value 207 216--*--> 5mIU/mL",
            "Condition 394 413--*--Tromboembolic event",
            "Condition 415 418--*--CVA",
            "Condition 422 447--*--transient ischemic attack",
            "Condition 449 452--*--AMI",
            "Scope 415 452--*--CVA or transient ischemic attack, AMI",
            "Temporal 454 523--*--less than 3 months prior to the intravitreal injection of bevacizumab",
            "Procedure 486 508--*--intravitreal injection",
            "Drug 512 523--*--bevacizumab",
            "Reference_point 482 523--*--the intravitreal injection of bevacizumab",
            "Condition 536 552--*--hypersensitivity",
            "Drug 557 568--*--bevacizumab",
            "Observation 525 532--*--History",
            "Person 219 224--*--Women",
            "Condition 228 251--*--child bearing potential",
            "Qualifier 271 280--*--effective",
            "Procedure 281 294--*--contraception",
            "Scope 219 251--*--Women of child bearing potential",
            "Temporal 307 323--*--during the trial",
            "Temporal 328 392--*--for at least 28 days following the last dose of study medication",
            "Multiplier 363 372--*--last dose",
            "Drug 376 392--*--study medication",
            "Reference_point 359 392--*--the last dose of study medication"
        ],
        "Text": "Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL). Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab. History of hypersensitivity for bevacizumab.. "
    },
    "NCT02984475_exc": {
        "Text": "Patients with renal impairment (serum creatinine more than twice the upper limit of normal).. Patients with heart failure.. Patients with sepsis or active infection.. Patients with diabetes mellitus (either primary or secondary to thalassemia).. regular consumption of medication with potential hepatotoxicity.. regular herbal medicine or antioxidant supplementation.. patients with gastrointestinal conditions preventing adsorption of oral medication.. ",
        "Annotations": [
            "Condition 14 30--*--renal impairment",
            "Measurement 32 48--*--serum creatinine",
            "Value 49 90--*--more than twice the upper limit of normal",
            "Condition 108 121--*--heart failure",
            "Condition 138 144--*--sepsis",
            "Condition 148 164--*--active infection",
            "Condition 181 198--*--diabetes mellitus",
            "Qualifier 207 214--*--primary",
            "Qualifier 218 242--*--secondary to thalassemia",
            "Scope 207 242--*--primary or secondary to thalassemia",
            "Condition 295 309--*--hepatotoxicity",
            "Drug 269 279--*--medication",
            "Drug 339 366--*--antioxidant supplementation",
            "Procedure 320 335--*--herbal medicine",
            "Non-query-able 369 452--*--patients with gastrointestinal conditions preventing adsorption of oral medication."
        ]
    },
    "NCT02764476_exc": {
        "Text": "Nonfluency or inability to communicate in English spoken language . Inability to participate or attend biweekly 30 minute session over 14 weeks . Frank psychosis . Active self harm urges . Serious medical illness . Active substance or alcohol use or dependence that could interfere with participation . Diagnoses of mental retardation, dementia or delirium . Pregnant women       .     . ",
        "Annotations": [
            "Non-query-able 0 65--*--Nonfluency or inability to communicate in English spoken language",
            "Non-query-able 67 142--*--Inability to participate or attend biweekly 30 minute session over 14 weeks",
            "Condition 150 159--*--psychosis",
            "Qualifier 144 149--*--Frank",
            "Condition 168 183--*--self harm urges",
            "Temporal 161 167--*--Active",
            "Condition 193 208--*--medical illness",
            "Qualifier 185 192--*--Serious",
            "Undefined_semantics 193 208--*--medical illness",
            "Subjective_judgement 185 192--*--Serious",
            "Undefined_semantics 185 192--*--Serious",
            "Condition 217 226;238 255--*--substance use or dependence",
            "Condition 230 255--*--alcohol use or dependence",
            "Subjective_judgement 256 295--*--that could interfere with participation",
            "Non-query-able 256 295--*--that could interfere with participation",
            "Condition 310 328--*--mental retardation",
            "Condition 330 338--*--dementia",
            "Condition 342 350--*--delirium",
            "Condition 352 360--*--Pregnant",
            "Person 361 366--*--women"
        ]
    },
    "NCT02323399_inc": {
        "Annotations": [
            "Person 10 13--*--age",
            "Value 17 41--*--between =12 and 16 years",
            "Context_Error 25 26--*--=",
            "Grammar_Error 43 52--*--inclusive",
            "Procedure 81 90--*--procedure",
            "Observation 65 90--*--scheduled for a procedure",
            "Procedure 116 136--*--neuraxial anesthesia",
            "Procedure 105 112;130 131--*--general t",
            "Scope 105 136--*--general or neuraxial anesthesia",
            "Procedure 189 202--*--physical exam",
            "Value 167 188--*--clinically acceptable",
            "Value 157 163--*--normal",
            "Scope 157 188--*--normal or clinically acceptable",
            "Condition 229 237--*--diabetes",
            "Qualifier 218 228--*--controlled",
            "Temporal 238 252--*--prior to entry",
            "Reference_point 247 252--*--entry",
            "Condition 265 269;279 288;296 310--*--mean diastolic blood pressure",
            "Condition 265 269;270 278;296 310--*--mean systolic blood pressure",
            "Value 316 323--*--78 mmHg",
            "Value 312 315;319 323--*--128 mmHg",
            "Qualifier 325 332--*--sitting",
            "Temporal 334 357--*--after 5 minutes of rest",
            "Reference_point 353 357--*--rest",
            "Scope 265 332--*--mean systolic/diastolic office blood pressure =128/78 mmHg (sitting",
            "Measurement 389 409--*--serum pregnancy test",
            "Measurement 380 385;395 409--*--urine pregnancy test",
            "Measurement 411 439--*--Human Chorionic Gonadotropin",
            "Value 449 457--*--negative",
            "Temporal 458 470--*--at Screening",
            "Temporal 475 480--*--Day 1",
            "Scope 380 440--*--urine or serum pregnancy test (Human Chorionic Gonadotropin)",
            "Scope 458 480--*--at Screening and Day 1",
            "Post-eligibility 482 565--*--Subject's parent or legal guardian gives informed consent and subject gives assent."
        ],
        "Text": "Subject's age is between =12 and 16 years, inclusive. Subject is scheduled for a procedure that requires general or neuraxial anesthesia. Subjects must have normal or clinically acceptable physical exam. Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest). Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1. Subject's parent or legal guardian gives informed consent and subject gives assent.. "
    },
    "NCT03416413_exc": {
        "Text": "Current DVT. Recurrent varicose veins. Arterial disease (ABPI<0.8). Vein diameter < 3mm. Preference for one of the treatment options. Patient who are unwilling to participate. Inability or unwillingness to complete questionnaires. Inability to attend follow-up appointments. Patient currently included in a study of varicose vein treatment. ",
        "Annotations": [
            "Procedure 8 11--*--DVT",
            "Temporal 0 7--*--Current",
            "Condition 23 37--*--varicose veins",
            "Multiplier 13 22--*--Recurrent",
            "Condition 39 55--*--Arterial disease",
            "Measurement 57 61--*--ABPI",
            "Value 61 65--*--<0.8",
            "Scope 57 65--*--ABPI<0.8",
            "Measurement 68 81--*--Vein diameter",
            "Value 82 87--*--< 3mm",
            "Non-representable 89 132--*--Preference for one of the treatment options",
            "Observation 150 174--*--unwilling to participate",
            "Observation 189 229--*--unwillingness to complete questionnaires",
            "Observation 176 185;203 229--*--Inability to complete questionnaires",
            "Observation 231 273--*--Inability to attend follow-up appointments",
            "Competing_trial 275 339--*--Patient currently included in a study of varicose vein treatment"
        ]
    },
    "NCT03288428_inc": {
        "Text": "elective Laparoscopic myomectomy patients 24hr post-operative patient controlled analgesia analgesia no mild or severe liver or renal disfunction. ",
        "Annotations": [
            "Qualifier 9 21--*--Laparoscopic",
            "Procedure 22 32--*--myomectomy",
            "Qualifier 0 8--*--elective",
            "Line 0 41--*--elective Laparoscopic myomectomy patients",
            "Line 42 61--*--24hr post-operative",
            "Line 62 100--*--patient controlled analgesia analgesia",
            "Line 101 145--*--no mild or severe liver or renal disfunction",
            "Temporal 42 61--*--24hr post-operative",
            "Procedure 62 90--*--patient controlled analgesia",
            "Non-representable 91 100--*--analgesia",
            "Negation 101 103--*--no",
            "Qualifier 104 108--*--mild",
            "Qualifier 112 118--*--severe",
            "Condition 128 145--*--renal disfunction",
            "Condition 119 124;134 145--*--liver disfunction",
            "Scope 119 145--*--liver or renal disfunction",
            "Scope 104 118--*--mild or severe"
        ]
    },
    "NCT02429583_exc": {
        "Annotations": [
            "Procedure 13 20--*--vaccine",
            "Temporal 21 58--*--within a month prior to study vaccine",
            "Reference_point 45 58--*--study vaccine",
            "Measurement 69 83--*--serum antibody",
            "Qualifier 92 112--*--Hep B surface antige",
            "Qualifier 121 144--*--core Hep B core antigen",
            "Scope 92 144--*--Hep B surface antigen and/or core Hep B core antigen",
            "Value 60 68--*--Positive",
            "Measurement 146 149--*--HIV",
            "Value 150 158--*--positive",
            "Measurement 164 167--*--HCV",
            "Value 168 176--*--negative",
            "Observation 198 222--*--History of HCV infection",
            "Competing_trial 254 405--*--Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study",
            "Post-eligibility 407 502--*--In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol",
            "Condition 607 623--*--immunodeficiency",
            "Condition 627 645--*--autoimmune disease",
            "Negation 647 661--*--in addition to",
            "Condition 662 675--*--HCV infection",
            "Drug 710 727--*--systemic steroids",
            "Procedure 737 765--*--immunomodulatory medications",
            "Procedure 776 798--*--anticancer medications",
            "Procedure 803 824--*--antiviral medications",
            "Scope 776 824--*--anticancer medications and antiviral medications",
            "Condition 937 945--*--diabetes",
            "Condition 947 970--*--coronary artery disease",
            "Condition 972 993--*--rheumatologic illness",
            "Condition 995 1005--*--malignancy",
            "Condition 1007 1022--*--substance abuse",
            "Post-eligibility 1096 1142--*--Unable to continue participation for 156 weeks",
            "Procedure 1164 1187--*--Hepatitis B vaccination",
            "Person 1192 1196--*--Male",
            "Person 1200 1206--*--female",
            "Value 1207 1226--*--< 18 and > 62 years",
            "Person 1230 1233--*--age",
            "Pregnancy_considerations 1235 1259--*--Is pregnant or lactating",
            "Condition 1272 1293--*--Hepatitis B infection",
            "Condition 1339 1348--*--cirrhosis"
        ],
        "Text": "Received any vaccine within a month prior to study vaccine. Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen. HIV positive. For HCV-negative, healthy volunteers: History of HCV infection or positive HCV antibody test. Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study. In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol. Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group). Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications. Any clinically significant acute or chronic medical condition requiring care by a primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation. Unable to continue participation for 156 weeks. History of previous Hepatitis B vaccination(s). Male or female < 18 and > 62 years of age. Is pregnant or lactating. History of Hepatitis B infection. Clinical, laboratory, or biopsy evidence of cirrhosis. "
    },
    "NCT03589105_exc": {
        "Annotations": [
            "Condition 21 35--*--progressive MS",
            "Qualifier 13 20--*--primary",
            "Procedure 62 65--*--MRI",
            "Mood 37 58--*--Inability to complete",
            "Condition 67 84--*--contraindications",
            "Procedure 89 92--*--MRI",
            "Measurement 127 133--*--weight",
            "Value 134 141--*--=140 kg",
            "Device 143 152--*--pacemaker",
            "Device 154 171--*--cochlear implants",
            "Device 185 214--*--foreign substances in the eye",
            "Device 216 243--*--intracranial vascular clips",
            "Procedure 245 252--*--surgery",
            "Temporal 253 291--*--within 6 weeks of entry into the study",
            "Reference_point 271 291--*--entry into the study",
            "Device 293 307--*--coronary stent",
            "Procedure 308 317--*--implanted",
            "Temporal 318 370--*--within 8 weeks prior to the time of the intended MRI",
            "Reference_point 342 370--*--the time of the intended MRI",
            "Procedure 367 370--*--MRI",
            "Mood 358 366--*--intended",
            "Scope 127 370--*--weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI",
            "Scope 67 92--*--contraindications for MRI",
            "Scope 67 370--*--contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI",
            "Scope 37 65--*--Inability to complete an MRI",
            "Condition 390 401--*--intolerance",
            "Drug 379 389--*--Gadolinium",
            "Condition 414 448--*--ischemic cerebrovascular disorders",
            "Condition 456 462--*--stroke",
            "Condition 464 489--*--transient ischemic attack",
            "Condition 494 521--*--ischemia of the spinal cord",
            "Scope 456 489--*--stroke, transient ischemic attack",
            "Condition 552 580;596 601--*--central nervous system (CNS) tumor",
            "Condition 584 601--*--spinal cord tumor",
            "Condition 609 619--*--meningioma",
            "Condition 621 627--*--glioma",
            "Scope 609 627--*--meningioma, glioma",
            "Scope 552 600--*--central nervous system (CNS) or spinal cord tumo",
            "Condition 689 699--*--myelopathy",
            "Condition 669 685--*--metabolic causes",
            "Condition 717 739--*--vitamin B12 deficiency",
            "Qualifier 707 716--*--untreated",
            "Scope 669 699--*--metabolic causes of myelopathy",
            "Scope 707 739--*--untreated vitamin B12 deficiency",
            "Condition 771 788--*--infectious causes",
            "Condition 792 802--*--myelopathy",
            "Condition 810 818--*--syphilis",
            "Condition 820 832--*--Lyme disease",
            "Condition 834 871--*--human T-lymphotropic virus 1 (HTLV-1)",
            "Condition 873 897--*--herpes zoster myelopathy",
            "Scope 810 897--*--syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy",
            "Scope 771 802--*--infectious causes of myelopathy",
            "Condition 933 970--*--progressive CNS degenerative disorder",
            "Qualifier 911 932--*--genetically inherited",
            "Condition 978 1000--*--hereditary paraparesis",
            "Condition 1009 1031--*--mitochondrial myopathy",
            "Condition 1033 1047--*--encephalopathy",
            "Condition 1049 1064--*--lactic acidosis",
            "Condition 1066 1072--*--stroke",
            "Condition 1002 1007;1074 1082--*--MELAS syndrome",
            "Scope 1009 1072--*--mitochondrial myopathy, encephalopathy, lactic acidosis, stroke",
            "Scope 978 1082--*--hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome",
            "Scope 911 970--*--genetically inherited progressive CNS degenerative disorder",
            "Condition 1085 1105--*--Neuromyelitis optica",
            "Observation 1107 1114--*--History",
            "Condition 1136 1165--*--systemic autoimmune disorders",
            "Condition 1186 1216--*--progressive neurologic disease",
            "Mood 1166 1185--*--potentially causing",
            "Condition 1224 1229--*--lupus",
            "Condition 1231 1266--*--anti-phospholipid antibody syndrome",
            "Condition 1268 1286--*--Sjogren's syndrome",
            "Condition 1288 1304--*--Beh\u00e7et's disease",
            "Condition 1306 1317--*--sarcoidosis",
            "Scope 1224 1317--*--lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Beh\u00e7et's disease, sarcoidosis",
            "Scope 1136 1216--*--systemic autoimmune disorders potentially causing progressive neurologic disease",
            "Qualifier 1331 1337--*--severe",
            "Qualifier 1339 1361--*--clinically significant",
            "Condition 1371 1389--*--spinal cord trauma",
            "Condition 1362 1367;1383 1389--*--brain trauma",
            "Scope 1362 1389--*--brain or spinal cord trauma",
            "Condition 1397 1415--*--cerebral contusion",
            "Condition 1417 1440--*--spinal cord compression",
            "Scope 1397 1440--*--cerebral contusion, spinal cord compression",
            "Scope 1331 1389--*--severe, clinically significant brain or spinal cord trauma",
            "Observation 1443 1462--*--Vulnerable patients",
            "Qualifier 1487 1567--*--Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code"
        ],
        "Text": "Diagnosis of primary progressive MS. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc\u2026). Gadolinium intolerance. History of ischemic cerebrovascular disorders (e.g., stroke, transient ischemic attack) or ischemia of the spinal cord. History or known presence of central nervous system (CNS) or spinal cord tumor (e.g., meningioma, glioma). History or known presence of potential metabolic causes of myelopathy (e.g., untreated vitamin B12 deficiency). History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy). History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome). Neuromyelitis optica. History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Beh\u00e7et's disease, sarcoidosis). History of severe, clinically significant brain or spinal cord trauma (e.g., cerebral contusion, spinal cord compression). Vulnerable patients (Patient referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code). "
    },
    "NCT02652572_inc": {
        "Text": "1. Age 18 years or older . 2. Diagnosis of venous leg ulcer(s), as clinically determined by the investigator by a positive venous reflux test (venous refilling <20 seconds) using Doppler ultrasound for at least 4 weeks prior to screening day, which have not adequately responded to conventional ulcer therapy. . 3. Designated venous leg ulcer meets the following criteria at both the screening and baseline visits. If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits: . 1. Present for at least 4 weeks . 2. CEAP Classification Stage 6 . 3. Surface ulcer with an area > 15cm2 post debridement . 4. Viable, granulating wound (investigator discretion) . 4. Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET). . 5. Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of study drug . 6. Signed informed consent . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 26 28--*--2.",
            "Parsing_Error 310 312--*--3.",
            "Parsing_Error 545 547--*--1.",
            "Parsing_Error 578 580--*--2.",
            "Parsing_Error 610 612--*--3.",
            "Parsing_Error 666 668--*--4.",
            "Parsing_Error 722 724--*--4.",
            "Parsing_Error 860 862--*--5.",
            "Parsing_Error 1156 1158--*--6.",
            "Value 7 24--*--18 years or older",
            "Person 3 6--*--Age",
            "Condition 42 61--*--venous leg ulcer(s)",
            "Measurement 122 140--*--venous reflux test",
            "Value 113 121--*--positive",
            "Measurement 142 158--*--venous refilling",
            "Value 159 170--*--<20 seconds",
            "Procedure 178 196--*--Doppler ultrasound",
            "Temporal 201 240--*--at least 4 weeks prior to screening day",
            "Reference_point 227 240--*--screening day",
            "Observation 268 277--*--responded",
            "Negation 253 256--*--not",
            "Qualifier 257 267--*--adequately",
            "Procedure 281 307--*--conventional ulcer therapy",
            "Condition 324 340--*--venous leg ulcer",
            "Parsing_Error 313 412--*--Designated venous leg ulcer meets the following criteria at both the screening and baseline visits.",
            "Condition 441 447--*--ulcers",
            "Multiplier 432 440--*--multiple",
            "Multiplier 449 461--*--at least one",
            "Condition 462 467--*--ulcer",
            "Parsing_Error 413 543--*--If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits:",
            "Temporal 560 576--*--at least 4 weeks",
            "Qualifier 548 555--*--Present",
            "Measurement 581 600--*--CEAP Classification",
            "Value 601 608--*--Stage 6",
            "Condition 613 626--*--Surface ulcer",
            "Value 640 647--*--> 15cm2",
            "Measurement 635 639;648 664--*--area post debridement",
            "Qualifier 669 675--*--Viable",
            "Qualifier 677 688--*--granulating",
            "Condition 689 694--*--wound",
            "Subjective_judgement 696 719--*--investigator discretion",
            "Condition 725 731--*--Ulcers",
            "Qualifier 737 765--*--extend through the epidermis",
            "Qualifier 737 743;774 792--*--extend through the muscle",
            "Negation 770 773--*--not",
            "Value 811 826--*--Stage II or III",
            "Measurement 852 856--*--IAET",
            "Condition 827 833--*--ulcers",
            "Qualifier 737 743;774 785;794 800--*--extend through the tendon",
            "Qualifier 737 743;774 785;805 809--*--extend through the bone",
            "Scope 725 809--*--Ulcers that extend through the epidermis but not through the muscle, tendon, or bone",
            "Scope 737 809--*--extend through the epidermis but not through the muscle, tendon, or bone",
            "Condition 882 904--*--childbearing potential",
            "Measurement 926 940--*--pregnancy test",
            "Value 917 925--*--negative",
            "Temporal 941 953--*--at screening",
            "Reference_point 944 953--*--screening",
            "Drug 976 998--*--hormonal contraceptive",
            "Device 1000 1019--*--intrauterine device",
            "Device 1021 1046--*--diaphragm with spermicide",
            "Device 1048 1070--*--condom with spermicide",
            "Observation 1075 1085--*--abstinence",
            "Temporal 1086 1154--*--throughout until 2 weeks after the last administration of study drug",
            "Reference_point 1121 1154--*--last administration of study drug",
            "Person 863 869--*--Female",
            "Scope 863 904--*--Female patients of childbearing potential",
            "Scope 917 1085--*--negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence",
            "Post-eligibility 1159 1182--*--Signed informed consent",
            "Non-query-able 1159 1182--*--Signed informed consent"
        ]
    },
    "NCT02680054_exc": {
        "Annotations": [
            "Measurement 0 5--*--HbA1c",
            "Value 6 30--*--greater than 75 mmol/mol",
            "Value 32 36--*--9.0%",
            "Post-eligibility 39 106--*--Child unwilling to agree to second insulin injection at a meal-time",
            "Condition 118 133--*--coeliac disease",
            "Qualifier 108 117--*--Untreated",
            "Condition 194 208--*--Food allergies",
            "Negation 210 215--*--other",
            "Condition 232 247--*--Coeliac Disease",
            "Person 250 261--*--Vegetarians",
            "Procedure 379 408--*--glucose-containing medication"
        ],
        "Text": "HbA1c greater than 75 mmol/mol (9.0%). Child unwilling to agree to second insulin injection at a meal-time. Untreated coeliac disease or other concomitant condition likely to affect BG control. Food allergies (other than controlled Coeliac Disease). Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat). Participant taking any glucose-containing medication concurrently. "
    },
    "NCT00319748_exc": {
        "Text": "Had/have the following prior/concurrent therapy: . Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed) . Investigational drugs/agents within 14 days of first dose of 852A . Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose) . Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions . Radiotherapy within 3 weeks of the first dose of 852A . Hematopoietic cell transplantation within 4 weeks of first dose of 852A . Evidence of active infection within 3 days of first dose of 852A . Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable) . Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication . History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk . Uncontrolled intercurrent or chronic illness . Active autoimmune disease requiring immunosuppressive therapy within 30 days . Active coagulation disorder not controlled with medication . Pregnant or lactating . Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated . Any history of brain metastases or any other active central nervous system (CNS) disease       .     . ",
        "Annotations": [
            "Drug 50 74--*--Systemic corticosteroids",
            "Temporal 96 123--*--within 7 days of first dose",
            "Drug 127 131--*--852A",
            "Drug 133 140;152 160--*--topical steroids",
            "Drug 144 160--*--inhaled steroids",
            "Scope 133 172--*--topical or inhaled steroids are allowed",
            "Drug 175 203--*--Investigational drugs/agents",
            "Temporal 204 232--*--within 14 days of first dose",
            "Drug 236 240--*--852A",
            "Procedure 242 267--*--Immunosuppressive therapy",
            "Drug 279 295--*--cytotoxic agents",
            "Temporal 296 324--*--within 14 days of first dose",
            "Drug 328 332--*--852A",
            "Drug 334 346--*--nitrosoureas",
            "Temporal 347 375--*--within 30 days of first dose",
            "Drug 378 424--*--Drugs known to induce QT interval prolongation",
            "Drug 378 392;432 458--*--Drugs known to induce Torsades de pointes",
            "Scope 378 458--*--Drugs known to induce QT interval prolongation and/or induce Torsades de pointes",
            "Procedure 533 545--*--Radiotherapy",
            "Temporal 546 578--*--within 3 weeks of the first dose",
            "Drug 582 586--*--852A",
            "Procedure 588 622--*--Hematopoietic cell transplantation",
            "Temporal 623 651--*--within 4 weeks of first dose",
            "Drug 655 659--*--852A",
            "Condition 673 689--*--active infection",
            "Observation 661 669--*--Evidence",
            "Temporal 690 717--*--within 3 days of first dose",
            "Drug 721 725--*--852A",
            "Condition 734 750--*--fungal infection",
            "Condition 754 775--*--pulmonary infiltrates",
            "Condition 777 798--*--prior treated disease",
            "Qualifier 799 805--*--stable",
            "Temporal 806 817--*--for 2 weeks",
            "Scope 734 775--*--fungal infection or pulmonary infiltrates",
            "Condition 833 849--*--Cardiac ischemia",
            "Condition 851 870--*--cardiac arrhythmias",
            "Condition 874 898--*--congestive heart failure",
            "Qualifier 899 925--*--uncontrolled by medication",
            "Observation 927 934--*--History",
            "Observation 942 959--*--clinical evidence",
            "Condition 1019 1091;964 981--*--could confound the results of the study or put the subject at undue risk a condition which",
            "Scope 927 962--*--History of, or clinical evidence of",
            "Condition 1106 1118;1130 1137--*--intercurrent illness",
            "Condition 1122 1137--*--chronic illness",
            "Qualifier 1093 1105--*--Uncontrolled",
            "Condition 1146 1164--*--autoimmune disease",
            "Qualifier 1165 1174--*--requiring",
            "Procedure 1175 1200--*--immunosuppressive therapy",
            "Temporal 1201 1215--*--within 30 days",
            "Condition 1224 1244--*--coagulation disorder",
            "Temporal 1139 1145--*--Active",
            "Temporal 1217 1223--*--Active",
            "Qualifier 1249 1275--*--controlled with medication",
            "Negation 1245 1248--*--not",
            "Condition 1277 1285--*--Pregnant",
            "Condition 1289 1298--*--lactating",
            "Condition 1311 1321--*--malignancy",
            "Temporal 1300 1310--*--Concurrent",
            "Value 1340 1356--*--at least 5 years",
            "Qualifier 1357 1369--*--disease free",
            "Qualifier 1326 1338--*--in remission",
            "Condition 1382 1409--*--localized (in-situ) disease",
            "Condition 1411 1427--*--basal carcinomas",
            "Condition 1432 1466--*--cutaneous squamous cell carcinomas",
            "Qualifier 1482 1500--*--adequately treated",
            "Scope 1382 1466--*--localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas",
            "Condition 1517 1533--*--brain metastases",
            "Observation 1506 1516--*--history of",
            "Condition 1537 1546;1554 1590--*--any other central nervous system (CNS) disease",
            "Temporal 1547 1553--*--active",
            "Scope 1517 1590--*--brain metastases or any other active central nervous system (CNS) disease",
            "Negation 818 830--*--is allowable",
            "Scope 777 830--*--prior treated disease stable for 2 weeks is allowable",
            "Negation 1371 1381--*--except for",
            "Scope 1382 1500--*--localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated",
            "Negation 161 172--*--are allowed",
            "Scope 133 160--*--topical or inhaled steroids",
            "Non-representable 459 531--*--unless best available drug required to treat life-threatening conditions",
            "Qualifier 84 94--*--injectable",
            "Qualifier 76 80--*--oral",
            "Scope 76 94--*--oral or injectable"
        ]
    },
    "NCT02668978_inc": {
        "Text": "Patients over the age of 18 years who are able to give their informed consent. Lobar and sublobar resections. Open, video-assisted thoracoscopic or robotic surgeries. Diagnostic or therapeutic procedures. ",
        "Annotations": [
            "Person 9 33--*--over the age of 18 years",
            "Observation 42 77--*--able to give their informed consent",
            "Procedure 89 108--*--sublobar resections",
            "Procedure 79 84;98 108--*--Lobar resections",
            "Procedure 148 165--*--robotic surgeries",
            "Qualifier 116 130--*--video-assisted",
            "Procedure 131 144;156 165--*--thoracoscopic surgeries",
            "Scope 131 165--*--thoracoscopic or robotic surgeries",
            "Procedure 181 203--*--therapeutic procedures",
            "Procedure 167 177;193 203--*--Diagnostic procedures"
        ]
    },
    "NCT02579928_exc": {
        "Text": "Current inpatient hospitalization or active suicidal ideation requiring referral for inpatient hospitalization for safety.. History of psychotic disorder or manic episode diagnosed by MINI-KID. History of substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology.. Pregnancy (urine pregnancy tests on the day of scans for menstruating girls).. Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.. ",
        "Annotations": [
            "Temporal 0 7--*--Current",
            "Visit 8 17--*--inpatient",
            "Temporal 37 43--*--active",
            "Condition 44 61--*--suicidal ideation",
            "Procedure 72 80--*--referral",
            "Visit 85 110--*--inpatient hospitalization",
            "Procedure 18 33--*--hospitalization",
            "Mood 62 71--*--requiring",
            "Observation 124 131--*--History",
            "Condition 135 153--*--psychotic disorder",
            "Condition 157 170--*--manic episode",
            "Procedure 184 192--*--MINI-KID",
            "Scope 135 170--*--psychotic disorder or manic episode",
            "Observation 194 201--*--History",
            "Condition 205 225--*--substance dependence",
            "Procedure 239 247--*--MINI-KID",
            "Drug 259 266--*--tobacco",
            "Negation 249 258--*--excluding",
            "Value 271 279--*--positive",
            "Measurement 280 296--*--urine toxicology",
            "Scope 205 296--*--substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology",
            "Condition 299 308--*--Pregnancy",
            "Procedure 310 331--*--urine pregnancy tests",
            "Temporal 332 351--*--on the day of scans",
            "Person 356 374--*--menstruating girls",
            "Negation 378 398--*--Inability to provide",
            "Observation 399 423--*--written informed consent",
            "Qualifier 441 492--*--Yale Human Investigation Committee (HIC) guidelines",
            "Qualifier 493 503--*--in English"
        ]
    },
    "NCT02323399_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02764476_inc": {
        "Text": "Adults 18-65 years, who are diagnosed with functional neurologic symptom or conversion disorder. If diagnosis of seizure type then video EEG with diagnosis confirmed by board-certified neurologist with subspecialty training in epilepsy and clinical neurophysiology using the criteria of the International Classification of the Epilepsies is required. If diagnosis of motor type, documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required. . Participants must have at least one symptom per month in the month prior to enrollment . Fluency in English spoken language . ",
        "Annotations": [
            "Value 7 18--*--18-65 years",
            "Person 0 6--*--Adults",
            "Person 7 18--*--18-65 years",
            "Condition 43 72--*--functional neurologic symptom",
            "Condition 76 95--*--conversion disorder",
            "Condition 113 125--*--seizure type",
            "Procedure 131 140--*--video EEG",
            "Measurement 275 337--*--criteria of the International Classification of the Epilepsies",
            "Condition 367 377--*--motor type",
            "Non-query-able 379 504--*--documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required.",
            "Condition 542 549--*--symptom",
            "Multiplier 529 541;550 559--*--at least one per month",
            "Temporal 560 592--*--in the month prior to enrollment",
            "Reference_point 579 592--*--to enrollment",
            "Non-query-able 594 628--*--Fluency in English spoken language"
        ]
    },
    "NCT03211741_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 18 years",
            "Person 18 31--*--either gender",
            "Informed_consent 33 136--*--Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed",
            "Condition 138 155--*--Visual impairment",
            "Condition 177 205--*--abnormal new vessel ingrowth",
            "Condition 213 226--*--macular edema",
            "Qualifier 251 263--*--intraretinal",
            "Qualifier 265 275--*--subretinal",
            "Qualifier 279 286--*--sub-RPE",
            "Procedure 318 345--*--ocular coherence tomography",
            "Condition 244 249--*--fluid",
            "Scope 251 286--*--intraretinal, subretinal or sub-RPE",
            "Scope 177 226--*--abnormal new vessel ingrowth and/or macular edema"
        ],
        "Text": "Age = 18 years of either gender. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.. "
    },
    "NCT02984475_inc": {
        "Text": "Diagnosed with Beta-Thalassemia Major and receiving regular blood transfusion and on iron chelating therapy.. Weight: equal to or over 35 kg.. Normal renal function.. ",
        "Annotations": [
            "Condition 15 37--*--Beta-Thalassemia Major",
            "Procedure 60 77--*--blood transfusion",
            "Qualifier 52 59--*--regular",
            "Procedure 85 107--*--iron chelating therapy",
            "Scope 60 107--*--blood transfusion and on iron chelating therapy",
            "Person 110 116--*--Weight",
            "Value 118 140--*--equal to or over 35 kg",
            "Condition 150 164--*--renal function",
            "Qualifier 143 149--*--Normal"
        ]
    },
    "NCT02429583_inc": {
        "Annotations": [
            "Post-eligibility 0 69--*--Willing to receive three doses of an FDA-approved Hepatitis B vaccine",
            "Condition 107 110;93 101--*--HCV infected",
            "Qualifier 81 92--*--chronically",
            "Person 187 196--*--volunteer",
            "Qualifier 179 186--*--Healthy"
        ],
        "Text": "Willing to receive three doses of an FDA-approved Hepatitis B vaccine. Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies). Healthy volunteer without significant medical problems. "
    },
    "NCT03288428_exc": {
        "Text": "can't understand patient controlled analgesia device refuse trial. ",
        "Annotations": [
            "Post-eligibility 0 65--*--can't understand patient controlled analgesia device refuse trial"
        ]
    },
    "NCT03416413_inc": {
        "Text": "Adults over 18 years of age. Symptomatic GSV or SSV vein reflux > 0.5 seconds on colour Duplex. Varicose vein tributary requiring treatment. ",
        "Annotations": [
            "Person 0 6--*--Adults",
            "Value 7 27--*--over 18 years of age",
            "Person 24 27--*--age",
            "Condition 41 44;52 63--*--GSV vein reflux",
            "Condition 48 63--*--SSV vein reflux",
            "Qualifier 64 77--*--> 0.5 seconds",
            "Procedure 81 94--*--colour Duplex",
            "Scope 41 63--*--GSV or SSV vein reflux",
            "Qualifier 96 119--*--Varicose vein tributary",
            "Mood 120 129--*--requiring",
            "Procedure 130 139--*--treatment"
        ]
    },
    "NCT00319748_inc": {
        "Text": "Adequate performance status: . Breast - Karnofsky score > 50; . Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642 . If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation. . Normal organ function within 14 days of study entry . Diagnosis of one of the following malignancies: . Metastatic breast cancer (BR) . Metastatic ovarian cancer (OV) . Metastatic endometrial cancer (EM) . Metastatic cervical cancer (CX) . Measurable metastatic disease (>1cm) in at least one site other than bone-only . Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease . Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen. . Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma). . Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens. . Measurable metastatic disease . Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens . Measurable metastatic disease . Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens. . ",
        "Annotations": [
            "Measurement 30 54--*--Breast - Karnofsky score",
            "Value 55 59--*--> 50",
            "Measurement 97 147--*--Gynecologic Oncology Group (GOG) performance score",
            "Value 148 150--*--\u22642",
            "Person 155 161--*--female",
            "Condition 169 191--*--childbearing potential",
            "Scope 155 191--*--female and of childbearing potential",
            "Observation 197 207--*--willing to",
            "Procedure 221 234--*--contraception",
            "Drug 236 244--*--hormonal",
            "Procedure 246 260--*--barrier method",
            "Procedure 262 272--*--abstinence",
            "Scope 236 272--*--hormonal, barrier method, abstinence",
            "Temporal 299 338--*--for the duration of study participation",
            "Temporal 274 294--*--prior to study entry",
            "Condition 341 362--*--Normal organ function",
            "Temporal 363 392--*--within 14 days of study entry",
            "Condition 443 467--*--Metastatic breast cancer",
            "Condition 474 499--*--Metastatic ovarian cancer",
            "Condition 506 535--*--Metastatic endometrial cancer",
            "Condition 542 568--*--Metastatic cervical cancer",
            "Condition 586 604--*--metastatic disease",
            "Qualifier 575 585--*--Measurable",
            "Value 606 610--*-->1cm",
            "Value 615 627--*--at least one",
            "Qualifier 628 653--*--site other than bone-only",
            "Observation 673 691--*--failure to respond",
            "Observation 655 669--*--Progression on",
            "Temporal 708 716--*--previous",
            "Procedure 717 737--*--chemotherapy regimen",
            "Condition 742 760--*--metastatic disease",
            "Scope 655 691--*--Progression on or failure to respond",
            "Observation 762 776--*--Progression on",
            "Temporal 777 782--*--prior",
            "Procedure 783 812--*--therapy with a hormonal agent",
            "Condition 816 833;859 867--*--estrogen receptor positive",
            "Condition 837 867--*--progesterone receptor positive",
            "Scope 816 867--*--estrogen receptor or progesterone receptor positive",
            "Condition 896 913--*--HER2-neu positive",
            "Procedure 783 795;881 892--*--therapy with trastuzumab",
            "Scope 777 913--*--prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive",
            "Observation 930 948--*--progressed through",
            "Procedure 949 956;972 979--*--hormone therapy",
            "Procedure 960 979--*--trastuzumab therapy",
            "Scope 930 979--*--progressed through hormone or trastuzumab therapy",
            "Procedure 1009 1029--*--chemotherapy regimen",
            "Measurement 1076 1129--*--Response Evaluation Criteria in Solid Tumors (RECIST)",
            "Condition 1043 1061--*--metastatic disease",
            "Condition 1195 1220--*--epithelial ovarian cancer",
            "Procedure 1170 1184--*--histologically",
            "Qualifier 1131 1144--*--Primary tumor",
            "Condition 1222 1243--*--fallopian tube cancer",
            "Condition 1248 1273--*--primary peritoneal cancer",
            "Qualifier 1279 1289--*--borderline",
            "Condition 1317 1337--*--epithelial carcinoma",
            "Scope 1275 1337--*--not borderline or low malignant potential epithelial carcinoma",
            "Scope 1195 1273--*--epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer",
            "Multiplier 1367 1379--*--at least two",
            "Temporal 1380 1388--*--previous",
            "Procedure 1389 1410--*--chemotherapy regimens",
            "Observation 1360 1366--*--failed",
            "Drug 1412 1422--*--Paclitaxel",
            "Drug 1478 1487--*--cisplatin",
            "Drug 1491 1502--*--carboplatin",
            "Condition 1567 1585--*--metastatic disease",
            "Qualifier 1556 1566--*--Measurable",
            "Measurement 1587 1601--*--Histologically",
            "Value 1602 1608--*--proven",
            "Scope 1609 1651--*--recurrent or persistent endometrial cancer",
            "Qualifier 1664 1694--*--amenable to curative treatment",
            "Negation 1660 1663--*--not",
            "Procedure 1700 1707--*--surgery",
            "Procedure 1715 1732--*--radiation therapy",
            "Scope 1700 1732--*--surgery and/or radiation therapy",
            "Value 1748 1749--*--2",
            "Temporal 1750 1758--*--previous",
            "Procedure 1759 1777--*--treatment regimens",
            "Observation 1741 1747--*--failed",
            "Condition 1790 1808--*--metastatic disease",
            "Qualifier 1779 1789--*--Measurable",
            "Measurement 1810 1824--*--Histologically",
            "Value 1825 1831--*--proven",
            "Condition 1856 1879--*--squamous cell carcinoma",
            "Qualifier 1845 1855--*--persistent",
            "Qualifier 1832 1841--*--recurrent",
            "Scope 1832 1855--*--recurrent or persistent",
            "Condition 1881 1904--*--adenosquamous carcinoma",
            "Condition 1909 1937--*--adenocarcinoma of the cervix",
            "Qualifier 1950 1980--*--amenable to curative treatment",
            "Negation 1946 1949--*--not",
            "Procedure 1986 1993--*--surgery",
            "Procedure 2001 2018--*--radiation therapy",
            "Value 2034 2035--*--2",
            "Procedure 2045 2063--*--treatment regimens",
            "Temporal 2036 2044--*--previous",
            "Condition 1633 1651--*--endometrial cancer",
            "Qualifier 1622 1632--*--persistent",
            "Qualifier 1609 1618--*--recurrent",
            "Scope 1609 1632--*--recurrent or persistent",
            "Scope 1856 1937--*--squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix",
            "Negation 1275 1278--*--not",
            "Qualifier 1293 1316--*--low malignant potential",
            "Scope 1279 1316--*--borderline or low malignant potential",
            "Scope 1412 1553--*--Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens",
            "Reference_point 283 294--*--study entry",
            "Reference_point 319 338--*--study participation",
            "Reference_point 381 392--*--study entry",
            "Qualifier 62 69--*--Ovarian",
            "Qualifier 71 82--*--endometrial",
            "Qualifier 86 94--*--cervical",
            "Scope 62 94--*--Ovarian, endometrial or cervical",
            "Measurement 9 27--*--performance status",
            "Value 0 8--*--Adequate",
            "Non-representable 0 27--*--Adequate performance status"
        ]
    },
    "NCT02680054_inc": {
        "Annotations": [
            "Condition 13 28--*--Type 1 diabetes",
            "Temporal 34 49--*--at least a year",
            "Drug 70 77--*--insulin",
            "Qualifier 64 69--*--daily",
            "Drug 118 125--*--insulin",
            "Drug 143 150--*--insulin",
            "Qualifier 130 142--*--rapid-acting",
            "Qualifier 100 117--*--basal long-acting",
            "Scope 100 150--*--basal long-acting insulin and rapid-acting insulin",
            "Measurement 170 175--*--HbA1c",
            "Value 176 189--*--< 75 mmol/mol",
            "Value 191 195--*--9.0%",
            "Informed_consent 198 311--*--Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study",
            "Non-query-able 314 375--*--Family have a freezer in which to safely store the test meals",
            "Post-eligibility 378 466--*--In the Investigator's opinion, is able and willing to comply with all trial requirements"
        ],
        "Text": "Diagnosis of Type 1 diabetes (for at least a year). On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.. HbA1c < 75 mmol/mol (9.0%). Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study.. Family have a freezer in which to safely store the test meals.. In the Investigator's opinion, is able and willing to comply with all trial requirements.. "
    },
    "NCT03589105_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*-->/=18 years",
            "Temporal 16 28--*--at screening",
            "Qualifier 44 59--*--relapsing forms",
            "Condition 63 87--*--multiple sclerosis (RMS)",
            "Qualifier 93 107--*--active disease",
            "Observation 131 147--*--imaging features",
            "Observation 119 127;139 147--*--clinical features",
            "Scope 119 147--*--clinical or imaging features",
            "Multiplier 153 165;183 204--*--at least one over a 6-month period",
            "Condition 166 182--*--clinical relapse",
            "Temporal 205 223--*--prior to screening",
            "Multiplier 237 249;379 401--*--at least one over a 3 months period",
            "Temporal 402 420--*--prior to screening",
            "Condition 250 280--*--T1 gadolinium-enhancing lesion",
            "Condition 305 314--*--T2 lesion",
            "Procedure 330 368--*--brain Magnetic Resonance Imaging (MRI)",
            "Qualifier 295 304--*--enlarging",
            "Temporal 284 287--*--new",
            "Scope 284 304--*--new and/or enlarging",
            "Scope 250 368--*--T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI)",
            "Scope 250 314--*--T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion",
            "Negation 426 428--*--no",
            "Multiplier 429 438--*--change of",
            "Procedure 439 475--*--Disease-Modifying Treatment(s) (DMT)",
            "Non-representable 476 546--*--compared to a previous MRI performed within 24 months before screening",
            "Scope 153 546--*--at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening",
            "Pregnancy_considerations 548 726--*--For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab",
            "Observation 751 785--*--beneficiary of healthcare coverage"
        ],
        "Text": "Age >/=18 years at screening. Patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features: (i) at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening. For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab. Participants should be beneficiary of healthcare coverage under the social security system. "
    },
    "NCT02652572_exc": {
        "Text": "1. Decrease in size of the designated target ulcer(s) by \u2265 30% during the 7-day screening period . 2. Cannot tolerate or comply with compression therapy. . 3. An ulcer which shows signs of severe clinical infection, defined as pus oozing from the ulcer site . 4. An ulcer positive for \u03b2-hemolytic streptococci upon culture . 5. The ulcer has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure or avascular ulcer beds . 6. Is highly exuding (i.e. requires daily change of dressing) . 7. Ankle brachial pressure index <0.65 . 8. Patients with active systemic infections . 9. Patients with clinically significant medical conditions as determined by the investigator including renal, hepatic, hematologic, neurologic or immune disease. Examples include but are not limited to: . 1. Renal insufficiency as an estimated GFR which is < 30 mL/min/1.7m2 . 2. Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range. . 3. Hepatic insufficiency defined as total bilirubin > 2 mg/dL or serum albumin < 25 g/L . 4. HbA1c > 9% . 5. Hemoglobin < 10 g/dL . 6. Hematocrit < 0.30 . 7. Platelet count < 100,000 . 10. Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer) . 11. Patients with severe rheumatoid arthritis (with more than 20 persistently inflamed joints, or below lower normal limit blood albumin level, or evidence of bone and cartilage damage on x-ray, or inflammation in tissues other than joints) and other collagen vascular diseases. . 12. Patients with active connective tissue disease . 13. Treatment with systemic corticosteroids (>15 mg/day), or current immunosuppressive agents . 14. Previous or current radiation therapy or likelihood to receive this therapy during study participation . 15. Pregnant or nursing patients . 16. Known prior inability or unavailability to complete required study visits during study participation . 17. Significant peripheral edema as per investigator's discretion . 18. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which, in the opinion of the investigator, may pose a threat to patient compliance . 19. Use of a platelet-derived growth factor within 28 days before screening . 20. Use of any investigational drug or therapy within 28 days before screening . 21. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 98 100--*--2.",
            "Parsing_Error 154 156--*--3.",
            "Parsing_Error 257 259--*--4.",
            "Parsing_Error 321 323--*--5.",
            "Parsing_Error 440 442--*--6.",
            "Parsing_Error 503 505--*--7.",
            "Parsing_Error 543 545--*--8.",
            "Parsing_Error 588 590--*--9.",
            "Parsing_Error 792 794--*--1.",
            "Parsing_Error 863 865--*--2.",
            "Parsing_Error 959 961--*--3.",
            "Parsing_Error 1048 1050--*--4.",
            "Parsing_Error 1063 1065--*--5.",
            "Parsing_Error 1088 1090--*--6.",
            "Parsing_Error 1110 1112--*--7.",
            "Parsing_Error 1139 1142--*--10.",
            "Parsing_Error 1261 1264--*--11.",
            "Parsing_Error 1541 1544--*--12.",
            "Parsing_Error 1593 1596--*--13.",
            "Parsing_Error 1688 1691--*--14.",
            "Parsing_Error 1796 1799--*--15.",
            "Parsing_Error 1830 1833--*--16.",
            "Parsing_Error 1936 1939--*--17.",
            "Parsing_Error 2003 2006--*--18.",
            "Parsing_Error 2230 2233--*--19.",
            "Parsing_Error 2307 2310--*--20.",
            "Parsing_Error 2387 2390--*--21.",
            "Condition 38 50--*--target ulcer",
            "Qualifier 3 19--*--Decrease in size",
            "Value 57 62--*--\u2265 30%",
            "Temporal 63 96--*--during the 7-day screening period",
            "Procedure 132 151--*--compression therapy",
            "Non-query-able 101 131--*--Cannot tolerate or comply with",
            "Post-eligibility 101 131--*--Cannot tolerate or comply with",
            "Condition 225 228--*--pus",
            "Condition 160 165--*--ulcer",
            "Qualifier 172 212--*--shows signs of severe clinical infection",
            "Subjective_judgement 172 212--*--shows signs of severe clinical infection",
            "Condition 187 212--*--severe clinical infection",
            "Condition 263 268--*--ulcer",
            "Qualifier 269 306--*--positive for \u03b2-hemolytic streptococci",
            "Measurement 344 350--*--slough",
            "Value 338 343--*--> 50%",
            "Condition 328 333--*--ulcer",
            "Observation 364 379--*--necrotic tissue",
            "Observation 381 385;406 414--*--bone exposure",
            "Observation 398 414--*--capsule exposure",
            "Observation 387 393;406 414--*--tendon exposure",
            "Observation 418 438--*--avascular ulcer beds",
            "Qualifier 446 460--*--highly exuding",
            "Subjective_judgement 446 460--*--highly exuding",
            "Multiplier 476 481--*--daily",
            "Procedure 482 500--*--change of dressing",
            "Measurement 506 535--*--Ankle brachial pressure index",
            "Value 536 541--*--<0.65",
            "Condition 567 586--*--systemic infections",
            "Temporal 560 566--*--active",
            "Condition 628 646--*--medical conditions",
            "Qualifier 605 627--*--clinically significant",
            "Observation 647 680--*--as determined by the investigator",
            "Subjective_judgement 647 680--*--as determined by the investigator",
            "Condition 691 696;741 748--*--renal disease",
            "Condition 734 748--*--immune disease",
            "Condition 698 705;741 748--*--hepatic disease",
            "Condition 707 718;741 748--*--hematologic disease",
            "Condition 720 730;741 748--*--neurologic disease",
            "Scope 691 748--*--renal, hepatic, hematologic, neurologic or immune disease",
            "Parsing_Error 750 790--*--Examples include but are not limited to:",
            "Condition 795 814--*--Renal insufficiency",
            "Measurement 821 834--*--estimated GFR",
            "Value 844 861--*--< 30 mL/min/1.7m2",
            "Measurement 875 893--*--blood biochemistry",
            "Value 905 956--*--3 times that of the upper limit of the normal range",
            "Value 866 874--*--Abnormal",
            "Condition 962 983--*--Hepatic insufficiency",
            "Measurement 995 1010--*--total bilirubin",
            "Value 1011 1020--*--> 2 mg/dL",
            "Measurement 1024 1037--*--serum albumin",
            "Value 1038 1046--*--< 25 g/L",
            "Scope 995 1046--*--total bilirubin > 2 mg/dL or serum albumin < 25 g/L",
            "Measurement 1051 1056--*--HbA1c",
            "Value 1057 1061--*--> 9%",
            "Measurement 1066 1076--*--Hemoglobin",
            "Value 1077 1086--*--< 10 g/dL",
            "Measurement 1091 1101--*--Hematocrit",
            "Value 1102 1108--*--< 0.30",
            "Measurement 1113 1127--*--Platelet count",
            "Value 1128 1137--*--< 100,000",
            "Condition 1177 1189--*--local cancer",
            "Condition 1165 1173;1183 1189--*--systemic cancer",
            "Temporal 1158 1164--*--active",
            "Condition 1193 1210--*--tumor of any kind",
            "Condition 1234 1258--*--non-melanoma skin cancer",
            "Negation 1212 1233--*--with the exception of",
            "Scope 1165 1210--*--systemic or local cancer or tumor of any kind",
            "Condition 1286 1306--*--rheumatoid arthritis",
            "Qualifier 1279 1285--*--severe",
            "Multiplier 1313 1325--*--more than 20",
            "Condition 1339 1354--*--inflamed joints",
            "Temporal 1326 1338--*--persistently",
            "Measurement 1384 1403--*--blood albumin level",
            "Value 1359 1383--*--below lower normal limit",
            "Condition 1420 1445--*--bone and cartilage damage",
            "Procedure 1449 1454--*--x-ray",
            "Condition 1459 1500--*--inflammation in tissues other than joints",
            "Condition 1512 1538--*--collagen vascular diseases",
            "Scope 1313 1500--*--more than 20 persistently inflamed joints, or below lower normal limit blood albumin level, or evidence of bone and cartilage damage on x-ray, or inflammation in tissues other than joints",
            "Condition 1566 1591--*--connective tissue disease",
            "Temporal 1559 1565--*--active",
            "Drug 1612 1636--*--systemic corticosteroids",
            "Value 1638 1648--*-->15 mg/day",
            "Procedure 1597 1606--*--Treatment",
            "Drug 1662 1686--*--immunosuppressive agents",
            "Temporal 1654 1661--*--current",
            "Procedure 1712 1729--*--radiation therapy",
            "Non-query-able 1733 1746--*--likelihood to",
            "Subjective_judgement 1733 1746--*--likelihood to",
            "Temporal 1692 1700--*--Previous",
            "Temporal 1704 1711--*--current",
            "Scope 1692 1711--*--Previous or current",
            "Condition 1800 1808--*--Pregnant",
            "Condition 1812 1819--*--nursing",
            "Non-query-able 1834 1934--*--Known prior inability or unavailability to complete required study visits during study participation",
            "Context_Error 1886 1907--*--required study visits",
            "Condition 1952 1968--*--peripheral edema",
            "Qualifier 1940 1951--*--Significant",
            "Subjective_judgement 1940 1951--*--Significant",
            "Subjective_judgement 1969 2001--*--as per investigator's discretion",
            "Condition 2009 2030--*--psychiatric condition",
            "Condition 2038 2055--*--suicidal ideation",
            "Condition 2068 2075;2084 2097--*--alcohol abuse problem",
            "Condition 2079 2097--*--drug abuse problem",
            "Subjective_judgement 2153 2187--*--in the opinion of the investigator",
            "Subjective_judgement 2193 2206--*--pose a threat",
            "Qualifier 2189 2228--*--may pose a threat to patient compliance",
            "Scope 2009 2097--*--psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem",
            "Drug 2243 2273--*--platelet-derived growth factor",
            "Temporal 2274 2305--*--within 28 days before screening",
            "Reference_point 2296 2305--*--screening",
            "Drug 2322 2342--*--investigational drug",
            "Procedure 2322 2337;2346 2353--*--investigational therapy",
            "Temporal 2354 2385--*--within 28 days before screening",
            "Reference_point 2376 2385--*--screening",
            "Subjective_judgement 2391 2513--*--Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study",
            "Context_Error 2391 2513--*--Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study",
            "Non-query-able 2391 2513--*--Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study"
        ]
    },
    "NCT02566863_inc": {
        "Text": "patients classified with American Society of Anesthesiologists Physical Status Classification System as 1 or 2 status. planned eye surgery under sedation. ",
        "Annotations": [
            "Measurement 111 117;25 100--*--status American Society of Anesthesiologists Physical Status Classification System",
            "Value 104 110--*--1 or 2",
            "Mood 119 126--*--planned",
            "Procedure 127 138--*--eye surgery",
            "Qualifier 139 153--*--under sedation",
            "Procedure 145 153--*--sedation"
        ]
    },
    "NCT03317197_inc": {
        "Annotations": [
            "Person 61 67--*--adults",
            "Person 68 72--*--aged",
            "Value 73 90--*--at least 19 years",
            "Condition 101 114--*--atraumatic CA",
            "Visit 115 126--*--outpatients",
            "Visit 143 145--*--ER",
            "Procedure 159 162--*--CPR"
        ],
        "Text": "The group of patients who participated in the study included adults aged at least 19 years among the atraumatic CA outpatients who came to the ER and received CPR.. "
    },
    "NCT02858804_inc": {
        "Text": "age=65 years. diagnosis with mantle cell lymphoma. Ann Arbor stage II,III or IV. ECOG=1 or if ECOG=2 but recover after pretreatment.. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 3 12--*--=65 years",
            "Condition 29 49--*--mantle cell lymphoma",
            "Measurement 51 66--*--Ann Arbor stage",
            "Value 67 69--*--II",
            "Value 70 73--*--III",
            "Value 77 79--*--IV",
            "Scope 67 79--*--II,III or IV",
            "Measurement 81 85--*--ECOG",
            "Value 85 87--*--=1",
            "Measurement 94 98--*--ECOG",
            "Value 98 100--*--=2",
            "Temporal 113 131--*--after pretreatment",
            "Reference_point 119 131--*--pretreatment",
            "Condition 105 112--*--recover",
            "Procedure 119 131--*--pretreatment"
        ]
    },
    "NCT00720031_exc": {
        "Annotations": [
            "Condition 0 27--*--Cardio-vascular pathologies",
            "Qualifier 43 55--*--uncontrolled",
            "Qualifier 29 38--*--evoluting",
            "Scope 29 55--*--evoluting and uncontrolled",
            "Condition 65 68--*--HTA",
            "Qualifier 58 64--*--severe",
            "Condition 71 89--*--cardiac deficiency",
            "Condition 98 103--*--angor",
            "Condition 112 122--*--arrhythmia",
            "Qualifier 105 111--*--severe",
            "Qualifier 91 97--*--severe",
            "Condition 125 147--*--Infectious pathologies",
            "Qualifier 148 157--*--evoluting",
            "Qualifier 162 186--*--requiring antibiotherapy",
            "Drug 172 186--*--antibiotherapy",
            "Scope 148 186--*--evoluting and requiring antibiotherapy",
            "Measurement 198 201--*--HIV",
            "Value 201 202--*--+",
            "Condition 198 202--*--HIV+",
            "Procedure 205 217--*--Transplanted",
            "Condition 254 280--*--severe auto-immune disease",
            "Condition 283 303--*--Psychiatric troubles",
            "Qualifier 309 344--*--do not allow the protocol follow-up",
            "Condition 347 355--*--Pregnant",
            "Condition 359 373--*--breast-feeding",
            "Person 374 379--*--women",
            "Procedure 385 398--*--contraception",
            "Negation 382 384--*--No"
        ],
        "Text": "Cardio-vascular pathologies, evoluting and uncontrolled, (severe HTA), cardiac deficiency, severe angor, severe arrhythmia. . Infectious pathologies evoluting and requiring antibiotherapy. . Patients HIV+. . Transplanted patients or patients suffering from severe auto-immune disease. . Psychiatric troubles that do not allow the protocol follow-up. . Pregnant or breast-feeding women. . No contraception.       .     . "
    },
    "NCT02334722_exc": {
        "Annotations": [
            "Negation 0 2--*--No",
            "Observation 9 16--*--history",
            "Condition 20 36--*--seizure activity",
            "Condition 39 47--*--Pregnant",
            "Observation 51 64--*--breastfeeding",
            "Condition 67 84--*--Renal dysfunction",
            "Measurement 86 90--*--CrCl",
            "Value 91 101--*--< 30ml/min",
            "Scope 86 101--*--CrCl < 30ml/min",
            "Measurement 105 138--*--Beck's Depression Inventory (BDI)",
            "Value 139 142--*--=14",
            "Condition 144 151--*--Allergy",
            "Drug 155 168--*--levetiracetam"
        ],
        "Text": "No known history of seizure activity.. Pregnant or breastfeeding.. Renal dysfunction (CrCl < 30ml/min).. Beck's Depression Inventory (BDI) =14. Allergy to levetiracetam.. "
    },
    "NCT02787070_inc": {
        "Text": "Infection with Plasmodium falciparum or P. vivax either alone or mixed. Age >12 months. Weight >5kg. Living in the study clusters. ",
        "Annotations": [
            "Condition 0 9--*--Infection",
            "Qualifier 15 36--*--Plasmodium falciparum",
            "Qualifier 40 48--*--P. vivax",
            "Scope 15 48--*--Plasmodium falciparum or P. vivax",
            "Person 72 75--*--Age",
            "Value 76 86--*-->12 months",
            "Person 88 94--*--Weight",
            "Value 95 99--*-->5kg",
            "Non-query-able 101 129--*--Living in the study clusters"
        ]
    },
    "NCT00351611_inc": {
        "Annotations": [
            "Condition 0 8--*--Epilepsy",
            "Condition 9 24--*--partial seizure",
            "Drug 60 79--*--antiepileptic drugs",
            "Multiplier 53 59--*--1 to 3"
        ],
        "Text": "Epilepsy partial seizure subjects.. Currently taking 1 to 3 antiepileptic drugs.. "
    },
    "NCT02645474_inc": {
        "Annotations": [
            "Person 0 5--*--adult",
            "Measurement 16 25--*--ASA class",
            "Value 26 32--*--1 to 3",
            "Qualifier 66 74--*--elective",
            "Procedure 82 92--*--mastectomy",
            "Procedure 75 81;96 110--*--breast quadrantectomy",
            "Scope 75 110--*--breast mastectomy or quadrantectomy"
        ],
        "Text": "adult patients. ASA class 1 to 3 patients. patients scheduled for elective breast mastectomy or quadrantectomy. "
    },
    "NCT02566863_exc": {
        "Text": "patient's refusal. contraindications to dexmedetomidine. diseases/drugs that influence on autonomic nervous system activity. ",
        "Annotations": [
            "Informed_consent 0 17--*--patient's refusal",
            "Condition 19 36--*--contraindications",
            "Drug 40 55--*--dexmedetomidine",
            "Condition 57 65--*--diseases",
            "Drug 66 71--*--drugs",
            "Qualifier 77 123--*--influence on autonomic nervous system activity"
        ]
    },
    "NCT02858804_exc": {
        "Text": "with centre neural system involvement. serious complications such as uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician. HIV positive or active HBV infection or other uncontrolled systematic infection. clinical central nervous dysfunction. serious surgery within 30 days. pregnancy or baby nursing period or un-contracepted child bearing period woman.. ",
        "Annotations": [
            "Condition 5 37--*--centre neural system involvement",
            "Condition 82 90--*--diabetes",
            "Qualifier 69 81--*--uncontrolled",
            "Condition 47 60--*--complications",
            "Qualifier 39 46--*--serious",
            "Condition 92 105--*--gastric ulcer",
            "Condition 123 139--*--angiocardiopathy",
            "Qualifier 115 122--*--serious",
            "Subjective_judgement 140 167--*--determined by the physician",
            "Scope 69 139--*--uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy",
            "Condition 169 181--*--HIV positive",
            "Condition 185 205--*--active HBV infection",
            "Condition 228 248--*--systematic infection",
            "Qualifier 215 227--*--uncontrolled",
            "Condition 259 286--*--central nervous dysfunction",
            "Procedure 296 303--*--surgery",
            "Qualifier 288 295--*--serious",
            "Temporal 304 318--*--within 30 days",
            "Observation 320 329--*--pregnancy",
            "Observation 333 352--*--baby nursing period",
            "Negation 356 359--*--un-",
            "Procedure 359 371--*--contracepted",
            "Observation 372 392--*--child bearing period",
            "Person 393 398--*--woman"
        ]
    },
    "NCT03317197_exc": {
        "Annotations": [
            "Person 9 14--*--women",
            "Person 19 33--*--young children",
            "Person 34 38--*--aged",
            "Value 39 48--*--<18 years",
            "Condition 138 153--*--terminal cancer",
            "Condition 65 83--*--underlying disease",
            "Qualifier 90 130--*--without the possibility of resuscitation",
            "Observation 171 202--*--do-not-resuscitate (DNR) status",
            "Condition 205 232--*--Death by excessive bleeding",
            "Condition 250 269--*--main artery rupture",
            "Qualifier 240 249--*--abdominal",
            "Scope 240 269--*--abdominal main artery rupture",
            "Condition 315 317--*--CA",
            "Visit 306 314--*--hospital",
            "Qualifier 303 314--*--in-hospital",
            "Drug 362 382--*--anti-cancer medicine",
            "Drug 353 360--*--steroid",
            "Procedure 387 414--*--immunosuppression treatment",
            "Temporal 415 424--*--before CA",
            "Condition 422 424--*--CA",
            "Competing_trial 427 482--*--Patients already been registered with other studies; or",
            "Temporal 329 339--*--previously",
            "Procedure 340 347--*--treated",
            "Scope 353 382--*--steroid, anti-cancer medicine",
            "Informed_consent 484 538--*--Patients from whom informed consent cannot be obtained"
        ],
        "Text": "Pregnant women and young children aged <18 years;. Patients with underlying disease cases without the possibility of resuscitation (e.g., terminal cancer);. Patients with do-not-resuscitate (DNR) status;. Death by excessive bleeding (e.g., abdominal main artery rupture);. Patients who have experienced in-hospital CA;. Patients previously treated with steroid, anti-cancer medicine, or immunosuppression treatment before CA;. Patients already been registered with other studies; or. Patients from whom informed consent cannot be obtained. "
    },
    "NCT02645474_exc": {
        "Annotations": [
            "Post-eligibility 0 17--*--patients' refusal",
            "Condition 19 35--*--contraindication",
            "Procedure 39 61--*--regional anaesthesia (",
            "Condition 61 75--*--coagulopathies",
            "Drug 88 109--*--anticoagulant therapy",
            "Condition 111 118--*--allergy",
            "Procedure 122 140--*--local anaesthetics",
            "Condition 142 151--*--infection",
            "Qualifier 155 168--*--puncture site",
            "Scope 61 168--*--coagulopathies, concurrent anticoagulant therapy, allergy to local anaesthetics, infection at puncture site"
        ],
        "Text": "patients' refusal. contraindication to regional anaesthesia (coagulopathies, concurrent anticoagulant therapy, allergy to local anaesthetics, infection at puncture site). "
    },
    "NCT00351611_exc": {
        "Annotations": [
            "Condition 13 25--*--eye diseases",
            "Qualifier 0 12--*--Pre-existing",
            "Condition 27 35--*--glaucoma",
            "Drug 64 74--*--pregabalin",
            "Condition 95 110--*--partial seizure",
            "Drug 144 154--*--pregabalin",
            "Observation 39 60--*--Insufficient response"
        ],
        "Text": "Pre-existing eye diseases (glaucoma).. Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.. "
    },
    "NCT02787070_exc": {
        "Text": "General danger signs or symptoms of severe malaria. Anaemia, defined as Hb <9g/dl. G6PD deficiency (as determined by FST). Pregnant women as determined by Urine \u00df-HCG pregnancy test. Known hypersensitivity to any of the drugs given. ",
        "Annotations": [
            "Condition 43 50--*--malaria",
            "Qualifier 36 42--*--severe",
            "Condition 52 59--*--Anaemia",
            "Measurement 72 74--*--Hb",
            "Value 75 81--*--<9g/dl",
            "Condition 83 98--*--G6PD deficiency",
            "Pregnancy_considerations 123 181--*--Pregnant women as determined by Urine \u00df-HCG pregnancy test",
            "Condition 189 205--*--hypersensitivity",
            "Drug 220 225--*--drugs"
        ]
    },
    "NCT02334722_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Value 24 33;7 16--*--and older >18 years",
            "Person 20 23--*--age",
            "Scope 7 33--*-->18 years of age and older",
            "Mood 56 75--*--will have undergone",
            "Procedure 76 94--*--surgical resection",
            "Procedure 98 104--*--biopsy",
            "Condition 110 136--*--supratentorial brain tumor",
            "Informed_consent 141 175--*--are able to consent for themselves",
            "Scope 76 104--*--surgical resection or biopsy",
            "Non-representable 178 241--*--Able to be randomized prior to or up to 48 hours after surgery."
        ],
        "Text": "Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.. Able to be randomized prior to or up to 48 hours after surgery.. "
    },
    "NCT00720031_inc": {
        "Annotations": [
            "Condition 7 15--*--melanoma",
            "Qualifier 0 6--*--HLA-A2",
            "Condition 40 53;68 78--*--loco-regional metastasis",
            "Condition 57 78--*--lymph node metastasis",
            "Condition 80 95--*--transit nodules",
            "Qualifier 100 121--*--surgically resectable",
            "Negation 96 99--*--not",
            "Procedure 100 110--*--surgically",
            "Condition 147 166--*--visceral metastasis",
            "Condition 134 143;156 166--*--cutaneous metastasis",
            "Qualifier 123 133--*--measurable",
            "Scope 134 166--*--cutaneous or visceral metastasis",
            "Observation 200 214--*--MART-1 antigen",
            "Observation 192 199;207 214--*--Melan-A antigen",
            "Procedure 220 232--*--chemotherapy",
            "Negation 217 219--*--No",
            "Drug 255 263--*--Deticene",
            "Negation 244 254--*--except for",
            "Temporal 269 308--*--before the first T cell clones infusion",
            "Reference_point 276 308--*--the first T cell clones infusion",
            "Procedure 313 325--*--radiotherapy",
            "Procedure 329 342--*--immunotherapy",
            "Temporal 343 378--*--in the last 4 weeks before infusion",
            "Reference_point 370 378--*--infusion",
            "Condition 390 398--*--melanoma",
            "Temporal 409 428--*--during the protocol",
            "Procedure 399 408--*--treatment",
            "Observation 431 446--*--Life expectancy",
            "Value 457 478--*--greater than 6 months",
            "Measurement 500 509--*--Karnowsky",
            "Value 510 525--*--greater than 80",
            "Measurement 527 531--*--ECOG",
            "Value 534 543--*--0, 1 or 2",
            "Measurement 577 580--*--HIV",
            "Value 564 572--*--negative",
            "Measurement 591 602--*--C hepatitis",
            "Measurement 585 586;593 602--*--B hepatitis",
            "Scope 577 602--*--HIV and B and C hepatitis",
            "Measurement 658 668--*--leucocytes",
            "Value 669 692--*--\u00b3 2000 elements per mm3",
            "Measurement 694 704--*--hemoglobin",
            "Value 705 715--*--\u00b3 10.5g/dl",
            "Measurement 717 726--*--platelets",
            "Value 727 744--*--\u00b3 100 000 per mm3",
            "Measurement 746 782--*--phosphatases alcalines transaminases",
            "Value 783 818--*--\u00a3 1 time 1/2 compared to the normal",
            "Observation 821 844--*--Signed informed consent",
            "Scope 220 342--*--chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy",
            "Temporal 627 656--*--at the beginning of the study",
            "Reference_point 630 656--*--the beginning of the study",
            "Scope 658 818--*--leucocytes \u00b3 2000 elements per mm3, hemoglobin \u00b3 10.5g/dl, platelets \u00b3 100 000 per mm3, phosphatases alcalines transaminases \u00a3 1 time 1/2 compared to the normal"
        ],
        "Text": "HLA-A2 melanoma patients with : . either loco-regional or lymph node metastasis . transit nodules not surgically resectable . measurable cutaneous or visceral metastasis . Patients' tumor express Melan-A/MART-1 antigen. . No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion. . No other melanoma treatment during the protocol. . Life expectancy should be greater than 6 months. . General state with Karnowsky greater than 80, ECOG = 0, 1 or 2. . Patient should be negative for HIV and B and C hepatitis. . Biological parameters at the beginning of the study: leucocytes \u00b3 2000 elements per mm3, hemoglobin \u00b3 10.5g/dl, platelets \u00b3 100 000 per mm3, phosphatases alcalines transaminases \u00a3 1 time 1/2 compared to the normal. . Signed informed consent . "
    },
    "NCT02464813_exc": {
        "Text": "Other spinal pathology or other associated medical condition. Major neurologic developmental delay. Need for anterior surgery or for vertebral column resection.. Preoperative opioid use. Inability to use PCA. ",
        "Annotations": [
            "Condition 6 22--*--spinal pathology",
            "Condition 32 60--*--associated medical condition",
            "Condition 62 98--*--Major neurologic developmental delay",
            "Procedure 109 125--*--anterior surgery",
            "Mood 100 108--*--Need for",
            "Procedure 133 159--*--vertebral column resection",
            "Temporal 162 174--*--Preoperative",
            "Drug 175 181--*--opioid",
            "Condition 187 203--*--Inability to use",
            "Procedure 204 207--*--PCA"
        ]
    },
    "NCT02511574_inc": {
        "Text": "gestational age between 20 weeks and 23 weeks and 6 days. singleton pregnancies. ",
        "Annotations": [
            "Measurement 0 15--*--gestational age",
            "Value 16 56--*--between 20 weeks and 23 weeks and 6 days",
            "Condition 58 79--*--singleton pregnancies"
        ]
    },
    "NCT02689089_exc": {
        "Text": "Suspected or confirmed active TB disease. Known allergies to any of the study medications by participant self-report. have a positive pregnancy test at screening, or. are not willing to use a reliable method of barrier contraception during the study, or. are breastfeeding. hormonal contraception. HIV infected participants who are on anti-retroviral drugs. other drugs that interact with 3HP (see Table 1). Known contact with an INH or rifampin resistant case. Weight < 10 kg. Evidence of possible liver damage defined by an aspartate transaminase (AST) level that is more than 3x the upper limit of normal in an asymptomatic patient. Porphyria reported by patient. Inability to adhere to protocol.. Patients may be excluded from the study for other reasons, at the investigator's discretion with detailed documentation.. ",
        "Annotations": [
            "Condition 23 32--*--active TB",
            "Condition 48 57--*--allergies",
            "Non-query-able 42 116--*--Known allergies to any of the study medications by participant self-report",
            "Pregnancy_considerations 118 161--*--have a positive pregnancy test at screening",
            "Pregnancy_considerations 167 249--*--are not willing to use a reliable method of barrier contraception during the study",
            "Pregnancy_considerations 255 272--*--are breastfeeding",
            "Procedure 274 296--*--hormonal contraception",
            "Condition 298 310--*--HIV infected",
            "Drug 335 356--*--anti-retroviral drugs",
            "Non-query-able 358 406--*--other drugs that interact with 3HP (see Table 1)",
            "Condition 446 455--*--resistant",
            "Drug 437 445--*--rifampin",
            "Drug 430 433--*--INH",
            "Scope 430 445--*--INH or rifampin",
            "Measurement 462 468--*--Weight",
            "Value 469 476--*--< 10 kg",
            "Condition 499 511--*--liver damage",
            "Measurement 526 548--*--aspartate transaminase",
            "Measurement 550 553--*--AST",
            "Value 569 607--*--more than 3x the upper limit of normal",
            "Condition 636 645--*--Porphyria",
            "Post-eligibility 667 698--*--Inability to adhere to protocol",
            "Non-query-able 701 819--*--Patients may be excluded from the study for other reasons, at the investigator's discretion with detailed documentatio"
        ]
    },
    "NCT03253796_inc": {
        "Text": "Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication. Has chronic back pain of =3 months duration by history. Has physician-diagnosed active nr-axSpA with disease duration <= 5 years. \u2022 Inflammatory back pain. \u2022 Arthritis (physician-diagnosed). \u2022 Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia). \u2022 Dactylitis (physician-diagnosed). \u2022 Psoriasis (physician-diagnosed). \u2022 History of physician-diagnosed inflammatory bowel disease (IBD). \u2022 History of uveitis confirmed by an ophthalmologist. \u2022 Good response to nonsteroidal anti-inflammatory drugs (NSAID). \u2022 Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD). \u2022 Elevated CRP. \u2022 Human leukocyte antigen B27 (HLA-B27)+ gene. Has a HLA-B27+ gene and 2 or more of the SpA characteristics listed above. Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI. Has an ASDAS >= 2.1 at Screening. Shows high disease activity at Screening and Baseline of both a Total Back Pain score of =4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of >= 4. Has an acceptable history of NSAID use. Has no history of untreated latent or active tuberculosis (TB) prior to Screening. Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB. ",
        "Annotations": [
            "Pregnancy_considerations 0 221--*--Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication",
            "Condition 227 244--*--chronic back pain",
            "Qualifier 248 266--*--=3 months duration",
            "Observation 270 277--*--history",
            "Condition 310 318--*--nr-axSpA",
            "Qualifier 303 309--*--active",
            "Measurement 324 340--*--disease duration",
            "Measurement 258 266--*--duration",
            "Value 248 257--*--=3 months",
            "Value 341 351--*--<= 5 years",
            "Qualifier 324 351--*--disease duration <= 5 years",
            "Condition 355 377--*--Inflammatory back pain",
            "Condition 381 390--*--Arthritis",
            "Condition 416 426--*--Enthesitis",
            "Qualifier 428 432--*--heel",
            "Condition 467 471--*--pain",
            "Condition 475 485--*--tenderness",
            "Qualifier 508 552--*--site of the insertion of the Achilles tendon",
            "Qualifier 556 570--*--plantar fascia",
            "Scope 508 570--*--site of the insertion of the Achilles tendon or plantar fascia",
            "Scope 467 485--*--pain or tenderness",
            "Condition 575 585--*--Dactylitis",
            "Condition 611 620--*--Psoriasis",
            "Condition 677 709--*--inflammatory bowel disease (IBD)",
            "Condition 724 731--*--uveitis",
            "Non-representable 732 763--*--confirmed by an ophthalmologist",
            "Observation 646 653--*--History",
            "Observation 713 720--*--History",
            "Drug 784 828--*--nonsteroidal anti-inflammatory drugs (NSAID)",
            "Observation 767 780--*--Good response",
            "Observation 832 846--*--Family history",
            "Condition 850 853--*--SpA",
            "Condition 867 889--*--ankylosing spondylitis",
            "Condition 891 900--*--psoriasis",
            "Condition 902 915--*--acute uveitis",
            "Condition 917 935--*--reactive arthritis",
            "Condition 940 943--*--IBD",
            "Scope 867 943--*--ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD",
            "Measurement 957 960--*--CRP",
            "Value 948 956--*--Elevated",
            "Condition 1003 1007;964 991--*--gene Human leukocyte antigen B27",
            "Condition 992 1002--*--(HLA-B27)+",
            "Condition 1015 1023--*--HLA-B27+",
            "Condition 1050 1053--*--SpA",
            "Multiplier 1033 1042--*--2 or more",
            "Measurement 1097 1100--*--CRP",
            "Value 1088 1096--*--elevated",
            "Temporal 1101 1113--*--at Screening",
            "Qualifier 1129 1135--*--active",
            "Condition 1136 1148--*--inflammation",
            "Qualifier 1156 1173--*--sacroiliac joints",
            "Procedure 1177 1180--*--MRI",
            "Measurement 1189 1194--*--ASDAS",
            "Value 1195 1201--*-->= 2.1",
            "Temporal 1202 1214--*--at Screening",
            "Measurement 1280 1301--*--Total Back Pain score",
            "Value 1305 1307--*--=4",
            "Measurement 1314 1379--*--Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score",
            "Value 1383 1387--*-->= 4",
            "Condition 1222 1243--*--high disease activity",
            "Temporal 1244 1269--*--at Screening and Baseline",
            "Observation 1407 1414--*--history",
            "Qualifier 1396 1406--*--acceptable",
            "Drug 1418 1423--*--NSAID",
            "Qualifier 1467 1473--*--active",
            "Qualifier 1447 1456--*--untreated",
            "Qualifier 1457 1463--*--latent",
            "Condition 1474 1491--*--tuberculosis (TB)",
            "Scope 1457 1473--*--latent or active",
            "Negation 1433 1435--*--no",
            "Observation 1436 1443--*--history",
            "Scope 1436 1491--*--history of untreated latent or active tuberculosis (TB)",
            "Temporal 1492 1510--*--prior to Screening",
            "Reference_point 1501 1510--*--Screening",
            "Observation 1530 1543--*--close contact",
            "Temporal 1523 1529--*--recent",
            "Observation 1551 1572--*--person with active TB",
            "Non-representable 1512 1692--*--Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB"
        ]
    },
    "NCT03259243_inc": {
        "Text": "Patient who undergoing gynecologic laparoscopic surgery. Patient who agrees to participate in this study. Patient able to speak and understand Thai. Patient able to complete the questionnaire. ",
        "Annotations": [
            "Procedure 23 55--*--gynecologic laparoscopic surgery",
            "Observation 157 191--*--able to complete the questionnaire",
            "Observation 69 104--*--agrees to participate in this study",
            "Informed_consent 57 104--*--Patient who agrees to participate in this study",
            "Observation 114 147--*--able to speak and understand Thai",
            "Post-eligibility 106 147--*--Patient able to speak and understand Thai"
        ]
    },
    "NCT00787254_exc": {
        "Annotations": [
            "Qualifier 0 24--*--Endoscopically confirmed",
            "Procedure 0 14--*--Endoscopically",
            "Qualifier 67 91--*--Endoscopically confirmed",
            "Procedure 67 81--*--Endoscopically",
            "Condition 99 132--*--upper gastrointestinal hemorrhage",
            "Temporal 92 98--*--active",
            "Temporal 133 141--*--on Day 1",
            "Reference_point 136 141--*--Day 1",
            "Condition 25 32--*--gastric",
            "Condition 40 55--*--duodenal ulcers",
            "Temporal 56 64--*--on Day 1",
            "Reference_point 59 64--*--Day 1",
            "Scope 25 55--*--gastric and/or duodenal ulcers",
            "Qualifier 171 186--*--aspirin-induced",
            "Drug 171 178--*--aspirin",
            "Condition 187 193--*--asthma",
            "Condition 197 223--*--hypersensitivity to NSAIDs",
            "Drug 217 223--*--NSAIDs",
            "Observation 155 167--*--past history",
            "Temporal 144 151--*--Current",
            "Scope 144 167--*--Current or past history",
            "Scope 187 223--*--asthma or hypersensitivity to NSAIDs",
            "Qualifier 250 282--*--affecting gastric acid secretion",
            "Procedure 242 249--*--surgery",
            "Mood 234 241--*--planned",
            "Temporal 226 230--*--Past",
            "Scope 226 241--*--Past or planned",
            "Condition 319 333--*--renal disorder",
            "Condition 308 315;325 333--*--hepatic disorder",
            "Qualifier 285 307--*--Clinically significant",
            "Subjective_judgement 285 307--*--Clinically significant",
            "Scope 308 333--*--hepatic or renal disorder",
            "Condition 344 363--*--cardiac dysfunction",
            "Condition 365 377--*--hypertension",
            "Condition 382 404--*--hematological disorder",
            "Qualifier 336 343--*--Serious",
            "Subjective_judgement 336 343--*--Serious",
            "Scope 344 404--*--cardiac dysfunction, hypertension, or hematological disorder"
        ],
        "Text": "Endoscopically confirmed gastric and/or duodenal ulcers on Day 1. . Endoscopically confirmed active upper gastrointestinal hemorrhage on Day 1. . Current or past history of aspirin-induced asthma or hypersensitivity to NSAIDs. . Past or planned surgery affecting gastric acid secretion. . Clinically significant hepatic or renal disorder. . Serious cardiac dysfunction, hypertension, or hematological disorder.       .     . "
    },
    "NCT02954029_inc": {
        "Text": "age 18 years or older. patients undergoing invasive procedures via the radial or femoral arteries. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 21--*--18 years or older",
            "Procedure 43 62--*--invasive procedures",
            "Temporal 32 42--*--undergoing",
            "Qualifier 71 77;89 97--*--radial arteries",
            "Qualifier 81 97--*--femoral arteries",
            "Scope 71 97--*--radial or femoral arteries"
        ]
    },
    "NCT02414399_exc": {
        "Annotations": [
            "Condition 0 16--*--Contraindication",
            "Drug 20 32--*--azithromycin",
            "Qualifier 41 46--*--other",
            "Drug 47 74--*--prophylactic antibiotic use"
        ],
        "Text": "Contraindication to azithromycin use and other prophylactic antibiotic use. "
    },
    "NCT02357654_inc": {
        "Text": "women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.. ",
        "Annotations": [
            "Person 0 5--*--women",
            "Procedure 17 20--*--IVF",
            "Procedure 21 25--*--ICSI",
            "Procedure 29 58--*--frozen embryo transfers (FET)",
            "Value 64 82--*--less than 40 years",
            "Person 83 86--*--old"
        ]
    },
    "NCT02464813_inc": {
        "Text": "Adolescent (10-21 years) undergoing spinal fusion for idiopathic scoliosis, spondylolisthesis or Scheuermann kyphosis.. Posterior spinal fusion. No contraindication for Pregabalin use. ASA I-III. Written informed consent. ",
        "Annotations": [
            "Person 0 10--*--Adolescent",
            "Value 12 23--*--10-21 years",
            "Person 18 23--*--years",
            "Scope 12 23--*--10-21 years",
            "Procedure 36 49--*--spinal fusion",
            "Condition 54 74--*--idiopathic scoliosis",
            "Condition 76 93--*--spondylolisthesis",
            "Condition 97 117--*--Scheuermann kyphosis",
            "Scope 54 117--*--idiopathic scoliosis, spondylolisthesis or Scheuermann kyphosis",
            "Procedure 120 143--*--Posterior spinal fusion",
            "Condition 148 164--*--contraindication",
            "Negation 145 147--*--No",
            "Drug 169 179--*--Pregabalin",
            "Measurement 185 188--*--ASA",
            "Value 189 194--*--I-III",
            "Informed_consent 196 220--*--Written informed consent"
        ]
    },
    "NCT02689089_inc": {
        "Text": "Males or non-pregnant, non-nursing females between the ages of 2-65 years. LTBI diagnosis as per Canadian TB Standards using either the Tuberculin Skin Test (TST) or the Interferon Gamma Release Assay (IGRA). Children 2-5 years with negative TSTs who have been in close contact with a case of active TB disease recently. Able and willing to provide fully informed consent or parent/guardian able to provide consent. ",
        "Annotations": [
            "Person 0 5--*--Males",
            "Pregnancy_considerations 9 34--*--non-pregnant, non-nursing",
            "Person 35 42--*--females",
            "Person 55 59--*--ages",
            "Value 63 73--*--2-65 years",
            "Condition 75 79--*--LTBI",
            "Measurement 136 156--*--Tuberculin Skin Test",
            "Measurement 158 161--*--TST",
            "Measurement 170 200--*--Interferon Gamma Release Assay",
            "Measurement 202 206--*--IGRA",
            "Scope 136 207--*--Tuberculin Skin Test (TST) or the Interferon Gamma Release Assay (IGRA)",
            "Person 209 217--*--Children",
            "Person 222 227--*--years",
            "Value 218 221--*--2-5",
            "Measurement 242 246--*--TSTs",
            "Value 233 241--*--negative",
            "Non-query-able 247 319--*--who have been in close contact with a case of active TB disease recently",
            "Informed_consent 321 414--*--Able and willing to provide fully informed consent or parent/guardian able to provide consent"
        ]
    },
    "NCT02511574_exc": {
        "Text": "no confirmation of the gestational age. ruptured membranes. painful regular uterine contractions. major fetal abnormalities. ",
        "Annotations": [
            "Negation 0 2--*--no",
            "Measurement 23 38--*--gestational age",
            "Condition 40 58--*--ruptured membranes",
            "Condition 60 96--*--painful regular uterine contractions",
            "Qualifier 98 103--*--major",
            "Condition 104 123--*--fetal abnormalities"
        ]
    },
    "NCT02954029_exc": {
        "Text": "congenital or acquired bleeding tendency. platelet count <50,000/ \u00b5L. hypersensitivity to shrimps, lobsters or beetles. ",
        "Annotations": [
            "Qualifier 14 22--*--acquired",
            "Qualifier 0 10--*--congenital",
            "Condition 23 40--*--bleeding tendency",
            "Scope 0 22--*--congenital or acquired",
            "Measurement 42 56--*--platelet count",
            "Value 57 68--*--<50,000/ \u00b5L",
            "Condition 70 86--*--hypersensitivity",
            "Qualifier 90 97--*--shrimps",
            "Qualifier 99 107--*--lobsters",
            "Qualifier 111 118--*--beetles",
            "Scope 90 118--*--shrimps, lobsters or beetles"
        ]
    },
    "NCT00787254_inc": {
        "Annotations": [
            "Drug 19 60--*--nonsteroid anti-inflammatory drug (NSAID)",
            "Temporal 71 107--*--on the day when consent was obtained",
            "Reference_point 74 107--*--the day when consent was obtained",
            "Condition 268 281--*--gastric ulcer",
            "Condition 285 299--*--duodenal ulcer",
            "Observation 257 264--*--history",
            "Scope 268 299--*--gastric ulcer or duodenal ulcer",
            "Observation 87 94--*--consent"
        ],
        "Text": "The patient was on nonsteroid anti-inflammatory drug (NSAID) treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started. . The patient was confirmed to have a history of gastric ulcer or duodenal ulcer. . "
    },
    "NCT03259243_exc": {
        "Text": "Patient with history of allergy in any kind anesthetic drug. Patient who pregnant. Patient who sign for single port gynecologic laparoscopic surgery or NOTE surgery. Patient whom the surgery is withhold or canceled. Patient whom the surgery is converted to laparotomy. ",
        "Annotations": [
            "Condition 24 31--*--allergy",
            "Drug 44 59--*--anesthetic drug",
            "Qualifier 35 43--*--any kind",
            "Observation 13 20--*--history",
            "Condition 73 81--*--pregnant",
            "Qualifier 104 115--*--single port",
            "Procedure 116 148--*--gynecologic laparoscopic surgery",
            "Procedure 152 164--*--NOTE surgery",
            "Procedure 183 190--*--surgery",
            "Observation 194 202--*--withhold",
            "Observation 206 214--*--canceled",
            "Scope 194 214--*--withhold or canceled",
            "Procedure 233 240--*--surgery",
            "Observation 244 256--*--converted to",
            "Procedure 257 267--*--laparotomy"
        ]
    },
    "NCT03253796_exc": {
        "Text": "Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4. Is a nursing or pregnant female, or intends to become pregnant within 6 months after receiving trial medication. Intends to donate eggs (female participants) or sperm (male participants) while receiving trial medication or within 6 months after trial medication. Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial. Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents. \u2022 Disease-modifying anti-rheumatic drugs (30 days off drug). \u2022 Live vaccinations (3 months off drug). \u2022 Investigational medications (30 days or 5 half-lives off drug, whichever is longer). \u2022 Bacille Calmette-Guerin (BCG) vaccination (12 months off drug). Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD. Has a history of latent or active granulomatous infection prior to Screening. Had a nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to Screening. Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced. Had a serious infection, has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline. Had a history of, or ongoing, chronic or recurrent infectious disease. Is known to be infected with human immunodeficiency virus (HIV) or seropositive for hepatitis C virus (HCV). Has had a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or malignancy. Has a history of lymphoproliferative disease. Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured). Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis. Has a history of or concurrent congestive heart failure of any grade. Has a transplanted organ (with the exception of a corneal transplant performed >= 3 months prior to baseline). Has current signs or symptoms of significant medical illness which could interfere with the trial, or require treatment that might interfere with the trial. Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years. ",
        "Annotations": [
            "Qualifier 4 13--*--bilateral",
            "Condition 14 26--*--sacroiliitis",
            "Qualifier 27 34--*--Grade 2",
            "Qualifier 38 48--*--unilateral",
            "Condition 49 61--*--sacroiliitis",
            "Qualifier 62 69--*--Grade 3",
            "Qualifier 73 80--*--Grade 4",
            "Scope 62 80--*--Grade 3 or Grade 4",
            "Condition 87 94--*--nursing",
            "Condition 98 106--*--pregnant",
            "Person 107 113--*--female",
            "Condition 136 144--*--pregnant",
            "Temporal 145 193--*--within 6 months after receiving trial medication",
            "Mood 118 135--*--intends to become",
            "Procedure 206 217--*--donate eggs",
            "Procedure 206 212;243 248--*--donate sperm",
            "Person 219 225--*--female",
            "Person 250 254--*--male",
            "Temporal 269 301--*--while receiving trial medication",
            "Temporal 305 343--*--within 6 months after trial medication",
            "Reference_point 327 343--*--trial medication",
            "Reference_point 285 301--*--trial medication",
            "Scope 206 268--*--donate eggs (female participants) or sperm (male participants)",
            "Scope 269 343--*--while receiving trial medication or within 6 months after trial medication",
            "Post-eligibility 345 476--*--Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial",
            "Drug 500 515--*--cytotoxic drugs",
            "Drug 527 539--*--chlorambucil",
            "Drug 541 557--*--cyclophosphamide",
            "Drug 559 575--*--nitrogen mustard",
            "Drug 586 603--*--alkylating agents",
            "Scope 527 603--*--chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents",
            "Drug 607 645--*--Disease-modifying anti-rheumatic drugs",
            "Temporal 647 663--*--30 days off drug",
            "Drug 668 685--*--Live vaccinations",
            "Temporal 687 704--*--3 months off drug",
            "Drug 709 736--*--Investigational medications",
            "Temporal 738 745;762 770--*--30 days off drug",
            "Temporal 749 770--*--5 half-lives off drug",
            "Scope 738 770--*--30 days or 5 half-lives off drug",
            "Drug 796 837--*--Bacille Calmette-Guerin (BCG) vaccination",
            "Temporal 839 857--*--12 months off drug",
            "Condition 877 899--*--inflammatory condition",
            "Condition 911 930--*--psoriatic arthritis",
            "Condition 939 951--*--Lyme disease",
            "Qualifier 932 938--*--active",
            "Condition 953 981--*--systemic lupus erythematosus",
            "Condition 983 1003--*--infectious arthritis",
            "Condition 1005 1015--*--vasculitis",
            "Condition 1017 1037--*--parvovirus infection",
            "Condition 1039 1059--*--rheumatoid arthritis",
            "Condition 1061 1075--*--active uveitis",
            "Condition 1080 1090--*--active IBD",
            "Scope 911 1090--*--psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD",
            "Qualifier 1119 1125--*--active",
            "Qualifier 1109 1115--*--latent",
            "Condition 1126 1149--*--granulomatous infection",
            "Temporal 1150 1168--*--prior to Screening",
            "Reference_point 1159 1168--*--Screening",
            "Scope 1109 1125--*--latent or active",
            "Condition 1176 1214--*--nontuberculous mycobacterial infection",
            "Condition 1218 1241--*--opportunistic infection",
            "Temporal 1242 1276--*--within 6 months prior to Screening",
            "Scope 1176 1241--*--nontuberculous mycobacterial infection or opportunistic infection",
            "Condition 1298 1306--*--infected",
            "Device 1307 1323--*--joint prosthesis",
            "Observation 1284 1291--*--history",
            "Drug 1341 1352--*--antibiotics",
            "Mood 1359 1368--*--suspected",
            "Condition 1369 1378--*--infection",
            "Device 1384 1400--*--joint prosthesis",
            "Condition 1461 1478--*--serious infection",
            "Procedure 1489 1501--*--hospitalized",
            "Condition 1509 1518--*--infection",
            "Drug 1545 1559--*--IV antibiotics",
            "Condition 1567 1576--*--infection",
            "Temporal 1577 1610--*--within 2 months prior to Baseline",
            "Qualifier 1653 1662--*--recurrent",
            "Qualifier 1642 1649--*--chronic",
            "Temporal 1633 1640--*--ongoing",
            "Observation 1618 1625--*--history",
            "Scope 1618 1640--*--history of, or ongoing",
            "Scope 1642 1662--*--chronic or recurrent",
            "Condition 1663 1681--*--infectious disease",
            "Condition 1712 1746--*--human immunodeficiency virus (HIV)",
            "Condition 1750 1790--*--seropositive for hepatitis C virus (HCV)",
            "Procedure 1802 1813--*--chest x-ray",
            "Temporal 1814 1848--*--within 2 months prior to Screening",
            "Condition 1863 1874--*--abnormality",
            "Mood 1875 1885--*--suggestive",
            "Temporal 1891 1898--*--current",
            "Qualifier 1899 1905--*--active",
            "Condition 1906 1915--*--infection",
            "Condition 1919 1929--*--malignancy",
            "Scope 1906 1929--*--infection or malignancy",
            "Condition 1948 1975--*--lymphoproliferative disease",
            "Condition 1987 1997--*--malignancy",
            "Temporal 1998 2029--*--within 5 years before screening",
            "Reference_point 2020 2029--*--screening",
            "Reference_point 1839 1848--*--Screening",
            "Condition 2046 2054;2070 2092--*--squamous carcinomas of the skin",
            "Condition 2059 2092--*--basal cell carcinomas of the skin",
            "Condition 2097 2114--*--carcinoma in situ",
            "Qualifier 2118 2124--*--cervix",
            "Qualifier 2139 2155--*--surgically cured",
            "Procedure 2139 2149--*--surgically",
            "Negation 2031 2041--*--exceptions",
            "Scope 2046 2155--*--squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured",
            "Condition 2181 2203--*--demyelinating diseases",
            "Observation 2164 2171--*--history",
            "Condition 2212 2230--*--multiple sclerosis",
            "Condition 2234 2248--*--optic neuritis",
            "Scope 2212 2248--*--multiple sclerosis or optic neuritis",
            "Condition 2281 2305--*--congestive heart failure",
            "Temporal 2270 2280--*--concurrent",
            "Observation 2256 2263--*--history",
            "Scope 2256 2280--*--history of or concurrent",
            "Procedure 2326 2344--*--transplanted organ",
            "Procedure 2370 2388--*--corneal transplant",
            "Temporal 2399 2428--*-->= 3 months prior to baseline",
            "Negation 2355 2367--*--exception of",
            "Condition 2476 2491--*--medical illness",
            "Qualifier 2464 2475--*--significant",
            "Observation 2504 2528--*--interfere with the trial",
            "Mood 2533 2540--*--require",
            "Procedure 2541 2550--*--treatment",
            "Observation 2562 2586--*--interfere with the trial",
            "Scope 2504 2586--*--interfere with the trial, or require treatment that might interfere with the trial",
            "Intoxication_considerations 2588 2716--*--Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years"
        ]
    },
    "NCT02357654_exc": {
        "Text": "day 3 transfers. ",
        "Annotations": [
            "Non-query-able 0 15--*--day 3 transfers"
        ]
    },
    "NCT02414399_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--1-59 months",
            "Temporal 47 68--*--greater than 6 months",
            "Observation 26 46--*--remain in study area",
            "Mood 18 22--*--Plan",
            "Procedure 70 94--*--Discharged from hospital",
            "Procedure 105 133--*--non-trauma related admission",
            "Visit 86 94--*--hospital"
        ],
        "Text": "Age 1-59 months,. Plan to remain in study area greater than 6 months. Discharged from hospital following non-trauma related admission. "
    },
    "NCT03262038_inc": {
        "Annotations": [
            "Person 0 10--*--3-17 years",
            "Value 0 10--*--3-17 years",
            "Measurement 12 18--*--weight",
            "Value 19 28--*--</= 100kg",
            "Procedure 56 76--*--orthopedic procedure",
            "Procedure 44 52;67 76--*--urologic procedure",
            "Drug 103 111--*--morphine",
            "Qualifier 91 102--*--intrathecal",
            "Scope 44 76--*--urologic or orthopedic procedure",
            "Condition 113 120--*--ability",
            "Procedure 138 184--*--pictorial pain assessment tools and techniques",
            "Procedure 128 134;148 184--*--verbal pain assessment tools and techniques",
            "Scope 128 184--*--verbal or pictorial pain assessment tools and techniques",
            "Informed_consent 186 229--*--informed consent and (if applicable) assent"
        ],
        "Text": "3-17 years. weight </= 100kg. scheduled for urologic or orthopedic procedure necessitating intrathecal morphine. ability to use verbal or pictorial pain assessment tools and techniques. informed consent and (if applicable) assent. "
    },
    "NCT00785213_exc": {
        "Annotations": [
            "Temporal 22 36--*--within 28 days",
            "Context_Error 0 63--*--Recent participation (within 28 days) in other research studies",
            "Post-eligibility 0 63--*--Recent participation (within 28 days) in other research studies",
            "Procedure 84 98--*--blood donation",
            "Procedure 102 117--*--plasma donation",
            "Qualifier 72 83--*--significant",
            "Temporal 65 71--*--Recent",
            "Scope 84 117--*--blood donation or plasma donation",
            "Undefined_semantics 72 83--*--significant",
            "Condition 119 127--*--Pregnant",
            "Condition 131 140--*--lactating",
            "Value 147 155--*--positive",
            "Temporal 156 168--*--at screening",
            "Measurement 173 207--*--human immunodeficiency virus (HIV)",
            "Measurement 249 272--*--hepatitis C virus (HCV)",
            "Measurement 209 244--*--hepatitis B surface antigen (HbsAg)",
            "Scope 173 272--*--human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)",
            "Condition 313 323--*--alcoholism",
            "Condition 327 337--*--drug abuse",
            "Observation 290 297--*--history",
            "Mood 301 309--*--evidence",
            "Temporal 274 280--*--Recent",
            "Temporal 282 288--*--2-year",
            "Scope 313 337--*--alcoholism or drug abuse",
            "Scope 290 309--*--history or evidence",
            "Post-eligibility 339 550--*--History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease",
            "Drug 579 584;599 615;626 655--*--drugs known to inhibit cytochrome (CYP) P450 enzymes",
            "Drug 579 584;599 607;619 655--*--drugs known to induce cytochrome (CYP) P450 enzymes",
            "Drug 579 584;599 615;663 684--*--drugs known to inhibit P-glycoprotein (P-gp)",
            "Drug 579 584;599 607;619 625;663 684--*--drugs known to induce P-glycoprotein (P-gp)",
            "Temporal 685 723--*--within 28 days prior to the first dose",
            "Temporal 728 748--*--throughout the study",
            "Scope 579 684--*--drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp)",
            "Condition 755 764--*--allergies",
            "Drug 768 783--*--quinine sulfate",
            "Drug 787 800--*--rosiglitazone",
            "Scope 768 800--*--quinine sulfate or rosiglitazone"
        ],
        "Text": "Recent participation (within 28 days) in other research studies . Recent significant blood donation or plasma donation . Pregnant or lactating . Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) . Recent (2-year) history or evidence of alcoholism or drug abuse . History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease . Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study . Drug allergies to quinine sulfate or rosiglitazone       .     . "
    },
    "NCT02322203_exc": {
        "Annotations": [
            "Procedure 20 46--*--lipid modification therapy",
            "Drug 77 84--*--statins",
            "Drug 86 94--*--fibrates",
            "Drug 99 121--*--bile acid sequestrants",
            "Scope 77 121--*--statins, fibrates and bile acid sequestrants",
            "Grammar_Error 95 98--*--and",
            "Drug 140 148--*--fish oil",
            "Subjective_judgement 124 240--*--Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study.",
            "Post-eligibility 124 240--*--Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study.",
            "Condition 256 275--*--acute liver disease",
            "Condition 286 306--*--peptic ulcer disease",
            "Temporal 279 285--*--active",
            "Measurement 332 348--*--uric acid levels",
            "Value 323 331--*--elevated",
            "Value 349 370--*--greater than 10 mg/dL",
            "Condition 374 378--*--gout",
            "Condition 380 389--*--Pregnancy",
            "Person 393 398--*--women",
            "Observation 409 422--*--breastfeeding",
            "Person 425 431--*--Female",
            "Drug 448 471--*--hormonal contraceptives",
            "Procedure 475 502--*--hormone replacement therapy",
            "Qualifier 561 572--*--stable dose",
            "Temporal 573 594--*--for at least 3 months",
            "Scope 448 502--*--hormonal contraceptives or hormone replacement therapy",
            "Grammar_Error 503 518--*--may be included",
            "Measurement 597 600--*--BMI",
            "Value 601 615--*--less than 18.5",
            "Measurement 631 637--*--weight",
            "Qualifier 643 666--*--varies greater than 20%",
            "Temporal 667 689--*--over the past 3 months",
            "Temporal 734 756--*--for at least six weeks",
            "Drug 812 815--*--BAS",
            "Drug 817 828--*--antibiotics",
            "Drug 830 844--*--anticoagulants",
            "Drug 846 861--*--anticonvulsants",
            "Drug 863 877--*--antiarrhythmic",
            "Drug 879 891--*--Cyclosporine",
            "Drug 893 906--*--Mycophenolate",
            "Drug 911 920--*--Synthroid",
            "Grammar_Error 907 910--*--and",
            "Scope 812 920--*--BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid",
            "Condition 936 952--*--chronic diarrhea",
            "Procedure 954 968--*--gastric bypass",
            "Procedure 972 991--*--lap band procedures",
            "Procedure 993 1001--*--ostomies",
            "Condition 1003 1026--*--bowel motility problems",
            "Condition 1037 1091--*--conditions that could affect intestinal fat absorption",
            "Undefined_semantics 1037 1091--*--conditions that could affect intestinal fat absorption",
            "Non-query-able 1094 1187--*--Subjects initiating new medications or patients on multiple medications may also be excluded.",
            "Condition 1189 1218--*--Inability to swallow capsules",
            "Condition 1257 1273--*--type II diabetes",
            "Condition 1247 1253;1265 1273--*--type I diabetes",
            "Measurement 1277 1282--*--HbA1c",
            "Value 1283 1300--*--greater than 6.5%",
            "Observation 1236 1243--*--history",
            "Scope 1247 1300--*--type I or type II diabetes or HbA1c greater than 6.5%",
            "Non-query-able 1303 1507--*--Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer.",
            "Subjective_judgement 1303 1507--*--Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer.",
            "Post-eligibility 1303 1507--*--Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer."
        ],
        "Text": "Subjects taking any lipid modification therapy, including but not limited to statins, fibrates and bile acid sequestrants. . Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study. . Subjects with acute liver disease or active peptic ulcer disease. . Subjects with elevated uric acid levels greater than 10 mg/dL or gout . Pregnancy or women currently breastfeeding. . Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months. . BMI less than 18.5 . Subjects with weight that varies greater than 20% over the past 3 months. . Subjects taking the following medications for at least six weeks, which may interfere with the study, will be excluded: BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid. Subjects with chronic diarrhea, gastric bypass or lap band procedures, ostomies, bowel motility problems, or other conditions that could affect intestinal fat absorption. . Subjects initiating new medications or patients on multiple medications may also be excluded. . Inability to swallow capsules . Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%. . Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer.       .     . "
    },
    "NCT02529475_inc": {
        "Annotations": [
            "Value 18 31--*--over 40 years",
            "Person 26 31--*--years",
            "Non-query-able 80 103--*--Informed consent signed",
            "Procedure 105 124--*--Medical examination",
            "Temporal 135 169--*--prior to participation in research",
            "Condition 199 216--*--inner ear disease",
            "Observation 188 195--*--history",
            "Negation 180 187--*--without",
            "Non-query-able 218 262--*--Recipient of a French social security scheme"
        ],
        "Text": "Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years). Informed consent signed. Medical examination performed prior to participation in research. Patients without history of inner ear disease. Recipient of a French social security scheme. "
    },
    "NCT00989261_exc": {
        "Annotations": [
            "Value 12 36--*--over the age of 85 years",
            "Person 21 24--*--age",
            "Subjective_judgement 44 81--*--at the discretion of the Investigator",
            "Post-eligibility 3 116--*--Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor.",
            "Condition 134 162--*--acute promyelocytic leukemia",
            "Condition 180 214--*--chronic myelogenous leukemia (CML)",
            "Condition 218 230--*--blast crisis",
            "Condition 235 238--*--AML",
            "Qualifier 239 249--*--in relapse",
            "Qualifier 253 263--*--refractory",
            "Temporal 264 310--*--after 3 or more previous lines of chemotherapy",
            "Multiplier 270 279--*--3 or more",
            "Temporal 280 288--*--previous",
            "Procedure 289 310--*--lines of chemotherapy",
            "Scope 239 263--*--in relapse or refractory",
            "Condition 339 342--*--AML",
            "Condition 357 360--*--MDS",
            "Temporal 346 356--*--antecedent",
            "Temporal 374 379--*--prior",
            "Condition 380 392--*--chemotherapy",
            "Scope 339 360--*--AML or antecedent MDS",
            "Condition 449 457--*--toxicity",
            "Qualifier 431 448--*--non-hematological",
            "Qualifier 408 430--*--clinically significant",
            "Subjective_judgement 408 430--*--clinically significant",
            "Value 466 474--*--Grade >1",
            "Measurement 478 490--*--NCI CTCAE v4",
            "Qualifier 466 490--*--Grade >1 by NCI CTCAE v4",
            "Procedure 502 514--*--chemotherapy",
            "Temporal 496 501--*--prior",
            "Temporal 554 583--*--within 100 days of transplant",
            "Condition 541 545--*--HSCT",
            "Temporal 532 540--*--have had",
            "Procedure 573 583--*--transplant",
            "Reference_point 573 583--*--transplant",
            "Drug 608 631--*--immunosuppressive drugs",
            "Qualifier 644 666--*--clinically significant",
            "Subjective_judgement 644 666--*--clinically significant",
            "Condition 667 692--*--graft-versus-host disease",
            "Procedure 703 712--*--treatment",
            "Mood 693 702--*--requiring",
            "Qualifier 725 733--*-->Grade 1",
            "Qualifier 745 762--*--non hematological",
            "Qualifier 734 744--*--persistent",
            "Multiplier 734 744--*--persistent",
            "Condition 763 771--*--toxicity",
            "Procedure 787 797--*--transplant",
            "Temporal 595 600--*--still",
            "Condition 820 857--*--central nervous system (CNS) leukemia",
            "Non-representable 859 1093--*--Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor.",
            "Drug 1136 1141--*--AC220",
            "Condition 1147 1191--*--Disseminated intravascular coagulation (DIC)",
            "Procedure 1246 1259--*--Major surgery",
            "Temporal 1260 1294--*--within 4 weeks prior to enrollment",
            "Reference_point 1284 1294--*--enrollment",
            "Procedure 1313 1330--*--Radiation therapy",
            "Temporal 1331 1354;1375 1380--*--within 4 weeks prior to study",
            "Temporal 1359 1380--*--concurrent with study",
            "Reference_point 1375 1380--*--study",
            "Scope 1331 1380--*--within 4 weeks prior to, or concurrent with study",
            "Condition 1416 1439--*--prolong QT/QTc interval",
            "Drug 1405 1439--*--drugs that prolong QT/QTc interval",
            "Drug 1451 1468--*--CYP3A4 inhibitors",
            "Drug 1506 1517--*--antibiotics",
            "Drug 1519 1530--*--antifungals",
            "Drug 1542 1556--*--antimicrobials",
            "Qualifier 1411 1439--*--that prolong QT/QTc interval",
            "Negation 1484 1505--*--with the exception of",
            "Scope 1506 1556--*--antibiotics, antifungals, and other antimicrobials",
            "Scope 1405 1468--*--drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors",
            "Condition 1746 1768--*--cardiovascular disease",
            "Qualifier 1718 1730--*--Uncontrolled",
            "Qualifier 1734 1745--*--significant",
            "Scope 1718 1745--*--Uncontrolled or significant",
            "Condition 1788 1796--*--pregnant",
            "Condition 1798 1807--*--lactating",
            "Mood 1812 1821--*--unwilling",
            "Condition 1849 1871--*--childbearing potential",
            "Condition 1829 1842--*--contraception",
            "Person 1877 1880--*--Men",
            "Mood 1889 1898--*--unwilling",
            "Drug 1906 1919--*--contraception",
            "Observation 1923 1967--*--their partners are of childbearing potential",
            "Non-representable 1923 1967--*--their partners are of childbearing potential",
            "Condition 1994 2003--*--infection",
            "Qualifier 1981 1993--*--uncontrolled",
            "Temporal 1973 1979--*--Active",
            "Condition 2009 2037--*--Human immunodeficiency virus",
            "Measurement 2009 2037--*--Human immunodeficiency virus",
            "Value 2038 2048--*--positivity",
            "Condition 2061 2072--*--hepatitis B",
            "Condition 2061 2070;2076 2077--*--hepatitis C",
            "Temporal 2054 2060--*--Active",
            "Condition 2094 2107--*--liver disease",
            "Temporal 2087 2093--*--active",
            "Scope 2061 2077--*--hepatitis B or C",
            "Condition 2124 2130--*--cancer",
            "Observation 2113 2120--*--History",
            "Condition 2170 2181--*--skin cancer",
            "Qualifier 2157 2169--*--nonmelanotic",
            "Qualifier 2139 2153--*--Stage 1 cervix",
            "Negation 2132 2138--*--except"
        ],
        "Text": "1. Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor. . 2. Diagnosis of acute promyelocytic leukemia . 3. Diagnosis of chronic myelogenous leukemia (CML) in blast crisis . 4. AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment . 5. AML or antecedent MDS secondary to prior chemotherapy . 6. Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy . 7. Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant . 8. Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor. . 9. Patients who have previously received AC220 . 10. Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical assessment) . 11. Major surgery within 4 weeks prior to enrollment in the study . 12. Radiation therapy within 4 weeks prior to, or concurrent with study . 13. Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient. . 14. Uncontrolled or significant cardiovascular disease . 15. Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential . 16. Men who are unwilling to use contraception if their partners are of childbearing potential . 17. Active, uncontrolled infection . 18. Human immunodeficiency virus positivity . 19. Active hepatitis B or C or other active liver disease . 20. History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       .     . "
    },
    "NCT01491295_inc": {
        "Annotations": [
            "Measurement 0 5--*--HBsAg",
            "Value 6 14--*--positive",
            "Temporal 19 37--*--more than 6 months",
            "Measurement 39 44--*--HBeAg",
            "Value 45 53--*--positive",
            "Measurement 57 62--*--HBeAg",
            "Value 63 71--*--negative",
            "Scope 39 71--*--HBeAg-positive or HBeAg-negative",
            "Person 75 78--*--Age",
            "Value 79 87--*--> 20 y/o",
            "Drug 96 106--*--lamivudine",
            "Drug 107 115--*--adefovir",
            "Temporal 130 146--*--more than 1 year",
            "Observation 163 184--*--lamivudine resistance",
            "Observation 186 191--*--LAM-R",
            "Measurement 202 209--*--HBV DNA",
            "Value 213 225--*--undetectable",
            "Value 227 237--*--< 20 IU/ml",
            "Temporal 239 256--*--during enrollment",
            "Reference_point 246 256--*--enrollment",
            "Scope 96 115--*--lamivudine/adefovir"
        ],
        "Text": "HBsAg-positive for more than 6 months (HBeAg-positive or HBeAg-negative).. Age > 20 y/o.. Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.. "
    },
    "NCT01184638_inc": {
        "Annotations": [
            "Informed_consent 0 31--*--Patients with informed consents",
            "Condition 41 69--*--basal disorders of neurology",
            "Condition 41 59;74 86--*--basal disorders of psychiatrics",
            "Negation 33 40--*--Without",
            "Scope 41 86--*--basal disorders of neurology and psychiatrics"
        ],
        "Text": "Patients with informed consents. Without basal disorders of neurology and psychiatrics. "
    },
    "NCT03333655_inc": {
        "Text": "Response assessment of complete response (CR), partial response (PR), long stable disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.. Availability of tumor biopsy material extracted and preserved by the investigating site.. ",
        "Annotations": [
            "Measurement 0 19--*--Response assessment",
            "Value 23 45--*--complete response (CR)",
            "Value 47 68--*--partial response (PR)",
            "Value 70 94--*--long stable disease (SD)",
            "Temporal 95 108--*--for >3 months",
            "Scope 23 94--*--complete response (CR), partial response (PR), long stable disease (SD)",
            "Qualifier 116 122--*--cancer",
            "Procedure 123 146--*--immunotherapy treatment",
            "Condition 151 168--*--metastatic cancer",
            "Condition 172 196--*--hematologic malignancies",
            "Procedure 214 226--*--marketed CPI",
            "Observation 238 291--*--participation in a Roche/Genentech CPI clinical trial",
            "Scope 151 196--*--metastatic cancer or hematologic malignancies",
            "Non-representable 294 381--*--Availability of tumor biopsy material extracted and preserved by the investigating site"
        ]
    },
    "NCT01642875_inc": {
        "Text": "Primary periampullary tumor. R0, R1 resection. Chronic pancreatitis requiring pancreatoduodenectomy. ",
        "Annotations": [
            "Qualifier 0 7--*--Primary",
            "Condition 8 27--*--periampullary tumor",
            "Procedure 33 45--*--R1 resection",
            "Procedure 29 31;36 45--*--R0 resection",
            "Condition 47 67--*--Chronic pancreatitis",
            "Observation 68 77--*--requiring",
            "Procedure 78 99--*--pancreatoduodenectomy"
        ]
    },
    "NCT03056287_inc": {
        "Text": "1) age 50-70 . 2) stroke within the past 6 to 60 months, . 3) major depressive disorder (PHQ-9 > 10) and diagnosed using the Structured Clinical Interview for Depression (SCID) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), . 4) residual paresis in the lower extremity (Fugl-Meyer LE motor score <34), . 5) ability to walk without assistance and without an AFO on the treadmill \u2265 30 seconds at speeds ranging from 0.2-0.8 m/s, . 6) no antidepressant medications or clinically able to discontinue medications, . 7) HRSD question #9 regarding suicide <2, . 8) provision of informed consent. In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist. . ",
        "Annotations": [
            "Person 3 6--*--age",
            "Value 7 12--*--50-70",
            "Condition 17 23--*--stroke",
            "Temporal 24 54--*--within the past 6 to 60 months",
            "Condition 60 85--*--major depressive disorder",
            "Measurement 87 92--*--PHQ-9",
            "Value 93 97--*--> 10",
            "Procedure 123 270--*--Structured Clinical Interview for Depression (SCID) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)",
            "Condition 276 292--*--residual paresis",
            "Qualifier 300 315--*--lower extremity",
            "Measurement 317 342--*--Fugl-Meyer LE motor score",
            "Value 343 346--*--<34",
            "Condition 353 387--*--ability to walk without assistance",
            "Measurement 403 423--*--AFO on the treadmill",
            "Value 424 436--*--\u2265 30 seconds",
            "Negation 392 399--*--without",
            "Qualifier 440 446--*--speeds",
            "Value 455 471--*--from 0.2-0.8 m/s",
            "Drug 480 494--*--antidepressant",
            "Negation 477 479--*--no",
            "Condition 510 552--*--clinically able to discontinue medications",
            "Undefined_semantics 510 552--*--clinically able to discontinue medications",
            "Subjective_judgement 510 552--*--clinically able to discontinue medications",
            "Measurement 558 574--*--HRSD question #9",
            "Value 593 595--*--<2",
            "Non-query-able 601 631--*--provision of informed consent.",
            "Post-eligibility 632 801--*--In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist.",
            "Parsing_Error 0 2--*--1)",
            "Parsing_Error 14 16--*--2)",
            "Parsing_Error 57 59--*--3)",
            "Parsing_Error 273 275--*--4)",
            "Parsing_Error 350 352--*--5)",
            "Parsing_Error 474 476--*--6)",
            "Parsing_Error 555 557--*--7)",
            "Parsing_Error 598 600--*--8)"
        ]
    },
    "NCT00785213_inc": {
        "Annotations": [
            "Value 15 33--*--18-45 years of age",
            "Condition 0 7--*--Healthy",
            "Person 8 14--*--adults",
            "Person 27 33--*--of age",
            "Condition 39 46--*--smoking",
            "Negation 35 38--*--Non",
            "Condition 52 60--*--pregnant",
            "Negation 48 51--*--Non",
            "Condition 79 97--*--surgically sterile",
            "Procedure 79 89--*--surgically",
            "Condition 62 77--*--post-menopausal",
            "Procedure 117 139--*--contraceptive measures",
            "Qualifier 107 116--*--effective",
            "Undefined_semantics 107 116--*--effective",
            "Scope 62 139--*--post-menopausal, surgically sterile or using effective contraceptive measures",
            "Scope 48 60--*--Non-pregnant",
            "Measurement 142 163--*--Body mass index (BMI)",
            "Value 164 188--*--less than or equal to 32",
            "Observation 224 239--*--medical history",
            "Procedure 244 264--*--physical examination",
            "Condition 190 207--*--Medically healthy",
            "Scope 224 264--*--medical history and physical examination",
            "Measurement 266 276--*--Hemoglobin",
            "Value 277 295--*--> or = to 11.5g/dL",
            "Temporal 333 363--*--within 28 days prior to dosing",
            "Reference_point 357 363--*--dosing",
            "Procedure 315 332--*--screening process",
            "Post-eligibility 365 412--*--Provision of voluntary written informed consent"
        ],
        "Text": "Healthy adults 18-45 years of age . Non-smoking . Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) . Body mass index (BMI) less than or equal to 32 . Medically healthy on the basis of medical history and physical examination . Hemoglobin > or = to 11.5g/dL . Completion of the screening process within 28 days prior to dosing . Provision of voluntary written informed consent . "
    },
    "NCT02322203_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Value 26 43--*--at least 18 years",
            "Person 47 50--*--age",
            "Temporal 51 72--*--at time of enrollment",
            "Reference_point 54 72--*--time of enrollment",
            "Post-eligibility 75 174--*--Subject understands the investigational nature of the study and provides written, informed consent."
        ],
        "Text": "Males and females who are at least 18 years of age at time of enrollment. . Subject understands the investigational nature of the study and provides written, informed consent. . "
    },
    "NCT03262038_exc": {
        "Annotations": [
            "Procedure 27 56--*--pictorial pain scoring scales",
            "Procedure 17 23;37 56--*--verbal pain scoring scales",
            "Condition 0 9--*--Inability",
            "Scope 17 56--*--verbal or pictorial pain scoring scales",
            "Condition 58 74--*--hypersensitivity",
            "Drug 78 113--*--selective 5-HT receptor antagonists",
            "Condition 125 152--*--congenital long QT syndrome",
            "Condition 161 179--*--hepatic impairment",
            "Qualifier 154 160--*--severe",
            "Condition 181 190--*--pregnancy",
            "Condition 194 201--*--nursing"
        ],
        "Text": "Inability to use verbal or pictorial pain scoring scales. hypersensitivity to selective 5-HT receptor antagonists. diagnosed congenital long QT syndrome. severe hepatic impairment. pregnancy or nursing mothers. "
    },
    "NCT00989261_inc": {
        "Annotations": [
            "Person 3 8--*--Males",
            "Person 13 20--*--females",
            "Person 21 24--*--age",
            "Value 25 34--*--\u226518 years",
            "Condition 45 52--*--relapse",
            "Condition 56 66--*--refractory",
            "Scope 45 66--*--relapse or refractory",
            "Multiplier 38 44--*--second",
            "Person 72 77--*--Males",
            "Person 82 89--*--females",
            "Person 90 93--*--age",
            "Value 94 103--*--\u226560 years",
            "Multiplier 107 112--*--first",
            "Condition 113 120--*--relapse",
            "Condition 124 134--*--refractory",
            "Scope 113 134--*--relapse or refractory",
            "Procedure 159 177--*--bone marrow sample",
            "Temporal 150 158--*--baseline",
            "Qualifier 189 215--*--Morphologically documented",
            "Qualifier 216 223--*--primary",
            "Condition 224 227--*--AML",
            "Condition 231 234--*--AML",
            "Condition 248 272--*--myelodysplastic syndrome",
            "Condition 274 277--*--MDS",
            "Value 283 287--*--\u226520%",
            "Measurement 288 299--*--bone marrow",
            "Measurement 303 320--*--peripheral blasts",
            "Scope 288 320--*--bone marrow or peripheral blasts",
            "Procedure 341 381--*--World Health Organization (WHO) criteria",
            "Procedure 396 412--*--pathology review",
            "Non-representable 442 480--*--Able to swallow the liquid study drug.",
            "Post-eligibility 442 480--*--Able to swallow the liquid study drug.",
            "Measurement 485 508--*--ECOG performance status",
            "Value 512 518--*--0 to 2",
            "Non-representable 520 972--*--7. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor.",
            "Condition 1037 1047--*--toxicities",
            "Qualifier 1019 1036--*--non-hematological",
            "Qualifier 996 1018--*--clinically significant",
            "Temporal 1053 1058--*--prior",
            "Qualifier 1077 1085--*--\u2264Grade 1",
            "Value 1077 1085--*--\u2264Grade 1",
            "Qualifier 1048 1068--*--from prior treatment",
            "Procedure 1059 1068--*--treatment",
            "Drug 1110 1125--*--FLT3 inhibitors",
            "Mood 1129 1138--*--permitted",
            "Procedure 1097 1104--*--therapy",
            "Procedure 1156 1165--*--treatment",
            "Drug 1171 1176--*--AC220",
            "Negation 1140 1146--*--except",
            "Measurement 1183 1199--*--Serum creatinine",
            "Value 1200 1210--*--\u22641.5 \u00d7 ULN",
            "Measurement 1215 1247--*--glomerular filtration rate (GFR)",
            "Value 1248 1259--*--> 30 mL/min",
            "Measurement 1265 1280--*--Serum potassium",
            "Measurement 1265 1270;1282 1291--*--Serum magnesium",
            "Measurement 1265 1270;1297 1304--*--Serum calcium",
            "Value 1322 1365--*--at least within institutional normal limits",
            "Scope 1265 1304--*--Serum potassium, magnesium, and calcium",
            "Measurement 1372 1393--*--Total serum bilirubin",
            "Value 1394 1404--*--\u22641.5 \u00d7 ULN",
            "Measurement 1410 1444--*--Serum aspartate transaminase (AST)",
            "Measurement 1452 1478--*--alanine transaminase (ALT)",
            "Value 1479 1489--*--\u22642.5 \u00d7 ULN",
            "Measurement 1550 1564--*--pregnancy test",
            "Value 1541 1549--*--negative",
            "Procedure 1566 1577--*--urine \u03b2-hCG",
            "Person 1495 1502--*--Females",
            "Condition 1506 1528--*--childbearing potential",
            "Scope 1495 1528--*--Females of childbearing potential",
            "Pregnancy_considerations 1585 1729--*--Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.",
            "Pregnancy_considerations 1495 1579--*--Females of childbearing potential must have a negative pregnancy test (urine \u03b2-hCG).",
            "Post-eligibility 1735 1777--*--Written informed consent must be provided."
        ],
        "Text": "1. Males and females age \u226518 years in second relapse or refractory. . 2. Males and females age \u226560 years in first relapse or refractory. . 3. Must have baseline bone marrow sample taken. . 4. Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS with \u226520% bone marrow or peripheral blasts), as defined by the World Health Organization (WHO) criteria, confirmed by pathology review at treating institution. . 5. Able to swallow the liquid study drug. . 6. ECOG performance status of 0 to 2 . 7. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor. . 8. Persistent chronic clinically significant non-hematological toxicities from prior treatment must be \u2264Grade 1. . 9. Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220. . 10. Serum creatinine \u22641.5 \u00d7 ULN and glomerular filtration rate (GFR) > 30 mL/min . 11. Serum potassium, magnesium, and calcium levels should be at least within institutional normal limits. . 12. Total serum bilirubin \u22641.5 \u00d7 ULN . 13. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) \u22642.5 \u00d7 ULN . 14. Females of childbearing potential must have a negative pregnancy test (urine \u03b2-hCG). . 15. Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study. . 16. Written informed consent must be provided. . "
    },
    "NCT02529475_exc": {
        "Annotations": [
            "Person 9 15--*--minors",
            "Person 31 72--*--legal protection regime type guardianship",
            "Condition 74 97--*--Respiratory pathologies",
            "Condition 99 113--*--cardiovascular",
            "Condition 115 120--*--renal",
            "Condition 122 130--*--diabetes",
            "Condition 132 146--*--Claustrophobia",
            "Condition 148 165--*--Contraindications",
            "Device 183 197--*--magnetic field",
            "Condition 199 216--*--Contraindications",
            "Drug 230 237--*--Dotarem"
        ],
        "Text": "Patients minors. Patients on a legal protection regime type guardianship. Respiratory pathologies, cardiovascular, renal, diabetes. Claustrophobia. Contraindications to exposure to a magnetic field. Contraindications to injecting Dotarem \u00ae. "
    },
    "NCT03333655_exc": {
        "Text": "Participants taking CPI combination therapies with chemotherapy are not permitted.. Pregnant, lactating, or intending to become pregnant during the study.. ",
        "Annotations": [
            "Procedure 20 45--*--CPI combination therapies",
            "Procedure 51 63--*--chemotherapy",
            "Condition 84 92--*--Pregnant",
            "Condition 94 103--*--lactating",
            "Mood 108 127--*--intending to become",
            "Condition 128 136--*--pregnant",
            "Temporal 137 153--*--during the study"
        ]
    },
    "NCT01184638_exc": {
        "Annotations": [
            "Condition 20 39--*--cognitive disorders",
            "Condition 46 76--*--chronic neurological disorders",
            "Observation 78 96--*--Cannot communicate",
            "Observation 117 129--*--Cannot stand",
            "Procedure 130 148--*--general anesthesia"
        ],
        "Text": "With the history of cognitive disorders. With chronic neurological disorders. Cannot communicate with investigators. Cannot stand general anesthesia. "
    },
    "NCT01491295_exc": {
        "Annotations": [
            "Condition 0 3;14 25--*--HCV coinfection",
            "Condition 14 25;5 8--*--coinfection HIV",
            "Condition 10 25--*--HDV coinfection",
            "Condition 41 44--*--HCC",
            "Condition 46 56--*--malignancy",
            "Condition 74 89--*--liver cirrhosis",
            "Qualifier 60 73--*--decompensated",
            "Qualifier 28 40--*--Uncontrolled",
            "Measurement 91 100--*--CTP score",
            "Value 101 104--*--= 7",
            "Condition 108 114--*--Uremia",
            "Measurement 127 137--*--Creatinine",
            "Value 138 147--*--= 2 mg/dl"
        ],
        "Text": "HCV, HIV, HDV coinfection.. Uncontrolled HCC, malignancy or decompensated liver cirrhosis (CTP score = 7).. Uremia patients or Creatinine = 2 mg/dl.. "
    },
    "NCT01642875_exc": {
        "Text": "Metastatic tumor. Locally unresectable tumor. Previous gastric resection. ASA IV-V. Age under 18 years. Preoperative complete parenteral or enteral feeding. Immunosuppressive therapy before operation. Severe malnutrition. Lack of the patient's consent for the trial participation, feeding tube insertion or epidural analgesia. ",
        "Annotations": [
            "Condition 11 16--*--tumor",
            "Qualifier 18 38--*--Locally unresectable",
            "Condition 39 44--*--tumor",
            "Qualifier 0 10--*--Metastatic",
            "Temporal 46 54--*--Previous",
            "Procedure 55 72--*--gastric resection",
            "Measurement 74 77--*--ASA",
            "Value 78 82--*--IV-V",
            "Person 84 87--*--Age",
            "Value 88 102--*--under 18 years",
            "Temporal 104 116--*--Preoperative",
            "Condition 117 136;148 155--*--complete parenteral feeding",
            "Condition 117 125;140 155--*--complete enteral feeding",
            "Scope 117 155--*--complete parenteral or enteral feeding",
            "Procedure 157 182--*--Immunosuppressive therapy",
            "Temporal 183 199--*--before operation",
            "Procedure 190 199--*--operation",
            "Reference_point 190 199--*--operation",
            "Qualifier 201 207--*--Severe",
            "Condition 208 220--*--malnutrition",
            "Informed_consent 222 325--*--Lack of the patient's consent for the trial participation, feeding tube insertion or epidural analgesia"
        ]
    },
    "NCT03056287_exc": {
        "Text": "1. Unable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking; . 2. history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's; . 3. History of oxygen dependence; . 4. Preexisting neurological disorders, dementia or previous stroke; . 5. History of major head trauma; . 6. Legal blindness or severe visual impairment; . 7. history of psychosis or other Axis I disorder that is primary; . 8. Life expectancy <1 yr.; . 9. Severe arthritis or other problems that limit passive range of motion; . 10. History of DVT or pulmonary embolism within 6 months; . 11. Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions; . 12. Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest; . 13. attempt of suicide in the last 2 years or at suicidal risk assessed by SCID interview; . 14. Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising \u2265 2 times per week (\u226520 minutes); . 16) Presence of non-MR compatible implants, pregnancy or severe claustrophobia.       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 281 283--*--3.",
            "Parsing_Error 114 116--*--2.",
            "Parsing_Error 315 317--*--4.",
            "Parsing_Error 384 386--*--5.",
            "Parsing_Error 418 420--*--6.",
            "Parsing_Error 534 536--*--8.",
            "Parsing_Error 467 469--*--7.",
            "Parsing_Error 562 564--*--9.",
            "Parsing_Error 637 640--*--10.",
            "Parsing_Error 696 699--*--11.",
            "Parsing_Error 794 797--*--12.",
            "Parsing_Error 876 879--*--13.",
            "Parsing_Error 968 971--*--14.",
            "Parsing_Error 1110 1113--*--16)",
            "Condition 3 39--*--Unable to ambulate at least 150 feet",
            "Temporal 40 45--*--prior",
            "Condition 49 55--*--stroke",
            "Reference_point 49 55--*--stroke",
            "Condition 72 97--*--intermittent claudication",
            "Qualifier 98 111--*--while walking",
            "Observation 117 124--*--history",
            "Condition 128 152--*--congestive heart failure",
            "Condition 154 182--*--unstable cardiac arrhythmias",
            "Condition 184 211--*--hypertrophic cardiomyopathy",
            "Condition 213 235--*--severe aortic stenosis",
            "Condition 237 243--*--angina",
            "Condition 247 262--*--dyspnea at rest",
            "Condition 247 254;266 278--*--dyspnea during ADL's",
            "Scope 128 278--*--congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's",
            "Condition 295 312--*--oxygen dependence",
            "Observation 284 291--*--History",
            "Condition 330 352--*--neurological disorders",
            "Condition 354 362--*--dementia",
            "Condition 375 381--*--stroke",
            "Temporal 366 374--*--previous",
            "Temporal 318 329--*--Preexisting",
            "Condition 398 415--*--major head trauma",
            "Observation 387 394--*--History",
            "Condition 440 464--*--severe visual impairment",
            "Condition 421 436--*--Legal blindness",
            "Condition 481 490--*--psychosis",
            "Condition 500 515--*--Axis I disorder",
            "Qualifier 524 531--*--primary",
            "Observation 470 477--*--history",
            "Observation 537 552--*--Life expectancy",
            "Value 553 558--*--<1 yr",
            "Condition 565 581--*--Severe arthritis",
            "Condition 591 634--*--problems that limit passive range of motion",
            "Undefined_semantics 591 634--*--problems that limit passive range of motion",
            "Condition 652 655--*--DVT",
            "Condition 659 677--*--pulmonary embolism",
            "Temporal 678 693--*--within 6 months",
            "Observation 641 648--*--History",
            "Scope 652 693--*--DVT or pulmonary embolism within 6 months",
            "Condition 713 721--*--diabetes",
            "Qualifier 700 712--*--Uncontrolled",
            "Condition 734 745--*--weight loss",
            "Condition 747 760--*--diabetic coma",
            "Condition 774 791--*--insulin reactions",
            "Multiplier 765 773--*--frequent",
            "Condition 798 817--*--Severe hypertension",
            "Measurement 823 831--*--systolic",
            "Value 832 841--*-->200 mmHg",
            "Measurement 846 855--*--diastolic",
            "Value 856 865--*-->110 mmHg",
            "Condition 880 898--*--attempt of suicide",
            "Temporal 899 918--*--in the last 2 years",
            "Condition 922 938--*--at suicidal risk",
            "Procedure 951 965--*--SCID interview",
            "Non-query-able 972 1107--*--Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising \u2265 2 times per week (\u226520 minutes)",
            "Context_Error 972 1107--*--Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising \u2265 2 times per week (\u226520 minutes)",
            "Device 1126 1152--*--non-MR compatible implants",
            "Condition 1154 1163--*--pregnancy",
            "Condition 1174 1188--*--claustrophobia",
            "Qualifier 1167 1173--*--severe"
        ]
    },
    "NCT02284737_inc": {
        "Annotations": [
            "Non-query-able 0 69--*--Provision of informed consent prior to any study specific procedures;",
            "Person 71 74--*--Men",
            "Person 79 84--*--women",
            "Value 85 103--*--18 years and older",
            "Person 88 93--*--years",
            "Qualifier 106 113--*--Group I",
            "Condition 114 117--*--PAH",
            "Measurement 132 136--*--mPAP",
            "Value 136 143--*--=25mmHg",
            "Measurement 145 149--*--PCWP",
            "Value 149 156--*--<15mmHg",
            "Measurement 161 164--*--PVR",
            "Measurement 174 188--*--(mPAP-PCWP)/CO",
            "Value 189 204--*-->3.0 Woods unit",
            "Scope 161 189--*--PVR[The PVR =(mPAP-PCWP)/CO]",
            "Scope 132 204--*--mPAP=25mmHg, PCWP<15mmHg and PVR[The PVR =(mPAP-PCWP)/CO]>3.0 Woods unit",
            "Scope 106 117--*--Group I PAH"
        ],
        "Text": "Provision of informed consent prior to any study specific procedures;. Men and women 18 years and older;. Group I PAH, defined as a mPAP=25mmHg, PCWP<15mmHg and PVR[The PVR =(mPAP-PCWP)/CO]>3.0 Woods unit.. "
    },
    "NCT02707809_exc": {
        "Annotations": [
            "Condition 0 8--*--allergic",
            "Observation 9 16--*--history",
            "Drug 20 35--*--dexmedetomidine",
            "Qualifier 37 47--*--refractory",
            "Condition 48 59--*--bradycardia",
            "Value 60 68--*--< 60 bpm",
            "Qualifier 69 86--*--despite treatment",
            "Procedure 77 86--*--treatment",
            "Qualifier 88 94--*--severe",
            "Condition 95 117--*--atrioventricular block",
            "Qualifier 119 122;131 137--*--2nd degree",
            "Qualifier 127 137--*--3rd degree",
            "Scope 119 137--*--2nd and 3rd degree",
            "Temporal 140 148--*--previous",
            "Procedure 149 168--*--operation of tongue"
        ],
        "Text": "allergic history to dexmedetomidine. refractory bradycardia < 60 bpm despite treatment. severe atrioventricular block (2nd and 3rd degree). previous operation of tongue. "
    },
    "NCT00862446_inc": {
        "Annotations": [
            "Visit 15 42--*--newborn intensive care unit",
            "Person 0 7--*--Infants",
            "Condition 44 59--*--TPN cholestasis",
            "Multiplier 63 81--*--at least 2.5 mg/dl",
            "Procedure 95 108--*--TPN treatment",
            "Multiplier 109 131--*--for at least one month",
            "Informed_consent 133 156--*--signed informed consent"
        ],
        "Text": "Infants in the newborn intensive care unit. TPN cholestasis of at least 2.5 mg/dl. Anticipated TPN treatment for at least one month. signed informed consent. "
    },
    "NCT02462317_inc": {
        "Annotations": [
            "Multiplier 0 5--*--First",
            "Multiplier 6 12--*--single",
            "Condition 13 19--*--stroke",
            "Qualifier 20 29--*--ischaemic",
            "Qualifier 33 45--*--haemorrhagic",
            "Condition 64 74--*--hemiplegia",
            "Scope 20 45--*--ischaemic or haemorrhagic",
            "Condition 76 81--*--Stoke",
            "Temporal 82 105--*--since less than 2 month",
            "Non-representable 107 130--*--A sufficient understood",
            "Condition 134 144--*--spasticity",
            "Measurement 149 162--*--Tardieu score",
            "Value 163 182--*--upper or equal to 2",
            "Multiplier 186 198--*--at least one",
            "Qualifier 216 236--*--muscle-triceps surae",
            "Qualifier 238 256--*--flexors of fingers",
            "Qualifier 261 266--*--wrist",
            "Qualifier 274 279--*--elbow",
            "Scope 216 279--*--muscle-triceps surae, flexors of fingers, of wrist and of elbow",
            "Informed_consent 281 295--*--A free consent"
        ],
        "Text": "First single stroke ischaemic or haemorrhagic responsible of an hemiplegia. Stoke since less than 2 month. A sufficient understood. A spasticity : a Tardieu score upper or equal to 2 on at least one of the following muscle-triceps surae, flexors of fingers, of wrist and of elbow. A free consent. "
    },
    "NCT03372304_inc": {
        "Annotations": [
            "Measurement 0 52--*--American Society of Anesthesiologists Classification",
            "Value 53 58--*--I-III",
            "Post-eligibility 61 160--*--ormal cognitive function in order to sign written, informed consent and to understand trial protoco",
            "Post-eligibility 163 227--*--Agreement to the trial protocol, including the randomized manner"
        ],
        "Text": "American Society of Anesthesiologists Classification I-III. Normal cognitive function in order to sign written, informed consent and to understand trial protocol. Agreement to the trial protocol, including the randomized manner. "
    },
    "NCT02754583_exc": {
        "Text": "School districts that are too difficult to reach (more than a 3-hour walk from the farthest place reachable by a four-wheel drive vehicle). School districts in the 2 urban regions of the study area. Refusal of village chief. All residents residing near to the well sites that are randomly selected for this study.. Refusal of participant [or parent/guardian]. ",
        "Annotations": [
            "Visit 0 48--*--School districts that are too difficult to reach",
            "Measurement 69 137--*--walk from the farthest place reachable by a four-wheel drive vehicle",
            "Value 50 68--*--more than a 3-hour",
            "Visit 140 197--*--School districts in the 2 urban regions of the study area",
            "Non-query-able 199 223--*--Refusal of village chief",
            "Observation 239 247--*--residing",
            "Visit 248 270--*--near to the well sites",
            "Informed_consent 315 358--*--Refusal of participant [or parent/guardian]"
        ]
    },
    "NCT02966236_inc": {
        "Text": "Complex kidney stone (staghorn calculi GUYS III and IV). ",
        "Annotations": [
            "Condition 0 20--*--Complex kidney stone",
            "Condition 22 38--*--staghorn calculi",
            "Measurement 39 43--*--GUYS",
            "Value 44 54--*--III and IV",
            "Scope 22 54--*--staghorn calculi GUYS III and IV"
        ]
    },
    "NCT02735902_exc": {
        "Annotations": [
            "Competing_trial 0 45--*--The patient is participating in another study",
            "Non-query-able 47 115--*--The patient is in an exclusion period determined by a previous study",
            "Informed_consent 117 182--*--The patient or his/her representative refuses to sign the consent",
            "Post-eligibility 184 258--*--It is impossible to correctly inform the patient or his/her representative",
            "Pregnancy_considerations 260 300--*--The patient is pregnant or breastfeeding",
            "Condition 320 336--*--contraindication",
            "Non-representable 302 409--*--The patient has a contraindication (or an incompatible drug association) for a treatment used in this study",
            "Device 429 443--*--coronary stent",
            "Temporal 448 467--*--less than 12 months",
            "Drug 583 590--*--aspirin",
            "Condition 591 598--*--allergy",
            "Observation 605 618--*--bleeding risk",
            "Qualifier 600 604--*--High",
            "Measurement 628 637--*--platelets",
            "Value 638 651--*--<50,000 / mm3",
            "Measurement 670 672--*--Hb",
            "Value 673 684--*--<8.5 g / dL",
            "Condition 697 720--*--intracranial hemorrhage",
            "Condition 724 741--*--subdural hematoma",
            "Procedure 743 757--*--major surgery,",
            "Procedure 758 782--*--parenchymal organ biopsy",
            "Condition 793 799--*--trauma",
            "Qualifier 786 792--*--severe",
            "Temporal 800 814--*--within 30 days",
            "Qualifier 833 839--*--active",
            "Condition 840 862--*--gastrointestinal ulcer",
            "Temporal 870 883--*--last 3 months",
            "Scope 697 799--*--intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma",
            "Scope 628 883--*--platelets <50,000 / mm3 during screening, Hb <8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months",
            "Negation 486 489--*--not",
            "Mood 490 497--*--require",
            "Procedure 498 507--*--treatment",
            "Drug 513 520--*--aspirin",
            "Drug 534 552--*--antiplatelet agent",
            "Qualifier 528 533--*--other",
            "Scope 513 552--*--aspirin or any other antiplatelet agent",
            "Observation 572 582--*--history of",
            "Observation 886 896--*--History of",
            "Condition 897 903--*--Stroke",
            "Temporal 904 924--*--in the last 3 months",
            "Qualifier 927 935--*--Moderate",
            "Qualifier 939 945--*--severe",
            "Condition 946 961--*--liver affection",
            "Qualifier 962 990--*--associated with coagulopathy",
            "Condition 978 990--*--coagulopathy",
            "Scope 927 945--*--Moderate or severe",
            "Qualifier 992 998--*--Active",
            "Condition 999 1022--*--infectious endocarditis",
            "Temporal 992 998--*--Active",
            "Qualifier 1024 1030--*--Active",
            "Temporal 1024 1030--*--Active",
            "Condition 1031 1036--*--tumor",
            "Procedure 1037 1044--*--treated",
            "Temporal 1045 1069--*--at the time of inclusion",
            "Measurement 1086 1103--*--expected survival",
            "Value 1104 1122--*--less than one year"
        ],
        "Text": "The patient is participating in another study. The patient is in an exclusion period determined by a previous study. The patient or his/her representative refuses to sign the consent. It is impossible to correctly inform the patient or his/her representative. The patient is pregnant or breastfeeding. The patient has a contraindication (or an incompatible drug association) for a treatment used in this study. The patient had a coronary stent for less than 12 months. The patient does not require treatment with aspirin or any other antiplatelet agent. The patient has a history of aspirin allergy. High bleeding risk; such as platelets <50,000 / mm3 during screening, Hb <8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months;. History of Stroke in the last 3 months;. Moderate or severe liver affection associated with coagulopathy. Active infectious endocarditis. Active tumor treated at the time of inclusion associated with expected survival less than one year. "
    },
    "NCT02888704_exc": {
        "Text": "Subjects who have systemic infection . Subjects who have human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) . Subjects who need to take the medicine which is prohibited during this study . Subjects who have asthma . Subjects who can not stop treatment with topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the treatment visit . Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test) . Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days . Subjects who had a serious adverse events during stem cell therapy . Subjects who had a hypersensitivity to antibiotics or antimycotics . Subjects who creatinine value is more than two times of the upper limit of the normal range at screening test . Subjects who aspartate transaminase/alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test . Subjects who have any other condition which the investigator judges would make patients unsuitable for study participation       .     . ",
        "Annotations": [
            "Condition 18 36--*--systemic infection",
            "Condition 56 90--*--human Immunodeficiency virus (HIV)",
            "Condition 92 115--*--hepatitis B virus (HBV)",
            "Condition 121 144--*--hepatitis C virus (HCV)",
            "Grammar_Error 117 120--*--and",
            "Context_Error 172 222--*--the medicine which is prohibited during this study",
            "Non-query-able 159 171--*--need to take",
            "Condition 242 248--*--asthma",
            "Non-query-able 263 275--*--can not stop",
            "Drug 291 307--*--topical steroids",
            "Context_Error 309 318--*--group 1~5",
            "Drug 321 337--*--oral antibiotics",
            "Procedure 339 367--*--whole body photochemotherapy",
            "Drug 369 391--*--immunosuppressive drug",
            "Temporal 392 413--*--within 4 weeks before",
            "Reference_point 418 433--*--treatment visit",
            "Scope 291 391--*--topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug",
            "Condition 435 443--*--Pregnant",
            "Condition 445 459--*--breast-feeding",
            "Person 460 465--*--women",
            "Person 469 474--*--women",
            "Non-query-able 479 493--*--plan to become",
            "Condition 494 502--*--pregnant",
            "Temporal 503 520--*--during this study",
            "Condition 533 555--*--childbearing potential",
            "Person 522 529--*--Females",
            "Measurement 577 597--*--urine pregnancy test",
            "Value 568 576--*--negative",
            "Scope 435 459--*--Pregnant, breast-feeding",
            "Non-query-able 600 713--*--Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days",
            "Context_Error 600 713--*--Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days",
            "Undefined_semantics 734 756--*--serious adverse events",
            "Condition 734 756--*--serious adverse events",
            "Temporal 757 763--*--during",
            "Reference_point 764 781--*--stem cell therapy",
            "Procedure 764 781--*--stem cell therapy",
            "Condition 802 818--*--hypersensitivity",
            "Drug 822 833--*--antibiotics",
            "Drug 837 849--*--antimycotics",
            "Scope 822 849--*--antibiotics or antimycotics",
            "Measurement 864 874--*--creatinine",
            "Value 884 942--*--more than two times of the upper limit of the normal range",
            "Temporal 943 960--*--at screening test",
            "Reference_point 946 960--*--screening test",
            "Measurement 975 1029--*--aspartate transaminase/alkaline transaminase (AST/ALT)",
            "Value 1039 1099--*--more than three times of the upper limit of the normal range",
            "Temporal 1100 1117--*--at screening test",
            "Reference_point 1103 1117--*--screening test",
            "Condition 1137 1156--*--any other condition",
            "Qualifier 1163 1241--*--the investigator judges would make patients unsuitable for study participation",
            "Subjective_judgement 1163 1241--*--the investigator judges would make patients unsuitable for study participation",
            "Undefined_semantics 1163 1241--*--the investigator judges would make patients unsuitable for study participation",
            "Context_Error 1163 1241--*--the investigator judges would make patients unsuitable for study participation"
        ]
    },
    "NCT00862446_exc": {
        "Annotations": [
            "Competing_trial 0 27--*--Enrollment in another trial",
            "Informed_consent 29 44--*--Lack of consent"
        ],
        "Text": "Enrollment in another trial. Lack of consent. "
    },
    "NCT02707809_inc": {
        "Annotations": [
            "Procedure 0 17--*--kidney transplant"
        ],
        "Text": "kidney transplant recipient. "
    },
    "NCT02284737_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Observation 14 28--*--breast feeding",
            "Observation 38 63--*--Estimated life expectancy",
            "Value 64 74--*--<12 months",
            "Mood 77 86--*--Scheduled",
            "Procedure 87 100--*--major surgery",
            "Temporal 101 121--*--in the next 6 months",
            "Measurement 424 427--*--WHO",
            "Value 428 448--*--group II, III, IV, V",
            "Condition 449 451--*--PH",
            "Condition 460 477--*--Renal dysfunction",
            "Qualifier 453 459--*--Severe",
            "Measurement 479 482--*--Ccr",
            "Value 482 492--*--<30 ml/min",
            "Scope 453 477--*--Severe Renal dysfunction",
            "Measurement 495 515--*--Blood platelet count",
            "Value 515 525--*--<100,000/L",
            "Observation 527 545--*--Expected life span",
            "Value 545 553--*--<6-month",
            "Condition 555 580--*--Systematical inflammation",
            "Condition 582 598--*--Malignant cancer",
            "Condition 603 627--*--Tricuspid valve stenosis",
            "Condition 629 659--*--Supra-pulmonary valve stenosis",
            "Condition 661 669--*--Allergic",
            "Drug 673 686--*--studied drugs",
            "Drug 673 680;690 705--*--studied metal materials",
            "Scope 673 705--*--studied drugs or metal materials",
            "Temporal 288 296--*--Previous",
            "Procedure 324 362--*--treatment with an investigational drug",
            "Drug 342 362--*--investigational drug",
            "Observation 297 320--*--enrolment in this study",
            "Device 366 372--*--device",
            "Observation 124 156--*--Inability to follow the protocol",
            "Observation 124 136;161 195--*--Inability to comply with follow-up requirements"
        ],
        "Text": "Pregnancy and breast feeding mother;. Estimated life expectancy <12 months;. Scheduled major surgery in the next 6 months;. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days.. WHO group II, III, IV, V PH. Severe Renal dysfunction (Ccr<30 ml/min). Blood platelet count<100,000/L. Expected life span<6-month. Systematical inflammation. Malignant cancer(s). Tricuspid valve stenosis, Supra-pulmonary valve stenosis. Allergic to studied drugs or metal materials.. "
    },
    "NCT02754583_inc": {
        "Text": "Community in a school district that is within the study area. Area within each school district that is in need of a well. ",
        "Annotations": [
            "Visit 15 60--*--school district that is within the study area",
            "Visit 79 120--*--school district that is in need of a well"
        ]
    },
    "NCT02462317_exc": {
        "Annotations": [
            "Drug 9 26--*--antispastic drugs",
            "Condition 28 44--*--Contraindication",
            "Drug 49 57--*--baclofen",
            "Drug 61 66--*--toxin",
            "Scope 49 66--*--baclofen or toxin",
            "Condition 82 99--*--epileptic seizure",
            "Temporal 68 78--*--Antecedent",
            "Condition 101 112--*--Psychiatric",
            "Temporal 113 123--*--antecedent",
            "Temporal 0 8--*--Previous"
        ],
        "Text": "Previous antispastic drugs. Contraindication for baclofen or toxin. Antecedent of epileptic seizure. Psychiatric antecedent. "
    },
    "NCT03372304_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02735902_inc": {
        "Annotations": [
            "Informed_consent 0 102--*--The patient or his/her representative must have given free and informed consent and signed the consent",
            "Non-query-able 104 173--*--The patient must be insured or beneficiary of a health insurance plan",
            "Post-eligibility 175 226--*--The patient is available for 12 months of follow-up",
            "Procedure 263 295--*--transcutaneous implant procedure",
            "Device 303 315--*--aortic valve",
            "Temporal 327 340--*--past 24 hours",
            "Drug 368 382--*--anti-vitamin K",
            "Drug 384 387--*--AVK",
            "Temporal 399 451--*--before percutaneous implantation of the aortic valve",
            "Reference_point 406 451--*--percutaneous implantation of the aortic valve"
        ],
        "Text": "The patient or his/her representative must have given free and informed consent and signed the consent. The patient must be insured or beneficiary of a health insurance plan. The patient is available for 12 months of follow-up. The patient underwent a successful transcutaneous implant procedure for an aortic valve within the past 24 hours. The patient was receiving anti-vitamin K (AVK) treatment before percutaneous implantation of the aortic valve. "
    },
    "NCT02966236_exc": {
        "Text": "Coronary artery disease - stent. Severe chronic renal failure. Congenital or acquired thrombophilia/thrombosis event. Known or suspected allergy. ",
        "Annotations": [
            "Condition 0 23--*--Coronary artery disease",
            "Device 26 31--*--stent",
            "Qualifier 33 39--*--Severe",
            "Qualifier 40 47--*--chronic",
            "Condition 48 61--*--renal failure",
            "Qualifier 63 73--*--Congenital",
            "Qualifier 77 85--*--acquired",
            "Condition 86 99--*--thrombophilia",
            "Condition 100 116--*--thrombosis event",
            "Scope 86 116--*--thrombophilia/thrombosis event",
            "Scope 63 85--*--Congenital or acquired",
            "Condition 137 144--*--allergy",
            "Mood 118 123--*--Known",
            "Mood 127 136--*--suspected",
            "Scope 118 136--*--Known or suspected"
        ]
    },
    "NCT02888704_inc": {
        "Text": "Of either gender, aged \u226519 and \u226470 years . Atopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria . Subacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months . Subjects with over moderate atopic dermatitis (SCORAD score > 20) . Subjects who understand and voluntarily sign an informed consent form . ",
        "Annotations": [
            "Person 18 22--*--aged",
            "Value 23 40--*--\u226519 and \u226470 years",
            "Condition 42 59--*--Atopic dermatitis",
            "Measurement 93 129--*--Hanifin and Rajka diagnosis criteria",
            "Condition 184 203--*--dermatitis symptoms",
            "Temporal 204 233--*--continually at least 6 months",
            "Grammar_Error 140 143--*--and",
            "Qualifier 144 151--*--chronic",
            "Qualifier 131 139--*--Subacute",
            "Scope 131 151--*--Subacute and chronic",
            "Condition 263 280--*--atopic dermatitis",
            "Measurement 282 294--*--SCORAD score",
            "Value 295 299--*--> 20",
            "Qualifier 249 262--*--over moderate",
            "Post-eligibility 302 371--*--Subjects who understand and voluntarily sign an informed consent form",
            "Non-query-able 302 371--*--Subjects who understand and voluntarily sign an informed consent form"
        ]
    },
    "NCT03475589_inc": {
        "Text": "Age of 18 and over, male or female;. Patients with histologically confirmed advanced (stage IV) gastric cancer, NSCLC, breast cancer or ovarian cancer, who choose monotherapy of oral vascular targeting drug (apatinib) due to intolerability or inappropriateness of other therapies;. Presence of measurable lesions (=10mm on spiral CT scan) subject to RECIST 1.1;. Blood pressured controlled at 150/100 mHg following drug administration;. An ECOG PS score of between 0 and 1;. A life expectancy of at least 3 months;. Subjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 7 18--*--18 and over",
            "Person 20 24--*--male",
            "Person 28 34--*--female",
            "Qualifier 51 75--*--histologically confirmed",
            "Procedure 51 65--*--histologically",
            "Qualifier 76 84--*--advanced",
            "Qualifier 86 94--*--stage IV",
            "Condition 96 110--*--gastric cancer",
            "Condition 112 117--*--NSCLC",
            "Condition 119 132--*--breast cancer",
            "Condition 136 150--*--ovarian cancer",
            "Procedure 163 174--*--monotherapy",
            "Drug 178 206--*--oral vascular targeting drug",
            "Drug 208 216--*--apatinib",
            "Non-representable 218 279--*--due to intolerability or inappropriateness of other therapies",
            "Scope 96 150--*--gastric cancer, NSCLC, breast cancer or ovarian cancer",
            "Condition 294 312--*--measurable lesions",
            "Value 314 319--*--=10mm",
            "Procedure 323 337--*--spiral CT scan",
            "Qualifier 350 360--*--RECIST 1.1",
            "Measurement 363 378--*--Blood pressured",
            "Qualifier 379 389--*--controlled",
            "Value 393 404--*--150/100 mHg",
            "Measurement 440 447--*--ECOG PS",
            "Value 457 472--*--between 0 and 1",
            "Observation 477 492--*--life expectancy",
            "Value 496 513--*--at least 3 months",
            "Informed_consent 516 667--*--Subjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up."
        ]
    },
    "NCT03011476_exc": {
        "Annotations": [
            "Condition 12 30--*--motor complication",
            "Qualifier 0 11--*--Significant",
            "Drug 59 64--*--Drugs",
            "Qualifier 65 99--*--related to acetylcholine metabolis",
            "Drug 76 89--*--acetylcholine"
        ],
        "Text": "Significant motor complication affecting daily activities. Drugs related to acetylcholine metabolism. "
    },
    "NCT02952365_exc": {
        "Annotations": [
            "Value 9 28--*--under the age of 21",
            "Person 19 22--*--age",
            "Condition 45 69--*--excessively thin corneas",
            "Condition 86 106--*--topographic evidence",
            "Condition 110 121--*--keratoconus",
            "Condition 138 159--*--ectatic eye disorders",
            "Condition 176 195--*--autoimmune diseases",
            "Condition 215 223--*--pregnant",
            "Condition 227 234--*--nursing"
        ],
        "Text": "Subjects under the age of 21.. Subjects with excessively thin corneas.. Subjects with topographic evidence of keratoconus.. Subjects with ectatic eye disorders.. Subjects with autoimmune diseases.. Subjects who are pregnant or nursing.. "
    },
    "NCT02961764_exc": {
        "Annotations": [
            "Qualifier 19 32--*--gram-negative",
            "Condition 33 43--*--infections",
            "Condition 55 65--*--infections",
            "Qualifier 45 54--*--anaerobic",
            "Condition 70 78--*--fungemia",
            "Condition 99 109--*--infections",
            "Qualifier 119 125--*--severe",
            "Qualifier 127 143--*--life threatening",
            "Person 233 243--*--drug users",
            "Condition 251 256--*--fever",
            "Condition 265 286--*--neurological disorder",
            "Qualifier 258 264--*--Severe",
            "Observation 298 308--*--immobility",
            "Device 326 336--*--wheelchair",
            "Scope 298 336--*--immobility or confined to a wheelchair",
            "Condition 393 402--*--infection",
            "Qualifier 338 363--*--Bilateral Lower extremity"
        ],
        "Text": "Known or suspected gram-negative infections, anaerobic infections, or fungemia. Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance. Injection drug users with a fever. Severe neurological disorder leading to immobility or confined to a wheelchair. Bilateral Lower extremity involvement of the suspected infection.. "
    },
    "NCT03209687_inc": {
        "Annotations": [
            "Procedure 19 66--*--Intra-Cytoplasmic Sperm Injection (ICSI) cycles",
            "Temporal 8 18--*--undergoing",
            "Person 0 7--*--Females",
            "Person 68 71--*--Age",
            "Value 72 95--*--between 20 and 40 years"
        ],
        "Text": "Females undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles. Age between 20 and 40 years. "
    },
    "NCT02983214_exc": {
        "Text": "Congestive heart failure, history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular extrasystoles or QTc prolongation.. Patients with atrial fibrillation taking any anticoagulant therapy or patients with a history of cardioembolic ischemic stroke or hemorrhagic stroke.. Patients with a history (= 12 months) of acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin.. Patients with hepatic impairment (child-Pugh staging, calibration = 5) or renal impairment (creatinine clearance = 30ml / min), recent peptic ulcer, a history of hypersensitivity to cilostazol, cancer patients undergoing treatment.. ",
        "Annotations": [
            "Condition 0 24--*--Congestive heart failure",
            "Condition 37 60--*--ventricular tachycardia",
            "Observation 26 36--*--history of",
            "Condition 62 86--*--ventricular fibrillation",
            "Condition 90 126--*--multifocal ventricular extrasystoles",
            "Condition 130 146--*--QTc prolongation",
            "Condition 163 182--*--atrial fibrillation",
            "Procedure 194 215--*--anticoagulant therapy",
            "Observation 235 245--*--history of",
            "Condition 260 275--*--ischemic stroke",
            "Qualifier 246 259--*--cardioembolic",
            "Condition 279 297--*--hemorrhagic stroke",
            "Scope 246 297--*--cardioembolic ischemic stroke or hemorrhagic stroke",
            "Scope 163 215--*--atrial fibrillation taking any anticoagulant therapy",
            "Observation 316 323--*--history",
            "Temporal 325 336--*--= 12 months",
            "Condition 341 364--*--acute coronary syndrome",
            "Procedure 375 400--*--dual antiplatelet therapy",
            "Procedure 424 435--*--monotherapy",
            "Drug 441 448--*--aspirin",
            "Scope 341 400--*--acute coronary syndrome receiving dual antiplatelet therapy",
            "Scope 341 448--*--acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin",
            "Condition 465 483--*--hepatic impairment",
            "Measurement 485 503--*--child-Pugh staging",
            "Value 505 520--*--calibration = 5",
            "Condition 525 541--*--renal impairment",
            "Measurement 543 563--*--creatinine clearance",
            "Value 564 576--*--= 30ml / min",
            "Temporal 579 585--*--recent",
            "Condition 586 598--*--peptic ulcer",
            "Observation 602 612--*--history of",
            "Condition 613 629--*--hypersensitivity",
            "Drug 633 643--*--cilostazol",
            "Condition 645 651--*--cancer",
            "Procedure 672 681--*--treatment"
        ]
    },
    "NCT02952365_inc": {
        "Annotations": [
            "Value 13 25--*--21 and older",
            "Person 9 12--*--age",
            "Condition 41 53--*--healthy eyes",
            "Procedure 94 107--*--LASIK surgery",
            "Temporal 73 83--*--previously",
            "Condition 123 148--*--residual refractive error"
        ],
        "Text": "Subjects age 21 and older. Subjects with healthy eyes. Subjects who have previously undergone LASIK surgery. Subjects with residual refractive error.. "
    },
    "NCT03475589_exc": {
        "Text": "Confirmed allergy to apatinin and or its excipients;. Hypertension (high blood pressure) that can not be controlled by drugs;. A history of active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery no older than 30 days;. NYHA III-IV heart function, or severe hepatic or renal insufficiency (Grade 4);. Presence of multiple factors that affect oral medications, such as difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction;. Pregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;. Patients who have a history of psychotropics abuse and can not quit, or who have mental disorders;. Participation in other drug clinical trial within the last 4 weeks;. Prior therapy with VEGFR inhibitors such as sorafenib and sunitinib;. Presence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;. Patients who can not tolerate apatinib treatment as judged by the investigator depending on the their medical history;. Patients that are considered ineligible for this study by the investigator.. ",
        "Annotations": [
            "Condition 10 17--*--allergy",
            "Drug 21 29--*--apatinin",
            "Drug 41 51--*--excipients",
            "Scope 21 51--*--apatinin and or its excipients",
            "Condition 54 66--*--Hypertension",
            "Condition 68 87--*--high blood pressure",
            "Qualifier 105 124--*--controlled by drugs",
            "Drug 119 124--*--drugs",
            "Negation 98 101--*--not",
            "Qualifier 140 146--*--active",
            "Condition 147 157--*--hemorragge",
            "Condition 159 164--*--ulcer",
            "Condition 166 188--*--intestinal perforation",
            "Condition 190 212--*--intestinal obstruction",
            "Condition 217 230--*--major surgery",
            "Temporal 231 252--*--no older than 30 days",
            "Scope 140 230--*--active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery",
            "Measurement 255 259--*--NYHA",
            "Value 260 266--*--III-IV",
            "Condition 267 281--*--heart function",
            "Qualifier 286 292--*--severe",
            "Condition 293 300;310 323--*--hepatic insufficiency",
            "Condition 304 323--*--renal insufficiency",
            "Qualifier 325 332--*--Grade 4",
            "Scope 293 323--*--hepatic or renal insufficiency",
            "Observation 357 393--*--factors that affect oral medications",
            "Condition 403 424--*--difficulty swallowing",
            "Condition 426 432--*--nausea",
            "Condition 434 442--*--vomiting",
            "Condition 444 460--*--chronic diarrhea",
            "Condition 465 487--*--intestinal obstruction",
            "Scope 403 487--*--difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction",
            "Pregnancy_considerations 490 683--*--Pregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;",
            "Observation 705 712--*--history",
            "Condition 730 735--*--abuse",
            "Drug 716 729--*--psychotropics",
            "Condition 766 782--*--mental disorders",
            "Non-representable 736 752--*--and can not quit",
            "Competing_trial 785 852--*--Participation in other drug clinical trial within the last 4 weeks;",
            "Drug 873 889--*--VEGFR inhibitors",
            "Drug 898 907--*--sorafenib",
            "Drug 912 921--*--sunitinib",
            "Scope 898 921--*--sorafenib and sunitinib",
            "Non-query-able 924 1058--*--Presence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;",
            "Condition 1081 1089--*--tolerate",
            "Negation 1077 1080--*--not",
            "Drug 1090 1098--*--apatinib",
            "Non-query-able 1180 1255--*--Patients that are considered ineligible for this study by the investigator."
        ]
    },
    "NCT03011476_inc": {
        "Annotations": [
            "Condition 0 17--*--Parkinson disease",
            "Measurement 31 93--*--United Kingdom Parkinson's disease Society Brain Bank Criteria",
            "Condition 95 115--*--Postural instability",
            "Condition 120 136--*--gait disturbance",
            "Measurement 148 162--*--Hoehn and Yahr",
            "Value 163 172--*--stage = 3",
            "Measurement 174 204--*--Mini-Mental status examination",
            "Value 205 208--*--= 2"
        ],
        "Text": "Parkinson disease diagnosed by United Kingdom Parkinson's disease Society Brain Bank Criteria. Postural instability and gait disturbance phenotype. Hoehn and Yahr stage = 3. Mini-Mental status examination = 24. "
    },
    "NCT02961764_inc": {
        "Annotations": [
            "Visit 16 41--*--Emergency Department (ED)",
            "Measurement 80 130--*--Acute Bacterial Skin and Skin Structure Infections",
            "Measurement 132 138--*--ABSSSI",
            "Qualifier 160 173--*--gram-positive",
            "Condition 174 183--*--infection"
        ],
        "Text": "Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Known or suspected gram-positive infection.. "
    },
    "NCT03209687_exc": {
        "Annotations": [
            "Condition 17 30--*--high response",
            "Person 0 7--*--Females",
            "Measurement 32 41--*--estradiol",
            "Temporal 42 70--*--at time of ovulation trigger",
            "Reference_point 53 70--*--ovulation trigger",
            "Value 74 86--*--> 5000 pg/ml",
            "Value 90 102--*--more than 15",
            "Measurement 103 110;115 124--*--oocytes retrieved",
            "Scope 32 124--*--estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved"
        ],
        "Text": "Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved). "
    },
    "NCT02983214_inc": {
        "Text": "Patients aged =50 years with DM2 and symptomatic PAD diagnosed clinically (according to Fontaine criteria, stage IIa or IIb and III) and by measuring the <U+0391><U+0392><U+0399>.. ",
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 23--*--=50 years",
            "Condition 29 32--*--DM2",
            "Condition 49 52--*--PAD",
            "Qualifier 37 48--*--symptomatic",
            "Measurement 88 105--*--Fontaine criteria",
            "Value 107 131--*--stage IIa or IIb and III",
            "Non-representable 137 178--*--by measuring the <U+0391><U+0392><U+0399>"
        ]
    },
    "NCT02974660_exc": {
        "Annotations": [
            "Informed_consent 0 10--*--no consent",
            "Condition 12 40--*--periprocedural complications",
            "Drug 67 74--*--heparin",
            "Drug 96 113--*--protamine sulfate",
            "Mood 41 50--*--requiring",
            "Scope 67 113--*--heparin or administration of protamine sulfate",
            "Condition 115 121--*--alergy",
            "Drug 125 129--*--fish",
            "Drug 131 140--*--protamine",
            "Drug 142 161--*--protamine derivates",
            "Drug 174 183--*--Humulin N",
            "Drug 185 194--*--Novolin N",
            "Drug 196 207--*--Novolin NPH",
            "Drug 209 219--*--Gensulin N",
            "Drug 221 229--*--SciLin N",
            "Drug 231 244--*--NPH Iletin II",
            "Drug 249 265--*--isophane insulin",
            "Scope 174 265--*--Humulin N, Novolin N, Novolin NPH, Gensulin N, SciLin N, NPH Iletin II and isophane insulin",
            "Observation 163 170--*--history",
            "Scope 125 161--*--fish, protamine, protamine derivates"
        ],
        "Text": "no consent. periprocedural complications requiring continuation of heparin or administration of protamine sulfate. alergy to fish, protamine, protamine derivates, history of Humulin N, Novolin N, Novolin NPH, Gensulin N, SciLin N, NPH Iletin II and isophane insulin intake. "
    },
    "NCT03113253_exc": {
        "Annotations": [
            "Condition 27 44--*--hypercoagulopathy",
            "Condition 46 66--*--deep vein thrombosis",
            "Condition 68 71--*--DVT",
            "Condition 74 92--*--pulmonary embolism",
            "Observation 16 23--*--history",
            "Condition 94 110--*--Renal impairment",
            "Condition 132 148--*--hypersensitivity",
            "Drug 152 167--*--tranexamic acid",
            "Condition 181 200--*--fibrinolytic states",
            "Condition 204 216--*--coagulopathy",
            "Observation 218 225--*--History",
            "Condition 229 240--*--convulsions"
        ],
        "Text": "Subjects with a history of hypercoagulopathy, deep vein thrombosis (DVT), pulmonary embolism. Renal impairment. Subjects with known hypersensitivity to tranexamic acid. Consecutive fibrinolytic states to coagulopathy. History of convulsions. "
    },
    "NCT03084588_exc": {
        "Text": "Preoperative renal failure requiring dialysis. Poorly controlled pulmonary disease (severe asthma or COPD) -Contraindication to regional anesthesia (recent anticoagulant use). Sleep apnea or morbid obesity with possible sleep apnea. Allergy to methadone. Significant preoperative pain requiring treatment with high doses of opioids (more than 6-8 Norco tablets or equivalence per day) or recent history of opioid abuse. ",
        "Annotations": [
            "Temporal 0 12--*--Preoperative",
            "Condition 13 26--*--renal failure",
            "Mood 27 36--*--requiring",
            "Procedure 37 45--*--dialysis",
            "Qualifier 47 64--*--Poorly controlled",
            "Condition 65 82--*--pulmonary disease",
            "Qualifier 84 90--*--severe",
            "Condition 91 97--*--asthma",
            "Condition 101 105--*--COPD",
            "Scope 91 105--*--asthma or COPD",
            "Scope 84 105--*--severe asthma or COPD",
            "Condition 108 124--*--Contraindication",
            "Procedure 128 147--*--regional anesthesia",
            "Temporal 149 155--*--recent",
            "Drug 156 169--*--anticoagulant",
            "Scope 108 147--*--Contraindication to regional anesthesia",
            "Scope 149 169--*--recent anticoagulant",
            "Condition 176 187--*--Sleep apnea",
            "Condition 191 205--*--morbid obesity",
            "Mood 211 219--*--possible",
            "Condition 220 231--*--sleep apnea",
            "Condition 233 240--*--Allergy",
            "Drug 244 253--*--methadone",
            "Condition 267 284--*--preoperative pain",
            "Qualifier 255 266--*--Significant",
            "Mood 285 294--*--requiring",
            "Multiplier 310 320--*--high doses",
            "Drug 324 331--*--opioids",
            "Multiplier 333 346;376 383--*--more than 6-8 per day",
            "Drug 347 360--*--Norco tablets",
            "Drug 364 375--*--equivalence",
            "Temporal 388 394--*--recent",
            "Observation 395 402--*--history",
            "Condition 406 418--*--opioid abuse",
            "Scope 333 383--*--more than 6-8 Norco tablets or equivalence per day"
        ]
    },
    "NCT03187639_inc": {
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 12--*--over 18",
            "Condition 33 43--*--chest pain",
            "Qualifier 14 29--*--Primary symptom",
            "Procedure 68 71--*--CTA",
            "Condition 48 64--*--contraindication",
            "Negation 45 47--*--No",
            "Informed_consent 73 125--*--Willing and able to provide written informed consent"
        ],
        "Text": "Aged over 18. Primary symptom of chest pain. No contraindication to CTA. Willing and able to provide written informed consent. "
    },
    "NCT03500211_inc": {
        "Text": "Pregnant patients who require a scheduled or non-urgent cesarean birth. Patient able to receive neuraxial analgesia. Patient able to give verbal and written consent for both cesarean birth and study. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Qualifier 32 41--*--scheduled",
            "Qualifier 45 55--*--non-urgent",
            "Procedure 56 70--*--cesarean birth",
            "Scope 32 55--*--scheduled or non-urgent",
            "Procedure 96 115--*--neuraxial analgesia",
            "Mood 80 95--*--able to receive",
            "Informed_consent 117 198--*--Patient able to give verbal and written consent for both cesarean birth and study"
        ]
    },
    "NCT03226080_exc": {
        "Text": "Inability to consent/refusal Allergy to any of the study medications Multiple traumatic injuries Contraindication to neuraxial or general anesthesia Pregnancy. ",
        "Annotations": [
            "Observation 0 20--*--Inability to consent",
            "Observation 21 28--*--refusal",
            "Line 0 28--*--Inability to consent/refusal",
            "Line 29 68--*--Allergy to any of the study medications",
            "Line 69 96--*--Multiple traumatic injuries",
            "Line 97 148--*--Contraindication to neuraxial or general anesthesia",
            "Line 149 158--*--Pregnancy",
            "Condition 29 36--*--Allergy",
            "Drug 51 68--*--study medications",
            "Condition 69 96--*--Multiple traumatic injuries",
            "Condition 97 113--*--Contraindication",
            "Procedure 117 126;138 148--*--neuraxial anesthesia",
            "Procedure 130 148--*--general anesthesia",
            "Condition 149 158--*--Pregnancy"
        ]
    },
    "NCT03434951_inc": {
        "Annotations": [
            "Qualifier 0 8--*--elective",
            "Qualifier 9 16--*--primary",
            "Procedure 17 40--*--total knee arthroplasty",
            "Measurement 42 45--*--ASA",
            "Value 46 51--*--I-III",
            "Informed_consent 53 68--*--written consent"
        ],
        "Text": "elective primary total knee arthroplasty. ASA I-III. written consent. "
    },
    "NCT02734173_exc": {
        "Annotations": [
            "Person 10 13--*--old",
            "Value 0 9--*--<18 years",
            "Qualifier 27 40--*--decompensated",
            "Condition 41 54--*--liver disease",
            "Measurement 56 63--*--HOMA IR",
            "Value 63 68--*--< 2.0",
            "Measurement 70 73--*--HIV",
            "Value 74 88--*--seropositivity",
            "Condition 106 115;90 101--*--infection Chronic HBV",
            "Condition 102 115;90 97--*--HIV infection Chronic",
            "Drug 124 154--*--immune suppressing medications",
            "Condition 163 173--*--malignancy",
            "Qualifier 156 162--*--Active"
        ],
        "Text": "<18 years old. Evidence of decompensated liver disease. HOMA IR< 2.0. HIV seropositivity. Chronic HBV/HIV infection. Use of immune suppressing medications. Active malignancy. "
    },
    "NCT03015818_exc": {
        "Text": "Inability to give informed consent. Pregnancy. Concurrent antibiotherapy. Certain infectious endocarditis. Concurrent anti-inflammatory therapy, including corticosteroid therapy. ",
        "Annotations": [
            "Informed_consent 0 34--*--Inability to give informed consent",
            "Condition 36 45--*--Pregnancy",
            "Drug 58 72--*--antibiotherapy",
            "Temporal 47 57--*--Concurrent",
            "Condition 82 105--*--infectious endocarditis",
            "Qualifier 74 81--*--Certain",
            "Temporal 107 117--*--Concurrent",
            "Procedure 118 143--*--anti-inflammatory therapy",
            "Drug 118 135--*--anti-inflammatory",
            "Procedure 155 177--*--corticosteroid therapy",
            "Drug 155 169--*--corticosteroid"
        ]
    },
    "NCT01908465_inc": {
        "Annotations": [
            "Condition 0 30--*--Irritable Bowel Syndrome (IBS)",
            "Qualifier 32 49--*--ROME III criteria",
            "Condition 65 73--*--diarrhea",
            "Qualifier 77 87--*--mixed form",
            "Scope 65 87--*--diarrhea or mixed form",
            "Person 89 92--*--age",
            "Value 93 104--*--18-65 years"
        ],
        "Text": "Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form. age 18-65 years. "
    },
    "NCT03084588_inc": {
        "Text": "All patients presenting for elective shoulder arthroscopic procedures will be eligible for enrollment.. ",
        "Annotations": [
            "Qualifier 28 36--*--elective",
            "Procedure 37 69--*--shoulder arthroscopic procedures"
        ]
    },
    "NCT03187639_exc": {
        "Annotations": [
            "Condition 0 19--*--Atrial fibrillation",
            "Temporal 23 32--*--new onset",
            "Condition 41 72--*--rate control has been difficult",
            "Condition 80 88--*--bigemini",
            "Condition 89 98--*--trigeminy",
            "Temporal 100 105--*--Prior",
            "Procedure 106 118--*--CABG surgery",
            "Condition 120 128--*--Allergic",
            "Drug 132 140--*--contrast",
            "Condition 142 167--*--Advanced renal impairment",
            "Condition 181 194--*--valve disease",
            "Qualifier 196 202--*--severe",
            "Condition 203 218--*--aortic stenosis",
            "Condition 222 235--*--regurgitation",
            "Scope 203 235--*--aortic stenosis or regurgitation",
            "Condition 244 264--*--mitral regurgitation",
            "Qualifier 237 243--*--severe",
            "Observation 267 282--*--Life expectancy",
            "Value 283 293--*--<12 months",
            "Competing_trial 295 353--*--Inclusion in another trial without prior agreement with CI"
        ],
        "Text": "Atrial fibrillation of new onset or when rate control has been difficult. Known bigemini/trigeminy. Prior CABG surgery. Allergic to contrast. Advanced renal impairment. Significant valve disease (severe aortic stenosis or regurgitation; severe mitral regurgitation). Life expectancy <12 months. Inclusion in another trial without prior agreement with CI. "
    },
    "NCT03113253_inc": {
        "Annotations": [
            "Procedure 20 41--*--burn excision surgery",
            "Temporal 9 19--*--undergoing",
            "Person 73 77--*--Male",
            "Person 81 87--*--female",
            "Value 88 99--*-->= 18 years",
            "Person 103 106--*--age",
            "Informed_consent 108 217--*--Subject or subject's medical decision maker agrees to participate in this study and provides informed consent"
        ],
        "Text": "Subjects undergoing burn excision surgery for standard of care purposes. Male or female >= 18 years of age. Subject or subject's medical decision maker agrees to participate in this study and provides informed consent. "
    },
    "NCT02974660_inc": {
        "Annotations": [
            "Procedure 34 38--*--TAVI",
            "Qualifier 23 33--*--successful",
            "Device 58 69--*--TAVI device",
            "Procedure 75 94--*--transfemoral access",
            "Device 128 152--*--vascular closure devices",
            "Informed_consent 154 187--*--provided written informed consent"
        ],
        "Text": "patients who underwent successful TAVI. with any approved TAVI device. via transfemoral access. with use of any of the approved vascular closure devices. provided written informed consent. "
    },
    "NCT02734173_inc": {
        "Annotations": [
            "Measurement 0 7--*--HCV RNA",
            "Condition 20 33--*--HCV infection",
            "Condition 57 68;73 82--*--chronic HCV infection",
            "Qualifier 88 98--*--Genotype 1",
            "Informed_consent 100 132--*--Able to provide informed consent",
            "Post-eligibility 134 177--*--Available for ongoing follow-up if required"
        ],
        "Text": "HCV RNA evidence of HCV infection. Documented history of chronic HCV RNA infection with Genotype 1. Able to provide informed consent. Available for ongoing follow-up if required. "
    },
    "NCT03434951_exc": {
        "Annotations": [
            "Procedure 0 14--*--rearthroplasty",
            "Measurement 16 19--*--ASA",
            "Value 20 24--*--IV-V",
            "Observation 26 51--*--inadequate spoken finnish",
            "Procedure 56 80--*--reliable pain assessment",
            "Condition 82 90--*--Dementia",
            "Condition 104 122--*--impaired cognition",
            "Condition 124 140--*--contraindication",
            "Drug 149 159;173 196--*--medication used in survey protocol",
            "Drug 163 196--*--substance used in survey protocol",
            "Scope 149 196--*--medication or substance used in survey protocol",
            "Measurement 198 204--*--weight",
            "Value 205 210--*--<50kg",
            "Measurement 214 217--*--BMI",
            "Value 218 227--*--=35 kg/m2",
            "Temporal 229 241--*--preoperative",
            "Measurement 242 246--*--SpO2",
            "Value 247 260--*--less than 93%",
            "Mood 262 280--*--clinical suspicion",
            "Observation 286 320--*--subject can not use PCA adequately",
            "Observation 322 329--*--history",
            "Condition 333 348--*--substance abuse",
            "Temporal 352 359--*--current",
            "Condition 360 384--*--excessive use of alcohol",
            "Temporal 386 398--*--preoperative",
            "Drug 413 423--*--pregabalin",
            "Drug 425 435--*--gabapentin",
            "Drug 439 453--*--strong opiates",
            "Scope 413 453--*--pregabalin, gabapentin or strong opiates"
        ],
        "Text": "rearthroplasty. ASA IV-V. inadequate spoken finnish for reliable pain assessment. Dementia or otherwise impaired cognition. contraindication for any medication or substance used in survey protocol. weight <50kg or BMI =35 kg/m2. preoperative SpO2 less than 93%. clinical suspicion that subject can not use PCA adequately. history of substance abuse or current excessive use of alcohol. preoperative use of either pregabalin, gabapentin or strong opiates. "
    },
    "NCT03226080_inc": {
        "Text": "ASA I-IV Age 55 or older Scheduled for operative repair of isolated intertrochanteric hip fracture. ",
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 8--*--I-IV",
            "Person 9 12--*--Age",
            "Value 13 24--*--55 or older",
            "Mood 25 38--*--Scheduled for",
            "Procedure 39 55--*--operative repair",
            "Qualifier 59 67--*--isolated",
            "Condition 68 98--*--intertrochanteric hip fracture",
            "Multiplier 59 67--*--isolated",
            "Line 25 98--*--Scheduled for operative repair of isolated intertrochanteric hip fracture",
            "Line 9 24--*--Age 55 or older",
            "Line 0 8--*--ASA I-IV"
        ]
    },
    "NCT03500211_exc": {
        "Text": "Patients requiring emergent cesarean birth. Patients allergic to lidocaine or adhesive. Patients who have already received an epidural during this admission or requiring general anesthesia for cesarean birth. Patients using chronic oral neuromodulators. Patients with cardiac disease or using anti-arrhythmic agents. Patients with fibromyalgia or chronic pain syndromes such as rheumatoid arthritis, osteoarthritis, or lupus.. Daily narcotic or opiate use for greater than the 2 months prior to enrollment in the study.. ",
        "Annotations": [
            "Procedure 19 42--*--emergent cesarean birth",
            "Condition 53 61--*--allergic",
            "Drug 65 74--*--lidocaine",
            "Drug 78 86--*--adhesive",
            "Scope 65 86--*--lidocaine or adhesive",
            "Procedure 126 134--*--epidural",
            "Temporal 135 156--*--during this admission",
            "Mood 160 169--*--requiring",
            "Procedure 170 188--*--general anesthesia",
            "Procedure 193 207--*--cesarean birth",
            "Drug 224 252--*--chronic oral neuromodulators",
            "Drug 293 315--*--anti-arrhythmic agents",
            "Condition 268 283--*--cardiac disease",
            "Condition 331 343--*--fibromyalgia",
            "Condition 347 369--*--chronic pain syndromes",
            "Condition 378 398--*--rheumatoid arthritis",
            "Condition 400 414--*--osteoarthritis",
            "Condition 419 424--*--lupus",
            "Scope 378 424--*--rheumatoid arthritis, osteoarthritis, or lupus",
            "Drug 433 441--*--narcotic",
            "Multiplier 427 432--*--Daily",
            "Drug 445 451--*--opiate",
            "Temporal 456 518--*--for greater than the 2 months prior to enrollment in the study",
            "Reference_point 495 518--*--enrollment in the study",
            "Scope 433 451--*--narcotic or opiate"
        ]
    },
    "NCT03015818_inc": {
        "Text": "age > 18. written informed consent. SVD defined on echocardiography by an alteration of bioprosthesis leaflets function with a mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm\u00b2, and/or an aortic regurgitation more or equal to grade 2 on 4.. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 8--*--> 18",
            "Informed_consent 10 34--*--written informed consent",
            "Condition 36 39--*--SVD",
            "Procedure 51 67--*--echocardiography",
            "Condition 74 119--*--alteration of bioprosthesis leaflets function",
            "Measurement 127 154--*--mean transvalvular gradient",
            "Value 155 164--*--> 20 mmHg",
            "Measurement 169 185--*--maximal velocity",
            "Value 186 193--*--= 3 m/s",
            "Measurement 198 220--*--effective orifice area",
            "Value 221 229--*--=1.2 cm\u00b2",
            "Condition 241 261--*--aortic regurgitation",
            "Value 262 278;285 291--*--more or equal to 2 on 4",
            "Measurement 279 284--*--grade",
            "Scope 127 229--*--mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm\u00b2",
            "Scope 74 291--*--alteration of bioprosthesis leaflets function with a mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm\u00b2, and/or an aortic regurgitation more or equal to grade 2 on 4"
        ]
    },
    "NCT01908465_exc": {
        "Annotations": [
            "Condition 0 11--*--IBS subtype",
            "Condition 17 29--*--constipation",
            "Drug 43 58--*--antidepressants",
            "Drug 62 85--*--H1-receptor antagonists",
            "Condition 87 96--*--pregnancy",
            "Observation 98 112--*--breast feeding",
            "Condition 135 141;156 163--*--kidney disease",
            "Condition 150 163--*--liver disease",
            "Qualifier 128 134--*--severe",
            "Condition 173 198--*--gastrointestinal diseases",
            "Scope 135 198--*--kidney- and/or liver disease or other gastrointestinal diseases"
        ],
        "Text": "IBS subtype with constipation. medication: antidepressants or H1-receptor antagonists. pregnancy, breast feeding. co-morbidity: severe kidney- and/or liver disease or other gastrointestinal diseases. "
    },
    "NCT02567214_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--> 50 years",
            "Measurement 16 31--*--Smoking history",
            "Value 32 47--*--> 10 packs/year",
            "Measurement 49 53--*--FEV1",
            "Value 54 75--*--30 - 79% of predicted",
            "Measurement 80 88--*--FEV1/FVC",
            "Value 89 94--*--< 70%",
            "Measurement 96 100--*--GOLD",
            "Value 101 104--*--2-3",
            "Scope 96 104--*--GOLD 2-3",
            "Scope 80 94--*--FEV1/FVC < 70%",
            "Measurement 107 110--*--FRC",
            "Value 111 128--*--> 120 % predicted",
            "Measurement 130 148--*--Borg dyspnea score",
            "Value 149 152--*--> 3",
            "Temporal 164 204--*--3-min constant rate shuttle walking test",
            "Qualifier 208 210--*--V3"
        ],
        "Text": "Age > 50 years. Smoking history > 10 packs/year. FEV1 30 - 79% of predicted and FEV1/FVC < 70% (GOLD 2-3). FRC > 120 % predicted. Borg dyspnea score > 3 during the 3-min constant rate shuttle walking test at V3. "
    },
    "NCT02749617_inc": {
        "Text": "Patients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group . Patients in whom a LEN-DEX-based treatment regimen is indicated . Adult patients \u2265 19 years of age who are able to freely provide informed consent . ",
        "Annotations": [
            "Condition 27 43--*--multiple myeloma",
            "Measurement 57 108--*--criteria of the International Myeloma Working Group",
            "Drug 133 136--*--DEX",
            "Drug 129 132--*--LEN",
            "Qualifier 129 142--*--LEN-DEX-based",
            "Procedure 143 160--*--treatment regimen",
            "Mood 161 173--*--is indicated",
            "Person 175 180--*--Adult",
            "Value 190 200--*--\u2265 19 years",
            "Person 204 207--*--age",
            "Observation 216 255--*--able to freely provide informed consent"
        ]
    },
    "NCT02137369_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 7 12--*--women",
            "Person 13 17--*--aged",
            "Value 18 29--*--18-60 years",
            "Qualifier 32 39--*--Primary",
            "Condition 65 90--*--Major Depressive Disorder",
            "Negation 92 99--*--without",
            "Condition 0 31;32 119--*--Men or women aged 18-60 years.",
            "Condition 100 118--*--psychotic features",
            "Measurement 176 218--*--Screening Hamilton Depression Rating Scale",
            "Measurement 220 224--*--HAMD",
            "Value 226 230--*--= 18",
            "Measurement 245 249--*--HAMD",
            "Qualifier 236 244--*--Baseline",
            "Value 250 254--*--= 15",
            "Pregnancy_considerations 257 404--*--If the patient is a woman of child-bearing potential, she must agree to use an acceptable form of birth control for duration of study participation",
            "Informed_consent 407 472--*--Able to understand and provide informed consent for participation"
        ],
        "Text": "Men or women aged 18-60 years.. Primary psychiatric diagnosis of Major Depressive Disorder, without psychotic features, confirmed via SCID-IV structured diagnostic interview.. Screening Hamilton Depression Rating Scale (HAMD) = 18; and Baseline HAMD = 15.. If the patient is a woman of child-bearing potential, she must agree to use an acceptable form of birth control for duration of study participation.. Able to understand and provide informed consent for participation.. "
    },
    "NCT02330757_inc": {
        "Annotations": [
            "Negation 6 13--*--without",
            "Condition 14 18--*--PCOS",
            "Qualifier 37 55--*--Rotterdam criteria",
            "Multiplier 70 80--*--at least 2",
            "Qualifier 81 94--*--cryopreserved",
            "Qualifier 95 107--*--good quality",
            "Observation 108 129--*--cleavage-stage embryo",
            "Qualifier 131 143--*--good quality",
            "Observation 144 166--*--cleavage-stage embryos",
            "Qualifier 175 203--*--stage-specific cell division",
            "Qualifier 205 242--*--have blastomeres of fairly equal size",
            "Qualifier 248 279--*--few to no cytoplasmic fragments",
            "Scope 175 279--*--stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments",
            "Scope 131 279--*--good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments",
            "Scope 95 129--*--good quality cleavage-stage embryo"
        ],
        "Text": "Women without PCOS as defined by the Rotterdam criteria.. Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).. "
    },
    "NCT02785549_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ]
    },
    "NCT02984228_exc": {
        "Annotations": [
            "Post-eligibility 0 31--*--Non-English speaking/illiterate",
            "Condition 60 85--*--cervical spine conditions",
            "Condition 33 40--*--Painful",
            "Drug 95 131--*--non-steroidal anti-inflammatory drug",
            "Drug 133 138--*--NSAID",
            "Drug 163 171--*--coumadin",
            "Drug 183 196--*--anticoagulant",
            "Condition 211 223--*--coagulopathy",
            "Condition 225 243--*--bleeding dyscrasia",
            "Measurement 248 262--*--platelet count",
            "Value 263 281--*--< 150,000/cubic mm",
            "Condition 283 300--*--Allergic reaction",
            "Observation 324 344--*--viscosupplementation",
            "Observation 304 311--*--poultry",
            "Scope 304 344--*--poultry or previous viscosupplementation",
            "Non-query-able 346 428--*--Involved in workers' compensation or active litigation involving affected shoulder",
            "Drug 456 461--*--NSAID",
            "Temporal 470 513--*--5 days prior to and 6 weeks after injection",
            "Reference_point 504 513--*--injection",
            "Procedure 526 550--*--corticosteroid injection",
            "Temporal 583 596--*--last 3 months",
            "Qualifier 563 571--*--shoulder",
            "Procedure 609 629--*--viscosupplementation",
            "Drug 633 653--*--platelet-rich plasma",
            "Qualifier 666 674--*--shoulder",
            "Scope 609 653--*--viscosupplementation or platelet-rich plasma",
            "Temporal 686 699--*--last 6 months",
            "Condition 719 727--*--fracture",
            "Qualifier 713 718--*--acute",
            "Condition 775 791--*--systemic illness",
            "Qualifier 762 774--*--uncontrolled",
            "Qualifier 793 805--*--uncontrolled",
            "Condition 806 814--*--diabetes",
            "Condition 816 844--*--human immunodeficiency virus",
            "Condition 846 856--*--vasculitis",
            "Condition 858 868--*--autoimmune",
            "Condition 869 889--*--inflammatory disease",
            "Scope 793 889--*--uncontrolled diabetes, human immunodeficiency virus, vasculitis, autoimmune/inflammatory disease",
            "Condition 892 903;919 928--*--Psychiatric disorders",
            "Condition 908 928--*--somatoform disorders",
            "Observation 729 739--*--History of",
            "Condition 740 754--*--shoulder tumor",
            "Mood 430 455--*--Inability to refrain from",
            "Observation 515 525--*--History of",
            "Observation 598 608--*--History of"
        ],
        "Text": "Non-English speaking/illiterate. Painful active, concurrent cervical spine conditions. Current non-steroidal anti-inflammatory drug (NSAID) use. History of taking coumadin or similar anticoagulant, have a known coagulopathy, bleeding dyscrasia, or platelet count < 150,000/cubic mm. Allergic reaction to poultry or previous viscosupplementation. Involved in workers' compensation or active litigation involving affected shoulder. Inability to refrain from NSAID use for 5 days prior to and 6 weeks after injection. History of corticosteroid injection to affected shoulder within the last 3 months. History of viscosupplementation or platelet-rich plasma to affected shoulder within the last 6 months. Presence of acute fracture. History of shoulder tumor. Known uncontrolled systemic illness (uncontrolled diabetes, human immunodeficiency virus, vasculitis, autoimmune/inflammatory disease). Psychiatric and somatoform disorders. "
    },
    "NCT02900443_inc": {
        "Annotations": [
            "Condition 34 54--*--autoimmune hepatitis",
            "Measurement 72 127--*--International Autoimmune Hepatitis Study Group criteria",
            "Measurement 200 215--*--EASL guidelines",
            "Procedure 165 174--*--treatment",
            "Condition 151 154--*--AIH",
            "Person 217 220--*--Age",
            "Value 221 231--*--= 18 years",
            "Informed_consent 233 306--*--Must provide informed consent and agree to comply with the trial protocol"
        ],
        "Text": "Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria. First presentation of AIH requiring treatment according to the current EASL guidelines. Age = 18 years. Must provide informed consent and agree to comply with the trial protocol. "
    },
    "NCT01709981_exc": {
        "Annotations": [
            "Procedure 25 45--*--coronary angiography",
            "Qualifier 9 24--*--diagnostic-only",
            "Drug 50 60--*--colchicine",
            "Multiplier 61 72--*--chronically",
            "Condition 85 96--*--intolerance",
            "Drug 100 110--*--colchicine",
            "Measurement 112 138--*--Glomerular filtration rate",
            "Value 139 151--*--<30mL/minute",
            "Procedure 158 166--*--dialysis",
            "Condition 175 185--*--malignancy",
            "Qualifier 168 174--*--Active",
            "Condition 189 198--*--infection",
            "Condition 211 225--*--myelodysplasia",
            "Drug 227 243--*--High-dose statin",
            "Temporal 249 277--*--<24 hours prior to procedure",
            "Reference_point 268 277--*--procedure",
            "Drug 286 299--*--oral steroids",
            "Drug 303 341--*--non-steroidal anti-inflammatory agents",
            "Drug 353 360--*--aspirin",
            "Negation 342 352--*--other than",
            "Temporal 361 376--*--within 72 hours",
            "Temporal 361 367;380 409--*--within 3 times the agent's half-life",
            "Reference_point 380 409--*--3 times the agent's half-life",
            "Reference_point 368 376--*--72 hours",
            "Scope 286 360--*--oral steroids or non-steroidal anti-inflammatory agents other than aspirin",
            "Scope 361 409--*--within 72 hours or 3 times the agent's half-life",
            "Drug 440 479--*--strong CYP3A4/P-glycoprotein inhibitors",
            "Drug 494 503--*--ritonavir",
            "Drug 505 517--*--ketoconazole",
            "Drug 519 533--*--clarithromycin",
            "Drug 535 547--*--cyclosporine",
            "Drug 549 558--*--diltiazem",
            "Drug 563 572--*--verapamil",
            "Scope 494 572--*--ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil",
            "Non-query-able 575 592--*--Unable to consent",
            "Non-query-able 594 628--*--Participating in a competing study"
        ],
        "Text": "Plan for diagnostic-only coronary angiography. On colchicine chronically. History of intolerance to colchicine. Glomerular filtration rate <30mL/minute or on dialysis. Active malignancy or infection. History of myelodysplasia. High-dose statin load <24 hours prior to procedure. Use of oral steroids or non-steroidal anti-inflammatory agents other than aspirin within 72 hours or 3 times the agent's half-life (whichever is longer). Use of strong CYP3A4/P-glycoprotein inhibitors (specifically ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil). Unable to consent. Participating in a competing study. "
    },
    "NCT02567214_exc": {
        "Annotations": [
            "Condition 0 24--*--Respiratory exacerbation",
            "Temporal 25 64--*--within the 2 months preceding the study",
            "Reference_point 55 64--*--the study",
            "Temporal 66 73--*--Current",
            "Condition 74 94--*--diagnostic of asthma",
            "Qualifier 96 107--*--Significant",
            "Condition 108 123--*--O2 desaturation",
            "Measurement 125 129--*--SpO2",
            "Value 130 135--*--< 85%",
            "Scope 125 135--*--SpO2 < 85%",
            "Qualifier 137 144--*--at rest",
            "Qualifier 148 163--*--during exercise",
            "Scope 137 163--*--at rest or during exercise",
            "Qualifier 177 184--*--another",
            "Condition 185 194--*--pathology",
            "Qualifier 206 234--*--influence exercise tolerance",
            "Procedure 243 254--*--home oxygen"
        ],
        "Text": "Respiratory exacerbation within the 2 months preceding the study. Current diagnostic of asthma. Significant O2 desaturation (SpO2 < 85%) at rest or during exercise. Presence of another pathology that could influence exercise tolerance. Use of home oxygen. "
    },
    "NCT02749617_exc": {
        "Text": "Concomitant antiplatelet or anticoagulant use . Calculated creatinine clearance < 30 mL/min by Cockcroft-Gault formula . Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times upper limit of normal (ULN) . Total bilirubin > 2 x ULN . Thrombocytopenia < 50 x 10 gigalitres (Gl) . High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time > 1.5 x ULN . Body weight <50 or >120 kg . Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors . Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug . Dexamethasone use within last 3 months . Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding . Life expectancy less than 3 months . Inability to swallow or issues with malabsorption . Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion       .     . ",
        "Annotations": [
            "Drug 12 24--*--antiplatelet",
            "Drug 28 41--*--anticoagulant",
            "Temporal 0 11--*--Concomitant",
            "Measurement 47 78--*--Calculated creatinine clearance",
            "Value 79 90--*--< 30 mL/min",
            "Measurement 94 117--*--Cockcroft-Gault formula",
            "Measurement 119 149--*--Alanine aminotransferase (ALT)",
            "Measurement 153 185--*--aspartate aminotransferase (AST)",
            "Value 186 223--*--> 3 times upper limit of normal (ULN)",
            "Measurement 225 240--*--Total bilirubin",
            "Value 241 250--*--> 2 x ULN",
            "Measurement 252 268--*--Thrombocytopenia",
            "Value 269 294--*--< 50 x 10 gigalitres (Gl)",
            "Condition 296 314--*--High bleeding risk",
            "Condition 332 358--*--prolonged prothrombin time",
            "Qualifier 318 331--*--spontaneously",
            "Measurement 362 399--*--activated partial thromboplastin time",
            "Value 400 411--*--> 1.5 x ULN",
            "Condition 413 424--*--Body weight",
            "Value 425 428;437 439--*--<50 kg",
            "Value 432 439--*-->120 kg",
            "Scope 425 439--*--<50 or >120 kg",
            "Drug 460 466--*--CYP3A4",
            "Drug 470 493--*--p-glycoprotein inducers",
            "Drug 470 484;497 507--*--p-glycoprotein inhibitors",
            "Temporal 441 452--*--Concomitant",
            "Drug 516 529--*--Ginkgo biloba",
            "Drug 597 610--*--Dexamethasone",
            "Temporal 615 635--*--within last 3 months",
            "Person 637 642--*--Women",
            "Condition 646 668--*--Childbearing potential",
            "Procedure 684 706--*--contraceptive measures",
            "Negation 669 676--*--without",
            "Condition 708 717--*--pregnancy",
            "Observation 721 735--*--breast feeding",
            "Observation 737 752--*--Life expectancy",
            "Value 753 771--*--less than 3 months",
            "Condition 773 793--*--Inability to swallow",
            "Condition 797 822--*--issues with malabsorption",
            "Undefined_semantics 797 822--*--issues with malabsorption",
            "Subjective_judgement 824 1001--*--Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion",
            "Context_Error 824 1001--*--Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion",
            "Drug 533 548--*--St. John's Wort",
            "Temporal 549 595--*--within 14 days before first dose of study drug",
            "Reference_point 571 595--*--first dose of study drug",
            "Multiplier 571 581--*--first dose",
            "Drug 585 595--*--study drug",
            "Scope 516 548--*--Ginkgo biloba or St. John's Wort"
        ]
    },
    "NCT02984228_inc": {
        "Annotations": [
            "Post-eligibility 0 25--*--English speaking/literate",
            "Person 27 30--*--Age",
            "Value 31 43--*--18-100 years",
            "Measurement 45 69--*--Visual analog score pain",
            "Value 70 74--*-->= 5",
            "Condition 113 117--*--pain",
            "Temporal 76 109--*--Greater than or equal to 3 months",
            "Temporal 118 141--*--after onset of symptoms",
            "Reference_point 124 141--*--onset of symptoms",
            "Mood 151 157--*--failed",
            "Procedure 158 181--*--conservative treatments",
            "Condition 199 214--*--glenohumeral OA",
            "Procedure 219 226--*--imaging",
            "Procedure 274 299--*--intra-articular injection",
            "Qualifier 309 327--*--glenohumeral joint",
            "Condition 238 256--*--relief of symptoms",
            "Qualifier 228 237--*--Transient"
        ],
        "Text": "English speaking/literate. Age 18-100 years. Visual analog score pain >= 5. Greater than or equal to 3 months of pain after onset of symptoms that has failed conservative treatments. Confirmation of glenohumeral OA via imaging. Transient relief of symptoms after diagnostic intra-articular injection into the glenohumeral joint. "
    },
    "NCT02785549_inc": {
        "Text": "Patient's written informed consent. Adequate cognitive capacity.. Adequate family support. No acute diverticulitis episode in the last 3 months. mNeff 0 acute diverticulitis (abdominal computed tomography scan). No antibiotic treatment in the last 2 weeks. Immunocompetence*. No significant comorbidities**. Good oral tolerance. Good symptom control. Maximum one of the following SIRS criteria (* T>38 \u00baC or <36\u00baC, L>12,000 or <4000/uL, HR>90 bpm, RR<20 rpm) or CRP>15 mg/dL. ",
        "Annotations": [
            "Post-eligibility 0 63--*--Patient's written informed consent. Adequate cognitive capacity",
            "Subjective_judgement 66 89--*--Adequate family support",
            "Condition 100 114--*--diverticulitis",
            "Qualifier 94 99--*--acute",
            "Temporal 123 143--*--in the last 3 months",
            "Measurement 145 150--*--mNeff",
            "Value 151 152--*--0",
            "Condition 159 173--*--diverticulitis",
            "Qualifier 153 158--*--acute",
            "Procedure 175 209--*--abdominal computed tomography scan",
            "Drug 215 235--*--antibiotic treatment",
            "Temporal 236 255--*--in the last 2 weeks",
            "Negation 212 214--*--No",
            "Condition 257 273--*--Immunocompetence",
            "Condition 291 304--*--comorbidities",
            "Negation 276 278--*--No",
            "Qualifier 279 290--*--significant",
            "Condition 313 327--*--oral tolerance",
            "Qualifier 308 312--*--Good",
            "Condition 334 349--*--symptom control",
            "Qualifier 329 333--*--Good",
            "Measurement 380 393--*--SIRS criteria",
            "Measurement 397 398--*--T",
            "Value 398 404--*-->38 \u00baC",
            "Value 408 413--*--<36\u00baC",
            "Measurement 415 416--*--L",
            "Value 416 423;432 435--*-->12,000 /uL",
            "Value 427 435--*--<4000/uL",
            "Measurement 437 439--*--HR",
            "Value 439 446--*-->90 bpm",
            "Measurement 448 450--*--RR",
            "Value 450 457--*--<20 rpm",
            "Measurement 462 465--*--CRP",
            "Value 465 474--*-->15 mg/dL",
            "Scope 398 413--*-->38 \u00baC or <36\u00baC",
            "Scope 416 435--*-->12,000 or <4000/uL",
            "Scope 0 65;66 90;91 144;145 211;212 256;257 275;276 307;308 328;329 350;351 458--*--Patient's written informed consent. Adequate cognitive capacity.",
            "Scope 394 458--*--(* T>38 \u00baC or <36\u00baC, L>12,000 or <4000/uL, HR>90 bpm, RR<20 rpm)"
        ]
    },
    "NCT01709981_inc": {
        "Annotations": [
            "Value 17 35--*--more than 18 years",
            "Person 39 42--*--age",
            "Procedure 60 80--*--coronary angiography",
            "Mood 47 59--*--referred for"
        ],
        "Text": "Patients must be more than 18 years of age and referred for coronary angiography. "
    },
    "NCT02900443_exc": {
        "Annotations": [
            "Condition 0 16--*--Overlap syndrome",
            "Condition 22 52--*--Primary Sclerosing Cholangitis",
            "Condition 54 57--*--PSC",
            "Condition 62 89--*--Primary Biliary Cholangitis",
            "Condition 91 94--*--PBC",
            "Measurement 97 112--*--Paris criteria,",
            "Measurement 129 158--*--Anti-Mitochondrial Antibodies",
            "Value 113 128--*--strong positive",
            "Measurement 160 163--*--AMA",
            "Procedure 171 183--*--liver biopsy",
            "Procedure 187 212--*--cholangiographic findings",
            "Condition 229 232--*--PBC",
            "Condition 236 239--*--PSC",
            "Scope 22 95--*--Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC)",
            "Scope 171 212--*--liver biopsy or cholangiographic findings",
            "Scope 229 239--*--PBC or PSC",
            "Condition 261 280--*--acute liver failure",
            "Condition 305 327--*--hepatic encephalopathy",
            "Condition 332 344--*--coagulopathy",
            "Measurement 346 349--*--INR",
            "Value 350 355--*--> 1.5",
            "Scope 305 356--*--hepatic encephalopathy and coagulopathy (INR > 1.5)",
            "Drug 381 391--*--prednisone",
            "Drug 392 404--*--prednisolone",
            "Drug 412 440--*--immunosuppressive medication",
            "Condition 470 490--*--autoimmune hepatitis",
            "Negation 459 464--*--other",
            "Condition 448 458--*--indication",
            "Scope 381 440--*--prednisone/prednisolone and/or immunosuppressive medication",
            "Condition 500 518--*--systemic infection",
            "Non-query-able 520 603--*--Other clinically significant medical conditions that could interfere with the trial",
            "Pregnancy_considerations 606 710--*--f female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures",
            "Post-eligibility 713 845--*--History of noncompliance with medical regimens, or patients who are considered to be potentially unreliable or unable to participate",
            "Post-eligibility 847 967--*--Mental instability or incompetence, such that the validity of informed consent or compliance with the trial is uncertain"
        ],
        "Text": "Overlap syndrome with Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC) (Paris criteria, strong positive Anti-Mitochondrial Antibodies (AMA), past liver biopsy or cholangiographic findings compatible with PBC or PSC).. Presentation with acute liver failure, defined as presence of hepatic encephalopathy and coagulopathy (INR > 1.5). Current treatment with prednisone/prednisolone and/or immunosuppressive medication for an indication other than autoimmune hepatitis. Current systemic infection. Other clinically significant medical conditions that could interfere with the trial. If female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures.. History of noncompliance with medical regimens, or patients who are considered to be potentially unreliable or unable to participate. Mental instability or incompetence, such that the validity of informed consent or compliance with the trial is uncertain. "
    },
    "NCT02137369_exc": {
        "Annotations": [
            "Condition 20 36--*--Bipolar Disorder",
            "Condition 38 46--*--Dementia",
            "Condition 48 72--*--Autism Spectrum Disorder",
            "Condition 74 87--*--Schizophrenia",
            "Condition 102 120--*--Psychotic Disorder",
            "Condition 123 141--*--Psychotic symptoms",
            "Condition 183 207--*--major depressive episode",
            "Condition 248 262--*--Panic disorder",
            "Condition 264 293--*--Obsessive Compulsive Disorder",
            "Condition 295 324--*--Posttraumatic Stress Disorder",
            "Condition 326 342--*--Anorexia Nervosa",
            "Condition 347 362--*--Bulimia Nervosa",
            "Condition 376 391--*--Drug Dependence",
            "Condition 365 372;381 391--*--Alcohol Dependence",
            "Temporal 219 233--*--past 12 months",
            "Scope 248 362--*--Panic disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Anorexia Nervosa, or Bulimia Nervosa",
            "Temporal 392 408--*--within 12 months",
            "Condition 365 372;412 417--*--Alcohol Abuse",
            "Condition 376 380;412 417--*--Drug Abuse",
            "Temporal 418 433--*--within 3 months",
            "Drug 445 453--*--nicotine",
            "Drug 458 466--*--caffeine",
            "Measurement 514 531--*--urine drug screen",
            "Scope 445 466--*--nicotine and caffeine",
            "Qualifier 557 563--*--severe",
            "Condition 564 584--*--Personality Disorder",
            "Condition 738 749--*--head injury",
            "Qualifier 730 737--*--serious",
            "Condition 693 715--*--neurological disorders",
            "Condition 773 790--*--medical illnesses",
            "Qualifier 752 759--*--Serious",
            "Qualifier 764 772--*--unstable",
            "Scope 752 772--*--Serious and unstable",
            "Condition 801 823--*--cardiovascular disease",
            "Condition 828 834--*--cancer",
            "Scope 801 834--*--cardiovascular disease and cancer",
            "Non-query-able 837 886--*--Active medical conditions with known mood changes",
            "Condition 888 897;910 919--*--endocrine disorders",
            "Condition 899 919--*--autoimmune disorders",
            "Condition 931 948--*--diabetes mellitus",
            "Pregnancy_considerations 951 1042--*--For women, pregnancy, lactation, or unwillingness to comply with birth control requirements",
            "Procedure 1073 1083--*--treatments",
            "Procedure 1097 1116--*--alternative therapy",
            "Temporal 1117 1161--*--within 2 weeks of the pre-treatment PET scan",
            "Reference_point 1139 1161--*--pre-treatment PET scan",
            "Scope 1073 1116--*--treatments or any other alternative therapy",
            "Condition 1198 1202--*--mood",
            "Drug 1214 1228--*--St John's Wort",
            "Drug 1230 1251--*--S-adenosyl methionine",
            "Drug 1253 1257--*--SAMe",
            "Drug 1260 1275--*--n-3 fatty acids",
            "Procedure 1280 1293--*--light therapy",
            "Scope 1214 1293--*--St John's Wort, S-adenosyl methionine (SAMe), n-3 fatty acids, or light therapy",
            "Drug 1303 1328--*--antidepressant medication",
            "Temporal 1329 1373--*--within 1 month of the pre-treatment PET scan",
            "Reference_point 1351 1373--*--pre-treatment PET scan",
            "Temporal 1375 1422--*--within 5 weeks for fluoxetine and protryptyline",
            "Reference_point 1394 1422--*--fluoxetine and protryptyline",
            "Non-query-able 1426 1726--*--Failure to achieve a much improved status (i.e. equivalent to >50% symptom reduction) with any lifetime treatment course of CBT (defined as a minimum of 4 sessions of a specified manual-driven therapy by a CBT-trained therapist) or escitalopram (defined as a minimum of 6 weeks of at least 10 mg/day)",
            "Condition 1759 1776--*--suicidal ideation",
            "Condition 1780 1803--*--self-injurious behavior",
            "Procedure 1828 1837--*--treatment",
            "Qualifier 1818 1827--*--immediate",
            "Scope 1752 1803--*--active suicidal ideation or self-injurious behavior",
            "Non-query-able 1974 2054--*--Currently responding to medication treatment, without clinical reasons to change",
            "Procedure 2107 2120--*--psychotherapy",
            "Qualifier 2101 2106--*--group",
            "Qualifier 2087 2097--*--individual",
            "Scope 2087 2106--*--individual or group",
            "Multiplier 2080 2086--*--weekly",
            "Condition 2145 2164--*--depressive symptoms",
            "Measurement 2167 2170--*--QTc",
            "Value 2171 2188--*-->500 milliseconds",
            "Temporal 2196 2208--*--at screening",
            "Reference_point 2199 2208--*--screening",
            "Procedure 2192 2195--*--EKG",
            "Condition 2211 2228--*--Contraindications",
            "Procedure 2233 2236--*--MRI",
            "Negation 2253 2256--*--not",
            "Device 2268 2277--*--pacemaker",
            "Device 2279 2293--*--aneurysm clips",
            "Device 2295 2311--*--neurostimulators",
            "Device 2313 2330--*--cochlear implants",
            "Device 2332 2337--*--metal",
            "Qualifier 2341 2345--*--eyes",
            "Device 2347 2359--*--steel worker",
            "Device 2361 2382--*--intra-uterine devices",
            "Scope 2268 2382--*--pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices",
            "Non-query-able 2403 2468--*--Maintenance or prophylactic therapy for stable medical conditions",
            "Drug 2471 2490--*--Hypnotic medication",
            "Condition 2573 2581--*--insomnia",
            "Temporal 2598 2649--*--the night before a PET/MRI or clinic ratings visit.",
            "Reference_point 2617 2624--*--PET/MRI",
            "Reference_point 2628 2649--*--clinic ratings visit.",
            "Scope 2617 2649--*--PET/MRI or clinic ratings visit.",
            "Negation 2594 2597--*--not",
            "Drug 2650 2675--*--Antipsychotic medications",
            "Temporal 152 207--*--at any time during the current major depressive episode",
            "Reference_point 171 207--*--the current major depressive episode",
            "Temporal 175 182--*--current",
            "Procedure 1884 1909--*--electroconvulsive therapy",
            "Temporal 1910 1930--*--in the past 6 months",
            "Temporal 1934 1971--*--during the current depressive episode",
            "Reference_point 1941 1971--*--the current depressive episode",
            "Temporal 1945 1952--*--current",
            "Condition 1953 1971--*--depressive episode",
            "Procedure 1365 1373--*--PET scan",
            "Drug 1394 1404--*--fluoxetine",
            "Drug 1409 1422--*--protryptyline",
            "Temporal 1351 1364--*--pre-treatment",
            "Scope 1910 1971--*--in the past 6 months or during the current depressive episode",
            "Qualifier 1752 1758--*--active"
        ],
        "Text": "Lifetime history of Bipolar Disorder, Dementia, Autism Spectrum Disorder, Schizophrenia, or any other Psychotic Disorder.. Psychotic symptoms occurring at any time during the current major depressive episode.. Current (past 12 months) diagnosis of Panic disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Anorexia Nervosa, or Bulimia Nervosa.. Alcohol or Drug Dependence within 12 months or Abuse within 3 months (excluding nicotine and caffeine) of baseline visit, as assessed by history and urine drug screen.. Clinical evidence of a severe Personality Disorder, as assessed by the study psychiatrist, which would impede participation or completion of the trial.. Known neurological disorders or documented serious head injury.. Serious and unstable medical illnesses including cardiovascular disease and cancer.. Active medical conditions with known mood changes (endocrine, autoimmune disorders).. Current diabetes mellitus.. For women, pregnancy, lactation, or unwillingness to comply with birth control requirements.. Use of any of the following treatments or any other alternative therapy within 2 weeks of the pre-treatment PET scan that may have beneficial effects on mood, including St John's Wort, S-adenosyl methionine (SAMe), n-3 fatty acids, or light therapy.. Use of antidepressant medication within 1 month of the pre-treatment PET scan (within 5 weeks for fluoxetine and protryptyline).. Failure to achieve a much improved status (i.e. equivalent to >50% symptom reduction) with any lifetime treatment course of CBT (defined as a minimum of 4 sessions of a specified manual-driven therapy by a CBT-trained therapist) or escitalopram (defined as a minimum of 6 weeks of at least 10 mg/day).. Clinically significant active suicidal ideation or self-injurious behavior necessitating immediate treatment, as determined by the investigator.. Received electroconvulsive therapy in the past 6 months or during the current depressive episode.. Currently responding to medication treatment, without clinical reasons to change.. Current treatment with weekly individual or group psychotherapy of any type targeted at depressive symptoms.. QTc >500 milliseconds on EKG at screening.. Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.. Maintenance or prophylactic therapy for stable medical conditions.. Hypnotic medication prescribed or approved by the study physician, (up to a three doses per week) for insomnia, as long if not the night before a PET/MRI or clinic ratings visit. Antipsychotic medications, whether prescribed for sleep or other indications, are prohibited.. "
    },
    "NCT02330757_exc": {
        "Annotations": [
            "Condition 0 4--*--PCOS",
            "Condition 8 24--*--polycystic ovary",
            "Procedure 28 43--*--ultrasound scan",
            "Scope 0 24--*--PCOS or polycystic ovary",
            "Qualifier 46 54--*--Moderate",
            "Qualifier 58 64--*--severe",
            "Condition 65 78--*--endometriosis",
            "Scope 46 64--*--Moderate or severe",
            "Condition 81 93--*--Hydrosalpinx",
            "Condition 96 117--*--Uterine abnormalities",
            "Condition 121 126--*--myoma",
            "Procedure 138 153--*--uterine surgery",
            "Temporal 129 137--*--Previous"
        ],
        "Text": "PCOS or polycystic ovary on ultrasound scan.. Moderate or severe endometriosis.. Hydrosalpinx.. Uterine abnormalities or myoma.. Previous uterine surgery.. "
    },
    "NCT03132259_exc": {
        "Text": "GCS less than 15. Preoperative Heart Rate less than 50 beat/min. No Beta-Blockers. Pregnant patients. Take any Alpha-Methyldopa, Clonodine, Other Alpha-2 Adrenergic Agonist. Hemodynamic unstable. Systolic BP more than 160mmHg. CAD. Renal insuffuciency. Allergy in dexmedethomidine and opioid. BMI more than 30. Denied consent. ",
        "Annotations": [
            "Measurement 0 3--*--GCS",
            "Value 4 16--*--less than 15",
            "Measurement 18 41--*--Preoperative Heart Rate",
            "Value 42 63--*--less than 50 beat/min",
            "Negation 65 67--*--No",
            "Drug 68 81--*--Beta-Blockers",
            "Condition 83 91--*--Pregnant",
            "Drug 111 127--*--Alpha-Methyldopa",
            "Drug 129 138--*--Clonodine",
            "Qualifier 140 145--*--Other",
            "Drug 146 172--*--Alpha-2 Adrenergic Agonist",
            "Condition 174 194--*--Hemodynamic unstable",
            "Measurement 196 207--*--Systolic BP",
            "Value 208 225--*--more than 160mmHg",
            "Condition 227 230--*--CAD",
            "Condition 232 251--*--Renal insuffuciency",
            "Condition 253 260--*--Allergy",
            "Drug 264 280--*--dexmedethomidine",
            "Drug 285 291--*--opioid",
            "Scope 264 291--*--dexmedethomidine and opioid",
            "Measurement 293 296--*--BMI",
            "Value 297 309--*--more than 30",
            "Informed_consent 311 325--*--Denied consent"
        ]
    },
    "NCT02827487_exc": {
        "Text": "Previous vaginal delivery.. Submucous myoma.. Uterine anomalies.. Undiagnosed vaginal bleeding.. Pelvic inflammatory disease.. ",
        "Annotations": [
            "Procedure 9 25--*--vaginal delivery",
            "Temporal 0 8--*--Previous",
            "Condition 28 43--*--Submucous myoma",
            "Condition 46 63--*--Uterine anomalies",
            "Condition 78 94--*--vaginal bleeding",
            "Qualifier 66 77--*--Undiagnosed",
            "Condition 97 124--*--Pelvic inflammatory disease"
        ]
    },
    "NCT02457442_inc": {
        "Annotations": [
            "Measurement 0 19--*--ASA physical status",
            "Value 20 21--*--1",
            "Value 25 26--*--2",
            "Scope 20 26--*--1 or 2",
            "Informed_consent 28 52--*--Written informed consent",
            "Condition 54 76--*--Cardiovascular disease",
            "Condition 78 95--*--Pulmonary disease",
            "Condition 97 110--*--Liver disease",
            "Condition 112 123--*--CNS disease",
            "Condition 125 132;141 146--*--Alcohol abuse",
            "Condition 136 146--*--drug abuse",
            "Multiplier 148 162--*--Chronic intake",
            "Drug 166 182--*--CNS active drugs",
            "Measurement 184 199--*--Body mass index",
            "Value 200 204--*--> 35",
            "Condition 206 223--*--Diabetes mellitus",
            "Condition 225 241--*--Hypersensitivity",
            "Condition 245 252--*--allergy",
            "Drug 267 278--*--study drugs",
            "Scope 225 252--*--Hypersensitivity or allergy"
        ],
        "Text": "ASA physical status 1 or 2. Written informed consent. Cardiovascular disease. Pulmonary disease. Liver disease. CNS disease. Alcohol or drug abuse. Chronic intake of CNS active drugs. Body mass index > 35. Diabetes mellitus. Hypersensitivity or allergy to one of the study drugs. "
    },
    "NCT00324363_inc": {
        "Text": "Treated with a stable dose of one of the following for at least 3 months prior to screening: * >=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy. . HbA1c between 7.1% and 11.0%, inclusive. . Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2. . ",
        "Annotations": [
            "Qualifier 15 26--*--stable dose",
            "Temporal 55 91--*--at least 3 months prior to screening",
            "Drug 109 136--*--immediate-release metformin",
            "Value 95 108--*-->=1000 mg/day",
            "Drug 141 150--*--metformin",
            "Value 151 164--*-->=1000 mg/day",
            "Drug 169 181--*--sulfonylurea",
            "Drug 186 198--*--sulfonylurea",
            "Drug 199 208--*--metformin",
            "Procedure 209 228--*--combination therapy",
            "Scope 141 181--*--metformin >=1000 mg/day and sulfonylurea",
            "Scope 95 228--*-->=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy",
            "Measurement 231 236--*--HbA1c",
            "Value 237 270--*--between 7.1% and 11.0%, inclusive",
            "Measurement 273 294--*--Body Mass Index (BMI)",
            "Value 295 320--*-->21 kg/m^2 and <35 kg/m^2",
            "Reference_point 82 91--*--screening",
            "Multiplier 30 50--*--one of the following"
        ]
    },
    "NCT02406885_exc": {
        "Text": "History of documented clotting/coagulation disorder. History of cancer (within the last year). Any diagnosis requiring anti-coagulation. History of hypersensitivity reaction to apixaban. Active clinically significant bleeding. Creatinine > 1.5 mg/dL. Participants currently receiving any type of anticoagulation or blood thinning medications, including heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS. Combined P-glycoprotein and strong cytochrome P450 (CYP) 3A4 inhibitor. Combined P-glycoprotein and moderate CYP 3A4 inhibitor. Combined P-glycoprotein inducer and strong CYP 3A4 inducer. Inducers of p-glycoprotein. Strong inducers of CYP 3A4. ",
        "Annotations": [
            "Condition 31 51--*--coagulation disorder",
            "Condition 22 30;43 51--*--clotting disorder",
            "Condition 64 70--*--cancer",
            "Temporal 83 92--*--last year",
            "Drug 119 135--*--anti-coagulation",
            "Condition 148 164--*--hypersensitivity",
            "Drug 177 185--*--apixaban",
            "Condition 217 225--*--bleeding",
            "Qualifier 205 216--*--significant",
            "Qualifier 187 193--*--Active",
            "Measurement 227 237--*--Creatinine",
            "Value 238 249--*--> 1.5 mg/dL",
            "Drug 296 311--*--anticoagulation",
            "Drug 315 341--*--blood thinning medications",
            "Drug 353 360--*--heparin",
            "Drug 362 391--*--low molecular weight heparins",
            "Drug 393 399--*--Plavix",
            "Drug 401 408--*--aspirin",
            "Drug 410 416--*--NSAIDS",
            "Scope 296 341--*--anticoagulation or blood thinning medications",
            "Scope 353 416--*--heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS",
            "Drug 427 441;479 488--*--P-glycoprotein inhibitor",
            "Drug 453 468;475 488--*--cytochrome P450 3A4 inhibitor",
            "Qualifier 446 452--*--strong",
            "Drug 499 513;535 544--*--P-glycoprotein inhibitor",
            "Drug 527 544--*--CYP 3A4 inhibitor",
            "Qualifier 518 526--*--moderate",
            "Drug 555 577--*--P-glycoprotein inducer",
            "Drug 589 604--*--CYP 3A4 inducer",
            "Qualifier 582 588--*--strong",
            "Drug 606 632--*--Inducers of p-glycoprotein",
            "Drug 641 660--*--inducers of CYP 3A4",
            "Qualifier 634 640--*--Strong"
        ]
    },
    "NCT02968602_exc": {
        "Annotations": [
            "Condition 11 32--*--organic brain disease",
            "Observation 0 10--*--History of",
            "Qualifier 34 40--*--DSM-IV",
            "Condition 54 61;75 85--*--Alcohol Dependence",
            "Condition 65 85--*--Substance Dependence",
            "Scope 54 85--*--Alcohol or Substance Dependence",
            "Temporal 86 112--*--within the last six months",
            "Drug 121 129--*--nicotine",
            "Negation 114 120--*--except",
            "Qualifier 134 139--*--DSM-5",
            "Condition 153 175--*--Substance Use Disorder",
            "Temporal 176 198--*--in the last six months",
            "Drug 207 215--*--nicotine",
            "Negation 200 206--*--except",
            "Qualifier 218 224--*--DSM-IV",
            "Condition 238 245;259 264--*--Alcohol Abuse",
            "Condition 249 264--*--Substance Abuse",
            "Scope 238 264--*--Alcohol or Substance Abuse",
            "Temporal 265 290--*--within the last one month",
            "Drug 299 307--*--nicotine",
            "Negation 292 298--*--except",
            "Qualifier 312 317--*--DSM-5",
            "Condition 331 353--*--Substance Use Disorder",
            "Temporal 354 376--*--in the last six months",
            "Drug 385 393--*--nicotine",
            "Negation 378 384--*--except",
            "Scope 312 394--*--DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)",
            "Condition 396 405--*--Pregnancy",
            "Condition 409 418--*--lactation",
            "Condition 427 444--*--liver dysfunction",
            "Qualifier 420 426--*--Severe",
            "Measurement 446 449--*--LFT",
            "Value 450 474--*--3X upper limit of normal",
            "Scope 446 474--*--LFT 3X upper limit of normal",
            "Condition 492 508--*--hypersensitivity",
            "Drug 512 525--*--tetracyclines",
            "Temporal 477 485--*--Previous",
            "Temporal 527 534--*--Current",
            "Procedure 535 544--*--treatment",
            "Drug 550 562--*--tetracycline",
            "Drug 550 562;566 576--*--tetracycline derivative",
            "Scope 550 576--*--tetracycline or derivative",
            "Drug 593 612--*--oral contraceptives",
            "Procedure 578 587--*--Treatment",
            "Observation 638 651--*--birth control",
            "Qualifier 623 634--*--second form",
            "Negation 614 620--*--unless",
            "Drug 692 706--*--cholestyramine",
            "Drug 710 720--*--colestipol",
            "Procedure 677 686--*--Treatment",
            "Scope 692 720--*--cholestyramine or colestipol",
            "Procedure 722 731--*--Treatment",
            "Drug 737 757--*--Urinary alkalinizers",
            "Drug 765 779--*--sodium lactate",
            "Drug 781 798--*--potassium citrate",
            "Scope 765 798--*--sodium lactate, potassium citrate",
            "Drug 816 824--*--warfarin",
            "Procedure 801 810--*--Treatment",
            "Drug 841 850--*--bupropion",
            "Drug 852 863--*--varenicline",
            "Drug 868 897--*--nicotine replacement products",
            "Scope 841 897--*--bupropion, varenicline, or nicotine replacement products",
            "Temporal 898 935--*--in the month prior to study inclusion",
            "Reference_point 920 935--*--study inclusion",
            "Procedure 826 835--*--Treatment",
            "Multiplier 937 957--*--Less than two months",
            "Procedure 958 967--*--treatment",
            "Drug 971 993--*--adjunctive medications",
            "Multiplier 998 1017--*--less than one month",
            "Multiplier 1021 1030--*--same dose",
            "Drug 1032 1045--*--beta blockers",
            "Drug 1047 1062--*--antidepressants",
            "Drug 1064 1080--*--mood stabilizers",
            "Drug 1082 1105--*--antianxiety medications",
            "Scope 1032 1105--*--beta blockers, antidepressants, mood stabilizers, antianxiety medications",
            "Condition 1108 1125--*--Medical condition",
            "Qualifier 1155 1230--*--would significantly increase the risk associated with the proposed protocol",
            "Condition 1244 1255--*--head injury",
            "Condition 1257 1265--*--seizures",
            "Condition 1270 1276--*--stroke",
            "Observation 1233 1240--*--History",
            "Scope 1244 1276--*--head injury, seizures, or stroke",
            "Measurement 1287 1310--*--urine toxicology screen",
            "Qualifier 1315 1348--*--substances of non-therapeutic use",
            "Value 1278 1286--*--Positive",
            "Temporal 1349 1377--*--prior to craving assessments",
            "Reference_point 1358 1377--*--craving assessments"
        ],
        "Text": "History of organic brain disease. DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine). DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine). Pregnancy or lactation. Severe liver dysfunction (LFT 3X upper limit of normal). Previous known hypersensitivity to tetracyclines. Current treatment with tetracycline or derivative. Treatment with oral contraceptives (unless a second form of birth control is used and documented). Treatment with cholestyramine or colestipol. Treatment with Urinary alkalinizers (e.g., sodium lactate, potassium citrate). Treatment with warfarin. Treatment with bupropion, varenicline, or nicotine replacement products in the month prior to study inclusion. Less than two months treatment of adjunctive medications AND less than one month on same dose: beta blockers, antidepressants, mood stabilizers, antianxiety medications.. Medical condition whose pathology or treatment would significantly increase the risk associated with the proposed protocol.. History of head injury, seizures, or stroke. Positive urine toxicology screen for substances of non-therapeutic use prior to craving assessments. "
    },
    "NCT02399033_inc": {
        "Text": "Age: 20-70 years old;. Gender: male or female;. clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients;. The expected survival> 3 months;. Child-Pugh grade in A-level;. KPS score with 50-100 points;. BCLC stage of 0-B;. conform to the indications of hepatectomy;. Viable tumor resection confirmed by two highly qualified surgical doctors;. No other surgical contraindications.. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment;. Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;. All patients must be prohibited donation during the treatment process and in 28 days after treatment;. In addition to the subjects, prohibitting other people taking this product.. patients have a good understanding and could coordinate with investigators for the trial.. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 5 20--*--20-70 years old",
            "Person 23 29--*--Gender",
            "Value 31 35--*--male",
            "Value 39 45--*--female",
            "Scope 31 45--*--male or female",
            "Condition 86 110--*--hepatocellular carcinoma",
            "Qualifier 48 82--*--clinical or pathological diagnosis",
            "Condition 112 115--*--HCC",
            "Qualifier 131 140--*--untreated",
            "Observation 156 173--*--expected survival",
            "Value 173 183--*--> 3 months",
            "Measurement 186 202--*--Child-Pugh grade",
            "Value 206 207--*--A",
            "Measurement 216 225--*--KPS score",
            "Value 231 244--*--50-100 points",
            "Measurement 247 257--*--BCLC stage",
            "Value 261 264--*--0-B",
            "Procedure 297 308--*--hepatectomy",
            "Observation 282 308--*--indications of hepatectomy",
            "Subjective_judgement 311 384--*--Viable tumor resection confirmed by two highly qualified surgical doctors",
            "Negation 387 389--*--No",
            "Observation 390 422--*--other surgical contraindications",
            "Person 425 430--*--women",
            "Observation 438 457--*--reproductive period",
            "Procedure 477 490--*--contraception",
            "Temporal 491 518--*--in 28 days before treatment",
            "Reference_point 509 518--*--treatment",
            "Temporal 520 548--*--during the treatment process",
            "Temporal 553 579--*--in 28 days after treatment",
            "Reference_point 531 540--*--treatment",
            "Reference_point 570 579--*--treatment",
            "Scope 491 579--*--in 28 days before treatment, during the treatment process and in 28 days after treatment",
            "Person 582 585--*--Men",
            "Procedure 605 618--*--contraception",
            "Negation 623 633--*--prohibited",
            "Procedure 647 661--*--sperm donation",
            "Temporal 662 690--*--during the treatment process",
            "Temporal 695 721--*--in 28 days after treatment",
            "Reference_point 673 682--*--treatment",
            "Reference_point 712 721--*--treatment",
            "Scope 662 721--*--during the treatment process and in 28 days after treatment",
            "Procedure 634 642--*--donation",
            "Negation 745 755--*--prohibited",
            "Procedure 756 764--*--donation",
            "Temporal 765 793--*--during the treatment process",
            "Reference_point 776 785--*--treatment",
            "Temporal 798 823--*--in 28 days after treatmen",
            "Reference_point 815 824--*--treatment",
            "Scope 765 824--*--during the treatment process and in 28 days after treatment",
            "Undefined_semantics 827 901--*--In addition to the subjects, prohibitting other people taking this product",
            "Subjective_judgement 904 992--*--patients have a good understanding and could coordinate with investigators for the trial",
            "Post-eligibility 995 1183--*--Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial"
        ]
    },
    "NCT02035800_exc": {
        "Text": "Patients not capable or willing to provide informed consent. Patients starting Adalimumab less than five half-lives after the interruption of a previous anti-TNF therapy.. ",
        "Annotations": [
            "Non-query-able 0 59--*--Patients not capable or willing to provide informed consent",
            "Drug 79 89--*--Adalimumab",
            "Temporal 90 169--*--less than five half-lives after the interruption of a previous anti-TNF therapy",
            "Reference_point 122 169--*--the interruption of a previous anti-TNF therapy",
            "Procedure 153 169--*--anti-TNF therapy",
            "Temporal 144 152--*--previous"
        ]
    },
    "NCT01009359_exc": {
        "Text": "Current unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)       .     . ",
        "Annotations": [
            "Condition 8 34--*--unstable medical condition",
            "Qualifier 8 16--*--unstable",
            "Temporal 0 7--*--Current",
            "Condition 41 56--*--unstable angina",
            "Condition 58 79--*--myocardial infarction",
            "Procedure 83 109--*--coronary revascularization",
            "Temporal 110 136--*--in the preceding 12 months",
            "Condition 138 153--*--cardiac failure",
            "Condition 155 176--*--chronic renal failure",
            "Condition 178 201--*--chronic hepatic disease",
            "Condition 210 227--*--pulmonary disease",
            "Condition 229 244--*--blood disorders",
            "Condition 264 272--*--diabetes",
            "Qualifier 253 263--*--controlled",
            "Negation 246 252--*--poorly",
            "Condition 274 291--*--chronic infection",
            "Qualifier 274 281--*--chronic",
            "Qualifier 203 209--*--severe",
            "Qualifier 178 185--*--chronic",
            "Qualifier 155 162--*--chronic",
            "Scope 41 291--*--unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection"
        ]
    },
    "NCT02732080_inc": {
        "Annotations": [
            "Condition 25 73--*--ST-elevation acute myocardial infarction (STEMI)",
            "Temporal 74 112--*--within 12 hours of their symptom onset",
            "Reference_point 93 112--*--their symptom onset",
            "Observation 121 148--*--TIMI-3 flow was established",
            "Qualifier 152 180--*--infarct related artery (IRA)",
            "Temporal 181 222--*--after balloon angioplasty or thrombectomy",
            "Procedure 187 206--*--balloon angioplasty",
            "Procedure 210 222--*--thrombectomy",
            "Reference_point 187 222--*--balloon angioplasty or thrombectomy",
            "Scope 187 222--*--balloon angioplasty or thrombectomy"
        ],
        "Text": "Patients presenting with ST-elevation acute myocardial infarction (STEMI) within 12 hours of their symptom onset in whom TIMI-3 flow was established in infarct related artery (IRA) after balloon angioplasty or thrombectomy.. "
    },
    "NCT03132259_inc": {
        "Text": "Age18-65. ASA 1-2. Elective TNTS resection of Pituitary Tumor. No narcotic before surgery as premedication. Able to Extubate. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 3 8--*--18-65",
            "Measurement 10 13--*--ASA",
            "Value 14 17--*--1-2",
            "Procedure 28 42--*--TNTS resection",
            "Condition 46 61--*--Pituitary Tumor",
            "Qualifier 19 27--*--Elective",
            "Negation 63 65--*--No",
            "Drug 66 74--*--narcotic",
            "Temporal 75 89--*--before surgery",
            "Reference_point 82 89--*--surgery",
            "Procedure 82 89--*--surgery",
            "Mood 108 115--*--Able to",
            "Procedure 116 124--*--Extubate"
        ]
    },
    "NCT02968602_inc": {
        "Annotations": [
            "Qualifier 0 6--*--DSM-IV",
            "Qualifier 10 15--*--DSM-5",
            "Condition 29 42--*--schizophrenia",
            "Condition 46 70--*--schizoaffective disorder",
            "Scope 29 70--*--schizophrenia or schizoaffective disorder",
            "Scope 0 15--*--DSM-IV or DSM-5",
            "Person 72 76--*--Male",
            "Person 80 86--*--Female",
            "Person 88 91--*--Age",
            "Value 93 107--*--18 to 65 years",
            "Person 109 118--*--Caucasian",
            "Person 122 135--*--Non-Caucasian",
            "Observation 137 142--*--Smoke",
            "Value 143 171--*--at least 10 cigarettes daily",
            "Measurement 173 193--*--Urine cotinine level",
            "Value 194 205--*--? 100 ng/ml",
            "Measurement 207 218--*--NicAlert(r)",
            "Value 227 230--*--? 3",
            "Scope 207 230--*--NicAlert(r) reading ? 3",
            "Scope 173 205--*--Urine cotinine level ? 100 ng/ml",
            "Observation 233 247--*--Agrees to wear",
            "Device 250 276--*--head mounted display (HMD)",
            "Temporal 277 297--*--for up to 45 minutes",
            "Observation 299 315--*--Able to complete",
            "Procedure 320 352--*--Evaluation to Sign Consent (ESC)",
            "Value 358 378--*--minimum score of 80%"
        ],
        "Text": "DSM-IV or DSM-5 diagnosis of schizophrenia or schizoaffective disorder. Male or Female. Age: 18 to 65 years. Caucasian or Non-Caucasian. Smoke at least 10 cigarettes daily. Urine cotinine level ? 100 ng/ml (NicAlert(r) reading ? 3). Agrees to wear a head mounted display (HMD) for up to 45 minutes. Able to complete the Evaluation to Sign Consent (ESC) with minimum score of 80%. "
    },
    "NCT02406885_inc": {
        "Text": "Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB). Signed written informed consent. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. Women must not be breastfeeding. ",
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 7 12--*--women",
            "Person 29 32--*--old",
            "Value 14 28--*--18 to 65 years",
            "Measurement 40 43--*--BMI",
            "Value 47 66--*--35 kg/m2 or greater",
            "Procedure 90 107--*--bariatric surgery",
            "Procedure 109 112--*--VSG",
            "Procedure 117 121--*--RYGB",
            "Scope 109 121--*--VSG and RYGB",
            "Informed_consent 124 155--*--Signed written informed consent",
            "Pregnancy_considerations 157 353--*--Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug",
            "Pregnancy_considerations 355 386--*--Women must not be breastfeeding"
        ]
    },
    "NCT00324363_exc": {
        "Text": "Have participated in this study previously, or any other study using exenatide or GLP-1 analogs. . Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening. . Have characteristics contraindicating metformin or sulfonylurea use. . Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening. . Have used drugs for weight loss within 1 month of screening.       .     . ",
        "Annotations": [
            "Drug 82 95--*--GLP-1 analogs",
            "Observation 21 31--*--this study",
            "Observation 47 62--*--any other study",
            "Drug 69 78--*--exenatide",
            "Scope 21 62--*--this study previously, or any other study",
            "Observation 122 136;175 180--*--interventional study",
            "Observation 138 145;175 180--*--medical study",
            "Observation 147 155;175 180--*--surgical study",
            "Observation 160 180--*--pharmaceutical study",
            "Temporal 181 208--*--within 30 days of screening",
            "Scope 122 180--*--interventional, medical, surgical, or pharmaceutical study",
            "Drug 249 258--*--metformin",
            "Drug 262 274--*--sulfonylurea",
            "Condition 216 248--*--characteristics contraindicating",
            "Scope 249 274--*--metformin or sulfonylurea",
            "Drug 304 321--*--exogenous insulin",
            "Multiplier 322 342--*--for more than 1 week",
            "Temporal 343 381--*--within the 3 months prior to screening",
            "Drug 394 415--*--drugs for weight loss",
            "Temporal 416 443--*--within 1 month of screening",
            "Scope 69 95--*--exenatide or GLP-1 analogs",
            "Reference_point 199 208--*--screening",
            "Reference_point 372 381--*--screening"
        ]
    },
    "NCT02457442_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT02827487_inc": {
        "Text": "Women with expected difficult IUD insertion like nulliparous women and women with previous cesarean section.. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Mood 11 19--*--expected",
            "Qualifier 20 29--*--difficult",
            "Procedure 30 43--*--IUD insertion",
            "Observation 49 60--*--nulliparous",
            "Person 61 66--*--women",
            "Person 71 76--*--women",
            "Temporal 82 90--*--previous",
            "Procedure 91 107--*--cesarean section",
            "Scope 49 66--*--nulliparous women",
            "Scope 71 107--*--women with previous cesarean section",
            "Scope 49 107--*--nulliparous women and women with previous cesarean section",
            "Scope 11 43--*--expected difficult IUD insertion"
        ]
    },
    "NCT01009359_inc": {
        "Text": "Able to give fully informed consent in writing . Males or females aged >/= 50 years . No significant disease or drug use . Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging: . Patient and designee capable of giving fully informed consent in writing . Patient fulfils DSM-IV and NINCDS-ADRA criteria for probable Alzheimers disease . ",
        "Annotations": [
            "Post-eligibility 0 46--*--Able to give fully informed consent in writing",
            "Person 48 53--*--Males",
            "Person 57 64--*--females",
            "Person 65 69--*--aged",
            "Value 70 82--*-->/= 50 years",
            "Condition 110 118--*--drug use",
            "Condition 99 106--*--disease",
            "Qualifier 87 98--*--significant",
            "Subjective_judgement 87 98--*--significant",
            "Negation 84 86--*--No",
            "Scope 87 118--*--significant disease or drug use",
            "Condition 143 151--*--dementia",
            "Condition 135 151--*--sign of dementia",
            "Condition 135 142;152 172--*--sign of cognitive impairment",
            "Condition 152 172--*--cognitive impairment",
            "Negation 120 130--*--Absence of",
            "Scope 135 172--*--sign of dementia/cognitive impairment",
            "Procedure 176 207--*--neuropsychological examinations",
            "Parsing_Error 207 234--*--Patients for brain imaging:",
            "Post-eligibility 236 308--*--Patient and designee capable of giving fully informed consent in writing",
            "Measurement 326 332;349 357--*--DSM-IV criteria",
            "Measurement 337 357--*--NINCDS-ADRA criteria",
            "Condition 371 389--*--Alzheimers disease",
            "Mood 362 370--*--probable",
            "Value 318 325--*--fulfils",
            "Scope 318 357--*--fulfils DSM-IV and NINCDS-ADRA criteria"
        ]
    },
    "NCT02732080_exc": {
        "Annotations": [
            "Procedure 0 11--*--Recanalized",
            "Condition 30 33--*--IRA",
            "Procedure 37 57--*--coronary angiography",
            "Qualifier 13 28--*--TIMI I-III flow",
            "Non-representable 60 177--*--Patients in whom TIMI-3 flow was not able to be established after wire crossing, balloon angioplasty or thrombectomy.",
            "Condition 179 184--*--STEMI",
            "Device 192 204--*--bypass-graft",
            "Condition 205 214--*--occlusion",
            "Qualifier 216 222--*--Severe",
            "Condition 223 236--*--heart failure",
            "Condition 240 257--*--cardiogenic shock",
            "Scope 223 257--*--heart failure or cardiogenic shock"
        ],
        "Text": "Recanalized (TIMI I-III flow) IRA at coronary angiography.. Patients in whom TIMI-3 flow was not able to be established after wire crossing, balloon angioplasty or thrombectomy.. STEMI due to bypass-graft occlusion. Severe heart failure or cardiogenic shock. "
    },
    "NCT02035800_inc": {
        "Text": "Patients aged of 18 and over,. Satisfying the 1987 American College of Rheumatology (ACR) criteria for RA. Receiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.. ",
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 17 28--*--18 and over",
            "Qualifier 46 98--*--1987 American College of Rheumatology (ACR) criteria",
            "Condition 103 105--*--RA",
            "Drug 135 145--*--Adalimumab",
            "Multiplier 146 151;165 180--*--40 mg every two weeks",
            "Qualifier 152 164--*--subcutaneous"
        ]
    },
    "NCT02399033_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Not_a_criteria 0 2--*--NA"
        ]
    },
    "NCT02747940_exc": {
        "Annotations": [
            "Condition 17 33--*--systemic illness",
            "Qualifier 11 16--*--major",
            "Condition 58 70--*--hypertension",
            "Qualifier 45 57--*--uncontrolled",
            "Condition 72 80--*--diabetes",
            "Condition 82 110--*--chronic renal insufficiency,",
            "Condition 111 130--*--autoimmune diseases",
            "Condition 134 146--*--malignancies",
            "Scope 45 146--*--uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies",
            "Condition 159 181--*--neurological disorders",
            "Condition 228 234--*--stroke",
            "Condition 238 259--*--peripheral neuropathy",
            "Condition 194 210--*--affect sensation",
            "Scope 228 259--*--stroke or peripheral neuropathy",
            "Condition 272 287--*--substance abuse",
            "Negation 289 295--*--except",
            "Drug 296 307--*--painkillers",
            "Qualifier 310 315--*--heavy",
            "Person 316 323--*--smokers",
            "Observation 354 364--*--cigarettes",
            "Multiplier 332 353--*--daily consumption >20",
            "Pregnancy_considerations 367 389--*--pregnancy or lactation",
            "Condition 395 411--*--contraindication",
            "Procedure 416 442--*--magnetic resonance imaging",
            "Procedure 444 447--*--MRI",
            "Condition 466 475--*--infection",
            "Condition 479 491--*--inflammation",
            "Temporal 509 542--*--at least 1 month before the study",
            "Reference_point 537 542--*--study",
            "Scope 466 491--*--infection or inflammation",
            "Qualifier 458 465--*--obvious"
        ],
        "Text": "history of major systemic illness, including uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies. history of neurological disorders which might affect sensation such as previous stroke or peripheral neuropathy. history of substance abuse (except painkillers). heavy smokers (with a daily consumption >20 cigarettes). pregnancy or lactation. any contraindication for magnetic resonance imaging (MRI). and any obvious infection or inflammation over a period of at least 1 month before the study.. "
    },
    "NCT02950558_inc": {
        "Annotations": [
            "Procedure 13 20--*--surgery",
            "Procedure 25 61--*--open reduction and internal fixation",
            "Condition 66 80--*--ankle fracture"
        ],
        "Text": "Referred for surgery for open reduction and internal fixation for ankle fracture. "
    },
    "NCT01993836_exc": {
        "Annotations": [
            "Person 0 33--*--Inmate of a correctional facility",
            "Person 40 49--*--prisoners",
            "Condition 53 62--*--Pregnancy",
            "Condition 118 140--*--malignant hyperthermia",
            "Observation 107 114;88 94--*--history family",
            "Observation 98 114--*--personal history",
            "Drug 176 184--*--propofol",
            "Drug 188 198--*--isoflurane",
            "Condition 206 213--*--allergy",
            "Condition 151 168--*--unable to receive",
            "Scope 176 198--*--propofol or isoflurane"
        ],
        "Text": "Inmate of a correctional facility (i.e. prisoners).. Pregnancy. Documented or suspected family or personal history of malignant hyperthermia.. Patient unable to receive either propofol or isoflurane due to allergy or other specific contraindication.. "
    },
    "NCT03461679_exc": {
        "Annotations": [
            "Post-eligibility 0 17--*--Unable to consent",
            "Condition 27 45--*--opioid consumption",
            "Qualifier 19 26--*--Chronic",
            "Condition 47 54--*--Allergy",
            "Drug 58 74--*--study medication",
            "Procedure 76 94--*--Lower limb surgery",
            "Non-query-able 111 146--*--Unable to complete baseline testing",
            "Condition 161 181--*--neurological deficit",
            "Qualifier 148 160--*--pre-existing",
            "Condition 183 199--*--Contraindication",
            "Procedure 203 221--*--spinal anaesthesia"
        ],
        "Text": "Unable to consent. Chronic opioid consumption. Allergy to study medication. Lower limb surgery preceding year. Unable to complete baseline testing, pre-existing neurological deficit. Contraindication to spinal anaesthesia. "
    },
    "NCT03351608_exc": {
        "Text": "Has any clinically significant condition or situation (eg, anatomical malformation that complicates intubation) other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.. Has a neuromuscular disorder that may affect NMB and/or trial assessments.. Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min).. Has or is suspected of having a family or personal history of malignant hyperthermia.. Has or is suspected of having an allergy to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia.. Has received or is planned to receive toremifene and/or fusidic acid via IV administration within 24 hours before or within 24 hours after administration of study treatment.. Has been previously treated with sugammadex or has participated in a sugammadex clinical trial.. Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days of signing the informed consent/assent for this current trial.. ",
        "Annotations": [
            "Qualifier 8 30--*--clinically significant",
            "Condition 31 40--*--condition",
            "Observation 44 53--*--situation",
            "Qualifier 59 82--*--anatomical malformation",
            "Negation 112 122--*--other than",
            "Condition 123 150--*--the condition being studied",
            "Observation 199 235--*--interfere with the trial evaluations",
            "Observation 199 213;239 260--*--interfere with optimal participation",
            "Scope 31 111--*--condition or situation (eg, anatomical malformation that complicates intubation)",
            "Scope 199 260--*--interfere with the trial evaluations or optimal participation",
            "Condition 282 304--*--neuromuscular disorder",
            "Observation 314 324--*--affect NMB",
            "Observation 314 320;332 349--*--affect trial assessments",
            "Scope 314 349--*--affect NMB and/or trial assessments",
            "Condition 355 373--*--dialysis-dependent",
            "Condition 409 435--*--severe renal insufficiency",
            "Measurement 448 491--*--estimated glomerular filtration rate (eGFR)",
            "Value 492 502--*--<30 ml/min",
            "Scope 409 503--*--severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min)",
            "Observation 548 564--*--personal history",
            "Observation 538 544--*--family",
            "Condition 568 590--*--malignant hyperthermia",
            "Scope 538 564--*--family or personal history",
            "Condition 626 633--*--allergy",
            "Procedure 637 653--*--study treatments",
            "Drug 682 689--*--opioids",
            "Drug 690 697--*--opiates",
            "Drug 699 715--*--muscle relaxants",
            "Drug 725 735--*--excipients",
            "Drug 746 756--*--medication",
            "Qualifier 740 745--*--other",
            "Procedure 772 790--*--general anesthesia",
            "Temporal 765 790--*--during general anesthesia",
            "Drug 667 677--*--excipients",
            "Scope 637 790--*--study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia",
            "Drug 831 841--*--toremifene",
            "Mood 812 822--*--planned to",
            "Drug 849 861--*--fusidic acid",
            "Qualifier 866 883--*--IV administration",
            "Temporal 884 906;932 965--*--within 24 hours before administration of study treatment",
            "Temporal 910 965--*--within 24 hours after administration of study treatment",
            "Reference_point 932 965--*--administration of study treatment",
            "Reference_point 932 965--*--administration of study treatment",
            "Scope 884 965--*--within 24 hours before or within 24 hours after administration of study treatment",
            "Scope 831 861--*--toremifene and/or fusidic acid",
            "Drug 1001 1011--*--sugammadex",
            "Temporal 977 987--*--previously",
            "Observation 1019 1034;1048 1062--*--participated in clinical trial",
            "Drug 1037 1047--*--sugammadex",
            "Scope 1001 1062--*--sugammadex or has participated in a sugammadex clinical trial",
            "Observation 1098 1150--*--has participated in an interventional clinical trial",
            "Observation 1068 1091;1115 1150--*--currently participating in an interventional clinical trial",
            "Drug 1159 1183--*--investigational compound",
            "Device 1187 1193--*--device",
            "Temporal 1194 1240--*--within 30 days of signing the informed consent",
            "Reference_point 1212 1240--*--signing the informed consent",
            "Temporal 1194 1232;1241 1247--*--within 30 days of signing the informed assent",
            "Reference_point 1212 1232;1241 1247--*--signing the informed assent",
            "Scope 1159 1193--*--investigational compound or device",
            "Scope 1068 1150--*--currently participating in or has participated in an interventional clinical trial",
            "Scope 1194 1247--*--within 30 days of signing the informed consent/assent"
        ]
    },
    "NCT03234816_inc": {
        "Text": "full term singleton pregnant women. Scheduled for elective Cesarean Delivery. Aged between 18 and 40 years. ",
        "Annotations": [
            "Qualifier 10 19--*--singleton",
            "Condition 20 28--*--pregnant",
            "Qualifier 0 9--*--full term",
            "Person 29 34--*--women",
            "Mood 36 49--*--Scheduled for",
            "Qualifier 50 58--*--elective",
            "Procedure 59 76--*--Cesarean Delivery",
            "Person 78 82--*--Aged",
            "Value 83 106--*--between 18 and 40 years"
        ]
    },
    "NCT00483106_inc": {
        "Text": "ADHD. ",
        "Annotations": [
            "Condition 0 4--*--ADHD"
        ]
    },
    "NCT02366819_inc": {
        "Text": "Histologically confirmed locally advanced gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral) adenocarcinomas are eligible for enrolment but will not be included in the primary analysis. Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx). All patients must have diagnostic laparoscopy with diagnostic washings for cytology; both cytology positive and negative patients are eligible for enrolment, but only cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible. Eastern Cooperative Oncology Group (ECOG) performance status =< 1. Eligible for surgery with curative intent. Absolute neutrophil count (ANC) >= 1250/ul. Hemoglobin >= 9 g/dL. Platelets >= 100,000/ul. Total bilirubin < 1.5 x upper limit of normal. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver metastases. Creatinine =< 1.5 x upper limit of normal. Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 will be allowed. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately. Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan. Signed informed consent. ",
        "Annotations": [
            "Condition 111 141--*--esophagogastric adenocarcinoma",
            "Condition 127 141;42 49--*--adenocarcinoma gastric",
            "Qualifier 25 41--*--locally advanced",
            "Scope 42 141--*--gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma",
            "Qualifier 90 106--*--mid-body stomach",
            "Qualifier 77 85;99 106--*--proximal stomach",
            "Scope 77 106--*--proximal and mid-body stomach",
            "Condition 167 182--*--adenocarcinomas",
            "Qualifier 143 157--*--distal gastric",
            "Qualifier 159 165--*--antral",
            "Non-query-able 183 258--*--are eligible for enrolment but will not be included in the primary analysis",
            "Condition 277 284--*--disease",
            "Qualifier 260 276--*--Locally advanced",
            "Procedure 302 323--*--endoscopic ultrasound",
            "Value 336 428--*--> primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)",
            "Procedure 325 328--*--EUS",
            "Procedure 464 475--*--laparoscopy",
            "Qualifier 453 463--*--diagnostic",
            "Procedure 492 513--*--washings for cytology",
            "Measurement 520 528--*--cytology",
            "Value 529 537--*--positive",
            "Value 542 550--*--negative",
            "Scope 529 550--*--positive and negative",
            "Non-query-able 593 706--*--nly cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible",
            "Measurement 708 742;750 768--*--Eastern Cooperative Oncology Group performance status",
            "Value 769 773--*--=< 1",
            "Measurement 744 748--*--ECOG",
            "Procedure 788 795--*--surgery",
            "Qualifier 801 809--*--curative",
            "Measurement 818 843--*--Absolute neutrophil count",
            "Measurement 845 848--*--ANC",
            "Value 850 860--*-->= 1250/ul",
            "Measurement 862 872--*--Hemoglobin",
            "Value 873 882--*-->= 9 g/dL",
            "Measurement 884 893--*--Platelets",
            "Value 894 907--*-->= 100,000/ul",
            "Measurement 909 924--*--Total bilirubin",
            "Value 925 954--*--< 1.5 x upper limit of normal",
            "Measurement 956 995--*--Serum glutamic oxaloacetic transaminase",
            "Measurement 997 1001--*--SGOT",
            "Measurement 1007 1044--*--serum glutamate pyruvate transaminase",
            "Measurement 1046 1050--*--SGPT",
            "Value 1052 1081--*--< 2.5 x upper limit of normal",
            "Negation 1095 1102--*--without",
            "Condition 1103 1119--*--liver metastases",
            "Measurement 1123 1127--*--SGOT",
            "Measurement 1132 1136--*--SGPT",
            "Value 1137 1164--*--< 5 x upper limit of normal",
            "Condition 1183 1199--*--liver metastases",
            "Scope 956 1051--*--Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)",
            "Scope 1123 1136--*--SGOT and SGPT",
            "Measurement 1201 1211--*--Creatinine",
            "Value 1212 1242--*--=< 1.5 x upper limit of normal",
            "Measurement 1284 1327--*--Response Evaluation Criteria in Solid Tumor",
            "Measurement 1329 1335--*--RECIST",
            "Value 1337 1340--*--1.1",
            "Pregnancy_considerations 1359 1760--*--omen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately",
            "Non-query-able 1762 2013--*--Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan",
            "Informed_consent 2015 2038--*--Signed informed consent"
        ]
    },
    "NCT03337503_inc": {
        "Annotations": [
            "Informed_consent 0 24--*--Written informed consent",
            "Person 26 31--*--Adult",
            "Value 42 61--*--older than 18 years",
            "Person 65 68--*--age",
            "Person 71 75--*--male",
            "Person 80 86--*--female",
            "Scope 42 68--*--older than 18 years of age",
            "Qualifier 93 100--*--chronic",
            "Qualifier 101 111--*--non-cancer",
            "Qualifier 116 122--*--cancer",
            "Condition 123 127--*--pain",
            "Scope 101 122--*--non-cancer and cancer",
            "Multiplier 129 158--*--at least 3 months in duration",
            "Measurement 186 221;237 255--*--average weekly pain intensity score on a 11 points NRS",
            "Value 222 236--*--greater than 4",
            "Informed_consent 257 294--*--Subject agreed to follow the protocol",
            "Qualifier 325 332--*--chronic",
            "Qualifier 333 343--*--non-cancer",
            "Qualifier 348 354--*--cancer",
            "Condition 355 359--*--pain",
            "Scope 333 354--*--non-cancer and cancer",
            "Measurement 361 364--*--not",
            "Drug 370 378--*--cannabis",
            "Temporal 399 419--*--in the last 12 weeks",
            "Condition 296 310--*--Na\u00efve cannabis",
            "Scope 361 419--*--not used cannabis in any presentation in the last 12 weeks",
            "Drug 441 448--*--opioids",
            "Drug 471 487--*--pain medications",
            "Qualifier 453 458--*--other",
            "Qualifier 502 513--*--stable dose",
            "Temporal 514 534--*--for the last 15 days",
            "Scope 441 487--*--opioids and other concomitant pain medications",
            "Procedure 574 581--*--MiniCog",
            "Condition 537 560--*--Normal cognitive status",
            "Condition 583 604--*--Normal liver function",
            "Measurement 617 643--*--aspartate aminotransferase",
            "Value 644 653--*--10-40 U/L",
            "Measurement 658 682--*--alanine aminotransferase",
            "Value 683 691--*--7-56 U/L",
            "Scope 617 691--*--aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L",
            "Condition 694 715--*--Normal renal function",
            "Measurement 728 750--*--serum creatinine level",
            "Value 751 762--*--<133 \u00b5mol/L",
            "Measurement 767 810--*--Estimated Glomerular Filtration Rate (eGFR)",
            "Value 811 838--*--greater than or equal to 60",
            "Scope 728 838--*--serum creatinine level <133 \u00b5mol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60",
            "Value 841 849--*--Negative",
            "Measurement 860 904--*--\u00dfhuman chorionic gonadotropin pregnancy test",
            "Non-representable 906 919--*--if applicable",
            "Non-query-able 922 984--*--Ability to read and respond to questions in French or English.",
            "Pregnancy_considerations 986 1258--*--A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration."
        ],
        "Text": "Written informed consent. Adult patients (older than 18 years of age), male and female, with chronic non-cancer and cancer pain (at least 3 months in duration). Patients experiencing an average weekly pain intensity score greater than 4 on a 11 points NRS. Subject agreed to follow the protocol. Na\u00efve cannabis patients with chronic non-cancer and cancer pain (not used cannabis in any presentation in the last 12 weeks). Patients receiving opioids and other concomitant pain medications should have a stable dose for the last 15 days.. Normal cognitive status according to MiniCog. Normal liver function (defined as aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L). Normal renal function (defined as serum creatinine level <133 \u00b5mol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60). Negative result on \u00dfhuman chorionic gonadotropin pregnancy test (if applicable). Ability to read and respond to questions in French or English.. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.. "
    },
    "NCT03329456_exc": {
        "Text": "Exclusion criteria are pregnancy, patients with contraindications to regional anesthesia, allergy to LAs, patients taking opioids regularly due to chronic pain, use of anticoagulation drugs other than acetylsalicylic acid or dipyridamole, atrioventricular block, diabetes.. ",
        "Annotations": [
            "Condition 23 32--*--pregnancy",
            "Condition 48 65--*--contraindications",
            "Procedure 69 88--*--regional anesthesia",
            "Condition 90 97--*--allergy",
            "Drug 101 104--*--LAs",
            "Drug 122 129--*--opioids",
            "Multiplier 130 139--*--regularly",
            "Condition 147 159--*--chronic pain",
            "Drug 168 189--*--anticoagulation drugs",
            "Drug 201 221--*--acetylsalicylic acid",
            "Drug 225 237--*--dipyridamole",
            "Condition 239 261--*--atrioventricular block",
            "Condition 263 271--*--diabetes",
            "Negation 190 200--*--other than",
            "Scope 201 237--*--acetylsalicylic acid or dipyridamole"
        ]
    },
    "NCT03177837_exc": {
        "Annotations": [
            "Condition 0 17--*--COPD exacerbation",
            "Qualifier 19 30--*--very severe",
            "Condition 31 35--*--COPD",
            "Condition 41 50--*--hypoxemia",
            "Qualifier 54 66--*--low altitude",
            "Measurement 68 76--*--FEV1/FVC",
            "Value 77 81--*--<0.7",
            "Measurement 83 87--*--FEV1",
            "Value 88 102--*--<40% predicted",
            "Measurement 104 121--*--oxygen saturation",
            "Qualifier 125 133--*--room air",
            "Value 134 138--*--<92%",
            "Qualifier 142 147--*--750 m",
            "Condition 186 208--*--cardiovascular disease",
            "Qualifier 173 185--*--uncontrolled",
            "Condition 151 164--*--Comorbidities",
            "Qualifier 216 224--*--unstable",
            "Condition 225 255--*--systemic arterial hypertension",
            "Condition 257 280--*--coronary artery disease",
            "Temporal 282 290--*--previous",
            "Condition 291 297--*--stroke",
            "Condition 299 302--*--OSA",
            "Condition 304 316--*--pneumothorax",
            "Temporal 317 337--*--in the last 2 months",
            "Scope 173 337--*--uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months",
            "Qualifier 340 348--*--Internal",
            "Qualifier 350 360--*--neurologic",
            "Qualifier 362 375--*--rheumatologic",
            "Qualifier 379 390--*--psychiatric",
            "Condition 391 398--*--disease",
            "Temporal 409 416--*--current",
            "Observation 423 430--*--smoking",
            "Qualifier 417 422--*--heavy",
            "Value 432 435--*-->20",
            "Measurement 436 454--*--cigarettes per day",
            "Scope 432 454--*-->20 cigarettes per day",
            "Scope 417 430--*--heavy smoking",
            "Scope 417 455--*--heavy smoking (>20 cigarettes per day)",
            "Scope 340 390--*--Internal, neurologic, rheumatologic or psychiatric",
            "Condition 463 476--*--renal failure",
            "Condition 480 487--*--allergy",
            "Drug 491 504--*--acetazolamide",
            "Drug 515 527--*--sulfonamides",
            "Qualifier 509 514--*--other",
            "Scope 491 527--*--acetazolamide and other sulfonamides"
        ],
        "Text": "COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7, FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).. Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.. Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (>20 cigarettes per day). Known renal failure or allergy to acetazolamide and other sulfonamides. "
    },
    "NCT02944929_exc": {
        "Text": "Patients who are unwilling to participate in the study. For the one under guardianship, the refusal of the patient will be the final decision even if the guardian is willing to participate.. Subjects who are unlikely to adhere to the study an/or poor adherence anticipated by the investigator.. Un-controlled progressive pathology.. Osteoarticular lesion which contraindicates part of the rehabilitation involved in the study.. Patients with other interventions planned prior to the end of the study period (orthosis, surgery etc.).. Surgery to the treated limb less than 6 months previously.. Pregnant woman.. ",
        "Annotations": [
            "Post-eligibility 0 188--*--Patients who are unwilling to participate in the study. For the one under guardianship, the refusal of the patient will be the final decision even if the guardian is willing to participate",
            "Post-eligibility 191 292--*--Subjects who are unlikely to adhere to the study an/or poor adherence anticipated by the investigator",
            "Non-query-able 295 330--*--Un-controlled progressive pathology",
            "Condition 333 354--*--Osteoarticular lesion",
            "Non-query-able 333 425--*--Osteoarticular lesion which contraindicates part of the rehabilitation involved in the study",
            "Non-query-able 428 531--*--Patients with other interventions planned prior to the end of the study period (orthosis, surgery etc.)",
            "Procedure 534 541--*--Surgery",
            "Qualifier 549 561--*--treated limb",
            "Temporal 562 580--*--less than 6 months",
            "Pregnancy_considerations 594 608--*--Pregnant woman"
        ]
    },
    "NCT02747940_inc": {
        "Annotations": [
            "Negation 9 15--*--devoid",
            "Condition 35 56--*--neurological diseases",
            "Condition 23 31;48 56--*--systemic diseases",
            "Scope 23 56--*--systemic or neurological diseases",
            "Condition 58 74--*--Chronic migraine",
            "Qualifier 79 87--*--ICHD-III",
            "Qualifier 89 138--*--International Classification of Headache Disorder",
            "Condition 150 162--*--Fibromyalgia",
            "Qualifier 172 204--*--American College of Rheumatology",
            "Qualifier 167 170;206 219--*--ACR 2010 criteria"
        ],
        "Text": "Control: devoid of any systemic or neurological diseases. Chronic migraine: by ICHD-III (International Classification of Headache Disorder) criteria. Fibromyalgia: by ACR (American College of Rheumatology) 2010 criteria. "
    },
    "NCT01993836_inc": {
        "Annotations": [
            "Value 18 26;34 42--*--60 years or older",
            "Person 30 33--*--age",
            "Procedure 44 51--*--Surgery",
            "Qualifier 52 86--*--scheduled to last at least 2 hours",
            "Non-representable 88 132--*--including time for anesthesia induction, etc",
            "Observation 135 159--*--English speaking ability",
            "Observation 162 194--*--Ability to give informed consent"
        ],
        "Text": "Surgical patients 60 years of age or older. Surgery scheduled to last at least 2 hours (including time for anesthesia induction, etc). English speaking ability.. Ability to give informed consent. "
    },
    "NCT02950558_exc": {
        "Annotations": [
            "Post-eligibility 0 42--*--Unable to give informed consent in English",
            "Post-eligibility 44 81--*--Unable to complete surveys in English",
            "Post-eligibility 83 142--*--Unable to understand instructions for using pump in English",
            "Post-eligibility 144 168--*--Unavailable for followup",
            "Condition 170 180--*--Polytrauma",
            "Procedure 193 208--*--other surgeries",
            "Condition 219 244--*--other orthopedic injuries",
            "Condition 287 301--*--ankle fracture",
            "Condition 303 312--*--Infection",
            "Condition 314 341--*--Peripheral vascular disease",
            "Condition 343 351--*--Diabetes",
            "Procedure 374 386--*--chemotherapy",
            "Condition 388 397--*--Pregnancy",
            "Pregnancy_considerations 399 418--*--Currently lactating",
            "Condition 420 433--*--Heart disease",
            "Condition 437 458--*--heart rhythm disorder",
            "Drug 469 490--*--anti-arrhythmic drugs",
            "Condition 492 515--*--Severe renal impairment",
            "Parsing_Error 517 548--*--Class 3 or worse kidney disease",
            "Condition 551 564--*--Liver disease",
            "Condition 579 592--*--liver failure",
            "Condition 566 575--*--cirrhosis",
            "Scope 566 592--*--cirrhosis or liver failure",
            "Condition 601 618--*--allergic reaction",
            "Drug 634 650--*--local anesthetic",
            "Drug 680 695--*--anti-coagulants",
            "Drug 699 720--*--anti-platelet therapy",
            "Qualifier 659 670--*--therapeutic",
            "Scope 680 720--*--anti-coagulants or anti-platelet therapy",
            "Qualifier 722 734--*--prophylactic",
            "Negation 783 786--*--not",
            "Drug 819 834--*--antidepressants",
            "Drug 844 867--*--psychiatric medications",
            "Multiplier 869 880--*--Single shot",
            "Procedure 881 898--*--local nerve block",
            "Temporal 899 915--*--prior to surgery",
            "Reference_point 908 915--*--surgery",
            "Procedure 946 966--*--neuraxial anesthesia",
            "Procedure 979 997--*--general anesthesia",
            "Negation 967 978--*--rather than",
            "Procedure 1006 1028--*--open reduction surgery",
            "Scope 946 997--*--neuraxial anesthesia rather than general anesthesia",
            "Procedure 1056 1073--*--analgesic therapy",
            "Qualifier 1048 1055--*--chronic",
            "Condition 1089 1101--*--chronic pain",
            "Qualifier 1080 1088--*--separate"
        ],
        "Text": "Unable to give informed consent in English. Unable to complete surveys in English. Unable to understand instructions for using pump in English. Unavailable for followup. Polytrauma; undergoing other surgeries or having other orthopedic injuries related to the precipitating cause of the ankle fracture. Infection. Peripheral vascular disease. Diabetes. Currently undergoing chemotherapy. Pregnancy. Currently lactating. Heart disease or heart rhythm disorder or taking anti-arrhythmic drugs. Severe renal impairment (Class 3 or worse kidney disease). Liver disease (cirrhosis or liver failure). Prior allergic reaction to any type of local anesthetic. Taking therapeutic doses of anti-coagulants or anti-platelet therapy (prophylactic doses started because of hospital admission are not an exclusion). Currently taking antidepressants or other psychiatric medications. Single shot local nerve block prior to surgery was ineffective. Selected for neuraxial anesthesia rather than general anesthesia for the open reduction surgery. Already receiving chronic analgesic therapy for a separate chronic pain condition. "
    },
    "NCT03351608_inc": {
        "Text": "Be categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1, 2, or 3.. Have a planned non-emergent surgical procedure or clinical situation (e.g., intubation) that requires moderate or deep NMB with either rocuronium or vecuronium.. Have a planned surgical procedure or clinical situation that would allow objective neuromuscular monitoring techniques to be applied with access to the arm for neuromuscular transmission monitoring.. Age between 2 to <17 years at Visit 2.. If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.. ",
        "Annotations": [
            "Measurement 18 83--*--American Society of Anesthesiologists (ASA) Physical Status Class",
            "Value 84 85--*--1",
            "Value 87 88--*--2",
            "Value 93 94--*--3",
            "Scope 84 94--*--1, 2, or 3",
            "Mood 104 111--*--planned",
            "Qualifier 112 124--*--non-emergent",
            "Procedure 125 143--*--surgical procedure",
            "Condition 147 165--*--clinical situation",
            "Procedure 173 183--*--intubation",
            "Scope 147 184--*--clinical situation (e.g., intubation)",
            "Procedure 216 219--*--NMB",
            "Qualifier 199 207--*--moderate",
            "Qualifier 211 215--*--deep",
            "Scope 199 215--*--moderate or deep",
            "Drug 232 242--*--rocuronium",
            "Drug 246 256--*--vecuronium",
            "Scope 232 256--*--rocuronium or vecuronium",
            "Mood 266 273--*--planned",
            "Procedure 274 292--*--surgical procedure",
            "Condition 296 314--*--clinical situation",
            "Procedure 332 377--*--objective neuromuscular monitoring techniques",
            "Qualifier 315 391--*--that would allow objective neuromuscular monitoring techniques to be applied",
            "Scope 266 292--*--planned surgical procedure",
            "Person 459 462--*--Age",
            "Value 463 485--*--between 2 to <17 years",
            "Temporal 486 496--*--at Visit 2",
            "Person 502 508--*--female",
            "Negation 536 539--*--not",
            "Condition 540 548--*--pregnant",
            "Negation 550 553--*--not",
            "Observation 554 567--*--breastfeeding",
            "Multiplier 573 585--*--at least one",
            "Condition 613 652--*--woman of childbearing potential (WOCBP)",
            "Negation 607 610--*--Not",
            "Condition 662 667--*--WOCBP",
            "Procedure 699 721--*--contraceptive guidance",
            "Temporal 722 749--*--during the treatment period",
            "Temporal 754 812--*--for at least 7 days after the last dose of study treatment",
            "Reference_point 780 812--*--the last dose of study treatment",
            "Reference_point 729 749--*--the treatment period",
            "Scope 722 812--*--during the treatment period and for at least 7 days after the last dose of study treatment",
            "Scope 662 812--*--WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment",
            "Scope 607 652--*--Not a woman of childbearing potential (WOCBP)",
            "Scope 607 812--*--Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment",
            "Scope 536 812--*--not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment"
        ]
    },
    "NCT03461679_inc": {
        "Annotations": [
            "Procedure 20 43--*--total knee arthroplasty",
            "Procedure 50 68--*--spinal anaesthesia",
            "Value 70 72;74 82--*--45 or older",
            "Person 72 73--*--y",
            "Measurement 84 87--*--ASA",
            "Value 88 91--*--1-3",
            "Measurement 93 96--*--BMI",
            "Value 97 102--*--18-35"
        ],
        "Text": "Patients undergoing total knee arthroplasty under spinal anaesthesia. 45y or older. ASA 1-3. BMI 18-35. "
    },
    "NCT02366819_exc": {
        "Text": "Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%. Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's disease, ulcerative colitis). Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0). Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0. Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment. Active uncontrolled bleeding. Pregnancy or breastfeeding. Major surgery within 4 weeks. Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be allowed and treated as in the *28/*28 dosing group. ",
        "Annotations": [
            "Condition 23 33--*--malignancy",
            "Qualifier 0 8--*--Previous",
            "Qualifier 12 22--*--concurrent",
            "Scope 0 22--*--Previous or concurrent",
            "Negation 35 41--*--except",
            "Condition 79 104--*--squamous cell skin cancer",
            "Condition 65 75;93 104--*--basal cell skin cancer",
            "Condition 114 129--*--cervical cancer",
            "Qualifier 106 113--*--in situ",
            "Qualifier 46 64--*--adequately treated",
            "Scope 65 104--*--basal cell or squamous cell skin cancer",
            "Non-query-able 134 250--*--any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%",
            "Scope 46 129--*--adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer",
            "Condition 252 278--*--Inflammatory bowel disease",
            "Qualifier 287 299--*--uncontrolled",
            "Procedure 313 322--*--treatment",
            "Condition 324 339--*--Crohn's disease",
            "Condition 341 359--*--ulcerative colitis",
            "Scope 324 359--*--Crohn's disease, ulcerative colitis",
            "Scope 252 322--*--Inflammatory bowel disease that is uncontrolled or on active treatment",
            "Condition 362 370--*--Diarrhea",
            "Measurement 398 470--*--National Cancer Institute Common Terminology Criteria for Adverse Events",
            "Value 372 390--*--grade 1 or greater",
            "Measurement 472 498--*--NCI-CTCAE, version [v] 4.0",
            "Condition 501 511--*--Neuropathy",
            "Measurement 535 551--*--NCI-CTCAE, v 4.0",
            "Value 513 531--*--grade 2 or greater",
            "Non-query-able 553 729--*--Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment",
            "Condition 751 759--*--bleeding",
            "Qualifier 731 737--*--Active",
            "Qualifier 738 750--*--uncontrolled",
            "Pregnancy_considerations 761 787--*--Pregnancy or breastfeeding",
            "Procedure 789 802--*--Major surgery",
            "Temporal 803 817--*--within 4 weeks",
            "Non-query-able 819 949--*--Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be allowed and treated as in the *28/*28 dosing group",
            "Scope 287 322--*--uncontrolled or on active treatment"
        ]
    },
    "NCT00483106_exc": {
        "Text": "Psychosis. Tourette syndrome. Intelligence quotient (IQ) < 70. Pervasive developmental disorder (PDD). ",
        "Annotations": [
            "Condition 0 9--*--Psychosis",
            "Condition 11 28--*--Tourette syndrome",
            "Measurement 30 51--*--Intelligence quotient",
            "Measurement 53 55--*--IQ",
            "Value 57 61--*--< 70",
            "Condition 63 95--*--Pervasive developmental disorder",
            "Condition 97 100--*--PDD"
        ]
    },
    "NCT03234816_exc": {
        "Text": "Cardiac morbidities. Hypertensive disorders of pregnancy,. Peripartum bleeding. Baseline systolic blood pressure (SBP) < 100 mmHg. Body mass index > 35. ",
        "Annotations": [
            "Condition 0 19--*--Cardiac morbidities",
            "Condition 21 56--*--Hypertensive disorders of pregnancy",
            "Condition 59 78--*--Peripartum bleeding",
            "Temporal 80 88--*--Baseline",
            "Measurement 89 112--*--systolic blood pressure",
            "Measurement 114 117--*--SBP",
            "Value 119 129--*--< 100 mmHg",
            "Measurement 131 146--*--Body mass index",
            "Value 147 151--*--> 35"
        ]
    },
    "NCT03329456_inc": {
        "Text": ". Inclusion criteria are American Society of Anesthesiologists (ASA) physical status I-III, age between 18 and 70 years and body mass index (BMI) between 20 and 35 kg/m2.. ",
        "Annotations": [
            "Measurement 25 62;69 84--*--American Society of Anesthesiologists physical status",
            "Measurement 64 67--*--ASA",
            "Value 85 90--*--I-III",
            "Person 92 95--*--age",
            "Value 96 119--*--between 18 and 70 years",
            "Measurement 124 139--*--body mass index",
            "Measurement 141 144--*--BMI",
            "Value 146 169--*--between 20 and 35 kg/m2"
        ]
    },
    "NCT03337503_exc": {
        "Annotations": [
            "Condition 6 10--*--pain",
            "Measurement 34 42--*--duration",
            "Value 12 30--*--less than 3 months",
            "Qualifier 0 5--*--Acute",
            "Scope 12 42--*--less than 3 months in duration",
            "Condition 79 95--*--hypersensitivity",
            "Drug 99 107--*--cannabis",
            "Drug 111 123--*--cannabinoids",
            "Scope 99 123--*--cannabis or cannabinoids",
            "Condition 62 75--*--adverse event",
            "Qualifier 54 61--*--serious",
            "Non-query-able 125 194--*--Inability to understand and comply with the instructions of the study",
            "Condition 220 235--*--cardiac disease",
            "Qualifier 208 219--*--significant",
            "Condition 248 279--*--unstable ischemic heart disease",
            "Condition 281 294--*--heart failure",
            "Qualifier 296 302--*--severe",
            "Qualifier 307 319--*--uncontrolled",
            "Condition 320 332--*--hypertension",
            "Observation 237 244--*--history",
            "Scope 248 332--*--unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension",
            "Qualifier 411 433--*--clinically significant",
            "Condition 434 444--*--arrhythmia",
            "Condition 448 469--*--myocardial infarction",
            "Scope 434 469--*--arrhythmia or myocardial infarction",
            "Mood 398 408--*--at risk of",
            "Scope 208 235--*--significant cardiac disease",
            "Condition 479 501--*--substance use disorder",
            "Qualifier 519 594--*--Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)",
            "Condition 617 639--*--dependence on cannabis",
            "Condition 656 683--*--cannabis use disorder (CUD)",
            "Qualifier 701 706--*--DSM 5",
            "Qualifier 729 734--*--DSM 5",
            "Condition 735 748--*--schizophrenia",
            "Condition 750 766--*--bipolar disorder",
            "Condition 780 789--*--psychosis",
            "Condition 798 809--*--intolerance",
            "Drug 813 825--*--cannabinoids",
            "Condition 849 866--*--suicidal ideation",
            "Temporal 827 834--*--Current",
            "Observation 838 845--*--history",
            "Scope 827 845--*--Current or history",
            "Pregnancy_considerations 868 1081--*--Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception",
            "Condition 1083 1101--*--Hepatic impairment",
            "Measurement 1226 1269--*--Estimated Glomerular Filtration Rate (eGFR)",
            "Value 1270 1273--*--<60",
            "Measurement 1103 1129--*--aspartate aminotransferase",
            "Value 1130 1158--*--more than three times normal",
            "Condition 1163 1188--*--renal function impairment",
            "Measurement 1190 1212--*--serum creatinine level",
            "Value 1213 1224--*-->133 \u00b5mol/L",
            "Scope 1190 1273--*--serum creatinine level >133 \u00b5mol/L, Estimated Glomerular Filtration Rate (eGFR) <60",
            "Condition 1276 1296--*--Cognitive impairment",
            "Procedure 1310 1317--*--MiniCog",
            "Drug 1362 1391--*--cannabinoid based medications",
            "Temporal 1392 1421--*--within 90 days of study entry",
            "Measurement 1490 1507--*--urine drug screen",
            "Value 1481 1489--*--Positive",
            "Drug 1512 1524--*--cannabinoids",
            "Drug 1568 1575--*--alcohol",
            "Drug 1577 1584--*--cocaine",
            "Drug 1586 1598--*--amphetamines",
            "Drug 1603 1619--*--methamphetamines",
            "Drug 1634 1641--*--opioids",
            "Qualifier 1621 1633--*--unprescribed",
            "Scope 1512 1642--*--cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)",
            "Competing_trial 1644 1724--*--Participation in another clinical trial within 30 days of enrolment in our trial"
        ],
        "Text": "Acute pain (less than 3 months in duration). Previous serious adverse event or hypersensitivity to cannabis or cannabinoids. Inability to understand and comply with the instructions of the study. Presence of significant cardiac disease (history of unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension) that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction. Current substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5). Life-time history of dependence on cannabis or diagnosis of cannabis use disorder (CUD) according to the DSM 5. Life-time history of DSM 5 schizophrenia, bipolar disorder, or previous psychosis with or intolerance to cannabinoids. Current or history of suicidal ideation. Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception. Hepatic impairment (aspartate aminotransferase more than three times normal) or renal function impairment (serum creatinine level >133 \u00b5mol/L, Estimated Glomerular Filtration Rate (eGFR) <60). Cognitive impairment according to MiniCog. The patient is currently using or has used cannabinoid based medications within 90 days of study entry and is unwilling to abstain for the duration of the study. Positive urine drug screen for cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids). Participation in another clinical trial within 30 days of enrolment in our trial. "
    },
    "NCT03177837_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 26 29--*--age",
            "Value 30 39--*--18-75 yrs",
            "Condition 42 46--*--COPD",
            "Qualifier 70 74--*--GOLD",
            "Measurement 76 80--*--FEV1",
            "Value 81 97--*--40-80% predicted",
            "Measurement 99 103--*--SpO2",
            "Value 104 108--*--=92%",
            "Qualifier 112 117--*--750 m",
            "Observation 147 169--*--living at low altitude",
            "Value 171 176--*--<800m",
            "Informed_consent 180 205--*--Written informed consent."
        ],
        "Text": "Male and female patients, age 18-75 yrs.. COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.. Born, raised and currently living at low altitude (<800m).. Written informed consent.. "
    },
    "NCT02944929_inc": {
        "Text": "Males and females aged between 18 to 75 years.. Adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained.. Single stroke having occurred more than 6 months before (previous TIA is accepted).. Capable of understanding instructions and participating in the definition of a therapeutic goal (Boston Diagnostic Aphasia Examination (BDAE) < 3).. Having previously undergone BTI. The last injection must have been performed at least 4 months prior to inclusion.. Affiliation to the French social security regime or a similar regime.. Patient (or the legal guardian if under guardian adult patient) has signed the informed consent form.. ",
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Person 18 22--*--aged",
            "Value 23 45--*--between 18 to 75 years",
            "Informed_consent 48 150--*--Adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained",
            "Condition 160 166--*--stroke",
            "Multiplier 153 159--*--Single",
            "Temporal 183 201--*--more than 6 months",
            "Condition 219 222--*--TIA",
            "Post-eligibility 238 333--*--Capable of understanding instructions and participating in the definition of a therapeutic goal",
            "Measurement 335 372--*--Boston Diagnostic Aphasia Examination",
            "Measurement 374 378--*--BDAE",
            "Value 380 383--*--< 3",
            "Procedure 415 418--*--BTI",
            "Procedure 429 438--*--injection",
            "Temporal 464 500--*--at least 4 months prior to inclusion",
            "Reference_point 491 500--*--inclusion",
            "Non-query-able 503 571--*--Affiliation to the French social security regime or a similar regime",
            "Informed_consent 574 674--*--Patient (or the legal guardian if under guardian adult patient) has signed the informed consent form"
        ]
    },
    "NCT01850147_inc": {
        "Annotations": [
            "Procedure 0 10--*--Histologic",
            "Procedure 14 23--*--cytologic",
            "Condition 51 56--*--NSCLC",
            "Qualifier 37 50--*--stage IIIB/IV",
            "Measurement 58 65--*--ECOG PS",
            "Value 67 70--*--0,1",
            "Undefined_semantics 105 123--*--measurable disease",
            "Qualifier 105 115--*--measurable",
            "Subjective_judgement 105 115--*--measurable",
            "Non-query-able 72 123--*--Unidimensional or bi-dimensional measurable disease",
            "Procedure 139 148--*--treatment",
            "Procedure 170 197--*--platinum-based chemotherapy",
            "Procedure 208 232--*--second-line chemotherapy",
            "Drug 237 257--*--1 EGF/EGFR inhibitor",
            "Qualifier 199 207--*--standard",
            "Scope 170 257--*--platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor",
            "Condition 271 290--*--disease progression",
            "Observation 259 267--*--Evidence",
            "Subjective_judgement 259 290--*--Evidence of disease progression",
            "Undefined_semantics 259 290--*--Evidence of disease progression",
            "Observation 292 307--*--Life expectancy",
            "Value 308 317--*-->12 weeks",
            "Measurement 319 330--*--Neutrophils",
            "Value 331 342--*--> 1.5 109/l",
            "Measurement 344 353--*--Platelets",
            "Value 354 365--*--> 100 109/l",
            "Measurement 367 377--*--Hemoglobin",
            "Value 378 385--*--> 9g/dl",
            "Measurement 387 402--*--Total bilirubin",
            "Value 403 412--*--< 1.5 UNL",
            "Measurement 429 439--*--ALT (SGPT)",
            "Value 440 449--*--< 2.5 UNL",
            "Measurement 414 424--*--AST (SGOT)",
            "Measurement 451 472--*--Alkaline phosphatases",
            "Value 473 480--*--< 5 UNL",
            "Measurement 482 492--*--Creatinine",
            "Value 493 500--*--< 1 UNL"
        ],
        "Text": "Histologic or cytologic diagnosis of stage IIIB/IV NSCLC . ECOG PS: 0,1 . Unidimensional or bi-dimensional measurable disease . Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor . Evidence of disease progression . Life expectancy >12 weeks . Neutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 9g/dl, Total bilirubin < 1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL, Creatinine < 1 UNL . "
    },
    "NCT01912651_inc": {
        "Text": "all adult patients with a nasal or facial skin/soft tissue defect requiring reconstruction limited to or including a full-thickness skin graft. ",
        "Annotations": [
            "Condition 35 65--*--facial skin/soft tissue defect",
            "Condition 26 31;42 65--*--nasal skin/soft tissue defect",
            "Procedure 76 90--*--reconstruction",
            "Mood 66 75--*--requiring",
            "Scope 26 65--*--nasal or facial skin/soft tissue defect",
            "Device 117 142--*--full-thickness skin graft"
        ]
    },
    "NCT02432404_inc": {
        "Annotations": [
            "Person 16 21--*--women",
            "Person 12 15--*--old",
            "Value 1 11--*--18-40 year",
            "Measurement 30 44--*--Amsel criteria",
            "Measurement 49 61--*--Nugent score",
            "Value 23 26--*--BV+",
            "Condition 76 78--*--BV",
            "Condition 23 25--*--BV",
            "Temporal 79 100--*--in the prior 6 months",
            "Scope 23 61--*--BV+ by Amsel criteria and Nugent score",
            "Pregnancy_considerations 143 215--*--Not intending or wishing to become pregnant over the course of the study",
            "Scope 30 61--*--Amsel criteria and Nugent score",
            "Observation 102 116--*--Willing to use",
            "Drug 121 129--*--NuvaRing",
            "Observation 238 262--*--written informed consent",
            "Observation 217 262--*--Capable of providing written informed consent"
        ],
        "Text": "=18-40 year old women. BV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months. Willing to use the NuvaRing as directed. Not intending or wishing to become pregnant over the course of the study. Capable of providing written informed consent. "
    },
    "NCT02939872_exc": {
        "Text": "Contraindication to antiplatelet therapy. Need to continue clopidogrel due to stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome. Major bleeding history or bleeding diathesis. Pregnancy. ",
        "Annotations": [
            "Condition 0 16--*--Contraindication",
            "Drug 20 40--*--antiplatelet therapy",
            "Multiplier 50 58--*--continue",
            "Drug 59 70--*--clopidogrel",
            "Condition 78 84--*--stroke",
            "Condition 86 104--*--peripheral disease",
            "Qualifier 106 117--*--significant",
            "Condition 118 133--*--carotid disease",
            "Temporal 137 143--*--recent",
            "Condition 144 167--*--acute coronary syndrome",
            "Mood 42 49--*--Need to",
            "Scope 78 167--*--stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome",
            "Scope 42 70--*--Need to continue clopidogrel",
            "Qualifier 169 174--*--Major",
            "Observation 184 191--*--history",
            "Condition 175 183--*--bleeding",
            "Condition 195 213--*--bleeding diathesis",
            "Condition 215 224--*--Pregnancy"
        ]
    },
    "NCT02396732_inc": {
        "Text": "Age 18 years or older. Blunt or penetrating trauma. Requires VTE thromboprophylaxis. High-risk for VTE. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--18 years or older",
            "Condition 32 50--*--penetrating trauma",
            "Condition 23 28;44 50--*--Blunt trauma",
            "Condition 61 64--*--VTE",
            "Procedure 65 83--*--thromboprophylaxis",
            "Mood 85 94--*--High-risk",
            "Condition 99 102--*--VTE"
        ]
    },
    "NCT03209011_exc": {
        "Text": "Active consumption of alcohol and/or drugs. Co-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus. History of autoimmune hepatitis. Psychiatric disease. Evidence of neoplastic diseases of the liver. ",
        "Annotations": [
            "Condition 7 29--*--consumption of alcohol",
            "Condition 37 42;7 21--*--drugs consumption of",
            "Condition 62 90--*--human immunodeficiency virus",
            "Condition 92 109--*--hepatitis C virus",
            "Condition 114 131--*--hepatitis D virus",
            "Condition 144 164--*--autoimmune hepatitis",
            "Qualifier 0 6--*--Active",
            "Scope 7 42--*--consumption of alcohol and/or drugs",
            "Observation 133 140--*--History",
            "Condition 166 185--*--Psychiatric disease",
            "Condition 199 218--*--neoplastic diseases",
            "Mood 187 198--*--Evidence of",
            "Qualifier 226 231--*--liver"
        ]
    },
    "NCT01850147_exc": {
        "Annotations": [
            "Condition 13 23--*--hemoptysis",
            "Qualifier 29 37--*--severity",
            "Value 38 47--*--> grade 3",
            "Measurement 51 69--*--NCI CTCAE criteria",
            "Temporal 70 105--*--within 4 weeks prior to study entry",
            "Reference_point 94 105--*--study entry",
            "Condition 120 132--*--hypertension",
            "Qualifier 107 119--*--Uncontrolled",
            "Condition 134 137--*--CHF",
            "Condition 139 145--*--angina",
            "Condition 149 160--*--arrhythmias",
            "Measurement 162 166--*--LVEF",
            "Value 167 174--*--< 1 UNL",
            "Condition 187 204--*--second malignancy",
            "Temporal 205 219--*--within 5 years",
            "Undefined_semantics 187 204--*--second malignancy",
            "Condition 235 238--*--HIV"
        ],
        "Text": "Pre-existing hemoptysis of a severity > grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry . Uncontrolled hypertension . CHF, angina or arrhythmias . LVEF < 1 UNL . Existing a second malignancy within 5 years . Infected with HIV       .     . "
    },
    "NCT01912651_exc": {
        "Text": "current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect.. ",
        "Annotations": [
            "Drug 56 66--*--antibiotic",
            "Condition 72 83--*--intolerance",
            "Drug 92 103--*--clindamycin",
            "Drug 108 118--*--cephalexin",
            "Condition 135 166--*--persistent cutaneous malignancy",
            "Qualifier 174 192--*--site of the defect",
            "Temporal 193 231--*--following the reconstructive procedure",
            "Reference_point 203 231--*--the reconstructive procedure",
            "Procedure 207 231--*--reconstructive procedure",
            "Temporal 19 45--*--within one week of surgery",
            "Temporal 11 17--*--recent",
            "Temporal 0 7--*--current",
            "Scope 0 46--*--current or recent (within one week of surgery)",
            "Scope 56 231--*--antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure"
        ]
    },
    "NCT02939872_inc": {
        "Text": "Age 19 and more. On dual or triple antiplatelet therapy and between 12months and 14months from Bioresorbable Vascular Scaffold implantation. No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--19 and more",
            "Procedure 28 55--*--triple antiplatelet therapy",
            "Procedure 20 24;35 55--*--dual antiplatelet therapy",
            "Temporal 60 139--*--between 12months and 14months from Bioresorbable Vascular Scaffold implantation",
            "Device 95 126--*--Bioresorbable Vascular Scaffold",
            "Procedure 127 139--*--implantation",
            "Reference_point 95 139--*--Bioresorbable Vascular Scaffold implantation",
            "Scope 20 55--*--dual or triple antiplatelet therapy",
            "Negation 141 143--*--No",
            "Observation 144 151--*--history",
            "Condition 155 160--*--death",
            "Qualifier 162 169--*--serious",
            "Condition 170 191--*--myocardial infarction",
            "Condition 193 199--*--stroke",
            "Multiplier 201 207--*--repeat",
            "Procedure 208 225--*--revascularization",
            "Qualifier 230 235--*--major",
            "Condition 236 244--*--bleeding",
            "Scope 155 244--*--death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding"
        ]
    },
    "NCT02432404_exc": {
        "Annotations": [
            "Condition 8 17--*--pregnancy",
            "Observation 19 51--*--Desire/intent to become pregnant",
            "Condition 43 51--*--pregnant",
            "Temporal 52 80--*--over the course of the study",
            "Person 82 87--*--Women",
            "Temporal 96 124--*--less than 6 weeks postpartum",
            "Reference_point 114 124--*--postpartum",
            "Procedure 147 169--*--hormonal contraceptive",
            "Observation 126 169--*--Contraindications to hormonal contraceptive",
            "Condition 215 235--*--deep vein thrombosis",
            "Person 248 253--*--women",
            "Observation 237 244--*--smoking",
            "Value 254 273--*--older than 35 years",
            "Scope 215 273--*--deep vein thrombosis, smoking in women older than 35 years",
            "Procedure 283 286--*--IUD",
            "Subjective_judgement 288 381--*--Unable to comprehend consent material because of language barrier or psychological difficulty"
        ],
        "Text": "Current pregnancy. Desire/intent to become pregnant over the course of the study. Women who are less than 6 weeks postpartum. Contraindications to hormonal contraceptive use per package insert, including history of deep vein thrombosis, smoking in women older than 35 years. Current IUD. Unable to comprehend consent material because of language barrier or psychological difficulty. "
    },
    "NCT03209011_inc": {
        "Text": "HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.. ",
        "Annotations": [
            "Condition 10 24--*--HBeAg positive",
            "Condition 0 5;16 24--*--HBsAg positive",
            "Temporal 25 47--*--for more than 6 months",
            "Scope 0 24--*--HBsAg and HBeAg positive",
            "Condition 49 67--*--HBV DNA detectable",
            "Measurement 73 82--*--ALT level",
            "Value 83 91--*--abnormal",
            "Temporal 92 115--*--lasted for three months",
            "Temporal 120 133--*--at least time",
            "Value 133 141--*--190 IU/L",
            "Procedure 145 166--*--liver puncture biopsy",
            "Condition 189 201--*--inflammation",
            "Negation 203 208--*--never",
            "Procedure 209 216--*--treated",
            "Temporal 217 232--*--before enrolled"
        ]
    },
    "NCT02396732_exc": {
        "Text": "Presence of VTE upon admission. Pregnant or nursing. Inability to give informed consent by patient or healthcare proxy. Contraindication to enoxaparin. Contraindication to aspirin. Epidural or subdural hematoma. Presence, or removal within the last 12 hours, of an epidural or spinal catheter, or recent (within the last 12 hours) epidural or spinal anesthesia/procedures. ",
        "Annotations": [
            "Condition 12 15--*--VTE",
            "Temporal 16 30--*--upon admission",
            "Condition 32 40--*--Pregnant",
            "Condition 44 51--*--nursing",
            "Observation 53 87--*--Inability to give informed consent",
            "Informed_consent 53 118--*--Inability to give informed consent by patient or healthcare proxy",
            "Condition 120 136--*--Contraindication",
            "Drug 140 150--*--enoxaparin",
            "Condition 152 168--*--Contraindication",
            "Drug 172 179--*--aspirin",
            "Condition 181 189;202 210--*--Epidural hematoma",
            "Condition 193 210--*--subdural hematoma",
            "Procedure 225 232;259 273--*--removal of an epidural",
            "Condition 212 220;259 273--*--Presence of an epidural",
            "Temporal 233 257--*--within the last 12 hours",
            "Condition 212 220;259 263;277 292--*--Presence of a spinal catheter",
            "Procedure 225 232;259 263;277 292--*--removal of a spinal catheter",
            "Scope 212 232;259 292--*--Presence, or removal of an epidural or spinal catheter",
            "Temporal 297 303--*--recent",
            "Temporal 305 329--*--within the last 12 hours",
            "Procedure 343 360--*--spinal anesthesia",
            "Procedure 331 339;350 360--*--epidural anesthesia",
            "Scope 331 360--*--epidural or spinal anesthesia"
        ]
    },
    "NCT03208244_exc": {
        "Text": "Sensitization (i.e. PRA >20%). Any liver disease in recipient. Albumin < 3g/dl or platelet count < 75 x 103/mL. Need for dual organ transplant. ",
        "Annotations": [
            "Condition 0 13--*--Sensitization",
            "Measurement 20 23--*--PRA",
            "Value 24 28--*-->20%",
            "Scope 20 28--*--PRA >20%",
            "Condition 35 48--*--liver disease",
            "Measurement 63 70--*--Albumin",
            "Value 71 78--*--< 3g/dl",
            "Measurement 82 96--*--platelet count",
            "Value 97 110--*--< 75 x 103/mL",
            "Measurement 121 142--*--dual organ transplant",
            "Mood 112 120--*--Need for"
        ]
    },
    "NCT03477851_exc": {
        "Text": "No consent. Spinal anesthesia or sciatic nerve block contraindicated. Known intolerance to tramadol or other contraindications for the drug. ",
        "Annotations": [
            "Observation 3 10--*--consent",
            "Negation 0 2--*--No",
            "Informed_consent 0 10--*--No consent",
            "Procedure 12 29--*--Spinal anesthesia",
            "Procedure 33 52--*--sciatic nerve block",
            "Condition 53 68--*--contraindicated",
            "Scope 12 52--*--Spinal anesthesia or sciatic nerve block",
            "Condition 76 87--*--intolerance",
            "Drug 91 99--*--tramadol",
            "Condition 109 126--*--contraindications",
            "Drug 131 139--*--the drug",
            "Qualifier 103 108--*--other"
        ]
    },
    "NCT03519568_inc": {
        "Annotations": [
            "Person 0 4--*--aged",
            "Value 5 15--*--= 6 months",
            "Informed_consent 17 47--*--sign the informed consent form",
            "Post-eligibility 49 160--*--the legal guardians participate in all the planned follow-up and be able to comply with all research procedures",
            "Multiplier 216 217--*--2",
            "Drug 218 256--*--needle recombinant hepatitis B vaccine",
            "Negation 267 269--*--no",
            "Drug 293 305--*--EV71 vaccine",
            "Negation 311 313--*--no",
            "Observation 314 321--*--history",
            "Condition 325 339--*--EV71 infection",
            "Procedure 270 281--*--inoculation",
            "Observation 282 289--*--history",
            "Observation 345 371--*--last vaccination intervals",
            "Value 372 381--*--= 14 days",
            "Measurement 383 394--*--temperature",
            "Value 395 407--*--= 37<U+2103>",
            "Person 409 413--*--aged",
            "Value 414 424--*--= 6 months",
            "Informed_consent 426 456--*--sign the informed consent form",
            "Post-eligibility 458 569--*--the legal guardians participate in all the planned follow-up and be able to comply with all research procedures",
            "Negation 580 582--*--no",
            "Procedure 583 594--*--inoculation",
            "Observation 595 602--*--history",
            "Drug 606 618--*--EV71 vaccine",
            "Negation 633 635--*--no",
            "Observation 636 643--*--history",
            "Condition 647 661--*--EV71 infection",
            "Observation 667 693--*--last vaccination intervals",
            "Value 694 703--*--= 14 days",
            "Measurement 705 716--*--temperature",
            "Value 717 729--*--= 37<U+2103>",
            "Person 731 735--*--aged",
            "Value 736 746--*--= 8 months",
            "Informed_consent 748 778--*--sign the informed consent form",
            "Informed_consent 1124 1154--*--sign the informed consent form",
            "Measurement 1081 1092--*--temperature",
            "Measurement 1460 1471--*--temperature",
            "Value 1093 1105--*--= 37<U+2103>",
            "Value 1472 1484--*--= 37<U+2103>",
            "Person 1107 1111--*--aged",
            "Value 1112 1122--*--= 8 months",
            "Post-eligibility 780 891--*--the legal guardians participate in all the planned follow-up and be able to comply with all research procedures",
            "Post-eligibility 1156 1267--*--the legal guardians participate in all the planned follow-up and be able to comply with all research procedures",
            "Negation 902 904--*--no",
            "Negation 1278 1280--*--no",
            "Procedure 905 916--*--inoculation",
            "Procedure 1281 1292--*--inoculation",
            "Observation 917 924--*--history",
            "Observation 1293 1300--*--history",
            "Drug 928 940--*--EV71 vaccine",
            "Drug 1304 1316--*--EV71 vaccine",
            "Negation 955 957--*--no",
            "Negation 1331 1333--*--no",
            "Observation 958 965--*--history",
            "Observation 1334 1341--*--history",
            "Condition 969 983--*--EV71 infection",
            "Condition 1345 1359--*--EV71 infection",
            "Observation 989 1015--*--last vaccination intervals",
            "Value 1016 1025--*--= 14 days",
            "Observation 1034 1072--*--last attenuated live vaccine intervals",
            "Value 1072 1079--*--=28days",
            "Value 1449 1458--*--= 28 days",
            "Observation 1410 1448--*--last attenuated live vaccine intervals",
            "Observation 1365 1391--*--last vaccination intervals",
            "Value 1392 1401--*--= 14 days"
        ],
        "Text": "aged = 6 months. sign the informed consent form. the legal guardians participate in all the planned follow-up and be able to comply with all research procedures. the subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection. the last vaccination intervals = 14 days. temperature = 37<U+2103>. aged = 6 months. sign the informed consent form. the legal guardians participate in all the planned follow-up and be able to comply with all research procedures. there is no inoculation history of EV71 vaccine, and there is no history of EV71 infection. the last vaccination intervals = 14 days. temperature = 37<U+2103>. aged = 8 months. sign the informed consent form. the legal guardians participate in all the planned follow-up and be able to comply with all research procedures. there is no inoculation history of EV71 vaccine, and there is no history of EV71 infection. the last vaccination intervals = 14 days and the last attenuated live vaccine intervals=28days. temperature = 37<U+2103>. aged = 8 months. sign the informed consent form. the legal guardians participate in all the planned follow-up and be able to comply with all research procedures. there is no inoculation history of EV71 vaccine, and there is no history of EV71 infection. the last vaccination intervals = 14 days and the last attenuated live vaccine intervals = 28 days. temperature = 37<U+2103>. "
    },
    "NCT02644629_exc": {
        "Text": "Active or past psychotic disorder, including a history of psychotic affective state. Mental Retardation or Autistic Spectrum Disorder. Prominent personality disorder. Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition.. Chronic nasal congestion. Active or recent drug or alcohol abuse. Substantial suicidality in a patient requiring admission but refuses to do so, and signs an \"against medical advice\" release form as part of clinical evaluation, and does not answer the terms for involuntary admission.. ",
        "Annotations": [
            "Condition 15 33--*--psychotic disorder",
            "Condition 58 83--*--psychotic affective state",
            "Temporal 0 6--*--Active",
            "Temporal 10 14--*--past",
            "Scope 0 14--*--Active or past",
            "Condition 85 103--*--Mental Retardation",
            "Condition 107 133--*--Autistic Spectrum Disorder",
            "Condition 135 165--*--Prominent personality disorder",
            "Condition 178 213--*--neurologic active medical condition",
            "Condition 167 174;189 213--*--Cardiac active medical condition",
            "Condition 230 233--*--CVA",
            "Condition 234 237--*--TIA",
            "Temporal 225 229--*--past",
            "Condition 239 262--*--Cardiovascular Accident",
            "Condition 263 288--*--Transient Ischemic Attack",
            "Scope 230 289--*--CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack)",
            "Qualifier 303 311--*--unstable",
            "Condition 312 329--*--medical condition",
            "Scope 167 213--*--Cardiac or neurologic active medical condition",
            "Scope 225 329--*--past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition",
            "Condition 340 356--*--nasal congestion",
            "Temporal 332 339--*--Chronic",
            "Condition 383 396--*--alcohol abuse",
            "Temporal 368 374--*--recent",
            "Temporal 358 364--*--Active",
            "Condition 375 379;391 396--*--drug abuse",
            "Scope 375 396--*--drug or alcohol abuse",
            "Scope 358 374--*--Active or recent",
            "Condition 410 421--*--suicidality",
            "Qualifier 398 409--*--Substantial",
            "Procedure 445 454--*--admission",
            "Non-representable 481 615--*--signs an \"against medical advice\" release form as part of clinical evaluation, and does not answer the terms for involuntary admission"
        ]
    },
    "NCT01490034_exc": {
        "Annotations": [],
        "Text": "    . "
    },
    "NCT01793831_exc": {
        "Text": "Diagnosis as CD first time or first year.. No history of using 5-ASA, biological or immunomodulatory therapy. ",
        "Annotations": [
            "Condition 13 15--*--CD",
            "Qualifier 16 26--*--first time",
            "Qualifier 30 40--*--first year",
            "Scope 16 40--*--first time or first year",
            "Negation 43 45--*--No",
            "Observation 46 53--*--history",
            "Drug 63 68--*--5-ASA",
            "Procedure 101 108;70 80--*--therapy biological",
            "Procedure 84 108--*--immunomodulatory therapy",
            "Scope 63 108--*--5-ASA, biological or immunomodulatory therapy"
        ]
    },
    "NCT03208244_inc": {
        "Text": "Recipient is Age = 18 years. Serum ALT within normal limits with no history of liver disease. Lack of sensitization (i.e. PRA < 20%) that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection. ",
        "Annotations": [
            "Person 13 16--*--Age",
            "Value 17 27--*--= 18 years",
            "Measurement 29 38--*--Serum ALT",
            "Value 39 59--*--within normal limits",
            "Negation 65 67--*--no",
            "Observation 68 75--*--history",
            "Condition 79 92--*--liver disease",
            "Negation 94 101--*--Lack of",
            "Condition 102 115--*--sensitization",
            "Measurement 122 125--*--PRA",
            "Value 126 131--*--< 20%",
            "Scope 122 131--*--PRA < 20%",
            "Scope 102 132--*--sensitization (i.e. PRA < 20%)",
            "Non-representable 133 245--*--that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection"
        ]
    },
    "NCT03477851_inc": {
        "Text": "Patients with foot fracture scheduled for surgical repair in spinal anesthesia. Informed consent. ",
        "Annotations": [
            "Condition 14 27--*--foot fracture",
            "Mood 28 41--*--scheduled for",
            "Procedure 42 57--*--surgical repair",
            "Procedure 61 78--*--spinal anesthesia",
            "Informed_consent 80 96--*--Informed consent"
        ]
    },
    "NCT03519568_exc": {
        "Annotations": [
            "Observation 4 11--*--history",
            "Observation 15 29--*--family history",
            "Condition 33 44--*--anaphylaxis",
            "Condition 46 56--*--convulsion",
            "Condition 58 66--*--epilepsy",
            "Condition 68 82--*--encephalopathy",
            "Condition 87 96--*--psychosis",
            "Scope 33 96--*--anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis",
            "Scope 4 29--*--history or family history",
            "Condition 120 141--*--inoculation allergies",
            "Qualifier 113 119--*--severe",
            "Observation 102 109--*--history",
            "Condition 178 194--*--malignant tumors",
            "Condition 157 173--*--immunodeficiency",
            "Temporal 195 222--*--during the treatment period",
            "Procedure 234 259--*--immunosuppressive therapy",
            "Drug 261 273--*--oral steroid",
            "Condition 278 281--*--HIV",
            "Condition 326 351--*--congenital immune disease",
            "Scope 157 194--*--immunodeficiency and malignant tumors",
            "Observation 306 320--*--family members",
            "Drug 353 379--*--Nonspecific immunoglobulin",
            "Temporal 393 409--*--within one month",
            "Measurement 411 422--*--temperature",
            "Value 422 435--*--=37.1<U+2103>",
            "Condition 440 459--*--infectious diseases",
            "Condition 476 492--*--thrombocytopenia",
            "Observation 465 472--*--history",
            "Qualifier 496 501--*--other",
            "Condition 502 518--*--thrombocytopenia",
            "Condition 546 565--*--respiratory disease",
            "Condition 567 582--*--acute infection",
            "Condition 586 617--*--chronic disease activity period",
            "Qualifier 619 625--*--severe",
            "Condition 626 648--*--cardiovascular disease",
            "Condition 660 674--*--kidney disease",
            "Condition 650 655;667 674--*--liver disease",
            "Condition 680 693--*--complications",
            "Condition 697 705--*--diabetes",
            "Condition 707 717;744 754--*--infectious dermatosis",
            "Condition 719 730;744 754--*--suppurative dermatosis",
            "Condition 735 754--*--allergic dermatosis",
            "Non-query-able 756 816--*--other conditions that may affect the evaluation of the trail",
            "Qualifier 822 829--*--serious",
            "Condition 830 844--*--adverse events",
            "Procedure 886 930--*--inoculation of the upper dose of the vaccine",
            "Non-representable 932 1051--*--the abnormality of 4 levels (local, systemic adverse reactions and vital signs) was judged to be related to vaccination",
            "Non-query-able 1053 1111--*--other new standards of exclusion criteria for first needle",
            "Non-query-able 1113 1173--*--other conditions that may affect the evaluation of the trail"
        ],
        "Text": "the history or family history of anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis. the history of severe inoculation allergies. patients with immunodeficiency and malignant tumors during the treatment period, receiving immunosuppressive therapy (oral steroid) or HIV due to low immunity, or family members have congenital immune disease. Nonspecific immunoglobulin was injected within one month. temperature=37.1<U+2103> and infectious diseases. the history of thrombocytopenia or other thrombocytopenia with a definite diagnosis. respiratory disease, acute infection or chronic disease activity period. severe cardiovascular disease, liver and kidney disease, and complications of diabetes. infectious, suppurative and allergic dermatosis. other conditions that may affect the evaluation of the trail. any serious adverse events that have a causal relationship with the inoculation of the upper dose of the vaccine. the abnormality of 4 levels (local, systemic adverse reactions and vital signs) was judged to be related to vaccination. other new standards of exclusion criteria for first needle. other conditions that may affect the evaluation of the trail. "
    },
    "NCT02644629_inc": {
        "Text": "Age 18-65. Diagnosis of MDD (Major Depressive Disorder), made or affirmed by a senior psychiatrist in Shalvata. MADRS score > 20. Treated with conventional anti-depressant, administered within a formal psychiatric clinic or by a certified psychiatrist.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 9--*--18-65",
            "Condition 24 27--*--MDD",
            "Condition 29 54--*--Major Depressive Disorder",
            "Measurement 112 123--*--MADRS score",
            "Value 124 128--*--> 20",
            "Drug 143 171--*--conventional anti-depressant",
            "Procedure 130 137--*--Treated"
        ]
    },
    "NCT01793831_inc": {
        "Text": "Moderate to severe CD define as HBI score > 4.. Montreal classification: no limitation, except age> 6.. ",
        "Annotations": [
            "Qualifier 0 8--*--Moderate",
            "Qualifier 12 18--*--severe",
            "Condition 19 21--*--CD",
            "Measurement 32 41--*--HBI score",
            "Value 42 45--*--> 4",
            "Scope 0 18--*--Moderate to severe",
            "Scope 32 45--*--HBI score > 4",
            "Non-representable 48 102--*--Montreal classification: no limitation, except age> 6."
        ]
    },
    "NCT01490034_inc": {
        "Annotations": [
            "Measurement 0 6--*--Weight",
            "Qualifier 7 13--*--stable",
            "Value 15 34--*--<3 kg weight change",
            "Temporal 35 55--*--within last 3 months",
            "Condition 58 93--*--Constant habitual activity patterns",
            "Observation 95 154--*--no deviation > 1x/wk at 30 min/session within last 3 months",
            "Condition 157 188--*--Constant habitual diet patterns",
            "Temporal 189 209--*--within last 3 months",
            "Observation 211 256--*--Willingness to eat a chocolate-flavored snack",
            "Temporal 257 273--*--at test sessions",
            "Temporal 257 259;278 302--*--at two week training period",
            "Condition 307 316--*--allergies",
            "Negation 304 306--*--No",
            "Observation 324 334--*--test foods",
            "Observation 340 358--*--planning to change",
            "Drug 366 405--*--medications known to influence appetite",
            "Drug 366 396;409 419--*--medications known to influence metabolism",
            "Scope 366 419--*--medications known to influence appetite or metabolism",
            "Negation 336 339--*--Not",
            "Condition 425 433--*--diabetic",
            "Negation 421 424--*--Not",
            "Condition 449 461--*--GI pathology",
            "Observation 438 445--*--history",
            "Negation 435 437--*--No",
            "Condition 467 473--*--smoker",
            "Negation 463 466--*--Non",
            "Temporal 474 494--*--for one year or more"
        ],
        "Text": "Weight stable (<3 kg weight change within last 3 months) . Constant habitual activity patterns (no deviation > 1x/wk at 30 min/session within last 3 months) . Constant habitual diet patterns within last 3 months . Willingness to eat a chocolate-flavored snack at test sessions and two week training period . No allergies to any test foods . Not planning to change use of medications known to influence appetite or metabolism . Not diabetic . No history of GI pathology . Non-smoker for one year or more . "
    },
    "NCT01664507_inc": {
        "Text": "croup children between 6 month and 5 years old. Westley croup score between 3 and 11. ",
        "Annotations": [
            "Value 15 42--*--between 6 month and 5 years",
            "Person 43 46--*--old",
            "Person 6 14--*--children",
            "Measurement 48 67--*--Westley croup score",
            "Value 68 84--*--between 3 and 11"
        ]
    },
    "NCT02106598_exc": {
        "Annotations": [
            "Condition 6 15--*--pregnancy",
            "Condition 19 33--*--breast-feeding",
            "Condition 36 74--*--Medical illness unrelated to the tumor",
            "Undefined_semantics 36 74--*--Medical illness unrelated to the tumor",
            "Subjective_judgement 75 191--*--which in the opinion of the attending physician and principal investigator will preclude administration of the agent",
            "Undefined_semantics 75 191--*--which in the opinion of the attending physician and principal investigator will preclude administration of the agent",
            "Post-eligibility 75 191--*--which in the opinion of the attending physician and principal investigator will preclude administration of the agent",
            "Condition 221 243--*--uncontrolled infection",
            "Undefined_semantics 221 243--*--uncontrolled infection",
            "Condition 245 272--*--chronic renal insufficiency",
            "Condition 274 295--*--myocardial infarction",
            "Temporal 296 320--*--within the past 6 months",
            "Condition 322 337--*--unstable angina",
            "Condition 339 358--*--cardiac arrhythmias",
            "Condition 370 397--*--chronic atrial fibrillation",
            "Negation 359 369--*--other than",
            "Condition 420 440--*--persistent hepatitis",
            "Measurement 445 471--*--New York Heart Association",
            "Value 472 496--*--Classification III or IV",
            "Condition 497 510--*--heart disease",
            "Undefined_semantics 497 510--*--heart disease",
            "Condition 402 416;431 440--*--chronic active hepatitis",
            "Grammar_Error 398 401--*--and"
        ],
        "Text": "Known pregnancy or breast-feeding. . Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the agent. This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.       .     . "
    },
    "NCT02369211_exc": {
        "Text": "Chronic opiate use. Liver disease (known history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, ALT/AST greater than 3 times upper limit of normal in the past 3 months). Allergy/hypersensitivity to acetaminophen. Patients with baseline dementia. Chronic diathesis. Chronic kidney disease. ",
        "Annotations": [
            "Multiplier 0 7--*--Chronic",
            "Drug 8 14--*--opiate",
            "Condition 20 33--*--Liver disease",
            "Observation 41 48--*--history",
            "Condition 52 63--*--hepatitis B",
            "Condition 52 61;67 68--*--hepatitis C",
            "Condition 70 79--*--cirrhosis",
            "Condition 81 109--*--nonalcoholic steatohepatitis",
            "Observation 111 118--*--history",
            "Condition 122 132--*--alcoholism",
            "Measurement 134 141--*--ALT/AST",
            "Value 142 184--*--greater than 3 times upper limit of normal",
            "Temporal 185 205--*--in the past 3 months",
            "Scope 52 68--*--hepatitis B or C",
            "Scope 41 205--*--history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, ALT/AST greater than 3 times upper limit of normal in the past 3 months",
            "Condition 208 215--*--Allergy",
            "Condition 216 232--*--hypersensitivity",
            "Drug 236 249--*--acetaminophen",
            "Scope 208 232--*--Allergy/hypersensitivity",
            "Temporal 265 273--*--baseline",
            "Condition 274 282--*--dementia",
            "Condition 292 301--*--diathesis",
            "Qualifier 284 291--*--Chronic",
            "Qualifier 303 310--*--Chronic",
            "Condition 311 325--*--kidney disease"
        ]
    },
    "NCT02277067_exc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 148 153--*--women",
            "Procedure 17 33--*--cesarean section",
            "Qualifier 39 57--*--general anesthesia",
            "Non-representable 76 145--*--because carbetocin is licensed for use with regional anaesthesia only",
            "Procedure 165 181--*--cesarean section",
            "Temporal 185 203--*--less than 37 weeks",
            "Measurement 207 216--*--gestation"
        ],
        "Text": "Women undergoing cesarean section with general anesthesia will be excluded, because carbetocin is licensed for use with regional anaesthesia only.. women undergoing cesarean section at less than 37 weeks of gestation.. "
    },
    "NCT02851303_inc": {
        "Annotations": [
            "Visit 8 41--*--University of New Mexico Hospital",
            "Person 0 4--*--Born",
            "Condition 65 74--*--gestation",
            "Value 43 64--*--Greater than 34 weeks",
            "Qualifier 84 92--*--in-utero",
            "Observation 93 106--*--drug exposure",
            "Drug 111 118--*--opioids",
            "Negation 119 124--*--other",
            "Drug 130 143--*--buprenorphine",
            "Qualifier 145 153--*--Maternal",
            "Qualifier 157 163--*--infant",
            "Measurement 164 181--*--urine drug screen",
            "Scope 145 163--*--Maternal or infant",
            "Value 182 190--*--positive",
            "Qualifier 195 204--*--methadone",
            "Qualifier 212 219--*--opioids",
            "Scope 195 219--*--methadone and/or opioids"
        ],
        "Text": "Born at University of New Mexico Hospital. Greater than 34 weeks gestation. Primary in-utero drug exposure was opioids other than buprenorphine. Maternal or infant urine drug screen positive for methadone and/or opioids on admission. "
    },
    "NCT02106598_inc": {
        "Annotations": [
            "Person 12 15--*--age",
            "Value 0 8;16 24--*--18 years or older",
            "Condition 64 72--*--melanoma",
            "Procedure 26 40--*--Histologically",
            "Value 41 50--*--confirmed",
            "Condition 74 87--*--breast cancer",
            "Condition 91 109--*--gynecologic cancer",
            "Visit 113 118--*--MSKCC",
            "Parsing_Error 120 164--*--Have one of the following disease histories:",
            "Condition 225 243--*--malignant melanoma",
            "Condition 247 260--*--breast cancer",
            "Qualifier 196 201--*--local",
            "Qualifier 203 211--*--regional",
            "Qualifier 213 223--*--metastatic",
            "Scope 196 223--*--local, regional, metastatic",
            "Temporal 166 181--*--Newly-diagnosed",
            "Multiplier 185 194--*--recurrent",
            "Scope 225 260--*--malignant melanoma or breast cancer",
            "Scope 166 194--*--Newly-diagnosed or recurrent",
            "Condition 352 357--*--tumor",
            "Procedure 327 343--*--radiographically",
            "Qualifier 304 312--*--Residual",
            "Value 344 351--*--evident",
            "Procedure 313 323--*--clinically",
            "Scope 304 351--*--Residual clinically or radiographically evident",
            "Condition 369 386--*--primary cutaneous",
            "Condition 391 408--*--mucosal melanomas",
            "Scope 369 408--*--primary cutaneous and mucosal melanomas",
            "Procedure 416 433--*--radiation therapy",
            "Procedure 435 447--*--chemotherapy",
            "Procedure 452 459--*--surgery",
            "Procedure 482 501--*--flap reconstruction",
            "Condition 472 501--*--requiring flap reconstruction",
            "Qualifier 509 529--*--head and neck region",
            "Temporal 410 415--*--Prior",
            "Procedure 571 588--*--excisional biopsy",
            "Temporal 562 570--*--previous",
            "Condition 610 628--*--gynecologic cancer",
            "Procedure 646 657--*--SLN mapping",
            "Procedure 662 679--*--surgical excision",
            "Condition 662 692--*--surgical excision is indicated",
            "Condition 646 657;680 692--*--SLN mapping is indicated",
            "Measurement 713 729--*--cardiac function",
            "Value 697 703--*--Normal",
            "Measurement 704 712--*--baseline",
            "Procedure 741 765--*--pre-operative evaluation",
            "Temporal 741 754--*--pre-operative",
            "Subjective_judgement 767 809--*--At the discretion of the operating surgeon",
            "Measurement 811 814--*--ANC",
            "Value 814 823--*-->1000/mcl",
            "Measurement 828 837--*--platelets",
            "Value 837 849--*-->100,000/mcl",
            "Subjective_judgement 852 894--*--At the discretion of the operating surgeon",
            "Measurement 896 911--*--Bilirubin level",
            "Value 915 926--*--< 2.0 mg/dl",
            "Condition 958 975--*--Gilbert's disease",
            "Negation 927 944--*--in the absence of",
            "Observation 947 954--*--history",
            "Condition 1021 1029--*--melanoma",
            "Condition 1070 1080--*--malignancy",
            "Condition 1092 1100--*--melanoma",
            "Negation 1081 1091--*--other than",
            "Condition 1112 1124--*--skin cancers",
            "Temporal 1125 1147--*--in the past five years",
            "Subjective_judgement 1168 1205--*--up to the discretion of the physician",
            "Grammar_Error 1102 1105--*--and",
            "Observation 1059 1066--*--history",
            "Post-eligibility 1208 1309--*--All patients of childbearing and child-creating age must be using an acceptable form of birth control",
            "Person 1311 1316--*--Women",
            "Condition 1325 1339--*--pre-menopausal",
            "Scope 1311 1339--*--Women who are pre-menopausal",
            "Measurement 1361 1381--*--serum pregnancy test",
            "Value 1352 1360--*--negative"
        ],
        "Text": "18 years of age or older . Histologically confirmed diagnosis of melanoma, breast cancer or gynecologic cancer at MSKCC . Have one of the following disease histories: . Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated . Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas . Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region. . Newly diagnosed patients with previous excisional biopsy. OR . Newly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated OR . Normal baseline cardiac function based upon pre-operative evaluation . At the discretion of the operating surgeon, ANC>1000/mcl and platelets>100,000/mcl. . At the discretion of the operating surgeon, Bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's). . For melanoma patients, If patients have a history of malignancy other than melanoma, and other skin cancers in the past five years, their inclusion is up to the discretion of the physician. . All patients of childbearing and child-creating age must be using an acceptable form of birth control . Women who are pre-menopausal must have a negative serum pregnancy test . "
    },
    "NCT01664507_exc": {
        "Text": "underlying lung or heart disase. contra indication to dexamethasone. immune deficient state. preterm birth. previous intubation or apnea history. ",
        "Annotations": [
            "Condition 19 31--*--heart disase",
            "Condition 11 15;25 31--*--lung disase",
            "Drug 54 67--*--dexamethasone",
            "Condition 33 50--*--contra indication",
            "Condition 69 91--*--immune deficient state",
            "Condition 93 106--*--preterm birth",
            "Procedure 117 127--*--intubation",
            "Condition 131 136--*--apnea",
            "Observation 137 144--*--history",
            "Temporal 108 116--*--previous",
            "Scope 117 136--*--intubation or apnea"
        ]
    },
    "NCT02277067_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 13 32--*--singleton pregnancy",
            "Procedure 44 60--*--cesarean section",
            "Value 61 75--*--after 37 weeks",
            "Measurement 79 88--*--gestation"
        ],
        "Text": "Women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.. "
    },
    "NCT02369211_inc": {
        "Text": "Patients undergoing robotic-assisted laparoscopic prostatectomy. =18 years old males. ASA class 1-4. ",
        "Annotations": [
            "Procedure 21 63--*--obotic-assisted laparoscopic prostatectomy",
            "Value 65 78--*--=18 years old",
            "Person 79 84--*--males",
            "Person 69 74--*--years",
            "Measurement 86 95--*--ASA class",
            "Value 96 99--*--1-4"
        ]
    },
    "NCT02851303_exc": {
        "Annotations": [
            "Person 0 4--*--Born",
            "Value 5 22--*--prior to 34 weeks",
            "Visit 24 52--*--Neonatal intensive care unit",
            "Condition 72 93--*--medical comorbidities",
            "Qualifier 64 71--*--Serious",
            "Observation 103 121--*--substance exposure",
            "Qualifier 122 130--*--in-utero",
            "Qualifier 135 148--*--buprenorphine",
            "Negation 157 160--*--not",
            "Drug 161 168--*--opioids"
        ],
        "Text": "Born prior to 34 weeks. Neonatal intensive care unit admission. Serious medical comorbidities. Primary substance exposure in-utero was buprenorphine, or was not opioids. "
    },
    "NCT02570347_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--18-65 years",
            "Condition 28 38--*--snake bite",
            "Condition 56 74--*--local envenomation",
            "Mood 44 55--*--features of",
            "Condition 88 105--*--systemic features",
            "Temporal 107 136--*--Less than 24 hours since bite",
            "Reference_point 132 136--*--bite",
            "Condition 132 136--*--bite",
            "Negation 143 145--*--No",
            "Temporal 146 151--*--prior",
            "Procedure 152 172--*--antibiotic treatment"
        ],
        "Text": "Age 18-65 years. History of snake bite with features of local envenomation with/without systemic features. Less than 24 hours since bite, AND. No prior antibiotic treatment. "
    },
    "NCT02535299_inc": {
        "Annotations": [
            "Temporal 0 16--*--Newly dignosised",
            "Condition 17 32--*--type 2 diabetes",
            "Qualifier 46 58--*--WHO criteria",
            "Measurement 59 86--*--glycated hemoglobin (HbA1c)",
            "Value 91 104--*--more than 10%",
            "Negation 107 119--*--Seronegative",
            "Condition 124 134--*--antibodies",
            "Qualifier 143 150--*--insulin",
            "Qualifier 152 163--*--islet cells",
            "Qualifier 168 201--*--glutamic acid decarboxylase (GAD)",
            "Scope 143 201--*--insulin, islet cells and glutamic acid decarboxylase (GAD)"
        ],
        "Text": "Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%;. Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);. "
    },
    "NCT03099863_inc": {
        "Text": "Adult women at least 18 years of age. Elective Female Pelvic Medicine and Reconstructive Surgery or Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair that require cystoscopy.. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 6 11--*--women",
            "Value 12 29--*--at least 18 years",
            "Person 33 36--*--age",
            "Qualifier 38 46--*--Elective",
            "Qualifier 47 60--*--Female Pelvic",
            "Procedure 74 96--*--Reconstructive Surgery",
            "Drug 61 69--*--Medicine",
            "Scope 61 96--*--Medicine and Reconstructive Surgery",
            "Qualifier 100 111--*--Gynecologic",
            "Qualifier 112 130--*--Minimally Invasive",
            "Procedure 131 140--*--surgeries",
            "Scope 100 140--*--Gynecologic Minimally Invasive surgeries",
            "Procedure 151 163--*--hysterectomy",
            "Procedure 165 182--*--suburethral sling",
            "Procedure 188 216--*--pelvic organ prolapse repair",
            "Procedure 230 240--*--cystoscopy",
            "Mood 222 229--*--require",
            "Scope 100 216--*--Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair"
        ]
    },
    "NCT03430284_exc": {
        "Text": "type 1 diabetes,specific types of diabetes,gestational diabetes or pregestational diabetes;. acute cardiovascular or cerebrovascular accidents within past 3 months;. severe hepatic or renal dysfunction;. malignant tumor;. allergic history or contraindication for any drugs in trials;. taking part in other clinical trials;. obviously poor compliance.. ",
        "Annotations": [
            "Condition 0 15--*--type 1 diabetes",
            "Condition 34 42--*--diabetes",
            "Qualifier 16 30--*--specific types",
            "Condition 43 63--*--gestational diabetes",
            "Condition 67 90--*--pregestational diabetes",
            "Condition 133 142;99 113--*--accidents cardiovascular",
            "Condition 117 142--*--cerebrovascular accidents",
            "Qualifier 93 98--*--acute",
            "Scope 99 142--*--cardiovascular or cerebrovascular accidents",
            "Temporal 143 163--*--within past 3 months",
            "Condition 184 201--*--renal dysfunction",
            "Condition 173 180;190 201--*--hepatic dysfunction",
            "Scope 173 201--*--hepatic or renal dysfunction",
            "Qualifier 166 172--*--severe",
            "Condition 204 219--*--malignant tumor",
            "Condition 222 230--*--allergic",
            "Temporal 231 238--*--history",
            "Condition 242 258--*--contraindication",
            "Drug 267 282--*--drugs in trials",
            "Qualifier 263 266--*--any",
            "Competing_trial 285 321--*--taking part in other clinical trials",
            "Qualifier 324 333--*--obviously",
            "Observation 334 349--*--poor compliance"
        ]
    },
    "NCT03539718_inc": {
        "Text": "Patients on regular hemodialysis 3sessions/wk.. Recent catheter insertion at beginning of the study.. Both males and females.. Age group = 18 ys.. ",
        "Annotations": [
            "Procedure 12 32--*--regular hemodialysis",
            "Multiplier 33 45--*--3sessions/wk",
            "Procedure 55 73--*--catheter insertion",
            "Temporal 74 99--*--at beginning of the study",
            "Temporal 48 54--*--Recent",
            "Reference_point 77 99--*--beginning of the study",
            "Person 107 112--*--males",
            "Person 117 124--*--females",
            "Person 127 136--*--Age group",
            "Value 137 144--*--= 18 ys"
        ]
    },
    "NCT02798237_exc": {
        "Annotations": [
            "Condition 0 20--*--cognitive impairment",
            "Measurement 22 58--*--Mini-Mental Status Examination score",
            "Observation 60 70--*--illiterate",
            "Value 71 80--*--13 points",
            "Observation 82 92--*--elementary",
            "Observation 97 110--*--middle school",
            "Value 111 120--*--18 points",
            "Observation 126 137--*--high-school",
            "Value 138 147--*--26 points",
            "Scope 82 110--*--elementary and middle school",
            "Condition 152 190--*--inability to respond to verbal command",
            "Scope 60 190--*--illiterate 13 points; elementary and middle school 18 points; and high-school 26 points; or inability to respond to verbal command",
            "Scope 22 190--*--Mini-Mental Status Examination score: illiterate 13 points; elementary and middle school 18 points; and high-school 26 points; or inability to respond to verbal command",
            "Condition 194 225--*--inability to walk independently",
            "Qualifier 230 249--*--at least 10 minutes",
            "Device 267 282--*--walking devices",
            "Condition 285 289--*--pain",
            "Condition 293 308--*--other disorders",
            "Qualifier 309 339--*--precluding their participation",
            "Scope 285 308--*--pain or other disorders",
            "Post-eligibility 285 339--*--pain or other disorders precluding their participation"
        ],
        "Text": "cognitive impairment (Mini-Mental Status Examination score: illiterate 13 points; elementary and middle school 18 points; and high-school 26 points; or inability to respond to verbal command);. inability to walk independently for at least 10 minutes, with or without walking devices;. pain or other disorders precluding their participation.. "
    },
    "NCT02555163_inc": {
        "Annotations": [
            "Visit 26 37--*--out-patient",
            "Procedure 38 48--*--cystoscopy",
            "Condition 54 78--*--papillary bladder tumour"
        ],
        "Text": "Patients diagnosed at the out-patient cystoscopy with papillary bladder tumour will be legible for inclusion. "
    },
    "NCT02620904_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02692651_inc": {
        "Text": "Patients 18 years of age or older with >3 unformed stools/24 hours with positive stool test for C. difficile.. Patients receiving = 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of = 5 days from the time of enrollment.. ",
        "Annotations": [
            "Person 21 24--*--age",
            "Value 25 33;9 17--*--or older 18 years",
            "Multiplier 39 41--*-->3",
            "Observation 42 57--*--unformed stools",
            "Temporal 58 66--*--24 hours",
            "Measurement 81 91--*--stool test",
            "Value 72 80--*--positive",
            "Qualifier 96 108--*--C. difficile",
            "Non-query-able 111 279--*--Patients receiving = 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of = 5 days from the time of enrollment."
        ]
    },
    "NCT03663387_exc": {
        "Annotations": [
            "Condition 13 25--*--hypertension",
            "Condition 29 46--*--metabolic disease",
            "Qualifier 0 12--*--Uncontrolled",
            "Scope 13 46--*--hypertension or metabolic disease",
            "Condition 48 75--*--Neurodegenerative disorders",
            "Condition 82 99--*--Parkinson disease",
            "Condition 101 104--*--LBD",
            "Condition 109 112--*--FTD",
            "Scope 82 112--*--Parkinson disease. LBD, or FTD",
            "Condition 116 124--*--Dementia",
            "Condition 128 153--*--Mild cognitive impairment",
            "Measurement 133 153--*--cognitive impairment",
            "Value 128 132--*--Mild",
            "Temporal 154 165--*--at baseline",
            "Scope 116 153--*--Dementia or Mild cognitive impairment",
            "Condition 167 193--*--Long life major depression",
            "Measurement 195 210--*--Baseline scores",
            "Value 211 214--*--=16",
            "Measurement 222 255--*--17-item Hamilton Depression Scale",
            "Temporal 256 267--*--at baseline",
            "Reference_point 259 267--*--baseline",
            "Condition 270 303--*--Long-life DSM-IV axis 1 disorders",
            "Condition 306 324--*--Mental retardation",
            "Condition 327 342--*--Substance abuse",
            "Temporal 345 355--*--Concurrent",
            "Drug 356 366--*--medication",
            "Qualifier 367 412--*--limiting validity of neuropsychological tests",
            "Qualifier 367 387;416 423--*--limiting validity of imaging",
            "Scope 367 423--*--limiting validity of neuropsychological tests or imaging",
            "Drug 426 442--*--Anti-depressants",
            "Qualifier 448 475--*--anti-cholinergic properties",
            "Drug 448 464--*--anti-cholinergic",
            "Drug 477 512--*--Monoamine oxidase inhibitors (MAOi)",
            "Drug 529 548--*--narcotic analgesics",
            "Multiplier 550 567--*-->2 doses per week",
            "Multiplier 514 525--*--Regular use",
            "Drug 578 590--*--neuroleptics",
            "Drug 599 624--*--anti-dementia medications",
            "Drug 626 633--*--Aricept",
            "Drug 635 641--*--Exelon",
            "Drug 643 651--*--Razadyne",
            "Scope 626 651--*--Aricept, Exelon, Razadyne",
            "Drug 657 666--*--memantine",
            "Drug 668 675--*--Namenda",
            "Drug 681 710--*--anti-Parkinsonian medications",
            "Drug 712 719--*--Sinemet",
            "Drug 721 731--*--amantadine",
            "Drug 733 746--*--bromocriptine",
            "Drug 748 757--*--pergolide",
            "Drug 759 769--*--selegeline",
            "Scope 712 769--*--Sinemet, amantadine, bromocriptine, pergolide, selegeline",
            "Drug 792 825;840 851--*--over the counter memory enhancing medications",
            "Drug 792 815;829 851--*--over the counter memory protecting medications",
            "Drug 858 871--*--ginkgo biloba",
            "Drug 873 881--*--vitamins",
            "Scope 858 881--*--ginkgo biloba, vitamins",
            "Scope 792 851--*--over the counter memory enhancing or protecting medications",
            "Non-representable 773 900--*--Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.",
            "Device 912 927--*--medical devices",
            "Procedure 955 966--*--MRI imaging",
            "Qualifier 937 966--*--incompatible with MRI imaging",
            "Measurement 969 988--*--Radiation exposures",
            "Value 989 1023--*--exceeding annual Rad Worker limits",
            "Condition 1026 1039--*--Heart failure",
            "Measurement 1040 1045--*--stage",
            "Value 1046 1047--*--D",
            "Qualifier 1062 1088--*--American Heart Association",
            "Condition 1095 1117--*--Chronic kidney disease",
            "Measurement 1121 1127--*--stages",
            "Value 1128 1131--*--= 4",
            "Qualifier 1148 1174--*--National Kidney Foundation",
            "Condition 1181 1192--*--Brain tumor",
            "Condition 1203 1223--*--neoplastic disorders",
            "Qualifier 1224 1241--*--outside the brain",
            "Qualifier 1309 1341--*--likely to affect brain structure",
            "Qualifier 1309 1331;1345 1353--*--likely to affect brain function",
            "Procedure 1281 1290--*--radiation",
            "Procedure 1292 1304--*--chemotherapy",
            "Scope 1181 1305--*--Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy)",
            "Scope 1310 1353--*--ikely to affect brain structure or function",
            "Condition 1356 1362--*--Stroke",
            "Condition 1435 1454--*--circulation infarct",
            "Qualifier 1425 1434--*--posterior",
            "Qualifier 1389 1403--*--total anterior",
            "Qualifier 1405 1421--*--partial anterior",
            "Scope 1389 1434--*--total anterior, partial anterior or posterior",
            "Measurement 1472 1518--*--Oxford Community Stroke Project classification",
            "Non-representable 1520 1623--*--Patients with clinically silent of lacunar strokes and transient ischemic attacks will not be excluded.",
            "Qualifier 1625 1636--*--Significant",
            "Condition 1637 1648--*--head trauma",
            "Condition 1651 1664--*--Hydrocephalus",
            "Observation 1680 1700--*--refusal to cooperate",
            "Observation 1667 1676--*--Hostility"
        ],
        "Text": "Uncontrolled hypertension or metabolic disease. Neurodegenerative disorders (i.e. Parkinson disease. LBD, or FTD).. Dementia or Mild cognitive impairment at baseline. Long life major depression. Baseline scores =16 on the 17-item Hamilton Depression Scale at baseline.. Long-life DSM-IV axis 1 disorders.. Mental retardation.. Substance abuse.. Concurrent medication limiting validity of neuropsychological tests or imaging.. Anti-depressants with anti-cholinergic properties. Monoamine oxidase inhibitors (MAOi). Regular use of narcotic analgesics (>2 doses per week).. Use of neuroleptics. Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline).. Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.. Implanted medical devices that are incompatible with MRI imaging.. Radiation exposures exceeding annual Rad Worker limits.. Heart failure stage D as defined by American Heart Association (7).. Chronic kidney disease in stages = 4, as defined per National Kidney Foundation (8).. Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy) is likely to affect brain structure or function.. Stroke when meeting criteria for total anterior, partial anterior or posterior circulation infarct according to the Oxford Community Stroke Project classification. Patients with clinically silent of lacunar strokes and transient ischemic attacks will not be excluded.. Significant head trauma.. Hydrocephalus.. Hostility or refusal to cooperate. "
    },
    "NCT03064568_inc": {
        "Annotations": [
            "Person 0 6--*--Female",
            "Person 7 10--*--age",
            "Value 11 20--*--20-50 y/o",
            "Mood 25 40--*--plan to undergo",
            "Procedure 41 61--*--abdominal myomectomy",
            "Qualifier 66 77--*--symptomatic",
            "Condition 78 94--*--myomatous uterus"
        ],
        "Text": "Female age 20-50 y/o who plan to undergo abdominal myomectomy for symptomatic myomatous uterus. "
    },
    "NCT02905734_exc": {
        "Annotations": [
            "Observation 0 34--*--Lack of understanding of the study",
            "Condition 36 53--*--contra-indication",
            "Procedure 57 85--*--nicotine replacement therapy",
            "Observation 101 144--*--incompatible with detention in police cells",
            "Condition 146 169--*--serious mental disorder",
            "Qualifier 196 221--*--outside Seine-Saint-Denis",
            "Observation 177 195--*--place of residence"
        ],
        "Text": "Lack of understanding of the study. contra-indication to nicotine replacement therapy. health status incompatible with detention in police cells. serious mental disorder. usual place of residence outside Seine-Saint-Denis. "
    },
    "NCT02502734_inc": {
        "Text": "Aged 5 years to less than 12 years at Visit 1. At least 15 (25%) children of the total study population must be aged 5 to less than 8 years. . Male or pre-menarchial female subjects. . Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1). . Normal range for their height and weight. Weight and height measurements should fall within the percentile range 3-97% of normal values for age according to Danish growth charts. . Have a documented diagnosis of persistent asthma, as defined by the National Institutes of Health for at least 3 months prior to the Screening Visit. . A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) >=80% predicted. There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement. . Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose). There must be no ICS use within 2 weeks of Visit 1 (Screening). . Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study. . Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement. The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC). (2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis. (3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call. . ",
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 34--*--5 years to less than 12 years",
            "Temporal 35 45--*--at Visit 1",
            "Reference_point 38 45--*--Visit 1",
            "Person 142 146--*--Male",
            "Person 150 164--*--pre-menarchial",
            "Person 165 171--*--female",
            "Scope 150 171--*--pre-menarchial female",
            "Person 200 214--*--pre-adolescent",
            "Condition 227 243--*--signs of puberty",
            "Negation 215 226--*--without any",
            "Measurement 245 257--*--Tanner Stage",
            "Value 258 259--*--1",
            "Scope 215 243--*--without any signs of puberty",
            "Measurement 286 292--*--height",
            "Value 263 275--*--Normal range",
            "Measurement 297 303--*--weight",
            "Measurement 305 311--*--Weight",
            "Measurement 316 322--*--height",
            "Value 348 381--*--within the percentile range 3-97%",
            "Not_a_criteria 47 140--*--At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.",
            "Condition 474 491--*--persistent asthma",
            "Qualifier 493 540--*--as defined by the National Institutes of Health",
            "Temporal 545 591--*--at least 3 months prior to the Screening Visit",
            "Reference_point 576 591--*--Screening Visit",
            "Qualifier 596 615--*--pre-bronchodilatory",
            "Measurement 616 657--*--forced expiratory flow in 1 second (FEV1)",
            "Temporal 658 680--*--at Visit 1 (Screening)",
            "Reference_point 661 680--*--Visit 1 (Screening)",
            "Value 681 696--*-->=80% predicted",
            "Drug 717 749--*--Short acting beta-agonist (SABA)",
            "Temporal 754 788--*--within 4 hours of this measurement",
            "Reference_point 772 788--*--this measurement",
            "Negation 714 716--*--no",
            "Procedure 818 834--*--asthma therapies",
            "Temporal 835 864--*--prior to entry into the study",
            "Reference_point 844 864--*--entry into the study",
            "Drug 866 878--*--SABA inhaler",
            "Drug 891 901--*--salbutamol",
            "Drug 1027 1059--*--leukotriene receptor antagonists",
            "Drug 1015 1023--*--cromones",
            "Drug 1092 1095--*--ICS",
            "Drug 1119 1129--*--budesonide",
            "Value 1130 1152--*--<=400 micrograms (mcg)",
            "Scope 866 1170--*--SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose)",
            "Procedure 1189 1192--*--ICS",
            "Negation 1186 1188--*--no",
            "Temporal 1197 1234--*--within 2 weeks of Visit 1 (Screening)",
            "Reference_point 1215 1234--*--Visit 1 (Screening)",
            "Drug 1267 1271--*--SABA",
            "Drug 1302 1313--*--rescue SABA",
            "Subjective_judgement 1237 1382--*--Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.",
            "Non-query-able 1237 1382--*--Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.",
            "Non-query-able 1384 1719--*--Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.",
            "Post-eligibility 1384 1719--*--Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.",
            "Subjective_judgement 1720 1939--*--The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).",
            "Non-query-able 1720 1939--*--The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).",
            "Post-eligibility 1720 1939--*--The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).",
            "Not_a_criteria 1940 2057--*--(2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis.",
            "Non-query-able 2058 2315--*--(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.",
            "Subjective_judgement 2058 2315--*--(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call."
        ]
    },
    "NCT02535299_exc": {
        "Annotations": [
            "Condition 0 24--*--Type 1 diabetes mellitus",
            "Condition 37 56--*--autoimmune diabetes",
            "Condition 70 80--*--antibodies",
            "Qualifier 84 91--*--insulin",
            "Qualifier 93 104--*--islet cells",
            "Qualifier 110 113--*--GAD",
            "Scope 84 113--*--insulin, islet cells, and GAD",
            "Condition 116 136--*--Gestational diabetes",
            "Condition 170 195--*--renal function impairment",
            "Condition 160 165;176 195--*--liver function impairment",
            "Condition 153 158;176 195--*--heart function impairment",
            "Qualifier 208 214--*--severe",
            "Condition 215 225--*--infections",
            "Condition 229 252--*--cerebrovascular disease",
            "Scope 215 252--*--infections or cerebrovascular disease"
        ],
        "Text": "Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to insulin, islet cells, and GAD;. Gestational diabetes;. patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease;. "
    },
    "NCT03539718_exc": {
        "Text": "Patients with intercurrent infections.. Patients with sepsis.. Patients receiving drugs affecting immune system like immunosuppressive drugs.. Patients on antibiotics.. ",
        "Annotations": [
            "Condition 14 37--*--intercurrent infections",
            "Condition 54 60--*--sepsis",
            "Drug 82 111--*--drugs affecting immune system",
            "Drug 117 140--*--immunosuppressive drugs",
            "Drug 155 166--*--antibiotics"
        ]
    },
    "NCT03430284_inc": {
        "Text": "35-75 years old;. diagnosed as type 2 diabetes according to the criteria of the World Health Organization in 1999.. ",
        "Annotations": [
            "Value 0 15--*--35-75 years old",
            "Person 12 15--*--old",
            "Condition 31 46--*--type 2 diabetes",
            "Qualifier 64 113--*--criteria of the World Health Organization in 1999"
        ]
    },
    "NCT03099863_exc": {
        "Text": "Surgeries that include: intradetrusor Botox, vaginal mesh excision, and fistula repair. Pregnancy. History of nephrolithiasis. Allergy to study medications. Congenital urogenital anomaly. Neurogenic bladder. ",
        "Annotations": [
            "Drug 38 43--*--Botox",
            "Qualifier 24 37--*--intradetrusor",
            "Procedure 45 66--*--vaginal mesh excision",
            "Device 45 57--*--vaginal mesh",
            "Procedure 72 86--*--fistula repair",
            "Condition 88 97--*--Pregnancy",
            "Condition 110 125--*--nephrolithiasis",
            "Observation 99 106--*--History",
            "Condition 127 134--*--Allergy",
            "Drug 138 155--*--study medications",
            "Qualifier 157 167--*--Congenital",
            "Condition 168 186--*--urogenital anomaly",
            "Condition 188 206--*--Neurogenic bladder"
        ]
    },
    "NCT02570347_exc": {
        "Annotations": [
            "Qualifier 0 10--*--Upper limb",
            "Condition 11 16--*--bites",
            "Multiplier 18 26--*--Multiple",
            "Multiplier 28 31--*--> 1",
            "Condition 33 38--*--bites",
            "Observation 40 58--*--Wound manipulation",
            "Condition 60 84--*--Extensive local necrosis",
            "Condition 60 75;88 93--*--Extensive local blebs",
            "Condition 95 108--*--Seriously-ill",
            "Condition 123 134--*--hypotension",
            "Condition 135 149--*--capillary leak",
            "Qualifier 150 166--*--life threatening",
            "Condition 167 175--*--bleeding",
            "Condition 188 198--*--cobra bite",
            "Mood 178 187--*--Suspected",
            "Condition 204 212--*--Pregnant",
            "Condition 213 227--*--breast-feeding",
            "Person 228 233--*--women"
        ],
        "Text": "Upper limb bites. Multiple (> 1) bites. Wound manipulation. Extensive local necrosis or blebs. Seriously-ill patients with hypotension/capillary leak/life threatening bleeding.. Suspected cobra bite, OR. Pregnant/breast-feeding women. "
    },
    "NCT02555163_exc": {
        "Annotations": [
            "Condition 0 28--*--Non papillary gross features",
            "Condition 36 41--*--tumor",
            "Qualifier 43 61--*--Anteriorly located",
            "Condition 62 67--*--tumor",
            "Non-representable 69 86--*--Patients criteria",
            "Observation 93 111--*--performance status",
            "Value 88 92--*--Poor",
            "Condition 124 127--*--BCG",
            "Condition 128 134--*--sepsis",
            "Condition 147 166--*--bladder irradiation",
            "Observation 113 120--*--History",
            "Observation 136 143--*--History",
            "Condition 168 186--*--Contracted bladder"
        ],
        "Text": "Non papillary gross features of the tumor. Anteriorly located tumor. Patients criteria. Poor performance status. History of BCG sepsis. History of bladder irradiation. Contracted bladder. "
    },
    "NCT02620904_inc": {
        "Annotations": [
            "Condition 0 24--*--Intrauterine fetal death",
            "Condition 41 66--*--absence of cardiac motion",
            "Procedure 70 80--*--ultrasound",
            "Temporal 104 144--*--at the time of admission to the hospital",
            "Reference_point 119 144--*--admission to the hospital",
            "Measurement 147 172--*--Estimated gestational age",
            "Value 173 194--*--greater than 20 weeks",
            "Condition 196 218--*--Hemodynamically stable",
            "Procedure 239 257--*--induction of labor",
            "Person 304 309--*--Women",
            "Multiplier 315 318--*--one",
            "Procedure 325 357--*--low transverse cesarean delivery"
        ],
        "Text": "Intrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by Attending physician at the time of admission to the hospital.. Estimated gestational age greater than 20 weeks. Hemodynamically stable and appropriate for induction of labor as per primary clinical health team in house. Women with one prior low transverse cesarean delivery. "
    },
    "NCT02798237_inc": {
        "Annotations": [
            "Person 13 16--*--age",
            "Value 0 9--*--= 20years",
            "Condition 32 38--*--stroke",
            "Temporal 40 48--*-->6months",
            "Observation 52 61--*--sedentary",
            "Observation 65 86--*--insufficiently active",
            "Non-query-able 89 161--*--have a writing medical permission to participate in the training program"
        ],
        "Text": "= 20years of age;. diagnosis of stroke (>6months);. sedentary or insufficiently active;. have a writing medical permission to participate in the training program.. "
    },
    "NCT02692651_exc": {
        "Text": "Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon).. Patients with an allergy to oral vancomycin or fidaxomicin.. Patients anticipated to receive metronidazole after enrollment.. Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for > 24 hours within the preceding 72 hours at the time of enrollment.. Patients anticipated to receive adjunctive C. difficile therapy (rifaxamin, nitazoxanide, tigecycline) after enrollment.. ",
        "Annotations": [
            "Condition 77 89--*--hypotenstion",
            "Condition 93 98--*--shock",
            "Condition 100 105--*--ileus",
            "Condition 109 126--*--bowel obstruction",
            "Condition 128 137--*--megacolon",
            "Non-query-able 0 75--*--Patients with severe-complicated disease that would compromise oral therapy",
            "Condition 158 165--*--allergy",
            "Drug 174 184--*--vancomycin",
            "Drug 188 199--*--fidaxomicin",
            "Qualifier 169 173--*--oral",
            "Scope 174 199--*--vancomycin or fidaxomicin",
            "Drug 234 247--*--metronidazole",
            "Mood 211 222--*--anticipated",
            "Drug 302 312--*--vancomycin",
            "Drug 316 329--*--metronidazole",
            "Qualifier 297 301--*--oral",
            "Multiplier 363 373--*--> 24 hours",
            "Temporal 385 430--*--preceding 72 hours at the time of enrollment.",
            "Reference_point 419 429--*--enrollment",
            "Scope 297 329--*--oral vancomycin or metronidazole",
            "Mood 441 452--*--anticipated",
            "Procedure 475 495--*--C. difficile therapy",
            "Drug 497 506--*--rifaxamin",
            "Drug 508 520--*--nitazoxanide",
            "Drug 522 533--*--tigecycline",
            "Scope 497 534--*--rifaxamin, nitazoxanide, tigecycline)"
        ]
    },
    "NCT03663387_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Value 25 44--*--between 40-85 years",
            "Person 45 48--*--old",
            "Non-representable 67 149--*--Younger subjects are not included as the risk for brain amyloid lesions is too low",
            "Observation 169 182--*--speak English",
            "Qualifier 192 206--*--first language",
            "Observation 222 244--*--proficiency in English",
            "Measurement 296 316--*--WAIS vocabulary test",
            "Value 284 288--*--> 11",
            "Scope 284 316--*--> 11 on the WAIS vocabulary test",
            "Condition 343 359--*--normal cognition",
            "Temporal 360 371--*--at baseline",
            "Measurement 375 403--*--Clinical Dementia Rating CDR",
            "Value 403 405--*--=0",
            "Measurement 407 437--*--Global Deterioration Scale GDS",
            "Value 437 439--*--<2",
            "Condition 466 485--*--good general health",
            "Observation 490 509--*--able to participate",
            "Procedure 524 537--*--imaging exams",
            "Procedure 517 519--*--LP",
            "Scope 517 537--*--LP and imaging exams",
            "Non-representable 539 644--*--This determination is made by the study neurologist and reviewed at a consensus meeting for each subject."
        ],
        "Text": "Male and female subjects between 40-85 years old will be enrolled. Younger subjects are not included as the risk for brain amyloid lesions is too low. All subjects will speak English as their first language or demonstrate proficiency in English (defined as reaching a scaled score of > 11 on the WAIS vocabulary test).. All subjects will have normal cognition at baseline: a Clinical Dementia Rating CDR=0, Global Deterioration Scale GDS<2.. All subjects will be in good general health and able to participate in the LP and imaging exams. This determination is made by the study neurologist and reviewed at a consensus meeting for each subject.. "
    },
    "NCT02502734_exc": {
        "Text": "A history of life-threatening asthma defined for this protocol as an asthma episode that required intubation, hypercapnea requiring non-invasive ventilatory support, respiratory arrest, hypoxic seizures or asthma-related syncopal episode(s). . Subjects with a history of asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a depot corticosteroid injection or emergency room attendance (within 3 months) or requiring hospitalization for asthma (within 6 months) prior to screening. . Significant, non-reversible active pulmonary disease (e.g. cystic fibrosis, bronchiectasis, tuberculosis). . Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study. . Any fracture in the leg to be measured within 6 months prior to the screening visit. . Any metabolic disorders or other diseases that may impact on normal growth patterns. . No major surgery requiring general anaesthesia for at least 3 months prior to the screening visit. . No febrile illnesses with temperature >39 degree celsius for more than five consecutive days within the week preceding the Screening Visit. . Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study. . Clinical visual evidence of candidiasis at Visit 1 (Screening). . Use of any of the prohibited medications listed in protocol. . Strenuous physical exercise within 3 hours of Visit 1 (Screening) . Drug allergies: Any adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the ELLIPTA Inhaler (i.e., lactose, FF). . Milk Protein Allergy: History of severe milk protein allergy. . The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). . Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day. . Unable to use the ELLIPTA inhaler and peak flow meter correctly. . An affiliation with the Investigator site: the parents/guardians or child is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator. . The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being. . Children in care: Children who are wards of the government or state are not eligible for participation in this study.       .     . ",
        "Annotations": [
            "Condition 30 36--*--asthma",
            "Qualifier 13 29--*--life-threatening",
            "Observation 2 9--*--history",
            "Procedure 98 108--*--intubation",
            "Condition 69 83--*--asthma episode",
            "Condition 110 121--*--hypercapnea",
            "Device 132 164--*--non-invasive ventilatory support",
            "Condition 166 184--*--respiratory arrest",
            "Condition 186 202--*--hypoxic seizures",
            "Condition 206 237--*--asthma-related syncopal episode",
            "Scope 69 237--*--asthma episode that required intubation, hypercapnea requiring non-invasive ventilatory support, respiratory arrest, hypoxic seizures or asthma-related syncopal episode",
            "Observation 259 266--*--history",
            "Condition 270 289--*--asthma exacerbation",
            "Drug 311 335--*--systemic corticosteroids",
            "Temporal 372 391--*--for at least 3 days",
            "Drug 397 427--*--depot corticosteroid injection",
            "Temporal 458 473--*--within 3 months",
            "Procedure 431 456--*--emergency room attendance",
            "Procedure 488 503--*--hospitalization",
            "Condition 508 514--*--asthma",
            "Temporal 516 531--*--within 6 months",
            "Condition 589 606--*--pulmonary disease",
            "Undefined_semantics 589 606--*--pulmonary disease",
            "Qualifier 554 565--*--Significant",
            "Subjective_judgement 554 565--*--Significant",
            "Qualifier 567 581--*--non-reversible",
            "Temporal 582 588--*--active",
            "Condition 613 628--*--cystic fibrosis",
            "Condition 630 644--*--bronchiectasis",
            "Condition 646 658--*--tuberculosis",
            "Scope 613 658--*--cystic fibrosis, bronchiectasis, tuberculosis",
            "Condition 707 735;745 762--*--viral infection of the upper respiratory tract",
            "Condition 694 703;713 735;745 762--*--bacterial infection of the upper respiratory tract",
            "Condition 707 729;739 762--*--viral infection of the lower respiratory tract",
            "Condition 694 703;713 729;739 762--*--bacterial infection of the lower respiratory tract",
            "Condition 707 729;764 769--*--viral infection of the sinus",
            "Condition 694 703;713 729;764 769--*--bacterial infection of the sinus",
            "Condition 707 729;773 783--*--viral infection of the middle ear",
            "Condition 694 703;713 729;773 783--*--bacterial infection of the middle ear",
            "Procedure 662 669--*--Culture",
            "Observation 684 693--*--suspected",
            "Scope 662 693--*--Culture-documented or suspected",
            "Scope 694 783--*--bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear",
            "Qualifier 796 804--*--resolved",
            "Negation 792 795--*--not",
            "Temporal 805 830--*--within 4 weeks of Visit 1",
            "Reference_point 823 830--*--Visit 1",
            "Observation 844 871--*--change in asthma management",
            "Subjective_judgement 876 910--*--in the opinion of the Investigator",
            "Non-query-able 912 933--*--is expected to affect",
            "Subjective_judgement 969 1014--*--subject's ability to participate in the study",
            "Non-query-able 969 1014--*--subject's ability to participate in the study",
            "Procedure 854 871--*--asthma management",
            "Condition 1021 1040--*--fracture in the leg",
            "Temporal 1056 1100--*--within 6 months prior to the screening visit",
            "Reference_point 1081 1100--*--the screening visit",
            "Condition 1107 1126--*--metabolic disorders",
            "Qualifier 1150 1186--*--may impact on normal growth patterns",
            "Subjective_judgement 1150 1186--*--may impact on normal growth patterns",
            "Undefined_semantics 1150 1186--*--may impact on normal growth patterns",
            "Condition 1130 1144--*--other diseases",
            "Scope 1107 1144--*--metabolic disorders or other diseases",
            "Condition 1192 1205--*--major surgery",
            "Undefined_semantics 1192 1205--*--major surgery",
            "Procedure 1216 1235--*--general anaesthesia",
            "Temporal 1236 1286--*--for at least 3 months prior to the screening visit",
            "Reference_point 1267 1286--*--the screening visit",
            "Condition 1292 1309--*--febrile illnesses",
            "Negation 1189 1191--*--No",
            "Grammar_Error 1189 1191--*--No",
            "Measurement 1315 1326--*--temperature",
            "Value 1327 1345--*-->39 degree celsius",
            "Temporal 1346 1381--*--for more than five consecutive days",
            "Temporal 1382 1427--*--within the week preceding the Screening Visit",
            "Reference_point 1408 1427--*--the Screening Visit",
            "Negation 1289 1291--*--No",
            "Qualifier 1434 1445--*--significant",
            "Subjective_judgement 1434 1445--*--significant",
            "Undefined_semantics 1434 1445--*--significant",
            "Condition 1446 1457--*--abnormality",
            "Condition 1461 1478--*--medical condition",
            "Scope 1446 1478--*--abnormality or medical condition",
            "Subjective_judgement 1430 1714--*--Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.",
            "Post-eligibility 1430 1714--*--Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.",
            "Context_Error 1430 1714--*--Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.",
            "Condition 1725 1740--*--visual evidence",
            "Condition 1744 1755--*--candidiasis",
            "Temporal 1756 1778--*--at Visit 1 (Screening)",
            "Reference_point 1759 1778--*--Visit 1 (Screening)",
            "Context_Error 1781 1841--*--Use of any of the prohibited medications listed in protocol.",
            "Drug 1799 1840--*--prohibited medications listed in protocol",
            "Condition 1843 1870--*--Strenuous physical exercise",
            "Temporal 1871 1908--*--within 3 hours of Visit 1 (Screening)",
            "Reference_point 1889 1908--*--Visit 1 (Screening)",
            "Condition 1910 1924--*--Drug allergies",
            "Drug 2002 2012;2035 2049--*--intranasal corticosteroid",
            "Drug 2026 2049--*--systemic corticosteroid",
            "Drug 2014 2021;2035 2049--*--inhaled corticosteroid",
            "Scope 2002 2049--*--intranasal, inhaled, or systemic corticosteroid",
            "Condition 1957 1966;1978 1994--*--immediate hypersensitivity",
            "Condition 1970 1994--*--delayed hypersensitivity",
            "Condition 1930 1946--*--adverse reaction",
            "Scope 1957 1994--*--immediate or delayed hypersensitivity",
            "Scope 1930 2049--*--adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid",
            "Condition 2078 2089--*--sensitivity",
            "Drug 2097 2132--*--constituents of the ELLIPTA Inhaler",
            "Drug 2140 2147--*--lactose",
            "Drug 2149 2151--*--FF",
            "Scope 2140 2151--*--lactose, FF",
            "Condition 2155 2175--*--Milk Protein Allergy",
            "Condition 2195 2215--*--milk protein allergy",
            "Qualifier 2188 2194--*--severe",
            "Non-query-able 2218 2518--*--The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",
            "Post-eligibility 2218 2518--*--The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",
            "Multiplier 2532 2543--*--more than 4",
            "Drug 2544 2578--*--investigational medicinal products",
            "Temporal 2579 2625--*--within 12 months prior to the first dosing day",
            "Reference_point 2605 2625--*--the first dosing day",
            "Drug 2646 2661--*--ELLIPTA inhaler",
            "Device 2666 2681--*--peak flow meter",
            "Condition 2628 2692--*--Unable to use the ELLIPTA inhaler and peak flow meter correctly.",
            "Non-query-able 2628 2692--*--Unable to use the ELLIPTA inhaler and peak flow meter correctly.",
            "Subjective_judgement 2628 2692--*--Unable to use the ELLIPTA inhaler and peak flow meter correctly.",
            "Non-query-able 2694 2915--*--An affiliation with the Investigator site: the parents/guardians or child is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator",
            "Non-query-able 2918 3370--*--The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being.",
            "Post-eligibility 2918 3370--*--The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being.",
            "Context_Error 3372 3488--*--Children in care: Children who are wards of the government or state are not eligible for participation in this study",
            "Non-query-able 3372 3488--*--Children in care: Children who are wards of the government or state are not eligible for participation in this study"
        ]
    },
    "NCT03064568_exc": {
        "Annotations": [
            "Drug 33 44--*--misoprostol",
            "Drug 48 59--*--vasopressin",
            "Condition 13 29--*--contraindication",
            "Scope 33 59--*--misoprostol or vasopressin",
            "Observation 61 77--*--personal history",
            "Condition 102 109;81 88--*--disease cardiac",
            "Condition 92 109--*--pulmonary disease",
            "Observation 111 118--*--history",
            "Temporal 122 127--*--prior",
            "Procedure 128 138--*--myomectomy",
            "Scope 81 109--*--cardiac or pulmonary disease"
        ],
        "Text": "Patient with contraindication to misoprostol or vasopressin, personal history or cardiac or pulmonary disease, history of prior myomectomy. "
    },
    "NCT02905734_inc": {
        "Annotations": [
            "Person 0 9--*--Arrestees",
            "Temporal 34 66--*--during detention in police cells",
            "Reference_point 41 66--*--detention in police cells",
            "Procedure 10 33--*--examined by a physician",
            "Value 73 84--*--18 or older",
            "Person 68 72--*--aged",
            "Observation 86 93--*--smoking",
            "Multiplier 94 124--*--at least 10 cigarettes per day",
            "Informed_consent 126 176--*--giving written consent to participate in the study",
            "Value 192 233--*--compatible with detention in police cells",
            "Measurement 178 191--*--health status"
        ],
        "Text": "Arrestees examined by a physician during detention in police cells. aged 18 or older. smoking at least 10 cigarettes per day. giving written consent to participate in the study. health status compatible with detention in police cells. "
    },
    "NCT03256864_exc": {
        "Text": "Patients who are recipients of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant. Patients who have a combined liver-kidney transplant.. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.. Existence of any surgical, medical or mental conditions, other than the current transplantation, which, in the opinion of the investigator, might interfere with the objectives of the study.. Pregnant or nursing (lactating) women.",
        "Annotations": [
            "Multiplier 31 39--*--multiple",
            "Procedure 40 51;73 84--*--solid organ transplants",
            "Procedure 55 84--*--islet cell tissue transplants",
            "Scope 40 84--*--solid organ or islet cell tissue transplants",
            "Temporal 94 104--*--previously",
            "Procedure 117 122;133 143--*--organ transplant",
            "Procedure 126 143--*--tissue transplant",
            "Scope 117 143--*--organ or tissue transplant",
            "Procedure 165 197--*--combined liver-kidney transplant",
            "Observation 200 207--*--History",
            "Condition 211 221--*--malignancy",
            "Qualifier 225 241--*--any organ system",
            "Negation 243 253--*--other than",
            "Condition 254 296--*--localized basal cell carcinoma of the skin",
            "Scope 243 296--*--other than localized basal cell carcinoma of the skin",
            "Qualifier 299 306--*--treated",
            "Qualifier 310 319--*--untreated",
            "Temporal 321 344--*--within the past 5 years",
            "Non-representable 346 419--*--regardless of whether there is evidence of local recurrence or metastases",
            "Scope 299 319--*--treated or untreated",
            "Condition 439 447;467 477--*--surgical conditions",
            "Condition 449 456;467 477--*--medical conditions",
            "Condition 460 477--*--mental conditions",
            "Negation 479 489--*--other than",
            "Temporal 494 501--*--current",
            "Procedure 502 517--*--transplantation",
            "Scope 439 477--*--surgical, medical or mental conditions",
            "Qualifier 562 610--*--might interfere with the objectives of the study",
            "Condition 613 621--*--Pregnant",
            "Observation 625 632--*--nursing",
            "Observation 634 643--*--lactating",
            "Person 645 650--*--women"
        ]
    },
    "NCT02105090_exc": {
        "Text": "amide and/or esther local anaesthetic allergy. paraben allergy. Child-Pugh grade B/C liver failure. renal insufficiency (calculated glomerular filtration rate under 60 ml/min/1.73 m2 according to Cockcroft-Gault scale ). dementia. those presenting with swallowing problem. chronic pain condition. chronic use of pain medication. pregnancy. lactation. ",
        "Annotations": [
            "Drug 0 5;20 37--*--amide local anaesthetic",
            "Drug 13 37--*--esther local anaesthetic",
            "Condition 38 45--*--allergy",
            "Scope 0 37--*--amide and/or esther local anaesthetic",
            "Condition 55 62--*--allergy",
            "Drug 47 54--*--paraben",
            "Measurement 64 80--*--Child-Pugh grade",
            "Value 81 82--*--B",
            "Value 83 84--*--C",
            "Scope 81 84--*--B/C",
            "Condition 85 98--*--liver failure",
            "Condition 100 119--*--renal insufficiency",
            "Measurement 121 158--*--calculated glomerular filtration rate",
            "Value 159 182--*--under 60 ml/min/1.73 m2",
            "Qualifier 196 217--*--Cockcroft-Gault scale",
            "Condition 221 229--*--dementia",
            "Condition 253 271--*--swallowing problem",
            "Condition 329 338--*--pregnancy",
            "Condition 273 295--*--chronic pain condition",
            "Multiplier 297 308--*--chronic use",
            "Drug 312 327--*--pain medication",
            "Condition 340 349--*--lactation"
        ]
    },
    "NCT02816762_exc": {
        "Annotations": [
            "Condition 0 24--*--Non diabetic nephropathy",
            "Qualifier 26 45--*--confirmed by biopsy",
            "Procedure 39 45--*--biopsy",
            "Procedure 49 57--*--Dialysis",
            "Condition 62 81--*--acute renal failure",
            "Temporal 82 110--*--within the 6 previous months",
            "Qualifier 147 155--*--relevant",
            "Qualifier 156 165--*--bilateral",
            "Condition 166 190--*--stenosis of renal artery",
            "Value 192 197--*--> 75%",
            "Measurement 200 232--*--Urinary albumin/creatinine ratio",
            "Value 233 254--*--higher than 3000 mg/g",
            "Temporal 256 277--*--at the baseline visit",
            "Measurement 280 303--*--Systolic blood pressure",
            "Value 304 314--*--= 180 mmHg",
            "Measurement 318 342--*--diastolic blood pressure",
            "Value 343 354--*--= 110 mm Hg",
            "Temporal 355 376--*--at the baseline visit",
            "Scope 280 354--*--Systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mm Hg",
            "Condition 379 385--*--Stroke",
            "Condition 387 412--*--transient ischemic attack",
            "Condition 414 437--*--acute coronary syndrome",
            "Procedure 442 457--*--hospitalization",
            "Condition 462 475--*--heart failure",
            "Qualifier 476 485--*--worsening",
            "Temporal 487 514--*--within the previous 30 days",
            "Scope 379 485--*--Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening",
            "Person 517 537--*--Professional drivers",
            "Person 539 554--*--risk profession",
            "Condition 558 577--*--respiratory failure",
            "Qualifier 580 586--*--Severe",
            "Condition 587 605--*--daytime sleepiness",
            "Measurement 607 631--*--Epworth sleepiness scale",
            "Value 632 635--*-->18",
            "Scope 580 605--*--Severe daytime sleepiness",
            "Scope 607 635--*--Epworth sleepiness scale >18",
            "Temporal 638 649--*--Concomitant",
            "Procedure 650 659--*--treatment",
            "Multiplier 665 675--*--high doses",
            "Drug 679 699--*--acetylsalicylic acid",
            "Multiplier 701 713--*--> 500 mg/day",
            "Temporal 718 728--*--continuous",
            "Procedure 729 738--*--treatment",
            "Drug 744 781--*--non-steroidal anti-inflammatory drugs",
            "Temporal 783 791--*--Previous",
            "Procedure 792 801--*--treatment",
            "Device 807 811--*--CPAP",
            "Non-query-able 813 895--*--Participation in another clinical trial within the 30 days prior to randomization."
        ],
        "Text": "Non diabetic nephropathy (confirmed by biopsy).. Dialysis for acute renal failure within the 6 previous months.. Evidence in the clinic history of relevant bilateral stenosis of renal artery (> 75%). Urinary albumin/creatinine ratio higher than 3000 mg/g, at the baseline visit.. Systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mm Hg at the baseline visit.. Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.. Professional drivers, risk profession or respiratory failure.. Severe daytime sleepiness (Epworth sleepiness scale >18). Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs. Previous treatment with CPAP. Participation in another clinical trial within the 30 days prior to randomization.. "
    },
    "NCT02671318_inc": {
        "Annotations": [
            "Procedure 6 23--*--kidney transplant",
            "Person 0 5--*--Adult",
            "Person 40 44--*--y.o.",
            "Value 35 39--*--> 18",
            "Condition 103 128--*--cytomegalovirus infection",
            "Drug 148 173--*--immunosuppressive regimen",
            "Drug 175 187--*--azathioprine",
            "Drug 191 204--*--mycophenolate",
            "Drug 206 216--*--tacrolimus",
            "Drug 221 231--*--prednisone",
            "Scope 175 231--*--azathioprine or mycophenolate, tacrolimus and prednisone"
        ],
        "Text": "Adult kidney transplant recipients > 18 y.o.. Kidney Transplant recipients, after the first episode of cytomegalovirus infection, using the current immunosuppressive regimen: azathioprine or mycophenolate, tacrolimus and prednisone.. "
    },
    "NCT03256864_inc": {
        "Text": "Liver Transplant Recipients have received liver transplantations for at least 6+1 months prior to enrollment. Liver Transplant Recipients have no acute rejection episodes within 3 months prior to the enrollment and are clinically stable. Liver Transplant Recipients have been treated with twice-daily regimen of tacrolimus(TAC) plus everolimus(EVR) and TAC and EVR trough levels have stayed within targeted ranges for at least 6 weeks prior to enrollment. Provide written informed consent prior to inclusion.. Liver transplant recipients who are 18-65 years of age of a primary liver transplant. Allograft functioning at an acceptable level as defined by the AST, ALT, Total Bilirubin levels =3 times ULN prior to enrollment.. Abbreviated MDRD eGFR = 30 mL/min/1.73m2. ",
        "Annotations": [
            "Person 0 27--*--Liver Transplant Recipients",
            "Procedure 42 64--*--liver transplantations",
            "Temporal 65 108--*--for at least 6+1 months prior to enrollment",
            "Reference_point 98 108--*--enrollment",
            "Person 110 137--*--Liver Transplant Recipients",
            "Negation 143 145--*--no",
            "Qualifier 146 151--*--acute",
            "Condition 152 170--*--rejection episodes",
            "Temporal 171 210--*--within 3 months prior to the enrollment",
            "Reference_point 196 210--*--the enrollment",
            "Condition 219 236--*--clinically stable",
            "Person 238 265--*--Liver Transplant Recipients",
            "Multiplier 289 300--*--twice-daily",
            "Drug 312 327--*--tacrolimus(TAC)",
            "Drug 333 348--*--everolimus(EVR)",
            "Measurement 353 356;365 378--*--TAC trough levels",
            "Measurement 361 378--*--EVR trough levels",
            "Scope 312 348--*--tacrolimus(TAC) plus everolimus(EVR)",
            "Value 391 413--*--within targeted ranges",
            "Temporal 414 454--*--for at least 6 weeks prior to enrollment",
            "Reference_point 444 454--*--enrollment",
            "Scope 353 378--*--TAC and EVR trough levels",
            "Observation 464 488--*--written informed consent",
            "Temporal 489 507--*--prior to inclusion",
            "Reference_point 498 507--*--inclusion",
            "Person 510 537--*--Liver transplant recipients",
            "Person 561 564--*--age",
            "Value 546 557--*--18-65 years",
            "Procedure 570 594--*--primary liver transplant",
            "Measurement 596 617--*--Allograft functioning",
            "Value 624 640--*--acceptable level",
            "Measurement 659 662--*--AST",
            "Measurement 664 667--*--ALT",
            "Measurement 669 684--*--Total Bilirubin",
            "Value 692 704--*--=3 times ULN",
            "Temporal 705 724--*--prior to enrollment",
            "Scope 659 684--*--AST, ALT, Total Bilirubin",
            "Scope 596 640--*--Allograft functioning at an acceptable level",
            "Scope 659 704--*--AST, ALT, Total Bilirubin levels =3 times ULN",
            "Measurement 739 748--*--MDRD eGFR",
            "Value 749 767--*--= 30 mL/min/1.73m2"
        ]
    },
    "NCT02105090_inc": {
        "Text": "elective procedure. weight over 40 kg. American Society of Anesthesiology class I-III. first upper GI endoscopy procedure. finnish or/and swedish speaking. ",
        "Annotations": [
            "Procedure 0 18--*--elective procedure",
            "Measurement 20 26--*--weight",
            "Value 27 37--*--over 40 kg",
            "Measurement 39 79--*--American Society of Anesthesiology class",
            "Value 80 85--*--I-III",
            "Multiplier 87 92--*--first",
            "Qualifier 93 101--*--upper GI",
            "Procedure 102 121--*--endoscopy procedure",
            "Observation 123 130;146 154--*--finnish speaking",
            "Observation 138 154--*--swedish speaking"
        ]
    },
    "NCT02816762_inc": {
        "Annotations": [
            "Value 14 32--*--18 to 80 years old",
            "Person 9 13--*--aged",
            "Condition 48 55--*--obesity",
            "Measurement 57 60--*--BMI",
            "Value 61 70--*--=25 kg/m2",
            "Condition 34 44--*--Overweight",
            "Scope 34 55--*--Overweight or obesity",
            "Condition 95 110--*--type 2 diabetes",
            "Multiplier 123 135--*--at least one",
            "Temporal 73 81--*--Previous",
            "Temporal 166 173--*--current",
            "Drug 189 212--*--oral antidiabetic drugs",
            "Drug 220 227--*--insulin",
            "Scope 189 227--*--oral antidiabetic drugs and/or insulin",
            "Measurement 234 249--*--fasting glucose",
            "Value 256 271--*--above 126 mg/dl",
            "Multiplier 272 295--*--on at least 2 occasions",
            "Measurement 300 319--*--blood glucose level",
            "Value 371 402--*--equal to or more than 200 mg/dl",
            "Temporal 320 367--*--at 2 hours after an oral glucose tolerance test",
            "Reference_point 337 367--*--an oral glucose tolerance test",
            "Procedure 340 367--*--oral glucose tolerance test",
            "Measurement 412 445--*--glycated hemoglobin (HbA1c) level",
            "Value 446 453--*--> 6.5 %",
            "Scope 166 453--*--current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %",
            "Condition 477 497--*--diabetic nephropathy",
            "Measurement 506 538--*--urinary albumin/creatinine ratio",
            "Value 539 547--*-->30 mg/g",
            "Measurement 555 591--*--estimated glomerular filtration rate",
            "Value 592 623--*--more than 20 ml/min per 1.73 m2",
            "Drug 657 697--*--angiotensin-converting enzyme inhibitors",
            "Multiplier 641 653--*--stable doses",
            "Drug 699 731--*--angiotensin II receptor blockers",
            "Drug 735 758--*--anti-aldosterone agents",
            "Temporal 759 781--*--in the last four weeks",
            "Scope 657 758--*--angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents"
        ],
        "Text": "Subjects aged 18 to 80 years old. Overweight or obesity (BMI =25 kg/m2). Previous diagnosis of type 2 diabetes, fulfilling at least one of the following criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %. Clinical diagnosis of diabetic nephropathy, with a urinary albumin/creatinine ratio >30 mg/g and an estimated glomerular filtration rate more than 20 ml/min per 1.73 m2.. Treatment with stable doses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents in the last four weeks.. "
    },
    "NCT02671318_exc": {
        "Annotations": [
            "Procedure 0 13--*--Re-transplant",
            "Measurement 34 57--*--panel reactive antibody",
            "Measurement 59 62--*--PRA",
            "Value 64 85--*--equal to or above 50%",
            "Value 87 94--*--class I",
            "Value 98 106--*--class II",
            "Scope 64 106--*--equal to or above 50%, class I or class II",
            "Condition 109 132--*--Acute rejection episode",
            "Temporal 140 152--*--last 30 days",
            "Measurement 177 191--*--Banff criteria",
            "Value 165 169--*--> 2A",
            "Measurement 194 197--*--GFR",
            "Value 205 216--*--< 40 ml/min",
            "Condition 219 230--*--Proteinuria",
            "Multiplier 231 240--*--> 0,5 g/l",
            "Measurement 243 253--*--Hemoglobin",
            "Value 254 262--*--< 10 g/l",
            "Measurement 270 280--*--leucocytes",
            "Value 281 296--*--< 4000 cels/mm3",
            "Measurement 304 313--*--platelets",
            "Value 314 332--*--< 150.000 cels/mm3",
            "Measurement 335 348--*--Triglycerides",
            "Value 349 360--*--> 500 mg/dl",
            "Drug 384 391--*--fibrate",
            "Measurement 394 411--*--Cholesterol total",
            "Value 412 423--*--> 300 mg/dl",
            "Drug 447 453--*--statin",
            "Condition 456 477--*--Hepatic abnormalities",
            "Condition 492 507--*--periphery edema",
            "Qualifier 480 491--*--Significant",
            "Condition 510 533--*--Pulmonary abnormalities",
            "Procedure 537 549--*--breast x-ray",
            "Value 550 563--*--abnormalities",
            "Condition 566 583--*--Hyper sensibility",
            "Drug 587 596--*--sirolimus"
        ],
        "Text": "Re-transplant;. Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II;. Acute rejection episode in the last 30 days, or episode > 2A in the Banff criteria;. GFR (MDRD) < 40 ml/min;. Proteinuria > 0,5 g/l;. Hemoglobin < 10 g/l and/or leucocytes < 4000 cels/mm3 and/or platelets < 150.000 cels/mm3;. Triglycerides > 500 mg/dl with or without use of fibrate;. Cholesterol total > 300 mg/dl with or without use of statin;. Hepatic abnormalities;. Significant periphery edema;. Pulmonary abnormalities or breast x-ray abnormalities;. Hyper sensibility to sirolimus formula;. "
    },
    "annotation": {},
    "NCT00943865_inc": {
        "Text": "men and women 30-55 years with BMI 30-40 and waist 95 cm or more . normal OGTT . normal treadmill stress test . plus 2 of 4: . 1. low serum levels of HDL cholesterol (<40 mg\u2044dL for men or < 50 mg \u2044dL for women); . 2. hypertriglyceridemia (triglyceride levels of 150 mg\u2044dL or greater); . 3. impaired glucose homeostasis (fasting plasma glucose concentration of 110 mg\u2044dL or greater or glucose of 140 mg\u2044dL or greater after OGTT or . 4. hypertension (systolic blood pressure \u2265 140 or diastolic blood pressure \u226590 mmHg or treatment with antihypertensive drugs). . ",
        "Annotations": [
            "Person 0 3--*--men",
            "Person 8 13--*--women",
            "Value 14 25--*--30-55 years",
            "Measurement 31 34--*--BMI",
            "Value 35 40--*--30-40",
            "Measurement 45 50--*--waist",
            "Value 51 64--*--95 cm or more",
            "Person 14 25--*--30-55 years",
            "Measurement 73 77--*--OGTT",
            "Value 66 72--*--normal",
            "Measurement 86 107--*--treadmill stress test",
            "Value 79 85--*--normal",
            "Multiplier 114 120--*--2 of 4",
            "Non-representable 109 121--*--plus 2 of 4:",
            "Parsing_Error 109 121--*--plus 2 of 4:",
            "Measurement 130 161--*--serum levels of HDL cholesterol",
            "Value 126 129--*--low",
            "Value 163 172--*--<40 mg\u2044dL",
            "Value 184 195--*--< 50 mg \u2044dL",
            "Person 177 180--*--men",
            "Person 200 205--*--women",
            "Scope 163 205--*--<40 mg\u2044dL for men or < 50 mg \u2044dL for women",
            "Condition 212 232--*--hypertriglyceridemia",
            "Measurement 234 253--*--triglyceride levels",
            "Value 257 277--*--150 mg\u2044dL or greater",
            "Scope 234 277--*--triglyceride levels of 150 mg\u2044dL or greater",
            "Condition 284 312--*--impaired glucose homeostasis",
            "Measurement 314 350--*--fasting plasma glucose concentration",
            "Value 354 374--*--110 mg\u2044dL or greater",
            "Measurement 378 385--*--glucose",
            "Value 389 409--*--140 mg\u2044dL or greater",
            "Procedure 416 420--*--OGTT",
            "Temporal 410 420--*--after OGTT",
            "Reference_point 416 420--*--OGTT",
            "Scope 314 420--*--fasting plasma glucose concentration of 110 mg\u2044dL or greater or glucose of 140 mg\u2044dL or greater after OGTT",
            "Qualifier 410 420--*--after OGTT",
            "Condition 428 440--*--hypertension",
            "Measurement 442 465--*--systolic blood pressure",
            "Value 466 471--*--\u2265 140",
            "Measurement 475 499--*--diastolic blood pressure",
            "Value 500 508--*--\u226590 mmHg",
            "Procedure 512 521--*--treatment",
            "Drug 527 549--*--antihypertensive drugs",
            "Scope 442 549--*--systolic blood pressure \u2265 140 or diastolic blood pressure \u226590 mmHg or treatment with antihypertensive drugs"
        ]
    },
    "NCT03530124_inc": {
        "Annotations": [
            "Measurement 10 34--*--gestational age at birth",
            "Value 0 9--*--=32 weeks",
            "Measurement 45 58--*--postnatal age",
            "Temporal 59 75--*--at randomization",
            "Value 36 44--*--=6 weeks",
            "Observation 85 97--*--hospitalized",
            "Temporal 98 109--*--after birth",
            "Reference_point 104 109--*--birth",
            "Mood 176 184--*--eligible",
            "Drug 196 212--*--2-month vaccines",
            "Non-query-able 214 298--*--English- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))",
            "Mood 304 311--*--planned",
            "Procedure 316 325--*--discharge",
            "Temporal 326 356--*--within 60 hours of study entry",
            "Reference_point 345 356--*--study entry",
            "Measurement 300 303--*--Not",
            "Informed_consent 358 505--*--The parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process"
        ],
        "Text": "=32 weeks gestational age at birth. =6 weeks postnatal age at randomization. Remains hospitalized after birth (has never been discharged home). Treating clinician deems infant eligible to receive 2-month vaccines. English- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s)). Not planned for discharge within 60 hours of study entry. The parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process. "
    },
    "NCT02656394_inc": {
        "Text": "1. Male or female of any race, at least 18 years of age at Visit 1 Screening. . 2. Has provided verbal and written informed consent. . 3. Be able and willing to follow instructions, including participation in all study assessments and visits. . 4. Currently being treated for glaucoma using at least two medications, and be willing to continue on the same regime. . 5. Suffers from at least two of the symptoms in the GLIA\u2122 Glaucoma Medication Ocular Side Effect Symptoms Questionnaire at a severity of 2 (moderate) or more. . 6. If a woman of childbearing potential, have a negative urine pregnancy test at Visit 1 and be using an adequate method of birth control throughout the study period. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 79 81--*--2.",
            "Parsing_Error 133 135--*--3.",
            "Parsing_Error 242 244--*--4.",
            "Parsing_Error 362 364--*--5.",
            "Parsing_Error 522 524--*--6.",
            "Person 3 7--*--Male",
            "Person 11 17--*--female",
            "Value 31 48--*--at least 18 years",
            "Person 52 55--*--age",
            "Temporal 56 76--*--at Visit 1 Screening",
            "Reference_point 59 76--*--Visit 1 Screening",
            "Post-eligibility 82 131--*--Has provided verbal and written informed consent.",
            "Non-query-able 82 131--*--Has provided verbal and written informed consent.",
            "Post-eligibility 136 240--*--Be able and willing to follow instructions, including participation in all study assessments and visits.",
            "Non-query-able 136 240--*--Be able and willing to follow instructions, including participation in all study assessments and visits.",
            "Condition 273 281--*--glaucoma",
            "Procedure 261 268--*--treated",
            "Temporal 245 254--*--Currently",
            "Multiplier 288 300--*--at least two",
            "Drug 301 312--*--medications",
            "Undefined_semantics 301 312--*--medications",
            "Non-query-able 321 340--*--willing to continue",
            "Multiplier 378 390--*--at least two",
            "Condition 398 406--*--symptoms",
            "Measurement 414 481--*--GLIA\u2122 Glaucoma Medication Ocular Side Effect Symptoms Questionnaire",
            "Value 487 500;512 519--*--severity of 2 or more",
            "Value 502 510--*--moderate",
            "Person 530 535--*--woman",
            "Condition 539 561--*--childbearing potential",
            "Measurement 579 599--*--urine pregnancy test",
            "Value 570 578--*--negative",
            "Temporal 600 610--*--at Visit 1",
            "Reference_point 603 610--*--Visit 1",
            "Device 636 659--*--method of birth control",
            "Qualifier 627 635--*--adequate",
            "Subjective_judgement 627 635--*--adequate",
            "Temporal 660 687--*--throughout the study period",
            "Reference_point 675 687--*--study period"
        ]
    },
    "NCT00812344_exc": {
        "Text": "Significant illness, trauma or surgical procedures. . Clinically significant laboratory abnormalities. . Clinically significant medical history       .     . ",
        "Annotations": [
            "Condition 12 19--*--illness",
            "Condition 21 27--*--trauma",
            "Procedure 31 50--*--surgical procedures",
            "Qualifier 0 11--*--Significant",
            "Subjective_judgement 0 11--*--Significant",
            "Scope 12 50--*--illness, trauma or surgical procedures",
            "Condition 76 100--*--laboratory abnormalities",
            "Procedure 76 86--*--laboratory",
            "Qualifier 53 75--*--Clinically significant",
            "Subjective_judgement 53 75--*--Clinically significant",
            "Observation 126 141--*--medical history",
            "Qualifier 103 125--*--Clinically significant"
        ]
    },
    "NCT03530124_exc": {
        "Annotations": [
            "Drug 11 15--*--DTaP",
            "Drug 17 20--*--IPV",
            "Drug 22 27--*--PCV13",
            "Drug 32 35--*--Hib",
            "Temporal 36 55--*--prior to enrollment",
            "Reference_point 45 55--*--enrollment",
            "Scope 11 35--*--DTaP, IPV, PCV13, or Hib",
            "Drug 166 170--*--DTaP",
            "Drug 172 175--*--IPV",
            "Drug 177 180--*--HBV",
            "Drug 182 187--*--PCV13",
            "Drug 192 195--*--Hib",
            "Mood 120 139--*--Anticipated receipt",
            "Temporal 196 241--*--during the first 60 hours after randomization",
            "Reference_point 228 241--*--randomization",
            "Scope 166 195--*--DTaP, IPV, HBV, PCV13, or Hib",
            "Qualifier 256 262--*--severe",
            "Condition 263 280--*--allergic reaction",
            "Condition 287 298--*--anaphylaxis",
            "Drug 326 345--*--hepatitis B vaccine",
            "Temporal 305 313--*--previous",
            "Scope 256 280--*--severe allergic reaction",
            "Qualifier 360 366--*--severe",
            "Condition 367 384--*--allergic reaction",
            "Condition 391 402--*--anaphylaxis",
            "Drug 411 454--*--component of the vaccines used in the study",
            "Drug 465 473--*--neomycin",
            "Drug 485 496--*--polymyxin B",
            "Drug 475 480--*--yeast",
            "Scope 465 496--*--neomycin, yeast and polymyxin B",
            "Scope 360 384--*--severe allergic reaction",
            "Condition 515 522--*--allergy",
            "Drug 509 514--*--latex",
            "Observation 498 505--*--History",
            "Condition 544 575--*--progressive neurologic disorder",
            "Qualifier 579 592--*--unknown cause",
            "Qualifier 535 543--*--unstable",
            "Observation 524 531--*--History",
            "Condition 594 614--*--Known cause of apnea",
            "Condition 626 646--*--apnea of prematurity",
            "Negation 615 625--*--other than",
            "Condition 648 670--*--Cyanotic heart disease",
            "Qualifier 672 682--*--congenital",
            "Qualifier 686 694--*--acquired",
            "Scope 672 694--*--congenital or acquired",
            "Non-query-able 697 805--*--Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff.",
            "Non-query-able 807 1003--*--Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol"
        ],
        "Text": "Receipt of DTaP, IPV, PCV13, or Hib prior to enrollment. Previous administration of the first dose of HBV is permitted. Anticipated receipt of any vaccine other than DTaP, IPV, HBV, PCV13, or Hib during the first 60 hours after randomization. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any hepatitis B vaccine. History of a severe allergic reaction (e.g. anaphylaxis) to any component of the vaccines used in the study including neomycin, yeast and polymyxin B. History of latex allergy. History of unstable progressive neurologic disorder of unknown cause. Known cause of apnea other than apnea of prematurity. Cyanotic heart disease (congenital or acquired). Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff.. Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol. "
    },
    "NCT00943865_exc": {
        "Text": "diabetes . ischemic heart disease or any abnormality on treadmill stress test . inflammatory or chronic disorder . pregnancy . lactation . creatinine level of 1,5 mg/dL or more . gastrointestinal problems or musculoskeletal disorders that would prevent them to follow the test diets or exercise interventions . liver dysfunction with a factor of at least 3 above the upper limit of normal in AST and ALT levels . thyroid dysfunction, with serum TSH out of normal limits . use of immunosuppressive drugs, corticosteroids or anorexigen       .     . ",
        "Annotations": [
            "Condition 0 8--*--diabetes",
            "Condition 10 32--*--ischemic heart disease",
            "Measurement 55 76--*--treadmill stress test",
            "Value 40 51--*--abnormality",
            "Condition 102 110;78 90--*--disorder inflammatory",
            "Condition 94 110--*--chronic disorder",
            "Condition 112 121--*--pregnancy",
            "Condition 123 132--*--lactation",
            "Measurement 134 150--*--creatinine level",
            "Value 154 171--*--1,5 mg/dL or more",
            "Condition 173 198--*--gastrointestinal problems",
            "Condition 202 227--*--musculoskeletal disorders",
            "Mood 239 246--*--prevent",
            "Negation 239 246--*--prevent",
            "Procedure 266 276--*--test diets",
            "Procedure 280 302--*--exercise interventions",
            "Scope 266 302--*--test diets or exercise interventions",
            "Scope 173 227--*--gastrointestinal problems or musculoskeletal disorders",
            "Condition 304 321--*--liver dysfunction",
            "Value 329 381--*--factor of at least 3 above the upper limit of normal",
            "Measurement 385 388;397 403--*--AST levels",
            "Measurement 393 403--*--ALT levels",
            "Scope 385 403--*--AST and ALT levels",
            "Condition 405 424--*--thyroid dysfunction",
            "Measurement 431 440--*--serum TSH",
            "Value 441 461--*--out of normal limits",
            "Drug 470 493--*--immunosuppressive drugs",
            "Drug 495 510--*--corticosteroids",
            "Drug 514 524--*--anorexigen"
        ]
    },
    "NCT00812344_inc": {
        "Text": "body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive . ",
        "Annotations": [
            "Measurement 0 21--*--body mass index (BMI)",
            "Value 22 44--*--between 19 to 30 kg/m2",
            "Measurement 49 60--*--body weight",
            "Value 69 91--*--50 to 100 kg inclusive"
        ]
    },
    "NCT02656394_exc": {
        "Text": "1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such as corneal opacities and scars, dystrophies, epithelial scarring, infections, blood clots, etc. . 2. Best corrected visual acuity (BCVA) at baseline <20/200. . 3. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study. . 4. A woman who is pregnant, nursing an infant, or planning a pregnancy. . 5. Has a known adverse reaction and/or sensitivity to the study drug or its components. . 6. Routine use (more than twice a week) of a chlorinated swimming pool. . 7. Unwilling or unable to cease using the following medications during the study period: Topical ocular cyclosporine (e.g. Restasis\u00ae), anti-histamines, antipsychotics, or eye gels. . 8. Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 241 243--*--2.",
            "Parsing_Error 302 304--*--3.",
            "Parsing_Error 450 452--*--4.",
            "Parsing_Error 523 525--*--5.",
            "Parsing_Error 612 614--*--6.",
            "Parsing_Error 685 687--*--7.",
            "Parsing_Error 867 869--*--8.",
            "Subjective_judgement 64 99--*--in the judgment of the investigator",
            "Non-query-able 100 137--*--will interfere with study assessments",
            "Context_Error 100 137--*--will interfere with study assessments",
            "Condition 147 164--*--corneal opacities",
            "Condition 147 154;169 174--*--corneal scars",
            "Condition 176 187--*--dystrophies",
            "Condition 189 208--*--epithelial scarring",
            "Condition 210 220--*--infections",
            "Condition 222 233--*--blood clots",
            "Condition 44 58--*--eye conditions",
            "Qualifier 100 137--*--will interfere with study assessments",
            "Scope 147 233--*--corneal opacities and scars, dystrophies, epithelial scarring, infections, blood clots",
            "Measurement 244 279--*--Best corrected visual acuity (BCVA)",
            "Value 292 299--*--<20/200",
            "Temporal 280 291--*--at baseline",
            "Reference_point 283 291--*--baseline",
            "Subjective_judgement 338 372--*--in the opinion of the investigator",
            "Subjective_judgement 374 401--*--may interfere significantly",
            "Non-query-able 374 401--*--may interfere significantly",
            "Person 455 460--*--woman",
            "Condition 468 476--*--pregnant",
            "Condition 478 485--*--nursing",
            "Non-query-able 500 508--*--planning",
            "Condition 511 520--*--pregnancy",
            "Condition 538 554;574 609--*--adverse reaction to the study drug or its components",
            "Condition 562 609--*--sensitivity to the study drug or its components",
            "Multiplier 628 650--*--more than twice a week",
            "Multiplier 615 626--*--Routine use",
            "Observation 657 682--*--chlorinated swimming pool",
            "Non-query-able 657 682--*--chlorinated swimming pool",
            "Post-eligibility 688 707--*--Unwilling or unable",
            "Non-query-able 688 707--*--Unwilling or unable",
            "Drug 774 801--*--Topical ocular cyclosporine",
            "Drug 808 817--*--Restasis\u00ae",
            "Drug 820 835--*--anti-histamines",
            "Drug 837 851--*--antipsychotics",
            "Drug 856 864--*--eye gels",
            "Temporal 749 772--*--during the study period",
            "Reference_point 760 772--*--study period",
            "Scope 774 864--*--Topical ocular cyclosporine (e.g. Restasis\u00ae), anti-histamines, antipsychotics, or eye gels",
            "Drug 895 915--*--investigational drug",
            "Context_Error 895 915--*--investigational drug",
            "Device 895 910;919 925--*--investigational device",
            "Context_Error 895 910;919 925--*--investigational device",
            "Drug 948 968--*--investigational drug",
            "Context_Error 948 968--*--investigational drug",
            "Temporal 979 1010--*--within 30 days prior to Visit 1",
            "Reference_point 1003 1010--*--Visit 1",
            "Device 948 963;972 978--*--investigational device",
            "Scope 895 978--*--investigational drug or device study or have used an investigational drug or device"
        ]
    },
    "NCT02862912_inc": {
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 12--*--I and II",
            "Person 13 18--*--women",
            "Person 30 33--*--old",
            "Value 20 29--*--18-45 yrs",
            "Condition 35 54--*--Singleton pregnancy",
            "Procedure 56 73--*--Cervical cerclage",
            "Qualifier 74 77;85 94--*--1st trimester",
            "Qualifier 81 94--*--2nd trimester",
            "Condition 98 107--*--pregnancy",
            "Procedure 124 141--*--spinal anesthesia",
            "Scope 74 94--*--1st or 2nd trimester",
            "Measurement 143 149--*--Height",
            "Value 150 162--*--150 - 180 cm",
            "Measurement 164 167--*--BMI",
            "Value 168 178--*--= 40 kg/m2"
        ],
        "Text": "ASA I and II women. 18-45 yrs old. Singleton pregnancy. Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia. Height 150 - 180 cm. BMI = 40 kg/m2.. "
    },
    "NCT02635893_exc": {
        "Text": "Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease,. Any debilitating disease prior to the SCI that caused exercise intolerance. Premorbid, ongoing major depression or psychosis, altered cognitive status. History of head injury or stroke,. Metal plate in skull. History of seizures. Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants.. Pregnant females, and. Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk.. Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease,. Any debilitating disease that causes exercise intolerance. Premorbid, ongoing major depression or psychosis, altered cognitive status. History of head injury or stroke,. Metal plate in skull. History of seizures. Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants.. Pregnant females, and. Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk.. ",
        "Annotations": [
            "Condition 13 29--*--medical problems",
            "Qualifier 0 12--*--Uncontrolled",
            "Condition 40 49;80 87--*--pulmonary disease",
            "Condition 69 87--*--orthopedic disease",
            "Condition 51 65;80 87--*--cardiovascular disease",
            "Scope 40 87--*--pulmonary, cardiovascular or orthopedic disease",
            "Condition 94 114--*--debilitating disease",
            "Temporal 115 131--*--prior to the SCI",
            "Condition 144 164--*--exercise intolerance",
            "Condition 185 201--*--major depression",
            "Condition 205 214--*--psychosis",
            "Condition 216 240--*--altered cognitive status",
            "Temporal 177 184--*--ongoing",
            "Qualifier 166 175--*--Premorbid",
            "Scope 185 214--*--major depression or psychosis",
            "Condition 253 264--*--head injury",
            "Condition 268 274--*--stroke",
            "Observation 242 252--*--History of",
            "Device 277 297--*--Metal plate in skull",
            "Condition 310 318--*--seizures",
            "Drug 330 382--*--drugs acting primarily on the central nervous system",
            "Drug 426 445--*--antipsychotic drugs",
            "Qualifier 390 417--*--lower the seizure threshold",
            "Drug 447 461--*--chlorpromazine",
            "Drug 463 472--*--clozapine",
            "Drug 477 502--*--tricyclic antidepressants",
            "Scope 447 472--*--chlorpromazine, clozapine",
            "Scope 426 502--*--antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants",
            "Scope 330 417--*--drugs acting primarily on the central nervous system, which lower the seizure threshold",
            "Condition 505 513--*--Pregnant",
            "Person 514 521--*--females",
            "Condition 536 552--*--cord compression",
            "Condition 558 564--*--syrinx",
            "Qualifier 572 583--*--spinal cord",
            "Condition 605 624--*--spinal cord disease",
            "Condition 633 648--*--spinal stenosis",
            "Condition 650 662--*--spina bifida",
            "Condition 666 689--*--herniated cervical disk",
            "Scope 633 689--*--spinal stenosis, spina bifida or herniated cervical disk",
            "Condition 761 779--*--orthopedic disease",
            "Condition 743 757;772 779--*--cardiovascular disease",
            "Condition 732 741;772 779--*--pulmonary disease",
            "Condition 705 721--*--medical problems",
            "Qualifier 692 704--*--Uncontrolled",
            "Scope 732 779--*--pulmonary, cardiovascular or orthopedic disease",
            "Scope 692 721--*--Uncontrolled medical problems",
            "Condition 786 806--*--debilitating disease",
            "Condition 819 839--*--exercise intolerance",
            "Qualifier 841 850--*--Premorbid",
            "Temporal 852 859--*--ongoing",
            "Condition 860 876--*--major depression",
            "Condition 880 889--*--psychosis",
            "Condition 891 915--*--altered cognitive status",
            "Scope 860 889--*--major depression or psychosis",
            "Condition 928 939--*--head injury",
            "Condition 943 949--*--stroke",
            "Observation 917 924--*--History",
            "Device 952 972--*--Metal plate in skull",
            "Condition 985 993--*--seizures",
            "Observation 974 984--*--History of",
            "Drug 1005 1057--*--drugs acting primarily on the central nervous system",
            "Qualifier 1065 1092--*--lower the seizure threshold",
            "Drug 1101 1120--*--antipsychotic drugs",
            "Drug 1122 1136--*--chlorpromazine",
            "Drug 1138 1147--*--clozapine",
            "Drug 1152 1177--*--tricyclic antidepressants",
            "Scope 1122 1147--*--chlorpromazine, clozapine",
            "Scope 1101 1177--*--antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants",
            "Scope 1005 1092--*--drugs acting primarily on the central nervous system, which lower the seizure threshold",
            "Condition 1180 1188--*--Pregnant",
            "Person 1189 1196--*--females",
            "Condition 1211 1227--*--cord compression",
            "Condition 1233 1239--*--syrinx",
            "Qualifier 1247 1258--*--spinal cord",
            "Condition 1280 1299--*--spinal cord disease",
            "Condition 1308 1323--*--spinal stenosis",
            "Condition 1325 1337--*--spina bifida",
            "Condition 1341 1364--*--herniated cervical disk",
            "Scope 1308 1364--*--spinal stenosis, spina bifida or herniated cervical disk"
        ]
    },
    "NCT02413970_inc": {
        "Annotations": [
            "Condition 33 36--*--OSA",
            "Qualifier 14 22--*--moderate",
            "Qualifier 26 32--*--severe",
            "Scope 14 32--*--moderate-to-severe",
            "Condition 103 106--*--OSA",
            "Measurement 111 114--*--AHI",
            "Value 108 110;114 117--*--20 =65",
            "Negation 186 189--*--not",
            "Procedure 215 227--*--CPAP therapy",
            "Person 423 426--*--Age",
            "Value 427 438--*--22 or above",
            "Post-eligibility 440 569--*--Willing and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation",
            "Post-eligibility 571 727--*--Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires",
            "Informed_consent 729 778--*--Willing and capable of providing informed consent"
        ],
        "Text": "Likely suffer moderate-to-severe OSA based on history and physical or have an established diagnosis of OSA (20=AHI=65) based on a prior in-lab Polysomnography. Documentation the subject not effectively treated with CPAP therapy. (Examples include non-compliance, discomfort, undesirable side effects, symptoms persist despite use). Subjects who have been prescribed, but refuse to try CPAP would be considered intolerant.. Age 22 or above. Willing and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation. Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires. Willing and capable of providing informed consent. "
    },
    "NCT03129555_inc": {
        "Annotations": [
            "Condition 15 18--*--VTE",
            "Visit 22 39--*--outpatient clinic",
            "Qualifier 46 65--*--discharge diagnosis",
            "Temporal 66 87--*--after hospitalization",
            "Reference_point 72 87--*--hospitalization",
            "Procedure 72 87--*--hospitalization",
            "Scope 22 87--*--outpatient clinic or as discharge diagnosis after hospitalization",
            "Procedure 100 112--*--prescription",
            "Drug 118 122--*--NOAC",
            "Qualifier 130 145--*--Danish pharmacy",
            "Temporal 146 200--*--within 14 days of discharge or outpatient clinic visit",
            "Reference_point 164 200--*--discharge or outpatient clinic visit",
            "Procedure 164 173--*--discharge",
            "Procedure 177 200--*--outpatient clinic visit",
            "Visit 177 194--*--outpatient clinic",
            "Scope 164 200--*--discharge or outpatient clinic visit",
            "Qualifier 92 99--*--claimed"
        ],
        "Text": "A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization.. A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.. "
    },
    "NCT00379366_inc": {
        "Text": "over 18 years . successful angioplasty (residual stenosis < 30%) on a significant stenosis (maximal systolic speed 3 times > from basal maximal systolic speed, stenosis > 70% on angiography) on the venous-prosthesis anastomosis or on the venous segment 5 cm after the anastomosis of a prosthetic haemodialysis vascular access (at least 1 month old) . social security affiliation . signed informed consent . ",
        "Annotations": [
            "Value 0 13--*--over 18 years",
            "Person 0 13--*--over 18 years",
            "Procedure 190 226;26 37--*--on the venous-prosthesis anastomosis angioplasty",
            "Qualifier 15 25--*--successful",
            "Measurement 39 56--*--residual stenosis",
            "Value 57 62--*--< 30%",
            "Condition 81 89--*--stenosis",
            "Qualifier 69 80--*--significant",
            "Measurement 91 113--*--maximal systolic speed",
            "Value 114 134--*--3 times > from basal",
            "Measurement 159 167--*--stenosis",
            "Value 168 173--*--> 70%",
            "Procedure 177 188--*--angiography",
            "Scope 91 188--*--maximal systolic speed 3 times > from basal maximal systolic speed, stenosis > 70% on angiography",
            "Procedure 230 278;26 37--*--on the venous segment 5 cm after the anastomosis angioplasty",
            "Observation 349 376--*--social security affiliation",
            "Observation 378 401--*--signed informed consent"
        ]
    },
    "NCT02823808_inc": {
        "Text": "Type 2 Diabetes Mellitus patients. Patient who had been diagnosed within the previous 12 months with HbA1c levels of 8.0-12.0%, did not have a medical history related to diabetes, and did not display proliferative retinopathy. ",
        "Annotations": [
            "Condition 0 24--*--Type 2 Diabetes Mellitus",
            "Measurement 101 106--*--HbA1c",
            "Value 117 126--*--8.0-12.0%",
            "Temporal 77 95--*--previous 12 months",
            "Negation 188 191--*--not",
            "Condition 200 225--*--proliferative retinopathy",
            "Negation 132 135--*--not",
            "Observation 143 178--*--medical history related to diabetes"
        ]
    },
    "NCT00317148_exc": {
        "Text": "Body mass index (BMI) of 35 kg/m2 or more. . Significant metabolic and endocrine diseases. . Diagnosis of cancer. . Use of steroids or drugs that interfere with the metabolism of estrogen. . Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization. . Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization. . Palpable fibroids or uterine prolapse: Grade 2 or 3. . Cigarette smoking       .     . ",
        "Annotations": [
            "Measurement 0 21--*--Body mass index (BMI)",
            "Value 25 41--*--35 kg/m2 or more",
            "Condition 56 65;80 88--*--metabolic diseases",
            "Condition 70 88--*--endocrine diseases",
            "Condition 104 110--*--cancer",
            "Drug 120 128--*--steroids",
            "Drug 132 184--*--drugs that interfere with the metabolism of estrogen",
            "Drug 198 215--*--systemic estrogen",
            "Drug 198 206;217 226--*--systemic progestin",
            "Drug 231 235--*--DHEA",
            "Temporal 236 277--*--in the eight weeks prior to randomization",
            "Scope 198 235--*--systemic estrogen, progestin, or DHEA",
            "Procedure 287 308--*--alternative therapies",
            "Drug 312 328--*--natural products",
            "Condition 338 361--*--postmenopausal symptoms",
            "Temporal 362 402--*--in the four weeks prior to randomization",
            "Scope 287 328--*--alternative therapies or natural products",
            "Condition 405 422--*--Palpable fibroids",
            "Condition 426 442--*--uterine prolapse",
            "Measurement 444 449--*--Grade",
            "Value 450 456--*--2 or 3",
            "Scope 405 442--*--Palpable fibroids or uterine prolapse",
            "Condition 459 476--*--Cigarette smoking"
        ]
    },
    "NCT01084993_inc": {
        "Annotations": [
            "Multiplier 0 12--*--At least two",
            "Non-representable 0 49--*--At least two of the following additional criteria",
            "Value 51 66--*--At least 70 yrs",
            "Person 67 70--*--old",
            "Person 72 78--*--Female",
            "Condition 87 95--*--Diabetes",
            "Measurement 97 117--*--Creatinine clearance",
            "Value 118 127--*--<60mL/min",
            "Condition 167 181--*--organ bleeding",
            "Condition 140 157;173 181--*--gastro-intestinal bleeding",
            "Qualifier 161 166--*--other",
            "Observation 129 136--*--History",
            "Scope 140 181--*--gastro-intestinal or other organ bleeding",
            "Condition 192 198--*--anemia",
            "Temporal 183 191--*--Baseline",
            "Procedure 208 217--*--treatment",
            "Drug 223 256--*--glycoproteins IIb-IIIa inhibitors",
            "Temporal 200 207--*--Current"
        ],
        "Text": "At least two of the following additional criteria. At least 70 yrs old. Female gender. Diabetes. Creatinine clearance <60mL/min. History of gastro-intestinal or other organ bleeding. Baseline anemia. Current treatment with glycoproteins IIb-IIIa inhibitors. "
    },
    "NCT01696617_inc": {
        "Text": "Age : 18-65. Patients with major depressive disorder according to DSM-IV criteria that have lasted >8 weeks. MADRS total score of 18 or higher. Patients who responded inadequately (a score of >18 on the MADRS) to first-line antidepressant treatment of 4 week duration. Current use of standard antidepressant treatment in monotherapy or combination of 2 antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d). ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 6 11--*--18-65",
            "Condition 27 52--*--major depressive disorder",
            "Measurement 66 81--*--DSM-IV criteria",
            "Temporal 92 107--*--lasted >8 weeks",
            "Measurement 109 114--*--MADRS",
            "Value 121 142--*--score of 18 or higher",
            "Measurement 203 208--*--MADRS",
            "Value 183 195--*--score of >18",
            "Qualifier 213 223--*--first-line",
            "Drug 224 238--*--antidepressant",
            "Temporal 249 258--*--of 4 week",
            "Observation 157 179--*--responded inadequately",
            "Qualifier 284 292--*--standard",
            "Drug 293 307--*--antidepressant",
            "Qualifier 321 332--*--monotherapy",
            "Multiplier 351 352--*--2",
            "Drug 353 368--*--antidepressants",
            "Drug 371 383--*--escitalopram",
            "Drug 399 409--*--fluoxetine",
            "Drug 424 437--*--paroxetine CR",
            "Drug 452 462--*--sertraline",
            "Drug 479 490--*--mirtazapine",
            "Drug 506 516--*--duloxetine",
            "Multiplier 385 396--*--10 - 20mg/d",
            "Multiplier 410 421--*--20 - 40mg/d",
            "Multiplier 438 449--*--25 - 50mg/d",
            "Multiplier 463 476--*--100 - 150mg/d",
            "Multiplier 492 503--*--15 - 45mg/d",
            "Multiplier 518 529--*--30 - 60mg/d",
            "Drug 534 548--*--venlafaxine ER",
            "Multiplier 549 560--*--150-225mg/d",
            "Scope 371 561--*--escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)",
            "Scope 284 368--*--standard antidepressant treatment in monotherapy or combination of 2 antidepressants"
        ]
    },
    "NCT02519777_exc": {
        "Annotations": [
            "Condition 0 25--*--Major depressive disorder",
            "Scope 31 49--*--psychotic features",
            "Condition 51 79--*--Traumatic Brain Injury (TBI)",
            "Condition 93 129--*--impact on activities of daily living",
            "Condition 131 150--*--Developmental delay",
            "Condition 152 172--*--intellectual deficit",
            "Condition 182 210--*--evere educational disability",
            "Condition 229 270--*--dependence for activities of daily living",
            "Scope 131 210--*--Developmental delay, intellectual deficit, and/or severe educational disability",
            "Condition 280 302--*--substance use disorder",
            "Temporal 272 279--*--Ongoing",
            "Condition 320 356--*--impact on activities of daily living",
            "Non-query-able 358 474--*--Difficult or impossible to determine whether cognitive or functional decline is due to substance use or HIV, or both",
            "Condition 488 500--*--intoxication",
            "Condition 504 514--*--withdrawal",
            "Condition 548 587--*--Central nervous system (CNS) infections",
            "Condition 548 576;591 615--*--Central nervous system (CNS) opportunistic conditions",
            "Condition 617 630--*--brain abscess",
            "Condition 681 691--*--meningitis",
            "Condition 708 729--*--neurologic impairment",
            "Multiplier 697 707--*--persistent",
            "Qualifier 632 641--*--bacterial",
            "Qualifier 643 656--*--mycobacterial",
            "Qualifier 658 664--*--fungal",
            "Qualifier 668 678--*--Toxoplasma",
            "Scope 632 678--*--bacterial, mycobacterial, fungal or Toxoplasma",
            "Condition 739 751--*--CNS lymphoma",
            "Condition 753 801--*--progressive multifocal leukoencephalopathy (PML)",
            "Qualifier 806 813--*--another",
            "Condition 814 837--*--structural brain lesion",
            "Condition 843 864--*--neurological sequelae",
            "Scope 617 864--*--brain abscess (bacterial, mycobacterial, fungal or Toxoplasma), meningitis with persistent neurologic impairment, primary CNS lymphoma, progressive multifocal leukoencephalopathy (PML), or another structural brain lesion with neurological sequelae",
            "Scope 548 615--*--Central nervous system (CNS) infections or opportunistic conditions",
            "Qualifier 866 871--*--Other",
            "Condition 872 886--*--CNS conditions",
            "Qualifier 888 905--*--non-opportunistic",
            "Qualifier 906 913--*--primary",
            "Qualifier 731 738--*--primary",
            "Qualifier 917 927--*--metastatic",
            "Condition 928 940--*--brain tumors",
            "Scope 906 927--*--primary or metastatic",
            "Qualifier 942 954--*--uncontrolled",
            "Condition 955 971--*--seizure disorder",
            "Condition 973 1003--*--progressive multiple sclerosis",
            "Condition 1005 1011--*--stroke",
            "Condition 1017 1038--*--neurological sequelae",
            "Condition 1043 1051--*--dementia",
            "Negation 1066 1076--*--other than",
            "Condition 1077 1080--*--HIV",
            "Condition 1086 1105--*--Alzheimer's disease",
            "Scope 1066 1080--*--other than HIV",
            "Scope 888 1106--*--non-opportunistic primary or metastatic brain tumors, uncontrolled seizure disorder, progressive multiple sclerosis, stroke with neurological sequelae, or dementia due to causes other than HIV (eg, Alzheimer's disease)",
            "Scope 866 886--*--Other CNS conditions",
            "Condition 1108 1130--*--Constitutional illness",
            "Condition 1147 1164--*--unexplained fever",
            "Multiplier 1136 1146--*--persistent",
            "Condition 1166 1174--*--diarrhea",
            "Qualifier 1176 1187--*--significant",
            "Condition 1188 1199--*--weight loss",
            "Condition 1201 1219--*--disabling weakness",
            "Scope 1136 1219--*--persistent unexplained fever, diarrhea, significant weight loss, disabling weakness",
            "Temporal 1221 1248--*--within 30 days of screening",
            "Qualifier 1256 1265--*--untreated",
            "Condition 1266 1280--*--B12 deficiency",
            "Condition 1284 1296--*--malnutrition",
            "Measurement 1298 1319--*--body mass index [BMI]",
            "Value 1320 1332--*--less than 18",
            "Temporal 1334 1346--*--at screening",
            "Scope 1266 1333--*--B12 deficiency or malnutrition (body mass index [BMI] less than 18)",
            "Temporal 1360 1367--*--current",
            "Condition 1368 1401--*--hepatitis C virus infection (HCV)",
            "Measurement 1407 1424--*--HCV antibody [Ab]",
            "Value 1425 1433--*--positive",
            "Mood 1348 1356--*--Evidence",
            "Temporal 1434 1469--*--within 90 days prior to study entry",
            "Measurement 1494 1508--*--plasma HCV RNA",
            "Value 1509 1517--*--negative",
            "Temporal 1518 1545--*--within the same time period",
            "Scope 1407 1545--*--HCV antibody [Ab] positive within 90 days prior to study entry unless also shown to be plasma HCV RNA negative within the same time period",
            "Qualifier 1548 1556--*--Unstable",
            "Qualifier 1561 1569--*--advanced",
            "Condition 1570 1583--*--liver disease",
            "Multiplier 1615 1627--*--at least one",
            "Condition 1646 1653--*--ascites",
            "Condition 1655 1669--*--encephalopathy",
            "Condition 1671 1683--*--coagulopathy",
            "Condition 1685 1700--*--hypoalbuminemia",
            "Condition 1702 1712;1724 1731--*--esophageal varices",
            "Condition 1716 1731--*--gastric varices",
            "Qualifier 1736 1746--*--persistent",
            "Condition 1747 1755--*--jaundice",
            "Scope 1646 1755--*--ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice",
            "Scope 1615 1755--*--at least one of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice",
            "Temporal 1758 1763--*--Prior",
            "Temporal 1767 1774--*--current",
            "Drug 1786 1801--*--CCR5 antagonist",
            "Drug 1811 1814--*--MVC",
            "Drug 1819 1837--*--cenicriviroc [CVC]",
            "Scope 1811 1837--*--MVC and cenicriviroc [CVC]",
            "Drug 1843 1862--*--integrase inhibitor",
            "Drug 1872 1875--*--RAL",
            "Drug 1877 1880--*--DTG",
            "Drug 1886 1904--*--elvitegravir [EVG]",
            "Scope 1872 1904--*--RAL, DTG, and elvitegravir [EVG]",
            "Scope 1786 1905--*--CCR5 antagonist (such as MVC and cenicriviroc [CVC]) and integrase inhibitor (such as RAL, DTG, and elvitegravir [EVG])",
            "Scope 1758 1774--*--Prior or current",
            "Observation 2076 2089--*--Breastfeeding",
            "Condition 2106 2143--*--AIDS-defining opportunistic infection",
            "Temporal 2144 2174--*--within 6 months prior to entry",
            "Temporal 2286 2292--*--Active",
            "Condition 2293 2301--*--syphilis",
            "Procedure 2305 2314--*--treatment",
            "Condition 2319 2327--*--syphilis",
            "Temporal 2328 2363--*--within 90 days prior to study entry",
            "Reference_point 2352 2363--*--study entry",
            "Temporal 2371 2377--*--Active",
            "Condition 2378 2386--*--syphilis",
            "Value 2401 2419--*--four-fold increase",
            "Measurement 2423 2454--*--serum rapid plasma reagin (RPR)",
            "Measurement 2458 2501--*--venereal disease research laboratory (VDRL)",
            "Condition 2535 2543--*--syphilis",
            "Temporal 2530 2534--*--past",
            "Value 2554 2562--*--reactive",
            "Temporal 2548 2553--*--newly",
            "Measurement 2563 2572--*--serum RPR",
            "Measurement 2576 2580--*--VDRL",
            "Procedure 2588 2614--*--reactive confirmatory test",
            "Procedure 2616 2641--*--enzyme immunoassays [EIA]",
            "Procedure 2645 2673--*--chemiluminescent assay [CIA]",
            "Procedure 2675 2717--*--T. pallidum particle agglutination [TP-PA]",
            "Procedure 2722 2772--*--fluorescent treponemal antibody absorbed [FTA-ABS]",
            "Scope 2616 2772--*--enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS]",
            "Scope 2563 2580--*--serum RPR or VDRL",
            "Scope 2423 2501--*--serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL)",
            "Scope 2401 2543--*--four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis",
            "Scope 2548 2773--*--newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])",
            "Scope 2401 2773--*--four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis, or newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])",
            "Condition 2782 2789--*--allergy",
            "Condition 2790 2801--*--sensitivity",
            "Condition 2809 2825--*--hypersensitivity",
            "Drug 2829 2854--*--components of study drugs",
            "Scope 2782 2825--*--allergy/sensitivity or any hypersensitivity",
            "Drug 1926 1936--*--medication",
            "Drug 1948 1963--*--antiretrovirals",
            "Qualifier 1965 1988--*--prohibited in the study",
            "Temporal 1907 1914--*--Current"
        ],
        "Text": "Major depressive disorder with psychotic features. Traumatic Brain Injury (TBI) with a clear impact on activities of daily living. Developmental delay, intellectual deficit, and/or severe educational disability resulting in some dependence for activities of daily living. Ongoing substance use disorder with significant impact on activities of daily living. Difficult or impossible to determine whether cognitive or functional decline is due to substance use or HIV, or both. Evidence of intoxication or withdrawal during the screening evaluation. Central nervous system (CNS) infections or opportunistic conditions: brain abscess (bacterial, mycobacterial, fungal or Toxoplasma), meningitis with persistent neurologic impairment, primary CNS lymphoma, progressive multifocal leukoencephalopathy (PML), or another structural brain lesion with neurological sequelae. Other CNS conditions: non-opportunistic primary or metastatic brain tumors, uncontrolled seizure disorder, progressive multiple sclerosis, stroke with neurological sequelae, or dementia due to causes other than HIV (eg, Alzheimer's disease). Constitutional illness (eg, persistent unexplained fever, diarrhea, significant weight loss, disabling weakness) within 30 days of screening. Known untreated B12 deficiency or malnutrition (body mass index [BMI] less than 18) at screening. Evidence of current hepatitis C virus infection (HCV) (ie, HCV antibody [Ab] positive within 90 days prior to study entry unless also shown to be plasma HCV RNA negative within the same time period). Unstable and advanced liver disease (as defined by the presence of at least one of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice). Prior or current use of any CCR5 antagonist (such as MVC and cenicriviroc [CVC]) and integrase inhibitor (such as RAL, DTG, and elvitegravir [EVG]). Current use of any medication, including antiretrovirals, prohibited in the study (refer to the A5324 protocol-specific web page [PSWP] for the prohibited medications). Breastfeeding. Presence of an AIDS-defining opportunistic infection within 6 months prior to entry. Note: Refer to the A5324 Manual of Operations (MOPS) for the list of AIDS-defining opportunistic infections.. Active syphilis or treatment for syphilis within 90 days prior to study entry. NOTE: Active syphilis is defined as four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis, or newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS]).. Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation. "
    },
    "NCT02862912_exc": {
        "Annotations": [
            "Condition 4 20--*--contraindication",
            "Drug 24 44--*--neuraxial anesthesia",
            "Observation 46 53--*--history",
            "Condition 57 75--*--neurologic disease",
            "Condition 83 101--*--multiple sclerosis",
            "Condition 103 118--*--spinal stenosis",
            "Condition 120 127;142 152--*--central neuropathy",
            "Condition 131 152--*--peripheral neuropathy",
            "Scope 83 152--*--multiple sclerosis, spinal stenosis, central or peripheral neuropathy",
            "Scope 46 152--*--history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy",
            "Scope 4 44--*--contraindication to neuraxial anesthesia",
            "Qualifier 168 175--*--chronic",
            "Temporal 155 167--*--Pre-existing",
            "Condition 176 185--*--back pain",
            "Scope 155 175--*--Pre-existing/chronic",
            "Drug 187 209--*--Ester local anesthetic",
            "Condition 210 217--*--allergy",
            "Drug 219 223--*--PABA",
            "Condition 224 231--*--allergy",
            "Observation 233 240--*--History",
            "Drug 244 267--*--atypical cholinesterase",
            "Non-representable 269 304--*--CP is metabolized by cholinesterase"
        ],
        "Text": "Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy). Pre-existing/chronic back pain. Ester local anesthetic allergy, PABA allergy. History of atypical cholinesterase (CP is metabolized by cholinesterase). "
    },
    "NCT02413970_exc": {
        "Annotations": [
            "Condition 10 22--*--mixed apneas",
            "Condition 0 7;16 22--*--Central apneas",
            "Value 23 28--*--> 25%",
            "Measurement 36 62--*--total apnea-hypopnea index",
            "Measurement 64 67--*--AHI",
            "Scope 0 22--*--Central + mixed apneas",
            "Non-query-able 70 231--*--Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate",
            "Non-query-able 233 321--*--Any condition or procedure that has compromised neurological control of the upper airway",
            "Non-query-able 323 416--*--Patients who are unable or do not have the necessary assistance to operate the patient remote",
            "Pregnancy_considerations 418 470--*--Patients who are pregnant or plan to become pregnant",
            "Procedure 498 524--*--magnetic resonance imaging",
            "Procedure 526 529--*--MRI",
            "Non-query-able 532 641--*--Patients with an implantable device that may be susceptible to unintended interaction with the Inspire system",
            "Measurement 644 659--*--Body Mass Index",
            "Measurement 661 664--*--BMI",
            "Value 669 673--*--> 32",
            "Condition 721 736--*--contraindicates",
            "Procedure 739 757--*--surgical procedure",
            "Procedure 764 782--*--general anesthesia",
            "Observation 858 873--*--life expectancy",
            "Value 874 885--*--< 12 months",
            "Condition 894 913--*--psychiatric disease",
            "Condition 915 932--*--psychotic illness",
            "Condition 934 950--*--major depression",
            "Condition 955 976--*--acute anxiety attacks",
            "Scope 915 976--*--psychotic illness, major depression, or acute anxiety attacks",
            "Non-query-able 1072 1159--*--Any other reason the investigator deems subject is unfit for participation in the study"
        ],
        "Text": "Central + mixed apneas > 25% of the total apnea-hypopnea index (AHI). Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate. Any condition or procedure that has compromised neurological control of the upper airway. Patients who are unable or do not have the necessary assistance to operate the patient remote. Patients who are pregnant or plan to become pregnant. Patients who will require magnetic resonance imaging (MRI). Patients with an implantable device that may be susceptible to unintended interaction with the Inspire system.. Body Mass Index (BMI) of > 32. Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator. Has a terminal illness with life expectancy < 12 months. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing. Any other reason the investigator deems subject is unfit for participation in the study. "
    },
    "NCT02635893_inc": {
        "Text": "Male and females between ages 18-85 years of age. SCI ( =1 month of injury). ASIA A, B,C and D. SCI above L5. Able to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients). Able to ambulate a few steps with or without an assistive device. Male and females between ages 18-85 years of age. Able to walk and complete lower-limb tests with both legs. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 16--*--females",
            "Value 17 24;30 48--*--between 18-85 years of age",
            "Person 25 29--*--ages",
            "Condition 50 53--*--SCI",
            "Temporal 56 74--*--=1 month of injury",
            "Measurement 77 81--*--ASIA",
            "Value 82 94--*--A, B,C and D",
            "Measurement 96 99--*--SCI",
            "Value 100 108--*--above L5",
            "Non-representable 110 235--*--Able to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients)",
            "Person 312 319--*--females",
            "Person 305 306--*--l",
            "Value 320 327;333 351--*--between 18-85 years of age",
            "Person 328 332--*--ages",
            "Condition 353 365--*--Able to walk",
            "Condition 237 265--*--Able to ambulate a few steps",
            "Qualifier 274 301--*--without an assistive device",
            "Qualifier 266 270;285 301--*--with assistive device",
            "Scope 266 301--*--with or without an assistive device",
            "Condition 353 360;370 395--*--Able to complete lower-limb tests",
            "Qualifier 396 410--*--with both legs"
        ]
    },
    "NCT03129555_exc": {
        "Annotations": [
            "Drug 20 24--*--NOAC",
            "Temporal 25 99--*--within 90 days prior to hospitalization or outpatient clinic visit for VTE",
            "Condition 96 99--*--VTE",
            "Reference_point 49 99--*--hospitalization or outpatient clinic visit for VTE",
            "Procedure 49 64--*--hospitalization",
            "Procedure 68 91--*--outpatient clinic visit",
            "Visit 68 85--*--outpatient clinic",
            "Visit 49 64--*--hospitalization",
            "Scope 49 99--*--hospitalization or outpatient clinic visit for VTE",
            "Drug 116 120--*--NOAC",
            "Observation 116 131--*--NOAC preference",
            "Non-representable 132 202--*--apart from preference consistent with current cluster randomized NOAC.",
            "Condition 210 227--*--contraindications",
            "Qualifier 204 209--*--Other",
            "Qualifier 246 280--*--Summary of Product Characteristics",
            "Drug 301 305--*--NOAC"
        ],
        "Text": "A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE.. Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC.. Other contraindications mentioned in the \"Summary of Product Characteristics\" for the respective NOAC.. "
    },
    "NCT00317148_inc": {
        "Text": "Healthy postmenopausal women with 50 or more moderate to severe hot flushes. . Women between 40 to 70 years of age. . ",
        "Annotations": [
            "Condition 8 22--*--postmenopausal",
            "Condition 0 7--*--Healthy",
            "Person 23 28--*--women",
            "Value 34 44--*--50 or more",
            "Condition 45 75--*--moderate to severe hot flushes",
            "Person 78 83--*--Women",
            "Value 84 106--*--between 40 to 70 years",
            "Person 110 113--*--age"
        ]
    },
    "NCT00379366_exc": {
        "Text": "contra-indications of radiotherapy . angioplasty with stenting       .     . ",
        "Annotations": [
            "Procedure 22 34--*--radiotherapy",
            "Condition 0 18--*--contra-indications",
            "Procedure 36 61--*--angioplasty with stenting"
        ]
    },
    "NCT02823808_exc": {
        "Text": "The use of weight-lowering drugs, any investigational blood-glucose or lipid-lowering agent (other than statins or ezetimibe) within the past 3 months. Previous treatment with systemic corticosteroids or a change in dosage of thyroid hormones in the previous 6 weeks. The use of insulin within the 3 months prior to screening. Others. ",
        "Annotations": [
            "Qualifier 11 26--*--weight-lowering",
            "Drug 27 32--*--drugs",
            "Qualifier 38 53--*--investigational",
            "Qualifier 71 85--*--lipid-lowering",
            "Qualifier 54 67--*--blood-glucose",
            "Drug 86 91--*--agent",
            "Scope 54 85--*--blood-glucose or lipid-lowering",
            "Temporal 137 150--*--past 3 months",
            "Negation 93 98--*--other",
            "Drug 104 111--*--statins",
            "Drug 115 124--*--ezetimibe",
            "Scope 104 124--*--statins or ezetimibe",
            "Scope 11 91--*--weight-lowering drugs, any investigational blood-glucose or lipid-lowering agent",
            "Drug 176 200--*--systemic corticosteroids",
            "Drug 226 242--*--thyroid hormones",
            "Qualifier 206 222--*--change in dosage",
            "Temporal 250 266--*--previous 6 weeks",
            "Scope 176 242--*--systemic corticosteroids or a change in dosage of thyroid hormones",
            "Drug 279 286--*--insulin",
            "Temporal 287 325--*--within the 3 months prior to screening",
            "Reference_point 316 325--*--screening",
            "Non-query-able 327 333--*--Others"
        ]
    },
    "NCT02519777_inc": {
        "Annotations": [
            "Non-representable 0 1178--*--a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. NOTE: The term \"licensed\" refers to a United States Food and Drug Administration (FDA)-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally. Non-US sites are encouraged to use US FDA-approved methods for IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA. OR",
            "Condition 1197 1210--*--HIV diagnosis",
            "Drug 1260 1295--*--Tenofovir disoproxil fumarate (TDF)",
            "Drug 1299 1335--*--tenofovir alafenamide fumarate (TAF)",
            "Procedure 1336 1382--*--TAF-containing fixed-dose combination regimens",
            "Drug 1384 1399--*--Ritonavir (RTV)",
            "Drug 1403 1420--*--cobicistat (COBI)",
            "Procedure 1421 1468--*--COBI-containing fixed-dose combination regimens",
            "Drug 1477 1480--*--TAF",
            "Drug 1470 1473--*--TDF",
            "Procedure 1481 1527--*--TAF-containing fixed-dose combination regimens",
            "Drug 1529 1532--*--RTV",
            "Drug 1536 1540--*--COBI",
            "Procedure 1541 1588--*--COBI-containing fixed-dose combination regimens",
            "Measurement 1590 1606--*--HIV-1 plasma RNA",
            "Value 1607 1629--*--less than 50 copies/mL",
            "Temporal 1639 1674--*--within 90 days prior to study entry",
            "Reference_point 1663 1674--*--study entry",
            "Non-representable 1675 2015--*--by any FDA-approved assay at any United States laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.",
            "Multiplier 2017 2033--*--No more than one",
            "Measurement 2034 2050--*--HIV-1 plasma RNA",
            "Value 2051 2106--*--greater than or equal to 50 and less than 200 copies/mL",
            "Temporal 2125 2145--*--in the past 6 months",
            "Measurement 2164 2180--*--HIV-1 plasma RNA",
            "Value 2181 2203--*--less than 50 copies/mL",
            "Temporal 2153 2163--*--subsequent",
            "Negation 2227 2229--*--no",
            "Measurement 2230 2246--*--plasma HIV-1 RNA",
            "Value 2247 2273--*--greater than 200 copies/mL",
            "Temporal 2274 2314--*--within the 6 months prior to study entry",
            "Condition 2317 2321--*--HAND",
            "Condition 2333 2336--*--ANI",
            "Condition 2338 2341--*--MND",
            "Condition 2346 2349--*--HAD",
            "Scope 2333 2349--*--ANI, MND, or HAD",
            "Temporal 2351 2386--*--within 60 days prior to study entry",
            "Value 2459 2524--*--more than one standard deviation below appropriate normative data",
            "Measurement 2435 2457--*--neurocognitive testing",
            "Multiplier 2525 2554--*--in two domains of functioning",
            "Qualifier 2407 2420--*--at least mild",
            "Value 2421 2431--*--impairment",
            "Condition 2563 2591--*--severely confounding factors",
            "Negation 2560 2562--*--no",
            "Scope 2407 2591--*--at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors",
            "Measurement 2594 2625--*--Absolute neutrophil count (ANC)",
            "Value 2626 2659--*--greater than or equal to 500/mm^3",
            "Measurement 2661 2671--*--Hemoglobin",
            "Value 2672 2705--*--greater than or equal to 7.5 g/dL",
            "Measurement 2707 2721--*--Platelet count",
            "Value 2722 2758--*--greater than or equal to 40,000/mm^3",
            "Measurement 2760 2770--*--Creatinine",
            "Value 2771 2826--*--less than or equal to 2.0 x upper limit of normal (ULN)",
            "Measurement 2828 2856--*--Aspartate transaminase (AST)",
            "Value 2857 2886--*--less than or equal to 5 x ULN",
            "Measurement 2888 2914--*--Alanine transaminase (ALT)",
            "Value 2915 2932--*--less than 3 x ULN",
            "Measurement 2934 2954--*--Alkaline phosphatase",
            "Value 2955 2984--*--less than or equal to 5 x ULN",
            "Measurement 2986 3001--*--Total bilirubin",
            "Value 3002 3021--*--less than 1.5 x ULN",
            "Drug 3071 3086--*--indinavir (IDV)",
            "Drug 3091 3107--*--atazanavir (ATV)",
            "Procedure 3119 3126--*--regimen",
            "Scope 3071 3107--*--indinavir (IDV)- or atazanavir (ATV)",
            "Temporal 3127 3151--*--at the time of screening",
            "Measurement 3153 3168--*--total bilirubin",
            "Value 3169 3198--*--less than or equal to 5 x ULN",
            "Scope 3071 3198--*--indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN",
            "Scope 2986 3021--*--Total bilirubin less than 1.5 x ULN",
            "Measurement 3215 3242--*--Creatinine clearance (CrCl)",
            "Value 3243 3277--*--greater than or equal to 60 mL/min",
            "Procedure 3311 3335--*--Cockcroft-Gault equation",
            "Pregnancy_considerations 3425 4115--*--Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC) / CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs within 48 hours prior to study entry",
            "Pregnancy_considerations 4117 4584--*--Females of reproductive potential must agree not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must use at least one reliable form of contraception. Female participants must use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment. More information on this criterion is available in the protocol.",
            "Person 4594 4599--*--women",
            "Person 4586 4589--*--Men",
            "Value 4600 4608;4616 4625--*--18 years and older",
            "Person 4612 4615--*--age",
            "Observation 4634 4650--*--able to complete",
            "Procedure 4655 4679--*--neuropsychological tests",
            "Post-eligibility 4681 4822--*--Ability and willingness of participant or a legally authorized representative (see protocol for more information) to provide informed consent",
            "Post-eligibility 4824 4878--*--Ability and willingness to take oral study medications"
        ],
        "Text": "a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. NOTE: The term \"licensed\" refers to a United States Food and Drug Administration (FDA)-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally. Non-US sites are encouraged to use US FDA-approved methods for IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA. OR. Documentation of HIV diagnosis in the medical record by a healthcare provider.. Tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF)/TAF-containing fixed-dose combination regimens. Ritonavir (RTV) to cobicistat (COBI)/COBI-containing fixed-dose combination regimens. TDF to TAF/TAF-containing fixed-dose combination regimens. RTV to COBI/COBI-containing fixed-dose combination regimens. HIV-1 plasma RNA less than 50 copies/mL obtained within 90 days prior to study entry by any FDA-approved assay at any United States laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.. No more than one HIV-1 plasma RNA greater than or equal to 50 and less than 200 copies/mL (only one \"blip\") in the past 6 months with a subsequent HIV-1 plasma RNA less than 50 copies/mL. NOTE: There should be no plasma HIV-1 RNA greater than 200 copies/mL within the 6 months prior to study entry.. HAND diagnosis (ANI, MND, or HAD) within 60 days prior to study entry. HAND is defined as at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors.. Absolute neutrophil count (ANC) greater than or equal to 500/mm^3. Hemoglobin greater than or equal to 7.5 g/dL. Platelet count greater than or equal to 40,000/mm^3. Creatinine less than or equal to 2.0 x upper limit of normal (ULN). Aspartate transaminase (AST) less than or equal to 5 x ULN. Alanine transaminase (ALT) less than 3 x ULN. Alkaline phosphatase less than or equal to 5 x ULN. Total bilirubin less than 1.5 x ULN. NOTE: If the potential participant is taking an indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN is acceptable.. Creatinine clearance (CrCl) greater than or equal to 60 mL/min, either measured or estimated by Cockcroft-Gault equation. NOTE: A calculator for estimating the CrCl can be found at www.fstrf.org/ACTG/ccc.html. Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC) / CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs within 48 hours prior to study entry. Females of reproductive potential must agree not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must use at least one reliable form of contraception. Female participants must use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment. More information on this criterion is available in the protocol.. Men and women 18 years of age and older who are able to complete the neuropsychological tests. Ability and willingness of participant or a legally authorized representative (see protocol for more information) to provide informed consent. Ability and willingness to take oral study medications. "
    },
    "NCT01696617_exc": {
        "Text": "Past history of hypersensitivity to aripiprazole. Primary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia. Clinically significant current Axis II (DSM-IV-TR) diagnosis. A significant risk of suicide corroborated by a score of =5 on item 10(suicidal thoughts) on the MADRS scale or by clinical judgment of the investigator. Pregnancy or in breast-feeding. Presence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function. Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics. Patients with past treatment failures of aripiprazole. ",
        "Annotations": [
            "Condition 16 32--*--hypersensitivity",
            "Drug 36 48--*--aripiprazole",
            "Condition 71 74--*--MDD",
            "Condition 80 97--*--psychotic feature",
            "Condition 99 115--*--bipolar disorder",
            "Condition 117 130--*--schizophrenia",
            "Condition 132 156--*--schizoaffective disorder",
            "Condition 164 182--*--psychotic disorder",
            "Qualifier 158 163--*--other",
            "Condition 186 203--*--anxiety disorder,",
            "Condition 226 236--*--drug abuse",
            "Condition 217 224;231 236--*--alcohol abuse",
            "Temporal 237 262--*--within the past 12 months",
            "Condition 282 290--*--dementia",
            "Scope 217 236--*--alcohol/ drug abuse",
            "Scope 80 202--*--psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder",
            "Qualifier 323 330--*--Axis II",
            "Condition 343 352--*--diagnosis",
            "Qualifier 332 341--*--DSM-IV-TR",
            "Observation 368 383--*--risk of suicide",
            "Qualifier 356 367--*--significant",
            "Measurement 451 462--*--MADRS scale",
            "Value 402 424--*--score of =5 on item 10",
            "Non-query-able 466 506--*--by clinical judgment of the investigator",
            "Pregnancy_considerations 508 538--*--Pregnancy or in breast-feeding",
            "Qualifier 554 561--*--serious",
            "Condition 562 577--*--medical illness",
            "Condition 588 595--*--cardiac",
            "Condition 597 604--*--hepatic",
            "Condition 606 611--*--renal",
            "Condition 613 624--*--respiratory",
            "Condition 626 640--*--endocrinologic",
            "Condition 642 652--*--neurologic",
            "Condition 657 676--*--hematologic disease",
            "Condition 680 697--*--physical disorder",
            "Non-query-able 540 760--*--Presence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function",
            "Drug 778 792--*--antipsychotics",
            "Drug 794 809--*--mood stabilizer",
            "Drug 817 841--*--psychotropic medications",
            "Negation 842 849--*--besides",
            "Drug 850 865--*--antidepressants",
            "Negation 867 873--*--except",
            "Drug 874 889--*--benzodiazepines",
            "Drug 893 906--*--beta blockers",
            "Drug 910 919--*--hypnotics",
            "Scope 874 919--*--benzodiazepines or beta blockers or hypnotics",
            "Scope 817 865--*--psychotropic medications besides antidepressants",
            "Drug 962 974--*--aripiprazole",
            "Observation 940 958--*--treatment failures"
        ]
    },
    "NCT01084993_exc": {
        "Annotations": [
            "Condition 0 11--*--Intolerance",
            "Condition 15 22--*--allergy",
            "Drug 26 29--*--ASA",
            "Scope 0 22--*--Intolerance or allergy",
            "Drug 31 42--*--clopidogrel",
            "Drug 46 57--*--ticlopidine",
            "Temporal 79 92--*--for 12 months",
            "Negation 58 68--*--precluding",
            "Procedure 69 78--*--treatment",
            "Scope 58 92--*--precluding treatment for 12 months",
            "Scope 26 57--*--ASA, clopidogrel or ticlopidine",
            "Competing_trial 94 149--*--Concurrent participation in other investigational study",
            "Condition 151 174--*--Femoral sheath (artery)"
        ],
        "Text": "Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for 12 months. Concurrent participation in other investigational study. Femoral sheath (artery). "
    },
    "NCT03088280_inc": {
        "Annotations": [
            "Procedure 8 25--*--kidney transplant",
            "Qualifier 0 7--*--Primary",
            "Person 38 44--*--adults"
        ],
        "Text": "Primary kidney transplant recipients, adults. "
    },
    "NCT03472495_exc": {
        "Text": "Limited English proficiency (LEP). Pregnant. Prisoners. Wolff Parkinson White syndrome. Administration of electrical or chemical cardioversion before screening. Administration of other antiarrhythmics for acute heart rate control (excluding adenosine). History of allergy or idiosyncratic reaction to diltiazem. Unable to take oral medications. Heart rate <60 beats/min. ",
        "Annotations": [
            "Observation 0 27--*--Limited English proficiency",
            "Observation 29 32--*--LEP",
            "Condition 35 43--*--Pregnant",
            "Person 45 54--*--Prisoners",
            "Condition 56 86--*--Wolff Parkinson White syndrome",
            "Procedure 120 142--*--chemical cardioversion",
            "Procedure 106 116;129 142--*--electrical cardioversion",
            "Temporal 143 159--*--before screening",
            "Reference_point 150 159--*--screening",
            "Scope 106 142--*--electrical or chemical cardioversion",
            "Drug 185 200--*--antiarrhythmics",
            "Qualifier 205 210--*--acute",
            "Procedure 211 229--*--heart rate control",
            "Negation 231 240--*--excluding",
            "Drug 241 250--*--adenosine",
            "Condition 264 271--*--allergy",
            "Condition 275 297--*--idiosyncratic reaction",
            "Drug 301 310--*--diltiazem",
            "Scope 264 297--*--allergy or idiosyncratic reaction",
            "Condition 312 326--*--Unable to take",
            "Drug 327 343--*--oral medications",
            "Measurement 345 355--*--Heart rate",
            "Value 356 369--*--<60 beats/min"
        ]
    },
    "NCT03390933_inc": {
        "Text": "currently on hemodialysis at a CDC dialysis unit. English speaking. able to provide informed consent. ",
        "Annotations": [
            "Temporal 0 9--*--currently",
            "Procedure 13 25--*--hemodialysis",
            "Visit 31 48--*--CDC dialysis unit",
            "Observation 50 66--*--English speaking",
            "Informed_consent 68 100--*--able to provide informed consent"
        ]
    },
    "NCT03134196_inc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT03088280_exc": {
        "Annotations": [
            "Measurement 0 3--*--PRA",
            "Value 4 9--*--> 50%",
            "Measurement 11 14--*--DSA",
            "Value 15 25--*--> 1500 MFI",
            "Condition 27 44--*--Retransplantation",
            "Mood 63 74--*--planning to",
            "Drug 83 96--*--mycophenolate",
            "Negation 97 107--*--instead of",
            "Drug 108 118--*--everolimus",
            "Mood 138 150--*--planning for",
            "Procedure 151 160--*--follow-up",
            "Visit 164 178--*--another center"
        ],
        "Text": "PRA > 50%. DSA > 1500 MFI. Retransplantation. Patients who are planning to receive mycophenolate instead of everolimus. Patients who have planning for follow-up in another center. "
    },
    "NCT03472495_inc": {
        "Text": ">/= 18 years old. Atrial fibrillation or flutter on electrocardiogram. Heart rate >110 beats/min. Systolic blood pressure >/= 90 mmHg. ",
        "Annotations": [
            "Value 0 16--*-->/= 18 years old",
            "Person 13 16--*--old",
            "Condition 18 37--*--Atrial fibrillation",
            "Condition 18 24;41 48--*--Atrial flutter",
            "Procedure 52 69--*--electrocardiogram",
            "Scope 18 48--*--Atrial fibrillation or flutter",
            "Measurement 71 81--*--Heart rate",
            "Value 82 96--*-->110 beats/min",
            "Measurement 98 121--*--Systolic blood pressure",
            "Value 122 133--*-->/= 90 mmHg"
        ]
    },
    "NCT03390933_exc": {
        "Text": "on hemodialysis for less than 3 months. comorbid psychotic, bipolar, substance use dependence, Alzheimer's or dementia. ",
        "Annotations": [
            "Procedure 3 15--*--hemodialysis",
            "Temporal 16 38--*--for less than 3 months",
            "Condition 49 58--*--psychotic",
            "Condition 60 67--*--bipolar",
            "Condition 69 93--*--substance use dependence",
            "Condition 95 106--*--Alzheimer's",
            "Condition 110 118--*--dementia",
            "Temporal 40 48--*--comorbid",
            "Scope 49 118--*--psychotic, bipolar, substance use dependence, Alzheimer's or dementia"
        ]
    },
    "NCT03134196_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT00599924_exc": {
        "Text": "Prior treatment with more than 6 cycles of traditional alkylating agent-based chemotherapy regimens . Prior treatment with more than 2 cycles of carboplating-based chemotherapy regimens . For colorectal cancer patients in the expanded cohorts, prior treatment with more than 2 systemic chemotherapy regimens in the metastatic setting       .     . ",
        "Annotations": [
            "Procedure 6 15--*--treatment",
            "Temporal 0 5--*--Prior",
            "Procedure 78 99--*--chemotherapy regimens",
            "Qualifier 55 77--*--alkylating agent-based",
            "Value 21 39--*--more than 6 cycles",
            "Qualifier 144 162--*--carboplating-based",
            "Value 122 140--*--more than 2 cycles",
            "Procedure 107 116--*--treatment",
            "Temporal 101 106--*--Prior",
            "Procedure 163 184--*--chemotherapy regimens",
            "Condition 190 207--*--colorectal cancer",
            "Procedure 248 257--*--treatment",
            "Temporal 242 247--*--prior",
            "Value 263 274--*--more than 2",
            "Procedure 275 305--*--systemic chemotherapy regimens",
            "Qualifier 313 323--*--metastatic"
        ]
    },
    "NCT02584140_inc": {
        "Annotations": [
            "Person 0 6--*--Female",
            "Temporal 7 15--*--at birth",
            "Reference_point 10 15--*--birth",
            "Person 41 47--*--gender",
            "Value 34 40--*--female",
            "Post-eligibility 72 132--*--Able to understand and provide consent in English or Spanish",
            "Measurement 134 137;150 169--*--HIV 4th generation test",
            "Value 138 146--*--negative",
            "Measurement 171 181--*--Ag/Ab test",
            "Measurement 201 218--*--enzymeimmunoassay",
            "Measurement 229 236--*--HIV RNA",
            "Measurement 220 223--*--EIA",
            "Scope 201 235--*--enzymeimmunoassay (EIA) and HIV RN",
            "Measurement 238 258--*--Creatinine clearance",
            "Value 259 270--*--= 60 ml/min",
            "Measurement 276 299--*--Cockcroft-Gault formula",
            "Observation 302 316--*--Condomless sex",
            "Temporal 317 337--*--in the last 3 months",
            "Multiplier 343 354--*--one or more",
            "Person 355 368--*--male partners",
            "Condition 372 390--*--unknown HIV status",
            "Observation 406 439--*--substantial risk of HIV infection",
            "Condition 426 439--*--HIV infection",
            "Observation 441 444--*--IDU",
            "Observation 446 454--*--bisexual",
            "Observation 456 469--*--sex for goods",
            "Observation 471 492--*--recently incarcerated",
            "Observation 494 532--*--from a country with HIV prevalence >1%",
            "Observation 534 564--*--interpersonal Partner Violence",
            "Condition 568 571--*--STI",
            "Condition 604 612--*--syphilis",
            "Condition 583 600--*--vaginal gonorrhea",
            "Condition 573 579;591 600--*--rectal gonorrhea",
            "Scope 573 612--*--rectal or vaginal gonorrhea or syphilis",
            "Temporal 624 648--*--during the last 6 months",
            "Procedure 660 685;692 695--*--post-exposure prophylaxis use",
            "Procedure 687 690--*--PEP",
            "Temporal 696 721--*--during the last 12 months",
            "Multiplier 728 740--*--at least one",
            "Observation 754 768--*--sexual partner",
            "Condition 741 753--*--HIV-infected",
            "Value 773 781--*--=4 weeks",
            "Observation 784 828--*--Sex for exchange of money, goods or services",
            "Person 49 52--*--Age",
            "Value 53 70--*--18 years or older"
        ],
        "Text": "Female at birth and identifies as female gender. Age 18 years or older. Able to understand and provide consent in English or Spanish. HIV negative by 4th generation test (Ag/Ab test) or combination of enzymeimmunoassay (EIA) and HIV RNA. Creatinine clearance = 60 ml/min (via Cockcroft-Gault formula). Condomless sex in the last 3 months with one or more male partners of unknown HIV status known to be at substantial risk of HIV infection (IDU, bisexual, sex for goods, recently incarcerated, from a country with HIV prevalence >1%, interpersonal Partner Violence);. STI (rectal or vaginal gonorrhea or syphilis) diagnosis during the last 6 months.. Previous post-exposure prophylaxis (PEP) use during the last 12 months.. Has at least one HIV-infected sexual partner for =4 weeks.. Sex for exchange of money, goods or services. "
    },
    "NCT02903407_inc": {
        "Text": "All patients admitted to the Duke CICU, who require intubation and sedation for mechanical ventilation that is expected to be >24 hours in duration will be included, unless they meet the specified exclusion criteria.. Patients intubated within one hour prior to care transition to the CICU will also be screened for inclusion.. ",
        "Annotations": [
            "Visit 29 38--*--Duke CICU",
            "Procedure 13 21--*--admitted",
            "Procedure 52 62--*--intubation",
            "Procedure 67 75--*--sedation",
            "Procedure 80 102--*--mechanical ventilation",
            "Multiplier 126 147--*-->24 hours in duration",
            "Mood 111 125--*--expected to be",
            "Scope 52 75--*--intubation and sedation",
            "Procedure 227 236--*--intubated",
            "Temporal 237 277--*--within one hour prior to care transition",
            "Procedure 262 277--*--care transition",
            "Reference_point 262 277--*--care transition"
        ]
    },
    "NCT02650024_exc": {
        "Text": "Amiodarone. P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort). Liver biopsy at any time showing mHAI stage 4 or higher fibrosis OR. FibroScan within 12 months demonstrating liver stiffness of =9.5 kilo Pascal or. AST to platelet ratio index (APRI) =2.0 and Fibrosis-4 (FIB-4) =3.25. NOTE: If APRI and FIB-4 are discordant one of the other forms of fibrosis staging must be used.. Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.. Hemochromatosis. Alpha-1 antitrypsin deficiency. Wilson's disease. Autoimmune hepatitis. Alcoholic liver disease. Drug-related liver disease. Severe NC confounding conditions (stroke, head injury, or developmental learning disability).. Regular use of anti-inflammatory drugs.. Current or recent treatment with pegylated interferon (PEG-IFN).. Other active inflammatory process (major infection, malignancy, rheumatoid arthritis/autoimmune disorder) within the prior 28 days.. Contraindications to magnetic resonance imaging (MRI).. Bleeding diathesis, thrombocytopenia, or use of anticoagulants that would contraindicate lumbar puncture.. Uncontrolled or active depression or other psychiatric disorder that in the opinion of the site investigator might preclude adherence to study requirements or impact NC functioning and assessments.. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.. Presence of active or acute AIDS-defining opportunistic infections within 12 weeks prior to study entry.. ",
        "Annotations": [
            "Drug 0 10--*--Amiodarone",
            "Drug 12 42--*--P-glycoprotein (P-gp) inducers",
            "Drug 50 58--*--rifampin",
            "Drug 60 75--*--St. John's wort",
            "Scope 50 75--*--rifampin, St. John's wort",
            "Procedure 78 90--*--Liver biopsy",
            "Measurement 111 121--*--mHAI stage",
            "Value 122 133--*--4 or higher",
            "Temporal 94 102--*--any time",
            "Procedure 147 156--*--FibroScan",
            "Temporal 157 173--*--within 12 months",
            "Measurement 188 203--*--liver stiffness",
            "Value 207 223--*--=9.5 kilo Pascal",
            "Measurement 228 262--*--AST to platelet ratio index (APRI)",
            "Value 263 267--*--=2.0",
            "Measurement 272 290--*--Fibrosis-4 (FIB-4)",
            "Value 291 296--*--=3.25",
            "Non-representable 298 393--*--NOTE: If APRI and FIB-4 are discordant one of the other forms of fibrosis staging must be used.",
            "Condition 401 408--*--allergy",
            "Condition 409 420--*--sensitivity",
            "Condition 428 444--*--hypersensitivity",
            "Drug 448 473--*--components of study drugs",
            "Scope 401 444--*--allergy/sensitivity or any hypersensitivity",
            "Condition 497 512--*--Hemochromatosis",
            "Condition 514 544--*--Alpha-1 antitrypsin deficiency",
            "Condition 546 562--*--Wilson's disease",
            "Condition 564 584--*--Autoimmune hepatitis",
            "Condition 586 609--*--Alcoholic liver disease",
            "Condition 611 637--*--Drug-related liver disease",
            "Condition 673 679--*--stroke",
            "Condition 681 692--*--head injury",
            "Condition 697 730--*--developmental learning disability",
            "Condition 646 671--*--NC confounding conditions",
            "Scope 673 730--*--stroke, head injury, or developmental learning disability",
            "Drug 749 772--*--anti-inflammatory drugs",
            "Drug 808 828--*--pegylated interferon",
            "Drug 830 837--*--PEG-IFN",
            "Procedure 793 802--*--treatment",
            "Temporal 786 792--*--recent",
            "Temporal 775 782--*--Current",
            "Scope 775 792--*--Current or recent",
            "Condition 847 874--*--active inflammatory process",
            "Qualifier 841 846--*--Other",
            "Condition 876 891--*--major infection",
            "Condition 893 903--*--malignancy",
            "Condition 905 925--*--rheumatoid arthritis",
            "Condition 926 945--*--autoimmune disorder",
            "Scope 876 945--*--major infection, malignancy, rheumatoid arthritis/autoimmune disorder",
            "Temporal 947 971--*--within the prior 28 days",
            "Procedure 995 1027--*--magnetic resonance imaging (MRI)",
            "Condition 974 991--*--Contraindications",
            "Condition 1030 1048--*--Bleeding diathesis",
            "Condition 1050 1066--*--thrombocytopenia",
            "Drug 1078 1092--*--anticoagulants",
            "Condition 1104 1118--*--contraindicate",
            "Procedure 1119 1134--*--lumbar puncture",
            "Temporal 1153 1159--*--active",
            "Qualifier 1137 1149--*--Uncontrolled",
            "Condition 1160 1170--*--depression",
            "Scope 1137 1159--*--Uncontrolled or active",
            "Condition 1180 1200--*--psychiatric disorder",
            "Qualifier 1174 1179--*--other",
            "Scope 1160 1200--*--depression or other psychiatric disorder",
            "Condition 1351 1376--*--alcohol use or dependence",
            "Condition 1343 1347;1359 1376--*--drug use or dependence",
            "Temporal 1336 1342--*--Active",
            "Scope 1343 1376--*--drug or alcohol use or dependence",
            "Temporal 1501 1506--*--acute",
            "Temporal 1491 1497--*--active",
            "Condition 1507 1545--*--AIDS-defining opportunistic infections",
            "Temporal 1546 1582--*--within 12 weeks prior to study entry",
            "Scope 1491 1506--*--active or acute"
        ]
    },
    "NCT03068897_exc": {
        "Annotations": [
            "Non-query-able 0 27--*--Not available for follow-up",
            "Condition 29 37--*--Pregnant",
            "Condition 41 55--*--breast-feeding",
            "Condition 57 78--*--Chronic pain syndrome",
            "Drug 101 121--*--analgesic medication",
            "Qualifier 97 100--*--any",
            "Multiplier 122 132;147 152--*--on a daily basis",
            "Multiplier 122 126;136 152--*--on a near-daily basis",
            "Scope 122 152--*--on a daily or near-daily basis",
            "Scope 97 152--*--any analgesic medication on a daily or near-daily basis",
            "Condition 154 162--*--Allergic",
            "Condition 169 179--*--intolerant",
            "Drug 183 210--*--investigational medications",
            "Scope 154 179--*--Allergic to or intolerant",
            "Condition 212 230--*--Contra-indications",
            "Drug 234 271--*--non-steroidal anti-inflammatory drugs",
            "Condition 287 303--*--hypersensitivity",
            "Drug 307 313--*--NSAIDs",
            "Drug 317 324--*--aspirin",
            "Scope 307 324--*--NSAIDs or aspirin",
            "Observation 276 283--*--history",
            "Temporal 328 334--*--active",
            "Observation 338 345--*--history",
            "Condition 349 369--*--peptic ulcer disease",
            "Condition 371 388--*--chronic dyspepsia",
            "Temporal 393 399--*--active",
            "Observation 403 410--*--history",
            "Condition 414 436--*--gastrointestinal bleed",
            "Scope 328 345--*--active or history",
            "Scope 349 388--*--peptic ulcer disease, chronic dyspepsia",
            "Scope 393 410--*--active or history",
            "Qualifier 440 446--*--Severe",
            "Condition 447 460--*--heart failure",
            "Measurement 462 466--*--NYHA",
            "Value 467 477--*--2 or worse",
            "Scope 462 477--*--NYHA 2 or worse",
            "Condition 482 494--*--hypertension",
            "Measurement 496 506--*--JNC7 stage",
            "Value 507 517--*--2 or worse",
            "Condition 522 544--*--Chronic kidney disease",
            "Temporal 559 566--*--Current",
            "Drug 574 589--*--anti-coagulants",
            "Condition 593 602--*--Hepatitis",
            "Condition 606 616--*--Alcoholism",
            "Scope 212 271--*--Contra-indications to non-steroidal anti-inflammatory drugs",
            "Scope 496 517--*--JNC7 stage 2 or worse",
            "Scope 276 616--*--history of hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism",
            "Condition 618 636--*--Contra-indications",
            "Drug 640 656--*--muscle relaxants",
            "Temporal 661 671--*--Concurrent",
            "Drug 679 703--*--centrally acting opioids",
            "Condition 708 724--*--Renal impairment",
            "Condition 729 746--*--Liver abnormality",
            "Condition 757 766--*--cirrhosis",
            "Condition 770 786--*--elevated enzymes",
            "Scope 757 786--*--cirrhosis or elevated enzymes",
            "Drug 831 842--*--fluvoxamine",
            "Drug 844 860--*--fluoroquinolones",
            "Drug 862 872--*--amiodarone",
            "Drug 874 884--*--mexiletine",
            "Drug 886 897--*--propafenone",
            "Drug 899 908--*--verapamil",
            "Drug 910 920--*--cimetidine",
            "Drug 922 932--*--famotidine",
            "Drug 934 943--*--acyclovir",
            "Drug 945 956--*--ticlopidine",
            "Drug 958 982--*--oral contraceptive pills",
            "Scope 831 982--*--fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills",
            "Scope 618 656--*--Contra-indications to muscle relaxants",
            "Scope 661 982--*--Concurrent use of centrally acting opioids; 2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4) Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills"
        ],
        "Text": "Not available for follow-up. Pregnant or breast-feeding. Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis. Allergic to or intolerant of investigational medications. Contra-indications to non-steroidal anti-inflammatory drugs: 1) history of hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism. Contra-indications to muscle relaxants: 1) Concurrent use of centrally acting opioids; 2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4) Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills. "
    },
    "NCT00959569_inc": {
        "Annotations": [
            "Measurement 0 22--*--end diastolic diameter",
            "Value 23 29--*-->60 mm",
            "Measurement 40 57--*--ejection fraction",
            "Value 58 62--*--<50%",
            "Informed_consent 64 88--*--written informed consent",
            "Person 90 93--*--age",
            "Value 94 103--*-->18 years"
        ],
        "Text": "end diastolic diameter >60 mm and/or an ejection fraction <50%. written informed consent. age >18 years. "
    },
    "NCT01806558_exc": {
        "Text": "1. Are unable to understand and sign the consent form . 2. Are pregnant or lactating . 3. Are physically unable to sit upright and still for 40 minutes . 4. Have undergone bilateral mastectomy . 5. Are not scheduled to undergo conventional ultrasound       .     . ",
        "Annotations": [
            "Non-query-able 3 53--*--Are unable to understand and sign the consent form",
            "Post-eligibility 3 53--*--Are unable to understand and sign the consent form",
            "Condition 62 70--*--pregnant",
            "Condition 74 83--*--lactating",
            "Condition 92 134--*--physically unable to sit upright and still",
            "Multiplier 135 149--*--for 40 minutes",
            "Procedure 169 189--*--bilateral mastectomy",
            "Negation 198 201--*--not",
            "Observation 202 211--*--scheduled",
            "Procedure 223 246--*--conventional ultrasound"
        ]
    },
    "NCT03404479_exc": {
        "Text": "Secondary knee osteoarthritis. Other inflammatory Knee Osteoarthritis (e.g. gout, rheumatoid arthritis, etc.). Patients presenting with gastroesophageal reflux disease, peptic ulcer.. Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment).. Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis, Crohn's disease) and drug absorption disorder.. Intestinal obstruction syndrome. Unexplained abdominal pain. ALT(Alanine aminotransferase) level of liver function test exceeded 5 times of reference range. Total bilirubin level exceeded 2 mg / dL. Serum albumin level less than 2 g / dL. Ascites. Hepatic encephalopathy. Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive. MDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less than 60 mL / m2. Patients with hyperkalemia (over 5.5 meq / L). history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors).. Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.. Medical history of hypersensitivity to the components of the investigational products. (The components of test drug 1 and 2, including the Rhein-based drug). Patients with an allergic reaction to sulfonamide.. Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.. Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.. Patients receiving contraindicated medication.. Alcohol and other drug abuse cases based on 6 months before screening.. Pregnant women or nursing mothers who are not willing to stop breastfeeding.. (1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female. (2) Female infertility due to surgery (no ovaries and / or uterus). (3) If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.. (4) Female subjects who agreed to abstinence during the clinical trial period.. If the subject is assured of an abstinence throughout the trial period.(e.g. clergy). However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence.. (5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:. Oral contraceptive. The contraceptive patch. Intra uterine device (IUD). contraceptive implant. contraceptive injection. intrauterine hormonal apparatus. Tubal ligation and infertility surgery. If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.. Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.. In addition to the above, other diseases that the investigator judges to be inappropriate.. ",
        "Annotations": [
            "Qualifier 0 9--*--Secondary",
            "Condition 10 29--*--knee osteoarthritis",
            "Qualifier 31 36--*--Other",
            "Condition 37 69--*--inflammatory Knee Osteoarthritis",
            "Condition 76 80--*--gout",
            "Condition 82 102--*--rheumatoid arthritis",
            "Scope 76 102--*--gout, rheumatoid arthritis",
            "Scope 31 69--*--Other inflammatory Knee Osteoarthritis",
            "Condition 136 167--*--gastroesophageal reflux disease",
            "Condition 169 181--*--peptic ulcer",
            "Condition 184 205--*--Helicobacter infected",
            "Negation 224 227--*--not",
            "Procedure 233 256--*--treated for eradication",
            "Condition 319 339--*--Short bowel syndrome",
            "Condition 355 381--*--inflammatory bowel disease",
            "Mood 345 354--*--can cause",
            "Qualifier 340 381--*--that can cause inflammatory bowel disease",
            "Condition 383 401--*--ulcerative colitis",
            "Condition 403 418--*--Crohn's disease",
            "Condition 424 448--*--drug absorption disorder",
            "Scope 383 418--*--ulcerative colitis, Crohn's disease",
            "Scope 319 381--*--Short bowel syndrome that can cause inflammatory bowel disease",
            "Condition 451 482--*--Intestinal obstruction syndrome",
            "Qualifier 484 495--*--Unexplained",
            "Condition 496 510--*--abdominal pain",
            "Measurement 512 547--*--ALT(Alanine aminotransferase) level",
            "Procedure 551 570--*--liver function test",
            "Value 571 606--*--exceeded 5 times of reference range",
            "Measurement 608 629--*--Total bilirubin level",
            "Value 630 648--*--exceeded 2 mg / dL",
            "Measurement 650 669--*--Serum albumin level",
            "Value 671 688--*--ess than 2 g / dL",
            "Condition 690 697--*--Ascites",
            "Condition 699 721--*--Hepatic encephalopathy",
            "Condition 723 734--*--Hepatitis B",
            "Condition 736 747--*--hepatitis C",
            "Condition 780 792--*--HIV positive",
            "Negation 749 758--*--excluding",
            "Condition 759 775--*--healthy carriers",
            "Qualifier 794 837--*--MDRD(Modification of Diet in Renal Disease)",
            "Measurement 838 874--*--Estimated Glomerular filtration rate",
            "Value 875 895--*--less than 60 mL / m2",
            "Condition 911 923--*--hyperkalemia",
            "Value 925 941--*--over 5.5 meq / L",
            "Condition 955 961--*--asthma",
            "Condition 963 977--*--acute rhinitis",
            "Condition 979 991--*--nasal polyps",
            "Condition 993 1003--*--angioedema",
            "Condition 1005 1014--*--urticaria",
            "Condition 1018 1036--*--allergic reactions",
            "Drug 1040 1047--*--aspirin",
            "Qualifier 1051 1056--*--other",
            "Drug 1057 1094--*--non-steroidal anti-inflammatory drugs",
            "Drug 1105 1121--*--COX-2 inhibitors",
            "Scope 1040 1122--*--aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors)",
            "Condition 1125 1141--*--Malignant tumors",
            "Negation 1142 1152--*--other than",
            "Condition 1153 1163;1181 1202--*--basal cell carcinoma of the skin",
            "Condition 1167 1202--*--squamous cell carcinoma of the skin",
            "Scope 1153 1202--*--basal cell or squamous cell carcinoma of the skin",
            "Condition 1204 1243--*--CIN(Cervical Intraepitherial Neoplasia)",
            "Condition 1248 1284--*--CIS(Carcinoma in situ) of the cervix",
            "Condition 1290 1315--*--intraepithelial carcinoma",
            "Temporal 1331 1361--*--Within 5 years of consent date",
            "Reference_point 1349 1361--*--consent date",
            "Scope 1125 1315--*--Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma",
            "Condition 1383 1399--*--hypersensitivity",
            "Drug 1407 1449--*--components of the investigational products",
            "Drug 1456 1481--*--components of test drug 1",
            "Drug 1456 1479;1486 1487--*--components of test drug 2",
            "Drug 1503 1519--*--Rhein-based drug",
            "Scope 1456 1519--*--components of test drug 1 and 2, including the Rhein-based drug",
            "Condition 1539 1556--*--allergic reaction",
            "Drug 1560 1571--*--sulfonamide",
            "Condition 1588 1609--*--galactose intolerance",
            "Condition 1611 1634--*--lapp lactase deficiency",
            "Condition 1638 1669--*--glucose-galactose malabsorption",
            "Non-representable 1672 1824--*--Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.",
            "Drug 1845 1871--*--contraindicated medication",
            "Condition 1874 1881;1897 1902--*--Alcohol abuse",
            "Condition 1892 1902--*--drug abuse",
            "Temporal 1918 1943--*--6 months before screening",
            "Scope 1874 1902--*--Alcohol and other drug abuse",
            "Pregnancy_considerations 1946 2021--*--Pregnant women or nursing mothers who are not willing to stop breastfeeding",
            "Condition 2028 2037--*--Menopause",
            "Qualifier 2039 2058--*--non-therapy-induced",
            "Condition 2059 2069--*--amenorrhea",
            "Multiplier 2073 2092--*--more than 12 months",
            "Scope 2039 2092--*--non-therapy-induced amenorrhea of more than 12 months",
            "Person 2094 2100--*--Female",
            "Person 2106 2112--*--Female",
            "Condition 2113 2124--*--infertility",
            "Qualifier 2125 2139--*--due to surgery",
            "Condition 2141 2151--*--no ovaries",
            "Condition 2141 2143;2161 2167--*--no uterus",
            "Scope 2113 2139--*--infertility due to surgery",
            "Scope 2141 2167--*--no ovaries and / or uterus",
            "Pregnancy_considerations 2174 2292--*--If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.",
            "Pregnancy_considerations 2298 2371--*--Female subjects who agreed to abstinence during the clinical trial period",
            "Pregnancy_considerations 2374 2458--*--If the subject is assured of an abstinence throughout the trial period.(e.g. clergy)",
            "Pregnancy_considerations 2460 2611--*--However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence",
            "Competing_trial 2989 3126--*--If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.",
            "Non-query-able 3128 3300--*--Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.",
            "Non-query-able 3302 3391--*--In addition to the above, other diseases that the investigator judges to be inappropriate",
            "Pregnancy_considerations 2614 2793--*--(5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:",
            "Drug 2795 2813--*--Oral contraceptive",
            "Device 2819 2838--*--contraceptive patch",
            "Device 2840 2866--*--Intra uterine device (IUD)",
            "Device 2868 2889--*--contraceptive implant",
            "Device 2891 2914--*--contraceptive injection",
            "Device 2916 2947--*--intrauterine hormonal apparatus",
            "Procedure 2949 2963--*--Tubal ligation",
            "Procedure 2968 2987--*--infertility surgery"
        ]
    },
    "NCT03354572_exc": {
        "Text": "Pregnancy or lactating. Allergy to NAC. History of chronic pain. Use of opioids or neuropathic analgesics. Use of NAC prior to trial (< 1 month of planned surgery). Alcoholism. Diabetes Mellitus (insulin therapy). Asthma or Chronic Obstructive pulmonary Disease. Known renal function disorders (MDRD <\u00f40). Known liver failure (bilirubin >1.Sx upper limit of normal). No written lC by patient. ",
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 13 22--*--lactating",
            "Condition 24 31--*--Allergy",
            "Drug 35 38--*--NAC",
            "Condition 51 63--*--chronic pain",
            "Observation 40 47--*--History",
            "Drug 72 79--*--opioids",
            "Drug 83 105--*--neuropathic analgesics",
            "Drug 114 117--*--NAC",
            "Temporal 118 132--*--prior to trial",
            "Reference_point 127 132--*--trial",
            "Temporal 134 143--*--< 1 month",
            "Mood 147 154--*--planned",
            "Procedure 155 162--*--surgery",
            "Scope 134 162--*--< 1 month of planned surgery",
            "Condition 165 175--*--Alcoholism",
            "Condition 177 194--*--Diabetes Mellitus",
            "Drug 196 203--*--insulin",
            "Condition 214 220--*--Asthma",
            "Condition 224 261--*--Chronic Obstructive pulmonary Disease",
            "Condition 269 293--*--renal function disorders",
            "Measurement 295 299--*--MDRD",
            "Value 300 303--*--<\u00f40",
            "Scope 295 303--*--MDRD <\u00f40",
            "Condition 312 325--*--liver failure",
            "Measurement 327 336--*--bilirubin",
            "Value 337 364--*-->1.Sx upper limit of normal",
            "Scope 327 364--*--bilirubin >1.Sx upper limit of normal",
            "Informed_consent 367 391--*--No written lC by patient"
        ]
    },
    "NCT02370069_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Value 21 29;37 45--*--18 years or older",
            "Person 33 36--*--age",
            "Temporal 46 76--*--at the time of the vaccination",
            "Reference_point 65 76--*--vaccination",
            "Procedure 65 76--*--vaccination",
            "Grammar_Error 6 9--*--and",
            "Condition 85 107--*--chronic kidney disease",
            "Qualifier 78 84--*--Severe",
            "Condition 109 116;85 107--*--Stage 4 chronic kidney disease",
            "Condition 109 114;121 122;85 107--*--Stage 5 chronic kidney disease",
            "Grammar_Error 117 120--*--and"
        ],
        "Text": "Males and females of 18 years of age or older at the time of the vaccination. Severe chronic kidney disease (Stage 4 and 5). "
    },
    "NCT02944604_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT02386800_exc": {
        "Annotations": [
            "Competing_trial 0 179--*--Patient has participated in a combination trial where ruxolitinib was dispensed in combination with another study medication and the patient is still receiving combination therapy",
            "Pregnancy_considerations 182 374--*--Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.",
            "Pregnancy_considerations 376 611--*--Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study duration inclusive of the 30-day safety follow up"
        ],
        "Text": "Patient has participated in a combination trial where ruxolitinib was dispensed in combination with another study medication and the patient is still receiving combination therapy.. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study duration inclusive of the 30-day safety follow up.. "
    },
    "NCT03067740_inc": {
        "Text": "Patients are of American Society of Anesthesiologists (ASA) physical status I and II, aged 8-14 years old, of both gender, with suspected acute appendicitis scheduled for laparoscopic appendicectomy.. ",
        "Annotations": [
            "Measurement 16 53;60 75--*--American Society of Anesthesiologists physical status",
            "Measurement 55 58--*--ASA",
            "Value 76 84--*--I and II",
            "Person 86 90--*--aged",
            "Value 91 105--*--8-14 years old",
            "Person 110 121--*--both gender",
            "Mood 128 137--*--suspected",
            "Condition 138 156--*--acute appendicitis",
            "Mood 157 170--*--scheduled for",
            "Procedure 171 198--*--laparoscopic appendicectomy"
        ]
    },
    "NCT01959061_inc": {
        "Text": "Histologically confirmed colorectal adenocarcinoma. Disease limited to the liver Unresectable disease by surgery or other local therapies. Age >18 years. ECOG performance status 0-2,Child pugh A or B. Expected survival = 3 months. Adequate hematological, hepatic, and renal function. ",
        "Annotations": [
            "Qualifier 0 24--*--Histologically confirmed",
            "Procedure 0 14--*--Histologically",
            "Condition 25 50--*--colorectal adenocarcinoma",
            "Observation 52 80--*--Disease limited to the liver",
            "Condition 81 101--*--Unresectable disease",
            "Procedure 105 112--*--surgery",
            "Procedure 122 137--*--local therapies",
            "Qualifier 116 121--*--other",
            "Scope 105 137--*--surgery or other local therapies",
            "Person 139 142--*--Age",
            "Value 143 152--*-->18 years",
            "Measurement 154 177--*--ECOG performance status",
            "Value 178 181--*--0-2",
            "Measurement 182 192--*--Child pugh",
            "Value 193 194--*--A",
            "Value 198 199--*--B",
            "Scope 193 199--*--A or B",
            "Observation 201 218--*--Expected survival",
            "Value 219 229--*--= 3 months",
            "Qualifier 231 239--*--Adequate",
            "Measurement 268 282--*--renal function",
            "Measurement 255 262;274 282--*--hepatic function",
            "Measurement 240 253;274 282--*--hematological function",
            "Scope 240 282--*--hematological, hepatic, and renal function"
        ]
    },
    "NCT03011177_inc": {
        "Annotations": [
            "Person 20 25--*--years",
            "Value 17 19;26 34--*--19 or older",
            "Temporal 35 47--*--on screening",
            "Reference_point 38 47--*--screening",
            "Condition 63 87--*--type 2 diabetes mellitus",
            "Measurement 110 115--*--HbA1c",
            "Value 103 107;118 123--*--7.0% 11.0%",
            "Temporal 124 146--*--at the screening visit",
            "Reference_point 131 140--*--screening",
            "Measurement 162 184--*--Fasting Plasma Glucose",
            "Value 185 194--*--<15mmol/L",
            "Value 195 203--*--270mg/dL",
            "Temporal 205 217--*--on screening",
            "Reference_point 208 217--*--screening"
        ],
        "Text": "Patients who are 19 years or older on screening. Patients with type 2 diabetes mellitus. Patients with 7.0% = HbA1c = 11.0% at the screening visit. Patients with Fasting Plasma Glucose <15mmol/L(270mg/dL) on screening. "
    },
    "NCT02650024_inc": {
        "Text": "Adult (= 18 years old) subjects with chronic genotype 1 HCV and NCI with a GDS greater than or equal to 0.5 (n=60).. Presence of chronic HCV infection based on chart review will be defined as positive for anti-HCV antibody or HCV RNA at least 6 months before screening.. For the HIV/HCV co-infected group only, subjects must have HIV. HIV status will be obtained through self report. Self report will be confirmed at screening using a HIV-1 point of care test. In the event that point of care test and self-report are discordant, then HIV status will be confirmed by a licensed Western blot or a second antibody test.. HIV/HCV co-infected subjects (n=12) must also have a HIV RNA measurement <50 copies/mL at the pre-treatment visit.. Platelets >150,000. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) <10x upper limit of normal. Creatinine clearance >30 milliliters/minute/1.73 centimeter squared. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Value 7 21--*--= 18 years old",
            "Person 18 21--*--old",
            "Qualifier 45 55--*--genotype 1",
            "Temporal 37 44--*--chronic",
            "Condition 56 59--*--HCV",
            "Condition 64 67--*--NCI",
            "Measurement 75 78--*--GDS",
            "Value 79 107--*--greater than or equal to 0.5",
            "Scope 56 67--*--HCV and NCI",
            "Temporal 129 136--*--chronic",
            "Condition 137 150--*--HCV infection",
            "Measurement 205 222--*--anti-HCV antibody",
            "Value 192 200--*--positive",
            "Measurement 226 233--*--HCV RNA",
            "Scope 205 233--*--anti-HCV antibody or HCV RNA",
            "Temporal 234 268--*--at least 6 months before screening",
            "Non-representable 271 617--*--For the HIV/HCV co-infected group only, subjects must have HIV. HIV status will be obtained through self report. Self report will be confirmed at screening using a HIV-1 point of care test. In the event that point of care test and self-report are discordant, then HIV status will be confirmed by a licensed Western blot or a second antibody test.",
            "Condition 619 622--*--HIV",
            "Condition 623 626--*--HCV",
            "Condition 627 638--*--co-infected",
            "Measurement 672 691--*--HIV RNA measurement",
            "Value 692 705--*--<50 copies/mL",
            "Temporal 706 732--*--at the pre-treatment visit",
            "Measurement 735 744--*--Platelets",
            "Scope 619 638--*--HIV/HCV co-infected",
            "Value 745 753--*-->150,000",
            "Measurement 755 787--*--Aspartate aminotransferase (AST)",
            "Measurement 788 818--*--Alanine aminotransferase (ALT)",
            "Value 819 845--*--<10x upper limit of normal",
            "Measurement 847 867--*--Creatinine clearance",
            "Value 868 914--*-->30 milliliters/minute/1.73 centimeter squared"
        ]
    },
    "NCT02903407_exc": {
        "Text": "Exclusion criteria include patients following resuscitation from cardiac arrest who are treated on the cooling protocol. patients who have suffered a neurologic event (seizure, stroke) or who have baseline dementia, both of which could limit delirium assessment. patients with child class B and C liver disease. patients with known allergy to study medications.. ",
        "Annotations": [
            "Procedure 46 79--*--resuscitation from cardiac arrest",
            "Qualifier 103 119--*--cooling protocol",
            "Condition 150 166--*--neurologic event",
            "Condition 168 175--*--seizure",
            "Condition 177 183--*--stroke",
            "Scope 168 183--*--seizure, stroke",
            "Condition 197 214--*--baseline dementia",
            "Non-representable 216 261--*--both of which could limit delirium assessment",
            "Measurement 277 288--*--child class",
            "Condition 297 310--*--liver disease",
            "Value 289 290--*--B",
            "Value 295 296--*--C",
            "Scope 289 296--*--B and C",
            "Condition 332 339--*--allergy",
            "Drug 343 360--*--study medications"
        ]
    },
    "NCT00599924_inc": {
        "Text": "Advanced solid tumor malignancy (during expansion at the maximum tolerated dose, entry will be limited to patients wtih adenocarcinoma of the colon or rectum) . Eastern Cooperative Oncology Group (ECOG) 0 or 1 . ",
        "Annotations": [
            "Condition 0 31--*--Advanced solid tumor malignancy",
            "Parsing_Error 33 157--*--during expansion at the maximum tolerated dose, entry will be limited to patients wtih adenocarcinoma of the colon or rectum",
            "Measurement 160 201--*--Eastern Cooperative Oncology Group (ECOG)",
            "Value 202 208--*--0 or 1"
        ]
    },
    "NCT02584140_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Temporal 10 23--*--at enrollment",
            "Reference_point 13 23--*--enrollment",
            "Subjective_judgement 26 301--*--Any condition, which in the opinion of the provider, will seriously compromise the participant's ability to comply with the protocol, including adherence to PrEP medication dosing, such as active, untreated or unstable major mental illness (i.e. untreated psychotic disorder)",
            "Qualifier 369 380--*--nephrotoxic",
            "Procedure 350 356--*--agents",
            "Procedure 384 389--*--drugs",
            "Qualifier 390 413--*--slow in renal excretion",
            "Undefined_semantics 304 333--*--Use of prohibited medications",
            "Observation 445 462--*--HIV vaccine trial",
            "Person 425 438--*--participation",
            "Temporal 416 424--*--Previous",
            "Person 464 476--*--Participants",
            "Procedure 520 527--*--placebo",
            "Mood 532 535--*--not",
            "Condition 580 601--*--Primary HIV Infection",
            "Condition 603 606--*--PHI",
            "Condition 556 564--*--symptoms",
            "Condition 547 552--*--Signs",
            "Scope 547 564--*--Signs or symptoms"
        ],
        "Text": "Pregnancy at enrollment.. Any condition, which in the opinion of the provider, will seriously compromise the participant's ability to comply with the protocol, including adherence to PrEP medication dosing, such as active, untreated or unstable major mental illness (i.e. untreated psychotic disorder).. Use of prohibited medications, in particular, agents known to be nephrotoxic or drugs slow in renal excretion.. Previous participation in an HIV vaccine trial. Participants that were documented to have received only placebo are not excluded.. Signs or symptoms suspicious for Primary HIV Infection (PHI).. "
    },
    "NCT00959569_exc": {
        "Annotations": [
            "Condition 9 25--*--unusual response",
            "Drug 29 36--*--esmolol",
            "Competing_trial 38 75--*--inclusion in other randomized studies",
            "Drug 77 84--*--esmolol",
            "Temporal 100 123--*--in the previous 30 days",
            "Procedure 135 144--*--operation",
            "Qualifier 125 134--*--emergency"
        ],
        "Text": "previous unusual response to esmolol. inclusion in other randomized studies. esmolol administration in the previous 30 days. emergency operation. "
    },
    "NCT01806558_inc": {
        "Text": "1. Have a finding of a mass lesion on mammography or breast MRI (BIRADS 0, 4 or 5) that is >0.5 cm and < 2 cm in size and has had or will have additional workup with focused ultrasound. . 2. Have a finding of a mass lesion on ultrasound (BIRADS 0, 4 or 5) that is > 0.5 cm and < 2 cm in size. . 3. Have a positive finding on MBI that is < 2 cm in size and requires additional diagnostic workup with focused ultrasound. . ",
        "Annotations": [
            "Condition 23 34--*--mass lesion",
            "Procedure 38 49--*--mammography",
            "Procedure 53 63--*--breast MRI",
            "Measurement 65 71--*--BIRADS",
            "Value 72 81--*--0, 4 or 5",
            "Condition 210 221--*--mass lesion",
            "Value 91 109--*-->0.5 cm and < 2 cm",
            "Measurement 113 117--*--size",
            "Scope 38 82--*--mammography or breast MRI (BIRADS 0, 4 or 5)",
            "Non-query-able 122 184--*--has had or will have additional workup with focused ultrasound",
            "Procedure 225 235--*--ultrasound",
            "Measurement 237 243--*--BIRADS",
            "Value 244 253--*--0, 4 or 5",
            "Value 263 282--*--> 0.5 cm and < 2 cm",
            "Measurement 286 290--*--size",
            "Grammar_Error 323 326--*--MBI",
            "Procedure 323 326--*--MBI",
            "Condition 303 319--*--positive finding",
            "Undefined_semantics 303 319--*--positive finding",
            "Value 335 341--*--< 2 cm",
            "Measurement 345 349--*--size",
            "Undefined_semantics 354 415--*--requires additional diagnostic workup with focused ultrasound",
            "Subjective_judgement 354 415--*--requires additional diagnostic workup with focused ultrasound"
        ]
    },
    "NCT03068897_inc": {
        "Annotations": [
            "Visit 11 13--*--ED",
            "Condition 40 43--*--LBP",
            "Observation 0 7--*--Present",
            "Condition 56 60--*--pain",
            "Qualifier 73 141--*--between the lower border of the scapulae and the upper gluteal folds",
            "Scope 0 43--*--Present to ED primary for management of LBP",
            "Scope 56 141--*--pain originating between the lower border of the scapulae and the upper gluteal folds",
            "Condition 143 153--*--Flank pain",
            "Condition 163 167--*--pain",
            "Qualifier 185 226--*--tissues lateral to the paraspinal muscles",
            "Negation 233 236--*--not",
            "Condition 342 365--*--urinary tract infection",
            "Condition 267 275--*--etiology",
            "Negation 303 306--*--non",
            "Condition 323 333--*--etiologies",
            "Qualifier 279 287--*--low back",
            "Condition 367 380--*--ovarian cysts",
            "Condition 385 407--*--influenza like illness",
            "Negation 416 424--*--excluded",
            "Scope 303 333--*--non-musculoskeletal etiologies",
            "Scope 342 407--*--urinary tract infection, ovarian cysts, or influenza like illness",
            "Condition 575 578--*--LBP",
            "Qualifier 544 557--*--non-radicular",
            "Qualifier 529 542--*--non-traumatic",
            "Qualifier 559 574--*--musculoskeletal",
            "Scope 251 287--*--Musculoskeletal etiology of low back",
            "Scope 529 578--*--non-traumatic, non-radicular, musculoskeletal LBP",
            "Non-representable 581 755--*--Patient is to be discharged home. Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study.",
            "Person 757 760--*--Age",
            "Value 761 766--*--18-64",
            "Person 797 803--*--adults",
            "Value 804 825--*--younger than 65 years",
            "Condition 859 866;878 885--*--adverse effects",
            "Drug 867 877--*--medication",
            "Person 893 900--*--elderly",
            "Mood 841 855--*--increased risk",
            "Negation 903 906--*--Non",
            "Qualifier 907 916--*--radicular",
            "Condition 917 921--*--pain",
            "Qualifier 307 322--*--musculoskeletal",
            "Qualifier 251 266--*--Musculoskeletal",
            "Negation 940 948--*--excluded",
            "Condition 956 960--*--pain",
            "Qualifier 970 1016--*--below the gluteal folds in a radicular pattern",
            "Condition 1019 1023--*--Pain",
            "Temporal 1024 1041--*--duration <2 weeks",
            "Temporal 1024 1032;1043 1052--*--duration 336 hours",
            "Scope 1024 1053--*--duration <2 weeks (336 hours)",
            "Temporal 1174 1179--*--acute",
            "Condition 1180 1193--*--attack of LBP",
            "Negation 1205 1211--*--cannot",
            "Condition 1195 1204--*--back pain",
            "Temporal 1161 1193--*--Prior to the acute attack of LBP",
            "Reference_point 1174 1193--*--acute attack of LBP",
            "Multiplier 1218 1253--*--more frequently than once per month",
            "Condition 1371 1374--*--LBP",
            "Qualifier 1357 1370--*--Non-traumatic",
            "Qualifier 1395 1401--*--direct",
            "Qualifier 1379 1390--*--substantial",
            "Condition 1402 1408--*--trauma",
            "Scope 1379 1401--*--substantial and direct",
            "Negation 1376 1378--*--no",
            "Qualifier 1416 1420--*--back",
            "Temporal 1421 1446--*--within the previous month",
            "Scope 1376 1446--*--no substantial and direct trauma to the back within the previous month",
            "Scope 1357 1374--*--Non-traumatic LBP",
            "Qualifier 1448 1470--*--Functionally impairing",
            "Condition 1471 1480--*--back pain",
            "Measurement 1513 1551--*--Roland-Morris Disability Questionnaire",
            "Temporal 1484 1492--*--baseline",
            "Value 1493 1505--*--score of > 5",
            "Scope 1448 1480--*--Functionally impairing back pain",
            "Scope 1484 1551--*--baseline score of > 5 on the Roland-Morris Disability Questionnaire"
        ],
        "Text": "Present to ED primary for management of LBP, defined as pain originating between the lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included.. Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded. The primary clinical diagnosis, at the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.. Patient is to be discharged home. Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study.. Age 18-64 Enrollment will be limited to adults younger than 65 years because of the increased risk of adverse medication effects in the elderly.. Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern.. Pain duration <2 weeks (336 hours). Patients with more than two weeks of pain are at increased risk of poor pain and functional outcomes.(9). Prior to the acute attack of LBP, back pain cannot occur more frequently than once per month. Patients with more frequent back pain are at increased risk of poor pain and functional outcomes.(9). Non-traumatic LBP: no substantial and direct trauma to the back within the previous month. Functionally impairing back pain: A baseline score of > 5 on the Roland-Morris Disability Questionnaire. "
    },
    "NCT02944604_inc": {
        "Annotations": [
            "Qualifier 0 6--*--Severe",
            "Qualifier 10 22--*--uncontrolled",
            "Condition 23 32--*--infection",
            "Scope 0 22--*--Severe or uncontrolled",
            "Condition 35 44--*--Sensitive",
            "Drug 48 59--*--the product",
            "Qualifier 63 68--*--other",
            "Drug 69 111--*--genetically engineered biological products",
            "Qualifier 117 141--*--Escherichia coli strains",
            "Condition 144 150;169 178--*--Mental disorders",
            "Condition 154 178--*--nervous system disorders",
            "Qualifier 181 187--*--Severe",
            "Condition 188 193;227 236--*--heart disorders",
            "Condition 195 199;227 236--*--lung disorders",
            "Condition 205 236--*--entral nervous system disorders",
            "Scope 188 236--*--heart, lung and central nervous system disorders",
            "Condition 239 247--*--Pregnant",
            "Condition 251 260--*--lactating",
            "Person 261 266--*--women",
            "Measurement 274 289--*--total bilirubin",
            "Measurement 269 273--*--TBIL",
            "Measurement 293 296--*--ALT",
            "Measurement 297 321--*--alanine aminotransferase",
            "Measurement 323 326--*--AST",
            "Measurement 327 359--*--glutamic-oxalacetic transaminase",
            "Value 361 370--*--> 2.5\u00d7ULN",
            "Condition 416 432--*--liver metastases",
            "Measurement 434 438--*--TBIL",
            "Measurement 440 443--*--ALT",
            "Measurement 444 447--*--AST",
            "Value 448 454--*-->5\u00d7ULN",
            "Measurement 457 459--*--Cr",
            "Measurement 460 470--*--creatinine",
            "Value 472 480--*-->1.5\u00d7ULN",
            "Scope 269 370--*--TBIL(total bilirubin ), ALT(alanine aminotransferase),AST(glutamic-oxalacetic transaminase) > 2.5\u00d7ULN",
            "Scope 416 454--*--liver metastases, TBIL, ALT,AST >5\u00d7ULN"
        ],
        "Text": "Severe or uncontrolled infection.. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.. Mental or nervous system disorders.. Severe heart, lung and central nervous system disorders.. Pregnant or lactating women.. TBIL(total bilirubin ), ALT(alanine aminotransferase),AST(glutamic-oxalacetic transaminase) > 2.5\u00d7ULN(upper limit of normal); if it were caused by liver metastases, TBIL, ALT,AST >5\u00d7ULN.. Cr(creatinine) >1.5\u00d7ULN.. "
    },
    "NCT02370069_exc": {
        "Annotations": [
            "Procedure 0 12--*--immunization",
            "Drug 18 23--*--PPV23",
            "Temporal 24 44--*--within the last year",
            "Condition 73 99--*--immunodeficiency condition",
            "Qualifier 63 72--*--suspected",
            "Qualifier 50 59--*--confirmed",
            "Condition 111 139;146 155--*--human immunodeficiency virus infection",
            "Condition 141 144--*--HIV",
            "Condition 157 182--*--haematological malignancy",
            "Condition 189 216--*--congenital immunodeficiency",
            "Scope 111 216--*--human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency",
            "Scope 50 72--*--confirmed or suspected",
            "Condition 229 245--*--allergic disease",
            "Condition 229 237;249 258--*--allergic reactions",
            "Scope 229 258--*--allergic disease or reactions",
            "Qualifier 272 315--*--exacerbated by any component of the vaccine",
            "Procedure 308 315--*--vaccine",
            "Condition 328 344--*--allergic disease",
            "Qualifier 358 387--*--stimulated by the vaccination",
            "Procedure 376 387--*--vaccination",
            "Procedure 411 436--*--immunosuppressive therapy",
            "Procedure 460 483--*--topical corticosteroids",
            "Negation 447 456--*--exception",
            "Temporal 485 506;527 541--*--for more than 14 days of vaccination",
            "Temporal 511 541--*--within 6 months of vaccination",
            "Scope 485 541--*--for more than 14 days and within 6 months of vaccination",
            "Reference_point 530 541--*--vaccination",
            "Procedure 584 599--*--immunoglobulins",
            "Procedure 611 625--*--blood products",
            "Temporal 626 649--*--during the study period",
            "Temporal 653 704--*--within the three months preceding the study vaccine",
            "Reference_point 637 649--*--study period",
            "Reference_point 691 704--*--study vaccine",
            "Grammar_Error 600 606--*--and/or",
            "Scope 584 625--*--immunoglobulins and/or any blood products",
            "Scope 626 704--*--during the study period or within the three months preceding the study vaccine",
            "Procedure 765 772--*--vaccine",
            "Procedure 757 761--*--drug",
            "Qualifier 723 738--*--investigational",
            "Qualifier 742 756--*--non-registered",
            "Scope 757 772--*--drug or vaccine",
            "Scope 723 756--*--investigational or non-registered",
            "Temporal 773 796--*--during the study period",
            "Temporal 800 842--*--within 30 days preceding the study vaccine",
            "Reference_point 784 796--*--study period",
            "Reference_point 829 842--*--study vaccine",
            "Scope 773 842--*--during the study period or within 30 days preceding the study vaccine",
            "Procedure 864 871--*--vaccine",
            "Temporal 872 962--*--during the period starting one month before the dose of vaccine and ending one month after",
            "Reference_point 916 935--*--the dose of vaccine",
            "Procedure 928 935--*--vaccine",
            "Condition 964 973--*--pregnancy"
        ],
        "Text": "immunization with PPV23 within the last year. any confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency. history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. history of allergic disease likely to be stimulated by the vaccination. history or records of immunosuppressive therapy (with the exception of topical corticosteroids) for more than 14 days and within 6 months of vaccination. history or evidence of administration of immunoglobulins and/or any blood products during the study period or within the three months preceding the study vaccine. use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the study vaccine. administration of a vaccine during the period starting one month before the dose of vaccine and ending one month after. pregnancy. "
    },
    "NCT03404479_inc": {
        "Text": "Subjects who voluntarily consented, after listening enough explanation for this study and investigational product.. Adult over 50 years of age.. At least one of the knee pain VAS score is 40mm or more.. Patients who require medication for more than 12 weeks due to osteoarthritis symptoms.. Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire.. Those who weigh more than 40kg. ",
        "Annotations": [
            "Informed_consent 0 114--*--Subjects who voluntarily consented, after listening enough explanation for this study and investigational product.",
            "Person 116 121--*--Adult",
            "Value 122 135--*--over 50 years",
            "Person 139 142--*--age",
            "Multiplier 145 157--*--At least one",
            "Condition 165 174--*--knee pain",
            "Measurement 175 184--*--VAS score",
            "Value 188 200--*--40mm or more",
            "Drug 224 234--*--medication",
            "Multiplier 239 257--*--more than 12 weeks",
            "Condition 265 288--*--osteoarthritis symptoms",
            "Non-query-able 291 466--*--Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire.",
            "Measurement 478 483--*--weigh",
            "Value 484 498--*--more than 40kg"
        ]
    },
    "NCT03354572_inc": {
        "Text": "Subjects scheduled for laparoscopic unilateral inguinal hernia repair. ASA 1 or2.. Age >18 years.. ",
        "Annotations": [
            "Mood 9 18--*--scheduled",
            "Qualifier 23 35--*--laparoscopic",
            "Procedure 47 69--*--inguinal hernia repair",
            "Qualifier 36 46--*--unilateral",
            "Measurement 71 74--*--ASA",
            "Value 75 80--*--1 or2",
            "Person 83 86--*--Age",
            "Value 87 96--*-->18 years"
        ]
    },
    "NCT01959061_exc": {
        "Text": "Pregnant or lactating women. Patients with severe organ dysfunction or failure. With severe cardiovascular disease, or mental. Extraliver metastases. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Condition 12 21--*--lactating",
            "Person 22 27--*--women",
            "Qualifier 43 49--*--severe",
            "Condition 50 67--*--organ dysfunction",
            "Condition 50 55;71 78--*--organ failure",
            "Scope 50 78--*--organ dysfunction or failure",
            "Condition 92 114--*--cardiovascular disease",
            "Condition 107 114;119 125--*--disease mental",
            "Qualifier 85 91--*--severe",
            "Scope 92 126--*--cardiovascular disease, or mental",
            "Condition 127 148--*--Extraliver metastases",
            "Qualifier 127 137--*--Extraliver",
            "Condition 138 148--*--metastases"
        ]
    },
    "NCT03067740_exc": {
        "Text": "The diagnosis of developmental delay, attention deficit disorder, chronic pain, psychiatric illness, previous open abdominal surgery, the presence of a gastrostomy, ventricular-peritoneal shunt or other abdominal prosthesis, immunosuppression, and those allergic to any of the medications.. ",
        "Annotations": [
            "Condition 17 36--*--developmental delay",
            "Condition 38 64--*--attention deficit disorder",
            "Condition 66 78--*--chronic pain",
            "Condition 80 99--*--psychiatric illness",
            "Temporal 101 109--*--previous",
            "Procedure 110 132--*--open abdominal surgery",
            "Device 152 163--*--gastrostomy",
            "Device 165 193--*--ventricular-peritoneal shunt",
            "Device 203 223--*--abdominal prosthesis",
            "Condition 225 242--*--immunosuppression",
            "Condition 254 262--*--allergic",
            "Drug 266 288--*--any of the medications"
        ]
    },
    "NCT03011177_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02386800_inc": {
        "Annotations": [
            "Competing_trial 0 321--*--Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol.",
            "Drug 379 390--*--ruxolitinib",
            "Non-query-able 323 425--*--Patient is currently benefiting from the treatment with ruxolitinib, as determined by the investigator",
            "Post-eligibility 427 644--*--Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures",
            "Condition 683 702--*--progressive disease",
            "Drug 773 784--*--ruxolitinib",
            "Informed_consent 786 1021--*--Written informed consent obtained prior to enrolling in roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness"
        ],
        "Text": "Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol.. Patient is currently benefiting from the treatment with ruxolitinib, as determined by the investigator. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. Patient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib. Written informed consent obtained prior to enrolling in roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.. "
    },
    "NCT03373669_exc": {
        "Text": "Presence of a significant medical or psychiatric condition (Examples include: Diagnosis and treatment of tuberculosis (TB) or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function, such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues). Ever having received oral cholera vaccine.. Receipt of an investigational product (within 30 days before vaccination).. History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).. History of chronic diarrhea (lasting for more than 2 weeks in the past 6 months). Current use of laxatives, antacids, or other agents to lower stomach acidity?. Planning to become pregnant in the next 2 years.. ",
        "Annotations": [
            "Condition 37 58--*--psychiatric condition",
            "Condition 26 33;49 58--*--medical condition",
            "Qualifier 14 25--*--significant",
            "Scope 26 58--*--medical or psychiatric condition",
            "Condition 105 122--*--tuberculosis (TB)",
            "Condition 126 129--*--HIV",
            "Procedure 92 101--*--treatment",
            "Condition 131 150--*--renal insufficiency",
            "Condition 152 167--*--hepatic disease",
            "Drug 177 198--*--parenteral medication",
            "Drug 169 173;188 198--*--oral medication",
            "Qualifier 199 234--*--known to affect the immune function",
            "Scope 169 198--*--oral or parenteral medication",
            "Drug 244 259--*--corticosteroids",
            "Drug 267 290--*--immunosuppressant drugs",
            "Qualifier 261 266--*--other",
            "Condition 295 306;317 323--*--behavioural issues",
            "Condition 310 323--*--memory issues",
            "Scope 295 323--*--behavioural or memory issues",
            "Scope 244 323--*--corticosteroids, other immunosuppressant drugs; or behavioural or memory issues",
            "Scope 169 234--*--oral or parenteral medication known to affect the immune function",
            "Scope 92 323--*--treatment of tuberculosis (TB) or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function, such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues",
            "Drug 347 367--*--oral cholera vaccine",
            "Competing_trial 370 444--*--Receipt of an investigational product (within 30 days before vaccination).",
            "Condition 457 466--*--diarrhoea",
            "Temporal 467 507--*--in 7 days prior to first dose of vaccine",
            "Reference_point 486 507--*--first dose of vaccine",
            "Value 520 522--*--=3",
            "Measurement 523 556--*--unformed loose stools in 24 hours",
            "Condition 571 587--*--chronic diarrhea",
            "Observation 560 567--*--History",
            "Observation 446 453--*--History",
            "Multiplier 589 618--*--lasting for more than 2 weeks",
            "Temporal 619 639--*--in the past 6 months",
            "Drug 657 666--*--laxatives",
            "Drug 668 676--*--antacids",
            "Drug 687 718--*--agents to lower stomach acidity",
            "Qualifier 681 686--*--other",
            "Pregnancy_considerations 721 769--*--Planning to become pregnant in the next 2 years."
        ]
    },
    "NCT02224040_exc": {
        "Text": "Allergy to ceftriaxone or macrolides . Major typhoid fever-associated complications . Inability to swallow oral medication . Underlying illness . Pregnancy . Lactation . Treatment within the past 4 days with an antibiotic that may be effective against typhoid fever       .     . ",
        "Annotations": [
            "Drug 11 22--*--ceftriaxone",
            "Drug 26 36--*--macrolides",
            "Condition 0 7--*--Allergy",
            "Scope 11 36--*--ceftriaxone or macrolides",
            "Qualifier 44 68--*--typhoid fever-associated",
            "Condition 44 57--*--typhoid fever",
            "Condition 69 82--*--complications",
            "Qualifier 38 43--*--Major",
            "Subjective_judgement 38 43--*--Major",
            "Drug 105 120--*--oral medication",
            "Condition 84 120--*--Inability to swallow oral medication",
            "Condition 122 140--*--Underlying illness",
            "Undefined_semantics 122 140--*--Underlying illness",
            "Condition 142 151--*--Pregnancy",
            "Condition 153 162--*--Lactation",
            "Temporal 174 196--*--within the past 4 days",
            "Drug 205 215--*--antibiotic",
            "Qualifier 228 259--*--effective against typhoid fever",
            "Condition 246 259--*--typhoid fever"
        ]
    },
    "NCT03347513_inc": {
        "Text": "Diagnosed Iron deficiency anemia.. H-pylori positive cases.. Second trimester pregnancy.. ",
        "Annotations": [
            "Condition 10 32--*--Iron deficiency anemia",
            "Condition 35 52--*--H-pylori positive",
            "Qualifier 61 77--*--Second trimester",
            "Condition 78 87--*--pregnancy",
            "Temporal 61 77--*--Second trimester"
        ]
    },
    "NCT03106389_inc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT01639664_exc": {
        "Text": "Age less than 14 years. Pregnancy. Estimated life expectancy (due to comorbidities) less than 90 days. Presence of relative or absolute contraindications to CPFA. Admission from an other ICU where the patient remained for more than 24 hours. Absence of informed consent. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--less than 14 years",
            "Condition 24 33--*--Pregnancy",
            "Person 35 60--*--Estimated life expectancy",
            "Value 84 101--*--less than 90 days",
            "Condition 115 123;136 153--*--relative contraindications",
            "Condition 127 153--*--absolute contraindications",
            "Procedure 157 161--*--CPFA",
            "Scope 115 153--*--relative or absolute contraindications",
            "Procedure 163 172--*--Admission",
            "Visit 178 190--*--an other ICU",
            "Observation 201 217--*--patient remained",
            "Multiplier 218 240--*--for more than 24 hours",
            "Informed_consent 242 269--*--Absence of informed consent"
        ]
    },
    "NCT03373669_inc": {
        "Text": "Age =1 year, stratified into different age groups. Living in the Waya Clinic Catchment Area. Good health condition, without clinically significant medical history (by participant or guardian, in case of minor). Not pregnant for female subjects.. Available to participate for the study duration, including all planned follow-up visits for up to 9 months from screening.. Signed informed consent. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 11--*--=1 year",
            "Non-representable 13 49--*--stratified into different age groups",
            "Visit 65 91--*--Waya Clinic Catchment Area",
            "Person 51 57--*--Living",
            "Condition 93 114--*--Good health condition",
            "Negation 116 123--*--without",
            "Qualifier 124 146--*--clinically significant",
            "Observation 147 162--*--medical history",
            "Negation 211 214--*--Not",
            "Condition 215 223--*--pregnant",
            "Person 228 234--*--female",
            "Post-eligibility 246 368--*--Available to participate for the study duration, including all planned follow-up visits for up to 9 months from screening.",
            "Informed_consent 370 393--*--Signed informed consent"
        ]
    },
    "NCT02224040_inc": {
        "Text": "Blood culture-proven typhoid fever (S. typhi or S. paratyphi) . Signed informed consent to participate in the study. . ",
        "Annotations": [
            "Measurement 0 13--*--Blood culture",
            "Value 14 20--*--proven",
            "Condition 21 34--*--typhoid fever",
            "Condition 36 44--*--S. typhi",
            "Condition 48 60--*--S. paratyphi",
            "Scope 36 60--*--S. typhi or S. paratyphi",
            "Post-eligibility 63 115--*--Signed informed consent to participate in the study.",
            "Non-query-able 63 115--*--Signed informed consent to participate in the study."
        ]
    },
    "NCT03347513_exc": {
        "Text": "Severe Iron deficiency anemia (hemoglobin < 8.0 g/dL).. Parasitic worm infection e.g. schistosomiasis, and hook worm by stool analysis.. Any cases giving clinical symptoms of gastritis e.g. nausea, vomiting, dull aching pain or soreness in the epigastrium.. Cases with history of gastric ulcer diagnosed by upper endoscopy.. Cases complaining of hematemesis.. ",
        "Annotations": [
            "Qualifier 0 6--*--Severe",
            "Condition 7 29--*--Iron deficiency anemia",
            "Measurement 31 41--*--hemoglobin",
            "Value 42 52--*--< 8.0 g/dL",
            "Scope 31 52--*--hemoglobin < 8.0 g/dL",
            "Scope 0 29--*--Severe Iron deficiency anemia",
            "Condition 56 80--*--Parasitic worm infection",
            "Condition 86 101--*--schistosomiasis",
            "Condition 107 116--*--hook worm",
            "Procedure 120 134--*--stool analysis",
            "Scope 86 116--*--schistosomiasis, and hook worm",
            "Mood 154 171--*--clinical symptoms",
            "Condition 175 184--*--gastritis",
            "Condition 190 196--*--nausea",
            "Condition 198 206--*--vomiting",
            "Condition 208 224--*--dull aching pain",
            "Condition 228 255--*--soreness in the epigastrium",
            "Scope 190 255--*--nausea, vomiting, dull aching pain or soreness in the epigastrium",
            "Scope 154 184--*--clinical symptoms of gastritis",
            "Condition 280 293--*--gastric ulcer",
            "Observation 269 276--*--history",
            "Procedure 307 322--*--upper endoscopy",
            "Condition 346 357--*--hematemesis"
        ]
    },
    "NCT01639664_inc": {
        "Text": "All patients admitted to the ICU in septic shock. All patients that develop septic shock while in the ICU. ",
        "Annotations": [
            "Procedure 13 21--*--admitted",
            "Visit 29 32--*--ICU",
            "Condition 36 48--*--septic shock",
            "Condition 76 88--*--septic shock",
            "Temporal 89 105--*--while in the ICU",
            "Reference_point 95 105--*--in the ICU"
        ]
    },
    "NCT03106389_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT03018171_exc": {
        "Text": "Suspect or certainty of fetal malformation,. Presence of conditions such as preeclampsia, multiparity, preterm labor. History of adverse reaction to a-2 adrenergic agonists. Nicotine addiction. Chronic use of opioid. ",
        "Annotations": [
            "Condition 24 42--*--fetal malformation",
            "Mood 11 20--*--certainty",
            "Mood 0 7--*--Suspect",
            "Scope 0 20--*--Suspect or certainty",
            "Condition 76 88--*--preeclampsia",
            "Condition 90 101--*--multiparity",
            "Condition 103 116--*--preterm labor",
            "Condition 129 145--*--adverse reaction",
            "Drug 149 172--*--a-2 adrenergic agonists",
            "Condition 174 192--*--Nicotine addiction",
            "Multiplier 194 205--*--Chronic use",
            "Drug 209 214--*--opioi"
        ]
    },
    "NCT02083991_inc": {
        "Text": "First or second single kidney (cadaveric or living donors) transplant recipients.. Considered for a standard immunosuppressive protocol.. Must be capable of giving written informed connect for participation in the study for 24 months.. ",
        "Annotations": [
            "Procedure 59 69;9 29--*--transplant second single kidney",
            "Procedure 0 5;16 29;59 69--*--First single kidney transplant",
            "Qualifier 31 40;51 57--*--cadaveric donors",
            "Qualifier 44 57--*--living donors",
            "Scope 31 57--*--cadaveric or living donors",
            "Mood 83 97--*--Considered for",
            "Procedure 100 135--*--standard immunosuppressive protocol",
            "Post-eligibility 138 234--*--Must be capable of giving written informed connect for participation in the study for 24 months."
        ]
    },
    "NCT02621541_exc": {
        "Annotations": [
            "Condition 0 10--*--vulnerable",
            "Qualifier 47 86--*--Finnish law concerning clinical studies",
            "Condition 88 96--*--disabled",
            "Person 98 106--*--children",
            "Condition 108 116--*--pregnant",
            "Condition 120 134--*--breast-feeding",
            "Person 135 140--*--women",
            "Observation 142 151--*--prisoners",
            "Scope 0 86--*--vulnerable study subjects such as described in Finnish law concerning clinical studies",
            "Scope 88 151--*--disabled, children, pregnant or breast-feeding women, prisoners"
        ],
        "Text": "vulnerable study subjects such as described in Finnish law concerning clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.. "
    },
    "NCT01911650_inc": {
        "Text": "1. age 18-65 years, inclusive . 2. diagnosis of moderate to severe AT, confirmed by Dr. Wilson using clinical symptoms and exam findings consistent with chronic AT (>6 month duration) - which includes pain while palpating the intratendinous swelling part of the Achilles tendon and relief of pain when tendon placed under tension - and pre-procedure US . 3. self-reported AT-related pain for at least 6 months and VAS (Visual Analog Scale) pain >5 (0-10 scale) . 4. self-reported failure of eccentric exercise protocol (at least 75% completion) . 5. self-reported failure of at least 2 of the 3 most common treatments for AT (NSAIDS, rest/ice or taping) . 6. patient considered surgery but decided to wait and/or refused surgery - . ",
        "Annotations": [
            "Value 7 29--*--18-65 years, inclusive",
            "Person 3 6--*--age",
            "Qualifier 47 65--*--moderate to severe",
            "Condition 66 68--*--AT",
            "Non-query-able 70 93--*--confirmed by Dr. Wilson",
            "Condition 152 162--*--chronic AT",
            "Temporal 164 181--*-->6 month duration",
            "Condition 200 276--*--pain while palpating the intratendinous swelling part of the Achilles tendon",
            "Condition 281 328--*--relief of pain when tendon placed under tension",
            "Condition 370 385--*--AT-related pain",
            "Observation 356 369--*--self-reported",
            "Temporal 386 407--*--for at least 6 months",
            "Measurement 412 442--*--VAS (Visual Analog Scale) pain",
            "Value 443 445--*-->5",
            "Qualifier 447 457--*--0-10 scale",
            "Scope 371 458--*--T-related pain for at least 6 months and VAS (Visual Analog Scale) pain >5 (0-10 scale)",
            "Condition 477 515--*--failure of eccentric exercise protocol",
            "Value 517 529--*--at least 75%",
            "Observation 463 476--*--self-reported",
            "Observation 546 559--*--self-reported",
            "Condition 560 620--*--failure of at least 2 of the 3 most common treatments for AT",
            "Drug 622 628--*--NSAIDS",
            "Procedure 630 634--*--rest",
            "Drug 635 638--*--ice",
            "Procedure 642 648--*--taping",
            "Scope 622 648--*--NSAIDS, rest/ice or taping",
            "Procedure 673 680--*--surgery",
            "Parsing_Error 654 725--*--patient considered surgery but decided to wait and/or refused surgery -"
        ]
    },
    "NCT02443623_exc": {
        "Text": "History of severe related adverse event(s) from previous participation in VA-001 or VA-006 trials or to any smallpox vaccination.. Eczema, history of eczema, exfoliative skin conditions, wounds, burns, or other skin conditions at the investigator's discretion.. A history of immunodeficiency.. Currently or has recently received radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH), corticosteroids, or immunosuppressive drugs.. Eye disease treated with topical steroids.. Known or suspected disorders of immunoglobulin synthesis.. Leukemia, lymphomas of any type, melanoma, or other malignant neoplasms affecting the bone marrow or lymphatic systems.. Has been diagnosed with cancer and who will be undergoing chemotherapy or radiation therapy during the vaccination healing time.. Is a transplant recipient (except for corneal transplant).. Is pregnant, planning pregnancy or breast feeding (female subjects of childbearing potential must have negative pregnancy test prior to vaccination).. Household or other close/intimate contact(s) under the age of 12 months.. History of allergies to phenol, any of the antibiotics listed in the vaccine content, or any other component of ACAM2000 or its diluents.. Subjects with kidney disease (except kidney stones).. Subjects with abnormal EKG at screening (if applicable). To mitigate the risk of enrolling at risk subjects and potentially jeopardizing subject safety an EKG will be performed prior to vaccination with ACAM2000 smallpox vaccine in all potential subjects =50 years old and for all potential subjects <50 with two cardiac risk factors as listed immediately below including; severely or morbidly obese or higher obesity classification (BMI =36); high blood pressure; high blood cholesterol; diabetes or high blood sugar; a first degree relative who had a heart condition before the age of 50; and current tobacco smokers.. Severely or morbidly obese or higher obesity classification (BMI =36). High blood pressure diagnosed by a doctor. High blood cholesterol diagnosed by a doctor. Diabetes or high blood sugar diagnosed by a doctor. A first degree relative (for example, mother, father, brother, sister) who had a heart condition before the age of 50. Currently smokes tobacco (cigarettes). Arrhythmia. Syncope related to cardiac disease. Previous myocardial infarction. Angina. Coronary artery disease. Congestive heart failure. Cardiomyopathy. Stroke or transient ischemic attack. Myocarditis. Pericarditis. Chest pain or shortness of breath with activity (such as climbing stairs), peripheral edema, heart palpitations, dry cough, irregular heartbeat, excessive fatigue, unexplained syncope. Other heart conditions being treated by a physician. ",
        "Annotations": [
            "Condition 26 39--*--adverse event",
            "Procedure 108 128--*--smallpox vaccination",
            "Undefined_semantics 48 97--*--previous participation in VA-001 or VA-006 trials",
            "Condition 131 137--*--Eczema",
            "Observation 139 156--*--history of eczema",
            "Condition 158 185--*--exfoliative skin conditions",
            "Condition 187 193--*--wounds",
            "Condition 195 200--*--burns",
            "Condition 205 226--*--other skin conditions",
            "Subjective_judgement 227 259--*--at the investigator's discretion",
            "Condition 264 291--*--history of immunodeficiency",
            "Procedure 329 341--*--radiotherapy",
            "Procedure 345 357--*--chemotherapy",
            "Temporal 311 319--*--recently",
            "Drug 359 386--*--adrenocorticotropic hormone",
            "Drug 388 392--*--ACTH",
            "Drug 395 410--*--corticosteroids",
            "Procedure 415 438--*--immunosuppressive drugs",
            "Scope 329 438--*--radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH), corticosteroids, or immunosuppressive drugs",
            "Condition 441 452--*--Eye disease",
            "Procedure 466 482--*--topical steroids",
            "Condition 504 541--*--disorders of immunoglobulin synthesis",
            "Qualifier 485 490--*--Known",
            "Qualifier 494 503--*--suspected",
            "Scope 485 503--*--Known or suspected",
            "Condition 544 552--*--Leukemia",
            "Condition 554 563--*--lymphomas",
            "Condition 577 585--*--melanoma",
            "Condition 596 615--*--malignant neoplasms",
            "Qualifier 616 641--*--affecting the bone marrow",
            "Condition 630 641--*--bone marrow",
            "Condition 645 662--*--lymphatic systems",
            "Qualifier 616 625;645 662--*--affecting lymphatic systems",
            "Scope 616 662--*--affecting the bone marrow or lymphatic systems",
            "Condition 674 695--*--diagnosed with cancer",
            "Procedure 723 735--*--chemotherapy",
            "Procedure 739 756--*--radiation therapy",
            "Temporal 757 792--*--during the vaccination healing time",
            "Reference_point 768 792--*--vaccination healing time",
            "Scope 723 756--*--chemotherapy or radiation therapy",
            "Person 800 820--*--transplant recipient",
            "Negation 822 828--*--except",
            "Condition 833 851--*--corneal transplant",
            "Condition 858 866--*--pregnant",
            "Observation 868 886--*--planning pregnancy",
            "Observation 890 904--*--breast feeding",
            "Person 1025 1050--*--close/intimate contact(s)",
            "Person 1061 1064--*--age",
            "Value 1051 1056;1068 1077--*--under 12 months",
            "Person 1006 1015--*--Household",
            "Condition 1091 1100--*--allergies",
            "Drug 1104 1110--*--phenol",
            "Procedure 1123 1134--*--antibiotics",
            "Qualifier 1135 1164--*--listed in the vaccine content",
            "Procedure 1149 1156--*--vaccine",
            "Drug 1192 1200--*--ACAM2000",
            "Drug 1192 1200;1208 1216--*--ACAM2000 diluents",
            "Scope 1104 1217--*--phenol, any of the antibiotics listed in the vaccine content, or any other component of ACAM2000 or its diluents.",
            "Condition 1233 1247--*--kidney disease",
            "Negation 1249 1255--*--except",
            "Condition 1256 1269--*--kidney stones",
            "Procedure 1296 1299--*--EKG",
            "Value 1287 1295--*--abnormal",
            "Temporal 1300 1312--*--at screening",
            "Reference_point 1303 1312--*--screening",
            "Non-query-able 1330 1891--*--To mitigate the risk of enrolling at risk subjects and potentially jeopardizing subject safety an EKG will be performed prior to vaccination with ACAM2000 smallpox vaccine in all potential subjects =50 years old and for all potential subjects <50 with two cardiac risk factors as listed immediately below including; severely or morbidly obese or higher obesity classification (BMI =36); high blood pressure; high blood cholesterol; diabetes or high blood sugar; a first degree relative who had a heart condition before the age of 50; and current tobacco smokers",
            "Condition 1915 1920--*--obese",
            "Qualifier 1906 1914--*--morbidly",
            "Qualifier 1894 1902--*--Severely",
            "Observation 1924 1953--*--higher obesity classification",
            "Measurement 1955 1958--*--BMI",
            "Value 1959 1962--*--=36",
            "Condition 1965 1984--*--High blood pressure",
            "Condition 2008 2030--*--High blood cholesterol",
            "Condition 2054 2062--*--Diabetes",
            "Condition 2066 2082--*--high blood sugar",
            "Person 2106 2129--*--A first degree relative",
            "Condition 2187 2202--*--heart condition",
            "Temporal 2203 2223--*--before the age of 50",
            "Reference_point 2214 2223--*--age of 50",
            "Person 2214 2217--*--age",
            "Value 2221 2223--*--50",
            "Person 2144 2150--*--mother",
            "Person 2152 2158--*--father",
            "Person 2160 2167--*--brother",
            "Person 2169 2175--*--sister",
            "Scope 2144 2175--*--mother, father, brother, sister",
            "Observation 2235 2249--*--smokes tobacco",
            "Observation 2235 2241;2251 2261--*--smokes cigarettes",
            "Condition 2264 2274--*--Arrhythmia",
            "Condition 2276 2283--*--Syncope",
            "Condition 2295 2310--*--cardiac disease",
            "Condition 2312 2342--*--Previous myocardial infarction",
            "Condition 2344 2350--*--Angina",
            "Condition 2352 2375--*--Coronary artery disease",
            "Condition 2377 2401--*--Congestive heart failure",
            "Condition 2403 2417--*--Cardiomyopathy",
            "Condition 2429 2454--*--transient ischemic attack",
            "Condition 2419 2425--*--Stroke",
            "Condition 2456 2467--*--Myocarditis",
            "Condition 2469 2481--*--Pericarditis",
            "Condition 2483 2493--*--Chest pain",
            "Condition 2497 2530--*--shortness of breath with activity",
            "Condition 2558 2574--*--peripheral edema",
            "Condition 2576 2594--*--heart palpitations",
            "Condition 2596 2605--*--dry cough",
            "Condition 2607 2626--*--irregular heartbeat",
            "Condition 2628 2645--*--excessive fatigue",
            "Condition 2659 2666--*--syncope",
            "Condition 2668 2690--*--Other heart conditions",
            "Person 906 912--*--female",
            "Observation 925 947--*--childbearing potential",
            "Value 958 966--*--negative",
            "Measurement 967 981--*--pregnancy test",
            "Temporal 982 1002--*--prior to vaccination",
            "Procedure 991 1002--*--vaccination",
            "Reference_point 991 1002--*--vaccination",
            "Scope 906 947--*--female subjects of childbearing potential"
        ]
    },
    "NCT02715518_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT02083991_exc": {
        "Text": "Diabetes mellitus or plasma glucose >11,1 at admission.. Receiving steroids at the time of transplantation or likely to need steroids after transplantation.. Multiorgan transplants and/or previously transplanted with any other organ than kidney.. Panel reacting antibodies(PRA) >25% in most recent test or considered to be of high risk for rejection which requires an enhanced immunosuppression.. Renal transplants from HLA-identical sibling.. Hypersensitivity to, or disability to take immunosuppressive drugs.. Blood group(ABO)-incompatible transplants.. Unlikely to comply with the study requirements.. Transplant from donor positive for HIV, HBsAg, Hepatitis C.. Female of childbearing potential planing/being pregnant or unwilling to use contraception.. ",
        "Annotations": [
            "Condition 0 17--*--Diabetes mellitus",
            "Measurement 21 35--*--plasma glucose",
            "Value 36 41--*-->11,1",
            "Temporal 42 54--*--at admission",
            "Drug 67 75--*--steroids",
            "Procedure 57 66--*--Receiving",
            "Temporal 76 106--*--at the time of transplantation",
            "Reference_point 91 106--*--transplantation",
            "Mood 110 124--*--likely to need",
            "Drug 125 133--*--steroids",
            "Temporal 134 155--*--after transplantation",
            "Reference_point 140 155--*--transplantation",
            "Procedure 158 180--*--Multiorgan transplants",
            "Temporal 188 198--*--previously",
            "Procedure 199 244--*--transplanted with any other organ than kidney",
            "Measurement 247 277--*--Panel reacting antibodies(PRA)",
            "Value 278 282--*-->25%",
            "Temporal 286 302--*--most recent test",
            "Mood 306 335--*--considered to be of high risk",
            "Condition 340 349--*--rejection",
            "Procedure 368 394--*--enhanced immunosuppression",
            "Procedure 397 414--*--Renal transplants",
            "Qualifier 420 441--*--HLA-identical sibling",
            "Condition 444 460--*--Hypersensitivity",
            "Condition 468 478--*--disability",
            "Drug 487 510--*--immunosuppressive drugs",
            "Qualifier 513 542--*--Blood group(ABO)-incompatible",
            "Procedure 543 554--*--transplants",
            "Non-query-able 557 604--*--Unlikely to comply with the study requirements.",
            "Condition 628 644--*--positive for HIV",
            "Condition 628 640;646 651--*--positive for HBsAg",
            "Condition 628 640;653 664--*--positive for Hepatitis C",
            "Procedure 606 616--*--Transplant",
            "Qualifier 622 627--*--donor",
            "Scope 628 664--*--positive for HIV, HBsAg, Hepatitis C",
            "Pregnancy_considerations 667 757--*--Female of childbearing potential planing/being pregnant or unwilling to use contraception."
        ]
    },
    "NCT03018171_inc": {
        "Text": "Written maternal informed consent. Singleton pregnancy. Gestational age = 37 weeks,. ASA I. BMI < 30. fetus in cephalic presentation. ",
        "Annotations": [
            "Post-eligibility 0 33--*--Written maternal informed consent",
            "Condition 35 54--*--Singleton pregnancy",
            "Measurement 56 71--*--Gestational age",
            "Value 72 82--*--= 37 weeks",
            "Measurement 85 88--*--ASA",
            "Value 89 90--*--I",
            "Measurement 92 95--*--BMI",
            "Value 96 100--*--< 30",
            "Condition 111 131--*--cephalic presentatio"
        ]
    },
    "NCT02621541_inc": {
        "Annotations": [
            "Condition 13 32--*--nonfunctional P-NET",
            "Mood 0 9--*--suspicion",
            "Procedure 36 46--*--primary CT",
            "Condition 52 68--*--hypervascularity",
            "Procedure 73 76--*--MRI",
            "Informed_consent 78 101--*--signed informed consent"
        ],
        "Text": "suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI. signed informed consent. "
    },
    "NCT02443623_inc": {
        "Text": "Signed written informed consent.. Age 18 to 65.. Normal and healthy (immune competent) as determined by medical history, physical exam, vital signs and clinical laboratory tests during the screening period.. If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process.. Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.. Negative HIV serology during screening period.. Subject must have been previously immunized for smallpox, at =3 years prior to commencement of screening assessments, and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination scar.. Female subjects of childbearing potential must agree to use highly effective birth control methods.. ",
        "Annotations": [
            "Post-eligibility 0 31--*--Signed written informed consent",
            "Person 34 37--*--Age",
            "Value 38 46--*--18 to 65",
            "Qualifier 49 55--*--Normal",
            "Qualifier 60 67--*--healthy",
            "Temporal 178 205--*--during the screening period",
            "Reference_point 189 205--*--screening period",
            "Observation 104 119--*--medical history",
            "Procedure 121 134--*--physical exam",
            "Measurement 136 147--*--vital signs",
            "Measurement 152 177--*--clinical laboratory tests",
            "Scope 104 177--*--medical history, physical exam, vital signs and clinical laboratory tests",
            "Measurement 231 268--*--quantitative IgA immunoglobulin level",
            "Value 273 306--*--lower than 15% below normal range",
            "Context_Error 208 368--*--If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process",
            "Undefined_semantics 371 475--*--Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.",
            "Measurement 486 498--*--HIV serology",
            "Value 477 485--*--Negative",
            "Temporal 499 522--*--during screening period",
            "Reference_point 506 522--*--screening period",
            "Condition 573 581--*--smallpox",
            "Procedure 559 568--*--immunized",
            "Temporal 587 641--*--3 years prior to commencement of screening assessments",
            "Reference_point 604 641--*--commencement of screening assessments",
            "Non-query-able 643 776--*--and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination",
            "Person 784 790--*--Female",
            "Condition 803 825--*--childbearing potential",
            "Procedure 861 882--*--birth control methods"
        ]
    },
    "NCT01911650_exc": {
        "Text": "1. bilateral AT . 2. insertional AT . 3. local steroid injection within 6 weeks or physical therapy within 4 weeks . 4. inability to comply with follow-up criteria . 5. history of surgery on the Achilles tendon or systemic diseases (general inflammatory diseases such as rheumatologic disorders and diabetes) . 6. daily use of opioids for pain . 7. anticoagulation or immunosuppressive therapy . 8. intent to use NSAIDs or steroids . 9. self-reported pregnancy       .     . ",
        "Annotations": [
            "Condition 3 15--*--bilateral AT",
            "Condition 20 34--*--insertional AT",
            "Procedure 39 62--*--local steroid injection",
            "Temporal 63 77--*--within 6 weeks",
            "Procedure 81 97--*--physical therapy",
            "Temporal 98 112--*--within 4 weeks",
            "Post-eligibility 117 160--*--inability to comply with follow-up criteria",
            "Subjective_judgement 117 160--*--inability to comply with follow-up criteria",
            "Non-query-able 117 160--*--inability to comply with follow-up criteria",
            "Observation 165 172--*--history",
            "Procedure 176 206--*--surgery on the Achilles tendon",
            "Condition 210 227--*--systemic diseases",
            "Condition 229 258--*--general inflammatory diseases",
            "Condition 267 290--*--rheumatologic disorders",
            "Condition 295 303--*--diabetes",
            "Scope 267 303--*--rheumatologic disorders and diabetes",
            "Drug 322 329--*--opioids",
            "Condition 334 338--*--pain",
            "Multiplier 309 314--*--daily",
            "Procedure 343 358;380 387--*--anticoagulation therapy",
            "Procedure 362 387--*--immunosuppressive therapy",
            "Drug 406 412--*--NSAIDs",
            "Drug 416 424--*--steroids",
            "Condition 443 452--*--pregnancy"
        ]
    },
    "NCT02715518_inc": {
        "Annotations": [
            "Mood 0 8--*--Symptoms",
            "Condition 12 21--*--ischaemia",
            "Qualifier 44 55--*--significant",
            "Multiplier 24 27--*--New",
            "Multiplier 31 43--*--presumed new",
            "Condition 56 73--*--ST-T wave changes",
            "Scope 44 74--*--significant ST-T wave changes",
            "Scope 24 43--*--New or presumed new",
            "Scope 44 73--*--significant ST-T wave changes",
            "Condition 90 110--*--pathological Q waves",
            "Procedure 114 117--*--ECG",
            "Procedure 120 127--*--Imaging",
            "Condition 128 136--*--evidence",
            "Multiplier 147 159--*--presumed new",
            "Multiplier 140 143--*--new",
            "Condition 160 185--*--loss of viable myocardium",
            "Scope 140 159--*--new or presumed new",
            "Condition 189 221--*--regional wall motion abnormality",
            "Scope 160 221--*--loss of viable myocardium or regional wall motion abnormality"
        ],
        "Text": "Symptoms of ischaemia.. New or presumed new significant ST-T wave changes. Development of pathological Q waves on ECG.. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.. "
    },
    "NCT03147599_inc": {
        "Text": "Men 18 years or older. ONB within 1 year post-surgery.. ",
        "Annotations": [
            "Person 0 3--*--Men",
            "Value 4 21--*--18 years or older",
            "Person 4 21--*--18 years or older",
            "Condition 23 26--*--ONB",
            "Temporal 27 53--*--within 1 year post-surgery",
            "Procedure 46 53--*--surgery",
            "Reference_point 46 53--*--surgery"
        ]
    },
    "NCT02678962_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 27--*--from 40 to 80 years old",
            "Qualifier 69 80--*--age related",
            "Condition 81 90--*--cataracts",
            "Qualifier 59 68--*--bilateral",
            "Procedure 110 138--*--cataract phacoemulsification",
            "Qualifier 100 109--*--bilateral",
            "Procedure 148 177--*--Intraocular Lens implantation",
            "Scope 110 177--*--cataract phacoemulsification combined Intraocular Lens implantation",
            "Non-query-able 180 256--*--Willing to undergo second eye surgery within 7 days after first eye surgery;",
            "Non-query-able 258 332--*--The potential postoperative visual acuity of 20/40 or better in both eyes;",
            "Measurement 347 381--*--measurement of corneal astigmatism",
            "Procedure 421 463--*--multifocal intraocular lenses implantation",
            "Value 408 416--*--suitable",
            "Temporal 334 346--*--Preoperative",
            "Post-eligibility 466 548--*--Capability to understand the informed consent and willing and able to attend study"
        ],
        "Text": "Age from 40 to 80 years old, either gender;. Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;. Willing to undergo second eye surgery within 7 days after first eye surgery;. The potential postoperative visual acuity of 20/40 or better in both eyes;. Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation;. Capability to understand the informed consent and willing and able to attend study. "
    },
    "NCT02996916_inc": {
        "Text": "Written informed consent obtained. Male and female subjects aged 20 years or older at informed consent. Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers. ",
        "Annotations": [
            "Informed_consent 0 33--*--Written informed consent obtained",
            "Person 35 39--*--Male",
            "Person 44 50--*--female",
            "Person 60 64--*--aged",
            "Value 65 82--*--20 years or older",
            "Temporal 83 102--*--at informed consent",
            "Reference_point 86 102--*--informed consent",
            "Condition 104 126--*--Essential hypertension",
            "Drug 150 185--*--angiotensin II receptor antagonists",
            "Drug 190 214--*--calcium channel blockers",
            "Negation 135 140--*--never",
            "Scope 150 214--*--angiotensin II receptor antagonists and calcium channel blockers"
        ]
    },
    "NCT02982577_exc": {
        "Annotations": [
            "Condition 0 11--*--Sensitivity",
            "Drug 15 26--*--pilocarpine",
            "Condition 38 56--*--Sj\u00f6gren's syndrome",
            "Qualifier 28 37--*--Secondary",
            "Condition 59 84--*--Type II diabetes mellitus",
            "Condition 87 91--*--AIDS",
            "Pregnancy_considerations 94 121--*--pregnant or lactating women",
            "Condition 124 132--*--Glaucoma",
            "Condition 148 154--*--asthma",
            "Qualifier 135 147--*--Uncontrolled",
            "Condition 157 194--*--Chronic obstructive pulmonary disease",
            "Condition 197 211--*--Renal diseases",
            "Condition 221 244--*--cardiovascular diseases",
            "Qualifier 214 220--*--Severe",
            "Condition 247 273--*--Gastrointestinal disorders",
            "Condition 276 297--*--Hepatic insufficiency"
        ],
        "Text": "Sensitivity to pilocarpine. Secondary Sj\u00f6gren's syndrome;. Type II diabetes mellitus;. AIDS;. pregnant or lactating women;. Glaucoma;. Uncontrolled asthma;. Chronic obstructive pulmonary disease;. Renal diseases;. Severe cardiovascular diseases;. Gastrointestinal disorders;. Hepatic insufficiency.. "
    },
    "NCT01313676_inc": {
        "Annotations": [
            "Visit 17 27--*--outpatient",
            "Post-eligibility 30 130--*--Informed consent: Subjects must give their signed and dated written informed consent to participate.",
            "Person 140 144--*--Male",
            "Person 148 154--*--female",
            "Pregnancy_considerations 156 448--*--Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.",
            "Person 450 453--*--Age",
            "Value 455 474--*-->=40 and <=80 years",
            "Person 478 481--*--age",
            "Temporal 482 494--*--at Screening",
            "Reference_point 485 494--*--Screening",
            "Multiplier 564 579--*-->=10 pack-years",
            "Observation 583 600--*--cigarette smoking",
            "Temporal 601 613--*--at screening",
            "Observation 553 560--*--history",
            "Temporal 547 552--*--prior",
            "Temporal 536 543--*--current",
            "Scope 536 552--*--current or prior",
            "Condition 625 641--*--Previous smokers",
            "Observation 672 687--*--stopped smoking",
            "Temporal 688 726--*--for at least 6 months prior to Visit 1",
            "Reference_point 719 726--*--Visit 1",
            "Scope 672 726--*--stopped smoking for at least 6 months prior to Visit 1",
            "Parsing_Error 729 749--*--Airflow Obstruction:",
            "Drug 781 790--*--albuterol",
            "Drug 791 801--*--salbutamol",
            "Temporal 776 801--*--post-albuterol/salbutamol",
            "Measurement 802 878--*--forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio",
            "Value 882 888--*--<=0.70",
            "Temporal 889 901--*--at Screening",
            "Qualifier 776 801--*--post-albuterol/salbutamol",
            "Reference_point 781 801--*--albuterol/salbutamol",
            "Qualifier 939 964--*--post-albuterol/salbutamol",
            "Temporal 939 964--*--post-albuterol/salbutamol",
            "Drug 944 953--*--albuterol",
            "Drug 954 964--*--salbutamol",
            "Reference_point 944 964--*--albuterol/salbutamol",
            "Measurement 965 969--*--FEV1",
            "Value 970 1011--*-->=50 and <=70% of predicted normal values",
            "Qualifier 1023 1059--*--using NHANES III reference equations",
            "Temporal 1095 1107--*--at Screening",
            "Reference_point 1098 1107--*--Screening",
            "Qualifier 1120 1139--*--Post-bronchodilator",
            "Temporal 1120 1139--*--Post-bronchodilator",
            "Drug 1125 1139--*--bronchodilator",
            "Reference_point 1125 1139--*--bronchodilator",
            "Procedure 1140 1150--*--spirometry",
            "Temporal 1169 1199--*--approximately 15 minutes after",
            "Multiplier 1234 1235--*--4",
            "Procedure 1236 1247--*--inhalations",
            "Qualifier 1216 1233--*--self-administered",
            "Multiplier 1261 1267--*--400mcg",
            "Drug 1272 1281--*--albuterol",
            "Drug 1282 1292--*--salbutamol",
            "Scope 1272 1292--*--albuterol/salbutamol",
            "Procedure 1299 1326--*--metered dose inhaler (MDI )",
            "Qualifier 1326 1355--*--with a valved-holding chamber",
            "Condition 1431 1447--*--Symptoms of COPD",
            "Value 1463 1480--*--score 2 or higher",
            "Measurement 1488 1535--*--modified Medical Research Council Dyspnea scale",
            "Parsing_Error 1547 1570--*--Cardiovascular disease:",
            "Value 1585 1596--*-->= 40 years",
            "Person 1600 1603--*--age",
            "Condition 1688 1717--*--coronary artery disease (CAD)",
            "Condition 1774 1807--*--peripheral vascular disease (PVD)",
            "Condition 1817 1823--*--stroke",
            "Temporal 1808 1816--*--Previous",
            "Observation 1718 1729--*--Established",
            "Observation 1739 1753--*--clinical signs",
            "Procedure 1757 1772--*--imaging studies",
            "Condition 1833 1835--*--MI",
            "Condition 1836 1853--*--Diabetes mellitus",
            "Condition 1859 1879--*--target organ disease",
            "Parsing_Error 1880 1882--*--OR",
            "Temporal 1824 1832--*--Previous",
            "Scope 1739 1772--*--clinical signs or imaging studies",
            "Observation 1632 1643--*--Established",
            "Observation 1653 1667--*--clinical signs",
            "Procedure 1671 1686--*--imaging studies",
            "Scope 1653 1686--*--clinical signs or imaging studies",
            "Value 1897 1907--*-->=60 years",
            "Person 1911 1914--*--age",
            "Condition 1959 1979--*--hypercholesterolemia",
            "Procedure 1947 1979--*--treated for hypercholesterolemia",
            "Procedure 1986 2010--*--treated for hypertension",
            "Condition 1998 2010--*--hypertension",
            "Condition 2029 2046--*--diabetes mellitus",
            "Procedure 2017 2046--*--treated for diabetes mellitus",
            "Procedure 2053 2092--*--treated for peripheral vascular disease",
            "Condition 2065 2092--*--peripheral vascular disease"
        ],
        "Text": "Type of subject: outpatient. . Informed consent: Subjects must give their signed and dated written informed consent to participate. . Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception. . Age: >=40 and <=80 years of age at Screening (Visit 1). . Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. . Airflow Obstruction: . Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1). . Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1). . Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated. . Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1) . Cardiovascular disease: . For patients >= 40 years of age: any one of the following: . Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR . For patients >=60 years of age: any 2 of the following: . Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease . "
    },
    "NCT02744976_inc": {
        "Text": "age =18 and <75 years;. patients with stable coronary artery disease referred to PCI in an artery suitable for IVUS pullback;. signed informed consent before PCI.. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 21--*--=18 and <75 years",
            "Qualifier 38 44--*--stable",
            "Condition 45 68--*--coronary artery disease",
            "Procedure 81 84--*--PCI",
            "Mood 69 80--*--referred to",
            "Qualifier 91 124--*--artery suitable for IVUS pullback",
            "Informed_consent 127 161--*--signed informed consent before PCI"
        ]
    },
    "NCT00356148_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 9 16--*--any age",
            "Value 22 27--*--early",
            "Measurement 28 33--*--stage",
            "Condition 34 47--*--breast cancer",
            "Measurement 49 54--*--stage",
            "Value 55 59--*--I-II",
            "Scope 49 59--*--stage I-II",
            "Measurement 65 114--*--American Society of Anesthesiologists (ASA) score",
            "Value 118 122--*--I-II",
            "Scope 22 33--*--early stage"
        ],
        "Text": "Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II. . "
    },
    "NCT00576173_exc": {
        "Text": "Patients who have taken either morphine with daily dose more than 120mg or Fentanyl with daily dose more than 50ug/hr . Patients with significant abnormalities in hepatic or renal function which would, in the opinion of the investigator, prevent the patients involvement in the study . Patients with significant clinical abnormalities in CNS, respiratory or cardiovascular function, which in the investigators judgement prevents participation in the study . Patients who have taken antidepressants or anti-epileptic drugs, sedative hypnotics, selective serotonin reuptake inhibitor, short-acting analgesics, topical medications and anesthetics and/or muscle relaxants when taking Tramadol/Acetaminophen       .     . ",
        "Annotations": [
            "Drug 31 39--*--morphine",
            "Multiplier 45 71--*--daily dose more than 120mg",
            "Drug 75 83--*--Fentanyl",
            "Multiplier 89 117--*--daily dose more than 50ug/hr",
            "Condition 145 169;179 187--*--abnormalities in hepatic function",
            "Condition 145 161;173 187--*--abnormalities in renal function",
            "Condition 319 339--*--abnormalities in CNS",
            "Condition 319 335;356 379--*--abnormalities in cardiovascular function",
            "Condition 319 335;341 352;371 379--*--abnormalities in respiratory function",
            "Drug 479 494--*--antidepressants",
            "Drug 498 518--*--anti-epileptic drugs",
            "Drug 520 538--*--sedative hypnotics",
            "Drug 540 578--*--selective serotonin reuptake inhibitor",
            "Drug 580 603--*--short-acting analgesics",
            "Drug 605 624--*--topical medications",
            "Drug 629 640--*--anesthetics",
            "Drug 648 664--*--muscle relaxants",
            "Drug 677 685--*--Tramadol",
            "Drug 686 699--*--Acetaminophen",
            "Scope 677 699--*--Tramadol/Acetaminophen",
            "Scope 479 664--*--antidepressants or anti-epileptic drugs, sedative hypnotics, selective serotonin reuptake inhibitor, short-acting analgesics, topical medications and anesthetics and/or muscle relaxants",
            "Temporal 665 699--*--when taking Tramadol/Acetaminophen",
            "Reference_point 670 699--*--taking Tramadol/Acetaminophen"
        ]
    },
    "NCT03168555_exc": {
        "Text": "small bowel resection. right sided hemicolectomy. known chronic diarrheal disease (celiac disease, lactose malabsorption, Inflammatory bowel diseases, incl microscopic colitis). pregnancy. wish for pregnancy within next three months. allergy to eggs. allergy to constituents in Xenbilox (capsules with chenodeoxycholic acid). acute cholecystitis within two months. chronic cholecystitis. cirrhosis of the liver. suspected obstructive choledocholithiasis. icterus. ",
        "Annotations": [
            "Procedure 0 21--*--small bowel resection",
            "Procedure 23 48--*--right sided hemicolectomy",
            "Condition 56 81--*--chronic diarrheal disease",
            "Condition 83 97--*--celiac disease",
            "Condition 99 120--*--lactose malabsorption",
            "Condition 122 149--*--Inflammatory bowel diseases",
            "Condition 156 175--*--microscopic colitis",
            "Scope 83 175--*--celiac disease, lactose malabsorption, Inflammatory bowel diseases, incl microscopic colitis",
            "Condition 178 187--*--pregnancy",
            "Temporal 208 232--*--within next three months",
            "Condition 198 207--*--pregnancy",
            "Mood 189 197--*--wish for",
            "Condition 234 241--*--allergy",
            "Drug 245 249--*--eggs",
            "Condition 251 258--*--allergy",
            "Drug 262 286--*--constituents in Xenbilox",
            "Drug 302 323--*--chenodeoxycholic acid",
            "Condition 326 345--*--acute cholecystitis",
            "Temporal 346 363--*--within two months",
            "Condition 365 386--*--chronic cholecystitis",
            "Condition 388 410--*--cirrhosis of the liver",
            "Mood 412 421--*--suspected",
            "Condition 422 453--*--obstructive choledocholithiasis",
            "Condition 455 462--*--icterus"
        ]
    },
    "NCT02830360_exc": {
        "Annotations": [
            "Informed_consent 0 47--*--Unable or unwilling to provide informed consent",
            "Condition 57 65--*--ischemia",
            "Qualifier 50 56--*--Active",
            "Condition 67 81--*--acute thrombus",
            "Procedure 95 115--*--coronary angiography",
            "Condition 128 146--*--ST segment changes",
            "Procedure 163 166--*--ECG",
            "Condition 199 201--*--VT",
            "Qualifier 179 189--*--reversible",
            "Condition 208 231--*--drug-induced arrhythmia",
            "Condition 245 268--*--acute coronary syndrome",
            "Temporal 269 284--*--within 30 days,",
            "Procedure 285 311--*--coronary revascularization",
            "Temporal 313 321--*--<90 days",
            "Procedure 322 336--*--bypass surgery",
            "Temporal 338 346--*--<30 days",
            "Procedure 347 381--*--percutaneous coronary intervention",
            "Condition 416 422--*--angina",
            "Measurement 392 412--*--CCS functional class",
            "Value 413 415--*--IV",
            "Non-query-able 424 554--*--Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia",
            "Scope 313 381--*--<90 days bypass surgery, <30 days percutaneous coronary intervention",
            "Scope 67 381--*--acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention",
            "Condition 643 650--*--allergy",
            "Condition 652 663--*--intolerance",
            "Condition 667 683--*--contraindication",
            "Scope 643 683--*--allergy, intolerance or contraindication",
            "Drug 584 603--*--antiarrhythmic drug",
            "Condition 714 739--*--left ventricular thrombus",
            "Device 743 760;772 778--*--mechanical aortic valves",
            "Device 743 753;765 778--*--mechanical mitral valves",
            "Procedure 797 824--*--catheter ablation procedure",
            "Condition 829 831--*--VT",
            "Condition 840 853--*--renal failure",
            "Measurement 855 875--*--Creatinine clearance",
            "Value 876 886--*--<15 mL/min",
            "Measurement 894 915--*--NYHA Functional class",
            "Value 916 918--*--IV",
            "Condition 919 932--*--heart failure",
            "Condition 939 955--*--systemic illness",
            "Observation 972 980--*--survival",
            "Value 984 991--*--<1 year",
            "Condition 1009 1043--*--ST elevation myocardial infarction",
            "Condition 1047 1066--*--non-ST elevation MI",
            "Temporal 1068 1077--*--< 30 days",
            "Non-query-able 1081 1164--*--ote that biomarker elevation alone after ventricular arrhythmias does not denote MI",
            "Condition 1171 1179--*--pregnant",
            "Scope 1009 1066--*--ST elevation myocardial infarction or non-ST elevation MI"
        ],
        "Text": "Unable or unwilling to provide informed consent.. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia.. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication. Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves. Have had a prior catheter ablation procedure for VT. Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year. Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI.. Are pregnant.. "
    },
    "NCT02964416_inc": {
        "Text": "Patients with craniotomy for supratentorial tumors under general anesthesia. American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients. Elective surgery. Patients with Glasgow Coma Scale (GCS) 15/15. ",
        "Annotations": [
            "Procedure 14 24--*--craniotomy",
            "Condition 29 50--*--supratentorial tumors",
            "Procedure 57 75--*--general anesthesia",
            "Measurement 77 115--*--American Society of Anaesthesiologists",
            "Measurement 117 120--*--ASA",
            "Value 122 123--*--2",
            "Measurement 135 138--*--ASA",
            "Value 139 140--*--3",
            "Qualifier 128 134--*--stable",
            "Procedure 151 167--*--Elective surgery",
            "Measurement 183 201--*--Glasgow Coma Scale",
            "Measurement 203 206--*--GCS",
            "Value 208 213--*--15/15"
        ]
    },
    "NCT03360981_exc": {
        "Annotations": [
            "Condition 0 27--*--acute myocardial infarction",
            "Condition 29 42--*--heart failure",
            "Condition 44 62--*--neoplastic disease",
            "Condition 64 80--*--chronic diseases",
            "Qualifier 86 121--*--may affect the inflammatory profile",
            "Qualifier 127 135--*--systemic",
            "Qualifier 140 150--*--epicardial",
            "Scope 127 150--*--systemic and epicardial",
            "Condition 152 158--*--cancer",
            "Condition 160 191--*--chronic intestinal inflammation",
            "Condition 193 202--*--hepatitis",
            "Condition 204 208--*--AIDS",
            "Scope 152 208--*--cancer, chronic intestinal inflammation, hepatitis, AIDS",
            "Scope 64 150--*--chronic diseases that may affect the inflammatory profile both systemic and epicardial",
            "Observation 211 226--*--life expectancy",
            "Value 227 237--*--< 6 months",
            "Procedure 248 252--*--CABG",
            "Temporal 239 247--*--previous",
            "Procedure 266 297--*--open heart surgery intervention",
            "Condition 299 322--*--acute coronary syndrome",
            "Qualifier 260 265--*--other"
        ],
        "Text": "acute myocardial infarction, heart failure, neoplastic disease, chronic diseases that may affect the inflammatory profile both systemic and epicardial (cancer, chronic intestinal inflammation, hepatitis, AIDS); life expectancy < 6 months, previous CABG and/or other open heart surgery intervention, acute coronary syndrome. "
    },
    "NCT02466113_inc": {
        "Annotations": [
            "Non-query-able 0 56--*--The informed consent has been obtained from the patient.",
            "Post-eligibility 0 56--*--The informed consent has been obtained from the patient.",
            "Condition 95 107--*--colon cancer",
            "Qualifier 86 94--*--stage II",
            "Measurement 129 152--*--ECOG health rating (PS)",
            "Value 154 163--*--0-1 score",
            "Value 115 128--*--moderate/good",
            "Drug 189 210--*--anti-cancer treatment",
            "Negation 186 188--*--no",
            "Temporal 211 233--*--before primary surgery",
            "Procedure 218 233--*--primary surgery",
            "Reference_point 218 233--*--primary surgery",
            "Procedure 256 273;296 311--*--radical operation negative margin",
            "Condition 278 290--*--colon cancer"
        ],
        "Text": "The informed consent has been obtained from the patient. . With confirmed diagnosis of stage II colon cancer. . With moderate/good ECOG health rating (PS): 0-1 score. . The patient receive no anti-cancer treatment before primary surgery. . The patient receive radical operation for colon cancer with negative margin. . "
    },
    "NCT03169127_exc": {
        "Text": "Presence of systemic diseases;. Presence of local inflammation and/or infection;. Any history of allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration;. Cardiovascular, kidney or hepatic diseases;. Patients who are making use of antidepressants, diuretics or anticoagulants;. Asthma and allergy to aspirin, ibuprofen or any other nonsteroidal antiinflammatory drug;. Regular use of any nonsteroidal antiinflammatory drug,. Pregnancy or breast feeding.. ",
        "Annotations": [
            "Condition 12 29--*--systemic diseases",
            "Condition 44 62--*--local inflammation",
            "Condition 44 49;70 79--*--local infection",
            "Observation 86 93--*--history",
            "Condition 97 114--*--allergic reaction",
            "Drug 118 135--*--local anesthetics",
            "Condition 137 162--*--gastrointestinal bleeding",
            "Condition 137 153;166 176--*--gastrointestinal ulceration",
            "Scope 97 176--*--allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration",
            "Condition 179 193;213 221--*--Cardiovascular diseases",
            "Condition 195 201;213 221--*--kidney diseases",
            "Condition 205 221--*--hepatic diseases",
            "Drug 255 270--*--antidepressants",
            "Drug 272 281--*--diuretics",
            "Drug 285 299--*--anticoagulants",
            "Condition 302 308--*--Asthma",
            "Condition 313 320--*--allergy",
            "Drug 324 331--*--aspirin",
            "Drug 333 342--*--ibuprofen",
            "Drug 356 390--*--nonsteroidal antiinflammatory drug",
            "Qualifier 346 355--*--any other",
            "Scope 324 390--*--aspirin, ibuprofen or any other nonsteroidal antiinflammatory drug",
            "Multiplier 393 404--*--Regular use",
            "Condition 412 446--*--nonsteroidal antiinflammatory drug",
            "Condition 449 458--*--Pregnancy",
            "Observation 462 476--*--breast feeding"
        ]
    },
    "NCT03221231_inc": {
        "Text": "Current DSM-IV diagnosis of cannabis dependence, >1 week detoxified and abstinent;. Able to provide written informed consent and to comply with study procedures.. Dutch speaking (Dutch as primary language).. ",
        "Annotations": [
            "Qualifier 8 14--*--DSM-IV",
            "Condition 28 47--*--cannabis dependence",
            "Multiplier 49 56--*-->1 week",
            "Condition 57 67--*--detoxified",
            "Condition 72 81--*--abstinent",
            "Scope 57 81--*--detoxified and abstinent",
            "Non-query-able 84 161--*--Able to provide written informed consent and to comply with study procedures.",
            "Non-query-able 163 206--*--Dutch speaking (Dutch as primary language)."
        ]
    },
    "NCT02996916_exc": {
        "Text": "Secondary hypertension or malignant hypertension. Diabetes mellitus. History or evidence of a stroke. Hepatic or hematologic abnormality. Mild Cognitive Impairment or Dementia. Serum potassium level = 5.5 mEq/L. Serum creatinine level = 3.0 mg/dL. Acute or chronic disease. Allergy to any drugs. Pregnancy. ",
        "Annotations": [
            "Condition 0 22--*--Secondary hypertension",
            "Condition 26 48--*--malignant hypertension",
            "Condition 50 67--*--Diabetes mellitus",
            "Observation 69 76--*--History",
            "Mood 80 88--*--evidence",
            "Condition 94 100--*--stroke",
            "Scope 69 88--*--History or evidence",
            "Condition 102 109;125 136--*--Hepatic abnormality",
            "Condition 113 136--*--hematologic abnormality",
            "Condition 138 163--*--Mild Cognitive Impairment",
            "Condition 167 175--*--Dementia",
            "Measurement 177 198--*--Serum potassium level",
            "Value 199 210--*--= 5.5 mEq/L",
            "Measurement 212 234--*--Serum creatinine level",
            "Value 235 246--*--= 3.0 mg/dL",
            "Condition 257 272--*--chronic disease",
            "Condition 248 253;265 272--*--Acute disease",
            "Condition 274 281--*--Allergy",
            "Drug 285 294--*--any drugs",
            "Condition 296 305--*--Pregnancy"
        ]
    },
    "NCT02678962_exc": {
        "Annotations": [
            "Condition 12 27--*--ocular diseases",
            "Temporal 0 11--*--Preexisting",
            "Condition 31 41--*--conditions",
            "Negation 42 52--*--other than",
            "Condition 65 74--*--cataracts",
            "Qualifier 53 64--*--age related",
            "Condition 81 98--*--contraindications",
            "Procedure 103 119--*--cataract surgery",
            "Temporal 122 133--*--Preexisting",
            "Condition 134 151--*--systemic diseases",
            "Condition 155 165--*--conditions",
            "Qualifier 171 208--*--may confound the results of the study",
            "Procedure 220 234--*--ocular surgery",
            "Temporal 211 219--*--Previous",
            "Condition 246 259--*--ocular trauma",
            "Qualifier 265 302--*--may confound the results of the study",
            "Scope 211 259--*--Previous ocular surgery history or ocular trauma",
            "Procedure 313 329--*--combined surgery",
            "Mood 305 312--*--Require",
            "Qualifier 335 372--*--may confound the results of the study",
            "Non-query-able 375 457--*--Previous participation in other clinical trial within 30 days of this study start;",
            "Drug 471 489--*--ocular medications",
            "Drug 459 467;478 489--*--Systemic medications",
            "Qualifier 495 539--*--may confound the outcome of the intervention",
            "Scope 459 489--*--Systemic or ocular medications",
            "Condition 541 549--*--Pregnant",
            "Condition 551 560--*--lactating",
            "Mood 565 583--*--planning to become",
            "Condition 584 592--*--pregnant",
            "Temporal 593 623--*--during the course of the trial",
            "Scope 541 592--*--Pregnant, lactating, or planning to become pregnant"
        ],
        "Text": "Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;. Preexisting systemic diseases or conditions that may confound the results of the study;. Previous ocular surgery history or ocular trauma that may confound the results of the study;. Require combined surgery that may confound the results of the study;. Previous participation in other clinical trial within 30 days of this study start;. Systemic or ocular medications that may confound the outcome of the intervention. Pregnant, lactating, or planning to become pregnant during the course of the trial;. "
    },
    "NCT03147599_exc": {
        "Text": "Upper urinary tract deterioration. Uncontrolled diabetes mellitus. Evident local or pelvic recurrence. Adjuvant chemotherapy. Chronic retention. Pouch stones. Urethral stricture or urethro-ileal maldirection. Sensitivity to Mebeverine. Untreated chronic constipation. Active symptomatic urinary infection. ",
        "Annotations": [
            "Condition 0 33--*--Upper urinary tract deterioration",
            "Condition 48 65--*--diabetes mellitus",
            "Qualifier 35 47--*--Uncontrolled",
            "Condition 84 101--*--pelvic recurrence",
            "Condition 75 80;91 101--*--local recurrence",
            "Procedure 103 124--*--Adjuvant chemotherapy",
            "Condition 126 143--*--Chronic retention",
            "Condition 145 157--*--Pouch stones",
            "Condition 159 177--*--Urethral stricture",
            "Condition 181 207--*--urethro-ileal maldirection",
            "Drug 224 234--*--Mebeverine",
            "Condition 209 220--*--Sensitivity",
            "Qualifier 236 245--*--Untreated",
            "Condition 246 266--*--chronic constipation",
            "Qualifier 275 286--*--symptomatic",
            "Qualifier 268 274--*--Active",
            "Condition 287 304--*--urinary infection"
        ]
    },
    "NCT01313676_exc": {
        "Annotations": [
            "Pregnancy_considerations 0 47--*--Pregnancy: Women who are pregnant or lactating.",
            "Condition 49 55--*--Asthma",
            "Condition 94 100--*--asthma",
            "Temporal 73 80--*--current",
            "Temporal 119 124--*--prior",
            "Observation 125 132--*--history",
            "Condition 136 142--*--asthma",
            "Condition 197 201--*--COPD",
            "Condition 205 235--*--alpha 1-antitrypsin deficiency",
            "Condition 315 319--*--COPD",
            "Condition 257 287--*--alpha-1 antitrypsin deficiency",
            "Condition 372 384--*--tuberculosis",
            "Condition 322 349--*--Other respiratory disorders",
            "Undefined_semantics 322 349--*--Other respiratory disorders",
            "Condition 386 397--*--lung cancer",
            "Condition 399 413--*--bronchiectasis",
            "Condition 415 426--*--sarcoidosis",
            "Condition 428 446--*--pulmonary fibrosis",
            "Condition 448 470--*--pulmonary hypertension",
            "Condition 472 498--*--interstitial lung diseases",
            "Condition 508 533--*--active pulmonary diseases",
            "Scope 372 533--*--tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases",
            "Procedure 536 550--*--Lung resection",
            "Procedure 554 569--*--transplantation",
            "Procedure 585 614--*--lung volume reduction surgery",
            "Temporal 615 654--*--within the 12 months prior to Screening",
            "Reference_point 645 654--*--Screening",
            "Procedure 671 686--*--lung transplant",
            "Condition 658 686--*--having had a lung transplant",
            "Condition 580 614--*--with lung volume reduction surgery",
            "Scope 580 686--*--with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant",
            "Scope 536 569--*--Lung resection or transplantation",
            "Condition 707 724--*--COPD exacerbation",
            "Qualifier 691 699--*--moderate",
            "Qualifier 700 706--*--severe",
            "Scope 691 706--*--moderate/severe",
            "Temporal 747 780--*--at least 14 days prior to Visit 1",
            "Observation 738 746--*--resolved",
            "Negation 734 737--*--not",
            "Temporal 785 849--*--at least 30 days following the last dose of oral corticosteroids",
            "Reference_point 812 849--*--the last dose of oral corticosteroids",
            "Condition 883 896--*--heart failure",
            "Qualifier 876 882--*--severe",
            "Measurement 898 924--*--New York Heart Association",
            "Value 925 933--*--class IV",
            "Measurement 988 1005--*--ejection fraction",
            "Value 1009 1013--*--<30%",
            "Device 1033 1077--*--implantable cardioverter defibrillator (ICD)",
            "Observation 1146 1161--*--life expectancy",
            "Value 1162 1170--*--<3 years",
            "Condition 1114 1140--*--life-threatening condition",
            "Condition 1183 1199--*--vascular disease",
            "Condition 1203 1207--*--COPD",
            "Subjective_judgement 1209 1265--*--that might prevent the subject from completing the study",
            "Negation 1172 1182--*--other than",
            "Scope 1183 1207--*--vascular disease or COPD",
            "Condition 1268 1299--*--End stage chronic renal disease",
            "Procedure 1333 1358--*--renal replacement therapy",
            "Procedure 1360 1372--*--hemodialysis",
            "Qualifier 1376 1386--*--peritoneal",
            "Scope 1360 1386--*--hemodialysis or peritoneal",
            "Condition 1390 1394;1400 1407--*--Drug allergy",
            "Condition 1395 1407--*--food allergy",
            "Condition 1436 1452--*--hypersensitivity",
            "Drug 1491 1504--*--beta-agonists",
            "Drug 1506 1520--*--corticosteroid",
            "Drug 1467 1484--*--study medications",
            "Undefined_semantics 1467 1484--*--study medications",
            "Scope 1491 1520--*--beta-agonists, corticosteroid",
            "Drug 1525 1560--*--components of the inhalation powder",
            "Drug 1567 1574--*--lactose",
            "Drug 1576 1594--*--magnesium stearate",
            "Scope 1567 1594--*--lactose, magnesium stearate",
            "Scope 1467 1595--*--study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate)",
            "Condition 1644 1664--*--milk protein allergy",
            "Qualifier 1637 1643--*--severe",
            "Observation 1626 1633--*--history",
            "Subjective_judgement 1671 1775--*--in the opinion of the study physician, contraindicates the subject's participation will also be excluded",
            "Drug 1783 1796--*--alcohol abuse",
            "Drug 1778 1782;1791 1796--*--Drug abuse",
            "Observation 1833 1840--*--history",
            "Drug 1855 1865--*--drug abuse",
            "Drug 1844 1851;1860 1865--*--alcohol abuse",
            "Temporal 1866 1889--*--within the last 2 years",
            "Scope 1844 1865--*--alcohol or drug abuse",
            "Procedure 1942 1973--*--long-term oxygen therapy (LTOT)",
            "Procedure 1977 2001--*--nocturnal oxygen therapy",
            "Multiplier 2015 2042--*--greater than 12 hours a day",
            "Scope 1942 2001--*--long-term oxygen therapy (LTOT) or nocturnal oxygen therapy",
            "Grammar_Error 2044 2105--*--Oxygen prn use (i.e. <=12 hours per day) is not exclusionary.",
            "Post-eligibility 2107 2375--*--Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures.",
            "Post-eligibility 2377 2611--*--Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.",
            "Parsing_Error 2613 2771--*--Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified):",
            "Drug 2918 2958--*--Inhaled Long acting beta-agonists (LABA)",
            "Temporal 2959 2967--*--48 hours",
            "Reference_point 2836 2845--*--Screening",
            "Drug 2968 2997--*--ICS/LABA combination products",
            "Temporal 2998 3006--*--48 hours",
            "Drug 3007 3030--*--Inhaled corticosteroids",
            "Temporal 3031 3039--*--48 hours",
            "Drug 3040 3050--*--Tiotropium",
            "Temporal 3051 3057--*--1 week",
            "Drug 3102 3117--*--corticosteroids",
            "Qualifier 3058 3066--*--Systemic",
            "Qualifier 3068 3072--*--Oral",
            "Qualifier 3074 3084--*--parenteral",
            "Qualifier 3086 3101--*--intra-articular",
            "Scope 3058 3101--*--Systemic, Oral, parenteral, intra-articular",
            "Temporal 3118 3125--*--30 days",
            "Drug 3145 3160--*--corticosteroids",
            "Qualifier 3127 3131--*--oral",
            "Qualifier 3136 3144--*--systemic",
            "Scope 3127 3144--*--oral and systemic",
            "Condition 3182 3200--*--COPD exacerbations",
            "Procedure 3176 3200--*--treat COPD exacerbations",
            "Temporal 3201 3217--*--during the study",
            "Reference_point 3208 3217--*--the study",
            "Not_a_criteria 3127 3217--*--oral and systemic corticosteroids may be used to treat COPD exacerbations during the study",
            "Drug 3219 3256--*--Cytochrome P450 3A4 strong inhibitors",
            "Drug 3432 3444--*--Itraconazole",
            "Drug 3447 3461--*--Clarithromycin",
            "Drug 3463 3476--*--Telithromycin",
            "Drug 3478 3488--*--Amiodarone",
            "Drug 3494 3504--*--Nefazodone",
            "Temporal 3505 3512--*--6 weeks",
            "Drug 3513 3523--*--Grapefruit",
            "Grammar_Error 3513 3548--*--Grapefruit is allowed up to Visit 1",
            "Drug 3664 3684--*--investigational drug",
            "Undefined_semantics 3664 3684--*--investigational drug",
            "Temporal 3685 3692--*--30 days",
            "Temporal 3696 3708--*--5 half lives",
            "Scope 3685 3708--*--30 days or 5 half lives",
            "Drug 3286 3301--*--antiretrovirals",
            "Drug 3303 3322--*--protease inhibitors",
            "Drug 3329 3338--*--Indinavir",
            "Drug 3340 3350--*--Nelfinavir",
            "Drug 3352 3361--*--Ritonavir",
            "Drug 3363 3373--*--Saquinavir",
            "Scope 3329 3373--*--Indinavir, Nelfinavir, Ritonavir, Saquinavir",
            "Drug 3376 3385;3399 3411--*--Imidazole anti-fungals",
            "Drug 3390 3411--*--Triazole anti-fungals",
            "Drug 3418 3430--*--Ketaconazole",
            "Scope 3376 3411--*--Imidazole and Triazole anti-fungals",
            "Scope 3418 3444--*--Ketaconazole, Itraconazole",
            "Scope 3286 3504--*--antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone",
            "Negation 2784 2786--*--No",
            "Reference_point 2863 2888--*--any time during the study"
        ],
        "Text": "Pregnancy: Women who are pregnant or lactating. . Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD). . alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD. . Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. . Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant. . A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable). . Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of <30% or if they have an implantable cardioverter defibrillator (ICD). . Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study. . End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal). . Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded. . Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years. . Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e. <=12 hours per day) is not exclusionary. . Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures. . Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study. . Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified): . Medication No use within the following time intervals prior to Screening or thereafter at any time during the study (unless otherwise specified) Inhaled Long acting beta-agonists (LABA) 48 hours ICS/LABA combination products 48 hours Inhaled corticosteroids 48 hours Tiotropium 1 week Systemic, Oral, parenteral, intra-articular corticosteroids 30 days (oral and systemic corticosteroids may be used to treat COPD exacerbations during the study) Cytochrome P450 3A4 strong inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone 6 weeks Grapefruit is allowed up to Visit 1, then limited to no more than one glass of grapefruit juice (250 mL/ 8 ounces) or one grapefruit per day Any other investigational drug 30 days or 5 half lives whichever is longer.       .     . "
    },
    "NCT00356148_exc": {
        "Annotations": [
            "Condition 0 24--*--Ductal carcinoma in situ",
            "Condition 26 30--*--DCIS",
            "Measurement 32 37--*--stage",
            "Condition 40 46--*--cancer",
            "Value 38 39--*--0",
            "Scope 26 46--*--DCIS; stage 0 cancer",
            "Value 62 80--*--distant metastatic",
            "Measurement 81 86--*--stage",
            "Value 50 58;70 80--*--Advanced metastatic",
            "Scope 50 80--*--Advanced or distant metastatic",
            "Procedure 103 122--*--neoadjuvant therapy",
            "Drug 150 161--*--antibiotics",
            "Temporal 162 183--*--within prior 3 months",
            "Observation 125 132--*--History",
            "Condition 197 213--*--immunodeficiency",
            "Observation 186 193--*--History",
            "Condition 225 241--*--remote infection",
            "Condition 255 263--*--reaction",
            "Observation 244 251--*--History",
            "Drug 267 284--*--study antibiotics",
            "Negation 287 296--*--Denial of",
            "Informed_consent 297 321--*--signing the consent form"
        ],
        "Text": "Ductal carcinoma in situ (DCIS; stage 0 cancer), . Advanced or distant metastatic stage, . Receiving any neoadjuvant therapy, . History of receiving any antibiotics within prior 3 months, . History of immunodeficiency, . Having a remote infection, . History of reaction to study antibiotics, . Denial of signing the consent form.       .     . "
    },
    "NCT02744976_exc": {
        "Text": "cardiac or non-cardiac illness with life expectancy of less than two years;. failure to advance the IVUS catheter through the culprit lesion;. acute coronary syndrome. congestive heart failure NYHA III-IV. diabetes mellitus. chronic kidney disease. previous PCI in the target vessel. heavily calcified vessels. allergy to metformin. ",
        "Annotations": [
            "Condition 11 30--*--non-cardiac illness",
            "Condition 0 7;23 30--*--cardiac illness",
            "Observation 36 51--*--life expectancy",
            "Value 55 74--*--less than two years",
            "Device 100 113--*--IVUS catheter",
            "Procedure 88 113--*--advance the IVUS catheter",
            "Qualifier 77 84--*--failure",
            "Qualifier 126 140--*--culprit lesion",
            "Condition 143 166--*--acute coronary syndrome",
            "Condition 168 192--*--congestive heart failure",
            "Measurement 193 197--*--NYHA",
            "Value 198 204--*--III-IV",
            "Condition 206 223--*--diabetes mellitus",
            "Condition 225 247--*--chronic kidney disease",
            "Procedure 258 261--*--PCI",
            "Temporal 249 257--*--previous",
            "Qualifier 269 283--*--target vessel",
            "Qualifier 269 282--*--target vessel",
            "Condition 284 309--*--heavily calcified vessels",
            "Condition 311 318--*--allergy",
            "Drug 322 331--*--metformin"
        ]
    },
    "NCT02982577_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 33--*--equal or superior to 18 years",
            "Person 41 48--*--genders",
            "Condition 86 106--*--psychiatric disorder",
            "Negation 61 68--*--without",
            "Condition 51 56--*--Lucid",
            "Condition 124 144--*--head and neck cancer",
            "Temporal 179 186--*--5 years",
            "Procedure 192 204--*--radiotherapy",
            "Qualifier 215 236--*--major salivary glands",
            "Qualifier 238 245--*--parotid",
            "Qualifier 247 260--*--submandibular",
            "Qualifier 265 275--*--sublingual",
            "Scope 238 275--*--parotid, submandibular and sublingual",
            "Condition 316 342--*--Primary Sj\u00f6gren's syndrome",
            "Qualifier 374 400--*--American-European criteria"
        ],
        "Text": "Age equal or superior to 18 years;. Both genders;. Lucid and without diagnosis of any psychiatric disorder;. Diagnosed with head and neck cancer and treated for a period of up to 5 years with radiotherapy where the major salivary glands (parotid, submandibular and sublingual) were included in the radiation field;. Primary Sj\u00f6gren's syndrome with the diagnosis made by the American-European criteria.. "
    },
    "NCT02830360_inc": {
        "Annotations": [
            "Condition 6 27--*--Myocardial Infarction",
            "Condition 43 57--*--monomorphic VT",
            "Qualifier 33 42--*--Sustained",
            "Procedure 72 83--*--12-lead ECG",
            "Procedure 87 99--*--rhythm strip",
            "Procedure 114 133--*--pharmacologic means",
            "Procedure 137 153--*--DC cardioversion",
            "Scope 72 99--*--12-lead ECG or rhythm strip",
            "Scope 114 153--*--pharmacologic means or DC cardioversion",
            "Multiplier 156 166--*--3 episodes",
            "Condition 170 172--*--VT",
            "Procedure 186 208--*--antitachycardia pacing",
            "Procedure 210 213--*--ATP",
            "Multiplier 257 267--*--5 episodes",
            "Condition 271 273--*--VT",
            "Procedure 287 309--*--antitachycardia pacing",
            "Procedure 311 314--*--ATP",
            "Multiplier 216 228--*--at least one",
            "Qualifier 242 253--*--symptomatic",
            "Multiplier 340 342--*--=1",
            "Procedure 355 365--*--ICD shocks",
            "Multiplier 369 370;374 382--*--3 episodes",
            "Condition 371 373--*--VT",
            "Temporal 383 398--*--within 24 hours"
        ],
        "Text": "Prior Myocardial Infarction and. Sustained monomorphic VT documented on 12-lead ECG or rhythm strip terminated by pharmacologic means or DC cardioversion. =3 episodes of VT treated with antitachycardia pacing (ATP), at least one of which was symptomatic. = 5 episodes of VT treated with antitachycardia pacing (ATP) regardless of symptoms. =1 appropriate ICD shocks,. =3 VT episodes within 24 hours. "
    },
    "NCT03168555_inc": {
        "Text": "planned elective cholecystectomy. ",
        "Annotations": [
            "Mood 0 7--*--planned",
            "Qualifier 8 16--*--elective",
            "Condition 17 32--*--cholecystectomy"
        ]
    },
    "NCT00576173_inc": {
        "Text": "Patients with a histologically, radiologically or haematologically confirmed malignancy whose pain is judged by the investigator to be caused by the malignancy . Patients must have been on a stable daily dose of weak opioids or strong opioids for at least 72 hours prior to the start the study and must remain at the same dosage for the duration of the study . Patients must have a VAS (Visual analog scale) >=40mm . ",
        "Annotations": [
            "Procedure 16 30--*--histologically",
            "Procedure 32 46--*--radiologically",
            "Procedure 50 66--*--haematologically",
            "Value 67 76--*--confirmed",
            "Condition 77 87--*--malignancy",
            "Condition 94 98--*--pain",
            "Scope 16 66--*--histologically, radiologically or haematologically",
            "Drug 211 223--*--weak opioids",
            "Drug 227 241--*--strong opioids",
            "Temporal 246 292--*--at least 72 hours prior to the start the study",
            "Scope 211 241--*--weak opioids or strong opioids",
            "Measurement 380 405--*--VAS (Visual analog scale)",
            "Value 406 412--*-->=40mm"
        ]
    },
    "NCT03169127_inc": {
        "Text": "Need of lower third molar surgeries. ",
        "Annotations": [
            "Procedure 26 35--*--surgeries",
            "Qualifier 8 25--*--lower third molar"
        ]
    },
    "NCT03221231_exc": {
        "Text": "Currently dependent on any substance other than cannabis, alcohol or nicotine;. History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);. An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;. An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;. Asthma;. Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);. Exclusion criteria for MRI: having metal in the body and/or having claustrophobia. ",
        "Annotations": [
            "Condition 10 19--*--dependent",
            "Drug 27 36--*--substance",
            "Negation 37 47--*--other than",
            "Drug 48 56--*--cannabis",
            "Drug 58 65--*--alcohol",
            "Drug 69 77--*--nicotine",
            "Scope 48 77--*--cannabis, alcohol or nicotine",
            "Condition 95 117--*--major internal disease",
            "Condition 129 137--*--diabetes",
            "Condition 139 161--*--cardiovascular disease",
            "Condition 163 175--*--lung disease",
            "Condition 186 200--*--kidney disease",
            "Condition 177 182;193 200--*--liver disease",
            "Scope 129 200--*--diabetes, cardiovascular disease, lung disease, liver or kidney disease",
            "Condition 232 253--*--neurological disorder",
            "Observation 221 228--*--history",
            "Qualifier 207 213--*--active",
            "Scope 207 228--*--active or any history",
            "Condition 284 300--*--seizure disorder",
            "Condition 302 310--*--epilepsy",
            "Condition 312 318--*--stroke",
            "Condition 320 340--*--neurological disease",
            "Condition 342 362--*--cognitive impairment",
            "Condition 364 375--*--head trauma",
            "Condition 381 412--*--prolonged loss of consciousness",
            "Qualifier 414 425--*-->10 minutes",
            "Condition 431 449--*--migraine headaches",
            "Scope 284 449--*--seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches",
            "Qualifier 455 461--*--active",
            "Observation 467 474--*--history",
            "Condition 480 500--*--psychiatric disorder",
            "Condition 532 542--*--depression",
            "Condition 544 557--*--schizophrenia",
            "Condition 559 575--*--bipolar disorder",
            "Condition 577 584--*--anxiety",
            "Condition 595 616--*--psychiatric disorders",
            "Qualifier 589 594--*--other",
            "Scope 532 616--*--depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders",
            "Scope 455 474--*--active or a history",
            "Condition 619 625--*--Asthma",
            "Condition 634 650--*--hypersensitivity",
            "Condition 654 661--*--allergy",
            "Drug 665 681--*--n-acetylcysteine",
            "Scope 634 661--*--hypersensitivity or allergy",
            "Procedure 696 711--*--chronic therapy",
            "Drug 763 779--*--n-acetylcysteine",
            "Temporal 780 817--*--within 30 days prior to randomization",
            "Drug 825 838--*--nitroglycerin",
            "Drug 840 854--*--ACE inhibitors",
            "Drug 858 880--*--antihypertensive drugs",
            "Drug 882 897--*--anti-coagulants",
            "Scope 825 897--*--nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants",
            "Condition 901 927--*--Exclusion criteria for MRI",
            "Device 936 953--*--metal in the body",
            "Condition 968 982--*--claustrophobia",
            "Scope 936 982--*--metal in the body and/or having claustrophobia"
        ]
    },
    "NCT03360981_inc": {
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 22--*-->18, <75",
            "Measurement 24 56--*--left ventricle ejection fraction",
            "Measurement 58 62--*--LVEF",
            "Value 64 68--*-->50%",
            "Condition 70 98--*--multivessel coronary disease",
            "Procedure 111 125--*--coronarography",
            "Procedure 151 155--*--CABG",
            "Mood 127 148--*--indication to receive",
            "Qualifier 157 163--*--stable",
            "Condition 164 167--*--CAD",
            "Condition 173 182--*--diabetics",
            "Condition 187 200--*--non diabetics"
        ],
        "Text": "patients aged >18, <75, left ventricle ejection fraction (LVEF) >50%, multivessel coronary disease detected by coronarography, indication to receive a CABG, stable CAD. All diabetics and non diabetics.. "
    },
    "NCT02964416_exc": {
        "Text": "Patients with a history of allergy or hypersensitivity to tramadol.. History of epilepsy or convulsions due to any reason.. Chronic usage of analgesic drugs.. Patients using monoamine oxidase inhibitors.. Patients with clinical signs of raised ICP.. Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2). Language barrier.. Patients taking B-blockers or Ca channel blockers.. Patients above 65 years of age ( Physiology difference). ",
        "Annotations": [
            "Condition 27 34--*--allergy",
            "Condition 38 54--*--hypersensitivity",
            "Drug 58 66--*--tramadol",
            "Scope 27 54--*--allergy or hypersensitivity",
            "Condition 80 88--*--epilepsy",
            "Condition 92 103--*--convulsions",
            "Drug 141 156--*--analgesic drugs",
            "Drug 174 202--*--monoamine oxidase inhibitors",
            "Measurement 244 247--*--ICP",
            "Value 237 243--*--raised",
            "Condition 250 257--*--Obesity",
            "Person 259 264--*--women",
            "Measurement 272 287--*--body mass index",
            "Value 288 297--*-->35 kg/m2",
            "Person 301 304--*--men",
            "Measurement 312 327--*--body mass index",
            "Value 328 337--*-->42 kg/m2",
            "Scope 259 337--*--women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2",
            "Post-eligibility 340 356--*--Language barrier",
            "Drug 389 408--*--Ca channel blockers",
            "Drug 375 385--*--B-blockers",
            "Person 438 441--*--age",
            "Value 420 434--*--above 65 years"
        ]
    },
    "NCT02466113_exc": {
        "Annotations": [
            "Condition 12 25--*--comorbidities",
            "Qualifier 5 11--*--severe",
            "Condition 35 57--*--cardiovascular disease",
            "Undefined_semantics 12 25--*--comorbidities",
            "Condition 59 96--*--chronic obstructive pulmonary disease",
            "Condition 98 115--*--diabetes mellitus",
            "Condition 121 146--*--chronic renal dysfunction",
            "Grammar_Error 117 120--*--and",
            "Scope 35 146--*--cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction",
            "Scope 5 25--*--severe comorbidities",
            "Condition 154 168--*--bad compliance",
            "Subjective_judgement 154 168--*--bad compliance",
            "Condition 172 202--*--contraindication to enrollment",
            "Subjective_judgement 172 202--*--contraindication to enrollment",
            "Undefined_semantics 172 202--*--contraindication to enrollment",
            "Condition 205 213--*--Pregnant",
            "Person 214 219--*--woman",
            "Condition 223 232--*--lactating",
            "Person 233 238--*--woman",
            "Scope 223 238--*--lactating woman",
            "Scope 205 219--*--Pregnant woman",
            "Condition 246 262--*--contraindication",
            "Procedure 274 295--*--adjuvant chemotherapy",
            "Subjective_judgement 246 262--*--contraindication",
            "Undefined_semantics 246 262--*--contraindication"
        ],
        "Text": "With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. . With bad compliance or contraindication to enrollment. . Pregnant woman or lactating woman. . With contraindication to receive adjuvant chemotherapy.       .     . "
    },
    "NCT02368743_inc": {
        "Annotations": [
            "Value 13 30--*--18 years or older",
            "Person 8 12--*--aged",
            "Condition 73 89--*--active proctitis",
            "Condition 93 117--*--distal proctosigmoiditis",
            "Qualifier 56 72--*--mild to moderate",
            "Scope 73 117--*--active proctitis or distal proctosigmoiditis",
            "Measurement 119 129--*--MAYO score",
            "Value 130 142--*--\u2265 3 and \u2264 10",
            "Temporal 199 237--*--within 6 months before study inclusion",
            "Reference_point 222 237--*--study inclusion",
            "Temporal 144 156--*--at inclusion",
            "Reference_point 147 156--*--inclusion",
            "Condition 276 292--*--active proctitis",
            "Condition 296 320--*--distal proctosigmoiditis",
            "Procedure 265 275--*--endoscopic",
            "Scope 276 320--*--active proctitis or distal proctosigmoiditis",
            "Measurement 322 345--*--Montreal classification",
            "Value 346 354--*--E1 or E2",
            "Qualifier 369 421--*--involvement not exceeding 25 cm from the anal margin",
            "Temporal 423 461--*--within 6 months before study inclusion",
            "Reference_point 446 461--*--study inclusion",
            "Drug 500 507--*--Pentasa",
            "Procedure 464 473--*--Treatment",
            "Condition 489 494--*--flare",
            "Temporal 609 635--*--during the inclusion visit",
            "Reference_point 620 635--*--inclusion visit",
            "Temporal 639 681--*--during the week before the inclusion visit",
            "Reference_point 646 681--*--the week before the inclusion visit",
            "Scope 609 681--*--during the inclusion visit or during the week before the inclusion visit",
            "Non-query-able 684 861--*--Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form"
        ],
        "Text": "Patient aged 18 years or older. . Patient suffering from mild to moderate active proctitis or distal proctosigmoiditis (MAYO score \u2265 3 and \u2264 10) at inclusion based on clinical and endoscopic findings within 6 months before study inclusion. . Patient with evidence of endoscopic active proctitis or distal proctosigmoiditis (Montreal classification E1 or E2 defined by an involvement not exceeding 25 cm from the anal margin) within 6 months before study inclusion. . Treatment of the current flare with Pentasa\u00ae to induce a remission initiated by the patient, the general practitioner or the gastroenterologist, during the inclusion visit or during the week before the inclusion visit. . Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form. . "
    },
    "NCT01236417_inc": {
        "Annotations": [
            "Condition 0 15--*--Post menopausal",
            "Person 16 21--*--women",
            "Observation 29 36--*--history",
            "Qualifier 40 57--*--estrogen positive",
            "Condition 58 71--*--breast cancer",
            "Drug 90 110--*--aromatase inhibitors",
            "Temporal 111 133--*--for at least one month",
            "Condition 179 189--*--arthralgia",
            "Qualifier 170 178--*--moderate",
            "Qualifier 162 166--*--mild",
            "Scope 162 178--*--mild to moderate",
            "Post-eligibility 192 240--*--Ability to understand and sign informed consent.",
            "Value 269 272--*--low",
            "Value 276 284--*--moderate",
            "Measurement 285 311--*--risk for moderate exercise",
            "Scope 269 284--*--low to moderate",
            "Measurement 326 341--*--ACSM guidelines"
        ],
        "Text": "Post menopausal women with a history of estrogen positive breast cancer who are receiving aromatase inhibitors for at least one month. . Patients must complain of mild to moderate arthralgia. . Ability to understand and sign informed consent. . Patients meet criteria for low to moderate risk for moderate exercise based oon the ACSM guidelines. . "
    },
    "NCT00676273_inc": {
        "Text": "Are at least 18 years of age . Demonstrate a positive cough stress test during complex multi-channel urodynamic testing . Demonstrate impact of stress urinary incontinence on quality of life questionnaire . Are able to comprehend and sign a written informed consent . Understand and are willing to comply with the study requirements, including agreeing to be available for the follow-up evaluations . Are psychologically stable and suitable for interventions determined by the investigator . Are ambulatory and able to use a toilet independently . ",
        "Annotations": [
            "Value 4 21--*--at least 18 years",
            "Person 25 28--*--age",
            "Measurement 53 70--*--cough stress test",
            "Value 44 52--*--positive",
            "Procedure 78 118--*--complex multi-channel urodynamic testing",
            "Condition 142 169--*--stress urinary incontinence",
            "Procedure 173 202--*--quality of life questionnaire",
            "Observation 208 226;236 262--*--able to comprehend a written informed consent",
            "Observation 208 215;231 262--*--able to sign a written informed consent",
            "Observation 283 328--*--willing to comply with the study requirements",
            "Observation 264 274;306 328--*--Understand the study requirements",
            "Condition 400 422--*--psychologically stable",
            "Condition 427 453--*--suitable for interventions",
            "Qualifier 454 484--*--determined by the investigator",
            "Scope 400 453--*--psychologically stable and suitable for interventions",
            "Condition 490 500--*--ambulatory",
            "Condition 505 539--*--able to use a toilet independently"
        ]
    },
    "NCT02952963_inc": {
        "Annotations": [
            "Qualifier 0 13--*--Uncomplicated",
            "Procedure 14 18--*--RYGB",
            "Temporal 29 64--*--minimum 3 months prior to the study",
            "Reference_point 55 64--*--the study",
            "Measurement 67 82--*--Fasting glucose",
            "Value 83 91--*--< 7,0 mM",
            "Measurement 93 98--*--HbA1c",
            "Value 99 112--*--< 48 mmol/mol",
            "Temporal 113 132--*--3 months after RYGB",
            "Reference_point 128 132--*--RYGB",
            "Procedure 128 132--*--RYGB",
            "Scope 67 112--*--Fasting glucose < 7,0 mM, HbA1c < 48 mmol/mol"
        ],
        "Text": "Uncomplicated RYGB performed minimum 3 months prior to the study.. Fasting glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB. "
    },
    "NCT01116882_inc": {
        "Annotations": [
            "Value 14 31--*--at least 18 years",
            "Person 32 35--*--old",
            "Procedure 82 122--*--percutaneous coronary intervention (PCI)",
            "Qualifier 58 65;75 81--*--single- vessel",
            "Qualifier 69 81--*--multi-vessel",
            "Scope 58 81--*--single- or multi-vessel",
            "Condition 148 161--*--target lesion",
            "Condition 173 200--*--in-stent restenotic lesions",
            "Qualifier 126 133--*--de novo",
            "Qualifier 137 147--*--restenotic",
            "Qualifier 173 181--*--in-stent",
            "Qualifier 182 192--*--restenotic",
            "Scope 126 161--*--de novo or restenotic target lesion",
            "Scope 126 201--*--de novo or restenotic target lesion (including in-stent restenotic lesions)",
            "Device 316 335--*--drug eluting stents",
            "Condition 236 263--*--amenable to stent treatment",
            "Device 302 312;329 335--*--bare metal stents",
            "Scope 302 335--*--bare metal or drug eluting stents",
            "Condition 410 445--*--coronary artery bypass graft (CABG)",
            "Qualifier 400 409--*--emergency",
            "Qualifier 390 396--*--urgent",
            "Qualifier 380 388--*--elective",
            "Scope 380 409--*--elective, urgent or emergency",
            "Condition 484 506--*--ischemic heart disease",
            "Observation 463 480--*--clinical evidence",
            "Procedure 530 546--*--functional study",
            "Value 521 529--*--positive",
            "Condition 587 609--*--stable angina pectoris",
            "Measurement 611 663--*--Canadian Cardiovascular Society Classification (CCS)",
            "Value 664 677--*--1, 2, 3, or 4",
            "Qualifier 587 593--*--stable",
            "Qualifier 680 688--*--unstable",
            "Condition 680 704--*--unstable angina pectoris",
            "Condition 721 729--*--ischemia",
            "Observation 710 720--*--documented",
            "Measurement 731 746--*--Braunwald Class",
            "Value 747 769--*--IB-C, IIB-C, or IIIB-C",
            "Condition 772 818--*--non-ST segment elevation myocardial infarction",
            "Condition 834 849--*--silent ischemia",
            "Qualifier 834 840--*--silent",
            "Observation 823 833--*--documented",
            "Procedure 894 919--*--percutaneous intervention",
            "Observation 866 873--*--willing",
            "Observation 878 882--*--able",
            "Visit 923 935--*--SOS hospital",
            "Post-eligibility 855 968--*--Subject is willing and able to undergo percutaneous intervention at SOS hospital, if randomized to SOS study arm.",
            "Post-eligibility 973 1074--*--Subject and the treating physician agree that the subject will comply with all follow-up evaluations.",
            "Post-eligibility 1079 1298--*--Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.",
            "Qualifier 1334 1341--*--de novo",
            "Condition 1308 1321--*--target lesion",
            "Scope 126 147--*--de novo or restenotic",
            "Qualifier 1345 1355--*--restenotic",
            "Qualifier 1367 1386--*--in-stent restenotic",
            "Scope 1334 1355--*--de novo or restenotic",
            "Scope 1334 1387--*--de novo or restenotic (including in-stent restenotic)",
            "Condition 1395 1417--*--coronary artery lesion",
            "Value 1426 1460--*--greater than 50 and less than 100%",
            "Measurement 1461 1469--*--stenosis",
            "Condition 1461 1469--*--stenosis",
            "Condition 1496 1509--*--target lesion",
            "Temporal 1516 1521--*--acute",
            "Temporal 1523 1540--*--less than 1 month",
            "Condition 1542 1557--*--total occlusion",
            "Observation 1574 1591--*--clinical symptoms",
            "Condition 1598 1612--*--Target lesions",
            "Condition 1639 1646--*--infarct",
            "Qualifier 1633 1646;1695 1710--*--in an infarct -related artery",
            "Procedure 1668 1679--*--primary PCI",
            "Negation 1651 1654--*--not",
            "Qualifier 1684 1710--*--non-infarct-related artery",
            "Value 1718 1732--*--70% or greater",
            "Measurement 1733 1741--*--stenosis",
            "Condition 1733 1741--*--stenosis",
            "Scope 1633 1710--*--in an infarct (if not treated with primary PCI) or non-infarct-related artery",
            "Temporal 1763 1846--*--more than 72 hours following the ST segment elevation myocardial infarction (STEMI)",
            "Reference_point 1792 1846--*--the ST segment elevation myocardial infarction (STEMI)",
            "Condition 1796 1846--*--ST segment elevation myocardial infarction (STEMI)",
            "Not_a_criteria 1849 2130--*--Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol inclusion/exclusion criteria listed above and below with the exception that a target lesion of 70% or greater stenosis may be treated with or without symptoms or abnormal stress test)"
        ],
        "Text": "1. Subject is at least 18 years old. . 2. Subject requires single- or multi-vessel percutaneous coronary intervention (PCI) of de novo or restenotic target lesion (including in-stent restenotic lesions). . 3. Subject's lesion(s) is (are) amenable to stent treatment with currently available FDA-approved bare metal or drug eluting stents. . 4. Subject is an acceptable candidate for elective, urgent or emergency coronary artery bypass graft (CABG). . 5. Subject has clinical evidence of ischemic heart disease in terms of a positive functional study, or documented symptoms. . 6. Documented stable angina pectoris [Canadian Cardiovascular Society Classification (CCS) 1, 2, 3, or 4], unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), non-ST segment elevation myocardial infarction, or documented silent ischemia. . 7. Subject is willing and able to undergo percutaneous intervention at SOS hospital, if randomized to SOS study arm. . 8. Subject and the treating physician agree that the subject will comply with all follow-up evaluations. . 9. Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site. . 10. The target lesion(s) is (are) de novo or restenotic (including in-stent restenotic) native coronary artery lesion(s) with greater than 50 and less than 100% stenosis (visual estimate), or the target lesion is an acute (less than 1 month) total occlusion as evidenced by clinical symptoms. . 11. Target lesions(s) is (are) located in an infarct (if not treated with primary PCI) or non-infarct-related artery with a 70% or greater stenosis (by visual estimate) more than 72 hours following the ST segment elevation myocardial infarction (STEMI). . Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol inclusion/exclusion criteria listed above and below with the exception that a target lesion of 70% or greater stenosis may be treated with or without symptoms or abnormal stress test). . "
    },
    "NCT01815580_inc": {
        "Text": "Adult men who have sex with men, and transgender women. Unaware of HIV status at enrollment in follow-up cohort. High risk for HIV infection. Willing to test for HIV. No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days. Willing to provide informed consent. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 6 31--*--men who have sex with men",
            "Person 37 54--*--transgender women",
            "Measurement 67 77--*--HIV status",
            "Value 56 63--*--Unaware",
            "Observation 56 77--*--Unaware of HIV status",
            "Temporal 78 111--*--at enrollment in follow-up cohort",
            "Reference_point 81 111--*--enrollment in follow-up cohort",
            "Condition 127 140--*--HIV infection",
            "Mood 113 126--*--High risk for",
            "Mood 142 152--*--Willing to",
            "Condition 153 165--*--test for HIV",
            "Negation 167 169--*--No",
            "Temporal 170 175--*--prior",
            "Procedure 176 179--*--ART",
            "Temporal 191 196--*--prior",
            "Procedure 197 211--*--administration",
            "Drug 224 249--*--post-exposure prophylaxis",
            "Drug 215 219;229 249--*--pre- exposure prophylaxis",
            "Temporal 250 269--*--in the last 30 days",
            "Scope 215 249--*--pre- and post-exposure prophylaxis",
            "Scope 170 269--*--prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days",
            "Observation 290 306--*--informed consent",
            "Mood 271 289--*--Willing to provide"
        ]
    },
    "NCT02704234_inc": {
        "Text": "women previously diagnosed with generalized vulvodynia . women previously diagnosed with localized vestibulodynia, . ",
        "Annotations": [
            "Condition 32 54--*--generalized vulvodynia",
            "Condition 88 112--*--localized vestibulodynia",
            "Person 0 5--*--women",
            "Person 56 61--*--women"
        ]
    },
    "NCT01236417_exc": {
        "Annotations": [
            "Post-eligibility 0 44--*--Inability to comply with study requirements.",
            "Condition 57 70--*--breast cancer",
            "Qualifier 46 56--*--Metastatic",
            "Condition 101 124--*--neuromuscular disorders",
            "Condition 115 124;87 97--*--disorders orthopedic",
            "Condition 167 187--*--Rheumatoid arthritis",
            "Condition 201 203--*--MI",
            "Condition 205 211--*--angina",
            "Condition 215 239--*--congestive heart failure",
            "Observation 190 197--*--History",
            "Scope 201 239--*--MI, angina or congestive heart failure",
            "Condition 242 250--*--Pregnant",
            "Condition 254 263--*--lactating",
            "Person 264 271--*--females",
            "Pregnancy_considerations 242 272--*--Pregnant or lactating females.",
            "Measurement 297 323--*--risk for moderate exercise",
            "Value 292 296--*--high",
            "Measurement 333 357--*--ACSM risk classification",
            "Observation 373 421--*--exceed minimal physical activity recommendations",
            "Non-query-able 360 550--*--Patients who exceed minimal physical activity recommendations from the US Surgeon General's Report: Accumulation of 30 minutes or more of moderate physical activity on most days of the week.",
            "Condition 552 566--*--Morbidly obese",
            "Measurement 572 575--*--BMI",
            "Value 576 580--*--\u2265 40"
        ],
        "Text": "Inability to comply with study requirements. . Metastatic breast cancer. . Patients with orthopedic or neuromuscular disorders that preclude participation in exercise. . Rheumatoid arthritis. . History of MI, angina or congestive heart failure. . Pregnant or lactating females. . Patients that are high risk for moderate exercise based on ACSM risk classification. . Patients who exceed minimal physical activity recommendations from the US Surgeon General's Report: Accumulation of 30 minutes or more of moderate physical activity on most days of the week. . Morbidly obese with BMI \u2265 40       .     . "
    },
    "NCT02368743_exc": {
        "Annotations": [
            "Condition 68 84--*--active proctitis",
            "Condition 88 112--*--distal proctosigmoiditis",
            "Procedure 54 63--*--treatment",
            "Undefined_semantics 54 63--*--treatment",
            "Scope 68 112--*--active proctitis or distal proctosigmoiditis",
            "Condition 140 147--*--colitis",
            "Condition 151 161--*--pancolitis",
            "Qualifier 128 138--*--left sided",
            "Scope 140 161--*--colitis or pancolitis",
            "Condition 184 193--*--proctitis",
            "Qualifier 177 183--*--severe",
            "Measurement 195 205--*--MAYO score",
            "Value 206 210--*--\u2265 11",
            "Temporal 211 223--*--at inclusion",
            "Drug 259 268--*--biologics",
            "Undefined_semantics 259 268--*--biologics",
            "Temporal 235 245--*--previously",
            "Procedure 246 253--*--treated",
            "Drug 292 309--*--immunosuppressive",
            "Temporal 310 347--*--within 1 month before study inclusion",
            "Reference_point 332 347--*--study inclusion",
            "Drug 371 386--*--corticosteroids",
            "Temporal 387 424--*--within 2 weeks before study inclusion",
            "Reference_point 409 424--*--study inclusion"
        ],
        "Text": "Patient included in an interventional study assessing treatment for active proctitis or distal proctosigmoiditis. . Patient with left sided, colitis or pancolitis. . Patient with severe proctitis (MAYO score \u2265 11 at inclusion). . Patient previously treated with biologics. . Patient treated with immunosuppressive within 1 month before study inclusion. . Patient treated with corticosteroids within 2 weeks before study inclusion.       .     . "
    },
    "NCT00676273_exc": {
        "Text": "Patients: . Who are pregnant or planning to become pregnant during the study or in the future . With a elevated post-void residual (defined as PVR > 100cc) . With a bleeding condition or on anti-coagulant therapy . With immunosuppression (i.e. HIV, lymphoma) . With multiple sclerosis or other progressive neurological disease . With evidence of a local or systemic infection, including urinary tract infection . With evidence of intrinsic sphincter deficiency as defined by a maximal urethral closure pressure of <20 cm H2O . Previous sub-urethral sling . Predominant overactive bladder symptoms       .     . ",
        "Annotations": [
            "Parsing_Error 0 9--*--Patients:",
            "Measurement 110 128--*--post-void residual",
            "Measurement 141 144--*--PVR",
            "Value 145 152--*--> 100cc",
            "Value 101 109--*--elevated",
            "Condition 162 180--*--bleeding condition",
            "Procedure 187 209--*--anti-coagulant therapy",
            "Condition 240 243--*--HIV",
            "Condition 245 253--*--lymphoma",
            "Observation 216 233--*--immunosuppression",
            "Scope 240 253--*--HIV, lymphoma",
            "Condition 261 279--*--multiple sclerosis",
            "Condition 289 321--*--progressive neurological disease",
            "Condition 351 369--*--systemic infection",
            "Condition 381 404--*--urinary tract infection",
            "Condition 342 347;360 369--*--local infection",
            "Scope 342 369--*--local or systemic infection",
            "Condition 423 453--*--intrinsic sphincter deficiency",
            "Measurement 470 503--*--maximal urethral closure pressure",
            "Value 507 517--*--<20 cm H2O",
            "Procedure 528 546--*--sub-urethral sling",
            "Temporal 519 527--*--Previous",
            "Condition 560 587--*--overactive bladder symptoms",
            "Qualifier 548 559--*--Predominant",
            "Condition 19 27--*--pregnant",
            "Mood 31 49--*--planning to become",
            "Condition 50 58--*--pregnant",
            "Temporal 59 75--*--during the study",
            "Temporal 79 92--*--in the future",
            "Scope 59 92--*--during the study or in the future",
            "Scope 19 58--*--pregnant or planning to become pregnant",
            "Condition 560 578--*--overactive bladder"
        ]
    },
    "NCT01116882_exc": {
        "Annotations": [
            "Condition 18 26--*--pregnant",
            "Observation 30 43--*--breastfeeding",
            "Condition 61 66--*--STEMI",
            "Temporal 67 82--*--within 72 hours",
            "Qualifier 112 127;151 157--*--infarct related artery",
            "Qualifier 131 157--*--non-infarct related artery",
            "Procedure 99 108--*--treatment",
            "Scope 112 157--*--infarct related or non-infarct related artery",
            "Condition 163 180--*--Cardiogenic shock",
            "Procedure 215 230--*--hospitalization",
            "Temporal 207 214--*--current",
            "Measurement 236 270--*--Left ventricular ejection fraction",
            "Value 271 284--*--less than 20%",
            "Drug 310 317--*--aspirin",
            "Drug 319 330--*--clopidogrel",
            "Drug 332 338--*--Plavix",
            "Drug 344 355--*--ticlopidine",
            "Drug 357 363--*--Ticlid",
            "Drug 366 373--*--heparin",
            "Drug 375 386--*--bivalirudin",
            "Observation 388 403--*--stainless steel",
            "Drug 408 422--*--contrast agent",
            "Condition 296 305--*--allergies",
            "Scope 310 422--*--aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent",
            "Measurement 472 486--*--platelet count",
            "Value 487 513--*--less than 75,000 cells/mm3",
            "Value 517 547--*--greater than 700,000 cells/mm3",
            "Measurement 553 556--*--WBC",
            "Value 557 582--*--less than 3,000 cells/mm3",
            "Scope 487 547--*--less than 75,000 cells/mm3 or greater than 700,000 cells/mm3",
            "Condition 597 622--*--chronic renal dysfunction",
            "Condition 588 593;605 622--*--Acute renal dysfunction",
            "Measurement 624 634--*--creatinine",
            "Value 635 657--*--greater than 2.5 mg/dl",
            "Value 661 680--*--less than 150\u00b5mol/L",
            "Scope 635 680--*--greater than 2.5 mg/dl or less than 150\u00b5mol/L",
            "Context_Error 687 1045--*--Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).",
            "Post-eligibility 687 1045--*--Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).",
            "Context_Error 1050 1084--*--Prior participation in this study.",
            "Temporal 1090 1139--*--Within 30 days prior to the index study procedure",
            "Reference_point 1114 1139--*--the index study procedure",
            "Procedure 1178 1211--*--coronary interventional procedure",
            "Temporal 1169 1177--*--previous",
            "Condition 1279 1284--*--STEMI",
            "Condition 1300 1306--*--Stroke",
            "Condition 1310 1335--*--transient ischemic attack",
            "Negation 1261 1264--*--not",
            "Temporal 1336 1361--*--within the prior 3 months",
            "Scope 1300 1335--*--Stroke or transient ischemic attack",
            "Condition 1375 1387--*--peptic ulcer",
            "Temporal 1368 1374--*--Active",
            "Condition 1391 1422--*--upper gastrointestinal bleeding",
            "Temporal 1423 1448--*--within the prior 3 months",
            "Scope 1375 1422--*--peptic ulcer or upper gastrointestinal bleeding",
            "Condition 1474 1480--*--sepsis",
            "Temporal 1467 1473--*--active",
            "Condition 1499 1532--*--left main coronary artery disease",
            "Qualifier 1487 1498--*--Unprotected",
            "Measurement 1534 1542--*--stenosis",
            "Condition 1534 1542--*--stenosis",
            "Value 1543 1559--*--greater than 50%",
            "Subjective_judgement 1567 1596--*--In the investigator's opinion",
            "Measurement 1656 1671--*--life expectancy",
            "Observation 1656 1671--*--life expectancy",
            "Value 1675 1693--*--less than one year",
            "Post-eligibility 1567 1840--*--In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study.",
            "Condition 1899 1914--*--coronary lesion",
            "Measurement 1899 1914--*--coronary lesion",
            "Value 1918 1940--*--less than 50% stenosis",
            "Condition 1932 1940--*--stenosis",
            "Condition 1994 2002--*--thrombus",
            "Procedure 2018 2044--*--target vessel thrombectomy",
            "Condition 2047 2058--*--tortuousity",
            "Value 2060 2082--*--greater than 60 degree",
            "Measurement 2083 2088--*--angle",
            "Procedure 2126 2155--*--stent delivery and deployment",
            "Qualifier 2104 2125--*--unsuitable for proper",
            "Subjective_judgement 2104 2125--*--unsuitable for proper",
            "Condition 2164 2177--*--calcification",
            "Qualifier 2158 2163--*--heavy",
            "Device 2228 2299--*--device other than percutaneous transluminal coronary angioplasty (PTCA)",
            "Procedure 2246 2299--*--percutaneous transluminal coronary angioplasty (PTCA)",
            "Negation 2235 2245--*--other than",
            "Procedure 2309 2324--*--stent placement",
            "Temporal 2300 2324--*--prior to stent placement",
            "Reference_point 2309 2324--*--stent placement",
            "Procedure 2351 2383--*--directional coronary atherectomy",
            "Procedure 2385 2398--*--excimer laser",
            "Procedure 2400 2422--*--rotational atherectomy",
            "Scope 2351 2422--*--directional coronary atherectomy, excimer laser, rotational atherectomy",
            "Mood 2202 2210--*--requires",
            "Procedure 2211 2220--*--treatment",
            "Condition 2188 2201--*--target lesion",
            "Device 2468 2488--*--saphenous vein graft",
            "Condition 2440 2446--*--lesion",
            "Qualifier 2455 2488--*--located in a saphenous vein graft",
            "Qualifier 2515 2539--*--within the native vessel",
            "Grammar_Error 2571 2583--*--are eligible",
            "Qualifier 2544 2570--*--accessed through the graft",
            "Scope 2515 2570--*--within the native vessel but accessed through the graft",
            "Non-representable 2590 2780--*--The target vessel is in a \"last remaining\" epicardial vessel (e.g. greater than 2 non-target epicardial vessels and the bypass grafts to these territories [if present] are totally occluded)."
        ],
        "Text": "1. The patient is pregnant or breastfeeding. . 2. Evidence of STEMI within 72 hours of the intended treatment on infarct related or non-infarct related artery. . 3. Cardiogenic shock on presentation or during current hospitalization. . 4. Left ventricular ejection fraction less than 20%. . 5. Known allergies to: aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which cannot be adequately premedicated). . 6. A platelet count less than 75,000 cells/mm3 or greater than 700,000 cells/mm3 or a WBC less than 3,000 cells/mm3. . 7. Acute or chronic renal dysfunction (creatinine greater than 2.5 mg/dl or less than 150\u00b5mol/L). . 8. Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials). . 9. Prior participation in this study. . 10. Within 30 days prior to the index study procedure, the subject has undergone a previous coronary interventional procedure of any kind. Note: This exclusion criterion does not apply to post-STEMI patients. . 11. Stroke or transient ischemic attack within the prior 3 months. . 12. Active peptic ulcer or upper gastrointestinal bleeding within the prior 3 months. . 13. Subject has active sepsis. . 14. Unprotected left main coronary artery disease (stenosis greater than 50%). . 15. In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study. . 16. Subject has normal or insignificant coronaries (i.e. coronary lesion(s) less than 50% stenosis). . 17. Any target vessel has evidence of: . excessive thrombus (e.g. requires target vessel thrombectomy) . tortuousity (greater than 60 degree angle) that makes it unsuitable for proper stent delivery and deployment, . heavy calcification. . 18. Any target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement (e.g. but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.). . 19. Any lesion that is located in a saphenous vein graft, however, lesions located within the native vessel but accessed through the graft are eligible. . 20. The target vessel is in a \"last remaining\" epicardial vessel (e.g. greater than 2 non-target epicardial vessels and the bypass grafts to these territories [if present] are totally occluded).       .     . "
    },
    "NCT02952963_exc": {
        "Annotations": [
            "Measurement 0 22--*--Fasting plasma glucose",
            "Value 23 31--*--> 7,0 mM",
            "Measurement 33 38--*--HbA1c",
            "Value 39 52--*--> 48 mmol/mol",
            "Temporal 53 72--*--3 months after RYGB",
            "Scope 0 52--*--Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol",
            "Qualifier 74 86--*--Dysregulated",
            "Condition 87 103--*--thyroid diseases",
            "Procedure 112 133--*--antithyroid treatment",
            "Condition 136 163--*--Late diabetic complications",
            "Condition 167 178--*--retinopathy",
            "Condition 180 199--*--renal insufficiency",
            "Condition 201 211--*--neuropathy",
            "Temporal 215 223--*--previous",
            "Condition 224 236--*--pancreatitis",
            "Scope 167 236--*--retinopathy, renal insufficiency, neuropathy or previous pancreatitis",
            "Condition 239 252--*--Complications",
            "Procedure 256 260--*--RYGB",
            "Condition 273 295--*--reactive hypoglycaemia",
            "Qualifier 297 303--*--severe",
            "Condition 304 311--*--dumping",
            "Condition 313 321--*--vomiting",
            "Condition 323 331--*--diarrhea",
            "Qualifier 333 339--*--severe",
            "Condition 340 354--*--abdominal pain",
            "Temporal 355 372--*--after food intake",
            "Reference_point 361 372--*--food intake",
            "Scope 313 372--*--vomiting, diarrhea, severe abdominal pain after food intake",
            "Scope 297 311--*--severe dumping",
            "Scope 273 373--*--reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)",
            "Scope 239 260--*--Complications to RYGB",
            "Procedure 375 390--*--Cholecystectomy"
        ],
        "Text": "Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol 3 months after RYGB. Dysregulated thyroid diseases, use of antithyroid treatment.. Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.. Complications to RYGB. Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake). Cholecystectomy.. "
    },
    "NCT01815580_exc": {
        "Text": "Prior receipt of investigational anti-HIV vaccine. Ongoing therapy with any of the following: Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents. Known allergy/sensitivity or any hypersensitivity to components of study drugs (ART) or their formulations. Active drug or alcohol use or dependence that would interfere with adherence to study requirements. Serious medical or psychiatric illness that would interfere with the ability to adhere to study requirements. Chronic or acute hepatitis B infection. Use of female hormonal products based on estrogen or derivatives. ",
        "Annotations": [
            "Temporal 0 5--*--Prior",
            "Qualifier 17 32--*--investigational",
            "Drug 33 49--*--anti-HIV vaccine",
            "Temporal 51 58--*--Ongoing",
            "Procedure 59 66--*--therapy",
            "Drug 94 118--*--Systemic corticosteroids",
            "Multiplier 120 132--*--Short course",
            "Multiplier 133 162--*--less than or equal to 21 days",
            "Condition 166 181--*--corticosteroids",
            "Negation 182 192--*--is allowed",
            "Scope 120 192--*--Short course less than or equal to 21 days of corticosteroids is allowed",
            "Drug 194 226--*--Systemic chemotherapeutic agents",
            "Drug 228 255--*--Nephrotoxic systemic agents",
            "Drug 267 282--*--aminoglycosides",
            "Drug 284 298--*--amphotericin B",
            "Drug 300 309--*--cidofovir",
            "Drug 311 320--*--cisplatin",
            "Drug 322 331--*--foscarnet",
            "Drug 333 344--*--pentamidine",
            "Procedure 346 373--*--Immunomodulatory treatments",
            "Drug 384 397--*--Interleukin-2",
            "Drug 399 421--*--Investigational agents",
            "Scope 94 421--*--Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents",
            "Condition 429 436--*--allergy",
            "Condition 437 448--*--sensitivity",
            "Condition 456 472--*--hypersensitivity",
            "Drug 476 501--*--components of study drugs",
            "Drug 503 506--*--ART",
            "Drug 508 529--*--or their formulations",
            "Scope 476 529--*--components of study drugs (ART) or their formulations",
            "Condition 546 557--*--alcohol use",
            "Condition 554 557--*--use",
            "Condition 538 542;561 571--*--drug dependence",
            "Condition 546 553;561 571--*--alcohol dependence",
            "Qualifier 577 629--*--would interfere with adherence to study requirements",
            "Scope 538 571--*--drug or alcohol use or dependence",
            "Temporal 531 537--*--Active",
            "Condition 650 669--*--psychiatric illness",
            "Condition 639 646;662 669--*--medical illness",
            "Qualifier 631 638--*--Serious",
            "Scope 639 669--*--medical or psychiatric illness",
            "Qualifier 675 739--*--would interfere with the ability to adhere to study requirements",
            "Condition 741 748;758 779--*--Chronic hepatitis B infection",
            "Condition 752 779--*--acute hepatitis B infection",
            "Drug 788 812--*--female hormonal products",
            "Qualifier 822 830;834 845--*--estrogen derivatives",
            "Qualifier 822 830--*--estrogen",
            "Scope 822 845--*--estrogen or derivatives"
        ]
    },
    "NCT02704234_exc": {
        "Text": "pregnancy . menopause . interstitial cystitis . irritable bowel syndrome . untreated vaginitis . cervicitis . pelvic inflammatory disease . any other pelvic pathology causing pain . concomitant physical therapy . concomitant biofeedback . concomitant massage . additional acupuncture       .     . ",
        "Annotations": [
            "Condition 0 9--*--pregnancy",
            "Condition 11 20--*--menopause",
            "Condition 22 43--*--interstitial cystitis",
            "Condition 45 69--*--irritable bowel syndrome",
            "Condition 71 90--*--untreated vaginitis",
            "Condition 92 102--*--cervicitis",
            "Condition 104 131--*--pelvic inflammatory disease",
            "Condition 143 159--*--pelvic pathology",
            "Qualifier 160 172--*--causing pain",
            "Undefined_semantics 137 172--*--other pelvic pathology causing pain",
            "Procedure 186 202--*--physical therapy",
            "Temporal 174 185--*--concomitant",
            "Temporal 204 215--*--concomitant",
            "Procedure 216 227--*--biofeedback",
            "Procedure 241 248--*--massage",
            "Temporal 229 240--*--concomitant",
            "Procedure 261 272--*--acupuncture"
        ]
    },
    "NCT03047538_exc": {
        "Text": "hypersensitivity to perindopril or to other ACE inhibitors, amlodipine, atorvastatin, dihydropyridines or to or statins. angioneurotic edema in medical history (hereditary / idiopathic or associated with prior treatment with ACE inhibitors). severe hypotension, shock, including cardiogenic shock. hemodynamically unstable heart failure. Active liver disease or unexplained persistent elevations of serum transaminases more than three times normal. Women of childbearing age without reliable contraception. pregnancy. breastfeeding. Patients with contraindications listed in the currently valid SP. ",
        "Annotations": [
            "Condition 0 16--*--hypersensitivity",
            "Drug 20 31--*--perindopril",
            "Drug 44 58--*--ACE inhibitors",
            "Drug 60 70--*--amlodipine",
            "Drug 72 84--*--atorvastatin",
            "Drug 86 102--*--dihydropyridines",
            "Drug 112 119--*--statins",
            "Qualifier 38 43--*--other",
            "Scope 20 119--*--perindopril or to other ACE inhibitors, amlodipine, atorvastatin, dihydropyridines or to or statins",
            "Condition 121 140--*--angioneurotic edema",
            "Qualifier 174 184--*--idiopathic",
            "Qualifier 161 171--*--hereditary",
            "Qualifier 188 198--*--associated",
            "Procedure 210 219--*--treatment",
            "Temporal 204 209--*--prior",
            "Drug 225 239--*--ACE inhibitors",
            "Scope 161 239--*--hereditary / idiopathic or associated with prior treatment with ACE inhibitors",
            "Condition 249 260--*--hypotension",
            "Condition 262 267--*--shock",
            "Condition 279 296--*--cardiogenic shock",
            "Qualifier 242 248--*--severe",
            "Scope 249 296--*--hypotension, shock, including cardiogenic shock",
            "Qualifier 298 322--*--hemodynamically unstable",
            "Condition 323 336--*--heart failure",
            "Condition 345 358--*--liver disease",
            "Measurement 399 418--*--serum transaminases",
            "Value 419 447--*--more than three times normal",
            "Value 385 395--*--elevations",
            "Qualifier 362 373--*--unexplained",
            "Qualifier 374 384--*--persistent",
            "Person 449 454--*--Women",
            "Person 458 474--*--childbearing age",
            "Qualifier 483 491--*--reliable",
            "Procedure 492 505--*--contraception",
            "Negation 475 482--*--without",
            "Condition 507 516--*--pregnancy",
            "Observation 518 531--*--breastfeeding",
            "Condition 547 564--*--contraindications",
            "Qualifier 565 597--*--listed in the currently valid SP"
        ]
    },
    "NCT02969876_inc": {
        "Annotations": [
            "Measurement 6 59;79 87--*--Diagnostic and Statistical Manual of Mental Disorders criteria",
            "Qualifier 61 71--*--Versions 4",
            "Qualifier 61 69;76 77--*--Versions 5",
            "Parsing_Error 72 75--*--and",
            "Scope 61 77--*--Versions 4 and 5",
            "Condition 96 121--*--Major Depressive Disorder",
            "Parsing_Error 92 95--*--and",
            "Measurement 124 156--*--Hamilton Depression Rating Scale",
            "Value 166 181--*--greater than 18",
            "Person 184 187--*--Men",
            "Person 192 197--*--women",
            "Parsing_Error 188 191--*--and",
            "Person 206 210--*--ages",
            "Value 198 205;213 222--*--between 18 and 65",
            "Parsing_Error 211 213--*-->="
        ],
        "Text": "Meets Diagnostic and Statistical Manual of Mental Disorders (Versions 4 and 5) criteria for and Major Depressive Disorder.. Hamilton Depression Rating Scale-17 score greater than 18.. Men and women between ages >=18 and 65.. "
    },
    "NCT02443844_inc": {
        "Annotations": [
            "Condition 18 52--*--non muscle invasive bladder cancer",
            "Person 96 99--*--old",
            "Value 76 95--*--between 40-80 years",
            "Person 53 57--*--male"
        ],
        "Text": "Patients who have non muscle invasive bladder cancer male patients patients between 40-80 years old. "
    },
    "NCT02015494_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Person 18 22--*--aged",
            "Value 23 34--*--18-40 years",
            "Person 38 41--*--age",
            "Temporal 42 68--*--at the time of vaccination",
            "Reference_point 49 68--*--time of vaccination",
            "Condition 72 83--*--good health",
            "Undefined_semantics 72 83--*--good health",
            "Observation 101 116--*--medical history",
            "Procedure 118 131--*--physical exam",
            "Procedure 133 155--*--laboratory assessments",
            "Subjective_judgement 160 211--*--the clinical judgment of the Principal Investigator",
            "Scope 101 211--*--medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator",
            "Non-query-able 213 374--*--Able to provide informed consent indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol",
            "Post-eligibility 376 916--*--If the subject is a female of childbearing potential, she must use adequate contraceptive precautions (e.g., intrauterine contraceptive device, oral contraceptives or other equivalent hormonal contraception) for 2 months prior to vaccination and continue to use such precautions for a minimum of three months after vaccination. She must also have a negative urine pregnancy test within 24 hours prior to receiving study vaccine. Women at least one year post-menopausal or surgically sterile will not be considered of childbearing potential.",
            "Non-query-able 918 984--*--Willing to receive the unlicensed vaccine given as an IM injection",
            "Drug 952 959--*--vaccine",
            "Procedure 972 984--*--IM injection",
            "Non-query-able 986 1055--*--Willing to provide multiple blood specimens collected by venipuncture"
        ],
        "Text": "Males and females aged 18-40 years of age at the time of vaccination in good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator . Able to provide informed consent indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol . If the subject is a female of childbearing potential, she must use adequate contraceptive precautions (e.g., intrauterine contraceptive device, oral contraceptives or other equivalent hormonal contraception) for 2 months prior to vaccination and continue to use such precautions for a minimum of three months after vaccination. She must also have a negative urine pregnancy test within 24 hours prior to receiving study vaccine. Women at least one year post-menopausal or surgically sterile will not be considered of childbearing potential. . Willing to receive the unlicensed vaccine given as an IM injection . Willing to provide multiple blood specimens collected by venipuncture . "
    },
    "NCT00182520_exc": {
        "Annotations": [
            "Qualifier 18 24--*--DSM-IV",
            "Qualifier 10 17--*--primary",
            "Condition 25 34--*--diagnosis",
            "Measurement 36 51--*--DSM-IV criteria",
            "Condition 56 80--*--body dysmorphic disorder",
            "Condition 82 108--*--bipolar affective disorder",
            "Condition 110 123--*--schizophrenia",
            "Condition 125 144--*--psychotic disorder,",
            "Condition 161 176--*--substance abuse",
            "Condition 153 160;171 176--*--alcohol abuse",
            "Scope 56 176--*--body dysmorphic disorder, bipolar affective disorder, schizophrenia, psychotic disorder, current alcohol/substance abuse",
            "Condition 229 254--*--major depressive disorder",
            "Qualifier 220 228--*--Comorbid",
            "Temporal 271 293--*--predates OCD diagnosis",
            "Reference_point 280 293--*--OCD diagnosis",
            "Procedure 295 324--*--Cognitive behavioural therapy",
            "Procedure 339 352--*--psychotherapy",
            "Qualifier 328 338--*--additional",
            "Temporal 353 372--*--in past four months",
            "Condition 374 381--*--Allergy",
            "Condition 385 401--*--hypersensitivity",
            "Drug 405 415--*--topiramate",
            "Scope 374 401--*--Allergy or hypersensitivity",
            "Measurement 417 420--*--BMI",
            "Value 421 425--*--< 20",
            "Condition 438 451--*--kidney stones",
            "Drug 208 218--*--topiramate",
            "Temporal 181 189--*--previous",
            "Observation 427 437--*--History of"
        ],
        "Text": "Any other primary DSM-IV diagnosis; DSM-IV criteria for body dysmorphic disorder, bipolar affective disorder, schizophrenia, psychotic disorder, current alcohol/substance abuse.. A previous adequate trial of topiramate. Comorbid major depressive disorder diagnosis which predates OCD diagnosis. Cognitive behavioural therapy or additional psychotherapy in past four months. Allergy or hypersensitivity to topiramate. BMI < 20. History of kidney stones. "
    },
    "NCT02713087_exc": {
        "Text": "Age younger than 18 yrs. or older than 75 yrs.. Pregnancy or nursing (negative pregnancy blood test). History of allergic reactions to phenylephrine or ephedrine. eGFR < 60ml/min/1.73m2. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 46--*--younger than 18 yrs. or older than 75 yrs.",
            "Condition 48 57--*--Pregnancy",
            "Condition 61 68--*--nursing",
            "Value 70 78--*--negative",
            "Measurement 79 99--*--pregnancy blood test",
            "Scope 48 68--*--Pregnancy or nursing",
            "Scope 70 99--*--negative pregnancy blood test",
            "Observation 102 109--*--History",
            "Condition 113 131--*--allergic reactions",
            "Drug 135 148--*--phenylephrine",
            "Drug 152 161--*--ephedrine",
            "Scope 135 161--*--phenylephrine or ephedrine",
            "Measurement 163 167--*--eGFR",
            "Value 168 185--*--< 60ml/min/1.73m2"
        ]
    },
    "NCT02882113_exc": {
        "Text": "Patients who have Tacrolimus trough level resulted as 2 ng/mg at the baseline.. Patients who are on steroid therapy due to positive result of acute rejection test before the baseline.. Patients who have received a transplant besides liver.. Patients who are allergic to IP or macrolide compounds.. Patients who are on cyclosporine, bosentan, or potassium sparing diuretic.. Patients with genetic diseases such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.. Pregnant or lactating women.. Patients not willing to adhere to study procedures/treatments.. ",
        "Annotations": [
            "Measurement 18 28--*--Tacrolimus",
            "Value 54 61--*--2 ng/mg",
            "Drug 100 107--*--steroid",
            "Measurement 142 162--*--acute rejection test",
            "Value 123 131--*--positive",
            "Procedure 214 224--*--transplant",
            "Qualifier 233 238--*--liver",
            "Condition 258 266--*--allergic",
            "Drug 270 272--*--IP",
            "Scope 270 295--*--IP or macrolide compounds",
            "Drug 276 285--*--macrolide",
            "Drug 318 330--*--cyclosporine",
            "Drug 332 340--*--bosentan",
            "Drug 345 371--*--potassium sparing diuretic",
            "Condition 388 404--*--genetic diseases",
            "Condition 413 434--*--galactose intolerance",
            "Condition 436 459--*--Lapp lactase deficiency",
            "Condition 464 495--*--glucose-galactose malabsorption",
            "Scope 413 495--*--galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption",
            "Pregnancy_considerations 498 525--*--Pregnant or lactating women",
            "Post-eligibility 528 589--*--Patients not willing to adhere to study procedures/treatments"
        ]
    },
    "NCT02825290_inc": {
        "Annotations": [
            "Value 0 11--*--20-40 years",
            "Person 12 15--*--old",
            "Person 16 21--*--women",
            "Condition 23 46--*--Spontaneously ovulating",
            "Person 47 52--*--women",
            "Visit 65 77--*--our IVF unit",
            "Procedure 82 111--*--frozen-thawed embryo transfer",
            "Value 113 125--*--At least one",
            "Measurement 126 144--*--top quality embryo"
        ],
        "Text": "20-40 years old women. Spontaneously ovulating women. Treated in our IVF unit for frozen-thawed embryo transfer. At least one top quality embryo. "
    },
    "NCT03506750_exc": {
        "Text": "previous retinal vein occlusion.. any intraocular surgery within the previous 12 months.. myopia of > or = to 8 diopters.. active ocular or periocular infection. treatment with an investigational agent for any condition 60 days prior to enrollment.. evidence of severe cardiac disease.. clinically significant peripheral vascular disease (previous surgery, amputation, or symptoms of claudication). uncontrolled hypertension (treated systolic blood pressure > 155 mmHg or diastolic blood pressure > 95 mmHg). stroke within the preceding 12 months.. ",
        "Annotations": [
            "Condition 9 31--*--retinal vein occlusion",
            "Temporal 0 8--*--previous",
            "Procedure 38 57--*--intraocular surgery",
            "Temporal 58 87--*--within the previous 12 months",
            "Condition 90 96--*--myopia",
            "Value 100 120--*--> or = to 8 diopters",
            "Condition 140 160--*--periocular infection",
            "Condition 130 136;151 160--*--ocular infection",
            "Scope 130 160--*--ocular or periocular infection",
            "Qualifier 123 129--*--active",
            "Competing_trial 162 247--*--treatment with an investigational agent for any condition 60 days prior to enrollment",
            "Qualifier 262 268--*--severe",
            "Condition 269 284--*--cardiac disease",
            "Mood 250 261--*--evidence of",
            "Qualifier 287 309--*--clinically significant",
            "Condition 310 337--*--peripheral vascular disease",
            "Procedure 339 355--*--previous surgery",
            "Procedure 357 367--*--amputation",
            "Condition 372 396--*--symptoms of claudication",
            "Scope 339 396--*--previous surgery, amputation, or symptoms of claudication",
            "Scope 287 337--*--clinically significant peripheral vascular disease",
            "Condition 412 424--*--hypertension",
            "Qualifier 399 411--*--uncontrolled",
            "Measurement 434 457--*--systolic blood pressure",
            "Qualifier 426 433--*--treated",
            "Value 458 468--*--> 155 mmHg",
            "Measurement 472 496--*--diastolic blood pressure",
            "Value 497 506--*--> 95 mmHg",
            "Scope 434 506--*--systolic blood pressure > 155 mmHg or diastolic blood pressure > 95 mmHg",
            "Scope 399 424--*--uncontrolled hypertension",
            "Condition 509 515--*--stroke",
            "Temporal 516 546--*--within the preceding 12 months"
        ]
    },
    "NCT03356834_exc": {
        "Annotations": [
            "Condition 17 20--*--HCV",
            "Temporal 0 11--*--Co-infected",
            "Condition 22 25--*--HIV",
            "Qualifier 29 34--*--other",
            "Condition 35 50--*--viral hepatitis",
            "Scope 17 50--*--HCV, HIV or other viral hepatitis",
            "Condition 66 69--*--HCC"
        ],
        "Text": "Co-infected with HCV, HIV or other viral hepatitis,. Diagnosis of HCC. "
    },
    "NCT01944800_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT03047538_inc": {
        "Text": "a very high cardiovascular risk and LDL-cholesterol> 1.8 mmol / l. a high cardiovascular risk and LDL-cholesterol> 2.5 mmol / l. Patient with a high or very high cardiovascular risk treated by lipidlowering therapy with statin. ",
        "Annotations": [
            "Condition 12 31--*--cardiovascular risk",
            "Qualifier 2 11--*--very high",
            "Measurement 36 51--*--LDL-cholesterol",
            "Value 51 65--*--> 1.8 mmol / l",
            "Condition 74 93--*--cardiovascular risk",
            "Qualifier 69 73--*--high",
            "Measurement 98 113--*--LDL-cholesterol",
            "Value 113 127--*--> 2.5 mmol / l",
            "Qualifier 152 161--*--very high",
            "Qualifier 144 148--*--high",
            "Condition 162 181--*--cardiovascular risk",
            "Procedure 193 214--*--lipidlowering therapy",
            "Drug 220 225--*--stati",
            "Scope 144 161--*--high or very high"
        ]
    },
    "NCT02015494_exc": {
        "Annotations": [
            "Drug 45 49--*--drug",
            "Drug 53 68--*--vaccine product",
            "Qualifier 11 26--*--investigational",
            "Qualifier 30 44--*--non-registered",
            "Scope 11 44--*--investigational or non-registered",
            "Temporal 69 133--*--within 30 days preceding the administration of the study vaccine",
            "Reference_point 94 133--*--the administration of the study vaccine",
            "Non-query-able 137 148--*--planned use",
            "Temporal 149 195--*--within the first six weeks of the study period",
            "Observation 137 148--*--planned use",
            "Reference_point 179 195--*--the study period",
            "Scope 69 195--*--within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period",
            "Scope 45 68--*--drug or vaccine product",
            "Context_Error 0 195--*--Use of any investigational or non-registered drug or vaccine product within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period",
            "Drug 248 265--*--influenza vaccine",
            "Qualifier 214 222--*--licensed",
            "Qualifier 226 247--*--other investigational",
            "Scope 214 247--*--licensed or other investigational",
            "Temporal 266 315--*--within 3 months prior to enrollment in this study",
            "Reference_point 291 315--*--enrollment in this study",
            "Observation 319 335--*--expected receipt",
            "Non-query-able 319 335--*--expected receipt",
            "Drug 339 364--*--any influenza vaccination",
            "Temporal 365 382--*--before the Day 21",
            "Reference_point 376 382--*--Day 21",
            "Observation 401 408--*--History",
            "Condition 412 433--*--excessive alcohol use",
            "Condition 435 445--*--drug abuse",
            "Condition 461 480--*--psychiatric illness",
            "Undefined_semantics 461 480--*--psychiatric illness",
            "Qualifier 449 460--*--significant",
            "Scope 412 480--*--excessive alcohol use, drug abuse or significant psychiatric illness",
            "Condition 482 493--*--Tobacco use",
            "Temporal 494 523--*--within 3 months of enrollment",
            "Reference_point 513 523--*--enrollment",
            "Temporal 528 566--*--throughout first 6 months of the study",
            "Reference_point 557 566--*--the study",
            "Condition 574 589--*--chronic illness",
            "Undefined_semantics 574 589--*--chronic illness",
            "Condition 597 602;613 620--*--liver disease",
            "Condition 606 620--*--kidney disease",
            "Scope 597 620--*--liver or kidney disease",
            "Procedure 647 654--*--therapy",
            "Temporal 635 646--*--concomitant",
            "Undefined_semantics 647 654--*--therapy",
            "Condition 663 682--*--any other condition",
            "Qualifier 688 749--*--could interfere with the subject's participation in the study",
            "Measurement 829 849--*--liver function tests",
            "Value 820 828--*--abnormal",
            "Qualifier 797 819--*--Clinically significant",
            "Subjective_judgement 797 819--*--Clinically significant",
            "Temporal 850 862--*--at screening",
            "Reference_point 853 862--*--screening",
            "Measurement 886 891;904 914--*--HBsAg antibodies",
            "Measurement 893 896;904 914--*--HCV antibodies",
            "Measurement 900 914--*--HIV antibodies",
            "Scope 886 914--*--HBsAg, HCV or HIV antibodies",
            "Value 864 872--*--Positive",
            "Condition 916 924--*--Pregnant",
            "Condition 928 937--*--lactating",
            "Person 938 944--*--female",
            "Condition 953 959--*--cancer",
            "Condition 991 997--*--cancer",
            "Procedure 977 997--*--treatment for cancer",
            "Temporal 998 1016--*--within three years",
            "Scope 953 997--*--cancer or have received treatment for cancer",
            "Condition 1044 1050--*--cancer",
            "Observation 1033 1040--*--history",
            "Condition 1059 1071--*--disease-free",
            "Procedure 1080 1089--*--treatment",
            "Negation 1072 1079--*--without",
            "Temporal 1090 1113--*--for three years or more",
            "Grammar_Error 1114 1126--*--are eligible",
            "Scope 1033 1126--*--history of cancer who are disease-free without treatment for three years or more are eligible",
            "Condition 1230 1260--*--impaired immune responsiveness",
            "Condition 1287 1304--*--diabetes mellitus",
            "Condition 1309 1329--*--autoimmune disorders",
            "Scope 1287 1329--*--diabetes mellitus and autoimmune disorders",
            "Temporal 1400 1426--*--within the past six months",
            "Drug 1428 1442--*--any medication",
            "Procedure 1446 1466--*--therapeutic modality",
            "Qualifier 1472 1497--*--affects the immune system",
            "Drug 1506 1519--*--allergy shots",
            "Drug 1521 1536--*--immune globulin",
            "Drug 1538 1548--*--interferon",
            "Drug 1550 1566--*--immunomodulators",
            "Procedure 1568 1585--*--radiation therapy",
            "Drug 1587 1602--*--cytotoxic drugs",
            "Drug 1606 1683--*--drugs known to be frequently associated with significant major organ toxicity",
            "Qualifier 1612 1683--*--known to be frequently associated with significant major organ toxicity",
            "Drug 1688 1712--*--systemic corticosteroids",
            "Qualifier 1714 1718--*--oral",
            "Qualifier 1722 1732--*--injectable",
            "Scope 1714 1732--*--oral or injectable",
            "Grammar_Error 1735 1783--*--Inhaled and topical corticosteroids are allowed.",
            "Scope 1428 1497--*--any medication or therapeutic modality that affects the immune system",
            "Scope 1506 1733--*--allergy shots, immune globulin, interferon, immunomodulators, radiation therapy, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable)",
            "Condition 1818 1835--*--allergic reaction",
            "Qualifier 1811 1817--*--severe",
            "Observation 1800 1807--*--history",
            "Temporal 1836 1863--*--after previous vaccinations",
            "Reference_point 1842 1863--*--previous vaccinations",
            "Condition 1867 1927--*--hypersensitivity to any seasonal influenza vaccine component",
            "Drug 1891 1927--*--seasonal influenza vaccine component",
            "Condition 1955 1978--*--Guillain-Barr\u00e9 Syndrome",
            "Procedure 1980 1996--*--Receipt of blood",
            "Procedure 1980 1990;2000 2014--*--Receipt of blood products",
            "Temporal 2015 2043--*--8 weeks prior to vaccination",
            "Reference_point 2032 2043--*--vaccination",
            "Temporal 2070 2126--*--during the three week study period following vaccination",
            "Reference_point 2081 2126--*--three week study period following vaccination",
            "Observation 2047 2069--*--planned administration",
            "Scope 1980 2014--*--Receipt of blood or blood products",
            "Scope 2015 2126--*--8 weeks prior to vaccination or planned administration during the three week study period following vaccination",
            "Procedure 2128 2145--*--Donation of blood",
            "Procedure 2128 2139;2149 2163--*--Donation of blood products",
            "Temporal 2164 2199--*--within 8 weeks prior to vaccination",
            "Reference_point 2188 2199--*--vaccination",
            "Temporal 2203 2237--*--during the three week study period",
            "Reference_point 2210 2237--*--the three week study period",
            "Scope 2164 2237--*--within 8 weeks prior to vaccination or during the three week study period",
            "Scope 2128 2163--*--Donation of blood or blood products",
            "Measurement 2252 2268--*--oral temperature",
            "Value 2269 2276--*-->100.4\u00b0",
            "Condition 2280 2293--*--acute disease",
            "Temporal 2294 2330--*--within 72 hours prior to vaccination",
            "Reference_point 2319 2330--*--vaccination",
            "Scope 2252 2293--*--oral temperature >100.4\u00b0 or acute disease",
            "Condition 2361 2369;2380 2387--*--moderate illness",
            "Condition 2373 2387--*--severe illness",
            "Measurement 2548 2563--*--Body Mass Index",
            "Value 2564 2569--*-->29.9",
            "Condition 2575 2598--*--disorder of coagulation",
            "Condition 2624 2633--*--influenza",
            "Temporal 2634 2663--*--within the previous 12 months",
            "Subjective_judgement 2665 2811--*--Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study",
            "Context_Error 2665 2811--*--Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study",
            "Post-eligibility 2665 2811--*--Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study"
        ],
        "Text": "Use of any investigational or non-registered drug or vaccine product within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period . Has received any licensed or other investigational influenza vaccine within 3 months prior to enrollment in this study or expected receipt of any influenza vaccination before the Day 21 blood collection . History of excessive alcohol use, drug abuse or significant psychiatric illness . Tobacco use within 3 months of enrollment and throughout first 6 months of the study . Has a chronic illness (e.g., liver or kidney disease), receiving a concomitant therapy or have any other condition that could interfere with the subject's participation in the study or in the interpretation of the study results . Clinically significant abnormal liver function tests at screening . Positive serology for HBsAg, HCV or HIV antibodies . Pregnant or lactating female . Having cancer or have received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding minor skin cancers, which are allowed unless located at the vaccination site . Persons with impaired immune responsiveness (of any cause), including diabetes mellitus and autoimmune disorders . Persons presently receiving or having a recent history of receiving (within the past six months) any medication or therapeutic modality that affects the immune system such as allergy shots, immune globulin, interferon, immunomodulators, radiation therapy, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable). Inhaled and topical corticosteroids are allowed. . Persons with a history of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component . Persons with a history of Guillain-Barr\u00e9 Syndrome . Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination . Donation of blood or blood products within 8 weeks prior to vaccination or during the three week study period following . An oral temperature >100.4\u00b0 or acute disease within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination; for example, those requiring an absence from work) with or without fever. . Body Mass Index >29.9 . Any disorder of coagulation . A clinical diagnosis of influenza within the previous 12 months . Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study       .     . "
    },
    "NCT02713087_inc": {
        "Text": "Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images). ASA (American Society of Anesthesiologist) status 1-3 (27). Written informed consent from participating patients. ",
        "Annotations": [
            "Mood 9 18--*--scheduled",
            "Procedure 23 60--*--supine-positioned elective craniotomy",
            "Qualifier 65 79--*--supratentorial",
            "Qualifier 80 89--*--malignant",
            "Negation 94 97--*--non",
            "Qualifier 98 107--*--malignant",
            "Condition 108 120--*--brain tumors",
            "Qualifier 121 135--*--3 cm or larger",
            "Scope 80 107--*--malignant and non-malignant",
            "Qualifier 153 182--*--largest diameter in any plane",
            "Procedure 186 188--*--MR",
            "Scope 153 188--*--largest diameter in any plane on MR",
            "Scope 65 196--*--supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images)",
            "Measurement 198 201;241 247--*--ASA status",
            "Measurement 203 239;241 247--*--American Society of Anesthesiologist status",
            "Scope 198 240--*--ASA (American Society of Anesthesiologist)",
            "Value 248 251--*--1-3",
            "Value 253 255--*--27",
            "Informed_consent 258 310--*--Written informed consent from participating patients"
        ]
    },
    "NCT00182520_inc": {
        "Annotations": [
            "Condition 32 35--*--OCD",
            "Qualifier 16 23--*--primary",
            "Qualifier 24 31--*--DSM- IV",
            "Drug 411 422--*--medications",
            "Qualifier 400 410--*--concurrent",
            "Qualifier 375 381--*--Stable",
            "Temporal 383 398--*--8 wks or longer",
            "Drug 433 448--*--benzodiazepines",
            "Drug 450 468--*--sedative hypnotics",
            "Drug 470 484--*--antipsychotics",
            "Drug 490 505--*--antidepressants",
            "Scope 433 505--*--benzodiazepines, sedative hypnotics, antipsychotics, and antidepressants",
            "Multiplier 53 60--*--14-week",
            "Drug 106 116--*--fluoxetine",
            "Multiplier 117 126--*--80 mg/day",
            "Drug 128 138--*--paroxetine",
            "Multiplier 139 148--*--60 mg/day",
            "Drug 150 161--*--fluvoxamine",
            "Multiplier 162 172--*--300 mg/day",
            "Drug 174 186--*--clomipramine",
            "Multiplier 187 197--*--250 mg/day",
            "Drug 199 209--*--sertraline",
            "Multiplier 210 220--*--200 mg/day",
            "Drug 222 232--*--citalopram",
            "Multiplier 233 242--*--60 mg/day",
            "Drug 244 256--*--escitalopram",
            "Multiplier 257 266--*--30 mg/day",
            "Condition 302 314--*--responses to",
            "Measurement 330 335--*--CGI-I",
            "Value 339 340--*--3",
            "Value 344 345--*--4",
            "Scope 339 345--*--3 or 4",
            "Measurement 347 353--*--Y-BOCS",
            "Value 354 372--*--reduction of < 35%",
            "Scope 330 372--*--CGI-I of 3 or 4, Y-BOCS reduction of < 35%",
            "Multiplier 81 98--*--one the following",
            "Scope 106 266--*--fluoxetine 80 mg/day, paroxetine 60 mg/day, fluvoxamine 300 mg/day, clomipramine 250 mg/day, sertraline 200 mg/day, citalopram 60 mg/day, escitalopram 30 mg/day",
            "Procedure 315 328--*--SRI treatment",
            "Scope 302 328--*--responses to SRI treatment",
            "Visit 0 10--*--Outpatient"
        ],
        "Text": "Outpatient with primary DSM- IV OCD. Completion of a 14-week open label trial of one the following SRI's: fluoxetine 80 mg/day, paroxetine 60 mg/day, fluvoxamine 300 mg/day, clomipramine 250 mg/day, sertraline 200 mg/day, citalopram 60 mg/day, escitalopram 30 mg/day and demonstrating a non or partial responses to SRI treatment (CGI-I of 3 or 4, Y-BOCS reduction of < 35%). Stable (8 wks or longer) concurrent medications including benzodiazepines, sedative hypnotics, antipsychotics, and antidepressants.. "
    },
    "NCT02443844_exc": {
        "Annotations": [
            "Temporal 18 26--*--previous",
            "Condition 27 43--*--prostate surgery",
            "Line 44 92--*--Patients who have muscle invasive bladder cancer",
            "Line 0 43--*--Patients who have previous prostate surgery",
            "Condition 78 92--*--bladder cancer",
            "Qualifier 62 77--*--muscle invasive"
        ],
        "Text": "Patients who have previous prostate surgery Patients who have muscle invasive bladder cancer. "
    },
    "NCT02969876_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03506750_inc": {
        "Text": "18 years or older. Type 1 or 2 diabetes. PDR patients requiring surgical intervention for complications of vitreous hemorrhage or traction retinal detachment and pre-operative IVC treatment.. women postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on effective contraception.. ",
        "Annotations": [
            "Value 0 17--*--18 years or older",
            "Person 12 17--*--older",
            "Condition 19 25;31 39--*--Type 1 diabetes",
            "Condition 19 23;29 39--*--Type 2 diabetes",
            "Condition 41 44--*--PDR",
            "Procedure 64 85--*--surgical intervention",
            "Mood 54 63--*--requiring",
            "Condition 107 126--*--vitreous hemorrhage",
            "Condition 130 157--*--traction retinal detachment",
            "Qualifier 162 175--*--pre-operative",
            "Procedure 176 189--*--IVC treatment",
            "Scope 107 189--*--vitreous hemorrhage or traction retinal detachment and pre-operative IVC treatment",
            "Pregnancy_considerations 192 312--*--women postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on effective contraception."
        ]
    },
    "NCT02882113_inc": {
        "Text": "19 years old and above.. Patients who previously have received a liver transplant over the last six months and within last three years.. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks.. Patients who have normal liver function and renal function.. Patients who have been monitored without complication such as acute rejection.. Patients willing to sign his/her consent.. ",
        "Annotations": [
            "Person 9 12--*--old",
            "Value 0 8;13 22--*--19 years and above",
            "Procedure 65 81--*--liver transplant",
            "Temporal 91 134--*--last six months and within last three years",
            "Drug 157 167--*--Tacrolimus",
            "Multiplier 194 205--*--twice a day",
            "Temporal 210 228--*--at least two weeks",
            "Qualifier 249 255--*--normal",
            "Condition 256 270--*--liver function",
            "Condition 275 289--*--renal function",
            "Negation 325 332--*--without",
            "Condition 333 345--*--complication",
            "Condition 354 369--*--acute rejection",
            "Informed_consent 372 412--*--Patients willing to sign his/her consent"
        ]
    },
    "NCT02825290_exc": {
        "Annotations": [
            "Procedure 0 3--*--PGD",
            "Multiplier 14 25--*--More than 4",
            "Temporal 26 34--*--previous",
            "Procedure 35 51--*--embryo transfers"
        ],
        "Text": "PGD patients. More than 4 previous embryo transfers. "
    },
    "NCT01944800_inc": {
        "Text": "intolerance of or allergy to ticagrelor or prasugrel. history of any stroke, transient ischemic attack or intracranial bleeding. known intracranial neoplasm, intracranial arteriovenous malformation or intracranial aneurysm. active bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding. fibrin-specific fibrinolytic therapy less than 24 h before randomization, non-fibrin-specific fibrinolytic therapy less than 48 h before randomization. known platelet count < 100.000/\u00b5L at the time of screening. known anemia (hemoglobin <10 g/dL) at the time of screening. oral anticoagulation that cannot be safely discontinued for the duration of the study. INR known to be greater than 1.5 at the time of screening. chronic renal insufficiency requiring dialysis. moderate or severe hepatic dysfunction (Child Pugh B or C). increased risk of bradycardia events (Sick Sinus, AV block grade II or III, bradycardia-induced syncope). index event is an acute complication (< 30 days) of PCI. concomitant medical illness that in the opinion of the investigator is associated with a life expectancy < 1 year. concomitant oral or i.v. therapy with strong CYP3A Inhibitors (e.g. ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d), CYP3A substrates with narrow therapeutic indices (e.g. cyclosporine, quinidine), or strong CYP3A inducers (e.g. rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital ) that cannot be safely discontinued. =1 doses of ticagrelor or prasugrel within 5 days before randomisation. no written informed consent. participation in another investigational drug study. previous enrolment in this study. for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study. Pregnancy, giving birth within the last 90 days, or lactation. inability to cooperate with protocol requirements. ",
        "Annotations": [
            "Drug 29 39--*--ticagrelor",
            "Condition 0 11--*--intolerance",
            "Condition 18 25--*--allergy",
            "Drug 43 52--*--prasugrel",
            "Scope 29 52--*--ticagrelor or prasugrel",
            "Scope 0 25--*--intolerance of or allergy",
            "Condition 69 75--*--stroke",
            "Condition 77 102--*--transient ischemic attack",
            "Condition 106 127--*--intracranial bleeding",
            "Condition 135 156--*--intracranial neoplasm",
            "Condition 158 197--*--intracranial arteriovenous malformation",
            "Condition 201 222--*--intracranial aneurysm",
            "Condition 231 239--*--bleeding",
            "Temporal 224 230--*--active",
            "Condition 241 351--*--clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding",
            "Scope 231 351--*--bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding",
            "Procedure 369 389--*--fibrinolytic therapy",
            "Qualifier 353 368--*--fibrin-specific",
            "Temporal 390 425--*--less than 24 h before randomization",
            "Procedure 447 467--*--fibrinolytic therapy",
            "Qualifier 427 446--*--non-fibrin-specific",
            "Temporal 468 503--*--less than 48 h before randomization",
            "Measurement 511 525--*--platelet count",
            "Value 526 538--*--< 100.000/\u00b5L",
            "Temporal 539 563--*--at the time of screening",
            "Reference_point 412 425--*--randomization",
            "Reference_point 490 503--*--randomization",
            "Reference_point 542 563--*--the time of screening",
            "Condition 571 577--*--anemia",
            "Measurement 579 589--*--hemoglobin",
            "Value 590 598--*--<10 g/dL",
            "Temporal 600 624--*--at the time of screening",
            "Reference_point 603 624--*--the time of screening",
            "Procedure 626 646--*--oral anticoagulation",
            "Qualifier 652 681--*--cannot be safely discontinued",
            "Temporal 682 711--*--for the duration of the study",
            "Reference_point 702 711--*--the study",
            "Measurement 713 716--*--INR",
            "Value 729 745--*--greater than 1.5",
            "Temporal 746 770--*--at the time of screening",
            "Reference_point 749 770--*--the time of screening",
            "Condition 772 799--*--chronic renal insufficiency",
            "Procedure 810 818--*--dialysis",
            "Condition 839 858--*--hepatic dysfunction",
            "Qualifier 832 838--*--severe",
            "Qualifier 820 828--*--moderate",
            "Scope 820 838--*--moderate or severe",
            "Measurement 860 870--*--Child Pugh",
            "Value 871 877--*--B or C",
            "Condition 898 916--*--bradycardia events",
            "Mood 880 894--*--increased risk",
            "Condition 918 928--*--Sick Sinus",
            "Condition 930 938--*--AV block",
            "Measurement 939 944--*--grade",
            "Value 945 954--*--II or III",
            "Condition 956 983--*--bradycardia-induced syncope",
            "Scope 918 983--*--Sick Sinus, AV block grade II or III, bradycardia-induced syncope",
            "Condition 1010 1022;1035 1041--*--complication of PCI",
            "Value 1024 1033--*--< 30 days",
            "Qualifier 1004 1009--*--acute",
            "Condition 1043 1070--*--concomitant medical illness",
            "Qualifier 1111 1156--*--is associated with a life expectancy < 1 year",
            "Procedure 1170 1174;1183 1190--*--oral therapy",
            "Procedure 1178 1190--*--i.v. therapy",
            "Drug 1196 1219--*--strong CYP3A Inhibitors",
            "Drug 1226 1238--*--ketoconazole",
            "Drug 1240 1252--*--itraconazole",
            "Drug 1254 1266--*--voriconazole",
            "Drug 1268 1281--*--telithromycin",
            "Drug 1283 1297--*--clarithromycin",
            "Drug 1299 1309--*--nefazodone",
            "Drug 1311 1320--*--ritonavir",
            "Drug 1322 1332--*--saquinavir",
            "Drug 1334 1344--*--nelfinavir",
            "Drug 1346 1355--*--indinavir",
            "Drug 1357 1367--*--atazanavir",
            "Drug 1369 1385--*--grapefruit juice",
            "Multiplier 1386 1393--*--> 1 L/d",
            "Scope 1226 1393--*--ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d",
            "Scope 1170 1190--*--oral or i.v. therapy",
            "Multiplier 1621 1629--*--=1 doses",
            "Drug 1633 1643--*--ticagrelor",
            "Drug 1647 1656--*--prasugrel",
            "Temporal 1657 1691--*--within 5 days before randomisation",
            "Reference_point 1678 1691--*--randomisation",
            "Scope 1633 1656--*--ticagrelor or prasugrel",
            "Non-query-able 1693 1720--*--no written informed consent",
            "Post-eligibility 1722 1773--*--participation in another investigational drug study",
            "Non-query-able 1775 1807--*--previous enrolment in this study",
            "Pregnancy_considerations 1809 1941--*--for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study",
            "Pregnancy_considerations 1943 2004--*--Pregnancy, giving birth within the last 90 days, or lactation",
            "Non-query-able 2006 2055--*--inability to cooperate with protocol requirements",
            "Drug 1396 1444--*--CYP3A substrates with narrow therapeutic indices",
            "Drug 1451 1463--*--cyclosporine",
            "Drug 1465 1474--*--quinidine",
            "Drug 1480 1501--*--strong CYP3A inducers",
            "Drug 1508 1516--*--rifampin",
            "Drug 1517 1527--*--rifampicin",
            "Drug 1529 1538--*--phenytoin",
            "Drug 1540 1553--*--carbamazepine",
            "Drug 1555 1567--*--dexamethason",
            "Drug 1569 1582--*--phenobarbital",
            "Scope 1508 1582--*--rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital",
            "Scope 1451 1474--*--cyclosporine, quinidine"
        ]
    },
    "NCT03356834_inc": {
        "Annotations": [
            "Condition 0 19--*--Chronic hepatitis B",
            "Drug 22 31--*--Antiviral",
            "Mood 32 43--*--experienced",
            "Observation 32 43--*--experienced",
            "Drug 69 72--*--TDF",
            "Procedure 69 91--*--TDF anti-HBV treatment",
            "Multiplier 59 68--*--long term",
            "Condition 78 81--*--HBV",
            "Measurement 94 101--*--HBV DNA",
            "Value 102 115--*--< 6 log IU/ml",
            "Qualifier 117 121--*--LLOD",
            "Informed_consent 124 182--*--Able to sign the consent form of anticipating in the study"
        ],
        "Text": "Chronic hepatitis B,. Antiviral experienced,. Currently on long term TDF anti-HBV treatment,. HBV DNA < 6 log IU/ml (LLOD). Able to sign the consent form of anticipating in the study. "
    },
    "NCT02102243_exc": {
        "Text": "Congestive heart failure or coronary artery disease. Blood pressure averaging > 159/99 mmHg. Serum creatinine > 1.5 mg/dL. Diabetes mellitus or other systemic illness. Left ventricular hypertrophy by echocardiography or ECG. Pregnancy. Hypersensitivity to spironolactone, chlorthalidone, amlodipine, human recombinant insulin or Definity. Any history of substance abuse (other than tobacco). History of gouty arthritis. Patients with right-to-left, bi-directional, or transient right-to-left cardiac shunts. Hypersensitivity to perflutren, blood, blood products or albumin. ",
        "Annotations": [
            "Condition 0 24--*--Congestive heart failure",
            "Condition 28 51--*--coronary artery disease",
            "Measurement 53 67--*--Blood pressure",
            "Value 78 91--*--> 159/99 mmHg",
            "Measurement 93 109--*--Serum creatinine",
            "Value 110 121--*--> 1.5 mg/dL",
            "Condition 123 140--*--Diabetes mellitus",
            "Condition 150 166--*--systemic illness",
            "Condition 168 196--*--Left ventricular hypertrophy",
            "Procedure 200 216--*--echocardiography",
            "Procedure 220 223--*--ECG",
            "Scope 200 223--*--echocardiography or ECG",
            "Condition 225 234--*--Pregnancy",
            "Condition 236 252--*--Hypersensitivity",
            "Drug 256 270--*--spironolactone",
            "Drug 272 286--*--chlorthalidone",
            "Drug 288 298--*--amlodipine",
            "Drug 300 325--*--human recombinant insulin",
            "Scope 256 325--*--spironolactone, chlorthalidone, amlodipine, human recombinant insulin",
            "Condition 354 369--*--substance abuse",
            "Observation 382 389--*--tobacco",
            "Negation 371 376--*--other",
            "Condition 403 418--*--gouty arthritis",
            "Qualifier 434 448--*--right-to-left,",
            "Qualifier 449 463--*--bi-directional",
            "Qualifier 468 477--*--transient",
            "Qualifier 478 491--*--right-to-left",
            "Condition 492 506--*--cardiac shunts",
            "Scope 468 491--*--transient right-to-left",
            "Scope 434 491--*--right-to-left, bi-directional, or transient right-to-left",
            "Condition 508 524--*--Hypersensitivity",
            "Drug 528 538--*--perflutren",
            "Procedure 540 545--*--blood",
            "Procedure 547 561--*--blood products",
            "Drug 565 572--*--albumin",
            "Scope 528 572--*--perflutren, blood, blood products or albumin"
        ]
    },
    "NCT02499185_exc": {
        "Annotations": [
            "Condition 8 27--*--acute kidney injury",
            "Measurement 28 33--*--Stage",
            "Value 34 37--*--2/3",
            "Procedure 50 67--*--kidney transplant",
            "Observation 39 46--*--History"
        ],
        "Text": "Ongoing acute kidney injury Stage 2/3. History of kidney transplant. "
    },
    "NCT02952378_inc": {
        "Annotations": [
            "Condition 25 32--*--Healthy",
            "Condition 4 11--*--healthy",
            "Person 96 104--*--patients",
            "Negation 34 41--*--without",
            "Condition 42 51--*--allergies",
            "Value 72 89--*--18 years or above",
            "Person 65 68--*--age",
            "Scope 25 89--*--Healthy, without allergies and with the age of 18 years or above",
            "Condition 106 117--*--Burn injury",
            "Value 118 131;158 159--*--exceeding 6-8 %",
            "Measurement 132 157--*--Total Burned Surface Area",
            "Scope 106 159--*--Burn injury exceeding 6-8 Total Burned Surface Area %"
        ],
        "Text": "For healthy individuals: Healthy, without allergies and with the age of 18 years or above.. For patients: Burn injury exceeding 6-8 Total Burned Surface Area %. "
    },
    "NCT02796378_exc": {
        "Annotations": [
            "Drug 0 26--*--Cholesterol-lowering drugs",
            "Condition 28 45--*--Diabetes Mellitus",
            "Condition 47 69--*--Cardiovascular disease",
            "Condition 78 87--*--arrythmia",
            "Condition 89 112--*--ischaemic heart disease",
            "Scope 78 112--*--arrythmia, ischaemic heart disease",
            "Condition 115 140--*--Musculoskeletal disorders",
            "Qualifier 141 192--*--preventing the subject to perform physical training",
            "Condition 194 210--*--Mental disorders",
            "Qualifier 211 271--*--preventing the subject to understand the project description"
        ],
        "Text": "Cholesterol-lowering drugs. Diabetes Mellitus. Cardiovascular disease such as arrythmia, ischaemic heart disease.. Musculoskeletal disorders preventing the subject to perform physical training. Mental disorders preventing the subject to understand the project description.. "
    },
    "NCT01579604_inc": {
        "Annotations": [
            "Condition 0 21--*--Cervical spine injury",
            "Observation 27 42--*--functional loss",
            "Qualifier 50 65--*--upper extremity",
            "Condition 98 112--*--C-spine injury",
            "Temporal 67 87--*--Greater than 4 month",
            "Observation 121 135--*--motor recovery",
            "Qualifier 114 120--*--Stable",
            "Condition 147 153--*--stable",
            "Qualifier 137 146--*--Medically",
            "Measurement 155 222--*--International Classification for Surgery of the Hand in Tetraplegia",
            "Value 226 229--*--0-5",
            "Temporal 230 241--*--at 6 months",
            "Measurement 264 273--*--extension",
            "Qualifier 258 263--*--thumb",
            "Qualifier 251 257--*--finger",
            "Value 243 250--*--Grade 0",
            "Scope 251 263--*--finger/thumb",
            "Temporal 274 285--*--at 6 months",
            "Post-eligibility 287 370--*--Subjects fluent in English or when not fluent, an appropriate translator is present"
        ],
        "Text": "Cervical spine injury with functional loss in the upper extremity. Greater than 4 months out from C-spine injury. Stable motor recovery. Medically stable. International Classification for Surgery of the Hand in Tetraplegia of 0-5 at 6 months. Grade 0 finger/thumb extension at 6 months. Subjects fluent in English or when not fluent, an appropriate translator is present. "
    },
    "NCT02773173_inc": {
        "Text": "Patients older than 18 years. Classification of the American Society of Anesthesiologists (ASA I-III). No cognitive deficits. Signed informed consent prior to surgery. ",
        "Annotations": [
            "Value 9 22--*--older than 18",
            "Person 23 28--*--years",
            "Measurement 30 89--*--Classification of the American Society of Anesthesiologists",
            "Measurement 91 94--*--ASA",
            "Value 95 100--*--I-III",
            "Negation 103 105--*--No",
            "Condition 106 124--*--cognitive deficits",
            "Informed_consent 126 166--*--Signed informed consent prior to surgery"
        ]
    },
    "NCT02102243_inc": {
        "Text": "Normotensive controls. Stage I (140-159/90-99 mmHg) untreated subjects with essential hypertension. Patients with PA and stage I (140-159/90-99 mmHg) hypertension. ",
        "Annotations": [
            "Procedure 13 21--*--controls",
            "Qualifier 0 12--*--Normotensive",
            "Condition 76 98--*--essential hypertension",
            "Qualifier 23 30--*--Stage I",
            "Qualifier 52 61--*--untreated",
            "Condition 114 116--*--PA",
            "Condition 150 162--*--hypertension",
            "Qualifier 121 128--*--stage I"
        ]
    },
    "NCT02796378_inc": {
        "Annotations": [
            "Measurement 9 26--*--blood-cholesterol",
            "Value 0 8--*--Elevated"
        ],
        "Text": "Elevated blood-cholesterol. "
    },
    "NCT02952378_exc": {
        "Annotations": [
            "Condition 0 13--*--Heart failure",
            "Condition 24 37--*--kidney injury",
            "Condition 24 30;38 45--*--kidney failure",
            "Mood 15 23--*--Signs of",
            "Scope 24 45--*--kidney injury/failure",
            "Qualifier 47 53--*--Severe",
            "Condition 54 63--*--allergies"
        ],
        "Text": "Heart failure. Signs of kidney injury/failure. Severe allergies. "
    },
    "NCT02499185_inc": {
        "Annotations": [
            "Person 0 10--*--= 18 years",
            "Value 0 10--*--= 18 years",
            "Condition 12 21--*--High risk",
            "Measurement 32 62--*--General Surgery AKI Risk Index",
            "Value 63 81--*--Class III, IV or V",
            "Procedure 83 106--*--Major abdominal surgery"
        ],
        "Text": "= 18 years. High risk patients: General Surgery AKI Risk Index Class III, IV or V. Major abdominal surgery. "
    },
    "NCT02773173_exc": {
        "Text": "Emergency surgery. Pregnancy or lactation. Immune disorders. Kidney or liver disease or advanced-stage cardiopulmonary. Patient refusal to participate in the study. Patients under 18 years or inability to consent. Associated neuromuscular disorders, contraindication for the use of rocuronium/ sugammadex, allergy or hypersensitivity to rocuronium / sugammadex. ",
        "Annotations": [
            "Procedure 0 17--*--Emergency surgery",
            "Condition 19 28--*--Pregnancy",
            "Condition 32 41--*--lactation",
            "Condition 43 59--*--Immune disorders",
            "Condition 71 84--*--liver disease",
            "Condition 61 67;77 84--*--Kidney disease",
            "Condition 88 118--*--advanced-stage cardiopulmonary",
            "Informed_consent 120 163--*--Patient refusal to participate in the study",
            "Person 183 188--*--years",
            "Value 174 182--*--under 18",
            "Condition 192 212--*--inability to consent",
            "Informed_consent 192 212--*--inability to consent",
            "Condition 225 248--*--neuromuscular disorders",
            "Condition 250 266--*--contraindication",
            "Drug 282 292--*--rocuronium",
            "Drug 294 304--*--sugammadex",
            "Scope 282 304--*--rocuronium/ sugammadex",
            "Condition 306 313--*--allergy",
            "Condition 317 333--*--hypersensitivity",
            "Drug 337 347--*--rocuronium",
            "Drug 350 360--*--sugammadex",
            "Scope 337 360--*--rocuronium / sugammadex",
            "Scope 306 333--*--allergy or hypersensitivity"
        ]
    },
    "NCT01579604_exc": {
        "Annotations": [
            "Person 9 16--*--patient",
            "Qualifier 0 8--*--Unstable",
            "Condition 18 35--*--Joint contracture",
            "Condition 37 47--*--Spasticity",
            "Observation 49 65--*--Loss of function",
            "Mood 84 95--*--improved by",
            "Procedure 105 120--*--tendon transfer",
            "Procedure 122 131--*--tenodesis",
            "Procedure 135 146--*--arthrodesis",
            "Scope 105 146--*--tendon transfer, tenodesis or arthrodesis",
            "Observation 178 188;202 211--*--recovering extension",
            "Qualifier 189 195--*--finger",
            "Qualifier 196 201--*--thumb",
            "Scope 189 201--*--finger/thumb",
            "Temporal 212 225--*--at 4-6 months",
            "Condition 255 273--*--spinal cord injury",
            "Temporal 227 249--*--Greater than 12 months",
            "Post-eligibility 275 347--*--Subject not fluent in English or an appropriate translator not available"
        ],
        "Text": "Unstable patient. Joint contracture. Spasticity. Loss of function is expected to be improved by reliable tendon transfer, tenodesis or arthrodesis that is available. Evidence of recovering finger/thumb extension at 4-6 months. Greater than 12 months from spinal cord injury. Subject not fluent in English or an appropriate translator not available. "
    },
    "NCT03336801_inc": {
        "Annotations": [
            "Mood 0 9--*--Scheduled",
            "Procedure 10 22--*--back surgery"
        ],
        "Text": "Scheduled back surgery. "
    },
    "NCT02477280_inc": {
        "Text": "18 years old or older.. ADHD is diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5 criteria).. Substance Use Disorder is diagnosed according to DSM-5 criteria.. Qb-score 1.3 or higher on at least one of the weighted summary parameters QbActivity, QbInattention or QbImpulsivity on the QbTest.. Participants are given their written informed consent to participate in the study.. ",
        "Annotations": [
            "Person 9 12--*--old",
            "Value 0 8;13 21--*--18 years or older",
            "Condition 24 28--*--ADHD",
            "Qualifier 125 130--*--DSM-5",
            "Condition 143 165--*--Substance Use Disorder",
            "Qualifier 192 197--*--DSM-5",
            "Measurement 209 217--*--Qb-score",
            "Value 218 231--*--1.3 or higher",
            "Informed_consent 342 423--*--Participants are given their written informed consent to participate in the study"
        ]
    },
    "NCT00752310_inc": {
        "Text": "Non-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection . Normal weight as defined by a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included . Able to comply with protocol requirements. Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis carried out at screening. . ",
        "Annotations": [
            "Condition 4 11--*--smoking",
            "Negation 0 3--*--Non",
            "Condition 16 23--*--smoking",
            "Multiplier 24 39;76 83--*--no more than 10 per day",
            "Observation 40 50--*--cigarettes",
            "Observation 57 63--*--cigars",
            "Multiplier 24 36;55 56;76 83--*--no more than 2 per day",
            "Multiplier 24 36;68 69;76 83--*--no more than 2 per day",
            "Observation 70 75--*--pipes",
            "Scope 24 83--*--no more than 10 cigarettes, or 2 cigars, or 2 pipes per day",
            "Temporal 84 124--*--for at least 3 months prior to selection",
            "Reference_point 115 124--*--selection",
            "Measurement 156 171--*--Body Mass Index",
            "Measurement 173 176--*--BMI",
            "Measurement 178 232--*--weight in kg divided by the square of height in meters",
            "Scope 173 232--*--BMI, weight in kg divided by the square of height in meters",
            "Value 237 274--*--18.0 to 30.0 kg/m2, extremes included",
            "Condition 126 139--*--Normal weight",
            "Observation 276 317--*--Able to comply with protocol requirements",
            "Condition 319 326--*--Healthy",
            "Procedure 345 363--*--medical evaluation",
            "Negation 381 388--*--absence",
            "Qualifier 396 415--*--clinically relevant",
            "Condition 416 427--*--abnormality",
            "Procedure 443 463--*--physical examination",
            "Procedure 465 480--*--medical history",
            "Procedure 482 499--*--electrocardiogram",
            "Procedure 507 518--*--vital signs",
            "Procedure 501 504--*--ECG",
            "Procedure 539 557;593 598--*--blood biochemistry tests",
            "Procedure 559 576;593 598--*--blood coagulation tests",
            "Procedure 582 598--*--hematology tests",
            "Procedure 605 615--*--urinalysis",
            "Temporal 628 640--*--at screening",
            "Reference_point 631 640--*--screening",
            "Scope 443 615--*--physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis"
        ]
    },
    "NCT02321202_exc": {
        "Annotations": [
            "Condition 0 32--*--Contraindication for hepatectomy",
            "Condition 44 71--*--gastrointestinal hemorrhage",
            "Condition 80 101--*--hemorrhagic disorders",
            "Qualifier 73 79--*--severe",
            "Condition 130 147--*--infectious lesion",
            "Qualifier 118 129--*--nonspecific",
            "Temporal 112 117--*--acute",
            "Condition 155 162--*--ascites",
            "Qualifier 149 154--*--overt",
            "Measurement 164 180--*--Child-Pugh Score",
            "Value 181 182--*--C",
            "Measurement 184 234--*--indocyanine green retention rate at 15min (ICGR15)",
            "Value 234 238--*--\uff1e30%",
            "Measurement 244 277--*--serum hepatitis B virus (HBV)-DNA",
            "Value 277 291--*--\uff1e126 copies/ml",
            "Measurement 296 332--*--serum alanine aminotransferase (ALT)",
            "Value 333 340--*--\uff1e 2\u00d7ULN",
            "Measurement 342 361--*--serum triglycerides",
            "Value 361 372--*--\uff1e2.0 mmol/L",
            "Condition 374 391--*--circulatory shock",
            "Condition 393 399--*--stroke",
            "Condition 401 428--*--acute myocardial infarction",
            "Condition 430 443--*--renal failure",
            "Condition 445 449--*--coma",
            "Qualifier 453 466--*--unknown cause",
            "Scope 44 466--*--gastrointestinal hemorrhage, severe hemorrhagic disorders, explicit acute nonspecific infectious lesion, overt ascites, Child-Pugh Score C, indocyanine green retention rate at 15min (ICGR15)\uff1e30%(12), serum hepatitis B virus (HBV)-DNA\uff1e126 copies/ml and serum alanine aminotransferase (ALT) \uff1e 2\u00d7ULN, serum triglycerides\uff1e2.0 mmol/L, circulatory shock, stroke, acute myocardial infarction, renal failure, coma of unknown cause",
            "Procedure 21 32--*--hepatectomy",
            "Condition 468 477--*--Pregnancy",
            "Person 479 482--*--Age",
            "Value 485 496--*--\uff1c18y or\uff1e75y",
            "Procedure 508 531--*--intraoperative ablation",
            "Condition 533 551--*--Unresectable tumor",
            "Drug 597 601;609 617--*--fish proteins",
            "Drug 605 617--*--egg proteins",
            "Condition 570 588--*--Allergic reactions",
            "Scope 597 617--*--fish or egg proteins"
        ],
        "Text": "Contraindication for hepatectomy, including gastrointestinal hemorrhage, severe hemorrhagic disorders, explicit acute nonspecific infectious lesion, overt ascites, Child-Pugh Score C, indocyanine green retention rate at 15min (ICGR15)\uff1e30%(12), serum hepatitis B virus (HBV)-DNA\uff1e126 copies/ml and serum alanine aminotransferase (ALT) \uff1e 2\u00d7ULN, serum triglycerides\uff1e2.0 mmol/L, circulatory shock, stroke, acute myocardial infarction, renal failure, coma of unknown cause . Pregnancy . Age of\uff1c18y or\uff1e75y . Performed intraoperative ablation . Unresectable tumor during operation . Allergic reactions against fish or egg proteins       .     . "
    },
    "NCT00752310_exc": {
        "Text": "No positive HIV 1 or HIV 2 test at screening . no history of significant skin disease such as, but not limited to rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria . no history of allergy to drugs such as, but not limited to, sulphonamides and penicillins . no previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication administered in this trial . no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period . no positive pregnancy test or breast feeding at screening       .     . ",
        "Annotations": [
            "Value 3 11--*--positive",
            "Measurement 12 17;27 31--*--HIV 1 test",
            "Measurement 21 31--*--HIV 2 test",
            "Temporal 32 44--*--at screening",
            "Reference_point 35 44--*--screening",
            "Scope 12 31--*--HIV 1 or HIV 2 test",
            "Condition 72 84--*--skin disease",
            "Observation 49 56--*--history",
            "Qualifier 60 71--*--significant",
            "Undefined_semantics 60 71--*--significant",
            "Condition 113 117--*--rash",
            "Condition 121 130--*--eruptions",
            "Condition 132 146--*--drug allergies",
            "Condition 148 160--*--food allergy",
            "Condition 162 172--*--dermatitis",
            "Condition 174 180--*--eczema",
            "Condition 182 191--*--psoriasis",
            "Condition 196 205--*--urticaria",
            "Scope 113 205--*--rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria",
            "Observation 210 217--*--history",
            "Condition 221 228--*--allergy",
            "Drug 267 280--*--sulphonamides",
            "Drug 285 296--*--penicillins",
            "Scope 267 296--*--sulphonamides and penicillins",
            "Procedure 705 719--*--pregnancy test",
            "Value 696 704--*--positive",
            "Observation 723 737--*--breast feeding",
            "Temporal 738 750--*--at screening",
            "Scope 696 737--*--positive pregnancy test or breast feeding",
            "Temporal 301 311--*--previously",
            "Qualifier 325 347--*--clinically significant",
            "Condition 348 355--*--allergy",
            "Condition 359 375--*--hypersensitivity",
            "Drug 390 434--*--excipients of the investigational medication",
            "Scope 348 375--*--allergy or hypersensitivity",
            "Person 466 472--*--female",
            "Condition 484 506--*--childbearing potential",
            "Negation 507 514--*--without",
            "Qualifier 522 531--*--effective",
            "Procedure 532 557--*--nonhormonal birth control",
            "Negation 570 573--*--not",
            "Mood 574 604--*--willing to continue practicing",
            "Procedure 611 632--*--birth control methods",
            "Temporal 633 691--*--for at least 30 days after the end of the treatment period",
            "Reference_point 660 691--*--the end of the treatment period"
        ]
    },
    "NCT02477280_exc": {
        "Text": "Affected by alcohol or drugs during the last month.. Untreated severe comorbid psychiatric or somatic illness.. Bloodpressure 150/95 or higher.. Irregular pulse, or pulse 100 or higher.. No counter indications according to the Medikinet pill.. Concurrent clinical diagnosis that significantly could affect test performance.. Concurrent prescription of medicines for ADHD or medicines that significantly could affect test performance.. ",
        "Annotations": [
            "Observation 12 19--*--alcohol",
            "Observation 23 28--*--drugs",
            "Temporal 40 50--*--last month",
            "Scope 12 28--*--alcohol or drugs",
            "Condition 102 109;79 90--*--illness psychiatric",
            "Condition 94 109--*--somatic illness",
            "Qualifier 53 62--*--Untreated",
            "Qualifier 63 69--*--severe",
            "Qualifier 70 78--*--comorbid",
            "Scope 53 78--*--Untreated severe comorbid",
            "Scope 79 109--*--psychiatric or somatic illness",
            "Measurement 112 125--*--Bloodpressure",
            "Value 126 142--*--150/95 or higher",
            "Measurement 155 160--*--pulse",
            "Value 145 154--*--Irregular",
            "Measurement 165 170--*--pulse",
            "Value 171 184--*--100 or higher",
            "Non-query-able 187 241--*--No counter indications according to the Medikinet pill",
            "Non-query-able 244 322--*--Concurrent clinical diagnosis that significantly could affect test performance",
            "Drug 352 361--*--medicines",
            "Condition 366 370--*--ADHD"
        ]
    },
    "NCT03336801_exc": {
        "Annotations": [
            "Measurement 0 44--*--American Association of Anesthesiology class",
            "Value 45 48--*--1-3",
            "Measurement 50 82--*--American Heart Association class",
            "Value 83 85--*-->3",
            "Measurement 87 90--*--BMI",
            "Value 91 94--*-->37",
            "Qualifier 96 111--*--Insulin treated",
            "Condition 112 120--*--diabetes",
            "Drug 96 103--*--Insulin",
            "Condition 122 131--*--Pregnancy",
            "Observation 135 149--*--breast feeding",
            "Condition 151 163--*--Sensistivity",
            "Condition 164 171--*--allergy",
            "Drug 180 197--*--anesthetic agents",
            "Scope 151 171--*--Sensistivity/allergy",
            "Observation 199 239--*--Inadequate understanding about the study",
            "Value 241 250--*--Depressed",
            "Measurement 251 266--*--kidney function",
            "Condition 274 277--*--AKI",
            "Condition 241 266--*--Depressed kidney function",
            "Value 279 288--*--Depressed",
            "Measurement 289 303--*--liver function",
            "Condition 279 303--*--Depressed liver function",
            "Qualifier 305 312--*--Genetic",
            "Condition 313 335--*--malignant hyperthermia"
        ],
        "Text": "American Association of Anesthesiology class 1-3. American Heart Association class >3. BMI >37. Insulin treated diabetes. Pregnancy or breast feeding. Sensistivity/allergy against anesthetic agents. Inadequate understanding about the study. Depressed kidney function and/or AKI. Depressed liver function. Genetic malignant hyperthermia. "
    },
    "NCT02321202_inc": {
        "Annotations": [
            "Condition 4 13--*--cirrhotic",
            "Condition 14 26--*--malnourished",
            "Condition 58 70--*--liver cancer",
            "Temporal 71 85--*--preoperatively",
            "Procedure 100 111--*--hepatectomy"
        ],
        "Text": "The cirrhotic malnourished patients who were diagnosed as liver cancer preoperatively and underwent hepatectomy were consecutively enrolled. . "
    },
    "NCT02269137_inc": {
        "Annotations": [
            "Multiplier 0 14--*--30 min or more",
            "Condition 42 49--*--seizure",
            "Condition 78 85--*--seizure",
            "Temporal 22 32--*--continuous",
            "Temporal 68 77--*--recurrent",
            "Qualifier 97 113--*--without recovery",
            "Scope 68 85--*--recurrent seizure",
            "Non-query-able 155 181--*--clinical data is complete."
        ],
        "Text": "30 min or more of (1) continuous clinical seizure activities or (2) recurrent seizure activities without recovery(returning to baseline)between seizures; . clinical data is complete. . "
    },
    "NCT01768195_inc": {
        "Annotations": [
            "Condition 0 9--*--treatment",
            "Condition 30 45--*--B-cell lymphoma",
            "Negation 10 15--*--naive",
            "Condition 47 61--*--HBsAg positive",
            "Temporal 62 73--*--at baseline",
            "Qualifier 88 103--*--rituximab-based",
            "Drug 88 97--*--rituximab",
            "Procedure 104 122--*--immunochemotherapy",
            "Observation 124 139--*--life expectancy",
            "Value 143 161--*--more than 3 months"
        ],
        "Text": "treatment-naive patients with B-cell lymphoma. HBsAg positive at baseline. treated with rituximab-based immunochemotherapy. life expectancy of more than 3 months. "
    },
    "NCT03208127_inc": {
        "Annotations": [
            "Person 13 16--*--Age",
            "Value 17 27--*--= 18 years",
            "Qualifier 33 63--*--MGH transplant center criteria",
            "Procedure 76 92--*--liver transplant",
            "Measurement 94 97--*--HCV",
            "Value 98 103--*--naive",
            "Condition 94 103--*--HCV naive",
            "Observation 105 134--*--Able to sign informed consent"
        ],
        "Text": "Recipient is Age = 18 years. Met MGH transplant center criteria, listed for liver transplant. HCV naive. Able to sign informed consent. "
    },
    "NCT02689817_exc": {
        "Text": "Existing sacral pressure ulcer, undergoing a cardiac procedure, or inability to provide informed consent.       .     . ",
        "Annotations": [
            "Condition 9 30--*--sacral pressure ulcer",
            "Procedure 45 62--*--cardiac procedure",
            "Undefined_semantics 45 62--*--cardiac procedure",
            "Condition 67 104--*--inability to provide informed consent",
            "Undefined_semantics 67 104--*--inability to provide informed consent",
            "Non-query-able 67 104--*--inability to provide informed consent",
            "Subjective_judgement 67 104--*--inability to provide informed consent"
        ]
    },
    "NCT02162433_exc": {
        "Text": "Known allergy or hypersensitivity reaction to dexmedetomidine. Organ dysfunction (renal/hepatic failure or leukemia). Cardiac disease (congenital or acquired). Airway or thoracic malformation. Cerebral palsy. Hypotonia. Need for premedication. Current/recent upper respiratory infection (within four weeks prior to the surgery). Asthma. Allergy or intolerance to clonidine. Non-English speaking parents/patients.. ",
        "Annotations": [
            "Condition 6 13--*--allergy",
            "Condition 17 33--*--hypersensitivity",
            "Drug 46 61--*--dexmedetomidine",
            "Scope 6 33--*--allergy or hypersensitivity",
            "Condition 63 80--*--Organ dysfunction",
            "Condition 88 103--*--hepatic failure",
            "Condition 107 115--*--leukemia",
            "Condition 82 87;96 103--*--renal failure",
            "Scope 82 115--*--renal/hepatic failure or leukemia",
            "Condition 118 133--*--Cardiac disease",
            "Qualifier 135 145--*--congenital",
            "Qualifier 149 157--*--acquired",
            "Scope 135 157--*--congenital or acquired",
            "Condition 170 191--*--thoracic malformation",
            "Condition 160 166;179 191--*--Airway malformation",
            "Condition 193 207--*--Cerebral palsy",
            "Condition 209 218--*--Hypotonia",
            "Drug 229 242--*--premedication",
            "Mood 220 228--*--Need for",
            "Temporal 244 251--*--Current",
            "Temporal 252 258--*--recent",
            "Condition 259 286--*--upper respiratory infection",
            "Temporal 288 326--*--within four weeks prior to the surgery",
            "Reference_point 315 326--*--the surgery",
            "Procedure 319 326--*--surgery",
            "Scope 244 258--*--Current/recent",
            "Condition 329 335--*--Asthma",
            "Condition 337 344--*--Allergy",
            "Condition 348 359--*--intolerance",
            "Drug 363 372--*--clonidine",
            "Observation 374 402--*--Non-English speaking parents",
            "Observation 374 394;403 411--*--Non-English speaking patients"
        ]
    },
    "NCT01669369_inc": {
        "Text": "histologically diagnosed primary classical osteosarcoma in extremities. staging IIB. MRI showing no skip lesion. receive standard neo-adjuvant chemotherapy, adjuvant chemotherapy,and standard surgical treatment. ",
        "Annotations": [
            "Procedure 0 14--*--histologically",
            "Qualifier 25 32--*--primary",
            "Condition 33 55--*--classical osteosarcoma",
            "Qualifier 56 70--*--in extremities",
            "Qualifier 72 83--*--staging IIB",
            "Procedure 85 88--*--MRI",
            "Negation 97 99--*--no",
            "Observation 100 111--*--skip lesion",
            "Procedure 121 155--*--standard neo-adjuvant chemotherapy",
            "Procedure 157 178--*--adjuvant chemotherapy",
            "Procedure 183 210--*--standard surgical treatment"
        ]
    },
    "NCT00718952_exc": {
        "Annotations": [
            "Condition 19 41--*--pulmonary hypertension",
            "Condition 175 205--*--chronic disease involved liver",
            "Temporal 166 171--*--acute",
            "Qualifier 158 165--*--serious",
            "Condition 175 199;207 213--*--chronic disease involved kidney",
            "Condition 175 199;219 224--*--chronic disease involved brain",
            "Scope 175 224--*--chronic disease involved liver, kidney, and brain",
            "Drug 247 263--*--CYP3A4-inhibitor",
            "Drug 267 274--*--nitrate",
            "Qualifier 240 246--*--potent",
            "Drug 350 360--*--sildenafil",
            "Condition 365 368--*--PAH",
            "Drug 379 389--*--sildenafil",
            "Drug 393 402--*--tadalafil",
            "Observation 411 446--*--contraindications in package insert",
            "Observation 57 102--*--refuse to subscribe written informed consents",
            "Observation 106 136--*--can't cooperate with the trial",
            "Condition 288 307--*--underlying diseases",
            "Scope 247 274--*--CYP3A4-inhibitor or nitrate",
            "Qualifier 4 15--*--other types",
            "Temporal 327 336--*--currently",
            "Scope 350 402--*--sildenafil for PAH or taking sildenafil or tadalafil"
        ],
        "Text": "The other types of pulmonary hypertension. . Subjects who refuse to subscribe written informed consents or can't cooperate with the trial well. . Subjects with serious acute or chronic disease involved liver, kidney, and brain or have to use potent CYP3A4-inhibitor or nitrate to treat the underlying diseases. . Subjects who are currently treated with sildenafil for PAH or taking sildenafil or tadalafil. . Other contraindications in package insert.       .     . "
    },
    "NCT02269137_exc": {
        "Annotations": [
            "Condition 0 15--*--hypoglycemia SE",
            "Condition 16 30--*--psychogenic SE",
            "Condition 41 50--*--pseudo-SE"
        ],
        "Text": "hypoglycemia SE;psychogenic SE;any other pseudo-SE       .     . "
    },
    "NCT01768195_exc": {
        "Annotations": [
            "Value 0 21--*--younger than 18 years",
            "Person 22 25--*--old",
            "Condition 27 41--*--HBsAg negative",
            "Temporal 42 53--*--at baseline",
            "Condition 55 63--*--pregnant",
            "Condition 67 76--*--lactating",
            "Person 77 82--*--women",
            "Scope 55 76--*--pregnant or lactating"
        ],
        "Text": "younger than 18 years old. HBsAg negative at baseline. pregnant or lactating women. "
    },
    "NCT02689817_inc": {
        "Text": "Patients undergoing an operation that is scheduled to last more than 2 hours . ",
        "Annotations": [
            "Procedure 23 32--*--operation",
            "Qualifier 41 76--*--scheduled to last more than 2 hours",
            "Temporal 54 76--*--last more than 2 hours",
            "Undefined_semantics 41 76--*--scheduled to last more than 2 hours",
            "Non-query-able 41 76--*--scheduled to last more than 2 hours"
        ]
    },
    "NCT01669369_exc": {
        "Text": "a history of non-standard treatment(chemotherapy or surgery). secondary osteosarcoma or well-differentiated parosteal osteosarcoma. evident dysfunction of cardia,liver and kidney, or pregnant women or women during lactation. ",
        "Annotations": [
            "Procedure 13 35--*--non-standard treatment",
            "Procedure 36 48--*--chemotherapy",
            "Procedure 52 59--*--surgery",
            "Scope 36 59--*--chemotherapy or surgery",
            "Observation 2 9--*--history",
            "Condition 62 84--*--secondary osteosarcoma",
            "Condition 108 130--*--parosteal osteosarcoma",
            "Qualifier 88 107--*--well-differentiated",
            "Condition 140 161--*--dysfunction of cardia",
            "Condition 140 154;172 178--*--dysfunction of kidney",
            "Condition 140 154;162 167--*--dysfunction of liver",
            "Condition 183 191--*--pregnant",
            "Condition 214 223--*--lactation"
        ]
    },
    "NCT02162433_inc": {
        "Text": "Patients between 3 to 16 years of age undergoing adenotonsillectomy, with or without myringotomy or myringoplasty. ASA 1 & 2. ",
        "Annotations": [
            "Value 9 30--*--between 3 to 16 years",
            "Person 34 37--*--age",
            "Procedure 49 67--*--adenotonsillectomy",
            "Temporal 38 48--*--undergoing",
            "Procedure 85 96--*--myringotomy",
            "Procedure 100 113--*--myringoplasty",
            "Scope 85 112--*--myringotomy or myringoplast",
            "Measurement 115 118--*--ASA",
            "Value 119 124--*--1 & 2"
        ]
    },
    "NCT03208127_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Observation 12 19--*--nursing",
            "Observation 21 30--*--lactating",
            "Person 32 37--*--women",
            "Condition 39 53--*--HIV positivity",
            "Measurement 39 42--*--HIV",
            "Value 43 53--*--positivity",
            "Procedure 64 85--*--dual organ transplant",
            "Mood 55 63--*--Need for",
            "Condition 91 108--*--contra-indication",
            "Procedure 112 133--*--liver transplantation"
        ],
        "Text": "Pregnant or nursing (lactating) women. HIV positivity. Need for dual organ transplant. Any contra-indication to liver transplantation per center protocol. "
    },
    "NCT00718952_inc": {
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 19--*--12-65",
            "Condition 32 65--*--idiopathic pulmonary hypertension",
            "Qualifier 67 103--*--connective tissue disease associated",
            "Condition 104 126--*--pulmonary hypertension",
            "Qualifier 128 152--*--congenital heart disease",
            "Condition 158 178--*--Eisenmenger syndrome",
            "Condition 191 213--*--pulmonary hypertension",
            "Measurement 225 251--*--6-minutes walking distance",
            "Value 252 261--*--150m-550m",
            "Temporal 216 224--*--Baseline",
            "Measurement 264 299--*--WHO pulmonary hypertension function",
            "Value 300 306--*--II-III",
            "Condition 312 353--*--non-responder to calcium channel blockers",
            "Drug 329 353--*--calcium channel blockers",
            "Observation 367 391--*--written informed consent"
        ],
        "Text": "Subjects aged 12-65. . Confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with Eisenmenger syndrome) associated pulmonary hypertension. . Baseline 6-minutes walking distance 150m-550m. . WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers. . Documented written informed consent. . "
    },
    "NCT03297125_exc": {
        "Text": "Optune compliance < 75%; they would be excluded from the final analyses.. History of craniectomy or significant skull defect (contraindication to Optune).. Active implantable medical device (i.e. DBS, spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).. Karnofsky Performance Status (KPS) < 60.. ",
        "Annotations": [
            "Observation 0 17--*--Optune compliance",
            "Multiplier 18 23--*--< 75%",
            "Non-query-able 25 71--*--they would be excluded from the final analyses",
            "Procedure 85 96--*--craniectomy",
            "Condition 112 124--*--skull defect",
            "Qualifier 100 111--*--significant",
            "Device 146 152--*--Optune",
            "Condition 126 142--*--contraindication",
            "Device 163 189--*--implantable medical device",
            "Device 196 199--*--DBS",
            "Device 201 223--*--spinal cord stimulator",
            "Device 225 234--*--pacemaker",
            "Device 236 249--*--defibrillator",
            "Device 251 273--*--vagus nerve stimulator",
            "Device 275 293--*--programmable shunt",
            "Scope 196 293--*--DBS, spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt",
            "Qualifier 156 162--*--Active",
            "Measurement 297 325--*--Karnofsky Performance Status",
            "Measurement 327 330--*--KPS",
            "Value 332 336--*--< 60"
        ]
    },
    "NCT03305575_inc": {
        "Text": "ASA classification II or III females. Age: 18-45 years old. BMI = 50 kg/m2. Singleton pregnancy. Simple prophylactic cervical cerclage. Planning neuraxial anesthesia. ",
        "Annotations": [
            "Measurement 0 18--*--ASA classification",
            "Value 19 28--*--II or III",
            "Person 29 36--*--females",
            "Person 38 41--*--Age",
            "Value 43 58--*--18-45 years old",
            "Measurement 60 63--*--BMI",
            "Value 64 74--*--= 50 kg/m2",
            "Condition 76 95--*--Singleton pregnancy",
            "Qualifier 104 116--*--prophylactic",
            "Qualifier 97 103--*--Simple",
            "Procedure 117 134--*--cervical cerclage",
            "Procedure 145 165--*--neuraxial anesthesia",
            "Mood 136 144--*--Planning"
        ]
    },
    "NCT02985710_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 10 17--*--females",
            "Grammar_Error 6 9--*--and",
            "Qualifier 42 47;84 89--*--Fabry na\u00efve",
            "Procedure 97 100--*--ERT",
            "Procedure 52 63--*--GLA enzymes",
            "Procedure 71 82--*--DNA testing",
            "Scope 52 82--*--GLA enzymes and/or DNA testing",
            "Condition 23 40--*--confirmed disease",
            "Context_Error 23 40--*--confirmed disease",
            "Condition 102 124--*--Mitochondrial diseases",
            "Procedure 126 150--*--electron transport chain",
            "Procedure 158 169--*--DNA testing",
            "Scope 126 169--*--electron transport chain and/or DNA testing",
            "Condition 174 200--*--connective tissue diseases",
            "Procedure 227 238--*--DNA testing",
            "Observation 202 219--*--clinical criteria",
            "Scope 202 238--*--clinical criteria and/or DNA testing",
            "Context_Error 42 47;84 89--*--Fabry na\u00efve",
            "Scope 42 100--*--Fabry (by GLA enzymes and/or DNA testing) na\u00efve and on ERT",
            "Scope 42 254--*--Fabry (by GLA enzymes and/or DNA testing) na\u00efve and on ERT, Mitochondrial diseases (electron transport chain and/or DNA testing) or connective tissue diseases (clinical criteria and/or DNA testing when available)",
            "Post-eligibility 256 353--*--Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure",
            "Non-query-able 256 353--*--Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure"
        ],
        "Text": "Males and females with confirmed disease: Fabry (by GLA enzymes and/or DNA testing) na\u00efve and on ERT, Mitochondrial diseases (electron transport chain and/or DNA testing) or connective tissue diseases (clinical criteria and/or DNA testing when available) . Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure . "
    },
    "NCT01765231_inc": {
        "Annotations": [
            "Observation 0 15--*--treatment-naive",
            "Condition 30 38--*--lymphoma",
            "Measurement 40 45--*--HBsAg",
            "Value 46 54--*--negative",
            "Measurement 55 60--*--HBcAb",
            "Value 61 69--*--positive",
            "Measurement 70 91--*--hepatitis B virus DNA",
            "Value 92 100--*--negative",
            "Temporal 101 112--*--at baseline",
            "Scope 40 100--*--HBsAg negative/HBcAb positive/hepatitis B virus DNA negative",
            "Procedure 127 139--*--chemotherapy",
            "Procedure 147 172--*--immunosuppressive therapy",
            "Observation 174 189--*--life expectancy",
            "Temporal 193 211--*--more than 3 months"
        ],
        "Text": "treatment-naive patients with lymphoma. HBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline. treated with chemotherapy and/or immunosuppressive therapy. life expectancy of more than 3 months. "
    },
    "NCT03103204_exc": {
        "Text": "Systemic diseases (diabetes, renal diseases, rheumatic diseases, osteoporosis and cardiovascular diseases). Pregnant and lactating women. HIV/ AIDS. periodontal treatment in the last year (before baseline appointment). Medication: Immunosuppressive drugs, antibiotics in the past three months (before baseline appointment) ). orthodontic appliance. ",
        "Annotations": [
            "Condition 138 141--*--HIV",
            "Condition 143 147--*--AIDS",
            "Condition 108 116--*--Pregnant",
            "Condition 121 130--*--lactating",
            "Person 131 136--*--women",
            "Condition 0 17--*--Systemic diseases",
            "Procedure 149 170--*--periodontal treatment",
            "Temporal 171 187--*--in the last year",
            "Temporal 189 216--*--before baseline appointment",
            "Procedure 196 216--*--baseline appointment",
            "Reference_point 196 216--*--baseline appointment",
            "Drug 231 254--*--Immunosuppressive drugs",
            "Drug 256 267--*--antibiotics",
            "Temporal 268 292--*--in the past three months",
            "Scope 231 267--*--Immunosuppressive drugs, antibiotics",
            "Temporal 294 321--*--before baseline appointment",
            "Procedure 301 321--*--baseline appointment",
            "Reference_point 301 321--*--baseline appointment",
            "Device 326 347--*--orthodontic appliance"
        ]
    },
    "NCT00650312_inc": {
        "Text": "1. Age: 18 years and older. . 2. Sex: Male and non-pregnant, non-lactating female . 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study. . 2. Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. Acceptable forms of contraception include the following: . (1) intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or (2) barrier methods containing or used in conjunction with a spermicidal agent, or (3) postmenopausal accompanied with a documented postmenopausal course of at least one year or surgical sterility (tubal ligation, oophorectomy or hysterectomy). . 3. During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form. . 3. Weight: At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of \"\"Desirable Weights of Adults\"\" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS). . 4. All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication. . ",
        "Annotations": [
            "Value 8 26--*--18 years and older",
            "Person 3 6--*--Age",
            "Person 37 41--*--Male",
            "Condition 50 58--*--pregnant",
            "Negation 46 49--*--non",
            "Negation 60 63--*--non",
            "Condition 64 73--*--lactating",
            "Person 74 80--*--female",
            "Scope 46 73--*--non-pregnant, non-lactating",
            "Measurement 1417 1423--*--Weight",
            "Value 1425 1439--*--At least 60 kg",
            "Value 1425 1433;1441 1448--*--At least 132 lbs",
            "Person 1454 1457--*--man",
            "Value 1425 1433;1462 1467--*--At least 48 kg",
            "Value 1425 1433;1469 1476--*--At least 106 lbs",
            "Person 1482 1487--*--women",
            "Scope 1425 1487--*--At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women",
            "Value 1492 1529--*--within 15% of Ideal Body Weight (IBW)",
            "Person 85 90--*--Women",
            "Condition 94 116--*--childbearing potential",
            "Value 127 135--*--negative",
            "Procedure 136 141;153 168--*--serum pregnancy tests",
            "Procedure 143 151--*--Beta HCG",
            "Temporal 179 225--*--within 14 days prior to the start of the study",
            "Reference_point 203 225--*--the start of the study",
            "Temporal 230 278--*--on the evening prior to each dose administration",
            "Reference_point 254 278--*--each dose administration",
            "Scope 85 116--*--Women of childbearing potential",
            "Scope 127 278--*--negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration",
            "Person 515 520--*--Women",
            "Condition 524 546--*--childbearing potential",
            "Procedure 561 571--*--abstinence",
            "Qualifier 587 602--*--acceptable form",
            "Procedure 606 619--*--contraception",
            "Temporal 620 656--*--throughout the duration of the study",
            "Scope 561 619--*--abstinence or be using an acceptable form of contraception",
            "Scope 515 546--*--Women of childbearing potential",
            "Device 720 739--*--intrauterine device",
            "Temporal 749 802--*--for at least 3 months prior to the start of the study",
            "Reference_point 780 802--*--the start of the study",
            "Temporal 817 849--*--in place during the study period",
            "Reference_point 833 849--*--the study period",
            "Procedure 858 873--*--barrier methods",
            "Drug 915 932--*--spermicidal agent",
            "Scope 858 932--*--barrier methods containing or used in conjunction with a spermicidal agent",
            "Condition 941 955--*--postmenopausal",
            "Temporal 1011 1028--*--at least one year",
            "Condition 1032 1050--*--surgical sterility",
            "Procedure 1052 1066--*--tubal ligation",
            "Procedure 1068 1080--*--oophorectomy",
            "Procedure 1084 1096--*--hysterectomy",
            "Scope 1052 1096--*--tubal ligation, oophorectomy or hysterectomy",
            "Scope 1032 1097--*--surgical sterility (tubal ligation, oophorectomy or hysterectomy)",
            "Person 1202 1207--*--women",
            "Condition 1211 1233--*--childbearing potential",
            "Procedure 1245 1298--*--spermicide containing barrier method of contraception",
            "Multiplier 1299 1313--*--in addition to",
            "Temporal 1320 1327--*--current",
            "Device 1328 1348--*--contraceptive device",
            "Scope 1202 1233--*--women of childbearing potential",
            "Scope 1245 1348--*--spermicide containing barrier method of contraception in addition to their current contraceptive device",
            "Temporal 1103 1133--*--During the course of the study",
            "Condition 1735 1741--*--normal",
            "Condition 1746 1753--*--healthy",
            "Procedure 1763 1791--*--pre-study medical evaluation",
            "Scope 1735 1753--*--normal and healthy",
            "Procedure 1793 1813--*--physical examination",
            "Procedure 1815 1836--*--laboratory evaluation",
            "Procedure 1838 1849--*--12-lead ECG",
            "Procedure 1851 1862;1879 1884--*--hepatitis B tests",
            "Procedure 1867 1884--*--hepatitis C tests",
            "Procedure 1886 1894--*--HIV test",
            "Procedure 1900 1917--*--urine drug screen",
            "Qualifier 1928 1939--*--amphetamine",
            "Qualifier 1941 1953--*--barbiturates",
            "Qualifier 1955 1969--*--benzodiazepine",
            "Qualifier 1971 1982--*--cannabinoid",
            "Qualifier 1984 1991--*--cocaine",
            "Qualifier 1993 2000--*--opiates",
            "Qualifier 2002 2015--*--phencyclidine",
            "Qualifier 2021 2030--*--methadone",
            "Scope 1928 2030--*--amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone",
            "Scope 1793 2030--*--physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone",
            "Temporal 2042 2096--*--within 14 days of the initial dose of study medication",
            "Reference_point 2060 2096--*--the initial dose of study medication"
        ]
    },
    "NCT03058835_exc": {
        "Annotations": [
            "Intoxication_considerations 0 97--*--Active alcohol or drug use or dependence which may interfere with adherence to study requirements",
            "Condition 99 111--*--HIV-infected",
            "Temporal 112 124--*--at screening",
            "Temporal 112 114;128 138--*--at enrollment",
            "Scope 112 138--*--at screening or enrollment",
            "Measurement 140 154--*--Estimated CrCl",
            "Value 155 166--*--< 60 mL/min",
            "Non-query-able 168 210--*--Past participation in an HIV vaccine study",
            "Value 212 220--*--Positive",
            "Measurement 221 253--*--Hepatitis B surface antigen test",
            "Condition 266 283--*--medical condition",
            "Condition 289 306--*--survival unlikely",
            "Condition 472 480--*--Pregnant",
            "Observation 484 498--*--breast feeding",
            "Pregnancy_considerations 500 535--*--Actively trying to achieve pregnanc",
            "Condition 336 345--*--condition",
            "Qualifier 387 425--*--make participation in the study unsafe",
            "Qualifier 429 470--*--interfere with achieving study objectives",
            "Scope 387 470--*--make participation in the study unsafe or interfere with achieving study objectives"
        ],
        "Text": "Active alcohol or drug use or dependence which may interfere with adherence to study requirements. HIV-infected at screening or enrollment. Estimated CrCl < 60 mL/min. Past participation in an HIV vaccine study. Positive Hepatitis B surface antigen test. Underlying medical condition with survival unlikely during follow-up period. Any condition that in the opinion of study staff would make participation in the study unsafe or interfere with achieving study objectives. Pregnant or breast feeding. Actively trying to achieve pregnancy. "
    },
    "NCT03044561_inc": {
        "Annotations": [
            "Condition 13 24--*--infertility",
            "Value 26 45--*--older than 20 years",
            "Person 49 52--*--age",
            "Value 57 80--*--not older than 40 years",
            "Measurement 87 102--*--Body mass index",
            "Measurement 104 107--*--BMI",
            "Value 109 114--*--20-29",
            "Person 121 126--*--women",
            "Multiplier 144 155--*--two or more",
            "Procedure 156 168--*--implantation",
            "Qualifier 169 176--*--failure",
            "Condition 191 225--*--inadequate endometrial development",
            "Mood 177 190--*--attributed to"
        ],
        "Text": "(1) cases of infertility, older than 20 years of age and not older than 40 years.. (2) Body mass index (BMI):20-29.. (3) women have experienced two or more implantation failure attributed to inadequate endometrial development.. "
    },
    "NCT02985710_exc": {
        "Annotations": [
            "Condition 14 23;47 55--*--cognitive problems",
            "Condition 25 36;47 55--*--psychiatric problems",
            "Condition 41 86--*--other problems that preclude informed consent",
            "Undefined_semantics 0 86--*--Subjects with cognitive, psychiatric, or other problems that preclude informed consent",
            "Subjective_judgement 41 86--*--other problems that preclude informed consent",
            "Condition 114 133--*--glucose intolerance",
            "Condition 137 145--*--diabetes",
            "Observation 103 110--*--history",
            "Procedure 159 171--*--chemotherapy",
            "Condition 197 212--*--bleeding wounds",
            "Condition 189 193;206 212--*--open wounds",
            "Qualifier 213 257--*--at any sensor plate contact surface location",
            "Device 283 301--*--implantable device",
            "Condition 315 327--*--missing hand",
            "Condition 315 322;338 341--*--missing leg",
            "Condition 346 354--*--Pregnant",
            "Observation 396 414--*--possible pregnancy",
            "Non-query-able 378 414--*--uncertain about a possible pregnancy",
            "Condition 425 471--*--sensitive to chemicals used to induce sweating",
            "Undefined_semantics 425 471--*--sensitive to chemicals used to induce sweating",
            "Condition 487 503--*--heat intolerance",
            "Condition 519 537--*--bleeding disorders",
            "Procedure 559 580--*--anticoagulant therapy",
            "Temporal 551 558--*--current",
            "Condition 596 603--*--keloids",
            "Qualifier 604 631--*--on the intended biopsy site",
            "Condition 645 661--*--hypersensitivity",
            "Drug 665 693--*--local amide-type anesthetics"
        ],
        "Text": "Subjects with cognitive, psychiatric, or other problems that preclude informed consent. . Patients with history of glucose intolerance or diabetes. . Patient on chemotherapy . People with any open or bleeding wounds at any sensor plate contact surface location . People with any type of implantable device . People with missing hand(s) and/or leg(s) . Pregnant women or women who are uncertain about a possible pregnancy . Patients sensitive to chemicals used to induce sweating . Patients with heat intolerance . Patients with bleeding disorders . Patients on current anticoagulant therapy . Patients with keloids on the intended biopsy site . People with hypersensitivity to local amide-type anesthetics       .     . "
    },
    "NCT01765231_exc": {
        "Annotations": [
            "Value 0 21--*--younger than 18 years",
            "Person 22 25--*--old",
            "Condition 27 41--*--HBsAg positive",
            "Condition 45 59--*--HBcAb negative",
            "Condition 63 93--*--hepatitis B virus DNA positive",
            "Temporal 94 105--*--at baseline",
            "Scope 27 93--*--HBsAg positive or HBcAb negative or hepatitis B virus DNA positive",
            "Condition 107 115--*--pregnant",
            "Condition 119 128--*--lactating",
            "Person 129 134--*--women"
        ],
        "Text": "younger than 18 years old. HBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline. pregnant or lactating women. "
    },
    "NCT03297125_inc": {
        "Text": "Newly diagnosed glioblastoma (GBM), WHO grade IV.. ",
        "Annotations": [
            "Condition 16 28--*--glioblastoma",
            "Condition 30 33--*--GBM",
            "Measurement 36 39--*--WHO",
            "Value 40 48--*--grade IV",
            "Qualifier 0 15--*--Newly diagnosed"
        ]
    },
    "NCT03305575_exc": {
        "Text": "Abdominal and complex cervical cerclage (e.g. bulging bag). Contraindication to neuraxial anesthesia. Known hypersensitivity to chloroprocaine (a.k.a. Ester allergy), paraaminobenzoic acid (PABA) or bupivacaine (a.k.a. Amide allergy). Pseudocholinesterase deficiency. Concomitant use with ergot-type oxytocic drugs. ",
        "Annotations": [
            "Procedure 22 39--*--cervical cerclage",
            "Qualifier 14 21--*--complex",
            "Qualifier 0 9--*--Abdominal",
            "Scope 0 21--*--Abdominal and complex",
            "Qualifier 46 57--*--bulging bag",
            "Condition 60 76--*--Contraindication",
            "Procedure 80 100--*--neuraxial anesthesia",
            "Condition 108 124--*--hypersensitivity",
            "Drug 128 142--*--chloroprocaine",
            "Condition 151 164--*--Ester allergy",
            "Drug 167 188--*--paraaminobenzoic acid",
            "Drug 190 194--*--PABA",
            "Drug 199 210--*--bupivacaine",
            "Condition 219 232--*--Amide allergy",
            "Scope 128 142;167 210--*--chloroprocaine paraaminobenzoic acid (PABA) or bupivacaine",
            "Condition 235 266--*--Pseudocholinesterase deficiency",
            "Temporal 268 279--*--Concomitant",
            "Drug 289 314--*--ergot-type oxytocic drugs"
        ]
    },
    "NCT00650312_exc": {
        "Text": "1. Institutionalized subjects will not be used. 2 Social Habits: . 1. Use of any tobacco products. . 2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication. . 3. Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication. . 4. Any recent, significant change in dietary or exercise habits. . 5. Positive test for any drug included in the urine drug screen. . 3. Medications: . 1. Use of any medication within the 14 days prior to the initial dose of study medication. . 2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication. . 3. Use of hormonal contraceptives and hormonal replacement therapy within three months prior to the initial dose of study medication. . 4. Diseases: . a. History of any significant chronic disease and/or hepatitis. b. History of drug and/or alcohol abuse. c. Acute illness at the time of either the prestudy medical evaluation or dosing. . d. Positive HIV, Hepatitis B, or Hepatitis C test. e. Renal disease or renal dysfunction (as suggested by serum creatinine levels greater than or equal to 1.5 mg/dL (for males) and greater than or equal to 1.4 mg/dL (for females) or abnormal creatinine clearance). . 5. Abnormal and clinically significant laboratory test results: . 1. Clinically significant deviation from the Guide for Clinically Relevant Abnormalities (see Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS). . 2. Abnormal and clinically relevant ECG tracing. 6. Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication. . 7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication. . 8. Allergy or hypersensitivity to metformin hydrochloride. 9. History of difficulty in swallowing medication, or any gastrointestinal disorder which could affect the drug absorption.       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Non-query-able 3 47--*--Institutionalized subjects will not be used.",
            "Parsing_Error 66 68--*--1.",
            "Parsing_Error 48 64--*--2 Social Habits:",
            "Drug 80 96--*--tobacco products",
            "Not_a_criteria 102 246--*--Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.",
            "Parsing_Error 99 101--*--2.",
            "Not_a_criteria 251 366--*--Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.",
            "Non-query-able 371 432--*--Any recent, significant change in dietary or exercise habits.",
            "Context_Error 437 498--*--Positive test for any drug included in the urine drug screen.",
            "Parsing_Error 248 250--*--3.",
            "Parsing_Error 368 370--*--4.",
            "Parsing_Error 434 436--*--5.",
            "Parsing_Error 500 502--*--3.",
            "Parsing_Error 517 519--*--1.",
            "Parsing_Error 609 611--*--2.",
            "Drug 531 541--*--medication",
            "Temporal 542 566--*--within the 14 days prior",
            "Reference_point 570 606--*--the initial dose of study medication",
            "Drug 623 672--*--medication known to alter hepatic enzyme activity",
            "Temporal 673 693--*--within 28 days prior",
            "Reference_point 697 733--*--the initial dose of study medication",
            "Parsing_Error 736 738--*--3.",
            "Drug 746 769--*--hormonal contraceptives",
            "Drug 774 802--*--hormonal replacement therapy",
            "Temporal 803 828--*--within three months prior",
            "Reference_point 832 868--*--the initial dose of study medication",
            "Parsing_Error 871 873--*--4.",
            "Parsing_Error 874 883--*--Diseases:",
            "Parsing_Error 885 887--*--a.",
            "Observation 888 895--*--History",
            "Condition 915 930--*--chronic disease",
            "Condition 938 947--*--hepatitis",
            "Qualifier 903 914--*--significant",
            "Subjective_judgement 903 914--*--significant",
            "Scope 903 947--*--significant chronic disease and/or hepatitis",
            "Condition 963 967;983 988--*--drug abuse",
            "Condition 975 988--*--alcohol abuse",
            "Observation 952 959--*--History",
            "Undefined_semantics 993 1071--*--Acute illness at the time of either the prestudy medical evaluation or dosing.",
            "Measurement 1085 1088;1118 1122--*--HIV test",
            "Measurement 1090 1101;1118 1122--*--Hepatitis B test",
            "Measurement 1106 1122--*--Hepatitis C test",
            "Scope 1085 1122--*--HIV, Hepatitis B, or Hepatitis C test",
            "Value 1076 1084--*--Positive",
            "Parsing_Error 949 951--*--b.",
            "Parsing_Error 990 992--*--c.",
            "Parsing_Error 1073 1075--*--d.",
            "Parsing_Error 1124 1126--*--e.",
            "Condition 1127 1140--*--Renal disease",
            "Condition 1144 1161--*--renal dysfunction",
            "Measurement 1179 1202--*--serum creatinine levels",
            "Value 1203 1237--*--greater than or equal to 1.5 mg/dL",
            "Person 1243 1248--*--males",
            "Person 1294 1301--*--females",
            "Value 1254 1288--*--greater than or equal to 1.4 mg/dL",
            "Condition 1306 1335--*--abnormal creatinine clearance",
            "Scope 1203 1302--*--greater than or equal to 1.5 mg/dL (for males) and greater than or equal to 1.4 mg/dL (for females)",
            "Scope 1179 1335--*--serum creatinine levels greater than or equal to 1.5 mg/dL (for males) and greater than or equal to 1.4 mg/dL (for females) or abnormal creatinine clearance",
            "Scope 1127 1161--*--Renal disease or renal dysfunction",
            "Parsing_Error 1339 1341--*--5.",
            "Parsing_Error 1342 1402--*--Abnormal and clinically significant laboratory test results:",
            "Parsing_Error 1404 1406--*--1.",
            "Subjective_judgement 1342 1402--*--Abnormal and clinically significant laboratory test results:",
            "Subjective_judgement 1407 1429--*--Clinically significant",
            "Context_Error 1449 1492--*--Guide for Clinically Relevant Abnormalities",
            "Non-query-able 1407 1557--*--Clinically significant deviation from the Guide for Clinically Relevant Abnormalities (see Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS)",
            "Parsing_Error 1560 1562--*--2.",
            "Condition 1563 1571;1596 1607--*--Abnormal ECG tracing",
            "Subjective_judgement 1576 1595--*--clinically relevant",
            "Parsing_Error 1609 1611--*--6.",
            "Non-query-able 1612 1744--*--Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.",
            "Parsing_Error 1746 1748--*--7.",
            "Non-query-able 1749 1861--*--Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.",
            "Parsing_Error 1863 1865--*--8.",
            "Drug 1897 1920--*--metformin hydrochloride",
            "Condition 1877 1893--*--hypersensitivity",
            "Condition 1866 1873--*--Allergy",
            "Parsing_Error 1922 1924--*--9.",
            "Condition 1936 1971--*--difficulty in swallowing medication",
            "Observation 1925 1932--*--History",
            "Condition 1980 2005--*--gastrointestinal disorder",
            "Qualifier 2018 2044--*--affect the drug absorption",
            "Subjective_judgement 2018 2044--*--affect the drug absorption"
        ]
    },
    "NCT03044561_exc": {
        "Annotations": [
            "Condition 4 25--*--Uterine abnormalities",
            "Condition 32 39;64 70--*--septate uterus",
            "Condition 41 51;64 70--*--bicornuate uterus",
            "Condition 56 70--*--fibroid uterus",
            "Condition 72 89--*--Asherman Syndrome",
            "Scope 32 89--*--septate, bicornuate and fibroid uterus, Asherman Syndrome",
            "Temporal 93 103--*--Concurrent",
            "Drug 111 127--*--organic nitrites",
            "Drug 132 140--*--nitrates",
            "Qualifier 143 149--*--Severe",
            "Condition 150 168--*--hepatic impairment",
            "Qualifier 171 177--*--Severe",
            "Condition 178 194--*--renal impairment",
            "Condition 197 208--*--Hypotension",
            "Condition 218 224--*--stroke",
            "Condition 228 240--*--heart attack",
            "Temporal 211 217--*--Recent",
            "Scope 218 240--*--stroke or heart attack"
        ],
        "Text": "(1) Uterine abnormalities (e.g. septate, bicornuate and fibroid uterus, Asherman Syndrome).. Concurrent use of organic nitrites and nitrates.. Severe hepatic impairment.. Severe renal impairment.. Hypotension.. Recent stroke or heart attack.. "
    },
    "NCT03058835_inc": {
        "Annotations": [
            "Value 0 13--*--18 - 64 years",
            "Person 14 17--*--old",
            "Non-query-able 19 39--*--Able to give consent",
            "Observation 41 56--*--unprotected sex",
            "Temporal 58 74--*--in past 6 months",
            "Multiplier 81 90--*--1 or more",
            "Person 91 116--*--men of unknown HIV status",
            "Procedure 118 138--*--evaluated for an STI",
            "Temporal 139 173--*--within 6 months prior to screening",
            "Reference_point 164 173--*--screening",
            "Observation 175 178--*--sex",
            "Person 204 224--*--HIV-infected partner",
            "Temporal 179 195--*--in last 6 months",
            "Observation 245 284--*--using previously used or shared needles",
            "Temporal 285 301--*--in past 6 months",
            "Drug 319 328--*--methadone",
            "Drug 330 343--*--buprenorphine",
            "Drug 348 356--*--suboxone",
            "Procedure 357 374--*--treatment program",
            "Temporal 375 391--*--in past 6 months",
            "Observation 395 433--*--engaging in high-risk sexual behaviors",
            "Person 226 229--*--IDU",
            "Scope 319 356--*--methadone, buprenorphine, or suboxone",
            "Observation 459 476--*--transactional sex",
            "Observation 482 495--*--sex for money",
            "Observation 482 489;497 502--*--sex for drugs",
            "Observation 482 489;507 514--*--sex for housing",
            "Scope 482 514--*--sex for money, drugs, or housing",
            "Observation 517 553--*--Infrequently uses condoms during sex",
            "Multiplier 559 568--*--1 or more",
            "Person 569 599--*--partners of unknown HIV status",
            "Observation 620 656--*--at substantial risk of HIV infection",
            "Person 658 661--*--IDU",
            "Person 665 686--*--bisexual male partner",
            "Measurement 689 693--*--CrCl",
            "Value 694 705--*--= 60 ml/min",
            "Condition 707 722--*--HIV- uninfected",
            "Person 723 728--*--women",
            "Procedure 738 742--*--PrEP",
            "Mood 729 737--*--desiring"
        ],
        "Text": "18 - 64 years old. Able to give consent. unprotected sex (in past 6 months) with 1 or more men of unknown HIV status. evaluated for an STI within 6 months prior to screening. sex in last 6 months with an HIV-infected partner. IDU with report of using previously used or shared needles in past 6 months or has been in a methadone, buprenorphine, or suboxone treatment program in past 6 months or engaging in high-risk sexual behaviors. individuals engaging in transactional sex (i.e sex for money, drugs, or housing). Infrequently uses condoms during sex with 1 or more partners of unknown HIV status who are known to be at substantial risk of HIV infection (IDU or bisexual male partner). CrCl = 60 ml/min. HIV- uninfected women desiring PrEP. "
    },
    "NCT03103204_inc": {
        "Text": "Moderate to advanced generalized chronic periodontitis. Body mass index: > 18.5 kg/m2. Minimum of 12 natural teeth. Smokers, non-smokers or former-smokers. ",
        "Annotations": [
            "Qualifier 0 20--*--Moderate to advanced",
            "Condition 21 54--*--generalized chronic periodontitis",
            "Measurement 56 71--*--Body mass index",
            "Value 73 85--*--> 18.5 kg/m2",
            "Multiplier 87 100--*--Minimum of 12",
            "Observation 101 114--*--natural teeth",
            "Condition 116 123--*--Smokers",
            "Condition 125 136--*--non-smokers",
            "Condition 140 154--*--former-smokers"
        ]
    },
    "NCT02281643_exc": {
        "Annotations": [
            "Condition 6 36--*--intolerance to the doxycycline",
            "Drug 25 36--*--doxycycline",
            "Measurement 37 48--*--Body weight",
            "Value 49 55--*--<40 kg",
            "Condition 56 65--*--Pregnancy",
            "Observation 69 82--*--breastfeeding",
            "Condition 101 118--*--allergic reaction",
            "Qualifier 94 100--*--severe",
            "Condition 122 133--*--anaphylaxis",
            "Condition 134 141;150 155--*--Alcohol abuse",
            "Condition 145 155--*--drug abuse",
            "Observation 83 93--*--History of",
            "Scope 94 155--*--severe allergic reaction or anaphylaxis Alcohol or drug abuse"
        ],
        "Text": "Known intolerance to the doxycycline Body weight <40 kg Pregnancy or breastfeeding History of severe allergic reaction or anaphylaxis Alcohol or drug abuse       .     . "
    },
    "NCT01816997_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 19--*--35-70 years old",
            "Measurement 21 42--*--Fasting blood glucose",
            "Value 43 56--*--100-125 mg/dL"
        ],
        "Text": "Age 35-70 years old. Fasting blood glucose 100-125 mg/dL. "
    },
    "NCT02858180_exc": {
        "Text": "Chronic HCV Infection with Genotype 2 or 3. Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 of SOF/LDV FDC. Carbamazepine, phenytoin, phenobarbital, oxcarbazepine. Rifabutin, rifampin or rifapentine. HIV regimens containing tenofovir or tipranavir/ritonavir. St. John's wort. Rosuvastatin. Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance. History of hepatic encephalopathy or variceal hemorrhage. Hepatitis B surface antigen positive. Hemoglobin (Hb) < 8 g/dL. Platelets = 50,000/mm3. alanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline phosphatase = 10 times upper limit of normal(ULN). Total bilirubin > 3 mg/dl. Severe renal impairment creatinine clearance (CrCl), i.e. < 30 mL/min.. History of major organ transplantation with an existing functional graft.. History of clinically-significant drug allergy to nucleoside/nucleotide analogs.. Pregnant women or women planning to become pregnant. Women who are breastfeeding. Active or recent history (= 1 year) of drug or alcohol abuse. ",
        "Annotations": [
            "Condition 0 21--*--Chronic HCV Infection",
            "Qualifier 27 37--*--Genotype 2",
            "Qualifier 27 35;41 42--*--Genotype 3",
            "Scope 27 42--*--Genotype 2 or 3",
            "Drug 44 54--*--Amiodarone",
            "Temporal 133 179--*--at least 60 days prior to day 1 of SOF/LDV FDC",
            "Reference_point 159 179--*--day 1 of SOF/LDV FDC",
            "Non-query-able 56 132--*--Subjects previously treated with amiodarone must have stopped the amiodarone",
            "Drug 181 194--*--Carbamazepine",
            "Drug 196 205--*--phenytoin",
            "Drug 207 220--*--phenobarbital",
            "Drug 222 235--*--oxcarbazepine",
            "Drug 237 246--*--Rifabutin",
            "Drug 248 256--*--rifampin",
            "Drug 260 271--*--rifapentine",
            "Non-query-able 273 285--*--HIV regimens",
            "Drug 297 306--*--tenofovir",
            "Drug 310 330--*--tipranavir/ritonavir",
            "Condition 332 347--*--St. John's wort",
            "Drug 349 361--*--Rosuvastatin",
            "Subjective_judgement 363 529--*--Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance",
            "Condition 542 564--*--hepatic encephalopathy",
            "Condition 568 587--*--variceal hemorrhage",
            "Measurement 589 616--*--Hepatitis B surface antigen",
            "Value 617 625--*--positive",
            "Measurement 627 637--*--Hemoglobin",
            "Measurement 639 641--*--Hb",
            "Value 643 651--*--< 8 g/dL",
            "Measurement 653 662--*--Platelets",
            "Value 663 675--*--= 50,000/mm3",
            "Measurement 677 701--*--alanine aminotransferase",
            "Measurement 703 706--*--ALT",
            "Measurement 709 735--*--aspartase aminotransferase",
            "Measurement 737 740--*--AST",
            "Measurement 746 766--*--alkaline phosphatase",
            "Value 767 799--*--= 10 times upper limit of normal",
            "Scope 677 766--*--alanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline phosphatase",
            "Measurement 806 821--*--Total bilirubin",
            "Value 822 831--*--> 3 mg/dl",
            "Condition 840 856--*--renal impairment",
            "Qualifier 833 839--*--Severe",
            "Measurement 857 877--*--creatinine clearance",
            "Measurement 879 883--*--CrCl",
            "Value 891 902--*--< 30 mL/min",
            "Condition 916 943--*--major organ transplantation",
            "Qualifier 952 977--*--existing functional graft",
            "Condition 1014 1026--*--drug allergy",
            "Qualifier 991 1013--*--clinically-significant",
            "Drug 1030 1040--*--nucleoside",
            "Drug 1041 1059--*--nucleotide analogs",
            "Scope 1030 1059--*--nucleoside/nucleotide analogs",
            "Pregnancy_considerations 1062 1113--*--Pregnant women or women planning to become pregnant",
            "Pregnancy_considerations 1115 1142--*--Women who are breastfeeding",
            "Observation 1191 1204--*--alcohol abuse",
            "Observation 1183 1187;1199 1204--*--drug abuse",
            "Temporal 1170 1178--*--= 1 year",
            "Scope 1183 1204--*--drug or alcohol abuse"
        ]
    },
    "NCT02550028_exc": {
        "Annotations": [
            "Observation 21 35--*--close to death",
            "Temporal 11 20--*--have been",
            "Person 0 6--*--Babies",
            "Condition 37 44--*--Seizure",
            "Qualifier 57 74--*--metabolic factors",
            "Condition 76 88--*--hypoglycemia",
            "Condition 90 102--*--hypocalcemia",
            "Condition 104 124--*--electrolyte disorder",
            "Scope 76 124--*--hypoglycemia, hypocalcemia, electrolyte disorder",
            "Person 127 133--*--Babies",
            "Drug 152 166--*--phenobarbitone",
            "Qualifier 170 179--*--any other",
            "Drug 180 205--*--anticonvulsive medication",
            "Temporal 206 228--*--before hospitalization",
            "Procedure 213 228--*--hospitalization",
            "Reference_point 213 228--*--hospitalization",
            "Scope 152 205--*--phenobarbitone or any other anticonvulsive medication",
            "Value 230 238--*--Abnormal",
            "Measurement 239 253--*--renal function",
            "Condition 230 253--*--Abnormal renal function"
        ],
        "Text": "Babies who have been close to death. Seizure occurred by metabolic factors (hypoglycemia, hypocalcemia, electrolyte disorder). Babies who have received phenobarbitone or any other anticonvulsive medication before hospitalization. Abnormal renal function. "
    },
    "NCT02705222_inc": {
        "Text": "Perimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause.. Failure of medical treatment for at least 3 months.. ",
        "Annotations": [
            "Person 0 14--*--Perimenopausal",
            "Person 15 20--*--women",
            "Condition 36 61--*--abnormal uterine bleeding",
            "Condition 63 74--*--menorrhagia",
            "Condition 76 88--*--metrorrhagia",
            "Condition 90 104--*--polymenorrhoea",
            "Condition 108 123--*--polymenorrhagia",
            "Scope 63 123--*--menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia",
            "Negation 125 132--*--without",
            "Condition 133 158--*--local gynecological cause",
            "Procedure 172 189--*--medical treatment",
            "Observation 161 168--*--Failure",
            "Multiplier 190 211--*--for at least 3 months"
        ]
    },
    "NCT03381755_exc": {
        "Text": "taken adenosine diphosphate (ADP) receptor antagonists within 2 weeks. Platelet count <100g/L;. A history of bleeding tendency;. Aspirin, ticagrelor or clopidogrel allergies;. Severe liver injury.. ",
        "Annotations": [
            "Drug 6 54--*--adenosine diphosphate (ADP) receptor antagonists",
            "Temporal 55 69--*--within 2 weeks",
            "Measurement 71 85--*--Platelet count",
            "Value 86 93--*--<100g/L",
            "Condition 109 126--*--bleeding tendency",
            "Observation 98 105--*--history",
            "Drug 129 136--*--Aspirin",
            "Drug 138 148--*--ticagrelor",
            "Drug 152 163--*--clopidogrel",
            "Condition 164 173--*--allergies",
            "Scope 129 163--*--Aspirin, ticagrelor or clopidogrel",
            "Condition 183 195--*--liver injury",
            "Qualifier 176 182--*--Severe"
        ]
    },
    "NCT03250507_inc": {
        "Annotations": [
            "Qualifier 0 8--*--Elective",
            "Procedure 9 36--*--open abdominal hysterectomy",
            "Qualifier 42 58--*--midline incision",
            "Person 60 63--*--age",
            "Value 64 74--*--> 18 years",
            "Measurement 76 133--*--American Society of Anesthesiologist classification score",
            "Measurement 135 153--*--ASA classification",
            "Value 155 158--*--1-3"
        ],
        "Text": "Elective open abdominal hysterectomy with midline incision, age > 18 years, American Society of Anesthesiologist classification score (ASA classification) 1-3.. "
    },
    "NCT01774019_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 15--*--18 or older",
            "Non-query-able 17 134--*--Willing and able to comply with the study procedures and provide written informed consent to participate in the study",
            "Condition 158 175--*--pancreatic cancer",
            "Mood 149 157--*--probable",
            "Condition 177 225--*--distal common bile duct (CBD) cholangiocarcinoma",
            "Condition 236 257--*--periampullary cancers",
            "Qualifier 230 235--*--other",
            "Scope 158 257--*--pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers",
            "Condition 284 312--*--Biliary obstructive symptoms",
            "Condition 284 303;316 321--*--Biliary obstructive signs",
            "Measurement 323 338--*--Bilirubin level",
            "Value 339 366--*--at/above 100 umol per liter",
            "Value 339 347;368 377--*--at/above 5.8 mg/dL",
            "Condition 380 406--*--Distal biliary obstruction",
            "Condition 423 440--*--pancreatic cancer",
            "Condition 442 471--*--distal CBD cholangiocarcinoma",
            "Condition 481 505--*--periampullary malignancy",
            "Qualifier 475 480--*--other",
            "Condition 519 545--*--distal biliary obstruction",
            "Procedure 596 601--*--stent",
            "Mood 562 573--*--would allow",
            "Qualifier 619 646--*--at least 2cm from the hilum",
            "Condition 657 677--*--deemed as resectable",
            "Procedure 681 703--*--pancreatic protocol CT",
            "Procedure 681 700;707 710--*--pancreatic protocol MRI",
            "Scope 681 710--*--pancreatic protocol CT or MRI",
            "Condition 712 730--*--Surgical candidate",
            "Qualifier 731 759--*--per pancreatobiliary surgeon",
            "Procedure 797 804--*--Surgery",
            "Mood 805 811--*--intent",
            "Temporal 812 826--*--within 4 weeks",
            "Procedure 843 861--*--surgical treatment",
            "Procedure 828 838;852 861--*--Endoscopic treatment"
        ],
        "Text": "Age 18 or older. Willing and able to comply with the study procedures and provide written informed consent to participate in the study. Diagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required). Biliary obstructive symptoms or signs. Bilirubin level at/above 100 umol per liter (5.8 mg/dL). Distal biliary obstruction consistent with pancreatic cancer, distal CBD cholangiocarcinoma or other periampullary malignancy. Location of distal biliary obstruction is such that it would allow the proximal end of a stent to be positioned at least 2cm from the hilum. Patients deemed as resectable by pancreatic protocol CT or MRI. Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion. Surgery intent within 4 weeks. Endoscopic and surgical treatment to be provided by same team. "
    },
    "NCT00527826_exc": {
        "Text": "Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis). . Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus). . Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ) . Having undergone lung surgery (e.g. lung resection including lung volume reduction surgery, lung transplant) or subjects scheduled for surgery. . Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor). . Subjects receiving chronic or prophylactic antibiotic therapy. . Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety. . Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse. . History of depression. . History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol. . Moderate or severe COPD exacerbation (requiring corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization) within the 4 weeks prior to Visit 1 . Lower respiratory tract infection within the 4 weeks prior to Visit 1 . . Pregnant or lactating female and female of childbearing potential. . Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK). . Subject participated in an investigational drug study within 30 days prior to Visit 1       .     . ",
        "Annotations": [
            "Condition 12 33--*--respiratory disorders",
            "Condition 37 46;53 74--*--signs for respiratory disorders",
            "Condition 81 87--*--asthma",
            "Condition 89 100--*--lung cancer",
            "Condition 102 113--*--sarcoidosis",
            "Condition 115 127--*--tuberculosis",
            "Condition 129 142--*--lung fibrosis",
            "Condition 144 159--*--cystic fibrosis",
            "Condition 161 175--*--bronchoectasis",
            "Scope 81 175--*--asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis",
            "Scope 12 74--*--respiratory disorders or signs for other respiratory disorders",
            "Condition 208 228--*--inflammatory disease",
            "Condition 241 245--*--COPD",
            "Condition 252 272--*--rheumatoid arthritis",
            "Condition 277 305--*--systemic lupus erythematosus",
            "Negation 230 240--*--other than",
            "Condition 330 359--*--alpha-1-antitrypsin deficient",
            "Procedure 392 404--*--lung surgery",
            "Procedure 411 425--*--lung resection",
            "Procedure 436 465--*--lung volume reduction surgery",
            "Procedure 467 482--*--lung transplant",
            "Procedure 510 517--*--surgery",
            "Observation 496 505--*--scheduled",
            "Drug 531 554--*--medication from Visit 1",
            "Drug 629 657--*--monoamine oxidase inhibitors",
            "Drug 662 687--*--tricyclic antidepressants",
            "Drug 693 702--*--ritonavir",
            "Drug 720 749--*--cytochrome P450 3A4 inhibitor",
            "Scope 629 750--*--monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor)",
            "Procedure 783 814--*--prophylactic antibiotic therapy",
            "Procedure 772 779;796 814--*--chronic antibiotic therapy",
            "Condition 826 846--*--uncontrolled disease",
            "Condition 866 889--*--psychological disorders",
            "Condition 1010 1017;1035 1040--*--alcohol abuse",
            "Condition 1019 1023;1035 1040--*--drug abuse",
            "Condition 1027 1040--*--solvent abuse",
            "Condition 1113 1129--*--drug sensitivity",
            "Condition 1156 1173--*--allergic reaction",
            "Drug 1177 1192--*--corticosteroids",
            "Drug 1196 1206--*--salmeterol",
            "Scope 1177 1206--*--corticosteroids or salmeterol",
            "Scope 1113 1173--*--drug sensitivity or clinically significant allergic reaction",
            "Condition 1228 1245--*--COPD exacerbation",
            "Qualifier 1221 1227--*--severe",
            "Qualifier 1209 1217--*--Moderate",
            "Scope 1209 1227--*--Moderate or severe",
            "Drug 1257 1272--*--corticosteroids",
            "Drug 1296 1311--*--corticosteroids",
            "Qualifier 1276 1292--*--increased dosage",
            "Drug 1319 1330--*--antibiotics",
            "Visit 1334 1349--*--hospitalization",
            "Scope 1257 1349--*--corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization",
            "Temporal 1351 1386--*--within the 4 weeks prior to Visit 1",
            "Condition 1388 1421--*--Lower respiratory tract infection",
            "Temporal 1422 1457--*--within the 4 weeks prior to Visit 1",
            "Condition 1461 1469--*--Pregnant",
            "Condition 1473 1482--*--lactating",
            "Person 1483 1489--*--female",
            "Condition 1504 1526--*--childbearing potential",
            "Person 1494 1500--*--female",
            "Scope 252 305--*--rheumatoid arthritis and systemic lupus erythematosus",
            "Scope 208 245--*--inflammatory disease, other than COPD",
            "Scope 436 482--*--lung volume reduction surgery, lung transplant",
            "Reference_point 1379 1386--*--Visit 1",
            "Reference_point 1450 1457--*--Visit 1",
            "Non-representable 1529 1764--*--Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK).",
            "Observation 1774 1819--*--participated in an investigational drug study",
            "Temporal 1820 1851--*--within 30 days prior to Visit 1",
            "Reference_point 1844 1851--*--Visit 1",
            "Qualifier 196 207--*--significant",
            "Qualifier 321 329--*--severely",
            "Observation 1043 1053--*--History of",
            "Condition 1054 1064--*--depression",
            "Non-representable 962 996--*--in the opinion of the investigator",
            "Scope 1010 1040--*--alcohol, drug or solvent abuse"
        ]
    },
    "NCT03140488_inc": {
        "Text": "Singleton pregnancy = 37 weeks gestation. Patient presented for induction of labor who is determined to be a candidate for oxytocin. Cephalic presentation. Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below). Meeting one of the following BMI category:. ",
        "Annotations": [
            "Condition 0 19--*--Singleton pregnancy",
            "Value 20 30--*--= 37 weeks",
            "Measurement 31 40--*--gestation",
            "Procedure 64 82--*--induction of labor",
            "Mood 50 63--*--presented for",
            "Condition 109 131--*--candidate for oxytocin",
            "Drug 123 131--*--oxytocin",
            "Observation 133 154--*--Cephalic presentation",
            "Value 156 166--*--Reassuring",
            "Measurement 167 190--*--fetal health assessment",
            "Negation 192 194--*--no",
            "Condition 195 212--*--abnormal findings",
            "Procedure 216 232--*--fetal assessment",
            "Scope 192 232--*--no abnormal findings in fetal assessment",
            "Scope 156 190--*--Reassuring fetal health assessment"
        ]
    },
    "NCT02557386_exc": {
        "Text": "Chronic pain more than 3 months. Drug abuse. Chronic use of analgesic drugs (more than 3 months). Psychiatric illness. Peripheral neuropathy. Drug allergy. Severe gastroesophageal reflux disease. ",
        "Annotations": [
            "Condition 0 12--*--Chronic pain",
            "Temporal 13 31--*--more than 3 months",
            "Condition 33 43--*--Drug abuse",
            "Temporal 45 52--*--Chronic",
            "Drug 60 75--*--analgesic drugs",
            "Temporal 77 95--*--more than 3 months",
            "Condition 98 117--*--Psychiatric illness",
            "Condition 119 140--*--Peripheral neuropathy",
            "Condition 147 154--*--allergy",
            "Drug 142 146--*--Drug",
            "Condition 163 194--*--gastroesophageal reflux disease",
            "Qualifier 156 162--*--Severe"
        ]
    },
    "NCT02609425_inc": {
        "Annotations": [
            "Condition 18 35--*--esophageal cancer",
            "Observation 51 61--*--candidates",
            "Qualifier 66 84--*--minimally invasive",
            "Qualifier 85 99--*--robot assisted",
            "Qualifier 100 110--*--Ivor Lewis",
            "Procedure 111 130--*--esophagogastrectomy",
            "Informed_consent 133 193--*--Patients who provide written informed consent for the study."
        ],
        "Text": "All patients with esophageal cancer who are deemed candidates for minimally invasive robot assisted Ivor Lewis esophagogastrectomy.. Patients who provide written informed consent for the study.. "
    },
    "NCT02858180_inc": {
        "Text": "Chronic HCV Infection of Genotype 1, 4, 5, or 6. HCV RNA > 103 IU/mL at screening. 18 years of age or older. Diagnosis of chronic HCV infection, defined as positive HCV antibody or HCV RNA more than 6 months prior to screening OR an assessment of fibrosis F2 or greater prior to screening.. NYHA Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.. NYHA Class IV: Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.. ejection fraction = 30%. hospitalized for heart failure in last 12 months. ILD criteria: diagnosis of interstitial lung disease with chronic supplemental oxygen requirement at rest and/or with exertion.. Forced expiratory volume (FEV1)< 30% predicted. OR any FEV1 with chronic supplemental oxygen requirement at rest and/or with exertion. OR any FEV1 with chronic hypercapnia (baseline partial pressure of arterial carbon dioxide [PaCO2] > 45). ",
        "Annotations": [
            "Condition 0 21--*--Chronic HCV Infection",
            "Qualifier 25 33;34 35--*--Genotype 1",
            "Qualifier 25 33;37 38--*--Genotype 4",
            "Qualifier 25 33;40 41--*--Genotype 5",
            "Qualifier 25 33;46 47--*--Genotype 6",
            "Scope 25 47--*--Genotype 1, 4, 5, or 6",
            "Measurement 49 56--*--HCV RNA",
            "Value 57 68--*--> 103 IU/mL",
            "Temporal 69 81--*--at screening",
            "Reference_point 72 81--*--screening",
            "Person 95 98--*--age",
            "Value 102 107;83 91--*--older 18 years",
            "Condition 122 143--*--chronic HCV infection",
            "Measurement 165 177--*--HCV antibody",
            "Value 156 164--*--positive",
            "Measurement 181 188--*--HCV RNA",
            "Temporal 189 226--*--more than 6 months prior to screening",
            "Reference_point 217 226--*--screening",
            "Measurement 233 255--*--assessment of fibrosis",
            "Value 256 269--*--F2 or greater",
            "Temporal 270 288--*--prior to screening",
            "Reference_point 279 288--*--screening",
            "Scope 156 226--*--positive HCV antibody or HCV RNA more than 6 months prior to screening",
            "Measurement 291 295--*--NYHA",
            "Value 296 305--*--Class III",
            "Non-query-able 307 511--*--Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.",
            "Non-query-able 528 788--*--Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.",
            "Measurement 513 517--*--NYHA",
            "Value 518 526--*--Class IV",
            "Measurement 790 807--*--ejection fraction",
            "Value 808 813--*--= 30%",
            "Observation 815 827--*--hospitalized",
            "Condition 832 845--*--heart failure",
            "Temporal 846 863--*--in last 12 months",
            "Measurement 865 877--*--ILD criteria",
            "Condition 892 917--*--interstitial lung disease",
            "Observation 923 962--*--chronic supplemental oxygen requirement",
            "Qualifier 963 970--*--at rest",
            "Qualifier 978 991--*--with exertion",
            "Parsing_Error 971 977--*--and/or",
            "Scope 963 991--*--at rest and/or with exertion",
            "Measurement 994 1018--*--Forced expiratory volume",
            "Measurement 1020 1024--*--FEV1",
            "Value 1025 1040--*--< 30% predicted",
            "Non-query-able 1042 1053--*--OR any FEV1",
            "Observation 1059 1098--*--chronic supplemental oxygen requirement",
            "Qualifier 1099 1106--*--at rest",
            "Qualifier 1114 1127--*--with exertion",
            "Parsing_Error 1107 1113--*--and/or",
            "Scope 1099 1127--*--at rest and/or with exertion",
            "Non-query-able 1129 1140--*--OR any FEV1",
            "Condition 1146 1165--*--chronic hypercapnia",
            "Measurement 1176 1219--*--partial pressure of arterial carbon dioxide",
            "Measurement 1221 1226--*--PaCO2",
            "Value 1228 1232--*--> 45"
        ]
    },
    "NCT01816997_exc": {
        "Annotations": [
            "Measurement 0 3--*--A1C",
            "Value 4 9--*-->7.0%",
            "Measurement 11 34--*--2hr glucose during OGTT",
            "Value 35 45--*-->200 mg/dL",
            "Measurement 47 64--*--Total cholesterol",
            "Value 65 75--*-->280 mg/dL",
            "Condition 86 94--*--diabetic",
            "Observation 95 102--*--history",
            "Temporal 77 85--*--Previous",
            "Condition 104 127--*--coronary artery disease",
            "Condition 129 136--*--Allergy",
            "Drug 140 152--*--rosuvastatin",
            "Drug 156 167--*--parvastatin",
            "Scope 140 167--*--rosuvastatin or parvastatin",
            "Temporal 169 177--*--Baseline",
            "Measurement 178 181--*--ALT",
            "Value 182 203--*--more than 3 times UNL",
            "Measurement 205 213--*--Serum Cr",
            "Value 214 225--*--> 2.0 mg/dL",
            "Condition 227 236--*--Pregnancy",
            "Observation 238 252--*--breast feeding",
            "Mood 256 266--*--plan to be",
            "Condition 267 275--*--pregnant",
            "Person 276 281--*--woman"
        ],
        "Text": "A1C >7.0%. 2hr glucose during OGTT >200 mg/dL. Total cholesterol >280 mg/dL. Previous diabetic history, coronary artery disease. Allergy to rosuvastatin or parvastatin. Baseline ALT more than 3 times UNL. Serum Cr > 2.0 mg/dL. Pregnancy, breast feeding or plan to be pregnant woman.. "
    },
    "NCT02281643_inc": {
        "Annotations": [
            "Measurement 132 158--*--hepatic laboratory profile",
            "Value 115 121--*--Normal",
            "Measurement 122 127;140 158--*--renal laboratory profile",
            "Measurement 0 14--*--M. perstans mg",
            "Value 15 23--*--positive",
            "Condition 31 50--*--Good general health",
            "Condition 63 112--*--clinical condition requiring long-term medication",
            "Drug 92 112--*--long-term medication",
            "Qualifier 82 112--*--requiring long-term medication",
            "Undefined_semantics 63 112--*--clinical condition requiring long-term medication",
            "Negation 51 58--*--without",
            "Parsing_Error 0 113--*--M. perstans mg-positive status Good general health without any clinical condition requiring long-term medication."
        ],
        "Text": "M. perstans mg-positive status Good general health without any clinical condition requiring long-term medication. . Normal renal and hepatic laboratory profiles . "
    },
    "NCT02550028_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Condition 15 19--*--term",
            "Person 20 24--*--baby",
            "Measurement 30 41--*--gestational",
            "Value 42 51--*-->37 weeks",
            "Measurement 56 69--*--postnatal age",
            "Value 70 83--*--< or= 28 days",
            "Measurement 85 96--*--Birthweight",
            "Value 97 103--*-->2500g",
            "Informed_consent 105 151--*--Written informed consent of parent or guardian"
        ],
        "Text": "Male or female term baby with gestational >37 weeks and postnatal age < or= 28 days. Birthweight >2500g. Written informed consent of parent or guardian. "
    },
    "NCT03381755_inc": {
        "Text": "After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.) treatment for 3 days, the platelet aggregation is effectively inhibited by light transmission aggregometry method and thromboela-stogram.. planned to undergo PCI recently. planned to DAPT for 1 year after PCI. ",
        "Annotations": [
            "Multiplier 6 15--*--half-dose",
            "Drug 16 26--*--ticagrelor",
            "Measurement 28 40--*--loading dose",
            "Value 41 45--*--90mg",
            "Multiplier 56 67--*--45mg bidpo.",
            "Scope 28 67--*--loading dose 90mg, and then 45mg bidpo.",
            "Temporal 69 89--*--treatment for 3 days",
            "Measurement 95 115--*--platelet aggregation",
            "Value 131 140--*--inhibited",
            "Qualifier 119 130--*--effectively",
            "Procedure 144 175--*--light transmission aggregometry",
            "Procedure 187 205--*--thromboela-stogram",
            "Scope 144 205--*--light transmission aggregometry method and thromboela-stogram",
            "Mood 208 226--*--planned to undergo",
            "Procedure 227 230--*--PCI",
            "Temporal 231 239--*--recently",
            "Scope 208 230--*--planned to undergo PCI",
            "Mood 241 251--*--planned to",
            "Procedure 252 256--*--DAPT",
            "Multiplier 257 267--*--for 1 year",
            "Temporal 268 277--*--after PCI",
            "Procedure 274 277--*--PCI",
            "Reference_point 274 277--*--PCI"
        ]
    },
    "NCT02705222_exc": {
        "Text": "Age < 45 or > 55 years.. Blood disorders or coagulopathy.. Diagnosed or suspected local gynecologic lesion (polyp, adenomyosis, myoma, malignancy or cervical pathology).. Use intrauterine contraceptive device.. Pregnancy related conditions.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--< 45 or > 55 years",
            "Condition 25 40--*--Blood disorders",
            "Condition 44 56--*--coagulopathy",
            "Condition 82 106--*--local gynecologic lesion",
            "Mood 59 68--*--Diagnosed",
            "Mood 72 81--*--suspected",
            "Scope 59 81--*--Diagnosed or suspected",
            "Condition 108 113--*--polyp",
            "Condition 115 126--*--adenomyosis",
            "Condition 128 133--*--myoma",
            "Condition 135 145--*--malignancy",
            "Condition 149 167--*--cervical pathology",
            "Scope 108 167--*--polyp, adenomyosis, myoma, malignancy or cervical pathology",
            "Device 175 208--*--intrauterine contraceptive device",
            "Condition 211 220--*--Pregnancy",
            "Condition 229 239--*--conditions",
            "Qualifier 211 228--*--Pregnancy related"
        ]
    },
    "NCT00527826_inc": {
        "Text": "Subject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria. . Male or female subjects, aged >=40 years. Females must be of Non Child Bearing Potential. The definition of Non Child Bearing Potential is as following: Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal. . Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) <50% of predicted normal and a baseline post- bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio <70%. . Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation (requiring oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization) within the 12 months preceding Visit 1. . Have stable COPD medication within 4 weeks prior to Visit 1 (no new medication added and no dosage changes in medication). . Current or ex-smokers with a smoking history of at least 10 pack years (number of pack years = [number of cigarettes per day / 20] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years). . Are currently managed at home (outpatients), are ambulatory and able to travel to the clinic. Subjects can be treated with all relevant COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants, beta-1-agonists (for cardiovascular indication), non-invasive ventilation, long term oxygen therapy and can have Cor Pulmonale. . A signed and dated written informed consent is obtained prior to participation. . Able to comply with the requirements of the protocol and be available for study visits over 52 weeks. . ",
        "Annotations": [
            "Condition 33 37--*--COPD",
            "Measurement 51 127--*--American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria",
            "Value 160 170--*-->=40 years",
            "Person 155 159--*--aged",
            "Person 130 134--*--Male",
            "Person 138 144--*--female",
            "Person 172 179--*--Females",
            "Condition 195 218--*--Child Bearing Potential",
            "Negation 191 194--*--Non",
            "Condition 242 265--*--Child Bearing Potential",
            "Negation 238 241--*--Non",
            "Person 283 290--*--Females",
            "Condition 322 341--*--functioning ovaries",
            "Condition 376 390--*--tubal ligation",
            "Condition 394 406--*--hysterectomy",
            "Condition 427 442--*--post-menopausal",
            "Person 411 418--*--females",
            "Scope 283 406--*--Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy",
            "Scope 411 442--*--females who are post-menopausal",
            "Scope 283 442--*--Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal",
            "Scope 238 265--*--Non Child Bearing Potential",
            "Condition 460 464--*--COPD",
            "Value 465 480--*--stage III or IV",
            "Measurement 494 507--*--GOLD criteria",
            "Measurement 540 593--*--Forced Expiratory Volume, measured at 1 second (FEV1)",
            "Value 594 618--*--<50% of predicted normal",
            "Temporal 520 539--*--post-bronchodilator",
            "Temporal 634 654--*--post- bronchodilator",
            "Measurement 655 698--*--FEV1/Inspiratory Vital Capacity (IVC) ratio",
            "Value 699 703--*--<70%",
            "Multiplier 723 733--*--at least 2",
            "Qualifier 746 752--*--severe",
            "Qualifier 734 742--*--moderate",
            "Condition 753 771--*--COPD exacerbations",
            "Scope 734 752--*--moderate or severe",
            "Drug 815 835--*--oral corticosteroids",
            "Drug 860 880--*--oral corticosteroids",
            "Qualifier 839 856--*--increasing dosage",
            "Drug 888 899--*--antibiotics",
            "Visit 903 918--*--hospitalization",
            "Temporal 920 958--*--within the 12 months preceding Visit 1",
            "Scope 815 918--*--oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization",
            "Drug 973 988--*--COPD medication",
            "Temporal 989 1020--*--within 4 weeks prior to Visit 1",
            "Qualifier 966 972--*--stable",
            "Condition 1099 1106--*--smokers",
            "Measurement 1114 1129--*--smoking history",
            "Value 1142 1155--*--10 pack years",
            "Scope 1157 1321--*--number of pack years = [number of cigarettes per day / 20] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years",
            "Temporal 1085 1092--*--Current",
            "Negation 1096 1098--*--ex",
            "Scope 1085 1098--*--Current or ex",
            "Observation 1339 1354--*--managed at home",
            "Visit 1347 1354--*--at home",
            "Procedure 1339 1346--*--managed",
            "Observation 1356 1367--*--outpatients",
            "Visit 1356 1367--*--outpatients",
            "Condition 1374 1384--*--ambulatory",
            "Observation 1389 1417--*--able to travel to the clinic",
            "Observation 1823 1847--*--written informed consent",
            "Temporal 1860 1882--*--prior to participation",
            "Observation 1885 1937--*--Able to comply with the requirements of the protocol",
            "Observation 1945 1971--*--available for study visits",
            "Visit 1959 1971--*--study visits",
            "Temporal 1972 1985--*--over 52 weeks",
            "Drug 1461 1476--*--COPD medication",
            "Drug 1492 1500--*--vaccines",
            "Drug 1502 1538--*--inhaled short-acting beta-2-agonists",
            "Drug 1550 1562--*--short-acting",
            "Drug 1566 1594--*--long-acting anticholinergics",
            "Drug 1596 1606--*--tiotropium",
            "Drug 1609 1633--*--systemic beta-2-agonists",
            "Drug 1635 1647--*--theophylline",
            "Drug 1649 1659--*--mucolytics",
            "Drug 1661 1673--*--antioxidants",
            "Drug 1675 1690--*--beta-1-agonists",
            "Condition 1696 1721--*--cardiovascular indication",
            "Condition 1724 1748--*--non-invasive ventilation",
            "Multiplier 1750 1759--*--long term",
            "Procedure 1760 1774--*--oxygen therapy",
            "Drug 1760 1766--*--oxygen",
            "Condition 1788 1801--*--Cor Pulmonale",
            "Scope 1461 1673--*--COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants"
        ]
    },
    "NCT01774019_exc": {
        "Annotations": [
            "Condition 0 18--*--Biliary strictures",
            "Condition 39 52--*--benign tumors",
            "Qualifier 29 38--*--confirmed",
            "Condition 54 72--*--Biliary strictures",
            "Condition 83 95--*--malignancies",
            "Negation 96 106--*--other than",
            "Condition 107 124--*--pancreatic cancer",
            "Condition 126 155--*--distal CBD cholangiocarcinoma",
            "Condition 160 187--*--other periampullary cancers",
            "Scope 107 187--*--pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",
            "Condition 189 229--*--Surgically altered biliary tract anatomy",
            "Procedure 251 266--*--cholecystectomy",
            "Temporal 245 250--*--prior",
            "Negation 231 234--*--not",
            "Procedure 268 292--*--Neoadjuvant chemotherapy",
            "Condition 305 315--*--malignancy",
            "Non-query-able 317 390--*--Palliative indication due to reasons other than surgical candidate status",
            "Procedure 401 429--*--biliary drainage by ERCP/PTC",
            "Temporal 392 400--*--Previous",
            "Condition 475 490--*--contraindicated",
            "Procedure 449 470--*--endoscopic techniques",
            "Non-query-able 492 553--*--Participation in another investigational trial within 90 days",
            "Condition 555 564--*--Pregnancy"
        ],
        "Text": "Biliary strictures caused by confirmed benign tumors. Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers. Surgically altered biliary tract anatomy, not including prior cholecystectomy. Neoadjuvant chemotherapy for current malignancy. Palliative indication due to reasons other than surgical candidate status. Previous biliary drainage by ERCP/PTC. Patients for whom endoscopic techniques are contraindicated. Participation in another investigational trial within 90 days. Pregnancy. "
    },
    "NCT03250507_exc": {
        "Annotations": [
            "Condition 15 37--*--chronic pain condition",
            "Qualifier 39 44--*--major",
            "Condition 45 77--*--unexpected surgical complication",
            "Multiplier 90 99--*--prolonged",
            "Procedure 100 110--*--intubation",
            "Qualifier 79 89--*--unexpected",
            "Observation 112 127--*--patient refusal",
            "Drug 129 145--*--local anesthetic",
            "Condition 146 153--*--allergy",
            "Condition 159 175--*--contraindication",
            "Drug 179 198--*--regional anesthesia",
            "Multiplier 200 214--*--greater than 2",
            "Multiplier 240 254--*--greater than 1",
            "Procedure 293 302--*--TAP block",
            "Person 227 235--*--resident",
            "Person 272 288--*--anesthesiologist",
            "Scope 200 288--*--greater than 2 attempts by resident and greater than 1 attempt by staff anesthesiologist"
        ],
        "Text": "Patient with a chronic pain condition, major unexpected surgical complication, unexpected prolonged intubation, patient refusal, local anesthetic allergy, any contraindication to regional anesthesia, greater than 2 attempts by resident and greater than 1 attempt by staff anesthesiologist for TAP block.. "
    },
    "NCT02609425_exc": {
        "Annotations": [
            "Condition 17 34--*--esophageal cancer",
            "Negation 42 45--*--not",
            "Observation 64 73--*--candidate",
            "Negation 84 87--*--not",
            "Observation 97 106--*--candidate",
            "Procedure 55 63--*--surgical",
            "Qualifier 115 135--*--Ivor Lewis technique",
            "Procedure 139 152--*--esophagectomy",
            "Condition 159 184--*--intrathoracic anastomosis",
            "Qualifier 154 184--*--with intrathoracic anastomosis",
            "Value 200 218--*--less than 18 years",
            "Person 222 225--*--age"
        ],
        "Text": "Any patient with esophageal cancer who is not deemed a surgical candidate or who is not deemed a candidate for the Ivor Lewis technique of esophagectomy (with intrathoracic anastomosis).. Any patient less than 18 years of age. "
    },
    "NCT02557386_inc": {
        "Text": "Male sex. ASA status I or II. BMI between 20 and 34 kg/m2. Cruciate ligament of the knee reconstructive surgery. No contraindications to general and regional anesthesia. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Measurement 10 20--*--ASA status",
            "Value 21 28--*--I or II",
            "Measurement 30 33--*--BMI",
            "Value 34 57--*--between 20 and 34 kg/m2",
            "Procedure 89 111--*--reconstructive surgery",
            "Qualifier 59 88--*--Cruciate ligament of the knee",
            "Condition 116 133--*--contraindications",
            "Procedure 149 168--*--regional anesthesia",
            "Procedure 137 144;158 168--*--general anesthesia",
            "Negation 113 115--*--No",
            "Scope 137 168--*--general and regional anesthesia"
        ]
    },
    "NCT03140488_exc": {
        "Text": "Non-reassuring fetal assessment at the time of recruitment. Previous cervical ripening agents (cytotec, cervidil, cervical Foley Balloon). <18 years of age. Prisoners. Any patients contraindicated for vaginal delivery. Multiple gestations. History of previous cesarean delivery. Patients with history of significant cardiac disease. Fetal demise. Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother. Ruptured membranes. Spontaneous labor (latent or active phase). Augmentation of labor (latent or active phase). ",
        "Annotations": [
            "Value 0 14--*--Non-reassuring",
            "Measurement 15 31--*--fetal assessment",
            "Temporal 32 58--*--at the time of recruitment",
            "Temporal 60 68--*--Previous",
            "Drug 69 93--*--cervical ripening agents",
            "Drug 95 102--*--cytotec",
            "Drug 104 112--*--cervidil",
            "Device 114 136--*--cervical Foley Balloon",
            "Scope 95 136--*--cytotec, cervidil, cervical Foley Balloon",
            "Person 152 155--*--age",
            "Value 139 148--*--<18 years",
            "Person 157 166--*--Prisoners",
            "Condition 181 196--*--contraindicated",
            "Procedure 201 217--*--vaginal delivery",
            "Observation 219 238--*--Multiple gestations",
            "Observation 240 247--*--History",
            "Temporal 251 259--*--previous",
            "Procedure 260 277--*--cesarean delivery",
            "Observation 293 300--*--history",
            "Qualifier 304 315--*--significant",
            "Condition 316 331--*--cardiac disease",
            "Condition 333 345--*--Fetal demise",
            "Measurement 347 369--*--Estimated fetal weight",
            "Value 370 393--*--greater than 4500 grams",
            "Condition 397 405--*--diabetic",
            "Value 410 420--*--5000 grams",
            "Negation 424 428--*--non-",
            "Condition 428 436--*--diabetic",
            "Scope 424 436--*--non-diabetic",
            "Scope 370 436--*--greater than 4500 grams in diabetic and 5000 grams in non-diabetic",
            "Condition 445 463--*--Ruptured membranes",
            "Condition 465 482--*--Spontaneous labor",
            "Qualifier 484 490;501 506--*--latent phase",
            "Qualifier 494 506--*--active phase",
            "Scope 484 506--*--latent or active phase",
            "Condition 509 530--*--Augmentation of labor",
            "Qualifier 532 538;549 554--*--latent phase",
            "Qualifier 542 554--*--active phase",
            "Scope 532 554--*--latent or active phase"
        ]
    },
    "NCT02926235_exc": {
        "Text": "All patients who were wheelchair bound preoperatively. All patients who cannot participate in an outpatient physical therapy program for 3 days per week after surgery. ",
        "Annotations": [
            "Qualifier 39 53--*--preoperatively",
            "Observation 22 38--*--wheelchair bound",
            "Negation 72 78--*--cannot",
            "Procedure 108 124--*--physical therapy",
            "Visit 97 107--*--outpatient",
            "Temporal 133 166--*--for 3 days per week after surgery",
            "Reference_point 159 166--*--surgery"
        ]
    },
    "NCT00502567_inc": {
        "Text": "histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent . measurable lesion by CT or other techniques according to RECIST . ",
        "Annotations": [
            "Condition 25 42--*--metastatic cancer",
            "Measurement 0 14--*--histologically",
            "Value 15 24--*--confirmed",
            "Procedure 78 95--*--radiation therapy",
            "Procedure 67 74--*--surgery",
            "Qualifier 51 63--*--not amenable",
            "Scope 67 95--*--surgery or radiation therapy",
            "Procedure 139 141--*--CT",
            "Condition 118 135--*--measurable lesion"
        ]
    },
    "NCT02299063_inc": {
        "Annotations": [
            "Person 0 4--*--aged",
            "Value 5 26--*--between 3 - 36 months",
            "Qualifier 35 42--*--primary",
            "Procedure 43 67--*--corrective heart surgery"
        ],
        "Text": "aged between 3 - 36 months. having primary corrective heart surgery. "
    },
    "NCT02361905_exc": {
        "Text": "submucosal leiomyoma,. endometrial hyperplasia with atypia,. history of uterine surgery. ",
        "Annotations": [
            "Condition 0 20--*--submucosal leiomyoma",
            "Condition 23 46--*--endometrial hyperplasia",
            "Qualifier 47 58--*--with atypia",
            "Observation 61 68--*--history",
            "Procedure 72 87--*--uterine surgery"
        ]
    },
    "NCT02557412_inc": {
        "Text": "Diagnosis of dyslipidemia: The existence of a previous clinical diagnostic of dyslipidemia associated with lipid-lowering therapy. It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl. Lipid-lowering treatment and diet, stable in the last month.. A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.. An apnea-hypopnea index between 5-30 h-1. ",
        "Annotations": [
            "Condition 13 25--*--dyslipidemia",
            "Procedure 107 129--*--lipid-lowering therapy",
            "Measurement 223 240--*--total cholesterol",
            "Value 241 254--*--= 200 mg / dl",
            "Measurement 256 269--*--triglycerides",
            "Value 270 283--*--= 180 mg / dl",
            "Measurement 285 300--*--HDL-cholesterol",
            "Value 301 313--*--= 40 mg / dl",
            "Measurement 317 332--*--LDL-cholesterol",
            "Value 333 346--*--= 150 mg / dl",
            "Procedure 348 372--*--Lipid-lowering treatment",
            "Procedure 348 362;377 381--*--Lipid-lowering diet",
            "Qualifier 383 389--*--stable",
            "Temporal 390 407--*--in the last month",
            "Condition 174 192--*--altered analytical",
            "Scope 223 346--*--total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl",
            "Condition 78 90--*--dyslipidemia",
            "Scope 78 129--*--dyslipidemia associated with lipid-lowering therapy",
            "Scope 78 346--*--dyslipidemia associated with lipid-lowering therapy. It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl",
            "Measurement 429 444--*--LDL-cholesterol",
            "Value 445 462--*--above 100 mg / dl",
            "Temporal 464 495--*--in the month prior to inclusion",
            "Reference_point 486 495--*--inclusion",
            "Measurement 501 521--*--apnea-hypopnea index",
            "Value 522 538--*--between 5-30 h-1"
        ]
    },
    "NCT01895946_inc": {
        "Annotations": [
            "Value 5 22--*--at least 18 years",
            "Person 0 4--*--Aged",
            "Condition 42 65--*--solid, malignant tumour",
            "Condition 77 85--*--lymphoma",
            "Negation 67 76--*--excluding",
            "Qualifier 95 127--*--resistance to standard therapies",
            "Qualifier 131 168--*--for which no standard therapies exist",
            "Scope 95 168--*--resistance to standard therapies or for which no standard therapies exist",
            "Multiplier 186 198--*--at least one",
            "Condition 199 205--*--lesion",
            "Qualifier 218 249--*--accurately assessed at baseline",
            "Procedure 253 281--*--Computerised Tomography (CT)",
            "Procedure 283 315--*--Magnetic Resonance Imaging (MRI)",
            "Procedure 319 330--*--plain X-ray",
            "Qualifier 338 370--*--suitable for repeated assessment",
            "Scope 253 330--*--Computerised Tomography (CT), Magnetic Resonance Imaging (MRI) or plain X-ray",
            "Value 401 419--*--more than 12 weeks",
            "Observation 372 397--*--Estimated life expectancy"
        ],
        "Text": "Aged at least 18 years . The presence of a solid, malignant tumour, excluding lymphoma, that is resistance to standard therapies or for which no standard therapies exist . The presence of at least one lesion that can be accurately assessed at baseline by Computerised Tomography (CT), Magnetic Resonance Imaging (MRI) or plain X-ray and is suitable for repeated assessment . Estimated life expectancy of more than 12 weeks . "
    },
    "NCT02959580_inc": {
        "Annotations": [
            "Condition 0 33--*--Idiopathic Granulomatous Mastitis"
        ],
        "Text": "Idiopathic Granulomatous Mastitis. "
    },
    "NCT02924090_inc": {
        "Annotations": [
            "Person 0 6--*--Adults",
            "Person 16 20--*--aged",
            "Value 21 35--*--18 to 85 years",
            "Condition 52 77--*--Major Depressive Disorder",
            "Condition 79 87;99 109--*--unipolar depression",
            "Condition 91 109--*--bipolar depression",
            "Procedure 122 125--*--ECT",
            "Temporal 111 121--*--Undergoing",
            "Visit 181 189--*--Manitoba",
            "Observation 159 177--*--Currently residing"
        ],
        "Text": "Adults patients aged 18 to 85 years. Diagnosed with Major Depressive Disorder, unipolar or bipolar depression. Undergoing ECT for treatment of their symptoms. Currently residing in Manitoba. "
    },
    "NCT01312012_inc": {
        "Text": "pregnant women in 30 to 32 weeks of gestation, with positive HBsAg and HBeAg,serum viral load above 8log10 copies per mL. ",
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Person 9 14--*--women",
            "Value 18 32--*--30 to 32 weeks",
            "Measurement 36 45--*--gestation",
            "Measurement 61 66--*--HBsAg",
            "Measurement 71 76--*--HBeAg",
            "Value 52 60--*--positive",
            "Scope 61 76--*--HBsAg and HBeAg",
            "Measurement 77 93--*--serum viral load",
            "Value 94 120--*--above 8log10 copies per mL"
        ]
    },
    "NCT02926235_inc": {
        "Text": "All patients will be undergoing a primary unilateral total knee arthroplasty for a diagnosis of osteoarthritis. ",
        "Annotations": [
            "Condition 96 110--*--osteoarthritis",
            "Procedure 42 76--*--unilateral total knee arthroplasty",
            "Qualifier 34 41--*--primary"
        ]
    },
    "NCT02361905_inc": {
        "Text": "hypoechoic uterine leiomyoma (echogenicity <3),. intramural leiomyomas with an ultrasonographic size <20 cm but >4cm,. indication to surgery (symptoms of menometrorrhagia,. menstrual disorder,. infertility,. pelvic pain or pelvic pressure. ",
        "Annotations": [
            "Condition 11 28--*--uterine leiomyoma",
            "Qualifier 0 10--*--hypoechoic",
            "Measurement 30 42--*--echogenicity",
            "Value 43 45--*--<3",
            "Scope 30 45--*--echogenicity <3",
            "Condition 49 70--*--intramural leiomyomas",
            "Measurement 79 100--*--ultrasonographic size",
            "Value 101 116--*--<20 cm but >4cm",
            "Mood 119 132--*--indication to",
            "Procedure 133 140--*--surgery",
            "Condition 154 170--*--menometrorrhagia",
            "Condition 173 191--*--menstrual disorder",
            "Condition 194 205--*--infertility",
            "Condition 208 219--*--pelvic pain",
            "Condition 223 238--*--pelvic pressure",
            "Scope 119 140--*--indication to surgery"
        ]
    },
    "NCT02299063_exc": {
        "Annotations": [
            "Procedure 7 14--*--surgery",
            "Temporal 0 6--*--recent",
            "Temporal 16 26--*--< 3 months",
            "Temporal 29 37--*--previous",
            "Procedure 38 50--*--chemotherapy",
            "Temporal 52 60--*--previous",
            "Procedure 61 90--*--transfusion of blood products",
            "Condition 92 120--*--neurodevelopmental disorders",
            "Condition 132 142--*--Trisomy 21",
            "Procedure 145 164--*--supplemental oxygen",
            "Mood 165 176--*--requirement",
            "Temporal 178 188--*--< 3 months",
            "Condition 191 197--*--asthma",
            "Procedure 208 223--*--regular therapy",
            "Condition 225 248--*--obstructive sleep apnea",
            "Temporal 266 276--*--concurrent",
            "Condition 277 286--*--infection",
            "Condition 290 302--*--inflammation",
            "Scope 277 302--*--infection or inflammation",
            "Condition 312 319--*--allergy",
            "Drug 323 352--*--dexmedetomidine hydrochloride"
        ],
        "Text": "recent surgery (< 3 months). previous chemotherapy. previous transfusion of blood products. neurodevelopmental disorders (including Trisomy 21). supplemental oxygen requirement (< 3 months). asthma requiring regular therapy. obstructive sleep apnea. the presence of concurrent infection or inflammation. a known allergy to dexmedetomidine hydrochloride. "
    },
    "NCT00502567_exc": {
        "Text": "Inadequate bone marrow reserve . history of poorly controlled hypertension       .     . ",
        "Annotations": [
            "Condition 0 30--*--Inadequate bone marrow reserve",
            "Condition 43 73--*--poorly controlled hypertension",
            "Observation 32 39--*--history"
        ]
    },
    "NCT02557412_exc": {
        "Text": "Apnea-hypopnea index of less than 5 h-1 or greater than 30 h-1.. Predominance of central apneas and hypopneas, defined as more than 25% of all respiratory events.. Professional drivers, risk profession or respiratory failure (according to criteria of the clinical pathway for diagnosis and treatment of sleep-disordered breathing).. Very excessive daytime sleepiness (Epworth Sleepiness Scale> 18).. Morbid obesity (BMI> 40 kg / m2).. Prior treatment with CPAP.. ",
        "Annotations": [
            "Measurement 0 20--*--Apnea-hypopnea index",
            "Value 24 62--*--less than 5 h-1 or greater than 30 h-1",
            "Condition 81 109--*--central apneas and hypopneas",
            "Value 122 135--*--more than 25%",
            "Measurement 139 161--*--all respiratory events",
            "Condition 65 77--*--Predominance",
            "Scope 65 109--*--Predominance of central apneas and hypopneas",
            "Person 164 184--*--Professional drivers",
            "Person 186 201--*--risk profession",
            "Condition 205 224--*--respiratory failure",
            "Procedure 239 329--*--criteria of the clinical pathway for diagnosis and treatment of sleep-disordered breathing",
            "Qualifier 333 347--*--Very excessive",
            "Condition 348 366--*--daytime sleepiness",
            "Measurement 368 392--*--Epworth Sleepiness Scale",
            "Value 392 396--*--> 18",
            "Scope 333 366--*--Very excessive daytime sleepiness",
            "Scope 368 396--*--Epworth Sleepiness Scale> 18",
            "Condition 400 414--*--Morbid obesity",
            "Measurement 416 419--*--BMI",
            "Value 419 431--*--> 40 kg / m2",
            "Procedure 456 460--*--CPAP",
            "Temporal 435 440--*--Prior"
        ]
    },
    "NCT01895946_exc": {
        "Annotations": [
            "Qualifier 0 22--*--Clinically significant",
            "Condition 23 58--*--abnormalities of glucose metabolism",
            "Condition 60 83--*--Spinal cord compression",
            "Condition 87 103--*--brain metastases",
            "Condition 111 123--*--asymptomatic",
            "Negation 104 110--*--unless",
            "Qualifier 125 132--*--treated",
            "Qualifier 137 143--*--stable",
            "Scope 111 168--*--asymptomatic, treated and stable (not requiring steroids)",
            "Drug 159 167--*--steroids",
            "Negation 145 148--*--not",
            "Scope 60 103--*--Spinal cord compression or brain metastases",
            "Qualifier 192 204--*--uncontrolled",
            "Condition 205 222--*--systemic diseases",
            "Qualifier 182 188--*--severe",
            "Scope 182 204--*--severe or uncontrolled",
            "Condition 234 259--*--active bleeding diatheses",
            "Condition 263 280--*--active infections",
            "Condition 291 302--*--hepatitis B",
            "Condition 310 344--*--Human Immunodeficiency Virus (HIV)",
            "Condition 291 300;304 305--*--hepatitis C",
            "Scope 291 344--*--hepatitis B, C and Human Immunodeficiency Virus (HIV)",
            "Scope 234 344--*--active bleeding diatheses or active infections including hepatitis B, C and Human Immunodeficiency Virus (HIV)",
            "Qualifier 358 380--*--clinically significant",
            "Undefined_semantics 358 380--*--clinically significant",
            "Condition 381 402--*--cardiac abnormalities",
            "Condition 404 428--*--uncontrolled hypotension",
            "Measurement 430 464--*--left ventricular ejection fraction",
            "Value 465 496--*--below the lower limit of normal",
            "Procedure 539 572--*--cardiac interventional procedures",
            "Qualifier 527 538--*--significant",
            "Subjective_judgement 527 538--*--significant",
            "Condition 576 599--*--bad reaction to AZD5363",
            "Drug 592 599--*--AZD5363",
            "Context_Error 574 648--*--A bad reaction to AZD5363 or any drugs similar to it in structure or class",
            "Non-query-able 574 648--*--A bad reaction to AZD5363 or any drugs similar to it in structure or class"
        ],
        "Text": "Clinically significant abnormalities of glucose metabolism . Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids) . Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and Human Immunodeficiency Virus (HIV) . Evidence of clinically significant cardiac abnormalities, uncontrolled hypotension, left ventricular ejection fraction below the lower limit of normal for the site or experience of significant cardiac interventional procedures . A bad reaction to AZD5363 or any drugs similar to it in structure or class       .     . "
    },
    "NCT01312012_exc": {
        "Text": "major systemic disease. Pregnant woman with infection of human immunodeficiency virus or hepatitis C virus. Pregnant woman is receiving any drug with antiviral activity or any form of drug therapy for hepatitis B virus. Pregnant woman whose ultrasonographic examination reveals congenital anomaly of the fetus. Pregnant woman whose amniocentesis reveals any genetic abnormality. ",
        "Annotations": [
            "Condition 0 22--*--major systemic disease",
            "Condition 24 32--*--Pregnant",
            "Condition 108 116--*--Pregnant",
            "Condition 220 228--*--Pregnant",
            "Condition 311 319--*--Pregnant",
            "Person 33 38--*--woman",
            "Person 117 122--*--woman",
            "Person 229 234--*--woman",
            "Person 320 325--*--woman",
            "Condition 57 85--*--human immunodeficiency virus",
            "Condition 89 106--*--hepatitis C virus",
            "Drug 140 168--*--drug with antiviral activity",
            "Procedure 184 196--*--drug therapy",
            "Condition 201 218--*--hepatitis B virus",
            "Procedure 241 269--*--ultrasonographic examination",
            "Value 278 309--*--congenital anomaly of the fetus",
            "Procedure 332 345--*--amniocentesis",
            "Value 358 377--*--genetic abnormality"
        ]
    },
    "NCT02959580_exc": {
        "Annotations": [
            "Condition 0 16--*--Breast Carcinoma"
        ],
        "Text": "Breast Carcinoma. "
    },
    "NCT02924090_exc": {
        "Annotations": [
            "Condition 0 26--*--Relative contraindications",
            "Procedure 30 41--*--ECT therapy",
            "Temporal 43 49--*--recent",
            "Condition 50 52--*--MI",
            "Condition 56 59--*--CVA",
            "Scope 50 59--*--MI or CVA",
            "Value 61 70--*--increased",
            "Measurement 71 92--*--intracranial pressure",
            "Condition 94 118--*--intracranial mass lesion",
            "Condition 120 141--*--intracranial aneurysm",
            "Condition 143 151--*--epilepsy",
            "Condition 159 177--*--cardiac arrhythmia",
            "Condition 179 195--*--pheochromocytoma",
            "Condition 197 206--*--pregnancy",
            "Scope 43 206--*--recent MI or CVA, increased intracranial pressure, intracranial mass lesion, intracranial aneurysm, epilepsy, known cardiac arrhythmia, pheochromocytoma, pregnancy",
            "Scope 0 41--*--Relative contraindications to ECT therapy",
            "Condition 209 226--*--Contraindications",
            "Drug 230 239--*--etomidate",
            "Condition 241 247--*--sepsis",
            "Qualifier 249 256--*--primary",
            "Qualifier 260 269--*--secondary",
            "Condition 270 291--*--adrenal insufficiency",
            "Condition 293 302--*--porphyria",
            "Qualifier 305 310--*--DSM-V",
            "Observation 326 342--*--lifetime history",
            "Condition 346 373--*--psychotic spectrum disorder",
            "Condition 375 379;391 401--*--Drug dependence",
            "Condition 383 401--*--alcohol dependence",
            "Temporal 412 436--*--within the past 3 months",
            "Condition 375 379;406 411--*--Drug abuse",
            "Condition 383 390;406 411--*--alcohol abuse",
            "Scope 375 411--*--Drug or alcohol dependence, or abuse",
            "Condition 438 458--*--soy-bean oil allergy"
        ],
        "Text": "Relative contraindications to ECT therapy (recent MI or CVA, increased intracranial pressure, intracranial mass lesion, intracranial aneurysm, epilepsy, known cardiac arrhythmia, pheochromocytoma, pregnancy). Contraindications to etomidate (sepsis, primary or secondary adrenal insufficiency, porphyria). DSM-V diagnosis of a lifetime history of psychotic spectrum disorder. Drug or alcohol dependence, or abuse within the past 3 months, soy-bean oil allergy. "
    },
    "NCT03275584_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--women",
            "Condition 16 30--*--Claustrophobic",
            "Negation 39 45--*--unable",
            "Procedure 61 72--*--examination",
            "Non-representable 74 137--*--Breastfeeding women unwilling to temporarily stop breastfeeding",
            "Condition 152 169--*--contra-indication",
            "Drug 174 186--*--dipyridamole",
            "Drug 188 201--*--aminophylline",
            "Drug 203 213--*--dobutamine",
            "Procedure 217 237--*--exercise stress test",
            "Scope 174 237--*--dipyridamole, aminophylline, dobutamine or exercise stress test"
        ],
        "Text": "Pregnant women. Claustrophobic patient unable to undergo the examination. Breastfeeding women unwilling to temporarily stop breastfeeding. Patient with contra-indication to: dipyridamole, aminophylline, dobutamine or exercise stress test (depending on the method of cardiovascular stress test chosen). "
    },
    "NCT03282006_inc": {
        "Annotations": [
            "Procedure 10 23--*--blood culture",
            "Value 0 6--*--E.coli",
            "Value 29 46--*--identical isolate",
            "Procedure 50 62--*--urine sample",
            "Measurement 73 76--*--CFU",
            "Value 64 72--*-->= 1.000",
            "Mood 90 104--*--clinical signs",
            "Condition 108 111--*--UTI",
            "Scope 64 76--*-->= 1.000 CFU"
        ],
        "Text": "E.coli in blood culture. AND identical isolate in urine sample (>= 1.000 CFU) OR relevant clinical signs of UTI. "
    },
    "NCT03198910_exc": {
        "Annotations": [],
        "Text": "    . "
    },
    "NCT03323047_exc": {
        "Annotations": [
            "Measurement 37 96--*--American Society of Anesthesiologists (ASA) physical status",
            "Value 9 29--*--Level III or greater",
            "Condition 174 192--*--chronic conditions",
            "Condition 276 305--*--neurodevelopmental conditions",
            "Observation 331 360--*--understanding the Oucher tool",
            "Condition 306 316--*--preventing",
            "Observation 204 266--*--limit our ability to develop the study according to objectives",
            "Scope 276 360--*--neurodevelopmental conditions preventing patients from understanding the Oucher tool",
            "Condition 373 386--*--renal disease",
            "Condition 362 369;379 386--*--Hepatic disease",
            "Condition 388 403--*--cardiac disease",
            "Condition 412 421--*--infection",
            "Qualifier 405 411--*--active",
            "Condition 423 440--*--diabetes mellitus",
            "Condition 442 461--*--sickle cell disease",
            "Condition 469 490--*--coagulation disorders",
            "Drug 549 559--*--analgesics",
            "Drug 536 544--*--steroids",
            "Drug 522 534--*--anti-emetics",
            "Temporal 492 506--*--pre- operative",
            "Procedure 507 516--*--treatment",
            "Scope 522 559--*--anti-emetics, steroids, or analgesics",
            "Drug 561 574--*--Acetaminophen",
            "Condition 575 582--*--allergy",
            "Drug 604 617--*--acetaminophen",
            "Temporal 618 640--*--within 24 h of surgery",
            "Condition 670 680--*--precluding",
            "Drug 692 699--*--opioids",
            "Drug 703 716--*--acetaminophen",
            "Condition 642 669--*--Complicating health factors",
            "Scope 692 716--*--opioids or acetaminophen",
            "Condition 748 757--*--interfere",
            "Procedure 763 778--*--pain assessment",
            "Procedure 783 793--*--management",
            "Condition 722 735--*--other factors",
            "Scope 763 793--*--pain assessment and management",
            "Measurement 804 812--*--weighing",
            "Value 813 828--*--more than 30 kg",
            "Non-representable 875 917--*--Patients who live without a home telephone",
            "Non-representable 919 963--*--patient living without parental supervision.",
            "Non-representable 829 873--*--that would exceed maximum dexamethasone dose"
        ],
        "Text": "Patients Level III or greater on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist). Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool. Hepatic or renal disease. cardiac disease. active infection. diabetes mellitus. sickle cell disease. known coagulation disorders. pre- operative treatment with anti-emetics, steroids, or analgesics. Acetaminophen allergy or already receiving acetaminophen within 24 h of surgery. Complicating health factors precluding the use of opioids or acetaminophen. any other factors which would interfere with pain assessment and management. Patients weighing more than 30 kg that would exceed maximum dexamethasone dose. Patients who live without a home telephone. patient living without parental supervision.. "
    },
    "NCT02765217_exc": {
        "Text": "Receiving antibiotic and/or probiotic, 8 weeks before the study. Chronic gastrointestinal system disorders. Congenital anomalies. Chronic diseases. Chemotherapy and radiotherapy. Pregnancy. ",
        "Annotations": [
            "Drug 10 20--*--antibiotic",
            "Drug 28 37--*--probiotic",
            "Temporal 39 63--*--8 weeks before the study",
            "Reference_point 54 63--*--the study",
            "Scope 10 37--*--antibiotic and/or probiotic",
            "Condition 65 106--*--Chronic gastrointestinal system disorders",
            "Condition 108 128--*--Congenital anomalies",
            "Condition 130 146--*--Chronic diseases",
            "Procedure 148 160--*--Chemotherapy",
            "Procedure 165 177--*--radiotherapy",
            "Condition 179 188--*--Pregnancy"
        ]
    },
    "NCT01217671_inc": {
        "Text": "Diagnosis of emphysema confirmed by CT scan. If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening . Male or female patients at least 18 years of age. . Able and willing to sign an informed consent. . Patient with record of congenital AAT deficiency of phenotype PiZZ (homozygote) or other rare phenotypes related to AAT deficiency and with AAT serum level \u2264 11 micromole. For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply. . FEV1/SVC <70% of predicted value post bronchodilator (SVC is slow VC) and FEV1 < 80% of predicted value post-bronchodilator . History of at least two moderate or severe exacerbations that required change in treatment (antibiotics, systemic steroids, hospitalization) in the last 18 months prior to date of screening , with at least one of these occurring within the last 12 months prior to screening. . Ability to comply with completion of electronic diary. . Ability to self-administer inhaled AAT. . No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency. . No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency. . No significant abnormalities in ECG per investigator judgment. . Negative for HBsAg and for antibodies to HCV, HIV-1. . AAT deficient patients who are either na\u00efve (not receiving IV augmentation therapy) or AAT deficient patients (receiving IV augmentation therapy), if they have been stable on regular therapy for at least 3 months prior to the screening visit and are willing to continue the same regime throughout this trial. Note that only sites in Germany can recruit patients who are currently being treated with IV AAT.Patients who stopped IV augmentation treatment 6 months prior to screening date and will not re-start this treatment for the course of the study will be considered Na\u00efve. . Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized. . ",
        "Annotations": [
            "Condition 13 22--*--emphysema",
            "Procedure 36 43--*--CT scan",
            "Procedure 65 72--*--CT scan",
            "Temporal 60 64--*--past",
            "Negation 76 89--*--not available",
            "Observation 50 72--*--report of past CT scan",
            "Procedure 117 124--*--CT scan",
            "Scope 50 89--*--report of past CT scan is not available",
            "Scope 50 156--*--report of past CT scan is not available at site documenting then a CT scan is to be performed at screening",
            "Temporal 144 156--*--at screening",
            "Reference_point 147 156--*--screening",
            "Person 158 162--*--Male",
            "Person 166 172--*--female",
            "Value 182 199--*--at least 18 years",
            "Person 203 206--*--age",
            "Post-eligibility 209 254--*--Able and willing to sign an informed consent.",
            "Condition 279 335--*--congenital AAT deficiency of phenotype PiZZ (homozygote)",
            "Condition 345 386--*--rare phenotypes related to AAT deficiency",
            "Measurement 396 411--*--AAT serum level",
            "Value 412 426--*--\u2264 11 micromole",
            "Procedure 451 478--*--IV AAT augmentation therapy",
            "Context_Error 428 524--*--For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply.",
            "Measurement 526 534--*--FEV1/SVC",
            "Value 535 558--*--<70% of predicted value",
            "Qualifier 559 578--*--post bronchodilator",
            "Temporal 559 578--*--post bronchodilator",
            "Drug 564 578--*--bronchodilator",
            "Measurement 600 604--*--FEV1",
            "Value 605 629--*--< 80% of predicted value",
            "Qualifier 630 649--*--post-bronchodilator",
            "Temporal 630 649--*--post-bronchodilator",
            "Drug 635 649--*--bronchodilator",
            "Reference_point 564 578--*--bronchodilator",
            "Reference_point 635 649--*--bronchodilator",
            "Multiplier 662 674--*--at least two",
            "Qualifier 675 683--*--moderate",
            "Qualifier 687 693--*--severe",
            "Condition 694 707--*--exacerbations",
            "Scope 675 693--*--moderate or severe",
            "Observation 722 741--*--change in treatment",
            "Qualifier 713 741--*--required change in treatment",
            "Drug 743 754--*--antibiotics",
            "Drug 756 773--*--systemic steroids",
            "Procedure 775 790--*--hospitalization",
            "Qualifier 756 764--*--systemic",
            "Temporal 792 840--*--in the last 18 months prior to date of screening",
            "Reference_point 823 840--*--date of screening",
            "Multiplier 848 860--*--at least one",
            "Temporal 880 924--*--within the last 12 months prior to screening",
            "Reference_point 915 924--*--screening",
            "Scope 743 790--*--antibiotics, systemic steroids, hospitalization",
            "Procedure 732 741--*--treatment",
            "Observation 994 1021--*--self-administer inhaled AAT",
            "Observation 938 980--*--comply with completion of electronic diary",
            "Post-eligibility 927 981--*--Ability to comply with completion of electronic diary.",
            "Post-eligibility 983 1022--*--Ability to self-administer inhaled AAT.",
            "Post-eligibility 1024 1258--*--No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.",
            "Subjective_judgement 1024 1258--*--No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.",
            "Post-eligibility 1260 1426--*--No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.",
            "Subjective_judgement 1260 1426--*--No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.",
            "Procedure 1460 1463--*--ECG",
            "Condition 1443 1463--*--abnormalities in ECG",
            "Qualifier 1431 1442--*--significant",
            "Negation 1428 1430--*--No",
            "Subjective_judgement 1428 1490--*--No significant abnormalities in ECG per investigator judgment.",
            "Measurement 1505 1510--*--HBsAg",
            "Value 1492 1500--*--Negative",
            "Measurement 1519 1536--*--antibodies to HCV",
            "Measurement 1538 1543--*--HIV-1",
            "Condition 1546 1559--*--AAT deficient",
            "Condition 1584 1589--*--na\u00efve",
            "Procedure 1605 1628--*--IV augmentation therapy",
            "Negation 1591 1604--*--not receiving",
            "Procedure 1667 1690--*--IV augmentation therapy",
            "Procedure 1729 1736--*--therapy",
            "Temporal 1737 1781--*--for at least 3 months prior to the screening",
            "Reference_point 1768 1781--*--the screening",
            "Observation 1796 1815--*--willing to continue",
            "Temporal 1832 1853--*--throughout this trial",
            "Reference_point 1843 1853--*--this trial",
            "Qualifier 1711 1717--*--stable",
            "Condition 2128 2136--*--pregnant",
            "Negation 2124 2127--*--Non",
            "Condition 2142 2151--*--lactating",
            "Negation 2138 2141--*--non",
            "Person 2152 2158--*--female",
            "Measurement 2185 2199--*--pregnancy test",
            "Value 2203 2211--*--negative",
            "Device 2230 2251--*--contraceptive methods",
            "Subjective_judgement 2252 2287--*--deemed reliable by the investigator",
            "Temporal 2300 2316--*--at least 2 years",
            "Condition 2317 2332--*--post-menopausal",
            "Condition 2336 2357--*--surgically sterilized",
            "Procedure 2336 2346--*--surgically",
            "Qualifier 2252 2287--*--deemed reliable by the investigator",
            "Scope 2317 2357--*--post-menopausal or surgically sterilized",
            "Scope 2124 2158--*--Non-pregnant, non-lactating female",
            "Scope 2185 2357--*--pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized"
        ]
    },
    "NCT02765217_inc": {
        "Text": "Children receiving amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) due to acute otitis media or acute sinusitis. ",
        "Annotations": [
            "Drug 19 47--*--amoxicilline-clavulanic acid",
            "Person 0 8--*--Children",
            "Value 49 64--*--50-90 mg/kg/day",
            "Multiplier 66 77--*--twice daily",
            "Condition 86 104--*--acute otitis media",
            "Condition 108 123--*--acute sinusitis"
        ]
    },
    "NCT03323047_inc": {
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 18 22--*--aged",
            "Value 23 33--*--3-13 years",
            "Measurement 62 121--*--American Society of Anesthesiologists (ASA) physical status",
            "Value 35 54--*--Level I or level II",
            "Condition 185 208--*--obstructive sleep apnea",
            "Multiplier 212 221--*--recurrent",
            "Condition 222 239--*--throat infections",
            "Qualifier 252 260--*--elective",
            "Condition 261 274--*--tonsillectomy",
            "Condition 291 304--*--adenoidectomy",
            "Informed_consent 306 390--*--Parents who agree to complete documentation and follow up at 14 days post-operation."
        ],
        "Text": "Healthy patients. aged 3-13 years. Level I or level II on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist). obstructive sleep apnea or recurrent throat infections. undergoing elective tonsillectomy with or without adenoidectomy. Parents who agree to complete documentation and follow up at 14 days post-operation.. "
    },
    "NCT03198910_inc": {
        "Annotations": [
            "Condition 14 51--*--pulmonary arterial hypertension (PAH)",
            "Condition 67 120--*--chronic thromboembolic pulmonary hypertension (CTEPH)",
            "Temporal 156 169--*-->12 month ago",
            "Condition 176 179--*--PAH",
            "Condition 190 195--*--CTEPH",
            "Qualifier 183 189--*--distal",
            "Non-query-able 206 235--*--consultation at the PH centre",
            "Visit 239 245--*--Zurich",
            "Temporal 246 285--*--between November 2015 and November 2016",
            "Visit 206 235--*--consultation at the PH centre",
            "Context_Error 126 135--*--prevalent"
        ],
        "Text": "Patients with pulmonary arterial hypertension (PAH) . Patients with chronic thromboembolic pulmonary hypertension (CTEPH) . All prevalent patients (diagnosed >12 month ago) with PAH or distal CTEPH who had a consultation at the PH centre in Zurich between November 2015 and November 2016) . "
    },
    "NCT03282006_exc": {
        "Annotations": [
            "Condition 0 19--*--Bacterial infection",
            "Qualifier 32 45--*--another organ",
            "Condition 52 61--*--pneumonia",
            "Condition 64 77--*--Severe sepsis",
            "Condition 83 101--*--multiorgan failure",
            "Condition 103 124--*--Perinephritic abscess",
            "Condition 126 138--*--Pyonephrosis",
            "Mood 139 148--*--requiring",
            "Procedure 149 157--*--drainage",
            "Condition 159 166--*--Allergy",
            "Drug 170 183--*--pivmecillinam",
            "Drug 213 226--*--pivmecillinam",
            "Condition 185 199--*--E.coli isolate",
            "Qualifier 200 226--*--resistant to pivmecillinam",
            "Condition 228 237--*--Pregnancy",
            "Observation 238 251--*--breastfeeding",
            "Condition 260 271--*--neutropenia",
            "Qualifier 253 259--*--Severe",
            "Condition 273 284--*--Prostatitis",
            "Qualifier 286 292--*--Severe",
            "Condition 293 307--*--kidney failure",
            "Measurement 309 313--*--eGFR",
            "Value 313 323--*--<15 ml/min",
            "Scope 309 323--*--eGFR<15 ml/min",
            "Scope 286 307--*--Severe kidney failure",
            "Drug 332 341--*--valproate"
        ],
        "Text": "Bacterial infection origin from another organ (e.g. pneumonia). Severe sepsis with multiorgan failure. Perinephritic abscess. Pyonephrosis requiring drainage. Allergy to pivmecillinam. E.coli isolate resistant to pivmecillinam. Pregnancy/breastfeeding. Severe neutropenia. Prostatitis. Severe kidney failure (eGFR<15 ml/min). Using valproate. "
    },
    "NCT03275584_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Qualifier 33 53--*--clinically indicated",
            "Procedure 54 111--*--positron emission tomography myocardial perfusion imaging",
            "Visit 119 165--*--Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al"
        ],
        "Text": "Adult patient being referred for clinically indicated positron emission tomography myocardial perfusion imaging at the Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al. "
    },
    "NCT01217671_exc": {
        "Text": "FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. . FEV1/SVC>=70% . History of lung transplant. . Any lung surgery within the past two years. . On any thoracic surgery waiting list. . End of last exacerbation less than 6 weeks prior to screening/re-screening visit. . Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. . Active smoking during the last 12 months from screening date. . Pregnancy or lactation. . Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. . Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. . Evidence of ongoing viral infection with HCV, HBV and/or HIV. . Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. . IgA Deficiency . History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. . Participation in another clinical trial within 30 days prior to baseline visit. . Inability to attend scheduled clinic visits and/or comply with the study protocol. . Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.       .     . ",
        "Annotations": [
            "Measurement 0 4--*--FEV1",
            "Value 5 11--*-->= 80%",
            "Measurement 15 19--*--FEV1",
            "Value 20 44--*--< 20% of predicted value",
            "Qualifier 45 64--*--post-bronchodilator",
            "Temporal 45 64--*--post-bronchodilator",
            "Drug 50 64--*--bronchodilator",
            "Reference_point 50 64--*--bronchodilator",
            "Measurement 67 75--*--FEV1/SVC",
            "Value 75 80--*-->=70%",
            "Procedure 93 108--*--lung transplant",
            "Observation 82 89--*--History",
            "Procedure 115 127--*--lung surgery",
            "Temporal 128 153--*--within the past two years",
            "Procedure 163 179--*--thoracic surgery",
            "Observation 163 192--*--thoracic surgery waiting list",
            "Condition 207 219--*--exacerbation",
            "Temporal 220 275--*--less than 6 weeks prior to screening/re-screening visit",
            "Reference_point 247 275--*--screening/re-screening visit",
            "Condition 301 323--*--intercurrent illnesses",
            "Qualifier 278 300--*--Clinically significant",
            "Subjective_judgement 278 300--*--Clinically significant",
            "Undefined_semantics 278 300--*--Clinically significant",
            "Negation 325 335--*--except for",
            "Condition 336 347;357 364--*--respiratory disease",
            "Condition 351 364--*--liver disease",
            "Qualifier 365 392--*--secondary to AAT deficiency",
            "Condition 378 392--*--AAT deficiency",
            "Scope 336 364--*--respiratory or liver disease",
            "Condition 406 413--*--cardiac",
            "Condition 415 422--*--hepatic",
            "Condition 424 429--*--renal",
            "Condition 431 440--*--endocrine",
            "Condition 442 454--*--neurological",
            "Condition 456 469--*--hematological",
            "Condition 471 481--*--neoplastic",
            "Condition 483 496--*--immunological",
            "Condition 498 506--*--skeletal",
            "Condition 510 515--*--other",
            "Undefined_semantics 510 515--*--other",
            "Scope 406 515--*--cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other",
            "Subjective_judgement 522 556--*--in the opinion of the investigator",
            "Post-eligibility 278 772--*--Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor.",
            "Condition 774 788--*--Active smoking",
            "Temporal 774 780--*--Active",
            "Temporal 789 834--*--during the last 12 months from screening date",
            "Reference_point 820 834--*--screening date",
            "Condition 837 846--*--Pregnancy",
            "Condition 850 859--*--lactation",
            "Person 862 867--*--Woman",
            "Condition 871 894--*--child-bearing potential",
            "Procedure 915 928--*--contraception",
            "Qualifier 906 914--*--adequate",
            "Subjective_judgement 906 914--*--adequate",
            "Subjective_judgement 929 964--*--deemed reliable by the investigator",
            "Negation 895 898--*--not",
            "Scope 862 893--*--Woman of child-bearing potentia",
            "Qualifier 929 964--*--deemed reliable by the investigator",
            "Pregnancy_considerations 862 965--*--Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator.",
            "Condition 979 990;999 1007--*--psychiatric disorder",
            "Condition 992 1007--*--mental disorder",
            "Condition 1015 1037--*--other medical disorder",
            "Undefined_semantics 1015 1037--*--other medical disorder",
            "Observation 1050 1103--*--impair the patient's ability to give informed consent",
            "Post-eligibility 967 1161--*--Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol.",
            "Scope 979 1037--*--psychiatric/ mental disorder or any other medical disorder",
            "Condition 1183 1198--*--viral infection",
            "Condition 1204 1207--*--HCV",
            "Condition 1209 1212--*--HBV",
            "Condition 1220 1223--*--HIV",
            "Scope 1204 1223--*--HCV, HBV and/or HIV",
            "Temporal 1175 1182--*--ongoing",
            "Condition 1238 1251--*--alcohol abuse",
            "Condition 1266 1279--*--alcohol abuse",
            "Observation 1255 1262--*--history",
            "Condition 1274 1279;1283 1290;1317 1322--*--abuse illegal drugs",
            "Condition 1274 1279;1298 1322--*--abuse legally prescribed drugs",
            "Scope 1266 1322--*--alcohol abuse or illegal and/or legally prescribed drugs",
            "Condition 1325 1339--*--IgA Deficiency",
            "Condition 1352 1376--*--life threatening allergy",
            "Qualifier 1352 1368--*--life threatening",
            "Condition 1378 1399--*--anaphylactic reaction",
            "Condition 1404 1454--*--systemic response to human plasma derived products",
            "Qualifier 1425 1445--*--human plasma derived",
            "Drug 1446 1454--*--products",
            "Observation 1341 1348--*--History",
            "Scope 1352 1454--*--life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products",
            "Non-query-able 1457 1536--*--Participation in another clinical trial within 30 days prior to baseline visit.",
            "Context_Error 1457 1536--*--Participation in another clinical trial within 30 days prior to baseline visit.",
            "Post-eligibility 1538 1620--*--Inability to attend scheduled clinic visits and/or comply with the study protocol.",
            "Post-eligibility 1622 1760--*--Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol."
        ]
    },
    "NCT02654912_inc": {
        "Annotations": [
            "Post-eligibility 0 34--*--anyone not excluded and consenting"
        ],
        "Text": "anyone not excluded and consenting. "
    },
    "NCT01943812_inc": {
        "Text": "Endometrial thickness = 7 mm after stimulation. 18-45 years. IVF/ICSI fertilisation. BMI > 18,5 <30 kg/m2. cycle length 25-34 days. ",
        "Annotations": [
            "Measurement 0 21--*--Endometrial thickness",
            "Value 22 28--*--= 7 mm",
            "Temporal 29 46--*--after stimulation",
            "Procedure 35 46--*--stimulation",
            "Reference_point 35 46--*--stimulation",
            "Value 48 53--*--18-45",
            "Person 54 59--*--years",
            "Procedure 61 64;70 83--*--IVF fertilisation",
            "Procedure 65 83--*--ICSI fertilisation",
            "Measurement 85 88--*--BMI",
            "Value 89 105--*--> 18,5 <30 kg/m2",
            "Measurement 107 119--*--cycle length",
            "Value 120 130--*--25-34 days"
        ]
    },
    "NCT03472508_exc": {
        "Annotations": [
            "Person 3 8--*--Women",
            "Condition 17 25--*--pregnant",
            "Observation 33 42--*--lactating",
            "Person 47 52--*--women",
            "Observation 57 75--*--intend to conceive",
            "Temporal 76 89--*--within a year",
            "Scope 47 89--*--women who intend to conceive within a year",
            "Scope 3 42--*--Women who are pregnant and/or lactating",
            "Observation 95 102--*--History",
            "Condition 106 115--*--allergies",
            "Drug 119 128--*--enalapril",
            "Drug 130 140--*--folic acid",
            "Drug 150 181--*--components of the compound drug",
            "Scope 119 181--*--enalapril, folic acid or other components of the compound drug",
            "Observation 187 194--*--History",
            "Condition 198 215--*--adverse reactions",
            "Condition 219 230--*--intolerance",
            "Drug 234 243--*--enalapril",
            "Qualifier 247 252--*--other",
            "Drug 253 267--*--ACE inhibitors",
            "Drug 304 314--*--folic acid",
            "Scope 198 230--*--adverse reactions or intolerance",
            "Scope 234 314--*--enalapril or other ACE inhibitors, or drugs or supplements containing folic acid",
            "Condition 346 368--*--secondary hypertension",
            "Mood 333 342--*--suspicion",
            "Mood 320 329--*--Diagnosis",
            "Scope 320 342--*--Diagnosis or suspicion",
            "Qualifier 380 387--*--serious",
            "Condition 388 406--*--medical conditions",
            "Condition 470 489--*--cardiac dysfunction",
            "Qualifier 449 469--*--clinically diagnosed",
            "Measurement 491 501--*--NYHA class",
            "Value 502 515--*--III and above",
            "Scope 491 515--*--NYHA class III and above",
            "Condition 518 557--*--hypertrophic obstructive cardiomyopathy",
            "Qualifier 559 581--*--clinically significant",
            "Condition 582 604--*--valvular heart disease",
            "Condition 606 629--*--acute coronary syndrome",
            "Temporal 630 654--*--within the last 3 months",
            "Procedure 659 699--*--percutaneous coronary intervention (PCI)",
            "Procedure 704 739--*--coronary artery bypass graft (CABG)",
            "Value 744 752--*--abnormal",
            "Temporal 753 767--*--pre-enrollment",
            "Measurement 768 776--*--ECG test",
            "Qualifier 790 812--*--clinically significant",
            "Condition 813 824--*--arrhythmias",
            "Condition 826 840--*--atrial flutter",
            "Condition 842 861--*--atrial fibrillation",
            "Condition 876 898--*--atrioventricular block",
            "Qualifier 863 871--*--grade II",
            "Qualifier 863 868;872 875--*--grade III",
            "Scope 863 875--*--grade II-III",
            "Scope 826 898--*--atrial flutter, atrial fibrillation, grade II-III atrioventricular block",
            "Scope 790 824--*--clinically significant arrhythmias",
            "Temporal 920 928--*--previous",
            "Condition 959 974--*--viral hepatitis",
            "Qualifier 997 1009--*--active phase",
            "Value 1011 1019--*--abnormal",
            "Measurement 1035 1054--*--liver function test",
            "Temporal 1020 1034--*--pre-enrollment",
            "Measurement 1064 1067--*--ALT",
            "Measurement 1069 1072--*--AST",
            "Measurement 1074 1077--*--GGT",
            "Measurement 1079 1083--*--TBIL",
            "Measurement 1088 1092--*--DBIL",
            "Value 1093 1119--*--3 times higher than normal",
            "Scope 1064 1092--*--ALT, AST, GGT, TBIL, or DBIL",
            "Measurement 1121 1124--*--ALB",
            "Value 1125 1132--*--= 30g/L",
            "Procedure 1135 1146--*--gastrectomy",
            "Procedure 1154 1171--*--gastrojejunostomy",
            "Condition 1173 1201--*--gastrointestinal dysfunction",
            "Temporal 1212 1226--*--pre-enrollment",
            "Measurement 1227 1243--*--serum creatinine",
            "Value 1244 1266--*--greater than 200umol/L",
            "Qualifier 1268 1286--*--clinical diagnosis",
            "Condition 1290 1311--*--renal artery stenosis",
            "Procedure 1330 1352--*--kidney transplantation",
            "Condition 1313 1328--*--isolated kidney",
            "Condition 1387 1402--*--type 1 diabetes",
            "Qualifier 1406 1418--*--uncontrolled",
            "Condition 1419 1434--*--type 2 diabetes",
            "Measurement 1436 1457--*--fasting blood glucose",
            "Value 1458 1475--*--above 11.1 mmol/L",
            "Temporal 1476 1493--*--at pre-enrollment",
            "Reference_point 1479 1493--*--pre-enrollment",
            "Scope 1436 1493--*--fasting blood glucose above 11.1 mmol/L at pre-enrollment",
            "Scope 1406 1434--*--uncontrolled type 2 diabetes",
            "Temporal 1496 1504--*--previous",
            "Condition 1518 1533--*--hyperthyroidism",
            "Observation 1538 1556--*--failure to correct",
            "Condition 1571 1594--*--pulmonary heart disease",
            "Condition 1596 1633--*--chronic obstructive pulmonary disease",
            "Temporal 1653 1659--*--recent",
            "Condition 1660 1685--*--transient ischemic attack",
            "Condition 1689 1695--*--stroke",
            "Temporal 1697 1721--*--within the last 3 months",
            "Scope 1660 1695--*--transient ischemic attack or stroke",
            "Qualifier 1724 1734--*--peripheral",
            "Qualifier 1738 1744--*--severe",
            "Condition 1745 1766--*--autonomic dysfunction",
            "Scope 1724 1744--*--peripheral or severe",
            "Condition 1768 1774;1786 1804--*--mental system dysfunction",
            "Condition 1778 1804--*--nervous system dysfunction",
            "Scope 1064 1132--*--ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L",
            "Observation 1806 1833--*--inability to express desire",
            "Condition 1841 1845;1857 1867--*--drug dependence",
            "Condition 1849 1867--*--alcohol dependence",
            "Condition 1869 1879--*--Malignancy",
            "Condition 1881 1893--*--malnutrition",
            "Condition 1895 1918--*--hematopoietic disorders",
            "Scope 449 1918--*--clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders",
            "Qualifier 1951 1962--*--Significant",
            "Condition 1963 1985--*--signs of abnormalities",
            "Measurement 1997 2013--*--laboratory tests",
            "Non-representable 2014 2305--*--or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;",
            "Drug 2336 2342--*--folate",
            "Drug 2344 2347--*--B12",
            "Drug 2352 2354--*--B6",
            "Observation 2420 2441--*--refusal to stop usage",
            "Observation 2405 2414--*--inability",
            "Temporal 2319 2328--*--currently",
            "Scope 2336 2354--*--folate, B12, or B6",
            "Drug 2464 2486--*--folic acid supplements",
            "Multiplier 2447 2460--*--Regular usage",
            "Drug 2490 2521--*--compounds containing folic acid",
            "Temporal 2522 2542--*--in the past 3 months",
            "Scope 2464 2521--*--folic acid supplements or compounds containing folic acid",
            "Scope 2447 2460;2522 2542--*--Regular usage in the past 3 months",
            "Observation 2548 2581--*--Participation in a clinical trial",
            "Drug 2588 2648--*--drug that has not yet been officially approved for marketing",
            "Temporal 2649 2690--*--within one month prior to the first visit",
            "Reference_point 2675 2690--*--the first visit"
        ],
        "Text": "(1)Women who are pregnant and/or lactating; or women who intend to conceive within a year;. (2)History of allergies to enalapril, folic acid or other components of the compound drug;. (3)History of adverse reactions or intolerance to enalapril or other ACE inhibitors, or drugs or supplements containing folic acid;. (4)Diagnosis or suspicion of secondary hypertension;. (5)Known serious medical conditions, including: Cardiovascular: patients with clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders and other serious diseases.. (6)Significant signs of abnormalities as seen in laboratory tests or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;. (7)Patients currently taking folate, B12, or B6, or any compounds containing them, who express an inability or a refusal to stop usage;. (8)Regular usage of folic acid supplements or compounds containing folic acid in the past 3 months;. (9)Participation in a clinical trial for a drug that has not yet been officially approved for marketing within one month prior to the first visit.. "
    },
    "NCT02390973_exc": {
        "Annotations": [
            "Condition 0 9--*--pregnancy",
            "Procedure 39 56--*--bariatric surgery",
            "Procedure 28 35;49 56--*--gastric surgery",
            "Procedure 16 26;49 56--*--esophageal surgery",
            "Condition 58 73--*--irritable bowel",
            "Condition 100 108--*--vomiting",
            "Condition 117 131--*--abdominal pain",
            "Qualifier 87 99--*--intermittent",
            "Condition 141 149--*--diarrhea",
            "Condition 153 165--*--constipation",
            "Scope 141 165--*--diarrhea or constipation",
            "Qualifier 133 140--*--chronic",
            "Qualifier 110 116--*--severe",
            "Condition 189 204--*--duodenal ulcers",
            "Condition 178 185;198 204--*--gastric ulcers",
            "Condition 220 234--*--hypoalbuminemy",
            "Qualifier 206 219--*--pre-operatory",
            "Condition 274 283;291 298--*--pulmonary disease",
            "Condition 263 270;291 298--*--cardiac disease",
            "Condition 254 261;291 298--*--hepatic disease",
            "Condition 247 252;291 298--*--renal disease",
            "Qualifier 284 290--*--severe",
            "Drug 309 323--*--corticosteroid",
            "Temporal 331 341--*--last month",
            "Non-query-able 343 477--*--evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations",
            "Condition 502 514--*--alcool abuse",
            "Condition 490 498--*--drug use",
            "Temporal 522 536--*--last 12 months",
            "Scope 490 514--*--drug use or alcool abuse",
            "Condition 549 588--*--gastro-intestinal inflammatory diseases"
        ],
        "Text": "pregnancy. past esophageal, gastric or bariatric surgery. irritable bowel, unexplained intermittent vomiting, severe abdominal pain, chronic diarrhea or constipation. history of gastric or duodenal ulcers. pre-operatory hypoalbuminemy. history of renal, hepatic, cardiac or pulmonary severe disease. taken of corticosteroid in the last month. evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations. history of drug use or alcool abuse in the last 12 months. history of gastro-intestinal inflammatory diseases. "
    },
    "NCT01803438_exc": {
        "Text": "Subject has documented typical atrial flutter.. Subject has any history of successful or unsuccessful treatment of AF with class I or III antiarrhythmic or sotalol with the intention to prevent an AF recurrence. Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed.. Subject had any previous left atrial ablation.. Subject had any previous cardiac surgery, e.g. prosthetic valves.. Subject has permanent pacemaker or defibrillator implant.. Subject has 2\u00b0 type II, 3\u00b0 degree AV-block or left/right bundle branch block pattern.. Subject has unstable angina pectoris.. Subject has history of previous myocardial infarction or percutaneous intervention during the last three months.. Subject has symptomatic carotid stenosis.. Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.. Subject has any contraindication for oral anticoagulation.. Subject has any history of previous transient ischemic attack or stroke.. Subject has known intra-cardiac thrombus formation.. Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).. Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.. Subject has hypertrophic cardiomyopathy.. Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.. Subject has sarcoidosis.. Subject has pulmonary vein stent.. Subject has myxoma. Exclusion criteria based on laboratory abnormalities. Subject has thrombocytosis (platelet count > 600,000 / \u00b5l) or thrombocytopenia (platelet count <100,000 / \u00b5l).. Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.. Subject has renal dysfunction with glomerular filtration rate < 60 ml / min.. Subject has known cryoglobulinaemia. General exclusion criteria. Subject has a reversible causes for AF like hyperthyroidism and alcoholism.. Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled.. Subject is a breastfeeding woman.. Subject has an active systemic infection.. Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators.. Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state.. Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.. Subject has a life expectancy of = 1 year.. Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.. ",
        "Annotations": [
            "Condition 31 45--*--atrial flutter",
            "Condition 115 117--*--AF",
            "Drug 138 152--*--antiarrhythmic",
            "Drug 156 163--*--sotalol",
            "Qualifier 123 130--*--class I",
            "Qualifier 123 128;134 137--*--class III",
            "Scope 123 137--*--class I or III",
            "Non-query-able 164 322--*--with the intention to prevent an AF recurrence. Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed",
            "Scope 138 163--*--antiarrhythmic or sotalol",
            "Procedure 355 370--*--atrial ablation",
            "Qualifier 350 354--*--left",
            "Procedure 398 413--*--cardiac surgery",
            "Device 420 437--*--prosthetic valves",
            "Device 452 471--*--permanent pacemaker",
            "Device 475 496--*--defibrillator implant",
            "Condition 523 541--*--3\u00b0 degree AV-block",
            "Condition 511 521;533 541--*--2\u00b0 type II AV-block",
            "Condition 550 575--*--right bundle branch block",
            "Condition 545 549;556 575--*--left bundle branch block",
            "Condition 598 622--*--unstable angina pectoris",
            "Condition 657 678--*--myocardial infarction",
            "Procedure 682 707--*--percutaneous intervention",
            "Temporal 719 736--*--last three months",
            "Scope 657 707--*--myocardial infarction or percutaneous intervention",
            "Condition 763 779--*--carotid stenosis",
            "Qualifier 751 762--*--symptomatic",
            "Condition 794 831--*--chronic obstructive pulmonary disease",
            "Condition 846 868--*--pulmonary hypertension",
            "Condition 906 918--*--lung disease",
            "Qualifier 894 905--*--significant",
            "Scope 846 918--*--pulmonary hypertension or any other evidence of significant lung disease",
            "Condition 937 953--*--contraindication",
            "Drug 958 978--*--oral anticoagulation",
            "Condition 1017 1042--*--transient ischemic attack",
            "Condition 1046 1052--*--stroke",
            "Condition 1073 1095--*--intra-cardiac thrombus",
            "Condition 1136 1159--*--congenital heart defect",
            "Qualifier 1124 1135--*--significant",
            "Negation 1178 1184--*--except",
            "Condition 1189 1209--*--patent foramen ovale",
            "Condition 1253 1277--*--congestive heart failure",
            "Measurement 1279 1289--*--NYHA class",
            "Value 1290 1292--*--II",
            "Value 1294 1297--*--III",
            "Value 1301 1303--*--IV",
            "Condition 1308 1320--*--sinus rhythm",
            "Scope 1290 1303--*--II, III or IV",
            "Condition 1335 1362--*--hypertrophic cardiomyopathy",
            "Measurement 1400 1411--*--QT interval",
            "Qualifier 1377 1385--*--abnormal",
            "Value 1386 1390--*--long",
            "Value 1394 1399--*--short",
            "Condition 1422 1438--*--Brugada syndrome",
            "Condition 1446 1476--*--inheriting ion channel disease",
            "Observation 1446 1490--*--inheriting ion channel disease on the family",
            "Condition 1507 1534--*--right ventricular dysplasia",
            "Qualifier 1492 1506--*--arrhythmogenic",
            "Scope 1386 1399--*--long or short",
            "Condition 1549 1560--*--sarcoidosis",
            "Device 1575 1595--*--pulmonary vein stent",
            "Condition 1610 1616--*--myxoma",
            "Non-query-able 1618 1670--*--Exclusion criteria based on laboratory abnormalities",
            "Condition 1684 1698--*--thrombocytosis",
            "Measurement 1700 1714--*--platelet count",
            "Value 1715 1729--*--> 600,000 / \u00b5l",
            "Condition 1734 1750--*--thrombocytopenia",
            "Measurement 1752 1766--*--platelet count",
            "Value 1767 1780--*--<100,000 / \u00b5l",
            "Condition 1826 1841--*--hyperthyroidism",
            "Condition 1845 1859--*--hypothyroidism",
            "Qualifier 1800 1809--*--untreated",
            "Qualifier 1813 1825--*--uncontrolled",
            "Scope 1826 1859--*--hyperthyroidism or hypothyroidism",
            "Scope 1800 1825--*--untreated or uncontrolled",
            "Condition 1874 1891--*--renal dysfunction",
            "Measurement 1897 1923--*--glomerular filtration rate",
            "Value 1924 1937--*--< 60 ml / min",
            "Condition 1958 1975--*--cryoglobulinaemia",
            "Condition 2049 2064--*--hyperthyroidism",
            "Condition 2069 2079--*--alcoholism",
            "Pregnancy_considerations 2082 2396--*--Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled",
            "Pregnancy_considerations 2399 2431--*--Subject is a breastfeeding woman",
            "Condition 2456 2474--*--systemic infection",
            "Qualifier 2449 2455--*--active",
            "Post-eligibility 2477 2609--*--Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators",
            "Post-eligibility 2612 2890--*--Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state",
            "Post-eligibility 2894 3054--*--egal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up",
            "Observation 3071 3086--*--life expectancy",
            "Value 3090 3098--*--= 1 year",
            "Competing_trial 3101 3365--*--Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager"
        ]
    },
    "NCT02590653_inc": {
        "Annotations": [
            "Post-eligibility 0 28--*--Signed Informed Consent Form",
            "Post-eligibility 30 101--*--Patients having physical and mental ability to participate in the study",
            "Person 120 125--*--sexes",
            "Value 115 119--*--both",
            "Person 126 130--*--aged",
            "Value 131 145--*--35 to 65 years",
            "Condition 170 204--*--ST-elevation myocardial infarction",
            "Procedure 218 221--*--ECG",
            "Measurement 234 244--*--troponin I",
            "Measurement 249 254--*--CK-MB",
            "Scope 218 254--*--ECG, as well as troponin I and CK-MB",
            "Condition 301 312;317 323--*--stenosis of artery",
            "Multiplier 313 316--*--one",
            "Condition 335 357--*--infarct-related artery",
            "Qualifier 276 300--*--hemodynamically relevant",
            "Procedure 372 392--*--coronary angiography",
            "Procedure 394 397--*--CAG",
            "Condition 409 436--*--occlusion of other arteries",
            "Multiplier 437 454--*--not exceeding 30%"
        ],
        "Text": "Signed Informed Consent Form. Patients having physical and mental ability to participate in the study. Patients of both sexes aged 35 to 65 years. Presence of documented ST-elevation myocardial infarction confirmed by ECG, as well as troponin I and CK-MB levels.. Presence of hemodynamically relevant stenosis of one artery (i.e., the infarct-related artery) confirmed by coronary angiography (CAG), with the occlusion of other arteries not exceeding 30%.. "
    },
    "NCT02195024_exc": {
        "Text": "Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance(s) are not measurable. Meet one or more of the contraindications for MRI including Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI. Cardiac surgery already scheduled in the next three months. Have other medical implants that may interact with MRI, e.g. abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve. Have other metallic artifacts/components in body that may interact with MRI. Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated. Subjects who require a legally authorized representative to obtain consent. Subjects who are immediate candidates for an ICD. Subjects with medical conditions that preclude the testing required by the protocol or limit study participation. Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study. Being pregnant. Have a life expectancy of less than three months. Subjects with exclusion criteria required by local law (e.g. age, breastfeeding). ",
        "Annotations": [
            "Procedure 0 16--*--Pacing threshold",
            "Qualifier 21 37--*--at 0.4 or 0.5 ms",
            "Condition 91 105--*--not measurable",
            "Procedure 46 63--*--sensing amplitude",
            "Procedure 74 83--*--impedance",
            "Scope 0 83--*--Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance",
            "Multiplier 112 123--*--one or more",
            "Condition 131 148--*--contraindications",
            "Procedure 153 156--*--MRI",
            "Condition 167 188--*--Psychiatric disorders",
            "Condition 190 197--*--anxiety",
            "Condition 199 213--*--claustrophobia",
            "Condition 214 231--*--Cardiac disorders",
            "Condition 249 265--*--contraindication",
            "Procedure 269 272--*--MRI",
            "Scope 167 272--*--Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI",
            "Procedure 274 289--*--Cardiac surgery",
            "Mood 298 307--*--scheduled",
            "Temporal 308 332--*--in the next three months",
            "Reference_point 320 332--*--three months",
            "Device 345 361--*--medical implants",
            "Condition 371 388--*--interact with MRI",
            "Device 395 455--*--abandoned implantable cardioverter defibrillator (ICD) leads",
            "Device 459 474--*--pacemaker leads",
            "Negation 475 485--*--other than",
            "Device 486 501--*--MRI conditional",
            "Device 503 518--*--lead extensions",
            "Device 526 548--*--active medical devices",
            "Qualifier 520 525--*--other",
            "Device 550 576--*--non-MRI compatible devices",
            "Device 578 594--*--mechanical valve",
            "Scope 395 594--*--abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve",
            "Scope 345 388--*--medical implants that may interact with MRI",
            "Device 607 625--*--metallic artifacts",
            "Device 607 615;626 636--*--metallic components",
            "Condition 654 662--*--interact",
            "Procedure 668 671--*--MRI",
            "Multiplier 693 699--*--single",
            "Multiplier 700 726--*--dose of 1.0 milligram (mg)",
            "Drug 727 748--*--dexamethasone acetate",
            "Condition 756 771--*--contraindicated",
            "Non-query-able 773 847--*--Subjects who require a legally authorized representative to obtain consent",
            "Temporal 866 875--*--immediate",
            "Mood 876 890--*--candidates for",
            "Procedure 894 897--*--ICD",
            "Condition 913 931--*--medical conditions",
            "Condition 937 945--*--preclude",
            "Procedure 950 981--*--testing required by the protoco",
            "Condition 986 1011--*--limit study participation",
            "Scope 937 1011--*--preclude the testing required by the protocol or limit study participation",
            "Non-query-able 1013 1274--*--Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study",
            "Condition 1282 1290--*--pregnant",
            "Observation 1299 1314--*--life expectancy",
            "Value 1318 1340--*--less than three months",
            "Post-eligibility 1342 1422--*--Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)"
        ]
    },
    "NCT02807857_exc": {
        "Annotations": [
            "Non-query-able 0 180--*--Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer",
            "Procedure 183 196--*--Major surgery",
            "Temporal 204 301--*--last 3 months prior to baseline or planned major surgery or cardiac intervention during the study",
            "Reference_point 227 300--*--baseline or planned major surgery or cardiac intervention during the stud",
            "Condition 304 310--*--Cancer",
            "Condition 332 346--*--co-morbidities",
            "Condition 399 412--*--Comorbidities",
            "Measurement 450 469;475 481--*--natriuretic peptide levels",
            "Measurement 471 473--*--NP",
            "Value 441 449--*--elevated",
            "Condition 483 502--*--renal insufficiency",
            "Measurement 505 509--*--eGFR",
            "Value 510 529--*--< 25 ml/min/1.73 m\u00b2",
            "Condition 597 612--*--cerebral trauma",
            "Temporal 577 595--*--less than 3 months",
            "Condition 644 668--*--cerebrovascular incident",
            "Temporal 624 642--*--less than 3 months",
            "Condition 689 715--*--acute exacerbation of COPD",
            "Temporal 727 740--*--last 3 months",
            "Scope 483 740--*--renal insufficiency, (eGFR < 25 ml/min/1.73 m\u00b2 calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months",
            "Non-query-able 743 834--*--Patients who are primarily managed and regularly followed-up by a cardiologist for their HF",
            "Observation 874 882--*--lifespan",
            "Temporal 944 962--*--less than 6 months"
        ],
        "Text": "Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.. Major surgery in the last 3 months prior to baseline or planned major surgery or cardiac intervention during the study.. Cancer or other significant co-morbidities implying that the patient's condition is unstable.. Comorbidities that can be associated with elevated natriuretic peptide (NP) levels: renal insufficiency, (eGFR < 25 ml/min/1.73 m\u00b2 calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.. Patients who are primarily managed and regularly followed-up by a cardiologist for their HF. Highly frail patients whose estimated lifespan due to comorbidities by the judgement of the investigator is less than 6 months.. "
    },
    "NCT01717911_exc": {
        "Text": "Previous treated with anti-diabetic medication. Pregnant or nursing women.. Impaired liver function (ALT > 120 U/L). Impaired renal function (Serum creatinine >1.5 mg/dL in male, >1.4 mg/dL in female ). Recently suffered from MI or CVA.. Patients are acute intercurrent illness.. 2-hour C-peptide level < 1.8 ng/mL.. ",
        "Annotations": [
            "Drug 22 46--*--anti-diabetic medication",
            "Temporal 0 8--*--Previous",
            "Procedure 9 16--*--treated",
            "Condition 48 56--*--Pregnant",
            "Condition 60 67--*--nursing",
            "Person 68 73--*--women",
            "Condition 76 99--*--Impaired liver function",
            "Measurement 101 104--*--ALT",
            "Value 105 114--*--> 120 U/L",
            "Scope 101 114--*--ALT > 120 U/L",
            "Condition 117 140--*--Impaired renal function",
            "Measurement 142 158--*--Serum creatinine",
            "Value 159 169--*-->1.5 mg/dL",
            "Person 173 177--*--male",
            "Person 193 199--*--female",
            "Value 179 189--*-->1.4 mg/dL",
            "Scope 159 199--*-->1.5 mg/dL in male, >1.4 mg/dL in female",
            "Condition 226 228--*--MI",
            "Condition 232 235--*--CVA",
            "Temporal 203 211--*--Recently",
            "Scope 226 235--*--MI or CVA",
            "Condition 251 277--*--acute intercurrent illness",
            "Measurement 280 302--*--2-hour C-peptide level",
            "Value 303 314--*--< 1.8 ng/mL"
        ]
    },
    "NCT02886962_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 21 26--*--years",
            "Value 16 20--*--= 18",
            "Procedure 40 52--*--hemodialysis",
            "Temporal 67 83--*--at least 1 month",
            "Condition 143 162--*--atrial fibrillation",
            "Qualifier 128 139--*--new episode",
            "Measurement 213 229--*--CHADS2VASC score",
            "Value 230 232--*--=2",
            "Observation 252 268--*--risk of bleeding",
            "Qualifier 247 251--*--high",
            "Measurement 287 300--*--HASBLED score",
            "Value 301 303--*--=3",
            "Measurement 321 337--*--CHADS2VASC score",
            "Condition 364 379--*--severe bleeding",
            "Qualifier 381 396--*--type 3a, 3b, 3c",
            "Qualifier 412 420--*--cerebral",
            "Qualifier 424 440--*--gastrointestinal",
            "Scope 412 440--*--cerebral or gastrointestinal",
            "Observation 481 486--*--falls",
            "Multiplier 466 468--*-->2",
            "Qualifier 455 464--*--recurrent",
            "Post-eligibility 489 579--*--Patient capable of understanding information about the study and of giving his/her consent",
            "Post-eligibility 581 637--*--Patient informed of the preliminary medical exam results",
            "Non-query-able 639 672--*--Patient with healthcare insurance",
            "Informed_consent 674 696--*--Written consent signed"
        ],
        "Text": "Adult patients (= 18 years). Patient on hemodialysis treatment for at least 1 month. Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal).. Patient with a CHADS2VASC score =2. Patient with high risk of bleeding as defined by (1) HASBLED score =3 OR (2) HASBLED = CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (>2) history of falls.. Patient capable of understanding information about the study and of giving his/her consent. Patient informed of the preliminary medical exam results. Patient with healthcare insurance. Written consent signed. "
    },
    "NCT02783859_inc": {
        "Text": "Hospitalised children aged 3-mo to 5-yrs (in Darwin, children have to be Indigenous). Have features of severe pneumonia on admission (temperature >37.5 celsius or a history of fever at home or observed at the referring clinic, age-adjusted tachypnoea [respiratory rate>50 if <12-months; respiratory rate>40 if >12-months] with chest wall recession and/or oxygen saturation <92% in air), and consolidation on chest X-ray as diagnosed by treating clinician. After 1-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and signs, oxygen saturation>90% in air and are ready to be switched to oral amoxicillin-clavulanate, and. Have symptoms of no longer than 7 days at point of hospitalisation.. ",
        "Annotations": [
            "Visit 0 12--*--Hospitalised",
            "Person 13 21--*--children",
            "Person 22 26--*--aged",
            "Value 27 40--*--3-mo to 5-yrs",
            "Condition 110 119--*--pneumonia",
            "Qualifier 103 109--*--severe",
            "Measurement 134 145--*--temperature",
            "Value 146 159--*-->37.5 celsius",
            "Person 227 230--*--age",
            "Condition 240 250--*--tachypnoea",
            "Measurement 252 268--*--respiratory rate",
            "Value 268 271--*-->50",
            "Value 275 285--*--<12-months",
            "Value 310 320--*-->12-months",
            "Measurement 287 303--*--respiratory rate",
            "Value 303 306--*-->40",
            "Person 227 230--*--age",
            "Condition 327 347--*--chest wall recession",
            "Measurement 355 372--*--oxygen saturation",
            "Value 373 384--*--<92% in air",
            "Scope 327 384--*--chest wall recession and/or oxygen saturation <92% in air",
            "Scope 134 384--*--temperature >37.5 celsius or a history of fever at home or observed at the referring clinic, age-adjusted tachypnoea [respiratory rate>50 if <12-months; respiratory rate>40 if >12-months] with chest wall recession and/or oxygen saturation <92% in air",
            "Condition 391 404--*--consolidation",
            "Procedure 408 419--*--chest X-ray",
            "Non-query-able 456 644--*--After 1-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and signs, oxygen saturation>90% in air and are ready to be switched to oral amoxicillin-clavulanate, and",
            "Condition 651 659--*--symptoms",
            "Temporal 663 712--*--no longer than 7 days at point of hospitalisation",
            "Reference_point 697 712--*--hospitalisation"
        ]
    },
    "NCT02042287_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT02654912_exc": {
        "Annotations": [
            "Condition 0 17--*--contraindications",
            "Drug 79 90--*--haloperidol",
            "Drug 100 109--*--Phenergan",
            "Drug 111 123--*--Promethazine",
            "Drug 92 98--*--artane",
            "Drug 126 140--*--chlorpromazine",
            "Drug 142 154--*--erythromycin",
            "Drug 156 168--*--Azithromycin",
            "Drug 170 184--*--clarithromycin",
            "Drug 186 198--*--Ketoconazole",
            "Drug 200 211--*--fluconazole",
            "Drug 213 223--*--mefloquine",
            "Drug 242 254--*--lumefantrine",
            "Drug 259 266--*--Coartem",
            "Drug 269 276--*--quinine",
            "Drug 278 285--*--Septrin",
            "Scope 79 285--*--haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin",
            "Condition 294 307--*--seriously ill",
            "Drug 326 348--*--antimalarial medicines",
            "Drug 361 378--*--artemisinin drugs",
            "Condition 350 357--*--allergy",
            "Condition 380 388--*--pregnant",
            "Person 389 394--*--women",
            "Condition 398 414--*--first trimester",
            "Qualifier 398 413--*--first trimester",
            "Person 415 423--*--children",
            "Value 424 438--*--under 3 months",
            "Person 442 445--*--age",
            "Condition 456 471--*--heart condition"
        ],
        "Text": "contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin. anyone seriously ill. currently taking antimalarial medicines. allergy to artemisinin drugs. pregnant women in first trimester. children under 3 months of age. reported heart condition. "
    },
    "NCT02390973_inc": {
        "Annotations": [
            "Measurement 0 3--*--BMI",
            "Value 4 8--*--= 35",
            "Condition 10 25--*--type 2 diabetes",
            "Measurement 27 32--*--HbA1c",
            "Value 33 40--*--= 6,5 %",
            "Measurement 44 60--*--fasting glycemia",
            "Value 61 69--*--=7mmol/l",
            "Measurement 73 93--*--non-fasting glycemia",
            "Value 94 103--*--=11mmol/l",
            "Informed_consent 105 120--*--able to consent"
        ],
        "Text": "BMI = 35. type 2 diabetes. HbA1c = 6,5 % or fasting glycemia =7mmol/l or non-fasting glycemia =11mmol/l. able to consent. "
    },
    "NCT03472508_inc": {
        "Annotations": [
            "Value 3 13--*--= 45 years",
            "Person 14 17--*--old",
            "Temporal 38 46--*--previous",
            "Mood 25 34--*--diagnosis",
            "Condition 60 82--*--essential hypertension",
            "Scope 25 46--*--diagnosis or previous",
            "Drug 118 140--*--antihypertensive drugs",
            "Drug 174 196--*--antihypertensive drugs",
            "Negation 164 167--*--not",
            "Temporal 197 220--*--within the last 2 weeks",
            "Multiplier 222 237;266 288--*--two consecutive at least one day apart",
            "Procedure 299 321--*--sitting blood pressure",
            "Measurement 381 411--*--diastolic blood pressure (DBP)",
            "Value 412 420--*--=90 mmHg",
            "Measurement 424 453--*--systolic blood pressure (SBP)",
            "Value 454 463--*--=140 mmHg",
            "Scope 381 463--*--diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg",
            "Temporal 101 110--*--currently",
            "Scope 164 220--*--not taken antihypertensive drugs within the last 2 weeks",
            "Scope 101 140--*--currently taking antihypertensive drugs",
            "Scope 222 463--*--two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg",
            "Non-representable 464 510--*--(the second blood pressure was measured at V1)",
            "Person 544 549--*--woman",
            "Observation 553 569--*--childbearing age",
            "Scope 544 569--*--woman of childbearing age",
            "Qualifier 591 599--*--reliable",
            "Observation 600 620--*--contraceptive method",
            "Temporal 621 637--*--during the trial",
            "Reference_point 628 637--*--the trial",
            "Mood 575 588--*--agrees to use",
            "Observation 676 702--*--signed an informed consent",
            "Observation 643 667--*--Voluntarily participates",
            "Procedure 735 762--*--gene polymorphism detection",
            "Observation 795 817--*--genotype already known",
            "Qualifier 783 794--*--MTHFR C677T",
            "Qualifier 723 734--*--MTHFR C677T",
            "Condition 844 871--*--good tolerance to enalapril",
            "Drug 862 871--*--enalapril",
            "Measurement 881 910--*--overall medication compliance",
            "Value 876 880--*--good",
            "Value 912 916--*-->80%",
            "Temporal 938 948--*--previously",
            "Condition 959 973;988 1001--*--good tolerance to ACEI drugs",
            "Drug 991 1001--*--ACEI drugs",
            "Observation 959 963;978 1001--*--good adherence to ACEI drugs",
            "Observation 1014 1032--*--medication history",
            "Scope 959 1001--*--good tolerance and adherence to ACEI drugs",
            "Scope 844 934--*--good tolerance to enalapril and good overall medication compliance (>80%) in run-in period",
            "Observation 1050 1088--*--continues to participate in this study",
            "Qualifier 1038 1049--*--Voluntarily"
        ],
        "Text": "(1)= 45 years old;. (2)A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg (the second blood pressure was measured at V1);. (3)If a study participant is a woman of childbearing age, she agrees to use a reliable contraceptive method during the trial;. (4)Voluntarily participates and has signed an informed consent form.. (1)Completed MTHFR C677T gene polymorphism detection in run-in period or MTHFR C677T genotype already known in advance;. (2)Exhibited good tolerance to enalapril and good overall medication compliance (>80%) in run-in period or previously exhibited good tolerance and adherence to ACEI drugs in previous medication history.. (3)Voluntarily continues to participate in this study.. "
    },
    "NCT01943812_exc": {
        "Text": "endometrial thickness < 7 mm or no triple layer endometrium and/or functional follicles. Uterine abnormality. Chronic medical disease. oocyte donation cycles. ",
        "Annotations": [
            "Measurement 0 21--*--endometrial thickness",
            "Value 22 28--*--< 7 mm",
            "Negation 32 34--*--no",
            "Observation 35 59--*--triple layer endometrium",
            "Observation 67 87--*--functional follicles",
            "Scope 35 87--*--triple layer endometrium and/or functional follicles",
            "Condition 89 108--*--Uterine abnormality",
            "Condition 110 133--*--Chronic medical disease",
            "Procedure 135 157--*--oocyte donation cycles"
        ]
    },
    "NCT02195024_inc": {
        "Text": "Approved clinical indication for pectoral pacemaker exchange (e.g. elective replacement indication (ERI), end of service (EOS)). a single or dual chamber MRI conditional pacemaker (BSCI) or. Any comparable successor IPG (MRI conditional system, BSCI) compatible with. Implanted Fineline-II-leads (BSCI), MRI conditional. The ascertained lead impedance is between 200 and 1500 Ohm.. All pacing capture thresholds (PCT) do not exceed 2.0 V @0.4 or 0.5 ms in pacemaker dependent patients. Male or female 18 years or older. Understand the nature of the procedure. Give written informed consent. Able to complete all testing required by the clinical protocol. Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms. Patient body height greater or equal to 140 cm. Pectoral implanted device. Subjects who are able and willing to undergo elective cardiac magnetic resonance (MR) scanning without sedation (MRI-group). Subjects who are geographically stable and available for follow-up at the study center for the length of the study. ",
        "Annotations": [
            "Condition 67 104--*--elective replacement indication (ERI)",
            "Condition 106 126--*--end of service (EOS)",
            "Scope 67 126--*--elective replacement indication (ERI), end of service (EOS)",
            "Condition 9 28--*--clinical indication",
            "Procedure 33 60--*--pectoral pacemaker exchange",
            "Scope 9 60--*--clinical indication for pectoral pacemaker exchange",
            "Qualifier 131 137;146 153--*--single chamber",
            "Qualifier 141 153--*--dual chamber",
            "Scope 131 153--*--single or dual chamber",
            "Device 170 179--*--pacemaker",
            "Device 181 185--*--BSCI",
            "Scope 131 179--*--single or dual chamber MRI conditional pacemaker",
            "Device 221 243--*--MRI conditional system",
            "Device 245 249--*--BSCI",
            "Device 206 219--*--successor IPG",
            "Qualifier 195 205--*--comparable",
            "Scope 195 219--*--comparable successor IPG",
            "Scope 221 249--*--MRI conditional system, BSCI",
            "Device 268 295--*--Implanted Fineline-II-leads",
            "Device 297 301--*--BSCI",
            "Qualifier 304 319--*--MRI conditional",
            "Qualifier 154 169--*--MRI conditional",
            "Scope 268 302--*--Implanted Fineline-II-leads (BSCI)",
            "Measurement 325 351--*--ascertained lead impedance",
            "Value 355 379--*--between 200 and 1500 Ohm",
            "Measurement 386 411--*--pacing capture thresholds",
            "Measurement 413 416--*--PCT",
            "Value 418 452--*--do not exceed 2.0 V @0.4 or 0.5 ms",
            "Condition 456 475--*--pacemaker dependent",
            "Scope 386 417--*--pacing capture thresholds (PCT)",
            "Person 486 490--*--Male",
            "Person 494 500--*--female",
            "Value 501 518--*--18 years or older",
            "Person 504 518--*--years or older",
            "Non-query-able 520 558--*--Understand the nature of the procedure",
            "Post-eligibility 560 589--*--Give written informed consent",
            "Post-eligibility 591 653--*--Able to complete all testing required by the clinical protocol",
            "Post-eligibility 655 736--*--Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms",
            "Measurement 746 757--*--body height",
            "Value 758 784--*--greater or equal to 140 cm",
            "Device 786 811--*--Pectoral implanted device",
            "Mood 839 857--*--willing to undergo",
            "Qualifier 858 866--*--elective",
            "Procedure 867 893;899 907--*--cardiac magnetic resonance scanning",
            "Procedure 895 897--*--MR",
            "Qualifier 908 924--*--without sedation",
            "Person 955 976--*--geographically stable",
            "Observation 981 1004--*--available for follow-up",
            "Visit 1005 1024--*--at the study center",
            "Temporal 1025 1052--*--for the length of the study",
            "Scope 955 1004--*--geographically stable and available for follow-up",
            "Scope 1005 1052--*--at the study center for the length of the study"
        ]
    },
    "NCT02590653_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT01803438_inc": {
        "Text": "Subject has been diagnosed with symptomatic paroxysmal atrial fibrillation as defined above and at least two symptomatic episodes in the last six months prior to inclusion.. At least one episode of AF must be documented during the prior year by any kind of ECG recording.. Subject has structural normal heart with an LVEF = 50%, thickness of the inter-ventricular septum =12 mm and left atrium diameters (short axis) < 46 mm obtained by transthoracic echocardiography.. Subject has normal ECG parameters (QRS width in the 12 channel surface ECG =120 ms, QTc - interval < 440 ms, PQ - interval = 210 ms; all parameters should be measured at sinus rhythm).. Subject is at least 18 and not older than 75years old.. Subject is able and willing to give informed consent.. ",
        "Annotations": [
            "Condition 44 74--*--paroxysmal atrial fibrillation",
            "Qualifier 32 43--*--symptomatic",
            "Multiplier 96 108--*--at least two",
            "Condition 121 129--*--episodes",
            "Qualifier 109 120--*--symptomatic",
            "Temporal 137 171--*--last six months prior to inclusion",
            "Reference_point 162 171--*--inclusion",
            "Multiplier 174 186--*--At least one",
            "Condition 187 194--*--episode",
            "Condition 198 200--*--AF",
            "Temporal 231 241--*--prior year",
            "Measurement 257 260--*--ECG",
            "Condition 303 308--*--heart",
            "Qualifier 296 302--*--normal",
            "Qualifier 285 295--*--structural",
            "Measurement 317 321--*--LVEF",
            "Value 322 328--*--= 50%,",
            "Measurement 329 370--*--thickness of the inter-ventricular septum",
            "Value 371 377--*--=12 mm",
            "Measurement 382 403--*--left atrium diameters",
            "Value 417 424--*--< 46 mm",
            "Measurement 405 415--*--short axis",
            "Procedure 437 467--*--transthoracic echocardiography",
            "Scope 317 424--*--LVEF = 50%, thickness of the inter-ventricular septum =12 mm and left atrium diameters (short axis) < 46 mm",
            "Procedure 489 492--*--ECG",
            "Value 482 488--*--normal",
            "Measurement 505 514--*--QRS width",
            "Qualifier 522 544--*--12 channel surface ECG",
            "Value 545 552--*--=120 ms",
            "Measurement 554 568--*--QTc - interval",
            "Value 569 577--*--< 440 ms",
            "Measurement 579 592--*--PQ - interval",
            "Value 593 601--*--= 210 ms",
            "Condition 640 652--*--sinus rhythm",
            "Scope 505 652--*--QRS width in the 12 channel surface ECG =120 ms, QTc - interval < 440 ms, PQ - interval = 210 ms; all parameters should be measured at sinus rhythm",
            "Person 706 709--*--old",
            "Value 667 705--*--at least 18 and not older than 75years",
            "Informed_consent 712 764--*--Subject is able and willing to give informed consent"
        ]
    },
    "NCT02807857_inc": {
        "Annotations": [
            "Informed_consent 0 99--*--Willing and able to provide written informed consent and accept study procedures and time schedule.",
            "Person 101 104--*--Age",
            "Value 105 115--*--= 18 years",
            "Condition 142 163--*--chronic heart failure",
            "Measurement 340 357--*--ejection fraction",
            "Value 359 364--*--= 40%"
        ],
        "Text": "Willing and able to provide written informed consent and accept study procedures and time schedule.. Age = 18 years.. Patients suffering from chronic heart failure (the heart failure diagnosis must have been made or confirmed by a cardiologist and/or hospital physician at any time in the patient's medical history).. Patients with reduced ejection fraction (= 40%) as confirmed at any time point in the patient's medical history.. "
    },
    "NCT02042287_inc": {
        "Text": "> 18 years old. Acute symptomatic BV. Signed informed consent. Insufficient knowledge of German. Illiteracy. Pregnancy. Acute illness. Known allergies against ingredients of the investigational products. ",
        "Annotations": [
            "Value 2 10--*--18 years",
            "Person 11 14--*--old",
            "Temporal 16 21--*--Acute",
            "Qualifier 22 33--*--symptomatic",
            "Condition 34 36--*--BV",
            "Informed_consent 38 61--*--Signed informed consent",
            "Observation 63 95--*--Insufficient knowledge of German",
            "Observation 97 107--*--Illiteracy",
            "Condition 109 118--*--Pregnancy",
            "Condition 120 133--*--Acute illness",
            "Condition 141 150--*--allergies",
            "Drug 159 202--*--ingredients of the investigational products"
        ]
    },
    "NCT02783859_exc": {
        "Text": "Current wheeze. Underlying chronic illness other than asthma (e.g. bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency) that could potentially influence the current illness. Severe malnutrition (weight-for-height Z-score <-3). Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis. Extra-pulmonary infection requiring antibiotic therapy (e.g. meningitis). Beta-lactam allergy. Previously enrolled. Lack a mobile phone and/or unable to return for follow-up clinic visits during the next 24 months. ",
        "Annotations": [
            "Condition 8 14--*--wheeze",
            "Condition 27 42--*--chronic illness",
            "Negation 43 48--*--other",
            "Condition 54 60--*--asthma",
            "Condition 67 81--*--bronchiectasis",
            "Condition 83 116--*--cyanotic congenital heart disease",
            "Condition 120 135--*--cardiac failure",
            "Condition 137 160--*--neuromuscular disorders",
            "Condition 162 178--*--immunodeficiency",
            "Scope 67 178--*--bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency",
            "Condition 241 253--*--malnutrition",
            "Qualifier 234 240--*--Severe",
            "Measurement 255 280--*--weight-for-height Z-score",
            "Value 281 284--*--<-3",
            "Condition 287 298;330 339--*--Complicated pneumonia",
            "Condition 351 363--*--tuberculosis",
            "Condition 300 308--*--effusion",
            "Condition 310 317--*--empyema",
            "Condition 321 328--*--abscess",
            "Scope 301 328--*--ffusion, empyema or abscess",
            "Qualifier 365 380--*--Extra-pulmonary",
            "Condition 381 390--*--infection",
            "Procedure 401 419--*--antibiotic therapy",
            "Condition 426 436--*--meningitis",
            "Condition 451 458--*--allergy",
            "Drug 439 450--*--Beta-lactam",
            "Competing_trial 460 479--*--Previously enrolled",
            "Post-eligibility 481 578--*--Lack a mobile phone and/or unable to return for follow-up clinic visits during the next 24 months"
        ]
    },
    "NCT02886962_exc": {
        "Annotations": [
            "Condition 7 17--*--indication",
            "Drug 21 41--*--oral anticoagulation",
            "Condition 49 68--*--atrial fibrillation",
            "Device 70 91--*--mechanic heart valves",
            "Condition 93 119--*--recurrent thrombophlebitis",
            "Condition 121 146--*--antiphospholipid syndrome",
            "Scope 70 146--*--mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome",
            "Observation 149 164--*--Life expectancy",
            "Value 165 175--*--< 6 months",
            "Condition 183 198--*--terminal cancer",
            "Procedure 201 227--*--Live donor transplantation",
            "Temporal 238 253--*--within 6 months",
            "Mood 228 237--*--scheduled",
            "Pregnancy_considerations 255 318--*--Pregnancy (\u00df-HCG blood-based assay)or nursing (lactating) women",
            "Pregnancy_considerations 320 412--*--Women of child bearing potential, unless they are using an effective method of birth control",
            "Non-query-able 414 446--*--Patient under legal guardianship",
            "Non-query-able 448 477--*--Patients under law protection",
            "Condition 485 501--*--hypersensibility",
            "Drug 505 513--*--coumadin",
            "Drug 517 524--*--indoine",
            "Scope 505 524--*--coumadin or indoine",
            "Condition 583 596--*--liver failure",
            "Qualifier 576 582--*--Severe"
        ],
        "Text": "Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome). Life expectancy < 6 months (e.g., terminal cancer). Live donor transplantation scheduled within 6 months. Pregnancy (\u00df-HCG blood-based assay)or nursing (lactating) women. Women of child bearing potential, unless they are using an effective method of birth control. Patient under legal guardianship. Patients under law protection. Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK). Severe liver failure (CI to oral AVK). "
    },
    "NCT01717911_inc": {
        "Text": "Recently diagnosed type 2 diabetic patients.. Fasting plasma glucose between 200-300 mg/dl (A1C level between 7% and 10%).. Those who age between 30 and 80 years old and can inject insulin by themselves.. ",
        "Annotations": [
            "Condition 19 34--*--type 2 diabetic",
            "Temporal 0 18--*--Recently diagnosed",
            "Measurement 46 68--*--Fasting plasma glucose",
            "Value 69 90--*--between 200-300 mg/dl",
            "Measurement 92 101--*--A1C level",
            "Value 102 120--*--between 7% and 10%",
            "Scope 92 120--*--A1C level between 7% and 10%",
            "Scope 46 90--*--Fasting plasma glucose between 200-300 mg/dl",
            "Value 138 165--*--between 30 and 80 years old",
            "Person 134 137--*--age",
            "Observation 170 173--*--can",
            "Procedure 174 188--*--inject insulin"
        ]
    },
    "NCT03236246_inc": {
        "Annotations": [
            "Measurement 0 36--*--Estimated glomerular filtration rate",
            "Value 37 62--*--=20 mL/min and <60 mL/min",
            "Measurement 64 67--*--Hgb",
            "Value 68 92--*--=8.5 g/dL and =11.5 g/dL",
            "Measurement 94 108--*--Serum ferritin",
            "Value 109 119--*--=500 ng/mL",
            "Measurement 124 146--*--transferrin saturation",
            "Measurement 148 152--*--TSAT",
            "Value 154 158--*--=25%",
            "Measurement 160 192--*--Serum intact parathyroid hormone",
            "Value 193 203--*--=600 pg/mL"
        ],
        "Text": "Estimated glomerular filtration rate =20 mL/min and <60 mL/min. Hgb =8.5 g/dL and =11.5 g/dL. Serum ferritin =500 ng/mL and transferrin saturation (TSAT) =25%. Serum intact parathyroid hormone =600 pg/mL. "
    },
    "NCT01856491_inc": {
        "Text": "Willing and capable of providing informed consent . Has an indication for implantation of a single or dual chamber ICD or CRT-D system in their respective geography . Subjects planned to be implanted with the RELIANCE 4-FRONT Passive Fixation Lead . Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol . Age 18 or above, or of legal age to give informed consent specific to state and national law . ",
        "Annotations": [
            "Post-eligibility 0 49--*--Willing and capable of providing informed consent",
            "Observation 58 68--*--indication",
            "Procedure 106 117;73 97--*--chamber ICD implantation of a single",
            "Procedure 101 117;73 90--*--dual chamber ICD implantation of a",
            "Procedure 121 133;73 90--*--CRT-D system implantation of a",
            "Scope 73 133--*--implantation of a single or dual chamber ICD or CRT-D system",
            "Observation 174 181--*--planned",
            "Procedure 188 245--*--implanted with the RELIANCE 4-FRONT Passive Fixation Lead",
            "Device 207 245--*--RELIANCE 4-FRONT Passive Fixation Lead",
            "Non-query-able 247 425--*--Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol",
            "Person 427 430--*--Age",
            "Value 431 442--*--18 or above",
            "Value 447 459--*--of legal age",
            "Scope 431 459--*--18 or above, or of legal age"
        ]
    },
    "NCT01884337_exc": {
        "Text": "Women who are pregnant or breastfeeding. Known or suspected, acquired or bleeding or coagulation disorder in the subject or a first degree relative. Active bleeding or at high risk for bleeding.. Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery. Active hepatobiliary disease. Hemoglobin <9 g/dL. Platelet count <100,000/mm3. Creatinine clearance <30 mL/min. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Observation 14 22--*--pregnant",
            "Observation 26 39--*--breastfeeding",
            "Mood 41 46--*--Known",
            "Mood 50 59--*--suspected",
            "Condition 85 105--*--coagulation disorder",
            "Condition 73 81;97 105--*--bleeding disorder",
            "Condition 61 69;97 105--*--acquired disorder",
            "Person 106 120--*--in the subject",
            "Person 126 147--*--first degree relative",
            "Scope 106 147--*--in the subject or a first degree relative",
            "Scope 61 105--*--acquired or bleeding or coagulation disorder",
            "Scope 41 59--*--Known or suspected",
            "Qualifier 149 155--*--Active",
            "Condition 156 164--*--bleeding",
            "Mood 168 184--*--at high risk for",
            "Condition 185 193--*--bleeding",
            "Procedure 236 243--*--surgery",
            "Condition 247 253--*--trauma",
            "Scope 236 253--*--surgery or trauma",
            "Qualifier 230 235--*--major",
            "Qualifier 211 225--*--ophthalmologic",
            "Qualifier 203 209--*--spinal",
            "Qualifier 196 201--*--Brain",
            "Scope 196 235--*--Brain, spinal, ophthalmologic, or major",
            "Temporal 254 277--*--within the past 90 days",
            "Procedure 293 306;311 318--*--elective knee surgery",
            "Procedure 293 301;307 318--*--elective hip surgery",
            "Negation 278 288--*--other than",
            "Scope 293 318--*--elective knee/hip surgery",
            "Qualifier 320 326--*--Active",
            "Condition 327 348--*--hepatobiliary disease",
            "Measurement 350 360--*--Hemoglobin",
            "Value 361 368--*--<9 g/dL",
            "Measurement 370 384--*--Platelet count",
            "Value 385 397--*--<100,000/mm3",
            "Measurement 399 419--*--Creatinine clearance",
            "Value 420 430--*--<30 mL/min"
        ]
    },
    "NCT02979561_exc": {
        "Text": "Signs of hemodynamic instability (i.e. systolic blood pressure <100 mm Hg.St. or episode of systolic blood pressure fall for =40 mm Hg. / or heart rate > 110 lasting more than 15 min) or need for ventilatory support within 12 hours prior to randomisation.. The indication for oral anticoagulation, associated with others disease.. malignant neoplasm of any location. Contraindications to warfarin or pradaxa according to Russian Instructions for medical use of these drugs. Indications for concomitant treatment with antiplatelet agents. Any stroke within 6 months before randomization. Intracranial hemorrhage in anamnesis. Active bleeding, bleeding diathesis.. Clinically significant bleeding within the last 30 days.. Trauma or extensive surgery within 1 month before randomization or surgery planned in the next 6 months after randomization.. Intracranial pathology: tumor, arteriovenous fistula or aneurysm.. Gastrointestinal bleeding in the previous 3 months.. Gastric ulcer or duodenal ulcer with clinical manifestations or endoscopically identified acute ulcer without signs of scarring during previous 30 days.. Uncontrolled hypertension (systolic blood pressure> 180 mm Hg. and / or diastolic blood pressure> 100 mm.hg in patients receiving antihypertensive drugs).. Pregnancy, lactation.. Life expectancy <6 months.. Clinically significant liver disease.. Creatinine clearance (estimated by Cockcroft-Gault) <30 ml / min.. hemoglobin level <90 g/l), thrombocytopenia <100x10^9 / L.. Patients who, in the opinion of the researcher, are not suitable for inclusion in the study, for example, due to the low likelihood of doctor's recommendations following.. Long-term use of NSAIDs. Current participation in another clinical study.. Allergic to contrast substance or radioisotope drugs used in procedures to assess endpoints of the study, which according to researchers, may be a contraindication to the implementation of these research methods.. ",
        "Annotations": [
            "Condition 9 32--*--hemodynamic instability",
            "Measurement 39 62--*--systolic blood pressure",
            "Value 63 77--*--<100 mm Hg.St.",
            "Measurement 92 120--*--systolic blood pressure fall",
            "Value 125 134--*--=40 mm Hg",
            "Measurement 141 151--*--heart rate",
            "Value 152 157--*--> 110",
            "Multiplier 158 182--*--lasting more than 15 min",
            "Procedure 196 215--*--ventilatory support",
            "Mood 187 195--*--need for",
            "Temporal 216 254--*--within 12 hours prior to randomisation",
            "Scope 39 182--*--systolic blood pressure <100 mm Hg.St. or episode of systolic blood pressure fall for =40 mm Hg. / or heart rate > 110 lasting more than 15 min",
            "Procedure 276 296--*--oral anticoagulation",
            "Mood 261 275--*--indication for",
            "Qualifier 331 340--*--malignant",
            "Condition 341 349--*--neoplasm",
            "Condition 367 384--*--Contraindications",
            "Drug 388 396--*--warfarin",
            "Drug 400 407--*--pradaxa",
            "Scope 388 407--*--warfarin or pradaxa",
            "Qualifier 421 457--*--Russian Instructions for medical use",
            "Drug 517 536--*--antiplatelet agents",
            "Temporal 490 501--*--concomitant",
            "Mood 474 485--*--Indications",
            "Condition 542 548--*--stroke",
            "Temporal 549 585--*--within 6 months before randomization",
            "Condition 587 610--*--Intracranial hemorrhage",
            "Procedure 614 623--*--anamnesis",
            "Condition 632 640--*--bleeding",
            "Condition 642 660--*--bleeding diathesis",
            "Qualifier 663 685--*--Clinically significant",
            "Condition 686 694--*--bleeding",
            "Temporal 695 718--*--within the last 30 days",
            "Condition 721 727--*--Trauma",
            "Procedure 731 748--*--extensive surgery",
            "Temporal 749 784--*--within 1 month before randomization",
            "Scope 721 748--*--Trauma or extensive surgery",
            "Procedure 788 795--*--surgery",
            "Mood 796 803--*--planned",
            "Temporal 804 844--*--in the next 6 months after randomization",
            "Condition 847 869--*--Intracranial pathology",
            "Condition 871 876--*--tumor",
            "Condition 878 899--*--arteriovenous fistula",
            "Condition 903 911--*--aneurysm",
            "Scope 871 911--*--tumor, arteriovenous fistula or aneurysm",
            "Condition 914 939--*--Gastrointestinal bleeding",
            "Temporal 940 964--*--in the previous 3 months",
            "Condition 967 980--*--Gastric ulcer",
            "Condition 984 998--*--duodenal ulcer",
            "Condition 1004 1027--*--clinical manifestations",
            "Qualifier 1031 1056--*--endoscopically identified",
            "Procedure 1031 1045--*--endoscopically",
            "Condition 1057 1068--*--acute ulcer",
            "Negation 1069 1076--*--without",
            "Condition 1077 1094--*--signs of scarring",
            "Temporal 1095 1118--*--during previous 30 days",
            "Qualifier 1121 1133--*--Uncontrolled",
            "Condition 1134 1146--*--hypertension",
            "Measurement 1148 1171--*--systolic blood pressure",
            "Value 1171 1182--*--> 180 mm Hg",
            "Measurement 1193 1217--*--diastolic blood pressure",
            "Value 1217 1228--*--> 100 mm.hg",
            "Drug 1251 1273--*--antihypertensive drugs",
            "Scope 1148 1273--*--systolic blood pressure> 180 mm Hg. and / or diastolic blood pressure> 100 mm.hg in patients receiving antihypertensive drugs",
            "Condition 1277 1286--*--Pregnancy",
            "Condition 1288 1297--*--lactation",
            "Observation 1300 1315--*--Life expectancy",
            "Value 1316 1325--*--<6 months",
            "Qualifier 1328 1350--*--Clinically significant",
            "Condition 1351 1364--*--liver disease",
            "Measurement 1367 1387--*--Creatinine clearance",
            "Qualifier 1402 1417--*--Cockcroft-Gault",
            "Value 1419 1431--*--<30 ml / min",
            "Measurement 1434 1450--*--hemoglobin level",
            "Value 1451 1458--*--<90 g/l",
            "Condition 1461 1477--*--thrombocytopenia",
            "Value 1478 1491--*--<100x10^9 / L",
            "Non-query-able 1494 1664--*--Patients who, in the opinion of the researcher, are not suitable for inclusion in the study, for example, due to the low likelihood of doctor's recommendations following.",
            "Drug 1683 1689--*--NSAIDs",
            "Multiplier 1666 1679--*--Long-term use",
            "Non-query-able 1691 1739--*--Current participation in another clinical study.",
            "Condition 1741 1749--*--Allergic",
            "Drug 1753 1771--*--contrast substance",
            "Drug 1775 1793--*--radioisotope drugs",
            "Scope 1753 1793--*--contrast substance or radioisotope drugs",
            "Qualifier 625 631--*--Active"
        ]
    },
    "NCT03056391_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 70 72--*--2.",
            "Parsing_Error 139 141--*--3.",
            "Parsing_Error 196 198--*--4.",
            "Non-query-able 3 68--*--Patient or relatives unable or unwilling to give informed consent",
            "Post-eligibility 3 68--*--Patient or relatives unable or unwilling to give informed consent",
            "Condition 73 89--*--Contraindication",
            "Condition 93 100--*--allergy",
            "Drug 104 115--*--paracetamol",
            "Drug 119 129--*--artesunate",
            "Scope 73 100--*--Contraindication or allergy",
            "Scope 104 129--*--paracetamol or artesunate",
            "Condition 148 157--*--cirrhosis",
            "Condition 162 194--*-->6 standard alcoholic drinks/day",
            "Condition 199 208--*--Pregnancy"
        ],
        "Text": "1. Patient or relatives unable or unwilling to give informed consent . 2. Contraindication or allergy to paracetamol or artesunate therapy . 3. Known cirrhosis, or >6 standard alcoholic drinks/day . 4. Pregnancy       .     . "
    },
    "NCT02946918_exc": {
        "Text": "AJCC Stage III or greater. Undifferentiated, Anaplastic or Medullary Thyroid Cancer. Planned postoperative TSH goal other than 0.1-0.5 mU/L. History of gastrointestinal malabsorption or gastric bypass surgery. Pregnancy. Use of medications that alter the absorption or metabolism of levothyroxine. Prior use of levothyroxine. ",
        "Annotations": [
            "Measurement 0 4--*--AJCC",
            "Value 5 25--*--Stage III or greater",
            "Condition 59 83--*--Medullary Thyroid Cancer",
            "Condition 45 55;69 83--*--Anaplastic Thyroid Cancer",
            "Condition 27 43;69 83--*--Undifferentiated Thyroid Cancer",
            "Measurement 107 110--*--TSH",
            "Qualifier 93 106--*--postoperative",
            "Value 127 139--*--0.1-0.5 mU/L",
            "Negation 116 126--*--other than",
            "Condition 152 182--*--gastrointestinal malabsorption",
            "Procedure 186 208--*--gastric bypass surgery",
            "Pregnancy_considerations 210 219--*--Pregnancy",
            "Drug 228 239--*--medications",
            "Observation 269 296--*--metabolism of levothyroxine",
            "Drug 283 296--*--levothyroxine",
            "Drug 311 324--*--levothyroxine",
            "Temporal 298 303--*--Prior",
            "Observation 255 265;280 296--*--absorption of levothyroxine",
            "Scope 255 296--*--absorption or metabolism of levothyroxine",
            "Negation 245 250--*--alter"
        ]
    },
    "NCT02632266_inc": {
        "Annotations": [
            "Person 15 22--*--infants",
            "Value 28 59--*--between 28 0/7 and 34 0/7 weeks",
            "Measurement 60 69--*--gestation",
            "Condition 0 6--*--Inborn",
            "Condition 7 14--*--preterm",
            "Observation 74 77;85 102--*--fed mother's own milk",
            "Observation 106 122;74 77--*--donor human milk fed"
        ],
        "Text": "Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk. "
    },
    "NCT03096613_exc": {
        "Annotations": [
            "Condition 0 19--*--Acute heart failure",
            "Condition 29 41--*--exacerbation",
            "Qualifier 23 28--*--acute",
            "Condition 45 66--*--chronic heart failure",
            "Temporal 67 90--*--within the past 2 weeks",
            "Scope 0 66--*--Acute heart failure or acute exacerbation of chronic heart failure",
            "Procedure 103 136--*--cardiac resynchronization therapy",
            "Procedure 140 161--*--heart transplantation",
            "Condition 175 190--*--malignant tumor",
            "Person 194 209--*--life expectancy",
            "Value 210 225--*--under 12 months",
            "Drug 239 250--*--medications",
            "Measurement 267 283--*--thyroid function",
            "Value 260 266--*--affect",
            "Drug 285 289--*--L-T4",
            "Drug 291 302--*--carbimazole",
            "Drug 304 320--*--propylthiouracil",
            "Drug 322 332--*--amiodarone",
            "Drug 334 341--*--lithium",
            "Scope 285 341--*--L-T4, carbimazole, propylthiouracil, amiodarone, lithium",
            "Condition 345 354--*--Pregnancy",
            "Condition 359 375--*--lactation period",
            "Non-query-able 378 442--*--Participation in another clinical trial within the past 30 days.",
            "Condition 444 460--*--Contraindication",
            "Condition 464 475--*--intolerance",
            "Procedure 479 501--*--evidence-based therapy",
            "Condition 506 509--*--CHF",
            "Drug 519 531--*--beta-blocker",
            "Drug 533 572--*--angiotensin-converting enzyme inhibitor",
            "Drug 576 604--*--angiotensin receptor blocker",
            "Scope 519 604--*--beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker",
            "Scope 444 475--*--Contraindication or intolerance",
            "Scope 444 509--*--Contraindication or intolerance to evidence-based therapy for CHF",
            "Procedure 637 655--*--trial treatment(s)",
            "Drug 637 642;659 667--*--trial diluents",
            "Scope 637 667--*--trial treatment(s) or diluents",
            "Condition 613 629--*--hypersensitivity",
            "Drug 697 704--*--placebo",
            "Qualifier 708 713--*--other",
            "Drug 714 732--*--comparator drug(s)",
            "Scope 697 732--*--placebo or other comparator drug(s)",
            "Scope 613 667--*--hypersensitivity to the trial treatment(s) or diluents",
            "Condition 745 766--*--adrenal insufficiency",
            "Qualifier 735 744--*--Untreated",
            "Condition 779 802--*--pituitary insufficiency",
            "Qualifier 769 778--*--Untreated",
            "Condition 815 829--*--thyrotoxicosis",
            "Qualifier 805 814--*--Untreated",
            "Drug 847 860--*--levothyroxine",
            "Condition 900 927--*--acute myocardial infarction",
            "Negation 866 882--*--not be initiated",
            "Procedure 832 841--*--Treatment",
            "Condition 929 946--*--acute myocarditis",
            "Condition 951 968--*--acute pancarditis",
            "Scope 900 968--*--acute myocardial infarction, acute myocarditis, or acute pancarditis",
            "Condition 978 995--*--renal dysfunction",
            "Qualifier 971 977--*--Severe",
            "Measurement 997 1001--*--eGFR",
            "Value 1001 1018--*--=30 ml/min/1.73m2",
            "Scope 997 1018--*--eGFR=30 ml/min/1.73m2",
            "Scope 971 995--*--Severe renal dysfunction",
            "Condition 1034 1052--*--hepatic impairment",
            "Qualifier 1022 1033--*--Significant",
            "Measurement 1054 1063--*--Serum GPT",
            "Value 1064 1073--*--> 120 U/L",
            "Post-eligibility 1077 1199--*--Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol."
        ],
        "Text": "Acute heart failure or acute exacerbation of chronic heart failure within the past 2 weeks.. Scheduled cardiac resynchronization therapy or heart transplantation.. History of malignant tumor or life expectancy under 12 months.. Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium).. Pregnancy and lactation period.. Participation in another clinical trial within the past 30 days.. Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.. Known hypersensitivity to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s).. Untreated adrenal insufficiency.. Untreated pituitary insufficiency.. Untreated thyrotoxicosis.. Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis.. Severe renal dysfunction (eGFR=30 ml/min/1.73m2).. Significant hepatic impairment (Serum GPT > 120 U/L).. Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol.. "
    },
    "NCT02416765_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 239 241--*--2.",
            "Parsing_Error 338 340--*--3.",
            "Parsing_Error 361 363--*--4.",
            "Parsing_Error 422 424--*--5.",
            "Parsing_Error 737 739--*--6.",
            "Parsing_Error 977 979--*--7.",
            "Parsing_Error 1173 1175--*--8.",
            "Parsing_Error 1306 1308--*--9.",
            "Condition 26 53--*--microvascular complications",
            "Measurement 68 104--*--estimated glomerular filtration rate",
            "Value 105 120--*--below 40 ml/min",
            "Condition 55 66--*--nephropathy",
            "Condition 123 133--*--neuropathy",
            "Condition 156 169--*--gastroparesis",
            "Condition 174 206--*--severe proliferative retinopathy",
            "Subjective_judgement 207 236--*--as judged by the investigator",
            "Qualifier 207 236--*--as judged by the investigator",
            "Scope 55 206--*--nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy",
            "Temporal 250 260--*--< 3 months",
            "Temporal 242 248--*--Recent",
            "Condition 262 287--*--acute macrovascular event",
            "Condition 293 316--*--acute coronary syndrome",
            "Condition 320 335--*--cardiac surgery",
            "Scope 293 335--*--acute coronary syndrome or cardiac surgery",
            "Condition 349 358--*--pregnancy",
            "Temporal 341 348--*--Ongoing",
            "Condition 371 391--*--hypoglycemic episode",
            "Qualifier 364 370--*--Severe",
            "Temporal 392 419--*--within 1 month of screening",
            "Drug 425 458--*--Agents affecting gastric emptying",
            "Undefined_semantics 425 458--*--Agents affecting gastric emptying",
            "Drug 460 468--*--Motilium",
            "Drug 471 479--*--Prandase",
            "Drug 482 489--*--Victoza",
            "Drug 492 498--*--Byetta",
            "Drug 504 510--*--Symlin",
            "Grammar_Error 500 503--*--and",
            "Scope 460 511--*--Motilium\u00ae, Prandase\u00ae, Victoza\u00ae, Byetta\u00ae and Symlin\u00ae",
            "Drug 524 549--*--oral anti-diabetic agents",
            "Drug 551 560--*--Metformin",
            "Drug 562 579--*--SGLT-2 inhibitors",
            "Drug 584 600--*--DPP-4 inhibitors",
            "Grammar_Error 580 583--*--and",
            "Scope 551 600--*--Metformin, SGLT-2 inhibitors and DPP-4 inhibitors",
            "Qualifier 614 625--*--stable dose",
            "Temporal 626 638--*--for 3 months",
            "Scope 614 638--*--stable dose for 3 months",
            "Negation 605 608--*--not",
            "Parsing_Error 640 735--*--Otherwise, these medications are acceptable and will be kept stable during the entire protocol.",
            "Drug 740 753--*--Oral steroids",
            "Negation 754 760--*--unless",
            "Qualifier 784 795--*--stable dose",
            "Qualifier 780 783;791 795--*--low dose",
            "Multiplier 802 815;830 837--*--10 mg or less per day",
            "Drug 819 829--*--prednisone",
            "Multiplier 841 860--*--physiological doses",
            "Multiplier 862 881--*--less than 35 mg/day",
            "Drug 886 900--*--hydrocortisone",
            "Drug 901 907--*--Cortef",
            "Scope 802 907--*--10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef",
            "Grammar_Error 911 974--*--Inhale steroids at stable dose in the last month are acceptable",
            "Drug 911 926--*--Inhale steroids",
            "Qualifier 930 941--*--stable dose",
            "Temporal 942 959--*--in the last month",
            "Condition 980 985;994 1009--*--Other medical illness",
            "Qualifier 986 993--*--serious",
            "Subjective_judgement 986 993--*--serious",
            "Context_Error 1010 1054--*--likely to interfere with study participation",
            "Context_Error 1010 1029;1058 1096--*--likely to interfere with the ability to complete the trial",
            "Subjective_judgement 1097 1132--*--by the judgment of the investigator",
            "Condition 1148 1169--*--psychiatric condition",
            "Qualifier 1139 1147--*--unstable",
            "Scope 980 1132--*--Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator",
            "Non-query-able 1176 1304--*--Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc).",
            "Non-query-able 1309 1404--*--Living or planned travel outside Montreal (> 1h of driving) area during closed-loop procedures.",
            "Procedure 1381 1403--*--closed-loop procedures",
            "Temporal 1374 1403--*--during closed-loop procedures",
            "Reference_point 1381 1403--*--closed-loop procedures"
        ],
        "Text": "1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. . 2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. . 3. Ongoing pregnancy. . 4. Severe hypoglycemic episode within 1 month of screening. . 5. Agents affecting gastric emptying (Motilium\u00ae, Prandase\u00ae, Victoza\u00ae, Byetta\u00ae and Symlin\u00ae) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol. . 6. Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef\u00ae). Inhale steroids at stable dose in the last month are acceptable. . 7. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition). . 8. Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc). . 9. Living or planned travel outside Montreal (> 1h of driving) area during closed-loop procedures.       .     . "
    },
    "NCT02152696_inc": {
        "Text": "Female with a persisting pregnancy of unknown location: . A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization. . Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing < 15% rise per day, or < 50% fall between the first and last value. . Patient is hemodynamically stable, hemoglobin >10 mg/dL . Greater than or 18 years of age . ",
        "Annotations": [
            "Person 0 6--*--Female",
            "Condition 25 34--*--pregnancy",
            "Qualifier 38 54--*--unknown location",
            "Condition 59 68--*--pregnancy",
            "Qualifier 72 88--*--unknown location",
            "Condition 105 114--*--pregnancy",
            "Person 120 125--*--woman",
            "Measurement 142 156--*--pregnancy test",
            "Value 133 141--*--positive",
            "Not_a_criteria 57 240--*--A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging.",
            "Parsing_Error 241 402--*--A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.",
            "Parsing_Error 54 55--*--:",
            "Procedure 403 413--*--Ultrasound",
            "Not_a_criteria 241 402--*--A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.",
            "Temporal 432 468--*--within 7 days prior to randomization",
            "Reference_point 455 468--*--randomization",
            "Condition 471 489--*--Persistence of hCG",
            "Measurement 522 525--*--hCG",
            "Multiplier 504 514--*--at least 2",
            "Temporal 534 548--*--over 2-14 days",
            "Value 559 577--*--< 15% rise per day",
            "Value 582 626--*--< 50% fall between the first and last value.",
            "Condition 639 661--*--hemodynamically stable",
            "Measurement 663 673--*--hemoglobin",
            "Value 674 683--*-->10 mg/dL",
            "Value 685 709--*--Greater than or 18 years",
            "Person 713 716--*--age"
        ]
    },
    "NCT01856491_exc": {
        "Text": "Known or suspected sensitivity to Dexamethasone Acetate (DXA) . Mechanical tricuspid heart valve . Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following: . Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits); . RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject); . Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations . Currently on the active heart transplant list . Documented life expectancy of less than 12 months . Women of childbearing potential who are or might be pregnant at the time of study enrollment (method of assessment upon physician discretion) . Currently requiring chronic dialysis       .     . ",
        "Annotations": [
            "Condition 19 61--*--sensitivity to Dexamethasone Acetate (DXA)",
            "Drug 34 61--*--Dexamethasone Acetate (DXA)",
            "Observation 9 18--*--suspected",
            "Observation 0 5--*--Known",
            "Scope 0 18--*--Known or suspected",
            "Device 63 95--*--Mechanical tricuspid heart valve",
            "Context_Error 97 364--*--Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:",
            "Parsing_Error 97 364--*--Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:",
            "Context_Error 366 472--*--Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);",
            "Non-query-able 366 472--*--Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);",
            "Non-query-able 474 580--*--RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);",
            "Context_Error 474 580--*--RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);",
            "Non-query-able 582 748--*--Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations",
            "Context_Error 582 748--*--Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations",
            "Observation 767 795--*--active heart transplant list",
            "Observation 808 823--*--life expectancy",
            "Value 827 846--*--less than 12 months",
            "Condition 857 879--*--childbearing potential",
            "Person 848 853--*--Women",
            "Observation 884 899--*--are or might be",
            "Condition 900 908--*--pregnant",
            "Temporal 909 940--*--at the time of study enrollment",
            "Scope 848 879--*--Women of childbearing potential",
            "Procedure 1011 1027--*--chronic dialysis",
            "Condition 1001 1027--*--requiring chronic dialysis",
            "Temporal 991 1000--*--Currently"
        ]
    },
    "NCT03236246_exc": {
        "Annotations": [
            "Measurement 0 15--*--Serum phosphate",
            "Value 16 26--*--<3.0 mg/dL",
            "Drug 45 49--*--iron",
            "Qualifier 41 43--*--IV",
            "Qualifier 28 39--*--Intravenous",
            "Temporal 63 96--*--within 4 weeks prior to Screening",
            "Reference_point 87 96--*--Screening",
            "Drug 98 131--*--Erythropoiesis-stimulating agents",
            "Drug 133 136--*--ESA",
            "Temporal 151 184--*--within 4 weeks prior to Screening",
            "Reference_point 175 184--*--Screening",
            "Procedure 186 203--*--Blood transfusion",
            "Temporal 204 237--*--within 4 weeks prior to Screening",
            "Reference_point 228 237--*--Screening"
        ],
        "Text": "Serum phosphate <3.0 mg/dL. Intravenous (IV) iron administered within 4 weeks prior to Screening. Erythropoiesis-stimulating agents (ESA) administered within 4 weeks prior to Screening. Blood transfusion within 4 weeks prior to Screening. "
    },
    "NCT02979561_inc": {
        "Text": "Men and women aged > 18 years. Angiographically confirmed acute massive pulmonary embolism with involvement of Central pulmonary arteries.. endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen), performed for treatment of the above-mentioned pulmonary embolism in less than 48 hours before randomization. The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy. Written informed consent signed by patient.. ",
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 8 13--*--women",
            "Person 14 18--*--aged",
            "Value 19 29--*--> 18 years",
            "Procedure 31 47--*--Angiographically",
            "Qualifier 31 57--*--Angiographically confirmed",
            "Qualifier 58 63--*--acute",
            "Qualifier 64 71--*--massive",
            "Condition 72 90--*--pulmonary embolism",
            "Condition 96 137--*--involvement of Central pulmonary arteries",
            "Condition 140 186--*--endovascular mechanical thrombus fragmentation",
            "Procedure 189 209--*--thrombolytic therapy",
            "Drug 217 260--*--recombinant tissue activator of plasminogen",
            "Temporal 329 371--*--in less than 48 hours before randomization",
            "Procedure 277 286--*--treatment",
            "Condition 310 328--*--pulmonary embolism",
            "Scope 140 261--*--endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen)",
            "Post-eligibility 520 561--*--ritten informed consent signed by patient",
            "Non-representable 373 517--*--The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy"
        ]
    },
    "NCT01884337_inc": {
        "Text": "Age =18 years. Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 13--*--=18 years",
            "Qualifier 35 43--*--elective",
            "Procedure 44 54;62 73--*--total knee replacement",
            "Procedure 44 49;58 73--*--total hip replacement",
            "Procedure 117 129;137 148;79 90--*--a total knee replacement revision of",
            "Qualifier 91 113--*--at least one component",
            "Procedure 117 118;133 148;79 90--*--a hip replacement revision of",
            "Scope 114 148;79 90--*--of a total knee or hip replacement revision of",
            "Scope 44 73--*--total knee or hip replacement",
            "Temporal 24 34--*--undergoing"
        ]
    },
    "NCT03056391_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 27 29--*--2.",
            "Parsing_Error 133 135--*--3.",
            "Parsing_Error 206 208--*--4.",
            "Parsing_Error 272 274--*--5.",
            "Person 11 14--*--age",
            "Value 15 25--*--\u2265 12 years",
            "Condition 42 61--*--P. knowlesi malaria",
            "Measurement 85 96--*--blood smear",
            "Value 76 84--*--positive",
            "Qualifier 97 130--*--with asexual forms of P. knowlesi",
            "Measurement 136 147--*--Temperature",
            "Value 148 152--*-->38C",
            "Temporal 218 233--*--within 18 hours",
            "Observation 209 217--*--Enrolled",
            "Reference_point 237 270--*--commencing antimalarial treatment",
            "Procedure 248 270--*--antimalarial treatment",
            "Non-query-able 275 380--*--Written informed consent from patient or attending relative able to and willing to give informed consent.",
            "Non-query-able 381 481--*--Consent form and information sheets will be translated into Malay and copies provided to the patient",
            "Not_a_criteria 381 482--*--Consent form and information sheets will be translated into Malay and copies provided to the patient.",
            "Post-eligibility 275 380--*--Written informed consent from patient or attending relative able to and willing to give informed consent."
        ],
        "Text": "1. Patient age \u2265 12 years . 2. Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi. . 3. Temperature >38C on admission or fever during the preceding 48 hours . 4. Enrolled within 18 hours of commencing antimalarial treatment . 5. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Malay and copies provided to the patient. . "
    },
    "NCT02632266_exc": {
        "Annotations": [
            "Person 0 15--*--Newborn infants",
            "Measurement 40 49--*--gestation",
            "Value 16 39--*--<28 weeks and >34 weeks",
            "Condition 62 86--*--life threatening illness",
            "Condition 103 124--*--chromosomal anomalies",
            "Condition 115 124;88 98--*--anomalies congenital",
            "Condition 126 152--*--gastrointestinal anomalies",
            "Condition 156 181--*--necrotizing enterocolitis",
            "Observation 186 207--*--fed premature formula"
        ],
        "Text": "Newborn infants <28 weeks and >34 weeks gestation, those with life threatening illness, congenital and chromosomal anomalies, gastrointestinal anomalies or necrotizing enterocolitis and fed premature formula. "
    },
    "NCT03096613_inc": {
        "Annotations": [
            "Value 5 22--*--18 years or older",
            "Person 0 4--*--Aged",
            "Person 24 28--*--male",
            "Person 32 38--*--female",
            "Condition 41 63--*--Systolic heart failure",
            "Measurement 69 102--*--New York Heart Association (NYHA)",
            "Value 103 115--*--class II-III",
            "Measurement 118 159--*--Left ventricular ejection fraction (LVEF)",
            "Value 160 173--*--less than 40%",
            "Procedure 177 193--*--echocardiography",
            "Temporal 194 228--*--during screening and randomization",
            "Condition 231 234--*--SCH",
            "Measurement 236 239--*--TSH",
            "Value 241 278--*--upper limits of normal (ULN) -10mIU/L",
            "Measurement 284 293--*--FT4 level",
            "Value 294 316--*--within reference range",
            "Scope 236 316--*--TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range",
            "Procedure 336 355--*--standard HF therapy",
            "Temporal 356 376--*--for at least 2 weeks",
            "Multiplier 393 404--*--target dose",
            "Multiplier 408 426--*--max tolerable dose",
            "Scope 393 426--*--target dose or max tolerable dose",
            "Non-query-able 429 455--*--Provided informed consent."
        ],
        "Text": "Aged 18 years or older, male or female.. Systolic heart failure with New York Heart Association (NYHA) class II-III.. Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.. SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).. Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.. Provided informed consent.. "
    },
    "NCT02946918_inc": {
        "Text": "Age > 18 years. Presumed AJCC (American Joint Committee on Cancer) tumor Stage I or II. Planned total or near-total thyroidectomy. Planned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively. Normal serum TSH within 12 months preceding surgery. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--> 18 years",
            "Measurement 25 29;67 80--*--AJCC tumor Stage I",
            "Measurement 31 65--*--American Joint Committee on Cancer",
            "Value 79 80--*--I",
            "Value 84 86--*--II",
            "Scope 79 86--*--I or II",
            "Procedure 116 129--*--thyroidectomy",
            "Qualifier 96 101--*--total",
            "Qualifier 105 115--*--near-total",
            "Scope 96 115--*--total or near-total",
            "Temporal 177 210--*--at least 18 weeks postoperatively",
            "Reference_point 195 210--*--postoperatively",
            "Condition 144 159--*--TSH suppression",
            "Value 160 172--*--0.1-0.5 mU/L",
            "Measurement 219 228--*--serum TSH",
            "Value 212 218--*--Normal",
            "Temporal 229 263--*--within 12 months preceding surgery",
            "Reference_point 256 263--*--surgery"
        ]
    },
    "NCT02152696_exc": {
        "Text": "Hemodynamically unstable in need of acute treatment . Most recent hCG > 5000 mIU/mL . Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion) . Diagnosis of gestational trophoblastic disease . Subject unwilling or unable to comply with study procedures . Known hypersensitivity to MTX . Presence of clinical contraindications for treatment with MTX . Prior medical or surgical management of this gestation . Subject unwilling to accept a blood transfusion       .     . ",
        "Annotations": [
            "Condition 0 24--*--Hemodynamically unstable",
            "Measurement 65 68--*--hCG",
            "Temporal 53 64--*--Most recent",
            "Value 69 82--*--> 5000 mIU/mL",
            "Non-query-able 84 197--*--Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion)",
            "Condition 212 245--*--gestational trophoblastic disease",
            "Non-query-able 247 306--*--Subject unwilling or unable to comply with study procedures",
            "Condition 314 337--*--hypersensitivity to MTX",
            "Drug 334 337--*--MTX",
            "Undefined_semantics 339 400--*--Presence of clinical contraindications for treatment with MTX",
            "Procedure 408 415;428 438--*--medical management",
            "Procedure 419 438--*--surgical management",
            "Condition 447 456--*--gestation",
            "Non-query-able 458 505--*--Subject unwilling to accept a blood transfusion",
            "Post-eligibility 458 505--*--Subject unwilling to accept a blood transfusion"
        ]
    },
    "NCT02416765_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 38 40--*--2.",
            "Parsing_Error 103 105--*--3.",
            "Parsing_Error 259 261--*--4.",
            "Parsing_Error 302 304--*--5.",
            "Person 3 8--*--Males",
            "Grammar_Error 9 12--*--and",
            "Person 13 20--*--females",
            "Person 32 35--*--old",
            "Value 21 35--*--\u2265 18 years old",
            "Condition 63 78--*--type 1 diabetes",
            "Temporal 79 100--*--for at least one year",
            "Procedure 136 156--*--insulin pump therapy",
            "Temporal 157 178--*--for at least 3 months",
            "Temporal 183 192--*--currently",
            "Drug 201 226--*--fast actin insulin analog",
            "Drug 228 234--*--Lispro",
            "Drug 236 242--*--Aspart",
            "Drug 246 255--*--Guilisine",
            "Scope 228 255--*--Lispro, Aspart or Guilisine",
            "Measurement 288 293--*--HbA1c",
            "Value 294 299--*--\u2264 10%",
            "Temporal 262 287--*--Last (less than 3 months)",
            "Procedure 321 342--*--carbohydrate counting",
            "Procedure 350 376--*--meal insulin dose strategy",
            "Temporal 305 314--*--Currently"
        ],
        "Text": "1. Males and females \u2265 18 years old. . 2. Clinical diagnosis of type 1 diabetes for at least one year. . 3. The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine). . 4. Last (less than 3 months) HbA1c \u2264 10%. . 5. Currently using carbohydrate counting as the meal insulin dose strategy. . "
    },
    "NCT00480129_exc": {
        "Annotations": [
            "Procedure 8 30--*--allergen immunotherapy",
            "Condition 32 65--*--upper respiratory tract infection",
            "Condition 67 76--*--Pregnancy",
            "Condition 98 117--*--lactose-intolerance",
            "Condition 121 142--*--allergies to cow-milk"
        ],
        "Text": "Ongoing allergen immunotherapy . upper respiratory tract infection . Pregnancy . Clinical history of lactose-intolerance or allergies to cow-milk       .     . "
    },
    "NCT03100513_exc": {
        "Text": "Patients with active GIT bleeding.. Patients with history of bowel obstruction, perforation.. Patients with history of allergy to PEG.. Treatment with rifaximin or neomycin in the previous 7 days.. Patients with major psychiatric illness.. Patients receiving benzodiazepines and narcotics.. Patients with compromised renal.. Patients receiving medications highly bound to plasma proteins eg. Warfarin.. Pregnant or lactating women.. Fulminant hepatic failure.. ",
        "Annotations": [
            "Qualifier 14 20--*--active",
            "Condition 21 33--*--GIT bleeding",
            "Condition 61 78--*--bowel obstruction",
            "Condition 61 66;80 91--*--bowel perforation",
            "Observation 50 57--*--history",
            "Scope 61 91--*--bowel obstruction, perforation",
            "Observation 108 115--*--history",
            "Condition 119 126--*--allergy",
            "Drug 130 133--*--PEG",
            "Drug 151 160--*--rifaximin",
            "Drug 164 172--*--neomycin",
            "Temporal 173 195--*--in the previous 7 days",
            "Scope 151 172--*--rifaximin or neomycin",
            "Condition 212 237--*--major psychiatric illness",
            "Drug 259 274--*--benzodiazepines",
            "Drug 279 288--*--narcotics",
            "Condition 305 322--*--compromised renal",
            "Drug 344 387--*--medications highly bound to plasma proteins",
            "Drug 392 400--*--Warfarin",
            "Condition 403 411--*--Pregnant",
            "Condition 415 424--*--lactating",
            "Person 425 430--*--women",
            "Condition 443 458--*--hepatic failure",
            "Qualifier 433 442--*--Fulminant"
        ]
    },
    "NCT02570321_inc": {
        "Annotations": [
            "Condition 0 13--*--Corneal ulcer",
            "Measurement 22 27--*--smear",
            "Qualifier 48 56--*--bacteria",
            "Qualifier 60 78--*--filamentous fungus",
            "Scope 48 78--*--bacteria or filamentous fungus",
            "Value 28 36--*--positive",
            "Measurement 80 101--*--Pinhole visual acuity",
            "Value 102 118--*--worse than 20/70",
            "Drug 165 190--*--antimicrobial medications",
            "Person 208 211--*--Age",
            "Value 212 225--*--over 18 years",
            "Non-query-able 227 290--*--Basic understanding of the study as determined by the physician",
            "Post-eligibility 292 333--*--Commitment to return for follow up visits"
        ],
        "Text": "Corneal ulcer that is smear positive for either bacteria or filamentous fungus. Pinhole visual acuity worse than 20/70 in the affected eye. Not treated already with antimicrobial medications at presentation. Age over 18 years. Basic understanding of the study as determined by the physician. Commitment to return for follow up visits. "
    },
    "NCT02621489_exc": {
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Measurement 17 29--*--autoantibody",
            "Value 30 38--*--positive",
            "Drug 67 82--*--GLP-1 analogues",
            "Drug 86 117--*--dipeptidyl peptidase inhibitors",
            "Scope 67 117--*--GLP-1 analogues or dipeptidyl peptidase inhibitors",
            "Temporal 118 133--*--within 6 months",
            "Condition 148 161--*--heart failure",
            "Qualifier 141 147--*--severe",
            "Measurement 177 181--*--NYHA",
            "Value 182 183--*--4",
            "Condition 186 204--*--Active myocarditis",
            "Device 221 243--*--artificial heart valve",
            "Qualifier 206 220--*--malfunctioning",
            "Condition 257 280--*--ventricular tachycardia",
            "Temporal 281 296--*--within 3 months",
            "Condition 328 363--*--third-degree atrioventricular block",
            "Condition 317 324;334 363--*--second- degree atrioventricular block",
            "Measurement 373 396--*--systolic blood pressure",
            "Qualifier 366 372--*--Supine",
            "Value 397 406--*--<85 mm Hg",
            "Value 410 420--*-->200 mm Hg",
            "Scope 397 420--*--<85 mm Hg or >200 mm Hg",
            "Condition 436 460--*--Primary renal impairment",
            "Measurement 462 482--*--creatinine clearance",
            "Value 483 494--*--< 45 ml/min",
            "Drug 511 520--*--metformin",
            "Condition 535 546--*--hypokalemia",
            "Condition 550 562--*--hyperkalemia",
            "Measurement 564 573--*--potassium",
            "Value 574 585--*--<3.5 mmol/l",
            "Value 589 600--*-->5.5 mmol/l",
            "Scope 574 600--*--<3.5 mmol/l or >5.5 mmol/l",
            "Scope 535 562--*--hypokalemia or hyperkalemia",
            "Condition 616 622--*--anemia",
            "Qualifier 604 615--*--Significant",
            "Measurement 624 626--*--Hb",
            "Value 627 635--*--< 90 g/l",
            "Condition 645 669--*--gastrointestinal disease",
            "Qualifier 638 644--*--Severe",
            "Condition 681 694--*--gastroparesis",
            "Measurement 728 743--*--Body mass index",
            "Measurement 745 748--*--BMI",
            "Value 750 760--*--> 45 kg/m2",
            "Condition 763 781--*--Malignant neoplasm",
            "Procedure 792 804--*--chemotherapy",
            "Procedure 806 813--*--surgery",
            "Procedure 815 824--*--radiation",
            "Procedure 828 846--*--palliative therapy",
            "Temporal 854 871--*--previous 5 years.",
            "Scope 792 846--*--chemotherapy, surgery, radiation or palliative therapy",
            "Negation 1008 1015--*--allowed",
            "Condition 886 925--*--intraepithelial squamous cell carcinoma",
            "Qualifier 933 937--*--skin",
            "Drug 951 962--*--topical 5FU",
            "Condition 981 1003--*--basal cell skin cancer",
            "Scope 886 1003--*--intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer",
            "Pregnancy_considerations 1037 1133--*--Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant",
            "Condition 1153 1166--*--alcohol abuse",
            "Condition 1144 1148;1161 1166--*--drug abuse",
            "Condition 1180 1185;1197 1209--*--acute pancreatitis",
            "Condition 1189 1209--*--chronic pancreatitis",
            "Non-query-able 1211 1281--*--Subjects considered by the Investigator to be unsuitable for the study"
        ],
        "Text": "Type 1 diabetes (autoantibody positive).. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors within 6 months. Known severe heart failure, classified as NYHA 4.. Active myocarditis; malfunctioning artificial heart valve.. History of ventricular tachycardia within 3 months before study entry; second- or third-degree atrioventricular block.. Supine systolic blood pressure <85 mm Hg or >200 mm Hg at screening.. Primary renal impairment, creatinine clearance < 45 ml/min if treated with metformin.. Uncorrected hypokalemia or hyperkalemia (potassium <3.5 mmol/l or >5.5 mmol/l).. Significant anemia (Hb < 90 g/l). Severe gastrointestinal disease, including gastroparesis. As judged by the Investigator.. Body mass index (BMI) > 45 kg/m2.. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.. Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant.. Current drug and alcohol abuse.. History of acute or chronic pancreatitis. Subjects considered by the Investigator to be unsuitable for the study.. "
    },
    "NCT02804646_exc": {
        "Annotations": [
            "Line 0 121--*--1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;",
            "Line 121 237--*--2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds;",
            "Line 238 442--*--3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension;",
            "Line 443 756--*--4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms;",
            "Line 757 785--*--5) have bleeding tendencies;",
            "Line 786 873--*--6) other researchers believe that patients should not participate in the present trial.",
            "Pregnancy_considerations 3 121--*--pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;",
            "Qualifier 133 139--*--severe",
            "Qualifier 140 145--*--acute",
            "Condition 146 155--*--infection",
            "Qualifier 163 177--*--not controlled",
            "Qualifier 195 202--*--chronic",
            "Qualifier 182 190--*--purulent",
            "Condition 203 212--*--infection",
            "Condition 214 236--*--delayed healing wounds",
            "Scope 182 236--*--purulent and chronic infection, delayed healing wounds",
            "Qualifier 254 260--*--severe",
            "Condition 261 274--*--heart disease",
            "Condition 286 310--*--congestive heart failure",
            "Qualifier 312 324--*--uncontrolled",
            "Qualifier 325 334--*--high-risk",
            "Condition 335 346--*--arrhythmias",
            "Condition 348 363--*--unstable angina",
            "Condition 365 386--*--myocardial infarction",
            "Qualifier 388 394--*--severe",
            "Condition 395 414--*--heart valve disease",
            "Qualifier 419 428--*--resistant",
            "Condition 429 441--*--hypertension",
            "Scope 286 441--*--congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension",
            "Condition 478 498--*--psychiatric diseases",
            "Condition 461 473;490 498--*--neurological diseases",
            "Condition 502 518--*--mental disorders",
            "Condition 543 558--*--poor compliance",
            "Condition 629 663--*--central nervous metastasis disease",
            "Condition 612 625;656 663--*--primary brain disease",
            "Negation 668 671--*--not",
            "Qualifier 677 687--*--controlled",
            "Scope 612 663--*--primary brain or central nervous metastasis disease",
            "Qualifier 694 705--*--significant",
            "Condition 706 726--*--cranial hypertension",
            "Condition 730 755--*--neuropsychiatric symptoms",
            "Condition 765 784--*--bleeding tendencies",
            "Scope 706 755--*--cranial hypertension or neuropsychiatric symptoms",
            "Non-query-able 789 873--*--other researchers believe that patients should not participate in the present trial."
        ],
        "Text": "1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.. "
    },
    "NCT01665417_exc": {
        "Annotations": [
            "Procedure 6 18--*--chemotherapy",
            "Temporal 0 5--*--Prior",
            "Line 0 18--*--Prior chemotherapy",
            "Procedure 25 34--*--treatment",
            "Drug 40 49--*--gefitinib",
            "Temporal 19 24--*--Prior",
            "Drug 51 60--*--erlotinib",
            "Drug 71 93--*--drugs that target EGFR",
            "Scope 40 93--*--gefitinib, erlotinib, or other drugs that target EGFR",
            "Line 19 93--*--Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR",
            "Post-eligibility 94 157--*--Patients must not be receiving any other investigational agents",
            "Condition 174 199--*--interstitial lung disease"
        ],
        "Text": "Prior chemotherapy Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR Patients must not be receiving any other investigational agents Any evidence of interstitial lung disease. "
    },
    "NCT00480129_inc": {
        "Annotations": [
            "Condition 22 39--*--allergic rhinitis",
            "Condition 49 63--*--sneeze attacks",
            "Condition 65 70;85 89--*--runny nose",
            "Condition 71 78;85 89--*--blocked nose",
            "Condition 79 89--*--itchy nose",
            "Condition 110 121--*--common cold",
            "Negation 97 104--*--absence",
            "Temporal 122 151--*--during the previous 12 months",
            "Measurement 174 189--*--skin prick test",
            "Value 165 173--*--positive",
            "Measurement 193 231--*--blood radio-allergosorbent test (RAST)",
            "Qualifier 235 240--*--grass",
            "Qualifier 248 262--*--ragweed pollen"
        ],
        "Text": "Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months. . History of positive skin prick test or blood radio-allergosorbent test (RAST) to grass and/or ragweed pollen . "
    },
    "NCT02804646_inc": {
        "Annotations": [
            "Qualifier 3 27--*--histologically confirmed",
            "Condition 88 114--*--non-small cell lung cancer",
            "Qualifier 129 143--*--wild-type EGFR",
            "Qualifier 148 160--*--ALK-negative",
            "Measurement 178 203--*--IASLC2009 new TNM staging",
            "Condition 207 218--*--lung cancer",
            "Value 219 246--*--stage <U+2162>B or <U+2163>",
            "Qualifier 259 268--*--untreated",
            "Qualifier 272 280--*--relapsed",
            "Temporal 281 318--*--after 1 year of lung cancer resection",
            "Reference_point 297 318--*--lung cancer resection",
            "Scope 259 280--*--untreated or relapsed",
            "Multiplier 328 340--*--at least one",
            "Condition 341 358--*--evaluable lesions",
            "Measurement 437 453--*--longest diameter",
            "Procedure 459 468--*--spiral CT",
            "Value 469 482--*--at least 10mm",
            "Procedure 488 498--*--regular CT",
            "Measurement 499 515--*--longest diameter",
            "Value 516 529--*--at least 20mm",
            "Person 535 539--*--Male",
            "Person 543 549--*--female",
            "Person 551 555--*--aged",
            "Value 556 570--*--18 to 75 years",
            "Measurement 575 582--*--ECOG PS",
            "Value 583 589--*--0 or 1",
            "Observation 594 611--*--expected survival",
            "Temporal 612 629--*--at least 3 months",
            "Condition 634 665--*--adequate hematological function",
            "Measurement 667 698--*--absolute neutrophil count (ANC)",
            "Value 699 716--*--at least 2\u00d710^9/L",
            "Measurement 721 735--*--platelet count",
            "Value 736 755--*--at least 100\u00d710^9/L",
            "Measurement 760 770--*--hemoglobin",
            "Value 771 786--*--at least 9 g/dL",
            "Scope 667 786--*--absolute neutrophil count (ANC) at least 2\u00d710^9/L and platelet count at least 100\u00d710^9/L and hemoglobin at least 9 g/dL",
            "Condition 791 814--*--adequate liver function",
            "Measurement 816 831--*--total bilirubin",
            "Value 832 869--*--less than upper limit of normal (ULN)",
            "Measurement 871 874--*--AST",
            "Measurement 879 882--*--ALT",
            "Value 883 930--*--less than 2.5 times upper limit of normal (ULN)",
            "Measurement 932 952--*--alkaline phosphatase",
            "Value 953 1002--*--less than 5 times the upper limit of normal (ULN)",
            "Condition 1007 1030--*--adequate renal function",
            "Measurement 1032 1048--*--serum creatinine",
            "Value 1049 1086--*--less than upper limit of normal (ULN)",
            "Measurement 1090 1121--*--calculated creatinine clearance",
            "Value 1122 1140--*--at least 60 mL/min",
            "Measurement 1146 1149--*--ECG",
            "Value 1153 1159--*--normal",
            "Negation 1170 1172--*--no",
            "Condition 1173 1203--*--non-healing wounds on the body",
            "Scope 1032 1140--*--serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min",
            "Scope 816 1002--*--total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)",
            "Drug 1245 1261--*--anticancer drugs",
            "Negation 1213 1225--*--not received",
            "Condition 1297 1318--*--non-metastatic tumors",
            "Qualifier 1331 1342--*--neoadjuvant",
            "Qualifier 1319 1327--*--adjuvant",
            "Procedure 1343 1355--*--chemotherapy",
            "Scope 1319 1342--*--adjuvant or neoadjuvant",
            "Temporal 1399 1423--*--ended more than 6 months",
            "Temporal 1288 1296--*--previous",
            "Non-representable 1429 1561--*--have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered",
            "Pregnancy_considerations 1567 1904--*--have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);",
            "Non-query-able 2032 2056--*--signed informed consent.",
            "Non-representable 1909 2027--*--previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;",
            "Line 2028 2056--*--15) signed informed consent.",
            "Line 1905 2027--*--14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;",
            "Line 1567 1904--*--have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);",
            "Line 1425 1562--*--12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered;",
            "Line 1205 1423--*--11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months",
            "Line 1146 1204--*--ECG is normal, there is no non-healing wounds on the body;",
            "Line 1007 1141--*--adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min;",
            "Line 791 1002--*--adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)",
            "Line 634 786--*--adequate hematological function: absolute neutrophil count (ANC) at least 2\u00d710^9/L and platelet count at least 100\u00d710^9/L and hemoglobin at least 9 g/dL",
            "Line 594 630--*--expected survival at least 3 months;",
            "Line 535 589--*--Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1",
            "Line 323 530--*--have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm)",
            "Line 165 318--*--According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection",
            "Line 3 161--*--histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative;"
        ],
        "Text": "1) histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative; 2) According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2\u00d710^9/L and platelet count at least 100\u00d710^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose); 14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions; 15) signed informed consent.. "
    },
    "NCT03100513_inc": {
        "Text": "Adult Patients with Overt Hepatic Encephalopathy.. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Condition 20 48--*--Overt Hepatic Encephalopathy"
        ]
    },
    "NCT02621489_inc": {
        "Annotations": [
            "Procedure 22 25--*--PCI",
            "Procedure 46 49--*--DES",
            "Condition 58 61--*--ACS",
            "Condition 103 106--*--T2D",
            "Person 210 214--*--Male",
            "Person 219 225--*--female",
            "Person 241 246--*--years",
            "Value 235 240--*--18-80",
            "Measurement 249 254--*--HbA1c",
            "Value 277 303--*--47 mmol/mol - 110 mmol/mol",
            "Informed_consent 306 334--*--Signed informed consent form"
        ],
        "Text": "Patients eligible for PCI with application of DES, due to ACS.. Patients with known or newly diagnosed T2D (type 2 diabetes is diagnosed according to current WHO criteria or by the use of anti-diabetic drugs). Male and female subjects 18-80 years.. HbA1c (accordingly to IFCC) 47 mmol/mol - 110 mmol/mol.. Signed informed consent form.. "
    },
    "NCT02570321_exc": {
        "Annotations": [
            "Condition 12 33--*--concomitant infection",
            "Condition 136 147--*--perforation",
            "Condition 164 185--*--Involvement of sclera",
            "Condition 221 241--*--autoimmune keratitis",
            "Condition 203 217;232 241--*--Non-infectious keratitis",
            "Procedure 254 277--*--corneal transplantation",
            "Procedure 288 307--*--intraocular surgery",
            "Negation 309 311--*--No",
            "Condition 312 328--*--light perception",
            "Measurement 350 371--*--Pinhole visual acuity",
            "Value 372 389--*--worse than 20/200",
            "Condition 454 474--*--cognitively impaired"
        ],
        "Text": "Evidence of concomitant infection on exam or gram stain (i.e. herpes, both bacteria and acanthamoeba on gram stain). Impending or frank perforation at recruitment. Involvement of sclera at presentation. Non-infectious or autoimmune keratitis. History of corneal transplantation or recent intraocular surgery. No light perception in the affected eye. Pinhole visual acuity worse than 20/200 in the unaffected eye. Participants who are decisionally and/or cognitively impaired. "
    },
    "NCT01665417_inc": {
        "Annotations": [
            "Condition 27 46--*--lung adenocarcinoma",
            "Procedure 0 10--*--Pathologic",
            "Value 11 23--*--confirmation",
            "Qualifier 47 70--*--with measurable disease",
            "Multiplier 83 95--*--at least one",
            "Condition 96 102--*--lesion",
            "Qualifier 108 160--*--can be accurately measured in at least one dimension",
            "Qualifier 232 241--*--untreated",
            "Qualifier 242 258--*--locally advanced",
            "Qualifier 262 272--*--metastatic",
            "Condition 273 278--*--NSCLC",
            "Scope 242 272--*--locally advanced or metastatic",
            "Condition 299 310--*--lung cancer",
            "Qualifier 311 315;329 353--*--with EGFR activating mutation",
            "Condition 355 371--*--exon 19 deletion",
            "Condition 373 378--*--L858R",
            "Scope 355 378--*--exon 19 deletion, L858R",
            "Scope 27 70--*--lung adenocarcinoma with measurable disease",
            "Line 0 200--*--Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT)",
            "Line 202 278--*--Patients must have previously untreated locally advanced or metastatic NSCLC",
            "Line 280 380--*--Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R)."
        ],
        "Text": "Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT); Patients must have previously untreated locally advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).. "
    },
    "NCT00926523_exc": {
        "Text": "Subject are pregnant . Subject is unable to perform tasks associated with study       .     . ",
        "Annotations": [
            "Condition 12 20--*--pregnant",
            "Post-eligibility 22 78--*--Subject is unable to perform tasks associated with study"
        ]
    },
    "NCT02789111_exc": {
        "Annotations": [
            "Multiplier 0 21--*--More than three doses",
            "Drug 29 35--*--opioid",
            "Temporal 36 62--*--within one week of surgery",
            "Reference_point 55 62--*--surgery",
            "Condition 64 73--*--Pregnancy",
            "Person 75 84--*--Prisoners",
            "Informed_consent 86 111--*--Unable to provide consent",
            "Procedure 113 130--*--Emergency surgery",
            "Condition 132 154--*--Chronic kidney disease",
            "Qualifier 155 162--*--stage 5",
            "Measurement 164 167--*--GFR",
            "Value 168 180--*--< 15 ml/min)",
            "Condition 189 207--*--hepatic impairment",
            "Qualifier 182 188--*--Severe",
            "Condition 216 237--*--myocardial infarction",
            "Temporal 246 263--*--the last 3 months"
        ],
        "Text": "More than three doses of any opioid within one week of surgery. Pregnancy. Prisoners. Unable to provide consent. Emergency surgery. Chronic kidney disease stage 5 (GFR < 15 ml/min). Severe hepatic impairment. Recent myocardial infarction (within the last 3 months). "
    },
    "NCT02589691_exc": {
        "Text": "contra-indication to inhalational induction (full stomach). contra-indication to the use of rocuronium. American Society of Anesthesiologists score (ASA) III or IV. intracranial surgery. parental refusal. absence of affiliation to social security. ",
        "Annotations": [
            "Condition 0 17--*--contra-indication",
            "Procedure 21 43--*--inhalational induction",
            "Qualifier 45 57--*--full stomach",
            "Condition 60 77--*--contra-indication",
            "Drug 92 102--*--rocuronium",
            "Measurement 104 153--*--American Society of Anesthesiologists score (ASA)",
            "Value 154 157--*--III",
            "Value 161 163--*--IV",
            "Scope 154 163--*--III or IV",
            "Procedure 165 185--*--intracranial surgery",
            "Informed_consent 187 203--*--parental refusal",
            "Observation 216 246--*--affiliation to social security",
            "Negation 205 212--*--absence"
        ]
    },
    "NCT03119766_exc": {
        "Annotations": [
            "Condition 0 16--*--Organic diseases",
            "Qualifier 24 40--*--digestive system",
            "Condition 42 82--*--gastro-oesophageal reflux disease (GERD)",
            "Condition 84 89--*--ulcer",
            "Condition 91 111--*--chronic pancreatitis",
            "Condition 113 127--*--cholelithiasis",
            "Condition 129 148--*--fatty liver disease",
            "Condition 150 159--*--hepatitis",
            "Condition 161 179--*--cirrhosis of liver",
            "Scope 42 179--*--gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver",
            "Scope 0 40--*--Organic diseases of the digestive system",
            "Condition 209 228--*--functional diseases",
            "Qualifier 236 252--*--digestive system",
            "Scope 209 252--*--functional diseases of the digestive system",
            "Condition 262 287--*--dyskinesia of cystic duct",
            "Condition 262 275;291 302--*--dyskinesia of gallbladder",
            "Condition 304 328--*--irritable bowel syndrome",
            "Scope 262 328--*--dyskinesia of cystic duct or gallbladder, irritable bowel syndrome",
            "Drug 355 377--*--proton pump inhibitors",
            "Drug 379 390--*--propulsives",
            "Drug 392 406--*--antispasmodics",
            "Drug 408 416--*--antacids",
            "Drug 421 441--*--bismuth preparations",
            "Observation 336 351--*--Discontinuation",
            "Temporal 442 481--*--less than 7 days prior to randomization",
            "Scope 355 441--*--proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations",
            "Procedure 484 505--*--H. Pylori eradication",
            "Temporal 506 540--*--within 2 months before study entry",
            "Reference_point 529 540--*--study entry",
            "Reference_point 468 481--*--randomization",
            "Condition 543 563--*--Intestinal infection",
            "Temporal 564 598--*--within 2 months before study entry",
            "Reference_point 587 598--*--study entry",
            "Observation 607 617--*--history of",
            "Mood 618 627--*--suspected",
            "Condition 628 646--*--malignant neoplasm",
            "Qualifier 650 663--*--various sites",
            "Scope 607 627--*--history of/suspected",
            "Condition 696 718--*--cardiovascular disease",
            "Measurement 737 763--*--New York Heart Association",
            "Value 687 695--*--class IV",
            "Condition 772 786--*--hypothyroidism",
            "Condition 788 805--*--diabetes mellitus",
            "Condition 807 829--*--chronic kidney disease",
            "Measurement 831 832--*--\u0421",
            "Value 832 835--*--3-5",
            "Condition 841 857--*--disease of liver",
            "Condition 863 882--*--portal hypertension",
            "Condition 890 911--*--severe decompensation",
            "Scope 841 882--*--disease of liver with portal hypertension",
            "Measurement 913 929--*--Child-Pugh score",
            "Value 930 933--*--> 6",
            "Scope 913 933--*--Child-Pugh score > 6",
            "Temporal 950 960--*--coexisting",
            "Condition 961 970--*--morbidity",
            "Non-query-able 978 1064--*--in the investigator's opinion, can prevent the patient from participating in the study",
            "Condition 1067 1074--*--Allergy",
            "Condition 1075 1086--*--intolerance",
            "Drug 1101 1148--*--components of medications used in the treatment",
            "Scope 1067 1086--*--Allergy/intolerance",
            "Condition 1151 1160--*--Pregnancy",
            "Observation 1162 1176--*--breast-feeding",
            "Non-representable 1179 1351--*--Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the investigational drugs.",
            "Mood 1353 1360--*--Planned",
            "Procedure 1361 1376--*--hospitalization",
            "Temporal 1377 1400--*--during the study period",
            "Procedure 1424 1444--*--treatment procedures",
            "Procedure 1410 1420;1434 1444--*--diagnostic procedures",
            "Scope 1410 1444--*--diagnostic or treatment procedures",
            "Condition 1447 1461--*--Drug addiction",
            "Measurement 1463 1474--*--alcohol use",
            "Value 1489 1518--*--over 2 units of alcohol a day",
            "Condition 1520 1535--*--mental diseases",
            "Drug 1548 1557--*--medicines",
            "Qualifier 1558 1614--*--listed in the section 'Prohibited concomitant treatment'",
            "Temporal 1619 1663--*--1 month prior to the enrollment in the trial",
            "Reference_point 1636 1663--*--the enrollment in the trial",
            "Competing_trial 1666 1753--*--Participation in other clinical trials within 3 months to the enrollment in this study.",
            "Non-representable 1755 2070--*--Patient is related to the research staff of the clinical investigative site who are directly involved in the trial or is the immediate family member of the investigator. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.",
            "Person 2080 2123--*--works for OOO \"NPF \"MATERIA MEDICA HOLDING\"",
            "Person 2138 2156--*--company's employee",
            "Person 2158 2183--*--temporary contract worker",
            "Person 2187 2205--*--appointed official",
            "Observation 2206 2273--*--responsible for carrying out the research or their immediate family",
            "Scope 2138 2273--*--company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family"
        ],
        "Text": "Organic diseases of the digestive system (gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver, etc.) .. Diagnosis of other functional diseases of the digestive system, such as dyskinesia of cystic duct or gallbladder, irritable bowel syndrome, etc.. Discontinuation of proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations less than 7 days prior to randomization.. H. Pylori eradication within 2 months before study entry.. Intestinal infection within 2 months before study entry.. Known history of/suspected malignant neoplasm of various sites.. Prior diagnosis of a class IV cardiovascular disease (according to the New York Heart Association, 1964), hypothyroidism, diabetes mellitus, chronic kidney disease (\u04213-5), or disease of liver with portal hypertension and/or severe decompensation (Child-Pugh score > 6).. Other severe coexisting morbidity which, in the investigator's opinion, can prevent the patient from participating in the study.. Allergy/intolerance to any of the components of medications used in the treatment.. Pregnancy, breast-feeding.. Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the investigational drugs.. Planned hospitalization during the study period, for any diagnostic or treatment procedures.. Drug addiction, alcohol use in the amount over 2 units of alcohol a day, mental diseases.. Intake of medicines listed in the section 'Prohibited concomitant treatment' for 1 month prior to the enrollment in the trial.. Participation in other clinical trials within 3 months to the enrollment in this study.. Patient is related to the research staff of the clinical investigative site who are directly involved in the trial or is the immediate family member of the investigator. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.. Patient works for OOO \"NPF \"MATERIA MEDICA HOLDING\" (i.e., is the company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family).. "
    },
    "NCT02609048_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 109 111--*--2.",
            "Parsing_Error 144 146--*--3.",
            "Parsing_Error 522 524--*--4.",
            "Parsing_Error 594 596--*--5.",
            "Parsing_Error 614 616--*--6.",
            "Post-eligibility 3 107--*--Must have given written informed consent (signed and dated) and any authorizations required by local law",
            "Value 112 142--*--18 to 75 years old (inclusive)",
            "Person 121 130--*--years old",
            "Person 147 151--*--Male",
            "Person 155 161--*--female",
            "Condition 182 185--*--PBC",
            "Multiplier 190 202--*--at least two",
            "Parsing_Error 210 228--*--following criteria",
            "Measurement 210 228--*--following criteria",
            "Measurement 280 331--*--Positive Anti-Mitochondrial Antibodies (AMA) titers",
            "Value 333 338--*-->1/40",
            "Measurement 342 360--*--immunofluorescence",
            "Value 364 375--*--M2 positive",
            "Measurement 379 420--*--enzyme linked immunosorbent assay (ELISA)",
            "Measurement 433 468--*--PBC-specific antinuclear antibodies",
            "Value 424 432--*--positive",
            "Scope 333 468--*-->1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies",
            "Measurement 242 244--*--AP",
            "Value 245 254--*--above ULN",
            "Temporal 255 278--*--for at least six months",
            "Procedure 481 493--*--liver biopsy",
            "Condition 517 520--*--PBC",
            "Qualifier 530 536;553 557--*--stable dose",
            "Qualifier 541 557--*--recommended dose",
            "Drug 561 565--*--UDCA",
            "Temporal 566 592--*--for the past twelve months",
            "Measurement 597 599--*--AP",
            "Value 600 612--*--\u2265 1.67 \u00d7 ULN",
            "Condition 632 654--*--reproductive potential",
            "Person 621 628--*--females",
            "Multiplier 663 675--*--at least one",
            "Device 676 697--*--barrier contraceptive",
            "Qualifier 704 710--*--second",
            "Device 721 741--*--birth control method",
            "Qualifier 711 720--*--effective",
            "Subjective_judgement 711 720--*--effective",
            "Temporal 742 758--*--during the study",
            "Temporal 763 805--*--for at least two weeks after the last dose",
            "Reference_point 792 805--*--the last dose",
            "Scope 621 654--*--females of reproductive potential",
            "Scope 663 805--*--at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose",
            "Person 811 815--*--male",
            "Device 845 858--*--contraception",
            "Device 866 873--*--condoms",
            "Qualifier 833 844--*--appropriate",
            "Subjective_judgement 833 844--*--appropriate",
            "Person 885 891--*--female",
            "Condition 904 926--*--reproductive potential",
            "Condition 941 949--*--pregnant",
            "Negation 930 940--*--not become",
            "Temporal 950 966--*--during the study",
            "Temporal 971 1013--*--for at least two weeks after the last dose",
            "Reference_point 1000 1013--*--the last dose",
            "Post-eligibility 807 1013--*--For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose",
            "Non-query-able 807 1013--*--For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose"
        ],
        "Text": "1. Must have given written informed consent (signed and dated) and any authorizations required by local law . 2. 18 to 75 years old (inclusive) . 3. Male or female with a diagnosis of PBC, by at least two of the following criteria: . History of AP above ULN for at least six months . Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies . Documented liver biopsy result consistent with PBC . 4. On a stable and recommended dose of UDCA for the past twelve months . 5. AP \u2265 1.67 \u00d7 ULN . 6. For females of reproductive potential, use of at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose. For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose . "
    },
    "NCT02924870_exc": {
        "Text": "osteoarticular, neuromuscular or cognitive limitation that prevents ambulation. previous diagnosis of active neoplastic disease. institutionalized patients; alcohol consumption >60 g/day. patient belonging to another health sector in the Community of Madrid or other community. participation in another study within 6 months prior.. ",
        "Annotations": [
            "Observation 0 14;43 53--*--osteoarticular limitation",
            "Observation 16 29;43 53--*--neuromuscular limitation",
            "Observation 33 53--*--cognitive limitation",
            "Negation 59 67--*--prevents",
            "Observation 68 78--*--ambulation",
            "Condition 109 127--*--neoplastic disease",
            "Person 129 146--*--institutionalized",
            "Observation 157 176--*--alcohol consumption",
            "Multiplier 177 186--*-->60 g/day",
            "Non-query-able 188 276--*--patient belonging to another health sector in the Community of Madrid or other community",
            "Competing_trial 278 331--*--participation in another study within 6 months prior."
        ]
    },
    "NCT02528136_inc": {
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Condition 8 16--*--pregnant",
            "Person 17 22--*--women",
            "Person 23 26--*--age",
            "Value 27 35--*--18 to 50",
            "Condition 37 56--*--Singleton pregnancy",
            "Measurement 60 75--*--gestational age",
            "Value 76 92--*--36 weeks or more",
            "Observation 94 131--*--Able to read and understand Norwegian"
        ],
        "Text": "Healthy pregnant women age 18 to 50. Singleton pregnancy at gestational age 36 weeks or more. Able to read and understand Norwegian.. "
    },
    "NCT02137538_inc": {
        "Annotations": [
            "Temporal 0 7--*--Current",
            "Measurement 8 14--*--height",
            "Value 15 39--*--less than 5th percentile",
            "Non-representable 40 46--*--AND/OR",
            "Measurement 48 70--*--Predicted adult height",
            "Qualifier 81 89--*--bone age",
            "Value 91 126--*--more than 10 cm below target height",
            "Qualifier 128 147--*--mid parental height",
            "Observation 150 169--*--Evidence of puberty",
            "Measurement 190 215--*--serum luteinizing hormone",
            "Condition 171 185--*--physical signs",
            "Value 216 226--*--> 0.3 IU/L",
            "Measurement 231 243--*--testosterone",
            "Value 244 254--*--> 15 ng/dl",
            "Scope 171 254--*--physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl"
        ],
        "Text": "Current height less than 5th percentile AND/OR. Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height). Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl. "
    },
    "NCT03420638_exc": {
        "Annotations": [
            "Qualifier 12 18--*--severe",
            "Condition 19 35--*--systemic disease",
            "Condition 49 70--*--coagulation disorders",
            "Temporal 72 79--*--Current",
            "Temporal 83 91--*--previous",
            "Observation 92 99--*--history",
            "Scope 72 91--*--Current or previous",
            "Condition 103 123--*--analgesic dependence",
            "Drug 103 112--*--analgesic",
            "Condition 125 132--*--Allergy",
            "Drug 147 170--*--drugs used in the study",
            "Person 172 177--*--Women",
            "Condition 178 186--*--pregnant",
            "Condition 190 199--*--lactating",
            "Person 204 209--*--women",
            "Mood 210 228--*--planning to become",
            "Condition 229 237--*--pregnant",
            "Condition 251 263--*--hearing loss",
            "Condition 277 305--*--cardiovascular comorbidities",
            "Condition 388 410--*--cognitive disabilities",
            "Condition 354 374--*--kidney comorbidities",
            "Condition 319 340--*--hepatic comorbidities"
        ],
        "Text": "Presence of severe systemic disease. Presence of coagulation disorders. Current or previous history of analgesic dependence. Allergy to any of the drugs used in the study. Women pregnant or lactating, or women planning to become pregnant. Presence of hearing loss. Presence of cardiovascular comorbidities. Presence of hepatic comorbidities. Presence of kidney comorbidities. Presence of cognitive disabilities. "
    },
    "NCT02550080_inc": {
        "Text": "Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration.. Subjects are dapsone-naive.. All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study.. All subjects are willing to complete the 6-weeks period clinical trial.. All subjects are written informed consent.. ",
        "Annotations": [
            "Condition 15 35--*--cutaneous vasculitis",
            "Condition 37 46--*--urticaria",
            "Condition 48 57--*--psoriasis",
            "Condition 59 63--*--acne",
            "Condition 65 86--*--bullous skin diseases",
            "Condition 88 106--*--sterile pustulosis",
            "Condition 108 115--*--leprosy",
            "Condition 117 139--*--pneumocystis pneumonia",
            "Drug 172 179--*--dapsone",
            "Drug 210 217--*--dapsone",
            "Negation 218 223--*--naive",
            "Non-query-able 226 346--*--All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study",
            "Post-eligibility 349 419--*--All subjects are willing to complete the 6-weeks period clinical trial",
            "Informed_consent 422 463--*--All subjects are written informed consent"
        ]
    },
    "NCT03119766_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 8 13--*--women",
            "Person 14 18--*--aged",
            "Value 19 30--*--18-45 years",
            "Condition 46 66--*--functional dyspepsia",
            "Measurement 81 104--*--Rome IV criteria (2016)",
            "Measurement 107 116--*--GIS score",
            "Value 120 130--*--at least 6",
            "Measurement 142 156--*--H. pylori test",
            "Value 133 141--*--Negative",
            "Post-eligibility 160 274--*--Availability of a signed patient information sheet (Informed Consent form) for participation in the clinical trial",
            "Pregnancy_considerations 277 370--*--Patients who agree to use an effective method of contraception throughout the clinical trial."
        ],
        "Text": "Men and women aged 18-45 years.. Diagnosis of functional dyspepsia, based on the Rome IV criteria (2016).. GIS score of at least 6.. Negative H. pylori test .. Availability of a signed patient information sheet (Informed Consent form) for participation in the clinical trial.. Patients who agree to use an effective method of contraception throughout the clinical trial.. "
    },
    "NCT02589691_inc": {
        "Text": "age <2 years. indication of general anesthesia with tracheal intubation. inhalational induction scheduled. written informed consent of both parents. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 12--*--<2 years",
            "Procedure 28 46--*--general anesthesia",
            "Procedure 52 71--*--tracheal intubation",
            "Mood 14 24--*--indication",
            "Procedure 73 95--*--inhalational induction",
            "Mood 96 105--*--scheduled",
            "Informed_consent 107 147--*--written informed consent of both parents"
        ]
    },
    "NCT00926523_inc": {
        "Text": "Subject are at least 18 years of age . Subject has confirmed Pulmonary Hypertension and Interstitial Lung Disease . Subject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test. . ",
        "Annotations": [
            "Value 12 29--*--at least 18 years",
            "Person 33 36--*--age",
            "Condition 60 82--*--Pulmonary Hypertension",
            "Condition 87 112--*--Interstitial Lung Disease",
            "Mood 50 59--*--confirmed",
            "Procedure 185 208--*--Pulmonary Exercise test",
            "Procedure 169 179--*--spirometry",
            "Procedure 143 159--*--study procedures",
            "Undefined_semantics 143 159--*--study procedures",
            "Scope 169 208--*--spirometry, and Pulmonary Exercise test"
        ]
    },
    "NCT02789111_inc": {
        "Annotations": [
            "Procedure 0 19--*--Major spine surgery",
            "Person 62 67--*--years",
            "Value 56 61--*--18-80"
        ],
        "Text": "Major spine surgery scheduled as part of clinical care. 18-80 years. "
    },
    "NCT02924870_inc": {
        "Text": "subjects older than 35 years. diagnosis of moderate to very severe COPD (FEV1 <80% predicted), according to the GesEPOC criteria, established at least 3 months. current or former smoker with an accumulated consumption >10 packs x year. hospital admission for COPD exacerbation. ",
        "Annotations": [
            "Person 23 28--*--years",
            "Value 9 22--*--older than 35",
            "Condition 67 71--*--COPD",
            "Qualifier 43 51--*--moderate",
            "Qualifier 55 66--*--very severe",
            "Measurement 73 77--*--FEV1",
            "Value 78 92--*--<80% predicted",
            "Measurement 112 129--*--GesEPOC criteria,",
            "Temporal 142 159--*--at least 3 months",
            "Scope 43 66--*--moderate to very severe",
            "Person 179 185--*--smoker",
            "Observation 206 217--*--consumption",
            "Multiplier 218 234--*-->10 packs x year",
            "Visit 245 254--*--admission",
            "Condition 259 276--*--COPD exacerbation"
        ]
    },
    "NCT02609048_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 182 184--*--2.",
            "Parsing_Error 207 209--*--3.",
            "Parsing_Error 237 239--*--4.",
            "Parsing_Error 263 265--*--5.",
            "Parsing_Error 298 300--*--6.",
            "Parsing_Error 350 352--*--7.",
            "Parsing_Error 395 397--*--8.",
            "Parsing_Error 425 427--*--9.",
            "Parsing_Error 456 459--*--10.",
            "Parsing_Error 502 505--*--11.",
            "Parsing_Error 613 616--*--12.",
            "Parsing_Error 682 685--*--13.",
            "Parsing_Error 728 731--*--14.",
            "Parsing_Error 785 788--*--15.",
            "Condition 5 22--*--medical condition",
            "Condition 35 38--*--PBC",
            "Negation 24 34--*--other than",
            "Subjective_judgement 45 74--*--in the investigator's opinion",
            "Non-query-able 3 180--*--A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)",
            "Post-eligibility 3 180--*--A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)",
            "Measurement 185 188--*--AST",
            "Measurement 192 195--*--ALT",
            "Value 196 205--*--> 3 \u00d7 ULN",
            "Measurement 210 225--*--Total bilirubin",
            "Value 226 235--*--> 2 \u00d7 ULN",
            "Condition 240 261--*--Auto-immune hepatitis",
            "Condition 266 296--*--Primary sclerosing cholangitis",
            "Condition 318 348--*--alpha-1-Antitrypsin deficiency",
            "Observation 307 314--*--history",
            "Condition 378 393--*--viral hepatitis",
            "Temporal 370 377--*--chronic",
            "Observation 359 366--*--history",
            "Measurement 398 413--*--Creatine kinase",
            "Value 414 423--*--above ULN",
            "Measurement 428 444--*--Serum creatinine",
            "Value 445 454--*--above ULN",
            "Person 464 471--*--females",
            "Condition 473 482--*--pregnancy",
            "Condition 486 500--*--breast-feeding",
            "Scope 473 500--*--pregnancy or breast-feeding",
            "Drug 513 523--*--colchicine",
            "Drug 525 537--*--methotrexate",
            "Drug 539 551--*--azathioprine",
            "Drug 556 573--*--systemic steroids",
            "Temporal 574 611--*--in the two months preceding screening",
            "Reference_point 602 611--*--screening",
            "Scope 513 573--*--colchicine, methotrexate, azathioprine, or systemic steroids",
            "Drug 632 640--*--fibrates",
            "Temporal 617 624--*--Current",
            "Drug 652 664--*--fenofibrates",
            "Drug 669 680--*--simvastatin",
            "Scope 632 680--*--fibrates, including fenofibrates, or simvastatin",
            "Procedure 696 726--*--experimental treatment for PBC",
            "Undefined_semantics 696 726--*--experimental treatment for PBC",
            "Context_Error 696 726--*--experimental treatment for PBC",
            "Drug 766 783--*--immunosuppressant",
            "Qualifier 755 765--*--unapproved",
            "Qualifier 739 751--*--experimental",
            "Scope 739 765--*--experimental or unapproved",
            "Undefined_semantics 739 765--*--experimental or unapproved",
            "Context_Error 739 765--*--experimental or unapproved",
            "Non-query-able 789 938--*--Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator",
            "Context_Error 789 938--*--Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator",
            "Post-eligibility 789 938--*--Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator",
            "Subjective_judgement 789 938--*--Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator"
        ],
        "Text": "1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment) . 2. AST or ALT > 3 \u00d7 ULN . 3. Total bilirubin > 2 \u00d7 ULN . 4. Auto-immune hepatitis . 5. Primary sclerosing cholangitis . 6. Known history of alpha-1-Antitrypsin deficiency . 7. Known history of chronic viral hepatitis . 8. Creatine kinase above ULN . 9. Serum creatinine above ULN . 10. For females, pregnancy or breast-feeding . 11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening . 12. Current use of fibrates, including fenofibrates, or simvastatin . 13. Use of an experimental treatment for PBC . 14. Use of experimental or unapproved immunosuppressant . 15. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator       .     . "
    },
    "NCT02137538_exc": {
        "Annotations": [
            "Measurement 0 8--*--Bone age",
            "Value 17 37--*--more than 14.0 years",
            "Measurement 39 67--*--Follicle stimulating hormone",
            "Value 68 77--*--> 20 IU/L"
        ],
        "Text": "Bone age reading more than 14.0 years. Follicle stimulating hormone > 20 IU/L. "
    },
    "NCT02528136_exc": {
        "Annotations": [
            "Condition 14 32--*--placenta pathology",
            "Condition 41 48--*--praevia",
            "Condition 50 56--*--acreta",
            "Condition 58 71--*--pre-eclampsia",
            "Scope 41 71--*--praevia, acreta, pre-eclampsia",
            "Condition 87 105--*--bleeding disorders",
            "Condition 116 144--*--vonWillebrand disease type I",
            "Condition 153 164--*--intolerance",
            "Multiplier 168 182--*--one of the two",
            "Drug 183 188--*--drugs",
            "Condition 205 222--*--prolonged QT-time",
            "Qualifier 226 231--*--other",
            "Condition 232 256--*--serious cardiac diseases",
            "Condition 259 264;275 282--*--Liver failure",
            "Condition 268 282--*--kidney failure",
            "Condition 285 293--*--Epilepsy",
            "Post-eligibility 296 390--*--Any medical reason why, in the opinion of the investigator, the patient should not participate"
        ],
        "Text": "Patients with placenta pathology such as praevia, acreta, pre-eclampsia. Patients with bleeding disorders including vonWillebrand disease type I.. Known intolerance to one of the two drugs.. Patients with prolonged QT-time or other serious cardiac diseases.. Liver or kidney failure.. Epilepsy.. Any medical reason why, in the opinion of the investigator, the patient should not participate. "
    },
    "NCT02550080_exc": {
        "Text": "Has previously received Dapsone therapy.. The subject or any of their healthcare providers is aware of the subjects HLA type.. Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin reductase deficiency. Satisfies any contraindications or restrictions to Dapsone therapy as listed in the product labels.. Current severe illness, including heart, liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.. Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al).. Pregnant women or women who are breastfeeding.. Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.. A positive result for HLA-B*1301 in those subjects randomised to the genetic screening arm.. ",
        "Annotations": [
            "Drug 24 31--*--Dapsone",
            "Non-query-able 42 124--*--The subject or any of their healthcare providers is aware of the subjects HLA type",
            "Condition 151 195--*--Glucose-6-phosphate dehydrogenase deficiency",
            "Condition 199 233--*--methemoglobin reductase deficiency",
            "Condition 249 266--*--contraindications",
            "Drug 286 293--*--Dapsone",
            "Condition 387 400--*--renal failure",
            "Condition 377 382;393 400--*--liver failure",
            "Condition 370 375;393 400--*--heart failure",
            "Condition 402 423--*--major organ allograft",
            "Condition 425 435--*--malignancy",
            "Procedure 457 469--*--chemotherapy",
            "Non-query-able 647 866--*--Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al)",
            "Pregnancy_considerations 870 914--*--regnant women or women who are breastfeeding",
            "Non-query-able 917 1049--*--Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required",
            "Measurement 1074 1084--*--HLA-B*1301",
            "Value 1054 1062--*--positive"
        ]
    },
    "NCT03420638_inc": {
        "Annotations": [
            "Mood 0 20--*--Scheduled to undergo",
            "Qualifier 21 30--*--bilateral",
            "Procedure 31 53--*--palatine tonsillectomy",
            "Multiplier 61 75--*--only procedure",
            "Procedure 66 75--*--procedure"
        ],
        "Text": "Scheduled to undergo bilateral palatine tonsillectomy as the only procedure. "
    },
    "NCT01581749_exc": {
        "Text": "implanted hardware or other material that would prohibit treatment planning or delivery. chemotherapy for a malignancy within the previous 5 years. history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years. hormone ablation for 2 months prior to treatment or during treatment. ",
        "Annotations": [
            "Non-query-able 0 87--*--implanted hardware or other material that would prohibit treatment planning or delivery",
            "Procedure 89 101--*--chemotherapy",
            "Condition 108 118--*--malignancy",
            "Temporal 119 146--*--within the previous 5 years",
            "Condition 162 181--*--invasive malignancy",
            "Negation 183 193--*--other than",
            "Condition 199 214--*--prostate cancer",
            "Condition 227 248--*--squamous skin cancers",
            "Condition 218 223;236 248--*--basal skin cancers",
            "Scope 199 248--*--prostate cancer,or basal or squamous skin cancers",
            "Temporal 250 270--*--within prior 5 years",
            "Scope 162 248--*--invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers",
            "Procedure 272 288--*--hormone ablation",
            "Temporal 289 320--*--for 2 months prior to treatment",
            "Reference_point 311 320--*--treatment",
            "Temporal 324 340--*--during treatment",
            "Reference_point 331 340--*--treatment",
            "Scope 289 340--*--for 2 months prior to treatment or during treatment"
        ]
    },
    "NCT02933671_exc": {
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 10--*--4 or 5",
            "Procedure 12 37--*--revision hip arthroplasty",
            "Condition 52 64--*--chronic pain",
            "Drug 80 86--*--opioid",
            "Qualifier 72 79--*--chronic",
            "Temporal 92 105--*--over 3 months",
            "Post-eligibility 133 191--*--inability to communicate pain scores or need for analgesia",
            "Condition 199 211--*--hip fracture",
            "Qualifier 193 198--*--acute",
            "Condition 213 222--*--Infection",
            "Qualifier 230 253--*--site of block placement",
            "Person 255 258--*--Age",
            "Value 259 306--*--under 18 years old or greater than 75 years old",
            "Pregnancy_considerations 308 322--*--Pregnant women",
            "Condition 324 335--*--Intolerance",
            "Condition 336 343--*--allergy",
            "Drug 347 364--*--local anesthetics",
            "Scope 324 343--*--Intolerance/allergy",
            "Person 366 372--*--Weight",
            "Value 373 379--*--<50 kg",
            "Condition 417 422--*--abuse",
            "Condition 401 410--*--addiction",
            "Qualifier 443 464--*--prescription medicine",
            "Qualifier 472 479--*--alcohol",
            "Qualifier 426 438--*--illicit drug",
            "Scope 426 479--*--illicit drug(s), prescription medicine(s), or alcohol",
            "Scope 401 422--*--addiction to or abuse",
            "Temporal 491 503--*--past 2 years",
            "Condition 519 526--*--anxiety",
            "Condition 528 541--*--schizophrenia",
            "Condition 552 572--*--psychiatric disorder",
            "Non-query-able 667 872--*--Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course"
        ],
        "Text": "ASA 4 or 5. revision hip arthroplasty. diagnosis of chronic pain. daily chronic opioid use (over 3 months of continuous opioid use). inability to communicate pain scores or need for analgesia. acute hip fracture. Infection at the site of block placement. Age under 18 years old or greater than 75 years old. Pregnant women. Intolerance/allergy to local anesthetics. Weight <50 kg. Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course.. "
    },
    "NCT02755701_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 23--*--= 19 and = 70 years",
            "Condition 38 53--*--liver cirrhosis",
            "Measurement 55 68--*--Serum albumin",
            "Value 75 84--*--= 3.5g/dl",
            "Procedure 86 96--*--ultrasound",
            "Procedure 100 107--*--CT scan",
            "Condition 118 125--*--ascites",
            "Qualifier 128 135--*--Grade 1",
            "Scope 86 107--*--ultrasound or CT scan",
            "Negation 138 140--*--No",
            "Drug 159 168--*--diuretics",
            "Drug 173 177--*--BCAA",
            "Scope 159 177--*--diuretics and BCAA",
            "Temporal 189 200--*--past 1 week",
            "Informed_consent 202 246--*--Voluntary consent to take part in this trial"
        ],
        "Text": "Age = 19 and = 70 years;. Presence of liver cirrhosis. Serum albumin level = 3.5g/dl, ultrasound or CT scan confirmed ascites (=Grade 1). No administration of diuretics and BCAA within the past 1 week. Voluntary consent to take part in this trial. "
    },
    "NCT02818816_inc": {
        "Annotations": [
            "Person 0 5--*--Males",
            "Person 6 10--*--aged",
            "Value 11 29--*--18 years and above",
            "Condition 60 79--*--prostatic carcinoma",
            "Procedure 90 106--*--prostate surgery"
        ],
        "Text": "Males aged 18 years and above. Patients with a diagnosis of prostatic carcinoma requiring prostate surgery. "
    },
    "NCT02933671_inc": {
        "Annotations": [
            "Non-query-able 0 16--*--English speaking",
            "Person 42 45--*--old",
            "Value 18 41--*--between 18 and 75 years",
            "Measurement 47 84--*--American Society of Anesthesiologists",
            "Measurement 86 89--*--ASA",
            "Value 91 94--*--1-3",
            "Procedure 115 145--*--primary total hip arthroplasty"
        ],
        "Text": "English speaking. between 18 and 75 years old. American Society of Anesthesiologists (ASA) 1-3 patients undergoing primary total hip arthroplasty. "
    },
    "NCT01581749_inc": {
        "Text": "histologically proven prostate adenocarcinoma within 1 year of enrollment. Low risk: Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0. Intermediate risk:Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0. ECOG Performance Status 0-1. No prior prostate radiation or other definitive therapy. ",
        "Annotations": [
            "Condition 22 45--*--prostate adenocarcinoma",
            "Qualifier 0 21--*--histologically proven",
            "Temporal 46 73--*--within 1 year of enrollment",
            "Reference_point 63 73--*--enrollment",
            "Measurement 85 92--*--Gleason",
            "Observation 75 83--*--Low risk",
            "Value 93 98--*--<or=6",
            "Measurement 101 104--*--PSA",
            "Value 105 111--*--<or=10",
            "Measurement 114 128--*--Clinical Stage",
            "Value 129 136--*--T1b-T2a",
            "Value 147 149--*--Mx",
            "Value 153 155--*--M0",
            "Value 137 139--*--Nx",
            "Value 143 145--*--N0",
            "Scope 129 155--*--T1b-T2a,Nx or N0, Mx or M0",
            "Scope 85 155--*--Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0",
            "Observation 157 174--*--Intermediate risk",
            "Measurement 175 182--*--Gleason",
            "Value 183 188--*--<or=6",
            "Measurement 191 194--*--PSA",
            "Value 194 200--*--<or=10",
            "Measurement 203 217--*--Clinical Stage",
            "Value 218 221--*--T2b",
            "Measurement 225 232--*--Gleason",
            "Value 232 234--*--=7",
            "Measurement 237 240--*--PSA",
            "Value 240 246--*--<or=10",
            "Measurement 249 263--*--Clinical Stage",
            "Value 264 271--*--T1b-T2b",
            "Measurement 275 282--*--Gleason",
            "Value 283 288--*--<or=6",
            "Measurement 291 294--*--PSA",
            "Value 295 310--*--> 10 & < or =20",
            "Measurement 313 327--*--Clinical Stage",
            "Value 328 336--*--T1b- T2b",
            "Value 338 340--*--Nx",
            "Value 344 346--*--NO",
            "Value 348 350--*--Mx",
            "Value 354 356--*--M0",
            "Scope 328 356--*--T1b- T2b, Nx or NO, Mx or M0",
            "Scope 275 356--*--Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0",
            "Scope 175 221--*--Gleason <or=6 & PSA<or=10 & Clinical Stage T2b",
            "Scope 225 271--*--Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b",
            "Scope 175 356--*--Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0",
            "Measurement 358 381--*--ECOG Performance Status",
            "Value 382 385--*--0-1",
            "Procedure 396 414--*--prostate radiation",
            "Negation 387 389--*--No",
            "Procedure 424 442--*--definitive therapy",
            "Scope 396 442--*--prostate radiation or other definitive therapy"
        ]
    },
    "NCT02818816_exc": {
        "Annotations": [
            "Procedure 23 52--*--ophthalmic surgical procedure",
            "Temporal 53 98--*--within 6 months of the beginning of the study",
            "Reference_point 93 98--*--study",
            "Condition 130 138--*--glaucoma",
            "Condition 144 155--*--abnormality",
            "Qualifier 163 169--*--cornea",
            "Condition 226 233--*--allergy",
            "Condition 235 251--*--hypersensitivity",
            "Drug 264 275--*--Brimonidine",
            "Scope 226 251--*--allergy/ hypersensitivity",
            "Condition 277 294--*--Contra-indication",
            "Drug 298 309--*--Brimonidine",
            "Drug 332 360--*--monoamine oxidase inhibitors",
            "Drug 362 365--*--MOA",
            "Informed_consent 368 423--*--Patients unwilling or unable to provide informed consen",
            "Observation 452 479--*--difficult airway management"
        ],
        "Text": "Patients having had an ophthalmic surgical procedure within 6 months of the beginning of the study.. Patients with a diagnosis of glaucoma. Any abnormality of the cornea which may prevent reliable applanation tonometry. Known allergy/ hypersensitivity reaction to Brimonidine. Contra-indication to Brimonidine including patients on monoamine oxidase inhibitors (MOA). Patients unwilling or unable to provide informed consent. Patients with anticipated difficult airway management (as this may require medications and/or airway manipulations resulting in increased IOP). "
    },
    "NCT02755701_exc": {
        "Annotations": [
            "Measurement 0 16--*--Child-Pugh score",
            "Value 17 21--*--> 12",
            "Condition 48 51--*--HCC",
            "Temporal 63 75--*--past 5 years",
            "Measurement 77 93--*--Serum creatinine",
            "Value 94 104--*--> 1.5mg/dl",
            "Measurement 106 121--*--Serum bilirubin",
            "Value 122 131--*--> 5.0mg/d",
            "Condition 151 164--*--complications",
            "Condition 168 171--*--SBP",
            "Condition 176 198--*--hepatic encephalopathy",
            "Measurement 199 215--*--West Haven grade",
            "Value 216 219--*--= 3",
            "Scope 168 220--*--SBP, or hepatic encephalopathy(West Haven grade = 3)",
            "Condition 247 260--*--organ failure",
            "Condition 264 301--*--acute exacerbation of liver cirrhosis",
            "Temporal 313 325--*--past 1 month",
            "Condition 358 377--*--respiratory disease",
            "Condition 347 354;370 377--*--cardiac disease",
            "Scope 347 377--*--cardiac or respiratory disease",
            "Qualifier 339 346--*--serious",
            "Condition 379 394--*--Contraindicated",
            "Drug 405 414--*--diuretics",
            "Drug 418 422--*--BCAA",
            "Scope 405 422--*--diuretics or BCAA",
            "Procedure 441 461--*--anti-viral treatment",
            "Condition 470 481--*--hepatitis C",
            "Condition 470 479;483 484--*--hepatitis B",
            "Scope 470 484--*--hepatitis C, B",
            "Temporal 496 508--*--past 1 month",
            "Pregnancy_considerations 510 537--*--Pregnant or lactating women",
            "Qualifier 539 546--*--Chronic",
            "Person 547 560--*--alcohol taker",
            "Pregnancy_considerations 562 640--*--Woman patients who do not agree to the contraception from baseline to 12 month",
            "Non-query-able 642 684--*--Unsuitable patients judged by investigator",
            "Competing_trial 686 749--*--Patients participating in another clinical trial within 1 month"
        ],
        "Text": "Child-Pugh score > 12. Having been diagnosed as HCC within the past 5 years. Serum creatinine > 1.5mg/dl. Serum bilirubin > 5.0mg/dl. Presence of such complications as SBP, or hepatic encephalopathy(West Haven grade = 3). Patients who experienced organ failure by acute exacerbation of liver cirrhosis within the past 1 month. Presence of serious cardiac or respiratory disease. Contraindicated to either diuretics or BCAA. Having commenced anti-viral treatment against hepatitis C, B within the past 1 month. Pregnant or lactating women. Chronic alcohol taker. Woman patients who do not agree to the contraception from baseline to 12 month. Unsuitable patients judged by investigator. Patients participating in another clinical trial within 1 month. "
    },
    "NCT02340169_inc": {
        "Text": "Patients aged 7 years and older must have provided written assent accompanied by written informed consent from patient's representative. Clinical diagnosis of stable plaque psoriasis with involvement of = 10% body surface area (excluding face and scalp). Physicians Global Assessment score of 3 or 4 at baseline. ",
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 31--*--7 years and older",
            "Post-eligibility 32 135--*--must have provided written assent accompanied by written informed consent from patient's representative",
            "Condition 166 182--*--plaque psoriasis",
            "Qualifier 159 165--*--stable",
            "Measurement 209 226--*--body surface area",
            "Negation 228 237--*--excluding",
            "Condition 238 242--*--face",
            "Condition 247 252--*--scalp",
            "Value 203 208--*--= 10%",
            "Grammar_Error 243 246--*--and",
            "Scope 238 252--*--face and scalp",
            "Measurement 255 289--*--Physicians Global Assessment score",
            "Value 293 294--*--3",
            "Value 298 299--*--4",
            "Temporal 300 311--*--at baseline",
            "Scope 293 299--*--3 or 4"
        ]
    },
    "NCT00730301_exc": {
        "Annotations": [
            "Procedure 6 29--*--endobronchial treatment",
            "Condition 34 43--*--emphysema",
            "Temporal 0 5--*--Prior",
            "Condition 45 52;69 76--*--Pleural disease",
            "Condition 56 76--*--interstitial disease",
            "Procedure 92 99--*--surgery",
            "Scope 45 76--*--Pleural or interstitial disease",
            "Negation 82 91--*--precludes",
            "Qualifier 82 99--*--precludes surgery",
            "Procedure 108 123--*--lung transplant",
            "Temporal 102 107--*--Prior",
            "Procedure 125 129--*--LVRS",
            "Procedure 131 148--*--median sternotomy",
            "Procedure 150 160--*--bullectomy",
            "Procedure 164 173--*--lobectomy",
            "Scope 108 174--*--lung transplant, LVRS, median sternotomy, bullectomy or lobectomy.",
            "Condition 199 213--*--bronchiectasis",
            "Qualifier 176 198--*--Clinically significant",
            "Procedure 242 249--*--surgery",
            "Condition 215 231--*--Pulmonary nodule",
            "Condition 272 294--*--respiratory infections",
            "Multiplier 262 271--*--recurrent",
            "Observation 251 258--*--History",
            "Multiplier 296 299;316 332--*--> 3 in the last year",
            "Procedure 300 315--*--hospitalization",
            "Scope 296 332--*--> 3 hospitalization in the last year",
            "Qualifier 335 357--*--Clinically significant",
            "Multiplier 359 382--*--> 4 Tablespoons per day",
            "Observation 384 401--*--sputum production",
            "Condition 403 408--*--Fever",
            "Measurement 419 435--*--white cell count",
            "Value 410 418--*--elevated",
            "Condition 458 474--*--active infection",
            "Mood 446 454--*--evidence",
            "Condition 476 487--*--Dysrhythmia",
            "Condition 499 510--*--pose a risk",
            "Temporal 511 526--*--during exercise",
            "Reference_point 518 526--*--exercise",
            "Temporal 511 517;530 538--*--during training",
            "Reference_point 530 538--*--training",
            "Scope 511 538--*--during exercise or training",
            "Condition 540 564--*--Congestive heart failure",
            "Temporal 565 576--*--within 6 mo",
            "Measurement 581 585--*--LVEF",
            "Value 586 591--*--< 45%",
            "Condition 616 629--*--Cor Pulmonale",
            "Mood 593 601--*--Evidence",
            "Observation 605 612--*--history",
            "Scope 593 612--*--Evidence or history",
            "Condition 631 650--*--Resting bradycardia",
            "Value 652 666--*--< 50 beats/min",
            "Condition 678 693--*--multifocal PVCs",
            "Multiplier 669 677--*--frequent",
            "Condition 695 725--*--complex ventricular arrhythmia",
            "Condition 727 740--*--sustained SVT",
            "Condition 770 777--*--syncope",
            "Qualifier 753 769--*--exercise-related",
            "Observation 742 749--*--History",
            "Condition 779 781--*--MI",
            "Temporal 782 793--*--within 6 mo",
            "Measurement 798 802--*--LVEF",
            "Value 803 808--*--< 45%",
            "Condition 1136 1166--*--Alpha-1-Antitrypsin Deficiency",
            "Condition 822 838--*--systemic disease",
            "Condition 842 851--*--neoplasia",
            "Qualifier 852 883--*--expected to compromise survival",
            "Scope 822 851--*--systemic disease or neoplasia",
            "Temporal 884 902--*--during 5-yr period",
            "Observation 1019 1053--*--enrolled in another clinical trial",
            "Observation 1066 1084--*--unable to complete",
            "Qualifier 1085 1134--*--3 minutes of unloaded peddling on cycle ergometer",
            "Condition 908 915--*--disease",
            "Condition 919 928--*--condition",
            "Qualifier 934 996--*--interferes with completion of initial or follow-up assessments",
            "Scope 908 928--*--disease or condition",
            "Temporal 1009 1018--*--currently"
        ],
        "Text": "Prior endobronchial treatment for emphysema . Pleural or interstitial disease that precludes surgery. . Prior lung transplant, LVRS, median sternotomy, bullectomy or lobectomy. . Clinically significant bronchiectasis . Pulmonary nodule requiring surgery . History of recurrent respiratory infections (> 3 hospitalization in the last year) . Clinically significant (> 4 Tablespoons per day) sputum production . Fever, elevated white cell count, or other evidence of active infection . Dysrhythmia that might pose a risk during exercise or training . Congestive heart failure within 6 mo and LVEF < 45% . Evidence or history of Cor Pulmonale . Resting bradycardia (< 50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT . History of exercise-related syncope . MI within 6 mo and LVEF < 45% . Evidence of systemic disease or neoplasia expected to compromise survival during 5-yr period . Any disease or condition that interferes with completion of initial or follow-up assessments . Patient is currently enrolled in another clinical trial . Patient is unable to complete 3 minutes of unloaded peddling on cycle ergometer . Alpha-1-Antitrypsin Deficiency       .     . "
    },
    "NCT02951520_exc": {
        "Text": "BMI > 30 kg.m-2,. ASA physical state >II. Allergy to the used local anesthetics. Infection at the injection site. age <18y. ",
        "Annotations": [
            "Measurement 0 3--*--BMI",
            "Value 4 15--*--> 30 kg.m-2",
            "Measurement 18 36--*--ASA physical state",
            "Value 37 40--*-->II",
            "Condition 42 49--*--Allergy",
            "Drug 62 79--*--local anesthetics",
            "Condition 81 90--*--Infection",
            "Qualifier 98 112--*--injection site",
            "Person 114 117--*--age",
            "Value 118 122--*--<18y"
        ]
    },
    "NCT03043495_inc": {
        "Text": "Patients undergoing surgeries in the upper limb (arm, forearm or hand). ",
        "Annotations": [
            "Procedure 20 29--*--surgeries",
            "Qualifier 37 47--*--upper limb",
            "Qualifier 49 52--*--arm",
            "Qualifier 54 61--*--forearm",
            "Qualifier 65 69--*--hand",
            "Scope 49 69--*--arm, forearm or hand"
        ]
    },
    "NCT02150590_inc": {
        "Annotations": [
            "Condition 0 37--*--chronic obstructive pulmonary disease",
            "Condition 39 43--*--COPD",
            "Measurement 46 56--*--GOLD grade",
            "Value 57 60--*--2-3",
            "Non-query-able 62 96--*--residents at low altitude (<800 m)"
        ],
        "Text": "chronic obstructive pulmonary disease (COPD), GOLD grade 2-3. residents at low altitude (<800 m). "
    },
    "NCT02631512_inc": {
        "Text": "Type I or II diabetes mellitus.. Target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old.. Ankle-brachial pressure index above 0.7.. ",
        "Annotations": [
            "Condition 0 4;10 30--*--Type II diabetes mellitus",
            "Condition 0 6;13 30--*--Type I diabetes mellitus",
            "Measurement 33 50--*--Target ulcer area",
            "Value 51 73--*--between 0.5 and 5 sqcm",
            "Temporal 79 100--*--more than 4 weeks old",
            "Measurement 103 132--*--Ankle-brachial pressure index",
            "Value 133 142--*--above 0.7"
        ]
    },
    "NCT01000155_inc": {
        "Annotations": [
            "Condition 13 32--*--sickle cell disease",
            "Mood 0 9--*--Diagnosis",
            "Qualifier 34 56--*--Clinically significant",
            "Condition 34 64--*--Clinically significant disease",
            "Multiplier 103 146;76 86--*--per year averaged over the previous 3 years at least 1",
            "Condition 87 102--*--painful episode",
            "Temporal 126 146--*--the previous 3 years",
            "Qualifier 112 146--*--averaged over the previous 3 years",
            "Observation 152 159--*--history",
            "Condition 163 171--*--priapism",
            "Condition 173 179--*--stroke",
            "Condition 181 201--*--acute chest syndrome",
            "Condition 203 221--*--avascular necrosis",
            "Condition 223 242--*--multi-organ failure",
            "Mood 250 258--*--need for",
            "Multiplier 259 266--*--chronic",
            "Qualifier 259 266--*--chronic",
            "Drug 267 287--*--narcotic medications",
            "Condition 292 296--*--pain",
            "Condition 302 321--*--sickle cell disease",
            "Scope 76 321--*--at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease",
            "Non-representable 323 704--*--Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea",
            "Value 706 714;722 730--*--18 years or older",
            "Person 718 721--*--age",
            "Non-representable 732 789--*--Hematologic laboratory values as outlined in the protocol",
            "Context_Error 732 789--*--Hematologic laboratory values as outlined in the protocol",
            "Context_Error 791 852--*--Non-hematologic laboratory values as outlined in the protocol",
            "Non-representable 791 852--*--Non-hematologic laboratory values as outlined in the protocol",
            "Procedure 872 884--*--donate blood",
            "Negation 865 868--*--not",
            "Mood 854 864;869 871--*--Must agree to",
            "Procedure 872 878;894 906--*--donate bodily fluid",
            "Temporal 907 934--*--while taking the study drug",
            "Reference_point 913 934--*--taking the study drug",
            "Drug 924 934--*--study drug",
            "Temporal 939 961--*--for 28 days thereafter",
            "Scope 907 961--*--while taking the study drug and for 28 days thereafter",
            "Scope 872 906--*--donate blood or other bodily fluid",
            "Condition 972 995--*--child-bearing potential",
            "Person 963 968--*--Women",
            "Scope 963 995--*--Women of child-bearing potential",
            "Person 997 1001--*--WCBP",
            "Measurement 1024 1044--*--serum pregnancy test",
            "Value 1015 1023--*--negative",
            "Temporal 1045 1089--*--72 hours or less prior to starting treatment",
            "Reference_point 1071 1089--*--starting treatment",
            "Procedure 1080 1089--*--treatment",
            "Scope 963 1002--*--Women of child-bearing potential (WCBP)",
            "Pregnancy_considerations 963 1089--*--Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment",
            "Condition 1100 1123--*--child-bearing potential",
            "Person 1091 1096--*--Women",
            "Person 1128 1131--*--men",
            "Mood 1132 1145--*--must agree to",
            "Multiplier 1150 1157--*--2 forms",
            "Procedure 1170 1183--*--contraception",
            "Qualifier 1161 1169--*--adequate",
            "Scope 1091 1131--*--Women of child-bearing potential and men",
            "Temporal 1184 1204--*--prior to study entry",
            "Temporal 1209 1248--*--for the duration of study participation",
            "Reference_point 1229 1248--*--study participation",
            "Reference_point 1193 1204--*--study entry"
        ],
        "Text": "Diagnosis of sickle cell disease . Clinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease . Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea . 18 years of age or older . Hematologic laboratory values as outlined in the protocol . Non-hematologic laboratory values as outlined in the protocol . Must agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter . Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment . Women of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation . "
    },
    "NCT03389061_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03063866_inc": {
        "Text": "Patients aged between 40 and 60 years old.. With Child score B or C. Presented for elective gastrointestinal endoscopy. ",
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 41--*--between 40 and 60 years old",
            "Measurement 49 60--*--Child score",
            "Value 61 62--*--B",
            "Value 66 67--*--C",
            "Scope 61 67--*--B or C",
            "Qualifier 83 91--*--elective",
            "Procedure 92 118--*--gastrointestinal endoscopy"
        ]
    },
    "NCT02340169_exc": {
        "Text": "Has other dermatological conditions that may interfere with clinical assessments. Allergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results. History of an adverse reaction to Cortrosyn\u2122 or similar test reagents. Chronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation. ",
        "Annotations": [
            "Subjective_judgement 0 80--*--Has other dermatological conditions that may interfere with clinical assessments",
            "Qualifier 108 123--*--corticosteroids",
            "Condition 131 152--*--drug hypersensitivity",
            "Condition 131 135;156 167--*--drug intolerance",
            "Condition 82 89--*--Allergy",
            "Condition 93 104--*--sensitivity",
            "Subjective_judgement 169 221--*--hat would compromise patient safety or study results",
            "Drug 108 123--*--corticosteroids",
            "Scope 82 104--*--Allergy or sensitivity",
            "Scope 131 167--*--drug hypersensitivity or intolerance",
            "Condition 237 253--*--adverse reaction",
            "Qualifier 257 266--*--Cortrosyn",
            "Drug 257 266--*--Cortrosyn",
            "Procedure 279 292--*--test reagents",
            "Qualifier 271 278--*--similar",
            "Qualifier 271 292--*--similar test reagents",
            "Scope 257 292--*--Cortrosyn\u2122 or similar test reagents",
            "Subjective_judgement 294 435--*--Chronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation"
        ]
    },
    "NCT02150590_exc": {
        "Annotations": [
            "Qualifier 0 8--*--unstable",
            "Condition 9 18--*--condition",
            "Condition 20 37--*--COPD exacerbation",
            "Condition 68 72--*--COPD",
            "Qualifier 39 43--*--mild",
            "Measurement 45 49--*--GOLD",
            "Value 50 52--*--1)",
            "Measurement 74 78--*--GOLD",
            "Value 79 80--*--4",
            "Qualifier 56 67--*--very severe",
            "Condition 68 72--*--COPD",
            "Procedure 99 113--*--oxygen therapy",
            "Condition 141 156--*--hypoventilation",
            "Condition 158 180--*--pulmonary hypertension",
            "Condition 209 231--*--cardiovascular disease",
            "Qualifier 200 208--*--unstable",
            "Qualifier 182 196--*--more than mild",
            "Scope 182 208--*--more than mild or unstable",
            "Non-query-able 233 282--*--use of drugs that affect respiratory center drive",
            "Condition 308 327--*--psychiatric disease",
            "Condition 294 304;320 327--*--neurologic disease",
            "Condition 284 292;320 327--*--internal disease",
            "Observation 392 399--*--smoking",
            "Qualifier 386 391--*--heavy",
            "Multiplier 401 423--*-->20 cigarettes per day",
            "Negation 426 435--*--inability",
            "Procedure 447 462--*--6 min walk test",
            "Condition 474 485--*--intolerance",
            "Observation 498 506--*--altitude",
            "Qualifier 489 497--*--moderate",
            "Value 508 514--*--<2600m",
            "Non-query-able 518 600--*--exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.",
            "Pregnancy_considerations 602 630--*--pregnant or nursing patients"
        ],
        "Text": "unstable condition, COPD exacerbation. mild (GOLD 1) or very severe COPD (GOLD 4). requirement for oxygen therapy at low altitude residence. hypoventilation. pulmonary hypertension. more than mild or unstable cardiovascular disease. use of drugs that affect respiratory center drive. internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day), inability to perform 6 min walk test.. previous intolerance to moderate altitude (<2600m).. exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.. pregnant or nursing patients. "
    },
    "NCT02631512_exc": {
        "Text": "Ulcers due to non-diabetic etiology.. Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status.. Ulcers older than 1 year.. Any of gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy.. ",
        "Annotations": [
            "Condition 0 6--*--Ulcers",
            "Qualifier 14 26--*--non-diabetic",
            "Condition 38 59--*--Uncontrolled diabetes",
            "Measurement 71 76--*--HbA1c",
            "Value 77 94--*--above 70 mmol/mol",
            "Condition 99 130--*--insufficient nutritional status",
            "Scope 71 130--*--HbA1c above 70 mmol/mol and insufficient nutritional status",
            "Condition 133 139--*--Ulcers",
            "Temporal 140 157--*--older than 1 year",
            "Condition 167 175--*--gangrene",
            "Multiplier 160 166--*--Any of",
            "Condition 177 190--*--osteomyelitis",
            "Condition 192 202--*--cellulitis",
            "Condition 207 231--*--Charcot osteoarthropathy",
            "Scope 167 231--*--gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy"
        ]
    },
    "NCT00730301_inc": {
        "Annotations": [
            "Procedure 21 34--*--HRCT Core Lab",
            "Condition 49 83--*--heterogeneous disease distribution",
            "Multiplier 88 100--*--at least one",
            "Condition 101 125--*--complete oblique fissure",
            "Person 128 131--*--Age",
            "Value 132 151--*--from 40 to 75 years",
            "Measurement 153 156--*--BMI",
            "Value 157 167--*--< 32 kg/m2",
            "Measurement 169 173--*--FEV1",
            "Value 174 198--*--< 40% of predicted value",
            "Measurement 200 208--*--FEV1/FVC",
            "Value 209 214--*--< 70%",
            "Measurement 216 219--*--TLC",
            "Value 220 236--*--> 120% predicted",
            "Measurement 238 240--*--RV",
            "Value 241 257--*--> 150% predicted",
            "Multiplier 272 279;307 309--*--< 20 mg qd",
            "Drug 280 290--*--prednisone",
            "Measurement 311 316--*--PaCO2",
            "Value 317 326--*--< 50mm Hg",
            "Measurement 328 332--*--PaO2",
            "Value 333 343--*--> 45 mm Hg",
            "Qualifier 344 355--*--on room air",
            "Measurement 357 367--*--6-min walk",
            "Value 371 376--*--> 50m",
            "Value 405 411--*--> 100m",
            "Negation 378 385--*--without",
            "Qualifier 386 400--*--rehabilitation",
            "Qualifier 418 432--*--rehabilitation",
            "Scope 371 433--*--> 50m (without rehabilitation) or > 100m (with rehabilitation)",
            "Condition 435 445--*--Nonsmoking",
            "Temporal 446 485--*--for 4 months prior to initial interview",
            "Reference_point 468 485--*--initial interview",
            "Temporal 490 510--*--throughout screening",
            "Reference_point 501 510--*--screening",
            "Condition 597 620--*--child bearing potential",
            "Negation 594 596--*--no",
            "Observation 637 674--*--willing and able to complete protocol",
            "Observation 524 575--*--agrees to all protocol required follow-up intervals",
            "Visit 556 575--*--follow-up intervals",
            "Procedure 684 704--*--baseline assessments",
            "Procedure 684 692;709 719--*--baseline procedures",
            "Scope 684 719--*--baseline assessments and procedures",
            "Condition 260 266--*--Stable"
        ],
        "Text": "Patient diagnosed by HRCT Core Lab with eligible heterogeneous disease distribution and at least one complete oblique fissure. . Age from 40 to 75 years . BMI < 32 kg/m2 . FEV1 < 40% of predicted value, FEV1/FVC < 70% . TLC > 120% predicted, RV > 150% predicted. . Stable with < 20 mg prednisone (or equivalent) qd . PaCO2 < 50mm Hg . PaO2 > 45 mm Hg on room air . 6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation) . Nonsmoking for 4 months prior to initial interview and throughout screening . The patient agrees to all protocol required follow-up intervals. . The patient has no child bearing potential . The patient is willing and able to complete protocol required baseline assessments and procedures . "
    },
    "NCT03043495_exc": {
        "Text": "Coagulopathies (with prothrombin concentration less than 60% or INR more than 1.5). In-ability to postpone anti-coagulation medications.. Infection or injury or a lesion at the block site.. Suspected cervical vertebral column injury necessitating using a neck collar.. A compromised lung on the contralateral side of the block (Pneumothorax, hemothorax or Pneumonectomy).. Traumatic vascular injuries or operative interventions (Surgical harvesting) involving arteries of the upper limb on the operative side.. Patients with communication difficulties.. Hypersensitivity to local anesthetics and/or Dexamethasone.. Patients on perioperative intravenous (IV) steroids.. ",
        "Annotations": [
            "Condition 0 14--*--Coagulopathies",
            "Measurement 21 46--*--prothrombin concentration",
            "Value 47 60--*--less than 60%",
            "Value 68 81--*--more than 1.5",
            "Measurement 64 67--*--INR",
            "Scope 21 81--*--prothrombin concentration less than 60% or INR more than 1.5",
            "Drug 107 135--*--anti-coagulation medications",
            "Mood 84 106--*--In-ability to postpone",
            "Condition 138 147--*--Infection",
            "Condition 151 157--*--injury",
            "Condition 163 169--*--lesion",
            "Qualifier 170 187--*--at the block site",
            "Scope 138 169--*--Infection or injury or a lesion",
            "Condition 200 232--*--cervical vertebral column injury",
            "Mood 190 199--*--Suspected",
            "Condition 271 287--*--compromised lung",
            "Qualifier 295 326--*--contralateral side of the block",
            "Condition 328 340--*--Pneumothorax",
            "Condition 342 352--*--hemothorax",
            "Condition 356 369--*--Pneumonectomy",
            "Scope 328 369--*--Pneumothorax, hemothorax or Pneumonectomy",
            "Condition 373 400--*--Traumatic vascular injuries",
            "Procedure 404 427--*--operative interventions",
            "Procedure 429 448--*--Surgical harvesting",
            "Qualifier 460 508--*--arteries of the upper limb on the operative side",
            "Scope 373 449--*--Traumatic vascular injuries or operative interventions (Surgical harvesting)",
            "Condition 525 551--*--communication difficulties",
            "Condition 554 570--*--Hypersensitivity",
            "Drug 574 591--*--local anesthetics",
            "Drug 599 612--*--Dexamethasone",
            "Scope 574 612--*--local anesthetics and/or Dexamethasone",
            "Temporal 627 640--*--perioperative",
            "Drug 641 666--*--intravenous (IV) steroids"
        ]
    },
    "NCT02951520_inc": {
        "Text": "Adult patients scheduled for arthroscopic knee ligament reconstruction. ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Mood 15 24--*--scheduled",
            "Procedure 29 70--*--arthroscopic knee ligament reconstruction"
        ]
    },
    "NCT01000155_exc": {
        "Annotations": [
            "Condition 14 27--*--hemoglobin SC",
            "Condition 31 46--*--SB+ thalassemia",
            "Procedure 68 87--*--transfusion program",
            "Qualifier 60 67--*--chronic",
            "Multiplier 60 67--*--chronic",
            "Procedure 116 132--*--RBC transfusions",
            "Negation 133 144--*--cannot have",
            "Value 145 166--*-->15% adult hemoglobin",
            "Condition 194 197--*--HIV",
            "Condition 206 217--*--hepatitis B",
            "Condition 221 232--*--hepatitis C",
            "Temporal 199 205--*--active",
            "Condition 234 242--*--Pregnant",
            "Observation 246 260--*--breast feeding",
            "Person 261 266--*--women",
            "Condition 298 308--*--malignancy",
            "Observation 287 294--*--history",
            "Condition 436 448--*--disease-free",
            "Temporal 449 469--*--for at least 5 years",
            "Mood 514 522--*--low risk",
            "Condition 527 556--*--recurrence of that malignancy",
            "Condition 541 556--*--that malignancy",
            "Subjective_judgement 478 504--*--deemed by the investigator",
            "Condition 682 703--*--breast cancer in situ",
            "Condition 670 678;689 703--*--cervical cancer in situ",
            "Temporal 645 668--*--within the past 5 years",
            "Condition 723 758--*--squamous cell carcinoma of the skin",
            "Condition 709 719;737 758--*--basal cell carcinoma of the skin",
            "Grammar_Error 596 608--*--are eligible",
            "Negation 596 608--*--are eligible",
            "Mood 612 621--*--diagnosed",
            "Mood 626 644--*--adequately treated",
            "Procedure 637 644--*--treated",
            "Qualifier 626 636--*--adequately",
            "Condition 787 797--*--thrombosis",
            "Condition 826 845--*--sickle cell disease",
            "Condition 860 875--*--thrombotic risk",
            "Mood 851 859;871 875--*--enhanced risk",
            "Observation 776 783--*--history",
            "Negation 815 825--*--other than",
            "Condition 860 870--*--thrombotic",
            "Condition 902 912--*--infections",
            "Qualifier 891 901--*--unresolved",
            "Condition 937 955--*--medical conditions",
            "Qualifier 967 997--*--compromise study participation",
            "Post-eligibility 914 997--*--Severe or uncontrolled medical conditions that could compromise study participation",
            "Drug 1011 1043--*--fetal hemoglobin inducing agents",
            "Qualifier 1011 1016--*--fetal",
            "Post-eligibility 1045 1200--*--Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy",
            "Context_Error 1045 1200--*--Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy",
            "Condition 1208 1225--*--allergic reaction",
            "Drug 1231 1260--*--histone deacetylase inhibitor",
            "Drug 1289 1302--*--valproic acid",
            "Procedure 1307 1316--*--treatment",
            "Condition 1320 1328--*--epilepsy",
            "Temporal 1329 1357--*--within 30 days of enrollment",
            "Reference_point 1347 1357--*--enrollment",
            "Drug 1390 1405--*--HDAC inhibitors",
            "Negation 1406 1416--*--other than",
            "Drug 1417 1430--*--valproic acid"
        ],
        "Text": "Subjects with hemoglobin SC or SB+ thalassemia . Subjects on chronic transfusion program . Subjects who have received RBC transfusions cannot have >15% adult hemoglobin . Known positive status for HIV, active hepatitis B or hepatitis C . Pregnant or breast feeding women . Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin . Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk . Subjects with unresolved infections . Severe or uncontrolled medical conditions that could compromise study participation . Subjects on fetal hemoglobin inducing agents . Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy . Known allergic reaction to a histone deacetylase inhibitor . Subjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment . Subjects who have received any HDAC inhibitors other than valproic acid       .     . "
    },
    "NCT03389061_inc": {
        "Annotations": [
            "Procedure 14 31--*--SOF/VEL treatment",
            "Qualifier 53 60--*--chronic",
            "Measurement 61 73--*--HCV genotype",
            "Value 74 85--*--1 through 6",
            "Temporal 99 134--*--at least 18 at the day of screening",
            "Reference_point 125 134--*--screening",
            "Post-eligibility 137 198--*--Patient is able and willing to sign the Informed Consent Form",
            "Post-eligibility 201 260--*--Patient is able and willing to follow protocol requirements"
        ],
        "Text": "Patients with SOF/VEL treatment for the treatment of chronic HCV genotype 1 through 6.. Patient is at least 18 at the day of screening.. Patient is able and willing to sign the Informed Consent Form.. Patient is able and willing to follow protocol requirements.. "
    },
    "NCT03063866_exc": {
        "Text": "Emergent condition like hematemesis.. Patients with moderate to severe hepatic encephalopathy.. Patients with hepatopulmonary syndrome.. Patients with known or suspected hypersensitivity to the used medication were also excluded from the study.. ",
        "Annotations": [
            "Condition 24 35--*--hematemesis",
            "Condition 0 18--*--Emergent condition",
            "Qualifier 64 70--*--severe",
            "Qualifier 52 60--*--moderate",
            "Condition 71 93--*--hepatic encephalopathy",
            "Scope 52 70--*--moderate to severe",
            "Condition 110 134--*--hepatopulmonary syndrome",
            "Condition 170 186--*--hypersensitivity",
            "Mood 160 169--*--suspected",
            "Mood 151 156--*--known",
            "Scope 151 169--*--known or suspected",
            "Drug 194 209--*--used medication"
        ]
    },
    "NCT03328052_exc": {
        "Text": "Diagnosis of a psychotic disorder.. History of, or current, open head brain trauma. Candidates with any metal, shrapnel or other similar objects in the head that could affect the QEEG. History of: craniotomy, cerebral metastases, cerebrovascular accident; current diagnosis of seizure disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features; or use of depot neuroleptics in last 12 months.. Uncontrolled thyroid disorders.. Known pregnancy and/or lactation, or intent to become pregnant during this study.. Chronic or acute pain requiring prescription pain medication(s) (narcotic or synthetic narcotic). Participation in any other therapeutic drug study within 60 days preceding inclusion.. ",
        "Annotations": [
            "Condition 15 33--*--psychotic disorder",
            "Condition 60 82--*--open head brain trauma",
            "Temporal 51 58--*--current",
            "Observation 36 43--*--History",
            "Scope 36 58--*--History of, or current",
            "Device 104 109--*--metal",
            "Device 111 119--*--shrapnel",
            "Device 137 156--*--objects in the head",
            "Procedure 179 183--*--QEEG",
            "Condition 168 174--*--affect",
            "Scope 104 156--*--metal, shrapnel or other similar objects in the head",
            "Procedure 197 207--*--craniotomy",
            "Condition 209 228--*--cerebral metastases",
            "Condition 230 254--*--cerebrovascular accident",
            "Condition 277 293--*--seizure disorder",
            "Condition 295 308--*--schizophrenia",
            "Condition 310 335--*--schizo-affective disorder",
            "Condition 337 345--*--dementia",
            "Condition 347 365--*--mental retardation",
            "Condition 370 386--*--major depression",
            "Condition 392 410--*--psychotic features",
            "Drug 422 440--*--depot neuroleptics",
            "Temporal 441 458--*--in last 12 months",
            "Observation 185 192--*--History",
            "Scope 197 458--*--craniotomy, cerebral metastases, cerebrovascular accident; current diagnosis of seizure disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features; or use of depot neuroleptics in last 12 months",
            "Condition 474 491--*--thyroid disorders",
            "Qualifier 461 473--*--Uncontrolled",
            "Pregnancy_considerations 494 575--*--Known pregnancy and/or lactation, or intent to become pregnant during this study.",
            "Qualifier 588 593--*--acute",
            "Qualifier 577 584--*--Chronic",
            "Condition 594 598--*--pain",
            "Scope 577 593--*--Chronic or acute",
            "Drug 609 637--*--prescription pain medication",
            "Drug 642 650--*--narcotic",
            "Drug 654 672--*--synthetic narcotic",
            "Scope 642 672--*--narcotic or synthetic narcotic",
            "Competing_trial 675 760--*--Participation in any other therapeutic drug study within 60 days preceding inclusion."
        ]
    },
    "NCT02573909_exc": {
        "Annotations": [
            "Procedure 8 15--*--surgery",
            "Procedure 22 41--*--regional anesthesia",
            "Mood 0 7--*--Planned",
            "Condition 43 59--*--contraindication",
            "Drug 67 77--*--study drug",
            "Condition 79 95--*--contraindication",
            "Procedure 103 118--*--lumbar puncture",
            "Condition 120 136--*--Contraindication",
            "Drug 140 149--*--oxycodone",
            "Condition 151 160--*--Pregnancy",
            "Condition 164 173--*--lactation",
            "Non-query-able 175 194--*--no informed consent"
        ],
        "Text": "Planned surgery under regional anesthesia. contraindication to the study drug. contraindication to the lumbar puncture. Contraindication to oxycodone. Pregnancy or lactation. no informed consent. "
    },
    "NCT03026088_inc": {
        "Text": "18-80 year, male or female.. Chronic Heart failure subjects with medical history of cardiac disease or other related cardiovascular disease.. Left ventricular ejection fraction (LVEF) less than or equal to (=<) 40 percent (%).. New York Heart Association (NYHA) class of II - IV. NYHA II : Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation.. NYHA III:Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation.. NYHA IV:Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort increased.. Signed Informed Consent Form (ICF).. ",
        "Annotations": [
            "Person 6 10--*--year",
            "Value 0 5--*--18-80",
            "Person 12 16--*--male",
            "Person 20 26--*--female",
            "Condition 29 50--*--Chronic Heart failure",
            "Condition 84 99--*--cardiac disease",
            "Condition 117 139--*--cardiovascular disease",
            "Qualifier 109 116--*--related",
            "Scope 84 139--*--cardiac disease or other related cardiovascular disease",
            "Measurement 142 176--*--Left ventricular ejection fraction",
            "Measurement 178 182--*--LVEF",
            "Value 184 205;211 221--*--less than or equal to 40 percent",
            "Value 207 209;211 213;223 224--*--=< 40 %",
            "Measurement 228 254;262 267--*--New York Heart Association class",
            "Value 271 278--*--II - IV",
            "Measurement 256 260--*--NYHA",
            "Non-query-able 280 437--*--NYHA II : Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation",
            "Non-query-able 440 593--*--NYHA III:Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation",
            "Non-query-able 596 758--*--NYHA IV:Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort increased",
            "Post-eligibility 761 795--*--Signed Informed Consent Form (ICF)"
        ]
    },
    "NCT03013790_exc": {
        "Text": "Patients with head trauma or Neurosurgical intervention. Patients <65 years of age. Patients with an expected life expectancy <48 hours. Blind patients. Patients with a seizure history. Patients with uncontrolled hypertension. Patients with a supratheraputic (>3.0) INR. Patients on strong CYP1A2 inhibitors: ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine. Patients who do not speak English or Spanish. ",
        "Annotations": [
            "Condition 14 25--*--head trauma",
            "Procedure 29 55--*--Neurosurgical intervention",
            "Value 66 75--*--<65 years",
            "Person 79 82--*--age",
            "Observation 101 125--*--expected life expectancy",
            "Value 126 135--*--<48 hours",
            "Condition 137 142--*--Blind",
            "Condition 169 176--*--seizure",
            "Observation 177 184--*--history",
            "Condition 200 225--*--uncontrolled hypertension",
            "Value 243 258--*--supratheraputic",
            "Value 260 264--*-->3.0",
            "Measurement 266 269--*--INR",
            "Drug 309 322--*--ciprofloxacin",
            "Drug 324 335--*--fluvoxamine",
            "Drug 337 348--*--methoxsalen",
            "Drug 350 359--*--ofloxacin",
            "Drug 361 371--*--primaquine",
            "Drug 283 307--*--strong CYP1A2 inhibitors",
            "Scope 309 371--*--ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine",
            "Negation 389 392--*--not",
            "Observation 393 406--*--speak English",
            "Observation 393 398;410 417--*--speak Spanish",
            "Scope 393 417--*--speak English or Spanish"
        ]
    },
    "NCT03328052_inc": {
        "Text": "Patients with a clinical diagnosis of depression who in the judgement of their physician require medication management may be eligible for enrollment. A score of 10 or more on the PHQ-9 instrument will be required for enrollment.. Some practices utilize the PHQ-2 and PHQ-9 are part of routine screening for depression. If the tests are performed routinely, they do not need to be repeated for study eligibility, and may be performed prior to informed consent for this study. If, however, the PHQ-9 is not routinely performed, informed consent must be performed prior to administration. Patients with a score below 10 will be considered screen failures and will not be enrolled or offered the MYnd testing.. Patients with non-psychotic comorbid conditions may be included.. Patients must be either medication treatment na\u00efve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment. Prohibited medications at the time of enrollment will include stimulants, benzodiazepines and THC. Prior therapy with these agents is permitted with a washout of >30 days.. Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.. ",
        "Annotations": [
            "Condition 38 48--*--depression",
            "Drug 97 107--*--medication",
            "Measurement 180 185--*--PHQ-9",
            "Value 153 172--*--score of 10 or more",
            "Non-representable 231 706--*--Some practices utilize the PHQ-2 and PHQ-9 are part of routine screening for depression. If the tests are performed routinely, they do not need to be repeated for study eligibility, and may be performed prior to informed consent for this study. If, however, the PHQ-9 is not routinely performed, informed consent must be performed prior to administration. Patients with a score below 10 will be considered screen failures and will not be enrolled or offered the MYnd testing.",
            "Condition 722 735;745 755--*--non-psychotic conditions",
            "Drug 798 808--*--medication",
            "Condition 829 849--*--behavioral illnesses",
            "Negation 819 824--*--na\u00efve",
            "Negation 858 860--*--no",
            "Qualifier 861 867--*--active",
            "Drug 868 878--*--medication",
            "Temporal 890 930--*--for at least 1 month prior to enrollment",
            "Drug 1006 1021--*--benzodiazepines",
            "Drug 1026 1029--*--THC",
            "Drug 994 1004--*--stimulants",
            "Non-representable 774 1103--*--Patients must be either medication treatment na\u00efve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment. Prohibited medications at the time of enrollment will include stimulants, benzodiazepines and THC. Prior therapy with these agents is permitted with a washout of >30 days.",
            "Non-query-able 1105 1371--*--Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs."
        ]
    },
    "NCT02573909_inc": {
        "Annotations": [
            "Procedure 8 43--*--gynecological lower abdomen surgery",
            "Mood 0 7--*--Planned",
            "Procedure 49 72--*--epidural pain treatment",
            "Non-query-able 74 99--*--Informed consent obtained"
        ],
        "Text": "Planned gynecological lower abdomen surgery with epidural pain treatment. Informed consent obtained. "
    },
    "NCT03026088_exc": {
        "Text": "Acute coronary syndrome (ACS) within 3 months.. Under beta-blocker treatment for the last 2 weeks.. Under other medicine treatment which may affect heart rate, like Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin treatment [more than (>) 0.125 milligram (mg)].. Uncontrolled Diabetes [hemoglobin A1c, (HbA1c) >7.5%].. Severe or uncontrolled hypertension [resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period].. Severe hypotension [resting SBP less than (<) 90mmHg, or resting DBP<50mmHg].. Resting heart rate <60 beat per minute (bpm).. Any contradiction to Bisoprolol according to label, including:. Acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy.. Cardiogenic shock.. Atrioventricular block of second or third degree (without a pacemaker).. Sick sinus syndrome.. Sinoatrial block.. Slowed heart rate, causing symptoms (symptomatic bradycardia),. Decreased blood pressure, causing symptoms (symptomatic hypotension),. Severe bronchial asthma or severe chronic obstructive pulmonary disease.. Sever forms of peripheral arterial occlusive disease and Raynaud's syndrome.. Untreated phaeochromocytoma.. Metabolic acidosis.. Hypersensitivity to bisoprolol or to any of the excipients.. Severe Arrhythmia including atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia.. Significant valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease.. Acute pulmonary edema.. Severe hepatic dysfunction, defined as:. Serum Alanine Aminotransferase (ALT) > triple the upper limit of the normal range; and/or. Serum Aspartate Aminotransferase (AST) > triple the upper limit of the normal value range and/or. Severe renal dysfunction, defined as:. Serum creatinine > twice the upper limit of the normal range. Chronic Kidney Disease (glomerular filtration rate <45 Milliliter per minute).. Hyperthyroidism or hypothyroidism.. Severe infectious disease, example (eg) Human Immunodeficiency Virus positive or active tuberculosis.. Severe autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.. Severe respiratory, digestive, hematological disease (including Anemia of Hb < 100 gram per litre) or tumor.. Known to be hypersensitivity to Bisoprolol, or any of the excipient.. Substance or alcohol abuse.. Received heart transplantation or pacemaker implantation; revascularization treatment within 3 months; or plan to receive above treatment in 6 months.. Currently undertaking other treatment that may affect the safety and/or efficacy evaluation, e.g. beta receptors agonists, et cetera.. No legal ability or legal ability is limited.. Subjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent.. Child-bearing period women without effective contraceptive measures, pregnancy and lactation.. Participation in another clinical trial within the past 90 days.. Other significant condition that in the Investigator's opinion would exclude the subject from the trial.. ",
        "Annotations": [
            "Condition 0 23--*--Acute coronary syndrome",
            "Condition 25 28--*--ACS",
            "Temporal 30 45--*--within 3 months",
            "Drug 54 66--*--beta-blocker",
            "Temporal 77 97--*--for the last 2 weeks",
            "Drug 165 209--*--Non-dihydropyridine calcium channel blockers",
            "Drug 211 220--*--NDHP-CCBs",
            "Drug 225 235--*--ivabradine",
            "Temporal 236 256--*--for the last 2 weeks",
            "Drug 264 271--*--Digoxin",
            "Multiplier 283 292;297 312--*--more than 0.125 milligram",
            "Value 294 295;297 302;314 316--*--> 0.125 mg",
            "Scope 165 235--*--Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine",
            "Non-query-able 100 158--*--Under other medicine treatment which may affect heart rate",
            "Condition 334 342--*--Diabetes",
            "Qualifier 321 333--*--Uncontrolled",
            "Measurement 344 358--*--hemoglobin A1c",
            "Measurement 361 366--*--HbA1c",
            "Value 368 373--*-->7.5%",
            "Condition 400 412--*--hypertension",
            "Qualifier 387 399--*--uncontrolled",
            "Qualifier 377 383--*--Severe",
            "Scope 377 399--*--Severe or uncontrolled",
            "Measurement 422 445--*--Systolic Blood Pressure",
            "Measurement 447 450--*--SBP",
            "Value 452 479--*-->180 millimeters of mercury",
            "Value 452 456;481 485--*-->180 mmHg",
            "Measurement 499 523--*--Diastolic Blood Pressure",
            "Measurement 525 528--*--DBP",
            "Value 530 538--*-->110mmHg",
            "Temporal 539 558--*--at screening period",
            "Reference_point 542 551--*--screening",
            "Qualifier 491 498--*--resting",
            "Qualifier 414 421--*--resting",
            "Scope 414 558--*--resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period",
            "Scope 414 538--*--resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg",
            "Condition 569 580--*--hypotension",
            "Qualifier 562 568--*--Severe",
            "Measurement 590 593--*--SBP",
            "Value 594 603;608 614--*--less than 90mmHg",
            "Qualifier 582 589--*--resting",
            "Qualifier 619 626--*--resting",
            "Measurement 627 630--*--DBP",
            "Value 630 637--*--<50mmHg",
            "Scope 582 637--*--resting SBP less than (<) 90mmHg, or resting DBP<50mmHg",
            "Measurement 649 659--*--heart rate",
            "Qualifier 641 648--*--Resting",
            "Value 660 679--*--<60 beat per minute",
            "Value 660 663;681 684--*--<60 bpm",
            "Drug 709 719--*--Bisoprolol",
            "Condition 692 705--*--contradiction",
            "Condition 752 771--*--Acute heart failure",
            "Condition 794 822--*--heart failure decompensation",
            "Procedure 833 862--*--intravenous inotropic therapy",
            "Condition 865 882--*--Cardiogenic shock",
            "Condition 885 917;927 933--*--Atrioventricular block of second degree",
            "Condition 885 910;921 933--*--Atrioventricular block of third degree",
            "Device 945 954--*--pacemaker",
            "Negation 935 942--*--without",
            "Condition 958 977--*--Sick sinus syndrome",
            "Condition 980 996--*--Sinoatrial block",
            "Condition 1006 1016--*--heart rate",
            "Qualifier 999 1005--*--Slowed",
            "Condition 1048 1059--*--bradycardia",
            "Qualifier 1036 1047--*--symptomatic",
            "Condition 1026 1034--*--symptoms",
            "Condition 1073 1087--*--blood pressure",
            "Qualifier 1063 1072--*--Decreased",
            "Condition 1097 1105--*--symptoms",
            "Condition 1119 1130--*--hypotension",
            "Qualifier 1107 1118--*--symptomatic",
            "Condition 1141 1157--*--bronchial asthma",
            "Qualifier 1134 1140--*--Severe",
            "Condition 1168 1205--*--chronic obstructive pulmonary disease",
            "Qualifier 1161 1167--*--severe",
            "Condition 1223 1260--*--peripheral arterial occlusive disease",
            "Condition 1265 1283--*--Raynaud's syndrome",
            "Qualifier 1208 1213--*--Sever",
            "Scope 1223 1283--*--peripheral arterial occlusive disease and Raynaud's syndrome",
            "Non-query-able 1261 1264--*--and",
            "Condition 1296 1313--*--phaeochromocytoma",
            "Qualifier 1286 1295--*--Untreated",
            "Condition 1316 1334--*--Metabolic acidosis",
            "Condition 1337 1353--*--Hypersensitivity",
            "Drug 1357 1367--*--bisoprolol",
            "Drug 1385 1395--*--excipients",
            "Qualifier 1374 1377--*--any",
            "Scope 1357 1395--*--bisoprolol or to any of the excipients",
            "Condition 1405 1415--*--Arrhythmia",
            "Qualifier 1398 1404--*--Severe",
            "Condition 1426 1445--*--atrial fibrillation",
            "Condition 1447 1461--*--atrial flutter",
            "Condition 1463 1487--*--ventricular fibrillation",
            "Condition 1489 1508--*--ventricular flutter",
            "Condition 1512 1535--*--ventricular tachycardia",
            "Scope 1426 1535--*--atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia",
            "Condition 1550 1572--*--valvular heart disease",
            "Qualifier 1538 1549--*--Significant",
            "Condition 1574 1598--*--congenital heart disease",
            "Condition 1600 1623--*--pulmonary heart disease",
            "Condition 1627 1650--*--perinatal heart disease",
            "Scope 1550 1650--*--valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease",
            "Condition 1653 1674--*--Acute pulmonary edema",
            "Condition 1684 1703--*--hepatic dysfunction",
            "Qualifier 1677 1683--*--Severe",
            "Measurement 1718 1748--*--Serum Alanine Aminotransferase",
            "Measurement 1750 1753--*--ALT",
            "Value 1755 1799--*--> triple the upper limit of the normal range",
            "Non-query-able 1801 1807--*--and/or",
            "Measurement 1809 1841--*--Serum Aspartate Aminotransferase",
            "Measurement 1843 1846--*--AST",
            "Value 1848 1898--*--> triple the upper limit of the normal value range",
            "Non-query-able 1899 1905--*--and/or",
            "Condition 1914 1931--*--renal dysfunction",
            "Qualifier 1907 1913--*--Severe",
            "Measurement 1946 1962--*--Serum creatinine",
            "Value 1963 2006--*--> twice the upper limit of the normal range",
            "Condition 2008 2030--*--Chronic Kidney Disease",
            "Measurement 2032 2058--*--glomerular filtration rate",
            "Value 2059 2084--*--<45 Milliliter per minute",
            "Condition 2088 2103--*--Hyperthyroidism",
            "Condition 2107 2121--*--hypothyroidism",
            "Condition 2131 2149--*--infectious disease",
            "Qualifier 2124 2130--*--Severe",
            "Condition 2164 2201--*--Human Immunodeficiency Virus positive",
            "Condition 2212 2224--*--tuberculosis",
            "Qualifier 2205 2211--*--active",
            "Scope 2164 2224--*--Human Immunodeficiency Virus positive or active tuberculosis",
            "Condition 2234 2252--*--autoimmune disease",
            "Qualifier 2227 2233--*--Severe",
            "Condition 2259 2278--*--lupus erythematosus",
            "Condition 2280 2298--*--multiple sclerosis",
            "Scope 2259 2298--*--lupus erythematosus, multiple sclerosis",
            "Condition 2308 2319;2346 2353--*--respiratory disease",
            "Condition 2321 2330;2346 2353--*--digestive disease",
            "Condition 2332 2353--*--hematological disease",
            "Qualifier 2301 2307--*--Severe",
            "Scope 2308 2353--*--respiratory, digestive, hematological disease",
            "Condition 2365 2371--*--Anemia",
            "Measurement 2375 2377--*--Hb",
            "Value 2378 2398--*--< 100 gram per litre",
            "Condition 2403 2408--*--tumor",
            "Condition 2423 2439--*--hypersensitivity",
            "Drug 2443 2453--*--Bisoprolol",
            "Drug 2469 2478--*--excipient",
            "Qualifier 2458 2461--*--any",
            "Scope 2443 2478--*--Bisoprolol, or any of the excipient",
            "Condition 2494 2507--*--alcohol abuse",
            "Condition 2481 2490;2502 2507--*--Substance abuse",
            "Procedure 2519 2540--*--heart transplantation",
            "Procedure 2544 2566--*--pacemaker implantation",
            "Procedure 2568 2585--*--revascularization",
            "Temporal 2596 2611--*--within 3 months",
            "Mood 2616 2623--*--plan to",
            "Temporal 2648 2659--*--in 6 months",
            "Scope 2519 2585--*--heart transplantation or pacemaker implantation; revascularization",
            "Procedure 2519 2540--*--heart transplantation",
            "Procedure 2544 2566--*--pacemaker implantation",
            "Procedure 2568 2585--*--revascularization",
            "Scope 2519 2585--*--heart transplantation or pacemaker implantation; revascularization",
            "Non-query-able 2662 2753--*--Currently undertaking other treatment that may affect the safety and/or efficacy evaluation",
            "Drug 2760 2783--*--beta receptors agonists",
            "Post-eligibility 2797 2841--*--No legal ability or legal ability is limited",
            "Post-eligibility 2845 2947--*--ubjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent",
            "Pregnancy_considerations 2950 3042--*--Child-bearing period women without effective contraceptive measures, pregnancy and lactation",
            "Non-query-able 3045 3108--*--Participation in another clinical trial within the past 90 days",
            "Post-eligibility 3111 3214--*--Other significant condition that in the Investigator's opinion would exclude the subject from the trial"
        ]
    },
    "NCT03013790_inc": {
        "Text": "Non-ventilated Patients over the age of 65. ",
        "Annotations": [
            "Person 33 36--*--age",
            "Value 24 28;40 42--*--over 65",
            "Procedure 4 14--*--ventilated",
            "Negation 0 3--*--Non"
        ]
    },
    "NCT03228017_exc": {
        "Text": "Unable to speak Spanish or English. Active smoking (within the past year). Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis. Known active cancer receiving treatment. Pregnancy. Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600). A history of severe bleeding or bleeding disorders. Current medication use which interact with either aspirin or atorvastatin. Chronic kidney disease (CrCl < 30ml/min). Congestive heart failure. Currently taking aspirin or a statin.. NSAID use within the past 48 hours. ",
        "Annotations": [
            "Non-query-able 0 34--*--Unable to speak Spanish or English",
            "Qualifier 36 42--*--Active",
            "Observation 43 50--*--smoking",
            "Value 52 72--*--within the past year",
            "Condition 117 124;75 85--*--disease Autoimmune",
            "Condition 104 124--*--inflammatory disease",
            "Condition 117 124;87 100--*--disease rheumatologic",
            "Negation 135 138--*--not",
            "Condition 139 148--*--psoriasis",
            "Condition 152 171--*--psoriatic arthritis",
            "Scope 139 171--*--psoriasis or psoriatic arthritis",
            "Scope 75 124--*--Autoimmune, rheumatologic or inflammatory disease",
            "Condition 186 192--*--cancer",
            "Qualifier 179 185--*--active",
            "Procedure 203 212--*--treatment",
            "Condition 214 223--*--Pregnancy",
            "Condition 225 231--*--Anemia",
            "Measurement 233 243--*--hemoglobin",
            "Value 244 253--*--< 9 mg/dl",
            "Condition 258 274--*--thrombocytopenia",
            "Measurement 276 290--*--Platelet count",
            "Value 291 294--*--<75",
            "Condition 300 314--*--thrombocytosis",
            "Measurement 316 330--*--Platelet count",
            "Value 331 335--*-->600",
            "Observation 340 347--*--history",
            "Qualifier 351 357--*--severe",
            "Condition 358 366--*--bleeding",
            "Condition 370 388--*--bleeding disorders",
            "Scope 351 388--*--severe bleeding or bleeding disorders",
            "Temporal 390 397--*--Current",
            "Drug 398 408--*--medication",
            "Drug 440 447--*--aspirin",
            "Drug 451 463--*--atorvastatin",
            "Condition 419 427--*--interact",
            "Scope 440 463--*--aspirin or atorvastatin",
            "Condition 465 487--*--Chronic kidney disease",
            "Measurement 489 493--*--CrCl",
            "Value 494 504--*--< 30ml/min",
            "Condition 507 531--*--Congestive heart failure",
            "Drug 550 557--*--aspirin",
            "Drug 563 569--*--statin",
            "Drug 572 577--*--NSAID",
            "Temporal 582 606--*--within the past 48 hours"
        ]
    },
    "NCT03511521_exc": {
        "Text": "Patients with 2 or more doses of methylprednisolone/prednisone per day. Steroids other than methylprednisolone or prednisone. Pregnancy. estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2. ",
        "Annotations": [
            "Multiplier 14 29;63 70--*--2 or more doses per day",
            "Drug 33 51--*--methylprednisolone",
            "Drug 52 62--*--prednisone",
            "Scope 33 62--*--methylprednisolone/prednisone",
            "Drug 92 110--*--methylprednisolone",
            "Drug 114 124--*--prednisone",
            "Drug 72 80--*--Steroids",
            "Negation 81 91--*--other than",
            "Scope 92 124--*--methylprednisolone or prednisone",
            "Condition 126 135--*--Pregnancy",
            "Measurement 137 180--*--estimated glomerular filtration rate (eGFR)",
            "Value 181 199--*--< 45 ml/min/1.73m2"
        ]
    },
    "NCT01857167_inc": {
        "Annotations": [
            "Measurement 3 18--*--Fasting glucose",
            "Value 19 24--*--> 7.0",
            "Drug 33 52--*--diabetes medication",
            "Condition 33 41--*--diabetes",
            "Undefined_semantics 33 52--*--diabetes medication",
            "Person 58 62--*--Male",
            "Person 64 75--*--35-80 years",
            "Value 64 75--*--35-80 years",
            "Person 77 83--*--female",
            "Condition 85 99--*--postmenopausal",
            "Person 100 111--*--to 80 years",
            "Value 100 111--*--to 80 years",
            "Scope 77 99--*--female, postmenopausal",
            "Post-eligibility 117 151--*--Agree to participant in the trial.",
            "Non-query-able 117 151--*--Agree to participant in the trial."
        ],
        "Text": "1. Fasting glucose > 7.0 or have diabetes medication; . 2. Male, 35-80 years; female, postmenopausal to 80 years; . 3. Agree to participant in the trial. . "
    },
    "NCT02101554_exc": {
        "Text": "Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year.. Hypersensitivity to morphine, naltrexone.. A life expectancy (assessed by investigator) of less than 6 months or is no longer capable of taking medication orally.. Undergone surgery within 3 days prior to the first day of dosing.. ",
        "Annotations": [
            "Measurement 0 38--*--Columbia-Suicide Severity Rating Scale",
            "Measurement 40 46--*--C-SSRS",
            "Condition 52 69--*--suicidal ideation",
            "Condition 52 60;74 82--*--suicidal behavior",
            "Temporal 83 95--*--in past year",
            "Scope 52 82--*--suicidal ideation and behavior",
            "Condition 98 114--*--Hypersensitivity",
            "Drug 118 126--*--morphine",
            "Drug 128 138--*--naltrexone",
            "Scope 118 138--*--morphine, naltrexone",
            "Observation 143 158--*--life expectancy",
            "Value 189 207--*--less than 6 months",
            "Non-query-able 211 259--*--is no longer capable of taking medication orally",
            "Procedure 272 279--*--surgery",
            "Temporal 280 326--*--within 3 days prior to the first day of dosing",
            "Reference_point 307 326--*--first day of dosing"
        ]
    },
    "NCT02186600_exc": {
        "Text": "Have osteoporosis . Have a 10 yr probability of hip fracture >3% or major fracture >20% based on results of the FRAX tool . Currently take bisphosphonates, estrogen replacement therapy, glucocorticosteroids, or other drugs affecting bone . Currently participate in a resistance training or high impact weight bearing exercise program two or more times weekly . Weigh >300 lbs . Have abnormal results for the following laboratory tests: serum 25(OH)D; serum creatinine; serum calcium; PTH; TSH . Have Paget's disease, heart disease, uncontrolled hypertension, renal disease, or other concomitant conditions that prohibit participation in exercises, risedronate therapy, or use of CaD supplements.       .     . ",
        "Annotations": [
            "Condition 5 17--*--osteoporosis",
            "Measurement 26 59--*--10 yr probability of hip fracture",
            "Condition 47 59--*--hip fracture",
            "Value 60 63--*-->3%",
            "Measurement 26 46;67 81--*--10 yr probability of major fracture",
            "Condition 67 81--*--major fracture",
            "Undefined_semantics 67 81--*--major fracture",
            "Value 82 86--*-->20%",
            "Drug 137 152--*--bisphosphonates",
            "Procedure 154 182--*--estrogen replacement therapy",
            "Drug 184 204--*--glucocorticosteroids",
            "Drug 215 235--*--drugs affecting bone",
            "Undefined_semantics 215 235--*--drugs affecting bone",
            "Condition 247 283--*--participate in a resistance training",
            "Non-query-able 247 283--*--participate in a resistance training",
            "Condition 247 261;287 322--*--participate in high impact weight bearing exercise",
            "Non-query-able 247 261;287 322--*--participate in high impact weight bearing exercise",
            "Multiplier 331 355--*--two or more times weekly",
            "Measurement 357 362--*--Weigh",
            "Value 363 371--*-->300 lbs",
            "Value 378 394--*--abnormal results",
            "Measurement 431 444--*--serum 25(OH)D",
            "Measurement 446 462--*--serum creatinine",
            "Measurement 464 477--*--serum calcium",
            "Measurement 479 482--*--PTH",
            "Measurement 484 487--*--TSH",
            "Condition 494 509--*--Paget's disease",
            "Condition 511 524--*--heart disease",
            "Condition 526 551--*--uncontrolled hypertension",
            "Condition 553 566--*--renal disease",
            "Condition 571 640--*--other concomitant conditions that prohibit participation in exercises",
            "Undefined_semantics 571 640--*--other concomitant conditions that prohibit participation in exercises",
            "Procedure 642 661--*--risedronate therapy",
            "Drug 673 688--*--CaD supplements"
        ]
    },
    "NCT03511521_inc": {
        "Text": "Patients receiving once daily dosing of methylprednisolone or prednisone in a dose of 10 mg/day or greater. Hyperglycemic (Glucose level > 126 mg/dL). Diabetic and nondiabetic patients. Expected duration of hospital stay and time on steroids >= 3 days. Patient of appropriate caregiver able to give Informed Consent. ",
        "Annotations": [
            "Multiplier 19 29--*--once daily",
            "Drug 40 58--*--methylprednisolone",
            "Drug 62 72--*--prednisone",
            "Multiplier 86 106--*--10 mg/day or greater",
            "Scope 40 72--*--methylprednisolone or prednisone",
            "Condition 108 121--*--Hyperglycemic",
            "Measurement 123 136--*--Glucose level",
            "Value 137 148--*--> 126 mg/dL",
            "Scope 123 148--*--Glucose level > 126 mg/dL",
            "Condition 164 175--*--nondiabetic",
            "Condition 151 159--*--Diabetic",
            "Measurement 186 220--*--Expected duration of hospital stay",
            "Measurement 225 241--*--time on steroids",
            "Value 242 251--*-->= 3 days",
            "Informed_consent 253 315--*--Patient of appropriate caregiver able to give Informed Consent"
        ]
    },
    "NCT01857167_exc": {
        "Annotations": [
            "Post-eligibility 3 37--*--Deny to sign the informed consent;",
            "Non-query-able 3 37--*--Deny to sign the informed consent;",
            "Condition 42 57--*--type 1 diabetes",
            "Condition 81 101--*--hypertriglyceridemia",
            "Measurement 105 125--*--fasting triglyceride",
            "Value 125 137--*-->4.56 mmol/L",
            "Observation 63 77--*--Family history",
            "Scope 81 137--*--hypertriglyceridemia or fasting triglyceride>4.56 mmol/L",
            "Qualifier 148 154--*--severe",
            "Condition 155 168--*--liver disease",
            "Condition 170 184--*--kidney disease",
            "Condition 188 194--*--cancer",
            "Context_Error 200 257--*--Participating in the other clinical trial within 30 days;",
            "Condition 262 276--*--Other diseases",
            "Condition 262 267;280 290--*--Other conditions",
            "Undefined_semantics 262 290--*--Other diseases or conditions",
            "Subjective_judgement 292 367--*--for which the doctor of the patients do not agree his or her participating.",
            "Qualifier 292 366--*--for which the doctor of the patients do not agree his or her participating",
            "Scope 262 290--*--Other diseases or conditions",
            "Non-query-able 262 367--*--Other diseases or conditions, for which the doctor of the patients do not agree his or her participating."
        ],
        "Text": "1. Deny to sign the informed consent; . 2. type 1 diabetes; . 3. Family history of hypertriglyceridemia or fasting triglyceride>4.56 mmol/L; . 4. Have severe liver disease, kidney disease or cancer; . 5. Participating in the other clinical trial within 30 days; . 6. Other diseases or conditions, for which the doctor of the patients do not agree his or her participating.       .     . "
    },
    "NCT03228017_inc": {
        "Text": "Subjects with a history of moderate to severe psoriatic disease. Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease. ",
        "Annotations": [
            "Qualifier 27 35--*--moderate",
            "Qualifier 39 45--*--severe",
            "Condition 46 63--*--psoriatic disease",
            "Scope 27 45--*--moderate to severe",
            "Observation 16 23--*--history",
            "Condition 74 81--*--Healthy",
            "Condition 105 122--*--psoriatic disease",
            "Condition 126 148--*--cardiovascular disease",
            "Negation 91 98--*--without",
            "Scope 105 148--*--psoriatic disease or cardiovascular disease"
        ]
    },
    "NCT02101554_inc": {
        "Text": "Children 7-17 with moderate to severe pain requiring around the clock treatment with an opioid analgesic.. Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to >20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing.. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Condition 38 42--*--pain",
            "Qualifier 19 27--*--moderate",
            "Qualifier 31 37--*--severe",
            "Drug 88 104--*--opioid analgesic",
            "Procedure 53 79--*--around the clock treatment",
            "Scope 19 37--*--moderate to severe",
            "Drug 174 188--*--opioid therapy",
            "Drug 231 239--*--morphine",
            "Multiplier 213 227--*-->20 mg per day",
            "Qualifier 190 200--*--equivalent",
            "Drug 231 239--*--morphine",
            "Temporal 257 316--*--3 consecutive days immediately prior to first day of dosing",
            "Reference_point 297 316--*--first day of dosing",
            "Scope 190 239--*--equivalent or equal to >20 mg per day of morphine"
        ]
    },
    "NCT02186600_inc": {
        "Text": "Women who are in their first 5 years of menopause . Have a T score between -1 and -2.49 at the femoral neck, total hip, or L1-L4 spine . Be 19 years of age or older . Have their health care provider's permission to enroll in the study. . ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Temporal 15 49--*--n their first 5 years of menopause",
            "Reference_point 40 49--*--menopause",
            "Condition 40 49--*--menopause",
            "Measurement 58 65--*--T score",
            "Temporal 66 86--*--between -1 and -2.49",
            "Qualifier 94 106--*--femoral neck",
            "Qualifier 108 117--*--total hip",
            "Qualifier 122 133--*--L1-L4 spine",
            "Value 138 162--*--19 years of age or older",
            "Person 150 153--*--age",
            "Non-query-able 164 232--*--Have their health care provider's permission to enroll in the study."
        ]
    },
    "NCT02205502_inc": {
        "Annotations": [
            "Procedure 18 26--*--suturing",
            "Condition 31 41--*--laceration",
            "Procedure 48 69--*--procedural anesthesia",
            "Drug 76 84--*--ketamine"
        ],
        "Text": "patients who need suturing for laceration under procedural anesthesia using ketamine. "
    },
    "NCT02316886_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--18 years or older",
            "Qualifier 38 50--*--asymptomatic",
            "Condition 51 74--*--coronary artery disease",
            "Qualifier 23 34--*--Symptomatic",
            "Scope 23 50--*--Symptomatic or asymptomatic",
            "Measurement 85 88--*--MLA",
            "Measurement 89 109--*--minimal luminal area",
            "Value 110 115--*--<4mm2",
            "Measurement 117 130--*--plaque burden",
            "Value 130 134--*-->70%",
            "Condition 136 153--*--Lipid-rich plaque",
            "Procedure 157 161--*--NIRS",
            "Procedure 162 202--*--Intracoronary Near-Infrared Spectroscopy",
            "Measurement 216 226--*--maxLCBI4mm",
            "Value 226 230--*-->315",
            "Multiplier 233 234--*--2",
            "Condition 235 260--*--target vulnerable lesions",
            "Mood 262 274--*--Eligible for",
            "Procedure 275 309--*--percutaneous coronary intervention",
            "Device 315 353--*--Absorb Bioresorbable Vascular Scaffold",
            "Device 357 381--*--Everolimus Eluting Stent",
            "Scope 315 381--*--Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent",
            "Post-eligibility 383 435--*--Willing and able to provide informed written consent",
            "Measurement 437 462--*--Reference vessel diameter",
            "Value 463 471--*--2.75-4.0",
            "Measurement 473 486--*--Lesion length",
            "Value 487 491--*--= 40"
        ],
        "Text": "Age 18 years or older. Symptomatic or asymptomatic coronary artery disease patients. MLA(minimal luminal area)<4mm2. plaque burden>70%. Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as maxLCBI4mm>315). 2 target vulnerable lesions. Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent. Willing and able to provide informed written consent. Reference vessel diameter 2.75-4.0. Lesion length = 40. "
    },
    "NCT03491059_inc": {
        "Annotations": [
            "Person 0 5--*--males",
            "Person 10 17--*--females",
            "Person 55 58--*--age",
            "Value 18 51--*--greater than or equal to 18 years",
            "Person 76 80--*--user",
            "Qualifier 68 75--*--regular",
            "Qualifier 84 96--*--e-cigarettes",
            "Multiplier 102 121--*--at least once daily",
            "Temporal 122 142--*--for the past 30 days",
            "Measurement 149 166--*--nicotine strength",
            "Value 167 175--*--> 6mg/ml",
            "Observation 184 199--*--medical history",
            "Qualifier 177 183--*--health",
            "Condition 201 210--*--abstinent",
            "Drug 220 227--*--tobacco",
            "Drug 228 236--*--nicotine",
            "Scope 220 236--*--tobacco/nicotine",
            "Temporal 241 269--*--for 4 hours prior to imaging",
            "Reference_point 262 269--*--imaging"
        ],
        "Text": "males and females greater than or equal to 18 years of age. current regular user of e-cigarettes (use at least once daily for the past 30 days) with nicotine strength > 6mg/ml. health medical history. abstinent from any tobacco/nicotine use for 4 hours prior to imaging. "
    },
    "NCT02990403_exc": {
        "Annotations": [
            "Qualifier 19 25--*--severe",
            "Condition 26 35--*--allergies",
            "Condition 37 43--*--trauma",
            "Observation 44 51--*--history",
            "Procedure 59 68--*--operation",
            "Observation 69 76--*--history",
            "Temporal 77 92--*--within 3 months",
            "Scope 19 76--*--severe allergies, trauma history and/or operation history",
            "Condition 113 127--*--mental illness",
            "Observation 102 109--*--history",
            "Observation 135 149--*--family history",
            "Condition 153 167--*--mental illness",
            "Qualifier 168 181--*--limb disabled",
            "Drug 191 199--*--medicine",
            "Qualifier 200 216--*--within one month",
            "Condition 229 241--*--major events",
            "Condition 252 263--*--mood swings",
            "Condition 286 302--*--surgical disease",
            "Procedure 286 294--*--surgical",
            "Condition 273 281;295 302--*--internal disease",
            "Procedure 327 347--*--physical examination",
            "Procedure 356 373--*--electrocardiogram",
            "Procedure 374 381;392 400--*--hepatic function",
            "Procedure 386 400--*--renal function",
            "Procedure 401 414--*--blood routine",
            "Procedure 419 432--*--urine routine",
            "Temporal 303 432--*--after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine",
            "Reference_point 309 432--*--having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine",
            "Scope 327 432--*--physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine",
            "Scope 273 302--*--internal and surgical disease",
            "Condition 435 457--*--chromosome aberrations",
            "Observation 461 481--*--anyone of the couple",
            "Qualifier 461 481--*--anyone of the couple",
            "Drug 502 507--*--drugs",
            "Condition 508 525--*--contraindications"
        ],
        "Text": "having experienced severe allergies, trauma history and/or operation history within 3 months.. with a history of mental illness and/or family history of mental illness limb disabled.. taking medicine within one month.. suffering major events or having mood swings.. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine). chromosome aberrations in anyone of the couple.. patients who have drugs contraindications. "
    },
    "NCT02316886_exc": {
        "Annotations": [
            "Device 83 90--*--Stented",
            "Condition 91 97--*--lesion",
            "Procedure 44 48--*--CABG",
            "Procedure 49 80--*--Coronary artery bypass grafting",
            "Device 99 111--*--Bypass graft",
            "Condition 112 118--*--lesion",
            "Multiplier 142 165--*--more than or equal to 3",
            "Condition 166 180--*--target lesions",
            "Multiplier 182 183--*--2",
            "Condition 184 198--*--target lesions",
            "Qualifier 199 229--*--in the same coronary territory",
            "Qualifier 231 248--*--Heavily calcified",
            "Qualifier 252 261--*--angulated",
            "Condition 262 268--*--lesion",
            "Scope 231 261--*--Heavily calcified or angulated",
            "Condition 270 288--*--Bifurcation lesion",
            "Multiplier 299 300--*--2",
            "Procedure 301 319--*--stenting technique",
            "Condition 321 337--*--Contraindication",
            "Mood 344 367--*--planned discontinuation",
            "Procedure 371 396--*--dual antiplatelet therapy",
            "Temporal 397 410--*--within 1 year",
            "Scope 321 367--*--Contraindication to or planned discontinuation",
            "Observation 412 427--*--Life expectancy",
            "Value 428 445--*--less than 2 years",
            "Procedure 455 470--*--cardiac surgery",
            "Mood 474 481--*--planned",
            "Mood 447 454--*--Planned",
            "Qualifier 482 487--*--major",
            "Procedure 488 507--*--non cardiac surgery",
            "Person 509 514--*--Woman",
            "Observation 523 536--*--breastfeeding",
            "Condition 538 546--*--pregnant",
            "Mood 550 568--*--planning to become",
            "Condition 569 577--*--pregnant",
            "Temporal 578 608--*--during the course of the study",
            "Scope 523 577--*--breastfeeding, pregnant or planning to become pregnant"
        ],
        "Text": "Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting). Stented lesion. Bypass graft lesion. The patients who have more than or equal to 3 target lesions. 2 target lesions in the same coronary territory. Heavily calcified or angulated lesion. Bifurcation lesion requiring 2 stenting technique. Contraindication to or planned discontinuation of dual antiplatelet therapy within 1 year. Life expectancy less than 2 years. Planned cardiac surgery or planned major non cardiac surgery. Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study. "
    },
    "NCT03491059_exc": {
        "Annotations": [
            "Person 6 18--*--regular user",
            "Procedure 22 34--*--e-cigarettes",
            "Negation 0 3--*--not",
            "Pregnancy_considerations 36 92--*--pregnant or lactating (only excluded from imaging study)",
            "Person 94 102--*--prisoner",
            "Post-eligibility 104 140--*--incapable of giving informed consent",
            "Post-eligibility 142 204--*--unable to lie flat on the scanner for extended periods of time",
            "Qualifier 206 214--*--unstable",
            "Condition 215 232--*--medical condition",
            "Condition 238 251--*--heart disease",
            "Condition 266 278--*--hypertension",
            "Qualifier 253 265--*--uncontrolled",
            "Condition 280 295--*--thyroid disease",
            "Condition 297 305--*--diabetes",
            "Condition 316 332--*--liver impairment",
            "Condition 307 312;322 332--*--renal impairment",
            "Condition 337 345--*--glaucoma",
            "Scope 238 344--*--heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucom",
            "Condition 347 368--*--prostatic hypertrophy",
            "Condition 370 376--*--stroke",
            "Condition 381 386--*--ulcer",
            "Condition 401 423--*--psychiatric conditions",
            "Condition 432 445--*--schizophrenia",
            "Condition 447 457--*--adult ADHD",
            "Condition 462 478--*--bipolar disorder",
            "Scope 432 478--*--schizophrenia, adult ADHD, or bipolar disorder",
            "Drug 506 529--*--psychiatric medications",
            "Drug 538 551--*--tranquilizers",
            "Drug 553 567--*--antipsychotics",
            "Drug 576 591--*--antidepressants",
            "Scope 538 591--*--tranquilizers, antipsychotics, and/or antidepressants",
            "Drug 600 611--*--medications",
            "Qualifier 621 639--*--inducers of CYP2A6",
            "Drug 643 671--*--nicotine metabolizing enzyme",
            "Drug 681 691--*--rifampicin",
            "Drug 693 706--*--dexamethasone",
            "Drug 708 721--*--phenobarbital",
            "Drug 733 754--*--anti-convulsant drugs",
            "Scope 681 754--*--rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs",
            "Non-query-able 756 788--*--unable to communicate in English",
            "Procedure 805 822--*--smokeless tobacco",
            "Procedure 824 842--*--tobacco cigarettes",
            "Multiplier 844 861--*--5 and fewer a day",
            "Scope 805 842--*--smokeless tobacco, tobacco cigarettes",
            "Non-query-able 865 952--*--ccasional use of pipes is permitted if subject abstains for the week prior to the study",
            "Person 968 973--*--years",
            "Value 954 967--*--older than 80"
        ],
        "Text": "not a regular user of e-cigarettes. pregnant or lactating (only excluded from imaging study). prisoner. incapable of giving informed consent. unable to lie flat on the scanner for extended periods of time. unstable medical condition like heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucoma. prostatic hypertrophy, stroke, or ulcer in past year. psychiatric conditions such as schizophrenia, adult ADHD, or bipolar disorder. current or regular use of psychiatric medications such as tranquilizers, antipsychotics, and/or antidepressants. use of medications that are inducers of CYP2A6 (a nicotine metabolizing enzyme) such as rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs. unable to communicate in English. current use of smokeless tobacco, tobacco cigarettes (5 and fewer a day). occasional use of pipes is permitted if subject abstains for the week prior to the study. older than 80 years. "
    },
    "NCT02205502_exc": {
        "Annotations": [
            "Drug 20 28--*--ketamine",
            "Drug 33 42--*--lidocaine",
            "Condition 0 16--*--contraindication",
            "Scope 20 42--*--ketamine and lidocaine",
            "Competing_trial 44 78--*--patients involved to other studies",
            "Measurement 97 145--*--American Society of Anesthesiologist (ASA) class",
            "Value 146 149;80 96--*--III more or equal to",
            "Observation 151 160--*--not alert"
        ],
        "Text": "contraindication to ketamine and lidocaine. patients involved to other studies. more or equal to American Society of Anesthesiologist (ASA) class III. not alert. "
    },
    "NCT02990403_inc": {
        "Annotations": [
            "Person 0 5--*--Woman",
            "Multiplier 14 15--*--2",
            "Condition 16 27--*--miscarriage",
            "Qualifier 28 59--*--before 12(th) week of gestation",
            "Temporal 28 59--*--before 12(th) week of gestation",
            "Reference_point 35 59--*--12(th) week of gestation",
            "Condition 92 105--*--thrombophilia",
            "Multiplier 111 120--*--recurrent",
            "Condition 121 135--*--pregnancy loss",
            "Informed_consent 137 157--*--Signed consent form."
        ],
        "Text": "Woman who had 2 miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form.. "
    },
    "NCT02695992_exc": {
        "Text": "Congestive heart failure. Ischemic heart disease. Hypotension (Systolic blood pressure <100 mmHg). Treatment with class I or III antiarrhythmic drugs. Severe hepatic or renal failure. Pregnancy or lactation. Hypersensitivity or contradictions to study drugs. Atrio-ventricular conduction disturbances. Thyrotoxicosis. Life limiting disease or substance abuse which may affect participation. ",
        "Annotations": [
            "Condition 0 24--*--Congestive heart failure",
            "Condition 26 48--*--Ischemic heart disease",
            "Condition 50 61--*--Hypotension",
            "Measurement 63 86--*--Systolic blood pressure",
            "Value 87 96--*--<100 mmHg",
            "Scope 63 96--*--Systolic blood pressure <100 mmHg",
            "Qualifier 114 121--*--class I",
            "Qualifier 114 119;125 128--*--class III",
            "Drug 129 149--*--antiarrhythmic drugs",
            "Scope 114 128--*--class I or III",
            "Qualifier 151 157--*--Severe",
            "Condition 169 182--*--renal failure",
            "Condition 158 165;175 182--*--hepatic failure",
            "Scope 158 182--*--hepatic or renal failure",
            "Condition 184 193--*--Pregnancy",
            "Condition 197 206--*--lactation",
            "Condition 208 224--*--Hypersensitivity",
            "Condition 228 242--*--contradictions",
            "Drug 246 257--*--study drugs",
            "Scope 208 242--*--Hypersensitivity or contradictions",
            "Condition 302 316--*--Thyrotoxicosis",
            "Condition 259 300--*--Atrio-ventricular conduction disturbances",
            "Condition 318 339--*--Life limiting disease",
            "Condition 343 358--*--substance abuse",
            "Qualifier 365 389--*--may affect participation",
            "Scope 318 358--*--Life limiting disease or substance abuse"
        ]
    },
    "NCT03376763_exc": {
        "Annotations": [
            "Condition 59 70--*--intolerance",
            "Condition 41 55--*--adverse events",
            "Qualifier 19 40--*--medically significant",
            "Drug 76 88--*--aripiprazole",
            "Temporal 89 112--*--during screening period",
            "Temporal 116 136--*--as prior experiences",
            "Scope 41 70--*--adverse events or intolerance",
            "Scope 89 136--*--during screening period or as prior experiences",
            "Qualifier 163 178--*--DSM-<U+2163>-TR",
            "Condition 205 218--*--schizophrenia",
            "Negation 194 204--*--other than",
            "Qualifier 163 167;182 183--*--DSM- 5",
            "Scope 163 183--*--DSM-<U+2163>-TR or 5",
            "Condition 230 254--*--schizoaffective disorder",
            "Condition 256 281--*--major depressive disorder",
            "Condition 283 299--*--bipolar disorder",
            "Condition 301 309--*--delirium",
            "Condition 311 319--*--dementia",
            "Condition 321 328--*--amnesia",
            "Condition 330 340;432 441--*--Borderline disorders",
            "Condition 342 350;432 441--*--Paranoid disorders",
            "Condition 352 362;432 441--*--Histrionic disorders",
            "Condition 364 375;432 441--*--Schizotypal disorders",
            "Condition 377 385;432 441--*--Schizoid disorders",
            "Condition 387 397;432 441--*--Antisocial disorders",
            "Qualifier 401 406--*--other",
            "Condition 407 416;432 441--*--cognitive disorders",
            "Condition 420 441--*--personality disorders",
            "Scope 407 441--*--cognitive or personality disorders",
            "Scope 230 441--*--schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders",
            "Scope 163 218--*--DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia",
            "Post-eligibility 444 584--*--Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.",
            "Drug 622 631--*--clozapine",
            "Drug 635 677--*--long-acting injectable antipsychotic drugs",
            "Temporal 678 716--*--within 3 months prior to the screening",
            "Reference_point 703 716--*--the screening",
            "Scope 622 677--*--clozapine or long-acting injectable antipsychotic drugs",
            "Multiplier 755 779--*--maximum maintenance dose",
            "Drug 812 831--*--oral antipsychotics",
            "Temporal 832 844--*--at screening",
            "Drug 852 864--*--Aripiprazole",
            "Drug 875 885--*--Olanzapine",
            "Drug 896 907--*--Risperidone",
            "Drug 919 929--*--Quetiapine",
            "Value 930 941--*--> 750mg/day",
            "Value 908 917--*--> 6mg/day",
            "Value 885 894--*-->20mg/day",
            "Value 864 873--*-->30mg/day",
            "Scope 852 941--*--Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone > 6mg/day, Quetiapine > 750mg/day",
            "Scope 755 831--*--maximum maintenance dose (as specified in each label) of oral antipsychotics",
            "Observation 980 997--*--violent behaviour",
            "Condition 1023 1041--*--committing suicide",
            "Mood 1003 1019--*--significant risk",
            "Mood 960 976--*--significant risk",
            "Condition 1114 1122--*--seizures",
            "Condition 1124 1154--*--neuroleptic malignant syndrome",
            "Qualifier 1156 1178--*--clinically significant",
            "Condition 1179 1197--*--tardive dyskinesia",
            "Non-representable 1199 1298--*--or other medical condition that would expose them to undue risk or interfere with study assessments",
            "Observation 1103 1110--*--history",
            "Scope 1114 1197--*--seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia",
            "Intoxication_considerations 1301 1490--*--Significant history of drug abuse disorder (including alcohol, as defined in DSM-5 substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening.",
            "Competing_trial 1492 1587--*--Subjects participating another interventional clinical trial within 30 days prior to screening.",
            "Pregnancy_considerations 1589 1672--*--Women who are pregnant, nursing, or who plan to become pregnant while in the trial.",
            "Post-eligibility 1674 1871--*--Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study."
        ],
        "Text": "Subject who showed medically significant adverse events or intolerance with aripiprazole during screening period or as prior experiences.. Subjects with a current DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders.. Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.. Subjects who have been treated with clozapine or long-acting injectable antipsychotic drugs within 3 months prior to the screening.. Subjects who have been treated over maximum maintenance dose (as specified in each label) of oral antipsychotics at screening. (e.g. Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone > 6mg/day, Quetiapine > 750mg/day). Subjects with a significant risk of violent behaviour or a significant risk of committing suicide based on history or investigator's judgment.. Subjects had a history of seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or other medical condition that would expose them to undue risk or interfere with study assessments.. Significant history of drug abuse disorder (including alcohol, as defined in DSM-5 substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening.. Subjects participating another interventional clinical trial within 30 days prior to screening.. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.. Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study.. "
    },
    "NCT02797548_inc": {
        "Text": "Planned non-cardiac surgery at least after 12 months of implantation of drug eluting stent. Low or intermediate risk level surgery. Written informed consent. ",
        "Annotations": [
            "Condition 8 27--*--non-cardiac surgery",
            "Temporal 28 90--*--at least after 12 months of implantation of drug eluting stent",
            "Reference_point 56 90--*--implantation of drug eluting stent",
            "Procedure 56 68--*--implantation",
            "Device 72 90--*--drug eluting stent",
            "Mood 0 7--*--Planned",
            "Procedure 99 130--*--intermediate risk level surgery",
            "Procedure 112 130;92 95--*--risk level surgery Low",
            "Observation 132 156--*--Written informed consent"
        ]
    },
    "NCT00404495_inc": {
        "Text": "Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease. . Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3 or 4) . Life expectancy \u2265 3 months . ",
        "Annotations": [
            "Condition 23 49--*--refractory medulloblastoma",
            "Condition 10 19;34 49--*--Recurrent medulloblastoma",
            "Procedure 67 85--*--standard treatment",
            "Qualifier 102 108--*--failed",
            "Scope 10 49--*--Recurrent or refractory medulloblastoma",
            "Condition 183 200--*--high-grade glioma",
            "Measurement 202 239--*--World Health Organization [WHO] grade",
            "Value 240 246--*--3 or 4",
            "Measurement 249 264--*--Life expectancy",
            "Value 265 275--*--\u2265 3 months",
            "Mood 120 132--*--not required"
        ]
    },
    "NCT02652637_exc": {
        "Annotations": [
            "Procedure 0 17--*--Emergency surgery",
            "Mood 18 24--*--needed",
            "Condition 26 43--*--Bowel obstruction",
            "Procedure 45 56--*--Colonoscopy",
            "Temporal 84 98--*--peroperatively",
            "Mood 57 66--*--scheduled",
            "Procedure 73 83--*--undertaken",
            "Procedure 124 146--*--mechanical preparation",
            "Condition 150 163--*--contradicting",
            "Drug 184 189--*--drugs",
            "Condition 168 175--*--Allergy",
            "Drug 191 194--*--PEG",
            "Drug 196 204--*--neomycin",
            "Drug 206 219--*--metronidazole",
            "Scope 191 219--*--PEG, neomycin, metronidazole"
        ],
        "Text": "Emergency surgery needed. Bowel obstruction. Colonoscopy scheduled to be undertaken peroperatively. Other reason indicating mechanical preparation or contradicting it. Allergy to used drugs (PEG, neomycin, metronidazole). "
    },
    "NCT03337581_exc": {
        "Annotations": [
            "Drug 12 27--*--dexmedetomidine",
            "Condition 0 8--*--allergic",
            "Drug 29 55--*--similar active ingredients",
            "Drug 59 69--*--excipients",
            "Scope 12 69--*--dexmedetomidine, similar active ingredients or excipients",
            "Condition 71 88--*--G-6-PD deficiency",
            "Condition 103 113--*--arrhythmia",
            "Observation 92 99--*--history",
            "Condition 115 124;144 152--*--bronchial diseases",
            "Condition 129 152--*--cardiovascular diseases",
            "Condition 154 177--*--abnormal liver function",
            "Scope 103 177--*--arrhythmia, bronchial and cardiovascular diseases, abnormal liver function",
            "Observation 191 198--*--history",
            "Drug 209 234--*--alpha 2 receptor agonists",
            "Drug 209 225;238 249--*--alpha 2 receptor antagonists",
            "Scope 209 249--*--alpha 2 receptor agonists or antagonists"
        ],
        "Text": "allergic to dexmedetomidine, similar active ingredients or excipients. G-6-PD deficiency. a history of arrhythmia, bronchial and cardiovascular diseases, abnormal liver function and so on. a history of use of alpha 2 receptor agonists or antagonists.. "
    },
    "NCT02797548_exc": {
        "Text": "Acute coronary syndrome within 1 month. Heart failure NYHA III to IV. Contraindication to Aspirin. On anticoagulant therapy. Emergent surgery. Cardiac surgery. High bleeding risk surgeries, e.g., Intra-cranial surgery, Intra-spinal surgery, Retinal surgery. Pregnancy or breast-feeding. Life expectancy less than 1year. ",
        "Annotations": [
            "Condition 0 23--*--Acute coronary syndrome",
            "Temporal 24 38--*--within 1 month",
            "Condition 40 53--*--Heart failure",
            "Measurement 54 58--*--NYHA",
            "Value 59 68--*--III to IV",
            "Condition 70 86--*--Contraindication",
            "Drug 90 97--*--Aspirin",
            "Procedure 102 123--*--anticoagulant therapy",
            "Procedure 125 141--*--Emergent surgery",
            "Procedure 143 158--*--Cardiac surgery",
            "Condition 160 188--*--High bleeding risk surgeries",
            "Condition 196 217--*--Intra-cranial surgery",
            "Condition 219 239--*--Intra-spinal surgery",
            "Condition 241 256--*--Retinal surgery",
            "Scope 196 256--*--Intra-cranial surgery, Intra-spinal surgery, Retinal surgery",
            "Condition 258 267--*--Pregnancy",
            "Condition 271 285--*--breast-feeding",
            "Observation 287 302--*--Life expectancy",
            "Value 303 318--*--less than 1year"
        ]
    },
    "NCT03376763_inc": {
        "Annotations": [
            "Informed_consent 0 109--*--Subjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).",
            "Person 111 115--*--Male",
            "Person 120 126--*--female",
            "Person 127 131--*--aged",
            "Value 132 150--*--=19 and < 65 years",
            "Condition 175 188--*--schizophrenia",
            "Qualifier 203 330--*--Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria",
            "Observation 338 356--*--history of illness",
            "Multiplier 357 381--*--for at least for 3 years",
            "Temporal 382 400--*--prior to screening",
            "Drug 421 449--*--atypical antipsychotic drugs",
            "Non-representable 451 600--*--and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening",
            "Non-representable 603 775--*--Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement.",
            "Post-eligibility 777 911--*--Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures."
        ],
        "Text": "Subjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).. Male and female aged =19 and < 65 years.. Subjects diagnosed of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria, and a history of illness for at least for 3 years prior to screening.. Subjects who take atypical antipsychotic drugs, and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening.. Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement.. Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures.. "
    },
    "NCT02695992_inc": {
        "Text": "Above 18 years of age. Symptomatic, permanent AF of at least three months duration. Resting heart rate =80 bpm. Signed informed consent. ",
        "Annotations": [
            "Person 18 21--*--age",
            "Value 0 14--*--Above 18 years",
            "Qualifier 23 34--*--Symptomatic",
            "Qualifier 36 45--*--permanent",
            "Condition 46 48--*--AF",
            "Multiplier 52 82--*--at least three months duration",
            "Scope 23 45--*--Symptomatic, permanent",
            "Measurement 84 102--*--Resting heart rate",
            "Value 103 110--*--=80 bpm",
            "Informed_consent 112 135--*--Signed informed consent"
        ]
    },
    "NCT02652637_inc": {
        "Annotations": [
            "Condition 20 35--*--colon resection",
            "Temporal 9 19--*--undergoing"
        ],
        "Text": "Patients undergoing colon resection. "
    },
    "NCT00404495_exc": {
        "Text": "Diagnosis of brainstem glioma . Concurrent administration of any other anti-tumor therapy . Pre-existing uncontrolled diarrhea       .     . ",
        "Annotations": [
            "Condition 13 29--*--brainstem glioma",
            "Procedure 70 88--*--anti-tumor therapy",
            "Condition 103 124--*--uncontrolled diarrhea",
            "Temporal 31 41--*--Concurrent",
            "Qualifier 60 69--*--any other"
        ]
    },
    "NCT03337581_inc": {
        "Annotations": [
            "Procedure 23 45--*--inguinal hernia repair",
            "Procedure 53 74--*--orthopedics operation",
            "Procedure 78 103--*--general surgery operation",
            "Person 107 115--*--children",
            "Person 117 121--*--aged",
            "Value 122 131--*--3-9 years",
            "Measurement 133 136--*--ASA",
            "Value 137 143--*--I - II",
            "Non-query-able 145 196--*--enter the operating room by himself without parents",
            "Condition 198 204;215 230--*--normal kidney function",
            "Condition 198 210;222 230--*--normal liver function",
            "Negation 232 234--*--no",
            "Observation 235 242--*--history",
            "Drug 246 267--*--anesthesia medication",
            "Condition 268 275--*--allergy"
        ],
        "Text": "selective operation of inguinal hernia repair<U+3001>orthopedics operation or general surgery operation in children. aged 3-9 years. ASA I - II. enter the operating room by himself without parents. normal liver and kidney function. no history of anesthesia medication allergy.. "
    },
    "NCT03513757_inc": {
        "Text": "All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.. ",
        "Annotations": [
            "Qualifier 27 37--*--outpatient",
            "Procedure 38 47--*--MRI scans",
            "Measurement 53 78--*--expected duration of scan",
            "Value 79 112--*--between 30 minutes and 75 minutes"
        ]
    },
    "NCT02072811_exc": {
        "Text": "No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol . Pregnancy . HIV infection . Active cancer . Active hepatitis virus infection       .     . ",
        "Annotations": [
            "Non-query-able 0 164--*--No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol",
            "Condition 166 175--*--Pregnancy",
            "Condition 177 190--*--HIV infection",
            "Condition 199 205--*--cancer",
            "Temporal 192 198--*--Active",
            "Condition 214 239--*--hepatitis virus infection",
            "Temporal 207 213--*--Active"
        ]
    },
    "NCT02951754_inc": {
        "Annotations": [
            "Person 0 5--*--White",
            "Person 6 15--*--Brazilian",
            "Person 19 35--*--European descent",
            "Qualifier 56 155--*--Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria",
            "Condition 160 164--*--ADHD",
            "Mood 166 177--*--Eligibility",
            "Drug 181 211--*--immediate-release MPH (IR-MPH)"
        ],
        "Text": "White Brazilian of European descent. Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD. Eligibility to immediate-release MPH (IR-MPH) treatment. "
    },
    "NCT03363295_exc": {
        "Annotations": [
            "Condition 0 8--*--Diabetic",
            "Condition 37 52--*--macular changes",
            "Qualifier 33 36--*--any",
            "Temporal 53 73--*--prior to the surgery",
            "Reference_point 62 73--*--the surgery",
            "Procedure 66 73--*--surgery",
            "Condition 75 95--*--epiretinal membranes",
            "Condition 97 116--*--age macular disease",
            "Condition 118 131--*--macular edema",
            "Scope 75 131--*--epiretinal membranes, age macular disease, macular edema",
            "Qualifier 154 157--*--any",
            "Condition 158 170--*--complication",
            "Procedure 178 205--*--phacoemulsification surgery",
            "Temporal 171 205--*--during phacoemulsification surgery",
            "Reference_point 178 205--*--phacoemulsification surgery"
        ],
        "Text": "Diabetic patients. Patients with any macular changes prior to the surgery (epiretinal membranes, age macular disease, macular edema...). Patients who had any complication during phacoemulsification surgery. "
    },
    "NCT02961582_exc": {
        "Text": "Obstructed outlet syndrome (objectified by defeacography). Irritable bowel syndrome (Rome-IV criteria for irritable bowel syndrome). Congenital or organic bowel pathology. Rectal prolapse. Anatomical limitations preventing placement of an electrode. Skin and perineal disease with risk of infection. Previous large bowel/rectal surgery. Stoma. Coexisting neurological disease. Significant psychological co-morbidity as assessed subjectively by the investigator. Being or attempting to become pregnant during study follow-up. ",
        "Annotations": [
            "Condition 0 26--*--Obstructed outlet syndrome",
            "Procedure 43 56--*--defeacography",
            "Condition 59 83--*--Irritable bowel syndrome",
            "Measurement 85 101--*--Rome-IV criteria",
            "Condition 106 130--*--irritable bowel syndrome",
            "Condition 147 170--*--organic bowel pathology",
            "Condition 133 143;155 170--*--Congenital bowel pathology",
            "Condition 172 187--*--Rectal prolapse",
            "Observation 189 211--*--Anatomical limitations",
            "Procedure 223 248--*--placement of an electrode",
            "Negation 212 222--*--preventing",
            "Non-query-able 189 248--*--Anatomical limitations preventing placement of an electrode",
            "Condition 259 275--*--perineal disease",
            "Condition 250 254;268 275--*--Skin disease",
            "Observation 281 298--*--risk of infection",
            "Parsing_Error 255 258--*--and",
            "Procedure 321 335--*--rectal surgery",
            "Procedure 309 320;328 335--*--large bowel surgery",
            "Parsing_Error 320 321--*--/",
            "Condition 337 342--*--Stoma",
            "Condition 355 375--*--neurological disease",
            "Condition 389 415--*--psychological co-morbidity",
            "Qualifier 377 388--*--Significant",
            "Subjective_judgement 416 460--*--as assessed subjectively by the investigator",
            "Pregnancy_considerations 462 523--*--Being or attempting to become pregnant during study follow-up"
        ]
    },
    "NCT03193684_exc": {
        "Text": "eGFR <60 T2DM patients on insulin, GLP-1 RA or SGLT2 treatment Major organ disease type 1 diabetes. ",
        "Annotations": [
            "Measurement 0 4--*--eGFR",
            "Value 5 8--*--<60",
            "Condition 9 13--*--T2DM",
            "Drug 26 33--*--insulin",
            "Drug 35 40--*--GLP-1",
            "Drug 41 43--*--RA",
            "Drug 47 52--*--SGLT2",
            "Condition 63 82--*--Major organ disease",
            "Condition 83 98--*--type 1 diabetes",
            "Scope 26 52--*--insulin, GLP-1 RA or SGLT2",
            "Line 0 8--*--eGFR <60",
            "Line 9 62--*--T2DM patients on insulin, GLP-1 RA or SGLT2 treatment",
            "Line 63 82--*--Major organ disease",
            "Line 83 98--*--type 1 diabetes"
        ]
    },
    "NCT03196843_exc": {
        "Text": "Patients with a history of any other malignancy.. Concomitant treatment with any other anticancer therapy.. Patient have contraindication to chemotherapy(eg.uncontrolled coronarism and heart failure; History of myocardial infarction within the past 6 months, Chronic obstructive pulmonary, uncontrolled epileptic attack and other disease that investigator consider it unsuitable for the chemotherapy). ",
        "Annotations": [
            "Condition 37 47--*--malignancy",
            "Qualifier 27 36--*--any other",
            "Observation 16 23--*--history",
            "Temporal 50 61--*--Concomitant",
            "Procedure 62 71--*--treatment",
            "Qualifier 77 86--*--any other",
            "Procedure 87 105--*--anticancer therapy",
            "Condition 121 137--*--contraindication",
            "Procedure 141 153--*--chemotherapy",
            "Qualifier 157 169--*--uncontrolled",
            "Condition 170 180--*--coronarism",
            "Condition 185 198--*--heart failure",
            "Scope 170 198--*--coronarism and heart failure",
            "Observation 200 207--*--History",
            "Condition 211 232--*--myocardial infarction",
            "Temporal 233 257--*--within the past 6 months",
            "Condition 259 288--*--Chronic obstructive pulmonary",
            "Qualifier 290 302--*--uncontrolled",
            "Condition 303 319--*--epileptic attack",
            "Qualifier 324 329--*--other",
            "Condition 330 337--*--disease",
            "Condition 368 399--*--unsuitable for the chemotherapy",
            "Procedure 387 399--*--chemotherapy",
            "Scope 157 399--*--uncontrolled coronarism and heart failure; History of myocardial infarction within the past 6 months, Chronic obstructive pulmonary, uncontrolled epileptic attack and other disease that investigator consider it unsuitable for the chemotherapy",
            "Scope 121 153--*--contraindication to chemotherapy"
        ]
    },
    "NCT03154931_exc": {
        "Annotations": [
            "Condition 0 8--*--Suicidal",
            "Condition 32 55--*--automutilation behavior",
            "Qualifier 25 31--*--severe",
            "Condition 63 81--*--psychotic symptoms",
            "Condition 89 109--*--lack of event memory"
        ],
        "Text": "Suicidal patients and/or severe automutilation behavior and/or psychotic symptoms and/or lack of event memory.       .     . "
    },
    "NCT02893228_inc": {
        "Text": "Patients undergoing surgery on shoulder, humerus, or clavicle. ",
        "Annotations": [
            "Procedure 20 27--*--surgery",
            "Qualifier 31 39--*--shoulder",
            "Qualifier 41 48--*--humerus",
            "Qualifier 53 61--*--clavicle",
            "Scope 31 61--*--shoulder, humerus, or clavicle"
        ]
    },
    "NCT03264911_inc": {
        "Annotations": [
            "Value 0 11--*--3 -15 years",
            "Person 12 15--*--old",
            "Measurement 115 119--*--RADT",
            "Condition 49 60--*--pharyngitis",
            "Mood 17 48--*--Clinical symptoms suggestive of",
            "Measurement 66 80--*--MC Isaac score",
            "Value 81 83--*--=3",
            "Measurement 85 113--*--Rapid-antigen detection test",
            "Value 121 129--*--positive",
            "Qualifier 134 138--*--GAS-",
            "Informed_consent 140 185--*--Signed informed parental/patient consent form"
        ],
        "Text": "3 -15 years old. Clinical symptoms suggestive of pharyngitis with MC Isaac score =3. Rapid-antigen detection test (RADT) positive for GAS-. Signed informed parental/patient consent form. "
    },
    "NCT03513757_exc": {
        "Text": "Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders.. All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.. ",
        "Annotations": [
            "Observation 0 16--*--Inpatient status",
            "Condition 18 38--*--airway abnormalities",
            "Condition 40 47--*--allergy",
            "Drug 55 72--*--study medications",
            "Drug 74 78--*--eggs",
            "Drug 83 86--*--soy",
            "Condition 92 115--*--mitochondrial disorders",
            "Scope 55 86--*--study medications, eggs and soy",
            "Condition 140 155--*--cardiac disease",
            "Condition 170 189--*--cardiac arrhythmias",
            "Observation 159 166--*--history"
        ]
    },
    "NCT02961582_inc": {
        "Text": "An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported). Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1). Refractory to conservative treatment. Age: 14-80 years. Straining during =25% of defecations. Lumpy or hard stools in =25% of defecations. Sensation of incomplete evacuation for =25% of defecations. Sensation of anorectal obstruction/blockage for =25% of defecations. Manual manoeuvres to facilitate =25% of defecations. ",
        "Annotations": [
            "Measurement 3 31--*--average defecation frequency",
            "Measurement 33 35--*--DF",
            "Value 40 51--*--<3 per week",
            "Procedure 63 86--*--3-week defecation diary",
            "Multiplier 112 124--*--at least one",
            "Measurement 148 192--*--Rome-IV criteria for idiopathic constipation",
            "Condition 169 192--*--idiopathic constipation",
            "Procedure 206 229--*--3-week defecation diary",
            "Qualifier 125 130--*--other",
            "Procedure 249 271--*--conservative treatment",
            "Qualifier 235 245--*--Refractory",
            "Person 273 276--*--Age",
            "Value 278 289--*--14-80 years",
            "Condition 291 300--*--Straining",
            "Multiplier 308 312--*--=25%",
            "Condition 316 327--*--defecations",
            "Observation 338 349--*--hard stools",
            "Observation 329 334;343 349--*--Lumpy stools",
            "Condition 361 372--*--defecations",
            "Multiplier 353 357--*--=25%",
            "Condition 374 408--*--Sensation of incomplete evacuation",
            "Multiplier 413 417--*--=25%",
            "Condition 421 432--*--defecations",
            "Condition 490 501--*--defecations",
            "Multiplier 482 486--*--=25%",
            "Condition 434 468--*--Sensation of anorectal obstruction",
            "Condition 434 456;469 477--*--Sensation of anorectal blockage",
            "Condition 543 554--*--defecations",
            "Multiplier 535 539--*--=25%",
            "Procedure 503 520--*--Manual manoeuvres",
            "Condition 131 140--*--criterion",
            "Scope 434 477--*--Sensation of anorectal obstruction/blockage",
            "Scope 329 349--*--Lumpy or hard stools",
            "Qualifier 88 104--*--patient-reported"
        ]
    },
    "NCT03193684_inc": {
        "Text": "eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy. ",
        "Annotations": [
            "Measurement 0 4--*--eGFR",
            "Value 4 14--*-->60 ml/min",
            "Condition 15 22--*--healthy",
            "Condition 34 49--*--type 2 diabetes",
            "Line 0 14--*--eGFR>60 ml/min",
            "Line 15 33--*--healthy volunteers",
            "Line 34 80--*--type 2 diabetes patients who otherwise healthy"
        ]
    },
    "NCT02072811_inc": {
        "Text": "Adult acute myeloid leukemia . Age: \u226518 and \u2264 60 . Clinical condition of the patient allows to carry out induction therapy: ECOG performance status: \u2264 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): \u22643 . Informed consent to participate in the study (ICF signed) . The second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level >10% on 7th day. . ",
        "Annotations": [
            "Condition 0 28--*--Adult acute myeloid leukemia",
            "Person 30 33--*--Age",
            "Value 35 47--*--\u226518 and \u2264 60",
            "Measurement 122 145--*--ECOG performance status",
            "Value 147 150--*--\u2264 2",
            "Measurement 159 215--*--Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I)",
            "Value 217 219--*--\u22643",
            "Post-eligibility 221 278--*--Informed consent to participate in the study (ICF signed)",
            "Measurement 362 386--*--percentage of the blasts",
            "Value 400 404--*-->10%",
            "Temporal 405 415--*--on 7th day"
        ]
    },
    "NCT03363295_inc": {
        "Annotations": [
            "Procedure 39 66--*--phacoemulsification surgery",
            "Mood 18 38--*--will be submitted to",
            "Visit 74 135--*--Hospital de Clinicas of State University of Campinas (BRAZIL)",
            "Value 146 159--*--over 18 years",
            "Person 160 163--*--old",
            "Mood 182 197--*--able to perform",
            "Procedure 198 204--*--SD-OCT",
            "Informed_consent 206 240--*--Patients who sign the consent form"
        ],
        "Text": "Any patients that will be submitted to phacoemulsification surgery in the Hospital de Clinicas of State University of Campinas (BRAZIL). Patients over 18 years old. Patients who are able to perform SD-OCT. Patients who sign the consent form. "
    },
    "NCT02951754_exc": {
        "Annotations": [
            "Condition 0 16--*--Contraindication",
            "Drug 21 27--*--IR-MPH",
            "Temporal 33 40--*--Current",
            "Procedure 41 60--*--stimulant treatment",
            "Mood 62 70--*--Evidence",
            "Qualifier 76 98--*--clinically significant",
            "Condition 99 119--*--neurological disease",
            "Qualifier 125 147--*--might affect cognition",
            "Condition 155 163--*--delirium",
            "Condition 165 173--*--dementia",
            "Condition 175 183--*--epilepsy",
            "Condition 185 196--*--head trauma",
            "Condition 202 220--*--multiple sclerosis",
            "Scope 155 220--*--delirium, dementia, epilepsy, head trauma, and multiple sclerosis",
            "Scope 76 147--*--clinically significant neurological disease that might affect cognition",
            "Temporal 223 230--*--Current",
            "Temporal 234 238--*--past",
            "Observation 239 246--*--history",
            "Condition 250 259--*--psychosis",
            "Scope 223 238--*--Current or past",
            "Measurement 261 298--*--Estimated intelligence quotient score",
            "Value 299 312--*--lower than 70"
        ],
        "Text": "Contraindication for IR-MPH use. Current stimulant treatment. Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis). Current or past history of psychosis. Estimated intelligence quotient score lower than 70. "
    },
    "NCT03154931_inc": {
        "Annotations": [
            "Measurement 0 32--*--Clinical Administered PTSD Scale",
            "Value 66 76--*-->30 points",
            "Value 51 61--*--Criteria A"
        ],
        "Text": "Clinical Administered PTSD Scale 5 Monthly version Criteria A and >30 points . "
    },
    "NCT03264911_exc": {
        "Annotations": [
            "Drug 20 29--*--B-lactams",
            "Condition 0 16--*--Hypersensitivity",
            "Temporal 31 42--*--concomitant",
            "Condition 43 50--*--disease",
            "Drug 78 89--*--antibiotics",
            "Procedure 65 72--*--treated",
            "Condition 107 124--*--Immunocompromised",
            "Drug 126 137--*--Antibiotics",
            "Temporal 138 149--*--within 72 h",
            "Condition 162 165--*--ARF",
            "Observation 151 158--*--history",
            "Condition 166 179--*--scarlet fever",
            "Condition 180 188--*--impetigo",
            "Condition 189 213--*--acute glomerulonephritis",
            "Scope 162 213--*--ARF,scarlet fever,impetigo,acute glomerulonephritis",
            "Condition 233 236--*--ARF",
            "Observation 215 229--*--Family history",
            "Condition 250 261--*--pharyngitis",
            "Qualifier 238 249--*--Complicated"
        ],
        "Text": "Hypersensitivity to B-lactams. concomitant disease which must be treated with antibiotics. chronic disease-Immunocompromised. Antibiotics within 72 h. history of ARF,scarlet fever,impetigo,acute glomerulonephritis. Family history of ARF. Complicated pharyngitis. "
    },
    "NCT02893228_exc": {
        "Text": "Patient refusal. Allergy to local anaesthesia. Severe coagulopathy. Contralateral phrenic nerve palsy. Local infection. Moderate to severe pulmonary dysfunction (GOLD II, II, IV). ",
        "Annotations": [
            "Qualifier 47 53--*--Severe",
            "Condition 54 66--*--coagulopathy",
            "Informed_consent 0 15--*--Patient refusal",
            "Condition 17 24--*--Allergy",
            "Drug 28 45--*--local anaesthesia",
            "Qualifier 68 81--*--Contralateral",
            "Condition 82 101--*--phrenic nerve palsy",
            "Condition 103 118--*--Local infection",
            "Qualifier 120 128--*--Moderate",
            "Qualifier 132 138--*--severe",
            "Condition 139 160--*--pulmonary dysfunction",
            "Measurement 162 166--*--GOLD",
            "Value 167 177--*--II, II, IV",
            "Scope 120 138--*--Moderate to severe",
            "Scope 162 177--*--GOLD II, II, IV"
        ]
    },
    "NCT03196843_inc": {
        "Text": "Before participate in the study, patients must understand the treatment plan and willing to participate in the study. Patients must have signed an approved informed consent.. Histopathologic confirmed squamous cell carcinoma of head and neck ,including oral cavity, oropharynx, larynx, or hypopharynx.. Ages=65 years,Not limited to gender.. ECOG performance status =2.. Patients with surgical contraindication or reject to surgery.. Postoperative TNM(primary tumor,regional nodes,metastasis) staging III~IV, positive surgical margin.. without evidence of distant metastases.. No contraindication to chemoradiotherapy.. Life expectancy > 3 months.. Available Organ function: white blood cell=3.5\u00d7109/L, Neutrophils =1.5\u00d7109/L, Hemoglobin =80g/L, Blood platelet>100\u00d7109/L; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)= 2.5 upper limit of normal(ULN); Total bilirubin (TBIL) <1.5 ULN;serum creatinine=1.5 ULN; creatinine clearance of = 50ml/min. ",
        "Annotations": [
            "Post-eligibility 0 173--*--Before participate in the study, patients must understand the treatment plan and willing to participate in the study. Patients must have signed an approved informed consent.",
            "Procedure 175 190--*--Histopathologic",
            "Condition 201 224--*--squamous cell carcinoma",
            "Qualifier 175 200--*--Histopathologic confirmed",
            "Qualifier 228 241--*--head and neck",
            "Qualifier 253 264--*--oral cavity",
            "Qualifier 266 276--*--oropharynx",
            "Qualifier 278 284--*--larynx",
            "Qualifier 289 300--*--hypopharynx",
            "Scope 253 300--*--oral cavity, oropharynx, larynx, or hypopharynx",
            "Person 303 307--*--Ages",
            "Value 307 316--*--=65 years",
            "Measurement 341 364--*--ECOG performance status",
            "Value 365 367--*--=2",
            "Condition 393 409--*--contraindication",
            "Procedure 384 392--*--surgical",
            "Observation 413 419--*--reject",
            "Procedure 423 430--*--surgery",
            "Measurement 447 450;492 499--*--TNM staging",
            "Qualifier 433 446--*--Postoperative",
            "Value 500 507--*--III~IV,",
            "Value 508 516--*--positive",
            "Measurement 517 532--*--surgical margin",
            "Condition 555 573--*--distant metastases",
            "Negation 535 542--*--without",
            "Mood 543 551--*--evidence",
            "Condition 579 595--*--contraindication",
            "Procedure 599 616--*--chemoradiotherapy",
            "Negation 576 578--*--No",
            "Observation 619 634--*--Life expectancy",
            "Value 635 645--*--> 3 months",
            "Measurement 674 690--*--white blood cell",
            "Value 690 700--*--=3.5\u00d7109/L",
            "Measurement 702 713--*--Neutrophils",
            "Value 714 724--*--=1.5\u00d7109/L",
            "Measurement 726 736--*--Hemoglobin",
            "Value 737 743--*--=80g/L",
            "Measurement 745 759--*--Blood platelet",
            "Value 759 769--*-->100\u00d7109/L",
            "Measurement 771 801--*--Alanine aminotransferase (ALT)",
            "Measurement 806 838--*--Aspartate aminotransferase (AST)",
            "Value 838 870--*--= 2.5 upper limit of normal(ULN)",
            "Measurement 872 894--*--Total bilirubin (TBIL)",
            "Value 895 903--*--<1.5 ULN",
            "Measurement 904 920--*--serum creatinine",
            "Value 920 928--*--=1.5 ULN",
            "Measurement 930 950--*--creatinine clearance",
            "Value 954 964--*--= 50ml/min"
        ]
    },
    "NCT02141061_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 184 186--*--2.",
            "Parsing_Error 229 231--*--3.",
            "Parsing_Error 290 292--*--4.",
            "Parsing_Error 338 340--*--5.",
            "Parsing_Error 631 633--*--6.",
            "Parsing_Error 818 820--*--7.",
            "Parsing_Error 932 934--*--8.",
            "Parsing_Error 1023 1025--*--9.",
            "Non-query-able 3 182--*--Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;",
            "Condition 187 194--*--Healthy",
            "Condition 196 209--*--premenopausal",
            "Person 210 216--*--female",
            "Person 217 220--*--age",
            "Value 221 226--*--18-47",
            "Condition 243 288--*--menstrual events that occur in regular cycles",
            "Observation 232 239--*--History",
            "Non-query-able 293 336--*--Agreement not to attempt to become pregnant",
            "Post-eligibility 293 336--*--Agreement not to attempt to become pregnant",
            "Non-query-able 341 459--*--Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication.",
            "Post-eligibility 341 459--*--Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication.",
            "Parsing_Error 460 629--*--Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide;",
            "Post-eligibility 460 629--*--Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide;",
            "Measurement 649 663--*--pregnancy test",
            "Value 640 648--*--negative",
            "Temporal 664 686--*--at the Screening visit",
            "Reference_point 671 686--*--Screening visit",
            "Parsing_Error 688 816--*--An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history",
            "Not_a_criteria 688 816--*--An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history",
            "Condition 821 845--*--Normal laboratory values",
            "Value 821 827--*--Normal",
            "Procedure 828 838--*--laboratory",
            "Measurement 828 838--*--laboratory",
            "Qualifier 849 873--*--clinically insignificant",
            "Subjective_judgement 849 873--*--clinically insignificant",
            "Condition 874 882--*--findings",
            "Temporal 883 895--*--at screening",
            "Reference_point 886 895--*--screening",
            "Subjective_judgement 896 929--*--as determined by the Investigator",
            "Non-query-able 935 1021--*--Subject is willing to remain in the clinic overnight for PK assessment on Days 0 and 8",
            "Post-eligibility 1026 1099--*--Ability to complete the study procedures in compliance with the protocol.",
            "Subjective_judgement 1026 1099--*--Ability to complete the study procedures in compliance with the protocol."
        ],
        "Text": "1. Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures; . 2. Healthy, premenopausal female age 18-47; . 3. History of menstrual events that occur in regular cycles . 4. Agreement not to attempt to become pregnant . 5. Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication. Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide; . 6. Has a negative pregnancy test at the Screening visit. An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history . 7. Normal laboratory values or clinically insignificant findings at screening as determined by the Investigator; . 8. Subject is willing to remain in the clinic overnight for PK assessment on Days 0 and 8 . 9. Ability to complete the study procedures in compliance with the protocol. . "
    },
    "NCT00543712_exc": {
        "Annotations": [
            "Procedure 0 16--*--Systemic therapy",
            "Procedure 20 32--*--radiotherapy",
            "Temporal 33 62--*--within 4 weeks prior to Day 1",
            "Reference_point 57 62--*--Day 1",
            "Scope 0 32--*--Systemic therapy or radiotherapy",
            "Temporal 64 69--*--Prior",
            "Procedure 70 77--*--therapy",
            "Drug 83 125--*--agents targeting the DR5 apoptosis pathway",
            "Qualifier 127 132--*--Major",
            "Procedure 133 151--*--surgical procedure",
            "Procedure 153 164--*--open biopsy",
            "Qualifier 169 180--*--significant",
            "Condition 181 197--*--traumatic injury",
            "Temporal 198 227--*--within 4 weeks prior to Day 1",
            "Reference_point 222 227--*--Day 1",
            "Scope 127 197--*--Major surgical procedure, open biopsy, or significant traumatic injury",
            "Mood 232 252--*--anticipation of need",
            "Qualifier 257 262--*--major",
            "Procedure 263 281--*--surgical procedure",
            "Temporal 282 312--*--during the course of the study",
            "Reference_point 303 312--*--the study",
            "Qualifier 314 319--*--Other",
            "Condition 320 341--*--invasive malignancies",
            "Temporal 342 371--*--within 5 years prior to Day 1",
            "Reference_point 366 371--*--Day 1",
            "Qualifier 379 385--*--active",
            "Condition 386 402--*--brain metastases",
            "Temporal 379 385--*--active",
            "Qualifier 404 416--*--Uncontrolled",
            "Condition 417 437--*--intercurrent illness",
            "Temporal 468 475--*--ongoing",
            "Qualifier 479 485--*--active",
            "Condition 486 495--*--infection",
            "Drug 506 528--*--parenteral antibiotics",
            "Temporal 529 542--*--at enrollment",
            "Scope 468 485--*--ongoing or active",
            "Scope 404 437--*--Uncontrolled intercurrent illness",
            "Scope 468 542--*--ongoing or active infection requiring parenteral antibiotics at enrollment",
            "Reference_point 532 542--*--enrollment",
            "Qualifier 544 566--*--Clinically significant",
            "Qualifier 568 579--*--symptomatic",
            "Condition 580 602--*--cardiovascular disease",
            "Measurement 604 637--*--New York Heart Association (NYHA)",
            "Value 638 657--*--Grade II or greater",
            "Condition 658 682--*--congestive heart failure",
            "Qualifier 684 691--*--serious",
            "Condition 692 710--*--cardiac arrhythmia",
            "Value 712 731--*--Grade II or greater",
            "Condition 732 759--*--peripheral vascular disease",
            "Observation 764 774--*--history of",
            "Qualifier 775 780--*--major",
            "Procedure 781 794--*--heart surgery",
            "Temporal 795 819--*--within 6 months of Day 1",
            "Reference_point 814 819--*--Day 1",
            "Scope 732 794;856 872--*--peripheral vascular disease, or history of major heart surgery limit compliance",
            "Observation 856 872--*--limit compliance",
            "Value 910 918--*--positive",
            "Measurement 923 934--*--hepatitis C",
            "Measurement 938 965--*--hepatitis B surface antigen",
            "Scope 923 965--*--hepatitis C or hepatitis B surface antigen",
            "Observation 967 974--*--History",
            "Qualifier 978 983--*--other",
            "Condition 984 991--*--disease",
            "Condition 993 1014--*--metabolic dysfunction",
            "Procedure 1016 1036--*--physical examination",
            "Condition 1016 1044--*--physical examination finding",
            "Condition 1049 1076--*--clinical laboratory finding",
            "Procedure 1049 1068--*--clinical laboratory",
            "Mood 1095 1107--*--suspicion of",
            "Condition 1110 1117--*--disease",
            "Condition 1121 1130--*--condition",
            "Condition 1136 1151--*--contraindicates",
            "Scope 1110 1130--*--disease or condition",
            "Scope 1095 1130--*--suspicion of a disease or condition",
            "Drug 1162 1182--*--investigational drug",
            "Observation 1197 1233--*--affect interpretation of the results",
            "Observation 1250 1281--*--render the patient at high risk",
            "Condition 1286 1309--*--treatment complications",
            "Scope 1136 1309--*--contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications",
            "Procedure 1318 1341--*--anticoagulation therapy",
            "Drug 1318 1333--*--anticoagulation",
            "Observation 1343 1375--*--Participation in clinical trials",
            "Observation 1379 1422--*--undergoing other investigational procedures",
            "Temporal 1423 1452--*--within 30 days prior to Day 1",
            "Reference_point 1438 1452--*--prior to Day 1",
            "Scope 1343 1422--*--Participation in clinical trials or undergoing other investigational procedures",
            "Condition 1454 1463--*--Pregnancy",
            "Observation 1467 1481--*--breast feeding",
            "Condition 1489 1500--*--sensitivity",
            "Drug 1504 1553--*--any of the products administered during the study",
            "Condition 1559 1567--*--disorder",
            "Negation 1573 1599--*--compromises the ability of",
            "Measurement 1615 1644--*--give written informed consent",
            "Procedure 1652 1680--*--comply with study procedures",
            "Scope 1615 1680--*--give written informed consent and/or comply with study procedures"
        ],
        "Text": "Systemic therapy or radiotherapy within 4 weeks prior to Day 1 . Prior therapy with agents targeting the DR5 apoptosis pathway . Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1, or anticipation of need for major surgical procedure during the course of the study . Other invasive malignancies within 5 years prior to Day 1 . Known active brain metastases . Uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring parenteral antibiotics at enrollment . Clinically significant, symptomatic cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade II or greater peripheral vascular disease, or history of major heart surgery within 6 months of Day 1, or any situation that would likely limit compliance with study requirements . Known to be positive for hepatitis C or hepatitis B surface antigen . History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications . Use of anticoagulation therapy . Participation in clinical trials or undergoing other investigational procedures within 30 days prior to Day 1 . Pregnancy or breast feeding . Known sensitivity to any of the products administered during the study . Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures       .     . "
    },
    "NCT02566928_inc": {
        "Annotations": [
            "Value 0 21--*--between 7 to 70 years",
            "Person 25 28--*--age",
            "Observation 30 47--*--fluent in English",
            "Observation 30 39;51 58--*--fluent in Spanish",
            "Mood 60 68--*--plans to",
            "Procedure 69 81--*--receive care",
            "Visit 89 112--*--Community Health Center",
            "Temporal 113 133--*--during the next year",
            "Condition 149 154--*--signs",
            "Condition 159 167--*--symptoms",
            "Condition 173 177--*--SSTI",
            "Scope 149 167--*--signs and symptoms",
            "Informed_consent 179 219--*--willing/able to provide informed consent"
        ],
        "Text": "between 7 to 70 years of age. fluent in English or Spanish. plans to receive care in the Community Health Center during the next year. presents with signs and symptoms of a SSTI. willing/able to provide informed consent. "
    },
    "NCT02689024_inc": {
        "Text": "adult patients aged = 55 years with. a radiographically confirmed hip fracture. ",
        "Annotations": [
            "Person 0 5--*--adult",
            "Person 15 19--*--aged",
            "Value 20 30--*--= 55 years",
            "Condition 66 78--*--hip fracture",
            "Procedure 39 55--*--radiographically"
        ]
    },
    "NCT02650388_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 75 years",
            "Qualifier 17 23--*--Severe",
            "Qualifier 25 36--*--symptomatic",
            "Condition 37 52--*--aortic stenosis",
            "Qualifier 55 64--*--High risk",
            "Procedure 69 84--*--cardiac surgery",
            "Qualifier 86 89--*--STS",
            "Qualifier 94 112--*--logistic Euroscore",
            "Scope 86 112--*--STS and logistic Euroscore",
            "Non-representable 117 186--*--According multidisciplinary (heart) team decision TAVI is preferable,",
            "Competing_trial 188 210--*--Willing to participate"
        ],
        "Text": "Age = 75 years,. Severe, symptomatic aortic stenosis,. High risk for cardiac surgery (STS and logistic Euroscore ),. According multidisciplinary (heart) team decision TAVI is preferable,. Willing to participate. "
    },
    "NCT02735577_exc": {
        "Annotations": [
            "Qualifier 8 14--*--severe",
            "Condition 15 33--*--alcohol withdrawal",
            "Mood 0 7--*--Risk of",
            "Condition 51 59--*--seizures",
            "Observation 40 47--*--history",
            "Condition 63 79--*--delirium tremens",
            "Scope 51 79--*--seizures or delirium tremens",
            "Condition 109 131--*--Substance Use Disorder",
            "Qualifier 90 98--*--Moderate",
            "Qualifier 102 108--*--Severe",
            "Temporal 82 89--*--Current",
            "Scope 90 108--*--Moderate or Severe",
            "Negation 133 143--*--other than",
            "Condition 144 151;174 187--*--Alcohol Use Disorders",
            "Condition 153 161;174 187--*--Nicotine Use Disorders",
            "Condition 165 187--*--Caffeine Use Disorders",
            "Scope 144 187--*--Alcohol, Nicotine or Caffeine Use Disorders",
            "Condition 209 225--*--Bipolar Disorder",
            "Observation 189 205--*--Lifetime history",
            "Condition 227 240--*--Schizophrenia",
            "Condition 244 268--*--Schizoaffective Disorder",
            "Scope 209 268--*--Bipolar Disorder, Schizophrenia or Schizoaffective Disorder",
            "Condition 282 302--*--psychiatric disorder",
            "Temporal 274 281--*--current",
            "Condition 315 335--*--Alcohol Use Disorder",
            "Non-representable 337 448--*--that, in the judgment of the investigator, will require treatment that will interfere with study participation.",
            "Negation 304 314--*--other than",
            "Temporal 450 457--*--Current",
            "Qualifier 458 464--*--severe",
            "Condition 465 475--*--depression",
            "Measurement 477 482--*--HAM-D",
            "Value 483 486--*-->24",
            "Condition 491 498--*--anxiety",
            "Measurement 500 505--*--HAM-A",
            "Value 506 509--*-->24",
            "Qualifier 458 464--*--severe",
            "Scope 458 510--*--severe depression (HAM-D >24) or anxiety (HAM-A >24)",
            "Condition 524 531;544 548--*--suicide risk",
            "Condition 535 548--*--violence risk",
            "Qualifier 512 523--*--Significant",
            "Scope 524 548--*--suicide or violence risk",
            "Drug 571 595--*--psychotropic medications",
            "Temporal 550 559--*--Currently",
            "Non-query-able 597 641--*--Legally mandated to participate in treatment",
            "Drug 675 685--*--disulfiram",
            "Observation 643 669--*--History of prior treatment",
            "Condition 700 717--*--socially unstable",
            "Qualifier 687 699--*--Sufficiently",
            "Condition 764 781--*--Contraindications",
            "Drug 785 795--*--disulfiram",
            "Condition 807 820--*--liver disease",
            "Condition 822 836--*--kidney disease",
            "Condition 838 853--*--cardiac disease",
            "Condition 855 871--*--seizure disorder",
            "Condition 873 887--*--hypothyroidism",
            "Condition 889 906--*--diabetes mellitus",
            "Condition 908 917--*--pregnancy",
            "Condition 921 930--*--lactation",
            "Condition 932 939--*--allergy",
            "Drug 943 953--*--disulfiram",
            "Drug 957 976--*--thiuran derivatives",
            "Scope 943 976--*--disulfiram or thiuran derivatives",
            "Scope 807 976--*--liver disease, kidney disease, cardiac disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation, allergy to disulfiram or thiuran derivatives",
            "Scope 764 795--*--Contraindications to disulfiram",
            "Condition 995 1013--*--medical conditions",
            "Condition 1003 1013;979 991--*--conditions Neurological",
            "Condition 1025 1034--*--interfere",
            "Procedure 1040 1052--*--MRI scanning",
            "Scope 979 1013--*--Neurological or medical conditions",
            "Condition 1070 1076--*--stroke",
            "Condition 1078 1085--*--seizure",
            "Condition 1087 1098--*--brain tumor",
            "Condition 1100 1115--*--brain infection",
            "Condition 1117 1139--*--traumatic brain injury",
            "Condition 1141 1159--*--multiple sclerosis",
            "Condition 1161 1169--*--dementia",
            "Device 1171 1191--*--metal device in body",
            "Condition 1193 1202--*--pregnancy",
            "Condition 1204 1218--*--claustrophobia",
            "Condition 1220 1235--*--color blindness",
            "Condition 1244 1262--*--hearing impairment",
            "Qualifier 1237 1243--*--severe",
            "Measurement 1264 1270--*--weight",
            "Value 1270 1279--*-->300 lbs.",
            "Condition 1281 1297--*--wheelchair-bound",
            "Drug 1340 1347--*--alcohol",
            "Drug 1349 1362--*--metronidazole",
            "Drug 1364 1373--*--isoniazid",
            "Drug 1375 1386--*--paraldehyde",
            "Drug 1388 1397--*--phenytoin",
            "Drug 1399 1407--*--warfarin",
            "Drug 1412 1424--*--theophylline",
            "Temporal 1300 1309--*--Currently",
            "Scope 1340 1424--*--alcohol, metronidazole, isoniazid, paraldehyde, phenytoin, warfarin, or theophylline",
            "Qualifier 1427 1438--*--Significant",
            "Condition 1439 1457--*--alcohol withdrawal",
            "Measurement 1459 1463--*--CIWA",
            "Value 1463 1465--*-->8",
            "Temporal 1467 1479--*--at screening",
            "Measurement 1500 1519--*--blood alcohol level",
            "Value 1523 1527--*--zero"
        ],
        "Text": "Risk of severe alcohol withdrawal (e.g. history of seizures or delirium tremens). Current Moderate or Severe Substance Use Disorder, other than Alcohol, Nicotine or Caffeine Use Disorders. Lifetime history of Bipolar Disorder, Schizophrenia or Schizoaffective Disorder. Any current psychiatric disorder, other than Alcohol Use Disorder, that, in the judgment of the investigator, will require treatment that will interfere with study participation.. Current severe depression (HAM-D >24) or anxiety (HAM-A >24). Significant suicide or violence risk. Currently taking any psychotropic medications. Legally mandated to participate in treatment. History of prior treatment with disulfiram. Sufficiently socially unstable as to preclude participation (e.g. homeless). Contraindications to disulfiram treatment (liver disease, kidney disease, cardiac disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation, allergy to disulfiram or thiuran derivatives). Neurological or medical conditions that would interfere with MRI scanning (e.g. history of stroke, seizure, brain tumor, brain infection, traumatic brain injury, multiple sclerosis, dementia, metal device in body, pregnancy, claustrophobia, color blindness, severe hearing impairment, weight>300 lbs., wheelchair-bound). Currently taking medications containing alcohol, metronidazole, isoniazid, paraldehyde, phenytoin, warfarin, or theophylline.. Significant alcohol withdrawal (CIWA>8) at screening, after confirming a blood alcohol level of zero.. "
    },
    "NCT02287259_inc": {
        "Text": "major depressive episode in type2 bipolar disorder or bipolar disorder NOS.(MADRS more than 20 point). 18years to 65years. subjects who sign the informed consent document. ",
        "Annotations": [
            "Condition 0 24--*--major depressive episode",
            "Condition 28 50--*--type2 bipolar disorder",
            "Condition 54 70--*--bipolar disorder",
            "Qualifier 71 74--*--NOS",
            "Measurement 76 81--*--MADRS",
            "Value 82 100--*--more than 20 point",
            "Scope 76 100--*--MADRS more than 20 point",
            "Scope 28 74--*--type2 bipolar disorder or bipolar disorder NOS",
            "Value 103 121--*--18years to 65years",
            "Person 116 121--*--years",
            "Observation 136 161--*--sign the informed consent"
        ]
    },
    "NCT01943409_exc": {
        "Annotations": [
            "Negation 11 18--*--without",
            "Procedure 19 21--*--PN",
            "Temporal 22 50--*--during their hospitalization",
            "Procedure 35 50--*--hospitalization",
            "Reference_point 29 50--*--their hospitalization"
        ],
        "Text": "\u2022 Patients without PN during their hospitalization. "
    },
    "NCT02141061_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 191 193--*--2.",
            "Parsing_Error 294 296--*--3.",
            "Parsing_Error 468 470--*--4.",
            "Parsing_Error 558 560--*--5.",
            "Parsing_Error 591 593--*--6.",
            "Parsing_Error 769 771--*--7.",
            "Parsing_Error 875 877--*--8.",
            "Parsing_Error 899 901--*--9.",
            "Parsing_Error 935 938--*--10.",
            "Parsing_Error 978 981--*--11.",
            "Parsing_Error 1053 1056--*--12.",
            "Condition 16 31--*--post-menopausal",
            "Person 32 37--*--woman",
            "Temporal 58 80--*--six (6) months or more",
            "Temporal 82 118--*--immediately prior to screening visit",
            "Condition 130 146--*--menstrual period",
            "Negation 120 127--*--without",
            "Procedure 157 169--*--hysterectomy",
            "Temporal 151 156--*--prior",
            "Procedure 177 189--*--oophorectomy",
            "Condition 205 213--*--pregnant",
            "Condition 217 226--*--lactating",
            "Non-query-able 230 292--*--is attempting or expecting to become pregnant during the study",
            "Post-eligibility 230 292--*--is attempting or expecting to become pregnant during the study",
            "Person 297 302--*--Women",
            "Measurement 324 337--*--liver enzymes",
            "Condition 341 354--*--liver disease",
            "Value 319 323--*--high",
            "Measurement 357 360--*--ALT",
            "Measurement 364 367--*--AST",
            "Value 368 387--*--exceeding 2.0 x ULN",
            "Scope 357 367--*--ALT or AST",
            "Measurement 392 407--*--total bilirubin",
            "Value 408 427--*--exceeding 1.5 x ULN",
            "Temporal 428 440--*--at screening",
            "Reference_point 431 440--*--screening",
            "Temporal 504 541--*--in the 30 days prior to the screening",
            "Reference_point 528 541--*--the screening",
            "Drug 483 503--*--investigational drug",
            "Person 561 566--*--Women",
            "Condition 585 589--*--PCOS",
            "Observation 574 581--*--history",
            "Drug 616 628--*--testosterone",
            "Drug 630 639--*--progestin",
            "Drug 641 649--*--androgen",
            "Drug 651 659--*--estrogen",
            "Drug 661 678--*--anabolic steroids",
            "Drug 680 684--*--DHEA",
            "Temporal 706 745--*--for at least 2 weeks prior to screening",
            "Temporal 750 766--*--during the study",
            "Reference_point 736 745--*--screening",
            "Drug 688 705--*--hormonal products",
            "Undefined_semantics 688 705--*--hormonal products",
            "Scope 616 705--*--testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products",
            "Drug 779 798--*--oral contraceptives",
            "Temporal 799 823--*--in the preceding 2 weeks",
            "Drug 832 845--*--Depo-Provera\u00ae",
            "Temporal 846 872--*--in the preceding 10 months",
            "Device 885 888--*--IUD",
            "Person 902 907--*--Women",
            "Drug 924 933--*--narcotics",
            "Person 939 944--*--Women",
            "Drug 962 976--*--spironolactone",
            "Condition 1024 1027--*--HIV",
            "Condition 1031 1042--*--Hepatitis A",
            "Condition 1031 1040;1044 1045--*--Hepatitis B",
            "Condition 1031 1040;1049 1050--*--Hepatitis C",
            "Non-query-able 1057 1323--*--Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study"
        ],
        "Text": "1. Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy . 2. Subject is pregnant or lactating or is attempting or expecting to become pregnant during the study . 3. Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 2.0 x ULN AND total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat). . 4. Received an investigational drug in the 30 days prior to the screening for this study . 5. Women with a history of PCOS . 6. Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study. . 7. Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera\u00ae in the preceding 10 months. . 8. Has an IUD in place . 9. Women currently using narcotics . 10. Women currently taking spironolactone . 11. Infectious disease screen is positive for HIV or Hepatitis A, B or C. . 12. Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study       .     . "
    },
    "NCT00543712_inc": {
        "Annotations": [
            "Person 83 86--*--Age",
            "Value 87 97--*--\u2265 18 years",
            "Condition 123 137--*--chondrosarcoma",
            "Measurement 99 109--*--Histologic",
            "Context_Error 168 186--*--Measurable disease",
            "Non-query-able 0 81--*--Ability to understand and willingness to sign a written informed consent document",
            "Context_Error 188 272--*--Previously treated or incurable disease without options for standard of care therapy",
            "Measurement 274 297--*--ECOG performance status",
            "Value 301 304--*--0-2",
            "Observation 306 321--*--Life expectancy",
            "Value 325 335--*--> 3 months",
            "Condition 353 375--*--reproductive potential",
            "Procedure 423 436--*--contraception",
            "Drug 444 462--*--contraceptive pill",
            "Device 464 489--*--intrauterine device [IUD]",
            "Device 491 507--*--physical barrier",
            "Scope 444 507--*--contraceptive pill, intrauterine device [IUD], physical barrier",
            "Temporal 509 529--*--throughout the trial",
            "Temporal 534 575--*--for 1 year following their final exposure"
        ],
        "Text": "Ability to understand and willingness to sign a written informed consent document . Age \u2265 18 years . Histologic diagnosis of chondrosarcoma, verifiable after enrollment . Measurable disease . Previously treated or incurable disease without options for standard of care therapy . ECOG performance status of 0-2 . Life expectancy of > 3 months . For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier) throughout the trial and for 1 year following their final exposure to study treatment . "
    },
    "NCT02650388_exc": {
        "Annotations": [
            "Observation 0 4--*--Died",
            "Temporal 5 16--*--before TAVI",
            "Informed_consent 18 44--*--Not willing to participate"
        ],
        "Text": "Died before TAVI. Not willing to participate. "
    },
    "NCT02689024_exc": {
        "Text": "multiple injuries (polytrauma patients). previous adverse reaction or known allergy to local anaesthetics or opioids or paracetamol. skin infection in proximity of injection site. delirious state at presentation in the ED. ",
        "Annotations": [
            "Condition 0 17--*--multiple injuries",
            "Condition 19 29--*--polytrauma",
            "Condition 50 66--*--adverse reaction",
            "Condition 76 83--*--allergy",
            "Procedure 87 105--*--local anaesthetics",
            "Drug 109 116--*--opioids",
            "Drug 120 131--*--paracetamol",
            "Scope 87 131--*--local anaesthetics or opioids or paracetamol",
            "Scope 50 83--*--adverse reaction or known allergy",
            "Condition 133 147--*--skin infection",
            "Qualifier 164 178--*--injection site",
            "Condition 180 189--*--delirious"
        ]
    },
    "NCT02566928_exc": {
        "Annotations": [
            "Informed_consent 0 52--*--The patient is unwilling to provide informed consent",
            "Condition 54 66--*--acutely sick",
            "Condition 81 87--*--crying",
            "Condition 89 97--*--wheezing",
            "Condition 99 107--*--bleeding",
            "Condition 109 118--*--screaming",
            "Condition 122 128--*--shaken",
            "Scope 81 128--*--crying, wheezing, bleeding, screaming or shaken",
            "Non-query-able 131 184--*--unable to participate in a discussion about the study"
        ],
        "Text": "The patient is unwilling to provide informed consent. acutely sick (for example, crying, wheezing, bleeding, screaming or shaken). unable to participate in a discussion about the study. "
    },
    "NCT01943409_inc": {
        "Annotations": [
            "Procedure 14 16--*--PN",
            "Temporal 17 45--*--during their hospitalization",
            "Reference_point 24 45--*--their hospitalization",
            "Procedure 30 45--*--hospitalization",
            "Procedure 56 68--*--hospitalized",
            "Visit 93 102--*--ICU wards",
            "Visit 81 89;97 102--*--surgical wards",
            "Visit 72 79;97 102--*--medical wards",
            "Scope 72 102--*--medical, surgical or ICU wards",
            "Informed_consent 104 218--*--Signed informed consent either from the patient, their legally authorized representative or a direct family member"
        ],
        "Text": "Patients with PN during their hospitalization. Patients hospitalized in medical, surgical or ICU wards. Signed informed consent either from the patient, their legally authorized representative or a direct family member. "
    },
    "NCT02735577_inc": {
        "Annotations": [
            "Person 12 16--*--ages",
            "Value 0 7;20 25--*--Between 21-60",
            "Condition 27 39--*--Right-handed",
            "Non-query-able 41 111--*--Capable of giving informed consent and complying with study procedures",
            "Value 132 160;200 227--*--minimum of 5 standard drinks on at least 4 days per week",
            "Measurement 121 129--*--drinking",
            "Person 165 168--*--men",
            "Value 172 189;200 227--*--4 standard drinks on at least 4 days per week",
            "Person 194 199--*--women",
            "Temporal 239 260--*--over the past 28 days",
            "Scope 132 227--*--minimum of 5 standard drinks for men or 4 standard drinks for women on at least 4 days per week",
            "Measurement 268 282--*--DSM-V criteria",
            "Value 262 267--*--Meets",
            "Condition 295 315--*--Alcohol Use Disorder",
            "Condition 339 359--*--Alcohol Use Disorder",
            "Procedure 325 334--*--treatment",
            "Mood 317 324--*--Seeking",
            "Non-representable 361 432--*--Agree to not seek additional treatment, apart from Alcoholics Anonymous",
            "Mood 434 441--*--Willing",
            "Condition 456 476--*--abstain from alcohol",
            "Qualifier 477 487--*--completely",
            "Post-eligibility 519 613--*--Willing to be hospitalized on a research unit for 24 hours, longer if detoxification is needed"
        ],
        "Text": "Between the ages of 21-60. Right-handed. Capable of giving informed consent and complying with study procedures. Reports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women on at least 4 days per week on average over the past 28 days. Meets DSM-V criteria for current Alcohol Use Disorder. Seeking treatment for Alcohol Use Disorder. Agree to not seek additional treatment, apart from Alcoholics Anonymous. Willing to attempt to abstain from alcohol completely for the duration of the study. Willing to be hospitalized on a research unit for 24 hours, longer if detoxification is needed.. "
    },
    "NCT02287259_exc": {
        "Text": "don't have Diabetes and abnormal metabolism of sugar. not noticed as bipolar disorder. have an organic brain disease. pregnant or breastfeeding women. don't have heart disease. have actively suicidal thought(Suicidal ideation score of MADRS is 6). who are judged by the investigator to should be excluded from the study. ",
        "Annotations": [
            "Negation 0 10--*--don't have",
            "Condition 11 19--*--Diabetes",
            "Condition 24 52--*--abnormal metabolism of sugar",
            "Scope 11 52--*--Diabetes and abnormal metabolism of sugar",
            "Negation 54 57--*--not",
            "Mood 58 65--*--noticed",
            "Condition 69 85--*--bipolar disorder",
            "Condition 95 116--*--organic brain disease",
            "Condition 118 126--*--pregnant",
            "Observation 130 143--*--breastfeeding",
            "Person 144 149--*--women",
            "Negation 151 161--*--don't have",
            "Condition 162 175--*--heart disease",
            "Condition 182 207--*--actively suicidal thought",
            "Measurement 208 240--*--Suicidal ideation score of MADRS",
            "Value 244 245--*--6",
            "Scope 208 245--*--Suicidal ideation score of MADRS is 6",
            "Observation 256 319--*--judged by the investigator to should be excluded from the study"
        ]
    },
    "NCT02385045_exc": {
        "Text": "Patients attending for a therapeutic endoscopic procedure e.g. variceal banding, stent insertion, balloon dilatation. . Patients with a known diagnosis e.g. upper gastrointestinal cancer . Patients previously treated with HP eradication therapy . Patients who had taken PPI, H2 receptor antagonists and antibiotics within 4 weeks . Patients with acute gastrointestinal bleeding . Patients who'd had previous gastric surgery . Patients with chronic liver disease . Patients with abnormal coagulation or any other contra-indication to use of standard biopsy in routine diagnostic endoscopic procedures . Patients who are unable or unwilling to give informed consent . Patients under the age of 18 years       .     . ",
        "Annotations": [
            "Procedure 25 57--*--therapeutic endoscopic procedure",
            "Procedure 63 79--*--variceal banding",
            "Procedure 81 96--*--stent insertion",
            "Procedure 98 116--*--balloon dilatation",
            "Scope 63 116--*--variceal banding, stent insertion, balloon dilatation",
            "Condition 156 185--*--upper gastrointestinal cancer",
            "Condition 135 150--*--known diagnosis",
            "Procedure 220 242--*--HP eradication therapy",
            "Drug 267 270--*--PPI",
            "Drug 272 295--*--H2 receptor antagonists",
            "Drug 300 311--*--antibiotics",
            "Temporal 312 326--*--within 4 weeks",
            "Grammar_Error 296 299--*--and",
            "Scope 267 311--*--PPI, H2 receptor antagonists and antibiotics",
            "Condition 348 373--*--gastrointestinal bleeding",
            "Qualifier 342 347--*--acute",
            "Procedure 403 418--*--gastric surgery",
            "Temporal 394 402--*--previous",
            "Procedure 442 455--*--liver disease",
            "Qualifier 434 441--*--chronic",
            "Condition 471 491--*--abnormal coagulation",
            "Condition 505 522--*--contra-indication",
            "Procedure 533 548--*--standard biopsy",
            "Procedure 560 592--*--diagnostic endoscopic procedures",
            "Non-query-able 594 655--*--Patients who are unable or unwilling to give informed consent",
            "Person 676 679--*--age",
            "Value 666 671;683 691--*--under 18 years"
        ]
    },
    "NCT03369379_inc": {
        "Annotations": [
            "Person 0 6--*--Female",
            "Value 16 35--*--older than 18 years",
            "Person 30 35--*--years",
            "Informed_consent 38 85--*--Patients who agree to participate in the study.",
            "Qualifier 107 115--*--ACR 1990",
            "Qualifier 107 110;120 124--*--ACR 2010",
            "Condition 138 150--*--Fibromyalgia",
            "Scope 107 124--*--ACR 1990 and 2010",
            "Negation 153 155--*--No",
            "Temporal 156 164--*--previous",
            "Value 172 181--*--vitamin D",
            "Scope 156 181--*--previous use of vitamin D",
            "Condition 229 241--*--fibromyalgia",
            "Qualifier 219 228--*--secondary",
            "Qualifier 208 215--*--primary",
            "Scope 208 228--*--primary or secondary"
        ],
        "Text": "Female patients older than 18 years.. Patients who agree to participate in the study.. Those that meet the ACR 1990 and 2010 criteria for Fibromyalgia.. No previous use of vitamin D.. Patients diagnosed with primary or secondary fibromyalgia.. "
    },
    "NCT01963754_exc": {
        "Annotations": [
            "Observation 3 10--*--smoking",
            "Condition 24 38--*--drug addiction",
            "Drug 54 70--*--local anesthetic",
            "Condition 71 78--*--allergy",
            "Procedure 124 136--*--radiotherapy",
            "Procedure 112 120--*--chemical",
            "Condition 141 156--*--Hepatic disease",
            "Condition 172 188--*--immunodepression",
            "Condition 204 213--*--Pregnancy",
            "Condition 229 237--*--Diabetes",
            "Condition 253 266--*--Heart disease"
        ],
        "Text": "If smoking and/or other drug addiction is present. If local anesthetic allergy is present. Patient subjected to chemical or radiotherapy. if Hepatic disease is present. If immunodepression is present. If Pregnancy is present. If Diabetes is present. If Heart disease is present. "
    },
    "NCT01322464_inc": {
        "Text": "Healthy males between 18 and 45 years of age (inclusive). . Body mass index to be between 18 to 30 kg/m2 (inclusive) as calculated by weight(Kg)/height(m2). . Subjects were to have no clinically significant abnormal findings on physical examination, ECG, medical history, or clinical laboratory results during screening. . Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels. . Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study). . Subjects were to have a negative screen for HIV I and II, HBsAg, and antibody to Hepatitis C virus. . Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine. . Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug. . Subjects were able to comply with the protocol and the restrictions and assessments therein. . Subjects were to give voluntary written informed consent to participate in the trial. . ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Value 14 37--*--between 18 and 45 years",
            "Person 41 44--*--age",
            "Measurement 59 74--*--Body mass index",
            "Value 81 103--*--between 18 to 30 kg/m2",
            "Qualifier 182 204--*--clinically significant",
            "Undefined_semantics 182 204--*--clinically significant",
            "Condition 205 222--*--abnormal findings",
            "Procedure 226 246--*--physical examination",
            "Procedure 248 251--*--ECG",
            "Observation 253 268--*--medical history",
            "Procedure 273 292--*--clinical laboratory",
            "Temporal 301 317--*--during screening",
            "Negation 179 181--*--no",
            "Scope 226 292--*--physical examination, ECG, medical history, or clinical laboratory",
            "Subjective_judgement 338 372--*--in the opinion of the investigator",
            "Measurement 470 486--*--serum creatinine",
            "Measurement 488 503--*--total bilirubin",
            "Measurement 509 528--*--transaminase levels",
            "Measurement 436 452--*--hepatic function",
            "Measurement 426 431;444 452--*--renal function",
            "Qualifier 382 404--*--clinically significant",
            "Condition 405 422--*--abnormal findings",
            "Scope 426 452--*--renal and hepatic function",
            "Scope 470 528--*--serum creatinine, total bilirubin, and transaminase levels",
            "Negation 379 381--*--no",
            "Condition 555 580--*--users of tobacco products",
            "Negation 551 554--*--non",
            "Temporal 582 633--*--minimum of 6 months prior to the start of the study",
            "Reference_point 611 633--*--the start of the study",
            "Measurement 670 686--*--screen for HIV I",
            "Measurement 670 684;691 693--*--screen for HIV II",
            "Value 661 669--*--negative",
            "Measurement 695 700--*--HBsAg",
            "Measurement 706 735--*--antibody to Hepatitis C virus",
            "Measurement 771 795--*--urine screen for alcohol",
            "Measurement 771 787;797 811--*--urine screen for drugs of abuse",
            "Measurement 771 787;834 842--*--urine screen for cotinine",
            "Value 762 770--*--negative",
            "Post-eligibility 845 1152--*--Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug.",
            "Post-eligibility 1154 1246--*--Subjects were able to comply with the protocol and the restrictions and assessments therein.",
            "Post-eligibility 1248 1332--*--Subjects were to give voluntary written informed consent to participate in the trial"
        ]
    },
    "NCT02267616_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 6 9--*--age",
            "Value 10 15--*--18-45",
            "Non-representable 17 234--*--Within 6 months of expiration or beyond the end of the FDA-approved duration of use of the levonorgestrel intrauterine device (LNG-IUD = 5 years) OR the etonogestrel-releasing subdermal implant (ENG implant = 3 years)",
            "Informed_consent 236 273--*--Able to consent in English or Spanish",
            "Negation 276 279--*--Not",
            "Condition 280 288--*--pregnant",
            "Temporal 289 314--*--at the time of enrollment"
        ],
        "Text": "Women age 18-45. Within 6 months of expiration or beyond the end of the FDA-approved duration of use of the levonorgestrel intrauterine device (LNG-IUD = 5 years) OR the etonogestrel-releasing subdermal implant (ENG implant = 3 years). Able to consent in English or Spanish.. Not pregnant at the time of enrollment. "
    },
    "NCT00235170_exc": {
        "Annotations": [
            "Condition 3 27--*--Congestive heart failure",
            "Procedure 33 37--*--CABG",
            "Procedure 41 81--*--Percutaneous Coronary Intervention (PCI)",
            "Procedure 114 127--*--major surgery",
            "Procedure 134 147--*--valve surgery",
            "Procedure 201 224--*--carotid end-arterectomy",
            "Procedure 226 259--*--abdominal aortic aneurysm surgery",
            "Procedure 151 163;174 199--*--resection of left ventricular aneurysm",
            "Procedure 151 170;191 199--*--resection of aortic aneurysm",
            "Procedure 271 295--*--Congenital heart disease",
            "Procedure 301 333--*--Transmural myocardial infarction",
            "Temporal 334 364--*--within the previous seven days",
            "Measurement 369 371--*--CK",
            "Negation 372 388--*--has not returned",
            "Value 392 398--*--normal",
            "Condition 404 414--*--Chest pain",
            "Qualifier 415 445--*--lasting longer than 30 minutes",
            "Temporal 446 475--*--within 12 hours pre-procedure",
            "Measurement 480 490--*--CK enzymes",
            "Value 491 499--*--positive",
            "Value 501 528--*--\u2265 2x the normal upper limit",
            "Scope 480 529--*--CK enzymes positive (\u2265 2x the normal upper limit)",
            "Condition 546 574--*--any cerebrovascular accident",
            "Observation 535 545--*--History of",
            "Condition 580 598--*--Left main stenosis",
            "Value 602 613--*--50% or more",
            "Condition 697 710;730 737--*--Single vessel disease",
            "Condition 712 728;730 737--*--single territory disease",
            "Mood 619 631--*--Intention to",
            "Multiplier 638 649--*--more than 1",
            "Qualifier 650 690--*--totally occluded major epicardial vessel",
            "Procedure 632 637--*--treat"
        ],
        "Text": "1. Congestive heart failure; . 2. CABG or Percutaneous Coronary Intervention (PCI) procedure; . 3. Planned need for major surgery (e.g. valve surgery or resection of aortic or left ventricular aneurysm, carotid end-arterectomy, abdominal aortic aneurysm surgery etc.); . 4. Congenital heart disease; . 5. Transmural myocardial infarction within the previous seven days and CK has not returned to normal; . 6. Chest pain lasting longer than 30 minutes within 12 hours pre-procedure, if CK enzymes positive (\u2265 2x the normal upper limit). . 7. History of any cerebrovascular accident; . 8. Left main stenosis of 50% or more; . 9. Intention to treat more than 1 totally occluded major epicardial vessel; . 10. Single vessel (single territory) disease.       .     . "
    },
    "NCT02419378_inc": {
        "Text": "Signed informed consent form (ICF). Age 18 to 55 years old (inclusive) as of the date the ICF is signed. Diagnosis of MS according to the McDonald criteria 2010 and cranial MRI scan demonstrating white matter lesions attributable to MS within 10 years before Screening. Onset of MS symptoms (as determined by a neurologist, either at present or retrospectively) within 10 years of the date the ICF is signed. EDSS score 0.0 to 5.0 (inclusive) at Screening. Patients with (highly) active RRMS disease course indicated to receive alemtuzumab according to the following conditions (at least 1 out of 3 conditions has to be fulfilled): 1. =2 MS relapses within 24 months, 2. clinical (=1 relapse) or MRI (new gadolinium enhancing lesions) disease activity under therapy with other diseasemodifying therapies, 3. severe relapse with high disease activity (=9 T2 hyperintense Lesions and =1 gadolinium enhancing lesion) on MRI.. Completion of all vaccinations required by the applicable immunization guidelines published by \"st\u00e4ndige Impfkommission\" (STIKO). History of chickenpox or positive test for antibodies against varicella zoster virus (VZV). ",
        "Annotations": [
            "Informed_consent 0 34--*--Signed informed consent form (ICF)",
            "Person 36 39--*--Age",
            "Value 40 60--*--18 to 55 years old (",
            "Condition 118 120--*--MS",
            "Measurement 138 160--*--McDonald criteria 2010",
            "Procedure 165 181--*--cranial MRI scan",
            "Temporal 236 268--*--within 10 years before Screening",
            "Scope 138 181--*--McDonald criteria 2010 and cranial MRI scan",
            "Condition 279 290--*--MS symptoms",
            "Temporal 362 377--*--within 10 years",
            "Measurement 409 419--*--EDSS score",
            "Value 420 430--*--0.0 to 5.0",
            "Condition 487 491--*--RRMS",
            "Qualifier 480 486--*--active",
            "Drug 528 539--*--alemtuzumab",
            "Condition 638 649--*--MS relapses",
            "Multiplier 635 637--*--=2",
            "Temporal 650 667--*--within 24 months,",
            "Condition 684 691--*--relapse",
            "Multiplier 681 683--*--=1",
            "Procedure 696 699--*--MRI",
            "Condition 815 822--*--relapse",
            "Qualifier 808 814--*--severe",
            "Condition 870 877--*--Lesions",
            "Qualifier 854 869--*--T2 hyperintense",
            "Multiplier 851 853--*--=9",
            "Condition 906 912--*--lesion",
            "Qualifier 885 905--*--gadolinium enhancing",
            "Multiplier 882 884--*--=1",
            "Procedure 917 920--*--MRI",
            "Condition 726 733--*--lesions",
            "Qualifier 705 725--*--gadolinium enhancing",
            "Qualifier 701 704--*--new",
            "Scope 671 734--*--clinical (=1 relapse) or MRI (new gadolinium enhancing lesions)",
            "Scope 851 912--*--=9 T2 hyperintense Lesions and =1 gadolinium enhancing lesion",
            "Non-query-able 923 1051--*--Completion of all vaccinations required by the applicable immunization guidelines published by \"st\u00e4ndige Impfkommission\" (STIKO)",
            "Condition 1064 1074--*--chickenpox",
            "Measurement 1087 1106--*--test for antibodies",
            "Value 1078 1086--*--positive",
            "Qualifier 1115 1137--*--varicella zoster virus",
            "Qualifier 1139 1142--*--VZV"
        ]
    },
    "NCT02883400_exc": {
        "Text": "dual organ transplant. ",
        "Annotations": [
            "Multiplier 0 4--*--dual",
            "Procedure 5 21--*--organ transplant"
        ]
    },
    "NCT02992028_inc": {
        "Text": "Rotator cuff tear patients undergoing arthroscopic rotator cuff tear. ",
        "Annotations": [
            "Condition 0 17--*--Rotator cuff tear",
            "Procedure 38 68--*--arthroscopic rotator cuff tear"
        ]
    },
    "NCT02868437_exc": {
        "Text": "History of curettage or other intrauterine surgery . History of post-abortion complication or infection       .     . ",
        "Annotations": [
            "Procedure 11 20--*--curettage",
            "Observation 0 7--*--History",
            "Procedure 30 50--*--intrauterine surgery",
            "Scope 11 50--*--curettage or other intrauterine surgery",
            "Condition 63 89--*--post-abortion complication",
            "Condition 63 76;93 102--*--post-abortion infection",
            "Scope 63 102--*--post-abortion complication or infection",
            "Observation 52 59--*--History"
        ]
    },
    "NCT02426944_exc": {
        "Text": "thrombus in the LA or LAA;. mechanical valve prosthesis;. mitral stenosis;. previous LAA ligation during cardiac surgery;. life expectancy less than 2 years;. comorbidities other than AF, which present an indication for anticoagulation;. patent foramen ovale with atrial septal aneurysm. mobile plaque in the aorta;. symptomatic atherosclerosis of the carotid artery;. pericardial effusion greater than 10 mm;. clinically significant bleeding within the 30 days prior to the scheduled procedure;. stroke or other cardioembolic event within the 30 days prior to the scheduled procedure;. acute coronary syndrome within the 90 days prior to the scheduled procedure,. gravidity,. significant valvular disease,. creatinine clearance less than 30 ml/min. ",
        "Annotations": [
            "Condition 0 8--*--thrombus",
            "Qualifier 16 18--*--LA",
            "Qualifier 22 25--*--LAA",
            "Scope 16 25--*--LA or LAA",
            "Device 28 55--*--mechanical valve prosthesis",
            "Condition 58 73--*--mitral stenosis",
            "Procedure 85 97--*--LAA ligation",
            "Procedure 105 120--*--cardiac surgery",
            "Observation 123 138--*--life expectancy",
            "Value 139 156--*--less than 2 years",
            "Condition 184 186--*--AF",
            "Negation 173 183--*--other than",
            "Condition 159 172--*--comorbidities",
            "Condition 205 215--*--indication",
            "Procedure 220 235--*--anticoagulation",
            "Scope 159 186--*--comorbidities other than AF",
            "Condition 238 258--*--patent foramen ovale",
            "Condition 264 286--*--atrial septal aneurysm",
            "Condition 288 314--*--mobile plaque in the aorta",
            "Condition 329 344--*--atherosclerosis",
            "Qualifier 317 328--*--symptomatic",
            "Qualifier 345 366--*--of the carotid artery",
            "Condition 369 389--*--pericardial effusion",
            "Qualifier 390 408--*--greater than 10 mm",
            "Qualifier 411 433--*--clinically significant",
            "Condition 434 442--*--bleeding",
            "Temporal 443 494--*--within the 30 days prior to the scheduled procedure",
            "Condition 497 503--*--stroke",
            "Qualifier 507 512--*--other",
            "Condition 513 532--*--cardioembolic event",
            "Temporal 533 584--*--within the 30 days prior to the scheduled procedure",
            "Reference_point 471 494--*--the scheduled procedure",
            "Reference_point 561 584--*--the scheduled procedure",
            "Scope 497 532--*--stroke or other cardioembolic event",
            "Condition 587 610--*--acute coronary syndrome",
            "Temporal 611 662--*--within the 90 days prior to the scheduled procedure",
            "Reference_point 639 662--*--the scheduled procedure",
            "Condition 665 674--*--gravidity",
            "Condition 689 705--*--valvular disease",
            "Qualifier 677 688--*--significant",
            "Measurement 708 728--*--creatinine clearance",
            "Value 729 748--*--less than 30 ml/min"
        ]
    },
    "NCT02385045_inc": {
        "Text": "\u2022 All patients attending for a routine diagnostic endoscopic procedure at St Mary's Hospital NHS Trust for dyspepsia and abdominal pain . ",
        "Annotations": [
            "Condition 107 116--*--dyspepsia",
            "Condition 121 135--*--abdominal pain",
            "Procedure 39 70--*--diagnostic endoscopic procedure",
            "Visit 74 102--*--St Mary's Hospital NHS Trust",
            "Scope 107 135--*--dyspepsia and abdominal pain"
        ]
    },
    "NCT01322464_exc": {
        "Text": "Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. . Subjects were not to have any history or presence or family history of schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder. . Subjects were not to have a postural drop of 20 mmHg or more in systolic blood pressure at screening. . Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation. . Subjects were not to have donated plasma within 90 days prior to study initiation. . Subjects were not to have donated blood within 90 days prior to study initiation. . Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation. . Subjects were not to have had treatment with any known enzyme-altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study. . Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drug or related compounds. . Subjects were not to use any prescription medication within 14 days prior to or during the study. . Subjects were not to use any over-the-counter medication within 7 days prior to or during the study. . Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).       .     . ",
        "Annotations": [
            "Undefined_semantics 0 211--*--Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.",
            "Condition 284 297--*--schizophrenia",
            "Condition 305 322--*--psychotic illness",
            "Condition 324 351--*--severe personality disorder",
            "Undefined_semantics 305 322--*--psychotic illness",
            "Condition 353 363--*--depression",
            "Condition 386 406--*--psychiatric disorder",
            "Qualifier 374 385--*--significant",
            "Undefined_semantics 374 406--*--significant psychiatric disorder",
            "Observation 266 280--*--family history",
            "Observation 243 250--*--history",
            "Observation 254 262--*--presence",
            "Scope 243 280--*--history or presence or family history",
            "Scope 284 406--*--schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder",
            "Measurement 473 496--*--systolic blood pressure",
            "Value 437 461--*--postural drop of 20 mmHg",
            "Temporal 497 509--*--at screening",
            "Temporal 587 620--*--90 days prior to study initiation",
            "Observation 538 579--*--participated in a previous clinical trial",
            "Context_Error 512 621--*--Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation.",
            "Procedure 649 663--*--donated plasma",
            "Temporal 664 704--*--within 90 days prior to study initiation",
            "Reference_point 688 704--*--study initiation",
            "Negation 637 640--*--not",
            "Negation 423 426--*--not",
            "Procedure 733 746--*--donated blood",
            "Negation 721 724--*--not",
            "Temporal 747 787--*--within 90 days prior to study initiation",
            "Reference_point 771 787--*--study initiation",
            "Observation 823 836--*--abnormal diet",
            "Observation 852 876--*--changes in eating habits",
            "Qualifier 840 851--*--substantial",
            "Temporal 877 917--*--within 30 days prior to study initiation",
            "Reference_point 901 917--*--study initiation",
            "Scope 823 876--*--abnormal diet or substantial changes in eating habits",
            "Negation 804 807--*--not",
            "Drug 975 997--*--enzyme-altering agents",
            "Drug 999 1011--*--barbiturates",
            "Drug 1013 1027--*--phenothiazines",
            "Drug 1029 1039--*--cimetidine",
            "Temporal 1046 1089--*--within 30 days prior to or during the study",
            "Condition 1134 1150--*--hypersensitivity",
            "Condition 1154 1176--*--idiosyncratic reaction",
            "Drug 1184 1194--*--study drug",
            "Negation 1114 1116--*--no",
            "Drug 1247 1270--*--prescription medication",
            "Temporal 1271 1294;1305 1314--*--within 14 days prior to the study",
            "Temporal 1298 1314--*--during the study",
            "Scope 1271 1314--*--within 14 days prior to or during the study",
            "Negation 1232 1235--*--not",
            "Temporal 1374 1396;1407 1416--*--within 7 days prior to the study",
            "Temporal 1400 1416--*--during the study",
            "Scope 1374 1416--*--within 7 days prior to or during the study",
            "Drug 1346 1373--*--over-the-counter medication",
            "Negation 1331 1334--*--not",
            "Condition 1469 1479--*--drug abuse",
            "Condition 1458 1465;1474 1479--*--alcohol abuse",
            "Temporal 1480 1513--*--within 2 years prior to the study",
            "Reference_point 1504 1513--*--the study",
            "Reference_point 1407 1416--*--the study",
            "Scope 1458 1479--*--alcohol or drug abuse",
            "Observation 1447 1454--*--history",
            "Condition 1551 1566--*--use of cannabis",
            "Negation 1572 1584--*--not excluded",
            "Grammar_Error 1572 1584--*--not excluded",
            "Negation 1433 1436--*--not",
            "Not_a_criteria 1514 1754--*--(subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study)"
        ]
    },
    "NCT02267616_exc": {
        "Annotations": [
            "Procedure 16 46--*--female sterilization procedure",
            "Mood 48 54--*--Desire",
            "Observation 59 69--*--conception",
            "Temporal 70 91--*--in the next 12 months",
            "Negation 93 96--*--Not",
            "Observation 97 112--*--sexually active",
            "Qualifier 120 132--*--male partner"
        ],
        "Text": "Have history of female sterilization procedure. Desire for conception in the next 12 months. Not sexually active with a male partner. "
    },
    "NCT03369379_exc": {
        "Annotations": [
            "Temporal 20 32--*--previous use",
            "Drug 36 45--*--vitamin D",
            "Condition 101 110;68 73--*--disorders renal",
            "Condition 101 110;75 80--*--disorders liver",
            "Condition 82 110--*--calcium metabolism disorders",
            "Condition 112 135--*--malabsorption disorders",
            "Condition 143 152--*--neoplasms",
            "Measurement 169 189--*--serum calcium levels",
            "Value 190 227--*--equal to or greater than 10.2 mg / dl"
        ],
        "Text": "Those subjects with previous use of vitamin D.. Known subjects with renal, liver, calcium metabolism disorders, malabsorption disorders, known neoplasms.. Subjects with serum calcium levels equal to or greater than 10.2 mg / dl.. "
    },
    "NCT01963754_inc": {
        "Annotations": [
            "Procedure 0 34--*--Single unit implant rehabilitation",
            "Qualifier 36 43--*--Maxilla",
            "Qualifier 48 56--*--mandible",
            "Informed_consent 58 84--*--Must accept treatment plan",
            "Informed_consent 86 112--*--Must sign informed consent",
            "Procedure 114 131--*--dental extraction",
            "Temporal 142 164--*--at least 3 month prior",
            "Value 176 189--*--at least 6 mm",
            "Measurement 193 206--*--residual bone",
            "Negation 208 215--*--Absence",
            "Condition 219 231--*--oral lesions",
            "Condition 233 267--*--keratinized tissue must be present"
        ],
        "Text": "Single unit implant rehabilitation. Maxilla and mandible. Must accept treatment plan. Must sign informed consent. dental extraction performed at least 3 month prior. Must have at least 6 mm of residual bone. Absence of oral lesions. keratinized tissue must be present. "
    },
    "NCT02419378_exc": {
        "Text": "Participation in another clinical trial at present or within 4 weeks of study entry. There may be exceptions at the discretion of the Investigator.. Has any progressive form of MS. Hypersensitivity to the active substance, or to any of the excipients of Lemtrada\u00ae. Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study. Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS. Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage. Known bleeding disorder (e.g,. dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency). Significant autoimmune disease including but not limited to immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis. History of malignancy, except basal skin cell carcinoma. Major psychiatric disorder that is not adequately controlled by treatment. Epileptic seizures that are not adequately controlled by Treatment. Active infection, e.g., deep-tissue infection, that the Investigator considers sufficiently serious to preclude study participation. In the Investigator's opinion, is at high risk for infection (e.g., indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection). Seropositivity for human immunodeficiency virus (HIV). Infection with hepatitis C Virus. Past or present hepatitis B infection (positive hepatitis B serology). Active infection with human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV). Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or active tuberculosis.. Invasive fungal infections in history and at present. Cervical cytology other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV) positivity. Any other illness or infection (latent or active) that, in the Investigator's opinion, could be exacerbated by study medication. Differential blood count < lower limit of normal (LLN) at Screening. Confirmed platelet count < the LLN of the evaluating laboratory at Screening or documented at <100,000/\u00b5L within the past year on a sample without platelet clumping. Presence (i.e., above the ULN) of anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO). Vaccination less than 6 weeks prior to treatment with Lemtrada.. Treatment with antineoplastic or immunosuppressive drugs within 8 weeks prior to study inclusion. Intolerance of pulsed corticosteroids, especially a history of steroid psychosis. Inability to undergo MRI with gadolinium administration. Of childbearing potential with a positive serum pregnancy test, pregnant or lactating. Female patients of childbearing potential: Unwilling to agree to use a reliable and acceptable contraceptive method (Pearl index <1) throughout the study period. These methods include: hormone releasing intrauterine device (IUD), hormonal-based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap [diaphragm or cervical cap combined with spermicide]).. ",
        "Annotations": [
            "Competing_trial 1 146--*--articipation in another clinical trial at present or within 4 weeks of study entry. There may be exceptions at the discretion of the Investigator",
            "Condition 177 179--*--MS",
            "Qualifier 157 168--*--progressive",
            "Condition 181 197--*--Hypersensitivity",
            "Drug 254 262--*--Lemtrada",
            "Post-eligibility 265 512--*--Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study",
            "Post-eligibility 514 629--*--Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS",
            "Post-eligibility 631 888--*--Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage",
            "Condition 896 913--*--bleeding disorder",
            "Condition 921 938--*--dysfibrinogenemia",
            "Condition 940 960--*--factor IX deficiency",
            "Condition 962 972--*--hemophilia",
            "Condition 974 998--*--Von Willebrand's disease",
            "Condition 1000 1038--*--disseminated intravascular coagulation",
            "Condition 1040 1043--*--DIC",
            "Condition 1046 1067--*--fibrinogen deficiency",
            "Condition 1072 1098--*--clotting factor deficiency",
            "Scope 921 1098--*--dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency",
            "Condition 1113 1131--*--autoimmune disease",
            "Condition 1161 1179--*--immune cytopenias,",
            "Condition 1180 1201--*--rheumatoid arthritis,",
            "Condition 1202 1230--*--systemic lupus erythematosus",
            "Condition 1238 1265--*--connective tissue disorders",
            "Condition 1267 1277--*--vasculitis",
            "Condition 1279 1305--*--inflammatory bowel disease",
            "Condition 1314 1323--*--psoriasis",
            "Qualifier 1307 1313--*--severe",
            "Scope 1161 1323--*--immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis",
            "Condition 1336 1346--*--malignancy",
            "Negation 1348 1354--*--except",
            "Condition 1355 1380--*--basal skin cell carcinoma",
            "Condition 1388 1408--*--psychiatric disorder",
            "Qualifier 1382 1387--*--Major",
            "Qualifier 1421 1442--*--adequately controlled",
            "Negation 1417 1420--*--not",
            "Condition 1457 1475--*--Epileptic seizures",
            "Qualifier 1489 1510--*--adequately controlled",
            "Negation 1485 1488--*--not",
            "Condition 1532 1541--*--infection",
            "Qualifier 1525 1531--*--Active",
            "Condition 1549 1570--*--deep-tissue infection",
            "Observation 1700 1718--*--risk for infection",
            "Qualifier 1695 1699--*--high",
            "Device 1726 1745--*--indwelling catheter",
            "Condition 1747 1756--*--dysphagia",
            "Condition 1762 1772--*--aspiration",
            "Condition 1774 1789--*--decubitus ulcer",
            "Condition 1808 1828--*--aspiration pneumonia",
            "Condition 1842 1865--*--urinary tract infection",
            "Qualifier 1832 1841--*--recurrent",
            "Scope 1726 1865--*--indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection",
            "Measurement 1887 1915--*--human immunodeficiency virus",
            "Measurement 1917 1920--*--HIV",
            "Value 1868 1882--*--Seropositivity",
            "Qualifier 1938 1955--*--hepatitis C Virus",
            "Condition 1923 1932--*--Infection",
            "Condition 1973 1994--*--hepatitis B infection",
            "Measurement 2005 2025--*--hepatitis B serology",
            "Value 1996 2004--*--positive",
            "Qualifier 2050 2072--*--human cytomegaly virus",
            "Qualifier 2074 2078--*--HCMV",
            "Qualifier 2081 2099--*--Epstein-Barr virus",
            "Qualifier 2101 2104--*--EBV",
            "Qualifier 2107 2129--*--varicella-zoster virus",
            "Qualifier 2131 2134--*--VZV",
            "Condition 2035 2044--*--infection",
            "Qualifier 2028 2034--*--Active",
            "Scope 2050 2135--*--human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV)",
            "Condition 2137 2156--*--Latent tuberculosis",
            "Negation 2157 2163--*--unless",
            "Procedure 2174 2199--*--anti-tuberculosis therapy",
            "Qualifier 2209 2218--*--completed",
            "Condition 2223 2242--*--active tuberculosis",
            "Condition 2254 2271--*--fungal infections",
            "Qualifier 2245 2253--*--Invasive",
            "Measurement 2299 2316--*--Cervical cytology",
            "Negation 2317 2322--*--other",
            "Qualifier 2328 2333--*--PAP I",
            "Qualifier 2337 2343--*--PAP II",
            "Qualifier 2345 2357--*--Papanicolaou",
            "Qualifier 2381 2401--*--human papillomavirus",
            "Qualifier 2362 2380--*--cervical high risk",
            "Qualifier 2403 2406--*--HPV",
            "Value 2408 2418--*--positivity",
            "Value 0 13--*--Participation",
            "Scope 2317 2407--*--other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV)",
            "Scope 2328 2358--*--PAP I or PAP II (Papanicolaou)",
            "Scope 2362 2407--*--cervical high risk human papillomavirus (HPV)",
            "Condition 2430 2437--*--illness",
            "Condition 2441 2450--*--infection",
            "Qualifier 2452 2458--*--latent",
            "Qualifier 2462 2468--*--active",
            "Temporal 2462 2468--*--active",
            "Non-representable 2476 2505--*--in the Investigator's opinion",
            "Qualifier 2516 2547--*--exacerbated by study medication",
            "Drug 2531 2547--*--study medication",
            "Scope 2452 2468--*--latent or active",
            "Scope 2430 2450--*--illness or infection",
            "Measurement 2549 2573--*--Differential blood count",
            "Value 2574 2603--*--< lower limit of normal (LLN)",
            "Temporal 2604 2616--*--at Screening",
            "Measurement 2628 2642--*--platelet count",
            "Qualifier 2618 2627--*--Confirmed",
            "Value 2643 2681--*--< the LLN of the evaluating laboratory",
            "Temporal 2682 2694--*--at Screening",
            "Value 2712 2723--*--<100,000/\u00b5L",
            "Temporal 2724 2744--*--within the past year",
            "Qualifier 2750 2782--*--sample without platelet clumping",
            "Scope 2643 2744--*--< the LLN of the evaluating laboratory at Screening or documented at <100,000/\u00b5L within the past year",
            "Value 2800 2813--*--above the ULN",
            "Value 2784 2792--*--Presence",
            "Measurement 2818 2882--*--anti-thyroid stimulating hormone receptor antibodies (anti-TSHR)",
            "Measurement 2887 2930--*--anti-thyroid peroxidase antibody (anti-TPO)",
            "Scope 2818 2930--*--anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO)",
            "Drug 2932 2943--*--Vaccination",
            "Temporal 2944 2994--*--less than 6 weeks prior to treatment with Lemtrada",
            "Reference_point 2971 2994--*--treatment with Lemtrada",
            "Procedure 2971 2980--*--treatment",
            "Drug 2986 2994--*--Lemtrada",
            "Procedure 2997 3006--*--Treatment",
            "Drug 3012 3026;3048 3053--*--antineoplastic drugs",
            "Drug 3030 3053--*--immunosuppressive drugs",
            "Temporal 3054 3093--*--within 8 weeks prior to study inclusion",
            "Reference_point 3078 3093--*--study inclusion",
            "Scope 3012 3053--*--antineoplastic or immunosuppressive drugs",
            "Drug 3110 3132--*--pulsed corticosteroids",
            "Observation 3147 3157--*--history of",
            "Condition 3158 3175--*--steroid psychosis",
            "Condition 3095 3106--*--Intolerance",
            "Condition 3177 3201--*--Inability to undergo MRI",
            "Procedure 3198 3201--*--MRI",
            "Drug 3207 3217--*--gadolinium",
            "Mood 3177 3189--*--Inability to",
            "Person 3237 3259--*--childbearing potential",
            "Value 3267 3275--*--positive",
            "Measurement 3276 3296--*--serum pregnancy test",
            "Condition 3298 3306--*--pregnant",
            "Condition 3310 3319--*--lactating",
            "Person 3321 3327--*--Female",
            "Person 3340 3362--*--childbearing potential",
            "Scope 3321 3362--*--Female patients of childbearing potential",
            "Pregnancy_considerations 3364 3728--*--Unwilling to agree to use a reliable and acceptable contraceptive method (Pearl index <1) throughout the study period. These methods include: hormone releasing intrauterine device (IUD), hormonal-based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap [diaphragm or cervical cap combined with spermicide])"
        ]
    },
    "NCT02883400_inc": {
        "Text": "liver transplant. ",
        "Annotations": [
            "Procedure 0 16--*--liver transplant"
        ]
    },
    "NCT02992028_exc": {
        "Text": "age <45 or >80. allergies to medications used in the study. history of renal diseases, a coagulation abnormality, a hepatic disease, or drug abuse. definite radiographic evidence of osteoarthritis of the glenohumeral joint. inflammatory arthritis including rheumatoid arthritis. a history of acute trauma. systemic conditions associated with chronic pain. a history of infection. an inability to understand the questionnaires. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 14--*--<45 or >80",
            "Condition 16 25--*--allergies",
            "Drug 29 40--*--medications",
            "Qualifier 41 58--*--used in the study",
            "Observation 60 67--*--history",
            "Condition 71 85--*--renal diseases",
            "Condition 89 112--*--coagulation abnormality",
            "Condition 116 131--*--hepatic disease",
            "Condition 136 146--*--drug abuse",
            "Scope 71 146--*--renal diseases, a coagulation abnormality, a hepatic disease, or drug abuse",
            "Mood 157 178--*--radiographic evidence",
            "Condition 182 196--*--osteoarthritis",
            "Qualifier 204 222--*--glenohumeral joint",
            "Procedure 157 169--*--radiographic",
            "Qualifier 148 156--*--definite",
            "Condition 224 246--*--inflammatory arthritis",
            "Condition 257 277--*--rheumatoid arthritis",
            "Condition 292 304--*--acute trauma",
            "Observation 281 288--*--history",
            "Condition 306 325--*--systemic conditions",
            "Qualifier 326 354--*--associated with chronic pain",
            "Condition 342 354--*--chronic pain",
            "Observation 358 365--*--history",
            "Condition 369 378--*--infection",
            "Observation 383 425--*--inability to understand the questionnaires"
        ]
    },
    "NCT00235170_inc": {
        "Annotations": [
            "Measurement 25 56--*--Canadian Cardiovascular Society",
            "Value 57 69--*--1, 2, 3 or 4",
            "Qualifier 17 23--*--stable",
            "Qualifier 74 82--*--unstable",
            "Measurement 84 99--*--Braunwald class",
            "Value 100 102--*--IB",
            "Condition 130 145--*--angina pectoris",
            "Condition 150 158--*--ischemia",
            "Condition 177 196--*--atypical chest pain",
            "Scope 17 158--*--stable (Canadian Cardiovascular Society 1, 2, 3 or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and ischemia",
            "Condition 219 231--*--asymptomatic",
            "Condition 262 282--*--myocardial ischaemia",
            "Observation 251 261--*--documented",
            "Procedure 289 312--*--treadmill exercise test",
            "Procedure 314 339--*--radionuclide scintigraphy",
            "Procedure 341 364--*--stress echocardiography",
            "Procedure 366 377--*--Holter tape",
            "Scope 289 377--*--treadmill exercise test, radionuclide scintigraphy, stress echocardiography, Holter tape",
            "Procedure 414 440--*--coronary revascularization",
            "Mood 401 413--*--eligible for",
            "Procedure 442 453--*--angioplasty",
            "Procedure 457 461--*--CABG",
            "Scope 442 461--*--angioplasty or CABG",
            "Value 468 478--*--At least 2",
            "Condition 479 486--*--lesions",
            "Qualifier 488 516--*--located in different vessels",
            "Qualifier 488 498;524 545--*--located in different territories",
            "Scope 488 545--*--located in different vessels and in different territories",
            "Procedure 571 589--*--stent implantation",
            "Observation 547 567--*--potentially amenable",
            "Condition 623 642--*--Multivessel disease",
            "Value 648 660--*--at least one",
            "Condition 661 688--*--significant stenosis in LAD",
            "Procedure 698 721--*--treatment of the lesion",
            "Qualifier 722 765--*--in another major epicardial coronary artery",
            "Condition 1364 1386--*--total occluded vessels",
            "Temporal 1390 1406--*--unknown duration",
            "Temporal 1419 1440--*--longer than one month",
            "Value 1457 1469--*--over 1.50 mm",
            "Measurement 1447 1456--*--reference",
            "Scope 1419 1469--*--longer than one month and a reference over 1.50 mm",
            "Measurement 1593 1601--*--stenosis",
            "Value 1605 1638--*--more than 50% in luminal diameter",
            "Condition 1550 1570--*--Significant stenosis",
            "Measurement 1714 1748--*--Left ventricular ejection fraction",
            "Value 1759 1771--*--at least 30%",
            "Value 104 106--*--IC",
            "Value 108 111--*--IIB",
            "Value 113 116--*--IIC",
            "Value 118 122--*--IIIB",
            "Value 124 128--*--IIIC",
            "Scope 100 128--*--IB, IC, IIB, IIC, IIIB, IIIC",
            "Qualifier 595 602--*--de novo",
            "Condition 603 617--*--native vessels",
            "Non-representable 767 1004--*--A two-vessel disease or a three-vessel disease may be viewed as a combination of a side branch and a main epicardial vessel provided they supply different territories; left anterior descending, left circumflex and right coronary artery);",
            "Condition 1009 1031--*--Total occluded vessels",
            "Multiplier 1033 1036--*--One",
            "Condition 1037 1075--*--total occluded major epicardial vessel",
            "Condition 1037 1051;1079 1090--*--total occluded side branch",
            "Scope 1037 1090--*--total occluded major epicardial vessel or side branch"
        ],
        "Text": "1. Patients with stable (Canadian Cardiovascular Society 1, 2, 3 or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and ischemia, or patients with atypical chest pain or even those who are asymptomatic provided they have documented myocardial ischaemia (e.g. treadmill exercise test, radionuclide scintigraphy, stress echocardiography, Holter tape); . 2. Patients who are eligible for coronary revascularization (angioplasty or CABG); . 3. At least 2 lesions (located in different vessels and in different territories) potentially amenable to stent implantation; . 4. de novo native vessels; . 5. Multivessel disease with at least one significant stenosis in LAD and with treatment of the lesion in another major epicardial coronary artery. A two-vessel disease or a three-vessel disease may be viewed as a combination of a side branch and a main epicardial vessel provided they supply different territories; left anterior descending, left circumflex and right coronary artery); . 6. Total occluded vessels. One total occluded major epicardial vessel or side branch can be included and targeted as long as one other major vessel has a significant stenosis amenable for SA, provided the age of occlusion is less than one month e.g. recent instability, infarction with ECG changes in the area subtended by the occluded vessel. Patients with total occluded vessels of unknown duration or existing longer than one month and a reference over 1.50 mm should not be included, not even as a third or fourth vessel to be dilated; . 7. Significant stenosis has been defined as a stenosis of more than 50% in luminal diameter (in at least one view, on visual interpretation or preferably by QCA); . 8. Left ventricular ejection fraction should be at least 30%. . "
    },
    "NCT02426944_inc": {
        "Text": "history of significant bleeding (i.e. bleeding which required intervention or hospitalization), even in the absence of anticoagulation treatment at the time of the bleeding event, or. a cardioembolic event, which occurred on anticoagulation, or. a high risk profile of the patient, defined as a CHA2DS2-VASc score = 3 and a HAS-BLED score = 2. ",
        "Annotations": [
            "Condition 23 31--*--bleeding",
            "Qualifier 11 22--*--significant",
            "Condition 38 46--*--bleeding",
            "Procedure 62 74--*--intervention",
            "Procedure 78 93--*--hospitalization",
            "Scope 62 93--*--intervention or hospitalization",
            "Scope 38 93--*--bleeding which required intervention or hospitalization",
            "Scope 11 31--*--significant bleeding",
            "Condition 186 205--*--cardioembolic event",
            "Drug 225 240--*--anticoagulation",
            "Temporal 213 240--*--occurred on anticoagulation",
            "Measurement 295 313--*--CHA2DS2-VASc score",
            "Value 314 317--*--= 3",
            "Measurement 324 338--*--HAS-BLED score",
            "Value 339 342--*--= 2",
            "Condition 248 265--*--high risk profile",
            "Scope 295 342--*--CHA2DS2-VASc score = 3 and a HAS-BLED score = 2"
        ]
    },
    "NCT02868437_inc": {
        "Text": "Subject has curettage for retained product after second trimester abortion . ",
        "Annotations": [
            "Procedure 12 21--*--curettage",
            "Procedure 66 74--*--abortion",
            "Qualifier 49 65--*--second trimester",
            "Condition 26 42--*--retained product"
        ]
    },
    "NCT02541955_exc": {
        "Annotations": [
            "Temporal 0 5--*--Prior",
            "Procedure 6 15--*--treatment",
            "Drug 21 27--*--Acthar",
            "Temporal 28 44--*--in the past 2mos",
            "Condition 68 89--*--RA flare requirements",
            "Multiplier 51 57--*--one of",
            "Drug 126 150--*--live attenuated vaccines",
            "Temporal 151 203--*--within 6 weeks prior to the first dose of study drug",
            "Reference_point 175 203--*--the first dose of study drug",
            "Multiplier 179 189--*--first dose",
            "Drug 193 203--*--study drug",
            "Drug 212 226--*--zoster vaccine",
            "Drug 118 122;142 150--*--live vaccines",
            "Scope 118 150--*--live or live attenuated vaccines"
        ],
        "Text": "Prior treatment with Acthar in the past 2mos. Meet one of the above RA flare requirements. Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine). "
    },
    "NCT02876484_exc": {
        "Text": "Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol 3 months after RYGB.. Dysregulated thyroid diseases, use of antithyroid treatment.. Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.. Complications to RYGB. Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake).. Cholecystectomy. ",
        "Annotations": [
            "Measurement 0 22--*--Fasting plasma glucose",
            "Value 23 31--*--> 7,0 mM",
            "Measurement 33 38--*--HbA1c",
            "Value 39 52--*--> 48 mmol/mol",
            "Temporal 53 72--*--3 months after RYGB",
            "Procedure 68 72--*--RYGB",
            "Reference_point 68 72--*--RYGB",
            "Scope 0 52--*--Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol",
            "Qualifier 75 87--*--Dysregulated",
            "Condition 88 104--*--thyroid diseases",
            "Procedure 113 134--*--antithyroid treatment",
            "Condition 137 164--*--Late diabetic complications",
            "Condition 168 179--*--retinopathy",
            "Condition 181 200--*--renal insufficiency",
            "Condition 202 212--*--neuropathy",
            "Condition 225 237--*--pancreatitis",
            "Temporal 216 224--*--previous",
            "Scope 168 212--*--retinopathy, renal insufficiency, neuropathy",
            "Condition 240 253--*--Complications",
            "Procedure 257 261--*--RYGB",
            "Condition 274 296--*--reactive hypoglycaemia",
            "Qualifier 298 304--*--severe",
            "Condition 305 312--*--dumping",
            "Condition 314 322--*--vomiting",
            "Condition 324 332--*--diarrhea",
            "Qualifier 334 340--*--severe",
            "Condition 341 355--*--abdominal pain",
            "Temporal 356 373--*--after food intake",
            "Reference_point 362 373--*--food intake",
            "Scope 314 373--*--vomiting, diarrhea, severe abdominal pain after food intake",
            "Scope 298 312--*--severe dumping",
            "Scope 274 374--*--reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)",
            "Scope 240 261--*--Complications to RYGB",
            "Procedure 377 392--*--Cholecystectomy"
        ]
    },
    "NCT02429765_exc": {
        "Text": "A diagnosis of sleep disordered breathing;. Nocturnal oxygen therapy.. ",
        "Annotations": [
            "Condition 15 41--*--sleep disordered breathing",
            "Procedure 44 68--*--Nocturnal oxygen therapy"
        ]
    },
    "NCT02541955_inc": {
        "Annotations": [
            "Condition 18 35--*--1987 ACR criteria",
            "Person 37 40--*--Age",
            "Value 41 58--*--> 18 years of age",
            "Temporal 60 68--*--Baseline",
            "Measurement 69 111--*--DAS28/Erythrocyte Sedimentation Rate (ESR)",
            "Value 112 117--*-->=3.2",
            "Multiplier 119 125--*--Stable",
            "Temporal 126 137--*--concomitant",
            "Drug 138 185--*--Disease Modifying Anti-Rheumatic Drugs (DMARDs)",
            "Multiplier 187 193--*--Stable",
            "Drug 194 204--*--prednisone",
            "Value 205 210--*--<10mg",
            "Measurement 226 245--*--Power Doppler score",
            "Value 249 253--*-->=10"
        ],
        "Text": "Patient must meet 1987 ACR criteria. Age > 18 years of age. Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) >=3.2. Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs). Stable prednisone <10mg or equivalent. Power Doppler score of >=10. "
    },
    "NCT02429765_inc": {
        "Text": "Moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) 30-79%predicted);. Resting functional residual capacity (FRC) >120% predicted;. Clinically stable and on stable triple therapy with an ICS/LABA and tiotropium;. Symptomatic: Baseline Dyspnea Index =8 and answer \"in the morning\" when asked about what time of day their COPD symptoms are worst.. ",
        "Annotations": [
            "Qualifier 0 18--*--Moderate to severe",
            "Condition 19 23--*--COPD",
            "Qualifier 25 44--*--post-bronchodilator",
            "Measurement 45 83--*--forced expiratory volume in 1 s (FEV1)",
            "Value 84 99--*--30-79%predicted",
            "Measurement 103 145--*--Resting functional residual capacity (FRC)",
            "Value 146 161--*-->120% predicted",
            "Procedure 189 210--*--stable triple therapy",
            "Condition 164 181--*--Clinically stable",
            "Drug 219 227--*--ICS/LABA",
            "Drug 232 242--*--tiotropium",
            "Scope 219 242--*--ICS/LABA and tiotropium",
            "Measurement 258 280--*--Baseline Dyspnea Index",
            "Value 281 283--*--=8",
            "Observation 329 375--*--what time of day their COPD symptoms are worst",
            "Value 296 310--*--in the morning"
        ]
    },
    "NCT02876484_inc": {
        "Text": "Uncomplicated RYGB performed minimum 3 months prior to the study.. Fasting plasma glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB. ",
        "Annotations": [
            "Procedure 14 18--*--RYGB",
            "Qualifier 0 13--*--Uncomplicated",
            "Temporal 29 64--*--minimum 3 months prior to the study",
            "Reference_point 55 64--*--the study",
            "Measurement 67 89--*--Fasting plasma glucose",
            "Value 90 98--*--< 7,0 mM",
            "Measurement 100 105--*--HbA1c",
            "Value 106 119--*--< 48 mmol/mol",
            "Temporal 120 139--*--3 months after RYGB",
            "Reference_point 135 139--*--RYGB",
            "Procedure 135 139--*--RYGB"
        ]
    },
    "NCT02851888_exc": {
        "Text": "Current or planned pregnancy. History of neuropathic pain, chronic pain syndrome, or preoperative use of narcotic or neuropathic pain medicine. Radiographic signs of osteoarthritis (> Tonis grade 1). Inability to attend follow up visits. Documented allergy to local anesthetic. ",
        "Annotations": [
            "Temporal 0 7--*--Current",
            "Mood 11 18--*--planned",
            "Condition 19 28--*--pregnancy",
            "Scope 0 18--*--Current or planned",
            "Condition 41 57--*--neuropathic pain",
            "Observation 30 37--*--History",
            "Condition 59 80--*--chronic pain syndrome",
            "Temporal 85 97--*--preoperative",
            "Drug 105 113;134 142--*--narcotic medicine",
            "Drug 117 142--*--neuropathic pain medicine",
            "Scope 105 142--*--narcotic or neuropathic pain medicine",
            "Scope 41 142--*--neuropathic pain, chronic pain syndrome, or preoperative use of narcotic or neuropathic pain medicine",
            "Mood 144 162--*--Radiographic signs",
            "Procedure 144 156--*--Radiographic",
            "Condition 166 180--*--osteoarthritis",
            "Measurement 184 195--*--Tonis grade",
            "Value 182 183;196 197--*--> 1",
            "Condition 200 209--*--Inability",
            "Observation 213 236--*--attend follow up visits",
            "Condition 249 256--*--allergy",
            "Drug 260 276--*--local anesthetic"
        ]
    },
    "NCT02897856_exc": {
        "Text": "Cardiac arrest. Head trauma. Drowning. Congenital heart disease. Inborn errors of metabolism. Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia). Hemodynamic instability. Allergy to benzodiazepines. Focal seizures with preserved level of consciousness. ",
        "Annotations": [
            "Condition 0 14--*--Cardiac arrest",
            "Condition 16 27--*--Head trauma",
            "Condition 29 37--*--Drowning",
            "Condition 39 63--*--Congenital heart disease",
            "Condition 65 92--*--Inborn errors of metabolism",
            "Condition 94 115--*--Electrolyte imbalance",
            "Condition 117 130--*--hypocalcaemia",
            "Condition 132 144--*--hyponatremia",
            "Condition 149 161--*--hypoglycemia",
            "Scope 117 161--*--hypocalcaemia, hyponatremia and hypoglycemia",
            "Condition 164 187--*--Hemodynamic instability",
            "Condition 189 196--*--Allergy",
            "Drug 200 215--*--benzodiazepines",
            "Condition 217 231--*--Focal seizures",
            "Condition 237 269--*--preserved level of consciousness"
        ]
    },
    "NCT01205334_inc": {
        "Annotations": [
            "Condition 34 57--*--glioblastoma multiforme",
            "Procedure 0 17--*--Histopathological",
            "Observation 0 30--*--Histopathological verification",
            "Measurement 64 67--*--WHO",
            "Value 68 76--*--grade IV",
            "Qualifier 78 90--*--in remission",
            "Qualifier 92 99--*--Group A",
            "Qualifier 125 132--*--Group B",
            "Temporal 109 115--*--active",
            "Qualifier 104 123--*--with active disease",
            "Scope 78 133--*--in remission (Group A) or with active disease (Group B)",
            "Qualifier 136 148--*--CMV-positive",
            "Condition 149 152--*--GBM",
            "Condition 59 62--*--GBM",
            "Condition 136 139--*--CMV",
            "Condition 154 170--*--CMV seropositive",
            "Observation 172 187--*--Life expectancy",
            "Value 188 206--*--6 weeks or greater",
            "Measurement 208 224--*--Karnofsky/Lansky",
            "Value 225 244--*--score 50 or greater",
            "Post-eligibility 246 310--*--Patient or parent/guardian capable of providing informed consent",
            "Measurement 312 321--*--Bilirubin",
            "Value 322 358--*--less than 1.5x upper limit of normal",
            "Measurement 360 363--*--AST",
            "Value 364 398--*--less than 3x upper limit of normal",
            "Measurement 468 482--*--Pulse oximetry",
            "Value 486 500--*--90% or greater",
            "Qualifier 501 512--*--on room air",
            "Pregnancy_considerations 514 688--*--Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom.",
            "Post-eligibility 690 808--*--Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.",
            "Procedure 742 764--*--antineoplastic therapy",
            "Negation 711 719--*--been off",
            "Temporal 765 807--*--for one month prior to entry in this study",
            "Reference_point 788 807--*--entry in this study",
            "Post-eligibility 810 935--*--Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent."
        ],
        "Text": "Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B). . CMV-positive GBM . CMV seropositive . Life expectancy 6 weeks or greater . Karnofsky/Lansky score 50 or greater . Patient or parent/guardian capable of providing informed consent . Bilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater . Pulse oximetry of 90% or greater on room air . Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom. . Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study. . Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. . "
    },
    "NCT03493919_exc": {
        "Text": "Progressive, unstable or uncontrolled clinical conditions.. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.. Clinical conditions.. Systemic administration of corticosteroids (PO/IV/IM) within 90 days prior to informed consent.. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.. Received immunoglobulins or any blood products within 180 days prior to informed consent.. Received an investigational or non-registered medicinal product within 30 days prior to informed consent.. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.. Any history of meningococcal vaccination or meningococcal and gonorrhoea diseases.. Enrolment in any activity requiring a blood donation greater than 50 mL during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period.. Administration of long-acting immune-modifying drugs at any time during the study period. Subjects with blood disorders.. Subjects with a history of difficulty in providing blood samples. Any antibiotic intake 7 days prior to blood collection.. Subjects who donated >450 mL of blood within 60 days prior to any blood collection visits.. Subjects who lost >200 mL during a single apheresis or who lost red blood cells on more than one occasion during apheresis within the previous 60 days.. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. Ongoing anaemia as indicated by haemoglobin values below the lower limit of the laboratory-specified reference range. If the finger prick method demonstrates an anaemia, no further protocol procedures will be performed, and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.. Pregnant or lactating female.. Female planning to become pregnant or planning to discontinue contraceptive precautions.. Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination. Family history of congenital or hereditary immunodeficiency.. Serious chronic illness.. History of chronic alcohol consumption and/or drug abuse.. ",
        "Annotations": [
            "Qualifier 25 37--*--uncontrolled",
            "Qualifier 13 21--*--unstable",
            "Qualifier 0 11--*--Progressive",
            "Condition 38 57--*--clinical conditions",
            "Scope 0 37--*--Progressive, unstable or uncontrolled",
            "Condition 60 76--*--Hypersensitivity",
            "Condition 88 95--*--allergy",
            "Drug 104 125--*--component of vaccines",
            "Drug 127 145--*--medicinal products",
            "Device 149 166--*--medical equipment",
            "Qualifier 167 202--*--whose use is foreseen in this study",
            "Scope 104 166--*--component of vaccines, medicinal products or medical equipment",
            "Scope 60 95--*--Hypersensitivity, including allergy",
            "Condition 240 256--*--contraindication",
            "Procedure 260 285--*--intramuscular vaccination",
            "Procedure 290 301--*--blood draws",
            "Scope 260 301--*--intramuscular vaccination and blood draws",
            "Non-representable 304 324--*--Clinical conditions.",
            "Qualifier 326 349--*--Systemic administration",
            "Drug 353 368--*--corticosteroids",
            "Qualifier 370 372--*--PO",
            "Qualifier 373 375--*--IV",
            "Qualifier 376 378--*--IM",
            "Scope 370 378--*--PO/IV/IM",
            "Temporal 380 420--*--within 90 days prior to informed consent",
            "Reference_point 404 420--*--informed consent",
            "Drug 460 483--*--immunomodulating agents",
            "Drug 441 455;477 483--*--antineoplastic agents",
            "Procedure 487 499--*--radiotherapy",
            "Temporal 500 540--*--within 90 days prior to informed consent",
            "Reference_point 524 540--*--informed consent",
            "Scope 441 499--*--antineoplastic and immunomodulating agents or radiotherapy",
            "Drug 552 567--*--immunoglobulins",
            "Drug 575 589--*--blood products",
            "Temporal 590 631--*--within 180 days prior to informed consent",
            "Reference_point 615 631--*--informed consent",
            "Scope 552 589--*--immunoglobulins or any blood products",
            "Qualifier 646 661--*--investigational",
            "Qualifier 665 679--*--non-registered",
            "Drug 680 697--*--medicinal product",
            "Temporal 698 738--*--within 30 days prior to informed consent",
            "Reference_point 722 738--*--informed consent",
            "Scope 646 679--*--investigational or non-registered",
            "Non-representable 741 888--*--Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.",
            "Drug 905 930--*--meningococcal vaccination",
            "Observation 894 901--*--history",
            "Condition 934 947;963 971--*--meningococcal diseases",
            "Condition 952 971--*--gonorrhoea diseases",
            "Scope 905 971--*--meningococcal vaccination or meningococcal and gonorrhoea diseases",
            "Procedure 1012 1026--*--blood donation",
            "Non-representable 974 1011--*--Enrolment in any activity requiring a",
            "Multiplier 1027 1045--*--greater than 50 mL",
            "Temporal 1046 1109--*--during the period starting 30 days before the first study visit",
            "Reference_point 1073 1109--*--30 days before the first study visit",
            "Temporal 1143 1179--*--for the duration of the study period",
            "Reference_point 1163 1179--*--the study period",
            "Scope 1046 1179--*--during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period",
            "Drug 1212 1234--*--immune-modifying drugs",
            "Temporal 1235 1270--*--at any time during the study period",
            "Reference_point 1254 1270--*--the study period",
            "Qualifier 1200 1211--*--long-acting",
            "Condition 1286 1301--*--blood disorders",
            "Observation 1320 1327--*--history",
            "Observation 1331 1368--*--difficulty in providing blood samples",
            "Drug 1374 1384--*--antibiotic",
            "Temporal 1392 1424--*--7 days prior to blood collection",
            "Reference_point 1408 1424--*--blood collection",
            "Procedure 1440 1447;1459 1464--*--donated blood",
            "Value 1448 1455--*-->450 mL",
            "Temporal 1465 1516--*--within 60 days prior to any blood collection visits",
            "Reference_point 1489 1516--*--any blood collection visits",
            "Measurement 1578 1598--*--lost red blood cells",
            "Value 1537 1544--*-->200 mL",
            "Multiplier 1554 1560--*--single",
            "Procedure 1561 1570--*--apheresis",
            "Procedure 1632 1641--*--apheresis",
            "Multiplier 1602 1624--*--more than one occasion",
            "Temporal 1642 1669--*--within the previous 60 days",
            "Reference_point 1649 1669--*--the previous 60 days",
            "Temporal 1672 1684--*--Concurrently",
            "Observation 1685 1701;1710 1724--*--participating in clinical study",
            "Temporal 1726 1761--*--at any time during the study period",
            "Reference_point 1745 1761--*--the study period",
            "Drug 1859 1866--*--vaccine",
            "Drug 1867 1874--*--product",
            "Scope 1859 1874--*--vaccine/product",
            "Qualifier 1818 1833--*--investigational",
            "Qualifier 1839 1858--*--non-investigational",
            "Scope 1818 1858--*--investigational or a non-investigational",
            "Temporal 1876 1883--*--Ongoing",
            "Condition 1884 1891--*--anaemia",
            "Measurement 1908 1919--*--haemoglobin",
            "Value 1927 1992--*--below the lower limit of the laboratory-specified reference range",
            "Procedure 2001 2020--*--finger prick method",
            "Condition 2037 2044--*--anaemia",
            "Non-representable 2096 2273--*--and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.",
            "Condition 2290 2298--*--reaction",
            "Condition 2302 2318--*--hypersensitivity",
            "Qualifier 2319 2376--*--likely to be exacerbated by any component of the vaccines",
            "Drug 2351 2376--*--component of the vaccines",
            "Scope 2290 2318--*--reaction or hypersensitivity",
            "Condition 2379 2387--*--Pregnant",
            "Observation 2391 2400--*--lactating",
            "Person 2401 2407--*--female",
            "Person 2410 2416--*--Female",
            "Observation 2417 2444--*--planning to become pregnant",
            "Mood 2448 2471--*--planning to discontinue",
            "Observation 2472 2497--*--contraceptive precautions",
            "Mood 2417 2428--*--planning to",
            "Observation 2429 2444--*--become pregnant",
            "Qualifier 2504 2513--*--confirmed",
            "Mood 2517 2526--*--suspected",
            "Condition 2527 2544;2565 2574--*--immunosuppressive condition",
            "Condition 2548 2574--*--immunodeficiency condition",
            "Observation 2584 2599--*--medical history",
            "Procedure 2604 2624--*--physical examination",
            "Scope 2584 2624--*--medical history and physical examination",
            "Scope 2527 2574--*--immunosuppressive or immunodeficiency condition",
            "Scope 2504 2526--*--confirmed or suspected",
            "Observation 2626 2640--*--Family history",
            "Condition 2658 2685--*--hereditary immunodeficiency",
            "Condition 2644 2654;2669 2685--*--congenital immunodeficiency",
            "Scope 2644 2685--*--congenital or hereditary immunodeficiency",
            "Qualifier 2688 2695--*--Serious",
            "Condition 2696 2711--*--chronic illness",
            "Condition 2725 2752--*--chronic alcohol consumption",
            "Condition 2760 2770--*--drug abuse",
            "Observation 2714 2721--*--History",
            "Scope 2725 2770--*--chronic alcohol consumption and/or drug abuse"
        ]
    },
    "NCT02804126_exc": {
        "Annotations": [
            "Condition 0 12--*--coagulopathy",
            "Condition 14 21--*--allergy",
            "Drug 28 45--*--local anesthetics",
            "Condition 47 57--*--depression",
            "Drug 59 79--*--antidepressant drugs",
            "Condition 91 99--*--epilepsy",
            "Drug 110 120--*--painkiller",
            "Temporal 121 135--*--before surgery",
            "Condition 137 157--*--addiction to alcohol",
            "Condition 137 149;161 179--*--addiction to recreational drugs"
        ],
        "Text": "coagulopathy. allergy to to local anesthetics. depression, antidepressant drugs treatment. epilepsy. usage of painkiller before surgery. addiction to alcohol or recreational drugs. "
    },
    "NCT01032109_inc": {
        "Annotations": [
            "Condition 0 28--*--choroidal neovascularization",
            "Qualifier 39 50--*--age-related",
            "Condition 51 70--*--macula degeneration",
            "Negation 72 74--*--no",
            "Temporal 75 83--*--previous",
            "Procedure 84 93--*--treatment",
            "Context_Error 72 93--*--no previous treatment",
            "Observation 97 106--*--follow-up",
            "Temporal 107 125--*--at least 12 months",
            "Measurement 138 151--*--visual acuity",
            "Temporal 129 137--*--baseline",
            "Value 167 190--*--letter score of 0 to 70",
            "Procedure 198 246--*--Early Treatment Diabetic Retinopathy Study chart"
        ],
        "Text": "choroidal neovascularization caused by age-related macula degeneration . no previous treatment . a follow-up at least 12 months . a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart . "
    },
    "NCT03125057_exc": {
        "Text": "Therapy area located outside of head and neck;. Other skin diseases that might interfere with the efficacy evaluation;. Therapy area was previously received isotope or PDT or other treatment which might interfere with the efficacy evaluation;. Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;. Scar diathesis;. Immunocompromised conditions;. Electrocardiographic abnormalities or organic heart diseases;. Coagulation disorders;. Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN);. Psychiatric diseases; Severe endocrinopathies;. Previous therapy of PWS within the last 4 weeks;. Participation in any clinical studies within the last 4 weeks;. Be judged not suitable to participate the study by the investigators. ",
        "Annotations": [
            "Non-representable 0 46--*--Therapy area located outside of head and neck;",
            "Condition 54 67--*--skin diseases",
            "Qualifier 79 117--*--interfere with the efficacy evaluation",
            "Drug 157 164--*--isotope",
            "Drug 168 171--*--PDT",
            "Procedure 181 190--*--treatment",
            "Qualifier 197 241--*--might interfere with the efficacy evaluation",
            "Scope 157 171--*--isotope or PDT",
            "Condition 244 251--*--Allergy",
            "Drug 255 265--*--porphyrins",
            "Condition 281 297--*--Photosensitivity",
            "Drug 270 279--*--analogues",
            "Condition 299 308--*--Porphyria",
            "Condition 310 331--*--Allergic constitution",
            "Scope 255 279--*--porphyrins and analogues",
            "Condition 334 348--*--Scar diathesis",
            "Condition 351 379--*--Immunocompromised conditions",
            "Condition 382 416--*--Electrocardiographic abnormalities",
            "Qualifier 420 427--*--organic",
            "Condition 428 442--*--heart diseases",
            "Procedure 382 402--*--Electrocardiographic",
            "Condition 445 466--*--Coagulation disorders",
            "Measurement 469 476;486 495--*--Hepatic functions",
            "Measurement 480 495--*--renal functions",
            "Value 496 504--*--abnormal",
            "Measurement 506 530--*--alanine aminotransferase",
            "Measurement 534 556--*--aspartate transaminase",
            "Measurement 560 575--*--total bilirubin",
            "Value 576 609--*--> 1.5 upper limit of normal [ULN]",
            "Scope 506 575--*--alanine aminotransferase or aspartate transaminase or total bilirubin",
            "Measurement 614 630--*--serum creatinine",
            "Measurement 634 653--*--blood urea nitrogen",
            "Value 654 663--*--> 1.5 ULN",
            "Scope 614 653--*--serum creatinine or blood urea nitrogen",
            "Scope 506 663--*--alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN",
            "Scope 469 504--*--Hepatic or renal functions abnormal",
            "Condition 667 687--*--Psychiatric diseases",
            "Qualifier 689 695--*--Severe",
            "Condition 696 712--*--endocrinopathies",
            "Temporal 715 723--*--Previous",
            "Procedure 724 731--*--therapy",
            "Temporal 739 762--*--within the last 4 weeks",
            "Observation 765 802--*--Participation in any clinical studies",
            "Temporal 803 826--*--within the last 4 weeks",
            "Non-query-able 829 897--*--Be judged not suitable to participate the study by the investigators",
            "Condition 735 738--*--PWS"
        ]
    },
    "NCT02851888_inc": {
        "Text": "Scheduled for arthroscopic labral repair with or without osteoplasty of the hip.. 18 to 50 years old. American Society of Anesthesiologists Physical Status (ASA PS) score of I or II.. ",
        "Annotations": [
            "Procedure 14 40--*--arthroscopic labral repair",
            "Procedure 57 68--*--osteoplasty",
            "Qualifier 76 79--*--hip",
            "Scope 57 79--*--osteoplasty of the hip",
            "Mood 0 9--*--Scheduled",
            "Person 97 100--*--old",
            "Value 82 96--*--18 to 50 years",
            "Measurement 102 155;165 170--*--American Society of Anesthesiologists Physical Status score",
            "Measurement 157 163--*--ASA PS",
            "Value 174 181--*--I or II"
        ]
    },
    "NCT02897856_inc": {
        "Text": "Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Value 9 28--*--6 month to 14 years",
            "Person 23 28--*--years",
            "Visit 58 77--*--pediatric emergency",
            "Observation 81 118--*--attended by emergency medical service",
            "Qualifier 128 134--*--active",
            "Condition 135 142--*--seizure",
            "Negation 151 153--*--no",
            "Device 154 172--*--intravenous access"
        ]
    },
    "NCT03493919_inc": {
        "Text": "Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.. Written informed consent obtained from the subject prior to performing any study specific procedure.. A male or female between, and including, 18 and 50 years of age at the time of the first study visit.. Healthy subjects as established by medical history and clinical examination before entering into the study. Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study.. Subjects must weigh at least 110 pounds (50 kg), but not to present obesity (BMI < 32kg/m2).. Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.. has practiced adequate contraception for 30 days prior to vaccination, and. has a negative pregnancy test on the day of vaccination and. has agreed to continue adequate contraception during the entire treatment period and for 1 month, after completion of the vaccination series.. ",
        "Annotations": [
            "Non-query-able 14 48--*--in the opinion of the investigator",
            "Observation 63 107--*--comply with the requirements of the protocol",
            "Observation 110 134--*--Written informed consent",
            "Procedure 185 209--*--study specific procedure",
            "Temporal 161 209--*--prior to performing any study specific procedure",
            "Reference_point 170 209--*--performing any study specific procedure",
            "Person 214 218--*--male",
            "Person 222 228--*--female",
            "Value 253 268--*--18 and 50 years",
            "Person 272 275--*--age",
            "Temporal 276 312--*--at the time of the first study visit",
            "Reference_point 291 312--*--the first study visit",
            "Condition 315 322--*--Healthy",
            "Observation 350 365--*--medical history",
            "Procedure 370 390--*--clinical examination",
            "Temporal 391 421--*--before entering into the study",
            "Reference_point 398 421--*--entering into the study",
            "Non-query-able 423 562--*--Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study.",
            "Measurement 578 583--*--weigh",
            "Value 584 603--*--at least 110 pounds",
            "Value 584 592;605 610--*--at least 50 kg",
            "Scope 584 611--*--at least 110 pounds (50 kg)",
            "Condition 632 639--*--obesity",
            "Measurement 641 644--*--BMI",
            "Negation 617 631--*--not to present",
            "Value 645 654--*--< 32kg/m2",
            "Person 658 664--*--Female",
            "Negation 677 681--*--non-",
            "Observation 681 703--*--childbearing potential",
            "Observation 775 787--*--pre-menarche",
            "Scope 641 654--*--BMI < 32kg/m2",
            "Temporal 789 796--*--current",
            "Condition 797 821--*--bilateral tubal ligation",
            "Condition 797 812;825 834--*--bilateral tubal occlusion",
            "Scope 797 834--*--bilateral tubal ligation or occlusion",
            "Condition 836 848--*--hysterectomy",
            "Procedure 797 821--*--bilateral tubal ligation",
            "Procedure 797 812;825 834--*--bilateral tubal occlusion",
            "Condition 850 871--*--bilateral ovariectomy",
            "Observation 875 889--*--post-menopause",
            "Procedure 850 871--*--bilateral ovariectomy",
            "Scope 775 889--*--pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause",
            "Scope 677 703--*--non-childbearing potential",
            "Scope 775 889--*--pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause",
            "Observation 915 928--*--contraception",
            "Qualifier 906 914--*--adequate",
            "Temporal 933 961--*--30 days prior to vaccination",
            "Reference_point 950 961--*--vaccination",
            "Value 974 982--*--negative",
            "Measurement 983 997--*--pregnancy test",
            "Temporal 998 1023--*--on the day of vaccination",
            "Reference_point 1012 1023--*--vaccination",
            "Multiplier 1043 1051--*--continue",
            "Observation 1052 1074--*--adequate contraception",
            "Temporal 1075 1109--*--during the entire treatment period",
            "Temporal 1114 1169--*--for 1 month, after completion of the vaccination series",
            "Reference_point 1133 1169--*--completion of the vaccination series",
            "Scope 1075 1169--*--during the entire treatment period and for 1 month, after completion of the vaccination series"
        ]
    },
    "NCT02804126_inc": {
        "Annotations": [
            "Non-query-able 0 16--*--obtained consent",
            "Condition 28 37--*--pregnancy",
            "Qualifier 18 27--*--singleton",
            "Procedure 39 63--*--subarachnoid anaesthesia"
        ],
        "Text": "obtained consent. singleton pregnancy. subarachnoid anaesthesia. "
    },
    "NCT01205334_exc": {
        "Annotations": [
            "Condition 20 29--*--infection",
            "Temporal 7 19--*--intercurrent",
            "Qualifier 0 6--*--Severe",
            "Condition 37 51--*--HIV positivity",
            "Condition 53 61--*--Pregnant",
            "Condition 65 74--*--lactating",
            "Condition 87 113--*--hypersensitivity reactions",
            "Drug 117 151--*--murine protein-containing products",
            "Drug 117 123--*--murine"
        ],
        "Text": "Severe intercurrent infection . Known HIV positivity . Pregnant or lactating . History of hypersensitivity reactions to murine protein-containing products.       .     . "
    },
    "NCT03125057_inc": {
        "Text": "Children with clinical diagnosis of PWS;. Age range: 7 to 14 years-old;. Voluntarily participated and Written informed consent signed. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Qualifier 14 32--*--clinical diagnosis",
            "Condition 36 39--*--PWS",
            "Person 42 45--*--Age",
            "Value 53 70--*--7 to 14 years-old",
            "Observation 102 133--*--Written informed consent signed",
            "Observation 73 97--*--Voluntarily participated"
        ]
    },
    "NCT01032109_exc": {
        "Annotations": [
            "Condition 0 28--*--choroidal neovascularization",
            "Condition 39 57--*--other eye diseases",
            "Qualifier 39 44--*--other",
            "Procedure 59 73--*--ocular surgery",
            "Temporal 74 98--*--within the past 3 mouths",
            "Condition 111 118--*--uveitis",
            "Observation 100 107--*--history",
            "Measurement 120 140--*--intraocular pressure",
            "Value 141 160--*--higher than 25 mmHg",
            "Condition 165 173--*--glaucoma",
            "Condition 205 226--*--thromboembolic events",
            "Qualifier 198 204--*--ocular",
            "Qualifier 186 194--*--systemic",
            "Scope 186 204--*--systemic or ocular"
        ],
        "Text": "choroidal neovascularization caused by other eye diseases . ocular surgery within the past 3 mouths . history of uveitis . intraocular pressure higher than 25 mmHg, or glaucoma . history of systemic or ocular thromboembolic events.       .     . "
    },
    "NCT01720394_exc": {
        "Annotations": [
            "Condition 0 15--*--fetal anomalies",
            "Condition 17 35--*--contra-indications",
            "Procedure 40 66--*--medical induction of labor",
            "Condition 68 89--*--placental pathologies",
            "Condition 91 96--*--St.p.",
            "Procedure 97 136--*--surgery with opening the uterine cavity",
            "Procedure 144 161--*--caesarean section",
            "Condition 164 168--*--PROM",
            "Condition 170 189--*--multiple gestations",
            "Value 191 203--*--< 37-0 weeks",
            "Measurement 207 216--*--gestation",
            "Condition 218 223--*--St.p.",
            "Procedure 224 237--*--cervical tear"
        ],
        "Text": "fetal anomalies. contra-indications for medical induction of labor. placental pathologies. St.p. surgery with opening the uterine cavity (incl. caesarean section). PROM. multiple gestations. < 37-0 weeks of gestation. St.p. cervical tear. "
    },
    "NCT02777424_inc": {
        "Annotations": [
            "Condition 13 48--*--spontaneous intracranial hemorrhage",
            "Condition 52 85--*--traumatic intracranial hemorrhage",
            "Mood 97 106--*--requiring",
            "Procedure 107 127--*--neurological surgery",
            "Condition 129 149--*--Coagulation disorder",
            "Measurement 161 163--*--PT",
            "Value 164 177--*--less than 60%",
            "Scope 161 177--*--PT less than 60%"
        ],
        "Text": "Patient with spontaneous intracranial hemorrhage or traumatic intracranial hemorrhage or patient requiring neurological surgery. Coagulation disorder defined by PT less than 60%. "
    },
    "NCT03217409_exc": {
        "Text": "Subjects with hypersensitivity reaction to Statin and Ezetimibe. Subjects with severe kidney disease. Subjects with HIV positive result at the screening. Pregnant or breast-feeding subjects. Subjects with taking any medication affecting level of LDL (Fenofibrate, Omega 3 fatty aicd etc.). Insulin-treated Subjects. Other exclusions applied. ",
        "Annotations": [
            "Condition 14 30--*--hypersensitivity",
            "Drug 43 49--*--Statin",
            "Drug 54 63--*--Ezetimibe",
            "Scope 43 63--*--Statin and Ezetimibe",
            "Qualifier 79 85--*--severe",
            "Condition 86 100--*--kidney disease",
            "Condition 116 128--*--HIV positive",
            "Temporal 136 152--*--at the screening",
            "Condition 154 162--*--Pregnant",
            "Condition 166 180--*--breast-feeding",
            "Procedure 246 249--*--LDL",
            "Drug 251 262--*--Fenofibrate",
            "Drug 216 226--*--medication",
            "Condition 227 236--*--affecting",
            "Drug 264 282--*--Omega 3 fatty aicd",
            "Scope 251 282--*--Fenofibrate, Omega 3 fatty aicd",
            "Drug 290 297--*--Insulin",
            "Non-representable 316 340--*--Other exclusions applied"
        ]
    },
    "NCT02117986_exc": {
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Observation 12 25--*--breastfeeding",
            "Observation 51 61--*--history of",
            "Condition 62 78--*--hypersensitivity",
            "Drug 82 90--*--colistin"
        ],
        "Text": "pregnant or breastfeeding patients. patient with a history of hypersensitivity to colistin. "
    },
    "NCT02464865_exc": {
        "Text": "pathological obesity. chronic diseases e.g. cerebral palsy, metabolic disease, etc.. diseases of red blood cells. on medication e.g. steroid, multivitamins, thiamine-containing vitamins, diuretic drugs. hemodialysis or peritoneal dialysis. bariatric surgery. ",
        "Annotations": [
            "Condition 0 20--*--pathological obesity",
            "Condition 22 38--*--chronic diseases",
            "Condition 44 58--*--cerebral palsy",
            "Condition 60 77--*--metabolic disease",
            "Scope 44 77--*--cerebral palsy, metabolic disease",
            "Condition 85 112--*--diseases of red blood cells",
            "Drug 133 140--*--steroid",
            "Drug 142 155--*--multivitamins",
            "Drug 157 185--*--thiamine-containing vitamins",
            "Drug 187 201--*--diuretic drugs",
            "Procedure 203 215--*--hemodialysis",
            "Procedure 219 238--*--peritoneal dialysis",
            "Procedure 240 257--*--bariatric surgery"
        ]
    },
    "NCT01720394_inc": {
        "Annotations": [
            "Condition 0 18--*--medical indication",
            "Procedure 23 41--*--induction of labor",
            "Value 43 51--*--18 years",
            "Person 55 58--*--age",
            "Informed_consent 60 83--*--signed informed consent",
            "Condition 85 106--*--cephalic presentation",
            "Condition 111 115--*--PROM",
            "Negation 108 110--*--no",
            "Value 117 121--*--37+0",
            "Value 124 128--*--42+0",
            "Measurement 129 147--*--weeks of gestation",
            "Scope 117 128--*--37+0 - 42+0",
            "Measurement 149 161--*--Bishop-Score",
            "Value 162 165--*--= 6",
            "Condition 170 187--*--contra-indication",
            "Negation 167 169--*--no",
            "Procedure 192 218--*--medical induction of labor",
            "Negation 220 222--*--no",
            "Mood 223 240--*--clinical signs of",
            "Condition 241 250--*--infection"
        ],
        "Text": "medical indication for induction of labor. 18 years of age. signed informed consent. cephalic presentation. no PROM. 37+0 - 42+0 weeks of gestation. Bishop-Score = 6. no contra-indication for medical induction of labor. no clinical signs of infection. "
    },
    "NCT02777424_exc": {
        "Annotations": [
            "Temporal 0 11--*--Concomitant",
            "Drug 21 45--*--oral anticoagulant drugs",
            "Condition 47 89--*--Acquired deficiency of coagulation factors",
            "Qualifier 90 120--*--whose treatment is established",
            "Condition 122 138--*--Hypersensitivity",
            "Drug 144 147--*--PCC",
            "Condition 160 176--*--thrombocytopenia",
            "Drug 188 195--*--heparin",
            "Condition 197 235--*--Disseminated intravascular coagulation",
            "Condition 237 249;257 265--*--Extracranial bleeding",
            "Qualifier 250 256--*--active",
            "Condition 267 283--*--Hypersensitivity",
            "Drug 287 296--*--vitamin K"
        ],
        "Text": "Concomitant use with oral anticoagulant drugs. Acquired deficiency of coagulation factors whose treatment is established. Hypersensitivity to a PCC. History of thrombocytopenia induced by heparin. Disseminated intravascular coagulation. Extracranial active bleeding. Hypersensitivity to vitamin K. "
    },
    "NCT02117986_inc": {
        "Annotations": [
            "Procedure 8 20--*--hospitalized",
            "Visit 24 43--*--critical care units",
            "Qualifier 65 85--*--multi drug resistant",
            "Condition 86 108--*--Gram negative bacteria",
            "Observation 109 120--*--susceptibly",
            "Multiplier 121 125--*--only",
            "Drug 129 137--*--colistin",
            "Non-representable 139 206--*--source of infection: blood, respiratory, intra abdominal or urinary"
        ],
        "Text": "patient hospitalized in critical care units. patient infected by multi drug resistant Gram negative bacteria susceptibly only to colistin. source of infection: blood, respiratory, intra abdominal or urinary. "
    },
    "NCT03217409_inc": {
        "Text": "Subjects = 19 or = 75 years of age. Subjects undergoing treatment for type 2 diabetes. Subjects undergoing treatment of statin for hypercholesterolemia. Fasting LDL-C = 250mg/dL at the screening visit. Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit. Fasting TG<500mg/dL. ",
        "Annotations": [
            "Value 9 27--*--= 19 or = 75 years",
            "Person 31 34--*--age",
            "Condition 70 85--*--type 2 diabetes",
            "Procedure 56 65--*--treatment",
            "Procedure 107 116--*--treatment",
            "Condition 131 151--*--hypercholesterolemia",
            "Drug 120 126--*--statin",
            "Scope 107 126--*--treatment of statin",
            "Measurement 153 166--*--Fasting LDL-C",
            "Measurement 202 215--*--Fasting LDL-C",
            "Value 167 177--*--= 250mg/dL",
            "Temporal 178 200--*--at the screening visit",
            "Value 216 224--*--=70mg/dL",
            "Value 228 238--*--= 160mg/dL",
            "Scope 216 237--*--=70mg/dL or = 160mg/d",
            "Temporal 239 266--*--at the randomization visit",
            "Measurement 267 277--*--Fasting TG",
            "Value 277 286--*--<500mg/dL",
            "Temporal 239 265--*--at the randomization visit"
        ]
    },
    "NCT02464865_inc": {
        "Text": "obese : weight for height > median + 3 standard deviations. simple obesity. ",
        "Annotations": [
            "Condition 0 5--*--obese",
            "Measurement 8 25--*--weight for height",
            "Value 26 58--*--> median + 3 standard deviations",
            "Scope 8 58--*--weight for height > median + 3 standard deviations",
            "Condition 60 74--*--simple obesity"
        ]
    },
    "NCT01701219_exc": {
        "Annotations": [
            "Observation 19 27--*--Cohort A",
            "Non-query-able 19 27--*--Cohort A",
            "Procedure 38 45--*--therapy",
            "Undefined_semantics 38 45--*--therapy",
            "Temporal 29 37--*--previous",
            "Temporal 46 68--*--for more than 48 hours",
            "Drug 78 131--*--parenteral antibiotic with activity against S. aureus",
            "Qualifier 100 131--*--with activity against S. aureus",
            "Observation 122 131--*--S. aureus",
            "Temporal 132 181--*--within 72 hours of positive blood culture results",
            "Reference_point 151 181--*--positive blood culture results",
            "Procedure 160 173--*--blood culture",
            "Value 151 159;174 181--*--positive results",
            "Observation 203 211--*--Cohort B",
            "Non-query-able 203 211--*--Cohort B",
            "Scope 29 182--*--previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results.",
            "Temporal 213 221--*--previous",
            "Procedure 222 229--*--therapy",
            "Undefined_semantics 222 229--*--therapy",
            "Temporal 230 252--*--for more than 48 hours",
            "Drug 262 310--*--parenteral antibiotic with activity against MRSA",
            "Qualifier 78 88--*--parenteral",
            "Qualifier 262 272--*--parenteral",
            "Qualifier 284 310--*--with activity against MRSA",
            "Observation 306 310--*--MRSA",
            "Drug 319 329--*--vancomycin",
            "Negation 312 318--*--except",
            "Drug 337 347--*--daptomycin",
            "Temporal 349 398--*--within 72 hours of positive blood culture results",
            "Reference_point 368 398--*--positive blood culture results",
            "Value 368 376;391 398--*--positive results",
            "Procedure 377 390--*--blood culture",
            "Scope 312 347--*--except vancomycin and/or daptomycin",
            "Condition 447 467--*--S. aureus bacteremia",
            "Observation 447 456--*--S. aureus",
            "Qualifier 447 456--*--S. aureus",
            "Temporal 468 483--*--within 3 months",
            "Condition 495 518--*--left-sided endocarditis",
            "Qualifier 495 505--*--left-sided",
            "Device 522 544--*--prosthetic heart valve",
            "Condition 550 563--*--Osteomyelitis",
            "Condition 567 593--*--prosthetic joint infection",
            "Temporal 601 610--*--new onset",
            "Qualifier 611 633--*--nonhardware-associated",
            "Condition 634 657--*--vertebral osteomyelitis",
            "Negation 594 600--*--except",
            "Condition 678 694--*--hypersensitivity",
            "Condition 698 715--*--allergic reaction",
            "Drug 723 751--*--\u03b2-lactam antibacterial agent",
            "Scope 678 715--*--hypersensitivity or allergic reaction",
            "Observation 663 670--*--History",
            "Condition 781 788;818 828--*--hepatic impairment",
            "Condition 806 828--*--immunologic impairment",
            "Condition 790 801;818 828--*--hematologic impairment",
            "Condition 834 842--*--Pregnant",
            "Condition 846 853--*--nursing",
            "Person 854 861--*--females",
            "Scope 213 421--*--previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence"
        ],
        "Text": "1. For subjects in Cohort A: previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results. . 2. For subjects in Cohort B: previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence. . 3. Previous episode of S. aureus bacteremia within 3 months. . 4. Known left-sided endocarditis or prosthetic heart valve. . 5. Osteomyelitis or prosthetic joint infection except new onset nonhardware-associated vertebral osteomyelitis. . 6. History of any hypersensitivity or allergic reaction to any \u03b2-lactam antibacterial agent. . 7. Evidence of significant hepatic, hematologic, or immunologic impairment. . 8. Pregnant or nursing females.       .     . "
    },
    "NCT02121145_exc": {
        "Text": "Primary groups: Vaccination against typhoid fever within 5 years before dosing.. History of clinical typhoid fever, clinical paratyphoid A or B fever.. Immunization with any other vaccine (oral or parenteral) within 4 weeks prior to study start or planned vaccination during the study. Current intake of antibiotics or end of antibiotic therapy <8 days before first IMP administration. Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational vaccine; oral corticosteroids in dosages of =0.5 mg/kg/d prednisolone or equivalent are excluded; inhaled or topical steroids are allowed. Acute or chronic clinically significant gastrointestinal disease. ",
        "Annotations": [
            "Observation 0 14--*--Primary groups",
            "Procedure 16 49--*--Vaccination against typhoid fever",
            "Condition 36 49--*--typhoid fever",
            "Temporal 50 78--*--within 5 years before dosing",
            "Reference_point 72 78--*--dosing",
            "Observation 81 88--*--History",
            "Condition 92 114--*--clinical typhoid fever",
            "Condition 116 138;144 149--*--clinical paratyphoid A fever",
            "Condition 116 136;142 149--*--clinical paratyphoid B fever",
            "Scope 92 149--*--clinical typhoid fever, clinical paratyphoid A or B fever",
            "Procedure 152 169;180 187--*--Immunization with vaccine",
            "Qualifier 170 179--*--any other",
            "Qualifier 189 193--*--oral",
            "Qualifier 197 207--*--parenteral",
            "Scope 189 207--*--oral or parenteral",
            "Temporal 209 244--*--within 4 weeks prior to study start",
            "Reference_point 233 244--*--study start",
            "Mood 248 255--*--planned",
            "Procedure 256 267--*--vaccination",
            "Temporal 268 284--*--during the study",
            "Reference_point 275 284--*--the study",
            "Drug 304 315--*--antibiotics",
            "Temporal 286 293--*--Current",
            "Multiplier 319 325--*--end of",
            "Procedure 326 344--*--antibiotic therapy",
            "Temporal 345 384--*--<8 days before first IMP administration",
            "Reference_point 360 384--*--first IMP administration",
            "Multiplier 386 393;416 430--*--Chronic administration",
            "Multiplier 395 414--*--longer than 14 days",
            "Drug 434 452--*--immunosuppressants",
            "Drug 462 484--*--immune-modifying drugs",
            "Qualifier 456 461--*--other",
            "Scope 434 484--*--immunosuppressants or other immune-modifying drugs",
            "Temporal 485 549--*--within 6 months before the first dose of investigational vaccine",
            "Reference_point 508 549--*--the first dose of investigational vaccine",
            "Drug 526 549--*--investigational vaccine",
            "Drug 551 571--*--oral corticosteroids",
            "Multiplier 575 582--*--dosages",
            "Value 586 598--*--=0.5 mg/kg/d",
            "Negation 630 638--*--excluded",
            "Qualifier 599 625--*--prednisolone or equivalent",
            "Non-representable 640 679--*--inhaled or topical steroids are allowed",
            "Qualifier 698 720--*--clinically significant",
            "Condition 721 745--*--gastrointestinal disease",
            "Qualifier 681 686--*--Acute",
            "Qualifier 690 697--*--chronic",
            "Scope 681 697--*--Acute or chronic"
        ]
    },
    "NCT02365870_exc": {
        "Text": "Unstable medical disease of comorbid psychiatric disease. Dementia. Subjects with less than one year duration of Parkinson's. Current treatment with a dopamine agonist. ",
        "Annotations": [
            "Condition 0 24--*--Unstable medical disease",
            "Condition 28 56--*--comorbid psychiatric disease",
            "Condition 58 66--*--Dementia",
            "Multiplier 82 109--*--less than one year duration",
            "Condition 113 124--*--Parkinson's",
            "Drug 151 167--*--dopamine agonist",
            "Temporal 126 133--*--Current"
        ]
    },
    "NCT03637946_inc": {
        "Annotations": [
            "Value 0 13--*--Over 18 years",
            "Person 17 20--*--age",
            "Condition 22 42--*--Systemically healthy",
            "Condition 44 55--*--Non-smoking",
            "Observation 63 80--*--good oral hygiene",
            "Condition 90 120--*--irreversible pulpal alteration",
            "Negation 83 89--*--Absent",
            "Condition 146 181--*--non-carious cervical lesion (LCNCs)",
            "Procedure 199 207--*--restored",
            "Mood 187 198--*--needs to be",
            "Condition 214 220--*--lesion",
            "Qualifier 231 242--*--non-carious",
            "Qualifier 244 257--*--non-retentive",
            "Value 264 292--*--at least 1 mm and up to 3 mm",
            "Measurement 293 298--*--depth",
            "Qualifier 307 337--*--involve both enamel and dentin",
            "Condition 383 399--*--hypersensitivity",
            "Non-representable 402 554--*--Presence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;",
            "Measurement 581 599--*--Depth Probing (PS)",
            "Measurement 601 627--*--Visible Plaque Index (IPV)",
            "Measurement 629 648--*--Gingival Index (GI)",
            "Measurement 653 677--*--Probing Bleed Index (SS)",
            "Measurement 705 707--*--PS",
            "Value 708 719--*--= 1 to 3 mm",
            "Value 724 727--*--= 0",
            "Value 735 742--*--score 0",
            "Value 750 757--*--score 0",
            "Measurement 745 747--*--SS",
            "Measurement 729 732--*--IPV",
            "Measurement 721 723--*--GI",
            "Scope 581 677--*--Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS)",
            "Scope 705 757--*--PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0"
        ],
        "Text": "Over 18 years of age; Systemically healthy; Non-smoking;. With good oral hygiene;. Absent irreversible pulpal alteration;. With the presence of a non-carious cervical lesion (LCNCs) that needs to be restored. This lesion should be non-carious, non-retentive, with at least 1 mm and up to 3 mm depth, should involve both enamel and dentin of vital teeth without mobility, and present hypersensitivity;. Presence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;. Periodontal parameters : Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS). The normal included were: PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0.. "
    },
    "NCT03216967_exc": {
        "Text": "Known proved BKV nephropathy. Hypersensitivity to everolimus, sirolimus or excipient. Concomitant treatment by leflunomide, cidofovir, sirolimus, Millepertuis (Hypericum Perforatum). Pregnant or lactating women. Women of child bearing potential unless they are using a birth control method. ",
        "Annotations": [
            "Qualifier 6 12--*--proved",
            "Condition 13 28--*--BKV nephropathy",
            "Condition 30 46--*--Hypersensitivity",
            "Drug 50 60--*--everolimus",
            "Drug 62 71--*--sirolimus",
            "Drug 75 84--*--excipient",
            "Scope 50 84--*--everolimus, sirolimus or excipient",
            "Temporal 86 97--*--Concomitant",
            "Drug 111 122--*--leflunomide",
            "Drug 124 133--*--cidofovir",
            "Drug 135 144--*--sirolimus",
            "Drug 146 158--*--Millepertuis",
            "Drug 160 180--*--Hypericum Perforatum",
            "Scope 111 181--*--leflunomide, cidofovir, sirolimus, Millepertuis (Hypericum Perforatum)",
            "Condition 183 191--*--Pregnant",
            "Condition 195 204--*--lactating",
            "Person 205 210--*--women",
            "Person 212 217--*--Women",
            "Condition 221 244--*--child bearing potential",
            "Negation 245 251--*--unless",
            "Procedure 269 289--*--birth control method"
        ]
    },
    "NCT01994382_inc": {
        "Annotations": [
            "Condition 77 80--*--CLL",
            "Condition 81 84--*--SLL",
            "Condition 88 115--*--B-cell Non-Hodgkin lymphoma",
            "Condition 117 122--*--DLBCL",
            "Condition 124 126--*--FL",
            "Condition 128 131--*--MCL",
            "Condition 133 136--*--MZL",
            "Condition 138 164--*--lymphoplasmacytic lymphoma",
            "Scope 117 164--*--DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma",
            "Scope 77 115--*--CLL/SLL or B-cell Non-Hodgkin lymphoma",
            "Value 25 39--*--at least 18yrs",
            "Person 43 46--*--age",
            "Procedure 52 66--*--histologically",
            "Value 67 76--*--confirmed",
            "Parsing_Error 168 186--*--Phase 2a Inclusion",
            "Procedure 188 200--*--Histological",
            "Condition 211 213--*--FL",
            "Measurement 214 219--*--Grade",
            "Value 220 224--*--1-3A",
            "Condition 225 229--*--iNHL",
            "Condition 248 266--*--refractory disease",
            "Condition 236 244;259 266--*--relapsed disease",
            "Condition 268 272--*--iNHL",
            "Condition 282 285--*--LPL",
            "Condition 286 288--*--WM",
            "Condition 290 293--*--MZL",
            "Scope 282 293--*--LPL/WM, MZL",
            "Scope 236 266--*--relapsed or refractory disease",
            "Condition 296 300--*--aNHL",
            "Condition 313 318--*--DLBCL",
            "Condition 320 322--*--FL",
            "Measurement 323 328--*--Grade",
            "Value 329 331--*--3B",
            "Condition 333 336--*--MCL",
            "Condition 342 357--*--transformed NHL",
            "Condition 363 379--*--relapsed disease",
            "Condition 381 384--*--CLL",
            "Condition 385 388--*--SLL",
            "Condition 390 394--*--PTCL",
            "Condition 399 403--*--CTCL",
            "Condition 410 412--*--MF",
            "Condition 413 415--*--SS",
            "Scope 410 415--*--MF/SS",
            "Scope 313 379--*--DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease",
            "Drug 467 482--*--BCL2 inhibitors",
            "Drug 456 459;472 482--*--BCR inhibitors",
            "Condition 488 498--*--intolerant",
            "Scope 456 482--*--BCR and/or BCL2 inhibitors",
            "Condition 506 514--*--relapsed",
            "Condition 515 533--*--refractory disease",
            "Temporal 534 544--*--afterwards",
            "Scope 506 533--*--relapsed/refractory disease",
            "Temporal 547 552--*--Prior",
            "Procedure 553 562--*--treatment",
            "Condition 567 586--*--lymphoid malignancy",
            "Condition 604 622--*--refractory disease",
            "Condition 591 602;615 622--*--progressive disease",
            "Drug 662 680--*--antibody conjugate",
            "Procedure 682 704--*--cytotoxic chemotherapy",
            "Drug 709 712--*--TKI",
            "Multiplier 624 641--*--\u2265 1 prior regimen",
            "Multiplier 643 655--*--min 2 cycles",
            "Scope 662 712--*--antibody conjugate, cytotoxic chemotherapy, or TKI",
            "Condition 739 758--*--Measureable disease",
            "Multiplier 771 781--*--\u2265 1 lesion",
            "Measurement 782 807--*--\u2265 1.5 cm single dimension",
            "Value 782 790--*--\u2265 1.5 cm",
            "Procedure 812 814--*--CT",
            "Procedure 816 822--*--CT/PET",
            "Condition 837 849--*--mass lesions",
            "Condition 828 833;842 849--*--nodal lesions",
            "Condition 864 887--*--circulating tumor cells",
            "Condition 896 927--*--Waldenstr\u00f6m's macroglobulinemia",
            "Measurement 940 945--*--IgM l",
            "Value 946 954--*--> 2X ULN",
            "Condition 960 964--*--CTCL",
            "Measurement 966 971--*--mSWAT",
            "Value 972 975--*--> 0",
            "Scope 828 849--*--nodal or mass lesions",
            "Scope 812 822--*--CT, CT/PET",
            "Scope 771 975--*--\u2265 1 lesion \u2265 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenstr\u00f6m's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0",
            "Non-query-able 977 1014--*--Ability to provide diagnostic reports",
            "Parsing_Error 1016 1033--*--General Inclusion",
            "Measurement 1035 1045--*--ECOG Score",
            "Value 1049 1055--*--0 or 1",
            "Measurement 1058 1073--*--Hematologic ANC",
            "Value 1074 1083--*--> 1000/uL",
            "Measurement 1088 1096--*--platelet",
            "Value 1097 1108--*--> 75,000/uL",
            "Measurement 1111 1127--*--Serum creatinine",
            "Value 1131 1140--*--< 1.5 ULN",
            "Measurement 1144 1159--*--calculated CrCl",
            "Value 1163 1174--*--> 50 mL/min",
            "Measurement 1176 1185--*--Bilirubin",
            "Value 1186 1197--*--< 20.0mg/dL",
            "Condition 1202 1210--*--Gilberts",
            "Value 1216 1227--*--< 2.5 mg/dL",
            "Scope 1186 1228--*--< 20.0mg/dL (if Gilberts then < 2.5 mg/dL)",
            "Measurement 1233 1240--*--AST/AST",
            "Value 1241 1250--*--< 2.5 ULN"
        ],
        "Text": "Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma). . Phase 2a Inclusion . Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory. . Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards. . Prior treatment for lymphoid malignancy for progressive /refractory disease . \u2265 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or TKI alone or in combination. . Measureable disease defined as: \u2265 1 lesion \u2265 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenstr\u00f6m's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0 . Ability to provide diagnostic reports . General Inclusion . ECOG Score of 0 or 1. . Hematologic ANC > 1000/uL and platelet > 75,000/uL, . Serum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min . Bilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN . "
    },
    "NCT01701219_inc": {
        "Annotations": [
            "Condition 15 25--*--bacteremia",
            "Parsing_Error 26 40--*--due solely to:",
            "Procedure 66 79--*--blood culture",
            "Multiplier 55 65--*--at least 1",
            "Observation 42 51--*--S. aureus",
            "Temporal 80 119--*--within 72 hours of beginning study drug",
            "Reference_point 99 119--*--beginning study drug",
            "Observation 135 139--*--MRSA",
            "Procedure 154 167--*--blood culture",
            "Temporal 145 153--*--baseline",
            "Multiplier 175 196--*--at least 1 additional",
            "Procedure 197 210--*--blood culture",
            "Temporal 211 276--*--after at least 72 hours of vancomycin and/or daptomycin treatment",
            "Reference_point 238 276--*--vancomycin and/or daptomycin treatment",
            "Drug 238 248--*--vancomycin",
            "Drug 256 266--*--daptomycin",
            "Procedure 256 276--*--daptomycin treatment",
            "Procedure 238 248;267 276--*--vancomycin treatment",
            "Person 293 297--*--Male",
            "Person 301 307--*--female",
            "Value 308 318--*--\u2265 18 years",
            "Person 322 325--*--age",
            "Person 334 340--*--female",
            "Condition 344 366--*--childbearing potential",
            "Observation 375 382--*--willing",
            "Procedure 386 412--*--practice sexual abstinence",
            "Multiplier 416 420--*--dual",
            "Procedure 421 445--*--methods of contraception",
            "Temporal 446 462--*--during treatment",
            "Temporal 467 521--*--for at least 30 days after the last dose of study drug",
            "Reference_point 494 521--*--the last dose of study drug",
            "Scope 386 445--*--practice sexual abstinence or dual methods of contraception",
            "Scope 334 366--*--female of childbearing potential",
            "Observation 527 538--*--Expectation",
            "Condition 542 550--*--survival",
            "Temporal 551 572--*--for at least 2 months"
        ],
        "Text": "1. Presence of bacteremia due solely to: . S. aureus on at least 1 blood culture within 72 hours of beginning study drug (Cohort A) OR . MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment (Cohort B). . 2. Male or female \u2265 18 years of age. . 3. If female of childbearing potential must be willing to practice sexual abstinence or dual methods of contraception during treatment and for at least 30 days after the last dose of study drug. . 4. Expectation of survival for at least 2 months. . "
    },
    "NCT02365870_inc": {
        "Text": "Diagnosis of DSM 5 Anxiety Disorder. Stable medical history and general health. On stable anti-parkinsonian therapy for 2 weeks before enrollment. ",
        "Annotations": [
            "Condition 13 35--*--DSM 5 Anxiety Disorder",
            "Observation 37 59--*--Stable medical history",
            "Condition 37 43;64 78--*--Stable general health",
            "Qualifier 83 89--*--stable",
            "Procedure 90 115--*--anti-parkinsonian therapy",
            "Multiplier 116 127--*--for 2 weeks",
            "Temporal 128 145--*--before enrollment"
        ]
    },
    "NCT02121145_inc": {
        "Text": "Male or female subjects aged =18 to =65 years. General good health as established by medical history and physical examination. Written informed consent. Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable.. Available for all visits scheduled in this study.. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Person 24 28--*--aged",
            "Value 29 45--*--=18 to =65 years",
            "Condition 47 66--*--General good health",
            "Qualifier 70 100--*--established by medical history",
            "Procedure 105 125--*--physical examination",
            "Observation 127 151--*--Written informed consent",
            "Person 153 160--*--Females",
            "Observation 164 186--*--childbearing potential",
            "Mood 192 204--*--agree to use",
            "Qualifier 208 219--*--efficacious",
            "Qualifier 220 228;240 246--*--hormonal method",
            "Qualifier 232 246--*--barrier method",
            "Procedure 250 263--*--birth control",
            "Temporal 264 280--*--during the study",
            "Scope 220 246--*--hormonal or barrier method",
            "Observation 282 292--*--Abstinence",
            "Scope 153 186--*--Females of childbearing potential",
            "Scope 192 292--*--agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence",
            "Observation 309 333--*--Available for all visits",
            "Qualifier 334 357--*--scheduled in this study"
        ]
    },
    "NCT03216967_inc": {
        "Text": "Adult patients. Kidney transplant recipients. Patients treated by a calcineurin inhibitor and mycophenolic acid. Viremia >= 3 log UI/ml. Patients who have given written informed consent. Negative pregnancy test (blood \u00df-HCG dosage). ",
        "Annotations": [
            "Person 0 5--*--Adult",
            "Procedure 16 33--*--Kidney transplant",
            "Drug 68 89--*--calcineurin inhibitor",
            "Drug 94 111--*--mycophenolic acid",
            "Measurement 113 120--*--Viremia",
            "Value 121 135--*-->= 3 log UI/ml",
            "Informed_consent 137 185--*--Patients who have given written informed consent",
            "Measurement 196 210--*--pregnancy test",
            "Value 187 195--*--Negative",
            "Measurement 212 230--*--blood \u00df-HCG dosage"
        ]
    },
    "NCT03637946_exc": {
        "Annotations": [
            "Condition 12 31--*--systemic alteration",
            "Qualifier 5 11--*--severe",
            "Drug 48 59--*--antibiotics",
            "Drug 64 83--*--anti-inflammatories",
            "Temporal 84 108--*--in the last three months",
            "Scope 48 83--*--antibiotics and anti-inflammatories",
            "Non-representable 111 216--*--With periodontium with periodontal parameters different from those established in the inclusion criteria.",
            "Condition 235 274--*--clinical signs of parafunctional habits",
            "Observation 277 284--*--Smoking",
            "Procedure 318 336--*--other restorations",
            "Temporal 337 358--*--in the last 12 months",
            "Condition 361 369--*--Pregnant",
            "Person 370 375--*--women",
            "Person 380 387--*--infants",
            "Scope 361 375--*--Pregnant women",
            "Non-representable 390 530--*--Periodontal sites that presented bleeding during crevicular fluid collection or sites that prevent proper collection of clinical parameters."
        ],
        "Text": "With severe systemic alteration;. In the use of antibiotics and anti-inflammatories in the last three months;. With periodontium with periodontal parameters different from those established in the inclusion criteria.. Individuals with clinical signs of parafunctional habits;. Smoking;. Individuals who have performed other restorations in the last 12 months;. Pregnant women and infants;. Periodontal sites that presented bleeding during crevicular fluid collection or sites that prevent proper collection of clinical parameters.. "
    },
    "NCT01994382_exc": {
        "Annotations": [
            "Condition 0 18--*--Richter's syndrome",
            "Condition 20 38--*--Burkitt's lymphoma",
            "Condition 43 64--*--Burkitt-like Lymphoma",
            "Condition 78 83--*--DLBCL",
            "Condition 89 103--*--Follicular NHL",
            "Procedure 126 136--*--transplant",
            "Procedure 142 160--*--stem cell infusion",
            "Temporal 161 168;222 230--*--90 days of Day 1",
            "Temporal 172 178--*--active",
            "Procedure 179 206--*--graft-versus-host treatment",
            "Temporal 207 230--*--within 8 weeks of Day 1",
            "Drug 252 266--*--SYK inhibitors",
            "Procedure 239 246--*--therapy",
            "Temporal 233 238--*--Prior",
            "Temporal 120 125--*--Prior",
            "Drug 292 315--*--strong CYP3A4 inhibitor",
            "Drug 292 305;317 324--*--strong CYP3A4 inducer",
            "Drug 326 345--*--acid reducing agent",
            "Drug 347 369--*--Proton pump inhibitors",
            "Condition 377 412--*--lymphomatous involvement of the CNS",
            "Undefined_semantics 377 412--*--lymphomatous involvement of the CNS",
            "Measurement 438 452--*--NCI CTCAE v4.0",
            "Value 453 462--*--\u2265 Grade 2",
            "Condition 473 494--*--drug-related toxicity",
            "Temporal 464 472--*--previous",
            "Condition 503 511--*--alopecia",
            "Negation 496 502--*--except",
            "Condition 513 531--*--erectile impotence",
            "Condition 533 544--*--hot flashes",
            "Condition 546 552--*--libido",
            "Condition 554 564--*--neuropathy",
            "Scope 503 564--*--alopecia, erectile impotence, hot flashes, libido, neuropathy",
            "Drug 574 593--*--monoclonal antibody",
            "Drug 595 615--*--radioimmunoconjugate",
            "Drug 617 640--*--antibody drug conjugate",
            "Procedure 642 654--*--phototherapy",
            "Procedure 656 668--*--radiotherapy",
            "Procedure 670 682--*--chemotherapy",
            "Procedure 684 697--*--immunotherapy",
            "Procedure 699 724--*--immunosuppressive therapy",
            "Temporal 744 758;786 794--*--within 3 weeks of Day 1",
            "Drug 766 777--*--alemtuzumab",
            "Temporal 778 794--*--8 weeks of Day 1",
            "Scope 574 724--*--monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy",
            "Scope 744 794--*--within 3 weeks or for alemtuzumab 8 weeks of Day 1",
            "Reference_point 789 794--*--Day 1",
            "Condition 801 805--*--CTCL",
            "Procedure 808 813--*--TSEBT",
            "Temporal 815 830--*--within 12 weeks",
            "Drug 849 864--*--topical steroid",
            "Observation 835 845--*--initiation",
            "Drug 866 882--*--nitrogen mustard",
            "Drug 887 903--*--topical retinoid",
            "Temporal 904 918--*--within 2 weeks",
            "Scope 849 903--*--topical steroid, nitrogen mustard, or topical retinoid",
            "Temporal 936 960--*--\u2265 4 weeks prior to Day 1",
            "Reference_point 955 960--*--Day 1",
            "Grammar_Error 961 968--*--allowed",
            "Condition 989 1006--*--infection for HIV",
            "Condition 1007 1012;989 1002--*--Hep B infection for",
            "Condition 1007 1010;1016 1017;989 1002--*--Hep C infection for",
            "Condition 1019 1026--*--HCV ab+",
            "Qualifier 1035 1039--*--PCR-",
            "Condition 1041 1048--*--HBV ab+",
            "Qualifier 1057 1063--*--HBsAg-",
            "Condition 1067 1083--*--undetectable DNA",
            "Scope 989 1017--*--infection for HIV/Hep B or C",
            "Condition 1092 1101--*--infection",
            "Procedure 1112 1130--*--systemic treatment",
            "Qualifier 1102 1130--*--requiring systemic treatment",
            "Condition 1145 1155--*--GI disease",
            "Qualifier 1133 1144--*--Significant",
            "Subjective_judgement 1133 1144--*--Significant",
            "Procedure 1180 1193--*--bowel surgery",
            "Procedure 1172 1179;1186 1193--*--gastric surgery",
            "Qualifier 1166 1171--*--major",
            "Subjective_judgement 1166 1171--*--major",
            "Condition 1195 1216--*--difficulty swallowing",
            "Condition 1220 1242--*--malabsorption syndrome",
            "Scope 1172 1193--*--gastric/bowel surgery",
            "Procedure 1251 1258--*--surgery",
            "Qualifier 1245 1250--*--Major",
            "Undefined_semantics 1245 1250--*--Major",
            "Subjective_judgement 1245 1250--*--Major",
            "Temporal 1259 1273--*--within 4 weeks",
            "Condition 1284 1296--*--malignancies",
            "Temporal 1297 1310--*--within 2 yrs.",
            "Non-query-able 1311 1346--*--unless relapse risk is small (< 5%)",
            "Subjective_judgement 1311 1346--*--unless relapse risk is small (< 5%)",
            "Undefined_semantics 1311 1346--*--unless relapse risk is small (< 5%)",
            "Drug 1364 1381--*--systemic steroids",
            "Multiplier 1382 1391--*-->20 mg QD",
            "Drug 1392 1402--*--prednisone",
            "Observation 1420 1433--*--Breastfeeding",
            "Condition 1437 1445--*--pregnant",
            "Person 1468 1475--*--females"
        ],
        "Text": "Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL from Follicular NHL are eligible). . Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment within 8 weeks of Day 1. . Prior therapy with SYK inhibitors. . Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton pump inhibitors . Known lymphomatous involvement of the CNS. . Persistent, unresolved NCI CTCAE v4.0 \u2265 Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy). . Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1. . For CTCL: (TSEBT) within 12 weeks, or initiation of topical steroid, nitrogen mustard, or topical retinoid within 2 weeks. (Stable topical \u2265 4 weeks prior to Day 1 allowed). . Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be HBsAg- or undetectable DNA . Active infection requiring systemic treatment, . Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or malabsorption syndrome. . Major surgery within 4 weeks . Previous malignancies within 2 yrs. unless relapse risk is small (< 5%). . Current use of systemic steroids >20 mg QD prednisone (or equivalent) . Breastfeeding or pregnant (intention to become) females or participation in other clinical trials       .     . "
    },
    "NCT01118871_exc": {
        "Text": "current alcohol abuse or drug dependence . pregnancy . active opportunistic infection or significant co-morbidities . current prohibited concomitant medication . a likelihood of diminished response to any of the study treatment arms, in the opinion of the investigator, based on HIV genotypic resistance testing       .     . ",
        "Annotations": [
            "Condition 8 21--*--alcohol abuse",
            "Condition 25 40--*--drug dependence",
            "Temporal 0 7--*--current",
            "Scope 8 40--*--alcohol abuse or drug dependence",
            "Condition 42 51--*--pregnancy",
            "Condition 60 83--*--opportunistic infection",
            "Condition 99 113--*--co-morbidities",
            "Qualifier 87 98--*--significant",
            "Undefined_semantics 87 98--*--significant",
            "Drug 146 156--*--medication",
            "Temporal 134 145--*--concomitant",
            "Temporal 115 122--*--current",
            "Qualifier 123 133--*--prohibited",
            "Post-eligibility 158 307--*--a likelihood of diminished response to any of the study treatment arms, in the opinion of the investigator, based on HIV genotypic resistance testing"
        ]
    },
    "NCT03619707_inc": {
        "Annotations": [
            "Condition 7 21--*--uterine cavity",
            "Qualifier 0 6--*--Normal",
            "Qualifier 23 29--*--Normal",
            "Measurement 30 52--*--Hormonal investigation",
            "Measurement 54 57--*--TSH",
            "Measurement 58 61--*--PRL",
            "Measurement 62 65--*--FBS",
            "Scope 54 65--*--TSH,PRL,FBS",
            "Procedure 67 96--*--Frozen embryo transfer cycles",
            "Multiplier 98 108--*--at least 2",
            "Condition 109 116--*--embryos",
            "Condition 118 125;139 150--*--Primary infertility",
            "Condition 129 138;139 150--*--secondary infertility",
            "Condition 152 167--*--tubal occlusion",
            "Observation 169 180--*--male factor",
            "Observation 182 193;218 225--*--unexplained factors",
            "Condition 195 208--*--endometriosis",
            "Observation 210 225--*--ovarian factors",
            "Scope 152 225--*--tubal occlusion, male factor, unexplained, endometriosis, ovarian factors",
            "Scope 118 150--*--Primary or secondary infertility",
            "Measurement 228 243--*--Body mass index",
            "Measurement 245 248--*--BMI",
            "Value 250 266--*--=18 to =30 kg/m2"
        ],
        "Text": "Normal uterine cavity. Normal Hormonal investigation: TSH,PRL,FBS. Frozen embryo transfer cycles: at least 2 embryos. Primary or secondary infertility: tubal occlusion, male factor, unexplained, endometriosis, ovarian factors\u2026. Body mass index (BMI) =18 to =30 kg/m2. "
    },
    "NCT02330705_exc": {
        "Text": "Advanced male factor infertility.. Polycystic ovary syndrome (PCOS) as defined by the Rotterdam criteria.. Endometriosis.. Tubal disease.. Uterine abnormalities or myoma.. Previous uterine surgery.. Metabolic or hormonal abnormalities.. ",
        "Annotations": [
            "Qualifier 0 8--*--Advanced",
            "Condition 9 32--*--male factor infertility",
            "Condition 35 67--*--Polycystic ovary syndrome (PCOS)",
            "Qualifier 86 104--*--Rotterdam criteria",
            "Condition 107 120--*--Endometriosis",
            "Condition 123 136--*--Tubal disease",
            "Condition 139 160--*--Uterine abnormalities",
            "Condition 164 169--*--myoma",
            "Procedure 181 196--*--uterine surgery",
            "Temporal 172 180--*--Previous",
            "Condition 199 208;221 234--*--Metabolic abnormalities",
            "Condition 212 234--*--hormonal abnormalities"
        ]
    },
    "NCT01680081_inc": {
        "Text": "Men and women patients, with age ranging 40-80.. Suspected coronary artery disease who are supposed to undergo invasive coronary angiography with appropriate clinical indications. Patients who are willing to sign the informed consent form. ",
        "Annotations": [
            "Person 8 13--*--women",
            "Person 0 3--*--Men",
            "Person 29 32--*--age",
            "Value 33 46--*--ranging 40-80",
            "Condition 59 82--*--coronary artery disease",
            "Mood 49 58--*--Suspected",
            "Procedure 111 140--*--invasive coronary angiography",
            "Mood 91 110--*--supposed to undergo",
            "Post-eligibility 180 238--*--Patients who are willing to sign the informed consent form"
        ]
    },
    "NCT02726009_inc": {
        "Annotations": [
            "Informed_consent 0 81--*--Has given written informed consent before any study-related activity is performed",
            "Qualifier 92 109--*--hormone-dependent",
            "Qualifier 83 91--*--Advanced",
            "Condition 110 125--*--prostate cancer",
            "Procedure 136 164--*--androgen deprivation therapy",
            "Drug 214 222--*--Firmagon",
            "Mood 227 235--*--intended",
            "Person 262 265--*--Age",
            "Value 266 322--*--greater than or equal to 18 years and less than 80 years",
            "Qualifier 324 332--*--Advanced",
            "Qualifier 333 350--*--hormone-dependent",
            "Condition 351 366--*--prostate cancer",
            "Non-query-able 367 416--*--without any other clinically significant disorder",
            "Measurement 418 457--*--Easten Cooperative Oncology Group score",
            "Value 458 461--*--= 2",
            "Measurement 463 466--*--PSA",
            "Value 467 476--*--= 2 ng/mL",
            "Observation 491 506--*--Life expectancy",
            "Value 510 528--*--at least 12 months"
        ],
        "Text": "Has given written informed consent before any study-related activity is performed. Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon\u00ae is intended to be used for treatment. Age greater than or equal to 18 years and less than 80 years. Advanced hormone-dependent prostate cancer without any other clinically significant disorder. Easten Cooperative Oncology Group score = 2. PSA = 2 ng/mL at screening. Life expectancy of at least 12 months as per the investigator's judgement. "
    },
    "NCT01118871_inc": {
        "Text": "HIV-1 infected males or females . over 18 years of age . signed informed consent . currently receiving a stable antiretroviral regimen comprising of: . two or more licensed NRTIs . one licensed NNRTI or boosted protease inhibitor . no previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing . failure of current antiretroviral regimen due to: . toxicity, intolerance or virological failure if receiving an NNRTI containing regimen at screening . toxicity or intolerance if receiving a boosted-protease inhibitor regimen at screening (with plasma HIV RNA < 400 copies/mL at screening) . willing to modify antiretroviral therapy, in accordance with the randomisation assignment . no previous exposure to etravirine . subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator . have no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen . female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study: . barrier contraceptives (condom, diaphragm with spermicide) . IUD or Depo PLUS a barrier contraceptive . female subjects of childbearing potential must have a negative pregnancy test. . ",
        "Annotations": [
            "Condition 0 14--*--HIV-1 infected",
            "Person 15 20--*--males",
            "Person 24 31--*--females",
            "Value 33 46--*--over 18 years",
            "Person 50 53--*--age",
            "Post-eligibility 55 78--*--signed informed consent",
            "Procedure 109 131--*--antiretroviral regimen",
            "Multiplier 148 159--*--two or more",
            "Drug 169 173--*--NRTI",
            "Qualifier 160 168--*--licensed",
            "Multiplier 176 179--*--one",
            "Qualifier 180 188--*--licensed",
            "Drug 189 194--*--NNRTI",
            "Drug 198 224--*--boosted protease inhibitor",
            "Scope 189 224--*--NNRTI or boosted protease inhibitor",
            "Drug 238 256--*--protease inhibitor",
            "Condition 238 267--*--protease inhibitor resistance",
            "Procedure 282 316--*--HIV-1 genotypic resistance testing",
            "Condition 282 287--*--HIV-1",
            "Condition 282 308--*--HIV-1 genotypic resistance",
            "Procedure 337 359--*--antiretroviral regimen",
            "Condition 318 359--*--failure of current antiretroviral regimen",
            "Temporal 329 336--*--current",
            "Condition 369 377--*--toxicity",
            "Condition 379 390--*--intolerance",
            "Condition 394 413--*--virological failure",
            "Drug 430 435--*--NNRTI",
            "Procedure 430 454--*--NNRTI containing regimen",
            "Temporal 455 467--*--at screening",
            "Scope 430 467--*--NNRTI containing regimen at screening",
            "Scope 369 413--*--toxicity, intolerance or virological failure",
            "Condition 469 477--*--toxicity",
            "Condition 481 492--*--intolerance",
            "Procedure 508 542--*--boosted-protease inhibitor regimen",
            "Drug 516 534--*--protease inhibitor",
            "Temporal 543 555--*--at screening",
            "Measurement 562 576--*--plasma HIV RNA",
            "Value 577 592--*--< 400 copies/mL",
            "Temporal 593 605--*--at screening",
            "Scope 508 606--*--boosted-protease inhibitor regimen at screening (with plasma HIV RNA < 400 copies/mL at screening)",
            "Scope 469 492--*--toxicity or intolerance",
            "Procedure 626 648--*--antiretroviral therapy",
            "Observation 608 615--*--willing",
            "Drug 723 733--*--etravirine",
            "Negation 699 701--*--no",
            "Temporal 702 710--*--previous",
            "Condition 747 758--*--good health",
            "Observation 764 779--*--medical history",
            "Procedure 781 794--*--physical exam",
            "Procedure 800 818--*--laboratory testing",
            "Scope 764 818--*--medical history, physical exam, and laboratory testing",
            "Condition 863 905--*--serologic evidence of active HBV infection",
            "Condition 892 905--*--HBV infection",
            "Measurement 928 955--*--hepatitis B surface antigen",
            "Value 919 927--*--negative",
            "Person 957 963--*--female",
            "Condition 981 1002--*--heterosexually active",
            "Condition 1010 1032--*--childbearing potential",
            "Condition 1044 1062--*--surgically sterile",
            "Procedure 1044 1054--*--surgically",
            "Negation 1040 1043--*--not",
            "Temporal 1066 1084--*--at least two years",
            "Condition 1085 1100--*--post menopausal",
            "Scope 1040 1100--*--not surgically sterile or at least two years post menopausal",
            "Procedure 1116 1129--*--contraception",
            "Pregnancy_considerations 957 1188--*--female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:",
            "Parsing_Error 957 1188--*--female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:",
            "Device 1190 1212--*--barrier contraceptives",
            "Device 1214 1220--*--condom",
            "Device 1222 1231--*--diaphragm",
            "Qualifier 1232 1247--*--with spermicide",
            "Scope 1214 1247--*--condom, diaphragm with spermicide",
            "Device 1250 1253--*--IUD",
            "Device 1257 1261--*--Depo",
            "Device 1269 1290--*--barrier contraceptive",
            "Measurement 1355 1369--*--pregnancy test",
            "Value 1346 1354--*--negative",
            "Condition 1311 1333--*--childbearing potential",
            "Person 1292 1298--*--female",
            "Scope 1292 1333--*--female subjects of childbearing potential"
        ]
    },
    "NCT02330705_inc": {
        "Text": "Mild male factor infertility or unexplained infertility.. ",
        "Annotations": [
            "Qualifier 0 4--*--Mild",
            "Condition 5 28--*--male factor infertility",
            "Condition 32 55--*--unexplained infertility"
        ]
    },
    "NCT03619707_exc": {
        "Annotations": [
            "Condition 22 39--*--medical condition",
            "Qualifier 12 21--*--untreated",
            "Condition 41 56--*--thyroid disease",
            "Condition 58 75--*--diabetes mellitus",
            "Condition 77 89--*--hypertension",
            "Condition 91 111--*--pulmonary conditions",
            "Condition 113 130--*--cardiac condition",
            "Scope 41 130--*--thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition",
            "Qualifier 0 11--*--Preexisting",
            "Multiplier 145 158--*--three or more",
            "Procedure 180 202--*--In Vitro Fertilization",
            "Procedure 204 207--*--IVF",
            "Qualifier 159 179--*--consecutively failed",
            "Temporal 216 237--*--after embryo transfer",
            "Reference_point 222 237--*--embryo transfer",
            "Procedure 222 237--*--embryo transfer",
            "Multiplier 250 263--*--three or more",
            "Condition 264 276--*--miscarriages",
            "Condition 287 294--*--allergy",
            "Drug 308 329--*--progesterone products"
        ],
        "Text": "Preexisting untreated medical condition (thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition\u2026). History of three or more consecutively failed In Vitro Fertilization (IVF) cycles after embryo transfer. History of three or more miscarriages. Previous allergy reactions to progesterone products. "
    },
    "NCT02726009_exc": {
        "Annotations": [
            "Procedure 23 42--*--hormonal management",
            "Condition 46 61--*--prostate cancer",
            "Condition 63 79--*--Contraindication",
            "Drug 100 108--*--Firmagon",
            "Drug 139 162--*--5-a-reductase inhibitor",
            "Procedure 194 210--*--curative therapy",
            "Condition 240 246--*--asthma",
            "Qualifier 230 239--*--untreated",
            "Qualifier 223 229--*--severe",
            "Condition 248 270--*--anaphylactic reactions",
            "Condition 281 290--*--urticaria",
            "Qualifier 274 280--*--severe",
            "Condition 298 308--*--angioedema",
            "Measurement 310 322--*--QTc interval",
            "Value 323 336--*--over 450 msec",
            "Observation 340 376--*--risk factors for torsades de pointes",
            "Drug 396 433--*--Class III anti arrhythmic medications",
            "Drug 383 391;406 433--*--Class IA anti arrhythmic medications",
            "Condition 435 441--*--Cancer",
            "Temporal 453 465--*--last 5 years",
            "Negation 466 472--*--except",
            "Condition 473 488--*--prostate cancer",
            "Condition 521 556--*--squamous cell carcinoma of the skin",
            "Condition 512 517;530 556--*--basal cell carcinoma of the skin",
            "Procedure 493 503--*--surgically",
            "Scope 512 556--*--basal or squamous cell carcinoma of the skin",
            "Scope 473 556--*--prostate cancer and surgically removed basal or squamous cell carcinoma of the skin",
            "Condition 598 613--*--biliary disease",
            "Condition 577 584;606 613--*--hepatic disease",
            "Qualifier 629 637--*--moderate",
            "Qualifier 641 647--*--severe",
            "Condition 648 674--*--chronic hepatic impairment",
            "Scope 629 647--*--moderate to severe",
            "Non-query-able 677 777--*--Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer",
            "Condition 792 809;880 890--*--Hepatitis B Virus infections",
            "Condition 817 834;880 890--*--Hepatitis C Virus infections",
            "Condition 811 814--*--HBV",
            "Condition 836 839--*--HCV",
            "Condition 845 873;880 890--*--Human Immunodeficiency Virus infections",
            "Condition 875 878--*--HIV"
        ],
        "Text": "Previous or concurrent hormonal management of prostate cancer. Contraindication for prescription of Firmagon\u00ae. Concurrent treatment with a 5-a-reductase inhibitor. Considered as a candidate for curative therapy. History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema. QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications. Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin. Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment). Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer. Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. "
    },
    "NCT01680081_exc": {
        "Text": "Contraindication of CT Known allergy to iodinated contrast media or history of contrast-induced nephropathy Decreased renal function: elevated serum creatinine(>1.5mg/dl) Contraindication to beta-blockers Severe arrhythmia: arterial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block). Contraindication of MRI Claustrophobia Metallic hazards Pacemaker implant eGFR<30 ml/min. Unstable or uncooperative patients. Limited life expectancy due to cancer or end-stage renal or liver disease. Evidence of severe symptomatic heart failure (NYHA Class III or IV). Previous myocardial infarction, coronary artery intervention, coronary artery bypass surgery, or other cardiac surgery. ",
        "Annotations": [
            "Condition 0 22--*--Contraindication of CT",
            "Condition 23 36--*--Known allergy",
            "Drug 40 64--*--iodinated contrast media",
            "Condition 79 107--*--contrast-induced nephropathy",
            "Measurement 118 132--*--renal function",
            "Value 108 117--*--Decreased",
            "Value 134 142--*--elevated",
            "Measurement 143 159--*--serum creatinine",
            "Value 160 169--*-->1.5mg/dl",
            "Drug 191 204--*--beta-blockers",
            "Condition 171 187--*--Contraindication",
            "Condition 212 222--*--arrhythmia",
            "Qualifier 205 211--*--Severe",
            "Condition 224 245--*--arterial fibrillation",
            "Condition 249 277--*--uncontrolled tachyarrhythmia",
            "Condition 282 313--*--advanced atrioventricular block",
            "Condition 325 349--*--third degree heart block",
            "Condition 315 321;331 349--*--second degree heart block",
            "Scope 315 349--*--second or third degree heart block",
            "Line 0 22--*--Contraindication of CT",
            "Line 23 107--*--Known allergy to iodinated contrast media or history of contrast-induced nephropathy",
            "Line 108 170--*--Decreased renal function: elevated serum creatinine(>1.5mg/dl)",
            "Line 171 204--*--Contraindication to beta-blockers",
            "Line 205 350--*--Severe arrhythmia: arterial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)",
            "Condition 352 368--*--Contraindication",
            "Procedure 372 375--*--MRI",
            "Condition 376 390--*--Claustrophobia",
            "Condition 391 407--*--Metallic hazards",
            "Device 408 425--*--Pacemaker implant",
            "Measurement 426 430--*--eGFR",
            "Value 430 440--*--<30 ml/min",
            "Scope 376 440--*--Claustrophobia Metallic hazards Pacemaker implant eGFR<30 ml/min",
            "Condition 454 476--*--uncooperative patients",
            "Condition 442 450;468 476--*--Unstable patients",
            "Person 486 501--*--life expectancy",
            "Value 478 485--*--Limited",
            "Condition 509 515--*--cancer",
            "Condition 519 534;544 551--*--end-stage renal disease",
            "Condition 538 551--*--liver disease",
            "Scope 509 551--*--cancer or end-stage renal or liver disease",
            "Qualifier 565 571--*--severe",
            "Qualifier 572 583--*--symptomatic",
            "Condition 584 597--*--heart failure",
            "Measurement 599 603--*--NYHA",
            "Value 604 619--*--Class III or IV",
            "Condition 631 652--*--myocardial infarction",
            "Temporal 622 630--*--Previous",
            "Procedure 654 682--*--coronary artery intervention",
            "Procedure 684 714--*--coronary artery bypass surgery",
            "Procedure 719 740--*--other cardiac surgery",
            "Scope 631 740--*--myocardial infarction, coronary artery intervention, coronary artery bypass surgery, or other cardiac surgery"
        ]
    },
    "NCT02612181_inc": {
        "Annotations": [
            "Condition 0 12--*--Septic shock",
            "Procedure 30 57--*--early goal directed therapy",
            "Post-eligibility 59 90--*--Agree to participate this study"
        ],
        "Text": "Septic shock patients despite early goal directed therapy. Agree to participate this study. "
    },
    "NCT02573597_inc": {
        "Text": "ASA I & II, Nulliparous and Multiparous, Spontaneous/Induced/Augmented Labor, Early active labor (cervix <5 cm (if known)), Pain (VPS) > 3, 18-45 years of age. ",
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 10--*--I & II",
            "Condition 12 23--*--Nulliparous",
            "Condition 28 39--*--Multiparous",
            "Procedure 61 76--*--Augmented Labor",
            "Procedure 53 60;71 76--*--Induced Labor",
            "Condition 41 52;71 76--*--Spontaneous Labor",
            "Condition 78 96--*--Early active labor",
            "Measurement 98 104--*--cervix",
            "Value 105 110--*--<5 cm",
            "Measurement 124 134--*--Pain (VPS)",
            "Value 135 138--*--> 3",
            "Value 140 151--*--18-45 years",
            "Person 155 158--*--age",
            "Scope 98 121--*--cervix <5 cm (if known)"
        ]
    },
    "NCT02488057_inc": {
        "Annotations": [
            "Person 0 16--*--Mexican-american",
            "Person 18 24--*--Female",
            "Measurement 26 29--*--BMI",
            "Value 30 35--*--30-42",
            "Informed_consent 37 69--*--willingness to complete protocol",
            "Condition 71 83--*--pre-diabetic",
            "Non-query-able 85 112--*--English or Spanish literate"
        ],
        "Text": "Mexican-american. Female. BMI 30-42. willingness to complete protocol. pre-diabetic. English or Spanish literate. "
    },
    "NCT02607163_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--NA"
        ]
    },
    "NCT02902120_exc": {
        "Annotations": [
            "Measurement 20 31;38 53--*--hepatitis B surface antigen",
            "Value 11 19--*--positive",
            "Measurement 62 69--*--HBV DNA",
            "Temporal 70 89--*--prior to enrollment",
            "Reference_point 79 89--*--enrollment",
            "Scope 20 69--*--hepatitis B (HBV) surface antigen, and/or HBV DNA",
            "Procedure 113 143--*--HCV protease inhibitor therapy",
            "Condition 145 161--*--HIV co-infection",
            "Drug 170 188--*--protease inhibitor",
            "Measurement 216 226--*--creatinine",
            "Value 204 212;227 244--*--Increase of 15% or greater",
            "Temporal 245 261--*--within one month",
            "Temporal 263 270--*--30 days",
            "Condition 308 332--*--hepatocellular carcinoma",
            "Condition 360 373--*--Liver disease",
            "Negation 396 401--*--other",
            "Observation 407 410--*--HCV",
            "Condition 418 441--*--decompensated cirrhotic",
            "Observation 412 414--*--F4",
            "Measurement 477 480--*--AST",
            "Measurement 484 487--*--ALT",
            "Value 488 492--*-->350",
            "Temporal 493 528--*--within 6 months prior to enrollment",
            "Reference_point 518 528--*--enrollment",
            "Scope 477 487--*--AST or ALT",
            "Measurement 452 468--*--Child Pugh class",
            "Value 469 475--*--B or C",
            "Measurement 530 537--*--Albumin",
            "Value 538 545--*--< 3g/dL",
            "Measurement 573 587--*--Platelet count",
            "Value 588 592--*--< 75",
            "Condition 654 661--*--allergy",
            "Condition 665 678--*--adverse event",
            "Drug 684 703--*--protease inhibitors",
            "Scope 654 678--*--allergy or adverse event",
            "Condition 721 739--*--acquisition of HCV",
            "Temporal 740 779--*--at the time of or after transplantation",
            "Reference_point 764 779--*--transplantation",
            "Pregnancy_considerations 781 812--*--Pregnant or breastfeeding women",
            "Drug 814 826--*--Cyclosporine",
            "Drug 828 843--*--St. John's Wort",
            "Drug 845 854--*--Efavirenz",
            "Drug 856 865--*--Phenytoin",
            "Drug 867 880--*--Carbamazepine",
            "Drug 882 890--*--Bosentan",
            "Drug 892 915--*--HIV protease inhibitors",
            "Drug 917 926--*--modafinil",
            "Drug 928 940--*--ketoconazole",
            "Drug 945 953--*--rifampin",
            "Temporal 958 985--*--within 7 days of enrollment",
            "Reference_point 975 985--*--enrollment",
            "Scope 814 953--*--Cyclosporine; St. John's Wort; Efavirenz; Phenytoin; Carbamazepine; Bosentan; HIV protease inhibitors; modafinil; ketoconazole; or rifampin",
            "Multiplier 1007 1022--*--more than 20 mg",
            "Drug 1023 1035--*--atorvastatin",
            "Multiplier 1007 1016;1037 1042--*--more than 10 mg",
            "Multiplier 1007 1016;1057 1062--*--more than 20 mg",
            "Drug 1043 1055--*--rosuvastatin",
            "Drug 1066 1077--*--fluvastatin",
            "Drug 1079 1089--*--lovastatin",
            "Drug 1093 1104--*--simvastatin",
            "Scope 1066 1104--*--fluvastatin, lovastatin or simvastatin"
        ],
        "Text": "Documented positive hepatitis B (HBV) surface antigen, and/or HBV DNA prior to enrollment. Any prior exposure to HCV protease inhibitor therapy. HIV co-infection if on a protease inhibitor based regimen. Increase in creatinine of 15% or greater within one month (30 days) of the screening visit. Evidence of hepatocellular carcinoma at the time of enrollment. Liver disease caused by an etiology other than HCV. F4 or decompensated cirrhotic patients. Child Pugh class B or C. AST or ALT >350 within 6 months prior to enrollment. Albumin < 3g/dL at the time of enrollment. Platelet count < 75 at the time of enrollment. History of clinically significant allergy or adverse event with protease inhibitors. Evidence of the acquisition of HCV at the time of or after transplantation. Pregnant or breastfeeding women. Cyclosporine; St. John's Wort; Efavirenz; Phenytoin; Carbamazepine; Bosentan; HIV protease inhibitors; modafinil; ketoconazole; or rifampin use within 7 days of enrollment. Coadministration of more than 20 mg atorvastatin; 10 mg rosuvastatin; 20 mg of fluvastatin, lovastatin or simvastatin. "
    },
    "NCT03034096_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--less than 18 years",
            "Measurement 24 66--*--American Society of Anesthesiologist Class",
            "Value 67 68--*--5",
            "Observation 70 95--*--Projected life expectancy",
            "Value 96 113--*--less than 30 days",
            "Mood 115 120--*--Known",
            "Mood 124 133--*--suspected",
            "Condition 134 150--*--hypersensitivity",
            "Drug 161 169--*--propofol",
            "Drug 176 179--*--egg",
            "Drug 183 186--*--soy",
            "Condition 187 194--*--allergy",
            "Drug 199 233--*--volatile general anesthetic agents",
            "Scope 176 186--*--egg or soy",
            "Scope 161 169;199 233--*--propofol volatile general anesthetic agents",
            "Scope 115 133--*--Known or suspected",
            "Condition 265 287--*--malignant hyperthermia",
            "Mood 235 240--*--Known",
            "Mood 244 253--*--suspected",
            "Observation 254 261--*--history",
            "Scope 235 253--*--Known or suspected"
        ],
        "Text": "Age less than 18 years. American Society of Anesthesiologist Class 5. Projected life expectancy less than 30 days. Known or suspected hypersensitivity to either propofol, e.g. egg or soy allergy, or volatile general anesthetic agents. Known or suspected history of malignant hyperthermia. "
    },
    "NCT02612181_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 3 7--*--< 18",
            "Condition 9 18--*--Pregnancy",
            "Condition 20 31--*--Bradycardia",
            "Measurement 33 35--*--HR",
            "Value 35 41--*--<55bpm",
            "Measurement 44 67--*--Systolic Blood Pressure",
            "Value 68 77--*--< 80 mmHg",
            "Measurement 80 102--*--Mean arterial pressure",
            "Value 103 112--*--< 50 mmHg",
            "Qualifier 113 131--*--on maximal support",
            "Scope 44 112--*--Systolic Blood Pressure < 80 mmHg / Mean arterial pressure < 50 mmHg",
            "Procedure 124 131--*--support",
            "Condition 133 138--*--Death",
            "Temporal 139 147--*--imminent",
            "Non-representable 149 176--*--Unlikely to survive 90 days",
            "Condition 178 197--*--Acute liver failure",
            "Condition 199 207--*--Dementia",
            "Condition 209 225--*--High-grade block",
            "Negation 226 243--*--in the absence of",
            "Device 258 267--*--pacemaker",
            "Qualifier 246 257--*--functioning"
        ],
        "Text": "Age< 18. Pregnancy. Bradycardia (HR<55bpm). Systolic Blood Pressure < 80 mmHg / Mean arterial pressure < 50 mmHg on maximal support. Death imminent. Unlikely to survive 90 days. Acute liver failure. Dementia. High-grade block in the absence of a functioning pacemaker.. "
    },
    "NCT02607163_inc": {
        "Text": "the patients undergoing ascending, arch and/or proximal descending aorta surgery with cardiopulmonary bypass. 20 - 100 yrs old. ",
        "Annotations": [
            "Procedure 24 33;67 80--*--ascending aorta surgery",
            "Procedure 35 39;67 80--*--arch aorta surgery",
            "Procedure 47 80--*--proximal descending aorta surgery",
            "Procedure 86 108--*--cardiopulmonary bypass",
            "Person 123 126--*--old",
            "Value 110 122--*--20 - 100 yrs"
        ]
    },
    "NCT02488057_exc": {
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Observation 28 57--*--moderate to vigorous activity",
            "Multiplier 58 84--*--more than 3 times per week",
            "Multiplier 10 24--*--30 min or more",
            "Condition 86 108--*--cardiovascular disease",
            "Condition 110 130--*--physical limitations",
            "Qualifier 145 158;168 185--*--aggravated by physical activity",
            "Qualifier 159 167--*--moderate",
            "Observation 187 203--*--planning to move",
            "Temporal 204 224--*--in next 12-24 months",
            "Condition 226 234--*--diabetic"
        ],
        "Text": "pregnant. 30 min or more of moderate to vigorous activity more than 3 times per week. cardiovascular disease. physical limitations that might be aggravated by moderate physical activity. planning to move in next 12-24 months. diabetic. "
    },
    "NCT02573597_exc": {
        "Text": "<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol. ",
        "Annotations": [
            "Measurement 10 19--*--gestation",
            "Value 0 9--*--<37 weeks",
            "Procedure 25 41--*--Cesarean Section",
            "Condition 43 61--*--Multiple Gestation",
            "Observation 21 24--*--H/o",
            "Condition 63 76--*--Pre-eclampsia",
            "Drug 78 87--*--Narcotics",
            "Temporal 88 136--*--within 3 hours prior to labor epidural placement",
            "Procedure 112 136--*--labor epidural placement",
            "Reference_point 112 136--*--labor epidural placement",
            "Condition 138 150--*--Chronic Pain",
            "Multiplier 166 173--*--chronic",
            "Drug 174 180--*--opiate",
            "Scope 166 180--*--chronic opiate",
            "Scope 25 193--*--Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption)",
            "Competing_trial 195 265--*--Women who are participating in another study that will impact protocol"
        ]
    },
    "NCT02902120_inc": {
        "Annotations": [
            "Person 21 24--*--age",
            "Value 0 17--*--At least 18 years",
            "Measurement 63 77--*--renal function",
            "Value 56 62--*--stable",
            "Temporal 82 121--*--one month (30 days) prior to enrollment",
            "Reference_point 111 121--*--enrollment",
            "Condition 128 149--*--Chronic HCV infection",
            "Temporal 150 174--*--prior to transplantation",
            "Reference_point 159 174--*--transplantation",
            "Measurement 191 202--*--HCV viremia",
            "Value 203 216--*--= 1,000 IU/ml",
            "Measurement 252 258--*--HCV Ab",
            "Value 259 269--*--positivity",
            "Measurement 273 284--*--HCV viremia",
            "Value 285 298--*--= 1,000 IU/ml",
            "Temporal 299 337--*--at least 6 months prior to enrollment.",
            "Reference_point 326 336--*--enrollment",
            "Scope 252 298--*--HCV Ab positivity or HCV viremia = 1,000 IU/ml",
            "Qualifier 350 360--*--genotype 1",
            "Condition 361 374--*--HCV infection",
            "Temporal 375 394--*--prior to enrollment",
            "Temporal 399 423--*--after their transplant i",
            "Reference_point 384 394--*--enrollment",
            "Reference_point 411 421--*--transplant",
            "Procedure 462 477--*--disease staging",
            "Qualifier 458 461--*--HCV",
            "Temporal 478 514--*--within 12 months prior to enrollment",
            "Reference_point 504 514--*--enrollment",
            "Procedure 518 530--*--liver biopsy",
            "Procedure 532 554--*--transient elastography",
            "Procedure 559 578--*--biochemical testing",
            "Scope 518 578--*--liver biopsy, transient elastography, or biochemical testing",
            "Informed_consent 580 645--*--Be able to give informed consent and comply with study guidelines",
            "Pregnancy_considerations 647 797--*--Women of childbearing age will be required to have a negative pregnancy test at enrollment and use birth control throughout the duration of treatment.",
            "Non-query-able 799 928--*--On the transplant waiting list followed by the University of Maryland's nephrology clinic or the Baltimore VA's nephrology clinic",
            "Procedure 941 953--*--hemodialysis",
            "Qualifier 933 940--*--chronic",
            "Non-query-able 954 1078--*--not yet on the transplant list and followed in the University's hemodialysis center or in the University's nephrology clinic",
            "Condition 1085 1107--*--chronic kidney disease",
            "Measurement 1113 1116--*--GFR",
            "Value 1117 1120--*--<50"
        ],
        "Text": "At least 18 years of age at the time of screening. Have stable renal function for one month (30 days) prior to enrollment. Have Chronic HCV infection prior to transplantation with documented HCV viremia = 1,000 IU/ml at screening and either documented HCV Ab positivity or HCV viremia = 1,000 IU/ml at least 6 months prior to enrollment.. Documented genotype 1 HCV infection prior to enrollment and after their transplant in the post-transplantation cohort. HCV disease staging within 12 months prior to enrollment by liver biopsy, transient elastography, or biochemical testing. Be able to give informed consent and comply with study guidelines. Women of childbearing age will be required to have a negative pregnancy test at enrollment and use birth control throughout the duration of treatment.. On the transplant waiting list followed by the University of Maryland's nephrology clinic or the Baltimore VA's nephrology clinic. On chronic hemodialysis not yet on the transplant list and followed in the University's hemodialysis center or in the University's nephrology clinic. Have chronic kidney disease with GFR <50. "
    },
    "NCT03034096_inc": {
        "Annotations": [
            "Procedure 0 9--*--Lobectomy",
            "Procedure 13 26--*--pneumonectomy",
            "Procedure 28 41--*--Esophagectomy",
            "Procedure 43 50;59 69--*--Radical cystectomy",
            "Procedure 71 85--*--Pancreatectomy",
            "Procedure 52 57;59 69--*--total cystectomy",
            "Procedure 87 106--*--Partial hepatectomy",
            "Procedure 108 149--*--Hyperthermic intraperitoneal chemotherapy",
            "Procedure 151 156--*--HIPEC",
            "Procedure 159 170--*--Gastrectomy",
            "Qualifier 172 180--*--subtotal",
            "Qualifier 184 189--*--total",
            "Scope 172 189--*--subtotal or total",
            "Procedure 192 207--*--Cholecystectomy",
            "Procedure 211 230--*--bile duct resection"
        ],
        "Text": "Lobectomy or pneumonectomy. Esophagectomy. Radical (total) cystectomy. Pancreatectomy. Partial hepatectomy. Hyperthermic intraperitoneal chemotherapy (HIPEC). Gastrectomy (subtotal or total). Cholecystectomy or bile duct resection. "
    },
    "NCT01891383_inc": {
        "Text": "Cases (with a history of TBI): . 1. Ages 50-95 years . 2. History of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaire\u2014OSU TBI-ID, and based on DoD/VA criteria) . 3. Residence in AFRH-Washington D.C. or the Veterans Home of California-Yountville . 4. MMSE score \u2265 20 . 5. Capacity to provide consent to participate in research (assessment made by study physician) . 6. Ability to read and write English . Controls (without a history of TBI): . 1. Ages 50-95 years . 2. No history of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaire\u2014OSU TBI-ID) . 3. Residence in AFRH-Washington or the Veterans Home of California-Yountville . 4. MMSE score \u2265 20 . 5. Capacity to provide consent or assent to participate in research . 6. Ability to read and write English - . ",
        "Annotations": [
            "Parsing_Error 0 30--*--Cases (with a history of TBI):",
            "Person 35 39--*--Ages",
            "Value 40 51--*--50-95 years",
            "Condition 67 89--*--traumatic brain injury",
            "Observation 56 63--*--History",
            "Qualifier 93 112--*--sufficient severity",
            "Subjective_judgement 93 112--*--sufficient severity",
            "Measurement 172 237--*--Ohio State University TBI Identification Questionnaire\u2014OSU TBI-ID",
            "Value 93 112--*--sufficient severity",
            "Visit 286 306--*--AFRH-Washington D.C.",
            "Visit 314 352--*--Veterans Home of California-Yountville",
            "Measurement 357 361--*--MMSE",
            "Value 362 372--*--score \u2265 20",
            "Non-query-able 377 468--*--Capacity to provide consent to participate in research (assessment made by study physician)",
            "Post-eligibility 377 468--*--Capacity to provide consent to participate in research (assessment made by study physician)",
            "Non-query-able 473 506--*--Ability to read and write English",
            "Post-eligibility 473 506--*--Ability to read and write English",
            "Parsing_Error 508 544--*--Controls (without a history of TBI):",
            "Person 549 553--*--Ages",
            "Value 554 565--*--50-95 years",
            "Condition 584 606--*--traumatic brain injury",
            "Qualifier 610 629--*--sufficient severity",
            "Measurement 689 754--*--Ohio State University TBI Identification Questionnaire\u2014OSU TBI-ID",
            "Negation 570 572--*--No",
            "Observation 573 580--*--history",
            "Subjective_judgement 610 629--*--sufficient severity",
            "Value 610 629--*--sufficient severity",
            "Visit 773 788--*--AFRH-Washington",
            "Visit 796 834--*--Veterans Home of California-Yountville",
            "Observation 760 769--*--Residence",
            "Observation 273 282--*--Residence",
            "Scope 286 352--*--AFRH-Washington D.C. or the Veterans Home of California-Yountville",
            "Scope 773 834--*--AFRH-Washington or the Veterans Home of California-Yountville",
            "Measurement 839 843--*--MMSE",
            "Value 844 854--*--score \u2265 20",
            "Non-query-able 859 923--*--Capacity to provide consent or assent to participate in research",
            "Post-eligibility 859 923--*--Capacity to provide consent or assent to participate in research",
            "Post-eligibility 928 963--*--Ability to read and write English -",
            "Non-query-able 928 963--*--Ability to read and write English -"
        ]
    },
    "NCT01932996_inc": {
        "Annotations": [
            "Person 10 18--*--Homeless",
            "Observation 20 26--*--Smoked",
            "Multiplier 27 50--*--at least 100 cigarettes",
            "Measurement 64 69--*--AUDIT",
            "Value 70 112--*--score of > or equal to 5, < or equal to 26",
            "Person 114 118--*--Aged",
            "Value 119 136--*--18 years or older",
            "Post-eligibility 138 202--*--Willing to attend study sessions and follow other study protocol"
        ],
        "Text": "Currently Homeless. Smoked at least 100 cigarettes in lifetime. AUDIT score of > or equal to 5, < or equal to 26. Aged 18 years or older. Willing to attend study sessions and follow other study protocol. "
    },
    "NCT02231892_exc": {
        "Annotations": [
            "Parsing_Error 5509 5511--*--2.",
            "Parsing_Error 5380 5382--*--1.",
            "Parsing_Error 5317 5320--*--12.",
            "Parsing_Error 5206 5208--*--2.",
            "Parsing_Error 4961 4963--*--1.",
            "Parsing_Error 4909 4912--*--11.",
            "Parsing_Error 4789 4791--*--2.",
            "Parsing_Error 4719 4721--*--1.",
            "Parsing_Error 4587 4590--*--10.",
            "Parsing_Error 4523 4525--*--2.",
            "Parsing_Error 4436 4438--*--1.",
            "Parsing_Error 4258 4260--*--9.",
            "Parsing_Error 4082 4084--*--2.",
            "Parsing_Error 3951 3953--*--1.",
            "Parsing_Error 3703 3705--*--8.",
            "Parsing_Error 3343 3345--*--2.",
            "Parsing_Error 3117 3119--*--1.",
            "Parsing_Error 2916 2918--*--7.",
            "Parsing_Error 2797 2799--*--2.",
            "Parsing_Error 2549 2551--*--1.",
            "Parsing_Error 2444 2446--*--6.",
            "Parsing_Error 2250 2252--*--2.",
            "Parsing_Error 2120 2122--*--1.",
            "Parsing_Error 1936 1938--*--5.",
            "Parsing_Error 1887 1889--*--2.",
            "Parsing_Error 1731 1733--*--1.",
            "Parsing_Error 1687 1689--*--4.",
            "Parsing_Error 1600 1602--*--2.",
            "Parsing_Error 1439 1441--*--1.",
            "Parsing_Error 1101 1103--*--3.",
            "Parsing_Error 1036 1038--*--2.",
            "Parsing_Error 708 710--*--1.",
            "Parsing_Error 556 558--*--2.",
            "Parsing_Error 0 2--*--1.",
            "Procedure 5528 5562--*--TMS safety screening questionnaire",
            "Not_a_criteria 5512 5563--*--Screening tool: TMS safety screening questionnaire.",
            "Not_a_criteria 5383 5507--*--Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago.",
            "Procedure 5341 5353--*--rTMS session",
            "Temporal 5354 5377--*--less than two weeks ago",
            "Procedure 5225 5267--*--Wechsler Abbreviated Scale of Intelligence",
            "Observation 5269 5284--*--Medical history",
            "Procedure 5286 5314--*--Adult ADHD Self-Report Scale",
            "Not_a_criteria 5209 5315--*--Screening tool: Wechsler Abbreviated Scale of Intelligence, Medical history, Adult ADHD Self-Report Scale.",
            "Not_a_criteria 4964 5108--*--Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner.",
            "Condition 5123 5127--*--ADHD",
            "Condition 5128 5130--*--LD",
            "Parsing_Error 5109 5204--*--Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks.",
            "Not_a_criteria 5109 5204--*--Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks.",
            "Parsing_Error 4964 5108--*--Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner.",
            "Parsing_Error 5383 5507--*--Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago.",
            "Parsing_Error 5512 5563--*--Screening tool: TMS safety screening questionnaire.",
            "Condition 4924 4943--*--learning disability",
            "Temporal 4947 4954--*--current",
            "Observation 4913 4920--*--History",
            "Condition 4955 4959--*--ADHD",
            "Measurement 4829 4849--*--urine pregnancy test",
            "Procedure 4808 4827--*--Medical assessments",
            "Temporal 4851 4881--*--at the beginning of each visit",
            "Reference_point 4854 4881--*--the beginning of each visit",
            "Procedure 4896 4899--*--TMS",
            "Procedure 4903 4906--*--MRI",
            "Scope 4896 4906--*--TMS or MRI",
            "Parsing_Error 4722 4787--*--Justification: it is unknown whether TMS poses a risk to fetuses.",
            "Not_a_criteria 4722 4787--*--Justification: it is unknown whether TMS poses a risk to fetuses.",
            "Condition 4591 4599--*--Pregnant",
            "Person 4600 4605--*--women",
            "Person 4609 4614--*--women",
            "Condition 4620 4642--*--reproductive potential",
            "Condition 4651 4666--*--sexually active",
            "Condition 4703 4716--*--contraception",
            "Qualifier 4684 4702--*--acceptable form of",
            "Subjective_judgement 4684 4702--*--acceptable form of",
            "Negation 4671 4674--*--not",
            "Scope 4591 4605--*--Pregnant women",
            "Scope 4609 4716--*--women with reproductive potential who are sexually active and not using an acceptable form of contraception",
            "Parsing_Error 4526 4585--*--Screening tool: physical assessment (EKG), medical history.",
            "Not_a_criteria 4526 4585--*--Screening tool: physical assessment (EKG), medical history.",
            "Parsing_Error 4439 4521--*--Justifications: the risk of TMS for individuals with a heart condition is unknown.",
            "Not_a_criteria 4439 4521--*--Justifications: the risk of TMS for individuals with a heart condition is unknown.",
            "Condition 4272 4293--*--myocardial infarction",
            "Condition 4295 4301--*--angina",
            "Condition 4303 4327--*--congestive heart failure",
            "Condition 4329 4343--*--cardiomyopathy",
            "Condition 4345 4351--*--stroke",
            "Condition 4355 4380--*--transient ischemic attack",
            "Condition 4389 4404--*--heart condition",
            "Qualifier 4415 4433--*--under medical care",
            "Temporal 4405 4414--*--currently",
            "Undefined_semantics 4389 4433--*--heart condition currently under medical care",
            "Observation 4261 4268--*--History",
            "Scope 4272 4380--*--myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack",
            "Not_a_criteria 2800 2851--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Parsing_Error 2800 2851--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Not_a_criteria 2852 2914--*--Potential diagnoses will be further evaluated by a counsellor.",
            "Not_a_criteria 3120 3230--*--Justification: The population of interest here is a healthy control population with no substance use disorder.",
            "Parsing_Error 3120 3230--*--Justification: The population of interest here is a healthy control population with no substance use disorder.",
            "Measurement 2932 2946--*--DSM V criteria",
            "Qualifier 2951 2969--*--moderate to severe",
            "Condition 2970 2992--*--substance use disorder",
            "Drug 3004 3012--*--nicotine",
            "Negation 2994 3003--*--excluding",
            "Observation 3015 3026--*--smoke daily",
            "Measurement 3031 3047--*--urine toxicology",
            "Value 3048 3056--*--positive",
            "Drug 3065 3082--*--illicit substance",
            "Qualifier 3083 3108--*--inconsistent with history",
            "Subjective_judgement 3083 3108--*--inconsistent with history",
            "Undefined_semantics 3031 3047--*--urine toxicology",
            "Undefined_semantics 3065 3082--*--illicit substance",
            "Parsing_Error 3231 3341--*--Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS.",
            "Not_a_criteria 3231 3341--*--Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS.",
            "Value 2919 2923--*--Meet",
            "Not_a_criteria 4137 4198--*--Potential diagnoses will be further evaluated by a counselor.",
            "Subjective_judgement 4137 4198--*--Potential diagnoses will be further evaluated by a counselor.",
            "Procedure 4199 4220--*--Drug Use Survey (DUS)",
            "Procedure 4222 4255--*--Substance Use Disorder Evaluation",
            "Not_a_criteria 4199 4256--*--Drug Use Survey (DUS), Substance Use Disorder Evaluation.",
            "Parsing_Error 4199 4256--*--Drug Use Survey (DUS), Substance Use Disorder Evaluation.",
            "Parsing_Error 4137 4198--*--Potential diagnoses will be further evaluated by a counselor.",
            "Procedure 4102 4135--*--SCID Screen Patient Questionnaire",
            "Parsing_Error 4085 4136--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Not_a_criteria 4085 4136--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Parsing_Error 3954 4080--*--Justification: the population of interest here is a healthy control population with no present or past substance use disorder.",
            "Not_a_criteria 3954 4080--*--Justification: the population of interest here is a healthy control population with no present or past substance use disorder.",
            "Measurement 3715 3729--*--DSM V criteria",
            "Value 3711 3714--*--met",
            "Qualifier 3734 3752--*--moderate to severe",
            "Condition 3753 3775--*--substance use disorder",
            "Drug 3787 3795--*--nicotine",
            "Drug 3797 3804--*--alcohol",
            "Drug 3809 3817--*--cannabis",
            "Negation 3777 3786--*--excluding",
            "Temporal 3819 3830--*--in the past",
            "Measurement 3844 3858--*--DSM V criteria",
            "Value 3840 3843--*--met",
            "Scope 3777 3817--*--excluding nicotine, alcohol and cannabis",
            "Qualifier 3863 3881--*--moderate to severe",
            "Condition 3882 3904--*--substance use disorder",
            "Drug 3909 3917--*--cannabis",
            "Drug 3921 3928--*--alcohol",
            "Temporal 3929 3948--*--in the past 5 years",
            "Scope 3909 3928--*--cannabis or alcohol",
            "Not_a_criteria 3398 3701--*--Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol.",
            "Parsing_Error 3398 3701--*--Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol.",
            "Parsing_Error 3346 3397--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Not_a_criteria 3346 3397--*--Screening tools: SCID Screen Patient Questionnaire.",
            "Procedure 3363 3396--*--SCID Screen Patient Questionnaire",
            "Observation 12 22--*--history of",
            "Condition 23 29--*--stroke",
            "Condition 31 44--*--brain lesions",
            "Condition 55 67--*--neurosurgery",
            "Temporal 46 54--*--previous",
            "Observation 73 92--*--personal history of",
            "Condition 93 100--*--seizure",
            "Condition 104 120--*--fainting episode",
            "Qualifier 124 137--*--unknown cause",
            "Condition 142 188--*--head trauma resulting in loss of consciousness",
            "Qualifier 190 213--*--lasting over 30 minutes",
            "Condition 222 229--*--sequela",
            "Measurement 230 237--*--lasting",
            "Value 238 258--*--longer than two days",
            "Scope 190 258--*--lasting over 30 minutes or with sequela lasting longer than two days",
            "Scope 93 258--*--seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than two days",
            "Scope 23 67--*--stroke, brain lesions, previous neurosurgery",
            "Non-representable 261 487--*--Justification: Stroke or head trauma can lower the seizure threshold, and are therefore contra-indications for TMS. Fainting episodes or syncope of unknown cause could indicate an undiagnosed condition associated with seizures",
            "Procedure 506 536--*--TMS adult safety questionnaire",
            "Observation 538 553--*--Medical History",
            "Procedure 490 499--*--Screening",
            "Scope 506 553--*--TMS adult safety questionnaire, Medical History",
            "Qualifier 559 571--*--First-degree",
            "Observation 572 589--*--family history of",
            "Condition 594 615--*--neurological disorder",
            "Qualifier 623 651--*--potentially hereditary basis",
            "Condition 663 672--*--migraines",
            "Condition 674 682--*--epilepsy",
            "Condition 687 705--*--multiple sclerosis",
            "Scope 663 705--*--migraines, epilepsy, or multiple sclerosis",
            "Scope 594 651--*--neurological disorder with a potentially hereditary basis",
            "Non-representable 711 1034--*--Justification: Neurological disorders can lower the seizure threshold, and are therefore contra-indications for TMS. First-degree family history of certain neurological disorders with a hereditary component increases the risk of the subject having an undiagnosed condition that is associated with lowered seizure threshold.",
            "Procedure 1039 1048--*--Screening",
            "Procedure 1055 1081--*--TMS adult safety screening",
            "Observation 1083 1098--*--Medical History",
            "Scope 1055 1098--*--TMS adult safety screening, Medical History",
            "Device 1104 1122--*--Cardiac pacemakers",
            "Device 1124 1142--*--neural stimulators",
            "Device 1144 1169--*--implantable defibrillator",
            "Device 1171 1197--*--implanted medication pumps",
            "Device 1199 1217--*--intracardiac lines",
            "Qualifier 1222 1227--*--acute",
            "Qualifier 1229 1237--*--unstable",
            "Condition 1238 1253--*--cardiac disease",
            "Device 1260 1281--*--intracranial implants",
            "Device 1288 1302--*--aneurysm clips",
            "Device 1304 1310--*--shunts",
            "Device 1312 1323--*--stimulators",
            "Device 1325 1342--*--cochlear implants",
            "Device 1347 1357--*--electrodes",
            "Device 1372 1408--*--metal object within or near the head",
            "Qualifier 1414 1436--*--precludes MRI scanning",
            "Negation 1414 1423--*--precludes",
            "Procedure 1424 1436--*--MRI scanning",
            "Scope 1288 1357--*--aneurysm clips, shunts, stimulators, cochlear implants, or electrodes",
            "Non-representable 1442 1598--*--Justification: Any metal around the head is a contraindication for both MRI and TMS, as both methods involve exposure to a relatively strong magnetic field.",
            "Non-representable 1734 1885--*--Justification: individuals with noise-induced hearing problems may be particularly vulnerable to the acoustic noise generated by TMS and MRI equipment.",
            "Non-representable 2123 2248--*--Justification: The use of certain medications or drugs can lower seizure threshold and is therefore contra-indicated for TMS.",
            "Non-representable 2552 2795--*--Justification: The population of interest here is a healthy control population with no psychiatric disorders. In subjects with depression, bipolar disorder, mania or hypomania, there is a small chance that TMS can trigger (hypo)manic symptoms.",
            "Procedure 1603 1612--*--Screening",
            "Procedure 1619 1645--*--TMS adult safety screening",
            "Procedure 1647 1667--*--MRI safety screening",
            "Observation 1669 1684--*--Medical History",
            "Scope 1619 1684--*--TMS adult safety screening, MRI safety screening, Medical History",
            "Condition 1690 1716--*--Noise-induced hearing loss",
            "Condition 1720 1728--*--tinnitus",
            "Procedure 1890 1899--*--Screening",
            "Procedure 1907 1933--*--TMS adult safety screening",
            "Qualifier 1939 1950--*--Current use",
            "Temporal 1960 1979--*--in the past 4 weeks",
            "Qualifier 1952 1959--*--any use",
            "Qualifier 1981 1992--*--chronic use",
            "Temporal 1993 2017--*--within 6 past six months",
            "Scope 1952 2017--*--any use in the past 4 weeks, chronic use within 6 past six months",
            "Temporal 1939 1950--*--Current use",
            "Drug 2026 2046--*--investigational drug",
            "Drug 2057 2068--*--medications",
            "Qualifier 2074 2086;2111 2117--*--psychotropic action",
            "Qualifier 2096 2117--*--pro-convulsive action",
            "Scope 2074 2117--*--psychotropic, anti or pro-convulsive action",
            "Scope 2026 2117--*--investigational drug or of any medications with psychotropic, anti or pro-convulsive action",
            "Procedure 2253 2262--*--Screening",
            "Procedure 2270 2304--*--MRI safety screening questionnaire",
            "Procedure 2270 2273--*--MRI",
            "Procedure 2274 2304--*--safety screening questionnaire",
            "Procedure 2306 2321--*--Medical history",
            "Procedure 2344 2369--*--Urine toxicology analyzes",
            "Qualifier 2403 2415--*--prescription",
            "Qualifier 2420 2435--*--nonprescription",
            "Drug 2436 2441--*--drugs",
            "Scope 2403 2435--*--prescription and nonprescription",
            "Scope 2270 2441--*--MRI safety screening questionnaire, Medical history, Medical Assessments: Urine toxicology analyzes for presence of a broad range of prescription and nonprescription drugs",
            "Observation 2447 2466--*--Lifetime history of",
            "Condition 2467 2492--*--major depressive disorder",
            "Condition 2494 2507--*--schizophrenia",
            "Condition 2509 2525--*--bipolar disorder",
            "Condition 2527 2532--*--mania",
            "Condition 2537 2546--*--hypomania",
            "Scope 2467 2546--*--major depressive disorder, schizophrenia, bipolar disorder, mania, or hypomania"
        ],
        "Text": "1. Personal history of stroke, brain lesions, previous neurosurgery, any personal history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than two days. . Justification: Stroke or head trauma can lower the seizure threshold, and are therefore contra-indications for TMS. Fainting episodes or syncope of unknown cause could indicate an undiagnosed condition associated with seizures. . Screening tool: TMS adult safety questionnaire, Medical History. . 2. First-degree family history of any neurological disorder with a potentially hereditary basis, including migraines, epilepsy, or multiple sclerosis. . 1. Justification: Neurological disorders can lower the seizure threshold, and are therefore contra-indications for TMS. First-degree family history of certain neurological disorders with a hereditary component increases the risk of the subject having an undiagnosed condition that is associated with lowered seizure threshold. . 2. Screening tool: TMS adult safety screening, Medical History. . 3. Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head that precludes MRI scanning. . 1. Justification: Any metal around the head is a contraindication for both MRI and TMS, as both methods involve exposure to a relatively strong magnetic field. . 2. Screening tool: TMS adult safety screening, MRI safety screening, Medical History. . 4. Noise-induced hearing loss or tinnitus. . 1. Justification: individuals with noise-induced hearing problems may be particularly vulnerable to the acoustic noise generated by TMS and MRI equipment. . 2. Screening tools: TMS adult safety screening. . 5. Current use (any use in the past 4 weeks, chronic use within 6 past six months) of any investigational drug or of any medications with psychotropic, anti or pro-convulsive action. . 1. Justification: The use of certain medications or drugs can lower seizure threshold and is therefore contra-indicated for TMS. . 2. Screening tools: MRI safety screening questionnaire, Medical history, Medical Assessments: Urine toxicology analyzes for presence of a broad range of prescription and nonprescription drugs. . 6. Lifetime history of major depressive disorder, schizophrenia, bipolar disorder, mania, or hypomania. . 1. Justification: The population of interest here is a healthy control population with no psychiatric disorders. In subjects with depression, bipolar disorder, mania or hypomania, there is a small chance that TMS can trigger (hypo)manic symptoms. . 2. Screening tools: SCID Screen Patient Questionnaire. Potential diagnoses will be further evaluated by a counsellor. . 7. Meet current DSM V criteria for moderate to severe substance use disorder (excluding nicotine), smoke daily, or urine toxicology positive for any illicit substance inconsistent with history given. . 1. Justification: The population of interest here is a healthy control population with no substance use disorder. Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS. . 2. Screening tools: SCID Screen Patient Questionnaire. Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol. . 8. Have met DSM V criteria for moderate to severe substance use disorder (excluding nicotine, alcohol and cannabis) in the past, or have met DSM V criteria for moderate to severe substance use disorder for cannabis or alcohol in the past 5 years. . 1. Justification: the population of interest here is a healthy control population with no present or past substance use disorder. . 2. Screening tools: SCID Screen Patient Questionnaire. Potential diagnoses will be further evaluated by a counselor. Drug Use Survey (DUS), Substance Use Disorder Evaluation. . 9. History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or any heart condition currently under medical care. . 1. Justifications: the risk of TMS for individuals with a heart condition is unknown. . 2. Screening tool: physical assessment (EKG), medical history. . 10. Pregnant women or women with reproductive potential who are sexually active and not using an acceptable form of contraception. . 1. Justification: it is unknown whether TMS poses a risk to fetuses. . 2. Screening tool: Medical assessments (urine pregnancy test) at the beginning of each visit that involves TMS or MRI. . 11. History of learning disability or current ADHD . 1. Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner. Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks. . 2. Screening tool: Wechsler Abbreviated Scale of Intelligence, Medical history, Adult ADHD Self-Report Scale. . 12. Participation in an rTMS session less than two weeks ago. . 1. Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago. . 2. Screening tool: TMS safety screening questionnaire.       .     . "
    },
    "NCT01942915_inc": {
        "Annotations": [
            "Condition 14 29--*--hepatocirrhosis"
        ],
        "Text": "Patients with hepatocirrhosis: according to the standard of child- pugh, liver functions to achieve class A or B patients, Including C class patients but can achieve B class after treatment . "
    },
    "NCT02337764_inc": {
        "Annotations": [
            "Condition 35 54--*--Parkinson's disease",
            "Measurement 99 140--*--UK Parkinson's Disease Society Brain Bank",
            "Drug 174 194--*--levodopa combination",
            "Temporal 204 214--*-->= 1 month",
            "Parsing_Error 219 247--*--has either of the following.",
            "Condition 249 271--*--Wearing off phenomenon",
            "Condition 273 291--*--Decreased response",
            "Drug 296 321--*--evodopa combination drugs",
            "Drug 354 379--*--levodopa combination drug",
            "Qualifier 380 414--*--without change in the dose regimen",
            "Person 464 468--*--aged",
            "Value 469 489--*-->= 30 and < 80 years"
        ],
        "Text": "The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank. . The participant has received a levodopa combination drug for >= 1 month and has either of the following. . Wearing off phenomenon . Decreased response to levodopa combination drugs . The participant has received a levodopa combination drug without change in the dose regimen. . The participant is an outpatient of either sex aged >= 30 and < 80 years. . "
    },
    "NCT02781610_exc": {
        "Text": "Previous randomization in this study. Treatment with IV antibiotics in the 6 weeks prior to Visit 1. Admission to the intensive care unit for current pulmonary exacerbation in the two weeks prior to Visit 2, unless admission was due to a desensitization protocol. Pneumothorax in the two weeks prior to Visit 2. Primary diagnosis for current hospitalization is unrelated to worsening lower respiratory symptoms (e.g., pulmonary clean out, distal intestinal obstruction syndrome (DIOS), sinusitis). Massive hemoptysis defined as > 250 cc in a 24 hour period or 100 cc/day over 4 consecutive days occurring in the two weeks prior to Visit 2. Current pulmonary exacerbation thought to be due to allergic bronchopulmonary aspergillosis (ABPA). At Visit 1, receiving ongoing treatment with a duration of more than 2 weeks with prednisone equivalent to >10mg/day. History of solid organ transplantation. Receiving antimicrobial therapy to treat non-tuberculous mycobacterium (e.g., M. abscessus, M. avium complex) in the two weeks prior to Visit 2. ",
        "Annotations": [
            "Non-query-able 0 36--*--Previous randomization in this study",
            "Drug 53 67--*--IV antibiotics",
            "Temporal 68 99--*--in the 6 weeks prior to Visit 1",
            "Reference_point 92 99--*--Visit 1",
            "Observation 101 137--*--Admission to the intensive care unit",
            "Visit 118 137--*--intensive care unit",
            "Condition 150 172--*--pulmonary exacerbation",
            "Temporal 173 206--*--in the two weeks prior to Visit 2",
            "Reference_point 199 206--*--Visit 2",
            "Procedure 238 262--*--desensitization protocol",
            "Negation 208 214--*--unless",
            "Condition 264 276--*--Pneumothorax",
            "Temporal 277 310--*--in the two weeks prior to Visit 2",
            "Reference_point 303 310--*--Visit 2",
            "Condition 312 329--*--Primary diagnosis",
            "Observation 334 357--*--current hospitalization",
            "Negation 361 370--*--unrelated",
            "Condition 384 410--*--lower respiratory symptoms",
            "Qualifier 374 383--*--worsening",
            "Condition 418 437--*--pulmonary clean out",
            "Condition 439 477--*--distal intestinal obstruction syndrome",
            "Condition 479 483--*--DIOS",
            "Condition 486 495--*--sinusitis",
            "Scope 411 496--*--(e.g., pulmonary clean out, distal intestinal obstruction syndrome (DIOS), sinusitis)",
            "Condition 506 516--*--hemoptysis",
            "Qualifier 498 505--*--Massive",
            "Multiplier 528 536--*--> 250 cc",
            "Temporal 537 556--*--in a 24 hour period",
            "Multiplier 560 570--*--100 cc/day",
            "Temporal 571 594--*--over 4 consecutive days",
            "Temporal 605 638--*--in the two weeks prior to Visit 2",
            "Reference_point 631 638--*--Visit 2",
            "Scope 528 594--*--> 250 cc in a 24 hour period or 100 cc/day over 4 consecutive days",
            "Condition 648 670--*--pulmonary exacerbation",
            "Condition 692 731--*--allergic bronchopulmonary aspergillosis",
            "Condition 733 737--*--ABPA",
            "Temporal 740 750;799 816--*--At Visit 1 more than 2 weeks",
            "Drug 822 832--*--prednisone",
            "Multiplier 847 856--*-->10mg/day",
            "Reference_point 743 750--*--Visit 1",
            "Condition 869 896--*--solid organ transplantation",
            "Drug 908 929--*--antimicrobial therapy",
            "Qualifier 939 968--*--non-tuberculous mycobacterium",
            "Qualifier 976 988--*--M. abscessus",
            "Qualifier 990 1006--*--M. avium complex",
            "Temporal 1008 1041--*--in the two weeks prior to Visit 2",
            "Reference_point 1034 1041--*--Visit 2"
        ]
    },
    "NCT02780427_inc": {
        "Text": "Children, aged between one and 24 months. classified as (American Society of Anesthesiologists) ASA physical status I or II, undergoing TEE were enrolled in the study.. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Person 10 14--*--aged",
            "Value 15 40--*--between one and 24 months",
            "Measurement 57 94--*--American Society of Anesthesiologists",
            "Measurement 96 115--*--ASA physical status",
            "Value 116 123--*--I or II",
            "Procedure 136 139--*--TEE"
        ]
    },
    "NCT00806273_exc": {
        "Text": "ASA 3+ . No current treatment plan at OHSU . Severely carious teeth resulting in inability to isolate for procedure . Unable to understand or sign consent form       .     . ",
        "Annotations": [
            "Condition 0 6--*--ASA 3+",
            "Observation 19 33--*--treatment plan",
            "Negation 8 10--*--No",
            "Temporal 11 18--*--current",
            "Visit 37 41--*--OHSU",
            "Condition 52 65--*--carious teeth",
            "Qualifier 43 51--*--Severely",
            "Condition 79 113--*--inability to isolate for procedure",
            "Post-eligibility 115 156--*--Unable to understand or sign consent form"
        ]
    },
    "NCT02337764_exc": {
        "Annotations": [
            "Measurement 20 41--*--Modified Hoehn & Yahr",
            "Value 42 49--*--stage 5",
            "Condition 117 139--*--wearing off phenomenon",
            "Temporal 62 64;72 79--*--at on-time",
            "Temporal 62 64;83 91--*--at off-time",
            "Value 54 61--*--stage 5",
            "Scope 62 91--*--at eather on-time or off-time",
            "Scope 54 139--*--stage 5 at eather on-time or off-time for the participant with wearing off phenomenon",
            "Condition 170 180--*--dyskinesia",
            "Qualifier 163 169--*--severe",
            "Condition 212 228--*--systemic disease",
            "Undefined_semantics 212 228--*--systemic disease",
            "Qualifier 203 211--*--unstable",
            "Subjective_judgement 203 211--*--unstable",
            "Measurement 253 290--*--Mini-Mental State Examinations (MMSE)",
            "Value 300 305--*--<= 24",
            "Condition 307 326--*--psychiatric disease",
            "Parsing_Error 231 327--*--The participant has a Mini-Mental State Examinations (MMSE) score of <= 24. psychiatric disease.",
            "Condition 385 397--*--hypertension",
            "Qualifier 362 384--*--clinically significant",
            "Subjective_judgement 362 384--*--clinically significant",
            "Condition 407 464--*--reactions associated with ingestion of tyramine-rich food",
            "Undefined_semantics 407 464--*--reactions associated with ingestion of tyramine-rich food",
            "Procedure 496 522--*--neurosurgical intervention",
            "Condition 527 546--*--Parkinson's disease",
            "Condition 554 565--*--pallidotomy",
            "Condition 567 578--*--thalamotomy",
            "Condition 580 602--*--deep brain stimulation",
            "Scope 554 602--*--pallidotomy, thalamotomy, deep brain stimulation",
            "Scope 496 546--*--neurosurgical intervention for Parkinson's disease",
            "Procedure 635 668--*--transcranial magnetic stimulation",
            "Temporal 669 684--*--within 6 months",
            "Drug 714 724--*--selegiline",
            "Drug 726 735--*--pethidine",
            "Drug 737 745--*--tramadol",
            "Drug 747 756--*--reserpine",
            "Drug 760 770--*--methyldopa",
            "Temporal 771 785--*--within 90 days",
            "Scope 714 770--*--selegiline, pethidine, tramadol, reserpine or methyldopa",
            "Parsing_Error 606 786--*--The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days.",
            "Procedure 817 837--*--levodopa monotherapy",
            "Drug 817 825--*--levodopa",
            "Drug 843 863--*--psychoneurotic agent",
            "Drug 867 908--*--antiemetic medication of dopamine agonist",
            "Temporal 909 923--*--within 14 days",
            "Undefined_semantics 867 908--*--antiemetic medication of dopamine agonist",
            "Undefined_semantics 843 863--*--psychoneurotic agent",
            "Scope 817 908--*--levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist",
            "Drug 969 979--*--quetiapine",
            "Drug 983 994--*--domperidone",
            "Qualifier 1002 1013--*--stable dose",
            "Temporal 1026 1036--*-->= 14 days",
            "Scope 969 994--*--quetiapine or domperidone",
            "Post-eligibility 1068 1150--*--The participant is required to take any of the excluded medications or treatments.",
            "Context_Error 1068 1150--*--The participant is required to take any of the excluded medications or treatments.",
            "Parsing_Error 1152 1218--*--The participant with laboratory data meeting any of the following:",
            "Measurement 1220 1230--*--Creatinine",
            "Value 1231 1265--*-->= 2 x upper limit of normal (ULN)",
            "Measurement 1267 1282--*--Total bilirubin",
            "Value 1283 1293--*-->= 2 x ULN",
            "Value 1306 1318--*-->= 1.5 x ULN",
            "Measurement 1302 1305--*--AST",
            "Measurement 1295 1298--*--ALT",
            "Scope 1295 1305--*--ALT or AST",
            "Measurement 1320 1323--*--ALP",
            "Value 1324 1334--*-->= 3 x ULN",
            "Post-eligibility 1336 1418--*--The participant has received any of the excluded medications or treatments during.",
            "Context_Error 1336 1418--*--The participant has received any of the excluded medications or treatments during."
        ],
        "Text": "The participant has Modified Hoehn & Yahr stage 5 (or stage 5 at eather on-time or off-time for the participant with wearing off phenomenon). . The participant has severe dyskinesia. . The participant has unstable systemic disease. . The participant has a Mini-Mental State Examinations (MMSE) score of <= 24. psychiatric disease. . The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food. . The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation). . The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days. . The participant has received levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days may be included in the study. . The participant is required to take any of the excluded medications or treatments. . The participant with laboratory data meeting any of the following: . Creatinine >= 2 x upper limit of normal (ULN) . Total bilirubin >= 2 x ULN . ALT or AST >= 1.5 x ULN . ALP >= 3 x ULN . The participant has received any of the excluded medications or treatments during.       .     . "
    },
    "NCT01942915_exc": {
        "Annotations": [
            "Measurement 28 44--*--child-pugh score",
            "Value 17 24--*--C class",
            "Condition 80 96--*--severe hepatitis",
            "Qualifier 65 76--*--acute phase",
            "Condition 135 154--*--cancer of the liver",
            "Condition 180 212--*--cardiopulmonary cerebral disease",
            "Qualifier 173 179--*--severe",
            "Condition 255 283--*--Highly allergic constitution",
            "Condition 320 334--*--mental disease",
            "Qualifier 302 319--*--moderately severe",
            "Undefined_semantics 320 334--*--mental disease"
        ],
        "Text": "1. Patients with C class by child-pugh score . 2. Patients in the acute phase of severe hepatitis . 3. Patients have been diagnosed with cancer of the liver . 4. Patients with severe cardiopulmonary cerebral disease, and in the failure state . 5. Patients in Highly allergic constitution . 6. Patients with moderately severe mental disease       .     . "
    },
    "NCT02781610_inc": {
        "Text": "Male or female =18 years of age at Visit 1. Documentation of a CF diagnosis. Enrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR) prior to Visit 1 (US sites only). At the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary exacerbation. Performed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3. Completed the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3. Willing to adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization. Willing to return for follow up Visit 3. Written informed consent obtained from the subject or subject's legal representative. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Person 28 31--*--age",
            "Value 15 24--*--=18 years",
            "Temporal 32 42--*--at Visit 1",
            "Reference_point 35 42--*--Visit 1",
            "Condition 63 65--*--CF",
            "Drug 241 255--*--IV antibiotics",
            "Condition 262 284--*--pulmonary exacerbation",
            "Temporal 189 211--*--At the time of Visit 1",
            "Reference_point 204 211--*--Visit 1",
            "Procedure 296 306--*--spirometry",
            "Temporal 307 317--*--at Visit 1",
            "Temporal 307 309;322 329--*--at Visit 2",
            "Temporal 364 374--*--at Visit 3",
            "Scope 307 329--*--at Visit 1 and Visit 2",
            "Mood 334 352--*--willing to perform",
            "Procedure 353 363--*--spirometry",
            "Reference_point 310 317--*--Visit 1",
            "Reference_point 322 329--*--Visit 2",
            "Reference_point 367 374--*--Visit 3",
            "Procedure 390 409--*--CRISS questionnaire",
            "Temporal 410 420--*--at Visit 1",
            "Temporal 410 412;425 432--*--at Visit 2",
            "Reference_point 413 420--*--Visit 1",
            "Reference_point 425 432--*--Visit 2",
            "Scope 410 432--*--at Visit 1 and Visit 2",
            "Mood 437 456--*--willing to complete",
            "Procedure 461 525--*--Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire",
            "Temporal 526 536--*--at Visit 3",
            "Reference_point 529 536--*--Visit 3",
            "Observation 77 154--*--Enrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR)",
            "Temporal 155 171--*--prior to Visit 1",
            "Reference_point 164 171--*--Visit 1",
            "Visit 173 181--*--US sites",
            "Mood 538 548--*--Willing to",
            "Non-representable 549 661--*--adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization",
            "Mood 663 673--*--Willing to",
            "Procedure 685 702--*--follow up Visit 3",
            "Observation 704 728--*--Written informed consent",
            "Qualifier 738 754--*--from the subject",
            "Qualifier 738 746;758 788--*--from the subject's legal representative",
            "Scope 738 788--*--from the subject or subject's legal representative"
        ]
    },
    "NCT01891383_exc": {
        "Text": "Cases (with a history of TBI): . 1. History of penetrating brain injury . 2. History of disabling neurological or psychiatric condition such as epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia . Controls (without a history of TBI): . History of disabling neurological or psychiatric condition such as epilepsy, multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia       .     . ",
        "Annotations": [
            "Parsing_Error 0 30--*--Cases (with a history of TBI):",
            "Observation 35 42--*--History",
            "Condition 46 70--*--penetrating brain injury",
            "Observation 75 82--*--History",
            "Condition 124 133;86 108--*--condition disabling neurological",
            "Condition 112 133;86 95--*--psychiatric condition disabling",
            "Condition 142 150--*--epilepsy",
            "Condition 160 182--*--posttraumatic epilepsy",
            "Negation 152 159--*--besides",
            "Condition 185 203--*--multiple sclerosis",
            "Condition 205 220--*--cortical stroke",
            "Condition 222 253--*--hypoxic-ischemic encephalopathy",
            "Condition 255 267--*--encephalitis",
            "Condition 272 285--*--schizophrenia",
            "Scope 86 285--*--disabling neurological or psychiatric condition such as epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia",
            "Parsing_Error 287 323--*--Controls (without a history of TBI):",
            "Observation 325 332--*--History",
            "Condition 336 358;374 383--*--disabling neurological condition",
            "Undefined_semantics 86 133--*--disabling neurological or psychiatric condition",
            "Condition 336 345;362 383--*--disabling psychiatric condition",
            "Condition 392 400--*--epilepsy",
            "Condition 402 420--*--multiple sclerosis",
            "Condition 422 437--*--cortical stroke",
            "Condition 439 470--*--hypoxic-ischemic encephalopathy",
            "Condition 472 484--*--encephalitis",
            "Condition 489 502--*--schizophrenia",
            "Scope 142 285--*--epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia",
            "Scope 86 133--*--disabling neurological or psychiatric condition"
        ]
    },
    "NCT02231892_inc": {
        "Annotations": [
            "Parsing_Error 1936 1938--*--2.",
            "Parsing_Error 1833 1835--*--1.",
            "Parsing_Error 1788 1790--*--5.",
            "Parsing_Error 1736 1738--*--2.",
            "Parsing_Error 1644 1646--*--1.",
            "Parsing_Error 1626 1628--*--4.",
            "Parsing_Error 646 648--*--2.",
            "Parsing_Error 558 560--*--1.",
            "Parsing_Error 535 537--*--3.",
            "Parsing_Error 355 357--*--2.",
            "Parsing_Error 86 88--*--1.",
            "Parsing_Error 59 61--*--2.",
            "Parsing_Error 16 18--*--1.",
            "Parsing_Error 0 14--*--Subjects must:",
            "Not_a_criteria 561 644--*--Justification: Many illnesses may alter neural functioning as well as fMRI signals.",
            "Non-query-able 19 57--*--Be able to give valid informed consent",
            "Post-eligibility 19 57--*--Be able to give valid informed consent",
            "Person 80 83--*--age",
            "Value 65 76--*--18 55 years",
            "Parsing_Error 89 233--*--Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals.",
            "Not_a_criteria 89 233--*--Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals.",
            "Not_a_criteria 234 353--*--In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age.",
            "Parsing_Error 234 353--*--In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age.",
            "Observation 374 381--*--History",
            "Not_a_criteria 383 533--*--Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range.",
            "Condition 544 555--*--good health",
            "Undefined_semantics 544 555--*--good health",
            "Subjective_judgement 544 555--*--good health",
            "Procedure 666 684--*--Medical Assessment",
            "Observation 686 701--*--Medical History",
            "Procedure 706 726--*--Physical Examination",
            "Measurement 757 768--*--Vital Signs",
            "Procedure 770 773--*--EKG",
            "Procedure 775 788--*--oral HIV test",
            "Measurement 790 796;804 815--*--height measurement",
            "Measurement 797 815--*--weight measurement",
            "Procedure 818 828--*--urinalysis",
            "Procedure 833 845--*--blood sample",
            "Procedure 881 884--*--CBC",
            "Procedure 886 912--*--complete metabolic profile",
            "Procedure 914 917--*--TSH",
            "Procedure 919 922--*--ESR",
            "Procedure 924 927--*--STS",
            "Procedure 932 935--*--HIV",
            "Measurement 969 990--*--salivary test for HIV",
            "Value 960 968--*--positive",
            "Grammar_Error 1056 1066--*--disqualify",
            "Measurement 1080 1091--*--Cholesterol",
            "Value 1092 1102--*-->250 mg/dl",
            "Measurement 1104 1114--*--Hemoglobin",
            "Value 1115 1126--*--< 10.5 g/dl",
            "Measurement 1128 1131--*--WBC",
            "Value 1132 1145--*--< 2400/microl",
            "Measurement 1147 1151--*--LFTs",
            "Value 1152 1162--*--> 3Xnormal",
            "Measurement 1164 1167--*--HCG",
            "Value 1168 1176--*--positive",
            "Measurement 1185 1198--*--serum glucose",
            "Value 1199 1210--*--> 200 mg/dl",
            "Measurement 1212 1225--*--Urine protein",
            "Value 1226 1230--*--> 1+",
            "Negation 1056 1066--*--disqualify",
            "Scope 1080 1230--*--Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+",
            "Not_a_criteria 1232 1337--*--The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation.",
            "Subjective_judgement 1232 1337--*--The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation.",
            "Measurement 1339 1352--*--Serum glucose",
            "Value 1353 1367--*--over 140 mg/dl",
            "Procedure 1395 1427--*--fasting serum glucose assessment",
            "Scope 1339 1367--*--Serum glucose over 140 mg/dl",
            "Condition 1629 1641--*--Right-handed",
            "Not_a_criteria 1647 1734--*--Justification: Using right-handed individuals will reduce variability in BOLD MRI data.",
            "Not_a_criteria 1739 1786--*--Screening tool: Edinburgh Handedness Inventory.",
            "Procedure 1755 1785--*--Edinburgh Handedness Inventory",
            "Measurement 1791 1803--*--Estimated IQ",
            "Value 1804 1831--*--greater than or equal to 85",
            "Not_a_criteria 1836 1934--*--Justification: Subjects must be able to perform a cognitively challenging task to a high standard.",
            "Procedure 1955 1997--*--Wechsler Abbreviated Scale of Intelligence"
        ],
        "Text": "Subjects must: . 1. Be able to give valid informed consent . 2. Be 18 55 years of age. . 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. . 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. . 3. Be in good health. . 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. . 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. . 4. Right-handed. . 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. . 2. Screening tool: Edinburgh Handedness Inventory. . 5. Estimated IQ greater than or equal to 85 . 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. . 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. . "
    },
    "NCT01932996_exc": {
        "Annotations": [
            "Procedure 7 24--*--smoking cessation",
            "Procedure 25 36--*--medications",
            "Procedure 40 53--*--interventions",
            "Temporal 54 69--*--in last 30 days",
            "Scope 25 53--*--medications or interventions",
            "Non-query-able 71 132--*--Unstable medical illness that requires immediate medical care",
            "Measurement 134 139--*--AUDIT",
            "Value 140 160--*--score of < 5 or > 26",
            "Condition 162 171--*--Pregnancy",
            "Condition 216 233--*--contraindications",
            "Procedure 181 209--*--Nicotine Replacement Therapy",
            "Procedure 211 214--*--NRT",
            "Condition 274 292--*--psychotic disorder",
            "Condition 296 322--*--major depressive disorders",
            "Qualifier 331 341--*--not stable",
            "Temporal 355 372--*--for past 3 months",
            "Temporal 257 270--*--past 6 months",
            "Condition 374 394--*--Cognitive impairment"
        ],
        "Text": "Use of smoking cessation medications or interventions in last 30 days. Unstable medical illness that requires immediate medical care. AUDIT score of < 5 or > 26. Pregnancy or other Nicotine Replacement Therapy (NRT) contraindications. Current history or in past 6 months of psychotic disorder or major depressive disorders that is not stable on treatment for past 3 months. Cognitive impairment. "
    },
    "NCT02780427_exc": {
        "Text": "Known allergy or hypersensitive reaction to dexmedetomidine. Organ dysfunction, and significant developmental delays or behavior problems. Cardiac arrhythmia. Known. acyanotic congenital heart disease or children after cardiac interventional procedures for follow-up examination.. ",
        "Annotations": [
            "Condition 6 13--*--allergy",
            "Condition 17 31--*--hypersensitive",
            "Drug 44 59--*--dexmedetomidine",
            "Scope 6 31--*--allergy or hypersensitive",
            "Condition 61 78--*--Organ dysfunction",
            "Condition 96 116--*--developmental delays",
            "Qualifier 84 95--*--significant",
            "Condition 120 137--*--behavior problems",
            "Condition 139 157--*--Cardiac arrhythmia",
            "Condition 166 200--*--acyanotic congenital heart disease",
            "Person 204 212--*--children",
            "Temporal 213 252--*--after cardiac interventional procedures",
            "Reference_point 219 252--*--cardiac interventional procedures",
            "Procedure 219 252--*--cardiac interventional procedures",
            "Procedure 257 278--*--follow-up examination",
            "Qualifier 253 278--*--for follow-up examination"
        ]
    },
    "NCT00806273_inc": {
        "Text": "ASA 1 . ASA 2 . Pts have current treatment plan at OHSU for extraction of some or all of remaining teeth and scheduled for delivery of a removable appliance post extraction . Teeth used are able to be isolated with rubber dam . Understand and sign consent form . ",
        "Annotations": [
            "Condition 0 5--*--ASA 1",
            "Condition 7 12--*--ASA 2",
            "Observation 31 53--*--treatment plan at OHSU",
            "Mood 107 120--*--scheduled for",
            "Non-representable 14 170--*--Pts have current treatment plan at OHSU for extraction of some or all of remaining teeth and scheduled for delivery of a removable appliance post extraction",
            "Non-representable 172 222--*--Teeth used are able to be isolated with rubber dam",
            "Post-eligibility 224 256--*--Understand and sign consent form"
        ]
    },
    "NCT01801072_exc": {
        "Annotations": [
            "Condition 11 19--*--seizures",
            "Temporal 20 40--*--within last 10 years",
            "Condition 53 61--*--epilepsy",
            "Condition 80 86--*--stroke",
            "Temporal 74 79--*--prior",
            "Drug 109 119--*--medication",
            "Qualifier 125 148--*--anti-epileptic activity",
            "Drug 150 156--*--keppra",
            "Drug 158 166--*--dilantin",
            "Drug 168 176--*--tegretol",
            "Drug 178 186--*--lamictal",
            "Drug 188 195--*--topamax",
            "Scope 150 195--*--keppra, dilantin, tegretol, lamictal, topamax",
            "Scope 109 148--*--medication with anti-epileptic activity",
            "Condition 204 215--*--Brain tumor",
            "Condition 217 225--*--Pregnant",
            "Condition 229 236--*--nursing",
            "Person 237 242--*--woman",
            "Drug 250 263--*--levetiracetam",
            "Condition 264 271--*--allergy"
        ],
        "Text": "History of seizures within last 10 years. History of epilepsy. History of prior stroke. Currently prescribed medication with anti-epileptic activity (keppra, dilantin, tegretol, lamictal, topamax, etc.). Brain tumor. Pregnant or nursing woman. Known levetiracetam allergy. "
    },
    "NCT03140423_exc": {
        "Annotations": [
            "Visit 28 32--*--ICUs",
            "Measurement 41 63--*--average length of stay",
            "Value 67 83--*--less than 2 days",
            "Non-query-able 86 253--*--HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded."
        ],
        "Text": "Exclusion criteria includes ICUs with an average length of stay of less than 2 days;. HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.. "
    },
    "NCT00198913_inc": {
        "Text": "type 2 diabetic, age 18 and over, informed consent, . ",
        "Annotations": [
            "Condition 0 15--*--type 2 diabetic",
            "Person 17 20--*--age",
            "Value 21 32--*--18 and over",
            "Informed_consent 34 50--*--informed consent"
        ]
    },
    "NCT03104816_exc": {
        "Annotations": [
            "Procedure 19 26--*--surgery",
            "Condition 31 51--*--neoplastic processes",
            "Drug 64 77--*--acetaminophen",
            "Condition 53 60--*--Allergy",
            "Condition 79 96--*--Liver dysfunction",
            "Value 101 109--*--elevated",
            "Measurement 110 130--*--Liver Function Tests",
            "Measurement 132 136--*--LFTs",
            "Condition 150 165--*--drug dependency",
            "Condition 139 146;155 165--*--Alcohol dependency",
            "Condition 167 185--*--Mental retardation",
            "Value 187 202--*--Less than 50 kg",
            "Measurement 206 212--*--weight",
            "Condition 214 221--*--regnant",
            "Person 222 227--*--women",
            "Drug 248 266--*--long-acting opioid",
            "Mood 238 247--*--requiring",
            "Drug 294 308--*--fentanyl patch",
            "Drug 310 319--*--oxycontin",
            "Multiplier 326 342--*--for over 3 weeks",
            "Temporal 343 371--*--immediately prior to surgery",
            "Scope 294 319--*--fentanyl patch, oxycontin"
        ],
        "Text": "Patients requiring surgery for neoplastic processes. Allergy to acetaminophen. Liver dysfunction and elevated Liver Function Tests (LFTs). Alcohol or drug dependency. Mental retardation. Less than 50 kg of weight. regnant women. Patients requiring long-acting opioid pain management (including fentanyl patch, oxycontin, etc) for over 3 weeks immediately prior to surgery. "
    },
    "NCT03247413_exc": {
        "Annotations": [
            "Negation 8 11--*--not",
            "Temporal 12 22--*--previously",
            "Mood 23 36--*--scheduled for",
            "Procedure 37 60--*--radiofrequency ablation",
            "Qualifier 68 76;98 104--*--cervical facets",
            "Qualifier 78 86;98 104--*--thoracic facets",
            "Qualifier 91 104--*--lumbar facets",
            "Qualifier 109 126--*--sacroiliac joints",
            "Scope 68 126--*--cervical, thoracic, or lumbar facets, or sacroiliac joints",
            "Procedure 131 146--*--anticoagulation",
            "Device 155 164--*--pacemaker",
            "Drug 131 146--*--anticoagulation",
            "Person 166 169--*--age",
            "Value 170 192--*--less than 18 years old",
            "Observation 198 214--*--English speaking",
            "Negation 194 197--*--non"
        ],
        "Text": "patient not previously scheduled for radiofrequency ablation of the cervical, thoracic, or lumbar facets, or sacroiliac joints. on anticoagulation. have a pacemaker. age less than 18 years old. non-English speaking. "
    },
    "NCT03195153_inc": {
        "Text": "diabetic patient;. therapy with aspirin and insulin;. patient well responders. ",
        "Annotations": [
            "Condition 0 8--*--diabetic",
            "Drug 32 39--*--aspirin",
            "Drug 44 51--*--insulin",
            "Condition 62 77--*--well responders"
        ]
    },
    "NCT02935855_inc": {
        "Text": "non-valvular atrial fibrillation. nondiabetic patients. type 1 and 2 diabetic patients. ",
        "Annotations": [
            "Condition 13 32--*--atrial fibrillation",
            "Qualifier 0 12--*--non-valvular",
            "Condition 37 45--*--diabetic",
            "Negation 34 37--*--non",
            "Condition 69 77--*--diabetic",
            "Qualifier 56 62--*--type 1",
            "Qualifier 56 60;67 68--*--type 2",
            "Scope 56 68--*--type 1 and 2"
        ]
    },
    "NCT00962364_exc": {
        "Annotations": [
            "Non-representable 0 67--*--none, all patients meeting the inclusion criteria will be eligible."
        ],
        "Text": "none, all patients meeting the inclusion criteria will be eligible.       .     . "
    },
    "NCT03140423_inc": {
        "Annotations": [
            "Visit 32 36--*--U.S.",
            "Visit 37 50--*--HCA hospitals",
            "Person 59 64--*--adult",
            "Visit 59 68--*--adult ICU",
            "Non-representable 71 160--*--Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs",
            "Visit 182 192--*--adult ICUs",
            "Person 182 187--*--adult",
            "Person 217 230--*--rare patients",
            "Value 231 255--*--<18 years and >=12 years",
            "Person 235 239--*--year"
        ],
        "Text": "Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;. Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs. All patients within adult ICUs are included, including rare patients <18 years and >=12 years.. "
    },
    "NCT01801072_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Value 7 16--*--=18 years",
            "Person 11 16--*--years",
            "Scope 7 16--*--=18 years",
            "Condition 31 52--*--intracranial aneurysm",
            "Qualifier 62 77--*--without rupture",
            "Qualifier 54 58;70 77--*--with rupture",
            "Scope 54 77--*--with or without rupture",
            "Procedure 113 128--*--surgical repair",
            "Condition 136 144--*--aneurysm",
            "Mood 101 112--*--recommended",
            "Qualifier 80 96--*--Treating surgeon"
        ],
        "Text": "Adult (=18 years). Presence of intracranial aneurysm (with or without rupture). Treating surgeon has recommended surgical repair of the aneurysm. "
    },
    "NCT03247413_inc": {
        "Annotations": [
            "Condition 36 44;86 96--*--cervical joint pain",
            "Condition 46 54;86 96--*--thoracic joint pain",
            "Condition 59 71;86 96--*--lumbar facet joint pain",
            "Condition 75 96--*--sacroiliac joint pain",
            "Procedure 119 139--*--medial branch blocks",
            "Observation 106 115--*--responded",
            "Mood 156 169--*--scheduled for",
            "Procedure 170 204--*--bilateral radiofrequency ablations",
            "Person 206 209--*--age",
            "Value 210 235--*--greater than 18 years old",
            "Observation 237 253--*--English speaking",
            "Scope 36 96--*--cervical, thoracic, or lumbar facet or sacroiliac joint pain"
        ],
        "Text": "patients with a diagnosis of either cervical, thoracic, or lumbar facet or sacroiliac joint pain who have responded to medial branch blocks and are already scheduled for bilateral radiofrequency ablations. age greater than 18 years old. English speaking. "
    },
    "NCT03104816_inc": {
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 4 9--*--I-III",
            "Mood 19 28--*--scheduled",
            "Qualifier 33 41--*--elective",
            "Qualifier 49 58--*--two level",
            "Qualifier 42 45;53 58--*--one level",
            "Procedure 59 92--*--minimally invasive lumbar fusions",
            "Scope 42 58--*--one or two level"
        ],
        "Text": "ASA I-III patients scheduled for elective one or two level minimally invasive lumbar fusions. "
    },
    "NCT00198913_exc": {
        "Text": "type 1 diabetic or non-diabetic       .     . ",
        "Annotations": [
            "Condition 0 15--*--type 1 diabetic",
            "Condition 19 31--*--non-diabetic"
        ]
    },
    "NCT02935855_exc": {
        "Text": "patients with cancer. patients with chronic inflammation diseases. ",
        "Annotations": [
            "Condition 14 20--*--cancer",
            "Condition 36 65--*--chronic inflammation diseases"
        ]
    },
    "NCT03195153_exc": {
        "Text": "not diabetic patient;. patients in dual antiplatelet therapy;. patient with severe renal failure;. patient poor responders. ",
        "Annotations": [
            "Condition 4 12--*--diabetic",
            "Negation 0 3--*--not",
            "Procedure 35 60--*--dual antiplatelet therapy",
            "Condition 83 96--*--renal failure",
            "Qualifier 76 82--*--severe",
            "Condition 107 122--*--poor responders"
        ]
    },
    "NCT00962364_inc": {
        "Annotations": [
            "Condition 0 27--*--acute myocardial infarction",
            "Condition 32 55--*--ischemic cardiomyopathy",
            "Condition 81 102--*--myocardial infarction",
            "Temporal 72 80--*--previous",
            "Scope 72 102--*--previous myocardial infarction",
            "Condition 107 129--*--dilated cardiomyopathy",
            "Condition 137 159--*--valvular heart disease",
            "Condition 161 187--*--hypertensive heart disease",
            "Condition 200 211--*--myocarditis",
            "Observation 189 196--*--history",
            "Condition 223 243--*--myocardial infection",
            "Negation 213 215--*--no",
            "Temporal 216 222--*--active"
        ],
        "Text": "acute myocardial infarction or . ischemic cardiomyopathy with or without previous myocardial infarction or . dilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present) . "
    },
    "NCT02560766_exc": {
        "Annotations": [
            "Condition 13 35--*--primary sleep disorder",
            "Negation 36 41--*--other",
            "Condition 47 50--*--RLS",
            "Measurement 103 117--*--Serum ferritin",
            "Value 124 134--*--< 20 ng/mL",
            "Condition 161 168--*--allergy",
            "Condition 170 186--*--hypersensitivity",
            "Condition 191 202--*--intolerance",
            "Scope 161 202--*--allergy, hypersensitivity, or intolerance",
            "Drug 206 214--*--HORIZANT",
            "Drug 228 238--*--gabapentin",
            "Drug 253 262--*--Neurontin",
            "Drug 265 272--*--Gralise",
            "Scope 253 273--*--Neurontin\u00ae, Gralise\u00ae",
            "Scope 206 273--*--HORIZANT or any other gabapentin products (eg, Neurontin\u00ae, Gralise\u00ae",
            "Condition 294 311--*--movement disorder",
            "Condition 376 395--*--Tourette's syndrome",
            "Condition 397 409--*--tic disorder",
            "Condition 411 442--*--periodic limb movement disorder",
            "Condition 444 448--*--PLMD",
            "Condition 451 466--*--sleep disorders",
            "Scope 376 466--*--Tourette's syndrome, tic disorder, periodic limb movement disorder [PLMD], sleep disorders",
            "Condition 576 598--*--substance use disorder",
            "Temporal 620 636--*--within 12 months",
            "Measurement 485 554--*--Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition",
            "Measurement 556 561--*--DSM-5",
            "Condition 696 716--*--psychiatric disorder",
            "Qualifier 684 695--*--significant",
            "Condition 748 758--*--depression",
            "Drug 775 790--*--antidepressants",
            "Condition 793 809--*--bipolar disorder",
            "Condition 814 827--*--schizophrenia",
            "Scope 748 827--*--depression (treatment with antidepressants), bipolar disorder, or schizophrenia",
            "Condition 843 883--*--attention-deficit hyperactivity disorder",
            "Condition 885 889--*--ADHD",
            "Negation 894 901--*--allowed",
            "Observation 1006 1023--*--suicidal behavior",
            "Condition 1027 1044--*--suicidal ideation",
            "Condition 1194 1210--*--seizure disorder",
            "Condition 1301 1328--*--complicated febrile seizure",
            "Condition 1356 1367--*--head injury",
            "Scope 1301 1367--*--complicated febrile seizure and history of significant head injury",
            "Non-query-able 1370 1758--*--Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of gabapentin enacarbil, or, in the investigator's judgment is considered to be clinically significant and may pose a safety concern, or, could interfere with the accurate assessment of safety or efficacy, or could potentially affect a patient's safety or study outcome",
            "Non-query-able 1761 1891--*--Clinically significant abnormal laboratory result or physical examination finding not resolved by the time of baseline assessments"
        ],
        "Text": "History of a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS.. Serum ferritin level < 20 ng/mL at screening.. History of allergy, hypersensitivity, or intolerance to HORIZANT or any other gabapentin products (eg, Neurontin\u00ae, Gralise\u00ae).. Suffering from a movement disorder that could mimic or confound the accurate diagnosis of RLS (eg, Tourette's syndrome, tic disorder, periodic limb movement disorder [PLMD], sleep disorders).. Currently meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for substance use disorder, or history thereof, within 12 months before dosing.. Current or past history of any significant psychiatric disorder including, but not limited to, depression (treatment with antidepressants), bipolar disorder, or schizophrenia.. Diagnosis of attention-deficit hyperactivity disorder (ADHD) is allowed, provided the patient is not receiving medication(s) known to affect the assessment of RLS.. History of suicidal behavior or suicidal ideation as indicated by the C-SSRS, administered at screening (the questionnaire is provided in Appendix 4), and as per investigator's judgment.. History of seizure disorder or at increased risk for development of a seizure disorder including, but not limited to, complicated febrile seizure and history of significant head injury.. Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of gabapentin enacarbil, or, in the investigator's judgment is considered to be clinically significant and may pose a safety concern, or, could interfere with the accurate assessment of safety or efficacy, or could potentially affect a patient's safety or study outcome.. Clinically significant abnormal laboratory result or physical examination finding not resolved by the time of baseline assessments.. "
    },
    "NCT03066440_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--> 18 Years",
            "Non-query-able 16 36--*--Physician discretion",
            "Condition 38 44;60 65--*--Septic shock",
            "Condition 48 65--*--hypovolemic shock",
            "Condition 93 107--*--cerebral edema",
            "Condition 111 130--*--multi-organ failure",
            "Mood 67 75--*--Signs of",
            "Qualifier 76 92--*--life-threatening",
            "Scope 93 130--*--cerebral edema or multi-organ failure",
            "Visit 156 170--*--emergency room",
            "Visit 174 203--*--pediatric intensive care unit",
            "Observation 205 215--*--Enrollment",
            "Temporal 221 275--*--more than 1 hr since arrival to emergency room or PICU",
            "Visit 253 267--*--emergency room",
            "Visit 271 275--*--PICU",
            "Temporal 131 203--*--upon presentation to the emergency room or pediatric intensive care unit",
            "Reference_point 136 203--*--presentation to the emergency room or pediatric intensive care unit",
            "Scope 156 203--*--emergency room or pediatric intensive care unit",
            "Scope 253 275--*--emergency room or PICU",
            "Reference_point 242 275--*--arrival to emergency room or PICU",
            "Condition 277 286--*--Pregnancy"
        ],
        "Text": "Age > 18 Years. Physician discretion. Septic or hypovolemic shock. Signs of life-threatening cerebral edema or multi-organ failure upon presentation to the emergency room or pediatric intensive care unit. Enrollment time more than 1 hr since arrival to emergency room or PICU. Pregnancy. "
    },
    "NCT01888965_exc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 9 32--*--child-bearing potential",
            "Condition 42 71--*--biologically able to conceive",
            "Multiplier 87 90--*--two",
            "Device 100 130--*--highly effective contraception",
            "Condition 142 150--*--pregnant",
            "Negation 73 76--*--not",
            "Scope 0 71--*--Women of child-bearing potential, who are biologically able to conceive",
            "Scope 73 150--*--not employing two forms of highly effective contraception or who are pregnant",
            "Person 153 158--*--Women",
            "Condition 167 181--*--breast-feeding",
            "Person 191 196--*--males",
            "Condition 183 190--*--Fertile",
            "Observation 197 227--*--unwilling to use contraception",
            "Non-query-able 183 227--*--Fertile males unwilling to use contraception",
            "Post-eligibility 183 227--*--Fertile males unwilling to use contraception",
            "Condition 243 259--*--brain metastases",
            "Condition 278 294--*--brain metastases",
            "Observation 267 274--*--history",
            "Procedure 324 337--*--major surgery",
            "Procedure 345 359--*--intra-thoracic",
            "Procedure 345 350;361 371--*--intra -abdominal",
            "Procedure 345 350;376 383--*--intra -pelvic",
            "Scope 345 383--*--intra-thoracic, -abdominal, or -pelvic",
            "Subjective_judgement 324 337--*--major surgery",
            "Value 385 430--*--</= 4 weeks prior to starting study treatment",
            "Reference_point 406 430--*--starting study treatment",
            "Undefined_semantics 447 474--*--recovered from such therapy",
            "Subjective_judgement 447 474--*--recovered from such therapy",
            "Condition 503 521--*--pulmonary embolism",
            "Condition 536 556--*--deep vein thrombosis",
            "Qualifier 526 535--*--untreated",
            "Temporal 557 581--*--within the past 6 months",
            "Observation 492 499--*--history",
            "Scope 503 556--*--pulmonary embolism, or untreated deep vein thrombosis",
            "Condition 583 627--*--Impairment of gastrointestinal (GI) function",
            "Condition 631 641--*--GI disease",
            "Qualifier 647 698--*--may significantly alter the absorption of dovitinib",
            "Undefined_semantics 647 698--*--may significantly alter the absorption of dovitinib",
            "Scope 583 641--*--Impairment of gastrointestinal (GI) function or GI disease",
            "Condition 728 745--*--active malignancy",
            "Temporal 746 769--*--within the past 5 years",
            "Condition 781 804--*--cervical cancer in situ",
            "Negation 770 776--*--except",
            "Condition 806 838--*--in situ carcinoma of the bladder",
            "Condition 842 876--*--non-melanoma carcinoma of the skin",
            "Scope 781 876--*--cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin",
            "Procedure 936 954--*--anticancer therapy",
            "Procedure 965 977--*--chemotherapy",
            "Procedure 979 992--*--immunotherapy",
            "Procedure 994 1010--*--hormonal therapy",
            "Drug 1015 1036--*--monoclonal antibodies",
            "Temporal 1037 1081--*--</= 2 weeks prior to starting the study drug",
            "Reference_point 1058 1081--*--starting the study drug",
            "Condition 1099 1146--*--recovered from the side effects of such therapy",
            "Negation 443 446--*--not",
            "Condition 447 474--*--recovered from such therapy",
            "Scope 965 1036--*--chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies",
            "Condition 1148 1157--*--Cirrhosis",
            "Condition 1159 1183--*--chronic active hepatitis",
            "Condition 1187 1215--*--chronic persistent hepatitis",
            "Drug 1254 1263--*--prasugrel",
            "Drug 1286 1295--*--isoniazid",
            "Drug 1297 1306--*--labetolol",
            "Drug 1308 1321--*--trovafloxacin",
            "Drug 1323 1332--*--tolcapone",
            "Drug 1338 1347--*--felbamate",
            "Negation 1265 1267--*--No",
            "Scope 1286 1347--*--isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",
            "Negation 1349 1351--*--No",
            "Drug 1370 1397--*--other investigational drugs",
            "Procedure 1401 1425--*--antineoplastic therapies",
            "Undefined_semantics 1370 1397--*--other investigational drugs",
            "Scope 1370 1425--*--other investigational drugs or antineoplastic therapies",
            "Condition 1442 1467--*--impaired cardiac function",
            "Qualifier 1471 1493--*--clinically significant",
            "Condition 1494 1510--*--cardiac diseases",
            "Subjective_judgement 1471 1493--*--clinically significant",
            "Undefined_semantics 1442 1467--*--impaired cardiac function"
        ],
        "Text": "Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant. . Women who are breast-feeding . Fertile males unwilling to use contraception . Patients with brain metastases or any history of brain metastases . Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) </= 4 weeks prior to starting study treatment or who have not recovered from such therapy . Patients with a history of pulmonary embolism, or untreated deep vein thrombosis within the past 6 months . Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib . The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin. . Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies </= 2 weeks prior to starting the study drug, or who have not recovered from the side effects of such therapy . Cirrhosis, chronic active hepatitis or chronic persistent hepatitis . Patients who are currently receiving prasugrel . No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate . No concurrent use of other investigational drugs or antineoplastic therapies. . Patients with impaired cardiac function or clinically significant cardiac diseases.       .     . "
    },
    "NCT01803828_exc": {
        "Text": "congenital or valvular cardiomyopathy;. ischemic heart disease;. endocrine diseases: male hypogonadism, hyperthyroidism, adrenal diseases, pituitary diseases. proliferative retinopathy or autonomic neuropathy;. contraindications to sildenafil use or CMR imaging;. ",
        "Annotations": [
            "Qualifier 14 22--*--valvular",
            "Qualifier 0 10--*--congenital",
            "Scope 0 22--*--congenital or valvular",
            "Condition 23 37--*--cardiomyopathy",
            "Condition 40 62--*--ischemic heart disease",
            "Condition 65 83--*--endocrine diseases",
            "Condition 85 102--*--male hypogonadism",
            "Condition 104 119--*--hyperthyroidism",
            "Condition 121 137--*--adrenal diseases",
            "Condition 139 157--*--pituitary diseases",
            "Scope 85 157--*--male hypogonadism, hyperthyroidism, adrenal diseases, pituitary diseases",
            "Condition 159 184--*--proliferative retinopathy",
            "Condition 188 208--*--autonomic neuropathy",
            "Condition 211 228--*--contraindications",
            "Drug 232 242--*--sildenafil",
            "Procedure 250 261--*--CMR imaging",
            "Scope 232 261--*--sildenafil use or CMR imaging"
        ]
    },
    "NCT03066440_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 26--*--between 0 and 18 years",
            "Measurement 28 37--*--Venous pH",
            "Value 38 52--*--less than 7.25",
            "Condition 54 63--*--Ketonuria",
            "Measurement 80 107--*--urine point-of-care testing",
            "Measurement 111 121--*--urinalysis",
            "Scope 80 121--*--urine point-of-care testing or urinalysis",
            "Condition 123 136--*--Hyperglycemia",
            "Measurement 138 151--*--Serum glucose",
            "Value 152 163--*--> 200 mg/dl",
            "Scope 138 163--*--Serum glucose > 200 mg/dl",
            "Measurement 166 183--*--Serum bicarbonate",
            "Value 184 194--*--<15 mmol/L",
            "Visit 196 200--*--PICU",
            "Procedure 201 210--*--admission"
        ],
        "Text": "Age between 0 and 18 years. Venous pH less than 7.25. Ketonuria as confirmed on urine point-of-care testing or urinalysis. Hyperglycemia (Serum glucose > 200 mg/dl). Serum bicarbonate <15 mmol/L. PICU admission. "
    },
    "NCT01888965_inc": {
        "Annotations": [
            "Parsing_Error 1 39--*--atients with a confirmed diagnosis of:",
            "Condition 52 64--*--colon cancer",
            "Qualifier 44 51--*--Stage 4",
            "Condition 72 90--*--s/p metastasectomy",
            "Procedure 76 90--*--metastasectomy",
            "Condition 94 119--*--post-initial chemotherapy",
            "Procedure 107 119--*--chemotherapy",
            "Drug 172 207--*--5-fluorouracil/leucovorin (5-FU/LV)",
            "Drug 227 238--*--bevacizumab",
            "Scope 172 238--*--5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab",
            "Procedure 123 153--*--maintenance \"standard of care\"",
            "Undefined_semantics 123 153--*--maintenance \"standard of care\"",
            "Multiplier 291 292--*--2",
            "Procedure 305 313--*--CT scans",
            "Qualifier 322 328--*--stable",
            "Condition 329 336--*--disease",
            "Undefined_semantics 329 336--*--disease",
            "Condition 379 405--*--treatment-related toxicity",
            "Temporal 373 378--*--prior",
            "Negation 341 344--*--not",
            "Condition 425 440--*--Pancreas cancer",
            "Condition 449 462--*--s/p resection",
            "Procedure 453 462--*--resection",
            "Condition 449 452;467 488--*--s/p adjuvant chemotherapy",
            "Procedure 467 488--*--adjuvant chemotherapy",
            "Condition 509 524--*--pancreas cancer",
            "Qualifier 492 508--*--locally advanced",
            "Condition 525 541--*--s/p chemotherapy",
            "Procedure 529 541--*--chemotherapy",
            "Condition 525 528;546 555--*--s/p radiation",
            "Procedure 546 555--*--radiation",
            "Procedure 565 577--*--chemotherapy",
            "Procedure 581 598--*--radiation therapy",
            "Temporal 621 670--*--between 2 weeks and 2 months prior to study start",
            "Reference_point 659 670--*--study start",
            "Condition 695 725--*--recovered from prior treatment",
            "Procedure 716 725--*--treatment",
            "Temporal 710 715--*--prior",
            "Scope 449 488--*--s/p resection and adjuvant chemotherapy",
            "Scope 492 555--*--locally advanced pancreas cancer s/p chemotherapy and radiation",
            "Observation 599 620--*--may have been stopped",
            "Scope 565 598--*--chemotherapy or radiation therapy",
            "Procedure 770 777--*--surgery",
            "Temporal 764 769--*--Prior",
            "Procedure 808 822--*--metastasectomy",
            "Procedure 789 804--*--tumor resection",
            "Temporal 848 890--*--at least 4 weeks prior to study enrollment",
            "Reference_point 874 890--*--study enrollment",
            "Scope 789 822--*--tumor resection or metastasectomy",
            "Context_Error 893 940--*--No concomitant anti-cancer treatment is allowed",
            "Post-eligibility 893 940--*--No concomitant anti-cancer treatment is allowed",
            "Person 942 945--*--Age",
            "Value 946 958--*-->/= 18 years",
            "Measurement 960 978--*--Performance status",
            "Value 982 985--*--0-1",
            "Measurement 1022 1036--*--renal function",
            "Measurement 1005 1016;1028 1036--*--bone marrow function",
            "Measurement 1028 1036;996 1003--*--function hepatic",
            "Value 987 995--*--Adequate",
            "Measurement 1038 1071--*--Partial thromboplastin time (PTT)",
            "Value 1080 1108--*--</= 1.5 x upper normal limit",
            "Measurement 1143 1179--*--INR (International Normalized Ratio)",
            "Value 1180 1185--*--< 1.5",
            "Observation 1188 1203--*--Life expectancy",
            "Value 1204 1216--*-->/= 4 months",
            "Context_Error 1221 1240--*--maintenance cohorts",
            "Observation 1221 1240--*--maintenance cohorts",
            "Value 1245 1257--*-->/= 6 months",
            "Observation 1262 1278--*--adjuvant cohorts",
            "Scope 1204 1278--*-->/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts",
            "Condition 1289 1311--*--childbearing potential",
            "Person 1280 1285--*--Women",
            "Measurement 1333 1353--*--serum pregnancy test",
            "Value 1324 1332--*--negative",
            "Temporal 1354 1401--*--within 14 days prior to initiation of treatment",
            "Reference_point 1378 1401--*--initiation of treatment",
            "Condition 1418 1427--*--lactating",
            "Negation 1411 1414--*--not",
            "Scope 1280 1311--*--Women of childbearing potential",
            "Non-query-able 1430 1548--*--Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent",
            "Post-eligibility 1430 1548--*--Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent"
        ],
        "Text": "Patients with a confirmed diagnosis of: . 1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance \"standard of care\", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1. . 2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less. . Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment. . No concomitant anti-cancer treatment is allowed . Age >/= 18 years . Performance status of 0-1 . Adequate hepatic, bone marrow, and renal function . Partial thromboplastin time (PTT) must be </= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) < 1.5. . Life expectancy >/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts . Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating. . Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent . "
    },
    "NCT02560766_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 16 26--*--adolescent",
            "Person 37 41--*--aged",
            "Value 42 56--*--13 to 17 years",
            "Condition 73 76--*--RLS",
            "Measurement 90 115--*--IRLSSG consensus criteria",
            "Measurement 147 171--*--Total RLS severity score",
            "Value 175 188--*--15 or greater",
            "Multiplier 295 338--*--at least 4 of 7 consecutive evenings/nights",
            "Condition 278 290--*--RLS symptoms",
            "Measurement 369 380--*--Body weight",
            "Value 381 401--*--greater than 33.4 kg",
            "Measurement 439 454--*--body mass index",
            "Measurement 456 459--*--BMI",
            "Value 467 486--*--5th-85th percentile",
            "Measurement 577 607--*--Estimated creatinine clearance",
            "Value 611 629--*--at least 60 mL/min",
            "Informed_consent 687 849--*--Signed patient and parent Institutional Review Board (IRB)-approved informed consent/assent form (as applicable) before any study-related procedures are performed"
        ],
        "Text": "Male and female adolescent patients, aged 13 to 17 years, diagnosed with RLS based on the IRLSSG consensus criteria (Allen RP 2014) (Appendix 2).. Total RLS severity score of 15 or greater on the IRLS rating scale at Visit 1 (screening) and at Visit 2 (baseline) (Appendix 8).. RLS symptoms for at least 4 of 7 consecutive evenings/nights during the screening period.. Body weight greater than 33.4 kg and a healthy weight using age-based body mass index (BMI) range 5th-85th percentile at screening and baseline. Appendix 3 contains BMI-for-age charts that can be consulted.. Estimated creatinine clearance of at least 60 mL/min (using the Cockcroft-Gault equation) at screening only.. Signed patient and parent Institutional Review Board (IRB)-approved informed consent/assent form (as applicable) before any study-related procedures are performed.. "
    },
    "NCT01803828_inc": {
        "Text": "age 35-75 years;. Diagnosis of Type 2 Diabetes from at least 3 years;. HbA1c < 10%;. normal blood pressure or controlled hypertension;. BMI < 40;. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 15--*--35-75 years",
            "Condition 31 46--*--Type 2 Diabetes",
            "Temporal 52 68--*--at least 3 years",
            "Measurement 71 76--*--HbA1c",
            "Value 77 82--*--< 10%",
            "Condition 85 106--*--normal blood pressure",
            "Condition 110 133--*--controlled hypertension",
            "Measurement 136 139--*--BMI",
            "Value 140 144--*--< 40"
        ]
    },
    "NCT02430740_exc": {
        "Annotations": [
            "Condition 0 18--*--polycystic ovaries",
            "Condition 30 47--*--thyroid pathology",
            "Qualifier 20 29--*--untreated",
            "Condition 49 78--*--hypogonadotropic hypogonadism",
            "Qualifier 80 88--*--untreaed",
            "Condition 89 107--*--hyperprolactinemia",
            "Condition 120 136--*--hypersensitivity",
            "Drug 109 119--*--study drug",
            "Condition 147 151--*--OHSS",
            "Temporal 138 146--*--previous",
            "Qualifier 153 163--*--unilateral",
            "Procedure 164 175--*--ovariectomy",
            "Condition 177 197--*--genital malformation",
            "Measurement 199 202--*--BMI",
            "Value 202 205--*-->40"
        ],
        "Text": "polycystic ovaries. untreated thyroid pathology. hypogonadotropic hypogonadism. untreaed hyperprolactinemia. study drug hypersensitivity. previous OHSS. unilateral ovariectomy. genital malformation. BMI>40. "
    },
    "NCT01117181_inc": {
        "Annotations": [
            "Condition 21 40--*--Alzheimer's disease",
            "Measurement 42 195--*--National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria",
            "Value 12 20--*--probable",
            "Value 0 8--*--Possible",
            "Scope 0 20--*--Possible or probable",
            "Measurement 203 232--*--Mini-Mental State Exam (MMSE)",
            "Value 233 257--*--score of 10-26 inclusive",
            "Measurement 259 263--*--MMSE",
            "Value 264 279--*--scores above 26",
            "Condition 324 326--*--AD",
            "Condition 423 429--*--apathy",
            "Person 434 453--*--at least four weeks",
            "Measurement 517 549--*--Neuropsychiatric Inventory (NPI)",
            "Value 554 569--*--Very frequently",
            "Measurement 621 624--*--NPI",
            "Value 629 639--*--Frequently",
            "Value 645 650--*--Often",
            "Measurement 698 701--*--NPI",
            "Observation 660 678--*--severity of apathy",
            "Observation 582 601--*--frequency of apathy",
            "Scope 628 651--*--'Frequently' or 'Often'",
            "Value 706 714--*--Moderate",
            "Value 720 726--*--Marked",
            "Scope 705 727--*--'Moderate' or 'Marked'",
            "Scope 582 727--*--frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked'",
            "Observation 478 497--*--frequency of apathy",
            "Drug 731 752--*--medication for apathy",
            "Condition 746 752--*--apathy",
            "Post-eligibility 729 806--*--A medication for apathy is appropriate, in the opinion of the study physician",
            "Parsing_Error 729 806--*--A medication for apathy is appropriate, in the opinion of the study physician",
            "Post-eligibility 808 961--*--Provision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver",
            "Post-eligibility 963 1157--*--Availability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study",
            "Post-eligibility 1159 1315--*--Sufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments",
            "Drug 1330 1344--*--AD medications",
            "Temporal 1345 1385--*--within the month preceding randomization",
            "Reference_point 1372 1385--*--randomization",
            "Observation 1320 1344--*--change to AD medications",
            "Negation 1317 1319--*--No",
            "Drug 1473 1534--*--selective serotonin reuptake inhibitor antidepressants(SSRIs)",
            "Qualifier 1457 1469--*--stable doses",
            "Procedure 1442 1451--*--Treatment",
            "Context_Error 1442 1757--*--Treatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization. Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis."
        ],
        "Text": "Possible or probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria), with Mini-Mental State Exam (MMSE) score of 10-26 inclusive; MMSE scores above 26 in those who nevertheless meet criteria for AD may be allowed with Steering Committee approval on a case by case basis . Clinically significant apathy for at least four weeks for which either 1) the frequency of apathy as assessed by the Neuropsychiatric Inventory (NPI) is 'Very frequently', or 2) the frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked' . A medication for apathy is appropriate, in the opinion of the study physician . Provision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver . Availability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study . Sufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments . No change to AD medications within the month preceding randomization, including starting, stopping, or dosage modifications . Treatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization. Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis. . "
    },
    "NCT02637453_inc": {
        "Annotations": [
            "Drug 29 48--*--antiarrhythmic drug",
            "Condition 3 11--*--response",
            "Negation 0 2--*--No",
            "Multiplier 15 28--*--more than one",
            "Non-query-able 50 99--*--or unwilling to receive long-term drug treatment.",
            "Post-eligibility 101 244--*--Can provide informed consent form expressing willingness to participate in the study and comply with follow-up tests and evaluation procedures.",
            "Person 246 250--*--Aged",
            "Value 251 262--*--18-80 years"
        ],
        "Text": "No response to more than one antiarrhythmic drug, or unwilling to receive long-term drug treatment.. Can provide informed consent form expressing willingness to participate in the study and comply with follow-up tests and evaluation procedures.. Aged 18-80 years.. "
    },
    "NCT03159507_exc": {
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Drug 17 21--*--fish",
            "Condition 23 31--*--Pregnant",
            "Person 32 37--*--women",
            "Condition 42 53--*--breast-feed",
            "Measurement 57 61;71 84--*--test for pregnancy",
            "Value 62 70--*--positive"
        ],
        "Text": "Allergy known to fish. Pregnant women who breast-feed or test positive for pregnancy. "
    },
    "NCT00455663_inc": {
        "Annotations": [
            "Condition 13 26--*--schizophrenia",
            "Condition 30 54--*--schizoaffective disorder",
            "Drug 161 183--*--atypical antipsychotic",
            "Observation 305 335--*--living in a stable environment",
            "Visit 84 93--*--inpatient",
            "Visit 95 110--*--hospitalization",
            "Temporal 115 121--*--recent",
            "Temporal 123 132--*--Currently",
            "Procedure 143 152--*--treatment",
            "Procedure 188 218--*--continuation on the medication",
            "Mood 228 239--*--recommended",
            "Non-query-able 241 293--*--Assumes primary responsibility for taking medication"
        ],
        "Text": "Diagnosis of schizophrenia or schizoaffective disorder . If entering the study as an inpatient, hospitalization was recent . Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended . Assumes primary responsibility for taking medication . Currently living in a stable environment . "
    },
    "NCT02595190_exc": {
        "Text": "1. Patients with lumbar common diseases(e.g., Lumbar disc, Lumbar spinal stenosis, Lumbar slippage, etc). 2. Researchers think that Patients with disease may be interference results(e.g., Spinal deformity, spine fracture, ankylosing spondylitis, spinal tuberculosis and spinal infection, spinal tumor, pelvic inflammatory disease and other disease of department of gynaecology, etc). 3. Patients with other nervous system diseases(e.g., cerebral tumor, neurinoma, trigeminal neuralgia,etc). 4. Patients with Magnetic resonance imaging contraindication ,including claustrophobic syndrome patients. 5. Patients with recent (less than 3 years) use chemical drugs or have obvious psychological problems. 6. In the past 2 months involved in other drugs or devices clinical trials. ",
        "Annotations": [
            "Condition 17 23;31 39--*--lumbar diseases",
            "Condition 46 57--*--Lumbar disc",
            "Condition 59 81--*--Lumbar spinal stenosis",
            "Condition 83 98--*--Lumbar slippage",
            "Scope 46 99--*--Lumbar disc, Lumbar spinal stenosis, Lumbar slippage,",
            "Condition 188 204--*--Spinal deformity",
            "Condition 206 221--*--spine fracture,",
            "Condition 222 244--*--ankylosing spondylitis",
            "Condition 246 265--*--spinal tuberculosis",
            "Condition 270 286--*--spinal infection",
            "Condition 288 300--*--spinal tumor",
            "Condition 302 329--*--pelvic inflammatory disease",
            "Condition 407 430--*--nervous system diseases",
            "Condition 437 451--*--cerebral tumor",
            "Condition 453 462--*--neurinoma",
            "Condition 464 484--*--trigeminal neuralgia",
            "Scope 437 484--*--cerebral tumor, neurinoma, trigeminal neuralgia",
            "Procedure 508 534--*--Magnetic resonance imaging",
            "Condition 535 551--*--contraindication",
            "Condition 563 586--*--claustrophobic syndrome",
            "Non-query-able 601 698--*--atients with recent (less than 3 years) use chemical drugs or have obvious psychological problems",
            "Competing_trial 703 774--*--In the past 2 months involved in other drugs or devices clinical trials"
        ]
    },
    "NCT03260881_inc": {
        "Text": "T2DM as defined by American Diabetes Association (ADA) criteria. Adult patients with T2DM who are indicated to receive liraglutide, not as first-line therapy, in addition to diet and exercise to improve glycemic control. Hemoglobin A1c (HbA1c) = 9%. Age = 18 years old. Body mass index (BMI) = 27 Kg/m2 and/or waist circumference = 102 cm (40 inches) in men and 88 cm (35 inches) in women, respectively.. Clinically and angiographically stable CAD who requires CABG as part of the standard medical care, as CAD does not represent a contraindication for using liraglutide. The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutide. ",
        "Annotations": [
            "Condition 0 4--*--T2DM",
            "Qualifier 19 63--*--American Diabetes Association (ADA) criteria",
            "Person 65 70--*--Adult",
            "Condition 85 89--*--T2DM",
            "Drug 119 130--*--liraglutide",
            "Mood 98 118--*--indicated to receive",
            "Qualifier 139 157--*--first-line therapy",
            "Negation 132 135--*--not",
            "Non-representable 159 219--*--in addition to diet and exercise to improve glycemic control",
            "Measurement 221 243--*--Hemoglobin A1c (HbA1c)",
            "Value 244 248--*--= 9%",
            "Person 250 253--*--Age",
            "Value 254 268--*--= 18 years old",
            "Measurement 270 291--*--Body mass index (BMI)",
            "Value 292 302--*--= 27 Kg/m2",
            "Measurement 310 329--*--waist circumference",
            "Value 330 338--*--= 102 cm",
            "Value 340 349--*--40 inches",
            "Person 354 357--*--men",
            "Value 362 367--*--88 cm",
            "Value 369 378--*--35 inches",
            "Person 383 388--*--women",
            "Scope 330 388--*--= 102 cm (40 inches) in men and 88 cm (35 inches) in women",
            "Qualifier 420 443--*--angiographically stable",
            "Condition 444 447--*--CAD",
            "Procedure 461 465--*--CABG",
            "Mood 452 460--*--requires",
            "Qualifier 405 415;437 443--*--Clinically stable",
            "Non-representable 504 691--*--as CAD does not represent a contraindication for using liraglutide. The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutide"
        ]
    },
    "NCT02714725_inc": {
        "Annotations": [
            "Person 15 19--*--aged",
            "Value 21 24--*-->18",
            "Person 27 32--*--males",
            "Person 37 44--*--females",
            "Qualifier 57 65--*--elective",
            "Procedure 102 109;66 94--*--surgery coronary artery bypass graft",
            "Procedure 96 100--*--CABG",
            "Procedure 115 137--*--cardiopulmonary bypass",
            "Procedure 139 142--*--CPB"
        ],
        "Text": "Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).. "
    },
    "NCT01117181_exc": {
        "Annotations": [
            "Condition 19 43--*--Major Depressive Episode",
            "Measurement 48 115--*--Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria",
            "Value 0 5--*--Meets",
            "Condition 140 161--*--agitation /aggression",
            "Qualifier 117 139--*--Clinically significant",
            "Undefined_semantics 117 139--*--Clinically significant",
            "Multiplier 186 220--*--frequency of agitation /aggression",
            "Condition 199 220--*--agitation /aggression",
            "Measurement 240 243--*--NPI",
            "Value 248 263--*--Very frequently",
            "Multiplier 276 310--*--frequency of agitation /aggression",
            "Condition 289 310--*--agitation /aggression",
            "Measurement 330 333--*--NPI",
            "Value 338 348--*--Frequently",
            "Measurement 403 406--*--NPI",
            "Value 411 419--*--Moderate",
            "Value 426 432--*--Marked",
            "Scope 410 433--*--'Moderate', or 'Marked'",
            "Qualifier 358 383--*--severity of the agitation",
            "Condition 374 383--*--agitation",
            "Condition 458 467--*--delusions",
            "Qualifier 435 457--*--Clinically significant",
            "Multiplier 492 514--*--frequency of delusions",
            "Condition 505 514--*--delusions",
            "Measurement 534 537--*--NPI",
            "Value 542 557--*--Very frequently",
            "Multiplier 570 592--*--frequency of delusions",
            "Condition 583 592--*--delusions",
            "Measurement 612 615--*--NPI",
            "Value 620 630--*--Frequently",
            "Qualifier 640 665--*--severity of the delusions",
            "Condition 656 665--*--delusions",
            "Measurement 685 688--*--NPI",
            "Value 693 701--*--Moderate",
            "Value 708 714--*--Marked",
            "Scope 692 715--*--'Moderate', or 'Marked'",
            "Condition 740 754--*--hallucinations",
            "Qualifier 717 739--*--Clinically significant",
            "Multiplier 779 806--*--frequency of hallucinations",
            "Condition 792 806--*--hallucinations",
            "Measurement 826 829--*--NPI",
            "Value 834 849--*--Very frequently",
            "Multiplier 862 889--*--frequency of hallucinations",
            "Condition 875 889--*--hallucinations",
            "Measurement 909 912--*--NPI",
            "Value 917 927--*--Frequently",
            "Qualifier 937 967--*--severity of the hallucinations",
            "Condition 953 967--*--hallucinations",
            "Measurement 987 990--*--NPI",
            "Value 995 1003--*--Moderate",
            "Value 1010 1016--*--Marked",
            "Scope 994 1017--*--'Moderate', or 'Marked'",
            "Scope 186 433--*--frequency of agitation /aggression as assessed by the NPI is 'Very frequently', or 2) the frequency of agitation /aggression as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'",
            "Scope 492 715--*--frequency of delusions as assessed by the NPI is 'Very frequently', or 2) the frequency of delusions as assessed by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked'",
            "Scope 779 1017--*--frequency of hallucinations as assessed by the NPI is 'Very frequently', or 2) the frequency of hallucinations as assessed by the NPI is 'Frequently' AND the severity of the hallucinations as assessed by the NPI is 'Moderate', or 'Marked'",
            "Drug 1034 1058--*--psychotropic medications",
            "Temporal 1059 1096--*--in the 2 weeks prior to randomization",
            "Reference_point 1083 1096--*--randomization",
            "Condition 1143 1151--*--dementia",
            "Procedure 1128 1151--*--treatments for dementia",
            "Drug 1153 1158--*--ChEIs",
            "Drug 1163 1172--*--memantine",
            "Scope 1153 1172--*--ChEIs and memantine",
            "Drug 1175 1229--*--selective serotonin reuptake inhibitor antidepressants",
            "Drug 1235 1244--*--trazodone",
            "Negation 1097 1118--*--with the exception of",
            "Scope 1128 1244--*--treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone",
            "Context_Error 1245 1313--*--(if used as an aid to facilitate sleep and not as an antidepressant)",
            "Drug 1315 1334--*--other psychotropics",
            "Drug 1358 1372--*--antipsychotics",
            "Negation 1336 1357--*--with the exclusion of",
            "Qualifier 1378 1384--*--stable",
            "Temporal 1385 1397--*--for 3 months",
            "Drug 1544 1559--*--methylphenidate",
            "Drug 1644 1659--*--methylphenidate",
            "Subjective_judgement 1730 1758--*--as judged by study physician",
            "Drug 1777 1850--*--medication that would prohibit the safe concurrent use of methylphenidate",
            "Drug 1835 1850--*--methylphenidate",
            "Temporal 1817 1827--*--concurrent",
            "Observation 1799 1807--*--prohibit",
            "Drug 1859 1887--*--monoamine oxidase inhibitors",
            "Drug 1892 1917--*--tricyclic antidepressants",
            "Scope 1859 1917--*--monoamine oxidase inhibitors and tricyclic antidepressants",
            "Procedure 1934 1961--*--psychiatric hospitalization",
            "Observation 1919 1927--*--Need for",
            "Temporal 1928 1933--*--acute",
            "Condition 1968 1976--*--suicidal",
            "Condition 1978 2003--*--Uncontrolled hypertension",
            "Qualifier 1978 1990--*--Uncontrolled",
            "Condition 2005 2030--*--medication non-compliance",
            "Temporal 2034 2047--*--past 3 months",
            "Measurement 2055 2072--*--diastolic reading",
            "Value 2076 2079--*--105",
            "Context_Error 2055 2072--*--diastolic reading",
            "Measurement 2095 2143--*--compartment pressure of the rectus sheath (CPRS)",
            "Qualifier 2080 2143--*--as verified by compartment pressure of the rectus sheath (CPRS)",
            "Scope 2005 2143--*--medication non-compliance or past 3 months with a diastolic reading of 105 as verified by compartment pressure of the rectus sheath (CPRS)",
            "Condition 2158 2181--*--coronary artery disease",
            "Qualifier 2146 2157--*--Symptomatic",
            "Temporal 2226 2250--*--at the time of screening",
            "Reference_point 2233 2250--*--time of screening",
            "Condition 2297 2322--*--unintentional weight loss",
            "Qualifier 2285 2296--*--significant",
            "Undefined_semantics 2285 2296--*--significant",
            "Condition 2252 2268--*--Lack of appetite",
            "Qualifier 2323 2359--*--as determined by the study physician",
            "Temporal 2360 2384--*--in the last three months",
            "Qualifier 2386 2397--*--Significant",
            "Undefined_semantics 2386 2397--*--Significant",
            "Condition 2398 2423--*--communicative impairments",
            "Undefined_semantics 2398 2423--*--communicative impairments",
            "Post-eligibility 2425 2539--*--Current participation in a clinical trial or in any study that may add significant burden or affect study outcomes",
            "Condition 2541 2556--*--Hyperthyroidism",
            "Condition 2567 2583--*--arteriosclerosis",
            "Qualifier 2558 2566--*--advanced",
            "Condition 2597 2619--*--cardiovascular disease",
            "Qualifier 2585 2596--*--symptomatic",
            "Qualifier 2621 2628--*--serious",
            "Condition 2629 2661--*--structural cardiac abnormalities",
            "Condition 2663 2677--*--cardiomyopathy",
            "Condition 2687 2713--*--heart rhythm abnormalities",
            "Qualifier 2679 2686--*--serious",
            "Observation 2720 2734--*--family history",
            "Condition 2738 2750--*--sudden death",
            "Condition 2754 2785--*--death related to heart problems",
            "Qualifier 2760 2785--*--related to heart problems",
            "Scope 2738 2785--*--sudden death or death related to heart problems",
            "Condition 2787 2795--*--Glaucoma",
            "Condition 2797 2813--*--pheochromocytoma",
            "Condition 2837 2853--*--hypersensitivity",
            "Drug 2857 2890--*--methylphenidate or its excipients",
            "Drug 2876 2890--*--its excipients",
            "Observation 2827 2836--*--suspected",
            "Observation 2818 2823--*--known",
            "Scope 2818 2836--*--known or suspected",
            "Condition 2892 2934--*--Central Nervous System (CNS) abnormalities",
            "Condition 2942 2959--*--cerebral aneurysm",
            "Condition 2974 2996--*--vascular abnormalities",
            "Condition 3005 3015--*--vasculitis",
            "Condition 3032 3038--*--stroke",
            "Temporal 3019 3031--*--pre-existing",
            "Condition 3040 3050--*--motor tics",
            "Observation 3056 3070--*--family history",
            "Condition 3087 3106--*--Tourette's syndrome",
            "Condition 3108 3116--*--seizures",
            "Condition 3118 3129--*--convulsions",
            "Observation 3074 3083--*--diagnosis",
            "Scope 3056 3083--*--family history or diagnosis",
            "Condition 3131 3139--*--epilepsy",
            "Scope 3118 3139--*--convulsions, epilepsy",
            "Qualifier 3145 3153--*--abnormal",
            "Condition 3154 3158--*--EEGs",
            "Post-eligibility 3160 3299--*--Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial"
        ],
        "Text": "Meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria . Clinically significant agitation /aggression for which either 1) the frequency of agitation /aggression as assessed by the NPI is 'Very frequently', or 2) the frequency of agitation /aggression as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked' . Clinically significant delusions for which either 1) the frequency of delusions as assessed by the NPI is 'Very frequently', or 2) the frequency of delusions as assessed by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked' . Clinically significant hallucinations for which either 1) the frequency of hallucinations as assessed by the NPI is 'Very frequently', or 2) the frequency of hallucinations as assessed by the NPI is 'Frequently' AND the severity of the hallucinations as assessed by the NPI is 'Moderate', or 'Marked' . Treatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis. Note that antipsychotics are expressly prohibited. . Treatment with methylphenidate is contraindicated in the opinion of the study physician . Failure of treatment with methylphenidate in the past for apathy after convincing evidence of an adequate trial as judged by study physician . Treatment with a medication that would prohibit the safe concurrent use of methylphenidate such as monoamine oxidase inhibitors and tricyclic antidepressants . Need for acute psychiatric hospitalization or is suicidal . Uncontrolled hypertension (medication non-compliance or past 3 months with a diastolic reading of 105 as verified by compartment pressure of the rectus sheath (CPRS)) . Symptomatic coronary artery disease deemed to be significant by study physician at the time of screening . Lack of appetite that results in significant unintentional weight loss as determined by the study physician in the last three months . Significant communicative impairments . Current participation in a clinical trial or in any study that may add significant burden or affect study outcomes . Hyperthyroidism, advanced arteriosclerosis, symptomatic cardiovascular disease, serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or a family history of sudden death or death related to heart problems . Glaucoma, pheochromocytoma, or known or suspected hypersensitivity to methylphenidate or its excipients . Central Nervous System (CNS) abnormalities (e.g., cerebral aneurysm) and/or other vascular abnormalities such as vasculitis or pre-existing stroke, motor tics or a family history or diagnosis of Tourette's syndrome, seizures (convulsions, epilepsy), or abnormal EEGs . Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial       .     . "
    },
    "NCT02430740_inc": {
        "Annotations": [
            "Person 0 6--*--female",
            "Condition 7 16--*--infertile",
            "Mood 26 34--*--eligible",
            "Procedure 39 52--*--IVF treatment"
        ],
        "Text": "female infertile patients eligible for IVF treatment. "
    },
    "NCT02637453_exc": {
        "Annotations": [
            "Condition 5 19--*--acute diseases",
            "Temporal 29 40--*--acute phase",
            "Condition 47 68--*--myocardial infarction",
            "Temporal 70 85--*--within 3 months",
            "Temporal 88 103--*--within 3 months",
            "Condition 110 129--*--acute heart failure",
            "Condition 137 156--*--cerebral infarction",
            "Scope 110 156--*--acute heart failure or new cerebral infarction",
            "Scope 29 156--*--acute phase after myocardial infarction (within 3 months), within 3 months after acute heart failure or new cerebral infarction",
            "Procedure 174 195--*--heart transplantation",
            "Mood 159 170--*--In the list",
            "Observation 198 215--*--Expected survival",
            "Value 216 232--*--less than 1 year",
            "Condition 246 266--*--hemorrhagic diseases",
            "Qualifier 240 245--*--other",
            "Procedure 271 292--*--anticoagulant therapy",
            "Condition 296 307--*--not allowed",
            "Condition 310 320--*--Thrombosis",
            "Qualifier 324 335--*--left atrium",
            "Condition 338 351--*--Heart failure",
            "Measurement 353 385--*--New York Heart Association(NYHA)",
            "Value 386 392--*--III/IV",
            "Measurement 396 414--*--eject fraction(EF)",
            "Value 414 418--*--<40%",
            "Qualifier 435 447--*--uncontrolled",
            "Condition 448 454--*--cancer",
            "Condition 480 496--*--renal impairment",
            "Condition 469 476;486 496--*--hepatic impairment",
            "Qualifier 457 468--*--Significant",
            "Scope 469 496--*--hepatic or renal impairment",
            "Measurement 505 530--*--alanine transaminase(ALT)",
            "Measurement 534 561--*--Aspartate transaminase(AST)",
            "Value 562 592--*-->2 times upper limit of normal",
            "Measurement 594 624--*--creatinine clearance rate(CCr)",
            "Value 624 628--*--<50%",
            "Scope 505 628--*--alanine transaminase(ALT) or Aspartate transaminase(AST) >2 times upper limit of normal, creatinine clearance rate(CCr)<50%",
            "Procedure 641 673--*--catheter radiofrequency ablation",
            "Condition 678 680--*--AF",
            "Procedure 684 699--*--cardiac surgery",
            "Pregnancy_considerations 702 839--*--Pregnant and lactating women, women who plan to become pregnant, or women of child bearing age not using reliable contraceptive measures."
        ],
        "Text": "With acute diseases, such as acute phase after myocardial infarction (within 3 months), within 3 months after acute heart failure or new cerebral infarction;. In the list of heart transplantation;. Expected survival less than 1 year;. With other hemorrhagic diseases and anticoagulant therapy is not allowed;. Thrombosis in left atrium;. Heart failure, New York Heart Association(NYHA) III/IV or eject fraction(EF)<40%;. Patients with uncontrolled cancer;. Significant hepatic or renal impairment (and/or alanine transaminase(ALT) or Aspartate transaminase(AST) >2 times upper limit of normal, creatinine clearance rate(CCr)<50%);. Previous catheter radiofrequency ablation for AF or cardiac surgery;. Pregnant and lactating women, women who plan to become pregnant, or women of child bearing age not using reliable contraceptive measures.. "
    },
    "NCT02595190_inc": {
        "Text": "1. Diagnosed with symptomatic sacral perineurial cysts(e.g., lumbosacral or perineal pain, fecal or urinary functions change, sexual function change, lower limb radiation pain, muscle abate, paresthesia, etc). 2. Visual analog scale more than or equal to 4. 3. Signed the informed consent. 4. Years, range 18-60. 5. Self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores < 50. 6. No Congenital,Mental and other Nervous system diseases. 7. No Serious Cardiac,Pulmonary,Hepatic and Nephritic disease. 8. No history of drug allergy. 9. No pain(including dysmenorrhea) or drug use (e.g., antipyretics,sleeping pills) within the last month. 10. MRI finding of sacral perineurial cysts, but without any clinical symptoms, included in the negative control group. 11. MRI finding healthy volunteers don't have sacral perineurial cysts, included in the negative control groupblank control group. ",
        "Annotations": [
            "Condition 30 55--*--sacral perineurial cysts(",
            "Qualifier 18 29--*--symptomatic",
            "Condition 76 89--*--perineal pain",
            "Condition 61 72;85 89--*--lumbosacral pain",
            "Condition 100 124--*--urinary functions change",
            "Condition 108 125;91 96--*--functions change, fecal",
            "Condition 126 148--*--sexual function change",
            "Condition 150 175--*--lower limb radiation pain",
            "Condition 177 189--*--muscle abate",
            "Condition 191 202--*--paresthesia",
            "Scope 61 202--*--lumbosacral or perineal pain, fecal or urinary functions change, sexual function change, lower limb radiation pain, muscle abate, paresthesia",
            "Measurement 213 232--*--Visual analog scale",
            "Value 233 256--*--more than or equal to 4",
            "Informed_consent 261 288--*--Signed the informed consent",
            "Person 293 298--*--Years",
            "Value 306 311--*--18-60",
            "Measurement 316 341--*--Self-rating anxiety scale",
            "Measurement 343 346--*--SAS",
            "Measurement 352 380--*--self-rating depression scale",
            "Measurement 382 385--*--SDS",
            "Value 387 398--*--scores < 50",
            "Scope 316 385--*--Self-rating anxiety scale (SAS) and self-rating depression scale (SDS",
            "Condition 434 457--*--Nervous system diseases",
            "Negation 403 405--*--No",
            "Condition 406 416;449 457--*--Congenital diseases",
            "Condition 417 423;449 456--*--Mental disease",
            "Scope 406 456--*--Congenital,Mental and other Nervous system disease",
            "Condition 503 520--*--Nephritic disease",
            "Condition 491 498--*--Hepatic",
            "Condition 481 490--*--Pulmonary",
            "Condition 473 480--*--Cardiac",
            "Condition 544 551--*--allergy",
            "Drug 539 543--*--drug",
            "Negation 556 558--*--No",
            "Negation 462 464--*--No",
            "Negation 525 527--*--No",
            "Condition 473 498--*--Cardiac,Pulmonary,Hepatic",
            "Condition 559 563--*--pain",
            "Temporal 647 657--*--last month",
            "Condition 574 586--*--dysmenorrhea",
            "Drug 591 595--*--drug",
            "Non-query-able 607 619--*--antipyretics",
            "Post-eligibility 783 908--*--MRI finding healthy volunteers don't have sacral perineurial cysts, included in the negative control groupblank control group",
            "Non-query-able 663 777--*--MRI finding of sacral perineurial cysts, but without any clinical symptoms, included in the negative control group"
        ]
    },
    "NCT03159507_inc": {
        "Annotations": [
            "Person 12 16--*--aged",
            "Value 17 27--*--19 or over",
            "Informed_consent 29 176--*--Available for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed."
        ],
        "Text": "Participant aged 19 or over. Available for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed.. "
    },
    "NCT00455663_exc": {
        "Annotations": [
            "Condition 23 34--*--head trauma",
            "Condition 36 52--*--seizure disorder",
            "Condition 57 75--*--mental retardation",
            "Observation 0 7--*--History",
            "Scope 23 75--*--head trauma, seizure disorder, or mental retardation",
            "Observation 77 84--*--History",
            "Condition 104 109;88 95--*--abuse alcohol",
            "Condition 99 109--*--drug abuse",
            "Condition 113 123;88 95--*--dependence alcohol",
            "Condition 113 123;99 103--*--dependence drug",
            "Temporal 124 144--*--within 1 month prior",
            "Scope 88 123--*--alcohol or drug abuse or dependence",
            "Temporal 181 202--*--within 6 months prior",
            "Observation 172 180--*--violence",
            "Observation 161 168--*--History"
        ],
        "Text": "History of significant head trauma, seizure disorder, or mental retardation . History of alcohol or drug abuse or dependence within 1 month prior to study entry . History of violence within 6 months prior to study entry       .     . "
    },
    "NCT03260881_exc": {
        "Text": "Patients with a personal or family history of medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2. Patients with a prior serious hypersensitivity reaction to liraglutide. Other contra-indications to liraglutide in accordance with risks and safety information included in the latest updated prescribing information. Type 1 diabetes, as defined by ADA criteria. Current use of other GLP-1A, dipeptidyl peptidase 4 (DPP4) or Sodium Glucose transporters 2 (SGLT2) inhibitors, thiazolidinediones (TZDs), pramlintide and fixed prandial insulin.. Patients with unstable CAD, assessed by the Cardiology team and defined as new onset angina, rest angina, rapidly increasing or crescendo angina. History of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy; acute or chronic infective diseases, cancer or chemotherapy, history of pulmonary, renal or liver diseases, and drug abuse. Patients with chronic and acute inflammatory conditions such as sepsis, rheumatoid arthritis, ectopic dermatitis, asthma, ulcerative colitis.. Current use of systemic corticosteroids in the 3 months prior this study.. Pregnant or breast-feeding women. Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice). ",
        "Annotations": [
            "Observation 16 24;35 42--*--personal history",
            "Observation 28 42--*--family history",
            "Condition 46 73--*--medullary thyroid carcinoma",
            "Condition 91 135--*--Multiple Endocrine Neoplasia syndrome type 2",
            "Scope 16 42--*--personal or family history",
            "Scope 46 135--*--medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2",
            "Condition 167 192--*--hypersensitivity reaction",
            "Drug 196 207--*--liraglutide",
            "Temporal 153 158--*--prior",
            "Qualifier 159 166--*--serious",
            "Drug 237 248--*--liraglutide",
            "Condition 215 233--*--contra-indications",
            "Qualifier 209 214--*--Other",
            "Condition 353 368--*--Type 1 diabetes",
            "Qualifier 384 396--*--ADA criteria",
            "Drug 419 425--*--GLP-1A",
            "Qualifier 413 418--*--other",
            "Drug 427 456;498 508--*--dipeptidyl peptidase 4 (DPP4) inhibitors",
            "Drug 460 508--*--Sodium Glucose transporters 2 (SGLT2) inhibitors",
            "Drug 510 535--*--thiazolidinediones (TZDs)",
            "Drug 537 548--*--pramlintide",
            "Drug 559 575--*--prandial insulin",
            "Condition 592 604--*--unstable CAD",
            "Condition 653 669--*--new onset angina",
            "Condition 671 682--*--rest angina",
            "Condition 684 702;716 722--*--rapidly increasing angina",
            "Condition 706 722--*--crescendo angina",
            "Scope 653 722--*--new onset angina, rest angina, rapidly increasing or crescendo angina",
            "Condition 735 756--*--diabetic ketoacidosis",
            "Procedure 758 766;780 795--*--pancreas transplantation",
            "Procedure 770 795--*--beta-cell transplantation",
            "Condition 800 808--*--diabetes",
            "Procedure 822 834--*--pancreatitis",
            "Procedure 838 852--*--pancreatectomy",
            "Scope 822 852--*--pancreatitis or pancreatectomy",
            "Qualifier 809 821--*--secondary to",
            "Qualifier 854 859--*--acute",
            "Qualifier 863 870--*--chronic",
            "Condition 871 889--*--infective diseases",
            "Condition 891 897--*--cancer",
            "Procedure 901 913--*--chemotherapy",
            "Condition 946 960--*--liver diseases",
            "Condition 937 942;952 960--*--renal diseases",
            "Condition 926 935;952 960--*--pulmonary diseases",
            "Condition 966 976--*--drug abuse",
            "Scope 854 870--*--acute or chronic",
            "Observation 724 731--*--History",
            "Scope 735 976--*--diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy; acute or chronic infective diseases, cancer or chemotherapy, history of pulmonary, renal or liver diseases, and drug abuse",
            "Qualifier 992 999--*--chronic",
            "Qualifier 1004 1009--*--acute",
            "Condition 1010 1033--*--inflammatory conditions",
            "Condition 1042 1048--*--sepsis",
            "Condition 1050 1070--*--rheumatoid arthritis",
            "Condition 1072 1090--*--ectopic dermatitis",
            "Condition 1092 1098--*--asthma",
            "Condition 1100 1118--*--ulcerative colitis",
            "Scope 1042 1118--*--sepsis, rheumatoid arthritis, ectopic dermatitis, asthma, ulcerative colitis",
            "Scope 992 1009--*--chronic and acute",
            "Temporal 1121 1128--*--Current",
            "Drug 1136 1160--*--systemic corticosteroids",
            "Temporal 1161 1193--*--in the 3 months prior this study",
            "Condition 1196 1204--*--Pregnant",
            "Condition 1208 1228--*--breast-feeding women",
            "Pregnancy_considerations 1230 1351--*--Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice)"
        ]
    },
    "NCT02714725_exc": {
        "Annotations": [
            "Post-eligibility 0 15--*--Patient refusal",
            "Procedure 18 37--*--Emergency surgeries",
            "Procedure 39 53--*--Redo surgeries",
            "Condition 55 64--*--Pregnancy",
            "Condition 66 76--*--Vasculitis",
            "Condition 78 90--*--Inflammation",
            "Condition 94 103--*--infection",
            "Qualifier 111 121--*--study site",
            "Scope 78 103--*--Inflammation or infection",
            "Condition 134 142--*--allergic",
            "Non-query-able 123 172--*--History of allergic reaction to study medications"
        ],
        "Text": "Patient refusal.. Emergency surgeries. Redo surgeries. Pregnancy. Vasculitis. Inflammation or infection at the study site. History of allergic reaction to study medications. "
    },
    "NCT02208739_exc": {
        "Annotations": [
            "Drug 28 47--*--systemic antibiotic",
            "Temporal 54 80--*--over the previous 4 months",
            "Observation 17 24--*--history",
            "Condition 100 108--*--pregnant",
            "Procedure 136 170--*--non-surgical periodontal treatment",
            "Temporal 171 195--*--within the past 6 months",
            "Procedure 223 253--*--surgical periodontal treatment",
            "Temporal 254 279--*--within the past 12 months",
            "Condition 299 306--*--smokers",
            "Condition 335 341--*--stroke",
            "Procedure 348 374--*--acute cardiovascular event",
            "Temporal 375 402--*--over the previous 12 months"
        ],
        "Text": "Patients who had history of systemic antibiotic usage over the previous 4 months . Patients who were pregnant . Patients who had received non-surgical periodontal treatment within the past 6 months . Patients who had received surgical periodontal treatment within the past 12 months . Patients who were smokers . Patients with a history of stroke or an acute cardiovascular event over the previous 12 months.       .     . "
    },
    "NCT02822001_exc": {
        "Text": "Patients unable to give informed consent.. Any patient whose condition will not allow for placement of the electrode PadSet.. Patients whose tracheas were not extubated in OR or PACU.. Patients with Impaired Renal Function with a have a known estimated CrCl<30 ml/min. Patients using oral contraception.. ",
        "Annotations": [
            "Informed_consent 0 40--*--Patients unable to give informed consent",
            "Condition 61 70--*--condition",
            "Negation 76 79--*--not",
            "Mood 80 85--*--allow",
            "Procedure 90 99--*--placement",
            "Device 107 123--*--electrode PadSet",
            "Procedure 159 168--*--extubated",
            "Qualifier 141 149--*--tracheas",
            "Negation 155 158--*--not",
            "Visit 172 174--*--OR",
            "Visit 178 182--*--PACU",
            "Scope 172 182--*--OR or PACU",
            "Condition 199 222--*--Impaired Renal Function",
            "Measurement 243 257--*--estimated CrCl",
            "Value 257 267--*--<30 ml/min",
            "Procedure 284 302--*--oral contraception",
            "Drug 284 302--*--oral contraception"
        ]
    },
    "NCT02707874_inc": {
        "Text": "Inpatients having major foot and ankle surgery that will benefit from continuous popliteal sciatic nerve block with an indwelling catheter. American Society Anesthesiologists (ASA) physical status I-III. 18-85 years of age, inclusive. 40-120 kg, inclusive. 150 cm of height or greater. ",
        "Annotations": [
            "Visit 0 10--*--Inpatients",
            "Procedure 18 46--*--major foot and ankle surgery",
            "Device 119 138--*--indwelling catheter",
            "Procedure 81 110--*--popliteal sciatic nerve block",
            "Qualifier 70 80--*--continuous",
            "Measurement 140 174;181 196--*--American Society Anesthesiologists physical status",
            "Measurement 176 179--*--ASA",
            "Value 197 202--*--I-III",
            "Person 219 222--*--age",
            "Value 204 215--*--18-85 years",
            "Person 242 244--*--kg",
            "Value 235 241--*--40-120",
            "Person 267 273--*--height",
            "Value 257 263;274 284--*--150 cm or greater"
        ]
    },
    "NCT00397215_exc": {
        "Annotations": [
            "Drug 31 55--*--MF59-containing vaccines",
            "Drug 62 67--*--Fluad",
            "Drug 72 80--*--Addigrip",
            "Drug 85 118--*--virosome-based influenza vaccines",
            "Drug 127 137--*--Inflexal V",
            "Drug 140 154--*--InfectoVac Flu",
            "Drug 159 166--*--Invivac",
            "Temporal 168 205--*--during the 2006-2007 influenza season",
            "Scope 127 167--*--Inflexal V\u2122, InfectoVac Flu\u2122 or Invivac\u2122",
            "Scope 62 81--*--Fluad\u2122 or Addigrip\u2122",
            "Scope 31 167--*--MF59-containing vaccines, e.g. Fluad\u2122 or Addigrip\u2122 or virosome-based influenza vaccines such as Inflexal V\u2122, InfectoVac Flu\u2122 or Invivac\u2122",
            "Temporal 244 258;317 349--*--within 2 weeks prior to enrolment in this study",
            "Temporal 244 250;289 296;317 349--*--within 4 weeks prior to enrolment in this study",
            "Drug 264 284--*--inactivated vaccines",
            "Drug 302 315--*--live vaccines",
            "Drug 226 243--*--licensed vaccines",
            "Scope 244 349--*--within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study",
            "Drug 380 387--*--vaccine",
            "Qualifier 392 422--*--foreseen by the study protocol",
            "Negation 388 391--*--not",
            "Temporal 423 436--*--up to 30 days",
            "Drug 454 465--*--vaccination",
            "Value 447 453--*--second",
            "Drug 471 483--*--H5N1 vaccine",
            "Temporal 521 538--*--more than 14 days",
            "Qualifier 486 493--*--Chronic",
            "Drug 543 561--*--immunosuppressants",
            "Drug 565 593--*--other immune-modifying drugs",
            "Temporal 594 617--*--within six months prior",
            "Scope 543 593--*--immunosuppressants or other immune-modifying drugs",
            "Condition 696 713;733 742--*--immunosuppressive condition",
            "Condition 717 742--*--immunodeficient condition",
            "Qualifier 673 682--*--confirmed",
            "Qualifier 686 695--*--suspected",
            "Scope 673 695--*--confirmed or suspected",
            "Scope 696 742--*--immunosuppressive or immunodeficient condition",
            "Condition 840 867--*--chronic alcohol consumption",
            "Condition 875 885--*--drug abuse",
            "Observation 829 836--*--History",
            "Scope 840 885--*--chronic alcohol consumption and/or drug abuse",
            "Condition 899 927--*--hypersensitivity to vaccines",
            "Observation 888 895--*--History",
            "Condition 941 957--*--allergic disease",
            "Condition 941 949;961 970--*--allergic reactions",
            "Observation 930 937--*--History",
            "Scope 1039 1065--*--egg and thiomersal allergy",
            "Condition 1039 1042;1058 1065--*--egg allergy",
            "Condition 1047 1065--*--thiomersal allergy",
            "Scope 941 970--*--allergic disease or reactions",
            "Condition 1109 1123;1142 1164--*--cardiovascular functional abnormality",
            "Condition 1125 1132;1142 1164--*--hepatic functional abnormality",
            "Condition 1136 1164--*--renal functional abnormality",
            "Condition 1098 1107;1142 1164--*--pulmonary functional abnormality",
            "Condition 1236 1249--*--Acute disease",
            "Temporal 1250 1274--*--at the time of enrolment",
            "Condition 1337 1354;1418 1426--*--chronic pulmonary disorder",
            "Condition 1337 1344;1356 1370;1418 1426--*--chronic cardiovascular disorder",
            "Condition 1337 1344;1372 1377;1418 1426--*--chronic renal disorder",
            "Condition 1337 1344;1379 1391;1418 1426--*--chronic neurological disorder",
            "Condition 1337 1344;1393 1404;1418 1426--*--chronic psychiatric disorder",
            "Condition 1337 1344;1408 1426--*--chronic metabolic disorder",
            "Drug 1506 1521--*--immunoglobulins",
            "Drug 1529 1547--*--any blood products",
            "Temporal 1548 1603--*--within the three months preceding the first vaccination",
            "Scope 1506 1547--*--immunoglobulins and/or any blood products",
            "Condition 1821 1830--*--condition",
            "Qualifier 1831 1836;1874 1926--*--which prevents the subject from participation in the study",
            "Non-representable 1838 1872--*--in the opinion of the investigator",
            "Non-representable 1817 1927--*--Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.",
            "Qualifier 1637 1652--*--investigational",
            "Qualifier 1656 1670--*--non-registered",
            "Drug 1671 1678--*--product",
            "Scope 1637 1670--*--investigational or non-registered",
            "Drug 1680 1684--*--drug",
            "Drug 1688 1695--*--vaccine",
            "Scope 1680 1695--*--drug or vaccine",
            "Negation 1697 1707--*--other than",
            "Drug 1712 1728--*--study vaccine(s)",
            "Qualifier 1697 1728--*--other than the study vaccine(s)",
            "Temporal 1729 1774--*--within 30 days prior to the first vaccination",
            "Reference_point 1753 1774--*--the first vaccination",
            "Procedure 1763 1774--*--vaccination",
            "Temporal 1757 1762--*--first",
            "Mood 1779 1786--*--planned",
            "Temporal 1791 1814--*--during the study period",
            "Procedure 1787 1790--*--use",
            "Qualifier 1277 1284--*--Serious",
            "Condition 1285 1300--*--chronic disease",
            "Scope 1337 1426--*--chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder",
            "Temporal 1607 1623--*--during the study",
            "Reference_point 1582 1603--*--the first vaccination",
            "Procedure 1592 1603--*--vaccination",
            "Temporal 1586 1591--*--first",
            "Scope 1548 1623--*--within the three months preceding the first vaccination or during the study",
            "Reference_point 1614 1623--*--the study"
        ],
        "Text": "Administration of the licensed MF59-containing vaccines, e.g. Fluad\u2122 or Addigrip\u2122 or virosome-based influenza vaccines such as Inflexal V\u2122, InfectoVac Flu\u2122 or Invivac\u2122 during the 2006-2007 influenza season. . Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. . Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination with H5N1 vaccine. . Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine. . Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). . History of chronic alcohol consumption and/or drug abuse. . History of hypersensitivity to vaccines. . History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (including egg and thiomersal allergy). . Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. . Acute disease at the time of enrolment. . Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination. . Administration of immunoglobulins and/or any blood products within the three months preceding the first vaccination or during the study. . Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period. . Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.       .     . "
    },
    "NCT03117608_inc": {
        "Annotations": [
            "Observation 9 42--*--provided written informed consent",
            "Person 54 58--*--aged",
            "Value 59 82--*--between 18 and 75 years",
            "Qualifier 90 101--*--symptomatic",
            "Condition 102 104;85 89--*--OA Knee",
            "Measurement 106 129--*--Kellgren-Lawrence grade",
            "Value 130 133--*--1-4",
            "Scope 106 133--*--Kellgren-Lawrence grade 1-4",
            "Observation 136 143--*--Failure",
            "Procedure 147 169--*--conservative treatment",
            "Temporal 170 191--*--for at least 3 months",
            "Observation 203 264--*--agreed to actively participate in the rehabilitation protocol",
            "Observation 203 240;269 286--*--agreed to actively participate in the follow-up program",
            "Person 289 293--*--Male",
            "Person 297 303--*--female",
            "Observation 324 340--*--childbearing age",
            "Person 315 320--*--Women",
            "Observation 361 388--*--method to prevent pregnancy",
            "Temporal 390 419--*--before the surgical treatment",
            "Reference_point 397 419--*--the surgical treatment",
            "Procedure 401 419--*--surgical treatment",
            "Scope 315 340--*--Women of childbearing age"
        ],
        "Text": "Patients provided written informed consent;. Patients aged between 18 and 75 years;. Knee symptomatic OA (Kellgren-Lawrence grade 1-4). Failure of conservative treatment for at least 3 months;. Patients agreed to actively participate in the rehabilitation protocol and follow-up program;. Male or female patients;. Women of childbearing age had to use a proven method to prevent pregnancy, before the surgical treatment.. "
    },
    "NCT03077204_inc": {
        "Text": "Age>18 years. Scheduled 1 or 2-level ACDF spine surgery. The capacity to provide informed consent.. Degenerative Disc Disease (as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies). Trauma (including fractures). Tumors. Deformities or curvatures (including kyphosis, lordosis, or scoliosis). Pseudoarthrosis. Failed previous fusion. Decompression of the spinal cord following total or partial cervical vertebrectomy. Spondylolisthesis. Spinal stenosis. Patients with current or recent history of malignancy or infectious disease.. The inability to provide informed consent.. Subject has marked local inflammation. Subject has any mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care.. Subject has a bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the devices.. Subject has bone abnormalities preventing safe screw fixation.. Subject has any open wounds.. Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis. Osteoporosis or osteopenia are relative contraindications, since this condition may limit the degree of obtainable correction and/or the amount of mechanical fixation.. Subject has a documented or suspected metal sensitivity.. Subject is pregnant.. Subject has anatomical structures or physiological performance that would interfere with implant utilization.. Subject has inadequate tissue coverage over the operative site.. Subject has other medical or surgical conditions which would preclude the potential benefit of surgery, such as congenital abnormalities, immunosuppressive disease, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or marked left shift in the WBC differential count.. Note: The Aviator Anterior Cervical Plating System is not approved or intended for screw attachment to the posterior elements (pedicles) of the cervical, thoracic, or lumbar spine. The surgeon must consider the levels of implantation, patient weight, patient activity level, and other patient conditions which may impact on the performance of the system.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 3 12--*-->18 years",
            "Qualifier 29 36--*--2-level",
            "Qualifier 24 25;30 36--*--1 -level",
            "Procedure 37 55--*--ACDF spine surgery",
            "Scope 24 36--*--1 or 2-level",
            "Non-query-able 57 98--*--The capacity to provide informed consent.",
            "Condition 100 125--*--Degenerative Disc Disease",
            "Condition 141 150--*--neck pain",
            "Qualifier 154 171--*--discogenic origin",
            "Condition 177 201--*--degeneration of the disc",
            "Observation 215 230--*--patient history",
            "Procedure 235 255--*--radiographic studies",
            "Condition 258 264--*--Trauma",
            "Condition 276 285--*--fractures",
            "Condition 288 294--*--Tumors",
            "Condition 296 307--*--Deformities",
            "Condition 311 321--*--curvatures",
            "Condition 333 341--*--kyphosis",
            "Condition 343 351--*--lordosis",
            "Condition 356 365--*--scoliosis",
            "Scope 333 365--*--kyphosis, lordosis, or scoliosis",
            "Scope 296 321--*--Deformities or curvatures",
            "Condition 368 383--*--Pseudoarthrosis",
            "Procedure 401 407--*--fusion",
            "Qualifier 385 391--*--Failed",
            "Temporal 392 400--*--previous",
            "Procedure 409 441--*--Decompression of the spinal cord",
            "Procedure 461 491--*--partial cervical vertebrectomy",
            "Procedure 452 457;469 491--*--total cervical vertebrectomy",
            "Scope 452 491--*--total or partial cervical vertebrectomy",
            "Condition 493 510--*--Spondylolisthesis",
            "Temporal 554 560--*--recent",
            "Temporal 543 550--*--current",
            "Observation 561 568--*--history",
            "Condition 572 582--*--malignancy",
            "Condition 586 604--*--infectious disease",
            "Condition 512 527--*--Spinal stenosis",
            "Non-query-able 607 649--*--The inability to provide informed consent.",
            "Condition 670 688--*--local inflammation",
            "Qualifier 663 669--*--marked",
            "Condition 706 712;730 738--*--mental disorder",
            "Condition 716 738--*--neuromuscular disorder",
            "Condition 782 798--*--fixation failure",
            "Qualifier 761 773--*--unacceptable",
            "Condition 802 815--*--complications",
            "Mood 774 781--*--risk of",
            "Scope 782 815--*--fixation failure or complications",
            "Scope 706 738--*--mental or neuromuscular disorder",
            "Condition 854 876--*--bone stock compromised",
            "Condition 880 887--*--disease",
            "Condition 889 898--*--infection",
            "Procedure 908 920--*--implantation",
            "Temporal 902 907--*--prior",
            "Observation 942 958--*--adequate support",
            "Procedure 966 989--*--fixation to the devices",
            "Measurement 927 933--*--cannot",
            "Scope 942 989--*--adequate support and/or fixation to the devices",
            "Scope 880 989--*--disease, infection or prior implantation which cannot provide adequate support and/or fixation to the devices",
            "Condition 1004 1022--*--bone abnormalities",
            "Procedure 1039 1053--*--screw fixation",
            "Negation 1023 1033--*--preventing",
            "Qualifier 1034 1038--*--safe",
            "Scope 1023 1053--*--preventing safe screw fixation",
            "Condition 1098 1117--*--rapid joint disease",
            "Condition 1119 1134--*--bone absorption",
            "Condition 1136 1146--*--osteopenia",
            "Condition 1148 1160--*--osteomalacia",
            "Condition 1169 1181--*--osteoporosis",
            "Condition 1183 1195--*--Osteoporosis",
            "Condition 1199 1209--*--osteopenia",
            "Condition 1223 1240--*--contraindications",
            "Qualifier 1214 1222--*--relative",
            "Condition 1396 1407--*--sensitivity",
            "Device 1390 1395--*--metal",
            "Mood 1366 1376--*--documented",
            "Mood 1380 1389--*--suspected",
            "Scope 1366 1389--*--documented or suspected",
            "Condition 1421 1429--*--pregnant",
            "Observation 1444 1465--*--anatomical structures",
            "Observation 1469 1494--*--physiological performance",
            "Observation 1506 1520;1529 1540--*--interfere with utilization",
            "Device 1521 1528--*--implant",
            "Scope 1444 1494--*--anatomical structures or physiological performance",
            "Condition 1555 1581--*--inadequate tissue coverage",
            "Qualifier 1591 1605--*--operative site",
            "Condition 1637 1656--*--surgical conditions",
            "Condition 1626 1633;1646 1656--*--medical conditions",
            "Negation 1669 1677--*--preclude",
            "Procedure 1703 1710--*--surgery",
            "Condition 1720 1744--*--congenital abnormalities",
            "Condition 1746 1771--*--immunosuppressive disease",
            "Value 1773 1782--*--elevation",
            "Measurement 1786 1804--*--sedimentation rate",
            "Qualifier 1805 1834--*--unexplained by other diseases",
            "Value 1836 1845--*--elevation",
            "Measurement 1849 1872--*--white blood count (WBC)",
            "Value 1884 1894--*--left shift",
            "Measurement 1902 1924--*--WBC differential count",
            "Non-representable 1927 2281--*--Note: The Aviator Anterior Cervical Plating System is not approved or intended for screw attachment to the posterior elements (pedicles) of the cervical, thoracic, or lumbar spine. The surgeon must consider the levels of implantation, patient weight, patient activity level, and other patient conditions which may impact on the performance of the system.",
            "Condition 1072 1083--*--open wounds"
        ]
    },
    "NCT02760251_inc": {
        "Text": "Informed consent as documented by signature (see informed consent form). Primary ITP according to the definition of Rodeghiero et al. (52) and a platelet count of <30x109/l. Age range: 18-45 years. Previously treated patients, with failure or intolerance to first-line therapy, or relapse after first-line therapy, i.e. corticosteroids, intravenous immunoglobulin (IVIG), or anti-D immunoglobulins. ",
        "Annotations": [
            "Post-eligibility 0 71--*--Informed consent as documented by signature (see informed consent form)",
            "Condition 73 84--*--Primary ITP",
            "Measurement 102 126--*--definition of Rodeghiero",
            "Measurement 145 159--*--platelet count",
            "Value 163 172--*--<30x109/l",
            "Scope 102 172--*--definition of Rodeghiero et al. (52) and a platelet count of <30x109/l",
            "Person 174 177--*--Age",
            "Value 185 196--*--18-45 years",
            "Observation 198 216--*--Previously treated",
            "Procedure 258 276--*--first-line therapy",
            "Qualifier 232 239--*--failure",
            "Qualifier 243 254--*--intolerance",
            "Condition 281 288--*--relapse",
            "Temporal 289 313--*--after first-line therapy",
            "Reference_point 295 313--*--first-line therapy",
            "Procedure 295 313--*--first-line therapy",
            "Drug 320 335--*--corticosteroids",
            "Drug 337 363--*--intravenous immunoglobulin",
            "Drug 375 397--*--anti-D immunoglobulins",
            "Drug 365 369--*--IVIG"
        ]
    },
    "NCT01218737_inc": {
        "Annotations": [
            "Procedure 32 57--*--ocular refractive surgery",
            "Condition 11 67--*--indicated to have an ocular refractive surgery performed",
            "Condition 69 75--*--myopia",
            "Condition 77 88--*--astigmatism",
            "Condition 90 102--*--hypermetropy",
            "Qualifier 111 123--*--Lasik method",
            "Scope 69 102--*--myopia, astigmatism, hypermetropy",
            "Condition 145 162--*--normal eye fundus",
            "Measurement 152 162--*--eye fundus",
            "Value 145 151--*--normal",
            "Measurement 177 203--*--intraocular pressure (IOP)",
            "Value 204 213--*--\u2264 20 mmHg"
        ],
        "Text": "Patient is indicated to have an ocular refractive surgery performed (myopia, astigmatism, hypermetropy) by the Lasik method. . Patient presents a normal eye fundus. . Patient has intraocular pressure (IOP) \u2264 20 mmHg. . "
    },
    "NCT03561753_inc": {
        "Annotations": [
            "Qualifier 20 29--*--untreated",
            "Qualifier 0 15--*--Newly diagnosed",
            "Measurement 30 42--*--sputum smear",
            "Value 43 51--*--positive",
            "Condition 52 64--*--tuberculosis",
            "Scope 0 29--*--Newly diagnosed and untreated",
            "Condition 74 90--*--Pulmonary lesion",
            "Condition 107 109--*--TB",
            "Procedure 113 137--*--radiological examination",
            "Qualifier 91 109--*--consistent with TB",
            "Value 139 147--*--Positive",
            "Measurement 148 162--*--sputum culture",
            "Condition 207 233--*--Mycobacterium tuberculosis",
            "Qualifier 182 196--*--bacterial type",
            "Measurement 235 267--*--MGIT drug sensitivity test (DST)",
            "Value 280 366--*--sensitive of the first-line drugs (isoniazid, streptomycin, rifampicin and ethambutol)",
            "Drug 297 313--*--first-line drugs",
            "Drug 315 324--*--isoniazid",
            "Drug 326 338--*--streptomycin",
            "Drug 340 350--*--rifampicin",
            "Drug 355 365--*--ethambutol",
            "Scope 315 365--*--isoniazid, streptomycin, rifampicin and ethambutol",
            "Person 369 372--*--Age",
            "Value 373 394--*--18 years-65 years old",
            "Person 396 401--*--Males",
            "Negation 405 409--*--non-",
            "Condition 409 417--*--pregnant",
            "Negation 419 423--*--non-",
            "Observation 423 430--*--nursing",
            "Person 431 438--*--females",
            "Scope 405 438--*--non-pregnant, non-nursing females",
            "Measurement 449 473--*--plasma aminotransferases",
            "Measurement 475 478--*--AST",
            "Measurement 480 483--*--ALT",
            "Measurement 440 445;456 473--*--Serum aminotransferases",
            "Scope 440 473--*--Serum or plasma aminotransferases",
            "Scope 475 483--*--AST, ALT",
            "Value 485 528--*--less than 3 times the upper limit of normal",
            "Qualifier 539 545--*--plasma",
            "Qualifier 530 535--*--Serum",
            "Measurement 546 561--*--total bilirubin",
            "Value 562 619--*--less than or equal to 2.5 times the upper limit of normal",
            "Scope 530 545--*--Serum or plasma",
            "Qualifier 630 636--*--plasma",
            "Qualifier 621 626--*--Serum",
            "Measurement 637 653--*--creatinine level",
            "Value 654 709--*--less than or equal to 2 times the upper limit of normal",
            "Scope 621 636--*--Serum or plasma",
            "Qualifier 711 716--*--Serum",
            "Qualifier 720 726--*--plasma",
            "Measurement 727 742--*--potassium level",
            "Value 743 777--*--greater than or equal to 3.5 meq/L",
            "Scope 711 726--*--Serum or plasma",
            "Measurement 779 795--*--Hemoglobin level",
            "Value 799 818--*--7.0 g/dL or greater",
            "Measurement 820 834--*--Platelet count",
            "Value 838 860--*--100,000/mm3 or greater",
            "Person 866 871--*--women",
            "Observation 875 897--*--childbearing potential",
            "Value 901 909--*--negative",
            "Measurement 910 924--*--pregnancy test",
            "Scope 866 897--*--women of childbearing potential",
            "Temporal 937 953--*--during screening",
            "Reference_point 944 953--*--screening",
            "Observation 964 988--*--written informed consent",
            "Observation 1006 1050--*--ability to attend scheduled follow-up visits",
            "Observation 1006 1016;1055 1080--*--ability to undergo study assessments",
            "Observation 1014 1050;990 1001--*--to attend scheduled follow-up visits Willingness",
            "Observation 1014 1016;1055 1080;990 1001--*--to undergo study assessments Willingness"
        ],
        "Text": "Newly diagnosed and untreated sputum smear positive tuberculosis patient. Pulmonary lesion consistent with TB by radiological examination. Positive sputum culture, identification of bacterial type confirmed Mycobacterium tuberculosis. MGIT drug sensitivity test (DST) results are sensitive of the first-line drugs (isoniazid, streptomycin, rifampicin and ethambutol).. Age 18 years-65 years old. Males or non-pregnant, non-nursing females. Serum or plasma aminotransferases (AST, ALT) less than 3 times the upper limit of normal. Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal. Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal. Serum or plasma potassium level greater than or equal to 3.5 meq/L. Hemoglobin level of 7.0 g/dL or greater. Platelet count of 100,000/mm3 or greater. For women of childbearing potential, a negative pregnancy test is required during screening. Provides written informed consent. Willingness and ability to attend scheduled follow-up visits and undergo study assessments.. "
    },
    "NCT03123562_exc": {
        "Annotations": [
            "Condition 0 8--*--Epilepsy",
            "Condition 10 23--*--Hydrocephalus",
            "Device 29 46--*--ventricular drain",
            "Condition 48 69--*--Coagulation disorders",
            "Condition 71 78--*--Allergy",
            "Drug 82 99--*--anesthetic agents",
            "Condition 101 125--*--Severe health conditions",
            "Undefined_semantics 101 125--*--Severe health conditions",
            "Subjective_judgement 101 125--*--Severe health conditions",
            "Condition 134 140--*--cancer",
            "Condition 142 158--*--failure of heart",
            "Condition 142 152;160 164--*--failure of lung",
            "Condition 142 152;166 171--*--failure of liver",
            "Condition 142 152;175 181--*--failure of kidney",
            "Scope 134 181--*--cancer, failure of heart, lung, liver or kidney",
            "Condition 190 200--*--infections",
            "Undefined_semantics 190 200--*--infections",
            "Temporal 183 189--*--Active"
        ],
        "Text": "Epilepsy . Hydrocephalus with ventricular drain . Coagulation disorders . Allergy to anesthetic agents . Severe health conditions such as cancer, failure of heart, lung, liver or kidney . Active infections       .     . "
    },
    "NCT00445029_inc": {
        "Annotations": [
            "Person 27 31--*--aged",
            "Value 32 55--*--from 18 to 65 years old",
            "Person 92 98--*--Female",
            "Procedure 123 143--*--contraceptive method",
            "Condition 435 462--*--allergic contact dermatitis",
            "Drug 466 493--*--para-phenylenediamine (PPD)",
            "Condition 520 538--*--contact dermatitis",
            "Drug 516 519--*--PPD",
            "Measurement 552 567--*--PPD patch tests",
            "Value 543 551--*--positive",
            "Scope 516 567--*--PPD contact dermatitis and positive PPD patch tests",
            "Condition 625 652--*--allergic contact dermatitis",
            "Drug 621 624--*--PPD",
            "Negation 607 609--*--No",
            "Measurement 670 684--*--PPD patch test",
            "Value 661 669--*--negative",
            "Scope 661 684--*--negative PPD patch test",
            "Condition 402 410--*--allergic",
            "Observation 587 594--*--healthy",
            "Mood 146 160--*--Feasibility of",
            "Post-eligibility 161 174--*--patch testing",
            "Person 58 70--*--Both genders",
            "Mood 195 205--*--be able to",
            "Informed_consent 206 246--*--understand and sign the Informed Consent",
            "Informed_consent 252 291--*--comply with all aspects of the protocol",
            "Scope 206 291--*--understand and sign the Informed Consent, and comply with all aspects of the protocol",
            "Observation 311 349--*--registered in a social security system",
            "Observation 360 385--*--health insurance coverage",
            "Non-query-able 360 385--*--health insurance coverage",
            "Non-query-able 311 349--*--registered in a social security system"
        ],
        "Text": "For both groups: . Patients aged from 18 to 65 years old. . Both genders eligible for study. . Female participants must use a contraceptive method. . Feasibility of patch testing. . Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol. . Patients must be registered in a social security system or with a health insurance coverage . \uf0d8 First group: allergic patients . Patients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests. . \uf0d8 Second group : healthy volunteers . No history of PPD allergic contact dermatitis, with a negative PPD patch test. . "
    },
    "NCT02201316_exc": {
        "Text": "Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). . History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter [mL]) of beer, 1 glass (100 mL) of wine or 1 (25 mL) measure of spirits. . History of sensitivity to heparin or heparin-induced thrombocytopenia. . History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. . Gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational product. . A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening . Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. . A positive pre-study drug/alcohol screen. . A positive test for Human Immunodeficiency Virus (HIV) antibody. . Pregnant females as determined by positive serum hCG test at screening or prior to dosing. . Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period. . Lactating females. . The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). . Exposure to more than four new chemical entities within 12 months prior to the first dosing day.       .     . ",
        "Annotations": [
            "Temporal 0 7--*--Current",
            "Temporal 11 18--*--chronic",
            "Observation 19 26--*--history",
            "Condition 30 43--*--liver disease",
            "Scope 0 18--*--Current or chronic",
            "Condition 65 86--*--biliary abnormalities",
            "Condition 54 61;73 86--*--hepatic abnormalities",
            "Condition 110 128--*--Gilbert's syndrome",
            "Negation 97 106--*--exception",
            "Condition 145 155--*--gallstones",
            "Qualifier 132 144--*--asymptomatic",
            "Scope 88 156--*--with the exception of Gilbert's syndrome or asymptomatic gallstones)",
            "Scope 30 86--*--liver disease, or known hepatic or biliary abnormalities",
            "Condition 170 197--*--regular alcohol consumption",
            "Observation 159 166--*--History",
            "Temporal 198 226--*--within 6 months of the study",
            "Reference_point 217 226--*--the study",
            "Measurement 242 263--*--average weekly intake",
            "Value 267 276--*-->21 units",
            "Person 281 286--*--males",
            "Value 290 299--*-->14 units",
            "Person 304 311--*--females",
            "Scope 267 311--*-->21 units for males or >14 units for females",
            "Parsing_Error 313 472--*--One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter [mL]) of beer, 1 glass (100 mL) of wine or 1 (25 mL) measure of spirits.",
            "Condition 485 507--*--sensitivity to heparin",
            "Drug 500 507--*--heparin",
            "Condition 511 543--*--heparin-induced thrombocytopenia",
            "Qualifier 511 526--*--heparin-induced",
            "Drug 511 518--*--heparin",
            "Drug 583 600--*--study medications",
            "Context_Error 583 600--*--study medications",
            "Condition 557 600--*--sensitivity to any of the study medications",
            "Context_Error 557 600--*--sensitivity to any of the study medications",
            "Observation 546 553--*--History",
            "Condition 640 644;654 661--*--drug allergy",
            "Condition 654 661--*--allergy",
            "Subjective_judgement 668 725--*--in the opinion of the investigator or GSK Medical Monitor",
            "Undefined_semantics 727 762--*--contraindicates their participation",
            "Subjective_judgement 727 762--*--contraindicates their participation",
            "Condition 765 789--*--Gastrointestinal disease",
            "Observation 798 831--*--gastrointestinal surgical history",
            "Procedure 798 823--*--gastrointestinal surgical",
            "Qualifier 842 894--*--affect the absorption of the investigational product",
            "Context_Error 842 894--*--affect the absorption of the investigational product",
            "Undefined_semantics 842 894--*--affect the absorption of the investigational product",
            "Measurement 918 945--*--Hepatitis B surface antigen",
            "Value 899 907--*--positive",
            "Temporal 908 917--*--pre-study",
            "Measurement 958 978--*--Hepatitis C antibody",
            "Value 949 957--*--positive",
            "Temporal 986 1014--*--within 3 months of screening",
            "Reference_point 1005 1014--*--screening",
            "Scope 899 978--*--positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody",
            "Grammar_Error 1024 1032--*--cotinine",
            "Measurement 1016 1039--*--Urinary cotinine levels",
            "Condition 1054 1061--*--smoking",
            "Condition 1076 1098--*--regular use of tobacco",
            "Observation 1065 1072--*--history",
            "Condition 1076 1090;1103 1131--*--regular use of nicotine-containing products",
            "Temporal 1132 1166--*--within 6 months prior to screening",
            "Reference_point 1157 1166--*--screening",
            "Scope 1016 1131--*--Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products",
            "Temporal 1180 1189--*--pre-study",
            "Measurement 1190 1194;1203 1209--*--drug screen",
            "Measurement 1195 1209--*--alcohol screen",
            "Scope 1190 1209--*--drug/alcohol screen",
            "Value 1171 1179--*--positive",
            "Measurement 1232 1275--*--Human Immunodeficiency Virus (HIV) antibody",
            "Value 1214 1222--*--positive",
            "Condition 1278 1286--*--Pregnant",
            "Person 1287 1294--*--females",
            "Measurement 1321 1335--*--serum hCG test",
            "Value 1312 1320--*--positive",
            "Temporal 1336 1348--*--at screening",
            "Temporal 1352 1367--*--prior to dosing",
            "Reference_point 1339 1348--*--screening",
            "Reference_point 1361 1367--*--dosing",
            "Scope 1336 1367--*--at screening or prior to dosing",
            "Non-query-able 1370 1498--*--Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.",
            "Undefined_semantics 1370 1498--*--Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.",
            "Context_Error 1370 1498--*--Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.",
            "Person 1510 1517--*--females",
            "Condition 1500 1509--*--Lactating",
            "Undefined_semantics 1520 1820--*--The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",
            "Post-eligibility 1520 1820--*--The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",
            "Multiplier 1834 1848--*--more than four",
            "Drug 1849 1870--*--new chemical entities",
            "Undefined_semantics 1849 1870--*--new chemical entities",
            "Temporal 1871 1917--*--within 12 months prior to the first dosing day",
            "Reference_point 1897 1917--*--the first dosing day"
        ]
    },
    "NCT03460002_exc": {
        "Annotations": [
            "Measurement 14 25--*--temperature",
            "Value 26 34--*--> 39.0\u25e6C",
            "Person 4 9--*--child",
            "Qualifier 40 46--*--severe",
            "Condition 47 60--*--acute illness",
            "Qualifier 61 94--*--as defined by the examining nurse",
            "Person 100 105--*--child",
            "Measurement 115 142--*--mid upper arm circumference",
            "Value 143 151--*--< 110 mm",
            "Value 156 178--*--is older than 6 months",
            "Person 159 162--*--old",
            "Non-representable 179 256--*--(most feasible local indicator of AIDS and chronic immunosuppressive disease)",
            "Person 262 267--*--child",
            "Condition 286 310--*--severe allergic reaction",
            "Temporal 311 351--*--after previous vaccination, drug or food",
            "Reference_point 317 351--*--previous vaccination, drug or food",
            "Procedure 326 337--*--vaccination",
            "Procedure 339 343--*--drug",
            "Procedure 347 351--*--food",
            "Scope 326 351--*--vaccination, drug or food",
            "Temporal 317 325--*--previous",
            "Competing_trial 354 453--*--the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old",
            "Observation 463 478--*--RECAMP-MV trial",
            "Observation 493 515--*--enrolled in RECAMP-OPV"
        ],
        "Text": "the child has temperature > 39.0\u25e6C or a severe acute illness as defined by the examining nurse. the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease). the child has experienced a severe allergic reaction after previous vaccination, drug or food.. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old. For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV. "
    },
    "NCT02707874_exc": {
        "Text": "Patients who undergo iliac crest bone graft harvesting as part of their surgery. Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve. Local infection. Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy. Chronic pain disorders. History of use of over 30mg oxycodone or equivalent per day. Allergy to local anesthetics. History of significant psychiatric conditions that may affect patient assessment. Pregnancy. Inability to provide informed consent. ",
        "Annotations": [
            "Procedure 21 54--*--iliac crest bone graft harvesting",
            "Condition 93 114--*--neurological deficits",
            "Condition 118 139--*--peripheral neuropathy",
            "Qualifier 167 180--*--sciatic nerve",
            "Scope 93 139--*--neurological deficits or peripheral neuropathy",
            "Condition 182 197--*--Local infection",
            "Condition 199 215--*--Contraindication",
            "Procedure 219 238--*--regional anesthesia",
            "Condition 244 262--*--bleeding diathesis",
            "Condition 264 276--*--coagulopathy",
            "Scope 244 276--*--bleeding diathesis, coagulopathy",
            "Condition 278 290--*--Chronic pain",
            "Multiplier 320 329;354 361--*--over 30mg per day",
            "Drug 330 339--*--oxycodone",
            "Drug 330 339;343 353--*--oxycodone equivalent",
            "Scope 330 353--*--oxycodone or equivalent",
            "Procedure 374 391--*--local anesthetics",
            "Condition 363 370--*--Allergy",
            "Non-query-able 393 473--*--History of significant psychiatric conditions that may affect patient assessment",
            "Condition 475 484--*--Pregnancy",
            "Informed_consent 486 523--*--Inability to provide informed consent"
        ]
    },
    "NCT02822001_inc": {
        "Text": "Patients undergoing surgery with general anesthesia,. Patients weighing = 80 pounds who are not -intubated prior to surgery,. Patients who are able to give informed consent.. ",
        "Annotations": [
            "Procedure 20 27--*--surgery",
            "Temporal 9 19--*--undergoing",
            "Qualifier 33 51--*--general anesthesia",
            "Procedure 33 51--*--general anesthesia",
            "Measurement 63 71--*--weighing",
            "Value 72 83--*--= 80 pounds",
            "Negation 92 95--*--not",
            "Procedure 97 106--*--intubated",
            "Temporal 107 123--*--prior to surgery",
            "Reference_point 116 123--*--surgery",
            "Procedure 116 123--*--surgery",
            "Informed_consent 126 172--*--Patients who are able to give informed consent"
        ]
    },
    "NCT02208739_inc": {
        "Annotations": [
            "Condition 83 104--*--Chronic periodontitis",
            "Qualifier 74 82--*--Advanced",
            "Qualifier 62 70--*--Moderate",
            "Scope 62 82--*--Moderate to Advanced",
            "Condition 33 46--*--teeth present",
            "Multiplier 21 32--*--at least 12",
            "Multiplier 120 129--*--2 or more",
            "Condition 130 149;170 211--*--interproximal sites with probing pocket depths of 5mm or more",
            "Value 200 211--*--5mm or more",
            "Multiplier 216 225--*--2 or more",
            "Condition 226 245;265 306--*--interproximal sites of probing attachment loss of 4mm or more",
            "Value 295 306--*--4mm or more",
            "Qualifier 313 328--*--bled on probing",
            "Procedure 321 328--*--probing"
        ],
        "Text": "Patients should have at least 12 teeth present . Patients with Moderate to Advanced Chronic periodontitis . Patients with 2 or more interproximal sites (not on same tooth) with probing pocket depths of 5mm or more and 2 or more interproximal sites (not on same tooth)of probing attachment loss of 4mm or more which bled on probing. . "
    },
    "NCT02760251_exc": {
        "Text": "Adults older than 45 and children younger than 18 years. Platelet count higher than 30x109/l at time of screening. Suspicion of secondary ITP. Positive family history for ITP. Presence or history of autoimmune disease as judged by the investigator. Hepatosplenomegaly. Presence or history of relevant hepatic disease as judged by the investigator. Presence or history of thromboembolic disease as judged by the investigator. Patients with splenectomy. Women who are pregnant or breast feeding. Intention to become pregnant during the course of the study. Lack of safe double contraception (see 7.1). Any vaccination 2 weeks prior start of the study. Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center. Known or suspected non-compliance, drug or alcohol abuse. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject. Participation in another study with investigational drug within the 30 days preceding and during the present study. Previous enrolment into the current study. Previous treatment with romiplostim or eltrombopag. Hypersensitivity to the active substance or to any of the excipients or to E. coli derived proteins. Enrolment of the investigator, his/her family members, employees and other dependent persons. ",
        "Annotations": [
            "Person 0 6--*--Adults",
            "Value 7 20--*--older than 45",
            "Person 25 33--*--children",
            "Value 34 55--*--younger than 18 years",
            "Measurement 57 71--*--Platelet count",
            "Value 72 92--*--higher than 30x109/l",
            "Temporal 93 113--*--at time of screening",
            "Reference_point 104 113--*--screening",
            "Condition 128 141--*--secondary ITP",
            "Observation 152 174--*--family history for ITP",
            "Parsing_Error 143 151--*--Positive",
            "Condition 199 217--*--autoimmune disease",
            "Parsing_Error 176 195--*--Presence or history",
            "Subjective_judgement 218 247--*--as judged by the investigator",
            "Subjective_judgement 317 346--*--as judged by the investigator",
            "Subjective_judgement 394 423--*--as judged by the investigator",
            "Condition 301 316--*--hepatic disease",
            "Qualifier 292 300--*--relevant",
            "Parsing_Error 269 288--*--Presence or history",
            "Parsing_Error 348 367--*--Presence or history",
            "Condition 371 393--*--thromboembolic disease",
            "Procedure 439 450--*--splenectomy",
            "Pregnancy_considerations 452 492--*--Women who are pregnant or breast feeding",
            "Pregnancy_considerations 494 553--*--Intention to become pregnant during the course of the study",
            "Pregnancy_considerations 555 598--*--Lack of safe double contraception (see 7.1)",
            "Procedure 604 615--*--vaccination",
            "Temporal 616 648--*--2 weeks prior start of the study",
            "Reference_point 630 648--*--start of the study",
            "Subjective_judgement 650 809--*--Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center",
            "Condition 854 867--*--alcohol abuse",
            "Condition 846 850;862 867--*--drug abuse",
            "Qualifier 830 844--*--non-compliance",
            "Scope 846 867--*--drug or alcohol abuse",
            "Post-eligibility 869 1003--*--Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject",
            "Non-query-able 1005 1119--*--Participation in another study with investigational drug within the 30 days preceding and during the present study",
            "Non-query-able 1121 1162--*--Previous enrolment into the current study",
            "Drug 1188 1199--*--romiplostim",
            "Drug 1203 1214--*--eltrombopag",
            "Condition 1216 1232--*--Hypersensitivity",
            "Non-query-able 1317 1409--*--Enrolment of the investigator, his/her family members, employees and other dependent persons",
            "Non-query-able 1233 1315--*--to the active substance or to any of the excipients or to E. coli derived proteins",
            "Condition 249 267--*--Hepatosplenomegaly"
        ]
    },
    "NCT01218737_exc": {
        "Annotations": [
            "Procedure 0 7--*--Surgery",
            "Condition 24 40--*--ocular pathology",
            "Temporal 15 23--*--previous",
            "Condition 54 58--*--scar",
            "Observation 59 79--*--change in the cornea",
            "Condition 81 89--*--glaucoma",
            "Condition 91 104--*--retinopathies",
            "Scope 54 104--*--scar/change in the cornea, glaucoma, retinopathies",
            "Condition 126 134--*--diabetes",
            "Condition 141 156--*--immunodepressed",
            "Condition 172 181--*--infection",
            "Qualifier 163 171--*--systemic",
            "Temporal 182 198--*--during the study",
            "Reference_point 189 198--*--the study",
            "Condition 226 245--*--ocular inflammation",
            "Condition 226 232;246 255--*--ocular infection",
            "Qualifier 257 266;350 358--*--bacterial etiology",
            "Qualifier 268 273;350 358--*--viral etiology",
            "Qualifier 275 281;350 358--*--fungal etiology",
            "Observation 293 302--*--Chlamydia",
            "Observation 307 320--*--Mycobacterium",
            "Observation 322 334--*--Acanthamoeba",
            "Condition 341 358--*--allergic etiology",
            "Qualifier 283 302--*--caused by Chlamydia",
            "Qualifier 283 289;304 320--*--caused by Mycobacterium",
            "Qualifier 283 292;322 334--*--caused by Acanthamoeba",
            "Scope 257 358--*--bacterial, viral, fungal, caused by Chlamydia, by Mycobacterium, Acanthamoeba or of allergic etiology",
            "Scope 226 255--*--ocular inflammation/infection",
            "Drug 388 407--*--topical antibiotics",
            "Qualifier 388 395--*--topical",
            "Drug 376 384;396 407--*--systemic antibiotics",
            "Qualifier 376 384--*--systemic",
            "Condition 412 428--*--ocular infection",
            "Temporal 429 452--*--in the previous 14 days",
            "Scope 376 407--*--systemic or topical antibiotics",
            "Condition 473 489--*--hypersensitivity",
            "Qualifier 504 534--*--components of the formulations"
        ],
        "Text": "Surgery and/or previous ocular pathology (presence of scar/change in the cornea, glaucoma, retinopathies, etc.). . Patient has diabetes or is immunodepressed. . Any systemic infection during the study. . Signs and/or symptoms of ocular inflammation/infection (bacterial, viral, fungal, caused by Chlamydia, by Mycobacterium, Acanthamoeba or of allergic etiology). . Have used any systemic or topical antibiotics for ocular infection in the previous 14 days. . Patient has known hypersensitivity to any of the components of the formulations used in the study.       .     . "
    },
    "NCT03117608_exc": {
        "Annotations": [
            "Observation 9 35--*--incapable to understanding",
            "Observation 40 44;9 21--*--will incapable to",
            "Temporal 73 81--*--previous",
            "Observation 102 108;56 72--*--trials participating in",
            "Qualifier 110 117--*--ongoing",
            "Qualifier 121 130--*--completed",
            "Temporal 131 150--*--within three months",
            "Scope 110 150--*--ongoing or completed within three months",
            "Procedure 163 181--*--surgically treated",
            "Condition 186 201--*--the same defect",
            "Temporal 202 217--*--within one year",
            "Condition 241 251--*--malignancy",
            "Condition 275 284;296 305--*--metabolic disorders",
            "Condition 288 305--*--thyroid disorders",
            "Condition 325 332;354 359--*--alcohol abuse",
            "Condition 336 340;354 359--*--drug abuse",
            "Condition 342 352;354 359--*--medication abuse",
            "Condition 383 392--*--synovitis",
            "Condition 404 423--*--valgus misalignment",
            "Condition 395 400;411 423--*--Varus misalignment",
            "Measurement 404 423--*--valgus misalignment",
            "Measurement 395 400;411 423--*--Varus misalignment",
            "Value 424 437--*--exceeding 15\u00b0",
            "Measurement 440 455--*--Body Mass Index",
            "Value 456 460--*--> 40",
            "Procedure 477 483--*--trauma",
            "Temporal 484 513--*--within 6 months pre-operative",
            "Reference_point 500 513--*--pre-operative",
            "Procedure 504 513--*--operative"
        ],
        "Text": "Patients incapable to understanding and will;. Patients participating in previous, concurrent or not, trials (ongoing or completed within three months);. Patients surgically treated for the same defect within one year;. Patients affected by malignancy;. Patients affected by metabolic or thyroid disorders;. Patients used to alcohol or drug (medication) abuse;. Patients affected by synovitis;. Varus or valgus misalignment exceeding 15\u00b0;. Body Mass Index > 40;. Patients with trauma within 6 months pre-operative.. "
    },
    "NCT00397215_inc": {
        "Annotations": [
            "Person 158 162--*--aged",
            "Value 163 180--*--61 years or above",
            "Condition 273 280--*--Healthy",
            "Condition 323 341--*--underlying disease",
            "Qualifier 307 322--*--well controlled",
            "Person 151 157--*--female",
            "Person 143 147--*--male",
            "Observation 220 244--*--Written informed consent",
            "Observation 49 106--*--can and will comply with the requirements of the protocol"
        ],
        "Text": "Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. . A male or female aged 61 years or above at the time of the first vaccination. . Written informed consent obtained from the subject. . Healthy subjects or subjects with well controlled underlying disease. . "
    },
    "NCT03077204_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT03123562_inc": {
        "Annotations": [
            "Condition 38 55--*--Neonatal Jaundice",
            "Condition 0 14--*--Cerebral palsy"
        ],
        "Text": "Cerebral palsy of any types caused by Neonatal Jaundice . "
    },
    "NCT03561753_exc": {
        "Annotations": [
            "Condition 0 12--*--Tuberculosis",
            "Qualifier 13 25--*--resistant to",
            "Drug 37 48--*--study drugs",
            "Drug 50 59--*--isoniazid",
            "Drug 61 69--*--rifampin",
            "Drug 71 74--*--EMB",
            "Drug 76 79--*--PZA",
            "Drug 81 84--*--CFZ",
            "Drug 86 89--*--Pto",
            "Scope 50 89--*--isoniazid, rifampin, EMB, PZA, CFZ, Pto",
            "Observation 92 123--*--Unable to take oral medications",
            "Condition 137 144--*--allergy",
            "Observation 126 133--*--History",
            "Condition 148 159--*--intolerance",
            "Drug 174 185--*--study drugs",
            "Scope 137 159--*--allergy or intolerance",
            "Measurement 187 209--*--Serum aminotransferase",
            "Measurement 211 214--*--AST",
            "Measurement 218 221--*--ALT",
            "Scope 211 221--*--AST or ALT",
            "Scope 187 222--*--Serum aminotransferase (AST or ALT)",
            "Value 223 257--*--3x upper limit of normal or higher",
            "Condition 259 267--*--Pregnant",
            "Observation 271 278--*--nursing",
            "Person 279 286--*--females",
            "Mood 291 298--*--plan to",
            "Observation 299 314--*--become pregnant",
            "Observation 318 323--*--nurse",
            "Temporal 324 347--*--during the study period",
            "Scope 299 323--*--become pregnant or nurse",
            "Person 349 354--*--Males",
            "Mood 355 366--*--planning to",
            "Observation 367 383--*--conceive a child",
            "Temporal 384 400--*--during the study",
            "Temporal 404 445--*--within 6 months of cessation of treatment",
            "Reference_point 423 445--*--cessation of treatment",
            "Reference_point 391 400--*--the study",
            "Scope 384 445--*--during the study or within 6 months of cessation of treatment",
            "Qualifier 479 485--*--active",
            "Condition 486 498--*--tuberculosis",
            "Temporal 499 550--*--within 6 months preceding initiation of study drugs",
            "Procedure 452 461--*--treatment",
            "Condition 577 589--*--tuberculosis",
            "Qualifier 604 626--*--central nervous system",
            "Qualifier 634 639--*--bones",
            "Qualifier 647 653--*--joints",
            "Qualifier 662 682--*--miliary tuberculosis",
            "Qualifier 690 714--*--pericardial tuberculosis",
            "Scope 604 714--*--central nervous system and/or bones and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis",
            "Mood 566 576--*--documented",
            "Mood 553 562--*--Suspected",
            "Scope 553 576--*--Suspected or documented",
            "Condition 717 729--*--HIV infected",
            "Condition 731 743--*--HBV infected",
            "Condition 747 759--*--HCV infected",
            "Non-representable 760 819--*--(these increase the risk of TB-drug induced hepatotoxicity)",
            "Measurement 821 827--*--Weight",
            "Value 828 845--*--less than 40.0 kg",
            "Condition 854 861--*--allergy",
            "Condition 865 876--*--intolerance",
            "Drug 891 908--*--study medications",
            "Scope 854 876--*--allergy or intolerance",
            "Condition 993 1016--*--M. tuberculosis isolate",
            "Qualifier 1040 1075--*--resistant to any of the study drugs",
            "Drug 1064 1075--*--study drugs",
            "Measurement 1078 1082--*--QTcF",
            "Value 1083 1093--*--> 500 msec",
            "Non-query-able 1095 1222--*--Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.",
            "Temporal 1224 1231--*--Current",
            "Mood 1235 1242--*--planned",
            "Observation 1243 1256--*--incarceration",
            "Observation 1266 1287--*--involuntary detention",
            "Scope 1243 1287--*--incarceration or other involuntary detention",
            "Scope 1224 1242--*--Current or planned",
            "Observation 1296 1334--*--participated in other clinical studies",
            "Drug 1350 1372--*--investigational agents",
            "Temporal 1373 1408--*--within 8 weeks prior to trial start",
            "Temporal 1412 1421--*--currently",
            "Observation 1422 1458--*--enrolled in an investigational study",
            "Reference_point 1397 1408--*--trial start",
            "Drug 1488 1504--*--medicinal agents",
            "Non-representable 1506 1665--*--Subjects who are participating in observational studies or who are in a follow up period of a trial that included drug therapy may be considered for inclusion."
        ],
        "Text": "Tuberculosis resistant to any of the study drugs (isoniazid, rifampin, EMB, PZA, CFZ, Pto). Unable to take oral medications.. History of allergy or intolerance to any of the study drugs. Serum aminotransferase (AST or ALT) 3x upper limit of normal or higher. Pregnant or nursing females, or plan to become pregnant or nurse during the study period. Males planning to conceive a child during the study or within 6 months of cessation of treatment.. Any treatment directed against active tuberculosis within 6 months preceding initiation of study drugs.. Suspected or documented tuberculosis involving the central nervous system and/or bones and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis.. HIV infected. HBV infected or HCV infected (these increase the risk of TB-drug induced hepatotoxicity). Weight less than 40.0 kg.. Known allergy or intolerance to any of the study medications.. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any of the study drugs.. QTcF > 500 msec. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.. Current or planned incarceration or other involuntary detention. Having participated in other clinical studies with dosing of investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational study that includes treatment with medicinal agents. Subjects who are participating in observational studies or who are in a follow up period of a trial that included drug therapy may be considered for inclusion.. "
    },
    "NCT03460002_inc": {
        "Annotations": [
            "Person 0 8--*--Children",
            "Person 9 13--*--aged",
            "Value 14 25--*--0-59 months",
            "Observation 26 99--*--living with families registered in the rural Bandim Health Project Health",
            "Visit 104 133--*--Person Surveillance Site"
        ],
        "Text": "Children aged 0-59 months living with families registered in the rural Bandim Health Project Health and Demographic Surveillance Site are included, provided a parent/guardian consent.. "
    },
    "NCT02201316_inc": {
        "Text": "Male and females aged between 18 and 65 years of age inclusive, at the time of signing the informed consent. . Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. . Body weight >= 50 kilogram (kg) and body mass index within the range 19 - 24.9 kg/m^2 (inclusive). . A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, \"documented\" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle. . Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit. . Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form . Alanine aminotransferase, alkaline phosphatase and bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). . Based on single or averaged corrected QT interval (QTc) values of triplicate electrocardiograms obtained over a brief recording period: QTcF < 450 msec . ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 16--*--females",
            "Grammar_Error 5 8--*--and",
            "Person 17 21--*--aged",
            "Value 22 45--*--between 18 and 65 years",
            "Person 49 52--*--age",
            "Temporal 64 107--*--at the time of signing the informed consent",
            "Reference_point 79 107--*--signing the informed consent",
            "Condition 110 117--*--Healthy",
            "Qualifier 118 174--*--as determined by a responsible and experienced physician",
            "Subjective_judgement 118 174--*--as determined by a responsible and experienced physician",
            "Undefined_semantics 118 174--*--as determined by a responsible and experienced physician",
            "Procedure 187 205--*--medical evaluation",
            "Observation 216 231--*--medical history",
            "Procedure 233 253--*--physical examination",
            "Procedure 255 271--*--laboratory tests",
            "Procedure 276 294--*--cardiac monitoring",
            "Condition 313 333--*--clinical abnormality",
            "Context_Error 370 436--*--are not specifically listed in the inclusion or exclusion criteria",
            "Value 438 465--*--outside the reference range",
            "Measurement 337 357--*--laboratory parameter",
            "Undefined_semantics 337 357--*--laboratory parameter",
            "Context_Error 499 514--*--may be included",
            "Non-query-able 296 731--*--A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.",
            "Post-eligibility 296 728--*--A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedur",
            "Measurement 733 744--*--Body weight",
            "Value 745 764--*-->= 50 kilogram (kg)",
            "Measurement 769 784--*--body mass index",
            "Value 785 818--*--within the range 19 - 24.9 kg/m^2",
            "Condition 895 917--*--childbearing potential",
            "Negation 891 894--*--Non",
            "Condition 929 943--*--pre-menopausal",
            "Person 944 951--*--females",
            "Person 835 841--*--female",
            "Procedure 970 984--*--tubal ligation",
            "Procedure 988 1000--*--hysterectomy",
            "Condition 1247 1261--*--postmenopausal",
            "Temporal 1273 1282--*--12 months",
            "Condition 1286 1308--*--spontaneous amenorrhea",
            "Measurement 1365 1399--*--follicle stimulating hormone (FSH)",
            "Value 1400 1454--*--> 40 milli-international units per milliliter (MlU/mL)",
            "Measurement 1459 1468--*--estradiol",
            "Value 1469 1505--*--< 40 picograms per mililiter (pg/mL)",
            "Value 1507 1530--*--<147 picomole per liter",
            "Scope 1365 1530--*--follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter",
            "Scope 929 1000--*--pre-menopausal females with a documented tubal ligation or hysterectomy",
            "Scope 929 1548--*--pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, \"documented\" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory]",
            "Procedure 1561 1594--*--hormone replacement therapy (HRT)",
            "Person 1550 1557--*--Females",
            "Measurement 1605 1622--*--menopausal status",
            "Value 1626 1634--*--in doubt",
            "Not_a_criteria 1550 1744--*--Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study.",
            "Parsing_Error 1745 1856--*--Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.",
            "Not_a_criteria 1745 1856--*--Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.",
            "Parsing_Error 1550 1744--*--Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study.",
            "Parsing_Error 1857 2016--*--For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT.",
            "Not_a_criteria 1857 2016--*--For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT.",
            "Parsing_Error 2017 2553--*--Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point.",
            "Post-eligibility 2017 2553--*--Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point.",
            "Not_a_criteria 2554 2715--*--Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle.",
            "Non-query-able 2554 2715--*--Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle.",
            "Post-eligibility 2554 2715--*--Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle.",
            "Context_Error 2717 2849--*--Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol.",
            "Post-eligibility 2717 2849--*--Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol.",
            "Parsing_Error 2850 2968--*--This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit.",
            "Post-eligibility 2850 2968--*--This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit.",
            "Non-query-able 2970 3105--*--Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form",
            "Measurement 3107 3131--*--Alanine aminotransferase",
            "Measurement 3133 3153--*--alkaline phosphatase",
            "Measurement 3158 3167--*--bilirubin",
            "Scope 3107 3167--*--Alanine aminotransferase, alkaline phosphatase and bilirubin",
            "Value 3168 3202--*--<=1.5x upper limit of normal (ULN)",
            "Measurement 3213 3222--*--bilirubin",
            "Value 3223 3231--*-->1.5xULN",
            "Measurement 3279 3295--*--direct bilirubin",
            "Grammar_Error 3203 3301--*--(isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)",
            "Measurement 3440 3444--*--QTcF",
            "Value 3445 3455--*--< 450 msec",
            "Qualifier 3313 3319--*--single",
            "Qualifier 3323 3331--*--averaged",
            "Scope 3313 3331--*--single or averaged",
            "Measurement 3332 3359--*--corrected QT interval (QTc)",
            "Procedure 3381 3399--*--electrocardiograms",
            "Temporal 3409 3438--*--over a brief recording period"
        ]
    },
    "NCT00445029_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Condition 12 21--*--lactating",
            "Person 22 27--*--women",
            "Condition 30 52--*--Evolutive skin disease",
            "Qualifier 60 72--*--testing zone",
            "Qualifier 74 84--*--lower back",
            "Procedure 168 191--*--Systemic corticotherapy",
            "Procedure 195 222--*--immunosuppressive treatment",
            "Temporal 223 248--*--during the previous month",
            "Scope 168 222--*--Systemic corticotherapy or immunosuppressive treatment",
            "Procedure 253 278--*--local corticoid treatment",
            "Temporal 279 294--*--the week before",
            "Condition 386 401--*--Exposure to sun",
            "Condition 386 397;405 418--*--Exposure to UV radiations",
            "Temporal 420 452--*--15 days before the patch testing",
            "Scope 386 418--*--Exposure to sun or UV radiations",
            "Condition 464 494--*--deprived of their civic rights",
            "Condition 496 506--*--in custody",
            "Condition 511 532--*--subject to a tutorial",
            "Condition 511 523;534 543;562 570--*--subject to a judiciary decision",
            "Condition 511 521;547 570--*--subject to administrative decision",
            "Condition 630 656--*--critical medical situation",
            "Condition 582 613--*--subject to a protection measure",
            "Qualifier 104 126--*--clinically significant",
            "Condition 127 134--*--disease",
            "Qualifier 136 143--*--chronic",
            "Qualifier 145 154--*--recurrent",
            "Qualifier 158 164--*--active",
            "Scope 136 164--*--chronic, recurrent or active",
            "Qualifier 315 320--*--Local",
            "Qualifier 324 332--*--systemic",
            "Drug 333 337--*--drug",
            "Qualifier 348 383--*--interacts with the outcome measures",
            "Scope 315 332--*--Local or systemic",
            "Reference_point 435 452--*--the patch testing",
            "Observation 675 693--*--personal situation",
            "Non-representable 694 789--*--judged by the investigator as unlikely to be compatible with optimal participation in the study",
            "Non-query-able 800 839--*--could constitute a risk for the patient",
            "Scope 694 839--*--judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient",
            "Observation 842 860--*--Linguistic barrier",
            "Condition 864 885--*--psychological profile",
            "Negation 886 896--*--preventing",
            "Informed_consent 914 938--*--signing the consent form",
            "Scope 842 885--*--Linguistic barrier or psychological profile",
            "Competing_trial 992 1031--*--participation in another clinical trial",
            "Temporal 949 987--*--still in an exclusion period following",
            "Competing_trial 1092 1124--*--participation in clinical trials",
            "Temporal 1125 1154--*--during the previous 12 months",
            "Reference_point 1132 1154--*--the previous 12 months",
            "Observation 1050 1087--*--earned more than 4500\u20ac in indemnities",
            "Non-query-able 1050 1087--*--earned more than 4500\u20ac in indemnities"
        ],
        "Text": "Pregnant or lactating women. . Evolutive skin disease on the testing zone (lower back). . Patients with a clinically significant disease (chronic, recurrent or active). . Systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid treatment the week before the patch testing. . Local or systemic drug use which interacts with the outcome measures. . Exposure to sun or UV radiations, 15 days before the patch testing. . Patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision. . Patients subject to a protection measure. . Patients in a critical medical situation. . Patients with a personal situation judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient. . Linguistic barrier or psychological profile preventing the patient from signing the consent form. . Patient still in an exclusion period following the participation in another clinical trial. . Patients having earned more than 4500\u20ac in indemnities for participation in clinical trials during the previous 12 months, including this study.       .     . "
    },
    "NCT03118232_inc": {
        "Annotations": [
            "Visit 0 13--*--Nursing homes",
            "Visit 84 105--*--Licensed nursing home",
            "Visit 109 122--*--Orange County",
            "Visit 126 153--*--Southern Los Angeles County",
            "Qualifier 154 168--*--serving adults",
            "Scope 84 153--*--Licensed nursing home in Orange County or Southern Los Angeles County",
            "Procedure 185 206--*--chlorhexidine bathing",
            "Drug 185 198--*--chlorhexidine",
            "Multiplier 170 181--*--Minimal use",
            "Multiplier 209 220--*--Minimal use",
            "Procedure 224 244--*--nasal decolonization",
            "Multiplier 247 258--*--Minimal use",
            "Value 270 274--*--<15%",
            "Measurement 278 329--*--residents receiving at least one chlorhexidine bath",
            "Multiplier 298 310--*--at least one",
            "Procedure 311 329--*--chlorhexidine bath",
            "Drug 311 324--*--chlorhexidine",
            "Scope 270 329--*--<15% of residents receiving at least one chlorhexidine bath",
            "Procedure 333 363--*--nasal decolonization treatment",
            "Temporal 364 394--*--during their nursing home stay",
            "Scope 333 394--*--nasal decolonization treatment during their nursing home stay",
            "Scope 270 394--*--<15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay"
        ],
        "Text": "Nursing homes will be eligible to participate if they meet the following criteria:. Licensed nursing home in Orange County or Southern Los Angeles County serving adults. Minimal use of chlorhexidine bathing*. Minimal use of nasal decolonization* *Minimal use defined as <15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay.. "
    },
    "NCT01078051_exc": {
        "Annotations": [
            "Not_a_criteria 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT02360631_exc": {
        "Text": "Renal impairment. Evidence or history of clinically significant allergic reactions to varenicline. A cardiovascular event in the past month. History of alcohol or drug dependence in the past year. Major depressive disorder in the last year requiring treatment. History of panic disorder, psychosis, bipolar disorder, or eating disorders. Use of tobacco products other than cigarettes in past 30 days. Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline. Pregnant, contemplating getting pregnant, or breastfeeding. Plans to move from Kansas City during the treatment and follow-up phase. Another household member enrolled in the study. Evidence of current severe major depressive disorder or suicidal ideation. ",
        "Annotations": [
            "Condition 0 16--*--Renal impairment",
            "Condition 64 72--*--allergic",
            "Drug 86 97--*--varenicline",
            "Condition 101 121--*--cardiovascular event",
            "Temporal 122 139--*--in the past month",
            "Condition 163 178--*--drug dependence",
            "Condition 152 159;168 178--*--alcohol dependence",
            "Scope 152 178--*--alcohol or drug dependence",
            "Temporal 182 195--*--the past year",
            "Condition 197 222--*--Major depressive disorder",
            "Temporal 230 239--*--last year",
            "Procedure 250 259--*--treatment",
            "Condition 272 286--*--panic disorder",
            "Condition 288 297--*--psychosis",
            "Condition 299 315--*--bipolar disorder",
            "Condition 320 336--*--eating disorders",
            "Observation 338 352--*--Use of tobacco",
            "Negation 362 372--*--other than",
            "Observation 373 383--*--cigarettes",
            "Temporal 387 399--*--past 30 days",
            "Procedure 408 423--*--pharmacotherapy",
            "Temporal 431 456--*--month prior to enrollment",
            "Reference_point 446 456--*--enrollment",
            "Pregnancy_considerations 494 552--*--Pregnant, contemplating getting pregnant, or breastfeeding",
            "Non-query-able 554 625--*--Plans to move from Kansas City during the treatment and follow-up phase",
            "Non-query-able 627 673--*--Another household member enrolled in the study",
            "Condition 702 727--*--major depressive disorder",
            "Qualifier 695 701--*--severe",
            "Condition 731 748--*--suicidal ideation"
        ]
    },
    "NCT03192020_exc": {
        "Text": "recurrent contracture in the finger to be treated. neurologic condition causing the loss of function of the finger to be treated. contraindication for collagenase clostridium histolyticym (Xiapex/Xiaflex \u00ae). pregnant or breast feeding. TPED > 135\u00b0 (Tubiana stage 4) in finger to be treated. rheumatoid arthritis. previous fracture in finger to be treated, which affects range of motion of MP or PIP joint. age > 80 years. ",
        "Annotations": [
            "Condition 10 21--*--contracture",
            "Qualifier 29 49--*--finger to be treated",
            "Qualifier 0 9--*--recurrent",
            "Condition 51 71--*--neurologic condition",
            "Condition 84 100--*--loss of function",
            "Qualifier 108 128--*--finger to be treated",
            "Condition 130 146--*--contraindication",
            "Drug 151 187--*--collagenase clostridium histolyticym",
            "Drug 189 195--*--Xiapex",
            "Drug 196 203--*--Xiaflex",
            "Scope 189 203--*--Xiapex/Xiaflex",
            "Condition 208 216--*--pregnant",
            "Observation 220 234--*--breast feeding",
            "Measurement 236 240--*--TPED",
            "Value 241 247--*--> 135\u00b0",
            "Measurement 249 256--*--Tubiana",
            "Value 257 264--*--stage 4",
            "Scope 236 247--*--TPED > 135\u00b0",
            "Scope 249 264--*--Tubiana stage 4",
            "Qualifier 269 289--*--finger to be treated",
            "Condition 291 311--*--rheumatoid arthritis",
            "Qualifier 334 354--*--finger to be treated",
            "Condition 322 330--*--fracture",
            "Temporal 313 321--*--previous",
            "Condition 362 385--*--affects range of motion",
            "Qualifier 389 391;399 404--*--MP joint",
            "Qualifier 395 404--*--PIP joint",
            "Scope 389 404--*--MP or PIP joint",
            "Person 406 409--*--age",
            "Value 410 420--*--> 80 years"
        ]
    },
    "NCT02254668_exc": {
        "Text": "Renal insufficiency (> 265 \u00b5mol/l). Incapability to give informed consent. Cardiogenic shock of patient with KILLIP III or IV. pregnant or breast feeding females. insufficient contraception (only for substudy 3). ",
        "Annotations": [
            "Condition 0 19--*--Renal insufficiency",
            "Informed_consent 36 73--*--Incapability to give informed consent",
            "Condition 75 92--*--Cardiogenic shock",
            "Measurement 109 115--*--KILLIP",
            "Value 116 125--*--III or IV",
            "Condition 127 135--*--pregnant",
            "Observation 139 153--*--breast feeding",
            "Person 154 161--*--females",
            "Qualifier 163 175--*--insufficient",
            "Procedure 176 189--*--contraception",
            "Non-representable 20 34--*--(> 265 \u00b5mol/l)"
        ]
    },
    "NCT03225469_exc": {
        "Text": "1. History of colorectal surgery . 2. Suspected or known digestive tract obstruction, stricture, or perforation . 3. Serious status of illness, such as severe renal failure whose creatinine clearance<30 ml/min, New York Heart Association grade III or grade IV congestive heart failure, or hemodynamic instability, etc. . 4. Incapable of completing bowel preparation\uff0csuch as dysphagia, allergy to purgatives, or impaired mental status, etc. . 5. Pregnancy or breastfeeding . 6. Incomplete colonoscopy due to causes except poor bowel preparation . 7. Unable to give informed consent . 8. Have participated in the study before.       .     . ",
        "Annotations": [
            "Procedure 14 32--*--colorectal surgery",
            "Observation 3 10--*--History",
            "Condition 56 83--*--digestive tract obstruction",
            "Condition 56 71;85 94--*--digestive tract stricture",
            "Condition 56 71;99 110--*--digestive tract perforation",
            "Parsing_Error 34 36--*--2.",
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 112 114--*--3.",
            "Condition 157 170--*--renal failure",
            "Measurement 177 197--*--creatinine clearance",
            "Value 197 207--*--<30 ml/min",
            "Qualifier 150 156--*--severe",
            "Measurement 209 235--*--New York Heart Association",
            "Value 236 257--*--grade III or grade IV",
            "Condition 258 282--*--congestive heart failure",
            "Condition 287 310--*--hemodynamic instability",
            "Undefined_semantics 115 140--*--Serious status of illness",
            "Subjective_judgement 115 140--*--Serious status of illness",
            "Scope 150 310--*--severe renal failure whose creatinine clearance<30 ml/min, New York Heart Association grade III or grade IV congestive heart failure, or hemodynamic instability",
            "Condition 115 140--*--Serious status of illness",
            "Parsing_Error 318 320--*--4.",
            "Condition 321 362--*--Incapable of completing bowel preparation",
            "Condition 371 380--*--dysphagia",
            "Condition 382 389--*--allergy",
            "Drug 393 403--*--purgatives",
            "Condition 408 430--*--impaired mental status",
            "Scope 371 430--*--dysphagia, allergy to purgatives, or impaired mental status",
            "Parsing_Error 438 440--*--5.",
            "Condition 441 450--*--Pregnancy",
            "Observation 454 467--*--breastfeeding",
            "Parsing_Error 469 471--*--6.",
            "Procedure 483 494--*--colonoscopy",
            "Condition 516 538--*--poor bowel preparation",
            "Negation 509 515--*--except",
            "Qualifier 472 482--*--Incomplete",
            "Parsing_Error 540 542--*--7.",
            "Parsing_Error 576 578--*--8.",
            "Observation 558 574--*--informed consent"
        ]
    },
    "NCT02273791_inc": {
        "Annotations": [
            "Condition 11 15--*--PCOS",
            "Person 0 5--*--Women",
            "Measurement 34 52--*--Rotterdam criteria",
            "Multiplier 67 77--*--at least 2",
            "Observation 105 126--*--cleavage-stage embryo",
            "Qualifier 92 96--*--good",
            "Qualifier 78 91--*--cryopreserved"
        ],
        "Text": "Women with PCOS as defined by the Rotterdam criteria.. Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).. "
    },
    "NCT02053246_exc": {
        "Text": "Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy. Women who are pregnant or nursing. Liver cirrhosis,. Primary valvular disease. Acute coronary syndrome. Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis. Severe bradycardia or greater than 1st degree heart block. Decompensated heart failure. Current use of a third generation beta-blocker (nebivolol, carvedilol, or labetalol) or high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent). ",
        "Annotations": [
            "Condition 16 29--*--heart failure",
            "Condition 41 62--*--diastolic dysfunction",
            "Negation 30 40--*--other than",
            "Condition 72 98--*--restrictive cardiomyopathy",
            "Condition 102 129--*--infiltrative cardiomyopathy",
            "Scope 72 129--*--restrictive cardiomyopathy or infiltrative cardiomyopathy",
            "Scope 16 62--*--heart failure other than diastolic dysfunction",
            "Person 131 136--*--Women",
            "Condition 145 153--*--pregnant",
            "Condition 157 164--*--nursing",
            "Condition 166 181--*--Liver cirrhosis",
            "Condition 184 208--*--Primary valvular disease",
            "Condition 210 233--*--Acute coronary syndrome",
            "Condition 235 247--*--Causes of PH",
            "Negation 248 258--*--other than",
            "Condition 267 280--*--heart failure",
            "Condition 291 316--*--chronic thromboembolic PH",
            "Condition 318 337--*--sickle-cell disease",
            "Condition 342 353--*--sarcoidosis",
            "Scope 291 353--*--chronic thromboembolic PH, sickle-cell disease, or sarcoidosis",
            "Condition 362 373--*--bradycardia",
            "Qualifier 355 361--*--Severe",
            "Qualifier 377 400--*--greater than 1st degree",
            "Condition 401 412--*--heart block",
            "Condition 428 441--*--heart failure",
            "Qualifier 414 427--*--Decompensated",
            "Drug 460 489--*--third generation beta-blocker",
            "Drug 491 500--*--nebivolol",
            "Drug 502 512--*--carvedilol",
            "Drug 517 526--*--labetalol",
            "Scope 491 526--*--nebivolol, carvedilol, or labetalol",
            "Multiplier 531 540--*--high dose",
            "Drug 544 561--*--any beta-blockers",
            "Multiplier 563 588--*--greater than 100 mg daily",
            "Drug 592 602--*--metoprolol",
            "Scope 563 602--*--greater than 100 mg daily of metoprolol",
            "Scope 531 561--*--high dose of any beta-blockers"
        ]
    },
    "NCT01349413_inc": {
        "Annotations": [
            "Condition 14 34--*--functional dyspepsia",
            "Qualifier 48 65--*--Rome III criteria",
            "Qualifier 71 88--*--inadequate relief",
            "Condition 92 110--*--dyspeptic symptoms",
            "Person 112 115--*--Age",
            "Value 116 119--*-->18",
            "Informed_consent 121 149--*--Provision of written consent"
        ],
        "Text": "Patients with functional dyspepsia that fulfill Rome III criteria with inadequate relief of dyspeptic symptoms. Age >18. Provision of written consent. "
    },
    "NCT02360631_inc": {
        "Text": "Self-identified African American. Smokes = 1 cigarette per day (cpd). Smoke on = 25 days of the past 30 days. Functioning telephone. Interested in quitting smoking. Interested in taking 3 months of varenicline. Willing to complete all study visits. ",
        "Annotations": [
            "Person 16 32--*--African American",
            "Observation 34 40--*--Smokes",
            "Multiplier 41 62--*--= 1 cigarette per day",
            "Observation 70 75--*--Smoke",
            "Multiplier 79 108--*--= 25 days of the past 30 days",
            "Non-query-able 110 131--*--Functioning telephone",
            "Mood 133 143--*--Interested",
            "Observation 147 163--*--quitting smoking",
            "Post-eligibility 133 163--*--Interested in quitting smoking",
            "Post-eligibility 165 209--*--Interested in taking 3 months of varenicline",
            "Post-eligibility 211 247--*--Willing to complete all study visits"
        ]
    },
    "NCT01078051_inc": {
        "Annotations": [
            "Condition 14 20--*--angina",
            "Condition 31 39--*--ischemia",
            "Qualifier 24 30--*--silent",
            "Qualifier 44 54--*--documented",
            "Condition 55 63--*--ischemia",
            "Grammar_Error 40 43--*--and",
            "Procedure 95 117--*--intracoronary stenting",
            "Person 119 122--*--Age",
            "Value 123 133--*--> 18 years",
            "Condition 150 153--*--CTO",
            "Qualifier 135 149--*--De novo lesion",
            "Value 177 183--*--2.5 mm",
            "Measurement 155 176;184 204--*--Reference vessel size by visual estimation",
            "Multiplier 206 218--*--At least one",
            "Condition 219 230--*--CTO lesions",
            "Qualifier 239 250;269 284--*--in proximal coronary artery",
            "Qualifier 254 284--*--mid epicardial coronary artery",
            "Condition 269 284--*--coronary artery",
            "Scope 239 284--*--in proximal or mid epicardial coronary artery",
            "Parsing_Error 287 401--*--If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery",
            "Condition 429 444--*--total occlusion",
            "Qualifier 404 428--*--Angiographically defined",
            "Temporal 450 458--*--3 months",
            "Subjective_judgement 460 693--*--If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)"
        ],
        "Text": "Patients with angina or silent ischemia and documented ischemia. Patients who are eligible for intracoronary stenting. Age > 18 years. De novo lesion CTO. Reference vessel size 2.5 mm by visual estimation. At least one CTO lesions located in proximal or mid epicardial coronary artery. (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery). Angiographically defined total occlusion over 3 months. If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals). "
    },
    "NCT03118232_exc": {
        "Annotations": [
            "Visit 0 13--*--Nursing homes",
            "Non-representable 50 86--*--if they meet the following criteria:",
            "Multiplier 99 108--*--routinely",
            "Procedure 115 129--*--decolonization",
            "Visit 141 166--*--psychiatric nursing homes",
            "Measurement 186 205--*--resident population",
            "Value 211 216--*-->=20%",
            "Observation 217 235--*--combative patients",
            "Visit 237 257--*--Pediatric facilities"
        ],
        "Text": "Nursing homes will not be eligible to participate if they meet the following criteria:. Facilities routinely using decolonization. Dedicated psychiatric nursing homes. Facilities with a resident population with >=20% combative patients. Pediatric facilities. "
    },
    "NCT02254668_inc": {
        "Text": "Patients with heart transplantation. Patient with coronary artery disease. Age between 18 and 80 years. ",
        "Annotations": [
            "Procedure 14 35--*--heart transplantation",
            "Condition 50 73--*--coronary artery disease",
            "Person 75 78--*--Age",
            "Value 79 102--*--between 18 and 80 years"
        ]
    },
    "NCT03192020_inc": {
        "Text": "patients with =20\u00b0 passive extension deficit (PED) in metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint, or TPED of =30\u00b0 in MP and PIP joints of finger/fingers II-V. age > 18 years. palpable cord. provision of informed consent. ability to fill the Finnish versions of questionnaires.. ",
        "Annotations": [
            "Condition 19 50--*--passive extension deficit (PED)",
            "Qualifier 14 18--*--=20\u00b0",
            "Qualifier 113 118;54 78--*--joint metacarpophalangeal (MP)",
            "Qualifier 82 118--*--proximal interphalangeal (PIP) joint",
            "Scope 54 118--*--metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint",
            "Condition 123 127--*--TPED",
            "Qualifier 131 135--*--=30\u00b0",
            "Qualifier 139 141--*--MP",
            "Qualifier 146 156--*--PIP joints",
            "Qualifier 160 179--*--finger/fingers II-V",
            "Person 181 184--*--age",
            "Value 185 195--*--> 18 years",
            "Condition 197 210--*--palpable cord",
            "Informed_consent 212 241--*--provision of informed consent",
            "Non-query-able 243 298--*--ability to fill the Finnish versions of questionnaires."
        ]
    },
    "NCT02273791_exc": {
        "Annotations": [
            "Condition 19 32--*--endometriosis",
            "Qualifier 12 18--*--severe",
            "Qualifier 0 8--*--Moderate",
            "Scope 0 18--*--Moderate or severe",
            "Condition 35 47--*--Hydrosalpinx",
            "Condition 50 71--*--Uterine abnormalities",
            "Condition 75 80--*--myoma",
            "Procedure 92 107--*--uterine surgery"
        ],
        "Text": "Moderate or severe endometriosis.. Hydrosalpinx.. Uterine abnormalities or myoma.. Previous uterine surgery.. "
    },
    "NCT03225469_inc": {
        "Text": "1. Individuals scheduled for undergoing colonoscopy at the Endoscopy Center of Wuxi people's Hospital in China . 2. Greater than the age of 18 . 3. Individuals living with other family members . 4. Outpatients . ",
        "Annotations": [
            "Visit 59 110--*--Endoscopy Center of Wuxi people's Hospital in China",
            "Procedure 40 51--*--colonoscopy",
            "Non-query-able 15 39--*--scheduled for undergoing",
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 112 114--*--2.",
            "Value 115 127;139 141--*--Greater than 18",
            "Person 132 135--*--age",
            "Parsing_Error 143 145--*--3.",
            "Non-query-able 146 190--*--Individuals living with other family members",
            "Parsing_Error 192 194--*--4.",
            "Visit 195 206--*--Outpatients"
        ]
    },
    "NCT02053246_inc": {
        "Text": "Adults (= 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure = 25 mmHg and pulmonary capillary wedge pressure = 15 mmHg). New York Heart Association class II-IV symptoms. Left ventricular ejection fraction (LVEF) = 45%. ",
        "Annotations": [
            "Person 0 6--*--Adults",
            "Value 8 18--*--= 18 years",
            "Person 22 25--*--age",
            "Condition 66 88--*--Pulmonary Hypertension",
            "Qualifier 32 65--*--World Health Organization Group 2",
            "Measurement 89 120--*--(Mean pulmonary artery pressure",
            "Value 121 130--*--= 25 mmHg",
            "Measurement 135 169--*--pulmonary capillary wedge pressure",
            "Value 170 179--*--= 15 mmHg",
            "Measurement 182 208--*--New York Heart Association",
            "Value 209 220--*--class II-IV",
            "Condition 221 229--*--symptoms",
            "Measurement 231 272--*--Left ventricular ejection fraction (LVEF)",
            "Value 273 278--*--= 45%"
        ]
    },
    "NCT01349413_exc": {
        "Annotations": [
            "Procedure 44 59--*--upper endoscopy",
            "Condition 12 29--*--organic pathology",
            "Procedure 69 83--*--investigations",
            "Scope 44 83--*--upper endoscopy or other investigations",
            "Condition 105 118--*--hiatus hernia",
            "Qualifier 97 104--*--sliding",
            "Measurement 133 143;153 177--*--flap valve disruption of morphology",
            "Value 144 152--*--grade IV",
            "Qualifier 178 207--*--at gastro-esophageal junction",
            "Drug 220 231--*--medications",
            "Condition 244 269--*--gastrointestinal motility",
            "Condition 283 294--*--acid reflux",
            "Condition 298 316--*--heartburn symptoms",
            "Temporal 320 343--*--more than twice a month",
            "Scope 283 316--*--acid reflux or heartburn symptoms",
            "Procedure 356 371--*--gastric surgery",
            "Condition 373 392--*--H. pylori infection",
            "Drug 401 404--*--PPI",
            "Drug 408 413--*--NSAID",
            "Temporal 414 433--*--in the past 4 weeks",
            "Scope 401 413--*--PPI or NSAID",
            "Condition 435 444--*--Pregnancy",
            "Condition 452 468--*--hypersensitivity",
            "Drug 472 475--*--PPI"
        ],
        "Text": "Presence of organic pathology identified by upper endoscopy or other investigations. Presence of sliding hiatus hernia as defined by flap valve grade IV disruption of morphology at gastro-esophageal junction. Concurrent medications that affect gastrointestinal motility. Presence of acid reflux or heartburn symptoms of more than twice a month. History of gastric surgery. H. pylori infection. Use of PPI or NSAID in the past 4 weeks. Pregnancy. Known hypersensitivity to PPI. "
    },
    "NCT02739295_inc": {
        "Text": "Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission. ",
        "Annotations": [
            "Condition 0 26--*--Toxic epidermal necrolysis",
            "Measurement 32 39--*--SCORTEN",
            "Value 40 46--*--1 to 5",
            "Temporal 47 59--*--at admission",
            "Reference_point 50 59--*--admission"
        ]
    },
    "NCT02691793_exc": {
        "Annotations": [
            "Qualifier 14 20--*--second",
            "Condition 21 36--*--primary cancer,",
            "Negation 37 43--*--except",
            "Condition 63 87--*--non-melanoma skin cancer",
            "Condition 108 136--*--in-situ cancer of the cervix",
            "Condition 147 158--*--solid tumor",
            "Non-query-able 147 221--*--solid tumor curatively treated with no evidence of disease for <= 5 years.",
            "Mood 55 62--*--treated",
            "Mood 100 107--*--treated",
            "Scope 55 136--*--treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix",
            "Condition 268 278--*--metastases",
            "Qualifier 240 262--*--central nervous system",
            "Qualifier 263 266--*--CNS",
            "Condition 287 303--*--active infection",
            "Pregnancy_considerations 332 359--*--Pregnancy or breast feeding",
            "Condition 375 390--*--cardiac problem",
            "Drug 420 429--*--sunitinib"
        ],
        "Text": "Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for <= 5 years.. Has known active central nervous system(CNS) metastases. Has an active infection requiring systemic therapy. Pregnancy or breast feeding. Patients with cardiac problem. Any previous treatment with sunitinib. "
    },
    "NCT03247738_exc": {
        "Annotations": [
            "Post-eligibility 0 45--*--Inability to provide written informed consent",
            "Condition 70 91--*--intracranial bleeding",
            "Qualifier 64 69--*--prior",
            "Drug 113 138--*--P2Y12 receptor antagonist",
            "Drug 140 151--*--ticlopidine",
            "Drug 153 164--*--clopidogrel",
            "Drug 166 175--*--prasugrel",
            "Drug 177 187--*--ticagrelor",
            "Scope 140 187--*--ticlopidine, clopidogrel, prasugrel, ticagrelor",
            "Temporal 196 209--*--prior 10 days",
            "Condition 217 226--*--allergies",
            "Drug 230 237--*--aspirin",
            "Drug 239 249--*--ticagrelor",
            "Drug 253 262--*--cangrelor",
            "Scope 230 262--*--aspirin, ticagrelor or cangrelor",
            "Drug 287 300--*--anticoagulant",
            "Qualifier 282 286--*--oral",
            "Drug 317 349--*--glycoprotein IIb/IIIa inhibitors",
            "Procedure 351 364--*--Fibrinolytics",
            "Temporal 365 380--*--within 24 hours",
            "Condition 382 397--*--Active bleeding",
            "Qualifier 399 408--*--High risk",
            "Condition 412 420--*--bleeding",
            "Measurement 428 442--*--platelet count",
            "Value 443 453--*--<80x106/mL",
            "Measurement 461 471--*--hemoglobin",
            "Value 472 480--*--<10 g/dL",
            "Condition 482 491--*--Intubated",
            "Temporal 502 524--*--prior to randomization",
            "Reference_point 511 524--*--randomization",
            "Measurement 533 553--*--creatinine clearance",
            "Value 554 567--*--<30 mL/minute",
            "Procedure 574 586--*--hemodialysis",
            "Condition 602 621--*--hepatic dysfunction",
            "Qualifier 595 601--*--severe",
            "Condition 637 656--*--sick sinus syndrome",
            "Condition 658 661--*--SSS",
            "Condition 678 686--*--AV block",
            "Qualifier 666 677--*--high degree",
            "Procedure 695 704--*--pacemaker",
            "Negation 687 694--*--without",
            "Drug 740 745--*--drugs",
            "Condition 763 780--*--CYP3A4 metabolism",
            "Drug 808 818--*--ticagrelor",
            "Mood 746 762--*--interfering with",
            "Drug 821 833--*--Ketoconazole",
            "Non-query-able 782 818--*--to avoid interaction with ticagrelor",
            "Drug 835 847--*--itraconazole",
            "Drug 849 861--*--voriconazole",
            "Drug 863 877--*--clarithromycin",
            "Drug 879 889--*--nefazodone",
            "Drug 891 900--*--ritonavir",
            "Drug 902 912--*--saquinavir",
            "Drug 914 924--*--nelfinavir",
            "Drug 926 935--*--indinavir",
            "Drug 937 947--*--atazanavir",
            "Drug 953 968--*--telithromizycin",
            "Scope 821 968--*--Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin",
            "Condition 971 979--*--Pregnant",
            "Condition 983 992--*--lactating",
            "Person 993 1000--*--females",
            "Scope 971 992--*--Pregnant or lactating"
        ],
        "Text": "Inability to provide written informed consent. Known history of prior intracranial bleeding. On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days. Known allergies to aspirin, ticagrelor or cangrelor. On treatment with oral anticoagulant. Treatment with glycoprotein IIb/IIIa inhibitors. Fibrinolytics within 24 hours. Active bleeding. High risk of bleeding. Known platelet count <80x106/mL. Known hemoglobin <10 g/dL. Intubated patients (prior to randomization). Known creatinine clearance <30 mL/minute or on hemodialysis.. Known severe hepatic dysfunction. Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection. Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.. Pregnant or lactating females.. "
    },
    "NCT02691793_inc": {
        "Annotations": [
            "Informed_consent 0 70--*--Provision of fully informed consent prior to study specific procedures",
            "Person 105 108--*--age",
            "Value 90 101--*-->= 19 years",
            "Measurement 110 120--*--RET fusion",
            "Value 121 129--*--positive",
            "Qualifier 133 145--*--FGFR2 fusion",
            "Qualifier 152 165--*--FGFR mutation",
            "Qualifier 166 176--*--Refractory",
            "Condition 177 188--*--solid tumor",
            "Scope 133 165--*--FGFR2 fusion/other FGFR mutation",
            "Qualifier 205 216--*--sensitivity",
            "Drug 220 229--*--Sunitinib",
            "Non-query-able 231 379--*--y Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy",
            "Measurement 382 405--*--ECOG Performance status",
            "Value 405 408--*--0-2",
            "Non-query-able 410 496--*--Have measurable or evaluated disease based on RECIST 1.1 as determined by investigator",
            "Measurement 499 524--*--Absolute neutrophil count",
            "Value 525 539--*-->= 1.5 x 109/L",
            "Measurement 541 551--*--Hemoglobin",
            "Value 552 561--*-->= 9g/dL,",
            "Measurement 562 571--*--Platelets",
            "Value 571 584--*-->=100 x 109/L",
            "Measurement 585 594--*--Bilirubin",
            "Value 595 625--*--<= 1.5 x upper limit of normal",
            "Measurement 626 629--*--AST",
            "Measurement 630 633--*--ALT",
            "Value 634 665--*--<= 2.5 X upper limit of normal(",
            "Condition 711 727--*--liver metastases",
            "Value 665 692--*--5.0 x upper limit of normal",
            "Measurement 729 739--*--Creatinine",
            "Value 739 751--*--<= 1.5 X UNL",
            "Measurement 626 629--*--AST",
            "Measurement 630 633--*--ALT",
            "Condition 932 955--*--Adequate heart function",
            "Measurement 941 955--*--heart function",
            "Value 932 940--*--Adequate",
            "Observation 765 788--*--child-bearing potential",
            "Procedure 805 836--*--adequate contraceptive measures",
            "Negation 844 850--*--not be",
            "Condition 851 865--*--breast feeding",
            "Value 882 890--*--negative",
            "Measurement 891 905--*--pregnancy test",
            "Temporal 906 930--*--prior to start of dosing",
            "Reference_point 915 930--*--start of dosing",
            "Scope 805 930--*--adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing"
        ],
        "Text": "Provision of fully informed consent prior to study specific procedures.. Patients must be >= 19 years of age. RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.. ECOG Performance status0-2. Have measurable or evaluated disease based on RECIST 1.1 as determined by investigator.. Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100 x 109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of normal(5.0 x upper limit of normal, for subject with liver metastases) Creatinine<= 1.5 X UNL. Patients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing. Adequate heart function. "
    },
    "NCT02739295_exc": {
        "Text": "Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission. Hypercoagulable state. Cardiac or peripheral arterial disease. Active malignancy. Myelodysplastic syndrome or hematological malignancy. Fructose intolerance. Pregnancy. Patient refusal. ",
        "Annotations": [
            "Condition 0 26--*--Toxic epidermal necrolysis",
            "Measurement 32 39--*--SCORTEN",
            "Value 40 46--*--6 or 7",
            "Temporal 47 59--*--at admission",
            "Reference_point 50 59--*--admission",
            "Condition 61 82--*--Hypercoagulable state",
            "Condition 95 122--*--peripheral arterial disease",
            "Condition 115 122;84 91--*--disease Cardiac",
            "Condition 131 141--*--malignancy",
            "Qualifier 124 130--*--Active",
            "Condition 143 167--*--Myelodysplastic syndrome",
            "Condition 171 195--*--hematological malignancy",
            "Condition 197 217--*--Fructose intolerance",
            "Drug 197 205--*--Fructose",
            "Pregnancy_considerations 219 228--*--Pregnancy",
            "Post-eligibility 230 245--*--Patient refusal"
        ]
    },
    "NCT03247738_inc": {
        "Annotations": [
            "Condition 14 19--*--STEMI",
            "Procedure 31 43--*--primary PPCI",
            "Person 45 48--*--Age",
            "Value 49 63--*--> 18 years old"
        ],
        "Text": "Patients with STEMI undergoing primary PPCI. Age > 18 years old. "
    },
    "NCT03149887_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 11 23--*--coagulopathy",
            "Condition 25 32--*--allergy",
            "Drug 36 47--*--bupivacaine",
            "Condition 49 62--*--renal failure",
            "Condition 64 85--*--hepatic insufficiency",
            "Condition 94 117--*--inappropriate candidate",
            "Procedure 122 135--*--usual therapy",
            "Mood 154 171--*--unable to receive",
            "Procedure 182 219--*--preoperative interscalene nerve block",
            "Temporal 221 232--*--preexisting",
            "Condition 233 245--*--nerve injury",
            "Qualifier 249 264--*--side of surgery",
            "Condition 266 288--*--refusal of nerve block",
            "Condition 290 299--*--infection",
            "Qualifier 303 322--*--site of nerve block",
            "Scope 221 322--*--preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block",
            "Scope 154 219--*--unable to receive the usual preoperative interscalene nerve block",
            "Scope 94 135--*--inappropriate candidate for usual therapy",
            "Scope 154 322--*--unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block"
        ],
        "Text": "Pregnancy, coagulopathy, allergy to bupivacaine, renal failure, hepatic insufficiency, and/or inappropriate candidate for usual therapy (specifically, if unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block).. "
    },
    "NCT02678728_inc": {
        "Annotations": [
            "Qualifier 20 34--*--thoracic aorta",
            "Procedure 35 42--*--surgery",
            "Condition 48 78--*--hypothermic circulatory arrest",
            "Person 91 94--*--age",
            "Value 80 87--*--over 20"
        ],
        "Text": "Patients undergoing thoracic aorta surgery with hypothermic circulatory arrest, over 20-of age. "
    },
    "NCT02431442_exc": {
        "Annotations": [
            "Measurement 0 21--*--Fasting blood glucose",
            "Value 22 32--*-->126 mg/dL",
            "Temporal 33 45--*--at screening",
            "Condition 47 59--*--Heterozygous",
            "Measurement 92 113--*--fasting blood glucose",
            "Value 114 124--*-->140 mg/dL",
            "Measurement 127 145--*--Resting heart rate",
            "Value 146 153--*--<45 bpm",
            "Value 157 164--*-->90 bpm",
            "Temporal 165 177--*--at screening",
            "Reference_point 168 177--*--screening",
            "Scope 146 164--*--<45 bpm or >90 bpm",
            "Measurement 189 222--*--thyroid stimulating hormone (TSH)",
            "Measurement 226 240--*--thyroxine (T4)",
            "Value 180 188--*--Abnormal",
            "Temporal 248 260--*--on screening",
            "Reference_point 251 260--*--screening",
            "Measurement 272 275--*--ALT",
            "Value 263 271--*--Elevated",
            "Measurement 279 295--*--serum creatinine",
            "Temporal 296 308--*--on screening",
            "Reference_point 299 308--*--screening",
            "Measurement 366 382--*--laboratory tests",
            "Undefined_semantics 366 382--*--laboratory tests",
            "Subjective_judgement 383 416--*--as determined by the Investigator",
            "Non-query-able 312 416--*--any clinically significant abnormalities on screening laboratory tests as determined by the Investigator",
            "Value 339 352--*--abnormalities",
            "Condition 448 456--*--diabetes",
            "Qualifier 430 447--*--medically treated",
            "Drug 430 439--*--medically",
            "Procedure 430 447--*--medically treated",
            "Condition 494 506--*--hypertension",
            "Qualifier 463 470--*--treated",
            "Drug 474 483--*--medically",
            "Scope 463 483--*--treated or medically",
            "Observation 419 426--*--History",
            "Condition 508 520--*--Heterozygous",
            "Context_Error 47 59--*--Heterozygous",
            "Condition 549 561--*--hypertension",
            "Procedure 589 598--*--treatment",
            "Qualifier 570 585--*--well controlled",
            "Grammar_Error 639 651--*--are eligible",
            "Parsing_Error 653 654--*--.",
            "Condition 670 681--*--skin lesion",
            "Qualifier 682 707--*--suspicious for malignancy",
            "Condition 697 707--*--malignancy",
            "Procedure 716 723--*--excised",
            "Temporal 724 738--*--prior to Day 1",
            "Reference_point 733 738--*--Day 1",
            "Condition 752 762--*--malignancy",
            "Observation 741 748--*--History",
            "Condition 782 808--*--cervical carcinoma in situ",
            "Qualifier 774 781--*--treated",
            "Procedure 774 781--*--treated",
            "Negation 763 773--*--except for",
            "Temporal 809 828--*--in the past 5 years",
            "Condition 879 896--*--medical condition",
            "Qualifier 856 878--*--clinically significant",
            "Subjective_judgement 856 878--*--clinically significant",
            "Undefined_semantics 856 878--*--clinically significant",
            "Observation 841 848--*--history",
            "Temporal 831 837--*--Active",
            "Scope 831 848--*--Active or history",
            "Condition 1059 1066;907 912--*--disease renal",
            "Condition 1045 1066--*--hematological disease",
            "Condition 1030 1041;1059 1066--*--psychiatric disease",
            "Condition 1018 1028;1059 1066--*--neurologic disease",
            "Condition 1007 1016;1059 1066--*--metabolic disease",
            "Condition 1059 1066;994 1005--*--disease immunologic",
            "Condition 1059 1066;983 992--*--disease endocrine",
            "Condition 1059 1066;968 981--*--disease genitourinary",
            "Condition 1059 1066;952 966--*--disease cardiovascular",
            "Condition 1059 1066;934 950--*--disease gastrointestinal",
            "Condition 1059 1066;923 932--*--disease pulmonary",
            "Condition 1059 1066;914 921--*--disease hepatic",
            "Qualifier 1068 1098--*--based on Investigator judgment",
            "Subjective_judgement 1068 1098--*--based on Investigator judgment",
            "Non-query-able 1068 1098--*--based on Investigator judgment",
            "Scope 907 1066--*--renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic, psychiatric or hematological disease",
            "Non-query-able 1101 1308--*--Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data.",
            "Context_Error 1101 1308--*--Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data.",
            "Subjective_judgement 1101 1308--*--Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data.",
            "Measurement 1319 1346--*--hepatitis B surface antigen",
            "Value 1310 1318--*--Positive",
            "Measurement 1357 1377--*--hepatitis C antibody",
            "Value 1348 1356--*--positive",
            "Measurement 1390 1398--*--HIV test",
            "Value 1381 1389--*--positive",
            "Temporal 1399 1411--*--at screening",
            "Reference_point 1402 1411--*--screening",
            "Observation 1417 1424--*--history",
            "Scope 1310 1398--*--Positive hepatitis B surface antigen, positive hepatitis C antibody or positive HIV test",
            "Procedure 1451 1463--*--liver biopsy",
            "Procedure 1465 1473--*--serology",
            "Procedure 1437 1444--*--testing",
            "Value 1428 1436--*--positive",
            "Scope 1451 1473--*--liver biopsy, serology",
            "Undefined_semantics 1437 1444--*--testing",
            "Context_Error 1437 1444--*--testing",
            "Condition 1495 1512--*--chronic hepatitis",
            "Condition 1486 1491;1503 1512--*--acute hepatitis",
            "Scope 1486 1512--*--acute or chronic hepatitis",
            "Procedure 1524 1555--*--12-lead electrocardiogram (ECG)",
            "Value 1515 1523--*--Abnormal",
            "Temporal 1556 1568--*--at screening",
            "Temporal 1556 1558;1572 1580--*--at pre-dose",
            "Reference_point 1559 1568--*--screening",
            "Reference_point 1572 1580--*--pre-dose",
            "Temporal 1582 1588--*--Day -1",
            "Temporal 1592 1597--*--Day 1",
            "Drug 1700 1718--*--experimental drugs",
            "Device 1700 1712;1722 1729--*--experimental devices",
            "Temporal 1730 1744--*--within 30 days",
            "Temporal 1730 1736;1748 1760--*--within 5 half lives",
            "Scope 1700 1729--*--experimental drugs or devices",
            "Scope 1730 1760--*--within 30 days or 5 half lives",
            "Context_Error 1700 1760--*--experimental drugs or devices within 30 days or 5 half lives",
            "Non-query-able 1700 1760--*--experimental drugs or devices within 30 days or 5 half lives",
            "Context_Error 1801 1874--*--Ongoing participation in a prior clinical study at the time of screening.",
            "Non-query-able 1801 1874--*--Ongoing participation in a prior clinical study at the time of screening.",
            "Procedure 1876 1890--*--Blood donation",
            "Temporal 1891 1924--*--within 60 days prior to screening",
            "Reference_point 1915 1924--*--screening",
            "Observation 1928 1944--*--intent to donate",
            "Non-query-able 1928 1944--*--intent to donate",
            "Temporal 1945 1983--*--within 60 days after Final Study Visit",
            "Reference_point 1966 1983--*--Final Study Visit",
            "Procedure 1986 2001--*--Hospitalization",
            "Procedure 2012 2019--*--surgery",
            "Qualifier 2006 2011--*--major",
            "Subjective_judgement 2006 2011--*--major",
            "Undefined_semantics 2006 2011--*--major",
            "Procedure 2073 2095--*--cardiovascular surgery",
            "Procedure 2060 2068;2088 2095--*--thoracic surgery",
            "Procedure 2049 2058;2088 2095--*--abdominal surgery",
            "Temporal 2096 2139--*--within the past 3 months prior to screening",
            "Reference_point 2130 2139--*--screening",
            "Condition 2173 2193--*--non-surgical illness",
            "Qualifier 2150 2172--*--clinically significant",
            "Subjective_judgement 2150 2172--*--clinically significant",
            "Undefined_semantics 2150 2172--*--clinically significant",
            "Subjective_judgement 2195 2225--*--based on Investigator judgment",
            "Temporal 2227 2251--*--within the past 3 months",
            "Scope 2049 2095--*--abdominal, thoracic, or cardiovascular surgery",
            "Procedure 2262 2278--*--elective surgery",
            "Observation 2254 2261--*--Planned",
            "Non-query-able 2254 2261--*--Planned",
            "Temporal 2279 2318--*--within 30 days of the Final Study Visit",
            "Reference_point 2301 2318--*--Final Study Visit",
            "Condition 2321 2339--*--Poor venous access",
            "Procedure 2365 2377--*--venipuncture",
            "Condition 2343 2377--*--inability to tolerate venipuncture",
            "Condition 2403 2424--*--drug hypersensitivity",
            "Condition 2403 2407;2428 2439--*--drug anaphylaxis",
            "Qualifier 2391 2402--*--significant",
            "Subjective_judgement 2391 2402--*--significant",
            "Observation 2380 2387--*--History",
            "Condition 2453 2481--*--hypersensitivity to proteins",
            "Condition 2453 2472;2489 2502--*--hypersensitivity to allergy shots",
            "Drug 2513 2537--*--prescription medications",
            "Drug 2574 2601--*--any prescription medication",
            "Temporal 2562 2570;2617 2642--*--last use greater than 5 half-lives",
            "Temporal 2674 2709--*--at least 14 days prior to admission",
            "Reference_point 2700 2709--*--admission",
            "Temporal 2543 2556--*--regular basis",
            "Observation 2442 2449--*--History",
            "Grammar_Error 2764 2774--*--is allowed",
            "Grammar_Error 2797 2915--*--Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions:",
            "Parsing_Error 2797 2915--*--Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions:",
            "Drug 2917 2934--*--Antihypertensives",
            "Multiplier 2936 2950--*--<3 medications",
            "Qualifier 2956 2967--*--stable dose",
            "Temporal 2968 2981--*--for \u2265 30 days",
            "Drug 2985 2992--*--Statins",
            "Multiplier 3007 3030--*--\u2264 half the maximum dose",
            "Qualifier 3045 3056--*--stable dose",
            "Temporal 3057 3066--*--\u22653 months",
            "Drug 3070 3078--*--Fibrates",
            "Qualifier 3091 3102--*--stable dose",
            "Temporal 3107 3116--*--\u22653 months",
            "Drug 3120 3126--*--Niacin",
            "Qualifier 3139 3150--*--stable dose",
            "Temporal 3155 3164--*--\u22653 months",
            "Drug 3168 3176--*--Thyroxin",
            "Qualifier 3178 3189--*--stable dose",
            "Temporal 3194 3203--*--\u2265 30 days",
            "Context_Error 3206 3327--*--The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above.",
            "Non-query-able 3206 3327--*--The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above.",
            "Drug 3336 3360--*--prescription medications",
            "Subjective_judgement 3329 3461--*--Use of prescription medications not listed above may be allowed at the discretion of the Investigator upon consultation with Rhythm.",
            "Drug 3472 3493--*--non-prescription drug",
            "Drug 3498 3515--*--herbal substances",
            "Temporal 3516 3532--*--during the study",
            "Grammar_Error 3494 3497--*--and",
            "Drug 3583 3608--*--any non-prescription drug",
            "Temporal 3630 3655;3670 3697--*--greater than 5 half-lives before receiving study drug",
            "Context_Error 3583 3608--*--any non-prescription drug",
            "Non-query-able 3700 3877--*--Inability to attend all study visits or to comply with protocol requirements including fasting and restrictions on alcohol, caffeine, nicotine and concomitant medication intake.",
            "Condition 3904 3922--*--drug/solvent abuse",
            "Observation 3893 3900--*--history",
            "Temporal 3923 3950--*--within 5 years of screening",
            "Reference_point 3941 3950--*--screening",
            "Measurement 3974 3993--*--drugs of abuse test",
            "Value 3956 3964--*--positive",
            "Temporal 3994 4006--*--at screening",
            "Reference_point 3997 4006--*--screening",
            "Measurement 4040 4051--*--breath test",
            "Measurement 4031 4038;4047 4051--*--alcohol test",
            "Scope 4031 4052--*--alcohol (breath test)",
            "Value 4022 4030--*--Positive",
            "Measurement 4056 4071--*--nicotine screen",
            "Temporal 4072 4090--*--at Screening Visit",
            "Reference_point 4075 4090--*--Screening Visit",
            "Scope 4022 4071--*--Positive alcohol (breath test) or nicotine screen",
            "Condition 4178 4191--*--alcohol abuse",
            "Observation 4167 4174--*--History",
            "Multiplier 4222 4241;4253 4260--*--three or more units per day",
            "Drug 4245 4252--*--alcohol",
            "Temporal 4262 4299--*--within 5 years of the Screening Visit",
            "Reference_point 4280 4299--*--the Screening Visit",
            "Observation 4302 4309--*--History",
            "Condition 4313 4320;4340 4343--*--tobacco use",
            "Condition 4324 4343--*--tobacco product use",
            "Condition 4351 4360--*--abstinent",
            "Temporal 4361 4411--*--for at least one year prior to the Screening Visit",
            "Reference_point 4392 4411--*--the Screening Visit",
            "Negation 4344 4350--*--unless",
            "Scope 4313 4343--*--tobacco or tobacco product use",
            "Parsing_Error 4413 4468--*--This criterion does not apply to heterozygous subjects.",
            "Not_a_criteria 4470 4516--*--Previously randomized and dosed in this study.",
            "Parsing_Error 4517 4572--*--This criterion does not apply to heterozygous subjects.",
            "Subjective_judgement 4574 4679--*--Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study.",
            "Non-query-able 4574 4679--*--Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study.",
            "Procedure 2741 2763--*--Hormonal contraception",
            "Person 2779 2785--*--female"
        ],
        "Text": "Fasting blood glucose >126 mg/dL at screening. Heterozygous subjects will be excluded for a fasting blood glucose >140 mg/dL. . Resting heart rate <45 bpm or >90 bpm at screening. . Abnormal thyroid stimulating hormone (TSH) or thyroxine (T4) levels on screening. . Elevated ALT or serum creatinine on screening or any clinically significant abnormalities on screening laboratory tests as determined by the Investigator. . History of medically treated diabetes or of treated or medically diagnosed hypertension. Heterozygous subjects who have diagnosed hypertension and are well controlled on treatment (Refer to Exclusion Criteria 20 below), are eligible. . . Presence of a skin lesion suspicious for malignancy, unless excised prior to Day 1. . History of malignancy except for treated cervical carcinoma in situ in the past 5 years. . Active or history of any clinically significant medical condition including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic, psychiatric or hematological disease, based on Investigator judgment. . Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data. . Positive hepatitis B surface antigen, positive hepatitis C antibody or positive HIV test at screening or a history of positive testing (e.g. liver biopsy, serology) suggesting acute or chronic hepatitis. . Abnormal 12-lead electrocardiogram (ECG) at screening or pre-dose (Day -1 or Day 1), except minor deviations deemed to be of no clinical significance by the Investigator. . Received any experimental drugs or devices within 30 days or 5 half lives, whichever is longer, prior to dosing. . Ongoing participation in a prior clinical study at the time of screening. . Blood donation within 60 days prior to screening or intent to donate within 60 days after Final Study Visit. . Hospitalization for major surgery including but not limited to abdominal, thoracic, or cardiovascular surgery within the past 3 months prior to screening, or for a clinically significant non-surgical illness, based on Investigator judgment, within the past 3 months. . Planned elective surgery within 30 days of the Final Study Visit. . Poor venous access or inability to tolerate venipuncture. . History of significant drug hypersensitivity or anaphylaxis. . History of hypersensitivity to proteins (e.g., allergy shots). . Use of prescription medications on a regular basis. The last use of any prescription medication must have been greater than 5 half-lives for the specific medication or at least 14 days prior to admission (Day -1), whichever is longer. Hormonal contraception is allowed for female subjects. . Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions: . Antihypertensives (<3 medications on a stable dose for \u2265 30 days); . Statins (dose must be \u2264 half the maximum dose; must be on a stable dose \u22653 months); . Fibrates (must be on stable dose for \u22653 months); . Niacin (must be on stable dose for \u22653 months); . Thyroxin (stable dose for \u2265 30 days); The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above. . Use of prescription medications not listed above may be allowed at the discretion of the Investigator upon consultation with Rhythm. . Use of a non-prescription drug and herbal substances during the study (through the Final Study Visit). The last dose of any non-prescription drug must have been taken greater than 5 half-lives for that drug before receiving study drug. . Inability to attend all study visits or to comply with protocol requirements including fasting and restrictions on alcohol, caffeine, nicotine and concomitant medication intake. . A significant history of drug/solvent abuse within 5 years of screening or a positive test for drugs of abuse test at screening or on Day -1. . Positive alcohol (breath test) or nicotine screen at Screening Visit or Day 1 (positive nicotine screen does not apply to heterozygous cohort). . History of alcohol abuse (defined as average intake of three or more units of alcohol per day) within 5 years of the Screening Visit. . History of tobacco or tobacco product use unless abstinent for at least one year prior to the Screening Visit. This criterion does not apply to heterozygous subjects. . Previously randomized and dosed in this study. This criterion does not apply to heterozygous subjects. . Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study.       .     . "
    },
    "NCT00846703_inc": {
        "Text": "Cytologically proven acute lymphoblastic leukemia (ALL). No relapse of a previously unrecognized ALL. Patients must meet one of the following risk criteria:. Standard-risk (SR) group meeting all of the following criteria:. Blasts < 1,000/\u00b5L in peripheral blood (PB) on day 8. Aged 1 to < 6 years. Initial WBC < 20,000/\u00b5L. M1 (5%) or M2 (= 5% to < 25%) blasts in bone marrow on day 15;. M1 marrow on day 33.. Aged < 1 or = 6 years and/or WBC = 20,000/\u00b5L. Blasts < 1,000/\u00b5L in PB on day 8. M1 or M2 marrow on day 15. M3 (= 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33.. Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15). Blasts = 1,000/\u00b5L in PB on day 8. M2 or M3 marrow on day 33. Translocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or t(4;11) [MLL/AF4+].. ",
        "Annotations": [
            "Condition 21 49--*--acute lymphoblastic leukemia",
            "Condition 51 54--*--ALL",
            "Qualifier 0 20--*--Cytologically proven",
            "Condition 97 100--*--ALL",
            "Qualifier 73 96--*--previously unrecognized",
            "Negation 57 59--*--No",
            "Condition 60 67--*--relapse",
            "Line 158 220--*--Standard-risk (SR) group meeting all of the following criteria",
            "Line 223 274--*--Blasts < 1,000/\u00b5L in peripheral blood (PB) on day 8",
            "Line 276 295--*--Aged 1 to < 6 years",
            "Line 297 320--*--Initial WBC < 20,000/\u00b5L",
            "Line 322 383--*--M1 (5%) or M2 (= 5% to < 25%) blasts in bone marrow on day 15",
            "Line 386 406--*--M1 marrow on day 33.",
            "Line 408 452--*--Aged < 1 or = 6 years and/or WBC = 20,000/\u00b5L",
            "Line 454 486--*--Blasts < 1,000/\u00b5L in PB on day 8",
            "Line 488 513--*--M1 or M2 marrow on day 15",
            "Line 515 612--*--M3 (= 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33",
            "Line 615 682--*--Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)",
            "Line 684 716--*--Blasts = 1,000/\u00b5L in PB on day 8",
            "Line 718 743--*--M2 or M3 marrow on day 33",
            "Line 745 834--*--Translocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or t(4;11) [MLL/AF4+]",
            "Measurement 158 171--*--Standard-risk",
            "Measurement 173 175--*--SR",
            "Multiplier 191 194--*--all",
            "Measurement 212 220--*--criteria",
            "Measurement 223 229--*--Blasts",
            "Value 230 240--*--< 1,000/\u00b5L",
            "Qualifier 244 260--*--peripheral blood",
            "Qualifier 262 264--*--PB",
            "Temporal 266 274--*--on day 8",
            "Person 276 280--*--Aged",
            "Value 281 295--*--1 to < 6 years",
            "Measurement 305 308--*--WBC",
            "Qualifier 297 304--*--Initial",
            "Value 309 320--*--< 20,000/\u00b5L",
            "Measurement 322 324;352 358--*--M1 blasts",
            "Measurement 333 335;352 358--*--M2 blasts",
            "Qualifier 362 373--*--bone marrow",
            "Value 325 328--*--(5%",
            "Value 337 350--*--= 5% to < 25%",
            "Temporal 374 383--*--on day 15",
            "Scope 322 358--*--M1 (5%) or M2 (= 5% to < 25%) blasts",
            "Condition 386 395--*--M1 marrow",
            "Temporal 396 405--*--on day 33",
            "Person 408 412--*--Aged",
            "Value 413 429--*--< 1 or = 6 years",
            "Measurement 437 440--*--WBC",
            "Value 441 452--*--= 20,000/\u00b5L",
            "Measurement 454 460--*--Blasts",
            "Value 461 471--*--< 1,000/\u00b5L",
            "Condition 475 477--*--PB",
            "Temporal 478 486--*--on day 8",
            "Condition 494 503--*--M2 marrow",
            "Condition 488 490;497 503--*--M1 marrow",
            "Temporal 504 513--*--on day 15",
            "Scope 488 503--*--M1 or M2 marrow",
            "Condition 515 517;526 532--*--M3 marrow",
            "Value 519 524--*--= 25%",
            "Temporal 533 542--*--on day 15",
            "Measurement 552 563--*--SR criteria",
            "Value 546 551--*--meets",
            "Condition 568 577--*--M3 marrow",
            "Temporal 578 587--*--on day 15",
            "Condition 593 602--*--M1 marrow",
            "Temporal 603 612--*--on day 33",
            "Scope 546 612--*--meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33",
            "Measurement 621 632--*--IR criteria",
            "Value 615 620--*--Meets",
            "Condition 637 646--*--M3 marrow",
            "Temporal 647 656--*--on day 15",
            "Value 658 661--*--not",
            "Measurement 662 664--*--SR",
            "Condition 669 671--*--M3",
            "Temporal 672 681--*--on day 15",
            "Measurement 684 690--*--Blasts",
            "Value 691 701--*--= 1,000/\u00b5L",
            "Qualifier 705 707--*--PB",
            "Temporal 708 716--*--on day 8",
            "Condition 724 733--*--M3 marrow",
            "Condition 718 720;727 733--*--M2 marrow",
            "Temporal 734 743--*--on day 33",
            "Scope 718 733--*--M2 or M3 marrow",
            "Measurement 745 766--*--Translocation t(9;22)",
            "Measurement 768 775--*--BCR/ABL",
            "Value 775 776--*--+",
            "Measurement 779 802--*--Philadelphia chromosome",
            "Value 803 811--*--positive",
            "Measurement 816 823--*--t(4;11)",
            "Measurement 825 832--*--MLL/AF4",
            "Value 832 833--*--+"
        ]
    },
    "NCT02227992_exc": {
        "Text": "Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;. Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing;. Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor;. Subjects who are known, current alcohol and/or drug abusers. Subjects admitted for trauma surgery. Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure.. Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected). TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST\u2122 or SURGICEL\u00ae to blood flow and pressure during healing and absorption of the product;. TBS with major arterial bleeding requiring suture or mechanical ligation;. Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine.. ",
        "Annotations": [
            "Condition 20 31--*--intolerance",
            "Procedure 35 49--*--blood products",
            "Non-query-able 53 140--*--to one of the components of the study product or is unwilling to receive blood products",
            "Pregnancy_considerations 143 234--*--Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing",
            "Post-eligibility 237 379--*--Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor",
            "Person 429 441--*--drug abusers",
            "Person 414 421;434 441--*--alcohol abusers",
            "Procedure 465 479--*--trauma surgery",
            "Non-query-able 481 605--*--Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure",
            "Condition 621 624--*--TBS",
            "Qualifier 656 678--*--Class III Contaminated",
            "Qualifier 682 708--*--Class IV Dirty or Infected",
            "Scope 656 708--*--Class III Contaminated or Class IV Dirty or Infected",
            "Non-query-able 711 987--*--TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST\u2122 or SURGICEL\u00ae to blood flow and pressure during healing and absorption of the produc",
            "Condition 991 994--*--TBS",
            "Condition 1000 1023--*--major arterial bleeding",
            "Procedure 1044 1063--*--mechanical ligation",
            "Procedure 1034 1040--*--suture",
            "Scope 1034 1063--*--suture or mechanical ligation",
            "Non-query-able 1066 1156--*--Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine"
        ]
    },
    "NCT03476850_inc": {
        "Text": "Patients undergoing laparoscopic assisted donor nephrectomy. Patients that have elected to have a nerve block. 18 years of age or older. Patients of ASA status I - III. ",
        "Annotations": [
            "Procedure 20 59--*--laparoscopic assisted donor nephrectomy",
            "Procedure 98 109--*--nerve block",
            "Mood 80 95--*--elected to have",
            "Value 111 119;127 135--*--18 years or older",
            "Person 123 126--*--age",
            "Measurement 149 159--*--ASA status",
            "Value 160 167--*--I - III"
        ]
    },
    "NCT02295202_exc": {
        "Text": "Smokers. Patients under chronic use of medications. Neurological diseases. Coronary artery disease. Acute heart failure. Chronic renal failure (GFR < 30 ml/min). Chronic obstructive pulmonary disease. Mild OSA and patients with BMI over 40 kg/m2.. ",
        "Annotations": [
            "Condition 0 7--*--Smokers",
            "Multiplier 24 35--*--chronic use",
            "Drug 39 50--*--medications",
            "Condition 52 73--*--Neurological diseases",
            "Condition 75 98--*--Coronary artery disease",
            "Condition 100 119--*--Acute heart failure",
            "Condition 129 142--*--renal failure",
            "Multiplier 121 128--*--Chronic",
            "Measurement 144 147--*--GFR",
            "Value 148 159--*--< 30 ml/min",
            "Scope 121 142--*--Chronic renal failure",
            "Condition 170 199--*--obstructive pulmonary disease",
            "Multiplier 162 169--*--Chronic",
            "Condition 201 209--*--Mild OSA",
            "Measurement 228 231--*--BMI",
            "Value 232 245--*--over 40 kg/m2"
        ]
    },
    "NCT02339974_exc": {
        "Text": "Heart Team assessment of operability (the heart team considers the patient to be a good surgical candidate).. Evidence of an acute myocardial infarction = 1 month (30 days) before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB = twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].. Untreated, severe, left sided valvular heart disease including mitral regurgitation or stenosis, and aortic regurgitation or stenosis.. Mean pulmonary artery pressures =40mmHG and PVR >4 woods units as assessed by right heart catheterization.. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure. Examples of permanent implant would include any new heart valve. Implantation of a permanent pacemaker is excluded.. Patients with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation.. Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), Thrombocytopenia (Plt < 50,000 cell/mL).. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.. Need for emergency surgery for any reason.. Left ventricular ejection fraction <40%.. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.. Active upper GI bleeding within 3 months (90 days) prior to procedure.. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.. Recent CVA clinically confirmed (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure.. Estimated life expectancy < 1 year from conditions other than TR.. Expectation that patient will not improve despite treatment of tricuspid regurgitation. Currently participating in another investigational cardiac device study or any other clinical trial, including drugs or biologics. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.. Active bacterial endocarditis within 6 months (180 days) of procedure.. Patients with signs or symptoms of SVC syndrome, or hepatic cirrhosis not felt due to passive congestion from TR.. ",
        "Annotations": [
            "Condition 42 106--*--heart team considers the patient to be a good surgical candidate",
            "Procedure 0 36--*--Heart Team assessment of operability",
            "Condition 125 152--*--acute myocardial infarction",
            "Temporal 153 202--*--= 1 month (30 days) before the intended treatment",
            "Condition 406 428--*--valvular heart disease",
            "Qualifier 395 405--*--left sided",
            "Qualifier 387 393--*--severe",
            "Qualifier 376 385--*--Untreated",
            "Condition 439 459--*--mitral regurgitation",
            "Condition 439 445;463 471--*--mitral stenosis",
            "Condition 477 497--*--aortic regurgitation",
            "Condition 477 483;501 509--*--aortic stenosis",
            "Scope 439 509--*--mitral regurgitation or stenosis, and aortic regurgitation or stenosis",
            "Measurement 512 543--*--Mean pulmonary artery pressures",
            "Value 544 551--*--=40mmHG",
            "Measurement 556 559--*--PVR",
            "Value 560 574--*-->4 woods units",
            "Condition 590 617--*--right heart catheterization",
            "Scope 512 574--*--Mean pulmonary artery pressures =40mmHG and PVR >4 woods units",
            "Procedure 645 662--*--cardiac procedure",
            "Qualifier 636 644--*--invasive",
            "Qualifier 624 635--*--therapeutic",
            "Device 678 695--*--permanent implant",
            "Temporal 714 751--*--within 30 days of the index procedure",
            "Reference_point 732 751--*--the index procedure",
            "Device 805 816--*--heart valve",
            "Device 836 855--*--permanent pacemaker",
            "Negation 859 867--*--excluded",
            "Procedure 904 912;930 938--*--surgical ablation",
            "Procedure 916 938--*--transcatheter ablation",
            "Condition 943 962--*--Atrial Fibrillation",
            "Mood 884 891--*--planned",
            "Temporal 892 903--*--concomitant",
            "Scope 904 938--*--surgical or transcatheter ablation",
            "Condition 965 975--*--Leukopenia",
            "Measurement 977 980--*--WBC",
            "Value 981 995--*--< 3000 cell/mL",
            "Condition 998 1010--*--acute anemia",
            "Measurement 1012 1015--*--Hgb",
            "Value 1016 1024--*--< 9 g/dL",
            "Condition 1027 1043--*--Thrombocytopenia",
            "Measurement 1045 1048--*--Plt",
            "Value 1049 1065--*--< 50,000 cell/mL",
            "Condition 1084 1107--*--respiratory instability",
            "Procedure 1118 1135--*--inotropic support",
            "Condition 1069 1080;1096 1107--*--Hemodynamic instability",
            "Procedure 1137 1159--*--mechanical ventilation",
            "Procedure 1163 1190--*--mechanical heart assistance",
            "Temporal 1191 1229--*--within 30 days of screening evaluation",
            "Reference_point 1209 1229--*--screening evaluation",
            "Scope 1118 1190--*--inotropic support, mechanical ventilation or mechanical heart assistance",
            "Scope 1069 1107--*--Hemodynamic or respiratory instability",
            "Procedure 1241 1258--*--emergency surgery",
            "Mood 1232 1240--*--Need for",
            "Measurement 1276 1310--*--Left ventricular ejection fraction",
            "Value 1311 1315--*--<40%",
            "Procedure 1318 1335--*--Echocardiographic",
            "Condition 1348 1365--*--intracardiac mass",
            "Condition 1348 1360;1367 1375--*--intracardiac thrombus",
            "Condition 1348 1360;1379 1389--*--intracardiac vegetation",
            "Scope 1348 1389--*--intracardiac mass, thrombus or vegetation",
            "Temporal 1392 1398--*--Active",
            "Condition 1399 1416--*--upper GI bleeding",
            "Temporal 1417 1461--*--within 3 months (90 days) prior to procedure",
            "Reference_point 1452 1461--*--procedure",
            "Condition 1472 1488--*--contraindication",
            "Condition 1492 1508--*--hypersensitivity",
            "Procedure 1516 1540--*--anticoagulation regimens",
            "Condition 1545 1554--*--inability",
            "Procedure 1561 1575--*--anticoagulated",
            "Temporal 1576 1599--*--for the study procedure",
            "Reference_point 1584 1599--*--study procedure",
            "Scope 1472 1508--*--contraindication or hypersensitivity",
            "Condition 1609 1612--*--CVA",
            "Procedure 1654 1666--*--neuroimaging",
            "Value 1667 1676--*--confirmed",
            "Condition 1677 1683--*--stroke",
            "Condition 1687 1718--*--transient ischemic attack (TIA)",
            "Scope 1677 1718--*--stroke or transient ischemic attack (TIA)",
            "Qualifier 1613 1650--*--clinically confirmed (by neurologist)",
            "Temporal 1719 1762--*--within 6 months (180 days) of the procedure",
            "Reference_point 1749 1762--*--the procedure",
            "Observation 1765 1790--*--Estimated life expectancy",
            "Value 1791 1799--*--< 1 year",
            "Non-query-able 1832 1918--*--Expectation that patient will not improve despite treatment of tricuspid regurgitation",
            "Non-query-able 1920 2221--*--Currently participating in another investigational cardiac device study or any other clinical trial, including drugs or biologics. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.",
            "Condition 2230 2252--*--bacterial endocarditis",
            "Temporal 2223 2229--*--Active",
            "Temporal 2253 2292--*--within 6 months (180 days) of procedure",
            "Reference_point 2280 2292--*--of procedure",
            "Condition 2330 2342--*--SVC syndrome",
            "Condition 2347 2364--*--hepatic cirrhosis",
            "Condition 2381 2407--*--passive congestion from TR"
        ]
    },
    "NCT02478515_exc": {
        "Annotations": [
            "Drug 24 39--*--anti-VEGF drugs",
            "Drug 43 57--*--corticosteroid",
            "Procedure 61 90--*--grid laser photocoagulation (",
            "Procedure 113 131--*--vitrectomy surgery",
            "Procedure 133 151--*--submacular surgery",
            "Procedure 162 183--*--surgical intervention",
            "Condition 188 191--*--RVO",
            "Non-query-able 193 276--*--Ocular disorders in the study eye that may confound interpretation of study results",
            "Measurement 278 282--*--BCVA",
            "Value 283 298--*--over 77 letters",
            "Pregnancy_considerations 328 359--*--The pregnant or lactating woman"
        ],
        "Text": "Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye). History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO. Ocular disorders in the study eye that may confound interpretation of study results. BCVA over 77 letters between screening and Day 0. The pregnant or lactating woman. "
    },
    "NCT02675153_inc": {
        "Text": "moderate to severe Crohn's Disease (basic HBI = 7) with stenosis. ",
        "Annotations": [
            "Qualifier 0 18--*--moderate to severe",
            "Condition 19 34--*--Crohn's Disease",
            "Measurement 36 45--*--basic HBI",
            "Value 46 49--*--= 7",
            "Condition 56 64--*--stenosis"
        ]
    },
    "NCT03120533_exc": {
        "Annotations": [
            "Parsing_Error 0 18--*--Healthy Volunteers",
            "Condition 33 50--*--contraindications",
            "Drug 20 32--*--Treprostinil",
            "Condition 58 74--*--hypersensitivity",
            "Drug 78 90--*--treprostinil",
            "Drug 94 115--*--any of the excipients",
            "Condition 117 148--*--Pulmonary arterial hypertension",
            "Condition 160 182--*--veno-occlusive disease",
            "Condition 184 208--*--Congestive heart failure",
            "Condition 223 251--*--left ventricular dysfunction",
            "Condition 260 281--*--hepatic insufficiency",
            "Qualifier 216 222--*--severe",
            "Qualifier 253 259--*--Severe",
            "Measurement 283 293--*--Child-Pugh",
            "Value 294 301--*--stage C",
            "Condition 313 335--*--gastrointestinal ulcer",
            "Qualifier 304 312--*--Evolving",
            "Condition 337 360--*--intracranial hemorrhage",
            "Condition 369 375--*--trauma",
            "Temporal 362 368--*--recent",
            "Condition 385 429--*--clinical condition that may lead to bleeding",
            "Undefined_semantics 385 429--*--clinical condition that may lead to bleeding",
            "Condition 431 441;454 476--*--Congenital valvular abnormalities",
            "Condition 445 476--*--acquired valvular abnormalities",
            "Qualifier 477 503--*--with cardiac repercussions",
            "Condition 512 534--*--ischemic heart disease",
            "Qualifier 505 511--*--Severe",
            "Condition 538 553--*--unstable angina",
            "Condition 555 576--*--Myocardial infarction",
            "Temporal 577 599--*--in the last six months",
            "Condition 601 636--*--Decompensated cardiac insufficiency",
            "Qualifier 637 661--*--not medically controlled",
            "Condition 670 681--*--arrhythmias",
            "Qualifier 663 669--*--Severe",
            "Condition 683 706--*--Cerebrovascular lesions",
            "Condition 716 741--*--transient ischemic attack",
            "Condition 743 749--*--stroke",
            "Scope 716 749--*--transient ischemic attack, stroke",
            "Temporal 765 793--*--within the last three months",
            "Context_Error 796 879--*--Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code",
            "Condition 881 889--*--pregnant",
            "Person 890 895--*--woman",
            "Condition 897 907--*--parturient",
            "Condition 909 916--*--nursing",
            "Observation 932 951--*--deprived of liberty",
            "Scope 881 951--*--pregnant woman, parturient, nursing mother, person deprived of liberty",
            "Context_Error 1079 1129--*--Subject in an exclusion period from another study,",
            "Non-query-able 1079 1129--*--Subject in an exclusion period from another study,",
            "Non-query-able 1131 1285--*--Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study",
            "Context_Error 1131 1285--*--Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study",
            "Condition 1287 1305--*--Systemic sclerosis",
            "Drug 1317 1325--*--Iloprost",
            "Temporal 1343 1364--*--in the previous month",
            "Temporal 1376 1398--*--in the following month",
            "Observation 1368 1375--*--planned",
            "Drug 1317 1325--*--Iloprost",
            "Non-query-able 1368 1398--*--planned in the following month",
            "Drug 1435 1443--*--bosentan",
            "Drug 1445 1455--*--sildenafil",
            "Drug 1459 1483--*--calcium channel blockers",
            "Temporal 1484 1505--*--in the previous month",
            "Temporal 1509 1531--*--in the following month",
            "Scope 1484 1531--*--in the previous month or in the following month",
            "Scope 1435 1483--*--bosentan, sildenafil or calcium channel blockers",
            "Procedure 1533 1554--*--Digital Sympathectomy",
            "Procedure 1558 1583--*--botulinum toxin injection",
            "Observation 1584 1591--*--planned",
            "Non-query-able 1584 1591--*--planned",
            "Temporal 1592 1614--*--in the following month",
            "Scope 1533 1583--*--Digital Sympathectomy or botulinum toxin injection",
            "Condition 1642 1656--*--digital ulcers",
            "Observation 1628 1641--*--superinfected",
            "Drug 1658 1670--*--Treprostinil",
            "Condition 1671 1688--*--contraindications",
            "Condition 1696 1712--*--hypersensitivity",
            "Drug 1716 1728--*--treprostinil",
            "Drug 1732 1753--*--any of the excipients",
            "Scope 1716 1753--*--treprostinil or any of the excipients",
            "Condition 1755 1786--*--Pulmonary arterial hypertension",
            "Condition 1798 1820--*--veno-occlusive disease",
            "Condition 1822 1846--*--Congestive heart failure",
            "Condition 1861 1889--*--left ventricular dysfunction",
            "Qualifier 1854 1860--*--severe",
            "Condition 1898 1919--*--hepatic insufficiency",
            "Qualifier 1891 1897--*--Severe",
            "Measurement 1921 1931--*--Child-Pugh",
            "Value 1932 1939--*--stage C",
            "Condition 1951 1973--*--gastrointestinal ulcer",
            "Condition 1975 1998--*--intracranial hemorrhage",
            "Condition 2007 2013--*--trauma",
            "Temporal 2000 2006--*--recent",
            "Condition 2023 2067--*--clinical condition that may lead to bleeding",
            "Undefined_semantics 2023 2067--*--clinical condition that may lead to bleeding",
            "Condition 2069 2079;2092 2114--*--Congenital valvular abnormalities",
            "Condition 2083 2114--*--acquired valvular abnormalities",
            "Qualifier 2115 2141--*--with cardiac repercussions",
            "Condition 2150 2172--*--ischemic heart disease",
            "Qualifier 2143 2149--*--Severe",
            "Condition 2176 2191--*--unstable angina",
            "Condition 2193 2214--*--Myocardial infarction",
            "Temporal 2215 2237--*--in the last six months",
            "Condition 2239 2274--*--Decompensated cardiac insufficiency",
            "Condition 2308 2319--*--arrhythmias",
            "Qualifier 2301 2307--*--Severe",
            "Condition 2321 2344--*--Cerebrovascular lesions",
            "Condition 2354 2379--*--transient ischemic attack",
            "Condition 2381 2387--*--stroke",
            "Temporal 2403 2431--*--within the last three months",
            "Scope 2354 2387--*--transient ischemic attack, stroke",
            "Scope 2000 2013--*--recent trauma",
            "Context_Error 2434 2517--*--Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code",
            "Condition 2519 2527--*--pregnant",
            "Person 2528 2533--*--woman",
            "Condition 2535 2545--*--parturient",
            "Condition 2547 2554--*--nursing",
            "Observation 2570 2589--*--deprived of liberty",
            "Observation 2637 2666--*--subject to a legal protection",
            "Scope 2519 2666--*--pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection",
            "Non-query-able 2717 2766--*--Subject in an exclusion period from another study",
            "Context_Error 2717 2766--*--Subject in an exclusion period from another study",
            "Non-query-able 2769 2923--*--Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study"
        ],
        "Text": "Healthy Volunteers . Treprostinil contraindications: Known hypersensitivity to treprostinil or any of the excipients, Pulmonary arterial hypertension related to veno-occlusive disease, Congestive heart failure due to severe left ventricular dysfunction, Severe hepatic insufficiency (Child-Pugh stage C), Evolving gastrointestinal ulcer, intracranial hemorrhage, recent trauma or other clinical condition that may lead to bleeding, Congenital or acquired valvular abnormalities with cardiac repercussions, Severe ischemic heart disease or unstable angina; Myocardial infarction in the last six months; Decompensated cardiac insufficiency not medically controlled; Severe arrhythmias; Cerebrovascular lesions (such as transient ischemic attack, stroke) that occurred within the last three months. . Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, can not Be included in clinical trials. . Subject in an exclusion period from another study, . Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study . Systemic sclerosis patients: . Iloprost cure carried out in the previous month or planned in the following month. . Initiation or change of dosage of bosentan, sildenafil or calcium channel blockers in the previous month or in the following month . Digital Sympathectomy or botulinum toxin injection planned in the following month. . Clinically superinfected digital ulcers . Treprostinil contraindications: Known hypersensitivity to treprostinil or any of the excipients, Pulmonary arterial hypertension related to veno-occlusive disease, Congestive heart failure due to severe left ventricular dysfunction, Severe hepatic insufficiency (Child-Pugh stage C), Evolving gastrointestinal ulcer, intracranial hemorrhage, recent trauma or other clinical condition that may lead to bleeding, Congenital or acquired valvular abnormalities with cardiac repercussions, Severe ischemic heart disease or unstable angina; Myocardial infarction in the last six months; Decompensated cardiac insufficiency not medically controlled; Severe arrhythmias; Cerebrovascular lesions (such as transient ischemic attack, stroke) that occurred within the last three months. . Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, can not Be included in clinical trials. . Subject in an exclusion period from another study, . Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study       .     . "
    },
    "NCT01742117_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT03044093_exc": {
        "Annotations": [
            "Condition 0 19--*--hematology diseases",
            "Condition 21 47--*--clotting factor deficiency"
        ],
        "Text": "hematology diseases. clotting factor deficiency. "
    },
    "NCT00846703_exc": {
        "Text": "No Down syndrome. No other major disease that prohibits study treatment (e.g., severe congenital heart disease). Not requiring significant therapy modification owing to study therapy associated complications. No complications due to other interventions. No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm. ",
        "Annotations": [
            "Negation 0 2--*--No",
            "Negation 18 20--*--No",
            "Negation 113 116--*--Not",
            "Negation 209 211--*--No",
            "Negation 254 256--*--No",
            "Condition 3 16--*--Down syndrome",
            "Condition 27 40--*--major disease",
            "Qualifier 21 26--*--other",
            "Condition 86 110--*--congenital heart disease",
            "Qualifier 79 85--*--severe",
            "Non-query-able 41 71--*--that prohibits study treatment",
            "Procedure 169 182--*--study therapy",
            "Condition 194 207--*--complications",
            "Non-query-able 113 207--*--Not requiring significant therapy modification owing to study therapy associated complications",
            "Non-query-able 255 369--*--o one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm",
            "Procedure 239 252--*--interventions",
            "Qualifier 233 238--*--other",
            "Condition 212 225--*--complications"
        ]
    },
    "NCT02431442_inc": {
        "Annotations": [
            "Post-eligibility 0 133--*--Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures.",
            "Non-query-able 0 133--*--Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures.",
            "Condition 143 148--*--obese",
            "Condition 135 142--*--Healthy",
            "Person 149 153--*--male",
            "Person 158 164--*--female",
            "Grammar_Error 154 157--*--and",
            "Person 176 180--*--aged",
            "Value 181 206--*--18 to 55 years, inclusive",
            "Condition 208 220--*--Heterozygous",
            "Context_Error 208 220--*--Heterozygous",
            "Value 237 261--*--18 to 65 years inclusive",
            "Parsing_Error 208 262--*--Heterozygous subjects may be 18 to 65 years inclusive.",
            "Condition 267 286--*--good general health",
            "Undefined_semantics 264 393--*--In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.",
            "Context_Error 264 393--*--In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.",
            "Subjective_judgement 264 393--*--In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.",
            "Measurement 395 410--*--Body Mass Index",
            "Value 414 436--*--30-40 kg/m2, inclusive",
            "Condition 438 450--*--Heterozygous",
            "Context_Error 438 450--*--Heterozygous",
            "Condition 505 517--*--heterozygous",
            "Measurement 538 541--*--BMI",
            "Value 542 566--*--27 -55 kg/ m2, inclusive",
            "Parsing_Error 438 567--*--Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive.",
            "Measurement 576 587--*--body weight",
            "Qualifier 569 575--*--Stable",
            "Temporal 588 616--*--during the previous 6 months",
            "Subjective_judgement 618 648--*--based on Investigator judgment",
            "Measurement 651 665--*--Blood pressure",
            "Value 666 678--*--<140/90 mmHg",
            "Temporal 679 699--*--at Screening and D-1",
            "Reference_point 682 699--*--Screening and D-1",
            "Parsing_Error 701 777--*--Measurement may be repeated within 24 hours, based on Investigator judgment.",
            "Subjective_judgement 701 777--*--Measurement may be repeated within 24 hours, based on Investigator judgment.",
            "Non-query-able 701 777--*--Measurement may be repeated within 24 hours, based on Investigator judgment.",
            "Condition 799 807--*--pregnant",
            "Negation 792 795--*--not",
            "Person 779 786--*--Females",
            "Measurement 833 853--*--serum pregnancy test",
            "Value 824 832--*--negative",
            "Temporal 861 894--*--at the Screening Visit and Day -1",
            "Reference_point 864 894--*--the Screening Visit and Day -1",
            "Post-eligibility 779 895--*--Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1.",
            "Condition 908 930--*--childbearing potential",
            "Non-query-able 897 1194--*--Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD.",
            "Post-eligibility 897 1194--*--Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD.",
            "Procedure 1195 1217--*--Hormonal contraception",
            "Temporal 1236 1272--*--at least 3 months prior to screening",
            "Reference_point 1263 1272--*--screening",
            "Post-eligibility 1274 1398--*--A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.",
            "Post-eligibility 1399 1519--*--Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.",
            "Non-query-able 1274 1398--*--A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.",
            "Non-query-able 1399 1519--*--Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.",
            "Non-query-able 1521 1831--*--Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study.",
            "Post-eligibility 1521 1831--*--Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study.",
            "Non-query-able 1833 2084--*--Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit.",
            "Post-eligibility 1833 2084--*--Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit.",
            "Non-query-able 2085 2271--*--Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.",
            "Post-eligibility 2085 2271--*--Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.",
            "Post-eligibility 2272 2397--*--Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.",
            "Non-query-able 2272 2397--*--Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution."
        ],
        "Text": "Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures. . Healthy obese male and female volunteers aged 18 to 55 years, inclusive. Heterozygous subjects may be 18 to 65 years inclusive. . In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities. . Body Mass Index of 30-40 kg/m2, inclusive. Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive. . Stable body weight during the previous 6 months, based on Investigator judgment. . Blood pressure <140/90 mmHg at Screening and D-1. Measurement may be repeated within 24 hours, based on Investigator judgment. . Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1. . Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD. Hormonal contraception must have started at least 3 months prior to screening. A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution. . Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study. . Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit. Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time. Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution. . "
    },
    "NCT02678728_exc": {
        "Annotations": [
            "Qualifier 0 8--*--Unstable",
            "Condition 9 19--*--vital sign",
            "Temporal 20 34--*--before surgery",
            "Procedure 27 34--*--surgery",
            "Reference_point 27 34--*--surgery",
            "Condition 43 60--*--pulmonary disease",
            "Procedure 71 91--*--consistent treatment",
            "Mood 61 70--*--requiring",
            "Qualifier 36 42--*--Severe",
            "Observation 93 103--*--Illiterate",
            "Condition 105 114--*--Pregnancy"
        ],
        "Text": "Unstable vital sign before surgery. Severe pulmonary disease requiring consistent treatment. Illiterate. Pregnancy. "
    },
    "NCT03149887_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 21 24--*--age",
            "Value 15 20;25 33--*--up to 75 years",
            "Qualifier 46 54--*--elective",
            "Visit 56 66--*--ambulatory",
            "Procedure 68 100--*--arthroscopic rotator cuff repair"
        ],
        "Text": "Adult patients up to age 75 years, undergoing elective, ambulatory, arthroscopic rotator cuff repair.. "
    },
    "NCT02295202_inc": {
        "Text": "Metabolic Syndrome (ATP III). Moderate to severe OSA. ",
        "Annotations": [
            "Condition 0 18--*--Metabolic Syndrome",
            "Measurement 20 23--*--ATP",
            "Value 24 27--*--III",
            "Qualifier 30 48--*--Moderate to severe",
            "Condition 49 52--*--OSA"
        ]
    },
    "NCT02227992_inc": {
        "Text": "Paediatric subjects aged =28 days (= 1 month) to <18 years, requiring non-emergent open hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures. i) The first 36 subjects to be enrolled will be subjects aged =1 years to <18 years. ii) The next 4 subjects to be enrolled will be subjects aged =28 days to <1 year.. The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study.. Presence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon;. Ability to firmly press trial treatment at TBS until 4 minutes after randomisation. ",
        "Annotations": [
            "Person 20 24--*--aged",
            "Value 25 58--*--=28 days (= 1 month) to <18 years",
            "Procedure 158 177--*--surgical procedures",
            "Qualifier 135 143--*--thoracic",
            "Qualifier 125 131--*--pelvic",
            "Qualifier 108 123--*--retroperitoneal",
            "Qualifier 97 106--*--abdominal",
            "Qualifier 88 95--*--hepatic",
            "Qualifier 83 87--*--open",
            "Qualifier 70 82--*--non-emergent",
            "Qualifier 145 156--*--non-cardiac",
            "Scope 88 157--*--hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac)",
            "Non-query-able 182 344--*--The first 36 subjects to be enrolled will be subjects aged =1 years to <18 years. ii) The next 4 subjects to be enrolled will be subjects aged =28 days to <1 year",
            "Informed_consent 347 966--*--The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study",
            "Non-query-able 970 1126--*--resence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon",
            "Post-eligibility 1129 1211--*--Ability to firmly press trial treatment at TBS until 4 minutes after randomisation"
        ]
    },
    "NCT03476850_exc": {
        "Text": "Chronic pain or narcotic usage during the preceding 30 days. Infection at or near the intended needle insertion site. Complex or altered abdominal wall anatomy. Weight <45kg. ",
        "Annotations": [
            "Condition 0 12--*--Chronic pain",
            "Drug 16 24--*--narcotic",
            "Temporal 31 59--*--during the preceding 30 days",
            "Scope 0 24--*--Chronic pain or narcotic",
            "Condition 61 70--*--Infection",
            "Qualifier 86 116--*--intended needle insertion site",
            "Condition 129 159--*--altered abdominal wall anatomy",
            "Condition 118 125;137 159--*--Complex abdominal wall anatomy",
            "Measurement 161 167--*--Weight",
            "Value 168 173--*--<45kg"
        ]
    },
    "NCT03120533_inc": {
        "Annotations": [
            "Parsing_Error 0 19--*--Healthy Volunteers:",
            "Value 28 45--*--at least 18 years",
            "Person 21 24--*--Age",
            "Device 62 82--*--contraceptive method",
            "Person 87 92--*--women",
            "Value 96 109--*--child-bearing",
            "Person 110 113--*--age",
            "Scope 87 113--*--women of child-bearing age",
            "Non-query-able 115 183--*--Person affiliated to social security or beneficiary of such a scheme",
            "Non-query-able 185 204--*--Signed consent form",
            "Not_a_criteria 206 234--*--Systemic sclerosis patients:",
            "Condition 236 254--*--Systemic sclerosis",
            "Measurement 267 281--*--EULAR criteria",
            "Value 255 262--*--meeting",
            "Multiplier 296 306;346 370--*--at least 2 on two different fingers",
            "Condition 307 345--*--ischemic digital cutaneous ulcerations",
            "Condition 377 391--*--digital ulcers",
            "Qualifier 407 413--*--active",
            "Measurement 439 478--*--North American working group definition",
            "Qualifier 480 689--*--epithelial denudation is clearly Visible at one place and the bed of de-epithelialized ulcer can be seen; Ulcerations distal to the proximal interphalangeal joint, not associated with calcinosis or bony relief",
            "Condition 692 698--*--Ulcers",
            "Measurement 705 715--*--major axis",
            "Value 756 762--*--\u2265 2 mm",
            "Qualifier 716 752--*--measured with the electronic caliper",
            "Person 764 767--*--Age",
            "Value 768 801--*--greater than or equal to 18 years",
            "Device 818 831--*--contraceptive",
            "Person 843 848--*--women",
            "Value 852 864--*--reproductive",
            "Person 865 868--*--age",
            "Scope 843 868--*--women of reproductive age",
            "Non-query-able 870 924--*--A person who is or is a beneficiary of social security",
            "Non-query-able 926 1009--*--Informed and signed consent signed by the patient or his / her legal representative"
        ],
        "Text": "Healthy Volunteers: . Age of at least 18 years . Existence of a contraceptive method for women of child-bearing age . Person affiliated to social security or beneficiary of such a scheme . Signed consent form . Systemic sclerosis patients: . Systemic sclerosis meeting the EULAR criteria. . Presence of at least 2 ischemic digital cutaneous ulcerations on two different fingers, with digital ulcers classified as \"active ulcers\" according to the North American working group definition: epithelial denudation is clearly Visible at one place and the bed of de-epithelialized ulcer can be seen; Ulcerations distal to the proximal interphalangeal joint, not associated with calcinosis or bony relief. . Ulcers whose major axis measured with the electronic caliper is \u2265 2 mm . Age greater than or equal to 18 years . Existence of a contraceptive method for women of reproductive age . A person who is or is a beneficiary of social security . Informed and signed consent signed by the patient or his / her legal representative. . "
    },
    "NCT02675153_exc": {
        "Text": "Allergic to sirolimus or serious side effects. Need emergency surgery. Accompanied with other severe disease (involve C.diff infection). Follow-up less than 1 year. ",
        "Annotations": [
            "Condition 0 8--*--Allergic",
            "Drug 12 21--*--sirolimus",
            "Qualifier 25 32--*--serious",
            "Condition 33 45--*--side effects",
            "Mood 47 51--*--Need",
            "Temporal 147 163--*--less than 1 year",
            "Measurement 137 146--*--Follow-up",
            "Procedure 52 69--*--emergency surgery",
            "Condition 94 108--*--severe disease",
            "Condition 118 134--*--C.diff infection"
        ]
    },
    "NCT02478515_inc": {
        "Annotations": [
            "Informed_consent 0 28--*--Signed informed consent form",
            "Condition 30 42--*--Macula edema",
            "Condition 56 60--*--BRVO",
            "Measurement 62 66--*--BCVA",
            "Value 70 86--*--77 to 20 letters",
            "Measurement 126 129--*--CRT",
            "Value 138 143--*--250\u00b5m"
        ],
        "Text": "Signed informed consent form. Macula edema secondary to BRVO. BCVA of 77 to 20 letters assessed with the use of ETDRS charts. CRT <U+2267>250\u00b5m. "
    },
    "NCT02339974_inc": {
        "Text": "Patients must be at least 21 years old.. The patient must have severe, symptomatic (ACC/AHA Stage D symptoms) tricuspid regurgitation (TR) as assessed by 2D echocardiogram with evidence of peripheral and central venous congestion (specifically lower extremity edema and abdominal ascites requiring diuretics.). The patient must be evaluated by a \"heart team\" of physicians including an interventional cardiologist, cardiothoracic surgeon, heart failure specialist, and imaging specialist, and presented for review at a local multi-disciplinary conference. By consensus, the heart team must agree (and verify in the case review process) that valve implantation will likely benefit the patient.. The heart team must agree that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Also, other factors which may increase the patients perceived surgical risk for inclusion in the trial will be clearly delineated if they are present. These include, but are not limited to the following as defined by VARC 2: Frailty, Hostile chest, porcelain aorta, IMA or other critical conduit crossing the midline or adherent to the posterior table of sternum, severe right ventricular (RV) dysfunction. The surgeons' consultation notes shall specify the medical or anatomic factors leading to that conclusion. At least one of the cardiac surgeon assessors must have interviewed and examined the patient.. The study patient provides informed consent and agrees to comply with all required post-procedure follow-up visits, including annual visits up to 5 years.. ",
        "Annotations": [
            "Person 35 38--*--old",
            "Value 17 34--*--at least 21 years",
            "Qualifier 63 69--*--severe",
            "Qualifier 71 82--*--symptomatic",
            "Condition 110 133--*--tricuspid regurgitation",
            "Condition 135 137--*--TR",
            "Measurement 84 91--*--ACC/AHA",
            "Value 92 99--*--Stage D",
            "Procedure 154 171--*--2D echocardiogram",
            "Condition 189 199;212 229--*--peripheral venous congestion",
            "Condition 204 229--*--central venous congestion",
            "Condition 244 265--*--lower extremity edema",
            "Condition 270 287--*--abdominal ascites",
            "Drug 298 307--*--diuretics",
            "Scope 189 229--*--peripheral and central venous congestion",
            "Scope 244 307--*--lower extremity edema and abdominal ascites requiring diuretics",
            "Non-query-able 311 691--*--The patient must be evaluated by a \"heart team\" of physicians including an interventional cardiologist, cardiothoracic surgeon, heart failure specialist, and imaging specialist, and presented for review at a local multi-disciplinary conference. By consensus, the heart team must agree (and verify in the case review process) that valve implantation will likely benefit the patient",
            "Non-query-able 694 1506--*--The heart team must agree that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Also, other factors which may increase the patients perceived surgical risk for inclusion in the trial will be clearly delineated if they are present. These include, but are not limited to the following as defined by VARC 2: Frailty, Hostile chest, porcelain aorta, IMA or other critical conduit crossing the midline or adherent to the posterior table of sternum, severe right ventricular (RV) dysfunction. The surgeons' consultation notes shall specify the medical or anatomic factors leading to that conclusion. At least one of the cardiac surgeon assessors must have interviewed and examined the patient.",
            "Post-eligibility 1508 1662--*--The study patient provides informed consent and agrees to comply with all required post-procedure follow-up visits, including annual visits up to 5 years."
        ]
    },
    "NCT03044093_inc": {
        "Annotations": [
            "Condition 0 7--*--healthy",
            "Condition 12 19--*--allergy",
            "Drug 29 40--*--these drugs",
            "Negation 9 11--*--no",
            "Qualifier 42 58--*--second trimester",
            "Condition 59 67--*--abortion"
        ],
        "Text": "healthy. no allergy known to these drugs. second trimester abortion. "
    },
    "NCT01742117_inc": {
        "Text": "Patient >18 years of age. Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD). Patient is eligible for PCI. Patient is willing and able to provide informed written consent. Patient not able to receive 12 months of dual anti-platelet therapy. Failure of index PCI. Patient or physician refusal to enroll in the study. Patient with known CYP2C19 genotype prior to randomization. Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure. Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery. Serum creatinine >2.5 mg/dL within 7 days of index procedure. Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.. History of intracranial hemorrhage. Known hypersensitivity to clopidogrel or ticagrelor or any of its components. Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint. Patient previously enrolled in this study. Patient is pregnant, lactating, or planning to become pregnant within 12 months. Patient has received an organ transplant or is on a waiting list for an organ transplant. Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure. Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.). Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor). Concomitant use of simvastatin/lovastatin > 40 mg qd. Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine). Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer). Known history of severe hepatic impairment. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions. Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding. Inability to take aspirin at a dosage of 100 mg or less. Current substance abuse (e.g., alcohol, cocaine, heroin, etc.). ",
        "Annotations": [
            "Person 21 24--*--age",
            "Value 8 17--*-->18 years",
            "Condition 48 71--*--acute coronary syndrome",
            "Condition 73 76--*--ACS",
            "Condition 88 111--*--coronary artery disease",
            "Condition 113 116--*--CAD",
            "Qualifier 81 87--*--stable",
            "Procedure 143 146--*--PCI",
            "Mood 130 138--*--eligible",
            "Post-eligibility 148 211--*--Patient is willing and able to provide informed written consent",
            "Condition 225 240--*--able to receive",
            "Procedure 254 280--*--dual anti-platelet therapy",
            "Temporal 241 250--*--12 months",
            "Procedure 299 302--*--PCI",
            "Temporal 293 298--*--index",
            "Observation 282 289--*--Failure",
            "Post-eligibility 304 355--*--Patient or physician refusal to enroll in the study",
            "Condition 376 392--*--CYP2C19 genotype",
            "Temporal 393 415--*--prior to randomization",
            "Reference_point 402 415--*--randomization",
            "Procedure 425 442--*--revascularization",
            "Mood 417 424--*--Planned",
            "Qualifier 446 456--*--any vessel",
            "Temporal 457 492--*--within 30 days post-index procedure",
            "Reference_point 477 492--*--index procedure",
            "Temporal 524 555--*--within 12 months post-procedure",
            "Reference_point 546 555--*--procedure",
            "Qualifier 500 523--*--of the target vessel(s)",
            "Scope 446 555--*--any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure",
            "Drug 588 599--*--clopidogrel",
            "Drug 603 613--*--ticagrelor",
            "Temporal 614 650--*--within the 12 month follow up period",
            "Procedure 664 680--*--elective surgery",
            "Mood 652 663--*--example for",
            "Scope 588 612--*--clopidogrel or ticagrelo",
            "Measurement 682 698--*--Serum creatinine",
            "Value 699 709--*-->2.5 mg/dL",
            "Temporal 710 742--*--within 7 days of index procedure",
            "Reference_point 727 742--*--index procedure",
            "Measurement 744 758--*--Platelet count",
            "Value 759 788--*--<80,000 or >700,000 cells/mm3",
            "Measurement 793 815--*--white blood cell count",
            "Value 816 832--*--<3,000 cells/mm3",
            "Temporal 876 914--*--within 7 days prior to index procedure",
            "Reference_point 899 914--*--index procedure",
            "Scope 744 832--*--Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3",
            "Condition 928 951--*--intracranial hemorrhage",
            "Condition 959 975--*--hypersensitivity",
            "Drug 979 990--*--clopidogrel",
            "Drug 994 1004--*--ticagrelor",
            "Drug 1008 1029--*--any of its components",
            "Scope 979 1004--*--clopidogrel or ticagrelor",
            "Non-query-able 1031 1149--*--Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint",
            "Non-query-able 1151 1192--*--Patient previously enrolled in this study",
            "Condition 1205 1213--*--pregnant",
            "Condition 1215 1224--*--lactating",
            "Mood 1229 1247--*--planning to become",
            "Condition 1248 1256--*--pregnant",
            "Temporal 1257 1273--*--within 12 months",
            "Procedure 1299 1315--*--organ transplant",
            "Mood 1319 1339--*--is on a waiting list",
            "Procedure 1347 1363--*--organ transplant",
            "Procedure 1410 1422--*--chemotherapy",
            "Mood 1373 1385--*--is receiving",
            "Mood 1389 1409--*--scheduled to receive",
            "Scope 1373 1409--*--is receiving or scheduled to receive",
            "Temporal 1423 1467--*--within 30 days before or after the procedure",
            "Reference_point 1454 1467--*--the procedure",
            "Procedure 1490 1515--*--immunosuppressive therapy",
            "Condition 1529 1546;1561 1568--*--immunosuppressive disease",
            "Condition 1550 1568--*--autoimmune disease",
            "Condition 1576 1604--*--human immunodeficiency virus",
            "Condition 1606 1633--*--systemic lupus erythematous",
            "Scope 1576 1633--*--human immunodeficiency virus, systemic lupus erythematous",
            "Procedure 1671 1699--*--oral anticoagulation therapy",
            "Multiplier 1663 1670--*--chronic",
            "Drug 1707 1727--*--vitamin K antagonist",
            "Drug 1729 1754--*--direct thrombin inhibitor",
            "Drug 1756 1775--*--Factor Xa inhibitor",
            "Scope 1707 1775--*--vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor",
            "Drug 1797 1808--*--simvastatin",
            "Drug 1809 1819--*--lovastatin",
            "Multiplier 1820 1830--*--> 40 mg qd",
            "Temporal 1778 1789--*--Concomitant",
            "Drug 1851 1875--*--potent CYP3A4 inhibitors",
            "Drug 1877 1887--*--atazanavir",
            "Drug 1889 1903--*--clarithromycin",
            "Drug 1905 1914--*--indinavir",
            "Drug 1916 1928--*--itraconazole",
            "Drug 1930 1942--*--ketoconazole",
            "Drug 1944 1954--*--nefazodone",
            "Drug 1956 1966--*--nelfinavir",
            "Drug 1968 1977--*--ritonavir",
            "Drug 1979 1989--*--saquinavir",
            "Drug 1991 2004--*--telithromycin",
            "Drug 2009 2021--*--voriconazole",
            "Drug 1851 1864;2026 2034--*--potent CYP3A4 inducers",
            "Drug 2036 2049--*--carbamazepine",
            "Drug 2051 2064--*--dexamethasone",
            "Drug 2066 2079--*--phenobarbital",
            "Drug 2081 2090--*--phenytoin",
            "Drug 2092 2100--*--rifampin",
            "Drug 2106 2117--*--rifapentine",
            "Scope 2036 2117--*--carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine",
            "Scope 1877 2021--*--atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole",
            "Temporal 1832 1843--*--Concomitant",
            "Condition 2120 2141--*--Non-cardiac condition",
            "Observation 2151 2166--*--life expectancy",
            "Temporal 2170 2188--*--less than one year",
            "Condition 2252 2270--*--hepatic impairment",
            "Qualifier 2245 2251--*--severe",
            "Condition 2297 2315--*--bleeding diathesis",
            "Condition 2319 2331--*--coagulopathy",
            "Procedure 2347 2365--*--blood transfusions",
            "Mood 2335 2346--*--will refuse",
            "Condition 2389 2410--*--pathological bleeding",
            "Qualifier 2382 2388--*--active",
            "Qualifier 2420 2426--*--active",
            "Condition 2427 2457--*--gastrointestinal (GI) bleeding",
            "Condition 2459 2476--*--Inability to take",
            "Drug 2477 2484--*--aspirin",
            "Multiplier 2500 2514--*--100 mg or less",
            "Condition 2524 2539--*--substance abuse"
        ]
    },
    "NCT00728156_inc": {
        "Annotations": [
            "Condition 14 18--*--T2DM",
            "Condition 23 26--*--CAS",
            "Condition 68 72--*--T2DM",
            "Qualifier 101 113--*--WHO criteria",
            "Condition 121 124--*--CAD",
            "Condition 163 169--*--Angina",
            "Measurement 184 207--*--exercise tolerance test",
            "Value 175 183--*--positive",
            "Qualifier 223 238--*--Q wave positive",
            "Condition 239 260--*--myocardial infarction",
            "Qualifier 209 215;230 238--*--enzyme positive",
            "Scope 209 238--*--enzyme and/or Q wave positive",
            "Condition 262 283--*--angiographic evidence",
            "Value 286 290--*-->50%",
            "Measurement 291 313--*--stenosis of one vessel",
            "Person 370 374--*--Aged",
            "Value 375 392--*--between 18 and 75",
            "Observation 403 449--*--written consent for participation in the trial",
            "Temporal 450 504--*--prior to any study-specific procedures or requirements",
            "Reference_point 459 504--*--any study-specific procedures or requirements",
            "Scope 286 313--*-->50% stenosis of one vessel",
            "Scope 163 207--*--Angina plus positive exercise tolerance test",
            "Qualifier 332 340--*--surgical",
            "Qualifier 316 328--*--percutaneous",
            "Procedure 341 367--*--coronary revascularisation",
            "Scope 316 340--*--percutaneous or surgical",
            "Scope 163 367--*--Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation"
        ],
        "Text": "Patients with T2DM and CAS as defined below: . Clinical definitions . T2DM: Diagnosed according to the WHO criteria [53]. . CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation. . Aged between 18 and 75 . Provided written consent for participation in the trial prior to any study-specific procedures or requirements. . "
    },
    "NCT02481518_exc": {
        "Annotations": [
            "Drug 21 30--*--cisplatin",
            "Temporal 31 51--*--before randomization",
            "Reference_point 38 51--*--randomization",
            "Condition 66 84--*--concurrent disease",
            "Qualifier 53 65--*--Uncontrolled",
            "Condition 86 95--*--Pregnancy"
        ],
        "Text": "Prior treatment with cisplatin before randomization. Uncontrolled concurrent disease. Pregnancy. "
    },
    "NCT02837783_inc": {
        "Annotations": [
            "Qualifier 14 31--*--protocol criteria",
            "Condition 49 54--*--IBS-C",
            "Condition 56 70--*--abdominal pain",
            "Condition 72 90--*--abdominal bloating",
            "Condition 95 110--*--abdominal girth"
        ],
        "Text": "Patient meets protocol criteria for diagnosis of IBS-C, abdominal pain, abdominal bloating and abdominal girth. "
    },
    "NCT02760459_inc": {
        "Text": "Age > 40 years (45). Primary knee osteoarthritis diagnosed using the American College of Rheumatology criteria (46). Undergoing elective, primary and unilateral total knee arthroplasty. American Society of Anesthesiology (ASA) physical status class 1-3. BMI < 40 kg/m2. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--> 40 years",
            "Condition 21 48--*--Primary knee osteoarthritis",
            "Qualifier 69 110--*--American College of Rheumatology criteria",
            "Procedure 161 184--*--total knee arthroplasty",
            "Qualifier 150 160--*--unilateral",
            "Qualifier 138 145--*--primary",
            "Qualifier 128 136--*--elective",
            "Measurement 186 220;227 248--*--American Society of Anesthesiology physical status class",
            "Value 249 252--*--1-3",
            "Measurement 222 225--*--ASA",
            "Measurement 254 257--*--BMI",
            "Value 258 268--*--< 40 kg/m2"
        ]
    },
    "NCT01794793_exc": {
        "Text": "Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason. Patient has participated in a Novartis sponsored combination trial where pasireotide was dispensed in combination with another study medication and is still receiving combination therapy. (only patients receiving pasireotide monotherapy can be included). Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. Placement of an intrauterine device (IUD) or intrauterine system (IUS). Barrier methods of contraception: Condom or Occlusive cap diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Sexually active males unless they use a condom during intercourse while taking drug and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR last dose and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid If a study patient or partner becomes pregnant or suspects being pregnant during the study or within 1 month after the final dose of pasireotide s.c. or 3 months after the final dose of pasireotide LAR, the Study Doctor needs to be informed immediately and ongoing study treatment with pasireotide has to be stopped immediately For patients taking pasireotide LAR, the future dose injections will be cancelled.. ",
        "Annotations": [
            "Non-query-able 0 202--*--Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",
            "Competing_trial 204 457--*--Patient has participated in a Novartis sponsored combination trial where pasireotide was dispensed in combination with another study medication and is still receiving combination therapy. (only patients receiving pasireotide monotherapy can be included)",
            "Pregnancy_considerations 463 650--*--nant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test",
            "Pregnancy_considerations 652 891--*--Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",
            "Procedure 893 913--*--Female sterilization",
            "Procedure 933 955--*--bilateral oophorectomy",
            "Procedure 972 984--*--hysterectomy",
            "Procedure 989 1003--*--tubal ligation",
            "Temporal 1004 1052--*--at least six weeks before taking study treatment",
            "Reference_point 1030 1052--*--taking study treatment",
            "Scope 893 1003--*--Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation",
            "Non-query-able 1054 1188--*--In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment",
            "Procedure 1190 1208--*--Male sterilization",
            "Temporal 1210 1246--*--at least 6 months prior to screening",
            "Reference_point 1237 1246--*--screening",
            "Non-query-able 1249 1355--*--For female subjects on the study the vasectomized male partner should be the sole partner for that subject",
            "Non-query-able 1358 1516--*--Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%)",
            "Procedure 1530 1550--*--hormone vaginal ring",
            "Procedure 1554 1587--*--transdermal hormone contraception",
            "Device 1605 1624--*--intrauterine device",
            "Device 1626 1629--*--IUD",
            "Device 1634 1653--*--intrauterine system",
            "Device 1655 1658--*--IUS",
            "Procedure 1680 1693--*--contraception",
            "Device 1695 1701--*--Condom",
            "Device 1705 1728--*--Occlusive cap diaphragm",
            "Device 1741 1751--*--vault caps",
            "Device 1732 1740;1747 1751--*--cervical caps",
            "Procedure 1758 1774--*--spermicidal foam",
            "Non-query-able 1661 1949--*--Barrier methods of contraception: Condom or Occlusive cap diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment",
            "Non-query-able 1951 2702--*--Sexually active males unless they use a condom during intercourse while taking drug and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR last dose and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid If a study patient or partner becomes pregnant or suspects being pregnant during the study or within 1 month after the final dose of pasireotide s.c. or 3 months after the final dose of pasireotide LAR, the Study Doctor needs to be informed immediately and ongoing study treatment with pasireotide has to be stopped immediately For patients taking pasireotide LAR, the future dose injections will be cancelled."
        ]
    },
    "NCT03513874_exc": {
        "Annotations": [
            "Condition 15 25--*--malignancy",
            "Condition 35 50--*--severe diseases",
            "Pregnancy_considerations 52 143--*--Female patients who are pregnant or breastfeeding before or during the three-year follow-up",
            "Observation 145 160--*--Poor compliance",
            "Observation 164 186--*--refusal to participate"
        ],
        "Text": "History of any malignancy or other severe diseases. Female patients who are pregnant or breastfeeding before or during the three-year follow-up. Poor compliance or refusal to participate.. "
    },
    "NCT03016741_exc": {
        "Annotations": [
            "Drug 21 33--*--enzalutamide",
            "Drug 37 56--*--abiraterone acetate",
            "Multiplier 57 70--*--for > 14 days",
            "Temporal 71 90--*--prior to enrollment",
            "Reference_point 80 90--*--enrollment",
            "Procedure 6 15--*--treatment",
            "Scope 21 56--*--enzalutamide or abiraterone acetate",
            "Procedure 137 149--*--chemotherapy",
            "Condition 154 162;172 178--*--prostate cancer",
            "Qualifier 166 171--*--other",
            "Condition 172 178--*--cancer",
            "Scope 154 178--*--prostate or other cancer",
            "Temporal 179 204--*--within the past 12 months",
            "Condition 210 237--*--residual cognitive deficits",
            "Procedure 253 265--*--chemotherapy",
            "Condition 270 275--*--mCRPC",
            "Non-representable 277 402--*--Patients/physicians planning treatment with chemotherapy during the 12 month period of the investigation are also ineligible.",
            "Condition 415 435--*--cognitive impairment",
            "Condition 415 424;439 450--*--cognitive dysfunction",
            "Condition 475 483--*--dementia",
            "Condition 485 504--*--Alzheimer's disease",
            "Condition 506 512--*--stroke",
            "Condition 518 545--*--residual cognitive deficits",
            "Condition 547 568--*--cognitive dysfunction",
            "Condition 591 606--*--substance abuse",
            "Condition 580 587;601 606--*--alcohol abuse",
            "Scope 415 450--*--cognitive impairment or dysfunction",
            "Condition 611 632--*--cognitive dysfunction",
            "Procedure 650 659--*--treatment",
            "Temporal 644 649--*--prior",
            "Condition 668 674--*--cancer",
            "Qualifier 664 667--*--any",
            "Scope 475 674--*--dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer",
            "Condition 693 700--*--seizure",
            "Condition 721 736--*--recurrent falls",
            "Condition 747 763--*--brain metastases",
            "Observation 701 708--*--history",
            "Observation 710 720--*--history of",
            "Condition 987 1007--*--intercurrent illness",
            "Qualifier 974 986--*--Uncontrolled",
            "Qualifier 1039 1051--*--uncontrolled",
            "Condition 1052 1060--*--diabetes",
            "Temporal 1062 1069--*--ongoing",
            "Qualifier 1073 1079--*--active",
            "Condition 1080 1089--*--infection",
            "Scope 1062 1079--*--ongoing or active",
            "Qualifier 1091 1102--*--symptomatic",
            "Condition 1103 1127--*--congestive heart failure",
            "Measurement 1129 1155--*--New York Heart Association",
            "Value 1156 1172--*--Class III and IV",
            "Condition 1173 1186--*--heart failure",
            "Scope 1129 1186--*--New York Heart Association Class III and IV heart failure",
            "Scope 1091 1127--*--symptomatic congestive heart failure",
            "Condition 1189 1213--*--unstable angina pectoris",
            "Condition 1215 1233--*--cardiac arrhythmia",
            "Condition 1238 1257--*--psychiatric illness",
            "Condition 1258 1275--*--social situations",
            "Condition 1276 1291--*--substance abuse",
            "Scope 1039 1291--*--uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse",
            "Scope 974 1007--*--Uncontrolled intercurrent illness",
            "Multiplier 1381 1387--*--second",
            "Condition 1388 1398--*--malignancy",
            "Qualifier 1363 1379--*--currently active",
            "Condition 1410 1435--*--non-melanoma skin cancers",
            "Negation 1399 1409--*--other than",
            "Condition 1634 1655--*--cognitive dysfunction",
            "Procedure 1667 1676--*--treatment",
            "Qualifier 1680 1687--*--another",
            "Condition 1688 1698--*--malignancy",
            "Drug 1771 1795--*--psychotropic medications",
            "Drug 1799 1812--*--illicit drugs",
            "Condition 1822 1837--*--alter cognition",
            "Condition 1822 1827;1839 1852--*--alter concentration",
            "Condition 1822 1827;1857 1865--*--alter behavior",
            "Scope 1771 1812--*--psychotropic medications or illicit drugs",
            "Scope 1822 1865--*--alter cognition, concentration, or behavior",
            "Non-representable 1867 2062--*--Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitte"
        ],
        "Text": "Prior treatment with enzalutamide or abiraterone acetate for > 14 days prior to enrollment and completion of baseline tests.. Receipt of chemotherapy for prostate or other cancer within the past 12 months with residual cognitive deficits, or receipt of chemotherapy for mCRPC. Patients/physicians planning treatment with chemotherapy during the 12 month period of the investigation are also ineligible.. History of cognitive impairment or dysfunction, including a history of dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer.. Patients with a seizure history, history of recurrent falls, or known brain metastases are excluded from this clinical trial because of their poor prognosis and because of their heightened risk of seizure or progressive cognitive and/or neurologic dysfunction that would confound the evaluation.. Uncontrolled intercurrent illness including, but not limited to, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.. Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers are not eligible. Patients are not considered to have a \"currently active\" malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year. Patients with cognitive dysfunction related to treatment of another malignancy, including a history of \"chemo-brain\", are ineligible.. Patients taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior. Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitted. "
    },
    "NCT02416869_inc": {
        "Text": "Healthy patients (ASA I). Bilateral symmetrically impacted lower third molars according to Pel-Gregory's and Winter's classification. ",
        "Annotations": [
            "Condition 0 16--*--Healthy patients",
            "Measurement 18 21--*--ASA",
            "Value 22 23--*--I",
            "Measurement 91 132--*--Pel-Gregory's and Winter's classification",
            "Value 26 77--*--Bilateral symmetrically impacted lower third molars"
        ]
    },
    "NCT02570230_inc": {
        "Text": "ASA physical status 1-3. elective thoracotomy. can operate patient-controlled analgesia (PCA) machine. ",
        "Annotations": [
            "Measurement 0 19--*--ASA physical status",
            "Value 20 23--*--1-3",
            "Procedure 34 45--*--thoracotomy",
            "Qualifier 25 33--*--elective",
            "Non-query-able 47 101--*--can operate patient-controlled analgesia (PCA) machine"
        ]
    },
    "NCT02481518_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--> 18 years",
            "Measurement 16 50--*--Eastern Cooperative Oncology Group",
            "Value 51 60--*--score 0-2",
            "Condition 78 98--*--Head and neck cancer",
            "Mood 103 107--*--plan",
            "Drug 127 136--*--cisplatin",
            "Measurement 138 154--*--Serum creatinine",
            "Value 155 165--*--=1.5 mg/dl",
            "Measurement 169 173--*--eGFR",
            "Value 173 192--*--=60(ml/min/1.73 m2)"
        ],
        "Text": "Age > 18 years. Eastern Cooperative Oncology Group score 0-2. First Diagnosed Head and neck cancer and plan for treatment with cisplatin. Serum creatinine =1.5 mg/dl or eGFR=60(ml/min/1.73 m2). "
    },
    "NCT02837783_exc": {
        "Annotations": [
            "Condition 32 45--*--watery stools",
            "Condition 23 28;39 45--*--loose stools",
            "Observation 12 22--*--history of",
            "Scope 23 45--*--loose or watery stools",
            "Condition 64 95--*--clinically significant findings",
            "Qualifier 100 111--*--unexplained",
            "Condition 112 149--*--clinically significant alarm symptoms",
            "Condition 200 217--*--medical condition",
            "Qualifier 223 255--*--may contribute to abdominal pain",
            "Condition 241 255--*--abdominal pain",
            "Qualifier 273 290--*--protocol-excluded",
            "Qualifier 294 316--*--clinically significant",
            "Observation 328 344--*--surgical history",
            "Observation 317 324;337 344--*--medical history",
            "Scope 317 344--*--medical or surgical history",
            "Scope 273 316--*--protocol-excluded or clinically significant",
            "Qualifier 350 386--*--could confound the study assessments",
            "Post-eligibility 257 386--*--Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments"
        ],
        "Text": "Patient has history of loose or watery stools. Patient has both clinically significant findings and unexplained clinically significant alarm symptoms. Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain. Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments. "
    },
    "NCT00728156_exc": {
        "Annotations": [
            "Drug 20 31--*--Clopidogrel",
            "Condition 0 16--*--Contraindication",
            "Condition 33 40--*--Smoking",
            "Condition 50 57--*--smokers",
            "Temporal 42 49--*--current",
            "Condition 75 87--*--quit smoking",
            "Temporal 88 108--*--less than six months",
            "Condition 111 121--*--Malignancy",
            "Mood 122 131--*--diagnosed",
            "Mood 135 154--*--under investigation",
            "Scope 122 154--*--diagnosed or under investigation",
            "Condition 157 181--*--Haematological disorders",
            "Condition 183 190--*--Anaemia",
            "Condition 192 202--*--malignancy",
            "Condition 204 222--*--bleeding disorders",
            "Scope 183 222--*--Anaemia, malignancy, bleeding disorders",
            "Person 225 230--*--Women",
            "Condition 234 257--*--child-bearing potential",
            "Drug 266 281--*--corticosteroids",
            "Drug 288 309--*--antithrombotic agents",
            "Drug 310 318--*--warfarin",
            "Condition 321 342--*--Chronic liver disease",
            "Condition 344 353--*--Cirrhosis",
            "Condition 355 365--*--malignancy",
            "Value 384 415--*--more than twice the upper limit",
            "Measurement 419 439--*--liver function tests",
            "Scope 344 439--*--Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests",
            "Observation 442 460--*--Unable to consent.",
            "Drug 475 502--*--investigational study drugs",
            "Temporal 503 537--*--within 1 year prior to study entry",
            "Temporal 539 547--*--Previous",
            "Observation 548 575--*--participation in this study"
        ],
        "Text": "Contraindication to Clopidogrel . Smoking (current smokers and patients who quit smoking less than six months) . Malignancy(diagnosed or under investigation) . Haematological disorders (Anaemia, malignancy, bleeding disorders) . Women of child-bearing potential . Use of corticosteroids/other antithrombotic agents(warfarin) . Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests) . Unable to consent. . Use of other investigational study drugs within 1 year prior to study entry . Previous participation in this study       .     . "
    },
    "NCT01794793_inc": {
        "Text": "Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives. Patient is currently benefiting from the treatment with pasireotide, as determined by the investigator. Patient has demonstrated compliance, as assessed by the investigator, with the parent study requirements. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. Written informed consent obtained prior to enrolling in roll-over study and receiving study medication \u2022 If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness. ",
        "Annotations": [
            "Competing_trial 0 295--*--Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives",
            "Non-query-able 297 399--*--Patient is currently benefiting from the treatment with pasireotide, as determined by the investigator",
            "Non-query-able 401 505--*--Patient has demonstrated compliance, as assessed by the investigator, with the parent study requirements",
            "Post-eligibility 507 610--*--Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures",
            "Informed_consent 612 848--*--Written informed consent obtained prior to enrolling in roll-over study and receiving study medication \u2022 If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness"
        ]
    },
    "NCT02760459_exc": {
        "Text": "History of active rheumatic diseases. History of previous musculoskeletal injury of the same knee for excluding patients with secondary knee osteoarthritis. History of previous surgery on the same knee. History of adverse effects from medications to be used in this study. Contraindication to spinal anesthesia. History of psychiatric disorders or cognitive impairment. Contraindication to corticosteroid agents. Poorly controlled diabetes mellitus (HbA1C > 7.5). Poorly controlled hypertension. History of ischemic heart disease or peripheral arterial disease or cerebrovascular disease. Hepatic insufficiency (Child-Pugh score > 5). Renal insufficiency (Creatinine clearance < 30 mL/min). History of cataracts or glaucoma or ocular hypertension. History of steroid or immunosuppressive drug use within 6 months of surgery. ",
        "Annotations": [
            "Condition 18 36--*--rheumatic diseases",
            "Qualifier 11 17--*--active",
            "Condition 58 80--*--musculoskeletal injury",
            "Qualifier 93 97--*--knee",
            "Condition 126 155--*--secondary knee osteoarthritis",
            "Procedure 177 184--*--surgery",
            "Qualifier 197 201--*--knee",
            "Non-representable 203 271--*--History of adverse effects from medications to be used in this study",
            "Condition 273 289--*--Contraindication",
            "Procedure 293 310--*--spinal anesthesia",
            "Condition 323 344--*--psychiatric disorders",
            "Condition 348 368--*--cognitive impairment",
            "Condition 370 386--*--Contraindication",
            "Drug 390 404--*--corticosteroid",
            "Condition 431 448--*--diabetes mellitus",
            "Qualifier 413 430--*--Poorly controlled",
            "Measurement 450 455--*--HbA1C",
            "Value 456 461--*--> 7.5",
            "Qualifier 464 481--*--Poorly controlled",
            "Condition 482 494--*--hypertension",
            "Condition 507 529--*--ischemic heart disease",
            "Condition 533 560--*--peripheral arterial disease",
            "Condition 564 587--*--cerebrovascular disease",
            "Condition 589 610--*--Hepatic insufficiency",
            "Measurement 612 628--*--Child-Pugh score",
            "Value 629 632--*--> 5",
            "Condition 635 654--*--Renal insufficiency",
            "Measurement 656 676--*--Creatinine clearance",
            "Value 677 688--*--< 30 mL/min",
            "Condition 702 711--*--cataracts",
            "Condition 715 723--*--glaucoma",
            "Condition 727 746--*--ocular hypertension",
            "Drug 759 766--*--steroid",
            "Drug 770 792--*--immunosuppressive drug",
            "Temporal 797 823--*--within 6 months of surgery",
            "Reference_point 816 823--*--surgery",
            "Scope 759 792--*--steroid or immunosuppressive drug"
        ]
    },
    "NCT03513874_inc": {
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Qualifier 29 42--*--ADA criterias",
            "Temporal 43 51--*--<5 years",
            "Person 54 57--*--Age",
            "Value 57 90--*--= 18 years and less than 70 years",
            "Negation 93 96--*--Non",
            "Condition 97 102--*--obese",
            "Measurement 115 118--*--BMI",
            "Value 119 137--*--less than 28 kg/m2",
            "Multiplier 152 164--*--at least one",
            "Condition 172 197--*--anti-islet autoantibodies",
            "Condition 199 203--*--GADA",
            "Condition 205 209--*--IA2A",
            "Condition 211 216--*--ZnT8A",
            "Scope 199 216--*--GADA, IA2A, ZnT8A",
            "Measurement 229 258--*--postprandial plasma C-peptide",
            "Measurement 218 225;242 258--*--Fasting plasma C-peptide",
            "Scope 218 258--*--Fasting or postprandial plasma C-peptide",
            "Value 259 279--*--more than 100 pmol/L",
            "Informed_consent 281 348--*--Written informed consent from the patient or family representative."
        ],
        "Text": "Type 1 diabetes according to ADA criterias <5 years.. Age= 18 years and less than 70 years.. Non-obese: defined as BMI less than 28 kg/m2. Positive for at least one of the anti-islet autoantibodies: GADA, IA2A, ZnT8A. Fasting or postprandial plasma C-peptide more than 100 pmol/L. Written informed consent from the patient or family representative.. "
    },
    "NCT02416869_exc": {
        "Text": "Heavy tobacco smokers. Drug and / or alcohol abusers. ",
        "Annotations": [
            "Condition 0 21--*--Heavy tobacco smokers",
            "Condition 37 52--*--alcohol abusers",
            "Condition 23 27;45 52--*--Drug abusers"
        ]
    },
    "NCT03016741_inc": {
        "Annotations": [
            "Condition 18 33--*--prostate cancer",
            "Drug 67 79--*--GnRH agonist",
            "Drug 67 71;83 93--*--GnRH antagonist",
            "Multiplier 102 122--*--for at least 1 month",
            "Temporal 123 142--*--prior to enrollment",
            "Procedure 52 61--*--treatment",
            "Scope 67 93--*--GnRH agonist or antagonist",
            "Non-query-able 145 403--*--Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.",
            "Person 405 408--*--Age",
            "Value 409 419--*--= 18 years",
            "Non-query-able 422 577--*--Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.",
            "Qualifier 607 617--*--metastatic",
            "Qualifier 618 635--*--hormone sensitive",
            "Condition 636 651--*--prostate cancer",
            "Condition 653 658--*--mHSPC",
            "Scope 607 651--*--metastatic hormone sensitive prostate cancer",
            "Qualifier 663 683--*--castration-resistant",
            "Qualifier 684 694--*--metastatic",
            "Condition 695 710--*--prostate cancer",
            "Condition 712 717--*--mCRPC",
            "Scope 663 710--*--castration-resistant metastatic prostate cancer",
            "Drug 758 777--*--abiraterone acetate",
            "Procedure 743 752--*--treatment",
            "Condition 779 784--*--mHSPC",
            "Condition 788 793--*--mCRPC",
            "Drug 798 810--*--enzalutamide",
            "Condition 812 817--*--mCRPC",
            "Scope 758 817--*--abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC",
            "Scope 798 818--*--enzalutamide (mCRPC)",
            "Scope 758 794--*--abiraterone acetate (mHSPC or mCRPC)",
            "Scope 663 818--*--castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)",
            "Procedure 1124 1136--*--chemotherapy",
            "Qualifier 1141 1158--*--hormone-sensitive",
            "Qualifier 1159 1169--*--metastatic",
            "Condition 1170 1185--*--prostate cancer",
            "Multiplier 1213 1242--*--lasted for more than 6 months",
            "Negation 1204 1207--*--not",
            "Temporal 1244 1313--*--At least 12 months must have elapsed since completion of chemotherapy",
            "Reference_point 1287 1313--*--completion of chemotherapy",
            "Procedure 1301 1313--*--chemotherapy",
            "Temporal 1343 1348--*--prior",
            "Qualifier 1349 1359--*--definitive",
            "Procedure 1360 1377--*--radiation therapy",
            "Procedure 1381 1388--*--surgery",
            "Scope 1360 1388--*--radiation therapy or surgery",
            "Temporal 1390 1484--*--At least 60 days must have elapsed since completion of definitive radiation therapy or surgery",
            "Procedure 1456 1473--*--radiation therapy",
            "Procedure 1477 1484--*--surgery",
            "Qualifier 1445 1455--*--definitive",
            "Reference_point 1431 1484--*--completion of definitive radiation therapy or surgery",
            "Qualifier 1512 1527--*--grade 2 or less",
            "Condition 1528 1543--*--adverse effects",
            "Temporal 1544 1571--*--at the time of registration",
            "Non-representable 1573 1696--*--Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed.",
            "Non-query-able 1698 1743--*--Patients must be able to take oral medication"
        ],
        "Text": "Have diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy for at least 1 month prior to enrollment.. Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.. Age = 18 years.. Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.. Have either newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) or castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC). Patients may have received the following prior AR directed therapy prior to enrollment: bicalutamide, ketoconazole. Prior to enrollment, patients may have received treatment with abiraterone acetate or enzalutamide for no more than 14 days before completing baseline studies.. Patients may have received chemotherapy for hormone-sensitive metastatic prostate cancer only, but it must not have lasted for more than 6 months. At least 12 months must have elapsed since completion of chemotherapy.. Patients may have received prior definitive radiation therapy or surgery. At least 60 days must have elapsed since completion of definitive radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration. Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed.. Patients must be able to take oral medication.. "
    },
    "NCT02570230_exc": {
        "Text": "allergy to morphine or ketamine. contraindicate to ketamine. remain intubated in the postoperative period. ",
        "Annotations": [
            "Condition 0 7--*--allergy",
            "Drug 11 19--*--morphine",
            "Drug 23 31--*--ketamine",
            "Scope 11 31--*--morphine or ketamine",
            "Condition 33 47--*--contraindicate",
            "Drug 51 59--*--ketamine",
            "Condition 68 77--*--intubated",
            "Temporal 78 105--*--in the postoperative period",
            "Reference_point 85 105--*--postoperative period",
            "Procedure 68 77--*--intubated"
        ]
    },
    "NCT03151603_inc": {
        "Text": "Women (18-75 years) with suspected UTI. at least two symptoms of UTI (dysuria, urgency of micturition, frequency, lower abdominal pain). Written informed consent. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 13 18--*--years",
            "Value 7 12--*--18-75",
            "Condition 35 38--*--UTI",
            "Qualifier 25 34--*--suspected",
            "Scope 0 19--*--Women (18-75 years)",
            "Condition 53 68--*--symptoms of UTI",
            "Multiplier 40 52--*--at least two",
            "Condition 70 77--*--dysuria",
            "Condition 79 101--*--urgency of micturition",
            "Condition 103 112--*--frequency",
            "Condition 114 134--*--lower abdominal pain",
            "Scope 70 134--*--dysuria, urgency of micturition, frequency, lower abdominal pain",
            "Post-eligibility 137 161--*--Written informed consent"
        ]
    },
    "NCT03355157_inc": {
        "Text": "Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements.. Female or male patients.. Age = 18 years old.. Metastatic invasive hormone receptor positive and HER2 negative breast cancer (histologically confirmed).. Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting.. Symptomatic or asymptomatic metastatic breast cancer.. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 grade = 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).. Life-expectancy > 6 months.. For female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods).. ",
        "Annotations": [
            "Non-query-able 0 324--*--Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements",
            "Person 327 333--*--Female",
            "Person 337 341--*--male",
            "Person 353 356--*--Age",
            "Value 357 371--*--= 18 years old",
            "Condition 438 451--*--breast cancer",
            "Qualifier 385 393--*--invasive",
            "Qualifier 374 384--*--Metastatic",
            "Qualifier 394 419--*--hormone receptor positive",
            "Qualifier 424 437--*--HER2 negative",
            "Scope 374 437--*--Metastatic invasive hormone receptor positive and HER2 negative",
            "Non-query-able 453 477--*--histologically confirmed",
            "Non-query-able 481 800--*--Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting.",
            "Condition 830 854--*--metastatic breast cancer",
            "Qualifier 817 829--*--asymptomatic",
            "Qualifier 802 813--*--Symptomatic",
            "Scope 802 829--*--Symptomatic or asymptomatic",
            "Observation 1096 1111--*--Life-expectancy",
            "Value 1112 1122--*--> 6 months",
            "Measurement 950 971--*--NCI CTCAE version 4.0",
            "Value 972 981--*--grade = 1",
            "Observation 857 867--*--Resolution",
            "Condition 875 894--*--acute toxic effects",
            "Procedure 904 923--*--anti-cancer therapy",
            "Procedure 927 945--*--surgical procedure",
            "Scope 904 946--*--anti-cancer therapy or surgical procedures",
            "Qualifier 898 903--*--prior",
            "Negation 983 989--*--except",
            "Condition 990 998--*--alopecia",
            "Non-query-able 983 1093--*--except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion)",
            "Pregnancy_considerations 1126 1419--*--or female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods)."
        ]
    },
    "NCT02986659_inc": {
        "Text": "Age 65 - 79. History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease). Cancer, with no active treatment in the last year. MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2. Decline physical function (walking speed < 1 m/s) Group 3 (Either or both). Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90. Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 11--*--65 - 79",
            "Condition 24 47--*--coronary artery disease",
            "Observation 13 20--*--History",
            "Condition 52 64--*--heart attack",
            "Condition 49 51--*--MI",
            "Condition 66 72--*--stroke",
            "Condition 74 87--*--heart failure",
            "Condition 92 117--*--peripheral artery disease",
            "Scope 49 117--*--MI/heart attack, stroke, heart failure, or peripheral artery disease",
            "Condition 120 126--*--Cancer",
            "Negation 133 135--*--no",
            "Procedure 136 152--*--active treatment",
            "Temporal 153 169--*--in the last year",
            "Condition 171 174--*--MCI",
            "Measurement 176 180--*--MoCA",
            "Value 181 187--*-->18<26",
            "Non-representable 188 243--*---inclusive of 1 point if <12 years of education Group 2",
            "Scope 176 187--*--MoCA >18<26",
            "Condition 245 270--*--Decline physical function",
            "Measurement 272 285--*--walking speed",
            "Value 286 293--*--< 1 m/s",
            "Non-representable 295 319--*--Group 3 (Either or both)",
            "Scope 272 293--*--walking speed < 1 m/s",
            "Condition 321 338--*--Abdominal obesity",
            "Value 340 345--*-->88cm",
            "Value 353 359--*-->102cm",
            "Measurement 321 330--*--Abdominal",
            "Person 346 351--*--women",
            "Person 360 363--*--men",
            "Scope 340 363--*-->88cm women, >102cm men",
            "Condition 369 381--*--hypertension",
            "Procedure 383 390--*--treated",
            "Measurement 394 416--*--resting blood pressure",
            "Value 417 424--*-->140/90",
            "Scope 383 424--*--treated or resting blood pressure >140/90",
            "Condition 426 443--*--Abdominal obesity",
            "Value 445 450--*-->88cm",
            "Value 458 464--*-->102cm",
            "Person 451 456--*--women",
            "Person 465 468--*--men",
            "Scope 445 468--*-->88cm women, >102cm men",
            "Condition 474 488--*--hyperlipidemia",
            "Procedure 490 497--*--treated",
            "Measurement 501 526--*--fasting total cholesterol",
            "Value 527 531--*-->240",
            "Observation 532 548--*--English literacy",
            "Observation 560 584--*--provide informed consent",
            "Mood 549 559--*--Willing to",
            "Scope 490 531--*--treated or fasting total cholesterol >240"
        ]
    },
    "NCT02969187_exc": {
        "Annotations": [
            "Measurement 0 3--*--BMI",
            "Value 4 22--*--<35 and > 60 kg/m2",
            "Condition 24 41--*--Inability to walk",
            "Condition 56 77--*--wheelchair dependence",
            "Condition 43 52--*--bed-bound",
            "Scope 43 77--*--bed-bound or wheelchair dependence",
            "Procedure 80 104--*--open abdominal surgeries",
            "Procedure 112 131--*--simple appendectomy",
            "Procedure 136 160--*--common OB/GYN procedures",
            "Qualifier 168 174--*--pelvis",
            "Procedure 176 188--*--hysterectomy",
            "Procedure 190 199--*--C-section",
            "Procedure 205 217--*--oophorectomy",
            "Procedure 219 233--*--tubal ligation",
            "Scope 176 233--*--hysterectomy, C-section, and oophorectomy, tubal ligation",
            "Scope 136 174--*--common OB/GYN procedures in the pelvis",
            "Negation 105 111--*--except",
            "Scope 112 234--*--simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation)",
            "Procedure 236 254;270 279--*--laparoscopic bowel resection",
            "Procedure 258 279--*--solid organ resection",
            "Procedure 287 315--*--laparoscopic cholecystectomy",
            "Negation 280 286--*--except",
            "Scope 236 279--*--laparoscopic bowel or solid organ resection",
            "Condition 317 331--*--ventral hernia",
            "Procedure 332 348--*--repair with mesh",
            "Temporal 350 362--*--Preoperative",
            "Condition 386 398--*--chronic pain",
            "Drug 371 377--*--opiate",
            "Multiplier 363 370--*--chronic",
            "Drug 410 416--*--opiate",
            "Multiplier 423 464--*--at least 60 mg/day of morphine equivalent",
            "Multiplier 465 479--*--for = 3 months",
            "Temporal 546 599--*--in the one year period prior to the bariatric surgery",
            "Reference_point 578 599--*--the bariatric surgery",
            "Procedure 582 599--*--bariatric surgery",
            "Scope 410 479--*--opiate usage at least 60 mg/day of morphine equivalent for = 3 months",
            "Scope 363 398--*--chronic opiate use for chronic pain",
            "Measurement 605 654--*--American Society of Anesthesiologists (ASA) score",
            "Value 655 658--*--> 3",
            "Condition 671 687--*--hypersensitivity",
            "Condition 691 707--*--adverse reaction",
            "Drug 711 722--*--bupivacaine",
            "Drug 726 735--*--narcotics",
            "Scope 671 707--*--hypersensitivity or adverse reaction",
            "Scope 711 735--*--bupivacaine or narcotics",
            "Non-query-able 737 763--*--Inability to speak English",
            "Condition 765 779--*--ventral hernia",
            "Procedure 780 786--*--repair",
            "Procedure 788 803--*--Cholecystectomy",
            "Condition 805 818--*--hiatal hernia",
            "Procedure 819 825--*--repair",
            "Procedure 831 852--*--posterior cruroplasty",
            "Condition 864 882--*--lysis of adhesions",
            "Qualifier 854 863--*--extensive",
            "Non-representable 884 955--*--other procedures that mandate addition of \"trocar(s)\" or \"feeding tube\"",
            "Drug 969 975--*--trocar",
            "Observation 982 1003--*--conversion of surgery",
            "Procedure 1007 1020--*--hand-assisted",
            "Procedure 1024 1028--*--open",
            "Procedure 996 1003--*--surgery",
            "Mood 957 968--*--Addition of"
        ],
        "Text": "BMI <35 and > 60 kg/m2. Inability to walk (bed-bound or wheelchair dependence). open abdominal surgeries except simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation). laparoscopic bowel or solid organ resection except laparoscopic cholecystectomy. ventral hernia repair with mesh. Preoperative chronic opiate use for chronic pain defined as opiate usage at least 60 mg/day of morphine equivalent for = 3 months (as defined by International Association for the Study of Pain22) in the one year period prior to the bariatric surgery. The American Society of Anesthesiologists (ASA) score > 3. History of hypersensitivity or adverse reaction to bupivacaine or narcotics. Inability to speak English. ventral hernia repair. Cholecystectomy. hiatal hernia repair with posterior cruroplasty. extensive lysis of adhesions. other procedures that mandate addition of \"trocar(s)\" or \"feeding tube\". Addition of trocar(s) or conversion of surgery to hand-assisted or open. "
    },
    "NCT02609698_exc": {
        "Annotations": [
            "Condition 18 35--*--contraindications",
            "Condition 39 55--*--hypersensitivity",
            "Procedure 67 87--*--antiplatelet therapy",
            "Scope 18 55--*--contraindications or hypersensitivity",
            "Condition 103 130--*--Acute Myocardial Infarction",
            "Condition 132 166--*--ST elevation myocardial infarction",
            "Condition 168 206--*--Non ST elevation myocardial infarction",
            "Scope 132 206--*--ST elevation myocardial infarction, Non ST elevation myocardial infarction",
            "Mood 226 240--*--anticipated to",
            "Procedure 249 258--*--treatment",
            "Procedure 262 269--*--surgery",
            "Procedure 319 339--*--antiplatelet therapy",
            "Temporal 340 361--*--for 2 weeks or longer",
            "Scope 249 269--*--treatment or surgery",
            "Condition 403 426--*--Chronic total occlusion",
            "Condition 428 431--*--CTO",
            "Condition 442 461--*--in-stent restenosis",
            "Condition 463 466--*--ISR",
            "Condition 491 508--*--cardiogenic shock",
            "Pregnancy_considerations 510 570--*--Women who are breastfeeding, pregnant, or desiring pregnancy",
            "Condition 598 608--*--hemorrhage",
            "Observation 626 641--*--life expectancy",
            "Value 645 661--*--less than 1 year",
            "Procedure 692 710;717 726--*--drug-eluting stent procedure",
            "Procedure 712 715--*--DES",
            "Temporal 738 751--*--past 6 months",
            "Non-query-able 753 829--*--Any other patients judged by the investigator to be unsuitable for the trial"
        ],
        "Text": "Patients with any contraindications or hypersensitivity related to antiplatelet therapy. Patients with Acute Myocardial Infarction (ST elevation myocardial infarction, Non ST elevation myocardial infarction). Patients who are anticipated to receive treatment or surgery that may require desisting the administration of antiplatelet therapy for 2 weeks or longer during the period of the clinical trial. Chronic total occlusion (CTO) lesions, in-stent restenosis (ISR). Patients experiencing cardiogenic shock. Women who are breastfeeding, pregnant, or desiring pregnancy. Patients with findings of hemorrhage. Patients with a life expectancy of less than 1 year. Patients who have received a drug-eluting stent (DES) procedure within the past 6 months. Any other patients judged by the investigator to be unsuitable for the trial. "
    },
    "NCT03351972_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Visit 6 17--*--outpatients",
            "Value 19 36--*--18 years or older",
            "Multiplier 39 57--*--routinely referred",
            "Procedure 62 97--*--small bowel video capsule endoscopy"
        ],
        "Text": "Adult outpatients (18 years or older). routinely referred for small bowel video capsule endoscopy (CE). "
    },
    "NCT02986659_exc": {
        "Text": "eGFR <45. Type 2 diabetes (HbA1c>6.5) or type 1 diabetes. Any tobacco or nicotine product use in the past year. Low vitamin B12 Levels (< 300 pg/mL). Self-reported severe difficulty or inability to walk 400m or climb 10 steps (from Q 2 and 19 on PAT-D). Self-reported difficulty or inability to perform basic ADL functions (from Q 10, 13, 14, 16 on PAT-D). Excessive alcohol use (>14 drinks/week). Cancer requiring treatment in past year (except skin). Dementia - diagnosed and/or MoCA score <18. Parkinson's or other neurological disease. Chronic liver disease or cirrhosis. End stage renal disease or on dialysis. Rheumatic conditions (Rheumatoid arthritis, lupus, and any other autoimmune disease the -PI deems them to be ineligible for). Thyroid problems the PI deems them to be ineligible for. Gout. Involved in another interventional study. Hemoglobin <8 or diagnosed with anemia. Recent unintentional weight change (+/- 10 lbs. in the last 12 months). BMI <18.5. Likely to not follow the protocol. PI deems unfit to participate. Already taking Metformin or any other drug intended to treat diabetes. ",
        "Annotations": [
            "Measurement 0 4--*--eGFR",
            "Value 5 8--*--<45",
            "Condition 10 25--*--Type 2 diabetes",
            "Measurement 27 32--*--HbA1c",
            "Value 32 36--*-->6.5",
            "Condition 41 56--*--type 1 diabetes",
            "Observation 73 93--*--nicotine product use",
            "Observation 62 69--*--tobacco",
            "Scope 62 93--*--tobacco or nicotine product use",
            "Temporal 101 110--*--past year",
            "Measurement 116 134--*--vitamin B12 Levels",
            "Value 136 147--*--< 300 pg/mL",
            "Non-query-able 150 252--*--Self-reported severe difficulty or inability to walk 400m or climb 10 steps (from Q 2 and 19 on PAT-D)",
            "Non-query-able 254 355--*--Self-reported difficulty or inability to perform basic ADL functions (from Q 10, 13, 14, 16 on PAT-D)",
            "Observation 367 378--*--alcohol use",
            "Multiplier 380 395--*-->14 drinks/week",
            "Condition 398 404--*--Cancer",
            "Procedure 415 424--*--treatment",
            "Temporal 428 437--*--past year",
            "Condition 453 461--*--Dementia",
            "Measurement 481 491--*--MoCA score",
            "Value 492 495--*--<18",
            "Condition 497 508--*--Parkinson's",
            "Condition 518 538--*--neurological disease",
            "Condition 540 561--*--Chronic liver disease",
            "Condition 565 574--*--cirrhosis",
            "Condition 576 599--*--End stage renal disease",
            "Procedure 606 614--*--dialysis",
            "Condition 616 636--*--Rheumatic conditions",
            "Condition 638 658--*--Rheumatoid arthritis",
            "Condition 660 665--*--lupus",
            "Condition 681 699--*--autoimmune disease",
            "Scope 638 699--*--Rheumatoid arthritis, lupus, and any other autoimmune disease",
            "Condition 742 758--*--Thyroid problems",
            "Condition 799 803--*--Gout",
            "Competing_trial 805 845--*--Involved in another interventional study",
            "Measurement 847 857--*--Hemoglobin",
            "Value 858 860--*--<8",
            "Condition 879 885--*--anemia",
            "Measurement 908 914--*--weight",
            "Value 923 934--*--+/- 10 lbs.",
            "Temporal 942 956--*--last 12 months",
            "Measurement 959 962--*--BMI",
            "Value 963 968--*--<18.5",
            "Post-eligibility 970 1003--*--Likely to not follow the protocol",
            "Non-query-able 1005 1034--*--PI deems unfit to participate",
            "Drug 1051 1060--*--Metformin",
            "Drug 1074 1078--*--drug",
            "Qualifier 1097 1105--*--diabetes"
        ]
    },
    "NCT03355157_exc": {
        "Text": "NA. . ",
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ]
    },
    "NCT03151603_exc": {
        "Text": "signs of complicated UTI (e. g. temperature > 38\u00b0C, loin tenderness). conditions that may lead to complicated infections (i.e. renal diseases, patients with urinary catheter). pregnancy/ breastfeeding. current self-medication with UU preparations e.g. z.B. Cystinol\u00ae, Uvalysat\u00ae, Arctuvan\u00ae. antibiotic use in the last 7 days. previous UTI in the past 2 weeks. history of pyelonephritis. contraindications for trial drugs. serious diseases. inability to understand trial Information. current participation in another clinical trial or participation in another clinical trial within the last 4 weeks. ",
        "Annotations": [
            "Condition 9 24--*--complicated UTI",
            "Condition 52 67--*--loin tenderness",
            "Measurement 32 43--*--temperature",
            "Value 44 50--*--> 38\u00b0C",
            "Scope 32 67--*--temperature > 38\u00b0C, loin tenderness",
            "Condition 70 80--*--conditions",
            "Condition 98 120--*--complicated infections",
            "Condition 127 141--*--renal diseases",
            "Device 157 173--*--urinary catheter",
            "Person 143 151--*--patients",
            "Scope 127 173--*--renal diseases, patients with urinary catheter",
            "Pregnancy_considerations 176 200--*--pregnancy/ breastfeeding",
            "Drug 231 246--*--UU preparations",
            "Drug 252 266--*--z.B. Cystinol\u00ae",
            "Drug 268 277--*--Uvalysat\u00ae",
            "Drug 279 288--*--Arctuvan\u00ae",
            "Scope 252 288--*--z.B. Cystinol\u00ae, Uvalysat\u00ae, Arctuvan\u00ae",
            "Qualifier 210 225--*--self-medication",
            "Drug 290 300--*--antibiotic",
            "Temporal 312 323--*--last 7 days",
            "Condition 334 337--*--UTI",
            "Temporal 345 357--*--past 2 weeks",
            "Condition 370 384--*--pyelonephritis",
            "Mood 386 407--*--contraindications for",
            "Drug 414 419--*--drugs",
            "Qualifier 408 413--*--trial",
            "Condition 429 437--*--diseases",
            "Qualifier 421 428--*--serious",
            "Post-eligibility 439 480--*--inability to understand trial Information",
            "Non-query-able 482 596--*--current participation in another clinical trial or participation in another clinical trial within the last 4 weeks"
        ]
    },
    "NCT02969187_inc": {
        "Annotations": [
            "Measurement 9 21--*--NIH criteria",
            "Condition 26 43--*--bariatric surgery",
            "Value 0 8--*--Fulfills",
            "Procedure 66 111--*--laparoscopic Roux-en Y gastric bypass (LRYGB)",
            "Procedure 115 152--*--laparoscopic sleeve gastrectomy (LSG)",
            "Qualifier 156 163--*--primary",
            "Scope 66 152--*--laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG)"
        ],
        "Text": "Fulfills NIH criteria for bariatric surgery. Planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure. "
    },
    "NCT03351972_exc": {
        "Annotations": [
            "Condition 0 9--*--dysphagia",
            "Condition 18 31--*--gastroparesis",
            "Qualifier 11 17--*--severe",
            "Procedure 42 62--*--endoscopic placement",
            "Device 66 73--*--capsule",
            "Mood 32 41--*--requiring",
            "Condition 75 98--*--small bowel obstruction",
            "Condition 100 109--*--pregnancy"
        ],
        "Text": "dysphagia. severe gastroparesis requiring endoscopic placement of capsule. small bowel obstruction. pregnancy. "
    },
    "NCT02609698_inc": {
        "Annotations": [
            "Person 9 13--*--aged",
            "Value 14 25--*--19 or older",
            "Informed_consent 27 109--*--Patients who have submitted a written consent to participate in the clinical trial",
            "Condition 111 125--*--De novo lesion",
            "Post-eligibility 127 212--*--Patients scheduled for elective intervention to treat ischemic cardiovascular disease"
        ],
        "Text": "Patients aged 19 or older. Patients who have submitted a written consent to participate in the clinical trial. De novo lesion. Patients scheduled for elective intervention to treat ischemic cardiovascular disease. "
    },
    "NCT02743598_exc": {
        "Annotations": [
            "Condition 30 42--*--pancreatitis",
            "Condition 44 71--*--Medullary thyroid carcinoma",
            "Condition 73 76--*--MTC",
            "Condition 81 125--*--Multiple Endocrine Neoplasia Syndrome Type 2",
            "Condition 127 132--*--MEN 2",
            "Condition 135 148--*--Gastroparesis",
            "Condition 150 157--*--Allergy",
            "Drug 161 172--*--liraglutide",
            "Drug 230 244--*--GLP-1 analogue",
            "Scope 161 244--*--liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue",
            "Observation 246 257--*--Weight loss",
            "Negation 264 269--*--other",
            "Drug 275 284--*--metformin",
            "Condition 286 310--*--Type 1 diabetes mellitus",
            "Condition 314 335--*--diabetic ketoacidosis",
            "Condition 367 375--*--dementia",
            "Condition 349 366--*--cognitive deficit",
            "Condition 388 399--*--head trauma",
            "Condition 405 426--*--loss of consciousness",
            "Multiplier 427 434--*-->30 min",
            "Condition 447 453--*--stroke",
            "Condition 463 485;492 500--*--central nervous system disorder",
            "Condition 509 517--*--seizures",
            "Condition 521 548--*--opportunistic CNS infection",
            "Scope 509 548--*--seizures or opportunistic CNS infection",
            "Condition 550 569--*--Renal insufficiency",
            "Measurement 581 601--*--creatinine clearance",
            "Value 602 613--*--< 60 mL/min",
            "Condition 622 646--*--opportunistic infections",
            "Qualifier 615 621--*--Active",
            "Pregnancy_considerations 648 674--*--Pregnancy or breastfeeding",
            "Visit 713 728--*--hospitalization",
            "Temporal 729 742--*--within 1 year",
            "Condition 747 770--*--acute coronary syndrome",
            "Condition 772 799--*--Decompensated heart failure",
            "Condition 801 816--*--Substance abuse",
            "Procedure 836 863--*--opioid substitution therapy",
            "Observation 825 832--*--alcohol",
            "Non-query-able 865 992--*--Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation"
        ],
        "Text": "Personal or family history of pancreatitis. Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2). Gastroparesis. Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue. Weight loss drugs other than metformin. Type 1 diabetes mellitus or diabetic ketoacidosis. Known major cognitive deficit dementia, history of head trauma with loss of consciousness >30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection. Renal insufficiency defined as creatinine clearance < 60 mL/min. Active opportunistic infections. Pregnancy or breastfeeding. Unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome. Decompensated heart failure. Substance abuse. Active alcohol or opioid substitution therapy. Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation. "
    },
    "NCT03360214_exc": {
        "Text": "Allergy to narcotic medications. Intake of any chronic opioids or pain medications preoperatively. ",
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Drug 11 31--*--narcotic medications",
            "Multiplier 47 54--*--chronic",
            "Drug 55 62--*--opioids",
            "Qualifier 43 46--*--any",
            "Drug 66 82--*--pain medications",
            "Temporal 83 97--*--preoperatively"
        ]
    },
    "NCT01088750_inc": {
        "Annotations": [
            "Non-representable 0 23--*--Stage IA or IIA disease",
            "Non-representable 25 38--*--Not specified",
            "Non-representable 40 56--*--No prior therapy"
        ],
        "Text": "Stage IA or IIA disease. Not specified. No prior therapy. "
    },
    "NCT00391690_inc": {
        "Text": "Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases . Prostate cancer patients with a rise in PSA under hormone therapy. . PSA criteria: . Patients who have undergone prostatectomy: any rise in PSA or . Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month. The first measurement must occur one month after the reference value and must be above the reference value. The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement. . Previous chemotherapy or radiotherapy must have been performed \u2265 8 weeks prior to study entry. . Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day) . Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value . Age: \u2265 18 years . Patient has given written informed consent prior to any study-specific procedures. Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study. . ",
        "Annotations": [
            "Measurement 14 28--*--histologically",
            "Value 29 38--*--confirmed",
            "Condition 52 67--*--prostate cancer",
            "Condition 95 110--*--bone metastases",
            "Condition 112 127--*--Prostate cancer",
            "Measurement 152 155--*--PSA",
            "Value 144 148--*--rise",
            "Procedure 162 177--*--hormone therapy",
            "Procedure 223 236--*--prostatectomy",
            "Measurement 250 253--*--PSA",
            "Value 242 246--*--rise",
            "Procedure 275 288--*--prostatectomy",
            "Negation 267 274--*--without",
            "Measurement 313 323--*--PSA levels",
            "Value 304 309--*--rises",
            "Value 290 291--*--2",
            "Temporal 292 303--*--consecutive",
            "Temporal 364 386--*--separated by one month",
            "Temporal 421 456--*--one month after the reference value",
            "Value 469 494--*--above the reference value",
            "Value 392 397--*--first",
            "Procedure 398 409--*--measurement",
            "Value 500 506--*--second",
            "Procedure 520 531--*--measurement",
            "Temporal 538 575--*--one month after the first measurement",
            "Value 584 618--*--greater than the first measurement",
            "Procedure 630 642--*--chemotherapy",
            "Procedure 646 658--*--radiotherapy",
            "Temporal 621 629--*--Previous",
            "Temporal 684 714--*--\u2265 8 weeks prior to study entry",
            "Scope 630 658--*--chemotherapy or radiotherapy",
            "Measurement 717 764--*--Eastern Cooperative Oncology Group (ECOG) score",
            "Value 768 777--*--0, 1 or 2",
            "Measurement 793 798;816 842--*--spend time in bed during the day",
            "Value 799 812--*--less than 50%",
            "Scope 717 777--*--Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2",
            "Scope 793 842--*--spend less than 50% of time in bed during the day",
            "Measurement 854 868--*--liver function",
            "Value 845 853--*--Adequate",
            "Measurement 871 906--*--serum total bilirubin concentration",
            "Value 907 950--*--less than 1.5 x upper limit of normal value",
            "Person 952 955--*--Age",
            "Value 957 967--*--\u2265 18 years",
            "Condition 1066 1077;1091 1100--*--psychiatric disorders",
            "Condition 1081 1100--*--addictive disorders",
            "Observation 1125 1131;1138 1154--*--giving informed consent",
            "Negation 1107 1114--*--prevent",
            "Scope 1066 1100--*--psychiatric or addictive disorders",
            "Non-representable 180 192--*--PSA criteria"
        ]
    },
    "NCT02743598_inc": {
        "Annotations": [
            "Condition 0 3--*--HIV",
            "Qualifier 4 14--*--controlled",
            "Temporal 30 47--*--at least 12 weeks",
            "Measurement 49 59--*--Viral load",
            "Value 60 72--*--< 200 copies",
            "Person 74 77--*--BMI",
            "Value 78 87--*-->27 to 45",
            "Condition 102 111--*--DM type 2",
            "Measurement 117 121--*--A1-C",
            "Value 122 130--*-->7 to 15",
            "Post-eligibility 132 204--*--Participants must be willing to comply with all study related procedures"
        ],
        "Text": "HIV controlled on therapy for at least 12 weeks. Viral load < 200 copies. BMI >27 to 45. Diagnosis of DM type 2 with A1-C >7 to 15. Participants must be willing to comply with all study related procedures. "
    },
    "NCT03360214_inc": {
        "Text": "Subjects must be female. Subjects must be 18 years or older. Subjects must be undergoing unilateral or bilateral mastectomy with tissue expander reconstruction. ",
        "Annotations": [
            "Person 17 23--*--female",
            "Value 42 59--*--18 years or older",
            "Person 54 59--*--older",
            "Qualifier 89 99--*--unilateral",
            "Qualifier 103 112--*--bilateral",
            "Procedure 113 123--*--mastectomy",
            "Procedure 129 159--*--tissue expander reconstruction",
            "Scope 89 112--*--unilateral or bilateral",
            "Temporal 78 88--*--undergoing"
        ]
    },
    "NCT01088750_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. "
    },
    "NCT00391690_exc": {
        "Text": "Prior treatment with a bisphosphonate . Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute. . Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or \u2265 12.0 mg/dl (3.00 mmol/L). . Patients with clinically symptomatic brain metastases . History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism . Severe physical or psychological concomitant diseases that might impair compliance with the provisions of the study protocol or that might impair the assessment of drug or patient safety, e.g. clinically significant ascites, cardiac failure, NYHA III or IV, clinically relevant pathologic findings in ECG . Known hypersensitivity to zoledronic acid or other bisphosphonates . Use of other investigational drugs 30 days prior to the date of randomization . Known history or present abuse of alcohol or drugs . Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study . Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. . Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants) . Other protocol defined inclusion/exclusion criteria may apply.       .     . ",
        "Annotations": [
            "Drug 23 37--*--bisphosphonate",
            "Temporal 0 5--*--Prior",
            "Measurement 48 62--*--renal function",
            "Value 39 47--*--Abnormal",
            "Measurement 81 112--*--calculated creatinine clearance",
            "Value 113 127--*--< 30 ml/minute",
            "Measurement 130 139;169 196--*--Corrected serum calcium concentration",
            "Value 197 208--*--< 8.0 mg/dl",
            "Value 210 221--*--2.00 mmol/L",
            "Value 226 238--*--\u2265 12.0 mg/dl",
            "Value 240 251--*--3.00 mmol/L",
            "Scope 197 251--*--< 8.0 mg/dl (2.00 mmol/L) or \u2265 12.0 mg/dl (3.00 mmol/L",
            "Observation 269 291--*--clinically symptomatic",
            "Condition 292 308--*--brain metastases",
            "Observation 310 317--*--History",
            "Condition 321 363--*--diseases with influence on bone metabolism",
            "Condition 372 387--*--Paget's disease",
            "Condition 392 419--*--primary hyperparathyroidism",
            "Scope 321 419--*--diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism",
            "Condition 428 436;466 474--*--physical diseases",
            "Condition 440 453;466 474--*--psychological diseases",
            "Condition 637 644--*--ascites",
            "Qualifier 614 636--*--clinically significant",
            "Condition 646 661--*--cardiac failure",
            "Measurement 663 667--*--NYHA",
            "Value 668 677--*--III or IV",
            "Qualifier 679 698--*--clinically relevant",
            "Observation 699 718--*--pathologic findings",
            "Procedure 722 725--*--ECG",
            "Scope 614 725--*--clinically significant ascites, cardiac failure, NYHA III or IV, clinically relevant pathologic findings in ECG",
            "Scope 428 474--*--physical or psychological concomitant diseases",
            "Condition 733 749--*--hypersensitivity",
            "Drug 753 768--*--zoledronic acid",
            "Drug 772 793--*--other bisphosphonates",
            "Scope 753 793--*--zoledronic acid or other bisphosphonates",
            "Drug 802 829--*--other investigational drugs",
            "Temporal 830 872--*--30 days prior to the date of randomization",
            "Observation 880 887--*--history",
            "Temporal 891 898--*--present",
            "Scope 880 898--*--history or present",
            "Condition 899 915--*--abuse of alcohol",
            "Condition 899 907;919 924--*--abuse of drugs",
            "Scope 899 924--*--abuse of alcohol or drugs",
            "Condition 1041 1056--*--dental problems",
            "Temporal 1026 1033--*--Current",
            "Condition 1067 1089--*--infection of the teeth",
            "Condition 1067 1083;1093 1100--*--infection of the jawbone",
            "Scope 1067 1100--*--infection of the teeth or jawbone",
            "Condition 1067 1083;1102 1109--*--infection of the maxilla",
            "Condition 1067 1083;1113 1123--*--infection of the mandibular",
            "Scope 1067 1083;1102 1123--*--infection of the maxilla or mandibular",
            "Condition 1126 1132;1144 1150--*--dental trauma",
            "Condition 1136 1150--*--fixture trauma",
            "Temporal 1157 1164--*--current",
            "Temporal 1168 1173--*--prior",
            "Condition 1187 1217--*--osteonecrosis of the jaw (ONJ)",
            "Condition 1222 1247--*--exposed bone in the mouth",
            "Condition 1255 1291--*--slow healing after dental procedures",
            "Scope 1187 1291--*--osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures",
            "Scope 1157 1173--*--current or prior",
            "Scope 1067 1291--*--infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures",
            "Temporal 1302 1316--*--within 6 weeks",
            "Temporal 1294 1300--*--Recent",
            "Observation 1321 1328--*--planned",
            "Procedure 1329 1335;1343 1350--*--dental surgery",
            "Procedure 1339 1350--*--jaw surgery",
            "Procedure 1357 1367--*--extraction",
            "Procedure 1369 1377--*--implants",
            "Scope 1357 1377--*--extraction, implants",
            "Scope 1329 1350--*--dental or jaw surgery",
            "Scope 1294 1328--*--Recent (within 6 weeks) or planned",
            "Non-query-able 926 1024--*--Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study",
            "Non-representable 1380 1442--*--Other protocol defined inclusion/exclusion criteria may apply."
        ]
    },
    "NCT02092467_inc": {
        "Annotations": [
            "Qualifier 0 18--*--Moderate to severe",
            "Condition 19 39--*--rheumatoid arthritis",
            "Drug 48 60--*--methotrexate",
            "Negation 61 68--*--without",
            "Observation 69 97--*--adequate control of symptoms",
            "Multiplier 104 116--*--at least one",
            "Condition 117 143--*--cardiovascular risk factor",
            "Temporal 149 156--*--current",
            "Observation 157 163--*--smoker",
            "Condition 165 184--*--high blood pressure",
            "Condition 186 209--*--high cholesterol levels",
            "Condition 211 228--*--diabetes mellitus",
            "Observation 230 237--*--history",
            "Condition 241 253--*--heart attack",
            "Observation 255 269--*--family history",
            "Condition 273 295--*--coronary heart disease",
            "Qualifier 297 312--*--extra-articular",
            "Condition 313 323--*--RA disease",
            "Scope 149 323--*--current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease"
        ],
        "Text": "Moderate to severe rheumatoid arthritis. Taking methotrexate without adequate control of symptoms. Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease). "
    },
    "NCT02951832_exc": {
        "Annotations": [
            "Condition 19 35--*--severe allergies",
            "Condition 37 43--*--trauma",
            "Procedure 59 68--*--operation",
            "Temporal 77 92--*--within 3 months",
            "Condition 113 127--*--mental illness",
            "Observation 135 149--*--family history",
            "Condition 153 167--*--mental illness",
            "Observation 102 109--*--history",
            "Condition 170 183--*--Limb disabled",
            "Drug 193 201--*--medicine",
            "Temporal 202 218--*--within one month",
            "Non-query-able 186 218--*--Taking medicine within one month",
            "Condition 231 243--*--major events",
            "Undefined_semantics 231 243--*--major events",
            "Subjective_judgement 231 243--*--major events",
            "Condition 254 265--*--mood swings"
        ],
        "Text": "Having experienced severe allergies, trauma history and/or operation history within 3 months; . With a history of mental illness and/or family history of mental illness; . Limb disabled; . Taking medicine within one month; . Suffering major events or having mood swings.       .     . "
    },
    "NCT02225548_inc": {
        "Annotations": [
            "Condition 13 43--*--idiopathic Parkinson's disease",
            "Qualifier 62 69--*--treated",
            "Measurement 71 89--*--motor fluctuations",
            "Value 90 118--*--<20% of subject's awake time",
            "Observation 213 228--*--Sexually active",
            "Person 252 257--*--males",
            "Person 276 279--*--age",
            "Value 259 272--*--40 - 64 years",
            "Multiplier 235 250--*--=1 attempt/week",
            "Condition 336 356--*--erectile dysfunction",
            "Qualifier 327 335--*--moderate",
            "Temporal 429 451--*--for more than 6 months",
            "Drug 497 506--*--tadalafil",
            "Condition 485 493--*--response",
            "Qualifier 474 484--*--incomplete",
            "Measurement 539 570--*--IIEF-5 drug-free baseline score",
            "Value 579 592--*--= 10 but = 16",
            "Measurement 601 638--*--IIEF-5 tadalafil-alone baseline score",
            "Value 647 651--*--= 18",
            "Observation 673 698--*--heterosexual relationship",
            "Qualifier 666 672--*--stable",
            "Temporal 703 720--*--at least 6 months",
            "Condition 767 787--*--erectile dysfunction",
            "Procedure 753 762--*--treatment",
            "Post-eligibility 727 787--*--Subject motivated to seek treatment for erectile dysfunction",
            "Measurement 805 835--*--total serum testosterone level",
            "Value 836 847--*--= 300 ng/dL",
            "Measurement 882 908--*--Hoehn and Yahr Scale score",
            "Value 912 917--*--1 - 3",
            "Informed_consent 919 980--*--Patient able to consent and comply with protocol requirements"
        ],
        "Text": "Diagnosis of idiopathic Parkinson's disease that is optimally treated (motor fluctuations <20% of subject's awake time). Subjects may be on levodopa therapy but must be stable at the time of entry into the study. Sexually active (i.e. =1 attempt/week) males, 40 - 64 years of age (inclusive) at time of screening. Diagnosis of moderate erectile dysfunction (defined according to the NIH Consensus Development Panel on Impotence) for more than 6 months and demonstrating and incomplete response to tadalafil alone. Subject demonstrating an IIEF-5 drug-free baseline score that is = 10 but = 16, and an IIEF-5 tadalafil-alone baseline score that is = 18. Subject in a stable heterosexual relationship for at least 6 months. (2). Subject motivated to seek treatment for erectile dysfunction.. Subject with a total serum testosterone level = 300 ng/dL, with or without supplementation. Hoehn and Yahr Scale score of 1 - 3. Patient able to consent and comply with protocol requirements. "
    },
    "NCT02380118_inc": {
        "Annotations": [
            "Visit 0 31--*--Accident & Emergency Department",
            "Procedure 52 76--*--parenteral drug sedation",
            "Mood 42 51--*--requiring"
        ],
        "Text": "Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.. "
    },
    "NCT02859480_exc": {
        "Text": "Taking other drugs which can influence the lipid profile (eg. Niacin, Fibrates;. Serum creatinine level > 2.0 mg/dL. Serum aspartate transaminase > 3 times upper limit of normal. Serum alanine transaminase > 3 times upper limit of normal. Having anaphylactic reaction for Rosuvastatin;. Having the other contraindications for Rosuvastatin;. Having plan to be pregnant;. Having life expectancy less than 1 year. ",
        "Annotations": [
            "Qualifier 7 12--*--other",
            "Drug 13 18--*--drugs",
            "Qualifier 25 56--*--can influence the lipid profile",
            "Measurement 43 56--*--lipid profile",
            "Drug 62 68--*--Niacin",
            "Drug 70 78--*--Fibrates",
            "Scope 62 78--*--Niacin, Fibrates",
            "Measurement 81 103--*--Serum creatinine level",
            "Value 104 115--*--> 2.0 mg/dL",
            "Measurement 117 145--*--Serum aspartate transaminase",
            "Value 146 177--*--> 3 times upper limit of normal",
            "Measurement 179 205--*--Serum alanine transaminase",
            "Value 206 237--*--> 3 times upper limit of normal",
            "Condition 246 267--*--anaphylactic reaction",
            "Drug 272 284--*--Rosuvastatin",
            "Condition 304 321--*--contraindications",
            "Drug 326 338--*--Rosuvastatin",
            "Mood 348 352--*--plan",
            "Condition 359 367--*--pregnant",
            "Observation 377 392--*--life expectancy",
            "Value 393 409--*--less than 1 year"
        ]
    },
    "NCT02600000_inc": {
        "Text": "Diagnosis of Heart Failure;. Lower left ventricular ejection fraction 45% (LVEF <45%) assessed by simple and recent echocardiogram;. Functional Class II and III by the New York Heart Association (NYHA). Clinically stable;. Ex-smokers over five years;. Maximal inspiratory pressure (MIP) <70% of predicted;. Forced expiratory volume/Forced vital capacity (FEV1 / FVC) > 70% of predicted;. ",
        "Annotations": [
            "Condition 13 26--*--Heart Failure",
            "Measurement 29 69--*--Lower left ventricular ejection fraction",
            "Value 70 73--*--45%",
            "Measurement 75 79--*--LVEF",
            "Value 80 84--*--<45%",
            "Scope 75 84--*--LVEF <45%",
            "Scope 29 73--*--Lower left ventricular ejection fraction 45%",
            "Procedure 116 130--*--echocardiogram",
            "Temporal 109 115--*--recent",
            "Measurement 168 201--*--New York Heart Association (NYHA)",
            "Value 144 160--*--Class II and III",
            "Condition 203 220--*--Clinically stable",
            "Condition 223 233--*--Ex-smokers",
            "Temporal 234 249--*--over five years",
            "Measurement 252 286--*--Maximal inspiratory pressure (MIP)",
            "Value 287 304--*--<70% of predicted",
            "Measurement 307 366--*--Forced expiratory volume/Forced vital capacity (FEV1 / FVC)",
            "Value 367 385--*--> 70% of predicted"
        ]
    },
    "NCT03497598_exc": {
        "Text": "UTIs = 12 within 1 year. Pregnancy or Lactation. Immune disease. Lactose intolerance. Urinary tract anomaly. Systemic infection. Newly started hormone therapy within the last 6 months. Antibiotic prophylaxis within the last 6 months. a-D-mannose intake within the last month. Use of catheters. Diabetes mellitus. Participation to other studies. ",
        "Annotations": [
            "Condition 0 4--*--UTIs",
            "Multiplier 7 23--*--12 within 1 year",
            "Temporal 10 23--*--within 1 year",
            "Condition 25 34--*--Pregnancy",
            "Condition 38 47--*--Lactation",
            "Condition 49 63--*--Immune disease",
            "Condition 73 84--*--intolerance",
            "Drug 65 72--*--Lactose",
            "Condition 65 84--*--Lactose intolerance",
            "Condition 86 107--*--Urinary tract anomaly",
            "Condition 109 127--*--Systemic infection",
            "Multiplier 129 142--*--Newly started",
            "Procedure 143 158--*--hormone therapy",
            "Temporal 159 183--*--within the last 6 months",
            "Procedure 185 207--*--Antibiotic prophylaxis",
            "Temporal 208 232--*--within the last 6 months",
            "Drug 185 195--*--Antibiotic",
            "Drug 234 245--*--a-D-mannose",
            "Temporal 253 274--*--within the last month",
            "Device 283 292--*--catheters",
            "Condition 294 311--*--Diabetes mellitus",
            "Competing_trial 313 343--*--Participation to other studies"
        ]
    },
    "NCT03400735_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Observation 13 26--*--breastfeeding",
            "Condition 28 35--*--Allergy",
            "Drug 47 57--*--penicillin",
            "Drug 61 75--*--cephalosporins",
            "Scope 47 75--*--penicillin or cephalosporins",
            "Condition 77 93--*--Renal impairment",
            "Condition 102 117--*--hepatic disease",
            "Qualifier 95 101--*--Active",
            "Drug 119 129--*--Antibiotic",
            "Negation 134 140--*--except",
            "Drug 141 152--*--study drugs",
            "Procedure 154 179--*--Immunosuppressive therapy",
            "Temporal 180 215--*--before 6 months of study initiation",
            "Reference_point 199 215--*--study initiation",
            "Drug 224 245--*--probenecid like drugs",
            "Drug 224 234--*--probenecid",
            "Qualifier 224 239--*--probenecid like"
        ],
        "Text": "Pregnancy or breastfeeding. Allergy against to penicillin or cephalosporins. Renal impairment. Active hepatic disease. Antibiotic use except study drugs. Immunosuppressive therapy before 6 months of study initiation. Use of probenecid like drugs. "
    },
    "NCT02469610_exc": {
        "Text": "Previous thoracic operation in the same side.. ",
        "Annotations": [
            "Temporal 0 8--*--Previous",
            "Procedure 9 27--*--thoracic operation",
            "Qualifier 35 44--*--same side"
        ]
    },
    "NCT02092467_exc": {
        "Annotations": [
            "Temporal 11 17--*--recent",
            "Temporal 0 7--*--Current",
            "Condition 18 27--*--infection",
            "Scope 0 17--*--Current or recent",
            "Qualifier 29 51--*--Clinically significant",
            "Condition 52 76--*--laboratory abnormalities",
            "Procedure 52 62--*--laboratory",
            "Condition 78 87--*--Pregnancy"
        ],
        "Text": "Current or recent infection. Clinically significant laboratory abnormalities. Pregnancy. "
    },
    "NCT02951832_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Person 6 10--*--aged",
            "Value 11 16--*--20-49",
            "Condition 28 51--*--regular menstrual cycle",
            "Measurement 65 81--*--menstrual period",
            "Value 85 100--*--between day 3-7",
            "Grammar_Error 102 105--*--and",
            "Value 117 134--*--between day 25-35",
            "Scope 85 134--*--between day 3-7, and the period between day 25-35",
            "Condition 147 155;169 176--*--internal disease",
            "Condition 160 176--*--surgical disease",
            "Context_Error 137 308--*--Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)",
            "Undefined_semantics 137 309--*--Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine).",
            "Non-query-able 137 309--*--Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)."
        ],
        "Text": "Women aged 20-49; . Having a regular menstrual cycle of which the menstrual period is between day 3-7, and the period between day 25-35; . Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine). . "
    },
    "NCT02225548_exc": {
        "Annotations": [
            "Procedure 38 47--*--treatment",
            "Condition 52 72--*--erectile dysfunction",
            "Temporal 73 89--*--during the study",
            "Procedure 101 116--*--oral medication",
            "Device 118 132--*--vacuum devices",
            "Device 134 154--*--constrictive devices",
            "Procedure 156 166--*--injections",
            "Device 168 190--*--urethral suppositories",
            "Procedure 192 196--*--gels",
            "Qualifier 202 218--*--over-the-counter",
            "Qualifier 222 237--*--nonprescription",
            "Procedure 238 249--*--medications",
            "Scope 202 237--*--over-the-counter or nonprescription",
            "Scope 101 250--*--oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications,",
            "Drug 310 327--*--dopamine agonists",
            "Drug 329 337--*--nitrates",
            "Drug 339 369--*--alpha-receptor blocking agents",
            "Drug 374 401--*--antihypertensive medication",
            "Condition 479 486--*--syncope",
            "Temporal 487 530--*--within the last 6 months prior to screening",
            "Reference_point 521 530--*--screening",
            "Condition 557 577--*--postural hypotension",
            "Qualifier 545 556--*--symptomatic",
            "Condition 586 595--*--dizziness",
            "Condition 599 607--*--fainting",
            "Qualifier 579 585--*--severe",
            "Scope 586 607--*--dizziness or fainting",
            "Condition 622 633--*--hypotension",
            "Measurement 648 671--*--systolic blood pressure",
            "Value 675 684--*--< 90 mmHG",
            "Condition 688 700--*--hypertension",
            "Measurement 716 739--*--systolic blood pressure",
            "Value 740 750--*--> 170 mmHG",
            "Measurement 764 788--*--diastolic blood pressure",
            "Value 789 799--*--> 110 mmHG",
            "Scope 716 799--*--systolic blood pressure > 170 mmHG or a resting diastolic blood pressure > 110 mmHG",
            "Condition 829 853--*--cardiovascular condition",
            "Condition 865 889--*--unstable angina pectoris",
            "Observation 906 921--*--sexual activity",
            "Negation 897 905--*--preclude",
            "Condition 949 970--*--myocardial infarction",
            "Condition 972 978--*--stroke",
            "Condition 999 1009--*--arrhythmia",
            "Qualifier 982 998--*--life-threatening",
            "Temporal 1010 1044--*--within 6 months prior to screening",
            "Reference_point 1035 1044--*--screening",
            "Scope 949 1009--*--myocardial infarction, stroke or life-threatening arrhythmia",
            "Condition 1072 1091--*--atrial fibrillation",
            "Condition 1072 1078;1092 1099--*--atrial flutter",
            "Qualifier 1059 1071--*--uncontrolled",
            "Temporal 1100 1112--*--at screening",
            "Scope 1072 1099--*--atrial fibrillation/flutter",
            "Condition 1178 1195--*--bleeding disorder",
            "Procedure 1223 1236--*--prostatectomy",
            "Condition 1248 1263--*--prostate cancer",
            "Procedure 1275 1299--*--nerve sparing techniques",
            "Procedure 1328 1347--*--surgical procedures",
            "Condition 1369 1396--*--benign prostate hypertrophy",
            "Negation 1401 1410--*--permitted",
            "Procedure 1434 1445--*--cryosurgery",
            "Procedure 1447 1458--*--cryotherapy",
            "Procedure 1462 1474--*--cryoablation",
            "Scope 1434 1474--*--cryosurgery, cryotherapy or cryoablation",
            "Condition 1489 1530--*--hereditary degenerative retinal disorders",
            "Condition 1539 1559--*--retinitis pigmentosa",
            "Condition 1613 1661--*--non-arteritic anterior ischemic optic neuropathy",
            "Condition 1663 1668--*--NAION",
            "Condition 1587 1601--*--loss of vision",
            "Condition 1705 1719--*--loss of vision",
            "Qualifier 1682 1691--*--temporary",
            "Qualifier 1695 1704--*--permanent",
            "Scope 1682 1704--*--temporary or permanent",
            "Qualifier 1731 1741--*--unilateral",
            "Condition 1742 1756--*--loss of vision",
            "Condition 1784 1810--*--congenital QT prolongation",
            "Condition 1827 1856--*--penile anatomical abnormality",
            "Condition 1864 1879--*--penile fibrosis",
            "Condition 1864 1870;1881 1890--*--penile fractures",
            "Condition 1895 1914--*--Peyronie's disease)",
            "Scope 1864 1913--*--penile fibrosis, fractures, or Peyronie's disease",
            "Observation 2098 2130--*--primary hypoactive sexual desire",
            "Condition 2148 2166--*--spinal cord injury",
            "Condition 2201 2206;2207 2220--*--acute liver disease",
            "Qualifier 2183 2189--*--severe",
            "Condition 2190 2197;2207 2220--*--chronic liver disease",
            "Condition 2283 2301--*--hepatic impairment",
            "Measurement 2243 2253--*--Child-Pugh",
            "Measurement 2269 2279--*--Child-Pugh",
            "Value 2254 2255--*--B",
            "Value 2280 2281--*--C",
            "Qualifier 2233 2241--*--moderate",
            "Qualifier 2261 2267--*--severe",
            "Scope 2190 2220--*--chronic or acute liver disease",
            "Condition 2283 2301--*--hepatic impairment",
            "Condition 2347 2368--*--hematological disease",
            "Scope 829 889--*--cardiovascular condition, including unstable angina pectoris",
            "Measurement 1125 1150--*--ventricular response rate",
            "Value 1151 1160--*--= 100 bpm",
            "Observation 1317 1327--*--history of",
            "Negation 1412 1433--*--with the exception of",
            "Observation 1576 1586--*--history of",
            "Observation 1773 1783--*--history of",
            "Non-representable 1922 1951--*--in the investigator's opinion",
            "Qualifier 1953 1998--*--could significantly impair sexual performance",
            "Qualifier 2339 2346--*--chronic",
            "Qualifier 2375 2397--*--could lead to priapism",
            "Condition 2406 2424--*--sickle cell anemia",
            "Condition 2426 2442--*--multiple myeloma",
            "Condition 2448 2456--*--leukemia",
            "Scope 2406 2456--*--sickle cell anemia, multiple myeloma, and leukemia",
            "Procedure 2058 2069--*--penile exam",
            "Qualifier 2316 2338--*--clinically significant",
            "Condition 1973 1998--*--impair sexual performance",
            "Condition 2389 2397--*--priapism",
            "Qualifier 2471 2477--*--active",
            "Condition 2478 2495--*--peptic ulceration",
            "Observation 2512 2522--*--history of",
            "Condition 2523 2533--*--malignancy",
            "Temporal 2534 2557--*--within the past 5 years",
            "Negation 2559 2569--*--other than",
            "Condition 2570 2578;2593 2604--*--squamous skin cancer",
            "Condition 2582 2604--*--basal cell skin cancer",
            "Scope 2570 2604--*--squamous or basal cell skin cancer",
            "Observation 2622 2632--*--history of",
            "Value 2635 2643--*--positive",
            "Measurement 2644 2688--*--test for Hepatitis B surface antigen (HbsAg)",
            "Measurement 2644 2652;2692 2703--*--test for Hepatitis C",
            "Scope 2644 2703--*--test for Hepatitis B surface antigen (HbsAg) or Hepatitis C",
            "Condition 2726 2742--*--hypersensitivity",
            "Qualifier 2767 2782--*--investigational",
            "Drug 2783 2794--*--medications",
            "Drug 2796 2824--*--monoamine oxidase inhibitors",
            "Drug 2826 2861--*--phosphodiesterase type 5 inhibitors",
            "Drug 2865 2882--*--phenylethylamines",
            "Scope 2767 2882--*--investigational medications, monoamine oxidase inhibitors, phosphodiesterase type 5 inhibitors or phenylethylamines",
            "Observation 2900 2910--*--history of",
            "Condition 2911 2915;2927 2932--*--drug abuse",
            "Condition 2919 2932--*--alcohol abuse",
            "Temporal 2933 2957--*--within the past 6 months",
            "Reference_point 2940 2957--*--the past 6 months",
            "Scope 2911 2932--*--drug or alcohol abuse",
            "Temporal 2968 2977--*--currently",
            "Observation 2978 2987;3000 3015--*--consuming alcohol per day",
            "Value 2988 2996--*--=5 units",
            "Observation 3032 3042--*--illiterate",
            "Negation 3046 3055--*--unable to",
            "Informed_consent 3056 3092--*--understand the Informed Consent Form",
            "Informed_consent 3056 3070;3112 3125--*--understand the subject diary",
            "Informed_consent 3056 3070;3094 3108--*--understand the questionnaires",
            "Scope 3056 3125--*--understand the Informed Consent Form, questionnaires or subject diary",
            "Non-representable 3140 3174--*--in the opinion of the investigator",
            "Informed_consent 3184 3239--*--noncompliant with the visit schedule or study procedure",
            "Qualifier 3259 3267--*--unstable",
            "Condition 3268 3275;3309 3317--*--medical disorder",
            "Condition 3277 3288;3309 3317--*--psychiatric disorder",
            "Condition 3293 3317--*--substance abuse disorder",
            "Scope 3268 3317--*--medical, psychiatric, or substance abuse disorder",
            "Non-representable 3323 3357--*--in the opinion of the investigator",
            "Qualifier 3361 3421--*--likely to affect the subject's ability to complete the study",
            "Qualifier 3425 3474--*--preclude the subject's participation in the study",
            "Scope 3361 3474--*--likely to affect the subject's ability to complete the study or preclude the subject's participation in the study",
            "Condition 3499 3517--*--neurologic disease",
            "Qualifier 3489 3498--*--any other",
            "Qualifier 3519 3531--*--Uncontrolled",
            "Condition 3532 3540--*--Diabetes",
            "Measurement 3542 3556--*--Hemoglobin A1C",
            "Value 3557 3562--*--> 7.5",
            "Scope 3542 3562--*--Hemoglobin A1C > 7.5",
            "Scope 3519 3540--*--Uncontrolled Diabetes",
            "Negation 8 17--*--unwilling",
            "Mood 21 33--*--cease use of"
        ],
        "Text": "Subject unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet. Subject receiving dopamine agonists, nitrates, alpha-receptor blocking agents, or antihypertensive medication (see other exclusionary medications listed below). Subject with a history of syncope within the last 6 months prior to screening. Subject with symptomatic postural hypotension (severe dizziness or fainting. Subject with hypotension and a resting systolic blood pressure of < 90 mmHG or hypertension with a resting systolic blood pressure > 170 mmHG or a resting diastolic blood pressure > 110 mmHG. Subject with any underlying cardiovascular condition, including unstable angina pectoris, which preclude sexual activity. Subject with a history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening. Subject with uncontrolled atrial fibrillation/flutter at screening (defined as ventricular response rate = 100 bpm). Subject with a bleeding disorder. Subject with a history of prostatectomy because of prostate cancer, including nerve sparing techniques. Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation. Subject with hereditary degenerative retinal disorders such as retinitis pigmentosa. Subject with a history of loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), history of temporary or permanent loss of vision, including unilateral loss of vision. Subject with a history of congenital QT prolongation. Subject with a penile anatomical abnormality (e.g., penile fibrosis, fractures, or Peyronie's disease) which, in the investigator's opinion, could significantly impair sexual performance. This will be based on subject's reported medical history (penile exam not required). Subject with primary hypoactive sexual desire.. Subject with a spinal cord injury. Subject with a severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment. Subject with clinically significant chronic hematological disease which could lead to priapism such as sickle cell anemia, multiple myeloma, and leukemia. Subject with active peptic ulceration. Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer). Subject with a history of a positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C. Subject with a known hypersensitivity to any component of the investigational medications, monoamine oxidase inhibitors, phosphodiesterase type 5 inhibitors or phenylethylamines. Subjects with a history of drug or alcohol abuse within the past 6 months. Subjects currently consuming =5 units of alcohol per day. Subject who is illiterate or unable to understand the Informed Consent Form, questionnaires or subject diary. Subject who, in the opinion of the investigator, will be noncompliant with the visit schedule or study procedures. Subject with any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or preclude the subject's participation in the study. Diagnosis of any other neurologic disease. Uncontrolled Diabetes (Hemoglobin A1C > 7.5). "
    },
    "NCT02380118_exc": {
        "Annotations": [
            "Condition 6 22--*--hypersensitivity",
            "Condition 26 42--*--contraindication",
            "Drug 50 61--*--study drugs",
            "Scope 6 42--*--hypersensitivity or contraindication",
            "Condition 63 83--*--reversible aetiology",
            "Condition 88 97--*--agitation",
            "Condition 104 115--*--hypotension",
            "Condition 117 124--*--hypoxia",
            "Condition 126 139--*--hypoglycaemia",
            "Scope 104 139--*--hypotension, hypoxia, hypoglycaemia",
            "Scope 63 97--*--reversible aetiology for agitation",
            "Condition 148 157--*--pregnancy",
            "Condition 159 183--*--acute alcohol withdrawal",
            "Person 194 198--*--aged",
            "Value 198 207--*-->75 years"
        ],
        "Text": "known hypersensitivity or contraindication to the study drugs. reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia). known pregnancy. acute alcohol withdrawal. patients aged>75 years.. "
    },
    "NCT02469610_inc": {
        "Text": "Thoracoscopic surgery candidate.. Over 18 years old.. No known allergy to Bupivacaine.. Patient is able to read understand and singe an inform consent.. ",
        "Annotations": [
            "Procedure 0 21--*--Thoracoscopic surgery",
            "Mood 22 31--*--candidate",
            "Value 34 51--*--Over 18 years old",
            "Person 48 51--*--old",
            "Condition 63 70--*--allergy",
            "Drug 74 85--*--Bupivacaine",
            "Negation 54 56--*--No",
            "Observation 99 111--*--able to read",
            "Observation 112 122--*--understand",
            "Observation 127 132--*--singe"
        ]
    },
    "NCT03400735_inc": {
        "Annotations": [
            "Condition 17 35--*--chronic bronchitis",
            "Condition 54 83--*--community-acquired pneumoniae",
            "Measurement 85 95--*--FEV1 value",
            "Value 96 104--*--= 30-80%",
            "Qualifier 123 134--*--mild-severe",
            "Qualifier 135 140--*--acute",
            "Condition 141 175--*--exacerbation of chronic bronchitis",
            "Scope 123 175--*--mild-severe acute exacerbation of chronic bronchitis",
            "Condition 177 181--*--AECB",
            "Measurement 184 201--*--Oxygen saturation",
            "Value 202 207--*--< 90%"
        ],
        "Text": "The diagnosis of chronic bronchitis. The diagnosis of community-acquired pneumoniae. FEV1 value = 30-80%. The diagnosis of mild-severe acute exacerbation of chronic bronchitis (AECB). Oxygen saturation < 90%. "
    },
    "NCT02600000_exc": {
        "Text": "Unstable angina;. Myocardial infarction and heart surgery up to three months before the survey;. Chronic respiratory diseases;. Hemodynamic instability;. Trauma recent face, nausea and vomiting.. Orthopedic and neurological diseases that may preclude the achievement of the cardiopulmonary test and Cardiac Rehabilitation exercises;. Psychological and / or cognitive impairments that restrict them to respond to questionnaires;. ",
        "Annotations": [
            "Condition 0 15--*--Unstable angina",
            "Condition 18 39--*--Myocardial infarction",
            "Procedure 44 57--*--heart surgery",
            "Temporal 58 94--*--up to three months before the survey",
            "Scope 18 57--*--Myocardial infarction and heart surgery",
            "Condition 97 125--*--Chronic respiratory diseases",
            "Condition 128 151--*--Hemodynamic instability",
            "Condition 154 160--*--Trauma",
            "Condition 174 180--*--nausea",
            "Condition 185 193--*--vomiting",
            "Condition 211 232--*--neurological diseases",
            "Condition 196 206--*--Orthopedic",
            "Qualifier 242 331--*--preclude the achievement of the cardiopulmonary test and Cardiac Rehabilitation exercises",
            "Condition 357 378--*--cognitive impairments",
            "Qualifier 384 426--*--restrict them to respond to questionnaires",
            "Condition 334 347;367 378--*--Psychological impairments"
        ]
    },
    "NCT03497598_inc": {
        "Text": "Women. = 3 UTIs within the last 12 months or = 2 UTIs within the last 6 months;. Laboratory urine culture: <103 CFUs. Age > 18 years. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 11 15--*--UTIs",
            "Multiplier 7 10--*--= 3",
            "Temporal 16 41--*--within the last 12 months",
            "Multiplier 45 48--*--= 2",
            "Condition 49 53--*--UTIs",
            "Temporal 54 78--*--within the last 6 months",
            "Measurement 81 105--*--Laboratory urine culture",
            "Value 107 116--*--<103 CFUs",
            "Person 118 121--*--Age",
            "Value 122 132--*--> 18 years"
        ]
    },
    "NCT02859480_inc": {
        "Text": "Patients underwent percutaneous coronary intervention with drug-eluting stent;. ",
        "Annotations": [
            "Procedure 19 53--*--percutaneous coronary intervention",
            "Device 59 77--*--drug-eluting stent"
        ]
    },
    "NCT02385448_exc": {
        "Annotations": [
            "Condition 0 18--*--Operative findings",
            "Negation 19 22--*--not",
            "Mood 23 33--*--suggestive",
            "Condition 37 55--*--endometriotic cyst",
            "Condition 57 74--*--Contraindications",
            "Drug 78 90--*--progestogens",
            "Drug 94 118--*--oral contraceptive pills",
            "Scope 78 118--*--progestogens or oral contraceptive pills",
            "Condition 146 168--*--menstrual irregularity",
            "Mood 120 145--*--Unwillingness to tolerate",
            "Mood 170 178--*--Planning",
            "Condition 179 188--*--pregnancy",
            "Temporal 189 212--*--within 2 years of study",
            "Non-query-able 214 263--*--Cannot understand English, Cantonese or Putonghua"
        ],
        "Text": "Operative findings not suggestive of endometriotic cyst. Contraindications to progestogens or oral contraceptive pills. Unwillingness to tolerate menstrual irregularity. Planning pregnancy within 2 years of study. Cannot understand English, Cantonese or Putonghua. "
    },
    "NCT02790593_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 21--*--less than 18 year",
            "Condition 36 52--*--arterial disease",
            "Qualifier 24 35--*--Significant",
            "Measurement 54 83--*--Ankle Brachial Pressure Index",
            "Value 84 88--*--<0\u20229",
            "Procedure 104 119--*--Arterial Duplex",
            "Condition 122 148--*--Acute Deep Vein Thrombosis",
            "Post-eligibility 150 219--*--Patient unable or unwilling to have high compression (30mmHg minimum)",
            "Condition 235 267--*--dexterity insufficiency of hands",
            "Condition 283 304--*--peripheral neuropathy",
            "Condition 306 316--*--Leg ulcers",
            "Condition 328 344--*--underlying cause",
            "Qualifier 320 327--*--another",
            "Condition 346 356--*--Leg ulcers",
            "Temporal 360 388--*--greater than 1 year duration",
            "Post-eligibility 390 455--*--Patients unable or unwilling to provide written, informed consent"
        ],
        "Text": "Age less than 18 years. Significant arterial disease (Ankle Brachial Pressure Index <0\u20229 or evidence on Arterial Duplex). Acute Deep Vein Thrombosis. Patient unable or unwilling to have high compression (30mmHg minimum). Patients with dexterity insufficiency of hands. Patients with peripheral neuropathy. Leg ulcers of another underlying cause. Leg ulcers of greater than 1 year duration. Patients unable or unwilling to provide written, informed consent. "
    },
    "NCT02531724_inc": {
        "Text": "Patients in the cardiothoracic intensive care after cardiac surgery with cardiopulmonary bypass. Acute kidney injury, defined as increase in S-creatinine 50% or 27 mol/L. Normal S-creatinine before surgery. ",
        "Annotations": [
            "Visit 16 45--*--cardiothoracic intensive care",
            "Temporal 46 95--*--after cardiac surgery with cardiopulmonary bypass",
            "Procedure 52 67--*--cardiac surgery",
            "Reference_point 52 95--*--cardiac surgery with cardiopulmonary bypass",
            "Procedure 73 95--*--cardiopulmonary bypass",
            "Condition 97 116--*--Acute kidney injury",
            "Measurement 129 153--*--increase in S-creatinine",
            "Value 154 169--*--50% or 27 mol/L",
            "Value 171 177--*--Normal",
            "Measurement 178 190--*--S-creatinine",
            "Temporal 191 205--*--before surgery",
            "Reference_point 198 205--*--surgery",
            "Procedure 198 205--*--surgery"
        ]
    },
    "NCT03382106_exc": {
        "Text": "Women only: Cannot be pregnant or nursing at baseline or plan to become pregnant during the course of the study. Body Mass Index (BMI) > 32. Weight > 220 pounds. Allergies to shell fish, seafood, eggs or iodine. Heart disease, kidney disease or diabetes. Diagnosis of asthma. Any metal in or on the body (that cannot be removed) between the nose and the abdomen. Any major organ system disease (by judgment of the study medical team). A glomerular filtration rate of 60 cc per minute or less.. Nitroglycerin usage or nitrates and use of phosphodiesterase 5 (PDE5) inhibitors. Prior history of hypersensitivity to sildenafil. Currently prescribed a phosphodiesterase (PDE) inhibitors medication (ex: Viagra, Cialis, etc). Known Pulmonary Hypertension. Has used e-cigarettes and marijuana <1 years. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Pregnancy_considerations 12 111--*--Cannot be pregnant or nursing at baseline or plan to become pregnant during the course of the study",
            "Measurement 113 134--*--Body Mass Index (BMI)",
            "Value 135 139--*--> 32",
            "Measurement 141 147--*--Weight",
            "Value 148 160--*--> 220 pounds",
            "Condition 162 171--*--Allergies",
            "Observation 175 185--*--shell fish",
            "Observation 187 194--*--seafood",
            "Observation 196 200--*--eggs",
            "Drug 204 210--*--iodine",
            "Scope 175 210--*--shell fish, seafood, eggs or iodine",
            "Condition 212 225--*--Heart disease",
            "Condition 227 241--*--kidney disease",
            "Condition 245 253--*--diabetes",
            "Condition 268 274--*--asthma",
            "Device 280 288;295 303--*--metal in the body",
            "Device 280 285;292 303--*--metal on the body",
            "Qualifier 329 361--*--between the nose and the abdomen",
            "Scope 280 303--*--metal in or on the body",
            "Condition 367 393--*--major organ system disease",
            "Measurement 437 463--*--glomerular filtration rate",
            "Value 467 491--*--60 cc per minute or less",
            "Drug 494 507--*--Nitroglycerin",
            "Drug 517 525--*--nitrates",
            "Drug 537 574--*--phosphodiesterase 5 (PDE5) inhibitors",
            "Scope 517 574--*--nitrates and use of phosphodiesterase 5 (PDE5) inhibitors",
            "Condition 593 609--*--hypersensitivity",
            "Drug 613 623--*--sildenafil",
            "Observation 576 589--*--Prior history",
            "Drug 648 682--*--phosphodiesterase (PDE) inhibitors",
            "Drug 699 705--*--Viagra",
            "Drug 707 713--*--Cialis",
            "Scope 699 713--*--Viagra, Cialis",
            "Condition 727 749--*--Pulmonary Hypertension",
            "Observation 755 772--*--used e-cigarettes",
            "Observation 755 759;777 786--*--used marijuana",
            "Temporal 787 795--*--<1 years",
            "Scope 755 786--*--used e-cigarettes and marijuana"
        ]
    },
    "NCT03059069_inc": {
        "Text": "Type 2 diabetic patients. Age = 50. Glycemic control: HbA1c = 10.0%. 10 = Beck Depression Inventory (BDI) <30 points. Participants who can undergo contraception in case of being in childbearing period. Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent. ",
        "Annotations": [
            "Condition 0 15--*--Type 2 diabetic",
            "Person 26 29--*--Age",
            "Value 30 34--*--= 50",
            "Measurement 54 59--*--HbA1c",
            "Value 60 67--*--= 10.0%",
            "Measurement 74 105--*--Beck Depression Inventory (BDI)",
            "Value 106 116--*--<30 points",
            "Pregnancy_considerations 118 200--*--Participants who can undergo contraception in case of being in childbearing period",
            "Post-eligibility 202 331--*--Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent"
        ]
    },
    "NCT02790593_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 17--*-->18 years old",
            "Measurement 31 43--*--surface area",
            "Value 19 30--*--1cm squared",
            "Condition 45 64--*--Venous incompetence",
            "Procedure 78 97--*--clinical assessment",
            "Procedure 102 124--*--duplex ultrasound scan",
            "Scope 78 124--*--clinical assessment and duplex ultrasound scan",
            "Condition 141 157--*--arterial disease",
            "Negation 126 128--*--No",
            "Procedure 159 174--*--Arterial Duplex",
            "Measurement 178 207--*--Ankle Brachial Pressure Index",
            "Value 208 212--*-->0.9",
            "Scope 159 212--*--Arterial Duplex or Ankle Brachial Pressure Index >0.9",
            "Post-eligibility 215 257--*--Patients able to complete trial procedures",
            "Observation 275 290--*--life expectancy",
            "Value 294 313--*--greater than 1 year"
        ],
        "Text": "Age >18 years old. 1cm squared surface area. Venous incompetence confirmed by clinical assessment and duplex ultrasound scan. No evidence of arterial disease (Arterial Duplex or Ankle Brachial Pressure Index >0.9). Patients able to complete trial procedures. Patients with a life expectancy of greater than 1 year. "
    },
    "NCT02385448_inc": {
        "Annotations": [
            "Condition 0 19--*--Good general health",
            "Value 21 56--*--Older than the age of legal consent",
            "Person 36 39--*--age",
            "Value 63 75--*--18 years old",
            "Procedure 78 89--*--Sonographic",
            "Condition 103 123--*--ovarian endometrioma",
            "Qualifier 129 150--*--diameter at least 4cm",
            "Multiplier 154 170--*--2 separate scans",
            "Temporal 171 193--*--at least 6 weeks apart",
            "Scope 78 150--*--Sonographic diagnosis of ovarian endometrioma with diameter at least 4cm",
            "Negation 195 197--*--No",
            "Condition 198 214--*--contraindication",
            "Drug 225 237--*--progesterone",
            "Drug 241 274--*--combined oral contraceptive pills",
            "Scope 225 274--*--progesterone or combined oral contraceptive pills",
            "Mood 280 290--*--attempting",
            "Procedure 294 302--*--conceive",
            "Temporal 310 336--*--at the time of study entry",
            "Temporal 340 374--*--for at least 2 years after surgery",
            "Scope 310 374--*--at the time of study entry or for at least 2 years after surgery",
            "Negation 276 279--*--Not",
            "Non-query-able 376 442--*--Willing and able to participate after the study has been explained"
        ],
        "Text": "Good general health. Older than the age of legal consent (i.e. 18 years old). Sonographic diagnosis of ovarian endometrioma with diameter at least 4cm on 2 separate scans at least 6 weeks apart. No contraindication to use of progesterone or combined oral contraceptive pills. Not attempting to conceive either at the time of study entry or for at least 2 years after surgery. Willing and able to participate after the study has been explained. "
    },
    "NCT02531724_exc": {
        "Text": "Ongoing treatment with inotropic drugs (not norepinephrine). Central venous oxygen saturation (ScvO2) < 60% despite optimization of hematocrit and volume status. Need of renal replacement therapy. Ongoing bleeding. Patient or next of kin does not consent with study participation. ",
        "Annotations": [
            "Temporal 0 7--*--Ongoing",
            "Procedure 8 17--*--treatment",
            "Drug 23 38--*--inotropic drugs",
            "Drug 44 58--*--norepinephrine",
            "Negation 40 43--*--not",
            "Measurement 61 101--*--Central venous oxygen saturation (ScvO2)",
            "Value 102 107--*--< 60%",
            "Procedure 116 142--*--optimization of hematocrit",
            "Observation 147 160--*--volume status",
            "Observation 108 115--*--despite",
            "Procedure 170 195--*--renal replacement therapy",
            "Mood 162 166--*--Need",
            "Temporal 197 204--*--Ongoing",
            "Condition 205 213--*--bleeding",
            "Informed_consent 215 279--*--Patient or next of kin does not consent with study participation"
        ]
    },
    "NCT03059069_exc": {
        "Text": "Type 1 diabetes, Secondary diabetes, gestational diabetes. Ongoing dementia treatment or anti-depressive disorder medication. Uncontrolled psychiatric disorder. BDI = 30 points. Heavy alcoholics. Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis). Allergy or hypersensitivity to target medication or any of its components. Renal failure, moderate or severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2), or ongoing dialysis. Abnormal liver function (AST/ALT > x3 upper normal limit). History of alcohol or drug abuse in the previous 3 months. Premenopausal women who are nursing or pregnant. Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS). chronic pancreatitis or pancreatic cancer. ",
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Condition 17 35--*--Secondary diabetes",
            "Condition 37 57--*--gestational diabetes",
            "Condition 67 75--*--dementia",
            "Procedure 76 85--*--treatment",
            "Drug 89 124--*--anti-depressive disorder medication",
            "Temporal 59 66--*--Ongoing",
            "Qualifier 126 138--*--Uncontrolled",
            "Measurement 161 164--*--BDI",
            "Value 165 176--*--= 30 points",
            "Qualifier 178 183--*--Heavy",
            "Condition 184 194--*--alcoholics",
            "Condition 207 228--*--chronic liver disease",
            "Condition 230 245--*--hemochromatosis",
            "Condition 247 267--*--liver cell carcinoma",
            "Condition 269 293--*--autoimmune liver disease",
            "Condition 295 310--*--liver cirrhosis",
            "Condition 312 335--*--chronic viral hepatitis",
            "Scope 230 335--*--hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis",
            "Condition 338 345--*--Allergy",
            "Condition 349 365--*--hypersensitivity",
            "Drug 369 386--*--target medication",
            "Scope 338 365--*--Allergy or hypersensitivity",
            "Condition 413 426--*--Renal failure",
            "Qualifier 428 436--*--moderate",
            "Qualifier 440 446--*--severe",
            "Condition 447 463--*--renal impairment",
            "Scope 428 446--*--moderate or severe",
            "Measurement 465 501--*--estimated glomerular filtration rate",
            "Value 502 521--*--< 30 mL/min/1.73 m2",
            "Temporal 527 534--*--ongoing",
            "Procedure 535 543--*--dialysis",
            "Scope 428 463--*--moderate or severe renal impairment",
            "Scope 465 521--*--estimated glomerular filtration rate < 30 mL/min/1.73 m2",
            "Measurement 554 568--*--liver function",
            "Value 545 553--*--Abnormal",
            "Measurement 570 577--*--AST/ALT",
            "Value 578 601--*--> x3 upper normal limit",
            "Scope 545 568--*--Abnormal liver function",
            "Scope 570 601--*--AST/ALT > x3 upper normal limit",
            "Condition 626 636--*--drug abuse",
            "Condition 615 622;631 636--*--alcohol abuse",
            "Temporal 637 661--*--in the previous 3 months",
            "Scope 615 636--*--alcohol or drug abuse",
            "Condition 663 676--*--Premenopausal",
            "Person 677 682--*--women",
            "Condition 691 698--*--nursing",
            "Condition 702 710--*--pregnant",
            "Condition 712 746--*--Human immunodeficiency virus (HIV)",
            "Condition 750 785--*--human immunodeficiency virus (AIDS)",
            "Condition 787 807--*--chronic pancreatitis",
            "Condition 811 828--*--pancreatic cancer"
        ]
    },
    "NCT03382106_inc": {
        "Text": "Between the age of 25 to 65 at baseline. Be willing to participate in a smoking cessation program. Be willing to attend all clinic visits. Must be currently smoking at least \u00bd pack/day at baseline (confirmed with cotinine level and CO Smokerlyzer. >5 pack-year history of smoking. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 0: FEV1=0.80 and FEV1/FVC>0.70 Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC). GOLD 1: FEV1=0.80 and FEV1/FVC < 0.70. GOLD 2: 0.50=FEV1<0.80 and FEV1/FVC < 0.70. Be willing to abstain from using any nicotine patches, e-cigarettes, or marijuana for the duration of the study.. ",
        "Annotations": [
            "Value 0 7;19 27--*--Between 25 to 65",
            "Person 12 15--*--age",
            "Temporal 28 39--*--at baseline",
            "Mood 44 66--*--willing to participate",
            "Procedure 72 97--*--smoking cessation program",
            "Non-query-able 99 137--*--Be willing to attend all clinic visits",
            "Observation 157 164--*--smoking",
            "Value 165 175--*--at least \u00bd",
            "Measurement 176 184--*--pack/day",
            "Temporal 185 196--*--at baseline",
            "Procedure 213 227--*--cotinine level",
            "Procedure 232 246--*--CO Smokerlyzer",
            "Measurement 251 260--*--pack-year",
            "Value 248 250--*-->5",
            "Observation 272 279--*--smoking",
            "Measurement 281 342--*--Global Initiative for Chronic Obstructive Lung Disease (GOLD)",
            "Value 343 344--*--0",
            "Measurement 346 350--*--FEV1",
            "Value 350 355--*--=0.80",
            "Measurement 360 368--*--FEV1/FVC",
            "Value 368 373--*-->0.70",
            "Non-representable 374 446--*--Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC)",
            "Scope 281 344--*--Global Initiative for Chronic Obstructive Lung Disease (GOLD) 0",
            "Scope 346 373--*--FEV1=0.80 and FEV1/FVC>0.70",
            "Measurement 448 452--*--GOLD",
            "Value 453 454--*--1",
            "Measurement 456 460--*--FEV1",
            "Value 460 465--*--=0.80",
            "Measurement 470 478--*--FEV1/FVC",
            "Value 479 485--*--< 0.70",
            "Scope 456 485--*--FEV1=0.80 and FEV1/FVC < 0.70",
            "Scope 448 454--*--GOLD 1",
            "Measurement 487 491--*--GOLD",
            "Value 492 493--*--2",
            "Scope 487 493--*--GOLD 2",
            "Measurement 500 504--*--FEV1",
            "Value 495 500;504 509--*--0.50= <0.80",
            "Measurement 514 522--*--FEV1/FVC",
            "Value 523 529--*--< 0.70",
            "Scope 495 529--*--0.50=FEV1<0.80 and FEV1/FVC < 0.70",
            "Non-query-able 531 643--*--Be willing to abstain from using any nicotine patches, e-cigarettes, or marijuana for the duration of the study."
        ]
    },
    "NCT03171987_inc": {
        "Annotations": [
            "Qualifier 366 371--*--acute",
            "Condition 372 398--*--non-specific low back pain",
            "Procedure 424 445--*--physical examinations",
            "Observation 412 419--*--history",
            "Scope 412 445--*--history and physical examinations",
            "Non-representable 0 129--*--All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations.",
            "Procedure 214 234--*--complete blood count",
            "Procedure 239 260--*--acute phase reactants",
            "Procedure 262 292--*--erythrocyte sedimentation rate",
            "Procedure 297 315--*--C-reactive protein",
            "Scope 262 315--*--erythrocyte sedimentation rate and C-reactive protein",
            "Procedure 176 203--*--diagnostic laboratory tests",
            "Condition 562 566--*--pain",
            "Qualifier 574 618--*--area between the 12th rib and buttock crease",
            "Condition 627 635--*--leg pain",
            "Negation 619 626--*--without",
            "Person 637 643--*--Female",
            "Person 647 651--*--male",
            "Value 653 666--*--20 - 80 years",
            "Person 670 673--*--age",
            "Condition 675 688--*--Low back pain",
            "Temporal 692 721--*--less than six weeks' duration",
            "Value 727 744--*--at least moderate",
            "Measurement 745 759--*--pain intensity",
            "Measurement 761 764--*--NRS",
            "Value 772 773--*--4",
            "Scope 727 759--*--at least moderate pain intensity",
            "Scope 761 773--*--NRS<U+2267>4"
        ],
        "Text": "All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations. To rule out any confounding etiologies, basic diagnostic laboratory tests including complete blood count and acute phase reactants (erythrocyte sedimentation rate and C-reactive protein) were performed. The patients diagnosed as having acute non-specific low back pain according to history and physical examinations were invited to participate and will be informed about the purpose and course of the study.. A primary complaint of pain in the area between the 12th rib and buttock crease without leg pain. Female or male, 20 - 80 years of age. Low back pain of less than six weeks' duration; and at least moderate pain intensity (NRS<U+2267>4). "
    },
    "NCT03304496_exc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Post-eligibility 11 127--*--Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent",
            "Condition 135 162--*--acute myocardial infarction",
            "Condition 168 188--*--ST segment elevation",
            "Temporal 189 237--*--in the first 12 hours from the onset of symptoms",
            "Reference_point 216 237--*--the onset of symptoms",
            "Condition 249 272--*--acute coronary syndrome",
            "Condition 290 311--*--acute pulmonary edema",
            "Condition 313 330--*--cardiogenic shock",
            "Condition 350 373--*--ventricular arrhythmias",
            "Qualifier 340 349--*--malignant",
            "Scope 290 374--*--acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias.",
            "Procedure 387 410--*--cardiac catheterization",
            "Qualifier 451 458--*--femoral",
            "Qualifier 460 468--*--brachial",
            "Qualifier 472 477--*--ulnar",
            "Scope 451 477--*--femoral, brachial or ulnar",
            "Non-query-able 480 615--*--Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge",
            "Non-query-able 618 657--*--Participating in another clinical trial",
            "Condition 663 671--*--allergic",
            "Drug 701 714--*--nitroglycerin",
            "Drug 724 732--*--nitrates",
            "Scope 701 732--*--nitroglycerin or other nitrates",
            "Condition 680 697--*--contraindications",
            "Scope 663 697--*--allergic or have contraindications",
            "Drug 739 768--*--phosphodiesterase 5 inhibitor",
            "Drug 770 780--*--sildenafil",
            "Drug 782 791--*--tadalafil",
            "Drug 793 801--*--avanafil",
            "Drug 803 813--*--vardenafil",
            "Scope 770 814--*--sildenafil, tadalafil, avanafil, vardenafil)",
            "Temporal 830 864--*--within 72 hours prior to the study",
            "Reference_point 859 864--*--study"
        ],
        "Text": "Pregnant.. Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent.. With acute myocardial infarction with ST segment elevation in the first 12 hours from the onset of symptoms.. With any acute coronary syndrome complicated with acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias.. In which a cardiac catheterization is planned a priori to be performed via femoral, brachial or ulnar.. Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge.. Participating in another clinical trial.. Be allergic or have contraindications to nitroglycerin or other nitrates.. Any phosphodiesterase 5 inhibitor (sildenafil, tadalafil, avanafil, vardenafil) has been taken within 72 hours prior to the study.. "
    },
    "NCT02196285_exc": {
        "Text": "Serious adverse reaction to any vaccination, as respiratory difficulty, angioedema and anaphylaxis; . Acute or chronic disease, as diabetes, heart disease, systemic arterial hypertension; . Use of anti-allergic with antigen injections in a maximum timeline of 14 days before the vaccination; . Use of immunoglobulin in the past 12 months before the study vaccination; . Use of blood products within 12 months before the vaccination; . Use of any vaccine type within 30 days before the vaccination of the study; . Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins; . Previous immunosuppressive or cytotoxic medication, in the last 6 months. Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study. . Use of any kind of medication under investigation within one year before the vaccination. . Unstable asthma or which may have required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid. . Coagulopathies diagnosed by a physician or report of capillary fragility (ex: bruises or bleedings without justifiable cause; . Convulsions, except the ones caused by fever, before 2 years old; . Psychiatric disease which difficults the adherence to the protocol, such as psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion; . Active malignant (p.e. any kind of cancer) or treated disease, to which the individual may relapse during the study; . Asplenia (absence of spleen or its removal); . Positive HIV in the screening examination of history of any immunosuppressant disease; . Positive serology for C hepatitis in the screening evaluation; . Positive Antigen HBs in the screening evaluation; . Alcoholism (CAGE criteria), used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision; . Abuse of illicit drugs, according to medical decision; . Acquired or congenital immunodeficiency; . Allergy to the vaccine compounds, as egg, neomycin and gelatin.       .     . ",
        "Annotations": [
            "Drug 298 312--*--immunoglobulin",
            "Temporal 313 363--*--in the past 12 months before the study vaccination",
            "Reference_point 342 363--*--the study vaccination",
            "Condition 8 24--*--adverse reaction",
            "Condition 48 70--*--respiratory difficulty",
            "Procedure 32 43--*--vaccination",
            "Condition 72 82--*--angioedema",
            "Condition 87 98--*--anaphylaxis",
            "Scope 48 98--*--respiratory difficulty, angioedema and anaphylaxis",
            "Condition 110 125--*--chronic disease",
            "Condition 130 138--*--diabetes",
            "Condition 101 106;118 125--*--Acute disease",
            "Condition 140 153--*--heart disease",
            "Condition 155 185--*--systemic arterial hypertension",
            "Scope 130 185--*--diabetes, heart disease, systemic arterial hypertension",
            "Scope 101 125--*--Acute or chronic disease",
            "Procedure 214 232--*--antigen injections",
            "Drug 195 208--*--anti-allergic",
            "Temporal 238 288--*--maximum timeline of 14 days before the vaccination",
            "Reference_point 273 288--*--the vaccination",
            "Drug 373 387--*--blood products",
            "Temporal 388 427--*--within 12 months before the vaccination",
            "Reference_point 412 427--*--the vaccination",
            "Drug 437 453--*--any vaccine type",
            "Temporal 454 504--*--within 30 days before the vaccination of the study",
            "Reference_point 476 504--*--the vaccination of the study",
            "Multiplier 507 518--*--Chronic use",
            "Drug 522 536--*--any medication",
            "Undefined_semantics 437 453--*--any vaccine type",
            "Undefined_semantics 522 536--*--any medication",
            "Procedure 545 555--*--homeopathy",
            "Drug 578 604--*--nasal physiologic solution",
            "Drug 609 617--*--vitamins",
            "Grammar_Error 605 608--*--and",
            "Drug 561 573--*--trivial ones",
            "Undefined_semantics 561 573--*--trivial ones",
            "Subjective_judgement 561 573--*--trivial ones",
            "Scope 578 617--*--nasal physiologic solution and vitamins",
            "Negation 538 544--*--except",
            "Scope 545 617--*--homeopathy, and trivial ones, as nasal physiologic solution and vitamins",
            "Drug 629 646;660 670--*--immunosuppressive medication",
            "Drug 650 670--*--cytotoxic medication",
            "Undefined_semantics 650 670--*--cytotoxic medication",
            "Undefined_semantics 629 646;660 670--*--immunosuppressive medication",
            "Temporal 672 692--*--in the last 6 months",
            "Scope 629 670--*--immunosuppressive or cytotoxic medication",
            "Parsing_Error 694 948--*--Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study.",
            "Not_a_criteria 694 948--*--Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study.",
            "Drug 969 999--*--medication under investigation",
            "Undefined_semantics 969 999--*--medication under investigation",
            "Temporal 1000 1038--*--within one year before the vaccination",
            "Reference_point 1023 1038--*--the vaccination",
            "Condition 1041 1056--*--Unstable asthma",
            "Qualifier 1075 1095--*--required urgent care",
            "Procedure 1097 1112--*--hospitalization",
            "Procedure 1084 1095--*--urgent care",
            "Procedure 1116 1126--*--intubation",
            "Qualifier 1075 1083;1097 1112--*--required hospitalization",
            "Qualifier 1075 1083;1116 1126--*--required intubation",
            "Temporal 1127 1150--*--within the last 2 years",
            "Drug 1177 1181;1197 1211--*--oral corticosteroid",
            "Drug 1185 1211--*--intravenous corticosteroid",
            "Scope 1075 1126--*--required urgent care, hospitalization or intubation",
            "Qualifier 1161 1181;1197 1211--*--requires use of oral corticosteroid",
            "Qualifier 1161 1176;1185 1211--*--requires use of intravenous corticosteroid",
            "Scope 1161 1211--*--requires use of oral or intravenous corticosteroid",
            "Scope 1075 1150--*--required urgent care, hospitalization or intubation within the last 2 years",
            "Scope 1075 1211--*--required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid",
            "Condition 1214 1228--*--Coagulopathies",
            "Condition 1267 1286--*--capillary fragility",
            "Condition 1292 1299--*--bruises",
            "Condition 1303 1312--*--bleedings",
            "Qualifier 1313 1338--*--without justifiable cause",
            "Non-query-able 1313 1338--*--without justifiable cause",
            "Scope 1292 1338--*--bruises or bleedings without justifiable cause",
            "Condition 1341 1352--*--Convulsions",
            "Temporal 1387 1405--*--before 2 years old",
            "Qualifier 1370 1385--*--caused by fever",
            "Negation 1354 1360--*--except",
            "Condition 1380 1385--*--fever",
            "Reference_point 1394 1405--*--2 years old",
            "Condition 1408 1427--*--Psychiatric disease",
            "Qualifier 1434 1474--*--difficults the adherence to the protocol",
            "Subjective_judgement 1434 1474--*--difficults the adherence to the protocol",
            "Undefined_semantics 1434 1474--*--difficults the adherence to the protocol",
            "Condition 1484 1493--*--psychosis",
            "Condition 1495 1525--*--obsessive-compulsive disorders",
            "Condition 1527 1542--*--bipolar disease",
            "Qualifier 1543 1558--*--under treatment",
            "Procedure 1549 1558--*--treatment",
            "Undefined_semantics 1543 1558--*--under treatment",
            "Drug 1598 1605--*--lithium",
            "Procedure 1583 1605--*--treatment with lithium",
            "Condition 1610 1624--*--suicidal ideas",
            "Temporal 1625 1663--*--in the last 5 years from the inclusion",
            "Reference_point 1650 1663--*--the inclusion",
            "Condition 1560 1605--*--diseases which require treatment with lithium",
            "Scope 1484 1663--*--psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion",
            "Condition 1673 1682;1720 1727--*--malignant disease",
            "Temporal 1666 1672--*--Active",
            "Condition 1701 1707--*--cancer",
            "Qualifier 1689 1697--*--any kind",
            "Condition 1712 1727--*--treated disease",
            "Procedure 1712 1719--*--treated",
            "Qualifier 1712 1719--*--treated",
            "Qualifier 1673 1682--*--malignant",
            "Subjective_judgement 1729 1781--*--to which the individual may relapse during the study",
            "Undefined_semantics 1729 1781--*--to which the individual may relapse during the study",
            "Non-query-able 1729 1781--*--to which the individual may relapse during the study",
            "Qualifier 1729 1764--*--to which the individual may relapse",
            "Temporal 1765 1781--*--during the study",
            "Reference_point 1772 1781--*--the study",
            "Scope 1666 1727--*--Active malignant (p.e. any kind of cancer) or treated disease",
            "Condition 1784 1792--*--Asplenia",
            "Negation 1794 1804--*--absence of",
            "Condition 1805 1811--*--spleen",
            "Procedure 1805 1811;1819 1826--*--spleen removal",
            "Scope 1794 1826--*--absence of spleen or its removal",
            "Measurement 1839 1842--*--HIV",
            "Value 1830 1838--*--Positive",
            "Temporal 1843 1871--*--in the screening examination",
            "Reference_point 1850 1871--*--screening examination",
            "Condition 1890 1915--*--immunosuppressant disease",
            "Undefined_semantics 1890 1915--*--immunosuppressant disease",
            "Measurement 1927 1951--*--serology for C hepatitis",
            "Value 1918 1926--*--Positive",
            "Temporal 1952 1979--*--in the screening evaluation",
            "Reference_point 1959 1979--*--screening evaluation",
            "Measurement 1991 2002--*--Antigen HBs",
            "Value 1982 1990--*--Positive",
            "Temporal 2003 2030--*--in the screening evaluation",
            "Reference_point 2010 2030--*--screening evaluation",
            "Condition 2033 2043--*--Alcoholism",
            "Measurement 2045 2058--*--CAGE criteria",
            "Value 2033 2043--*--Alcoholism",
            "Not_a_criteria 2061 2321--*--used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision;",
            "Condition 2323 2345--*--Abuse of illicit drugs",
            "Subjective_judgement 2347 2376--*--according to medical decision",
            "Condition 2379 2387;2402 2418--*--Acquired immunodeficiency",
            "Condition 2391 2418--*--congenital immunodeficiency",
            "Condition 2421 2453--*--Allergy to the vaccine compounds",
            "Drug 2436 2453--*--vaccine compounds",
            "Drug 2458 2461--*--egg",
            "Drug 2463 2471--*--neomycin",
            "Drug 2476 2483--*--gelatin",
            "Scope 2458 2483--*--egg, neomycin and gelatin"
        ]
    },
    "NCT03208998_exc": {
        "Annotations": [
            "Condition 7 29--*--consumption of alcohol",
            "Condition 37 42;7 21--*--drugs consumption of",
            "Qualifier 0 6--*--Active",
            "Scope 7 42--*--consumption of alcohol and/or drugs",
            "Condition 62 90--*--human immunodeficiency virus",
            "Condition 92 109--*--hepatitis C virus",
            "Condition 114 131--*--hepatitis D virus",
            "Condition 144 164--*--autoimmune hepatitis",
            "Condition 166 185--*--Psychiatric disease",
            "Condition 199 218--*--neoplastic diseases",
            "Qualifier 226 231--*--liver"
        ],
        "Text": "Active consumption of alcohol and/or drugs. Co-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus. History of autoimmune hepatitis. Psychiatric disease. Evidence of neoplastic diseases of the liver. "
    },
    "NCT01261832_inc": {
        "Annotations": [
            "Condition 0 27--*--Acute Myocardial Infarction",
            "Procedure 39 81--*--Primary percutaneous coronary intervention"
        ],
        "Text": "Acute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.. "
    },
    "NCT03541980_inc": {
        "Text": "Any patient age 4-16 years with sickle cell disease who presents the Pediatric ER with acute sickle cell pain crisis with a pain of 6/10 or higher. ",
        "Annotations": [
            "Person 12 15--*--age",
            "Value 16 26--*--4-16 years",
            "Condition 32 51--*--sickle cell disease",
            "Visit 69 81--*--Pediatric ER",
            "Condition 87 116--*--acute sickle cell pain crisis",
            "Measurement 124 128--*--pain",
            "Value 132 146--*--6/10 or higher"
        ]
    },
    "NCT02431559_exc": {
        "Text": "1. Prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies. . 2. Subjects with platinum-refractory disease, defined as disease progression while receiving first line platinum-based therapy. . 3. Clinically significant persistent immune-related adverse events following prior therapy. . 4. Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage. . 5. Subjects with clinically significant cardiovascular disease. This includes: . 1. Resisted hypertension . 2. Myocardial infarction or unstable angina within 6 months prior to Day 1 of the study. . 3. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication. . 4. Baseline ejection fraction \u2264 50% as assessed by echocardiogram or MUGA. . 5. New York Heart Association (NYHA) Class II or higher congestive heart failure. . 6. Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit. . 6. History of pneumonitis or interstitial lung disease. . 7. Active, suspected or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis). Vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted. . 8. Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only. . 9. Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who require drainage gastrostomy tube and/or parenteral hydration or nutrition. . 10. Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity. . 11. History of severe allergic reactions to any unknown allergens or components of the study drugs. . 12. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders). . 13. Prior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study. . 14. Mental impairment that may compromise compliance with the requirements of the study. . 15. Lack of availability for immunological and clinical follow-up assessment. . 16. Women who are breastfeeding or pregnant as evidenced by positive serum pregnancy test . 17. Subjects unwilling to use acceptable methods of contraception. . -Female subjects should refrain from breastfeeding throughout this period. . 18. Any condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk. . 19. Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment. . 20. History of allogeneic organ transplant       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 191 193--*--2.",
            "Parsing_Error 320 322--*--3.",
            "Parsing_Error 413 415--*--4.",
            "Parsing_Error 764 766--*--5.",
            "Parsing_Error 844 846--*--1.",
            "Parsing_Error 870 872--*--2.",
            "Parsing_Error 960 962--*--3.",
            "Parsing_Error 1216 1218--*--4.",
            "Parsing_Error 1292 1294--*--5.",
            "Parsing_Error 1375 1377--*--6.",
            "Parsing_Error 1521 1523--*--6.",
            "Parsing_Error 1578 1580--*--7.",
            "Parsing_Error 2107 2109--*--8.",
            "Parsing_Error 3503 3506--*--20.",
            "Parsing_Error 3388 3391--*--19.",
            "Parsing_Error 3181 3184--*--18.",
            "Parsing_Error 3037 3040--*--17.",
            "Parsing_Error 2946 2949--*--16.",
            "Parsing_Error 2867 2870--*--15.",
            "Parsing_Error 2777 2780--*--14.",
            "Parsing_Error 2669 2672--*--13.",
            "Parsing_Error 2570 2573--*--12.",
            "Parsing_Error 2469 2472--*--11.",
            "Parsing_Error 2394 2397--*--10.",
            "Parsing_Error 2230 2232--*--9.",
            "Drug 21 32--*--doxorubicin",
            "Drug 34 37--*--PLD",
            "Drug 51 64--*--anthracycline",
            "Drug 66 75--*--motolimod",
            "Drug 86 98--*--TLR agonists",
            "Drug 100 108--*--MEDI4736",
            "Drug 112 133--*--checkpoint inhibitors",
            "Drug 143 153--*--anti-CTLA4",
            "Drug 158 166;178 188--*--anti-PD1 antibodies",
            "Drug 167 188--*--anti-PD-L1 antibodies",
            "Scope 143 188--*--anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies",
            "Grammar_Error 154 157--*--and",
            "Temporal 3 8--*--Prior",
            "Scope 21 188--*--doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies",
            "Condition 208 235--*--platinum-refractory disease",
            "Undefined_semantics 208 235--*--platinum-refractory disease",
            "Condition 248 267--*--disease progression",
            "Temporal 268 317--*--while receiving first line platinum-based therapy",
            "Reference_point 284 317--*--first line platinum-based therapy",
            "Condition 357 386--*--immune-related adverse events",
            "Temporal 387 410--*--following prior therapy",
            "Reference_point 397 410--*--prior therapy",
            "Qualifier 323 345--*--Clinically significant",
            "Qualifier 346 356--*--persistent",
            "Subjective_judgement 323 345--*--Clinically significant",
            "Undefined_semantics 323 345--*--Clinically significant",
            "Condition 479 490--*--CNS disease",
            "Condition 502 521--*--primary brain tumor",
            "Condition 523 531--*--seizures",
            "Qualifier 536 546--*--controlled",
            "Negation 532 535--*--not",
            "Drug 552 576--*--standard medical therapy",
            "Condition 582 598--*--brain metastases",
            "Temporal 604 650--*--within six months prior to Day 1 of this study",
            "Reference_point 631 650--*--Day 1 of this study",
            "Condition 663 687--*--cerebrovascular accident",
            "Condition 689 692--*--CVA",
            "Condition 694 700--*--stroke",
            "Scope 689 700--*--CVA, stroke",
            "Condition 703 734--*--transient ischemic attack (TIA)",
            "Condition 738 761--*--subarachnoid hemorrhage",
            "Scope 663 761--*--cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage",
            "Condition 804 826--*--cardiovascular disease",
            "Qualifier 781 803--*--clinically significant",
            "Subjective_judgement 781 803--*--clinically significant",
            "Undefined_semantics 781 803--*--clinically significant",
            "Parsing_Error 828 842--*--This includes:",
            "Condition 847 868--*--Resisted hypertension",
            "Condition 873 894--*--Myocardial infarction",
            "Condition 898 913--*--unstable angina",
            "Temporal 914 957--*--within 6 months prior to Day 1 of the study",
            "Reference_point 939 957--*--Day 1 of the study",
            "Condition 982 1004--*--ventricular arrhythmia",
            "Scope 873 913--*--Myocardial infarction or unstable angina",
            "Condition 1012 1035--*--ventricular tachycardia",
            "Condition 1039 1063--*--ventricular fibrillation",
            "Scope 1012 1063--*--ventricular tachycardia or ventricular fibrillation",
            "Qualifier 974 981--*--serious",
            "Observation 963 970--*--History",
            "Condition 1068 1087--*--cardiac arrhythmias",
            "Drug 1098 1125--*--anti-arrhythmic medications",
            "Qualifier 1088 1125--*--requiring anti-arrhythmic medications",
            "Condition 1138 1157--*--atrial fibrillation",
            "Negation 1127 1133--*--except",
            "Qualifier 1166 1213--*--well controlled with anti-arrhythmic medication",
            "Drug 1187 1213--*--anti-arrhythmic medication",
            "Measurement 1228 1245--*--ejection fraction",
            "Temporal 1219 1227--*--Baseline",
            "Value 1246 1251--*--\u2264 50%",
            "Procedure 1267 1281--*--echocardiogram",
            "Procedure 1285 1289--*--MUGA",
            "Scope 1267 1289--*--echocardiogram or MUGA",
            "Measurement 1295 1328--*--New York Heart Association (NYHA)",
            "Value 1329 1347--*--Class II or higher",
            "Condition 1348 1372--*--congestive heart failure",
            "Condition 1396 1415--*--peripheral ischemia",
            "Qualifier 1378 1395--*--Grade 2 or higher",
            "Value 1384 1395--*--2 or higher",
            "Temporal 1428 1433--*--brief",
            "Value 1435 1443--*--< 24 hrs",
            "Condition 1457 1465--*--ischemia",
            "Procedure 1478 1488--*--surgically",
            "Negation 1474 1477--*--non",
            "Condition 1501 1518--*--permanent deficit",
            "Negation 1493 1500--*--without",
            "Negation 1417 1423--*--except",
            "Scope 1428 1518--*--brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit",
            "Condition 1535 1546--*--pneumonitis",
            "Condition 1550 1575--*--interstitial lung disease",
            "Observation 1524 1531--*--History",
            "Condition 1619 1637--*--autoimmune disease",
            "Condition 1649 1675--*--inflammatory bowel disease",
            "Condition 1677 1691--*--celiac disease",
            "Condition 1693 1716--*--Wegner's granulomatosis",
            "Condition 1725 1748--*--Hashimoto's thyroiditis",
            "Condition 1750 1770--*--rheumatoid arthritis",
            "Condition 1772 1777--*--lupus",
            "Condition 1779 1790--*--scleroderma",
            "Condition 1779 1790;1799 1807--*--scleroderma variants",
            "Condition 1809 1827--*--multiple sclerosis",
            "Condition 1829 1846--*--myasthenia gravis",
            "Scope 1649 1846--*--inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis",
            "Condition 1849 1857--*--Vitiligo",
            "Condition 1859 1883--*--type I diabetes mellitus",
            "Condition 1885 1908--*--residual hypothyroidism",
            "Condition 1916 1936--*--autoimmune condition",
            "Qualifier 1909 1936--*--due to autoimmune condition",
            "Drug 1952 1971--*--hormone replacement",
            "Qualifier 1942 1971--*--requiring hormone replacement",
            "Qualifier 1987 2015--*--requiring systemic treatment",
            "Procedure 1997 2015--*--systemic treatment",
            "Negation 1983 1986--*--not",
            "Condition 1973 1982--*--psoriasis",
            "Qualifier 2031 2052--*--not expected to recur",
            "Subjective_judgement 2031 2052--*--not expected to recur",
            "Condition 2020 2030--*--conditions",
            "Undefined_semantics 2020 2030--*--conditions",
            "Temporal 2127 2169--*--within 2 years prior to Day 1 of the study",
            "Reference_point 2151 2169--*--Day 1 of the study",
            "Condition 2116 2126--*--malignancy",
            "Procedure 2201 2222--*--surgical intervention",
            "Negation 2171 2181--*--except for",
            "Condition 2182 2187--*--those",
            "Undefined_semantics 2182 2187--*--those",
            "Condition 2247 2264;2274 2305--*--clinical symptoms of gastrointestinal obstruction",
            "Condition 2268 2305--*--signs of gastrointestinal obstruction",
            "Device 2325 2350--*--drainage gastrostomy tube",
            "Procedure 2358 2378--*--parenteral hydration",
            "Procedure 2358 2368;2382 2391--*--parenteral nutrition",
            "Condition 2404 2420--*--immunodeficiency",
            "Condition 2424 2427--*--HIV",
            "Condition 2429 2440--*--Hepatitis B",
            "Condition 2444 2455--*--Hepatitis C",
            "Condition 2491 2509--*--allergic reactions",
            "Qualifier 2484 2490--*--severe",
            "Observation 2473 2480--*--History",
            "Drug 2510 2567--*--to any unknown allergens or components of the study drugs",
            "Context_Error 2510 2567--*--to any unknown allergens or components of the study drugs",
            "Condition 2588 2597--*--illnesses",
            "Qualifier 2580 2587--*--serious",
            "Subjective_judgement 2580 2587--*--serious",
            "Undefined_semantics 2580 2587--*--serious",
            "Condition 2613 2645--*--infections requiring antibiotics",
            "Undefined_semantics 2613 2645--*--infections requiring antibiotics",
            "Qualifier 2605 2612--*--serious",
            "Condition 2647 2665--*--bleeding disorders",
            "Scope 2605 2665--*--serious infections requiring antibiotics, bleeding disorders",
            "Procedure 2679 2688--*--treatment",
            "Context_Error 2673 2775--*--Prior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study.",
            "Condition 2781 2798--*--Mental impairment",
            "Observation 2808 2829--*--compromise compliance",
            "Context_Error 2781 2865--*--Mental impairment that may compromise compliance with the requirements of the study.",
            "Observation 2964 2977--*--breastfeeding",
            "Condition 2981 2989--*--pregnant",
            "Person 2950 2955--*--Women",
            "Measurement 3015 3035--*--serum pregnancy test",
            "Value 3006 3014--*--positive",
            "Scope 2964 2989--*--breastfeeding or pregnant",
            "Person 3106 3112--*--Female",
            "Observation 3142 3155--*--breastfeeding",
            "Temporal 3156 3179--*--throughout this period.",
            "Reference_point 3167 3178--*--this period",
            "Non-query-able 3185 3386--*--Any condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk.",
            "Procedure 3410 3422--*--donate blood",
            "Negation 3406 3409--*--not",
            "Temporal 3423 3437--*--while on study",
            "Reference_point 3429 3437--*--on study",
            "Temporal 3442 3500--*--for at least 90 days following the last MEDI4736 treatment",
            "Reference_point 3473 3500--*--the last MEDI4736 treatment",
            "Scope 3423 3500--*--while on study and for at least 90 days following the last MEDI4736 treatment",
            "Procedure 3518 3545--*--allogeneic organ transplant",
            "Observation 3507 3514--*--History",
            "Temporal 2673 2678--*--Prior",
            "Negation 3129 3141--*--refrain from",
            "Negation 2871 2878--*--Lack of",
            "Procedure 2896 2909;2923 2943--*--immunological follow-up assessment",
            "Procedure 2914 2943--*--clinical follow-up assessment",
            "Scope 2896 2943--*--immunological and clinical follow-up assessment",
            "Mood 2879 2895--*--availability for",
            "Condition 3050 3059--*--unwilling",
            "Qualifier 3067 3077--*--acceptable",
            "Procedure 3089 3102--*--contraception"
        ]
    },
    "NCT03164304_exc": {
        "Annotations": [
            "Condition 11 39--*--Non-proteinuric hypertension",
            "Person 0 5--*--Women",
            "Qualifier 41 47--*--severe",
            "Condition 48 64--*--renal impairment",
            "Condition 66 83--*--Myasthenia gravis",
            "Value 85 96--*--High amount",
            "Measurement 100 118--*--magnesium in blood",
            "Value 120 123;132 138--*--Low amount",
            "Value 127 138--*--high amount",
            "Measurement 142 158--*--calcium in blood",
            "Scope 120 138--*--Low or high amount",
            "Condition 160 177--*--Myocardial damage",
            "Condition 179 192--*--diabetic coma",
            "Condition 194 205--*--heart block"
        ],
        "Text": "Women with Non-proteinuric hypertension. severe renal impairment. Myasthenia gravis. High amount of magnesium in blood. Low or high amount of calcium in blood. Myocardial damage, diabetic coma, heart block. "
    },
    "NCT02408120_inc": {
        "Annotations": [
            "Observation 9 33--*--admitted to the hospital",
            "Condition 56 73--*--medical illnesses",
            "Qualifier 48 55--*--chronic",
            "Qualifier 39 44--*--acute",
            "Scope 39 55--*--acute or chronic",
            "Condition 104 120--*--surgical illness",
            "Condition 124 130--*--trauma",
            "Qualifier 94 103--*--emergency",
            "Qualifier 81 89--*--elective",
            "Scope 81 103--*--elective and emergency",
            "Grammar_Error 90 93--*--and",
            "Scope 104 130--*--surgical illness or trauma",
            "Condition 149 173--*--Type 2 diabetes mellitus",
            "Value 178 187--*-->3 months",
            "Procedure 209 213--*--diet",
            "Drug 240 264--*--oral antidiabetic agents",
            "Drug 293 300--*--insulin",
            "Drug 266 289;301 308--*--non-insulin injectables therapy",
            "Measurement 310 330--*--Blood glucose levels",
            "Value 339 361--*-->140 mg and <400 mg/dL",
            "Negation 362 369--*--without",
            "Qualifier 370 389--*--laboratory evidence",
            "Condition 393 414--*--diabetic ketoacidosis"
        ],
        "Text": "Subjects admitted to the hospital with acute or chronic medical illnesses or for elective and emergency surgical illness or trauma. Known history of Type 2 diabetes mellitus for >3 months. Treated with either diet alone, any combination of oral antidiabetic agents, non-insulin injectables or insulin therapy. Blood glucose levels between >140 mg and <400 mg/dL without laboratory evidence of diabetic ketoacidosis. "
    },
    "NCT03115320_inc": {
        "Text": "- Patient with IVF cycle and therefore having frozen-thawed embryos. Regular menstruation cycle. Patient's willingness to participate in the study. ",
        "Annotations": [
            "Procedure 15 24--*--IVF cycle",
            "Device 46 67--*--frozen-thawed embryos",
            "Condition 69 95--*--Regular menstruation cycle",
            "Informed_consent 97 146--*--Patient's willingness to participate in the study"
        ]
    },
    "NCT02884115_exc": {
        "Annotations": [
            "Condition 0 43--*--Human immunodeficiency virus (HIV)-infected",
            "Temporal 45 53--*--Baseline",
            "Procedure 54 62--*--serology",
            "Value 72 83--*--nonreactive",
            "Measurement 84 92--*--RPR test",
            "Observation 94 117--*--follow-up is inadequate",
            "Condition 119 127--*--Allergic",
            "Drug 131 141--*--penicillin",
            "Condition 143 151--*--Pregnant",
            "Person 152 157--*--woman"
        ],
        "Text": "Human immunodeficiency virus (HIV)-infected. Baseline serology showed a nonreactive RPR test. follow-up is inadequate. Allergic to penicillin. Pregnant woman. "
    },
    "NCT03325023_inc": {
        "Text": "Written consent for participation in the clinical trial. Age 18 to 45 years Irregular menstruation (> 35 days) or secondary amenorrhea> 3 months. ",
        "Annotations": [
            "Informed_consent 0 55--*--Written consent for participation in the clinical trial",
            "Person 57 60--*--Age",
            "Value 61 75--*--18 to 45 years",
            "Condition 76 98--*--Irregular menstruation",
            "Line 57 75--*--Age 18 to 45 years",
            "Line 76 144--*--Irregular menstruation (> 35 days) or secondary amenorrhea> 3 months",
            "Value 100 109--*--> 35 days",
            "Condition 114 134--*--secondary amenorrhea",
            "Temporal 134 144--*--> 3 months"
        ]
    },
    "NCT03040024_exc": {
        "Annotations": [
            "Procedure 0 17--*--Emergency surgery",
            "Visit 0 9--*--Emergency",
            "Procedure 19 44--*--Monitored Anesthesia Care",
            "Procedure 52 71--*--regional anesthesia",
            "Multiplier 72 77--*--alone",
            "Negation 78 85--*--without",
            "Mood 86 95--*--plans for",
            "Procedure 96 114--*--general anesthesia",
            "Scope 52 114--*--regional anesthesia alone without plans for general anesthesia",
            "Procedure 117 124--*--Surgery",
            "Qualifier 139 142--*--eye",
            "Qualifier 144 151--*--eyebrow",
            "Qualifier 153 161--*--forehead",
            "Qualifier 166 179--*--frontal scalp",
            "Non-representable 180 205--*--near the sensor placement",
            "Scope 139 179--*--eye, eyebrow, forehead, or frontal scalp",
            "Observation 207 227--*--Poor health literacy",
            "Condition 229 236--*--Allergy",
            "Condition 262 275--*--drug reaction",
            "Drug 279 287--*--ketamine",
            "Scope 229 275--*--Allergy, or have experienced any drug reaction",
            "Condition 289 297--*--Pregnant",
            "Condition 301 310--*--lactating",
            "Qualifier 325 331--*--active",
            "Condition 332 350--*--alcohol withdrawal",
            "Temporal 312 321--*--Currently"
        ],
        "Text": "Emergency surgery. Monitored Anesthesia Care (i.e., regional anesthesia alone without plans for general anesthesia). Surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement. Poor health literacy. Allergy, or have experienced any drug reaction to ketamine. Pregnant or lactating. Currently in active alcohol withdrawal. "
    },
    "NCT02196285_inc": {
        "Text": "Male . Age between 18 and 49 years old; . Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications); . Willing to strictly follow the study protocol; . Capacity for understanding and signing in the Informed Consent Form; . To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion; . Intellectual level which allows to filling in the diaries for registering of symptoms at home; . Willing to undergo to serological testing to HIV, HBV and HCV; . Being in good health, with no significant medical history; . Physical examination at screening period without clinically significant changes; . Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision. . ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 6 9--*--Age",
            "Value 10 37--*--between 18 and 49 years old",
            "Non-query-able 40 283--*--Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);",
            "Non-query-able 285 331--*--Willing to strictly follow the study protocol;",
            "Post-eligibility 40 283--*--Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);",
            "Post-eligibility 285 331--*--Willing to strictly follow the study protocol;",
            "Post-eligibility 333 401--*--Capacity for understanding and signing in the Informed Consent Form;",
            "Non-query-able 333 401--*--Capacity for understanding and signing in the Informed Consent Form;",
            "Non-query-able 403 561--*--To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;",
            "Post-eligibility 403 561--*--To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;",
            "Undefined_semantics 563 657--*--Intellectual level which allows to filling in the diaries for registering of symptoms at home;",
            "Post-eligibility 563 657--*--Intellectual level which allows to filling in the diaries for registering of symptoms at home;",
            "Non-query-able 563 657--*--Intellectual level which allows to filling in the diaries for registering of symptoms at home;",
            "Procedure 681 707--*--serological testing to HIV",
            "Procedure 681 703;709 712--*--serological testing to HBV",
            "Procedure 681 703;717 720--*--serological testing to HCV",
            "Non-query-able 659 721--*--Willing to undergo to serological testing to HIV, HBV and HCV;",
            "Post-eligibility 659 721--*--Willing to undergo to serological testing to HIV, HBV and HCV;",
            "Condition 732 743--*--good health",
            "Undefined_semantics 732 743--*--good health",
            "Subjective_judgement 723 781--*--Being in good health, with no significant medical history;",
            "Procedure 783 803--*--Physical examination",
            "Temporal 804 823--*--at screening period",
            "Reference_point 807 823--*--screening period",
            "Undefined_semantics 783 863--*--Physical examination at screening period without clinically significant changes;",
            "Subjective_judgement 783 863--*--Physical examination at screening period without clinically significant changes;",
            "Subjective_judgement 865 1028--*--Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.",
            "Post-eligibility 865 1028--*--Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision."
        ]
    },
    "NCT03171987_exc": {
        "Annotations": [
            "Condition 27 43--*--spinal pathology",
            "Device 48 63--*--spinal implants",
            "Qualifier 19 26--*--serious",
            "Mood 9 18--*--suspected",
            "Mood 0 5--*--Known",
            "Scope 19 63--*--serious spinal pathology and spinal implants",
            "Mood 0 18--*--Known or suspected",
            "Procedure 65 86--*--Lumbar spinal surgery",
            "Temporal 87 118--*--within the preceding six months",
            "Qualifier 120 127--*--Serious",
            "Condition 128 141--*--comorbidities",
            "Condition 142 152--*--preventing",
            "Drug 169 180--*--paracetamol",
            "Qualifier 182 193--*--Alternative",
            "Procedure 194 203--*--treatment",
            "Condition 208 221--*--low back pain",
            "Temporal 222 243--*--in previous two weeks",
            "Condition 245 272--*--Chronic neurological lesion",
            "Condition 274 304--*--Chronic musculoskeletal lesion",
            "Condition 313 319--*--cancer",
            "Qualifier 306 312--*--Active",
            "Condition 321 330--*--Pregnancy",
            "Drug 339 354--*--pain medication",
            "Negation 356 362--*--except",
            "Drug 363 374--*--paracetamol",
            "Temporal 376 389--*--within 3 days",
            "Condition 417 428--*--skin lesion",
            "Condition 432 444--*--inflammation",
            "Qualifier 410 416--*--active",
            "Scope 417 444--*--skin lesion or inflammation",
            "Condition 452 459--*--allergy",
            "Device 463 473--*--skin patch"
        ],
        "Text": "Known or suspected serious spinal pathology and spinal implants. Lumbar spinal surgery within the preceding six months. Serious comorbidities preventing prescription of paracetamol. Alternative treatment for low back pain in previous two weeks. Chronic neurological lesion. Chronic musculoskeletal lesion. Active cancer. Pregnancy. Use of pain medication (except paracetamol) within 3 days. Treatment site has active skin lesion or inflammation. Known allergy to skin patch. "
    },
    "NCT03304496_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 8 13--*--women",
            "Person 28 33--*--years",
            "Value 14 27--*--older than 18",
            "Mood 35 44--*--scheduled",
            "Procedure 72 90--*--coronary procedure",
            "Visit 128 181--*--the National Institute of Cardiology \"Ignacio Chavez\"",
            "Procedure 239 262--*--cardiac catheterization",
            "Condition 223 234--*--indications",
            "Visit 98 124--*--department of hemodynamics",
            "Condition 264 277--*--Thoracic pain",
            "Qualifier 291 297--*--Stable",
            "Condition 298 322--*--chronic coronary disease",
            "Condition 324 351--*--Acute myocardial infarction",
            "Condition 357 377--*--ST segment elevation",
            "Procedure 408 427--*--reperfusion therapy",
            "Qualifier 401 407--*--timely",
            "Negation 393 400--*--without",
            "Temporal 429 464--*--with less than 4 weeks of evolution",
            "Reference_point 455 464--*--evolution",
            "Condition 466 493--*--Acute myocardial infarction",
            "Condition 499 519--*--ST-segment elevation",
            "Procedure 532 552--*--thrombolytic therapy",
            "Qualifier 521 531--*--successful",
            "Mood 560 572--*--will undergo",
            "Procedure 573 594--*--drug-invasive therapy",
            "Condition 596 623--*--Acute myocardial infarction",
            "Negation 624 631--*--without",
            "Condition 632 652--*--ST segment elevation",
            "Condition 654 669--*--Unstable angina",
            "Condition 675 698--*--acute coronary syndrome",
            "Procedure 703 712--*--intervene",
            "Qualifier 733 739--*--artery",
            "Qualifier 713 732--*--non-infarct-related",
            "Condition 741 748--*--Disease",
            "Qualifier 756 767--*--heart valve",
            "Condition 769 780--*--Myocarditis",
            "Condition 784 796--*--pericarditis",
            "Condition 806 820--*--cardiomyopathy",
            "Qualifier 798 805--*--Dilated",
            "Condition 843 866--*--cardiac transplantation",
            "Condition 834 839;851 866--*--renal transplantation",
            "Condition 894 918--*--Congenital heart disease",
            "Qualifier 933 961--*--knowing the coronary anatomy",
            "Temporal 962 991--*--prior to surgical correction.",
            "Reference_point 971 990--*--surgical correction",
            "Procedure 1005 1014--*--procedure",
            "Qualifier 1048 1058--*--diagnostic",
            "Procedure 1069 1089--*--coronary angiography",
            "Qualifier 1090 1094--*--only",
            "Procedure 1096 1116--*--left catheterization",
            "Procedure 1118 1122;1133 1148--*--left catheterization",
            "Procedure 1127 1148--*--right catheterization",
            "Scope 1118 1148--*--left and right catheterization",
            "Procedure 1069 1089--*--coronary angiography",
            "Procedure 1069 1089--*--coronary angiography",
            "Scope 1069 1148--*--coronary angiography only, left catheterization, left and right catheterization",
            "Qualifier 1155 1166--*--therapeutic",
            "Scope 264 990--*--Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction",
            "Procedure 1177 1211--*--percutaneous coronary intervention",
            "Procedure 1213 1216--*--PCI",
            "Procedure 1235 1250--*--stent placement",
            "Scope 1048 1250--*--diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement",
            "Procedure 1262 1268--*--access",
            "Qualifier 1255 1261--*--priori",
            "Qualifier 1286 1304--*--left radial artery",
            "Qualifier 1277 1282;1291 1304--*--right radial artery",
            "Scope 1277 1304--*--right or left radial artery",
            "Condition 1323 1328--*--pulse",
            "Qualifier 1307 1322--*--Radial arterial",
            "Measurement 1357 1366--*--palpation",
            "Value 1347 1353--*--absent",
            "Value 1336 1343--*--present",
            "Scope 1336 1353--*--present or absent",
            "Measurement 1369 1383;1395 1399--*--Modified Allen test",
            "Measurement 1387 1399--*--Barbeau test",
            "Value 1410 1418--*--positive",
            "Scope 1369 1399--*--Modified Allen or Barbeau test",
            "Condition 1432 1454--*--collateral palmar flow",
            "Qualifier 1420 1428--*--presence"
        ],
        "Text": "Men and women older than 18 years, scheduled consecutively to perform a coronary procedure in the department of hemodynamics of the National Institute of Cardiology \"Ignacio Chavez\".. Patients may have any of the following indications for cardiac catheterization: Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction.. The planned procedure can be any of the following: For diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement.. A priori access must be right or left radial artery.. Radial arterial pulse may be present or absent by palpation.. Modified Allen or Barbeau test should be positive (presence of collateral palmar flow).. "
    },
    "NCT02431559_inc": {
        "Text": "1. Subjects must have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with measureable disease (as defined by RECIST 1.1.) after first or second line platinum-based chemotherapy, for which treatment with PLD is indicated. Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound. Platinum-resistant is defined as having a platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy. . Subjects are allowed to have received, but are not required to have received: . one additional cytotoxic regimen and/or PARP inhibitor for management of recurrent or persistent disease. . biologic therapy (e.g., bevacizumab) as part of their primary treatment regimen or part of their treatment for management of recurrent or persistent disease. . 2. Histologic documentation of the original primary tumor. . 3. Documented radiographic disease progression < 12 months after the last dose of first- or second-line platinum-based chemotherapy. . 4. Subjects in Phase 2 must have disease amenable to biopsy and must be willing to undergo pre- and post-treatment tumor biopsies. Optional for Phase 1. . Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry. . 5. ECOG performance status of 0 or 1. . 6. Laboratory parameters for vital functions should be in the normal range. Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified, regardless of clinical significance: . Hemoglobin: \u2265 9 g/dL . Neutrophil count: \u2265 1.5 x 109/L . Platelet count: \u2265 100,000/mm3 . Serum creatinine, \u2264 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine Clearance \u2265 50 mL/min (by Cockcroft-Gault formula) . Serum bilirubin: \u2264 1.2 mg/dL . AST/ALT: \u2264 2.5 x ULN . Alkaline phosphatase: \u2264 2.5 x ULN . 7. Age \u226518 years. . 8. Able and willing to give valid written informed consent. . 9. Body weight > 30 kg . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 972 974--*--2.",
            "Parsing_Error 1032 1034--*--3.",
            "Parsing_Error 1166 1168--*--4.",
            "Parsing_Error 1503 1505--*--5.",
            "Parsing_Error 1542 1544--*--6.",
            "Measurement 1833 1843--*--Hemoglobin",
            "Value 1845 1853--*--\u2265 9 g/dL",
            "Value 1873 1886--*--\u2265 1.5 x 109/L",
            "Measurement 1855 1871--*--Neutrophil count",
            "Value 1904 1917--*--\u2265 100,000/mm3",
            "Measurement 1888 1902--*--Platelet count",
            "Measurement 1919 1935--*--Serum creatinine",
            "Value 1937 1985--*--\u2264 1.5x Institutional Upper Limit of Normal (ULN)",
            "Measurement 1990 2010--*--Creatinine Clearance",
            "Value 2011 2022--*--\u2265 50 mL/min",
            "Qualifier 2027 2050--*--Cockcroft-Gault formula",
            "Measurement 2053 2068--*--Serum bilirubin",
            "Value 2070 2081--*--\u2264 1.2 mg/dL",
            "Condition 104 132--*--primary peritoneal carcinoma",
            "Condition 123 132;85 99--*--carcinoma fallopian tube",
            "Condition 123 132;65 83--*--carcinoma epithelial ovarian",
            "Qualifier 22 31--*--recurrent",
            "Qualifier 35 45--*--persistent",
            "Qualifier 46 64--*--platinum-resistant",
            "Scope 65 132--*--epithelial ovarian, fallopian tube, or primary peritoneal carcinoma",
            "Scope 22 45--*--recurrent or persistent",
            "Condition 138 157--*--measureable disease",
            "Temporal 186 197;208 240--*--after first line platinum-based chemotherapy",
            "Reference_point 192 197;208 240--*--first line platinum-based chemotherapy",
            "Temporal 186 191;201 240--*--after second line platinum-based chemotherapy",
            "Reference_point 201 240--*--second line platinum-based chemotherapy",
            "Scope 186 240--*--after first or second line platinum-based chemotherapy",
            "Procedure 252 270--*--treatment with PLD",
            "Drug 267 270--*--PLD",
            "Qualifier 274 283--*--indicated",
            "Undefined_semantics 274 283--*--indicated",
            "Subjective_judgement 274 283--*--indicated",
            "Procedure 285 307--*--Platinum-based therapy",
            "Drug 337 348--*--carboplatin",
            "Drug 350 359--*--cisplatin",
            "Drug 363 394--*--another organoplatinum compound",
            "Not_a_criteria 285 395--*--Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound.",
            "Scope 337 394--*--carboplatin, cisplatin or another organoplatinum compound",
            "Measurement 438 466--*--platinum-free interval (PFI)",
            "Temporal 470 537--*--< 12 months after first- or second-line platinum-based chemotherapy",
            "Reference_point 488 537--*--first- or second-line platinum-based chemotherapy",
            "Condition 396 414--*--Platinum-resistant",
            "Condition 549 568--*--disease progression",
            "Procedure 585 624--*--second-line platinum-based chemotherapy",
            "Scope 549 624--*--disease progression while receiving second-line platinum-based chemotherapy",
            "Scope 438 624--*--platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy",
            "Parsing_Error 627 704--*--Subjects are allowed to have received, but are not required to have received:",
            "Drug 721 738--*--cytotoxic regimen",
            "Drug 746 760--*--PARP inhibitor",
            "Multiplier 706 720--*--one additional",
            "Scope 721 760--*--cytotoxic regimen and/or PARP inhibitor",
            "Condition 803 810--*--disease",
            "Temporal 792 802--*--persistent",
            "Temporal 779 788--*--recurrent",
            "Scope 779 802--*--recurrent or persistent",
            "Drug 837 848--*--bevacizumab",
            "Undefined_semantics 803 810--*--disease",
            "Procedure 813 829--*--biologic therapy",
            "Procedure 867 892--*--primary treatment regimen",
            "Temporal 951 961--*--persistent",
            "Temporal 938 947--*--recurrent",
            "Scope 938 961--*--recurrent or persistent",
            "Condition 962 969--*--disease",
            "Procedure 910 919--*--treatment",
            "Context_Error 938 969--*--recurrent or persistent disease",
            "Undefined_semantics 938 969--*--recurrent or persistent disease",
            "Procedure 975 985--*--Histologic",
            "Condition 1007 1029--*--original primary tumor",
            "Value 986 999--*--documentation",
            "Procedure 1046 1058--*--radiographic",
            "Condition 1059 1078--*--disease progression",
            "Temporal 1079 1163--*--< 12 months after the last dose of first- or second-line platinum-based chemotherapy",
            "Reference_point 1097 1163--*--the last dose of first- or second-line platinum-based chemotherapy",
            "Condition 1199 1225--*--disease amenable to biopsy",
            "Subjective_judgement 1199 1225--*--disease amenable to biopsy",
            "Undefined_semantics 1199 1225--*--disease amenable to biopsy",
            "Non-query-able 1238 1295--*--willing to undergo pre- and post-treatment tumor biopsies",
            "Post-eligibility 1238 1295--*--willing to undergo pre- and post-treatment tumor biopsies",
            "Parsing_Error 1297 1318--*--Optional for Phase 1.",
            "Not_a_criteria 1320 1501--*--Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry.",
            "Measurement 1506 1529--*--ECOG performance status",
            "Value 1533 1539--*--0 or 1",
            "Measurement 1545 1586--*--Laboratory parameters for vital functions",
            "Undefined_semantics 1545 1586--*--Laboratory parameters for vital functions",
            "Value 1604 1616--*--normal range",
            "Measurement 2083 2090--*--AST/ALT",
            "Value 2092 2103--*--\u2264 2.5 x ULN",
            "Measurement 2105 2125--*--Alkaline phosphatase",
            "Value 2127 2138--*--\u2264 2.5 x ULN",
            "Parsing_Error 2140 2142--*--7.",
            "Person 2143 2146--*--Age",
            "Value 2147 2156--*--\u226518 years",
            "Parsing_Error 2159 2161--*--8.",
            "Non-query-able 2162 2218--*--Able and willing to give valid written informed consent.",
            "Post-eligibility 2162 2218--*--Able and willing to give valid written informed consent.",
            "Parsing_Error 2220 2222--*--9.",
            "Measurement 2223 2234--*--Body weight",
            "Value 2235 2242--*--> 30 kg"
        ]
    },
    "NCT03541980_exc": {
        "Text": "Patient with fever (38C or 100.4F). Patient less than age 4 years. Patient greater than age 16 years. Patient with hypersensitivity/allergy to either morphine, NSAIDs, or acetaminophen. Patient received acetaminophen within the past 4 hours. Patient with known liver disease or renal disease. Patient not requiring IV morphine (pain score 5/10 or less). Patient enrolled in the study within the past 72 hours. ",
        "Annotations": [
            "Condition 13 18--*--fever",
            "Value 20 23--*--38C",
            "Value 27 33--*--100.4F",
            "Scope 20 33--*--38C or 100.4F",
            "Value 44 53;58 65--*--less than 4 years",
            "Person 54 57--*--age",
            "Value 75 87;92 100--*--greater than 16 years",
            "Person 88 91--*--age",
            "Condition 115 131--*--hypersensitivity",
            "Condition 132 139--*--allergy",
            "Drug 150 158--*--morphine",
            "Drug 160 166--*--NSAIDs",
            "Drug 171 184--*--acetaminophen",
            "Scope 150 184--*--morphine, NSAIDs, or acetaminophen",
            "Scope 115 139--*--hypersensitivity/allergy",
            "Drug 203 216--*--acetaminophen",
            "Temporal 217 240--*--within the past 4 hours",
            "Condition 261 274--*--liver disease",
            "Condition 278 291--*--renal disease",
            "Negation 301 304--*--not",
            "Mood 305 314--*--requiring",
            "Drug 315 326--*--IV morphine",
            "Measurement 328 338--*--pain score",
            "Value 339 351--*--5/10 or less",
            "Scope 301 326--*--not requiring IV morphine",
            "Scope 328 351--*--pain score 5/10 or less",
            "Observation 362 383--*--enrolled in the study",
            "Temporal 384 408--*--within the past 72 hours"
        ]
    },
    "NCT03208998_inc": {
        "Annotations": [
            "Condition 10 24--*--HBeAg positive",
            "Condition 0 5;16 24--*--HBsAg positive",
            "Temporal 25 47--*--for more than 6 months",
            "Scope 0 24--*--HBsAg and HBeAg positive",
            "Condition 49 67--*--HBV DNA detectable",
            "Measurement 73 82--*--ALT level",
            "Value 83 91--*--abnormal",
            "Temporal 92 115--*--lasted for three months",
            "Temporal 120 133--*--at least time",
            "Value 133 141--*--190 IU/L",
            "Procedure 145 166--*--liver puncture biopsy",
            "Condition 189 201--*--inflammation",
            "Negation 203 208--*--never",
            "Procedure 209 216--*--treated",
            "Temporal 217 232--*--before enrolled",
            "Reference_point 224 232--*--enrolled",
            "Procedure 224 232--*--enrolled"
        ],
        "Text": "HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.. "
    },
    "NCT01261832_exc": {
        "Annotations": [
            "Condition 24 40--*--hypersensitivity",
            "Condition 44 60--*--contraindication",
            "Drug 98 105--*--Heparin",
            "Drug 107 114--*--Aspirin",
            "Drug 116 127--*--Clopidogrel",
            "Drug 129 139--*--Cilostazol",
            "Scope 24 60--*--hypersensitivity or contraindication",
            "Scope 98 139--*--Heparin, Aspirin, Clopidogrel, Cilostazol",
            "Qualifier 141 153--*--Uncontrolled",
            "Condition 154 166--*--hypertension",
            "Condition 179 197--*--bleeding diathesis",
            "Observation 168 175--*--History",
            "Condition 207 219--*--coagulopathy",
            "Condition 231 263--*--heparin-induced thrombocytopenia",
            "Observation 269 295--*--refuses blood transfusions",
            "Procedure 277 295--*--blood transfusions",
            "Procedure 307 315--*--hemogram",
            "Temporal 298 306--*--Baseline",
            "Measurement 321 323--*--Hb",
            "Value 323 330--*--<10g/dL",
            "Measurement 334 343--*--PLT count",
            "Value 343 354--*--<100,000/\u03bcL",
            "Scope 321 354--*--Hb<10g/dL or PLT count<100,000/\u03bcL",
            "Drug 380 388--*--warfarin",
            "Drug 390 400--*--cilostazol",
            "Drug 422 442--*--anti-platelet agents",
            "Drug 450 457--*--aspirin",
            "Drug 462 473--*--clopidogrel",
            "Negation 443 449--*--except",
            "Scope 450 473--*--aspirin and clopidogrel",
            "Condition 495 517--*--genitourinary bleeding",
            "Condition 475 491;509 517--*--Gastrointestinal bleeding",
            "Temporal 518 543--*--within the prior 3 months",
            "Scope 475 517--*--Gastrointestinal or genitourinary bleeding",
            "Procedure 548 561--*--major surgery",
            "Temporal 562 577--*--within 2 months",
            "Condition 580 589--*--Pregnancy"
        ],
        "Text": "The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol. Uncontrolled hypertension. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.. Baseline hemogram with Hb<10g/dL or PLT count<100,000/\u03bcL. Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.. Pregnancy. "
    },
    "NCT03325023_exc": {
        "Text": "Ovarian cancer, adrenal gland tumor, endometrial cancer, cervical cancer, breast cancer. Congenital adrenal hyperplasia (17-OH-progesterone> 2.5 ng / mL). Clinically diagnosed Cushing's disease, acromegaly, gigantism. Type I or II diabetes. Unexplained bleeding from the genital tract. Hormone treatment within the last 2 months. ",
        "Annotations": [
            "Condition 0 14--*--Ovarian cancer",
            "Condition 16 35--*--adrenal gland tumor",
            "Condition 37 55--*--endometrial cancer",
            "Condition 57 72--*--cervical cancer",
            "Condition 74 87--*--breast cancer",
            "Condition 89 119--*--Congenital adrenal hyperplasia",
            "Measurement 121 139--*--17-OH-progesterone",
            "Value 139 152--*--> 2.5 ng / mL",
            "Scope 121 152--*--17-OH-progesterone> 2.5 ng / mL",
            "Qualifier 155 175--*--Clinically diagnosed",
            "Condition 176 193--*--Cushing's disease",
            "Condition 195 205--*--acromegaly",
            "Condition 207 216--*--gigantism",
            "Scope 176 216--*--Cushing's disease, acromegaly, gigantism",
            "Condition 218 224;231 239--*--Type I diabetes",
            "Condition 218 222;228 239--*--Type II diabetes",
            "Condition 241 261--*--Unexplained bleeding",
            "Qualifier 271 284--*--genital tract",
            "Procedure 286 303--*--Hormone treatment",
            "Drug 286 293--*--Hormone",
            "Temporal 304 328--*--within the last 2 months"
        ]
    },
    "NCT03040024_inc": {
        "Annotations": [
            "Condition 21 40--*--otolaryngeal cancer",
            "Temporal 45 55--*--undergoing",
            "Procedure 56 63--*--surgery",
            "Procedure 69 87--*--general anesthesia",
            "Informed_consent 89 126--*--Competent to provide informed consent"
        ],
        "Text": "Current diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia. Competent to provide informed consent. "
    },
    "NCT02408120_exc": {
        "Annotations": [
            "Not_a_criteria 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT03164304_inc": {
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--women",
            "Procedure 15 26--*--admitted to",
            "Visit 27 48--*--Women health hospital",
            "Qualifier 69 75--*--severe",
            "Condition 76 89--*--pre-eclampsia"
        ],
        "Text": "Pregnant women admitted to Women health hospital with a diagnosis of severe pre-eclampsia. "
    },
    "NCT02884115_inc": {
        "Annotations": [
            "Condition 0 14--*--Early Syphilis",
            "Qualifier 38 46--*--Serofast",
            "Temporal 50 82--*--6 Months after Initial Treatment",
            "Reference_point 65 82--*--Initial Treatment",
            "Procedure 73 82--*--Treatment",
            "Multiplier 65 72--*--Initial"
        ],
        "Text": "Early Syphilis Cases Determined to Be Serofast at 6 Months after Initial Treatment. "
    },
    "NCT03115320_exc": {
        "Text": "- Irregular menstrual cycle demanding preparing endometrium with hormones for frozen-thawed embryo. No frozen embryos after IVF cycle. Allergy to Pregnyl\u00ae or some of its ingredients in the medication or other contraindications due to Pregnyl\u00ae. ",
        "Annotations": [
            "Condition 2 27--*--Irregular menstrual cycle",
            "Procedure 38 98--*--preparing endometrium with hormones for frozen-thawed embryo",
            "Procedure 124 133--*--IVF cycle",
            "Negation 100 102--*--No",
            "Observation 103 117--*--frozen embryos",
            "Condition 135 142--*--Allergy",
            "Drug 146 153--*--Pregnyl",
            "Drug 158 181--*--some of its ingredients",
            "Scope 146 181--*--Pregnyl\u00ae or some of its ingredients",
            "Condition 209 226--*--contraindications",
            "Drug 234 241--*--Pregnyl"
        ]
    },
    "NCT02647788_inc": {
        "Text": "Patients undergoing ambulatory hand surgery for carpal tunnel and trigger finger, under local anesthesia with or without sedation.. ",
        "Annotations": [
            "Qualifier 20 30--*--ambulatory",
            "Procedure 31 43--*--hand surgery",
            "Condition 48 61--*--carpal tunnel",
            "Condition 66 80--*--trigger finger",
            "Scope 48 80--*--carpal tunnel and trigger finger",
            "Procedure 88 104--*--local anesthesia"
        ]
    },
    "NCT02510404_exc": {
        "Text": "1. Patients with other uncontrolled infections (see 2.3.2 for definitions) . 2. Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies in the last 28 days . 3. Received donor lymphocyte infusion in last 28 days . 4. Diagnosis of Omenn's syndrome or MHC class I deficiency . 5. Active and uncontrolled malignancy . 6. Pregnant or lactating . 7. Unable to wean steroids to \u22640.5 mg/kg/day prednisone. . 8. Patients with Grade 3 hyperbilirubinemia       .     . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 76 78--*--2.",
            "Parsing_Error 192 194--*--3.",
            "Parsing_Error 247 249--*--4.",
            "Parsing_Error 307 309--*--5.",
            "Parsing_Error 346 348--*--6.",
            "Parsing_Error 372 374--*--7.",
            "Parsing_Error 430 432--*--8.",
            "Condition 17 46--*--other uncontrolled infections",
            "Context_Error 17 46--*--other uncontrolled infections",
            "Undefined_semantics 17 46--*--other uncontrolled infections",
            "Drug 101 104--*--ATG",
            "Drug 106 113--*--Campath",
            "Drug 124 170--*--T cell immunosuppressive monoclonal antibodies",
            "Temporal 171 190--*--in the last 28 days",
            "Scope 101 170--*--ATG, Campath, or other T cell immunosuppressive monoclonal antibodies",
            "Procedure 204 229--*--donor lymphocyte infusion",
            "Temporal 230 245--*--in last 28 days",
            "Condition 263 279--*--Omenn's syndrome",
            "Condition 283 305--*--MHC class I deficiency",
            "Condition 334 344--*--malignancy",
            "Qualifier 321 333--*--uncontrolled",
            "Temporal 310 316--*--Active",
            "Condition 349 357--*--Pregnant",
            "Condition 361 370--*--lactating",
            "Drug 390 398--*--steroids",
            "Value 402 416--*--\u22640.5 mg/kg/day",
            "Procedure 385 389--*--wean",
            "Drug 417 427--*--prednisone",
            "Negation 375 381--*--Unable",
            "Condition 455 473--*--hyperbilirubinemia",
            "Qualifier 447 454--*--Grade 3"
        ]
    },
    "NCT02701777_exc": {
        "Text": "Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease. Any debilitating disease prior to the SCI that caused exercise intolerance. Premorbid, ongoing major depression or psychosis, altered cognitive status. History of head injury or stroke. Metal plate in skull. History of seizures. Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2). Pregnant females. Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk. Individuals with scalp shrapnel, cochlear implants, or aneurysm clips.. ",
        "Annotations": [
            "Qualifier 0 12--*--Uncontrolled",
            "Condition 13 29--*--medical problems",
            "Condition 40 49;80 87--*--pulmonary disease",
            "Condition 51 65;80 87--*--cardiovascular disease",
            "Condition 69 87--*--orthopedic disease",
            "Scope 40 87--*--pulmonary, cardiovascular or orthopedic disease",
            "Condition 143 163--*--exercise intolerance",
            "Condition 93 113--*--debilitating disease",
            "Temporal 114 130--*--prior to the SCI",
            "Reference_point 123 130--*--the SCI",
            "Qualifier 165 174--*--Premorbid",
            "Temporal 176 183--*--ongoing",
            "Condition 184 200--*--major depression",
            "Condition 204 213--*--psychosis",
            "Condition 215 239--*--altered cognitive status",
            "Scope 184 213--*--major depression or psychosis",
            "Condition 252 263--*--head injury",
            "Condition 267 273--*--stroke",
            "Device 275 295--*--Metal plate in skull",
            "Condition 308 316--*--seizures",
            "Observation 241 248--*--History",
            "Scope 252 273--*--head injury or stroke",
            "Observation 297 304--*--History",
            "Drug 328 380--*--drugs acting primarily on the central nervous system",
            "Qualifier 388 415--*--lower the seizure threshold",
            "Condition 434 442--*--Pregnant",
            "Person 443 450--*--females",
            "Condition 460 476--*--cord compression",
            "Condition 482 488--*--syrinx",
            "Qualifier 496 507--*--spinal cord",
            "Condition 557 572--*--spinal stenosis",
            "Condition 529 548--*--spinal cord disease",
            "Condition 574 586--*--spina bifida",
            "Condition 588 590--*--MS",
            "Condition 595 609--*--herniated disk",
            "Scope 557 609--*--spinal stenosis, spina bifida, MS, or herniated disk",
            "Device 628 642--*--scalp shrapnel",
            "Device 644 661--*--cochlear implants",
            "Device 666 680--*--aneurysm clips"
        ]
    },
    "NCT01631058_exc": {
        "Text": "Allergy to any of proposed medications. Patients with any active infection including HBV, HCV and HIV.. ",
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Drug 18 38--*--proposed medications",
            "Condition 58 74--*--active infection",
            "Condition 85 88--*--HBV",
            "Condition 90 93--*--HCV",
            "Condition 98 101--*--HIV",
            "Scope 85 101--*--HBV, HCV and HIV"
        ]
    },
    "NCT02283996_exc": {
        "Annotations": [
            "Non-query-able 0 29--*--Non-English speaking patients",
            "Pregnancy_considerations 31 132--*--Pregnant women (women of childbearing potential will be advised to undergo regular pregnancy testing)",
            "Competing_trial 134 207--*--Patients who had previously undergone operative therapy for the condition"
        ],
        "Text": "Non-English speaking patients. Pregnant women (women of childbearing potential will be advised to undergo regular pregnancy testing). Patients who had previously undergone operative therapy for the condition. "
    },
    "NCT02647788_exc": {
        "Text": "ASA> 3;. Coagulopathy;. Renal disease,. Liver disease,. History of recent gastro-intestinal bleeding. Pregnancy.. Diagnosis of chronic pain currently taking opioid pain medication or with a history of drug abuse.. Patients with a self-described allergy to ASA, acetaminophen, NSAIDS and codeine.. All patients receiving a brachial plexus block for anesthesia and/or analgesia. ",
        "Annotations": [
            "Measurement 0 3--*--ASA",
            "Value 3 6--*--> 3",
            "Condition 9 21--*--Coagulopathy",
            "Condition 24 37--*--Renal disease",
            "Condition 40 53--*--Liver disease",
            "Condition 74 100--*--gastro-intestinal bleeding",
            "Temporal 67 73--*--recent",
            "Condition 102 111--*--Pregnancy",
            "Condition 127 139--*--chronic pain",
            "Drug 157 179--*--opioid pain medication",
            "Observation 190 200--*--history of",
            "Condition 201 211--*--drug abuse",
            "Condition 245 252--*--allergy",
            "Drug 256 259--*--ASA",
            "Drug 261 274--*--acetaminophen",
            "Drug 276 282--*--NSAIDS",
            "Drug 287 294--*--codeine",
            "Scope 256 294--*--ASA, acetaminophen, NSAIDS and codeine",
            "Procedure 322 343--*--brachial plexus block"
        ]
    },
    "NCT01631058_inc": {
        "Text": "All renal (only) male and female recipients aged = 60, years undergoing kidney transplantation from a living or deceased donor, including Expanded Criteria Donors (ECD).. Panel Reactive Antibody (PRA) < 30%.. Patients who consented to participate in the study by signing the informed consent form before the transplant surgery to the 1st post-operative day).. ",
        "Annotations": [
            "Person 17 21--*--male",
            "Person 26 32--*--female",
            "Measurement 44 48--*--aged",
            "Value 49 53--*--= 60",
            "Condition 33 43;4 9--*--recipients renal",
            "Procedure 72 94--*--kidney transplantation",
            "Qualifier 102 108;121 126--*--living donor",
            "Qualifier 112 126--*--deceased donor",
            "Qualifier 138 168--*--Expanded Criteria Donors (ECD)",
            "Scope 102 127--*--living or deceased donor,",
            "Measurement 171 200--*--Panel Reactive Antibody (PRA)",
            "Value 201 206--*--< 30%",
            "Informed_consent 209 357--*--Patients who consented to participate in the study by signing the informed consent form before the transplant surgery to the 1st post-operative day)"
        ]
    },
    "NCT02510404_inc": {
        "Text": "1. Diagnosis of primary immunodeficiency with established plan to undergo myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant for treatment thereof or diagnosis of a form of primary immunodeficiency for which hematopoietic stem cell transplantation is not indicated. . 2. Active infection with EBV, CMV, and/or Adenovirus, unable to be successfully controlled with standard therapy. . 3. Steroids less than 0.5 mg/kg/day prednisone . 4. Karnofsky/Lansky score of \u2265 50 . 5. ANC greater than 500/\u00b5L. . 6. Bilirubin <2x, AST <3x, Serum creatinine <2x upper limit of normal, Hgb >8.0 . 7. Pulse oximetry of > 90% on room air . 8. Negative pregnancy test (if female of childbearing potential) . 9. Patient or parent/guardian capable of providing informed consent. . ",
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 297 299--*--2.",
            "Parsing_Error 412 414--*--3.",
            "Parsing_Error 460 462--*--4.",
            "Parsing_Error 495 497--*--5.",
            "Parsing_Error 524 526--*--6.",
            "Parsing_Error 605 607--*--7.",
            "Parsing_Error 645 647--*--8.",
            "Parsing_Error 711 713--*--9.",
            "Condition 16 40--*--primary immunodeficiency",
            "Procedure 109 154;74 87--*--allogeneic hematopoietic stem cell transplant myeloablative",
            "Procedure 91 154--*--non-myeloablative allogeneic hematopoietic stem cell transplant",
            "Condition 203 227--*--primary immunodeficiency",
            "Procedure 238 277--*--hematopoietic stem cell transplantation",
            "Negation 281 294--*--not indicated",
            "Scope 74 154--*--myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant",
            "Condition 322 325--*--EBV",
            "Condition 327 330--*--CMV",
            "Condition 339 349--*--Adenovirus",
            "Qualifier 351 363;377 387--*--unable to be controlled",
            "Procedure 393 409--*--standard therapy",
            "Scope 322 349--*--EBV, CMV, and/or Adenovirus",
            "Drug 415 423--*--Steroids",
            "Multiplier 424 447--*--less than 0.5 mg/kg/day",
            "Drug 448 458--*--prednisone",
            "Measurement 463 485--*--Karnofsky/Lansky score",
            "Value 489 493--*--\u2265 50",
            "Measurement 498 501--*--ANC",
            "Value 502 521--*--greater than 500/\u00b5L",
            "Measurement 527 536--*--Bilirubin",
            "Value 537 540--*--<2x",
            "Measurement 542 545--*--AST",
            "Value 546 549--*--<3x",
            "Measurement 551 567--*--Serum creatinine",
            "Value 568 593--*--<2x upper limit of normal",
            "Measurement 595 598--*--Hgb",
            "Value 599 603--*-->8.0",
            "Measurement 608 622;632 643--*--Pulse oximetry on room air",
            "Value 626 631--*--> 90%",
            "Measurement 657 671--*--pregnancy test",
            "Value 648 656--*--Negative",
            "Condition 686 708--*--childbearing potential",
            "Person 676 682--*--female",
            "Scope 676 708--*--female of childbearing potential",
            "Post-eligibility 714 778--*--Patient or parent/guardian capable of providing informed consent",
            "Non-query-able 714 779--*--Patient or parent/guardian capable of providing informed consent."
        ]
    },
    "NCT02701777_inc": {
        "Text": "Male and females between ages 18-85 years. Right handed. Able to complete precision grips with both hands. Able to complete full wrist flexion-extension bilaterally. Able to walk unassisted. Able to complete full ankle flexion-extension bilaterally. Male and females between ages 18-85 years. SCI ( 2 months of injury). Spinal Cord injury at or above L5. The ability to produce a visible precision grip force with one hand. Able to perform some small wrist flexion and extension. The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles. No subjects will be excluded based on their race, religion, ethnicity, gender or HIV status.. ASIA A,B,C, or D. ",
        "Annotations": [
            "Person 9 16--*--females",
            "Person 0 4--*--Male",
            "Value 17 24;30 41--*--between 18-85 years",
            "Person 25 29--*--ages",
            "Condition 43 55--*--Right handed",
            "Procedure 65 105--*--complete precision grips with both hands",
            "Procedure 115 164--*--complete full wrist flexion-extension bilaterally",
            "Procedure 174 189--*--walk unassisted",
            "Mood 57 64--*--Able to",
            "Mood 107 114--*--Able to",
            "Mood 166 173--*--Able to",
            "Mood 191 198--*--Able to",
            "Procedure 199 248--*--complete full ankle flexion-extension bilaterally",
            "Person 250 254--*--Male",
            "Person 259 266--*--females",
            "Value 267 274;280 291--*--between 18-85 years",
            "Person 275 279--*--ages",
            "Condition 293 296--*--SCI",
            "Temporal 299 317--*--2 months of injury",
            "Condition 320 338--*--Spinal Cord injury",
            "Qualifier 339 353--*--at or above L5",
            "Procedure 370 422--*--produce a visible precision grip force with one hand",
            "Mood 355 369--*--The ability to",
            "Mood 424 431--*--Able to",
            "Procedure 445 478--*--small wrist flexion and extension",
            "Mood 480 494--*--The ability to",
            "Procedure 505 571--*--small visible contraction with dorsiflexion and hip flexor muscles",
            "Non-representable 573 665--*--No subjects will be excluded based on their race, religion, ethnicity, gender or HIV status.",
            "Measurement 667 671--*--ASIA",
            "Value 672 683--*--A,B,C, or D"
        ]
    },
    "NCT02283996_inc": {
        "Annotations": [
            "Person 19 24--*--years",
            "Value 16 18;25 33--*--18 or older",
            "Condition 74 93--*--adhesive capsulitis",
            "Measurement 112 151--*--American Academy of Orthopedic Surgeons",
            "Non-query-able 153 353--*--Self-limiting condition resulting from any inflammatory process about the shoulder in which capsular scar tissue is produced, resulting in pain and limited range of motion; also called frozen shoulder",
            "Post-eligibility 355 407--*--Must be amenable to randomization into either cohort"
        ],
        "Text": "Patient must be 18 years or older. Must meet the following definition for adhesive capsulitis as defined by the American Academy of Orthopedic Surgeons: Self-limiting condition resulting from any inflammatory process about the shoulder in which capsular scar tissue is produced, resulting in pain and limited range of motion; also called frozen shoulder. Must be amenable to randomization into either cohort. "
    },
    "NCT00122070_exc": {
        "Annotations": [
            "Condition 4 12--*--pregnant",
            "Condition 16 25--*--lactating",
            "Observation 28 101--*--Have participated in any other studies involving investigational products",
            "Temporal 102 147--*--within 30 days prior to entry into this study",
            "Reference_point 126 146--*--entry into this stud",
            "Condition 168 193--*--acute withdrawal syndrome",
            "Drug 199 204--*--drugs",
            "Drug 208 215--*--alcohol",
            "Scope 199 215--*--drugs or alcohol",
            "Condition 246 259--*--Schizophrenia",
            "Condition 261 285--*--Schizoaffective Disorder",
            "Condition 287 312--*--Schizophreniform Disorder",
            "Condition 316 334--*--Bipolar I Disorder",
            "Non-query-able 488 671--*--Have an unstable medical disorder as determined by physical examination or laboratory testing. The primary investigator will be responsible for making this judgment based on the above",
            "Non-query-able 674 781--*--Had an unsatisfactory response to a previous adequate trial of quetiapine as judged by a study investigator",
            "Non-representable 894 1023--*--Patients who are currently receiving quetiapine therapy may not undergo a washout period and then restart quetiapine in the study",
            "Procedure 355 421--*--Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)",
            "Scope 246 334--*--Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or Bipolar I Disorder",
            "Non-representable 784 891--*--Patients cannot begin psychotherapy during the study period, but may continue if started prior to the study"
        ],
        "Text": "Are pregnant or lactating. . Have participated in any other studies involving investigational products within 30 days prior to entry into this study. . Are undergoing an acute withdrawal syndrome from drugs or alcohol. . Have an Axis I diagnosis of Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or Bipolar I Disorder as diagnosed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), and pertinent subsequent for ruling out exclusionary diagnoses. . Have an unstable medical disorder as determined by physical examination or laboratory testing. The primary investigator will be responsible for making this judgment based on the above. . Had an unsatisfactory response to a previous adequate trial of quetiapine as judged by a study investigator. . Patients cannot begin psychotherapy during the study period, but may continue if started prior to the study. . Patients who are currently receiving quetiapine therapy may not undergo a washout period and then restart quetiapine in the study.       .     . "
    },
    "NCT02019160_exc": {
        "Annotations": [
            "Condition 17 30--*--uncooperative",
            "Observation 35 54--*--difficult to manage",
            "Subjective_judgement 61 66--*--major",
            "Condition 67 84--*--systemic diseases",
            "Qualifier 61 66--*--major",
            "Temporal 96 105--*--long-term",
            "Drug 106 116--*--medication",
            "Scope 17 54--*--uncooperative and difficult to manage"
        ],
        "Text": "Children who are uncooperative and difficult to manage, have major systemic diseases, or are on long-term medication will be excluded.       .     . "
    },
    "NCT02907554_inc": {
        "Text": "Male and females aged 18 to 70 years. Brain death. Male and females aged 18 to 70 years. Indication of kidney transplantation. Informed consent. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 16--*--females",
            "Person 17 21--*--aged",
            "Value 22 36--*--18 to 70 years",
            "Condition 38 49--*--Brain death",
            "Person 51 55--*--Male",
            "Person 60 67--*--females",
            "Person 68 72--*--aged",
            "Value 73 87--*--18 to 70 years",
            "Procedure 103 125--*--kidney transplantation",
            "Mood 89 99--*--Indication",
            "Informed_consent 127 143--*--Informed consent"
        ]
    },
    "NCT02653131_exc": {
        "Text": "HPN < 12 months. metabolically unstable. cancer as the reason for intestinal failure. ",
        "Annotations": [
            "Measurement 0 3--*--HPN",
            "Value 4 15--*--< 12 months",
            "Condition 17 39--*--metabolically unstable",
            "Condition 41 47--*--cancer",
            "Condition 66 84--*--intestinal failure"
        ]
    },
    "NCT01715584_inc": {
        "Text": "age over 40. composite head and neck tumor resection. treated hypertension. hypertension medications taken on morning of surgery (except diuretics). ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 11--*--over 40",
            "Procedure 13 52--*--composite head and neck tumor resection",
            "Condition 62 74--*--hypertension",
            "Qualifier 54 61--*--treated",
            "Drug 76 100--*--hypertension medications",
            "Temporal 107 128--*--on morning of surgery",
            "Drug 137 146--*--diuretics",
            "Negation 130 136--*--except"
        ]
    },
    "NCT02765035_inc": {
        "Text": "Person is >18 years old.. Person is a unilateral transfemoral or knee-disarticulation amputee with stabilized residual limb.. Person is a K2, K3 or K4 ambulator based on Medicare Functional Classification Level (MFCL).. Person is currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee for at least 6 months.. Person was never fitted with microprocessor controlled prosthetic knee joint.. Person is willing and able to independently provide informed consent.. Person is willing to comply with study procedures.. Person wears prosthesis daily and = 8 hours/day.. Person is walking on average 1km/day.. Person is walking not slower than 3km/h (~0.8m/s) (based on 10m walk test conducted during recruiting).. Person is walking on level ground in a step over step manner.. ",
        "Annotations": [
            "Person 20 23--*--old",
            "Value 10 19--*-->18 years",
            "Non-query-able 26 123--*--Person is a unilateral transfemoral or knee-disarticulation amputee with stabilized residual limb",
            "Measurement 170 210--*--Medicare Functional Classification Level",
            "Measurement 212 216--*--MFCL",
            "Value 138 150--*--K2, K3 or K4",
            "Device 254 264--*--prosthesis",
            "Device 303 318--*--prosthetic knee",
            "Qualifier 273 302--*--non-microprocessor controlled",
            "Temporal 323 340--*--at least 6 months",
            "Negation 354 359--*--never",
            "Device 398 419--*--prosthetic knee joint",
            "Qualifier 372 397--*--microprocessor controlled",
            "Informed_consent 422 490--*--Person is willing and able to independently provide informed consent",
            "Post-eligibility 493 542--*--Person is willing to comply with study procedures",
            "Device 558 568--*--prosthesis",
            "Multiplier 569 592--*--daily and = 8 hours/day",
            "Observation 605 612--*--walking",
            "Multiplier 624 631--*--1km/day",
            "Observation 644 651--*--walking",
            "Multiplier 652 673--*--not slower than 3km/h",
            "Observation 749 756--*--walking",
            "Non-query-able 739 799--*--Person is walking on level ground in a step over step manner"
        ]
    },
    "NCT03397914_exc": {
        "Text": "Age less than one year or over 18 years. Patients with renal impairment. Colistin use less than 72 hours. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--less than one year",
            "Value 26 39--*--over 18 years",
            "Scope 4 39--*--less than one year or over 18 years",
            "Condition 55 71--*--renal impairment",
            "Drug 73 81--*--Colistin",
            "Temporal 86 104--*--less than 72 hours"
        ]
    },
    "NCT00806936_exc": {
        "Text": "Known or suspected allergy to trial product(s) or related products . Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit . Subjects who previously enrolled in this study . Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods . The receipt of any investigational product within 3 months prior to this trial       .     . ",
        "Annotations": [
            "Condition 19 46--*--allergy to trial product(s)",
            "Condition 19 26;50 66--*--allergy related products",
            "Drug 30 46--*--trial product(s)",
            "Drug 50 66--*--related products",
            "Non-query-able 68 200--*--Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit",
            "Post-eligibility 68 200--*--Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit",
            "Context_Error 202 248--*--Subjects who previously enrolled in this study",
            "Post-eligibility 202 248--*--Subjects who previously enrolled in this study",
            "Condition 261 283--*--childbearing potential",
            "Person 250 257--*--Females",
            "Condition 292 300--*--pregnant",
            "Condition 302 316--*--breast-feeding",
            "Condition 337 345--*--pregnant",
            "Mood 320 336--*--intend to become",
            "Procedure 372 393--*--contraceptive methods",
            "Qualifier 363 371--*--adequate",
            "Negation 353 356--*--not",
            "Pregnancy_considerations 250 393--*--Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods",
            "Drug 414 437--*--investigational product",
            "Temporal 438 473--*--within 3 months prior to this trial",
            "Reference_point 463 473--*--this trial"
        ]
    },
    "NCT03350815_inc": {
        "Annotations": [
            "Informed_consent 0 145--*--Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent",
            "Pregnancy_considerations 147 223--*--Male or non-pregnant, non-lactating female patients at least 18 years of age",
            "Qualifier 238 246--*--moderate",
            "Qualifier 250 256--*--severe",
            "Condition 257 284--*--Ankylosing Spondylitis (AS)",
            "Scope 238 256--*--moderate to severe",
            "Condition 307 326--*--radiologic evidence",
            "Procedure 307 317--*--radiologic",
            "Temporal 290 295--*--prior",
            "Measurement 342 375--*--Modified New York criteria for AS",
            "Value 327 337--*--fulfilling",
            "Condition 384 386--*--AS",
            "Qualifier 377 383--*--Active",
            "Measurement 399 464--*--total Bath Ankylosing Spondylitis Disease Activity index (BASDAI)",
            "Value 465 468--*--= 4",
            "Temporal 476 487--*--at baseline",
            "Condition 489 500--*--Spinal pain",
            "Measurement 516 534--*--BASDAI question #2",
            "Value 535 541--*--= 4 cm",
            "Temporal 552 563--*--at baseline",
            "Measurement 596 621--*--visual analog scale (VAS)",
            "Value 622 629--*--= 40 mm",
            "Temporal 641 652--*--at baseline",
            "Condition 565 580--*--Total back pain",
            "Drug 683 729--*--non-steroidal anti-inflammatory drugs (NSAIDs)",
            "Multiplier 737 759--*--maximum tolerated dose",
            "Temporal 760 810--*--for at least 4 weeks prior to their Baseline Visit",
            "Reference_point 790 810--*--their Baseline Visit",
            "Condition 820 839--*--inadequate response",
            "Temporal 843 864--*--for less than 4 weeks",
            "Condition 868 893--*--withdrawn for intolerance",
            "Condition 868 881;895 903--*--withdrawn for toxicity",
            "Condition 907 924--*--contraindications",
            "Scope 868 924--*--withdrawn for intolerance, toxicity or contraindications",
            "Drug 1011 1021;958 982--*--inhibitors Cyclooxygenase-1 (COX-1)",
            "Drug 986 1021--*--Cyclooxygenase-2 (COX-2) inhibitors",
            "Drug 941 947--*--NSAIDs",
            "Temporal 1022 1070--*--for at least 2 weeks before their Baseline Visit",
            "Reference_point 1050 1070--*--their Baseline Visit",
            "Scope 941 1021--*--NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors",
            "Drug 1100 1144--*--tumor necrosis factor alpha (TNFa) inhibitor",
            "Multiplier 1146 1163--*--not more than one",
            "Condition 1190 1209--*--inadequate response",
            "Multiplier 1255 1268--*--approved dose",
            "Temporal 1269 1308--*--for at least 3 months prior to baseline",
            "Procedure 1233 1242--*--treatment",
            "Temporal 1225 1232--*--current",
            "Temporal 1213 1221--*--previous",
            "Scope 1213 1232--*--previous or current",
            "Condition 1321 1331--*--intolerant",
            "Drug 1358 1373--*--anti-TNFa agent",
            "Scope 1100 1164--*--tumor necrosis factor alpha (TNFa) inhibitor (not more than one)",
            "Scope 1190 1373--*--inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent",
            "Condition 1375 1403--*--Total ankylosis of the spine",
            "Competing_trial 1405 1540--*--Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.",
            "Condition 1553 1569--*--hypersensitivity",
            "Drug 1584 1595--*--study drugs",
            "Drug 1603 1613--*--excipients",
            "Drug 1620 1653--*--drugs of similar chemical classes",
            "Scope 1584 1653--*--study drugs or its excipients or to drugs of similar chemical classes",
            "Procedure 1656 1667--*--Chest x-ray",
            "Procedure 1669 1702--*--computerized tomography (CT) scan",
            "Procedure 1707 1745--*--chest magnetic resonance imaging (MRI)",
            "Temporal 1763 1770--*--ongoing",
            "Condition 1771 1781--*--infectious",
            "Condition 1785 1802--*--malignant process",
            "Temporal 1813 1847--*--within 3 months prior to screening",
            "Scope 1771 1802--*--infectious or malignant process",
            "Scope 1656 1745--*--Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI)",
            "Drug 1910 1921--*--secukinumab",
            "Drug 1935 1948--*--biologic drug",
            "Qualifier 1929 1934--*--other",
            "Drug 1968 1990--*--Interleukin-17 (IL-17)",
            "Condition 1958 1967--*--targeting",
            "Drug 1992 2020--*--Interleukin-12/23 (IL-12/23)",
            "Drug 2029 2043--*--IL-17 receptor",
            "Drug 2058 2089--*--biologic immunomodulating agent",
            "Negation 2091 2097--*--except",
            "Drug 2114 2118--*--TNFa",
            "Scope 1968 2089--*--Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent",
            "Scope 1910 1948--*--secukinumab or any other biologic drug",
            "Multiplier 2144 2157--*--more than one",
            "Drug 2158 2173--*--anti-TNFa agent",
            "Procedure 2208 2232--*--corticosteroid injection",
            "Qualifier 2196 2207--*--intravenous",
            "Qualifier 2179 2192--*--intramuscular",
            "Scope 2179 2207--*--intramuscular or intravenous",
            "Temporal 2233 2263--*--within 2 weeks before baseline",
            "Reference_point 2255 2263--*--baseline",
            "Procedure 2280 2306--*--intra-articular injections",
            "Drug 2313 2327--*--corticosteroid",
            "Temporal 2329 2359--*--within 4 weeks before baseline",
            "Procedure 2389 2413--*--cell-depleting therapies",
            "Temporal 2361 2369--*--Previous",
            "Drug 2431 2461--*--high potency opioid analgesics",
            "Drug 2469 2478--*--methadone",
            "Drug 2480 2493--*--hydromorphone",
            "Drug 2495 2503--*--morphine",
            "Scope 2469 2503--*--methadone, hydromorphone, morphine"
        ],
        "Text": "Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent. Male or non-pregnant, non-lactating female patients at least 18 years of age. Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS. Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline. Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline. Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline. Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications. Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit. Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent. Total ankylosis of the spine. Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician.. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa. Patients who have taken more than one anti-TNFa agent. Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline. Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline. Previous treatment with any cell-depleting therapies. Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine). "
    },
    "NCT01715714_inc": {
        "Annotations": [
            "Multiplier 12 19--*--chronic",
            "Drug 20 26--*--statin",
            "Procedure 27 36--*--treatment",
            "Value 38 46--*-->30 days",
            "Procedure 71 75--*--CABG",
            "Qualifier 62 70--*--isolated",
            "Mood 48 57--*--scheduled",
            "Procedure 122 150--*--revascularisation procedures",
            "Qualifier 87 112--*--on- or off-pump or repeat",
            "Qualifier 114 120--*--redo's",
            "Condition 152 158;171 177--*--Stable angina",
            "Condition 162 177--*--unstable angina",
            "Condition 189 237--*--non ST-segment-elevation acute coronary syndrome",
            "Condition 239 247--*--NSTE-ACS",
            "Person 250 253--*--Age",
            "Value 254 264--*--= 18 years",
            "Non-query-able 266 290--*--Written informed consent"
        ],
        "Text": "Patients on chronic statin treatment (>30 days) scheduled for isolated CABG, including on- or off-pump or repeat (redo's) revascularisation procedures. Stable or unstable angina, including non ST-segment-elevation acute coronary syndrome (NSTE-ACS). Age = 18 years. Written informed consent. "
    },
    "NCT02579200_exc": {
        "Annotations": [
            "Condition 0 20--*--Inability to perform",
            "Procedure 21 35--*--exercise tests",
            "Condition 62 81--*--cognitive disorders",
            "Condition 47 58;72 81--*--psychiatric disorders",
            "Condition 125 134;83 107--*--disorders Progressive neurological",
            "Condition 111 134;83 94--*--neuromuscular disorders Progressive",
            "Condition 150 177--*--impact on exercise capacity",
            "Scope 83 134--*--Progressive neurological or neuromuscular disorders"
        ],
        "Text": "Inability to perform exercise tests. Diagnosed psychiatric or cognitive disorders. Progressive neurological or neuromuscular disorders having a major impact on exercise capacity. "
    },
    "NCT02653131_inc": {
        "Text": "patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months. stable metabolic status. benign disease. ",
        "Annotations": [
            "Measurement 19 50--*--home parenteral nutrition (HPN)",
            "Condition 62 82--*--short bowel syndrome",
            "Temporal 83 105--*--for at least 12 months",
            "Scope 19 82--*--home parenteral nutrition (HPN) because of short bowel syndrome",
            "Measurement 114 130--*--metabolic status",
            "Qualifier 107 113--*--stable",
            "Condition 132 146--*--benign disease"
        ]
    },
    "NCT01715584_exc": {
        "Text": "patient refusal. age less than 40 or over 80 years. combined surgical procedures. emergency surgery. Left ventricular ejection fraction less than 50 per cent. calculated creatinine clearance less than 60 mL per minute. ",
        "Annotations": [
            "Observation 0 15--*--patient refusal",
            "Person 17 20--*--age",
            "Value 21 33--*--less than 40",
            "Value 37 50--*--over 80 years",
            "Scope 21 50--*--less than 40 or over 80 years",
            "Procedure 52 80--*--combined surgical procedures",
            "Procedure 82 99--*--emergency surgery",
            "Measurement 101 135--*--Left ventricular ejection fraction",
            "Value 136 157--*--less than 50 per cent",
            "Measurement 159 190--*--calculated creatinine clearance",
            "Value 191 217--*--less than 60 mL per minute"
        ]
    },
    "NCT02019160_inc": {
        "Annotations": [
            "Person 0 15--*--Kindergarteners",
            "Person 96 114--*--Preschool children",
            "Person 115 119--*--aged",
            "Value 120 129--*--3-4 years",
            "Condition 139 150--*--tooth decay"
        ],
        "Text": "Kindergarteners who have joined our outreach dental service will be invited to join this study. Preschool children aged 3-4 years who have tooth decay and are attending the first year of kindergarten will be invited to join this study. . "
    },
    "NCT00122070_inc": {
        "Annotations": [
            "Person 91 94--*--age",
            "Value 83 90;95 110--*--between 18 and 55 years",
            "Condition 243 246--*--BPD",
            "Qualifier 218 238--*--Meet DSM-IV criteria",
            "Observation 115 152--*--able to speak, read and write English",
            "Observation 115 122;157 183--*--able to follow simple instructions",
            "Observation 8 32--*--written informed consent",
            "Temporal 33 78--*--before beginning any study related activities",
            "Reference_point 50 78--*--any study related activities",
            "Procedure 266 338--*--Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II)"
        ],
        "Text": "Provide written informed consent before beginning any study related activities . Be between age 18 and 55 years . Be able to speak, read and write English and follow simple instructions for completing self-rated scales . Meet DSM-IV criteria for BPD as assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). . "
    },
    "NCT02907554_exc": {
        "Text": "Contra-indication for multiorgan procurement (infections, cancer, etc). Preexistent chronic renal failure.. Refusal for organ procurement by the donor (confirmed by the French national register or reported by the next-of-kin).. Need for a double kidney transplantation.. Need for a multiorgan transplantation. ",
        "Annotations": [
            "Condition 0 17--*--Contra-indication",
            "Procedure 22 44--*--multiorgan procurement",
            "Condition 46 56--*--infections",
            "Condition 58 64--*--cancer",
            "Scope 46 64--*--infections, cancer",
            "Scope 0 44--*--Contra-indication for multiorgan procurement",
            "Condition 84 105--*--chronic renal failure",
            "Temporal 72 83--*--Preexistent",
            "Procedure 120 137--*--organ procurement",
            "Observation 108 115;138 150--*--Refusal by the donor",
            "Qualifier 169 193--*--French national register",
            "Qualifier 197 224--*--reported by the next-of-kin",
            "Scope 169 224--*--French national register or reported by the next-of-kin",
            "Mood 228 236--*--Need for",
            "Procedure 239 268--*--double kidney transplantation",
            "Mood 271 279--*--Need for",
            "Procedure 282 308--*--multiorgan transplantation"
        ]
    },
    "NCT03397914_inc": {
        "Text": "Age between one year and 18 years. Sepsis due to MDR or minimally susceptible gram-negative bacteria. History of MDR gram-negative infection or sepsis due to organisms sensitive to colistin.. Culture result consistent with MDR gram negative for this febrile neutropenic episode.. Patient in sepsis and colistin was administered empirically to increase antibiotic coverage.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 33--*--between one year and 18 years",
            "Condition 35 41--*--Sepsis",
            "Qualifier 49 52--*--MDR",
            "Condition 56 100--*--minimally susceptible gram-negative bacteria",
            "Qualifier 113 116--*--MDR",
            "Condition 117 140--*--gram-negative infection",
            "Condition 144 150--*--sepsis",
            "Scope 117 150--*--gram-negative infection or sepsis",
            "Qualifier 168 189--*--sensitive to colistin",
            "Observation 158 167--*--organisms",
            "Qualifier 223 226--*--MDR",
            "Condition 227 240--*--gram negative",
            "Condition 291 297--*--sepsis",
            "Drug 302 310--*--colistin",
            "Procedure 315 339--*--administered empirically"
        ]
    },
    "NCT03350815_exc": {
        "Annotations": [],
        "Text": "NA. "
    },
    "NCT00806936_inc": {
        "Text": "After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject, any type 2 diabetic previously inadequately controlled with two or more OADs is eligible for the study . The selection of the subjects will be at the discretion of the individual investigator . ",
        "Annotations": [
            "Condition 114 129--*--type 2 diabetic",
            "Qualifier 141 164--*--inadequately controlled",
            "Temporal 130 140--*--previously",
            "Multiplier 170 181--*--two or more",
            "Condition 182 186--*--OADs",
            "Non-representable 214 300--*--The selection of the subjects will be at the discretion of the individual investigator",
            "Non-representable 0 108--*--After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject"
        ]
    },
    "NCT02765035_exc": {
        "Text": "Person is under 18 years of age.. Person who weighs more than 136kg.. Person who weighs less than 50kg.. Person who is pregnant.. Person has a history of chronic skin breakdown on the residual limb.. Person has conditions that would prevent participation and pose increased risk (e.g. unstable cardiovascular conditions that preclude physical activity such as walking).. Person falls = once a week due to the reasons that could not be corrected by the new prosthesis (for ex. problems with vestibular system).. Person is using under arm axillary crutches or walker.. Person in an emergency, life threatening situation.. Person is unwilling/unable to follow instructions.. Person who is not available to follow the entire study protocol.. Person who is participating in another study or intends to participate in another study during this study duration.. Person who cannot personally provide their consent.. Person who is not wearing prosthesis 8hours/day on average.. Person who has a score on 10m walk test less than 3km/h (~0.8m/s) (based on 10m walk test conducted during recruiting).. Person who walks on average less than 1km per day.. Person who is not able to walk on level ground in a step over step manner.. ",
        "Annotations": [
            "Person 28 31--*--age",
            "Value 10 24--*--under 18 years",
            "Person 45 51--*--weighs",
            "Value 52 67--*--more than 136kg",
            "Person 81 87--*--weighs",
            "Value 88 102--*--less than 50kg",
            "Condition 119 127--*--pregnant",
            "Condition 162 176--*--skin breakdown",
            "Qualifier 154 161--*--chronic",
            "Qualifier 184 197--*--residual limb",
            "Non-query-able 200 369--*--Person has conditions that would prevent participation and pose increased risk (e.g. unstable cardiovascular conditions that preclude physical activity such as walking).",
            "Observation 378 383--*--falls",
            "Multiplier 386 397--*--once a week",
            "Non-query-able 371 508--*--Person falls = once a week due to the reasons that could not be corrected by the new prosthesis (for ex. problems with vestibular system)",
            "Device 527 554--*--under arm axillary crutches",
            "Device 558 564--*--walker",
            "Observation 591 617--*--life threatening situation",
            "Observation 580 589;608 617--*--emergency situation",
            "Post-eligibility 620 668--*--Person is unwilling/unable to follow instruction",
            "Post-eligibility 672 735--*--Person who is not available to follow the entire study protocol",
            "Competing_trial 738 853--*--Person who is participating in another study or intends to participate in another study during this study duration.",
            "Informed_consent 855 905--*--Person who cannot personally provide their consent",
            "Negation 922 925--*--not",
            "Device 934 944--*--prosthesis",
            "Multiplier 945 955--*--8hours/day",
            "Measurement 995 1008--*--10m walk test",
            "Value 1009 1024--*--less than 3km/h",
            "Value 1027 1034--*--0.8m/s)",
            "Observation 1101 1106--*--walks",
            "Multiplier 1119 1139--*--ess than 1km per day",
            "Non-query-able 1142 1215--*--Person who is not able to walk on level ground in a step over step manner"
        ]
    },
    "NCT02579200_inc": {
        "Annotations": [
            "Condition 22 26--*--COPD",
            "Condition 31 33--*--HF",
            "Procedure 50 68--*--clinical treatment",
            "Qualifier 40 49--*--optimized",
            "Scope 22 33--*--COPD and HF",
            "Value 110 117--*--Reduced",
            "Measurement 118 152--*--left ventricular ejection fraction",
            "Value 154 158--*--<50%",
            "Condition 176 194--*--airway obstruction",
            "Qualifier 161 175--*--Non-reversible",
            "Measurement 216 224--*--FEV1/FVC",
            "Qualifier 196 215--*--post-bronchodilator",
            "Value 225 230--*--< 0.7",
            "Measurement 235 239--*--FEV1",
            "Value 240 246--*--< 80 %",
            "Scope 196 246--*--post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %",
            "Scope 161 194--*--Non-reversible airway obstruction",
            "Condition 249 276--*--Respiratory muscle weakness",
            "Measurement 278 284--*--Pi,max",
            "Value 285 294--*--< 70cmH2O",
            "Condition 308 329--*--dyspnea on daily life",
            "Temporal 297 307--*--Persistent",
            "Temporal 331 339--*--Baseline",
            "Measurement 340 365--*--Dyspnea Index focal score",
            "Value 366 372--*--<or= 8",
            "Scope 331 372--*--Baseline Dyspnea Index focal score <or= 8",
            "Scope 297 329--*--Persistent dyspnea on daily life"
        ],
        "Text": "Previous diagnoses of COPD and HF under optimized clinical treatment as judged by the accompanying physician. Reduced left ventricular ejection fraction (<50%). Non-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %). Respiratory muscle weakness (Pi,max < 70cmH2O). Persistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).. "
    },
    "NCT01715714_exc": {
        "Annotations": [
            "Procedure 16 40--*--cardiovascular procedure",
            "Procedure 44 48--*--CABG",
            "Temporal 4 15--*--concomitant",
            "Procedure 72 87--*--carotid surgery",
            "Procedure 62 68;80 87--*--aortic surgery",
            "Procedure 55 60;80 87--*--valve surgery",
            "Scope 55 87--*--valve, aortic or carotid surgery",
            "Condition 90 138--*--Acute ST-segment-elevation myocardial infarction",
            "Condition 140 145--*--STEMI",
            "Condition 148 156--*--NSTE-ACS",
            "Condition 162 179--*--cardiogenic shock",
            "Procedure 200 215--*--salvage surgery",
            "Mood 180 190--*--warranting",
            "Temporal 216 253--*--within 12 hrs from hospital admission",
            "Reference_point 235 253--*--hospital admission",
            "Scope 148 179--*--NSTE-ACS with cardiogenic shock",
            "Condition 266 285--*--atrial fibrillation",
            "Condition 289 303--*--muscle disease",
            "Condition 305 313--*--myopathy",
            "Measurement 331 341--*--creatinine",
            "Value 341 372--*-->2x upper limit of normal (ULN)",
            "Procedure 374 382--*--dialysis",
            "Procedure 384 401--*--kidney transplant",
            "Scope 331 401--*--creatinine>2x upper limit of normal (ULN), dialysis, kidney transplant",
            "Condition 324 329;414 425--*--renal dysfunction",
            "Condition 406 425--*--hepatic dysfunction",
            "Measurement 427 430--*--AST",
            "Measurement 431 434--*--ALT",
            "Value 434 441--*-->2x ULN",
            "Procedure 443 459--*--liver transplant",
            "Condition 463 471--*--neoplasm",
            "Scope 427 441--*--AST/ALT>2x ULN",
            "Scope 427 471--*--AST/ALT>2x ULN, liver transplant or neoplasm",
            "Mood 474 486--*--Inability of",
            "Drug 487 496--*--oral drug",
            "Observation 487 503--*--oral drug intake",
            "Negation 474 483--*--Inability"
        ],
        "Text": "Any concomitant cardiovascular procedure to CABG (i.e. valve, aortic or carotid surgery). Acute ST-segment-elevation myocardial infarction (STEMI). NSTE-ACS with cardiogenic shock warranting emergent salvage surgery within 12 hrs from hospital admission. History of atrial fibrillation or muscle disease (myopathy). Current renal (creatinine>2x upper limit of normal (ULN), dialysis, kidney transplant) or hepatic dysfunction (AST/ALT>2x ULN, liver transplant or neoplasm). Inability of oral drug intake. "
    },
    "NCT03173092_exc": {
        "Annotations": [
            "Negation 0 7--*--Failure",
            "Condition 16 31--*--fully recovered",
            "Value 42 76--*--less than or equal to [<=] Grade 1",
            "Measurement 77 85--*--toxicity",
            "Procedure 124 136--*--chemotherapy",
            "Scope 0 31--*--Failure to have fully recovered",
            "Scope 42 85--*--less than or equal to [<=] Grade 1 toxicity",
            "Procedure 139 152--*--Major surgery",
            "Temporal 153 185--*--within 14 days before enrollment",
            "Procedure 188 200--*--Radiotherapy",
            "Temporal 201 233--*--within 14 days before enrollment",
            "Observation 242 265--*--involved field is small",
            "Temporal 267 273--*--7 days",
            "Scope 201 233;242 273--*--within 14 days before enrollment involved field is small, 7 days",
            "Condition 371 405--*--Central nervous system involvement",
            "Condition 408 417--*--Infection",
            "Procedure 428 455--*--systemic antibiotic therapy",
            "Qualifier 459 464--*--other",
            "Qualifier 465 472--*--serious",
            "Condition 473 482--*--infection",
            "Temporal 483 521--*--within 14 days before study enrollment",
            "Condition 557 582--*--cardiovascular conditions",
            "Qualifier 594 606--*--uncontrolled",
            "Condition 607 619--*--hypertension",
            "Qualifier 621 633--*--uncontrolled",
            "Condition 634 653--*--cardiac arrhythmias",
            "Qualifier 655 666--*--symptomatic",
            "Condition 667 691--*--congestive heart failure",
            "Condition 693 708--*--unstable angina",
            "Condition 713 734--*--myocardial infarction",
            "Temporal 735 759--*--within the past 6 months",
            "Qualifier 544 556--*--uncontrolled",
            "Temporal 536 543--*--current",
            "Scope 594 759--*--uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months",
            "Scope 536 582--*--current uncontrolled cardiovascular conditions",
            "Procedure 762 780--*--Systemic treatment",
            "Temporal 782 830--*--within 14 days before the first dose of ixazomib",
            "Reference_point 804 830--*--the first dose of ixazomib",
            "Drug 822 830--*--ixazomib",
            "Drug 837 879--*--strong cytochrome P450 3A (CYP3A) inducers",
            "Drug 881 889--*--rifampin",
            "Drug 891 902--*--rifapentine",
            "Drug 904 913--*--rifabutin",
            "Drug 915 928--*--carbamazepine",
            "Drug 930 939--*--phenytoin",
            "Drug 941 954--*--phenobarbital",
            "Scope 881 954--*--rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital",
            "Drug 967 980--*--Ginkgo biloba",
            "Drug 984 999--*--St. John's wort",
            "Scope 837 999--*--strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort",
            "Qualifier 1013 1019--*--active",
            "Temporal 1002 1009--*--Ongoing",
            "Condition 1020 1038--*--systemic infection",
            "Qualifier 1040 1046--*--active",
            "Condition 1047 1058;1064 1079--*--hepatitis B virus infection",
            "Condition 1062 1079--*--C virus infection",
            "Scope 1047 1079--*--hepatitis B or C virus infection",
            "Scope 1002 1019--*--Ongoing or active",
            "Measurement 1090 1118--*--human immunodeficiency virus",
            "Value 1119 1127--*--positive",
            "Condition 1163 1173--*--malignancy",
            "Temporal 1174 1212--*--within 2 years before study enrollment",
            "Temporal 1216 1226--*--previously",
            "Qualifier 1242 1249--*--another",
            "Condition 1250 1260--*--malignancy",
            "Condition 1286 1302--*--residual disease",
            "Mood 1270 1285--*--any evidence of",
            "Condition 1322 1346--*--non-melanoma skin cancer",
            "Condition 1350 1367--*--carcinoma in situ",
            "Qualifier 1371 1379--*--any type",
            "Negation 1384 1396--*--not excluded",
            "Procedure 1420 1438--*--complete resection",
            "Scope 1322 1379--*--non-melanoma skin cancer or carcinoma in situ of any type",
            "Qualifier 1445 1482--*--greater than or equal to (>=) Grade 2",
            "Condition 1483 1504--*--peripheral neuropathy",
            "Qualifier 1509 1516--*--Grade 1",
            "Condition 1522 1526--*--pain",
            "Scope 1509 1526--*--Grade 1 with pain",
            "Scope 1445 1504--*--greater than or equal to (>=) Grade 2 peripheral neuropathy",
            "Drug 1581 1583--*--PD",
            "Qualifier 1587 1605--*--first-line therapy",
            "Competing_trial 1608 1661--*--Participation in other interventional clinical trials",
            "Temporal 1741 1782--*--within 30 days of the start of this trial",
            "Temporal 1787 1824--*--throughout the duration of this trial",
            "Reference_point 1759 1782--*--the start of this trial",
            "Reference_point 1798 1824--*--the duration of this trial",
            "Scope 1741 1824--*--within 30 days of the start of this trial and throughout the duration of this trial"
        ],
        "Text": "Failure to have fully recovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.. Major surgery within 14 days before enrollment.. Radiotherapy within 14 days before enrollment (if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib.). Central nervous system involvement.. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.. Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.. Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.. PD on first-line therapy.. Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.. "
    },
    "NCT03424993_inc": {
        "Text": "Habitual dietary sodium intake > 3400mg per day. ",
        "Annotations": [
            "Measurement 9 30--*--dietary sodium intake",
            "Value 31 47--*--> 3400mg per day"
        ]
    },
    "NCT02303171_exc": {
        "Text": "Women with systemic lupus erythematosus (SLE). Women with active thromboembolic disorders. Women with history of previous thromboembolic disorders. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 11 45--*--systemic lupus erythematosus (SLE)",
            "Person 47 52--*--Women",
            "Person 91 96--*--Women",
            "Qualifier 58 64--*--active",
            "Condition 65 89--*--thromboembolic disorders",
            "Observation 102 109--*--history",
            "Temporal 113 121--*--previous",
            "Condition 122 146--*--thromboembolic disorders"
        ]
    },
    "NCT03122119_exc": {
        "Annotations": [
            "Person 19 22--*--age",
            "Value 26 28;9 14--*--18 under",
            "Non-representable 29 189--*--(Subjects under the age of 18 will not be included in this study due to the continued growth and development of their joints and unstudied effects on children.)",
            "Value 191 195;207 209--*--Over 80",
            "Person 200 203--*--age",
            "Condition 211 232--*--Multiple pain sources",
            "Condition 237 264--*--multifactorial pain sources",
            "Non-representable 265 400--*--that complicated or confound diagnosing the SI joint as the primary and predominant pain generator that may contribute to low back pain",
            "Condition 432 448--*--lumbar diagnosis",
            "Condition 450 470--*--lumbar radiculopathy",
            "Condition 481 510--*--extra-articular hip pathology",
            "Condition 472 477;486 510--*--intra -articular hip pathology",
            "Condition 522 532;570 579--*--acetabulum pathology",
            "Condition 537 549;570 579--*--femoral head pathology",
            "Condition 551 579--*--lumbo-sacral joint pathology",
            "Condition 581 608--*--intervertebral disk disease",
            "Condition 610 627--*--spondylolisthesis",
            "Condition 628 639--*--spondylosis",
            "Condition 640 672--*--spondylolysis of lumbar vertebra",
            "Scope 472 510--*--intra or extra-articular hip pathology",
            "Scope 522 672--*--acetabulum and femoral head, lumbo-sacral joint pathology, intervertebral disk disease, spondylolisthesis/spondylosis/spondylolysis of lumbar vertebra",
            "Scope 211 264--*--Multiple pain sources and multifactorial pain sources",
            "Scope 432 672--*--lumbar diagnosis, lumbar radiculopathy, intra or extra-articular hip pathology to include acetabulum and femoral head, lumbo-sacral joint pathology, intervertebral disk disease, spondylolisthesis/spondylosis/spondylolysis of lumbar vertebra",
            "Condition 675 691--*--Immunosuppressed",
            "Condition 692 710--*--immune compromised",
            "Condition 712 736--*--Underlying comorbidities",
            "Qualifier 742 770--*--contraindicate the procedure",
            "Condition 742 756--*--contraindicate",
            "Procedure 761 770--*--procedure",
            "Condition 801 813--*--polycythemia",
            "Condition 815 835--*--coagulation disorder",
            "Condition 840 850--*--malignancy",
            "Scope 801 850--*--polycythemia, coagulation disorder, or malignancy",
            "Scope 712 770--*--Underlying comorbidities that contraindicate the procedure"
        ],
        "Text": "Patients under the age of 18 (Subjects under the age of 18 will not be included in this study due to the continued growth and development of their joints and unstudied effects on children.). Over the age of 80. Multiple pain sources and multifactorial pain sources that complicated or confound diagnosing the SI joint as the primary and predominant pain generator that may contribute to low back pain (including but not limited to: lumbar diagnosis, lumbar radiculopathy, intra or extra-articular hip pathology to include acetabulum and femoral head, lumbo-sacral joint pathology, intervertebral disk disease, spondylolisthesis/spondylosis/spondylolysis of lumbar vertebra). Immunosuppressed/immune compromised. Underlying comorbidities that contraindicate the procedure (including but not limited to polycythemia, coagulation disorder, or malignancy).. "
    },
    "NCT01799681_exc": {
        "Annotations": [
            "Condition 4 27--*--neurological conditions",
            "Condition 39 41--*--PD",
            "Negation 28 38--*--other than",
            "Condition 75 99--*--cardiopulmonary diseases",
            "Condition 56 71;91 99--*--musculoskeletal diseases",
            "Qualifier 44 55--*--significant",
            "Subjective_judgement 44 55--*--significant",
            "Undefined_semantics 44 55--*--significant",
            "Scope 56 99--*--musculoskeletal or cardiopulmonary diseases",
            "Condition 108 155--*--disorders that may affect balance or locomotion",
            "Undefined_semantics 108 155--*--disorders that may affect balance or locomotion",
            "Procedure 168 178;193 210--*--structured exercise programs",
            "Procedure 168 189;202 210--*--structured behavioral programs",
            "Temporal 211 231--*--in the past 3 months",
            "Scope 168 210--*--structured behavioral or exercise programs",
            "Procedure 255 286--*--regular physical rehabilitation",
            "Temporal 287 297--*--at present",
            "Condition 300 318--*--unstable condition",
            "Drug 322 351--*--anti-parkinsonian medications",
            "Undefined_semantics 300 351--*--unstable condition on anti-parkinsonian medications",
            "Procedure 354 383--*--surgical interventions for PD",
            "Condition 381 383--*--PD",
            "Condition 403 421--*--cognitive deficits",
            "Measurement 427 464--*--mini-mental state examination, (MMSE)",
            "Value 465 471--*--<24/30",
            "Condition 386 399;413 421--*--communication deficits",
            "Scope 386 421--*--communication or cognitive deficits",
            "Multiplier 511 524--*--more than two",
            "Condition 525 530--*--falls",
            "Temporal 531 556--*--in the previous 12 months",
            "Observation 500 507--*--history"
        ],
        "Text": "any neurological conditions other than PD; . significant musculoskeletal or cardiopulmonary diseases; . other disorders that may affect balance or locomotion; . taken any structured behavioral or exercise programs in the past 3 months . or they are receiving regular physical rehabilitation at present; . unstable condition on anti-parkinsonian medications; . surgical interventions for PD; . communication or cognitive deficits with mini-mental state examination, (MMSE) <24/30 (Folstein et al., 1975); . a history of more than two falls in the previous 12 months.       .     . "
    },
    "NCT01424020_inc": {
        "Annotations": [
            "Observation 0 22--*--French Native language",
            "Value 24 32;37 45--*--18 years or older",
            "Person 33 36--*--old",
            "Informed_consent 47 61--*--Signed consent",
            "Observation 63 103--*--Covered by the French social care system"
        ],
        "Text": "French Native language. 18 years old or older. Signed consent. Covered by the French social care system. "
    },
    "NCT02226887_inc": {
        "Text": "Patients undergoing a loop ileostomy closure. ",
        "Annotations": [
            "Procedure 22 44--*--loop ileostomy closure"
        ]
    },
    "NCT02838810_inc": {
        "Text": "CHB patients who had received single NAs for more than 12 months.. Hepatitis B e antigen (HBeAg)-negative.. Hepatitis B surface antigen (HBsAg) positive and <1000 IU/mL.. Hepatitis B virus DNA <100 IU/mL.. ",
        "Annotations": [
            "Drug 37 40--*--NAs",
            "Qualifier 30 36--*--single",
            "Condition 0 3--*--CHB",
            "Temporal 45 64--*--more than 12 months",
            "Measurement 67 88--*--Hepatitis B e antigen",
            "Measurement 90 95--*--HBeAg",
            "Value 97 105--*--negative",
            "Measurement 108 135--*--Hepatitis B surface antigen",
            "Measurement 137 142--*--HBsAg",
            "Value 144 152--*--positive",
            "Value 157 168--*--<1000 IU/mL",
            "Measurement 171 192--*--Hepatitis B virus DNA",
            "Value 193 203--*--<100 IU/mL"
        ]
    },
    "NCT02893293_exc": {
        "Annotations": [
            "Condition 0 17--*--Contraindications",
            "Procedure 22 48--*--magnetic resonance imaging",
            "Condition 50 63--*--Hemosiderosis",
            "Condition 64 79--*--hemochromatosis"
        ],
        "Text": "Contraindications for magnetic resonance imaging. Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol arm). "
    },
    "NCT03008005_inc": {
        "Text": "Able to give informed consent. Right-handed. Age between 18-50 years old,. Physically and neurologically healthy [confirmed by a comprehensive medical history]. Current PTSD diagnosis. ",
        "Annotations": [
            "Post-eligibility 0 29--*--Able to give informed consent",
            "Condition 31 43--*--Right-handed",
            "Person 45 48--*--Age",
            "Value 49 72--*--between 18-50 years old",
            "Condition 90 112--*--neurologically healthy",
            "Condition 105 112;75 85--*--healthy Physically",
            "Procedure 129 158--*--comprehensive medical history",
            "Condition 169 173--*--PTSD",
            "Temporal 161 168--*--Current"
        ]
    },
    "NCT00183885_inc": {
        "Annotations": [
            "Qualifier 0 12--*--Unresectable",
            "Condition 39 63--*--hepatocellular carcinoma",
            "Measurement 14 28--*--histologically",
            "Value 29 38--*--confirmed",
            "Qualifier 77 101--*--disease limited to liver",
            "Procedure 291 297--*--biopsy",
            "Measurement 315 332--*--alpha-fetoprotein",
            "Value 336 358--*--greater than 500 ng/mL",
            "Qualifier 589 607--*--measurable disease",
            "Procedure 618 635--*--radiation therapy",
            "Qualifier 654 672--*--measurable disease",
            "Qualifier 681 708--*--outside the radiation field",
            "Measurement 732 757--*--Zubrod performance status",
            "Value 761 764--*--0-2",
            "Measurement 788 813--*--predicted life expectancy",
            "Value 817 834--*--at least 12 weeks",
            "Measurement 872 889--*--granulocyte count",
            "Temporal 858 871--*--pre-treatment",
            "Measurement 897 926--*--segmented neutrophils + bands",
            "Value 931 965--*--greater than or equal to 1,500/mm3",
            "Measurement 969 985--*--hemoglobin level",
            "Value 989 1021--*--greater than or equal to 9 gm/dl",
            "Measurement 1027 1041--*--platelet count",
            "Value 1042 1077--*--greater than or equal to 50,000/mm3",
            "Scope 872 1077--*--granulocyte count (i.e., segmented neutrophils + bands) of greater than or equal to 1,500/mm3, a hemoglobin level of greater than or equal to 9 gm/dl, and platelet count greater than or equal to 50,000/mm3",
            "Measurement 1258 1272--*--renal function",
            "Value 1249 1257--*--adequate",
            "Measurement 1292 1323--*--calculated creatinine clearance",
            "Value 1324 1328--*--\u2265 60",
            "Measurement 1359 1375--*--hepatic function",
            "Value 1350 1358--*--adequate",
            "Measurement 1395 1410--*--serum bilirubin",
            "Value 1411 1475--*--less than or equal to 2x the institutional upper limit of normal",
            "Condition 1573 1580--*--ascites",
            "Negation 1560 1572--*--may not have",
            "Condition 1588 1595--*--ascites",
            "Qualifier 1604 1627--*--responsive to diuretics",
            "Procedure 489 507--*--blood sample drawn",
            "Qualifier 483 488--*--20 cc",
            "Informed_consent 467 475--*--agree to",
            "Procedure 523 535--*--routine labs",
            "Multiplier 536 567--*--with each cycle of chemotherapy",
            "Scope 483 535--*--20 cc blood sample drawn in addition to routine labs"
        ],
        "Text": "Unresectable, histologically confirmed hepatocellular carcinoma with evident disease limited to liver. . Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed. The requirement for biopsy may be waived if alpha-fetoprotein is greater than 500 ng/mL and in the investigators opinion not explained by a concurrent hepatic inflammatory process. . Patients must agree to have a 20 cc blood sample drawn in addition to routine labs with each cycle of chemotherapy. . Patients must have measurable disease. If prior radiation therapy was administered, measurable disease must be outside the radiation field. . Patients must have a Zubrod performance status of 0-2. . Patients must have a predicted life expectancy of at least 12 weeks. . Patients must have a pre-treatment granulocyte count (i.e., segmented neutrophils + bands) of greater than or equal to 1,500/mm3, a hemoglobin level of greater than or equal to 9 gm/dl, and platelet count greater than or equal to 50,000/mm3. The granulocyte requirement may be waived if in the investigator's opinion the lower count reflects hypersplenism with adequate bone marrow reserves. . Patients must have adequate renal function as documented by a calculated creatinine clearance \u2265 60. . Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2x the institutional upper limit of normal, regardless of whether patients have liver involvement secondary to tumor. Patients may not have ascites or the ascites must be responsive to diuretics. . "
    },
    "NCT02884401_inc": {
        "Text": "Participants must present a diagnosis of osteoporosis based on DXA measurement of the bone mineral density at the femur neck and/or total hip and/or lumbar spine (T value 2.5 SD or more below the young female adult mean) within the past 24 months.. Not in treatment with anti-resorptive agents (like bisphosphonates and denosumab) for more than 4 consecutive years, in order to reduce the risk of medication-related osteonecrosis of the jaws (Lo et al., 2010).. = 50 years old.. In self-reported menopause, defined as the permanent cessation of ovulation, for at least one year (Soules et al., 2001).. Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g. gap in the area of a second premolar and first molar, with first premolar in place).. Residual alveolar width = 4 mm (Milinkovic and Cordaro, 2014), residual alveolar height >8 mm, enough inter-arch space for a crown (at least 5 mm) and a minimum distance of 7 mm from the adjacent teeth (Shah and Lum, 2008). The width and height will be confirmed after x-ray examination in Visit 2.. Possibility to restore a functional occlusion with a minimum of four occlusal units (i.e. pairs of occluding posterior teeth).. Willingness to replace the missing tooth/teeth with dental implants. Registration with a GDP. ",
        "Annotations": [
            "Condition 41 53--*--osteoporosis",
            "Procedure 63 66--*--DXA",
            "Measurement 86 106--*--bone mineral density",
            "Qualifier 114 124--*--femur neck",
            "Qualifier 132 141--*--total hip",
            "Qualifier 149 161--*--lumbar spine",
            "Scope 114 161--*--femur neck and/or total hip and/or lumbar spine",
            "Temporal 232 246--*--past 24 months",
            "Measurement 163 170--*--T value",
            "Value 171 219--*--2.5 SD or more below the young female adult mean",
            "Negation 249 252--*--Not",
            "Drug 271 293--*--anti-resorptive agents",
            "Drug 300 315--*--bisphosphonates",
            "Drug 320 329--*--denosumab",
            "Scope 300 329--*--bisphosphonates and denosumab",
            "Temporal 335 365--*--more than 4 consecutive years,",
            "Person 473 476--*--old",
            "Value 462 472--*--= 50 years",
            "Condition 496 505--*--menopause",
            "Condition 532 554--*--cessation of ovulation",
            "Qualifier 522 531--*--permanent",
            "Temporal 560 577--*--at least one year",
            "Non-query-able 602 833--*--Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g. gap in the area of a second premolar and first molar, with first premolar in place)",
            "Measurement 836 859--*--Residual alveolar width",
            "Value 860 866--*--= 4 mm",
            "Measurement 899 923--*--residual alveolar height",
            "Value 924 929--*-->8 mm",
            "Non-query-able 931 1133--*--enough inter-arch space for a crown (at least 5 mm) and a minimum distance of 7 mm from the adjacent teeth (Shah and Lum, 2008). The width and height will be confirmed after x-ray examination in Visit 2",
            "Post-eligibility 1136 1261--*--Possibility to restore a functional occlusion with a minimum of four occlusal units (i.e. pairs of occluding posterior teeth)",
            "Post-eligibility 1264 1331--*--Willingness to replace the missing tooth/teeth with dental implants",
            "Non-query-able 1333 1356--*--Registration with a GDP"
        ]
    },
    "NCT02579733_exc": {
        "Annotations": [
            "Drug 14 26--*--azathioprine",
            "Drug 30 39--*--biologics",
            "Procedure 40 47--*--therapy",
            "Scope 14 39--*--azathioprine or biologics"
        ],
        "Text": "Patients with azathioprine or biologics therapy. "
    },
    "NCT02303171_inc": {
        "Text": "Pregnant women with APS diagnosed according to the revised classification criteria for APS in 2006 in Sydney, Australia. Early pregnancy body weight is 50-90 Kg. ",
        "Annotations": [
            "Condition 0 8--*--Pregnant",
            "Person 9 14--*--women",
            "Condition 20 23--*--APS",
            "Qualifier 51 119--*--revised classification criteria for APS in 2006 in Sydney, Australia",
            "Temporal 121 136--*--Early pregnancy",
            "Measurement 137 148--*--body weight",
            "Value 152 160--*--50-90 Kg"
        ]
    },
    "NCT03173092_inc": {
        "Annotations": [
            "Multiplier 33 41--*--3 cycles",
            "Drug 47 57--*--bortezomib",
            "Procedure 64 81--*--induction regimen",
            "Qualifier 105 120--*--NCCN guidelines",
            "Value 131 165--*--no evidence of disease progression",
            "Measurement 180 193--*--IMWG criteria",
            "Measurement 295 325--*--criteria for a diagnosis of MM",
            "Value 287 290--*--all",
            "Condition 214 252--*--light chain and free light chain (FLC)",
            "Mood 379 390--*--eligible to",
            "Procedure 405 416--*--IRD regimen",
            "Measurement 419 479--*--Eastern Cooperative Oncology Group (ECOG) performance status",
            "Value 512 522--*--0, 1, or 2",
            "Temporal 523 544--*--at time of enrollment"
        ],
        "Text": "Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.. Participants with light chain and free light chain (FLC) only may be enrolled if they meet all the criteria for a diagnosis of MM.. Participants must be considered by their physician eligible to receiving the IRD regimen.. Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.. "
    },
    "NCT03424993_exc": {
        "Text": "Abnormal resting ECG. Current abnormal blood panel (assessed by comprehensive metabolic panel, lipid panel and complete blood count).. Hypertension (currently taking anti-hypertensive medications or resting blood pressure >140/90 mmHg). Medical history of cardiovascular disease, malignant cancer, diabetes or kidney disease. Obesity (Body Mass Index > 30). Current pregnancy. Unable to provide consent. ",
        "Annotations": [
            "Value 0 8--*--Abnormal",
            "Procedure 9 20--*--resting ECG",
            "Temporal 22 29--*--Current",
            "Value 30 38--*--abnormal",
            "Procedure 39 50--*--blood panel",
            "Procedure 78 93--*--metabolic panel",
            "Procedure 95 106--*--lipid panel",
            "Procedure 111 131--*--complete blood count",
            "Scope 78 131--*--metabolic panel, lipid panel and complete blood count",
            "Condition 135 147--*--Hypertension",
            "Drug 166 195--*--anti-hypertensive medications",
            "Measurement 199 221--*--resting blood pressure",
            "Value 222 234--*-->140/90 mmHg",
            "Scope 166 234--*--anti-hypertensive medications or resting blood pressure >140/90 mmHg",
            "Condition 256 278--*--cardiovascular disease",
            "Condition 280 296--*--malignant cancer",
            "Condition 298 306--*--diabetes",
            "Condition 310 324--*--kidney disease",
            "Condition 326 333--*--Obesity",
            "Measurement 335 350--*--Body Mass Index",
            "Value 351 355--*--> 30",
            "Condition 366 375--*--pregnancy",
            "Temporal 358 365--*--Current",
            "Scope 335 355--*--Body Mass Index > 30",
            "Informed_consent 377 402--*--Unable to provide consent"
        ]
    },
    "NCT03122119_inc": {
        "Annotations": [
            "Condition 13 25--*--sacroiliitis",
            "Person 27 30--*--Age",
            "Value 31 45--*--18 to 80 years",
            "Condition 51 72--*--Chronic low back pain",
            "Condition 74 92--*--SI joint pathology",
            "Non-representable 93 126--*--is the predominant source of pain",
            "Value 128 136--*--Positive",
            "Measurement 137 161--*--Fortin Finger Test (PMT)",
            "Non-representable 163 214--*--Joint anatomy is identifiable using ultrasonography",
            "Negation 228 230--*--no",
            "Qualifier 231 236--*--other",
            "Condition 237 284--*--comorbidities that contraindicate the procedure",
            "Procedure 308 324--*--physical therapy",
            "Procedure 329 354--*--corticosteroid injections",
            "Drug 361 376--*--ocal anesthetic",
            "Non-representable 377 470--*---Previous injections of lidocaine and corticosteroid provided at least minor immediate relief",
            "Negation 485 488--*--not",
            "Procedure 500 524--*--corticosteroid injection",
            "Qualifier 532 540--*--SI joint",
            "Temporal 541 569--*--within the last three months",
            "Observation 584 608--*--consent to the procedure"
        ],
        "Text": "Diagnosis of sacroiliitis. Age 18 to 80 years old. Chronic low back pain. SI joint pathology is the predominant source of pain. Positive Fortin Finger Test (PMT). Joint anatomy is identifiable using ultrasonography. Patient has no other comorbidities that contraindicate the procedure. Patient has attempted physical therapy and corticosteroid injections with local anesthetic -Previous injections of lidocaine and corticosteroid provided at least minor immediate relief. Patient must not have had a corticosteroid injection in the SI joint within the last three months. Patient must consent to the procedure. "
    },
    "NCT02226887_exc": {
        "Text": "Patients under 18. Pregnancy and Lactation. Patients allergic to polyglycolic / trimethylene carbonate. Carrier of prosthetic mesh in the ostomy. Patients presenting midline hernia.. Patients affected by inflammatory bowel disease. ",
        "Annotations": [
            "Person 9 17--*--under 18",
            "Value 9 17--*--under 18",
            "Condition 19 28--*--Pregnancy",
            "Condition 33 42--*--Lactation",
            "Condition 53 61--*--allergic",
            "Drug 65 77;93 102--*--polyglycolic carbonate",
            "Drug 80 102--*--trimethylene carbonate",
            "Scope 65 102--*--polyglycolic / trimethylene carbonate",
            "Device 115 130--*--prosthetic mesh",
            "Procedure 138 144--*--ostomy",
            "Condition 166 180--*--midline hernia",
            "Condition 204 230--*--inflammatory bowel disease"
        ]
    },
    "NCT03008005_exc": {
        "Text": "clinically significant medical or neurologic condition or neurocognitive dysfunction that would affect function and/or task performance and/or interfere with the study protocol. any current (or within past 2 months) medical condition requiring medication that would interact with dronabinol or interfere with the study protocol. risk of harm to self or others that requires immediate intervention. presence of contraindications, current or past allergic or adverse reaction, or known sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide). lack of fluency in English. positive drug screen or alcohol breathalyzer. unwilling/unable to sign informed consent document. currently pregnant (positive pregnancy test), planning pregnancy, or lactating (women). under 18 or over 50 years of age. traumatic brain injury (as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient). inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and/or a preliminary session in a mock scanner. left-handed;. presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles). anticipation of a required drug test in the 4 weeks following the study.. current diagnosis of a mood, anxiety, or other disorder that is more clinically salient than PTSD. current moderate or severe alcohol/drug use disorder or in the past 8 weeks. current or past diagnosis of bipolar and other related disorders, schizophrenia spectrum, or other psychotic disorders. concomitant treatments with medication known to have drug interactions with dronabinol, such as, central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc).. ",
        "Annotations": [
            "Qualifier 0 22--*--clinically significant",
            "Condition 34 54--*--neurologic condition",
            "Condition 23 30;45 54--*--medical condition",
            "Condition 58 84--*--neurocognitive dysfunction",
            "Scope 23 84--*--medical or neurologic condition or neurocognitive dysfunction",
            "Temporal 182 189--*--current",
            "Temporal 194 214--*--within past 2 months",
            "Condition 216 233--*--medical condition",
            "Drug 244 254--*--medication",
            "Mood 260 279--*--would interact with",
            "Drug 280 290--*--dronabinol",
            "Mood 294 327--*--interfere with the study protocol",
            "Scope 260 327--*--would interact with dronabinol or interfere with the study protocol",
            "Non-query-able 329 396--*--risk of harm to self or others that requires immediate intervention",
            "Condition 410 427--*--contraindications",
            "Temporal 429 436--*--current",
            "Temporal 440 444--*--past",
            "Condition 445 453;465 473--*--allergic reaction",
            "Condition 457 473--*--adverse reaction",
            "Condition 484 495--*--sensitivity",
            "Drug 499 526--*--cannabinoid-like substances",
            "Drug 528 538--*--dronabinol",
            "Drug 539 548--*--marijuana",
            "Drug 549 557--*--cannabis",
            "Drug 558 561--*--THC",
            "Drug 563 578--*--cannabinoid oil",
            "Drug 580 590--*--sesame oil",
            "Drug 592 599--*--gelatin",
            "Drug 601 609--*--glycerin",
            "Drug 615 631--*--titanium dioxide",
            "Scope 528 631--*--dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide",
            "Scope 445 473--*--allergic or adverse reaction",
            "Scope 429 444--*--current or past",
            "Non-query-able 634 660--*--lack of fluency in English",
            "Measurement 671 682--*--drug screen",
            "Value 662 670--*--positive",
            "Measurement 686 706--*--alcohol breathalyzer",
            "Scope 671 706--*--drug screen or alcohol breathalyzer",
            "Post-eligibility 708 758--*--unwilling/unable to sign informed consent document",
            "Temporal 760 769--*--currently",
            "Condition 770 778--*--pregnant",
            "Measurement 789 803--*--pregnancy test",
            "Value 780 788--*--positive",
            "Mood 806 814--*--planning",
            "Condition 815 824--*--pregnancy",
            "Condition 829 838--*--lactating",
            "Scope 760 778--*--currently pregnant",
            "Value 848 873--*--under 18 or over 50 years",
            "Person 877 880--*--age",
            "Condition 882 904--*--traumatic brain injury",
            "Non-representable 906 1507--*--as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient",
            "Condition 1577 1591--*--claustrophobia",
            "Condition 1523 1570--*--tolerate small, enclosed spaces without anxiety",
            "Mood 1510 1519--*--inability",
            "Negation 1510 1519--*--inability",
            "Procedure 1611 1622--*--self-report",
            "Condition 1671 1682--*--left-handed",
            "Device 1697 1722--*--ferrous-containing metals",
            "Device 1746 1760--*--aneurysm clips",
            "Device 1762 1770--*--shrapnel",
            "Device 1771 1789--*--retained particles",
            "Scope 1746 1789--*--aneurysm clips, shrapnel/retained particles",
            "Temporal 1829 1863--*--in the 4 weeks following the study",
            "Procedure 1819 1828--*--drug test",
            "Mood 1792 1807--*--anticipation of",
            "Condition 1889 1893;1913 1921--*--mood disorder",
            "Condition 1895 1902;1913 1921--*--anxiety disorder",
            "Condition 1913 1921--*--disorder",
            "Qualifier 1907 1912--*--other",
            "Condition 1959 1963--*--PTSD",
            "Qualifier 1930 1963--*--more clinically salient than PTSD",
            "Scope 1889 1921--*--mood, anxiety, or other disorder",
            "Qualifier 1973 1981--*--moderate",
            "Qualifier 1985 1991--*--severe",
            "Condition 1992 1999;2005 2017--*--alcohol use disorder",
            "Condition 2000 2017--*--drug use disorder",
            "Scope 1992 2017--*--alcohol/drug use disorder",
            "Scope 1973 1991--*--moderate or severe",
            "Temporal 2021 2040--*--in the past 8 weeks",
            "Condition 2071 2078--*--bipolar",
            "Qualifier 2083 2088--*--other",
            "Condition 2089 2106--*--related disorders",
            "Condition 2108 2130--*--schizophrenia spectrum",
            "Condition 2141 2160--*--psychotic disorders",
            "Procedure 2174 2184--*--treatments",
            "Drug 2190 2200--*--medication",
            "Condition 2215 2232--*--drug interactions",
            "Drug 2238 2248--*--dronabinol",
            "Drug 2259 2293--*--central nervous system depressants",
            "Drug 2295 2307--*--barbiturates",
            "Drug 2309 2324--*--benzodiazepines",
            "Drug 2326 2335--*--buspirone",
            "Drug 2337 2344--*--lithium",
            "Scope 2295 2344--*--barbiturates, benzodiazepines, buspirone, lithium",
            "Drug 2355 2377--*--anticholinergic agents",
            "Drug 2379 2387--*--atropine",
            "Drug 2389 2400--*--scopolamine",
            "Drug 2402 2416--*--antihistamines",
            "Scope 2379 2416--*--atropine, scopolamine, antihistamines",
            "Scope 2259 2422--*--central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc)",
            "Scope 410 495--*--contraindications, current or past allergic or adverse reaction, or known sensitivity"
        ]
    },
    "NCT02838810_exc": {
        "Text": "Patients with liver cirrhosis, Hepatocellular Carcinoma or AFP >2 ULN or other malignancies.. Patients with other factors causing liver diseases.. Pregnant and lactating women.. Patients with concomitant HIV infection or congenital immune deficiency diseases.. Patients with diabetes, autoimmune diseases.. Patients with important organ dysfunctions.. Patients with serious complications (e.g., infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding.). Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.. Patients with a previous use of IFN anti hepatitis B virus treatment or have NAs drug resistance.. Patients who can't come back to clinic for follow-up on schedule.. ",
        "Annotations": [
            "Condition 14 29--*--liver cirrhosis",
            "Condition 31 55--*--Hepatocellular Carcinoma",
            "Measurement 59 62--*--AFP",
            "Value 63 69--*-->2 ULN",
            "Condition 79 91--*--malignancies",
            "Condition 130 144--*--liver diseases",
            "Non-query-able 94 144--*--Patients with other factors causing liver diseases",
            "Pregnancy_considerations 147 175--*--Pregnant and lactating women",
            "Condition 204 217--*--HIV infection",
            "Qualifier 192 203--*--concomitant",
            "Condition 221 258--*--congenital immune deficiency diseases",
            "Condition 275 283--*--diabetes",
            "Condition 285 304--*--autoimmune diseases",
            "Condition 331 349--*--organ dysfunctions",
            "Qualifier 321 330--*--important",
            "Qualifier 366 373--*--serious",
            "Condition 374 387--*--complications",
            "Condition 395 404--*--infection",
            "Condition 406 428--*--hepatic encephalopathy",
            "Condition 430 450--*--hepatorenal syndrome",
            "Condition 452 477--*--gastrointestinal bleeding",
            "Scope 395 477--*--infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding",
            "Procedure 502 516;537 544--*--antineoplastic therapy",
            "Procedure 520 544--*--immunomodulatory therapy",
            "Scope 502 544--*--antineoplastic or immunomodulatory therapy",
            "Temporal 552 566--*--past 12 months",
            "Drug 601 604--*--IFN",
            "Qualifier 605 627--*--anti hepatitis B virus",
            "Condition 655 665--*--resistance",
            "Drug 646 654--*--NAs drug",
            "Post-eligibility 668 732--*--Patients who can't come back to clinic for follow-up on schedule"
        ]
    },
    "NCT02893293_inc": {
        "Annotations": [
            "Condition 0 13--*--Osteonecrosis",
            "Procedure 23 44--*--decompression surgery",
            "Mood 15 22--*--planned",
            "Procedure 50 81--*--autologous stem cell transplant"
        ],
        "Text": "Osteonecrosis. planned decompression surgery with autologous stem cell transplant. "
    },
    "NCT01424020_exc": {
        "Annotations": [
            "Observation 0 21--*--Unable to participate",
            "Qualifier 26 48--*--administrative reasons",
            "Condition 50 70--*--Psychiatric troubles",
            "Condition 72 84--*--Pain at rest",
            "Condition 88 110--*--critical limb ischemia",
            "Condition 112 126--*--Unable to walk",
            "Observation 132 151--*--wheelchair subjects"
        ],
        "Text": "Unable to participate for administrative reasons. Psychiatric troubles. Pain at rest or critical limb ischemia. Unable to walk (ex: wheelchair subjects). "
    },
    "NCT01799681_inc": {
        "Annotations": [
            "Condition 15 17--*--PD",
            "Qualifier 18 34--*--by a neurologist",
            "Non-query-able 18 34--*--by a neurologist",
            "Person 60 64--*--aged",
            "Value 65 79--*--30 to 85 years",
            "Measurement 85 114--*--modified Hoehn and Yahr (H&Y)",
            "Value 115 129--*--stage 1.5 to 3",
            "Non-query-able 175 247--*--able and willing to give written consent for participation in the study;",
            "Post-eligibility 175 247--*--able and willing to give written consent for participation in the study;",
            "Observation 249 280--*--living at home in the community",
            "Condition 283 309;324 359--*--able to walk independently with or without an assistive device",
            "Multiplier 310 323--*--for 30 metres"
        ],
        "Text": "diagnosed with PD by a neurologist (Fahn and Elton, 1987); . aged 30 to 85 years; . at modified Hoehn and Yahr (H&Y) stage 1.5 to 3 (Hoehn and Yahr ,1967; Goetz et al., 2004); . able and willing to give written consent for participation in the study; . living at home in the community; . able to walk independently for 30 metres with or without an assistive device. . "
    },
    "NCT02579733_inc": {
        "Annotations": [
            "Condition 0 18--*--Ulcerative colitis",
            "Qualifier 33 51--*--moderate to severe",
            "Condition 76 94--*--clinical remission",
            "Temporal 95 133--*--by the first course of corticosteroids",
            "Reference_point 102 133--*--first course of corticosteroids",
            "Multiplier 102 114--*--first course",
            "Drug 118 133--*--corticosteroids",
            "Negation 154 161--*--without",
            "Drug 162 169--*--steroid",
            "Temporal 174 192--*--during last 1 year",
            "Measurement 194 218--*--Endoscopic Mayo subscore",
            "Value 219 221--*-->0"
        ],
        "Text": "Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids. Newly diagnosed or without steroid use during last 1 year. Endoscopic Mayo subscore >0. "
    },
    "NCT00183885_exc": {
        "Annotations": [
            "Procedure 33 45--*--chemotherapy",
            "Condition 50 70--*--unresectable disease",
            "Qualifier 100 112--*--uncontrolled",
            "Qualifier 90 96--*--active",
            "Condition 113 122--*--infection",
            "Scope 90 112--*--active or uncontrolled",
            "Procedure 140 153--*--HIV infection",
            "Condition 177 188--*--hepatitis B",
            "Qualifier 170 176--*--active",
            "Scope 170 188--*--active hepatitis B",
            "Drug 207 217--*--lamivudine",
            "Condition 240 251--*--hepatitis C",
            "Qualifier 233 239--*--active",
            "Scope 233 251--*--active hepatitis C",
            "Measurement 272 283--*--liver tests",
            "Value 284 291--*--qualify",
            "Condition 315 336--*--psychiatric disorders",
            "Qualifier 348 370--*--interfere with consent",
            "Qualifier 348 362;374 383--*--interfere with follow-up",
            "Condition 385 393--*--Pregnant",
            "Condition 397 406--*--lactating",
            "Person 407 412--*--women",
            "Condition 431 453--*--reproductive potential",
            "Procedure 508 538--*--effective contraceptive method",
            "Qualifier 565 571--*--severe",
            "Condition 572 590--*--concurrent disease",
            "Non-query-able 592 634--*--which in the judgment of the investigator,",
            "Observation 676 697--*--entry into this study",
            "Mood 658 675--*--inappropriate for"
        ],
        "Text": "Patients who have received prior chemotherapy for unresectable disease . Patients with any active or uncontrolled infection, including known HIV infection. (Patients with active hepatitis B will be placed on lamivudine. Patients with active hepatitis C will be eligible if liver tests qualify (5.1.9) . Patients with psychiatric disorders that would interfere with consent or follow-up. Pregnant or lactating women. Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. . Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study.       .     . "
    },
    "NCT02884401_exc": {
        "Text": "On chronic treatment (i.e., two weeks or more) with any medication severely affecting oral status (e.g. participants with gingival hypertrophy caused by anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive) or bone metabolism (e.g. anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants).. Affected by systemic diseases recognized to severely affect bone metabolism (e.g. Cushing's syndrome, Addison's disease, diabetes mellitus type 1, leukaemia, pernicious anaemia, malabsorption syndromes, chronic liver disease, rheumatoid arthritis).. Knowingly affected by HIV or Hepatitis.. History of local radiation therapy in the last five years.. Affected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed.. Presenting an acute endodontic/periodontal lesion in the neighboring areas to the implant site.. Completely edentulous. With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e.g. sharp knife edge ridge). Severe bruxism or clenching habits. Smokers of > 5 cigarettes a day.. A daily alcohol intake >2 units/day.. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.. Patients unable or not willing to return for follow-ups.. ",
        "Annotations": [
            "Procedure 11 20--*--treatment",
            "Temporal 28 45--*--two weeks or more",
            "Condition 511 529--*--Cushing's syndrome",
            "Condition 531 548--*--Addison's disease",
            "Condition 550 574--*--diabetes mellitus type 1",
            "Condition 576 585--*--leukaemia",
            "Condition 587 605--*--pernicious anaemia",
            "Condition 607 630--*--malabsorption syndromes",
            "Condition 632 653--*--chronic liver disease",
            "Condition 655 675--*--rheumatoid arthritis",
            "Drug 214 231--*--immunosuppressive",
            "Drug 191 203--*--cyclosporine",
            "Drug 170 189--*--calcium antagonists",
            "Drug 153 168--*--anti-epileptics",
            "Condition 122 142--*--gingival hypertrophy",
            "Scope 153 231--*--anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive",
            "Observation 236 251--*--bone metabolism",
            "Drug 258 271--*--anticoagulant",
            "Drug 299 306--*--steroid",
            "Multiplier 325 344;361 366--*--equal or more 2.5mg a day",
            "Drug 348 360--*--prednisolone",
            "Temporal 377 386--*-->3 months",
            "Drug 390 405--*--anticonvulsants",
            "Drug 407 425--*--immunosuppressants",
            "Scope 258 426--*--anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants)",
            "Condition 708 717--*--Hepatitis",
            "Condition 701 704--*--HIV",
            "Procedure 731 754--*--local radiation therapy",
            "Temporal 762 777--*--last five years",
            "Post-eligibility 781 963--*--ffected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed",
            "Condition 997 1015--*--periodontal lesion",
            "Condition 1009 1015;986 996--*--lesion endodontic",
            "Condition 1074 1084--*--edentulous",
            "Qualifier 1063 1073--*--Completely",
            "Non-query-able 1086 1206--*--With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e.g. sharp knife edge ridge)",
            "Observation 1226 1242--*--clenching habits",
            "Observation 1215 1222--*--bruxism",
            "Person 1244 1251--*--Smokers",
            "Observation 1259 1269--*--cigarettes",
            "Multiplier 1255 1258;1270 1275--*--> 5 a day",
            "Observation 1286 1293--*--alcohol",
            "Multiplier 1301 1313--*-->2 units/day",
            "Non-query-able 1316 1677--*--Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial",
            "Post-eligibility 1680 1735--*--Patients unable or not willing to return for follow-ups"
        ]
    },
    "NCT03088904_exc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT01929434_exc": {
        "Annotations": [
            "Condition 0 22--*--Intracranial infection",
            "Condition 48 74--*--circulatory system disease",
            "Condition 32 43;60 74--*--respiratory system disease",
            "Qualifier 25 31--*--Severe",
            "Scope 32 75--*--respiratory and circulatory system diseases",
            "Condition 78 102--*--Hematologic malignancies",
            "Condition 140 144--*--AIDS",
            "Condition 146 163--*--hepatitis B virus",
            "Condition 165 182--*--hepatitis C virus",
            "Condition 187 195--*--syphilis",
            "Condition 220 226--*--Tumors",
            "Grammar_Error 183 186--*--and",
            "Condition 241 259--*--metabolic diseases",
            "Condition 229 236;251 259--*--Genetic diseases"
        ],
        "Text": "Intracranial infection. . Severe respiratory and circulatory system diseases. . Hematologic malignancies. . Positive serological tests such as AIDS, hepatitis B virus, hepatitis C virus and syphilis \uff08antigen or antibody\uff09. . Tumors. . Genetic and metabolic diseases.       .     . "
    },
    "NCT01497639_exc": {
        "Annotations": [
            "Temporal 0 8--*--previous",
            "Procedure 9 22--*--brain surgery",
            "Condition 25 45--*--cognitive impairment",
            "Value 47 59--*--< 120 points",
            "Measurement 67 95--*--Mattis Dementia Rating Scale",
            "Qualifier 98 116--*--moderate-to-severe",
            "Condition 117 127--*--depression",
            "Value 129 140--*--> 25 points",
            "Measurement 148 173--*--Beck Depression Inventory",
            "Condition 183 196--*--brain atrophy",
            "Procedure 212 238--*--magnetic resonance imaging",
            "Post-eligibility 240 369--*--other medical or psychiatric coexisting disorders that could increase the surgical risk or interfere with completion of the trial"
        ],
        "Text": "previous brain surgery;. cognitive impairment (< 120 points on the Mattis Dementia Rating Scale). moderate-to-severe depression (> 25 points on the Beck Depression Inventory). marked brain atrophy as detected by magnetic resonance imaging. other medical or psychiatric coexisting disorders that could increase the surgical risk or interfere with completion of the trial. "
    },
    "NCT02774317_exc": {
        "Text": "Patients who are being prepared for surgery, or during or after surgery.. Patients with congenital anomalies, chromosomal anomalies, or heart defects.. Patients whose parents refuse to consent.. ",
        "Annotations": [
            "Procedure 36 43--*--surgery",
            "Mood 17 35--*--being prepared for",
            "Temporal 48 54;64 71--*--during surgery",
            "Temporal 58 71--*--after surgery",
            "Condition 88 108--*--congenital anomalies",
            "Condition 110 131--*--chromosomal anomalies",
            "Condition 136 149--*--heart defects",
            "Non-query-able 152 193--*--Patients whose parents refuse to consent."
        ]
    },
    "NCT02821819_inc": {
        "Annotations": [
            "Person 0 13--*--Premenopausal",
            "Person 14 19--*--women",
            "Person 33 36--*--old",
            "Value 21 32--*--18-35 years",
            "Measurement 38 48--*--FSH levels",
            "Value 49 60--*--< 10 mIU/ml",
            "Measurement 62 65--*--AFC",
            "Value 65 69--*--> 10",
            "Condition 71 85--*--Regular cycles",
            "Measurement 87 90--*--BMI",
            "Value 91 95--*--< 28",
            "Informed_consent 97 120--*--Signed informed consent"
        ],
        "Text": "Premenopausal women. 18-35 years old. FSH levels < 10 mIU/ml. AFC> 10. Regular cycles. BMI < 28. Signed informed consent. "
    },
    "NCT03088904_inc": {
        "Annotations": [
            "Non-query-able 0 2--*--NA"
        ],
        "Text": "NA. . "
    },
    "NCT01497639_inc": {
        "Annotations": [
            "Person 0 4--*--ages",
            "Value 8 22--*--7 and 75 years",
            "Condition 31 41--*--disability",
            "Condition 84 92--*--dystonia",
            "Qualifier 74 83--*--segmental",
            "Qualifier 59 70--*--generalized",
            "Qualifier 51 58--*--primary",
            "Scope 59 83--*--generalized or segmental",
            "Qualifier 102 109--*--optimal",
            "Procedure 110 133--*--pharmacologic treatment",
            "Measurement 135 151--*--disease duration",
            "Value 155 171--*--at least 5 years"
        ],
        "Text": "ages of 7 and 75 years. marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment. disease duration of at least 5 years.. "
    },
    "NCT01929434_inc": {
        "Annotations": [
            "Condition 27 41--*--cerebral palsy",
            "Non-query-able 44 100--*--Patients' curator must be able to give voluntary consent",
            "Post-eligibility 44 100--*--Patients' curator must be able to give voluntary consent"
        ],
        "Text": "Patients with diagnosis of cerebral palsy. . Patients' curator must be able to give voluntary consent. . "
    },
    "NCT02821819_exc": {
        "Annotations": [
            "Condition 0 4--*--PCOS",
            "Drug 26 40--*--gonadotrophins",
            "Condition 15 22--*--Allergy",
            "Competing_trial 42 82--*--Concomitant participation in other trial"
        ],
        "Text": "PCOS patients. Allergy to gonadotrophins. Concomitant participation in other trial. "
    },
    "NCT02774317_inc": {
        "Text": "Nonsurgical neonates and babies up to age 6 months with INR 1.5 or more who are deemed clinically to need plasma infusion.. ",
        "Annotations": [
            "Person 12 20--*--neonates",
            "Condition 0 11--*--Nonsurgical",
            "Person 25 31--*--babies",
            "Value 32 50--*--up to age 6 months",
            "Person 38 41--*--age",
            "Measurement 56 59--*--INR",
            "Value 60 71--*--1.5 or more",
            "Procedure 106 121--*--plasma infusion",
            "Condition 101 105--*--need"
        ]
    },
    "NCT01567605_exc": {
        "Text": "cauda equina or conus lesion. currently use ventilator. colostomy, or do not perform regular bowel care for any reason. any skin breakdown (pressure sores). do not speak English. are under 19 years old. are pregnant or think you might be pregnant. medical/psychiatric condition or substance abuse that is likely to affect your ability to complete this study. currently using medications containing lidocaine. allergy to lidocaine. ",
        "Annotations": [
            "Qualifier 0 12--*--cauda equina",
            "Qualifier 16 21--*--conus",
            "Condition 22 28--*--lesion",
            "Scope 0 21--*--cauda equina or conus",
            "Temporal 30 39--*--currently",
            "Procedure 44 54--*--ventilator",
            "Procedure 56 65--*--colostomy",
            "Procedure 85 103--*--regular bowel care",
            "Negation 70 84--*--do not perform",
            "Condition 124 138--*--skin breakdown",
            "Condition 140 154--*--pressure sores",
            "Negation 160 163--*--not",
            "Observation 164 177--*--speak English",
            "Value 183 197--*--under 19 years",
            "Person 198 201--*--old",
            "Condition 207 215--*--pregnant",
            "Mood 219 237--*--think you might be",
            "Condition 238 246--*--pregnant",
            "Condition 248 255;268 277--*--medical condition",
            "Condition 256 277--*--psychiatric condition",
            "Condition 281 296--*--substance abuse",
            "Temporal 359 368--*--currently",
            "Drug 375 407--*--medications containing lidocaine",
            "Drug 420 429--*--lidocaine",
            "Condition 409 416--*--allergy"
        ]
    },
    "NCT02483715_exc": {
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Condition 12 19--*--nursing",
            "Person 20 25--*--woman",
            "Scope 0 19--*--pregnant or nursing",
            "Condition 47 54--*--illness",
            "Temporal 35 46--*--concomitant",
            "Qualifier 27 34--*--serious",
            "Condition 59 74--*--malignant tumor",
            "Qualifier 78 86--*--any kind",
            "Observation 88 98--*--history of",
            "Condition 99 115--*--hypersensitivity",
            "Drug 119 129--*--test drugs",
            "Qualifier 131 138--*--serious",
            "Condition 139 147--*--bleeding",
            "Temporal 148 178--*--during the course of the ulcer",
            "Temporal 180 188--*--previous",
            "Procedure 189 204--*--gastric surgery",
            "Drug 216 229--*--bismuth salts",
            "Drug 231 235--*--PPIs",
            "Drug 240 251--*--antibiotics",
            "Temporal 252 273--*--in the previous month",
            "Scope 216 251--*--bismuth salts, PPIs, or antibiotics"
        ],
        "Text": "pregnant or nursing woman. serious concomitant illness and malignant tumor of any kind. history of hypersensitivity to test drugs. serious bleeding during the course of the ulcer. previous gastric surgery. receiving bismuth salts, PPIs, or antibiotics in the previous month.. "
    },
    "NCT02970773_exc": {
        "Annotations": [
            "Procedure 4 28--*--anti-coagulation therapy",
            "Drug 41 52--*--rivaroxaban",
            "Negation 30 40--*--apart from",
            "Condition 76 92--*--Hypersensitivity",
            "Condition 96 103--*--allergy",
            "Drug 107 127--*--factor Xa inhibitors",
            "Scope 76 103--*--Hypersensitivity or allergy",
            "Condition 129 157--*--Acute bacterial endocarditis",
            "Condition 159 176--*--Bleeding disorder",
            "Condition 198 213--*--active bleeding",
            "Condition 215 237--*--Gastrointestinal ulcer",
            "Condition 215 231;241 246--*--Gastrointestinal tumor",
            "Condition 248 267--*--Hepatic dysfunction",
            "Observation 283 296--*--bleeding risk",
            "Qualifier 273 282--*--increased",
            "Condition 298 311--*--Renal failure",
            "Procedure 334 342--*--dialysis",
            "Pregnancy_considerations 344 372--*--Pregnancy and breast feeding",
            "Procedure 374 385--*--Gastrectomy",
            "Procedure 387 412--*--biliopancreatic diversion",
            "Procedure 427 437--*--re-routing",
            "Procedure 414 423--*--resection",
            "Qualifier 441 457--*--small intestines",
            "Scope 414 437--*--resection or re-routing",
            "Device 459 471--*--Feeding tube",
            "Observation 480 494--*--blood donation",
            "Measurement 532 556--*--alanine-aminotransferase",
            "Measurement 558 562--*--ALAT",
            "Measurement 565 591--*--aspartate-aminotransferase",
            "Measurement 593 597--*--ASAT",
            "Measurement 600 626--*--gamma-glutamyl transferase",
            "Measurement 628 635--*--gammaGT",
            "Measurement 638 657--*--alkalic phosphatase",
            "Measurement 659 661--*--AP",
            "Measurement 664 673--*--bilirubin",
            "Measurement 675 682--*--amylase",
            "Measurement 684 690--*--lipase",
            "Measurement 692 702--*--cystatin C",
            "Measurement 704 714--*--creatinine",
            "Measurement 716 738--*--white blood cell count",
            "Measurement 740 751--*--haemoglobin",
            "Measurement 753 767--*--platelet count",
            "Measurement 769 786--*--prothrombin time,",
            "Measurement 787 791--*--aPTT",
            "Measurement 793 803--*--fibrinogen",
            "Measurement 805 818--*--thrombin time",
            "Measurement 820 830--*--factors II",
            "Measurement 820 827;831 832--*--factors V",
            "Measurement 820 827;833 836--*--factors VII",
            "Measurement 820 827;841 842--*--factors X",
            "Scope 532 842--*--alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time, factors II,V,VII and X",
            "Value 496 509--*--Abnormalities",
            "Non-query-able 844 918--*--Use of therapeutic or recreational drugs influencing plasmatic coagulation"
        ],
        "Text": "Any anti-coagulation therapy (apart from rivaroxaban for second objective). Hypersensitivity or allergy to factor Xa inhibitors. Acute bacterial endocarditis. Bleeding disorder. Clinically relevant active bleeding. Gastrointestinal ulcer or tumor. Hepatic dysfunction with increased bleeding risk. Renal failure / patients undergoing dialysis. Pregnancy and breast feeding. Gastrectomy, biliopancreatic diversion, resection or re-routing of small intestines. Feeding tube. Recent blood donation. Abnormalities of laboratory values: alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time, factors II,V,VII and X. Use of therapeutic or recreational drugs influencing plasmatic coagulation. "
    },
    "NCT03019562_inc": {
        "Text": "19-65 years of age. ASA physical status classification I or II. Scheduled for total hip replacement surgery. ",
        "Annotations": [
            "Value 0 11--*--19-65 years",
            "Person 15 18--*--age",
            "Measurement 20 54--*--ASA physical status classification",
            "Value 55 62--*--I or II",
            "Procedure 78 106--*--total hip replacement surger",
            "Mood 64 77--*--Scheduled for"
        ]
    },
    "NCT02908919_inc": {
        "Text": "Subjects referred to diagnostic or therapeutic colonoscopy.. ",
        "Annotations": [
            "Observation 21 31--*--diagnostic",
            "Observation 35 46--*--therapeutic",
            "Procedure 47 58--*--colonoscopy",
            "Scope 21 46--*--diagnostic or therapeutic"
        ]
    },
    "NCT01824537_inc": {
        "Text": "Couple must have been in a new relationship that started no more than six months prior to study entry. Both partners plan on remaining in Montreal for at least 1 year. Plan on having continued sexual contact with partner. Be willing to comply with study procedures. ",
        "Annotations": [
            "Observation 27 43--*--new relationship",
            "Temporal 57 101--*--no more than six months prior to study entry",
            "Observation 125 146--*--remaining in Montreal",
            "Multiplier 147 166--*--for at least 1 year",
            "Mood 168 175--*--Plan on",
            "Mood 117 124--*--plan on",
            "Observation 176 220--*--having continued sexual contact with partner",
            "Informed_consent 222 264--*--Be willing to comply with study procedures"
        ]
    },
    "NCT00279552_inc": {
        "Annotations": [
            "Condition 27 49--*--vitamin B12 deficiency",
            "Mood 9 18--*--suspected",
            "Measurement 63 81--*--plasma vitamin B12",
            "Value 82 110--*--below the reference interval",
            "Value 112 123--*--<200 pmol/L"
        ],
        "Text": "Patients suspected to have vitamin B12 deficiency defined as a plasma vitamin B12 below the reference interval (<200 pmol/L). . "
    },
    "NCT02548013_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 54 56--*--2.",
            "Parsing_Error 80 82--*--3.",
            "Parsing_Error 105 107--*--4.",
            "Parsing_Error 133 135--*--5.",
            "Parsing_Error 219 221--*--6.",
            "Parsing_Error 362 364--*--7.",
            "Measurement 14 29--*--gestational age",
            "Value 30 52--*--between 27 to 34 weeks",
            "Condition 3 8--*--PPROM",
            "Condition 57 78--*--Cephalic presentation",
            "Observation 83 103--*--Clear amniotic fluid",
            "Measurement 108 124--*--Oral temperature",
            "Value 125 131--*--> 38 C",
            "Post-eligibility 136 217--*--Near distance from the hospital (the patient can reach hospital within one hour )",
            "Non-query-able 136 217--*--Near distance from the hospital (the patient can reach hospital within one hour )",
            "Non-query-able 222 360--*--Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home .",
            "Subjective_judgement 222 360--*--Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home .",
            "Condition 378 393--*--fetal condition",
            "Condition 365 373;384 393--*--Maternal condition",
            "Qualifier 401 407--*--stable",
            "Temporal 408 442--*--after hospitalization for 72 hours",
            "Reference_point 414 429--*--hospitalization",
            "Scope 365 393--*--Maternal and fetal condition"
        ],
        "Text": "1. PPROM with gestational age between 27 to 34 weeks . 2. Cephalic presentation . 3. Clear amniotic fluid . 4. Oral temperature > 38 C . 5. Near distance from the hospital (the patient can reach hospital within one hour ) . 6. Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home . . 7. Maternal and fetal condition remain stable after hospitalization for 72 hours . "
    },
    "NCT03019562_exc": {
        "Text": "Allergic to study drugs. Patient with asthma or COPD, patient who is severely respiratory depressed. Renal of hepatic insufficiency. Epileptic status. Intracranial lesion associated with increased intracranial pressure. Acute abdomen, patient who has diagnosed paralytic ileus or suspicious ileus. Pregnant or lactating women. ",
        "Annotations": [
            "Condition 0 8--*--Allergic",
            "Drug 12 23--*--study drugs",
            "Condition 38 44--*--asthma",
            "Condition 48 52--*--COPD",
            "Qualifier 69 77--*--severely",
            "Condition 78 99--*--respiratory depressed",
            "Condition 110 131--*--hepatic insufficiency",
            "Condition 101 106;118 131--*--Renal insufficiency",
            "Condition 133 149--*--Epileptic status",
            "Condition 151 170--*--Intracranial lesion",
            "Measurement 197 218--*--intracranial pressure",
            "Value 187 196--*--increased",
            "Condition 220 233--*--Acute abdomen",
            "Condition 261 276--*--paralytic ileus",
            "Condition 280 296--*--suspicious ileus",
            "Condition 298 306--*--Pregnant",
            "Condition 310 319--*--lactating",
            "Person 320 324--*--wome"
        ]
    },
    "NCT02483715_inc": {
        "Annotations": [
            "Qualifier 20 37--*--H. pylori related",
            "Condition 38 55--*--chronic gastritis",
            "Condition 69 82--*--peptic ulcers",
            "Person 91 95--*--aged",
            "Value 96 121--*--greater than 20 years old",
            "Procedure 150 169--*--eradication therapy",
            "Mood 130 148--*--willing to receive"
        ],
        "Text": "Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.. "
    },
    "NCT01567605_inc": {
        "Text": "traumatic spinal cord injury at least one year ago. regular bowel care routine (at least four weeks). ",
        "Annotations": [
            "Condition 0 28--*--traumatic spinal cord injury",
            "Temporal 29 50--*--at least one year ago",
            "Observation 52 78--*--regular bowel care routine",
            "Temporal 80 99--*--at least four weeks"
        ]
    },
    "NCT02970773_inc": {
        "Annotations": [
            "Condition 15 26--*--tetraplegia",
            "Qualifier 6 14--*--complete",
            "Temporal 31 48--*--at least 3 months",
            "Person 50 53--*--Age",
            "Value 54 73--*--from 18 to 74 years",
            "Measurement 75 90--*--Body mass index",
            "Measurement 92 95--*--BMI",
            "Value 97 115--*--from 18 to 35kg/m2",
            "Informed_consent 118 160--*--nformed consent as documented by signature"
        ],
        "Text": "Motor complete tetraplegia for at least 3 months. Age from 18 to 74 years. Body mass index (BMI) from 18 to 35kg/m2. Informed consent as documented by signature. "
    },
    "NCT01824537_exc": {
        "Text": "Volunteers must not have been vaccinated against HPV-Gardasil-9 (both partners). Any history of cervical, penile, oral or anal cancers. Being pregnant or plan on immediately becoming pregnant. ",
        "Annotations": [
            "Negation 16 19--*--not",
            "Temporal 20 29--*--have been",
            "Procedure 30 40--*--vaccinated",
            "Condition 49 63--*--HPV-Gardasil-9",
            "Observation 81 92--*--Any history",
            "Condition 127 134;96 104--*--cancers cervical",
            "Condition 106 112;127 134--*--penile cancers",
            "Condition 114 118;127 134--*--oral cancers",
            "Condition 122 134--*--anal cancers",
            "Condition 142 150--*--pregnant",
            "Mood 154 182--*--plan on immediately becoming",
            "Condition 183 191--*--pregnant"
        ]
    },
    "NCT02908919_exc": {
        "Text": "ileus. known or suspected bowel obstruction. active bowel inflammation. pregnancy. any presence of serious medical conditions ( esp. cardiac, renal, liver diseases). history of prior colonic or rectal surgery. inability to obtain valid data from. ",
        "Annotations": [
            "Condition 0 5--*--ileus",
            "Mood 7 12--*--known",
            "Mood 16 25--*--suspected",
            "Condition 26 43--*--bowel obstruction",
            "Scope 7 25--*--known or suspected",
            "Temporal 45 51--*--active",
            "Condition 52 70--*--bowel inflammation",
            "Condition 72 81--*--pregnancy",
            "Condition 99 125--*--serious medical conditions",
            "Condition 133 140;155 163--*--cardiac diseases",
            "Condition 149 163--*--liver diseases",
            "Condition 142 147;155 163--*--renal diseases",
            "Scope 133 163--*--cardiac, renal, liver diseases",
            "Observation 166 176--*--history of",
            "Temporal 177 182--*--prior",
            "Procedure 183 190;201 208--*--colonic surgery",
            "Procedure 194 208--*--rectal surgery",
            "Scope 183 208--*--colonic or rectal surgery",
            "Non-query-able 210 245--*--inability to obtain valid data from"
        ]
    },
    "NCT00279552_exc": {
        "Annotations": [
            "Condition 18 26--*--pregnant",
            "Condition 28 35--*--nursing",
            "Observation 43 80--*--able to give written informed consent",
            "Negation 39 42--*--not"
        ],
        "Text": "Patients who were pregnant, nursing or not able to give written informed consent were excluded.       .     . "
    },
    "NCT02548013_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Condition 39 59--*--rupture of membranes",
            "Negation 16 25--*--equivocal",
            "Condition 64 78--*--advanced labor",
            "Condition 83 105--*--intrauterine infection",
            "Condition 110 126--*--vaginal bleeding",
            "Parsing_Error 127 129--*--or",
            "Measurement 149 165--*--fetal heart rate",
            "Qualifier 134 148--*--non reassuring",
            "Subjective_judgement 134 148--*--non reassuring",
            "Context_Error 134 148--*--non reassuring"
        ],
        "Text": "1. Patient with equivocal diagnosis of rupture of membranes . 2. advanced labor . 3. intrauterine infection . 4. vaginal bleeding or . 5. non reassuring fetal heart rate.       .     . "
    },
    "NCT03623789_inc": {
        "Text": "Patients with osteoarthritis of the hip secondary to degeneration, inflammatory arthritis, gouty arthritis, acetabular dysplasia or osteonecrosis of the femoral head, and undergoing primary unilateral minimally invasive THA. Age > 18 years and < 90 years. Failure of medical treatment or rehabilitation.. Hemoglobin > 11g/dl,. No use of non-steroid anti-inflammatory agent one week before operation. ",
        "Annotations": [
            "Condition 14 28--*--osteoarthritis",
            "Qualifier 36 39--*--hip",
            "Qualifier 40 65--*--secondary to degeneration",
            "Condition 53 65--*--degeneration",
            "Condition 67 89--*--inflammatory arthritis",
            "Condition 91 106--*--gouty arthritis",
            "Condition 108 128--*--acetabular dysplasia",
            "Condition 132 145--*--osteonecrosis",
            "Qualifier 153 165--*--femoral head",
            "Temporal 171 181--*--undergoing",
            "Qualifier 182 189--*--primary",
            "Qualifier 190 200--*--unilateral",
            "Procedure 201 223--*--minimally invasive THA",
            "Scope 108 145--*--acetabular dysplasia or osteonecrosis",
            "Person 225 228--*--Age",
            "Value 229 239--*--> 18 years",
            "Value 244 254--*--< 90 years",
            "Qualifier 256 263--*--Failure",
            "Procedure 267 284--*--medical treatment",
            "Procedure 288 302--*--rehabilitation",
            "Scope 267 302--*--medical treatment or rehabilitation",
            "Measurement 305 315--*--Hemoglobin",
            "Value 316 324--*--> 11g/dl",
            "Drug 337 372--*--non-steroid anti-inflammatory agent",
            "Temporal 373 398--*--one week before operation",
            "Reference_point 389 398--*--operation",
            "Negation 327 329--*--No"
        ]
    },
    "NCT00305097_inc": {
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 22--*--at least 18 years",
            "Observation 31 38;55 87--*--ability to give written informed consent",
            "Observation 43 54;55 87--*--willingness to give written informed consent",
            "Measurement 90 105--*--Body mass index",
            "Value 106 117--*--25-35 kg/m2",
            "Multiplier 128 143;166 173--*--at least 2 cups per day",
            "Drug 147 165--*--caffeinated coffee",
            "Observation 182 206--*--willing to be randomized",
            "Condition 237 248--*--Non-smoking"
        ],
        "Text": "Aged at least 18 years with an ability and willingness to give written informed consent. . Body mass index 25-35 kg/m2 . Users of at least 2 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions. . Non-smoking . "
    },
    "NCT01807897_inc": {
        "Annotations": [
            "Person 0 7--*--Veteran",
            "Visit 34 82--*--Veterans Health Administration healthcare system",
            "Person 84 87--*--Age",
            "Value 88 96--*--18 years",
            "Condition 121 142--*--chronic heart failure",
            "Measurement 144 176--*--American Heart Association Stage",
            "Value 177 180--*--C-D",
            "Measurement 182 186--*--LVEF",
            "Value 187 191--*--<45%",
            "Negation 193 195--*--No",
            "Qualifier 196 202--*--change",
            "Drug 213 232--*--cardiac medications",
            "Temporal 233 267--*--for 4 weeks prior to randomization",
            "Reference_point 254 267--*--randomization",
            "Informed_consent 269 304--*--Ability to provide informed consent",
            "Condition 354 377--*--obstructive sleep apnea",
            "Condition 325 332;366 377--*--central sleep apnea",
            "Condition 336 349;366 377--*--mixed central sleep apnea",
            "Qualifier 318 324--*--severe",
            "Qualifier 306 314--*--Moderate",
            "Measurement 393 413--*--apnea-hypopnea index",
            "Measurement 415 418--*--AHI",
            "Value 420 439--*--15 events per hour,",
            "Measurement 447 458--*--central AHI",
            "Value 459 473--*-->5 events/hour",
            "Scope 393 473--*--apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour",
            "Scope 325 377--*--central or mixed central and obstructive sleep apnea",
            "Scope 306 324--*--Moderate to severe"
        ],
        "Text": "Veteran receiving care within the Veterans Health Administration healthcare system. Age 18 years. Physician diagnosis of chronic heart failure, American Heart Association Stage C-D. LVEF <45%. No change in active cardiac medications for 4 weeks prior to randomization. Ability to provide informed consent. Moderate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour. "
    },
    "NCT00867958_exc": {
        "Text": "1. Patient has an allergy to nickel. . 2. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease. . 3. Patient is participating in another clinical trial which may affect this study's outcomes. . 4. Patient has been taking regular steroid medication. . 5. Patient has contraindications to general anesthesia. . 6. Patient has preexisting sphincter problems or evidence of extensive local disease in the pelvis.       .     . ",
        "Annotations": [
            "Condition 18 35--*--allergy to nickel",
            "Drug 29 35--*--nickel",
            "Condition 68 85--*--bowel obstruction",
            "Condition 87 106--*--bowel strangulation",
            "Condition 108 119--*--peritonitis",
            "Condition 121 138--*--bowel perforation",
            "Condition 149 167--*--systemic infection",
            "Condition 140 145;158 167--*--local infection",
            "Condition 169 183--*--ischemic bowel",
            "Condition 185 199--*--carcinomatosis",
            "Condition 222 248--*--inflammatory bowel disease",
            "Qualifier 203 221--*--extensively spread",
            "Post-eligibility 254 344--*--Patient is participating in another clinical trial which may affect this study's outcomes.",
            "Context_Error 254 344--*--Patient is participating in another clinical trial which may affect this study's outcomes.",
            "Drug 381 399--*--steroid medication",
            "Multiplier 373 380--*--regular",
            "Condition 417 456--*--contraindications to general anesthesia",
            "Procedure 438 456--*--general anesthesia",
            "Condition 486 504--*--sphincter problems",
            "Condition 530 557--*--local disease in the pelvis",
            "Qualifier 520 529--*--extensive",
            "Mood 508 519--*--evidence of"
        ]
    },
    "NCT02473809_inc": {
        "Text": "Informed consent. Diagnosis of type 2 diabetes (HbA1c > 48 mmol/mol). Age older than 30 years. ",
        "Annotations": [
            "Informed_consent 0 16--*--Informed consent",
            "Condition 31 46--*--type 2 diabetes",
            "Measurement 48 53--*--HbA1c",
            "Value 54 67--*--> 48 mmol/mol",
            "Person 70 73--*--Age",
            "Value 74 93--*--older than 30 years"
        ]
    },
    "NCT02745704_exc": {
        "Annotations": [
            "Condition 14 29--*--liver cirrhosis",
            "Condition 31 55--*--Hepatocellular Carcinoma",
            "Condition 65 77--*--malignancies",
            "Non-representable 80 130--*--Patients with other factors causing liver diseases",
            "Pregnancy_considerations 133 161--*--Pregnant and lactating women",
            "Condition 190 203--*--HIV infection",
            "Qualifier 178 189--*--concomitant",
            "Condition 207 245--*--congenital immune deficiency diseases.",
            "Condition 261 269--*--diabetes",
            "Condition 271 290--*--autoimmune diseases",
            "Condition 317 335--*--organ dysfunctions",
            "Qualifier 352 359--*--serious",
            "Condition 360 373--*--complications",
            "Condition 381 390--*--infection",
            "Condition 392 414--*--hepatic encephalopathy",
            "Condition 416 436--*--hepatorenal syndrome",
            "Condition 438 463--*--gastrointestinal bleeding",
            "Scope 381 463--*--infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding",
            "Procedure 488 502;523 530--*--antineoplastic therapy",
            "Procedure 506 530--*--immunomodulatory therapy",
            "Temporal 538 552--*--past 12 months",
            "Scope 488 530--*--antineoplastic or immunomodulatory therapy",
            "Post-eligibility 555 619--*--Patients who can't come back to clinic for follow-up on schedule"
        ],
        "Text": "Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.. Patients with other factors causing liver diseases.. Pregnant and lactating women.. Patients with concomitant HIV infection or congenital immune deficiency diseases.. Patients with diabetes, autoimmune diseases.. Patients with important organ dysfunctions.. Patients with serious complications (e.g., infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding.). Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.. Patients who can't come back to clinic for follow-up on schedule.. "
    },
    "NCT02035904_exc": {
        "Text": "preexisting pectoral, axillar, thoracic homolateral pain. habitual opioid consumption;. drug-alcoholics addiction ;. ICU postoperative recovery;. kidney failure (creatinin > 2 g/dl, creatinin <clearance 30 ml/h) and/or hepatic failure (cholinesterase < 2000 UI);. cardiac arrhythmias o;. Epilepsy;. Psychiatric, cognitive disorders, mental retardation;. Coagulopathies (INR > 2, activated partial thromboplastin time - aPTT>44 sec);. platelet count less than 100.000/mm3;. BMI > 30;. Allergies to study drugs.. ",
        "Annotations": [
            "Condition 31 39;52 56--*--thoracic pain",
            "Qualifier 40 51--*--homolateral",
            "Condition 22 29;52 56--*--axillar pain",
            "Condition 12 20;52 56--*--pectoral pain",
            "Scope 12 39;52 56--*--pectoral, axillar, thoracic pain",
            "Observation 67 85--*--opioid consumption",
            "Qualifier 58 66--*--habitual",
            "Condition 93 113--*--alcoholics addiction",
            "Condition 104 113;88 92--*--addiction drug",
            "Observation 117 143--*--ICU postoperative recovery",
            "Condition 146 160--*--kidney failure",
            "Measurement 162 171--*--creatinin",
            "Measurement 182 202--*--creatinin <clearance",
            "Value 203 210--*--30 ml/h",
            "Value 172 180--*--> 2 g/dl",
            "Condition 219 234--*--hepatic failure",
            "Measurement 236 250--*--cholinesterase",
            "Value 251 260--*--< 2000 UI",
            "Scope 162 210--*--creatinin > 2 g/dl, creatinin <clearance 30 ml/h",
            "Condition 264 283--*--cardiac arrhythmias",
            "Condition 288 296--*--Epilepsy",
            "Condition 299 331--*--Psychiatric, cognitive disorders",
            "Condition 333 351--*--mental retardation",
            "Condition 354 368--*--Coagulopathies",
            "Measurement 370 373--*--INR",
            "Value 374 377--*--> 2",
            "Measurement 379 423--*--activated partial thromboplastin time - aPTT",
            "Value 423 430--*-->44 sec",
            "Scope 370 430--*--INR > 2, activated partial thromboplastin time - aPTT>44 sec",
            "Measurement 434 448--*--platelet count",
            "Value 449 470--*--less than 100.000/mm3",
            "Measurement 473 476--*--BMI",
            "Value 477 481--*--> 30",
            "Condition 484 493--*--Allergies",
            "Drug 497 508--*--study drugs"
        ]
    },
    "NCT02892968_inc": {
        "Text": "At the cluster level, ED physicians practicing at a participating site will be eligible. . At the patient level, all hip fractures seen by a participating ED physician will be eligible . ",
        "Annotations": [
            "Condition 116 128--*--hip fracture",
            "Non-query-able 0 88--*--At the cluster level, ED physicians practicing at a participating site will be eligible.",
            "Non-query-able 130 183--*--seen by a participating ED physician will be eligible",
            "Context_Error 0 20--*--At the cluster level",
            "Context_Error 90 110--*--At the patient level",
            "Parsing_Error 90 110--*--At the patient level",
            "Parsing_Error 0 20--*--At the cluster level"
        ]
    },
    "NCT02894645_inc": {
        "Annotations": [
            "Condition 23 48--*--non-Burkitt B-lineage ALL",
            "Qualifier 0 9--*--Confirmed",
            "Value 50 63--*--1 to 17 years",
            "Person 67 70--*--age",
            "Measurement 95 109--*--Renal function",
            "Value 110 137--*--within normal range for age",
            "Measurement 139 153--*--Liver function",
            "Value 154 181--*--within normal range for age",
            "Observation 183 202--*--Able to participate",
            "Procedure 226 235--*--treatment",
            "Multiplier 210 222--*--full 2 years"
        ],
        "Text": "Confirmed diagnosis of non-Burkitt B-lineage ALL. 1 to 17 years of age (before 18th birthday). Renal function within normal range for age. Liver function within normal range for age. Able to participate in the full 2 years of treatment. "
    },
    "NCT03623789_exc": {
        "Text": "Preoperative Hemoglobin <U+2266>11 g/dl. History of infection or intraarticular fracture of the affective hip. Renal function deficiency (GFR <30 ml/min/1.73m2). Elevated liver enzyme (aspartate transaminase (AST)/ alanine transaminase(ALT) level are more than twice normal range) , history of liver cirrhosis, impaired liver function(elevated total bilirubin level) and coagulopathy (including long-term use anticoagulant). History of deep vein thrombosis, ischemic heart disease or stroke. Contraindications of tranexamic acid, floseal, or rivaroxaban. Allergy to tranexamic acid, floseal, rivaroxaban, or the excipients. History of heparin-induced thrombocytopenia (HIT). Coagulopathy or bleeding tendency caused by organ dysfunction, such as cirrhosis, bone marrow suppression etc.. Patient who have active bleeding disorder, such as intracranial hemorrhage, upper gastrointestinal bleeding, hematuria.. Patients with known allergies to materials of bovine origin.. ",
        "Annotations": [
            "Temporal 0 12--*--Preoperative",
            "Measurement 13 23--*--Hemoglobin",
            "Value 24 39--*--<U+2266>11 g/dl",
            "Condition 52 61--*--infection",
            "Condition 65 88--*--intraarticular fracture",
            "Qualifier 96 109--*--affective hip",
            "Scope 52 88--*--infection or intraarticular fracture",
            "Observation 41 48--*--History",
            "Condition 111 136--*--Renal function deficiency",
            "Measurement 138 141--*--GFR",
            "Value 142 159--*--<30 ml/min/1.73m2",
            "Scope 138 159--*--GFR <30 ml/min/1.73m2",
            "Measurement 171 183--*--liver enzyme",
            "Value 162 170--*--Elevated",
            "Measurement 185 246--*--aspartate transaminase (AST)/ alanine transaminase(ALT) level",
            "Value 251 279--*--more than twice normal range",
            "Observation 283 290--*--history",
            "Condition 294 309--*--liver cirrhosis",
            "Condition 311 334--*--impaired liver function",
            "Value 335 343--*--elevated",
            "Measurement 344 365--*--total bilirubin level",
            "Condition 371 383--*--coagulopathy",
            "Multiplier 395 408--*--long-term use",
            "Drug 409 422--*--anticoagulant",
            "Scope 395 422--*--long-term use anticoagulant",
            "Condition 436 456--*--deep vein thrombosis",
            "Condition 458 480--*--ischemic heart disease",
            "Condition 484 490--*--stroke",
            "Condition 492 509--*--Contraindications",
            "Drug 513 528--*--tranexamic acid",
            "Drug 530 537--*--floseal",
            "Drug 542 553--*--rivaroxaban",
            "Scope 513 553--*--tranexamic acid, floseal, or rivaroxaban",
            "Condition 555 562--*--Allergy",
            "Drug 566 581--*--tranexamic acid",
            "Drug 583 590--*--floseal",
            "Drug 592 603--*--rivaroxaban",
            "Drug 612 622--*--excipients",
            "Scope 566 622--*--tranexamic acid, floseal, rivaroxaban, or the excipients",
            "Condition 635 673--*--heparin-induced thrombocytopenia (HIT)",
            "Observation 624 631--*--History",
            "Condition 675 687--*--Coagulopathy",
            "Condition 691 708--*--bleeding tendency",
            "Condition 719 736--*--organ dysfunction",
            "Condition 746 755--*--cirrhosis",
            "Condition 757 780--*--bone marrow suppression",
            "Scope 746 780--*--cirrhosis, bone marrow suppression",
            "Scope 675 708--*--Coagulopathy or bleeding tendency",
            "Qualifier 804 810--*--active",
            "Condition 811 828--*--bleeding disorder",
            "Condition 838 861--*--intracranial hemorrhage",
            "Condition 863 894--*--upper gastrointestinal bleeding",
            "Condition 896 905--*--hematuria",
            "Scope 838 905--*--intracranial hemorrhage, upper gastrointestinal bleeding, hematuria",
            "Condition 928 937--*--allergies",
            "Drug 941 967--*--materials of bovine origin"
        ]
    },
    "NCT02473809_exc": {
        "Text": "Type 1 diabetes. Treatment with insulin. Body weight > 140 kg. HbA1c > 75 mmol/mol. Treatment with GLP-1 analogues, Dipeptidyl peptidase-4 inhibitors, or glitazones. Chronic kidney disease. Hepatic disease. Pancreatitis. Inflammatory bowel disease. Osteoporosis. Family or personal history of medullary thyroid carcinoma. Treatment with glucocorticoids. Hormone replacement therapy. Diabetic gastroparesis. Pregnancy or lactation. ",
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Drug 32 39--*--insulin",
            "Procedure 17 26--*--Treatment",
            "Measurement 41 52--*--Body weight",
            "Value 53 61--*--> 140 kg",
            "Measurement 63 68--*--HbA1c",
            "Value 69 82--*--> 75 mmol/mol",
            "Drug 99 114--*--GLP-1 analogues",
            "Drug 116 149--*--Dipeptidyl peptidase-4 inhibitors",
            "Drug 154 164--*--glitazones",
            "Condition 207 219--*--Pancreatitis",
            "Condition 166 188--*--Chronic kidney disease",
            "Condition 190 205--*--Hepatic disease",
            "Condition 221 247--*--Inflammatory bowel disease",
            "Condition 249 261--*--Osteoporosis",
            "Condition 293 320--*--medullary thyroid carcinoma",
            "Observation 273 289--*--personal history",
            "Observation 263 269--*--Family",
            "Scope 263 289--*--Family or personal history",
            "Drug 337 352--*--glucocorticoids",
            "Procedure 322 331--*--Treatment",
            "Procedure 354 381--*--Hormone replacement therapy",
            "Condition 383 405--*--Diabetic gastroparesis",
            "Condition 407 416--*--Pregnancy",
            "Condition 420 429--*--lactation"
        ]
    },
    "NCT02745704_inc": {
        "Annotations": [
            "Condition 0 3--*--CHB",
            "Drug 30 33--*--NAs",
            "Temporal 38 58--*--more than 12 months.",
            "Measurement 60 81--*--Hepatitis B e antigen",
            "Value 90 98--*--negative",
            "Measurement 103 113--*--anti-HBeAg",
            "Value 114 122--*--positive",
            "Measurement 83 88--*--HBeAg",
            "Measurement 125 152--*--Hepatitis B surface antigen",
            "Measurement 154 159--*--HBsAg",
            "Value 161 169--*--positive",
            "Value 174 185--*--<1500 IU/mL",
            "Measurement 188 209--*--Hepatitis B virus DNA",
            "Value 210 224--*--not detectable"
        ],
        "Text": "CHB patients who had received NAs for more than 12 months.. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL.. Hepatitis B virus DNA not detectable(Roche Cobas).. "
    },
    "NCT00867958_inc": {
        "Text": "1. Patient is over 18 years old. . 2. Patient is scheduled for a non-emergency procedure. . 3. Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures. . ",
        "Annotations": [
            "Value 14 31--*--over 18 years old",
            "Person 22 31--*--years old",
            "Procedure 64 87--*--non-emergency procedure",
            "Qualifier 64 77--*--non-emergency",
            "Mood 48 57--*--scheduled",
            "Post-eligibility 90 210--*--3. Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures."
        ]
    },
    "NCT01807897_exc": {
        "Annotations": [
            "Observation 0 15--*--Hospitalization",
            "Condition 20 42--*--acute decompensated HF",
            "Temporal 43 66--*--within previous 30 days",
            "Observation 68 83--*--Hospitalization",
            "Condition 88 109--*--myocardial infarction",
            "Procedure 113 128--*--cardiac surgery",
            "Temporal 129 152--*--within previous 90 days",
            "Scope 88 128--*--myocardial infarction or cardiac surgery",
            "Device 168 198--*--left ventricular assist device",
            "Procedure 211 232--*--heart transplantation",
            "Condition 252 264--*--hypertension",
            "Qualifier 234 251--*--Poorly controlled",
            "Condition 296 304--*--diabetes",
            "Qualifier 278 295--*--Poorly controlled",
            "Measurement 306 311--*--HbA1c",
            "Value 312 317--*--> 9.0",
            "Condition 327 340--*--renal failure",
            "Qualifier 320 326--*--Severe",
            "Measurement 346 382--*--estimated glomerular filtration rate",
            "Value 383 393--*--<30 ml/min",
            "Condition 401 407--*--stroke",
            "Condition 413 434--*--functional impairment",
            "Non-query-able 438 595--*--other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records",
            "Condition 604 620--*--chronic insomnia",
            "Observation 642 656--*--sleep duration",
            "Value 657 665--*--<4 hours",
            "Condition 674 692--*--daytime sleepiness",
            "Measurement 705 729--*--Epworth Sleepiness Scale",
            "Value 730 748--*--score 18 or higher",
            "Non-query-able 752 856--*--a report of falling asleep driving during the previous year, and deemed a safety risk by study physician",
            "Measurement 872 896--*--oxyhemoglobin saturation",
            "Qualifier 864 871--*--resting",
            "Qualifier 858 863--*--Awake",
            "Value 897 901--*--<89%",
            "Condition 903 912--*--Pregnancy",
            "Non-query-able 914 1005--*--Smoking by subject or other person in the subject's bedroom, or other open flame in bedroom",
            "Device 1024 1055--*--positive airway pressure device",
            "Device 1081 1114--*--bi-level positive airway pressure",
            "Device 1067 1077;1099 1114--*--continuous airway pressure",
            "Device 1118 1144--*--adaptive servo-ventilation",
            "Procedure 1149 1176--*--supplemental oxygen therapy",
            "Scope 1067 1144--*--continuous or bi-level positive airway pressure or adaptive servo-ventilation"
        ],
        "Text": "Hospitalization for acute decompensated HF within previous 30 days. Hospitalization for myocardial infarction or cardiac surgery within previous 90 days. Presence of a left ventricular assist device. History of heart transplantation. Poorly controlled hypertension (>170/>110). Poorly controlled diabetes (HbA1c > 9.0). Severe renal failure with estimated glomerular filtration rate <30 ml/min. Prior stroke with functional impairment or other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records. Severe chronic insomnia, with reported usual sleep duration <4 hours. Severe daytime sleepiness, defined as Epworth Sleepiness Scale score 18 or higher or a report of falling asleep driving during the previous year, and deemed a safety risk by study physician. Awake resting oxyhemoglobin saturation <89%. Pregnancy. Smoking by subject or other person in the subject's bedroom, or other open flame in bedroom. Current use of a positive airway pressure device (including continuous or bi-level positive airway pressure or adaptive servo-ventilation) or supplemental oxygen therapy. "
    },
    "NCT00305097_exc": {
        "Annotations": [
            "Condition 113 122--*--pregnancy",
            "Observation 126 139--*--breastfeeding",
            "Condition 141 158--*--diabetes mellitus",
            "Condition 160 173--*--heart disease",
            "Condition 175 181--*--stroke",
            "Condition 183 195--*--hypertension",
            "Condition 197 220--*--malabsorption syndromes",
            "Condition 222 226--*--GERD",
            "Observation 230 240--*--history of",
            "Condition 241 246--*--ulcer",
            "Condition 14 56--*--illness that may affect the study outcomes",
            "Condition 14 26;60 104--*--illness that would make participation potentially harmful",
            "Scope 113 246--*--pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer",
            "Scope 14 104--*--illness that may affect the study outcomes or would make participation potentially harmful",
            "Measurement 299 315--*--hepatic function",
            "Value 290 298--*--Abnormal",
            "Measurement 317 336--*--liver function test",
            "Value 337 361--*--> twice the normal range",
            "Measurement 373 387--*--renal function",
            "Value 364 372--*--abnormal",
            "Measurement 389 399--*--creatinine",
            "Value 400 411--*--> 1.1 mg/dl",
            "Measurement 414 436--*--fasting plasma glucose",
            "Value 437 458--*--in the diabetic range",
            "Value 460 473--*-->/= 126 mg/dl",
            "Measurement 479 493--*--blood pressure",
            "Value 494 507--*--> 140/90 mmHg",
            "Condition 518 528--*--alcoholism",
            "Condition 532 542--*--drug abuse",
            "Drug 553 604--*--medications that could interfere with the treatment",
            "Drug 615 630--*--bronchodilators",
            "Drug 632 653--*--quinolone antibiotics",
            "Drug 655 683--*--monoamine oxidase inhibitors",
            "Drug 685 696--*--anxiolytics",
            "Drug 698 708--*--ranitidine",
            "Drug 710 725--*--corticosteroids",
            "Drug 727 741--*--growth hormone",
            "Drug 743 760--*--antihypertensives",
            "Scope 615 760--*--bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, antihypertensives",
            "Observation 272 287--*--medical history"
        ],
        "Text": "Any condition/illness that may affect the study outcomes or would make participation potentially harmful such as pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer, according to a detailed medical history. . Abnormal hepatic function (liver function test > twice the normal range), abnormal renal function (creatinine > 1.1 mg/dl), fasting plasma glucose in the diabetic range (>/= 126 mg/dl), or blood pressure > 140/90 mmHg. . Present alcoholism or drug abuse or use of medications that could interfere with the treatment including bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, antihypertensives.       .     . "
    },
    "NCT02035904_inc": {
        "Text": "F; age 18 to 70. American Society of Anesthesiologists (ASA) I e II;. breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection;. immediate sub-pectoral prosthetic reconstruction;. signed informed consent.. ",
        "Annotations": [
            "Person 0 1--*--F",
            "Person 3 6--*--age",
            "Value 7 15--*--18 to 70",
            "Measurement 17 60--*--American Society of Anesthesiologists (ASA)",
            "Value 61 67--*--I e II",
            "Condition 70 83--*--breast cancer",
            "Measurement 86 89--*--DIN",
            "Value 90 95--*--2 e 3",
            "Measurement 99 102--*--LIN",
            "Value 103 112--*--2 e 3 sec",
            "Condition 139 164--*--nipple-sparing mastectomy",
            "Mood 125 138--*--scheduled for",
            "Condition 166 183--*--simple mastectomy",
            "Condition 185 208--*--skin-sparing mastectomy",
            "Condition 210 234--*--skin-reducing mastectomy",
            "Condition 238 254--*--lymphnode biopsy",
            "Condition 259 278--*--axillary dissection",
            "Scope 86 123--*--DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli",
            "Procedure 291 329--*--sub-pectoral prosthetic reconstruction",
            "Qualifier 281 290--*--immediate",
            "Non-query-able 332 355--*--signed informed consent"
        ]
    },
    "NCT02894645_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--less than one year",
            "Value 30 61--*--greater than/equals to 18 years",
            "Person 26 29--*--age",
            "Temporal 63 71--*--Previous",
            "Procedure 72 81--*--treatment",
            "Drug 87 103--*--cytotoxic agents",
            "Drug 107 125--*--high-dose steroids",
            "Scope 87 125--*--cytotoxic agents or high-dose steroids",
            "Condition 127 157--*--Mixed phenotype acute leukemia",
            "Condition 159 163--*--MPAL",
            "Condition 166 169--*--ALL",
            "Qualifier 173 182--*--secondary",
            "Condition 183 193--*--malignancy",
            "Scope 173 193--*--secondary malignancy",
            "Condition 195 203;213 227--*--Abnormal liver function",
            "Condition 195 209;219 227--*--Abnormal renal function",
            "Observation 229 248--*--Doubtful compliance",
            "Observation 252 291--*--unable to afford full course of therapy"
        ],
        "Text": "Age less than one year or age greater than/equals to 18 years. Previous treatment with cytotoxic agents or high-dose steroids. Mixed phenotype acute leukemia (MPAL). ALL as secondary malignancy. Abnormal renal or liver function. Doubtful compliance or unable to afford full course of therapy. "
    },
    "NCT02892968_exc": {
        "Text": "ED physicians who work casually (less than 0.25 Full Time Equivalent) . ED Physicians who are routinely using U/S guided RA for hip fracture patients, or decline participation in the trial. . Patients' age less than 65 years; . Patients who are delirious on initial assessment by ED physician or severe dementia . Patients with communication problems (critically ill, unconscious, language barrier despite use of secure telephone-based translation service) . Patients with allergies to narcotics or local anesthetic; or anticoagulant use (e.g. warfarin, dabigatran, rivaroxaban). . Patients with hip fractures not requiring surgery (e.g. greater trochanter avulsion) will also be excluded.       .     . ",
        "Annotations": [
            "Non-query-able 0 69--*--ED physicians who work casually (less than 0.25 Full Time Equivalent)",
            "Non-query-able 71 188--*--ED Physicians who are routinely using U/S guided RA for hip fracture patients, or decline participation in the trial.",
            "Value 204 222--*--less than 65 years",
            "Person 200 203--*--age",
            "Condition 242 251--*--delirious",
            "Temporal 252 273--*--on initial assessment",
            "Reference_point 255 273--*--initial assessment",
            "Condition 300 308--*--dementia",
            "Qualifier 293 299--*--severe",
            "Condition 324 346--*--communication problems",
            "Undefined_semantics 324 346--*--communication problems",
            "Condition 348 362--*--critically ill",
            "Condition 364 375--*--unconscious",
            "Condition 377 393--*--language barrier",
            "Scope 348 393--*--critically ill, unconscious, language barrier",
            "Condition 468 477--*--allergies",
            "Drug 481 490--*--narcotics",
            "Drug 494 510--*--local anesthetic",
            "Scope 481 510--*--narcotics or local anesthetic",
            "Drug 515 528--*--anticoagulant",
            "Drug 539 547--*--warfarin",
            "Drug 549 559--*--dabigatran",
            "Drug 561 572--*--rivaroxaban",
            "Scope 539 572--*--warfarin, dabigatran, rivaroxaban",
            "Condition 590 603--*--hip fractures",
            "Procedure 618 625--*--surgery",
            "Qualifier 608 625--*--requiring surgery",
            "Negation 604 607--*--not",
            "Condition 632 659--*--greater trochanter avulsion",
            "Undefined_semantics 590 625--*--hip fractures not requiring surgery",
            "Scope 590 625--*--hip fractures not requiring surgery"
        ]
    },
    "NCT00343668_inc": {
        "Annotations": [
            "Condition 35 60--*--adenocarcinoma of stomach",
            "Qualifier 22 34--*--unresectable",
            "Measurement 0 14--*--Pathologically",
            "Value 15 21--*--proven",
            "Condition 96 103--*--disease",
            "Qualifier 67 95--*--uni-dimensionally measurable",
            "Measurement 114 130--*--longest diameter",
            "Procedure 139 159--*--conventional CT scan",
            "Value 105 113;131 135--*--at least 2 cm",
            "Procedure 161 166--*--x-ray",
            "Procedure 170 190--*--physical examination",
            "Procedure 202 216--*--spiral CT scan",
            "Measurement 114 130--*--longest diameter",
            "Value 105 113;195 198--*--at least 1cm",
            "Scope 105 216--*--at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan",
            "Person 219 222--*--Age",
            "Value 223 241--*--18 to 70 years old",
            "Measurement 243 268--*--Estimated life expectancy",
            "Value 272 290--*--more than 3 months",
            "Measurement 292 315--*--ECOG performance status",
            "Value 319 329--*--2 or lower",
            "Measurement 340 360--*--bone marrow function",
            "Value 331 339--*--Adequate",
            "Measurement 361 392--*--absolute neutrophil count [ANC]",
            "Value 393 402--*--\u22651,500/\u00b5L",
            "Measurement 404 414--*--hemoglobin",
            "Value 415 424--*--\u22659.0 g/dL",
            "Measurement 429 438--*--platelets",
            "Value 439 450--*--\u2265100,000/\u00b5L",
            "Scope 361 450--*--absolute neutrophil count [ANC] \u22651,500/\u00b5L, hemoglobin \u22659.0 g/dL,and platelets \u2265100,000/\u00b5L",
            "Measurement 462 477--*--kidney function",
            "Value 453 461--*--Adequate",
            "Measurement 479 495--*--serum creatinine",
            "Value 496 507--*--< 1.5 mg/dL",
            "Measurement 519 533--*--liver function",
            "Value 510 518--*--Adequate",
            "Measurement 535 556--*--serum total bilirubin",
            "Value 557 595--*--< 2 times the upper normal limit (UNL)",
            "Measurement 597 623--*--serum transaminases levels",
            "Value 624 632;679 682--*--<3 times UNL",
            "Condition 661 677--*--liver metastasis",
            "Value 634 642;679 682--*--<5 times UNL",
            "Scope 624 682--*--<3 times [<5 times for patients with liver metastasis] UNL",
            "Scope 535 682--*--serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL",
            "Procedure 694 706--*--chemotherapy",
            "Temporal 688 693--*--prior",
            "Negation 685 687--*--No",
            "Procedure 717 738--*--adjuvant chemotherapy",
            "Temporal 711 716--*--prior",
            "Temporal 748 783--*--at least 6 months before enrollment",
            "Procedure 809 830--*--adjuvant chemotherapy",
            "Temporal 803 808--*--prior",
            "Drug 836 848--*--capecitabine",
            "Drug 852 855--*--S-1",
            "Drug 859 881--*--camptothecin analogues",
            "Negation 886 894--*--excluded",
            "Procedure 906 923--*--radiation therapy",
            "Temporal 928 962--*--at least 4 weeks before enrollment",
            "Negation 897 899--*--No",
            "Temporal 900 905--*--prior",
            "Reference_point 773 783--*--enrollment",
            "Negation 784 795--*--was allowed",
            "Scope 711 795--*--prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed",
            "Reference_point 952 962--*--enrollment"
        ],
        "Text": "Pathologically proven unresectable adenocarcinoma of stomach . With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan) . Age 18 to 70 years old . Estimated life expectancy of more than 3 months . ECOG performance status of 2 or lower . Adequate bone marrow function(absolute neutrophil count [ANC] \u22651,500/\u00b5L, hemoglobin \u22659.0 g/dL,and platelets \u2265100,000/\u00b5L) . Adequate kidney function (serum creatinine < 1.5 mg/dL) . Adequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL) . No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. (but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded) . No prior radiation therapy for at least 4 weeks before enrollment in the study . "
    },
    "NCT03387059_exc": {
        "Text": "Clinically significant systemic disease (such as diabetes, metabolic syndrome, immunological diseases, diagnosed thrombophilia, porphyria, or any other medical condition requiring the use of low-molecular weight heparin therapy). Polycystic ovary syndrome (PCOS) according to Rotterdam Consensus Criteria (European Society of Human Reproduction and Embryology [ESHRE]/American Society for Reproductive Medicine [ASRM], 2003). Poor ovarian response (POR) according to the European Society of Human Reproduction and Embryology (ESHRE) Criteria. RIF (repeated implantation failure), defined as greater than or equals to (>=) 2 previous failed embryo transfers. Endometriosis III-IV stage or adenomyosis. Clinically significant findings on exam or ultrasound, such as salpingitis, hydrosalpynx or evidence of ovarian cysts. Known hypersensitivity to any of the components of the solution. Known hypersensitivity to vaginal progesterone or its excipients. Other protocol defined exclusion criteria could apply. ",
        "Annotations": [
            "Condition 23 39--*--systemic disease",
            "Qualifier 0 22--*--Clinically significant",
            "Condition 49 57--*--diabetes",
            "Condition 59 77--*--metabolic syndrome",
            "Condition 79 101--*--immunological diseases",
            "Condition 103 126--*--diagnosed thrombophilia",
            "Condition 128 137--*--porphyria",
            "Condition 152 169--*--medical condition",
            "Drug 191 219--*--low-molecular weight heparin",
            "Scope 49 227--*--diabetes, metabolic syndrome, immunological diseases, diagnosed thrombophilia, porphyria, or any other medical condition requiring the use of low-molecular weight heparin therapy",
            "Scope 0 39--*--Clinically significant systemic disease",
            "Condition 230 262--*--Polycystic ovary syndrome (PCOS)",
            "Qualifier 276 304--*--Rotterdam Consensus Criteria",
            "Qualifier 306 423--*--European Society of Human Reproduction and Embryology [ESHRE]/American Society for Reproductive Medicine [ASRM], 2003",
            "Condition 426 453--*--Poor ovarian response (POR)",
            "Qualifier 471 541--*--European Society of Human Reproduction and Embryology (ESHRE) Criteria",
            "Condition 543 578--*--RIF (repeated implantation failure)",
            "Value 591 623--*--greater than or equals to (>=) 2",
            "Measurement 624 656--*--previous failed embryo transfers",
            "Condition 658 671--*--Endometriosis",
            "Qualifier 672 684--*--III-IV stage",
            "Condition 688 699--*--adenomyosis",
            "Qualifier 701 723--*--Clinically significant",
            "Procedure 736 740--*--exam",
            "Procedure 744 754--*--ultrasound",
            "Condition 764 775--*--salpingitis",
            "Condition 777 789--*--hydrosalpynx",
            "Condition 805 818--*--ovarian cysts",
            "Mood 793 801--*--evidence",
            "Scope 736 754--*--exam or ultrasound",
            "Observation 724 732--*--findings",
            "Scope 701 754--*--Clinically significant findings on exam or ultrasound",
            "Scope 764 818--*--salpingitis, hydrosalpynx or evidence of ovarian cysts",
            "Condition 826 842--*--hypersensitivity",
            "Non-representable 820 884--*--Known hypersensitivity to any of the components of the solution",
            "Condition 891 907--*--hypersensitivity",
            "Drug 911 931--*--vaginal progesterone",
            "Drug 939 949--*--excipients",
            "Drug 857 883--*--components of the solution",
            "Non-representable 951 1004--*--Other protocol defined exclusion criteria could apply"
        ]
    },
    "NCT02445339_exc": {
        "Annotations": [
            "Qualifier 0 6--*--Active",
            "Condition 7 24--*--opioid dependence",
            "Qualifier 26 31--*--Acute",
            "Qualifier 35 42--*--chronic",
            "Condition 43 47--*--pain",
            "Scope 26 42--*--Acute or chronic",
            "Procedure 58 74--*--opioid treatment",
            "Condition 76 94--*--Acute liver injury",
            "Measurement 96 133--*--liver aminotransferase concentrations",
            "Value 134 168--*-->5 times the upper limit of normal",
            "Scope 96 168--*--liver aminotransferase concentrations >5 times the upper limit of normal",
            "Condition 171 187--*--Health condition",
            "Qualifier 188 219--*--considered unsafe for inclusion",
            "Non-query-able 221 267--*--at discretion of PI and/or attending physician",
            "Observation 290 312--*--willingness to consent",
            "Negation 270 277--*--Lack of",
            "Observation 278 286;302 312--*--capacity to consent",
            "Scope 278 312--*--capacity or willingness to consent",
            "Condition 355 373--*--alcohol dependence",
            "Procedure 335 350--*--pharmacotherapy",
            "Temporal 314 323--*--Currently",
            "Negation 375 388--*--not including",
            "Procedure 389 398--*--treatment",
            "Condition 402 435--*--acute alcohol withdrawal syndrome",
            "Temporal 438 446--*--Previous",
            "Qualifier 447 458--*--significant",
            "Condition 459 475--*--adverse reaction",
            "Drug 479 489--*--naltrexone",
            "Drug 493 500--*--diluent",
            "Scope 479 500--*--naltrexone or diluent",
            "Condition 502 510--*--Pregnant",
            "Condition 512 519--*--nursing",
            "Negation 524 527--*--not",
            "Procedure 555 568--*--birth control",
            "Qualifier 534 551--*--effective methods",
            "Person 570 579--*--Prisoners",
            "Qualifier 595 630--*--Office of Human Research Protection",
            "Temporal 632 657--*--at the time of enrollment",
            "Reference_point 635 657--*--the time of enrollment",
            "Non-representable 692 866--*--However, subjects who become prisoners after being enrolled will be included and not be withdrawn from the study. Patients on parole or probation are eligible for enrollment."
        ],
        "Text": "Active opioid dependence. Acute or chronic pain requiring opioid treatment. Acute liver injury (liver aminotransferase concentrations >5 times the upper limit of normal). Health condition considered unsafe for inclusion (at discretion of PI and/or attending physician). Lack of capacity or willingness to consent. Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome). Previous significant adverse reaction to naltrexone or diluent. Pregnant, nursing, or not using effective methods of birth control. Prisoners (as defined by Office of Human Research Protection) at the time of enrollment ARE NOT ELIGIBLE for study entry. However, subjects who become prisoners after being enrolled will be included and not be withdrawn from the study. Patients on parole or probation are eligible for enrollment.. "
    },
    "NCT02525991_inc": {
        "Text": "Male and female patients between the ages of 18-65 years, inclusive. Patients (or legal representative) willing and able to provide written Informed Consent Form.. Psychiatric patients already diagnosed of schizophrenia or bipolar disorder, according to the Diagnostic and Statistical Manual of Mental Disorders- IV, Diagnostic and Statistical Manual of Mental Disorders- V or International Code of Disease criteria.. Patients with an on-going agitation episode, or with a previous one within the 6 months prior to screening, attended and managed in the hospital setting.. Previously treated with ADASUVE\u00ae with a positive outcome (responders) according to (CGI-I) scale (defined as having a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation). Patients free of active respiratory disease such as acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (asthma, chronic obstructive pulmonary disease or emphysema).. Requirement of family or other caregiver support at study investigator criteria (defined as a patient's relative or caregiver (male or female) = 80 year old, who spend = 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures).. Availability of patient's medical records data about the previous treatment with ADASUVE\u00ae at hospital setting.. If a female is of childbearing potential and sexually active (except if female is surgically sterile or post-menopausal with history of no menses for at least 24 months), patient must be non-lactating and non-pregnant (with a negative pregnancy test result at baseline visit) and have to agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study.. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 37 41--*--ages",
            "Value 45 56--*--18-65 years",
            "Informed_consent 69 161--*--Patients (or legal representative) willing and able to provide written Informed Consent Form",
            "Condition 206 219--*--schizophrenia",
            "Condition 223 239--*--bipolar disorder",
            "Measurement 258 315--*--Diagnostic and Statistical Manual of Mental Disorders- IV",
            "Measurement 317 373--*--Diagnostic and Statistical Manual of Mental Disorders- V",
            "Measurement 377 415--*--International Code of Disease criteria",
            "Scope 206 240--*--schizophrenia or bipolar disorder,",
            "Scope 258 415--*--Diagnostic and Statistical Manual of Mental Disorders- IV, Diagnostic and Statistical Manual of Mental Disorders- V or International Code of Disease criteria",
            "Condition 444 461--*--agitation episode",
            "Temporal 486 524--*--within the 6 months prior to screening",
            "Reference_point 515 524--*--screening",
            "Drug 597 604--*--ADASUVE",
            "Measurement 691 702--*--CGI-I score",
            "Value 706 712--*--1 or 2",
            "Temporal 716 763--*--2 hours after administration of the inhalation)",
            "Reference_point 730 763--*--administration of the inhalation)",
            "Negation 774 778--*--free",
            "Condition 789 808--*--respiratory disease",
            "Qualifier 782 788--*--active",
            "Condition 817 840--*--acute respiratory signs",
            "Condition 817 834;841 849--*--acute respiratory symptoms",
            "Condition 857 865--*--wheezing",
            "Condition 882 897--*--airways disease",
            "Qualifier 875 881--*--active",
            "Condition 899 905--*--asthma",
            "Condition 907 944--*--chronic obstructive pulmonary disease",
            "Condition 948 957--*--emphysema",
            "Scope 899 957--*--asthma, chronic obstructive pulmonary disease or emphysema",
            "Scope 817 866--*--acute respiratory signs/symptoms (e.g., wheezing)",
            "Non-query-able 961 1342--*--Requirement of family or other caregiver support at study investigator criteria (defined as a patient's relative or caregiver (male or female) = 80 year old, who spend = 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures",
            "Non-query-able 1346 1455--*--Availability of patient's medical records data about the previous treatment with ADASUVE\u00ae at hospital setting",
            "Pregnancy_considerations 1458 1885--*--If a female is of childbearing potential and sexually active (except if female is surgically sterile or post-menopausal with history of no menses for at least 24 months), patient must be non-lactating and non-pregnant (with a negative pregnancy test result at baseline visit) and have to agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study"
        ]
    },
    "NCT01064752_inc": {
        "Text": "1. HIV infection with plasma and CSF HIV RNA concentrations (using Roche Amplicor assay) > 1,000 copies/ mL (available after baseline LP). . 2. Off antiretroviral therapy (ART) for > 6 weeks before the study and no plans to begin treatment for the study duration. (The decision of whether or not a subject takes antiretroviral therapy will be made by the subject in consultation with his/her primary care provider prior to screening for this study.) . 3. Predicted adherence to the medication. . 4. Capable of providing informed consent. . 5. > 18 years old . 6. CD4 cell counts >150 cells/\u03bcL (though likely most, if not all, will be >250 cells/\u03bcL). . 7. When available, subjects will be screened for stability of blood CD4 and HIV RNA levels. . ",
        "Annotations": [
            "Condition 3 16--*--HIV infection",
            "Measurement 22 28;45 58--*--plasma concentration",
            "Measurement 33 58--*--CSF HIV RNA concentration",
            "Procedure 67 87--*--Roche Amplicor assay",
            "Value 89 107--*--> 1,000 copies/ mL",
            "Procedure 147 175--*--antiretroviral therapy (ART)",
            "Condition 143 175--*--Off antiretroviral therapy (ART)",
            "Temporal 180 206--*--> 6 weeks before the study",
            "Reference_point 197 206--*--the study",
            "Mood 214 228--*--plans to begin",
            "Procedure 229 238--*--treatment",
            "Temporal 239 261--*--for the study duration",
            "Reference_point 247 252--*--study",
            "Negation 211 213--*--no",
            "Context_Error 229 238--*--treatment",
            "Non-representable 453 491--*--Predicted adherence to the medication.",
            "Post-eligibility 496 534--*--Capable of providing informed consent.",
            "Value 541 549--*--18 years",
            "Person 550 553--*--old",
            "Measurement 558 573--*--CD4 cell counts",
            "Value 574 587--*-->150 cells/\u03bcL",
            "Value 629 642--*-->250 cells/\u03bcL",
            "Not_a_criteria 649 737--*--When available, subjects will be screened for stability of blood CD4 and HIV RNA levels."
        ]
    },
    "NCT02515773_inc": {
        "Text": "Inpatient or outpatient age 8-19 years inclusive; participants must live with a parent, guardian, or caregiver;. Fluent in English;. Diagnosed or told by a clinician that they have any of the following bipolar spectrum disorders (BSD): bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV);. Body mass index >85%ile for age and sex by standard growth charts;. Received a new or ongoing prescription for at least one SGA (i.e., olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine) that is not prescribed as a PRN medication;. ",
        "Annotations": [
            "Person 0 9--*--Inpatient",
            "Person 13 23--*--outpatient",
            "Person 24 27--*--age",
            "Value 28 38--*--8-19 years",
            "Non-query-able 113 131--*--Fluent in English;",
            "Non-query-able 50 110--*--participants must live with a parent, guardian, or caregiver",
            "Condition 202 228--*--bipolar spectrum disorders",
            "Condition 230 233--*--BSD",
            "Condition 236 245--*--bipolar I",
            "Condition 247 257--*--bipolar II",
            "Condition 259 300--*--unspecified bipolar and related disorders",
            "Condition 302 340--*--Disruptive Mood Dysregulation Disorder",
            "Condition 342 346--*--DMDD",
            "Condition 349 369--*--cyclothymic disorder",
            "Condition 371 416--*--other specified bipolar and related disorders",
            "Condition 429 466--*--mood disorder not otherwise specified",
            "Scope 236 466--*--bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified",
            "Measurement 510 525--*--Body mass index",
            "Value 526 533--*-->85%ile",
            "Multiplier 621 633--*--at least one",
            "Drug 634 637--*--SGA",
            "Drug 645 655--*--olanzapine",
            "Drug 657 666--*--clozapine",
            "Drug 668 679--*--risperidone",
            "Drug 681 691--*--quetiapine",
            "Drug 693 705--*--aripiprazole",
            "Drug 707 718--*--ziprasidone",
            "Drug 720 731--*--iloperidone",
            "Drug 733 743--*--lurasidone",
            "Drug 745 757--*--paliperidone",
            "Drug 759 772--*--brexpiprazole",
            "Drug 776 787--*--cariprazine",
            "Scope 645 787--*--olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine"
        ]
    },
    "NCT02203019_exc": {
        "Annotations": [
            "Condition 25 34--*--allergies",
            "Drug 38 46--*--propofol",
            "Drug 48 63--*--dexmedetomidine",
            "Drug 65 73--*--fentanyl",
            "Observation 75 79--*--eggs",
            "Observation 83 95--*--egg products",
            "Observation 100 103--*--soy",
            "Observation 107 119--*--soy products",
            "Scope 38 119--*--propofol, dexmedetomidine, fentanyl, eggs or egg products, or soy or soy products",
            "Measurement 124 134--*--heart rate",
            "Value 135 160--*--less than 50 beats/minute",
            "Condition 177 191--*--AV heart block",
            "Qualifier 164 171--*--grade 2",
            "Qualifier 164 169;175 176--*--grade 3",
            "Scope 164 176--*--grade 2 or 3",
            "Measurement 193 215--*--Mean arterial pressure",
            "Value 216 233--*--less than 55 mmHg",
            "Procedure 254 273--*--fluid resuscitation",
            "Procedure 278 289--*--vasopressor",
            "Measurement 308 326--*--triglyceride level",
            "Value 327 338--*--> 400 mg/dl"
        ],
        "Text": "Patients with documented allergies to propofol, dexmedetomidine, fentanyl, eggs or egg products, or soy or soy products.. A heart rate less than 50 beats/minute or grade 2 or 3 AV heart block. Mean arterial pressure less than 55 mmHg despite appropriate fluid resuscitation and vasopressor support.. Current triglyceride level > 400 mg/dl. "
    },
    "NCT00343668_exc": {
        "Annotations": [
            "Condition 22 36--*--adenocarcinoma",
            "Condition 6 11--*--tumor",
            "Condition 38 77--*--Central nervous system (CNS) metastases",
            "Procedure 87 96--*--radiation",
            "Condition 101 115--*--CNS metastases",
            "Condition 117 143--*--Gastric outlet obstruction",
            "Condition 147 169--*--intestinal obstruction",
            "Condition 183 208--*--gastrointestinal bleeding",
            "Observation 171 182--*--Evidence of",
            "Condition 226 238--*--bony lesions",
            "Value 242 250--*--the sole",
            "Qualifier 251 268--*--evaluable disease",
            "Observation 290 300--*--history of",
            "Condition 301 309--*--neoplasm",
            "Condition 321 335--*--stomach cancer",
            "Condition 367 391--*--non-melanoma skin cancer",
            "Condition 395 432--*--in situ carcinoma of the cervix uteri",
            "Procedure 359 366--*--treated",
            "Qualifier 348 358--*--curatively",
            "Scope 367 432--*--non-melanoma skin cancer or in situ carcinoma of the cervix uteri",
            "Condition 434 442--*--Pregnant",
            "Condition 446 455--*--lactating",
            "Person 456 461--*--women",
            "Condition 472 494--*--childbearing potential",
            "Person 463 468--*--women",
            "Procedure 518 531--*--contraception",
            "Negation 495 508--*--not employing",
            "Condition 539 554--*--serious illness",
            "Condition 558 576--*--medical conditions",
            "Condition 578 602--*--Unstable cardiac disease",
            "Procedure 611 620--*--treatment",
            "Condition 622 643--*--myocardial infarction",
            "Temporal 644 680--*--within 6 months prior to study entry",
            "Condition 705 715;731 740--*--neurologic disorders",
            "Condition 719 740--*--psychiatric disorders",
            "Condition 751 759--*--dementia",
            "Condition 763 771--*--seizures",
            "Scope 751 771--*--dementia or seizures",
            "Scope 705 740--*--neurologic or psychiatric disorders",
            "Observation 682 689--*--History",
            "Condition 793 802--*--infection",
            "Qualifier 780 792--*--uncontrolled",
            "Temporal 773 779--*--Active",
            "Condition 810 817;829 847--*--serious medical conditions",
            "Observation 871 908--*--ability of the patient to participate",
            "Drug 963 980--*--experimental drug",
            "Temporal 923 934--*--Concomitant",
            "Procedure 1017 1029--*--chemotherapy",
            "Procedure 1031 1047--*--hormonal therapy",
            "Procedure 1052 1065--*--immunotherapy",
            "Temporal 1005 1016--*--concomitant",
            "Scope 1017 1065--*--chemotherapy, hormonal therapy, or immunotherapy",
            "Drug 1084 1094--*--medication",
            "Drug 1079 1083--*--drug",
            "Temporal 1067 1078--*--concomitant",
            "Scope 1079 1094--*--drug medication",
            "Drug 1153 1161--*--Warfarin",
            "Drug 1163 1176--*--phenprocoumon",
            "Measurement 1187 1204--*--bleeding tendency",
            "Measurement 1218 1250--*--blood concentration of phenytoin",
            "Value 1209 1217--*--Increase",
            "Drug 1256 1266--*--sorivudine",
            "Drug 1335 1346--*--allopurinol",
            "Value 1178 1186--*--increase",
            "Drug 1314 1330--*--fluoropyrimidine",
            "Scope 472 531--*--childbearing potential not employing adequate contraception",
            "Non-representable 1178 1204--*--increase bleeding tendency",
            "Non-representable 1209 1250--*--Increase blood concentration of phenytoin",
            "Non-representable 1096 1148--*--The following drugs cause drug interaction with S-1.",
            "Negation 310 320--*--other than",
            "Negation 337 347--*--except for",
            "Negation 0 5--*--Other"
        ],
        "Text": "Other tumor type than adenocarcinoma . Central nervous system (CNS) metastases or prior radiation for CNS metastases . Gastric outlet obstruction or intestinal obstruction . Evidence of gastrointestinal bleeding . The patient has bony lesions as the sole evaluable disease. . Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri . Pregnant or lactating women, women of childbearing potential not employing adequate contraception . Other serious illness or medical conditions . Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry . History of significant neurologic or psychiatric disorders including dementia or seizures . Active uncontrolled infection . Other serious underlying medical conditions which could impair the ability of the patient to participate in the study . Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy . concomitant drug medication; The following drugs cause drug interaction with S-1. . i. Warfarin, phenprocoumon: increase bleeding tendency ii. Increase blood concentration of phenytoin iii. sorivudine: inhibit DPD -> increase toxicity according to fluoropyrimidine iv. allopurinol : decrease activity of S-1       .     . "
    },
    "NCT02445339_inc": {
        "Annotations": [
            "Observation 0 7;19 27--*--English speaking",
            "Observation 11 27--*--Spanish speaking",
            "Visit 30 50--*--Emergency Department",
            "Person 60 64--*--Aged",
            "Value 65 70--*--18-80",
            "Multiplier 81 83--*-->4",
            "Visit 84 111--*--emergency department visits",
            "Temporal 112 128--*--within 12 months",
            "Temporal 147 163--*--12-month periods",
            "Multiplier 133 146--*--2 consecutive",
            "Person 217 229--*--incarcerated",
            "Person 233 250--*--institutionalized",
            "Scope 217 250--*--incarcerated or institutionalized",
            "Temporal 187 213--*--extended by up to 6 months",
            "Qualifier 273 335--*--Diagnostic and Statistical Manual version IV (DSM-IV) criteria",
            "Condition 340 358--*--alcohol dependence",
            "Qualifier 364 378--*--DSM-V criteria",
            "Condition 383 403--*--alcohol use disorder",
            "Qualifier 405 411--*--severe",
            "Multiplier 419 431--*--\u22652 days/week",
            "Condition 435 449--*--heavy drinking",
            "Value 451 453--*-->4",
            "Measurement 454 464--*--drinks/day",
            "Observation 485 501--*--informed consent",
            "Mood 467 484--*--Capable of giving"
        ],
        "Text": "English or Spanish speaking*. Emergency Department patient. Aged 18-80. Have had >4 emergency department visits within 12 months for 2 consecutive 12-month periods. Period of time can be extended by up to 6 months if incarcerated or institutionalized for \u2265 6 months.. Meet Diagnostic and Statistical Manual version IV (DSM-IV) criteria for alcohol dependence or & DSM-V criteria for alcohol use disorder, severe.. Have \u22652 days/week of heavy drinking (>4 drinks/day). Capable of giving informed consent.. "
    },
    "NCT03387059_inc": {
        "Text": "All infertile women treated with intracytoplasmic sperm injection (ICSI)/Fertilization in Vitro and Embryo Transfer (FIVET). Less than or equal to (<=) 1 previous failed embryo transfer. Eumenorrheic normo-gonadotropic women. Basal follicle-stimulating hormone (FSH) <=12 International unit per liter (IU/L). Anti-mullerian hormone (AMH) greater than (>) 1.1 nanogram per milliliter (ng/mL). Ovarian Reserve: number of antral follicles 2 millimeter (mm) between 6 <= antral follicle count (AFC) <= 16. Follicles > 16 mm at the triggering day between 5-14. Body Mass Index (BMI) between 18 <= BMI <= 27 kilogram per meter square (kg/m^2). Indication for Fresh Embryo transfer. Normal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx). Undergoing Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering. Progesterone (P4) serum level at the HCG triggering day <= 1.5 ng/mL (Day O/Randomization). Estradiol (E2) <= 3000 picogram/milliliter (pg/mL) at the human chorionic gonadotropin (HCG) triggering day (Day 0/Randomization). Subjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care. Other protocol defined inclusion criteria could apply. ",
        "Annotations": [
            "Condition 4 13--*--infertile",
            "Person 14 19--*--women",
            "Procedure 33 72--*--intracytoplasmic sperm injection (ICSI)",
            "Procedure 73 123--*--Fertilization in Vitro and Embryo Transfer (FIVET)",
            "Value 125 153--*--Less than or equal to (<=) 1",
            "Measurement 154 185--*--previous failed embryo transfer",
            "Condition 187 199--*--Eumenorrheic",
            "Condition 200 218--*--normo-gonadotropic",
            "Person 219 224--*--women",
            "Measurement 226 266--*--Basal follicle-stimulating hormone (FSH)",
            "Value 267 307--*--<=12 International unit per liter (IU/L)",
            "Measurement 309 337--*--Anti-mullerian hormone (AMH)",
            "Value 338 390--*--greater than (>) 1.1 nanogram per milliliter (ng/mL)",
            "Measurement 409 453--*--number of antral follicles 2 millimeter (mm)",
            "Value 454 500--*--between 6 <= antral follicle count (AFC) <= 16",
            "Measurement 502 519--*--Follicles > 16 mm",
            "Value 542 554--*--between 5-14",
            "Temporal 520 541--*--at the triggering day",
            "Measurement 556 577--*--Body Mass Index (BMI)",
            "Value 578 636--*--between 18 <= BMI <= 27 kilogram per meter square (kg/m^2)",
            "Mood 638 652--*--Indication for",
            "Procedure 653 674--*--Fresh Embryo transfer",
            "Procedure 701 716--*--ultrasound exam",
            "Observation 676 697--*--Normal uterine cavity",
            "Negation 724 738--*--no presence of",
            "Condition 739 751--*--hydrosalpinx",
            "Scope 724 751--*--no presence of hydrosalpinx",
            "Procedure 765 802--*--Assisted Reproductive Technique (ART)",
            "Procedure 807 824--*--oocyte maturation",
            "Procedure 828 873--*--human chorionic gonadotropin (HCG) triggering",
            "Temporal 754 764--*--Undergoing",
            "Scope 765 873--*--Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering",
            "Measurement 875 904--*--Progesterone (P4) serum level",
            "Temporal 905 930--*--at the HCG triggering day",
            "Reference_point 908 930--*--the HCG triggering day",
            "Value 931 943--*--<= 1.5 ng/mL",
            "Reference_point 945 964--*--Day O/Randomization",
            "Measurement 967 981--*--Estradiol (E2)",
            "Value 982 1017--*--<= 3000 picogram/milliliter (pg/mL)",
            "Reference_point 1021 1074--*--the human chorionic gonadotropin (HCG) triggering day",
            "Temporal 1018 1074--*--at the human chorionic gonadotropin (HCG) triggering day",
            "Reference_point 1076 1095--*--Day 0/Randomization",
            "Informed_consent 1098 1222--*--Subjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care",
            "Non-representable 1224 1277--*--Other protocol defined inclusion criteria could apply"
        ]
    },
    "NCT02515773_exc": {
        "Text": "Patients will be excluded if they have had exposure to a total daily dose of MET 1000 mg bid for at least 2 weeks in the past 3 months;. Patients will be excluded if they could not tolerate MET during the recommended titration schedule outlined in the protocol;. Major neurological or medical illnesses that affect weight gain (e.g., unstable thyroid disease) or require a systemic medication that might impact weight or glucose regulation (e.g., diabetes mellitus [insulin], chronic renal failure [steroids]);. Fasting glucose = 126 mg/dL on 2 occasions during screening indicating need for prompt treatment;. If lab results are available in the last 6 months, then a serum creatinine =1.3 mg/dL on 2 occasions during screening and/or follow-up, indicating potential impairment of renal functioning;. Pregnant or breast feeding;. Children and caregivers who are unable to complete assessments for any reason;. ",
        "Annotations": [
            "Drug 77 80--*--MET",
            "Multiplier 81 92--*--1000 mg bid",
            "Temporal 97 134--*--at least 2 weeks in the past 3 months",
            "Condition 177 189--*--not tolerate",
            "Drug 190 193--*--MET",
            "Condition 343 358--*--thyroid disease",
            "Qualifier 334 342--*--unstable",
            "Condition 447 464--*--diabetes mellitus",
            "Drug 466 473--*--insulin",
            "Condition 476 497--*--chronic renal failure",
            "Drug 499 507--*--steroids",
            "Measurement 512 527--*--Fasting glucose",
            "Value 528 539--*--= 126 mg/dL",
            "Multiplier 543 546--*--2 o",
            "Measurement 669 685--*--serum creatinine",
            "Value 686 696--*--=1.3 mg/dL",
            "Multiplier 700 701--*--2",
            "Pregnancy_considerations 802 828--*--Pregnant or breast feeding",
            "Informed_consent 831 908--*--Children and caregivers who are unable to complete assessments for any reason"
        ]
    },
    "NCT01064752_exc": {
        "Text": "1. Taking a tetracycline within 6 months or history of adverse reaction to minocycline or another tetracycline. . 2. Enhanced risk from lumbar puncture, including documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis. . 3. Pregnancy or expectation of pregnancy during the study. . 4. Active opportunistic infection or active neurological disease that might confound evaluation. . 5. ADC Stage > 1. . 6. Hemoglobin < 10 Gms/dL. . 7. BUN or creatine above the normal limits. . 8. Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of toxicity.       .     . ",
        "Annotations": [
            "Drug 12 24--*--tetracycline",
            "Temporal 25 40--*--within 6 months",
            "Observation 44 51--*--history",
            "Condition 55 71--*--adverse reaction",
            "Drug 75 86--*--minocycline",
            "Drug 98 110--*--tetracycline",
            "Scope 75 110--*--minocycline or another tetracycline",
            "Procedure 135 150--*--lumbar puncture",
            "Mood 116 129--*--Enhanced risk",
            "Condition 186 206--*--cerebral mass lesion",
            "Qualifier 207 261--*--predisposing to brain herniation or bleeding diathesis",
            "Mood 207 222--*--predisposing to",
            "Condition 223 239--*--brain herniation",
            "Condition 243 261--*--bleeding diathesis",
            "Scope 223 261--*--brain herniation or bleeding diathesis",
            "Mood 162 172--*--documented",
            "Mood 176 185--*--suspected",
            "Scope 162 185--*--documented or suspected",
            "Scope 162 261--*--documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis",
            "Scope 116 150--*--Enhanced risk from lumbar puncture",
            "Condition 267 276--*--Pregnancy",
            "Mood 280 291--*--expectation",
            "Condition 295 304--*--pregnancy",
            "Temporal 305 321--*--during the study",
            "Scope 267 304--*--Pregnancy or expectation of pregnancy",
            "Condition 334 357--*--opportunistic infection",
            "Qualifier 334 347--*--opportunistic",
            "Temporal 327 333--*--Active",
            "Condition 368 388--*--neurological disease",
            "Temporal 361 367--*--active",
            "Measurement 425 434--*--ADC Stage",
            "Value 435 438--*--> 1",
            "Measurement 444 454--*--Hemoglobin",
            "Value 455 466--*--< 10 Gms/dL",
            "Measurement 472 475--*--BUN",
            "Measurement 479 487--*--creatine",
            "Value 488 511--*--above the normal limits",
            "Scope 472 487--*--BUN or creatine",
            "Drug 570 581--*--minocycline",
            "Non-representable 545 581--*--reduce the metabolism of minocycline",
            "Non-representable 517 628--*--Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of toxicity."
        ]
    },
    "NCT02525991_exc": {
        "Text": "Patient diagnosed with dementia.. Patients with serious and unstable illnesses including current hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis).. Patients with a history of allergic reactions to loxapine or amoxapine. Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded.. Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device.. ",
        "Annotations": [
            "Condition 23 31--*--dementia",
            "Qualifier 48 55--*--serious",
            "Qualifier 60 68--*--unstable",
            "Scope 48 68--*--serious and unstable",
            "Condition 97 104--*--hepatic",
            "Condition 106 111--*--renal",
            "Condition 113 130--*--gastroenterologic",
            "Condition 132 143--*--respiratory",
            "Condition 145 159--*--cardiovascular",
            "Condition 241 251--*--neurologic",
            "Condition 225 239--*--endocrinologic",
            "Condition 171 193--*--ischemic heart disease",
            "Condition 198 222--*--congestive heart failure",
            "Condition 263 269--*--stroke",
            "Condition 271 296--*--transient ischemic attack",
            "Condition 298 321--*--subarachnoidal bleeding",
            "Condition 323 334--*--brain tumor",
            "Condition 336 350--*--encephalopathy",
            "Condition 356 366--*--meningitis",
            "Scope 263 366--*--stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis",
            "Scope 171 223--*--ischemic heart disease and congestive heart failure)",
            "Scope 97 366--*--hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis",
            "Condition 397 415--*--allergic reactions",
            "Drug 419 427--*--loxapine",
            "Drug 431 440--*--amoxapine",
            "Scope 419 440--*--loxapine or amoxapine",
            "Competing_trial 442 563--*--Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded",
            "Post-eligibility 566 684--*--Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device"
        ]
    },
    "NCT02203019_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 8 13--*--women",
            "Person 26 29--*--old",
            "Value 14 25--*--18-89 years",
            "Condition 53 59--*--sepsis",
            "Temporal 81 109--*--within the previous 24 hours",
            "Procedure 123 145--*--mechanical ventilation",
            "Informed_consent 152 229--*--provide informed consent either personally or by an authorized representative"
        ],
        "Text": "Men and women 18-89 years old. with the diagnosis of sepsis (as specified below) within the previous 24 hours. who require mechanical ventilation, and. provide informed consent either personally or by an authorized representative.. "
    },
    "NCT02874092_exc": {
        "Text": "History of sensitivity to study medications or any of their excipients. RA cohort: Previous intolerance to MTX. Current treatment with antiplatelet therapy. Absolute indication for anti-platelet therapy. Need for chronic oral anticoagulant therapy. Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy). Renal failure (eGFR <30 or requiring dialysis). A known bleeding diathesis, hemostatic or coagulation disorder, or prior major bleeding. Prior stroke. Active pathological bleeding. History of intracranial haemorrhage. Life expectancy <12 months based on investigator's judgement. Patients considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree atrioventricular [AV)] block) unless already treated with a permanent pacemaker. Anemia (hematocrit < 27%). Platelet count < 100,000/ml. Concomitant use of strong CYP 3A inhibitors or inducers. History of thrombocytopenia or neutropenia. Pregnant or nursing women, or females with a positive pregnancy test at screening. Females of child bearing potential not using acceptable method of birth control prior to or during study. Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse). ",
        "Annotations": [
            "Condition 11 22--*--sensitivity",
            "Drug 26 43--*--study medications",
            "Condition 72 74--*--RA",
            "Condition 92 103--*--intolerance",
            "Drug 107 110--*--MTX",
            "Procedure 135 155--*--antiplatelet therapy",
            "Temporal 112 119--*--Current",
            "Procedure 181 202--*--anti-platelet therapy",
            "Mood 157 180--*--Absolute indication for",
            "Mood 204 212--*--Need for",
            "Procedure 213 247--*--chronic oral anticoagulant therapy",
            "Condition 249 274--*--Severe hepatic impairment",
            "Condition 280 287--*--ascites",
            "Condition 313 325--*--coagulopathy",
            "Mood 295 312--*--clinical signs of",
            "Scope 280 325--*--ascites and/or clinical signs of coagulopathy",
            "Condition 328 341--*--Renal failure",
            "Measurement 343 347--*--eGFR",
            "Value 348 351--*--<30",
            "Mood 355 364--*--requiring",
            "Procedure 365 373--*--dialysis",
            "Scope 343 373--*--eGFR <30 or requiring dialysis",
            "Condition 384 402--*--bleeding diathesis",
            "Condition 418 438--*--coagulation disorder",
            "Condition 404 414;430 438--*--hemostatic disorder",
            "Condition 449 463--*--major bleeding",
            "Condition 471 477--*--stroke",
            "Temporal 479 485--*--Active",
            "Temporal 465 470--*--Prior",
            "Temporal 443 448--*--prior",
            "Condition 486 507--*--pathological bleeding",
            "Condition 520 544--*--intracranial haemorrhage",
            "Observation 509 516--*--History",
            "Measurement 546 561--*--Life expectancy",
            "Value 562 572--*--<12 months",
            "Non-representable 573 606--*--based on investigator's judgement",
            "Condition 645 663--*--bradycardic events",
            "Mood 634 644--*--at risk of",
            "Condition 677 696--*--sick sinus syndrome",
            "Condition 710 751--*--third degree atrioventricular [AV)] block",
            "Condition 700 706;716 751--*--second degree atrioventricular [AV)] block",
            "Device 783 802--*--permanent pacemaker",
            "Negation 753 759--*--unless",
            "Scope 677 751--*--sick sinus syndrome or second or third degree atrioventricular [AV)] block",
            "Condition 804 810--*--Anemia",
            "Measurement 812 822--*--hematocrit",
            "Value 823 828--*--< 27%",
            "Scope 812 828--*--hematocrit < 27%",
            "Measurement 831 845--*--Platelet count",
            "Value 846 858--*--< 100,000/ml",
            "Drug 879 903--*--strong CYP 3A inhibitors",
            "Drug 879 892;907 915--*--strong CYP 3A inducers",
            "Condition 928 944--*--thrombocytopenia",
            "Condition 948 959--*--neutropenia",
            "Observation 917 924--*--History",
            "Scope 928 959--*--thrombocytopenia or neutropenia",
            "Condition 961 969--*--Pregnant",
            "Condition 973 980--*--nursing",
            "Person 981 986--*--women",
            "Person 991 998--*--females",
            "Value 1006 1014--*--positive",
            "Measurement 1015 1029--*--pregnancy test",
            "Temporal 1030 1042--*--at screening",
            "Scope 961 986--*--Pregnant or nursing women",
            "Scope 991 1042--*--females with a positive pregnancy test at screening",
            "Reference_point 1033 1042--*--screening",
            "Person 1044 1051--*--Females",
            "Condition 1055 1078--*--child bearing potential",
            "Qualifier 1089 1099--*--acceptable",
            "Observation 1100 1123--*--method of birth control",
            "Temporal 1124 1132;1143 1148--*--prior to study",
            "Temporal 1136 1148--*--during study",
            "Scope 1124 1148--*--prior to or during study",
            "Negation 1079 1082--*--not",
            "Observation 1162 1171;1187 1218--*--inability to comply with study procedures",
            "Observation 1162 1171;1187 1201;1226 1235--*--inability to comply with follow up",
            "Condition 1241 1248;1257 1262--*--alcohol abuse",
            "Condition 1252 1262--*--drug abuse",
            "Scope 1241 1262--*--alcohol or drug abuse",
            "Scope 1162 1235--*--inability of the patient to comply with study procedures and/or follow up",
            "Mood 1150 1161--*--Concern for"
        ]
    },
    "NCT01942109_exc": {
        "Annotations": [
            "Qualifier 0 12--*--uncontrolled",
            "Condition 13 25--*--hypertension",
            "Qualifier 27 39--*--uncontrolled",
            "Condition 40 48--*--diabetes",
            "Measurement 50 60--*--creatinine",
            "Value 61 72--*--> 2,5 mg/dl",
            "Measurement 74 83--*--potassium",
            "Value 84 93--*--> 6 mg/dl",
            "Condition 95 118--*--acute coronary syndrome",
            "Condition 120 147--*--hypertrophic cardiomyopathy"
        ],
        "Text": "uncontrolled hypertension. uncontrolled diabetes. creatinine > 2,5 mg/dl. potassium > 6 mg/dl. acute coronary syndrome. hypertrophic cardiomyopathy. "
    },
    "NCT02371200_inc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 119 121--*--2.",
            "Parsing_Error 204 206--*--3.",
            "Parsing_Error 249 251--*--4.",
            "Parsing_Error 353 355--*--5.",
            "Parsing_Error 429 431--*--6.",
            "Parsing_Error 616 618--*--7.",
            "Parsing_Error 703 705--*--8.",
            "Condition 28 40--*--GTC seizures",
            "Condition 49 60--*--primary GTC",
            "Condition 64 86--*--partial onset seizures",
            "Condition 92 116--*--secondary generalization",
            "Scope 49 116--*--primary GTC or partial onset seizures with secondary generalization",
            "Observation 17 24--*--history",
            "Procedure 166 181--*--vEEG monitoring",
            "Condition 193 201--*--seizures",
            "Procedure 131 153--*--admitted to a hospital",
            "Person 215 221--*--female",
            "Person 207 211--*--Male",
            "Person 230 238--*--the ages",
            "Value 222 229;242 246--*--between 2-99",
            "Measurement 259 282--*--upper arm circumference",
            "Qualifier 292 334--*--adequate for proper fit of the EMG monitor",
            "Undefined_semantics 292 334--*--adequate for proper fit of the EMG monitor",
            "Value 336 349--*--at least 14cm",
            "Condition 373 395--*--childbearing potential",
            "Person 359 365--*--female",
            "Scope 359 395--*--female and of childbearing potential",
            "Measurement 412 426--*--pregnancy test",
            "Value 403 411--*--negative",
            "Post-eligibility 432 614--*--Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.",
            "Non-query-able 432 614--*--Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.",
            "Post-eligibility 619 701--*--Subject and/or Primary Caregiver must be competent to follow all study procedures.",
            "Non-query-able 619 700--*--Subject and/or Primary Caregiver must be competent to follow all study procedures",
            "Non-query-able 706 753--*--Is able to read, speak, and understand English."
        ],
        "Text": "1. Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization. . 2. Is being admitted to a hospital for routine vEEG monitoring related to seizures. . 3. Male or female between the ages of 2-99. . 4. Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm). . 5. If female and of childbearing potential, has a negative pregnancy test. . 6. Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. . 7. Subject and/or Primary Caregiver must be competent to follow all study procedures. . 8. Is able to read, speak, and understand English. . "
    },
    "NCT03407625_inc": {
        "Text": "37 weeks gestation or greater. Living, singleton fetus. No major fetal malformations. Cephalic presentation. No prior uterine scar. Intact fetal membranes. Qualifies for prostaglandin administration according to current Parkland protocol. Have a cervical dilation of 2 centimeters or less, measured at the level of the internal os. Have an indication for induction or attempted induction of labor according to Parkland protocol. ",
        "Annotations": [
            "Condition 9 18--*--gestation",
            "Value 0 8;22 29--*--37 weeks greater",
            "Condition 39 54--*--singleton fetus",
            "Qualifier 31 37--*--Living",
            "Condition 59 84--*--major fetal malformations",
            "Negation 56 58--*--No",
            "Condition 86 107--*--Cephalic presentation",
            "Negation 109 111--*--No",
            "Condition 118 130--*--uterine scar",
            "Condition 139 154--*--fetal membranes",
            "Qualifier 132 138--*--Intact",
            "Procedure 170 198--*--prostaglandin administration",
            "Procedure 220 237--*--Parkland protocol",
            "Condition 246 263--*--cervical dilation",
            "Multiplier 267 288--*--2 centimeters or less",
            "Qualifier 319 330--*--internal os",
            "Condition 340 350--*--indication",
            "Procedure 355 364;388 396--*--induction of labor",
            "Qualifier 368 377--*--attempted",
            "Procedure 410 427--*--Parkland protocol",
            "Procedure 378 387--*--induction",
            "Scope 355 396--*--induction or attempted induction of labor"
        ]
    },
    "NCT02536976_exc": {
        "Text": "Known or suspected alcohol or substance abuse in the preceding 12 months.. Women who are pregnant or breastfeeding.. Women of childbearing potential (WOCP) who are not using at least one method of contraception.. Patients with severe renal impairment (CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2), or moderate or severe hepatic impairment (Child-Pugh classes B or C).. Patients with bladder outlet obstruction (BOO) that, in the opinion of the study urologist, would expose them to risk of urinary retention during treatment with mirabegron.. Patients treated with drugs metabolized by the CYP2D6 pathway.. Patients with supine systolic blood pressure (SBP) = 180 mm Hg, or diastolic blood pressure (DBP) = 110 mm Hg.. Clinically significant, uncontrolled cardiac arrhythmia, unstable angina, congestive heart failure (NYHA Class 3 or 4), or history of myocardial infarction in the preceding 2 years.. History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.. Any major urological procedure in the preceding 90 days.. Any major surgical procedure in the preceding 30 days.. Previously treated with mirabegron within 60 days prior to the baseline visit (Visit 2), or previously having failed treatment with mirabegron regardless of duration and timing of treatment.. Current or previous, within the 60 days preceding the baseline visit (Visit 2), treatment with antimuscarinic agents for OAB symptoms; and, willingness to not use antimuscarinic agents for the duration of the study.. Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2).. Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study.. Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures.. ",
        "Annotations": [
            "Condition 30 45--*--substance abuse",
            "Condition 19 26;40 45--*--alcohol abuse",
            "Temporal 53 72--*--preceding 12 months",
            "Scope 19 45--*--alcohol or substance abuse",
            "Pregnancy_considerations 75 114--*--Women who are pregnant or breastfeeding",
            "Pregnancy_considerations 117 210--*--Women of childbearing potential (WOCP) who are not using at least one method of contraception",
            "Condition 234 250--*--renal impairment",
            "Qualifier 227 233--*--severe",
            "Measurement 252 256--*--CLcr",
            "Value 257 268--*--= 29 mL/min",
            "Measurement 273 277--*--eGFR",
            "Value 278 297--*--= 29 mL/min/1.73 m2",
            "Scope 252 297--*--CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2",
            "Condition 322 340--*--hepatic impairment",
            "Qualifier 315 321--*--severe",
            "Qualifier 303 311--*--moderate",
            "Scope 303 321--*--moderate or severe",
            "Measurement 342 360--*--Child-Pugh classes",
            "Value 361 362--*--B",
            "Value 366 367--*--C",
            "Scope 361 367--*--B or C",
            "Condition 385 411--*--bladder outlet obstruction",
            "Condition 413 416--*--BOO",
            "Drug 532 542--*--mirabegron",
            "Observation 484 509--*--risk of urinary retention",
            "Non-query-able 545 606--*--Patients treated with drugs metabolized by the CYP2D6 pathway",
            "Measurement 630 653--*--systolic blood pressure",
            "Qualifier 623 629--*--supine",
            "Measurement 655 658--*--SBP",
            "Value 660 671--*--= 180 mm Hg",
            "Measurement 676 700--*--diastolic blood pressure",
            "Measurement 702 705--*--DBP",
            "Value 707 718--*--= 110 mm Hg",
            "Condition 758 776--*--cardiac arrhythmia",
            "Qualifier 745 757--*--uncontrolled",
            "Condition 778 793--*--unstable angina",
            "Condition 795 819--*--congestive heart failure",
            "Measurement 821 831--*--NYHA Class",
            "Value 832 833--*--3",
            "Value 837 838--*--4",
            "Scope 832 838--*--3 or 4",
            "Condition 855 876--*--myocardial infarction",
            "Temporal 884 901--*--preceding 2 years",
            "Condition 915 921--*--cancer",
            "Temporal 929 946--*--preceding 2 years",
            "Negation 947 952--*--other",
            "Condition 1038 1061--*--cervical cancer in situ",
            "Condition 1013 1033--*--basal cell carcinoma",
            "Condition 1024 1033;996 1009--*--carcinoma squamous cell",
            "Qualifier 980 994--*--non-metastatic",
            "Scope 996 1061--*--squamous cell or basal cell carcinoma, or cervical cancer in situ",
            "Qualifier 958 978--*--successfully treated",
            "Procedure 1068 1094--*--major urological procedure",
            "Temporal 1102 1119--*--preceding 90 days",
            "Procedure 1126 1150--*--major surgical procedure",
            "Temporal 1158 1175--*--preceding 30 days",
            "Drug 1202 1212--*--mirabegron",
            "Temporal 1213 1255--*--within 60 days prior to the baseline visit",
            "Reference_point 1241 1255--*--baseline visit",
            "Drug 1465 1486--*--antimuscarinic agents",
            "Condition 1491 1503--*--OAB symptoms",
            "Temporal 1391 1438--*--within the 60 days preceding the baseline visit",
            "Reference_point 1424 1438--*--baseline visit",
            "Post-eligibility 1510 1584--*--willingness to not use antimuscarinic agents for the duration of the study",
            "Competing_trial 1587 1738--*--Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2)",
            "Non-query-able 1741 1946--*--Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study",
            "Non-query-able 1949 2086--*--Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures"
        ]
    },
    "NCT02068365_exc": {
        "Text": "Evidence of decompensated liver disease (Childs B-C), hepato-cellular carcinoma, pre-existing severe depression or other psychiatric disease, significant cardiac disease, significant renal disease, seizure disorders or severe retinopathy.. received telbivudine as the antiviral therapy or have received more than one NA in the past.. received interferon or peginterferon treatment in the past.. received antiviral therapy for any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment (including supraphysiologic doses of steroids and radiation) within the past 6 months.. Positive test at screening for anti-HIV, anti-HCV.. Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded. Exception: patients who have had a limited (<=7 days) course of acyclovir for herpetic lesions more than 1 month prior to the first administration of test drug are not excluded.. Serum total bilirubin > 3 times the upper limit of normal at screening.. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease.. History or other evidence of a medical condition associated with chronic liver disease other than HBV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia).. Women with ongoing pregnancy or who are breast feeding.. Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening.. Hemoglobin < 11.5 g/dL for females and < 12.5 g/dL for men at screening.. Serum creatinine level >120 umol/ml for men and >105 umol/ml for women at screening.. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as major depression or psychosis, a period of treatment with an antidepressant medication or major tranquilizer at therapeutic doses for depression or psychosis for at least 3 months, a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease.. History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).. History or other evidence of chronic pulmonary disease associated with functional limitation. Severe cardiac disease (e.g., NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases).. History of a severe seizure disorder or current anticonvulsant use.. Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is >=20% within 2 years. Patients with a lesion suspicious of hepatic malignancy on a screening imaging study will only be eligible if the likelihood of carcinoma is <=10% following an appropriate evaluation.. History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids) <=6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.. Major organ transplantation.. Thyroid disease with thyroid function poorly controlled on prescribed medications. Patients with abnormal thyroid stimulating hormone or T4 concentrations, with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.. History or other evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. Inability or unwillingness to provide informed consent or abide by the requirements of the study.. History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.. Patients with a value of alpha-fetoprotein >100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months.. Evidence of drug and/or alcohol abuse (20g/day for women & 30g/day for men).. Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening. Any known history of hypersensitivity to interferon.. ",
        "Annotations": [
            "Qualifier 12 25--*--decompensated",
            "Condition 26 39--*--liver disease",
            "Measurement 41 47--*--Childs",
            "Value 48 51--*--B-C",
            "Scope 12 39--*--decompensated liver disease",
            "Scope 41 51--*--Childs B-C",
            "Condition 54 79--*--hepato-cellular carcinoma",
            "Temporal 81 93--*--pre-existing",
            "Qualifier 94 100--*--severe",
            "Condition 101 111--*--depression",
            "Condition 121 140--*--psychiatric disease",
            "Qualifier 115 120--*--other",
            "Condition 154 169--*--cardiac disease",
            "Qualifier 142 153--*--significant",
            "Qualifier 171 182--*--significant",
            "Condition 183 196--*--renal disease",
            "Condition 198 215--*--seizure disorders",
            "Qualifier 219 225--*--severe",
            "Condition 226 237--*--retinopathy",
            "Scope 94 140--*--severe depression or other psychiatric disease",
            "Drug 249 260--*--telbivudine",
            "Procedure 268 285--*--antiviral therapy",
            "Multiplier 303 316--*--more than one",
            "Condition 317 319--*--NA",
            "Temporal 320 331--*--in the past",
            "Drug 343 353--*--interferon",
            "Drug 357 370--*--peginterferon",
            "Procedure 371 380--*--treatment",
            "Temporal 381 392--*--in the past",
            "Scope 343 370--*--interferon or peginterferon",
            "Procedure 404 421--*--antiviral therapy",
            "Drug 430 449--*--systemic anti-viral",
            "Procedure 451 466;488 497--*--anti-neoplastic treatment",
            "Procedure 470 497--*--immuno-modulatory treatment",
            "Multiplier 509 531--*--supraphysiologic doses",
            "Drug 535 543--*--steroids",
            "Procedure 548 557--*--radiation",
            "Scope 509 557--*--supraphysiologic doses of steroids and radiation",
            "Scope 404 497--*--antiviral therapy for any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment",
            "Temporal 559 583--*--within the past 6 months",
            "Value 586 594--*--Positive",
            "Measurement 595 599;613 625--*--test for anti-HIV",
            "Measurement 595 599;613 616;627 635--*--test for anti-HCV",
            "Temporal 600 612--*--at screening",
            "Scope 595 599;613 635--*--test for anti-HIV, anti-HCV",
            "Mood 655 671--*--expected to need",
            "Procedure 672 698--*--systemic antiviral therapy",
            "Temporal 737 788--*--at any time during their participation in the study",
            "Reference_point 756 788--*--their participation in the study",
            "Drug 872 881--*--acyclovir",
            "Multiplier 843 850;862 868--*--limited course",
            "Multiplier 852 860--*--<=7 days",
            "Condition 886 902--*--herpetic lesions",
            "Temporal 903 967--*--more than 1 month prior to the first administration of test drug",
            "Reference_point 930 967--*--the first administration of test drug",
            "Mood 972 984--*--not excluded",
            "Negation 808 817--*--Exception",
            "Measurement 987 1008--*--Serum total bilirubin",
            "Value 1009 1044--*--> 3 times the upper limit of normal",
            "Temporal 1045 1057--*--at screening",
            "Condition 1089 1097--*--bleeding",
            "Condition 1103 1121--*--esophageal varices",
            "Qualifier 1125 1130--*--other",
            "Condition 1131 1185--*--conditions consistent with decompensated liver disease",
            "Condition 1219 1236--*--medical condition",
            "Condition 1253 1274--*--chronic liver disease",
            "Negation 1275 1285--*--other than",
            "Condition 1286 1289--*--HBV",
            "Scope 1275 1289--*--other than HBV",
            "Condition 1297 1312--*--hemochromatosis",
            "Condition 1314 1334--*--autoimmune hepatitis",
            "Condition 1336 1360--*--metabolic liver diseases",
            "Condition 1371 1379--*--Wilson's",
            "Condition 1384 1413--*--alpha1-antitrypsin deficiency",
            "Condition 1415 1438--*--alcoholic liver disease",
            "Condition 1440 1455--*--toxin exposures",
            "Condition 1457 1468--*--thalassemia",
            "Scope 1371 1468--*--Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia",
            "Scope 1297 1468--*--hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia",
            "Person 1472 1477--*--Women",
            "Condition 1491 1500--*--pregnancy",
            "Temporal 1483 1490--*--ongoing",
            "Observation 1512 1526--*--breast feeding",
            "Measurement 1529 1545--*--Neutrophil count",
            "Value 1546 1561--*--<1500 cells/mm3",
            "Measurement 1565 1579--*--platelet count",
            "Value 1580 1597--*--<90,000 cells/mm3",
            "Temporal 1598 1610--*--at screening",
            "Scope 1529 1597--*--Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3",
            "Measurement 1613 1623--*--Hemoglobin",
            "Value 1624 1635--*--< 11.5 g/dL",
            "Person 1640 1647--*--females",
            "Value 1652 1663--*--< 12.5 g/dL",
            "Person 1668 1671--*--men",
            "Temporal 1672 1684--*--at screening",
            "Scope 1624 1671--*--< 11.5 g/dL for females and < 12.5 g/dL for men",
            "Measurement 1687 1709--*--Serum creatinine level",
            "Value 1710 1722--*-->120 umol/ml",
            "Person 1727 1730--*--men",
            "Value 1735 1747--*-->105 umol/ml",
            "Person 1752 1757--*--women",
            "Temporal 1758 1770--*--at screening",
            "Scope 1710 1757--*-->120 umol/ml for men and >105 umol/ml for women",
            "Condition 1791 1810--*--psychiatric disease",
            "Qualifier 1784 1790--*--severe",
            "Condition 1823 1833--*--depression",
            "Qualifier 1835 1841--*--Severe",
            "Condition 1842 1861--*--psychiatric disease",
            "Condition 1876 1892--*--major depression",
            "Condition 1896 1905--*--psychosis",
            "Procedure 1919 1928--*--treatment",
            "Drug 1937 1962--*--antidepressant medication",
            "Drug 1966 1984--*--major tranquilizer",
            "Multiplier 1988 2005--*--therapeutic doses",
            "Condition 2010 2020--*--depression",
            "Condition 2024 2033--*--psychosis",
            "Temporal 2034 2055--*--for at least 3 months",
            "Condition 2059 2075--*--suicidal attempt",
            "Procedure 2077 2092--*--hospitalization",
            "Condition 2097 2116--*--psychiatric disease",
            "Condition 2133 2143--*--disability",
            "Condition 2153 2172--*--psychiatric disease",
            "Scope 1937 1984--*--antidepressant medication or major tranquilizer",
            "Scope 1876 2172--*--major depression or psychosis, a period of treatment with an antidepressant medication or major tranquilizer at therapeutic doses for depression or psychosis for at least 3 months, a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease",
            "Scope 1835 1861--*--Severe psychiatric disease",
            "Scope 1784 1833--*--severe psychiatric disease, especially depression",
            "Condition 2226 2252--*--inflammatory bowel disease",
            "Condition 2186 2218--*--immunologically mediated disease",
            "Condition 2254 2289--*--idiopathic thrombocytopenic purpura",
            "Condition 2291 2310--*--lupus erythematosus",
            "Condition 2312 2339--*--autoimmune hemolytic anemia",
            "Condition 2341 2352--*--scleroderma",
            "Qualifier 2354 2360--*--severe",
            "Condition 2361 2370--*--psoriasis",
            "Condition 2372 2392--*--rheumatoid arthritis",
            "Scope 2226 2392--*--inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis",
            "Condition 2425 2450--*--chronic pulmonary disease",
            "Condition 2467 2488--*--functional limitation",
            "Qualifier 2490 2496--*--Severe",
            "Condition 2497 2512--*--cardiac disease",
            "Measurement 2520 2524--*--NYHA",
            "Value 2525 2551--*--Functional Class III or IV",
            "Condition 2553 2574--*--myocardial infarction",
            "Temporal 2575 2590--*--within 6 months",
            "Condition 2592 2620--*--ventricular tachyarrhythmias",
            "Temporal 2631 2638--*--ongoing",
            "Procedure 2639 2648--*--treatment",
            "Condition 2650 2665--*--unstable angina",
            "Qualifier 2669 2674--*--other",
            "Qualifier 2675 2686--*--significant",
            "Condition 2687 2710--*--cardiovascular diseases",
            "Scope 2490 2512--*--Severe cardiac disease",
            "Scope 2520 2710--*--NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases",
            "Qualifier 2727 2733--*--severe",
            "Condition 2734 2750--*--seizure disorder",
            "Drug 2762 2776--*--anticonvulsant",
            "Temporal 2754 2761--*--current",
            "Temporal 2798 2804--*--active",
            "Mood 2808 2817--*--suspected",
            "Condition 2818 2824--*--cancer",
            "Scope 2798 2817--*--active or suspected",
            "Condition 2841 2851--*--malignancy",
            "Measurement 2862 2880--*--risk of recurrence",
            "Value 2884 2904--*-->=20% within 2 years",
            "Condition 2922 2928--*--lesion",
            "Mood 2929 2939--*--suspicious",
            "Condition 2943 2961--*--hepatic malignancy",
            "Procedure 2967 2990--*--screening imaging study",
            "Measurement 3020 3043--*--likelihood of carcinoma",
            "Value 3047 3052--*--<=10%",
            "Scope 2922 2990--*--lesion suspicious of hepatic malignancy on a screening imaging study",
            "Qualifier 3122 3130--*--systemic",
            "Procedure 3131 3146;3189 3198--*--anti-neoplastic treatment",
            "Procedure 3172 3198--*--immunomodulatory treatment",
            "Procedure 3158 3167--*--radiation",
            "Qualifier 3210 3218--*--systemic",
            "Drug 3219 3234--*--corticosteroids",
            "Scope 3131 3235--*--anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids)",
            "Temporal 3236 3284--*--<=6 months prior to the first dose of study drug",
            "Reference_point 3256 3284--*--the first dose of study drug",
            "Mood 3292 3303--*--expectation",
            "Procedure 3314 3323--*--treatment",
            "Mood 3324 3338--*--will be needed",
            "Temporal 3339 3367--*--at any time during the study",
            "Procedure 3370 3397--*--Major organ transplantation",
            "Condition 3400 3415--*--Thyroid disease",
            "Measurement 3421 3437--*--thyroid function",
            "Value 3438 3455--*--poorly controlled",
            "Qualifier 3456 3481--*--on prescribed medications",
            "Value 3497 3505--*--abnormal",
            "Measurement 3506 3533--*--thyroid stimulating hormone",
            "Measurement 3537 3554--*--T4 concentrations",
            "Scope 3497 3554--*--abnormal thyroid stimulating hormone or T4 concentrations",
            "Scope 3497 3554--*--abnormal thyroid stimulating hormone or T4 concentrations",
            "Measurement 3574 3606--*--antibodies to thyroid peroxidase",
            "Value 3561 3570--*--elevation",
            "Condition 3615 3657--*--clinical manifestations of thyroid disease",
            "Qualifier 3702 3708--*--severe",
            "Condition 3709 3720--*--retinopathy",
            "Condition 3727 3740--*--CMV retinitis",
            "Condition 3742 3761--*--macula degeneration",
            "Scope 3727 3761--*--CMV retinitis, macula degeneration",
            "Scope 3702 3720--*--severe retinopathy",
            "Qualifier 3766 3785--*--clinically relevant",
            "Condition 3786 3811--*--ophthalmological disorder",
            "Condition 3819 3836--*--diabetes mellitus",
            "Condition 3840 3852--*--hypertension",
            "Scope 3819 3852--*--diabetes mellitus or hypertension",
            "Post-eligibility 3854 3951--*--Inability or unwillingness to provide informed consent or abide by the requirements of the study.",
            "Post-eligibility 3953 4112--*--History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.",
            "Measurement 4139 4156--*--alpha-fetoprotein",
            "Value 4157 4167--*-->100 ng/mL",
            "Temporal 4249 4279--*--at least the previous 3 months",
            "Reference_point 4258 4279--*--the previous 3 months",
            "Condition 4189 4198--*--stability",
            "Value 4200 4213--*--less than 10%",
            "Measurement 4214 4222--*--increase",
            "Scope 4200 4222--*--less than 10% increase",
            "Negation 4182 4188--*--unless",
            "Condition 4306 4319--*--alcohol abuse",
            "Condition 4294 4298;4314 4319--*--drug abuse",
            "Multiplier 4321 4328--*--20g/day",
            "Multiplier 4341 4348--*--30g/day",
            "Person 4353 4356--*--men",
            "Person 4333 4338--*--women",
            "Scope 4321 4356--*--20g/day for women & 30g/day for men",
            "Post-eligibility 4360 4472--*--Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening",
            "Condition 4495 4511--*--hypersensitivity",
            "Drug 4515 4525--*--interferon"
        ]
    },
    "NCT01098383_inc": {
        "Text": "A formal diagnosis of Autism or Pervasive Developmental Disorder not otherwise specified (PDD-NOS), given by a child neurologist.. Age: 10-18 years.. A signed parental consent form.. ",
        "Annotations": [
            "Condition 22 28--*--Autism",
            "Condition 32 88--*--Pervasive Developmental Disorder not otherwise specified",
            "Condition 90 97--*--PDD-NOS",
            "Non-query-able 100 128--*--given by a child neurologist",
            "Person 131 134--*--Age",
            "Value 136 147--*--10-18 years",
            "Informed_consent 150 180--*--A signed parental consent form"
        ]
    },
    "NCT02632760_inc": {
        "Annotations": [
            "Condition 14 21--*--anaemia",
            "Person 23 28--*--males",
            "Measurement 29 31--*--Hb",
            "Value 32 40--*--<130 g/L",
            "Person 42 49--*--females",
            "Value 50 58--*--<120 g/L",
            "Scope 23 28;32 58--*--males <130 g/L, females <120 g/L",
            "Scope 23 58--*--males Hb <130 g/L, females <120 g/L",
            "Qualifier 71 79--*--elective",
            "Procedure 80 95--*--cardiac surgery",
            "Mood 101 121--*--available to receive",
            "Drug 122 132--*--trial drug",
            "Temporal 133 161--*--1- 10 weeks prior to surgery",
            "Reference_point 154 161--*--surgery",
            "Procedure 154 161--*--surgery"
        ],
        "Text": "Patients with anaemia (males Hb <130 g/L, females <120 g/L) undergoing elective cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgery. "
    },
    "NCT02643381_inc": {
        "Annotations": [
            "Person 0 5--*--Adult",
            "Person 15 19--*--male",
            "Person 23 29--*--female",
            "Procedure 41 74--*--emergency endotracheal intubation"
        ],
        "Text": "Adult patient (male or female) requiring emergency endotracheal intubation.. "
    },
    "NCT02779374_exc": {
        "Annotations": [
            "Condition 0 18--*--Abnormal karyotype",
            "Procedure 29 35;49 61--*--pelvic radiotherapy",
            "Procedure 39 61--*--abdominal radiotherapy",
            "Temporal 20 28--*--Previous",
            "Scope 29 61--*--pelvic or abdominal radiotherapy",
            "Procedure 72 91--*--surgical management",
            "Condition 95 112--*--ovarian pathology",
            "Temporal 63 71--*--Previous",
            "Condition 131 136;154 164--*--renal malignancy",
            "Condition 145 152;154 164--*--cardiac malignancy",
            "Condition 138 143;154 164--*--liver malignancy",
            "Condition 114 129--*--Chronic disease",
            "Undefined_semantics 114 129--*--Chronic disease",
            "Scope 131 164--*--renal, liver, cardiac, malignancy"
        ],
        "Text": "Abnormal karyotype . Previous pelvic or abdominal radiotherapy . Previous surgical management of ovarian pathology . Chronic disease: renal, liver, cardiac, malignancy       .     . "
    },
    "NCT00639795_inc": {
        "Text": "Age greater than 18 . Planned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedure . ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 19--*--greater than 18",
            "Procedure 29 41--*--thoracoscopy",
            "Subjective_judgement 47 115--*--low probability(by surgeon estimate) of conversion to open procedure",
            "Undefined_semantics 47 115--*--low probability(by surgeon estimate) of conversion to open procedure",
            "Non-query-able 21 115--*--Planned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedure",
            "Qualifier 47 115--*--low probability(by surgeon estimate) of conversion to open procedure"
        ]
    },
    "NCT02256943_inc": {
        "Text": "Healthy. Male. >7 Metabolic Equivalents. Written informed consent. Chronic pain syndrome. Drug abuse. Alcohol abuse. Suspicion of neurologic dysfunction at tested sites. Ongoing treatment with antidepressants. Ongoing treatment with analgesics. Pretreatment with any CYP3A inducers or inhibitors. Known allergy to tested drugs. Elevated eye pressure. Obstructive uropathy. Heart disease. Pulmonary disease. Neurological disease. Psychiatric illness. ",
        "Annotations": [
            "Condition 0 7--*--Healthy",
            "Person 9 13--*--Male",
            "Value 15 17--*-->7",
            "Measurement 18 39--*--Metabolic Equivalents",
            "Informed_consent 41 65--*--Written informed consent",
            "Condition 67 88--*--Chronic pain syndrome",
            "Condition 90 100--*--Drug abuse",
            "Condition 102 115--*--Alcohol abuse",
            "Mood 117 126--*--Suspicion",
            "Condition 130 152--*--neurologic dysfunction",
            "Qualifier 156 168--*--tested sites",
            "Temporal 170 177--*--Ongoing",
            "Procedure 178 187--*--treatment",
            "Drug 193 208--*--antidepressants",
            "Temporal 210 217--*--Ongoing",
            "Procedure 218 227--*--treatment",
            "Drug 233 243--*--analgesics",
            "Procedure 245 257--*--Pretreatment",
            "Drug 267 281--*--CYP3A inducers",
            "Drug 267 272;285 295--*--CYP3A inhibitors",
            "Scope 267 295--*--CYP3A inducers or inhibitors",
            "Condition 303 310--*--allergy",
            "Drug 314 326--*--tested drugs",
            "Condition 328 349--*--Elevated eye pressure",
            "Condition 351 371--*--Obstructive uropathy",
            "Condition 373 386--*--Heart disease",
            "Condition 388 405--*--Pulmonary disease",
            "Condition 407 427--*--Neurological disease",
            "Condition 429 448--*--Psychiatric illness"
        ]
    },
    "NCT00586898_inc": {
        "Text": "-Patients residing in the following clinical states wit! be considered: A. Rising PSA: Patients with a history of localized disease who have undergone definitive radiation or surgery. These patients must demonstrate progression of disease biochemically as outlined below. Patients in this group may not have radiographically evident disease. . B. Non-castrate metastatic: Patients must present with radiographic evidence of metastatic disease at the time of diagnosis or after treatment for localized disease. These patients must show newly detected disease or progressing disease in bone or in soft tissue. Biochemical progression is defined as: minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50% . Diagnosis of prostate adenocarcinoma histologically confirmed at MSKCC. . Patient must have level of serum testosterone above the lower limit of normal. . Karnofskcy performance status (KPS) >_70%. . Patients must have adequate organ function as defined by the following laboratory criteria: . WBC >_3500/mm3, platelet count >_100,000/mm3. . Bilirubin <2.0 mg/dl or SGOT <3.0 X the upper limit of normal. . Creatinine <_1.6 mg/dl or creatinine clearance >_60 cc/min. . Prior hormonal therapy is allowed as: . 1. Neoadjuvant treatment prior to radiation therapy or radical prostatectomy, provided that the total duration of exposure does not exceed 10 months. . 2. One cycle of intermittent therapy up to a maximum exposure of 10 months. . Patients must be at least 18 years of age. . Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment . ",
        "Annotations": [
            "Parsing_Error 0 56--*---Patients residing in the following clinical states wit!",
            "Parsing_Error 57 74--*--be considered: A.",
            "Measurement 82 85--*--PSA",
            "Value 75 81--*--Rising",
            "Observation 103 113--*--history of",
            "Condition 114 131--*--localized disease",
            "Procedure 162 171--*--radiation",
            "Procedure 175 182--*--surgery",
            "Qualifier 151 161--*--definitive",
            "Scope 162 182--*--radiation or surgery",
            "Observation 216 238--*--progression of disease",
            "Qualifier 239 252--*--biochemically",
            "Qualifier 308 332--*--radiographically evident",
            "Condition 333 340--*--disease",
            "Qualifier 346 358--*--Non-castrate",
            "Qualifier 359 369--*--metastatic",
            "Observation 398 419--*--radiographic evidence",
            "Procedure 398 410--*--radiographic",
            "Condition 423 441--*--metastatic disease",
            "Temporal 442 466--*--at the time of diagnosis",
            "Temporal 470 507--*--after treatment for localized disease",
            "Procedure 476 485--*--treatment",
            "Condition 490 507--*--localized disease",
            "Reference_point 476 507--*--treatment for localized disease",
            "Reference_point 445 466--*--the time of diagnosis",
            "Scope 442 507--*--at the time of diagnosis or after treatment for localized disease",
            "Scope 346 369--*--Non-castrate metastatic",
            "Temporal 534 548--*--newly detected",
            "Condition 549 556;580 587--*--disease in bone",
            "Condition 560 579;591 605--*--progressing disease in soft tissue",
            "Condition 549 556;591 605--*--disease in soft tissue",
            "Condition 560 587--*--progressing disease in bone",
            "Observation 607 630--*--Biochemical progression",
            "Measurement 736 773--*--Minimal % increase in range of values",
            "Value 775 778--*--50%",
            "Measurement 698 724--*--Minimal Baseline PSA value",
            "Value 725 735--*--(ng/ml): 2",
            "Measurement 646 675--*--minimum no. of determinations",
            "Value 677 678--*--3",
            "Measurement 679 687--*--Interval",
            "Value 689 697--*-->2 weeks",
            "Scope 646 778--*--minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50%",
            "Scope 549 605--*--disease or progressing disease in bone or in soft tissue",
            "Condition 793 816--*--prostate adenocarcinoma",
            "Procedure 817 831--*--histologically",
            "Value 832 841--*--confirmed",
            "Qualifier 817 841--*--histologically confirmed",
            "Measurement 871 898--*--level of serum testosterone",
            "Value 899 930--*--above the lower limit of normal",
            "Measurement 933 968--*--Karnofskcy performance status (KPS)",
            "Value 969 974--*-->_70%",
            "Value 996 1004--*--adequate",
            "Measurement 1005 1019--*--organ function",
            "Observation 996 1019--*--adequate organ function",
            "Measurement 1070 1073--*--WBC",
            "Value 1074 1084--*-->_3500/mm3",
            "Measurement 1086 1100--*--platelet count",
            "Value 1101 1114--*-->_100,000/mm3",
            "Measurement 1117 1126--*--Bilirubin",
            "Value 1127 1137--*--<2.0 mg/dl",
            "Measurement 1141 1145--*--SGOT",
            "Value 1146 1178--*--<3.0 X the upper limit of normal",
            "Measurement 1181 1191--*--Creatinine",
            "Value 1192 1203--*--<_1.6 mg/dl",
            "Measurement 1207 1227--*--creatinine clearance",
            "Value 1228 1239--*-->_60 cc/min",
            "Temporal 1242 1247--*--Prior",
            "Procedure 1248 1264--*--hormonal therapy",
            "Mood 1265 1275--*--is allowed",
            "Procedure 1284 1305--*--Neoadjuvant treatment",
            "Temporal 1306 1357--*--prior to radiation therapy or radical prostatectomy",
            "Procedure 1315 1332--*--radiation therapy",
            "Procedure 1336 1357--*--radical prostatectomy",
            "Reference_point 1315 1357--*--radiation therapy or radical prostatectomy",
            "Measurement 1377 1403--*--total duration of exposure",
            "Value 1404 1429--*--does not exceed 10 months",
            "Multiplier 1435 1444--*--One cycle",
            "Procedure 1448 1468--*--intermittent therapy",
            "Measurement 1477 1493--*--maximum exposure",
            "Value 1497 1506--*--10 months",
            "Value 1526 1543--*--at least 18 years",
            "Person 1547 1550--*--age",
            "Informed_consent 1572 1607--*--signed an informed consent document"
        ]
    },
    "NCT02733159_exc": {
        "Annotations": [
            "Condition 10 27;46 64--*--symptomatic brain metastatic disease",
            "Condition 10 21;31 64--*--symptomatic leptomeningeal metastatic disease",
            "Qualifier 0 9--*--Untreated",
            "Condition 78 100--*--psychiatric conditions",
            "Undefined_semantics 78 100--*--psychiatric conditions",
            "Condition 67 74;90 100--*--Medical conditions",
            "Subjective_judgement 67 128--*--Medical or psychiatric conditions comprising informed consent",
            "Non-query-able 67 128--*--Medical or psychiatric conditions comprising informed consent",
            "Subjective_judgement 131 321--*--Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.",
            "Context_Error 131 321--*--Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.",
            "Procedure 323 335--*--Radiotherapy",
            "Temporal 336 365--*--within 4 weeks of trial entry",
            "Reference_point 354 365--*--trial entry",
            "Condition 375 393--*--autoimmune disease",
            "Temporal 368 374--*--Active",
            "Procedure 412 430--*--systemic treatment",
            "Temporal 431 446--*--in past 2 years",
            "Drug 465 473--*--steroids",
            "Multiplier 448 461--*--Chronic usage",
            "Drug 483 511--*--immunosuppressant medication",
            "Undefined_semantics 483 511--*--immunosuppressant medication",
            "Condition 534 545--*--pneumonitis",
            "Observation 523 530--*--history",
            "Condition 573 585--*--autoimmunity",
            "Condition 548 585--*--Any evidence of clinical autoimmunity"
        ],
        "Text": "Untreated symptomatic brain or leptomeningeal metastatic disease. . Medical or psychiatric conditions comprising informed consent. . Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol. . Radiotherapy within 4 weeks of trial entry. . Active autoimmune disease that has required systemic treatment in past 2 years . Chronic usage of steroids or other immunosuppressant medication. . Previous history of pneumonitis. . Any evidence of clinical autoimmunity.       .     . "
    },
    "NCT03407625_exc": {
        "Text": "latex allergy. non-reassuring fetal status. HIV. active herpes outbreak. Prior uterine scar. Contraindication to prostaglandins according to current Parkland protocol. Contraindication to vaginal delivery. ",
        "Annotations": [
            "Condition 6 13--*--allergy",
            "Drug 0 5--*--latex",
            "Condition 30 42--*--fetal status",
            "Qualifier 15 29--*--non-reassuring",
            "Condition 44 47--*--HIV",
            "Condition 56 62--*--herpes",
            "Qualifier 49 55--*--active",
            "Condition 79 91--*--uterine scar",
            "Condition 93 109--*--Contraindication",
            "Drug 113 127--*--prostaglandins",
            "Procedure 149 166--*--Parkland protocol",
            "Condition 168 184--*--Contraindication",
            "Procedure 188 204--*--vaginal delivery"
        ]
    },
    "NCT02371200_exc": {
        "Annotations": [
            "Parsing_Error 0 2--*--1.",
            "Parsing_Error 64 66--*--2.",
            "Parsing_Error 212 214--*--3.",
            "Parsing_Error 259 261--*--4.",
            "Parsing_Error 366 368--*--5.",
            "Parsing_Error 387 389--*--6.",
            "Condition 41 61--*--generalized seizures",
            "Observation 30 37--*--history",
            "Negation 8 11--*--not",
            "Condition 81 92--*--GTC seizure",
            "Negation 71 74--*--not",
            "Temporal 93 113--*--within the last year",
            "Drug 157 177--*--anti-epileptic drugs",
            "Procedure 144 177--*--reduction of anti-epileptic drugs",
            "Temporal 178 209--*--during their hospital admission",
            "Reference_point 191 209--*--hospital admission",
            "Negation 121 124--*--not",
            "Device 215 242--*--Intracranial EEG electrodes",
            "Measurement 276 299--*--upper arm circumference",
            "Qualifier 304 346--*--adequate for proper fit of the EMG monitor",
            "Negation 300 303--*--not",
            "Non-query-able 304 346--*--adequate for proper fit of the EMG monitor",
            "Value 348 362--*--less than 14cm",
            "Person 378 384--*--female",
            "Condition 369 377--*--Pregnant",
            "Non-query-able 390 437--*--Subject/Caregiver is unable to provide consent.",
            "Post-eligibility 390 437--*--Subject/Caregiver is unable to provide consent."
        ],
        "Text": "1. Does not have a documented history of generalized seizures. . 2. Has not had a GTC seizure within the last year AND is not expected to have a reduction of anti-epileptic drugs during their hospital admission. . 3. Intracranial EEG electrodes are being used . 4. The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm). . 5. Pregnant female. . 6. Subject/Caregiver is unable to provide consent.       .     . "
    },
    "NCT01942109_inc": {
        "Annotations": [
            "Condition 0 13--*--heart failure",
            "Measurement 14 18--*--NYHA",
            "Value 19 24--*--II-IV",
            "Procedure 35 44--*--treatment",
            "Temporal 26 34--*--previous",
            "Drug 50 59--*--diuretics",
            "Person 61 64--*--age",
            "Value 64 73--*-->18 years"
        ],
        "Text": "heart failure NYHA II-IV. previous treatment with diuretics. age>18 years. "
    },
    "NCT02874092_inc": {
        "Text": "RA cohort: Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995). OA cohort: Diagnosis of osteoarthritis made by physician.. ",
        "Annotations": [
            "Condition 0 2--*--RA",
            "Drug 21 24--*--MTX",
            "Multiplier 28 40--*--stable doses",
            "Multiplier 44 62--*--10 to 25 mg weekly",
            "Temporal 63 84--*--for at least 12 weeks",
            "Measurement 93 98--*--DAS28",
            "Value 102 115--*--3.2 or higher",
            "Non-representable 116 221--*--(The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)",
            "Condition 223 225--*--OA",
            "Condition 247 261--*--osteoarthritis",
            "Observation 262 279--*--made by physician",
            "Scope 21 221--*--MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)",
            "Scope 247 279--*--osteoarthritis made by physician"
        ]
    },
    "NCT02632760_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 17 33--*--hypersensitivity",
            "Drug 37 47--*--study drug",
            "Drug 49 70--*--ferric carboxymaltose",
            "Condition 124 141--*--haemoglobinopathy",
            "Condition 142 154--*--thalassaemia",
            "Mood 114 123--*--suspected",
            "Mood 105 110--*--Known",
            "Scope 105 123--*--Known or suspected",
            "Scope 124 154--*--haemoglobinopathy/thalassaemia",
            "Condition 156 175--*--Bone marrow disease",
            "Condition 177 193--*--Haemochromatosis",
            "Procedure 195 209--*--Renal dialysis",
            "Drug 211 225--*--Erythropoietin",
            "Drug 229 236--*--IV iron",
            "Temporal 237 260--*--in the previous 4 weeks",
            "Scope 211 236--*--Erythropoietin or IV iron"
        ],
        "Text": "Pregnancy. Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients. Known or suspected haemoglobinopathy/thalassaemia. Bone marrow disease. Haemochromatosis. Renal dialysis. Erythropoietin or IV iron in the previous 4 weeks. "
    },
    "NCT01098383_exc": {
        "Text": "an underlying infectious disease. chromosomal abnormality. metabolic disorder. specific brain related disorder (such as tuberous sclerosis). history of fetal cytomegalovirus infection. birth asphyxia. a history of major head injury. a chronic use of non-steroidal anti-inflammatory drugs, (NSAID). known brain damage. Epilepsy. Abnormal Electro-cardiogram (ECG). Epileptiform EEG. Use of psychostimulants, anti-depressants, neuroleptics or anti-convulsive agents within the past month.. Lack of cooperation in the screening phase. ",
        "Annotations": [
            "Condition 14 32--*--infectious disease",
            "Qualifier 3 13--*--underlying",
            "Condition 34 57--*--chromosomal abnormality",
            "Condition 59 77--*--metabolic disorder",
            "Condition 102 110--*--disorder",
            "Qualifier 88 93--*--brain",
            "Condition 120 138--*--tuberous sclerosis",
            "Condition 158 183--*--cytomegalovirus infection",
            "Qualifier 152 157--*--fetal",
            "Condition 185 199--*--birth asphyxia",
            "Condition 214 231--*--major head injury",
            "Condition 235 246--*--chronic use",
            "Drug 250 287--*--non-steroidal anti-inflammatory drugs",
            "Drug 290 295--*--NSAID",
            "Condition 304 316--*--brain damage",
            "Condition 318 326--*--Epilepsy",
            "Measurement 337 355--*--Electro-cardiogram",
            "Measurement 357 360--*--ECG",
            "Value 328 336--*--Abnormal",
            "Measurement 376 379--*--EEG",
            "Value 363 375--*--Epileptiform",
            "Drug 388 404--*--psychostimulants",
            "Drug 406 422--*--anti-depressants",
            "Drug 424 436--*--neuroleptics",
            "Drug 440 462--*--anti-convulsive agents",
            "Temporal 463 484--*--within the past month",
            "Scope 388 462--*--psychostimulants, anti-depressants, neuroleptics or anti-convulsive agents",
            "Post-eligibility 487 529--*--Lack of cooperation in the screening phase"
        ]
    },
    "NCT02068365_inc": {
        "Text": "Male & female patients >= 18 and < 70 years of age. Positive HBeAg before starting NA treatment. Treated by a single NA (lamivudine, adefovir, entecavir or tenofovir) for 6 months to 5 years. Developed HBeAg seroconversion (HBeAg negative and ant-HBe negative) with undetectable HBV DNA by PCR based assay on NA treatment.. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug. Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completion. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 7 13--*--female",
            "Value 23 43--*-->= 18 and < 70 years",
            "Person 47 50--*--age",
            "Measurement 61 66--*--HBeAg",
            "Value 52 60--*--Positive",
            "Temporal 67 95--*--before starting NA treatment",
            "Reference_point 74 95--*--starting NA treatment",
            "Drug 121 131--*--lamivudine",
            "Drug 133 141--*--adefovir",
            "Drug 143 152--*--entecavir",
            "Drug 156 165--*--tenofovir",
            "Multiplier 110 116--*--single",
            "Drug 117 119--*--NA",
            "Procedure 97 104--*--Treated",
            "Scope 121 165--*--lamivudine, adefovir, entecavir or tenofovir",
            "Temporal 167 190--*--for 6 months to 5 years",
            "Measurement 202 207--*--HBeAg",
            "Value 208 222--*--seroconversion",
            "Measurement 224 229--*--HBeAg",
            "Measurement 243 250--*--ant-HBe",
            "Value 230 238--*--negative",
            "Value 251 259--*--negative",
            "Scope 224 259--*--HBeAg negative and ant-HBe negative",
            "Value 266 278--*--undetectable",
            "Measurement 279 286--*--HBV DNA",
            "Procedure 290 305--*--PCR based assay",
            "Drug 309 311--*--NA",
            "Procedure 312 321--*--treatment",
            "Value 324 332--*--Negative",
            "Measurement 342 362--*--serum pregnancy test",
            "Measurement 333 338;348 362--*--urine pregnancy test",
            "Scope 333 362--*--urine or serum pregnancy test",
            "Person 368 373--*--women",
            "Condition 377 399--*--childbearing potential",
            "Scope 368 399--*--women of childbearing potential",
            "Temporal 412 474--*--within the 24-hour period prior to the first dose of test drug",
            "Reference_point 447 474--*--the first dose of test drug",
            "Pregnancy_considerations 476 599--*--Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completion"
        ]
    },
    "NCT02536976_inc": {
        "Text": "Aged 25-80 at screening. Subjects older than 80 will be allowed at the discretion of the PI.. Ambulatory (defined as able to ambulate at least 10 meters, with or without assistance).. Clinical Diagnosis of PD based on the United Kingdom Brain Bank diagnostic criteria for PD.. At least 8 micturitions per 24 hours and. At least 3 urgency episodes per 3-day diary.. A MoCA score between 19 and 28 (inclusive) at screening. For those on cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29 (inclusive) at screening.. Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.. Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent.. Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks.. Be on a stable regimen of antiparkinson's medications at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.. If taking cognitive enhancers (donepezil, rivastigmine, memantine, galantamine), must be on stable dose at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.. ",
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 10--*--25-80",
            "Non-query-able 25 91--*--Subjects older than 80 will be allowed at the discretion of the PI",
            "Person 94 104--*--Ambulatory",
            "Non-query-able 106 180--*--defined as able to ambulate at least 10 meters, with or without assistance",
            "Condition 206 208--*--PD",
            "Measurement 222 267--*--United Kingdom Brain Bank diagnostic criteria",
            "Condition 288 300--*--micturitions",
            "Multiplier 277 287;301 313--*--At least 8 per 24 hours",
            "Condition 330 346--*--urgency episodes",
            "Multiplier 319 329;347 363--*--At least 3 per 3-day diary.",
            "Measurement 367 377--*--MoCA score",
            "Value 378 395--*--between 19 and 28",
            "Procedure 435 454--*--cognitive enhancers",
            "Drug 456 465--*--donepezil",
            "Drug 467 479--*--rivastigmine",
            "Drug 481 490--*--memantine",
            "Drug 492 503--*--galantamine",
            "Measurement 507 517--*--MoCA score",
            "Value 518 535--*--between 19 and 29",
            "Scope 456 503--*--donepezil, rivastigmine, memantine, galantamine",
            "Scope 435 535--*--cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29",
            "Informed_consent 563 726--*--Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care",
            "Informed_consent 729 832--*--Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent",
            "Post-eligibility 835 1012--*--Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks",
            "Drug 1041 1068--*--antiparkinson's medications",
            "Temporal 1069 1104--*--at least 30 days prior to screening",
            "Reference_point 1095 1104--*--screening",
            "Procedure 1191 1210--*--cognitive enhancers",
            "Drug 1212 1221--*--donepezil",
            "Drug 1223 1235--*--rivastigmine",
            "Drug 1237 1246--*--memantine",
            "Drug 1248 1259--*--galantamine",
            "Scope 1212 1259--*--donepezil, rivastigmine, memantine, galantamine",
            "Qualifier 1273 1284--*--stable dose",
            "Temporal 1285 1320--*--at least 30 days prior to screening",
            "Reference_point 1311 1320--*--screening"
        ]
    },
    "NCT02643381_exc": {
        "Annotations": [
            "Person 0 8--*--Children",
            "Value 10 19--*--<18 years",
            "Person 20 23--*--old",
            "Scope 10 23--*--<18 years old",
            "Person 27 32--*--Women",
            "Condition 53 61--*--pregnant",
            "Procedure 100 110--*--randomized",
            "Temporal 89 99--*--previously",
            "Procedure 151 174--*--endotracheal intubation",
            "Observation 143 150--*--require",
            "Drug 183 202--*--sedative medication",
            "Negation 175 182--*--without",
            "Condition 229 248--*--full cardiac arrest",
            "Condition 273 280--*--allergy",
            "Drug 284 292--*--ketamine",
            "Drug 296 305--*--etomidate",
            "Scope 284 305--*--ketamine or etomidate",
            "Condition 308 413--*--Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial"
        ],
        "Text": "Children (<18 years old).. Women who are known to be pregnant.. Any patient who has been previously randomized in the EvK Trial.. Patients who require endotracheal intubation without sedative medication. For example, patients in full cardiac arrest.. Patients with a known allergy to ketamine or etomidate.. Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial.. "
    },
    "NCT00586898_exc": {
        "Text": "Clinically significant cardiac disease (New York Heart Association Class III/IV),or severe debilitating puhnonary disease. . Uncontrolled serious active infection. . Anticipated survival of less than 3 months. . Active CNS or epiduraltumor . Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests.       .     . ",
        "Annotations": [
            "Condition 23 38--*--cardiac disease",
            "Measurement 40 66--*--New York Heart Association",
            "Value 67 79--*--Class III/IV",
            "Qualifier 11 22--*--significant",
            "Condition 91 121--*--debilitating puhnonary disease",
            "Qualifier 84 90--*--severe",
            "Condition 152 161--*--infection",
            "Qualifier 124 144--*--Uncontrolled serious",
            "Observation 164 184--*--Anticipated survival",
            "Value 188 206--*--less than 3 months",
            "Condition 216 219;231 236--*--CNS tumor",
            "Condition 223 236--*--epiduraltumor",
            "Condition 238 247--*--Inability",
            "Observation 251 264--*--unwillingness",
            "Informed_consent 268 302--*--comply with the treatment protocol",
            "Procedure 304 313--*--follow-up",
            "Post-eligibility 318 332--*--research tests",
            "Scope 268 332--*--comply with the treatment protocol, follow-up, or research tests",
            "Scope 238 264--*--Inability or unwillingness"
        ]
    },
    "NCT02733159_inc": {
        "Annotations": [
            "Condition 46 51--*--NSCLC",
            "Qualifier 25 37--*--PD-L1 status",
            "Procedure 53 59--*--Biopsy",
            "Temporal 68 101--*--within 70 days of first treatment",
            "Reference_point 86 120--*--first treatment with pembrolizumab",
            "Drug 107 120--*--pembrolizumab",
            "Measurement 123 146--*--ECOG performance status",
            "Value 147 148--*--2",
            "Observation 151 166--*--Life expectancy",
            "Measurement 230 289--*--Response Evaluation Criteria in Solid Tumours (RECIST) v1.1",
            "Value 180 208--*--Uni-dimensionally measurable",
            "Condition 209 216--*--disease",
            "Context_Error 209 216--*--disease",
            "Procedure 291 345--*--Computerised Tomography (CT) scan of chest and abdomen",
            "Temporal 346 386--*--within 28 days of starting pembrolizumab",
            "Reference_point 364 386--*--starting pembrolizumab",
            "Drug 373 386--*--pembrolizumab",
            "Measurement 424 438--*--Platelet count",
            "Value 439 452--*--\u2265100 x 109 /L",
            "Measurement 455 466--*--Neutrophils",
            "Value 467 479--*--\u22651.5 x 109/L",
            "Measurement 482 493--*--Haemoglobin",
            "Value 494 501--*--\u2265 9g/dL",
            "Parsing_Error 389 422--*--Adequate haematological function:",
            "Parsing_Error 504 530--*--Adequate hepatic function:",
            "Measurement 532 547--*--Serum bilirubin",
            "Value 548 582--*--\u22641.5 x upper limit of normal (ULN)",
            "Measurement 585 604--*--Serum transaminases",
            "Value 605 615--*--\u22642.5 x ULN",
            "Measurement 643 663--*--Creatinine clearance",
            "Value 664 678--*--<1.5 times ULN",
            "Temporal 679 689--*--concurrent",
            "Measurement 695 715--*--creatinine clearance",
            "Value 716 726--*-->50 ml/min",
            "Measurement 627 641--*--renal function",
            "Value 618 626--*--Adequate",
            "Scope 643 726--*--Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min",
            "Post-eligibility 729 847--*--Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.",
            "Non-query-able 729 847--*--Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses."
        ],
        "Text": "Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab. . ECOG performance status 2. . Life expectancy > 12 weeks. . Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 . Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab. . Adequate haematological function: . Platelet count \u2265100 x 109 /L. . Neutrophils \u22651.5 x 109/L. . Haemoglobin \u2265 9g/dL. . Adequate hepatic function: . Serum bilirubin \u22641.5 x upper limit of normal (ULN). . Serum transaminases \u22642.5 x ULN. . Adequate renal function: Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min. . Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. . "
    },
    "NCT02779374_inc": {
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 11 14--*--POI",
            "Person 90 94--*--aged",
            "Value 95 113--*--less than 40 years",
            "Condition 122 132--*--amenorrhea",
            "Temporal 136 152--*--at least 4 month",
            "Measurement 158 167--*--FSH level",
            "Value 168 181--*--above 25 IU/L",
            "Multiplier 183 197--*--repeated twice",
            "Temporal 198 212--*-->4 weeks apart",
            "Scope 90 213--*--aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart)"
        ],
        "Text": "Women with POI: For the purpose of the research women is considered to have POI if she is aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart). . "
    },
    "NCT02256943_exc": {
        "Text": "NA. ",
        "Annotations": []
    },
    "NCT00639795_exc": {
        "Text": "Age less than 18 . Clinical or laboratory evidence of systemic infection . Current pregnancy as assessed by preoperative urine HCG test . Serious, uncontrolled, non-malignant illness . Malignant illness requiring systemic chemotherapy in the last 6 months . Documented allergy to oxycodone, morphine sulfate or acetaminophen . Contraindication to peripheral nerve blockade or general anesthesia including: . 1. patient refusal . 2. active infection at site of planned block . 3. documented allergy to any local or general anesthetic medications . 4. significant coagulopathy( prothrombin time >15 seconds, INR>1.5 . 5. pre-existing neuropathy and medical conditions or deformities which would compromise block or anesthetic safety . Planned pleurodesis . Current use of high dose inhaled or systemic steroids . Current use of Amiodarone (Cordarone) . Morbid obesity (BMI=40kg/m2) . Patients with clinically significant mental health issues such as psychosis requiring treatment with antipsychotic medications. . Patients unable to consent . Patients with active infections requiring antibiotics within one month of registration . Participation in other clinical trials that may interfere with this study       .     . ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 16--*--less than 18",
            "Undefined_semantics 18 71--*--Clinical or laboratory evidence of systemic infection",
            "Temporal 106 118--*--preoperative",
            "Measurement 119 133--*--urine HCG test",
            "Value 81 90--*--pregnancy",
            "Condition 81 90--*--pregnancy",
            "Condition 158 179--*--non-malignant illness",
            "Qualifier 144 156--*--uncontrolled",
            "Qualifier 135 142--*--Serious",
            "Condition 181 198--*--Malignant illness",
            "Procedure 209 230--*--systemic chemotherapy",
            "Temporal 231 251--*--in the last 6 months",
            "Drug 275 284--*--oxycodone",
            "Drug 286 302--*--morphine sulfate",
            "Drug 306 319--*--acetaminophen",
            "Condition 264 271--*--allergy",
            "Scope 275 319--*--oxycodone, morphine sulfate or acetaminophen",
            "Condition 321 366--*--Contraindication to peripheral nerve blockade",
            "Condition 321 340;370 388--*--Contraindication to general anesthesia",
            "Non-query-able 401 419--*--1. patient refusal",
            "Non-query-able 421 465--*--2. active infection at site of planned block",
            "Undefined_semantics 467 535--*--3. documented allergy to any local or general anesthetic medications",
            "Condition 552 564--*--coagulopathy",
            "Qualifier 540 551--*--significant",
            "Measurement 566 582--*--prothrombin time",
            "Value 583 594--*-->15 seconds",
            "Measurement 596 599--*--INR",
            "Value 599 603--*-->1.5",
            "Scope 566 603--*--prothrombin time >15 seconds, INR>1.5",
            "Condition 621 631--*--neuropathy",
            "Temporal 608 620--*--pre-existing",
            "Undefined_semantics 636 719--*--medical conditions or deformities which would compromise block or anesthetic safety",
            "Condition 729 740--*--pleurodesis",
            "Non-query-able 721 740--*--Planned pleurodesis",
            "Drug 787 795--*--steroids",
            "Qualifier 767 774--*--inhaled",
            "Qualifier 778 786--*--systemic",
            "Scope 767 786--*--inhaled or systemic",
            "Qualifier 757 766--*--high dose",
            "Temporal 742 749--*--Current",
            "Drug 812 822--*--Amiodarone",
            "Drug 824 833--*--Cordarone",
            "Temporal 797 804--*--Current",
            "Condition 836 850--*--Morbid obesity",
            "Measurement 852 855--*--BMI",
            "Value 856 863--*--40kg/m2",
            "Condition 903 923--*--mental health issues",
            "Condition 932 941--*--psychosis",
            "Drug 967 992--*--antipsychotic medications",
            "Procedure 952 961--*--treatment",
            "Qualifier 880 902--*--clinically significant",
            "Scope 880 941--*--clinically significant mental health issues such as psychosis",
            "Non-query-able 995 1021--*--Patients unable to consent",
            "Condition 1044 1054--*--infections",
            "Temporal 1037 1043--*--active",
            "Drug 1065 1076--*--antibiotics",
            "Temporal 1077 1109--*--within one month of registration",
            "Non-query-able 1111 1184--*--Participation in other clinical trials that may interfere with this study"
        ]
    },
    "NCT02056301_inc": {
        "Annotations": [
            "Person 9 12--*--age",
            "Value 13 24--*--8- 18 years",
            "Line 25 109--*--2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure",
            "Line 110 160--*--3) American Society of Anesthesiology Status I-III",
            "Procedure 48 90--*--minimally invasive pectus excavatum repair",
            "Qualifier 95 109--*--Nuss procedure",
            "Measurement 113 154--*--American Society of Anesthesiology Status",
            "Value 155 160--*--I-III"
        ],
        "Text": "Patients age 8- 18 years 2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure 3) American Society of Anesthesiology Status I-III. "
    },
    "NCT02200978_exc": {
        "Annotations": [
            "Condition 18 22--*--coma",
            "Condition 24 34--*--convulsion",
            "Condition 38 47--*--paralysis",
            "Condition 55 78--*--intracranial hemorrhage",
            "Qualifier 82 104--*--central nervous system",
            "Condition 105 113--*--leukemia",
            "Temporal 114 126--*--at diagnosis",
            "Scope 55 113--*--intracranial hemorrhage or central nervous system leukemia",
            "Scope 18 47--*--coma, convulsion or paralysis"
        ],
        "Text": "Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.. "
    },
    "NCT02673359_inc": {
        "Text": "Women with singleton pregnancy.. History of preterm labor and/or midtrimester miscarriage in a previous pregnancy.. Cervical length of 15-25 mm by transvaginal sonography (TVS) at 16-24 weeks of gestation.. ",
        "Annotations": [
            "Person 0 5--*--Women",
            "Condition 11 30--*--singleton pregnancy",
            "Condition 44 57--*--preterm labor",
            "Condition 65 89--*--midtrimester miscarriage",
            "Temporal 95 103--*--previous",
            "Condition 104 113--*--pregnancy",
            "Scope 95 113--*--previous pregnancy",
            "Scope 44 89--*--preterm labor and/or midtrimester miscarriage",
            "Measurement 116 131--*--Cervical length",
            "Value 135 143--*--15-25 mm",
            "Procedure 147 176--*--transvaginal sonography (TVS)",
            "Value 180 191--*--16-24 weeks",
            "Measurement 195 204--*--gestation",
            "Temporal 177 204--*--at 16-24 weeks of gestation",
            "Reference_point 180 204--*--16-24 weeks of gestation"
        ]
    },
    "NCT01491763_inc": {
        "Annotations": [
            "Measurement 14 26--*--Ph (BCR/ABL)",
            "Value 27 35--*--positive",
            "Qualifier 36 43--*--de novo",
            "Value 44 54--*--< 55 years",
            "Person 55 58--*--old",
            "Non-representable 59 128--*--(it is advisable to include patients over 55 years LAL07OPH protocol)",
            "Measurement 131 149--*--Performance status",
            "Value 150 153--*--0-2",
            "Condition 255 286--*--functional impairment of organs",
            "Non-representable 154 235--*--(Appendix B) may include patients with performance status > 2 attributable to LAL",
            "Negation 247 254--*--without",
            "Measurement 304 319--*--total bilirubin",
            "Measurement 321 324--*--AST",
            "Measurement 326 329--*--ALT",
            "Measurement 331 338--*--alfa-GT",
            "Measurement 343 363--*--alkaline phosphatase",
            "Value 364 407--*--less than 3 times the upper limit of normal",
            "Scope 304 363--*--total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase",
            "Scope 304 407--*--total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal",
            "Scope 247 286--*--without functional impairment of organs",
            "Measurement 435 451--*--serum creatinine",
            "Value 452 461--*--< 2 mg/dL",
            "Measurement 465 485--*--clearance creatinine",
            "Value 486 497--*--> 30 ml/min",
            "Non-representable 498 541--*--(except renal function attributable to LAL)",
            "Measurement 542 558--*--cardiac function",
            "Value 572 578--*--normal",
            "Measurement 580 594--*--ventricular EF",
            "Value 595 600--*--> 50%",
            "Negation 602 612--*--absence of",
            "Condition 613 647--*--severe chronic respiratory disease",
            "Scope 542 578--*--cardiac function (Appendix B) normal",
            "Scope 580 600--*--ventricular EF > 50%",
            "Non-representable 649 805--*--In the event that alterations are secondary to the disease is at the discretion of the investigator to determine if the patient can be included in the trial",
            "Scope 304 648--*--total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease."
        ],
        "Text": "Patients with Ph (BCR/ABL) positive de novo < 55 years old (it is advisable to include patients over 55 years LAL07OPH protocol).. Performance status 0-2 (Appendix B) may include patients with performance status > 2 attributable to LAL.. Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease. In the event that alterations are secondary to the disease is at the discretion of the investigator to determine if the patient can be included in the trial.. "
    },
    "NCT03480607_exc": {
        "Text": "known allergy to any of drugs used. coagulopathy. any wound or infection related to puncture site. major illness. failure to gain consent of parents.. ",
        "Annotations": [
            "Condition 6 13--*--allergy",
            "Drug 24 34--*--drugs used",
            "Condition 36 48--*--coagulopathy",
            "Condition 54 59--*--wound",
            "Condition 63 72--*--infection",
            "Qualifier 84 97--*--puncture site",
            "Scope 54 72--*--wound or infection",
            "Observation 130 148--*--consent of parents",
            "Negation 114 129--*--failure to gain",
            "Informed_consent 114 148--*--failure to gain consent of parents",
            "Qualifier 99 104--*--major",
            "Condition 105 112--*--illness"
        ]
    },
    "NCT02056301_exc": {
        "Annotations": [
            "Mood 3 10--*--Refusal",
            "Device 14 31--*--epidural catheter",
            "Condition 35 44--*--Pregnancy",
            "Condition 48 56--*--Bleeding",
            "Observation 57 64--*--History",
            "Non-query-able 68 117--*--Inability to understand how to use the PCA device",
            "Drug 121 131--*--Medication",
            "Qualifier 132 166--*--interfering with blood coagulation",
            "Condition 179 187--*--allergic",
            "Drug 191 208--*--local anesthetics",
            "Line 0 31--*--1) Refusal of epidural catheter",
            "Line 32 44--*--2) Pregnancy",
            "Line 45 64--*--3) Bleeding History",
            "Line 65 117--*--4) Inability to understand how to use the PCA device",
            "Line 118 166--*--5) Medication interfering with blood coagulation",
            "Line 167 208--*--6) Patients allergic to local anesthetics",
            "Line 209 251--*--7) Patient refusal to participate in study",
            "Line 252 274--*--8) Developmental delay",
            "Non-query-able 212 251--*--Patient refusal to participate in study",
            "Condition 255 274--*--Developmental delay"
        ],
        "Text": "1) Refusal of epidural catheter 2) Pregnancy 3) Bleeding History 4) Inability to understand how to use the PCA device 5) Medication interfering with blood coagulation 6) Patients allergic to local anesthetics 7) Patient refusal to participate in study 8) Developmental delay. "
    },
    "NCT02673359_exc": {
        "Text": "Age < 20 or > 35 years.. Congenital uterine malformation.. Multifetal pregnancy.. Known major fetal structural or chromosomal abnormality.. Known allergy or contraindication (relative or absolute) to progesterone therapy.. Presence of contraindication to cervical cerclage.. Medical conditions complicating pregnancy.. Vaginal bleeding.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 8--*--< 20",
            "Value 12 22--*--> 35 years",
            "Scope 4 22--*--< 20 or > 35 years",
            "Condition 25 56--*--Congenital uterine malformation",
            "Condition 59 79--*--Multifetal pregnancy",
            "Condition 114 137--*--chromosomal abnormality",
            "Condition 94 110--*--fetal structural",
            "Qualifier 88 93--*--major",
            "Scope 94 137--*--fetal structural or chromosomal abnormality",
            "Condition 146 153--*--allergy",
            "Condition 157 173--*--contraindication",
            "Qualifier 175 183--*--relative",
            "Qualifier 187 195--*--absolute",
            "Procedure 200 220--*--progesterone therapy",
            "Scope 175 195--*--relative or absolute",
            "Scope 146 173--*--allergy or contraindication",
            "Condition 235 251--*--contraindication",
            "Procedure 255 272--*--cervical cerclage",
            "Condition 275 293--*--Medical conditions",
            "Qualifier 294 316--*--complicating pregnancy",
            "Condition 319 335--*--Vaginal bleeding"
        ]
    },
    "NCT02200978_inc": {
        "Annotations": [
            "Value 9 27--*--less than 16 years",
            "Person 28 31--*--old",
            "Measurement 53 61--*--PML-RARa",
            "Value 62 70--*--positive",
            "Condition 71 99--*--acute promyelocytic leukemia"
        ],
        "Text": "Patients less than 16 years old with newly diagnosed PML-RARa positive acute promyelocytic leukemia.. "
    },
    "NCT03480607_inc": {
        "Text": "American society of anesthesiologist (ASA) physical status I or II. ",
        "Annotations": [
            "Measurement 0 36;43 58--*--American society of anesthesiologist physical status",
            "Measurement 38 41--*--ASA",
            "Value 59 66--*--I or II"
        ]
    },
    "NCT01491763_exc": {
        "Annotations": [
            "Qualifier 4 17--*--other variety",
            "Condition 21 24--*--LAL",
            "Observation 42 49--*--history",
            "Condition 53 76--*--coronary artery disease",
            "Condition 90 116--*--hypertensive heart disease",
            "Condition 103 116;78 86--*--heart disease valvular",
            "Scope 53 116--*--coronary artery disease, valvular or hypertensive heart disease",
            "Condition 132 153--*--chronic liver disease",
            "Condition 169 196--*--chronic respiratory failure",
            "Condition 198 211--*--Renal failure",
            "Condition 223 226--*--LAL",
            "Negation 212 215--*--not",
            "Mood 216 222--*--due to",
            "Value 242 250--*--positive",
            "Measurement 251 261--*--HIV status",
            "Negation 263 265--*--No",
            "Qualifier 266 273--*--serious",
            "Condition 274 300--*--neurological abnormalities",
            "Mood 301 307--*--due to",
            "Condition 308 311--*--LAL",
            "Non-representable 313 397--*--Impact on overall severe (grade 3 or 4 of the WHO scale) not attributable to the LAL",
            "Observation 399 407--*--Pregnant",
            "Observation 411 424--*--breastfeeding",
            "Qualifier 434 446--*--blast crisis",
            "Condition 447 450--*--CML"
        ],
        "Text": "Any other variety of LAL. Patients with a history of coronary artery disease, valvular or hypertensive heart disease. Patients with chronic liver disease. Patients with chronic respiratory failure. Renal failure not due to LAL. Patients with positive HIV status. No serious neurological abnormalities due to LAL. Impact on overall severe (grade 3 or 4 of the WHO scale) not attributable to the LAL. Pregnant or breastfeeding. initial blast crisis CML. "
    },
    "NCT03472846_exc": {
        "Annotations": [
            "Condition 0 24--*--Diabetes mellitus type 1",
            "Condition 26 45--*--renal insufficiency",
            "Qualifier 46 53--*--III-V \u00b0",
            "Condition 55 72--*--Cirrhosis hepatis",
            "Measurement 74 79--*--Child",
            "Value 80 91--*--B or higher",
            "Qualifier 74 91--*--Child B or higher",
            "Multiplier 94 101--*--Chronic",
            "Condition 102 115--*--alcohol abuse",
            "Condition 117 134--*--rheumatic disease",
            "Condition 136 138--*--RA",
            "Condition 140 143--*--SpA",
            "Condition 145 148--*--SLE",
            "Scope 136 148--*--RA, SpA, SLE",
            "Condition 151 163--*--Malignancies",
            "Temporal 165 173--*--<5 years",
            "Condition 176 191--*--Eating Disorder",
            "Condition 193 209--*--anorexia nervosa",
            "Condition 211 218--*--bulimia",
            "Scope 193 218--*--anorexia nervosa, bulimia",
            "Procedure 221 247--*--bone-specific pretreatment",
            "Drug 249 253--*--DMAB",
            "Drug 255 259--*--TPTD",
            "Drug 281 286--*--SERMs",
            "Drug 261 279--*--strontium ranelate",
            "Non-representable 288 323--*--Bisphosphonate treatment is allowed",
            "Scope 249 286--*--DMAB, TPTD, strontium ranelate, SERMs"
        ],
        "Text": "Diabetes mellitus type 1. renal insufficiency III-V \u00b0. Cirrhosis hepatis (Child B or higher). Chronic alcohol abuse. rheumatic disease (RA, SpA, SLE). Malignancies (<5 years). Eating Disorder (anorexia nervosa, bulimia). bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed. "
    },
    "NCT03064867_exc": {
        "Text": "Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4.0 (except clinically insignificant toxicities such as alopecia). . Subjects receiving any other investigational agents. . Patients with active tumor lysis syndrome (TLS) either from laboratory or clinical changes. . Patients with active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma. . History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this study. . Subjects with uncontrolled intercurrent illness . . HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with Venetoclax. In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated. HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment. . Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody. . Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation . Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing. . Women who are pregnant or lactating . Malabsorption syndrome or other condition that precludes enteral route of administration . Chemotherapy or radiation within 3 weeks of the first scheduled study treatment. . Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, \"in-situ\" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels). Patients who have had completed all anti-cancer treatment for another primary malignancy more than 2 years prior to screening are eligible if they are not considered to have a \"currently active\" malignancy based on having less than a 30% risk of relapse. . Major surgery, other than diagnostic surgery, within 2 weeks. . Medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent). Brief (<15 days) treatment with glucocorticoids (prednisone 100 mg by mouth daily, or equivalent) is acceptable. . Known allergy to both xanthine oxidase inhibitors and rasburicase. . Use of warfarin is prohibited. Anticoagulation with low-molecular weight heparin (i.e. enoxaparin) or direct thrombin inhibitors is permitted. . The following concomitant medications are not allowed from 7 days prior to the first dose of study drug and during venetoclax administration: Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to rifampin, carbamazepine. . Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment. . Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary. . Moderate/Weak CYP3A inducers such as efavirenz and oxcarbazepine . CYP2C8 substrates such as thiazolidinediones (glitazones) and select statins (because of expected inhibition of the metabolism of CYP2C8 substrates) by venetoclax . CYP2C9 substrates such as tolbutamide (because of expected inhibition of the metabolism of CYP2C9 substrates by venetoclax. It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin.       .     . ",
        "Annotations": [
            "Context_Error 0 155--*--Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4.0 (except clinically insignificant toxicities such as alopecia).",
            "Context_Error 157 209--*--Subjects receiving any other investigational agents.",
            "Condition 232 258--*--tumor lysis syndrome (TLS)",
            "Condition 325 361--*--central nervous system (CNS) disease",
            "Condition 385 403--*--meningeal lymphoma",
            "Qualifier 373 384--*--symptomatic",
            "Condition 413 437--*--CNS parenchymal lymphoma",
            "Scope 373 437--*--symptomatic meningeal lymphoma or known CNS parenchymal lymphoma",
            "Condition 458 476--*--allergic reactions",
            "Qualifier 451 457--*--severe",
            "Drug 491 557--*--compounds of similar chemical or biologic composition to rituximab",
            "Drug 491 547;561 592--*--compounds of similar chemical or biologic composition to other agents used in this study",
            "Undefined_semantics 491 592--*--compounds of similar chemical or biologic composition to rituximab or other agents used in this study",
            "Scope 491 592--*--compounds of similar chemical or biologic composition to rituximab or other agents used in this study",
            "Undefined_semantics 595 642--*--Subjects with uncontrolled intercurrent illness",
            "Condition 646 658--*--HIV-positive",
            "Procedure 671 705--*--combination antiretroviral therapy",
            "Parsing_Error 913 1024--*--Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.",
            "Not_a_criteria 913 1024--*--Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.",
            "Not_a_criteria 1025 1164--*--HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment.",
            "Measurement 1204 1227--*--hepatitis B virus (HBV)",
            "Measurement 1229 1264--*--hepatitis B surface antigen (HBsAg)",
            "Measurement 1269 1295--*--hepatitis C (HCV) antibody",
            "Value 1178 1186--*--positive",
            "Measurement 1328 1340--*--HCV antibody",
            "Value 1315 1323--*--positive",
            "Measurement 1362 1365--*--HCV",
            "Value 1349 1357--*--negative",
            "Scope 1315 1340--*--positive for HCV antibody",
            "Procedure 1369 1400--*--polymerase chain reaction (PCR)",
            "Condition 1471 1484--*--HBV infection",
            "Measurement 1506 1545--*--total hepatitis B core antibody [HBcAb]",
            "Value 1497 1505--*--positive",
            "Measurement 1559 1564--*--HBsAg",
            "Value 1550 1558--*--negative",
            "Measurement 1585 1592--*--HBV DNA",
            "Value 1596 1608--*--undetectable",
            "Scope 1497 1564--*--positive total hepatitis B core antibody [HBcAb] and negative HBsAg",
            "Grammar_Error 1566 1581--*--may be included",
            "Non-query-able 1610 1672--*--These patients must be willing to undergo monthly DNA testing.",
            "Person 1674 1679--*--Women",
            "Condition 1688 1696--*--pregnant",
            "Condition 1700 1709--*--lactating",
            "Condition 1711 1733--*--Malabsorption syndrome",
            "Condition 1743 1799--*--condition that precludes enteral route of administration",
            "Undefined_semantics 1743 1799--*--condition that precludes enteral route of administration",
            "Drug 1801 1813--*--Chemotherapy",
            "Procedure 1817 1826--*--radiation",
            "Temporal 1827 1880--*--within 3 weeks of the first scheduled study treatment",
            "Reference_point 1845 1880--*--the first scheduled study treatment",
            "Temporal 1883 1899--*--Less than 2-year",
            "Condition 1900 1912--*--disease free",
            "Condition 1926 1944--*--primary malignancy",
            "Qualifier 1918 1925--*--another",
            "Condition 1957 2001--*--squamous or basal cell carcinoma of the skin",
            "Condition 2003 2036--*--\"in-situ\" carcinoma of the cervix",
            "Condition 2003 2036;2040 2046--*--\"in-situ\" carcinoma of the cervix breast",
            "Condition 2048 2077--*--superficial bladder carcinoma",
            "Condition 2101 2126--*--localized prostate cancer",
            "Measurement 2139 2177--*--prostate specific antigen (PSA) levels",
            "Value 2132 2138--*--normal",
            "Scope 1957 2177--*--squamous or basal cell carcinoma of the skin, \"in-situ\" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels",
            "Procedure 2216 2237--*--anti-cancer treatment",
            "Condition 2250 2268--*--primary malignancy",
            "Qualifier 2242 2249--*--another",
            "Temporal 2269 2292--*--more than 2 years prior",
            "Reference_point 2296 2305--*--screening",
            "Negation 2306 2318--*--are eligible",
            "Procedure 2436 2449--*--Major surgery",
            "Procedure 2462 2480--*--diagnostic surgery",
            "Temporal 2482 2496--*--within 2 weeks",
            "Drug 2552 2576--*--systemic corticosteroids",
            "Drug 2593 2603--*--prednisone",
            "Multiplier 2604 2625--*--higher than 10 mg/day",
            "Multiplier 2542 2551--*--high dose",
            "Condition 2499 2516--*--Medical condition",
            "Undefined_semantics 2499 2516--*--Medical condition",
            "Temporal 2527 2534--*--chronic",
            "Scope 2584 2625--*--doses of prednisone higher than 10 mg/day",
            "Temporal 2649 2657--*--<15 days",
            "Drug 2674 2689--*--glucocorticoids",
            "Drug 2691 2701--*--prednisone",
            "Multiplier 2702 2708;2718 2723--*--100 mg daily",
            "Grammar_Error 2740 2753--*--is acceptable",
            "Drug 2778 2805--*--xanthine oxidase inhibitors",
            "Drug 2810 2821--*--rasburicase",
            "Condition 2762 2769--*--allergy",
            "Condition 2762 2769--*--allergy",
            "Drug 2831 2839--*--warfarin",
            "Procedure 2855 2870--*--Anticoagulation",
            "Drug 2876 2904--*--low-molecular weight heparin",
            "Drug 2911 2921--*--enoxaparin",
            "Drug 2926 2952--*--direct thrombin inhibitors",
            "Grammar_Error 2953 2966--*--is permitted.",
            "Temporal 3027 3039--*--7 days prior",
            "Reference_point 3047 3071--*--first dose of study drug",
            "Drug 3083 3093--*--venetoclax",
            "Procedure 3083 3108--*--venetoclax administration",
            "Drug 3110 3134--*--Strong CYP3A4 inhibitors",
            "Drug 3164 3175--*--fluconazole",
            "Drug 3177 3189--*--ketoconazole",
            "Drug 3195 3209--*--clarithromycin",
            "Drug 3213 3235--*--strong CYP3A4 inducers",
            "Drug 3264 3272--*--rifampin",
            "Drug 3274 3287--*--carbamazepine",
            "Scope 3264 3287--*--rifampin, carbamazepine",
            "Scope 3164 3209--*--fluconazole, ketoconazole, and clarithromycin",
            "Scope 3027 3108--*--7 days prior to the first dose of study drug and during venetoclax administration",
            "Scope 3110 3287--*--Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to rifampin, carbamazepine",
            "Drug 3301 3320--*--live-virus vaccines",
            "Temporal 3321 3341--*--within 28 days prior",
            "Reference_point 3345 3378--*--the initiation of study treatment",
            "Non-query-able 3382 3390--*--need for",
            "Drug 3391 3410--*--live-virus vaccines",
            "Temporal 3414 3429--*--any time during",
            "Reference_point 3430 3445--*--study treatment",
            "Observation 3382 3390--*--need for",
            "Undefined_semantics 3448 3588--*--Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.",
            "Context_Error 3448 3588--*--Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.",
            "Drug 3599 3618--*--Weak CYP3A inducers",
            "Drug 3590 3598;3604 3618--*--Moderate CYP3A inducers",
            "Drug 3627 3636--*--efavirenz",
            "Drug 3641 3654--*--oxcarbazepine",
            "Scope 3590 3618--*--Moderate/Weak CYP3A inducers",
            "Scope 3627 3654--*--efavirenz and oxcarbazepine",
            "Drug 3656 3673--*--CYP2C8 substrates",
            "Undefined_semantics 3656 3673--*--CYP2C8 substrates",
            "Drug 3682 3700--*--thiazolidinediones",
            "Drug 3702 3712--*--glitazones",
            "Drug 3725 3732--*--statins",
            "Qualifier 3718 3724--*--select",
            "Drug 3820 3837--*--CYP2C9 substrates",
            "Drug 3846 3857--*--tolbutamide",
            "Drug 3973 3990--*--CYP2C9 substrates",
            "Drug 4031 4040--*--phenytoin",
            "Qualifier 3998 4022--*--narrow therapeutic index",
            "Subjective_judgement 3944 4040--*--It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin",
            "Non-representable 796 912--*--In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy.",
            "Negation 2451 2461--*--other than",
            "Negation 1946 1956--*--other than"
        ]
    },
    "NCT01793519_exc": {
        "Text": "Had dose increase of anti-TNF agent or DMARD in the last 6 months. Had change of anti-TNF agent or DMARD in the last 6 months. Treated currently with golimumab or certolizumab. Treated with greater than 10 mg of prednisone (or equivalent) daily in the last 6 months. Treated with greater than 5 mg of prednisone (or equivalent) daily in the last 3 months. Treated with intramuscular or intravenous corticosteroids in the last 6 months for RA activity. Treated with anakinra, abatacept, or tocilizumab in the last 6 months. Treated with rituximab in the last 12 months. Treated with an investigational RA drug in the last 6 months. Pregnant (or anticipate pregnancy during the study period) or lactating women. Absence of documentation in the medical record of clinical remission for the last 6 months. Unwilling to discontinue anti-TNF agent. Absence of documentation of negative tuberculin skin test, negative QuantiFERON-TB Gold test, or treatment for latent tuberculosis prior to starting treatment with the anti-TNF agent. Treatment of solid malignancy or non-melanoma skin cancer within the past 5 years, or any history of melanoma or hematologic or lymphoproliferative malignancy. Absence of documentation of age-appropriate cancer screening at the time of randomization. Absence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment. Unable to provide informed consent. Anticipate not being available or able to comply with the schedule of study visits. ",
        "Annotations": [
            "Drug 21 35--*--anti-TNF agent",
            "Drug 39 44--*--DMARD",
            "Multiplier 4 17--*--dose increase",
            "Scope 21 44--*--anti-TNF agent or DMARD",
            "Drug 81 95--*--anti-TNF agent",
            "Drug 99 104--*--DMARD",
            "Procedure 71 77--*--change",
            "Scope 81 104--*--anti-TNF agent or DMARD",
            "Temporal 45 65--*--in the last 6 months",
            "Temporal 105 125--*--in the last 6 months",
            "Drug 150 159--*--golimumab",
            "Drug 163 175--*--certolizumab",
            "Multiplier 190 208--*--greater than 10 mg",
            "Drug 212 222--*--prednisone",
            "Multiplier 239 244--*--daily",
            "Temporal 245 265--*--in the last 6 months",
            "Multiplier 280 297--*--greater than 5 mg",
            "Drug 301 311--*--prednisone",
            "Multiplier 328 333--*--daily",
            "Temporal 334 354--*--in the last 3 months",
            "Qualifier 369 382--*--intramuscular",
            "Qualifier 386 397--*--intravenous",
            "Drug 398 413--*--corticosteroids",
            "Temporal 414 434--*--in the last 6 months",
            "Condition 439 441--*--RA",
            "Scope 369 397--*--intramuscular or intravenous",
            "Drug 465 473--*--anakinra",
            "Drug 475 484--*--abatacept",
            "Drug 489 500--*--tocilizumab",
            "Temporal 501 521--*--in the last 6 months",
            "Scope 465 500--*--anakinra, abatacept, or tocilizumab",
            "Drug 536 545--*--rituximab",
            "Temporal 546 567--*--in the last 12 months",
            "Qualifier 585 600--*--investigational",
            "Drug 601 608--*--RA drug",
            "Temporal 609 629--*--in the last 6 months",
            "Condition 631 639--*--Pregnant",
            "Condition 693 702--*--lactating",
            "Person 703 708--*--women",
            "Mood 644 654;665 688--*--anticipate during the study period",
            "Condition 655 664--*--pregnancy",
            "Negation 710 720--*--Absence of",
            "Condition 760 778--*--clinical remission",
            "Temporal 779 800--*--for the last 6 months",
            "Mood 802 811--*--Unwilling",
            "Procedure 815 826--*--discontinue",
            "Drug 827 841--*--anti-TNF agent",
            "Negation 843 853--*--Absence of",
            "Value 871 879--*--negative",
            "Procedure 880 900--*--tuberculin skin test",
            "Value 902 910--*--negative",
            "Measurement 911 935--*--QuantiFERON-TB Gold test",
            "Qualifier 954 960--*--latent",
            "Condition 961 973--*--tuberculosis",
            "Procedure 940 949--*--treatment",
            "Temporal 974 1025--*--prior to starting treatment with the anti-TNF agent",
            "Reference_point 983 1025--*--starting treatment with the anti-TNF agent",
            "Procedure 992 1025--*--treatment with the anti-TNF agent",
            "Drug 1011 1025--*--anti-TNF agent",
            "Condition 1040 1056--*--solid malignancy",
            "Condition 1060 1084--*--non-melanoma skin cancer",
            "Temporal 1085 1108--*--within the past 5 years",
            "Condition 1128 1136--*--melanoma",
            "Condition 1140 1151--*--hematologic",
            "Condition 1155 1185--*--lymphoproliferative malignancy",
            "Scope 1040 1084--*--solid malignancy or non-melanoma skin cancer",
            "Procedure 1231 1247--*--cancer screening",
            "Qualifier 1215 1230--*--age-appropriate",
            "Temporal 1248 1276--*--at the time of randomization",
            "Reference_point 1251 1276--*--the time of randomization",
            "Measurement 1315 1337--*--hepatitis B serologies",
            "Value 1306 1314--*--negative",
            "Negation 1278 1288--*--Absence of",
            "Procedure 1364 1373--*--treatment",
            "Condition 1378 1397--*--chronic hepatitis B",
            "Negation 1339 1349--*--absence of",
            "Non-representable 1350 1363--*--completion of",
            "Procedure 1413 1444--*--suppressive antiviral treatment",
            "Negation 1402 1409--*--absence",
            "Informed_consent 1446 1480--*--Unable to provide informed consent",
            "Post-eligibility 1482 1564--*--Anticipate not being available or able to comply with the schedule of study visits"
        ]
    },
    "NCT03208465_exc": {
        "Annotations": [
            "Condition 0 17--*--Contraindications",
            "Drug 21 34--*--empagliflozin",
            "Drug 36 47--*--Sitagliptin",
            "Scope 21 47--*--empagliflozin, Sitagliptin",
            "Drug 49 64--*--DPP4 inhibitors",
            "Drug 68 116--*--Sodium-glucose cotransporter-2(SGLT2) inhibitors",
            "Temporal 117 144--*--within the previous 4 weeks",
            "Scope 49 116--*--DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors",
            "Drug 146 153--*--Insulin",
            "Procedure 164 172--*--diabetes",
            "Condition 174 194--*--Poor glucose control",
            "Measurement 196 201--*--HbA1C",
            "Value 201 206--*-->10 %",
            "Scope 196 206--*--HbA1C>10 %",
            "Condition 209 232--*--Acute coronary syndrome",
            "Device 234 239--*--Stent",
            "Procedure 240 249--*--placement",
            "Temporal 250 278--*--within the previous 6 months",
            "Temporal 326 354--*--within the previous 6 months",
            "Procedure 289 325--*--coronary artery bypass graft surgery",
            "Temporal 280 288--*--Previous",
            "Procedure 364 381--*--revascularization",
            "Temporal 382 397--*--within 6 months",
            "Mood 356 363--*--Planned",
            "Condition 399 412--*--Heart failure",
            "Drug 423 437--*--loop diuretics",
            "Condition 446 474--*--left ventricular hypertrophy",
            "Qualifier 439 445--*--Severe",
            "Measurement 476 514--*--left ventricular septal wall thickness",
            "Value 515 521--*--> 13mm",
            "Scope 439 474--*--Severe left ventricular hypertrophy",
            "Scope 476 521--*--left ventricular septal wall thickness > 13mm",
            "Qualifier 524 535--*--Significant",
            "Condition 536 549--*--renal disease",
            "Measurement 564 584--*--creatinine clearance",
            "Value 588 599--*--< 30 ml/min",
            "Scope 524 549--*--Significant renal disease",
            "Scope 564 599--*--creatinine clearance of < 30 ml/min",
            "Condition 602 617--*--Hepatic disease",
            "Condition 621 646--*--biliary tract obstruction",
            "Condition 663 687--*--hepatic enzyme elevation",
            "Qualifier 651 662--*--significant",
            "Measurement 689 709--*--alanine transaminase",
            "Measurement 713 739--*--Aspartate Aminotransferase",
            "Value 740 771--*--> 3 times upper limit of normal",
            "Scope 689 739--*--alanine transaminase or Aspartate Aminotransferase",
            "Scope 689 771--*--alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal",
            "Device 774 793--*--Radiopaque material",
            "Qualifier 811 821--*--chest wall",
            "Procedure 867 888--*--adenosine stress test",
            "Condition 847 863--*--Contraindication",
            "Post-eligibility 890 1113--*--Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.",
            "Condition 1125 1133--*--pregnant",
            "Condition 1137 1151--*--breast-feeding",
            "Condition 1155 1178--*--child-bearing potential",
            "Observation 1180 1204--*--Expected life expectancy",
            "Value 1205 1213--*--< 1 year",
            "Non-query-able 1215 1298--*--Unwillingness or inability to comply with the procedures described in this protocol"
        ],
        "Text": "Contraindications to empagliflozin, Sitagliptin. DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors within the previous 4 weeks. Insulin requiring diabetes. Poor glucose control (HbA1C>10 %). Acute coronary syndrome. Stent placement within the previous 6 months. Previous coronary artery bypass graft surgery within the previous 6 months. Planned revascularization within 6 months. Heart failure requiring loop diuretics. Severe left ventricular hypertrophy (left ventricular septal wall thickness > 13mm). Significant renal disease manifested by creatinine clearance of < 30 ml/min). Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal). Radiopaque material implanted in the chest wall (metal, silicone, etc.). Contraindication to adenosine stress test. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.. Patient's pregnant or breast-feeding or child-bearing potential. Expected life expectancy < 1 year. Unwillingness or inability to comply with the procedures described in this protocol. "
    },
    "NCT03280017_inc": {
        "Text": "American Society of Anesthesiologist physical status 1-3. Scheduled for elective video-assisted thoracic surgery. Able to operate a patient-controlled analgesia device (PCA). ",
        "Annotations": [
            "Measurement 0 52--*--American Society of Anesthesiologist physical status",
            "Value 53 56--*--1-3",
            "Qualifier 72 80--*--elective",
            "Mood 58 71--*--Scheduled for",
            "Procedure 81 112--*--video-assisted thoracic surgery",
            "Device 132 167--*--patient-controlled analgesia device",
            "Device 169 172--*--PCA"
        ]
    },
    "NCT03079141_inc": {
        "Text": "Age of = 18 years of age and able to give written informed consent;. Active chronic central serous chorioretinopathy (cCSC);. Subjective visual loss > 6 weeks, interpreted as onset of active disease;. Foveal subretinal fluid (SRF), on optical coherence tomography (OCT), at Baseline Examination;. =1 ill-defined hyperfluorescent leakage areas on fluorescein angiography (FA) with retinal pigment epithelial window defect(s) that are compatible with cCSC;. Hyperfluorescent areas on indocyanine green angiography (ICGA).. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 7 17--*--= 18 years",
            "Observation 29 66--*--able to give written informed consent",
            "Qualifier 69 75--*--Active",
            "Qualifier 76 83--*--chronic",
            "Condition 84 123--*--central serous chorioretinopathy (cCSC)",
            "Condition 126 148--*--Subjective visual loss",
            "Temporal 149 158--*--> 6 weeks",
            "Non-representable 160 199--*--interpreted as onset of active disease;",
            "Condition 201 230--*--Foveal subretinal fluid (SRF)",
            "Procedure 235 269--*--optical coherence tomography (OCT)",
            "Temporal 271 294--*--at Baseline Examination",
            "Reference_point 274 294--*--Baseline Examination",
            "Multiplier 297 299--*--=1",
            "Qualifier 300 311--*--ill-defined",
            "Condition 312 342--*--hyperfluorescent leakage areas",
            "Procedure 346 374--*--fluorescein angiography (FA)",
            "Condition 380 423--*--retinal pigment epithelial window defect(s)",
            "Non-representable 424 453--*--that are compatible with cCSC",
            "Condition 456 478--*--Hyperfluorescent areas",
            "Procedure 482 518--*--indocyanine green angiography (ICGA)"
        ]
    },
    "NCT03472846_inc": {
        "Annotations": [
            "Condition 0 14--*--Postmenopausal",
            "Person 15 20--*--women",
            "Person 22 25--*--Age",
            "Value 26 37--*--60-80 years",
            "Measurement 39 46--*--T-score",
            "Procedure 60 63--*--DXA",
            "Qualifier 47 63--*--according to DXA",
            "Value 65 70--*--<-2.5",
            "Mood 72 86--*--indication for",
            "Procedure 87 107--*--osteoporosis therapy",
            "Condition 87 99--*--osteoporosis",
            "Qualifier 121 145--*--international guidelines"
        ],
        "Text": "Postmenopausal women. Age 60-80 years. T-score according to DXA: <-2.5. indication for osteoporosis therapy according to international guidelines. "
    },
    "NCT03208465_inc": {
        "Annotations": [
            "Person 0 3--*--Men",
            "Person 7 12--*--women",
            "Value 13 30--*--at least 19 years",
            "Person 34 37--*--age",
            "Condition 39 63--*--Type 2 diabetes mellitus",
            "Condition 72 95--*--coronary artery disease",
            "Qualifier 65 71--*--Stable",
            "Measurement 97 144--*--Global myocardial perfusion reserve (MPR) index",
            "Value 145 150--*--< 2.5",
            "Informed_consent 276 301--*--informed, written consent"
        ],
        "Text": "Men or women at least 19 years of age. Type 2 diabetes mellitus. Stable coronary artery disease. Global myocardial perfusion reserve (MPR) index < 2.5. The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.. "
    },
    "NCT01793519_inc": {
        "Text": "Age greater than or equal to 18 years. Have RA, as defined by the 1987 revised American College of Rheumatology criteria. In sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine). DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment. If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6.. ",
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 37--*--greater than or equal to 18 years",
            "Condition 44 46--*--RA",
            "Qualifier 66 120--*--1987 revised American College of Rheumatology criteria",
            "Condition 125 153--*--sustained clinical remission",
            "Multiplier 154 175--*--for the last 6 months",
            "Drug 214 224--*--etanercept",
            "Drug 226 236--*--infliximab",
            "Drug 241 251--*--adalimumab",
            "Multiplier 257 283--*--greater than or equal to 1",
            "Drug 284 289--*--DMARD",
            "Drug 291 303--*--methotrexate",
            "Drug 305 323--*--hydroxychloroquine",
            "Drug 325 338--*--sulfasalazine",
            "Drug 340 351--*--leflunomide",
            "Drug 353 364--*--minocycline",
            "Drug 366 378--*--cyclosporine",
            "Drug 380 392--*--azathioprine",
            "Drug 394 398--*--gold",
            "Drug 400 413--*--penicillamine",
            "Scope 291 413--*--methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine",
            "Measurement 416 421--*--DAS28",
            "Value 432 445--*--less than 2.6",
            "Multiplier 460 487--*--over the preceding 6 months",
            "Multiplier 494 506--*--at least one",
            "Procedure 507 512--*--visit",
            "Procedure 454 459--*--visit",
            "Multiplier 446 459--*--on each visit",
            "Temporal 513 541--*--2-4 months before enrollment",
            "Non-representable 543 705--*--If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6."
        ]
    },
    "NCT03064867_inc": {
        "Text": "Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc. . Subjects must have received no more than 2 prior systemic therapies for lymphoma. Prior therapy with systemic rituximab monotherapy or conventional chemotherapy (i.e. bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other) \u00b1 rituximab for indolent non-Hodgkin's lymphoma (NHL) \u00b1 maintenance/extended-use rituximab will count as 1 line of systemic therapy. . Eastern Cooperative Oncology Group (ECOG) Performance status \u2264 2 . Subjects must have normal organ and marrow function as defined below: . Hemoglobin \u2265 8.0 g/dl . Absolute neutrophil count \u2265 1,000/mcL . Platelet count \u2265 75,000/mcL . Total bilirubin \u2264 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN. . Aspartate transaminase (AST) (SGOT) \u2264 2.5 X institutional ULN . Alanine transaminase (ALT) (SGPT) \u2264 2.5 X institutional ULN . International normalized ratio (INR) > 1.5 \u00d7ULN . Patients must have a calculated serum creatinine clearance > 50 mL/min using Cockcroft-Gault calculation or based on 24-hour urine collection performed within 7 days prior to treatment. . Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow: . HBsAg negative, HBcAb negative, HBsAb positive patients are eligible. . Patients who test positive for HBsAg are ineligible . Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow: . If HBV DNA is positive, the subject is ineligible. . If HBV DNA is negative, the subject may be included but must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment . Subjects must have the ability to understand and the willingness to sign a written informed consent document. . For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer. . A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). . For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: . With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab. Men must refrain from donating sperm during this same period. . With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo. . ",
        "Annotations": [
            "Procedure 0 12--*--Histological",
            "Value 13 25--*--confirmation",
            "Condition 63 78--*--B-cell lymphoma",
            "Qualifier 57 62--*--large",
            "Qualifier 49 56--*--diffuse",
            "Procedure 91 156--*--rituximab and anthracycline-containing systemic treatment regimen",
            "Drug 165 171--*--R-CHOP",
            "Drug 173 182--*--rituximab",
            "Drug 184 200--*--cyclophosphamide",
            "Drug 202 213--*--doxorubicin",
            "Drug 215 226--*--vincristine",
            "Drug 232 242--*--prednisone",
            "Scope 173 242--*--rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone",
            "Drug 245 252--*--R-EPOCH",
            "Drug 254 263--*--rituximab",
            "Drug 265 284--*--etoposide phosphate",
            "Drug 286 296--*--prednisone",
            "Drug 298 317--*--vincristine sulfate",
            "Drug 319 335--*--cyclophosphamide",
            "Drug 337 362--*--doxorubicin hydrochloride",
            "Scope 254 362--*--rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride",
            "Drug 365 376--*--R-HyperCVAD",
            "Drug 378 387--*--rituximab",
            "Drug 389 405--*--cyclophosphamide",
            "Drug 407 426--*--vincristine sulfate",
            "Drug 428 453--*--doxorubicin hydrochloride",
            "Drug 455 468--*--dexamethasone",
            "Scope 378 468--*--rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone",
            "Drug 91 100--*--rituximab",
            "Drug 105 118--*--anthracycline",
            "Scope 165 473--*--R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc",
            "Temporal 79 84--*--after",
            "Reference_point 85 156--*--prior rituximab and anthracycline-containing systemic treatment regimen",
            "Multiplier 504 518--*--no more than 2",
            "Temporal 519 524--*--prior",
            "Procedure 525 556--*--systemic therapies for lymphoma",
            "Drug 586 595--*--rituximab",
            "Procedure 577 585;596 607--*--systemic monotherapy",
            "Temporal 558 563--*--Prior",
            "Procedure 611 636--*--conventional chemotherapy",
            "Drug 643 655--*--bendamustine",
            "Drug 657 660--*--CVP",
            "Drug 662 678--*--Cyclophosphamide",
            "Drug 680 699--*--Vincristine Sulfate",
            "Drug 701 711--*--Prednisone",
            "Scope 662 711--*--Cyclophosphamide, Vincristine Sulfate, Prednisone",
            "Drug 725 734--*--rituximab",
            "Condition 748 776--*--non-Hodgkin's lymphoma (NHL)",
            "Qualifier 739 747--*--indolent",
            "Drug 804 813--*--rituximab",
            "Scope 643 721--*--bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other",
            "Qualifier 779 790--*--maintenance",
            "Qualifier 791 803--*--extended-use",
            "Scope 779 803--*--maintenance/extended-use",
            "Measurement 857 917--*--Eastern Cooperative Oncology Group (ECOG) Performance status",
            "Value 918 921--*--\u2264 2",
            "Condition 942 954;966 974--*--normal organ function",
            "Condition 942 948;959 974--*--normal marrow function",
            "Scope 923 992--*--Subjects must have normal organ and marrow function as defined below:",
            "Measurement 994 1004--*--Hemoglobin",
            "Value 1005 1015--*--\u2265 8.0 g/dl",
            "Measurement 1017 1042--*--Absolute neutrophil count",
            "Value 1043 1054--*--\u2265 1,000/mcL",
            "Measurement 1056 1070--*--Platelet count",
            "Value 1071 1083--*--\u2265 75,000/mcL",
            "Measurement 1085 1100--*--Total bilirubin",
            "Value 1101 1140--*--\u2264 1.5 X the upper limit of normal (ULN)",
            "Condition 1167 1197--*--impaired bilirubin conjugation",
            "Condition 1206 1215--*--Gilbert's",
            "Value 1230 1237;1246 1253--*--maximum 2.5 ULN",
            "Scope 1101 1253--*--\u2264 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN",
            "Measurement 1256 1291--*--Aspartate transaminase (AST) (SGOT)",
            "Value 1292 1317--*--\u2264 2.5 X institutional ULN",
            "Measurement 1319 1352--*--Alanine transaminase (ALT) (SGPT)",
            "Value 1353 1378--*--\u2264 2.5 X institutional ULN",
            "Measurement 1380 1416--*--International normalized ratio (INR)",
            "Value 1417 1427--*--> 1.5 \u00d7ULN",
            "Measurement 1461 1487--*--serum creatinine clearance",
            "Value 1488 1499--*--> 50 mL/min",
            "Qualifier 1506 1533--*--Cockcroft-Gault calculation",
            "Qualifier 1546 1570--*--24-hour urine collection",
            "Temporal 1581 1600--*--within 7 days prior",
            "Reference_point 1604 1613--*--treatment",
            "Scope 1506 1570--*--Cockcroft-Gault calculation or based on 24-hour urine collection",
            "Parsing_Error 1616 1753--*--Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow:",
            "Measurement 1755 1760--*--HBsAg",
            "Value 1761 1769--*--negative",
            "Measurement 1771 1776--*--HBcAb",
            "Value 1777 1785--*--negative",
            "Measurement 1787 1792--*--HBsAb",
            "Value 1793 1801--*--positive",
            "Measurement 1857 1862--*--HBsAg",
            "Value 1844 1852--*--positive",
            "Grammar_Error 1863 1877--*--are ineligible",
            "Measurement 1893 1898--*--HBsAg",
            "Value 1899 1907--*--negative",
            "Measurement 1913 1918--*--HBcAb",
            "Value 1919 1927--*--positive",
            "Procedure 1971 1986--*--HBV DNA testing",
            "Parsing_Error 1879 2042--*--Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow",
            "Measurement 2048 2055--*--HBV DNA",
            "Value 2059 2067--*--positive",
            "Grammar_Error 2045 2094--*--If HBV DNA is positive, the subject is ineligible",
            "Measurement 2100 2107--*--HBV DNA",
            "Value 2111 2119--*--negative",
            "Non-query-able 2153 2242--*--must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment",
            "Non-query-able 2244 2352--*--Subjects must have the ability to understand and the willingness to sign a written informed consent document",
            "Post-eligibility 2355 2683--*--For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer.",
            "Not_a_criteria 2685 2969--*--A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)",
            "Parsing_Error 2972 3145--*--For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:",
            "Non-query-able 2972 3145--*--For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:",
            "Post-eligibility 2972 3144--*--For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below",
            "Post-eligibility 3147 3420--*--With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab.",
            "Non-query-able 3421 3482--*--Men must refrain from donating sperm during this same period.",
            "Non-query-able 3484 3673--*--With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo."
        ]
    },
    "NCT03280017_exc": {
        "Text": "History of morphine allergy. History of bupivacaine allergy. Contraindication for ketamine infusion. Contraindication for thoracic paravertebral block. Anticipated postoperative positive pressure ventilation. Body mass index more than 35. Any known psychiatric disorder. ",
        "Annotations": [
            "Drug 11 19--*--morphine",
            "Condition 20 27--*--allergy",
            "Observation 0 7--*--History",
            "Drug 40 51--*--bupivacaine",
            "Condition 52 59--*--allergy",
            "Observation 29 36--*--History",
            "Condition 61 77--*--Contraindication",
            "Drug 82 90--*--ketamine",
            "Procedure 82 99--*--ketamine infusion",
            "Condition 101 117--*--Contraindication",
            "Qualifier 122 130--*--thoracic",
            "Procedure 131 150--*--paravertebral block",
            "Temporal 164 177--*--postoperative",
            "Procedure 178 207--*--positive pressure ventilation",
            "Mood 152 163--*--Anticipated",
            "Scope 164 207--*--postoperative positive pressure ventilation",
            "Measurement 209 224--*--Body mass index",
            "Value 225 237--*--more than 35",
            "Condition 249 269--*--psychiatric disorder"
        ]
    },
    "NCT03079141_exc": {
        "Text": "Any previous treatments for active CSC;. Previous prescription of mineralocorticoid receptor antagonists, for cCSC or for other diseases;. Current treatment with corticosteroids (topical or systemic), corticosteroid use within 3 months before possible start of trial treatment, or anticipated start of corticosteroid treatment within the first 2 years from the start of the trial period;. Evidence of another diagnosis that can explain serous SRF or visual loss;. Best-corrected visual acuity < 20/200 (Snellen equivalent);. Profound chorioretinal atrophy in central macular area on ophthalmoscopy and OCT;. Myopia > 6D;. Visual loss and/or serous detachment on OCT < 6 weeks;. Continuous and/or progressive visual loss > 18 months or serous detachment on OCT > 18 months;. No hyperfluorescence on ICGA;. Intraretinal edema on OCT;. (relative) Contraindications for FA or ICGA;. (relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening. (relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;. Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on ophthalmoscopy and/or FA/ICGA of the study eye.. ",
        "Annotations": [
            "Qualifier 28 34--*--active",
            "Condition 35 38--*--CSC",
            "Procedure 13 23--*--treatments",
            "Temporal 4 12--*--previous",
            "Temporal 41 49--*--Previous",
            "Drug 66 104--*--mineralocorticoid receptor antagonists",
            "Condition 110 114--*--cCSC",
            "Condition 122 136--*--other diseases",
            "Scope 110 136--*--cCSC or for other diseases",
            "Drug 162 177--*--corticosteroids",
            "Temporal 139 146--*--Current",
            "Qualifier 179 186--*--topical",
            "Qualifier 190 198--*--systemic",
            "Scope 179 198--*--topical or systemic",
            "Procedure 201 219--*--corticosteroid use",
            "Temporal 220 276--*--within 3 months before possible start of trial treatment",
            "Reference_point 243 276--*--possible start of trial treatment",
            "Procedure 302 326--*--corticosteroid treatment",
            "Temporal 327 386--*--within the first 2 years from the start of the trial period",
            "Reference_point 334 386--*--the first 2 years from the start of the trial period",
            "Mood 281 292--*--anticipated",
            "Non-representable 389 462--*--Evidence of another diagnosis that can explain serous SRF or visual loss;",
            "Measurement 464 492--*--Best-corrected visual acuity",
            "Value 493 501--*--< 20/200",
            "Qualifier 525 533--*--Profound",
            "Condition 534 555--*--chorioretinal atrophy",
            "Qualifier 559 579--*--central macular area",
            "Procedure 583 597--*--ophthalmoscopy",
            "Procedure 602 605--*--OCT",
            "Scope 583 605--*--ophthalmoscopy and OCT",
            "Measurement 608 614--*--Myopia",
            "Value 615 619--*--> 6D",
            "Condition 622 633--*--Visual loss",
            "Condition 641 658--*--serous detachment",
            "Procedure 662 665--*--OCT",
            "Temporal 666 675--*--< 6 weeks",
            "Scope 622 658--*--Visual loss and/or serous detachment",
            "Qualifier 678 688--*--Continuous",
            "Qualifier 696 707--*--progressive",
            "Condition 708 719--*--visual loss",
            "Scope 678 707--*--Continuous and/or progressive",
            "Temporal 720 731--*--> 18 months",
            "Condition 735 752--*--serous detachment",
            "Procedure 756 759--*--OCT",
            "Temporal 760 771--*--> 18 months",
            "Measurement 798 802--*--ICGA",
            "Value 777 794--*--hyperfluorescence",
            "Negation 774 776--*--No",
            "Condition 805 823--*--Intraretinal edema",
            "Procedure 827 830--*--OCT",
            "Condition 844 861--*--Contraindications",
            "Procedure 866 868--*--FA",
            "Procedure 872 876--*--ICGA",
            "Scope 866 876--*--FA or ICGA",
            "Condition 890 907--*--Contraindications",
            "Procedure 912 934--*--photodynamic treatment",
            "Condition 936 945--*--pregnancy",
            "Condition 947 956--*--porphyria",
            "Qualifier 958 966--*--severely",
            "Condition 967 991--*--disturbed liver function",
            "Scope 936 991--*--pregnancy, porphyria, severely disturbed liver function",
            "Scope 890 934--*--Contraindications for photodynamic treatment",
            "Non-representable 994 1120--*--Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening",
            "Condition 1139 1156--*--contraindications",
            "Drug 1175 1185--*--eplerenone",
            "Condition 1197 1209--*--hyperkalemia",
            "Condition 1211 1235--*--abnormal renal clearance",
            "Measurement 1220 1235--*--renal clearance",
            "Value 1211 1219--*--abnormal",
            "Condition 1237 1265--*--severe hepatic insufficiency",
            "Measurement 1267 1277--*--Child-Pugh",
            "Value 1278 1279--*--C",
            "Condition 1282 1306--*--type 2 diabetes mellitus",
            "Condition 1312 1328--*--microalbuminuria",
            "Scope 1282 1328--*--type 2 diabetes mellitus with microalbuminuria",
            "Temporal 1330 1341--*--concomitant",
            "Drug 1349 1370--*--potassium supplements",
            "Drug 1372 1399--*--potassium-sparing diuretics",
            "Drug 1401 1425--*--strong CYP3A4 inhibitors",
            "Drug 1452 1465--*--ACE-inhibitor",
            "Drug 1473 1508--*--angiotensin receptor blocking agent",
            "Scope 1452 1508--*--ACE-inhibitor and an angiotensin receptor blocking agent",
            "Scope 1349 1508--*--potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent",
            "Non-representable 1511 1638--*--Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;",
            "Condition 1640 1651--*--Soft drusen",
            "Qualifier 1655 1666--*--treated eye",
            "Qualifier 1670 1680--*--fellow eye",
            "Scope 1655 1680--*--treated eye or fellow eye",
            "Condition 1691 1719--*--choroidal neovascularization",
            "Procedure 1723 1737--*--ophthalmoscopy",
            "Procedure 1745 1747--*--FA",
            "Procedure 1748 1752--*--ICGA",
            "Qualifier 1760 1769--*--study eye",
            "Scope 1723 1752--*--ophthalmoscopy and/or FA/ICGA"
        ]
    },
    "NCT02062489_exc": {
        "Annotations": [
            "Condition 18 31--*--other cancers",
            "Temporal 32 48--*--at the same time",
            "Condition 72 85--*--other cancers",
            "Negation 86 92--*--except",
            "Condition 93 129--*--controlled skin basal cell carcinoma",
            "Condition 133 161--*--skin squamous cell carcinoma",
            "Condition 165 199--*--carcinoma in situ of cervix uterus",
            "Scope 93 199--*--controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus",
            "Temporal 220 226--*--active",
            "Condition 227 237--*--infections",
            "Negation 248 251--*--not",
            "Qualifier 252 277--*--suitable for chemotherapy",
            "Qualifier 298 304--*--severe",
            "Condition 305 327--*--non-cancerous diseases",
            "Procedure 359 386--*--neoadjuvant hormone therapy",
            "Condition 407 431--*--bilateral breast cancers",
            "Condition 435 439--*--DCIS",
            "Condition 443 468--*--metastatic breast cancers",
            "Procedure 525 546--*--anti-cancer therapies",
            "Observation 555 586--*--attending other clinical trials",
            "Condition 606 614--*--pregnant",
            "Condition 618 629--*--lactational",
            "Procedure 658 671--*--contraception",
            "Negation 639 657--*--refuse to practice",
            "Temporal 672 694--*--during the whole trial",
            "Post-eligibility 697 835--*--The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish.",
            "Condition 855 863--*--allergic",
            "Drug 895 904--*--tamoxifen",
            "Condition 875 891--*--contraindication",
            "Scope 855 891--*--allergic history or contraindication"
        ],
        "Text": "The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;. The patients have active infections that were not suitable for chemotherapy;. The patients have severe non-cancerous diseases.. The patients have history of neoadjuvant hormone therapy.. The patients have bilateral breast cancers or DCIS or metastatic breast cancers.. The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials.. The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.. The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish.. The patients have allergic history or contraindication of tamoxifen.. "
    },
    "NCT02816164_inc": {
        "Annotations": [
            "Condition 25 46--*--primary breast cancer",
            "Qualifier 0 24--*--Histologically confirmed",
            "Procedure 0 14--*--Histologically",
            "Drug 65 74--*--docetaxel",
            "Mood 48 64--*--Planned to start",
            "Procedure 88 93--*--FEC-D",
            "Procedure 97 101--*--AC-D",
            "Multiplier 106 120--*--first cycle of",
            "Procedure 122 137--*--dose-dense AC-T",
            "Procedure 139 141--*--TC",
            "Procedure 143 148--*--FEC-D",
            "Procedure 152 168--*--TAC chemotherapy",
            "Scope 88 101--*--FEC-D or AC-D",
            "Scope 106 120;65 74--*--first cycle of docetaxel",
            "Person 183 186--*--age",
            "Value 170 179--*--=19 years",
            "Informed_consent 188 218--*--Able to provide verbal consent"
        ],
        "Text": "Histologically confirmed primary breast cancer. Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy. =19 years of age. Able to provide verbal consent. "
    },
    "NCT02041299_exc": {
        "Annotations": [
            "Condition 0 21--*--Thalassemia syndromes",
            "Condition 24 54--*--Myelodysplastic syndrome (MDS)",
            "Condition 58 71--*--myelofibrosis",
            "Condition 74 97--*--Diamond Blackfan anemia",
            "Condition 100 127--*--Primary bone marrow failure",
            "Measurement 139 142--*--LIC",
            "Value 143 151--*-->30 mg/g",
            "Temporal 130 138--*--Baseline",
            "Procedure 168 171--*--MRI",
            "Mood 156 167--*--measured by",
            "Post-eligibility 175 303--*--Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox",
            "Procedure 315 343--*--discontinuation of treatment",
            "Condition 349 360--*--deferiprone",
            "Condition 364 376--*--deferoxamine",
            "Scope 349 376--*--deferiprone or deferoxamine",
            "Condition 424 440--*--hypersensitivity",
            "Condition 444 466--*--idiosyncratic reaction",
            "Drug 470 481--*--deferiprone",
            "Drug 485 497--*--deferoxamine",
            "Scope 470 497--*--deferiprone or deferoxamine",
            "Scope 424 466--*--hypersensitivity or idiosyncratic reaction",
            "Drug 513 524--*--hydroxyurea",
            "Temporal 525 539--*--within 30 days",
            "Condition 553 563--*--malignancy",
            "Value 578 586--*--abnormal",
            "Measurement 587 601--*--liver function",
            "Measurement 603 621--*--serum ALT level(s)",
            "Value 622 653--*--> 5 times upper limit of normal",
            "Temporal 654 666--*--at screening",
            "Measurement 670 687--*--creatinine levels",
            "Value 688 718--*-->2 times upper limit of normal",
            "Temporal 719 731--*--at screening",
            "Scope 603 731--*--serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening",
            "Scope 578 601--*--abnormal liver function",
            "Condition 746 762--*--unstable illness",
            "Qualifier 737 744--*--serious",
            "Qualifier 764 793--*--as judged by the Investigator",
            "Temporal 795 851--*--during the past 3 months before screening/baseline visit",
            "Condition 977 996--*--immunologic disease",
            "Condition 963 973;989 996--*--neurologic disease",
            "Condition 947 961;989 996--*--endocrinologic disease",
            "Condition 931 945;989 996--*--cardiovascular disease",
            "Condition 918 929;989 996--*--respiratory disease",
            "Condition 898 916;989 996--*--gastro-enterologic disease",
            "Condition 891 896;989 996--*--renal disease",
            "Condition 882 889;989 996--*--hepatic disease",
            "Scope 882 996--*--hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease",
            "Qualifier 999 1021--*--Clinically significant",
            "Qualifier 1022 1030--*--abnormal",
            "Procedure 1031 1042--*--12-lead ECG",
            "Condition 1043 1051--*--findings",
            "Measurement 1054 1069--*--Cardiac MRI T2*",
            "Value 1070 1075--*--<10ms",
            "Condition 1078 1099--*--Myocardial infarction",
            "Condition 1101 1115--*--cardiac arrest",
            "Condition 1119 1134--*--cardiac failure",
            "Temporal 1135 1180--*--within 1 year before screening/baseline visit",
            "Scope 1078 1134--*--Myocardial infarction, cardiac arrest or cardiac failure",
            "Condition 1183 1200--*--Unable to undergo",
            "Procedure 1201 1204--*--MRI",
            "Post-eligibility 1206 1423--*--Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging"
        ],
        "Text": "Thalassemia syndromes;. Myelodysplastic syndrome (MDS) or myelofibrosis;. Diamond Blackfan anemia;. Primary bone marrow failure;. Baseline LIC >30 mg/g dw (measured by MRI);. Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;. Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events;. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;. Treated with hydroxyurea within 30 days;. History of malignancy;. Evidence of abnormal liver function (serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening);. A serious, unstable illness, as judged by the Investigator, during the past 3 months before screening/baseline visit including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease;. Clinically significant abnormal 12-lead ECG findings;. Cardiac MRI T2* <10ms;. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening/baseline visit;. Unable to undergo MRI. Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging. "
    },
    "NCT00425789_exc": {
        "Text": "Patients will be excluded if they have known middle ear disease, chronic lung disease or claustrophobia       .     . ",
        "Annotations": [
            "Condition 45 63--*--middle ear disease",
            "Condition 65 85--*--chronic lung disease",
            "Condition 89 103--*--claustrophobia"
        ]
    },
    "NCT03335904_inc": {
        "Annotations": [
            "Condition 0 12--*--normotensive",
            "Measurement 14 74--*--forced expiratory volume in 1s : forced vital capacity ratio",
            "Value 75 81--*--> 0.75",
            "Negation 83 85--*--no",
            "Observation 86 101--*--medical history",
            "Condition 105 119;136 143--*--cardiovascular disease",
            "Condition 124 143--*--respiratory disease",
            "Scope 105 143--*--cardiovascular and respiratory disease",
            "Negation 145 148--*--not",
            "Drug 156 167--*--medications",
            "Negation 168 178--*--other than",
            "Drug 179 198--*--oral contraceptives",
            "Scope 156 198--*--medications other than oral contraceptives",
            "Negation 200 209--*--free from",
            "Condition 210 221--*--sleep apnea",
            "Measurement 223 238--*--body mass index",
            "Value 239 257--*--less than 30 kg/m2"
        ],
        "Text": "normotensive. forced expiratory volume in 1s : forced vital capacity ratio > 0.75. no medical history of cardiovascular and respiratory disease. not taking medications other than oral contraceptives. free from sleep apnea. body mass index less than 30 kg/m2. "
    },
    "NCT00440245_exc": {
        "Text": "asthma and COPD. ",
        "Annotations": [
            "Condition 0 6--*--asthma",
            "Condition 11 15--*--COPD"
        ]
    },
    "NCT02456532_exc": {
        "Annotations": [
            "Condition 18 33--*--medical disease",
            "Qualifier 0 5--*--acute",
            "Qualifier 9 17--*--unstable",
            "Scope 0 17--*--acute or unstable",
            "Condition 63 82--*--psychiatric disease",
            "Condition 84 94--*--alcoholism",
            "Condition 98 108--*--drug abuse",
            "Condition 120 143--*--primary sleep disorders"
        ],
        "Text": "acute or unstable medical disease,. current or past history of psychiatric disease, alcoholism or drug abuse, and other primary sleep disorders. "
    },
    "NCT03340740_inc": {
        "Annotations": [
            "Condition 11 28--*--allergic rhinitis",
            "Condition 30 38--*--Wheezing"
        ],
        "Text": "History of allergic rhinitis. Wheezing. "
    },
    "NCT03255044_exc": {
        "Annotations": [
            "Condition 6 22--*--hypersensitivity",
            "Drug 26 32--*--statin",
            "Drug 49 56--*--statins",
            "Temporal 57 93--*--during the past month prior to study",
            "Reference_point 64 93--*--the past month prior to study",
            "Measurement 96 112--*--Serum creatinine",
            "Value 113 122--*--> 3 mg/dl",
            "Condition 136 149--*--liver disease",
            "Measurement 151 164--*--liver enzymes",
            "Value 165 197--*--2.5 folds the upper normal limit",
            "Qualifier 124 135--*--Significant",
            "Scope 151 197--*--liver enzymes 2.5 folds the upper normal limit",
            "Scope 124 149--*--Significant liver disease",
            "Condition 199 209--*--Malignancy",
            "Condition 211 220--*--Pregnancy",
            "Condition 224 233--*--lactation"
        ],
        "Text": "Known hypersensitivity to statin. Treatment with statins during the past month prior to study.. Serum creatinine > 3 mg/dl. Significant liver disease: liver enzymes 2.5 folds the upper normal limit. Malignancy. Pregnancy or lactation. "
    },
    "NCT03339284_inc": {
        "Text": "patients with renal cancer coming to the laparoscopic radical nephrectomy. ",
        "Annotations": [
            "Condition 14 26--*--renal cancer",
            "Qualifier 41 53--*--laparoscopic",
            "Procedure 54 73--*--radical nephrectomy"
        ]
    },
    "NCT02816164_exc": {
        "Annotations": [
            "Condition 0 16--*--Contraindication",
            "Drug 20 30--*--Filgrastim"
        ],
        "Text": "Contraindication to Filgrastim. "
    },
    "NCT02062489_inc": {
        "Annotations": [
            "Non-query-able 0 48--*--The patients signed the written informed consent",
            "Qualifier 76 84--*--operable",
            "Qualifier 85 95--*--unilateral",
            "Qualifier 96 104--*--invasive",
            "Condition 105 119--*--breast cancers",
            "Condition 128 146--*--distant metastasis",
            "Negation 120 127--*--without",
            "Measurement 147 152--*--stage",
            "Value 153 167--*--I, II, and III",
            "Scope 120 146--*--without distant metastasis",
            "Condition 174 186--*--breast tumor",
            "Measurement 189 208--*--positive ER/PR rate",
            "Value 212 215--*--<1%",
            "Measurement 221 243--*--positive ER-beta1 rate",
            "Value 247 251--*--=10%",
            "Procedure 255 258--*--IHC",
            "Scope 189 251--*--positive ER/PR rate is <1%, and positive ER-beta1 rate is =10%",
            "Procedure 293 320--*--neoadjuvant hormone therapy",
            "Negation 279 289--*--no history",
            "Condition 341 365--*--normal cardiac functions",
            "Procedure 369 385--*--echocardiography",
            "Measurement 402 413--*--ECOG scores",
            "Value 418 422--*--=0-2",
            "Person 425 431--*--Female",
            "Value 447 454--*--= 18yrs",
            "Value 460 467--*--= 65yrs",
            "Scope 447 467--*--= 18yrs, and = 65yrs",
            "Pregnancy_considerations 470 563--*--The patients are non-pregnant, and disposed to practice contraception during the whole trial.",
            "Procedure 588 612--*--neoadjuvant chemotherapy",
            "Procedure 618 625--*--surgery",
            "Procedure 647 665--*--radical mastectomy",
            "Qualifier 629 646--*--directly modified",
            "Scope 588 625--*--neoadjuvant chemotherapy plus surgery",
            "Procedure 669 694--*--breast-conserving surgery",
            "Procedure 701 727--*--sentinel lymph node biopsy",
            "Procedure 731 761--*--axillary lymph node dissection",
            "Temporal 763 795--*--after diagnosis of breast cancer",
            "Reference_point 769 795--*--diagnosis of breast cancer",
            "Scope 588 762--*--neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection)",
            "Procedure 821 833--*--chemotherapy",
            "Procedure 835 852--*--radiation therapy",
            "Procedure 856 872--*--targeted therapy",
            "Drug 873 882--*--herceptin",
            "Reference_point 890 897--*--surgery",
            "Temporal 884 897--*--after surgery",
            "Procedure 890 897--*--surgery",
            "Qualifier 915 934--*--2013 NCCN guideline",
            "Scope 821 883--*--chemotherapy, radiation therapy or targeted therapy(herceptin)",
            "Non-query-able 937 989--*--The results of patients' blood tests are as follows:"
        ],
        "Text": "The patients signed the written informed consent. The patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III). The breast tumor's positive ER/PR rate is <1%, and positive ER-beta1 rate is =10% by IHC.. The patients have no history of neoadjuvant hormone therapy.. The patients have normal cardiac functions by echocardiography.. The patients' ECOG scores are =0-2.. Female patient who is = 18yrs, and = 65yrs.. The patients are non-pregnant, and disposed to practice contraception during the whole trial.. The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.. The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline.. The results of patients' blood tests are as follows:. "
    },
    "NCT02041299_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Value 15 24--*--= 2 years",
            "Person 28 31--*--age",
            "Condition 39 58--*--sickle cell disease",
            "Procedure 73 91--*--Hb electrophoresis",
            "Procedure 95 114--*--more specific tests",
            "Scope 73 114--*--Hb electrophoresis or more specific tests",
            "Condition 119 154--*--other conditions with iron overload",
            "Multiplier 160 168--*--repeated",
            "Procedure 169 187--*--blood transfusions",
            "Measurement 230 242--*--Baseline LIC",
            "Value 243 250--*-->7 mg/g",
            "Procedure 267 270--*--MRI",
            "Multiplier 301 316--*--no less than 20",
            "Procedure 317 337--*--transfusions of RBCs",
            "Multiplier 367 377;390 398--*--at least 1 per year",
            "Temporal 399 418--*--in the last 2 years",
            "Procedure 378 389--*--transfusion",
            "Condition 431 472--*--expected to have a continuing requirement",
            "Temporal 509 541--*--during the duration of the trial"
        ],
        "Text": "Male or female = 2 years of age;. Have sickle cell disease (confirmed by Hb electrophoresis or more specific tests) or other conditions with iron overload from repeated blood transfusions (see exclusion criteria for exceptions);. Baseline LIC >7 mg/g dw (measured by MRI);. Patients who have received no less than 20 transfusions of RBCs;. Patients who have received at least 1 transfusion per year in the last 2 years and who are expected to have a continuing requirement (based on Investigator's judgement) during the duration of the trial. "
    },
    "NCT00425789_inc": {
        "Text": "The study will include 40 post-deep peel women (exoderm), older than 18 years old, treated by the same dermatologist (dr. Landau). . The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel. Prior to treatment, each patient will be signed on informed consent and will have complete physical examination. . The control group will be matched by the following parameters: age, skin color and type, and indication for peeling, and will be picked up by the dermatologist. . ",
        "Annotations": [
            "Condition 31 40--*--deep peel",
            "Person 41 46--*--women",
            "Condition 48 55--*--exoderm",
            "Value 58 77--*--older than 18 years",
            "Person 78 81--*--old",
            "Non-representable 132 265--*--The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel.",
            "Observation 384 397--*--control group",
            "Person 443 446--*--age",
            "Person 448 458--*--skin color",
            "Person 463 467--*--type",
            "Scope 443 467--*--age, skin color and type"
        ]
    },
    "NCT02456532_inc": {
        "Annotations": [
            "Condition 19 27--*--insomnia",
            "Qualifier 0 5--*--DSM-5"
        ],
        "Text": "DSM-5 diagnosis of insomnia. "
    },
    "NCT00440245_inc": {
        "Text": "asthma or COPD. ",
        "Annotations": [
            "Condition 0 6--*--asthma",
            "Condition 10 14--*--COPD"
        ]
    },
    "NCT03335904_exc": {
        "Annotations": [
            "Condition 11 23--*--hypertension",
            "Observation 0 7--*--history",
            "Condition 31 54--*--impaired renal function",
            "Condition 56 69--*--liver disease",
            "Condition 71 84--*--heart failure",
            "Condition 86 107--*--myocardial infarction",
            "Condition 109 132--*--coronary artery disease",
            "Observation 134 140--*--smoked",
            "Temporal 141 161--*--within the past year",
            "Measurement 163 183--*--apnea hypopnea index",
            "Value 184 203--*--> 5 events per hour"
        ],
        "Text": "history of hypertension. known impaired renal function. liver disease. heart failure. myocardial infarction. coronary artery disease. smoked within the past year. apnea hypopnea index > 5 events per hour. "
    },
    "NCT03339284_exc": {
        "Text": "age under 18y or over 85y. diabetes type 1 with complications. no co-operation or inadequate finnish language skills. persistent pain for other reason. severe hepatic insufficiency or paracetamol (acetaminophen) is contraindicated for other reason. any type of steroid in regular use. oxycodone contraindicated. medications changing notably paracetamol (acetaminophen) and/or ropivacaine metabolism in regular use. ",
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 25--*--under 18y or over 85y",
            "Condition 27 42--*--diabetes type 1",
            "Condition 48 61--*--complications",
            "Observation 66 78--*--co-operation",
            "Negation 63 65--*--no",
            "Observation 82 116--*--inadequate finnish language skills",
            "Condition 118 133--*--persistent pain",
            "Qualifier 138 150--*--other reason",
            "Qualifier 152 158--*--severe",
            "Condition 159 180--*--hepatic insufficiency",
            "Drug 184 195--*--paracetamol",
            "Drug 197 210--*--acetaminophen",
            "Condition 215 230--*--contraindicated",
            "Drug 261 268--*--steroid",
            "Multiplier 272 283--*--regular use",
            "Drug 285 294--*--oxycodone",
            "Condition 295 310--*--contraindicated",
            "Drug 341 352--*--paracetamol",
            "Drug 354 367--*--acetaminophen",
            "Drug 376 387--*--ropivacaine",
            "Multiplier 402 413--*--regular use",
            "Scope 341 387--*--paracetamol (acetaminophen) and/or ropivacaine"
        ]
    },
    "NCT03255044_inc": {
        "Annotations": [
            "Person 14 19--*--years",
            "Value 0 13--*--older than 18",
            "Person 24 34--*--both sexes",
            "Qualifier 52 58--*--stable",
            "Condition 59 80--*--chronic heart failure",
            "Measurement 81 91--*--NYHA class",
            "Value 92 98--*--II-III",
            "Measurement 100 117--*--ejection fraction",
            "Value 118 124--*--< 40 %",
            "Procedure 140 159--*--2D echocardiography",
            "Non-representable 161 275--*--who have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling."
        ],
        "Text": "older than 18 years (of both sexes). diagnosed with stable chronic heart failure NYHA class II-III. ejection fraction < 40 % as assessed by 2D echocardiography. who have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling.. "
    },
    "NCT03340740_exc": {
        "Annotations": [
            "Drug 7 20--*--antihistamine",
            "Temporal 21 45--*--within the past 72 hours",
            "Condition 47 74--*--Chronic Pulmonary Condition",
            "Condition 86 92--*--asthma",
            "Negation 75 80--*--other",
            "Condition 100 116--*--contraindication",
            "Drug 120 130--*--cetirizine",
            "Condition 139 158--*--asthma exacerbation",
            "Procedure 169 182--*--resuscitation",
            "Qualifier 132 138--*--Severe"
        ],
        "Text": "Use of antihistamine within the past 72 hours. Chronic Pulmonary Condition other than asthma. Other contraindication to cetirizine. Severe asthma exacerbation requiring resuscitation. "
    },
    "NCT02546856_inc": {
        "Text": "Patient with \"de novo\" heart Failure and LVEF <= 40% admitted in hospital, without contraindications for BB prescription with cardiologist up-titration prescription and without having achieved BB target dose previous discharge and signing informed consent.. ",
        "Annotations": [
            "Qualifier 14 21--*--de novo",
            "Condition 23 36--*--heart Failure",
            "Measurement 41 45--*--LVEF",
            "Value 46 52--*--<= 40%",
            "Procedure 53 61--*--admitted",
            "Visit 65 73--*--hospital",
            "Negation 75 82--*--without",
            "Condition 83 100--*--contraindications",
            "Drug 105 107--*--BB"
        ]
    },
    "NCT02787863_exc": {
        "Annotations": [
            "Condition 20 42--*--pneumococcal infection",
            "Procedure 0 11--*--Vaccination",
            "Drug 73 104--*--preparations of immune globulin",
            "Procedure 108 125--*--blood transfusion",
            "Temporal 126 176--*--within last three months prior to clinical studies",
            "Scope 73 125--*--preparations of immune globulin or blood transfusion",
            "Temporal 194 211--*--more than 14 days",
            "Temporal 179 192--*--Prolonged use",
            "Drug 213 231--*--immunosuppressants",
            "Qualifier 235 240--*--other",
            "Drug 241 264--*--immunosuppressive drugs",
            "Temporal 265 312--*--within 6 months prior to the start of the study",
            "Scope 213 264--*--immunosuppressants or other immunosuppressive drugs",
            "Condition 342 359;379 388--*--immunosuppressive condition",
            "Condition 363 388--*--immunodeficient condition",
            "Condition 400 413--*--HIV infection",
            "Scope 342 388--*--immunosuppressive or immunodeficient condition",
            "Non-representable 416 469--*--A history or currently hematologic and other cancers;",
            "Measurement 482 508--*--reaction for HIV infection",
            "Value 473 481--*--positive",
            "Measurement 482 494;510 527--*--reaction for viral hepatitis B",
            "Measurement 482 494;532 543--*--reaction for hepatitis C",
            "Scope 482 543--*--reaction for HIV infection, viral hepatitis B and hepatitis C",
            "Condition 575 604--*--cardio-vascular insufficiency",
            "Condition 562 573;591 604--*--respiratory insufficiency",
            "Condition 606 620--*--impaired liver",
            "Condition 606 614;625 640--*--impaired kidney function",
            "Temporal 684 701--*--at visit number 1",
            "Scope 562 640--*--respiratory, cardio-vascular insufficiency, impaired liver and kidney function",
            "Condition 715 733--*--congenital defects",
            "Condition 745 761--*--chronic diseases",
            "Qualifier 769 780--*--acute stage",
            "Qualifier 796 816--*--clinically important",
            "Qualifier 737 744--*--serious",
            "Condition 817 829--*--exacerbation",
            "Condition 841 862--*--diseases of the liver",
            "Qualifier 833 840--*--chronic",
            "Condition 841 856;864 870--*--diseases of the kidney",
            "Condition 841 856;872 886;896 902--*--diseases of the cardiovascular system",
            "Condition 841 856;888 902--*--diseases of the nervous system",
            "Condition 904 919--*--mental diseases",
            "Condition 923 942--*--metabolic disorders",
            "Condition 1006 1021--*--cystic fibrosis",
            "Condition 1023 1035--*--lung abscess",
            "Condition 1037 1044--*--empyema",
            "Qualifier 1046 1052--*--active",
            "Condition 1053 1065--*--tuberculosis",
            "Condition 1084 1108--*--congestive heart failure",
            "Condition 1110 1123--*--malabsorption",
            "Condition 1143 1158--*--hepatic failure",
            "Condition 1133 1138;1151 1158--*--renal failure",
            "Qualifier 1125 1132--*--chronic",
            "Scope 1133 1158--*--renal and hepatic failure",
            "Condition 1160 1169--*--cirrhosis",
            "Condition 1171 1181--*--malignancy",
            "Condition 1183 1199--*--immunodeficiency",
            "Condition 1201 1223--*--cirrhosis of the liver",
            "Scope 995 1223--*--pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver",
            "Scope 841 902--*--diseases of the liver, kidney, cardiovascular, nervous system",
            "Scope 817 942--*--exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders",
            "Scope 715 780--*--congenital defects or serious chronic diseases in the acute stage",
            "Qualifier 1227 1233--*--Severe",
            "Condition 1234 1252--*--allergic reactions",
            "Qualifier 1306 1311--*--acute",
            "Condition 1312 1322;1343 1352--*--infectious illnesses",
            "Condition 1330 1352--*--communicable illnesses",
            "Temporal 1353 1382--*--within 1 month prior to study",
            "Scope 1312 1352--*--infectious and/or communicable illnesses",
            "Condition 1404 1417--*--alcohol abuse",
            "Condition 1425 1433--*--drug use",
            "Qualifier 1396 1403--*--chronic",
            "Scope 1404 1433--*--alcohol abuse and/or drug use",
            "Condition 1436 1448--*--Exacerbation",
            "Condition 1452 1468--*--chronic diseases",
            "Observation 1471 1484--*--Breastfeeding",
            "Condition 1487 1496--*--Pregnancy",
            "Observation 1499 1515;1526 1540--*--Participation in clinical study",
            "Qualifier 1516 1525--*--any other",
            "Temporal 1541 1565--*--within the last 3 months",
            "Reference_point 1377 1382--*--study"
        ],
        "Text": "Vaccination against pneumococcal infection in anamnesis;. Application of preparations of immune globulin or blood transfusion within last three months prior to clinical studies;. Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs within 6 months prior to the start of the study;. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection;. A history or currently hematologic and other cancers;. A positive reaction for HIV infection, viral hepatitis B and hepatitis C;. The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney function, established during a physical examination at visit number 1;. Pronounced congenital defects or serious chronic diseases in the acute stage, including any clinically important exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders, confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver);. Severe allergic reactions in anamnesis of autoimmune disease;. The presence of acute infectious and/or communicable illnesses within 1 month prior to study;. History of chronic alcohol abuse and/or drug use;. Exacerbation of chronic diseases;. Breastfeeding;. Pregnancy;. Participation in any other clinical study within the last 3 months.. "
    },
    "NCT02396420_inc": {
        "Annotations": [
            "Value 62 89--*--greater than or equal to 40",
            "Person 57 61--*--aged",
            "Value 94 124--*--less than or equal to 89 years",
            "Scope 62 124--*--greater than or equal to 40 and less than or equal to 89 years",
            "Value 161 181--*--between 90g and 200g",
            "Measurement 147 160--*--prostate size",
            "Procedure 200 203--*--MRI",
            "Condition 229 264--*--lower urinary tract symptoms (LUTS)",
            "Temporal 269 312--*--at least 6 months prior to study enrollment",
            "Reference_point 296 312--*--study enrollment",
            "Measurement 329 339--*--IPSS score",
            "Value 343 354--*--at least 13",
            "Temporal 355 366--*--at baseline",
            "Reference_point 358 366--*--baseline",
            "Condition 387 418--*--refractory to medical treatment",
            "Condition 420 456--*--contraindicated to medical treatment",
            "Condition 461 486--*--refuses medical treatment",
            "Condition 504 530--*--refuses surgical treatment",
            "Condition 537 575--*--contraindicated for surgical treatment",
            "Measurement 631 634--*--PSA",
            "Temporal 622 630--*--baseline",
            "Value 635 645--*--< 4.0ng/mL",
            "Measurement 688 691--*--PSA",
            "Temporal 679 687--*--baseline",
            "Value 692 703--*-->/= 4 ng/mL",
            "Measurement 719 734--*--prostate biopsy",
            "Value 710 718--*--negative",
            "Multiplier 736 746--*--minimum 12",
            "Procedure 747 758--*--core biopsy",
            "Temporal 760 786--*--within the prior 12 months",
            "Scope 622 759--*--baseline PSA < 4.0ng/mL (no prostate biopsy required) OR baseline PSA >/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy)",
            "Scope 679 733--*--baseline PSA >/= 4 ng/mL AND a negative prostate biops",
            "Observation 21 44--*--signed informed consent"
        ],
        "Text": "Patient has provided signed informed consent . Patient is aged greater than or equal to 40 and less than or equal to 89 years of age . Patient has a prostate size between 90g and 200g, as determined by MRI . Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment . Patient has an IPSS score of at least 13 at baseline . Patient is either: refractory to medical treatment, contraindicated to medical treatment, OR refuses medical treatment . Patient either: refuses surgical treatment OR is contraindicated for surgical treatment . Patient meets ONE of the following criteria: baseline PSA < 4.0ng/mL (no prostate biopsy required) OR baseline PSA >/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy) within the prior 12 months . "
    },
    "NCT02202369_inc": {
        "Annotations": [
            "Procedure 35 55--*--lumbar decompression",
            "Procedure 35 41;60 66--*--lumbar fusion",
            "Qualifier 22 34--*--single level",
            "Person 104 107--*--age",
            "Value 68 78;86 100--*--> 18 years and < 70 years",
            "Post-eligibility 109 277--*--The subject is willing and able to understand, sign and date the study specific patient informed consent and HIPAA authorization to volunteer participation in the study"
        ],
        "Text": "Subjects undergoing a single level lumbar decompression and fusion. > 18 years of age and < 70 years of age. The subject is willing and able to understand, sign and date the study specific patient informed consent and HIPAA authorization to volunteer participation in the study. "
    },
    "NCT03499639_inc": {
        "Text": "patients were 18 years old or more,. naive to HCV treatment,. HCV genotype 4,. compensated liver disease.. ",
        "Annotations": [
            "Value 14 34--*--18 years old or more",
            "Person 23 26--*--old",
            "Procedure 46 59--*--HCV treatment",
            "Negation 37 42--*--naive",
            "Measurement 62 74--*--HCV genotype",
            "Value 75 76--*--4",
            "Qualifier 79 90--*--compensated",
            "Condition 91 104--*--liver disease"
        ]
    },
    "NCT00401245_inc": {
        "Annotations": [
            "Condition 10 17--*--healthy",
            "Condition 19 33--*--postmenopausal",
            "Person 34 39--*--woman",
            "Condition 64 75--*--hot flushes",
            "Temporal 104 122--*--At least 12 months",
            "Condition 126 148--*--spontaneous amenorrhea",
            "Temporal 150 167--*--At least 6 months",
            "Condition 171 193--*--spontaneous amenorrhea",
            "Measurement 199 246--*--serum follicle-stimulating hormone (FSH) levels",
            "Value 247 258--*--> 40 mIU/mL",
            "Temporal 260 289--*--At least 6 weeks postsurgical",
            "Procedure 290 312--*--bilateral oophorectomy",
            "Procedure 290 312;322 342--*--bilateral oophorectomy without hysterectomy",
            "Procedure 290 312;314 318;330 342--*--bilateral oophorectomy with hysterectomy",
            "Scope 314 342--*--with or without hysterectomy",
            "Scope 290 343--*--bilateral oophorectomy (with or without hysterectomy)",
            "Condition 345 360--*--Hysterectomized",
            "Procedure 369 391--*--bilateral oophorectomy",
            "Negation 361 368--*--without",
            "Measurement 401 417--*--serum FSH levels",
            "Value 418 428--*-->40 mIU/mL",
            "Scope 150 258--*--At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL",
            "Scope 260 343--*--At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy)",
            "Scope 345 428--*--Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL",
            "Line 104 148--*--At least 12 months of spontaneous amenorrhea",
            "Scope 150 258--*--At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL",
            "Multiplier 78 102--*--Meets 1 of the following"
        ],
        "Text": "Generally healthy, postmenopausal woman who seeks treatment for hot flushes. . Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL. . "
    },
    "NCT02759861_exc": {
        "Annotations": [
            "Pregnancy_considerations 0 207--*--Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn. Eligible patients of reproductive potential should use adequate contraception if sexually active.",
            "Post-eligibility 209 369--*--Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety.",
            "Condition 371 381--*--Malignancy",
            "Temporal 403 417--*--within 5 years",
            "Procedure 436 445--*--treatment",
            "Qualifier 426 435--*--localized",
            "Temporal 419 425--*--recent",
            "Condition 449 457;480 496--*--squamous cell skin cancer",
            "Condition 461 496--*--non-invasive basal cell skin cancer",
            "Negation 501 510--*--permitted",
            "Scope 449 496--*--squamous or non-invasive basal cell skin cancer",
            "Condition 512 538--*--cervical carcinoma in situ",
            "Negation 542 549--*--allowed",
            "Procedure 567 574--*--treated",
            "Qualifier 553 566--*--appropriately",
            "Temporal 575 593--*--prior to screening",
            "Non-representable 596 656--*--subjects under evaluation for a malignancy are not eligible.",
            "Condition 673 696--*--hepatitis B virus (HBV)",
            "Condition 700 734--*--human immunodeficiency virus (HIV)",
            "Post-eligibility 736 825--*--Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit.",
            "Condition 833 849--*--hypersensitivity",
            "Drug 853 856--*--LDV",
            "Drug 857 860--*--SOF",
            "Scope 853 860--*--LDV/SOF"
        ],
        "Text": "Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn. Eligible patients of reproductive potential should use adequate contraception if sexually active.. Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety.. Malignancy diagnosed or treated within 5 years (recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to screening); subjects under evaluation for a malignancy are not eligible.. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV). Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit.. Known hypersensitivity to LDV/SOF. "
    },
    "NCT03033745_exc": {
        "Text": "Ongoing serious bacterial infections at the time of screening.. Other significant medical conditions that could increase the risk to the subject.. Females who are pregnant, breast feeding, or planning a pregnancy during the course study.. Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment.. ",
        "Annotations": [
            "Condition 16 36--*--bacterial infections",
            "Qualifier 8 15--*--serious",
            "Temporal 37 61--*--at the time of screening",
            "Reference_point 52 61--*--screening",
            "Non-query-able 64 144--*--Other significant medical conditions that could increase the risk to the subject",
            "Pregnancy_considerations 147 237--*--Females who are pregnant, breast feeding, or planning a pregnancy during the course study.",
            "Non-query-able 239 371--*--Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment."
        ]
    },
    "NCT03091881_inc": {
        "Text": "Type I diabetic patients. Parturients presented for Cesarean section. ",
        "Annotations": [
            "Condition 0 15--*--Type I diabetic",
            "Condition 26 37--*--Parturients",
            "Measurement 52 68--*--Cesarean section"
        ]
    },
    "NCT03080493_inc": {
        "Annotations": [
            "Value 0 15;32 49--*--15 weeks 0 days - 23 weeks 5 days",
            "Measurement 16 31--*--gestational age",
            "Temporal 66 94--*--at time of dilator insertion",
            "Reference_point 77 94--*--dilator insertion",
            "Observation 96 129--*--Able to read and write in English",
            "Observation 131 179--*--Active cell phone with text messaging capability",
            "Observation 181 190--*--Ride home",
            "Procedure 196 213--*--dilator insertion"
        ],
        "Text": "15 weeks 0 days gestational age - 23 weeks 5 days gestational age at time of dilator insertion. Able to read and write in English. Active cell phone with text messaging capability. Ride home from dilator insertion clinic appointment. "
    },
    "NCT02546856_exc": {
        "Text": "Contraindications for BB.. Living in a nursing home.. Life expectancy < 6 months.. Unable to self-care or mental disease without caregiver.. Unable to weight. Without phone. Unable to go to clinic visit.. ",
        "Annotations": [
            "Condition 0 17--*--Contraindications",
            "Drug 22 24--*--BB",
            "Visit 39 51--*--nursing home",
            "Observation 27 33--*--Living",
            "Observation 54 69--*--Life expectancy",
            "Value 70 80--*--< 6 months",
            "Condition 83 102--*--Unable to self-care",
            "Condition 106 120--*--mental disease",
            "Qualifier 121 138--*--without caregiver",
            "Procedure 151 157--*--weight",
            "Condition 141 147--*--Unable",
            "Observation 167 172--*--phone",
            "Negation 159 166--*--Without",
            "Observation 174 180--*--Unable",
            "Observation 184 202--*--go to clinic visit"
        ]
    },
    "NCT02787863_inc": {
        "Annotations": [
            "Person 15 25--*--both sexes",
            "Value 26 39--*--from 18 years",
            "Person 26 39--*--from 18 years",
            "Condition 60 88--*--community-acquired pneumonia",
            "Condition 90 94--*--COPD",
            "Condition 98 114--*--Bronchial Asthma",
            "Non-query-able 117 202--*--The presence of signed and dated informed consent to participate in a clinical study;",
            "Post-eligibility 204 260--*--The ability to perform the requirements of the Protocol;",
            "Pregnancy_considerations 262 352--*--For women of childbearing age is a negative result of a pregnancy test before vaccination.",
            "Qualifier 400 424--*--radiologically confirmed",
            "Procedure 400 414--*--radiologically",
            "Condition 425 456--*--infiltration of the lung tissue",
            "Multiplier 474 486--*--at least two",
            "Condition 520 531--*--acute fever",
            "Temporal 532 552--*--early in the disease",
            "Measurement 554 565--*--temperature",
            "Value 566 574--*--> 38.0\u00b0C",
            "Condition 577 594--*--cough with sputum",
            "Condition 618 627--*--pneumonia",
            "Condition 600 614--*--physical signs",
            "Condition 638 647;667 672--*--crepitate rales",
            "Condition 655 672--*--fine bubble rales",
            "Condition 674 698--*--bronchial breathing hard",
            "Condition 700 731--*--shortening of percussion sounds",
            "Scope 638 731--*--crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds",
            "Scope 600 627--*--physical signs of pneumonia",
            "Measurement 734 746--*--leukocytosis",
            "Value 747 759--*--> 10*10 9 /l",
            "Measurement 767 777--*--stab shift",
            "Value 778 783--*--> 10%",
            "Scope 520 783--*--acute fever early in the disease (temperature > 38.0\u00b0C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%",
            "Condition 912 919--*--dyspnea",
            "Condition 354 382--*--community-acquired pneumonia",
            "Scope 400 783--*--radiologically confirmed infiltration of the lung tissue; the presence of at least two of the following clinical signs: acute fever early in the disease (temperature > 38.0\u00b0C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%",
            "Qualifier 921 932--*--progressive",
            "Qualifier 934 951--*--worsens over time",
            "Qualifier 954 977--*--increases with exertion",
            "Qualifier 979 989--*--persistent",
            "Condition 991 1004--*--chronic cough",
            "Condition 1056 1077--*--chronic expectoration",
            "Condition 1130 1137--*--Smoking",
            "Condition 1093 1105--*--risk factors",
            "Condition 1139 1181--*--occupational dust pollutants and chemicals",
            "Condition 1195 1230--*--wheeze on auscultation of the chest",
            "Condition 1238 1267--*--distant wheezing in the chest",
            "Qualifier 1184 1194--*--widespread",
            "Observation 1269 1283--*--family history",
            "Condition 1287 1291--*--COPD",
            "Procedure 1293 1304--*--spirometric",
            "Condition 1337 1364--*--fixed bronchial obstruction",
            "Scope 1130 1181--*--Smoking, occupational dust pollutants and chemicals",
            "Scope 921 989--*--progressive (worsens over time), increases with exertion, persistent",
            "Condition 906 910--*--COPD",
            "Scope 912 1364--*--dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction"
        ],
        "Text": "Individuals of both sexes from 18 years with a diagnosis of community-acquired pneumonia, COPD or Bronchial Asthma;. The presence of signed and dated informed consent to participate in a clinical study;. The ability to perform the requirements of the Protocol;. For women of childbearing age is a negative result of a pregnancy test before vaccination.. community-acquired pneumonia: the presence of radiologically confirmed infiltration of the lung tissue; the presence of at least two of the following clinical signs: acute fever early in the disease (temperature > 38.0\u00b0C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%; the occurrence of the disease outside the hospital and the organized groups (such as nursing homes, sanatoriums, etc.).. COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction.. "
    },
    "NCT00401245_exc": {
        "Annotations": [
            "Condition 13 29--*--seizure disorder",
            "Condition 50 75--*--childhood febrile seizure",
            "Multiplier 43 49--*--single",
            "Observation 0 7--*--History",
            "Observation 78 85--*--History",
            "Condition 101 121;122 129;139 146--*--clinically important hepatic disease",
            "Condition 101 121;133 146--*--clinically important renal disease",
            "Condition 101 121;150 171--*--clinically important other medical disease",
            "Observation 193 200--*--history",
            "Condition 204 229--*--major depressive disorder",
            "Condition 231 247--*--bipolar disorder",
            "Condition 249 267--*--psychotic disorder",
            "Condition 272 300--*--generalized anxiety disorder",
            "Qualifier 301 318--*--requiring therapy",
            "Scope 204 300--*--major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder",
            "Scope 101 171--*--clinically important hepatic or renal disease or other medical disease",
            "Negation 30 40--*--other than"
        ],
        "Text": "History of a seizure disorder other than a single childhood febrile seizure. . History or presence of clinically important hepatic or renal disease or other medical disease. . Presence or recent history of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy.       .     . "
    },
    "NCT03499639_exc": {
        "Text": "Patients with combined HCV/HBV co-infection. hepatocellular carcinoma (HCC). decompensated liver cirrhosis (Child-Pugh score above 6). non-genotype 4. ",
        "Annotations": [
            "Condition 23 26;34 43--*--HCV infection",
            "Condition 27 30;34 43--*--HBV infection",
            "Condition 45 75--*--hepatocellular carcinoma (HCC)",
            "Condition 91 106--*--liver cirrhosis",
            "Qualifier 77 90--*--decompensated",
            "Measurement 108 124--*--Child-Pugh score",
            "Value 125 132--*--above 6",
            "Condition 139 149--*--genotype 4",
            "Negation 135 138--*--non"
        ]
    },
    "NCT02202369_exc": {
        "Annotations": [
            "Condition 14 27--*--liver disease",
            "Measurement 40 59--*--liver function test",
            "Value 60 71--*--abnormality",
            "Condition 88 101--*--renal disease",
            "Measurement 114 140--*--glomerular filtration rate",
            "Value 141 158--*--< 60mL/min/1.73m2",
            "Drug 202 208--*--opioid",
            "Qualifier 177 185--*--baseline",
            "Qualifier 187 200--*--pre-operative",
            "Multiplier 213 259--*--greater than 30 mg of morphine equivalents/day",
            "Condition 283 301--*--alcohol dependence",
            "Condition 324 347--*--illicit drug dependence",
            "Person 372 375--*--age",
            "Value 358 368--*--< 18 years",
            "Person 393 396--*--age",
            "Value 380 389--*-->70 years",
            "Condition 407 415--*--allergic",
            "Drug 423 433--*--medication",
            "Condition 494 510--*--seizure disorder"
        ],
        "Text": "Patients with liver disease (documented liver function test abnormality). Patients with renal disease (documented glomerular filtration rate < 60mL/min/1.73m2). Patients with a baseline (pre-operative) opioid use greater than 30 mg of morphine equivalents/day.. Patients with active alcohol dependence. Patients with active illicit drug dependence. Patients < 18 years of age and >70 years of age. Patients allergic to any medication given in either arm (list medications). Patients who have a seizure disorder. "
    },
    "NCT02396420_exc": {
        "Annotations": [
            "Condition 33 46--*--rectal cancer",
            "Condition 21 28;40 46--*--bladder cancer",
            "Condition 11 19;40 46--*--prostate cancer",
            "Procedure 59 105--*--transurethral resection of the prostate (TURP)",
            "Procedure 107 128--*--open prostate surgery",
            "Procedure 133 147--*--radiofrequency",
            "Procedure 151 170--*--microwave therapies",
            "Procedure 183 195;233 240--*--open bladder surgery",
            "Procedure 226 240--*--pelvic surgery",
            "Procedure 197 215;233 240--*--rectosigmoid colon surgery",
            "Non-query-able 242 322--*--Patient is unwilling to discontinue alpha blockers 1 month after study treatment",
            "Drug 278 292--*--alpha blockers",
            "Drug 360 387--*--5-alph reductase inhibitors",
            "Temporal 293 322--*--1 month after study treatment",
            "Reference_point 307 322--*--study treatment",
            "Temporal 388 417--*--1 month after study treatment",
            "Non-query-able 324 417--*--Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment",
            "Condition 419 437--*--Neurogenic bladder",
            "Condition 447 493--*--neurologic disorder impacting bladder function",
            "Condition 502 521--*--Parkinson's disease",
            "Condition 523 541--*--multiple sclerosis",
            "Condition 543 569--*--cerebral vascular accident",
            "Condition 573 581--*--diabetes",
            "Scope 419 437;502 581--*--Neurogenic bladder Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes",
            "Condition 616 634--*--urethral pathology",
            "Undefined_semantics 616 634--*--urethral pathology",
            "Condition 646 664--*--urethral stricture",
            "Condition 666 690--*--bladder neck contracture",
            "Condition 695 709--*--bladder atonia",
            "Condition 605 612;625 634--*--bladder pathology",
            "Undefined_semantics 605 612;625 634--*--bladder pathology",
            "Scope 605 634--*--bladder or urethral pathology",
            "Scope 646 709--*--urethral stricture, bladder neck contracture, or bladder atonia",
            "Condition 718 729--*--prostatitis",
            "Condition 733 756--*--urinary tract infection",
            "Temporal 711 717--*--Active",
            "Condition 758 772--*--Cystolithiasis",
            "Temporal 773 797--*--within the past 3 months",
            "Measurement 799 815--*--Serum creatinine",
            "Value 816 826--*--> 1.7mg/dL",
            "Drug 853 871--*--oral anticoagulant",
            "Temporal 872 905--*--2-5 days prior to study treatment",
            "Reference_point 890 905--*--study treatment",
            "Non-query-able 828 905--*--Inability to discontinue oral anticoagulant 2-5 days prior to study treatment",
            "Condition 907 931--*--Coagulation disturbances",
            "Undefined_semantics 907 931--*--Coagulation disturbances",
            "Procedure 950 967--*--medical treatment",
            "Qualifier 936 946--*--normalized",
            "Negation 932 935--*--not",
            "Condition 988 995--*--allergy",
            "Drug 969 987--*--Iodinated contrast",
            "Non-query-able 969 1071--*--Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated",
            "Condition 1081 1088--*--allergy",
            "Drug 1073 1080--*--Gelatin",
            "Condition 1103 1130--*--peripheral vascular disease",
            "Qualifier 1096 1102--*--severe",
            "Condition 1140 1172--*--iliac arterial occlusive disease",
            "Qualifier 1134 1139--*--major",
            "Subjective_judgement 1134 1139--*--major",
            "Subjective_judgement 1096 1102--*--severe",
            "Post-eligibility 1174 1202--*--Interest in future fertility",
            "Non-query-able 1174 1202--*--Interest in future fertility",
            "Condition 1227 1245--*--cardiac arrhythmia",
            "Condition 1255 1270--*--cardiac disease",
            "Condition 1282 1306--*--congestive heart failure",
            "Condition 1322 1339--*--diabetes mellitus",
            "Qualifier 1309 1321--*--uncontrolled",
            "Condition 1364 1383--*--respiratory disease",
            "Qualifier 1341 1363--*--clinically significant",
            "Non-query-able 1341 1363--*--clinically significant",
            "Subjective_judgement 1341 1363--*--clinically significant",
            "Condition 1394 1411--*--immunosuppression",
            "Non-query-able 1413 1524--*--Other condition that the Investigator believes puts the patient at risk for a complication during the procedure",
            "Post-eligibility 1413 1524--*--Other condition that the Investigator believes puts the patient at risk for a complication during the procedure"
        ],
        "Text": "History of prostate, bladder, or rectal cancer . History of transurethral resection of the prostate (TURP), open prostate surgery, or radiofrequency or microwave therapies . History of open bladder, rectosigmoid colon, or other pelvic surgery . Patient is unwilling to discontinue alpha blockers 1 month after study treatment . Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment . Neurogenic bladder or other neurologic disorder impacting bladder function such as Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes . Any other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia . Active prostatitis or urinary tract infection . Cystolithiasis within the past 3 months . Serum creatinine > 1.7mg/dL . Inability to discontinue oral anticoagulant 2-5 days prior to study treatment . Coagulation disturbances not normalized by medical treatment . Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated . Gelatin allergy . Known severe peripheral vascular disease or major iliac arterial occlusive disease . Interest in future fertility . Clinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression . Other condition that the Investigator believes puts the patient at risk for a complication during the procedure       .     . "
    },
    "NCT03091881_exc": {
        "Text": "Contraindications for spinal anesthesia (like bleeding diathesis or regional infection at site of neuroaxial block). Known allergy to Granisetron or local anaesthetic (heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule). Pregnancy induced hypertension. Congenital or rheumatic heart diseases. Antepartum haemorrhage. Fetal destress or gestational age < 36 week. ",
        "Annotations": [
            "Condition 0 17--*--Contraindications",
            "Procedure 22 39--*--spinal anesthesia",
            "Condition 46 64--*--bleeding diathesis",
            "Condition 68 86--*--regional infection",
            "Qualifier 90 114--*--site of neuroaxial block",
            "Scope 46 86--*--bleeding diathesis or regional infection",
            "Condition 123 130--*--allergy",
            "Drug 134 145--*--Granisetron",
            "Drug 149 166--*--local anaesthetic",
            "Drug 168 185--*--heavy bupivacaine",
            "Drug 187 213--*--Marcaine Spinal 0.5% Heavy",
            "Qualifier 215 221--*--5mg/ml",
            "Qualifier 223 241--*--AstraZeneca ampule",
            "Scope 168 241--*--heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule",
            "Scope 134 242--*--Granisetron or local anaesthetic (heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule)",
            "Condition 244 253--*--Pregnancy",
            "Condition 262 274--*--hypertension",
            "Qualifier 244 261--*--Pregnancy induced",
            "Qualifier 276 286--*--Congenital",
            "Qualifier 290 299--*--rheumatic",
            "Condition 300 314--*--heart diseases",
            "Scope 276 299--*--Congenital or rheumatic",
            "Condition 316 338--*--Antepartum haemorrhage",
            "Condition 340 354--*--Fetal destress",
            "Measurement 358 373--*--gestational age",
            "Value 374 383--*--< 36 week"
        ]
    },
    "NCT02759861_inc": {
        "Annotations": [
            "Post-eligibility 0 74--*--The subject must be willingly and able to provide written informed consent",
            "Value 80 104--*--19 years of age or older",
            "Person 76 79--*--Age",
            "Non-representable 105 137--*--(The age of consent in Nebraska)",
            "Negation 153 158--*--na\u00efve",
            "Procedure 143 152--*--treatment",
            "Condition 139 142--*--HCV",
            "Drug 199 215--*--Interferon (IFN)",
            "Drug 217 220--*--RBV",
            "Non-representable 225 302--*--other FDA approved or experimental HCV-specific direct-acting antiviral agent",
            "Negation 174 176--*--no",
            "Temporal 177 182--*--prior",
            "Scope 199 220--*--Interferon (IFN), RBV",
            "Scope 139 158--*--HCV treatment-na\u00efve",
            "Scope 174 302--*--no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent",
            "Measurement 304 317--*--HCV RNA level",
            "Temporal 318 368--*--at most 6 months prior to the Baseline/Day 1 visit",
            "Reference_point 344 368--*--the Baseline/Day 1 visit",
            "Measurement 371 385--*--HCV genotyping",
            "Value 386 408--*--1a, 1b, or mixed 1a/ab",
            "Non-representable 410 487--*--Any non-definitive results will exclude the subject from study participation.",
            "Condition 489 503--*--Alcohol misuse",
            "Measurement 522 577--*--Alcohol Use Disorders Identification Test (AUDIT) score",
            "Value 598 601--*--> 8",
            "Procedure 664 676--*--liver biopsy",
            "Condition 685 694--*--cirrhosis",
            "Measurement 701 714--*--Metavir score",
            "Measurement 722 733--*--Ishak score",
            "Value 715 718--*--= 4",
            "Value 734 737--*--> 5",
            "Scope 701 737--*--Metavir score = 4 or Ishak score > 5",
            "Procedure 740 749--*--Fibroscan",
            "Condition 758 767--*--cirrhosis",
            "Value 779 789--*--> 12.5 kPa",
            "Scope 758 789--*--cirrhosis or results > 12.5 kPa",
            "Measurement 791 811--*--FIBRO Spect II index",
            "Measurement 850 878--*--platelet ration index (APRI)",
            "Value 882 885--*--> 2",
            "Temporal 886 902--*--during Screening",
            "Value 828 836--*--F3 or F4",
            "Value 844 847--*--AST",
            "Procedure 904 916--*--Liver biopsy",
            "Temporal 917 944--*--within 2 years of Screening",
            "Condition 964 973--*--cirrhosis",
            "Negation 953 960--*--absence",
            "Procedure 975 984--*--Fibroscan",
            "Temporal 985 1017--*--within 6 months of Baseline/Day1",
            "Value 1035 1045--*--= 12.5 kPa",
            "Measurement 1047 1067--*--FIBRO Spect II Index",
            "Value 1084 1090--*--F0- F2",
            "Measurement 1095 1099--*--APRI",
            "Value 1103 1106--*--= 1",
            "Temporal 1107 1123--*--during Screening",
            "Procedure 1125 1138--*--Liver imaging",
            "Temporal 1139 1172--*--within 6 months of Baseline/Day 1",
            "Condition 1184 1213--*--hepatocellular carcinoma HCC)",
            "Negation 1176 1183--*--exclude",
            "Measurement 1227 1230--*--ALT",
            "Measurement 1271 1274--*--AST",
            "Value 1231 1269--*--< 10 x the upper limit of normal (ULN)",
            "Value 1275 1285--*--< 10 x ULN",
            "Measurement 1287 1303--*--Direct bilirubin",
            "Value 1304 1315--*--< 2.0 x ULN",
            "Measurement 1317 1326--*--Platelets",
            "Value 1327 1335--*--> 50,000",
            "Measurement 1337 1342--*--HbA1c",
            "Value 1343 1349--*--< 8.5%",
            "Measurement 1351 1378--*--Creatinine clearance (CLcr)",
            "Value 1379 1391--*--= 60 mL /min",
            "Qualifier 1414 1438--*--Cockcroft-Gault equation",
            "Measurement 1440 1450--*--Hemoglobin",
            "Value 1451 1460--*--= 11 g/dL",
            "Person 1465 1471--*--female",
            "Value 1482 1491--*--= 12 g/dL",
            "Person 1496 1500--*--male",
            "Scope 1451 1500--*--= 11 g/dL for female subjects; = 12 g/dL for male",
            "Measurement 1512 1519--*--Albumin",
            "Value 1520 1530--*--= 2.5 g/dL",
            "Measurement 1532 1535--*--INR",
            "Value 1536 1547--*--= 1.5 x ULN",
            "Condition 1573 1583--*--hemophilia",
            "Condition 1590 1638--*--stable on an anticoagulant regimen affecting INR",
            "Negation 1548 1554--*--unless",
            "Scope 1573 1638--*--hemophilia or is stable on an anticoagulant regimen affecting INR",
            "Non-query-able 1641 1748--*--Subject has not been treated with any investigational drug or device within 30 days of the screening visit."
        ],
        "Text": "The subject must be willingly and able to provide written informed consent. Age 19 years of age or older (The age of consent in Nebraska). HCV treatment-na\u00efve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent. HCV RNA level at most 6 months prior to the Baseline/Day 1 visit.. HCV genotyping 1a, 1b, or mixed 1a/ab. Any non-definitive results will exclude the subject from study participation.. Alcohol misuse as defined by the Alcohol Use Disorders Identification Test (AUDIT) score subjects must score > 8 (associated with harmful or hazardous drinking). History of a liver biopsy showing cirrhosis (e.g. Metavir score = 4 or Ishak score > 5). Fibroscan showing cirrhosis or results > 12.5 kPa. FIBRO Spect II index consistent with F3 or F4 AND an AST : platelet ration index (APRI) of > 2 during Screening. Liver biopsy within 2 years of Screening showing absence of cirrhosis. Fibroscan within 6 months of Baseline/Day1 with a result of = 12.5 kPa. FIBRO Spect II Index consistent with F0- F2 AND APRI of = 1 during Screening. Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma HCC) is required. ALT < 10 x the upper limit of normal (ULN). AST < 10 x ULN. Direct bilirubin < 2.0 x ULN. Platelets > 50,000. HbA1c < 8.5%. Creatinine clearance (CLcr) = 60 mL /min, as calculated by the Cockcroft-Gault equation. Hemoglobin = 11 g/dL for female subjects; = 12 g/dL for male subjects.. Albumin = 2.5 g/dL. INR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.. Subject has not been treated with any investigational drug or device within 30 days of the screening visit.. "
    },
    "NCT03033745_inc": {
        "Text": "Male or female on stable dose of IgPro20 (Hizentra) therapy.. Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.. Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.. With infusion parameters as specified below:. Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.. Total weekly IgPro20 dose of = 50 mL (= 10 g).. Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.. Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1. The dose (volume) per injection site should not exceed 25 mL.. ",
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 8 14--*--female",
            "Drug 33 40--*--IgPro20",
            "Drug 42 50--*--Hizentra",
            "Qualifier 18 29--*--stable dose",
            "Pregnancy_considerations 62 269--*--Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening",
            "Condition 286 289--*--PID",
            "Condition 315 347--*--common variable immunodeficiency",
            "Condition 351 378--*--X-linked agammaglobulinemia",
            "Measurement 398 438--*--Pan American Group for Immune Deficiency",
            "Measurement 447 486--*--European Society of Immune Deficiencies",
            "Non-query-able 439 442--*--and",
            "Scope 398 486--*--Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies",
            "Scope 315 378--*--common variable immunodeficiency or X-linked agammaglobulinemia",
            "Qualifier 551 574--*--pump-assisted infusions",
            "Drug 578 585--*--IgPro20",
            "Multiplier 603 642--*--flow rate of 25 mL/h per injection site",
            "Qualifier 593 602--*--tolerated",
            "Temporal 643 678--*--for at least 1 month prior to Day 1",
            "Reference_point 673 678--*--Day 1",
            "Qualifier 687 693--*--weekly",
            "Drug 694 701--*--IgPro20",
            "Multiplier 710 717--*--= 50 mL",
            "Multiplier 719 725--*--= 10 g",
            "Qualifier 745 768--*--pump-assisted infusions",
            "Drug 772 779--*--IgPro20",
            "Multiplier 793 824--*--volumes of 25 mL/injection site",
            "Qualifier 783 792--*--tolerated",
            "Temporal 825 860--*--for at least 1 month prior to Day 1",
            "Reference_point 855 860--*--Day 1",
            "Qualifier 879 887--*--frequent",
            "Drug 922 929--*--IgPro20",
            "Multiplier 1012 1030;947 984--*--per injection site flow rate of approximately 0.5 mL/min",
            "Multiplier 1000 1010--*--25-30 mL/h",
            "Temporal 1031 1066--*--for at least 1 month prior to Day 1",
            "Reference_point 1061 1066--*--Day 1",
            "Multiplier 889 907--*--2-7 times per week",
            "Negation 1112 1115--*--not",
            "Multiplier 1116 1129--*--exceed 25 mL."
        ]
    },
    "NCT03080493_exc": {
        "Annotations": [
            "Drug 15 25--*--gabapentin",
            "Temporal 0 7--*--Current",
            "Drug 29 39--*--pregabalin",
            "Scope 15 39--*--gabapentin or pregabalin",
            "Condition 41 48--*--Allergy",
            "Drug 52 62--*--gabapentin",
            "Drug 64 77--*--acetaminophen",
            "Drug 79 86--*--codeine",
            "Drug 91 100--*--ibuprofen",
            "Scope 52 100--*--gabapentin, acetaminophen, codeine, or ibuprofen",
            "Qualifier 102 115--*--Self reported",
            "Condition 116 129--*--renal disease",
            "Qualifier 131 137--*--severe",
            "Condition 138 161--*--impaired renal function",
            "Scope 102 129--*--Self reported renal disease",
            "Scope 131 161--*--severe impaired renal function",
            "Qualifier 164 177--*--Self reported",
            "Temporal 178 185--*--current",
            "Qualifier 189 196--*--chronic",
            "Condition 197 209--*--narcotic use",
            "Scope 178 196--*--current or chronic",
            "Multiplier 219 228--*--daily use",
            "Non-representable 231 368--*--Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data"
        ],
        "Text": "Current use of gabapentin or pregabalin. Allergy to gabapentin, acetaminophen, codeine, or ibuprofen. Self reported renal disease (severe impaired renal function). Self reported current or chronic narcotic use (typical daily use). Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data. "
    },
    "NCT02251249_inc": {
        "Text": "Patient over 18 years weighing between 65 and 85 Kg. Referred for STEMI within 6 hours from beginning of chest pain or stable coronary artery disease requiring a loading dose of Prasugrel or Ticagrelor according to the international recommendations.. No previous treatment with Clopidogrel, Prasugrel or Ticagrelor.. Patient fasting for at least 6 hours.. Affiliate or receiving a social security system.. Written informed consent.. ",
        "Annotations": [
            "Person 16 21--*--years",
            "Value 8 15--*--over 18",
            "Measurement 22 30--*--weighing",
            "Value 31 51--*--between 65 and 85 Kg",
            "Condition 66 71--*--STEMI",
            "Multiplier 162 174--*--loading dose",
            "Drug 178 187--*--Prasugrel",
            "Drug 191 201--*--Ticagrelor",
            "Scope 178 201--*--Prasugrel or Ticagrelor",
            "Temporal 72 115--*--within 6 hours from beginning of chest pain",
            "Reference_point 92 115--*--beginning of chest pain",
            "Condition 126 149--*--coronary artery disease",
            "Qualifier 119 125--*--stable",
            "Negation 251 253--*--No",
            "Drug 278 289--*--Clopidogrel",
            "Drug 291 300--*--Prasugrel",
            "Drug 304 314--*--Ticagrelor",
            "Scope 278 314--*--Clopidogrel, Prasugrel or Ticagrelor",
            "Observation 325 332--*--fasting",
            "Temporal 333 354--*--for at least 6 hours.",
            "Non-query-able 356 403--*--Affiliate or receiving a social security system",
            "Condition 105 115--*--chest pain",
            "Temporal 254 262--*--previous",
            "Procedure 263 272--*--treatment",
            "Observation 406 430--*--Written informed consent"
        ]
    },
    "NCT01743755_exc": {
        "Annotations": [
            "Condition 0 17--*--Immunocompromised",
            "Condition 74 90--*--immunodeficiency",
            "Qualifier 65 73--*--acquired",
            "Qualifier 51 61--*--congenital",
            "Scope 51 73--*--congenital or acquired",
            "Procedure 115 127--*--chemotherapy",
            "Temporal 128 149--*--less than 6 weeks ago",
            "Drug 174 189--*--corticosteroids",
            "Temporal 190 209--*--in the last 6 weeks",
            "Procedure 234 262--*--immunosuppressive medication",
            "Temporal 263 282--*--in the last 6 weeks",
            "Drug 289 300--*--cyclosporin",
            "Drug 302 318--*--cyclophosphamide",
            "Drug 320 332--*--azathioprine",
            "Scope 289 332--*--cyclosporin, cyclophosphamide, azathioprine",
            "Condition 350 387--*--chronic obstructive pulmonary disease",
            "Drug 399 423--*--systemic corticosteroids",
            "Visit 447 466--*--intensive care unit",
            "Condition 493 516--*--tropical worm infection",
            "Drug 533 546--*--dexamethasone",
            "Condition 547 558--*--intolerance",
            "Pregnancy_considerations 561 593--*--Pregnant and breastfeeding women"
        ],
        "Text": "Immunocompromised patients:. Patients with a known congenital or acquired immunodeficiency.. Patients who received chemotherapy less than 6 weeks ago.. Patients who received corticosteroids in the last 6 weeks.. Patients who received immunosuppressive medication in the last 6 weeks (e.g. cyclosporin, cyclophosphamide, azathioprine).. Patients with chronic obstructive pulmonary disease who are on systemic corticosteroids.. Patients who require intensive care unit treatment.. Patients with tropical worm infection.. Patients with dexamethasone intolerance.. Pregnant and breastfeeding women.. "
    },
    "NCT02985242_exc": {
        "Annotations": [
            "Condition 0 15--*--Type 1 diabetes",
            "Condition 30 54--*--diabetes mellitus type 2",
            "Qualifier 17 29--*--uncontrolled",
            "Measurement 60 75--*--fasting glucose",
            "Value 76 89--*--> 13.3 mmol/l",
            "Condition 136 152--*--hypersensitivity",
            "Drug 156 169--*--empagliflozin",
            "Drug 171 182--*--glimepiride",
            "Condition 231 247--*--hypersensitivity",
            "Drug 251 264--*--sulfonylureas",
            "Drug 266 278--*--sulfonamides",
            "Drug 282 298--*--SGLT2 inhibitors",
            "Scope 251 298--*--sulfonylureas, sulfonamides or SGLT2 inhibitors",
            "Scope 156 182--*--empagliflozin, glimepiride",
            "Condition 338 359--*--hypoglycemic episodes",
            "Qualifier 331 337--*--severe",
            "Multiplier 322 330--*--multiple",
            "Temporal 371 385--*--last two years",
            "Drug 394 401--*--Insulin",
            "Drug 403 418--*--SGLT2-inhibitor",
            "Drug 420 441--*--sulfonylurea derivate",
            "Drug 447 454--*--glinide",
            "Scope 394 454--*--Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide",
            "Temporal 462 475--*--past 3 months",
            "Condition 498 511--*--macular edema",
            "Qualifier 515 524--*--both eyes",
            "Procedure 544 576--*--intravitreal anti-VEGF treatment",
            "Qualifier 581 590--*--both eyes",
            "Non-query-able 623 977--*--Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included. Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included",
            "Negation 1013 1020--*--prevent",
            "Procedure 1027 1041--*--ophthalmoscopy",
            "Condition 1181 1200--*--vitreous hemorrhage",
            "Condition 1202 1217--*--mature cataract",
            "Condition 1219 1238--*--macular pathologies",
            "Negation 1239 1244--*--other",
            "Condition 1250 1270--*--diabetic maculopathy",
            "Condition 1283 1295--*--ketoacidosis",
            "Condition 1299 1317--*--metabolic acidosis",
            "Drug 1326 1340--*--loop diuretics",
            "Condition 1357 1377--*--urogenital infection",
            "Multiplier 1353 1356;1377 1382--*--> 1 /year",
            "Condition 1399 1405--*--stroke",
            "Condition 1407 1432--*--transient ischemic attack",
            "Condition 1434 1437--*--TIA",
            "Condition 1449 1464--*--angina pectoris",
            "Qualifier 1440 1448--*--instable",
            "Condition 1468 1489--*--myocardial infarction",
            "Temporal 1497 1534--*--last 3 months prior to baseline visit",
            "Reference_point 1520 1534--*--baseline visit",
            "Scope 1399 1489--*--stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction",
            "Condition 1536 1560--*--congestive heart failure",
            "Measurement 1561 1587--*--New York Heart Association",
            "Measurement 1589 1593--*--NYHA",
            "Value 1595 1605--*--III and IV",
            "Condition 1626 1662--*--left ventricular outflow obstruction",
            "Condition 1614 1622;1663 1670--*--valvular disease",
            "Qualifier 1607 1613--*--severe",
            "Scope 1614 1670--*--valvular or left ventricular outflow obstruction disease",
            "Procedure 1679 1691--*--intervention",
            "Condition 1694 1713--*--atrial fibrillation",
            "Condition 1694 1700;1714 1721--*--atrial flutter",
            "Measurement 1729 1759--*--mean ventricular response rate",
            "Qualifier 1760 1767--*--at rest",
            "Value 1768 1789--*-->100 beats per minute",
            "Scope 1694 1721--*--atrial fibrillation/flutter",
            "Condition 1799 1829--*--lower urinary tract infections",
            "Qualifier 1791 1798--*--chronic",
            "Negation 1835 1838--*--not",
            "Condition 1846 1870--*--asymptomatic bacteriuria",
            "Measurement 1873 1877--*--eGFR",
            "Value 1878 1897--*--< 60 ml/min/1,73 m2",
            "Condition 1941 1957--*--chronic diarrhea",
            "Condition 1981 1997--*--volume depletion",
            "Measurement 2003 2013--*--hematocrit",
            "Value 2014 2020--*--> 48 %",
            "Person 2022 2027--*--women",
            "Value 2033 2039--*--> 53 %",
            "Person 2041 2044--*--men",
            "Measurement 2003 2013--*--hematocrit",
            "Scope 2003 2045--*--hematocrit > 48 % (women) and > 53 % (men)",
            "Observation 2056 2082--*--risk for volume depletion,",
            "Qualifier 2047 2055--*--elevated",
            "Condition 2154 2175--*--chronic liver disease",
            "Condition 2193 2209--*--active hepatitis",
            "Measurement 2228 2248--*--alanine transaminase",
            "Measurement 2250 2253--*--ALT",
            "Measurement 2258 2280--*--aspartate transaminase",
            "Measurement 2282 2285--*--AST",
            "Value 2287 2314--*--> 3 x upper limit of normal",
            "Scope 2228 2286--*--alanine transaminase (ALT) or aspartate transaminase (AST)",
            "Measurement 2388 2416--*--human immunodeficiency virus",
            "Value 2370 2384--*--seropositivity",
            "Non-query-able 2419 2516--*--acute illness at screening or randomization according to judgement by the investigator or patient",
            "Condition 2526 2539--*--alcohol abuse",
            "Condition 2518 2522;2534 2539--*--drug abuse",
            "Condition 2558 2578--*--psychiatric diseases",
            "Condition 2541 2554;2570 2578--*--psychosomatic diseases",
            "Visit 2589 2604--*--hospitalization",
            "Temporal 2616 2630--*--last 12 months",
            "Scope 2541 2578--*--psychosomatic or psychiatric diseases",
            "Condition 2661 2671--*--malignancy",
            "Negation 2677 2686--*--exception",
            "Condition 2690 2700;2718 2727;2728 2739--*--basal cell carcinoma of the skin",
            "Condition 2704 2739--*--squamous cell carcinoma of the skin",
            "Condition 2745 2779--*--cervical intraepithelial neoplasia",
            "Temporal 2781 2811--*--5 years prior to randomization",
            "Reference_point 2798 2811--*--randomization",
            "Scope 2690 2779--*--basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia",
            "Non-query-able 2815 2975--*--ny medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigator\u00b4s judgment",
            "Competing_trial 2977 3101--*--current participation in any other clinical trial or participation in another clinical trial within 30 days before screening"
        ],
        "Text": "Type 1 diabetes. uncontrolled diabetes mellitus type 2 with fasting glucose > 13.3 mmol/l confirmed on a second day. known or suspected hypersensitivity to empagliflozin, glimepiride, or any excipients; and / or known or suspected hypersensitivity to sulfonylureas, sulfonamides or SGLT2 inhibitors in general. history of multiple severe hypoglycemic episodes within the last two years. use of Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide within past 3 months. clinical significant macular edema in both eyes and indication for intravitreal anti-VEGF treatment for both eyes at screening or baseline visit. Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included. Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included.. eye diseases or pathologies that prevent clear ophthalmoscopy and evaluation of study parameters, thus not allowing study participation according to the investigator\u00b4s judgment, such as (but not only) vitreous hemorrhage, mature cataract, macular pathologies other than diabetic maculopathy. history of ketoacidosis or metabolic acidosis. use of loop diuretics. history of > 1 urogenital infection/year. any history of stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction within last 3 months prior to baseline visit. congestive heart failure New York Heart Association (NYHA) III and IV. severe valvular or left ventricular outflow obstruction disease needing intervention;. atrial fibrillation/flutter with a mean ventricular response rate at rest >100 beats per minute. chronic lower urinary tract infections (but not simple asymptomatic bacteriuria). eGFR < 60 ml/min/1,73 m2 (MDRD-formula, confirmed on a second day). chronic diarrhea, any clinical signs of volume depletion or a hematocrit > 48 % (women) and > 53 % (men). elevated risk for volume depletion, e.g. history of severe volume depletion that required medical therapy. chronic liver disease (including known active hepatitis) and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) > 3 x upper limit of normal (ULN) (confirmed on a second day). Subjects with known seropositivity to human immunodeficiency virus.. acute illness at screening or randomization according to judgement by the investigator or patient. drug or alcohol abuse. psychosomatic or psychiatric diseases requiring hospitalization during the last 12 months. clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization). any medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigator\u00b4s judgment. current participation in any other clinical trial or participation in another clinical trial within 30 days before screening. "
    },
    "NCT03413891_exc": {
        "Annotations": [
            "Non-query-able 0 148--*--Subjects with any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study",
            "Pregnancy_considerations 151 173--*--Pregnancy or lactation",
            "Condition 181 189--*--allergic",
            "Drug 202 217--*--tranexamic acid"
        ],
        "Text": "Subjects with any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study.. Pregnancy or lactation. Known allergic reaction to tranexamic acid. "
    },
    "NCT01890759_exc": {
        "Annotations": [
            "Temporal 21 48--*--4 weeks preceding inclusion",
            "Reference_point 39 48--*--inclusion",
            "Observation 52 73--*--planned participation",
            "Context_Error 0 200--*--Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.",
            "Post-eligibility 0 200--*--Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.",
            "Drug 217 224--*--vaccine",
            "Temporal 225 272--*--in the 4 weeks preceding each trial vaccination",
            "Reference_point 250 272--*--each trial vaccination",
            "Temporal 307 354--*--in the 4 weeks following each trial vaccination",
            "Reference_point 332 354--*--each trial vaccination",
            "Observation 276 291--*--planned receipt",
            "Drug 299 306--*--vaccine",
            "Parsing_Error 356 367--*--except for:",
            "Drug 373 394--*--influenza vaccination",
            "Temporal 418 456--*--at least 2 weeks before study vaccines",
            "Reference_point 442 456--*--study vaccines",
            "Negation 356 366--*--except for",
            "Procedure 464 475;517 528--*--measles (M) vaccination",
            "Procedure 479 508;517 528--*--measles, mumps, rubella (MMR) vaccination",
            "Temporal 556 606--*--concomitantly with the first dose of study vaccine",
            "Reference_point 575 606--*--the first dose of study vaccine",
            "Scope 464 528--*--measles (M) or measles, mumps, rubella (MMR) routine vaccination",
            "Visit 676 688--*--Indian sites",
            "Drug 690 722--*--oral poliomyelitis vaccine (OPV)",
            "Temporal 732 772--*--during National Immunization Days (NIDs)",
            "Reference_point 739 772--*--National Immunization Days (NIDs)",
            "Temporal 732 738;777 825--*--during supplementary immunization activity days (SIADs)",
            "Reference_point 777 825--*--supplementary immunization activity days (SIADs)",
            "Scope 732 825--*--during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs)",
            "Procedure 836 877--*--vaccination against meningococcal disease",
            "Drug 894 907--*--study vaccine",
            "Drug 911 940--*--another meningococcal vaccine",
            "Drug 953 969--*--immune globulins",
            "Drug 971 976--*--blood",
            "Drug 980 1002--*--blood-derived products",
            "Temporal 1003 1023--*--in the past 3 months",
            "Scope 953 1002--*--immune globulins, blood or blood-derived products",
            "Condition 1058 1083--*--acquired immunodeficiency",
            "Condition 1044 1054;1067 1083--*--congenital immunodeficiency",
            "Procedure 1099 1124--*--immunosuppressive therapy",
            "Procedure 1134 1158--*--anti-cancer chemotherapy",
            "Procedure 1162 1179--*--radiation therapy",
            "Temporal 1181 1210--*--within the preceding 6 months",
            "Procedure 1225 1256--*--systemic corticosteroid therapy",
            "Multiplier 1215 1224--*--long-term",
            "Drug 1258 1268--*--prednisone",
            "Temporal 1283 1316--*--for more than 2 consecutive weeks",
            "Temporal 1317 1341--*--within the past 3 months",
            "Scope 1134 1179--*--anti-cancer chemotherapy or radiation therapy",
            "Observation 1034 1043--*--suspected",
            "Observation 1025 1030--*--Known",
            "Scope 1025 1043--*--Known or suspected",
            "Scope 1044 1083--*--congenital or acquired immunodeficiency",
            "Condition 1355 1377--*--meningococcal diseases",
            "Procedure 1408 1421--*--serologically",
            "Procedure 1426 1443--*--microbiologically",
            "Value 1379 1388--*--confirmed",
            "Non-query-able 1445 1537--*--At high risk, in the opinion of the Investigator, for meningococcal disease during the trial",
            "Subjective_judgement 1445 1537--*--At high risk, in the opinion of the Investigator, for meningococcal disease during the trial",
            "Condition 1558 1583--*--systemic hypersensitivity",
            "Drug 1598 1616--*--vaccine components",
            "Observation 1621 1628--*--history",
            "Condition 1634 1659--*--life-threatening reaction",
            "Drug 1667 1674--*--vaccine",
            "Drug 1701 1708--*--vaccine",
            "Qualifier 1675 1692--*--used in the trial",
            "Context_Error 1675 1692--*--used in the trial",
            "Context_Error 1539 1746--*--Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances",
            "Condition 1754 1770--*--thrombocytopenia",
            "Condition 1772 1788--*--contraindicating",
            "Procedure 1789 1814--*--intramuscular vaccination",
            "Condition 1816 1833--*--Bleeding disorder",
            "Drug 1849 1863--*--anticoagulants",
            "Temporal 1864 1898--*--in the 3 weeks preceding inclusion",
            "Reference_point 1889 1898--*--inclusion",
            "Condition 1900 1916--*--contraindicating",
            "Procedure 1917 1942--*--intramuscular vaccination",
            "Scope 1816 1863--*--Bleeding disorder, or receipt of anticoagulants",
            "Visit 1950 1967--*--emergency setting",
            "Procedure 1972 1984--*--hospitalized",
            "Qualifier 1985 1998--*--involuntarily",
            "Condition 1972 1998--*--hospitalized involuntarily",
            "Subjective_judgement 2000 2129--*--Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion",
            "Visit 2156 2168--*--Indian sites",
            "Qualifier 2170 2178--*--Moderate",
            "Qualifier 2182 2188--*--severe",
            "Condition 2189 2202--*--acute illness",
            "Condition 2189 2194;2203 2212--*--acute infection",
            "Subjective_judgement 2214 2248--*--according to investigator judgment",
            "Temporal 2250 2275--*--on the day of vaccination",
            "Reference_point 2253 2275--*--the day of vaccination",
            "Condition 2279 2294--*--febrile illness",
            "Measurement 2296 2307--*--temperature",
            "Value 2308 2316--*--\u2265 38.0\u00b0C",
            "Scope 2189 2212--*--acute illness/infection",
            "Scope 2170 2188--*--Moderate or severe",
            "Scope 2170 2317--*--Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \u2265 38.0\u00b0C)",
            "Visit 2345 2358--*--Russian sites",
            "Condition 2360 2373--*--Acute disease",
            "Temporal 2390 2415--*--on the day of vaccination",
            "Reference_point 2393 2415--*--the day of vaccination",
            "Condition 2419 2434--*--febrile illness",
            "Measurement 2436 2456--*--axillary temperature",
            "Value 2457 2465--*--\u2265 37.0\u00b0C",
            "Scope 2360 2466--*--Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature \u2265 37.0\u00b0C)",
            "Non-query-able 2469 2594--*--A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.",
            "Not_a_criteria 2469 2594--*--A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.",
            "Drug 2626 2644--*--antibiotic therapy",
            "Qualifier 2615 2625--*--injectable",
            "Qualifier 2607 2611--*--oral",
            "Scope 2607 2625--*--oral or injectable",
            "Temporal 2645 2690--*--within 72 hours prior to the first blood draw",
            "Reference_point 2670 2690--*--the first blood draw",
            "Non-query-able 2692 2810--*--Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study",
            "Condition 2832 2855--*--Guillain-Barr\u00e9 Syndrome",
            "Observation 2821 2828--*--history"
        ],
        "Text": "Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. . Receipt of any vaccine in the 4 weeks preceding each trial vaccination or planned receipt of any vaccine in the 4 weeks following each trial vaccination, except for: . (i) influenza vaccination, which may be received at least 2 weeks before study vaccines. . (ii) measles (M) or measles, mumps, rubella (MMR) routine vaccination, which can be administered concomitantly with the first dose of study vaccine as per routine immunization schedule . (iii) for subjects enrolled at Indian sites: oral poliomyelitis vaccine (OPV) received during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs) . Previous vaccination against meningococcal disease with either the study vaccine or another meningococcal vaccine . Receipt of immune globulins, blood or blood-derived products in the past 3 months . Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) . History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically . At high risk, in the opinion of the Investigator, for meningococcal disease during the trial . Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances . Known thrombocytopenia, contraindicating intramuscular vaccination . Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination . In an emergency setting, or hospitalized involuntarily . Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion . For subjects enrolled at Indian sites: Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \u2265 38.0\u00b0C). . For subjects enrolled at Russian sites: Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature \u2265 37.0\u00b0C). . A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided. . Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw . Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study . Personal history of Guillain-Barr\u00e9 Syndrome.       .     . "
    },
    "NCT02476461_inc": {
        "Annotations": [
            "Condition 12 34--*--Dupuytrens contracture",
            "Qualifier 0 11--*--symptomatic",
            "Condition 40 53--*--palpable cord",
            "Qualifier 55 68--*--involving MCP",
            "Measurement 70 92--*--total contracture size",
            "Value 93 108--*--over 30 degrees"
        ],
        "Text": "symptomatic Dupuytrens contracture with palpable cord, involving MCP, total contracture size over 30 degrees. "
    },
    "NCT02251249_exc": {
        "Text": "Allergy or contraindication to paracetamol, Prasugrel or Ticagrelor. Paracetamol ingestion in the previous 48 hours. Patient treated with drugs supposed to alter gastric emptying times (calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics).. Conditions or pathologies supposed to alter gastric emptying times (Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease).. Presence of vomiting. Cardiogenic shock, ventricular arrhythmia or resuscitated cardiac arrest. Hepatic insufficiency. Severe respiratory disease. Pregnant or breastfeeding women. ",
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Condition 11 27--*--contraindication",
            "Drug 31 42--*--paracetamol",
            "Drug 44 53--*--Prasugrel",
            "Drug 57 67--*--Ticagrelor",
            "Scope 31 67--*--paracetamol, Prasugrel or Ticagrelor",
            "Scope 0 27--*--Allergy or contraindication",
            "Drug 69 80--*--Paracetamol",
            "Temporal 91 115--*--in the previous 48 hours",
            "Drug 186 205--*--calcium antagonists",
            "Procedure 207 234--*--Alimentary tract treatments",
            "Drug 236 253--*--opioid analgesics",
            "Drug 255 280--*--tricyclic antidepressants",
            "Drug 282 293--*--antibiotics",
            "Condition 365 384--*--Thyroid dysfunction",
            "Condition 386 407--*--chronic renal failure",
            "Condition 409 428--*--Parkinson's disease",
            "Condition 430 441--*--scleroderma",
            "Condition 443 454--*--amyloidosis",
            "Condition 460 484--*--gastrointestinal disease",
            "Condition 500 510--*--malignancy",
            "Condition 529 540;557 564--*--psychiatric disease",
            "Condition 544 564--*--neurological disease",
            "Qualifier 520 528--*--advanced",
            "Scope 529 564--*--psychiatric or neurological disease",
            "Condition 580 588--*--vomiting",
            "Condition 590 607--*--Cardiogenic shock",
            "Condition 609 631--*--ventricular arrhythmia",
            "Condition 648 662--*--cardiac arrest",
            "Qualifier 635 647--*--resuscitated",
            "Condition 664 685--*--Hepatic insufficiency",
            "Condition 694 713--*--respiratory disease",
            "Qualifier 687 693--*--Severe",
            "Drug 138 184--*--drugs supposed to alter gastric emptying times",
            "Scope 186 293--*--calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics",
            "Condition 311 363--*--pathologies supposed to alter gastric emptying times",
            "Condition 297 307;323 363--*--Conditions supposed to alter gastric emptying times",
            "Scope 297 363--*--Conditions or pathologies supposed to alter gastric emptying times",
            "Scope 365 564--*--Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease",
            "Condition 715 723--*--Pregnant",
            "Observation 727 740--*--breastfeeding",
            "Person 741 746--*--women"
        ]
    },
    "NCT01743755_inc": {
        "Annotations": [
            "Person 3 8--*--years",
            "Value 0 2;9 17--*--18 or older",
            "Procedure 19 35--*--Chest radiograph",
            "Condition 48 57--*--opacities",
            "Qualifier 44 47--*--new",
            "Condition 60 65--*--Cough",
            "Condition 81 87--*--sputum",
            "Measurement 89 93--*--Temp",
            "Value 94 102--*-->38,0 \u00b0C",
            "Value 106 114--*--<36,0 \u00b0C",
            "Scope 94 114--*-->38,0 \u00b0C or <36,0 \u00b0C",
            "Observation 116 137--*--Audible abnormalities",
            "Procedure 141 158--*--chest examination",
            "Condition 175 184--*--pneumonia",
            "Condition 186 198--*--Leukocytosis",
            "Multiplier 200 217--*-->10.000 cells/mm3",
            "Condition 245 255--*--leucopenia",
            "Multiplier 257 272--*--<4000 cells/mm3",
            "Multiplier 220 234;236 240--*--leftward shift >10%",
            "Scope 200 241--*-->10.000 cells/mm3), leftward shift (>10%)",
            "Measurement 275 293--*--C-reactive protein",
            "Value 294 303--*--> 15 mg/l",
            "Value 305 353--*--three fold higher than the upper limit of normal"
        ],
        "Text": "18 years or older. Chest radiograph showing new opacities.. Cough. Production of sputum. Temp >38,0 \u00b0C or <36,0 \u00b0C. Audible abnormalities by chest examination compatible with pneumonia. Leukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leucopenia (<4000 cells/mm3). C-reactive protein > 15 mg/l (three fold higher than the upper limit of normal). "
    },
    "NCT02985242_inc": {
        "Annotations": [
            "Person 0 5--*--women",
            "Person 10 13--*--men",
            "Person 39 42--*--age",
            "Value 14 35--*--between 18 - 80 years",
            "Condition 44 68--*--type 2 diabetes mellitus",
            "Condition 94 114--*--diabetic retinopathy",
            "Qualifier 70 75--*--early",
            "Qualifier 79 93--*--moderate stage",
            "Scope 70 93--*--early to moderate stage",
            "Measurement 116 121--*--ETDRS",
            "Value 123 125--*--20",
            "Value 151 153--*--35",
            "Scope 123 153--*--20 (microaneurysms only) to 35",
            "Qualifier 222 226--*--eyes",
            "Measurement 235 240--*--HbA1c",
            "Value 242 248--*--\u00b1 0.5%",
            "Temporal 254 271--*--at least 12 weeks",
            "Procedure 273 295--*--antidiabetic treatment",
            "Observation 308 312--*--diet",
            "Drug 314 323--*--metformin",
            "Drug 325 329--*--DPP4",
            "Drug 331 335--*--GLP1",
            "Drug 337 349--*--pioglitazone",
            "Drug 351 359--*--acarbose",
            "Scope 308 359--*--diet, metformin, DPP4, GLP1, pioglitazone, acarbose",
            "Measurement 389 394--*--HbA1c",
            "Value 395 413--*--= 6.5 and = 10.0 %",
            "Person 415 430--*--body mass index",
            "Value 431 441--*--< 46 kg/m2",
            "Measurement 450 464--*--blood pressure",
            "Value 465 478--*--= 150/95 mmHg",
            "Non-query-able 479 757--*--(confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines",
            "Procedure 782 804--*--surgical sterilization",
            "Procedure 808 832--*--bilateral tubal ligation",
            "Procedure 836 858--*--bilateral oophorectomy",
            "Scope 808 858--*--bilateral tubal ligation or bilateral oophorectomy",
            "Temporal 759 775--*--at least 6 weeks",
            "Procedure 860 872--*--hysterectomy",
            "Person 879 884--*--years",
            "Value 874 878--*--= 50",
            "Observation 892 912--*--postmenopausal state",
            "Temporal 913 921--*--> 1 year",
            "Pregnancy_considerations 923 1403--*--< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (\u00df-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication",
            "Pregnancy_considerations 1406 1802--*--correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)",
            "Pregnancy_considerations 1804 1900--*--true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)",
            "Non-query-able 1902 1947--*--sexual relationship only with female partners",
            "Non-query-able 1949 1970--*--sterile male partners",
            "Informed_consent 1972 2069--*--signed written informed consent and willingness to comply with treatment and follow-up procedures",
            "Post-eligibility 2071 2177--*--capability of understanding the investigational nature, potential risks and benefits of the clinical trial"
        ],
        "Text": "women and men between 18 - 80 years of age. type 2 diabetes mellitus. early to moderate stage diabetic retinopathy (ETDRS: 20 (microaneurysms only) to 35 (microaneurysms/ hemorrhages and/or hard exsudates)) in one or both eyes. stable HbA1c (\u00b1 0.5%) for at least 12 weeks. antidiabetic treatment with either diet, metformin, DPP4, GLP1, pioglitazone, acarbose, or respective combinations. HbA1c = 6.5 and = 10.0 %. body mass index < 46 kg/m2. office blood pressure = 150/95 mmHg (confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines. at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy. hysterectomy. = 50 years and in postmenopausal state > 1 year. < 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (\u00df-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication:. correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository). true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception). sexual relationship only with female partners. sterile male partners. signed written informed consent and willingness to comply with treatment and follow-up procedures. capability of understanding the investigational nature, potential risks and benefits of the clinical trial. "
    },
    "NCT03413891_inc": {
        "Annotations": [
            "Mood 9 22--*--scheduled for",
            "Procedure 23 40--*--dental extraction",
            "Drug 58 66--*--edoxaban",
            "Drug 68 76--*--apixaban",
            "Drug 78 89--*--rivaroxaban",
            "Drug 93 103--*--dabigatran",
            "Scope 58 103--*--edoxaban, apixaban, rivaroxaban or dabigatran",
            "Temporal 152 180--*--on the day of the extraction",
            "Reference_point 170 180--*--extraction",
            "Negation 105 108--*--Not",
            "Drug 138 151--*--anticoagulant",
            "Qualifier 133 137--*--oral",
            "Post-eligibility 182 233--*--Provision of signed and dated informed consent form",
            "Post-eligibility 235 336--*--Stated willingness to comply with all study procedures and availability for the duration of the study"
        ],
        "Text": "Patients scheduled for dental extraction and treated with edoxaban, apixaban, rivaroxaban or dabigatran. Not having taken the direct oral anticoagulant on the day of the extraction. Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study. "
    },
    "NCT01890759_inc": {
        "Annotations": [
            "Person 0 4--*--Male",
            "Person 9 15--*--female",
            "Person 25 29--*--aged",
            "Value 30 44--*--9 to 17 months",
            "Temporal 45 68--*--on the day of inclusion",
            "Reference_point 48 68--*--the day of inclusion",
            "Grammar_Error 5 8--*--and",
            "Non-query-able 70 196--*--Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable)",
            "Non-query-able 198 343--*--Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures.",
            "Post-eligibility 198 343--*--Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures."
        ],
        "Text": "Male and female subjects aged 9 to 17 months on the day of inclusion . Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable) . Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures. . "
    },
    "NCT02476461_exc": {
        "Annotations": [
            "Temporal 0 8--*--previous",
            "Qualifier 9 16--*--treated",
            "Condition 17 39--*--dupuytrens contracture",
            "Qualifier 40 49--*--same hand",
            "Multiplier 51 65--*--more than tree",
            "Condition 66 85--*--fingers involvement",
            "Non-representable 87 113--*--we will not include thumbs",
            "Condition 115 127--*--other things",
            "Qualifier 128 151--*--affecting hand function",
            "Measurement 153 156--*--ASA",
            "Value 156 158--*-->3",
            "Observation 160 176--*--expected to live",
            "Value 177 193--*--under five years",
            "Drug 195 207--*--Tetracycline",
            "Temporal 218 234--*--within two weeks",
            "Condition 236 245--*--pregnancy",
            "Condition 247 254--*--nursing",
            "Condition 256 263--*--allergy",
            "Observation 267 291--*--clostridium histolyticum",
            "Competing_trial 293 319--*--participant in other trial"
        ],
        "Text": "previous treated dupuytrens contracture same hand. more than tree fingers involvement. we will not include thumbs. other things affecting hand function. ASA>3. expected to live under five years. Tetracycline treatment within two weeks. pregnancy. nursing. allergy to clostridium histolyticum. participant in other trial. "
    },
    "NCT01410890_exc": {
        "Annotations": [
            "Competing_trial 0 87--*--The patient is participating in another clinical study using an investigational product",
            "Non-query-able 90 191--*--The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study"
        ],
        "Text": "The patient is participating in another clinical study using an investigational product.. The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.. "
    },
    "NCT03164096_exc": {
        "Annotations": [
            "Condition 14 26--*--coagulopathy",
            "Procedure 36 60--*--anti-coagulation therapy",
            "Condition 63 87--*--Gastrointestinal disease",
            "Condition 90 105--*--motion sickness",
            "Condition 108 125--*--diabetes mellitus",
            "Condition 142 154--*--preeclampsia"
        ],
        "Text": "Patients with coagulopathy or under anti-coagulation therapy.. Gastrointestinal disease,. motion sickness.. diabetes mellitus.. Patients with preeclampsia,. "
    },
    "NCT01346436_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 17--*--<18 years old",
            "Post-eligibility 19 75--*--Patient unable to communicate or to understand the study",
            "Post-eligibility 77 121--*--Patient refusing to participate to the study",
            "Condition 123 139--*--contraindication",
            "Procedure 143 154--*--laparoscopy"
        ],
        "Text": "Age <18 years old. Patient unable to communicate or to understand the study. Patient refusing to participate to the study. contraindication to laparoscopy. "
    },
    "NCT03181984_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 11 29--*--14 to 65 years-old",
            "Condition 56 71--*--Port-wine Stain",
            "Drug 93 103--*--hemoporfin",
            "Post-eligibility 159 231--*--Written informed consent signed and agreed to receive periodic follow-up"
        ],
        "Text": "Age range: 14 to 65 years-old;. Clinically diagnosed of Port-wine Stain;. Patients receiving hemoporfin based upon the clinical judgment of the investigator;. Written informed consent signed and agreed to receive periodic follow-up. "
    },
    "NCT02562456_exc": {
        "Text": "severe behavioral issues. presence of fistula or abscess near the selected tooth. presence of pulp exposure in the selected tooth. presence of mobility in the selected tooth. ",
        "Annotations": [
            "Condition 7 24--*--behavioral issues",
            "Qualifier 0 6--*--severe",
            "Condition 38 45--*--fistula",
            "Condition 49 56--*--abscess",
            "Qualifier 57 80--*--near the selected tooth",
            "Scope 38 56--*--fistula or abscess",
            "Condition 94 107--*--pulp exposure",
            "Qualifier 115 129--*--selected tooth",
            "Condition 143 151--*--mobility",
            "Qualifier 159 173--*--selected tooth"
        ]
    },
    "NCT02077556_inc": {
        "Annotations": [
            "Procedure 8 26--*--kidney transplants",
            "Qualifier 0 7--*--De novo",
            "Person 42 45--*--old",
            "Value 28 41--*--20 - 65 years",
            "Measurement 74 98--*--alanine aminotransferase",
            "Measurement 47 73--*--aspartate aminotransferase",
            "Value 99 145--*--within 2 times the upper limit of normal range",
            "Scope 47 98--*--aspartate aminotransferase/alanine aminotransferase"
        ],
        "Text": "De novo kidney transplants. 20 - 65 years old. aspartate aminotransferase/alanine aminotransferase within 2 times the upper limit of normal range. "
    },
    "NCT01410890_inc": {
        "Annotations": [
            "Post-eligibility 0 109--*--The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent",
            "Condition 140 161--*--GAA enzyme deficiency",
            "Qualifier 167 171--*--skin",
            "Qualifier 173 178--*--blood",
            "Qualifier 183 196--*--muscle tissue",
            "Multiplier 204 205--*--2",
            "Observation 216 234--*--GAA gene mutations",
            "Scope 167 196--*--skin, blood, or muscle tissue",
            "Condition 256 269--*--Pompe disease",
            "Person 237 243--*--Infant",
            "Person 248 255--*--toddler",
            "Non-query-able 237 552--*--Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.",
            "Pregnancy_considerations 554 861--*--The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study",
            "Non-representable 864 919--*--For patients previously treated with alglucosidase alfa",
            "Drug 945 963--*--alglucosidase alfa",
            "Temporal 964 985--*--for at least 6 months"
        ],
        "Text": "The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent.. The patient has a confirmed GAA enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.. Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.. The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.. For patients previously treated with alglucosidase alfa the patient has received alglucosidase alfa for at least 6 months.. "
    },
    "NCT01346436_inc": {
        "Annotations": [
            "Person 0 5--*--women",
            "Condition 14 38--*--pelvic floor dysfunction",
            "Informed_consent 41 56--*--nformed consent"
        ],
        "Text": "women. proven pelvic floor dysfunction. informed consent. "
    },
    "NCT03164096_inc": {
        "Annotations": [
            "Person 0 5--*--adult",
            "Person 6 12--*--female",
            "Observation 6 20--*--female partner",
            "Person 22 26--*--aged",
            "Value 27 41--*--18 to 40 years",
            "Procedure 67 83--*--cesarean section",
            "Qualifier 58 66--*--elective",
            "Mood 44 57--*--scheduled for"
        ],
        "Text": "adult female partner. aged 18 to 40 years.. scheduled for elective cesarean section.. "
    },
    "NCT02077556_exc": {
        "Annotations": [
            "Condition 0 9--*--Pregnancy",
            "Condition 11 23--*--Tuberculosis",
            "Condition 25 36;42 49--*--Hepatitis B carrier",
            "Condition 25 34;40 49--*--Hepatitis C carrier",
            "Measurement 58 86--*--Human immunodeficiency virus",
            "Value 87 95--*--positive",
            "Procedure 104 121--*--Retransplantation",
            "Procedure 136 151--*--transplantation",
            "Qualifier 125 135--*--multiorgan",
            "Condition 164 184--*--rheumatoid arthritis",
            "Non-query-able 186 260--*--Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity"
        ],
        "Text": "Pregnancy. Tuberculosis. Hepatitis B or C carrier status. Human immunodeficiency virus-positive status. Retransplantation or multiorgan transplantation. History of rheumatoid arthritis. Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity. "
    },
    "NCT03181984_exc": {
        "Annotations": [
            "Condition 0 7--*--Allergy",
            "Drug 11 21--*--porphyrins",
            "Drug 11 21;26 35--*--porphyrins analogues",
            "Condition 37 53--*--Photosensitivity",
            "Condition 55 64--*--Porphyria",
            "Condition 66 87--*--Allergic constitution",
            "Scope 11 35--*--porphyrins and analogues",
            "Condition 90 104--*--Scar diathesis",
            "Pregnancy_considerations 107 210--*--Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application",
            "Post-eligibility 213 281--*--Be judged not suitable to participate the study by the investigators"
        ],
        "Text": "Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;. Scar diathesis;. Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application;. Be judged not suitable to participate the study by the investigators. "
    },
    "NCT02562456_inc": {
        "Text": "Children aging between 3 and 6 years. presenting good health conditions. whose parents or legal guardians accept and sign the consent form. with at least one occlusal or occlusal proximal caries lesion in primary molars. only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement. ",
        "Annotations": [
            "Person 0 8--*--Children",
            "Person 9 14--*--aging",
            "Value 15 36--*--between 3 and 6 years",
            "Condition 49 71--*--good health conditions",
            "Informed_consent 73 138--*--whose parents or legal guardians accept and sign the consent form",
            "Multiplier 145 157--*--at least one",
            "Qualifier 170 187--*--occlusal proximal",
            "Qualifier 158 166--*--occlusal",
            "Condition 188 201--*--caries lesion",
            "Qualifier 205 219--*--primary molars",
            "Scope 158 187--*--occlusal or occlusal proximal",
            "Condition 274 288--*--caries lesions",
            "Condition 294 312--*--dentin involvement",
            "Qualifier 242 268--*--occlusal-proximal surfaces",
            "Qualifier 226 234;260 268--*--occlusal surfaces",
            "Scope 226 268--*--occlusal and/or occlusal-proximal surfaces",
            "Scope 274 312--*--caries lesions with dentin involvement"
        ]
    },
    "NCT03252249_inc": {
        "Text": "Aged =18 years. Clinical diagnosis of acute coronary syndrome. In the opinion of the attending clinician requires dual anti-platelet therapy with aspirin and a P2Y12 receptor antagonist. Resident in Scotland with a Community Health Index (CHI) number. The attending clinician has equipoise regarding the duration of therapy. Provision of informed consent. ",
        "Annotations": [
            "Person 0 4--*--Aged",
            "Value 5 14--*--=18 years",
            "Condition 38 61--*--acute coronary syndrome",
            "Procedure 114 140--*--dual anti-platelet therapy",
            "Drug 146 153--*--aspirin",
            "Drug 160 185--*--P2Y12 receptor antagonist",
            "Mood 105 113--*--requires",
            "Person 187 195--*--Resident",
            "Visit 199 207--*--Scotland",
            "Non-representable 215 250--*--Community Health Index (CHI) number",
            "Non-representable 252 323--*--The attending clinician has equipoise regarding the duration of therapy",
            "Informed_consent 325 354--*--Provision of informed consent"
        ]
    },
    "NCT02109081_inc": {
        "Text": "patients = 70 years of age, undergoing a noncardiac surgical procedure under general anesthesia, with an anticipated duration of postoperative admission of at least 2 days.. ",
        "Annotations": [
            "Person 23 26--*--age",
            "Value 9 19--*--= 70 years",
            "Procedure 41 70--*--noncardiac surgical procedure",
            "Procedure 77 95--*--general anesthesia",
            "Mood 105 116--*--anticipated",
            "Measurement 117 152--*--duration of postoperative admission",
            "Value 156 171--*--at least 2 days",
            "Procedure 143 152--*--admission",
            "Temporal 129 142--*--postoperative"
        ]
    },
    "NCT02763007_exc": {
        "Text": "eGFR(Epidermal growth factor receptor) < 50mL/min. AST(aspartate aminotransferase)/ALT(alanine aminotransaminase) >2.5 upper limit of normal. Pregnant or lactating women. Subject who the investigator deems inappropriate to participate in this study. Patients with a history of bladder cancer or patients with active bladder cancer. Patients with uninvestigated macroscopic hematuria. Patients with cardiac failure or a history of cardiac failure (New York Heart Association [NYHA] Stages 3 to 4). Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose. ",
        "Annotations": [
            "Measurement 0 4--*--eGFR",
            "Measurement 5 37--*--Epidermal growth factor receptor",
            "Value 39 49--*--< 50mL/min",
            "Measurement 51 54--*--AST",
            "Measurement 55 81--*--aspartate aminotransferase",
            "Measurement 83 86--*--ALT",
            "Measurement 87 112--*--alanine aminotransaminase",
            "Value 114 140--*-->2.5 upper limit of normal",
            "Scope 51 112--*--AST(aspartate aminotransferase)/ALT(alanine aminotransaminase",
            "Pregnancy_considerations 142 169--*--Pregnant or lactating women",
            "Non-query-able 171 248--*--Subject who the investigator deems inappropriate to participate in this study",
            "Condition 277 291--*--bladder cancer",
            "Qualifier 309 315--*--active",
            "Condition 316 330--*--bladder cancer",
            "Condition 361 382--*--macroscopic hematuria",
            "Qualifier 346 360--*--uninvestigated",
            "Condition 398 413--*--cardiac failure",
            "Observation 419 445--*--history of cardiac failure",
            "Measurement 447 473;481 487--*--New York Heart Association Stages",
            "Value 488 494--*--3 to 4",
            "Measurement 475 479--*--NYHA",
            "Scope 398 445--*--cardiac failure or a history of cardiac failure",
            "Condition 511 527--*--genetic problems",
            "Condition 536 557--*--galactose intolerance",
            "Condition 559 582--*--Lapp lactase deficiency",
            "Condition 586 617--*--glucose-galactose malabsorption",
            "Scope 536 617--*--galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption"
        ]
    },
    "NCT02509949_exc": {
        "Annotations": [
            "Condition 27 37--*--drug abuse",
            "Observation 16 23--*--history",
            "Observation 53 60--*--history",
            "Condition 64 77--*--schizophrenia",
            "Temporal 40 52--*--preoperative",
            "Condition 79 87--*--epilepsy",
            "Condition 89 101--*--parkinsonism",
            "Drug 110 134--*--cholinesterase inhibitor",
            "Condition 136 160--*--inability to communicate",
            "Condition 189 193--*--coma",
            "Condition 195 212--*--profound dementia",
            "Condition 217 233--*--language barrier"
        ],
        "Text": "Patients with a history of drug abuse;. preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).. "
    },
    "NCT02918851_exc": {
        "Text": "Any significant acute or chronic medical illness or problem, including, but not limited to, diabetes, hypertension, cardiac disease, asthma, chronic obstructive lung disease. Current or recent (last 60 days) tobacco or nicotine use. History of sickle cell trait or disease or any other acquired or hereditary hematological abnormality. History of fainting or other significant adverse reaction during phlebotomy or donation of blood. Known prolonged QTc (or evidence of such at screening) on electrocardiogram defined as >470 ms. Known or suspected illicit drug or alcohol abuse. Known or suspected HIV, Hepatitis B, or Hepatitis C infection. History of thrombophilia or anticoagulant therapy. Pregnancy. Obesity defined as BMI>30. Recent history of blood donation: a) Single whole blood unit donation within the past 8 weeks; b) Double RBC donation by apheresis within the past 16 weeks; or c) Plasma donation by apheresis within the past 4 weeks. Inadequate RBC mass based on TBV <4500 ml (above) or screening Hb <14 g/dL. ",
        "Annotations": [
            "Condition 92 100--*--diabetes",
            "Condition 102 114--*--hypertension",
            "Condition 116 131--*--cardiac disease",
            "Condition 133 139--*--asthma",
            "Condition 141 173--*--chronic obstructive lung disease",
            "Scope 92 173--*--diabetes, hypertension, cardiac disease, asthma, chronic obstructive lung disease",
            "Condition 33 48--*--medical illness",
            "Qualifier 16 21--*--acute",
            "Qualifier 25 32--*--chronic",
            "Scope 16 32--*--acute or chronic",
            "Observation 208 215;228 231--*--tobacco use",
            "Observation 219 231--*--nicotine use",
            "Scope 208 231--*--tobacco or nicotine use",
            "Temporal 194 206--*--last 60 days",
            "Condition 244 261--*--sickle cell trait",
            "Condition 244 255;265 272--*--sickle cell disease",
            "Condition 298 334--*--hereditary hematological abnormality",
            "Condition 286 294;309 334--*--acquired hematological abnormality",
            "Condition 347 355--*--fainting",
            "Procedure 401 411--*--phlebotomy",
            "Condition 377 393--*--adverse reaction",
            "Observation 415 432--*--donation of blood",
            "Scope 401 432--*--phlebotomy or donation of blood",
            "Measurement 450 453--*--QTc",
            "Procedure 492 509--*--electrocardiogram",
            "Value 521 528--*-->470 ms",
            "Condition 549 561;573 578--*--illicit drug abuse",
            "Condition 565 578--*--alcohol abuse",
            "Condition 599 602;632 641--*--HIV infection",
            "Condition 604 615;632 641--*--Hepatitis B infection",
            "Condition 620 641--*--Hepatitis C infection",
            "Condition 654 667--*--thrombophilia",
            "Drug 671 692--*--anticoagulant therapy",
            "Condition 694 703--*--Pregnancy",
            "Measurement 724 727--*--BMI",
            "Condition 705 712--*--Obesity",
            "Value 727 730--*-->30",
            "Observation 750 764--*--blood donation",
            "Non-query-able 767 947--*--) Single whole blood unit donation within the past 8 weeks; b) Double RBC donation by apheresis within the past 16 weeks; or c) Plasma donation by apheresis within the past 4 weeks",
            "Observation 960 968--*--RBC mass",
            "Qualifier 949 959--*--Inadequate",
            "Measurement 978 981--*--TBV",
            "Value 982 990--*--<4500 ml",
            "Measurement 1012 1014--*--Hb",
            "Value 1015 1023--*--<14 g/dL",
            "Scope 978 1023--*--TBV <4500 ml (above) or screening Hb <14 g/dL"
        ]
    },
    "NCT00609531_inc": {
        "Annotations": [
            "Visit 0 17--*--Ambulatory status",
            "Visit 19 29--*--outpatient",
            "Temporal 31 49--*--at time of consent",
            "Value 55 66--*--10-55 years",
            "Person 51 54--*--Age",
            "Condition 90 114--*--Autism Spectrum Disorder",
            "Measurement 116 118--*--IQ",
            "Value 119 146--*--greater than or equal to 70",
            "Measurement 172 220--*--Children's Yale-Brown Obsessive Compulsive Scale",
            "Value 154 168--*--greater than 8",
            "Drug 230 253--*--psychoactive medication",
            "Negation 222 229--*--Free of",
            "Temporal 258 266;268 277--*--at least one month",
            "Temporal 258 266;294 303--*--at least two weeks",
            "Temporal 258 266;342 351--*--at least five days",
            "Drug 282 292--*--fluoxetine",
            "Drug 314 319--*--SSRIs",
            "Drug 324 336--*--neuroleptics",
            "Scope 314 336--*--SSRIs and neuroleptics",
            "Drug 356 366--*--stimulants",
            "Temporal 367 388--*--prior to MRI scanning",
            "Drug 453 478--*--anticonvulsant medication",
            "Condition 483 499--*--seizure disorder",
            "Temporal 414 439--*--greater than three months",
            "Qualifier 400 412--*--stable doses",
            "Scope 258 366--*--at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants",
            "Negation 390 399--*--excepting",
            "Qualifier 68 86--*--Clinical diagnosis"
        ],
        "Text": "Ambulatory status (outpatient) at time of consent . Age 10-55 years . Clinical diagnosis of Autism Spectrum Disorder . IQ greater than or equal to 70 . Score greater than 8 on Children's Yale-Brown Obsessive Compulsive Scale . Free of psychoactive medication for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder] . "
    },
    "NCT02904785_inc": {
        "Annotations": [
            "Condition 37 64--*--primary knee osteoarthritis",
            "Measurement 66 85--*--Kellgren & Lawrence",
            "Value 86 98--*--I, II or III",
            "Qualifier 0 8;24 33--*--Clinical diagnosis",
            "Qualifier 13 33--*--radiologic diagnosis",
            "Non-query-able 102 153--*--Capability to understand the Informed Consent Form;",
            "Post-eligibility 102 153--*--Capability to understand the Informed Consent Form;",
            "Condition 155 167--*--Chronic pain",
            "Temporal 172 195--*--at least 3 months prior",
            "Reference_point 199 208--*--inclusion",
            "Procedure 222 225--*--VAS",
            "Qualifier 210 225--*--measured by VAS",
            "Measurement 228 231--*--VAS",
            "Value 232 242--*--4 or above",
            "Parsing_Error 227 244--*--(VAS 4 or above);",
            "Condition 257 269--*--skin injures",
            "Negation 246 253--*--Absence",
            "Condition 271 281--*--infections",
            "Condition 285 290--*--tumor",
            "Reference_point 298 309--*--target knee",
            "Non-query-able 312 350--*--Availability to comply with the visits",
            "Post-eligibility 312 350--*--Availability to comply with the visits"
        ],
        "Text": "Clinical and radiologic diagnosis of primary knee osteoarthritis (Kellgren & Lawrence I, II or III); . Capability to understand the Informed Consent Form; . Chronic pain for at least 3 months prior to inclusion, measured by VAS. (VAS 4 or above); . Absence of skin injures, infections or tumor in the target knee; . Availability to comply with the visits. . "
    },
    "NCT02627560_inc": {
        "Annotations": [
            "Condition 0 13--*--breast cancer",
            "Measurement 26 47--*--unilateral mastectomy",
            "Temporal 15 25--*--undergoing",
            "Procedure 64 88--*--axillary node dissection",
            "Informed_consent 90 188--*--received adequate oral and written information about the study and signed an informed-consent form"
        ],
        "Text": "breast cancer. undergoing unilateral mastectomy with or without axillary node dissection. received adequate oral and written information about the study and signed an informed-consent form. "
    },
    "NCT02762851_inc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 14--*--= 18 years",
            "Measurement 19 69--*--NYHA (New York Heart Association) functional class",
            "Value 70 84--*--II, III and IV"
        ],
        "Text": "Age = 18 years and NYHA (New York Heart Association) functional class II, III and IV. "
    },
    "NCT03495609_inc": {
        "Text": "premenopausal women. BRCA1 carrier. ",
        "Annotations": [
            "Condition 0 13--*--premenopausal",
            "Person 14 19--*--women",
            "Condition 21 34--*--BRCA1 carrier"
        ]
    },
    "NCT02361892_exc": {
        "Annotations": [
            "Condition 0 23--*--endometrial hyperplasia",
            "Condition 29 35--*--atypia",
            "Procedure 38 64--*--estrogen-progestin therapy",
            "Temporal 65 98--*--in the 2 months before enrollment",
            "Condition 101 120--*--autoimmune diseases",
            "Condition 123 130;166 175--*--chronic disorders",
            "Condition 132 141;166 175--*--metabolic disorders",
            "Condition 143 151;166 175--*--systemic disorders",
            "Condition 156 175--*--endocrine disorders",
            "Condition 187 203--*--hyperandrogenism",
            "Condition 205 223--*--hyperprolactinemia",
            "Condition 225 242--*--diabetes mellitus",
            "Condition 247 262--*--thyroid disease",
            "Scope 187 262--*--hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease",
            "Scope 123 175--*--chronic, metabolic, systemic and endocrine disorders",
            "Condition 265 294--*--hypogonadotropic hypogonadism",
            "Condition 297 323--*--majors clinical conditions"
        ],
        "Text": "endometrial hyperplasia with atypia,. estrogen-progestin therapy in the 2 months before enrollment,. autoimmune diseases,. chronic, metabolic, systemic and endocrine disorders, including hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease,. hypogonadotropic hypogonadism,. majors clinical conditions. "
    },
    "NCT00904202_exc": {
        "Annotations": [
            "Condition 9 31--*--neurological condition",
            "Condition 70 84--*--pain diagnosis",
            "Negation 32 42--*--other than",
            "Qualifier 48 84--*--associated with their pain diagnosis",
            "Undefined_semantics 92 126--*--in the opinion of the investigator",
            "Drug 209 237--*--lidocaine-containing product",
            "Qualifier 243 268--*--could not be discontinued",
            "Temporal 269 294--*--while receiving lidocaine",
            "Drug 285 294--*--lidocaine",
            "Reference_point 275 294--*--receiving lidocaine",
            "Drug 311 340--*--class 1 anti-arrhythmic drugs",
            "Drug 348 358--*--mexiletine",
            "Drug 360 369--*--tocainide",
            "Scope 348 369--*--mexiletine, tocainide"
        ],
        "Text": "1. Had a neurological condition other than that associated with their pain diagnosis which, in the opinion of the investigator, would interfere with their ability to participate in the study . 2. Were taking a lidocaine-containing product that could not be discontinued while receiving lidocaine . 3. Were taking class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)       .     . "
    },
    "NCT02918851_inc": {
        "Text": "Habitual exerciser defined as = 30 minutes of at least moderate or high intensity exercise = 3 times per week. After consent, and at the subsequent screening visit, a VO2 max test will be performed, and subjects with a low value (< 35 mL/kg/min) will be excluded (screen failure). Based on our previous experience, we anticipate that <10% of the subjects will fall into this category. Men: (0.006012 x H3) + (14.6 x W) + 604 = TBV. Women: (0.005835 x H3) + (15 x W) + 183 = TBV [H=height in inches; W=weight in pounds]. Has access to transportation to visit the blood collection facility and to return to Stony Brook for all study visits.. ",
        "Annotations": [
            "Non-query-able 0 383--*--Habitual exerciser defined as = 30 minutes of at least moderate or high intensity exercise = 3 times per week. After consent, and at the subsequent screening visit, a VO2 max test will be performed, and subjects with a low value (< 35 mL/kg/min) will be excluded (screen failure). Based on our previous experience, we anticipate that <10% of the subjects will fall into this category",
            "Person 385 388--*--Men",
            "Measurement 427 430--*--TBV",
            "Value 390 426--*--(0.006012 x H3) + (14.6 x W) + 604 =",
            "Person 432 437--*--Women",
            "Measurement 474 477--*--TBV",
            "Value 439 471--*--(0.005835 x H3) + (15 x W) + 183",
            "Non-query-able 520 638--*--Has access to transportation to visit the blood collection facility and to return to Stony Brook for all study visits."
        ]
    },
    "NCT02763007_inc": {
        "Text": "Completed \"ALO-IIT-012(PEAK study)\", without major protocol deviations.. Male, or female, 19 years to 75 years.. Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study. Subjects completed PEAK can be included within 30 days after End Of the Study. Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.. ",
        "Annotations": [
            "Post-eligibility 0 70--*--Completed \"ALO-IIT-012(PEAK study)\", without major protocol deviations",
            "Person 73 77--*--Male",
            "Person 82 88--*--female",
            "Person 105 110--*--years",
            "Value 90 104--*--19 years to 75",
            "Pregnancy_considerations 113 304--*--Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study",
            "Post-eligibility 306 383--*--Subjects completed PEAK can be included within 30 days after End Of the Study",
            "Post-eligibility 385 508--*--Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study"
        ]
    },
    "NCT02509949_inc": {
        "Annotations": [
            "Person 0 3--*--age",
            "Value 4 23--*--> 17 and < 60 years",
            "Measurement 26 66--*--American Society of Anesthesiology (ASA)",
            "Value 67 72--*--I-III",
            "Procedure 88 122--*--living donor renal transplantation",
            "Mood 75 87--*--admitted for"
        ],
        "Text": "age > 17 and < 60 years;. American Society of Anesthesiology (ASA) I-III;. admitted for living donor renal transplantation.. "
    },
    "NCT03252249_exc": {
        "Text": "Clear indication for specific duration of dual anti-platelet therapy. Type 2 myocardial infarction. Contraindication to aspirin or P2Y12 receptor antagonist. Non-resident of Scotland. Previous recruitment into the trial. Inability or unwilling to give informed consent. ",
        "Annotations": [
            "Procedure 42 68--*--dual anti-platelet therapy",
            "Condition 0 38--*--Clear indication for specific duration",
            "Condition 70 98--*--Type 2 myocardial infarction",
            "Condition 100 116--*--Contraindication",
            "Condition 120 127--*--aspirin",
            "Condition 131 156--*--P2Y12 receptor antagonist",
            "Scope 120 156--*--aspirin or P2Y12 receptor antagonist",
            "Person 158 170--*--Non-resident",
            "Visit 174 182--*--Scotland",
            "Competing_trial 184 219--*--Previous recruitment into the trial",
            "Informed_consent 221 268--*--Inability or unwilling to give informed consent"
        ]
    },
    "NCT02109081_exc": {
        "Text": "1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.. ",
        "Annotations": [
            "Line 0 50--*--1) preoperative diagnosis of delirium or dementia;",
            "Line 51 185--*--2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing;",
            "Line 186 235--*--3) language barriers that would preclude testing;",
            "Line 236 289--*--4) preoperative steroid use within 3 days of surgery;",
            "Line 293 337--*--5) anticipation of postoperative intubation.",
            "Condition 29 37--*--delirium",
            "Condition 41 49--*--dementia",
            "Temporal 3 15--*--preoperative",
            "Scope 29 49--*--delirium or dementia",
            "Measurement 54 64--*--MMSE score",
            "Value 68 82--*--= 20 out of 30",
            "Temporal 86 98--*--preoperative",
            "Qualifier 108 122--*--more than mild",
            "Condition 123 143--*--cognitive impairment",
            "Scope 54 82--*--MMSE score of = 20 out of 30",
            "Scope 108 143--*--more than mild cognitive impairment",
            "Condition 148 156--*--delirium",
            "Temporal 160 172--*--preoperative",
            "Procedure 173 184--*--CAM testing",
            "Observation 189 206--*--language barriers",
            "Temporal 239 251--*--preoperative",
            "Drug 252 259--*--steroid",
            "Temporal 264 288--*--within 3 days of surgery",
            "Reference_point 281 288--*--surgery",
            "Procedure 281 288--*--surgery",
            "Temporal 312 325--*--postoperative",
            "Procedure 326 336--*--intubation",
            "Mood 296 308--*--anticipation"
        ]
    },
    "NCT02904785_exc": {
        "Annotations": [
            "Condition 11 31--*--spinal cord stenosis",
            "Observation 0 7--*--History",
            "Condition 56 76--*--lumbar radiculopathy",
            "Condition 35 52--*--clinical symptoms",
            "Condition 96 117--*--neurological diseases",
            "Observation 79 86--*--History",
            "Temporal 90 95--*--onset",
            "Scope 79 95--*--History or onset",
            "Condition 120 136--*--Generalized pain",
            "Condition 140 152--*--fibromyalgia",
            "Condition 155 172--*--Inability to walk",
            "Procedure 186 198--*--knee surgery",
            "Reference_point 206 217--*--target knee",
            "Observation 175 182--*--History",
            "Condition 240 254--*--osteoarthritis",
            "Condition 220 236--*--Secondary causes",
            "Undefined_semantics 220 254--*--Secondary causes of osteoarthritis",
            "Drug 264 271--*--statins",
            "Drug 276 286--*--quinolones",
            "Temporal 287 307--*--in the previous year",
            "Condition 335 355--*--psychiatric diseases",
            "Temporal 327 334--*--ongoing",
            "Qualifier 310 322--*--Uncontrolled",
            "Procedure 358 382--*--Invasive knee treatments",
            "Drug 388 403--*--hyaluronic acid",
            "Procedure 388 412--*--hyaluronic acid infusion",
            "Drug 414 429--*--corticosteroids",
            "Drug 434 446--*--anaesthetics",
            "Reference_point 455 466--*--target knee",
            "Temporal 468 491--*--up to 6 months previous",
            "Reference_point 495 510--*--study inclusion",
            "Scope 358 446--*--Invasive knee treatments with hyaluronic acid infusion, corticosteroids and anaesthetics"
        ],
        "Text": "History of spinal cord stenosis or clinical symptoms of lumbar radiculopathy; . History or onset neurological diseases; . Generalized pain or fibromyalgia; . Inability to walk; . History of knee surgery in the target knee; . Secondary causes of osteoarthritis; . Use of statins and quinolones in the previous year; . Uncontrolled and ongoing psychiatric diseases; . Invasive knee treatments with hyaluronic acid infusion, corticosteroids and anaesthetics, in the target knee, up to 6 months previous to study inclusion.       .     . "
    },
    "NCT00609531_exc": {
        "Annotations": [
            "Person 0 3--*--Age",
            "Value 4 22--*--less than 10 years",
            "Value 26 47--*--greater than 55 years",
            "Scope 4 47--*--less than 10 years or greater than 55 years",
            "Temporal 49 67--*--at time of consent",
            "Measurement 69 81--*--Estimated IQ",
            "Value 82 86--*--< 70",
            "Condition 88 109--*--Uncontrolled epilepsy",
            "Value 119 151--*--within 6 months prior to consent",
            "Condition 111 118--*--seizure",
            "Context_Error 157 276--*--Presence of medical conditions that might interfere with participation, or where participation would be contraindicated",
            "Condition 289 308--*--neurological injury",
            "Observation 278 285--*--History",
            "Condition 310 321--*--head trauma",
            "Condition 341 357--*--seizure disorder",
            "Qualifier 323 340--*--poorly-controlled",
            "Condition 359 366--*--seizure",
            "Temporal 367 398--*--within the preceding six months",
            "Condition 401 407--*--stroke",
            "Condition 415 427--*--neurosurgery",
            "Temporal 409 414--*--prior",
            "Observation 432 463--*--under the care of a neurologist",
            "Observation 432 451;467 479--*--under the care of a neurosurgeon",
            "Scope 310 479--*--head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or neurosurgeon",
            "Condition 519 533--*--claustrophobia",
            "Observation 508 515--*--History",
            "Device 535 544;560 577--*--Implanted metal in the body",
            "Device 548 577--*--irremovable metal in the body",
            "Condition 637 646--*--pregnancy",
            "Temporal 629 636--*--Current",
            "Not_a_criteria 647 884--*--(as verified by testing prior to both initial dose administration of citalopram or placebo and prior to magnetic resonance imaging) due to the risk that may be associated with SSRI treatment and magnetic resonance imaging on fetal health",
            "Condition 894 927--*--contraindications to SSRI therapy",
            "Condition 977 982--*--mania",
            "Temporal 996 1015--*--during SSRI therapy",
            "Condition 986 995--*--hypomania",
            "Scope 977 995--*--mania or hypomania",
            "Condition 1026 1038--*--drug allergy",
            "Observation 945 952--*--history",
            "Context_Error 1041 1109--*--Concomitant medication that would interfere with study participation",
            "Drug 1128 1138--*--citalopram",
            "Observation 1117 1124--*--history",
            "Temporal 1111 1116--*--Prior",
            "Procedure 1139 1148--*--treatment",
            "Qualifier 1149 1156--*--failure",
            "Context_Error 1111 1190--*--Prior history of citalopram treatment failure at appropriate doses and duration",
            "Non-query-able 1192 1288--*--Prior history of treatment failure to two previous SSRI trials at appropriate doses and duration",
            "Drug 1307 1330--*--psychoactive medication",
            "Drug 1342 1358--*--study medication",
            "Subjective_judgement 1370 1382--*--stable doses",
            "Temporal 1384 1409--*--greater than three months",
            "Drug 1423 1448--*--anticonvulsant medication",
            "Condition 1453 1469--*--seizure disorder",
            "Drug 1474 1489--*--diphenhydramine",
            "Scope 1360 1510--*--excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl\u00ae)for sleep",
            "Negation 1331 1341--*--other than",
            "Negation 1360 1369--*--excepting",
            "Observation 60 67--*--consent",
            "Reference_point 60 67--*--consent",
            "Procedure 915 927--*--SSRI therapy",
            "Scope 977 1038--*--mania or hypomania during SSRI therapy, or known drug allergy"
        ],
        "Text": "Age less than 10 years or greater than 55 years, at time of consent . Estimated IQ < 70 . Uncontrolled epilepsy (seizure within 6 months prior to consent) . 4. Presence of medical conditions that might interfere with participation, or where participation would be contraindicated . History of neurological injury: head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or neurosurgeon as determined by interview . History of claustrophobia . Implanted or irremovable metal in the body (including certain tattoos and permanent make-up) . Current pregnancy (as verified by testing prior to both initial dose administration of citalopram or placebo and prior to magnetic resonance imaging) due to the risk that may be associated with SSRI treatment and magnetic resonance imaging on fetal health . Medical contraindications to SSRI therapy as determined by history (including induction of mania or hypomania during SSRI therapy, or known drug allergy) . Concomitant medication that would interfere with study participation . Prior history of citalopram treatment failure at appropriate doses and duration . Prior history of treatment failure to two previous SSRI trials at appropriate doses and duration . Ongoing need for psychoactive medication other than study medication [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl\u00ae)for sleep]       .     . "
    },
    "NCT00904202_inc": {
        "Annotations": [
            "Condition 22 25--*--PHN",
            "Condition 27 29--*--DN",
            "Condition 31 35--*--CRPS",
            "Condition 37 59--*--carpal tunnel syndrome",
            "Condition 61 75--*--HIV neuropathy",
            "Condition 65 75--*--neuropathy",
            "Condition 61 64--*--HIV",
            "Condition 88 106--*--sensory neuropathy",
            "Qualifier 77 87--*--idiopathic",
            "Condition 117 138--*--peripheral neuropathy",
            "Condition 213 216--*--PHN",
            "Multiplier 236 245--*-->3 months",
            "Temporal 246 264--*--after rash healing",
            "Reference_point 252 264--*--rash healing",
            "Condition 252 264--*--rash healing",
            "Condition 231 235--*--pain",
            "Condition 283 285--*--DN",
            "Condition 300 306;313 321--*--Type I diabetes",
            "Condition 300 304;310 321--*--Type II diabetes",
            "Qualifier 326 333--*--painful",
            "Qualifier 334 340--*--distal",
            "Qualifier 341 350--*--symmetric",
            "Condition 351 378--*--sensorimotor polyneuropathy",
            "Condition 395 412--*--dynamic allodynia",
            "Scope 300 378--*--Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy",
            "Subjective_judgement 140 193--*--upon mutual agreement of the sponsor and investigator",
            "Condition 456 460--*--CRPS",
            "Measurement 483 557--*--IASP (International Association for the Study of Pain) diagnostic criteria",
            "Value 471 474--*--met",
            "Condition 576 598--*--carpal tunnel syndrome",
            "Procedure 640 673--*--clinical neurological examination",
            "Condition 681 689;702 707--*--Phalen's signs",
            "Condition 694 707--*--Tinel's signs",
            "Scope 681 707--*--Phalen's and Tinel's signs",
            "Procedure 710 727--*--electrodiagnostic",
            "Multiplier 741 746--*--daily",
            "Temporal 767 794--*--at least 3 months' duration",
            "Condition 747 763--*--painful symptoms",
            "Condition 813 827--*--HIV neuropathy",
            "Condition 842 845--*--HIV",
            "Condition 847 866--*--subjective symptoms",
            "Condition 878 899--*--peripheral neuropathy",
            "Qualifier 870 877--*--painful",
            "Multiplier 905 910--*--daily",
            "Condition 911 927--*--painful symptoms",
            "Temporal 931 958--*--at least 3 months' duration",
            "Scope 842 958--*--HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration",
            "Condition 977 1006--*--idiopathic sensory neuropathy",
            "Condition 1021 1025--*--pain",
            "Temporal 1029 1056--*--at least 3 months' duration",
            "Measurement 1080 1097--*--daily pain rating",
            "Temporal 1098 1122--*--during the baseline week",
            "Reference_point 1109 1122--*--baseline week",
            "Qualifier 1072 1079--*--average",
            "Value 1139 1153--*--greater than 4",
            "Procedure 1161 1196--*--0-to-10 numerical pain rating scale",
            "Drug 1247 1264--*--analgesic regimen",
            "Drug 1280 1289--*--lidocaine",
            "Drug 1293 1303--*--gabapentin",
            "Scope 1280 1303--*--lidocaine or gabapentin"
        ],
        "Text": "1. Had a diagnosis of PHN, DN, CRPS, carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy (upon mutual agreement of the sponsor and investigator) . 2. Patients with PHN must have had pain >3 months after rash healing . 3. Patients with DN must have had Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with or without dynamic allodynia of the lower extremities . 4. Patients with CRPS must have met current IASP (International Association for the Study of Pain) diagnostic criteria . 5. Patients with carpal tunnel syndrome must have had a diagnosis by combination clinical neurological examination (e.g., Phalen's and Tinel's signs), electrodiagnostic testing, and daily painful symptoms of at least 3 months' duration . 6. Patients with HIV neuropathy must have had HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration . 7. Patients with idiopathic sensory neuropathy must have had pain of at least 3 months' duration . 8. Reached an average daily pain rating during the baseline week of pain ratings greater than 4 on the 0-to-10 numerical pain rating scale (Question 5 of the BPI) . 9. Had never received an analgesic regimen that contained lidocaine or gabapentin . "
    },
    "NCT02361892_inc": {
        "Annotations": [
            "Condition 0 10--*--submucosal",
            "Condition 27 48--*--subserosal leiomyomas",
            "Condition 13 23;38 48--*--intramural leiomyomas",
            "Mood 51 59--*--symptoms",
            "Condition 63 79--*--menometrorrhagia",
            "Condition 82 100--*--menstrual disorder",
            "Condition 103 114--*--infertility",
            "Condition 117 128--*--pelvic pain"
        ],
        "Text": "submucosal,. intramural or subserosal leiomyomas,. symptoms of menometrorrhagia,. menstrual disorder,. infertility,. pelvic pain. "
    },
    "NCT02762851_exc": {
        "Annotations": [
            "Condition 0 21--*--Anaphylactic reaction",
            "Drug 48 75--*--trivalent influenza vaccine",
            "Drug 44 47--*--TIV",
            "Condition 84 132--*--IgE( Immunoglobulin E)-mediated hypersensitivity",
            "Drug 136 140--*--eggs",
            "Condition 155 160--*--hives",
            "Condition 162 194--*--swelling of the mouth and throat",
            "Condition 196 219--*--difficulty in breathing",
            "Condition 221 232--*--hypotension",
            "Condition 237 242--*--shock",
            "Scope 155 242--*--hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock",
            "Condition 244 267--*--Guillain-Barr\u00e9 syndrome",
            "Temporal 268 318--*--within eight weeks of a previous influenza vaccine",
            "Reference_point 290 318--*--a previous influenza vaccine",
            "Temporal 292 300--*--previous",
            "Drug 301 318--*--influenza vaccine",
            "Condition 320 341--*--Anaphylactic reaction",
            "Drug 345 353--*--neomycin",
            "Drug 377 394--*--influenza vaccine",
            "Temporal 395 429--*--in two of the three previous years"
        ],
        "Text": "Anaphylactic reaction to a previous dose of TIV(trivalent influenza vaccine). Known IgE( Immunoglobulin E)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock. Guillain-Barr\u00e9 syndrome within eight weeks of a previous influenza vaccine. Anaphylactic reaction to neomycin. Patients who have had influenza vaccine in two of the three previous years. "
    },
    "NCT02627560_exc": {
        "Annotations": [
            "Condition 0 8--*--pregnant",
            "Observation 12 25--*--breastfeeding",
            "Condition 33 55--*--thromboembolic disease",
            "Mood 64 76--*--high risk of",
            "Condition 77 92--*--thromboembolism",
            "Procedure 105 126--*--extra anticoagulation",
            "Condition 167 174--*--allergy",
            "Drug 178 193--*--tranexamic acid",
            "Drug 194 205--*--Cyklokapron",
            "Scope 178 205--*--tranexamic acid/Cyklokapron"
        ],
        "Text": "pregnant or breastfeeding. known thromboembolic disease or with high risk of thromboembolism, warranting extra anticoagulation in connection with the procedure. known allergy to tranexamic acid/Cyklokapron\u00ae. "
    },
    "NCT03495609_exc": {
        "Text": "History of allergic reaction to compounds of similar chemical or biologic composition to hCG. receiving medication that could interfere with the study protocol objectives (hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin). previous treatment with follicle stimulating hormone for assisted reproduction. uncontrolled intercurrent illness. Heart disease. Severe cognitive decline. Psychiatric desease. HIV positive. Hepatitis B or C infection. ",
        "Annotations": [
            "Observation 0 7--*--History",
            "Condition 11 28--*--allergic reaction",
            "Drug 32 92--*--compounds of similar chemical or biologic composition to hCG",
            "Drug 89 92--*--hCG",
            "Drug 104 114--*--medication",
            "Qualifier 120 170--*--could interfere with the study protocol objectives",
            "Drug 172 195--*--hormonal contraceptives",
            "Drug 197 206--*--androgens",
            "Drug 208 218--*--prednisone",
            "Drug 220 236--*--thyroid hormones",
            "Drug 238 245--*--insulin",
            "Scope 172 245--*--hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin",
            "Temporal 248 256--*--previous",
            "Temporal 94 103--*--receiving",
            "Procedure 257 266--*--treatment",
            "Drug 272 300--*--follicle stimulating hormone",
            "Procedure 305 326--*--assisted reproduction",
            "Qualifier 328 340--*--uncontrolled",
            "Condition 341 361--*--intercurrent illness",
            "Condition 363 376--*--Heart disease",
            "Qualifier 378 384--*--Severe",
            "Condition 385 402--*--cognitive decline",
            "Condition 404 423--*--Psychiatric desease",
            "Condition 425 437--*--HIV positive",
            "Condition 439 450;456 465--*--Hepatitis B infection",
            "Condition 439 448;454 465--*--Hepatitis C infection"
        ]
    },
    "kb_shortcuts": {}
}